CBR-001-570-969-0,RFM-000-001-1,CBR-001-570-969-0,O=c1[nH]c(=O)[nH]c(n1)C(=O)[O-],CBR-HVAC-04520
CBR-001-570-970-3,RFM-000-002-2,CBR-001-570-970-3,O=C(c1ccc2c(c1O)cccc2)Oc1ccccc1,analog of CBR-HVAC-08765
CBR-001-570-971-4,RFM-000-003-3,CBR-001-570-971-4,OCC(COc1ccc(cc1)Cl)O,CBR-HVAC-09007
CBR-001-570-972-5,RFM-000-004-4,CBR-001-570-972-5,OC(=O)c1cc(O)c(c(c1)O)O,CBR-HVAC-09011
CBR-001-570-973-6,RFM-000-005-5,CBR-001-570-973-6,OC(=O)c1ccccc1,CBR-HVAC-09141
CBR-001-570-974-7,RFM-000-006-6,CBR-001-570-974-7,Brc1cc(Br)c(c(c1)Br)O,CBR-HVAC-09143
CBR-001-570-975-8,RFM-000-007-7,CBR-001-570-975-8,SC(=S)N1CCCC1,CBR-HVAC-09326
CBR-001-570-976-9,RFM-000-008-8,CBR-001-570-976-9,OC(=O)CCC(C(=O)O)NC(=O)c1ccc(cc1)NCc1cnc2c(n1)c(=O)[nH]c(n2)N,CBR-HVAC-01327: Dihydrofolate reductase Inhibitor; Folate Receptor Ligands; Chemopreventive Agents; Colorectal Cancer Therapy; Dental Agents; Hematopoietic Agents; Micronutrient; Ovarian Cancer Therapy; Therapy of Vitamin-Related Disorders; Treatment of Disorders of the Coronary Arteries and Atherosclerosis
CBR-001-570-977-0,RFM-000-009-9,CBR-001-570-977-0,OC(=O)[C@@H]1O[C@@H](O[C@@H]2[C@@H](O[C@H]([C@H]([C@H]2O)O)O)C(=O)O)[C@H]([C@H]([C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@H]([C@@H]([C@@H]1O)O)O)O)O,analog of CBR-HVAC-09533
CBR-001-570-978-1,RFM-000-010-2,CBR-001-570-978-1,NCCC[C@H]1NC(=O)[C@H](CCCCNC(=O)[C@@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)[C@H](CC)C)Cc1ccccc1)Cc1[nH]cnc1)CC(=O)O)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](NC(=O)[C@@H](NC(=O)C1CSC(=N1)C(C(CC)C)N)CC(C)C)CCC(=O)O,CBR-HVAC-09543
CBR-001-570-979-2,RFM-000-011-3,CBR-001-570-979-2,COc1ccc(c(c1)O)C(=O)c1ccccc1,CBR-HVAC-09625
CBR-001-570-980-5,RFM-000-012-4,CBR-001-570-980-5,*C(C(F)(F)*)(F)F,CBR-HVAC-09644
CBR-001-570-981-6,RFM-000-013-5,CBR-001-570-981-6,CC(=O)Nc1ccc(cc1)C=NNC(=S)N,CBR-HVAC-09691
CBR-001-570-982-7,RFM-000-014-6,CBR-001-570-982-7,CCOc1ccc(cc1)N=Nc1ccc(cc1N)N,CBR-HVAC-09975
CBR-001-570-983-8,RFM-000-015-7,CBR-001-570-983-8,CC(=O)Nc1cccc(c1)O,CBR-HVAC-09993
CBR-001-570-984-9,RFM-000-016-8,CBR-001-570-984-9,Oc1ccc(cc1)C1(OC(=O)c2c1cccc2)c1ccc(cc1)O,CBR-HVAC-10032
CBR-001-570-985-0,RFM-000-017-9,CBR-001-570-985-0,O=C(c1ccccc1C(=O)O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,CBR-HVAC-10033
CBR-001-570-986-1,RFM-000-018-0,CBR-001-570-986-1,Oc1ccc2c(c1)oc(=O)cc2C,CBR-HVAC-10049
CBR-001-570-987-2,RFM-000-019-1,CBR-001-570-987-2,Oc1ccc(cc1)C1(OS(=O)(=O)c2c1cccc2)c1ccc(cc1)O,CBR-HVAC-10074
CBR-001-570-988-3,RFM-000-020-4,CBR-001-570-988-3,OCc1ccccc1O,CBR-HVAC-10119
CBR-001-570-989-4,RFM-000-021-5,CBR-001-570-989-4,CCOC(=O)C(=C(c1ccccc1)c1ccccc1)C#N,CBR-HVAC-10261
CBR-001-570-990-7,RFM-000-022-6,CBR-001-570-990-7,CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC,CBR-HVAC-10345
CBR-001-570-991-8,RFM-000-023-7,CBR-001-570-991-8,CCCCCCCCCCCCCCCC(=O)OC[C@H]([C@H]1OC[C@@H]([C@H]1O)O)O,CBR-HVAC-10368
CBR-001-570-992-9,RFM-000-024-8,CBR-001-570-992-9,COc1nc(N)nc2c1nc[nH]2,CBR-HVAC-11138
CBR-001-570-993-0,RFM-000-025-9,CBR-001-570-993-0,CN(C(=O)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1CCCCc2c1cccc2)C,CBR-HVAC-00707: Urinary Incontinence Therapy; Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Agonists; Vasopressin V2 receptor Agonist; Vasopressin 2 agonist
CBR-001-570-994-1,RFM-000-026-0,CBR-001-570-994-1,Oc1ccc(cc1)CCCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1,CBR-HVAC-14224
CBR-001-570-995-2,RFM-000-027-1,CBR-001-570-995-2,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2c1nc(N)[nH]c2=O,analog of CBR-HVAC-03696
CBR-001-570-996-3,RFM-000-028-2,CBR-001-570-996-3,CNCC(C(C(C(CO)O)O)O)O,uninteresting counterion of CBR-HVAC-00937
CBR-001-570-997-4,RFM-000-029-3,CBR-001-570-997-4,O=C1NCC(=O)NC1,CBR-HVAC-08207:  DNA inhibitor
CBR-001-570-998-5,RFM-000-030-6,CBR-001-570-998-5,OC/C(=N\NC(=O)CCCCCN1C(=O)C=CC1=O)/[C@@]1(O)C[C@H](O[C@H]2C[C@H](N)[C@@H]([C@@H](O2)C)O)c2c(C1)c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2OC,CBR-HVAC-05830: Gastric Cancer Therapy;Sarcoma Therapy;Glioblastoma Multiforme Therapy;Small Cell Lung Cancer Therapy;Kaposi's Sarcoma Therapy;Multiple Myeloma Therapy;Solid Tumors Therapy;Breast Cancer Therapy;Oncolytic Drugs;Pancreatic Cancer Therapy;Ovarian Cancer Therapy; DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs;
CBR-001-570-999-6,RFM-000-031-7,CBR-001-570-999-6,[O-][N+](=O)c1ccc(c2c1cccn2)O,CBR-HVAC-00957:  DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-000-6,RFM-000-032-8,CBR-001-571-000-6,Oc1ccc(cc1)O,CBR-HVAC-01387:  Melanin inhibitor
CBR-001-571-001-7,RFM-000-033-9,CBR-001-571-001-7,Cn1cnc2c1c(=O)[nH]c(=O)n2C,CBR-HVAC-01254:  Phosphodiesterase inhibitor
CBR-001-571-002-8,RFM-000-034-0,CBR-001-571-002-8,OCCN(c1nc(N2CCCCC2)c2c(n1)c(nc(n2)N(CCO)CCO)N1CCCCC1)CCO,CBR-HVAC-14230
CBR-001-571-003-9,RFM-000-035-1,CBR-001-571-003-9,OC(=O)CCC(=O)C(=O)O,CBR-HVAC-08247: Pyridoxamine phosphate aminotransferase stimulant; Treatment of Osteoporosis
CBR-001-571-004-0,RFM-000-036-2,CBR-001-571-004-0,CC[C@@H]1/C=C(\C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@@H](C[C@@H]2OC)C)C(=O)C(=O)N2[C@H](C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]1CC[C@@H]([C@@H](C1)OC)Cl)/C)CCCC2,"CBR-HVAC-04208: Dermatologic Drugs;Antipruritics;Dry Eye Syndrome, Treatment for;Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs; Calcineurin (PP-2B) Inhibitors;Cytokine Production Inhibitors;FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors;Signal Transduction Modulators; Calcineurin Inhibitor;"
CBR-001-571-005-1,RFM-000-037-3,CBR-001-571-005-1,CC(C(C(=O)O)N)O,CBR-HVAC-08435:  Unidentified pharmacological activity
CBR-001-571-006-2,RFM-000-038-4,CBR-001-571-006-2,CN1C[C@H](C[C@H]2[C@H]1Cc1cn(c3c1c2ccc3)C)NS(=O)(=O)N(C)C,CBR-HVAC-14489: 5-Hydroxytryptamine 2A receptor Antagonist; 5-Hydroxytryptamine 2C receptor; Antiparkinsonian
CBR-001-571-007-3,RFM-000-039-5,CBR-001-571-007-3,NCCCC(CC(=O)NCC1NC(=O)C(CO)NC(=O)C(N)CNC(=O)C(NC(=O)/C(=C/NC(=O)N)/NC1=O)C1CCNC(=N)N1)N,CBR-HVAC-09552: 16S-rRNA of 30S ribosomal subunit; 23S-rRNA of 50S ribosomal subunit Inhibitor; Inhibitor;
CBR-001-571-008-4,RFM-000-040-8,CBR-001-571-008-4,O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2c(O1)cccc2,CBR-HVAC-03741: Anxiolytics; Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Antagonist; 5 Hydroxytryptamine receptor antagonist
CBR-001-571-009-5,RFM-000-041-9,CBR-001-571-009-5,CN1CCC(CC1)c1cn(c2c1cc(cc2)OS(=O)(=O)c1c(F)cccc1F)C,CBR-HVAC-00366: 5-hydroxytryptamine 6 receptor Antagonist; 5 Hydroxytryptamine 6 receptor antagonist
CBR-001-571-010-8,RFM-000-042-0,CBR-001-571-010-8,NC(=O)c1cccnc1,"CBR-HVAC-01394: Acne Therapy;Type 1 Diabetes, Agents for;Diabetic Neuropathy, Agents for;Therapy of Vitamin-Related Disorders;Stroke, Treatment ofPoly  ADP-ribose polymerase Inhibitor; Unidentified pharmacological activity"
CBR-001-571-011-9,RFM-000-043-1,CBR-001-571-011-9,COc1ccc2c(c1C)nc(cc2O[C@@H]1C[C@@H]2C(C1)C(=O)N(C)CCCC/C=C\[C@H]1[C@](NC2=O)(C1)C(=O)NS(=O)(=O)C1CC1)c1scc(n1)C(C)C,CBR-HVAC-06555: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors; NS3/4A protease Inhibitor; HCV nonstructural protein 3 inhibitor; Serine protease inhibitor
CBR-001-571-012-0,RFM-000-044-2,CBR-001-571-012-0,Cc1cccc(c1NC1=NCCCS1)C,CBR-HVAC-10013: Alpha adrenergic receptor Agonist;
CBR-001-571-013-1,RFM-000-045-3,CBR-001-571-013-1,Clc1ccc(cc1)C(CN1CCN(CC1)Cc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)O,"CBR-HVAC-11046: Analgesic Drugs;Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators;Sodium Channel  Blockers; Sodium channel Blocker;"
CBR-001-571-014-2,RFM-000-046-4,CBR-001-571-014-2,OCCCCN1C(=O)N(C(=O)C1(C)C)c1ccc(c(c1)C(F)(F)F)C#N,CBR-HVAC-00524: Androgen receptor Antagonist; Androgen receptor antagonist
CBR-001-571-015-3,RFM-000-047-5,CBR-001-571-015-3,C=CCc1ccccc1OCC(CNC(C)C)O,"CBR-HVAC-03323: Angina pectoris, Treatment of;Antiarrhythmic Drugs;Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators"
CBR-001-571-016-4,RFM-000-048-6,CBR-001-571-016-4,CN(CCOC(c1ccccc1)c1ccccc1)C,"CBR-HVAC-03096: Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis;Allergic Skin Disorders, Treatment for;Nausea and Vomiting, Treatment of; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist;"
CBR-001-571-017-5,RFM-000-049-7,CBR-001-571-017-5,CCN(CCNC(=O)c1ccc(cc1)N)CC,CBR-HVAC-02674: Antiarrhythmic DrugsMonoamine oxidase Inhibitor; Sodium channel antagonist
CBR-001-571-018-6,RFM-000-050-0,CBR-001-571-018-6,CCOC(=O)c1c[nH]cn1,CBR-HVAC-02913: Antibacterial Drugs
CBR-001-571-019-7,RFM-000-051-1,CBR-001-571-019-7,Nc1ccc(cc1)S(=O)(=O)Nc1onc(c1C)C,CBR-HVAC-05928: Antibacterial Drugs; Endothelin Receptor Antagonists;Signal Transduction Modulators; Dihydrofolate reductase Inhibitor;
CBR-001-571-020-0,RFM-000-052-2,CBR-001-571-020-0,FC(=C)c1sc(c(c1Br)C)CNCCCNc1cc(=O)c2c([nH]1)cccc2,CBR-HVAC-00136: Antibacterial Drugs; Methionyl-tRNA Synthetase Inhibitors; Methionyl-tRNA synthetase Inhibitor; Methionyl-tRNA synthetase inhibitor
CBR-001-571-021-1,RFM-000-053-3,CBR-001-571-021-1,OCC(C(C(CO)O)O)O,CBR-HVAC-04873: Antibacterial Drugs;Antiinfectives (Not Specified)
CBR-001-571-022-2,RFM-000-054-4,CBR-001-571-022-2,CC(Cn1c(C)ncc1[N+](=O)[O-])O,CBR-HVAC-01558: Antibacterial Drugs;Antitrichomonals Microtubule inhibitor; Acetylcholinesterase inhibitor
CBR-001-571-023-3,RFM-000-055-5,CBR-001-571-023-3,Oc1cccc2c1nccc2,CBR-HVAC-04449: Antibacterial Drugs;Antiviral Drugs;Antifungal Agents
CBR-001-571-024-4,RFM-000-056-6,CBR-001-571-024-4,C[N+](=C1C=CC(=C(c2ccc(cc2)N(C)C)c2ccc(cc2)N(C)C)C=C1)C,CBR-HVAC-06477: Antibacterial Drugs;Oncolytic Drugs;Antifungal Agents; Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B; p27Kip1) Degradation Inhibitors;Signal Transduction Modulators;TNFR1 (p55/CD120a) Modulators
CBR-001-571-025-5,RFM-000-057-7,CBR-001-571-025-5,Clc1ccc(c(c1)C(=O)Nc1ccc(cc1Cl)[N+](=O)[O-])O,CBR-HVAC-05219: Antibacterial Drugs;Oncolytic Drugs;Treatment of Helminthic Diseases;Antiviral Drugs; Autophagy Inducers;Pseudomonas aeruginosa Quorum Sensing Inhibitors;Wnt Signaling Inhibitors; SARS-CoV proteinase Inhibitor;
CBR-001-571-026-6,RFM-000-058-8,CBR-001-571-026-6,CCn1cc(C(=O)O)c(=O)c2c1nc(C)cc2,CBR-HVAC-02870: Antibacterial DrugsDNA gyrase Inhibitor;
CBR-001-571-027-7,RFM-000-059-9,CBR-001-571-027-7,OCC(=O)N1CCN(CC1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,CBR-HVAC-04747: Antibacterial Drugs; Bacterial protein synthesis inhibitor; Ribosome binding agent; Protein 30S ribosomal subunit inhibitor
CBR-001-571-028-8,RFM-000-060-2,CBR-001-571-028-8,O[C@@H]1CS[C@H]([C@@H]([C@H]1O)O)Oc1ccc2c(c1)oc(=O)cc2C,CBR-HVAC-05380: Anticoagulants; Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitor; Glycosaminoglycan stimulant; Indirect thrombin inhibitor; Serine protease inhibitor
CBR-001-571-029-9,RFM-000-061-3,CBR-001-571-029-9,OC(=O)C[N+](C)(C)C,"CBR-HVAC-01405: Anticoagulants;Aminoacidopathies, Treatment for; Nitric Oxide (NO) DonorsMethionine synthase stimulant"
CBR-001-571-030-2,RFM-000-062-4,CBR-001-571-030-2,O=C1CCC(=O)N1C[C@H]1CC[C@@H]2N(C1)CCN(C2)c1ncccn1,CBR-HVAC-04108: Antidepressants;Anxiolytics; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist; 5 Hydroxytryptamine 1A receptor antagonist
CBR-001-571-031-3,RFM-000-063-5,CBR-001-571-031-3,O=C(N1CCCCC1)C=CC=Cc1ccc2c(c1)OCO2,"CBR-HVAC-04891: Antiepileptic Drugs;Pharmacological Tools;Antiarthritic Drugs;Lipoprotein Disorders, Treatment of ;Oncolytic Drugs;Antidepressants;Non-Opioid Analgesics;Dermatologic Drugs; ACAT Inhibitors;Antioxidants;GABA(A) Receptor Modulators;MAO-A Inhibitors;MAO-B Inhibitors;N-Formyl Peptide Receptor 2 (FPR2; FPRL1; LXA4) Agonists;PPARgamma Antagonists;Pregnane X Receptor (PXR) Agonists;Signal Transduction Modulators;TRPV1 (Vanilloid VR1 Receptor) Agonists; Monoamine oxidase Inhibitor;"
CBR-001-571-032-4,RFM-000-064-6,CBR-001-571-032-4,Nc1c(F)cnc(=O)[nH]1,CBR-HVAC-02846: Antifungal AgentsThymidylate synthase Inhibitor;
CBR-001-571-033-5,RFM-000-065-7,CBR-001-571-033-5,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)OCC(C)(C)CCCCc1c3CN(C(=O)O2)Cc3ccc1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,CBR-HVAC-06530: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors; NS3/4A PROTEASE Inhibitor; HCV nonstructural protein 3 inhibitor; HCV nonstructural protein 4A inhibitor
CBR-001-571-034-6,RFM-000-066-8,CBR-001-571-034-6,O=C(C(C)C)O[C@@H]1[C@@H](COC(=O)C(C)C)O[C@H]([C@]1(C)F)n1ccc(nc1=O)N,CBR-HVAC-00713: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B RNA-DEPENDENT RNA POLYMERASE Inhibitor; HCV nonstructural protein 5B inhibitor
CBR-001-571-035-7,RFM-000-067-9,CBR-001-571-035-7,CCCCCCCCCCCCCCCCCCCCCCO,CBR-HVAC-01651: Anti-Herpes Labialis Drugs;Anti-Herpes Simplex Virus Drugs Lipase clearing factor inhibitor
CBR-001-571-036-8,RFM-000-068-0,CBR-001-571-036-8,[S-]C(=S)OC1CC2CC1C1C2CCC1,CBR-HVAC-06888: Anti-Herpes Simplex Virus Drugs;Anti-Papilloma Virus Drugs; Phospholipase C Inhibitors;Signal Transduction Modulators; PHOSPHATIDYLCHOLINE-SPECIFIC PHOSPHOLIPASE C Inhibitor;
CBR-001-571-037-9,RFM-000-069-1,CBR-001-571-037-9,CC(Nc1cccnc1N1CCN(CC1)C(=O)c1cc2c([nH]1)ccc(c2)NS(=O)(=O)C)C,CBR-HVAC-02195: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-571-038-0,RFM-000-070-4,CBR-001-571-038-0,Nc1ccc2c(c1)[n+](C)c1c(c2)ccc(c1)N.Nc1ccc2c(c1)nc1c(c2)ccc(c1)N,CBR-HVAC-04021: Anti-HIV Agents; HIF-2 alpha; HIF-1 alpha Inhibitor;
CBR-001-571-039-1,RFM-000-071-5,CBR-001-571-039-1,NC(=O)c1cnccn1,CBR-HVAC-03489: Antimycobacterial Agents;Treatment of Tuberculosis; Fatty Acid Synthase (FAS) Inhibitors
CBR-001-571-040-4,RFM-000-072-6,CBR-001-571-040-4,CCNC(=O)[C@@H]1C[C@](C1)(F)c1ccc(c(c1)F)CN1CCCC1,"CBR-HVAC-00307: Antinarcoleptic Drugs;Alzheimer's Dementia, Treatment of ;Tourette's Syndrome, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Histamine H3 Receptor Antagonists;Signal Transduction Modulators; Histamine H3 receptor Antagonist; Histamine H3 receptor antagonist"
CBR-001-571-041-5,RFM-000-073-7,CBR-001-571-041-5,COc1cc(ccc1OCCN1CCCC1)n1cnc2c(c1=O)sc(c2)c1ccc(cc1)Cl,CBR-HVAC-00168: Antiobesity Drugs; Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists;Signal Transduction Modulators; Melanin concentrating hormone receptor 1 Antagonist; Melanin concentrating hormone-1 receptor antagonist
CBR-001-571-042-6,RFM-000-074-8,CBR-001-571-042-6,OC(=O)C[C@@H]1CC[C@H](CC1)c1ccc(cc1)c1nc(C(=O)N)c(nc1C)C,CBR-HVAC-06923: Antiobesity Drugs;Antidiabetic Drugs; Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitors; Diacylglycerol acyl transferase -1 Inhibitor;
CBR-001-571-043-7,RFM-000-075-9,CBR-001-571-043-7,OC(=O)CC1CCCc2c1n(Cc1ccc(cc1)S(=O)(=O)C)c1c2cc(cc1F)F,CBR-HVAC-08958: Antiplatelet Therapy;Antiallergy/Antiasthmatic Drugs; Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A2 receptor Antagonist;
CBR-001-571-044-8,RFM-000-076-0,CBR-001-571-044-8,CN1CCc2c([C@H](C1)c1cccc3c1OCC3)cc(c(c2)Cl)O,CBR-HVAC-04329: Antipsychotic Drugs; Dopamine D1 Antagonists;Signal Transduction Modulators; Dopamine receptor D1 Antagonist;
CBR-001-571-045-9,RFM-000-077-1,CBR-001-571-045-9,Clc1ccc2c(c1)c(cn2c1ccc(cc1)F)C1CCN(CC1)CCN1CCNC1=O,CBR-HVAC-02803: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; Alpha-1 adrenergic receptor; Potassium channel hERG; 5-Hydroxytryptamine 2A receptor; Dopamine receptor D2 Antagonist; Blocker; 5 Hydroxytryptamine 2 receptor antagonist; Dopamine D2 receptor antagonist; Alpha 1 adrenoreceptor antagonist
CBR-001-571-046-0,RFM-000-078-2,CBR-001-571-046-0,O=C(c1cccc(c1Cl)C(F)(F)F)N[C@@H](c1ccccc1)[C@@H]1CCCCN1,CBR-HVAC-05984: Antipsychotic Drugs; GlyT-1 Inhibitors
CBR-001-571-047-1,RFM-000-079-3,CBR-001-571-047-1,OCCN1CCN(CC1)CCC=C1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-03115: Antipsychotic Drugs;Antidepressants; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2 Antagonists
CBR-001-571-048-2,RFM-000-080-6,CBR-001-571-048-2,O=C(N1CCC[C@](C1)(CCCN1CCC(CC1)(c1ccccc1)N(C(=O)C)C)c1ccc(c(c1)Cl)Cl)c1ccccc1,CBR-HVAC-04640: Antipsychotic Drugs;Antidepressants; Signal Transduction Modulators;Tachykinin NK3 Antagonists; Neurokinin receptor 3 Antagonist;
CBR-001-571-049-3,RFM-000-081-7,CBR-001-571-049-3,COc1cccc(c1OC)C(C1CCN(CC1)CCc1ccc(cc1)F)O,"CBR-HVAC-04258: Antipsychotic Drugs;Sleep Disorders, Treatment of; Signal Transduction Modulators;5-HT2A Antagonists; 5-Hydroxytryptamine 2A receptor Antagonist; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-571-050-6,RFM-000-082-8,CBR-001-571-050-6,CCOc1ccccc1C(=O)N,CBR-HVAC-06516: Antipyretics;Antiarthritic Drugs;Non-Opioid Analgesics
CBR-001-571-051-7,RFM-000-083-9,CBR-001-571-051-7,NC(C(=O)O)CC[S+](C)C,"CBR-HVAC-06398: Antiulcer Drugs;Agents for Gastritis;Inflammatory Bowel Disease, Agents for"
CBR-001-571-052-8,RFM-000-084-0,CBR-001-571-052-8,CCOC(=O)c1ncc2c(c1C)c1c(cccc1[nH]2)OC(C)C,CBR-HVAC-10450: Benzodiazepine receptor Antagonist; Benzodiazepine receptor agonist; GABA(A) BZ Site Receptor Antagonists; Signal Transduction Modulators; Antipsychotic; Neuroprotectant
CBR-001-571-053-9,RFM-000-085-1,CBR-001-571-053-9,Fc1ccc2c(c1)c1c(cn(c(=O)c1n2C)c1ccccc1)C(=O)N1CCCC1,CBR-HVAC-05365: Anxiolytics; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; GABA-A receptor Agonist; GABA A receptor agonist
CBR-001-571-054-0,RFM-000-086-2,CBR-001-571-054-0,CCCNCCOc1ccc(cc1F)NC(=O)c1c[nH]c2c1C(=O)CCC2,CBR-HVAC-09462: Anxiolytics; GABA(A) Receptor Partial Agonists;Signal Transduction Modulators; GABAA RECEPTOR Partial Agonist;
CBR-001-571-055-1,RFM-000-087-3,CBR-001-571-055-1,OCCOCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-03102: Anxiolytics;AntipruriticsHistamine H1 receptor Antagonist;
CBR-001-571-056-2,RFM-000-088-4,CBR-001-571-056-2,CC(CCC(=O)CC1N(c2ccc3c(n2)nc(cc3)Cl)C(=O)c2c1cccc2)C,"CBR-HVAC-00782: Anxiolytics;Prevention of Premature Ejaculation;Neurologic Drugs (Miscellaneous);Generalized Anxiety Disorder (GAD), Treatment of; GABA(A) BZ Site Receptor Partial Agonists;Signal Transduction Modulators; GABA-A receptor Agonist; Benzodiazepine receptor agonist"
CBR-001-571-057-3,RFM-000-089-5,CBR-001-571-057-3,Fc1ccc(cc1)C(c1ccc(cc1)F)(c1ccccc1)C(=O)N,"CBR-HVAC-00774: Asthma Therapy;Sickle Cell Anemia, Agents for; Intermediate Conductance K(Ca) 3.1 (IKCa1; Gardos channel, SK41, IK1) Channel Blockers; POTASSIUM CHANNEL KCA3.1 Blocker; Potassium channel antagonist"
CBR-001-571-058-4,RFM-000-090-8,CBR-001-571-058-4,O=C(c1ccccc1c1ccc(cc1)C(F)(F)F)Nc1ccc2c(c1)CCN(C2)Cc1ncn[nH]1,"CBR-HVAC-05274: Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein Inhibitor;"
CBR-001-571-059-5,RFM-000-091-9,CBR-001-571-059-5,NC(=O)[C@@H]1CC[C@@H](N1)c1ccc(cc1)OCc1ccccc1F,"CBR-HVAC-06597: Bipolar Disorder, Treatment of;Neuropathic Pain, Treatment of;Antidepressants;Cognition Disorders, Treatment of; MAO-B Inhibitors;Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers"
CBR-001-571-060-8,RFM-000-092-0,CBR-001-571-060-8,O=C1O[C@@H](C/C=C(/C)\CCC[C@@H]([C@@H]([C@H](C(=O)C([C@H](C1)O)(C)C)C)O)C)/C(=C/c1csc(n1)C)/C,CBR-HVAC-14204
CBR-001-571-061-9,RFM-000-093-1,CBR-001-571-061-9,COc1cc(ccc1OC(F)F)c1ccc(=O)[nH]n1,CBR-HVAC-03791: Bronchodilators; Phosphodiesterase PDE3 Inhibitors;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4; Phosphodiesterase 3 Inhibitor; Phosphodiesterase 3 inhibitor; Phosphodiesterase 4 inhibitor
CBR-001-571-062-0,RFM-000-094-2,CBR-001-571-062-0,Oc1cc(O)c2c(c1)oc(cc2=O)c1ccccc1,CBR-HVAC-05273: Cancer Multidrug Resistance Modulators;Oncolytic Drugs; Antiinflammatory Drugs;Antioxidants;Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors
CBR-001-571-063-1,RFM-000-095-3,CBR-001-571-063-1,CCOc1ccc(cn1)c1ccc(cc1)Cn1c(CC(C(=O)O)(C)C)c(c2c1ccc(c2)OCc1ccc(cn1)C)SC(C)(C)C,CBR-HVAC-00050: Cardiovascular Diseases (Not Specified);Asthma Therapy; 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors; 5-Lipoxygenase activating protein Inhibitor; Five lipoxygenase activating protein antagonist; Leucotriene synthesis inhibitor
CBR-001-571-064-2,RFM-000-096-4,CBR-001-571-064-2,OCC(C(C(C(CO)O)O)O)O,"CBR-HVAC-01295: Cerebrovascular Diseases, Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Cystic Fibrosis, Treatment of ;Diagnostic Agents;Diuretics;Antiglaucoma Agents;Treatment of Renal Diseases Mucolytic agent"
CBR-001-571-065-3,RFM-000-097-5,CBR-001-571-065-3,COc1cc(C(C)C)c2c(c1)S(=O)(=O)N(C2=O)COc1cc(=O)n2c(n1)c(OCCN1CCCCC1)ccc2,"CBR-HVAC-11479: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Acute Respiratory Distress Syndrome (ARDS), Agents for; Leukocyte Elastase Inhibitors; Elastase 2, neutrophil Inhibitor;"
CBR-001-571-066-4,RFM-000-098-6,CBR-001-571-066-4,NC(=O)Nc1c(oc2c1ccc(c2)OS(=O)(=O)C)C(=O)c1ccc(cc1Cl)Cl,"CBR-HVAC-05350: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy;Bronchodilators; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor;"
CBR-001-571-067-5,RFM-000-099-7,CBR-001-571-067-5,N#Cc1ccc(cc1)c1ccc2c(c1)cc(o2)CCN1CCC[C@H]1C,"CBR-HVAC-05915: Cognition Disorders, Treatment of; Histamine H3 Receptor Antagonists;Histamine H3 Receptor Inverse Agonists;Signal Transduction Modulators; Histamine H3 receptor Antagonist; Histamine H3 receptor antagonist"
CBR-001-571-068-6,RFM-000-100-3,CBR-001-571-068-6,O=C(c1ccc(cc1)F)NN1CCN(CC1)C(=O)C,"CBR-HVAC-04886: Cognition Disorders, Treatment of;Alzheimer's Dementia, Treatment of 5-Hydroxytryptamine receptor Inhibitor; 5 Hydroxytryptamine uptake stimulant; Somatostatin receptor agonist"
CBR-001-571-069-7,RFM-000-101-4,CBR-001-571-069-7,OC(=O)CCCNC(=O)c1cccnc1,"CBR-HVAC-03950: Cognition Disorders, Treatment of;Anxiolytics Potassium channel agonist; Chloride channel agonist"
CBR-001-571-070-0,RFM-000-102-5,CBR-001-571-070-0,CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C,"CBR-HVAC-06335: Colorectal Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Endocrine Cancer Therapy;Melanoma Therapy;Leukemia Therapy;Hematologic Agents (Miscellaneous);Female Reproductive System Cancer Therapy;Head and Neck Cancer Therapy;Breast Cancer Therapy;Liver Cancer Therapy;Cervical Cancer Therapy;Myeloid Leukemia Therapy;Rheumatoid Arthritis, Treatment of;Lymphocytic Leukemia Therapy;Multiple Myeloma Therapy;Non-Small Cell Lung Cancer Therapy;Cancer of Unspecified Body Location/System;Pancreatic Cancer Therapy;Ovarian Cancer Therapy; MEK1 Inhibitors;MEK2 Inhibitors;Signal Transduction Modulators; MEK1; MEK2; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 2 Inhibitor; Inhibitor; MEK inhibitor"
CBR-001-571-071-1,RFM-000-103-6,CBR-001-571-071-1,O=c1cc[nH]c(=O)[nH]1,"CBR-HVAC-02853: Dermatologic Drugs;Disorders Associated with Cancer Therapy, Treatment of"
CBR-001-571-072-2,RFM-000-104-7,CBR-001-571-072-2,Oc1ccc2c(c1)Oc1c(C32OC(=O)c2c3cccc2)ccc(c1)O,CBR-HVAC-06905: Diagnostic Agents;Diagnostic for Cancer
CBR-001-571-073-3,RFM-000-105-8,CBR-001-571-073-3,COc1nc(OC)nc(c1)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-09868: Dihydrofolate reductase Inhibitor;
CBR-001-571-074-4,RFM-000-106-9,CBR-001-571-074-4,Nc1ccc(cc1)S(=O)(=O)Nc1nccc(n1)C,CBR-HVAC-09663: Dihydropteroate synthase Inhibitor;
CBR-001-571-075-5,RFM-000-107-0,CBR-001-571-075-5,Nc1ccc(cc1)S(=O)(=O)Nc1noc(c1)C,CBR-HVAC-09666: Dihydropteroate synthase Inhibitor;
CBR-001-571-076-6,RFM-000-108-1,CBR-001-571-076-6,OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)n1cc(I)c(nc1=O)N,CBR-HVAC-00290: DNA polymerase Inhibitor; DNA synthesis inhibitor
CBR-001-571-077-7,RFM-000-109-2,CBR-001-571-077-7,CNCC(=O)c1ccc(c(c1)O)O,CBR-HVAC-10169: Dopamine beta-oxidase Inhibitor;
CBR-001-571-078-8,RFM-000-110-5,CBR-001-571-078-8,O=C(N1CCC(CC1)n1c(=O)[nH]c2c1cccn2)N[C@@H]1CC[C@H](CN(C1=O)CC(F)(F)F)c1cccc(c1F)F,"CBR-HVAC-00785: Endocrine Disorders (Not Specified);Antimigraine Drugs;Angina pectoris, Treatment of; Calcitonin Gene-Related Peptides (CGRP) Antagonists;Signal Transduction Modulators; Calcitonin gene related peptide receptor Antagonist; Calcitonin receptor-like receptor antagonist"
CBR-001-571-079-9,RFM-000-111-6,CBR-001-571-079-9,N#CC(c1nc2c(s1)cccc2)c1ccnc(n1)OCc1ccc(cc1)CN1CCOCC1,"CBR-HVAC-05924: Endometriosis Therapy;Cystic Fibrosis, Treatment of ;Multiple Sclerosis, Agents for; SAPK1 (JNK) Inhibitors;Signal Transduction ModulatorsJNK1 inhibitor; JNK2 inhibitor; JNK3 inhibitor"
CBR-001-571-080-2,RFM-000-112-7,CBR-001-571-080-2,O=C(Nc1ccc(c(c1)Cl)Cl)Nc1ccc(cc1)Cl,CBR-HVAC-09449: Epoxide hydrolase Inhibitor;
CBR-001-571-081-3,RFM-000-113-8,CBR-001-571-081-3,CCC[C@H]1CN(C(=O)C1)[C@H](C(=O)N)CC,"CBR-HVAC-00887: Extrapyramidal Disorders, Treatment of;Antiepileptic Drugs;Neuropathic Pain, Treatment of; Synaptic Vesicle Glycoprotein 2A (SV2A) Ligands; Synaptic vesicle glycoprotein 2A Inhibitor; Sodium channel antagonist; Sodium/calcium exchange inhibitor"
CBR-001-571-082-4,RFM-000-114-9,CBR-001-571-082-4,NNC(=O)c1ccncc1,CBR-HVAC-09606: GABA receptor; Fatty acid synthase subunit alpha; Amine oxidase Inhibitor;
CBR-001-571-083-5,RFM-000-115-0,CBR-001-571-083-5,CCCCCCCCC(=O)N[C@@H]([C@@H](c1ccc2c(c1)OCCO2)O)CN1CCCC1,CBR-HVAC-14166
CBR-001-571-084-6,RFM-000-116-1,CBR-001-571-084-6,CC(=O)Nc1ccc(cc1)C(=O)O,CBR-HVAC-09146: General control protein GCN4 Inhibitor;
CBR-001-571-085-7,RFM-000-117-2,CBR-001-571-085-7,CC(=O)Nc1nnc(s1)S(=O)(=O)N,"CBR-HVAC-03132: Heart Failure Therapy;Antiglaucoma Agents;Cardiovascular Genetic Disorders, Treatment of;Antiepileptic Drugs; Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VI Inhibitors;Carbonic Anhydrase Type XIII Inhibitors;Carbonic Anhydrase Type XIV Inhibitors; Carbonic anhydrase Inhibitor;"
CBR-001-571-086-8,RFM-000-118-3,CBR-001-571-086-8,CCOC(=O)[C@@H](C[C@@H](Cc1ccc(cc1)c1ccccc1)NC(=O)CCC(=O)O)C.CCCCC(=O)N([C@H](C(=O)O)C(C)C)Cc1ccc(cc1)c1ccccc1c1nnn[nH]1,"CBR-HVAC-06709 Heart Failure Therapy;Hypertension, Treatment of; Angiotensin AT1 Antagonists;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors;Signal Transduction Modulators; Neutral endopeptidase Inhibitor;"
CBR-001-571-087-9,RFM-000-119-4,CBR-001-571-087-9,[O-]S(=O)(=O)CCCS(=O)(=O)[O-],"CBR-HVAC-05439: Hematologic Agents (Miscellaneous);Amyloidosis, Treatment of;Type 2 Diabetes, Agents for; Antiamyloidogenic Agents"
CBR-001-571-088-0,RFM-000-120-7,CBR-001-571-088-0,NCCCCCC(=O)O,CBR-HVAC-02619: Hemostatics;Other Ocular MedicationsTissue plasminogen activator Inhibitor; Plasminogen activator inhibitor; Plasmin inhibitor
CBR-001-571-089-1,RFM-000-121-8,CBR-001-571-089-1,CC(OC(=O)C(=C1SC=CS1)C(=O)OC(C)C)C,CBR-HVAC-01545: Hepatoprotectants Protein synthesis stimulant
CBR-001-571-090-4,RFM-000-122-9,CBR-001-571-090-4,CCCN(CCc1ccc(c(c1)O)O)CCC,"CBR-HVAC-10008: Hypertension, Treatment of; Dopamine D2 Agonists;Signal Transduction Modulators; Dopamine receptor D2 Agonist;"
CBR-001-571-091-5,RFM-000-123-0,CBR-001-571-091-5,CCOC(=O)[C@@H](CC1(CCCC1)C(=O)N[C@H]1CCc2c(N(C1=O)CC(=O)O)cccc2)CCc1ccccc1,"CBR-HVAC-04882: Heart Failure Therapy;Diabetic Nephropathy, Agents for;Pulmonary Hypertension, Treatment of;Hypertension, Treatment of; Endothelin-Converting Enzyme (ECE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors;"
CBR-001-571-092-6,RFM-000-124-1,CBR-001-571-092-6,CCN(C(=S)[S-])CC,CBR-HVAC-02643: Immunomodulators Angiogenesis inhibitor
CBR-001-571-093-7,RFM-000-125-2,CBR-001-571-093-7,O=C(c1ccc(cc1)C(F)(F)F)NN1C(=O)[C@@H]2[C@H](C1=O)[C@@H]1C=C[C@H]2[C@@H]2[C@H]1C2,CBR-HVAC-00692: Immunostimulants;Antiviral Drugs; Orthopoxvirus Egress InhibitorsUnidentified pharmacological activity
CBR-001-571-094-8,RFM-000-126-3,CBR-001-571-094-8,Cl[Te-]1(Cl)(Cl)OCCO1,"CBR-HVAC-00686: Inflammatory Bowel Disease, Agents for;Immunomodulators;Age-Related Macular Degeneration, Treatment of;Antipsoriatics;Anti-Papilloma Virus Drugs;Chemopreventive Agents;Atopic Dermatitis, Agents for;Hair Growth Stimulants;Anti-Hepatitis C Virus Drugs;Coagulation Disorders Therapy; HCV NS3 Protease Inhibitors; AlphaVbeta3 integrin; Alpha4beta1 integrin; Reverse transcriptase Inhibitor; Antagonist; Antagonist; Alphavbeta3 integrin antagonist; Alpha4beta1 integrin antagonist; Interleukin 17 antagonist; Interleukin 1beta converting enzyme inhibitor; Interleukin 18 antagonist; Interleukin 17 receptor antagonist"
CBR-001-571-095-9,RFM-000-127-4,CBR-001-571-095-9,O=C(Nc1ccccc1C)Nc1ccc(cc1)CC(=O)N1CCOC[C@H]1C(=O)N1CCC(CC1)CC(=O)O,CBR-HVAC-11634: Integrin alpha4 beta1 Antagonist;
CBR-001-571-096-0,RFM-000-128-5,CBR-001-571-096-0,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)CO)Cl,"CBR-HVAC-02059: Interstitial Lung Diseases, Treatment of;Esophageal Diseases, Treatment of;Hypertension, Treatment of;Diabetic Nephropathy, Agents for;Stroke, Treatment of;Bone, Muscles and Connective Tissue Genetic Disorders, Treatment of;Heart Failure Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Treatment of Renal Diseases; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor Antagonist; Angiotensin II 1 antagonist"
CBR-001-571-097-1,RFM-000-129-6,CBR-001-571-097-1,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1n1cncc1,"CBR-HVAC-02718: Ischemic Stroke, Treatment of;Antiepileptic Drugs; AMPA Receptor Antagonists;Signal Transduction Modulators; AMPA receptor Antagonist; AMPA receptor antagonist"
CBR-001-571-098-2,RFM-000-130-9,CBR-001-571-098-2,C/C=C/C[C@H]([C@H]([C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)O)C,CBR-HVAC-14289
CBR-001-571-099-3,RFM-000-131-0,CBR-001-571-099-3,Clc1ccccc1C(n1cncc1)(c1ccccc1)c1ccccc1,CBR-HVAC-01746: Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-571-100-9,RFM-000-132-1,CBR-001-571-100-9,OC[C@H]1N[C@H]([C@@H]([C@@H]1O)O)c1c[nH]c2c1[nH]cnc2=O,CBR-HVAC-02762: Leukemia Therapy;Solid Tumors Therapy;Lymphocytic Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy;Antipsoriatics;Hematological Cancer Therapy; Purine-Nucleoside Phosphorylase Inhibitors; Purine nucleoside phosphorylase Inhibitor; Purine nucleoside phosphorylase inhibitor; Immunosuppressant
CBR-001-571-101-0,RFM-000-133-2,CBR-001-571-101-0,Clc1ccccc1c1ccccc1C(O)(C)C,analog of CBR-HVAC-07807
CBR-001-571-102-1,RFM-000-134-3,CBR-001-571-102-1,CO[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2NC1CCCCC1)CO,"CBR-HVAC-04077: Lipoprotein Disorders, Treatment of ;Analgesic Drugs;Hypertension, Treatment of;Antidiabetic Drugs; Adenosine A1 Agonists;Signal Transduction Modulators; Adenosine A1 receptor Agonist;"
CBR-001-571-103-2,RFM-000-135-4,CBR-001-571-103-2,COc1ccc(cc1C(=O)NCc1ccc(cc1)C(F)(F)F)CC1SC(=O)NC1=O,"CBR-HVAC-04895: Lipoprotein Disorders, Treatment of ;Type 2 Diabetes, Agents for; Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Thiazolidinedione; Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist; Insulin sensitizer; Peroxisome proliferator-activated receptor alpha/gamma agoni"
CBR-001-571-104-3,RFM-000-136-5,CBR-001-571-104-3,NCCc1c[nH]cn1,"CBR-HVAC-01282: Liver and Biliary Tract Disorders, Treatment of;Anti-Hepatitis C Virus Drugs;Migraine, Prophylactic Treatment of;Immunomodulators;Colorectal Cancer Therapy;Renal Cancer Therapy;Sarcoma Therapy;Melanoma Therapy;Prostate Cancer Therapy;Treatment of Mucositis;Myeloid Leukemia Therapy;Disorders Associated with Cancer Therapy, Treatment of;Diagnostic Agents; Histamine Receptor Agonists;NADPH Oxidase (NOX) Inhibitors;Signal Transduction Modulators; Histamine H1 receptor; Histamine H2 receptor Agonist; Histamine H2 receptor agonist"
CBR-001-571-105-4,RFM-000-137-6,CBR-001-571-105-4,CCCCOc1ccc(cc1)OCCCN1CCOCC1,CBR-HVAC-06391: Local AnestheticsSodium channel Antagonist;
CBR-001-571-106-5,RFM-000-138-7,CBR-001-571-106-5,CCC1(OCCc2c1[nH]c1c2cccc1CC)CC(=O)O,CBR-HVAC-02473: Lymphocytic Leukemia Therapy; Apoptosis Inducers; Prostaglandin G/H synthase Inhibitor; Mcl-1 antagonist; Cyclooxygenase 2 inhibitor
CBR-001-571-107-6,RFM-000-139-8,CBR-001-571-107-6,OCC(CO)(CO)N,"CBR-HVAC-06758: Metabolic Disorders (Not Specified);Disorders of Ventilation, Treatment of"
CBR-001-571-108-7,RFM-000-140-1,CBR-001-571-108-7,O=c1[nH]c2c([nH]1)[nH]c(=O)[nH]c2=O,"CBR-HVAC-05616: Multiple Sclerosis, Agents for"
CBR-001-571-109-8,RFM-000-141-2,CBR-001-571-109-8,CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)C(=O)Nc1cnc(c(c1)Nc1nccc(n1)c1cccnc1)C,CBR-HVAC-07038: Myeloid Leukemia Therapy; Abl1 Kinase Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Signal Transduction Modulators
CBR-001-571-110-1,RFM-000-142-3,CBR-001-571-110-1,C1CN=C(N1)COc1ccccc1C1CC1,CBR-HVAC-07646: Nasal Decongestants Alpha 1 adrenoreceptor agonist; Alpha 2 adrenoreceptor agonist
CBR-001-571-111-2,RFM-000-143-4,CBR-001-571-111-2,COc1cc(N)c(cc1C(=O)NC1CN2CCC1CC2)Cl,"CBR-HVAC-03397: Prokinetic Agents;Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-571-112-3,RFM-000-144-5,CBR-001-571-112-3,CN1CCN(CC1)c1ncc(c(c1)c1ccccc1C)N(C(=O)C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)C,"CBR-HVAC-06075: Nausea and Vomiting, Treatment of;Urinary Incontinence Therapy; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators;Tachykinin NK1 Antagonists; NEUROKININ RECEPTOR 1 Antagonist;"
CBR-001-571-113-4,RFM-000-145-6,CBR-001-571-113-4,Cn1ccc(=O)c(c1C)O,"CBR-HVAC-01485: Neurodegenerative Diseases, Treatment of;Treatment of Renal Diseases;Antagonists to Metals;Anti-HIV Agents;Hematopoiesis Disorders Therapy;Neurologic Drugs (Miscellaneous);Motor Function Disorders, Treatment of; Chelating Agents;Cytochrome P450 CYP4F2 Inhibitors; Lipoxygenase 5 Inhibitor; Chelating agent; Iron absorption inhibitor; Reducing agent"
CBR-001-571-114-5,RFM-000-146-7,CBR-001-571-114-5,OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CS)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)C)Cc1nc[nH]c1,"CBR-HVAC-05302: Neurologic Cancer Therapy;Oncolytic Drugs;Renal Cancer Therapy;Inflammatory Bowel Disease, Agents for; Angiogenesis Inhibitors;Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha5beta1 (VLA-5) Antagonists;Signal Transduction Modulators; Integrin alpha5 beta1; Integrin alpha5 beta3 Antagonist;"
CBR-001-571-115-6,RFM-000-147-8,CBR-001-571-115-6,COc1ccc(cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)Cl,"CBR-HVAC-02591: Neurologic Drugs (Miscellaneous);Antiplatelet Therapy;Lesions of the Spinal Cord and Related Structures, Treatment of;Ischemic Stroke, Treatment of;Antidiabetic Drugs;Type 1 Diabetes, Agents for;Type 2 Diabetes, Agents for; K(ATP) Channel Blockers;K(ir) 6.2/SUR1 Blockers;TRPA1 Agonists; Potassium channel Blocker; ATP-sensitive potassium channel antagonist"
CBR-001-571-116-7,RFM-000-148-9,CBR-001-571-116-7,CCN(CC(=O)Nc1c(C)cccc1C)CC,"CBR-HVAC-00083: Neuropathic Pain, Treatment of;Asthma Therapy;Antiarrhythmic Drugs;Analgesic Drugs;Anesthetic Drugs;Ophthalmic Drugs;Urologic Drugs;Local Anesthetics;Antimigraine Drugs; Drugs Acting on Sodium Channels (Voltage-Gated); Sodium channel Blocker; Potassium channel antagonist; Membrane integrity inhibitor; Voltage-gated sodium channel antagonist"
CBR-001-571-117-8,RFM-000-149-0,CBR-001-571-117-8,C[N+](CCCCCC[N+](C)(C)C)(C)C,CBR-HVAC-02824: Nicotinic cholinergic receptor Antagonist; Interferon receptor agonist
CBR-001-571-118-9,RFM-000-150-3,CBR-001-571-118-9,O=c1cc[nH]c(=S)[nH]1,"CBR-HVAC-09234: Nitic acid synthase, neuronal; Tyrosinase Inhibitor;"
CBR-001-571-119-0,RFM-000-151-4,CBR-001-571-119-0,CCNC(=O)Nc1ccc(cc1)c1nc2CN(CCc2c(n1)N1CCOC[C@@H]1C)C1COC1,CBR-HVAC-07162: Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy; Pim-3 Kinase Inhibitors;Signal Transduction Modulators; mTOR Inhibitor;
CBR-001-571-120-3,RFM-000-152-5,CBR-001-571-120-3,Brc1cccc(c1)c1cc(nc2c1c(N)ncn2)c1ccc(nc1)N1CCOCC1,CBR-HVAC-11101: Non-Opioid Analgesics;Antiarthritic Drugs; Adenosine Kinase Inhibitors; Adenosine kinase Inhibitor;
CBR-001-571-121-4,RFM-000-153-6,CBR-001-571-121-4,CNCCCC1(SC(c2c1cccc2)(C)C)c1ccccc1,CBR-HVAC-08909: Norepinephrine transporter Inhibitor;
CBR-001-571-122-5,RFM-000-154-7,CBR-001-571-122-5,Nc1nc(OCc2ccccc2)c2c(n1)[nH]cn2,CBR-HVAC-00402: O6-Alkylguanine-DNA alkyltransferase Inhibitor; DNA inhibitor
CBR-001-571-123-6,RFM-000-155-8,CBR-001-571-123-6,NCCS,"CBR-HVAC-06860: Ocular Genetic Disorders, Treatment of ; Tissue Transglutaminase (TGM2) InhibitorsCystine antagonist"
CBR-001-571-124-7,RFM-000-156-9,CBR-001-571-124-7,CCCN(c1ccc(cc1)/N=N/c1ccccc1C(=O)O)CCC,analog of CBR-HVAC-05863
CBR-001-571-125-8,RFM-000-157-0,CBR-001-571-125-8,CN(CCNC(=O)COc1c2cccc1Cc1cccc(c1OCC(=O)NCCN(C)C)Cc1c(c(Cc3c(c(C2)ccc3)OCC(=O)NCCN(C)C)ccc1)OCC(=O)NCCN(C)C)C,CBR-HVAC-06181: Oncolytic Drugs;Solid Tumors Therapy; Angiogenesis Inhibitors;Apoptosis Inducers
CBR-001-571-126-9,RFM-000-158-1,CBR-001-571-126-9,O=C1O[Sb]2OC1C(O[Sb]1OC(=O)C(C(O2)C(=O)O)O1)C(=O)O,CBR-HVAC-07232: Oncolytic Drugs;Treatment of Helminthic Diseases;Antileishmanials; Apoptosis Inducers
CBR-001-571-127-0,RFM-000-159-2,CBR-001-571-127-0,CC(=O)NCCCCCCNC(=O)C,CBR-HVAC-03401: Oncolytic DrugsDNA topoisomerase I Inhibitor; Unidentified pharmacological activity
CBR-001-571-128-1,RFM-000-160-5,CBR-001-571-128-1,COc1cc(cc(c1O)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@@H](c2c1cc1OCOc1c2)O,CBR-HVAC-14248
CBR-001-571-129-2,RFM-000-161-6,CBR-001-571-129-2,OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,"CBR-HVAC-03400: Osteoarthritis, Treatment of;Antiarthritic Drugs;Analgesic Drugs;Rheumatoid Arthritis, Treatment of;Ankylosing Spondylitis, Treatment ofProstaglandin G/H synthase 2 Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor"
CBR-001-571-130-5,RFM-000-162-7,CBR-001-571-130-5,C=CCN1C[C@H](C)N(C[C@H]1C)[C@@H](c1cccc(c1)OC)c1ccc(cc1)C(=O)N(CC)CC,CBR-HVAC-14231
CBR-001-571-131-6,RFM-000-163-8,CBR-001-571-131-6,Oc1cc(cc(c1O)S(=O)(=O)O)S(=O)(=O)O,CBR-HVAC-10131: Phosvitin kinase I Inhibitor;
CBR-001-571-132-7,RFM-000-164-9,CBR-001-571-132-7,CC(C(Cl)(Cl)Cl)(O)C,CBR-HVAC-09965: Potassium channel hERG Blocker;
CBR-001-571-133-8,RFM-000-165-0,CBR-001-571-133-8,OC(=O)CC[C@@H]1NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](C)NC(=O)[C@H]4N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)O)CSSC[C@H](NC(=O)CNC(=O)C(NC3=O)[C@H](O)C)C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)O)CSSC[C@@H](C(=O)N2)N)CC(=O)N)CCC4,CBR-HVAC-14261
CBR-001-571-134-9,RFM-000-166-1,CBR-001-571-134-9,CCCCN1CCC(CC1)COC(=O)c1cc(Cl)c(c2c1OCCO2)N,CBR-HVAC-14234
CBR-001-571-135-0,RFM-000-167-2,CBR-001-571-135-0,OC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,CBR-HVAC-09825: Prostaglandin G/H synthase Inhibitor;
CBR-001-571-136-1,RFM-000-168-3,CBR-001-571-136-1,O=C(NS(=O)(=O)C)COCCCCN(c1cnc(c(n1)c1ccccc1)c1ccccc1)C(C)C,"CBR-HVAC-05831: Pulmonary Hypertension, Treatment of;Raynaud's Phenomenon, Treatment for ;Antiplatelet Therapy;Atherosclerosis Therapy; Prostanoid IP Agonists;Signal Transduction Modulators; Prostacyclin receptor Agonist;"
CBR-001-571-137-2,RFM-000-169-4,CBR-001-571-137-2,OC(=O)CCc1cc(ccc1OCc1ccc2c(c1)onc2O)C(=O)c1ccc(cc1O)OC1CCCC1,"CBR-HVAC-00634: Rheumatoid Arthritis, Treatment of; AP-1 Inhibitors;Signal Transduction Modulators; Activator protein 1 Inhibitor; Transcription factor AP-1 inhibitor"
CBR-001-571-138-3,RFM-000-170-7,CBR-001-571-138-3,OC(=O)CC(C(=O)O)S,"Ligand for CBR-HVAC-05176 (Aurothiomalate), probably not interesting on its own."
CBR-001-571-139-4,RFM-000-171-8,CBR-001-571-139-4,CCOc1ccc(cc1)c1nn2c(c1c1ccc(cc1)S(=O)(=O)C)cccn2,"CBR-HVAC-05174: Rheumatoid Arthritis, Treatment of;Osteoarthritis, Treatment of;Antimigraine Drugs;Non-Opioid Analgesics;Neuropathic Pain, Treatment of; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-571-140-7,RFM-000-172-9,CBR-001-571-140-7,Clc1ccc2c(c1)c1=NCCn1c1n2cnc1c1noc(n1)C1CC1,CBR-HVAC-10899: Sedative/HypnoticsGABA-A receptor Agonist;
CBR-001-571-141-8,RFM-000-173-0,CBR-001-571-141-8,CCC1(O)CC(=O)OCc2c1cc1c3nc4ccccc4cc3Cn1c2=O,CBR-HVAC-14301: DNA topoisomerase I inhibitor; Multidrug resistance protein (MRP) inhibitor
CBR-001-571-142-9,RFM-000-174-1,CBR-001-571-142-9,COC1(COc2c(O1)cccc2)C1=NCCN1,"CBR-HVAC-03353: Antidepressants;Stroke, Treatment of; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha 2 adrenoreceptor antagonist"
CBR-001-571-143-0,RFM-000-175-2,CBR-001-571-143-0,CCC1(Cc2c(O1)cccc2)C1=NCCN1,"CBR-HVAC-03790: Stroke, Treatment of; alpha2-Adrenoceptor Antagonists;Signal Transduction ModulatorsAlpha 2 adrenoreceptor antagonist; Acetylcholine release stimulant"
CBR-001-571-144-1,RFM-000-176-3,CBR-001-571-144-1,CCN(C(=O)c1c(O)c2c(Cl)cccc2n(c1=O)C)c1ccccc1,"CBR-HVAC-00888: Systemic Lupus Erythematosus, Agents for;Multiple Sclerosis, Agents for;Huntington's Disease, Treatment of;Immunomodulators;Nephritis, Agents for;Irritable Bowel Syndrome, Agents for Immunosuppressant"
CBR-001-571-145-2,RFM-000-177-4,CBR-001-571-145-2,COc1cc(ccc1C(=O)N1CCC(CC1)N1C(=O)OCc2c1cccc2)OC1CCN(CC1)C(=O)C,CBR-HVAC-11213: Tocolytics; Oxytocin (OT) Antagonists;Signal Transduction Modulators; Oxytocin receptor Antagonist;
CBR-001-571-146-3,RFM-000-178-5,CBR-001-571-146-3,CN1CCc2c([C@@H]3[C@@H]1CCc1c3cccc1)cc(c(c2)Cl)O,"CBR-HVAC-00282: Treatment of Alcohol Dependency;Treatment of Cocaine Dependency;Tourette's Syndrome, Treatment of;Psychiatric Disorders (Not Specified);Mood Disorders, Treatment of;Antiobesity Drugs;Multisystem Genetic Disorders, Treatment of ; Dopamine D1 Antagonists;Dopamine D5 Antagonists;Signal Transduction Modulators; Dopamine receptor D1; Dopamine receptor D5 Antagonist; Dopamine D1 receptor antagonist; Dopamine D5 receptor antagonist"
CBR-001-571-147-4,RFM-000-179-6,CBR-001-571-147-4,n1nnc([nH]1)c1n[nH]c2c1CCC2,"CBR-HVAC-06305: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Lipoprotein Disorders, Treatment of ; Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Partial Agonists;Signal Transduction Modulators; ;"
CBR-001-571-148-5,RFM-000-180-9,CBR-001-571-148-5,CSc1nc2c([nH]1)cc(c(c2)Cl)Oc1cccc(c1Cl)Cl,CBR-HVAC-01866: Treatment of Helminthic Diseases; DNA Methyltransferase 1 (DNMT1) Inhibitors; Beta tubulin Inhibitor; Microtubule inhibitor; Acetylcholinesterase inhibitor
CBR-001-571-149-6,RFM-000-181-0,CBR-001-571-149-6,c1scc(n1)c1nc2c([nH]1)cccc2,CBR-HVAC-05218: Treatment of Helminthic Diseases;Oncolytic DrugsMitochondrial fumarate reductase Inhibitor;
CBR-001-571-150-9,RFM-000-182-1,CBR-001-571-150-9,COc1ccc2c(c1)CCN1[C@H]2C[C@H]2[C@@H](C1)CCCN2S(=O)(=O)CC,CBR-HVAC-14222
CBR-001-571-151-0,RFM-000-183-2,CBR-001-571-151-0,O=C(c1ccc(cc1)F)NP(=O)(N)N,"CBR-HVAC-07838: Treatment of Renal Diseases;Lipoprotein Disorders, Treatment of  Urease inhibitor"
CBR-001-571-152-1,RFM-000-184-3,CBR-001-571-152-1,CCCc1cc(ccn1)C(=S)N,CBR-HVAC-05742: Treatment of Tuberculosis
CBR-001-571-153-2,RFM-000-185-4,CBR-001-571-153-2,Fc1ccc(c(c1)[C@H]1OC[C@@H](C[C@@H]1N)N1Cc2c(C1)cn(n2)S(=O)(=O)C)F,"CBR-HVAC-00890: Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor; Dipeptidyl peptidase 4 (DPP IV) inhibitor"
CBR-001-571-154-3,RFM-000-186-5,CBR-001-571-154-3,O=C(C(c1ccc(cc1)S(=O)(=O)C)CC1CCCC1)Nc1nccs1,"CBR-HVAC-05522: Type 2 Diabetes, Agents for; Glucokinase Activators;Glucose Lowering Agents; Glucokinase Activator; Hexokinase stimulant"
CBR-001-571-155-4,RFM-000-187-6,CBR-001-571-155-4,CCc1cnc(nc1)N1CCC(CC1)c1scc(n1)COc1ccc(cc1)n1cnnn1,"CBR-HVAC-06741: Type 2 Diabetes, Agents for; Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119)  Agonists;Signal Transduction Modulators; G protein-coupled receptor 119 Agonist;"
CBR-001-571-156-5,RFM-000-188-7,CBR-001-571-156-5,Clc1ccc(c(c1)Cl)S(=O)(=O)Nc1cc(Cl)c(c(c1)Cl)Oc1cnc2c(c1)cccc2,"CBR-HVAC-00756: Type 2 Diabetes, Agents for; Insulin Sensitizers;PPARgamma Partial Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor gamma Agonist; Peroxisome proliferator-activated receptor gamma agonist; Insulin sensitizer"
CBR-001-571-157-6,RFM-000-189-8,CBR-001-571-157-6,CC1(CC1)NC1=NS(=O)(=O)c2c(N1)cc(s2)Cl,"CBR-HVAC-02703: Type 2 Diabetes, Agents for;Type 1 Diabetes, Agents for; Apoptosis Inhibitors;K(ir) 6.2/SUR1 Activators; Kir6.2-SUR1 channel Opener; ATP-sensitive potassium channel agonist"
CBR-001-571-158-7,RFM-000-190-1,CBR-001-571-158-7,CN(CC#CCCC(=O)C(c1ccccc1)(C1CCC1)O)C,CBR-HVAC-04250: Urinary Incontinence Therapy
CBR-001-571-159-8,RFM-000-191-2,CBR-001-571-159-8,O=c1[nH]cnc2c1cn[nH]2,"CBR-HVAC-05481: Urolithiasis, Agents for;Treatment of Gout;Diabetic Nephropathy, Agents for;Heart Failure Therapy;Unidentified Activity;Uricosurics; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Xanthine Oxidase Inhibitors"
CBR-001-571-160-1,RFM-000-192-3,CBR-001-571-160-1,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,"CBR-HVAC-01266: Neuropathic Pain, Treatment of;Dry Eye Syndrome, Treatment for;Osteoarthritis, Treatment of;Analgesic Drugs;Migraine, Prophylactic Treatment of; TRPV1 (Vanilloid VR1 Receptor) Agonists; Capsaicin receptor Agonist; Vanilloid receptor 1 agonist"
CBR-001-571-168-9,RFM-000-193-4,CBR-001-571-168-9,CC1CC(OC(=O)C(c2ccccc2)O)CC(C1)(C)C,CBR-HVAC-00995:  Calcium channel antagonist;
CBR-001-571-169-0,RFM-000-194-5,CBR-001-571-169-0,COc1cc(ccc1Nc1c2ccccc2nc2c1cccc2)NS(=O)(=O)C,CBR-HVAC-01367: Oncolytic Drugs; DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; Topoisomerase II Inhibitor; DNA topoisomerase II inhibitor;
CBR-001-571-170-3,RFM-000-195-6,CBR-001-571-170-3,[O-]S(=O)(=O)c1c2ccc(cc2ccc1C(C)(C)C)C(C)(C)C,CBR-HVAC-09094:
CBR-001-571-171-4,RFM-000-196-7,CBR-001-571-171-4,Clc1cc(NCc2cccs2)c(cc1S(=O)(=O)N)c1nnn[nH]1,CBR-HVAC-01913: Diuretics;  Na-K-Cl cotransporter Blocker; Electrolyte reabsorption inhibitor; Diuretic;
CBR-001-571-172-5,RFM-000-197-8,CBR-001-571-172-5,O=C(Cc1c(Cl)cccc1Cl)NC(=N)N,CBR-HVAC-02436:  Alpha-2A adrenergic receptor Agonist; Alpha 2 adrenoreceptor agonist;
CBR-001-571-173-6,RFM-000-198-9,CBR-001-571-173-6,CCCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@H]1N(C[C@H]2[C@@H]1C2(C)C)C(=O)[C@H](C(C)(C)C)NC(=O)NC1(CCCCC1)CS(=O)(=O)C(C)(C)C,CBR-HVAC-00701: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors; NS 3 protease Inhibitor; HCV nonstructural protein 3 inhibitor; Serine protease inhibitor;
CBR-001-571-174-7,RFM-000-199-0,CBR-001-571-174-7,O=C(N1CSCC1)[C@H]1NC[C@H](C1)N1CCN(CC1)c1cc(nn1c1ccccc1)C,"CBR-HVAC-02197: Type 2 Diabetes, Agents for;Antiobesity Drugs; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; DIPEPTIDYL PEPTIDASE 4 Inhibitor; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue;"
CBR-001-571-175-8,RFM-000-200-6,CBR-001-571-175-8,OCC(CCn1cnc2c1nc(N)[nH]c2=O)CO,CBR-HVAC-01901
CBR-001-571-176-9,RFM-000-201-7,CBR-001-571-176-9,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@H]1CCCCCc1c(O2)nc2cc(OC)ccc2n1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,CBR-HVAC-14298
CBR-001-571-177-0,RFM-000-202-8,CBR-001-571-177-0,NCC(c1ccc(cc1)Cl)CC(=O)O,"CBR-HVAC-00062: Gastroesophageal Reflux Disease, Agents for;Gastric Emptying Disorders,Treatment of;Antispastic Drugs;Non-Ulcer Dyspepsia, Agents for;Mental Retardation, Treatment of;Antispastic Drugs and Drugs for Muscle Spasms;Autism, Treatment of; GABA(B) Positive Allosteric Modulators;GABA(B) Receptor Agonists;Signal Transduction Modulators; GABA B receptor Agonist; GABA B receptor agonist;"
CBR-001-571-178-1,RFM-000-203-9,CBR-001-571-178-1,O=c1[nH][nH]c2c3c1cccc3nc(n2)CN1Cc2c(C1)cccc2,CBR-HVAC-07217: Solid Tumors Therapy;Hematological Cancer Therapy;Antineoplastic Enhancing Agents; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors;Signal Transduction Modulators; ;
CBR-001-571-179-2,RFM-000-204-0,CBR-001-571-179-2,NC(=O)C(c1ccccc1)(c1ccccc1)CCn1ccnc1C,CBR-HVAC-01617: Urinary Incontinence Therapy; Muscarinic M1 Antagonists;Muscarinic M3 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M3 Antagonist; Muscarinic M1 receptor antagonist; Muscarinic M3 receptor antagonist;
CBR-001-571-180-5,RFM-000-205-1,CBR-001-571-180-5,ClCC(=O)Nc1sc2c(c1C#N)CCCCC2,CBR-HVAC-11879:  Thyrotropin releasing hormone receptor Agonist;
CBR-001-571-181-6,RFM-000-206-2,CBR-001-571-181-6,CNC(=O)Oc1cccc2c1cccc2,CBR-HVAC-09553:  Acetylcholinesterase Inhibitor;
CBR-001-571-182-7,RFM-000-207-3,CBR-001-571-182-7,OC(=O)Cn1c(=O)n(C)c2c(c1=O)n(C)cn2,CBR-HVAC-08723:
CBR-001-571-183-8,RFM-000-208-4,CBR-001-571-183-8,NC(=O)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08701:
CBR-001-571-184-9,RFM-000-209-5,CBR-001-571-184-9,OC(=O)c1cc(N=Nc2ccc(cc2)S(=O)(=O)Nc2ccccn2)ccc1O,"CBR-HVAC-01400: Inflammatory Bowel Disease, Agents for;Antidiarrheal Agents;Rheumatoid Arthritis, Treatment of; NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; Lipoxygenase 5 Inhibitor; Disease modifying antirheumatic drug; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor; Lipoxygenase inhibitor; TP receptor antagonist;"
CBR-001-571-185-0,RFM-000-210-8,CBR-001-571-185-0,Nc1nnc(c(n1)N)c1cccc(c1Cl)Cl,"CBR-HVAC-01461: Bipolar Disorder, Treatment of;Treatment of Eating Disorders;Antipsychotic Drugs;Multiple Sclerosis, Agents for;Antiepileptic Drugs;Neuropathic Pain, Treatment of; Glutamate Release Inhibitors;Signal Transduction Modulators;Sodium Channel  Blockers; Sodium channel Blocker; Voltage-gated sodium channel antagonist;"
CBR-001-571-186-1,RFM-000-211-9,CBR-001-571-186-1,C[n+]1cccc(c1)OC(=O)N(C)C,"CBR-HVAC-05299: Myasthenia Gravis, Agents for;Constipation, Agents for; Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Inhibitor;"
CBR-001-571-187-2,RFM-000-212-0,CBR-001-571-187-2,CCCCN(CC(c1cc(Cl)cc2c1c1ccc(cc1C2=Cc1ccc(cc1)Cl)Cl)O)CCCC,CBR-HVAC-05083: Antimalarials;
CBR-001-571-188-3,RFM-000-213-1,CBR-001-571-188-3,c1ccc(cc1)CCNc1scc(n1)c1ccccc1,CBR-HVAC-07811:  Immunosuppressant;
CBR-001-571-189-4,RFM-000-214-2,CBR-001-571-189-4,OC(=O)c1cc(nc2c1cccc2)c1ccccc1,CBR-HVAC-09764:
CBR-001-571-190-7,RFM-000-215-3,CBR-001-571-190-7,O=C1NC(=O)NC1(c1ccccc1)c1ccccc1,"CBR-HVAC-03130: Calcium channel antagonist; IKr potassium channel; Potassium channel antagonist; Sodium Channel Blockers; Sodium channel Inhibitor; Sodium channel antagonist; Antiarrhythmic; Antiarrhythmic Drugs; Anticonvulsant; Antiepileptic Drugs; Antineuralgic; Neuropathic Pain, Treatment of; Neuropathy, Treatment of"
CBR-001-571-191-8,RFM-000-216-4,CBR-001-571-191-8,OCCn1c(C)ncc1[N+](=O)[O-],"CBR-HVAC-02294: Cytochrome P450 CYP1A2 Inhibitors; The 5-nitro group of metronidazole undergoes reductive trasnformation to an active intermediate which then exerts an inhibitory or lethal effect against DNA. The reduced metabolite also causes loss of the helical structure of the DNA with subsequent DNA strand breakage.; Acne Therapy; Antiamebics; Antibacterial; Antibacterial Drugs; Antibacterial Ophthalmic Drugs; Antibiotics; Antifungal Agents; Antiprotozoal; Antitrichomonals; Dermatologic Drugs; Gastrointestinal Disorders (Not Specified); Inflammatory Bowel Disease, Agents for; Treatment of Protozoal Diseases; Treatment of Tuberculosis"
CBR-001-571-192-9,RFM-000-217-5,CBR-001-571-192-9,CCCCOC(=O)c1ccc(cc1)N,CBR-HVAC-02821:  Calcium channel T-type Inhibitor; Sodium channel antagonist;
CBR-001-571-193-0,RFM-000-218-6,CBR-001-571-193-0,OC(=O)CCC(=O)O,CBR-HVAC-02390:  Gastrin stimulant;
CBR-001-571-194-1,RFM-000-219-7,CBR-001-571-194-1,OC(=O)COc1ccc(cc1)Cl,CBR-HVAC-08039:  Unidentified pharmacological activity;
CBR-001-571-195-2,RFM-000-220-0,CBR-001-571-195-2,CC(=O)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-09862:  Carbonic anhydrase Inhibitor;
CBR-001-571-196-3,RFM-000-221-1,CBR-001-571-196-3,NC(C(=O)O)CS,CBR-HVAC-07701:  Reducing agent;
CBR-001-571-197-4,RFM-000-222-2,CBR-001-571-197-4,Ic1cc(I)c2c(c1O)nccc2,CBR-HVAC-05215: Antiamebics;  Catechol-O-methyltransferase Inhibitor;
CBR-001-571-198-5,RFM-000-223-3,CBR-001-571-198-5,Ic1cc(I)c(c(c1)I)O,CBR-HVAC-04767: Antiarthritic Drugs; Cyclooxygenase (COX) Inhibitors;Leukotriene Synthesis Inhibitors;Lipoxygenase Inhibitors;Signal Transduction Modulators;  5 Lipoxygenase inhibitor; L-selectin antagonist;
CBR-001-571-199-6,RFM-000-224-4,CBR-001-571-199-6,CCN(C(=S)SSC(=S)N(CC)CC)CC,CBR-HVAC-03119: Treatment of Alcohol Dependency;Treatment of Cocaine Dependency;Melanoma Therapy;Anticataract Agents;Prostate Cancer Therapy;Glioblastoma Multiforme Therapy;Solid Tumors Therapy; Aldehyde Dehydrogenase-2 (ALDH2) Inhibitors;DNA Methyltransferase 1 (DNMT1) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;TRPA1 Agonists; Aldehyde dehydrogenase Inhibitor;
CBR-001-571-200-2,RFM-000-225-5,CBR-001-571-200-2,CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC,analog of CBR-HVAC-10248
CBR-001-571-201-3,RFM-000-226-6,CBR-001-571-201-3,CNCCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F,CBR-HVAC-00938:  5-Hydroxytryptamine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor; 5 Hydroxytryptamine 2C receptor antagonist;
CBR-001-571-202-4,RFM-000-227-7,CBR-001-571-202-4,SCC(=O)Nc1ccccc1,CBR-HVAC-10334:
CBR-001-571-203-5,RFM-000-228-8,CBR-001-571-203-5,Oc1ccc2c(c1)oc(=O)s2,CBR-HVAC-10100:  Carbonic anhydrase II Inhibitor;
CBR-001-571-204-6,RFM-000-229-9,CBR-001-571-204-6,COc1ccc(c(c1)C(C)(C)C)O,CBR-HVAC-09718:  Prostaglandin G/H synthase Inhibitor;
CBR-001-571-205-7,RFM-000-230-2,CBR-001-571-205-7,OCCn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-06087: Bronchodilators;Oncolytic Drugs;Antiepileptic Drugs; Adenosine A1 Antagonists;Signal Transduction Modulators; Adenosine receptor Antagonist;
CBR-001-571-206-8,RFM-000-231-3,CBR-001-571-206-8,CN1C(=O)CCS(=O)(=O)C1c1ccc(cc1)Cl,CBR-HVAC-03103: Anxiolytics;  Benzodiazepine receptor Agonist;
CBR-001-571-207-9,RFM-000-232-4,CBR-001-571-207-9,OC(=O)C1CSCN1,CBR-HVAC-05532: Hepatoprotectants;Oncolytic Drugs;
CBR-001-571-208-0,RFM-000-233-5,CBR-001-571-208-0,NC(=O)CCC(C(=O)O)N,CBR-HVAC-02573:  Glucagon-like peptide 1 agonist;
CBR-001-571-209-1,RFM-000-234-6,CBR-001-571-209-1,O=c1[nH]c(=O)n(cc1F)C1CCCO1,CBR-HVAC-01361: Thymidylate synthase Inhibitor; Thymidylate synthase inhibitor; Orotate phosphoribosyltransferase inhibitor; DNA synthesis inhibitor; Dihydropyrimidine dehydrogenase inhibitor
CBR-001-571-210-4,RFM-000-235-7,CBR-001-571-210-4,NC(C(S)(C)C)C(=O)O,"CBR-HVAC-01246: Treatment of Renal Diseases;Rheumatoid Arthritis, Treatment of;Wilson Disease, Agent for;  Collagenase Inhibitor; Disease modifying antirheumatic drug; Chelating agent; Metallic radical formation inhibitor;"
CBR-001-571-211-5,RFM-000-236-8,CBR-001-571-211-5,OC(=O)CCc1nc(c(o1)c1ccccc1)c1ccccc1,CBR-HVAC-01949:  Prostaglandin H synthase; Prostaglandin G synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor;
CBR-001-571-212-6,RFM-000-237-9,CBR-001-571-212-6,CNCCc1ccccn1,"CBR-HVAC-02572: Antidepressants;Multisystem Genetic Disorders, Treatment of ;Antipsychotic Drugs;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Ear disorders, treatment of;Antiobesity Drugs; Histamine H1 Receptor Agonists;Histamine H3 Receptor Antagonists;MAO-A Inhibitors;MAO-B Inhibitors;Signal Transduction Modulators; Histamine H3 receptor Inhibitor; Histamine receptor agonist;"
CBR-001-571-213-7,RFM-000-238-0,CBR-001-571-213-7,Nc1ccc(cc1)S(=O)(=O)N=C(N)N,CBR-HVAC-10041:
CBR-001-571-214-8,RFM-000-239-1,CBR-001-571-214-8,CC(=O)OCC[N+](C)(C)C,CBR-HVAC-09532:  Nicotinic acetylcholine receptor Inhibitor;
CBR-001-571-215-9,RFM-000-240-4,CBR-001-571-215-9,OC(=O)c1ccccc1Nc1c(Cl)ccc(c1Cl)C,"CBR-HVAC-02317: Rheumatoid Arthritis, Treatment of;Osteoarthritis, Treatment of;Non-Opioid Analgesics;  15-Lipoxygenase; Prostaglandin synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin receptor antagonist;"
CBR-001-571-216-0,RFM-000-241-5,CBR-001-571-216-0,ClCCN(C(COc1ccccc1)C)Cc1ccccc1,"CBR-HVAC-05255: Hypertension, Treatment of;  Alpha adrenergic receptor Antagonist;"
CBR-001-571-217-1,RFM-000-242-6,CBR-001-571-217-1,Fc1ccc(c(c1)F)C(Cn1cncn1)(Cn1cncn1)O,CBR-HVAC-01958: Antifungal Agents;Treatment of AIDS-Associated Disorders; Cytochrome P450 Inhibitors; Lanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor; Sterol demethylase inhibitor;
CBR-001-571-218-2,RFM-000-243-7,CBR-001-571-218-2,CCCN(S(=O)(=O)c1ccc(cc1)C(=O)O)CCC,CBR-HVAC-05233: Treatment of Gout;Uricosurics;Heart Failure Therapy; MRP-1 Inhibitors;TRPV2 (Vanilloid VR2 Receptor) Agonists; Multidrug resistance associated protein 2 Inhibitor;
CBR-001-571-219-3,RFM-000-244-8,CBR-001-571-219-3,N#CC(c1ccc(c(c1)Oc1ccccc1)F)OC(=O)C1C(C1(C)C)C=C(Cl)Cl,CBR-HVAC-10055:
CBR-001-571-220-6,RFM-000-245-9,CBR-001-571-220-6,O=C(c1ccccc1)OCCn1c(C)ncc1[N+](=O)[O-],CBR-HVAC-09379:
CBR-001-571-221-7,RFM-000-246-0,CBR-001-571-221-7,OP(=O)(C(P(=O)(O)O)(Cc1cccnc1)O)O,"CBR-HVAC-01314: Treatment of Osteoporosis;Bone Diseases, Treatment of;Treatment of Paget's Disease; Farnesyl Pyrophosphate Synthase Inhibitors;  Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor; Osteoblast stimulant;"
CBR-001-571-222-8,RFM-000-247-1,CBR-001-571-222-8,COC(=O)C1=C(C#N)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC(C)C)C,"CBR-HVAC-01802: Alzheimer's Dementia, Treatment of ;Hypertension, Treatment of; Calcium Channel Blockers; Calcium channel L-type Blocker; L-type calcium channel antagonist; T-type calcium channel antagonist;"
CBR-001-571-223-9,RFM-000-248-2,CBR-001-571-223-9,COc1cc2CCN3[C@H](c2cc1OC)Cc1c(C3)c(OC)c(cc1)OC,CBR-HVAC-14177
CBR-001-571-224-0,RFM-000-249-3,CBR-001-571-224-0,Clc1ccc(cc1)OC(C(=O)OCCOC(=O)c1cccnc1)(C)C,"CBR-HVAC-02128: Lipoprotein Disorders, Treatment of ; PPARalpha Agonists;Signal Transduction Modulators;  Lipase clearing factor stimulant; Prostaglandin receptor agonist; Thromboxane receptor antagonist;"
CBR-001-571-225-1,RFM-000-250-6,CBR-001-571-225-1,CCc1oc2c(c1C(=O)c1ccc(cc1)O)cccc2,CBR-HVAC-10023:
CBR-001-571-226-2,RFM-000-251-7,CBR-001-571-226-2,C1CCC2C(C1)[NH2+][Pt][NH2+]2,CBR-HVAC-08246:  DNA inhibitor;
CBR-001-571-234-2,RFM-000-252-8,CBR-001-571-234-2,OC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C,CBR-HVAC-02425: Beta-lactamase Inhibitor; Lactamase inhibitor
CBR-001-571-235-3,RFM-000-253-9,CBR-001-571-235-3,CCN[C@H]1C[C@H](C)S(=O)(=O)c2c1cc(s2)S(=O)(=O)N,CBR-HVAC-02353: Carbonic anhydrase II Inhibitor; Carbonic anhydrase inhibitor
CBR-001-571-236-4,RFM-000-254-0,CBR-001-571-236-4,COCC1=C(C(=O)OC(OC(=O)OC(C)C)C)N2[C@H](SC1)[C@@H](C2=O)NC(=O)C(=NOC)c1csc(n1)N,CBR-HVAC-02328: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-571-237-5,RFM-000-255-1,CBR-001-571-237-5,Fc1ccc(cc1)n1cc(C(=O)O)c(=O)c2c1cc(N1CCNCC1)c(c2)F,CBR-HVAC-14167
CBR-001-571-238-6,RFM-000-256-2,CBR-001-571-238-6,COc1c(N2C[C@@H]3[C@H](C2)CCCN3)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-02242: Antibacterial Ophthalmic Drugs;Antibacterial Drugs;Treatment of Tuberculosis; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; Topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-239-7,RFM-000-257-3,CBR-001-571-239-7,COC(=O)c1cc(OC)c2c(c1c1c(cc(c3c1OCO3)OC)C(=O)OC)OCO2,CBR-HVAC-03485: Anti-Hepatitis B Virus Drugs;Hepatoprotectants;
CBR-001-571-240-0,RFM-000-258-4,CBR-001-571-240-0,OCC(=O)N1CCC(CC1)c1n[nH]c(c1c1ccncn1)c1ccc(cc1)Cl,CBR-HVAC-06182: Antiarthritic Drugs; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators; P38 MAP KINASE Inhibitor;
CBR-001-571-241-1,RFM-000-259-5,CBR-001-571-241-1,CCOP(=O)(c1ccc(o1)c1nc(sc1C(=O)C(C)(C)C)N)OCC,analog of CBR-HVAC-06389
CBR-001-571-242-2,RFM-000-260-8,CBR-001-571-242-2,COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC/C=C/c1ccccc1)C,"CBR-HVAC-07642: L-type calcium channel antagonist; N-type calcium channel antagonist; Hypertension, Treatment of"
CBR-001-571-243-3,RFM-000-261-9,CBR-001-571-243-3,CC[N+](=C1C=CC(=C(c2ccc(cc2S(=O)(=O)[O-])S(=O)(=O)[O-])c2ccc(cc2)N(CC)CC)C=C1)CC,analog of CBR-HVAC-08724
CBR-001-571-244-4,RFM-000-262-0,CBR-001-571-244-4,[O-][n+]1ccccc1SSc1cccc[n+]1[O-],analog of CBR-HVAC-09000
CBR-001-571-245-5,RFM-000-263-1,CBR-001-571-245-5,CN(CCC=C1c2cc(ccc2OCc2c1cccc2)CC(=O)O)C,"CBR-HVAC-01306: Allergic Skin Disorders, Treatment for;Eczema, Treatment of;Antiallergic Ophthalmic Agents;Antipruritics;Allergy, Treatment of;Dermatologic Drugs;Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis;Antipsoriatics;Urticaria, Treatment for; Histamine H1 Receptor Antagonists;Mediator Release Inhibitors;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-571-246-6,RFM-000-264-2,CBR-001-571-246-6,CCOC(=O)c1ccc(cc1)NC(=O)/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,analog of CBR-HVAC-11070
CBR-001-571-247-7,RFM-000-265-3,CBR-001-571-247-7,COCCCN1CC(NCC)c2c(S1(=O)=O)sc(c2)S(=O)(=O)N,CBR-HVAC-01672: Antiglaucoma Agents; Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VII Inhibitors; Carbonic anhydrase II Inhibitor; Carbonic anhydrase inhibitor
CBR-001-571-248-8,RFM-000-266-4,CBR-001-571-248-8,Nc1ccc(cc1)S(=O)(=O)Nc1ncccn1,CBR-HVAC-09662: Dihydropteroate synthase Inhibitor
CBR-001-571-249-9,RFM-000-267-5,CBR-001-571-249-9,Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,CBR-HVAC-10043
CBR-001-571-250-2,RFM-000-268-6,CBR-001-571-250-2,OC(=O)CCC(C(=O)O)NC(=O)c1ccc(cc1)NCc1cnc2c(n1)c(N)nc(n2)N,"CBR-HVAC-02576: Rheumatoid Arthritis, Treatment of;Antipsoriatics;Lymphocytic Leukemia Therapy; Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors; Dihydrofolate reductase Inhibitor"
CBR-001-571-251-3,RFM-000-269-7,CBR-001-571-251-3,OC(=O)C(=O)CBr,CBR-HVAC-06230: Pancreatic Cancer Therapy;Oncolytic Drugs;Digestive/Gastrointestinal Cancer Therapy;Liver Cancer Therapy; Apoptosis Inducers;Hexokinase 2 Inhibitors;
CBR-001-571-252-4,RFM-000-270-0,CBR-001-571-252-4,OC(=O)Cn1c2ccccc2c(=O)c2c1cccc2,CBR-HVAC-05494: Female Reproductive System Cancer Therapy;Immunomodulators; Interferon Inducers;Signal Transduction Modulators;
CBR-001-571-253-5,RFM-000-271-1,CBR-001-571-253-5,Ic1cc(Cl)c2c(c1O)nccc2,"CBR-HVAC-02775: Antibacterial Drugs;Alzheimer's Dementia, Treatment of ;Antiamebics;Antifungal Agents; Antiamyloidogenic Agents;Apoptosis Inducers;Carbonic Anhydrase Inhibitors;Chelating Agents; Catechol-O-methyltransferase Inhibitor"
CBR-001-571-254-6,RFM-000-272-2,CBR-001-571-254-6,Nc1ccc(cc1)S(=O)(=O)c1ccc(cc1)N,"CBR-HVAC-01378: Atopic Dermatitis, Agents for;Antipruritics;Antibiotics;Acne Therapy;Treatment of Leprosy;Dermatologic Drugs;Alzheimer's Dementia, Treatment of ; Dihydropteroate Synthase (DHPS) Inhibitors; Dihydropteroate synthase Inhibitor"
CBR-001-571-255-7,RFM-000-273-3,CBR-001-571-255-7,COC(=O)Nc1[nH]c2c(n1)cc(cc2)C(=O)c1ccc(cc1)F,CBR-HVAC-01804: Treatment of Helminthic DiseasesTubulin Inhibitor
CBR-001-571-256-8,RFM-000-274-4,CBR-001-571-256-8,OC(=O)CCc1nc2c([nH]1)cccc2,CBR-HVAC-08234
CBR-001-571-257-9,RFM-000-275-5,CBR-001-571-257-9,O=c1n(CC2OC2)c(=O)n(c(=O)n1CC1OC1)CC1OC1,CBR-HVAC-02537: Oncolytic Drugs
CBR-001-571-258-0,RFM-000-276-6,CBR-001-571-258-0,O=c1c(Cl)c(SCc2ccc(cc2)C(C)(C)C)cnn1C(C)(C)C,CBR-HVAC-10005
CBR-001-571-259-1,RFM-000-277-7,CBR-001-571-259-1,COc1ccc2c(c1)c(CCNC(=O)C)c[nH]2,"CBR-HVAC-01389: Sleep Disorders, Treatment of;Cognition Disorders, Treatment of;Neurologic Drugs (Miscellaneous);Treatment of Cachexia;Agents for Liver Fibrosis;Migraine, Prophylactic Treatment of;Respiratory Disorders (Not Specified);Stroke, Treatment of;Liver Cancer Therapy; Antioxidants;Apoptosis Inducers;Free Radical Scavengers;NOS2 Expression Inhibitors;TH Expression Enhancers; Melatonin receptor Agonist"
CBR-001-571-260-4,RFM-000-278-8,CBR-001-571-260-4,CCCCNC(=O)NS(=O)(=O)c1ccc(cc1)C,"CBR-HVAC-02874: Antidiabetic Drugs;Type 2 Diabetes, Agents for; K(ATP) Channel Blockers; Phosphodiesterase Inhibitor"
CBR-001-571-261-5,RFM-000-279-9,CBR-001-571-261-5,CCN(CCOC(=O)c1ccc(cc1)N)CC,CBR-HVAC-00965: Potassium channel; Sodium channel Blocker; Inhibitor
CBR-001-571-262-6,RFM-000-280-2,CBR-001-571-262-6,CCCc1cc(=O)[nH]c(=S)[nH]1,CBR-HVAC-03173: Thyroid Disease TherapyDehydropeptidase 1 Inhibitor
CBR-001-571-263-7,RFM-000-281-3,CBR-001-571-263-7,OCc1cc(ccc1O)C(CNC(C)(C)C)O,CBR-HVAC-02587: Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Inhibitor; Beta-2-adrenergic-receptor-agonists; Short-acting beta 2 adrenoceptor (SABA) agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Bronchodilator; Bronchodilators; Obstructive Airways Disease; Respiratory Tract Disorders; Treatment of Autoimmune Diseases
CBR-001-571-264-8,RFM-000-282-4,CBR-001-571-264-8,Clc1ccc(c(c1)Cc1ccccc1)O,CBR-HVAC-09134
CBR-001-571-265-9,RFM-000-283-5,CBR-001-571-265-9,COc1ccc2c(c1)c(CC(=O)O)c(n2C(=O)c1ccc(cc1)Cl)C,"CBR-HVAC-02306: Osteoarthritis, Treatment of;Non-Opioid Analgesics;Congenital Malformations, Treatment of; Cyclooxygenase-3 Inhibitors;NADH Oxidase (NOX) Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor"
CBR-001-571-266-0,RFM-000-284-6,CBR-001-571-266-0,O=c1[nH]c(=O)[nH]c(c1)C(=O)O,CBR-HVAC-06392: Cardioprotective Agents
CBR-001-571-267-1,RFM-000-285-7,CBR-001-571-267-1,OC(COc1ccc(cc1)CC(=O)N)CNC(C)C,"CBR-HVAC-02790: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Inhibitor"
CBR-001-571-268-2,RFM-000-286-8,CBR-001-571-268-2,CCCSc1ccc2c(c1)nc([nH]2)NC(=O)OC,CBR-HVAC-01665: Treatment of Helminthic DiseasesAlpha tubulin Inhibitor
CBR-001-571-269-3,RFM-000-287-9,CBR-001-571-269-3,NCC(CC(=O)O)O,CBR-HVAC-08647: GABA receptor Inhibitor
CBR-001-571-270-6,RFM-000-288-0,CBR-001-571-270-6,CCCCOc1ccc(cc1)CC(=O)NO,"CBR-HVAC-01658: Antipruritics;Topical Antiinflammatory Agents;Hemorrhoid, Treatment ofCyclooxygenase 2; Cyclooxygenase 1; Lipoxygenase 5 Inhibitor; Inhibitor; Inhibitor"
CBR-001-571-271-7,RFM-000-289-1,CBR-001-571-271-7,CN(CCN(c1ccccn1)Cc1ccc(cc1)Cl)C,"CBR-HVAC-05265: Allergy, Treatment of;Pancreatic Cancer Therapy;Asthma Therapy;Oncolytic Drugs; Focal Adhesion Kinase (FAK) Inhibitors;Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist;"
CBR-001-571-272-8,RFM-000-290-4,CBR-001-571-272-8,OCC(CN1CCN(CC1)c1ccccc1)O,CBR-HVAC-02305: AntitussivesAlpha adrenergic receptor; Histamine H1 receptor Binder; Inhibitor
CBR-001-571-273-9,RFM-000-291-5,CBR-001-571-273-9,OC(=O)c1cc(c(cc1NCc1ccco1)Cl)S(=O)(=O)N,CBR-HVAC-01503: Na-K-Cl cotransporter Inhibitor
CBR-001-571-274-0,RFM-000-292-6,CBR-001-571-274-0,Cc1ccc(c(c1)OCCCC(C(=O)O)(C)C)C,"CBR-HVAC-02792: Smoking Cessation, Aid to;Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ; PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor alpha Agonist"
CBR-001-571-275-1,RFM-000-293-7,CBR-001-571-275-1,O=c1oc2ccccc2c(c1Cc1c(=O)oc2c(c1O)cccc2)O,CBR-HVAC-03157: Anticoagulants; NADPH Quinone Oxidoreductase 1 (NQO1) Inhibitors ; Vitamin K epoxide reductase Inhibitor
CBR-001-571-276-2,RFM-000-294-8,CBR-001-571-276-2,CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cccc(c1)Cl,"CBR-HVAC-02833: Diabetic Neuropathy, Agents for;Antidepressants; Signal Transduction Modulators;5-HT Reuptake Inhibitors;5-HT2A Antagonists; Norepinephrine transporter; 5-Hydroxytryptamine 2A receptor; 5-Hydroxytryptamine transporter Antagonist; Inhibitor"
CBR-001-571-277-3,RFM-000-295-9,CBR-001-571-277-3,O=C1Cc2ccccc2N(c2c1cccc2)C(=O)N,"CBR-HVAC-01501: Antiepileptic Drugs;Neuropathic Pain, Treatment of; Sodium Channel  Blockers; Cytochrome P450 2A6 Inducer"
CBR-001-571-278-4,RFM-000-296-0,CBR-001-571-278-4,COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)NCc1cccnc1,CBR-HVAC-00089: Antiplatelet Therapy; Prostanoid TP Antagonists;Signal Transduction Modulators; Angiotensin converting enzyme Inhibitor
CBR-001-571-279-5,RFM-000-297-1,CBR-001-571-279-5,Brc1cc(CN(C2CCCCC2)C)c(c(c1)Br)N,CBR-HVAC-05929: Mucolytics
CBR-001-571-280-8,RFM-000-298-2,CBR-001-571-280-8,Oc1ccccc1C(=O)Oc1ccccc1C(=O)O,"CBR-HVAC-06063: Osteoarthritis, Treatment of;Type 2 Diabetes, Agents for;Rheumatoid Arthritis, Treatment of; NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; Cyclooxygenase 2; Cyclooxygenase 1 Inhibitor; Inhibitor"
CBR-001-571-281-9,RFM-000-299-3,CBR-001-571-281-9,OS(=O)(=O)c1ccc2c(c1)nc([nH]2)c1ccccc1,CBR-HVAC-10287
CBR-001-571-282-0,RFM-000-300-9,CBR-001-571-282-0,OS(=O)(=O)CS(=O)(=O)O,CBR-HVAC-08868
CBR-001-571-283-1,RFM-000-301-0,CBR-001-571-283-1,O=C(Nc1cccc(c1)C1=NCCN1)Nc1cccc(c1)C1=NCCN1,CBR-HVAC-08800: TNF alpha Inhibitor
CBR-001-571-284-2,RFM-000-302-1,CBR-001-571-284-2,COc1c(CC=C(CCC(=O)OCCN2CCOCC2)C)c(O)c2c(c1C)COC2=O,"CBR-HVAC-01810: Myasthenia Gravis, Agents for;Antiinfectives (Not Specified);Atopic Dermatitis, Agents for;Treatment of Renal Diseases;Myelodysplastic Syndrome Therapy;Treatment of Autoimmune Diseases;Immunosuppressants;Dermatologic Drugs;Scleroderma, Agents for;Interstitial Lung Diseases, Treatment of;Antipsoriatics;Treatment of Transplant Rejection;Systemic Lupus Erythematosus, Agents for; Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Signal Transduction Modulators; Inosine-5'-monophosphate dehydrogenase Inhibitor"
CBR-001-571-285-3,RFM-000-303-2,CBR-001-571-285-3,OCCOCn1cnc2c1nc(N)[nH]c2=O,CBR-HVAC-01423: Anti-Varicella Zoster Virus Drugs;Anti-Herpes Simplex Virus Drugs;Anti-Herpes Virus Drugs;Anti-Herpes Labialis Drugs;Antiviral Ophthalmic Drugs;Antiviral Drugs; DNA Polymerase Inhibitors; DNA polymerase Inhibitor
CBR-001-571-286-4,RFM-000-304-3,CBR-001-571-286-4,FCc1nc2ccc(cc2c(=O)n1c1ccccc1C)N,CBR-HVAC-01602: Smooth Muscle Relaxants
CBR-001-571-287-5,RFM-000-305-4,CBR-001-571-287-5,Clc1ccc(c(c1)c1nc(N)nc(n1)N)Cl,CBR-HVAC-01904: Antiulcer Drugs;Antidiabetic DrugsPhosphodiesterase 4 Inhibitor
CBR-001-571-288-6,RFM-000-306-5,CBR-001-571-288-6,SCCS(=O)(=O)[O-],CBR-HVAC-02287: Chemoprotective Agents;Antineoplastic Enhancing Agents; Antioxidants;
CBR-001-571-289-7,RFM-000-307-6,CBR-001-571-289-7,O=C(CNC(=O)C(Cc1ccccc1)CSC(=O)C)OCc1ccccc1,CBR-HVAC-02402: Neprilysin Inhibitor
CBR-001-571-290-0,RFM-000-308-7,CBR-001-571-290-0,OC(=O)CCCCCC(C1=C(C)C(=O)C(=C(C1=O)C)C)c1ccccc1,"CBR-HVAC-01571: Asthma Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A2 receptor Inhibitor"
CBR-001-571-291-1,RFM-000-309-8,CBR-001-571-291-1,[Ag]N(S(=O)(=O)c1ccc(cc1)N)c1ncccn1,CBR-HVAC-03803: Anti-HIV Agents;Antibacterial Drugs; Botulinum Neurotoxin Type A Light Chain (BoNT/A LC) (Clostridium botulinum) Inhibitors;
CBR-001-571-292-2,RFM-000-310-1,CBR-001-571-292-2,Oc1ccc(cc1)NC(=O)c1ccccc1O,CBR-HVAC-07224: Hepatoprotectants;Choleretic Agents; Ribonucleoside-Diphosphate Reductase Inhibitors;
CBR-001-571-293-3,RFM-000-311-2,CBR-001-571-293-3,c1cnc(nc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2,CBR-HVAC-02079: Antiparkinsonian Drugs; alpha2-Adrenoceptor Antagonists;Dopamine D2 Agonists;Dopamine D3 Agonists;Signal Transduction Modulators; Dopamine receptor D3; Dopamine receptor D2 Agonist
CBR-001-571-294-4,RFM-000-312-3,CBR-001-571-294-4,SCC(C(=O)N1CCCC1C(=O)O)C,"CBR-HVAC-01520: Endometriosis Therapy;Heart Failure Therapy;Hypertension, Treatment of;Diabetic Retinopathy, Agents for;Diabetic Nephropathy, Agents for; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin I converting enzyme Inhibitor"
CBR-001-571-295-5,RFM-000-313-4,CBR-001-571-295-5,Clc1ccc(c(c1)Cl)C(Cn1ccnc1)OCc1ccsc1Cl,CBR-HVAC-01748: Antifungal AgentsLanosterol 14 alpha-demethylase Inhibitor
CBR-001-571-296-6,RFM-000-314-5,CBR-001-571-296-6,O=C(C(C)(C)C)OCOP(=O)(OCOC(=O)C(C)(C)C)COCCn1cnc2c1ncnc2N,CBR-HVAC-02113: Anti-HIV Agents;Anti-Hepatitis B Virus Drugs; DNA Polymerase Inhibitors; DNA polymerase Inhibitor
CBR-001-571-297-7,RFM-000-315-6,CBR-001-571-297-7,Fc1cc2c(cc1N1CCNCC1)n1C(C)Sc1c(c2=O)C(=O)O,CBR-HVAC-03911: Antibacterial DrugsDNA topoisomerase II Inhibitor
CBR-001-571-298-8,RFM-000-316-7,CBR-001-571-298-8,COc1ccc2c(c1)nc([nH]2)SCc1ncc(c(c1C)OC)C,CBR-HVAC-03259: Gastric Antisecretory Drugs; H+/K+-ATPase Inhibitors;
CBR-001-571-299-9,RFM-000-317-8,CBR-001-571-299-9,O[Hg]c1c([O-])c(Br)cc2c1Oc1cc([O-])c(cc1C12OC(=O)c2c1cccc2)Br,CBR-HVAC-09160: Carbonic anhydrase II Inhibitor
CBR-001-571-300-5,RFM-000-318-9,CBR-001-571-300-5,O=C(c1ccccn1)O[Cr](OC(=O)c1ccccn1)OC(=O)c1ccccn1,"CBR-HVAC-05593: Antidiabetic Drugs;Type 2 Diabetes, Agents for;Gynecological Disorders, Treatment of ;Antidepressants;Cognition Disorders, Treatment of;Type 1 Diabetes, Agents for;Antiobesity Drugs"
CBR-001-571-301-6,RFM-000-319-0,CBR-001-571-301-6,CNCCC(c1cccs1)Oc1cccc2c1cccc2,CBR-HVAC-01729: Antidepressants;Pharmacological Tools; Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators; 5-hydroxytryptamine transporter Inhibitor
CBR-001-571-302-7,RFM-000-320-3,CBR-001-571-302-7,CN1C2CCCC1CC(C2)NC(=O)c1n[nH]c2c1cccc2,CBR-HVAC-07876: Granisetron Impurity B having 5-HT antagonist activity
CBR-001-571-303-8,RFM-000-321-4,CBR-001-571-303-8,OCCC#Cc1nc(c(n1CCCc1ccccc1)c1ccncc1)c1ccc(cc1)F,"CBR-HVAC-05101: Inflammatory Bowel Disease, Agents for;Antiarthritic Drugs; IL-1beta Production Inhibitors;MAPK p38 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; p38 Mitogen-activated protein kinase Inhibitor"
CBR-001-571-304-9,RFM-000-322-5,CBR-001-571-304-9,ON=Cc1cccc[n+]1C,CBR-HVAC-07051: Treatment of PoisoningAcetylcholinesterase Reactivator
CBR-001-571-305-0,RFM-000-323-6,CBR-001-571-305-0,NC(=N)N1CCc2c(C1)cccc2,"CBR-HVAC-03151: Hypertension, Treatment ofCYP2D1 Inhibitor"
CBR-001-571-306-1,RFM-000-324-7,CBR-001-571-306-1,O=C(c1cccnc1Nc1cccc(c1)C(F)(F)F)OCCN1CCOCC1,CBR-HVAC-01161: Antiarthritic Drugs
CBR-001-571-307-2,RFM-000-325-8,CBR-001-571-307-2,Cc1cccc(c1)Oc1cnc(=O)[nH]c1,"CBR-HVAC-05821: Antiulcer Drugs;Type 2 Diabetes, Agents for; Lyn Kinase Activators;Signal Transduction Modulators;"
CBR-001-571-308-3,RFM-000-326-9,CBR-001-571-308-3,O=CC[C@H]1C[C@@H](C)[C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]([C@H]1O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@H]1O)N(C)C)O[C@@H]1O[C@@H](C)[C@@H]([C@](C1)(C)O)O)OC)OC(=O)CC)C)O[C@H]1CC[C@@H]([C@H](O1)C)N(C)C,CBR-HVAC-09659: 50S-ribosomal subunit Binder
CBR-001-571-309-4,RFM-000-327-0,CBR-001-571-309-4,Fc1cc(F)cc(c1)C(=O)Nc1ccc(cc1)[C@H](CNS(=O)(=O)C(C)C)C,"CBR-HVAC-09349: Glutamate receptor, ionotropic, AMPA Agonist"
CBR-001-571-310-7,RFM-000-328-1,CBR-001-571-310-7,OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)O)n1cnc2c1nc(N)[nH]c2=O,CBR-HVAC-06055: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors;
CBR-001-571-311-8,RFM-000-329-2,CBR-001-571-311-8,COc1cc(N)cn[n+]1c1ccccc1,"CBR-HVAC-03065: Hypotension, Treatment ofMonoamine oxidase B Inhibitor"
CBR-001-571-312-9,RFM-000-330-5,CBR-001-571-312-9,[O-]C(=O)CN(CC(=O)[O-])CCN1CC(=O)O[Mn]OC(=O)C1,CBR-HVAC-09574
CBR-001-571-325-4,RFM-000-331-6,CBR-001-571-325-4,Nc1sc(c2c1CNCC2)N,analog of CBR-HVAC-07725
CBR-001-571-326-5,RFM-000-332-7,CBR-001-571-326-5,Sc1cccc[n+]1[O-],CBR-HVAC-02367
CBR-001-571-327-6,RFM-000-333-8,CBR-001-571-327-6,O=c1ccc2c(o1)cccc2,CBR-HVAC-06083: Antidiabetic Drugs
CBR-001-571-328-7,RFM-000-334-9,CBR-001-571-328-7,CN(c1c(C)n(n(c1=O)c1ccccc1)C)C,CBR-HVAC-09697: Prostaglandin G/H synthase Inhibitor;
CBR-001-571-329-8,RFM-000-335-0,CBR-001-571-329-8,NCP(=O)(O)O,CBR-HVAC-09171: Adam metallopeptidase domain 15; Integrin alpha5 beta1; Integrin alpha5 beta3 Inhibitor;
CBR-001-571-330-1,RFM-000-336-1,CBR-001-571-330-1,CCCCCCCCCCCCOC(=O)c1cc(O)c(c(c1)O)O,CBR-HVAC-09784: Antiviral Drugs;Antibacterial Drugs;Oncolytic DrugsSqualene epoxidase Inhibitor;
CBR-001-571-331-2,RFM-000-337-2,CBR-001-571-331-2,OCc1cc(ccc1O)C(CNC(C)(C)C)O,CBR-HVAC-02587: Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Inhibitor; Beta-2-adrenergic-receptor-agonists; Short-acting beta 2 adrenoceptor (SABA) agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Bronchodilator; Bronchodilators; Obstructive Airways Disease; Respiratory Tract Disorders; Treatment of Autoimmune Diseases
CBR-001-571-332-3,RFM-000-338-3,CBR-001-571-332-3,OC(=O)Cc1ccc(cc1)NC(=O)C,"CBR-HVAC-03496: Rheumatoid Arthritis, Treatment of"
CBR-001-571-333-4,RFM-000-339-4,CBR-001-571-333-4,O=C(NS(=O)(=O)c1ccc(cc1)C)NN1CC2C(C1)CCC2,"CBR-HVAC-01591: Type 2 Diabetes, Agents for; K(ATP) Channel Blockers; Potassium channel Blocker; ATP-sensitive potassium channel antagonist; Sulfonylurea; Insulin secretagogue"
CBR-001-571-334-5,RFM-000-340-7,CBR-001-571-334-5,Clc1ccc(cc1)OC(C(=O)C(C)(C)C)n1cncc1,CBR-HVAC-05592: Dermatologic Drugs;Antifungal Agents; Enzyme Inducers
CBR-001-571-335-6,RFM-000-341-8,CBR-001-571-335-6,Cc1ccc2c(n1)c(O)c(cc2Cl)Cl,CBR-HVAC-09762
CBR-001-571-336-7,RFM-000-342-9,CBR-001-571-336-7,S=c1[nH]cnc2c1[nH]cn2,"CBR-HVAC-05246: Cell-cycle specific for the S phase of cell division. Converted to thioinosinic acid by the enzyme hypoxanthine-guanine phosphoribosyltransferase. Thioinosinic acid then inhibits reactions involving inosinic acid. Also, both thioinosinic acid and 6-methylthioinosinate (also formed from mercaptopurine) inhibit RNA synthesis.; Immunosuppressant; Protein synthesis inhibitor; Purine Antagonists; Antineoplastic; Immunosuppressant; Inflammatory Bowel Disease, Agents for; Leukemia Therapy; Lymphocytic Leukemia Therapy; Myeloid Leukemia Therapy"
CBR-001-571-337-8,RFM-000-343-0,CBR-001-571-337-8,O=C(C(C)C)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CBR-HVAC-03069: Androgen receptor Inhibitor; Androgen receptor antagonist
CBR-001-571-338-9,RFM-000-344-1,CBR-001-571-338-9,NCCS(=O)(=O)O,"CBR-HVAC-04993: Pancreatic Disorders, Treatment of;Diabetic Neuropathy, Agents for;Bone Resorption Inhibitors;Antiarthritic Drugs;Cardiovascular Diseases (Not Specified);Psychiatric Disorders (Not Specified);Bipolar Disorder, Treatment of;Therapy of Inborn Errors of Metabolism; Angiogenesis Inducers;Antioxidants"
CBR-001-571-339-0,RFM-000-345-2,CBR-001-571-339-0,NC(=O)CN1CCCC1=O,"CBR-HVAC-01891: Cognition Disorders, Treatment of;Myoclonus, Treatment ofAcetylcholine receptor agonist"
CBR-001-571-340-3,RFM-000-346-3,CBR-001-571-340-3,COc1cc2c(CCNC(=O)CN)c[nH]c2cc1,analog of CBR-HVAC-11440
CBR-001-571-341-4,RFM-000-347-4,CBR-001-571-341-4,Cc1nn(c(c1)C)c1ccccc1O,analog of CBR-HVAC-07249
CBR-001-571-342-5,RFM-000-348-5,CBR-001-571-342-5,Clc1ccc2c(c1)nc(cc2)/C=C/c1cccc(c1)[C@H](CCc1ccccc1C(O)(C)C)SCC1(CC1)C(=O)O,analog of CBR-HVAC-10930
CBR-001-571-343-6,RFM-000-349-6,CBR-001-571-343-6,Clc1ccc(cc1)CCC(Sc1c(Cl)cccc1Cl)Cn1cncc1,CBR-HVAC-02201: Antifungal AgentsLanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor; Sterol demethylase inhibitor
CBR-001-571-344-7,RFM-000-350-9,CBR-001-571-344-7,Fc1ccccc1c1nc2c(n1)cn(cc2)Cc1ccc(nn1)c1ccc(cc1C(F)(F)F)C(F)(F)F,CBR-HVAC-00139: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) InhibitorsProtease/peptidase inhibitor; HCV nonstructural protein 5B inhibitor
CBR-001-571-345-8,RFM-000-351-0,CBR-001-571-345-8,CN1CCN(CC1)c1nnc2c(c1)N(C)c1c(O2)cccc1,CBR-HVAC-09456: NOREPINEPHRINE TRANSPORTER; SEROTONIN REUPTAKE TRANSPORTER Inhibitor;
CBR-001-571-346-9,RFM-000-352-1,CBR-001-571-346-9,CCOC(=O)C(c1c(=O)oc2c(c1O)cccc2)c1c(=O)oc2c(c1O)cccc2,CBR-HVAC-09850: Vitamin K Antagonist;
CBR-001-571-347-0,RFM-000-353-2,CBR-001-571-347-0,CCOc1cc(ccc1OCC)C=C1NCCc2c1cc(OCC)c(c2)OCC,CBR-HVAC-05250: Antispastic Drugs; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators
CBR-001-571-348-1,RFM-000-354-3,CBR-001-571-348-1,CCCCCCCCCCCCN,CBR-HVAC-02336: Alpha adrenergic receptor Agonist; Unidentified pharmacological activity
CBR-001-571-349-2,RFM-000-355-4,CBR-001-571-349-2,OC(=O)Cn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-08944
CBR-001-571-350-5,RFM-000-356-5,CBR-001-571-350-5,O=c1ccoc(c1O)C,ligand of CBR-HVAC-07818
CBR-001-571-351-6,RFM-000-357-6,CBR-001-571-351-6,CC(C(Cc1ccc(cc1)Cl)(O)C)CN(C)C,CBR-HVAC-09086
CBR-001-571-352-7,RFM-000-358-7,CBR-001-571-352-7,CCOC(=O)c1ccc(cc1)OC(=O)CCCCCNC(=N)N,"CBR-HVAC-05425: AP-1 Inhibitors; NF-kappaB (NFKB) Activation Inhibitors; Protease/peptidase inhibitor; Serine Protease Inhibitors; Serine protease Inhibitor; Signal Transduction Modulators; Anticoagulants; Pancreatic Disorders, Treatment of; Serine protease inhibitor"
CBR-001-571-353-8,RFM-000-359-8,CBR-001-571-353-8,CCCn1c2[nH]c(nc2c(=O)n(c1=O)CCC)C1CCCC1,CBR-HVAC-04056
CBR-001-571-354-9,RFM-000-360-1,CBR-001-571-354-9,COc1cc(NC)c(cc1C(=O)N[C@@H]1CCN([C@@H]1C)Cc1ccccc1)Cl,CBR-HVAC-01788: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2; Dopamine receptor D3 Inhibitor; Dopamine D2 receptor antagonist; Dopamine D3 receptor antagonist
CBR-001-571-355-0,RFM-000-361-2,CBR-001-571-355-0,NC(=O)C[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)CCSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)NCC(=O)N)CCCNC(=N)N)Cc1ccc(cc1)O,"CBR-HVAC-01270: Urinary Incontinence Therapy;Oncolytic Drugs;Diabetes Insipidus, Agents for;Hemostatics;Hemophilia A, Agents for;Coagulation Disorders Therapy;Treatment of Diabetic Complications; Angiogenesis Inhibitors;Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Agonists; Vasopressin V1 receptor; Vasopressin V2 receptor Inhibitor; Vasopressin 2 agonist"
CBR-001-571-356-1,RFM-000-362-3,CBR-001-571-356-1,NNC(=O)CCCCCC(=O)NN,CBR-HVAC-09530: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR BETA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA Modulator; Modulator; Modulator;
CBR-001-571-357-2,RFM-000-363-4,CBR-001-571-357-2,OC[C@H]1O[C@H](C[C@@H]1O)n1ccc(nc1=O)N,CBR-HVAC-14260
CBR-001-571-358-3,RFM-000-364-5,CBR-001-571-358-3,CN1CC2CCCC(C1)C2OC(=O)C(c1ccccc1)(C1CCCC1)O,"CBR-HVAC-07378: Ear disorders, treatment of; Muscarinic Agonists;Signal Transduction Modulators"
CBR-001-571-359-4,RFM-000-365-6,CBR-001-571-359-4,CCCCCC=CCCC(=O)N[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)Oc1c2cc3cc1Oc1ccc(cc1Cl)C[C@@H]1C(=O)NC(C(=O)N[C@H]3C(=O)N[C@H]3C(=O)N[C@@H]([C@@H](c4ccc(O2)c(Cl)c4)O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2NC(=O)C)O)O)C(=O)N[C@H](c2c(c4cc3ccc4O)c(cc(c2)O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@@H]2O)O)O)C(=O)O)c2cc(O)cc(c2)Oc2cc(CC[C@H](C(=O)N1)N)ccc2O,"CBR-HVAC-09869: Glycopeptide antibiotic active against Gram-positive bacteria. It is a glycopeptide antiobiotic extracted from Actinoplanes teichomyceticus, with a similar spectrum of activity to vancomycin.; Antibiotic; Antibiotics"
CBR-001-571-360-7,RFM-000-366-7,CBR-001-571-360-7,Oc1cc(O)c2c(c1)O[C@@H]([C@@H](C2c1c(O)cc(c2c1O[C@@H]([C@@H](C2)O)c1ccc(c(c1)O)O)O)O)c1ccc(c(c1)O)O,CBR-HVAC-05564: Hair Growth Stimulants; Protein Kinase C (PKC) Inhibitors;Signal Transduction Modulators
CBR-001-571-361-8,RFM-000-367-8,CBR-001-571-361-8,Fc1ccc(cc1)Cn1c(NC2CCNCC2)nc2c1cccc2,CBR-HVAC-09463: HISTAMINE H1 RECEPTOR Antagonist;
CBR-001-571-362-9,RFM-000-368-9,CBR-001-571-362-9,OCCOc1c(C)cc(cc1C)c1nc2cc(OC)cc(c2c(=O)[nH]1)OC,"CBR-HVAC-06794: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Atherosclerosis Therapy;Antidiabetic Drugs;Cardiovascular Diseases (Not Specified);Alzheimer's Dementia, Treatment of ; APOA1 Expression Enhancers;Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors;HDL-Cholesterol Increasing Agents; APOA1 Stimulator;"
CBR-001-571-363-0,RFM-000-369-0,CBR-001-571-363-0,Nc1ncc(c(c1)C(F)(F)F)c1cc(nc(n1)N1CCOCC1)N1CCOCC1,CBR-HVAC-00735: Ovarian Cancer Therapy;Head and Neck Cancer Therapy;Hematopoiesis Disorders Therapy;Glioblastoma Multiforme Therapy;Liver Cancer Therapy;Colorectal Cancer Therapy;Melanoma Therapy;Bladder Cancer Therapy ;Digestive/Gastrointestinal Cancer Therapy;Oncolytic Drugs;Breast Cancer Therapy;Endocrine Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Lymphocytic Leukemia Therapy;Prostate Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Pancreatic Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Female Reproductive System Cancer Therapy; Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Signal Transduction Modulators; Phosphoinositide 3-kinase Inhibitor; PI3 kinase inhibitor; Protein kinase inhibitor
CBR-001-571-364-1,RFM-000-370-3,CBR-001-571-364-1,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C1(C)C)c1ccc(c(c1)C(F)(F)F)C#N,CBR-HVAC-02245: Liver Cancer Therapy;Pancreatic Cancer Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;Female Reproductive System Cancer Therapy; Androgen Receptor Antagonists;Signal Transduction Modulators; Androgen receptor Antagonist; Androgen receptor antagonist
CBR-001-571-365-2,RFM-000-371-4,CBR-001-571-365-2,O=C(c1ccc(cc1Cl)S(=O)(=O)C)Nc1ccc(c(c1)c1ccccn1)Cl,"CBR-HVAC-06738: Digestive/Gastrointestinal Cancer Therapy;Colorectal Cancer Therapy;Basal Cell Carcinoma Therapy;Breast Cancer Therapy;Ovarian Cancer Therapy;Neurologic Cancer Therapy;Immunomodulators;Brain Cancer Therapy;Myelodysplastic Syndrome Therapy;Sarcoma Therapy;Oncolytic Drugs;Myeloid Leukemia Therapy;Prostate Cancer Therapy;Multiple Myeloma Therapy;Interstitial Lung Diseases, Treatment of;Small Cell Lung Cancer Therapy;Glioblastoma Multiforme Therapy;Pancreatic Cancer Therapy; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Hedgehog Signaling Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators;Smoothened (Smo) Receptor Antagonists; Smoothened homolog Inhibitor; Hedgehog pathway inhibitor; Angiogenesis inhibitor"
CBR-001-571-366-3,RFM-000-372-5,CBR-001-571-366-3,CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c1c[nH]c2c1cc(cn2)c1ccc(cc1)Cl)F,CBR-HVAC-06402: Colorectal Cancer Therapy;Endocrine Cancer Therapy;Multiple Myeloma Therapy;Brain Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Melanoma Therapy;Leukemia Therapy; Raf kinase B Inhibitors;Signal Transduction Modulators; B-RAF; BRAF Inhibitor; B-raf kinase inhibitor; Protein kinase inhibitor;2018-01-24: ARB# 18-000006
CBR-001-571-367-4,RFM-000-373-6,CBR-001-571-367-4,CNC(=O)c1nccc(c1)Oc1ccc(c(c1)F)NC(=O)Nc1ccc(c(c1)C(F)(F)F)Cl,"CBR-HVAC-06197: Hematological Cancer Therapy;Pancreatic Cancer Therapy;Renal Cancer Therapy;Melanoma Therapy;Liver Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Age-Related Macular Degeneration, Treatment of;Cancer of Unspecified Body Location/System;Colorectal Cancer Therapy;Genitourinary Cancer Therapy;Sarcoma Therapy;Oncolytic Drugs;Female Reproductive System Cancer Therapy; Angiogenesis Inhibitors;FGFR Inhibitors;KIT (C-KIT) Inhibitors;MAPK p38 Inhibitors;PDGFR Family Inhibitors;Raf Kinase Inhibitors;RET Inhibitors;Signal Transduction Modulators;Tie2 Receptor Inhibitors;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; BRAF; GLYCINAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; C-kit inhibitor; RET tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Raf kinase inhibitor"
CBR-001-571-368-5,RFM-000-374-7,CBR-001-571-368-5,CC[C@@H](c1nc2cccc(c2c(=O)n1c1ccccc1)F)Nc1ncnc2c1nc[nH]2,"CBR-HVAC-06320: Hematological Cancer Therapy;Oncolytic Drugs;Hematopoiesis Disorders Therapy;Drugs for Allergic Rhinitis;Lymphoma Therapy;Non-Hodgkin's Lymphoma Therapy;Lymphocytic Leukemia Therapy;Inflammation, Treatment of;Pancreatic Cancer Therapy; Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators; PHOSPHOINOSITIDE-3 KINASE DELTA Inhibitor; PI3 kinase delta inhibitor; Protein kinase inhibitor; CC chemokine ligand antagonist"
CBR-001-571-369-6,RFM-000-375-8,CBR-001-571-369-6,COc1ccc(cc1)n1nc(nc1c1ccc(cc1)OC)OC,"CBR-HVAC-05909: Inflammation, Treatment of; Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Signal Transduction Modulators; CYCLOOXYGENASE 1 Inhibitor;"
CBR-001-571-370-9,RFM-000-376-9,CBR-001-571-370-9,CCC(n1c(O)nc2c1nc(C#C)cn2)CC,"CBR-HVAC-00691: Amyotrophic Lateral Sclerosis, Agents for;Myasthenia Gravis, Agents for;Peripheral Vascular Disease, Treatment of; Troponin Activators; Troponin Activator; Troponin calcium combination agonist"
CBR-001-571-371-0,RFM-000-377-0,CBR-001-571-371-0,O=C(c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl)NC1CCNCC1,CBR-HVAC-00599: Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy;Multiple Myeloma Therapy;Solid Tumors Therapy; Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;CDK9 Inhibitors;Signal Transduction Modulators; Cyclin-dependent kinase 7; Cyclin-dependent kinase 2; 26S Proteasome; Cyclin-dependent kinase 9; Cyclin-dependent kinase 1 Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 5 inhibitor; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 9 inhibitor; Cell cycle inhibitor
CBR-001-571-372-1,RFM-000-378-1,CBR-001-571-372-1,O=C1SCC(=O)N1Cc1ccc2c(c1)/C(=C/c1[nH]cc(c1)CN1CCOCC1)/C(=O)N2,CBR-HVAC-07096: Solid Tumors Therapy; Angiogenesis Inhibitors;AXL Kinase Inhibitors;FGFR1 Inhibitors;FGFR2 Inhibitors;FGFR3 Inhibitors;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators
CBR-001-571-373-2,RFM-000-379-2,CBR-001-571-373-2,CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1scc(n1)c1cccnc1)C,"CBR-HVAC-00891: Non-Small Cell Lung Cancer Therapy;Lymphoma Therapy;Head and Neck Cancer Therapy;Gastric Cancer Therapy;Ovarian Cancer Therapy;Amyotrophic Lateral Sclerosis, Agents for;Prostate Cancer Therapy;Rheumatoid Arthritis, Treatment of;Digestive/Gastrointestinal Cancer Therapy;Colorectal Cancer Therapy;Asthma Therapy;Breast Cancer Therapy;Multiple Sclerosis, Agents for;Pancreatic Cancer Therapy;Antiallergy/Antiasthmatic Drugs;Melanoma Therapy;Liver Cancer Therapy;Glioblastoma Multiforme Therapy;Multiple Myeloma Therapy;Alzheimer's Dementia, Treatment of ; Angiogenesis Inhibitors;FGFR3 Inhibitors;KIT (C-KIT) Inhibitors;Lyn Kinase Inhibitors;Signal Transduction Modulators;Tyrosine Kinase Inhibitors; PROTO-ONCOGENE TYROSINE-PROTEIN KINASE KIT Inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; Fibroblast growth factor receptor 3 antagonist; LYN tyrosine kinase inhibitor"
CBR-001-571-374-3,RFM-000-380-5,CBR-001-571-374-3,NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N,"CBR-HVAC-01500: Pancreatic Disorders, Treatment of; Tryptase Inhibitors; Trypsin; Tryptase Inhibitor; Kallikrein inhibitor"
CBR-001-571-375-4,RFM-000-381-6,CBR-001-571-375-4,OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCNC(=N)N)CC(C)C)Cc1c[nH]c2c1cccc2)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1nc[nH]c1,CBR-HVAC-08473: Luteinizing hormone releasing hormone (LHRH) agonist
CBR-001-571-376-5,RFM-000-382-7,CBR-001-571-376-5,C=CC1=C(C)C2=N/C/1=C\c1[nH]c(c(c1C)CC)/C=C/1\N=C3/C(=C/4\N/C(=C\2)/[C@@H](C)C4CCC(=O)O)/CC(=O)C3=C1C,analog of CBR-HVAC-08434
CBR-001-571-377-6,RFM-000-383-8,CBR-001-571-377-6,CCc1c(C)c2n3c1C=C1C(=C(C4=[N+]1[Sn]13[N+]3=C(C(=C(C3=C2)CC)C)C=c2n1c(=C4)c(c2C)CCC(=O)O)CCC(=O)O)C,CBR-HVAC-05133: Decyclizing-heme-oxygenase-inhibitors; HEME OXYGENASE Inhibitor; Haem oxygenase 1 inhibitor; Heme Oxygenase (HO) Inhibitors; Heme oxygenase inhibitor; Liver Disorders; Metabolic Disorders; Treatment of Hyperbilirubinemia
CBR-001-571-378-7,RFM-000-384-9,CBR-001-571-378-7,COc1ccc(cc1)C(C(=O)N)N1CCCCC1,analog of CBR-HVAC-09708
CBR-001-571-379-8,RFM-000-385-0,CBR-001-571-379-8,OCc1c[nH]c2c1cccc2,"CBR-HVAC-05177: Immunostimulants;Chemopreventive Agents; Aryl Hydrocarbon Receptor (AhR) Agonists;Indoleamine 2,3-dioxygenase Inhibitors;Signal Transduction Modulators"
CBR-001-571-380-1,RFM-000-386-1,CBR-001-571-380-1,COc1c(O)cc2c(c1CC=C(C)C)c(=O)c1c(o2)cc(c(c1O)CC=C(C)C)O,CBR-HVAC-11570: Oncolytic Drugs;Anti-Helicobacter Pylori Agents;Antiulcer Drugs;Antiobesity Drugs; Acidic Sphingomyelinase (A-SMase) Inhibitors;Antioxidants;Fatty Acid Synthase (FAS) Inhibitors; Calcium ATPase Inhibitor;
CBR-001-571-381-2,RFM-000-387-2,CBR-001-571-381-2,O=C(NC(C(=O)NCC(=O)O)CSSCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)CCC(C(=O)O)N,"CBR-HVAC-05354: Antipsoriatics;Ophthalmic Drugs;Breast Cancer Therapy;Myelodysplastic Syndrome Therapy;Ovarian Cancer Therapy;Treatment of Tuberculosis;Hepatoprotectants;Radioprotectants/Radiomitigators;Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment ofDisulfide isomerase Inhibitor;"
CBR-001-571-382-3,RFM-000-388-3,CBR-001-571-382-3,Nc1nc2c(s1)cc(cc2)OC(F)(F)F,"CBR-HVAC-01905: Multiple Sclerosis, Agents for;Posttraumatic Stress Disorder (PTSD), Treatment of;Huntington's Disease, Treatment of;Atopic Dermatitis, Agents for;Melanoma Therapy;Neurologic Drugs (Miscellaneous);Breast Cancer Therapy;Acute Myocardial Infarction, Treatment of;Alzheimer's Dementia, Treatment of ;Autism, Treatment of;Obsessive-Compulsive Disorder (OCD), Treatment of;Bipolar Disorder, Treatment of;Antipsoriatics;Antidepressants;Antiparkinsonian Drugs;Amyotrophic Lateral Sclerosis, Agents for;Antiarrhythmic Drugs; Glutamate Release Inhibitors;K(V) 4.3 Channel Blockers;Signal Transduction Modulators;Sodium Channel  Blockers; Sodium channel Blocker; Glutamate antagonist; Dopamine receptor agonist; Sodium channel antagonist"
CBR-001-571-383-4,RFM-000-389-4,CBR-001-571-383-4,NC(=N)NC(=O)c1nc(Cl)c(nc1N)N,"CBR-HVAC-04040: Hypertension, Treatment of;Diuretics; Epithelial Sodium Channels (ENaC) Blockers;Na+/H+ Exchanger (NHE) Inhibitors"
CBR-001-571-384-5,RFM-000-390-7,CBR-001-571-384-5,NCC(=O)CCC(=O)O,"CBR-HVAC-01253: Antianemics;Ischemia, Treatment of;Acne Therapy;Dermatologic Drugs;Type 2 Diabetes, Agents for;Antifungal Agents;Basal Cell Carcinoma Therapy;Inflammatory Bowel Disease, Agents for;Premalignant Conditions Therapy;Restenosis Treatment of;Skin Cancer Therapy;Actinic Keratoses, Agents for;Diagnostic for Cancer;Esophageal Diseases, Treatment of;Neurologic Drugs (Miscellaneous)Delta-aminolevulinic acid dehydrase Inhibitor; Not applicable"
CBR-001-571-385-6,RFM-000-391-8,CBR-001-571-385-6,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2,"CBR-HVAC-03111: Nausea and Vomiting, Treatment of;Antipsychotic Drugs; Dopamine Receptor Antagonists;Signal Transduction Modulators"
CBR-001-571-386-7,RFM-000-392-9,CBR-001-571-386-7,CN1CCN(CC1)c1c(F)cc2c3c1OC[C@@H](n3cc(c2=O)C(=O)O)C,CBR-HVAC-02258: DNA gyrase; Topoisomerase IV Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-387-8,RFM-000-393-0,CBR-001-571-387-8,Oc1cc(O)cc(c1)O,CBR-HVAC-05874: Antispasmodics
CBR-001-571-388-9,RFM-000-394-1,CBR-001-571-388-9,[O-][N+](=O)c1ccccc1O,analog of CBR-HVAC-09164
CBR-001-571-389-0,RFM-000-395-2,CBR-001-571-389-0,NC(=O)c1nc[nH]c1N,CBR-HVAC-10325
CBR-001-571-390-3,RFM-000-396-3,CBR-001-571-390-3,[O-][N+](=O)c1cnc(s1)N,CBR-HVAC-09705: Natriuretic peptide receptor A Activator;
CBR-001-571-391-4,RFM-000-397-4,CBR-001-571-391-4,COc1cc(ccc1O)C(=O)C,"CBR-HVAC-05976: Hypertension, Treatment of;Antiparkinsonian Drugs;Diabetic Neuropathy, Agents for;Inflammatory Bowel Disease, Agents for;Atherosclerosis Therapy;Treatment of Shock;Respiratory Disorders (Not Specified); NADPH Oxidase (NOX) Inhibitors; NADPH oxidase Inhibitor;"
CBR-001-571-392-5,RFM-000-398-5,CBR-001-571-392-5,Ic1cc(c2c(c1O)nccc2)S(=O)(=O)O,CBR-HVAC-10104
CBR-001-571-393-6,RFM-000-399-6,CBR-001-571-393-6,NCCCC(=O)O,CBR-HVAC-08926
CBR-001-571-394-7,RFM-000-400-2,CBR-001-571-394-7,Nc1ccc(c(c1)C(=O)O)O,"CBR-HVAC-01390: Gastrointestinal Disorders (Not Specified);Irritable Bowel Syndrome, Agents for;Inflammatory Bowel Disease, Agents for; Arylamine N-acetyltransferase 1 (NAT1) Inhibitors;beta-Catenin Inhibitors;Protein Phosphatase 2A (PP-2A) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase; Beta-lactamase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-571-395-8,RFM-000-401-3,CBR-001-571-395-8,O=C1C(CCc2c1c1ccccc1n2C)Cn1ccnc1C,CBR-HVAC-02474: 5-Hydroxytryptamine 3 receptor Antagonist; 5 Hydroxytryptamine 3 receptor antagonist
CBR-001-571-396-9,RFM-000-402-4,CBR-001-571-396-9,CCOC(=O)c1ccc(cc1)O,CBR-HVAC-09084: Oestrogen receptor Antagonist;
CBR-001-571-397-0,RFM-000-403-5,CBR-001-571-397-0,COc1cccc(c1O)C=O,CBR-HVAC-11738
CBR-001-571-398-1,RFM-000-404-6,CBR-001-571-398-1,Nc1ccc(c(c1)O)C(=O)O,"CBR-HVAC-01506: Treatment of Tuberculosis;Inflammatory Bowel Disease, Agents forPteroic acid synthesising enzyme Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-571-399-2,RFM-000-405-7,CBR-001-571-399-2,OCc1ccc(o1)CO,CBR-HVAC-07428: Unidentified pharmacological activity
CBR-001-571-400-8,RFM-000-406-8,CBR-001-571-400-8,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1)C,"CBR-HVAC-01799: Hypertension, Treatment of;Lipoprotein Disorders, Treatment of ; Calcium Channel Blockers; Calcium channel Antagonist; L-type calcium channel antagonist"
CBR-001-571-401-9,RFM-000-407-9,CBR-001-571-401-9,Cc1cn([C@@H]2O[C@@H](C=C2)CO)c(=O)[nH]c1=O,CBR-HVAC-01606: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleoside reverse transcriptase inhibitor; DNA directed RNA polymerase inhibitor
CBR-001-571-402-0,RFM-000-408-0,CBR-001-571-402-0,Nc1ccc(cc1)S(=O)(=O)N,CBR-HVAC-05926: Antibacterial Drugs;Antifungal Agents; Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors
CBR-001-571-403-1,RFM-000-409-1,CBR-001-571-403-1,OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1ccc2c(c1)c(=O)cc(o2)C(=O)O,analog of CBR-HVAC-08431
CBR-001-571-404-2,RFM-000-410-4,CBR-001-571-404-2,O=CN1C(CNc2ccc(cc2)C(=O)N[C@H](C(=O)O)CCC(=O)O)CNc2c1c(=O)nc([nH]2)N,CBR-HVAC-01348: Antidote; Antineoplastic; Cancer; Chemopreventive Agents; Colorectal Cancer Therapy; Haematological Disorders; Oncolytic Drugs; Osteosarcoma Therapy; Treatment of Mucositis; Treatment of Poisoning
CBR-001-571-405-3,RFM-000-411-5,CBR-001-571-405-3,CNC(=O)Oc1ccc2c(c1)C1(C)CCN(C1N2C)C,"CBR-HVAC-02441: Alzheimer's Dementia, Treatment of ;Gastrointestinal Disorders (Not Specified);Antiglaucoma Agents; Acetylcholinesterase (AChE) Inhibitors;Butyrylcholinesterase Inhibitors; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor"
CBR-001-571-406-4,RFM-000-412-6,CBR-001-571-406-4,NCCOc1ccc(cc1OC)CC(=O)NCCCc1ccc(c(c1)C)C,"CBR-HVAC-04900: Antipruritics;Non-Opioid Analgesics;Neuropathic Pain, Treatment of;Diabetic Neuropathy, Agents for; TRPV1 (Vanilloid VR1 Receptor) Ligands; Vascular endothelial growth factor receptor 2 Agonist; Neurokinin 1 receptor antagonist; Vanilloid receptor 1 agonist"
CBR-001-571-407-5,RFM-000-413-7,CBR-001-571-407-5,COCCOC(=O)C(=Cc1ccc(cc1)N1CCCCC1)C#N,analog of CBR-HVAC-07276
CBR-001-571-408-6,RFM-000-414-8,CBR-001-571-408-6,COc1ccc(cc1)NC(=O)CCC(=O)NCCc1ccccc1,analog of CBR-HVAC-08193
CBR-001-571-429-1,RFM-000-415-9,CBR-001-571-429-1,CCOC(=O)c1c(C)nc(c(c1c1cccc(c1Cl)Cl)C(=O)OC)C,analog of CBR-HVAC-07657
CBR-001-571-430-4,RFM-000-416-0,CBR-001-571-430-4,COc1ccc2c(c1)nc([nH]2)S(=O)Cc1ncc(c(c1C)OC)C,"CBR-HVAC-03183: Anti-Helicobacter Pylori Agents;Gastroesophageal Reflux Disease, Agents for; H+/K+-ATPase Inhibitors;"
CBR-001-571-431-5,RFM-000-417-1,CBR-001-571-431-5,Cc1ccc2c(c1)[nH]c(c2Sc1ccc(cc1)Cl)C(=O)NCc1ccccn1,analog of CBR-HVAC-10836
CBR-001-571-432-6,RFM-000-418-2,CBR-001-571-432-6,CCc1ccc(cc1)NC(=O)N1CCN(CC1)c1ccccc1OC,analog of CBR-HVAC-10795
CBR-001-571-433-7,RFM-000-419-3,CBR-001-571-433-7,O/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C=C,CBR-HVAC-02051: Antibiotics;Antibacterial Drugs; Cell Wall Biosynthesis Inhibitors; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-571-434-8,RFM-000-420-6,CBR-001-571-434-8,CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)OCOC(=O)C(C)(C)C)/C=C\c1scnc1C,CBR-HVAC-02047: Antibacterial Drugs;Antibiotics; Cell Wall Biosynthesis Inhibitors; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-571-435-9,RFM-000-421-7,CBR-001-571-435-9,Clc1cccc2c1c(=O)n(c(c2)[C@@H](Nc1ncnc2c1nc[nH]2)C)c1ccccc1,"CBR-HVAC-06988: Asthma Therapy;Rheumatoid Arthritis, Treatment of;Non-Hodgkin's Lymphoma Therapy;Hematological Cancer Therapy;Lymphocytic Leukemia Therapy;Inflammatory Bowel Disease, Agents for;Multiple Sclerosis, Agents for;Systemic Lupus Erythematosus, Agents for;Inflammation, Treatment of;Lymphoma Therapy; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor"
CBR-001-571-436-0,RFM-000-422-8,CBR-001-571-436-0,OCC(C(c1ccc(cc1)[N+](=O)[O-])O)NC(=O)C,analog of CBR-HVAC-09410
CBR-001-571-437-1,RFM-000-423-9,CBR-001-571-437-1,CCN1CCN(C(=O)C1=O)CC(=O)N1CCC(C1)c1cccc(c1)Cl,analog of CBR-HVAC-03650
CBR-001-571-438-2,RFM-000-424-0,CBR-001-571-438-2,COc1ccccc1N1CCN(CC1)C(=O)c1ccc(cc1)CN1CCCCC1,analog of CBR-HVAC-04416
CBR-001-571-439-3,RFM-000-425-1,CBR-001-571-439-3,COc1ccc(cc1)CN1C(SC(C1=O)C)c1cccnc1,analog of CBR-HVAC-04559
CBR-001-571-440-6,RFM-000-426-2,CBR-001-571-440-6,CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC,CBR-HVAC-02382: Sodium channel Blocker; Sodium channel antagonist; Potassium channel antagonist; Membrane integrity inhibitor
CBR-001-571-441-7,RFM-000-427-3,CBR-001-571-441-7,CSc1nn2c(c1S(=O)(=O)c1ccccc1)[nH]c(=O)cc2C,analog of CBR-HVAC-07491
CBR-001-571-442-8,RFM-000-428-4,CBR-001-571-442-8,CN1CCCC(CC1)n1nc(Cc2ccc(cc2)Cl)c2c(c1=O)cccc2,CBR-HVAC-01728: Drugs for Allergic Rhinitis;Antiallergic Ophthalmic Agents;Treatment of Upper Respiratory Tract Disorders; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist; Histamine release inhibitor; Immunosuppressant
CBR-001-571-443-9,RFM-000-429-5,CBR-001-571-443-9,COc1ccc(cc1)c1n/c(=N/c2ccccc2)/sn1c1ccccc1,analog of CBR-HVAC-07143
CBR-001-571-444-0,RFM-000-430-8,CBR-001-571-444-0,O=C(CC1=C(C)/C(=C\c2ccc(cc2)S(=O)C)/c2c1cc(F)cc2)NCc1ccncc1,analog of CBR-HVAC-05222
CBR-001-571-445-1,RFM-000-431-9,CBR-001-571-445-1,COc1ccc(cc1)c1sc(nc1c1ccccc1)NC(=O)c1cc(OC)c(c(c1)OC)OC,analog of CBR-HVAC-07218
CBR-001-571-446-2,RFM-000-432-0,CBR-001-571-446-2,CCCc1c2CCCCc2cc2c1oc(cc2=O)C(=O)OCC,analog of CBR-HVAC-07849
CBR-001-571-447-3,RFM-000-433-1,CBR-001-571-447-3,COc1ccc2c(c1)c(=O)n1c(n2)CCC1,analog of CBR-HVAC-07598
CBR-001-571-448-4,RFM-000-434-2,CBR-001-571-448-4,NCCCC(CC(=O)NC1CNC(=O)C(NC(=O)/C(=C/NC(=O)N)/NC(=O)C(NC(=O)C(NC1=O)CO)CO)C1CC(O)NC(=N1)N)N,CBR-HVAC-09678: 16S-rRNA of 30S ribosomal subunit Binder; 23S-rRNA of 50S ribosomal subunit; Antibacterial
CBR-001-571-449-5,RFM-000-435-3,CBR-001-571-449-5,O=C1c2ccccc2c2c1c1ccccc1c(=O)n2CC1CC1,analog of CBR-HVAC-11978
CBR-001-571-450-8,RFM-000-436-4,CBR-001-571-450-8,O=C1O[C@@H](C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C(=O)C([C@H](C1)O)(C)C)C)O)C)/C(=C/c1csc(n1)C)/C,CBR-HVAC-04698: Non-Small Cell Lung Cancer Therapy;Liver Cancer Therapy;Ovarian Cancer Therapy;Solid Tumors Therapy;Digestive/Gastrointestinal Cancer Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;Colorectal Cancer Therapy;Female Reproductive System Cancer Therapy; Antimitotic Drugs;Apoptosis Inducers;Microtubule-Stabilizing Agents; Beta-tubulin; Hypoxia-inducible factor 1 Inhibitor; Inhibitor; Microtubule stimulant
CBR-001-571-451-9,RFM-000-437-5,CBR-001-571-451-9,O=c1n(CCNCCn2c(=O)c3cccc4c3c(c2=O)ccc4)c(=O)c2c3c1cccc3ccc2,analog of CBR-HVAC-04688
CBR-001-571-452-0,RFM-000-438-6,CBR-001-571-452-0,O=c1cc(C)c2c(o1)cc(c1c2occ1C)C,analog of CBR-HVAC-08179
CBR-001-571-453-1,RFM-000-439-7,CBR-001-571-453-1,Clc1ccc2c(c1)[nH]cc2C1=CCNCC1,analog of CBR-HVAC-08428
CBR-001-571-454-2,RFM-000-440-0,CBR-001-571-454-2,N#CC1(CC1)NC(=O)[C@H](CC(F)(C)C)N[C@H](C(F)(F)F)c1ccc(cc1)c1ccc(cc1)S(=O)(=O)C,"CBR-HVAC-00877: Oncolytic Drugs;Antiarthritic Drugs;Breast Cancer Therapy;Osteoarthritis, Treatment of;Treatment of Osteoporosis; Cathepsin K Inhibitors; Cathepsin K Inhibitor; Cathepsin K inhibitor; Bone resorption inhibitor; Protease/peptidase inhibitor"
CBR-001-571-455-3,RFM-000-441-1,CBR-001-571-455-3,OCC(CCn1cnc2c1nc(N)nc2)CO,CBR-HVAC-14303
CBR-001-571-456-4,RFM-000-442-2,CBR-001-571-456-4,COc1cc2c(cc1OC)nc1n(c2=O)cc(cc1)C(=O)O,analog of CBR-HVAC-08283
CBR-001-571-457-5,RFM-000-443-3,CBR-001-571-457-5,NC(=O)CN1C(=O)CC(Sc2c1cccc2)c1ccccc1,analog of CBR-HVAC-08600
CBR-001-571-458-6,RFM-000-444-4,CBR-001-571-458-6,CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O,CBR-HVAC-14195: CDK1/Cyclin B Inhibitors; CDK2/Cyclin A Inhibitors; CDK5/p25 Inhibitors; Checkpoint Kinase 1 (Chk1) Inhibitors; Cytoplasmic Tyrosine-Protein Kinase BMX Inhibitors; G Protein-Coupled Receptor GPR35 Agonists; Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors; Leucine-Rich Repeat Kinase 2 (LRRK2; Dardarin) Inhibitors; Na+/H+ Exchanger (NHE) Inhibitors; PROTEIN TYROSINE KINASE C Antagonist; Protein Kinase B (PKB/Akt) Inhibitors; Protein Kinase C (PKC) Inhibitors; Ribosomal Protein S6 Kinase alpha-1 (RSK-1; MAPKAPK-1a) Inhibitors; Signal Transduction Modulators; Anticancer; Antifungal Agents; Antihypertensive; Antiplatelet Therapy
CBR-001-571-459-7,RFM-000-445-5,CBR-001-571-459-7,O/N=C(/c1cc(ccc1O)C(C)(C)C)\c1ccccc1,analog of CBR-HVAC-03452
CBR-001-571-460-0,RFM-000-446-6,CBR-001-571-460-0,COc1ccc2c(c1)cc([nH]2)C(=O)N1CC(C)CC(C1)C,analog of CBR-HVAC-06878
CBR-001-571-461-1,RFM-000-447-7,CBR-001-571-461-1,CCCCCCCCCCCC(=O)NCCc1c[nH]c2c1cc(OC)cc2,analog of CBR-HVAC-04307
CBR-001-571-462-2,RFM-000-448-8,CBR-001-571-462-2,NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-03514: Antibacterial Drugs; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-463-3,RFM-000-449-9,CBR-001-571-463-3,CC[C@H]1CN2CC[C@H]1C[C@H]2[C@@H](c1ccnc2c1cc(OC)cc2)O,CBR-HVAC-14312
CBR-001-571-464-4,RFM-000-450-2,CBR-001-571-464-4,CN1CCC2(CC1)CCN(C2)C(=O)CCC(=O)c1ccc(cc1)F,analog of CBR-HVAC-08857
CBR-001-571-465-5,RFM-000-451-3,CBR-001-571-465-5,OCC1O[C@@H](NC(=O)N(N=O)C)C(C([C@@H]1O)O)O,analog of CBR-HVAC-04381
CBR-001-571-466-6,RFM-000-452-4,CBR-001-571-466-6,CO[C@@H]1C[C@@H](CC[C@H]1O)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C1)C)/C)O)OC)C)C)/C)C,CBR-HVAC-14184
CBR-001-571-467-7,RFM-000-453-5,CBR-001-571-467-7,CC[C@@H]1/C=C(\C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@@H](C[C@@H]2OC)C)C(=O)C(=O)N2[C@H](C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]1CC[C@H]([C@@H](C1)OC)O)/C)CCCC2,CBR-HVAC-14178
CBR-001-571-468-8,RFM-000-454-6,CBR-001-571-468-8,N1CC(C1)Oc1ccccc1c1onc(n1)c1ccccc1,analog of CBR-HVAC-07939
CBR-001-571-470-2,RFM-000-455-7,CBR-001-571-470-2,N1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2,analog of CBR-HVAC-08845
CBR-001-571-471-3,RFM-000-456-8,CBR-001-571-471-3,COc1cc2c(cc1OC)CCn1c2cc(NCC(C)C)nc1=O,analog of CBR-HVAC-01138
CBR-001-571-472-4,RFM-000-457-9,CBR-001-571-472-4,COc1cc(/C=C\c2ccc(c(c2)OP(=O)([O-])[O-])OC)cc(c1OC)OC,"CBR-HVAC-00719: Ophthalmic Drugs;Breast Cancer Therapy;Age-Related Macular Degeneration, Treatment of;Endocrine Cancer Therapy;Neurologic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Cervical Cancer Therapy;Antiarthritic Drugs;Prostate Cancer Therapy;Ovarian Cancer Therapy;Antiglaucoma Agents;Colorectal Cancer Therapy;Lung Cancer Therapy;Antipsoriatics;Head and Neck Cancer Therapy;Liver Cancer Therapy; Antimitotic Drugs;Apoptosis Inducers;Tubulin Polymerization Inhibitors;Vascular Disrupting Agents (VDA); CADHERIN 5 Inhibitor; Tubulin inhibitor; VE-cadherin antagonist; Angiogenesis inhibitor; Microtubule inhibitor; Apoptosis stimulant"
CBR-001-571-473-5,RFM-000-458-0,CBR-001-571-473-5,O[C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2)C(=O)C,CBR-HVAC-01345: Leukemia Therapy;Myeloid Leukemia Therapy;Antineoplastic Antibiotics;Antibiotics and AlkaloidsRNA synthesis inhibitor; Radical formation stimulant; DNA topoisomerase II inhibitor; DNA topoisomerase I inhibitor
CBR-001-571-474-6,RFM-000-459-1,CBR-001-571-474-6,COCCCN1CCC(CC1)NC(=O)c1cc(Cl)c(c2c1OCC2)N,"CBR-HVAC-01465: Irritable Bowel Syndrome, Agents for;Prokinetic Agents;Constipation, Agents for; Signal Transduction Modulators;5-HT4 Agonists; 5-Hydroxytryptamine 4 receptor Agonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-571-475-7,RFM-000-460-4,CBR-001-571-475-7,ClCCN(P1(=O)OCCCN1CCCl)CCCl,CBR-HVAC-01750: Oncolytic DrugsDNA inhibitor; DNA synthesis inhibitor
CBR-001-571-476-8,RFM-000-461-5,CBR-001-571-476-8,OC(=O)c1ccccc1OP(=O)(O)O,CBR-HVAC-01943: Analgesic DrugsPhosphodiesterase 4 inhibitor
CBR-001-571-477-9,RFM-000-462-6,CBR-001-571-477-9,CCC12CCCN3C2c2n(C(=O)C1)c1c(c2CC3)cccc1,CBR-HVAC-02042: Alpha 1 adrenoreceptor antagonist
CBR-001-571-478-0,RFM-000-463-7,CBR-001-571-478-0,CC(=O)Oc1cc(ccc1C(=O)O)C(F)(F)F,"CBR-HVAC-02098: Antiplatelet Therapy;Cognition Disorders, Treatment of; ; COX Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Phosphodiesterase 4 inhibitor; Thromboxane synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-571-479-1,RFM-000-464-8,CBR-001-571-479-1,CC(=O)OCC(=O)[C@@]1(O)CCC2[C@]1(C)CC=C1C2CCC2=CC(=O)CC[C@]12C,"CBR-HVAC-02102: Age-Related Macular Degeneration, Treatment of;Diabetic Retinopathy, Agents for;Antiglaucoma Agents;Ophthalmic Drugs; Angiogenesis Inhibitors; ; Angiogenesis inhibitor; Corticosteroid agonist"
CBR-001-571-480-4,RFM-000-465-9,CBR-001-571-480-4,COc1cc(Cc2cnc(nc2N)N)cc(c1Br)OC,CBR-HVAC-02662: Antibacterial Drugs; Dihydrofolate Reductase (DHFR) Inhibitors; Dihydrofolate reductase Inhibitor; Dihydrofolate reductase inhibitor
CBR-001-571-481-5,RFM-000-466-0,CBR-001-571-481-5,CN(CCOC(c1ccccn1)(c1ccccc1)C)C,CBR-HVAC-02822: ; ; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist
CBR-001-571-482-6,RFM-000-467-1,CBR-001-571-482-6,CCC(NCCNC(CO)CC)CO,CBR-HVAC-02871: Antimycobacterial Agents;Treatment of Tuberculosis; Cell Wall Biosynthesis Inhibitors; Arabinosyl transferase Inhibitor;
CBR-001-571-483-7,RFM-000-468-2,CBR-001-571-483-7,CN1CCN(CC1)C(c1ccccc1)c1ccccc1,"CBR-HVAC-03138: Atopic Dermatitis, Agents for;Antimigraine Drugs;Ear disorders, treatment of;Nausea and Vomiting, Treatment of; Drugs Acting on Histamine Receptors;Signal Transduction Modulators; Histamine H1 receptor Agonist;"
CBR-001-571-484-8,RFM-000-469-3,CBR-001-571-484-8,O=C1OC2C(C1C)(O)C13C4(C2O)C(OC3=O)CC(C24C(O1)OC(=O)C2O)C(C)(C)C,"CBR-HVAC-03335: Ischemic Stroke, Treatment of;Chemopreventive Agents;Antiallergy/Antiasthmatic Drugs;Septic Shock, Treatment of ; Antioxidants;GABA(A) Receptor Antagonists;Glycine Receptor Antagonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; PLATELET ACTIVATING FACTOR RECEPTOR Antagonist;"
CBR-001-571-485-9,RFM-000-470-6,CBR-001-571-485-9,OC(=O)CN1C(=S)C(Oc2c1cccc2C(C)C)C(C)C,CBR-HVAC-03662: Symptomatic Antidiabetic Agents; Aldose Reductase Inhibitors; Aldose reductase Inhibitor; Aldose reductase inhibitor
CBR-001-571-486-0,RFM-000-471-7,CBR-001-571-486-0,CCCn1c(=O)n(c2ccc(cc2)Cl)c2c(c1=O)[nH]cn2,"CBR-HVAC-04200: Chronic Obstructive Bronchitis, Agents for; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor"
CBR-001-571-487-1,RFM-000-472-8,CBR-001-571-487-1,OCc1ccc(o1)C=O,"CBR-HVAC-05988: Treatment of Osteoporosis;Sickle Cell Anemia, Agents for; ; Hemoglobin Modulator;"
CBR-001-571-488-2,RFM-000-473-9,CBR-001-571-488-2,Oc1cccc(c1)c1nc2nc(N)nc(c2nc1c1cccc(c1)O)N,"CBR-HVAC-06088: Asthma Therapy;Oncolytic Drugs;Acute Myocardial Infarction, Treatment of; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; Phosphoinositide 3 kinase Inhibitor;"
CBR-001-571-489-3,RFM-000-474-0,CBR-001-571-489-3,CCCNS(=O)(=O)Nc1ncnc(c1c1ccc(cc1)Br)OCCOc1ncc(cn1)Br,"CBR-HVAC-06265: Pulmonary Hypertension, Treatment of;Cardiovascular Genetic Disorders, Treatment of;Glioblastoma Multiforme Therapy;Scleroderma, Agents for;Interstitial Lung Diseases, Treatment of; Endothelin ETA Receptor Antagonists;Endothelin ETB Receptor Antagonists;Signal Transduction Modulators; ENDOTHELIN RECEPTOR Antagonist; Endothelin A receptor antagonist; Endothelin B receptor antagonist"
CBR-001-571-490-6,RFM-000-475-1,CBR-001-571-490-6,CN1CCN(CC1)Cc1ccc(cc1C(F)(F)F)NC(=O)c1ccc(c(c1)C#Cc1cnc2n1nccc2)C,CBR-HVAC-06519: Myeloid Leukemia Therapy;Lymphocytic Leukemia Therapy;Female Reproductive System Cancer Therapy;Lung Cancer Therapy;Leukemia Therapy;Squamous Cell Carcinoma Therapy;Digestive/Gastrointestinal Cancer Therapy;Endocrine Cancer Therapy;Astrocytoma Therapy; Abl1 Kinase Inhibitors;Angiogenesis Inhibitors;Apoptosis Inducers;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;FGFR Inhibitors;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;PDGFR Family Inhibitors;RET Inhibitors;Signal Transduction Modulators; Bcr-ABL tyrosine kinase Inhibitor; Bcr-Abl inhibitor; VEGFR tyrosine kinase inhibitor; Fibroblast growth factor receptor 1 antagonist; Fibroblast growth factor receptor 2 antagonist; Fibroblast growth factor receptor 3 antagonist; Fibroblast growth factor receptor 4 antagonist; Flt-3 kinase inhibitor; TIE-2 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Angiogenesis inhibitor; Angiopoietin inhibitor
CBR-001-571-491-7,RFM-000-476-2,CBR-001-571-491-7,C=CCn1c(=O)c2c(n1c1cccc(n1)C(O)(C)C)nc(nc2)Nc1ccc(cc1)N1CCN(CC1)C,CBR-HVAC-06749: Cervical Cancer Therapy;Head and Neck Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Ovarian Cancer Therapy;Oncolytic Drugs;Female Reproductive System Cancer Therapy;Gastric Cancer Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Glioblastoma Multiforme Therapy; Signal Transduction Modulators;Wee1 Kinase Inhibitors; Wee-1 protein kinase Inhibitor;
CBR-001-571-492-8,RFM-000-477-3,CBR-001-571-492-8,O=c1ccc2c(o1)cc1c(c2)cco1,CBR-HVAC-06938: Antipsoriatics
CBR-001-571-493-9,RFM-000-478-4,CBR-001-571-493-9,O=C(c1onc(n1)c1cc(Br)c(c(c1)Br)O)NCc1ccc(cc1)Oc1ccccc1,CBR-HVAC-06961: Treatment of Renal Diseases;Antidiarrheal Agents; CFTR Channel Inhibitors; Cystic Fibrosis Transmembrane Conductance Regulator Inhibitor;
CBR-001-571-494-0,RFM-000-479-5,CBR-001-571-494-0,COC(=O)N[C@H](C(=O)N1CC2(C[C@H]1c1ncc([nH]1)c1ccc3c(c1)C(F)(F)c1c3ccc(c1)c1ccc3c(c1)[nH]c(n3)[C@@H]1[C@H]3CC[C@@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C3)CC2)C(C)C,CBR-HVAC-07053: Anti-Hepatitis C Virus Drugs; HCV NS5A Inhibitors; ; HCV nonstructural protein 5A inhibitor
CBR-001-571-495-1,RFM-000-480-8,CBR-001-571-495-1,Fc1ccc(nc1)C(=O)Nc1ccc(c(c1)[C@@]12COC[C@H]2CSC(=N1)N)F,"CBR-HVAC-07085: Alzheimer's Dementia, Treatment of ; beta-Secretase 1 (BACE1) Inhibitors;beta-Secretase 2 (BACE2) Inhibitors; BACE Inhibitor; Secretase beta inhibitor"
CBR-001-571-496-2,RFM-000-481-9,CBR-001-571-496-2,COc1ccc(cc1)S(=O)(=O)N1CCCC1C(=O)Nc1cc(C)cc(c1)C,"CBR-HVAC-07203: Sleep Disorders, Treatment of; Orexin OX-1 Antagonists;Orexin OX-2 Antagonists;Signal Transduction Modulators; ;"
CBR-001-571-497-3,RFM-000-482-0,CBR-001-571-497-3,COP(=O)(N1C[C@H]2C[C@H](C1)c1n(C2)c(=O)ccc1)OC,CBR-HVAC-07334: Hepatoprotectants
CBR-001-571-498-4,RFM-000-483-1,CBR-001-571-498-4,COC(=O)c1c(C)nc(c(c1c1ccccc1[N+](=O)[O-])C(=O)OC)C,analog of CBR-HVAC-07685 (CRE-319M2)
CBR-001-571-499-5,RFM-000-484-2,CBR-001-571-499-5,O=C(NC1C(=O)N2C1SCC(=C2C(=O)O)Cl)COc1ccccc1,CBR-HVAC-08008: Cell wall synthesis inhibitor
CBR-001-571-500-1,RFM-000-485-3,CBR-001-571-500-1,NC(=O)C1c2ccccc2CCc2c1cccc2,CBR-HVAC-08653:
CBR-001-571-501-2,RFM-000-486-4,CBR-001-571-501-2,Clc1ccc2c(c1)s[nH]c2=O,CBR-HVAC-08661:
CBR-001-571-502-3,RFM-000-487-5,CBR-001-571-502-3,ClNS(=O)(=O)c1ccccc1,CBR-HVAC-08677:
CBR-001-571-503-4,RFM-000-488-6,CBR-001-571-503-4,CC[C@@]12CN3CCc4c([C@@](C[C@@H]([C@H]2O1)C3)(C(=O)OC)c1cc2c(cc1OC)N([C@@H]1[C@@]32CCN2[C@H]3[C@@](CC)(C=CC2)[C@H]([C@]1(O)C(=O)OC)OC(=O)C)C)[nH]c1c4cccc1,CBR-HVAC-08925:
CBR-001-571-504-5,RFM-000-489-7,CBR-001-571-504-5,Cc1ccc(c(c1)c1n[nH]c(c1)c1ccccc1)O,CBR-HVAC-09203: ; ; Cystic fibrosis transmembrane conductance regulator Modulator;
CBR-001-571-505-6,RFM-000-490-0,CBR-001-571-505-6,NC(=O)N1c2ccccc2C2C(c3c1cccc3)O2,CBR-HVAC-09695: ; ; Sodium channel Blocker;
CBR-001-571-506-7,RFM-000-491-1,CBR-001-571-506-7,CC[N+]1(CC)CCC(C1)OC(=O)C(c1ccccc1)(c1ccccc1)O,CBR-HVAC-09721: ; ; Muscarinic acetylcholine receptor Antagonist;
CBR-001-571-507-8,RFM-000-492-2,CBR-001-571-507-8,[NH-]c1on[n+](c1)N1CCOCC1,"CBR-HVAC-05115: Choline acetyltransferase Agonist; Angina pectoris, Treatment of;Vasodilators; Nitric Oxide (NO) Donors;"
CBR-001-571-508-9,RFM-000-493-3,CBR-001-571-508-9,CCC(C(c1ccc(cc1)O)CC)C(c1ccc(cc1)O)C,CBR-HVAC-10250:
CBR-001-571-509-0,RFM-000-494-4,CBR-001-571-509-0,COc1ccc(cc1)OC(C(=O)O)C,CBR-HVAC-10278: ; ; Sweet taste receptor T1R3 Inhibitor;
CBR-001-571-510-3,RFM-000-495-5,CBR-001-571-510-3,O=c1[nH]nc2n1c1ccccc1SC2,CBR-HVAC-10929: Antispastic Drugs
CBR-001-571-511-4,RFM-000-496-6,CBR-001-571-511-4,C=CCNC(=O)N1CC(C1)Oc1ccc(cc1)Cl,CBR-HVAC-11097: Anxiolytics
CBR-001-571-512-5,RFM-000-497-7,CBR-001-571-512-5,OCCNn1c(=O)c2cc(cc3c2c(c1=O)ccc3)[N+](=O)[O-],"CBR-HVAC-11416: Analgesic Drugs;Neuropathic Pain, Treatment of; ; Nerve growth factor receptor Antagonist;"
CBR-001-571-513-6,RFM-000-498-8,CBR-001-571-513-6,OC(=O)CCc1ccccc1Oc1ccc(cc1Cl)Cl,analog of CBR-HVAC-02839
CBR-001-571-514-7,RFM-000-499-9,CBR-001-571-514-7,CC[C@H]1Cn2nc(c3c2c(N1CC1CC1)cc(n3)C)c1ccc(cc1Cl)Cl,"CBR-HVAC-14447: CRF1 Receptor Antagonists; Signal Transduction Modulators; Anxiolytics; Irritable Bowel Syndrome, Agents for"
CBR-001-571-515-8,RFM-000-500-5,CBR-001-571-515-8,OCC(CNC(=O)CC1(C2CC3CC1CC(C2)C3)c1ccccc1)O,analog of CBR-HVAC-06733 (analog of BMS-816336)
CBR-001-571-516-9,RFM-000-501-6,CBR-001-571-516-9,Fc1ccc2c(c1)C(=NCc1n2cnc1C(=O)N)c1ccccc1Br,CBR-HVAC-14444: Benzodiazepine receptor agonist; GABA(A) Receptor Modulators; GABA-A receptor Modulator; Signal Transduction Modulators; Anticonvulsant; Antiepileptic Drugs; Antipsychotic; Anxiolytic; Anxiolytics
CBR-001-571-517-0,RFM-000-502-7,CBR-001-571-517-0,COC(=O)Nc1[nH]c2c(n1)cc(cc2)C(=O)c1ccccc1,CBR-HVAC-00084: Neurologic Cancer Therapy;Treatment of Helminthic Diseases;Lung Cancer Therapy; Apoptosis Inducers;Hedgehog Signaling Inhibitors; Catalase; Glutathione peroxidase Inhibitor; Microtubule inhibitor; Acetylcholinesterase inhibitor
CBR-001-571-518-1,RFM-000-503-8,CBR-001-571-518-1,O=C1OCC2=C1CC[C@]1([C@H]2C[C@H]2[C@@]3([C@@]41O[C@H]4[C@@H]1O[C@@]1([C@H]3O)C(C)C)O2)C,CBR-HVAC-14218
CBR-001-571-519-2,RFM-000-504-9,CBR-001-571-519-2,OC(=O)CCc1c[nH]c2c1cccc2,"CBR-HVAC-00277: Neurological Genetic Disorders, Treatment of ;Alzheimer's Dementia, Treatment of ;Huntington's Disease, Treatment of;Stroke, Treatment of; beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Free Radical Scavengers; Beta amyloid Inhibitor; Reducing agent; Beta amyloid protein antagonist"
CBR-001-571-520-5,RFM-000-505-0,CBR-001-571-520-5,O=C(Cc1ccccc1)N[C@H](C(=O)O)CCC(=O)N,CBR-HVAC-00296: Prostate Cancer TherapyPeptide antagonist
CBR-001-571-521-6,RFM-000-506-1,CBR-001-571-521-6,CNCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)C)Cc1nc[nH]c1)C(C)C)Cc1ccc(cc1)O)C(C)C)CCCNC(=N)N,CBR-HVAC-00411: ANGIOTENSIN II RECEPTOR TYPE 1; Angiotensin II receptor type 1 Antagonist; Angiotensin II antagonist
CBR-001-571-522-7,RFM-000-507-2,CBR-001-571-522-7,OCC1OC(C(C1O)O)n1ccc(=O)[nH]c1=O,"CBR-HVAC-00420: Antiepileptic Drugs;Bipolar Disorder, Treatment of;Neurodegenerative Diseases, Treatment of;AnxiolyticsDopamine receptor agonist"
CBR-001-571-523-8,RFM-000-508-3,CBR-001-571-523-8,O[C@H]1[C@@H](N)CC(O[C@H]1C)O[C@H]1C[C@@](O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2)C(=O)C,CBR-HVAC-01345: Leukemia Therapy;Myeloid Leukemia Therapy;Antineoplastic Antibiotics;Antibiotics and Alkaloids; RNA synthesis inhibitor; Radical formation stimulant; DNA topoisomerase II inhibitor; DNA topoisomerase I inhibitor
CBR-001-571-524-9,RFM-000-509-4,CBR-001-571-524-9,OC(=O)CCCCC(SCc1ccccc1)CCSCc1ccccc1,CBR-HVAC-00672: Pancreatic Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Hematological Cancer Therapy;Myeloid Leukemia Therapy;Myelodysplastic Syndrome Therapy;Sarcoma Therapy;Lymphoma Therapy;Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Colorectal Cancer Therapy;Digestive/Gastrointestinal Cancer TherapyRibonucleotide reductase Inhibitor; Unidentified pharmacological activity
CBR-001-571-525-0,RFM-000-510-7,CBR-001-571-525-0,Fc1ccccc1c1onc(n1)c1cccc(c1)C(=O)O,"CBR-HVAC-00796: Therapy of Inborn Errors of Metabolism;Cystic Fibrosis, Treatment of ;Metabolic and Nutritional Genetic Disorders, Treatment of ;Hemophilia, Agents for;Ocular Genetic Disorders, Treatment of ;Muscular Dystrophy, Agents forRibosomal readthrough stimulant"
CBR-001-571-526-1,RFM-000-511-8,CBR-001-571-526-1,OC(=O)C1CCn2c1ccc2C(=O)c1ccccc1,CBR-HVAC-00898: Non-Opioid AnalgesicsCyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-571-527-2,RFM-000-512-9,CBR-001-571-527-2,CN(CCC=C1c2ccccc2CCc2c1cccc2)C,CBR-HVAC-00916: Histamine receptor; 5-Hydroxytryptamine receptor; Acetylcholine receptor Inhibitor; Adrenergic transmitter uptake inhibitor; 5 Hydroxytryptamine uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor; Tricyclic antidepressant
CBR-001-571-528-3,RFM-000-513-0,CBR-001-571-528-3,NC1CONC1=O,"CBR-HVAC-00925: Smoking Cessation, Aid to;Obsessive-Compulsive Disorder (OCD), Treatment of;Psychiatric Disorders (Not Specified);Treatment of Tuberculosis;Anxiolytics;Neuropathic Pain, Treatment of;Treatment of Substance Dependency; Cell Wall Biosynthesis Inhibitors;Drugs Acting on NMDA Receptors;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Agonist; Glycine NMDA associated agonist"
CBR-001-571-529-4,RFM-000-514-1,CBR-001-571-529-4,OC(=O)C(Cc1ccc(cc1)O)N,CBR-HVAC-00942: Tyrosine hydroxylase Inhibitor; Prolactin inhibitor; Adrenoreceptor agonist
CBR-001-571-530-7,RFM-000-515-2,CBR-001-571-530-7,COCC(=O)Nc1c(I)c(C(=O)NCC(CO)O)c(c(c1I)C(=O)N(CC(CO)O)C)I,CBR-HVAC-00955: Peptide agonist
CBR-001-571-531-8,RFM-000-516-3,CBR-001-571-531-8,OC(=O)C(Cc1c[nH]c2c1cccc2)N,CBR-HVAC-01000: 5-Hydroxytryptamine receptor Agonist; DOPA decarboxylase stimulant; 5 Hydroxytryptamine receptor agonist
CBR-001-571-532-9,RFM-000-517-4,CBR-001-571-532-9,COc1cc(ccc1c1nc2c([nH]1)cccn2)S(=O)C,CBR-HVAC-01135: Positive Inotropic AgentsPhosphodiesterase 3 Inhibitor; Phosphodiesterase inhibitor
CBR-001-571-533-0,RFM-000-518-5,CBR-001-571-533-0,[O-][N+](=O)c1cncn1CCN1CCOCC1,CBR-HVAC-01209: Antitrichomonals;Oncolytic DrugsUnidentified pharmacological activity
CBR-001-571-534-1,RFM-000-519-6,CBR-001-571-534-1,OC(=O)c1ccc(cc1)N,CBR-HVAC-01240: Unidentified pharmacological activity
CBR-001-571-535-2,RFM-000-520-9,CBR-001-571-535-2,CC(CCc1ccccc1)NCC(c1ccc(c(c1)C(=O)N)O)O,"CBR-HVAC-01290: Angina pectoris, Treatment of;Hypertension, Treatment of; alpha-Adrenoceptor Antagonists;beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenoceptor; Beta-2 adrenoreceptor Agonist; Blocker; Alpha 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor antagonist"
CBR-001-571-536-3,RFM-000-521-0,CBR-001-571-536-3,OC(COc1cccc2c1cccc2)CNC(C)C,"CBR-HVAC-01313: Treatment of Cocaine Dependency;Anxiolytics;Hypertension, Treatment of;Angina pectoris, Treatment of;Cardiovascular Genetic Disorders, Treatment of;Antimigraine Drugs;Tuberous Sclerosis, Treatment of;Extrapyramidal Disorders, Treatment of;Antiinfectives (Not Specified);Dermatologic Drugs;Analgesic Drugs;Acute Myocardial Infarction, Treatment of;Antiarrhythmic Drugs;Migraine, Prophylactic Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction ModulatorsBeta adrenoreceptor antagonist"
CBR-001-571-537-4,RFM-000-522-1,CBR-001-571-537-4,OC(=O)CCCCC1SSCC1,"CBR-HVAC-01324: Type 2 Diabetes, Agents for;Diabetic Neuropathy, Agents for;Treatment of Poisoning;Neuropathic Pain, Treatment of;Hearing loss, treatment of; Aldehyde Dehydrogenase-2 (ALDH2) Activators;Antioxidants;Protein Kinase Activators;Reverse Transcriptase Inhibitors;Signal Transduction ModulatorsReducing agent"
CBR-001-571-538-5,RFM-000-523-2,CBR-001-571-538-5,OC(c1ccccc1Cl)CNC(C)(C)C,CBR-HVAC-01362: Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction ModulatorsLong-acting beta 2 adrenoceptor (LABA) agonist; Beta 2 adrenoreceptor agonist
CBR-001-571-539-6,RFM-000-524-3,CBR-001-571-539-6,NC(=O)N1c2ccccc2C=Cc2c1cccc2,"CBR-HVAC-01374: Treatment of Alcohol Dependency;Bipolar Disorder, Treatment of;Cancer Associated Disorders, Treatment of;Neuropathic Pain, Treatment of;Antiepileptic Drugs; Drugs Acting on Potassium Channels;Sodium Channel  Blockers; Sodium channel Blocker; Sodium channel antagonist"
CBR-001-571-540-9,RFM-000-525-4,CBR-001-571-540-9,OCC1OC(C(C1O)O)n1ccc(nc1=O)N,"CBR-HVAC-01377: Myeloid Leukemia Therapy;Prostate Cancer Therapy;Sarcoma Therapy;Lymphoma Therapy;Genital Warts, Treatment for;Oncolytic Drugs;Lymphocytic Leukemia Therapy; Antimetabolites;DNA Polymerase Inhibitors; DNA polymerase Inhibitor; DNA synthesis inhibitor"
CBR-001-571-541-0,RFM-000-526-5,CBR-001-571-541-0,COc1c2oc(=O)ccc2cc2c1occ2,"CBR-HVAC-01391: Immunosuppressants;Treatment of Transplant Rejection;Antipsoriatics;Lymphoma Therapy;Inflammatory Bowel Disease, Agents for; Acetylcholinesterase (AChE) Inhibitors;Cytochrome P450 CYP1A2 Inhibitors;DNA-Damaging DrugsCYP2A6 inhibitor"
CBR-001-571-542-1,RFM-000-527-6,CBR-001-571-542-1,OC(=O)c1cccnc1,"CBR-HVAC-01393: Lipoprotein Disorders, Treatment of ;Diabetic Nephropathy, Agents for;Metabolic Disorders (Not Specified);Ischemic Stroke, Treatment of;Other Ocular MedicationsAcetylcholinesterase; Arbutin synthase; Cholinesterase; Muscarinic acetylcholine receptor M2 Inhibitor; Vitamin B3 agonist"
CBR-001-571-543-2,RFM-000-528-7,CBR-001-571-543-2,NC(=N)c1ccc(cc1)OCCCCCOc1ccc(cc1)C(=N)N,"CBR-HVAC-01395: Non-Small Cell Lung Cancer Therapy;Pancreatic Cancer Therapy;Liver Cancer Therapy;Ovarian Cancer Therapy;Pneumocystis jiroveci Pneumonia, Agents for;Antileishmanials;Antitrypanosomals;Digestive/Gastrointestinal Cancer Therapy;Colorectal Cancer Therapy;Melanoma Therapy; PRL Phosphatase Inhibitors;Signal Transduction Modulators; Glyceraldehyde 3-phosphate dehydrogenase Inhibitor; Nuclease unspecified inhibitor; DNA repair enzyme inhibitor"
CBR-001-571-544-3,RFM-000-529-8,CBR-001-571-544-3,CC(=O)Nc1ccc(cc1)O,CBR-HVAC-01403: Non-Opioid Analgesics;Antipyretics; Cyclooxygenase-3 Inhibitors;Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-571-545-4,RFM-000-530-1,CBR-001-571-545-4,Nc1cnccc1N,CBR-HVAC-01462: Neurologic Drugs (Miscellaneous)Potassium channel Blocker; Potassium channel antagonist
CBR-001-571-546-5,RFM-000-531-2,CBR-001-571-546-5,OC(=O)Cc1cccc(c1N)C(=O)c1ccccc1,CBR-HVAC-01463: Cyclooxygenase inhibitor; Arachidonic acid inhibitor; Platelet aggregation inhibitor
CBR-001-571-547-6,RFM-000-532-3,CBR-001-571-547-6,OC(=O)CCNC(=O)c1ccc(cc1)N=Nc1ccc(c(c1)C(=O)O)O,"CBR-HVAC-01478: Inflammatory Bowel Disease, Agents forMyeloperoxidase; Platelet activating factor Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor; TP receptor antagonist"
CBR-001-571-548-7,RFM-000-533-4,CBR-001-571-548-7,C[C@H]1[C@H](NC(=O)/C(=N\OC(C(=O)O)(C)C)/c2csc(n2)N)C(=O)N1S(=O)(=O)O,CBR-HVAC-01502: Respiratory Disorders (Not Specified);Antibiotics; ; Beta-lactamase Inhibitor; Cell wall synthesis inhibitor
CBR-001-571-549-8,RFM-000-534-5,CBR-001-571-549-8,OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,CBR-HVAC-01504: Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Hyaluronic acid stimulant
CBR-001-571-550-1,RFM-000-535-6,CBR-001-571-550-1,O=C1NCC(O1)COc1cc(C)cc(c1)C,"CBR-HVAC-01580: Muscle Spasms, Drugs forUnidentified pharmacological activity"
CBR-001-571-551-2,RFM-000-536-7,CBR-001-571-551-2,N#Cc1ccc(cc1)Nc1nc(N)c(c(n1)Oc1c(C)cc(cc1C)C#N)Br,CBR-HVAC-01581: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-571-552-3,RFM-000-537-8,CBR-001-571-552-3,O=C(Nc1c(C)cccc1C)CN1CCN(CC1)CCCC(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-01598: VasodilatorsAngiotensin II receptor; Sodium channel Inhibitor; Calcium channel antagonist
CBR-001-571-553-4,RFM-000-538-9,CBR-001-571-553-4,OCC1OC(CC1O)n1cc(C)c(=O)[nH]c1=O,likely enantiomer of CBR-HVAC-01605
CBR-001-571-554-5,RFM-000-539-0,CBR-001-571-554-5,CCC(n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OC[C@@H]1CO[C@@](O1)(Cn1cncn1)c1ccc(cc1Cl)Cl)C,CBR-HVAC-01629: Prostate Cancer Therapy;Treatment of Neutropenia;Antifungal Agents;Non-Small Cell Lung Cancer Therapy;Basal Cell Carcinoma Therapy; Angiogenesis Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Lanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor; Sterol demethylase inhibitor
CBR-001-571-555-6,RFM-000-540-3,CBR-001-571-555-6,CCOC(=O)Nc1on[n+](c1)N1CCOCC1,CBR-HVAC-01683: Nitric oxide stimulant
CBR-001-571-556-7,RFM-000-541-4,CBR-001-571-556-7,CCOC(=O)c1ncn2c1CN(C)C(=O)c1c2ccc(c1)F,"CBR-HVAC-01690: Sleep Disorders, Treatment of;Antagonists to Benzodiazepines; GABA(A) BZ Site Receptor Antagonists;Signal Transduction Modulators; Benzodiazepine receptor Blocker; Benzodiazepine receptor antagonist"
CBR-001-571-557-8,RFM-000-542-5,CBR-001-571-557-8,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1OCCNC1,CBR-HVAC-01704: Antidepressants; alpha2-Adrenoceptor Antagonists;Norepinephrine Transporter (NET) Inhibitors;Signal Transduction Modulators; Alpha-2 adrenergic receptor Antagonist; Adrenergic transmitter uptake inhibitor; Alpha 2 adrenoreceptor antagonist
CBR-001-571-558-9,RFM-000-543-6,CBR-001-571-558-9,CCS(=O)(=O)CCn1c(C)ncc1[N+](=O)[O-],CBR-HVAC-01708: Antibacterial Drugs;Antimalarials;Treatment of Protozoal Diseases; Cytochrome P450 CYP1A2 InhibitorsUnidentified pharmacological activity
CBR-001-571-559-0,RFM-000-544-7,CBR-001-571-559-0,O=c1oc2c(c(=O)n1c1ccccn1)N(C)S(=O)(=O)c1c2cccc1,CBR-HVAC-01774: Analgesic DrugsProstaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-571-560-3,RFM-000-545-8,CBR-001-571-560-3,COc1ccccc1OCC(CN1CCN(CC1)CC(=O)Nc1c(C)cccc1C)O,"CBR-HVAC-01854: Irritable Bowel Syndrome, Agents for;Heart Failure Therapy;Angina pectoris, Treatment of;Peripheral Vascular Disease, Treatment of;Type 2 Diabetes, Agents for;Antiarrhythmic Drugs;Muscular Dystrophy, Agents for;Pulmonary Hypertension, Treatment of;Cardiovascular Diseases (Not Specified); Cytochrome P450 CYP2D6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Late Sodium Current (INaL) Blockers;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Voltage-gated sodium channel Inhibitor; Partial fatty acid oxidation inhibitor; Sodium channel antagonist"
CBR-001-571-561-4,RFM-000-546-9,CBR-001-571-561-4,FC(Oc1ccc(cc1OCC1CC1)C(=O)Nc1c(Cl)cncc1Cl)F,"CBR-HVAC-01873: Antipsoriatics;Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs;Liver and Biliary Tract Disorders, Treatment of;Brain Cancer Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor"
CBR-001-571-562-5,RFM-000-547-0,CBR-001-571-562-5,O=C(N1CC(=O)N2C(C1)c1ccccc1CC2)C1CCCCC1,CBR-HVAC-01923: Treatment of Helminthic DiseasesGlutathione S-transferase Inhibitor; Membrane permeability enhancer
CBR-001-571-563-6,RFM-000-548-1,CBR-001-571-563-6,OC(=O)Cc1ccc(cc1)c1ccccc1,"CBR-HVAC-01947: Non-Opioid Analgesics;Antiarthritic Drugs;Inflammation, Treatment ofProstaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-571-564-7,RFM-000-549-2,CBR-001-571-564-7,CCOC(=O)C1=CC2(CC)CCCN3C2c2n1c1ccccc1c2CC3,"CBR-HVAC-02032: Cognition Disorders, Treatment of;Stroke, Treatment of; Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase PDE1 Inhibitors;Signal Transduction Modulators; Calcium/calmodulin-dependent cGMP phosphodiesterase Inhibitor; Phosphodiesterase 1 inhibitor; Sodium channel antagonist"
CBR-001-571-565-8,RFM-000-550-5,CBR-001-571-565-8,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1ccc(nc1=O)N)COP(=O)(O)O,analog of CBR-HVAC-02067
CBR-001-571-566-9,RFM-000-551-6,CBR-001-571-566-9,N[C@@H](C[N+](C)(C)C)CC(=O)O,CBR-HVAC-10514: Androgen receptor Inhibitor; Androgen receptor antagonist
CBR-001-571-567-0,RFM-000-552-7,CBR-001-571-567-0,N#Cc1cc(c2ccncc2)c([nH]c1=O)C,CBR-HVAC-02196: Heart Failure Therapy; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase Inhibitor; Phosphodiesterase 3 inhibitor
CBR-001-571-568-1,RFM-000-553-8,CBR-001-571-568-1,OC(=O)C(c1ccc(cc1)CC1CCCC1=O)C,"CBR-HVAC-02225: Analgesic Drugs;Antiarthritic Drugs;Inflammation, Treatment ofCyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-571-569-2,RFM-000-554-9,CBR-001-571-569-2,OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)/N=C/N1CCCCCC1,CBR-HVAC-02283: Penicillin binding protein 2 Inhibitor; Cell wall synthesis inhibitor
CBR-001-571-570-5,RFM-000-555-0,CBR-001-571-570-5,CC(N(C(C)C)CCC(c1ccccn1)(c1ccccc1)C(=O)N)C,CBR-HVAC-02293: Antiarrhythmic DrugsSodium channel Blocker; Sodium channel antagonist
CBR-001-571-571-6,RFM-000-556-1,CBR-001-571-571-6,O=C1CN2[C@@H]3C[C@H]1C[C@H]2C[C@H](C3)OC(=O)c1c[nH]c2c1cccc2,CBR-HVAC-02310: 5-Hydroxytryptamine 3 receptor Antagonist; 5 Hydroxytryptamine 3 receptor antagonist
CBR-001-571-572-7,RFM-000-557-2,CBR-001-571-572-7,OC(=O)C(Cc1c[nH]c2c1cc(O)cc2)N,CBR-HVAC-02352: Neurotransmitter agonist
CBR-001-571-573-8,RFM-000-558-3,CBR-001-571-573-8,Oc1ccc(cc1)OCc1ccccc1,CBR-HVAC-02359: Melanin inhibitor
CBR-001-571-574-9,RFM-000-559-4,CBR-001-571-574-9,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@H]([C@@H]([C@H]2O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)N)O)N)[C@@H](C[C@@H]1O)N,CBR-HVAC-14175
CBR-001-571-575-0,RFM-000-560-7,CBR-001-571-575-0,OC(=O)Cc1ccc(n1C)C(=O)c1ccc(cc1)C,CBR-HVAC-02395: Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-571-576-1,RFM-000-561-8,CBR-001-571-576-1,O=C(Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)Nc1cccc(c1)C(=O)Nc1cc(ccc1C)C(=O)Nc1ccc(c2c1c(cc(c2)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,CBR-HVAC-02420: EGF; FGF; Reverse transcriptase; P2 receptor; Vascular endothelial growth factor; Low density lipoprotein receptor; IGF; PDGFR beta; Transforming growth factor beta Antagonist; Inhibitor; Unidentified pharmacological activity
CBR-001-571-577-2,RFM-000-562-9,CBR-001-571-577-2,CCOC(=O)c1ccc(cc1)N,CBR-HVAC-02426: Local AnestheticsSodium channel Nav1.8 Blocker; Sodium channel antagonist
CBR-001-571-578-3,RFM-000-563-0,CBR-001-571-578-3,OC(=O)c1ccccc1Nc1cccc(c1C)C,CBR-HVAC-02438: Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-571-579-4,RFM-000-564-1,CBR-001-571-579-4,Oc1ccc(cc1)C=Cc1cc(O)cc(c1)O,"CBR-HVAC-02444: Chemopreventive Agents;Multiple Myeloma Therapy;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Type 2 Diabetes, Agents for;Huntington's Disease, Treatment of;Antipsoriatics;Oncolytic Drugs;Other Ocular Medications;Alzheimer's Dementia, Treatment of ;Anti-Herpes Virus Drugs;Neuromuscular Genetic Disorders, Treatment of;Neurologic Drugs (Miscellaneous);Antiobesity Drugs;Colorectal Cancer Therapy;Chemoprotective Agents; Angiogenesis Inhibitors;APOA1 Expression Enhancers;Apoptosis Inducers;beta-Secretase 1 (BACE1) Inhibitors;DNA Topoisomerase II Inhibitors;Extracellular-regulated Kinase (ERK) Activators;Lipid Peroxidation Inhibitors;MAO-A Inhibitors;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers;NF-kappaB (NFKB) Modulators;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Signal Transduction Modulators;Thioredoxin Reductase Inhibitors;Xanthine Oxidase Inhibitors; COX-1; Estrogen receptor Agonist; Inhibitor; Reducing agent"
CBR-001-571-580-7,RFM-000-565-2,CBR-001-571-580-7,COCCc1ccc(cc1)OCC(CNC(C)C)O,CBR-HVAC-02467: Beta-2 adrenergic receptor; Beta-1 adrenergic receptor Agonist; Beta 1 adrenoreceptor antagonist
CBR-001-571-581-8,RFM-000-566-3,CBR-001-571-581-8,O=C([C@@H](c1ccccc1)O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1CS(=O)(=O)[O-],CBR-HVAC-02471: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-571-582-9,RFM-000-567-4,CBR-001-571-582-9,Cc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-02480: Lipoxygenase 5 Inhibitor; Membrane integrity inhibitor; Reducing agent
CBR-001-571-583-0,RFM-000-568-5,CBR-001-571-583-0,CCc1c(C)[nH]c2c1C(=O)C(CC2)CN1CCOCC1,CBR-HVAC-02586: Antipsychotic DrugsDopamine receptor D2 Blocker; Dopamine D2 receptor antagonist; Dopamine D5 receptor antagonist
CBR-001-571-584-1,RFM-000-569-6,CBR-001-571-584-1,NCCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)CCC(=O)N)Cc1ccccc1,CBR-HVAC-14308
CBR-001-571-585-2,RFM-000-570-9,CBR-001-571-585-2,OCCCNC(=O)C(C(CO)(C)C)O,CBR-HVAC-02596: Antimalarials;Dermatologic Drugs;Treatment of Upper Respiratory Tract DisordersUnidentified pharmacological activity
CBR-001-571-586-3,RFM-000-571-0,CBR-001-571-586-3,CSc1ccc(cc1)OCc1ncc(n1C)[N+](=O)[O-],CBR-HVAC-02612: Antileishmanials;AntitrypanosomalsUnidentified pharmacological activity
CBR-001-571-587-4,RFM-000-572-1,CBR-001-571-587-4,NC(=O)NC1NC(=O)NC1=O,"CBR-HVAC-02613: Wound-Healing Agents;Dermatological Genetic Disorders, Treatment of;Antipsoriatics;Cognition Disorders, Treatment of;Antiobesity DrugsUnidentified pharmacological activity"
CBR-001-571-588-5,RFM-000-573-2,CBR-001-571-588-5,C[C@H](Cn1cnc2c1ncnc2N)OCP(=O)(O)O,CBR-HVAC-02614: Anti-HIV Agents;Anti-Hepatitis B Virus Drugs;Microbicides; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleotide reverse transcriptase inhibitor
CBR-001-571-589-6,RFM-000-574-3,CBR-001-571-589-6,CN1CCCCC1C(=O)Nc1c(C)cccc1C,CBR-HVAC-02621: Potassium channel antagonist; Voltage-gated sodium channel antagonist
CBR-001-571-590-9,RFM-000-575-4,CBR-001-571-590-9,CN(CCc1c[nH]c2c1cc(cc2)Cn1cncn1)C,"CBR-HVAC-02631: Acute Attacks of Migraine, Treatment of; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 1D receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist; 5 Hydroxytryptamine 1B receptor agonist"
CBR-001-571-591-0,RFM-000-576-5,CBR-001-571-591-0,OC[C@H]([C@H]1O[C@H]2[C@@H]([C@H]1O)OC(O2)(C)C)O,analog of CBR-HVAC-02681
CBR-001-571-592-1,RFM-000-577-6,CBR-001-571-592-1,O=C(c1cnn2c1nccc2c1ccncc1)c1ccccn1,"CBR-HVAC-02710: Generalized Anxiety Disorder (GAD), Treatment of; GABA(A) Receptor Modulators;Signal Transduction Modulators; GABA-A receptor Modulator; GABA A receptor agonist"
CBR-001-571-593-2,RFM-000-578-7,CBR-001-571-593-2,COC(=O)C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])C(=O)OC)C,"CBR-HVAC-02787: Hypertension, Treatment of;Angina pectoris, Treatment of;Raynaud's Phenomenon, Treatment for ; Antioxidants;Calcium Channel Blockers;Nuclear Factor of Activated T-cells, Cytoplasmic 2 (NFAT1, NFATC2) Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Calcium channel Blocker; Calcium channel antagonist"
CBR-001-571-594-3,RFM-000-579-8,CBR-001-571-594-3,CCCC1C(=O)n2n(C1=O)c1cc(C)ccc1nc2N(C)C,"CBR-HVAC-02797: Treatment of Gout;Rheumatoid Arthritis, Treatment of;Ankylosing Spondylitis, Treatment of; Xanthine Oxidase InhibitorsCyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-571-595-4,RFM-000-580-1,CBR-001-571-595-4,COc1c(N2CCNC(C2)C)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-02799: Treatment of Tuberculosis;Antibacterial Drugs;Antibacterial Ophthalmic Drugs; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-596-5,RFM-000-581-2,CBR-001-571-596-5,COc1ccc2c(c1C(F)(F)F)cccc2C(=S)N(CC(=O)O)C,CBR-HVAC-02837: Symptomatic Antidiabetic Agents; Aldose Reductase Inhibitors; Aldose reductase Inhibitor; Aldose reductase inhibitor
CBR-001-571-597-6,RFM-000-582-3,CBR-001-571-597-6,CCn1cc(C(=O)O)c(=O)c2c1cc(N1CCN(CC1)C)c(c2)F,CBR-HVAC-02901: Antibacterial DrugsTopoisomerase IV Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-598-7,RFM-000-583-4,CBR-001-571-598-7,CNCC(c1ccc(c(c1)OC(=O)C(C)(C)C)OC(=O)C(C)(C)C)O,CBR-HVAC-02166: Antiglaucoma Agents; Adrenergic receptor Agonist; Adrenoreceptor agonist; Alpha adrenoreceptor agonist
CBR-001-571-599-8,RFM-000-584-5,CBR-001-571-599-8,N#Cc1[nH]c2c(c1)c(OCC(CN1CCN(CC1)C(c1ccccc1)c1ccccc1)O)ccc2,CBR-HVAC-02971: Heart Failure TherapySodium channel Opener; Sodium channel agonist
CBR-001-571-600-4,RFM-000-585-6,CBR-001-571-600-4,CCCCCCCCCCCCCCCCCCNC(=O)OCC(COP(=O)(OCC[n+]1ccsc1)O)OC,CBR-HVAC-02983: ; Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Platelet activating factor receptor Antagonist; Platelet activating factor antagonist
CBR-001-571-601-5,RFM-000-586-7,CBR-001-571-601-5,OCC1OC(O)C(C(C1O)O)NC(=O)N(N=O)C,CBR-HVAC-03071: Pancreatic Cancer Therapy; DNA Alkylating Drugs
CBR-001-571-602-6,RFM-000-587-8,CBR-001-571-602-6,O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C,CBR-HVAC-03087: Neuromuscular BlockersNicotinic acetylcholine receptor Antagonist;
CBR-001-571-603-7,RFM-000-588-9,CBR-001-571-603-7,CCc1nc(C)ccc1O,CBR-HVAC-03256: Retinoprotectors; Antioxidants;Lipid Peroxidation Inhibitors
CBR-001-571-604-8,RFM-000-589-0,CBR-001-571-604-8,CO/N=C(/c1csc(n1)N)\C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)C,CBR-HVAC-14282
CBR-001-571-605-9,RFM-000-590-3,CBR-001-571-605-9,NC(=N)NCCC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)O)CC(=O)O)N,CBR-HVAC-14302
CBR-001-571-606-0,RFM-000-591-4,CBR-001-571-606-0,CCCc1c(OCC(COc2ccc(c(c2CCC)O)C(=O)C)O)ccc2c1oc(cc2=O)C(=O)O,"CBR-HVAC-03389: Angina pectoris, Treatment of;Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; Cysteinyl leukotriene receptor Antagonist; Leucotriene D4 antagonist; Leucotriene E4 antagonist"
CBR-001-571-607-1,RFM-000-592-5,CBR-001-571-607-1,Nc1cc(nc(=N)n1O)N1CCCCC1,CBR-HVAC-01898: ATP-sensitive potassium channel Activator; ATP-sensitive potassium channel agonist; K(ATP) Channel Activators; Polarisation stimulant; Renin secretion stimulant; Antihypertensive; Hair Growth Stimulants; Vasodilator
CBR-001-571-608-2,RFM-000-593-6,CBR-001-571-608-2,Nc1nncs1,CBR-HVAC-03454: Oncolytic DrugsInosine monophosphate dehydrogenase inhibitor
CBR-001-571-609-3,RFM-000-594-7,CBR-001-571-609-3,Clc1ccc(c(c1)O)Oc1ccc(cc1Cl)Cl,CBR-HVAC-03516: Treatment of Mucositis;Antibacterial Drugs; Bacterial Fatty Acid Biosynthesis Inhibitors ;DNA Methyltransferase 1 (DNMT1) Inhibitors;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors; Enoyl-(acyl carrier protein) reductase Inhibitor;
CBR-001-571-610-6,RFM-000-595-8,CBR-001-571-610-6,CN(C(=N)NNc1c(C)cccc1C)C,CBR-HVAC-03631: Antiarrhythmic DrugsSodium channel Blocker; Sodium channel antagonist
CBR-001-571-611-7,RFM-000-596-9,CBR-001-571-611-7,CCC(C(=O)O)(CC(=O)Nc1cccc(c1)/C=C/c1scc(n1)C1CCC1)CC,CBR-HVAC-04005: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist; Leucotriene D4 antagonist
CBR-001-571-612-8,RFM-000-597-0,CBR-001-571-612-8,O=C1CCC(N1)C(=O)O,"CBR-HVAC-03814 Cognition Disorders, Treatment of;Treatment of Nutritional Disorders;Sickle Cell Anemia, Agents for;"
CBR-001-571-613-9,RFM-000-598-1,CBR-001-571-613-9,CN1C[C@@H](C[C@H]2[C@H]1Cc1cn(c3c1c2ccc3)C(C)C)C(=O)N[C@H]1CCC[C@H]1O,"CBR-HVAC-10896: Cognition Disorders, Treatment of;Antiplatelet Therapy; Signal Transduction Modulators;5-HT2A Antagonists;5-HT7 Antagonists; 5-Hydroxytryptamine 7 receptor; 5-Hydroxytryptamine 2 receptor Antagonist;"
CBR-001-571-614-0,RFM-000-599-2,CBR-001-571-614-0,Cc1nc(C)c(nc1C)C,"CBR-HVAC-03859: Stroke, Treatment of;Angina pectoris, Treatment ofThromboxane A synthase Inhibitor; Unidentified pharmacological activity"
CBR-001-571-615-1,RFM-000-600-8,CBR-001-571-615-1,CN1[C@@H]2CC[C@H]1CC(C2)NC(=O)n1c(=O)n(c2c1cccc2)C(C)C,CBR-HVAC-14490: 5-Hydroxytryptamine 4 receptor Agonist; Analgesic
CBR-001-571-616-2,RFM-000-601-9,CBR-001-571-616-2,c1ccc(cc1)C(c1ccccc1)O[C@@H]1CCCN(C1)CCc1ccc2c(c1)OCO2,"CBR-HVAC-03954: Irritable Bowel Syndrome, Agents for;Urinary Incontinence Therapy; Muscarinic M3 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M3 Antagonist; Muscarinic M3 receptor antagonist"
CBR-001-571-617-3,RFM-000-602-0,CBR-001-571-617-3,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC/C=C/c1ccccc1)C,"CBR-HVAC-04008: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Calcium channel Antagonist; N-type calcium channel antagonist; L-type calcium channel antagonist"
CBR-001-571-618-4,RFM-000-603-1,CBR-001-571-618-4,Clc1ccc2c(c1)C(=C(c1cccs1)O)C(=O)N2C(=O)N,CBR-HVAC-04047: Antiarthritic Drugs; Cyclooxygenase (COX) Inhibitors;Signal Transduction Modulators
CBR-001-571-619-5,RFM-000-604-2,CBR-001-571-619-5,CC(C(Cc1ccc(c(c1)O)O)C)Cc1ccc(c(c1)O)O,"CBR-HVAC-04052: Actinic Keratoses, Agents for;Type 2 Diabetes, Agents for;Prostate Cancer Therapy; IGF-1R Inhibitors;Lipoxygenase Inhibitors;Signal Transduction Modulators; Lipoxygenase 5 Inhibitor;"
CBR-001-571-620-8,RFM-000-605-3,CBR-001-571-620-8,O=C(N[C@H](c1ccccc1)CNC(=O)[C@@](Cc1c[nH]c2c1cccc2)(NC(=O)OC1C2CC3CC1CC(C2)C3)C)CCC(=O)O,CBR-HVAC-04127: Anxiolytics; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin receptor Antagonist; CCK B receptor antagonist
CBR-001-571-621-9,RFM-000-606-4,CBR-001-571-621-9,N#Cc1c(sc2c1CC(=O)O[Sr]OC2=O)N1CC(=O)O[Sr]OC(=O)C1,CBR-HVAC-04147: Bone Formation Stimulants;Bone Resorption Inhibitors;Treatment of Osteoporosis; Calcium-Sensing Receptor (CaSR) Agonists;Signal Transduction Modulators; Increasing bone formation and decreasing bone resorption leading to a rebalance of bone turnover in favor of bone formation; Bone formation stimulant; Bone resorption inhibitor
CBR-001-571-622-0,RFM-000-607-5,CBR-001-571-622-0,C[C@H](CNC(CC(=O)N[C@@H]1CCc2c(N(C1=O)Cc1ccc(cc1)c1ccccc1c1nn[nH]n1)cccc2)(C)C)O,CBR-HVAC-14286
CBR-001-571-623-1,RFM-000-608-6,CBR-001-571-623-1,COc1ccccc1CN[C@H]1C2CCN([C@H]1C(c1ccccc1)c1ccccc1)CC2,"CBR-HVAC-14443: Neurokinin 1 receptor antagonist; Neurokinin receptor 1 Antagonist; Signal Transduction Modulators; Substance P uptake inhibitor; Tachykinin NK1 Antagonists; Analgesic; Anti-HIV Agents; Anti-inflammatory; Antipsychotic; Anxiolytic; Non-Opioid Analgesics; Pancreatic Disorders, Treatment of"
CBR-001-571-624-2,RFM-000-609-7,CBR-001-571-624-2,CN1CCN(CC1)c1c(F)cc2c3c1OC[C@@H](n3cc(c2=O)C(=O)O)C,CBR-HVAC-02258: DNA gyrase; Topoisomerase IV Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-625-3,RFM-000-610-0,CBR-001-571-625-3,CC[C@@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)Cc1ccc(cc1)O)CCC(=O)O)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](Cc1ccccc1)N)CCCNC(=N)N)CC(=O)N)Cc1ccccc1)CCC(=O)O)CCC(=O)O)C,CBR-HVAC-13389: Thrombin Inhibitor; Anticoagulant
CBR-001-571-626-4,RFM-000-611-1,CBR-001-571-626-4,CC(C1O[C@H]2[C@H](O1)C[NH2+][Pt-2]1([NH2+]C2)OC(=O)CC(=O)O1)C,CBR-HVAC-04577: Lung Cancer Therapy;Gastric Cancer Therapy;Liver Cancer Therapy;Head and Neck Cancer Therapy; DNA-Damaging Drugs
CBR-001-571-627-5,RFM-000-612-2,CBR-001-571-627-5,O=C(Nc1cc(N(C)C)c2c(c1O)C(=O)C1=C(O)[C@]3([C@@H](C[C@@H]1C2)[C@H](N(C)C)C(=C(C3=O)C(=O)N)O)O)CNC(C)(C)C,CBR-HVAC-04615: Myeloid Leukemia Therapy;Antibiotics;Antibacterial Drugs; 30S Ribosomal Protein Inhibitors; 16S-rRNA of 30S ribosomal subunit Binder;
CBR-001-571-628-6,RFM-000-613-3,CBR-001-571-628-6,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](OC2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C[C@H](C(=O)[C@H]([C@@H]2[C@]1(C)OC(=O)N2CCCCn1cnc(c1)c1cccnc1)C)C)(C)OC,CBR-HVAC-04777: Antibiotics; Cytochrome P450 CYP2D6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; 23S-rRNA of 50S ribosomal subunit Binder;
CBR-001-571-629-7,RFM-000-614-4,CBR-001-571-629-7,O=C(c1ccc(c(c1)Cl)F)N[C@H]1c2cc(ccc2OC([C@H]1O)(C)C)C(=O)C,"CBR-HVAC-00046: Migraine, Prophylactic Treatment of;Antiepileptic Drugs;Antimigraine Drugs; Gap junction modulators; 5-HYDROXYTRYPTAMINE 1D RECEPTOR Agonist; Nitric oxide inhibitor; Gap junction inhibitor"
CBR-001-571-630-0,RFM-000-615-5,CBR-001-571-630-0,O=C([C@@H](NC(=O)[C@@H]1CCCN1C(=O)Nc1ccccc1[N+](=O)[O-])Cc1ccc2c(c1)cccc2)N(Cc1ccccc1)C,CBR-HVAC-04859: Non-Opioid Analgesics; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin receptor 1 Antagonist; Neurokinin 1 receptor antagonist
CBR-001-571-631-1,RFM-000-616-6,CBR-001-571-631-1,COc1c(OC)ncnc1NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-05216: Antimalarials; Dihydropteroate Synthase (DHPS) Inhibitors; Dihydropteroate synthase Inhibitor;
CBR-001-571-632-2,RFM-000-617-7,CBR-001-571-632-2,Nc1cccc2c1c(=O)[nH][nH]c2=O,CBR-HVAC-05239: Immunomodulators
CBR-001-571-633-3,RFM-000-618-8,CBR-001-571-633-3,O=Cc1c(COP(=O)(O)O)cnc(c1O)C,"CBR-HVAC-05338: Stroke, Treatment of;Tardive Dyskinesia, Treatment of;Cardioprotective Agents;Metabolic and Nutritional Genetic Disorders, Treatment of ;Lipoprotein Disorders, Treatment of ;Hypertension, Treatment of"
CBR-001-571-634-4,RFM-000-619-9,CBR-001-571-634-4,Clc1ccc(cc1)C(=O)c1c(N)sc2c1CCCC2,"CBR-HVAC-05403: Neuropathic Pain, Treatment of; Adenosine Receptor Modulators;Signal Transduction Modulators; ADENOSINE A1 RECEPTOR Modulator;"
CBR-001-571-635-5,RFM-000-620-2,CBR-001-571-635-5,NCC(=O)N[C@H](C(=O)NCC(=O)O)Cc1ccc(cc1)O,analog of CBR-HVAC-05463
CBR-001-571-636-6,RFM-000-621-3,CBR-001-571-636-6,NC(=NC(=O)c1nc(Cl)c(nc1N)N)NCc1ccccc1,"CBR-HVAC-05705: Cystic Fibrosis, Treatment of ; Epithelial Sodium Channels (ENaC) Blockers"
CBR-001-571-637-7,RFM-000-622-4,CBR-001-571-637-7,OC(=O)c1ccccn1,CBR-HVAC-05816: Anti-Herpes Simplex Virus Drugs;Immunomodulators;Acne Therapy;Antiviral Ophthalmic Drugs;Anti-Herpes Labialis Drugs; Chelating Agents
CBR-001-571-638-8,RFM-000-623-5,CBR-001-571-638-8,O=C([C@@H](C1=CCC=CC1)N)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C,CBR-HVAC-05353: Antibiotics;Antibacterial Drugs; Penicillin binding protein; Transpeptidase Inhibitor;
CBR-001-571-639-9,RFM-000-624-6,CBR-001-571-639-9,c1ccc2c(c1)c(c[nH]2)Cc1c[nH]c2c1cccc2,"CBR-HVAC-05912: Chemopreventive Agents;Premalignant Conditions Therapy;Prostate Cancer Therapy;Immunostimulants;Cervical Cancer Therapy; Androgen Receptor Antagonists;Aryl Hydrocarbon Receptor (AhR) Agonists;beta-Glucuronidase Inhibitors;Indoleamine 2,3-dioxygenase Inhibitors;Signal Transduction Modulators; Androgen receptor Antagonist;"
CBR-001-571-640-2,RFM-000-625-7,CBR-001-571-640-2,CCCNC(C(=O)Nc1ccccc1C)C,CBR-HVAC-05942: Anesthetic DrugsSodium channel Blocker;
CBR-001-571-641-3,RFM-000-626-8,CBR-001-571-641-3,COC(=O)c1cccnc1,CBR-HVAC-05944: Treatment of Diabetic Complications
CBR-001-571-642-4,RFM-000-627-9,CBR-001-571-642-4,Oc1cccc(c1)C1CNCCO1,analog of CBR-HVAC-06092
CBR-001-571-643-5,RFM-000-628-0,CBR-001-571-643-5,CCSc1ccc2c(c1)N(CCCN1CCN(CC1)C)c1c(S2)cccc1,"CBR-HVAC-06190: Nausea and Vomiting, Treatment ofDopamine receptor Blocker;"
CBR-001-571-644-6,RFM-000-629-1,CBR-001-571-644-6,COc1c(C)cnc(c1C)Cn1cnc2c1nc(N)nc2Cl,CBR-HVAC-06329: Digestive/Gastrointestinal Cancer Therapy;Breast Cancer Therapy;Solid Tumors Therapy;Lymphocytic Leukemia Therapy; Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor;
CBR-001-571-645-7,RFM-000-630-4,CBR-001-571-645-7,CO[C@@H]([C@@H]1Cc2cc3cc(O[C@@H]4O[C@H](C)[C@@H]([C@@H](C4)O[C@H]4C[C@@H](O)[C@@H]([C@H](O4)C)O)O)c(c(c3c(c2C(=O)[C@H]1O[C@@H]1O[C@H](C)[C@H]([C@@H](C1)O[C@@H]1O[C@H](C)[C@H]([C@@H](C1)O[C@@H]1O[C@H](C)[C@H]([C@@](C1)(C)O)O)O)O)O)O)C)C(=O)[C@H]([C@H](O)C)O,CBR-HVAC-14255
CBR-001-571-646-8,RFM-000-631-5,CBR-001-571-646-8,O[C@H]1C2C(=C([C@]3([C@@H]1[C@H](N(C)C)C(=C(C3=O)C(=O)N)O)O)O)C(=O)c1c(C2=C)c(Cl)ccc1O,CBR-HVAC-06368: Treatment of Mucositis;Antibiotics;Acne Therapy
CBR-001-571-647-9,RFM-000-632-6,CBR-001-571-647-9,CCCCc1ccc(cc1O)O,CBR-HVAC-06387: Skin-Whitening Agents; Melanin Inhibitors;Tyrosinase Inhibitors
CBR-001-571-648-0,RFM-000-633-7,CBR-001-571-648-0,Clc1ccc(cc1)C(=O)c1ccc(cc1)OC(C(=O)O)(C)C,"CBR-HVAC-06396: Lipoprotein Disorders, Treatment of ;Edema, Treatment of"
CBR-001-571-649-1,RFM-000-634-8,CBR-001-571-649-1,CCCCCCCCCC(=O)OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-06475: Antipsychotic Drugs;Antipsoriatics; Dopamine D2 Antagonists;Signal Transduction Modulators
CBR-001-571-650-4,RFM-000-635-9,CBR-001-571-650-4,Cn1cc[nH]c1=S,CBR-HVAC-06483: Thyroid Disease Therapy; Antithyroid Drugs;Signal Transduction Modulators
CBR-001-571-651-5,RFM-000-636-0,CBR-001-571-651-5,CCOC(=O)[C@H](Cc1ccc(cc1)c1cc(nc(n1)N)O[C@@H](C(F)(F)F)c1ccc(cc1n1ccc(n1)C)Cl)N,"CBR-HVAC-06544: Endocrine Cancer Therapy;Inflammatory Bowel Disease, Agents for; Signal Transduction Modulators;Tryptophan Hydroxylase 1 (TPH1) Inhibitors;5-HT Release Inhibitors; TPH Inhibitor;"
CBR-001-571-652-6,RFM-000-637-1,CBR-001-571-652-6,O=C(Nc1ccc(c(c1)O)C(=O)O)COS(=O)(=O)c1ccc(cc1)C,CBR-HVAC-06602: Oncolytic Drugs; Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators
CBR-001-571-653-7,RFM-000-638-2,CBR-001-571-653-7,COc1cc(/C=C/C(=O)Nc2ccccc2C(=O)O)ccc1OC,"CBR-HVAC-01826: Antiglaucoma Agents;Rheumatoid Arthritis, Treatment of;Restenosis Treatment of;Atopic Dermatitis, Agents for;Multiple Sclerosis, Agents for;Uricosurics;Antiallergic Ophthalmic Agents;Drugs for Allergic Rhinitis;Antiarthritic Drugs;Asthma Therapy;Urologic Drugs; IFN-gamma Production Inhibitors;IL-10 Production Enhancers;IL-2 Production Inhibitors;IL-4 Modulators;Indoleamine 2,3-dioxygenase Activators;Signal Transduction Modulators;TNF-alpha Production Inhibitors;TRPV2 (Vanilloid VR2 Receptor) Antagonists;Urate Transporter 1 (URAT1) Inhibitors; Transforming growth factor beta Inhibitor; Histamine release inhibitor; Transforming growth factor beta 1 antagonist; Histamine receptor antagonist"
CBR-001-571-654-8,RFM-000-639-3,CBR-001-571-654-8,CN1C/C=C/CCOc2cccc(c2)c2nc(Nc3cc(C1)ccc3)ncc2,CBR-HVAC-06688: Lymphocytic Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy;Hematological Cancer Therapy;Multiple Myeloma Therapy;Solid Tumors Therapy; CDK9/Cyclin T1 Inhibitors;Cyclin-Dependent Kinase Inhibitors;ERK5 Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators
CBR-001-571-655-9,RFM-000-640-6,CBR-001-571-655-9,OC(COC(=O)N)COc1ccc(cc1)Cl,"CBR-HVAC-07064: Muscle Spasms, Drugs for"
CBR-001-571-656-0,RFM-000-641-7,CBR-001-571-656-0,COc1ccccc1OCC(COC(=O)N)O,CBR-HVAC-07325: Sedative/Hypnotics
CBR-001-571-657-1,RFM-000-642-8,CBR-001-571-657-1,C=CC(=O)Nc1cccc(c1)Nc1nc(ncc1C(F)(F)F)Nc1ccc(cc1OC)N1CCN(CC1)C(=O)C,CBR-HVAC-07332: Non-Small Cell Lung Cancer Therapy; Apoptosis Inducers;EGFR (Thr790Met Mutant) Inhibitors;Signal Transduction ModulatorsEGFR kinase inhibitor
CBR-001-571-658-2,RFM-000-643-9,CBR-001-571-658-2,CCOC(=O)c1cncn1[C@@H](c1ccccc1)C,CBR-HVAC-01688: Intravenous Anesthetics; GABA receptor Modulator; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-571-659-3,RFM-000-644-0,CBR-001-571-659-3,OC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F,CBR-HVAC-07581: Unidentified pharmacological activity
CBR-001-571-660-6,RFM-000-645-1,CBR-001-571-660-6,N#CCC(=O)c1ccccc1,CBR-HVAC-07651: Unidentified pharmacological activity
CBR-001-571-661-7,RFM-000-646-2,CBR-001-571-661-7,Nc1ccc(cc1)OCCCCCOc1ccc(cc1)N,CBR-HVAC-07712: Unidentified pharmacological activity
CBR-001-571-662-8,RFM-000-647-3,CBR-001-571-662-8,OCC(=O)CO,CBR-HVAC-07738: Alpha adrenoreceptor antagonist
CBR-001-571-663-9,RFM-000-648-4,CBR-001-571-663-9,COC(=O)Cc1c2cc(OC)ccc2n(c1C)C(=O)c1ccc(cc1)Cl,CBR-HVAC-15132: PROSTAGLANDIN G/H SYNTHASE-2 Inhibitor; NON-STEROIDAL ANTI-INFLAMMATORY
CBR-001-571-664-0,RFM-000-649-5,CBR-001-571-664-0,CCCCCC(CCCC(=O)[O-])O,CBR-HVAC-08013: ATP-sensitive potassium channel antagonist
CBR-001-571-665-1,RFM-000-650-8,CBR-001-571-665-1,CCOC(=O)C1=C[C@]2(CC)CCCN3[C@@H]2c2n1c1ccccc1c2CC3,"CBR-HVAC-02032: Cognition Disorders, Treatment of;Stroke, Treatment of; Nav1.8 (SNS/PN3) Sodium Channel Blockers;Phosphodiesterase PDE1 Inhibitors;Signal Transduction Modulators; Calcium/calmodulin-dependent cGMP phosphodiesterase Inhibitor; Phosphodiesterase 1 inhibitor; Sodium channel antagonist"
CBR-001-571-666-2,RFM-000-651-9,CBR-001-571-666-2,OC(=O)C(COP(=O)(O)O)N,CBR-HVAC-08198: Membrane integrity inhibitor
CBR-001-571-667-3,RFM-000-652-0,CBR-001-571-667-3,COC(=O)c1csc(c1N)C,analog of CBR-HVAC-08284
CBR-001-571-668-4,RFM-000-653-1,CBR-001-571-668-4,CCN(CCc1onc(n1)c1ccccc1)CC,CBR-HVAC-08706
CBR-001-571-669-5,RFM-000-654-2,CBR-001-571-669-5,CCOC(=O)CCC(=O)N,analog of CBR-HVAC-08707
CBR-001-571-670-8,RFM-000-655-3,CBR-001-571-670-8,NCCCCC(C(=O)O)NCNC(=O)C1=C(O)[C@@H](N(C)C)[C@H]2[C@](C1=O)(O)C(=C1[C@H](C2)[C@](C)(O)c2c(C1=O)c(O)ccc2)O,analog of CBR-HVAC-08752 (APICYCLINE)
CBR-001-571-671-9,RFM-000-656-4,CBR-001-571-671-9,CC(c1ccc(c2c(c1)c(C)cc2)C)C,CBR-HVAC-08762: Testosterone 5 alpha reductase Inhibitor;
CBR-001-571-672-0,RFM-000-657-5,CBR-001-571-672-0,CN1[C@@H]2C=C[C@H]1C[C@H](C2)OC(=O)C(c1cccs1)(c1cccs1)O,CBR-HVAC-08586: Respiratory system agent; Anti-inflammatory;
CBR-001-571-673-1,RFM-000-658-6,CBR-001-571-673-1,O=C1Nc2ccc(cc2C(O1)(C)C)Br,CBR-HVAC-08882: Anxiolytics
CBR-001-571-674-2,RFM-000-659-7,CBR-001-571-674-2,OC(=O)CCC(C(=O)O)N,CBR-HVAC-08887
CBR-001-571-675-3,RFM-000-660-0,CBR-001-571-675-3,CC(c1ccc(cc1)O)(C)C,analog of CBR-HVAC-08937 (MERCUROBUTOL)
CBR-001-571-676-4,RFM-000-661-1,CBR-001-571-676-4,Nc1ccc(cc1)S(=O)(=O)O,CBR-HVAC-08963
CBR-001-571-677-5,RFM-000-662-2,CBR-001-571-677-5,Clc1ccc(c2c1cccn2)O,CBR-HVAC-09008
CBR-001-571-678-6,RFM-000-663-3,CBR-001-571-678-6,CCOC(=O)C1(CCCNC1=O)c1ccccc1,analog of CBR-HVAC-09052
CBR-001-571-679-7,RFM-000-664-4,CBR-001-571-679-7,CN1C(C)(C)CC(CC1(C)C)OC(=O)CCCCCCCCC(=O)OC1CC(C)(C)N(C(C1)(C)C)C,analog of CBR-HVAC-09095
CBR-001-571-680-0,RFM-000-665-5,CBR-001-571-680-0,NC(=O)CCC(C(=O)O)NC(=O)C,CBR-HVAC-09097
CBR-001-571-681-1,RFM-000-666-6,CBR-001-571-681-1,N#Cc1ccc(cc1C(F)(F)F)N1CCCC1C(C(F)(F)F)O,CBR-HVAC-09205: ANDROGEN RECEPTOR Modulator;
CBR-001-571-682-2,RFM-000-667-7,CBR-001-571-682-2,N1CCN(CC1)c1ccc2c(n1)cccc2,"CBR-HVAC-09251: Motor Function Disorders, Treatment of;Pharmacological Tools; Signal Transduction Modulators;5-HT2A Agonists;5-HT3 Agonists; 5-Hydroxytryptamine receptor Agonist;"
CBR-001-571-683-3,RFM-000-668-8,CBR-001-571-683-3,IC(I)I,CBR-HVAC-09270
CBR-001-571-684-4,RFM-000-669-9,CBR-001-571-684-4,Oc1ccc(cc1)Cl,CBR-HVAC-09274
CBR-001-571-685-5,RFM-000-670-2,CBR-001-571-685-5,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-02037: DNA gyrase; DNA topoisomerase IV Inhibitor; Protein 50S ribosomal subunit inhibitor; Protein synthesis inhibitor
CBR-001-571-686-6,RFM-000-671-3,CBR-001-571-686-6,N#Cc1ccc(cc1)c1csc(n1)[C@@H]([C@@](c1cc(F)ccc1F)(Cn1cncn1)O)C,CBR-HVAC-09374: Antifungal; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors; Cytochrome P450 CYP3A4 Inhibitors; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; ANTIFUNGAL; Antifungal Agents4
CBR-001-571-687-7,RFM-000-672-4,CBR-001-571-687-7,Nc1ccc(cc1)S(=O)(=O)N1CCCCCC1,analog of CBR-HVAC-09406
CBR-001-571-688-8,RFM-000-673-5,CBR-001-571-688-8,O=C(N(C)C)Oc1ccc[n+](c1)Cc1ccccc1,CBR-HVAC-09414: CHOLINESTERASE Inhibitor;
CBR-001-571-689-9,RFM-000-674-6,CBR-001-571-689-9,OCC1CCCN1C(=O)OC(C)(C)C,CBR-HVAC-09517
CBR-001-571-690-2,RFM-000-675-7,CBR-001-571-690-2,Clc1cc(Cl)c(cc1OCC#CI)Cl,CBR-HVAC-09596
CBR-001-571-691-3,RFM-000-676-8,CBR-001-571-691-3,COc1ccc(cc1)O,CBR-HVAC-09612
CBR-001-571-692-4,RFM-000-677-9,CBR-001-571-692-4,OCCC1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(=O)C,CBR-HVAC-09641: 5-Hydroxytryptamine receptor Antagonist;
CBR-001-571-693-5,RFM-000-678-0,CBR-001-571-693-5,Nc1ccc(cc1)S(=O)(=O)Nc1ccccn1,CBR-HVAC-09667: Dihydropteroate synthase Inhibitor;
CBR-001-571-694-6,RFM-000-679-1,CBR-001-571-694-6,Cc1cc2c(o1)c(C)c1c(c2)c(C)cc(=O)o1,CBR-HVAC-09675
CBR-001-571-695-7,RFM-000-680-4,CBR-001-571-695-7,CC(=O)Oc1cc(C)c(c2c1cccc2)OC(=O)C,CBR-HVAC-09709
CBR-001-571-696-8,RFM-000-681-5,CBR-001-571-696-8,Brc1cc(Br)c2c(c1O)nccc2,CBR-HVAC-09733: Catechol-O-methyltransferase Inhibitor;
CBR-001-571-697-9,RFM-000-682-6,CBR-001-571-697-9,C=CCC(C(=O)NC(=O)N)C(C)C,CBR-HVAC-09740
CBR-001-571-698-0,RFM-000-683-7,CBR-001-571-698-0,Oc1cc(C)c(c(c1)C)Cl,CBR-HVAC-09761
CBR-001-571-699-1,RFM-000-684-8,CBR-001-571-699-1,CCC(C(c1ccc(c(c1)O)O)O)NC(C)C,CBR-HVAC-09804: Beta-2 adrenergic receptor Agonist;
CBR-001-571-700-7,RFM-000-685-9,CBR-001-571-700-7,CCCCCCc1ccc(cc1O)O,CBR-HVAC-09841: Oncolytic Drugs;Dermatologic Drugs; Apoptosis Inducers; Tyrosinase Inhibitor;
CBR-001-571-701-8,RFM-000-686-0,CBR-001-571-701-8,CCOC(=O)c1c(N)sc2c1CCN(C2)Cc1ccccc1,CBR-HVAC-09863: Prostaglandin G/H synthase Inhibitor;
CBR-001-571-702-9,RFM-000-687-1,CBR-001-571-702-9,CCC(OC(=O)c1ccccc1)(CN(C)C)C,CBR-HVAC-09911
CBR-001-571-703-0,RFM-000-688-2,CBR-001-571-703-0,COC(=O)c1ccc(c(c1)N)O,CBR-HVAC-09926
CBR-001-571-704-1,RFM-000-689-3,CBR-001-571-704-1,NCCc1ccc(cc1)O,CBR-HVAC-09970: Alpha adrenergic receptor Agonist;
CBR-001-571-705-2,RFM-000-690-6,CBR-001-571-705-2,CC(=O)Nc1ccccc1,CBR-HVAC-09982
CBR-001-571-706-3,RFM-000-691-7,CBR-001-571-706-3,COC(=O)C(NC(=O)C(CC(=O)O)N)Cc1ccccc1,CBR-HVAC-10036: Ionotropic glutamate receptor NMDA Binder;
CBR-001-571-707-4,RFM-000-692-8,CBR-001-571-707-4,CC(Cc1ccc(cc1)Cl)NC(=O)OC(C)(C)C,analog of CBR-HVAC-10126
CBR-001-571-708-5,RFM-000-693-9,CBR-001-571-708-5,CNCC(c1cccc(c1)C(F)(F)F)OC,CBR-HVAC-10133
CBR-001-571-709-6,RFM-000-694-0,CBR-001-571-709-6,Clc1cc(Cl)c(cc1O)Cl,CBR-HVAC-10137
CBR-001-571-710-9,RFM-000-695-1,CBR-001-571-710-9,Oc1ccc(c(c1)C(=O)O)O,CBR-HVAC-10141: Atherosclerosis Therapy; Antioxidants;Free Radical Scavengers;LDL Antioxidants; Opioid receptor Agonist;
CBR-001-571-711-0,RFM-000-696-2,CBR-001-571-711-0,CCCS(=O)c1ccc2c(c1)nc([nH]2)NC(=O)OC,CBR-HVAC-10179
CBR-001-571-712-1,RFM-000-697-3,CBR-001-571-712-1,Oc1ccc2c(c1)cccc2,CBR-HVAC-10193
CBR-001-571-713-2,RFM-000-698-4,CBR-001-571-713-2,NCC1OC(OC2C(N)CC(C(C2O)OC2OCC(C(C2O)NC)(C)O)N)C(C(C1O)O)O,CBR-HVAC-10220
CBR-001-571-714-3,RFM-000-699-5,CBR-001-571-714-3,OC(=O)Cc1sc(nc1c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-10264: Prostaglandin synthetase Inhibitor;
CBR-001-571-715-4,RFM-000-700-1,CBR-001-571-715-4,CC(C(=O)O)CN(c1c(I)cc(c(c1I)N)I)C(=O)C,CBR-HVAC-10274
CBR-001-571-716-5,RFM-000-701-2,CBR-001-571-716-5,CCCCNC(=O)OCC#CI,CBR-HVAC-10276: Cholinesterase Inhibitor;
CBR-001-571-717-6,RFM-000-702-3,CBR-001-571-717-6,OC1C(=O)OCC1(C)C,CBR-HVAC-10284
CBR-001-571-718-7,RFM-000-703-4,CBR-001-571-718-7,NC(C(=O)O)Cc1ccccc1,CBR-HVAC-10286
CBR-001-571-719-8,RFM-000-704-5,CBR-001-571-719-8,CN(CCOc1ccccc1Cc1ccccc1)C,CBR-HVAC-10288: Histamine H1 receptor Antagonist;
CBR-001-571-720-1,RFM-000-705-6,CBR-001-571-720-1,Oc1c(O)cccc1O,CBR-HVAC-10304
CBR-001-571-721-2,RFM-000-706-7,CBR-001-571-721-2,CCCCCCCCCCCCCCCCCC(=O)N,CBR-HVAC-10314
CBR-001-571-722-3,RFM-000-707-8,CBR-001-571-722-3,CCCCCCCCCCCCCCCCCCOCCO,CBR-HVAC-10315
CBR-001-571-723-4,RFM-000-708-9,CBR-001-571-723-4,CC(=O)Nc1c(I)cc(c(c1I)C(=O)O)I,CBR-HVAC-10369
CBR-001-571-724-5,RFM-000-709-0,CBR-001-571-724-5,N#C/N=C(/NCCSCc1nc[nH]c1C)\NC,CBR-HVAC-02429: Histamine H2 receptor Inhibitor; Unidentified pharmacological activity
CBR-001-571-725-6,RFM-000-710-3,CBR-001-571-725-6,O=CN1CCC(CC1)C(=O)NCCN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1,CBR-HVAC-10434: Antiplatelet Therapy;Treatment of Intermittent Claudication; Signal Transduction Modulators;5-HT2A Antagonists; 5-Hydroxytryptamine 2A receptor Antagonist;
CBR-001-571-726-7,RFM-000-711-4,CBR-001-571-726-7,CC(=O)NCCc1c(Cc2ccccc2)[nH]c2c1cccc2,CBR-HVAC-10475: Pharmacological Tools;Antidepressants; Melatonin MT2 Antagonists;Signal Transduction Modulators; Melatonin receptor Antagonist;
CBR-001-571-727-8,RFM-000-712-5,CBR-001-571-727-8,O1CCN(CC1)CCNc1nnc2c(c1)CCCc1c2cccc1,CBR-HVAC-10612: Muscarinic acetylcholine receptor M1 Agonist;
CBR-001-571-728-9,RFM-000-713-6,CBR-001-571-728-9,Oc1c2Cc3cc(cc(c3O)Cc3cc(cc(c3O)Cc3cc(cc(Cc4c(c(Cc5c(c(Cc1cc(c2)S(=O)(=O)O)cc(c5)S(=O)(=O)O)O)cc(c4)S(=O)(=O)O)O)c3O)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O,CBR-HVAC-10675: AnticoagulantsCoagulation factor Xa; Thrombin Inhibitor;
CBR-001-571-729-0,RFM-000-714-7,CBR-001-571-729-0,CCOP(=O)(C(=Cc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)P(=O)(OCC)OCC)OCC,"CBR-HVAC-10905: Lipoprotein Disorders, Treatment of ; Farnesoid X Receptor (FXR) Agonists;HMG-CoA Reductase Inhibitors;Signal Transduction Modulators; HMG-CoA reductase; Pregnane X receptor Inhibitor; Agonist;"
CBR-001-571-730-3,RFM-000-715-8,CBR-001-571-730-3,OCC1Oc2c(C1)cc(cc2)OC,analog of CBR-HVAC-11111
CBR-001-571-731-4,RFM-000-716-9,CBR-001-571-731-4,CC[C@@H]([C@H](C(=O)N[C@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](C(=O)O)Cc1ccccc1)Cc1[nH]cnc1)NC(=O)[C@H](NC(=O)[C@H](C(C)C)N)Cc1ccc(cc1)O)C,analog of CBR-HVAC-11152
CBR-001-571-732-5,RFM-000-717-0,CBR-001-571-732-5,Oc1ccc(c(c1)CNc1ccc(cc1)C(=O)OC12CC3CC(C2)CC(C1)C3)O,CBR-HVAC-11230: Oncolytic Drugs; Abl Kinase Inhibitors;Angiogenesis Inhibitors;Apoptosis Inducers;Signal Transduction Modulators; BCR-ABL; ABL Inhibitor;
CBR-001-571-733-6,RFM-000-718-1,CBR-001-571-733-6,CC(C[C@@H](C(=O)N[C@H](C(=O)NC(C)(C)C)Cc1ccc(cc1)OCc1ccccc1)N(Cc1ccc(cc1)C(C)(C)C)C)C,"CBR-HVAC-11320: Stroke, Treatment of;Non-Opioid Analgesics; N-Type Calcium Channel (Ca(v) 2.2) Blockers; Calcium channel N-type Blocker;"
CBR-001-571-734-7,RFM-000-719-2,CBR-001-571-734-7,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NCc1ccccc1,analog of CBR-HVAC-11338
CBR-001-571-735-8,RFM-000-720-5,CBR-001-571-735-8,OC(=O)CCCn1c(=O)c2cccc3c2c(c1=O)ccc3,CBR-HVAC-11382: Antibacterial DrugsAldose reductase Inhibitor;
CBR-001-571-736-9,RFM-000-721-6,CBR-001-571-736-9,O=C(NS(=O)(=O)Oc1c(cccc1C(C)C)C(C)C)Cc1c(cc(cc1C(C)C)C(C)C)C(C)C,"CBR-HVAC-11441: Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ;Alzheimer's Dementia, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-571-737-0,RFM-000-722-7,CBR-001-571-737-0,OCC1=C(C)C[C@@H](OC1=O)[C@H]([C@H]1CCC2[C@]1(C)CCC1[C@H]2C[C@@H]2[C@]3([C@]1(C)C(=O)C=C[C@@H]3O)O2)C,"CBR-HVAC-11493: Oncolytic Drugs;Hepatoprotectants;Immunosuppressants;Age-Related Macular Degeneration, Treatment of; Acetylcholinesterase (AChE) Inhibitors;Angiogenesis Inhibitors;Antioxidants;Apoptosis Inducers;Butyrylcholinesterase Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Protein Kinase C (PKC) Inhibitors;Signal Transduction Modulators"
CBR-001-571-738-1,RFM-000-723-8,CBR-001-571-738-1,CC(=O)OCC(CCn1cnc2c1nc(N)nc2)COC(=O)C,"CBR-HVAC-02103: Ear disorders, treatment of;Anti-Herpes Virus Drugs;Anti-Herpes Simplex Virus Drugs;Anti-Hepatitis B Virus Drugs;Anti-Varicella Zoster Virus Drugs; DNA Polymerase Inhibitors; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor"
CBR-001-571-739-2,RFM-000-724-9,CBR-001-571-739-2,CNC(=O)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(Cl)nc2NCc1cccc(c1)I,"CBR-HVAC-05220: Liver and Biliary Tract Disorders, Treatment of;Liver Cancer Therapy;Anti-Hepatitis C Virus Drugs; Adenosine A3 Agonists;Signal Transduction Modulators; Adenosine A3 receptor agonist"
CBR-001-571-740-5,RFM-000-725-0,CBR-001-571-740-5,CC#CC(=O)Nc1ncc2c(c1)c(ncn2)Nc1ccc(c(c1)Cl)F,CBR-HVAC-14305
CBR-001-571-741-6,RFM-000-726-1,CBR-001-571-741-6,OC(=O)c1ccc2c(c1)[nH]nn2,CBR-HVAC-11668: P-GLYCOPROTEIN 1; P-Glycoprotein Inhibitor;
CBR-001-571-742-7,RFM-000-727-2,CBR-001-571-742-7,N#CCNC(=O)C1(CCCCC1)NC(=O)c1ccc(cc1)c1csc(n1)N1CCN(CC1)C,CBR-HVAC-11694: Treatment of Osteoporosis; Cathepsin K Inhibitors; Protease; Cathepsin K Inhibitor;
CBR-001-571-743-8,RFM-000-728-3,CBR-001-571-743-8,O1CCN(CC1)CCOc1ccc2c(c1)nccc2c1c2CCCn2nc1c1ccccn1,CBR-HVAC-11828: Oncolytic Drugs; Activin Receptor Like Kinase 5 (ALK5; TbetaR-I) Inhibitors;Signal Transduction Modulators; TGF-BETA RECEPTOR TYPE 1; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR Inhibitor;
CBR-001-571-744-9,RFM-000-729-4,CBR-001-571-744-9,CCOC(=O)c1ncn2c1[C@@H]1CCCN1C(=O)c1c2ccc(c1)OC,"CBR-HVAC-11832: Antidepressants;Alzheimer's Dementia, Treatment of ; GABA(A) Receptor Subunit Alpha-5 (GABRA5) Inverse Agonists;Signal Transduction Modulators; GABA-A receptor alpha 5 Inverse Agonist;"
CBR-001-571-745-0,RFM-000-730-7,CBR-001-571-745-0,Nc1nccn2c1c(nc2[C@@H]1C[C@](C1)(C)O)c1ccc2c(c1)nc(cc2)c1ccccc1,CBR-HVAC-06799: Breast Cancer Therapy;Sarcoma Therapy;Liver Cancer Therapy;Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Multiple Myeloma Therapy;Endocrine Cancer Therapy;Prostate Cancer Therapy; IGF-1R Inhibitors;Insulin Receptor Antagonists;Signal Transduction Modulators;
CBR-001-571-746-1,RFM-000-731-8,CBR-001-571-746-1,O=C1OCC(=C1c1ccccc1)c1ccc(cc1)S(=O)(=O)C,"CBR-HVAC-02838: Treatment of Dysmenorrhea;Analgesic Drugs;Osteoarthritis, Treatment of;Non-Opioid Analgesics;Rheumatoid Arthritis, Treatment of;Dental Agents;Colorectal Cancer Therapy;Alzheimer's Dementia, Treatment of ;Acute Attacks of Migraine, Treatment of;Antiarthritic Drugs; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Cyclooxygenase 2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-571-747-2,RFM-000-732-9,CBR-001-571-747-2,Oc1cc2CC[C@@H]3[C@@H](c2cc1O)c1ccccc1CN3,"CBR-HVAC-03969:Treatment of Cocaine Dependency;Antiparkinsonian Drugs;Antipsychotic Drugs;Cognition Disorders, Treatment of; Dopamine D1 Agonists;Signal Transduction Modulators; Dopamine receptor D1 Agonist; Dopamine D1 receptor agonist"
CBR-001-571-748-3,RFM-000-733-0,CBR-001-571-748-3,CN(CCNC(=O)COc1c2cccc1Cc1cccc(c1OCC(=O)NCCN(C)C)Cc1c(c(Cc3c(c(C2)ccc3)OCC(=O)NCCN(C)C)ccc1)OCC(=O)NCCN(C)C)C,"CBR-HVAC-06181: Selective allosteric inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumor angiogenesis;KM-0118 is an apoptosis inducer in phase I clinical studies at OncoEthix for the treatment of solid tumors"
CBR-001-571-749-4,RFM-000-734-1,CBR-001-571-749-4,CO[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](O[C@@H]([C@@H]([C@@H]2O)O)C)Oc2cccc3c2c2oc(=O)c4c5c2c(c3O)c(=O)oc5ccc4C)O[C@@H]([C@@H]1O)C,analog of CBR-HVAC-03275 (Elsamitrucin)
CBR-001-571-750-7,RFM-000-735-2,CBR-001-571-750-7,COc1nc(N)nc2c1ncn2[C@@H]1O[C@@H]([C@H]([C@@]1(C)O)O)COP(=O)(Oc1cccc2c1cccc2)N[C@H](C(=O)OCC(C)(C)C)C,CBR-HVAC-06959: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; ;
CBR-001-571-751-8,RFM-000-736-3,CBR-001-571-751-8,CC([C@@H](C(=O)N1CCC[C@H]1B(O)O)N)C,"CBR-HVAC-02712: Melanoma Therapy;Brain Cancer Therapy;Lymphocytic Leukemia Therapy;Type 2 Diabetes, Agents for;Immunostimulants;Non-Hodgkin's Lymphoma Therapy;Hematopoietic Agents;Chemoprotective Agents;Pancreatic Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Dipeptidyl Peptidase II (DPPII; DPP2; DPP7) Inhibitors;Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Dipeptidyl Peptidase IX (DPP9; DPRP2) Inhibitors;Dipeptidyl Peptidase VIII (DPP8) Inhibitors;Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor; Growth factor receptor agonist; Dipeptide hydrolase inhibitor; Fibroblast activation protein inhibitor; Immunostimulant; Serine protease inhibitor; Dipeptidyl peptidase 9 (DPP IX) inhibitor; Dipeptidyl peptidase 8 (DPP VIII) inhibitor"
CBR-001-571-752-9,RFM-000-737-4,CBR-001-571-752-9,OC(=O)CCN(C(=O)c1ccc2c(c1)nc(n2C)CNc1ccc(cc1)C(=N)N)c1ccccn1,CBR-HVAC-05495: Anticoagulants;Antiarrhythmic Drugs;Cardiovascular Diseases (Not Specified); Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; ; Direct thrombin inhibitor; Serine protease inhibitor
CBR-001-571-753-0,RFM-000-738-5,CBR-001-571-753-0,OC(=O)c1ccc(nc1)C#Cc1ccc2c(c1)C(C)(C)CCS2,CBR-HVAC-03839: Antipsoriatics;Acne Therapy; Drugs Acting on Retinoid Receptors;Signal Transduction Modulators; ;
CBR-001-571-754-1,RFM-000-739-6,CBR-001-571-754-1,N#CCC1(CN(C1)S(=O)(=O)CC)n1ncc(c1)c1ncnc2c1cc[nH]2,"CBR-HVAC-00851: Diabetic Nephropathy, Agents for;Antipsoriatics;Inflammation, Treatment of;Rheumatoid Arthritis, Treatment of; Jak1 Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators; Janus kinase 1; Janus kinase 2 Inhibitor; Inhibitor; Janus kinase 1 inhibitor; Janus kinase 2 inhibitor"
CBR-001-571-755-2,RFM-000-740-9,CBR-001-571-755-2,CCNC(=O)c1noc(c1c1ccc(cc1)CN1CCOCC1)c1cc(C(C)C)c(cc1O)O,CBR-HVAC-06670: Oncolytic Drugs; Apoptosis Inducers;Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor;
CBR-001-571-756-3,RFM-000-741-0,CBR-001-571-756-3,Clc1ccc(cc1)CCCOCCCN1CCCCC1,"CBR-HVAC-00892: Sleep Disorders, Treatment of;Antinarcoleptic Drugs;Cognition Disorders, Treatment of; Histamine H3 Receptor Antagonists;Histamine H3 Receptor Inverse Agonists;Signal Transduction Modulators; Histamine H3 receptor Inverse Agonist; Histamine H3 receptor antagonist"
CBR-001-571-757-4,RFM-000-742-1,CBR-001-571-757-4,CCOCCn1c(nc2c1cccc2)C1CCN(CC1)CCc1ccc(cc1)C(C(=O)O)(C)C,"CBR-HVAC-01705: Urticaria, Treatment for;Allergy, Treatment of;Antiallergic Ophthalmic Agents;Drugs for Allergic Rhinitis;Asthma Therapy; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-571-758-5,RFM-000-743-2,CBR-001-571-758-5,C1CCN(CC1)CCOc1ccc(cc1)c1cnc2n(c1)ncc2c1ccncc1,CBR-HVAC-14238
CBR-001-571-759-6,RFM-000-744-3,CBR-001-571-759-6,C/C/1=C\CC[C@@]2(C)O[C@@H]2[C@@H]2[C@@H](CC1)C(=C)C(=O)O2,"CBR-HVAC-03475: Anti-Hepatitis C Virus Drugs;Oncolytic Drugs;Antileishmanials;Septic Shock, Treatment of ;Atherosclerosis Therapy; Adiponectin Receptor 2 (ADIPOR2) Agonists;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; NF-kappaB Inhibitor;"
CBR-001-571-760-9,RFM-000-745-4,CBR-001-571-760-9,COc1cnc(nc1)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-09664: Dihydropteroate synthase Inhibitor;
CBR-001-571-761-0,RFM-000-746-5,CBR-001-571-761-0,CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)CC,"CBR-HVAC-01677: Antipsychotic Drugs;Disorders Associated with Cancer Therapy, Treatment of;Nausea and Vomiting, Treatment of;Obsessive-Compulsive Disorder (OCD), Treatment of; Dopamine D2 Antagonists;Dopamine D3 Antagonists;Signal Transduction Modulators; Dopamine receptor D3; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist; Dopamine D3 receptor antagonist"
CBR-001-571-762-1,RFM-000-747-6,CBR-001-571-762-1,CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)c(ccc2)C(=O)OC(OC(=O)OC1CCCCC1)C,"CBR-HVAC-01373: Heart Failure Therapy;Non-Opioid Analgesics;Hypertension, Treatment of;Restenosis Treatment of;Diabetic Retinopathy, Agents for;Diabetic Nephropathy, Agents for;Treatment of Cocaine Dependency;Stroke, Treatment of;Antimigraine Drugs; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor Antagonist; Angiotensin II 1 antagonist"
CBR-001-571-763-2,RFM-000-748-7,CBR-001-571-763-2,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2,"CBR-HVAC-02207: Hypertension, Treatment of; Signal Transduction Modulators;5-HT2 Antagonists; 5-Hydroxytryptamine 2 receptor Agonist; Collagen stimulant; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-571-764-3,RFM-000-749-8,CBR-001-571-764-3,CCC(C(=O)O)(Oc1ccc(cc1)C1(CCCCC1)c1ccc(cc1)OC(C(=O)O)(CC)C)C,"CBR-HVAC-01628: Lipoprotein Disorders, Treatment of Lipase clearing factor stimulant"
CBR-001-571-765-4,RFM-000-750-1,CBR-001-571-765-4,OC1=C(CC2CCC(CC2)C(C)(C)C)C(=O)c2c(C1=O)cccc2,CBR-HVAC-03181: Theilericides;Antileishmanials
CBR-001-571-766-5,RFM-000-751-2,CBR-001-571-766-5,CN1CCC(=C2c3ccccc3C=Cc3c2cccc3)CC1,"CBR-HVAC-03084: Treatment of Cachexia;Analgesic Drugs;Urticaria, Treatment for;Antimigraine Drugs;Drugs for Allergic Rhinitis; Histamine H1 Receptor Antagonists;Signal Transduction Modulators;5-HT2B Antagonists; Histamine H1 receptor Antagonist;"
CBR-001-571-767-6,RFM-000-752-3,CBR-001-571-767-6,N#Cc1ccc(cc1)C(n1cncn1)c1ccc(cc1)C#N,CBR-HVAC-01881: Treatment of Growth Hormone Deficiency;Breast Cancer Therapy;Cancer of Unspecified Body Location/System;Female Reproductive System Cancer Therapy; Aromatase Inhibitors; Aromatase Inhibitor; Aromatase inhibitor; Estrogen receptor antagonist
CBR-001-571-768-7,RFM-000-753-4,CBR-001-571-768-7,Oc1ccc(cc1)CCC(=O)c1c(O)cc(cc1O)O,CBR-HVAC-05128: Ultraviolet Light Absorbers;Antiplatelet Therapy;Hepatoprotectants; Antioxidants;ICAM1 Expression Inhibitors;VCAM1 Expression Inhibitors; GLUT-1 Inhibitor;
CBR-001-571-769-8,RFM-000-754-5,CBR-001-571-769-8,CC(C[N+](C)(C)C)OC(=O)N,"CBR-HVAC-02875: Urologic Drugs;Gastroesophageal Reflux Disease, Agents for;Cancer Associated Disorders, Treatment of;Hemorrhoid, Treatment of; Muscarinic Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Inhibitor;"
CBR-001-571-770-1,RFM-000-755-6,CBR-001-571-770-1,CCCCCCCCCCCCCCOS(=O)(=O)[O-],"CBR-HVAC-06504: Peripheral Vascular Disease, Treatment of"
CBR-001-571-771-2,RFM-000-756-7,CBR-001-571-771-2,ICCCCCCCCCCCCCCCCC(=O)O,analog of CBR-HVAC-03904 (Iodostearic acid)
CBR-001-571-772-3,RFM-000-757-8,CBR-001-571-772-3,CC(CC(=O)N)C,"CBR-HVAC-00512: Antiepileptic Drugs;Antimigraine Drugs;Neurologic Drugs (Miscellaneous);Bipolar Disorder, Treatment of; ; Alcohol dehydrogenase Inhibitor; Cell cycle inhibitor; Histone deacetylase inhibitor"
CBR-001-571-773-4,RFM-000-758-9,CBR-001-571-773-4,Oc1ccc(cc1)c1coc2c(c1=O)c(O)cc(c2)O,"CBR-HVAC-02575: Bone Diseases, Treatment of;Gynecological Disorders, Treatment of ;Treatment of Erectile Dysfunction;Melanoma Therapy;Prostate Cancer Therapy;Ophthalmic Drugs;Bladder Cancer Therapy ;Renal Failure, Agents for;Anti-HIV Agents;Radioprotectants/Radiomitigators;Endometriosis Therapy;Cystic Fibrosis, Treatment of ;Treatment of Poisoning;Chemopreventive Agents; Angiogenesis Inhibitors;Antioxidants;Apoptosis Inducers;CFTR Channel Activators;DNA Topoisomerase II Inhibitors;EGFR (HER1; erbB1) Inhibitors;NADH Oxidase (NOX) Inhibitors;Signal Transduction Modulators;Tyrosine Kinase Inhibitors; Epidermal growth factor receptor Inhibitor; Unidentified pharmacological activity"
CBR-001-571-774-5,RFM-000-759-0,CBR-001-571-774-5,O=C1CCc2c(N1)ccc(c2)OCCCCc1nnnn1C1CCCCC1,"CBR-HVAC-01464: Treatment of Intermittent Claudication;Osteoarthritis, Treatment of;Antiplatelet Therapy;Cognition Disorders, Treatment of;Stroke, Treatment of;Peripheral Vascular Disease, Treatment of;Treatment of Peripheral Obstructive Vascular Disease;Inflammatory Bowel Disease, Agents for; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase Inhibitor; Phosphodiesterase 3 inhibitor; Platelet aggregation inhibitor"
CBR-001-571-775-6,RFM-000-760-3,CBR-001-571-775-6,C[C@@H]1C[C@H]2O[C@@H]2/C=C\C=C\C(=O)Cc2c(C(=O)O1)c(O)cc(c2Cl)O,CBR-HVAC-14232
CBR-001-571-776-7,RFM-000-761-4,CBR-001-571-776-7,COc1cc2CN(CCc3ccc(cc3)NC(=O)c3cccc4c3[nH]c3c(OC)cccc3c4=O)CCc2cc1OC,"CBR-HVAC-04316:ATP-binding cassette, subfamily B (MDR/TAP), member 1"
CBR-001-571-777-8,RFM-000-762-5,CBR-001-571-777-8,NCCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](Cc2ccc(cc2)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)CCC(=O)N)Cc1ccccc1,CBR-HVAC-14173
CBR-001-571-778-9,RFM-000-763-6,CBR-001-571-778-9,CC(CCNc1ncccc1C(=O)N1CCN(CC1)Cc1ccccc1)C,"CBR-HVAC-07062: Posttraumatic Stress Disorder (PTSD), Treatment of;Alzheimer's Dementia, Treatment of ;Neurologic Drugs (Miscellaneous);Antidepressants; Neurotrophic Agents;Signal Transduction Modulators; ;"
CBR-001-571-779-0,RFM-000-764-7,CBR-001-571-779-0,COC(=O)OC[C@H]1O[C@@H](Oc2cc(C)cc(c2C(=O)CCc2ccc3c(c2)cco3)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-05038: Antidiabetic Drugs; SGLT-2 Inhibitors; Sodium/glucose cotransporter Inhibitor;
CBR-001-571-780-3,RFM-000-765-8,CBR-001-571-780-3,C[S+](C[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2N)CC[C@@H](C(=O)[O-])N,CBR-HVAC-02424 Ademetionine: Methyltransferase stimulant
CBR-001-571-781-4,RFM-000-766-9,CBR-001-571-781-4,CN1CCC(CC1)N(c1ccccc1)Cc1ccccc1,CBR-HVAC-09746: Histamine receptor Antagonist;
CBR-001-571-782-5,RFM-000-767-0,CBR-001-571-782-5,CCCCCC(CC(=O)CCc1ccc(c(c1)OC)O)O,"CBR-HVAC-05197: Antioxidants; Apoptosis Inducers; Nitric Oxide Synthase Inhibitors; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Colorectal Cancer Therapy; Non-Opioid Analgesics"
CBR-001-571-783-6,RFM-000-768-1,CBR-001-571-783-6,OC1Cc2ccccc2N(c2c1cccc2)C(=O)N,"CBR-HVAC-02690: Antiepileptic Drugs;Bipolar Disorder, Treatment of; Sodium Channel  Blockers; Leukocyte function-associated antigen-1 Antagonist; Voltage-gated sodium channel antagonist"
CBR-001-571-784-7,RFM-000-769-2,CBR-001-571-784-7,COc1ccc2c(c1)ccc(c2)C(C(=O)Oc1ccc(cc1)C(=S)N)C,"CBR-HVAC-06719: Inflammation, Treatment of;Analgesic Drugs; Cyclooxygenase (COX) Inhibitors;Signal Transduction Modulators; Cyclooxygenase 2; Cyclooxygenase 1; TNF alpha Inhibitor;"
CBR-001-571-785-8,RFM-000-770-5,CBR-001-571-785-8,CCc1cc2C(=O)c3c4ccc(cc4[nH]c3C(c2cc1N1CCC(CC1)N1CCOCC1)(C)C)C#N,CBR-HVAC-07116: Non-Small Cell Lung Cancer Therapy; ALK Inhibitors;ALK Tyrosine Kinase Receptor (L1196M Mutant) Inhibitors;Signal Transduction Modulators; ALK KINASE Inhibitor; ALK receptor tyrosine kinase inhibitor
CBR-001-571-786-9,RFM-000-771-6,CBR-001-571-786-9,CCCCCCCCCCCCCCCCCCOP(=O)(OC1CC[N+](CC1)(C)C)O,CBR-HVAC-02601: Pancreatic Cancer Therapy;Ovarian Cancer Therapy;Solid Tumors Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Leukemia Therapy;Oncolytic Drugs;Digestive/Gastrointestinal Cancer Therapy;Breast Cancer Therapy;Multiple Myeloma Therapy;Prostate Cancer Therapy;Neurologic Cancer Therapy;Melanoma Therapy;Non-Hodgkin's Lymphoma Therapy;Head and Neck Cancer Therapy;Sarcoma Therapy;Lymphoma Therapy;Respiratory/Thoracic Cancer Therapy;Renal Cancer Therapy;Brain Cancer Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;Phosphatidylinositol 3-Kinase (PI3K) Activators;Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators; Mitogen-activated protein kinase; Protein tyrosine kinase C; AKT Inhibitor; Inhibitor; Inhibitor; Protein kinase B inhibitor; Protein kinase inhibitor; PI3 kinase inhibitor
CBR-001-571-787-0,RFM-000-772-7,CBR-001-571-787-0,O=C(N1CCCC(c2c1cccc2)N(C)C)c1ccc(cc1)NC(=O)c1ccccc1C,CBR-HVAC-01758: Treatment of Renal Diseases;Heart Failure Therapy; Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Antagonists; ; Vasopressin 2 antagonist; Diuretic
CBR-001-571-788-1,RFM-000-773-8,CBR-001-571-788-1,CC(c1ccccc1OCC1=NCCN1)C,CBR-HVAC-10171
CBR-001-571-789-2,RFM-000-774-9,CBR-001-571-789-2,OC(=O)c1cc2c(s1)cccc2,"CBR-HVAC-03439: Bone Diseases, Treatment of; ; Calcium channel Inhibitor; Bone formation stimulant"
CBR-001-571-790-5,RFM-000-775-0,CBR-001-571-790-5,Oc1cc(O)c2c(c1)oc(cc2=O)c1ccc(c(c1)O)O,"CBR-HVAC-04887: Chronic Obstructive Bronchitis, Agents for;Chemopreventive Agents;Antidiabetic Drugs; Aldose Reductase Inhibitors;alpha-Glucosidase Inhibitors;Antiinflammatory Drugs;Antioxidants;Apoptosis Inducers;MAO-A Inhibitors;Nitric Oxide (NO) Production Inhibitors;Xanthine Oxidase Inhibitors; ;"
CBR-001-571-791-6,RFM-000-776-1,CBR-001-571-791-6,[O-][n+]1cc(ncc1C)C(=O)O,"CBR-HVAC-01609: Lipoprotein Disorders, Treatment of ; ; Hormone-sensitive lipase Inhibitor; Cholesterol inhibitor"
CBR-001-571-792-7,RFM-000-777-2,CBR-001-571-792-7,OC(=O)C(c1ccc2c(c1)CC(=O)c1c(S2)cccc1)C,"CBR-HVAC-02110: Non-Opioid Analgesics;Treatment of Upper Respiratory Tract Disorders;Antiarthritic Drugs;Rheumatoid Arthritis, Treatment of; Cyclooxygenase (COX) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase 2 Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-571-793-8,RFM-000-778-3,CBR-001-571-793-8,CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)C(=O)OCc1oc(=O)oc1C)C(O)(C)C,"CBR-HVAC-04659: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Treatment of Renal Diseases;Heart Failure Therapy;Antiarrhythmic Drugs;Hypertension, Treatment of;Diabetic Nephropathy, Agents for; Angiotensin AT1 Antagonists;Signal Transduction Modulators; ; Angiotensin II 1 antagonist"
CBR-001-571-794-9,RFM-000-779-4,CBR-001-571-794-9,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)c1n[nH]c(c1O)C(=O)N,CBR-HVAC-08623: OMP decarboxylase Inhibitor;
CBR-001-571-795-0,RFM-000-780-7,CBR-001-571-795-0,OCCOCc1c(C)oc2c1cc1c(C)cc(=O)oc1c2C,analog of CBR-HVAC-05127 (Amotosalen hydrochloride)
CBR-001-571-796-1,RFM-000-781-8,CBR-001-571-796-1,CO[C@@H]1[C@H](O)[C@H](O[C@H]1n1cc(C#CC)c(=O)[nH]c1=O)CO,analog of CBR-HVAC-03922 (netivudine)
CBR-001-571-797-2,RFM-000-782-9,CBR-001-571-797-2,CO[C@@H]1[C@H](O)[C@H](O[C@H]1n1cc(C)c(nc1=O)N)CO,analog of CBR-HVAC-05438 (Ro-09-4889)
CBR-001-571-798-3,RFM-000-783-0,CBR-001-571-798-3,OC[C@H]1O[C@H](C[C@H]1O)N1CNC(=NC1=O)N,CBR-HVAC-06023: Anti-HIV Agents;
CBR-001-571-799-4,RFM-000-784-1,CBR-001-571-799-4,CC(=O)O[C@H]1C[C@@H](O[C@@H]1COC(=O)C)n1cc(F)c(=O)[nH]c1=O,analog of CBR-HVAC-08480 (TT-82)
CBR-001-571-800-0,RFM-000-785-2,CBR-001-571-800-0,OC(=O)CCSC(c1cccc(c1)C=Cc1ccc2c(n1)cc(cc2)Cl)SCCC(=O)N(C)C,CBR-HVAC-03628: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist; Leucotriene D4 antagonist
CBR-001-571-801-1,RFM-000-786-3,CBR-001-571-801-1,COCCN(Cc1ccc2c(c1)n1cc(sc1n2)C(=O)N(C1CCCCC1)C)C,"CBR-HVAC-11980: Ischemic Stroke, Treatment of;Non-Opioid Analgesics; mgluR1 Antagonists;Signal Transduction Modulators; Metabotropic glutamate 1 receptor Antagonist;"
CBR-001-571-802-2,RFM-000-787-4,CBR-001-571-802-2,CC(C(=O)O)Oc1ccc(cc1)Oc1cnc2c(n1)cc(cc2)Cl,CBR-HVAC-00229: Oncolytic Drugs; DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; DNA topoisomerase II beta Inhibitor; DNA topoisomerase II inhibitor; Cell cycle inhibitor
CBR-001-571-803-3,RFM-000-788-5,CBR-001-571-803-3,OC[C@H]1O[C@H](CC1F)n1cnc2c1nc(N)[nH]c2=O,CBR-HVAC-07976: DNA directed DNA polymerase inhibitor; Nucleoside reverse transcriptase inhibitor
CBR-001-571-804-4,RFM-000-789-6,CBR-001-571-804-4,CC(c1ccc2c(c1)c(=O)c1c(o2)nc(c(c1)C(=O)O)N)C,CBR-HVAC-01404: Antiallergy/Antiasthmatic Drugs;Wound-Healing Agents;Treatment of Mucositis; Mediator Release Inhibitors; Heat shock protein 90 Suppressor; Histamine release inhibitor
CBR-001-571-805-5,RFM-000-790-9,CBR-001-571-805-5,Cc1noc(c1)CCCOc1c(C)cc(cc1C)c1noc(n1)C(F)(F)F,CBR-HVAC-00042: Antiviral Drugs; Viral Entry Inhibitors; ; Unidentified pharmacological activity
CBR-001-571-806-6,RFM-000-791-0,CBR-001-571-806-6,Oc1ccc(cc1)C1COc2c(C1)ccc(c2)O,"CBR-HVAC-06921: Benign Prostatic Hyperplasia Therapy;Alzheimer's Dementia, Treatment of ;Treatment of Hot Flushes;Agents for Osteopetrosis; Antioxidants;Estrogen Receptor (ER) beta Agonists;Signal Transduction Modulators; Estrogen receptor beta Agonist;"
CBR-001-571-807-7,RFM-000-792-1,CBR-001-571-807-7,O=c1[nH]cc(cc1N)c1ccncc1,CBR-HVAC-02209: Heart Failure Therapy; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 3 Inhibitor; Phosphodiesterase 3 inhibitor
CBR-001-571-808-8,RFM-000-793-2,CBR-001-571-808-8,OC(=O)[C@H]([N+](C)(C)C)Cc1nc([nH]c1)S,CBR-HVAC-02405: Reducing agent
CBR-001-571-809-9,RFM-000-794-3,CBR-001-571-809-9,OCC1OC(C(C1O)F)n1cnc2c1nc(Cl)nc2N,"CBR-HVAC-01902: Solid Tumors Therapy;Antipsoriatics;Hematological Cancer Therapy;Hematopoiesis Disorders Therapy;Leukemia Therapy;Myeloid Leukemia Therapy;Myelodysplastic Syndrome Therapy;Oncolytic Drugs;Non-Hodgkin's Lymphoma Therapy;Multiple Sclerosis, Agents for;Multiple Myeloma Therapy;Lymphocytic Leukemia Therapy; DNA Polymerase Inhibitors;Ribonucleoside-Diphosphate Reductase Inhibitors; DNA POLYMERASE; RIBONUCLEOTIDE REDUCTASE Inhibitor; DNA synthesis inhibitor; DNA repair enzyme inhibitor; Ribonucleoside triphosphate reductase inhibitor"
CBR-001-571-810-2,RFM-000-795-4,CBR-001-571-810-2,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)C(=O)O)Cl,"CBR-HVAC-04462: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 1 Blocker;"
CBR-001-571-811-3,RFM-000-796-5,CBR-001-571-811-3,NCCCNCCSP(=O)(O)O,"CBR-HVAC-01911: Treatment of Mucositis;Radioprotectants/Radiomitigators;Myelodysplastic Syndrome Therapy;Cancer Associated Disorders, Treatment of;Chemoprotective Agents;Liver Cancer Therapy; The ability of Amifostine to differentially protect normal tissues is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol metabolite as well as a higher rate constant for uptake into cells; Oxygen scavenger; Reducing agent; Free radical scavenger"
CBR-001-571-812-4,RFM-000-797-6,CBR-001-571-812-4,CCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](/C=C/CCCCCCCCCCCCC)O)COP(=O)(OCC[N+](C)(C)C)[O-],analog of CBR-HVAC-11501 (SPHINGOMYELIN)
CBR-001-571-813-5,RFM-000-798-7,CBR-001-571-813-5,CCC(N(C(=O)c1cc2ccccc2c(n1)c1ccccc1Cl)C)C,CBR-HVAC-05295: Pharmacological Tools; Constitutive Androstane Receptor (CAR) Antagonists;Peripheral Benzodiazepine Receptor (PBR) Antagonists;Pregnane X Receptor (PXR) Agonists;Signal Transduction Modulators; Peripheral benzodiazepine receptor Agonist; Translocator protein antagonist
CBR-001-571-814-6,RFM-000-799-8,CBR-001-571-814-6,CC(Oc1ccc2c(c1)oc1c(c2=O)cc(cc1)C(=O)O)C,CBR-HVAC-15140: Platelet aggregation inhibitor; Prostaglandin E receptor 1 Antagonist; Prostaglandin E receptor 2; Prostanoid EP1 Receptor Antagonists; Prostanoid EP2 Receptor Antagonists; Signal Transduction Modulators; Anti-asthmatic; Pharmacological Tools
CBR-001-571-815-7,RFM-000-800-4,CBR-001-571-815-7,O=c1c2cccc3c2c(cn1C1CN2CCC1CC2)CCC3,"CBR-HVAC-04175: Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; ;"
CBR-001-571-816-8,RFM-000-801-5,CBR-001-571-816-8,NC(=N)NCCC(=O)O,CBR-HVAC-08216: Insulin sensitizer
CBR-001-571-817-9,RFM-000-802-6,CBR-001-571-817-9,OC(=O)c1ccc2c(c1)CCC2(N)C(=O)O,"CBR-HVAC-11521: Antiepileptic Drugs;Cognition Disorders, Treatment of; mgluR1 Antagonists;Signal Transduction Modulators; Metabotropic glutamate receptor 1 Antagonist;"
CBR-001-571-818-0,RFM-000-803-7,CBR-001-571-818-0,Oc1cc2CCNCC(c2cc1O)c1ccccc1,CBR-HVAC-08345: Dopamine D1 receptor agonist; Diuretic; Cyclic AMP stimulant
CBR-001-571-819-1,RFM-000-804-8,CBR-001-571-819-1,NCCC(C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)Cc1ccccc1)CC(C)C)CCN)C(O)C)NC(=O)C(C(O)C)NC(=O)C(NC(=O)CCCCC(CC)C)CCN,"CBR-HVAC-09643: It intercalates into bacterial cell membrane binding to the lipid A region of liposaccharides, in particular to phosphatidylethanolamine, and renders the osmotic barrier ineffective and leads to loss of cell contents and bacterial cell death."
CBR-001-571-820-4,RFM-000-805-9,CBR-001-571-820-4,NNc1nnc(c2c1cccc2)NN,CBR-HVAC-09781
CBR-001-571-821-5,RFM-000-806-0,CBR-001-571-821-5,Fc1cc2C3(CCOc2cc1)NC(=O)NC3=O,CBR-HVAC-02907: Symptomatic Antidiabetic Agents; Aldose Reductase Inhibitors; Aldose reductase Inhibitor; Aldose reductase inhibitor
CBR-001-571-822-6,RFM-000-807-1,CBR-001-571-822-6,OC[C@@H]1O[C@@H]([C@H]([C@H]1O)O)n1c(NC(C)C)nc2c1cc(Cl)c(c2)Cl,CBR-HVAC-00041: Anti-Cytomegalovirus Drugs; Signal Transduction Modulators;UL97 Kinase Inhibitors; UL97 protein kinase Inhibitor; Cytomegalovirus UL97 protein kinase inhibitor; Protein kinase inhibitor
CBR-001-571-823-7,RFM-000-808-2,CBR-001-571-823-7,COc1ccccc1OC(=O)c1ccccc1OC(=O)C,CBR-HVAC-01850: Mucolytic agent; Immunosuppressant
CBR-001-571-824-8,RFM-000-809-3,CBR-001-571-824-8,OCc1ccc(o1)C=O,"CBR-HVAC-05988: Treatment of Osteoporosis;Sickle Cell Anemia, Agents for; ; Hemoglobin Modulator;"
CBR-001-571-825-9,RFM-000-810-6,CBR-001-571-825-9,COc1cc(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)c(cc1OC)Br,"CBR-HVAC-01994: Irritable Bowel Syndrome, Agents for;Antispasmodics; ; Calcium channel Blocker; T-type calcium channel antagonist; Voltage-gated sodium channel antagonist"
CBR-001-571-826-0,RFM-000-811-7,CBR-001-571-826-0,C[C@H]1Cc2c(N1C(=O)Cc1nc(cc(=O)[nH]1)N1CCOCC1)cccc2,CBR-HVAC-14241
CBR-001-571-827-1,RFM-000-812-8,CBR-001-571-827-1,O=C([C@@H](c1ccccc1)N)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)OC1OC(=O)c2c1cccc2)(C)C,CBR-HVAC-10045: Penicillin binding protein Inhibitor;
CBR-001-571-828-2,RFM-000-813-9,CBR-001-571-828-2,N[C@H](c1ccccc1)C(=O)N[C@H]1[C@H]2CCC(=C(N2C1=O)C(=O)O)Cl,CBR-HVAC-01884: Cell wall synthesis inhibitor
CBR-001-571-829-3,RFM-000-814-0,CBR-001-571-829-3,O=C1NCCN1c1ncc(s1)[N+](=O)[O-],CBR-HVAC-10009
CBR-001-571-830-6,RFM-000-815-1,CBR-001-571-830-6,CCN(CCNc1ccc(c2c1c(=O)c1c(s2)cccc1)CO)CC,CBR-HVAC-10202
CBR-001-571-831-7,RFM-000-816-2,CBR-001-571-831-7,OCC1OC(C(C1OP(=O)(OC(CNC(=O)CCC1(C)C(CC(=O)N)C2N3C1=C(C)C1=[N+]4[Co]53([N+]3=C(C(C(C23C)(C)CC(=O)N)CCC(=O)N)C(=C2[N+]5=C(C=C4C(C1CCC(=O)N)(C)C)C(C2(C)CC(=O)N)CCC(=O)N)C)C)C)O)O)n1cnc2c1cc(C)c(c2)C,analog of CBR-HVAC-09876 (MECOBALAMIN)
CBR-001-571-832-8,RFM-000-817-3,CBR-001-571-832-8,OC[C@H]([C@H](C1OC(OCC2OC(OC3C(CO)OC(C(C3O)O)O)C(C(C2O)O)O)(CC(C1NC(=O)C)O)C(=O)[O-])O)O,CBR-HVAC-14283
CBR-001-571-833-9,RFM-000-818-4,CBR-001-571-833-9,OCC1OC(OC2C(COC3OC(C)C(C(C3O)O)O)OC(C(C2O)O)Oc2cc(O)c3c(c2)O[C@@H](CC3=O)c2ccc(c(c2)O)OC)C(C(C1O)O)O,"CBR-HVAC-06454: Lipoprotein Disorders, Treatment of"
CBR-001-571-834-0,RFM-000-819-5,CBR-001-571-834-0,OC[C@H]1O[C@H]([C@H](C1O)O)n1cnc2c1cc(Cl)c(c2)Cl,analog of CBR-HVAC-10688 (TCRB)
CBR-001-571-835-1,RFM-000-820-8,CBR-001-571-835-1,OCC1CS[As](S1)c1ccc(cc1)Nc1nc(N)nc(n1)N,CBR-HVAC-05137: Antitrypanosomals; ; Adenosine transporter Inhibitor;
CBR-001-571-836-2,RFM-000-821-9,CBR-001-571-836-2,NC(=O)C(c1ccccc1)(c1ccccc1)CC[N+]1(C)CCCCC1,CBR-HVAC-09242
CBR-001-571-837-3,RFM-000-822-0,CBR-001-571-837-3,N[C@@H]1[C@@H]2[C@H]1CN(C2)c1nc2c(cc1F)c(=O)c(cn2c1ccc(cc1F)F)C(=O)O,CBR-HVAC-02844: DNA gyrase; Topoisomerase IV Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-571-838-4,RFM-000-823-1,CBR-001-571-838-4,CN1CCN(CC1)CCCCN1C(=O)CN(C1=O)/N=C/c1ccc(o1)c1ccc(cc1)Cl,CBR-HVAC-02326: Antiarrhythmic Drugs; Potassium Channel Blockers; Alpha-1 adrenergic receptor; Beta adrenergic receptor; Potassium channel Antagonist; Inhibitor; Potassium channel antagonist; Polarisation inhibitor
CBR-001-571-839-5,RFM-000-824-2,CBR-001-571-839-5,OC[C@H]1O[C@H](C(C1O)O)n1cnc(n1)C(=N)N,CBR-HVAC-03800: Anti-Hepatitis C Virus Drugs;Antiviral Drugs; Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors; Reverse transcriptase Inhibitor;
CBR-001-571-840-8,RFM-000-825-3,CBR-001-571-840-8,O=C1NC(=O)CN1/N=C/c1ncc(o1)c1ccc(cc1)Br,CBR-HVAC-01175: Antispastic DrugsNeuromuscular nicotinic receptor antagonist; Calcium channel antagonist
CBR-001-571-841-9,RFM-000-826-4,CBR-001-571-841-9,O[C@@H]1[C@@H](N2CCCC2)c2cc(ccc2OC1(C)C)C#N,CBR-HVAC-08188: Calcium channel antagonist
CBR-001-571-842-0,RFM-000-827-5,CBR-001-571-842-0,O=C(C(c1cccs1)(c1cccs1)O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2,"CBR-HVAC-01996: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy; Muscarinic M3 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M3 Antagonist; Muscarinic M3 receptor antagonist; Long-acting muscarinic antagonist"
CBR-001-571-843-1,RFM-000-828-6,CBR-001-571-843-1,CC(=O)Nc1ccc(cc1)C1=NNC(=O)C[C@H]1C,CBR-HVAC-05772: Heart Failure Therapy; K(ATP) Channel Activators; ;
CBR-001-571-845-3,RFM-000-829-7,CBR-001-571-845-3,CC1CS(=O)(=O)CCN1/N=C/c1ccc(o1)[N+](=O)[O-],CBR-HVAC-01612: Neurologic Cancer Therapy;Antitrypanosomals;Brain Cancer Therapy; ; Lipoamide dehydrogenase Inhibitor; DNA inhibitor
CBR-001-571-846-4,RFM-000-830-0,CBR-001-571-846-4,CC(CCCCn1c(=O)c2n(C)cnc2n(c1=O)C)O,CBR-HVAC-14259
CBR-001-571-847-5,RFM-000-831-1,CBR-001-571-847-5,O[C@H](COc1ccc(cc1)O)CNC(C)C,CBR-HVAC-01713: Positive Inotropic Agents; beta-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Agonist; Beta 1 adrenoreceptor agonist
CBR-001-571-848-6,RFM-000-832-2,CBR-001-571-848-6,CN1C2CCC1CC(C2)OC(=O)c1c[nH]c2c1cccc2,CBR-HVAC-02236
CBR-001-571-849-7,RFM-000-833-3,CBR-001-571-849-7,CC[C@@H]1SC2(NC1=O)CCN(CC2)C,"CBR-HVAC-05506: Sjogren's Syndrome, Agents for;Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; Muscarinic M1 Agonists;Signal Transduction Modulators; MUSCARINIC ACETYLCHOLINE M1 RECEPTOR Agonist;"
CBR-001-571-850-0,RFM-000-834-4,CBR-001-571-850-0,N=C(NC(=N)Nc1ccc(cc1)Cl)NCCCCCCNC(=N)NC(=N)Nc1ccc(cc1)Cl,CBR-HVAC-02776: ATPase Inhibitor; Membrane integrity inhibitor; Membrane permeability enhancer
CBR-001-571-851-1,RFM-000-835-5,CBR-001-571-851-1,CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1,CBR-HVAC-10003: Calcium channel Blocker;
CBR-001-571-852-2,RFM-000-836-6,CBR-001-571-852-2,CCC(C(=O)O)Cc1c(I)cc(c(c1I)N)I,CBR-HVAC-10232: Deiodinase 2 Inhibitor;
CBR-001-571-853-3,RFM-000-837-7,CBR-001-571-853-3,Cc1ccc(cc1)C1(O)CCN(CC1)CCCC(=O)c1ccc(cc1)F,CBR-HVAC-08850: Dopamine receptor Antagonist;
CBR-001-571-854-4,RFM-000-838-8,CBR-001-571-854-4,CCN(CC(COC(=O)c1ccc(cc1)N)(C)C)CC,CBR-HVAC-10229: Dopamine transporter Binder;
CBR-001-571-855-5,RFM-000-839-9,CBR-001-571-855-5,CN(C(CN1c2ccccc2Sc2c1nccc2)C)C,CBR-HVAC-10357: H1-receptor Antagonist;
CBR-001-571-856-6,RFM-000-840-2,CBR-001-571-856-6,CN(CCn1c2ccccc2n(c2c(c1=O)cccc2)C)C,CBR-HVAC-09778: Histamine H1 receptor; Muscarinic acetylcholine receptor; Noradrenaline transporter Antagonist; Inhibitor;
CBR-001-571-857-7,RFM-000-841-3,CBR-001-571-857-7,Oc1ccc(cc1)C(C(N1CCC(CC1)Cc1ccccc1)C)O,CBR-HVAC-02413: Ionotropic glutamate receptor NMDA Modulator; Unidentified pharmacological activity
CBR-001-571-858-8,RFM-000-842-4,CBR-001-571-858-8,c1ccc2c(c1)N(CC1CN3CCC1CC3)c1c(S2)cccc1,CBR-HVAC-14170
CBR-001-571-859-9,RFM-000-843-5,CBR-001-571-859-9,CCCCN(CCCC)CCCOC(=O)c1ccc(cc1)N,CBR-HVAC-09737: Phospholipase A2 Inhibitor;
CBR-001-571-860-2,RFM-000-844-6,CBR-001-571-860-2,CC(c1c(C)n(n(c1=O)c1ccccc1)C)C,CBR-HVAC-09899: Prostaglandin G/H synthase Inhibitor;
CBR-001-571-861-3,RFM-000-845-7,CBR-001-571-861-3,CCCn1cnc2c1c(=O)n(CCCCC(=O)C)c(=O)n2C,"CBR-HVAC-02778: Alzheimer's Dementia, Treatment of ;Neuropathic Pain, Treatment of; Acetylcholinesterase (AChE) Inhibitors;Adenosine Reuptake Inhibitors;Signal Transduction Modulators; Phosphodiesterase Inhibitor; Phosphodiesterase inhibitor; Adenosine uptake inhibitor"
CBR-001-571-862-4,RFM-000-846-8,CBR-001-571-862-4,CCCCn1c(=O)c2n(cnc2n(c1=O)CCCC)CC(=O)C,"CBR-HVAC-03180: Antiallergy/Antiasthmatic Drugs;Ischemic Stroke, Treatment of;Cognition Disorders, Treatment of;Cardiovascular Diseases (Not Specified); Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase inhibitor"
CBR-001-571-863-5,RFM-000-847-9,CBR-001-571-863-5,CN1C(=O)CC(C1=O)(C)c1ccccc1,CBR-HVAC-04215: Antiepileptic Drugs
CBR-001-571-864-6,RFM-000-848-0,CBR-001-571-864-6,O=S1(=O)CCCCN1c1ccc(cc1)S(=O)(=O)N,CBR-HVAC-06664: Antiepileptic Drugs; Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Carbonic Anhydrase Type VII Inhibitors;Carbonic Anhydrase Type XII Inhibitors; Carbonic anhydrase Inhibitor;
CBR-001-571-865-7,RFM-000-849-1,CBR-001-571-865-7,CCCCCCCCCCCCCCCCCC(=O)NCC(COP(=O)(OCC[N+](C)(C)C)O)OCC,CBR-HVAC-11390: Anti-HIV Agents
CBR-001-571-866-8,RFM-000-850-4,CBR-001-571-866-8,COc1ccc(cc1)n1nc(cc1c1ccc(cc1)Cl)CCC(=O)N(O)C,CBR-HVAC-01145: Antiinflammatory Ophthalmic Agents;Antipsoriatics;Antiallergy/Antiasthmatic Drugs; Cyclooxygenase (COX) Inhibitors;Lipoxygenase Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; ; Cyclooxygenase inhibitor; 5 Lipoxygenase inhibitor; Leucotriene receptor antagonist
CBR-001-571-867-9,RFM-000-851-5,CBR-001-571-867-9,N#Cc1ccc2c(c1)N(CC(CN(C)C)C)c1c(S2)cccc1,CBR-HVAC-05309: Antipsychotic Drugs;Anxiolytics; Signal Transduction Modulators;5-HT2C Antagonists;5-HT3 Antagonists; 5-Hydroxytryptamine receptor Inhibitor;
CBR-001-571-868-0,RFM-000-852-6,CBR-001-571-868-0,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=S)[nH]c2c1cccc2,CBR-HVAC-02279: Antipsychotic DrugsDopamine D2 receptor antagonist
CBR-001-571-869-1,RFM-000-853-7,CBR-001-571-869-1,CCN(CCOC(=O)C1(CCCCC1)C1CCCCC1)CC,CBR-HVAC-03163: Antispasmodics; Muscarinic M1 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Antagonist;
CBR-001-571-870-4,RFM-000-854-8,CBR-001-571-870-4,Clc1ccc(cc1)C(=O)c1c(Cl)cc(cc1Cl)Cn1nnc(c1N)C(=O)N,CBR-HVAC-00241: Brain Cancer Therapy;Solid Tumors Therapy; Angiogenesis Inhibitors;Anti-VEGF;Signal Transduction Modulators; ; Cyclooxygenase inhibitor; Angiogenesis inhibitor; Calcium channel antagonist; Apoptosis stimulant; Vascular endothelial growth factor (VEGF)receptor antagonist; PI3 kinase inhibitor
CBR-001-571-871-5,RFM-000-855-9,CBR-001-571-871-5,Oc1cc(O)cc(c1)C(CNCCCn1cnc2c1c(=O)n(C)c(=O)n2C)O,CBR-HVAC-01780: Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-571-872-6,RFM-000-856-0,CBR-001-571-872-6,OC(c1cc(O)cc(c1)O)CNC(C)(C)C,"CBR-HVAC-02571: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Bronchodilators;Antidiabetic Drugs;Treatment of Preterm Labor;Female Infertility, Agents for; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta adrenergic receptor Agonist; Short-acting beta 2 adrenoceptor (SABA) agonist; Beta 2 adrenoreceptor agonist"
CBR-001-571-873-7,RFM-000-857-1,CBR-001-571-873-7,NCCCC(Nc1cc(OC)cc2c1nccc2)C,CBR-HVAC-02381: DNA inhibitor
CBR-001-571-874-8,RFM-000-858-2,CBR-001-571-874-8,CCCOc1ccc(cc1c1nc2c(CCC)nn(c2c(=O)[nH]1)C)S(=O)(=O)NCCC1CCCN1C,"CBR-HVAC-01664: Heart Failure Therapy;Benign Prostatic Hyperplasia Therapy;Hypertension, Treatment of;Cardiovascular Genetic Disorders, Treatment of;Treatment of Erectile Dysfunction;Raynaud's Phenomenon, Treatment for ; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor"
CBR-001-571-875-9,RFM-000-859-3,CBR-001-571-875-9,CCCN(C(C(=O)Nc1c(C)cccc1C)CC)CC,CBR-HVAC-03080: Local Anesthetics; ; Sodium channel Binder;
CBR-001-571-876-0,RFM-000-860-6,CBR-001-571-876-0,[O-][N+](=O)OCc1cccc(c1)OC(=O)c1ccccc1OC(=O)C,"CBR-HVAC-04944: Metabolic Disorders (Not Specified);Restenosis Treatment of;Treatment of Diabetic Complications;Type 2 Diabetes, Agents for;Stroke, Treatment of;Peripheral Arterial Disease, Treatment of;Chemopreventive Agents;Antiplatelet Therapy; Cyclooxygenase (COX) Inhibitors;Insulin Sensitizers;Nitric Oxide (NO) Donors;Signal Transduction Modulators; COX-1 Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Nitric oxide stimulant; I kappa kinase inhibitor; Platelet aggregation inhibitor"
CBR-001-571-877-1,RFM-000-861-7,CBR-001-571-877-1,OC(=O)C(CC(=O)c1ccc(cc1N)Cl)N,"CBR-HVAC-00587: Neuropathic Pain, Treatment of;Antiparkinsonian Drugs;Antipsychotic Drugs;Huntington's Disease, Treatment of;Antidepressants;Antiepileptic Drugs; NMDA Glycine B Receptor Antagonists;Signal Transduction Modulators; NMDA RECEPTOR GLYCINE BINDING SITE Antagonist; Glycine NMDA associated antagonist"
CBR-001-571-878-2,RFM-000-862-8,CBR-001-571-878-2,CN(CCn1c(=O)c2cc(cc3c2c(c1=O)ccc3)[N+](=O)[O-])C,CBR-HVAC-03937: Oncolytic Drugs; DNA-Intercalating Drugs; DNA topoisomerase II Inhibitor; DNA inhibitor
CBR-001-571-879-3,RFM-000-863-9,CBR-001-571-879-3,CCCCCCCCCCCCCCSCC(=O)O,"CBR-HVAC-06137: Oncolytic Drugs;Lipoprotein Disorders, Treatment of ; Antiinflammatory Drugs;Lipid Peroxidation Inhibitors; ;"
CBR-001-571-880-6,RFM-000-864-0,CBR-001-571-880-6,Cc1onc(c1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NN1CCCCCC1,"CBR-HVAC-05301: Type 2 Diabetes, Agents for; ; ATP-dependent potassium channel Blocker;"
CBR-001-571-881-7,RFM-000-865-1,CBR-001-571-881-7,Clc1ccc2c(c1)nn(n2)c1cc(C)cc(c1O)C(C)(C)C,CBR-HVAC-10336
CBR-001-571-882-8,RFM-000-866-2,CBR-001-571-882-8,CC(c1ncc(n1C([2H])([2H])[2H])[N+](=O)[O-])C,CBR-HVAC-08832
CBR-001-571-883-9,RFM-000-867-3,CBR-001-571-883-9,OCCCCCNCCn1cnc2c1ncnc2N,CBR-HVAC-11897
CBR-001-571-884-0,RFM-000-868-4,CBR-001-571-884-0,Fc1ccc(cc1)C(CCCN1CCC(CC1)(O)c1ccc(cc1)Cl)O,CBR-HVAC-11546
CBR-001-571-885-1,RFM-000-869-5,CBR-001-571-885-1,CN1CCCCC1CCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)C,CBR-HVAC-08985
CBR-001-571-886-2,RFM-000-870-8,CBR-001-571-886-2,O=C1N(Cc2c1cc(c(c2)Cl)S(=O)(=O)N)C1CCCCC1,CBR-HVAC-09831
CBR-001-571-887-3,RFM-000-871-9,CBR-001-571-887-3,COc1cc(O)ccc1C(=O)/C=C/c1ccc(c(c1)O)O,analog of CBR-HVAC-11431: (HX-0835)
CBR-001-571-888-4,RFM-000-872-0,CBR-001-571-888-4,COC(=O)[C@H]1CC[C@H]2[C@]1(C)CCC1[C@H]2CC[C@H]2[C@]1(C)C=CC(=O)N2,"analog of CBR-HVAC-07401 (5alpha-reductase inhibitors,Merck)"
CBR-001-571-890-8,RFM-000-873-1,CBR-001-571-890-8,OCC1OCC(C([C@@H]1O)O)O,analog of CBR-HVAC-06616 (Pro-xylane)
CBR-001-571-891-9,RFM-000-874-2,CBR-001-571-891-9,COC1=C(C)C(=O)C2=C(C1=O)[C@@H](COC(=O)N)[C@]1(N2C[C@H]2[C@@H]1N2)OC,analog of CBR-HVAC-07959 (KD-0122)
CBR-001-571-892-0,RFM-000-875-3,CBR-001-571-892-0,NCCCCCNC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)N(Cc1cnc2c(n1)c(N)nc(n2)N)C,analog of CBR-HVAC-07731
CBR-001-571-893-1,RFM-000-876-4,CBR-001-571-893-1,CCCCCCCC/C=C\CCCCCCC(C(=O)O)O,"CBR-HVAC-06275: Hypertension, Treatment of;Oncolytic Drugs;Neurologic Cancer Therapy;Solid Tumors Therapy;Sleep Disorders, Treatment of; Fatty Acid Amide Hydrolase (FAAH) Inhibitors;Protein Kinase C (PKC) Activators;Signal Transduction Modulators; Unidentified pharmacological activity"
CBR-001-571-894-2,RFM-000-877-5,CBR-001-571-894-2,OC(=O)CCC(=O)Oc1c(cc(cc1C(C)(C)C)SC(Sc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)(C)C)C(C)(C)C,"CBR-HVAC-05015: Atherosclerosis Therapy;Type 2 Diabetes, Agents for;Restenosis Treatment of; Antioxidants;CCL2 Expression Inhibitors;ERK1 Inhibitors;ERK2 Inhibitors;MAPK p38 Inhibitors;SAPK1 (JNK) Inhibitors;SAPK2 (p38beta) Inhibitors;Signal Transduction Modulators;VCAM1 Expression Inhibitors; Vascular cell adhesion molecule 1 Inhibitor;"
CBR-001-571-895-3,RFM-000-878-6,CBR-001-571-895-3,CCCc1n(C)nc2c1nc([nH]c2=O)c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC1)C,analog of CBR-HVAC-11517
CBR-001-571-896-4,RFM-000-879-7,CBR-001-571-896-4,CCCc1nn(c2c1[nH]c(nc2=O)c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC1)CCO)C,"CBR-HVAC-14397: Treatment of Erectile Dysfunction;Hypertension, Treatment of;Antiplatelet Therapy;Angina pectoris, Treatment of; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators"
CBR-001-571-897-5,RFM-000-880-0,CBR-001-571-897-5,COc1ncnc(c1)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08699: CYP2C Inhibitor;
CBR-001-571-898-6,RFM-000-881-1,CBR-001-571-898-6,O=C(C(c1ccccc1)(c1ccccc1)O)OC1CCC[N+](C1)(C)C,CBR-HVAC-15139: Inhibit the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation.; Muscarinic Receptor Antagonists; Signal Transduction Modulators; Anticholinergic; Antiulcer Drugs
CBR-001-571-899-7,RFM-000-882-2,CBR-001-571-899-7,CC(C(=O)OC(Cc1ccc(cc1)Cl)(C)C)N,CBR-HVAC-10387: Antidepressants; Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5-Hydroxytryptamine transporter Antagonist;
CBR-001-571-950-3,RFM-000-883-3,CBR-001-571-950-3,OC(=O)O.ClCC1CO1.NCC=C,CBR-HVAC-01316: The agent acts by binding phosphorus in the gastrointestinal tract and allows elimination of phosphorus through normal digestive processes.; Phosphate antagonist
CBR-001-571-951-4,RFM-000-884-4,CBR-001-571-951-4,OC(COc1ccc(cc1)COCCOC(C)C)CNC(C)C,"CBR-HVAC-01541: Heart Failure Therapy;Angina pectoris, Treatment of;Antiarrhythmic Drugs;Hypertension, Treatment of;Cardiovascular Diseases (Not Specified); beta1-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Antagonist; Beta 1 adrenoreceptor antagonist"
CBR-001-571-952-5,RFM-000-885-5,CBR-001-571-952-5,CN(CCC=C1c2ccccc2C(c2c1cccc2)(C)C)C,CBR-HVAC-09247
CBR-001-571-953-6,RFM-000-886-6,CBR-001-571-953-6,COC[C@]12CC[C@@H]([C@@]34[C@@H]2[C@@H](OC)[C@H](C3N(C1)CC)[C@@]1([C@@H]2[C@H]4C[C@@]([C@@H]2C(=O)c2ccc(cc2)OC)([C@H](C1)OC)O)OC(=O)C)OC,CBR-HVAC-09435
CBR-001-571-954-7,RFM-000-887-7,CBR-001-571-954-7,CN(/C(=N/c1ccc(cc1)/N=C/c1ccc(cc1)/C=N/c1ccc(cc1)/N=C(/N(C)C)\C)/C)C,CBR-HVAC-03761: Treatment of Helminthic Diseases; Nicotinic Receptor Agonists;Signal Transduction Modulators; ;
CBR-001-571-955-8,RFM-000-888-8,CBR-001-571-955-8,COc1ccc(cc1)c1oc2c(CC=C(C)C)c(O)cc(c2c(=O)c1O)O,CBR-HVAC-06136: Oncolytic Drugs;Liver Cancer Therapy;Breast Cancer Therapy; ; ;
CBR-001-571-956-9,RFM-000-889-9,CBR-001-571-956-9,C[C@H]([C@H]1C(=O)N2[C@@H]1SC(=C2C(=O)O)[C@H]1CCCO1)O,CBR-HVAC-03515: Antibiotics; ; ; Cell wall synthesis inhibitor
CBR-001-571-957-0,RFM-000-890-2,CBR-001-571-957-0,CCCCCCCN(CCCC(c1ccc(cc1)NS(=O)(=O)C)O)CC,CBR-HVAC-02076 Antiarrhythmic Drugs; Potassium Channel Blockers; IKr potassium channel Blocker; Polarisation inhibitor; Sodium channel antagonist; Potassium channel antagonist
CBR-001-571-958-1,RFM-000-891-3,CBR-001-571-958-1,OC(=O)CCCCCCCCOC(=O)/C=C(/C[C@@H]1OC[C@@H]([C@H]([C@H]1O)O)C[C@@H]1O[C@H]1[C@H]([C@@H](O)C)C)\C,CBR-HVAC-03364: Antibacterial Drugs; ; ISOLEUCYL-TRNA SYNTHETASE Inhibitor;
CBR-001-571-959-2,RFM-000-892-4,CBR-001-571-959-2,ClCC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCO)/c1ccccc1,"CBR-HVAC-05357: Treatment of Osteoporosis;Hormone Replacement Therapy;Disorders of Sexual Function and Reproduction, Treatment of; Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators; Estrogen receptor Modulator; Selective estrogen receptor modulator; Estrogen receptor agonist; Estrogen receptor antagonist"
CBR-001-571-960-5,RFM-000-893-5,CBR-001-571-960-5,CCN[C@H]1C[C@H](C)S(=O)(=O)c2c1cc(s2)S(=O)(=O)N,CBR-HVAC-02353: Carbonic anhydrase II Inhibitor; Carbonic anhydrase inhibitor
CBR-001-571-962-7,RFM-000-894-6,CBR-001-571-962-7,CCCCS(=O)(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OCCCCC1CCNCC1,"CBR-HVAC-01447: Angina pectoris, Treatment of;Acute Myocardial Infarction, Treatment of;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Stroke, Treatment of;Antiplatelet Therapy; Inhibitors of Blood Coagulation Pathways;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Signal Transduction Modulators; Integrin alpha2b beta3 Antagonist; GPIIb IIIa receptor antagonist; Platelet aggregation inhibitor"
CBR-001-571-963-8,RFM-000-895-7,CBR-001-571-963-8,Cc1ccc2c(c1Sc1ccncc1)c(=O)[nH]c(n2)N,CBR-HVAC-04421: Solid Tumors Therapy;Liver Cancer Therapy; Antimetabolites;Antimitotic Drugs;Thymidylate Synthase Inhibitors; Thymidylate synthase Inhibitor; Thymidylate synthase inhibitor
CBR-001-571-964-9,RFM-000-896-8,CBR-001-571-964-9,C[C@H]1SC[C@]2(O1)CN1CC[C@H]2CC1,"CBR-HVAC-01718: Sjogren's Syndrome, Agents for;Radioprotectants/Radiomitigators;Alzheimer's Dementia, Treatment of ; Muscarinic M1 Agonists;Muscarinic M3 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Inhibitor; Muscarinic M1 receptor agonist"
CBR-001-571-965-0,RFM-000-897-9,CBR-001-571-965-0,O[C@H](CN1CCN(C[C@H]1C(=O)NC(C)(C)C)Cc1cccnc1)C[C@@H](C(=O)N[C@@H]1[C@H](O)Cc2c1cccc2)Cc1ccccc1,CBR-HVAC-01985: Kaposi's Sarcoma Therapy;Anti-HIV Agents; HIV Protease Inhibitors; Protease Inhibitor; HIV protease inhibitor
CBR-001-571-966-1,RFM-000-898-0,CBR-001-571-966-1,OC[C@H]1O[C@@H](OC[C@@H]([C@@H](Cc2ccc(c(c2)OC)O)CO[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)Cc2ccc(c(c2)OC)O)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-05144: Metabolic Disorders (Not Specified);Cardioprotective Agents;Lipoprotein Disorders, Treatment of ; Angiogenesis Inducers;Antioxidants;Apoptosis Inhibitors;HDL-Cholesterol Increasing Agents; PLATELET ACTIVATING FACTOR RECEPTOR Antagonist;"
CBR-001-571-967-2,RFM-000-899-1,CBR-001-571-967-2,N#Cc1ccc2c(c1)c(CCCCN1CCN(CC1)c1ccc3c(c1)cc(o3)C(=O)N)c[nH]2,"CBR-HVAC-04745: Antidepressants;Treatment of Opioid Dependency;Treatment of Hot Flushes;Generalized Anxiety Disorder (GAD), Treatment of; Signal Transduction Modulators;5-HT Reuptake Inhibitors;5-HT1A Receptor Partial Agonists; 5-HYDROXYTRYPTAMINE 1A RECEPTOR; Serotonin 1A receptor; 5-Hydroxytryptamine 1A Receptor Antagonist; Agonist; 5 Hydroxytryptamine uptake inhibitor; 5 Hydroxytryptamine 1A receptor agonist"
CBR-001-571-968-3,RFM-000-900-7,CBR-001-571-968-3,CCCCCOc1ccc(cc1)c1ccc(cc1)c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC1=O)[C@H](O)C)C[C@@H](C2)O)[C@@H]([C@H](c1ccc(cc1)O)O)O)[C@H](O)C)C,"CBR-HVAC-02033: Glucan synthase Inhibitor; Cell wall synthesis inhibitor; 1,3-Beta-glucan synthase inhibitor"
CBR-001-571-969-4,RFM-000-901-8,CBR-001-571-969-4,NC(=O)C[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)CCSSC[C@H](NC1=O)C(=O)N1CCCC1C(=O)N[C@@H](C(=O)NCC(=O)N)CCCNC(=N)N)Cc1ccc(cc1)O,"CBR-HVAC-01270: Urinary Incontinence Therapy;Oncolytic Drugs;Diabetes Insipidus, Agents for;Hemostatics;Hemophilia A, Agents for;Coagulation Disorders Therapy;Treatment of Diabetic Complications; Angiogenesis Inhibitors;Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Agonists; Vasopressin V1 receptor; Vasopressin V2 receptor Inhibitor; Vasopressin 2 agonist"
CBR-001-571-970-7,RFM-000-902-9,CBR-001-571-970-7,O=C1CCC[C@H]2N1C[C@@H]1CCC[N+]3([C@@H]1[C@@H]2CCC3)[O-],"CBR-HVAC-05460: Asthma Therapy;Antibacterial Drugs;Fibrosis, Treatment of;Anti-Hepatitis B Virus Drugs;Immunomodulators;Hepatoprotectants;Anti-Hepatitis C Virus Drugs; ; ;"
CBR-001-571-971-8,RFM-000-903-0,CBR-001-571-971-8,Fc1ccc(cc1)[C@H]1[C@H](OCCN1Cc1n[nH]c(=O)[nH]1)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C,"CBR-HVAC-04928: Antidepressants;Disorders Associated with Cancer Therapy, Treatment of;Antipruritics;Nausea and Vomiting, Treatment of;AIDS Medicines;Treatment of Substance Dependency; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Tachykinin receptor 1 Inhibitor; Neurokinin 1 receptor antagonist"
CBR-001-571-972-9,RFM-000-904-1,CBR-001-571-972-9,CN1CCC[C@@H]1Cc1c[nH]c2c1cc(cc2)CCS(=O)(=O)c1ccccc1,CBR-HVAC-02248: Antimigraine Drugs; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 1D receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist; 5 Hydroxytryptamine 1B receptor agonist
CBR-001-571-973-0,RFM-000-905-2,CBR-001-571-973-0,Fc1ccc(cc1)Nc1nc(c(c(n1)C)C)N1CCc2c(C1C)cccc2,"CBR-HVAC-01716: Antiulcer Drugs;Gastroesophageal Reflux Disease, Agents for; Reversible H+/K+-ATPase Inhibitors ; H+/K+-ATPase; Na+/K+-ATPase Inhibitor; Potassium-competitive acid antagonist"
CBR-001-571-974-1,RFM-000-906-3,CBR-001-571-974-1,CN(CCc1c[nH]c2c1cc(cc2)CS(=O)(=O)N1CCCC1)C,CBR-HVAC-02204: Antimigraine Drugs; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-Hydroxytryptamine 7 receptor; 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1F receptor; 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 1B receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist; 5 Hydroxytryptamine 1B receptor agonist; 5 Hydroxytryptamine 1F receptor agonist
CBR-001-571-975-2,RFM-000-907-4,CBR-001-571-975-2,O=C1[C@@H](NC(=O)c2c(C)onc2c2c(F)cccc2Cl)[C@@H]2N1[C@@H](C(=O)O)C(S2)(C)C,CBR-HVAC-02873: Antibiotics; ; ;
CBR-001-571-976-3,RFM-000-908-5,CBR-001-571-976-3,CC[C@H](Nc1nc(NCc2ccccc2)c2c(n1)n(cn2)C(C)C)CO,CBR-HVAC-00608: CDK Inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 9 inhibitor; Cyclin-dependent kinase 7 inhibitor; Apoptosis stimulant
CBR-001-571-977-4,RFM-000-909-6,CBR-001-571-977-4,OC[C@H]1O[C@@H](O[C@H]2CC[C@]3(C(=CC[C@@H]4[C@@H]3CC[C@]3([C@H]4C[C@H]4[C@@H]3[C@H](C)[C@]3(O4)CC[C@H](CN3)C)C)C2)C)[C@@H]([C@H]([C@@H]1O[C@@H]1O[C@@H](C)[C@@H]([C@H]([C@H]1O)O)O)O)O[C@@H]1O[C@@H](C)[C@@H]([C@H]([C@H]1O)O)O,CBR-HVAC-03684
CBR-001-571-978-5,RFM-000-910-9,CBR-001-571-978-5,C=C[C@H]1[C@@H](OC=C2C1=CCOC2=O)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O,CBR-HVAC-08791: Hair Growth Stimulants; Steroid 5alpha-Reductase Type 2 Inhibitors; ;
CBR-001-571-979-6,RFM-000-911-0,CBR-001-571-979-6,CCCCCOc1ccc(cc1)c1onc(c1)c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)C(NC1=O)[C@H](O)C)C[C@@H](C2)O)[C@@H]([C@H](c1ccc(c(c1)OS(=O)(=O)O)O)O)O)[C@@H](CC(=O)N)O)C,"CBR-HVAC-05034: Antifungal Agents; 1,3-beta-Glucan Synthase Inhibitors; Glucan synthase Inhibitor;"
CBR-001-571-980-9,RFM-000-912-1,CBR-001-571-980-9,COc1cc(ccc1OC)c1cc(=O)c2c(o1)cc(c(c2O)OC)O,CBR-HVAC-09878: Oncolytic Drugs;Agents for Gastritis;Cytoprotectants;Antiallergy/Antiasthmatic Drugs; Antioxidants;Apoptosis Inducers; Lipoxygenase 5 Inhibitor;
CBR-001-571-981-0,RFM-000-913-2,CBR-001-571-981-0,CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]1C2C[C@H](O)[C@]2(C1CC[C@@H]2[C@@H](CCC(=O)O)C)C)O)C,CBR-HVAC-00725: Liver X receptor Activator; Acyl CoA desaturase-1 inhibitor; Cholesterol 7 alpha hydroxylase stimulant; ABCA1 transporter stimulant
CBR-001-571-982-1,RFM-000-914-3,CBR-001-571-982-1,Clc1ccc(c(c1)C(=O)Nc1ccc(cc1)S(=O)(=O)N1CCOCC1)NS(=O)(=O)c1ccc(s1)Cl,"CBR-HVAC-00312: Treatment of Peripheral Obstructive Vascular Disease;Peripheral Arterial Disease, Treatment of;Pulmonary Hypertension, Treatment of;Valvular Heart Disorders Therapy;Neuropathic Pain, Treatment of; Guanylate Cyclase Activators; Soluble guanylate cyclase Stimulator; Guanylate cyclase stimulant"
CBR-001-571-983-2,RFM-000-915-4,CBR-001-571-983-2,COc1cc(/C=C/C(=O)N2CCN(CC2)CC(=O)N2CCCC2)cc(c1OC)OC,CBR-HVAC-01471: Vasodilators; ; ; Calcium channel agonist; Alpha adrenoreceptor antagonist
CBR-001-571-984-3,RFM-000-916-5,CBR-001-571-984-3,COC(=O)C[C@@](C(=O)O[C@@H]1C(=C[C@]23[C@@H]1c1cc4OCOc4cc1CCN3CCC2)OC)(CCCC(O)(C)C)O,CBR-HVAC-02307: Solid Tumors Therapy;Myeloid Leukemia Therapy;Myelodysplastic Syndrome Therapy;Hematological Cancer Therapy; Angiogenesis Inhibitors;Apoptosis Inducers; Protein tyrosine kinase Inhibitor; Apoptosis stimulant; Angiogenesis inhibitor
CBR-001-571-985-4,RFM-000-917-6,CBR-001-571-985-4,OC[C@H]1O[C@@H](Oc2cc(/C=C/c3ccc(cc3)O)cc(c2)O)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-05764: Ischemic Stroke, Treatment of;Antiinfectives (Not Specified);Irritable Bowel Syndrome, Agents for;Asthma Therapy;Hemostatics;Analgesic Drugs;Antiplatelet Therapy; ICAM1 Expression Inhibitors;VCAM1 Expression Inhibitors;Xanthine Oxidase Inhibitors; ;"
CBR-001-571-986-5,RFM-000-918-7,CBR-001-571-986-5,COc1ccc2c(c1CN(C)C)oc(c(c2=O)C)c1ccccc1,CBR-HVAC-09808
CBR-001-571-987-6,RFM-000-919-8,CBR-001-571-987-6,C=CC(=O)Nc1cc2c(ncnc2cc1OCCCN1CCOCC1)Nc1ccc(c(c1)Cl)F,CBR-HVAC-05160: Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators; ERBB2; EGF; EGFR; ABL; KIT; ERBB3; ERBB4; AKT Antagonist; Inhibitor; ErbB-2 tyrosine kinase inhibitor; EGFR kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; ErbB-3 antagonist; Tyrosine kinase inhibitor (TKI)
CBR-001-571-988-7,RFM-000-920-1,CBR-001-571-988-7,C=CCNc1nc(nc(n1)NCC=C)N1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F,"CBR-HVAC-02290: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; ; ; Neurotransmitter agonist"
CBR-001-571-989-8,RFM-000-921-2,CBR-001-571-989-8,N#Cc1cc(ccc1OC(C)C)c1onc(n1)c1cccc2c1CCC2NCCC(=O)O,analog of CBR-HVAC-07135: (ozanimod)
CBR-001-571-990-1,RFM-000-922-3,CBR-001-571-990-1,COc1cc2CC[n+]3c(c2cc1OC)c(C)c1c(c3)c(OC)c(cc1)OC,CBR-HVAC-03886: Treatment of Helminthic Diseases;Treatment of Erectile Dysfunction;Antiplatelet Therapy; Aldose Reductase Inhibitors; ;
CBR-001-571-991-2,RFM-000-923-4,CBR-001-571-991-2,ClCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1CCC1=CC(=O)CC[C@]21C)F)(C)C,CBR-HVAC-03179: Topical Antiinflammatory Agents; ; ;
CBR-001-571-992-3,RFM-000-924-5,CBR-001-571-992-3,O[C@@H]1C[C@]2(C)[C@@H]([C@@]3([C@@H]1C(C)(C)[C@@H](O)CC3)C)C[C@H]([C@H]1[C@@]2(C)CC[C@@H]1[C@@]1(C)CCCC(O1)(C)C)O,CBR-HVAC-10051: Calcium channel Blocker;
CBR-001-571-993-4,RFM-000-925-6,CBR-001-571-993-4,COc1c(C/C=C(/CCC(=O)O)\C)c(O)c2c(c1C)COC2=O,"CBR-HVAC-01356: Treatment of Transplant Rejection;Systemic Lupus Erythematosus, Agents for;Immunosuppressants;Antipsoriatics;Treatment of Autoimmune Diseases; Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors; Inosine monophosphate dehydrogenase Inhibitor; Inosine monophosphate dehydrogenase inhibitor; Immunosuppressant"
CBR-001-571-994-5,RFM-000-926-7,CBR-001-571-994-5,O=C1C=C[C@]2(C(=C1)[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2([C@H]1CC[C@]2(OC(=O)C)C(=O)C)C)C,CBR-HVAC-07324: Antiinflammatory Ophthalmic Agents; ; Phospholipase A2 Inducer;
CBR-001-571-995-6,RFM-000-927-8,CBR-001-571-995-6,CCCCCCC(=O)O[C@@]1(C#C)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,CBR-HVAC-07363: Contraceptives; ; ;
CBR-001-571-996-7,RFM-000-928-9,CBR-001-571-996-7,COc1c(OC)ccc2c1c[n+](C)c1c2ccc2c1cc1OCOc1c2,CBR-HVAC-00188: PROTEIN KINASE C INHIBITOR; DNA repair enzyme inhibitor
CBR-001-571-997-8,RFM-000-929-0,CBR-001-571-997-8,OCCONC(=O)c1cc(C)c(=O)n(c1Nc1ccc(cc1F)I)C,CBR-HVAC-11809: MEK1/2 kinase inhibitor
CBR-001-571-998-9,RFM-000-930-3,CBR-001-571-998-9,COc1cc2c(cc1O)occ(c2=O)c1ccc(cc1)O,"CBR-HVAC-05721: Treatment of Osteoporosis;Treatment of Postmenopausal Syndrome ;Neurodegenerative Diseases, Treatment of;Chemopreventive Agents; Antiinflammatory Drugs;Antioxidants;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;IL-1beta Release Inhibitors;Nitric Oxide (NO) Production Inhibitors;Signal Transduction Modulators;TNF-alpha Release Inhibitors; ;"
CBR-001-571-999-0,RFM-000-931-4,CBR-001-571-999-0,Clc1cccc(c1NC1=NCCN1)Cl,"CBR-HVAC-03457: Neuropathic Pain, Treatment of;Nausea and Vomiting, Treatment of;Gastrointestinal Disorders (Not Specified);Hypertension, Treatment of;Treatment of Opioid Dependency;Diabetic Neuropathy, Agents for;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Treatment of Mucositis; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators; ;"
CBR-001-572-000-0,RFM-000-932-5,CBR-001-572-000-0,COc1cc(CCNCC(COc2cccc(c2)C)O)ccc1OC,"CBR-HVAC-01833: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; BETA-1 ADRENERGIC RECEPTOR Blocker; Beta 1 adrenoreceptor antagonist"
CBR-001-572-001-1,RFM-000-933-6,CBR-001-572-001-1,C[C@@H]1CC[C@]2([C@@H]([C@H]1C)C1=CC[C@H]3[C@@]([C@@]1(CC2)C)(C)CC[C@@H]1[C@]3(C)C[C@@H](O)[C@@H](C1(C)C)O)C(=O)O,"CBR-HVAC-06096: Type 2 Diabetes, Agents for;Oncolytic Drugs; Antiinflammatory Drugs;Diacylglycerol Acyltransferase (DGAT) Inhibitors;Glucose Lowering Agents;Protein Tyrosine Phosphatase PTP-1B Inhibitors;Signal Transduction Modulators;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; ;"
CBR-001-572-002-2,RFM-000-934-7,CBR-001-572-002-2,O=C1/C(=C\2/C(=O)Nc3c2cccc3)/Nc2c1cccc2,CBR-HVAC-00812: Myeloid Leukemia Therapy; CDK1 Inhibitors;CDK2 Inhibitors;CDK4 Inhibitors;CDK5 Inhibitors;Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors;Signal Transduction Modulators; CDK5/p25; Glycogen synthase kinase-3 beta Inhibitor; Inhibitor; Unidentified pharmacological activity
CBR-001-572-003-3,RFM-000-935-8,CBR-001-572-003-3,OC(C(C)(C)C)/C=C/c1ccc2c(c1)OCO2,CBR-HVAC-02114: Antiepileptic Drugs; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP2C19 Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;GABA Aminotransferase Inhibitors;GABA Reuptake Inhibitors;GABA(A) Receptor Modulators;Lactate Dehydrogenase Inhibitors;Signal Transduction Modulators; CYP1A2; CYP2C19; CYP3A4 Inhibitor; Inhibitor; Inhibitor; Sodium channel antagonist
CBR-001-572-004-4,RFM-000-936-9,CBR-001-572-004-4,OC(=O)c1cc(O)c2c(n1)c(=O)cc1c2nc2ccccc2o1,CBR-HVAC-04225: Anticataract Agents; AGE Inhibitors (Maillard's Reaction Inhibitors); ;
CBR-001-572-005-5,RFM-000-937-0,CBR-001-572-005-5,CCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@@H](C)C(=O)C2,CBR-HVAC-09573
CBR-001-572-006-6,RFM-000-938-1,CBR-001-572-006-6,COc1cc2c(cc1OC)CCN([C@H]2Cc1ccc(cc1)Oc1cc(ccc1O)C[C@H]1N(C)CCc2c1cc(OC)c(c2)OC)C,"CBR-HVAC-03053: Antiarrhythmic Drugs;Hypertension, Treatment of;Antiplatelet Therapy; ; Calcium channel Blocker;"
CBR-001-572-007-7,RFM-000-939-2,CBR-001-572-007-7,Oc1ccc2c(c1)[C@@]1(C)CCCCC[C@@H](C2)[C@@H]1N,CBR-HVAC-02669: Opioid Analgesics; Opioid Receptor Agonists-Antagonists;Signal Transduction Modulators; Opioid receptor Agonist; Antagonist; Opioid mu receptor agonist; Opioid kappa receptor antagonist
CBR-001-572-008-8,RFM-000-940-5,CBR-001-572-008-8,ClC[C@H]1O[C@@]([C@H]([C@@H]1O)O)(CCl)O[C@H]1O[C@H](CO)[C@@H]([C@@H]([C@H]1O)O)Cl,CBR-HVAC-10317
CBR-001-572-009-9,RFM-000-941-6,CBR-001-572-009-9,CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@@H]([C@@H](O2)C)O)c2c(C1)c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2OC,CBR-HVAC-02912: Ovarian Cancer Therapy;Bladder Cancer Therapy ; ; Topoisomerase II Inhibitor;
CBR-001-572-010-2,RFM-000-942-7,CBR-001-572-010-2,O=C1OC(=O)[C@@]2([C@@]1(C)[C@@H]1CC[C@@H]2O1)C,CBR-HVAC-05513: Antiviral Drugs;Pharmacological Tools;Oncolytic Drugs;Dermatologic Drugs; Apoptosis Inducers;Heat Shock Factor Protein 1 (HSF1) Inhibitors;Protein phosphatase 1 (PP-1) Inhibitors;Protein Phosphatase 2A (PP-2A) Inhibitors;Signal Transduction Modulators; Protein phosphatase 1; Protein phosphatase 2A Inhibitor;
CBR-001-572-011-3,RFM-000-943-8,CBR-001-572-011-3,C=CC(c1cc(/C=C/C(=O)c2ccc(cc2)O)c(cc1O)OC)(C)C,CBR-HVAC-04636: Dermatologic Drugs;Oncolytic Drugs;Antileishmanials; Cytochrome P450 CYP3A4 Inhibitors;DNA Topoisomerase I Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Xanthine oxidase Inhibitor;
CBR-001-572-012-4,RFM-000-944-9,CBR-001-572-012-4,Clc1ccc(cc1)C(c1ccccc1)(OCCN1CCCCCC1)C,CBR-HVAC-01714: Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist
CBR-001-572-013-5,RFM-000-945-0,CBR-001-572-013-5,CNC(=O)C[C@H](C(=O)N[C@H](c1ccc(cc1)O)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C)N,CBR-HVAC-02886: Antibiotics; ; Penicillin binding protein Inhibitor;
CBR-001-572-014-6,RFM-000-946-1,CBR-001-572-014-6,CNCC(c1ccc(c(c1)OC(=O)C(C)(C)C)OC(=O)C(C)(C)C)O,CBR-HVAC-02166: Antiglaucoma Agents; ; Adrenergic receptor Agonist; Adrenoreceptor agonist; Alpha adrenoreceptor agonist
CBR-001-572-015-7,RFM-000-947-2,CBR-001-572-015-7,CN(Cc1cccc2c1cccc2)C/C=C/c1ccccc1,CBR-HVAC-01497: Antifungal Agents; ; Squalene epoxidase Inhibitor; Squalene epoxidase inhibitor; Steroid synthesis inhibitor
CBR-001-572-016-8,RFM-000-948-3,CBR-001-572-016-8,C=C[C@@]1(C)CC(=O)[C@]2([C@@](O1)(C)[C@@H](OC(=O)C)[C@H]([C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C)O)O,"CBR-HVAC-03271: Antiglaucoma Agents;Leukemia Therapy;Antiplatelet Therapy;Hypertension, Treatment of;Bronchodilators;Heart Failure Therapy;Oncolytic Drugs; Adenylate Cyclase Activators; ;"
CBR-001-572-017-9,RFM-000-949-4,CBR-001-572-017-9,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C21CCC2)c1cnc(c(c1)C(F)(F)F)C#N,CBR-HVAC-06683: Androgen receptor antagonist
CBR-001-572-018-0,RFM-000-950-7,CBR-001-572-018-0,NC(=O)OCCCc1ccccc1,CBR-HVAC-10076
CBR-001-572-019-1,RFM-000-951-8,CBR-001-572-019-1,Cc1ccccc1N1CCN(CC1)CCc1nnc2n1CCCC2,CBR-HVAC-02301: Antiglaucoma Agents; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha adrenergic receptor Antagonist; Alpha adrenoreceptor antagonist
CBR-001-572-020-4,RFM-000-952-9,CBR-001-572-020-4,CCOC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C)C(=O)COC(=O)CC,"CBR-HVAC-02022: Antipsoriatics;Atopic Dermatitis, Agents for;Dermatologic Drugs;Eczema, Treatment of; ; Phospholipase A2 inhibitor protein Inducer; Corticosteroid agonist; Immunosuppressant"
CBR-001-572-021-5,RFM-000-953-0,CBR-001-572-021-5,Clc1cc2NC(CC3CCCC3)NS(=O)(=O)c2cc1S(=O)(=O)N,"CBR-HVAC-03159: Hypertension, Treatment of;Diuretics;Heart Failure Therapy; ; ;"
CBR-001-572-022-6,RFM-000-954-1,CBR-001-572-022-6,COc1c(OC)cc2c(c1OC)c1c(cc(c(c1OC)OC)OC)C[C@@H]([C@@](C2)(C)O)C,"CBR-HVAC-09362: Antipsychotic Drugs;Cognition Disorders, Treatment of;Hepatoprotectants; Acetylcholine Release Enhancers;Signal Transduction Modulators; ;"
CBR-001-572-023-7,RFM-000-955-2,CBR-001-572-023-7,Nc1nc(cs1)/C(=N\OCC(=O)O)/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)C=C,CBR-HVAC-02811: Antibiotics; ; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-024-8,RFM-000-956-3,CBR-001-572-024-8,O=C([C@@H](c1ccccc1)N)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)OCc1oc(=O)oc1C)(C)C,CBR-HVAC-02044: Cell wall synthesis inhibitor
CBR-001-572-025-9,RFM-000-957-4,CBR-001-572-025-9,OC(=O)[C@@H](CSCCCC/C=C(/C(=O)O)\NC(=O)[C@@H]1CC1(C)C)N,CBR-HVAC-03370: Inhibitors of Degradation of Drugs;beta-Lactam Enhancers; Dehydropeptidase I Inhibitors; Dehydropeptidase 1 Inhibitor;
CBR-001-572-026-0,RFM-000-958-5,CBR-001-572-026-0,OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2ccc(s2)c2ccc(cc2)F)C)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-06629: Diabetic Nephropathy, Agents for;Antiobesity Drugs;Type 1 Diabetes, Agents for;Type 2 Diabetes, Agents for; SGLT-2 Inhibitors; Sodium/glucose cotransporter 2 Inhibitor; Sodium/glucose cotransporter 2 inhibitor"
CBR-001-572-027-1,RFM-000-959-6,CBR-001-572-027-1,O=C(N1C[C@@H](C[C@H]1C(=O)O)C1CCCCC1)CP(=O)(CCCCc1ccccc1)O,"CBR-HVAC-03252: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; ;"
CBR-001-572-028-2,RFM-000-960-9,CBR-001-572-028-2,S=C(Nc1ccc(cc1c1[nH]nnn1)Br)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F,CBR-HVAC-14244
CBR-001-572-029-3,RFM-000-961-0,CBR-001-572-029-3,C[C@]12CCCC[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2)C,CBR-HVAC-10006
CBR-001-572-030-6,RFM-000-962-1,CBR-001-572-030-6,O[C@H]1CC[C@]2(C(=CCC3C2CC[C@]2(C3CC[C@@H]2C(=O)COC(=O)C)C)C1)C,CBR-HVAC-08768
CBR-001-572-031-7,RFM-000-963-2,CBR-001-572-031-7,CC(=O)Oc1ccc(cc1C(=O)O)Br,CBR-HVAC-10198
CBR-001-572-032-8,RFM-000-964-3,CBR-001-572-032-8,CCCOc1ccc(cc1NC(=O)C)[N+](=O)[O-],CBR-HVAC-10088
CBR-001-572-033-9,RFM-000-965-4,CBR-001-572-033-9,CN(CCCN1c2ccccc2Sc2c1cc(cc2)C(=O)C)C,CBR-HVAC-09174
CBR-001-572-034-0,RFM-000-966-5,CBR-001-572-034-0,CC(=O)Nc1cc(ccc1O)[As](=O)(O)O,CBR-HVAC-09704
CBR-001-572-035-1,RFM-000-967-6,CBR-001-572-035-1,OC(=O)COc1ccccc1/C=N/NC(=O)c1ccncc1,CBR-HVAC-08711
CBR-001-572-036-2,RFM-000-968-7,CBR-001-572-036-2,CCN(CC(CNc1c2cc(OC)ccc2nc2c1ccc(c2)Cl)O)CC,CBR-HVAC-08809
CBR-001-572-037-3,RFM-000-969-8,CBR-001-572-037-3,Nc1ncnc(n1)Nc1ccccc1,CBR-HVAC-09393
CBR-001-572-038-4,RFM-000-970-1,CBR-001-572-038-4,CC(=O)Nc1ncc(s1)[N+](=O)[O-],CBR-HVAC-09703
CBR-001-572-039-5,RFM-000-971-2,CBR-001-572-039-5,CCn1c(=O)n(CC=C)c(cc1=O)N,CBR-HVAC-09396
CBR-001-572-040-8,RFM-000-972-3,CBR-001-572-040-8,CC(=O)OC1CCC2(C(=CCC3C2CCC2(C3CCC2OC(=O)C)C)C1)C,Analog of CBR-HVAC-09953 sent to us in error
CBR-001-572-041-9,RFM-000-973-4,CBR-001-572-041-9,c1csc(c1)c1cn2c(n1)SCC2,analog of CBR-HVAC-09404 sent to us in error
CBR-001-572-042-0,RFM-000-974-5,CBR-001-572-042-0,Clc1ccc(c(c1)Cl)C1(OCCO1)Cn1cncn1,CBR-HVAC-08998
CBR-001-572-043-1,RFM-000-975-6,CBR-001-572-043-1,c1ccc2c(cc1)ccc2,CBR-HVAC-10175
CBR-001-572-044-2,RFM-000-976-7,CBR-001-572-044-2,CCCCNCC(c1ccc(cc1)O)O,CBR-HVAC-09744
CBR-001-572-045-3,RFM-000-977-8,CBR-001-572-045-3,CCCCNC(=O)n1c(NC(=O)OC)nc2c1cccc2,CBR-HVAC-10054
CBR-001-572-046-4,RFM-000-978-9,CBR-001-572-046-4,CCc1oc2c(c1C(=O)c1cc(I)c(c(c1)I)O)cccc2,CBR-HVAC-09722
CBR-001-572-047-5,RFM-000-979-0,CBR-001-572-047-5,O=C(c1ccccc1)OC1CN2CCC1CC2,CBR-HVAC-09129
CBR-001-572-048-6,RFM-000-980-3,CBR-001-572-048-6,O=C(c1ccccc1)Nc1ccc(c(c1)O)C(=O)O,CBR-HVAC-08802
CBR-001-572-049-7,RFM-000-981-4,CBR-001-572-049-7,Clc1cc(Cl)c(c(c1)S(=O)c1cc(Cl)cc(c1O)Cl)O,CBR-HVAC-10187
CBR-001-572-050-0,RFM-000-982-5,CBR-001-572-050-0,S=C=Nc1ccc(cc1)N=C=S,CBR-HVAC-09729
CBR-001-572-051-1,RFM-000-983-6,CBR-001-572-051-1,CCCCN1CCCC1C(=O)Nc1c(C)cc(cc1C)C,CBR-HVAC-09915
CBR-001-572-052-2,RFM-000-984-7,CBR-001-572-052-2,CCN(CCNC(c1ccccc1)C(=O)OCCC(C)C)CC,CBR-HVAC-08839
CBR-001-572-053-3,RFM-000-985-8,CBR-001-572-053-3,COc1cc(cc(c1OC)OC)C(=O)NCCCCCC(=O)O,CBR-HVAC-10161
CBR-001-572-054-4,RFM-000-986-9,CBR-001-572-054-4,COC(=S)NCCn1c(C)ncc1[N+](=O)[O-],CBR-HVAC-08811
CBR-001-572-055-5,RFM-000-987-0,CBR-001-572-055-5,COc1ccc(cc1)C(=C(c1ccc(cc1)OC)Cl)c1ccc(cc1)OC,CBR-HVAC-09758
CBR-001-572-056-6,RFM-000-988-1,CBR-001-572-056-6,CC(Cc1ccccc1)NCc1ccccc1Cl,CBR-HVAC-10204
CBR-001-572-057-7,RFM-000-989-2,CBR-001-572-057-7,C/C=C/C(=O)N(c1ccccc1C)CC,CBR-HVAC-09565
CBR-001-572-058-8,RFM-000-990-5,CBR-001-572-058-8,COC1(C)CC(c2ccccc2)c2c(O1)c1ccccc1oc2=O,CBR-HVAC-08640
CBR-001-572-059-9,RFM-000-991-6,CBR-001-572-059-9,O=C1c2c3CCCC(c3ccc2c2c(C1=O)c(C)co2)(C)C,"CBR-HVAC-12013: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; Antihypertensive; Apoptosis Inducers; IL-1beta Production Inhibitors; Nitric Oxide (NO) Production Inhibitors; Pregnane X Receptor (PXR) Agonists; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Antihypertensive; Atherosclerosis Therapy; Oncolytic Drugs; Stroke, Treatment of; Vasodilators"
CBR-001-572-060-2,RFM-000-992-7,CBR-001-572-060-2,Clc1ccc2c(c1)C(=[N+]([O-])CC(=N2)O)c1ccccc1,CBR-HVAC-09769
CBR-001-572-061-3,RFM-000-993-8,CBR-001-572-061-3,Nc1cc(C)[n+](c2c1cccc2)CCCCCCCCCC[n+]1c(C)cc(c2c1cccc2)N,CBR-HVAC-09771
CBR-001-572-062-4,RFM-000-994-9,CBR-001-572-062-4,Brc1cc(ccc1OCCCOc1ccc(cc1Br)C(=N)N)C(=N)N,CBR-HVAC-09779
CBR-001-572-063-5,RFM-000-995-0,CBR-001-572-063-5,CC(CC(=O)OCC1=CO[C@H]([C@H]2[C@@H]1C[C@@H]([C@@]12CO1)OC(=O)C)OC(=O)CC(C)C)C,CBR-HVAC-08979
CBR-001-572-064-6,RFM-000-996-1,CBR-001-572-064-6,O=C(C1C(=O)c2c(C1=O)cccc2)C(c1ccccc1)c1ccccc1,CBR-HVAC-08642
CBR-001-572-065-7,RFM-000-997-2,CBR-001-572-065-7,CC[n+]1c(/C=C/C=C/C=c/2\sc3c(n2CC)cccc3)sc2c1cccc2,CBR-HVAC-10228
CBR-001-572-066-8,RFM-000-998-3,CBR-001-572-066-8,CCCCCCCCCCCC[N+](CCOc1ccccc1)(C)C,CBR-HVAC-09083
CBR-001-572-067-9,RFM-000-999-4,CBR-001-572-067-9,O[C@H]1C[C@@]2(C)[C@@H](C[C@H]1O)C(=O)C=C1[C@@H]2CC[C@]2([C@@]1(O)CC[C@@H]2[C@]([C@@H](CCC(O)(C)C)O)(O)C)C,CBR-HVAC-10016
CBR-001-572-068-0,RFM-001-000-4,CBR-001-572-068-0,CN1[C@H]2CC[C@@H]1C(=CC2)C(=O)O,CBR-HVAC-08785
CBR-001-572-069-1,RFM-001-001-5,CBR-001-572-069-1,CC([C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)[C@H](OC(=O)[C@@H](N(C(=O)[C@H](OC(=O)[C@@H](N(C1=O)C)C(C)C)C(C)C)C)C(C)C)C(C)C)C,CBR-HVAC-08666
CBR-001-572-070-4,RFM-001-002-6,CBR-001-572-070-4,O=C1C=C2C3CC(C)(CCC3(C)CCC2(C2(C1C1(C)CCC(C(C1CC2)(C)C)O)C)C)C(=O)O,CBR-HVAC-02319
CBR-001-572-071-5,RFM-001-003-7,CBR-001-572-071-5,CCOc1ccc(cc1)NC(=S)Nc1ccc(cc1)OCC,CBR-HVAC-10058
CBR-001-572-072-6,RFM-001-004-8,CBR-001-572-072-6,Clc1ccc(cc1)OCC1=NCCc2c1cccc2,CBR-HVAC-08953
CBR-001-572-073-7,RFM-001-005-9,CBR-001-572-073-7,CC(N(Cc1c(C(C)C)c(=O)n(n1C)c1ccccc1)C)Cc1ccccc1,CBR-HVAC-09799
CBR-001-572-074-8,RFM-001-006-0,CBR-001-572-074-8,OC1C2(C)CCC(C1(C)C)C2,CBR-HVAC-10263
CBR-001-572-075-9,RFM-001-007-1,CBR-001-572-075-9,Clc1ccc(cc1)OCC(=O)N1CCN(CC1)Cc1ccc2c(c1)OCO2,CBR-HVAC-10348
CBR-001-572-076-0,RFM-001-008-2,CBR-001-572-076-0,CCN(CCC(=O)N1c2ccccc2Sc2c1cc(cc2)C(F)(F)F)CC,CBR-HVAC-09048
CBR-001-572-077-1,RFM-001-009-3,CBR-001-572-077-1,CCS(=O)(=O)c1ccc(cc1)F,CBR-HVAC-09977
CBR-001-572-078-2,RFM-001-010-6,CBR-001-572-078-2,COc1cc(/C=N/NC(=O)c2ccncc2)ccc1O,CBR-HVAC-08805
CBR-001-572-079-3,RFM-001-011-7,CBR-001-572-079-3,CC(=O)c1ccc(c(c1O)O)O,CBR-HVAC-09032
CBR-001-572-080-6,RFM-001-012-8,CBR-001-572-080-6,ClN(S(=O)(=O)c1ccc(cc1)C(=O)O)Cl,CBR-HVAC-10270
CBR-001-572-081-7,RFM-001-013-9,CBR-001-572-081-7,Clc1cc(Cl)c(c(c1O)Cc1c(O)c(Cl)cc(c1Cl)Cl)Cl,CBR-HVAC-09598
CBR-001-572-082-8,RFM-001-014-0,CBR-001-572-082-8,CCCCC(CN1CN(CC(CCCC)CC)CC(C1)(C)N)CC,CBR-HVAC-09797
CBR-001-572-083-9,RFM-001-015-1,CBR-001-572-083-9,OC(=O)CCC(=O)OCC(=O)C1CCC2C1(C)CCC1C2CCC2C1(C)CCC(=O)C2,CBR-HVAC-09907
CBR-001-572-084-0,RFM-001-016-2,CBR-001-572-084-0,OCC1OC(C(C1O)O)n1cnc2c1nc[nH]c2=O,CBR-HVAC-10353
CBR-001-572-085-1,RFM-001-017-3,CBR-001-572-085-1,COc1ccc(cc1)S(=O)(=O)Nc1nnc(s1)CC(C)C,CBR-HVAC-10277
CBR-001-572-086-2,RFM-001-018-4,CBR-001-572-086-2,CC(=O)Oc1cccc(c1)C,CBR-HVAC-08842
CBR-001-572-087-3,RFM-001-019-5,CBR-001-572-087-3,C1N2CN3CN1CN(C2)C3,CBR-HVAC-09819
CBR-001-572-088-4,RFM-001-020-8,CBR-001-572-088-4,COC(=O)c1ccccc1O,CBR-HVAC-09827
CBR-001-572-089-5,RFM-001-021-9,CBR-001-572-089-5,OC(=O)Cc1ccc2c(c1)N(C)c1c(S2)cccc1,CBR-HVAC-08764
CBR-001-572-090-8,RFM-001-022-0,CBR-001-572-090-8,Cc1cc2CCCS(=O)(=O)c2cc1S(=O)(=O)N,CBR-HVAC-10019
CBR-001-572-091-9,RFM-001-023-1,CBR-001-572-091-9,NC(=S)N/N=C\1/c2ccccc2N(C1=O)C,CBR-HVAC-09866
CBR-001-572-092-0,RFM-001-024-2,CBR-001-572-092-0,Cc1nccnc1N1CCCCC1,CBR-HVAC-09249
CBR-001-572-093-1,RFM-001-025-3,CBR-001-572-093-1,N=C(N1CCOCC1)NC(=N)N,CBR-HVAC-08906
CBR-001-572-094-2,RFM-001-026-4,CBR-001-572-094-2,Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)S(=O)(=O)N,CBR-HVAC-08964
CBR-001-572-095-3,RFM-001-027-5,CBR-001-572-095-3,O=C(c1cccnc1)Nc1c(=O)n(n(c1C)C)c1ccccc1,CBR-HVAC-10030
CBR-001-572-096-4,RFM-001-028-6,CBR-001-572-096-4,Oc1ccc(cc1)C(=O)N/N=C/c1ccc(o1)[N+](=O)[O-],CBR-HVAC-10364
CBR-001-572-097-5,RFM-001-029-7,CBR-001-572-097-5,[O-][N+](=O)c1ccc(o1)/C=N/NC(=O)c1cc(cc(c1O)[N+](=O)[O-])[N+](=O)[O-],CBR-HVAC-10031
CBR-001-572-098-6,RFM-001-030-0,CBR-001-572-098-6,CCOc1cc(cc(c1OCC)OCC)c1nccc2c1cc(OC)c(c2)OC,CBR-HVAC-09058
CBR-001-572-099-7,RFM-001-031-1,CBR-001-572-099-7,COC1CC(OC2C(C)C(=O)OC(C)C(C)C(O)C(C(=O)C3(CC(C(C2C)OC2OC(C)CC(C2O)N(C)C)C)CO3)C)OC(C1O)C,CBR-HVAC-10366
CBR-001-572-100-3,RFM-001-032-2,CBR-001-572-100-3,O[C@@H]1C[C@H](N(C1)C(=O)C)C(=O)O,CBR-HVAC-08705
CBR-001-572-101-4,RFM-001-033-3,CBR-001-572-101-4,COC(=O)Nc1[nH]c2c(n1)cc(cc2)S(=O)c1ccccc1,CBR-HVAC-10017
CBR-001-572-102-5,RFM-001-034-4,CBR-001-572-102-5,CCn1cc(C(=O)O)c(=O)c2c1cc1OCOc1c2,CBR-HVAC-08783
CBR-001-572-103-6,RFM-001-035-5,CBR-001-572-103-6,Brc1[nH]c2c(n1)n(C)c(=O)n(c2=O)C,CBR-HVAC-10283: Diuretic
CBR-001-572-104-7,RFM-001-036-6,CBR-001-572-104-7,CCC(=O)c1ccc(cc1)N,CBR-HVAC-08910
CBR-001-572-105-8,RFM-001-037-7,CBR-001-572-105-8,CCOc1ccc(cc1)C(=O)OCCN(CC)CC,CBR-HVAC-09928
CBR-001-572-106-9,RFM-001-038-8,CBR-001-572-106-9,CC(=O)C[C@H]1CCCCN1,CBR-HVAC-10112
CBR-001-572-107-0,RFM-001-039-9,CBR-001-572-107-0,NC(=O)NNc1ccccc1,CBR-HVAC-09265
CBR-001-572-108-1,RFM-001-040-2,CBR-001-572-108-1,CC(=CC1C(C1(C)C)C(=O)OCc1cccc(c1)Oc1ccccc1)C,CBR-HVAC-10075
CBR-001-572-109-2,RFM-001-041-3,CBR-001-572-109-2,CC(=O)NS(=O)(=O)c1ccc(cc1)NC(=O)c1ccccc1C(=O)O,CBR-HVAC-08680
CBR-001-572-110-5,RFM-001-042-4,CBR-001-572-110-5,CCN(CCCNc1cc(OC)cc2c1nccc2)CC,CBR-HVAC-08793
CBR-001-572-111-6,RFM-001-043-5,CBR-001-572-111-6,Nc1ccc2c(c1)nc1c(c2)ccc(c1)N,CBR-HVAC-04044
CBR-001-572-112-7,RFM-001-044-6,CBR-001-572-112-7,ClCC(CN1CC[N+]2(CC1)CC[N+]1(CC2)CCN(CC1)CC(CCl)O)O,CBR-HVAC-08755
CBR-001-572-113-8,RFM-001-045-7,CBR-001-572-113-8,CC(Nc1c(C)n(n(c1=O)c1ccccc1)C)C,CBR-HVAC-09934
CBR-001-572-114-9,RFM-001-046-8,CBR-001-572-114-9,Cc1cc(C)nc(n1)NS(=O)(=O)c1ccc(cc1)/N=N/c1ccc(c(c1)C(=O)O)O,CBR-HVAC-08681
CBR-001-572-115-0,RFM-001-047-9,CBR-001-572-115-0,CC1CC[C@@]2(NC1)O[C@@H]1[C@H]([C@@H]2C)C2([C@@H](C1)[C@@H]1CC=C3C(C1CC2)(C)CCC(C3)O)C,CBR-HVAC-10311
CBR-001-572-116-1,RFM-001-048-0,CBR-001-572-116-1,CCc1nnc(s1)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08688
CBR-001-572-117-2,RFM-001-049-1,CBR-001-572-117-2,Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(n1)cccc2,CBR-HVAC-08692
CBR-001-572-118-3,RFM-001-050-4,CBR-001-572-118-3,Nc1ccc(cc1)S(=O)(=O)Nc1cc(C)nc(n1)C,CBR-HVAC-09855
CBR-001-572-119-4,RFM-001-051-5,CBR-001-572-119-4,CCCCC1(COC(=O)CCC(=O)O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,CBR-HVAC-10044
CBR-001-572-120-7,RFM-001-052-6,CBR-001-572-120-7,O=c1n(Cl)c(=O)n(c(=O)n1Cl)Cl,CBR-HVAC-09109
CBR-001-572-121-8,RFM-001-053-7,CBR-001-572-121-8,C[n+]1cccc(c1)C(=O)N,CBR-HVAC-11900
CBR-001-572-122-9,RFM-001-054-8,CBR-001-572-122-9,COc1cc(cc(c1OC)OC)C(=O)N1CCOCC1,CBR-HVAC-08865
CBR-001-572-123-0,RFM-001-055-9,CBR-001-572-123-0,C1CCN2C(=NCCC2)CC1,CBR-HVAC-11787
CBR-001-572-124-1,RFM-001-056-0,CBR-001-572-124-1,CN1CCN(CC1)C(=O)c1ccc(cc1)CN1CCOCC1,analog of CBR-HVAC-06685
CBR-001-572-125-2,RFM-001-057-1,CBR-001-572-125-2,CCOCCn1nc(c2c1c(nc(n2)N1CCC(CC1)C(=O)O)Nc1nccc(c1)C)CC,CBR-HVAC-14221
CBR-001-572-126-3,RFM-001-058-2,CBR-001-572-126-3,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1COc2c(O1)cccc2,CBR-HVAC-02475: Benign Prostatic Hyperplasia Therapy; alpha1-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist
CBR-001-572-127-4,RFM-001-059-3,CBR-001-572-127-4,O=C(Nc1ccccc1C(=O)N)CCN1CCN(CC1)c1nsc2c1cccc2,analog of CBR-HVAC-04496
CBR-001-572-128-5,RFM-001-060-6,CBR-001-572-128-5,Cn1c(=O)ccc2c1cccc2,analog of CBR-HVAC-04389
CBR-001-572-129-6,RFM-001-061-7,CBR-001-572-129-6,CCOC(=O)c1cnc([nH]c1=O)Nc1ccc(cc1)OC,analog of CBR-HVAC-00006
CBR-001-572-130-9,RFM-001-062-8,CBR-001-572-130-9,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1ccc(cc1=O)N,analog of CBR-HVAC-11544
CBR-001-572-131-0,RFM-001-063-9,CBR-001-572-131-0,CC(=O)OC1CCC2(C(=CCC3C2CCC2(C3CCC2C(=O)C)C)C1)C,analog of CBR-HVAC-06707
CBR-001-572-132-1,RFM-001-064-0,CBR-001-572-132-1,CCONC(=O)c1cc(Br)ccc1O,analog of CBR-HVAC-08803
CBR-001-572-133-2,RFM-001-065-1,CBR-001-572-133-2,OCC1OC(C(C1O)O)n1cnc2c1ncnc2S,analog of CBR-HVAC-11371
CBR-001-572-134-3,RFM-001-066-2,CBR-001-572-134-3,NNC(=S)N/N=C(\c1ccccn1)/C,analog of CBR-HVAC-10671
CBR-001-572-135-4,RFM-001-067-3,CBR-001-572-135-4,Clc1ccc2c(c1)oc(=O)cc2NC1CCN(CC1)CCCc1ccccc1,analog of CBR-HVAC-11762
CBR-001-572-136-5,RFM-001-068-4,CBR-001-572-136-5,Cc1ccc2c(c1)c(=O)c(co2)c1nnn[nH]1,analog of CBR-HVAC-05805
CBR-001-572-137-6,RFM-001-069-5,CBR-001-572-137-6,COc1ccc2c(c1)ncnc2N1CCc2c(C1)cccc2,analog of CBR-HVAC-02554
CBR-001-572-138-7,RFM-001-070-8,CBR-001-572-138-7,O=C(Nc1cccc2c1cn[nH]2)N[C@@H]1CCc2c1ccc(c2)C(C)(C)C,CBR-HVAC-00208: Non-Opioid Analgesics; TRPV1 (Vanilloid VR1 Receptor) Antagonists; TRPV1 receptor Antagonist; Vanilloid receptor 1 antagonist
CBR-001-572-139-8,RFM-001-071-9,CBR-001-572-139-8,NC1CCN(C1)c1cccnc1,CBR-HVAC-05914: Analgesic Drugs; Drugs Acting on Acetylcholine Receptors (Nicotinic);Signal Transduction Modulators; NICOTINIC ACETYLCHOLINE RECEPTOR Agonist;
CBR-001-572-140-1,RFM-001-072-0,CBR-001-572-140-1,CCOC(=O)c1cnc([nH]c1=O)C(C)C,analog of CBR-HVAC-03005
CBR-001-572-141-2,RFM-001-073-1,CBR-001-572-141-2,CC(=O)O[C@@H]1C[C@]2(C)[C@H](CC[C@@]2(C2C1[C@@]1(C)CC[C@@H](C[C@H]1CC2)OC(=O)C)O)c1ccc(=O)oc1,analog of CBR-HVAC-00326
CBR-001-572-142-3,RFM-001-074-2,CBR-001-572-142-3,O=C(COc1ccc(cc1)Cl)OCCN(C12C[C@@H]3C[C@H](C2)C[C@H](C1)C3)C,analog of CBR-HVAC-01101
CBR-001-572-143-4,RFM-001-075-3,CBR-001-572-143-4,CCCC(=O)C1=C(Nc2ccccc2)CC(C(C1=O)C(=O)OC)(C)C,analog of CBR-HVAC-10570
CBR-001-572-144-5,RFM-001-076-4,CBR-001-572-144-5,NS(=O)(=O)c1sc2n(n1)cc(n2)c1ccccc1,CBR-HVAC-14239
CBR-001-572-145-6,RFM-001-077-5,CBR-001-572-145-6,CCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)CC[C@H]2[C@H]1CCC1=CC(=O)CC[C@]21C)(C)C,analog of CBR-HVAC-08770
CBR-001-572-146-7,RFM-001-078-6,CBR-001-572-146-7,COC(c1ccccc1)(c1ccccc1)CCN(C)C,analog of CBR-HVAC-09387
CBR-001-572-147-8,RFM-001-079-7,CBR-001-572-147-8,Clc1cccc(c1NC1=NCCN1)Cl,"CBR-HVAC-03457: Neuropathic Pain, Treatment of;Nausea and Vomiting, Treatment of;Gastrointestinal Disorders (Not Specified);Hypertension, Treatment of;Treatment of Opioid Dependency;Diabetic Neuropathy, Agents for;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Treatment of Mucositis; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators;"
CBR-001-572-148-9,RFM-001-080-0,CBR-001-572-148-9,OC[C@H]1OC(C[C@H]1O)n1cc(C)c(nc1=O)NC,analog of CBR-HVAC-04628
CBR-001-572-149-0,RFM-001-081-1,CBR-001-572-149-0,COc1cc(Cl)ccc1C(=O)NCC(N(C)C)C,analog of CBR-HVAC-09071
CBR-001-572-150-3,RFM-001-082-2,CBR-001-572-150-3,CCC1CN(C)CCC1(OC(=O)C)c1ccccc1,analog of CBR-HVAC-09696
CBR-001-572-151-4,RFM-001-083-3,CBR-001-572-151-4,C=CCC1(C)C(=O)N(c2c1cccc2)c1ccccc1,analog of CBR-HVAC-09121
CBR-001-572-152-5,RFM-001-084-4,CBR-001-572-152-5,O=C(Nc1ccccc1)Nc1ccc(cc1)S(=O)(=O)C,analog of CBR-HVAC-09148
CBR-001-572-153-6,RFM-001-085-5,CBR-001-572-153-6,NC1=NCC(O1)c1ccc(cc1)Br,analog of CBR-HVAC-10002
CBR-001-572-154-7,RFM-001-086-6,CBR-001-572-154-7,CCCC(C1(CC)C(=O)NC(=O)N=C1[O-])C,analog of CBR-HVAC-03095
CBR-001-572-155-8,RFM-001-087-7,CBR-001-572-155-8,S=C(N1CCN(CC1)c1ccccc1F)Nc1ccc(cc1)[N+](=O)[O-],analog of CBR-HVAC-01119
CBR-001-572-156-9,RFM-001-088-8,CBR-001-572-156-9,CCN1CCN(CC1)CCC(=O)Nc1ccccc1C,analog of CBR-HVAC-03646
CBR-001-572-157-0,RFM-001-089-9,CBR-001-572-157-0,CC12Cc3conc3CC1CCC1C2CCC2(C1CCC2(C)O)C,CBR-HVAC-09988
CBR-001-572-158-1,RFM-001-090-2,CBR-001-572-158-1,O=CN1CCC23C4C1Cc1c3c(OC2C(C=C4)O)c(cc1)OC,analog of CBR-HVAC-00798
CBR-001-572-159-2,RFM-001-091-3,CBR-001-572-159-2,COc1ccc2c(c1)[C@@]13CCNC(C2)C3CCC(=O)C1,analog of CBR-HVAC-01258
CBR-001-572-160-5,RFM-001-092-4,CBR-001-572-160-5,Cc1cccc(c1)/C=N/Nc1nc(OCCc2ccccn2)nc(c1)N1CCOCC1,"CBR-HVAC-00390: Rheumatoid Arthritis, Treatment of;Antipsoriatics;Multiple Sclerosis, Agents for;Immunomodulators;Inflammatory Bowel Disease, Agents for; IL-12 Production Inhibitors;Signal Transduction Modulators; Interleukin 12; Interleukin 23 Inhibitor; Interleukin 12 antagonist; Interleukin 23 antagonist;2017-11-14: ARB# 16-000706"
CBR-001-572-161-6,RFM-001-093-5,CBR-001-572-161-6,OCC#CCOc1ccc(cc1)S(=O)(=O)N1CCSC([C@@H]1C(=O)NO)(C)C,"CBR-HVAC-06129: Rheumatoid Arthritis, Treatment of; Angiogenesis Inhibitors;Disintegrin And Metalloproteinase Domain-Containing Protein 17 (ADAM17; TACE) Inhibitors;Matrix Metalloproteinase Inhibitors;Signal Transduction Modulators; TNF alpha converting enzyme; Matrix metalloproteinase 13 Inhibitor; TNF convertase inhibitor; Matrix metalloproteinase inhibitor; Tumour necrosis factor alpha antagonist"
CBR-001-572-162-7,RFM-001-094-6,CBR-001-572-162-7,CCN(CCCN(C1Cc2c(C1)cccc2)c1ccccc1)CC,CBR-HVAC-01669: Antiarrhythmic Drugs; Na+/Ca2+ Exchanger (NCX) Inhibitors; Sodium channel Blocker; Membrane integrity inhibitor; Voltage-gated sodium channel antagonist
CBR-001-572-163-8,RFM-001-095-7,CBR-001-572-163-8,COC[C@]1(OC)CC[C@@H]2[C@]1(C)C[C@H](c1ccc(cc1)/C=N/O)C1=C3CCC(=O)C=C3CC[C@@H]21,"CBR-HVAC-04707: Hormone Replacement Therapy;Gynecological Disorders, Treatment of ;Endometriosis Therapy; Selective Progesterone Receptor Modulators (SPRM);Signal Transduction Modulators; PROGESTERONE RECEPTOR Modulator;"
CBR-001-572-164-9,RFM-001-096-8,CBR-001-572-164-9,O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C)C,analog of CBR-HVAC-03208
CBR-001-572-165-0,RFM-001-097-9,CBR-001-572-165-0,CN(CCCNCC1CCCCC1)C,analog of CBR-HVAC-00431
CBR-001-572-166-1,RFM-001-098-0,CBR-001-572-166-1,COc1ccc(cc1)CC(=O)NCc1ccccc1c1ccccc1C(=O)NCCc1cccnc1,"CBR-HVAC-05798: Sleep Apnea, Treatment of;Antiarrhythmic Drugs; Potassium Channel Blockers; ; Potassium channel antagonist"
CBR-001-572-167-2,RFM-001-099-1,CBR-001-572-167-2,CCCCC[C@@H](/C=C/[C@H]1CCC(=O)[C@@H]1CCCCCCC(=O)O)O,CBR-HVAC-00918: Bronchodilators; ; ; Prostaglandin receptor agonist
CBR-001-572-168-3,RFM-001-100-7,CBR-001-572-168-3,Fc1ccc(cc1)C(=O)N1CCN(CC1)C(c1ccccc1)c1ccccc1,analog of CBR-HVAC-06374
CBR-001-572-169-4,RFM-001-101-8,CBR-001-572-169-4,C[C@@H]1COCCN1c1cc(nc(n1)c1cccc2c1cc[nH]2)C1(CC1)S(=O)(=O)C,CBR-HVAC-14214
CBR-001-572-170-7,RFM-001-102-9,CBR-001-572-170-7,COc1ccc(cc1)NS(=O)(=O)c1c(F)cccc1F,analog of CBR-HVAC-05064
CBR-001-572-171-8,RFM-001-103-0,CBR-001-572-171-8,OC[C@H](C(C(F)(F)F)C(F)(F)F)NS(=O)(=O)c1ccc(s1)Cl,"CBR-HVAC-06518: Alzheimer's Dementia, Treatment of ; gamma-Secretase Inhibitors; Gamma-secretase Inhibitor; Secretase gamma inhibitor"
CBR-001-572-172-9,RFM-001-104-1,CBR-001-572-172-9,CCN(C(c1ccccc1)c1ccccc1)C,analog of CBR-HVAC-05694
CBR-001-572-173-0,RFM-001-105-2,CBR-001-572-173-0,O=C1NCC(=O)/C/1=C\NCc1ccccc1,CBR-HVAC-07521: Melatonin 3 receptor agonist
CBR-001-572-174-1,RFM-001-106-3,CBR-001-572-174-1,COc1cccc2c1C(=O)c1c(C2=O)c(O)c2c(c1O)C(OC1CC(N)C(C(O1)C)O)CC(C2)(O)C(=O)C,CBR-HVAC-14249
CBR-001-572-175-2,RFM-001-107-4,CBR-001-572-175-2,CN(CCOC(c1ccccc1)c1ccccc1)C,"CBR-HVAC-03096: Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis;Allergic Skin Disorders, Treatment for;Nausea and Vomiting, Treatment of; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist;"
CBR-001-572-176-3,RFM-001-108-5,CBR-001-572-176-3,O=C(Cc1ccc(cc1)c1ccccc1)NCCN1CCCCC1,analog of CBR-HVAC-07526
CBR-001-572-177-4,RFM-001-109-6,CBR-001-572-177-4,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1c(NN=C(C)C)nc2c1ncnc2N,analog of CBR-HVAC-00903
CBR-001-572-178-5,RFM-001-110-9,CBR-001-572-178-5,N#Cc1ccc(cc1)[C@@H]1CN(C[C@@]21C(=O)N(C(=O)N2C)c1cc(Cl)cc(c1)Cl)c1ccc(cn1)C(=O)O,CBR-HVAC-06442: Bronchodilators;Treatment of Autoimmune Diseases;Antiarthritic Drugs; Cell Adhesion Inhibitors;LFA-1/ICAM-1 Interaction Inhibitors; LFA-1 Antagonist; Lymphocyte function-associated molecule inhibitor; Integrin antagonist
CBR-001-572-179-6,RFM-001-111-0,CBR-001-572-179-6,CC(C1CCCN1Cc1[nH]c(=O)c2c(n1)c1ccccc1o2)C,analog of CBR-HVAC-06823
CBR-001-572-180-9,RFM-001-112-1,CBR-001-572-180-9,OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1)C)C,CBR-HVAC-14285
CBR-001-572-181-0,RFM-001-113-2,CBR-001-572-181-0,COc1c(ccc(c1OC)OC)C(=O)c1c(C)oc2c1cc(O)cc2,analog of CBR-HVAC-00624
CBR-001-572-182-1,RFM-001-114-3,CBR-001-572-182-1,O[C@H]1CCC2[C@]1(C)CCC1C2CC[C@@]2([C@]1(C)C=CC(C2)(C)O)C,analog of CBR-HVAC-09954
CBR-001-572-183-2,RFM-001-115-4,CBR-001-572-183-2,COc1ccccc1N1CCN(CC1)C(=O)c1cccc2c1cccc2,analog of CBR-HVAC-00541
CBR-001-572-184-3,RFM-001-116-5,CBR-001-572-184-3,OC(=O)C(Cc1ccccc1)NCc1ccccc1,analog of CBR-HVAC-07563
CBR-001-572-185-4,RFM-001-117-6,CBR-001-572-185-4,OC(c1ccccc1)CNCc1ccc(cc1)C(=O)O,analog of CBR-HVAC-07564
CBR-001-572-186-5,RFM-001-118-7,CBR-001-572-186-5,CN(CCOC(c1cccc(c1)C)c1ccccc1)C,analog of CBR-HVAC-09550
CBR-001-572-187-6,RFM-001-119-8,CBR-001-572-187-6,CCN(CCOC(=O)c1ccc(cc1)N)CC,CBR-HVAC-00965: Potassium channel; Sodium channel Blocker; Inhibitor; Corticosteroid antagonist; Sigma 1 receptor agonist; CXC chemokine receptor 4 antagonist; CC chemokine receptor 5 antagonist
CBR-001-572-188-7,RFM-001-120-1,CBR-001-572-188-7,Cc1cc2n(c1C(=O)c1ccc(cc1)Oc1ccccc1)cccc2,analog of CBR-HVAC-01090
CBR-001-572-189-8,RFM-001-121-2,CBR-001-572-189-8,O=C(CNC(=O)C(NC(=O)C(CC(C)C)N)Cc1ccccc1)NCC(=O)NC(C(=O)O)Cc1ccc(cc1)O,analog of CBR-HVAC-11512
CBR-001-572-190-1,RFM-001-122-3,CBR-001-572-190-1,NC1=N[N+](CC1)(C)c1cccc(c1)C(F)(F)F,analog of CBR-HVAC-07582
CBR-001-572-191-2,RFM-001-123-4,CBR-001-572-191-2,c1ccc(cc1)C1CCc2c(O1)cccc2,analog of CBR-HVAC-07584
CBR-001-572-192-3,RFM-001-124-5,CBR-001-572-192-3,OCCOc1ccc(cc1)CNC(CO)(C)C,analog of CBR-HVAC-03523
CBR-001-572-193-4,RFM-001-125-6,CBR-001-572-193-4,NC(=O)Nc1cc(Cl)ccc1OCC(=O)N1CCN(C[C@H]1C)Cc1ccc(cc1)F,"CBR-HVAC-05487: Nephritis, Agents for;Multiple Sclerosis, Agents for;Treatment of Transplant Rejection;Multiple Myeloma Therapy; Chemokine CCR1 Antagonists;Signal Transduction Modulators; C-C chemokine receptor type 1 Antagonist; CC chemokine receptor 1 antagonist; Immunosuppressant; Chemokine receptor antagonist"
CBR-001-572-194-5,RFM-001-126-7,CBR-001-572-194-5,O=C1CC2C(C1(CC2)S(=O)(=O)O)(C)C,analog of CBR-HVAC-09275
CBR-001-572-195-6,RFM-001-127-8,CBR-001-572-195-6,CC(=O)Oc1ccccc1C(=O)Oc1ccccc1,CBR-HVAC-14297
CBR-001-572-196-7,RFM-001-128-9,CBR-001-572-196-7,CCN(CCNC(=O)C(c1ccccc1)(c1ccccc1)O)CC,analog of CBR-HVAC-10189
CBR-001-572-197-8,RFM-001-129-0,CBR-001-572-197-8,CCN(CCn1c(=O)c(Cc2cc(OC)c(c(c2)OC)OC)nc2c1cccc2)CC,analog of CBR-HVAC-01006
CBR-001-572-198-9,RFM-001-130-3,CBR-001-572-198-9,CO[C@@]12CC[C@@]3(C[C@@H]1[C@@](C(C)(C)C)(O)C)[C@@]14[C@H]2Oc2c4c(C[C@H]3[N+](CC1)(C)CC1CC1)ccc2O,analog of CBR-HVAC-01262
CBR-001-572-199-0,RFM-001-131-4,CBR-001-572-199-0,CCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCNC(=O)c1cccnc1)C,analog of CBR-HVAC-04014
CBR-001-572-200-6,RFM-001-132-5,CBR-001-572-200-6,CO[C@@]1(NC(=O)CSC[C@H](C(=O)O)N)C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C,CBR-HVAC-02217 Reproductive Effect; Cell wall synthesis inhibitor
CBR-001-572-201-7,RFM-001-133-6,CBR-001-572-201-7,CON=C(C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)COC(=O)N)c1ccco1,CBR-HVAC-02330 Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-202-8,RFM-001-134-7,CBR-001-572-202-8,OC1CCN(CC1)Cc1cccc(c1)Nc1ncnc2c1cccc2,analog of CBR-HVAC-05795
CBR-001-572-203-9,RFM-001-135-8,CBR-001-572-203-9,ClCCN(c1ccccc1)CCCl,analog of CBR-HVAC-08781
CBR-001-572-204-0,RFM-001-136-9,CBR-001-572-204-0,Cc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Cl,analog of CBR-HVAC-00582
CBR-001-572-205-1,RFM-001-137-0,CBR-001-572-205-1,CCCCC(=O)c1ccccc1C(=O)c1ccc2c(c1)nc([nH]2)NC(=O)OC,analog of CBR-HVAC-02266
CBR-001-572-206-2,RFM-001-138-1,CBR-001-572-206-2,CN1C2CCC1CC(C2)OC(=O)C1(CCCC1)c1ccccc1,analog of CBR-HVAC-07641
CBR-001-572-207-3,RFM-001-139-2,CBR-001-572-207-3,C=CCNC(=O)/C=C/c1ccccc1,analog of CBR-HVAC-07645
CBR-001-572-208-4,RFM-001-140-5,CBR-001-572-208-4,Cc1ccc(s1)/C=N/NC(=S)N,analog of CBR-HVAC-01170
CBR-001-572-209-5,RFM-001-141-6,CBR-001-572-209-5,Clc1ccc(cc1)C(c1ccccc1)N1CCN(CC1)C/C=C/c1ccccc1,CBR-HVAC-10341
CBR-001-572-210-8,RFM-001-142-7,CBR-001-572-210-8,CCCCCCN1CCC(=CC1)c1ccc(cc1)Cl,analog of CBR-HVAC-10872
CBR-001-572-211-9,RFM-001-143-8,CBR-001-572-211-9,O=C1CN=C(c2c(N1)ccc(c2)[N+](=O)[O-])c1cc(ccc1Cl)[N+](=O)[O-],analog of CBR-HVAC-02073
CBR-001-572-212-0,RFM-001-144-9,CBR-001-572-212-0,OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@H]([C@@H]1/C=C/[C@H](COc1cccc(c1)Cl)O)O,CBR-HVAC-10080 Prostaglandin F receptor 2 alpha Agonist;
CBR-001-572-213-1,RFM-001-145-0,CBR-001-572-213-1,CCN(CCCOc1ccc(cc1Cl)Cl)CC,analog of CBR-HVAC-09774
CBR-001-572-214-2,RFM-001-146-1,CBR-001-572-214-2,O=C1CC[C@]2(C(=C1Cl)CCC1C2CC[C@]2(C1CCC2O)C)C,CBR-HVAC-09832
CBR-001-572-215-3,RFM-001-147-2,CBR-001-572-215-3,FCSC(=O)[C@@]1(OC(=O)CC)[C@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(C2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F,"CBR-HVAC-04117: Asthma Therapy;Esophageal Diseases, Treatment of;Drugs for Allergic Rhinitis;Antiallergy/Antiasthmatic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Atopic Dermatitis, Agents for;Allergic Skin Disorders, Treatment for;Treatment of Upper Respiratory Tract Disorders; Glucocorticoid receptor Binder; Glucocorticoid agonist"
CBR-001-572-216-4,RFM-001-148-3,CBR-001-572-216-4,O=C1CN=C(c2c(N1)ccc(c2)Cl)c1ccc(cc1)F,analog of CBR-HVAC-00924
CBR-001-572-217-5,RFM-001-149-4,CBR-001-572-217-5,COc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@@H]4C=C[C@@H]1O)C,CBR-HVAC-14168
CBR-001-572-218-6,RFM-001-150-7,CBR-001-572-218-6,CN1C[C@H]2C[C@@H]1CN2c1cc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-04252: Antibacterial Drugs; DNA gyrase Inhibitor;
CBR-001-572-219-7,RFM-001-151-8,CBR-001-572-219-7,OC(=O)C1CCCN1C(=O)C12CC3CC(C2)CC(C1)C3,analog of CBR-HVAC-00251
CBR-001-572-220-0,RFM-001-152-9,CBR-001-572-220-0,CSCCOC(=O)C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])C(=O)OCCSC)C,analog of CBR-HVAC-07684
CBR-001-572-221-1,RFM-001-153-0,CBR-001-572-221-1,Brc1cc(Br)c2c(c1)[C@H](NCCCNc1cc(=O)c3c([nH]1)ccs3)CCO2,CBR-HVAC-02759: Gastrointestinal Disorders (Not Specified);Antidiarrheal Agents;Antibacterial Drugs; Methionyl-tRNA Synthetase Inhibitors; Methionyl tRNA synthetase Inhibitor; Methionyl-tRNA synthetase inhibitor
CBR-001-572-222-2,RFM-001-154-1,CBR-001-572-222-2,OCC1OC(CC1N=[N+]=[N-])n1cc(C)c(nc1=O)N,CBR-HVAC-03875: Anti-HIV Agents; ; Reverse transcriptase Inhibitor; RNA directed DNA polymerase inhibitor
CBR-001-572-223-3,RFM-001-155-2,CBR-001-572-223-3,C/C(=N/CC/N=C(/C=C(/O)\C)\C)/C=C(\O)/C,ligand of CBR-HVAC-05187
CBR-001-572-224-4,RFM-001-156-3,CBR-001-572-224-4,CN(CCOC(=O)NCCCCNC(=O)OCCN(C)C)C,analog of CBR-HVAC-04041
CBR-001-572-225-5,RFM-001-157-4,CBR-001-572-225-5,CNCC12CC3CC(C2)CC(C1)C3,analog of CBR-HVAC-10129
CBR-001-572-226-6,RFM-001-158-5,CBR-001-572-226-6,CCCCOc1ccc(cc1)C(=O)OC1CC(C)N(CC1C)C,analog of CBR-HVAC-09766
CBR-001-572-227-7,RFM-001-159-6,CBR-001-572-227-7,CC(CC(C(=O)N[C@@H](C(=O)O)CCCNC(=N)N)NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)[C@@H](NC(=O)C(Cc1ccc(cc1)O)N)C)C,"CBR-HVAC-03253: Antiulcer Drugs;Angina pectoris, Treatment of; mu-Opioid Agonists;Signal Transduction Modulators; Opioid receptor mu; Opioid receptor delta Agonist;"
CBR-001-572-228-8,RFM-001-160-9,CBR-001-572-228-8,O=C(c1ccc(cc1)NS(=O)(=O)c1ccc2c(c1)c(=O)n(c(=O)[nH]2)C)N1CCCC1,analog of CBR-HVAC-09500
CBR-001-572-229-9,RFM-001-161-0,CBR-001-572-229-9,CN(CC/C=C\1/c2ccccc2CC(c2c1cccc2)O)C,analog of CBR-HVAC-09231
CBR-001-572-230-2,RFM-001-162-1,CBR-001-572-230-2,CCc1ccc(cc1)/C=C/1\SC(=N)NC1=O,analog of CBR-HVAC-04372
CBR-001-572-231-3,RFM-001-163-2,CBR-001-572-231-3,Brc1cccc(c1)Cn1c(NCC2CCCO2)nc2c1c(=O)n(c(=O)n2C)C,analog of CBR-HVAC-05708
CBR-001-572-232-4,RFM-001-164-3,CBR-001-572-232-4,CC1CCCC(C1)OC(=O)C[N+](CCCCCCCCCC[N+](CC(=O)C1CC(C)CCC1C(C)C)(C)C)(C)C,analog of CBR-HVAC-07343
CBR-001-572-233-5,RFM-001-165-4,CBR-001-572-233-5,OC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)c[nH]3,analog of CBR-HVAC-07718
CBR-001-572-234-6,RFM-001-166-5,CBR-001-572-234-6,CC1CCC2=C(C1)c1c(O)cc(cc1OC2(C)C)C,analog of CBR-HVAC-00394
CBR-001-572-235-7,RFM-001-167-6,CBR-001-572-235-7,COC(c1ccccc1)(c1ccccc1)C(=O)OC(CN(C)C)C,analog of CBR-HVAC-01719
CBR-001-572-236-8,RFM-001-168-7,CBR-001-572-236-8,COc1cc(CCNCC(c2ccccc2)O)ccc1OC,analog of CBR-HVAC-02928
CBR-001-572-237-9,RFM-001-169-8,CBR-001-572-237-9,COc1ccc2c3c1OC1C43CC[N+](C(C2)C4C=CC1O)(C)C,analog of CBR-HVAC-09989
CBR-001-572-238-0,RFM-001-170-1,CBR-001-572-238-0,CC(Cc1ccc(cc1)C(F)(F)F)N,analog of CBR-HVAC-02642
CBR-001-572-239-1,RFM-001-171-2,CBR-001-572-239-1,CN(CC1CCc2c(C1=O)cccc2)C,analog of CBR-HVAC-10449
CBR-001-572-240-4,RFM-001-172-3,CBR-001-572-240-4,CCCCN(Cc1ccco1)Cc1ccccc1,analog of CBR-HVAC-10108
CBR-001-572-241-5,RFM-001-173-4,CBR-001-572-241-5,O=CN1CCC23C4C1Cc1c3c(OC2C(C=C4)OC(=O)C)c(cc1)OC,analog of CBR-HVAC-05963
CBR-001-572-242-6,RFM-001-174-5,CBR-001-572-242-6,O=C(Nc1cc(nn1c1ccccc1)C)CNC(c1ccccc1)c1ccccc1,analog of CBR-HVAC-01015
CBR-001-572-243-7,RFM-001-175-6,CBR-001-572-243-7,CC(=O)CC(c1c(=O)oc2c(c1O)cccc2)(C)C,analog of CBR-HVAC-07749
CBR-001-572-244-8,RFM-001-176-7,CBR-001-572-244-8,CCC(Cc1cc(OC)c(cc1OC)C)N,CBR-HVAC-14272
CBR-001-572-245-9,RFM-001-177-8,CBR-001-572-245-9,N#Cc1cc(c2ccccc2)c([nH]c1=O)C,analog of CBR-HVAC-03862
CBR-001-572-246-0,RFM-001-178-9,CBR-001-572-246-0,COc1ccc2c(c1)CCN=C2Cc1ccc(c(c1)OC)OC,analog of CBR-HVAC-05250
CBR-001-572-247-1,RFM-001-179-0,CBR-001-572-247-1,OC(=O)C(Cc1ccc(cc1)CP(=O)(O)O)N,CBR-HVAC-14226
CBR-001-572-248-2,RFM-001-180-3,CBR-001-572-248-2,O=C1N=C(CN1c1ccccc1)N1CCCC1,analog of CBR-HVAC-00519
CBR-001-572-249-3,RFM-001-181-4,CBR-001-572-249-3,N1CCN(CC1)c1cccc2c1OCCO2,"CBR-HVAC-00653: Antipsychotic Drugs;Antiparkinsonian Drugs;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Cognition Disorders, Treatment of; Signal Transduction Modulators;5-HT1A Receptor Agonists;5-HT1B Agonists;5-HT2C Antagonists; 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 2C receptor Agonist; Agonist; Antagonist; 5 Hydroxytryptamine 1A receptor agonist; 5 Hydroxytryptamine 1B receptor agonist"
CBR-001-572-250-6,RFM-001-182-5,CBR-001-572-250-6,CC(Oc1ccc(cc1)c1cc(=O)c2c(o1)cc(cc2OC(C)C)OC(C)C)C,analog of CBR-HVAC-07781
CBR-001-572-251-7,RFM-001-183-6,CBR-001-572-251-7,CCOC(=O)C(c1ccc2c(c1)ccc(c2)OC)C,analog of CBR-HVAC-07786
CBR-001-572-252-8,RFM-001-184-7,CBR-001-572-252-8,NC1CCN(CC1)c1ccc(nn1)c1ccccc1Cl,analog of CBR-HVAC-03185
CBR-001-572-253-9,RFM-001-185-8,CBR-001-572-253-9,Clc1ccc2c(c1)C(=NCc1n2cnn1)c1ccccc1Cl,analog of CBR-HVAC-01739
CBR-001-572-254-0,RFM-001-186-9,CBR-001-572-254-0,O=c1oc2cc(ccc2c(c1C)C)OS(=O)(=O)C,analog of CBR-HVAC-03357
CBR-001-572-255-1,RFM-001-187-0,CBR-001-572-255-1,CCCNCCc1ccccc1,analog of CBR-HVAC-10110
CBR-001-572-256-2,RFM-001-188-1,CBR-001-572-256-2,OC(=O)C[C@@H]1COc2c1ccc(c2)OCc1cccc(c1)c1c(C)cc(cc1C)OCCCS(=O)(=O)C,"CBR-HVAC-00784: Type 2 Diabetes, Agents for; Free Fatty Acid Receptor 1 (FFAR1;  GPR40) Agonists;Insulin Secretagogues;Signal Transduction Modulators; Free fatty acid receptor 1 Agonist; GPR40 agonist; Insulin secretagogue"
CBR-001-572-257-3,RFM-001-189-2,CBR-001-572-257-3,CN(C(=O)[C@@H]1CCCN1C(=O)NCc1ccc(cc1C)C(=O)N1CCCCc2c1cccc2)C,CBR-HVAC-00707: Urinary Incontinence Therapy; Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Agonists; Vasopressin V2 receptor Agonist; Vasopressin 2 agonist
CBR-001-572-258-4,RFM-001-190-5,CBR-001-572-258-4,CC(NCC#N)CCc1ccccc1,analog of CBR-HVAC-09790
CBR-001-572-259-5,RFM-001-191-6,CBR-001-572-259-5,COc1ccc(cc1)CCNC(=O)COc1cc(O)c2c(c1)oc(cc2=O)c1ccccc1,analog of CBR-HVAC-10424
CBR-001-572-260-8,RFM-001-192-7,CBR-001-572-260-8,COc1ccc(cc1[C@@]1(F)C(=O)Nc2c1ccc(c2)C(F)(F)F)Cl,"CBR-HVAC-05151: Neurological Genetic Disorders, Treatment of ;Stroke, Treatment of; Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;Voltage-Gated K(V) 7 (KCNQ) Channel Activators; Large-conductance calcium-activated potassium channel Opener;"
CBR-001-572-261-9,RFM-001-193-8,CBR-001-572-261-9,[O-][N+](=O)c1ccc(o1)c1nc2c([nH]1)cccc2,analog of CBR-HVAC-07841
CBR-001-572-262-0,RFM-001-194-9,CBR-001-572-262-0,COc1cc(CNC(=O)c2cc(ccc2NC)[N+](=O)[O-])ccc1OC(F)F,analog of CBR-HVAC-09328
CBR-001-572-263-1,RFM-001-195-0,CBR-001-572-263-1,COc1cccc(c1OC)C1N2C(=O)CN(C(=O)[C@@H]2Cc2c1[nH]c1c2cccc1)CCC1=CCCCC1,analog of CBR-HVAC-11247
CBR-001-572-264-2,RFM-001-196-1,CBR-001-572-264-2,COc1ccc(cc1OC)CCN(CCCC(c1cc(OC)c(c(c1)OC)OC)(C(C)C)C#N)C,"CBR-HVAC-01832: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Calcium channel L-type Blocker; L-type calcium channel antagonist"
CBR-001-572-265-3,RFM-001-197-2,CBR-001-572-265-3,Fc1cn(c(=O)nc1NC(=O)c1ccccc1)C1OC(C(C1OC(=O)c1ccccc1)OC(=O)c1ccccc1)COC(=O)c1ccccc1,analog of CBR-HVAC-02523
CBR-001-572-266-4,RFM-001-198-3,CBR-001-572-266-4,O=C(Nc1ccccc1)/C=C/c1c([nH]c2c1c(Cl)cc(c2)Cl)C(=O)O,"CBR-HVAC-04512: Stroke, Treatment of; NMDA Glycine-Site Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; Glycine NMDA associated antagonist"
CBR-001-572-267-5,RFM-001-199-4,CBR-001-572-267-5,Fc1ccc2c(c1)c1CN(CCc1[nH]2)C(=O)CCc1c[nH]c2c1cccc2,analog of CBR-HVAC-02502
CBR-001-572-268-6,RFM-001-200-0,CBR-001-572-268-6,COCCn1nc2c(c1CC)nc([nH]c2=O)c1cc(cnc1OCC)S(=O)(=O)N1CCN(CC1)CC,"CBR-HVAC-00348: Pulmonary Hypertension, Treatment of;Treatment of Erectile Dysfunction;Urologic Drugs; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; ; Phosphodiesterase 5 inhibitor"
CBR-001-572-269-7,RFM-001-201-1,CBR-001-572-269-7,CC(=O)O[C@H]1C[C@H](O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]2[C@@H]3C[C@@H](OC(=O)C)[C@]3([C@]2(O)CC[C@@H]3C2=CC(=O)OC2)C)C)O[C@@H]([C@H]1O[C@H]1C[C@H](OC(=O)C)[C@@H]([C@H](O1)C)O[C@H]1C[C@H](OC(=O)C)[C@@H]([C@H](O1)C)OC(=O)C)C,analog of CBR-HVAC-01620
CBR-001-572-270-0,RFM-001-202-2,CBR-001-572-270-0,COc1cc(cc(c1OC)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@@H](c2c1cc1OCOc1c2)NC(=O)c1ccc(cc1)[N+](=O)[O-],analog of CBR-HVAC-04466
CBR-001-572-271-1,RFM-001-203-3,CBR-001-572-271-1,O=C(NC(c1ccc(cc1)S(=O)(=O)N)C)Nc1ccccn1,analog of CBR-HVAC-08797
CBR-001-572-272-2,RFM-001-204-4,CBR-001-572-272-2,CCOc1ccc(cc1)S(=O)(=O)Nc1ncccn1,analog of CBR-HVAC-09593
CBR-001-572-273-3,RFM-001-205-5,CBR-001-572-273-3,CC[C@@H](n1cc(c2c1cc(cc2C(=O)NCc1c(C)cc([nH]c1=O)C)c1ccc(nc1)N1CCNCC1)C)C,CBR-HVAC-07881: Non-Hodgkin's Lymphoma Therapy; Histone-Lysine N-Methyltransferase EZH2 Inhibitors; ; Histone methyltransferase inhibitor
CBR-001-572-274-4,RFM-001-206-6,CBR-001-572-274-4,Clc1ccc(cc1)C(=O)Nc1ccc2c(c1)nc(n2C)C,analog of CBR-HVAC-11719
CBR-001-572-275-5,RFM-001-207-7,CBR-001-572-275-5,OC(=O)/C=C\c1ccccc1,delivered in error
CBR-001-572-276-6,RFM-001-208-8,CBR-001-572-276-6,O=C(C1COc2c(O1)cccc2)NCCCn1ncccc1=O,analog of CBR-HVAC-00077
CBR-001-572-278-8,RFM-001-209-9,CBR-001-572-278-8,Cc1nc2ccc(cc2c2c1CCN2c1ccc(cc1)C(C)C)Oc1ccccc1,analog of CBR-HVAC-07118
CBR-001-572-279-9,RFM-001-210-2,CBR-001-572-279-9,COc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@@H]4CCC1=O)C,CBR-HVAC-14205
CBR-001-572-280-2,RFM-001-211-3,CBR-001-572-280-2,C/C=C/1\CN2CC[C@H]1CC2[C@@H](c1ccnc2c1cc(OC)cc2)O,analog of CBR-HVAC-07350
CBR-001-572-281-3,RFM-001-212-4,CBR-001-572-281-3,CC[C@H]1C[C@@H]2CN3C1[C@@H](C2)c1[nH]c2c(c1CC3)cccc2,analog of CBR-HVAC-03420
CBR-001-572-282-4,RFM-001-213-5,CBR-001-572-282-4,Cc1cc(SCCN2CCCCC2)nc2c1cccc2,analog of CBR-HVAC-03565
CBR-001-572-283-5,RFM-001-214-6,CBR-001-572-283-5,NCC(=O)NC1Cc2c(C1)cccc2,analog of CBR-HVAC-00370
CBR-001-572-284-6,RFM-001-215-7,CBR-001-572-284-6,CC(=O)O[C@H]1CCC2[C@]1(C)CCC1C2CCC2=CC(=O)CC[C@]12C,analog of CBR-HVAC-02485
CBR-001-572-285-7,RFM-001-216-8,CBR-001-572-285-7,COc1ccc(cc1)[C@H]([C@H](c1ccccc1)N)O,analog of CBR-HVAC-10142
CBR-001-572-286-8,RFM-001-217-9,CBR-001-572-286-8,OCC1OC(C(C1O)O)Nc1ccc(cc1)C(=O)O,CBR-HVAC-05782 Oncolytic Drugs;
CBR-001-572-287-9,RFM-001-218-0,CBR-001-572-287-9,COc1cc(O)c(c2c1[C@H](C)NC(C2)C)c1c(C)cc(c2c1cccc2OC)OC,analog of CBR-HVAC-10787
CBR-001-572-288-0,RFM-001-219-1,CBR-001-572-288-0,OCC(CCc1ccc(cc1Cl)Sc1cccc(c1)OCc1ccccc1)(CO)N,"CBR-HVAC-00628: Treatment of Transplant Rejection;Treatment of Autoimmune Diseases;Systemic Lupus Erythematosus, Agents for;Immunosuppressants;Inflammatory Bowel Disease, Agents for;Multiple Sclerosis, Agents for;Hematological Cancer Therapy; Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Signal Transduction Modulators; Sphingosine 1-phosphate receptor Agonist; Sphingosine 1-phosphate receptor agonist"
CBR-001-572-289-1,RFM-001-220-4,CBR-001-572-289-1,COc1cc(C)ccc1OCC(=O)N1CCC(Sc2c1cccc2)C,analog of CBR-HVAC-02735
CBR-001-572-290-4,RFM-001-221-5,CBR-001-572-290-4,OC(c1cc(O)cc(c1)O)CNC(C)(C)C,"CBR-HVAC-02571: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Bronchodilators;Antidiabetic Drugs;Treatment of Preterm Labor;Female Infertility, Agents for; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta adrenergic receptor Agonist; Short-acting beta 2 adrenoceptor (SABA) agonist; Beta 2 adrenoreceptor agonist"
CBR-001-572-291-5,RFM-001-222-6,CBR-001-572-291-5,Cc1ccc(c(c1)C)NC(=O)NC1N=C(c2ccccc2)c2c(N(C1=O)C)cccc2,analog of CBR-HVAC-03793
CBR-001-572-292-6,RFM-001-223-7,CBR-001-572-292-6,Cc1noc(n1)/C(=C/c1cccc(c1)c1cc(cc2c1nccc2)C(S(=O)(=O)C)(C)C)/c1ccc(cc1)S(=O)(=O)C,"CBR-HVAC-05568: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Antiarthritic Drugs;Bronchodilators;Cognition Disorders, Treatment of; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor;"
CBR-001-572-293-7,RFM-001-224-8,CBR-001-572-293-7,OC[C@H]1O[C@@H](OC2[C@@H](O)CC(O[C@@H]2C)OC2[C@@H](O)CC(O[C@@H]2C)OC2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]2CC[C@]3([C@H](C2)CC[C@@H]2C3C[C@@H](O)[C@]3([C@]2(O)CC[C@@H]3C2=CC(=O)OC2)C)C)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-14311
CBR-001-572-294-8,RFM-001-225-9,CBR-001-572-294-8,O=CN1C(CNc2ccc(cc2)C(=O)N[C@H](C(=O)O)CCC(=O)O)CNc2c1c(=O)nc([nH]2)N,CBR-HVAC-01348: Treatment of Mucositis;Chemopreventive Agents;Treatment of Poisoning;Colorectal Cancer Therapy;Osteosarcoma Therapy;Oncolytic Drugs; ; ; Unidentified pharmacological activity
CBR-001-572-295-9,RFM-001-226-0,CBR-001-572-295-9,Oc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C,CBR-HVAC-03092: Opioid Analgesics; mu-Opioid Agonists;NMDA Antagonists;Signal Transduction Modulators; Opioid receptor mu Agonist;
CBR-001-572-296-0,RFM-001-227-1,CBR-001-572-296-0,CN(CC(=O)c1ccc(cc1)Cl)CCCN1c2ccccc2CCc2c1cccc2,CBR-HVAC-02174: Antidepressants; ; ; Tricyclic antidepressant; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor
CBR-001-572-297-1,RFM-001-228-2,CBR-001-572-297-1,S=C(Nc1cccc(c1)Cl)Nc1ccc(cc1)F,analog of CBR-HVAC-09030
CBR-001-572-298-2,RFM-001-229-3,CBR-001-572-298-2,OC(=O)C(Oc1ccc(cc1Cl)Cl)C,analog of CBR-HVAC-09984
CBR-001-572-299-3,RFM-001-230-6,CBR-001-572-299-3,O=C1Nc2ccc(cc2C(=NC1O)c1ccc(cc1)Cl)Br,analog of CBR-HVAC-01293
CBR-001-572-300-9,RFM-001-231-7,CBR-001-572-300-9,Fc1cc(F)c2c(c1)c(cc(n2)C)NC(=O)c1cccc(c1)S(=O)(=O)N1CCN(CC1)C(=O)C,analog of CBR-HVAC-00789
CBR-001-572-301-0,RFM-001-232-8,CBR-001-572-301-0,CC[C@]1(O)C(=O)OCc2c1cc1c3nc4cccc(c4cc3Cn1c2=O)OC,analog of CBR-HVAC-04444
CBR-001-572-302-1,RFM-001-233-9,CBR-001-572-302-1,Clc1ccc(cc1)C(=O)NS(=O)(=O)c1ccc(cc1)Cl,analog of CBR-HVAC-11778
CBR-001-572-303-2,RFM-001-234-0,CBR-001-572-303-2,O=C(Cn1cnc2c1c(=O)n(C)c(=O)n2C)OCC(=O)c1cc(C)c(cc1C)C,analog of CBR-HVAC-00172
CBR-001-572-304-3,RFM-001-235-1,CBR-001-572-304-3,CNCC(=O)c1ccccc1,analog of CBR-HVAC-09818
CBR-001-572-305-4,RFM-001-236-2,CBR-001-572-305-4,COc1ccc2c3c1O[C@@H]1C43CCNC(C2)C4=CC=C1,analog of CBR-HVAC-09969
CBR-001-572-306-5,RFM-001-237-3,CBR-001-572-306-5,NCCc1ccc2c(c1)OCO2,analog of CBR-HVAC-09828
CBR-001-572-307-6,RFM-001-238-4,CBR-001-572-307-6,CC1CCC2N(C1)CCc1c2n(Cc2ccccc2)c2c1cccc2,analog of CBR-HVAC-10000
CBR-001-572-308-7,RFM-001-239-5,CBR-001-572-308-7,Fc1ccc(cc1)S(=O)(=O)N1CCn2c3C1CCCc3c1c2ccc(c1)C1CCCCC1,analog of CBR-HVAC-00181
CBR-001-572-309-8,RFM-001-240-8,CBR-001-572-309-8,COc1cc(ccc1OCCN1CCOCC1)C(=O)C,analog of CBR-HVAC-08614
CBR-001-572-310-1,RFM-001-241-9,CBR-001-572-310-1,CN(Cc1ccccc1Sc1cccc(c1)O)C,CBR-HVAC-03953 Antidepressants; Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5 Hydroxytryptamine receptor antagonist; 5 Hydroxytryptamine uptake inhibitor
CBR-001-572-311-2,RFM-001-242-0,CBR-001-572-311-2,NCCCCCCCNc1cc(OC)cc2c1nccc2,analog of CBR-HVAC-05546
CBR-001-572-312-3,RFM-001-243-1,CBR-001-572-312-3,O=C1SC(C(=O)N1)Cc1cccc(c1)Oc1ccccc1,analog of CBR-HVAC-07109
CBR-001-572-313-4,RFM-001-244-2,CBR-001-572-313-4,CCN(CCOC(=O)c1ccc(cc1)N)CC,CBR-HVAC-00965: Potassium channel; Sodium channel Blocker; Inhibitor; Corticosteroid antagonist; Sigma 1 receptor agonist; CXC chemokine receptor 4 antagonist; CC chemokine receptor 5 antagonist
CBR-001-572-314-5,RFM-001-245-3,CBR-001-572-314-5,[N-]=[N+]=N[C@@H]1C[C@H](O[C@H]1n1ccc(=O)[nH]c1=O)CO,analog of CBR-HVAC-03876
CBR-001-572-315-6,RFM-001-246-4,CBR-001-572-315-6,CCCN1CCO[C@H]2[C@H]1CCc1c2cc(cc1)O,CBR-HVAC-03889: Antiparkinsonian Drugs; Dopamine D2 Agonists;Signal Transduction Modulators; Dopamine receptor D2 Agonist; Dopamine D2 receptor agonist
CBR-001-572-316-7,RFM-001-247-5,CBR-001-572-316-7,CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)C12CC3CC2CC(C1)C3O,analog of CBR-HVAC-04722
CBR-001-572-317-8,RFM-001-248-6,CBR-001-572-317-8,O=C1CN=C(c2c(N1Cc1ccc(cc1)[N+](=O)[O-])cccc2)c1ccccc1,analog of CBR-HVAC-01304
CBR-001-572-318-9,RFM-001-249-7,CBR-001-572-318-9,CN(CCC(c1ccccc1)Oc1ccccc1OCc1ccccc1)C,analog of CBR-HVAC-10010
CBR-001-572-319-0,RFM-001-250-0,CBR-001-572-319-0,CCn1c(=O)n(Cc2ccc(cc2)[N+](=O)[O-])c2c(c1=O)cccc2,analog of CBR-HVAC-01072
CBR-001-572-320-3,RFM-001-251-1,CBR-001-572-320-3,Clc1cc(Cc2cc(Cl)cc(c2O)[N+](=O)[O-])c(c(c1)[N+](=O)[O-])O,analog of CBR-HVAC-10194
CBR-001-572-321-4,RFM-001-252-2,CBR-001-572-321-4,CNCCc1cnc[nH]1,CBR-HVAC-06479: Antimigraine Drugs; Histamine H3 Receptor Agonists;Signal Transduction Modulators; ;
CBR-001-572-322-5,RFM-001-253-3,CBR-001-572-322-5,Clc1ccc(cc1Cl)Nc1c2ccccc2nc2c1cccc2,analog of CBR-HVAC-01196
CBR-001-572-323-6,RFM-001-254-4,CBR-001-572-323-6,O=c1[nH]c2c(n1C1CCNCC1)cccc2,analog of CBR-HVAC-11229
CBR-001-572-324-7,RFM-001-255-5,CBR-001-572-324-7,CO[C@@H]([C@](C(=O)OCC1=CCN2[C@H]1[C@@H](O)CC2)(C(C)C)O)C,analog of CBR-HVAC-10420
CBR-001-572-325-8,RFM-001-256-6,CBR-001-572-325-8,O=C1c2ccccc2C(/C/1=C\c1ccccc1)NC1CCCCC1,"CBR-HVAC-06916: Wound-Healing Agents;Inflammation, Treatment of;Pharmacological Tools; Angiogenesis Inhibitors;MKP-3 Inhibitors;Signal Transduction Modulators; ;"
CBR-001-572-326-9,RFM-001-257-7,CBR-001-572-326-9,Clc1ccc2c(c1)nccc2Nc1ccc(c(c1)O)CNC(C)(C)C,CBR-HVAC-05792: Antimalarials; ; ;
CBR-001-572-327-0,RFM-001-258-8,CBR-001-572-327-0,COc1ccc(cn1)c1ccc2c(c1)c1c(cn2)n(c(=O)n1c1ccc(c(c1)C(F)(F)F)N1CCNCC1)C,CBR-HVAC-06803: Solid Tumors Therapy; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; ;
CBR-001-572-328-1,RFM-001-259-9,CBR-001-572-328-1,COc1cc(CCN(c2cn[nH]c(=O)c2Br)C)ccc1OC,analog of CBR-HVAC-03567
CBR-001-572-329-2,RFM-001-260-2,CBR-001-572-329-2,CCCCNc1nc(NC)nc(c1SC)Cl,analog of CBR-HVAC-08105
CBR-001-572-330-5,RFM-001-261-3,CBR-001-572-330-5,COCC(=O)N(c1ccccc1)C1CCN(CC1)CCc1ccccc1,analog of CBR-HVAC-01156
CBR-001-572-331-6,RFM-001-262-4,CBR-001-572-331-6,CN1CCc2c([C@H](C1)c1cccc3c1OCC3)cc(c(c2)Cl)O,CBR-HVAC-04329: Antipsychotic Drugs; Dopamine D1 Antagonists;Signal Transduction Modulators; Dopamine receptor D1 Antagonist;
CBR-001-572-332-7,RFM-001-263-5,CBR-001-572-332-7,O[C@@H]1CS[C@H]([C@@H]([C@H]1O)O)Oc1ccc2c(c1)oc(=O)cc2C,CBR-HVAC-05380: Anticoagulants; Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitor; Glycosaminoglycan stimulant; Indirect thrombin inhibitor; Serine protease inhibitor
CBR-001-572-333-8,RFM-001-264-6,CBR-001-572-333-8,COc1cc(/C=N/NC(=O)CSc2cc(C)nc3c2cccc3)cc(c1OC)OC,analog of CBR-HVAC-08113
CBR-001-572-334-9,RFM-001-265-7,CBR-001-572-334-9,COc1ccccc1NS(=O)(=O)/C=C/c1ccccc1,analog of CBR-HVAC-11907
CBR-001-572-335-0,RFM-001-266-8,CBR-001-572-335-0,OC(=O)CCC/C=C\[C@H]1C2CCC([C@@H]1CNS(=O)(=O)c1ccc(cc1C)Cl)CC2,CBR-HVAC-05094: Chemopreventive Agents;Non-Opioid Analgesics; Prostanoid EP1 Antagonists;Prostanoid TP Antagonists;Signal Transduction Modulators; PROSTAGLANDIN EP1 RECEPTOR Antagonist; Prostaglandin EP1 receptor antagonist
CBR-001-572-336-1,RFM-001-267-9,CBR-001-572-336-1,c1ccc(cc1)C(c1ccccn1)Nc1nc2c(o1)cccc2,analog of CBR-HVAC-04474
CBR-001-572-337-2,RFM-001-268-0,CBR-001-572-337-2,Fc1ccc(c(c1)C)[C@H]1C[C@H](CCN1C(=O)N([C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)C)N1CCN2[C@H](C1)CCC2=O,"CBR-HVAC-00577: Posttraumatic Stress Disorder (PTSD), Treatment of;Antipruritics;Anxiolytics;Antidepressants; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin 1 receptor Antagonist; Neurokinin 1 receptor antagonist"
CBR-001-572-338-3,RFM-001-269-1,CBR-001-572-338-3,O=C1CCC2(C(=C1)C(=CC1C2CCC2(C1CC[C@]2(OC(=O)C)C(=O)C)C)Cl)C,CBR-HVAC-02769: Androgen receptor Antagonist; Estradiol 17 beta dehydrogenase stimulant; Estrone sulfotransferase stimulant; Benign Prostatic Hyperplasia Therapy; Endometriosis Therapy; Progestational steroid; Prostate Cancer Therapy; Treatment of Dysmenorrhea
CBR-001-572-339-4,RFM-001-270-4,CBR-001-572-339-4,ON1C(C)(C)CC(CC1(C)C)OC(=O)C,analog of CBR-HVAC-00456
CBR-001-572-340-7,RFM-001-271-5,CBR-001-572-340-7,CC(OC(=O)C1=C(C)NC(=C(C1c1ccc2c(c1)OCO2)C(=O)OC(C)C)C)C,analog of CBR-HVAC-03333
CBR-001-572-341-8,RFM-001-272-6,CBR-001-572-341-8,Cc1cc(c(c(c1CC1=NCCN1)C)O)C(C)(C)C,CBR-HVAC-00834: Nasal Decongestants;Ophthalmic Drugs;Dermatologic Drugs; alpha1A-Adrenoceptor Agonists;alpha2A(2D)-Adrenoceptor Agonists;Signal Transduction Modulators; Cyclooxygenase Inhibitor; Unidentified pharmacological activity
CBR-001-572-342-9,RFM-001-273-7,CBR-001-572-342-9,CC(C(C)(C)C)N/C(=N\C#N)/Nc1ccncc1,"CBR-HVAC-01550: K(ATP) Channel Activators; Potassium channel Opener; Potassium channel agonist; Antihypertensive; Hypertension, Treatment of; Vasodilator"
CBR-001-572-343-0,RFM-001-274-8,CBR-001-572-343-0,COC1C(OC(=O)C)C(OC2CC[C@]3([C@H](C2)CCC2[C@@H]3CC[C@]3(C2(O)CC[C@H]3c2ccc(=O)oc2)C)C=O)OC(C1OC(=O)C)C,analog of CBR-HVAC-08141
CBR-001-572-344-1,RFM-001-275-9,CBR-001-572-344-1,C=CCn1c(=O)c(C(=O)Nc2cccc(c2C)C)c(c2c1cccc2)O,analog of CBR-HVAC-00610
CBR-001-572-345-2,RFM-001-276-0,CBR-001-572-345-2,CN1CCC(CC1)OC(=O)C(c1ccccc1)(c1ccccc1)O,analog of CBR-HVAC-08931
CBR-001-572-346-3,RFM-001-277-1,CBR-001-572-346-3,Clc1ccc(cc1)CCCOc1n[nH]c(=O)c(c1NCc1cccnc1)Br,CBR-HVAC-00039: Asthma Therapy;Treatment of Intermittent Claudication; Phosphodiesterase PDE3 Inhibitors;Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators;Thromboxane Synthase Inhibitors; Phosphodiesterase 5; Phosphodiesterase 3; Thromboxane A synthase Inhibitor; Phosphodiesterase 3 inhibitor; Phosphodiesterase 5 inhibitor; Thromboxane synthase inhibitor; Platelet aggregation inhibitor; Phosphodiesterase 4 inhibitor
CBR-001-572-347-4,RFM-001-278-2,CBR-001-572-347-4,CCCCc1nnc(n1c1ccccc1)S,analog of CBR-HVAC-10868
CBR-001-572-348-5,RFM-001-279-3,CBR-001-572-348-5,C=CCSc1nnc(s1)c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,analog of CBR-HVAC-11315
CBR-001-572-349-6,RFM-001-280-6,CBR-001-572-349-6,CN1CCC(CC1)OC(=O)C(c1ccccc1)c1ccccc1,analog of CBR-HVAC-08932
CBR-001-572-350-9,RFM-001-281-7,CBR-001-572-350-9,COc1cc(NCCCC(N)C)c2c(c1)cccn2,CBR-HVAC-12310
CBR-001-572-351-0,RFM-001-282-8,CBR-001-572-351-0,NC(=S)N/N=C/c1ccncc1,CBR-HVAC-07385 Treatment of Tuberculosis;
CBR-001-572-352-1,RFM-001-283-9,CBR-001-572-352-1,O=C[C@]12CC[C@@H](C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2([C@]1(O)CC[C@@H]2C1=CC(=O)OC1)C)OC1OC(C)C(C(C1O)O)O,analog of CBR-HVAC-07219
CBR-001-572-353-2,RFM-001-284-0,CBR-001-572-353-2,CC(=O)NCC(=O)N1[C@H]2CC[C@@H]1c1c2ccc(c1)Nc1ncc(c(n1)NC1CCC1)C(F)(F)F,CBR-HVAC-12052: Oncolytic Drugs; Antimitotic Drugs;Aurora Kinase Inhibitors;Signal Transduction Modulators; ;
CBR-001-572-354-3,RFM-001-285-1,CBR-001-572-354-3,CN[C@@H]1CCN(C1)c1cc(nc(n1)N)NC1(C)CC1,analog of CBR-HVAC-06736
CBR-001-572-355-4,RFM-001-286-2,CBR-001-572-355-4,O=C(Nc1ncc(s1)C)Cc1ccc(cc1)NC(=O)C,analog of CBR-HVAC-06437
CBR-001-572-356-5,RFM-001-287-3,CBR-001-572-356-5,CC(C(C1CNc2c(N1)c(=O)[nH]c(n2)N)O)O,CBR-HVAC-02374: Phenylalanine hydroxylase Stimulator; Unidentified pharmacological activity
CBR-001-572-357-6,RFM-001-288-4,CBR-001-572-357-6,Nc1ccn(c(=O)n1)[C@H]1CO[C@H](S1)CO,CBR-HVAC-00294: Non-nucleoside reverse transcriptase Inhibitor; RNA directed DNA polymerase inhibitor; DNA synthesis inhibitor
CBR-001-572-358-7,RFM-001-289-5,CBR-001-572-358-7,CCC(=O)C(c1ccccc1)(c1ccccc1)CCN1CCOCC1,analog of CBR-HVAC-09994
CBR-001-572-359-8,RFM-001-290-8,CBR-001-572-359-8,COc1ccc2c3c1OC1(C43CCN(C(C2)C4C=CC1O)C)C,analog of CBR-HVAC-09640
CBR-001-572-360-1,RFM-001-291-9,CBR-001-572-360-1,CCCCN1CCC(CC1)CNC(=O)c1c2OCCCn2c2c1cccc2,"CBR-HVAC-04769: Antiarrhythmic Drugs;Heart Failure Therapy;Irritable Bowel Syndrome, Agents for; Signal Transduction Modulators;5-HT4 Antagonists; 5-Hydroxytryptamine 4 receptor Antagonist; 5 Hydroxytryptamine 4 receptor antagonist"
CBR-001-572-361-2,RFM-001-292-0,CBR-001-572-361-2,Clc1ccc(cc1)C1=NCC(=O)N(c2c1cc(Cl)cc2)C,CBR-HVAC-14182
CBR-001-572-362-3,RFM-001-293-1,CBR-001-572-362-3,O=C(c1ccc(cc1)F)CCCN1CCC(CC1)(N1CCCCC1)C(=O)N,CBR-HVAC-05283: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2 Antagonists; 5-Hydroxytryptamine 2A receptor; 5-Hydroxytryptamine 2C receptor Antagonist;
CBR-001-572-363-4,RFM-001-294-2,CBR-001-572-363-4,CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,CBR-HVAC-01323: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-572-364-5,RFM-001-295-3,CBR-001-572-364-5,NCC[C@@H](C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)CCN)Cc1ccccc1)CC(C)C)CCN)[C@H](O)C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)CCCCC(CC)C)CCN,analog of CBR-HVAC-03451
CBR-001-572-365-6,RFM-001-296-4,CBR-001-572-365-6,OC[C@H]1O[C@@H](Oc2ccccc2C=O)[C@@H]([C@H]([C@@H]1O)O)O,analog of CBR-HVAC-09896
CBR-001-572-366-7,RFM-001-297-5,CBR-001-572-366-7,CCOP(=S)(Oc1ccc2c(c1C)oc(=O)cc2C)OCC,analog of CBR-HVAC-09056
CBR-001-572-367-8,RFM-001-298-6,CBR-001-572-367-8,Cc1ccc2c(c1)C(=NCC(=O)N2CCCCN1CCN(CC1)c1ccccc1)c1ccccc1,analog of CBR-HVAC-01743
CBR-001-572-368-9,RFM-001-299-7,CBR-001-572-368-9,O=C1C=C[C@]2(C(=C1)CCC1C2(F)C(O)C[C@]2(C1CC(C2(O)C(=O)COC(=O)c1cccc(c1)S(=O)(=O)[O-])C)C)C,analog of CBR-HVAC-05328
CBR-001-572-369-0,RFM-001-300-3,CBR-001-572-369-0,NC[C@H](CC(=O)O)CC(C)C,"CBR-HVAC-01533: Fibromyalgia, Treatment of;Analgesic Drugs;Social Phobia, Treatment for;Generalized Anxiety Disorder (GAD), Treatment of;Non-Opioid Analgesics;Antipsychotic Drugs;Anxiolytics;Antiepileptic Drugs;Extrapyramidal Disorders, Treatment of;Treatment of Hot Flushes;Neuropathic Pain, Treatment of; Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands;L-Type Calcium Channel Blockers; Voltage-gated calcium channel, alpha2-delta subunit Binder; Calcium channel antagonist;2016-04-01: controlled substance"
CBR-001-572-370-3,RFM-001-301-4,CBR-001-572-370-3,CC(NC(=N)NC(=N)Nc1ccc(cc1)Cl)C,CBR-HVAC-04999: Antimalarials; Dihydrofolate Reductase (DHFR) Inhibitors; Thymidylate synthase; Dihydrofolate reductase Inhibitor; Inhibitor;
CBR-001-572-371-4,RFM-001-302-5,CBR-001-572-371-4,CCCCN(CCc1ccc(c(c1)O)O)CCCC,analog of CBR-HVAC-11235
CBR-001-572-372-5,RFM-001-303-6,CBR-001-572-372-5,O=C(N1c2ccccc2Sc2c1cccc2)CN1CCCC1,analog of CBR-HVAC-08846
CBR-001-572-373-6,RFM-001-304-7,CBR-001-572-373-6,CCC(C(=O)O[C@H]1[C@H](O)[C@H]2[C@H]([C@H]3[C@]1(O)[C@@H]1[C@H](OC(=O)C)C[C@H]4[C@]5([C@]1(C3)O[C@@]4(O)[C@H](CC5)OC(=O)C(C(OC(=O)C)C)(O)C)C)CN1[C@H]([C@@]2(C)O)CC[C@@H](C1)C)C,analog of CBR-HVAC-09264
CBR-001-572-374-7,RFM-001-305-8,CBR-001-572-374-7,N[C@H]1CCCC[C@H]1Nc1ncc(c(n1)Nc1cccc(c1)n1nccn1)C(=O)N,"CBR-HVAC-00027: Antiallergy/Antiasthmatic Drugs;Inflammation, Treatment of;Systemic Lupus Erythematosus, Agents for;Rheumatoid Arthritis, Treatment of;Oncolytic Drugs; Signal Transduction Modulators;Syk Kinase Inhibitors; Spleen tyrosine kinase Inhibitor; Syk tyrosine kinase inhibitor"
CBR-001-572-375-8,RFM-001-306-9,CBR-001-572-375-8,COC(=O)C1C(CC2N(C1CC2)C)OC(=O)c1ccccc1,CBR-HVAC-10116: Sodium channel Blocker;
CBR-001-572-376-9,RFM-001-307-0,CBR-001-572-376-9,Oc1ccc(nn1)N1CCN(CC1)c1ccccc1,analog of CBR-HVAC-03387
CBR-001-572-377-0,RFM-001-308-1,CBR-001-572-377-0,Clc1cccc(c1)[C@]1(O)OCC(N[C@H]1C)(C)C,"CBR-HVAC-05696: Fibromyalgia, Treatment of;Bipolar Disorder, Treatment of;Antiobesity Drugs;Neuropathic Pain, Treatment of;Restless Legs Syndrome, Treatment of;Antidepressants; Dopamine Reuptake Inhibitors;Nicotinic alpha4beta2 Antagonists;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators; Dopamine transporter; Norepinephrine transporter Inhibitor; Adrenergic transmitter uptake inhibitor; Dopamine reuptake inhibitor"
CBR-001-572-378-1,RFM-001-309-2,CBR-001-572-378-1,O=C1CS/C(=C/C(=O)Nc2ccccc2Cl)/N1,analog of CBR-HVAC-03229
CBR-001-572-379-2,RFM-001-310-5,CBR-001-572-379-2,OC(=O)CCn1c2CC[C@H](Cc2c2c1cccc2)NS(=O)(=O)c1ccc(cc1)F,"CBR-HVAC-01951: Drugs for Allergic Rhinitis;Atopic Dermatitis, Agents for; CCL2 Expression Inhibitors;Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists;Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A2 receptor Antagonist; Thromboxane A2 receptor antagonist; Prostaglandin H2 receptor antagonist; TP receptor antagonist"
CBR-001-572-380-5,RFM-001-311-6,CBR-001-572-380-5,COc1ccc(cc1OC)S(=O)(=O)N1c2ccc(cc2[C@]([C@@H]1C(=O)N1CCC[C@H]1C(=O)N)(O)c1ccccc1Cl)Cl,CBR-HVAC-04492: Treatment of Dysmenorrhea;Treatment of Preterm Labor;Oncolytic Drugs;Heart Failure Therapy; Signal Transduction Modulators;Vasopressin (AVP) V1a Receptor Antagonists; Vasopressin V1a receptor Antagonist; Vasopressin 1 antagonist
CBR-001-572-381-6,RFM-001-312-7,CBR-001-572-381-6,OC[C@H]1O[C@@H](Oc2nn(c(c2Cc2ccc(cc2)OC(C)C)C)C(C)C)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-14217
CBR-001-572-382-7,RFM-001-313-8,CBR-001-572-382-7,OC(CNc1cn[nH]c(=O)c1Cl)COc1cccc2c1cccc2,analog of CBR-HVAC-02953
CBR-001-572-383-8,RFM-001-314-9,CBR-001-572-383-8,COC1/C=C/OC2(C)Oc3c(C2=O)c2c(O)cc(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C\C(C(C(C(C(C(C1C)OC(=O)C)C)O)C)O)C)/C,CBR-HVAC-00112: Antibiotics; Protein 50S ribosomal subunit inhibitor; DNA directed RNA polymerase inhibitor
CBR-001-572-384-9,RFM-001-315-0,CBR-001-572-384-9,OC[C@H]1O[C@H](O[C@H]2[C@@H](O[C@@H]([C@H]([C@@H]2O)O)CO[C@@H]2O[C@@H](C)[C@@H]([C@H]([C@H]2O)O)O)Oc2c3Oc4ccc(cc4)[C@@H](O[C@@H]4C[C@@H](N)[C@H]([C@@H](O4)C)O)[C@@H]4NC(=O)[C@H](NC(=O)[C@H]5c(c3)cc2Oc2ccc(cc2)[C@@H](O)[C@@H]2C(=O)N[C@H](C(=O)N5)c3cc(O)c(c(c3)Oc3cc([C@H](C(=O)N2)N)ccc3O)C)c2ccc(c(c2)c2c([C@@H](NC4=O)C(=O)OC)cc(cc2O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@@H]2O)O)O)O)O)[C@H]([C@H]([C@@H]1O)O)OC1O[C@@H]([C@H]([C@@H]1O)O)CO,analog of CBR-HVAC-08668
CBR-001-572-385-0,RFM-001-316-1,CBR-001-572-385-0,Clc1ccc(cc1)C1(O)CCN(CC1)C(=O)c1cn(c2c1cccc2)Cc1ccccc1,analog of CBR-HVAC-07189
CBR-001-572-386-1,RFM-001-317-2,CBR-001-572-386-1,COC(=O)c1oc(nc1C)c1ccc(cc1)Cl,analog of CBR-HVAC-03890
CBR-001-572-387-2,RFM-001-318-3,CBR-001-572-387-2,O=CCC1CC(C)C(=O)/C=C/C2(C)OC2C(C(OC(=O)CC(C(C1OC1OC(C)CC(C1O)N(C)C)C)O)CC)C,CBR-HVAC-08292: Protein 50S ribosomal subunit inhibitor
CBR-001-572-388-3,RFM-001-319-4,CBR-001-572-388-3,O=S1(=O)N[C@H]2CCCN2c2c1cccc2,"CBR-HVAC-02745: Cognition Disorders, Treatment of;Stroke, Treatment of; AMPA Receptor Positive Allosteric Modulators;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Modulator; AMPA receptor antagonist"
CBR-001-572-389-4,RFM-001-320-7,CBR-001-572-389-4,OC(=O)C(NS(=O)(=O)c1cccs1)Cc1c[nH]c2c1cccc2,analog of CBR-HVAC-05017
CBR-001-572-390-7,RFM-001-321-8,CBR-001-572-390-7,NC(=O)C[C@@H](C(=O)N[C@H]([C@@H](CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)O)Cc1ccccc1)NC(=O)c1ccc2c(n1)cccc2,CBR-HVAC-02648: Microbicides;Anti-HIV Agents; HIV Protease Inhibitors; Protease Inhibitor; HIV protease inhibitor
CBR-001-572-391-8,RFM-001-322-9,CBR-001-572-391-8,COc1ccc(cc1OC)CCNC(=O)c1ccc(cc1)[N+](=O)[O-],analog of CBR-HVAC-10433
CBR-001-572-392-9,RFM-001-323-0,CBR-001-572-392-9,COc1ccc(cc1)N1C(=O)C2(C1c1ccc(cc1)OC)CCCCC2,analog of CBR-HVAC-04393
CBR-001-572-393-0,RFM-001-324-1,CBR-001-572-393-0,COc1ccc2c(c1)CC[C@@H]([C@@H]2c1ccccc1)CN(CC(=O)O)C,CBR-HVAC-05520: Antipsychotic Drugs;Treatment of Alcohol Dependency; GlyT-1 Inhibitors; Glycine transporter 1 Inhibitor;
CBR-001-572-394-1,RFM-001-325-2,CBR-001-572-394-1,CCOC(=O)C1=Cc2cc(Cl)cc(c2OC1C(F)(F)F)Cl,analog of CBR-HVAC-07126
CBR-001-572-395-2,RFM-001-326-3,CBR-001-572-395-2,CCNC(=O)C1OC(C(C1O)O)n1cnc2c1ncnc2N,CBR-HVAC-14273
CBR-001-572-396-3,RFM-001-327-4,CBR-001-572-396-3,CCN1c2ccc(cc2C(=CC1(C)C)C)C(c1ccccc1)(c1ccccc1)c1ccccc1,analog of CBR-HVAC-08336
CBR-001-572-397-4,RFM-001-328-5,CBR-001-572-397-4,Fc1ccc(cc1)c1c[n+](c2n1CCC2)CCc1ccccc1,analog of CBR-HVAC-10668
CBR-001-572-398-5,RFM-001-329-6,CBR-001-572-398-5,CC1CCC2(OC1)OC1C(C2C)C2(C(C1)C1CC(O)C3C(C1CC2)(C)CCC(C3)O)C,analog of CBR-HVAC-00361
CBR-001-572-399-6,RFM-001-330-9,CBR-001-572-399-6,OC(=O)Cc1cc(C)cc(c1)C,analog of CBR-HVAC-03410
CBR-001-572-400-2,RFM-001-331-0,CBR-001-572-400-2,NS(=O)(=O)c1ccc(cc1)N1CCN(CC1)CC[C@@H]1OCCc2c1cccc2,CBR-HVAC-04741: Antipsychotic Drugs; Dopamine D4 Antagonists;Signal Transduction Modulators; Dopamine receptor D4 Antagonist; Dopamine D4 receptor antagonist
CBR-001-572-401-3,RFM-001-332-1,CBR-001-572-401-3,Cc1onc(c1)NC(=O)c1ccc(c(c1)C)C,analog of CBR-HVAC-00442
CBR-001-572-402-4,RFM-001-333-2,CBR-001-572-402-4,CCCn1nc(ccc1=O)c1ccccc1,analog of CBR-HVAC-08365
CBR-001-572-403-5,RFM-001-334-3,CBR-001-572-403-5,COc1cc(OC)ccc1S(=O)(=O)N1c2ccc(cc2[C@@](C1=O)(N1C[C@@H](C[C@H]1C(=O)N(C)C)O)c1ccccc1OC)Cl,CBR-HVAC-11021: Anxiolytics;Antidepressants; Signal Transduction Modulators;Vasopressin (AVP) V1b Receptor Antagonists; Vasopressin V1b receptor Antagonist;
CBR-001-572-404-6,RFM-001-335-4,CBR-001-572-404-6,CC1CCN(CC1)Cc1nc2c(n1CC(=O)c1ccccc1)c(=O)n(c(=O)n2C)C,analog of CBR-HVAC-11679
CBR-001-572-405-7,RFM-001-336-5,CBR-001-572-405-7,C#CCN([C@H](c1ccc(c(c1)F)C)CC1CC1)c1sc(c(n1)c1cc(C)c(cc1Cl)OC)C,"CBR-HVAC-05490: Antidepressants;Anxiolytics;Posttraumatic Stress Disorder (PTSD), Treatment of; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing factor 1 Antagonist; Corticotropin releasing factor 1 receptor antagonist; Corticotropin releasing factor antagonist"
CBR-001-572-406-8,RFM-001-337-6,CBR-001-572-406-8,O=c1cc(C)c2c(o1)cc(cc2)OS(=O)(=O)[O-],analog of CBR-HVAC-11461
CBR-001-572-407-9,RFM-001-338-7,CBR-001-572-407-9,O=C(Nc1ccc(cc1)S(=O)(=O)c1ccc(cc1)NC(=O)CCC(=O)O)CCC(=O)O,analog of CBR-HVAC-08748
CBR-001-572-408-0,RFM-001-339-8,CBR-001-572-408-0,S=C1CN=C(c2c(N1)ccc(c2)Cl)c1ccccc1,analog of CBR-HVAC-08860
CBR-001-572-409-1,RFM-001-340-1,CBR-001-572-409-1,Nc1cc(N)c(cc1/N=N/c1ccc(cc1)S(=O)(=O)N)C,analog of CBR-HVAC-08698
CBR-001-572-410-4,RFM-001-341-2,CBR-001-572-410-4,Cc1cc(n(n1)c1ccccc1)NS(=O)(=O)c1ccccc1,analog of CBR-HVAC-08744
CBR-001-572-411-5,RFM-001-342-3,CBR-001-572-411-5,O=C(NS(=O)(=O)c1ccccc1)Nc1ccc(c(c1)C)C(C)C,analog of CBR-HVAC-02506
CBR-001-572-412-6,RFM-001-343-4,CBR-001-572-412-6,OC(CN1CCN(CC1)c1ccc(cc1)F)COc1ccccc1C,analog of CBR-HVAC-00221
CBR-001-572-413-7,RFM-001-344-5,CBR-001-572-413-7,CCCCNc1c2C(O)CC(Cc2nc2c1cccc2)(C)C,analog of CBR-HVAC-03908
CBR-001-572-414-8,RFM-001-345-6,CBR-001-572-414-8,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCSCC1,CBR-HVAC-00110: Treatment of Tuberculosis;Antibacterial Drugs; ; ; Protein 30S ribosomal subunit inhibitor
CBR-001-572-415-9,RFM-001-346-7,CBR-001-572-415-9,c1ccc(cc1)C1=N[C@H]([C@H](N1)c1ccccc1)c1ccccc1,analog of CBR-HVAC-03985
CBR-001-572-416-0,RFM-001-347-8,CBR-001-572-416-0,COc1cccc(c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C)OC,CBR-HVAC-02850: Antibiotics; Penicillin binding protein Inhibitor;
CBR-001-572-417-1,RFM-001-348-9,CBR-001-572-417-1,N#Cc1cccc(c1)[C@@H]([C@@H](NC(=O)C(Oc1ccc(cn1)C(F)(F)F)(C)C)C)Cc1ccc(cc1)Cl,"CBR-HVAC-06435: Antiobesity Drugs;Smoking Cessation, Aid to; Cannabinoid CB1 Inverse Agonists;Signal Transduction Modulators; ; Cannabinoid CB1 receptor antagonist"
CBR-001-572-418-2,RFM-001-349-0,CBR-001-572-418-2,CC(=O)c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,analog of CBR-HVAC-03690
CBR-001-572-419-3,RFM-001-350-3,CBR-001-572-419-3,Fc1cccc(c1)n1ncc2c1CC(C)(C)CC2NC(=O)c1[nH]nc(c1)C(=O)C,analog of CBR-HVAC-00572
CBR-001-572-420-6,RFM-001-351-4,CBR-001-572-420-6,O=C1C=C[C@]2(C(=C1)CC[C@@H]1C2CC[C@]2(C1CCC(=O)O2)C)C,"CBR-HVAC-05502: Male Infertility, Agents for;Breast Cancer Therapy; Aromatase Inhibitors; Estrogen receptor Inhibitor;"
CBR-001-572-421-7,RFM-001-352-5,CBR-001-572-421-7,CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,analog of CBR-HVAC-10096
CBR-001-572-422-8,RFM-001-353-6,CBR-001-572-422-8,CC(COc1ccc(cc1)Cc1cnc(nc1N)N)C,analog of CBR-HVAC-05533
CBR-001-572-423-9,RFM-001-354-7,CBR-001-572-423-9,OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)C)CCCNC(=N)N)CC(C)C)CCCNC(=O)N)Cc1ccc(cc1)O)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(cc1)Cl)NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)C,CBR-HVAC-02458: Gonadotropin-releasing hormone receptor Inhibitor; Luteinizing hormone releasing hormone (LHRH) antagonist
CBR-001-572-424-0,RFM-001-355-8,CBR-001-572-424-0,COC1=CCC2[C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1OC,analog of CBR-HVAC-09983
CBR-001-572-425-1,RFM-001-356-9,CBR-001-572-425-1,CC(C1C(=O)NC(=S)NC1=O)C,analog of CBR-HVAC-09909
CBR-001-572-426-2,RFM-001-357-0,CBR-001-572-426-2,CCN(CCOc1ccc2c(c1)C(=O)c1c2ccc(c1)OCCN(CC)CC)CC,CBR-HVAC-01070: Nicotinic acetylchloine receptor alpha7 Agonist; Interferon receptor agonist
CBR-001-572-427-3,RFM-001-358-1,CBR-001-572-427-3,CCCC(=O)OCC(=O)Nc1scc(n1)c1ccc(cc1)OC,analog of CBR-HVAC-03304
CBR-001-572-428-4,RFM-001-359-2,CBR-001-572-428-4,COC(=O)CSc1nc(c(o1)c1ccccc1)c1ccccc1,analog of CBR-HVAC-01018
CBR-001-572-429-5,RFM-001-360-5,CBR-001-572-429-5,OC[C@H]1O[C@@H](OC2CC[C@]3([C@H](C2)CCC2C3CC[C@]3(C2CC2C3[C@H](C)[C@@](O2)(O)CCC(CO[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)C)C)C)[C@@H]([C@H]([C@@H]1O[C@@H]1O[C@@H](C)[C@@H]([C@H]([C@H]1O)O)O)O)O[C@@H]1O[C@@H](CO)[C@@H]([C@H]([C@H]1O)O)O,analog of CBR-HVAC-03408
CBR-001-572-430-8,RFM-001-361-6,CBR-001-572-430-8,OCCSCC(=O)[C@@]1(O)CCC2[C@]1(C)CCC1C2CCC2=CC(=O)CC[C@]12C,analog of CBR-HVAC-08786
CBR-001-572-431-9,RFM-001-362-7,CBR-001-572-431-9,COC(=O)c1ccccc1NC(=O)CN(C)C,analog of CBR-HVAC-10120
CBR-001-572-432-0,RFM-001-363-8,CBR-001-572-432-0,O=C1CCC2C3(C1)CCN(C2Cc1c3cc(O)cc1)C,analog of CBR-HVAC-03012
CBR-001-572-433-1,RFM-001-364-9,CBR-001-572-433-1,N#CC(c1ccccc1)(c1ccccc1)CCN1CCNCC1,analog of CBR-HVAC-08457
CBR-001-572-434-2,RFM-001-365-0,CBR-001-572-434-2,OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1cnc2c1ncnc2N[C@H]1CCC[C@@H]1O,"CBR-HVAC-14442: Adenosine A1 Agonists; Adenosine A1 receptor Agonist; Adenosine A1 receptor agonist; Signal Transduction Modulators; Analgesic; Antidiabetic Drugs; Antilipolytic; Cardioprotectant; Cardioprotectants; Lipoprotein Disorders, Treatment of ; Vasodilator"
CBR-001-572-435-3,RFM-001-366-1,CBR-001-572-435-3,COc1cccc(c1)[C@@]1(O)CCCC[C@@H]1CN(C)C,CBR-HVAC-01325: Opioid receptor mu Agonist; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor;2016-04-01: controlled substance
CBR-001-572-436-4,RFM-001-367-2,CBR-001-572-436-4,Clc1ccc2c(c1)C(=NCc1n2cnn1)c1ccccc1Cl,analog of CBR-HVAC-02786
CBR-001-572-437-5,RFM-001-368-3,CBR-001-572-437-5,CCOc1ccccc1c1nc(c([nH]1)c1ccccc1)c1ccccc1,analog of CBR-HVAC-08469
CBR-001-572-438-6,RFM-001-369-4,CBR-001-572-438-6,CN1CCC(=C2c3ccccc3SCc3c2cccc3)CC1,analog of CBR-HVAC-09217
CBR-001-572-439-7,RFM-001-370-7,CBR-001-572-439-7,CCCCN(c1nc(C)nc2c1c(C)cn2c1c(C)cc(cc1C)C)CC,CBR-HVAC-14233
CBR-001-572-440-0,RFM-001-371-8,CBR-001-572-440-0,CCCN([C@@H]1CCc2c(C1)c1cc([nH]c1cc2)C#N)CCC,CBR-HVAC-10573: Anxiolytics;Antidepressants; Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist;
CBR-001-572-441-1,RFM-001-372-9,CBR-001-572-441-1,Fc1ccc(cc1)C(=O)CCCN1CCc2c(C1)c1cc(F)ccc1[nH]2,analog of CBR-HVAC-08485
CBR-001-572-442-2,RFM-001-373-0,CBR-001-572-442-2,COc1ccccc1N1CCN(CC1)C(=O)c1cccc2c1oc(c1ccccc1)c(c2=O)C,analog of CBR-HVAC-04603
CBR-001-572-443-3,RFM-001-374-1,CBR-001-572-443-3,CCCOc1ccc(cc1OC)CNc1ncnc2c1[nH]cn2,analog of CBR-HVAC-04666
CBR-001-572-444-4,RFM-001-375-2,CBR-001-572-444-4,COc1ccc(cc1NC(=O)CCN1CC(C1)N1CCCCC1C)C,analog of CBR-HVAC-01132
CBR-001-572-445-5,RFM-001-376-3,CBR-001-572-445-5,O[C@@H](CN(S(=O)(=O)C)C)CN1C2CCC1CC(C2)NC(=O)c1cc2ccccc2n(c1=O)C(C)C,"CBR-HVAC-00710: Prokinetic Agents;Alzheimer's Dementia, Treatment of ;Gastric Emptying Disorders,Treatment of; Signal Transduction Modulators;5-HT4 Agonists; 5-Hydroxytryptamine 4 receptor Agonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-572-446-6,RFM-001-377-4,CBR-001-572-446-6,Clc1ccc(c(c1)C(=O)c1ccccc1)NS(=O)(=O)c1ccc(cc1)C(C)(C)C,analog of CBR-HVAC-08512
CBR-001-572-447-7,RFM-001-378-5,CBR-001-572-447-7,O=C1NC/C=C/C(=C/C(O)CC(=O)Cc2nc(C(=O)NC(C(=O)OC(C(/C=C/1)C)C(C)C)C)co2)/C,analog of CBR-HVAC-08522
CBR-001-572-448-8,RFM-001-379-6,CBR-001-572-448-8,CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]1[C@H]([C@H]2/C=C/c2ccc(cn2)c2cccc(c2)F)[C@H](OC1=O)C,CBR-HVAC-05985: Antiplatelet Therapy; Cytochrome P450 CYP3A4 Inhibitors;PAR1 Antagonists;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators; PROTEASE-ACTIVATED RECEPTOR 1 Antagonist; Protease-activated receptor-1 antagonist
CBR-001-572-449-9,RFM-001-380-9,CBR-001-572-449-9,CSc1ccc(cc1)Sc1ccc(cc1CN(C)C)Cl,analog of CBR-HVAC-11076
CBR-001-572-450-2,RFM-001-381-0,CBR-001-572-450-2,OC[C@H](c1ccccc1)C(=O)OC1C[C@@H]2CC[C@H](C1)N2C,CBR-HVAC-14279
CBR-001-572-451-3,RFM-001-382-1,CBR-001-572-451-3,Oc1ccc(cc1C)C1CC2C(C1(C)CC2)(C)C,analog of CBR-HVAC-01584
CBR-001-572-452-4,RFM-001-383-2,CBR-001-572-452-4,O=C([C@@H]1CCCN1)Nc1ccc(cc1)c1ccnc(n1)Nc1ccc(cc1)N1CCOCC1,CBR-HVAC-06599: Hematopoiesis Disorders Therapy; Jak2 Inhibitors;Signal Transduction Modulators; Janus kinase 2 Inhibitor;
CBR-001-572-453-5,RFM-001-384-3,CBR-001-572-453-5,CCOc1ccc(cc1)/C=c\1/[nH]c(=O)/c(=C\c2ccc(cc2)OCC)/[nH]c1=O,analog of CBR-HVAC-10589
CBR-001-572-454-6,RFM-001-385-4,CBR-001-572-454-6,CCN(CCOCCOC(c1c(C)cccc1C)c1c(C)cccc1C)CC,analog of CBR-HVAC-09096
CBR-001-572-455-7,RFM-001-386-5,CBR-001-572-455-7,Fc1cc2c(cc1N1CCOCC1)n(cc(c2=O)C(=O)O)C1CC1,analog of CBR-HVAC-03872
CBR-001-572-456-8,RFM-001-387-6,CBR-001-572-456-8,N#Cc1cc(ccc1OCC(C)(C)C)n1ncc(c1)C(=O)O,CBR-HVAC-08541: Xanthine Oxidase Inhibitors; Xanthine oxidase Inhibitor; Xanthine oxidase inhibitor; Xanthine-oxidase-inhibitors; Antineoplastic; Metabolic Disorders; Rheumatic Disease; Treatment of Disorders of Purine and Pyrimidine Metabolism; Treatment of Gout; Uricosuric
CBR-001-572-457-9,RFM-001-388-7,CBR-001-572-457-9,Fc1ccc(cc1)NC(=O)N1CCN(CC1)c1cccc(c1)C(F)(F)F,analog of CBR-HVAC-00482
CBR-001-572-458-0,RFM-001-389-8,CBR-001-572-458-0,O=c1[nH]c2c(n1C1CCN(CC1)CC1(C)OCc3c(n4c1ccc4)cccc3)cccc2,CBR-HVAC-03629: Antidiarrheal Agents; Calmodulin Antagonists; Calmodulin receptor Inhibitor; Calmodulin antagonist
CBR-001-572-459-1,RFM-001-390-1,CBR-001-572-459-1,OC1CCC/C=C/c2cc(O)cc(c2C(=O)O[C@H](CCC1)C)O,analog of CBR-HVAC-09964
CBR-001-572-460-4,RFM-001-391-2,CBR-001-572-460-4,COc1ccc(cc1)c1cc2c(n1Cc1ccccc1)ccc(c2)OC(=O)C,analog of CBR-HVAC-02962
CBR-001-572-462-6,RFM-001-392-3,CBR-001-572-462-6,CN(C1C(=C(C(=O)N)C(=O)C2(C1CC1C(=C2O)C(=O)c2c(C1(C)O)cccc2O)O)O)C,CBR-HVAC-02777: 16S-rRNA of 30S ribosomal subunit Binder; 30S Ribosomal Protein Inhibitors; Protein 30S ribosomal subunit inhibitor; Protein Arginine Deiminase Inhibitors; Acne Therapy; Antibacterial; Antibiotics
CBR-001-572-463-7,RFM-001-393-4,CBR-001-572-463-7,CCC1OC(=O)C(C)C(OC2OC(C)C(C(C2)(C)OC)O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC(C(=O)C(C(C1(C)O)O)C)C)(C)O,CBR-HVAC-01380: 23S-rRNA of 50S ribosomal subunit Binder; Protein 50S ribosomal subunit inhibitor
CBR-001-572-464-8,RFM-001-394-5,CBR-001-572-464-8,CCC1OC(=O)C(C)C(OC2OC(C)C(C(C2)(C)OC)O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC(CN(C(C(C1(C)O)O)C)C)C)(C)O,CBR-HVAC-02199: 23S-rRNA of 50S ribosomal subunit Binder; Protein 50S ribosomal subunit inhibitor; Protein synthesis inhibitor
CBR-001-572-465-9,RFM-001-395-6,CBR-001-572-465-9,NCCCC(CC(=O)NC1CNC(=O)C(NC(=O)/C(=C/NC(=O)N)/NC(=O)C(NC(=O)C(NC1=O)CO)CO)C1CC(O)NC(=N1)N)N,CBR-HVAC-09678: 23S-rRNA of 50S ribosomal subunit; 16S-rRNA of 30S ribosomal subunit Binder;
CBR-001-572-466-0,RFM-001-396-7,CBR-001-572-466-0,CC(C(C)(C)C)C,CBR-HVAC-08472: 5 Hydroxytryptamine 1D receptor agonist
CBR-001-572-467-1,RFM-001-397-8,CBR-001-572-467-1,CN1C2CCC1CC(C2)OC(=O)c1cc(C)cc(c1)C,CBR-HVAC-08476: 5 Hydroxytryptamine 2 receptor antagonist
CBR-001-572-468-2,RFM-001-398-9,CBR-001-572-468-2,NCc1ccccc1Sc1ccccc1CO,CBR-HVAC-07528: 5 Hydroxytryptamine receptor agonist
CBR-001-572-469-3,RFM-001-399-0,CBR-001-572-469-3,CCCCCCCCCCCCCCCC(=O)OCC(C(c1ccc(cc1)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,CBR-HVAC-09560: 50S-ribosomal subunit Inhibitor;
CBR-001-572-470-6,RFM-001-400-6,CBR-001-572-470-6,NCCc1cc(OC)c(c(c1)OC)OC,CBR-HVAC-09805: 5-Hydroxytryptamine 2 receptor Agonist; ;2016-04-01: controlled substance
CBR-001-572-471-7,RFM-001-401-7,CBR-001-572-471-7,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCc1c(C)nc2n(c1=O)cccc2,CBR-HVAC-10060: 5-Hydroxytryptamine 2 receptor Antagonist;
CBR-001-572-472-8,RFM-001-402-8,CBR-001-572-472-8,COc1cccc(c1)CCc1ccccc1OCC(OC(=O)CCC(=O)O)CN(C)C,CBR-HVAC-02574: 5-Hydroxytryptamine 2 receptor Antagonist; Platelet aggregation inhibitor; 5 Hydroxytryptamine 2A receptor antagonist
CBR-001-572-473-9,RFM-001-403-9,CBR-001-572-473-9,CCN(CCOC(=O)C(Cc1cccc2c1cccc2)CC1CCCO1)CC,CBR-HVAC-01491: 5-Hydroxytryptamine 2A receptor Agonist; Alpha adrenoreceptor antagonist
CBR-001-572-474-0,RFM-001-404-0,CBR-001-572-474-0,O=c1[nH]c2c(n1CCN1CCN(CC1)c1cccc(c1)C(F)(F)F)cccc2,CBR-HVAC-04448: Treatment of Female Sexual Dysfunction;Antidepressants; Signal Transduction Modulators;5-HT1A Receptor Agonists;5-HT2A Antagonists; ; 5 Hydroxytryptamine 1A receptor agonist; 5 Hydroxytryptamine 2A receptor antagonist; Dopamine D4 receptor agonist
CBR-001-572-475-1,RFM-001-405-1,CBR-001-572-475-1,CC[N+](CCOC(=O)C(c1ccccc1)(C1CCCCC1)O)(CC)C,CBR-HVAC-09626: Acetylcholine receptor Blocker;
CBR-001-572-476-2,RFM-001-406-2,CBR-001-572-476-2,CCOP(=S)(Oc1cc(C)nc(n1)C(C)C)OCC,CBR-HVAC-10056: Acetylcholinesterase Inhibitor;
CBR-001-572-477-3,RFM-001-407-3,CBR-001-572-477-3,COP(=O)(OC=C(Cl)Cl)OC,CBR-HVAC-10007: Acetylcholinesterase Inhibitor;
CBR-001-572-478-4,RFM-001-408-4,CBR-001-572-478-4,CC(OP(=O)(OC(C)C)F)C,CBR-HVAC-09605: Acetylcholinesterase Inhibitor;
CBR-001-572-479-5,RFM-001-409-5,CBR-001-572-479-5,CN(CCc1c[nH]c2c1cc(C[C@H]1COC(=O)N1)cc2)C,"CBR-HVAC-01763: Acute Attacks of Migraine, Treatment of;Lesions of the Spinal Cord and Related Structures, Treatment of; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist; 5 Hydroxytryptamine 1B receptor agonist"
CBR-001-572-480-8,RFM-001-410-8,CBR-001-572-480-8,COc1ccc(cc1OC)CCN(CCCC(c1ccc(c(c1)OC)OC)(C(C)C)C#N)C,"CBR-HVAC-00020: Acute Myocardial Infarction, Treatment of;Antiepileptic Drugs;Angina pectoris, Treatment of;Osteoarthritis, Treatment of;Hypertension, Treatment of;Antiarrhythmic Drugs; Calcium Channel Blockers;Dopamine D2 Antagonists;L-Type Calcium Channel Blockers;Signal Transduction Modulators; ; Calcium channel antagonist"
CBR-001-572-481-9,RFM-001-411-9,CBR-001-572-481-9,Oc1nc2nc3ccccc3nc2c(n1)O,CBR-HVAC-10064: Adenosine A2B Antagonists;Signal Transduction Modulators; Adenosine A2B receptor Antagonist;
CBR-001-572-482-0,RFM-001-412-0,CBR-001-572-482-0,Oc1nc(O)c2c(n1)ncn2C,CBR-HVAC-11928: Adenosine receptor Antagonist;
CBR-001-572-483-1,RFM-001-413-1,CBR-001-572-483-1,CNCC(c1ccc(c(c1)O)O)O,CBR-HVAC-02639: Adrenergic receptor Agonist; Adrenoreceptor agonist; Antiglaucoma Agents; Sympathomimetic
CBR-001-572-484-2,RFM-001-414-2,CBR-001-572-484-2,O=CN(/C(=C(/SC(=O)c1ccccc1)\CCOP(=O)(O)O)/C)Cc1cnc(nc1N)C,CBR-HVAC-02595: Advanced glycosylation end product receptor antagonist
CBR-001-572-485-3,RFM-001-415-3,CBR-001-572-485-3,OC(=O)c1c[nH]c(=O)[nH]c1=O,"CBR-HVAC-05507: Agents for Acute Alcoholic Hepatitis;Disorders Associated with Cancer Therapy, Treatment of; ; ;"
CBR-001-572-486-4,RFM-001-416-4,CBR-001-572-486-4,OC(=O)COc1cc(OCC=C(C)C)ccc1C(=O)/C=C/c1ccc(cc1)OCC=C(C)C,CBR-HVAC-02134: Agents for Gastritis;Antiulcer Drugs; ; Histamine H2 receptor Antagonist; Prostaglandin dehydrogenase inhibitor; Mucus protecting agent; Antacid
CBR-001-572-487-5,RFM-001-417-5,CBR-001-572-487-5,N[C@H](C(=O)O)C(C)C,"CBR-HVAC-05526: Agents for Liver Cirrhosis;Liver and Biliary Tract Disorders, Treatment of;Metabolic Disorders (Not Specified); ; ;"
CBR-001-572-488-6,RFM-001-418-6,CBR-001-572-488-6,Clc1ccc2c(c1)C(=NCC(=O)N2C)c1ccccc1,"CBR-HVAC-01274: Agents for Premedication;Anxiolytics;Muscle Spasms, Drugs for;Sleep Disorders, Treatment of;Treatment of Alcohol Dependency;Antiepileptic Drugs; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; Benzodiazepine receptor Agonist; Benzodiazepine receptor agonist;2016-04-01: controlled substance"
CBR-001-572-489-7,RFM-001-419-7,CBR-001-572-489-7,CN(CC/C=C/1\c2cc(ccc2OCc2c1cccc2)CC(=O)O)C,"CBR-HVAC-01306: Allergic Skin Disorders, Treatment for;Eczema, Treatment of;Antiallergic Ophthalmic Agents;Antipruritics;Allergy, Treatment of;Dermatologic Drugs;Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis;Antipsoriatics;Urticaria, Treatment for; Histamine H1 Receptor Antagonists;Mediator Release Inhibitors;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-572-490-0,RFM-001-420-0,CBR-001-572-490-0,Fc1ccc(c(c1)NC1=NCCN1)C,CBR-HVAC-01033: Alpha 2 adrenoreceptor agonist
CBR-001-572-491-1,RFM-001-421-1,CBR-001-572-491-1,C1CN=C(N1)Cc1cccc2c1cccc2,CBR-HVAC-00982: Alpha adrenergic receptor Agonist; Antagonist; Peptide agonist
CBR-001-572-492-2,RFM-001-422-2,CBR-001-572-492-2,Brc1c(ccc2c1nccn2)NC1=NCCN1,CBR-HVAC-09549: Alpha adrenergic receptor Inhibitor;
CBR-001-572-493-3,RFM-001-423-3,CBR-001-572-493-3,Clc1ccc(cc1)Sc1cc(Cl)c(cc1Cl)Cl,CBR-HVAC-11990: Insecticide
CBR-001-572-494-4,RFM-001-424-4,CBR-001-572-494-4,CC(Cc1cccc(c1)O)N,CBR-HVAC-01549: Alpha adrenoceptor Agonist; Alpha adrenoreceptor agonist
CBR-001-572-495-5,RFM-001-425-5,CBR-001-572-495-5,COc1ccc(c(c1)C(C(N)C)O)OC,CBR-HVAC-02362: Alpha-1 adrenergic receptor Agonist; Alpha 1a adrenoreceptor agonist
CBR-001-572-496-6,RFM-001-426-6,CBR-001-572-496-6,NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,CBR-HVAC-02788: Alpha-1 adrenergic receptor Agonist; Unidentified pharmacological activity;2016-04-01: controlled substance
CBR-001-572-497-7,RFM-001-427-7,CBR-001-572-497-7,ClCCN(Cc1ccccc1)Cc1ccccc1,CBR-HVAC-09971: Alpha-1 adrenergic receptor Blocker;
CBR-001-572-498-8,RFM-001-428-8,CBR-001-572-498-8,Nc1c2CCCCc2nc2c1CCC2,"CBR-HVAC-02453: Alzheimer's Dementia, Treatment of ; Acetylcholinesterase (AChE) Inhibitors; Potassium channel antagonist; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M1; Acetylcholinesterase; Muscarinic acetylcholine receptor M3 Antagonist; Inhibitor; Partial Agonist; Acetylcholinesterase inhibitor"
CBR-001-572-499-9,RFM-001-429-9,CBR-001-572-499-9,CC(=O)Nc1ccc(cc1)C(=O)NC(C)(C)C,"CBR-HVAC-05292: Alzheimer's Dementia, Treatment of ;AIDS Dementia, Treatment of;Neuropathic Pain, Treatment of;Antiparkinsonian Drugs; Antioxidants;Apoptosis Inhibitors;MAPK p38 Inhibitors;Signal Transduction Modulators;TNF-alpha Release Inhibitors; Mitogen-activated protein kinase Inhibitor;"
CBR-001-572-500-5,RFM-001-430-2,CBR-001-572-500-5,COc1ccc2c(c1)ccc(c2)[C@@H](C(=O)O)C,"CBR-HVAC-03093: Alzheimer's Dementia, Treatment of ;Analgesic Drugs;Ankylosing Spondylitis, Treatment of;Rheumatoid Arthritis, Treatment of;Antiarthritic Drugs;Non-Opioid Analgesics;Osteoarthritis, Treatment of;Treatment of Dysmenorrhea;Treatment of Gout; Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor"
CBR-001-572-501-6,RFM-001-431-3,CBR-001-572-501-6,Nc1c2CCCCc2nc2c1cccc2,"CBR-HVAC-02391: Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of; Acetylcholinesterase (AChE) Inhibitors;Butyrylcholinesterase Inhibitors; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor; Potassium channel antagonist"
CBR-001-572-502-7,RFM-001-432-4,CBR-001-572-502-7,O=CN(/C(=C(/SS/C(=C(/N(Cc1cnc(nc1N)C)C=O)\C)/CCOC(=O)C(C)C)\CCOC(=O)C(C)C)/C)Cc1cnc(nc1N)C,"CBR-HVAC-00122: Alzheimer's Dementia, Treatment of ;Ischemia, Treatment of;Antiepileptic Drugs;Treatment of Erectile Dysfunction;Myasthenia Gravis, Agents for; ; ; Pyruvate carboxylase stimulant; Nicotinic receptor antagonist"
CBR-001-572-503-8,RFM-001-433-5,CBR-001-572-503-8,ONC(=O)c1cccnc1,CBR-HVAC-07894: Ammonia scavenger
CBR-001-572-504-9,RFM-001-434-6,CBR-001-572-504-9,O=c1cc(n(n1c1ccccc1)C)C,CBR-HVAC-05746: Analgesic Drugs; ; Prostaglandin G/H synthase 1 Inhibitor;
CBR-001-572-505-0,RFM-001-435-7,CBR-001-572-505-0,C#CC1(O)CCC2C1(C)CCC1C2CCC2=Cc3c(CC12C)cno3,"CBR-HVAC-02016: Analgesic Drugs;Diabetic Nephropathy, Agents for;Antianemics;Hematopoiesis Disorders Therapy;Endometriosis Therapy;Female Reproductive System Cancer Therapy;Diabetic Retinopathy, Agents for;Drugs for Allergic Rhinitis;Hematologic Genetic Disorders, Treatment of ; Signal Transduction Modulators;TNF-alpha Modulators; Gonadotropin-releasing hormone receptor Inhibitor; Luteinizing hormone releasing hormone (LHRH) antagonist"
CBR-001-572-506-1,RFM-001-436-8,CBR-001-572-506-1,O=C(OC1CCC2C1(C)CCC1C2CCC2=CC(=O)CCC12)CCc1ccccc1,CBR-HVAC-06505: Analgesic Drugs;Hematopoiesis Disorders Therapy; ; ;
CBR-001-572-507-2,RFM-001-437-9,CBR-001-572-507-2,OCC(=O)[C@@]1(O)CCC2C1(C)CCC1C2CCC2=CC(=O)CCC12C,CBR-HVAC-02600: Androgen receptor antagonist
CBR-001-572-508-3,RFM-001-438-0,CBR-001-572-508-3,C1CCC(CC1)(N1CCCCC1)c1ccccc1,CBR-HVAC-05121: Anesthetic Drugs; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; ;2016-04-01: controlled substance
CBR-001-572-509-4,RFM-001-439-1,CBR-001-572-509-4,CC(COCC(N1CCCC1)CN(c1ccccc1)Cc1ccccc1)C,"CBR-HVAC-02161: Angina pectoris, Treatment of;Antiarrhythmic Drugs; Calcium Channel Blockers;Cytochrome P450 CYP3A4 Inhibitors; Calcium channel Antagonist; L-type calcium channel antagonist"
CBR-001-572-510-7,RFM-001-440-4,CBR-001-572-510-7,OC(=O)[C@H](c1ccc(cc1)O)N,"CBR-HVAC-05543: Angina pectoris, Treatment of;Heart Failure Therapy; Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors; ; Pyruvate dehydrogenase stimulant"
CBR-001-572-511-8,RFM-001-441-5,CBR-001-572-511-8,CCN(c1cc(C)nc2n1ncn2)CC,"CBR-HVAC-01667: Angina pectoris, Treatment of;Restenosis Treatment of;Acute Myocardial Infarction, Treatment of; Protein Kinase Activators;Signal Transduction Modulators; PDGFR Antagonist; Calcium channel antagonist; Platelet aggregation inhibitor"
CBR-001-572-512-9,RFM-001-442-6,CBR-001-572-512-9,N#Cc1cc(ccc1OCC(C)C)c1nc(c(s1)C(=O)O)C,"CBR-HVAC-02148: Angina pectoris, Treatment of;Uricosurics;Treatment of Gout; Xanthine Oxidase Inhibitors; Xanthine oxidase Inhibitor; Xanthine oxidase inhibitor"
CBR-001-572-513-0,RFM-001-443-7,CBR-001-572-513-0,C=CCSCC1Nc2cc(Cl)c(cc2S(=O)(=O)N1)S(=O)(=O)N,CBR-HVAC-10073: Angiotensin converting enzyme Inhibitor;
CBR-001-572-514-1,RFM-001-444-8,CBR-001-572-514-1,CCOC(=O)[C@@H](N[C@H](C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(=O)O)C)CCc1ccccc1,CBR-HVAC-02029: Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor
CBR-001-572-515-2,RFM-001-445-9,CBR-001-572-515-2,CCOC(=O)[C@@H](N[C@H](C(=O)N1C(=O)N(C[C@H]1C(=O)O)C)C)CCc1ccccc1,CBR-HVAC-02461: Angiotensin I converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor
CBR-001-572-516-3,RFM-001-446-0,CBR-001-572-516-3,CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)c(ccc2)C(=O)O,CBR-HVAC-02377: ANGIOTENSIN II TYPE 1 RECEPTOR Blocker; Angiotensin II antagonist
CBR-001-572-517-4,RFM-001-447-1,CBR-001-572-517-4,OC(=O)c1ccc(cc1)n1nc(nc1c1ccccc1O)c1ccccc1O,CBR-HVAC-01939: Antagonists to Metals;Myelodysplastic Syndrome Therapy; Chelating Agents; ; Iron absorption inhibitor; Chelating agent
CBR-001-572-518-5,RFM-001-448-2,CBR-001-572-518-5,OC(=O)C(=O)Nc1cccc(c1)c1nnn[nH]1,CBR-HVAC-02280: Antiallergic Ophthalmic Agents; Mediator Release Inhibitors; ; Slow releasing substance antagonist; Histamine release inhibitor
CBR-001-572-519-6,RFM-001-449-3,CBR-001-572-519-6,CC(C(=O)c1c(nn2c1cccc2)C(C)C)C,"CBR-HVAC-02135: Antiallergic Ophthalmic Agents;Amyotrophic Lateral Sclerosis, Agents for;Antiallergy/Antiasthmatic Drugs;Neurologic Drugs (Miscellaneous);Cerebrovascular Diseases, Treatment of;Treatment of Substance Dependency;Neurological Genetic Disorders, Treatment of ;Neuropathic Pain, Treatment of;Treatment of Opioid Dependency;Analgesic Drugs;Multiple Sclerosis, Agents for;Treatment of Alcohol Dependency; Leukotriene CysLT1 (LTD4) Antagonists;Macrophage Migration Inhibitory Factor (MIF) Modulators;Mediator Release Inhibitors;Phosphodiesterase PDE10A Inhibitors;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TLR4 (LPS) Receptor Antagonists; Phosphodiesterase Inhibitor; Phosphodiesterase 4 inhibitor; Leucotriene receptor antagonist; Nitric oxide synthase inhibitor; Phosphodiesterase 10A inhibitor; Phosphodiesterase 11 inhibitor; Macrophage migration inhibiting factor inhibitor; Toll-like receptor 4 antagonist"
CBR-001-572-520-9,RFM-001-450-6,CBR-001-572-520-9,Cc1cccn2c1ncc(c2=O)c1nnn[nH]1,CBR-HVAC-03798: Antiallergic Ophthalmic Agents;Drugs for Allergic Rhinitis;Antiallergy/Antiasthmatic Drugs; Mediator Release Inhibitors; ;
CBR-001-572-521-0,RFM-001-451-7,CBR-001-572-521-0,CCOc1cc(ccc1OC)[C@H](N1C(=O)c2c(C1=O)c(ccc2)NC(=O)C)CS(=O)(=O)C,"CBR-HVAC-06174: Antiallergy/Antiasthmatic Drugs;Analgesic Drugs;Psoriatic Arthritis, Treatment of ;Dermatologic Drugs;Acne Therapy;Gynecological Disorders, Treatment of ;Ophthalmic Drugs;Systemic Lupus Erythematosus, Agents for;Antipsoriatics;Ankylosing Spondylitis, Treatment of;Vasculitis, Agents for;Rheumatoid Arthritis, Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Inflammatory Bowel Disease, Agents for; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP2A6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor; Tumour necrosis factor alpha antagonist"
CBR-001-572-522-1,RFM-001-452-8,CBR-001-572-522-1,O=C(Nc1c(C)cccc1C)CN1CCCCCC1,CBR-HVAC-01035: Antiarrhythmic Drugs; ; ; Sodium channel antagonist
CBR-001-572-523-2,RFM-001-453-9,CBR-001-572-523-2,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CN(C)C)c1ccccc1CC2,CBR-HVAC-02673: Antiarrhythmic Drugs; ; ; Sodium channel antagonist
CBR-001-572-524-3,RFM-001-454-0,CBR-001-572-524-3,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN(CC)CC)c1c(S2)cccc1,CBR-HVAC-02499: Antiarrhythmic Drugs; ; CALCIUM CHANNEL; SODIUM CHANNEL Blocker; Blocker; Unidentified pharmacological activity
CBR-001-572-525-4,RFM-001-455-1,CBR-001-572-525-4,CCN(CCNC(=O)c1ccc(cc1)NC(=O)C)CC,CBR-HVAC-01244: Antiarrhythmic Drugs; ; Sodium channel Blocker; Polarisation inhibitor
CBR-001-572-526-5,RFM-001-456-2,CBR-001-572-526-5,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1c(S2)cccc1,CBR-HVAC-01696: Antiarrhythmic Drugs; ; Sodium channel Blocker; Sodium channel antagonist
CBR-001-572-527-6,RFM-001-457-3,CBR-001-572-527-6,CCCCc1oc2c(c1C(=O)c1ccc(cc1)OCCCN(CCCC)CCCC)cc(cc2)NS(=O)(=O)C,CBR-HVAC-01446: Antiarrhythmic Drugs; alpha-Adrenoceptor Antagonists;beta-Adrenoceptor Antagonists;Cytochrome P450 CYP2D6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators; Potassium channel hERG1 Blocker; Polarisation inhibitor; Alpha adrenoreceptor antagonist; Beta adrenoreceptor antagonist; Ion channel antagonist
CBR-001-572-528-7,RFM-001-458-4,CBR-001-572-528-7,O=C(c1cc(OCC(F)(F)F)ccc1OCC(F)(F)F)NCC1CCCCN1,CBR-HVAC-01554: Antiarrhythmic Drugs; Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers; Sodium channel; Potassium channel Blocker; Voltage-gated sodium channel antagonist
CBR-001-572-529-8,RFM-001-459-5,CBR-001-572-529-8,CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)O,CBR-HVAC-00090: Antiarrhythmic Drugs; Potassium Channel Subfamily K Member 2 (TREK-1; KCNK2) Blockers;Potassium Channel Subfamily K Member 3 (TASK-1; KCNK3) Blockers; Beta adrenergic receptor Antagonist; Voltage-gated sodium channel antagonist
CBR-001-572-530-1,RFM-001-460-8,CBR-001-572-530-1,O=C1N=C(NC1(c1ccccc1)c1ccccc1)O,"CBR-HVAC-03130: Antiarrhythmic Drugs;Neuropathic Pain, Treatment of;Antiepileptic Drugs; Sodium Channel  Blockers"
CBR-001-572-531-2,RFM-001-461-9,CBR-001-572-531-2,CCN1C[C@@]2(CCC(C34[C@@H]1C(CC23)[C@@]1(O)CC(C2CC4[C@]1(O)[C@H]2OC)OC)OC)OC(=O)c1ccccc1NC(=O)C,CBR-HVAC-03051: Antiarrhythmic Drugs;Opioid Analgesics;Local Anesthetics;Antipyretics; ; ;
CBR-001-572-532-3,RFM-001-462-0,CBR-001-572-532-3,OCC1OC(C(C1O)O)n1cnc2c1ncnc2N,"CBR-HVAC-00079: Antiarrhythmic Drugs;Vasodilators;Stress Agents;Acute Myocardial Infarction, Treatment of;Analgesic Drugs; Adenosine Receptor Agonists;Signal Transduction Modulators; Adenosine receptor Antagonist; Adenosine receptor agonist; Angiogenesis stimulant"
CBR-001-572-533-4,RFM-001-463-1,CBR-001-572-533-4,COc1ccccc1OC(=O)C(c1ccc(cc1)CC(C)C)C,CBR-HVAC-02676: Antiarthritic Drugs; Cyclooxygenase-3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-572-534-5,RFM-001-464-2,CBR-001-572-534-5,Fc1ccc(cc1)c1nc2n(c1c1ccncc1)CCS2,CBR-HVAC-10468: Antiarthritic Drugs; MAPK p38 Inhibitors;Signal Transduction Modulators; COX; Lipoxygenase 5; p38 Mitogen-activated protein kinase Inhibitor;
CBR-001-572-535-6,RFM-001-465-3,CBR-001-572-535-6,CC(=O)Oc1ccc(cc1C(=O)O)/N=N/c1ccc(cc1)S(=O)(=O)Nc1nc(C)cc(n1)C,CBR-HVAC-02733: Antiarthritic Drugs;Immunosuppressants; ; ; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Immunosuppressant
CBR-001-572-536-7,RFM-001-466-4,CBR-001-572-536-7,OC(=O)C(c1ccc(c(c1)F)c1ccccc1)C,"CBR-HVAC-00793: Antiarthritic Drugs;Non-Opioid Analgesics;Antiinflammatory Ophthalmic Agents;Rheumatoid Arthritis, Treatment of;Osteoarthritis, Treatment of; ; COX-1; COX-2 INHIBITOR; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-572-537-8,RFM-001-467-5,CBR-001-572-537-8,CC(Cc1ccc(cc1)C(C(=O)O)C)C,"CBR-HVAC-01286: Antiarthritic Drugs;Osteoarthritis, Treatment of;Rheumatoid Arthritis, Treatment of;Antimigraine Drugs;Non-Opioid Analgesics;Ankylosing Spondylitis, Treatment of; Cyclooxygenase-3 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-572-538-9,RFM-001-468-6,CBR-001-572-538-9,N#CCC(=O)N1CC[C@H]([C@H](C1)N(c1ncnc2c1cc[nH]2)C)C,"CBR-HVAC-00093: Antiarthritic Drugs;Treatment of Transplant Rejection;Immunosuppressants;Systemic Lupus Erythematosus, Agents for;Antipsoriatics;Dry Eye Syndrome, Treatment for;Asthma Therapy;Atopic Dermatitis, Agents for;Hair Growth Stimulants;Rheumatoid Arthritis, Treatment of;Psoriatic Arthritis, Treatment of ;Ocular Antiinflammatory and Antiinfective Agents;Ankylosing Spondylitis, Treatment of;Inflammatory Bowel Disease, Agents for; Jak1 Inhibitors;Jak2 Inhibitors;Jak3 Inhibitors;Signal Transduction Modulators; JAK3 kinase Inhibitor; Janus kinase 3 inhibitor; Janus kinase 1 inhibitor"
CBR-001-572-539-0,RFM-001-469-7,CBR-001-572-539-0,CC(C(=O)NC1C(=O)N2C1SC(C2C(=O)O)(C)C)Oc1ccccc1,CBR-HVAC-06729: Antibacterial Drugs; ; ;
CBR-001-572-540-3,RFM-001-470-0,CBR-001-572-540-3,OC(=O)c1cn2[C@@H](C)COc3c2c(c1=O)cc(c3C1(N)CC1)F,CBR-HVAC-02086: Antibacterial Drugs; ; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-572-541-4,RFM-001-471-1,CBR-001-572-541-4,CN1CCN(CC1)c1c(F)cc2c3c1SCCn3cc(c2=O)C(=O)O,CBR-HVAC-01785: Antibacterial Drugs; ; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-572-542-5,RFM-001-472-2,CBR-001-572-542-5,O=C(C(c1ccccc1)NC(=O)N1CCNC1=O)NC1C(=O)N2C1SC(C2C(=O)O)(C)C,CBR-HVAC-02213: Antibacterial Drugs; ; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-543-6,RFM-001-473-3,CBR-001-572-543-6,NC1CCN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-03514: Antibacterial Drugs; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-572-544-7,RFM-001-474-4,CBR-001-572-544-7,F[C@H]1C[C@H]1n1cc(C(=O)O)c(=O)c2c1c(Cl)c(N1C[C@H](C3(C1)CC3)N)c(c2)F,CBR-HVAC-04221: Antibacterial Drugs; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; DNA gyrase; DNA topoisomerase IV Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-572-545-8,RFM-001-475-5,CBR-001-572-545-8,O/N=C(/c1cccc(c1)C(F)(F)F)\Nc1ccccc1,CBR-HVAC-11825: Antibacterial Drugs; DNA-Directed RNA Polymerase Inhibitors; RNA POLYMERASE Inhibitor;
CBR-001-572-546-9,RFM-001-476-6,CBR-001-572-546-9,CCn1cc(C(=O)O)c(=O)c2c1c(F)c(N1CCNC(C1)C)c(c2)F,CBR-HVAC-02175: Antibacterial Drugs;Antibacterial Ophthalmic Drugs; ; DNA gyrase; Topoisomerase IV Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-572-547-0,RFM-001-477-7,CBR-001-572-547-0,Ic1cc(I)c(c(c1O)I)O,CBR-HVAC-01963: Antibacterial Drugs;Dermatologic Drugs;Antiviral Drugs;Antifungal Agents; ; ; Unidentified pharmacological activity
CBR-001-572-548-1,RFM-001-478-8,CBR-001-572-548-1,COc1c(N2C[C@@H]3[C@H](C2)CCCN3)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-02242: Antibacterial Ophthalmic Drugs;Antibacterial Drugs;Treatment of Tuberculosis; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; Topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-572-549-2,RFM-001-479-9,CBR-001-572-549-2,COc1cc2CCN([C@H]3c2cc1Oc1c2c(CCN([C@H]2Cc2ccc(Oc4cc(C3)ccc4OC)cc2)C)cc2c1OCO2)C,CBR-HVAC-05346: Antibiotics and Alkaloids;Oncolytic Drugs;Anti-HIV Agents;Antimalarials;Cancer Multidrug Resistance Modulators; Apoptosis Inducers;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; Nuclear factor kappa B Inhibitor;
CBR-001-572-550-5,RFM-001-480-2,CBR-001-572-550-5,CC(=O)OC1CC2(C(/C/1=C(\C(=O)O)/CCC=C(C)C)CC(C1C2(C)CCC2C1(C)CCC(C2C)O)O)C,CBR-HVAC-02609: Antibiotics; ; ; Protein synthesis inhibitor
CBR-001-572-551-6,RFM-001-481-3,CBR-001-572-551-6,COCCOCC1NC2C(C)CC(C)(O)C(OC3OC(C)CC(C3O)N(C)C)C(C)C(C(C(=O)OC(C(C(O1)C2C)(C)O)CC)C)OC1OC(C)C(C(C1)(C)OC)O,CBR-HVAC-01566: Antibiotics; ; 23S-rRNA of 50S ribosomal subunit Binder; Protein 50S ribosomal subunit inhibitor
CBR-001-572-552-7,RFM-001-482-4,CBR-001-572-552-7,NC(c1ccccc1)C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)C,CBR-HVAC-02252: Antibiotics; ; PENICILLIN BINDING PROTEIN 1A; PENICILLIN BINDING PROTEIN 1B; PENICILLIN-BINDING PROTEIN 2A; PENICILLIN-BINDING PROTEIN 2B; PENICILLIN-BINDING PROTEIN 3 Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-553-8,RFM-001-483-5,CBR-001-572-553-8,O=C(N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[n+]1ccccc1)Cc1cccs1,CBR-HVAC-02852: Antibiotics; ; Penicillin binding protein Inhibitor;
CBR-001-572-554-9,RFM-001-484-6,CBR-001-572-554-9,CC(=O)OCC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)Cc1cccs1,CBR-HVAC-05211: Antibiotics; ; Penicillin binding protein Inhibitor;
CBR-001-572-555-0,RFM-001-485-7,CBR-001-572-555-0,CCCC1CN(C(C1)C(=O)NC(C1OC(SC)C(C(C1O)O)O)C(O)C)C,CBR-HVAC-07133: Antibiotics; ; PEPTIDYL TRANSFERASE Inhibitor;
CBR-001-572-556-1,RFM-001-486-8,CBR-001-572-556-1,CCOC(=O)CCC(=O)OC1C(OC(CC1N(C)C)C)OC1C(C)C(OC2OC(C)C(C(C2)(C)OC)O)C(C)C(=O)OC(CC)C(C(C(C(=O)C(CC1(C)O)C)C)O)(C)O,CBR-HVAC-07170: Antibiotics; Cytochrome P450 CYP3A4 Inhibitors;Motilin Receptor Agonists;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; ;
CBR-001-572-557-2,RFM-001-487-9,CBR-001-572-557-2,CC(=O)CC(c1c(=O)oc2c(c1O)cccc2)c1ccc(cc1)[N+](=O)[O-],CBR-HVAC-05267: Anticoagulants; ; Vitamin K epoxide reductase Antagonist;
CBR-001-572-558-3,RFM-001-488-0,CBR-001-572-558-3,O=C(Nc1scc(c1C(=O)O)c1cccs1)CCCCC(=O)Nc1scc(c1C(=O)O)c1cccs1,CBR-HVAC-12033: Anticoagulants; Plasminogen Activator Inhibitor (PAI-1) Inhibitors; PLASMINOGEN ACTIVATOR INHIBITOR-1 Inhibitor;
CBR-001-572-559-4,RFM-001-489-1,CBR-001-572-559-4,CC(=O)CC(c1c(=O)oc2c(c1O)cccc2)c1ccccc1,"CBR-HVAC-07094: Anticoagulants; Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors"
CBR-001-572-560-7,RFM-001-490-4,CBR-001-572-560-7,COc1ccc(cc1)n1nc(c2c1C(=O)N(CC2)c1ccc(cc1)N1CCCCC1=O)C(=O)N,"CBR-HVAC-06252: Anticoagulants;Angina pectoris, Treatment of;Stroke, Treatment of; Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways; Coagulation factor Xa Inhibitor; Direct Factor Xa inhibitor; Serine protease inhibitor"
CBR-001-572-561-8,RFM-001-491-5,CBR-001-572-561-8,OCC(OCn1cnc2c1nc(N)nc2O)CO,CBR-HVAC-03788: Anti-Cytomegalovirus Drugs; DNA Polymerase Inhibitors; ;
CBR-001-572-562-9,RFM-001-492-6,CBR-001-572-562-9,CCC(=O)c1ccc(cc1)OCC(CN1CCN(CC1)c1ccccc1)O,CBR-HVAC-05800: Antidepressants; ; ;
CBR-001-572-563-0,RFM-001-493-7,CBR-001-572-563-0,O=C(c1ccc(cc1)Cl)NCCCN1CCOCC1,CBR-HVAC-04185: Antidepressants; ; ;
CBR-001-572-564-1,RFM-001-494-8,CBR-001-572-564-1,Cc1cc(nnc1NCCN1CCOCC1)c1ccccc1,CBR-HVAC-01582: Antidepressants; ; Acetylcholinesterase Inhibitor; 5 Hydroxytryptamine uptake inhibitor
CBR-001-572-565-2,RFM-001-495-9,CBR-001-572-565-2,Fc1ccc(cc1)C1CCNCC1COc1ccc2c(c1)OCO2,CBR-HVAC-02183: Antidepressants; Signal Transduction Modulators;5-HT Reuptake Inhibitors; ; 5 Hydroxytryptamine uptake inhibitor
CBR-001-572-566-3,RFM-001-496-0,CBR-001-572-566-3,Clc1cccc(c1)N1CCNCC1,CBR-HVAC-03935: Antidepressants; Signal Transduction Modulators;5-HT2B Agonists;5-HT2C Agonists; ;
CBR-001-572-567-4,RFM-001-497-1,CBR-001-572-567-4,Nc1ccc(cn1)C#Cc1cnn2c1nc(cc2C(F)(F)F)c1ccc(cc1)C(F)(F)F,"CBR-HVAC-07301: Antidepressants;Alzheimer's Dementia, Treatment of ; mgluR2 Negative Allosteric Modulators;mgluR3 Antagonists;Signal Transduction Modulators; ; Glutamate 2 receptor antagonist; Glutamate 3 receptor antagonist"
CBR-001-572-568-5,RFM-001-498-2,CBR-001-572-568-5,Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2,"CBR-HVAC-01431: Antidepressants;Antipsychotic Drugs;Anxiolytics;Autism, Treatment of;Bipolar Disorder, Treatment of; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; 5-Hydroxytryptamine 2 receptor Antagonist; 5 Hydroxytryptamine 2A receptor agonist; Dopamine D2 receptor agonist; Alpha 1 adrenoreceptor antagonist; Dopamine receptor antagonist; 5 Hydroxytryptamine receptor antagonist; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-572-569-6,RFM-001-499-3,CBR-001-572-569-6,Cc1ccc(c(c1)C)Sc1ccccc1N1CCNCC1,"CBR-HVAC-05999: Antidepressants;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Treatment of Eating Disorders;Generalized Anxiety Disorder (GAD), Treatment of; Serotonin Transporter (SERT) Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors;5-HT1A Receptor Agonists;5-HT1B Partial Agonists;5-HT1D Antagonists;5-HT3 Antagonists;5-HT7 Antagonists; 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 3 receptor Inhibitor; Antagonist; Partial Agonist; Inhibitor; Antagonist; Antagonist; Agonist; Agonist; 5 Hydroxytryptamine 1A receptor agonist; 5 Hydroxytryptamine 7 receptor antagonist; 5 Hydroxytryptamine 1B receptor agonist; 5 Hydroxytryptamine uptake inhibitor; 5 Hydroxytryptamine 1D receptor antagonist; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-572-570-9,RFM-001-500-9,CBR-001-572-570-9,CCCN(CCC)CCc1cccc2c1CC(=O)N2,"CBR-HVAC-02383: Antidepressants;Fibromyalgia, Treatment of;Antiparkinsonian Drugs;Restless Legs Syndrome, Treatment of; Dopamine D2 Agonists;Dopamine Receptor Modulators;Signal Transduction Modulators; Dopamine receptor Agonist; Dopamine D2 receptor agonist; Dopamine D3 receptor agonist"
CBR-001-572-571-0,RFM-001-501-0,CBR-001-572-571-0,Clc1cccc(n1)SC1CCNCC1,CBR-HVAC-01104: Antidepressants;Non-Opioid Analgesics; Signal Transduction Modulators;5-HT1B Agonists; ; 5 Hydroxytryptamine 1 receptor agonist; 5 Hydroxytryptamine 3 receptor antagonist
CBR-001-572-572-1,RFM-001-502-1,CBR-001-572-572-1,O=c1cccc2n1C[C@@H]1CNC[C@H]2C1,"CBR-HVAC-05168: Antidepressants;Smoking Cessation, Aid to; Nicotinic alpha1beta1deltagamma Receptor Ligands;Nicotinic alpha2beta2 Receptor Ligands;Nicotinic alpha3beta2 Receptor Ligands;Nicotinic alpha3beta4 Agonists;Nicotinic alpha4beta2 Partial Agonists;Nicotinic alpha4beta4 Receptor Ligands;Signal Transduction Modulators; ;"
CBR-001-572-573-2,RFM-001-503-2,CBR-001-572-573-2,Clc1cccc(c1)C(=O)C(NC(C)(C)C)C,"CBR-HVAC-01365: Antidepressants;Treatment of Female Sexual Dysfunction;Smoking Cessation, Aid to;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Psychiatric Disorders (Not Specified);Antiobesity Drugs;Treatment of Substance Dependency;Neuropathic Pain, Treatment of;Inflammatory Bowel Disease, Agents for; Dopamine Transporter (DAT) Inhibitors;Norepinephrine Transporter (NET) Inhibitors;Signal Transduction Modulators; Dopamine transporter Inhibitor; Dopamine reuptake inhibitor; Adrenergic transmitter uptake inhibitor; Norepinephrine/dopamine dual reuptake inhibitor"
CBR-001-572-574-3,RFM-001-504-3,CBR-001-572-574-3,C[n+]1cccc(c1)C(=O)O,CBR-HVAC-06246: Antidiabetic Drugs; ; ;
CBR-001-572-575-4,RFM-001-505-4,CBR-001-572-575-4,CN1CCC/C/1=N\C(=N\c1ccccc1)\N1CCOCC1,CBR-HVAC-02924: Antidiabetic Drugs; ; ; Potassium channel antagonist
CBR-001-572-576-5,RFM-001-506-5,CBR-001-572-576-5,OC(=O)Cn1c(=O)c2cccc3c2c(c1=O)ccc3,CBR-HVAC-02774: Antidiabetic Drugs; Aldose Reductase Inhibitors; Aldose Reductase; L-HEXONATE DEHYDROGENASE Inhibitor; Aldose reductase inhibitor
CBR-001-572-577-6,RFM-001-507-6,CBR-001-572-577-6,OC[C@H]1OC(Oc2cc(O)cc(c2C(=O)CCc2ccc(cc2)O)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-05262: Antidiabetic Drugs; SGLT-1 Inhibitors;SGLT-2 Inhibitors; ;
CBR-001-572-578-7,RFM-001-508-7,CBR-001-572-578-7,CCOC(=O)c1c(CSc2ccccc2)n(c2c1c(CN(C)C)c(O)c(c2)Br)C,CBR-HVAC-04325: Antidiabetic Drugs;Antiviral Drugs;Anti-Influenza Virus Drugs;Immunostimulants; Viral Entry Inhibitors; ;;2017-11-14: ARB# 17-000617
CBR-001-572-579-8,RFM-001-509-8,CBR-001-572-579-8,C1CCN(CC1)CCOc1cccc(c1)c1n[nH]c2c1cc(cc2)c1[nH]ncn1,"CBR-HVAC-05761: Antidiabetic Drugs;Immunomodulators;Antiobesity Drugs;Nephritis, Agents for;Myeloid Leukemia Therapy; SAPK1 (JNK) Inhibitors;Signal Transduction Modulators; c-Jun N-terminal kinase 2; c-Jun N-terminal kinase 1 Inhibitor;"
CBR-001-572-580-1,RFM-001-510-1,CBR-001-572-580-1,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc(c1N)C(=O)N,"CBR-HVAC-04195: Antidiabetic Drugs;Lymphocytic Leukemia Therapy;Hematological Cancer Therapy;Antimalarials;Acute Myocardial Infarction, Treatment of;Cervical Cancer Therapy;Coronary Bypass Surgery;Multiple Myeloma Therapy;Non-Hodgkin's Lymphoma Therapy; AMP-Activated Protein Kinase (AMPK) Activators;Apoptosis Inducers;Signal Transduction Modulators; ;"
CBR-001-572-581-2,RFM-001-511-2,CBR-001-572-581-2,OC[C@@H]([C@@H](Cc1ccc(c(c1)OC)O)CO)Cc1ccc(c(c1)OC)O,CBR-HVAC-05989: Antidiabetic Drugs;Oncolytic Drugs;Breast Cancer Therapy; Antioxidants;Glucose Lowering Agents; ;
CBR-001-572-582-3,RFM-001-512-3,CBR-001-572-582-3,CNC(=N)NC(=O)Nc1c(C)cccc1C,CBR-HVAC-01787: Antidiarrheal Agents; ; Alpha 2 receptor Agonist; Alpha 2 adrenoreceptor agonist
CBR-001-572-583-4,RFM-001-513-4,CBR-001-572-583-4,CCC1(c2ccccc2)C(=O)N(COC)C(=O)N(C1=O)COC,CBR-HVAC-01052: Antiepileptic Drugs; ; ; GABA receptor agonist; Chloride channel agonist
CBR-001-572-584-5,RFM-001-514-5,CBR-001-572-584-5,O=C(N1CCCCC1)/C=C/c1ccc2c(c1)OCO2,CBR-HVAC-03501: Antiepileptic Drugs; ; ; Unidentified pharmacological activity
CBR-001-572-585-6,RFM-001-515-6,CBR-001-572-585-6,O=C(c1cccnc1)N1CCN(CC1)c1cccc(c1)C(F)(F)F,CBR-HVAC-10537: Antiepileptic Drugs; ; GABA-A receptor Activator;
CBR-001-572-586-7,RFM-001-516-7,CBR-001-572-586-7,CCN1C(=O)NC(C1=O)c1ccccc1,CBR-HVAC-07286: Antiepileptic Drugs; ; Sodium channel Blocker;
CBR-001-572-587-8,RFM-001-517-8,CBR-001-572-587-8,CCOC(=O)Nc1ccc(cc1N)NCc1ccc(cc1)F,"CBR-HVAC-02277: Antiepileptic Drugs;Amyotrophic Lateral Sclerosis, Agents for;Neuropathic Pain, Treatment of; GABA Aminotransferase Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Voltage-Gated K(V) 7.2/7.3 (KCNQ2/3) Channel Activators;Voltage-Gated K(V) 7.3 (KCNQ3) Channel Activators; KCNQ channel Opener; Potassium channel agonist; GABA receptor agonist;2016-04-01: controlled substance"
CBR-001-572-588-9,RFM-001-518-9,CBR-001-572-588-9,O=C(c1ccc(cc1)N)Nc1c(C)cccc1C,CBR-HVAC-03547: Antiepileptic Drugs;Antiarrhythmic Drugs; ; Sodium channel Antagonist; Sodium channel antagonist
CBR-001-572-589-0,RFM-001-519-0,CBR-001-572-589-0,N#Cc1cc(F)ccc1c1cc(ccc1F)c1cnc2n1ccc(c2F)C(O)(C)C,CBR-HVAC-09359: Antiepileptic Drugs;Anxiolytics; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; GABA A receptor Agonist;
CBR-001-572-590-3,RFM-001-520-3,CBR-001-572-590-3,NC(=O)CN1CC(CC1=O)c1ccccc1,"CBR-HVAC-06970: Antiepileptic Drugs;Cerebrovascular Diseases, Treatment of; ; ;"
CBR-001-572-591-4,RFM-001-521-4,CBR-001-572-591-4,Clc1ccc(c(c1)Cl)CO/N=C(/c1ccc(cc1Cl)Cl)\Cn1cncc1,CBR-HVAC-02202: Antifungal Agents; ; Pregnane X receptor Activator; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-572-592-5,RFM-001-522-5,CBR-001-572-592-5,CC[C@H](n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OC[C@@H]1CO[C@@](C1)(Cn1cncn1)c1ccc(cc1F)F)[C@@H](O)C,CBR-HVAC-01562: Antifungal Agents;Antitrypanosomals; Lanosterol 14alpha-demethylase Inhibitors; 14-Alpha demethylase Inhibitor; Cell wall synthesis inhibitor; Sterol demethylase inhibitor
CBR-001-572-593-6,RFM-001-523-6,CBR-001-572-593-6,COc1cc(/C=C/C(=O)Nc2ccccc2C(=O)O)ccc1OC,"CBR-HVAC-01826: Antiglaucoma Agents;Rheumatoid Arthritis, Treatment of;Restenosis Treatment of;Atopic Dermatitis, Agents for;Multiple Sclerosis, Agents for;Uricosurics;Antiallergic Ophthalmic Agents;Drugs for Allergic Rhinitis;Antiarthritic Drugs;Asthma Therapy;Urologic Drugs; IFN-gamma Production Inhibitors;IL-10 Production Enhancers;IL-2 Production Inhibitors;IL-4 Modulators;Indoleamine 2,3-dioxygenase Activators;Signal Transduction Modulators;TNF-alpha Production Inhibitors;TRPV2 (Vanilloid VR2 Receptor) Antagonists;Urate Transporter 1 (URAT1) Inhibitors; Transforming growth factor beta Inhibitor; Histamine release inhibitor; Transforming growth factor beta 1 antagonist; Histamine receptor antagonist"
CBR-001-572-594-7,RFM-001-524-7,CBR-001-572-594-7,O=C1CCC[C@H]2N1C[C@@H]1CCCN3[C@@H]1[C@@H]2CCC3,CBR-HVAC-03583: Anti-Hepatitis B Virus Drugs;Oncolytic Drugs;Analgesic Drugs; ; ;
CBR-001-572-595-8,RFM-001-525-8,CBR-001-572-595-8,COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(cc1)[C@@H]1CC[C@H](N1c1ccc(cc1)C(C)(C)C)c1ccc(cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)C(C)C,CBR-HVAC-07045: Anti-Hepatitis C Virus Drugs; HCV NS5A Inhibitors; ; HCV nonstructural protein 5A inhibitor
CBR-001-572-596-9,RFM-001-526-9,CBR-001-572-596-9,CC([C@@H](C(=O)OCCOCn1cnc2c1nc(N)[nH]c2=O)N)C,CBR-HVAC-02255: Anti-Hepatitis C Virus Drugs;Anti-Herpes Virus Drugs;Anti-Herpes Simplex Virus Drugs;Anti-Varicella Zoster Virus Drugs;Anti-Herpes Labialis Drugs;Antipsychotic Drugs; DNA Polymerase Inhibitors; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-572-597-0,RFM-001-527-0,CBR-001-572-597-0,NC12CC3CC(C2)CC(C1)C3,"CBR-HVAC-00830: Anti-Hepatitis C Virus Drugs;Multiple Sclerosis, Agents for;Anti-Influenza A Virus Drugs;Fatigue, Treatment of;Antiparkinsonian Drugs; Dopamine Receptor Agonists;M2 Channel Inhibitors;NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; NMDA receptor antagonist"
CBR-001-572-598-1,RFM-001-528-1,CBR-001-572-598-1,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc(n1)C(=O)N,"CBR-HVAC-03077: Anti-Hepatitis E Virus Drugs;Anti-Papilloma Virus Drugs;Antiviral Drugs;Immunostimulants;Anti-Influenza A Virus Drugs;Severe Acute Respiratory Syndrome (SARS), Treatment of;Breast Cancer Therapy;Anti-Hepatitis C Virus Drugs;Anti-RSV Drugs;Myeloid Leukemia Therapy; Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors; Viral RNA-dependent RNA polymerase; Inosine-5'-monophosphate dehydrogenase Inhibitor; Inhibitor; Inosine monophosphate dehydrogenase inhibitor"
CBR-001-572-599-2,RFM-001-529-2,CBR-001-572-599-2,OCC(CCn1cnc2c1nc(N)[nH]c2=O)CO,CBR-HVAC-01901: Anti-Herpes Labialis Drugs; DNA Polymerase Inhibitors; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-572-600-8,RFM-001-530-5,CBR-001-572-600-8,N#C/C=C/c1cc(C)c(c(c1)C)Nc1ccnc(n1)Nc1ccc(cc1)C#N,CBR-HVAC-01578: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-572-601-9,RFM-001-531-6,CBR-001-572-601-9,OC[C@@H]1CC[C@@H](O1)n1cnc2c1nc[nH]c2=O,CBR-HVAC-03748: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor;
CBR-001-572-602-0,RFM-001-532-7,CBR-001-572-602-0,Cc1ccnc2c1[nH]c(=O)c1c(n2C2CC2)nccc1,CBR-HVAC-01604: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-572-603-1,RFM-001-533-8,CBR-001-572-603-1,C[C@H](Cn1cnc2c1ncnc2N)OC[P@@](=O)(N[C@H](C(=O)OC(C)C)C)Oc1ccccc1,CBR-HVAC-00865: Anti-HIV Agents;Anti-Hepatitis B Virus Drugs; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleotide reverse transcriptase inhibitor
CBR-001-572-604-2,RFM-001-534-9,CBR-001-572-604-2,N#Cc1ccc(cc1)Nc1nccc(n1)Nc1c(C)cc(cc1C)C,CBR-HVAC-00837: Anti-HIV Agents;Microbicides; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-572-605-3,RFM-001-535-0,CBR-001-572-605-3,CC(C[C@@H](C(=O)O)NC(=O)OCC1c2ccccc2c2c1cccc2)C,CBR-HVAC-04172: Antiinflammatory Drugs; ; ICAM 1 antagonist
CBR-001-572-606-4,RFM-001-536-1,CBR-001-572-606-4,CCOC(=O)C1=C[C@H]([C@@H]([C@H](C1)N)NC(=O)C)OC(CC)CC,CBR-HVAC-00385: Anti-Influenza Virus Drugs; Neuraminidase (Sialidase) Inhibitors; ; Neuraminidase inhibitor
CBR-001-572-607-5,RFM-001-537-2,CBR-001-572-607-5,CCOC(=O)C1=C(C)NC(=C(C1c1ccccc1/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C,"CBR-HVAC-01686: Antileishmanials;Hypertension, Treatment of; Calcium Channel Blockers; Calcium channel Blocker; L-type calcium channel antagonist"
CBR-001-572-608-6,RFM-001-538-3,CBR-001-572-608-6,COc1ccc2c(n1)c(Nc1cc(CN3CCCC3)c(c(c1)CN1CCCC1)O)c1c(n2)cc(cc1)Cl,CBR-HVAC-02525: Antimalarials; ; ; Polarisation stimulant; Membrane permeability inhibitor
CBR-001-572-609-7,RFM-001-539-4,CBR-001-572-609-7,CCN(Cc1cc(ccc1O)Nc1ccnc2c1ccc(c2)Cl)CC,CBR-HVAC-02858: Antimalarials; ; Histamine N-methyltransferase Inhibitor;
CBR-001-572-610-0,RFM-001-540-7,CBR-001-572-610-0,CN1CCC(=C2c3ccsc3CCc3c2cccc3)CC1,CBR-HVAC-02275: Antimigraine Drugs; ; 5-Hydroxytryptamine 2 receptor Antagonist; 5 Hydroxytryptamine 2A receptor antagonist
CBR-001-572-611-1,RFM-001-541-8,CBR-001-572-611-1,Clc1ccc(cc1)OC(c1ccnc2n1ncn2)C,"CBR-HVAC-07571: Antimigraine Drugs;Stroke, Treatment of;Antiepileptic Drugs; ; ; GABA A receptor antagonist"
CBR-001-572-612-2,RFM-001-542-9,CBR-001-572-612-2,COC1/C=C/OC2(C)Oc3c(C2=O)c2c(O)c(/C=N/N=C/N4CCCCC4)c(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C\C(C(C(C(C(C(C1C)OC(=O)C)C)O)C)O)C)/C,CBR-HVAC-03200: Antimycobacterial Agents;Antibiotics; ; ;
CBR-001-572-613-3,RFM-001-543-0,CBR-001-572-613-3,Clc1ccc(cc1)C1(O)c2ccccc2C2=NCCN12,"CBR-HVAC-01961: Antinarcoleptic Drugs;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Muscular Dystrophy, Agents for;Antiobesity Drugs; Dopamine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; Dopamine transporter Inhibitor; Adrenoreceptor agonist; Dopamine receptor agonist;2016-04-01: controlled substance"
CBR-001-572-614-4,RFM-001-544-1,CBR-001-572-614-4,CCCCCCCCCCCCCCCCOc1nc2ccc(cc2c(=O)o1)C,CBR-HVAC-05390: Antiobesity Drugs; Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors; LIPASE Inhibitor; Lipase inhibitor
CBR-001-572-615-5,RFM-001-545-2,CBR-001-572-615-5,COc1ccc(cc1N1CCNCC1)NS(=O)(=O)c1sc2c(c1C)cc(cc2)Cl,"CBR-HVAC-05126: Antiobesity Drugs;Antipsychotic Drugs;Alzheimer's Dementia, Treatment of ; Signal Transduction Modulators;5-HT6 Antagonists; 5-hydroxytryptamine 6 receptor Antagonist;"
CBR-001-572-616-6,RFM-001-546-3,CBR-001-572-616-6,CN([C@H]1CCN(C1)Cc1ccc(cc1C(F)(F)F)C(=O)Nc1ccc(c(c1)Nc1nccc(n1)c1cncnc1)C)C,CBR-HVAC-00667: Antiparkinsonian Drugs;Lymphocytic Leukemia Therapy;Leukemia Therapy;Brain Cancer Therapy;Prostate Cancer Therapy;Myeloid Leukemia Therapy;Bone Resorption Inhibitors; Abl1 Kinase Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Fyn Kinase Inhibitors;Lyn Kinase Inhibitors;Signal Transduction Modulators; Tyrosine kinase Lyn; BCR-ABL Inhibitor; Bcr-Abl inhibitor; LYN tyrosine kinase inhibitor
CBR-001-572-617-7,RFM-001-547-4,CBR-001-572-617-7,N#Cc1ccccc1c1cc(cn(c1=O)c1ccccc1)c1ccccn1,"CBR-HVAC-02268: Antiparkinsonian Drugs;Neuropathic Pain, Treatment of;Migraine, Prophylactic Treatment of;Multiple Sclerosis, Agents for;Antiepileptic Drugs; AMPA Receptor Antagonists;Signal Transduction Modulators; AMPA receptor Antagonist; AMPA receptor antagonist;2016-04-01: controlled substance"
CBR-001-572-618-8,RFM-001-548-5,CBR-001-572-618-8,Oc1ccc(cc1)[C@@H]([C@@H](N1CCC(CC1)(O)c1ccccc1)C)O,"CBR-HVAC-04543: Antiparkinsonian Drugs;Stroke, Treatment of; NR2B Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA 2B Antagonist; NMDA receptor antagonist"
CBR-001-572-619-9,RFM-001-549-6,CBR-001-572-619-9,CCC(c1ccc(cc1)N1Cc2c(C1=O)cccc2)C(=O)O,CBR-HVAC-01626: Antiplatelet Therapy;Anticoagulants; ; Cyclooxygenase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Platelet aggregation inhibitor
CBR-001-572-620-2,RFM-001-550-9,CBR-001-572-620-2,OC(=O)CCCCN(Cc1ccc(cc1)C(=O)O)CCc1ccccc1OCc1ccc(cc1)CCc1ccccc1,CBR-HVAC-05508: Antiplatelet Therapy;Heart Failure Therapy; Soluble Guanylate Cyclase (sGC) Activators; GUANYLATE CYCLASE Activator; Guanylate cyclase stimulant
CBR-001-572-621-3,RFM-001-551-0,CBR-001-572-621-3,Clc1ccccc1CN1CCc2c(C1)ccs2,"CBR-HVAC-02190: Antiplatelet Therapy;Stroke, Treatment of;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; P2Y12 (P2T) Antagonists;Signal Transduction Modulators; PDGFR Inhibitor; Purinoreceptor P2Y12 antagonist; Platelet aggregation inhibitor; Purinoreceptor P2 antagonist"
CBR-001-572-622-4,RFM-001-552-1,CBR-001-572-622-4,CCOc1c(OCC)cc2c(c1F)C(=N)N(C2)CC(=O)c1cc(N2CCOCC2)c(c(c1)C(C)(C)C)OC,CBR-HVAC-00356: Antiplatelet Therapy;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Inhibitors of Blood Coagulation Pathways;PAR1 Antagonists;Signal Transduction Modulators;Thrombin Inhibitors; Protease activated receptor 1 Antagonist; Protease-activated receptor-1 antagonist
CBR-001-572-623-5,RFM-001-553-2,CBR-001-572-623-5,OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CCC2=CC(=O)CCC12C,CBR-HVAC-01386: Antipruritics;Endocrine Disorders (Not Specified);Dermatologic Drugs; ; Phospholipase A2 Inhibitor; Corticosteroid agonist
CBR-001-572-624-6,RFM-001-554-3,CBR-001-572-624-6,CN([C@@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O)C(=O)/C=C/c1ccoc1,"CBR-HVAC-00087: Antipruritics;Opioid Analgesics;Atopic Dermatitis, Agents for; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist; Opioid kappa receptor agonist"
CBR-001-572-625-7,RFM-001-555-4,CBR-001-572-625-7,COc1cc(C)c(c(c1C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,"CBR-HVAC-01813: Antipsoriatics;Allergic Skin Disorders, Treatment for; ; Retinoic acid receptor beta; Retinoic acid receptor alpha; Retinoic acid receptor gamma Inhibitor; Inhibitor; Inhibitor; Protein synthesis inhibitor; Microbial collagenase inhibitor; Retinoic acid receptor agonist"
CBR-001-572-626-8,RFM-001-556-5,CBR-001-572-626-8,COc1cc2c(ncnc2cc1OC)Nc1cccc(c1)Br,CBR-HVAC-04661: Antipsoriatics;Oncolytic Drugs; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; c-SRC; EGFR Inhibitor; EGFR kinase inhibitor
CBR-001-572-627-9,RFM-001-557-6,CBR-001-572-627-9,OCCN1CCN(CC1)C1Cc2ccc(cc2Sc2c1cc(cc2)C(C)C)F,CBR-HVAC-02140: Antipsychotic Drugs; ; Dopamine receptor D1; Dopamine receptor D2 Antagonist; Dopamine receptor antagonist
CBR-001-572-628-0,RFM-001-558-7,CBR-001-572-628-0,CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)c1ccc(cc1)F)c1ccc(cc1)Cl,CBR-HVAC-03421: Antipsychotic Drugs; Cytochrome P450 CYP1A1 Inhibitors;Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist;
CBR-001-572-629-1,RFM-001-559-8,CBR-001-572-629-1,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2,CBR-HVAC-03116: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Blocker;
CBR-001-572-630-4,RFM-001-560-1,CBR-001-572-630-4,O=C(N(C)C)N[C@@H]1CC[C@H](CC1)CCN1CCN(CC1)c1cccc(c1Cl)Cl,"CBR-HVAC-00909: Antipsychotic Drugs;Antidepressants;Bipolar Disorder, Treatment of; Dopamine D2 Antagonists;Dopamine D2 Receptor Partial Agonists;Dopamine D3 Antagonists;Dopamine D3 Partial Agonists;Signal Transduction Modulators; Dopamine receptor D2; Dopamine receptor D3 Partial Agonist; Dopamine D2 receptor agonist; Dopamine D3 receptor agonist"
CBR-001-572-631-5,RFM-001-561-2,CBR-001-572-631-5,O=C(c1ncn2c1[C@@H]1CCCN1C(=O)c1c2cccc1Br)OC(C)(C)C,CBR-HVAC-03036: Antipsychotic Drugs;Anxiolytics;Antiepileptic Drugs; GABA(A) BZ Site Receptor Partial Agonists;Signal Transduction Modulators; Benzodiazepine receptor Agonist; Benzodiazepine receptor agonist
CBR-001-572-632-6,RFM-001-562-3,CBR-001-572-632-6,Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCCC2O,"CBR-HVAC-01489: Antipsychotic Drugs;Autism, Treatment of;Antidepressants;Obsessive-Compulsive Disorder (OCD), Treatment of;Tourette's Syndrome, Treatment of;Bipolar Disorder, Treatment of; Dopamine D2 Antagonists;Dopamine D2 Receptor Ligands;Signal Transduction Modulators;5-HT2A Receptor Ligands; P-Glycoprotein Inhibitor; 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 7 receptor antagonist; Dopamine D2 receptor antagonist"
CBR-001-572-633-7,RFM-001-563-4,CBR-001-572-633-7,CN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)C,"CBR-HVAC-04028: Antipsychotic Drugs;Prion Diseases, Treatment of; Antimitotic Drugs;Dopamine D2 Antagonists;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors;Signal Transduction Modulators; Dopamine receptor D2; 5-Hydroxytryptamine 1A receptor Inhibitor;"
CBR-001-572-634-8,RFM-001-564-5,CBR-001-572-634-8,CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C,"CBR-HVAC-00856: Antipsychotic Drugs;Sleep Disorders, Treatment of; Signal Transduction Modulators;5-HT2A Inverse Agonists; 5-Hydroxytryptamine 2A receptor Inverse Agonist; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-572-635-9,RFM-001-565-6,CBR-001-572-635-9,CCN(CCNC(=O)c1cc(ccc1OC)S(=O)(=O)C)CC,"CBR-HVAC-01671: Antipsychotic Drugs;Treatment of Alcohol Dependency;Tourette's Syndrome, Treatment of; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist"
CBR-001-572-636-0,RFM-001-566-7,CBR-001-572-636-0,O=C(C(c1ccccc1)(c1ccccc1)O)OC1C[N+]2(C)CCC1CC2,CBR-HVAC-03170: Antispasmodics; ; Muscarinic acetylcholine receptor Antagonist;
CBR-001-572-637-1,RFM-001-567-8,CBR-001-572-637-1,Nc1ccc(cc1)C1=NN(C(=O)C)[C@@H](Cc2c1cc1OCOc1c2)C,"CBR-HVAC-00499: Antispastic Drugs and Drugs for Muscle Spasms;Amyotrophic Lateral Sclerosis, Agents for;Ischemic Stroke, Treatment of;Tardive Dyskinesia, Treatment of;Multiple Sclerosis, Agents for;Glioblastoma Multiforme Therapy;Antiepileptic Drugs;Neurologic Cancer Therapy; AMPA Receptor Antagonists;Kainate Receptor Antagonists;Signal Transduction Modulators; IONOTROPIC GLUTAMATE RECEPTOR AMPA Antagonist; AMPA receptor antagonist"
CBR-001-572-638-2,RFM-001-568-9,CBR-001-572-638-2,O=C1NC2=Nc3c(CN2C1)c(Cl)c(cc3)Cl,CBR-HVAC-02577: Antithrombocythemic; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; cAMP phosphodiesterase Inhibitor; Phosphodiesterase 3 inhibitor
CBR-001-572-639-3,RFM-001-569-0,CBR-001-572-639-3,CC(=O)NCC(=O)O,delivered in error
CBR-001-572-640-6,RFM-001-570-3,CBR-001-572-640-6,Cc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C,CBR-HVAC-06224: Antitussives;Antiepileptic Drugs; sigma1 Receptor Ligands;Signal Transduction Modulators; ;
CBR-001-572-641-7,RFM-001-571-4,CBR-001-572-641-7,OC(=O)CCCCCNC(=O)C,CBR-HVAC-01252: Antiulcer Drugs; ; ; Gastrin inhibitor; 5 Alpha reductase inhibitor; Reducing agent
CBR-001-572-642-8,RFM-001-572-5,CBR-001-572-642-8,O=C(NC1CCCCC1)CN1CCNCC1,CBR-HVAC-02914: Antiulcer Drugs; ; ; Mucus protecting agent
CBR-001-572-643-9,RFM-001-573-6,CBR-001-572-643-9,OC(=O)/C=C/c1ccc(cc1)O,CBR-HVAC-05911: Antiulcer Drugs; Antioxidants; ;
CBR-001-572-644-0,RFM-001-574-7,CBR-001-572-644-0,CCCN(C(=O)C(NC(=O)c1ccccc1)CCC(=O)O)CCC,CBR-HVAC-01661: Antiulcer Drugs; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin receptor Antagonist; CCK receptor antagonist
CBR-001-572-645-1,RFM-001-575-8,CBR-001-572-645-1,N#CCc1c(C)nc2n1cccc2OCc1ccccc1,CBR-HVAC-08330: Antiulcer Drugs; Reversible H+/K+-ATPase Inhibitors ; ; Potassium-competitive acid antagonist
CBR-001-572-646-2,RFM-001-576-9,CBR-001-572-646-2,O=C(C1c2ccccc2Oc2c1cccc2)OCC[N+](C(C)C)(C(C)C)C,CBR-HVAC-03164: Antiulcer Drugs;Antispasmodics; Muscarinic Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Antagonist;
CBR-001-572-647-3,RFM-001-577-0,CBR-001-572-647-3,OCC1OC(C(C1O)O)n1cnc2c1ncnc2N(C)C,CBR-HVAC-10883: Antiviral Drugs; ; ;
CBR-001-572-648-4,RFM-001-578-1,CBR-001-572-648-4,Brc1ccc2c(c1)C=CC(=O)C2=O,CBR-HVAC-05855: Antiviral Drugs; ; ;
CBR-001-572-649-5,RFM-001-579-2,CBR-001-572-649-5,OC1C(O)C(OC1n1cnc2c1ncnc2N)COP(=O)(O)O,CBR-HVAC-08514: Antiviral Drugs;Oncolytic Drugs; ; ; DNA directed DNA polymerase inhibitor
CBR-001-572-650-8,RFM-001-580-5,CBR-001-572-650-8,COc1cc(OCC(CN2CCN(CC2)c2ccccc2OC)O)cc(c1OC)OC,CBR-HVAC-03054: Anxiolytics; ; Gamma-aminobutyric acid receptor Agonist; GABA receptor agonist
CBR-001-572-651-9,RFM-001-581-6,CBR-001-572-651-9,CCC(Nc1cc(C)nc(c1C)Oc1c(C)cc(cc1C)C)CC,CBR-HVAC-06724: Anxiolytics; CRF1 Receptor Antagonists;Signal Transduction Modulators; CRF1 RECEPTOR ANTAGONIST;
CBR-001-572-652-0,RFM-001-582-7,CBR-001-572-652-0,O=C1N(CCCCN2CCN(CC2)c2ccccn2)C(=O)C2(C(C1CC2)(C)C)C,CBR-HVAC-04754: Anxiolytics; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT1A Receptor Agonists;5-HT3 Antagonists; ;
CBR-001-572-653-1,RFM-001-583-8,CBR-001-572-653-1,NNC(=O)CN1C(=O)CN=C(c2c1ccc(c2)Br)c1ccccc1,CBR-HVAC-04751: Anxiolytics; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; ;
CBR-001-572-654-2,RFM-001-584-9,CBR-001-572-654-2,CCc1cc2c(s1)n1c(CN=C2c2ccccc2Cl)nnc1C,CBR-HVAC-01636: Anxiolytics;Sedative/Hypnotics; GABA(A) BZ Site Receptor Agonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Benzodiazepine receptor Agonist; Benzodiazepine receptor agonist
CBR-001-572-655-3,RFM-001-585-0,CBR-001-572-655-3,OC(=O)C1CCC(CC1)c1cc2cccnc2c(n1)c1cccc(c1)F,"CBR-HVAC-05910: Asthma Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Phosphodiesterase PDE4A Inhibitors;Phosphodiesterase PDE4B Inhibitors;Phosphodiesterase PDE4D Inhibitors;Signal Transduction Modulators;TNF-alpha Release Inhibitors; ;"
CBR-001-572-656-4,RFM-001-586-1,CBR-001-572-656-4,FCSC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F,"CBR-HVAC-04117: Asthma Therapy;Esophageal Diseases, Treatment of;Drugs for Allergic Rhinitis;Antiallergy/Antiasthmatic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Atopic Dermatitis, Agents for;Allergic Skin Disorders, Treatment for;Treatment of Upper Respiratory Tract Disorders; ; Glucocorticoid receptor Binder; Glucocorticoid agonist"
CBR-001-572-657-5,RFM-001-587-2,CBR-001-572-657-5,Nc1cc(nc(=N)n1O)N1CCCCC1,CBR-HVAC-01898: ATP-sensitive potassium channel Activator; ATP-sensitive potassium channel agonist; K(ATP) Channel Activators; Polarisation stimulant; Renin secretion stimulant; Antihypertensive; Hair Growth Stimulants; Vasodilator
CBR-001-572-658-6,RFM-001-588-3,CBR-001-572-658-6,COc1ccc2c(c1)c(CCNC(=O)C)ccc2,"CBR-HVAC-01838: Autism, Treatment of;Antidepressants;Bipolar Disorder, Treatment of; Melatonin MT1 Agonists;Melatonin MT2 Agonists;Signal Transduction Modulators;5-HT2C Antagonists; 5-Hydroxytryptamine 2C receptor; Melatonin receptor 1; Melatonin receptor 2 Agonist; Antagonist; Melatonin 1 receptor agonist; Melatonin 2 receptor agonist; 5 Hydroxytryptamine 2C receptor antagonist; 5 Hydroxytryptamine receptor agonist; 5 Hydroxytryptamine 2C receptor agonist"
CBR-001-572-659-7,RFM-001-589-4,CBR-001-572-659-7,O=C(c1ccccc1)NC1CCN(CC1)CCc1c[nH]c2c1cccc2,"CBR-HVAC-02173: Benign Prostatic Hyperplasia Therapy;Antimigraine Drugs;Hypertension, Treatment of; alpha1-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist"
CBR-001-572-660-0,RFM-001-590-7,CBR-001-572-660-0,CO[C@@H](C(=O)N1CCN(CC1)c1nc(N)c2c(n1)cc(c(c2)OC)OC)C,CBR-HVAC-00811: Benign Prostatic Hyperplasia Therapy;Heart Failure Therapy; alpha1-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Blocker; Alpha 1 adrenoreceptor antagonist
CBR-001-572-661-1,RFM-001-591-8,CBR-001-572-661-1,COc1ccccc1N1CCN(CC1)CC(COc1cccc2c1cccc2)O,CBR-HVAC-01848: Benign Prostatic Hyperplasia Therapy;Urinary Incontinence Therapy;Urologic Drugs; alpha1D-Adrenoceptor Antagonists;Cytochrome P450 CYP2C9 Inhibitors;Signal Transduction Modulators; Alpha adrenergic receptor Antagonist; Agonist; Alpha 1 adrenoreceptor antagonist; Calcium channel antagonist
CBR-001-572-662-2,RFM-001-592-9,CBR-001-572-662-2,OC1=Nc2ccc(cc2C(=NC1)c1ccccc1Cl)Cl,CBR-HVAC-01744: Benzodiazepine receptor agonist
CBR-001-572-663-3,RFM-001-593-0,CBR-001-572-663-3,O=C1NC(=O)C(C(=O)N1C)(C)C1=CCCCC1,CBR-HVAC-09693: Benzodiazepine receptor Agonist;
CBR-001-572-664-4,RFM-001-594-1,CBR-001-572-664-4,OC(COc1nsnc1N1CCOCC1)CNC(C)(C)C,CBR-HVAC-02394: Beta adrenergic receptor Inhibitor; Beta adrenoreceptor antagonist
CBR-001-572-665-5,RFM-001-595-2,CBR-001-572-665-5,OC(COc1ccc(cc1)NC(=O)C)CNC(C)C,CBR-HVAC-10151: Beta-1 adrenergic receptor Blocker;
CBR-001-572-666-6,RFM-001-596-3,CBR-001-572-666-6,OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1ccccc1)O,CBR-HVAC-02476: Beta-2 adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-572-667-7,RFM-001-597-4,CBR-001-572-667-7,CN1CCN(CC1)C1=Nc2cc(Cl)ccc2Nc2c1cccc2,"CBR-HVAC-00382: Bipolar Disorder, Treatment of;Antipsychotic Drugs; Dopamine D4 Antagonists;Signal Transduction Modulators;5-HT2 Antagonists; Dopamine receptor D5; Dopamine receptor D1; Dopamine receptor D2; Dopamine receptor D4; Dopamine receptor D3 Inhibitor; Dopamine receptor antagonist; Alpha 1 adrenoreceptor antagonist; 5 Hydroxytryptamine receptor antagonist"
CBR-001-572-668-8,RFM-001-598-5,CBR-001-572-668-8,O=C(c1ccc(cc1)CNc1nccc(n1)c1cccnc1)Nc1ccccc1N,CBR-HVAC-00663: Bladder Cancer Therapy ;Non-Hodgkin's Lymphoma Therapy;Lymphoma Therapy;Myelodysplastic Syndrome Therapy;Lymphocytic Leukemia Therapy;Sarcoma Therapy;Myeloid Leukemia Therapy;Pancreatic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Oncolytic Drugs; Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor
CBR-001-572-669-9,RFM-001-599-6,CBR-001-572-669-9,OC(=O)Cc1cccc2c1oc1c(C)c(C)ccc1c2=O,CBR-HVAC-04057: Bladder Cancer Therapy ;Renal Cancer Therapy;Oncolytic Drugs;Antiviral Drugs;Ovarian Cancer Therapy;Prostate Cancer Therapy;Lung Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Interferon Inducers;Signal Transduction Modulators;Vascular Disrupting Agents (VDA); NUCLEAR FACTOR KAPPA B; VEGFR 2 KINASE Modulator; Angiogenesis inhibitor
CBR-001-572-670-2,RFM-001-600-2,CBR-001-572-670-2,O=C1Nc2c(/C/1=C/c1[nH]c(cc1C)C)cccc2,CBR-HVAC-04902: Brain Cancer Therapy;Colorectal Cancer Therapy;Head and Neck Cancer Therapy;Prostate Cancer Therapy;Oncolytic Drugs;Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Kaposi's Sarcoma Therapy;Melanoma Therapy;Astrocytoma Therapy;Breast Cancer Therapy; Angiogenesis Inhibitors;Flt3 (FLK2/STK1) Inhibitors;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Vascular endothelial growth factor receptor Blocker; Inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor
CBR-001-572-671-3,RFM-001-601-3,CBR-001-572-671-3,ClCCN(C(=O)NC(P(=O)(OCC)OCC)C)N=O,CBR-HVAC-01707: Brain Cancer Therapy;Melanoma Therapy; DNA-Damaging Drugs; ; DNA synthesis inhibitor; Ribonucleoside triphosphate reductase inhibitor; Glutathione reductase inhibitor; Thioredoxin reductase inhibitor
CBR-001-572-672-4,RFM-001-602-4,CBR-001-572-672-4,O=c1c2ccccc2nc2n1CCCCC2,CBR-HVAC-05793: Bronchodilators; ; ;
CBR-001-572-673-5,RFM-001-603-5,CBR-001-572-673-5,CC(Cn1cnc2c1c(=O)n(C)c(=O)n2C)C,CBR-HVAC-03952: Bronchodilators; ; Neurokinin receptor 1 Antagonist; Phosphodiesterase inhibitor
CBR-001-572-674-6,RFM-001-604-6,CBR-001-572-674-6,CCCn1c(=O)[nH]c(=O)c2c1nc[nH]2,CBR-HVAC-01067: Bronchodilators; Adenosine A2B Antagonists;Signal Transduction Modulators; Adenosine A2B receptor Antagonist; Phosphodiesterase inhibitor
CBR-001-572-675-7,RFM-001-605-7,CBR-001-572-675-7,Cc1cc2n(n1)c(=N)[nH]c(=N)[nH]2,CBR-HVAC-07709: Bronchodilators;Antiallergy/Antiasthmatic Drugs; ; ; Histamine receptor antagonist; Phosphodiesterase inhibitor; Leucotriene receptor antagonist
CBR-001-572-676-8,RFM-001-606-8,CBR-001-572-676-8,CCN(CCOc1ccccc1C(=O)CCc1ccccc1)CC,CBR-HVAC-01382: Calcium channel antagonist
CBR-001-572-677-9,RFM-001-607-9,CBR-001-572-677-9,CCN(CCSC(=O)C(c1ccccc1)c1ccccc1)CC,CBR-HVAC-08950: Calcium channel Antagonist;
CBR-001-572-678-0,RFM-001-608-0,CBR-001-572-678-0,ClCCC(=O)NCc1ccccc1,CBR-HVAC-09747: Calcium channel Blocker;
CBR-001-572-679-1,RFM-001-609-1,CBR-001-572-679-1,OCCN(CC(=O)N(C(Cc1ccccc1)(C)C)C)CC(=O)N(C(Cc1ccccc1)(C)C)C,CBR-HVAC-09927: Calcium channel L-type Inhibitor;
CBR-001-572-680-4,RFM-001-610-4,CBR-001-572-680-4,Clc1ccc2c(c1)C(O)CCCN2C(=O)c1ccc(cc1C)NC(=O)c1ccccc1C,"CBR-HVAC-01601: Cancer Associated Disorders, Treatment of;Renal Failure, Agents for;Heart Failure Therapy;Treatment of Renal Diseases;Liver and Biliary Tract Disorders, Treatment of;Cardiovascular Diseases (Not Specified); Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Antagonists; Vasopressin V2 receptor Antagonist; Vasopressin 2 antagonist; Diuretic"
CBR-001-572-681-5,RFM-001-611-5,CBR-001-572-681-5,Clc1cc2N=C(CSCc3ccccc3)NS(=O)(=O)c2cc1S(=O)(=O)N,CBR-HVAC-09546: Carbonic anhydrase Inhibitor; Antihypertensive; Diuretic
CBR-001-572-682-6,RFM-001-612-6,CBR-001-572-682-6,CCOc1ccc2c(c1)sc(n2)S(=O)(=O)N,CBR-HVAC-09580: Carbonic anhydrase Inhibitor;
CBR-001-572-683-7,RFM-001-613-7,CBR-001-572-683-7,CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2c(n1C)cccc2,"CBR-HVAC-04425: Cardioprotective Agents;Treatment of Renal Diseases;Hypertension, Treatment of;Cardiovascular Diseases (Not Specified);Alzheimer's Dementia, Treatment of ;Metabolic Disorders (Not Specified);Stroke, Treatment of;Diabetic Nephropathy, Agents for; Angiotensin AT1 Antagonists;PPARalpha Partial Agonists;PPARgamma Modulators;Signal Transduction Modulators; Angiotensin II receptor type 1 Inhibitor; Angiotensin II 1 antagonist"
CBR-001-572-684-8,RFM-001-614-8,CBR-001-572-684-8,O=C1O[C@H](CN1c1ccc(cc1)N1CCOCC1=O)CNC(=O)c1ccc(s1)Cl,CBR-HVAC-01425: Cardiovascular Diseases (Not Specified);Anticoagulants; Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways; Coagulation factor Xa Inhibitor; Direct Factor Xa inhibitor; Serine protease inhibitor
CBR-001-572-685-9,RFM-001-615-9,CBR-001-572-685-9,OC1CN(C2=CC(=O)C(=O)C=C12)C,CBR-HVAC-10072: Catechol-O-methyltransferase Inhibitor;
CBR-001-572-686-0,RFM-001-616-0,CBR-001-572-686-0,CO/N=C(\c1csc(n1)N)/C(=O)NC1C(=O)N2C1SCC(=C2C(=O)[O-])CSc1nc(=O)c(nn1C)O,CBR-HVAC-02329: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-687-1,RFM-001-617-1,CBR-001-572-687-1,Sc1cccc[n+]1[O-],CBR-HVAC-02367: Chelating agent; Iron absorption inhibitor
CBR-001-572-688-2,RFM-001-618-2,CBR-001-572-688-2,Fc1ccc(cc1)N1CCN(CC1)C(=O)Cn1nc(c(c1C)Cl)C(F)(F)F,CBR-HVAC-09324: Chemokine receptor Antagonist;
CBR-001-572-689-3,RFM-001-619-3,CBR-001-572-689-3,OC/C(=C\CCC1(C)C2CC3C1(C)C3C2)/C,CBR-HVAC-05898: Chemopreventive Agents; ; ;
CBR-001-572-690-6,RFM-001-620-6,CBR-001-572-690-6,COc1ccc(cc1O)c1cc(=O)c2c(o1)cc(cc2O)OC1OC(COC2OC(C)C(C(C2O)O)O)C(C(C1O)O)O,"CBR-HVAC-01830: Chemopreventive Agents;Treatment of Diabetic Complications;Hemorrhoid, Treatment of;Peripheral Vascular Disease, Treatment of; Aryl Hydrocarbon Receptor (AhR) Agonists;Signal Transduction Modulators; ; Membrane permeability inhibitor"
CBR-001-572-691-7,RFM-001-621-7,CBR-001-572-691-7,S=c1ssc(c1C)c1cnccn1,"CBR-HVAC-02478: Chemopreventive Agents;Treatment of Mucositis;Oncolytic Drugs;Liver and Biliary Tract Disorders, Treatment of; Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activators;Signal Transduction Modulators; ; Glutathione S transferase stimulant; Membrane integrity inhibitor; Membrane permeability enhancer; Angiogenesis inhibitor"
CBR-001-572-692-8,RFM-001-622-8,CBR-001-572-692-8,[O-]S(=O)(=O)CCSSCCS(=O)(=O)[O-],CBR-HVAC-00836: Chemoprotective Agents; ; ; Tubulin stimulant; Tubulin inhibitor
CBR-001-572-693-9,RFM-001-623-9,CBR-001-572-693-9,ClCC1CO1.C=CCNCCCCCC[N+](C)(C)C.CCCCCCCCCCNCC=C.NCC=C,CBR-HVAC-01709: Cholesterol 7-alpha hydroxylase Inhibitor; Cholesterol inhibitor
CBR-001-572-694-0,RFM-001-624-0,CBR-001-572-694-0,Cn1c(=O)n(C)c2c(c1=O)n(cn2)CC1OCCO1,"CBR-HVAC-01779: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Bronchodilators;Respiratory Disorders (Not Specified); Adenosine A1 Antagonists;Signal Transduction Modulators; Phosphodiesterase Inhibitor; Adenosine A1 receptor antagonist; Phosphodiesterase 4 inhibitor"
CBR-001-572-695-1,RFM-001-625-1,CBR-001-572-695-1,ONC(=O)CS(=O)C(c1ccccc1)c1ccccc1,CBR-HVAC-01981: CNS Stimulants;Antidepressants; ; Alpha-1 adrenergic receptor Agonist; Alpha adrenoreceptor agonist
CBR-001-572-696-2,RFM-001-626-2,CBR-001-572-696-2,CC(NC(=O)c1cccnc1)CNC(=O)c1cccnc1,CBR-HVAC-00897: Coagulation Disorders Therapy; Free Radical Scavengers;Lipid Peroxidation Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase; PARP) Inhibitors;Signal Transduction Modulators; POLY ADP-RIBOSE POLYMERASE; Poly (ADP-ribose) polymerase Inhibitor; Oxygen scavenger; Lipoxygenase inhibitor; Na+ K+ transporting ATPase inhibitor; Free radical scavenger
CBR-001-572-697-3,RFM-001-627-3,CBR-001-572-697-3,O=C(CN1CCCC1=O)NCCN(C(C)C)C(C)C,"CBR-HVAC-01712: Cognition Disorders, Treatment of; ; ; Acetylcholine receptor agonist"
CBR-001-572-698-4,RFM-001-628-4,CBR-001-572-698-4,O=C(c1ccccc1)C[n+]1cscc1,"CBR-HVAC-10772: Cognition Disorders, Treatment of;Symptomatic Antidiabetic Agents; ; ;"
CBR-001-572-699-5,RFM-001-629-5,CBR-001-572-699-5,CCN(C(=O)Oc1cccc(c1)[C@@H](N(C)C)C)C,"CBR-HVAC-01953: Cognition Disorders, Treatment of;Treatment of Substance Dependency;Alzheimer's Dementia, Treatment of ; Acetylcholinesterase (AChE) Inhibitors;Butyrylcholinesterase Inhibitors; Cholinesterase Inhibitor; Acetylcholinesterase inhibitor; Butyrylcholinesterase inhibitor"
CBR-001-572-700-1,RFM-001-630-8,CBR-001-572-700-1,O[C@@H]([C@@H](NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,"CBR-HVAC-01864: Colorectal Cancer Therapy;Anti-Herpes Virus Drugs;Anti-HIV Agents;Premalignant Conditions Therapy;Head and Neck Cancer Therapy;Systemic Lupus Erythematosus, Agents for;Cervical Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Severe Acute Respiratory Syndrome (SARS), Treatment of;Sarcoma Therapy;Glioblastoma Multiforme Therapy;Oncolytic Drugs;Hematological Cancer Therapy;Pancreatic Cancer Therapy; HIV-1 Protease Inhibitors;Liver Carboxylesterase 1 (CES1; PMPMEase) Inhibitors;Proteasome Inhibitors; Protease Inhibitor; HIV protease inhibitor"
CBR-001-572-701-2,RFM-001-631-9,CBR-001-572-701-2,COc1cc2c(cc1OCCCN1CCN(CC1)C)ncc(c2Nc1cc(OC)c(cc1Cl)Cl)C#N,"CBR-HVAC-05503: Colorectal Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Ischemic Stroke, Treatment of;Treatment of Renal Diseases;Leukemia Therapy;Myeloid Leukemia Therapy;Pancreatic Cancer Therapy;Glioblastoma Multiforme Therapy; Abl1 Kinase Inhibitors;Apoptosis Inducers;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Signal Transducer and Activator of Transcription 5 (STAT5) Inhibitors;Signal Transduction Modulators;Src Kinase Inhibitors; ABL; BCR-ABL; SRC; c-SRC Inhibitor; Src inhibitor; Bcr-Abl inhibitor; Apoptosis stimulant; Abl receptor tyrosine kinase inhibitor"
CBR-001-572-702-3,RFM-001-632-0,CBR-001-572-702-3,COc1cc2c(ncnc2cc1OCCCN1CCCC1)Oc1ccc2c(c1F)cc([nH]2)C,"CBR-HVAC-00059: Colorectal Cancer Therapy;Prostate Cancer Therapy;Melanoma Therapy;Myeloid Leukemia Therapy;Leukemia Therapy;Cancer Associated Disorders, Treatment of;Respiratory/Thoracic Cancer Therapy;Endocrine Cancer Therapy;Lymphoma Therapy;Small Cell Lung Cancer Therapy;Liver Cancer Therapy;Myelodysplastic Syndrome Therapy;Glioblastoma Multiforme Therapy;Digestive/Gastrointestinal Cancer Therapy;Gastric Cancer Therapy;Ovarian Cancer Therapy;Breast Cancer Therapy;Head and Neck Cancer Therapy;Solid Tumors Therapy;Sarcoma Therapy;Renal Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Angiogenesis Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; Vascular endothelial growth factor receptor Inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; C-kit inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor"
CBR-001-572-703-4,RFM-001-633-1,CBR-001-572-703-4,OCC(NC(=O)c1c(I)c(C(=O)NC(CO)CO)c(c(c1I)NC(=O)[C@@H](O)C)I)CO,CBR-HVAC-02084: Contrast Media; ; ; Not applicable
CBR-001-572-704-5,RFM-001-634-2,CBR-001-572-704-5,O=C(c1cccnc1Nc1cccc(c1)C(F)(F)F)OC1OC(=O)c2c1cccc2,"CBR-HVAC-01868: Correction of Mucus Abnormalities;Mucolytics;Antiarthritic Drugs; Calcium-activated Chloride Channels 1 Blockers;Mucin Production, Inhibitors; Calcium-activated chloride channel Blocker; Cyclooxygenase inhibitor"
CBR-001-572-705-6,RFM-001-635-3,CBR-001-572-705-6,ClCC(=O)C1(O)C(C)CC2C1(C)CC(O)C1(C2CCC2=CC(=O)C=CC12C)F,CBR-HVAC-01409: Corticosteroid agonist
CBR-001-572-706-7,RFM-001-636-4,CBR-001-572-706-7,O=C1c2ccccc2CN2N1Cc1ccccc1C2=O,CBR-HVAC-02666: Cyclooxygenase inhibitor
CBR-001-572-707-8,RFM-001-637-5,CBR-001-572-707-8,OC(=O)Cc1cc(n(c1C)c1ccc(cc1)Cl)C,CBR-HVAC-01028: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-572-708-9,RFM-001-638-6,CBR-001-572-708-9,O=C(Nc1ccccn1)Cc1ccc(cc1)c1ccccc1,CBR-HVAC-01276: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-572-709-0,RFM-001-639-7,CBR-001-572-709-0,O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC=C2c2cccnc2)C)C1)C,CBR-HVAC-02412: CYP17 Inhibitor; Unidentified pharmacological activity
CBR-001-572-710-3,RFM-001-640-0,CBR-001-572-710-3,COc1ncnc(c1)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08699: CYP2C Inhibitor;
CBR-001-572-711-4,RFM-001-641-1,CBR-001-572-711-4,Nc1ccc(cc1)S(=O)(=O)Nc1oc(c(n1)C)C,CBR-HVAC-08700: CYP2C Inhibitor;
CBR-001-572-712-5,RFM-001-642-2,CBR-001-572-712-5,O=C(C(c1cccs1)(c1cccs1)O)O[C@@H]1C[C@@H]2[C@@H]3[C@H]([C@H](C1)[N+]2(C)C)O3,"CBR-HVAC-01991: Long-acting muscarinic antagonist; Muscarinic M3 Receptor Antagonists; Muscarinic M3 receptor antagonist; Muscarinic Receptor Antagonists; Muscarinic acetylcholine receptor Antagonist; Signal Transduction Modulators; Anticholinergic; Asthma Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Cystic Fibrosis, Treatment of"
CBR-001-572-713-6,RFM-001-643-3,CBR-001-572-713-6,O=C(Nc1c(C)cccc1C)CN1CCCC1,CBR-HVAC-10117: Delta-aminolevulinate synthetase Inducer;
CBR-001-572-714-7,RFM-001-644-4,CBR-001-572-714-7,O[C@H]1C[C@H]2C[C@@H]([C@@]1(C)O)C2(C)C,CBR-HVAC-06548: Dermatologic Drugs; ; ;
CBR-001-572-715-8,RFM-001-645-5,CBR-001-572-715-8,O[C@H]1CN[C@@H](C1)C(=O)O,CBR-HVAC-06455: Dermatologic Drugs; ; ;
CBR-001-572-716-9,RFM-001-646-6,CBR-001-572-716-9,CCCCCCCCC(=O)NCc1ccc(c(c1)OC)O,CBR-HVAC-10011: Dermatologic Drugs; ; ;
CBR-001-572-717-0,RFM-001-647-7,CBR-001-572-717-0,CCOC(=O)c1ccccc1OC(=O)CCCCCCCC(=O)Oc1ccccc1C(=O)OCC,CBR-HVAC-05458: Dermatologic Drugs;Acne Therapy;Antipsoriatics; ; ; Unidentified pharmacological activity
CBR-001-572-718-1,RFM-001-648-8,CBR-001-572-718-1,C/C(=C\c1ccccc1)/C=C\1/SC(=S)N(C1=O)CC(=O)O,"CBR-HVAC-00797: Diabetic Nephropathy, Agents for;Diabetic Neuropathy, Agents for;Diabetic Retinopathy, Agents for;Diabetic Myocardiopathy, Agents for; Aldose Reductase Inhibitors; ALDOSE REDUCATASE Inhibitor; Aldose reductase inhibitor"
CBR-001-572-719-2,RFM-001-649-9,CBR-001-572-719-2,COc1ccc(cc1)C(C1(O)CCCCC1)CN(C)C,"CBR-HVAC-01731: Diabetic Neuropathy, Agents for;Antidepressants;Treatment of Hot Flushes;Urinary Incontinence Therapy;Neuropathy, Treatment of ;Generalized Anxiety Disorder (GAD), Treatment of;Posttraumatic Stress Disorder (PTSD), Treatment of;Treatment of Substance Dependency;Social Phobia, Treatment for;Anxiolytics;Neuropathic Pain, Treatment of; Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; Alpha-1 adrenergic receptor Inhibitor; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor"
CBR-001-572-720-5,RFM-001-650-2,CBR-001-572-720-5,OC1C(=O)C(O)C(=O)C(=O)C1=O,CBR-HVAC-10099: Diagnostic Agents; ; ;
CBR-001-572-721-6,RFM-001-651-3,CBR-001-572-721-6,O[C@H](COc1ccc(cc1)CCC(=O)OC[C@@H]1COC(O1)(C)C)CNCCNC(=O)N1CCOCC1,"CBR-HVAC-01443: Diagnostic Agents;Acute Myocardial Infarction, Treatment of;Antiarrhythmic Drugs; beta1-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Antagonist; Beta 1 adrenoreceptor antagonist"
CBR-001-572-722-7,RFM-001-652-4,CBR-001-572-722-7,Clc1cccc(c1)Nc1nc2cc(ccc2c2c1ccnc2)C(=O)O,CBR-HVAC-06770: Digestive/Gastrointestinal Cancer Therapy;Multiple Myeloma Therapy;Premalignant Conditions Therapy;Solid Tumors Therapy; Casein Kinase II (CK2) Inhibitors;Signal Transduction Modulators; Casein kinase II Inhibitor;
CBR-001-572-723-8,RFM-001-653-5,CBR-001-572-723-8,OC(=O)c1ccc(nc1)SSc1ccc(cn1)C(=O)O,CBR-HVAC-07677: Dihydrofolate reductase inhibitor
CBR-001-572-724-9,RFM-001-654-6,CBR-001-572-724-9,Nc1ccc(cc1)S(=O)(=O)Nc1ccc(nn1)Cl,CBR-HVAC-08684: Dihydropteroate synthase Inhibitor;
CBR-001-572-725-0,RFM-001-655-7,CBR-001-572-725-0,Nc1ccc(cc1)S(=O)(=O)Nc1nnc(s1)C,CBR-HVAC-09665: Dihydropteroate synthase Inhibitor;
CBR-001-572-726-1,RFM-001-656-8,CBR-001-572-726-1,CN(C(=N)NC(=N)N)C,"CBR-HVAC-01298: Disorders of Sexual Function and Reproduction, Treatment of;Antiobesity Drugs;Antiparkinsonian Drugs;Colorectal Cancer Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Female Reproductive System Cancer Therapy;Pancreatic Cancer Therapy;Liver and Biliary Tract Disorders, Treatment of;Breast Cancer Therapy;Multisystem Genetic Disorders, Treatment of ;Lymphocytic Leukemia Therapy;Type 2 Diabetes, Agents for;Antidiabetic Drugs;Melanoma Therapy;Adenomatous Polyposis Therapy;Gynecological Disorders, Treatment of ; AMP-Activated Protein Kinase (AMPK) Activators;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands;Insulin Sensitizers;Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; ; Gluconeogenesis inhibitor; Biguanide; Insulin sensitizer"
CBR-001-572-727-2,RFM-001-657-9,CBR-001-572-727-2,O=C1CC[C@]2(C(=C1)C=C[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]12CCC(=O)O1)C)C,CBR-HVAC-03161: Diuretics; Mineralocorticoid Receptor (MR) Antagonists;Signal Transduction Modulators; Mineralocorticoid receptor Antagonist;
CBR-001-572-728-3,RFM-001-658-0,CBR-001-572-728-3,CCN1CCCC(C1)OC(=O)C(c1ccccc1)c1ccccc1,CBR-HVAC-10012: DNA gyrase Inhibitor;
CBR-001-572-729-4,RFM-001-659-1,CBR-001-572-729-4,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-02037: DNA gyrase; DNA topoisomerase IV Inhibitor; Protein 50S ribosomal subunit inhibitor; Protein synthesis inhibitor
CBR-001-572-730-7,RFM-001-660-4,CBR-001-572-730-7,C1O[Pt]OC1=O,CBR-HVAC-03250
CBR-001-572-731-8,RFM-001-661-5,CBR-001-572-731-8,OCC(OCn1cnc2c1nc(N)[nH]c2=O)CO,CBR-HVAC-02435: DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-572-732-9,RFM-001-662-6,CBR-001-572-732-9,CCC(=O)C(C(=O)CC)CCCCCCOc1ccc(cc1Cl)OC,CBR-HVAC-01049: DNA synthesis inhibitor
CBR-001-572-733-0,RFM-001-663-7,CBR-001-572-733-0,O=C1C2=C(OC(CC2)(C)C)c2c(C1=O)cccc2,CBR-HVAC-00435: DNA topoisomerase I Inhibitor;
CBR-001-572-734-1,RFM-001-664-8,CBR-001-572-734-1,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccccc4cc3Cn1c2=O,CBR-HVAC-00106: DNA topoisomerase I Inhibitor; DNA topoisomerase I inhibitor
CBR-001-572-735-2,RFM-001-665-9,CBR-001-572-735-2,Sc1nc(O)c(c(n1)O)C(=O)Nc1ccccc1,CBR-HVAC-03278: Oncolytic Drugs;Uricosurics; DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs;Urate Transporter 1 (URAT1) Inhibitors; DNA topoisomerase II Inhibitor;
CBR-001-572-736-3,RFM-001-666-0,CBR-001-572-736-3,CC(CC1C(=O)N2CCCC2C2(N1C(=O)C(O2)(NC(=O)C1CN(C)C2C(C1)c1cccc3c1c(C2)c[nH]3)C(C)C)O)C,CBR-HVAC-01413: DOPAMINE RECEPTOR Agonist; Alpha adrenoreceptor antagonist; Prolactin inhibitor; Alpha 2 adrenoreceptor agonist; Dopamine D2 receptor agonist
CBR-001-572-737-4,RFM-001-667-1,CBR-001-572-737-4,OC(=O)C(Cc1ccccc1)NC(=O)C,CBR-HVAC-02364: Dopamine receptor agonist; Dopamine reuptake inhibitor; Acetylcholine receptor agonist
CBR-001-572-738-5,RFM-001-668-2,CBR-001-572-738-5,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-02434: Dopamine receptor D2 Antagonist; 5 Hydroxytryptamine receptor antagonist
CBR-001-572-739-6,RFM-001-669-3,CBR-001-572-739-6,Fc1ccc2c(c1)c1CN(CCc1n2CC(=O)O)C(=O)c1cccc2c1cccc2,"CBR-HVAC-06881: Drugs for Allergic Rhinitis;Hair Growth Stimulants;Atopic Dermatitis, Agents for;Asthma Therapy; Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists;Signal Transduction Modulators; ; CRTH2 antagonist"
CBR-001-572-740-9,RFM-001-670-6,CBR-001-572-740-9,Fc1ccc(cc1)Cn1c(nc2c1cccc2)N1CCC(CC1)N(c1nccc(=O)[nH]1)C,"CBR-HVAC-01766: Drugs for Allergic Rhinitis;Urticaria, Treatment for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Potassium channel hERG Inhibitor; Histamine H1 receptor antagonist; Membrane permeability inhibitor"
CBR-001-572-741-0,RFM-001-671-7,CBR-001-572-741-0,Clc1ccc2c(c1)CCc1c(C2=C2CCNCC2)nccc1,"CBR-HVAC-01740: Drugs for Allergic Rhinitis;Urticaria, Treatment for;Antipruritics; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-572-742-1,RFM-001-672-8,CBR-001-572-742-1,CC(=O)OCC(CCn1cnc2c1nc(N)nc2)COC(=O)C,"CBR-HVAC-02103: Ear disorders, treatment of;Anti-Herpes Virus Drugs;Anti-Herpes Simplex Virus Drugs;Anti-Hepatitis B Virus Drugs;Anti-Varicella Zoster Virus Drugs; DNA Polymerase Inhibitors; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor"
CBR-001-572-743-2,RFM-001-673-9,CBR-001-572-743-2,COc1ccc2c(c1)ccc(c2)OCC1(CN(C1)C(=O)c1ccc(cc1)F)C(=O)O,CBR-HVAC-11878: Endometriosis Therapy; Prostanoid EP2 Antagonists;Signal Transduction Modulators; Prostaglandin EP2 receptor Antagonist;
CBR-001-572-744-3,RFM-001-674-0,CBR-001-572-744-3,Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C,CBR-HVAC-09577: Estrogen receptor Agonist;
CBR-001-572-745-4,RFM-001-675-1,CBR-001-572-745-4,CC[C@H]([C@@H](c1ccc(cc1)O)CC)c1ccc(cc1)O,CBR-HVAC-09796: Estrogen receptor Agonist;
CBR-001-572-746-5,RFM-001-676-2,CBR-001-572-746-5,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OC,CBR-HVAC-09615: Estrogen receptor Inhibitor;
CBR-001-572-747-6,RFM-001-677-3,CBR-001-572-747-6,OCCCSC[C@@H](C(=O)O)N,CBR-HVAC-01883: Expectorants; ; ; Mucolytic agent
CBR-001-572-748-7,RFM-001-678-4,CBR-001-572-748-7,O=C(c1ccc2c(c1)OCO2)N1CCCCC1,"CBR-HVAC-04680: Fatigue, Treatment of;Cognition Disorders, Treatment of; AMPA Receptor Modulators;Signal Transduction Modulators; ;"
CBR-001-572-749-8,RFM-001-679-5,CBR-001-572-749-8,O=C(Nc1ccc(cc1)c1nc(nc(n1)N1CCOCC1)N1CCOCC1)Nc1ccc(cc1)C(=O)N1CCC(CC1)N(C)C,CBR-HVAC-00658: Female Reproductive System Cancer Therapy;Colorectal Cancer Therapy;Solid Tumors Therapy;Myeloid Leukemia Therapy; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; Protein kinase Inhibitor; PI3 kinase inhibitor; mTOR kinase inhibitor
CBR-001-572-750-1,RFM-001-680-8,CBR-001-572-750-1,COC(=O)c1ccc2c(c1)NC(=O)/C/2=C(/c1ccccc1)\Nc1ccc(cc1)N(C(=O)CN1CCN(CC1)C)C,CBR-HVAC-02262: FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FMS-LIKE TYROSINE KINASE 3; LCK KINASE; LYN KINASE; PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA; PLATELET-DERIVED GROWTH FACTOR RECEPTOR BETA; SRC KINASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 Inhibitor; Inhibitor; Inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Src inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; LYN tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor
CBR-001-572-751-2,RFM-001-681-9,CBR-001-572-751-2,CN1CCN2C(C1)c1ccccc1Cc1c2nccc1,"CBR-HVAC-01786: Fibromyalgia, Treatment of;Sleep Apnea, Treatment of;Treatment of Eating Disorders;Antidepressants;Sleep Disorders, Treatment of;Treatment of Substance Dependency; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators;5-HT2A Antagonists;5-HT3 Antagonists; Dopamine receptor; 5-Hydroxytryptamine receptor Antagonist; Antagonist; Alpha 2 adrenoreceptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-572-752-3,RFM-001-682-0,CBR-001-572-752-3,CN(CC(C1(O)CCCCC1)c1ccc(cc1)O)C,"CBR-HVAC-02249: Fibromyalgia, Treatment of;Treatment of Postmenopausal Syndrome ;Neuropathic Pain, Treatment of;Antidepressants; Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; Norepinephrine transporter; 5-Hydroxytryptamine transporter Antagonist; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor"
CBR-001-572-753-4,RFM-001-683-1,CBR-001-572-753-4,OCc1c(CSSCc2cnc(c(c2CO)O)C)cnc(c1O)C,CBR-HVAC-10038: GABA receptor Inhibitor;
CBR-001-572-754-5,RFM-001-684-2,CBR-001-572-754-5,CN1CCN(CC1)C(=O)O[C@H]1c2nccnc2C(=O)N1c1ccc(cn1)Cl,CBR-HVAC-00080: GABA receptor; GABAA RECEPTOR Agonist; Non-benzodiazepine hypnotic; Benzodiazepine receptor agonist; GABA A receptor agonist
CBR-001-572-755-6,RFM-001-685-3,CBR-001-572-755-6,CCC(c1ccccc1)(C(=O)N)C(=O)N,CBR-HVAC-09694: GABA-A receptor Agonist;
CBR-001-572-756-7,RFM-001-686-4,CBR-001-572-756-7,CCC1(C)CC(=O)NC(=O)C1,CBR-HVAC-09748: GABA-A receptor Antagonist;
CBR-001-572-757-8,RFM-001-687-5,CBR-001-572-757-8,COc1c(OC)ccc2c1C(=O)O[C@@H]2[C@@H]1N(C)CCc2c1cc1OCOc1c2,CBR-HVAC-09842: GABA-A receptor Inhibitor;
CBR-001-572-758-9,RFM-001-688-6,CBR-001-572-758-9,O[C@@H]1CC[C@]2([C@@H](C1)CCC1C2C(=O)C[C@]2(C1CCC2C(=O)C)C)C,CBR-HVAC-02825: GABA-A receptor Modulator; Chloride channel agonist; General pump inhibitor
CBR-001-572-759-0,RFM-001-689-7,CBR-001-572-759-0,FC(COCC(F)(F)F)(F)F,CBR-HVAC-10266: Gamma-aminobutyric acid receptor Blocker;
CBR-001-572-760-3,RFM-001-690-0,CBR-001-572-760-3,Clc1ccc(cc1)C(=O)NC(C(=O)O)Cc1c[nH]c2c1cccc2,CBR-HVAC-00125: Gastric Antisecretory Drugs;Antiulcer Drugs; ; CCK/GASTRIN RECEPTOR Antagonist; Gastrin inhibitor; CCK receptor antagonist
CBR-001-572-761-4,RFM-001-691-1,CBR-001-572-761-4,O=C(N1CCN(CC1)C(=O)c1cc(ccc1F)Cc1n[nH]c(=O)c2c1cccc2)C1CC1,CBR-HVAC-00899: Gastric Cancer Therapy;Small Cell Lung Cancer Therapy;Prostate Cancer Therapy;Breast Cancer Therapy;Female Reproductive System Cancer Therapy;Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Head and Neck Cancer Therapy;Pancreatic Cancer Therapy;Colorectal Cancer Therapy;Sarcoma Therapy;Melanoma Therapy; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors;Poly(ADP-ribose)polymerase-3 (PARP-3; ARTD3) Inhibitors;Signal Transduction Modulators; POLY [ADP-RIBOSE] POLYMERASE Inhibitor; ADP ribose polymerase 1 inhibitor; ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor
CBR-001-572-762-5,RFM-001-692-2,CBR-001-572-762-5,COc1cc(cc(c1OC)OC)C(=S)N1CCOCC1,CBR-HVAC-01818: Gastrin inhibitor
CBR-001-572-763-6,RFM-001-693-3,CBR-001-572-763-6,O[C@@H]1CC[C@H](CC1)NCc1cc(Br)cc(c1N)Br,"CBR-HVAC-03593: Gaucher's Disease, Agents for;Mucolytics; Glucosylceramidase (beta-Glucocerebrosidase; beta-Glucosidase) Inhibitors; Sodium channel Blocker; Glucosylceramidase stimulant"
CBR-001-572-764-7,RFM-001-694-4,CBR-001-572-764-7,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,"CBR-HVAC-00381: Generalized Anxiety Disorder (GAD), Treatment of;Antiepileptic Drugs;Respiratory Disorders (Not Specified);Anxiolytics;Treatment of Substance Dependency;Autism, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Signal Transduction Modulators;5-HT1A Receptor Partial Agonists; Melatonin receptor; 5-HT 1a receptor Agonist; Modulator; 5 Hydroxytryptamine 1A receptor agonist"
CBR-001-572-765-8,RFM-001-695-5,CBR-001-572-765-8,O=C1CC[C@]2(C(=C1)C(=CC1C2CC[C@]2(C1CC[C@]2(OC(=O)C)C(=O)C)C)C)C,"CBR-HVAC-01355: Gynecological Disorders, Treatment of ;Solid Tumors Therapy;Psychiatric Disorders (Not Specified);Treatment of AIDS-Associated Disorders;Female Reproductive System Cancer Therapy;Breast Cancer Therapy;Treatment of Cachexia;Cancer Associated Disorders, Treatment of; Progesterone Receptor Agonists;Signal Transduction Modulators; MINERALOCORTICOID RECEPTOR Inhibitor; Antagonist; Progesterone receptor agonist; DNA inhibitor"
CBR-001-572-766-9,RFM-001-696-6,CBR-001-572-766-9,O=C1C=CC2(C(N1)CCC1C2CCC2(C1CCC2C(=O)NC(C)(C)C)C)C,CBR-HVAC-00096: Hair Growth Stimulants;Benign Prostatic Hyperplasia Therapy;Hirsutism Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Ophthalmic Drugs;Treatment of Male Sexual Dysfunction;Chemopreventive Agents; Androgen Receptor Antagonists;Signal Transduction Modulators;Steroid 5alpha-Reductase Inhibitors; 5 ALPHA-REDUCTASE Inhibitor; 5 Alpha reductase Type II inhibitor
CBR-001-572-767-0,RFM-001-697-7,CBR-001-572-767-0,Oc1cc(O)c2c(c1)oc(c(c2=O)O)c1cc(O)c(c(c1)O)O,"CBR-HVAC-02365: Hair Growth Stimulants;Lipoprotein Disorders, Treatment of ;Oncolytic Drugs;Immunosuppressants;Chemopreventive Agents;Allergy, Treatment of;Antidiabetic Drugs; Androgen Receptor Ligands;Antioxidants;Cytochrome P450 CYP3A4 Inhibitors;Signal Transduction Modulators; Akt serine/threonine kinase Inhibitor; RNA directed DNA polymerase inhibitor"
CBR-001-572-768-1,RFM-001-698-8,CBR-001-572-768-1,Nc1ccn(c(=O)n1)[C@@H]1O[C@@H]([C@]([C@H]1O)(O)C#C)CO,CBR-HVAC-00670: Head and Neck Cancer Therapy;Solid Tumors Therapy; Apoptosis Inducers;DNA-Directed RNA Polymerase Inhibitors; RNA POLYMERASE Inhibitor; RNA synthesis inhibitor; RNA polymerase inhibitor
CBR-001-572-769-2,RFM-001-699-9,CBR-001-572-769-2,O=c1ccc2c([nH]1)ccnc2C,CBR-HVAC-03372: Heart Failure Therapy; ; Phosphodiesterase 3 Inhibitor; Phosphodiesterase inhibitor
CBR-001-572-770-5,RFM-001-700-5,CBR-001-572-770-5,COc1ccc(cc1)c1nc2c([nH]1)ccc(c2)C1=NNC(=O)CC1C,CBR-HVAC-01828: Heart Failure Therapy; Calcium Sensitizers;Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase Inhibitor; Phosphodiesterase 3 inhibitor; Calcium sensitizer
CBR-001-572-771-6,RFM-001-701-6,CBR-001-572-771-6,O=C1NC(c2c1cccc2)(O)c1ccc(c(c1)S(=O)(=O)N)Cl,"CBR-HVAC-03145: Heart Failure Therapy;Diabetes Insipidus, Agents for;Diuretics;Hypertension, Treatment of; Carbonic Anhydrase Type VII Inhibitors; Carbonic anhydrase Inhibitor;"
CBR-001-572-772-7,RFM-001-702-7,CBR-001-572-772-7,CCCCc1ncc(n1Cc1ccc(cc1)C(=O)O)/C=C(/C(=O)O)\Cc1cccs1,"CBR-HVAC-01647: Heart Failure Therapy;Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor Antagonist; Angiotensin II 1 antagonist"
CBR-001-572-773-8,RFM-001-703-8,CBR-001-572-773-8,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1ccco1,"CBR-HVAC-02185: Heart Failure Therapy;Hypertension, Treatment of;Treatment of Alcohol Dependency;Posttraumatic Stress Disorder (PTSD), Treatment of;Benign Prostatic Hyperplasia Therapy;Mood Disorders, Treatment of;Smoking Cessation, Aid to;Raynaud's Phenomenon, Treatment for ; alpha1-Adrenoceptor Antagonists;Apoptosis Inducers;CDK1 Inhibitors;Signal Transduction Modulators; Alpha-1 adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist"
CBR-001-572-774-9,RFM-001-704-9,CBR-001-572-774-9,CC(NC(=O)NS(=O)(=O)c1cnccc1Nc1cccc(c1)C)C,"CBR-HVAC-02238: Heart Failure Therapy;Loop Diuretics;Diuretics;Hypertension, Treatment of; ; Thromboxane A2 receptor Inhibitor; Diuretic; Thromboxane A2 receptor antagonist; Aldosterone antagonist; Electrolyte reabsorption inhibitor; TP receptor antagonist"
CBR-001-572-775-0,RFM-001-705-0,CBR-001-572-775-0,O=C[C@@]12CC[C@@H](C[C@@]2(O)CCC2C1CC[C@]1([C@]2(O)CC[C@@H]1C1=CC(=O)OC1)C)O,CBR-HVAC-06012: Heart Failure Therapy;Positive Inotropic Agents;Oncolytic Drugs; Na+/K+-ATPase Inhibitors; ;
CBR-001-572-776-1,RFM-001-706-1,CBR-001-572-776-1,O=C(c1ccccc1)C[n+]1csc(c1C)C,"CBR-HVAC-05042: Heart Failure Therapy;Type 1 Diabetes, Agents for;Treatment of Erectile Dysfunction;Diabetic Nephropathy, Agents for;Treatment of Renal Diseases;Hypertension, Treatment of; AGE Crosslink Breakers; ; Glycosylation inhibitor"
CBR-001-572-777-2,RFM-001-707-2,CBR-001-572-777-2,Fc1ccc2c(c1)n(C)cc(c2=O)S(=O)C,CBR-HVAC-02834: Heart Failure Therapy;Vasodilators; ; ; Phosphodiesterase 3 inhibitor
CBR-001-572-778-3,RFM-001-708-3,CBR-001-572-778-3,OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)c2c(c3c1nccc3)cccc2,CBR-HVAC-07282: Hematological Cancer Therapy;Oncolytic Drugs; Notch Signaling Inhibitors; NOTCH-1 Inhibitor;
CBR-001-572-779-4,RFM-001-709-4,CBR-001-572-779-4,CC[C@@H](c1nc2cccc(c2c(=O)n1c1ccccc1)F)Nc1ncnc2c1nc[nH]2,"CBR-HVAC-06320: Hematological Cancer Therapy;Oncolytic Drugs;Hematopoiesis Disorders Therapy;Drugs for Allergic Rhinitis;Lymphoma Therapy;Non-Hodgkin's Lymphoma Therapy;Lymphocytic Leukemia Therapy;Inflammation, Treatment of;Pancreatic Cancer Therapy; Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators; PHOSPHOINOSITIDE-3 KINASE DELTA Inhibitor; PI3 kinase delta inhibitor; Protein kinase inhibitor; CC chemokine ligand antagonist"
CBR-001-572-780-7,RFM-001-710-7,CBR-001-572-780-7,COCCN1CCN(CC1)Cc1ccc(cc1)c1n[nH]c2c1C(=O)c1c2cccc1NC(=O)NN1CCOCC1,CBR-HVAC-06151: Hematological Cancer Therapy;Solid Tumors Therapy; Apoptosis Inducers;CDK/Cyclin Complex Inhibitors;Signal Transduction Modulators; CDK-Cyclin Inhibitor;
CBR-001-572-781-8,RFM-001-711-8,CBR-001-572-781-8,CN1CCCN(CC1)c1ccc2c(n1)n1c(c(c2=O)C(=O)NCc2cnc(cn2)C)sc2c1cccc2,CBR-HVAC-06748: Hematological Cancer Therapy;Solid Tumors Therapy; RNA Polymerase Inhibitors; RNA polymerase I Inhibitor;
CBR-001-572-782-9,RFM-001-712-9,CBR-001-572-782-9,CC(C(=O)N)C,CBR-HVAC-04532: Hematopoietic Agents; ; ; Globin stimulant; Gene expression stimulant
CBR-001-572-783-0,RFM-001-713-0,CBR-001-572-783-0,COc1cc2C[C@](C)(O)[C@@H](C)Cc3c(c2c(c1OC)OC)c(OC)c1c(c3)OCO1,"CBR-HVAC-03318: Hepatoprotectants;Ischemic Stroke, Treatment of;Agents for Liver Fibrosis; Lipid Peroxidation Inhibitors; ;"
CBR-001-572-784-1,RFM-001-714-1,CBR-001-572-784-1,OC[C@]1(C)C(O)CCC2([C@@H]1CCC(=C)[C@H]2C/C=C\1/C(O)COC1=O)C,"CBR-HVAC-06122: Hepatoprotectants;Treatment of Autoimmune Diseases;Antidiabetic Drugs;Choleretic Agents;Anti-HIV Agents;Antiarthritic Drugs;Oncolytic Drugs;Immunostimulants;Neurodegenerative Diseases, Treatment of;Antibacterial Drugs; Apoptosis Inhibitors;Nitric Oxide (NO) Production Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; ;"
CBR-001-572-785-2,RFM-001-715-2,CBR-001-572-785-2,OC(c1ccccc1)(c1ccccc1)C1CCNCC1,CBR-HVAC-09742: Histamine H1 receptor Antagonist;
CBR-001-572-786-3,RFM-001-716-3,CBR-001-572-786-3,OC(=O)C(c1ccc(cc1)C(CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O)O)(C)C,CBR-HVAC-02423: Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist
CBR-001-572-787-4,RFM-001-717-4,CBR-001-572-787-4,OC(c1ccccc1)(c1ccccc1)C1CN2CCC1CC2,CBR-HVAC-10307: Histamine H1 receptor Blocker;
CBR-001-572-788-5,RFM-001-718-5,CBR-001-572-788-5,CN(CCC(c1ccccn1)c1ccc(cc1)Cl)C,CBR-HVAC-02332: Histamine H1 receptor Inhibitor; Histamine receptor antagonist
CBR-001-572-789-6,RFM-001-719-6,CBR-001-572-789-6,N#CN/C(=N\CCSCc1nc[nH]c1C)/NC,CBR-HVAC-02429: Histamine H2 receptor Inhibitor; Unidentified pharmacological activity
CBR-001-572-790-9,RFM-001-720-9,CBR-001-572-790-9,O=C(C12CC3CC(C2)CC(C1)C3)Nc1ccccc1C(=O)O,CBR-HVAC-07874: Histamine release inhibitor; 5 Hydroxytryptamine release inhibitor
CBR-001-572-791-0,RFM-001-721-0,CBR-001-572-791-0,N#CC(c1cc(C)c(cc1Cl)NC(=O)c1cc(I)cc(c1O)I)c1ccc(cc1)Cl,CBR-HVAC-10082: Histidine kinase Inhibitor;
CBR-001-572-792-1,RFM-001-722-1,CBR-001-572-792-1,O=C(C(=O)NC1CC(C)(C)NC(C1)(C)C)Nc1ccc(cc1)Cl,CBR-HVAC-09494: HIV GP120 Inhibitor;
CBR-001-572-793-2,RFM-001-723-2,CBR-001-572-793-2,NC(=O)C1CCCc2c1[nH]c1c2cc(cc1)Cl,"CBR-HVAC-00655: Huntington's Disease, Treatment of;Pharmacological Tools; NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Inhibitors; Sirtuin 1 Inhibitor; Sirtuin 1 inhibitor"
CBR-001-572-794-3,RFM-001-724-3,CBR-001-572-794-3,CCOC(=O)[C@@H](N[C@H](C(=O)N1Cc2cc(OC)c(cc2C[C@H]1C(=O)O)OC)C)CCc1ccccc1,"CBR-HVAC-00962: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-572-795-4,RFM-001-725-4,CBR-001-572-795-4,CC(OC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC1CN(C1)C(c1ccccc1)c1ccccc1)N)C,"CBR-HVAC-01546: Hypertension, Treatment of; Calcium Channel Blockers; Calcium channel Antagonist; L-type calcium channel antagonist"
CBR-001-572-796-5,RFM-001-726-5,CBR-001-572-796-5,COc1nc(C)nc(c1NC1=NCCN1)Cl,"CBR-HVAC-01856: Hypertension, Treatment of; Imidazoline I1 Receptor Agonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Agonist; Imidazoline I1 receptor agonist; Alpha 2 adrenoreceptor agonist"
CBR-001-572-797-6,RFM-001-727-6,CBR-001-572-797-6,C1CN=C(O1)NC(C1CC1)C1CC1,"CBR-HVAC-02090: Hypertension, Treatment of; Imidazoline I1 Receptor Agonists;Signal Transduction Modulators; Imidazoline receptor 1 Agonist; Imidazoline I1 receptor agonist; Alpha 2 adrenoreceptor agonist"
CBR-001-572-798-7,RFM-001-728-7,CBR-001-572-798-7,CC(C(C)(C)C)N/C(=N/C#N)/Nc1ccncc1,"CBR-HVAC-01550: Hypertension, Treatment of; K(ATP) Channel Activators; Potassium channel Opener; Potassium channel agonist"
CBR-001-572-799-8,RFM-001-729-8,CBR-001-572-799-8,COC([C@@H](C(=O)O)Oc1nc(OC)cc(n1)OC)(c1ccccc1)c1ccccc1,"CBR-HVAC-04787: Hypertension, Treatment of;Acute Myocardial Infarction, Treatment of;Restenosis Treatment of;Heart Failure Therapy; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor; Endothelin B receptor Antagonist; Endothelin A receptor antagonist"
CBR-001-572-800-4,RFM-001-730-1,CBR-001-572-800-4,COC(=O)C1=C(C)NC(=C(C1c1ccccc1OC(F)F)C(=O)OC)C,"CBR-HVAC-01128: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Calcium channel Blocker; Calcium channel antagonist"
CBR-001-572-801-5,RFM-001-731-2,CBR-001-572-801-5,CCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1Cl)Cl)C(=O)OC)C,"CBR-HVAC-01493: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Calcium channel Blocker; L-type calcium channel antagonist"
CBR-001-572-802-6,RFM-001-732-3,CBR-001-572-802-6,COC(=O)C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])C(=O)OCC(C)C)C,"CBR-HVAC-01801: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Calcium channel Blocker; L-type calcium channel antagonist"
CBR-001-572-803-7,RFM-001-733-4,CBR-001-572-803-7,NCCOCC1=C(C(=O)OCC)C(C(=C(N1)C)C(=O)OC)c1ccccc1Cl,"CBR-HVAC-02781: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Dihydropyridine calcium channel Blocker; Calcium channel antagonist"
CBR-001-572-804-8,RFM-001-734-5,CBR-001-572-804-8,COC(=O)CCc1ccc(cc1)OCC(CNC(C)C)O,"CBR-HVAC-01381: Hypertension, Treatment of;Antiarrhythmic Drugs; beta1-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Blocker; Beta 1 adrenoreceptor agonist"
CBR-001-572-805-9,RFM-001-735-6,CBR-001-572-805-9,COC(=O)C1=C(C)NC(=C(C1c1cccc2c1non2)C(=O)OC(C)C)C,"CBR-HVAC-00013: Hypertension, Treatment of;Bipolar Disorder, Treatment of;Antiparkinsonian Drugs;Treatment of Opioid Dependency;Cognition Disorders, Treatment of; Calcium Channel Blockers; Calcium channel Blocker; L-type calcium channel antagonist"
CBR-001-572-806-0,RFM-001-736-7,CBR-001-572-806-0,CC(=O)SCCC(=O)N1[C@@H](C)CCC[C@H]1C(=O)O,"CBR-HVAC-04593: Hypertension, Treatment of;Heart Failure Therapy; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor;"
CBR-001-572-807-1,RFM-001-737-8,CBR-001-572-807-1,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1)C,"CBR-HVAC-01799: Hypertension, Treatment of;Lipoprotein Disorders, Treatment of ; Calcium Channel Blockers; Calcium channel Antagonist; L-type calcium channel antagonist"
CBR-001-572-808-2,RFM-001-738-9,CBR-001-572-808-2,CCCOCCn1c2cc(ncc2nc(c1=O)N1CCN(CC1)CCO)c1ccc(nc1)OC,"CBR-HVAC-07004: Hypertension, Treatment of;Stroke, Treatment of; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; ;"
CBR-001-572-809-3,RFM-001-739-0,CBR-001-572-809-3,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1CCCO1,"CBR-HVAC-03365: Hypertension, Treatment of;Urologic Drugs;Benign Prostatic Hyperplasia Therapy; alpha1-Adrenoceptor Antagonists;Phosphoglycerate Kinase 1 (Pgk1) Activators;Signal Transduction Modulators; Alpha-1 adrenergic receptor Inhibitor; Alpha 1 adrenoreceptor antagonist"
CBR-001-572-810-6,RFM-001-740-3,CBR-001-572-810-6,Clc1ccc(c(c1)Nc1ccccc1C(=O)O)C(=O)O,"CBR-HVAC-01941: Immunomodulators;Rheumatoid Arthritis, Treatment of; ; ; Immunosuppressant"
CBR-001-572-811-7,RFM-001-741-4,CBR-001-572-811-7,O=C1CCC(N1)C(=O)N1CSCC1C(=O)O,CBR-HVAC-01944: Immunostimulants; ; ; T cell stimulant; Interleukin 2 agonist; Interferon receptor agonist
CBR-001-572-812-8,RFM-001-742-5,CBR-001-572-812-8,Nc1nc(O)c(c(n1)c1ccccc1)Br,CBR-HVAC-01172: Immunostimulants;Bladder Cancer Therapy ; Interferon Inducers;Signal Transduction Modulators; ; Interferon receptor agonist
CBR-001-572-813-9,RFM-001-743-6,CBR-001-572-813-9,N#Cc1ccc(cc1)[C@@H]1CN(C[C@]21N(C)C(=O)N(C2=O)c1cc(Cl)cc(c1)Cl)Cc1scc(c1)C(=O)O,CBR-HVAC-06399: Immunosuppressants;Antipsoriatics; Cell Adhesion Inhibitors;Integrin alphaLbeta2 (LFA-1) Antagonists;LFA-1/ICAM-1 Interaction Inhibitors;Signal Transduction Modulators; LFA-1 Antagonist;
CBR-001-572-814-0,RFM-001-744-7,CBR-001-572-814-0,ClCCN(P1(=O)NCCCO1)CCCl,"CBR-HVAC-02848: Immunosuppressants;Melanoma Therapy;Multisystem Genetic Disorders, Treatment of ;Treatment of Renal Diseases;Hematopoiesis Disorders Therapy;Systemic Lupus Erythematosus, Agents for;Inflammatory Bowel Disease, Agents for;Ovarian Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Scleroderma, Agents for;Multiple Myeloma Therapy;Endocrine Cancer Therapy;Neurologic Cancer Therapy;Oncolytic Drugs;Disease-Modifying Anti-Rheumatic Drugs;Treatment of Autoimmune Diseases;Neurologic Drugs (Miscellaneous);Lymphoma Therapy; Apoptosis Inducers;BCL2 Expression Inhibitors;LGALS1 Expression Inhibitors; ;"
CBR-001-572-815-1,RFM-001-745-8,CBR-001-572-815-1,COc1ccc2c(c1)sc(n2)NC(=O)Nc1ccccc1,"CBR-HVAC-05613: Immunosuppressants;Systemic Lupus Erythematosus, Agents for; ; ;"
CBR-001-572-816-2,RFM-001-746-9,CBR-001-572-816-2,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc(c1O)C(=O)N,"CBR-HVAC-03371: Immunosuppressants;Treatment of Transplant Rejection;Treatment of Renal Diseases;Treatment of Autoimmune Diseases;Rheumatoid Arthritis, Treatment of; Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors; Inosine-5'-monophosphate dehydrogenase Inhibitor;"
CBR-001-572-817-3,RFM-001-747-0,CBR-001-572-817-3,Fc1ccc(cc1)C(=O)C1CN(C)CCC1(O)c1ccc(cc1)F,"CBR-HVAC-01118: Inflammation, Treatment of; ; ; Unidentified pharmacological activity"
CBR-001-572-818-4,RFM-001-748-1,CBR-001-572-818-4,OCCNC(=O)/C=C/c1ccccc1,"CBR-HVAC-01976: Inflammation, Treatment of;Muscle Spasms, Drugs for;Antispastic Drugs and Drugs for Muscle Spasms; ; ; Calcium channel antagonist; Platelet activating factor antagonist; Bradykinin receptor antagonist"
CBR-001-572-819-5,RFM-001-749-2,CBR-001-572-819-5,O=C(C1CC1)Nc1nn2c(n1)cccc2c1ccc(cc1)C(=O)N1CC(C1)(C)C,"CBR-HVAC-07084: Inflammatory Bowel Disease, Agents for;Antipsoriatics;Antiarthritic Drugs;Systemic Lupus Erythematosus, Agents for; Jak1 Inhibitors;Signal Transduction Modulators; ; Janus kinase 1 inhibitor"
CBR-001-572-820-8,RFM-001-750-5,CBR-001-572-820-8,CN1CCN(CC1)C(=O)c1nc2c([nH]1)cc(cc2)Cl,"CBR-HVAC-12039: Inflammatory Bowel Disease, Agents for;Drugs for Allergic Rhinitis;Antiallergy/Antiasthmatic Drugs; Histamine H4 Receptor Antagonists;Signal Transduction Modulators; Histamine H4 receptor Antagonist;"
CBR-001-572-821-9,RFM-001-751-6,CBR-001-572-821-9,O=C1CCC(C(=O)N1)N1C(=O)c2c(C1=O)cccc2,"CBR-HVAC-02784: Inflammatory Bowel Disease, Agents for;Leukemia Therapy;Myelodysplastic Syndrome Therapy;Dental Agents;Multiple Sclerosis, Agents for;Musculoskeletal Cancer Therapy;Ovarian Cancer Therapy;Analgesic Drugs;Non-Hodgkin's Lymphoma Therapy;Cognition Disorders, Treatment of;Melanoma Therapy;Anti-HIV Agents;Glioblastoma Multiforme Therapy;Treatment of Cachexia;Small Cell Lung Cancer Therapy;Antiarthritic Drugs;Amyotrophic Lateral Sclerosis, Agents for;Amyloidosis, Treatment of;Prostate Cancer Therapy;Breast Cancer Therapy;Kaposi's Sarcoma Therapy;Brain Cancer Therapy;Female Reproductive System Cancer Therapy;Treatment of AIDS-Associated Disorders;Neurologic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Multiple Myeloma Therapy;Liver Cancer Therapy;Neuropathy, Treatment of ;Neurologic Drugs (Miscellaneous);Lymphocytic Leukemia Therapy;Colorectal Cancer Therapy;Myeloid Leukemia Therapy;Renal Cancer Therapy;Treatment of Leprosy;Lymphoma Therapy;Scleroderma, Agents for;Interstitial Lung Diseases, Treatment of;Pancreatic Disorders, Treatment of;Age-Related Macular Degeneration, Treatment of; Angiogenesis Inhibitors;Cereblon (CRBN) Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; TNF alpha Inhibitor; Tumour necrosis factor alpha antagonist"
CBR-001-572-822-0,RFM-001-752-7,CBR-001-572-822-0,CN1CCN(CC1)c1nc2ccccc2c(n1)C1=C(C(=O)NC1=O)c1c[nH]c2c1cccc2,"CBR-HVAC-05714: Inflammatory Bowel Disease, Agents for;Non-Hodgkin's Lymphoma Therapy;Treatment of Transplant Rejection;Melanoma Therapy;Antipsoriatics;Immunomodulators;Ophthalmic Drugs; Protein Kinase PKC alpha Inhibitors;Protein Kinase PKC beta Inhibitors;Protein Kinase PKC delta Inhibitors;Protein Kinase PKC epsilon Inhibitors;Protein Kinase PKC theta Inhibitors;Signal Transduction Modulators; ; Protein kinase C inhibitor; Immunosuppressant; Protein kinase inhibitor; T cell inhibitor"
CBR-001-572-823-1,RFM-001-753-8,CBR-001-572-823-1,Cn1cnc(c1Sc1ncnc2c1[nH]cn2)[N+](=O)[O-],"CBR-HVAC-01368: Inflammatory Bowel Disease, Agents for;Treatment of Transplant Rejection;Rheumatoid Arthritis, Treatment of;Immunomodulators;Immunosuppressants;Disease-Modifying Anti-Rheumatic Drugs;Treatment of Autoimmune Diseases; Purine Antagonists; Rac-1 Activator; Immunosuppressant"
CBR-001-572-824-2,RFM-001-754-9,CBR-001-572-824-2,COC(C(Cl)Cl)(F)F,CBR-HVAC-01392: Inhalation Anesthetics;Analgesic Drugs; ; ; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-572-825-3,RFM-001-755-0,CBR-001-572-825-3,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1ncc(=O)[nH]c1=O,CBR-HVAC-09165: Interferon alpha Inhibitor;
CBR-001-572-826-4,RFM-001-756-1,CBR-001-572-826-4,Cc1ccc(=O)n(c1)c1ccccc1,"CBR-HVAC-01588: Interstitial Lung Diseases, Treatment of;Agents for Liver Fibrosis;Respiratory Disorders (Not Specified);Therapy of Inborn Errors of Metabolism;Treatment of Renal Diseases;Diabetic Nephropathy, Agents for;Multiple Sclerosis, Agents for;Neurologic Drugs (Miscellaneous); Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators;TGF-beta Inhibitors;TNF-alpha Production Inhibitors; ; Fibroblast growth factor antagonist; Transforming growth factor beta 1 antagonist; Tumour necrosis factor alpha antagonist; P38 kinase inhibitor"
CBR-001-572-827-5,RFM-001-757-2,CBR-001-572-827-5,ON(C(c1cc2c(s1)cccc2)C)C(=O)N,"CBR-HVAC-02668: Interstitial Lung Diseases, Treatment of;Antiallergy/Antiasthmatic Drugs;Myeloid Leukemia Therapy;Acne Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Respiratory/Thoracic Cancer Therapy; Leukotriene Synthesis Inhibitors;Signal Transduction Modulators;5-Lipoxygenase Inhibitors; Lipoxygenase 5 Inhibitor; 5 Lipoxygenase inhibitor; Leucotriene synthesis inhibitor"
CBR-001-572-828-6,RFM-001-758-3,CBR-001-572-828-6,CCOC(=O)c1cncn1C(c1ccccc1)C,CBR-HVAC-01688: Intravenous Anesthetics; ; GABA receptor Modulator; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-572-829-7,RFM-001-759-4,CBR-001-572-829-7,CCCC(C1(CC)C(=O)NC(=NC1=O)[S-])C,CBR-HVAC-03083: Intravenous Anesthetics; ; GABA-A receptor Inhibitor;
CBR-001-572-830-0,RFM-001-760-7,CBR-001-572-830-0,CC(c1cccc(c1OCOP(=O)([O-])[O-])C(C)C)C,CBR-HVAC-02652: Intravenous Anesthetics;Anesthetic Drugs; ; ; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-572-831-1,RFM-001-761-8,CBR-001-572-831-1,CCCCCCCCOc1ccccc1C(=O)Nc1ccc(cc1)C(=O)OCC[N+](CC)(CC)C,"CBR-HVAC-01993: Irritable Bowel Syndrome, Agents for;Antispasmodics; Muscarinic Antagonists;Signal Transduction Modulators; Tachykinin receptor 2; Muscarinic acetylcholine receptor Antagonist; Inhibitor; Muscarinic receptor antagonist; T-type calcium channel antagonist"
CBR-001-572-832-2,RFM-001-762-9,CBR-001-572-832-2,O=C(c1cn(c2c1cccc2)C)[C@@H]1CCc2c(C1)[nH]cn2,"CBR-HVAC-01427: Irritable Bowel Syndrome, Agents for;Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-572-833-3,RFM-001-763-0,CBR-001-572-833-3,[O-]/[N+](=C\c1ccc(cc1S(=O)(=O)[O-])S(=O)(=O)[O-])/C(C)(C)C,"CBR-HVAC-05005: Ischemic Stroke, Treatment of;Prostate Cancer Therapy;Neurologic Cancer Therapy; Free Radical Scavengers; ; Free radical scavenger"
CBR-001-572-834-4,RFM-001-764-1,CBR-001-572-834-4,OC(=O)[C@@H](Cc1ccc(c(c1)O)O)O,"CBR-HVAC-06471: Ischemic Stroke, Treatment of;Vasodilators; ; ;"
CBR-001-572-835-5,RFM-001-765-2,CBR-001-572-835-5,Fc1ccc(c(c1)F)C(OP(=O)(O)O)(Cn1cncn1)Cn1cncn1,CBR-HVAC-01983: Lanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-836-6,RFM-001-766-3,CBR-001-572-836-6,Fc1ccc(c(c1)F)[C@]([C@H](c1ncncc1F)C)(Cn1cncn1)O,CBR-HVAC-02080: Lanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-837-7,RFM-001-767-4,CBR-001-572-837-7,Nc1ccncc1,"CBR-HVAC-02298: Lesions of the Spinal Cord and Related Structures, Treatment of;Ischemic Stroke, Treatment of;Neurological Genetic Disorders, Treatment of ;Neurologic Drugs (Miscellaneous);Multiple Sclerosis, Agents for;Antiparkinsonian Drugs; Potassium Channel Blockers; Potassium channel Blocker; Unidentified pharmacological activity"
CBR-001-572-838-8,RFM-001-768-5,CBR-001-572-838-8,Nc1nc(C)c(c(n1)N)c1ccc(c(c1)Cl)Cl,CBR-HVAC-01043: Leukemia Therapy; ; Histamine N-methyltransferase Inhibitor; Folate antagonist; RNA directed RNA polymerase inhibitor
CBR-001-572-839-9,RFM-001-769-6,CBR-001-572-839-9,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(s1)N(Cc1ccc2c(c1)c(=O)[nH]c(n2)C)C,CBR-HVAC-03699: Leukemia Therapy;Oncolytic Drugs;Solid Tumors Therapy;Colorectal Cancer Therapy; Pyrimidine Antagonists;Thymidylate Synthase Inhibitors; Thymidylate synthase Inhibitor;
CBR-001-572-840-2,RFM-001-770-9,CBR-001-572-840-2,ClCc1nc2sc3c(c2c(=O)[nH]1)CCCC3,"CBR-HVAC-10838: Lipoprotein Disorders, Treatment of ; ; ;"
CBR-001-572-841-3,RFM-001-771-0,CBR-001-572-841-3,CCCc1ncc(s1)C(=O)O,"CBR-HVAC-09106: Lipoprotein Disorders, Treatment of ; ; ;"
CBR-001-572-842-4,RFM-001-772-1,CBR-001-572-842-4,CC(OC(=O)C1=CN(CC(c2c1[nH]c1c2cccc1)(C)C)C(=O)c1ccc(c(c1)F)F)C,"CBR-HVAC-06586: Lipoprotein Disorders, Treatment of ; Farnesoid X Receptor (FXR) Agonists;Signal Transduction Modulators; Farnesoid X-activated receptor Agonist; Farnesoid X receptor agonist; Farnesoid X receptor antagonist"
CBR-001-572-843-5,RFM-001-773-2,CBR-001-572-843-5,CCOP(=O)(Cc1ccc(cc1)C(=O)Nc1ccc(cc1C#N)Br)OCC,"CBR-HVAC-04121: Lipoprotein Disorders, Treatment of ; HDL-Cholesterol Increasing Agents;Lipoprotein Lipase (LPL) Activators; Lipoprotein lipase Activator;"
CBR-001-572-844-6,RFM-001-774-3,CBR-001-572-844-6,CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c1ccccc1,"CBR-HVAC-02654: Lipoprotein Disorders, Treatment of ;Antidiabetic Drugs; ; Acyl CoA:cholesterol acyltransferase Inhibitor; Gluconeogenesis inhibitor; Insulin sensitizer; HMGCoA reductase inhibitor"
CBR-001-572-845-7,RFM-001-775-4,CBR-001-572-845-7,CCCCCCCCCCCCCCOc1ccc(o1)C(=O)O,"CBR-HVAC-07960: Lipoprotein Disorders, Treatment of ;Antiparkinsonian Drugs; Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors;Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors; ; Acetyl CoA transferase inhibitor"
CBR-001-572-846-8,RFM-001-776-5,CBR-001-572-846-8,Oc1cc2OC(C(Cc2c(c1)O)O)c1cc(=O)c(c2c(c1)c(cc(c2O)O)C1Oc2cc(O)cc(c2CC1O)O)O,"CBR-HVAC-05492: Lipoprotein Disorders, Treatment of ;Cerebrovascular Diseases, Treatment of;Chemopreventive Agents;Antiarthritic Drugs; Antiinflammatory Drugs;Aromatase Inhibitors;Fatty Acid Synthase (FAS) Inhibitors;Nitric Oxide (NO) Production Inhibitors;Triacylglycerol Lipase (Hormone-Sensitive Lipase) Inhibitors; ;"
CBR-001-572-847-9,RFM-001-777-6,CBR-001-572-847-9,Oc1ccc(cc1)[C@@H]1[C@@H](CC[C@@H](c2ccc(cc2)F)O)C(=O)N1c1ccc(cc1)F,"CBR-HVAC-01922: Liver and Biliary Tract Disorders, Treatment of;Treatment of Diabetic Complications;Lipoprotein Disorders, Treatment of ; Cholesterol Absorption Inhibitors;Liver Bile Acid Transporter (LBAT) Inhibitors;Niemann-Pick C1-like protein 1 (NPC1L1) Inhibitors; Niemann-Pick C1-Like 1 Inhibitor; Niemann-Pick C1-like 1 protein antagonist; Cholesterol absorption inhibitor"
CBR-001-572-848-0,RFM-001-778-7,CBR-001-572-848-0,COc1cc2c(ccnc2cc1OC)Oc1ccc(c(c1)Cl)NC(=O)Nc1noc(c1)C,"CBR-HVAC-00824: Liver Cancer Therapy;Breast Cancer Therapy;Renal Cancer Therapy;Age-Related Macular Degeneration, Treatment of;Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy;Ovarian Cancer Therapy;Female Reproductive System Cancer Therapy;Astrocytoma Therapy;Sarcoma Therapy;Oncolytic Drugs;Colorectal Cancer Therapy; Angiogenesis Inhibitors;Signal Transduction Modulators;Tyrosine Kinase Inhibitors;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3 Inhibitor; Inhibitor; Inhibitor; VEGFR tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor"
CBR-001-572-849-1,RFM-001-779-8,CBR-001-572-849-1,N#CC(c1ccc(cc1)n1c(=O)n(c2c1c1cc(ccc1nc2)c1cnc2c(c1)cccc2)C)(C)C,CBR-HVAC-00358: Liver Cancer Therapy;Cancer of Unspecified Body Location/System;Brain Cancer Therapy;Renal Cancer Therapy;Prostate Cancer Therapy;Leukemia Therapy;Bladder Cancer Therapy ;Pancreatic Cancer Therapy;Lymphocytic Leukemia Therapy;Breast Cancer Therapy; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; mTOR; Phosphoinositide 3 kinase Inhibitor; Inhibitor; PI3 kinase inhibitor; mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; Protein kinase inhibitor
CBR-001-572-850-4,RFM-001-780-1,CBR-001-572-850-4,CCCNC(C(=O)Nc1c(C)csc1C(=O)OC)C,CBR-HVAC-06103: Local Anesthetics; ; Sodium channel Inhibitor;
CBR-001-572-851-5,RFM-001-781-2,CBR-001-572-851-5,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,CBR-HVAC-02579: Local Anesthetics;Analgesic Drugs; Sodium Channel  Blockers; Sodium channel Inhibitor; Sodium channel antagonist
CBR-001-572-852-6,RFM-001-782-3,CBR-001-572-852-6,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC(CN(CCC(c1ccccc1)c1ccccc1)C)(C)C)C,CBR-HVAC-02455: L-type calcium channel Blocker; L-type calcium channel antagonist
CBR-001-572-853-7,RFM-001-783-4,CBR-001-572-853-7,CN1CCCC(C1)CN1c2ccccc2Sc2c1cccc2,CBR-HVAC-01297: Membrane permeability enhancer
CBR-001-572-854-8,RFM-001-784-5,CBR-001-572-854-8,OC(=O)COc1ccc(cc1C)SCc1sc(nc1C)c1ccc(cc1)C(F)(F)F,"CBR-HVAC-05479: Metabolic Disorders (Not Specified);Atherosclerosis Therapy;Type 2 Diabetes, Agents for;Lipoprotein Disorders, Treatment of ; Insulin Sensitizers;PPARdelta Agonists;Signal Transduction Modulators; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA Agonist; Peroxisome proliferator-activated receptor beta/delta agon"
CBR-001-572-855-9,RFM-001-785-6,CBR-001-572-855-9,O=C(c1ccc(c(c1)Cl)F)N[C@H]1c2cc(ccc2OC([C@H]1O)(C)C)C(=O)C,"CBR-HVAC-00046: Migraine, Prophylactic Treatment of;Antiepileptic Drugs;Antimigraine Drugs; Gap junction modulators; 5-HYDROXYTRYPTAMINE 1D RECEPTOR Agonist; Nitric oxide inhibitor; Gap junction inhibitor"
CBR-001-572-856-0,RFM-001-786-7,CBR-001-572-856-0,COC[C@H](C(=O)NCc1ccccc1)NC(=O)C,"CBR-HVAC-01807: Migraine, Prophylactic Treatment of;Antiepileptic Drugs;Osteoarthritis, Treatment of;Neuropathic Pain, Treatment of;Diabetic Neuropathy, Agents for; NMDA Glycine-Site Antagonists;Signal Transduction Modulators;Sodium Channel  Blockers; Voltage-gated sodium channel Inactivator; Voltage-gated sodium channel antagonist; Collapsin-response mediator protein 2 stimulant; Collapsin-response mediator protein 2 inhibitor;2016-04-01: controlled substance"
CBR-001-572-857-1,RFM-001-787-8,CBR-001-572-857-1,N#Cc1c[nH]cc1c1cccc2c1OC(O2)(F)F,CBR-HVAC-10265: MITOGEN ACTIVATED PROTEIN KINASE Inhibitor;
CBR-001-572-858-2,RFM-001-788-9,CBR-001-572-858-2,CC(NNC(=O)c1ccncc1)C,CBR-HVAC-09845: Monoamine oxidase Inhibitor;
CBR-001-572-859-3,RFM-001-789-0,CBR-001-572-859-3,O=C(NCc1ccccc1)CCNNC(=O)c1ccncc1,CBR-HVAC-10029: Monoamine oxidase Inhibitor;
CBR-001-572-860-6,RFM-001-790-3,CBR-001-572-860-6,O=C(C(C)(C)C)NNCc1ccccc1,CBR-HVAC-10293: Monoamine oxidase Inhibitor;
CBR-001-572-861-7,RFM-001-791-4,CBR-001-572-861-7,CCOC(=O)CSCCC1NC(CS1)C(=O)O,CBR-HVAC-01692: Mucolytics; ; ; Mucolytic agent
CBR-001-572-862-8,RFM-001-792-5,CBR-001-572-862-8,c1ccc(cn1)CSc1ncccn1,CBR-HVAC-00778: Mucolytics; ; ; Mucolytic agent
CBR-001-572-863-9,RFM-001-793-6,CBR-001-572-863-9,CCNC(=O)NCc1cccc(c1)Cl,CBR-HVAC-02497: Mucus protecting agent
CBR-001-572-864-0,RFM-001-794-7,CBR-001-572-864-0,CS(=O)(=O)c1ccc(cc1)c1nc2n(c1)cccc2,CBR-HVAC-01861: Mucus protecting agent
CBR-001-572-865-1,RFM-001-795-8,CBR-001-572-865-1,CC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-08703: Multidrug resistance associated protein 2 Stimulator;
CBR-001-572-866-2,RFM-001-796-9,CBR-001-572-866-2,C[C@@H]1O[C@H](C)CN(C1)c1ccc(cn1)NC(=O)c1cccc(c1C)c1ccc(cc1)OC(F)(F)F,CBR-HVAC-06899: Multiple Myeloma Therapy;Gastric Cancer Therapy;Agents for Liver Cirrhosis;Hematological Cancer Therapy;Breast Cancer Therapy;Female Reproductive System Cancer Therapy;Glioblastoma Multiforme Therapy;Hematopoiesis Disorders Therapy;Pancreatic Cancer Therapy;Liver Cancer Therapy;Oncolytic Drugs;Prostate Cancer Therapy;Ovarian Cancer Therapy;Small Cell Lung Cancer Therapy;Brain Cancer Therapy;Leukemia Therapy;Basal Cell Carcinoma Therapy;Treatment of Autoimmune Diseases; Signal Transduction Modulators;Smoothened (Smo) Receptor Antagonists; ; Hedgehog pathway inhibitor
CBR-001-572-867-3,RFM-001-797-0,CBR-001-572-867-3,COc1ccc(cc1C12CC3CC(C2)CC(C1)C3)c1ccc2c(c1)ccc(c2)C(=O)O,"CBR-HVAC-03834: Multiple Sclerosis, Agents for;Acne Therapy; ; Retinoic acid receptor gamma; Retinoic acid receptor beta Inhibitor; Retinoic acid beta receptor agonist; Protein synthesis inhibitor; Microbial collagenase inhibitor; Retinoic acid gamma receptor agonist"
CBR-001-572-868-4,RFM-001-798-1,CBR-001-572-868-4,CCC(C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1)(C)C,"CBR-HVAC-04906: Multiple Sclerosis, Agents for;Antiparkinsonian Drugs;Antiglaucoma Agents;Alzheimer's Dementia, Treatment of ; FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors;Neurotrophic Agents;Signal Transduction Modulators; FK506 binding protein 1A Inhibitor; Cyclophilin inhibitor"
CBR-001-572-869-5,RFM-001-799-2,CBR-001-572-869-5,N#C/C(=C(/O)\C)/C(=O)Nc1ccc(cc1)C(F)(F)F,"CBR-HVAC-04249: Multiple Sclerosis, Agents for;Disease-Modifying Anti-Rheumatic Drugs;Immunosuppressants; Dihydroorotate Dehydrogenase (DHODH) Inhibitors;MMP-2 (Gelatinase A) Inhibitors;MMP9 Expression Inhibitors;MMP-9 (Gelatinase B) Inhibitors; Dihydroorotate dehydrogenase Inhibitor;"
CBR-001-572-870-8,RFM-001-800-8,CBR-001-572-870-8,NCCCCC(C(=O)N1CCCC1C(=O)O)NC(C(=O)O)CCc1ccccc1,"CBR-HVAC-01909: Multiple Sclerosis, Agents for;Treatment of Renal Diseases;Treatment of Diabetic Complications;Hypertension, Treatment of;Heart Failure Therapy;Acute Myocardial Infarction, Treatment of;Migraine, Prophylactic Treatment of;Respiratory Disorders (Not Specified); Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-572-871-9,RFM-001-801-9,CBR-001-572-871-9,OCC(c1ccccc1)C(=O)OC1CC2N(C(C1)C1C2O1)C,CBR-HVAC-02388: Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist
CBR-001-572-872-0,RFM-001-802-0,CBR-001-572-872-0,OCC(c1ccccc1)C(=O)OC1CC2CCC(C1)[N+]2(C)C(C)C,CBR-HVAC-02407: Muscarinic acetylcholine receptor Inhibitor; Muscarinic receptor antagonist
CBR-001-572-873-1,RFM-001-803-1,CBR-001-572-873-1,OC(c1ccccc1)(c1ccccc1)CCN1CCCCC1,CBR-HVAC-08859: Muscarinic acetylcholine receptor M2 Antagonist;
CBR-001-572-874-2,RFM-001-804-2,CBR-001-572-874-2,O=C(N1c2ccccc2Sc2c1cccc2)CN1CCN(CC1)Cc1ccc2c(c1)OCO2,CBR-HVAC-01924: Muscarinic receptor antagonist; 5 Hydroxytryptamine receptor antagonist
CBR-001-572-875-3,RFM-001-805-3,CBR-001-572-875-3,OC[C@H]1O[C@@H](Oc2cc3CC[C@@H](c4c(c3c(c2OC)OC)ccc(c(=O)c4)SC)NC(=O)C)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-01812: Muscle Spasms, Drugs for; ; GABA-A receptor Inhibitor; GABA A receptor antagonist"
CBR-001-572-876-4,RFM-001-806-4,CBR-001-572-876-4,OCC(=O)[C@@]1(O)[C@H](C)CC2C1(C)CC=C1C2CCC2=CC(=O)C=CC12C,Analog of CBR-HVAC-06761 (VBP-15)
CBR-001-572-877-5,RFM-001-807-5,CBR-001-572-877-5,C[n+]1cccc(c1)OC(=O)N(CCCCCCN(C(=O)Oc1ccc[n+](c1)C)C)C,"CBR-HVAC-05918: Myasthenia Gravis, Agents for;Gastric Emptying Disorders,Treatment of;Urologic Drugs; Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Inhibitor;"
CBR-001-572-878-6,RFM-001-808-6,CBR-001-572-878-6,BrCCC(=O)N1CCN(CC1)C(=O)CCBr,CBR-HVAC-03239: Myeloid Leukemia Therapy;Antithrombocythemic; ; ;
CBR-001-572-879-7,RFM-001-809-7,CBR-001-572-879-7,ClCCN(CCCl)C,CBR-HVAC-05257: Myeloid Leukemia Therapy;Cancer of Unspecified Body Location/System;Non-Hodgkin's Lymphoma Therapy;Lymphoma Therapy;Lymphocytic Leukemia Therapy;Sarcoma Therapy; DNA Alkylating Drugs; ;
CBR-001-572-880-0,RFM-001-810-0,CBR-001-572-880-0,CC(c1c(O)ccc2c1CC[C@@H]1[C@]2(C)CCCC1(C)C)C,CBR-HVAC-10069: NADH-cytochrome c reductase Inhibitor;
CBR-001-572-881-1,RFM-001-811-1,CBR-001-572-881-1,CNC(C(c1ccccc1)O)C,CBR-HVAC-01278: Nasal Decongestants;Antitussives; ; ; Adrenoreceptor agonist
CBR-001-572-882-2,RFM-001-812-2,CBR-001-572-882-2,Cc1cc(cc(c1CC1=NCCN1)C)C(C)(C)C,CBR-HVAC-02212: Nasal Decongestants;Ophthalmic Drugs; alpha2A(2D)-Adrenoceptor Agonists;alpha2B-Adrenoceptor Agonists;alpha2C-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Agonist; Alpha 2 adrenoreceptor agonist
CBR-001-572-883-3,RFM-001-813-3,CBR-001-572-883-3,Clc1ccc(cc1)C(c1ccccc1)N1CCN(CC1)Cc1ccc(cc1)C(C)(C)C,"CBR-HVAC-03137: Nausea and Vomiting, Treatment of;Antimigraine Drugs; ; Histamine receptor Antagonist;"
CBR-001-572-884-4,RFM-001-814-4,CBR-001-572-884-4,CN1C2CCC1CC(C2)OC(=O)c1c[nH]c2c1cccc2,"CBR-HVAC-02236: Nausea and Vomiting, Treatment of;Fibromyalgia, Treatment of;Antipsychotic Drugs; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 4 receptor; 5-Hydroxytryptamine 3 receptor Antagonist; Dopamine receptor antagonist"
CBR-001-572-885-5,RFM-001-815-5,CBR-001-572-885-5,CCN1CC(C(C1=O)(c1ccccc1)c1ccccc1)CCN1CCOCC1,"CBR-HVAC-01439: Nausea and Vomiting, Treatment of;Respiratory Disorders (Not Specified);Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Potassium Channel Subfamily K Member 3 (TASK-1; KCNK3) Blockers;Potassium Channel Subfamily K Member 9 (TASK-3; KCNK9) Blockers; ; Unidentified pharmacological activity"
CBR-001-572-886-6,RFM-001-816-6,CBR-001-572-886-6,COc1ccc(cc1OC1CCCC1)C1CNC(=O)C1,"CBR-HVAC-02524: Neurodegenerative Diseases, Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Antidepressants;Alzheimer's Dementia, Treatment of ;Multiple Sclerosis, Agents for; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor; Interleukin 1b antagonist"
CBR-001-572-887-7,RFM-001-817-7,CBR-001-572-887-7,CN(CCOC(=O)COc1ccc(cc1)Cl)C,"CBR-HVAC-10065: Neurodegenerative Diseases, Treatment of;Cognition Disorders, Treatment of; Antioxidants;Free Radical Scavengers; ;"
CBR-001-572-888-8,RFM-001-818-8,CBR-001-572-888-8,OCc1cc(ccc1OC)c1ccc2c(n1)nc(nc2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,CBR-HVAC-06639: Neurologic Cancer Therapy;Liver Cancer Therapy;Oncolytic Drugs; mTOR Complex 1 (mTORC1) Inhibitors;mTOR Complex 2 (mTORC2) Inhibitors;Signal Transduction Modulators; mTOR Inhibitor;
CBR-001-572-889-9,RFM-001-819-9,CBR-001-572-889-9,NC(=O)OCC(c1ccccc1)COC(=O)N,"CBR-HVAC-01892: Neurologic Drugs (Miscellaneous);Antiepileptic Drugs;Bipolar Disorder, Treatment of; GABA(A) Receptor Modulators;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA; GABA-A receptor Agonist; Antagonist; Carbonic anhydrase inhibitor"
CBR-001-572-890-2,RFM-001-820-2,CBR-001-572-890-2,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)C)C)C,"CBR-HVAC-04782: Neurologic Drugs (Miscellaneous);Female Infertility, Agents for;Treatment of Preterm Labor;Stroke, Treatment of;Endometriosis Therapy;Hormone Replacement Therapy;Gynecological Disorders, Treatment of ; ; ; Progesterone receptor agonist"
CBR-001-572-891-3,RFM-001-821-3,CBR-001-572-891-3,COC(=O)C(CCCN/C(=N\[N+](=O)[O-])/N)N,"CBR-HVAC-04477: Neurologic Drugs (Miscellaneous);Treatment of Shock;Pharmacological Tools;Non-Opioid Analgesics;Stroke, Treatment of; Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators; NITRIC OXIDE SYNTHASE Inhibitor;"
CBR-001-572-892-4,RFM-001-822-4,CBR-001-572-892-4,COC1/C=C/OC2(C)Oc3c(C2=O)c2c(O)c(/C=N/N4CCN(CC4)C)c(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C\C(C(C(C(C(C(C1C)OC(=O)C)C)O)C)O)C)/C,CBR-HVAC-02445: Neurologic Drugs (Miscellaneous);Treatment of Tuberculosis;Antimycobacterial Agents;Treatment of Leprosy;Acne Therapy; Bacterial Fatty Acid Biosynthesis Inhibitors ;Cell Wall Biosynthesis Inhibitors;DNA-Directed RNA Polymerase Inhibitors;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors;Enzyme Inducers; DNA-dependent RNA polymerase beta Inhibitor; DNA directed RNA polymerase inhibitor
CBR-001-572-893-5,RFM-001-823-5,CBR-001-572-893-5,OC(=O)CCCCCCNC1c2ccccc2N(S(=O)(=O)c2c1ccc(c2)Cl)C,"CBR-HVAC-01778: Neurological Genetic Disorders, Treatment of ;Irritable Bowel Syndrome, Agents for;Respiratory Disorders (Not Specified);Antidepressants;Non-Ulcer Dyspepsia, Agents for; Signal Transduction Modulators;5-HT Reuptake Enhancers; 5-Hydroxytryptamine transporter Blocker; 5 Hydroxytryptamine uptake stimulant"
CBR-001-572-894-6,RFM-001-824-6,CBR-001-572-894-6,CCCCCCCCc1ccc(cc1)CCC(CO)(CO)N,"CBR-HVAC-01445: Neurological Genetic Disorders, Treatment of ;Neuropathy, Treatment of ;Asthma Therapy;Treatment of Transplant Rejection;Amyotrophic Lateral Sclerosis, Agents for;Multiple Sclerosis, Agents for;Immunosuppressants;Antipsychotic Drugs; Apoptosis Inducers;Cytochrome P450 CYP4F2 Inhibitors;Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg3 (S1P3) Receptor Agonists;Lysophospholipid edg6 (S1P4) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists;Signal Transduction Modulators;Sphingosine Kinase 1 (SphK1) Inhibitors; Sphingosine-1-phosphate receptor 3; Sphingosine-1-phosphate receptor 5; Sphingosine-1-phosphate receptor 1; Sphingosine-1-phosphate receptor 4 Modulator; Sphingosine 1-phosphate 1 receptor agonist; Sphingosine 1-phosphate 5 receptor agonist; Immunosuppressant"
CBR-001-572-895-7,RFM-001-825-7,CBR-001-572-895-7,CCCCc1cc2ccccc2c(n1)OCCN(C)C,CBR-HVAC-10124: Nicotinic acetylcholine receptor Agonist;
CBR-001-572-896-8,RFM-001-826-8,CBR-001-572-896-8,COC(=O)[C@@H]1CC(=O)C[C@H]1C(=O)OC,CBR-HVAC-12019: no known biological function
CBR-001-572-897-9,RFM-001-827-9,CBR-001-572-897-9,CCN(CCOC(=O)C(c1ccccc1)c1ccccc1)CC,CBR-HVAC-09698: Nicotinic acetylcholine receptor Antagonist;
CBR-001-572-898-0,RFM-001-828-0,CBR-001-572-898-0,CNC(=N)NCCC[C@@H](C(=O)O)N,CBR-HVAC-02708: Nitric oxide synthase Inhibitor; Nitric oxide inhibitor; Nitric oxide synthase inhibitor
CBR-001-572-899-1,RFM-001-829-1,CBR-001-572-899-1,OC(=O)C1NCCN(C1)CCCP(=O)(O)O,CBR-HVAC-07678: NMDA receptor antagonist
CBR-001-572-900-7,RFM-001-830-4,CBR-001-572-900-7,O=C1NC(=O)C(=C1c1cn(c2c1cccc2)C1CCN(CC1)Cc1ccccn1)c1cn(c2c1cccc2)C,CBR-HVAC-00884: Non-Hodgkin's Lymphoma Therapy;Non-Small Cell Lung Cancer Therapy;Neurologic Cancer Therapy;Solid Tumors Therapy;Oncolytic Drugs;Ovarian Cancer Therapy;Multiple Myeloma Therapy;Prostate Cancer Therapy;Renal Cancer Therapy;Glioblastoma Multiforme Therapy;Colorectal Cancer Therapy;Pancreatic Cancer Therapy;Antineoplastic Enhancing Agents;Breast Cancer Therapy; Angiogenesis Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Protein Kinase B (PKB/Akt) Inhibitors;Protein Kinase PKC beta Inhibitors;Signal Transduction Modulators; Protein Kinase C Inhibitor; Protein kinase C beta inhibitor; Angiogenesis inhibitor; Apoptosis stimulant
CBR-001-572-901-8,RFM-001-831-5,CBR-001-572-901-8,CN1CCC(CC1)CNc1ccc2n(n1)c(cn2)c1cccc(c1)OC(F)(F)F,CBR-HVAC-06744: Non-Hodgkin's Lymphoma Therapy;Prostate Cancer Therapy; Apoptosis Inducers;Flt3 (FLK2/STK1) Inhibitors;Pim Kinase Inhibitors;Pim-1 Kinase Inhibitors;Signal Transduction Modulators; PIM-1 protein kinase Inhibitor; Pim-1 kinase inhibitor; Pim-2 kinase inhibitor; Pim-3 kinase inhibitor; Apoptosis stimulant; Cell cycle inhibitor
CBR-001-572-902-9,RFM-001-832-6,CBR-001-572-902-9,Oc1ccc(cc1)NC(=O)CN1C(=O)c2c(S1(=O)=O)cccc2,CBR-HVAC-05244: Non-Opioid Analgesics; ; ;
CBR-001-572-903-0,RFM-001-833-7,CBR-001-572-903-0,CN(C(=O)c1sc2n(c1C)c1c(n2)ccc(c1)N)C1CCCCC1,CBR-HVAC-11909: Non-Opioid Analgesics; mgluR1 Antagonists;Signal Transduction Modulators; Metabotropic glutamate receptor 1 Antagonist;
CBR-001-572-904-1,RFM-001-834-8,CBR-001-572-904-1,O=C(N1CCN(CC1)C(c1ccccc1)c1ccccc1)CC(c1ccccc1)c1ccccc1,CBR-HVAC-00351: Non-Opioid Analgesics; N-Type Calcium Channel (Ca(v) 2.2) Blockers; ; N-type calcium channel antagonist
CBR-001-572-905-2,RFM-001-835-9,CBR-001-572-905-2,CC(=O)Nc1sc2c(n1)c(ccc2)Oc1ncnc(c1)c1ccc(cc1)C(F)(F)F,"CBR-HVAC-06133: Non-Opioid Analgesics; TRPV1 (Vanilloid VR1 Receptor) Antagonists; Transient receptor potential cation channel, subfamily V, member 1 Antagonist; Vanilloid receptor 1 antagonist"
CBR-001-572-906-3,RFM-001-836-0,CBR-001-572-906-3,OC(=O)Cc1ccc(c(c1)Cl)OCc1ccccc1,"CBR-HVAC-05784: Non-Opioid Analgesics;Inflammation, Treatment of;Antiarthritic Drugs; ; ;"
CBR-001-572-907-4,RFM-001-837-1,CBR-001-572-907-4,Nc1ccc(c(n1)N)/N=N/c1ccccc1,CBR-HVAC-01733: Non-Opioid Analgesics;Local Anesthetics;Treatment of Renal Diseases; ; Beta-lactamase; Chymotrypsinogen; Malate dehydrogenase Inhibitor; Unidentified pharmacological activity
CBR-001-572-908-5,RFM-001-838-2,CBR-001-572-908-5,COc1cc(OC)cc2c1c(C)c(o2)C(=O)c1ccc(cc1)Br,"CBR-HVAC-11397: Non-Opioid Analgesics;Neuropathic Pain, Treatment of; ; ;"
CBR-001-572-909-6,RFM-001-839-3,CBR-001-572-909-6,OC(=O)Cc1ccc2c(c1)C(=O)c1ccccc1CO2,"CBR-HVAC-05597: Non-Opioid Analgesics;Rheumatoid Arthritis, Treatment of;Inflammation, Treatment of; ; ;"
CBR-001-572-910-9,RFM-001-840-6,CBR-001-572-910-9,Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2,"CBR-HVAC-01741: Non-Ulcer Dyspepsia, Agents for;Gastrointestinal Disorders (Not Specified);Prokinetic Agents;Gastroesophageal Reflux Disease, Agents for;Nausea and Vomiting, Treatment of;Pituitary Disorder Therapy; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Dopamine Receptor Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist"
CBR-001-572-911-0,RFM-001-841-7,CBR-001-572-911-0,CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)N,"CBR-HVAC-01291: Non-Ulcer Dyspepsia, Agents for;Nausea and Vomiting, Treatment of;Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-572-912-1,RFM-001-842-8,CBR-001-572-912-1,C[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C,CBR-HVAC-07741: Not applicable
CBR-001-572-913-2,RFM-001-843-9,CBR-001-572-913-2,OC(=O)c1ccc(cc1)OCCCOc1ccc(cc1)C(=O)O,CBR-HVAC-07761: Not applicable
CBR-001-572-914-3,RFM-001-844-0,CBR-001-572-914-3,OC[C@H]1O[C@@H](O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-01317: Not applicable
CBR-001-572-915-4,RFM-001-845-1,CBR-001-572-915-4,Clc1cc(NC(=O)c2c(O)c(Cl)cc(c2Cl)Cl)c(c(c1)Cl)O,CBR-HVAC-10050: Oncolytic Drugs; ; ;
CBR-001-572-916-5,RFM-001-846-2,CBR-001-572-916-5,O=C1CCC2=C3C=C[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C)O)C,CBR-HVAC-09986: Oncolytic Drugs; Androgen Receptor Agonists;Signal Transduction Modulators; Mineralocorticoid receptor Antagonist; ;2016-04-01: controlled substance
CBR-001-572-917-6,RFM-001-847-3,CBR-001-572-917-6,NC(=S)NN=C1C=CC(=NN=C(N)N)C=C1,CBR-HVAC-01168: Oncolytic Drugs; DNA-Damaging Drugs; ; Unidentified pharmacological activity
CBR-001-572-918-7,RFM-001-848-4,CBR-001-572-918-7,OCCNCCn1c2c3ccccc3C(=O)c2c2c(c1=O)cccc2,CBR-HVAC-00197: Oncolytic Drugs; DNA-Intercalating Drugs; DNA topoisomerase II Inhibitor; L lactate dehydrogenase stimulant
CBR-001-572-919-8,RFM-001-849-5,CBR-001-572-919-8,Cc1ccc(cc1)S(=O)(=O)NC(=O)Nc1ccc(cc1)Cl,CBR-HVAC-10488: Oncolytic Drugs; Tumor NADH Oxidase (tNOX) Inhibitors; ;
CBR-001-572-920-1,RFM-001-850-8,CBR-001-572-920-1,Clc1ccc(cc1)Nc1cc2nc3ccccc3n(c2c/c/1=N\C(C)C)c1ccc(cc1)Cl,CBR-HVAC-03575: Oncolytic Drugs;Antibacterial Drugs;Treatment of Leprosy;Treatment of Tuberculosis; ; ;
CBR-001-572-921-2,RFM-001-851-9,CBR-001-572-921-2,OCC1OC(Oc2cc3ccc(=O)oc3cc2O)C(C(C1O)O)O,CBR-HVAC-10247: Oncolytic Drugs;Antifungal Agents; ; Lipoxygenase Inhibitor;
CBR-001-572-922-3,RFM-001-852-0,CBR-001-572-922-3,CC[C@@H](C(C)C)CC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CC[C@@H](C2)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)C,CBR-HVAC-06278: Oncolytic Drugs;Antiplatelet Therapy;Chemopreventive Agents;Immunostimulants; Platelets Adhesion Inhibitors; ;
CBR-001-572-923-4,RFM-001-853-1,CBR-001-572-923-4,CCOC(=O)c1ccc(nc1)C#Cc1ccc2c(c1)C(C)(C)CCS2,"CBR-HVAC-01687: Oncolytic Drugs;Antipsoriatics;Neurological Genetic Disorders, Treatment of ;Acne Therapy;Dermatologic Drugs;Basal Cell Carcinoma Therapy; Ornithine Decarboxylase Inhibitors;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists;Signal Transduction Modulators; Ornithine decarboxylase Inhibitor; Retinoic acid alpha receptor agonist; Retinoic acid beta receptor agonist; Retinoic acid gamma receptor agonist"
CBR-001-572-924-5,RFM-001-854-2,CBR-001-572-924-5,O=C1C=CC[C@H]2N1C[C@@H]1CCCN3[C@@H]1[C@@H]2CCC3,CBR-HVAC-05193: Oncolytic Drugs;Bronchodilators; ; ;
CBR-001-572-925-6,RFM-001-855-3,CBR-001-572-925-6,COc1cc(cc(c1O)OC)[C@H]1C2C(=O)OCC2C(c2c1cc1OCOc1c2)O[C@@H]1O[C@@H]2CO[C@@H](O[C@H]2[C@H]([C@H]1O)O)C,CBR-HVAC-00081: Oncolytic Drugs;Cervical Cancer Therapy;Genitourinary Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Neurologic Cancer Therapy;Osteosarcoma Therapy;Small Cell Lung Cancer Therapy;Endocrine Cancer Therapy;Hematologic Agents (Miscellaneous);Lymphoma Therapy;Ovarian Cancer Therapy; DNA Topoisomerase II alpha Inhibitors;DNA-Intercalating Drugs; DNA topoisomerase II Inhibitor; DNA inhibitor; DNA repair enzyme inhibitor; DNA topoisomerase II inhibitor; Cell cycle inhibitor
CBR-001-572-926-7,RFM-001-856-4,CBR-001-572-926-7,Oc1cc(cc2c1C(=O)c1c(C2=O)cccc1O)C(=O)O,"CBR-HVAC-06315: Oncolytic Drugs;Diabetic Nephropathy, Agents for;Antiarthritic Drugs; Cytochrome P450 CYP2C19 Inhibitors;Macrophage Scavenger Receptor Ligands;Signal Transduction Modulators; Interleukin 1 receptor Antagonist;"
CBR-001-572-927-8,RFM-001-857-5,CBR-001-572-927-8,CCC1CN2CCc3c(C2CC1CC1NCCc2c1cc(OC)c(c2)OC)cc(c(c3)OC)OC,CBR-HVAC-05517: Oncolytic Drugs;Emetics;Treatment of Protozoal Diseases; ; ;
CBR-001-572-928-9,RFM-001-858-6,CBR-001-572-928-9,OC(=O)Cc1cccc2c1oc(cc2=O)c1ccccc1,CBR-HVAC-03477: Oncolytic Drugs;Immunomodulators; Angiogenesis Inhibitors; ; Unidentified pharmacological activity
CBR-001-572-929-0,RFM-001-859-7,CBR-001-572-929-0,ClCCN(C(=O)NCc1cnc(nc1N)C)N=O,CBR-HVAC-01616: Oncolytic Drugs;Neurologic Cancer Therapy;Lung Cancer Therapy; Apoptosis Inducers; ; DNA inhibitor; DNA synthesis inhibitor
CBR-001-572-930-3,RFM-001-860-0,CBR-001-572-930-3,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@@H]1N(C)CCc2c1c(OC)c1c(c2)OCO1,"CBR-HVAC-02440: Oncolytic Drugs;Non-Hodgkin's Lymphoma Therapy;Neurodegenerative Diseases, Treatment of;Fibrosis, Treatment of;Multiple Myeloma Therapy;Prostate Cancer Therapy;Antitussives; Antimitotic Drugs;Apoptosis Inducers;Tubulin Polymerization Inhibitors; Bradykinin receptor Blocker; Tubulin inhibitor; Apoptosis stimulant"
CBR-001-572-931-4,RFM-001-861-1,CBR-001-572-931-4,COc1ccc(cc1)N(c1nc(C)nc2c1cccc2)C,CBR-HVAC-00765: Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy;Brain Cancer Therapy;Melanoma Therapy; Antimitotic Drugs;Apoptosis Inducers;Tubulin Polymerization Inhibitors;Vascular Disrupting Agents (VDA); Tubulin Inhibitor; Tubulin inhibitor; Microtubule inhibitor
CBR-001-572-932-5,RFM-001-862-2,CBR-001-572-932-5,O[C@H]1O[C@@H]2COC(O[C@@H]2[C@@H]([C@H]1O)O)c1ccccc1,"CBR-HVAC-03393: Oncolytic Drugs;Opioid Analgesics; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; ; Unidentified pharmacological activity"
CBR-001-572-933-6,RFM-001-863-3,CBR-001-572-933-6,COc1ccc(cc1C(=O)N1CCN(CC1)c1cccc(c1)Cl)Cl,"CBR-HVAC-11950: Oncolytic Drugs;Prion Diseases, Treatment of; Antimitotic Drugs;Tubulin Polymerization Inhibitors; ;"
CBR-001-572-934-7,RFM-001-864-4,CBR-001-572-934-7,CNC(=O)c1nccc(c1)COc1nnc(c2c1occ2)Nc1ccc(cc1)Cl,CBR-HVAC-00821: Oncolytic Drugs;Renal Cancer Therapy;Colorectal Cancer Therapy;Gastric Cancer Therapy; Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; Vascular endothelial growth factor receptor 2; PDGFR beta; KIT; Vascular endothelial growth factor receptor 3 Inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; C-kit inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib
CBR-001-572-935-8,RFM-001-865-5,CBR-001-572-935-8,Clc1ccc(cc1)Cn1cc(c2c1cccc2)C(=O)C(=O)Nc1ccncc1,CBR-HVAC-00598: Oncolytic Drugs;Solid Tumors Therapy;Breast Cancer Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors; TUBULIN Inhibitor; Tubulin inhibitor; Mitotic inhibitor
CBR-001-572-936-9,RFM-001-866-6,CBR-001-572-936-9,OC(=O)C(CC(=O)c1ccc(cc1)c1ccc(cc1)Cl)CSc1ccccc1,"CBR-HVAC-10407: Oncolytic Drugs;Treatment of Transplant Rejection;Osteoarthritis, Treatment of; Angiogenesis Inhibitors;MMP-2 (Gelatinase A) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-9 (Gelatinase B) Inhibitors; Matrix metalloproteinase 1 Inhibitor;"
CBR-001-572-937-0,RFM-001-867-7,CBR-001-572-937-0,CCC1(CCCCN(C1)C)c1cccc(c1)O,CBR-HVAC-02176: Opioid Analgesics; ; Opioid receptor mu Agonist; Opioid receptor agonist
CBR-001-572-938-1,RFM-001-868-8,CBR-001-572-938-1,CN(c1c(C)n(n(c1=O)c1ccccc1)C)CS(=O)(=O)[O-],CBR-HVAC-03638: Opioid Analgesics; Cyclooxygenase-3 Inhibitors;Drugs Acting on Opioid and Opioid-Like Receptors;Signal Transduction Modulators; COX-3 Inhibitor;
CBR-001-572-939-2,RFM-001-869-9,CBR-001-572-939-2,C=CCN1CC[C@@]23[C@@]4(C1Cc1c3c(O[C@H]2C(=O)CC4)c(cc1)O)O,CBR-HVAC-02633: Opioid receptor Antagonist; Opioid receptor antagonist
CBR-001-572-940-5,RFM-001-870-2,CBR-001-572-940-5,CC(=O)Oc1cc(cc2c1C(=O)c1c(C2=O)cccc1OC(=O)C)C(=O)O,"CBR-HVAC-01531: Osteoarthritis, Treatment of;Diabetic Nephropathy, Agents for;Type 2 Diabetes, Agents for;Treatment of Gout;Dermatological Genetic Disorders, Treatment of; Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;IL-1beta Inhibitors;Signal Transduction Modulators; Interleukin 1 Inhibitor; Interleukin 1b antagonist; Interleukin 1b agonist"
CBR-001-572-941-6,RFM-001-871-3,CBR-001-572-941-6,CCOC(=O)c1ccc(cc1)OC(=O)CCCCCNC(=N)N,"CBR-HVAC-05425: Pancreatic Disorders, Treatment of;Anticoagulants; AP-1 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Serine Protease Inhibitors;Signal Transduction Modulators; ; Protease/peptidase inhibitor"
CBR-001-572-942-7,RFM-001-872-4,CBR-001-572-942-7,CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)NC(=N)N)C,"CBR-HVAC-03366: Pancreatic Disorders, Treatment of;Gastroesophageal Reflux Disease, Agents for; Protease Inhibitors;Trypsin Inhibitors; ; Protease/peptidase inhibitor"
CBR-001-572-943-8,RFM-001-873-5,CBR-001-572-943-8,O=C(C(c1ccc(cc1)O)N)NC1C(=O)N2C1SC(C2C(=O)O)(C)C,CBR-HVAC-02646: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-944-9,RFM-001-874-6,CBR-001-572-944-9,NC(c1ccccc1)C(=O)NC1C(=O)N2C1SC(C2C(=O)O)(C)C,CBR-HVAC-01366: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-945-0,RFM-001-875-7,CBR-001-572-945-0,O=C(NC1C(=O)N2C1SCC(=C2C(=O)O)CSc1nnc(s1)C)Cn1cnnn1,CBR-HVAC-01334: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-572-946-1,RFM-001-876-8,CBR-001-572-946-1,Ic1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCOCC1,CBR-HVAC-11600: Pharmacological Tools; Cannabinoid CB1 Antagonists;Signal Transduction Modulators; Cannabinoid receptor 1 Antagonist;
CBR-001-572-947-2,RFM-001-877-9,CBR-001-572-947-2,CC(NCCN(S(=O)(=O)c1ccc(cc1Cl)Cl)C(C)C)C,CBR-HVAC-07201: Pharmacological Tools; TRPV4 Antagonists; ;
CBR-001-572-948-3,RFM-001-878-0,CBR-001-572-948-3,COc1ccccc1CNCCCCCCNCCCCCCCCNCCCCCCNCc1ccccc1OC,CBR-HVAC-00810: Pharmacological Tools;Antiarrhythmic Drugs; Muscarinic M2 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M2 Antagonist; Muscarinic M2 receptor antagonist
CBR-001-572-949-4,RFM-001-879-1,CBR-001-572-949-4,OC1COC(C(C1O)O)Nc1ccc(cc1)C(=O)O,CBR-HVAC-01190: Phosphodiesterase inhibitor; Protein synthesis inhibitor
CBR-001-572-950-7,RFM-001-880-4,CBR-001-572-950-7,CCCCOc1cc(ccc1OC)CC1CNC(=O)N1,CBR-HVAC-10392: Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor;
CBR-001-572-951-8,RFM-001-881-5,CBR-001-572-951-8,CCCCCCCC(=O)O,CBR-HVAC-00071: Antioxidants; Acne Therapy; Antifungal
CBR-001-572-952-9,RFM-001-882-6,CBR-001-572-952-9,Clc1ccc(cc1)[C@@H]1CC[C@H](CC1)C1=C(O)C(=O)c2c(C1=O)cccc2,"CBR-HVAC-01962: Pneumocystis jiroveci Pneumonia, Agents for; Cytochrome b-c1 Complex (Complex III subunit 3) (Plasmodium falciparum) Inhibitors;Type ll NADH:Quinone Oxidoreductase (PfNDH2) (Plasmodium falciparum) Inhibitors; Cytochrome bc1 Inhibitor; Mitochondrial electron transport inhibitor; Dihydroorotate dehydrogenase inhibitor"
CBR-001-572-953-0,RFM-001-883-7,CBR-001-572-953-0,CCCCc1oc2c(c1C(=O)c1cc(I)c(c(c1)I)OCCN(CC)CC)cccc2,CBR-HVAC-02155: Potassium channel Kv1.2; Potassium channel Kv Blocker; Polarisation inhibitor; Alpha adrenoreceptor antagonist; Beta adrenoreceptor antagonist; Potassium channel antagonist; Voltage-gated sodium channel antagonist
CBR-001-572-954-1,RFM-001-884-8,CBR-001-572-954-1,Clc1ccc2c(c1)nc(o2)O,"CBR-HVAC-09561: Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 Opener;"
CBR-001-572-955-2,RFM-001-885-9,CBR-001-572-955-2,Oc1ccc(cc1)C(=NNc1ccc(cc1[N+](=O)[O-])[N+](=O)[O-])c1ccc(cc1)O,CBR-HVAC-00546: Premalignant Conditions Therapy;Immunomodulators;Colorectal Cancer Therapy;Oncolytic Drugs; Estrogen Receptor (ER) Antagonists;Signal Transduction Modulators; Estrogen receptor Modulator; Estrogen receptor antagonist; DNA directed RNA polymerase inhibitor
CBR-001-572-956-3,RFM-001-886-0,CBR-001-572-956-3,O[C@@H]1CC[C@]2([C@H](C1)CC[C@@H]1[C@@H]2CC[C@]2(C1=CC[C@@H]2C(=O)C)C)C,analog of CBR-HVAC-02415 sent to us in error
CBR-001-572-957-4,RFM-001-887-1,CBR-001-572-957-4,COC1CN(CCCOc2ccc(cc2)F)CCC1NC(=O)c1cc(Cl)c(cc1OC)N,"CBR-HVAC-02817: Prokinetic Agents;Gastroesophageal Reflux Disease, Agents for;Gastric Emptying Disorders,Treatment of;Non-Ulcer Dyspepsia, Agents for; ; 5-Hydroxytryptamine 3 receptor; 5-Hydroxytryptamine 4 receptor Agonist; Muscarinic receptor agonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-572-958-5,RFM-001-888-2,CBR-001-572-958-5,CCOc1cc(N)c(cc1C(=O)NCC1OCCN(C1)Cc1ccc(cc1)F)Cl,"CBR-HVAC-03663: Prokinetic Agents;Gastrointestinal Disorders (Not Specified);Gastroesophageal Reflux Disease, Agents for; Signal Transduction Modulators;5-HT4 Agonists; 5-Hydroxytryptamine 4 receptor Agonist; 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-572-959-6,RFM-001-889-3,CBR-001-572-959-6,Cc1cnc(s1)NC(=O)C1=C(O)c2ccccc2S(=O)(=O)N1C,CBR-HVAC-02583: Prostaglandin G/H synthase 2 Inhibitor; Sodium channel antagonist; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor
CBR-001-572-960-9,RFM-001-890-6,CBR-001-572-960-9,O=C(C1=C(O)c2ccccc2S(=O)(=O)N1C)Nc1ccccn1,CBR-HVAC-02457: Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-572-961-0,RFM-001-891-7,CBR-001-572-961-0,COc1cc2c(cc1OCCCN1CCCCC1)ncnc2N1CCN(CC1)C(=O)Nc1ccc(cc1)OC(C)C,CBR-HVAC-00360: Prostate Cancer Therapy;Brain Cancer Therapy;Renal Cancer Therapy;Myeloid Leukemia Therapy; Angiogenesis Inhibitors;Antimitotic Drugs;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators; FMS-related tyrosine kinase 3; PDGFR; KIT Inhibitor; Flt-3 kinase inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor
CBR-001-572-962-1,RFM-001-892-8,CBR-001-572-962-1,CN(C1C(=C(C(=O)N)C(=O)C2(C1C(O)C1C(C)c3cccc(c3C(=O)C1=C2O)O)O)O)C,CBR-HVAC-02450: Protein 30S ribosomal subunit inhibitor
CBR-001-572-963-2,RFM-001-893-9,CBR-001-572-963-2,OC(=O)COc1nn(c2c1cccc2)Cc1ccccc1,CBR-HVAC-01456: Protein synthesis inhibitor
CBR-001-572-964-3,RFM-001-894-0,CBR-001-572-964-3,NCCCCCN,CBR-HVAC-09720: Protein tyrosine phosphatase Inhibitor;
CBR-001-572-965-4,RFM-001-895-1,CBR-001-572-965-4,CCCOc1ccccc1c1nc(O)c2c(n1)[nH]nn2,"CBR-HVAC-08551: Pulmonary Hypertension, Treatment of;Analgesic Drugs; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; ; Phosphodiesterase 5 inhibitor; Histamine release inhibitor"
CBR-001-572-966-5,RFM-001-896-2,CBR-001-572-966-5,COC([C@@H](C(=O)O)Oc1nc(C)cc(n1)C)(c1ccccc1)c1ccccc1,"CBR-HVAC-01797: Pulmonary Hypertension, Treatment of;Heart Failure Therapy;Scleroderma, Agents for;Hypertension, Treatment of;Renal Failure, Agents for;Interstitial Lung Diseases, Treatment of; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist; Endothelin A receptor antagonist"
CBR-001-572-967-6,RFM-001-897-3,CBR-001-572-967-6,CCOc1ccc(cc1c1[nH]c(=O)c2n(n1)c(CCC)nc2C)S(=O)(=O)N1CCN(CC1)CC,"CBR-HVAC-01642: Raynaud's Phenomenon, Treatment for ;Benign Prostatic Hyperplasia Therapy;Pulmonary Hypertension, Treatment of;Treatment of Erectile Dysfunction;Urinary Incontinence Therapy;Treatment of Renal Diseases; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor"
CBR-001-572-968-7,RFM-001-898-4,CBR-001-572-968-7,OC(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)cc(cc3)Cl)CCc2ccccc2C(O)(C)C)CC1,"CBR-HVAC-04538: Respiratory Disorders (Not Specified);Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs;Asthma Therapy;Esophageal Diseases, Treatment of;Treatment of Upper Respiratory Tract Disorders;Sickle Cell Anemia, Agents for;Drugs for Allergic Rhinitis;Migraine, Prophylactic Treatment of; Leukotriene Antagonists;Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Cysteinyl leukotriene receptor Antagonist; Leucotriene D4 antagonist; Leucotriene receptor antagonist"
CBR-001-572-969-8,RFM-001-899-5,CBR-001-572-969-8,CNC(=O)c1n(CC)cnc1C(=O)NC,"CBR-HVAC-04019: Respiratory Stimulants;Antiallergy/Antiasthmatic Drugs;Cognition Disorders, Treatment of; ; ;"
CBR-001-572-970-1,RFM-001-900-1,CBR-001-572-970-1,OC/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,CBR-HVAC-09652: Retinol-binding protein Binder;
CBR-001-572-971-2,RFM-001-901-2,CBR-001-572-971-2,CC[C@](C(=O)NCC(F)(F)F)(Nc1ccnc(n1)c1c[nH]c2c1cccn2)C,"CBR-HVAC-00731: Rheumatoid Arthritis, Treatment of; Jak2 Inhibitors;Jak3 Inhibitors;Signal Transduction Modulators; c-Jun N-terminal kinase 3 Inhibitor; Janus kinase 3 inhibitor; Tyrosine kinase inhibitor (TKI)"
CBR-001-572-972-3,RFM-001-902-3,CBR-001-572-972-3,Fc1ccc(c(c1)F)Sc1ccc2n(n1)cnc(=O)c2c1c(Cl)cccc1Cl,"CBR-HVAC-00048: Rheumatoid Arthritis, Treatment of;Myelodysplastic Syndrome Therapy;Alzheimer's Dementia, Treatment of ; Antiinflammatory Drugs;MAPK p38 Inhibitors;Signal Transduction Modulators; p38 Mitogen-activated protein kinase Inhibitor; P38 kinase inhibitor"
CBR-001-572-973-4,RFM-001-903-4,CBR-001-572-973-4,Cc1onc(c1c1ccc(cc1)S(=O)(=O)N)c1ccccc1,"CBR-HVAC-02795: Rheumatoid Arthritis, Treatment of;Osteoarthritis, Treatment of;Treatment of Dysmenorrhea;Non-Opioid Analgesics;Antimigraine Drugs; Cytochrome P450 CYP2C9 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase 2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-572-974-5,RFM-001-904-5,CBR-001-572-974-5,O=C([C@H](NC(=O)C(N)(C)C)COCc1ccccc1)N1CCC2(CC1)CN(c1c2cccc1)S(=O)(=O)C,"CBR-HVAC-04738: Sarcopenia, Treatment of;Treatment of Renal Diseases;Alzheimer's Dementia, Treatment of ;Endocrine Disorders (Not Specified);Treatment of Growth Hormone Deficiency;Fibromyalgia, Treatment of; Growth Hormone Secretagogues;Signal Transduction Modulators; GROWTH HORMONE SECRETAGOGUE RECEPTOR Agonist; Growth hormone releasing factor agonist; Growth hormone secretagogue receptor agonist"
CBR-001-572-975-6,RFM-001-905-6,CBR-001-572-975-6,CCN(c1cccc(c1)c1ccnc2n1ncc2C#N)C(=O)C,CBR-HVAC-01490: Sedative/Hypnotics; Cytochrome P450 CYP3A4 Inhibitors;GABA(A) BZ Site 1 (Omega-1) Receptor Agonists;Signal Transduction Modulators; GABA receptor Agonist; Non-benzodiazepine hypnotic; Benzodiazepine receptor agonist;2016-04-01: controlled substance
CBR-001-572-976-7,RFM-001-906-7,CBR-001-572-976-7,COC(=O)C1=C(C)N(C(=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC)C)C,CBR-HVAC-07507: Selectin antagonist
CBR-001-572-977-8,RFM-001-907-8,CBR-001-572-977-8,COc1ccc(cc1)C(=O)N1CCCC1=O,"CBR-HVAC-01827: Senile Dementia, Treatment of;Mood Disorders, Treatment of; ; Ionotropic glutamate receptor AMPA Modulator; AMPA receptor agonist"
CBR-001-572-978-9,RFM-001-908-9,CBR-001-572-978-9,O=C(Nc1ccccc1C(=O)O)Nc1cccc(c1)C(F)(F)F,"CBR-HVAC-11228: Sickle Cell Anemia, Agents for; Chloride Channel Blockers; Chloride channel Blocker;"
CBR-001-572-979-0,RFM-001-909-0,CBR-001-572-979-0,CC(=O)Oc1sc2c(c1)CN(CC2)C(c1ccccc1F)C(=O)C1CC1,"CBR-HVAC-01516: Sickle Cell Anemia, Agents for;Cardiovascular Diseases (Not Specified);Antiplatelet Therapy;Hematopoiesis Disorders Therapy; P2Y12 (P2T) Antagonists;Signal Transduction Modulators; P2Y purinoceptor 12 Inhibitor; Purinoreceptor P2Y12 antagonist; Platelet aggregation inhibitor; Purinoreceptor P2 antagonist"
CBR-001-572-980-3,RFM-001-910-3,CBR-001-572-980-3,Fc1ccc(c(c1)C(F)(F)F)C(=O)N(C1CCN(CC1)c1nnc(c2c1cccc2)c1ccnn1C)C,CBR-HVAC-07081: Small Cell Lung Cancer Therapy;Brain Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Sarcoma Therapy; Hedgehog Signaling Inhibitors;Signal Transduction Modulators;Smoothened (Smo) Receptor Antagonists; HEDGEHOG PROTEIN Antagonist;
CBR-001-572-981-4,RFM-001-911-4,CBR-001-572-981-4,CN/C(=N/S(=O)(=O)c1ccc(cc1)Cl)/N1N=C(C(C1)c1ccccc1)c1ccc(cc1)Cl,"CBR-HVAC-05637: Smoking Cessation, Aid to;Antiobesity Drugs;Antipsychotic Drugs; Cannabinoid CB1 Antagonists;Signal Transduction Modulators; Cannabinoid receptor 1 Antagonist; Cannabinoid CB1 receptor antagonist"
CBR-001-572-982-5,RFM-001-912-5,CBR-001-572-982-5,O=C(c1ccc(cc1)Cl)NCCN1CCOCC1,"CBR-HVAC-01738: Social Phobia, Treatment for;Antidepressants; MAO-A Inhibitors; Monoamine oxidase A Inhibitor; Monoamine oxidase A inhibitor"
CBR-001-572-983-6,RFM-001-913-6,CBR-001-572-983-6,CCCCOc1nc2ccccc2c(c1)C(=O)NCCN(CC)CC,CBR-HVAC-09763: Sodium channel Blocker;
CBR-001-572-984-7,RFM-001-914-7,CBR-001-572-984-7,NC(=NC(=O)c1ccc(c(c1)S(=O)(=O)C)C(C)C)N,CBR-HVAC-04632
CBR-001-572-985-8,RFM-001-915-8,CBR-001-572-985-8,NC(=N)NC(=O)c1nc(Cl)c(nc1N)N,"CBR-HVAC-04040: Epithelial Sodium Channels (ENaC) Blockers; Na+/H+ Exchanger (NHE) Inhibitors; Sodium/hydrogen exchanger Inhibitor; Antikaliuretic; Diuretic; Diuretics; Hypertension, Treatment of"
CBR-001-572-986-9,RFM-001-916-9,CBR-001-572-986-9,C=CCc1cccc(c1O)/C=N\NC(=O)CN1CCN(CC1)Cc1ccccc1,CBR-HVAC-06466: Solid Tumors Therapy;Oncolytic Drugs;Brain Cancer Therapy;Lymphoma Therapy; Apoptosis Inducers;Procaspase 3 Activators;Signal Transduction Modulators; Caspase-3 Stimulator;
CBR-001-572-987-0,RFM-001-917-0,CBR-001-572-987-0,OP(=O)(C(P(=O)(O)O)(Cn1cncc1)O)O,"CBR-HVAC-01957: Solid Tumors Therapy;Prostate Cancer Therapy;Neurologic Cancer Therapy;Bone Resorption Inhibitors;Rheumatoid Arthritis, Treatment of;Premalignant Conditions Therapy;Neuropathic Pain, Treatment of;Sickle Cell Anemia, Agents for;Treatment of Osteoporosis;Treatment of Hypercalcemia;Oncolytic Drugs;Bone Diseases, Treatment of;Breast Cancer Therapy;Bone Cancer Therapy;Treatment of Paget's Disease; Angiogenesis Inhibitors;Drugs Targeting Tumor-Associated Macrophages;Farnesyl Pyrophosphate Synthase Inhibitors;MMP9 Expression Inhibitors; Farnesyl diphosphate synthase Inhibitor; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor"
CBR-001-572-988-1,RFM-001-918-1,CBR-001-572-988-1,CC(CCON=O)C,CBR-HVAC-09738: Specific Antidotes; ; ;
CBR-001-572-989-2,RFM-001-919-2,CBR-001-572-989-2,O=C(N(C)C)Oc1cccc(c1)[N+](C)(C)C,CBR-HVAC-01302: Specific Antidotes; Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor
CBR-001-572-990-5,RFM-001-920-5,CBR-001-572-990-5,OCCOc1cc(O)c2c(c1)oc(c(c2=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@@H](C)[C@@H]([C@H]([C@H]2O)O)O)[C@H]([C@@H]([C@H]1O)O)O)c1ccc(c(c1)OCCO)OCCO,"CBR-HVAC-04062: Specific Antidotes;Diabetic Retinopathy, Agents for; Antioxidants; ;"
CBR-001-572-991-6,RFM-001-921-6,CBR-001-572-991-6,CC(CCc1ccc(cc1)O)NCCc1ccc(c(c1)O)O,"CBR-HVAC-02167: Stress Agents;Heart Failure Therapy;Septic Shock, Treatment of ; beta1-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Agonist; Beta 1 adrenoreceptor agonist; Alpha 1 adrenoreceptor agonist; Beta 2 adrenoreceptor agonist"
CBR-001-572-992-7,RFM-001-922-7,CBR-001-572-992-7,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(nc2N)n1ncc(c1)C(=O)NC,CBR-HVAC-05347: Stress Agents;Hematopoiesis Disorders Therapy; Adenosine A2A Agonists;Signal Transduction Modulators; Adenosine A2A receptor Agonist;
CBR-001-572-993-8,RFM-001-923-8,CBR-001-572-993-8,OC[C@@H]([C@H](CO)O)O,"CBR-HVAC-01193: Stroke, Treatment of; ; ; Unidentified pharmacological activity"
CBR-001-572-994-9,RFM-001-924-9,CBR-001-572-994-9,OC(=O)C1(N)CC1,"CBR-HVAC-04257: Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; Glycine NMDA associated agonist"
CBR-001-572-995-0,RFM-001-925-0,CBR-001-572-995-0,O=C(Nc1c(C)cccc1C)CN1CCCC1=O,"CBR-HVAC-03247: Stroke, Treatment of;Alzheimer's Dementia, Treatment of ; ; CALCIUM CHANNEL Activator; Agonist; Choline acetyltransferase stimulant; Calcium channel agonist; GABA receptor agonist; Nicotinic receptor agonist"
CBR-001-572-996-1,RFM-001-926-1,CBR-001-572-996-1,COc1cc(CCN2CCN(CC2)CCCc2ccccc2)ccc1OC,"CBR-HVAC-00531: Stroke, Treatment of;Antidepressants;Treatment of Substance Dependency; Acetylcholine Release Enhancers;sigma1 Receptor Agonists;Signal Transduction Modulators; SIGMA 1 RECEPTOR Agonist; Sigma 1 receptor agonist"
CBR-001-572-997-2,RFM-001-927-2,CBR-001-572-997-2,N#Cc1cc2nc(O)c(nc2cc1[N+](=O)[O-])O,"CBR-HVAC-07822: Stroke, Treatment of;Antipsychotic Drugs; AMPA Receptor Antagonists;NMDA Antagonists;Signal Transduction Modulators; ; Unidentified pharmacological activity"
CBR-001-572-998-3,RFM-001-928-3,CBR-001-572-998-3,CCCN(c1nc(C)nc(c1Cl)Nc1c(Cl)cc(cc1Cl)Cl)CC1CC1,"CBR-HVAC-09191: Stroke, Treatment of;Irritable Bowel Syndrome, Agents for; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing hormone receptor 1 Antagonist;"
CBR-001-572-999-4,RFM-001-929-4,CBR-001-572-999-4,C=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(CC2N(CC3)CC2CC2)ccc1O)O,"CBR-HVAC-02226: Stroke, Treatment of;Treatment of Alcohol Dependency;Treatment of Substance Dependency;Antagonists to Narcotics;Psychiatric Disorders (Not Specified);Antipsychotic Drugs;Liver and Biliary Tract Disorders, Treatment of; delta-Opioid Antagonists;kappa-Opioid Antagonists;mu-Opioid Antagonists;Signal Transduction Modulators;TLR4 (LPS) Receptor Antagonists; Opioid receptor Antagonist; Opioid mu receptor antagonist; Opioid kappa receptor antagonist"
CBR-001-573-000-4,RFM-001-930-7,CBR-001-573-000-4,CC(=O)NCCCS(=O)(=O)O,"CBR-HVAC-02399: Tardive Dyskinesia, Treatment of;Mental Retardation, Treatment of;Treatment of Substance Dependency;Neurologic Drugs (Miscellaneous);Psychiatric Disorders (Not Specified);Tinnitus, treatment of;Treatment of Alcohol Dependency;Treatment of Bulimia;Posttraumatic Stress Disorder (PTSD), Treatment of;Autism, Treatment of;Extrapyramidal Disorders, Treatment of; Drugs Acting on Glutamate Receptors (Metabotropic; mgluR);NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Inhibitor; GABA receptor agonist"
CBR-001-573-001-5,RFM-001-931-8,CBR-001-573-001-5,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@@H]3[C@]([C@H]2[C@@H]([C@]2(C(C1=C(C)[C@@H](OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)c1ccccc1)O)C2)(C)C)O)OC(=O)c1ccccc1)(CO3)OC(=O)C,CBR-HVAC-00283: Taxane; Beta tubulin antagonist; Microtubule stimulant
CBR-001-573-002-6,RFM-001-932-9,CBR-001-573-002-6,CCOc1ccc2c(c1)c(N)c1c(n2)cc(cc1)N,CBR-HVAC-09815: Telomerase Inhibitor;
CBR-001-573-003-7,RFM-001-933-0,CBR-001-573-003-7,OC(=O)CN1CCNC1=N,CBR-HVAC-04546: Therapy of Inborn Errors of Metabolism;Oncolytic Drugs;Antiviral Drugs; ; Creatine kinase Inhibitor; Unidentified pharmacological activity
CBR-001-573-004-8,RFM-001-934-1,CBR-001-573-004-8,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)[nH]c1=O,CBR-HVAC-00912: Thymidylate synthase Inhibitor; DNA synthesis inhibitor
CBR-001-573-005-9,RFM-001-935-2,CBR-001-573-005-9,CC1OC(C(C1O)O)n1cc(F)c(=O)[nH]c1=O,CBR-HVAC-01619: Thymidylate synthase Inhibitor; Thymidylate synthase inhibitor
CBR-001-573-006-0,RFM-001-936-3,CBR-001-573-006-0,O=c1[nH]c(=O)n(cc1F)C1CCCO1,CBR-HVAC-01361: Thymidylate synthase Inhibitor; Thymidylate synthase inhibitor; Orotate phosphoribosyltransferase inhibitor; DNA synthesis inhibitor; Dihydropyrimidine dehydrogenase inhibitor
CBR-001-573-007-1,RFM-001-937-4,CBR-001-573-007-1,OC(=O)CCc1c(I)cc(c(c1I)/N=C/N(C)C)I,CBR-HVAC-10078: Thyroid hormone receptor Inhibitor;
CBR-001-573-008-2,RFM-001-938-5,CBR-001-573-008-2,O=C1CC[C@H](N1)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1nc[nH]c1,CBR-HVAC-00017: Thyroid-stimulating hormone receptor Stimulator; Thyrotropin releasing hormone receptor agonist
CBR-001-573-009-3,RFM-001-939-6,CBR-001-573-009-3,O=C1NC(=O)C2C1C1C=CC2C2C1C1C2C(=O)NC1=O,CBR-HVAC-02538: Topoisomerase II Inhibitor; DNA inhibitor
CBR-001-573-010-6,RFM-001-940-9,CBR-001-573-010-6,N#Cc1ccc2c(c1)COC2(CCCN(C)C)c1ccc(cc1)F,"CBR-HVAC-01265: Treatment of Alcohol Dependency;Antidepressants;Mood Disorders, Treatment of;Anxiolytics;Bipolar Disorder, Treatment of;Treatment of Opioid Dependency;Huntington's Disease, Treatment of;Autism, Treatment of; Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5-Hydroxytryptamine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor"
CBR-001-573-011-7,RFM-001-941-0,CBR-001-573-011-7,CC[C@@H](C(=O)O[C@H]1C[C@@H](C)C=C2[C@H]1[C@@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@H](C=C2)C)C,"CBR-HVAC-00025: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Rheumatoid Arthritis, Treatment of;Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ;Ischemic Stroke, Treatment of;Irritable Bowel Syndrome, Agents for;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Antiviral Drugs;Chemopreventive Agents;Neurologic Drugs (Miscellaneous); HMG-CoA Reductase Inhibitors; ; HMGCoA reductase inhibitor"
CBR-001-573-012-8,RFM-001-942-1,CBR-001-573-012-8,NS(=O)(=O)Cc1noc2c1cccc2,"CBR-HVAC-01916: Treatment of Eating Disorders;Migraine, Prophylactic Treatment of;Neuropathic Pain, Treatment of;Sleep Apnea, Treatment of;Fibromyalgia, Treatment of;Dystonia, Treatment of;Smoking Cessation, Aid to;Antiobesity Drugs;Antiepileptic Drugs;Antiparkinsonian Drugs; Sodium Channel  Blockers;T-Type Calcium Channel Blockers; Sodium channel Blocker; GABA receptor agonist"
CBR-001-573-013-9,RFM-001-943-2,CBR-001-573-013-9,c1ccc(nc1)N1CCN(CC1)Cc1nc2c([nH]1)cccc2,CBR-HVAC-05982: Treatment of Erectile Dysfunction; Dopamine D4 Agonists;Signal Transduction Modulators; Dopamine receptor D4 Agonist;
CBR-001-573-014-0,RFM-001-944-3,CBR-001-573-014-0,CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)Cc1nc[nH]c1)Cc1ccccc1)CCCNC(=N)N)Cc1c[nH]c2c1cccc2)C(=O)O)NC(=O)C,CBR-HVAC-05378: Treatment of Erectile Dysfunction;Treatment of Female Sexual Dysfunction;Treatment of Renal Diseases; Melanocortin MC3 Receptor Agonists;Melanocortin MC4 Receptor Agonists;Signal Transduction Modulators; Melanocortin receptor Agonist;
CBR-001-573-015-1,RFM-001-945-4,CBR-001-573-015-1,O=c1[nH]c2c(n1CCN1CCN(CC1)c1cccc(c1)C(F)(F)F)cccc2,CBR-HVAC-04448: Treatment of Female Sexual Dysfunction;Antidepressants; Signal Transduction Modulators;5-HT1A Receptor Agonists;5-HT2A Antagonists; ; 5 Hydroxytryptamine 1A receptor agonist; 5 Hydroxytryptamine 2A receptor antagonist; Dopamine D4 receptor agonist
CBR-001-573-016-2,RFM-001-946-5,CBR-001-573-016-2,CCCOc1ccc2c(c1)nc([nH]2)NC(=O)OC,CBR-HVAC-05521: Treatment of Helminthic Diseases; DNA Polymerase Inhibitors; DNA polymerase Inhibitor;
CBR-001-573-017-3,RFM-001-947-6,CBR-001-573-017-3,O=C(N1CCc2c([C@@H]1c1ccccc1)cccc2)O[C@H]1CN2CCC1CC2,CBR-HVAC-01399: Treatment of Hot Flushes;Urinary Incontinence Therapy;Urologic Drugs; Muscarinic M3 Antagonists;Signal Transduction Modulators; MUSCARINIC RECEPTOR M3 Antagonist; Muscarinic M3 receptor antagonist
CBR-001-573-018-4,RFM-001-948-7,CBR-001-573-018-4,COc1cc(OC)cc(c1C(=O)CCCN1CCCC1)OC,CBR-HVAC-01822: Treatment of Intermittent Claudication; ; Alpha adrenergic receptor Antagonist; Alpha adrenoreceptor antagonist; Calcium channel antagonist
CBR-001-573-019-5,RFM-001-949-8,CBR-001-573-019-5,C[C@@H](CCC[C@]1(C)CCc2c(O1)c(C)c(c(c2C)OC(=O)C)C)CCC[C@@H](CCCC(C)C)C,"CBR-HVAC-02881: Treatment of Nutritional Disorders;Atopic Dermatitis, Agents for; Antioxidants; ;"
CBR-001-573-020-8,RFM-001-950-1,CBR-001-573-020-8,NCC(=O)N[C@H](C(=O)O)CCC(=O)N,CBR-HVAC-04815: Treatment of Opioid Dependency;Chemoprotective Agents; ; ;
CBR-001-573-021-9,RFM-001-951-2,CBR-001-573-021-9,Oc1ccc2c(c1)C=CC1C2CCC2(C1CCC2=O)C,"analog of CBR-HVAC-05260 (Delta(8,9)-dehydroestrone sulfate) sent to us in error"
CBR-001-573-022-0,RFM-001-952-3,CBR-001-573-022-0,S[C@H]([C@@H](C(=O)O)S)C(=O)O,CBR-HVAC-01318: Treatment of Poisoning;Radiopharmaceuticals;Diagnostic Agents; Chelating Agents; ; Chelating agent
CBR-001-573-023-1,RFM-001-953-4,CBR-001-573-023-1,CC1CCC2C31CCC(C(C3)C2(C)C)(C)O,CBR-HVAC-06652: Treatment of Postmenopausal Syndrome ;Sedative/Hypnotics; ; ;
CBR-001-573-025-3,RFM-001-954-5,CBR-001-573-025-3,OCCCN1CCc2c1c(cc(c2)C[C@H](NCCOc1ccccc1OCC(F)(F)F)C)C(=O)N,CBR-HVAC-02082: Treatment of Renal Diseases;Benign Prostatic Hyperplasia Therapy;Urologic Drugs; alpha1A-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist
CBR-001-573-026-4,RFM-001-955-6,CBR-001-573-026-4,Cc1[nH]c2c(n1)CCN(c1c2cccc1)C(=O)c1ccc(cc1)NC(=O)c1ccccc1c1ccccc1,CBR-HVAC-01717: Treatment of Renal Diseases;Diuretics;Heart Failure Therapy; Oxytocin (OT) Antagonists;Signal Transduction Modulators;Vasopressin (AVP) V1a Receptor Antagonists;Vasopressin (AVP) V2 Receptor Antagonists; Vasopressin V1a receptor; Vasopressin V2 receptor Antagonist; Vasopressin 1A antagonist; Vasopressin 2 antagonist
CBR-001-573-027-5,RFM-001-956-7,CBR-001-573-027-5,Cc1ccc(cc1)C(=O)c1cc(O)c(c(c1)[N+](=O)[O-])O,"CBR-HVAC-02793: Treatment of Substance Dependency;Antiparkinsonian Drugs;Neurological Genetic Disorders, Treatment of ;Psychiatric Disorders (Not Specified);Antipsychotic Drugs;Amyloidosis, Treatment of; COMT Inhibitors;Cytochrome P450 CYP2C9 Inhibitors;Transthyretin Amyloid Inhibitors; Catechol-O-methyltransferase Inhibitor; Catechol O methyltransferase inhibitor"
CBR-001-573-028-6,RFM-001-957-8,CBR-001-573-028-6,NS(=O)(=O)OCC12OCC3C(C2OC(O1)(C)C)OC(O3)(C)C,"CBR-HVAC-01484: Treatment of Substance Dependency;Treatment of Cocaine Dependency;Antiobesity Drugs;Inflammatory Bowel Disease, Agents for;Antiepileptic Drugs;Antimigraine Drugs;Bipolar Disorder, Treatment of;Treatment of Nutritional Disorders;Treatment of Alcohol Dependency;Obsessive-Compulsive Disorder (OCD), Treatment of;Psychiatric Disorders (Not Specified);Migraine, Prophylactic Treatment of;Neuropathic Pain, Treatment of;Smoking Cessation, Aid to;Treatment of Eating Disorders;Cerebrovascular Diseases, Treatment of; AMPA Receptor Antagonists;Carbonic Anhydrase Type II Inhibitors;Kainate Receptor Antagonists;Signal Transduction Modulators;Sodium Channel  Blockers; Carbonic anhydrase Inhibitor; Carbonic anhydrase inhibitor ; GABA A receptor agonist; AMPA receptor antagonist; Kainate receptor antagonist; Voltage-gated sodium channel antagonist"
CBR-001-573-029-7,RFM-001-958-9,CBR-001-573-029-7,CCc1nccc(c1)C(=S)N,CBR-HVAC-02876: Treatment of Tuberculosis; Cell Wall Biosynthesis Inhibitors; Fatty acid synthase subunit alpha Inhibitor;
CBR-001-573-030-0,RFM-001-959-0,CBR-001-573-030-0,COc1nc2ccc(cc2cc1[C@H]([C@](c1cccc2c1cccc2)(CCN(C)C)O)c1ccccc1)Br,CBR-HVAC-06144: Treatment of Tuberculosis; Proton-Translocating ATP Synthetase (F0F1 ATPase) Inhibitors; ATP synthase Inhibitor; Adenosinetriphosphate synthase inhibitor
CBR-001-573-031-1,RFM-001-960-3,CBR-001-573-031-1,O=C(c1ccncc1)N/N=C/c1ccccc1O,CBR-HVAC-08815: Treatment of Tuberculosis;Antimalarials;Cardioprotective Agents;Antagonists to Metals; Antioxidants;Chelating Agents; ;
CBR-001-573-032-2,RFM-001-961-4,CBR-001-573-032-2,CN(C(=O)COC(=O)Cc1ccc(cc1)OC(=O)c1ccc(cc1)NC(=N)N)C,"CBR-HVAC-03366: Peptide-hydrolase-inhibitors; Protease Inhibitors; Protease/peptidase inhibitor; Serine protease Inhibitor; Trypsin; Trypsin Inhibitors; Antihyperlipidemic; Cancer; Gastroesophageal Reflux Disease, Agents for; Pancreatic Disorders, Treatment of; Protease inhibitor; Serine protease inhibitor; Trypsin inhibitor"
CBR-001-573-033-3,RFM-001-962-5,CBR-001-573-033-3,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)(O)c1ccc(c(c1)C(F)(F)F)Cl,CBR-HVAC-01960: T-Type calcium channel Antagonist; Dopamine receptor antagonist
CBR-001-573-034-4,RFM-001-963-6,CBR-001-573-034-4,COC(=O)Nc1[nH]c2c(n1)cc(cc2)Sc1ccccc1,CBR-HVAC-09786: Tubulin Inhibitor;
CBR-001-573-035-5,RFM-001-964-7,CBR-001-573-035-5,COC(=O)Nc1nc2c([nH]1)cc(cc2)C(=O)c1cccs1,CBR-HVAC-01130: Tubulin inhibitor; Microtubule inhibitor
CBR-001-573-036-6,RFM-001-965-8,CBR-001-573-036-6,OCCN1C[C@H](O)[C@H]([C@@H]([C@H]1CO)O)O,"CBR-HVAC-00085: Type 2 Diabetes, Agents for; alpha-Glucosidase Inhibitors;SGLT-1 Inhibitors;SGLT-3 Activators; Alpha-glucoside hydrolase Inhibitor; Alpha glucosidase inhibitor"
CBR-001-573-037-7,RFM-001-966-9,CBR-001-573-037-7,CCC1=C(C)CN(C1=O)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)N[C@@H]1CC[C@H](CC1)C,"CBR-HVAC-01634: Type 2 Diabetes, Agents for; Cytochrome P450 CYP2C9 Inhibitors;K(ATP) Channel Blockers; Sulfonylurea receptor Binder; ATP-sensitive potassium channel antagonist; Sulfonylurea; Insulin secretagogue; Insulinotropin agonist"
CBR-001-573-038-8,RFM-001-967-0,CBR-001-573-038-8,CCOc1cc(ccc1C(=O)O)CC(=O)N[C@H](c1ccccc1N1CCCCC1)CC(C)C,"CBR-HVAC-01701: Type 2 Diabetes, Agents for; Cytochrome P450 CYP3A4 Inhibitors;Insulin Secretagogues;Signal Transduction Modulators; Sulfonylurea receptor Binder; ATP-sensitive potassium channel antagonist; Meglitinide; Insulin secretagogue"
CBR-001-573-039-9,RFM-001-968-1,CBR-001-573-039-9,N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(C1)CC(C2)(C3)O,"CBR-HVAC-05374: Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor;"
CBR-001-573-040-2,RFM-001-969-2,CBR-001-573-040-2,CON(C(=O)[C@@H]([C@@H](NC(=O)c1cc2c([nH]1)ccc(c2)Cl)Cc1ccccc1)O)C,"CBR-HVAC-11942: Type 2 Diabetes, Agents for; Glycogen Phosphorylase a Inhibitors; Glycogen phosphorylase Inhibitor;"
CBR-001-573-041-3,RFM-001-970-5,CBR-001-573-041-3,COc1cc(ccc1OC)S(=O)(=O)N1CCCN(CC1)S(=O)(=O)c1ccc(c(c1)OC)OC,"CBR-HVAC-06679: Type 2 Diabetes, Agents for; G-Protein Coupled Bile Acid Receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) Agonists;Signal Transduction Modulators; ;"
CBR-001-573-042-4,RFM-001-971-6,CBR-001-573-042-4,CC([C@@H]1CC[C@H](CC1)C(=O)N[C@@H](C(=O)O)Cc1ccccc1)C,"CBR-HVAC-02130: Type 2 Diabetes, Agents for;Antidiabetic Drugs; Insulin Secretagogues;K(ir) 6.2/SUR1 Blockers;Signal Transduction Modulators; Potassium channel Inhibitor; ATP-sensitive potassium channel antagonist; Meglitinide; Insulin secretagogue"
CBR-001-573-043-5,RFM-001-972-7,CBR-001-573-043-5,CC(=O)/N=c/1\sc(nn1C)S(=O)(=O)N,"CBR-HVAC-05320: Type 2 Diabetes, Agents for;Oncolytic Drugs;Antiepileptic Drugs;Antiglaucoma Agents; Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Insulin Sensitizers;Signal Transduction Modulators; Carbonic anhydrase Inhibitor;"
CBR-001-573-044-6,RFM-001-973-8,CBR-001-573-044-6,OC[C@H]1O[C@@H](Oc2ccc(cc2)O)C([C@H](C1O)O)O,CBR-HVAC-10370: Tyrosinase Inhibitor;
CBR-001-573-045-7,RFM-001-974-9,CBR-001-573-045-7,COc1cc2OC(C)(C)C=Cc2c2c1c(=O)c1c(n2C)cccc1,CBR-HVAC-01139: Unidentified pharmacological activity
CBR-001-573-046-8,RFM-001-975-0,CBR-001-573-046-8,NC(=N)NCCCC(C(=O)O)N,CBR-HVAC-02325: Unidentified pharmacological activity
CBR-001-573-047-9,RFM-001-976-1,CBR-001-573-047-9,c1ccc2c(c1)C1=N/C/2=N\c2c3ccccc3c3n2[Zn]n2/c(=N\1)/c1ccccc1/c/2=N/C1=N/C(=N\3)/c2c1cccc2,CBR-HVAC-04549: Apoptosis Inducers; Caspase 3 Activators; Caspase 9 Activators; Radical formation agonist; Reactive-oxygen-species-stimulants; Signal Transduction Modulators; Anticancer; Cancer; Photosensitizer; Radical donator; Radiochemosensitizer
CBR-001-573-048-0,RFM-001-977-2,CBR-001-573-048-0,O=C(N(c1ccc(cc1)OC(=O)c1ccco1)C)C(Cl)Cl,CBR-HVAC-07739: Unidentified pharmacological activity
CBR-001-573-049-1,RFM-001-978-3,CBR-001-573-049-1,O=C(C12CC3CC(C2)CC(C1)C3)NCCc1ccc(c(c1)O)O,CBR-HVAC-01189: Unidentified pharmacological activity
CBR-001-573-050-4,RFM-001-979-4,CBR-001-573-050-4,CCC(=O)NO,CBR-HVAC-08549: Urease inhibitor; Alkalising agent non gastric
CBR-001-573-051-5,RFM-001-980-7,CBR-001-573-051-5,OC(=O)COc1ccc(c(c1Cl)Cl)C(=O)c1cccs1,CBR-HVAC-02845: Uric acid diuretic
CBR-001-573-052-6,RFM-001-981-8,CBR-001-573-052-6,CCN(CC#CCOC(=O)C(c1ccccc1)(C1CCCCC1)O)CC,CBR-HVAC-02339: Urinary Incontinence Therapy; Anticholinergics;Muscarinic Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Antagonist; Muscarinic M1 receptor antagonist; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Muscarinic M4 receptor antagonist
CBR-001-573-053-7,RFM-001-982-9,CBR-001-573-053-7,OCc1ccc(c(c1)[C@@H](c1ccccc1)CCN(C(C)C)C(C)C)OC(=O)C(C)C,CBR-HVAC-01473: Urinary Incontinence Therapy; Muscarinic Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist
CBR-001-573-054-8,RFM-001-983-0,CBR-001-573-054-8,O=C(Cc1csc(n1)N)Nc1ccc(cc1)CCNC[C@@H](c1ccccc1)O,"CBR-HVAC-05205: Urinary Incontinence Therapy;Type 2 Diabetes, Agents for;Urologic Drugs; beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-3 adrenergic receptor Agonist; Beta 3 adrenoreceptor agonist"
CBR-001-573-055-9,RFM-001-984-1,CBR-001-573-055-9,COc1ccccc1N1CCN(CC1)CCCNc1cc(=O)n(c(=O)n1C)C,"CBR-HVAC-01849: Urologic Drugs;Hypertension, Treatment of; alpha1-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Blocker; Alpha adrenoreceptor antagonist; 5 Hydroxytryptamine 1A receptor agonist"
CBR-001-573-056-0,RFM-001-985-2,CBR-001-573-056-0,O=C(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,"CBR-HVAC-02115: Urticaria, Treatment for;Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis;Allergic Skin Disorders, Treatment for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist;2017-11-14: ARB# 16-000830"
CBR-001-573-057-1,RFM-001-986-3,CBR-001-573-057-1,O=c1[nH]c2c(n1CCCN1CCN(CC1)C(c1ccccc1)c1ccccc1)cccc2,"CBR-HVAC-01928: Urticaria, Treatment for;Drugs for Allergic Rhinitis;Eczema, Treatment of;Antiallergic Ophthalmic Agents;Atopic Dermatitis, Agents for;Allergic Skin Disorders, Treatment for;Dermatologic Drugs;Antiallergy/Antiasthmatic Drugs; Mediator Release Inhibitors; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-573-058-2,RFM-001-987-4,CBR-001-573-058-2,CCN(c1ccc(cc1)n1nc2c(n1)cc(c(c2)N)C)CC,CBR-HVAC-08348: Utrophin enhancer
CBR-001-573-059-3,RFM-001-988-5,CBR-001-573-059-3,FC(c1ccc(cc1)Nc1ncnc2c1ccc(c2)c1ncccc1C(F)(F)F)(F)F,CBR-HVAC-08085: Vanilloid receptor 1 antagonist
CBR-001-573-060-6,RFM-001-989-6,CBR-001-573-060-6,OC[C@H]1O[C@@H](Oc2c(oc3c(c2=O)c(O)cc(c3)O)c2ccc(c(c2)O)O)[C@@H]([C@H]([C@H]1O)O)O,"CBR-HVAC-05194: Vasodilators;Non-Opioid Analgesics;Stroke, Treatment of; alpha-Glucosidase Inhibitors;Antiinflammatory Drugs;Antioxidants;Free Radical Scavengers; ;"
CBR-001-573-061-7,RFM-001-990-9,CBR-001-573-061-7,CCCCOC(=O)C(=C)C#N,CBR-HVAC-06537: Wound-Healing Agents;Coagulation Disorders Therapy; ; ;
CBR-001-573-186-9,RFM-001-991-0,CBR-001-573-186-9,CC[N+](c1cccc(c1)O)(C)C,CBR-HVAC-09575 ; ; Acetylcholinesterase Inhibitor;
CBR-001-573-187-0,RFM-001-992-1,CBR-001-573-187-0,CCOC(=O)c1cccnc1,CBR-HVAC-09793 Acetylcholinesterase Inhibitor;
CBR-001-573-188-1,RFM-001-993-2,CBR-001-573-188-1,C#CCO[C@H]1CN2CCC1CC2,"CBR-HVAC-04424 Alzheimer's Dementia, Treatment of ; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Agonist; Muscarinic M1 receptor agonist"
CBR-001-573-189-2,RFM-001-994-3,CBR-001-573-189-2,O=Cc1cnc2n1CCc1c(C2=C2CCN(CC2)C)cccc1,CBR-HVAC-01782 Antiallergic Ophthalmic Agents;Antiallergy/Antiasthmatic Drugs; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; H1 histamine receptor Antagonist; Histamine H1 receptor antagonist
CBR-001-573-190-5,RFM-001-995-4,CBR-001-573-190-5,CCc1c(CC(=O)N)c2c(n1Cc1ccccc1)ccc(c2)OCCCP(=O)(O)O,CBR-HVAC-11175 Antiallergy/Antiasthmatic Drugs; Secretory Phospholipase A2 (sPLA2) Inhibitors;Signal Transduction Modulators; Phospholipase A2 group XII Inhibitor;
CBR-001-573-191-6,RFM-001-996-5,CBR-001-573-191-6,Fc1ccc(cc1)C(c1ccc(cc1)F)OCCN1CCN(CC1)CCCc1ccccc1,CBR-HVAC-00617 Antiarrhythmic Drugs;Treatment of Cocaine Dependency; Dopamine Reuptake Inhibitors;Signal Transduction Modulators; CALCIUM CHANNEL; DOPAMINE TRANSPORTER; HERG CHANNEL; SODIUM CHANNEL Modulator; Dopamine reuptake inhibitor; Monoamine oxidase A inhibitor; Monoamine oxidase B inhibitor
CBR-001-573-192-7,RFM-001-997-6,CBR-001-573-192-7,CCOC(CN1c2ccccc2[C@@](C1=O)(CC(=O)Nc1ccc(cc1)C)NC(=O)Nc1ccc(cc1)C)OCC,CBR-HVAC-10798 Antiarthritic Drugs;Gastric Antisecretory Drugs;Oncolytic Drugs; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin B receptor Antagonist;
CBR-001-573-193-8,RFM-001-998-7,CBR-001-573-193-8,OC(=O)Cc1c(c2ccc(cc2)Cl)c(c2n1CC(C2)(C)C)c1ccccc1,"CBR-HVAC-00806 Antiarthritic Drugs;Inflammation, Treatment of;Osteoarthritis, Treatment of;Non-Opioid Analgesics; Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators;5-Lipoxygenase Inhibitors; CYCLOXYGENASE; LIPOXYGENASE 5 Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; 5 Lipoxygenase inhibitor"
CBR-001-573-194-9,RFM-001-999-8,CBR-001-573-194-9,O=S1(=O)CCN(CN1)CN1CCS(=O)(=O)NC1,CBR-HVAC-01931 Antibacterial Drugs;Oncolytic Drugs; ; ; Cell wall synthesis inhibitor; Apoptosis stimulant
CBR-001-573-195-0,RFM-002-000-8,CBR-001-573-195-0,CON=C(c1csc(n1)N)C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)CSc1nc(c(s1)CC(=O)O)C,CBR-HVAC-02054 Antibiotics; ; Penicillin binding protein 3 Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-196-1,RFM-002-001-9,CBR-001-573-196-1,NCCCC[C@@H](C(=O)N[C@@H]1[C@H](C)SC[C@@H]2NC(=O)[C@H](NC(=O)[C@@H](NC1=O)C)[C@H](C)SC[C@H](NC(=O)[C@@H](NC2=O)Cc1cnc[nH]1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(=C)C(=O)N[C@H](C(=O)O)CCCCN)C(C)C)Cc1cnc[nH]1)[C@H](CC)C)CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CS[C@@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CS[C@@H](C)[C@H](NC(=O)[C@@H]3CSC[C@@H](NC(=O)/C(=C/C)/NC(=O)[C@H]([C@H](CC)C)N)C(=O)N[C@@H]([C@H](CC)C)C(=O)NC(=C)C(=O)N[C@H](C(=O)N3)CC(C)C)C(=O)N3[C@H](C(=O)NCC(=O)N2)CCC3)CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N1)CCSC)CC(C)C)CC(=O)N)CCSC,CBR-HVAC-04833 Antibiotics;Anti-Helicobacter Pylori Agents; ; ;
CBR-001-573-198-3,RFM-002-002-0,CBR-001-573-198-3,CNCCCC12CCC(c3c1cccc3)c1c2cccc1,CBR-HVAC-03128 Antidepressants; ; Norepinephrine transporter Inhibitor;
CBR-001-573-199-4,RFM-002-003-1,CBR-001-573-199-4,O=C1NC(=O)C(S1)Cc1ccc(cc1)C(=O)CCc1nc(oc1C)c1ccccc1,"CBR-HVAC-03913 Antidiabetic Drugs;Lipoprotein Disorders, Treatment of ; Insulin Sensitizers;PPARgamma Agonists;Signal Transduction Modulators; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Agonist; Unidentified pharmacological activity"
CBR-001-573-200-0,RFM-002-004-2,CBR-001-573-200-0,CC(OC(=O)[C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)F)n1ccc(=O)[nH]c1=O)C)C,CBR-HVAC-06981 Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B polymerase Inhibitor;
CBR-001-573-201-1,RFM-002-005-3,CBR-001-573-201-1,OC(=O)C(c1ccc2c(c1)Cc1c(O2)nccc1)C,CBR-HVAC-02109 Antiinflammatory Ophthalmic Agents; ; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-573-202-2,RFM-002-006-4,CBR-001-573-202-2,OC[C@@H]1O[C@@H](OC([C@@H](C(=O)N[C@@H]([C@H]([C@@H](C(=O)N[C@H](C(=O)NCCc2scc(n2)c2scc(n2)C(=O)NCCC[S+](C)C)[C@H](O)C)C)O)C)NC(=O)c2nc(nc(c2C)N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)c2nc[nH]c2)[C@H]([C@H]([C@@H]1O)O)O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@@H]1O)OC(=O)N)O,CBR-HVAC-05125 Antineoplastic Antibiotics; ; ;
CBR-001-573-203-3,RFM-002-007-5,CBR-001-573-203-3,O=C1CCCC(=O)C1C(=O)c1ccc(cc1[N+](=O)[O-])C(F)(F)F,"CBR-HVAC-02071 Antiparkinsonian Drugs;Therapy of Inborn Errors of Metabolism;Dermatologic Drugs;Thyroid Disease Therapy;Restless Legs Syndrome, Treatment of; 4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitors; 4-Hydroxyphenylpyruvate dioxygenase Inhibitor; 4-hydroxyphenylpyruvate dioxygenase inhibitor"
CBR-001-573-204-4,RFM-002-008-6,CBR-001-573-204-4,C/C(=C\CC[C@]1(C)CCc2c(O1)c(C)cc(c2)O)/CC/C=C(/CCC=C(C)C)\C,"CBR-HVAC-04206 Antiplatelet Therapy;Lipoprotein Disorders, Treatment of ; Apoptosis Inducers;HMG-CoA Reductase Inhibitors; ;"
CBR-001-573-205-5,RFM-002-009-7,CBR-001-573-205-5,O=C1NC/C=C\C(=C\[C@@H](O)CC(=O)Cc2nc(C(=O)N3C(=CCC3)C(=O)O[C@@H]([C@@H](/C=C/1)C)C(C)C)co2)\C,CBR-HVAC-03974 Antiulcer Drugs; CCK Receptor Antagonists;Signal Transduction Modulators; Cholecystokinin B receptor Inhibitor;
CBR-001-573-206-6,RFM-002-010-0,CBR-001-573-206-6,CCCCCCCCCCCCCCCCNc1ccc(cc1)C(=O)O,"CBR-HVAC-07612 Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ; ; ; Cholesterol inhibitor"
CBR-001-573-207-7,RFM-002-011-1,CBR-001-573-207-7,N#Cc1ccc(cc1C(F)(F)F)NC(=O)C(CS(=O)(=O)c1ccc(cc1)F)(O)C,CBR-HVAC-01552 Breast Cancer Therapy;Prostate Cancer Therapy; Androgen Receptor Antagonists;Signal Transduction Modulators; Androgen receptor Inhibitor; Androgen receptor antagonist
CBR-001-573-208-8,RFM-002-012-2,CBR-001-573-208-8,O=NSC(C(C(=O)O)NC(=O)C)(C)C,CBR-HVAC-04500 Bronchodilators;Oncolytic Drugs; Nitric Oxide (NO) Donors;Protein Tyrosine Phosphatase PTP-1B Inhibitors;Signal Transduction Modulators; ; Unidentified pharmacological activity
CBR-001-573-209-9,RFM-002-013-3,CBR-001-573-209-9,ClC1=C(NCCN2CCOCC2)C(=O)c2c(C1=O)cccn2,CBR-HVAC-11869 Cell division cycle 25 Inhibitor;
CBR-001-573-210-2,RFM-002-014-4,CBR-001-573-210-2,OCC1=CCC(CC1)C(=C)C,"CBR-HVAC-00505 Chemopreventive Agents;Actinic Keratoses, Agents for;Breast Cancer Therapy;Colorectal Cancer Therapy;Ovarian Cancer Therapy;Prostate Cancer Therapy;Neurologic Cancer Therapy;Pancreatic Cancer Therapy; Apoptosis Inducers; ANDROGEN RECEPTOR Inhibitor; Farnesyltransferase inhibitor; Cell cycle inhibitor; Apoptosis stimulant"
CBR-001-573-211-3,RFM-002-015-5,CBR-001-573-211-3,Oc1ccc(cc1)c1oc2cc(O)cc(c2c(=O)c1O)O,"CBR-HVAC-10079 Chemopreventive Agents;Alzheimer's Dementia, Treatment of ;Antiarthritic Drugs; Antioxidants;Apoptosis Inducers;Drugs Acting on Quorum Sensing Signaling;Estrogen-Related Receptor alpha (ERRalpha, ERR1) Inverse Agonists;Estrogen-Related Receptor gamma (ERRgamma) Inverse Agonists;Jak3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Signal Transducer and Activator of Transcription 6 (STAT6) Inhibitors;Signal Transduction Modulators;Xanthine Oxidase Inhibitors; Nitric oxide synthase; COX-2 Modulator;"
CBR-001-573-212-4,RFM-002-016-6,CBR-001-573-212-4,O=C(c1ccccc1)OCc1ccccc1,CBR-HVAC-09547 Chymotrypsinogen; Malate dehydrogenase; Beta-lactamase Inhibitor;
CBR-001-573-213-5,RFM-002-017-7,CBR-001-573-213-5,CCCN1CCC(CC1)c1cccc(c1)S(=O)(=O)C,"CBR-HVAC-00678 Cognition Disorders, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Huntington's Disease, Treatment of;Antiparkinsonian Drugs;Antipsychotic Drugs; Dopamine D2 Receptor Ligands;Signal Transduction Modulators; Dopamine receptor Modulator; Dopamine D2 receptor antagonist"
CBR-001-573-214-6,RFM-002-018-8,CBR-001-573-214-6,O=C(C(c1cccnc1)(C)C)c1cccnc1,"CBR-HVAC-03160 Cushing's Syndrome, Agents for; Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Mineralocorticoid Receptor (MR) Antagonists;Signal Transduction Modulators;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; 11-Beta hydroxylase Inhibitor;"
CBR-001-573-215-7,RFM-002-019-9,CBR-001-573-215-7,CCOc1ccccc1C(=O)O,CBR-HVAC-07392 Cyclooxygenase inhibitor
CBR-001-573-216-8,RFM-002-020-2,CBR-001-573-216-8,Clc1ccc(cc1)C(=O)NC(C(=O)O)Cc1cc(=O)[nH]c2c1cccc2,"CBR-HVAC-01475 Dry Eye Syndrome, Treatment for;Antiinflammatory Ophthalmic Agents;Treatment of Mucositis;Sjogren's Syndrome, Agents for;Antiulcer Drugs;Inflammatory Bowel Disease, Agents for; Free Radical Scavengers;Mucin Production, Enhancers; ; Oxygen scavenger; Mucus protecting agent; Prostaglandin synthase stimulant"
CBR-001-573-217-9,RFM-002-021-3,CBR-001-573-217-9,Cc1ncsc1CCCl,CBR-HVAC-00994 GABA receptor Inhibitor; GABA A receptor agonist
CBR-001-573-218-0,RFM-002-022-4,CBR-001-573-218-0,ONC(=O)CCCCCCOc1cc2c(ncnc2cc1OC)Nc1cccc(c1)C#C,CBR-HVAC-00284 Head and Neck Cancer Therapy;Solid Tumors Therapy; Apoptosis Inducers;EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Histone Deacetylase (HDAC) Inhibitors;Signal Transduction Modulators; HER-2; Histone deacetylase; EGFR Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Histone deacetylase inhibitor; Apoptosis stimulant; Tyrosine kinase inhibitor (TKI)
CBR-001-573-219-1,RFM-002-023-5,CBR-001-573-219-1,CN(Cc1ccccc1)CC#C,"CBR-HVAC-02859 Hypertension, Treatment of; MAO Inhibitors; Monoamine oxidase Inhibitor;"
CBR-001-573-220-4,RFM-002-024-6,CBR-001-573-220-4,O=C(O[C@H](C(=O)O)Cc1ccc(c(c1)O)O)/C=C/c1ccc(c2c1[C@H](C(=O)OC(C(=O)O)Cc1ccc(c(c1)O)O)C(O2)c1ccc(c(c1)O)O)O,"CBR-HVAC-05379 Ischemic Stroke, Treatment of;Agents for Liver Fibrosis;Alzheimer's Dementia, Treatment of ;Angina pectoris, Treatment of; Antioxidants;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors; ;"
CBR-001-573-221-5,RFM-002-025-7,CBR-001-573-221-5,CCCCCCCCCCC(C(=O)Nc1c(OC)cc(cc1OC)OC)(C)C,"CBR-HVAC-03714 Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor; Acetyl CoA transferase inhibitor"
CBR-001-573-222-6,RFM-002-026-8,CBR-001-573-222-6,CCOC(=O)C(Oc1ccc(cc1)Cl)(C)C,"CBR-HVAC-05443 Lipoprotein Disorders, Treatment of ; PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor alpha Agonist;"
CBR-001-573-223-7,RFM-002-027-9,CBR-001-573-223-7,CC(OC(=O)C(Oc1ccc(cc1)C(=O)c1ccc(cc1)Cl)(C)C)C,"CBR-HVAC-01480 Lipoprotein Disorders, Treatment of ;Cardiovascular Diseases (Not Specified);Agents for Liver Cirrhosis; APOA1 Expression Enhancers;PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor alpha Agonist; Peroxisome proliferator-activated receptor alpha agonist; Lipase clearing factor stimulant"
CBR-001-573-224-8,RFM-002-028-0,CBR-001-573-224-8,CO[C@@H]1C[C@@H](CC[C@H]1OC(=O)C(CO)(CO)C)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(=C/C=C/C=C\[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C1)C)/C)O)OC)C)C)/C)C,"CBR-HVAC-04669 Liver Cancer Therapy;Renal Cancer Therapy;Cervical Cancer Therapy;Pancreatic Cancer Therapy;Sarcoma Therapy;Breast Cancer Therapy;Neurologic Cancer Therapy;Multiple Myeloma Therapy;Prostate Cancer Therapy;Multiple Sclerosis, Agents for;Non-Small Cell Lung Cancer Therapy;Rheumatoid Arthritis, Treatment of;Myelodysplastic Syndrome Therapy;Ovarian Cancer Therapy;Melanoma Therapy;Glioblastoma Multiforme Therapy;Solid Tumors Therapy;Female Reproductive System Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Leukemia Therapy;Lymphoma Therapy;Endocrine Cancer Therapy;Bladder Cancer Therapy ;Lymphocytic Leukemia Therapy;Colorectal Cancer Therapy; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Signal Transduction Modulators; mTOR kinase Inhibitor; mTOR kinase inhibitor; Cell cycle inhibitor; Immunosuppressant; Protein kinase inhibitor"
CBR-001-573-225-9,RFM-002-029-1,CBR-001-573-225-9,CC[C@H](Nc1cc(C(=O)N[C@@H]2C[C@@H]3CC[C@H](C2)N3c2ccc(cn2)C(=O)C2CC2)c(cc1C(=O)N)C)C,CBR-HVAC-06728 Melanoma Therapy;Solid Tumors Therapy; Heat Shock Protein 90 (HSP90) Inhibitors; ;
CBR-001-573-226-0,RFM-002-030-4,CBR-001-573-226-0,C=CC1CCC2C(C1)O2,CBR-HVAC-11881 Muscarinic acetylcholine receptor Antagonist;
CBR-001-573-227-1,RFM-002-031-5,CBR-001-573-227-1,ONC(=O)CCCCCCC(=O)Nc1ccccc1,"CBR-HVAC-01980 Neurologic Drugs (Miscellaneous);Breast Cancer Therapy;Myeloid Leukemia Therapy;Renal Cancer Therapy;Neurologic Cancer Therapy;Bladder Cancer Therapy ;Therapy of Inborn Errors of Metabolism;Anti-HIV Agents;Non-Small Cell Lung Cancer Therapy;Multiple Myeloma Therapy;Head and Neck Cancer Therapy;Prostate Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy;Sarcoma Therapy;Allergic Skin Disorders, Treatment for;Gastric Cancer Therapy;Antineoplastic Enhancing Agents;Colorectal Cancer Therapy;Myelodysplastic Syndrome Therapy;Oncolytic Drugs;Melanoma Therapy;Glioblastoma Multiforme Therapy; Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 3 (HDAC3) Inhibitors;Histone Deacetylase 6 (HDAC6) Inhibitors; Histone deacetylase 1; Histone deacetylase 3; Histone deacetylase 2; Histone deacetylase 6 Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor"
CBR-001-573-228-2,RFM-002-032-6,CBR-001-573-228-2,C=CC(CCC=C(C)C)(O)C,CBR-HVAC-06193 Non-Opioid Analgesics;Sedative/Hypnotics; Nitric Oxide (NO) Production Inhibitors; ;
CBR-001-573-229-3,RFM-002-033-7,CBR-001-573-229-3,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O,CBR-HVAC-01653 Oncolytic Drugs; Pyrimidine Antagonists;Thymidylate Synthase Inhibitors; ; Thymidylate synthase inhibitor
CBR-001-573-230-6,RFM-002-034-8,CBR-001-573-230-6,COc1c(OC)ccc2c1c[n+]1CCc3c(c1c2)cc1c(c3)OCO1,"CBR-HVAC-02847 Oncolytic Drugs;Antidiabetic Drugs;Antileishmanials;Antibacterial Drugs;Ophthalmic Drugs;Lipoprotein Disorders, Treatment of ; Acetylcholinesterase (AChE) Inhibitors;AMP-Activated Protein Kinase (AMPK) Activators;Apoptosis Inducers;LDL-Receptor Up-Regulators;Protein Tyrosine Phosphatase PTP-1B Inhibitors;Signal Transduction Modulators;Triglyceride Lowering Agents; Prostaglandin G/H synthase 2 Inhibitor;"
CBR-001-573-231-7,RFM-002-035-9,CBR-001-573-231-7,S=C=NCCCCS(=O)C,"CBR-HVAC-05651 Oncolytic Drugs;Ischemia, Treatment of;Alzheimer's Dementia, Treatment of ;Type 2 Diabetes, Agents for;Chemopreventive Agents;Anti-Helicobacter Pylori Agents; Angiogenesis Inhibitors;Antioxidants;Apoptosis Inducers;Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activators;Phagocytosis Inducers;Quorum Sensing Signaling Inhibitors;Signal Transduction Modulators; ;"
CBR-001-573-232-8,RFM-002-036-0,CBR-001-573-232-8,FC(c1nc2c(n1c1nc(nc(n1)N1CCOCC1)N1CCOCC1)cccc2)F,"CBR-HVAC-00585 Oncolytic Drugs;Rheumatoid Arthritis, Treatment of;Solid Tumors Therapy; Angiogenesis Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; Phosphatidylinositol 3-kinase Inhibitor; PI3 kinase inhibitor"
CBR-001-573-233-9,RFM-002-037-1,CBR-001-573-233-9,OCC1(CO)N2CCC(C1=O)CC2,CBR-HVAC-11892 p53 tumor suppressor protein Modulator;
CBR-001-573-234-0,RFM-002-038-2,CBR-001-573-234-0,Oc1ccc(cc1)[C@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C)NC(=O)c1cnc(cc1O)C,CBR-HVAC-02220 Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-235-1,RFM-002-039-3,CBR-001-573-235-1,OC(=O)c1ccc(cc1)C#Cc1ccc2c(c1)C(C)(C)CCC2(C)C,CBR-HVAC-06735 Pharmaceutical Aids; Retinoid RAR Agonists;Signal Transduction Modulators; Retinoid X receptor; Retinoid acid receptor Agonist;
CBR-001-573-236-2,RFM-002-040-6,CBR-001-573-236-2,OC1=C2C(=NC(=O)C2(C)C)c2c(C1=O)cccc2,CBR-HVAC-09299 Pharmacological Tools; Protein Tyrosine Phosphatase (PTP) Inhibitors;Signal Transduction Modulators; Protein tyrosine phosphatase Inhibitor;
CBR-001-573-237-3,RFM-002-041-7,CBR-001-573-237-3,CCCCCCCCCCCCCCCC(=O)NCCO,CBR-HVAC-01305 PPAR-ALPHA Agonist; Unidentified pharmacological activity
CBR-001-573-238-4,RFM-002-042-8,CBR-001-573-238-4,Fc1ccc(cc1)c1cc(nn1c1ccc(cc1)S(=O)(=O)C)C(F)(F)F,CBR-HVAC-11295 Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor;
CBR-001-573-239-5,RFM-002-043-9,CBR-001-573-239-5,O=C(C(O)(C)C)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CBR-HVAC-05355 Prostate Cancer Therapy; Androgen Receptor Antagonists;Signal Transduction Modulators; ;
CBR-001-573-240-8,RFM-002-044-0,CBR-001-573-240-8,O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC=C2n2cnc3c2cccc3)C)C1)C,"CBR-HVAC-00739 Prostate Cancer Therapy; Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators; Androgen receptor; 17-Alpha-hydroxylase/17,20 lyase Antagonist; Inhibitor; Selective androgen receptor modulator; Androgen receptor antagonist; 17,20 lyase inhibitor"
CBR-001-573-241-9,RFM-002-045-1,CBR-001-573-241-9,COCC1(CO)N2CCC(C1=O)CC2,CBR-HVAC-06912 Prostate Cancer Therapy;Leukemia Therapy;Ovarian Cancer Therapy; Apoptosis Inducers; ; p53 stimulant
CBR-001-573-242-0,RFM-002-046-2,CBR-001-573-242-0,CNC(=O)c1nccc(c1)Oc1ccc(cc1)NC(=O)Nc1ccc(c(c1)C(F)(F)F)Cl,"CBR-HVAC-05500 Pulmonary Hypertension, Treatment of;Ovarian Cancer Therapy;Head and Neck Cancer Therapy;Sarcoma Therapy;Neurologic Cancer Therapy;Melanoma Therapy;Non-Small Cell Lung Cancer Therapy;Lung Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Hematological Cancer Therapy;Neurologic Drugs (Miscellaneous);Prostate Cancer Therapy;Genitourinary Cancer Therapy;Glioblastoma Multiforme Therapy;Bladder Cancer Therapy ;Breast Cancer Therapy;Oncolytic Drugs;Liver Cancer Therapy;Myeloid Leukemia Therapy;Endocrine Cancer Therapy;Renal Cancer Therapy;Cervical Cancer Therapy;Small Cell Lung Cancer Therapy;Myelodysplastic Syndrome Therapy;Non-Hodgkin's Lymphoma Therapy;Hypertension, Treatment of;Colorectal Cancer Therapy;Pancreatic Cancer Therapy;Multiple Myeloma Therapy;Respiratory/Thoracic Cancer Therapy;Female Reproductive System Cancer Therapy; Angiogenesis Inhibitors;Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;PDGFRbeta Inhibitors;Raf kinase B Inhibitors;Raf kinase C Inhibitors;RET Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; RAF Inhibitor; B-raf kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; RET tyrosine kinase inhibitor; Flt-3 kinase inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor; C-kit inhibitor; Raf kinase inhibitor; C-raf kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib"
CBR-001-573-243-1,RFM-002-047-3,CBR-001-573-243-1,O=C(OCc1cccnc1)NCc1ccc(cc1)C(=O)Nc1ccccc1N,"CBR-HVAC-00749 Renal Cancer Therapy;Prostate Cancer Therapy;Allergic Skin Disorders, Treatment for;Liver and Biliary Tract Disorders, Treatment of;Solid Tumors Therapy;Lymphocytic Leukemia Therapy;Myeloid Leukemia Therapy;Multiple Myeloma Therapy;Non-Small Cell Lung Cancer Therapy;Lymphoma Therapy;Myelodysplastic Syndrome Therapy;Breast Cancer Therapy;Melanoma Therapy;Antipsychotic Drugs; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase 1; Histone deacetylase 3 Inhibitor; Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor"
CBR-001-573-244-2,RFM-002-048-4,CBR-001-573-244-2,CCCCCCCCCCCC[N+](CC(=O)O)(C)C,CBR-HVAC-10992 Reverse transcriptase Inhibitor;
CBR-001-573-245-3,RFM-002-049-5,CBR-001-573-245-3,OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1Cl)Br)F,"CBR-HVAC-00736 Sarcoma Therapy;Multiple Myeloma Therapy;Digestive/Gastrointestinal Cancer Therapy;Endocrine Cancer Therapy;Melanoma Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Treatment of AIDS-Associated Disorders;Neurologic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Liver Cancer Therapy;Ovarian Cancer Therapy;Colorectal Cancer Therapy;Female Reproductive System Cancer Therapy;Pancreatic Cancer Therapy;Neurological Genetic Disorders, Treatment of ;Gastric Cancer Therapy;Breast Cancer Therapy; Apoptosis Inducers;Extracellular-Regulated Kinase (ERK) Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;Signal Transduction Modulators; Mitogen-activated protein 2 kinase 1; Mitogen-activated protein 2 kinase 2 Inhibitor; MEK inhibitor"
CBR-001-573-246-4,RFM-002-050-8,CBR-001-573-246-4,COc1ccc(cc1c1c(Br)cnn1C)NC(=O)Nc1ccc(cc1F)F,"CBR-HVAC-00066 Sleep Disorders, Treatment of;Antipsychotic Drugs; Signal Transduction Modulators;5-HT2A Inverse Agonists; 5-Hydroxytryptamine 2A receptor Inverse Agonist; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-573-247-5,RFM-002-051-9,CBR-001-573-247-5,O=Cc1c(O)c(O)c(c2c1c(O)c(c(c2)C)c1c(C)cc2c(c1O)c(C=O)c(c(c2C(C)C)O)O)C(C)C,CBR-HVAC-00580 Small Cell Lung Cancer Therapy;Lymphocytic Leukemia Therapy;Oncolytic Drugs;Glioblastoma Multiforme Therapy;Chemopreventive Agents;Head and Neck Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Digestive/Gastrointestinal Cancer Therapy;Prostate Cancer Therapy;Antipsoriatics; Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors;Bcl-2 Inhibitors;Growth Factor Modulators;Lipid Peroxidation Inhibitors;Mcl-1 Inhibitors;RNA-Binding Protein Musashi Homolog 1 (MSI1)  Inhibitors;Signal Transduction Modulators;11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors; ; Bcl2 inhibitor; Bcl-XL inhibitor; Mcl-1 antagonist
CBR-001-573-248-6,RFM-002-052-0,CBR-001-573-248-6,C1CCC(NC1)c1cccnc1,"CBR-HVAC-03549 Smoking Cessation, Aid to; Nicotinic Receptor Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor Agonist;"
CBR-001-573-249-7,RFM-002-053-1,CBR-001-573-249-7,CO[C@@H]1[C@@H](CC[C@@]2([C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)CO2)OC(=O)NC(=O)CCl,CBR-HVAC-03981 Solid Tumors Therapy;Renal Cancer Therapy;Lymphoma Therapy;Leukemia Therapy;Prostate Cancer Therapy; Angiogenesis Inhibitors;Methionine Aminopeptidase-2 (MetAP2) Inhibitors; Methionine aminopeptidase 2 Inhibitor; Angiogenesis inhibitor; Fibroblast growth factor antagonist; Cell cycle inhibitor
CBR-001-573-250-0,RFM-002-054-2,CBR-001-573-250-0,Clc1ccc(cc1)C(=O)NCCc1ccc(cc1)OC(C(=O)O)(C)C,"CBR-HVAC-02125 Therapy of Inborn Errors of Metabolism;Liver and Biliary Tract Disorders, Treatment of;Agents for Liver Cirrhosis;Anti-Hepatitis C Virus Drugs;Lipoprotein Disorders, Treatment of ;Myeloid Leukemia Therapy; HSD11B1 Expression Inhibitors;PPARalpha Agonists;PPARdelta Agonists;PPARgamma Agonists;Signal Transduction Modulators;11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; HMG-CoA reductase Blocker; Lipase clearing factor stimulant; Peroxisome proliferator-activated receptor pan agonist"
CBR-001-573-251-1,RFM-002-055-3,CBR-001-573-251-1,Oc1cc2c(=O)oc3c4c2c(c1O)oc(=O)c4cc(c3O)O,"CBR-HVAC-10329 Treatment of Diabetic Complications;Treatment of Renal Diseases;Oncolytic Drugs;Anti-HIV Agents;Anti-Hepatitis B Virus Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Anti-Hepatitis C Virus Drugs; Aldose Reductase Inhibitors;Antioxidants;Apoptosis Inducers;beta-Secretase 1 (BACE1) Inhibitors;Drugs Acting on Quorum Sensing Signaling;Glutathione Transferase Inhibitors;HCV NS3 NS4A Protease Inhibitors;HIV Integrase Inhibitors;Reverse Transcriptase Inhibitors; Aldose reductase Inhibitor;"
CBR-001-573-252-2,RFM-002-056-4,CBR-001-573-252-2,[O-][N+](=O)c1ccc(c(c1)Oc1ccccc1)NS(=O)(=O)C,CBR-HVAC-01863 Treatment of Dysmenorrhea;Antiarthritic Drugs;Analgesic Drugs; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase 2 Inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor; Matrix metalloproteinase inhibitor
CBR-001-573-253-3,RFM-002-057-5,CBR-001-573-253-3,OP(=O)(C(P(=O)(O)O)(Cc1cnc2n1cccc2)O)O,CBR-HVAC-01956 Treatment of Osteoporosis;Breast Cancer Therapy;Multiple Myeloma Therapy;Bone Resorption Inhibitors;Bladder Cancer Therapy ;Lung Cancer Therapy; ; Purinergic P2X2/3 receptor Antagonist; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor
CBR-001-573-254-4,RFM-002-058-6,CBR-001-573-254-4,CC#C[C@H](c1ccc(cc1)OCc1cccc(c1)c1ccc(cc1)C(F)(F)F)CC(=O)O,"CBR-HVAC-06585 Type 2 Diabetes, Agents for; Free Fatty Acid Receptor 1 (FFAR1;  GPR40) Agonists;Signal Transduction Modulators; G protein-coupled receptor 40 Agonist;"
CBR-001-573-255-5,RFM-002-059-7,CBR-001-573-255-5,CC(OC(=O)N1CCC(CC1)Oc1ncnc2c1cnn2c1ccc(cc1F)S(=O)(=O)C)C,"CBR-HVAC-06370 Type 2 Diabetes, Agents for; Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119)  Agonists;Signal Transduction Modulators; ;"
CBR-001-573-256-6,RFM-002-060-0,CBR-001-573-256-6,CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-06002 Type 2 Diabetes, Agents for;Liver and Biliary Tract Disorders, Treatment of;Type 1 Diabetes, Agents for; Cytochrome P450 CYP1A1 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;SGLT-2 Inhibitors; Sodium/glucose cotransporter (SGLT-2) Inhibitor; Sodium/glucose cotransporter 2 inhibitor"
CBR-001-573-257-7,RFM-002-061-1,CBR-001-573-257-7,Oc1nc(O)c2c(n1)[nH]nc2,CBR-HVAC-05200 Uricosurics;Heart Failure Therapy; Xanthine Oxidase Inhibitors; ;
CBR-001-573-258-8,RFM-002-062-2,CBR-001-573-258-8,CCCCCCCCCCCCCCCCOP(=O)(OCC[N+](C)(C)C)O,"CBR-HVAC-02273 Urticaria, Treatment for;Antifungal Agents;Breast Cancer Therapy;Antileishmanials;Atopic Dermatitis, Agents for;Allergic Skin Disorders, Treatment for; Angiogenesis Inhibitors; Protein kinase C Inhibitor; Membrane integrity inhibitor"
CBR-001-573-259-9,RFM-002-063-3,CBR-001-573-259-9,CC/C(=C\C(=N/O)\C(=O)N)/C([N+](=O)[O-])C,"CBR-HVAC-03883 Vasodilators;Angina pectoris, Treatment of;Antiplatelet Therapy; Nitric Oxide (NO) Donors; ; Nitric oxide stimulant"
CBR-001-573-260-2,RFM-002-064-4,CBR-001-573-260-2,COc1cc(cc(c1O)[N+](=O)[O-])C(=O)C,analog of CBR-HVAC-00233 (NSC-361456)
CBR-001-573-261-3,RFM-002-065-5,CBR-001-573-261-3,OC(=O)COc1cc2OC(C)(C)CC(=O)c2c(c1)O,analog of CBR-HVAC-00295 (Debio-1452)
CBR-001-573-262-4,RFM-002-066-6,CBR-001-573-262-4,OC(=O)C1CSC(=N1)c1ccccc1O,analog of CBR-HVAC-00439 (cianopramine)
CBR-001-573-263-5,RFM-002-067-7,CBR-001-573-263-5,O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl,CBR-HVAC-01428
CBR-001-573-264-6,RFM-002-068-8,CBR-001-573-264-6,NCCCN1C(=O)NC2(C1=O)CCCCC2,analog of CBR-HVAC-02509 (spiromustine)
CBR-001-573-265-7,RFM-002-069-9,CBR-001-573-265-7,CCN(CC(=O)Nc1ccc(cc1C(=O)c1ccccc1)Cl)CC,analog of CBR-HVAC-02540 (arclofenin)
CBR-001-573-266-8,RFM-002-070-2,CBR-001-573-266-8,COc1ccc2c(c1OC)C(OC2=O)C1N(C)CCc2c1c(OC)c1c(c2)OCO1,analog of CBR-HVAC-03264 (Tritoqualine)
CBR-001-573-267-9,RFM-002-071-3,CBR-001-573-267-9,CC(OC(=O)C1=C(C)NC(=C(C1c1ccc(cc1)[N+](=O)[O-])C(=O)OC(C)C)C)C,analog of CBR-HVAC-03497 (CD-349)
CBR-001-573-268-0,RFM-002-072-4,CBR-001-573-268-0,CCOC(=O)c1ccccc1NC(=O)c1ccc(cc1)NC(=O)CC,analog of CBR-HVAC-03680 (AM-682)
CBR-001-573-269-1,RFM-002-073-5,CBR-001-573-269-1,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN1CCN(CC1)C)C,analog of CBR-HVAC-03840 (Iganidipine hydrochloride)
CBR-001-573-270-4,RFM-002-074-6,CBR-001-573-270-4,CCCC(=O)NCC(=O)N1CCCC1(C)C,analog of CBR-HVAC-04528 (SNK-882)
CBR-001-573-271-5,RFM-002-075-7,CBR-001-573-271-5,O=C(N1CCN(CC1)c1ccccc1O)C1CCN(CC1)c1ccccc1[N+](=O)[O-],analog of CBR-HVAC-05141 (REC-15/3079)
CBR-001-573-272-6,RFM-002-076-8,CBR-001-573-272-6,ClCCN(c1ccc(cc1)CC(C(=O)NC(C(=O)OCC)CC(=O)OCC)NC(=O)C)CCCl,analog of CBR-HVAC-05664 (Melphalan flufenamide)
CBR-001-573-273-7,RFM-002-077-9,CBR-001-573-273-7,OCC(CNC(=O)CC1(C2CC3CC1CC(C2)C3)c1ccccc1)O,analog of CBR-HVAC-06733 (analog of BMS-816336)
CBR-001-573-274-8,RFM-002-078-0,CBR-001-573-274-8,O=C(c1cccc(c1F)C)N1CCCC1C(O)(C)C,analog of CBR-HVAC-07167 (AZD-2927)
CBR-001-573-275-9,RFM-002-079-1,CBR-001-573-275-9,COc1cc(C)ccc1OCC(=O)NC1(Cc2c(C1)cccc2)C(=O)O,analog of CBR-HVAC-07303 (2-(4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino)-Indian-2-carboxylic acid (Aventis))
CBR-001-573-276-0,RFM-002-080-4,CBR-001-573-276-0,Brc1c(ccc2c1nccn2)NC1=NCCN1,CBR-HVAC-09549
CBR-001-573-277-1,RFM-002-081-5,CBR-001-573-277-1,CN1CCC(CC1)OC1c2cc(C)ccc2SCc2c1cccc2,analog of CBR-HVAC-08444 (tipetropium bromide)
CBR-001-573-278-2,RFM-002-082-6,CBR-001-573-278-2,O=C(Nc1ccccc1)OCC(COC(=O)Nc1ccccc1)(C)C,analog of CBR-HVAC-08899 (CYCLARBAMATE)
CBR-001-573-279-3,RFM-002-083-7,CBR-001-573-279-3,CCOc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,analog of CBR-HVAC-08967 (SULFAPROXYLINE)
CBR-001-573-280-6,RFM-002-084-8,CBR-001-573-280-6,OC(c1ccccc1)(c1ccccc1)C1CC1,analog of CBR-HVAC-09230 (CYPROLIDOL)
CBR-001-573-281-7,RFM-002-085-9,CBR-001-573-281-7,O=C(C(c1ccccc1)(C1CCCC1)O)OCC[N+](C)(C)C,analog of CBR-HVAC-09239 (ENDOBENZYLINE BROMIDE)
CBR-001-573-282-8,RFM-002-086-0,CBR-001-573-282-8,O=C(Nc1cc(ccc1F)N1CCOC1=O)CCc1ccncc1,analog of CBR-HVAC-09317 (VRC-331)
CBR-001-573-283-9,RFM-002-087-1,CBR-001-573-283-9,COc1ccccc1N1CCN(CC1)CC(c1ccc(cc1)F)O,analog of CBR-HVAC-09402 (ANISOPIROL)
CBR-001-573-284-0,RFM-002-088-2,CBR-001-573-284-0,CCOC(=O)N1c2ccccc2Sc2c1cccc2,analog of CBR-HVAC-09809 (DIMETHOXANATE)
CBR-001-573-285-1,RFM-002-089-3,CBR-001-573-285-1,COc1ccc(cc1)S(=O)(=O)Nc1nc2ccccc2nc1Nc1ccc(cc1)C(=O)C,analog of CBR-HVAC-11856 (XL-765)
CBR-001-573-286-2,RFM-002-090-6,CBR-001-573-286-2,COc1ccccc1CCC(=O)Oc1cccc2c1cccc2,analog of CBR-HVAC-11982 (Bunaprolast)
CBR-001-573-287-3,RFM-002-091-7,CBR-001-573-287-3,OCc1cccnc1,CBR-HVAC-08224
CBR-001-573-288-4,RFM-002-092-8,CBR-001-573-288-4,S=c1[nH]cnc2c1[nH]cn2,"CBR-HVAC-05246: Cell-cycle specific for the S phase of cell division. Converted to thioinosinic acid by the enzyme hypoxanthine-guanine phosphoribosyltransferase. Thioinosinic acid then inhibits reactions involving inosinic acid. Also, both thioinosinic acid and 6-methylthioinosinate (also formed from mercaptopurine) inhibit RNA synthesis.; Immunosuppressant; Protein synthesis inhibitor; Purine Antagonists; Antineoplastic; Immunosuppressant; Inflammatory Bowel Disease, Agents for; Leukemia Therapy; Lymphocytic Leukemia Therapy; Myeloid Leukemia Therapy"
CBR-001-573-289-5,RFM-002-093-9,CBR-001-573-289-5,C[N+](Cc1ccccc1)(CCOc1ccccc1)C,CBR-HVAC-09725
CBR-001-573-290-8,RFM-002-094-0,CBR-001-573-290-8,O=C1C(c2ccc(cc2)F)C(=O)c2c1cccc2,CBR-HVAC-10238
CBR-001-573-291-9,RFM-002-095-1,CBR-001-573-291-9,OCC(COP(=O)(O)O)O,CBR-HVAC-10251
CBR-001-573-292-0,RFM-002-096-2,CBR-001-573-292-0,COc1cccc2c1n(CC1CCCCC1)cc2C(=O)N1CCN(C(C1)C)C,CBR-HVAC-11861
CBR-001-573-293-1,RFM-002-097-3,CBR-001-573-293-1,c1ccc(nc1)CN(Cc1ccccn1)CCN(Cc1ccccn1)Cc1ccccn1,CBR-HVAC-12021
CBR-001-573-294-2,RFM-002-098-4,CBR-001-573-294-2,COCCCOc1ccnc(c1C)CS(=O)c1nc2c([nH]1)cccc2,"CBR-HVAC-03750: Anti-Helicobacter Pylori Agents;Antiulcer Drugs;Gastroesophageal Reflux Disease, Agents for; H+/K+-ATPase Inhibitors; H+/K+ ATPase Inhibitor; H+ K+ transporting ATPase inhibitor; Gastrin inhibitor"
CBR-001-573-295-3,RFM-002-099-5,CBR-001-573-295-3,C[C@H]([C@H]1C(=O)N2[C@@H]1[C@@H](C)C(=C2C(=O)O)S[C@@H]1CN[C@@H](C1)C(=O)N(C)C)O,"CBR-HVAC-00984: Cell Wall Biosynthesis Inhibitors; Cell wall synthesis inhibitor; Cell-wall-inhibitors; It interferes with the integrity of the bacterial cell wall by binding to membrane proteins engaged in cell wall peptidoglycan synthesis.; Antibacterial; Antibacterial Drugs; Antibiotics; Bacterial Infections; Sepsis, Treatment of"
CBR-001-573-296-4,RFM-002-100-1,CBR-001-573-296-4,OC[C@@]12[C@H](O)C[C@@H](C[C@@]2(O)CC[C@@H]2C1C(O)C[C@]1([C@]2(O)CC[C@@H]1C1=CC(=O)OC1)C)O[C@H]1OC(C)[C@H](C(C1O)O)O,CBR-HVAC-14257
CBR-001-573-297-5,RFM-002-101-2,CBR-001-573-297-5,CC(=O)NNC(=O)N1Cc2ccccc2Oc2c1cc(Cl)cc2,CBR-HVAC-14210
CBR-001-573-298-6,RFM-002-102-3,CBR-001-573-298-6,CO/N=C(/c1nsc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C[n+]1ccn2c1cccn2,CBR-HVAC-01796: Antibiotics; Penicillin binding protein 5 Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-299-7,RFM-002-103-4,CBR-001-573-299-7,COCCCOc1cc(ccc1OC)C[C@H](C(C)C)C[C@@H]([C@H](C[C@H](C(=O)NCC(C(=O)N)(C)C)C(C)C)O)N,CBR-HVAC-00923: Renin Inhibitor; Renin inhibitor
CBR-001-573-300-3,RFM-002-104-5,CBR-001-573-300-3,CCC(C(C)(C)C)N(C(=O)c1cc(C)cc(c1)C)NC(=O)c1cccc(c1C)OC,analog of CBR-HVAC-06904
CBR-001-573-301-4,RFM-002-105-6,CBR-001-573-301-4,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)OC)O,analog of CBR-HVAC-02904
CBR-001-573-302-5,RFM-002-106-7,CBR-001-573-302-5,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(c(c2)F)F)c2c(n1)n(nn2)[C@@H]1C[C@@H]([C@H]([C@H]1O)O)OCCO,CBR-HVAC-05285: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Cardiovascular Diseases (Not Specified);Antiplatelet Therapy; P2Y12 (P2T) Antagonists;Signal Transduction Modulators; Purinoreceptor P2Y12 antagonist
CBR-001-573-303-6,RFM-002-107-8,CBR-001-573-303-6,Ic1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1,CBR-HVAC-14191
CBR-001-573-304-7,RFM-002-108-9,CBR-001-573-304-7,CCOC(=O)[C@@H](C[C@H](Cc1ccc(cc1)c1ccccc1)NC(=O)CCC(=O)O)C,"CBR-HVAC-06709: Heart Failure Therapy;Hypertension, Treatment of; Angiotensin AT1 Antagonists;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors;Signal Transduction Modulators; Neutral endopeptidase Inhibitor;"
CBR-001-573-305-8,RFM-002-109-0,CBR-001-573-305-8,C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@H](C(C)(C)C)NC(=O)OC(C)(C)C)Oc1ncc(c2c1cc(Cl)cc2)OC)C(=O)NS(=O)(=O)C1CC1,CBR-HVAC-00900: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; HCV NS3 PROTEASE Inhibitor; HCV nonstructural protein 3 inhibitor
CBR-001-573-306-9,RFM-002-110-3,CBR-001-573-306-9,Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@H]1CCCCN1,CBR-HVAC-06528: Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Solid Tumors Therapy;Melanoma Therapy;Colorectal Cancer Therapy; Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Signal Transduction Modulators; Mitogen-activated protein 2 kinase 1 Inhibitor;
CBR-001-573-307-0,RFM-002-111-4,CBR-001-573-307-0,CC1NCCN(C1)c1cc2n(cc(c(=O)c2cc1F)C(=O)O)c1ccc(cc1F)F,CBR-HVAC-02656: Antibacterial Drugs; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-573-308-1,RFM-002-112-5,CBR-001-573-308-1,CC(=O)N(C(C(=O)c1ccc2c(c1)OCO2)C)C,analog of CBR-HVAC-04518
CBR-001-573-309-2,RFM-002-113-6,CBR-001-573-309-2,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccccc1,CBR-HVAC-10040
CBR-001-573-310-5,RFM-002-114-7,CBR-001-573-310-5,NCCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O)Cc1ccc(cc1)O)C(C)C)CC(=O)O)NC(=O)C(CCCNC(=N)N)N,CBR-HVAC-02137: Immunomodulators; Peptide agonist; Interleukin 2 agonist; Cell cycle inhibitor
CBR-001-573-311-6,RFM-002-115-8,CBR-001-573-311-6,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@@H]([C@](C2)(C)OC)O)[C@H](C)[C@H]([C@@]2(OC(=C(C)C2)[C@@H]([C@H]([C@]1(C)O)O)C)C)O[C@@H]1O[C@H](C)C[C@@H]([C@H]1O)N(C)C,analog of CBR-HVAC-04480
CBR-001-573-312-7,RFM-002-116-9,CBR-001-573-312-7,OCC(=O)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-12099 betamethasone
CBR-001-573-313-8,RFM-002-117-0,CBR-001-573-313-8,Oc1cc(O)c2c(c1)[o+]c(c(c2)O[C@@H]1O[C@H](CO[C@@H]2O[C@@H](C)[C@@H]([C@H]([C@H]2O)O)O)[C@H]([C@@H]([C@H]1O)O)O)c1ccc(c(c1)O)O,analog of CBR-HVAC-07961
CBR-001-573-314-9,RFM-002-118-1,CBR-001-573-314-9,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)NCC1CNc2c(N1C)c(=O)nc([nH]2)N,CBR-HVAC-14188
CBR-001-573-315-0,RFM-002-119-2,CBR-001-573-315-0,NCCCC[C@@H](C(=O)N[C@H](C(=O)O)CCCCN)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1)CC(C)C)C)CCCNC(=N)N)CC(C)C)CO)C)CC(C)C,analog of CBR-HVAC-06216
CBR-001-573-316-1,RFM-002-120-5,CBR-001-573-316-1,CCCCc1nc(C)c(c(=O)n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)CC(=S)N(C)C,"CBR-HVAC-02271: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor Antagonist; Angiotensin II 1 antagonist"
CBR-001-573-317-2,RFM-002-121-6,CBR-001-573-317-2,CC[C@H](CCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCNCS(=O)(=O)[O-])NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])[C@H](O)C)CCNCS(=O)(=O)[O-])[C@H](O)C)CCNCS(=O)(=O)[O-])C,CBR-HVAC-14274
CBR-001-573-318-3,RFM-002-122-7,CBR-001-573-318-3,CC(CC1NC(=O)[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](NC(=O)[C@H](NC1=O)Cc1c[nH]c2c1cccc2)CC(=O)O)C(C)C)C,"CBR-HVAC-04189; Acute Myocardial Infarction, Treatment of;Edema, Treatment of;Pulmonary Hypertension, Treatment of;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist;"
CBR-001-573-319-4,RFM-002-123-8,CBR-001-573-319-4,C#CCO[C@H]1CN2CCC1CC2,"CBR-HVAC-04424; Alzheimer's Dementia, Treatment of ; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Agonist; Muscarinic M1 receptor agonist"
CBR-001-573-320-7,RFM-002-124-9,CBR-001-573-320-7,Fc1ccc(c(c1)F)CNC(=O)c1cn2C[C@H]3OC[C@@H](N3C(=O)c2c(c1=O)O)C,CBR-HVAC-00679; Anti-HIV Agents; HIV Integrase Inhibitors; HIV integrase; INTEGRASE Inhibitor; HIV integrase inhibitor
CBR-001-573-321-8,RFM-002-125-0,CBR-001-573-321-8,COc1cc(cc(c1OC)OC)C(=O)NC1CCCNC1,CBR-HVAC-01816; Antiulcer Drugs; ; ; Glucosamine synthetase stimulant
CBR-001-573-322-9,RFM-002-126-1,CBR-001-573-322-9,Fc1cccc(c1Cn1nnc(c1)C(=O)N)F,"CBR-HVAC-01429; Anxiolytics;Anesthetic Drugs;Generalized Anxiety Disorder (GAD), Treatment of;Antiepileptic Drugs;Neuropathic Pain, Treatment of;Bipolar Disorder, Treatment of; Sodium Channel  Blockers; GABA-B receptor Antagonist; Blocker; Voltage-gated sodium channel antagonist"
CBR-001-573-323-0,RFM-002-127-2,CBR-001-573-323-0,COCCN(C(=O)CCCC#Cc1cccc2c1c(=O)n(c(n2)Cn1nc(c2c1ncnc2N)c1cccc(c1)O)Cc1ccccc1Cl)CCOC,"CBR-HVAC-07222; Asthma Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; ; PI3 kinase gamma inhibitor; PI3 kinase delta inhibitor"
CBR-001-573-324-1,RFM-002-128-3,CBR-001-573-324-1,CC(NCC(c1ccc(cc1)O)O)CCc1ccc(cc1)O,CBR-HVAC-01198; Cardiovascular Diseases (Not Specified); beta-Adrenoceptor Agonists;Signal Transduction Modulators; ; Beta adrenoreceptor agonist
CBR-001-573-325-2,RFM-002-129-4,CBR-001-573-325-2,[O-]S(=O)(=O)Oc1ccc(cc1)C(c1ccccn1)c1ccc(cc1)OS(=O)(=O)[O-],"CBR-HVAC-06536; Constipation, Agents for"
CBR-001-573-326-3,RFM-002-130-7,CBR-001-573-326-3,OC(COc1ccc(cc1)CCOCC1CC1)CNC(C)C,"CBR-HVAC-01260; Hypertension, Treatment of;Angina pectoris, Treatment of;Antiglaucoma Agents; beta1-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Antagonist; Beta 1 adrenoreceptor antagonist"
CBR-001-573-327-4,RFM-002-131-8,CBR-001-573-327-4,NC(=N)NCCC[C@@H](C(=O)N1CC[C@H](C[C@@H]1C(=O)O)C)NS(=O)(=O)c1cccc2c1NCC(C2)C,"CBR-HVAC-01603; Ischemic Stroke, Treatment of;Treatment of Peripheral Obstructive Vascular Disease;Anticoagulants;Cerebrovascular Diseases, Treatment of; Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; Thrombin Inhibitor; Direct thrombin inhibitor; Protease/peptidase inhibitor"
CBR-001-573-328-5,RFM-002-132-9,CBR-001-573-328-5,CC(NCCCn1c(Sc2cc3OCOc3cc2I)nc2c1ncnc2N)C,"CBR-HVAC-06460; Lymphocytic Leukemia Therapy;Breast Cancer Therapy;Sarcoma Therapy;Alzheimer's Dementia, Treatment of ;Solid Tumors Therapy;Lymphoma Therapy; Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor;"
CBR-001-573-329-6,RFM-002-133-0,CBR-001-573-329-6,OC[C@H]1O[C@H](Oc2cc(O)cc3c2c2cc(ccc2O)[C@H]2NC(=O)[C@@H]4NC(=O)[C@H]5NC(=O)[C@@H](Cc6ccc(Oc7cc4cc(Oc4ccc([C@H]([C@@H](C(=O)N[C@@H]3C(=O)NCCCN(C)C)NC2=O)O)cc4Cl)c7O[C@@H]2O[C@H](C(=O)O)[C@H]([C@@H]([C@H]2NC(=O)CCCCCCCCC(C)C)O)O)cc6)NC(=O)[C@H](NC)c2cc(Oc3cc5c(Cl)c(c3)O)c(O)cc2)[C@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-05037; Sepsis, Treatment of;Antibacterial Drugs; Cell Wall Biosynthesis Inhibitors; ; Cell wall synthesis inhibitor"
CBR-001-573-330-9,RFM-002-134-1,CBR-001-573-330-9,C[C@]12N[C@@H](c3c2cccc3)Cc2c1cccc2,"CBR-HVAC-00440; Stroke, Treatment of;Antiepileptic Drugs;Prion Diseases, Treatment of;Cognition Disorders, Treatment of; NMDA Antagonists;Signal Transduction Modulators; NMDA RECEPTOR Antagonist; NMDA receptor antagonist; Apoptosis inhibitor"
CBR-001-573-331-0,RFM-002-135-2,CBR-001-573-331-0,CCOC(=O)[C@@H](N[C@H]1CS[C@@H](CN(C1=O)CC(=O)O)c1cccs1)CCc1ccccc1,CBR-HVAC-01682; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor
CBR-001-573-332-1,RFM-002-136-3,CBR-001-573-332-1,OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)c(O)ccc1O)NCCNCCO,CBR-HVAC-00086; DNA gyrase; Topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; Immunosuppressant
CBR-001-573-334-3,RFM-002-137-4,CBR-001-573-334-3,NCCC(P(=O)(O)[O-])(P(=O)(O)[O-])O,CBR-HVAC-02369; Farnesyl diphosphate synthase Inhibitor; Hypocalcaemic agent
CBR-001-573-335-4,RFM-002-138-5,CBR-001-573-335-4,NC(=O)C1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)C,CBR-HVAC-09829; Dopamine receptor D2 Blocker;
CBR-001-573-336-5,RFM-002-139-6,CBR-001-573-336-5,CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,analog of CBR-HVAC-04118
CBR-001-573-337-6,RFM-002-140-9,CBR-001-573-337-6,COc1cc2N(C)[C@@H]3[C@@]4(c2cc1[C@]1(C[C@@H]2CN(CCc5c1[nH]c1c5cccc1)C[C@](C2)(O)CC)C(=O)OC)CCN1[C@H]4[C@@]([C@H]([C@]3(O)C(=O)N)O)(CC)C=CC1,CBR-HVAC-02031: Oncolytic Drugs; Beta tubulin Inhibitor; Microtubule inhibitor; Tubulin inhibitor; Vinca alkaloid
CBR-001-573-338-7,RFM-002-141-0,CBR-001-573-338-7,OC(=O)c1cccc(c1)c1cccc(c1O)N/N=C\1/C(=NN(C1=O)c1ccc(c(c1)C)C)C,CBR-HVAC-01459: Leukemia Therapy;Antianemics;Antithrombocytopenic;Antithrombocythemic; Signal Transduction Modulators;Thrombopoietin Receptor (TpoR) Agonists; Thrombopoietin receptor Agonist; Thrombopoietin agonist
CBR-001-573-339-8,RFM-002-142-1,CBR-001-573-339-8,N#CC(c1c(Cl)cc(cc1Cl)n1ncc(=O)[nH]c1=O)c1ccc(cc1)Cl,CBR-HVAC-14440: Antiprotozoal; Coccidiostat; Treatment of Protozoal Diseases
CBR-001-573-340-1,RFM-002-143-2,CBR-001-573-340-1,CC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N)Cc1ccccc1)CCCNC(=N)N)Cc1ccc(cc1)O,CBR-HVAC-14207
CBR-001-573-341-2,RFM-002-144-3,CBR-001-573-341-2,CNc1cccc(n1)CCOc1ccc2c(c1)CN(CC(F)(F)F)C(=O)[C@@H](C2)CC(=O)O,"CBR-HVAC-05062: Treatment of Osteoporosis;Rheumatoid Arthritis, Treatment of;Disease-Modifying Anti-Rheumatic Drugs; Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alphavbeta5 Antagonists;Signal Transduction Modulators; Integrin alpha5 beta5; Integrin alpha5 beta3 Antagonist; Alphavbeta3 integrin antagonist; Angiogenesis inhibitor; Integrin antagonist"
CBR-001-573-342-3,RFM-002-145-4,CBR-001-573-342-3,NCCC[C@@H]1NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2c[nH]c3c2cccc3)NC(=O)CCCCCCCCC)CC(=O)N)CC(=O)O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC(=O)O)C)CC(=O)O)CO)[C@H](CC(=O)O)C)CC(=O)c1ccccc1N,"CBR-HVAC-03324: Antibiotics;Antibacterial Drugs; Drugs Acting on Potassium Channels; Binds to bacterial membranes and causes a rapid depolarization of membrane potential. The loss of membrane potential leads to inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death;"
CBR-001-573-343-4,RFM-002-146-5,CBR-001-573-343-4,CC(=O)O[C@@]12CO[C@@H]1C[C@@H]([C@@]1(C2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@@H]([C@H](c3ccccc3)NC(=O)OC(C)(C)C)O)C(=C(C2(C)C)[C@H](C1=O)O)C)C)O,CBR-HVAC-14250
CBR-001-573-344-5,RFM-002-147-6,CBR-001-573-344-5,OC1CCN(CC1)c1c(F)cc2c3c1CCC(n3cc(c2=O)C(=O)O)C,CBR-HVAC-00384: Antibacterial Drugs;Acne Therapy; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-573-345-6,RFM-002-148-7,CBR-001-573-345-6,CO[C@@H]1C[C@@H](CC[C@@H]1n1cnnn1)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C1)C)/C)O)OC)C)C)/C)C,CBR-HVAC-05184: Restenosis Treatment of; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Signal Transduction Modulators; mTOR (mechanistic target of rapamycin) Inhibitor;
CBR-001-573-346-7,RFM-002-149-8,CBR-001-573-346-7,COC(=O)[C@@H]1C2=c3c(C1=O)c(/c/1=C/C4=N/C(=C\c5n([Mg]n31)c(/C=C/1\N=C2[C@@H](CCC(=O)OC/C=C(/CCCC(CCCC(CCCC(C)C)C)C)\C)[C@@H]1C)c(c5C(=O)C)C)/[C@@H]([C@H]4CC)C)C,analog of CBR-HVAC-09476
CBR-001-573-347-8,RFM-002-150-1,CBR-001-573-347-8,C/C=C/C(=O)N(C(C(=O)N(C)C)CC)CC,CBR-HVAC-09837: Stimulating respiratory bulbar centers;
CBR-001-573-348-9,RFM-002-151-2,CBR-001-573-348-9,COC(=O)c1cc2cc3CC[C@@]4(Oc3c(c2c(=O)o1)O)Cc1c(O4)c(O)c2c(c1O)C(=O)C=C(C2=O)OC,analog of CBR-HVAC-11236
CBR-001-573-350-3,RFM-002-152-3,CBR-001-573-350-3,CCC(NCC(=O)Nc1c(C)cccc1Cl)C,analog of CBR-HVAC-09714
CBR-001-573-351-4,RFM-002-153-4,CBR-001-573-351-4,Cc1cc2c(cc1F)nc1c(c2N)CCCC1,analog of CBR-HVAC-03992
CBR-001-573-352-5,RFM-002-154-5,CBR-001-573-352-5,Fc1ccc(cc1F)CN1CCC(CC1)Nc1ccc(nn1)C(F)(F)F,CBR-HVAC-06605: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist;;2017-11-14: ARB# 16-000827
CBR-001-573-353-6,RFM-002-155-6,CBR-001-573-353-6,c1ccc(cc1)OCCNC1CCN(CC1)c1nc2c(s1)cccc2,analog of CBR-HVAC-03747
CBR-001-573-354-7,RFM-002-156-7,CBR-001-573-354-7,Oc1cccc(c1)NC(=O)c1ccc(c(c1)O)O,analog of CBR-HVAC-06007
CBR-001-573-355-8,RFM-002-157-8,CBR-001-573-355-8,Nc1cc(Cl)c(c(c1)Cl)Sc1ccccc1Cl,analog of CBR-HVAC-09310
CBR-001-573-356-9,RFM-002-158-9,CBR-001-573-356-9,CCCNc1nnc(c(c1)CC)c1ccccc1,analog of CBR-HVAC-04209
CBR-001-573-357-0,RFM-002-159-0,CBR-001-573-357-0,N#Cc1c(C)nc(cc1N1CCSCC1)C,analog of CBR-HVAC-03535
CBR-001-573-358-1,RFM-002-160-3,CBR-001-573-358-1,O=C(CN1CCCCCC1=O)NC(CC(=O)O)C,analog of CBR-HVAC-04399
CBR-001-573-359-2,RFM-002-161-4,CBR-001-573-359-2,CSc1ccccc1OCC(CNC(C)C)O,CBR-HVAC-08445: Beta adrenoreceptor antagonist
CBR-001-573-360-5,RFM-002-162-5,CBR-001-573-360-5,Nc1nc(nc(n1)n1cncc1)N1CCOCC1,analog of CBR-HVAC-11470
CBR-001-573-361-6,RFM-002-163-6,CBR-001-573-361-6,OCCc1ccc(cc1)OCCn1cncc1,CBR-HVAC-08067: Thromboxane synthase inhibitor
CBR-001-573-362-7,RFM-002-164-7,CBR-001-573-362-7,N#Cc1ccc(cc1)Cn1cncc1CN1CCN(C(=O)C1)c1cccc(c1)Cl,CBR-HVAC-04884: Solid Tumors Therapy; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators; Protein farnesyltransferase Inhibitor;
CBR-001-573-363-8,RFM-002-165-8,CBR-001-573-363-8,CC(c1c(O)cc(cc1O)/C=C/c1ccccc1)C,"CBR-HVAC-06308: Antipsoriatics;Inflammation, Treatment of;Atopic Dermatitis, Agents forLymphocyte-specific tyrosine kinase inhibitor; Casein kinase 2 inhibitor; T cell inhibitor"
CBR-001-573-364-9,RFM-002-166-9,CBR-001-573-364-9,Nc1ccc(cc1)S(=O)(=O)N(c1onc(c1C)C)C(=O)C,CBR-HVAC-09668: ; Dihydropteroate synthase Inhibitor;
CBR-001-573-365-0,RFM-002-167-0,CBR-001-573-365-0,OC(=O)Cc1ccc2c(c1)cco2,analog of CBR-HVAC-05854 (DBFA)
CBR-001-573-366-1,RFM-002-168-1,CBR-001-573-366-1,Fc1ccc(cc1)C(c1ccccc1F)(n1cncc1)c1ccccc1,CBR-HVAC-01875: Antifungal Agents; Sterol demethylase Inhibitor; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-573-367-2,RFM-002-169-2,CBR-001-573-367-2,Fc1cnc(nc1)[C@@H](Nc1ncc(c(n1)Nc1n[nH]c(c1)C)Cl)C,CBR-HVAC-06638: Hematopoiesis Disorders Therapy;Liver Cancer Therapy; Jak1 Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators;
CBR-001-573-368-3,RFM-002-170-5,CBR-001-573-368-3,CCC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F)C(=O)COC(=O)CC,CBR-HVAC-00063: Glucocorticoid receptor Agonist; Glucocorticoid agonist
CBR-001-573-369-4,RFM-002-171-6,CBR-001-573-369-4,CC[C@H]1N(C2CCCC2)c2nc(ncc2N(C1=O)C)Nc1ccc(cc1OC)C(=O)NC1CCN(CC1)C,CBR-HVAC-06295: Solid Tumors Therapy;Myeloid Leukemia Therapy;Small Cell Lung Cancer Therapy;Pancreatic Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Antimitotic Drugs;Polo-like Kinase-1 (Plk-1) Inhibitors;Signal Transduction Modulators; Polo-like kinase 1 Modulator;
CBR-001-573-370-7,RFM-002-172-7,CBR-001-573-370-7,CN(C/C=C/C(=O)Nc1cc2c(ncnc2cc1O[C@@H]1COCC1)Nc1ccc(c(c1)Cl)F)C,CBR-HVAC-05737: Head and Neck Cancer Therapy;Colorectal Cancer Therapy;Bladder Cancer Therapy ;Pancreatic Cancer Therapy;Neurologic Cancer Therapy;Female Reproductive System Cancer Therapy;Gastric Cancer Therapy;Prostate Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Glioblastoma Multiforme Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators; EGFR; ERBB2; ERBB4; HER2 Inhibitor; Inhibitor; Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-573-371-8,RFM-002-173-8,CBR-001-573-371-8,CCOc1ccn(c(=O)c1C(=O)Nc1ccc(c(c1)F)Oc1ccnc(c1Cl)N)c1ccc(cc1)F,"CBR-HVAC-06755: Solid Tumors Therapy; AXL Kinase Inhibitors;Flt3 (FLK2/STK1) Inhibitors;HGFR (MET; c-Met) Inhibitors;Macrophage Stimulating 1 Receptor (MST1R, RON) Inhibitors;Mer Receptor Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Kinase Receptor TYRO3 Inhibitors; Met proto-oncogene (hepatocyte growth factor receptor) Antagonist;"
CBR-001-573-372-9,RFM-002-174-9,CBR-001-573-372-9,COc1cc2c(cc1OC)CC(C2=O)CC1CCN(CC1)Cc1ccccc1,CBR-HVAC-02578: ; Cholinesterase Inhibitor; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Sigma 1 receptor agonist; Acetylcholinesterase inhibitor
CBR-001-573-373-0,RFM-002-175-0,CBR-001-573-373-0,O=C1NC(=O)/C(=C/c2ccc3c(c2)c(ccn3)c2ccncc2)/S1,CBR-HVAC-06690: Oncolytic Drugs; Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Signal Transduction Modulators; Phosphoinositide 3 kinase Inhibitor;
CBR-001-573-374-1,RFM-002-176-1,CBR-001-573-374-1,CC1=Cc2cc3OCOc3cc2C(=NN1)c1ccc(cc1)N,CBR-HVAC-10622: Antiepileptic Drugs;Antispastic Drugs; AMPA Receptor Antagonists;Kainate Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Antagonist;
CBR-001-573-375-2,RFM-002-177-2,CBR-001-573-375-2,Cn1ncc(c1)c1ccc2n(n1)c(nn2)C(c1ccc2c(c1)cccn2)(F)F,CBR-HVAC-06633: Solid Tumors Therapy; HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators; c-MET Inhibitor; MET tyrosine kinase inhibitor
CBR-001-573-376-3,RFM-002-178-3,CBR-001-573-376-3,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)[nH]c2c(c1=O)cccc2,"CBR-HVAC-02207: Hypertension, Treatment of; Signal Transduction Modulators;5-HT2 Antagonists; 5-Hydroxytryptamine 2 receptor Agonist; Collagen stimulant; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-573-377-4,RFM-002-179-4,CBR-001-573-377-4,CCCNC(=O)Nc1ccc(cc1Cl)Oc1ncnc2c1cc(OC)c(c2)OC,CBR-HVAC-11311: Oncolytic Drugs; Angiogenesis Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Vascular endothelial growth factor receptor Inhibitor;
CBR-001-573-378-5,RFM-002-180-7,CBR-001-573-378-5,FC(c1ccc(cc1)/C=C/c1occ(n1)COc1ccc(cc1)CCCCn1nncc1)(F)F,CBR-HVAC-05639: Breast Cancer Therapy; HER2 (erbB2) Inhibitors;Signal Transduction Modulators; HER-2 Inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-573-379-6,RFM-002-181-8,CBR-001-573-379-6,O=C(c1sccc1NCc1ccnc2c1cccc2)Nc1ccc(cc1)OC(F)(F)F,CBR-HVAC-06105: Solid Tumors Therapy; Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; C-kit inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor
CBR-001-573-380-9,RFM-002-182-9,CBR-001-573-380-9,Cn1ncc(c1)c1ccc2n(n1)c(nn2)Sc1ccc2c(c1)cccn2,CBR-HVAC-06546: Solid Tumors Therapy; HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators; C-MET Inhibitor;
CBR-001-573-381-0,RFM-002-183-0,CBR-001-573-381-0,O=C(C1CCNCC1)Nc1ncc(s1)SCc1ncc(o1)C(C)(C)C,CBR-HVAC-05559: Hematological Cancer Therapy;Multiple Myeloma Therapy;Solid Tumors Therapy; CDK2/Cyclin E Inhibitors;CDK7 Inhibitors;CDK9 Inhibitors;Signal Transduction Modulators; CDK2; CDK7; CDK9 Inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor; Cyclin-dependent kinase 9 inhibitor; Mcl-1 antagonist; Cell cycle inhibitor
CBR-001-573-382-1,RFM-002-184-1,CBR-001-573-382-1,O=C(c1cnc2c(c1O)cccc2)Nc1cc(O)c(cc1C(C)(C)C)C(C)(C)C,"CBR-HVAC-06373: Cystic Fibrosis, Treatment of ; CFTR Channel Activators; CF transmembrane conductance regulator agonist"
CBR-001-573-383-2,RFM-002-185-2,CBR-001-573-383-2,O=C(N1CCN(CC1)Cc1sc2c(c1C)nc(nc2N1CCOCC1)c1cnc(nc1)N)[C@@H](O)C,CBR-HVAC-00052: Prostate Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Breast Cancer Therapy;Female Reproductive System Cancer Therapy;Renal Cancer Therapy; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; mTOR; Phosphoinositide 3-kinase Inhibitor; Inhibitor; PI3 kinase inhibitor; mTOR kinase inhibitor
CBR-001-573-384-3,RFM-002-186-3,CBR-001-573-384-3,CN1CC[C@@H]([C@@H](C1)O)c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O,CBR-HVAC-00055: Cancer of Unspecified Body Location/System;Sarcoma Therapy;Multiple Myeloma Therapy;Gastric Cancer Therapy;Melanoma Therapy;Oncolytic Drugs;Pancreatic Cancer Therapy;Breast Cancer Therapy;Head and Neck Cancer Therapy;Hematological Cancer Therapy;Solid Tumors Therapy;Myeloid Leukemia Therapy;Ovarian Cancer Therapy;Renal Cancer Therapy;Lymphocytic Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy;Prostate Cancer Therapy;Colorectal Cancer Therapy;Lung Cancer Therapy;Liver Cancer Therapy;Leukemia Therapy; Apoptosis Inducers;Bcl-2 Inhibitors;CDK1 Inhibitors;CDK2 Inhibitors;CDK4 Inhibitors;CDK6 Inhibitors;CDK7 Inhibitors;CDK9/Cyclin T1 Inhibitors;Mcl-1 Inhibitors;Signal Transduction Modulators;Survivin Inhibitors;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors; CDK Inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 9 inhibitor; Cell cycle inhibitor; Cyclin-dependent kinase 7 inhibitor; Apoptosis stimulant; Cyclin-dependent kinase 6 inhibitor
CBR-001-573-385-4,RFM-002-187-4,CBR-001-573-385-4,Fc1ccc(cn1)NC(=O)[C@]1(C)CCCN1c1nc(Nc2n[nH]c(c2)C2CC2)c2n(n1)ccc2,CBR-HVAC-00641: Breast Cancer Therapy; IGF-1R Inhibitors;Signal Transduction Modulators; IGF1R Inhibitor; IGF-1 receptor tyrosine kinase inhibitor
CBR-001-573-386-5,RFM-002-188-5,CBR-001-573-386-5,CN[C@H](C(=O)N[C@H]1CN(CC[C@@H]2N(C1=O)[C@@H](CC2)C(=O)NC(c1ccccc1)c1ccccc1)C(=O)CC(C)C)C,CBR-HVAC-06886: Solid Tumors Therapy;Head and Neck Cancer Therapy;Ovarian Cancer Therapy;Breast Cancer Therapy;Myeloid Leukemia Therapy;Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy;Lymphoma Therapy; Apoptosis Inducers;Inhibitor  of Apoptosis Protein 1 (IAP1) Inhibitors;Inhibitor  of Apoptosis Protein 2 (IAP2) Inhibitors;Signal Transduction Modulators;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors; XIAP; c-IAP1; c-IAP2 Inhibitor; Inhibitor; Inhibitor;
CBR-001-573-387-6,RFM-002-189-6,CBR-001-573-387-6,Clc1ccc(c(c1)Cl)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCC1CCOCC1,CBR-HVAC-06053: Non-Opioid Analgesics; Cannabinoid CB2 Agonists;Signal Transduction Modulators; Cannabinoid receptor 2 Agonist;
CBR-001-573-388-7,RFM-002-190-9,CBR-001-573-388-7,CON(Cc1ccc(c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)C(C(=O)[C@]3(C(=O)C1C2=O)O)C(=O)N)O)C,CBR-HVAC-07240 Dermatologic Drugs;Antibacterial Drugs;Acne Therapy; Protein 30S ribosomal subunit inhibitor
CBR-001-573-389-8,RFM-002-191-0,CBR-001-573-389-8,CNC(=O)c1cccc(c1)c1ccc2c(n1)nc(nc2N1CCOC[C@@H]1C)N1CCOC[C@@H]1C,CBR-HVAC-06974: Solid Tumors Therapy;Renal Cancer Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Female Reproductive System Cancer Therapy;Breast Cancer Therapy; mTOR Complex 1 (mTORC1) Inhibitors;mTOR Complex 2 (mTORC2) Inhibitors;Signal Transduction Modulators; mTOR Inhibitor;
CBR-001-573-390-1,RFM-002-192-1,CBR-001-573-390-1,O=C(NC(C)(C)C)N[C@@H](C(C)(C)C)C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(C(=O)C(=O)N)CC1CCC1)C2(C)C,CBR-HVAC-06259: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors;3alpha-Hydroxysteroid Dehydrogenase Inhibitors; NS3 protease Inhibitor;
CBR-001-573-391-2,RFM-002-193-2,CBR-001-573-391-2,C1CCN(CC1)CCOc1cccc(c1)c1n[nH]c2c1cc(cc2)c1[nH]ncn1,CBR-HVAC-05761
CBR-001-573-392-3,RFM-002-194-3,CBR-001-573-392-3,CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1nccc(c1)Oc1ccc(c(c1)F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F,CBR-HVAC-00273: Solid Tumors Therapy;Liver Cancer Therapy;Glioblastoma Multiforme Therapy;Melanoma Therapy;Head and Neck Cancer Therapy; Angiogenesis Inhibitors;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Vascular endothelial growth factor receptor 2; c-MET Antagonist; MET tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor
CBR-001-573-393-4,RFM-002-195-4,CBR-001-573-393-4,CC(=O)N[C@H]1[C@H](O)O[C@@H]([C@@H]([C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@H]([C@@H]([C@H]1O)O)O)O)OS(=O)(=O)O,CBR-HVAC-09215:
CBR-001-573-394-5,RFM-002-196-5,CBR-001-573-394-5,Ic1ccc(c(c1)F)Nc1c(ccc(c1F)F)C(=O)N1CC(C1)(O)[C@@H]1CCCCN1,CBR-HVAC-06528: Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Solid Tumors Therapy;Melanoma Therapy;Colorectal Cancer Therapy; Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Signal Transduction Modulators; Mitogen-activated protein 2 kinase 1 Inhibitor;
CBR-001-573-395-6,RFM-002-197-6,CBR-001-573-395-6,COc1cc(C(=O)Nc2ccc(cc2)CCN2CCc3c(C2)cc(c(c3)OC)OC)c(cc1OC)NC(=O)c1cnc2c(c1)cccc2,CBR-HVAC-00472: Cancer Multidrug Resistance Modulators; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; P-Glycoprotein Inhibitor; P glycoprotein inhibitor; MRP inhibitor
CBR-001-573-396-7,RFM-002-198-7,CBR-001-573-396-7,OC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)c1ccc(nc1)c1nnn(n1)C,CBR-HVAC-06221: Treatment of Tuberculosis;Antibacterial Drugs
CBR-001-573-397-8,RFM-002-199-8,CBR-001-573-397-8,OC(=O)c1cc(cc2c1nc(n2Cc1cccc(c1C)C(F)(F)F)C)N1CCOCC1,CBR-HVAC-07185: Solid Tumors Therapy;Prostate Cancer Therapy; Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Signal Transduction Modulators;
CBR-001-573-398-9,RFM-002-200-4,CBR-001-573-398-9,O=C(Nc1ccc(cc1)O)/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,"CBR-HVAC-00030: Prostate Cancer Therapy;Brain Cancer Therapy;Head and Neck Cancer Therapy;Cystic Fibrosis, Treatment of ;Ovarian Cancer Therapy;Neurologic Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Bladder Cancer Therapy ;Breast Cancer Therapy;Antidiabetic Drugs;Solid Tumors Therapy;Lymphocytic Leukemia Therapy;Age-Related Macular Degeneration, Treatment of;Lung Cancer Therapy; Apoptosis Inducers;Retinoid RARbeta Agonists;Retinoid RARgamma Agonists;Signal Transduction Modulators; Retinoic acid receptor; Vascular endothelial growth factor receptor; FGFR Antagonist; Inhibitor; Modulator; Apoptosis stimulant; Retinoic acid alpha receptor agonist"
CBR-001-573-399-0,RFM-002-201-5,CBR-001-573-399-0,O=CC([C@@]1(O)C[C@H](O[C@H]2C[C@H](N)[C@@H]([C@@H](O2)C)O)c2c(C1)c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2OC)NNC(=O)CCCCCN1C(=O)C=CC1=O,analog of CBR-HVAC-05830
CBR-001-573-400-6,RFM-002-202-6,CBR-001-573-400-6,Clc1ccc(cc1)C1=C(CCC(C1)(C)C)CN1CCN(CC1)c1ccc(c(c1)Oc1cnc2c(c1)cc[nH]2)C(=O)NS(=O)(=O)c1ccc(c(c1)[N+](=O)[O-])NCC1CCOCC1,CBR-HVAC-00151: ; BCL-2 Inhibitor; Unidentified pharmacological activity
CBR-001-573-401-7,RFM-002-203-7,CBR-001-573-401-7,OC(=O)CC1ONC(=C1)c1ccccc1,"CBR-HVAC-06270: Inflammation, Treatment of;Rheumatoid Arthritis, Treatment of;Type 1 Diabetes, Agents for;Antipsoriatics; Cytokine Modulators;Signal Transduction Modulators; Cytokine antagonist; Tumour necrosis factor alpha antagonist"
CBR-001-573-402-8,RFM-002-204-8,CBR-001-573-402-8,ONC(=O)/C=C/c1ccn(c1)S(=O)(=O)c1ccc(cc1)CN(C)C,CBR-HVAC-00695: Colorectal Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Non-Small Cell Lung Cancer Therapy;Lymphoma Therapy;Liver Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Pancreatic Cancer Therapy;Oncolytic Drugs; Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor
CBR-001-573-403-9,RFM-002-205-9,CBR-001-573-403-9,O=C(/C=C\n1cnc(n1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)NNc1cnccn1,"CBR-HVAC-07209: Glioblastoma Multiforme Therapy;Cancer of Unspecified Body Location/System;Small Cell Lung Cancer Therapy;Myeloid Leukemia Therapy;Prostate Cancer Therapy;Colorectal Cancer Therapy;Lymphocytic Leukemia Therapy;Squamous Cell Carcinoma Therapy;Multiple Myeloma Therapy;Neurologic Cancer Therapy;Breast Cancer Therapy;Solid Tumors Therapy;Myelodysplastic Syndrome Therapy;Non-Hodgkin's Lymphoma Therapy;Sarcoma Therapy;Wound-Healing Agents;Digestive/Gastrointestinal Cancer Therapy;Hematological Cancer Therapy;Female Reproductive System Cancer Therapy; Apoptosis Inducers;Exportin-1 (CRM1, XPO1) Antagonists;Signal Transduction Modulators; CRM1 inhibitor"
CBR-001-573-404-0,RFM-002-206-0,CBR-001-573-404-0,O=C(c1ccccc1c1ccc(cc1)C(F)(F)F)NC1CCN(CC1)CCCCC1(C(=O)NCC(F)(F)F)c2ccccc2c2c1cccc2,"CBR-HVAC-04825: Lipoprotein Disorders, Treatment of ; Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein Inhibitor; Microsomal trigylceride transfer protein inhibitor"
CBR-001-573-405-1,RFM-002-207-1,CBR-001-573-405-1,COc1cccc(n1)c1cc(F)ccc1[C@@H]1NC(=O)c2c(C1)nc(nc2C)N,CBR-HVAC-06962: Solid Tumors Therapy;Oncolytic Drugs; Heat Shock Protein 90 (HSP90) Inhibitors; HEAT SHOCK PROTEIN 90 Inhibitor;
CBR-001-573-406-2,RFM-002-208-2,CBR-001-573-406-2,Cc1cc(nn1Cc1ccnc(c1)N1CCN(CC1)C1CC1)c1onc(n1)c1ccc(cc1)OC(F)(F)F,CBR-HVAC-07024: Oncolytic Drugs; Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors; HYPOXIA-INDUCIBLE FACTOR-1ALPHA Inhibitor;
CBR-001-573-407-3,RFM-002-209-3,CBR-001-573-407-3,Clc1ccc(c(c1)Cl)C(=O)NS(=O)(=O)c1ccc(s1)Br,CBR-HVAC-05900: Non-Small Cell Lung Cancer Therapy;Renal Cancer Therapy;Melanoma Therapy;Ovarian Cancer Therapy;Myeloid Leukemia Therapy;Sarcoma Therapy;Breast Cancer Therapy; Apoptosis Inducers; Apoptosis stimulant
CBR-001-573-408-4,RFM-002-210-6,CBR-001-573-408-4,CC(=O)Nc1cccc2c1c(Sc1ccc(cc1)Cl)c(n2CC(=O)O)C,"CBR-HVAC-06025: Asthma Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Urticaria, Treatment for; Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists;Signal Transduction Modulators;"
CBR-001-573-409-5,RFM-002-211-7,CBR-001-573-409-5,N[C@@H]1CCCN(C1)c1c(cccc1c1ccccc1)/C=C/1\SC(=O)NC1=O,CBR-HVAC-07186: Solid Tumors Therapy;Myeloid Leukemia Therapy;Lymphoma Therapy;Antineoplastic Enhancing Agents; Pim-1 Kinase Inhibitors;Pim-2 Kinase Inhibitors;Pim-3 Kinase Inhibitors;Signal Transduction Modulators;
CBR-001-573-410-8,RFM-002-212-8,CBR-001-573-410-8,O[C@H]1CC[C@]2([C@@H](C1)CC[C@@H]1[C@@H]2CC[C@]2([C@]1(O)CC[C@]2(O)c1ccoc1)C)C,"CBR-HVAC-00694: Hypertension, Treatment of; Na+, K+ ATPase Modulator; Na+ K+ transporting ATPase inhibitor"
CBR-001-573-412-0,RFM-002-213-9,CBR-001-573-412-0,ONC(=O)C[C@H](C(=O)N[C@H](C(=O)NC)Cc1c[nH]c2c1cccc2)CC(C)C,"CBR-HVAC-04420: Corneal Wound Healing Agents;Inflammatory Bowel Disease, Agents for;Ear disorders, treatment of;Antineurotoxic Agents;Restenosis Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy; Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors; Matrix metalloproteinase Inhibitor; Matrix metalloproteinase inhibitor"
CBR-001-573-413-1,RFM-002-214-0,CBR-001-573-413-1,CC[C@@H](OC(=O)N[C@H](c1cccc(c1)NC(=O)Nc1ccc(c(c1)OC)c1cnco1)C)CC#N,CBR-HVAC-05448: Hematological Cancer Therapy;Oncolytic Drugs;Solid Tumors Therapy;Pancreatic Cancer Therapy;Treatment of Autoimmune Diseases; Inosine 5'-Monophosphate Dehydrogenase Type II (IMPDH II) Inhibitors; INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE Inhibitor; Inosine monophosphate dehydrogenase inhibitor
CBR-001-573-414-2,RFM-002-215-1,CBR-001-573-414-2,O=C1CC[C@@]2(N1)CC[C@@](NC2)(CO[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)c1ccccc1,"CBR-HVAC-05933: Respiratory Disorders (Not Specified);Disorders Associated with Cancer Therapy, Treatment of; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin-1 receptor Antagonist;"
CBR-001-573-415-3,RFM-002-216-2,CBR-001-573-415-3,CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@H](C([C@@H]1O)(F)F)n1ccc(nc1=O)N,CBR-HVAC-06199: Pancreatic Cancer Therapy;Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy; Ribonucleotide reductase Inhibitor; DNA synthesis inhibitor; DNA repair enzyme inhibitor; Cell cycle inhibitor; Apoptosis stimulant
CBR-001-573-416-4,RFM-002-217-3,CBR-001-573-416-4,Clc1ccc2c(c1)NC(=c1c(=N2)cccc1)N1CCNCC1,CBR-HVAC-11951: ; Thrombin Inhibitor;
CBR-001-573-417-5,RFM-002-218-4,CBR-001-573-417-5,CN(C(=O)c1ccc(cc1)S(=O)(=O)c1ccc(c(c1)Cl)NC(=O)[C@](C(F)(F)F)(O)C)C,"CBR-HVAC-11665: Type 2 Diabetes, Agents for; Pyruvate Dehydrogenase Kinase 2 (PDHK2; PDK2) Inhibitors;Signal Transduction Modulators; Pyruvate dehydrogenase kinase 2 Inhibitor;"
CBR-001-573-418-6,RFM-002-219-5,CBR-001-573-418-6,OC(=O)C(=O)c1cn(c2c1cc(cc2)c1ccc(cc1)OC(F)(F)F)Cc1ccccc1,CBR-HVAC-06046: Asthma Therapy;Thrombolytics;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Plasminogen Activator Inhibitor (PAI-1) Inhibitors; PLASMINOGEN ACTIVATOR INHIBITOR-1 Antagonist; Plasminogen activator inhibitor-1 inhibitor
CBR-001-573-419-7,RFM-002-220-8,CBR-001-573-419-7,CCN(CCN(C(=O)Cn1c(SCc2ccc(cc2)F)nc(=O)c2c1CCC2)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F)CC,"CBR-HVAC-05624: Stroke, Treatment of;Cardiovascular Diseases (Not Specified);Asthma Therapy;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Acute Myocardial Infarction, Treatment of;Rheumatoid Arthritis, Treatment of;Atherosclerosis Therapy;Antipsoriatics;Antidiabetic Drugs;Diabetic Retinopathy, Agents for; Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 Inhibitor;"
CBR-001-573-420-0,RFM-002-221-9,CBR-001-573-420-0,CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@@H]1O[C@H](SC)[C@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-06793: Type 2 Diabetes, Agents for;Type 1 Diabetes, Agents for; SGLT-1 Inhibitors;SGLT-2 Inhibitors; Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 1 inhibitor"
CBR-001-573-421-1,RFM-002-222-0,CBR-001-573-421-1,COc1ccc(cc1)C[C@H](NC[C@@H](c1ccc(c2c1ccc(n2)O)O)O)C,CBR-HVAC-03327: Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor Agonist; Long-acting beta 2 adrenoceptor (LABA) agonist; Beta 2 adrenoreceptor agonist
CBR-001-573-422-2,RFM-002-223-1,CBR-001-573-422-2,NCCC[C@]1(SC(=NN1C(=O)N(OC)C)c1cc(F)ccc1F)c1ccccc1,"CBR-HVAC-06531: Solid Tumors Therapy;Multiple Myeloma Therapy;Myeloid Leukemia Therapy; Antimitotic Drugs;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors;"
CBR-001-573-423-3,RFM-002-224-2,CBR-001-573-423-3,COc1ccc(c2c1nc(s2)NC(=O)N1CCC(CC1)(C)O)N1CCOCC1,CBR-HVAC-00750: Neurologic Drugs (Miscellaneous);Treatment of Substance Dependency;Antiparkinsonian Drugs;Treatment of Cocaine Dependency; Adenosine A2A Antagonists;Signal Transduction Modulators; Adenosine A2a receptor Antagonist; Adenosine A2a receptor antagonist; Adenosine receptor antagonist
CBR-001-573-424-4,RFM-002-225-3,CBR-001-573-424-4,COC(=O)N(c1c(N)nc(nc1N)c1nn(c2c1cccn2)Cc1ccccc1F)C,"CBR-HVAC-00091: Pulmonary Hypertension, Treatment of;Treatment of Autoimmune Diseases;Cystic Fibrosis, Treatment of ;Raynaud's Phenomenon, Treatment for ; Soluble Guanylate Cyclase (sGC) Activators; Guanylate cyclase Stimulator; Guanylate cyclase stimulant"
CBR-001-573-425-5,RFM-002-226-4,CBR-001-573-425-5,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2c(c1)cccc2,CBR-HVAC-05967: Oncolytic Drugs; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor;
CBR-001-573-426-6,RFM-002-227-5,CBR-001-573-426-6,N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F,"CBR-HVAC-06763: Treatment of Renal Diseases;Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue"
CBR-001-573-427-7,RFM-002-228-6,CBR-001-573-427-7,CC(N1CCN(CC1)Cc1cnc(o1)c1cc(cc2c1cn[nH]2)c1cccc2c1cc[nH]2)C,"CBR-HVAC-07067: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators;"
CBR-001-573-428-8,RFM-002-229-7,CBR-001-573-428-8,CN1CCc2c(C1)sc(n2)C(=O)N[C@@H]1C[C@H](CC[C@@H]1NC(=O)C(=O)Nc1ccc(cn1)Cl)C(=O)N(C)C,CBR-HVAC-06148: Anticoagulants; Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways; FACTOR XA Inhibitor; Factor Xa inhibitor; Serine protease inhibitor
CBR-001-573-429-9,RFM-002-230-0,CBR-001-573-429-9,N#Cc1c[nH]c(n1)C(=O)Nc1ccc(cc1C1=CCCCC1)C1CCN(CC1)C(=O)CN(C)C,"CBR-HVAC-06993: Bone Cancer Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Rheumatoid Arthritis, Treatment of; Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors;Signal Transduction Modulators; FMS-related receptor tyrosine kinase-3; Colony stimulating factor-1 receptor Inhibitor; Colony stimulating factor antagonist"
CBR-001-573-430-2,RFM-002-231-1,CBR-001-573-430-2,CN(CCCC1(CCCN(C)C)c2ccccc2Nc2c1cc(Cl)cc2)C,analog of CBR-HVAC-08878
CBR-001-573-431-3,RFM-002-232-2,CBR-001-573-431-3,COc1ccc2c(c1O)CNCC2c1ccc(c(c1)O)O,analog of CBR-HVAC-04152
CBR-001-573-432-4,RFM-002-233-3,CBR-001-573-432-4,Cl[Ru-2](Cl)(Cl)(Cl)(Cl)Cl,analog of CBR-HVAC-05229 (NAMI-A)
CBR-001-573-433-5,RFM-002-234-4,CBR-001-573-433-5,[N-]=[N+]=CC(=O)CNC(=O)C(C(C)C)NC(=O)C(NC(=O)OCc1ccccc1)CC(C)C,CBR-HVAC-10849:
CBR-001-573-434-6,RFM-002-235-5,CBR-001-573-434-6,Cl[Al+3](Cl)Cl,CBR-HVAC-01255: Not applicable
CBR-001-573-435-7,RFM-002-236-6,CBR-001-573-435-7,OCCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,CBR-HVAC-02567: Disease modifying antirheumatic drug
CBR-001-573-436-8,RFM-002-237-7,CBR-001-573-436-8,CCOc1ccccc1OCCNC(Cc1ccc(c(c1)S(=O)(=O)N)OC)C,CBR-HVAC-02303: Urinary Incontinence Therapy;Benign Prostatic Hyperplasia Therapy;Urologic Drugs; alpha1-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Inhibitor; Alpha 1 adrenoreceptor antagonist
CBR-001-573-437-9,RFM-002-238-8,CBR-001-573-437-9,CCN(CCn1c(=N)onc1c1ccccc1)CC,CBR-HVAC-09801:
CBR-001-573-438-0,RFM-002-239-9,CBR-001-573-438-0,OC(=O)C(CCCC(C(=O)O)(Cl)Cl)(Cl)Cl,analog of CBR-HVAC-04637
CBR-001-573-439-1,RFM-002-240-2,CBR-001-573-439-1,N#Cc1c(NCc2cccnc2)[nH]c(nc1=O)C,CBR-HVAC-03746: Heart Failure Therapy; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase inhibitor
CBR-001-573-440-4,RFM-002-241-3,CBR-001-573-440-4,NC(=O)c1cc([nH]c1c1ccccc1)c1ccncc1,CBR-HVAC-11870: ; CDC7 protein kinase Inhibitor;
CBR-001-573-441-5,RFM-002-242-4,CBR-001-573-441-5,CCc1cccc(c1n1c(=O)c2ccccc2n(c1=O)C)C,analog of CBR-HVAC-09499
CBR-001-573-442-6,RFM-002-243-5,CBR-001-573-442-6,Cc1ccc2c(c1)n(C(C)C)c(=O)nc2c1ccccc1,CBR-HVAC-01535: Antiarthritic Drugs; Antiinflammatory Drugs; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-573-443-7,RFM-002-244-6,CBR-001-573-443-7,C1CNC(=C2COc3c(O2)cccc3)N1,"CBR-HVAC-00503: Stroke, Treatment of;Antipsychotic Drugs; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor; Imidazoline receptor Antagonist; Modulator; Alpha 2 adrenoreceptor antagonist; Imidazoline I2 receptor agonist; Imidazoline I1 receptor agonist"
CBR-001-573-444-8,RFM-002-245-7,CBR-001-573-444-8,COC(=O)C1=CCCN(C1)C,CBR-HVAC-00164: ; Muscarinic acetylcholine receptor Agonist; Muscarinic receptor agonist
CBR-001-573-445-9,RFM-002-246-8,CBR-001-573-445-9,C=CCNC(=O)SC1=NCCS1,analog of CBR-HVAC-11174
CBR-001-573-446-0,RFM-002-247-9,CBR-001-573-446-0,COC1=CC(=O)OC1C(c1ccc(cc1Cl)Cl)O,CBR-HVAC-14278
CBR-001-573-447-1,RFM-002-248-0,CBR-001-573-447-1,O=C(C1CCCCC1)Nc1on[n+](c1)N1CCOCC1,CBR-HVAC-09015:
CBR-001-573-448-2,RFM-002-249-1,CBR-001-573-448-2,CC(N1CCN(C(=C2NCCN2)C1)C(C)C)C,"CBR-HVAC-11474: Antidiabetic Drugs;Type 2 Diabetes, Agents for; Alpha-2 adrenergic receptor Blocker;"
CBR-001-573-449-3,RFM-002-250-4,CBR-001-573-449-3,COc1cc(O)ccc1CCCc1ccc(cc1)O,analog of CBR-HVAC-06349
CBR-001-573-450-6,RFM-002-251-5,CBR-001-573-450-6,CC1CCC(C(C1)OC(=O)c1cccnc1)C(C)C,analog of CBR-HVAC-02036 (ciclonicate)
CBR-001-573-451-7,RFM-002-252-6,CBR-001-573-451-7,CC(=O)NCC1CN(C(=O)O1)c1ccc(cc1)C(=O)C,CBR-HVAC-03625: Antibacterial DrugsProtein 30S ribosomal subunit inhibitor
CBR-001-573-452-8,RFM-002-253-7,CBR-001-573-452-8,CCn1c(O)nnc1c1ccc(cc1)Cl,"CBR-HVAC-03910: Stroke, Treatment of;Antiepileptic Drugs; NMDA Antagonists;Signal Transduction Modulators;"
CBR-001-573-453-9,RFM-002-254-8,CBR-001-573-453-9,CCN1CC[C@@]23C(C1)[C@@H](CC(=O)N2)c1c(O3)ccc(c1)Cl,analog of CBR-HVAC-02518 (lortalamine)
CBR-001-573-454-0,RFM-002-255-9,CBR-001-573-454-0,CC(C12CCC(OO1)(C=C2)C)C,CBR-HVAC-10183:
CBR-001-573-455-1,RFM-002-256-0,CBR-001-573-455-1,NC(=S)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08742:
CBR-001-573-456-2,RFM-002-257-1,CBR-001-573-456-2,CCN(CCOC(c1ccccc1)c1ccccc1)CC,CBR-HVAC-09240:
CBR-001-573-457-3,RFM-002-258-2,CBR-001-573-457-3,CN(CCC1=C(C(c2ccccn2)C)c2c(C1)cccc2)C,CBR-HVAC-09811: Histamine H1 receptor Antagonist;
CBR-001-573-458-4,RFM-002-259-3,CBR-001-573-458-4,CCC(NS(=O)(=O)CCN1C(=O)c2c(C1=O)cccc2)C,analog of CBR-HVAC-01012
CBR-001-573-459-5,RFM-002-260-6,CBR-001-573-459-5,CCOc1ccc(cc1)n1c(N)nc2c1ccc(c2)C(F)(F)F,analog of CBR-HVAC-10618
CBR-001-573-460-8,RFM-002-261-7,CBR-001-573-460-8,c1ccc2c(c1)C1CNC(C2)c2c1cccc2,analog of CBR-HVAC-11503
CBR-001-573-461-9,RFM-002-262-8,CBR-001-573-461-9,NC(=O)N(CC1=Cc2c(OC1)ccc(c2)Oc1ccccc1)O,CBR-HVAC-02689: Antiallergy/Antiasthmatic Drugs; Lipoxygenase Inhibitors; 5-LIPOOXYGENASE Inhibitor; 5 Lipoxygenase inhibitor
CBR-001-573-462-0,RFM-002-263-9,CBR-001-573-462-0,OC(=O)[C@@H](NC(=O)C)CSSC[C@@H](C(=O)O)NC(=O)C,CBR-HVAC-05008: Atherosclerosis Therapy;Immunomodulators
CBR-001-573-463-1,RFM-002-264-0,CBR-001-573-463-1,CC(NCC(c1ccc(c(c1)NS(=O)(=O)C)O)O)C,CBR-HVAC-09232: ; Beta adrenergic receptor Agonist;
CBR-001-573-464-2,RFM-002-265-1,CBR-001-573-464-2,O=C1N2CCC[C@H]2COc2c1cccn2,"CBR-HVAC-06001: Antidepressants;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; AMPA Receptor Modulators;Signal Transduction Modulators; AMPA RECEPTOR Modulator;"
CBR-001-573-465-3,RFM-002-266-2,CBR-001-573-465-3,CC(=O)Oc1ccc(cc1C(=O)O)c1ccc(cc1)F,CBR-HVAC-09976:
CBR-001-573-466-4,RFM-002-267-3,CBR-001-573-466-4,CN(/N=N/c1ccc(cc1)C(=O)O)C,CBR-HVAC-02934: Oncolytic DrugsDNA inhibitor
CBR-001-573-467-5,RFM-002-268-4,CBR-001-573-467-5,CC(=O)SCC(C(=O)Nc1cccc(c1)C(=O)O)C,analog of CBR-HVAC-10788
CBR-001-573-468-6,RFM-002-269-5,CBR-001-573-468-6,CCOC(=O)Cc1ccc(cc1)c1ccccc1,CBR-HVAC-02564: Antiarthritic Drugs; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-573-469-7,RFM-002-270-8,CBR-001-573-469-7,CN(CCOC(c1ccc(cc1)Cl)(c1ccccc1)C)C,CBR-HVAC-09759: ; Histamine receptor Antagonist;
CBR-001-573-470-0,RFM-002-271-9,CBR-001-573-470-0,CCCCCCCCCCCC[N+](C)(C)C,analog of CBR-HVAC-09756: (CETRIMIDE)
CBR-001-573-471-1,RFM-002-272-0,CBR-001-573-471-1,O=C1NC(=O)NC(=O)C1(c1ccccc1)c1ccccc1,CBR-HVAC-00200: Antiepileptic Drugs; GABA-A receptor Agonist; GABA A receptor agonist
CBR-001-573-472-2,RFM-002-273-1,CBR-001-573-472-2,O=C(CP(=O)([O-])[O-])NC(C(=O)[O-])CC(=O)[O-],CBR-HVAC-02896: Cancer Multidrug Resistance Modulators;Oncolytic Drugs;Antiviral Drugs; Antimetabolites;Aspartate Carbamoyltransferase Inhibitors; Aspartate transcarbamylase Inhibitor; Aspartate carbamoyltransferase inhibitor
CBR-001-573-473-3,RFM-002-274-2,CBR-001-573-473-3,Cc1cc2cc3cccc(c3c(c2c(c1)O)O)O,CBR-HVAC-09019:
CBR-001-573-474-4,RFM-002-275-3,CBR-001-573-474-4,CCOP(=S)(c1ccccc1)Oc1cccnc1,analog of CBR-HVAC-10136
CBR-001-573-475-5,RFM-002-276-4,CBR-001-573-475-5,Cc1cc(C)n(c(=O)c1)O,CBR-HVAC-08898: ; Deoxyhypusine hydroxylase Inhibitor;
CBR-001-573-477-7,RFM-002-277-5,CBR-001-573-477-7,CCc1c(C)[nH]c2c1C(=O)C(CC2)CN(C)C,analog of CBR-HVAC-08208
CBR-001-573-478-8,RFM-002-278-6,CBR-001-573-478-8,CN1CCC2=C(C1)C(c1ccccc1)c1c2cccc1,CBR-HVAC-10239: ; Histamine 1 receptor Antagonist;
CBR-001-573-479-9,RFM-002-279-7,CBR-001-573-479-9,Clc1ccc(cc1)NNC(=N)c1ccccc1,analog of CBR-HVAC-07596
CBR-001-573-480-2,RFM-002-280-0,CBR-001-573-480-2,Clc1ccc(cc1)N1C(=NC(=NC1(C)C)N)N,CBR-HVAC-08794: ; Dihydrofolate reductase Inhibitor;
CBR-001-573-481-3,RFM-002-281-1,CBR-001-573-481-3,O=C(C(C)(C)C)Nc1c(C)cc(c2c1N(CC2)CC1CC1)C,analog of CBR-HVAC-10978
CBR-001-573-482-4,RFM-002-282-2,CBR-001-573-482-4,O=C1C(c2ccc(cc2)C(F)(F)F)C(=O)c2c1cccc2,CBR-HVAC-08643:
CBR-001-573-483-5,RFM-002-283-3,CBR-001-573-483-5,OC(=O)c1cc(/N=N/c2ccc(c(c2)C(=O)O)O)ccc1O,"CBR-HVAC-02182: Inflammatory Bowel Disease, Agents for; Na+, K+ ATPase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-573-484-6,RFM-002-284-4,CBR-001-573-484-6,Cc1nc(c([nH]1)c1ccccc1)c1cccnc1,analog of CBR-HVAC-11621
CBR-001-573-485-7,RFM-002-285-5,CBR-001-573-485-7,NC(=O)OC1CC2CC3CC1CC(C2)C3,analog of CBR-HVAC-08871
CBR-001-573-486-8,RFM-002-286-6,CBR-001-573-486-8,O=C(C(c1ccccc1)O)OC1CC(C)N(C(C1)(C)C)C,CBR-HVAC-09839:
CBR-001-573-487-9,RFM-002-287-7,CBR-001-573-487-9,N=C(Nc1ccc(c(c1)Cl)Cl)NC(=N)NC(C)C,CBR-HVAC-05498: Antimalarials
CBR-001-573-488-0,RFM-002-288-8,CBR-001-573-488-0,CN1CCc2c(C1O)cc1c(c2)OCO1,CBR-HVAC-09843:
CBR-001-573-489-1,RFM-002-289-9,CBR-001-573-489-1,CN(/C=N/c1cccc(n1)O)C,analog of CBR-HVAC-03669
CBR-001-573-490-4,RFM-002-290-2,CBR-001-573-490-4,CC(C(c1ccc(cc1)Cl)(O)C)(c1ccc(cc1)Cl)O,analog of CBR-HVAC-08629
CBR-001-573-491-5,RFM-002-291-3,CBR-001-573-491-5,CC(=O)OC(C(=O)OC(C(=O)O)C)C,analog of CBR-HVAC-04660 (LAC-83)
CBR-001-573-492-6,RFM-002-292-4,CBR-001-573-492-6,CS(=O)CC(=O)c1ccccn1,CBR-HVAC-08622:
CBR-001-573-493-7,RFM-002-293-5,CBR-001-573-493-7,CCN1CCOC2C1Cc1c(OC)ccc(c1C2)SC,analog of CBR-HVAC-03390 (SDZ-NVI-085)
CBR-001-573-494-8,RFM-002-294-6,CBR-001-573-494-8,[O-][N+](=O)CC(c1ccccc1)SCc1ccc(cc1)Cl,analog of CBR-HVAC-08901
CBR-001-573-495-9,RFM-002-295-7,CBR-001-573-495-9,C=CCC1(C(=O)NC(=O)NC1=O)C1CCC=C1,CBR-HVAC-09770:
CBR-001-573-496-0,RFM-002-296-8,CBR-001-573-496-0,COC(=O)C1CSC(=N1)c1ncccc1O,analog of CBR-HVAC-10550
CBR-001-573-497-1,RFM-002-297-9,CBR-001-573-497-1,OC(c1ccc(cc1)Cl)(c1ccc(cc1)Cl)C1CC1,CBR-HVAC-08968:
CBR-001-573-498-2,RFM-002-298-0,CBR-001-573-498-2,Nc1ccc(cc1)S(=O)(=O)Nc1scc(n1)C,CBR-HVAC-08696:
CBR-001-573-499-3,RFM-002-299-1,CBR-001-573-499-3,OCC1OC(CC1O)n1cc(Br)c(=O)[nH]c1=O,CBR-HVAC-02320: Head and Neck Cancer Therapy;Bladder Cancer Therapy ; Antimetabolites; DNA synthesis inhibitor
CBR-001-573-500-9,RFM-002-300-7,CBR-001-573-500-9,C=CCn1nc(n(c1=O)C)c1ccc(cc1)Cl,analog of CBR-HVAC-11528
CBR-001-573-502-1,RFM-002-301-8,CBR-001-573-502-1,COc1nccc(n1)c1c(ncn1C1CCC(CC1)O)c1ccc(cc1)F,"CBR-HVAC-11060: Stroke, Treatment of;Antipsoriatics;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; IL-1 Inhibitors;MAPK p38 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; p38 Mitogen-activated protein kinase Inhibitor;"
CBR-001-573-503-2,RFM-002-302-9,CBR-001-573-503-2,CCC(CC1CCC(O1)C(C(=O)OC(CC1CCC(O1)C(C(=O)O)C)C)C)O,CBR-HVAC-09529:
CBR-001-573-504-3,RFM-002-303-0,CBR-001-573-504-3,COc1cc(OC)c2c(c1)c(c1c(c2O)CO[C@H]([C@H]1O)C)c1c2[C@H](O)[C@H](C)OCc2c(c2c1cc(OC)cc2OC)O,analog of CBR-HVAC-11530
CBR-001-573-505-4,RFM-002-304-1,CBR-001-573-505-4,COC1CC(OC(C1OC1CC(OC)C(C(O1)C)OC1CC(OC)C(C(O1)C)OC1CC(OC)C(C(O1)C)OC1OC(CO)C(C(C1O)O)O)C)OC1C(OC)CC(OC1C)OC1CCC2(C(=CCC3C2CC(OC(=O)/C(=C/C)/C)C2(C3(O)CCC2C(=O)C)C)C1)C,analog of CBR-HVAC-06474 (P-57AS3)
CBR-001-573-506-5,RFM-002-305-2,CBR-001-573-506-5,CCC12CCCN3C2c2n(C(C1)O)c1c(c2CC3)cccc1,CBR-HVAC-14280
CBR-001-573-507-6,RFM-002-306-3,CBR-001-573-507-6,NCCCC[C@H](C(=O)N[C@@H](C(=O)O)CO)N,CBR-HVAC-04046: Immunomodulators
CBR-001-573-508-7,RFM-002-307-4,CBR-001-573-508-7,O=C([C@@H](Cc1c[nH]c2c1cccc2)N)N[C@@H](C(=O)O)C,analog of CBR-HVAC-07271 (MRZ-99030)
CBR-001-573-509-8,RFM-002-308-5,CBR-001-573-509-8,CCC(=O)Nc1nnc(s1)S(=O)(=O)N,analog of CBR-HVAC-08942
CBR-001-573-510-1,RFM-002-309-6,CBR-001-573-510-1,CN1CCCC(C1)C(=O)Nc1c(C)cccc1C,analog of CBR-HVAC-08176
CBR-001-573-511-2,RFM-002-310-9,CBR-001-573-511-2,COc1cccc(c1c1ccc(cc1)C[C@@H](C(=O)O)NC(=O)c1c(Cl)cccc1Cl)OC,"CBR-HVAC-05235: Rheumatoid Arthritis, Treatment of;Asthma Therapy;Inflammatory Bowel Disease, Agents for;Multiple Sclerosis, Agents for; Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Signal Transduction Modulators; Integrin alpha4 beta1; Integrin alpha4 beta7 Antagonist;"
CBR-001-573-512-3,RFM-002-311-0,CBR-001-573-512-3,O=C(/C=C/c1cccnc1)NCc1ccc(cc1)C(=O)Nc1cc(F)ccc1N,CBR-HVAC-06579: Histone Deacetylase (HDAC) Inhibitors; Breast Cancer Therapy; Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs
CBR-001-573-513-4,RFM-002-312-1,CBR-001-573-513-4,COc1ccsc1CNCC[C@]1(CCOC2(C1)CCCC2)c1ccccn1,CBR-HVAC-00625: Opioid Analgesics; mu-Opioid Receptor Ligands;Signal Transduction Modulators; MU-OPIOID RECEPTOR Agonist; Opioid mu receptor agonist
CBR-001-573-514-5,RFM-002-313-2,CBR-001-573-514-5,O=C1CCCN1c1ccc(nc1)Oc1ccc2c(c1)CCN(CC2)C1CCC1,"CBR-HVAC-06099: Multiple Sclerosis, Agents for;Antipsychotic Drugs;Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of; Histamine H3 Receptor Antagonists;Signal Transduction Modulators; HISTAMINE H3 RECEPTOR Antagonist;"
CBR-001-573-515-6,RFM-002-314-3,CBR-001-573-515-6,OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2cc3c(s2)cccc3)F)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-06667: Type 1 Diabetes, Agents for;Type 2 Diabetes, Agents for; SGLT-2 Inhibitors; SGLT2 Inhibitor; Sodium/glucose cotransporter 2 inhibitor"
CBR-001-573-516-7,RFM-002-315-4,CBR-001-573-516-7,Nc1cccc(c1C)Cn1ccc(cc1=O)OCCc1cccs1,CBR-HVAC-00606: ; Enoyl-(acyl carrier protein) reductase FabI Inhibitor; FABI inhibitor
CBR-001-573-517-8,RFM-002-316-5,CBR-001-573-517-8,OC(=O)CCCCCCNC1c2ccccc2CCc2c1cccc2,CBR-HVAC-01950: Antidepressants;Treatment of Substance Dependency; Dopamine Receptor Agonists;Signal Transduction Modulators; Dopamine receptor Agonist; Tricyclic antidepressant; Dopamine reuptake inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-573-518-9,RFM-002-317-6,CBR-001-573-518-9,Fc1cc(cnc1N1CCN(CC1)C(=O)c1cc(ccc1O[C@H](C(F)(F)F)C)S(=O)(=O)C)C(F)(F)F,"CBR-HVAC-00828: Antipsychotic Drugs;Obsessive-Compulsive Disorder (OCD), Treatment of; GlyT-1 Inhibitors; Glycine transporter 1 Inhibitor; Glycine transporter 1 inhibitor"
CBR-001-573-519-0,RFM-002-318-7,CBR-001-573-519-0,COc1ccc(cc1)Nc1ccn(n1)c1ccccc1,CBR-HVAC-03406: ; 5-LIPOXYGENASE; CYCLOOXYGENASE Inhibitor; Lipoxygenase inhibitor; Cyclooxygenase inhibitor
CBR-001-573-520-3,RFM-002-319-8,CBR-001-573-520-3,C=C1CCN(CC1)[C@@H]([C@@](c1ccc(cc1F)F)(Cn1cncn1)O)C,CBR-HVAC-04690: Antifungal AgentsCell wall synthesis inhibitor
CBR-001-573-521-4,RFM-002-320-1,CBR-001-573-521-4,COc1c(cc(cc1C(C)(C)C)n1ccc(=O)[nH]c1=O)c1ccc2c(c1)ccc(c2)NS(=O)(=O)C,CBR-HVAC-06782: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B polymerase Inhibitor; HCV nonstructural protein 5B inhibitor
CBR-001-573-522-5,RFM-002-321-2,CBR-001-573-522-5,Fc1ccc(c(c1)F)[C@]([C@H](n1cnc2c(c1=O)ccc(c2)Cl)C)(Cn1ncnc1)O,CBR-HVAC-00639: Antifungal Agents; LANOSTEROL 14 ALPHA-DEMETHYLASE Inhibitor; Sterol demethylase inhibitor
CBR-001-573-523-6,RFM-002-322-3,CBR-001-573-523-6,Fc1ccc(cc1)n1cc(c2c1cccc2)CCCCN1CCC2(CC1)OCc1c2cccc1,"CBR-HVAC-04333: Antidepressants;Oncolytic Drugs;Generalized Anxiety Disorder (GAD), Treatment of; sigma2 Receptor Ligands;Signal Transduction Modulators; OPIOID RECEPTOR SIGMA 2 AGONIST; Sigma 2 receptor antagonist"
CBR-001-573-524-7,RFM-002-323-4,CBR-001-573-524-7,C=Cc1ccccc1S(=O)(=O)[O-],monomeric unit of CBR-HVAC-07957
CBR-001-573-525-8,RFM-002-324-5,CBR-001-573-525-8,CN1CCC(CC1)C(=O)c1cccc(n1)NC(=O)c1c(F)cc(cc1F)F,"CBR-HVAC-00747: Antimigraine Drugs;Acute Attacks of Migraine, Treatment of; Signal Transduction Modulators;5-HT1F Agonists; 5 Hydroxytryptamine 1F receptor agonist"
CBR-001-573-526-9,RFM-002-325-6,CBR-001-573-526-9,COc1cc2CCN3[C@H](c2cc1O)Cc1c(C3)c(OC)c(cc1)O,"CBR-HVAC-03445: Sedative/Hypnotics;Non-Opioid Analgesics;Antipsychotic Drugs;Hypertension, Treatment of;Tardive Dyskinesia, Treatment of; Dopamine D1 Agonists;Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D1; Dopamine receptor D2 Agonist; Antagonist;"
CBR-001-573-527-0,RFM-002-326-7,CBR-001-573-527-0,CO/N=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)/C=C\c1scnc1C)/c1csc(n1)N,CBR-HVAC-10339:
CBR-001-573-528-1,RFM-002-327-8,CBR-001-573-528-1,CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@]12OC[C@@](O1)(CO)[C@H]([C@@H]([C@H]2O)O)O,"CBR-HVAC-00847: Antiobesity Drugs;Type 2 Diabetes, Agents for; SGLT-2 Inhibitors; Sodium-dependent glucose cotransporter (SGLT) 2 Inhibitor; Sodium/glucose cotransporter 2 inhibitor"
CBR-001-573-529-2,RFM-002-328-9,CBR-001-573-529-2,OCCN(S(=O)(=O)C)c1cc2oc(c(c2cc1C1CC1)C(=O)NC)c1ccc(cc1)F,CBR-HVAC-00365: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B protease Inhibitor; HCV nonstructural protein 5B inhibitor
CBR-001-573-530-5,RFM-002-329-0,CBR-001-573-530-5,CC(=O)OC(C(=O)OCC[N+](C)(C)C)C,"CBR-HVAC-01559: Nausea and Vomiting, Treatment of; Muscarinic receptor m2 Stimulator; Muscarinic M1 receptor antagonist"
CBR-001-573-531-6,RFM-002-330-3,CBR-001-573-531-6,C=C[C@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@H](C(C)(C)C)NC(=O)OC(C)(C)C)Oc1ncc(c2c1cc(Cl)cc2)OC)C(=O)NS(=O)(=O)C1CC1,CBR-HVAC-00900: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; HCV NS3 PROTEASE Inhibitor; HCV nonstructural protein 3 inhibitor
CBR-001-573-532-7,RFM-002-331-4,CBR-001-573-532-7,COc1ccnc(c1C)CS(=O)c1nc2c([nH]1)ccc(c2)n1cccc1,"CBR-HVAC-01855: Gastroesophageal Reflux Disease, Agents for;Anti-Helicobacter Pylori Agents;Esophageal Diseases, Treatment of;Antiulcer Drugs; H+/K+-ATPase Inhibitors; H+/K+ ATPase; Proton pump Inhibitor; H+ K+ transporting ATPase inhibitor"
CBR-001-573-533-8,RFM-002-332-5,CBR-001-573-533-8,O=C(CC(C(=O)O)C)/C=C(/[C@H]1C[C@@H]([C@@]2([C@]1(C)CC(=O)C1=C2[C@@H](O)C[C@@H]2[C@]1(C)CCC(=O)C2(C)C)C)O)\C,analog of CBR-HVAC-07221: (Ganoderic acid A)
CBR-001-573-534-9,RFM-002-333-6,CBR-001-573-534-9,COc1cccc(c1)c1ccc(c(c1)F)NC(=O)C1=C(CCC1)C(=O)O,"CBR-HVAC-00767: Inflammatory Bowel Disease, Agents for;Rheumatoid Arthritis, Treatment of;Multiple Sclerosis, Agents for;Systemic Lupus Erythematosus, Agents for;Immunomodulators;Disease-Modifying Anti-Rheumatic Drugs; Anti-IFN-gamma;Anti-IL-17;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Signal Transduction Modulators; IL-17; Dihydroorotate dehydrogenase Inhibitor; Antagonist; Dihydroorotate dehydrogenase inhibitor; Immunosuppressant; Interleukin 17 antagonist"
CBR-001-573-536-1,RFM-002-334-7,CBR-001-573-536-1,COc1cc(O)c(cc1OC)C(=O)Nc1scc(n1)C(=O)NCCN(C(C)C)C(C)C,"CBR-HVAC-05028: Non-Ulcer Dyspepsia, Agents for; Acetylcholinesterase (AChE) Inhibitors; MUSCARINIC ACETYLCHOLINE M1 RECEPTOR; MUSCARINIC ACETYLCHOLINE M2 RECEPTOR Antagonist;"
CBR-001-573-537-2,RFM-002-335-8,CBR-001-573-537-2,COC(=O)CCC[N+](C)(C)C,CBR-HVAC-06296: Hair Growth Stimulants; Muscarinic Agonists;Signal Transduction Modulators;
CBR-001-573-538-3,RFM-002-336-9,CBR-001-573-538-3,OC1CN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)c1nc(N)c(cc1F)F,CBR-HVAC-00842:DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-573-539-4,RFM-002-337-0,CBR-001-573-539-4,[O-][N+](=O)c1ccc(o1)/C=N/N1CC(OC1=O)CSC,CBR-HVAC-05669: Antitrichomonals;Antibacterial Drugs
CBR-001-573-540-7,RFM-002-338-1,CBR-001-573-540-7,O[C@H]1CC[C@]2([C@@H](C1)CC[C@@H]1[C@@H]2CC[C@]2([C@]31O[C@@H]3C[C@@H]2c1ccc(=O)oc1)C)C,"CBR-HVAC-03458: Cardiovascular Diseases (Not Specified);Respiratory Stimulants; Na+, K+ ATPase Inhibitor;"
CBR-001-573-541-8,RFM-002-339-2,CBR-001-573-541-8,CN1[C@@H]2CCC[C@H]1C[C@H](C2)NC(=O)c1nn(c2c1cccc2)C,"CBR-HVAC-03556: Nausea and Vomiting, Treatment of;Disorders Associated with Cancer Therapy, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist;"
CBR-001-573-542-9,RFM-002-340-5,CBR-001-573-542-9,OC(c1ccccc1)(C1CCCC1)COC1CN2CCC1CC2,CBR-HVAC-14220
CBR-001-573-543-0,RFM-002-341-6,CBR-001-573-543-0,OC(c1cc(Cl)c(c(c1)Cl)N)CNC(C)(C)C,CBR-HVAC-00792: Bronchodilators;Urinary Incontinence Therapy;Therapy of Inborn Errors of Metabolism; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-573-544-1,RFM-002-342-7,CBR-001-573-544-1,CCOc1cc(OCC)c(cc1C(=O)CCC(=O)O)OCC,"CBR-HVAC-01703: Pancreatic Disorders, Treatment of;Liver and Biliary Tract Disorders, Treatment ofMuscarinic receptor antagonist"
CBR-001-573-545-2,RFM-002-343-8,CBR-001-573-545-2,OC(=O)[C@@H]1CCCN(C1)CCC=C(c1sccc1C)c1sccc1C,"CBR-HVAC-02189: Generalized Anxiety Disorder (GAD), Treatment of;Antiepileptic Drugs;Treatment of Cocaine Dependency;Treatment of Substance Dependency;Antipsychotic Drugs;Neuropathic Pain, Treatment of;Sleep Disorders, Treatment of; GAT-1 Inhibitors; Sodium and chloride dependent GABA transporter 1 Inhibitor; GABA uptake inhibitor"
CBR-001-573-546-3,RFM-002-344-9,CBR-001-573-546-3,COc1cc2N(C)[C@@H]3[C@@]4(c2cc1[C@]1(C[C@@H]2CN(CCc5c1[nH]c1c5cccc1)C[C@](C2)(O)CC)C(=O)OC)CCN1[C@H]4[C@@]([C@H]([C@]3(O)C(=O)N)O)(CC)C=CC1,CBR-HVAC-02031: Oncolytic Drugs; Beta tubulin Inhibitor; Microtubule inhibitor; Tubulin inhibitor; Vinca alkaloid
CBR-001-573-547-4,RFM-002-345-0,CBR-001-573-547-4,CC(=CCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1)C,CBR-HVAC-02814: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-573-548-5,RFM-002-346-1,CBR-001-573-548-5,COc1cc2c(cc1OC)CC[N+](C2Cc1ccc(c(c1)OC)OC)(C)CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCc2c(C1Cc1ccc(c(c1)OC)OC)cc(c(c2)OC)OC,CBR-HVAC-01336: Neuromuscular Blockers; Cholinergic receptor Antagonist; Neuromuscular nicotinic receptor antagonist
CBR-001-573-549-6,RFM-002-347-2,CBR-001-573-549-6,CCCCCN(CCC(P(=O)(O)O)(P(=O)(O)O)O)C,"CBR-HVAC-02819: Analgesic Drugs;Prostate Cancer Therapy;Breast Cancer Therapy;Treatment of Osteoporosis;Treatment of Hypercalcemia;Bone Diseases, Treatment of;Bone Resorption Inhibitors; Farnesyl diphosphate synthase Inhibitor; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor"
CBR-001-573-550-9,RFM-002-348-3,CBR-001-573-550-9,COc1cc(N)c(cc1C(=O)NC1CCN(CC1)Cc1ccccc1)Cl,CBR-HVAC-01821: ; Dopamine receptor D2 Antagonist; Dopamine receptor antagonist
CBR-001-573-551-0,RFM-002-349-4,CBR-001-573-551-0,CO[C@@]1(NC(=O)C(c2ccc(cc2)O)C(=O)[O-])C(=O)N2[C@@H]1OCC(=C2C(=O)[O-])CSc1nnnn1C,CBR-HVAC-02866: Antibiotics; Penicillin binding protein Inhibitor;
CBR-001-573-552-1,RFM-002-350-7,CBR-001-573-552-1,Clc1ccc(cc1)[C@@](c1ccccc1)(OCC[C@H]1CCCN1C)C,CBR-HVAC-02448: ; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist
CBR-001-573-553-2,RFM-002-351-8,CBR-001-573-553-2,CCCCCNC(=N)N/N=C/c1c[nH]c2c1cc(OC)cc2,"CBR-HVAC-04940: Irritable Bowel Syndrome, Agents for;Prokinetic Agents;Gastrointestinal Disorders (Not Specified);Constipation, Agents for;Gastroesophageal Reflux Disease, Agents for;Non-Ulcer Dyspepsia, Agents for; Signal Transduction Modulators;5-HT4 Partial Agonists; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-573-554-3,RFM-002-352-9,CBR-001-573-554-3,COc1ccc2c3c1O[C@@H]1[C@@]3(CCN(C2)C)C=C[C@@H](C1)O,CBR-HVAC-02347: ; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor
CBR-001-573-555-4,RFM-002-353-0,CBR-001-573-555-4,OC(=O)CN1C(=O)C(CCc2c1cccc2)N[C@H](C(=O)O)CCc1ccccc1,CBR-HVAC-14322
CBR-001-573-556-5,RFM-002-354-1,CBR-001-573-556-5,CCN(CC(=O)Oc1ccc(cc1)NC(=O)C)CC,CBR-HVAC-02186: Non-Opioid AnalgesicsCyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-573-557-6,RFM-002-355-2,CBR-001-573-557-6,CC(N1CCCCC1)COc1ccccc1Cc1ccccc1,CBR-HVAC-01548: Unidentified pharmacological activity
CBR-001-573-558-7,RFM-002-356-3,CBR-001-573-558-7,CCN(CCOCCOC(=O)C1(CCCC1)c1ccccc1)CC,CBR-HVAC-09752: ; Opioid receptor sigma 1 Agonist;
CBR-001-573-559-8,RFM-002-357-4,CBR-001-573-559-8,Clc1ccc2c(c1)nccc2N1CCN(CC1)CCCN1CCN(CC1)c1ccnc2c1ccc(c2)Cl,CBR-HVAC-06016: Antimalarials; Cytochrome P450 CYP3A4 Inhibitors;
CBR-001-573-560-1,RFM-002-358-5,CBR-001-573-560-1,O=C([C@@H](c1ccccc1)N)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C)(C)C,CBR-HVAC-02045: Antibiotics; beta-Lactamase Inhibitors; Transpeptidase; Beta lactamase Inhibitor; Cell wall synthesis inhibitor; Lactamase inhibitor
CBR-001-573-561-2,RFM-002-359-6,CBR-001-573-561-2,OCC(OCn1cnc2c1nc(N)nc2O)COC(=O)[C@H](C(C)C)N,"CBR-HVAC-02227: Inflammatory Bowel Disease, Agents for;Anti-Cytomegalovirus Drugs;Kaposi's Sarcoma Therapy; DNA Polymerase Inhibitors; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor; DNA synthesis inhibitor"
CBR-001-573-562-3,RFM-002-360-9,CBR-001-573-562-3,O=C1N(CCCCN2CCN(CC2)c2nsc3c2cccc3)C(=O)C2C1CCCC2,CBR-HVAC-01929: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; Dopamine receptor D2; 5-Hydroxytryptamine 2 receptor Antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist
CBR-001-573-563-4,RFM-002-361-0,CBR-001-573-563-4,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N1CCCCC1)C)CC[C@]1([C@H]3C[C@@H]([C@@H]1OC(=O)C)[N+]1(C)CCCCC1)C,CBR-HVAC-01363: Non-depolarizing Blocking Drugs; Nicotinic acetylcholine receptor Inhibitor; Neuromuscular nicotinic receptor antagonist
CBR-001-573-564-5,RFM-002-362-1,CBR-001-573-564-5,CCN(C(=O)Nc1ccc(c(c1)C(=O)C)OCC(CNC(C)(C)C)O)CC,"CBR-HVAC-02165: Bone, Muscles and Connective Tissue Genetic Disorders, Treatment of;Cardiovascular Diseases (Not Specified);Hypertension, Treatment of;Angina pectoris, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Antagonist; Beta 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor antagonist"
CBR-001-573-565-6,RFM-002-363-2,CBR-001-573-565-6,C[n+]1c2ccccc2c(=O)n2c1c1[n-]c3c(c1CC2)cccc3,"CBR-HVAC-07715: Stroke, Treatment of;Hypertension, Treatment of;Cognition Disorders, Treatment of;Vascular Dementia, Treatment of; Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase inhibitor"
CBR-001-573-566-7,RFM-002-364-3,CBR-001-573-566-7,CCn1cc(C(=O)O)c(=O)c2c1nc(cc2)Cc1ccccc1,CBR-HVAC-10077: ; Dopamine transporter Inhibitor;
CBR-001-573-567-8,RFM-002-365-4,CBR-001-573-567-8,Sc1ncc(c(n1)O)I,CBR-HVAC-08974:
CBR-001-573-568-9,RFM-002-366-5,CBR-001-573-568-9,O=C(C(c1cccs1)(c1cccs1)O)OC1CC2C=CC(C1)[N+]2(C)C,CBR-HVAC-14171
CBR-001-573-569-0,RFM-002-367-6,CBR-001-573-569-0,OC[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@@H]1C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N)CC(=O)N)CCCNC(=N)N)CCCNC(=N)N)Cc1ccccc1)CC(C)C)Cc1ccccc1)Cc1ccc(cc1)O)CCCNC(=N)N)CO)CCC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](Cc1ccccc1)N)CCCNC(=N)N)CC(=O)O)CCC(=O)O)CCC(=O)O)Cc1ccccc1)CCC(=O)N)CO)Cc1ccccc1)C,analog of CBR-HVAC-06192
CBR-001-573-570-3,RFM-002-368-7,CBR-001-573-570-3,OCCN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-01974: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D1; Dopamine receptor D2 Inhibitor; Dopamine D2 receptor antagonist; Dopamine D1 receptor antagonist
CBR-001-573-571-4,RFM-002-369-8,CBR-001-573-571-4,O[C@H]1[C@H](OC2=CC(=O)CC2)c2cc(ccc2OC1(C)C)C#N,"CBR-HVAC-03818: Antiallergy/Antiasthmatic Drugs;Hypertension, Treatment of; Potassium Channel Activators; Potassium channel Agonist; Potassium channel agonist"
CBR-001-573-572-5,RFM-002-370-1,CBR-001-573-572-5,COc1cc(ccc1O)CC(=O)OCC1=C[C@H]2[C@H]3O[C@]4(O[C@]2([C@H]2[C@@](C1)(O)C(=O)C(=C2)C)[C@@H](C[C@@]3(O4)C(=C)C)C)Cc1ccccc1,"CBR-HVAC-05117: Neuropathic Pain, Treatment of;Urologic Drugs;Analgesic Drugs; TRPV1 (Vanilloid VR1 Receptor) Agonists; Vascular endothelial growth factor receptor 2 Agonist;"
CBR-001-573-573-6,RFM-002-371-2,CBR-001-573-573-6,COc1ccc(cc1N1CCNCC1)S(=O)(=O)Nc1cc(Cl)cc(c1OC)Cl,CBR-HVAC-08325: 5 Hydroxytryptamine 6 receptor antagonist
CBR-001-573-574-7,RFM-002-372-3,CBR-001-573-574-7,OCC(=O)[C@@]1(O)C[C@H](OC2CC(N)C(C(O2)C)OC2CCCCO2)c2c(C1)c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2OC,CBR-HVAC-01846: ; DNA topoisomerase Inhibitor; DNA topoisomerase II inhibitor
CBR-001-573-575-8,RFM-002-373-4,CBR-001-573-575-8,CC[N+](CCSC1=CC(=Nc2c(N1)cccc2)c1ccc(cc1)Sc1ccccc1)(CC)C,CBR-HVAC-09366:
CBR-001-573-576-9,RFM-002-374-5,CBR-001-573-576-9,NCCCC[C@@H](C(=O)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)[C@@H](NC(=O)C(N)(C)C)Cc1c[nH]cn1,"CBR-HVAC-05087: Gastric Emptying Disorders,Treatment of;Treatment of Growth Hormone Deficiency; GHS Receptor Agonists;Growth Hormone Secretagogues;Signal Transduction Modulators; GHRELIN RECEPTOR Agonist;"
CBR-001-573-577-0,RFM-002-375-6,CBR-001-573-577-0,CCC(=O)[C@@]1(C)CC[C@@H]2[C@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@H]21,"CBR-HVAC-01623: Gynecological Disorders, Treatment of ; Protein Kinase B (PKB/Akt) Activators;Signal Transduction Modulators; Estradiol 17 beta dehydrogenase stimulant; Estrone sulfotransferase stimulant; Progesterone receptor agonist"
CBR-001-573-578-1,RFM-002-376-7,CBR-001-573-578-1,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCCNC(=N)N)Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)N)CO,analog of CBR-HVAC-07073
CBR-001-573-579-2,RFM-002-377-8,CBR-001-573-579-2,OC[C@H]1O[C@H](C[C@@H]1O)n1cc2cc(oc2nc1=O)C,analog of CBR-HVAC-05465
CBR-001-573-580-5,RFM-002-378-9,CBR-001-573-580-5,Oc1ccc(cc1)C(c1cc(ccc1O)/C=N/n1nnnc1C)c1cc(ccc1O)/C=N/n1nnnc1C,CBR-HVAC-05190: Antiviral Drugs;Asthma Therapy;Anti-RSV Drugs; Viral Fusion Inhibitors;
CBR-001-573-581-6,RFM-002-379-0,CBR-001-573-581-6,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCCCN)CCSC)CC(=O)O)CC(C)C)CCSC)C(C)C)Cc1ccc(cc1)O)CC(=O)O)C(C)C)CO)CCC(=O)O)CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCSC)CO,analog of CBR-HVAC-06942
CBR-001-573-582-7,RFM-002-380-3,CBR-001-573-582-7,NCCCC(Nc1cc(OC)c(c2c1nc(OC)cc2C)Oc1cccc(c1)C(F)(F)F)C,CBR-HVAC-00840: AntimalarialsDNA inhibitor
CBR-001-573-583-8,RFM-002-381-4,CBR-001-573-583-8,NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)[C@H](O)C)Cc1ccccc1)C(C)C)Cc1ccccc1)CC(C)C)[C@H](CC)C,analog of CBR-HVAC-05504
CBR-001-573-584-9,RFM-002-382-5,CBR-001-573-584-9,NCCCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](C(=O)O)[C@H](O)C)N,"CBR-HVAC-03919: Inflammatory Bowel Disease, Agents for;Non-Opioid Analgesics"
CBR-001-573-585-0,RFM-002-383-6,CBR-001-573-585-0,COc1cc2C(=N[C@@H]3[C@H](c2cc1OC)CN(CC3)C)c1ccc(cc1)NC(=O)C,CBR-HVAC-03740: ; Phosphodiesterase PDE3 Inhibitors;Phosphodiesterase PDE4 Inhibitors;Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Phosphodiesterase 4; Phosphodiesterase 3 Inhibitor; Phosphodiesterase inhibitor; Platelet activating factor antagonist
CBR-001-573-586-1,RFM-002-384-7,CBR-001-573-586-1,COc1ccc(cc1OS(=O)(=O)O)c1cc(=O)c2c(o1)cc(cc2OS(=O)(=O)O)O[C@@H]1O[C@H](COC2O[C@@H](C)[C@@H]([C@H]([C@H]2OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O)[C@H]([C@@H]([C@H]1OS(=O)(=O)O)OS(=O)(=O)O)OS(=O)(=O)O,analog of CBR-HVAC-03999
CBR-001-573-587-2,RFM-002-385-8,CBR-001-573-587-2,FCC(=O)C(NC(=O)[C@H](C(C)C)NC(=O)OCc1ccc(cc1Cl)Cl)CC(=O)O,"CBR-HVAC-11709: Acute Myocardial Infarction, Treatment of;Ischemic Stroke, Treatment of;Renal Failure, Agents for; Apoptosis Inhibitors;Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Caspase 3 Inhibitors;Caspase 7 Inhibitors;Caspase 8 Inhibitors;Caspase 9 Inhibitors;Signal Transduction Modulators; Caspase Inhibitor;"
CBR-001-573-588-3,RFM-002-386-9,CBR-001-573-588-3,N#CC1=C(N)Oc2c(C1c1cc(Br)c(c(c1)OC)OC)ccc(c2N)N,CBR-HVAC-06040: Antineoplastic Enhancing Agents;Solid Tumors Therapy;Oncolytic Drugs;Endocrine Cancer Therapy;Lymphoma Therapy;Lung Cancer Therapy; Antimitotic Drugs;Apoptosis Inducers;Caspase Activators;Microtubule Inhibitors;Signal Transduction Modulators;Vascular Disrupting Agents (VDA); TUBULIN Inhibitor;
CBR-001-573-589-4,RFM-002-387-0,CBR-001-573-589-4,CCCCC([C@@H](/C=C/[C@H]1[C@H](O)CC(=C)[C@@H]1C/C=C\CCCC(=O)O)O)(C)C,CBR-HVAC-03035: Uterine StimulantsProstaglandin F2 alpha receptor agonist
CBR-001-573-590-7,RFM-002-388-1,CBR-001-573-590-7,CC(=O)Oc1ccccc1C(=O)Oc1c(C)occc1=O,CBR-HVAC-00508: Antiplatelet TherapyCyclooxygenase inhibitor
CBR-001-573-591-8,RFM-002-389-2,CBR-001-573-591-8,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1C/C=C\CCCC(=O)O2)O,analog of CBR-HVAC-09493
CBR-001-573-592-9,RFM-002-390-5,CBR-001-573-592-9,CCN(CCO[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CCO2)C)C1)C)CC,analog of CBR-HVAC-08482
CBR-001-573-593-0,RFM-002-391-6,CBR-001-573-593-0,C[C@H](c1cccc2c1cccc2)NCCCc1cccc(c1)C(F)(F)F,CBR-HVAC-01711: Treatment of Hypercalcemia;Treatment of Hyperparathyroidism;Endocrine Cancer Therapy;Cardiovascular Diseases (Not Specified);Prostate Cancer Therapy; Calcium-Sensing Receptor (CaSR) Agonists;Cytochrome P450 CYP1A2 Inhibitors;Signal Transduction Modulators; Calcium-sensing receptor Agonist; Hypercalcaemic agent; Calcium sensitizer; Calcium-sensing receptor agonist
CBR-001-573-594-1,RFM-002-392-7,CBR-001-573-594-1,OC[C@@]1(O)C[C@@]23C[C@H]1CC[C@H]3[C@]1([C@H](CC2)c2ccoc2CC1)C,CBR-HVAC-06499: Chemoprotective Agents;Hepatoprotectants;Antiarthritic Drugs; Antioxidants;
CBR-001-573-595-2,RFM-002-393-8,CBR-001-573-595-2,CCCCC[C@H]([C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)C(=C/C=C/C=C/C=C/C=C/[C@@H]([C@H](OC1=O)C)O)C)O,CBR-HVAC-14324
CBR-001-573-596-3,RFM-002-394-9,CBR-001-573-596-3,Clc1ccc(cc1)C(=O)N1CCC(=Cc2ccc(cc2)C2=NCCO2)CC1,"CBR-HVAC-09527: Lipoprotein Disorders, Treatment of ; Lanosterol Synthase Inhibitors; 2,3-OXIDOSQUALENE CYCLASE Inhibitor;"
CBR-001-573-597-4,RFM-002-395-0,CBR-001-573-597-4,C/C(=C\CSC[C@@H](C(=O)O)NC(=O)C)/CC/C=C(/CCC=C(C)C)\C,CBR-HVAC-06191: Oncolytic Drugs;Topical Antiinflammatory Agents
CBR-001-573-598-5,RFM-002-396-1,CBR-001-573-598-5,CCCCCOc1ccc(c2c1cccc2)C(=O)c1cccc2c1cccc2,CBR-HVAC-06257: Analgesic Drugs; Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists;Signal Transduction Modulators;
CBR-001-573-599-6,RFM-002-397-2,CBR-001-573-599-6,COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(c(c2)OC)OC)ccc1OC,"CBR-HVAC-05773: Acne Therapy;Prostate Cancer Therapy;Wound-Healing Agents;Hair Growth Stimulants;Neuromuscular Genetic Disorders, Treatment of;Atopic Dermatitis, Agents for; Androgen Receptor Degradation Enhancers;Signal Transduction Modulators; Androgen receptor Antagonist;"
CBR-001-573-600-2,RFM-002-398-3,CBR-001-573-600-2,CC(N[C@H]1CCn2c3c([C@@H]1O)cccc3nc2O)C,CBR-HVAC-08305: Beta 2 adrenoreceptor agonist
CBR-001-573-601-3,RFM-002-399-4,CBR-001-573-601-3,CNCC(c1ccc(c(c1)OC)O)O,analog of CBR-HVAC-08719
CBR-001-573-602-4,RFM-002-400-0,CBR-001-573-602-4,OC(=O)C(Oc1ccc(cc1)CNC(=O)c1sc(nc1C)c1ccc(cc1)C(F)(F)F)(C)C,"CBR-HVAC-06301: Lipoprotein Disorders, Treatment of ;Antidiabetic Drugs; PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator-activated receptor alpha Agonist;"
CBR-001-573-603-5,RFM-002-401-1,CBR-001-573-603-5,CC[C@@H]1/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@H]([C@H]([C@@H](/C=C/C(=O)O[C@H]2[C@H]([C@@H](CC1)O[C@]1(O[C@H](C[C@@H](O)C)[C@@H](CC1=O)C)[C@@H]2C)C)C)O)C,CBR-HVAC-08888: ; ATP synthase Inhibitor;
CBR-001-573-604-6,RFM-002-402-2,CBR-001-573-604-6,CNC(=O)c1ccccc1Sc1ccc2c(c1)[nH]nc2/C=C/c1ccccn1,"CBR-HVAC-01259: Non-Small Cell Lung Cancer Therapy;Prostate Cancer Therapy;Cancer of Unspecified Body Location/System;Pancreatic Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Renal Cancer Therapy;Neurological Genetic Disorders, Treatment of ;Gastric Cancer Therapy;Endocrine Cancer Therapy;Head and Neck Cancer Therapy;Breast Cancer Therapy;Liver Cancer Therapy;Glioblastoma Multiforme Therapy;Colorectal Cancer Therapy;Melanoma Therapy; Angiogenesis Inhibitors;PDGFR Family Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; PDGFR; VEGFR Inhibitor; Tyrosine kinase inhibitor (TKI); VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; C-kit inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib"
CBR-001-573-605-7,RFM-002-403-3,CBR-001-573-605-7,OC[C@H]([C@H]([C@@H]([C@@H]([C@H](CC(=O)C(=O)O)O)NC(=O)C)O)O)O,CBR-HVAC-08352: Mucolytic agent
CBR-001-573-606-8,RFM-002-404-4,CBR-001-573-606-8,C/C=C(\C(=O)O[C@H]1C(=C[C@]23[C@]1(O)[C@H](O)C(=C[C@H](C3=O)[C@H]1[C@@H](C[C@H]2C)C1(C)C)CO)C)/C,"CBR-HVAC-05815: Dermatologic Drugs;Myeloid Leukemia Therapy;Bladder Cancer Therapy ;Leukemia Therapy;Genital Warts, Treatment for;Squamous Cell Carcinoma Therapy;Skin Cancer Therapy;Actinic Keratoses, Agents for;Basal Cell Carcinoma Therapy; Protein Kinase C (PKC) Activators;Signal Transduction Modulators; Protein tyrosine kinase C Activator;"
CBR-001-573-607-9,RFM-002-405-5,CBR-001-573-607-9,NCCCP(=O)(CC)O,CBR-HVAC-14306
CBR-001-573-608-0,RFM-002-406-6,CBR-001-573-608-0,CO[C@@H]1[C@H](OCC2=C/C=C/C[C@H](O)/C(=C\[C@H](CC)[C@H](C(=CC(=CC[C@H](OC2=O)[C@H](O)C)C)C)O[C@@H]2OC(C)(C)C([C@@H]([C@@H]2O)O)OC(=O)C(C)C)/C)O[C@@H]([C@H]([C@@H]1O)OC(=O)c1c(O)c(Cl)c(c(c1CC)Cl)O)C,CBR-HVAC-01280: Antidiarrheal Agents;Antibacterial Drugs; RNA Polymerase Inhibitors; DNA directed RNA polymerase inhibitor
CBR-001-573-609-1,RFM-002-407-7,CBR-001-573-609-1,CCCCC[C@@H](/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)O)C=CC1=O)O,CBR-HVAC-10915: ; Peroxisome proliferator activated receptor gamma Agonist;
CBR-001-573-610-4,RFM-002-408-8,CBR-001-573-610-4,OC(=O)c1oc2c(c1)cc(cc2)Cc1cccnc1,CBR-HVAC-03056: Antiplatelet Therapy; Thromboxane Synthase Inhibitors; Thromboxane A2 synthase Inhibitor; Thromboxane synthase inhibitor
CBR-001-573-611-5,RFM-002-409-9,CBR-001-573-611-5,CCCC1(CCC1)[C@@H](C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC)O,CBR-HVAC-02428
CBR-001-573-612-6,RFM-002-410-2,CBR-001-573-612-6,OCCOCCN1CCN(CC1)C1=Nc2ccccc2Sc2c1cccc2,"CBR-HVAC-01937: Bipolar Disorder, Treatment of;Antipsychotic Drugs;Treatment of Alcohol Dependency;Generalized Anxiety Disorder (GAD), Treatment of;Psychiatric Disorders (Not Specified);Cognition Disorders, Treatment of;Antidepressants;Treatment of Substance Dependency;Sleep Disorders, Treatment of;Obsessive-Compulsive Disorder (OCD), Treatment of; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; 5-Hydroxytryptamine 2A receptor Antagonist; Dopamine D2 receptor antagonist; Dopamine D1 receptor antagonist; 5 Hydroxytryptamine 1A receptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist; Alpha 1 adrenoreceptor antagonist; Alpha 2 adrenoreceptor antagonist; Histamine H1 receptor antagonist"
CBR-001-573-613-7,RFM-002-411-3,CBR-001-573-613-7,COc1ccc(cc1O[C@H]1C[C@H]2C[C@@H]1CC2)C1CNC(=O)NC1,"CBR-HVAC-04679: Antidepressants;Antipsoriatics;Bronchodilators;Atopic Dermatitis, Agents for; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor;"
CBR-001-573-614-8,RFM-002-412-4,CBR-001-573-614-8,CC#CCC([C@@H](/C=C/C1[C@H](O)C[C@H]2[C@@H]1c1cccc(c1O2)CCCC(=O)O)O)C,"CBR-HVAC-01529: Lesions of the Spinal Cord and Related Structures, Treatment of;Diabetic Neuropathy, Agents for;Pulmonary Hypertension, Treatment of;Peripheral Vascular Disease, Treatment of;Treatment of Intermittent Claudication;Antiplatelet Therapy;Renal Failure, Agents for; NOS3 Expression Enhancers;Prostacyclin Analogs; Prostacyclin receptor Agonist; Prostaglandin IP2 receptor agonist"
CBR-001-573-615-9,RFM-002-413-5,CBR-001-573-615-9,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O)O,CBR-HVAC-03977: Antiglaucoma Agents
CBR-001-573-616-0,RFM-002-414-6,CBR-001-573-616-0,CCCCC([C@@H](/C=C/[C@H]1C=CC(=O)[C@@H]1C/C=C\CCCC(=O)O)O)(C)C,analog of CBR-HVAC-07899
CBR-001-573-617-1,RFM-002-415-7,CBR-001-573-617-1,CCc1nc2c(n1c1ccc(cc1)CCNC(=O)NS(=O)(=O)c1ccc(cc1)C)cc(nc2C)C,"CBR-HVAC-00054: Allergy, Treatment of;Inflammation, Treatment of;Treatment of Other Autoimmune Disorders;Osteoarthritis, Treatment of;Non-Opioid Analgesics; Prostanoid EP4 Antagonists;Signal Transduction Modulators; Prostaglandin EP4 receptor antagonist"
CBR-001-573-618-2,RFM-002-416-8,CBR-001-573-618-2,CCCCCn1cc(c2c1cccc2)c1scc(n1)CN(C(C)C)CCOC,analog of CBR-HVAC-07150
CBR-001-573-619-3,RFM-002-417-9,CBR-001-573-619-3,CC(N(C(C)C)CCc1c[nH]c2c1cccc2)C,CBR-HVAC-05839: Psychiatric Disorders (Not Specified)
CBR-001-573-620-6,RFM-002-418-0,CBR-001-573-620-6,OC(=O)CC(CC(/C=C/c1c(c2ccc(cc2)F)c2c(n1C(C)C)cccc2)O)O,"CBR-HVAC-02222: Breast Cancer Therapy;Lipoprotein Disorders, Treatment of ;Treatment of Erectile Dysfunction; Apoptosis Inducers;HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor"
CBR-001-573-621-7,RFM-002-419-1,CBR-001-573-621-7,O=C(NS(=O)(=O)C)CCC/C=C\C[C@H]1C(=O)C[C@H]([C@@H]1/C=C/[C@H](COc1ccccc1)O)O,CBR-HVAC-01862: Uterine Stimulants; Prostanoid EP receptor 1; Prostanoid EP receptor 3 Agonist; Prostaglandin E2 receptor agonist
CBR-001-573-622-8,RFM-002-420-4,CBR-001-573-622-8,OC[C@@]1(O)C[C@@]23C[C@H]1CCC3[C@]1(C(CC2)c2ccoc2C=C1)C,CBR-HVAC-06500: Hepatoprotectants;Antiarthritic Drugs;Chemoprotective Agents; Antioxidants;
CBR-001-573-623-9,RFM-002-421-5,CBR-001-573-623-9,OCCC1CCCCN1C(=O)OC(CC)C,CBR-HVAC-10246:
CBR-001-573-624-0,RFM-002-422-6,CBR-001-573-624-0,CCc1ccccc1n1c(=C)[nH]c2c(c1=O)cccc2,CBR-HVAC-10258
CBR-001-573-625-1,RFM-002-423-7,CBR-001-573-625-1,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O,"CBR-HVAC-01288: Antiglaucoma Agents;Age-Related Macular Degeneration, Treatment of;Ophthalmic Drugs; Potassium Channel Activators; Prostaglandin F receptor 2 alpha Inhibitor; Potassium channel agonist; Fatty acid stimulant"
CBR-001-573-626-2,RFM-002-424-8,CBR-001-573-626-2,CCCC=c1[nH]n(c(=O)n1Cc1ccc(cc1)c1ccccc1S(=O)(=O)NC(=O)c1sccc1C)c1ccccc1C(F)(F)F,analog of CBR-HVAC-11203
CBR-001-573-627-3,RFM-002-425-9,CBR-001-573-627-3,OC[C@@H]1[C@@H](O)[C@H](O)[C@@H]([C@@H]2N1C(=O)C(=O)N2)O,"CBR-HVAC-00104: Immunomodulators;Neuromuscular Genetic Disorders, Treatment of; alpha-Mannosidase Inhibitors; Endoplasmic reticulum alpha-mannosidase 1 Inhibitor; Unidentified pharmacological activity"
CBR-001-573-628-4,RFM-002-426-0,CBR-001-573-628-4,O=c1cc(oc2c1cccc2c1ccccc1)N1CCOCC1,CBR-HVAC-00102: ; Phosphoinositide 3 kinase Inhibitor; PI3 kinase alpha inhibitor; PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor
CBR-001-573-629-5,RFM-002-427-1,CBR-001-573-629-5,OC[C@H](Cn1ccc(nc1=O)N)OCP(=O)(O)O,CBR-HVAC-01438: Anti-Papilloma Virus Drugs;Antiviral Drugs;Anti-Cytomegalovirus Drugs;Anti-Herpes Simplex Virus Drugs; DNA Polymerase Inhibitors; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-573-630-8,RFM-002-428-2,CBR-001-573-630-8,C/C(=C\CSc1ccccc1C(=O)N)/CC/C=C(/CCC=C(C)C)\C,CBR-HVAC-06856: Oncolytic Drugs
CBR-001-573-631-9,RFM-002-429-3,CBR-001-573-631-9,[O-]C(=O)CC/C=C\CC[C@H]1[C@@H](OCc2ccc(cc2)c2ccccc2)CC(=O)[C@@H]1N1CCOCC1,CBR-HVAC-08593: Antiplatelet Therapy; Prostanoid EP4 Antagonists;Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A2 receptor Antagonist;
CBR-001-573-632-0,RFM-002-430-6,CBR-001-573-632-0,CC(CCOc1ccc(cc1)NC(=S)Nc1ccc(cc1)OCCC(C)C)C,CBR-HVAC-09022:
CBR-001-573-633-1,RFM-002-431-7,CBR-001-573-633-1,OC(=O)CCCCCCc1c(O)nc(n1CCC(C1CCCCC1)O)O,CBR-HVAC-02927: Antiplatelet Therapy;Treatment of Erectile Dysfunction; Prostanoid DP (DP1) Agonists;Signal Transduction Modulators; Prostaglandin D2 receptor Agonist; Prostaglandin D receptor agonist; Platelet aggregation inhibitor
CBR-001-573-634-2,RFM-002-432-8,CBR-001-573-634-2,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC,CBR-HVAC-01307: ; Diacylglycerol acyltransferase Inhibitor; Cholesterol inhibitor; Omega 3 fatty acid stimulant
CBR-001-573-635-3,RFM-002-433-9,CBR-001-573-635-3,Nc1nc(S)c2c(n1)[nH]cn2,CBR-HVAC-05276: Leukemia Therapy; Purine Antagonists;
CBR-001-573-636-4,RFM-002-434-0,CBR-001-573-636-4,ClCC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](Cc1ccccc1)N)CCCNC(=N)N,CBR-HVAC-10522: ; Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; Thrombin Inhibitor;
CBR-001-573-637-5,RFM-002-435-1,CBR-001-573-637-5,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2[C@H](C)CC2=C1CCC(=O)C2,CBR-HVAC-02014: Treatment of Postmenopausal Syndrome ;Breast Cancer Therapy;Treatment of Female Sexual Dysfunction;Treatment of Osteoporosis; Androgen Receptor Agonists;Apoptosis Inducers;Estrogen Receptor (ER) Agonists;Progesterone Receptor Agonists;Signal Transduction Modulators;Steryl Sulfatase Inhibitors; Estrogen receptor Modulator; Estrogen receptor agonist; Progesterone receptor agonist; Androgen receptor agonist; Selective estrogen receptor modulator
CBR-001-573-638-6,RFM-002-436-2,CBR-001-573-638-6,COc1cccc(c1)CN(C(=O)CC(C)(C)C)[C@H]1C[C@H](N(C1)Cc1ccc2c(c1)OCO2)C(=O)N1CCNCC1,CBR-HVAC-05538: Basal Cell Carcinoma Therapy; Hedgehog Signaling Inhibitors;Signal Transduction Modulators;Smoothened (Smo) Receptor Antagonists; Sonic hedgehog Antagonist; Hedgehog pathway inhibitor; Angiogenesis inhibitor
CBR-001-573-639-7,RFM-002-437-3,CBR-001-573-639-7,CCCCCC(c1cccc(c1)OCc1ccc2c(n1)cccc2)O,CBR-HVAC-03233: Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Lipoxygenase Inhibitors;Signal Transduction Modulators;
CBR-001-573-640-0,RFM-002-438-4,CBR-001-573-640-0,Fc1ccc(c(c1)F)c1nc(ccc1C(=O)N)N(c1c(F)cccc1F)C(=O)N,"CBR-HVAC-00485: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Osteoarthritis, Treatment of;Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for; MAPK p38 Inhibitors;Signal Transduction Modulators; Mitogen-activated protein kinase 14 Inhibitor; P38 kinase inhibitor"
CBR-001-573-641-1,RFM-002-439-5,CBR-001-573-641-1,Clc1cc2NC(NS(=O)(=O)c2cc1S(=O)(=O)N)C1CC2CC1C=C2,"CBR-HVAC-05400: Hypertension, Treatment of; AMPA Receptor Positive Allosteric Modulators;GABA(A) Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Modulator;"
CBR-001-573-642-2,RFM-002-440-8,CBR-001-573-642-2,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)OC)O,analog of CBR-HVAC-01641
CBR-001-573-643-3,RFM-002-441-9,CBR-001-573-643-3,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H]([C@@H]1C/C=C\CCCC(=O)O)O)O,CBR-HVAC-00932: ; Prostaglandin E receptor 2 Modulator; Prostaglandin E2 receptor agonist
CBR-001-573-644-4,RFM-002-442-0,CBR-001-573-644-4,Cc1ccccc1Cn1c(=O)c2CN(CCc2n2c1=NCC2)Cc1ccccc1,CBR-HVAC-07205: Leukemia Therapy;Brain Cancer Therapy;Solid Tumors Therapy;Oncolytic Drugs;Non-Hodgkin's Lymphoma Therapy; Apoptosis Inducers;Drugs Acting on TRAIL;Extracellular-Regulated Kinase (ERK) Inhibitors;Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators;
CBR-001-573-645-5,RFM-002-443-1,CBR-001-573-645-5,CCOC(=O)[C@H](CCC(=O)N[C@H](C(=O)N[C@H](c1ccccc1)C(=O)OCC)CSCc1ccccc1)N,"CBR-HVAC-00654: Myelodysplastic Syndrome Therapy;Antineoplastic Enhancing Agents;Disorders Associated with Cancer Therapy, Treatment of;Treatment of Neutropenia; Glutathione-s-transferase P1 (GSTP1) Inhibitors; GLUTATHIONE S-TRANSFERASE P1-1 Inhibitor; Glutathione S transferase inhibitor; Immunostimulant"
CBR-001-573-646-6,RFM-002-444-2,CBR-001-573-646-6,O=C(c1ccc(cc1)OCCCCc1ccccc1)Nc1cccc2c1oc(cc2=O)c1[nH]nnn1,"CBR-HVAC-03465: Asthma Therapy;Drugs for Allergic Rhinitis;Treatment of Upper Respiratory Tract Disorders;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene CysLT2  (LTC4) Antagonists;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; Leucotriene C4 antagonist; Leucotriene D4 antagonist; Leucotriene receptor antagonist"
CBR-001-573-647-7,RFM-002-445-3,CBR-001-573-647-7,N#C/C(=C\c1ccc(c(c1)OC)OC)/c1cccnc1,CBR-HVAC-10667: Oncolytic Drugs; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; EGFR Inhibitor;
CBR-001-573-648-8,RFM-002-446-4,CBR-001-573-648-8,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)Cc2c1cc(n2c1ccccc1)CCCCC(=O)[O-])O,CBR-HVAC-03000: Antiallergy/Antiasthmatic Drugs; Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; Lipoxygenase 5 Inhibitor; Prostaglandin D2 receptor agonist; Thromboxane A2 receptor antagonist
CBR-001-573-649-9,RFM-002-447-5,CBR-001-573-649-9,O=C(Nc1cc(Br)c(c(c1)Br)Oc1ccc(c(c1)C(C)C)O)CC(=O)O,CBR-HVAC-00377: ; Thyroid hormone receptor beta Agonist; Thyroid hormone receptor beta agonist
CBR-001-573-650-2,RFM-002-448-6,CBR-001-573-650-2,Clc1ccc(cc1)C(c1ccc(cc1)Cl)N1CC(C1)N(S(=O)(=O)C)c1cc(F)cc(c1)F,"CBR-HVAC-05618: Antipsychotic Drugs;Alzheimer's Dementia, Treatment of ;Lipoprotein Disorders, Treatment of ;Antiobesity Drugs;Antiparkinsonian Drugs;Metabolic Disorders (Not Specified); Cannabinoid CB1 Antagonists;Signal Transduction Modulators; Cannabinoid receptor 1 Antagonist; Cannabinoid CB1 receptor antagonist"
CBR-001-573-651-3,RFM-002-449-7,CBR-001-573-651-3,OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)n1cc(I)c(=O)[nH]c1=O,CBR-HVAC-02541: Antiviral DrugsDNA directed DNA polymerase inhibitor
CBR-001-573-652-4,RFM-002-450-0,CBR-001-573-652-4,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1C/C(=C/CCCC(=O)OC)/C2)O,analog of CBR-HVAC-03991
CBR-001-573-653-5,RFM-002-451-1,CBR-001-573-653-5,Nc1nc(nc(c1N1CCOCC1)N)c1nn(c2c1cccn2)Cc1ccccc1F,"CBR-HVAC-05318: Hypertension, Treatment of;Vasodilators;Heart Failure Therapy; Soluble Guanylate Cyclase (sGC) Activators; GUANYLYL CYCLASE Stimulator;"
CBR-001-573-654-6,RFM-002-452-2,CBR-001-573-654-6,N[C@H](Cc1cc(F)c(cc1F)F)CC(=O)N1CCn2c(C1)nnc2C(F)(F)F,"CBR-HVAC-01479: Type 2 Diabetes, Agents for;Antithrombocytopenic;Acute Myocardial Infarction, Treatment of;Inflammation, Treatment of; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;HMG-CoA Reductase Inhibitors;Signal Transduction Modulators;TNFSF6 Expression Inhibitors; Dipeptidyl peptidase 4 Inhibitor; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue"
CBR-001-573-655-7,RFM-002-453-3,CBR-001-573-655-7,O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](OCCC(O)(C)C)C)C)/C1,CBR-HVAC-02024: Antipsoriatics;Keratolytics;Treatment of Hyperparathyroidism;Dermatologic Drugs; Vitamin D3 receptor Agonist; Vitamin D agonist
CBR-001-573-656-8,RFM-002-454-4,CBR-001-573-656-8,COc1ccc(cc1)/C=C/CCCCOc1ccc(cc1CCC(=O)O)C(=O)c1cccc(c1)C(=O)O,CBR-HVAC-10423: ; Leukotriene B4 receptor Antagonist;
CBR-001-573-657-9,RFM-002-455-5,CBR-001-573-657-9,ONC(=O)c1ccc(c(c1)O)O,CBR-HVAC-03510: Oncolytic Drugs;Anti-HIV Agents; Antimetabolites;Ribonucleoside-Diphosphate Reductase Inhibitors; Ribonucleotide reductase Inhibitor; Ribonucleoside triphosphate reductase inhibitor; Ribonucleoside diphosphate reductase inhibitor
CBR-001-573-658-0,RFM-002-456-6,CBR-001-573-658-0,C/C=C/C/C=C/CCC(=O)[C@H]1O[C@H]1C(=O)N,CBR-HVAC-11419: ; Fatty acid synthase Inhibitor;
CBR-001-573-659-1,RFM-002-457-7,CBR-001-573-659-1,O=C(Nc1cnc2c(c1c1ccccc1Cl)cc(c(c2)C)C)Nc1ccc(cc1F)F,"CBR-HVAC-10610: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-573-660-4,RFM-002-458-8,CBR-001-573-660-4,O=C(N(C1CCCCC1)C)CCCOc1ccc2c(c1)ccc(=O)[nH]2,CBR-HVAC-01109: Oncolytic Drugs;Restenosis Treatment of; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 3 Inhibitor; Phosphodiesterase 4 inhibitor; Platelet aggregation inhibitor
CBR-001-573-661-5,RFM-002-459-9,CBR-001-573-661-5,CC/C(=C(\c1ccc(cc1)O)/c1ccc(cc1)OCCN(C)C)/c1ccccc1,CBR-HVAC-14169
CBR-001-573-662-6,RFM-002-460-2,CBR-001-573-662-6,O=CN(CCCP(=O)(O)[O-])O,CBR-HVAC-00777: Antimalarials;Antibiotics; 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) Inhibitors; Protein synthesis inhibitor
CBR-001-573-663-7,RFM-002-461-3,CBR-001-573-663-7,O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2([C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-])C)C,CBR-HVAC-02603: ; Glucocorticoid receptor Agonist; Glucocorticoid agonist
CBR-001-573-664-8,RFM-002-462-4,CBR-001-573-664-8,CSc1ccc(cc1)CC(N)C,CBR-HVAC-09782:
CBR-001-573-665-9,RFM-002-463-5,CBR-001-573-665-9,CCCCCn1cc(c2c1cccc2)C(=O)C12CC3CC(C2)CC(C1)C3,CBR-HVAC-09483: ; CANNABINOID RECEPTOR TYPE 1; CANNABINOID RECEPTOR TYPE 2 Agonist; Agonist;
CBR-001-573-666-0,RFM-002-464-6,CBR-001-573-666-0,O[C@@H]1CN2[C@@H]([C@@H]1O)[C@H](O)CCC2,CBR-HVAC-03557: Oncolytic Drugs; alpha-Mannosidase Inhibitors; Glycosidase; Alpha-mannosidase II Inhibitor;
CBR-001-573-667-1,RFM-002-465-7,CBR-001-573-667-1,OC(=O)[C@H]([N+](C)(C)C)Cc1nc([nH]c1)S,"CBR-HVAC-06403: Cognition Disorders, Treatment of;Dermatologic Drugs;Anticataract Agents; Antioxidants;Free Radical Scavengers;"
CBR-001-573-668-2,RFM-002-466-8,CBR-001-573-668-2,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)C(=O)O)Cl,"CBR-HVAC-04462: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 1 Blocker;"
CBR-001-573-669-3,RFM-002-467-9,CBR-001-573-669-3,Oc1nc(c(s1)Cc1ccc2c(c1)ccc(c2)OCc1ccccc1F)O,"CBR-HVAC-02723: Type 2 Diabetes, Agents for; Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor delta; Peroxisome proliferator-activated receptor gamma Agonist; Agonist; Agonist; Peroxisome proliferator-activated receptor gamma agonist; Thiazolidinedione; Peroxisome proliferator-activated receptor gamma antagonist; Insulin sensitizer; PPAR gamma partial agonist"
CBR-001-573-670-6,RFM-002-468-0,CBR-001-573-670-6,C[C@@H]1CC[C@]2(C([C@H]1C)C1=CC(=O)C3[C@@]([C@@]1(CC2)C)(C)CCC1[C@]3(C)CC[C@H]([C@]1(C)C(=O)O)O)C,CBR-HVAC-03879: Antiarthritic Drugs; P-Glycoprotein (MDR-1; ABCB1) Inhibitors;
CBR-001-573-671-7,RFM-002-469-1,CBR-001-573-671-7,CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(c1OC)Cl,"CBR-HVAC-03195: Nausea and Vomiting, Treatment of;Antipsychotic Drugs; Dopamine D2 Antagonists;Dopamine D3 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist"
CBR-001-573-672-8,RFM-002-470-4,CBR-001-573-672-8,CO[C@@H]1[C@@H](CC[C@@]2([C@H]1[C@@]1(C)O[C@@H]1CC=C(C)C)CO2)OC(=O)/C=C/C=C/C=C/C=C/C(=O)O,CBR-HVAC-02879: Antidiarrheal Agents;Antiobesity Drugs;Antifungal Agents; Angiogenesis Inhibitors;Methionine Aminopeptidase-2 (MetAP2) Inhibitors; METHIONYL AMINOPEPTIDASE 2 Inhibitor; Unidentified pharmacological activity
CBR-001-573-673-9,RFM-002-471-5,CBR-001-573-673-9,OCCNCCNc1ccc(c2c1C(=O)c1c(C2=O)cccc1)NCCNCCO,CBR-HVAC-00405:Oncolytic
CBR-001-573-674-0,RFM-002-472-6,CBR-001-573-674-0,Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2nccnc2)C)cc(c1)C(F)(F)F,CBR-HVAC-06568: Myeloid Leukemia Therapy; Abl1 Kinase Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Signal Transduction Modulators;
CBR-001-573-675-1,RFM-002-473-7,CBR-001-573-675-1,COc1ccc2c(c1C)nc(cc2O[C@@H]1C[C@@H]2[C@@H](C1)C(=O)N(C)CCCC/C=C\[C@H]1[C@](NC2=O)(C1)C(=O)NS(=O)(=O)C1CC1)c1scc(n1)C(C)C,CBR-HVAC-06555: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors; NS3/4A protease Inhibitor; HCV nonstructural protein 3 inhibitor; Serine protease inhibitor
CBR-001-573-676-2,RFM-002-474-8,CBR-001-573-676-2,NC(=NC(=O)c1ccc(c(c1)S(=O)(=O)C)C(C)C)N,"CBR-HVAC-04632: Coronary Bypass Surgery;Acute Myocardial Infarction, Treatment of; Na+/H+ Exchanger type 1 (NHE-1) Inhibitors; Sodium/hydrogen exchange inhibitor"
CBR-001-573-677-3,RFM-002-475-9,CBR-001-573-677-3,C[C@@H]1CN(C[C@H]1c1[nH]c(=O)c2c(n1)n(nc2)C1CCOCC1)Cc1ncccn1,"CBR-HVAC-00033: Hematopoiesis Disorders Therapy;Alzheimer's Dementia, Treatment of ; Phosphodiesterase PDE9A Inhibitors;Signal Transduction Modulators; PDE 9a Inhibitor; Phosphodiesterase 9A inhibitor"
CBR-001-573-678-4,RFM-002-476-0,CBR-001-573-678-4,Oc1ccc2c(c1)CN[C@H](C2)C(=O)N[C@@H](C(C)C)CN1CC[C@@]([C@H](C1)C)(C)c1cccc(c1)O,CBR-HVAC-02765: OPIOID RECEPTOR KAPPA Antagonist; Signal Transduction Modulators; kappa-Opioid Receptor Antagonists; ANTI-DEPRESSANTANXIOLYTICNARCOTIC AGENT; Treatment of Cocaine Dependency; Treatment of Opioid Dependency
CBR-001-573-679-5,RFM-002-477-1,CBR-001-573-679-5,O=C(c1ccc(cc1)[C@H](N)C)Nc1ccnc2c1cc[nH]2,"CBR-HVAC-00615: Antiallergy/Antiasthmatic Drugs;Vasodilators;Hypertension, Treatment of;Ophthalmic Drugs;Angina pectoris, Treatment of;Antiglaucoma Agents; Rho Kinase Inhibitors;Signal Transduction Modulators; Rho-associated, coiled-coil containing protein kinase Inhibitor; Rho-associated kinase inhibitor; Protein kinase inhibitor"
CBR-001-573-680-8,RFM-002-478-2,CBR-001-573-680-8,CN[C@@H]1Cc2cccc3c2n(C1)c(O)n3,CBR-HVAC-10406: Antiparkinsonian Drugs; Dopamine D2 Agonists;Signal Transduction Modulators; Dopamine receptor D2 Agonist;
CBR-001-573-681-9,RFM-002-479-3,CBR-001-573-681-9,NCCc1cn(c2c1cccc2)S(=O)(=O)c1c(Cl)nc2n1ccs2,"CBR-HVAC-05938: Anxiolytics;Generalized Anxiety Disorder (GAD), Treatment of;Antipsychotic Drugs; Signal Transduction Modulators;5-HT6 Agonists; 5-HYDROXYTRYPTAMINE 6 RECEPTOR Agonist; 5 Hydroxytryptamine 6 receptor agonist"
CBR-001-573-682-0,RFM-002-480-6,CBR-001-573-682-0,Oc1cccc(c1)Nc1ncc(c(n1)Nc1cccc(c1)O)F,CBR-HVAC-09208: Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis; Signal Transduction Modulators;Syk Kinase Inhibitors; Spleen tyrosine kinase Inhibitor;
CBR-001-573-683-1,RFM-002-481-7,CBR-001-573-683-1,COc1cc(N)c(cc1C(=O)NC1CCN(CC1)Cc1ccc(cc1)F)Cl,analog of CBR-HVAC-12016
CBR-001-573-684-2,RFM-002-482-8,CBR-001-573-684-2,OCCOc1ncnc(c1Oc1cccc(c1)OC)NS(=O)(=O)c1ccc(cc1)C(C)(C)C,CBR-HVAC-10927: ; Endothelin Receptor Antagonists;Signal Transduction Modulators; Endothelin receptor Antagonist;
CBR-001-573-685-3,RFM-002-483-9,CBR-001-573-685-3,NC1CCN(CC1)c1cccc(n1)Br,CBR-HVAC-07665: Alpha adrenoreceptor agonist; 5 Hydroxytryptamine receptor agonist
CBR-001-573-686-4,RFM-002-484-0,CBR-001-573-686-4,NCC(=O)N1CCn2c(C1(C)C)nc(c2Nc1ccc(cc1)Cl)c1ccc(cc1)F,CBR-HVAC-14183
CBR-001-573-687-5,RFM-002-485-1,CBR-001-573-687-5,COc1c(OC)ccnc1CS(=O)c1nc2c([nH]1)ccc(c2)OC(F)F,CBR-HVAC-01424: H+ K+ transporting ATPase inhibitor
CBR-001-573-688-6,RFM-002-486-2,CBR-001-573-688-6,CCn1c(SC)nnc1c1ccncc1,CBR-HVAC-11717: ; Melanin concentrating hormone receptor Antagonist;
CBR-001-573-689-7,RFM-002-487-3,CBR-001-573-689-7,Nc1nc(O)c(c(n1)c1ccccc1)I,CBR-HVAC-05777: Immunomodulators;Oncolytic Drugs;Antiviral Drugs
CBR-001-573-690-0,RFM-002-488-4,CBR-001-573-690-0,OC(=O)c1cccc(c1)Nc1cc(C(C)C)c(c(c1)C(C)C)O,analog of CBR-HVAC-08251 (R-840)
CBR-001-573-691-1,RFM-002-489-5,CBR-001-573-691-1,COc1ccc(cc1C1CCN(C1)Cc1ccc2c(c1)OCCO2)OC,analog of CBR-HVAC-05622
CBR-001-573-692-2,RFM-002-490-8,CBR-001-573-692-2,CCN(C(=O)C1CCN(CC1)C(C)C)C(Cc1ccc(cc1)OC)C,analog of CBR-HVAC-01071
CBR-001-573-693-3,RFM-002-491-9,CBR-001-573-693-3,Fc1cc(ccc1Oc1ccc(cn1)C(=O)N)CN1CCCC1,analog of CBR-HVAC-06850
CBR-001-573-694-4,RFM-002-492-0,CBR-001-573-694-4,CC(=O)OC1CCC2(C(C1(C)C)CCC1(C2C(=O)C=C2C1(C)CCC1(C2CC(C)(CC1)C(=O)O)C)C)C,CBR-HVAC-01511: Mucus protecting agent
CBR-001-573-695-5,RFM-002-493-1,CBR-001-573-695-5,CN1C2CCC1CC(C2)OC(=O)c1cc(Cl)cc(c1)Cl,"CBR-HVAC-02965: Antimigraine Drugs;Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-573-696-6,RFM-002-494-2,CBR-001-573-696-6,COc1cc(CN2CCN(CC2)c2ccc(cc2)F)cc(c1OC)OC,CBR-HVAC-08500: Alpha 2 adrenoreceptor agonist
CBR-001-573-697-7,RFM-002-495-3,CBR-001-573-697-7,Clc1ccc(nn1)N1CCN(CC1)C/C=C/c1ccccc1,CBR-HVAC-01100: Unidentified pharmacological activity
CBR-001-573-698-8,RFM-002-496-4,CBR-001-573-698-8,O=C(C1CCN(CC1)c1ccnc(n1)C(F)(F)F)NC1CCCCCC1,analog of CBR-HVAC-03574
CBR-001-573-699-9,RFM-002-497-5,CBR-001-573-699-9,[O-][N+](=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2SC(=O)C(C)(C)C,analog of CBR-HVAC-05349
CBR-001-573-700-5,RFM-002-498-6,CBR-001-573-700-5,CC1(NCCc2c1cccc2)c1ccccc1,"CBR-HVAC-10647: Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-573-701-6,RFM-002-499-7,CBR-001-573-701-6,COc1ccc(cc1)c1[nH]c(nc1c1ccc(cc1)OC)c1ccccc1F,analog of CBR-HVAC-01143
CBR-001-573-702-7,RFM-002-500-3,CBR-001-573-702-7,O=S(=O)(c1c(nn2c1ncc1c2CCNC1)N1CCNCC1)c1ccccc1,analog of CBR-HVAC-06984
CBR-001-573-703-8,RFM-002-501-4,CBR-001-573-703-8,COc1cccc(c1)C(CN1CCN(CC1)c1ccccc1OC)O,analog of CBR-HVAC-09144
CBR-001-573-704-9,RFM-002-502-5,CBR-001-573-704-9,COc1c(OC)cc(cc1C(Nc1cc(ccc1S(=O)(=O)C)N1CCNCC1)C)Cl,"CBR-HVAC-06434: Antiobesity Drugs;Cognition Disorders, Treatment of;Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; Signal Transduction Modulators;5-HT6 Antagonists; 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR 6 Antagonist;"
CBR-001-573-705-0,RFM-002-503-6,CBR-001-573-705-0,NC(=O)[C@@H]1CCCN1,CBR-HVAC-10279:
CBR-001-573-706-1,RFM-002-504-7,CBR-001-573-706-1,c1ccc(cc1)Oc1cccnc1,"CBR-HVAC-00489: Cognition Disorders, Treatment of; HIV-1 Reverse transcriptase Inhibitor; Unidentified pharmacological activity"
CBR-001-573-707-2,RFM-002-505-8,CBR-001-573-707-2,O=C(NCC(=O)O)CNC(=O)[C@H](Cc1ccc(cc1)O)N,CBR-HVAC-03336: Immunomodulators; Interleukin 2 receptor Inducer;
CBR-001-573-708-3,RFM-002-506-9,CBR-001-573-708-3,Cc1ccc(c(c1)C)Oc1ccccc1c1csc(n1)N=C1NCCCN1,CBR-HVAC-04502: Antifungal Agents; Cell Membrane Disrupting Agents;Sterol 24-Methyltransferase Inhibitors; Unidentified pharmacological activity
CBR-001-573-709-4,RFM-002-507-0,CBR-001-573-709-4,O=C(N[C@@H]([C@H](OC(C)(C)C)C)C(=O)OCc1ccccc1)OCc1ccccc1,analog of CBR-HVAC-08254
CBR-001-573-710-7,RFM-002-508-1,CBR-001-573-710-7,CCn1c2ccccc2nc(c1=O)N(C)C,analog of CBR-HVAC-10441 (L-0066)
CBR-001-573-711-8,RFM-002-509-2,CBR-001-573-711-8,O=C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2N(CCc1c[nH]c2c1cccc2)C)NC1CC1,analog of CBR-HVAC-10841
CBR-001-573-712-9,RFM-002-510-5,CBR-001-573-712-9,CC(=O)SCC(C(=O)O)CC(=O)c1ccc(cc1)C,"CBR-HVAC-03769: Immunomodulators;Rheumatoid Arthritis, Treatment of; Interleukin 1; Interleukin 6 Antagonist; Interleukin 1 antagonist; Interleukin 6 antagonist; Metalloproteinase-1 inhibitor"
CBR-001-573-713-0,RFM-002-511-6,CBR-001-573-713-0,C#Cc1cnc(nc1O)O,"CBR-HVAC-00631: Liver Cancer Therapy;Pancreatic Cancer Therapy;Antineoplastic Enhancing Agents;Inhibitors of the Degradation of Anticancer Drugs;Disorders Associated with Cancer Therapy, Treatment of;Colorectal Cancer Therapy;Breast Cancer Therapy; Dihydropyrimidine Dehydrogenase Inhibitors; Dihydropyrimidine dehydrogenase Inhibitor; Dihydropyrimidine dehydrogenase inhibitor"
CBR-001-573-714-1,RFM-002-512-7,CBR-001-573-714-1,O=C(N[C@H](C(=O)O)Cc1cnc[nH]1)CCNC(=O)C,CBR-HVAC-05562: Anticataract Agents; Antioxidants;
CBR-001-573-715-2,RFM-002-513-8,CBR-001-573-715-2,C[C@@H]1CC[C@H]([C@@H](C1)OC(=O)[C@@H]1CCC(=O)N1)C(C)C,analog of CBR-HVAC-04088: (Crilvastatin)
CBR-001-573-716-3,RFM-002-514-9,CBR-001-573-716-3,CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@H](O[C@H]1n1ccc(=O)[nH]c1=O)COC(=O)C,"CBR-HVAC-00906: Bipolar Disorder, Treatment of;Specific Antidotes;Chemoprotective Agents;Colorectal Cancer Therapy;Antidepressants;Treatment of Renal Diseases;Treatment of Disorders of Purine and Pyrimidine Metabolism;Neurologic Drugs (Miscellaneous);Gastric Cancer Therapy;Therapy of Inborn Errors of Metabolism;Pancreatic Cancer Therapy;Autism, Treatment ofUnidentified pharmacological activity"
CBR-001-573-717-4,RFM-002-515-0,CBR-001-573-717-4,C[C@H]1CCn2c(C(=O)N(C1)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F)c(c1ccc(cc1)C)c1c(c2=O)nccc1,"CBR-HVAC-08403: Urinary Incontinence Therapy;Antidepressants;Irritable Bowel Syndrome, Agents for; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin 1 receptor antagonist"
CBR-001-573-718-5,RFM-002-516-1,CBR-001-573-718-5,OC(=O)C1CCc2c1cc(Cl)c(c2)C1CCCCC1,"CBR-HVAC-01940: Antipyretics;Non-Opioid Analgesics;Inflammation, Treatment of; Prostaglandin synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor"
CBR-001-573-719-6,RFM-002-517-2,CBR-001-573-719-6,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN2N1C(=O)[C@H](CCC2=O)NC(=O)c1nccc2c1cccc2,"CBR-HVAC-02717: Osteoarthritis, Treatment of;Rheumatoid Arthritis, Treatment of; Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Signal Transduction Modulators; Interleukin-1 beta-converting enzyme Inhibitor; Interleukin 1beta converting enzyme inhibitor"
CBR-001-573-720-9,RFM-002-518-3,CBR-001-573-720-9,OC1CCC2(C34C1Oc1c4c(CC2N(CC3)CC2CCC2)ccc1OC(=O)C12CC3CC(C2)CC(C1)C3)O,analog of CBR-HVAC-06238 (Sebacoyl dinalbuphine ester)
CBR-001-573-721-0,RFM-002-519-4,CBR-001-573-721-0,COc1cc(ccc1OC)N(C(=O)c1ccc(cc1)[N+](=O)[O-])CCCN(CCc1ccc(c(c1)OC)OC)C,"CBR-HVAC-04042: Antiarrhythmic Drugs;Angina pectoris, Treatment of; Calcium Channel Blockers;Potassium Channel Blockers; L-type calcium channel Blocker; Inhibitor; Polarisation inhibitor; Calcium channel antagonist; Potassium channel antagonist"
CBR-001-573-722-1,RFM-002-520-7,CBR-001-573-722-1,Fc1cccc(c1)c1[nH]c(nc1c1ccccc1)S(=O)(=O)C(C(F)F)(F)F,analog of CBR-HVAC-01163
CBR-001-573-723-2,RFM-002-521-8,CBR-001-573-723-2,Clc1ccc(cc1)C(C(=C)c1ccccc1Cl)(Cn1cncn1)O,CBR-HVAC-04099: Antifungal Agents
CBR-001-573-724-3,RFM-002-522-9,CBR-001-573-724-3,OCC(COc1cccc(c1)C(=O)c1cnn(c1N)c1ccc(cc1)F)O,"CBR-HVAC-00116: Pancreatic Cancer Therapy;Rheumatoid Arthritis, Treatment of; IL-12 Production Enhancers;MAPK p38 Inhibitors;Signal Transduction Modulators; p38 Mitogen-activated protein kinase Inhibitor; P38 kinase inhibitor"
CBR-001-573-725-4,RFM-002-523-0,CBR-001-573-725-4,Brc1cc2c(s1)n1cnnc1CN=C2c1ccccc1Cl,analog of CBR-HVAC-01426
CBR-001-573-726-5,RFM-002-524-1,CBR-001-573-726-5,CN(CC(CC1c2ccccc2CCc2c1cccc2)C)C,CBR-HVAC-03127: Antidepressants; Alpha-1A adrenergic receptor Antagonist;
CBR-001-573-727-6,RFM-002-525-2,CBR-001-573-727-6,COC(=O)[C@@H](NC(=O)N1CCN(C(=O)[C@@H]1Cc1ccccc1)Cc1[nH]cnc1C)CC(C)C,CBR-HVAC-14287
CBR-001-573-728-7,RFM-002-526-3,CBR-001-573-728-7,CONC(=O)c1ccc(c(c1)Nc1ncnn2c1c(C)c(c2)C(=O)NCc1ccccn1)C,analog of CBR-HVAC-06540
CBR-001-573-729-8,RFM-002-527-4,CBR-001-573-729-8,CCCCCCCCCc1ccc(cc1)OCCOCCOCCOCCOCCOCCOCCOCCOCCO,CBR-HVAC-05254: Vaginal Spermicides
CBR-001-573-730-1,RFM-002-528-5,CBR-001-573-730-1,COc1nc2ccc(cc2nc1NC(=O)N1CCN(CC1)c1cc(OC)cc(c1)OC)F,CBR-HVAC-06430: Solid Tumors Therapy;Oncolytic Drugs; Antimitotic Drugs;Apoptosis Inducers;Microtubule Inhibitors;p68 RNA Helicase Inhibitors; p68 RNA helicase inhibitor
CBR-001-573-731-2,RFM-002-529-6,CBR-001-573-731-2,CN1CCN(CC1)C1Cc2cc(Cl)ccc2Sc2c1cccc2,analog of CBR-HVAC-02274
CBR-001-573-732-3,RFM-002-530-9,CBR-001-573-732-3,Fc1ccc(cc1)c1ccc(c(n1)C)C(=O)Nc1ccc2c(c1)nc(s2)C,CBR-HVAC-00427: ; Vanilloid receptor 1 Antagonist; Vanilloid receptor 1 antagonist
CBR-001-573-733-4,RFM-002-531-0,CBR-001-573-733-4,NC(=N)N/N=C/C(=C)NNC(=N)N,CBR-HVAC-02895: Treatment of AIDS-Associated Disorders;Oncolytic Drugs; Polyamine Biosynthesis Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors; Polyamine synthesis inhibitor; DNA synthesis inhibitor
CBR-001-573-734-5,RFM-002-532-1,CBR-001-573-734-5,O=C(Nc1scc(n1)c1ccccc1)OCC(Cl)(Cl)Cl,CBR-HVAC-01095: Immunostimulant
CBR-001-573-735-6,RFM-002-533-2,CBR-001-573-735-6,CN1CCN(CC1)[C@H]1C[C@@H](c2c1cccc2)c1ccccc1,analog of CBR-HVAC-05080
CBR-001-573-736-7,RFM-002-534-3,CBR-001-573-736-7,O=C1N(Cc2ccc(o2)C(F)(F)F)c2c(C31COc1c3cc3OCOc3c1)cccc2,"CBR-HVAC-07100: Osteoarthritis, Treatment of;Analgesic Drugs; Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers; Sodium channel antagonist"
CBR-001-573-737-8,RFM-002-535-4,CBR-001-573-737-8,Clc1ccc2c(c1)c(nc(=O)n2CC(F)(F)F)c1ccccc1,CBR-HVAC-01162: Cyclooxygenase inhibitor
CBR-001-573-738-9,RFM-002-536-5,CBR-001-573-738-9,CCC/N=C/1\S/C(=C/c2ccc(c(c2)Cl)OCCO)/C(=O)N1c1ccccc1C,analog of CBR-HVAC-00724 (ponesimod)
CBR-001-573-739-0,RFM-002-537-6,CBR-001-573-739-0,Clc1cc(cc(c1)Cl)C1C(=C(C)Nc2n1ncc2)C(=O)N1CCCCC1,analog of CBR-HVAC-05551
CBR-001-573-740-3,RFM-002-538-7,CBR-001-573-740-3,COc1cccc(c1)c1nccc2c1cc(c1noc(n1)C)c(n2)O,"CBR-HVAC-05070: Alzheimer's Dementia, Treatment of ; GABA(A) BZ Site Receptor Inverse Agonists;GABA(A) Receptor Inverse Agonists;GABA(A) Receptor Modulators;Signal Transduction Modulators; Benzodiazepine receptor Partial Inverse Agonist; Benzodiazepine receptor inverse agonist"
CBR-001-573-741-4,RFM-002-539-8,CBR-001-573-741-4,COc1cccc(c1)C(=O)CCNC(C(c1ccccc1)O)C,CBR-HVAC-06236: Antibacterial Drugs;Heart Failure Therapy;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Drugs Acting on Adrenoceptors;Signal Transduction Modulators;
CBR-001-573-742-5,RFM-002-540-1,CBR-001-573-742-5,C1CN2CCC1C(C2)Oc1ccc(nn1)c1ccccc1,analog of CBR-HVAC-06514
CBR-001-573-743-6,RFM-002-541-2,CBR-001-573-743-6,C#Cc1ccc2c(c1)CCC1=C(C(=O)CCN21)C,analog of CBR-HVAC-04985
CBR-001-573-744-7,RFM-002-542-3,CBR-001-573-744-7,Clc1ccc(cc1)Oc1ccc(cc1)OCc1cc(C)cc(=O)n1O,CBR-HVAC-03659: Antifungal Agents; Lipoxygenase 5 Inhibitor; 5 Lipoxygenase inhibitor
CBR-001-573-745-8,RFM-002-543-4,CBR-001-573-745-8,CC(CCCC(C1CCC2C1(C)CCC1C2CCC2C1(C)CCC(=O)N2C)C)C,analog of CBR-HVAC-04554 (L-733692)
CBR-001-573-746-9,RFM-002-544-5,CBR-001-573-746-9,Clc1ccc(cc1)c1cc2ccccc2c2=NCCn12,analog of CBR-HVAC-03757
CBR-001-573-747-0,RFM-002-545-6,CBR-001-573-747-0,CC(c1ccc(c(c1)Cl)N1CC=CC1)C(=O)O,CBR-HVAC-02672: ; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-573-748-1,RFM-002-546-7,CBR-001-573-748-1,OC12N=C(SC1Cc1c2cccc1)c1ccc(cc1)C(C)(C)C,analog of CBR-HVAC-05345
CBR-001-573-749-2,RFM-002-547-8,CBR-001-573-749-2,Cc1cc(ccc1NC(=O)c1cnn(c1C)c1ncccc1C(F)(F)F)C(=O)NC1CC1,analog of CBR-HVAC-06775
CBR-001-573-750-5,RFM-002-548-9,CBR-001-573-750-5,CCCCN(CC(c1cc(nc2c1cc(Cl)cc2Cl)c1ccc(cc1)Cl)O)CCCC,analog of CBR-HVAC-06515
CBR-001-573-751-6,RFM-002-549-0,CBR-001-573-751-6,CN(Cc1nccn1c1ccc(c(c1)F)NC(=O)c1cc(nn1c1ccc2c(c1)c(N)no2)C(F)(F)F)C,CBR-HVAC-05549: Anticoagulants; Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways; Coagulation factor Xa Inhibitor; Factor Xa inhibitor; Serine protease inhibitor
CBR-001-573-752-7,RFM-002-550-3,CBR-001-573-752-7,CCCCN1CCC(CC1)NC(=O)c1c[nH]c2c1cccn2,analog of CBR-HVAC-02739
CBR-001-573-753-8,RFM-002-551-4,CBR-001-573-753-8,CCc1c(cnn1c1ccc(cc1)C)C(=O)N[C@@H]1CC[C@H](CC1)CO,analog of CBR-HVAC-06986
CBR-001-573-754-9,RFM-002-552-5,CBR-001-573-754-9,O=C(c1cc2c(o1)cccc2)N1CCN(CC1)Cc1ccccc1,CBR-HVAC-10402:
CBR-001-573-755-0,RFM-002-553-6,CBR-001-573-755-0,CN1CC[C@@H]2[C@H](C1)c1cc(C)ccc1N2,CBR-HVAC-03182: Antiarrhythmic Drugs; Antioxidants; Alpha 1 adrenoreceptor antagonist
CBR-001-573-756-1,RFM-002-554-7,CBR-001-573-756-1,OC(COc1cccc(c1)C)CNC(C)C,CBR-HVAC-10208: ; Beta adrenergic receptor Antagonist;
CBR-001-573-757-2,RFM-002-555-8,CBR-001-573-757-2,CCC(C(CC)C)C(=O)N,CBR-HVAC-05416: Antiepileptic Drugs;Anxiolytics
CBR-001-573-758-3,RFM-002-556-9,CBR-001-573-758-3,CCCC(=O)OCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1Cl)Cl)C(=O)OC)C,"CBR-HVAC-04743: Hypertension, Treatment of; Calcium Channel Blockers; Dihydropyridine calcium channel Blocker;"
CBR-001-573-759-4,RFM-002-557-0,CBR-001-573-759-4,CCOc1ccc(cc1)C(=O)CCC(=O)N1CCC(=CC1)c1ccc(cc1)OC,analog of CBR-HVAC-11844
CBR-001-573-760-7,RFM-002-558-1,CBR-001-573-760-7,COc1ccc2c(c1)nc([nH]2)SCCN1CCOCC1,analog of CBR-HVAC-05059
CBR-001-573-761-8,RFM-002-559-2,CBR-001-573-761-8,CCCCOCCOC(=O)c1cccnc1,CBR-HVAC-09717:
CBR-001-573-762-9,RFM-002-560-5,CBR-001-573-762-9,O=C(N1CCCC2C1CCC2)c1ccc(cc1)c1onc(n1)C1CC1,analog of CBR-HVAC-11405
CBR-001-573-763-0,RFM-002-561-6,CBR-001-573-763-0,NNC(CCc1ccc2c(c1)OCO2)C,CBR-HVAC-10310: ; Monoamine oxidase Inhibitor;
CBR-001-573-764-1,RFM-002-562-7,CBR-001-573-764-1,O=C(C(=O)c1c(cc2n1cccc2)c1ccccc1)Nc1ccc(cc1)N1CCCCC1,analog of CBR-HVAC-11883
CBR-001-573-765-2,RFM-002-563-8,CBR-001-573-765-2,CN1CCc2c(C1)c1ccccc1n2Cc1ccccc1,CBR-HVAC-10021: ; Histamine H1 receptor Antagonist;
CBR-001-573-766-3,RFM-002-564-9,CBR-001-573-766-3,Clc1ccc2c(c1)COB2O,CBR-HVAC-00250: Antifungal Agents; Leucyl-tRNA Synthetase Inhibitors; LEUCYL-TRNA SYNTHETASE Inhibitor; Leucyl-tRNA synthetase inhibitor
CBR-001-573-767-4,RFM-002-565-0,CBR-001-573-767-4,C1CC2=Nc3c(CN2C1)cccc3,"CBR-HVAC-06291: Smoking Cessation, Aid to;Treatment of Alcohol Dependency; Acetylcholinesterase (AChE) Inhibitors;MAO-A Inhibitors; Acetylcholinesterase; Butyrylcholinesterase; Monoamine oxidase A Inhibitor;"
CBR-001-573-768-5,RFM-002-566-1,CBR-001-573-768-5,CC(=CCSCC(C(=O)O)N)C,CBR-HVAC-08227: Mucolytic agent
CBR-001-573-769-6,RFM-002-567-2,CBR-001-573-769-6,O=c1cnc2c3n1C(CN1CCC(CC1)NCc1ncc4c(c1)CCCO4)Cn3c(=O)cc2,CBR-HVAC-07254: Antibacterial Drugs; DNA Topoisomerase II Inhibitors; DNA topoisomerase II inhibitor
CBR-001-573-770-9,RFM-002-568-3,CBR-001-573-770-9,Oc1nc2c(n1C1CCN(CC1)CCOc1ccccc1)cccc2,"CBR-HVAC-05579: Antiparkinsonian Drugs;Extrapyramidal Disorders, Treatment of; Dopamine Receptor Antagonists;Signal Transduction Modulators; Dopamine receptor Antagonist;"
CBR-001-573-771-0,RFM-002-569-4,CBR-001-573-771-0,Clc1ccccc1Cn1cncc1,analog of CBR-HVAC-07808
CBR-001-573-772-1,RFM-002-570-7,CBR-001-573-772-1,CCC(c1ccccc1)C(=O)OCCN(CC)CC,CBR-HVAC-09716:
CBR-001-573-773-2,RFM-002-571-8,CBR-001-573-773-2,NNC(COc1ccccc1)C,CBR-HVAC-08824: ; Monoamine oxidase Irreversible inhibitor;
CBR-001-573-774-3,RFM-002-572-9,CBR-001-573-774-3,COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl,CBR-HVAC-04453: Antiallergy/Antiasthmatic Drugs;Antiarthritic Drugs; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor; Superoxide dismutase inhibitor
CBR-001-573-775-4,RFM-002-573-0,CBR-001-573-775-4,OC(c1ccc(cc1)[N+](=O)[O-])CNC(C)C,CBR-HVAC-01540: Beta adrenoreceptor antagonist
CBR-001-573-776-5,RFM-002-574-1,CBR-001-573-776-5,Clc1ccc(cc1)OC(C(=O)OCCn1cnc2c1c(=O)n(C)c(=O)n2C)(C)C,"CBR-HVAC-05602: Lipoprotein Disorders, Treatment of Lipase clearing factor inhibitor; Platelet aggregation inhibitor"
CBR-001-573-777-6,RFM-002-575-2,CBR-001-573-777-6,CNC1CCc2c(C1)c1ccccc1[nH]2,analog of CBR-HVAC-09228: (CYCLINDOLE)
CBR-001-573-778-7,RFM-002-576-3,CBR-001-573-778-7,C1CNCCN(CCCNCCNC1)Cc1ccc(cc1)CN1CCNCCCNCCNCCC1,"CBR-HVAC-04437: Anti-HIV Agents;Alzheimer's Dementia, Treatment of ;Myeloid Leukemia Therapy;Solid Tumors Therapy;Antianemics;Hematological Cancer Therapy;Brain Cancer Therapy;Heart Failure Therapy;Renal Cancer Therapy;Hematopoietic Agents;Rheumatoid Arthritis, Treatment of;Immunostimulants; Chelating Agents;Chemokine CXCR4 (SDF-1 Receptor) Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators; C-X-C chemokine receptor type 4 Antagonist;"
CBR-001-573-779-8,RFM-002-577-4,CBR-001-573-779-8,N[C@H](c1ccccc1)Cc1ccccn1,"CBR-HVAC-04649: Ischemic Stroke, Treatment of;Antidepressants;Autism, Treatment of; NMDA Antagonists;Signal Transduction Modulators; NMDA GLUTAMATE RECEPTOR Antagonist; NMDA receptor antagonist; Sigma receptor antagonist"
CBR-001-573-780-1,RFM-002-578-5,CBR-001-573-780-1,O=C(C(c1cccc(c1)C(=O)c1ccccc1)C)Nc1nccc(c1)C,CBR-HVAC-02105: Antiarthritic Drugs; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 Inhibitor; Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-573-781-2,RFM-002-579-6,CBR-001-573-781-2,COC1CCN(CC1)S(=O)(=O)c1c(Cl)cccc1Cl,analog of CBR-HVAC-05857
CBR-001-573-782-3,RFM-002-580-9,CBR-001-573-782-3,OC(CN1CCN(CC1)C(=O)C(C)(C)C)COc1ccccc1,analog of CBR-HVAC-07910
CBR-001-573-783-4,RFM-002-581-0,CBR-001-573-783-4,Cc1nnc2n1nc(cc2)c1cccc(c1)C(F)(F)F,CBR-HVAC-07650: GABA receptor agonist
CBR-001-573-784-5,RFM-002-582-1,CBR-001-573-784-5,CCCC(=O)N1CCCN(CC1)c1nc(N)c2c(n1)cc(c(c2)OC)OC,"CBR-HVAC-01435: Antiglaucoma Agents;Hypertension, Treatment of;Ophthalmic Drugs; alpha1-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Inhibitor; Alpha 1 adrenoreceptor antagonist"
CBR-001-573-785-6,RFM-002-583-2,CBR-001-573-785-6,Nc1nc(=O)n(cc1F)[C@@H]1CS[C@@H](O1)CO,CBR-HVAC-02346: Anti-HIV Agents;Anti-Hepatitis B Virus Drugs; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleoside reverse transcriptase inhibitor
CBR-001-573-786-7,RFM-002-584-3,CBR-001-573-786-7,Fc1ccc(cc1)CNC(=O)C1N=C(N(C(=O)C1=O)C)C(NC(=O)c1nnc(o1)C)(C)C,"CBR-HVAC-01618: Multiple Sclerosis, Agents for;Lesions of the Spinal Cord and Related Structures, Treatment of;Anti-HIV Agents;Microbicides; HIV Integrase Inhibitors; Integrase Inhibitor; HIV integrase inhibitor"
CBR-001-573-787-8,RFM-002-585-4,CBR-001-573-787-8,COc1cc2N(C)[C@@H]3[C@@]4(c2cc1[C@]1(C[C@@H]2CN(CCc5c1[nH]c1c5cccc1)C[C@](C2)(O)CC)C(=O)OC)CCN1[C@H]4[C@@]([C@H]([C@]3(O)C(=O)OC)OC(=O)C)(CC)C=CC1,CBR-HVAC-14253
CBR-001-573-788-9,RFM-002-586-5,CBR-001-573-788-9,OCCNC(=O)C(c1ccc(cc1)CC(C)C)C,CBR-HVAC-02142: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-573-789-0,RFM-002-587-6,CBR-001-573-789-0,COc1ccc(cc1)N1CCN(CC1)C(=O)CCCc1c[nH]c2c1cccc2,analog of CBR-HVAC-04131
CBR-001-573-790-3,RFM-002-588-7,CBR-001-573-790-3,COC(=O)[C@H](CS)N,CBR-HVAC-10358:
CBR-001-573-791-4,RFM-002-589-8,CBR-001-573-791-4,CO/N=C(/C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C)\c1csc(n1)N,CBR-HVAC-02215: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-792-5,RFM-002-590-1,CBR-001-573-792-5,OCCOC(=O)NCc1ccccc1,CBR-HVAC-08650:
CBR-001-573-793-6,RFM-002-591-2,CBR-001-573-793-6,O=C(C12CC3CC(C2)CC(C1)C3)NCCN1CCN(CC1)c1ncccn1,CBR-HVAC-03967: Anxiolytics;Antidepressants; Signal Transduction Modulators;5-HT1A Receptor Agonists;5-HT2A Antagonists; 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 2 receptor Agonist; Antagonist; 5 Hydroxytryptamine 1A receptor agonist; 5 Hydroxytryptamine 2A receptor antagonist
CBR-001-573-794-7,RFM-002-592-3,CBR-001-573-794-7,Fc1ccc2c(c1)COB2O,CBR-HVAC-06342: Antifungal Agents; Leucyl-tRNA Synthetase Inhibitors;
CBR-001-573-795-8,RFM-002-593-4,CBR-001-573-795-8,c1ccc(cc1)NCc1nc2c([nH]1)cccc2,analog of CBR-HVAC-10620
CBR-001-573-796-9,RFM-002-594-5,CBR-001-573-796-9,COc1cc2c(cc1OC)CCN1C2CC(=O)C(C1)CC(C)C,"CBR-HVAC-00018: Extrapyramidal Disorders, Treatment of;Tourette's Syndrome, Treatment of;Huntington's Disease, Treatment of;Tardive Dyskinesia, Treatment of; Signal Transduction Modulators;Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors; Vesicular monoamine transporter 2 inhibitor"
CBR-001-573-797-0,RFM-002-595-6,CBR-001-573-797-0,CC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](c1ccc(cc1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@H]21)C(=O)C,"CBR-HVAC-01757: Female Contraceptives;Gynecological Disorders, Treatment of ;Postcoital Contraceptives;Treatment of Postmenopausal Syndrome ;Premenstrual Syndrome, Treatment of; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP2A6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Selective Progesterone Receptor Modulators (SPRM);Signal Transduction Modulators; Progesterone receptor Modulator; Progesterone receptor agonist; Progesterone receptor antagonist; Glucocorticoid antagonist"
CBR-001-573-798-1,RFM-002-596-7,CBR-001-573-798-1,OCCOc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cc1)C(C)(C)C)c1ncccn1,"CBR-HVAC-01498: Scleroderma, Agents for;Melanoma Therapy;Heart Failure Therapy;Diabetic Nephropathy, Agents for;Hypertension, Treatment of;Interstitial Lung Diseases, Treatment of;Asthma Therapy;Pulmonary Hypertension, Treatment of; Endothelin ETA Receptor Antagonists;Endothelin ETB Receptor Antagonists;Signal Transduction Modulators; Endothelin B receptor; Endothelin A receptor Inhibitor; Endothelin A receptor antagonist; Endothelin B receptor antagonist"
CBR-001-573-799-2,RFM-002-597-8,CBR-001-573-799-2,CSCCC(C(=O)OCC(=O)Nc1ccccc1)NC(=O)COc1ccccc1,analog of CBR-HVAC-08387
CBR-001-573-800-8,RFM-002-598-9,CBR-001-573-800-8,OC(c1ccccc1)CNc1ccccn1,CBR-HVAC-09791:
CBR-001-573-801-9,RFM-002-599-0,CBR-001-573-801-9,NC(=N)NC(=O)c1cnccn1,"CBR-HVAC-04134: Diuretics;Type 2 Diabetes, Agents for;Uricosurics; Sodium channel Blocker; Diuretic"
CBR-001-573-802-0,RFM-002-600-6,CBR-001-573-802-0,c1ccc2c(c1)[nH]nc2,uninteresting ligand of CBR-HVAC-00237
CBR-001-573-803-1,RFM-002-601-7,CBR-001-573-803-1,O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1,"CBR-HVAC-02972: Hypertension, Treatment of; Signal Transduction Modulators;5-HT2A Antagonists; 5-Hydroxytryptamine 2 receptor; Alpha-1 adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist"
CBR-001-573-804-2,RFM-002-602-8,CBR-001-573-804-2,O=C1NNC(=C(C1)C)c1scc(c1)n1cncc1,"CBR-HVAC-03194: Antiplatelet Therapy;Hypertension, Treatment of;Vasodilators; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 3 Inhibitor; Alpha adrenoreceptor antagonist; Platelet aggregation inhibitor"
CBR-001-573-805-3,RFM-002-603-9,CBR-001-573-805-3,COC(=O)C1CCN(CC1)c1nc(N)c2c(n1)cc(c(c2)OC)OC,analog of CBR-HVAC-08132
CBR-001-573-806-4,RFM-002-604-0,CBR-001-573-806-4,CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)O)C,CBR-HVAC-02146: ; Protease Inhibitor; HIV protease inhibitor
CBR-001-573-807-5,RFM-002-605-1,CBR-001-573-807-5,CCCCC([C@@]1(O)CC[C@H]2[C@H](O1)CC(=O)[C@H]2CCCCCCC(=O)O)(F)F,"CBR-HVAC-14277: Chloride channel protein 2 Activator; Chloride channel-2 agonist; Chloride-channel-agonists; ClC-2 Channel Activators; Chloride channel activator; Constipation, Agents for; Digestive System Disorders; Irritable Bowel Syndrome, Agents for; Laxative"
CBR-001-573-808-6,RFM-002-606-2,CBR-001-573-808-6,COc1cc(cc(c1OC)OC)C(=O)NCc1ccc(cc1)OCCN(C)C,"CBR-HVAC-05668: Nausea and Vomiting, Treatment of; Dopamine receptor D2 Inhibitor;"
CBR-001-573-809-7,RFM-002-607-3,CBR-001-573-809-7,O=C(Nc1c(C)cccc1C)NC1=CCCN1C,"CBR-HVAC-05582: Muscle Spasms, Drugs for; Dopamine receptor agonist"
CBR-001-573-810-0,RFM-002-608-4,CBR-001-573-810-0,NC(=O)c1c(O)nc[nH]1,CBR-HVAC-02936: INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE Inhibitor; ANTI-CANCER; Oncolytic Drugs
CBR-001-573-811-1,RFM-002-609-5,CBR-001-573-811-1,NCC1(C)Cc2c(C1)cccc2,CBR-HVAC-03984: Antidepressants; alpha2-Adrenoceptor Antagonists;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators; Alpha 2 adrenoreceptor antagonist; Adrenergic transmitter uptake inhibitor
CBR-001-573-812-2,RFM-002-610-8,CBR-001-573-812-2,OC(=O)c1ccccc1NCCc1ccccc1,"CBR-HVAC-01942: Inflammation, Treatment ofCyclooxygenase inhibitor; Prostaglandin receptor antagonist"
CBR-001-573-813-3,RFM-002-611-9,CBR-001-573-813-3,CCN(C(=O)CSc1ccc(nn1)Cl)CC,CBR-HVAC-09411:
CBR-001-573-814-4,RFM-002-612-0,CBR-001-573-814-4,C=CCN1Cc2ccccc2c2c(C1)cccc2,CBR-HVAC-09743: ; Alpha-1 adrenergic receptor Antagonist;
CBR-001-573-815-5,RFM-002-613-1,CBR-001-573-815-5,NC(=N)NCC1COc2c(O1)cccc2,CBR-HVAC-09792:
CBR-001-573-816-6,RFM-002-614-2,CBR-001-573-816-6,Oc1ccc(cc1)C1CNCCc2c1cc(O)c(c2Cl)O,"CBR-HVAC-02987: Renal Failure, Agents for;Hypertension, Treatment of; Dopamine D1 Agonists;Signal Transduction Modulators; Dopamine receptor D1 Agonist; Dopamine D1 receptor agonist"
CBR-001-573-817-7,RFM-002-615-3,CBR-001-573-817-7,O=C(C(Oc1ccccc1)(C)C)OCCN1CCOCC1,CBR-HVAC-08619:
CBR-001-573-818-8,RFM-002-616-4,CBR-001-573-818-8,CC(c1ccccc1)NC(=O)C1CSCN1C(=O)c1ccccc1,CBR-HVAC-03459: Oncolytic Drugs;ImmunostimulantsImmunostimulant
CBR-001-573-819-9,RFM-002-617-5,CBR-001-573-819-9,c1ccc(cn1)CSc1nc(c([nH]1)c1ccccc1)c1ccccc1,analog of CBR-HVAC-07616
CBR-001-573-820-2,RFM-002-618-6,CBR-001-573-820-2,c1cnc2c(c1)CNC2,CBR-HVAC-09486:
CBR-001-573-821-3,RFM-002-619-7,CBR-001-573-821-3,Brc1ccc(cc1)NC1C2CC3CC1CC(C2)C3,CBR-HVAC-05077: Anxiolytics;CNS Stimulants;Immunostimulants
CBR-001-573-822-4,RFM-002-620-0,CBR-001-573-822-4,[O-][n+]1cc[n+](c2c1cccc2)[O-],CBR-HVAC-08735:
CBR-001-573-823-5,RFM-002-621-1,CBR-001-573-823-5,COc1ccc2c(c1)c(c[nH]2)C1=CCNCC1,CBR-HVAC-02897: Antidepressants; Signal Transduction Modulators;5-HT1A Receptor Agonists;5-HT1B Agonists; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 1A receptor Agonist; 5 Hydroxytryptamine 1 receptor agonist
CBR-001-573-824-6,RFM-002-622-2,CBR-001-573-824-6,O=C1CC=C(NN1C)C(=O)N,CBR-HVAC-08894
CBR-001-573-825-7,RFM-002-623-3,CBR-001-573-825-7,OC(=O)C[C@@H]1NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC1=O)Cc1c[nH]c3c1cccc3)CCC2)C(=O)N,"CBR-HVAC-01888: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Coagulation Disorders Therapy;Acute Myocardial Infarction, Treatment of;Hematopoiesis Disorders Therapy;Restenosis Treatment of;Antiplatelet Therapy; Inhibitors of Blood Coagulation Pathways;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Signal Transduction Modulators; Integrin alpha3b beta3 Antagonist; GPIIb IIIa receptor antagonist; Platelet aggregation inhibitor"
CBR-001-573-826-8,RFM-002-624-4,CBR-001-573-826-8,CO[C@H]1/C=C\O[C@@]2(C)Oc3c(C2=O)c2C4=NC5(NC4=C(C(=O)c2c(c3C)O)NC(=O)/C(=C\C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)/C)CCN(CC5)CC(C)C,CBR-HVAC-01793: Treatment of Tuberculosis;Antimycobacterial Agents; DNA-Directed RNA Polymerase Inhibitors; DNA-dependent RNA polymerase beta Inhibitor; DNA directed RNA polymerase inhibitor
CBR-001-573-827-9,RFM-002-625-5,CBR-001-573-827-9,Cn1ncc(c1)CCN1CCN(CC1)c1ccccc1Cl,CBR-HVAC-08900:
CBR-001-573-828-0,RFM-002-626-6,CBR-001-573-828-0,Cc1ccc(c(c1)C)Nc1ncccc1C(=O)O,analog of CBR-HVAC-08763
CBR-001-573-829-1,RFM-002-627-7,CBR-001-573-829-1,CN1CCC2(CC1)CC(NC(=O)Nc1cccc3c1cccc3)c1c(O2)cccc1,analog of CBR-HVAC-11632
CBR-001-573-830-4,RFM-002-628-8,CBR-001-573-830-4,CCN(c1ccc(cc1NC1=Nc2c3c1cccc3ccc2)S(=O)(=O)N1CCOCC1)CC,analog of CBR-HVAC-10413
CBR-001-573-831-5,RFM-002-629-9,CBR-001-573-831-5,O=C(NC1CC1)/C=C/c1cccc(c1)F,CBR-HVAC-07644: Antiepileptic Drugs;Smooth Muscle RelaxantsDopamine receptor agonist
CBR-001-573-832-6,RFM-002-630-2,CBR-001-573-832-6,O=C(C(Oc1ccc(cc1)Cl)(C)C)N1CSCC1C(=O)O,"CBR-HVAC-05580: Lipoprotein Disorders, Treatment of ;Treatment of Disorders of Purine and Pyrimidine MetabolismLipase clearing factor stimulant; Cholesterol inhibitor"
CBR-001-573-833-7,RFM-002-631-3,CBR-001-573-833-7,NC(=O)NCCN1CCN(CC1)c1cccc(c1)C(F)(F)F,CBR-HVAC-07836: Unidentified pharmacological activity
CBR-001-573-834-8,RFM-002-632-4,CBR-001-573-834-8,O=C1COc2c(N1)ccc(c2)C(=O)N1CCN(CC1)C(=O)c1ccc(cc1)Cl,analog of CBR-HVAC-05063
CBR-001-573-835-9,RFM-002-633-5,CBR-001-573-835-9,Cc1onc(n1)Cn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-02982: Antitussives;BronchodilatorsUnidentified pharmacological activity
CBR-001-573-836-0,RFM-002-634-6,CBR-001-573-836-0,Cn1c(=O)n(CC(=C)C)c(cc1=O)N,CBR-HVAC-09398:
CBR-001-573-837-1,RFM-002-635-7,CBR-001-573-837-1,COC(=O)C(NC(=O)Cc1c2cc(OC)ccc2n(c1C)C(=O)c1ccc(cc1)Cl)C,analog of CBR-HVAC-08756
CBR-001-573-838-2,RFM-002-636-8,CBR-001-573-838-2,C[C@@H]1NC(=O)CO[C@H]1c1ccccc1,CBR-HVAC-09047:
CBR-001-573-839-3,RFM-002-637-9,CBR-001-573-839-3,FC(c1cccc(c1)C1CNCCO1)(F)F,CBR-HVAC-05577: Non-Opioid Analgesics
CBR-001-573-840-6,RFM-002-638-0,CBR-001-573-840-6,O=C(C(C)(C)C)NCCCC(=O)O,CBR-HVAC-02112: Anxiolytics;Antidepressants; CRF Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing factor antagonist
CBR-001-573-841-7,RFM-002-639-1,CBR-001-573-841-7,NCCCC(C(=O)O)(C(F)F)N,"CBR-HVAC-02304: Adenomatous Polyposis Therapy;Antitrypanosomals;Colorectal Cancer Therapy;Excessive Facial Hair in Women, Treatment of;Esophageal Diseases, Treatment of;Skin Cancer Therapy;Bladder Cancer Therapy ;Chemopreventive Agents;Astrocytoma Therapy;Neurologic Cancer Therapy;Gastric Cancer Therapy; Ornithine Decarboxylase Inhibitors; Ornithine decarboxylase Inhibitor; Ornithine decarboxylase inhibitor"
CBR-001-573-842-8,RFM-002-640-4,CBR-001-573-842-8,CCCCNC(=O)c1ccc(cc1O)Cl,CBR-HVAC-09003:
CBR-001-573-843-9,RFM-002-641-5,CBR-001-573-843-9,O=C1NCCNC1c1cccs1,"CBR-HVAC-10386: Cognition Disorders, Treatment of;Diabetic Retinopathy, Agents for; AGE Inhibitors (Maillard's Reaction Inhibitors);"
CBR-001-573-844-0,RFM-002-642-6,CBR-001-573-844-0,Clc1ccc(cc1)C(c1ccccc1)N1CCN(CC1)Cc1cccc(c1)C,"CBR-HVAC-03139: Smoking Cessation, Aid to;Nausea and Vomiting, Treatment of; Constitutive Androstane Receptor (CAR) Agonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist;"
CBR-001-573-845-1,RFM-002-643-7,CBR-001-573-845-1,CCN(CCOC(=O)c1ccc(cc1Cl)N)CC,CBR-HVAC-05679: Analgesic Drugs; Sodium channel; Ionotropic glutamate receptor NMDA; Nicotinic acetylcholine receptor Antagonist; Blocker;
CBR-001-573-846-2,RFM-002-644-8,CBR-001-573-846-2,Cc1ccc(cc1)C(=O)OCCn1cncc1,analog of CBR-HVAC-11994
CBR-001-573-847-3,RFM-002-645-9,CBR-001-573-847-3,CCN(CCNC(=O)c1ccccc1O)CC,CBR-HVAC-09883:
CBR-001-573-848-4,RFM-002-646-0,CBR-001-573-848-4,OC(COc1ccccc1C(C)(C)C)CNC(C)C,analog of CBR-HVAC-08943
CBR-001-573-849-5,RFM-002-647-1,CBR-001-573-849-5,FC(c1ccc(cc1)C1=CCNCC1)(F)F,analog of CBR-HVAC-07666
CBR-001-573-850-8,RFM-002-648-2,CBR-001-573-850-8,OC(c1ccccc1)COC(=O)N,CBR-HVAC-10316:
CBR-001-573-851-9,RFM-002-649-3,CBR-001-573-851-9,O=S(=O)(c1cccc2c1ccnc2)N1CCNCCC1,"CBR-HVAC-02247: Cerebrovascular Diseases, Treatment of;Angina pectoris, Treatment of;Antiparkinsonian Drugs;Pulmonary Hypertension, Treatment of;Stroke, Treatment of;Vasodilators; Calcium Sensitizers;Rho Kinase Inhibitors;Signal Transduction Modulators; Rho kinase Inhibitor; Rho-associated kinase inhibitor; Protein kinase inhibitor"
CBR-001-573-852-0,RFM-002-650-6,CBR-001-573-852-0,CC(c1ccc(cc1)C(=O)NCCOc1ccc(cc1)C(=O)O)C,"CBR-HVAC-03688: Lipoprotein Disorders, Treatment of Cholesterol inhibitor"
CBR-001-573-853-1,RFM-002-651-7,CBR-001-573-853-1,CCCCCNCC(=O)N,"CBR-HVAC-02945: Antiepileptic Drugs;Cognition Disorders, Treatment of;Antidepressants;Antiparkinsonian Drugs; Monoamine oxidase B Inhibitor; Glycine NMDA associated agonist; Monoamine oxidase B inhibitor"
CBR-001-573-854-2,RFM-002-652-8,CBR-001-573-854-2,CC(Cc1ccc(cc1)O)N,CBR-HVAC-09604:
CBR-001-573-855-3,RFM-002-653-9,CBR-001-573-855-3,Cc1nccn1Cc1ccccn1,"CBR-HVAC-05175: Alzheimer's Dementia, Treatment of Unidentified pharmacological activity"
CBR-001-573-856-4,RFM-002-654-0,CBR-001-573-856-4,CC(Cc1ccc(cc1)C(C(=O)OCc1ccccn1)C)C,CBR-HVAC-02144: Topical Antiinflammatory Agents; Cyclooxygenase-3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-573-857-5,RFM-002-655-1,CBR-001-573-857-5,NCC1CN(C(=O)C1)Cc1ccccc1,"CBR-HVAC-02726: Alzheimer's Dementia, Treatment of ; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Agonist; Muscarinic M1 receptor agonist"
CBR-001-573-858-6,RFM-002-656-2,CBR-001-573-858-6,OC(=O)c1ccc(cn1)Cc1ccccc1,analog of CBR-HVAC-08202: (picotrin diolamine)
CBR-001-573-859-7,RFM-002-657-3,CBR-001-573-859-7,CCC1(CC)C(=O)NC(=O)N(C1=O)C,CBR-HVAC-09618:
CBR-001-573-860-0,RFM-002-658-4,CBR-001-573-860-0,NCC1(CCC(C1)C)CC(=O)O,CBR-HVAC-14262
CBR-001-573-861-1,RFM-002-659-5,CBR-001-573-861-1,CNC(=O)c1ccc2c(c1)S(=O)(=O)c1c(C2=O)cccc1,CBR-HVAC-07583: Monoamine oxidase A inhibitor
CBR-001-573-862-2,RFM-002-660-8,CBR-001-573-862-2,O=C(c1ccc2c(c1)OCCCO2)Nc1c(C)noc1C,analog of CBR-HVAC-11126
CBR-001-573-863-3,RFM-002-661-9,CBR-001-573-863-3,O=C(Cc1ccccc1)NC1CCC(=O)NC1=O,CBR-HVAC-00630: Non-Small Cell Lung Cancer Therapy;Astrocytoma Therapy;Digestive/Gastrointestinal Cancer Therapy;Head and Neck Cancer Therapy;Brain Cancer Therapy;Breast Cancer Therapy;Lymphoma Therapy;Non-Hodgkin's Lymphoma Therapy;Melanoma Therapy;Endocrine Cancer Therapy;Neurologic Cancer Therapy;Multiple Myeloma Therapy;Colorectal Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Prostate Cancer Therapy;Skin Cancer Therapy;Cancer of Unspecified Body Location/System;Lung Cancer Therapy;Pancreatic Cancer Therapy; Apoptosis Inducers; DNA inhibitor
CBR-001-573-864-4,RFM-002-662-0,CBR-001-573-864-4,O=C(NCc1ccc(cc1)C(=O)O)NC[C@@H]1OCCN(C1)Cc1ccc(c(c1)Cl)Cl,analog of CBR-HVAC-05703
CBR-001-573-865-5,RFM-002-663-1,CBR-001-573-865-5,COc1cc(/C=C\c2ccc(c(c2OP(=O)([O-])[O-])OP(=O)([O-])[O-])OC)cc(c1OC)OC,CBR-HVAC-00266: Solid Tumors Therapy;Liver Cancer Therapy;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy; Vascular Disrupting Agents (VDA); TUBULIN Inhibitor; Angiogenesis inhibitor; Tubulin inhibitor
CBR-001-573-866-6,RFM-002-664-2,CBR-001-573-866-6,CCCCCCCC(=O)c1ccc(c(c1)C(=O)O)O,CBR-HVAC-06560: Acne Therapy
CBR-001-573-867-7,RFM-002-665-3,CBR-001-573-867-7,COc1cc(ccc1OC)C(=O)N1CCCc2c1ccc(c2)c1[nH][nH]c(=O)sc1C,CBR-HVAC-03831: Calcium channel agonist; Phosphodiesterase 3 Inhibitor; Phosphodiesterase 3 inhibitor; Phosphodiesterase PDE3 Inhibitors; Phosphoric-diester-hydrolase-inhibitors; Signal Transduction Modulators; Antiplatelet Therapy; Calcium sensitiser; Heart Failure; Heart Failure Therapy; Phosphodiesterase 3 inhibitor; Vasodilators
CBR-001-573-868-8,RFM-002-666-4,CBR-001-573-868-8,Oc1ccc(c(c1)C[C@]1(C)[C@@H](C)CC[C@]2([C@H]1CCC=C2C)C)O,CBR-HVAC-03274: Antiviral Drugs;Anti-HIV Agents;Oncolytic Drugs; Reverse transcriptase Inhibitor; Protein synthesis inhibitor;2018-01-24: ARB# 18-000002
CBR-001-573-869-9,RFM-002-667-5,CBR-001-573-869-9,CCCCN1C(=S)N(C(=O)C1=O)CCCC,CBR-HVAC-10953:
CBR-001-573-870-2,RFM-002-668-6,CBR-001-573-870-2,CC[C@@H]([C@@H](C(=O)N1CSCC1)N)C,"CBR-HVAC-05203: Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Insulin Secretagogues;Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue; Protease/peptidase inhibitor; Dipeptide hydrolase inhibitor"
CBR-001-573-871-3,RFM-002-669-7,CBR-001-573-871-3,O=C(N([C@@H]1CC[C@@]2(C[C@H]1N1CCCC1)CCCO2)C)Cc1ccccc1,CBR-HVAC-14268: analog of CBR-HVAC-03297
CBR-001-573-872-4,RFM-002-670-0,CBR-001-573-872-4,CCOC(=O)Nc1ccc(cc1)SCC1CO[C@](O1)(Cn1cncc1)c1ccc(cc1Cl)Cl,CBR-HVAC-02498: Treatment of Protozoal Diseases;Oncolytic Drugs; Microtubule Inhibitor; Microtubule inhibitor
CBR-001-573-873-5,RFM-002-671-1,CBR-001-573-873-5,c1ccc(cc1)C(c1ccccc1)N1CCN(CC1)CCCC1(OCCO1)c1ccccc1,"CBR-HVAC-03495: Migraine, Prophylactic Treatment of;Antimigraine Drugs; Calcium Channel Blockers;Signal Transduction Modulators;5-HT2 Antagonists; Calcium channel; 5-Hydroxytryptamine 2 receptor Antagonist; Blocker; 5 Hydroxytryptamine 2 receptor antagonist; Calcium channel antagonist"
CBR-001-573-874-6,RFM-002-672-2,CBR-001-573-874-6,OC1CCCc2c1c(N)c1c(n2)cccc1,"CBR-HVAC-03765: Cognition Disorders, Treatment of; Acetylcholinesterase (AChE) Inhibitors;Butyrylcholinesterase Inhibitors; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor"
CBR-001-573-875-7,RFM-002-673-3,CBR-001-573-875-7,Nc1on[n+](n1)c1ccc(c(c1)Cl)Cl,CBR-HVAC-11249:
CBR-001-573-876-8,RFM-002-674-4,CBR-001-573-876-8,CC(C(=O)c1ccc(c(c1)O)O)C,CBR-HVAC-05804: ; COMT Inhibitors;
CBR-001-573-877-9,RFM-002-675-5,CBR-001-573-877-9,CC(N1CCC(CC1)N(c1ccc(cc1)Cl)C(=O)Cc1ccccc1)C,CBR-HVAC-01537: Antiarrhythmic Drugs; Sodium channel Blocker; Sodium channel antagonist
CBR-001-573-878-0,RFM-002-676-6,CBR-001-573-878-0,O=C1NC2=Nc3c(CN2[C@@H]1C)c(Cl)ccc3,CBR-HVAC-01042: Phosphodiesterase 3 Inhibitor; Phosphodiesterase inhibitor
CBR-001-573-879-1,RFM-002-677-7,CBR-001-573-879-1,Cc1occc(=O)c1O[V](=O)Oc1c(=O)ccoc1C,CBR-HVAC-04960: Wound-Healing Agents;Antidiabetic Drugs; Protein tyrosine phosphatase Inhibitor;
CBR-001-573-880-4,RFM-002-678-8,CBR-001-573-880-4,CC(Nc1cccnc1N1CCN(CC1)C(=O)c1cc2c([nH]1)ccc(c2)O)C,analog of CBR-HVAC-04198
CBR-001-573-881-5,RFM-002-679-9,CBR-001-573-881-5,Cc1c(C)c2OC(C)(CCc2c(c1O)C)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1,"CBR-HVAC-10812: Stroke, Treatment of; Lipid Peroxidation Inhibitors;"
CBR-001-573-882-6,RFM-002-680-2,CBR-001-573-882-6,CN1CCN(CC1)C1=Nc2cc(F)ccc2Cc2c1cccc2,CBR-HVAC-01121: ; Muscarinic acetylcholine receptor M1 Agonist; Alpha 1 adrenoreceptor antagonist
CBR-001-573-883-7,RFM-002-681-3,CBR-001-573-883-7,O=C(c1ccccc1)OC(COc1cccc2c1cc([nH]2)C)CNC(C)(C)C,"CBR-HVAC-01587: Hypertension, Treatment of; beta1-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Blocker; Adrenoreceptor agonist; Reducing agent; Beta 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor antagonist"
CBR-001-573-884-8,RFM-002-682-4,CBR-001-573-884-8,O=NSC[C@H](C(=O)N1CCC[C@H]1C(=O)O)C,"CBR-HVAC-10799: Vasodilators;Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors;Nitric Oxide (NO) Donors;Protein Tyrosine Phosphatase PTP-1B Inhibitors;Signal Transduction Modulators; Angiotensin converting enzyme Inhibitor;"
CBR-001-573-885-9,RFM-002-683-5,CBR-001-573-885-9,CN1CCN(CC1)C1=Nc2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-05129: Antipsychotic Drugs; Dopamine receptor D2 Blocker;
CBR-001-573-886-0,RFM-002-684-6,CBR-001-573-886-0,NC(c1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)Cl,CBR-HVAC-02052: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-887-1,RFM-002-685-7,CBR-001-573-887-1,Oc1nc2c(nc1O)cc(c(c2[N+](=O)[O-])Cl)Cl,"CBR-HVAC-04534: Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; Glycine NMDA associated antagonist"
CBR-001-573-888-2,RFM-002-686-8,CBR-001-573-888-2,CC(C[C@@H](C(=O)O)N[C@H](C(=O)O)Cc1cncn1Cc1cc(Cl)cc(c1)Cl)C,"CBR-HVAC-05450: Antidiabetic Drugs;Inflammatory Bowel Disease, Agents for;Antiobesity Drugs; Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Inhibitors; Angiotensin I converting enzyme 2 Inhibitor; ACE-related carboxypeptidase inhibitor; Serine carboxypeptidase inhibitor"
CBR-001-573-889-3,RFM-002-687-9,CBR-001-573-889-3,OC(=O)CCCCO/N=C(\c1cccc(c1)C(F)(F)F)/c1cccnc1,"CBR-HVAC-03589: Hypertension, Treatment of;Inflammatory Bowel Disease, Agents for; Prostanoid TP Antagonists;Signal Transduction Modulators;Thromboxane Synthase Inhibitors; Thromboxane A synthase; Thromboxane A2 receptor Antagonist; Inhibitor; Thromboxane synthase inhibitor; Thromboxane A2 receptor antagonist; Prostaglandin receptor antagonist; TP receptor antagonist"
CBR-001-573-890-6,RFM-002-688-0,CBR-001-573-890-6,CC(C(OC(=O)N)C)C(OC(=O)N)C,CBR-HVAC-08961:
CBR-001-573-891-7,RFM-002-689-1,CBR-001-573-891-7,Fc1ccc(c2c1OC1CNCC1O2)F,analog of CBR-HVAC-03351
CBR-001-573-892-8,RFM-002-690-4,CBR-001-573-892-8,Cc1cccc(c1)COC(=O)N(C)C,analog of CBR-HVAC-08589
CBR-001-573-893-9,RFM-002-691-5,CBR-001-573-893-9,NC(=O)OCCn1c(C)ncc1[N+](=O)[O-],CBR-HVAC-08810:
CBR-001-573-894-0,RFM-002-692-6,CBR-001-573-894-0,Clc1cncc(n1)C1CN2CCC1CC2,"CBR-HVAC-10815: Cognition Disorders, Treatment of; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1 Agonist;"
CBR-001-573-895-1,RFM-002-693-7,CBR-001-573-895-1,Cc1ccc(c(c1)C)CNC1CCCCC1,analog of CBR-HVAC-08471
CBR-001-573-896-2,RFM-002-694-8,CBR-001-573-896-2,CCC1(CC)C(=O)NC(=S)NC1=O,CBR-HVAC-09225:
CBR-001-573-897-3,RFM-002-695-9,CBR-001-573-897-3,NC(=O)CN1Cc2ccccc2OC1=O,CBR-HVAC-02529: Monoamine oxidase inhibitor
CBR-001-573-898-4,RFM-002-696-0,CBR-001-573-898-4,CN(C(CNc1c(C)cccc1C)C)C,CBR-HVAC-07888: Unidentified pharmacological activity
CBR-001-573-899-5,RFM-002-697-1,CBR-001-573-899-5,CCCCCCC1(CO1)C(=O)OC,analog of CBR-HVAC-08828
CBR-001-573-900-1,RFM-002-698-2,CBR-001-573-900-1,OC[C@H](NCc1ccc2c(c1)c1ccccc1n2CC)C,analog of CBR-HVAC-04247
CBR-001-573-901-2,RFM-002-699-3,CBR-001-573-901-2,NC(=O)CN1C=CCC(=C1)C(=O)N,CBR-HVAC-06271: Liver Cancer Therapy;Pharmaceutical Aids
CBR-001-573-902-3,RFM-002-700-9,CBR-001-573-902-3,CCc1[nH]c(nc1C(=O)c1ccncc1)O,CBR-HVAC-01053: Heart Failure Therapy; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 3 Inhibitor; Phosphodiesterase 3 inhibitor
CBR-001-573-903-4,RFM-002-701-0,CBR-001-573-903-4,Cc1ncccc1OCC1CCCN1,"CBR-HVAC-04818: Antipsychotic Drugs;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Alzheimer's Dementia, Treatment of ; Nicotinic Receptor Partial Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha4; Nicotinic acetylcholine receptor beta2 Partial Agonist; Neuronal nicotinic receptor antagonist; Neuronal nicotinic receptor agonist"
CBR-001-573-904-5,RFM-002-702-1,CBR-001-573-904-5,O=C1NC(=O)C(C1)c1cccc(c1)Br,CBR-HVAC-01210: Glycine NMDA associated antagonist
CBR-001-573-905-6,RFM-002-703-2,CBR-001-573-905-6,Cc1cccc(n1)C(=O)Nc1nnn[nH]1,CBR-HVAC-02937: Antiallergy/Antiasthmatic Drugs; Mediator Release Inhibitors; 5 Hydroxytryptamine release inhibitor; Histamine receptor antagonist
CBR-001-573-906-7,RFM-002-704-3,CBR-001-573-906-7,NS(=O)(=O)NCc1csc2c1cccc2,CBR-HVAC-00397: Antiepileptic Drugs; CARBONIC ANHYDRASE 2 Inhibitor; Unidentified pharmacological activity
CBR-001-573-907-8,RFM-002-705-4,CBR-001-573-907-8,CCOC(=O)c1ccccc1OC(=O)N,CBR-HVAC-03821:
CBR-001-573-908-9,RFM-002-706-5,CBR-001-573-908-9,Clc1ccc(cn1)OCC1CCN1,"CBR-HVAC-11007: Neuropathic Pain, Treatment of;Non-Opioid Analgesics; Nicotinic Receptor Agonists;Signal Transduction Modulators; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA4BETA2 Agonist;"
CBR-001-573-909-0,RFM-002-707-6,CBR-001-573-909-0,CS(=O)(=O)OCOS(=O)(=O)C,CBR-HVAC-11333:
CBR-001-573-910-3,RFM-002-708-7,CBR-001-573-910-3,CO[C@@H]1C[C@H]2[C@@H](C1)CC(=O)C2,analog of CBR-HVAC-03319
CBR-001-573-911-4,RFM-002-709-8,CBR-001-573-911-4,O=c1ccc2c(o1)c1c(C)coc1cc2,analog of CBR-HVAC-08177
CBR-001-573-912-5,RFM-002-710-1,CBR-001-573-912-5,NC(=O)OCC(Cl)(Cl)Cl,CBR-HVAC-09919:
CBR-001-573-913-6,RFM-002-711-2,CBR-001-573-913-6,SCC(C(=O)O)NC(=N)N,CBR-HVAC-03493: Expectorants;Mucolytics
CBR-001-573-914-7,RFM-002-712-3,CBR-001-573-914-7,COC(=O)CCNC(=O)C1CSC(N1)C,CBR-HVAC-09389:
CBR-001-573-915-8,RFM-002-713-4,CBR-001-573-915-8,N#Cc1c(N)[nH]c(c1C)c1ccccc1F,"CBR-HVAC-04903: Urinary Incontinence Therapy; Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators; Potassium channel Activator; Calcium-activated potassium channel agonist"
CBR-001-573-916-9,RFM-002-714-5,CBR-001-573-916-9,CCc1cc(nc(n1)N)N1CCC(C1)N,analog of CBR-HVAC-06940 (JNJ-39758979)
CBR-001-573-917-0,RFM-002-715-6,CBR-001-573-917-0,c1ccc(cn1)N1CCC2(C1)CCCN2,CBR-HVAC-02694: ; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 4 BETA 2 Partial Agonist; Neuronal nicotinic receptor antagonist
CBR-001-573-918-1,RFM-002-716-7,CBR-001-573-918-1,CNC(=O)ON(C(=O)NC)C(=O)C,CBR-HVAC-03042: Oncolytic Drugs; Antimetabolites; Acetylcholinesterase Inhibitor; Ribonucleoside triphosphate reductase inhibitor
CBR-001-573-919-2,RFM-002-717-8,CBR-001-573-919-2,CC(Cc1c[nH]c(c1)C(=O)O)C,analog of CBR-HVAC-03980
CBR-001-573-920-5,RFM-002-718-9,CBR-001-573-920-5,COc1cccc(c1)C1CC1CNC(=O)C,analog of CBR-HVAC-07542
CBR-001-573-921-6,RFM-002-719-0,CBR-001-573-921-6,ClC(C(=O)N(c1ccc(cc1)O)C)Cl,CBR-HVAC-09780:
CBR-001-573-922-7,RFM-002-720-3,CBR-001-573-922-7,Nc1cc2ccccc2nc1C(O)(C)C,analog of CBR-HVAC-07380
CBR-001-573-923-8,RFM-002-721-4,CBR-001-573-923-8,Clc1cccc(c1)Nc1ccncc1,"CBR-HVAC-09197: Cognition Disorders, Treatment of; Alpha-2 adrenergic receptor Antagonist;"
CBR-001-573-924-9,RFM-002-722-5,CBR-001-573-924-9,CN(c1nc(C)c(nc1C)C)C,CBR-HVAC-08880:
CBR-001-573-925-0,RFM-002-723-6,CBR-001-573-925-0,CCC1(C)OC(=O)N(C1=O)C,CBR-HVAC-09628:
CBR-001-573-926-1,RFM-002-724-7,CBR-001-573-926-1,COCc1ncc([n+](c1)[O-])C,"CBR-HVAC-03310: Lipoprotein Disorders, Treatment of Cholesterol inhibitor"
CBR-001-573-927-2,RFM-002-725-8,CBR-001-573-927-2,COc1c(ccc(c1OC)OC)CN1CCN(CC1)CC(=O)O,analog of CBR-HVAC-07958
CBR-001-573-928-3,RFM-002-726-9,CBR-001-573-928-3,OCc1ccccc1S(=O)(=O)O,monomer unit of the polymeric drug CBR-HVAC-10282
CBR-001-573-929-4,RFM-002-727-0,CBR-001-573-929-4,Fc1cccc(c1)c1nn(c(=S)n1C)C,"CBR-HVAC-03621: Antidepressants;Cognition Disorders, Treatment of; GABA(A) Receptor Agonists;Signal Transduction Modulators; GABA-A receptor Agonist; Adenosine A1 receptor antagonist"
CBR-001-573-930-7,RFM-002-728-1,CBR-001-573-930-7,CN1C(=O)CN(C1=N)c1ccccc1,CBR-HVAC-09412: Diuretics; MINERAL CORTICOID RECEPTOR Antagonist;
CBR-001-573-931-8,RFM-002-729-2,CBR-001-573-931-8,S=C1NCCC(O1)COc1ccccc1,CBR-HVAC-08602:
CBR-001-573-932-9,RFM-002-730-5,CBR-001-573-932-9,O=CNc1ncc(s1)[N+](=O)[O-],CBR-HVAC-10267:
CBR-001-573-933-0,RFM-002-731-6,CBR-001-573-933-0,Clc1ccc2c(c1)C(=O)N1C(O2)CCO1,CBR-HVAC-01102: Cyclooxygenase inhibitor
CBR-001-573-934-1,RFM-002-732-7,CBR-001-573-934-1,CCCCNC1CCc2c(C1)scn2,analog of CBR-HVAC-03697
CBR-001-573-935-2,RFM-002-733-8,CBR-001-573-935-2,[O-][N+](=O)C1C(=O)c2c(C1=O)ccc(c2)C,analog of CBR-HVAC-10042: (NIVIMEDONE)
CBR-001-573-936-3,RFM-002-734-9,CBR-001-573-936-3,ClCCOS(=O)(=O)CS(=O)(=O)C,CBR-HVAC-04542: Oncolytic DrugsDNA inhibitor
CBR-001-573-937-4,RFM-002-735-0,CBR-001-573-937-4,CCC(c1ccccc1)(CC(=O)N)O,CBR-HVAC-05189: Antiepileptic Drugs
CBR-001-573-938-5,RFM-002-736-1,CBR-001-573-938-5,C1CN=C(N1)Sc1c[nH]c2c1cccc2,CBR-HVAC-02093: Nasal DecongestantsAlpha adrenoreceptor agonist
CBR-001-573-939-6,RFM-002-737-2,CBR-001-573-939-6,NC(Cc1ccccc1)COC(=O)N,"CBR-HVAC-05009: Sleep Apnea, Treatment of;Antidepressants;Antinarcoleptic Drugs"
CBR-001-573-940-9,RFM-002-738-3,CBR-001-573-940-9,COc1cc(N)c(cc1C(=O)NCCCS(=O)(=O)Cc1ccccc1)Cl,analog of CBR-HVAC-11444
CBR-001-573-941-0,RFM-002-739-4,CBR-001-573-941-0,CN(C(=O)NC)N=O,CBR-HVAC-03895: Oncolytic Drugs; DNA-Damaging Drugs;
CBR-001-573-942-1,RFM-002-740-7,CBR-001-573-942-1,Nc1ccc(cc1)/C(=N\c1ccccc1)/N,analog of CBR-HVAC-05140
CBR-001-573-943-2,RFM-002-741-8,CBR-001-573-943-2,COc1ccc(cc1)/C=N/NC1=NCCN1,analog of CBR-HVAC-07914
CBR-001-573-944-3,RFM-002-742-9,CBR-001-573-944-3,O=C(c1cccs1)NCCS(=O)(=O)O,CBR-HVAC-04093: Mucolytics
CBR-001-573-945-4,RFM-002-743-0,CBR-001-573-945-4,COc1cc(CN2CCN(CC2)CC(=O)O)cc(c1OC)OC,analog of CBR-HVAC-04055
CBR-001-573-946-5,RFM-002-744-1,CBR-001-573-946-5,CN(CCc1cc2c([nH]1)cccc2)C,CBR-HVAC-09810: ; 5-Hydroxytryptamine receptor Agonist;
CBR-001-573-947-6,RFM-002-745-2,CBR-001-573-947-6,SCC(=O)NCC(=O)NCC(=O)O,analog of CBR-HVAC-08037
CBR-001-573-948-7,RFM-002-746-3,CBR-001-573-948-7,CSCc1cnc(c(c1CNCC)O)C,"CBR-HVAC-05803: Cognition Disorders, Treatment ofUnidentified pharmacological activity"
CBR-001-573-949-8,RFM-002-747-4,CBR-001-573-949-8,CC(c1ccc(cc1)Cl)(CC(O)(C)C)O,CBR-HVAC-08695:
CBR-001-573-950-1,RFM-002-748-5,CBR-001-573-950-1,Clc1cc(C=C2NCCN2)cc(c1N)Cl,CBR-HVAC-03531: Nasal Decongestants;
CBR-001-573-951-2,RFM-002-749-6,CBR-001-573-951-2,CNC(=S)C1(CCCS1)c1ccccn1,CBR-HVAC-05781: Gastric Antisecretory Drugs; H+/K+-ATPase Inhibitors; Gastrin inhibitor
CBR-001-573-952-3,RFM-002-750-9,CBR-001-573-952-3,Cc1cccc(c1C)C(c1c[nH]cn1)O,analog of CBR-HVAC-08064
CBR-001-573-953-4,RFM-002-751-0,CBR-001-573-953-4,CCc1c(C)c2n3c1C=C1C(=C(C4=[N+]1[Sn]13[N+]3=C(C(=C(C3=C2)CC)C)C=c2n1c(=C4)c(c2C)CCC(=O)O)CCC(=O)O)C,CBR-HVAC-05133: Decyclizing-heme-oxygenase-inhibitors; HEME OXYGENASE Inhibitor; Haem oxygenase 1 inhibitor; Heme Oxygenase (HO) Inhibitors; Heme oxygenase inhibitor; Liver Disorders; Metabolic Disorders; Treatment of Hyperbilirubinemia
CBR-001-573-954-5,RFM-002-752-1,CBR-001-573-954-5,NC(=O)Nc1ccc(cc1)[As](=O)(O)O,CBR-HVAC-09702:
CBR-001-573-955-6,RFM-002-753-2,CBR-001-573-955-6,CC(=O)Nc1ccc(cc1)OC(C)(C)C,CBR-HVAC-10200:
CBR-001-573-956-7,RFM-002-754-3,CBR-001-573-956-7,Clc1ccc2c(c1)C1N(CCc3c1cccc3)CC(=O)N2C,CBR-HVAC-08896:
CBR-001-573-957-8,RFM-002-755-4,CBR-001-573-957-8,OCC(=O)Nc1ccc(cc1)[As](=O)([O-])[O-],CBR-HVAC-10103: Antiamebic
CBR-001-573-958-9,RFM-002-756-5,CBR-001-573-958-9,CCN(CCOC(=O)c1cccnc1)CC,CBR-HVAC-09807:
CBR-001-573-959-0,RFM-002-757-6,CBR-001-573-959-0,N1C[C@@H]2C[C@H](C1)c1c2cc2c(c1)nccn2,"CBR-HVAC-05837: Treatment of Cocaine Dependency;Alzheimer's Dementia, Treatment of ;Antiparkinsonian Drugs;Antidepressants;Neurologic Drugs (Miscellaneous);Smoking Cessation, Aid to;Treatment of Alcohol Dependency;Treatment of Substance Dependency; Nicotinic alpha3beta4 Agonists;Nicotinic alpha4beta2 Partial Agonists;Nicotinic alpha6beta2 Partial Agonists;Nicotinic alpha7 Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha4beta2; Nicotinic acetylcholine receptor alpha7 Modulator;"
CBR-001-573-960-3,RFM-002-758-7,CBR-001-573-960-3,CCN(CC(=O)Nc1ccccc1Cl)CCN(CC)CC,CBR-HVAC-10114:
CBR-001-573-961-4,RFM-002-759-8,CBR-001-573-961-4,O/N=C(/c1ccc(c(c1)O)O)\N,CBR-HVAC-07454: Oncolytic Drugs; Ribonucleoside-Diphosphate Reductase Inhibitors; Ribonucleoside triphosphate reductase inhibitor
CBR-001-573-962-5,RFM-002-760-1,CBR-001-573-962-5,OC(=O)C1=Cc2cc(Cl)c(c(c2OC1C(F)(F)F)C)C,analog of CBR-HVAC-07129
CBR-001-573-963-6,RFM-002-761-2,CBR-001-573-963-6,CN1CCCC(=C(c2cccs2)c2cccs2)C1,CBR-HVAC-08620:
CBR-001-573-964-7,RFM-002-762-3,CBR-001-573-964-7,CC(=O)NC(=O)c1ccccc1O,CBR-HVAC-09882:
CBR-001-573-965-8,RFM-002-763-4,CBR-001-573-965-8,CN(CCN(c1ccccn1)Cc1ccccc1)C,CBR-HVAC-09676: ; Histamine H1 receptor Inhibitor;
CBR-001-573-966-9,RFM-002-764-5,CBR-001-573-966-9,C[C@@H]1CN(CCCn2c3ccccc3c3c2cccc3)C[C@@H](N1)C,CBR-HVAC-02902: Oncolytic Drugs;Antipsychotic Drugs; sigma Receptor Antagonists;Signal Transduction Modulators; Opioid receptor sigma-1 Antagonist; Sigma 1 receptor antagonist
CBR-001-573-967-0,RFM-002-765-6,CBR-001-573-967-0,O=C1C=CC2(C(=C1)CCC1C2C(O)CC2(C1CCC2=O)C)C,analog of CBR-HVAC-01357
CBR-001-573-968-1,RFM-002-766-7,CBR-001-573-968-1,C=CC1=C(C)C2=Cc3[nH]c(c(c3C)CCC(=O)O)C=C3N=C(C=c4[nH]c(=CC1=N2)c(C)c4C=C)C(=C3CCC(=O)O)C,CBR-HVAC-10271
CBR-001-573-969-2,RFM-002-767-8,CBR-001-573-969-2,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1,CBR-HVAC-03134: Antiparkinsonian Drugs; Anticholinergics;Signal Transduction Modulators; Dopamine transporter Inhibitor;
CBR-001-573-970-5,RFM-002-768-9,CBR-001-573-970-5,c1ccc2c(n1)c(ccc2)O[Ga](Oc1cccc2c1nccc2)Oc1cccc2c1nccc2,CBR-HVAC-04439: Oncolytic Drugs; DNA-Damaging Drugs; Ribonucleotide reductase Inhibitor;
CBR-001-573-971-6,RFM-002-769-0,CBR-001-573-971-6,NCCCC[C@@H](C(=O)Nc1ccc(cc1C)c1nc2c(s1)ccc(c2)F)N,CBR-HVAC-05433: DNA modulator; Cytochrome p450 1A1 modulator
CBR-001-573-972-7,RFM-002-770-3,CBR-001-573-972-7,NC(=NCCNS(=O)(=O)c1cccc2c1ccnc2)N,CBR-HVAC-09468: ; CALCIUM CHANNEL; MYOSIN LIGHT CHAIN KINASE; PROTEIN KINASE A; PROTEIN KINASE G Inhibitor; Inhibitor; Blocker; Inhibitor;
CBR-001-573-973-8,RFM-002-771-4,CBR-001-573-973-8,N#CC(=CC=Cc1ccc(c(c1)O)O)C(=O)NCc1ccccc1,CBR-HVAC-00124: ; BCR-ABL; JANUS KINASE 2 Inhibitor; Janus kinase 2 inhibitor; Bcr-Abl inhibitor; Apoptosis stimulant
CBR-001-573-974-9,RFM-002-772-5,CBR-001-573-974-9,CCn1cc(C(=O)O)c(=O)c2c1cc(Cl)cc2,analog of CBR-HVAC-08124
CBR-001-573-975-0,RFM-002-773-6,CBR-001-573-975-0,OC(c1ccccn1)(c1ccccn1)C1=CC(=C(c2ccccn2)c2ccccn2)C=C1,analog of CBR-HVAC-08732
CBR-001-573-976-1,RFM-002-774-7,CBR-001-573-976-1,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-])C)C,analog of CBR-HVAC-09603
CBR-001-573-977-2,RFM-002-775-8,CBR-001-573-977-2,Clc1ccc(cc1)Cc1[nH]c2c(n1)n(C)c(=O)n(c2=O)C,analog of CBR-HVAC-11798
CBR-001-573-978-3,RFM-002-776-9,CBR-001-573-978-3,COc1cccc2c1CC(N)CS2,analog of CBR-HVAC-03595
CBR-001-573-979-4,RFM-002-777-0,CBR-001-573-979-4,CCC(C(=O)NC(=O)NC(=O)C)(CC)Br,CBR-HVAC-09711:
CBR-001-573-980-7,RFM-002-778-1,CBR-001-573-980-7,O=NC(c1csc(n1)N)C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C=C,analog of CBR-HVAC-02051
CBR-001-573-981-8,RFM-002-779-2,CBR-001-573-981-8,CO[C@@]1(NC(=O)C2SC(=C(C(=O)O)C(=O)N)S2)C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C,CBR-HVAC-02231: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-982-9,RFM-002-780-5,CBR-001-573-982-9,CCC1NC(=O)c2c(N1)cc(c(c2)S(=O)(=O)N)Cl,"CBR-HVAC-03150: Diuretics;Hypertension, Treatment of; Sodium channel; Potassium channel Inhibitor; Inhibitor;"
CBR-001-573-983-0,RFM-002-781-6,CBR-001-573-983-0,CN1C(CSCC(F)(F)F)Nc2c(S1(=O)=O)cc(c(c2)Cl)S(=O)(=O)N,"CBR-HVAC-03149: Hypertension, Treatment of;Diuretics; Sodium chloride cotransporter Inhibitor;"
CBR-001-573-984-1,RFM-002-782-7,CBR-001-573-984-1,OCCN(c1c(I)c(C(=O)NCC(CO)O)c(c(c1I)C(=O)NCC(CO)O)I)C(=O)CO,CBR-HVAC-01970: Contrast MediaNot applicable
CBR-001-573-985-2,RFM-002-783-8,CBR-001-573-985-2,NCc1ccccc1CC(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1CC(=O)O,CBR-HVAC-02056: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-986-3,RFM-002-784-9,CBR-001-573-986-3,CCN(C(=O)N[C@@H]1CN(C)C2C(C1)c1cccc3c1c(C2)c[nH]3)CC,"CBR-HVAC-15119: 5-HT2A Receptor Antagonists; 5-HT2B Receptor Antagonists; Alpha 2 adrenoreceptor antagonist; Dopamine Autoreceptor Agonists; Dopamine D2 Receptor Partial Agonists; Dopamine D2 receptor agonist; Dopamine receptor Agonist; Dopamine-D2-receptor-agonists; Platelet aggregation inhibitor; Prolactin Secretion Inhibitors; Serotonin-2-receptor-agonists; Signal Transduction Modulators; Antischizophrenic; Connective Tissue Disorders; Endocrine Disorders; Fibromyalgia, Treatment of; Parkinson's Disease and Movement Disorders; Psychotic Disorders; Pulmonary Hypertension, Treatment of; Respiratory Tract Disorders; Rheumatic Disease; Scleroderma, Agents for; Treatment of Hyperprolactinemia"
CBR-001-573-987-4,RFM-002-785-0,CBR-001-573-987-4,O=C(c1cccnc1)OCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1,CBR-HVAC-01926: ; Plasminogen activator inhibitor Inhibitor; Vitamin B3 agonist
CBR-001-573-988-5,RFM-002-786-1,CBR-001-573-988-5,OC(=O)c1cc(N2CCCC2)c(c(c1)S(=O)(=O)N)Oc1ccccc1,CBR-HVAC-01914: Loop Diuretics; Carbonic anhydrase Inhibitor; Diuretic
CBR-001-573-989-6,RFM-002-787-2,CBR-001-573-989-6,O[C@@H](COc1ccccc1C1CCCC1)CNC(C)(C)C,"CBR-HVAC-02210: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Blocker; Beta 2 adrenoreceptor antagonist"
CBR-001-573-990-9,RFM-002-788-3,CBR-001-573-990-9,CC(OC(=O)c1ccccc1)CNC1CCCCC1,CBR-HVAC-09601: ; Sodium channel Inhibitor;
CBR-001-573-991-0,RFM-002-789-4,CBR-001-573-991-0,CCOC(=O)C1=Cc2cc(Cl)ccc2OC1C(F)(F)F,analog of CBR-HVAC-06142
CBR-001-573-992-1,RFM-002-790-7,CBR-001-573-992-1,CCCC(C1(CC)C(=O)NC(=NC1=O)[S-])C,CBR-HVAC-03083: Intravenous Anesthetics; GABA-A receptor Inhibitor;
CBR-001-573-993-2,RFM-002-791-8,CBR-001-573-993-2,OCCN1COc2c(C1=O)cccc2,analog of CBR-HVAC-04312
CBR-001-573-994-3,RFM-002-792-9,CBR-001-573-994-3,O=C(c1ccc(o1)Cl)N1CC2C(C1)CNC2,"CBR-HVAC-06867: Alzheimer's Dementia, Treatment of ;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Extrapyramidal Disorders, Treatment of; Nicotinic alpha4beta2 Agonists;Signal Transduction Modulators; Neuronal nicotinic receptor agonist; Alpha-4 nicotinic receptor agonist; Beta-2 nicotinic receptor agonist"
CBR-001-573-995-4,RFM-002-793-0,CBR-001-573-995-4,COc1cc2c(cc1OCCCN1CCCCC1)ncnc2N1CCN(CC1)C(=O)Nc1ccc(cc1)OC(C)C,CBR-HVAC-00360: Prostate Cancer Therapy;Brain Cancer Therapy;Renal Cancer Therapy;Myeloid Leukemia Therapy; Angiogenesis Inhibitors;Antimitotic Drugs;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators; FMS-related tyrosine kinase 3; PDGFR; KIT Inhibitor; Flt-3 kinase inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor
CBR-001-573-996-5,RFM-002-794-1,CBR-001-573-996-5,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)O[C@@H]1CCN(C1)Cc1ccccc1)C,CBR-HVAC-02375: ; Calcium channel Antagonist; Calcium channel antagonist
CBR-001-573-997-6,RFM-002-795-2,CBR-001-573-997-6,FC(c1ccc(nc1Cl)N1CCNCC1)(F)F,CBR-HVAC-11568: Antidepressants; Signal Transduction Modulators;5-HT2C Agonists; 5-Hydroxytryptamine 2C receptor Agonist;
CBR-001-573-998-7,RFM-002-796-3,CBR-001-573-998-7,CO/N=C(/c1csc(n1)N)\C(=O)N[C@H]1C2SCC=C(N2C1=O)C(=O)O,CBR-HVAC-02221: ; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-573-999-8,RFM-002-797-4,CBR-001-573-999-8,NC(=N)N/N=C/c1c(Cl)cccc1Cl,CBR-HVAC-01555: ; Alpha-2 adrenergic receptor Agonist; Alpha 2 adrenoreceptor agonist
CBR-001-574-000-8,RFM-002-798-5,CBR-001-574-000-8,Sc1nnc(s1)c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-10543: Cyclooxygenase (COX) Inhibitors;Lipoxygenase Inhibitors;Signal Transduction Modulators; COX; Lipoxygenase 5 Inhibitor;
CBR-001-574-001-9,RFM-002-799-6,CBR-001-574-001-9,S=C(NNC(=C)c1ccccn1)NNC(=S)Nc1ccccc1Cl,CBR-HVAC-04181: Antiviral Drugs; Ribonucleoside-Diphosphate Reductase Inhibitors; Ribonuclease inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-574-002-0,RFM-002-800-2,CBR-001-574-002-0,Oc1nc2c(n1C1CCN(CC1)C1CCOCC1)cc(c(c2)F)C,CBR-HVAC-14288
CBR-001-574-003-1,RFM-002-801-3,CBR-001-574-003-1,OC(=O)CC(C[N+](C)(C)C)OC(=O)C,"CBR-HVAC-02318: Disorders Associated with Cancer Therapy, Treatment of;Therapy of Inborn Errors of Metabolism;Psychiatric Disorders (Not Specified);Cerebrovascular Diseases, Treatment of;Alzheimer's Dementia, Treatment of ;Diabetic Neuropathy, Agents for;Treatment of Renal Diseases;Cancer Associated Disorders, Treatment of; Carnitine acetyltransferase Stimulator; Carnitine O-acetyltransferase stimulant"
CBR-001-574-004-2,RFM-002-802-4,CBR-001-574-004-2,COc1ccccc1N1CCN(CC1)CCCC(=O)c1ccc(cc1)F,CBR-HVAC-09824: ; Muscarinic acetylcholine receptor; Tryptamine receptor; Histamine H1 receptor; Dopamine receptor; Adrenergic receptor Antagonist;
CBR-001-574-005-3,RFM-002-803-5,CBR-001-574-005-3,CN(C(=O)NC(C(C(C(CO)O)O)O)C=O)N=O,CBR-HVAC-08377: DNA inhibitor; DNA synthesis inhibitor
CBR-001-574-006-4,RFM-002-804-6,CBR-001-574-006-4,Clc1ccc(c(c1)Cl)Oc1cc2ccccc2oc1=O,analog of CBR-HVAC-11653
CBR-001-574-007-5,RFM-002-805-7,CBR-001-574-007-5,CCCCNc1ccc(c(c1)O)C(=O)OCC[NH+](CC)CC,analog of CBR-HVAC-09889
CBR-001-574-008-6,RFM-002-806-8,CBR-001-574-008-6,Nc1nc(c(s1)c1ccccc1)N,CBR-HVAC-09397:
CBR-001-574-009-7,RFM-002-807-9,CBR-001-574-009-7,CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,CBR-HVAC-01323: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-574-010-0,RFM-002-808-0,CBR-001-574-010-0,CC(CC(C(=O)NC(C(=O)O)Cc1c[nH]c2c1cccc2)N)C,analog of CBR-HVAC-08591 (BNC-210)
CBR-001-574-011-1,RFM-002-809-1,CBR-001-574-011-1,Cc1cc(nn2c1nnc2)N1CCCCC1,CBR-HVAC-02481: BronchodilatorsPhosphodiesterase inhibitor
CBR-001-574-012-2,RFM-002-810-4,CBR-001-574-012-2,[O-][N+](=O)/C(=C\c1ccc(o1)Br)/Br,CBR-HVAC-05131: Antibacterial Drugs;Antifungal Agents; Cell Wall Biosynthesis Inhibitors;MurA Transferase Inhibitors; Protein synthesis inhibitor; DNA synthesis inhibitor; RNA synthesis inhibitor
CBR-001-574-013-3,RFM-002-811-5,CBR-001-574-013-3,Cc1ccc(c2c1cccn2)O,CBR-HVAC-08663: ; Angiotensin I converting enzyme 2 Inhibitor;
CBR-001-574-014-4,RFM-002-812-6,CBR-001-574-014-4,CCOC(=O)C1=C(C)NC(=C(C1c1ccccc1OC(F)F)C(=O)OC)C,analog of CBR-HVAC-03571
CBR-001-574-015-5,RFM-002-813-7,CBR-001-574-015-5,OCCOc1ccc(cc1)C1CCCCC1,analog of CBR-HVAC-10359 (MENFEGOL)
CBR-001-574-016-6,RFM-002-814-8,CBR-001-574-016-6,O=C(C(=O)c1c[nH]c2c1cccc2)N1CCN(CC1)Cc1ccccc1,analog of CBR-HVAC-09307
CBR-001-574-017-7,RFM-002-815-9,CBR-001-574-017-7,CCN1C(=O)c2cc(ccc2Oc2c1cccc2)NC(=O)c1ccc(cc1)C(F)(F)F,analog of CBR-HVAC-11785
CBR-001-574-018-8,RFM-002-816-0,CBR-001-574-018-8,COc1ccc(cc1)c1ccc(cc1)S(=O)(=O)NC(C(=O)O)CC(C)C,analog of CBR-HVAC-09059
CBR-001-574-019-9,RFM-002-817-1,CBR-001-574-019-9,Cc1ccc2c(c1)CCCN2C(=O)C1CCc2c(C1)nc([nH]2)C,analog of CBR-HVAC-04280
CBR-001-574-020-2,RFM-002-818-2,CBR-001-574-020-2,Clc1ccc(cc1)Nc1nnc(c2c1cccc2)Cc1ccncc1,CBR-HVAC-05105: Angiogenesis Inhibitors;Aromatase Inhibitors;KIT (C-KIT) Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; Vascular endothelial growth factor receptor Inhibitor; VEGFR-2 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Angiogenesis inhibitor; ErbB-4 tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor
CBR-001-574-021-3,RFM-002-819-3,CBR-001-574-021-3,N1CCN(CC1)c1nc2c(n1Cc1ccccc1)cccc2,"CBR-HVAC-04413: Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-574-022-4,RFM-002-820-6,CBR-001-574-022-4,CC(Cc1sc(nc1c1ccc(o1)P(=O)(O)O)N)C,"CBR-HVAC-05903: Type 2 Diabetes, Agents for; Fructose-1,6-Bisphosphatase Inhibitors;"
CBR-001-574-023-5,RFM-002-821-7,CBR-001-574-023-5,O=S(CCCC(C(F)(F)F)(F)F)CCCCCCCCCC1Cc2cc(O)ccc2C2C1C1CCC(C1(CC2)C)O,CBR-HVAC-01574: Treatment of Aberrations of Pubertal Development;Female Reproductive System Cancer Therapy;Breast Cancer Therapy;Ovarian Cancer Therapy;Prostate Cancer Therapy; Estrogen Receptor (ER) Antagonists;Signal Transduction Modulators;Soluble Epoxide Hydrolase Inhibitors; Estrogen receptor Antagonist; Estrogen receptor antagonist; DNA directed DNA polymerase inhibitor
CBR-001-574-024-6,RFM-002-822-8,CBR-001-574-024-6,CCC1(O)C(=O)OCc2c1cc1c3nc4ccc(cc4c(c3Cn1c2=O)CC)OC(=O)N1CCC(CC1)N1CCCCC1,CBR-HVAC-00280: DNA topoisomerase I inhibitor
CBR-001-574-025-7,RFM-002-823-9,CBR-001-574-025-7,OCC1OC(OC2C(OC(C(C2O)O)OC2C(NC(=O)C)C(O)OC(C2O)CO)C(=O)O)C(C(C1O)OC1OC(C(=O)O)C(C(C1O)O)O)NC(=O)C,CBR-HVAC-00021: ; Alpha-1 antitrypsin Modulator; Angiogenesis stimulant
CBR-001-574-026-8,RFM-002-824-0,CBR-001-574-026-8,OCC1CC(C(O1)n1cnc2c1ncnc2N)O,CBR-HVAC-00417: DNA inhibitor; Apoptosis stimulant
CBR-001-574-027-9,RFM-002-825-1,CBR-001-574-027-9,OC(=O)CCC(C(=O)O)NC(=O)c1ccc(cc1)CCc1c[nH]c2c1c(O)nc(n2)N,CBR-HVAC-02061: Colorectal Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Gastric Cancer Therapy;Lymphoma Therapy;Female Reproductive System Cancer Therapy;Lung Cancer Therapy;Solid Tumors Therapy;Bone Cancer Therapy;Bladder Cancer Therapy ;Cervical Cancer Therapy;Pancreatic Cancer Therapy;Neurologic Cancer Therapy;Renal Cancer Therapy;Small Cell Lung Cancer Therapy;Musculoskeletal Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Osteosarcoma Therapy;Ovarian Cancer Therapy;Head and Neck Cancer Therapy; Antimetabolites;Apoptosis Inducers;Dihydrofolate Reductase (DHFR) Inhibitors;Glycinamide Ribonucleotide Formyltransferase (GARTFase) Inhibitors;Thymidylate Synthase Inhibitors; Thymidylate synthase; Dihydrofolate reductase; Dihydrofolate transferase Inhibitor; Thymidylate synthase inhibitor; Dihydrofolate reductase inhibitor; Phosphoribosylglycinamide formyltransferase inhibitor
CBR-001-574-028-0,RFM-002-826-2,CBR-001-574-028-0,Cn1ncc(c1)c1cnc2c(c1)c(=O)c1cc(ccc1cc2)NS(=O)(=O)N(CC1COCCO1)C,CBR-HVAC-00393: MET tyrosine kinase inhibitor
CBR-001-574-029-1,RFM-002-827-3,CBR-001-574-029-1,Nc1ccn(c(=O)n1)C1CCC(O1)CO,CBR-HVAC-01899: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleoside reverse transcriptase inhibitor
CBR-001-574-030-4,RFM-002-828-4,CBR-001-574-030-4,OC(CC(/C=C/c1c(nc2c(c1c1ccc(cc1)F)cccc2)C1CC1)O)CC(=O)O,CBR-HVAC-01525: ; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor
CBR-001-574-031-5,RFM-002-829-5,CBR-001-574-031-5,CCC(C(=O)OC1CC(O)C=C2C1C(CCC(CC(CC(=O)O)O)O)C(C=C2)C)C,CBR-HVAC-00147: ; Axl kinase Inhibitor; HMGCoA reductase inhibitor
CBR-001-574-032-6,RFM-002-830-8,CBR-001-574-032-6,OCC1OC(C(C1O)O)n1cnc2c1nc(F)nc2N,CBR-HVAC-02563: Lymphocytic Leukemia Therapy;Non-Hodgkin's Lymphoma TherapyUnidentified pharmacological activity
CBR-001-574-033-7,RFM-002-831-9,CBR-001-574-033-7,OCCONC(=O)c1ccc2n(c1Nc1ccc(cc1F)I)cnc2,CBR-HVAC-06927: Solid Tumors Therapy; Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Signal Transduction Modulators;
CBR-001-574-034-8,RFM-002-832-0,CBR-001-574-034-8,ClCCN(C(=O)Oc1ccc2c(c1)CCC1C2CCC2(C1CCC2OP(=O)([O-])[O-])C)CCCl,CBR-HVAC-02062: Prostate Cancer Therapy; Antimitotic Drugs;DNA Alkylating Drugs; Estrogen receptor Modulator; DNA inhibitor; DNA synthesis inhibitor; Microtubule inhibitor; Estrogen receptor agonist
CBR-001-574-035-9,RFM-002-833-1,CBR-001-574-035-9,N#Cc1ccccc1OCC(CNC(C)(C)C)O,CBR-HVAC-02121: ; Beta adrenergic receptor Antagonist; Beta adrenoreceptor antagonist; Adrenoreceptor agonist
CBR-001-574-036-0,RFM-002-834-2,CBR-001-574-036-0,N#Cc1ccc2c(c1)c1C[C@@H](Cc1n2Cc1ccccn1)NC(=O)OC(C)C,CBR-HVAC-07179: Prostate Cancer Therapy;Treatment of Erectile Dysfunction; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators;
CBR-001-574-037-1,RFM-002-835-3,CBR-001-574-037-1,CCCCCCOc1nsnc1C1=CCCN(C1)C,"CBR-HVAC-04452: Alzheimer's Dementia, Treatment of ; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M4 Agonist; Muscarinic M1 receptor agonist"
CBR-001-574-038-2,RFM-002-836-4,CBR-001-574-038-2,OC(=O)C1CCC(CC1)CNCc1ccc(cc1)F,analog of CBR-HVAC-08547
CBR-001-574-039-3,RFM-002-837-5,CBR-001-574-039-3,CCOC(=O)c1ccc(cc1)NC(=O)C1=C(C)OCCS1,analog of CBR-HVAC-10621
CBR-001-574-040-6,RFM-002-838-6,CBR-001-574-040-6,Clc1ccc(cc1)Cn1c(cc2c1cccc2)C(=O)O,analog of CBR-HVAC-07500
CBR-001-574-041-7,RFM-002-839-7,CBR-001-574-041-7,OC[C@H]1O[C@H]([C@@H]([C@H]([C@@H]1O)O)O)C1C(=O)C(C(=O)/C=C/c2ccc(cc2)O)C(=O)C(C1=O)(O)[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-06497: Ischemic Stroke, Treatment of; Antioxidants;"
CBR-001-574-042-8,RFM-002-840-0,CBR-001-574-042-8,CCCc1c(O)ccc2c1oc(cc2=O)C(=O)O,analog of CBR-HVAC-02490
CBR-001-574-043-9,RFM-002-841-1,CBR-001-574-043-9,O=C1c2c3ccccc3c(=O)n(c2c2c1cccc2)Cc1ccc2c(c1)OCO2,analog of CBR-HVAC-06421
CBR-001-574-044-0,RFM-002-842-2,CBR-001-574-044-0,COc1ccccc1N1CCN(CC1)CC(N(C(=O)C1CCCCC1)c1ccccn1)C,analog of CBR-HVAC-04366
CBR-001-574-045-1,RFM-002-843-3,CBR-001-574-045-1,COc1ccc(cc1F)c1cc(nn1c1ccc(cc1)S(=O)(=O)N)C(F)F,CBR-HVAC-11134: Antiarthritic Drugs; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor;
CBR-001-574-046-2,RFM-002-844-4,CBR-001-574-046-2,C=CCn1c(=O)c2c(n1c1cccc(n1)C(O)(C)C)nc(nc2)Nc1ccc(cc1)N1CCN(CC1)C,CBR-HVAC-06749: Cervical Cancer Therapy;Head and Neck Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Ovarian Cancer Therapy;Oncolytic Drugs;Female Reproductive System Cancer Therapy;Gastric Cancer Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Glioblastoma Multiforme Therapy; Signal Transduction Modulators;Wee1 Kinase Inhibitors; Wee-1 protein kinase Inhibitor;
CBR-001-574-047-3,RFM-002-845-5,CBR-001-574-047-3,O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@@H](C(O)(C)C)C)C)C)/C1,CBR-HVAC-06750: Treatment of Hyperparathyroidism
CBR-001-574-048-4,RFM-002-846-6,CBR-001-574-048-4,OC(=O)C(c1c(C)nc2c(c1c1ccc3c(c1)CCCO3)cccc2)OC(C)(C)C,analog of CBR-HVAC-09430
CBR-001-574-049-5,RFM-002-847-7,CBR-001-574-049-5,Brc1ccc(cc1)c1c(OCCOc2ncc(cn2)Br)ncnc1NS(=O)(=O)N,"CBR-HVAC-06651: Hypertension, Treatment of;Pulmonary Hypertension, Treatment of; Endothelin ETA Receptor Antagonists;Endothelin ETB Receptor Antagonists;Signal Transduction Modulators;"
CBR-001-574-050-8,RFM-002-848-8,CBR-001-574-050-8,CO[C@@H]1CC[C@H](CC1)N(c1cc(sc1C(=O)O)C1=CCCCC1)C(=O)[C@@H]1CC[C@H](CC1)C,CBR-HVAC-08508: HCV nonstructural protein 5B inhibitor
CBR-001-574-051-9,RFM-002-849-9,CBR-001-574-051-9,O=C([C@@H]([C@@H](C(=O)N)CC1CC1)CCC(F)(F)F)N[C@H]1N=C(c2ccccc2)c2c(NC1=O)c(F)ccc2,CBR-HVAC-14202
CBR-001-574-052-0,RFM-002-850-2,CBR-001-574-052-0,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O,CBR-HVAC-05681: beta-Lactam Enhancers; beta-Lactamase Inhibitors; Beta-lactamase Inhibitor;
CBR-001-574-053-1,RFM-002-851-3,CBR-001-574-053-1,CONC(=N)c1ccc(cc1)c1ccc(o1)c1ccc(cc1)C(=N)NOC,"CBR-HVAC-04898: DNA Topoisomerase II Inhibitors; DNA inhibitor; DNA synthesis inhibitor; DNA topoisomerase II Inhibitor; DNA-inhibitors; Antibacterial; Antimalarials; Antiparasitic; Antitrypanosomals; Cancer; Fungicide; Mycoses; Oncolytic Drugs; Parasitic Infections; Pneumocystis jiroveci Pneumonia, Agents for"
CBR-001-574-054-2,RFM-002-852-4,CBR-001-574-054-2,Oc1nc(c(s1)Cc1ccc(cc1)OCc1nc2c(n1C)cc(cc2)Oc1cc(C)c(c(c1)C)N)O,CBR-HVAC-06802 Endocrine Cancer Therapy;Sarcoma Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy; PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor gamma Activator;
CBR-001-574-055-3,RFM-002-853-5,CBR-001-574-055-3,[N-]=[N+]=N[C@]1(COC(=O)C(C)C)O[C@H]([C@@H]([C@@H]1OC(=O)C(C)C)OC(=O)C(C)C)n1ccc(nc1=O)N,CBR-HVAC-06108: Antiviral Drugs;Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B protease Inhibitor; HCV nonstructural protein 5B inhibitor
CBR-001-574-056-4,RFM-002-854-6,CBR-001-574-056-4,COc1cn(nc(c1=O)c1ccnn1c1ccccc1)c1ccc(cc1F)n1cccn1,CBR-HVAC-07283: Antipsychotic Drugs; Phosphodiesterase PDE10A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 10A inhibitor
CBR-001-574-057-5,RFM-002-855-7,CBR-001-574-057-5,N#Cc1ccc(cc1C(F)(F)F)N1C(=O)N([C@](C1=O)(CO)c1ccccc1)C,"CBR-HVAC-07021: Muscular Dystrophy, Agents for;Treatment of Cachexia; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators;"
CBR-001-574-058-6,RFM-002-856-8,CBR-001-574-058-6,COCCOc1ccc(cc1)N1CCN(CC1)CCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1,"CBR-HVAC-05656: Extrapyramidal Disorders, Treatment of;Antiparkinsonian Drugs; Adenosine A2A Antagonists;Signal Transduction Modulators; Adenosine A2A receptor Antagonist; Adenosine A2a receptor antagonist; Adenosine receptor antagonist"
CBR-001-574-059-7,RFM-002-857-9,CBR-001-574-059-7,OC(=O)[C@@H]1Cc2c(CN1C(=O)C(c1ccccc1)c1ccccc1)ncn2Cc1ccc(c(c1)C)N(C)C,"CBR-HVAC-04106: Hypertension, Treatment of;Pharmacological Tools; Angiotensin AT2 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 2 Antagonist; Angiotensin II 2 antagonist"
CBR-001-574-060-0,RFM-002-858-0,CBR-001-574-060-0,O=C(C(C)C)O[C@@H]1[C@@H](COC(=O)C(C)C)O[C@H]([C@]1(C)F)n1ccc(nc1=O)N,CBR-HVAC-00713: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B RNA-DEPENDENT RNA POLYMERASE Inhibitor; HCV nonstructural protein 5B inhibitor
CBR-001-574-061-1,RFM-002-859-1,CBR-001-574-061-1,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O,CBR-HVAC-05681: beta-Lactam Enhancers; beta-Lactamase Inhibitors; Beta-lactamase Inhibitor;
CBR-001-574-062-2,RFM-002-860-4,CBR-001-574-062-2,[O-][N+](=O)c1cn2c(n1)OC[C@H](C2)OCc1ccc(nc1)c1ccc(cc1)OC(F)(F)F,CBR-HVAC-07134: Treatment of Tuberculosis
CBR-001-574-063-3,RFM-002-861-5,CBR-001-574-063-3,CCCN(C(=O)C1=Cc2ccc(cc2NC(=C1)N)c1ccc(cc1)C(=O)N1CCCC1)CCC,CBR-HVAC-06577: Head and Neck Cancer Therapy;Ovarian Cancer Therapy;Female Reproductive System Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Drugs for Allergic Rhinitis;Oncolytic Drugs;Immunomodulators;Solid Tumors Therapy; Signal Transduction Modulators;TLR8 Receptor Agonists; Toll-like receptor 8 agonist; Immunostimulant
CBR-001-574-064-4,RFM-002-862-6,CBR-001-574-064-4,ON/C(=N/c1ccc(c(c1)Cl)F)/c1nonc1N,"CBR-HVAC-12023: Indoleamine 2,3-dioxygenase inhibitor. tool compound"
CBR-001-574-065-5,RFM-002-863-7,CBR-001-574-065-5,COc1ccc(cn1)[C@]1(O)CC[C@@H](CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,CBR-HVAC-05983:C-C chemokine receptor 2 antagonist
CBR-001-574-066-6,RFM-002-864-8,CBR-001-574-066-6,Fc1ccc2c(c1)c1CCO[C@@]3(c1[nH]2)CC[C@@](CC3)(N(C)C)c1ccccc1,CBR-HVAC-06086:Opioid ORL1 receptor agonist
CBR-001-574-067-7,RFM-002-865-9,CBR-001-574-067-7,C[C@@H](C(=O)N[C@]1(C[C@H]([C@@H]2[C@H]1[C@H]2C(=O)O)Sc1[nH]cnn1)C(=O)O)N,"CBR-HVAC-07163: Bipolar Disorder, Treatment of;Antipsychotic Drugs; mgluR2 Agonists;Signal Transduction Modulators;"
CBR-001-574-068-8,RFM-002-866-0,CBR-001-574-068-8,C[C@H]([C@H]1C(=O)N2[C@@H]1SC(=C2C(=O)OCc1oc(=O)oc1C)[C@H]1CCCO1)O,CBR-HVAC-04291: Antibacterial Drugs;Antibiotics; Cell wall synthesis inhibitor; Lactamase inhibitor
CBR-001-574-069-9,RFM-002-867-1,CBR-001-574-069-9,CN1CCN(CC1)C(=O)Cc1csc(n1)NS(=O)(=O)c1cccc(c1C)Cl,CBR-HVAC-14186
CBR-001-574-070-2,RFM-002-868-2,CBR-001-574-070-2,Oc1ccc2c(c1)c(C)c(n2Cc1ccc(cc1)OCCN1CCCCCC1)c1ccc(cc1)O,"CBR-HVAC-01432: Endometriosis Therapy;Treatment of Osteoporosis;Hematologic Genetic Disorders, Treatment of ;Treatment of Postmenopausal Syndrome ; Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators; Estrogen receptor Modulator; Estrogen receptor agonist; Selective estrogen receptor modulator; Bone resorption inhibitor"
CBR-001-574-071-3,RFM-002-869-3,CBR-001-574-071-3,Clc1cnc2c(c1)c(c[nH]2)Cc1ccc(nc1)NCc1ccc(nc1)C(F)(F)F,"CBR-HVAC-06882: Breast Cancer Therapy;Multiple Sclerosis, Agents for;Rheumatoid Arthritis, Treatment of;Glioblastoma Multiforme Therapy;Oncolytic Drugs;Lymphoma Therapy;Myeloid Leukemia Therapy;Systemic Lupus Erythematosus, Agents for;Prostate Cancer Therapy;Melanoma Therapy; Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Signal Transduction Modulators;"
CBR-001-574-072-4,RFM-002-870-6,CBR-001-574-072-4,COc1cnc(c2c1c(cn2COP(=O)(O)O)C(=O)C(=O)N1CCN(CC1)C(=O)c1ccccc1)n1cnc(n1)C,CBR-HVAC-06969:GP120env antagonist
CBR-001-574-074-6,RFM-002-871-7,CBR-001-574-074-6,Cc1ccc(c(c1)C(=O)N1C[C@@H](CC[C@H]1C)COc1ccc(cn1)F)c1ncccn1,CBR-HVAC-06845:hypocretin (orexin) receptor 1; hypocretin (orexin) receptor 2
CBR-001-574-075-7,RFM-002-872-8,CBR-001-574-075-7,CCOc1cc(ccc1C1=N[C@@]([C@@](N1C(=O)N1CCN(CC1)CCCS(=O)(=O)C)(C)c1ccc(cc1)Cl)(C)c1ccc(cc1)Cl)C(C)(C)C,CBR-HVAC-08577: MDM2 Antagonist;
CBR-001-574-076-8,RFM-002-873-9,CBR-001-574-076-8,CN1CCN(CC1)c1ccc(c(c1)NC1CCOCC1)C(=O)Nc1n[nH]c2c1cc(cc2)Cc1cc(F)cc(c1)F,CBR-HVAC-06873: Melanoma Therapy;Solid Tumors Therapy;Colorectal Cancer Therapy;Neurologic Cancer Therapy;Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy; ALK Inhibitors;Antimitotic Drugs;Aurora-B (ARK2) Kinase Inhibitors;High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors;IGF-1R Inhibitors;Jak2 Inhibitors;ROS1 (MCF3) Inhibitors;Signal Transduction Modulators; ALK receptor tyrosine kinase inhibitor; ROS receptor tyrosine kinase inhibitor; TrkA tyrosine kinase inhibitor
CBR-001-574-077-9,RFM-002-874-0,CBR-001-574-077-9,Cn1ncc(c1)c1cnc2c(n1)n(nn2)[C@H](c1ccc2n(c1)ccn2)C,CBR-HVAC-07117: Renal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Gastric Cancer Therapy; HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators; MET tyrosine kinase inhibitor
CBR-001-574-078-0,RFM-002-875-1,CBR-001-574-078-0,CNc1ncc2c(n1)nc(c(c2)c1cc(NC(=O)NCCC(C)(C)C)c(cc1C)F)C,CBR-HVAC-07331: Oncolytic Drugs; Raf kinase A Inhibitors;Raf kinase B Inhibitors;Raf kinase C Inhibitors;Signal Transduction Modulators;
CBR-001-574-079-1,RFM-002-876-2,CBR-001-574-079-1,NC(=N)Nc1scc(n1)CSCCN/C=N/S(=O)(=O)c1ccc(cc1)Br,CBR-HVAC-03619: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Histamine-H2-receptor-antagonists; Mucus protecting agent; Signal Transduction Modulators; Antiulcer; Gastric Antisecretory Drugs; Peptic Ulcer Disease
CBR-001-574-080-4,RFM-002-877-3,CBR-001-574-080-4,CCO[C@@H]1OC(=O)CC1NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)(C)C)NC(=O)c1ccc(c(c1)Cl)N,CBR-HVAC-05785: Antiepileptic Drugs;Antipsoriatics; Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Signal Transduction Modulators; Interleukin 1beta converting enzyme inhibitor; Interleukin 18 antagonist
CBR-001-574-081-5,RFM-002-878-4,CBR-001-574-081-5,FC(c1ccc(cc1)CNc1ccc(cn1)Cc1c[nH]c2c1cccn2)(F)F,"CBR-HVAC-08960: Rheumatoid Arthritis, Treatment of;Multiple Sclerosis, Agents for; Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors;KIT (C-KIT) Inhibitors;Signal Transduction Modulators; c-Kit; FMS-related tyrosine kinase 3 Inhibitor;"
CBR-001-574-082-6,RFM-002-879-5,CBR-001-574-082-6,Cn1ncc(c1)c1cnc2c(c1)c(=O)c1cc(ccc1cc2)CS(=O)(=O)NCc1ccccn1,"CBR-HVAC-06711: Solid Tumors Therapy; Apoptosis Inducers;HGFR (MET; c-Met) Inhibitors;Macrophage Stimulating 1 Receptor (MST1R, RON) Inhibitors;Signal Transduction Modulators; C-MET Inhibitor;"
CBR-001-574-083-7,RFM-002-880-8,CBR-001-574-083-7,NCCCC[C@@H](C(=O)N1CCN(CC1)c1ccncc1)NC(=O)[C@H](NC(=O)N1CCC(CC1)N1Cc2ccccc2NC1=O)Cc1cc(Br)c(c(c1)Br)O,CBR-HVAC-11011: Antimigraine Drugs; Calcitonin Gene-Related Peptides (CGRP) Antagonists;Signal Transduction Modulators; CALCITONIN GENE-RELATED PEPTIDE Antagonist;
CBR-001-574-084-8,RFM-002-881-9,CBR-001-574-084-8,O=C([C@@H]1C[C@@]1(COc1cnc(nc1C)C)c1cccc(c1)F)Nc1ccc(cn1)F,"CBR-HVAC-07212: Sleep Disorders, Treatment of; Orexin OX-1 Antagonists;Orexin OX-2 Antagonists;Signal Transduction Modulators; Orexin receptor antagonist"
CBR-001-574-085-9,RFM-002-882-0,CBR-001-574-085-9,Cc1cc(ccc1Oc1ccn2c(c1)ncn2)Nc1ncnc2c1cc(cc2)NC1=NC(CO1)(C)C,CBR-HVAC-06601: Breast Cancer Therapy; HER2 (erbB2) Inhibitors;Signal Transduction Modulators; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-574-086-0,RFM-002-883-1,CBR-001-574-086-0,C=CC(=O)Nc1cc2c(ncnc2cc1C#CC(N1CCN(CC1)C)(C)C)Nc1ccc(c(c1)Cl)F,CBR-HVAC-05763: Oncolytic Drugs;Solid Tumors Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators; ERBB2; EGFR Antagonist; Inhibitor;
CBR-001-574-087-1,RFM-002-884-2,CBR-001-574-087-1,OCC1OC(OC2C(OC(C(C2O)OS(=O)(=O)O)OC2C(COS(=O)(=O)O)OC(C(C2O)NC(=O)C)O)C(=O)O)C(C(C1OC1OC(C(=O)O)C(C(C1OS(=O)(=O)O)O)O)OS(=O)(=O)O)NS(=O)(=O)O,analog of CBR-HVAC-09576
CBR-001-574-088-2,RFM-002-885-3,CBR-001-574-088-2,O[C@H]([C@H](COS(=O)(=O)C)O)COS(=O)(=O)C,CBR-HVAC-05401: Hematological Cancer Therapy;Myeloid Leukemia Therapy;Ovarian Cancer Therapy; DNA Alkylating Drugs;
CBR-001-574-089-3,RFM-002-886-4,CBR-001-574-089-3,OC(=O)/C=C/c1cc(F)c(c(c1)F)[C@H]1N(CC(F)(C)C)[C@H](C)Cc2c1[nH]c1c2cccc1,CBR-HVAC-07379: Breast Cancer Therapy; Selective Estrogen Receptor Destabilizers (SERD);Signal Transduction Modulators;
CBR-001-574-090-6,RFM-002-887-5,CBR-001-574-090-6,COc1cc(Nc2ncc(c(n2)Nc2ccc3c(n2)N(COP(=O)(O)O)C(=O)C(O3)(C)C)F)cc(c1OC)OC,"CBR-HVAC-06322: Treatment of Renal Diseases;Myeloid Leukemia Therapy;Solid Tumors Therapy;Nephritis, Agents for;Antithrombocytopenic;Antianemics;Rheumatoid Arthritis, Treatment of;Non-Hodgkin's Lymphoma Therapy; Apoptosis Inducers;Flt3 (FLK2/STK1) Inhibitors;Signal Transduction Modulators;Syk Kinase Inhibitors; SPLEEN TYROSINE KINASE Inhibitor;"
CBR-001-574-091-7,RFM-002-888-6,CBR-001-574-091-7,NCCNc1nonc1/C(=N/O)/Nc1ccc(c(c1)Br)F,analog of CBR-HVAC-06991
CBR-001-574-092-8,RFM-002-889-7,CBR-001-574-092-8,CN[C@H](C(=O)N[C@H](C(=O)N([C@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@H](C(=O)N[C@H](c1nccs1)Cc1ccccc1)C)OC)OC)[C@H](CC)C)C)C(C)C)C(C)C,analog of CBR-HVAC-03864 (Dolastatin 10)
CBR-001-574-093-9,RFM-002-890-0,CBR-001-574-093-9,CCN(Cc1cccc(c1)OCc1scc(c1)c1cscc1)C/C=C/C#CC(C)(C)C,"CBR-HVAC-10881: Lipoprotein Disorders, Treatment of ; Squalene Monooxygenase Inhibitors; Squalene epoxidase Inhibitor;"
CBR-001-574-094-0,RFM-002-891-1,CBR-001-574-094-0,COc1ccc2c(c1)CN(CC2c1ccc(c(c1)Cl)Cl)C,CBR-HVAC-07732: Dopamine reuptake inhibitor
CBR-001-574-095-1,RFM-002-892-2,CBR-001-574-095-1,C[C@H]([C@H]1C(=O)N2[C@@H]1[C@@H](C)C(=C2C(=O)O)SC1CN(C1)C1=NCCS1)O,CBR-HVAC-10234:
CBR-001-574-096-2,RFM-002-893-3,CBR-001-574-096-2,COc1cccc(c1)c1ccc(cc1)[C@H](C(F)(F)F)Oc1nc(N)nc(c1)c1ccc(cc1)C[C@@H](C(=O)O)N,"CBR-HVAC-06427: Irritable Bowel Syndrome, Agents for; Tryptophan Hydroxylase 1 (TPH1) Inhibitors; Tryptophan hydroxylase Inhibitor;"
CBR-001-574-097-3,RFM-002-894-4,CBR-001-574-097-3,Nc1nc(c2ccco2)c2c(n1)n(nn2)Cc1ccc(c(c1)C)N,CBR-HVAC-05885: Antiparkinsonian Drugs;Cancer Immunotherapy; Adenosine A2A Antagonists;Signal Transduction Modulators; Adenosine A2A receptor; Dopamine receptor Antagonist; Agonist;
CBR-001-574-098-4,RFM-002-895-5,CBR-001-574-098-4,CCCCCOc1ccc(cc1)c1ccc(cc1)c1ccc(cc1)C(=O)NC1CC(O)C(O)NC(=O)C2C(O)C(CN2C(=O)C(NC(=O)C(NC(=O)C2N(C(=O)C(NC1=O)C(O)C)CC(C2)O)C(C(c1ccc(cc1)O)O)O)C(O)C)C,"CBR-HVAC-02033: Glucan synthase Inhibitor; Cell wall synthesis inhibitor; 1,3-Beta-glucan synthase inhibitor"
CBR-001-574-099-5,RFM-002-896-6,CBR-001-574-099-5,Oc1nccc2c1ccc(c2)OC1CCNCC1,CBR-HVAC-09339:Rho kinase Inhibitor
CBR-001-574-100-1,RFM-002-897-7,CBR-001-574-100-1,CCC([C@@H]([C@H]1[C@H](NC(=N)N)C[C@@H]([C@H]1O)C(=O)O)NC(=O)C)CC,CBR-HVAC-00009: Anti-Influenza Virus Drugs;Anti-Influenza A Virus Drugs;Anti-Influenza B Virus Drugs; Neuraminidase (Sialidase) Inhibitors; Neuraminidase Inhibitor; Neuraminidase inhibitor
CBR-001-574-101-2,RFM-002-898-8,CBR-001-574-101-2,OC(=O)[C@H](c1c(C)nc2c(c1c1ccc3c4c1nccc4CCO3)cccc2)OC(C)(C)C,CBR-HVAC-07268: Anti-HIV Agents; HIV Integrase Inhibitors;
CBR-001-574-102-3,RFM-002-899-9,CBR-001-574-102-3,Fc1ccc(cc1)n1c(C)nc(c1C)C#Cc1ccnc(c1)Cl,CBR-HVAC-06168:Glutamate 5 receptor antagonist
CBR-001-574-103-4,RFM-002-900-5,CBR-001-574-103-4,CCn1c(=O)c(cc2c1nc(N)nc2C)c1n[nH]cc1,CBR-HVAC-07164: Ovarian Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Breast Cancer Therapy;Lymphoma Therapy;Non-Small Cell Lung Cancer Therapy;Oncolytic Drugs;Solid Tumors Therapy;Glioblastoma Multiforme Therapy; mTOR Complex 1 (mTORC1) Inhibitors;mTOR Complex 2 (mTORC2) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Signal Transduction Modulators; PI3 kinase alpha inhibitor; mTOR kinase inhibitor; Cell cycle inhibitor; Protein kinase inhibitor
CBR-001-574-104-5,RFM-002-901-6,CBR-001-574-104-5,NCCCOc1cccc(c1c1[nH]nc(c1)Nc1cnc(cn1)C#N)OC,CBR-HVAC-07027: Ovarian Cancer Therapy;Oncolytic Drugs;Digestive/Gastrointestinal Cancer Therapy;Breast Cancer Therapy; Checkpoint Kinase 1 (Chk1) Inhibitors;Signal Transduction Modulators;
CBR-001-574-105-6,RFM-002-902-7,CBR-001-574-105-6,O=C(C1CC1)Nc1nccc(c1)Oc1cc(F)c(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F,CBR-HVAC-07260: Solid Tumors Therapy; Angiogenesis Inhibitors;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators;Tie2 Receptor Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors; MET tyrosine kinase inhibitor; Vascular endothelial growth factor receptor 2 antagonist; TIE-2 tyrosine kinase inhibitor;2018-01-24: ARB# 18-000003
CBR-001-574-106-7,RFM-002-903-8,CBR-001-574-106-7,Nc1ncnc2c1c(cn2[C@@H]1C[C@@H](C1)CN1CCC1)c1cccc(c1)OCc1ccccc1,CBR-HVAC-11656: Oncolytic Drugs; IGF-1R Inhibitors;Signal Transduction Modulators; IGF1R Inhibitor;
CBR-001-574-107-8,RFM-002-904-9,CBR-001-574-107-8,Clc1ccc(cc1)Cn1c(CC(C(=O)O)(C)C)c(c2c1ccc(c2)OCc1ccc2c(n1)cccc2)SC(C)(C)C,"CBR-HVAC-01225: Inflammatory Bowel Disease, Agents for; Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; 5-Lipoxygenase-activating protein (FLAP) inhibitor hinders biosynthesis of all leukotrienes; Five lipoxygenase activating protein antagonist; 5 Lipoxygenase inhibitor; Leucotriene B4 antagonist"
CBR-001-574-108-9,RFM-002-905-0,CBR-001-574-108-9,CN[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1sc(nc1c1ccccc1)c1ncco1)C1CCCCC1)C,CBR-HVAC-07313:Inhibitor of Apoptosis Proteins (IAP) Inhibitors
CBR-001-574-109-0,RFM-002-906-1,CBR-001-574-109-0,C#C[C@]1(O)CCC2[C@]1(C)CCC1C2CCC2=C[C@H](CC[C@]12C)O,analog of CBR-HVAC-06485
CBR-001-574-110-3,RFM-002-907-2,CBR-001-574-110-3,N#CCCOC(=O)C1=C(C)NC(=C(C1c1cccc2c1cc(cn2)c1ccccc1)C#N)C,analog of CBR-HVAC-04374
CBR-001-574-111-4,RFM-002-908-3,CBR-001-574-111-4,OC[C@@H]([C@@H]([C@@H](Cn1c2cc(C)c(cc2nc2c1nc(=O)[nH]c2=O)C)O)O)O,"CBR-HVAC-01486: Keratoconus, Treatment for;Ophthalmic Drugs;Therapy of Vitamin-Related Disorders; AMPA receptor; Ionotropic glutamate receptor kainate; Ionotropic glutamate receptor NMDA Inhibitor; Unidentified pharmacological activity"
CBR-001-574-112-5,RFM-002-909-4,CBR-001-574-112-5,Cc1ccc(cc1)C(=O)Nc1ccc(cc1)C1=NCCN1,analog of CBR-HVAC-07314
CBR-001-574-113-6,RFM-002-910-7,CBR-001-574-113-6,OC(=O)c1ccc2c(c1)c(=O)n1c(n2)cccc1,"CBR-HVAC-01183: Antiallergy/Antiasthmatic Drugs;Lipoprotein Disorders, Treatment of ;Uricosurics; Mediator Release Inhibitors; Histamine H1 receptor Antagonist; Leucotriene C antagonist; Leucotriene D4 antagonist; Leucotriene E4 antagonist"
CBR-001-574-114-7,RFM-002-911-8,CBR-001-574-114-7,CCN(CCOc1cccc(c1)O)CC,analog of CBR-HVAC-09395
CBR-001-574-115-8,RFM-002-912-9,CBR-001-574-115-8,O=C(Cc1ccc(cc1)F)NC1CCc2c(C1)[nH]c1c2cc(cc1)C,analog of CBR-HVAC-11905
CBR-001-574-116-9,RFM-002-913-0,CBR-001-574-116-9,Cn1c(nnc1S(=O)(=O)C)c1ccccc1,CBR-HVAC-03819: Antispastic Drugs; Glycine receptor Agonist; Unidentified pharmacological activity
CBR-001-574-117-0,RFM-002-914-1,CBR-001-574-117-0,Oc1ccc(cc1C(=O)c1cccs1)C(C)(C)C,analog of CBR-HVAC-01220
CBR-001-574-118-1,RFM-002-915-2,CBR-001-574-118-1,CC(C(=O)c1ccc(cc1)C)CN1CCCC1,analog of CBR-HVAC-03433 (Inaperisone hydrochloride)
CBR-001-574-119-2,RFM-002-916-3,CBR-001-574-119-2,OCC(=O)Nc1ccc(cc1)[As](=O)(O)O,CBR-HVAC-10103:
CBR-001-574-120-5,RFM-002-917-4,CBR-001-574-120-5,COc1cc(cc(c1OC)OC)c1cc(=O)c2c(o1)ccc(c2)OCC(=O)O,analog of CBR-HVAC-00846
CBR-001-574-121-6,RFM-002-918-5,CBR-001-574-121-6,CN(Cc1ccc(cc1)C1CCCCC1)C,analog of CBR-HVAC-09688
CBR-001-574-122-7,RFM-002-919-6,CBR-001-574-122-7,Oc1oc2c(n1)cccc2N1CCNCC1,analog of CBR-HVAC-00771
CBR-001-574-123-8,RFM-002-920-9,CBR-001-574-123-8,NCc1cc(cc(c1O)S(=O)(=O)C)C(C)(C)C,CBR-HVAC-07985: VasodilatorsPotassium sparing diuretic
CBR-001-574-124-9,RFM-002-921-0,CBR-001-574-124-9,Oc1nc2c(o1)c(ccc2)N1CCN(CC1)Cc1cccc(c1)c1ccccc1,"CBR-HVAC-05571: Antiparkinsonian Drugs;Antipsychotic Drugs;Bipolar Disorder, Treatment of; Dopamine D2 Antagonists;Dopamine D2 Receptor Partial Agonists;Signal Transduction Modulators;5-HT1A Receptor Agonists; Dopamine D2 receptor antagonist; Dopamine D2 receptor agonist; 5 Hydroxytryptamine 1A receptor agonist"
CBR-001-574-125-0,RFM-002-922-1,CBR-001-574-125-0,COc1ccc(cc1)Nc1c(cnc2c1cc(cc2)C(=O)O)C(=O)O,analog of CBR-HVAC-07315
CBR-001-574-126-1,RFM-002-923-2,CBR-001-574-126-1,CSc1cc(C)nc(c1NC(=O)CN1CCN(CC1)CCSc1nc2c([nH]1)cccc2)SC,CBR-HVAC-11823: Atherosclerosis Therapy; ACAT 1 Inhibitors; ACYL COENZYME A:CHOLESTEROL O-ACYL TRANSFERASE 1 Inhibitor;
CBR-001-574-127-2,RFM-002-924-3,CBR-001-574-127-2,OCCCCSc1ccc(cc1)Cl,"CBR-HVAC-05827: Allergic Skin Disorders, Treatment forUnidentified pharmacological activity"
CBR-001-574-128-3,RFM-002-925-4,CBR-001-574-128-3,OCc1ccc(cc1O)[C@@H](C(=O)O)N,CBR-HVAC-02933: ImmunostimulantsImmunostimulant; Interleukin 2 agonist
CBR-001-574-129-4,RFM-002-926-5,CBR-001-574-129-4,COc1ccc2c(n1)nc([nH]2)S(=O)Cc1ncc(c(c1C)OC)C,"CBR-HVAC-00584: H+ K+ transporting ATPase inhibitor; H+/K+-ATPase Inhibitors; Immune Checkpoint Inhibitors; Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Inhibitors; Proton pump Inhibitor; Gastric Antisecretory Drugs; Gastric antisecretory"
CBR-001-574-130-7,RFM-002-927-6,CBR-001-574-130-7,CCOC(=O)[C@@H]1CSC(N1)c1ccc(c(c1)OC)OC,analog of CBR-HVAC-09283
CBR-001-574-131-8,RFM-002-928-7,CBR-001-574-131-8,OCC(NC1CC(O)(CO)C(C(C1O)O)O)CO,"CBR-HVAC-01966: Type 2 Diabetes, Agents for; alpha-Glucosidase Inhibitors; Alpha-glucosidase Inhibitor; Alpha glucosidase inhibitor"
CBR-001-574-132-9,RFM-002-929-8,CBR-001-574-132-9,O=C(O[C@H]1CC[C@]2(C(C1(C)C)CC[C@@]1(C2CC[C@H]2[C@@]1(C)CC[C@@]1(C2[C@@H](CC1)C(=C)C)C(=O)O)C)C)CCC(=O)O,analog of CBR-HVAC-04904 (Bevirimat dimeglumine)
CBR-001-574-133-0,RFM-002-930-1,CBR-001-574-133-0,COc1ccc2c(c1)c(CCNC(=O)c1occ(c(=O)c1)OC)c[nH]2,analog of CBR-HVAC-12030
CBR-001-574-134-1,RFM-002-931-2,CBR-001-574-134-1,CN[C@@H]1CC[C@@H](c2c1cccc2)c1ccc(c(c1)Cl)Cl,"CBR-HVAC-01727: Myelodysplastic Syndrome Therapy;Obsessive-Compulsive Disorder (OCD), Treatment of;Treatment of Eating Disorders;Premenstrual Syndrome, Treatment of;Antidepressants;Antifungal Agents;Social Phobia, Treatment for;Autism, Treatment of;Treatment of Substance Dependency;Psychiatric Disorders (Not Specified);Generalized Anxiety Disorder (GAD), Treatment of;Posttraumatic Stress Disorder (PTSD), Treatment of;Anxiolytics;Mental Retardation, Treatment of; Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5-Hydroxytryptamine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor"
CBR-001-574-135-2,RFM-002-932-3,CBR-001-574-135-2,COc1cc2c(cc1Oc1cc(OC)c(cc1CC1N(C)CCc3c1cc(OC)c(c3)OC)OC)CC1c3c2c(O)c(OC)cc3CCN1C,analog of CBR-HVAC-03488
CBR-001-574-136-3,RFM-002-933-4,CBR-001-574-136-3,CC(=O)O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC[C@@H]2OC(=O)c2ccccc2)C)C1)C,CBR-HVAC-09952:
CBR-001-574-137-4,RFM-002-934-5,CBR-001-574-137-4,CCC(C(c1ccc(c2c1ccc(n2)O)O)O)NC(C)C,CBR-HVAC-01398: Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor Agonist; Long-acting beta 2 adrenoceptor (LABA) agonist; Beta 2 adrenoreceptor agonist
CBR-001-574-138-5,RFM-002-935-6,CBR-001-574-138-5,CC(=O)O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC[C@@H]2O)C)C1)C,CBR-HVAC-09951:
CBR-001-574-139-6,RFM-002-936-7,CBR-001-574-139-6,CCCC(C(=O)O)NC(C(=O)N1C2CCCCC2CC1C(=O)O)C,"CBR-HVAC-03503: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors;"
CBR-001-574-140-9,RFM-002-937-8,CBR-001-574-140-9,Cc1cn(C2OC(C=C2)CO)c(=O)[nH]c1=O,CBR-HVAC-01606: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleoside reverse transcriptase inhibitor; DNA directed RNA polymerase inhibitor
CBR-001-574-141-0,RFM-002-938-9,CBR-001-574-141-0,Clc1ccc(cc1)NC(=O)c1c(C)nsc1NC(=O)c1ccccc1,CBR-HVAC-01242: Antiviral DrugsDNA synthesis inhibitor
CBR-001-574-142-1,RFM-002-939-0,CBR-001-574-142-1,CC[N+](Cc1ccccc1Cl)(CCNC(=O)C(=O)NCC[N+](Cc1ccccc1Cl)(CC)CC)CC,CBR-HVAC-09535: ; Acetylcholinesterase Inhibitor;
CBR-001-574-143-2,RFM-002-940-3,CBR-001-574-143-2,CN1CCc2c3C1Cc1ccc(c(c1c3ccc2)O)O,CBR-HVAC-01364: Treatment of Erectile Dysfunction;Antiparkinsonian Drugs;Treatment of Female Sexual Dysfunction; Dopamine D2 Agonists;Signal Transduction Modulators;TRPA1 Modulators; Dopamine receptor D2; Dopamine receptor D1; Dopamine receptor D4; Dopamine receptor D5; Dopamine receptor D3 Agonist; Agonist; Agonist; Agonist; Agonist; Dopamine receptor agonist
CBR-001-574-144-3,RFM-002-941-4,CBR-001-574-144-3,Oc1cc(c(cc1S(=O)(=O)[O-])O)S(=O)(=O)[O-],CBR-HVAC-07736: Membrane permeability inhibitor
CBR-001-574-145-4,RFM-002-942-5,CBR-001-574-145-4,Clc1ccc(c(c1)Cl)C(Cn1cncc1)OCc1ccc(cc1)Sc1ccccc1,CBR-HVAC-02949: Antifungal Agents; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-574-146-5,RFM-002-943-6,CBR-001-574-146-5,Clc1ccc(c(c1)Cl)C(Cn1ccnc1)OCc1csc2c1cccc2Cl,"CBR-HVAC-02324: Antifungal Agents;Antibacterial Drugs;Inflammation, Treatment of; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Cell wall synthesis inhibitor"
CBR-001-574-147-6,RFM-002-944-7,CBR-001-574-147-6,Clc1ccc(cc1)Cn1cc(c2c1cccc2)C(=O)C(=O)Nc1ccncc1,CBR-HVAC-00598: Oncolytic Drugs;Solid Tumors Therapy;Breast Cancer Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors; TUBULIN Inhibitor; Tubulin inhibitor; Mitotic inhibitor
CBR-001-574-148-7,RFM-002-945-8,CBR-001-574-148-7,C#CC1(CCCCC1)OCC(CN1CCN(CC1)c1ccccc1OC)O,CBR-HVAC-08917:
CBR-001-574-149-8,RFM-002-946-9,CBR-001-574-149-8,NCCc1cc[nH]n1,CBR-HVAC-09707: ; Histamine H2 receptor Agonist;
CBR-001-574-150-1,RFM-002-947-0,CBR-001-574-150-1,CCC1C(=O)OCC1Cc1cncn1C,"CBR-HVAC-01312: Radioprotectants/Radiomitigators;Antiglaucoma Agents;Sjogren's Syndrome, Agents for; Muscarinic Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Agonist; Muscarinic receptor agonist"
CBR-001-574-152-3,RFM-002-948-1,CBR-001-574-152-3,COc1c(OC)ccnc1CS(=O)c1nc2c([nH]1)ccc(c2)OC(F)F,CBR-HVAC-01424: Gastric Antisecretory Drugs; H+/K+-ATPase Inhibitors; H+/K+ ATPase Inhibitor; H+ K+ transporting ATPase inhibitor
CBR-001-574-153-4,RFM-002-949-2,CBR-001-574-153-4,Cc1cnc(nc1)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08704:
CBR-001-574-154-5,RFM-002-950-5,CBR-001-574-154-5,O/N=C/c1cccc[n+]1COC[n+]1ccc(cc1)C(=O)N,CBR-HVAC-04229: Specific Antidotes; Acetylcholinesterase Activator; Acetylcholinesterase stimulant
CBR-001-574-155-6,RFM-002-951-6,CBR-001-574-155-6,CCCC(C1(CC)C(=O)NC(=NC1=O)[O-])C,CBR-HVAC-03088: Agents for Premedication;Sedative/Hypnotics; GABA(A) Receptor Modulators;Signal Transduction Modulators; GABA-A receptor Agonist;
CBR-001-574-156-7,RFM-002-952-7,CBR-001-574-156-7,Nc1ccc(c(c1)O)C(=O)Oc1ccccc1,CBR-HVAC-09638:
CBR-001-574-157-8,RFM-002-953-8,CBR-001-574-157-8,CCCCNC(=N)NC(=N)N,CBR-HVAC-09734:
CBR-001-574-158-9,RFM-002-954-9,CBR-001-574-158-9,COc1ccccc1OCC(CNC(C)C)O,"CBR-HVAC-01852: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenoreceptor antagonist"
CBR-001-574-159-0,RFM-002-955-0,CBR-001-574-159-0,CNS(=O)(=O)Cc1ccc2c(c1)c(CCN(C)C)c[nH]2,"CBR-HVAC-01319: Antimigraine Drugs;Acute Attacks of Migraine, Treatment of; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist"
CBR-001-574-160-3,RFM-002-956-1,CBR-001-574-160-3,NNc1nncc2c1cccc2,CBR-HVAC-02350: ; Benzodiazepine receptor Inhibitor; Calcium channel antagonist
CBR-001-574-161-4,RFM-002-957-2,CBR-001-574-161-4,CN(CCOC(c1ccccn1)c1ccc(cc1)Cl)C,CBR-HVAC-02634: Treatment of Upper Respiratory Tract Disorders;Drugs for Allergic Rhinitis; Histamine H1 Receptor Antagonists;L-Type Calcium Channel Blockers;Signal Transduction Modulators; Histamine H1 receptor Blocker; Histamine receptor antagonist
CBR-001-574-162-5,RFM-002-958-3,CBR-001-574-162-5,CCCCCCCCCCCCNC(=O)C[N+](Cc1ccccc1)(C)C,CBR-HVAC-09082:
CBR-001-574-163-6,RFM-002-959-4,CBR-001-574-163-6,CO/N=C(/c1csc(n1)N)\C(=O)NC1C2SCC=C(N2C1=O)C(=O)O,CBR-HVAC-02221: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-574-164-7,RFM-002-960-7,CBR-001-574-164-7,O=CNc1cc(ccc1O)C(CNC(Cc1ccc(cc1)OC)C)O,"CBR-HVAC-04834: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor Agonist;"
CBR-001-574-165-8,RFM-002-961-8,CBR-001-574-165-8,OCC(CCl)(CCl)CO,CBR-HVAC-08903:
CBR-001-574-166-9,RFM-002-962-9,CBR-001-574-166-9,O=C(Nc1c(I)cc(c(c1I)C(=O)O)I)COCC(=O)Nc1c(I)cc(c(c1I)C(=O)O)I,analog of CBR-HVAC-02309
CBR-001-574-167-0,RFM-002-963-0,CBR-001-574-167-0,Clc1ccc(cc1)CC1C(=O)N=C2N(C1=O)CCS2,CBR-HVAC-02685: Immunosuppressant
CBR-001-574-168-1,RFM-002-964-1,CBR-001-574-168-1,CNC1(C)C2CCC(C1(C)C)C2,"CBR-HVAC-00768: Autism, Treatment of;Diabetic Retinopathy, Agents for;Inflammatory Bowel Disease, Agents for;Age-Related Macular Degeneration, Treatment of;Antidepressants;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Tourette's Syndrome, Treatment of;Hypertension, Treatment of;Smoking Cessation, Aid to;Antidiarrheal Agents;Treatment of Alcohol Dependency; Nicotinic Receptor Antagonists;Signal Transduction Modulators; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA4BETA2 Antagonist; Nicotinic receptor antagonist"
CBR-001-574-169-2,RFM-002-965-2,CBR-001-574-169-2,OCCc1sc[n+](c1C)Cc1cnc(nc1N)C,CBR-HVAC-09672: ; Acetylcholinesterase Inhibitor;
CBR-001-574-170-5,RFM-002-966-3,CBR-001-574-170-5,COc1cc(cc(c1OC)OC)C(=O)OC(CN1CCOCC1)COCCC12C[C@@H]3C[C@H](C2)C[C@H](C1)C3,analog of CBR-HVAC-10163
CBR-001-574-171-6,RFM-002-967-4,CBR-001-574-171-6,C#CC1(CCCCC1)OCC(CN1CCN(CC1)c1cccc(c1)C(F)(F)F)O,CBR-HVAC-08430: Dopamine receptor antagonist; Alpha adrenoreceptor antagonist
CBR-001-574-172-7,RFM-002-968-5,CBR-001-574-172-7,CNC1C(O)C(OCC1(C)O)OC1C(N)CC(C(C1O)OC1OC(CCC1N)[C@@H](N)C)N,analog of CBR-HVAC-07865
CBR-001-574-173-8,RFM-002-969-6,CBR-001-574-173-8,COc1ccc2c(c1)n(CC(=O)O)c(c2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-10138: ; Prostaglandin G/H synthase Inhibitor;
CBR-001-574-174-9,RFM-002-970-9,CBR-001-574-174-9,OC(COC1CCC(CC1)C(C)(C)C)CNC(C)C,analog of CBR-HVAC-10951
CBR-001-574-175-0,RFM-002-971-0,CBR-001-574-175-0,O=C(Nc1nc(cn1C)O)Nc1cccc(c1)Cl,"CBR-HVAC-00464: Mental Retardation, Treatment of;Anxiolytics; mgluR5 Antagonists;Signal Transduction Modulators; Metabotropic glutamate receptor 5 Antagonist; Glutamate 5 receptor antagonist"
CBR-001-574-176-1,RFM-002-972-1,CBR-001-574-176-1,[NH3+][Pt-2]1([NH3+])OC(=O)C2(C(=O)O1)CCC2,"CBR-HVAC-03491: DNA Alkylating Drugs; DNA inhibitor; NAD+ ADP-Ribosyltransferase (poly(ADP-ribose) Polymerase; PARP) Inhibitors; Signal Transduction Modulators; Anticancer; Bladder Cancer Therapy ; Brain Cancer Therapy; Breast Cancer Therapy; Cervical Cancer Therapy; Female Reproductive System Cancer Therapy; Genitourinary Cancer Therapy; Head and Neck Cancer Therapy; Lung Cancer Therapy; Lymphocytic Leukemia Therapy; Lymphoma Therapy; Melanoma Therapy; Neurologic Cancer Therapy; Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Ocular Genetic Disorders, Treatment of ; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Prostate Cancer Therapy; Renal Cancer Therapy; Respiratory/Thoracic Cancer Therapy; Small Cell Lung Cancer Therapy"
CBR-001-574-177-2,RFM-002-973-2,CBR-001-574-177-2,COc1cc(ccc1OC)CC1NCCc2c1cc(OC)c(c2)OC,analog of CBR-HVAC-01819
CBR-001-574-178-3,RFM-002-974-3,CBR-001-574-178-3,CC(=O)O[C@@]1(CCC2[C@]1(C)C[C@H](c1ccc(cc1)N(C)C)C1=C3CCC(=O)C=C3CCC21)C(=O)C,"CBR-HVAC-01757: Female Contraceptives;Gynecological Disorders, Treatment of ;Postcoital Contraceptives;Treatment of Postmenopausal Syndrome ;Premenstrual Syndrome, Treatment of; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP2A6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Selective Progesterone Receptor Modulators (SPRM);Signal Transduction Modulators; Progesterone receptor Modulator; Progesterone receptor agonist; Progesterone receptor antagonist; Glucocorticoid antagonist"
CBR-001-574-179-4,RFM-002-975-4,CBR-001-574-179-4,O=C(c1ccncc1)NNC(=C)c1ccco1,CBR-HVAC-08806
CBR-001-574-180-7,RFM-002-976-5,CBR-001-574-180-7,O=C(C(c1ccccc1)(c1ccccc1)O)OC1CC2CCC(C1)[N+]12CCCC1,"CBR-HVAC-01515: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Urinary Incontinence Therapy; Muscarinic Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist"
CBR-001-574-181-8,RFM-002-977-6,CBR-001-574-181-8,OC(COc1cccc(c1C)C)CNC(C)(C)C,CBR-HVAC-01037: ; Beta adrenergic receptor Antagonist; Beta adrenoreceptor antagonist
CBR-001-574-182-9,RFM-002-978-7,CBR-001-574-182-9,COc1ccc2c3c1O[C@@]1(C3(CCN(C2)C)C=C[C@@H](C1)O)C,analog of CBR-HVAC-11610
CBR-001-574-183-0,RFM-002-979-8,CBR-001-574-183-0,Nc1ccc(cc1)S(=O)(=O)Nc1nc(C)nc(c1Cl)C,CBR-HVAC-08686:
CBR-001-574-184-1,RFM-002-980-1,CBR-001-574-184-1,Cc1ccc2c(c1)c1CCCC3c1n2CCN3,CBR-HVAC-01596: ; Monoamine oxidase A Inhibitor; Monoamine oxidase A inhibitor
CBR-001-574-185-2,RFM-002-981-2,CBR-001-574-185-2,OC(=O)c1ccc(cc1)/N=N/c1ccc(c(c1)C(=O)O)O,CBR-HVAC-14187
CBR-001-574-186-3,RFM-002-982-3,CBR-001-574-186-3,CCCCCCOC(=O)/N=C(\c1ccc(cc1)NCc1nc2c(n1C)ccc(c2)C(=O)N(c1ccccn1)CCC(=O)OCC)/N,CBR-HVAC-05537: Anticoagulants; Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; Thrombin Inhibitor;
CBR-001-574-187-4,RFM-002-983-4,CBR-001-574-187-4,O=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,CBR-HVAC-00802: Opioid receptor Antagonist; Opioid receptor antagonist
CBR-001-574-188-5,RFM-002-984-5,CBR-001-574-188-5,CC(=O)OC1CN2CCC1CC2,CBR-HVAC-10061: ; Muscarinic acetylcholine receptor Agonist;
CBR-001-574-189-6,RFM-002-985-6,CBR-001-574-189-6,CCc1c(C)nc2n(c1=O)c(C)ccc2,CBR-HVAC-07633: Beta 1 adrenoreceptor antagonist
CBR-001-574-190-9,RFM-002-986-7,CBR-001-574-190-9,O=C1O[Pt]2(OC1=O)(O)(O)N[C@H]1[C@H](N2)CCCC1,analog of CBR-HVAC-10977
CBR-001-574-191-0,RFM-002-987-8,CBR-001-574-191-0,N[Pt](Cl)(Cl)N,CBR-HVAC-09562:
CBR-001-574-192-1,RFM-002-988-9,CBR-001-574-192-1,CN1C(SC(=S)N(C1c1ccccc1)C)c1ccccc1,CBR-HVAC-11079: ; Lipoprotein lipase Inhibitor;
CBR-001-574-193-2,RFM-002-989-0,CBR-001-574-193-2,[O-]C(=O)CCN[N+](C)(C)C,"CBR-HVAC-01921: Angina pectoris, Treatment of;Acute Myocardial Infarction, Treatment of; Fatty Acid Oxidation Inhibitors;gamma-Butyrobetaine Dioxygenase (BBOX; BBOX1) Inhibitors; Carnitine palmitoyltransferase Inhibitor; Gamma butyrobetaine hydroxylase inhibitor"
CBR-001-574-194-3,RFM-002-990-3,CBR-001-574-194-3,CCC(c1ccc(cc1)CC(CN1C[C@H](C)O[C@@H](C1)C)C)(C)C,CBR-HVAC-01627: Antifungal Agents; Delta-8-delta-7 isomerase Inhibitor; Membrane integrity inhibitor
CBR-001-574-195-4,RFM-002-991-4,CBR-001-574-195-4,Clc1cccc(c1)B(c1ccc(c(c1)Cl)C)OC(=O)c1ncccc1O,analog of CBR-HVAC-06336 (AN-0128)
CBR-001-574-196-5,RFM-002-992-5,CBR-001-574-196-5,CCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-],"CBR-HVAC-07371: Angina pectoris, Treatment of;Vasodilators;Heart Failure Therapy"
CBR-001-574-197-6,RFM-002-993-6,CBR-001-574-197-6,C[C@H](COc1cn2c(c1C)c(ncn2)Oc1ccc2c(c1F)cc([nH]2)C)O,CBR-HVAC-06208: Oncolytic Drugs; Alcohol Dehydrogenase Inhibitors;Angiogenesis Inhibitors;FGFR1 Inhibitors;FGFR2 Inhibitors;FGFR3 Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;
CBR-001-574-198-7,RFM-002-994-7,CBR-001-574-198-7,Fc1ccc(cc1)[C@H]1Nc2cc(F)cc3c2c([C@@H]1c1ncnn1C)n[nH]c3=O,CBR-HVAC-00854: Female Reproductive System Cancer Therapy;Solid Tumors Therapy;Hematological Cancer Therapy;Antineoplastic Enhancing Agents;Breast Cancer Therapy; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors;Signal Transduction Modulators; PARP Inhibitor; ADP ribose polymerase 1 inhibitor; ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor
CBR-001-574-199-8,RFM-002-995-8,CBR-001-574-199-8,OC(=O)C[C@@H]1NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N(C(=O)[C@H](NC1=O)Cc1ccccc1)C)C(C)C,CBR-HVAC-04955: Prostate Cancer Therapy;Head and Neck Cancer Therapy;Lymphoma Therapy;Melanoma Therapy;Non-Small Cell Lung Cancer Therapy;Kaposi's Sarcoma Therapy;Neurologic Cancer Therapy;Pancreatic Cancer Therapy;Myeloid Leukemia Therapy;Glioblastoma Multiforme Therapy;Lung Cancer Therapy;Antiarthritic Drugs; Angiogenesis Inhibitors;Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alphavbeta5 Antagonists;Signal Transduction Modulators; Alphavbeta3 integrin antagonist; Alphavbeta5 integrin antagonist; Angiogenesis inhibitor; Integrin antagonist
CBR-001-574-200-4,RFM-002-996-9,CBR-001-574-200-4,CNC(=O)c1ccc(cc1)Nc1ncc(c(n1)NCc1nccnc1N(S(=O)(=O)C)C)C(F)(F)F,CBR-HVAC-06851: Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Respiratory/Thoracic Cancer Therapy;Cancer of Unspecified Body Location/System; Drugs Targeting Cancer Stem Cells;Focal Adhesion Kinase 1 (FADK1; PTK2) Inhibitors;Focal Adhesion Kinase 2 (FADK2; PTK2B; PYK2) Inhibitors;Signal Transduction Modulators; Focal adhesion kinase inhibitor
CBR-001-574-201-5,RFM-002-997-0,CBR-001-574-201-5,OCCn1ncc(c1)/C=C/c1n[nH]c2c1cc(cc2)O[C@@H](c1c(Cl)cncc1Cl)C,CBR-HVAC-00269: Oncolytic Drugs; Angiogenesis Inhibitors;FGFR1 Inhibitors;FGFR2 Inhibitors;FGFR3 Inhibitors;FGFR4 Inhibitors;Signal Transduction Modulators; FIBROBLAST GROWTH FACTOR RECEPTOR Inhibitor; Fibroblast growth factor receptor antagonist
CBR-001-574-202-6,RFM-002-998-1,CBR-001-574-202-6,Oc1nnc(n1c1ccc2c(c1)ccn2C)c1cc(C(C)C)c(cc1O)O,CBR-HVAC-00881: Prostate Cancer Therapy;Pancreatic Cancer Therapy;Female Reproductive System Cancer Therapy;Lymphocytic Leukemia Therapy;Small Cell Lung Cancer Therapy;Liver Cancer Therapy;Lung Cancer Therapy;Colorectal Cancer Therapy;Breast Cancer Therapy;Melanoma Therapy;Ovarian Cancer Therapy;Sarcoma Therapy;Myeloid Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Oncolytic Drugs;Digestive/Gastrointestinal Cancer Therapy;Multiple Myeloma Therapy;Gastric Cancer Therapy; Apoptosis Inducers;Heat Shock Protein 90 (HSP90) Inhibitors;Signal Transduction Modulators; Heat shock protein 90 Inhibitor; Heat shock protein 90 antagonist
CBR-001-574-203-7,RFM-002-999-2,CBR-001-574-203-7,CN1CCN(CC1)Cc1ccc2c(c1)CN(C2)C(=O)c1cc(C(C)C)c(cc1O)O,CBR-HVAC-00647: Breast Cancer Therapy;Head and Neck Cancer Therapy;Melanoma Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Solid Tumors Therapy; Apoptosis Inducers;Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor; Heat shock protein 90 antagonist
CBR-001-574-204-8,RFM-003-000-2,CBR-001-574-204-8,COc1cc2nccc(c2cc1C(=O)N)Oc1ccc(c(c1)Cl)NC(=O)NC1CC1,CBR-HVAC-05934: Endocrine Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Osteosarcoma Therapy;Neurologic Cancer Therapy;Renal Cancer Therapy;Female Reproductive System Cancer Therapy;Liver Cancer Therapy;Melanoma Therapy;Ovarian Cancer Therapy;Lung Cancer Therapy;Lymphoma Therapy; Angiogenesis Inhibitors;FGFR1 Inhibitors;KIT (C-KIT) Inhibitors;PDGFRbeta Inhibitors;RET Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR Antagonist; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; C-kit inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; FGF receptor 4 tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib; RET tyrosine kinase inhibitor; Angiogenesis inhibitor
CBR-001-574-205-9,RFM-003-001-3,CBR-001-574-205-9,N#Cc1cccc(c1)c1ccc(=O)n(n1)Cc1cccc(c1)c1ncc(cn1)OCC1CCN(CC1)C,CBR-HVAC-06971: Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Liver Cancer Therapy; HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators;
CBR-001-574-206-0,RFM-003-002-4,CBR-001-574-206-0,CN(C(=O)c1cc2c(n1C1CCCC1)nc(nc2)Nc1ccc(cn1)N1CCNCC1)C,CBR-HVAC-00734: Digestive/Gastrointestinal Cancer Therapy;Liver Cancer Therapy;Lymphoma Therapy;Melanoma Therapy;Sarcoma Therapy;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Neurologic Cancer Therapy;Solid Tumors Therapy;Cancer of Unspecified Body Location/System; CDK4 Inhibitors;CDK6 Inhibitors;Jak3 Inhibitors;Signal Transduction Modulators; CYCLIN DEPENDANT KINASE 4; CYCLIN DEPENDENT KINASE 6 Inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CBR-001-574-207-1,RFM-003-003-5,CBR-001-574-207-1,NCCCN(C(c1nc2cc(Cl)ccc2c(=O)n1Nc1ccccc1)CC#C)C(=O)c1cccc(c1F)Cl,"CBR-HVAC-06723: Solid Tumors Therapy;Hematological Cancer Therapy; Antimitotic Drugs;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors;"
CBR-001-574-208-2,RFM-003-004-6,CBR-001-574-208-2,COc1cc(F)c(cc1c1ccc(cc1CN1C(=O)O[C@@H]([C@@H]1C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F)C(C)C,"CBR-HVAC-00869: Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; Cholesteryl Ester Transfer Protein (CETP) Inhibitors;HDL-Cholesterol Increasing Agents; Cholesterol ester transfer protein antagonist"
CBR-001-574-209-3,RFM-003-005-7,CBR-001-574-209-3,COc1cc2ncnc(c2cc1NC(=O)/C=C/CN1CCCCC1)Nc1ccc(c(c1)Cl)F,CBR-HVAC-00872: Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy;Brain Cancer Therapy;Head and Neck Cancer Therapy;Squamous Cell Carcinoma Therapy;Glioblastoma Multiforme Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators; HER2; HER4; HER1 Inhibitor; Inhibitor; Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-574-210-6,RFM-003-006-8,CBR-001-574-210-6,O=C(N(c1nc(c(s1)S(=O)(=O)N)C)C)Cc1ccc(cc1)c1ccccn1,CBR-HVAC-05697: Anti-Herpes Simplex Virus Drugs; Helicase Primase Inhibitors; Helicase-primase Inhibitor;
CBR-001-574-211-7,RFM-003-007-9,CBR-001-574-211-7,CC(CC(=O)Nc1n[nH]c2c1CN(C2(C)C)C(=O)C1CCN(CC1)C)C,CBR-HVAC-06997: Solid Tumors Therapy;Leukemia Therapy; CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors;CDK5/p25 Inhibitors;Signal Transduction Modulators; CDK Inhibitor;
CBR-001-574-212-8,RFM-003-008-0,CBR-001-574-212-8,COc1cc(Nc2ncc(c(n2)Nc2ccc3c(n2)NC(=O)C(O3)(C)C)F)cc(c1OC)OC,"CBR-HVAC-06204: Antianemics;Disease-Modifying Anti-Rheumatic Drugs;Rheumatoid Arthritis, Treatment of;Asthma Therapy;Ocular Genetic Disorders, Treatment of ;Myeloid Leukemia Therapy;Antithrombocytopenic; Apoptosis Inducers;Flt3 (FLK2/STK1) Inhibitors;IL-2 Production Inhibitors;IL-6 Production Inhibitors;Signal Transduction Modulators;Syk Kinase Inhibitors;TNF-alpha Production Inhibitors;"
CBR-001-574-213-9,RFM-003-009-1,CBR-001-574-213-9,Cc1nc2c([nH]1)cc(cc2)n1ncc(c1N)C(=O)c1cc2c([nH]1)cccc2,CBR-HVAC-07278: Oncolytic Drugs;Solid Tumors Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;FGFR1 Inhibitors;FGFR2 Inhibitors;FGFR3 Inhibitors;Signal Transduction Modulators; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3 Inhibitor; Inhibitor; Inhibitor;
CBR-001-574-214-0,RFM-003-010-4,CBR-001-574-214-0,COC[C@@H](C(=O)N[C@H](C(=O)C1(C)OC1)Cc1ccccc1)NC(=O)[C@@H](NC(=O)c1cnc(s1)C)COC,CBR-HVAC-00699: Solid Tumors Therapy;Liver Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Multiple Myeloma Therapy; Proteasome Inhibitors; PROTEASOME Inhibitor; Proteasome inhibitor
CBR-001-574-215-1,RFM-003-011-5,CBR-001-574-215-1,OC(=O)Cn1nnc(n1)c1onc(c1)N1CCC(CC1)Oc1cc(F)ccc1Br,CBR-HVAC-06764: Antidiabetic Drugs; Stearoyl-CoA Desaturase (delta-9 Desaturase; SCD; SCD1) Inhibitors; Stearoyl-CoA desaturase Inhibitor;
CBR-001-574-216-2,RFM-003-012-6,CBR-001-574-216-2,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc([nH]1)c1ccc(cc1)c1ccc(cc1)c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)C(C)C,CBR-HVAC-00794
CBR-001-574-217-3,RFM-003-013-7,CBR-001-574-217-3,COc1ccc(cc1)S(=O)(=O)N(c1ccccc1/C=C/c1cc[n+](cc1)[O-])C(=O)C,CBR-HVAC-04935: Solid Tumors Therapy; Antimitotic Drugs; POLO-LIKE KINASE 1 Inhibitor;
CBR-001-574-218-4,RFM-003-014-8,CBR-001-574-218-4,N#C/C(=C\1/SC[C@H](S1)c1ccc(cc1Cl)Cl)/n1cncc1,CBR-HVAC-01737: Antifungal Agents; Lanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor; Sterol demethylase inhibitor
CBR-001-574-219-5,RFM-003-015-9,CBR-001-574-219-5,O=C(C[C@@H]1N=C(c2ccc(cc2)Cl)c2c(n3c1nnc3C)sc(c2C)C)Nc1ccc(cc1)O,"CBR-HVAC-05012: Neurologic Cancer Therapy;Oncolytic Drugs;Myeloid Leukemia Therapy;Inflammatory Bowel Disease, Agents for;Solid Tumors Therapy;Hematological Cancer Therapy;Brain Cancer Therapy; Bromodomain-Containing Protein 2 (Brd2) Inhibitors;Bromodomain-Containing Protein 3 (Brd3, RING3-like protein) Inhibitors;Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors;E-Selectin Inhibitors;VCAM-1 Antagonists;"
CBR-001-574-220-8,RFM-003-016-0,CBR-001-574-220-8,O=C(N[C@@H](Cc1ccccc1)CC[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)N(Cc1csc(n1)C(C)C)C)CCN1CCOCC1)OCc1cncs1,CBR-HVAC-06839: Antiviral Activity Enhancers;AIDS Medicines; Cytochrome P450 CYP3A4 Inhibitors;HIV Protease Inhibitors; Cytochrome P450 3A Inhibitor; Cytochrome P450 inhibitor
CBR-001-574-221-9,RFM-003-017-1,CBR-001-574-221-9,NC1CCN(CC1)c1cccc2c1nc(cc2)n1cnc2c1ccc(c2)OCC1(C)COC1,CBR-HVAC-00605: Non-Small Cell Lung Cancer Therapy;Neurologic Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Myeloid Leukemia Therapy; Angiogenesis Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators; PDGFR beta Inhibitor; Platelet-derived growth factor receptor alpha kinase inhib; Platelet-derived growth factor receptor beta kinase inhib; Angiogenesis inhibitor
CBR-001-574-222-0,RFM-003-018-2,CBR-001-574-222-0,OC[C@@H](Cn1c2cc(F)c(cc2cc1C(CO)(C)C)NC(=O)C1(CC1)c1ccc2c(c1)OC(O2)(F)F)O,"CBR-HVAC-00644: Cystic Fibrosis, Treatment of ; CFTR Channel (DeltaF508-CFTR Mutant) Correctors;Drugs Acting on ABC Transporters; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) Corrector; CF transmembrane conductance regulator agonist"
CBR-001-574-223-1,RFM-003-019-3,CBR-001-574-223-1,CNc1cccc(n1)CCOc1ccc2c(c1)CN(CC(F)(F)F)C(=O)[C@@H](C2)CC(=O)O,"CBR-HVAC-05062: Treatment of Osteoporosis;Rheumatoid Arthritis, Treatment of;Disease-Modifying Anti-Rheumatic Drugs; Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alphavbeta5 Antagonists;Signal Transduction Modulators; Integrin alpha5 beta5; Integrin alpha5 beta3 Antagonist; Alphavbeta3 integrin antagonist; Angiogenesis inhibitor; Integrin antagonist"
CBR-001-574-224-2,RFM-003-020-6,CBR-001-574-224-2,OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccccc1Cl)O,CBR-HVAC-08272: Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 9 inhibitor; Cell cycle inhibitor
CBR-001-574-225-3,RFM-003-021-7,CBR-001-574-225-3,COc1cc2c(ncnc2cc1OC)Oc1cccc(c1)NC(=O)Nc1noc(c1)C(C(F)(F)F)(C)C,CBR-HVAC-06950: Oncolytic Drugs; EGFR (HER1; erbB1) Inhibitors;Raf kinase B Inhibitors;RET Inhibitors;Signal Transduction Modulators; BRAF Inhibitor;
CBR-001-574-226-4,RFM-003-022-8,CBR-001-574-226-4,CCC(CC1(CCCCC1)C(=O)Nc1ccccc1SC(=O)C(C)C)CC,"CBR-HVAC-00068: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Lipoprotein Disorders, Treatment of ; Cholesteryl Ester Transfer Protein (CETP) Inhibitors;HDL-Cholesterol Increasing Agents; Cholesterol ester transfer protein Inhibitor; Cholesterol ester transfer protein antagonist"
CBR-001-574-227-5,RFM-003-023-9,CBR-001-574-227-5,O[C@@H]1CC[C@H](CC1)NC(=O)[C@@H]1N[C@H]([C@]2([C@H]1c1cccc(c1F)Cl)C(=O)Nc1c2ccc(c1)Cl)CC(C)(C)C,CBR-HVAC-07028: Oncolytic Drugs;Hematological Cancer Therapy;Solid Tumors Therapy; MDM2 (hdm2) Inhibitors; MDM2 P53-BINDING PROTEIN Antagonist;
CBR-001-574-228-6,RFM-003-024-0,CBR-001-574-228-6,N#CC(c1c(Cl)cc(cc1Cl)n1ncc(=O)[nH]c1=O)c1ccc(cc1)Cl,CBR-HVAC-14440: Antiprotozoal; Coccidiostat; Treatment of Protozoal Diseases
CBR-001-574-229-7,RFM-003-025-1,CBR-001-574-229-7,CC(NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2c1[C@H](C)C[C@H]2O)c1ccc(cc1)Cl)C,CBR-HVAC-07012: Oncolytic Drugs;Digestive/Gastrointestinal Cancer Therapy;Prostate Cancer Therapy;Breast Cancer Therapy; PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors;PKB gamma/Akt3 Inhibitors;Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators; Protein kinase B inhibitor
CBR-001-574-230-0,RFM-003-026-2,CBR-001-574-230-0,Clc1ccccc1n1[nH]c2c(c1=O)c(c1cccc(c1)N(C)C)n(c(=O)c2)C,"CBR-HVAC-07137: Agents for Liver Fibrosis;Diabetic Nephropathy, Agents for;Interstitial Lung Diseases, Treatment of; NOX 1 Inhibitors;NOX 4 Inhibitors; NADPH oxidase 1 inhibitor; NADPH oxidase 4 inhibitor"
CBR-001-574-231-1,RFM-003-027-3,CBR-001-574-231-1,OC(=O)[C@@]1(CC[C@H](CC1)Oc1cccc(c1F)Cl)Cc1cccc(n1)Nc1nccs1,CBR-HVAC-06606: Oncolytic Drugs; Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Signal Transduction Modulators; Aurora Kinase Inhibitor;
CBR-001-574-232-2,RFM-003-028-4,CBR-001-574-232-2,NC[C@@H](NC(=O)c1sc(c(c1)c1c(Cl)cnn1C)Cl)Cc1cccc(c1)F,CBR-HVAC-06796: Ovarian Cancer Therapy;Prostate Cancer Therapy;Hematopoiesis Disorders Therapy;Oncolytic Drugs;Multiple Myeloma Therapy;Gastric Cancer Therapy;Female Reproductive System Cancer Therapy;Lymphocytic Leukemia Therapy; Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators; Protein kinase B inhibitor
CBR-001-574-233-3,RFM-003-029-5,CBR-001-574-233-3,CCc1ccc(nc1)C(=O)COc1ccc(cc1)Cc1sc(nc1O)O,"CBR-HVAC-04411: Type 2 Diabetes, Agents for;Antiparkinsonian Drugs;Alzheimer's Dementia, Treatment of ;Renal and Urinary System Genetic Disorders, Treatment of ; Insulin Sensitizers;Signal Transduction Modulators;"
CBR-001-574-234-4,RFM-003-030-8,CBR-001-574-234-4,COc1cc(ccc1NC(=O)[C@@H]1N[C@H]([C@]([C@H]1c1cccc(c1F)Cl)(C#N)c1ccc(cc1F)Cl)CC(C)(C)C)C(=O)O,CBR-HVAC-00247: Hematological Cancer Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Antithrombocythemic; MDM2 (hdm2) Inhibitors; MDM2 Inhibitor; MDM2 inhibitor
CBR-001-574-235-5,RFM-003-031-9,CBR-001-574-235-5,Clc1ccc2c(c1)C(=NCc1c2nc(nc1)Nc1ccc(cc1)C(=O)O)c1c(F)cccc1F,CBR-HVAC-06138: Solid Tumors Therapy; Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Signal Transduction Modulators; Aurora kinase A Inhibitor; Aurora kinase inhibitor; Mitotic inhibitor; Protein kinase inhibitor
CBR-001-574-236-6,RFM-003-032-0,CBR-001-574-236-6,CCc1cc(ccc1CN1CC(C1)C(=O)O)/C(=N/OCc1ccc(c(c1)C(F)(F)F)C1CCCCC1)/C,"CBR-HVAC-00861: Multiple Sclerosis, Agents for;Idiopathic Inflammatory Myopathies, Agents for; Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Ligands;Signal Transduction Modulators; Lysosphingolipid receptor; Sphingosine 1-phosphate receptor Modulator; Sphingosine 1-phosphate 1 receptor agonist; Sphingosine 1-phosphate 5 receptor agonist; Immunosuppressant"
CBR-001-574-237-7,RFM-003-033-1,CBR-001-574-237-7,O=C1Nc2ccccc2c2c([C@@H]1NC(=O)C(C(=O)NCC(C(F)(F)F)(F)F)(C)C)cccc2,"CBR-HVAC-06227: Oncolytic Drugs;Solid Tumors Therapy;Melanoma Therapy;Glioblastoma Multiforme Therapy;Sarcoma Therapy;Alzheimer's Dementia, Treatment of ;Renal Cancer Therapy;Pancreatic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Prostate Cancer Therapy;Colorectal Cancer Therapy;Breast Cancer Therapy; Drugs Acting on Notch Receptors;gamma-Secretase Inhibitors;Signal Transduction Modulators; Gamma secretase Inhibitor;"
CBR-001-574-238-8,RFM-003-034-2,CBR-001-574-238-8,NC(=O)[C@@H]1CCCN1C(=O)Nc1nc(c(s1)c1ccnc(c1)C(C(F)(F)F)(C)C)C,CBR-HVAC-00825: Pancreatic Cancer Therapy;Head and Neck Cancer Therapy;Solid Tumors Therapy;Colorectal Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Multiple Myeloma Therapy;Gastric Cancer Therapy; Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Signal Transduction Modulators; PI3 kinase alpha inhibitor
CBR-001-574-239-9,RFM-003-035-3,CBR-001-574-239-9,CN(Cc1cccc(c1)N/C(=C/1\C(=O)Nc2c1ccc(c2)C(=O)N(C)C)/c1ccccc1)C,analog of CBR-HVAC-07136
CBR-001-574-240-2,RFM-003-036-4,CBR-001-574-240-2,COc1ccc(c(c1C(=O)c1cnc(nc1N)NC1CCN(CC1)S(=O)(=O)C)F)F,CBR-HVAC-06261: Oncolytic Drugs; CDK1/Cyclin B Inhibitors;CDK2/Cyclin E Inhibitors;CDK4/Cyclin D1 Inhibitors;Signal Transduction Modulators; CYCLIN-DEPENDENT KINASE Inhibitor;
CBR-001-574-241-3,RFM-003-037-5,CBR-001-574-241-3,COc1cccc(c1)Nc1c(cnc2c1cc(cc2C)S(=O)(=O)c1cccc(c1)C(=O)N(C)C)C(=O)N,"CBR-HVAC-06162: Drugs for Allergic Rhinitis;Antiallergy/Antiasthmatic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor; Tumour necrosis factor alpha antagonist"
CBR-001-574-242-4,RFM-003-038-6,CBR-001-574-242-4,O=C(Nc1ccc(cn1)c1cnccn1)Cc1cnc(c(c1)C)c1ccnc(c1)C,CBR-HVAC-07156: Breast Cancer Therapy;Colorectal Cancer Therapy;Pancreatic Cancer Therapy;Melanoma Therapy; Protein-Serine O-Palmitoleoyltransferase Porcupine (PORCN) Inhibitors;Wnt Signaling Inhibitors;
CBR-001-574-243-5,RFM-003-039-7,CBR-001-574-243-5,COc1ccc(c(c1)Nc1nc2ccccc2nc1NS(=O)(=O)c1cccc(c1)NC(=O)C(N)(C)C)Cl,CBR-HVAC-07196: Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Female Reproductive System Cancer Therapy;Lymphoma Therapy;Solid Tumors Therapy;Glioblastoma Multiforme Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; PI3 kinase inhibitor; Protein kinase inhibitor
CBR-001-574-244-6,RFM-003-040-0,CBR-001-574-244-6,OB([C@@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)CC(C)C)O,CBR-HVAC-06872:
CBR-001-574-245-7,RFM-003-041-1,CBR-001-574-245-7,N#Cc1ccc(cc1Cn1c(cc(=O)n(c1=O)C)N1CCC[C@H](C1)N)F,"CBR-HVAC-06641: Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue; Protease/peptidase inhibitor; Dipeptide hydrolase inhibitor"
CBR-001-574-246-8,RFM-003-042-2,CBR-001-574-246-8,O=C([C@@H](c1cscc1)C(=O)O)NC1C(=O)N2C1SC(C2C(=O)O)(C)C,CBR-HVAC-01359: ; Beta-lactamase Inhibitor; Lactamase inhibitor; Cell wall synthesis inhibitor
CBR-001-574-247-9,RFM-003-043-3,CBR-001-574-247-9,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1c1ccc(cc1)c1nnco1,CBR-HVAC-04998: Treatment of Intermittent Claudication;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Prostate Cancer Therapy;Ovarian Cancer Therapy; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; ENDOTHELIN A RECEPTOR Antagonist; Endothelin A receptor antagonist
CBR-001-574-248-0,RFM-003-044-4,CBR-001-574-248-0,Cc1cc([C@H](Nc2ccccc2C(=O)O)C)c2n(c1)c(=O)cc(n2)N1CCOCC1,CBR-HVAC-06931: Coagulation Disorders Therapy; Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators;
CBR-001-574-249-1,RFM-003-045-5,CBR-001-574-249-1,O=C(Nc1cc(Br)c(cc1OC[C@@H]1CNCCO1)C)Nc1cnc(cn1)C,CBR-HVAC-00109: Non-Small Cell Lung Cancer Therapy;Pancreatic Cancer Therapy; Checkpoint Kinase 1 (Chk1) Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Signal Transduction Modulators; CHK-1 Inhibitor; Checkpoint kinase 1 inhibitor; DNA repair enzyme inhibitor
CBR-001-574-250-4,RFM-003-046-6,CBR-001-574-250-4,C/C=C/1\NC(=O)[C@H]2CSSCC/C=C/[C@@H](OC(=O)[C@@H](NC1=O)C(C)C)CC(=O)N[C@@H](C(=O)N2)C(C)C,CBR-HVAC-02088: Sarcoma Therapy;Lung Cancer Therapy;Melanoma Therapy;Pancreatic Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Small Cell Lung Cancer Therapy;Anti-HIV Agents;Renal Cancer Therapy;Prostate Cancer Therapy;Brain Cancer Therapy;Colorectal Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy;Endocrine Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Myeloid Leukemia Therapy;Multiple Myeloma Therapy;Antineoplastic Antibiotics; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor
CBR-001-574-251-5,RFM-003-047-7,CBR-001-574-251-5,CO[C@@H]1C[C@@H](CC[C@@H]1n1cnnn1)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C1)C)/C)O)OC)C)C)/C)C,CBR-HVAC-05184: Restenosis Treatment of; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Signal Transduction Modulators; mTOR (mechanistic target of rapamycin) Inhibitor;
CBR-001-574-252-6,RFM-003-048-8,CBR-001-574-252-6,CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@H](C(=O)NCCC(C)C)CC(C)C,"CBR-HVAC-03467: Stroke, Treatment of;Alzheimer's Dementia, Treatment of ; Antiamyloidogenic Agents;Calpain Inhibitors; Cysteine protease Inhibitor; Protease/peptidase inhibitor; Lysosomal carboxypeptidase B inhibitor"
CBR-001-574-253-7,RFM-003-049-9,CBR-001-574-253-7,O=C(Nc1ccccc1N)/C=C/c1ccn(c1)S(=O)(=O)c1ccc(cc1)c1cnn(c1)C,CBR-HVAC-06787: Hematological Cancer Therapy;Small Cell Lung Cancer Therapy; Antimitotic Drugs;Histone Deacetylase 1 (HDAC1) Inhibitors;Histone Deacetylase 2 (HDAC2) Inhibitors;Histone Deacetylase 3 (HDAC3) Inhibitors;
CBR-001-574-254-8,RFM-003-050-2,CBR-001-574-254-8,COC(=O)N[C@H](CNc1nccc(n1)c1cn(nc1c1cc(Cl)cc(c1F)NS(=O)(=O)C)C(C)C)C,CBR-HVAC-07099: Colorectal Cancer Therapy;Melanoma Therapy; Raf kinase B Inhibitors;Signal Transduction Modulators; B-raf kinase inhibitor
CBR-001-574-255-9,RFM-003-051-3,CBR-001-574-255-9,CNC(=O)c1ccc(c(c1)n1c(C)cc(c(c1=O)Br)OCc1ccc(cc1F)F)C,"CBR-HVAC-00316: Osteoarthritis, Treatment of;Analgesic Drugs;Neuropathic Pain, Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Rheumatoid Arthritis, Treatment of; MAPK p38 Inhibitors;Signal Transduction Modulators; p38 map kinase Inhibitor; P38 kinase inhibitor"
CBR-001-574-256-0,RFM-003-052-4,CBR-001-574-256-0,Nc1nc(nn1c1nnc2c(c1)CCCc1c2cccc1)Nc1ccc2c(c1)CC[C@H](CC2)N1CCCC1,CBR-HVAC-07001: Oncolytic Drugs;Myeloid Leukemia Therapy;Non-Small Cell Lung Cancer Therapy; AXL Kinase Inhibitors;Signal Transduction Modulators;
CBR-001-574-257-1,RFM-003-053-5,CBR-001-574-257-1,CN(C[C@@H]1CC[C@H](CC1)Nc1c(cnc2c1nc(cc2)c1cc(Cl)c(c(c1)Cl)O)C(=O)C)C,"CBR-HVAC-07294: Oncolytic Drugs; Maternal Embryonic Leucine Zipper Kinase (MELK, PK38) Inhibitors;Signal Transduction Modulators;"
CBR-001-574-258-2,RFM-003-054-6,CBR-001-574-258-2,CC(=O)N1CCN(CC1)CCOc1ccc(cc1)C1CCN(CC1)C1=Nn2c(CC1)nnc2C(F)(F)F,CBR-HVAC-07047: Prostate Cancer Therapy; Drugs Acting on Androgen Receptor;Signal Transduction Modulators; Androgen receptor Modulator;
CBR-001-574-259-3,RFM-003-055-7,CBR-001-574-259-3,COc1cc(ccc1Nc1ncc(c(n1)Nc1ccccc1P(=O)(C)C)Cl)N1CCC(CC1)N(C)C,CBR-HVAC-00676: Anaplastic lymphoma kinase receptor tyrosine kinase Inhibitor; ALK receptor tyrosine kinase inhibitor; ROS receptor tyrosine kinase inhibitor; EGFR antagonist
CBR-001-574-260-6,RFM-003-056-8,CBR-001-574-260-6,C=CC(=O)N1CCC(CC1)Oc1cc2c(ncnc2cc1OC)Nc1ccc(c(c1F)Cl)Cl,CBR-HVAC-06939: Head and Neck Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Gastric Cancer Therapy;Solid Tumors Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators; PAN-HER Inhibitor;
CBR-001-574-261-7,RFM-003-057-9,CBR-001-574-261-7,Clc1cccc2c1c(=O)n(c(c2)[C@@H](Nc1ncnc2c1nc[nH]2)C)c1ccccc1,"CBR-HVAC-06988: Asthma Therapy;Rheumatoid Arthritis, Treatment of;Non-Hodgkin's Lymphoma Therapy;Hematological Cancer Therapy;Lymphocytic Leukemia Therapy;Inflammatory Bowel Disease, Agents for;Multiple Sclerosis, Agents for;Systemic Lupus Erythematosus, Agents for;Inflammation, Treatment of;Lymphoma Therapy; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor"
CBR-001-574-262-8,RFM-003-058-0,CBR-001-574-262-8,N#Cc1ccc(cc1)NC(=O)N[C@@H]1CCN([C@H](C1)c1nc2c([nH]1)cccc2)C,CBR-HVAC-00661: Solid Tumors Therapy;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy; Hedgehog Signaling Inhibitors; HEDGEHOG PROTEIN Inhibitor; Hedgehog pathway inhibitor
CBR-001-574-263-9,RFM-003-059-1,CBR-001-574-263-9,O1CCN(CC1)c1ccc(cc1)Nc1nc(cn2c1ncc2)c1ccc2c(c1)[nH]nc2,"CBR-HVAC-07348: Rheumatoid Arthritis, Treatment of;Hematological Cancer Therapy;Myeloid Leukemia Therapy;Lymphocytic Leukemia Therapy; Signal Transduction Modulators;Syk Kinase Inhibitors; Syk tyrosine kinase inhibitor"
CBR-001-574-264-0,RFM-003-060-4,CBR-001-574-264-0,Cc1cccc(n1)c1[nH]c(nc1c1ccc2n(c1)ncn2)CNc1ccccc1F,CBR-HVAC-07197: Oncolytic Drugs;Solid Tumors Therapy; Activin Receptor Like Kinase 5 (ALK5; TbetaR-I) Inhibitors;Signal Transduction Modulators;
CBR-001-574-265-1,RFM-003-061-5,CBR-001-574-265-1,Nc1oc2c(n1)cc(cc2)c1nn(c2c1c(N)ncn2)C(C)C,CBR-HVAC-06900: Non-Hodgkin's Lymphoma Therapy;Lung Cancer Therapy;Renal Cancer Therapy;Multiple Myeloma Therapy;Non-Small Cell Lung Cancer Therapy;Glioblastoma Multiforme Therapy;Breast Cancer Therapy;Lymphocytic Leukemia Therapy;Solid Tumors Therapy;Prostate Cancer Therapy;Female Reproductive System Cancer Therapy;Endocrine Cancer Therapy;Skin Cancer Therapy;Oncolytic Drugs; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;mTOR Complex 1 (mTORC1) Inhibitors;mTOR Complex 2 (mTORC2) Inhibitors;Signal Transduction Modulators;
CBR-001-574-266-2,RFM-003-062-6,CBR-001-574-266-2,CCC([C@@H]([C@H]1[C@H](NC(=N)N)C[C@@H]([C@H]1O)C(=O)O)NC(=O)C)CC,CBR-HVAC-00009: Anti-Influenza Virus Drugs;Anti-Influenza A Virus Drugs;Anti-Influenza B Virus Drugs; Neuraminidase (Sialidase) Inhibitors; Neuraminidase Inhibitor; Neuraminidase inhibitor
CBR-001-574-267-3,RFM-003-063-7,CBR-001-574-267-3,COc1cccc(n1)N(C(=S)Oc1ccc2c(c1)CCCC2)C,CBR-HVAC-01844: Antifungal Agents; Squalene Monooxygenase Inhibitors (Fungal); Squalene epoxidase Inhibitor; Squalene epoxidase inhibitor; Cell wall synthesis inhibitor
CBR-001-574-268-4,RFM-003-064-8,CBR-001-574-268-4,CNC(=O)c1ccccc1Nc1cc(ncc1C(F)(F)F)Nc1ccc(cc1OC)N1CCOCC1,CBR-HVAC-06937: Solid Tumors Therapy;Myeloid Leukemia Therapy;Oncolytic Drugs;Lymphocytic Leukemia Therapy; Focal Adhesion Kinase (FAK) Inhibitors;Signal Transduction Modulators; FOCAL ADHESION KINASE Inhibitor;
CBR-001-574-269-5,RFM-003-065-9,CBR-001-574-269-5,COCC(=O)NC/C=C/c1ccc2c(c1)c(ncn2)Nc1ccc(c(c1)C)Oc1ccc(nc1)C,CBR-HVAC-05921: Breast Cancer Therapy; HER2 (erbB2) Inhibitors;Signal Transduction Modulators; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-574-270-8,RFM-003-066-0,CBR-001-574-270-8,NC[C@@](c1ccc(cc1)Cl)(c1ccc(cc1)c1c[nH]nc1)O,CBR-HVAC-06640: Solid Tumors Therapy; cAMP-Dependent Protein Kinase (PKA) Inhibitors;Protein Kinase B (PKB/Akt) Inhibitors;Protein Kinase C (PKC) Inhibitors;Protein Kinase G (PKG) Inhibitors;Rho Kinase 1 (ROCK 1; p160-ROCK) Inhibitors;Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors;Ribosomal Protein S6 Kinase beta  (p70S6K) Inhibitors;Signal Transduction Modulators;
CBR-001-574-271-9,RFM-003-067-1,CBR-001-574-271-9,CC(c1noc(n1)N1CCC(CC1)COc1ccc(nc1)c1ccc(cc1)S(=O)(=O)C)C,"CBR-HVAC-06844: Type 2 Diabetes, Agents for;Lipoprotein Disorders, Treatment of ; Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119)  Agonists;Signal Transduction Modulators; G-protein coupled receptor-119 Agonist;"
CBR-001-574-272-0,RFM-003-068-2,CBR-001-574-272-0,COc1ncc(cc1NS(=O)(=O)c1ccc(cc1F)F)c1ccc2c(c1)c(ccn2)c1ccnnc1,"CBR-HVAC-00259: Lymphoma Therapy;Interstitial Lung Diseases, Treatment of;Solid Tumors Therapy; mTOR Complex 1 (mTORC1) Inhibitors;mTOR Complex 2 (mTORC2) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; MTOR KINASE; PHOSPHOINOSITIDE 3-KINASE Inhibitor; PI3 kinase inhibitor; mTOR kinase inhibitor"
CBR-001-574-273-1,RFM-003-069-3,CBR-001-574-273-1,CNC(=O)c1nn(c2c1C(C)(C)Cc1c2nc(nc1)Nc1ccc(cc1)N1CCN(CC1)C)C,CBR-HVAC-00659: Respiratory/Thoracic Cancer Therapy;Breast Cancer Therapy;Liver Cancer Therapy;Solid Tumors Therapy;Oncolytic Drugs; CDK1 Inhibitors;CDK2 Inhibitors;CDK2/Cyclin A Inhibitors;CDK4 Inhibitors;CDK5 Inhibitors;High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors;Signal Transduction Modulators; Tropomyosin receptor kinase A Inhibitor; Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 4 inhibitor; TrkA tyrosine kinase inhibitor
CBR-001-574-274-2,RFM-003-070-6,CBR-001-574-274-2,Cc1cccc(c1C)C(c1c[nH]cn1)C,"CBR-HVAC-01340: Nausea and Vomiting, Treatment of;Analgesic Drugs;Neurologic Drugs (Miscellaneous);Sedative/Hypnotics; alpha2-Adrenoceptor Agonists;Extracellular-regulated Kinase (ERK) Activators;Signal Transduction Modulators; Alpha-2 adrenergic receptor Agonist; Alpha 2 adrenoreceptor agonist"
CBR-001-574-275-3,RFM-003-071-7,CBR-001-574-275-3,Cn1ncc(c1)c1cnn2c1nc(C1CCCNC1)c(c2N)Br,CBR-HVAC-00656: Oncolytic Drugs;Solid Tumors Therapy;Leukemia Therapy;Myeloid Leukemia Therapy;Lymphoma Therapy; Checkpoint Kinase 1 (Chk1) Inhibitors;Signal Transduction Modulators; Checkpoint kinase 1 Inhibitor; Checkpoint kinase 1 inhibitor
CBR-001-574-276-4,RFM-003-072-8,CBR-001-574-276-4,COc1cccc2c1C(=O)C(C(=O)N(c1ccc(cc1)C(F)(F)F)C)C(=O)N2C,CBR-HVAC-00822: Renal Cancer Therapy;Liver Cancer Therapy;Oncolytic Drugs;Gastric Cancer Therapy;Prostate Cancer Therapy;Ovarian Cancer Therapy; Angiogenesis Inhibitors;Histone Deacetylase 4 (HDAC4) Inhibitors;S100A9 Inhibitors; Angiogenesis inhibitor; Angiogenesis inhibitor
CBR-001-574-277-5,RFM-003-073-9,CBR-001-574-277-5,CN1CCN(CC1)C(=O)C1C2CCC(C1C(=O)O)O2,"CBR-HVAC-06798: Ischemia, Treatment of;Myeloid Leukemia Therapy;Solid Tumors Therapy; Protein Phosphatase 2A (PP-2A) Inhibitors;Signal Transduction Modulators;"
CBR-001-574-278-6,RFM-003-074-0,CBR-001-574-278-6,COc1ccnc2c1c(c[nH]2)C(=O)C(=O)N1CCN(C[C@H]1C)C(=O)c1ccccc1,CBR-HVAC-05615: Anti-HIV Agents; Anti-gp120;HIV Attachment Inhibitors; CD4-GP120 Antagonist; GP120env antagonist
CBR-001-574-279-7,RFM-003-075-1,CBR-001-574-279-7,Nc1ncc(cn1)c1nc(nc2c1CCN2S(=O)(=O)C)N1CCOCC1,CBR-HVAC-07060: Solid Tumors Therapy; Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; Phosphoinositide 3-kinase Inhibitor;
CBR-001-574-280-0,RFM-003-076-2,CBR-001-574-280-0,N#CC1(CC1)NC(=O)[C@H](CC(F)(C)C)N[C@H](C(F)(F)F)c1ccc(cc1)c1ccc(cc1)S(=O)(=O)C,"CBR-HVAC-00877: Oncolytic Drugs;Antiarthritic Drugs;Breast Cancer Therapy;Osteoarthritis, Treatment of;Treatment of Osteoporosis; Cathepsin K Inhibitors; Cathepsin K Inhibitor; Cathepsin K inhibitor; Bone resorption inhibitor; Protease/peptidase inhibitor"
CBR-001-574-281-1,RFM-003-077-3,CBR-001-574-281-1,O[C@@H]1CC[C@H](CC1)Nc1cc(ccc1C(=O)N)n1nc(c2c1CC(C)(C)CC2=O)C(F)(F)F,CBR-HVAC-06369: Oncolytic Drugs;Anti-Herpes Simplex Virus Drugs; Heat Shock Protein 90 (HSP90) Inhibitors; HSP90 Inhibitor;
CBR-001-574-282-2,RFM-003-078-4,CBR-001-574-282-2,Fc1ccc(cc1)[C@H]1[C@H](OCCN1C=c1[nH]c(=O)n([nH]1)P(=O)(O)O)O[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C,"CBR-HVAC-01433: Nausea and Vomiting, Treatment of;Disorders Associated with Cancer Therapy, Treatment of; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Tachykinin receptor 1 Antagonist; Neurokinin 1 receptor antagonist"
CBR-001-574-283-3,RFM-003-079-5,CBR-001-574-283-3,OC(=O)[C@@H]1CC[C@H](CC1)CN1CCC[C@@H](c2c1c(C)cc(c2)C)N(c1nnn(n1)C)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-00746: Lipoprotein Disorders, Treatment of ;Cardiovascular Diseases (Not Specified); Cholesteryl Ester Transfer Protein (CETP) Inhibitors;HDL-Cholesterol Increasing Agents; Cholesteryl ester transfer protein Inhibitor; Cholesterol ester transfer protein antagonist"
CBR-001-574-284-4,RFM-003-080-8,CBR-001-574-284-4,OC(=O)CC[C@@H]1CC[C@](CC1)(c1cc(F)ccc1F)S(=O)(=O)c1ccc(cc1)Cl,"CBR-HVAC-06337: Lymphocytic Leukemia Therapy;Breast Cancer Therapy;Brain Cancer Therapy;Solid Tumors Therapy;Alzheimer's Dementia, Treatment of ;Pancreatic Cancer Therapy; gamma-Secretase Inhibitors;Notch Signaling Inhibitors; Secretase gamma inhibitor; Notch pathway inhibitor; Protease/peptidase inhibitor"
CBR-001-574-285-5,RFM-003-081-9,CBR-001-574-285-5,OCCn1nc(c2c1c1nc(ncc1CC2)Nc1cc(ccc1OC(F)(F)F)N1CCN(CC1)C)C(=O)N,CBR-HVAC-06783: Solid Tumors Therapy; Antimitotic Drugs;Polo-like Kinase-1 (Plk-1) Inhibitors;Signal Transduction Modulators;
CBR-001-574-286-6,RFM-003-082-0,CBR-001-574-286-6,ClCC[N+](c1ccc(cc1)C[C@@H](C(=O)O)N)(CCCl)[O-],CBR-HVAC-00178: Lymphoma Therapy;Solid Tumors Therapy; Angiogenesis Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors; HYPOXIA INDUCIBLE FACTOR-1 ALPHA Inhibitor; Hypoxia-inducible factor 1 alpha antagonist; Angiogenesis inhibitor
CBR-001-574-287-7,RFM-003-083-1,CBR-001-574-287-7,O=C1CC[C@@]2(C(=C1)C=C[C@@H]1[C@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)C)C)C,CBR-HVAC-02403: ; Hydroxysteroid (17-beta) dehydrogenase; Sulfatase Inhibitor; Progesterone receptor agonist
CBR-001-574-288-8,RFM-003-084-2,CBR-001-574-288-8,COCCN(C(=O)Cc1c(c(O)cc(c1CC)O)C(=O)c1ccc(c(c1)OC)OCCN1CCOCC1)CCOC,CBR-HVAC-06600: Non-Hodgkin's Lymphoma Therapy;Lymphocytic Leukemia Therapy;Multiple Myeloma Therapy; Heat Shock Protein 90 (HSP90) Inhibitors; HEAT SHOCK PROTEIN 90 Inhibitor;
CBR-001-574-289-9,RFM-003-085-3,CBR-001-574-289-9,Cn1cc(nc1C1CCN(CC1)c1ncnc2c1cn[nH]2)c1ccc(c(c1)C(F)(F)F)F,CBR-HVAC-06843: Solid Tumors Therapy; Ribosomal Protein S6 Kinase beta  (p70S6K) Inhibitors;Signal Transduction Modulators;
CBR-001-574-290-2,RFM-003-086-4,CBR-001-574-290-2,O=C(Nc1ccc(nn1)CCCCc1nnc(s1)NC(=O)Cc1ccccn1)Cc1cccc(c1)OC(F)(F)F,CBR-HVAC-07360: Multiple Myeloma Therapy;Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy; Glutaminase Inhibitors;
CBR-001-574-291-3,RFM-003-087-5,CBR-001-574-291-3,Clc1cc(Br)c2c(c1)CCc1c([C@@H]2C2CCN(CC2)C(=O)CC2CCN(CC2)C(=O)N)ncc(c1)Br,"CBR-HVAC-00045: Oncolytic Drugs;Prostate Cancer Therapy;Myeloid Leukemia Therapy;Neurologic Cancer Therapy;Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Anti-Hepatitis D Virus Drugs;Multisystem Genetic Disorders, Treatment of ;Head and Neck Cancer Therapy;Myelodysplastic Syndrome Therapy;Glioblastoma Multiforme Therapy;Breast Cancer Therapy; Apoptosis Inducers;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators; Farnesyltransferase Inhibitor; Farnesyltransferase inhibitor; P glycoprotein inhibitor; MRP inhibitor"
CBR-001-574-292-4,RFM-003-088-6,CBR-001-574-292-4,Fc1cc2CN(CCn3c2c(c1)c(c3)C1=C(C(=O)NC1=O)c1cnc2n1cccc2)C(=O)N1CCCCC1,"CBR-HVAC-05969: Type 2 Diabetes, Agents for;Pancreatic Cancer Therapy;Leukemia Therapy;Oncolytic Drugs; Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors;Signal Transduction Modulators;"
CBR-001-574-293-5,RFM-003-089-7,CBR-001-574-293-5,CCN(C(=O)c1ccc(cc1)C1=CC2(CCNCC2)Oc2c1c(O)ccc2)CC,CBR-HVAC-14235
CBR-001-574-294-6,RFM-003-090-0,CBR-001-574-294-6,NCCCN(C(=c1[nH]c2cc(Cl)ccc2c(=O)n1Cc1ccccc1)C(C)C)C(=O)c1ccc(cc1)C,"CBR-HVAC-00424: Leukemia Therapy;Myelodysplastic Syndrome Therapy;Multiple Myeloma Therapy;Head and Neck Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Ovarian Cancer Therapy;Melanoma Therapy;Colorectal Cancer Therapy;Solid Tumors Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;Renal Cancer Therapy;Liver Cancer Therapy;Non-Hodgkin's Lymphoma Therapy; Antimitotic Drugs;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors; Kinesin spindle protein Inhibitor; Kinesin inhibitor"
CBR-001-574-295-7,RFM-003-091-1,CBR-001-574-295-7,NCC(=O)O[C@@H]1CC[C@H](CC1)Nc1cc(ccc1C(=O)N)n1nc(c2c1CC(C)(C)CC2=O)C(F)(F)F,CBR-HVAC-06446: Lung Cancer Therapy;Prostate Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy;Hematological Cancer Therapy;Antineoplastic Enhancing Agents;Oncolytic Drugs;Neurologic Cancer Therapy; Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor;
CBR-001-574-296-8,RFM-003-092-2,CBR-001-574-296-8,NCCN[C@H]1NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H](C[C@H]1O)NC(=O)CCCCCCCC[C@@H](C[C@@H](CC)C)C)[C@H](O)C)C[C@@H](C2)O)[C@@H]([C@H](c1ccc(cc1)O)O)O)[C@@H](CCN)O,"CBR-HVAC-01553: Antifungal Agents;Treatment of Neutropenia; 1,3-beta-Glucan Synthase Inhibitors; Beta-1,3-glucan synthase Inhibitor; 1,3-Beta-glucan synthase inhibitor; Cell wall synthesis inhibitor"
CBR-001-574-297-9,RFM-003-093-3,CBR-001-574-297-9,OC[C@@H](Cn1cnc2c(c1=O)c(Nc1ccc(cc1F)I)c(c(=O)n2C)F)O,CBR-HVAC-06774: Solid Tumors Therapy; MEK1 Inhibitors;Signal Transduction Modulators; MEK protein kinase Inhibitor;
CBR-001-574-298-0,RFM-003-094-4,CBR-001-574-298-0,OC[C@@H](n1ccc(cc1=O)c1ccnc(n1)Nc1ccnn1C)c1ccc(c(c1)F)Cl,CBR-HVAC-07330: Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Melanoma Therapy;Solid Tumors Therapy; ERK1 Inhibitors;ERK2 Inhibitors;Signal Transduction Modulators; EXTRACELLULAR SIGNAL REGULATED KINASE Inhibitor;
CBR-001-574-299-1,RFM-003-095-5,CBR-001-574-299-1,CNC(=O)CN1CCC(CC1)Oc1cc2c(ncnc2cc1OC)Nc1cccc(c1F)Cl,CBR-HVAC-06406: Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Gastric Cancer Therapy;Solid Tumors Therapy;Breast Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER3 (erbB3) Inhibitors;Signal Transduction Modulators; ERBB2; ERBB3 Inhibitor; Inhibitor;
CBR-001-574-300-7,RFM-003-096-6,CBR-001-574-300-7,O=C(/C=C\n1cnc(n1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)NNc1ccccn1,"CBR-HVAC-07210: Non-Hodgkin's Lymphoma Therapy;Anti-Influenza Virus Drugs; Exportin-1 (CRM1, XPO1) Antagonists;Signal Transduction Modulators; CRM1 inhibitor"
CBR-001-574-301-8,RFM-003-097-7,CBR-001-574-301-8,CNCc1cc(n(c1)S(=O)(=O)c1cccnc1)c1ccccc1F,"CBR-HVAC-00791: Esophageal Diseases, Treatment of;Antiulcer Drugs; H+/K+-ATPase Inhibitors; Potassium channel Inhibitor; Potassium-competitive acid antagonist"
CBR-001-574-302-9,RFM-003-098-8,CBR-001-574-302-9,O=C(Nc1ccccc1Br)N[C@@H]1CCN(C1)c1ccc(cn1)C(F)(F)F,"CBR-HVAC-00428: Treatment of Upper Respiratory Tract Disorders;Non-Opioid Analgesics;Antipruritics;Acute Attacks of Migraine, Treatment of; TRPV1 (Vanilloid VR1 Receptor) Antagonists; Transient receptor potential channel V1 Antagonist; Vanilloid receptor 1 antagonist"
CBR-001-574-303-0,RFM-003-099-9,CBR-001-574-303-0,CNC(=O)c1nccc(c1)Oc1ccc(c(c1)F)NC(=O)Nc1cc(nn1c1ccc2c(c1)cccn2)C(C)(C)C,CBR-HVAC-00260: Lymphocytic Leukemia Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy; Abl1 Kinase Inhibitors;Angiogenesis Inhibitors;Apoptosis Inducers;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Lyn Kinase Inhibitors;Signal Transduction Modulators;Tie2 Receptor Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors; Bcr protein; PDGFR gene; Abl tyrosine kinase; Flt3 tyrosine kinase; TIE tyrosine kinase receptor; Raf B protein kinase; Kit tyrosine kinase; Src tyrosine kinase; VEGF-2 receptor Inhibitor; Antagonist; Bcr-Abl inhibitor; VEGFR-2 tyrosine kinase inhibitor; TIE-2 tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor;2018-01-24: ARB# 18-000010
CBR-001-574-304-1,RFM-003-100-5,CBR-001-574-304-1,CN1CCN(CC1)c1nc(/C=C/c2ccccc2)nc(c1)Nc1n[nH]c(c1)C,CBR-HVAC-00635: Sarcoma Therapy;Myeloid Leukemia Therapy;Multiple Myeloma Therapy;Liver Cancer Therapy;Breast Cancer Therapy;Ovarian Cancer Therapy; Angiogenesis Inhibitors;Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Aurora kinase; FGFR; FMS-related tyrosine kinase 3; KIT; Platelet-derived growth factor receptor; Vascular endothelial growth factor receptor 2; Janus kinase 2 Inhibitor; Aurora kinase inhibitor; C-kit inhibitor; Colony stimulating factor 1 receptor antagonist; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; EphA receptor kinase inhibitor; Src inhibitor; Angiogenesis inhibitor; Flt-3 inhibitor; FGF receptor 3 tyrosine kinase inhibitor
CBR-001-574-305-2,RFM-003-101-6,CBR-001-574-305-2,Nc1nc(cc(n1)c1ccc(c2c1cccc2)F)C(C)C,"CBR-HVAC-05003: Migraine, Prophylactic Treatment of; Signal Transduction Modulators;5-HT2B Antagonists; 5-Hydroxytryptamine 2B receptor Antagonist; 5 Hydroxytryptamine 2B receptor antagonist"
CBR-001-574-306-3,RFM-003-102-7,CBR-001-574-306-3,CN[C@H]1CN(C[C@@H]1OC)c1ccc2c(n1)n(cc(c2=O)C(=O)O)c1nccs1,CBR-HVAC-00875: Solid Tumors Therapy;Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy;Small Cell Lung Cancer Therapy;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy;Ovarian Cancer Therapy; DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; TOPOISOMERASE II Inhibitor; DNA-dependent protein kinase inhibitor; Apoptosis stimulant; DNA topoisomerase II inhibitor; Cell cycle inhibitor
CBR-001-574-307-4,RFM-003-103-8,CBR-001-574-307-4,C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc1ccc(c(c1)Cl)OCc1cccc(c1)F,CBR-HVAC-00227: Oncolytic Drugs; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators; EGFR; ERBB2 TYROSINE KINASE; ERBB4 TYROSINE KINASE Inhibitor; Inhibitor; Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor
CBR-001-574-308-5,RFM-003-104-9,CBR-001-574-308-5,COc1c(OCCCN2CCOCC2)ccc2c1nc(NC(=O)c1cnc(nc1)N)n1c2=NCC1,CBR-HVAC-06952: Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy; Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators; PI3 kinase inhibitor
CBR-001-574-309-6,RFM-003-105-0,CBR-001-574-309-6,CN[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)Nc1snnc1c1ccccc1)C1CCCCC1)C,CBR-HVAC-06948: Solid Tumors Therapy; Apoptosis Inducers;Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Signal Transduction Modulators;
CBR-001-574-310-9,RFM-003-106-1,CBR-001-574-310-9,C1/C=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nc(c3cc(CO1)ccc3)ccn2,CBR-HVAC-06622: Myeloid Leukemia Therapy;Hematopoiesis Disorders Therapy;Lymphoma Therapy;Colorectal Cancer Therapy; CDK2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators; Janus kinase 2; FLT-3 Inhibitor; Inhibitor;
CBR-001-574-311-0,RFM-003-107-2,CBR-001-574-311-0,N#Cc1n(C)nc2c1c1cnc(c(c1)O[C@H](C)c1c(C(=O)N(C2)C)ccc(c1)F)N,CBR-HVAC-07335: Non-Small Cell Lung Cancer Therapy; ALK Inhibitors;ALK Tyrosine Kinase Receptor (L1196M Mutant) Inhibitors;Apoptosis Inducers;ROS1 (MCF3) Inhibitors;Signal Transduction Modulators;
CBR-001-574-312-1,RFM-003-108-3,CBR-001-574-312-1,O=C(Cc1ccc(cn1)c1ccc(cc1)OCCN1CCOCC1)NCc1ccccc1,"CBR-HVAC-00629: Gastric Cancer Therapy;Lymphoma Therapy;Actinic Keratoses, Agents for;Solid Tumors Therapy;Prostate Cancer Therapy;Antipsoriatics;Dermatologic Drugs;Myeloid Leukemia Therapy;Oncolytic Drugs;Breast Cancer Therapy; Antimitotic Drugs;Signal Transduction Modulators;Src Kinase Inhibitors;Tubulin Polymerization Inhibitors; Src protein tryrosine kinase Inhibitor; Src inhibitor; Tubulin polymerization inhibitor"
CBR-001-574-313-2,RFM-003-109-4,CBR-001-574-313-2,OC(=O)C(OCc1nn(c2c1cccc2)Cc1ccccc1)(C)C,"CBR-HVAC-00511: Nephritis, Agents for;Restenosis Treatment of;Irritable Bowel Syndrome, Agents for;Rheumatoid Arthritis, Treatment of; NF-kappaB (NFKB) Modulators;Signal Transduction Modulators; TNF alpha Inhibitor; MCP-1 antagonist"
CBR-001-574-314-3,RFM-003-110-7,CBR-001-574-314-3,COCCOc1ccc(cc1)Nc1ncc(c(n1)Nc1cccc(c1)NC(=O)C=C)F,"CBR-HVAC-00674: Lymphocytic Leukemia Therapy;Lymphoma Therapy;Treatment of Autoimmune Diseases;Rheumatoid Arthritis, Treatment of;Non-Hodgkin's Lymphoma Therapy; Bruton's Tyrosine Kinase (BTK) Inhibitors;EGFR (HER1; erbB1) Inhibitors;ITK (EMT) Kinase Inhibitors;Jak3 Inhibitors;Signal Transduction Modulators; BTK TYROSINE KINASE Inhibitor; Bruton's tyrosine kinase inhibitor"
CBR-001-574-315-4,RFM-003-111-8,CBR-001-574-315-4,CN(CCN(c1ccccn1)Cc1cccs1)C,CBR-HVAC-09817: ; Histamine H1 receptor Antagonist;
CBR-001-574-316-5,RFM-003-112-9,CBR-001-574-316-5,[O-][Si](=O)[O-],CBR-HVAC-02400: Unidentified pharmacological activity
CBR-001-574-317-6,RFM-003-113-0,CBR-001-574-317-6,NC(=O)c1cc(N2CC2)c(cc1[N+](=O)[O-])[N+](=O)[O-],CBR-HVAC-03238: Liver Cancer Therapy; DNA-Damaging Drugs;
CBR-001-574-318-7,RFM-003-114-1,CBR-001-574-318-7,COc1cc(ccc1OC)C[C@H]([C@H](Cc1ccc(c(c1)OC)OC)C)C,CBR-HVAC-00474: Head and Neck Cancer Therapy;Microbicides;Neurologic Cancer Therapy;Treatment of Autoimmune Diseases;Premalignant Conditions Therapy;Anti-Herpes Simplex Virus Drugs;Leukemia Therapy;Antineoplastic Enhancing Agents;Anti-Papilloma Virus Drugs;Anti-Influenza Virus Drugs;Cancer Multidrug Resistance Modulators; Antimitotic Drugs;Apoptosis Inducers;Tat Inhibitors; Tat protein Inhibitor; Apoptosis stimulant; Survivin inhibitor; Cell cycle inhibitor; Cyclin-dependent kinase 1 inhibitor
CBR-001-574-319-8,RFM-003-115-2,CBR-001-574-319-8,CCNC(=O)/C=C/c1cccc(c1)Br,CBR-HVAC-05596: Antiepileptic Drugs
CBR-001-574-320-1,RFM-003-116-3,CBR-001-574-320-1,ClC(C(F)(F)F)Br,CBR-HVAC-03081: Inhalation Anesthetics
CBR-001-574-321-2,RFM-003-117-4,CBR-001-574-321-2,COc1cc(Cc2cnc(nc2N)N)cc(c1OC)OC,CBR-HVAC-01267: ; Dihydrofolate reductase Inhibitor; Sulfonamide antibiotic; Dihydrofolate reductase inhibitor; PABA antagonist
CBR-001-574-322-3,RFM-003-118-5,CBR-001-574-322-3,CC(C[C@@H]([C@H](CC(=O)N[C@H](C(=O)N[C@H]([C@H](CC(=O)O)O)CC(C)C)C)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C)C,CBR-HVAC-10572: ; Aspartic protease Inhibitor;
CBR-001-574-323-4,RFM-003-119-6,CBR-001-574-323-4,OC[C@H]([C@H]([C@@H](C(=O)CO)O)O)O,CBR-HVAC-09588:
CBR-001-574-324-5,RFM-003-120-9,CBR-001-574-324-5,N#Cc1ccc(c2c1nn[nH]2)NC(=O)Nc1ccccc1Br,"CBR-HVAC-00224: Inflammatory Bowel Disease, Agents for;Antiarthritic Drugs;Asthma Therapy; Chemokine CXCR2  (IL-8 beta Receptor) Antagonists;Chemokine CXCR2  (IL-8 beta Receptor) Inverse Agonists;Signal Transduction Modulators; C-X-C chemokine receptor type 2 Antagonist; CXC chemokine receptor 2 antagonist; Interleukin 8 antagonist"
CBR-001-574-325-6,RFM-003-121-0,CBR-001-574-325-6,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F,CBR-HVAC-01968: Anti-Herpes Simplex Virus Drugs; Thymidylate Synthase Inhibitors; Thymidylate synthase Inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-574-326-7,RFM-003-122-1,CBR-001-574-326-7,Clc1cnc(c(c1)c1ccc(cc1)S(=O)(=O)C)c1ccc(nc1)C,"CBR-HVAC-01488: Non-Opioid Analgesics;Ankylosing Spondylitis, Treatment of;Rheumatoid Arthritis, Treatment of;Treatment of Dysmenorrhea;Antiarthritic Drugs;Osteoarthritis, Treatment of; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase 2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-574-327-8,RFM-003-123-2,CBR-001-574-327-8,N#Cc1ccc(cc1Cl)N1N=C2[C@@H]([C@@H]1C1CCCC1)CCc1c2ccc(c1)C(=O)O,"CBR-HVAC-00131: Mineralocorticoid Receptor (MR) Antagonists; Mineralocorticoid antagonist; Mineralocorticoid receptor antagonist; Signal Transduction Modulators; Antidiabetic; Diabetic Nephropathy, Agents for"
CBR-001-574-328-9,RFM-003-124-3,CBR-001-574-328-9,Cl[Mn]Cl,CBR-HVAC-09420:
CBR-001-574-329-0,RFM-003-125-4,CBR-001-574-329-0,O=C(c1cccnc1)O[C@@H]1[C@@H](COC(=O)c2cccnc2)O[C@]([C@H]1OC(=O)c1cccnc1)(O)COC(=O)c1cccnc1,CBR-HVAC-09849:
CBR-001-574-330-3,RFM-003-126-5,CBR-001-574-330-3,Cc1nccn1c1ccc(cc1)Sc1cccc(c1)C1(CCOCC1)C(=O)N,CBR-HVAC-05428: Antiallergy/Antiasthmatic Drugs; 5-Lipoxygenase Inhibitors; 15-Lipoxygenase Inhibitor; 5 Lipoxygenase inhibitor
CBR-001-574-331-4,RFM-003-127-6,CBR-001-574-331-4,ClCCN(C(=O)NC1CCCCC1)N=O,CBR-HVAC-01751: Oncolytic Drugs; DNA Alkylating Drugs; DNA inhibitor; DNA synthesis inhibitor
CBR-001-574-332-5,RFM-003-128-7,CBR-001-574-332-5,OC[C@H]1O[C@H](S[Au])[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-04016: Rheumatoid Arthritis, Treatment of;Oncolytic Drugs;Anti-HIV Agents; Protein Kinase PKC iota Inhibitors;Signal Transduction Modulators;"
CBR-001-574-333-6,RFM-003-129-8,CBR-001-574-333-6,O=C(c1ccccc1c1ccc(cc1)C(F)(F)F)Nc1ccc2c(c1)CCN(C2)Cc1ncn[nH]1,"CBR-HVAC-05274: Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein Inhibitor;"
CBR-001-574-334-7,RFM-003-130-1,CBR-001-574-334-7,CCCCCCCCCCOc1cc2c(cc1OCC)ncc(c2O)C(=O)OCC,CBR-HVAC-07227: Antimalarials;Treatment of Protozoal Diseases;Anticoccidials
CBR-001-574-335-8,RFM-003-131-2,CBR-001-574-335-8,NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(C1)CCc1ccc2c(c1)CCO2,CBR-HVAC-02077: Urinary Incontinence Therapy; Muscarinic M3 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M3 Antagonist; Muscarinic M3 receptor antagonist
CBR-001-574-336-9,RFM-003-132-3,CBR-001-574-336-9,CNC(=S)n1nc(nc1N)c1ccc(cc1)Cl,CBR-HVAC-02677: ; Interleukin 5 receptor Inhibitor; Unidentified pharmacological activity
CBR-001-574-337-0,RFM-003-133-4,CBR-001-574-337-0,Cc1cc2c(cc1C(=C)c1ccc(cc1)C(=O)O)C(C)(C)CCC2(C)C,"CBR-HVAC-01370: Antipsychotic Drugs;Non-Small Cell Lung Cancer Therapy;Dermatologic Drugs;Breast Cancer Therapy;Atopic Dermatitis, Agents for;Antiparkinsonian Drugs;Lung Cancer Therapy;Hematological Cancer Therapy;Renal Cancer Therapy;Antipsoriatics;Cushing's Syndrome, Agents for;Chemopreventive Agents;Non-Hodgkin's Lymphoma Therapy;Alzheimer's Dementia, Treatment of ;Head and Neck Cancer Therapy;Endocrine Cancer Therapy; ABCA1 Expression Enhancers;Extracellular-Regulated Kinase (ERK) Inhibitors;Retinoid RXR Agonists;SAPK1 (JNK) Inhibitors;Signal Transduction Modulators; Retinoic acid receptor beta; Retinoic acid receptor alpha; Retinoic acid receptor gamma Inhibitor; Retinoid X alpha receptor agonist; Retinoid X beta receptor agonist; Retinoid X gamma receptor agonist"
CBR-001-574-338-1,RFM-003-134-5,CBR-001-574-338-1,C=CC[N+]1(CCCC1)[C@H]1C[C@@H]2[C@]([C@H]1OC(=O)C)(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@@H]([C@H](C2)O)N1CCOCC1,CBR-HVAC-01989: Non-depolarizing Blocking Drugs; Nicotinic acetylcholine receptor Antagonist; Neuromuscular nicotinic receptor antagonist
CBR-001-574-339-2,RFM-003-135-6,CBR-001-574-339-2,CCCCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,CBR-HVAC-01323: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-574-340-5,RFM-003-136-7,CBR-001-574-340-5,O=C1C[C@@H]2OCC=C3[C@H]4[C@@H]2[C@@H]2N1c1ccccc1[C@]12CCN([C@H]1C4)C3,CBR-HVAC-15160: Glycine receptor Antagonist; Nicotinic acetylcholine receptor alpha7
CBR-001-574-341-6,RFM-003-137-8,CBR-001-574-341-6,OC(=O)CCCC[C@@H]1SC[C@H]2[C@@H]1NC(=N)N2,"CBR-HVAC-05760: Respiratory Disorders (Not Specified);Ischemic Stroke, Treatment of; Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Neuronal Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators; Nitric oxide synthase Inhibitor; Inhibitor;"
CBR-001-574-342-7,RFM-003-138-9,CBR-001-574-342-7,[NH-]c1on[n+](c1)N1CCOCC1,"CBR-HVAC-05115: Angina pectoris, Treatment of;Vasodilators; Nitric Oxide (NO) Donors;"
CBR-001-574-343-8,RFM-003-139-0,CBR-001-574-343-8,CCCN1CCC[C@H]2[C@H]1Cc1c[nH]nc1C2,"CBR-HVAC-03257: Hypertension, Treatment of; Dopamine D2 Agonists;Signal Transduction Modulators; Dopamine D2 receptor agonist"
CBR-001-574-344-9,RFM-003-140-3,CBR-001-574-344-9,CC(COC(=O)c1ccc(cc1)N)C,CBR-HVAC-09890:
CBR-001-574-345-0,RFM-003-141-4,CBR-001-574-345-0,O=C(c1cnc2c(c1O)scc2)N[C@H]1CN2CCC1CC2,"CBR-HVAC-04676: Gastroesophageal Reflux Disease, Agents for;Constipation, Agents for;Prokinetic Agents;Non-Ulcer Dyspepsia, Agents for; Signal Transduction Modulators;5-HT3 Agonists; 5-HYDROXYTRYPTAMINE 3 RECEPTOR Agonist;"
CBR-001-574-346-1,RFM-003-142-5,CBR-001-574-346-1,OCC(COP(=O)(OCC[N+](C)(C)C)O)O,"CBR-HVAC-02260: Cognition Disorders, Treatment of; Acetylcholine Precursors;Signal Transduction Modulators; Acetylcholine receptor agonist; Membrane permeability enhancer"
CBR-001-574-347-2,RFM-003-143-6,CBR-001-574-347-2,N#CC(=NNc1ccc(cc1)C1=C(C)CC(=O)NN1)C#N,"CBR-HVAC-01579: Heart Failure Therapy;Treatment of Renal Diseases;Cardiovascular Diseases (Not Specified);Amyotrophic Lateral Sclerosis, Agents for; Calcium Sensitizers;K(ATP) Channel Activators;Nitric Oxide (NO) Production Inhibitors; Phosphodiesterase Inhibitor; Troponin calcium combination agonist; ATP-sensitive potassium channel agonist; Calcium sensitizer"
CBR-001-574-348-3,RFM-003-144-7,CBR-001-574-348-3,NC(=O)c1ncn2c1nnn(c2=O)C,CBR-HVAC-03285: Colorectal Cancer Therapy;Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy;Small Cell Lung Cancer Therapy;Sarcoma Therapy;Pancreatic Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Brain Cancer Therapy;Melanoma Therapy;Myeloid Leukemia Therapy;Astrocytoma Therapy;Myelodysplastic Syndrome Therapy;Endocrine Cancer Therapy;Glioblastoma Multiforme Therapy;Leukemia Therapy;Lymphoma Therapy;Neurologic Cancer Therapy; DNA Alkylating Drugs;DNA Topoisomerase II alpha Inhibitors; DNA inhibitor
CBR-001-574-349-4,RFM-003-145-8,CBR-001-574-349-4,Clc1ccc2c(c1)nc(c(c2O)c1cccc(c1)Oc1ccccc1)O,"CBR-HVAC-10611: Antiepileptic Drugs;Stroke, Treatment of;Nausea and Vomiting, Treatment of;Non-Opioid Analgesics; NMDA Glycine B Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-574-350-7,RFM-003-146-9,CBR-001-574-350-7,OC[C@H]1O[C@H]([C@@H]([C@@H]1NC(=O)[C@H](Cc1ccc(cc1)OC)N)O)n1cnc2c1ncnc2N(C)C,CBR-HVAC-10004:
CBR-001-574-351-8,RFM-003-147-0,CBR-001-574-351-8,CN(c1nc(nc(n1)N(C)C)N(C)C)C,CBR-HVAC-01759: Ovarian Cancer Therapy; DNA Alkylating Drugs; DNA synthesis inhibitor
CBR-001-574-352-9,RFM-003-148-1,CBR-001-574-352-9,COc1cccc(c1c1cc(nn1c1ccnc2c1ccc(c2)Cl)C(=O)NC1(C(=O)O)C2CC3CC1CC(C2)C3)OC,"CBR-HVAC-04385: Prostate Cancer Therapy;Small Cell Lung Cancer Therapy;Inflammatory Bowel Disease, Agents for; Carboxypeptidase A Inhibitors;Neurotensin NTS1 (NT1) Receptor Antagonists;Signal Transduction Modulators; Neurotensin receptor Antagonist;"
CBR-001-574-353-0,RFM-003-149-2,CBR-001-574-353-0,Sc1nc(O)c(c(n1)O)C(=O)Nc1ccccc1,CBR-HVAC-03278: Oncolytic Drugs;Uricosurics; DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs;Urate Transporter 1 (URAT1) Inhibitors; DNA topoisomerase II Inhibitor;
CBR-001-574-354-1,RFM-003-150-5,CBR-001-574-354-1,N#CC1C[C@]2(C)[C@H]3CC[C@]4([C@H]([C@@H]3CC[C@]32[C@@H](C1=O)O3)CC[C@@H]4O)C,"CBR-HVAC-03064: 3-Beta hydroxysteroid dehydrogenase Inhibitor; 3-hydroxysteroid-dehydrogenase-inhibitors; 3beta-Hydroxy-delta5-steroid dehydrogenase inhibitor; Antiglucocorticoids; Estrogen Receptor (ER) beta Modulators; Estrogen receptor beta antagonist; Estrogen-receptor-antagonists; Signal Transduction Modulators; Signal-transduction-pathway-inhibitors; Aldosteronism, Treatment of; Alzheimer's Disease and Cognition Disorders; Antiadrenergic; Breast Cancer Therapy; Cancer; Cushing's Syndrome, Agents for; Endocrine Disorders; Prostate Cancer Therapy"
CBR-001-574-355-2,RFM-003-151-6,CBR-001-574-355-2,CCOC(=O)N1CSCC1C(=O)O,CBR-HVAC-01694: MucolyticsMucolytic agent
CBR-001-574-356-3,RFM-003-152-7,CBR-001-574-356-3,C1CCn2c(CC1)nnn2,CBR-HVAC-02597: ; Gamma-aminobutyric acid A receptor Antagonist; GABA A receptor antagonist
CBR-001-574-357-4,RFM-003-153-8,CBR-001-574-357-4,Oc1cc(O)c2c(c1)O[C@@H]([C@@H](C2)OC(=O)c1cc(O)c(c(c1)O)O)c1cc(O)c(c(c1)O)O,"CBR-HVAC-04284: Antiparkinsonian Drugs; Angiogenesis Inhibitors;Antioxidants;AP-1 Inhibitors;Aromatase Inhibitors;Bacterial Efflux Pump Inhibitors;beta-Amyloid (Abeta) Aggregation Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;beta-Secretase (BACE) Inhibitors;DNA Gyrase Inhibitors;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;Fatty Acid Synthase (FAS) Inhibitors;HCV NS3 Protease Inhibitors;Indoleamine 2,3-dioxygenase Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;PDGFR Family Inhibitors;Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors;Proteasome Inhibitors;SGLT-1 Inhibitors;Signal Transduction Modulators;Telomerase Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Viral Attachment Inhibitors;Wnt Signaling Inhibitors;"
CBR-001-574-358-5,RFM-003-154-9,CBR-001-574-358-5,CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-04252: Antibacterial Drugs; DNA gyrase Inhibitor;
CBR-001-574-359-6,RFM-003-155-0,CBR-001-574-359-6,COc1ccc2c(c1)CN(CCS2)C(=O)CCN1CCC(CC1)Cc1ccccc1,"CBR-HVAC-04662: Antiarrhythmic Drugs;Cardiovascular Diseases (Not Specified);Acute Myocardial Infarction, Treatment of; Calcium Channel Blockers;RyR2/FKBP12.6 Complex Antagonists; Protein kinase C Activator; Calcium channel antagonist; Potassium channel antagonist; Sodium channel antagonist"
CBR-001-574-360-9,RFM-003-156-1,CBR-001-574-360-9,OC[C@H]1O[C@@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]([C@@H](c4ccc(O3)c(Cl)c4)O)NC(=O)[C@@H](CC(C)C)NC)c3ccc(c(c3)c3c(O)cc(cc3[C@H](NC2=O)C(=O)O)O)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@@H](C)[C@H]([C@@](C1)(C)N)O,CBR-HVAC-03517: Antibacterial Ophthalmic Drugs;Antibiotics;Antibacterial Drugs;Treatment of Neutropenia; Cell Wall Biosynthesis Inhibitors; Penicillin binding protein 2 Binder;
CBR-001-574-361-0,RFM-003-157-2,CBR-001-574-361-0,CC1CCC2(O1)C(=CCCC2(C)C)C,analog of CBR-HVAC-06126
CBR-001-574-362-1,RFM-003-158-3,CBR-001-574-362-1,CN1CCN(CC1)C1=Nc2ccccc2Nc2c1cc(cc2)OS(=O)(=O)C(F)(F)F,CBR-HVAC-10650: Antipsychotic Drugs; Dopamine receptor D1; Dopamine receptor D2 Partial Agonist;
CBR-001-574-363-2,RFM-003-159-4,CBR-001-574-363-2,CC(Cc1c[nH]c2c1cc(OCc1cccs1)cc2)N,CBR-HVAC-11576: ; 5-Hydroxytryptamine 2B receptor Agonist;
CBR-001-574-364-3,RFM-003-160-7,CBR-001-574-364-3,Nc1cc2c(c3c1cccc3)ccc1c2cccc1,CBR-HVAC-03612:
CBR-001-574-365-4,RFM-003-161-8,CBR-001-574-365-4,C[C@@H](P(=O)(O)O)NC(=O)[C@@H](N)C,CBR-HVAC-01016: Cell wall synthesis inhibitor
CBR-001-574-366-5,RFM-003-162-9,CBR-001-574-366-5,CNC(=S)NS(=O)(=O)c1cc(CCNC(=O)c2cc(Cl)ccc2OC)ccc1OC,CBR-HVAC-04979: Antiarrhythmic Drugs; K(ATP) Channel Blockers; Potassium channel Blocker; Potassium channel antagonist
CBR-001-574-367-6,RFM-003-163-0,CBR-001-574-367-6,O=C1CCC2=C3[C@H](C[C@]4([C@H](C3CCC2=C1)CC[C@@]14OCCC1=C)C)c1ccc(cc1)C(=O)C,CBR-HVAC-04468: Breast Cancer Therapy;Contraceptives; Progesterone Receptor Antagonists;Signal Transduction Modulators; PROGESTERONE RECEPTOR Antagonist;
CBR-001-574-368-7,RFM-003-164-1,CBR-001-574-368-7,O=c1c(C)coc2c1cccc2,CBR-HVAC-08608:
CBR-001-574-369-8,RFM-003-165-2,CBR-001-574-369-8,C1CCN(CC1)C[C@@H]1CONC(=N1)c1cccnc1,"CBR-HVAC-10999: Antiatherosclerotic; Apoptosis inhibitor; Cardioprotectant; Heat shock protein agonist; P38 kinase stimulant; Protein-synthesis-stimulants; Vasoprotectant; Acute Myocardial Infarction, Treatment of; Antiatherosclerotic; Atherosclerosis Therapy; Cardioprotectant; Cardiovascular Diseases (Not Specified); Diabetes; Diabetic Neuropathy, Agents for; Ischaemic Heart Disease; Pain; Restenosis Treatment of; Skin Disorders; Treatment of Diabetic Complications; Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Vasoprotectant"
CBR-001-574-370-1,RFM-003-166-3,CBR-001-574-370-1,COc1cc(CNC(=O)CCCC/C=C\C(C)C)ccc1O,"CBR-HVAC-01266: Neuropathic Pain, Treatment of;Dry Eye Syndrome, Treatment for;Osteoarthritis, Treatment of;Analgesic Drugs;Migraine, Prophylactic Treatment of; TRPV1 (Vanilloid VR1 Receptor) Agonists; Capsaicin receptor Agonist; Vanilloid receptor 1 agonist"
CBR-001-574-371-2,RFM-003-167-4,CBR-001-574-371-2,OC(=O)/C=C/c1ccc(cc1)Cn1ccnc1,"CBR-HVAC-01938: Dry Eye Syndrome, Treatment for;Cerebrovascular Diseases, Treatment of; Thromboxane Synthase Inhibitors; Thromboxane synthase Inhibitor; Thromboxane synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-574-372-3,RFM-003-168-5,CBR-001-574-372-3,O=C(C1C(=O)c2ccccc2S(=O)(=O)N1C)Nc1nccs1,CBR-HVAC-02772: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-574-373-4,RFM-003-169-6,CBR-001-574-373-4,CCOCCOC(=O)/C=C/c1ccc(cc1)OC,CBR-HVAC-10340:
CBR-001-574-374-5,RFM-003-170-9,CBR-001-574-374-5,N#Cc1ccc(cc1)C1CCCc2n1cnc2,CBR-HVAC-01732: Oncolytic Drugs; Aromatase Inhibitors; Aromatase Inhibitor; Aromatase inhibitor; Estrogen receptor antagonist
CBR-001-574-375-6,RFM-003-171-0,CBR-001-574-375-6,N#Cc1cc(ccc1C#N)Oc1ccc2c(c1)COB2O,"CBR-HVAC-00632: Atopic Dermatitis, Agents for;Antifungal Agents;Antipsoriatics; Antiinflammatory Drugs;Phosphodiesterase PDE4 Inhibitors;Phosphodiesterase PDE7 Inhibitors;Signal Transduction Modulators; PHOSPHODIESTERASE 4 Inhibitor; Phosphodiesterase 4 inhibitor; Tumour necrosis factor alpha antagonist; Interleukin 12 antagonist; Interleukin 23 antagonist; Phosphodiesterase 7 inhibitor"
CBR-001-574-376-7,RFM-003-172-1,CBR-001-574-376-7,O=C1O[C@@H]2O[C@@]3(C)CC[C@@H]4[C@]2([C@H]([C@H]1C)CC[C@H]4C)OO3,CBR-HVAC-02447: ; Cytochrome oxidase; Sarco-endoplasmic reticulum calcium ATPase Inhibitor; DNA synthesis inhibitor
CBR-001-574-377-8,RFM-003-173-2,CBR-001-574-377-8,OC(=O)Cc1cccc(c1N)C(=O)c1ccc(cc1)Br,"CBR-HVAC-02789: Other Ocular Medications;Antiinflammatory Ophthalmic Agents;Dry Eye Syndrome, Treatment for;Analgesic Drugs; COX-2 Expression Inhibitors; Prostaglandin synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-574-378-9,RFM-003-174-3,CBR-001-574-378-9,CC1=C(C(=O)OCCN(c2ccccc2)Cc2ccccc2)C(C(=C(N1)C)P1(=O)OCC(CO1)(C)C)c1cccc(c1)[N+](=O)[O-],"CBR-HVAC-01570: Hypertension, Treatment of;Angina pectoris, Treatment of;Treatment of Renal Diseases; Calcium Channel Blockers; Calcium channel L-type; Calcium channel T-type Blocker; L-type calcium channel antagonist; T-type calcium channel antagonist"
CBR-001-574-379-0,RFM-003-175-4,CBR-001-574-379-0,CCOC(=O)OC(OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2c1cccc2)C,CBR-HVAC-01698: ; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-574-380-3,RFM-003-176-5,CBR-001-574-380-3,O[C@H]([C@H](C(=O)O)O)[C@H]([C@@H](C(=O)O)O)O,a component of CBR-HVAC-02763
CBR-001-574-381-4,RFM-003-177-6,CBR-001-574-381-4,C=CCOc1ccccc1OCC(CNC(C)C)O,CBR-HVAC-00953: ; 5-Hydroxytryptamine 1A receptor; Beta adrenergic receptor Antagonist; Beta adrenoreceptor antagonist
CBR-001-574-382-5,RFM-003-178-7,CBR-001-574-382-5,OCC(COc1ccccc1C)O,CBR-HVAC-10360:
CBR-001-574-383-6,RFM-003-179-8,CBR-001-574-383-6,CCOC(=O)N(C1CC1)Cc1ccccc1,CBR-HVAC-08694:
CBR-001-574-384-7,RFM-003-180-1,CBR-001-574-384-7,Oc1ncc(c(c1)O)Cl,CBR-HVAC-04519: Inhibitors of the Degradation of Anticancer Drugs; Dihydropyrimidine Dehydrogenase Inhibitors;
CBR-001-574-385-8,RFM-003-181-2,CBR-001-574-385-8,NCC[C@@H](C(=O)N[C@@H]1C[C@H](N)[C@H]([C@@H]([C@H]1O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)N)O)O)O[C@H]1O[C@H](CN)[C@H]([C@@H]([C@H]1O)O)O)O,CBR-HVAC-00920: 16S Ribosomal Protein Inhibitors; 16S-rRNA of 30S ribosomal subunit Inhibitor; 30S Ribosomal Protein Inhibitors; Protein 30S ribosomal subunit inhibitor; Protein synthesis inhibitor; Antibacterial; Antibiotics
CBR-001-574-386-9,RFM-003-182-3,CBR-001-574-386-9,COc1c2c(=O)cc(oc2c(c2c1cco2)OC)C,CBR-HVAC-02522: Unidentified pharmacological activity
CBR-001-574-387-0,RFM-003-183-4,CBR-001-574-387-0,CC(=O)Oc1ccc(cc1)C(c1ccccn1)c1ccc(cc1)OC(=O)C,CBR-HVAC-02422: Unidentified pharmacological activity
CBR-001-574-388-1,RFM-003-184-5,CBR-001-574-388-1,CN1CCCC(CC1)n1[nH]c(=Cc2ccc(cc2)Cl)c2c(c1=O)cccc2,analog of CBR-HVAC-01728
CBR-001-574-389-2,RFM-003-185-6,CBR-001-574-389-2,NCCCCC(C(=O)NC(C(=O)NC(C(=O)O)CCCCN)CC(C)C)NC(=O)C1CCCN1C(=O)C(NC(=O)C(C(CC)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)C(Cc1ccc(cc1)O)N)CC(C)C)CCCNC(=N)N)CCCNC(=N)N)CCCNC(=N)N,CBR-HVAC-04855: Opioid Analgesics; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist;
CBR-001-574-390-5,RFM-003-186-7,CBR-001-574-390-5,O[C@@H]1CC[C@@H](O)[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@@H](O2)C[C@H](/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@@H]([C@H]([C@@H]([C@@H](OC(=O)C[C@@H](C[C@@H](C1)O)O)C)C)O)C)O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@@H]1O)N)O)C(=O)O,analog of CBR-HVAC-01329
CBR-001-574-391-6,RFM-003-187-8,CBR-001-574-391-6,CC[C@]12C=CC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)C#C,CBR-HVAC-02015: Endometriosis Therapy; Progesterone Receptor Antagonists;Signal Transduction Modulators; Estrogen receptor Binder; Estradiol 17 beta dehydrogenase stimulant; Estrone sulfotransferase stimulant; Progesterone receptor antagonist
CBR-001-574-392-7,RFM-003-188-9,CBR-001-574-392-7,OC(=O)Cc1cc(C)ccc1Nc1c(F)cccc1Cl,"CBR-HVAC-01593: Treatment of Gout;Osteoarthritis, Treatment of;Treatment of Dysmenorrhea;Rheumatoid Arthritis, Treatment of;Non-Opioid Analgesics; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-574-393-8,RFM-003-189-0,CBR-001-574-393-8,CCC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F)C(=O)CCl,"CBR-HVAC-01410: Dermatologic Drugs;Antipsoriatics;Eczema, Treatment of;Atopic Dermatitis, Agents for; Antiinflammatory Drugs; Phospholipase A2 Inhibitor; Glucocorticoid agonist"
CBR-001-574-394-9,RFM-003-190-3,CBR-001-574-394-9,CCCCCCCCCCCCCCCC(=O)OC[C@@H]([C@H]1OC(=O)C(=O)C1O)O,analog of CBR-HVAC-10333
CBR-001-574-395-0,RFM-003-191-4,CBR-001-574-395-0,ClCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)Cl,CBR-HVAC-10020: ; Glucocorticoid receptor Inhibitor;
CBR-001-574-396-1,RFM-003-192-5,CBR-001-574-396-1,CN1CCC(CC1)OC(c1ccccc1)c1ccccc1,"CBR-HVAC-07188: Allergy, Treatment of; Dopamine Reuptake Inhibitors;Histamine H1 Receptor Antagonists;Signal Transduction Modulators;"
CBR-001-574-397-2,RFM-003-193-6,CBR-001-574-397-2,OC[C@@H]1C=C[C@@H](C1)n1cnc2c1nc(N)nc2NC1CC1,CBR-HVAC-01986
CBR-001-574-398-3,RFM-003-194-7,CBR-001-574-398-3,CCCCCC[N+](Cc1ccccc1)(C)C,analog of CBR-HVAC-09755
CBR-001-574-399-4,RFM-003-195-8,CBR-001-574-399-4,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN(Cc1ccccc1)C)C,"CBR-HVAC-02308: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Calcium channel Blocker; Calcium channel antagonist"
CBR-001-574-400-0,RFM-003-196-9,CBR-001-574-400-0,CN(CC/C=C\1/c2ccccc2OCc2c1cccc2)C,CBR-HVAC-02580: ; Sodium channel Antagonist; Serotonin and norepinephrine reuptake inhibitor; Histamine H1 receptor antagonist
CBR-001-574-401-1,RFM-003-197-0,CBR-001-574-401-1,CC(C(=O)Nc1c(C)cccc1C)N,CBR-HVAC-02191: Antiarrhythmic Drugs; Sodium channel Modulator; Voltage-gated sodium channel antagonist
CBR-001-574-402-2,RFM-003-198-1,CBR-001-574-402-2,O[C@@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]1[C@@H]2C[C@H](O)[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)NCCS(=O)(=O)O)C)C)O)C,"CBR-HVAC-07252: Type 2 Diabetes, Agents for;Liver and Biliary Tract Disorders, Treatment of;Antiobesity Drugs; G-Protein Coupled Bile Acid Receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) Agonists;Signal Transduction Modulators;"
CBR-001-574-403-3,RFM-003-199-2,CBR-001-574-403-3,Cc1cccc(c1)N(C(=S)Oc1ccc2c(c1)cccc2)C,CBR-HVAC-02880: Antifungal Agents; Squalene Monooxygenase Inhibitors (Fungal); Squalene epoxidase Inhibitor;
CBR-001-574-404-4,RFM-003-200-8,CBR-001-574-404-4,CCOC(=O)OC(OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)NC(=O)[C@@H](c1ccccc1)N)C,CBR-HVAC-02158: ; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-574-405-5,RFM-003-201-9,CBR-001-574-405-5,COc1ccc(cc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)Cl,"CBR-HVAC-02591: Neurologic Drugs (Miscellaneous);Antiplatelet Therapy;Lesions of the Spinal Cord and Related Structures, Treatment of;Ischemic Stroke, Treatment of;Antidiabetic Drugs;Type 1 Diabetes, Agents for;Type 2 Diabetes, Agents for; K(ATP) Channel Blockers;K(ir) 6.2/SUR1 Blockers;TRPA1 Agonists; Potassium channel Blocker; ATP-sensitive potassium channel antagonist"
CBR-001-574-406-6,RFM-003-202-0,CBR-001-574-406-6,CCCCC([C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O)O)(C)C,CBR-HVAC-14164
CBR-001-574-407-7,RFM-003-203-1,CBR-001-574-407-7,CCC[C@@H](C(=O)OCC)N[C@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O)C,"CBR-HVAC-00088: Cardiovascular Diseases (Not Specified);Hypertension, Treatment of;Treatment of Substance Dependency;Stroke, Treatment of;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Heart Failure Therapy;Ischemia, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-574-408-8,RFM-003-204-2,CBR-001-574-408-8,O[C@@H]1CC[C@]2([C@@H](C1)CC[C@@H]1[C@@H]2C[C@H](O)[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)O)C)C)C,CBR-HVAC-00072: Dermatologic Drugs; G-Protein Coupled Bile Acid Receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) Agonists;Signal Transduction Modulators; Unidentified pharmacological activity
CBR-001-574-409-9,RFM-003-205-3,CBR-001-574-409-9,BrCC(C(F)F)(F)F,CBR-HVAC-09922:
CBR-001-574-410-2,RFM-003-206-4,CBR-001-574-410-2,CN1CCC(CC1)c1c[nH]c2c1cc(cc2)NC(=O)c1ccc(cc1)F,CBR-HVAC-05048: Antimigraine Drugs; Signal Transduction Modulators;5-HT1F Agonists; 5-Hydroxytryptamine 1F receptor Agonist; 5 Hydroxytryptamine 1F receptor agonist
CBR-001-574-411-3,RFM-003-207-5,CBR-001-574-411-3,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)CC[C@H]1CNc2c(C1)c(=O)nc([nH]2)N,CBR-HVAC-04090: DNA synthesis inhibitor; Folate antagonist; GAR transformylase inhibitor
CBR-001-574-412-4,RFM-003-208-6,CBR-001-574-412-4,C/C(=C\C=C\C=C(\C=C\C=C(\C=C\C1=C(C)C(=O)CCC1(C)C)/C)/C)/C=C/C=C(/C=C/C1=C(C)C(=O)CCC1(C)C)\C,CBR-HVAC-10337: Acne Therapy;Oncolytic Drugs; Antioxidants;
CBR-001-574-413-5,RFM-003-209-7,CBR-001-574-413-5,C1CN2C(=N[C@H](C2)c2ccccc2)S1,CBR-HVAC-02223: Immunomodulators;Antimalarials;Oncolytic Drugs;Treatment of Helminthic Diseases;Antianemics; Nicotinic Receptor Agonists;Signal Transduction Modulators; Alkaline phosphatase Agonist; Inhibitor; Immunostimulant
CBR-001-574-414-6,RFM-003-210-0,CBR-001-574-414-6,Nc1[nH]c2c(n1)n(CC1CC1)c(=O)n(c2=O)CC1CC1,"CBR-HVAC-04075: Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor"
CBR-001-574-415-7,RFM-003-211-1,CBR-001-574-415-7,CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC,CBR-HVAC-02492: Antiviral Drugs;ImmunomodulatorsInterferon receptor agonist
CBR-001-574-416-8,RFM-003-212-2,CBR-001-574-416-8,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C2=O)c2c([O-])cc(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)/C,CBR-HVAC-00112: AntibioticsDNA directed RNA polymerase inhibitor
CBR-001-574-417-9,RFM-003-213-3,CBR-001-574-417-9,CCCCCCCCCCCCC(=O)N1CCCCC1CNC(=O)[C@H](CCCCN)N,CBR-HVAC-10560: Oncolytic Drugs; Protein Kinase C (PKC) Inhibitors;Signal Transduction Modulators; Protein tyrosine kinase C Inhibitor;
CBR-001-574-418-0,RFM-003-214-4,CBR-001-574-418-0,CCCC(C(=O)N)CCC,"CBR-HVAC-03133: Bipolar Disorder, Treatment of;Antiepileptic Drugs; GABAergic Transmission Enhancers;Signal Transduction Modulators; Epoxide hydrolase Inhibitor;"
CBR-001-574-419-1,RFM-003-215-5,CBR-001-574-419-1,Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1,"CBR-HVAC-02659: Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy;Antiobesity Drugs;Smoking Cessation, Aid to;Type 2 Diabetes, Agents for;Treatment of Alcohol Dependency;Antiparkinsonian Drugs; Cannabinoid CB1 Antagonists;IL-6 Production Inhibitors;Signal Transduction Modulators; Cannabinoid receptor 1 Antagonist; Cannabinoid CB1 receptor antagonist"
CBR-001-574-420-4,RFM-003-216-6,CBR-001-574-420-4,OC[C@H]([C@H]([C@@H]([C@H](C(=O)O)O)O)O[C@@H]1O[C@H](CO)[C@@H]([C@@H]([C@H]1O)O)O)O,CBR-HVAC-06418: Dermatologic Drugs; Antioxidants;Chelating Agents;Matrix Metalloproteinase Inhibitors;
CBR-001-574-421-5,RFM-003-217-7,CBR-001-574-421-5,Clc1cc2N=CNS(=O)(=O)c2cc1S(=O)(=O)N,"CBR-HVAC-03144: Diuretics;Hypertension, Treatment of; Carbonic anhydrase Inhibitor;"
CBR-001-574-422-6,RFM-003-218-8,CBR-001-574-422-6,Cc1ncc[nH]1,Monomeric unit of the copolymer CBR-HVAC-01749
CBR-001-574-423-7,RFM-003-219-9,CBR-001-574-423-7,CCCCC(COC(=O)/C=C/c1ccc(cc1)OC)CC,CBR-HVAC-00921: Unidentified pharmacological activity
CBR-001-574-424-8,RFM-003-220-2,CBR-001-574-424-8,O=C1OC(CN1/N=C/c1ccc(o1)[N+](=O)[O-])CN1CCOCC1,CBR-HVAC-08876:
CBR-001-574-425-9,RFM-003-221-3,CBR-001-574-425-9,O=C(Nc1ccc2c(c1)c(N)cc(n2)C)Nc1ccc2c(c1)c(N)cc(n2)C,CBR-HVAC-09140: Antibacterial Drugs; Anthrax Lethal Factor Inhibitors;C5a Anaphylatoxin Chemotactic Receptor 1 (C5aR; CD88) Antagonists;Heparin Neutralizers;Signal Transduction Modulators;
CBR-001-574-426-0,RFM-003-222-4,CBR-001-574-426-0,CCN(CCNC(=O)c1c(C)[nH]c(c1C)/C=C/1\C(=O)Nc2c1cc(F)cc2)CC,CBR-HVAC-05606: Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2; Dardarin) Inhibitors;PDGFRbeta Inhibitors;RET Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; PDGFR beta Inhibitor; VEGFR tyrosine kinase inhibitor; Flt-3 kinase inhibitor; C-kit inhibitor; Colony stimulating factor 1 receptor antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist; RET tyrosine kinase inhibitor; Angiogenesis inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib; Platelet-derived growth factor receptor alpha kinase inhib
CBR-001-574-427-1,RFM-003-223-5,CBR-001-574-427-1,CC(C[N+](C)(C)C)OC(=O)C,CBR-HVAC-09616: ; Muscarinic acetylcholine receptor Agonist;
CBR-001-574-428-2,RFM-003-224-6,CBR-001-574-428-2,BrC(C(=O)NC(=O)N)C(C)C,CBR-HVAC-09731:
CBR-001-574-429-3,RFM-003-225-7,CBR-001-574-429-3,CC(CC(C(=O)NC(C(=O)NC(C(=O)O)CC(C)C)CCC(=O)N)NC(=O)C(Cc1c[nH]c2c1cccc2)NC(=O)C(Cc1cnc[nH]1)NC(=O)C(Cc1c[nH]c2c1cccc2)N)C,analog of CBR-HVAC-06240
CBR-001-574-430-6,RFM-003-226-8,CBR-001-574-430-6,O=C(c1cccnc1)O[C@@H]1[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c2cccnc2)[C@H]([C@@H]([C@H]1OC(=O)c1cccnc1)OC(=O)c1cccnc1)OC(=O)c1cccnc1,CBR-HVAC-14266
CBR-001-574-431-7,RFM-003-227-9,CBR-001-574-431-7,O=C1/C(=C/c2cnc3n2CCOC3)/[C@@H]2N1C(=CS2)C(=O)O,analog of CBR-HVAC-05991
CBR-001-574-432-8,RFM-003-228-0,CBR-001-574-432-8,CS(=O)(=O)OCCCCOS(=O)(=O)C,CBR-HVAC-01371: Hematologic Agents (Miscellaneous);Myeloid Leukemia Therapy; Antimitotic Drugs;DNA-Damaging Drugs; Glutathione S-transferase Inhibitor; DNA inhibitor
CBR-001-574-433-9,RFM-003-229-1,CBR-001-574-433-9,Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1c1ccccc1,CBR-HVAC-05099: Antibacterial Drugs; CYP2C Inhibitor;
CBR-001-574-434-0,RFM-003-230-4,CBR-001-574-434-0,Clc1ccc(cc1)Cn1c(CN2CCCC2)nc2c1cccc2,CBR-HVAC-02463: ; Histamine H1 receptor Antagonist; HCV nonstructural protein 4B inhibitor
CBR-001-574-435-1,RFM-003-231-5,CBR-001-574-435-1,CC(CC(c1ccc(cc1)OCCOCC[N+](Cc1ccccc1)(C)C)(C)C)(C)C,CBR-HVAC-01328: ; CYP2C9; CYP3A4 Inhibitor; Sodium channel antagonist; Potassium channel antagonist; Membrane integrity inhibitor
CBR-001-574-436-2,RFM-003-232-6,CBR-001-574-436-2,O=C(c1cc(O)c(c(c1)OC(=O)c1cc(O)c(c(c1)O)O)O)O[C@@H]1[C@@H](COC(=O)c2cc(O)c(c(c2)OC(=O)c2cc(O)c(c(c2)O)O)O)O[C@H]([C@@H]([C@H]1OC(=O)c1cc(O)c(c(c1)OC(=O)c1cc(O)c(c(c1)O)O)O)OC(=O)c1cc(O)c(c(c1)OC(=O)c1cc(O)c(c(c1)O)O)O)OC(=O)c1cc(O)c(c(c1)OC(=O)c1cc(O)c(c(c1)O)O)O,CBR-HVAC-10318: ; Drugs Acting on Quorum Sensing Signaling;poly(ADP-ribose) Glycohydrolase (PARG) Inhibitors; Epidermal growth factor receptor tyrosine kinase Inhibitor;
CBR-001-574-437-3,RFM-003-233-7,CBR-001-574-437-3,OCC(CNC(=O)c1c(I)c(N(C(=O)C)CC(CN(c2c(I)c(C(=O)NCC(CO)O)c(c(c2I)C(=O)NCC(CO)O)I)C(=O)C)O)c(c(c1I)C(=O)NCC(CO)O)I)O,CBR-HVAC-02095: Contrast MediaNot applicable
CBR-001-574-438-4,RFM-003-234-8,CBR-001-574-438-4,Clc1ccc(cc1)Oc1ccc(cc1Cl)NC(=O)c1cc(I)cc(c1O)I,CBR-HVAC-10046:
CBR-001-574-439-5,RFM-003-235-9,CBR-001-574-439-5,OC(=O)CCCc1ccccc1,"CBR-HVAC-02288: Cystic Fibrosis, Treatment of ;Aminoacidopathies, Treatment for;Myeloid Leukemia Therapy;Alzheimer's Dementia, Treatment of ;Glioblastoma Multiforme Therapy;Brain Cancer Therapy;Lymphoma Therapy;Huntington's Disease, Treatment of;Neurologic Drugs (Miscellaneous);Prostate Cancer Therapy;Colorectal Cancer Therapy; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors;Pharmacological Chaperones;Pyruvate Dehydrogenase Kinase (PDHK; PDK) Inhibitors;Signal Transduction Modulators; Histone deacetylase 1 Inhibitor; Unidentified pharmacological activity"
CBR-001-574-440-8,RFM-003-236-0,CBR-001-574-440-8,C[C@H]([C@H]1C(=O)N2[C@@H]1[C@@H](C)C(=C2C(=O)[O-])SC1C[n+]2n(C1)cnc2)O,"CBR-HVAC-01557: Antibiotics;Septic Shock, Treatment of Cell wall synthesis inhibitor"
CBR-001-574-441-9,RFM-003-237-1,CBR-001-574-441-9,Clc1cc(Sc2cc(Cl)cc(c2O)Cl)c(c(c1)Cl)O,CBR-HVAC-02427: Autotaxin inhibitor
CBR-001-574-442-0,RFM-003-238-2,CBR-001-574-442-0,O=C1C=C(c2ccccc2)N(C(=O)C1=C(c1ccccc1)N)C,analog of CBR-HVAC-08316
CBR-001-574-443-1,RFM-003-239-3,CBR-001-574-443-1,COc1ccc2c(c1)C(=O)N(C(=O)C2(C)C)CCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,"CBR-HVAC-01836: Type 2 Diabetes, Agents for; K(ATP) Channel Blockers; Potassium channel Blocker; ATP-sensitive potassium channel antagonist; Sulfonylurea; Insulin secretagogue"
CBR-001-574-444-2,RFM-003-240-6,CBR-001-574-444-2,CC(=O)SC[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)Cc1ccccc1)C,CBR-HVAC-02057: ; Angiotensin I converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor; Adrenoreceptor antagonist
CBR-001-574-445-3,RFM-003-241-7,CBR-001-574-445-3,C[C@@H]1CC[C@@]2(OC1)O[C@@H]1[C@H]([C@@H]2C)[C@@]2([C@@H](C1)[C@@H]1CC=C3[C@]([C@H]1CC2)(C)CC[C@@H](C3)O)C,CBR-HVAC-10346: Oncolytic Drugs;Chemopreventive Agents; Apoptosis Inducers;
CBR-001-574-446-4,RFM-003-242-8,CBR-001-574-446-4,COc1cc2C[C@@H](c2cc1OC)CN(CCCN1CCc2c(CC1=O)cc(c(c2)OC)OC)C,CBR-HVAC-02608: ; Beta adrenergic receptor Blocker; Sodium channel antagonist; Potassium channel antagonist; HCN channel antagonist
CBR-001-574-447-5,RFM-003-243-9,CBR-001-574-447-5,O=C(Cc1ccccc1)NC(=O)N,CBR-HVAC-09634: ; Dihydrofolate reductase Inhibitor;
CBR-001-574-448-6,RFM-003-244-0,CBR-001-574-448-6,N=C1C=CC(=C(c2ccc(c(c2)C)N)c2ccc(c(c2)C)N)C=C1,CBR-HVAC-09004:
CBR-001-574-449-7,RFM-003-245-1,CBR-001-574-449-7,O=C1C(c2ccccc2)C(=O)c2c1cccc2,CBR-HVAC-03156: Anticoagulants; Vitamin K epoxide reductase Antagonist;
CBR-001-574-450-0,RFM-003-246-2,CBR-001-574-450-0,NCCCCCCN,ligand of CBR-HVAC-04785
CBR-001-574-451-1,RFM-003-247-3,CBR-001-574-451-1,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CCCC[C@H]12,CBR-HVAC-05850:
CBR-001-574-452-2,RFM-003-248-4,CBR-001-574-452-2,CCOC(=O)COc1ccc2c(c1Cl)oc(=O)c(c2C)CCN(CC)CC,CBR-HVAC-02149: Vasodilators;Antiplatelet Therapy; Thromboxane A2 synthase Inhibitor; Platelet aggregation inhibitor; Tumour necrosis factor receptor antagonist; Platelet activating factor antagonist
CBR-001-574-453-3,RFM-003-249-5,CBR-001-574-453-3,CN(CCOc1cc(C)c(cc1C(C)C)OC(=O)C)C,CBR-HVAC-02411: ; Alpha-1 adrenergic receptor Antagonist; Unidentified pharmacological activity
CBR-001-574-454-4,RFM-003-250-8,CBR-001-574-454-4,OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O,CBR-HVAC-01268: Immunosuppressant
CBR-001-574-455-5,RFM-003-251-9,CBR-001-574-455-5,OC1C2OP(=O)(O)OCC2OC1n1c(Cl)nc2c1ncnc2N,CBR-HVAC-00486: Colorectal Cancer TherapyCyclic AMP stimulant; DNA synthesis inhibitor
CBR-001-574-456-6,RFM-003-252-0,CBR-001-574-456-6,OC(=O)c1ccccc1OC1CN(C1)C(c1ccccc1)c1ccccc1,analog of CBR-HVAC-10736
CBR-001-574-457-7,RFM-003-253-1,CBR-001-574-457-7,OC(=O)[C@H]([C@@H](c1ccc(c(c1)O)O)O)N,"CBR-HVAC-01886: Fibromyalgia, Treatment of;Neurologic Drugs (Miscellaneous);Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Antiparkinsonian Drugs;Hypotension, Treatment of; COMT Inhibitors;Norepinephrine Precursors;Signal Transduction Modulators; Beta adrenoreceptor agonist"
CBR-001-574-458-8,RFM-003-254-2,CBR-001-574-458-8,CN(CCCN1c2ccccc2Sc2c1cccc2)C,CBR-HVAC-03928: Antipsychotic Drugs; Dopamine Receptor Antagonists;Signal Transduction Modulators;
CBR-001-574-459-9,RFM-003-255-3,CBR-001-574-459-9,Oc1ccc2c(n1)cc(cc2)OCCCCN1CCN(CC1)c1cccc2c1ccs2,"CBR-HVAC-00889: Antidepressants;Mood Disorders, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Antipsychotic Drugs;Posttraumatic Stress Disorder (PTSD), Treatment of; alpha1B-Adrenoceptor Antagonists;Dopamine D2 Receptor Partial Agonists;Signal Transduction Modulators;5-HT1A Receptor Partial Agonists;5-HT2A Antagonists; Dopamine D2 receptor agonist; Dopamine D3 receptor agonist; 5 Hydroxytryptamine 1A receptor agonist; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-574-460-2,RFM-003-256-4,CBR-001-574-460-2,OC(=O)c1ccccc1S,component of CBR-HVAC-09110
CBR-001-574-461-3,RFM-003-257-5,CBR-001-574-461-3,CC1(CC)CC(=O)NC1=O,CBR-HVAC-04187: Antiepileptic Drugs; Calcium channel T-type Blocker;
CBR-001-574-462-4,RFM-003-258-6,CBR-001-574-462-4,CC[C@@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H]1CCC(=O)N1)CCCNC(=N)N)CCC(=O)N)C,CBR-HVAC-10168: ; Angiotensin I converting enzyme Inhibitor;
CBR-001-574-463-5,RFM-003-259-7,CBR-001-574-463-5,OC[C@@H]1CC[C@@H](O1)n1cnc2c1ncnc2N,CBR-HVAC-03578: AIDS Medicines;Antiviral Drugs; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleoside reverse transcriptase inhibitor
CBR-001-574-464-6,RFM-003-260-0,CBR-001-574-464-6,CC[N+](CCOc1ccc(cc1)/C=C/c1ccccc1)(CC)CC,CBR-HVAC-09065: Antispastic Drugs and Drugs for Muscle Spasms;Oncolytic Drugs; Angiogenesis Inhibitors;Apoptosis Inducers;Nicotinic alpha7 Antagonists;Signal Transduction Modulators;
CBR-001-574-465-7,RFM-003-261-1,CBR-001-574-465-7,Cn1ncc(c1)c1[nH]c2c3c1cn[nH]c(=O)c3cc(c2)NC(=O)[C@@H](C1CCCCC1)N,CBR-HVAC-06432: Solid Tumors Therapy;Antineoplastic Enhancing Agents; Checkpoint Kinase 1 (Chk1) Inhibitors;Signal Transduction Modulators; Checkpoint kinase 1 Inhibitor;
CBR-001-574-466-8,RFM-003-262-2,CBR-001-574-466-8,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cc(F)c(=O)[nH]c1=O,analog of CBR-HVAC-04908
CBR-001-574-467-9,RFM-003-263-3,CBR-001-574-467-9,CCN(CCNc1ccc2c3c1c(=O)c1cc(O)ccc1n3cn2)CC,"CBR-HVAC-04750: Multiple Sclerosis, Agents for;Breast Cancer Therapy;Colorectal Cancer Therapy;Solid Tumors Therapy;Hematological Cancer Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs;Flt3 (FLK2/STK1) Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Signal Transduction Modulators;Vascular Endothelial Growth Factor (VEGF) Inhibitors; FLT3; Topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; Flt-3 kinase inhibitor"
CBR-001-574-468-0,RFM-003-264-4,CBR-001-574-468-0,COCC(=O)O[C@]1(CCN(CCCc2nc3c([nH]2)cccc3)C)CCc2c([C@@H]1C(C)C)ccc(c2)F,CBR-HVAC-02826: ; Calcium channel T-type Antagonist; T-type calcium channel antagonist; Angiogenesis inhibitor
CBR-001-574-469-1,RFM-003-265-5,CBR-001-574-469-1,NCc1ccc(cc1)S(=O)(=O)N,CBR-HVAC-01556: ; Carbonic anhydrase Inhibitor; Unidentified pharmacological activity
CBR-001-574-470-4,RFM-003-266-6,CBR-001-574-470-4,OCCCCO,CBR-HVAC-05738: Antinarcoleptic Drugs;Pharmacological Tools
CBR-001-574-471-5,RFM-003-267-7,CBR-001-574-471-5,CCOC(=O)n1ccn(c1=S)C,CBR-HVAC-06501: Thyroid Disease Therapy
CBR-001-574-472-6,RFM-003-268-8,CBR-001-574-472-6,O=c1oc2cc(ccc2c2c1CCCCC2)OS(=O)(=O)N,CBR-HVAC-05440: Breast Cancer Therapy;Female Reproductive System Cancer Therapy;Prostate Cancer Therapy; Carbonic Anhydrase Type II Inhibitors;Steryl Sulfatase Inhibitors; Steroid sulfatase inhibitor
CBR-001-574-473-7,RFM-003-269-9,CBR-001-574-473-7,N#Cc1c[nH]c2c1cccc2C(=O)N1CCN(CC1)CCc1ccc(cc1)F,CBR-HVAC-00550: ; 5-Hydroxytryptamine 2A receptor Antagonist; 5 Hydroxytryptamine 2A receptor antagonist
CBR-001-574-474-8,RFM-003-270-2,CBR-001-574-474-8,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1[nH]cc(n1)c1ccc2c(c1)O[C@H](n1c2cc2c1ccc(c2)c1c[nH]c(n1)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)c1ccccc1)C(C)C,CBR-HVAC-07321: Anti-Hepatitis C Virus Drugs; HCV NS5A Inhibitors;
CBR-001-574-475-9,RFM-003-271-3,CBR-001-574-475-9,COc1ccc(cc1)C(=O)CC(=O)c1ccc(cc1)C(C)(C)C,CBR-HVAC-09542:
CBR-001-574-476-0,RFM-003-272-4,CBR-001-574-476-0,CC(=O)[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CC[C@@H](C2)OS(=O)(=O)O,analog of CBR-HVAC-05445 (Prasterone sulfate)
CBR-001-574-477-1,RFM-003-273-5,CBR-001-574-477-1,NC(c1ccccc1)C(=O)OCCC(C)C,CBR-HVAC-08639:
CBR-001-574-478-2,RFM-003-274-6,CBR-001-574-478-2,Clc1ccc2c(c1)/C(=C/c1[nH]c(cc1C)C)/C(=O)N2,CBR-HVAC-09451: Oncolytic Drugs;Leukemia Therapy; Angiogenesis Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Fms-related tyrosine kinase 3; KIT; PDGFR; VEGFR-2 Inhibitor;
CBR-001-574-479-3,RFM-003-275-7,CBR-001-574-479-3,CCC(c1ccccc1)C(=O)NC(=O)N,CBR-HVAC-08631:
CBR-001-574-480-6,RFM-003-276-8,CBR-001-574-480-6,OC1CCC2C1(C)CCC1C2CCC2=CCCCC12,analog of CBR-HVAC-09582
CBR-001-574-481-7,RFM-003-277-9,CBR-001-574-481-7,O=NC1CC[C@H]2C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@]2(O)C#C)CC,CBR-HVAC-05496: Contraceptives;Hormone Replacement Therapy; Progesterone receptor Agonist;
CBR-001-574-482-8,RFM-003-278-0,CBR-001-574-482-8,CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C)C(=O)C,"CBR-HVAC-02584: Treatment of Preterm Labor;Female Reproductive System Cancer Therapy;Gynecological Disorders, Treatment of ; Cytostatic activity on endometrial carcinoma; Progesterone receptor agonist"
CBR-001-574-483-9,RFM-003-279-1,CBR-001-574-483-9,CN/C(=C\[N+](=O)[O-])/NCCSCc1csc(n1)CN(C)C,"CBR-HVAC-01770: Gastric Antisecretory Drugs;Agents for Gastritis;Gastroesophageal Reflux Disease, Agents for;Esophageal Diseases, Treatment of; Histamine H2 Receptor Antagonists;Signal Transduction Modulators; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist"
CBR-001-574-484-0,RFM-003-280-4,CBR-001-574-484-0,O=C([C@H](S(=O)(=O)[O-])c1ccccc1)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[n+]1ccc(cc1)C(=O)N,CBR-HVAC-02049: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-574-485-1,RFM-003-281-5,CBR-001-574-485-1,Fc1cccc(c1c1nnc2n1nc(OCc1ncnn1C)c(c2)C1CCC1)F,CBR-HVAC-06725: Anxiolytics; GABA(A) BZ Site Receptor Modulators;Signal Transduction Modulators; GABA A receptor alpha-2 subunit; Benzodiazepine receptor; GABA A receptor alpha-3 subunit Agonist; GABA A alpha2 agonist; GABA A alpha3 agonist
CBR-001-574-486-2,RFM-003-282-6,CBR-001-574-486-2,Oc1ccc(cc1)c1[nH]c2c(c1)c(ncn2)N[C@@H](c1ccccc1)C,CBR-HVAC-05022: Solid Tumors Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators; EGFR Inhibitor; ErbB-2 tyrosine kinase inhibitor; EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-574-487-3,RFM-003-283-7,CBR-001-574-487-3,Clc1c[nH]c2c1cccc2NS(=O)(=O)c1ccc(cc1)S(=O)(=O)N,CBR-HVAC-00488: Gastric Cancer Therapy;Breast Cancer Therapy;Melanoma Therapy;Colorectal Cancer Therapy;Pancreatic Cancer Therapy;Head and Neck Cancer Therapy;Myeloid Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Small Cell Lung Cancer Therapy; Apoptosis Inducers;Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type IV Inhibitors;Carbonic Anhydrase Type IX Inhibitors;Carbonic Anhydrase Type VB Inhibitors;Drugs Targeting Cell Cycle Proteins;Signal Transduction Modulators; Carbonic anhydrase Inhibitor; Sulfonamide antibiotic; p53 stimulant; p21 stimulant; Cyclin-dependent kinase inhibitor; DNA topoisomerase II inhibitor; Cell cycle inhibitor
CBR-001-574-488-4,RFM-003-284-8,CBR-001-574-488-4,O=C1N(CCCCN2CCN(CC2)c2ncccn2)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1,"CBR-HVAC-01946: Generalized Anxiety Disorder (GAD), Treatment of;Antipsychotic Drugs;Antidepressants; Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Partial Agonist; 5 Hydroxytryptamine 1A receptor agonist"
CBR-001-574-489-5,RFM-003-285-9,CBR-001-574-489-5,CC(CNCc1ccc(cc1)c1ccccc1S(=O)(=O)N1CCCC1)C,"CBR-HVAC-06979: Bipolar Disorder, Treatment of;Antidepressants; kappa-Opioid Antagonists;Signal Transduction Modulators; OPIOID RECEPTOR KAPPA Modulator;"
CBR-001-574-490-8,RFM-003-286-0,CBR-001-574-490-8,NC(C(=O)NC(C(=O)O)Cc1ccc(cc1)O)C(C)C,"CBR-HVAC-05392: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors;"
CBR-001-574-491-9,RFM-003-287-1,CBR-001-574-491-9,O=C(N1CC(=O)N2C(C1)c1ccccc1CC2)C1CCCCC1,CBR-HVAC-01923: Treatment of Helminthic Diseases; Glutathione S-transferase Inhibitor; Membrane permeability enhancer
CBR-001-574-492-0,RFM-003-288-2,CBR-001-574-492-0,CCP(=[Au]S[C@@H]1O[C@H](COC(=O)C)[C@H]([C@@H]([C@H]1OC(=O)C)OC(=O)C)OC(=O)C)(CC)CC,CBR-HVAC-09541: ; Neutrophil 5-lipoxygenase; Thioredoxin reductase Inhibitor;
CBR-001-574-493-1,RFM-003-289-3,CBR-001-574-493-1,CCCN(C1CCc2c(C1)cc(cc2)O)CCC,CBR-HVAC-11913: ; 5-Hydroxytryptamine 1 receptor; Dopamine D3 receptor Modulator; Agonist;
CBR-001-574-494-2,RFM-003-290-6,CBR-001-574-494-2,Fc1ccc(cc1)C(=O)C1CCN(CC1)CC(=O)c1ccc2c(c1)cccc2,"CBR-HVAC-10458: Cognition Disorders, Treatment of;Stroke, Treatment of; Calcium Channel Blockers;"
CBR-001-574-495-3,RFM-003-291-7,CBR-001-574-495-3,Clc1ccc(cc1)N1CCN(CC1)Cc1c[nH]c2c1cccn2,"CBR-HVAC-11091: Amyotrophic Lateral Sclerosis, Agents for;Extrapyramidal Disorders, Treatment of;Antipsychotic Drugs; Dopamine D4 Antagonists;Signal Transduction Modulators; Dopamine receptor D4 Antagonist;"
CBR-001-574-496-4,RFM-003-292-8,CBR-001-574-496-4,N1CCC(CC1)c1ccccc1,analog of CBR-HVAC-07787
CBR-001-574-497-5,RFM-003-293-9,CBR-001-574-497-5,CC(=O)Oc1ccc(cc1)C(=C1CCCCC1)c1ccc(cc1)OC(=O)C,CBR-HVAC-02100: ; Estrogen receptor beta Antagonist; Luteinizing hormone releasing hormone (LHRH) agonist
CBR-001-574-498-6,RFM-003-294-0,CBR-001-574-498-6,NC1CCN(C1)c1nc2n(cc(c(=O)c2cc1F)C(=O)O)c1ccc(cc1F)F,CBR-HVAC-02314: Antibacterial Ophthalmic Drugs;Antibacterial Drugs; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; DNA topoisomerase II inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-574-499-7,RFM-003-295-1,CBR-001-574-499-7,CCN(CCNC(=O)c1ccc(cc1)NS(=O)(=O)C)CC,CBR-HVAC-03820: Antiarrhythmic Drugs; IKr potassium channel Blocker; Potassium channel antagonist; Polarisation inhibitor
CBR-001-574-500-3,RFM-003-296-2,CBR-001-574-500-3,COCCCN1C[C@H](NCC)c2c(S1(=O)=O)sc(c2)S(=O)(=O)N,CBR-HVAC-01672: Antiglaucoma Agents; Carbonic Anhydrase Type II Inhibitors;Carbonic Anhydrase Type VII Inhibitors; Carbonic anhydrase II Inhibitor; Carbonic anhydrase inhibitor
CBR-001-574-501-4,RFM-003-297-3,CBR-001-574-501-4,CN(CCOC(=O)COc1ccc(cc1)Cl)C,"CBR-HVAC-10065: Neurodegenerative Diseases, Treatment of;Cognition Disorders, Treatment of; Antioxidants;Free Radical Scavengers;"
CBR-001-574-502-5,RFM-003-298-4,CBR-001-574-502-5,Oc1ccccc1,CBR-HVAC-09637: ; Albumin; Succinate oxidase Inhibitor;
CBR-001-574-503-6,RFM-003-299-5,CBR-001-574-503-6,COc1ccc(cc1)CN(c1ncccn1)CCN(C)C,CBR-HVAC-10321:
CBR-001-574-504-7,RFM-003-300-1,CBR-001-574-504-7,[Hg+]c1ccccc1,CBR-HVAC-09043:
CBR-001-574-505-8,RFM-003-301-2,CBR-001-574-505-8,OCCN(CCCOc1ccc2c(c1)ncnc2Nc1n[nH]c(c1)CC(=O)Nc1cccc(c1)F)CC,CBR-HVAC-06423: Solid Tumors Therapy;Hematological Cancer Therapy; Antimitotic Drugs;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;Signal Transduction Modulators;
CBR-001-574-506-9,RFM-003-302-3,CBR-001-574-506-9,OC(=O)CCC(=O)O[C@H]1O[C@@H]2OC3(C)CC[C@@H]4[C@]2([C@H]([C@H]1C)CC[C@H]4C)OO3,CBR-HVAC-02625: DNA synthesis inhibitor
CBR-001-574-507-0,RFM-003-303-4,CBR-001-574-507-0,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)Cc1cn3c(nc1C2)nc1c3cccc1,CBR-HVAC-11486 Pharmacological Tools; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin receptor 1 Antagonist;
CBR-001-574-508-1,RFM-003-304-5,CBR-001-574-508-1,CO[C@@H]1[C@@H](OC(=O)N)[C@@H](O)[C@@H](OC1(C)C)Oc1ccc2c(c1C)oc(=O)c(c2O)NC(=O)c1ccc(c(c1)CC=C(C)C)O,CBR-HVAC-02869: Antibacterial Drugs;Oncolytic Drugs; DNA Gyrase Inhibitors;Heat Shock Protein 90 (HSP90) Inhibitors;Signal Transduction Modulators; DNA gyrase Inhibitor;
CBR-001-574-509-2,RFM-003-305-6,CBR-001-574-509-2,COc1ccccc1CN[C@@H]1CCCN[C@@H]1c1ccccc1,"CBR-HVAC-04392: Non-Opioid Analgesics;Nausea and Vomiting, Treatment of; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin receptor 1 Antagonist; Neurokinin 1 receptor antagonist"
CBR-001-574-510-5,RFM-003-306-7,CBR-001-574-510-5,O=C([C@@H]1[C@H](C1(C)C)C=C(Cl)Cl)OCc1c(F)c(F)cc(c1F)F,analog of CBR-HVAC-10201
CBR-001-574-511-6,RFM-003-307-8,CBR-001-574-511-6,NC(=O)[C@@H](NCc1ccc(cc1)OCc1ccccc1F)C,"CBR-HVAC-00115: Neuropathic Pain, Treatment of;Analgesic Drugs; Sodium Channel  Blockers; Sodium channel Antagonist; Voltage-gated sodium channel antagonist; Calcium channel antagonist; Substance P release inhibitor; Calcium channel agonist"
CBR-001-574-512-7,RFM-003-308-9,CBR-001-574-512-7,c1ccc2c(c1)cccc2,CBR-HVAC-10192:
CBR-001-574-513-8,RFM-003-309-0,CBR-001-574-513-8,Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)ccs2)c1ccc(cc1)F,CBR-HVAC-03235: Antipsychotic Drugs;Anxiolytics;Treatment of Alcohol Dependency;Antidepressants; Signal Transduction Modulators;5-HT2A Antagonists; 5-Hydroxytryptamine 2 receptor Antagonist; 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 2C receptor antagonist
CBR-001-574-515-0,RFM-003-310-3,CBR-001-574-515-0,CC(=O)OC/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,CBR-HVAC-06158: Chemopreventive Agents;Therapy of Vitamin-Related Disorders; Antioxidants;
CBR-001-574-516-1,RFM-003-311-4,CBR-001-574-516-1,OCC(CCn1cnc2c1nc(N)nc2O)CO,CBR-HVAC-01901: DNA Polymerase Inhibitors; DNA directed DNA polymerase inhibitor; DNA polymerase Inhibitor; Anti-Herpes Labialis Drugs; Antiviral; DNA polymerase inhibitor
CBR-001-574-517-2,RFM-003-312-5,CBR-001-574-517-2,O=C(CC12CCCN2CCC1)Nc1c(C)cccc1C,CBR-HVAC-01444: Antiarrhythmic Drugs; Sodium Channel  Blockers; Sodium channel Antagonist; Voltage-gated sodium channel antagonist
CBR-001-574-518-3,RFM-003-313-6,CBR-001-574-518-3,ClC=C(Cl)Cl,CBR-HVAC-10226:
CBR-001-574-519-4,RFM-003-314-7,CBR-001-574-519-4,COC1CNCCC1NC(=O)c1cc(Cl)c(cc1OC)N,"CBR-HVAC-04835: Prokinetic Agents;Gastroesophageal Reflux Disease, Agents for; Muscarinic acetylcholine receptor Agonist;"
CBR-001-574-520-7,RFM-003-315-8,CBR-001-574-520-7,C[C@@H](CCC[C@]1(C)CCc2c(O1)c(C)c(c(c2C)O)C)CCC[C@@H](CCCC(C)C)C,CBR-HVAC-02872: Antioxidants; Cytosolic phospholipase A2 Inhibitor;
CBR-001-574-521-8,RFM-003-316-9,CBR-001-574-521-8,CCCCCCCCCCCCCCCCOP(=O)(OCC[N+](C)(C)C)O,"CBR-HVAC-02273: Urticaria, Treatment for;Antifungal Agents;Breast Cancer Therapy;Antileishmanials;Atopic Dermatitis, Agents for;Allergic Skin Disorders, Treatment for; Angiogenesis Inhibitors; Protein kinase C Inhibitor; Membrane integrity inhibitor"
CBR-001-574-522-9,RFM-003-317-0,CBR-001-574-522-9,Cc1ccccn1,an uninteresting ligand which is part of picoplatin.
CBR-001-574-523-0,RFM-003-318-1,CBR-001-574-523-0,OC(=O)C1C(=O)C2(C(C1CC2)(C)C)C,CBR-HVAC-08795:
CBR-001-574-524-1,RFM-003-319-2,CBR-001-574-524-1,CCCN(C(=O)Cc1c(nc2n1cc(Cl)cc2)c1ccc(cc1)Cl)CCC,CBR-HVAC-02832: Anxiolytics; Peripheral benzodiazepine receptor Agonist; Benzodiazepine receptor agonist
CBR-001-574-525-2,RFM-003-320-5,CBR-001-574-525-2,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(I)c(=O)[nH]c1=O,CBR-HVAC-01388: ; Thymidylate synthase Inhibitor; DNA directed DNA polymerase inhibitor; DNA directed RNA polymerase inhibitor
CBR-001-574-526-3,RFM-003-321-6,CBR-001-574-526-3,CCCCCCCCCCCCCCCC(=O)OC/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,CBR-HVAC-06159: Chemopreventive Agents;Premalignant Conditions Therapy;Therapy of Vitamin-Related Disorders; Antioxidants;
CBR-001-574-527-4,RFM-003-322-7,CBR-001-574-527-4,[O-]C(=O)C(CC(=O)[O-])(CC(=O)[O-])O,CBR-HVAC-14439: Antibacterial Drugs; Anticoagulants
CBR-001-574-528-5,RFM-003-323-8,CBR-001-574-528-5,Clc1ccc(c(c1)Cl)C1(OCC(O1)COc1ccc(cc1)N1CCN(CC1)C(C)C)Cn1cncn1,CBR-HVAC-01538: Antifungal Agents; Lanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor; Sterol demethylase inhibitor
CBR-001-574-529-6,RFM-003-324-9,CBR-001-574-529-6,CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3,CBR-HVAC-02783: Antiparkinsonian Drugs; Calcium-Activated K(Ca) Channel Blockers;Dopamine Receptor Agonists;K(V) 1.5 (KCNA5) Channel Blockers;Signal Transduction Modulators; Dopamine receptor Agonist; Dopamine D1 receptor agonist; Dopamine D2 receptor agonist; Prolactin inhibitor
CBR-001-574-530-9,RFM-003-325-0,CBR-001-574-530-9,O=C1C(=O)C2=C1NCCCN2CCP(=O)(O)O,"CBR-HVAC-04354: Neuropathic Pain, Treatment of;Ischemic Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Glycine NMDA associated antagonist"
CBR-001-574-531-0,RFM-003-326-1,CBR-001-574-531-0,Oc1cc2CCNC(c2cc1O)Cc1cccc2c1cccc2,"CBR-HVAC-06041: Sepsis, Treatment of; NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide (NO) Production Inhibitors;NOS2 Expression Inhibitors;Signal Transduction Modulators; Janus kinase 2 inhibitor; STAT transcription factor 1 inhibitor; Tumour necrosis factor alpha antagonist; Transcription factor NF-kappaB inhibitor; Interleukin 6 antagonist"
CBR-001-574-532-1,RFM-003-327-2,CBR-001-574-532-1,COc1cc2N(C)[C@@H]3[C@@]4(c2cc1[C@]1(C[C@@H]2CN(CCc5c1[nH]c1c5cccc1)C[C@](C2)(O)CC)C(=O)OC)CCN1[C@H]4[C@@]([C@H]([C@]3(O)C(=O)N)O)(CC)C=CC1,CBR-HVAC-02031: Oncolytic Drugs; Beta tubulin Inhibitor; Microtubule inhibitor; Tubulin inhibitor; Vinca alkaloid
CBR-001-574-533-2,RFM-003-328-3,CBR-001-574-533-2,OC(=O)[C@@H](N[C@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)O)C)CCc1ccccc1,CBR-HVAC-02083: ; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor
CBR-001-574-534-3,RFM-003-329-4,CBR-001-574-534-3,C[C@H]([C@@H]1[C@H]2CC(=C(N2C1=O)C(=O)O)SCCNC=N)O,CBR-HVAC-02040: ; Beta-lactamase; Penicillin binding protein 2 Inhibitor; Cell wall synthesis inhibitor
CBR-001-574-535-4,RFM-003-330-7,CBR-001-574-535-4,OCC1OC(=O)N(C1)c1cccc(c1)C,CBR-HVAC-01600: Antidepressants; MAO-A Inhibitors; Monoamine oxidase A Inhibitor; Monoamine oxidase A inhibitor
CBR-001-574-536-5,RFM-003-331-8,CBR-001-574-536-5,Nc1ccc(cc1)S(=O)(=O)Nc1nccc(n1)C,CBR-HVAC-09663: Dihydropteroate synthase Inhibitor;
CBR-001-574-537-6,RFM-003-332-9,CBR-001-574-537-6,Brc1cc(Br)c(c(c1)C(=O)Nc1cccc(c1)C(F)(F)F)O,CBR-HVAC-09105:
CBR-001-574-538-7,RFM-003-333-0,CBR-001-574-538-7,O=C(NS(=O)(=O)c1ccc(cc1)Cl)Nc1ccc(cc1)N(C)C,CBR-HVAC-08817:
CBR-001-574-539-8,RFM-003-334-1,CBR-001-574-539-8,O=C(c1sccc1S(=O)(=O)Nc1onc(c1Cl)C)Cc1cc2OCOc2cc1C,"CBR-HVAC-04812: Heart Failure Therapy;Pulmonary Hypertension, Treatment of;Coronary Bypass Surgery;Hypertension, Treatment of;Treatment of Renal Diseases; Cytochrome P450 CYP2C9 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist;"
CBR-001-574-540-1,RFM-003-335-2,CBR-001-574-540-1,CN1CCN2C(C1)c1ccccc1Cc1c2cccc1,CBR-HVAC-02178: Antidepressants; Signal Transduction Modulators;5-HT2A Antagonists; Histamine H1 receptor Inhibitor; 5 Hydroxytryptamine 2 receptor antagonist
CBR-001-574-541-2,RFM-003-336-3,CBR-001-574-541-2,COc1nccnc1NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08689:
CBR-001-574-542-3,RFM-003-337-4,CBR-001-574-542-3,O=C(c1cccc2c1oc(c1ccccc1)c(c2=O)C)OCCN1CCCCC1,CBR-HVAC-02169: ; Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist
CBR-001-574-543-4,RFM-003-338-5,CBR-001-574-543-4,CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C,"CBR-HVAC-00145: Pancreatic Cancer Therapy;Renal Cancer Therapy;Liver Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Colorectal Cancer Therapy;Gastric Cancer Therapy;Breast Cancer Therapy;Skin Cancer Therapy;Neurologic Cancer Therapy;Cancer Associated Disorders, Treatment of;Ovarian Cancer Therapy;Solid Tumors Therapy;Head and Neck Cancer Therapy; Dihydropyrimidine Dehydrogenase Inhibitors;Pyrimidine Antagonists; Thymidylate synthase Inhibitor; Thymidylate synthase inhibitor; DNA synthesis inhibitor; RNA synthesis inhibitor"
CBR-001-574-544-5,RFM-003-339-6,CBR-001-574-544-5,CCCCC(COC(=O)CC(S(=O)(=O)[O-])C(=O)OCC(CCCC)CC)CC,CBR-HVAC-03434
CBR-001-574-545-6,RFM-003-340-9,CBR-001-574-545-6,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc(nc1=O)N,CBR-HVAC-02342: Antimetabolites; Apoptosis Inducers; DNA Methyltransferase (DNMT) Inhibitors; DNA methylase inhibitor; DNA synthesis inhibitor; Orotidine-5'-phosphate decarboxylase Inhibitor; RNA synthesis inhibitor; Antineoplastic; Brain Cancer Therapy; Breast Cancer Therapy; Colorectal Cancer Therapy; Digestive/Gastrointestinal Cancer Therapy; Head and Neck Cancer Therapy; Hematopoiesis Disorders Therapy; Immunomodulators; Leukemia Therapy; Lymphocytic Leukemia Therapy; Melanoma Therapy; Multiple Myeloma Therapy; Myelodysplastic Syndrome Therapy; Myeloid Leukemia Therapy; Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Prostate Cancer Therapy; Respiratory/Thoracic Cancer Therapy; Sarcoma Therapy; Solid Tumors Therapy; Squamous Cell Carcinoma Therapy
CBR-001-574-546-7,RFM-003-341-0,CBR-001-574-546-7,FC[C@H]([C@@H](c1ccc(cc1)S(=O)(=O)C)O)NC(=O)C(Cl)Cl,CBR-HVAC-05112: Antibacterial DrugsProtein 50S ribosomal subunit inhibitor
CBR-001-574-547-8,RFM-003-342-1,CBR-001-574-547-8,O=C(C(S(=O)(=O)[O-])c1ccccc1)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)[O-])(C)C,CBR-HVAC-01568: Cell wall synthesis inhibitor
CBR-001-574-548-9,RFM-003-343-2,CBR-001-574-548-9,COc1cc(Cc2cnc(nc2N)N)c(cc1OC)C,CBR-HVAC-10018:
CBR-001-574-549-0,RFM-003-344-3,CBR-001-574-549-0,CCCC(=O)c1cc(F)ccc1OCC(CNC(C)(C)C)O,"CBR-HVAC-01638: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Antagonist; Beta adrenoreceptor antagonist"
CBR-001-574-550-3,RFM-003-345-4,CBR-001-574-550-3,CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)[C@H](C1CCCCC1)NC(=O)c1nccnc1,CBR-HVAC-01631: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors; NS3/4A protease Inhibitor; HCV nonstructural protein 3 inhibitor; Serine protease inhibitor
CBR-001-574-551-4,RFM-003-346-5,CBR-001-574-551-4,CC/C=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)OCOC(=O)C(C)(C)C)COC(=O)N,CBR-HVAC-01715: AntibioticsCell wall synthesis inhibitor
CBR-001-574-552-5,RFM-003-347-6,CBR-001-574-552-5,C/C(=C\C=C\C=C(\C=C\C=C(\C=C\C1=C(C)CCCC1(C)C)/C)/C)/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C,CBR-HVAC-05734: Oncolytic Drugs; Antioxidants;
CBR-001-574-553-6,RFM-003-348-7,CBR-001-574-553-6,O=CNc1coc2c(c1=O)cc(c(c2)NS(=O)(=O)C)Oc1ccccc1,"CBR-HVAC-03903: Disease-Modifying Anti-Rheumatic Drugs;Systemic Lupus Erythematosus, Agents for;Rheumatoid Arthritis, Treatment of; NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor; Cyclooxygenase 2 inhibitor; Disease modifying antirheumatic drug; Interleukin 1b antagonist; Interleukin 6 antagonist; Interleukin 8 antagonist; Tumour necrosis factor receptor antagonist"
CBR-001-574-554-7,RFM-003-349-8,CBR-001-574-554-7,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]2[C@@H]1[C@@H]1CC[C@]3([C@]1(CC2)C)CCC(=O)O3)C,CBR-HVAC-01422: ; Androgen receptor; Mineralocorticoid receptor Blocker; Aldosterone antagonist
CBR-001-574-555-8,RFM-003-350-1,CBR-001-574-555-8,CCC1(C(=O)NCNC1=O)c1ccccc1,CBR-HVAC-01632: Antiepileptic Drugs; Beta-lactamase; Chymotrypsinogen; Malate dehydrogenase Inhibitor; Unidentified pharmacological activity
CBR-001-574-556-9,RFM-003-351-2,CBR-001-574-556-9,COc1c(OC)cc2c(c1OC)c1ccc(c(=O)cc1[C@H](CC2)NC(=O)C)OC,"CBR-HVAC-01376: Treatment of Gout;Cardiovascular Diseases (Not Specified);Vasculitis, Agents for;Hematologic Genetic Disorders, Treatment of ;Antibiotics and Alkaloids; Antimitotic Drugs;Tubulin Polymerization Inhibitors; Beta tubulin Inhibitor; Microtubule inhibitor; Tubulin inhibitor"
CBR-001-574-557-0,RFM-003-352-3,CBR-001-574-557-0,OC(=O)CC[C@@H](C(=O)O)NC(=O)N,CBR-HVAC-01375: Metabolic Disorders (Not Specified); Carbamoyl Phosphate Synthetase 1 (CPS1) Activators; Carbamoyl phosphate synthetase 1 Activator; Carbamoyl phosphate synthetase 1 stimulant
CBR-001-574-558-1,RFM-003-353-4,CBR-001-574-558-1,C=CS(=O)(=O)[O-],CBR-HVAC-09115:
CBR-001-574-559-2,RFM-003-354-5,CBR-001-574-559-2,Nc1nc(N)c2c(n1)nc(c(n2)c1ccccc1)N,CBR-HVAC-00998: ; Dihydrofolate reductase Inhibitor; Potassium sparing diuretic
CBR-001-574-560-5,RFM-003-355-6,CBR-001-574-560-5,OC[C@H]1O[C@@]([C@H]([C@@H]1O[C@@H]1O[C@H](CO)[C@@H]([C@@H]([C@H]1O)O)O)O)(O)CO,CBR-HVAC-14252
CBR-001-574-561-6,RFM-003-356-7,CBR-001-574-561-6,CN1CCC2(CC1)COc1c2cc2c(c1)CCN2C(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C,CBR-HVAC-11285: Antidepressants;Anxiolytics; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Antagonists; 5-Hydroxytryptamine 1B receptor Antagonist;
CBR-001-574-562-7,RFM-003-357-8,CBR-001-574-562-7,OCC/C(=C(/N(Cc1cnc(nc1N)C)C=O)\C)/SSCC1CCCO1,CBR-HVAC-06115: Therapy of Vitamin-Related Disorders
CBR-001-574-563-8,RFM-003-358-9,CBR-001-574-563-8,O=C1CC[C@]2(C(=C1)[C@@H]1C[C@@H]1[C@@H]1[C@@H]2CC[C@]2([C@H]1[C@@H]1C[C@@H]1[C@]12CCC(=O)O1)C)C,"CBR-HVAC-02418: Mineralocorticoid Receptor (MR) Antagonists; Mineralocorticoid receptor Binder; Progesterone receptor; Signal Transduction Modulators; Acne Therapy; Contraceptive; Hormone Replacement Therapy; Premenstrual Syndrome, Treatment of"
CBR-001-574-564-9,RFM-003-359-0,CBR-001-574-564-9,CONC1=C(C)[C@H](O[C@]2(C1)C[C@@H]1C[C@H](O2)C/C=C(\C)/C[C@@H](C)/C=C/C=C\2/[C@]3([C@H](C(=O)O1)C=C(C)[C@H]([C@H]3OC2)O)O)/C(=C/C(C)C)/C,CBR-HVAC-03718: Treatment of Helminthic Diseases; Chloride channel antagonist
CBR-001-574-565-0,RFM-003-360-3,CBR-001-574-565-0,NCCCNCCCCNCCCN,CBR-HVAC-14212
CBR-001-574-566-1,RFM-003-361-4,CBR-001-574-566-1,COc1ccc2c(c1)ccc(c2)CCC(=O)C,"CBR-HVAC-01837: Rheumatoid Arthritis, Treatment of;Osteoarthritis, Treatment of; UTRN (Utrophin gene) Expression Enhancers;3alpha-Hydroxysteroid Dehydrogenase Inhibitors; Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-574-567-2,RFM-003-362-5,CBR-001-574-567-2,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2[C@H](O)C[C@]2([C@H]1CC[C@@H]2C(=O)C)C)C,CBR-HVAC-01358: Androgen receptor antagonist; RNA synthesis inhibitor
CBR-001-574-568-3,RFM-003-363-6,CBR-001-574-568-3,ClCCN(c1ccc(cc1)C[C@@H](C(=O)O)N)CCCl,CBR-HVAC-02361: DNA inhibitor
CBR-001-574-569-4,RFM-003-364-7,CBR-001-574-569-4,OC[C@H]([C@@H](c1ccc(cc1)[N+](=O)[O-])O)NC(=O)C(Cl)Cl,CBR-HVAC-02862: Antibacterial Drugs; 30S Ribosomal Protein Inhibitors; 50S-ribosomal subunit Inhibitor;
CBR-001-574-570-7,RFM-003-365-8,CBR-001-574-570-7,CCc1nc(N)nc(c1c1ccc(cc1)Cl)N,"CBR-HVAC-02443: Amyotrophic Lateral Sclerosis, Agents for;Therapy of Inborn Errors of Metabolism;Antimalarials;Treatment of Protozoal Diseases;Lymphocytic Leukemia Therapy;Treatment of Renal Diseases; Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones;Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators; Dihydrofolate reductase Inhibitor; Hexosaminidase stimulant"
CBR-001-574-571-8,RFM-003-366-9,CBR-001-574-571-8,O=C(Nc1ccc(cc1)C(=O)O)CCn1cnc2c1ncnc2O,"CBR-HVAC-00028: Lesions of the Spinal Cord and Related Structures, Treatment of;Disorders Associated with Cancer Therapy, Treatment of;Alzheimer's Dementia, Treatment of ;Antiparkinsonian Drugs; Neurotrophic Agents;Signal Transduction Modulators; NERVE GROWTH FACTOR RECEPTOR Agonist; Nerve growth factor agonist; Neurotrophin-3 receptor agonist; Oxygenase stimulant"
CBR-001-574-572-9,RFM-003-367-0,CBR-001-574-572-9,OC(=O)CC1=C(C)/C(=C\c2ccc(cc2)S(=O)C)/c2c1cc(F)cc2,"CBR-HVAC-01315: Ankylosing Spondylitis, Treatment of;Chemopreventive Agents;Osteoarthritis, Treatment of;Treatment of Gout;Rheumatoid Arthritis, Treatment of;Melanoma Therapy;Non-Opioid Analgesics; ABCC1 Expression Enhancers;ABCC3 Expression Enhancers;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Unidentified pharmacological activity"
CBR-001-574-573-0,RFM-003-368-1,CBR-001-574-573-0,NC1CC1c1ccccc1,CBR-HVAC-03123: Antidepressants; Cytochrome P450 CYP2A6 Inhibitors;Lysine-Specific Histone Demethylase 1A (KDM1A; LSD1) Inhibitors;MAO-A Inhibitors;MAO-B Inhibitors; Monoamine oxidase A; Monoamine oxidase B Inhibitor;
CBR-001-574-574-1,RFM-003-369-2,CBR-001-574-574-1,Cc1cc(ccc1/N=N/c1c(O)c2c(N)cc(cc2cc1S(=O)(=O)O)S(=O)(=O)O)c1ccc(c(c1)C)/N=N/c1c(O)c2c(N)cc(cc2cc1S(=O)(=O)O)S(=O)(=O)O,CBR-HVAC-09683
CBR-001-574-575-2,RFM-003-370-5,CBR-001-574-575-2,O=C([C@@H](NC(=O)c1ccccc1)Cc1ccc(cc1)O)Nc1ccc(cc1)C(=O)O,CBR-HVAC-02002: Not applicable
CBR-001-574-576-3,RFM-003-371-6,CBR-001-574-576-3,Cc1ccc(cc1)N(c1cccc(c1)O)C=C1NCCN1,analog of CBR-HVAC-03121
CBR-001-574-577-4,RFM-003-372-7,CBR-001-574-577-4,O=C(O[C@H]1CC[C@]2(C(C1(C)C)CC[C@@]1([C@@H]2C(=O)C=C2[C@@]1(C)CC[C@@]1([C@H]2CC(C)(CC1)C(=O)O)C)C)C)CCC(=O)O,"CBR-HVAC-00769: Wound-Healing Agents;Antipsoriatics;Acute Myocardial Infarction, Treatment of;Huntington's Disease, Treatment of; 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; 11 Beta hydroxysteroid dehydrogenase inhibitor"
CBR-001-574-578-5,RFM-003-373-8,CBR-001-574-578-5,OC[C@H]1O[C@H](O[C@H]2[C@H](N)C[C@@H]([C@H]([C@@H]2O)O[C@H]2O[C@H](CN)[C@H]([C@@H]([C@H]2O)O)O)N)[C@@H]([C@H]([C@@H]1O)N)O,CBR-HVAC-02882: Antibiotics; 16S Ribosomal Protein Inhibitors;30S Ribosomal Protein Inhibitors;
CBR-001-574-579-6,RFM-003-374-9,CBR-001-574-579-6,NCC(c1cccc(c1)O)O,CBR-HVAC-09433: ; ALPHA ADRENERGIC RECEPTOR Agonist;
CBR-001-574-580-9,RFM-003-375-0,CBR-001-574-580-9,O=C(NS(=O)(=O)c1ccc(cc1)C(=O)C)NC1CCCCC1,CBR-HVAC-03175: Antidiabetic Drugs; K(ATP) Channel Blockers; Sulfonylurea receptor Inhibitor;
CBR-001-574-581-0,RFM-003-376-1,CBR-001-574-581-0,OC(=O)CCc1c(C)[nH]c(c1C)/C=C/1\C(=O)Nc2c1cccc2,CBR-HVAC-00833: Breast Cancer Therapy;Gastric Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Solid Tumors Therapy;Liver Cancer Therapy; Angiogenesis Inhibitors;Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;FGFR1 Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;TANK-Binding Kinase 1 (TBK1; NAK; T2K) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors; Protein tyrosine kinase Inhibitor; VEGFR-2 tyrosine kinase inhibitor; Fibroblast growth factor receptor antagonist; FGF receptor 1 tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; Apoptosis stimulant; VEGFR tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib
CBR-001-574-582-1,RFM-003-377-2,CBR-001-574-582-1,Oc1cc2O[C@H](c3ccc(c(c3)O)O)[C@H](Cc2c(c1)O)O,"CBR-HVAC-14445: Antioxidants; Drugs Acting on Quorum Sensing Signaling; Fatty Acid Synthase (FAS) Inhibitors; Free radical scavenger; Immunostimulant; LDL Antioxidants; Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers; Reducing agent; beta-Secretase (BACE) Inhibitors; Chemopreventive Agents; Hepatoprotectants; Lipoprotein Disorders, Treatment of ; Treatment of Autoimmune Diseases"
CBR-001-574-583-2,RFM-003-378-3,CBR-001-574-583-2,NCCCCNC(=N)N,CBR-HVAC-04020: Treatment of Alcohol Dependency;Treatment of Opioid Dependency; alpha2-Adrenoceptor Agonists;Imidazoline Receptor Agonists;Nitric Oxide Synthase Inhibitors;Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1; PC1; NEC1) Inhibitors;Proprotein Convertase Subtilisin/Kexin-Type 6 (PCSK6; PACE4; PC7A) Inhibitors;Signal Transduction Modulators;
CBR-001-574-584-3,RFM-003-379-4,CBR-001-574-584-3,ClCC(Cn1c(C)ncc1[N+](=O)[O-])O,CBR-HVAC-05210: Treatment of Protozoal Diseases;Antibacterial Drugs
CBR-001-574-585-4,RFM-003-380-7,CBR-001-574-585-4,FC(c1cc2NCNS(=O)(=O)c2cc1S(=O)(=O)N)(F)F,"CBR-HVAC-03146: Diuretics;Hypertension, Treatment of"
CBR-001-574-586-5,RFM-003-381-8,CBR-001-574-586-5,NC[C@H]1C[C@@]1(c1ccccc1)C(=O)N(CC)CC,"CBR-HVAC-01349: Anxiolytics;Ischemic Stroke, Treatment of;Antidepressants; Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5-hydroxytryptamine receptor Antagonist; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor"
CBR-001-574-587-6,RFM-003-382-9,CBR-001-574-587-6,CC([N+](C(C)C)(CCC(c1ccccc1)(c1ccccc1)C(=O)N)C)C,CBR-HVAC-03168: Antispasmodics; Muscarinic acetylcholine receptor Antagonist;
CBR-001-574-588-7,RFM-003-383-0,CBR-001-574-588-7,OC(=O)[C@]1(C)CCC[C@]2([C@H]1CCc1c2cc(c(c1)C(C)C)S(=O)(=O)O)C,CBR-HVAC-02404: ; Pepsin Inhibitor; Gastrin inhibitor; Mucus protecting agent; Urease inhibitor
CBR-001-574-589-8,RFM-003-384-1,CBR-001-574-589-8,CN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C,CBR-HVAC-03114: Antipsychotic Drugs; Dopamine receptor Inhibitor;
CBR-001-574-590-1,RFM-003-385-2,CBR-001-574-590-1,O=C1NCC2(O1)CCN(CC2)CCc1ccccc1,CBR-HVAC-00926: ; Histamine H1 receptor Antagonist; Mucolytic agent; Histamine receptor antagonist
CBR-001-574-591-2,RFM-003-386-3,CBR-001-574-591-2,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@@H]3C([C@H]2[C@@H]([C@]2(C(C1=C(C)[C@@H](OC(=O)[C@@H]([C@H](c1ccccc1)NC(=O)OC(C)(C)C)O)C2)(C)C)O)OC(=O)c1ccccc1)(CO3)OC(=O)C,CBR-HVAC-01795: Ovarian Cancer Therapy;Glioblastoma Multiforme Therapy;Head and Neck Cancer Therapy;Genitourinary Cancer Therapy;Prostate Cancer Therapy;Bladder Cancer Therapy ;Small Cell Lung Cancer Therapy;Neurologic Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Gastric Cancer Therapy;Lung Cancer Therapy;Breast Cancer Therapy; Antimitotic Drugs;Microtubule-Stabilizing Agents; Tubulin Inhibitor; Taxane; Microtubule inhibitor
CBR-001-574-592-3,RFM-003-387-4,CBR-001-574-592-3,CCOc1ccc(cc1OCC)Cc1nccc2c1cc(OCC)c(c2)OCC,analog of CBR-HVAC-10028 (ETHAVERINE)
CBR-001-574-593-4,RFM-003-388-5,CBR-001-574-593-4,OC(=O)c1cccnc1Nc1cccc(c1C)Cl,CBR-HVAC-01294: Non-Opioid AnalgesicsCyclooxygenase inhibitor
CBR-001-574-594-5,RFM-003-389-6,CBR-001-574-594-5,CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)Cc1ccccc1)Cc1nc[nH]c1)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCCNC(=N)N)Cc1ccc(cc1)O)C,CBR-HVAC-15131: Angiotensin II receptor type 1 Agonist; Antineoplastic; Cancer; Cardiovascular Diseases (Not Specified); Oncolytic Drugs
CBR-001-574-595-6,RFM-003-390-9,CBR-001-574-595-6,CC[C@@H]([C@@H]1NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCC(=O)N)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)C,"CBR-HVAC-02592: Autism, Treatment of;Antimigraine Drugs;Uterine Stimulants and Tocolytics;Analgesic Drugs;Treatment of Alcohol Dependency;Disorders of Sexual Function and Reproduction, Treatment of;Antipsychotic Drugs;Hemostatics;Posttraumatic Stress Disorder (PTSD), Treatment of;Antidepressants;Acute Myocardial Infarction, Treatment of;Gynecological Disorders, Treatment of ;Multisystem Genetic Disorders, Treatment of ; Oxytocin receptor Antagonist; Oxytocin receptor agonist"
CBR-001-574-596-7,RFM-003-391-0,CBR-001-574-596-7,Clc1ccc(c(c1)Cl)C(Cn1cncc1)OCc1c(Cl)cccc1Cl,CBR-HVAC-01287: Antifungal AgentsSterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-574-597-8,RFM-003-392-1,CBR-001-574-597-8,COc1ccc(cc1)CC(N(CCCCOC(=O)c1ccc(c(c1)OC)OC)CC)C,CBR-HVAC-00948: Muscarinic receptor antagonist
CBR-001-574-598-9,RFM-003-393-2,CBR-001-574-598-9,CC(=O)Nc1ccc(cc1)OC(=O)c1ccccc1OC(=O)C,CBR-HVAC-09685:
CBR-001-574-599-0,RFM-003-394-3,CBR-001-574-599-0,FC(OC(C(Cl)F)(F)F)F,CBR-HVAC-01871: Inhalation Anesthetics; Calcium dependent ATPase Activator; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-574-600-6,RFM-003-395-4,CBR-001-574-600-6,OC(C1CCc2c(O1)ccc(c2)F)CNCC(C1CCc2c(O1)ccc(c2)F)O,"CBR-HVAC-01451: Heart Failure Therapy;Cardiovascular Diseases (Not Specified);Peripheral Arterial Disease, Treatment of;Hypertension, Treatment of;Cardiovascular Genetic Disorders, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Antagonist; Beta 1 adrenoreceptor antagonist"
CBR-001-574-601-7,RFM-003-396-5,CBR-001-574-601-7,CN(CCc1c[nH]c2c1cc(C[C@@H]1COC(=O)N1)cc2)C,"CBR-HVAC-01763: Acute Attacks of Migraine, Treatment of;Lesions of the Spinal Cord and Related Structures, Treatment of; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist; 5 Hydroxytryptamine 1B receptor agonist"
CBR-001-574-602-8,RFM-003-397-6,CBR-001-574-602-8,CN(Cc1cccc2c1cccc2)Cc1ccc(cc1)C(C)(C)C,CBR-HVAC-02162: Antifungal Agents; Squalene epoxidase Inhibitor; Steroid synthesis inhibitor; Squalene epoxidase inhibitor
CBR-001-574-603-9,RFM-003-398-7,CBR-001-574-603-9,O=C(N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C)COc1ccccc1,CBR-HVAC-14165
CBR-001-574-604-0,RFM-003-399-8,CBR-001-574-604-0,COP(=S)(SCN1C(=O)c2c(C1=O)cccc2)OC,CBR-HVAC-08693:
CBR-001-574-605-1,RFM-003-400-4,CBR-001-574-605-1,SCC(C(=O)O)NC(=O)C,"CBR-HVAC-02410: Mucolytics;Cystic Fibrosis, Treatment of ; Collagenase Inhibitor; Reducing agent; Oxygen radical formation inhibitor; Mucolytic agent"
CBR-001-574-606-2,RFM-003-401-5,CBR-001-574-606-2,CCOC(=O)C(/C=C(/CP(=O)(O)O)\C)N,"CBR-HVAC-04384: Stroke, Treatment of;Antiepileptic Drugs; NMDA Antagonists;Signal Transduction Modulators;"
CBR-001-574-607-3,RFM-003-402-6,CBR-001-574-607-3,NCCCN([C@@H](c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1)C(C)C)C(=O)c1ccc(cc1)C,"CBR-HVAC-06069: Lymphoma Therapy;Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy; Antimitotic Drugs;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors;"
CBR-001-574-608-4,RFM-003-403-7,CBR-001-574-608-4,CCn1cc(C(=O)O)c(=O)c2c1nc(nc2)N1CCNCC1,CBR-HVAC-01675: DNA topoisomerase II inhibitor
CBR-001-574-609-5,RFM-003-404-8,CBR-001-574-609-5,Nc1ccc(cc1)[As](=O)(O)O,CBR-HVAC-09070:
CBR-001-574-610-8,RFM-003-405-9,CBR-001-574-610-8,C[C@H](CCC[C@@H](CCCC(C)C)C)CCC[C@](CCC1=C(C)C(=O)C(=C(C1=O)C)C)(O)C,CBR-HVAC-14199
CBR-001-574-611-9,RFM-003-406-0,CBR-001-574-611-9,C=CCN1CC[C@@]23[C@@]4([C@H]1Cc1c3c(O[C@H]2C(=O)CC4)c(cc1)O)O,CBR-HVAC-02633: Opioid receptor Antagonist; Opioid receptor antagonist
CBR-001-574-612-0,RFM-003-407-1,CBR-001-574-612-0,COc1ccc(cc1OC)CCN1CCC[C@@H](C1)CN1CCc2c(CC1=O)cc(c(c2)OC)OC,"CBR-HVAC-03591: Angina pectoris, Treatment of;Antiarrhythmic DrugsSodium channel antagonist; Potassium channel antagonist; HCN channel antagonist"
CBR-001-574-613-1,RFM-003-408-2,CBR-001-574-613-1,COC(=O)C(NC(=O)C(CC(C)C)N)CC(C)C,CBR-HVAC-06559: Treatment of Transplant Rejection; Apoptosis Inducers;
CBR-001-574-614-2,RFM-003-409-3,CBR-001-574-614-2,OCC1OC(CC1O)n1cc(CC)c(=O)[nH]c1=O,CBR-HVAC-14309
CBR-001-574-615-3,RFM-003-410-6,CBR-001-574-615-3,COc1ccc(cc1)C(=O)/C(=C(/c1ccc2c(c1)OCO2)\C(=O)O)/Cc1cc(OC)c(c(c1)OC)OC,"CBR-HVAC-04592: Pulmonary Hypertension, Treatment of; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist; Endothelin A receptor antagonist"
CBR-001-574-616-4,RFM-003-411-7,CBR-001-574-616-4,OC[C@H]1O[C@@H](Oc2ccc3c(c2)oc(=O)cc3C)[C@@H]([C@H]([C@@H]1O)O)NC(=O)C,analog of CBR-HVAC-04720
CBR-001-574-617-5,RFM-003-412-8,CBR-001-574-617-5,CCCCCN(C(=O)C(NC(=O)c1ccc(c(c1)Cl)Cl)CCC(=O)O)CCCCC,"CBR-HVAC-02682: Pancreatic Disorders, Treatment of; CCK1 (CCKA) Antagonists;Signal Transduction Modulators; Cholecystokinin A receptor Antagonist; CCK receptor antagonist"
CBR-001-574-618-6,RFM-003-413-9,CBR-001-574-618-6,CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO,CBR-HVAC-01396: Membrane integrity inhibitor
CBR-001-574-619-7,RFM-003-414-0,CBR-001-574-619-7,O=NSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,"CBR-HVAC-04501: Asthma Therapy;Cystic Fibrosis, Treatment of ;Treatment of Erectile Dysfunction;Disorders of Sexual Function and Reproduction, Treatment of;Wound-Healing Agents;Stroke, Treatment of; Nitric Oxide (NO) Donors;Protein Tyrosine Phosphatase PTP-1B Inhibitors;Signal Transduction Modulators; Nitric oxide stimulant"
CBR-001-574-620-0,RFM-003-415-1,CBR-001-574-620-0,ONC(=O)C[C@@H](C(=O)O)N,CBR-HVAC-04122: Antiviral Drugs;Anti-HIV Agents
CBR-001-574-621-1,RFM-003-416-2,CBR-001-574-621-1,Fc1ccc(cc1)CC1CCN(CC1)C(=O)C(=O)Nc1ccc2c(c1)oc(n2)O,"CBR-HVAC-00363: Neuropathic Pain, Treatment of;Non-Opioid Analgesics; NR2B Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA 2B Antagonist; NMDA receptor, subunit 2B antagonist"
CBR-001-574-622-2,RFM-003-417-3,CBR-001-574-622-2,C/C(=C\C(C(=O)O)N)/CP(=O)(O)O,"CBR-HVAC-04388: Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; NMDA receptor antagonist"
CBR-001-574-623-3,RFM-003-418-4,CBR-001-574-623-3,COc1cc(N)c(cc1C(=O)NC1CN2CCC1CC2)Cl,"CBR-HVAC-03397: Prokinetic Agents;Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-574-624-4,RFM-003-419-5,CBR-001-574-624-4,NC1=NC(N(C(=N1)N)OCCCOc1cc(Cl)c(cc1Cl)Cl)(C)C,CBR-HVAC-07566: Antimalarials; Dihydrofolate Reductase (DHFR) Inhibitors; Unidentified pharmacological activity
CBR-001-574-625-5,RFM-003-420-8,CBR-001-574-625-5,COc1cc(C(C)C)c(cc1S(=O)(=O)N)Oc1cnc(nc1N)N,CBR-HVAC-07429: Purinoreceptor P2X3 antagonist
CBR-001-574-626-6,RFM-003-421-9,CBR-001-574-626-6,Fc1cc2CCC(n3c2c(c1)c(=O)c(c3)C(=O)O)C,CBR-HVAC-01595: DNA topoisomerase II inhibitor
CBR-001-574-627-7,RFM-003-422-0,CBR-001-574-627-7,CCCCCN(C(=O)C(NC(=O)c1ccc(c(c1)Cl)Cl)CCC(=O)O)CCCOC,"CBR-HVAC-00801: Pancreatic Disorders, Treatment of; CCK1 (CCKA) Antagonists;Signal Transduction Modulators; CHOLECYSTOKININ A RECEPTOR Antagonist; CCK A receptor antagonist"
CBR-001-574-628-8,RFM-003-423-1,CBR-001-574-628-8,CC(NC(C)(C)C)CC(c1ccccc1)c1ccccc1,CBR-HVAC-02829: Urinary Incontinence Therapy; Calcium channel Antagonist; Muscarinic receptor antagonist; Calcium channel antagonist
CBR-001-574-629-9,RFM-003-424-2,CBR-001-574-629-9,CCC(=O)c1c(O)cc(cc1O)O,CBR-HVAC-09053:
CBR-001-574-630-2,RFM-003-425-3,CBR-001-574-630-2,COc1cc(C(=O)NC2CCN(CC2)C)c(cc1Nc1ncc2c(n1)N(CC(C(=O)N2C)(F)F)C1CCCC1)F,CBR-HVAC-06889: Solid Tumors Therapy; Antimitotic Drugs;Polo-like Kinase-1 (Plk-1) Inhibitors;Signal Transduction Modulators; Polo-like kinase 1 Inhibitor;
CBR-001-574-631-3,RFM-003-426-4,CBR-001-574-631-3,C=C/C=C/CC1=C(C)[C@H](CC1=O)OC(=O)[C@@H]1C(C1(C)C)C=C(C)C.C=C/C=C/CC1=C(C)C(CC1=O)OC(=O)[C@@H]1C(C1(C)C)/C=C(/C(=O)OC)\C,CBR-HVAC-09650: Potassium channel Kv Binder;
CBR-001-574-632-4,RFM-003-427-5,CBR-001-574-632-4,Oc1nc(c(s1)Cc1ccc(cc1)OCCN(c1ccccn1)C)O,"CBR-HVAC-01932: Antidiabetic Drugs;Cognition Disorders, Treatment of;Chemopreventive Agents;Type 2 Diabetes, Agents for;Inflammatory Bowel Disease, Agents for;Preventive Agents;Antipsoriatics;Alzheimer's Dementia, Treatment of ;Rheumatoid Arthritis, Treatment of;Atherosclerosis Therapy;Cushing's Syndrome, Agents for;Disorders of Sexual Function and Reproduction, Treatment of;Lymphoma Therapy;Restenosis Treatment of;Endocrine Cancer Therapy;Treatment of Renal Diseases; Cytochrome P450 CYP2C9 Inhibitors;Insulin Sensitizers;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor gamma Agonist; Peroxisome proliferator-activated receptor gamma agonist; Insulin sensitizer; Thiazolidinedione"
CBR-001-574-633-5,RFM-003-428-6,CBR-001-574-633-5,Br/C=C/c1cn([C@H]2C[C@@H]([C@H](O2)CO)O)c(=O)[nH]c1=O,CBR-HVAC-02468: ; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-574-634-6,RFM-003-429-7,CBR-001-574-634-6,NCCONC(=CCCCOC)c1ccc(cc1)C(F)(F)F,"CBR-HVAC-01281: Autism, Treatment of;Obsessive-Compulsive Disorder (OCD), Treatment of;Social Phobia, Treatment for;Antidepressants;Treatment of Eating Disorders; Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5-Hydroxytryptamine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor"
CBR-001-574-635-7,RFM-003-430-0,CBR-001-574-635-7,CCCCCCCCCCCCCC[N+](CCC[Si](OC)(OC)OC)(C)C,analog of CBR-HVAC-02542 (disiquonium chloride)
CBR-001-574-636-8,RFM-003-431-1,CBR-001-574-636-8,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)NCc1cnc2c(n1)c(O)nc(n2)N,CBR-HVAC-01327: Dihydrofolate reductase Inhibitor; Unidentified pharmacological activity
CBR-001-574-637-9,RFM-003-432-2,CBR-001-574-637-9,[O-][N+](=O)c1ccc(cc1)[As](=O)(O)O,CBR-HVAC-08864:
CBR-001-574-638-0,RFM-003-433-3,CBR-001-574-638-0,COC(=O)Nc1nc2c([nH]1)cccc2,CBR-HVAC-00185: Oncolytic Drugs;Antifungal Agents;Anti-HIV Agents;Solid Tumors TherapyMicrotubule inhibitor; Tubulin inhibitor; RNA synthesis inhibitor
CBR-001-574-639-1,RFM-003-434-4,CBR-001-574-639-1,CCN(C(=O)N1CCN(CC1)C)CC,CBR-HVAC-05217: Treatment of Helminthic Diseases; 15-Lipoxygenase Inhibitor;
CBR-001-574-640-4,RFM-003-435-5,CBR-001-574-640-4,C=CCSS(=O)CC=C,"CBR-HVAC-03835: Antibacterial Drugs;Oncolytic Drugs;Lipoprotein Disorders, Treatment of ;Antiplatelet Therapy;Antidiabetic Drugs;Antifungal Agents;Atherosclerosis Therapy;Inflammatory Bowel Disease, Agents for; Antioxidants;Cathepsin B Inhibitors;Cathepsin L Inhibitors;Cytokine Production Inhibitors;Falcipain 2 Inhibitors;Signal Transduction Modulators;TRPA1 Agonists; Nitric oxide synthase Inhibitor;"
CBR-001-574-641-5,RFM-003-436-6,CBR-001-574-641-5,O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OS(=O)(=O)O,CBR-HVAC-11710: ; Estrogen receptor Agonist;
CBR-001-574-642-6,RFM-003-437-7,CBR-001-574-642-6,CN(CCc1ccccc1)CCc1ccccc1,CBR-HVAC-08946:
CBR-001-574-643-7,RFM-003-438-8,CBR-001-574-643-7,CCCNC(=O)NS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-03174: Antidiabetic Drugs; K(ATP) Channel Blockers; Alcohol dehydrogenase Inhibitor;
CBR-001-574-644-8,RFM-003-439-9,CBR-001-574-644-8,O=Cc1ccc(cc1O)N1CCOCC1,CBR-HVAC-11557: ; DNA-dependent protein kinase Inhibitor;
CBR-001-574-645-9,RFM-003-440-2,CBR-001-574-645-9,COc1ccc2c(c1)CCC(=C2c1ccc(cc1)OCCN1CCCC1)c1ccccc1,CBR-HVAC-01152: ; Estrogen receptor Antagonist; Estrogen receptor antagonist
CBR-001-574-646-0,RFM-003-441-3,CBR-001-574-646-0,[O-]C(=O)CC(C(=O)[O-])N,CBR-HVAC-01353: Metallic radical formation stimulant
CBR-001-574-647-1,RFM-003-442-4,CBR-001-574-647-1,OC[C@@H]1[C@@H](O)C[C@@H](C1=C)n1cnc2c1nc(N)nc2O,CBR-HVAC-01907: Anti-Hepatitis B Virus Drugs; DNA Polymerase Inhibitors;Solute Carrier Family 22 Member 3 (SLC22A3) Inhibitors; DNA polymerase Inhibitor; DNA directed DNA polymerase inhibitor
CBR-001-574-648-2,RFM-003-443-5,CBR-001-574-648-2,CC(c1ccc(cc1)O)(CC(C)(C)C)C,CBR-HVAC-11003:
CBR-001-574-649-3,RFM-003-444-6,CBR-001-574-649-3,CCC(c1ccccc1)(N(C)C)COC(=O)c1cc(OC)c(c(c1)OC)OC,"CBR-HVAC-01402: Antispasmodics;Irritable Bowel Syndrome, Agents for; Opioid Receptor Agonists;Signal Transduction Modulators;Sodium Channel  Blockers; Opioid receptor Agonist; Muscarinic receptor antagonist; Opioid receptor agonist"
CBR-001-574-650-6,RFM-003-445-7,CBR-001-574-650-6,CCCCCc1ccc(cc1O)C,CBR-HVAC-09739:
CBR-001-574-651-7,RFM-003-446-8,CBR-001-574-651-7,O=C(CCC(=O)O)OCC[C@@]12CC[C@H](C2C2[C@](CC1)(C)[C@]1(C)CCC3[C@](C1CC2)(C)CCC(C3(C)C)OC(=O)C)C(C)C,analog of CBR-HVAC-07132
CBR-001-574-652-8,RFM-003-447-9,CBR-001-574-652-8,NC(=O)CCN1CCN(CC1)C1Cc2cc(Cl)ccc2Sc2c1ccc(c2)F,CBR-HVAC-11075: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor Antagonist;
CBR-001-574-653-9,RFM-003-448-0,CBR-001-574-653-9,Clc1ccc2c(c1)nccc2N1CCN(CC1)CCCN1CCN(CC1)CCCN1CCN(CC1)CCCN1CCN(CC1)c1ccnc2c1ccc(c2)Cl,analog of CBR-HVAC-05783
CBR-001-574-654-0,RFM-003-449-1,CBR-001-574-654-0,Cc1ccc2c(c1)C(=O)c1ccccc1CS2,analog of CBR-HVAC-08440
CBR-001-574-655-1,RFM-003-450-4,CBR-001-574-655-1,COc1cc(cc(c1OC)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@@H](c2c1cc1OCOc1c2)NC(=O)Cc1ccccc1,analog of CBR-HVAC-11622
CBR-001-574-656-2,RFM-003-451-5,CBR-001-574-656-2,CC[C@H]1CC2CN3C1[C@](C2)(C(=O)OC)c1[nH]c2c(c1CC3)cccc2,CBR-HVAC-14251
CBR-001-574-657-3,RFM-003-452-6,CBR-001-574-657-3,COc1cccc2c1C(=O)c1c(C2=O)c(O)c2c(c1O)[C@@H](OC1CC(N)C(C(O1)C)O)C[C@](C2)(O)C(O)C,analog of CBR-HVAC-05653
CBR-001-574-658-4,RFM-003-453-7,CBR-001-574-658-4,OC[C@H]1O[C@@H](OC(=O)[C@@]23CCC(C[C@H]3C3=CCC4[C@@]([C@@]3(C[C@@H]2O)C)(C)CCC2[C@]4(C)CC[C@@H](C2(C)C)O)(C)C)[C@@H]([C@H]([C@@H]1O)O)O,analog of CBR-HVAC-03906
CBR-001-574-659-5,RFM-003-454-8,CBR-001-574-659-5,NCCC(c1cccc(c1)OCC1CCCCC1)O,"CBR-HVAC-06891: Diabetic Retinopathy, Agents for;Age-Related Macular Degeneration, Treatment of; Retinoid Isomerohydrolase (RPE65) Inhibitors; Unidentified pharmacological activity"
CBR-001-574-660-8,RFM-003-455-9,CBR-001-574-660-8,CCCSc1nc(ccc1C(=O)NC1CCCCC1)N1CCC[C@H](C1)CC(=O)O,"CBR-HVAC-06691: Type 2 Diabetes, Agents for;Hypertension, Treatment of;Ophthalmic Drugs;Antiglaucoma Agents;Antiobesity Drugs; 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1 Inhibitor;"
CBR-001-574-661-9,RFM-003-456-0,CBR-001-574-661-9,CCOc1noc2c1ccc(c2)OCCC1CCN(CC1)c1ccc(nn1)C,CBR-HVAC-06056: Anti-Rhinovirus Drugs; Viral Entry Inhibitors; CAPSID VIRAL PROTEIN Inhibitor;
CBR-001-574-662-0,RFM-003-457-1,CBR-001-574-662-0,CCCCCCCCCCCCCC[C@H]([C@H]([C@H](CO)N)O)O,CBR-HVAC-06282: Antiulcer Drugs
CBR-001-574-663-1,RFM-003-458-2,CBR-001-574-663-1,OS(=O)(=O)CCS(=O)(=O)O,"CBR-HVAC-03099: Sedative/Hypnotics;Antiepileptic Drugs;Stroke, Treatment of; GABA(A) Receptor Modulators;MAPK p38 Inhibitors;Signal Transduction Modulators;"
CBR-001-574-664-2,RFM-003-459-3,CBR-001-574-664-2,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N[C@H](C(=O)N)Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](Cc1ccccc1)N)Cc1c[nH]c2c1cccc2,"CBR-HVAC-03609: Liver Cancer Therapy;Inflammatory Bowel Disease, Agents for;Antidiarrheal Agents;Pancreatic Disorders, Treatment of;Oncolytic Drugs;Gastrointestinal Disorders (Not Specified);Esophageal Diseases, Treatment of;Endocrine Cancer Therapy;Treatment of Acromegaly; Growth Hormone Release Inhibitors;Receptor Tyrosine Kinase Inhibitors;Signal Transduction Modulators;Somatostatin Agonists; Growth hormone antagonist; Somatostatin receptor agonist"
CBR-001-574-665-3,RFM-003-460-6,CBR-001-574-665-3,CC(OC(=O)c1cn(Cc2c(F)cccc2F)c2c(c1=O)c(CN(Cc1ccccc1)C)c(s2)c1ccc(cc1)NC(=O)C(C)C)C,"CBR-HVAC-11480: Gynecological Disorders, Treatment of ;Oncolytic Drugs; GnRH (LHRH) Antagonists;Signal Transduction Modulators; Gonadotropin-releasing hormone receptor Antagonist;"
CBR-001-574-666-4,RFM-003-461-7,CBR-001-574-666-4,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)Cc1ccccc1)CCC(=O)O)Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)N)Cc1ccccc1)CC(C)C)CC(C)C)CCCNC(=N)N)CC(=O)N)CC(=O)N)CC(=O)O,analog of CBR-HVAC-05511
CBR-001-574-667-5,RFM-003-462-8,CBR-001-574-667-5,CCSCc1ccc2c(c1)c1c3C(=O)NCc3c3c4c1n2[C@H]1C[C@]([C@](O1)(n4c1c3cc(cc1)CSCC)C)(O)C(=O)OC,"CBR-HVAC-04639: Asthma Therapy;Cognition Disorders, Treatment of;Antiparkinsonian Drugs;Alzheimer's Dementia, Treatment of ; MAP3K11 (MLK3) Inhibitors;Neurotrophic Agents;Signal Transduction Modulators; Mitogen-activated protein 3 kinase 9 Inhibitor; JNK inhibitor; Protein kinase inhibitor"
CBR-001-574-668-6,RFM-003-463-9,CBR-001-574-668-6,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)Cc1ccccc1)C)C)Cc1c[nH]c2c1cccc2,CBR-HVAC-03391: Antidiabetic Drugs;Antiallergy/Antiasthmatic Drugs;Non-Opioid Analgesics; Growth Hormone Release Inhibitors;Signal Transduction Modulators; Somatostatin receptor 1; Somatostatin receptor 2 Agonist; Antagonist; Growth hormone releasing factor antagonist; Insulinotropin antagonist
CBR-001-574-669-7,RFM-003-464-0,CBR-001-574-669-7,CSCC[C@@H](C(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](N(C(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](CCCNC(=N)N)N)C)Cc1ccccc1)CC(C)C,CBR-HVAC-03933: SAPK1 (JNK) Activators; Substance P Antagonist; Substance-P-inhibitors; Anticancer; Cancer; Oncolytic Drugs
CBR-001-574-670-0,RFM-003-465-1,CBR-001-574-670-0,OC(=O)C[C@@H](C(=O)N([C@H](C(=O)N)Cc1ccccc1)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)OC(C)(C)C)CCCCNC(=O)Nc1ccccc1C,CBR-HVAC-11765: ; CCK1 (CCKA) Agonists;Signal Transduction Modulators; Cholecystokinin A receptor Agonist;
CBR-001-574-671-1,RFM-003-466-2,CBR-001-574-671-1,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)C)CC(=O)O)C(C)C)C)CCC(=O)O)CCC(=O)N)CCCNC(=N)N)CCCNC(=N)N)CC(C)C)C)NC(=O)[C@H](CCCCN)N,analog of CBR-HVAC-03376
CBR-001-574-672-2,RFM-003-467-3,CBR-001-574-672-2,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)[C@H](O)C)Cc1ccccc1)[C@H](O)C)NC(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](Cc1ccccc1)N)Cc1ccccc1)Cc1ccccc1,CBR-HVAC-14198
CBR-001-574-673-3,RFM-003-468-4,CBR-001-574-673-3,CC(C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)O)Cc1ccccc1)Cc1ccc(cc1)O)N)C,CBR-HVAC-14193
CBR-001-574-674-4,RFM-003-469-5,CBR-001-574-674-4,CC(C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(C)C)CC(=O)O)NC(=O)Cc1ccc(cc1)NC(=O)Nc1ccccc1C)C,CBR-HVAC-05155: Antiallergy/Antiasthmatic Drugs; Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists;Signal Transduction Modulators; Integrin alpha4 beta1 Antagonist;
CBR-001-574-675-5,RFM-003-470-8,CBR-001-574-675-5,Cc1ccc2c(c1)C=Cc1c(C2c2cn(Cc3ccc(o3)C(=O)Nc3nnn[nH]3)c(=O)[nH]c2=S)ccc(c1)C,CBR-HVAC-05660: Antipsoriatics; P2Y2 Antagonists;Signal Transduction Modulators;
CBR-001-574-676-6,RFM-003-471-9,CBR-001-574-676-6,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N)CCSC)CC(C)C)Cc1ccccc1)Cc1ccccc1)CCC(=O)N)CCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N,CBR-HVAC-03586: Wound-Healing Agents;Hair Growth Stimulants; Neurokinin receptor 1 Antagonist;
CBR-001-574-677-7,RFM-003-472-0,CBR-001-574-677-7,OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)[C@H](O)C)Cc1ccc(cc1)O)CC(=O)N)[C@H](O)C)[C@H](O)C)[C@H](O)C)NC(=O)[C@H](N)C,"CBR-HVAC-06267: Antipsoriatics;Alzheimer's Dementia, Treatment of ;Anti-HIV Agents; Chemokine CCR5 Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators;"
CBR-001-574-678-8,RFM-003-473-1,CBR-001-574-678-8,CC[C@@H]([C@@H](C(=O)N[C@H]1CCC(=O)NCC(NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(=O)NCC(NC(=O)[C@H]2N(C1=O)CCC2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccc(cc1)O)CCCNC(=N)N)CC(C)C)CCCNC(=N)N)Cc1ccc(cc1)O)NC(=O)[C@H]([C@H](CC)C)N)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccc(cc1)O)CCCNC(=N)N)CC(C)C)CCCNC(=N)N)Cc1ccc(cc1)O)N)C,"CBR-HVAC-11583: Pharmacological Tools;Hypertension, Treatment of; Neuropeptide Y1 (NPY Y1) Antagonists;Neuropeptide Y4 (NPY Y4) Agonists;Signal Transduction Modulators; Neuropeptide Y receptor 1 Antagonist;"
CBR-001-574-679-9,RFM-003-474-2,CBR-001-574-679-9,COc1ccc(cc1)C[C@@H]1NC(=O)CC2(CCCCC2)SSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccccc1)CCC(=O)N)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CCCNC(=N)N,CBR-HVAC-14265
CBR-001-574-680-2,RFM-003-475-3,CBR-001-574-680-2,NC(=N)NCCC[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C,CBR-HVAC-14295
CBR-001-574-681-3,RFM-003-476-4,CBR-001-574-681-3,NCCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(cc2)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)CC(C)C)Cc1ccccc1,analog of CBR-HVAC-01320 (terlipressin)
CBR-001-574-682-4,RFM-003-477-5,CBR-001-574-682-4,NC(=N)NCCC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N)CCCNC(=N)N)CCCNC(=N)N)CCCNC(=N)N)NC(=O)[C@H](NC(=O)[C@@H](CCCNC(=N)N)N)CCCNC(=N)N,CBR-HVAC-14174
CBR-001-574-683-5,RFM-003-478-6,CBR-001-574-683-5,NCCCC[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)N)C)CC(C)C,analog of CBR-HVAC-05305
CBR-001-574-684-6,RFM-003-479-7,CBR-001-574-684-6,NC(=N)NCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N)NC(=O)c1ccc2c(c1O)cccc2,CBR-HVAC-04526: Antiallergy/Antiasthmatic Drugs; Tryptase Inhibitor;
CBR-001-574-685-7,RFM-003-480-0,CBR-001-574-685-7,CC[C@@H]([C@@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2nc[nH]c2)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)C(C)C)C(C)C)CCC(=O)N)CC(=O)O)Cc1c[nH]c2c1cccc2)Cc1nc[nH]c1)C(=O)N[C@H](C(=O)N)[C@H](O)C)N)C,CBR-HVAC-11855: ; COMPLEMENT C3 Inhibitor;
CBR-001-574-686-8,RFM-003-481-1,CBR-001-574-686-8,NCCC1NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)C(NC(=O)[C@H](CC(=O)O)N)C(SSC[C@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)O)C(=O)N[C@H](C(=O)O)C(C)C)(C)C)Cc1c[nH]c2c1cccc2,CBR-HVAC-14267
CBR-001-574-687-9,RFM-003-482-2,CBR-001-574-687-9,Clc1cccc(c1)C(n1cncc1)c1ccc2c(c1)[nH]cn2,CBR-HVAC-02507: Antipsoriatics;Oncolytic Drugs; Aromatase Inhibitors;Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors; Cytochrome P450 Inhibitor; Cytochrome P450 inhibitor
CBR-001-574-688-0,RFM-003-483-3,CBR-001-574-688-0,COc1ccc(cc1OC1CCCC1)[C@@H](c1ccccc1)Cc1ccncc1,CBR-HVAC-04621: Bronchodilators;Antiallergy/Antiasthmatic Drugs; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor
CBR-001-574-689-1,RFM-003-484-4,CBR-001-574-689-1,SCCCC(C(=O)O)CCC(=O)O,"CBR-HVAC-05745: Neuropathic Pain, Treatment of;Disorders Associated with Cancer Therapy, Treatment of;Diabetic Neuropathy, Agents for; Glutamate Carboxypeptidase II (NAALADase; NAAG Peptidase, FOLH1, PSMA) Inhibitors; Glutamate carboxypeptidase II Inhibitor;"
CBR-001-574-690-4,RFM-003-485-5,CBR-001-574-690-4,CN(C(=O)NC1(CCN(CC1)CCC[C@@]1(CCCN(C1)C(=O)c1ccccc1)c1ccc(c(c1)Cl)Cl)c1ccccc1)C,CBR-HVAC-05352: Antipsychotic Drugs;Antidepressants;Antiallergy/Antiasthmatic Drugs; Signal Transduction Modulators;Tachykinin NK3 Antagonists; Neurokinin receptor 3 Antagonist;
CBR-001-574-691-5,RFM-003-486-6,CBR-001-574-691-5,C[C@@H]1C[C@@]([C@H]2C1[C@@H]2C(=O)O)(N)C(=O)O,CBR-HVAC-14247
CBR-001-574-692-6,RFM-003-487-7,CBR-001-574-692-6,Cn1c2ccccc2c2c1CCNCC2,CBR-HVAC-08218: 5 Hydroxytryptamine 2C receptor agonist; 5 Hydroxytryptamine 2A receptor agonist; 5 Hydroxytryptamine 2B receptor agonist
CBR-001-574-693-7,RFM-003-488-8,CBR-001-574-693-7,CN1CCCC1CCSc1ccc(cc1)O,"CBR-HVAC-04942: Alzheimer's Dementia, Treatment of ; Nicotinic alpha4beta4 Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha4 Agonist; Acetylcholine release stimulant; Nicotinic receptor agonist"
CBR-001-574-694-8,RFM-003-489-9,CBR-001-574-694-8,c1ccc(cc1)C(c1ccccc1)OC1CCN(CC1)CCCc1nnn[nH]1,CBR-HVAC-10635: Antiallergy/Antiasthmatic Drugs; Hematopoietic Prostaglandin D2 Synthase Inhibitors;Histamine H1 Receptor Antagonists;Mediator Release Inhibitors;Signal Transduction Modulators; Prostaglandin synthase Inhibitor;
CBR-001-574-695-9,RFM-003-490-2,CBR-001-574-695-9,N#C/N=C(/NCCSCc1csc(n1)N=C(N)N)\NC,CBR-HVAC-10068: ; Histamine H2 receptor Antagonist;
CBR-001-574-696-0,RFM-003-491-3,CBR-001-574-696-0,CNC(=O)c1ccc2c(c1)CCO[C@H]2CCN1CCN(CC1)c1ccc(cc1)OC,CBR-HVAC-11256: Antimigraine Drugs; Signal Transduction Modulators;5-HT1D Agonists; 5-Hydroxytryptamine 1D receptor Agonist;
CBR-001-574-697-1,RFM-003-492-4,CBR-001-574-697-1,CCC(c1ccccc1)(N(CC1CC1)C)C/C=C/c1ccccc1,CBR-HVAC-04301: Antidiarrheal Agents;Antidepressants; sigma-Receptor Ligands;Signal Transduction Modulators; Opioid receptor sigma Agonist; Sigma receptor agonist
CBR-001-574-698-2,RFM-003-493-5,CBR-001-574-698-2,COc1ccc(cc1)n1[nH]c2c(c1=O)cnc1c2CCCCC1,CBR-HVAC-03685: Benzodiazepine receptor Antagonist; Benzodiazepine receptor agonist; GABA(A) BZ Site Receptor Partial Agonists; Signal Transduction Modulators; Anticonvulsant; Anxiolytic; Anxiolytics
CBR-001-574-699-3,RFM-003-494-6,CBR-001-574-699-3,Cc1ccc(cc1)C12CNCC2C1,CBR-HVAC-05723: Non-Opioid Analgesics; NMDA Antagonists;Norepinephrine Transporter (NET) Inhibitors;Serotonin Transporter (SERT) Inhibitors;Signal Transduction Modulators; Dopamine transporter; Norepinephrine transporter; Alpha-2 adrenergic receptor; 5-Hydroxytryptamine transporter; 5-Hydroxytryptamine 1A receptor Agonist; Inhibitor; Glutamate antagonist; Adrenergic transmitter uptake inhibitor; 5 Hydroxytryptamine uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor
CBR-001-574-700-9,RFM-003-495-7,CBR-001-574-700-9,CCCn1c(=O)c2[nH]c(nc2n(c1=O)CC)c1cnn(c1)Cc1cccc(c1)C(F)(F)F,CBR-HVAC-00154
CBR-001-574-701-0,RFM-003-496-8,CBR-001-574-701-0,CCOCOC[C@@H](NC(=O)c1ccc(cc1)Oc1ccccc1)C[C@@H](C(=O)NO)C,"CBR-HVAC-05195: Osteoarthritis, Treatment of;Inflammatory Bowel Disease, Agents for; Matrix Metalloproteinase Inhibitors; Matrix metalloproteinase Inhibitor; Disease-modifying osteoarthritis drug; Matrix metalloproteinase inhibitor"
CBR-001-574-702-1,RFM-003-497-9,CBR-001-574-702-1,Fc1ccc(cc1)N1CCN(CC1)CCCN1c2cccc3c2c(S1(=O)=O)ccc3,CBR-HVAC-04027: Antipsychotic Drugs; Dopamine D4 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; Dopamine receptor D4; 5-Hydroxytryptamine 2A receptor Antagonist; 5 Hydroxytryptamine 2A receptor antagonist; Dopamine D4 receptor antagonist
CBR-001-574-703-2,RFM-003-498-0,CBR-001-574-703-2,FC(c1cccc(c1)C1=CCN(CC1)CCc1ccc2c(c1)cccc2)(F)F,"CBR-HVAC-04012: Alzheimer's Dementia, Treatment of ;Multiple Sclerosis, Agents for;Amyotrophic Lateral Sclerosis, Agents for;Disorders Associated with Cancer Therapy, Treatment of; Neurotrophic Factor Enhancers;Signal Transduction Modulators;5-HT1A Receptor Agonists; Nerve growth factor; 5-Hydroxytryptamine 1A receptor Agonist; Agonist; 5 Hydroxytryptamine 1A receptor agonist; Nerve growth factor agonist"
CBR-001-574-704-3,RFM-003-499-1,CBR-001-574-704-3,CO[C@H]1CC=C2[C@]3(C1)N(CC2)CCC1=C3CC(=O)OC1,CBR-HVAC-06635: Antispastic Drugs and Drugs for Muscle Spasms;Pharmacological Tools; Nicotinic alpha2beta4 Receptor Ligands;Nicotinic alpha4beta2 Antagonists;Nicotinic alpha4beta2alpha5 Antagonists;Signal Transduction Modulators;
CBR-001-574-705-4,RFM-003-500-7,CBR-001-574-705-4,N#Cc1ccc2c(c1)[C@@H](N(C(=O)C)O)[C@@H](C(O2)(C)C)O,analog of CBR-HVAC-08540
CBR-001-574-706-5,RFM-003-501-8,CBR-001-574-706-5,NC(C1(CCC1)c1ccc(cc1)Cl)CC(C)C,CBR-HVAC-00148: Urinary Incontinence Therapy;Treatment of Erectile Dysfunction; Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; Adrenergic transmitter uptake inhibitor; Dopamine reuptake inhibitor
CBR-001-574-707-6,RFM-003-502-9,CBR-001-574-707-6,OCCSc1sc(c2c1C(=O)CC(C2)(C)C)c1nccs1,CBR-HVAC-11601: ; GABA-A receptor alpha 5 Agonist;
CBR-001-574-708-7,RFM-003-503-0,CBR-001-574-708-7,COc1cc2c(CCNC(=O)C)c[nH]c2cc1Cl,analog of CBR-HVAC-04889 (beta-Methyl-6-chloromelatonin)
CBR-001-574-709-8,RFM-003-504-1,CBR-001-574-709-8,CCCCCCCCCN1C[C@H](O)[C@H]([C@@H]([C@H]1CO)O)O,CBR-HVAC-14181
CBR-001-574-710-1,RFM-003-505-2,CBR-001-574-710-1,N#Cc1ccc(cc1)c1ccc(cc1)S(=O)(=O)Nc1cccc(n1)N,"CBR-HVAC-06524: Type 2 Diabetes, Agents for; 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) Inhibitor;"
CBR-001-574-711-2,RFM-003-506-3,CBR-001-574-711-2,CCCOc1cc(ccc1OC)[C@]1(C)CNC(=O)O1,"CBR-HVAC-11334: Multiple Sclerosis, Agents for; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; Phosphodiesterase 4 Inhibitor;"
CBR-001-574-712-3,RFM-003-507-4,CBR-001-574-712-3,O=C(CC(C)(C)C)Nc1c(F)cc(cc1F)C(=O)/N=c/1\sccn1COP(=O)(O)O,CBR-HVAC-06680: Antiparkinsonian Drugs; Adenosine A2A Antagonists;Signal Transduction Modulators; Adenosine A2A receptor Antagonist;
CBR-001-574-713-4,RFM-003-508-5,CBR-001-574-713-4,N#C/C(=C\c1ccc(c(c1)O)O)/C(=O)NCCCCc1ccccc1,"CBR-HVAC-11117: Septic Shock, Treatment of ; Signal Transduction Modulators;Tyrosine Kinase Inhibitors; Protein tyrosine kinase Inhibitor;"
CBR-001-574-714-5,RFM-003-509-6,CBR-001-574-714-5,S=C(N1CCC(CC1)c1c[nH]cn1)NC1CCCCC1,CBR-HVAC-10575: Antipsychotic Drugs; Histamine H3 Receptor Antagonists;Histamine H3 Receptor Inverse Agonists;Signal Transduction Modulators; Histamine H3 receptor Antagonist;
CBR-001-574-715-6,RFM-003-510-9,CBR-001-574-715-6,N[C@@H](Cc1ccccc1)CNc1nc(c2ccncc2)c(c(=O)n1C)c1ccc2c(c1)cccc2,CBR-HVAC-05888: Antiarthritic Drugs; MAPK p38 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; p38 MAP kinase Inhibitor; P38 kinase inhibitor
CBR-001-574-716-7,RFM-003-511-0,CBR-001-574-716-7,FC(COc1c(cc(cc1C(C)(C)C)C(C)(C)C)/C(=C\C=C\C(=C\C(=O)O)\C)/C)F,CBR-HVAC-14216
CBR-001-574-717-8,RFM-003-512-1,CBR-001-574-717-8,C/C=C\1/NC(=O)C(NC(=O)c2csc(n2)C23CCC(=NC3c3csc(n3)C(NC(=O)c3nc(C(NC(=O)C4N=C1SC4)C(C(O)C)(O)C)sc3)C(C)OC(=O)c1cc(C(O)C)c3c(n1)C(O)C(C=C3)NC(C(=O)NC(C(=O)NC(=C)C(=O)NC(C(=O)N2)C)C)C(CC)C)c1scc(n1)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)C(O)C,CBR-HVAC-08669: Antineoplastic Antibiotics;Miscellaneous Antibiotics; FOXM1 Expression Inhibitors;
CBR-001-574-718-9,RFM-003-513-2,CBR-001-574-718-9,O[C@@H]1[C@H](c2cc(OCCCC(F)(F)F)ccc2OC1(C)C)N(S(=O)(=O)C)C,CBR-HVAC-11193
CBR-001-574-719-0,RFM-003-514-3,CBR-001-574-719-0,OC(COc1ccc(cc1)c1nc(cn1C)C(F)(F)F)CNCCOc1ccc(c(c1)C(=O)N)O,CBR-HVAC-07619: Beta 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor agonist
CBR-001-574-720-3,RFM-003-515-4,CBR-001-574-720-3,COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCN1CCC(CC1)(c1ccccc1)c1ccccc1)C,CBR-HVAC-00076: Cancer Multidrug Resistance Modulators; Protein kinase C Inhibitor; Calmodulin antagonist; Protein kinase C inhibitor
CBR-001-574-721-4,RFM-003-516-5,CBR-001-574-721-4,OC(=O)CCC(C(=O)O)CP(=O)(O)O,CBR-HVAC-08572: ; Glutamate carboxypeptidase II Inhibitor;
CBR-001-574-722-5,RFM-003-517-6,CBR-001-574-722-5,CSc1ccc(cc1)[C@H]1CN2CCC[C@H]2c2c1cccc2,CBR-HVAC-10666: Antidepressants; Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5-Hydroxytryptamine transporter Inhibitor;
CBR-001-574-723-6,RFM-003-518-7,CBR-001-574-723-6,OC(=O)c1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2,"CBR-HVAC-03767: Hypertension, Treatment of; Dopamine receptor D2 Agonist; Dopamine D2 receptor agonist"
CBR-001-574-724-7,RFM-003-519-8,CBR-001-574-724-7,OC(=O)Cc1ccc(cc1)OCCNC[C@@H](c1ccccc1)O,CBR-HVAC-04565: Antiobesity Drugs;Antidiabetic Drugs; beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-3 adrenergic receptor Agonist; Beta 3 adrenoreceptor agonist; Insulin sensitizer
CBR-001-574-725-8,RFM-003-520-1,CBR-001-574-725-8,Brc1ccc(cc1)C[C@@]1(C)N(C)C(=O)N(C1=O)c1cc(Cl)cc(c1)Cl,CBR-HVAC-00517: Antiallergy/Antiasthmatic Drugs;Antiarthritic Drugs;Treatment of Autoimmune Diseases; Cell Adhesion Inhibitors;Integrin alphaLbeta2 (LFA-1) Antagonists;LFA-1/ICAM-1 Interaction Inhibitors;Signal Transduction Modulators; Lymphocyte function-associated antigen 1 Inhibitor; Lymphocyte function-associated molecule inhibitor
CBR-001-574-726-9,RFM-003-521-2,CBR-001-574-726-9,CN(C(=O)c1ccc(c(c1)Cl)Cl)[C@@H]1CCCC[C@@H]1N1CCCC1,CBR-HVAC-10837: Antiepileptic Drugs; Sodium channel Blocker;
CBR-001-574-727-0,RFM-003-522-3,CBR-001-574-727-0,Cc1onc(c1)c1nncc2n1nc(c2C(C)(C)C)OCc1ncnn1C,"CBR-HVAC-05535: Antidepressants;Cognition Disorders, Treatment of; GABA(A) Receptor Subunit Alpha-5 (GABRA5) Inverse Agonists;Signal Transduction Modulators;"
CBR-001-574-728-1,RFM-003-523-4,CBR-001-574-728-1,c1ccc(cc1)c1ncc([nH]1)CN1CCN(CC1)c1ncccn1,CBR-HVAC-04617: Antipsychotic Drugs; Dopamine D4 Antagonists;Signal Transduction Modulators; Dopamine receptor D4 Antagonist; Dopamine D4 receptor antagonist
CBR-001-574-729-2,RFM-003-524-5,CBR-001-574-729-2,CNCCCC1(OC(c2c1cccc2)(C)C)c1ccccc1,CBR-HVAC-01124: Antidepressants;Diagnostic Agents; Norepinephrine Transporter (NET) Inhibitors;Signal Transduction Modulators; Norepinephrine transporter Inhibitor; Unidentified pharmacological activity
CBR-001-574-730-5,RFM-003-525-6,CBR-001-574-730-5,NCCCC[C@@H](C(=O)Nc1ccc(cc1C)c1nc2c(s1)ccc(c2)F)N,CBR-HVAC-05433: Solid Tumors Therapy; Aryl Hydrocarbon Receptor (AhR) Agonists;Signal Transduction Modulators; CYP1A1 Modulator;
CBR-001-574-731-6,RFM-003-526-7,CBR-001-574-731-6,O[C@@H]1CC[C@H](CC1)Nc1nc(nc2c1cc[nH]2)c1ccccc1,"CBR-HVAC-05638: Cardiovascular Diseases (Not Specified);Renal Failure, Agents for;Heart Failure Therapy; Adenosine A1 Antagonists;Signal Transduction Modulators; Adenosine A1 receptor antagonist"
CBR-001-574-732-7,RFM-003-527-8,CBR-001-574-732-7,Cc1cc2c(n1C)nc(nc2N1CCCC1)N1CCCC1,CBR-HVAC-04788: Antiallergy/Antiasthmatic Drugs; Antioxidants; GABA-A receptor Modulator;
CBR-001-574-733-8,RFM-003-528-9,CBR-001-574-733-8,CCOC(=O)c1ncc2c(c1C)c1c(cccc1[nH]2)OC(C)C,CBR-HVAC-10450: Benzodiazepine receptor Antagonist; Benzodiazepine receptor agonist; GABA(A) BZ Site Receptor Antagonists; Signal Transduction Modulators; Antipsychotic; Neuroprotectant
CBR-001-574-734-9,RFM-003-529-0,CBR-001-574-734-9,O=c1[nH]cc(c(=O)n1CCCN1CCN(CC1)c1ccccc1OCC(F)(F)F)C,CBR-HVAC-14227
CBR-001-574-735-0,RFM-003-530-3,CBR-001-574-735-0,NCCCP(=O)(C(OCC)OCC)O,"CBR-HVAC-10549: Anxiolytics;Antidepressants;Cognition Disorders, Treatment of; GABA(B) Receptor Antagonists;Signal Transduction Modulators; GABA-B receptor Antagonist;"
CBR-001-574-736-1,RFM-003-531-4,CBR-001-574-736-1,OC(=O)CN1CCC(CC1)N1CCN(CC1)c1ccc(cc1)C(=N)N,CBR-HVAC-10727: Antiplatelet Therapy; Inhibitors of Blood Coagulation Pathways;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Signal Transduction Modulators; Integrin alpha2b beta3; Glycoprotein IIb-IIIa Antagonist;
CBR-001-574-737-2,RFM-003-532-5,CBR-001-574-737-2,CN1C[C@@H](C[C@H]2[C@H]1Cc1cn(c3c1c2ccc3)C(C)C)C(=O)N[C@H]1CCC[C@H]1O,"CBR-HVAC-10896: Cognition Disorders, Treatment of;Antiplatelet Therapy; Signal Transduction Modulators;5-HT2A Antagonists;5-HT7 Antagonists; 5-Hydroxytryptamine 7 receptor; 5-Hydroxytryptamine 2 receptor Antagonist;"
CBR-001-574-738-3,RFM-003-533-6,CBR-001-574-738-3,COCc1c(ncc2c1c1cc(OCc3ccccc3)ccc1[nH]2)C(=O)OCC,CBR-HVAC-14194
CBR-001-574-739-4,RFM-003-534-7,CBR-001-574-739-4,N#Cc1ccc2c(c1)[C@@H](N(C(=O)C)OCc1ccccc1)[C@@H](C(O2)(C)C)O,"CBR-HVAC-04153: Hypertension, Treatment of;Angina pectoris, Treatment of; Potassium Channel Activators; Potassium channel Opener;"
CBR-001-574-740-7,RFM-003-535-8,CBR-001-574-740-7,Clc1ccc(cc1)Cn1c(CC(C(=O)O)(C)C)c(c2c1ccc(c2)F)C,CBR-HVAC-03615: Antiplatelet Therapy; Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A2 receptor Antagonist; Thromboxane receptor antagonist; Platelet aggregation inhibitor
CBR-001-574-741-8,RFM-003-536-9,CBR-001-574-741-8,COc1c(C)cnc(c1C)Cn1cc(c2c1nc(N)nc2Cl)C#CCC(O)(C)C,CBR-HVAC-14228
CBR-001-574-742-9,RFM-003-537-0,CBR-001-574-742-9,Cc1cc(C)c(c(c1)C)NC(=O)N(C1CCCCCC1)Cc1ccc2c(c1)Cc1c2cccc1,"CBR-HVAC-04259: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor; Acetyl CoA transferase inhibitor"
CBR-001-574-743-0,RFM-003-538-1,CBR-001-574-743-0,Clc1ccc(cc1)N/C=C(\c1onc(c1)C)/C(=O)Nc1ccc(cc1)Cl,CBR-HVAC-11929: ; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA7 Modulator;
CBR-001-574-744-1,RFM-003-539-2,CBR-001-574-744-1,N#Cc1ccc(nc1)NCCNCC(=O)N1CCC[C@H]1C#N,"CBR-HVAC-05202: Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor;"
CBR-001-574-745-2,RFM-003-540-5,CBR-001-574-745-2,Fc1ccccc1S(=O)(=O)N1CCOc2c1cccc2N1CCNCC1,"CBR-HVAC-05973: Alzheimer's Dementia, Treatment of ; Signal Transduction Modulators;5-HT6 Antagonists; G protein-coupled receptor Antagonist;"
CBR-001-574-746-3,RFM-003-541-6,CBR-001-574-746-3,CN1C[C@H](C[C@H]2[C@H]1Cc1cn(c3c1c2ccc3)C)NS(=O)(=O)N(C)C,CBR-HVAC-14489: 5-Hydroxytryptamine 2A receptor Antagonist; 5-Hydroxytryptamine 2C receptor; Antiparkinsonian
CBR-001-574-747-4,RFM-003-542-7,CBR-001-574-747-4,COc1cc2CCN(c2cc1C(F)(F)F)C(=O)Nc1cc(F)cc(c1)c1cccnc1,CBR-HVAC-11286: Anxiolytics;Antidepressants;Antiparkinsonian Drugs; Signal Transduction Modulators;5-HT2C Antagonists; 5-Hydroxytryptamine 1C receptor Inverse Agonist;
CBR-001-574-748-5,RFM-003-543-8,CBR-001-574-748-5,NCCCP(=O)(CC1CCCCC1)O,CBR-HVAC-11420: ; GABA-B receptor Antagonist;
CBR-001-574-750-9,RFM-003-544-9,CBR-001-574-750-9,Fc1nccc(c1)CC1(Cc2ccnc(c2)F)c2ccccc2C(=O)c2c1cccc2,"CBR-HVAC-04646: Alzheimer's Dementia, Treatment of ; Acetylcholine Release Enhancers;Signal Transduction Modulators; Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 Blocker; Acetylcholine release stimulant"
CBR-001-574-751-0,RFM-003-545-0,CBR-001-574-751-0,CCCCCCCCCCCC(=O)c1c(O)c(C(=O)CCCCCCCCCCC)c(c(c1O)C1CC(Oc2c1ccc(c2)O)c1ccc(cc1)O)O,"CBR-HVAC-11533: Inflammation, Treatment of; Phospholipase A2 (PLA2) Inhibitors;Signal Transduction Modulators; Phospholipase A2 group II Inhibitor;"
CBR-001-574-752-1,RFM-003-546-1,CBR-001-574-752-1,c1ccc(cn1)C1CCC2CCN1CC2,"CBR-HVAC-09127: Cognition Disorders, Treatment of;Smoking Cessation, Aid to; Nicotinic alpha3beta4 Agonists;Nicotinic alpha4beta2 Antagonists;Nicotinic alpha6beta2 Receptor Ligands;Nicotinic alpha7 Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha7 Agonist;"
CBR-001-574-753-2,RFM-003-547-2,CBR-001-574-753-2,OC(=O)Cn1c(cc2c1cccc2)C(=O)Nc1scc(n1)c1ccccc1Cl,CBR-HVAC-10408: Pancreatic Cancer Therapy;Treatment of Eating Disorders; CCK1 (CCKA) Antagonists;Signal Transduction Modulators; Cholecystokinin A receptor Antagonist;
CBR-001-574-754-3,RFM-003-548-3,CBR-001-574-754-3,Clc1ccc2c(c1)nc(c(c2O)C(=O)C1CC1)O,"CBR-HVAC-10691: Stroke, Treatment of;Antiepileptic Drugs; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-574-755-4,RFM-003-549-4,CBR-001-574-755-4,COc1cccc(c1)[C@H](NCCCc1ccccc1Cl)C,CBR-HVAC-04553: Treatment of Hyperparathyroidism; Calcium-Sensing Receptor (CaSR) Agonists;Signal Transduction Modulators; Calcium-sensing receptor Agonist; Hypercalcaemic agent; Calcium-sensing receptor antagonist
CBR-001-574-756-5,RFM-003-550-7,CBR-001-574-756-5,N#Cc1ccc(cc1)N(n1cnnc1)Cc1ccc(cc1)Br,"CBR-HVAC-04419: Gynecological Disorders, Treatment of ;Breast Cancer Therapy;Endometriosis Therapy; Aromatase Inhibitors; Aromatase Inhibitor;"
CBR-001-574-757-6,RFM-003-551-8,CBR-001-574-757-6,OC(=O)c1cccc(c1)COc1ccc2c(c1)occ(c2=O)c1ccc(cc1)NS(=O)(=O)C,CBR-HVAC-07878: Treatment of Alcohol Dependency;Treatment of Cocaine Dependency; Aldehyde Dehydrogenase-2 (ALDH2) Inhibitors; Aldehyde dehydrogenase inhibitor
CBR-001-574-758-7,RFM-003-552-9,CBR-001-574-758-7,CCC([C@@H]1NC(=O)[C@H](Cc2ccc(cc2)O)N(C)C(=O)CCCSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCC(=O)N)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)C,CBR-HVAC-01564: ; Oxytocin receptor Agonist; Oxytocin receptor agonist
CBR-001-574-759-8,RFM-003-553-0,CBR-001-574-759-8,Clc1ccc(c(c1)Cl)/C(=C/n1cncn1)/Cl,CBR-HVAC-03845: Antiepileptic Drugs; GABA-A receptor Agonist; GABA A receptor agonist
CBR-001-574-760-1,RFM-003-554-1,CBR-001-574-760-1,Fc1ccc(cc1)C(CCCN1CCN(CC1)c1ncc(cn1)F)O,"CBR-HVAC-03315: Ischemic Stroke, Treatment of;Antipsychotic Drugs; NMDA Antagonists;sigma Receptor Antagonists;Signal Transduction Modulators; Opioid receptor sigma; 5-Hydroxytryptamine 1A receptor Agonist; Antagonist; Sigma receptor antagonist; 5 Hydroxytryptamine 1A receptor agonist"
CBR-001-574-761-2,RFM-003-555-2,CBR-001-574-761-2,OC(=O)[C@@H]1NCC[C@@H](C1)CP(=O)(O)O,"CBR-HVAC-02729: Anxiolytics;Stroke, Treatment of;Antiepileptic Drugs; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; NMDA receptor antagonist"
CBR-001-574-762-3,RFM-003-556-3,CBR-001-574-762-3,CNC(=O)c1ccc2c(c1)CCO[C@H]2CCN1CCN(CC1)c1ccc(cc1)C(=O)N,"CBR-HVAC-05398: Acute Attacks of Migraine, Treatment of; Signal Transduction Modulators;5-HT1D Agonists; 5-Hydroxytryptamine 1D receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist"
CBR-001-574-763-4,RFM-003-557-4,CBR-001-574-763-4,COc1cc2CCN(C(c2cc1O)CCc1ccc(cc1)Cl)C,analog of CBR-HVAC-09998
CBR-001-574-764-5,RFM-003-558-5,CBR-001-574-764-5,COc1ccccc1CN[C@H]1C2CCN([C@H]1C(c1ccccc1)c1ccccc1)CC2,"CBR-HVAC-14443: Neurokinin 1 receptor antagonist; Neurokinin receptor 1 Antagonist; Signal Transduction Modulators; Substance P uptake inhibitor; Tachykinin NK1 Antagonists; Analgesic; Anti-HIV Agents; Anti-inflammatory; Antipsychotic; Anxiolytic; Non-Opioid Analgesics; Pancreatic Disorders, Treatment of"
CBR-001-574-765-6,RFM-003-559-6,CBR-001-574-765-6,NC(=NC(=O)c1cnn(c1C1CC1)c1cccc2c1cccn2)N,"CBR-HVAC-05436: Acute Myocardial Infarction, Treatment of;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Na+/H+ Exchanger type 1 (NHE-1) Inhibitors; Na+/H+ exchanger Inhibitor;"
CBR-001-574-766-7,RFM-003-560-9,CBR-001-574-766-7,N#Cc1ccccc1OCC(CNCCNC(=O)Nc1ccccc1)O,CBR-HVAC-07909: ; beta1-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenoreceptor antagonist; Adrenoreceptor agonist
CBR-001-574-767-8,RFM-003-561-0,CBR-001-574-767-8,O=C(N1CCc2c1cc(c(c2)C)C(F)(F)F)Nc1ccc(nc1)Oc1cccnc1C,CBR-HVAC-05013: Antidepressants;Anxiolytics; Signal Transduction Modulators;5-HT2C Antagonists; 5-Hydroxytryptamine 2C receptor Antagonist;
CBR-001-574-768-9,RFM-003-562-1,CBR-001-574-768-9,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)COc1c(OC)cccc1C(C)C,CBR-HVAC-05336: Treatment of Erectile Dysfunction;Treatment of Female Sexual Dysfunction; alpha1B-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1B adrenergic receptor Antagonist;
CBR-001-574-769-0,RFM-003-563-2,CBR-001-574-769-0,OC(=O)c1cc2cc(O)c(cc2c(n1)C(=O)c1ccc(c(c1)O)O)O,CBR-HVAC-11242: Anxiolytics;Antidiabetic Drugs;Antidepressants; IGF1R Inhibitor;
CBR-001-574-770-3,RFM-003-564-3,CBR-001-574-770-3,CCCNC(=O)N1N=C(c2ccc(cc2)N)c2c(C1C)cc1c(c2)OCO1,"CBR-HVAC-11453: Antiepileptic Drugs;Stroke, Treatment of; AMPA Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Antagonist;"
CBR-001-574-771-4,RFM-003-565-4,CBR-001-574-771-4,COc1cc(COc2cc(N)c(cc2C(=O)CCC2CCN(CC2)CCNS(=O)(=O)C)Cl)cc(c1)OC,"CBR-HVAC-11131: Irritable Bowel Syndrome, Agents for;Pharmacological Tools; Signal Transduction Modulators;5-HT4 Antagonists; 5-Hydroxytryptamine 4 receptor Antagonist;"
CBR-001-574-772-5,RFM-003-566-5,CBR-001-574-772-5,Oc1ccc2c(c1)c(CCCCN1CCC(=CC1)c1ccccc1)c[nH]2,"CBR-HVAC-03374: Hypertension, Treatment of;Antidepressants;Antipsychotic Drugs; Dopamine Autoreceptor Agonists;Signal Transduction Modulators; Dopamine receptor D2; 5-Hydroxytryptamine transporter Agonist; Inhibitor; Dopamine receptor agonist; 5 Hydroxytryptamine uptake inhibitor; 5 Hydroxytryptamine 1A receptor agonist"
CBR-001-574-773-6,RFM-003-567-6,CBR-001-574-773-6,CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(c1OC)Br,CBR-HVAC-02768: Dopamine D2 Antagonists; Dopamine D2 receptor antagonist; Dopamine receptor D2 Antagonist; Dopamine-D2-receptor-antagonists; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs; Psychotic Disorders
CBR-001-574-774-7,RFM-003-568-7,CBR-001-574-774-7,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2N[C@H]1CCC[C@@H]1O,"CBR-HVAC-14442: Adenosine A1 Agonists; Adenosine A1 receptor Agonist; Adenosine A1 receptor agonist; Signal Transduction Modulators; Analgesic; Antidiabetic Drugs; Antilipolytic; Cardioprotectant; Cardioprotectants; Lipoprotein Disorders, Treatment of ; Vasodilator"
CBR-001-574-775-8,RFM-003-569-8,CBR-001-574-775-8,OC(=O)C1=CC(=O)C(O1)(C)c1ccccc1,"CBR-HVAC-02888: Lipoprotein Disorders, Treatment of ; G protein-coupled receptor 109A; G protein-coupled receptor 109B Agonist; Agonist; Cholesterol inhibitor"
CBR-001-574-776-9,RFM-003-570-1,CBR-001-574-776-9,CCCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)c(=O)n(cc2)CC(=O)N(C)C,CBR-HVAC-14315: Angiotensin II receptor Antagonist; Antihypertensive
CBR-001-574-777-0,RFM-003-571-2,CBR-001-574-777-0,CC1CCN(CC1)CCCC(=O)c1ccc(cc1)F,"CBR-HVAC-01296: Treatment of Substance Dependency;Sleep Disorders, Treatment of;Anxiolytics;Analgesic Drugs;Antipsychotic Drugs;Treatment of Alcohol Dependency; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2 Antagonists; Dopamine receptor D4 Agonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 1A receptor antagonist"
CBR-001-574-778-1,RFM-003-572-3,CBR-001-574-778-1,CC(c1nnc(n1c1cccc2c1non2)c1ccc(nc1)c1ccccc1)C,"CBR-HVAC-06776: Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; GlyT-1 Inhibitors; Glycine transporter 1 inhibitor"
CBR-001-574-779-2,RFM-003-573-4,CBR-001-574-779-2,O=C1CN=C(c2c(N1)ccc(c2)Cl)c1[nH]ccc1,CBR-HVAC-10552: Leukemia Therapy;Anti-HIV Agents; Runt-Related Transcription Factor 1 (RUNX1) Inhibitors;Signal Transduction Modulators;Tat Inhibitors; Reverse transcriptase Tat protein Inhibitor;
CBR-001-574-780-5,RFM-003-574-5,CBR-001-574-780-5,Fc1ccc(cc1)CN1C[C@@H](C)N(C[C@@H]1C)C(=O)c1cc2c(cn(c2cc1Cl)C)C(=O)C(=O)N(C)C,"CBR-HVAC-00574: Multiple Myeloma Therapy;Myelodysplastic Syndrome Therapy;Rheumatoid Arthritis, Treatment of; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators; p38 Mitogen-activated protein kinase Inhibitor; P38 kinase inhibitor"
CBR-001-574-781-6,RFM-003-575-6,CBR-001-574-781-6,ONC(=O)[C@H]([C@H](C(=O)N1CCCCC1)CC1CCCC1)CN1C(=O)N(C(C1=O)(C)C)C,CBR-HVAC-04790: Antiarthritic Drugs; Collagenase Inhibitors; MATRIX METALLOPROTEINASE; TNF-ALPHA CONVERTING ENZYME Inhibitor; Metalloproteinase-1 inhibitor
CBR-001-574-782-7,RFM-003-576-7,CBR-001-574-782-7,COP(=O)(C(c1ccc(cc1)Cl)OP(=O)(OC)OC)OC,"CBR-HVAC-02908: Lipoprotein Disorders, Treatment of ; PPARgamma Antagonists;Signal Transduction Modulators; Cholesterol inhibitor; Renin inhibitor"
CBR-001-574-783-8,RFM-003-577-8,CBR-001-574-783-8,CO/N=C/C1=CCCN(C1)C,"CBR-HVAC-03762: Cognition Disorders, Treatment of; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Agonist; Muscarinic M1 receptor agonist"
CBR-001-574-784-9,RFM-003-578-9,CBR-001-574-784-9,Clc1ncc(cn1)NC(=O)c1ccc(c(c1)F)F,"CBR-HVAC-05949: Neuropathic Pain, Treatment of;Antiepileptic Drugs; Voltage-Gated K(V) 7.2 (KCNQ2) Channel Activators;Voltage-Gated K(V) 7.3 (KCNQ3) Channel Activators;"
CBR-001-574-785-0,RFM-003-579-0,CBR-001-574-785-0,O=c1[nH]c2cc(c(cc2n(c1=O)CP(=O)(O)O)N1CCOCC1)C(F)(F)F,"CBR-HVAC-05024: Ischemic Stroke, Treatment of; AMPA Receptor Antagonists;Kainate Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Antagonist;"
CBR-001-574-786-1,RFM-003-580-3,CBR-001-574-786-1,CCCCCOc1c(OC)ccc2c1nc(O)c(c2)C(=O)NCc1ccc2c(c1)OCO2,CBR-HVAC-11976: Immunomodulators; Cannabinoid CB2 Inverse Agonists;Signal Transduction Modulators; Cannabinoid receptor 1; Cannabinoid receptor 2 Antagonist; Modulator;
CBR-001-574-787-2,RFM-003-581-4,CBR-001-574-787-2,OC[C@H]1OC([C@@H]([C@@H]1O)O)n1c(Cl)nc2c1ncnc2N,CBR-HVAC-05166: Oncolytic Drugs;Lymphocytic Leukemia Therapy; Autophagy Inducers;Telomerase Inhibitors;
CBR-001-574-788-3,RFM-003-582-5,CBR-001-574-788-3,O=C(N1CCC(CC1)c1cnc[nH]1)CCCCC1CCCCC1,"CBR-HVAC-10519: Cognition Disorders, Treatment of; Histamine H3 Receptor Antagonists;Signal Transduction Modulators; Histamine H3 receptor Antagonist;"
CBR-001-574-789-4,RFM-003-583-6,CBR-001-574-789-4,CCn1ccnc1CC1COc2c(O1)cccc2,CBR-HVAC-02894: Antidepressants; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Antagonist; Alpha 2 adrenoreceptor antagonist
CBR-001-574-790-7,RFM-003-584-7,CBR-001-574-790-7,CCCN(CCc1ccc(c(c1)OCCc1ccccc1)OC)CCC,CBR-HVAC-04476: Antipsychotic Drugs; sigma1 Receptor Antagonists;Signal Transduction Modulators; OPIOID RECEPTOR SIGMA 1 Antagonist; Sigma 1 receptor antagonist
CBR-001-574-791-8,RFM-003-585-8,CBR-001-574-791-8,CCN(C(=O)Cn1c2nc(ncc2n(c1=O)C)c1ccccc1)Cc1ccccc1,"CBR-HVAC-05334: Antidepressants;Generalized Anxiety Disorder (GAD), Treatment of;Anxiolytics; Peripheral Benzodiazepine Receptor (PBR) Ligands;Signal Transduction Modulators; Benzodiazepine receptor Agonist;"
CBR-001-574-792-9,RFM-003-586-9,CBR-001-574-792-9,O[C@@H]1C[C@H](N(C1)C(=O)c1cn(c2c1cccc2)C)C(=O)N[C@H](C(=O)N(Cc1ccccc1)C)Cc1ccc2c(c1)cccc2,CBR-HVAC-04214: Antimigraine Drugs; Signal Transduction Modulators;Tachykinin NK1 Antagonists; NK1 receptor Antagonist;
CBR-001-574-793-0,RFM-003-587-0,CBR-001-574-793-0,OC(=O)CCC/C=C\C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)C(F)(F)F,CBR-HVAC-07907: Thromboxane receptor antagonist
CBR-001-574-794-1,RFM-003-588-1,CBR-001-574-794-1,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2c(O1)cccc2,"CBR-HVAC-11590: Hypertension, Treatment of;Anxiolytics; Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist;"
CBR-001-574-795-2,RFM-003-589-2,CBR-001-574-795-2,CCN(c1cccc(c1)C)CCNC(=O)Nc1ccccc1Br,CBR-HVAC-11731: ; Vanilloid receptor 1 Antagonist;
CBR-001-574-796-3,RFM-003-590-5,CBR-001-574-796-3,CNc1cc2[nH]c(=O)n(c(=O)c2cc1F)c1ccc(cc1)NC(=O)NS(=O)(=O)c1ccc(s1)Cl,CBR-HVAC-06618: Antiplatelet Therapy; P2Y12 (P2T) Antagonists;Signal Transduction Modulators; P2Y12 ADP RECEPTOR Antagonist; Purinoreceptor P2Y12 antagonist; Platelet aggregation inhibitor; Purinoreceptor P2 antagonist
CBR-001-574-797-4,RFM-003-591-6,CBR-001-574-797-4,CC(Oc1cccc(c1)CC(=O)N1CCC[C@](C1)(CC[N+]12CCC(CC1)(CC2)c1ccccc1)c1ccc(c(c1)Cl)Cl)C,"CBR-HVAC-10439: Antiallergy/Antiasthmatic Drugs;Inflammatory Bowel Disease, Agents for; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin receptor 1 Antagonist;;2017-11-14: ARB# 16-000825"
CBR-001-574-798-5,RFM-003-592-7,CBR-001-574-798-5,CCN(C(=O)N[C@@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC,CBR-HVAC-02358: ; Dopamine receptor D2 Agonist; Dopamine D2 receptor agonist; Prolactin inhibitor; 5 Hydroxytryptamine 2B receptor antagonist
CBR-001-574-799-6,RFM-003-593-8,CBR-001-574-799-6,CC(=O)NCCCOc1ccc(cc1)C(=O)N1CCC(CC1)N1C(=O)CCc2c1cccc2,"CBR-HVAC-04223: Heart Failure Therapy;Hypertension, Treatment of; Signal Transduction Modulators;Vasopressin (AVP) V1a Receptor Antagonists; Vasopressin V1 receptor Antagonist; Vasopressin 1 antagonist"
CBR-001-574-800-2,RFM-003-594-9,CBR-001-574-800-2,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)nc2n(c1=O)CCCC2,CBR-HVAC-10521: 5 Hydroxytryptamine 2 receptor antagonist; 5-Hydroxytryptamine 2A receptor Antagonist; Platelet aggregation inhibitor; Antiplatelet Therapy; Antithrombotic; Vasodilators
CBR-001-574-801-3,RFM-003-595-0,CBR-001-574-801-3,O=C1c2c(NCC[N+](C)(C)[O-])ccc(c2C(=O)c2c1c(O)ccc2O)NCC[N+](C)(C)[O-],CBR-HVAC-04309: Solid Tumors Therapy;Bladder Cancer Therapy ;Oncolytic Drugs;Digestive/Gastrointestinal Cancer Therapy;Glioblastoma Multiforme Therapy;Lymphocytic Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy; DNA Topoisomerase II Inhibitors; DNA topoisomerase II Inhibitor; DNA directed RNA polymerase inhibitor; DNA inhibitor; DNA topoisomerase II inhibitor
CBR-001-574-802-4,RFM-003-596-1,CBR-001-574-802-4,OC(=O)c1n[nH]c2c1C[C@@H]1[C@H]2C1,"CBR-HVAC-06734: Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ; Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;"
CBR-001-574-803-5,RFM-003-597-2,CBR-001-574-803-5,NCCc1c[nH]c2c1cc(OCC(=O)N1CCN(CC1)c1ccc(cc1)C#N)cc2,CBR-HVAC-00426: Antimigraine Drugs; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-HYDROXYTRYPTAMINE 1B RECEPTOR; 5-HYDROXYTRYPTAMINE 1D RECEPTOR Agonist; 5 Hydroxytryptamine 1D receptor agonist; 5 Hydroxytryptamine 1B receptor agonist
CBR-001-574-804-6,RFM-003-598-3,CBR-001-574-804-6,NC(=O)c1ccc(c2c1C[C@H](CO2)N(C1CCC1)C1CCC1)F,"CBR-HVAC-04776: Gastrointestinal Disorders (Not Specified);Antidepressants;Anxiolytics;Irritable Bowel Syndrome, Agents for;Urinary Incontinence Therapy; Signal Transduction Modulators;5-HT1A Receptor Antagonists; 5-Hydroxytryptamine 1A receptor Antagonist; 5 Hydroxytryptamine 1A receptor antagonist"
CBR-001-574-805-7,RFM-003-599-4,CBR-001-574-805-7,CN1CCc2c(CC1)cccc2Cl,"CBR-HVAC-02991: Hypertension, Treatment of; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Antagonist;"
CBR-001-574-806-8,RFM-003-600-0,CBR-001-574-806-8,CSc1cc2CCN(c2cc1C(F)(F)F)C(=O)Nc1cccnc1,CBR-HVAC-10640: Anxiolytics; Signal Transduction Modulators;5-HT2B Antagonists;5-HT2C Antagonists; 5-Hydroxytryptamine 2B receptor; 5-Hydroxytryptamine 2C receptor Antagonist;
CBR-001-574-807-9,RFM-003-601-1,CBR-001-574-807-9,CN(c1cccc2c1cccc2S(=O)(=O)Nc1onc(c1C)C)C,"CBR-HVAC-11030: Hypertension, Treatment of; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist;"
CBR-001-574-808-0,RFM-003-602-2,CBR-001-574-808-0,COC(=O)c1c(c2cc(OC)c(c(c2)OC)OC)c2ccnc(c2c(=O)n1Cc1ccnc(c1)C)OCc1ncccn1,CBR-HVAC-11456: Phosphodiesterase 5A Inhibitor
CBR-001-574-809-1,RFM-003-603-3,CBR-001-574-809-1,CN(CC(=O)O)CCC(c1ccc(cc1)F)Oc1ccc(cc1)c1ccccc1,CBR-HVAC-07450: Antipsychotic Drugs; GlyT-1 Inhibitors; Glycine transporter 1 inhibitor
CBR-001-574-810-4,RFM-003-604-4,CBR-001-574-810-4,CN(CCCSc1ccccc1NC(=O)/C=C/c1ccccc1)C,CBR-HVAC-10047: ; 5-Hydroxytryptamine receptor Antagonist;
CBR-001-574-811-5,RFM-003-605-5,CBR-001-574-811-5,CCOc1cc2ncc(c(c2cc1NC(=O)/C=C/CN(C)C)Nc1ccc(c(c1)Cl)OCc1cccc(c1)F)C#N,CBR-HVAC-06132: Oncolytic Drugs; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; Epidermal growth factor receptor; Erbb2 Inhibitor;
CBR-001-574-812-6,RFM-003-606-6,CBR-001-574-812-6,CN1CCN(CC1)c1ncc(c(n1)N)c1cc(Cl)cc(c1Cl)Cl,"CBR-HVAC-04064: Stroke, Treatment of; Glutamate Release Inhibitors;Nav1.2 (Brain Type II) Sodium Channel Blockers;N-Type Calcium Channel (Ca(v) 2.2) Blockers;Signal Transduction Modulators; Neuronal sodium channel; Calcium channel Blocker; Voltage-gated sodium channel antagonist"
CBR-001-574-813-7,RFM-003-607-7,CBR-001-574-813-7,COc1cc(ccc1OCCN1CCCC1)n1cnc2c(c1=O)sc(c2)c1ccc(cc1)Cl,CBR-HVAC-00168: Antiobesity Drugs; Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists;Signal Transduction Modulators; Melanin concentrating hormone receptor 1 Antagonist; Melanin concentrating hormone-1 receptor antagonist
CBR-001-574-814-8,RFM-003-608-8,CBR-001-574-814-8,CCOc1ccc(cc1)n1c(=C(N(C(=O)Cc2ccc(cc2)OC(F)(F)F)Cc2cccnc2)C)[nH]c2c(c1=O)cccn2,CBR-HVAC-05847
CBR-001-574-815-9,RFM-003-609-9,CBR-001-574-815-9,C=Cc1cc(O)cc2c1oc(n2)c1ccc(c(c1)F)O,"CBR-HVAC-00551: Inflammatory Bowel Disease, Agents for;Endometriosis Therapy;Sepsis, Treatment of;Rheumatoid Arthritis, Treatment of; Estrogen Receptor (ER) beta Agonists;Signal Transduction Modulators; Estrogen receptor beta Agonist; Estrogen receptor beta agonist"
CBR-001-574-816-0,RFM-003-610-2,CBR-001-574-816-0,COc1cc(OC)ccc1/C=C/1\CCCN=C1c1cccnc1,"CBR-HVAC-04689: Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs;Autism, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Nicotinic alpha7 Partial Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha7 Agonist;"
CBR-001-574-817-1,RFM-003-611-3,CBR-001-574-817-1,OC(=O)Cn1nnnc1c1cscc1,CBR-HVAC-04544: Symptomatic Antidiabetic Agents; Aldose Reductase Inhibitors; Aldose reductase Inhibitor;
CBR-001-574-818-2,RFM-003-612-4,CBR-001-574-818-2,CCCCNC(=O)C(CCC)N,analog of CBR-HVAC-08012
CBR-001-574-819-3,RFM-003-613-5,CBR-001-574-819-3,N#Cc1ccc(c(c1)Cl)NC(C(O)(C)C)C,analog of CBR-HVAC-07262
CBR-001-574-820-6,RFM-003-614-6,CBR-001-574-820-6,CCOc1ccc(cc1)OCC(=O)C1CCCC1,analog of CBR-HVAC-08138
CBR-001-574-821-7,RFM-003-615-7,CBR-001-574-821-7,COCC(CN1CCN(CC1)C(c1ccc(cc1)Cl)C)O,analog of CBR-HVAC-08309
CBR-001-574-822-8,RFM-003-616-8,CBR-001-574-822-8,CN(CC(Cc1cccc(c1)Cl)O)C,analog of CBR-HVAC-07656
CBR-001-574-823-9,RFM-003-617-9,CBR-001-574-823-9,OC(=O)C(c1ccc2c(c1)Cc1c2cccc1)C,"CBR-HVAC-01219: Inflammation, Treatment ofCyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-574-824-0,RFM-003-618-0,CBR-001-574-824-0,C=CCC(Cc1ccccc1)N,CBR-HVAC-09699:
CBR-001-574-825-1,RFM-003-619-1,CBR-001-574-825-1,COc1ccc(cc1)n1c(O)ncc1C,CBR-HVAC-08813: ; Glucose-6-phosphate dehydrogenase Inhibitor;
CBR-001-574-827-3,RFM-003-620-4,CBR-001-574-827-3,COc1ccc(cc1)N1CCN(CC1)C(=O)c1ccnc2c1cccc2,analog of CBR-HVAC-00159
CBR-001-574-828-4,RFM-003-621-5,CBR-001-574-828-4,OC(COc1ccc(cc1)C#N)CNCCCS(=O)(=O)C,analog of CBR-HVAC-03915
CBR-001-574-829-5,RFM-003-622-6,CBR-001-574-829-5,C=CCCCCCSC(=N)N,analog of CBR-HVAC-05813
CBR-001-574-830-8,RFM-003-623-7,CBR-001-574-830-8,CCCNCC(COc1ccc(cc1)SC)O,analog of CBR-HVAC-08447
CBR-001-574-831-9,RFM-003-624-8,CBR-001-574-831-9,OCC(C(C)C)NS(=O)(=O)c1ccc(s1)Cl,analog of CBR-HVAC-09289
CBR-001-574-832-0,RFM-003-625-9,CBR-001-574-832-0,CCN(c1nc(nc(n1)NN)N(CC)CC)CC,CBR-HVAC-09055:
CBR-001-574-833-1,RFM-003-626-0,CBR-001-574-833-1,N#Cc1cc(CNCCOc2cccc(c2)C)cc(c1)F,analog of CBR-HVAC-10381
CBR-001-574-834-2,RFM-003-627-1,CBR-001-574-834-2,CC(Nc1ncccn1)C,CBR-HVAC-02653: Nerve growth factor agonist
CBR-001-574-835-3,RFM-003-628-2,CBR-001-574-835-3,NCC1(CN)CCCCC1,uninteresting ligand of CBR-HVAC-08359
CBR-001-574-836-4,RFM-003-629-3,CBR-001-574-836-4,CN1CCN(CC1)NS(=O)(=O)c1ccc(cc1)F,analog of CBR-HVAC-10894
CBR-001-574-837-5,RFM-003-630-6,CBR-001-574-837-5,O=C1CCC(C(=O)N1)N1C(=O)C2C(C1=O)CCC2,analog of CBR-HVAC-08399
CBR-001-574-838-6,RFM-003-631-7,CBR-001-574-838-6,COc1ccc(cc1)C(CNC(Cc1ccccc1)C)O,analog of CBR-HVAC-07470 (arformoterol tartrate)
CBR-001-574-839-7,RFM-003-632-8,CBR-001-574-839-7,OC(COc1cc(C)ccc1Cl)CNC(C)C,CBR-HVAC-00992: analog of bupranolol
CBR-001-574-840-0,RFM-003-633-9,CBR-001-574-840-0,COCC(OC(=O)[C@H](Cc1ccc(c(c1)O)O)N)C,analog of CBR-HVAC-11753
CBR-001-574-841-1,RFM-003-634-0,CBR-001-574-841-1,OC(=O)c1snc(c1N)c1cccc(c1)C(F)(F)F,CBR-HVAC-01171: ; XANTHINE OXIDASE Inhibitor; Xanthine oxidase inhibitor
CBR-001-574-842-2,RFM-003-635-1,CBR-001-574-842-2,COc1ccc(c(c1)Cl)C(CC(CC(C)(C)C)C)O,analog of CBR-HVAC-08034
CBR-001-574-843-3,RFM-003-636-2,CBR-001-574-843-3,CCCc1ccc(cc1)C(Cn1cncc1)O,analog of CBR-HVAC-00776
CBR-001-574-844-4,RFM-003-637-3,CBR-001-574-844-4,CNCC/C=C/c1cncnc1,analog of CBR-HVAC-11684
CBR-001-574-845-5,RFM-003-638-4,CBR-001-574-845-5,CC(Cc1ccc(cc1C)N(C)C)N,CBR-HVAC-07455: Monoamine oxidase inhibitor
CBR-001-574-846-6,RFM-003-639-5,CBR-001-574-846-6,CCN(CCOc1c(Br)cccc1CO)CC,analog of CBR-HVAC-08607
CBR-001-574-847-7,RFM-003-640-8,CBR-001-574-847-7,O/N=C/c1cc[n+](cc1)COC[n+]1ccc(cc1)/C=N/O,CBR-HVAC-06906: Treatment of Poisoning; Acetylcholinesterase Reactivator;
CBR-001-574-848-8,RFM-003-641-9,CBR-001-574-848-8,Brc1cc(Br)c(c(c1)C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F)O,analog of CBR-HVAC-09525
CBR-001-574-849-9,RFM-003-642-0,CBR-001-574-849-9,CCOc1ccc2c(c1)O/C(=C\c1ccc(c(c1OC)OC)OC)/C2=O,analog of CBR-HVAC-02705
CBR-001-574-850-2,RFM-003-643-1,CBR-001-574-850-2,NC(=O)OCC[N+](C)(C)C,CBR-HVAC-02849: Antiglaucoma Agents; Cholinergics;Signal Transduction Modulators; Muscarinic acetylcholine receptor Antagonist;
CBR-001-574-851-3,RFM-003-644-2,CBR-001-574-851-3,OC(COc1ccccc1OCc1onc(n1)C)CNC(C)(C)C,"CBR-HVAC-04648: Angina pectoris, Treatment of;Hypertension, Treatment of;Antiglaucoma Agents; beta-Adrenoceptor Antagonists;Signal Transduction Modulators;"
CBR-001-574-852-4,RFM-003-645-3,CBR-001-574-852-4,OCC(C(C(=O)NCCCC(=O)O)O)(C)C,CBR-HVAC-07588: GABA receptor agonist
CBR-001-574-853-5,RFM-003-646-4,CBR-001-574-853-5,COCCOc1cc2c(ncnc2cc1OCCOC)Nc1cccc(c1)C#C,CBR-HVAC-02168: Gastric Cancer Therapy;Myelodysplastic Syndrome Therapy;Neurologic Cancer Therapy;Agents for Viral Hepatitis;Prostate Cancer Therapy;Renal Cancer Therapy;Colorectal Cancer Therapy;Premalignant Conditions Therapy;Breast Cancer Therapy;Pancreatic Cancer Therapy;Brain Cancer Therapy;Bladder Cancer Therapy ;Astrocytoma Therapy;Gastrointestinal Disorders (Not Specified);Hematological Cancer Therapy;Sarcoma Therapy;Cervical Cancer Therapy;Solid Tumors Therapy;Melanoma Therapy;Ovarian Cancer Therapy;Head and Neck Cancer Therapy;Glioblastoma Multiforme Therapy;Digestive/Gastrointestinal Cancer Therapy;Myeloid Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Liver Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; EGFR; ERBB2 Inhibitor; EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-574-854-6,RFM-003-647-5,CBR-001-574-854-6,Ic1ccc2n(c1)cc(n2)c1ccccc1,analog of CBR-HVAC-07919
CBR-001-574-855-7,RFM-003-648-6,CBR-001-574-855-7,CN(S(=O)(=O)c1cccc(c1)c1cs/c(=N\c2ccccc2)/n1Cc1ccccc1)C,analog of CBR-HVAC-08043
CBR-001-574-856-8,RFM-003-649-7,CBR-001-574-856-8,CCCOc1ccc(cc1)c1nc2n(c1)cccc2,analog of CBR-HVAC-10864
CBR-001-574-857-9,RFM-003-650-0,CBR-001-574-857-9,COc1ccc2c(c1)c1CCN=C3c1n2CCN3C,CBR-HVAC-09248:
CBR-001-574-858-0,RFM-003-651-1,CBR-001-574-858-0,CN(CCC(c1ccccn1)c1ccc(cc1)Br)C,CBR-HVAC-05687: Antiallergy/Antiasthmatic Drugs;Drugs for Allergic Rhinitis; Histamine Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist;
CBR-001-574-859-1,RFM-003-652-2,CBR-001-574-859-1,N#Cc1cccnc1N1CCOCC1,analog of CBR-HVAC-03520
CBR-001-574-860-4,RFM-003-653-3,CBR-001-574-860-4,COc1ccccc1N1CCN(CC1)C(=O)Cn1c(=O)[nH]c2c(c1=O)cccc2,analog of CBR-HVAC-00339
CBR-001-574-861-5,RFM-003-654-4,CBR-001-574-861-5,OC(=O)c1ccccc1O,CBR-HVAC-02387: Keratolytic
CBR-001-574-862-6,RFM-003-655-5,CBR-001-574-862-6,Cc1ccc2c(c1)c(NC(=O)c1ccccc1)c([nH]2)C(=O)O,analog of CBR-HVAC-11587
CBR-001-574-863-7,RFM-003-656-6,CBR-001-574-863-7,CC[C@H]1[C@@H]2CC3N([C@@H]1O)[C@@H]1C2C(O)[C@]2([C@H]3N(C)c3c2cccc3)C1,CBR-HVAC-06469: Antiarrhythmic Drugs;Diagnostic Agents; Potassium channel hERG Blocker;
CBR-001-574-864-8,RFM-003-657-7,CBR-001-574-864-8,CCC(C1OC2(C=CC1C)OC1C/C=C(\C)/C(OC3CC(OC)C(C(O3)C)OC3CC(OC)C(C(O3)C)NC(=O)C)C(C)/C=C/C=C\3/C4(C(C(=O)OC(C2)C1)C=C(C)C(C4OC3)O)O)C,analog of CBR-HVAC-10215 (EPRINOMECTIN)
CBR-001-574-865-9,RFM-003-658-8,CBR-001-574-865-9,CN(CCNC(=O)c1cccc2c1nccc2)C,analog of CBR-HVAC-00231 (SN-22995)
CBR-001-574-866-0,RFM-003-659-9,CBR-001-574-866-0,O=C(c1ccc(cc1)n1cnc2c(c1=O)cccc2)NC1CC1,analog of CBR-HVAC-07499
CBR-001-574-867-1,RFM-003-660-2,CBR-001-574-867-1,CCC1(c2ccccc2)C(=O)N(COC)C(=O)N(C1=O)COC,CBR-HVAC-01052: Antiepileptic Drugs; Acts as benzodiazepine receptor agonist; GABA receptor agonist; Chloride channel agonist
CBR-001-574-868-2,RFM-003-661-3,CBR-001-574-868-2,O=C1CC[C@]2(C(=C1)C=CC1C2CC[C@]2(C1CC[C@]2(O)C(=O)C)C)C,analog of CBR-HVAC-09867 (NOMEGESTROL)
CBR-001-574-869-3,RFM-003-662-4,CBR-001-574-869-3,Cn1c(nc2c1c(=O)n(c(=O)n2C)C)N1CCOCC1,analog of CBR-HVAC-09418
CBR-001-574-870-6,RFM-003-663-5,CBR-001-574-870-6,CCCn1c2cc(Cl)ccc2n(c1=O)CCC,analog of CBR-HVAC-09227
CBR-001-574-871-7,RFM-003-664-6,CBR-001-574-871-7,O=C1N/C(=N\c2ccccc2Cl)/S/C/1=C\c1ccncc1,analog of CBR-HVAC-11819
CBR-001-574-872-8,RFM-003-665-7,CBR-001-574-872-8,CCOc1ccc(cc1)C(=O)Nc1ccccc1OC(=O)c1ccc(cc1)OCC,analog of CBR-HVAC-11977
CBR-001-574-873-9,RFM-003-666-8,CBR-001-574-873-9,NCC(=O)NC(c1ccccc1)(Cc1ccccc1)C,"CBR-HVAC-03891: Huntington's Disease, Treatment of;Antiepileptic Drugs;Autism, Treatment of; NMDA Antagonists;Signal Transduction Modulators;"
CBR-001-574-874-0,RFM-003-667-9,CBR-001-574-874-0,NC1CCN(CC1)c1nc2c(o1)ccc(n2)C,analog of CBR-HVAC-06571
CBR-001-574-875-1,RFM-003-668-0,CBR-001-574-875-1,COc1cc(/C=C\c2ccc(c(c2)N)OC)cc(c1OC)OC,CBR-HVAC-05026: Solid Tumors Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors; TUBULIN INHIBITOR;
CBR-001-574-876-2,RFM-003-669-1,CBR-001-574-876-2,COc1ccc(cc1)C[C@H]1C(=O)N[C@@H](C)C(=O)N(C)[C@H]2Cc3ccc(cc3)Oc3cc(C[C@H](N(C2=O)C)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1C)C)C)ccc3OC,CBR-HVAC-11185: Oncolytic Drugs
CBR-001-574-877-3,RFM-003-670-4,CBR-001-574-877-3,O=C1NC(=O)C2(N1)CC(Oc1c2cc(F)cc1)C(=O)N,"CBR-HVAC-04410: Diabetic Neuropathy, Agents for;Treatment of Diabetic Complications; Aldose Reductase Inhibitors; Aldose reductase Inhibitor; Aldose reductase inhibitor"
CBR-001-574-878-4,RFM-003-671-5,CBR-001-574-878-4,COc1cc(ccc1OC)c1nc(Nc2ncccc2C(=O)N)n2c(c1)ncc2,CBR-HVAC-11566:Tyrosine kinase inhibitor
CBR-001-583-135-3,RFM-003-672-6,CBR-001-583-135-3,O=c1[nH]c(nc2c1cccc2)N1CCNCC1,CBR-HVAC-05841: Antidiabetic Drugs; ; ;
CBR-001-583-136-4,RFM-003-673-7,CBR-001-583-136-4,CCC(C(=O)O)(C)C,"CBR-HVAC-06727: Sickle Cell Anemia, Agents for;Antianemics; ; ; Unidentified pharmacological activity"
CBR-001-583-137-5,RFM-003-674-8,CBR-001-583-137-5,OCC([C@H](C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@@H](C(CO)(C)C)O)O)(C)C,"CBR-HVAC-04654: Lipoprotein Disorders, Treatment of ;Anticataract Agents;Therapy of Vitamin-Related Disorders; ; ;"
CBR-001-583-138-6,RFM-003-675-9,CBR-001-583-138-6,C=C[C@]1(C)CC[C@H](C[C@@H]1C(=C)C)C(=C)C,CBR-HVAC-04996: Oncolytic Drugs; Angiogenesis Inhibitors;Signal Transduction Modulators;VEGFR Inhibitors; ;
CBR-001-583-139-7,RFM-003-676-0,CBR-001-583-139-7,CO[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2OC,CBR-HVAC-07742: Guanylate cyclase stimulant
CBR-001-583-140-0,RFM-003-677-1,CBR-001-583-140-0,OCC(CS)S,CBR-HVAC-07322: Antagonists to Metals;Treatment of Poisoning; ; ;
CBR-001-583-141-1,RFM-003-678-2,CBR-001-583-141-1,COc1cccc(c1)OCC1CNCCO1,CBR-HVAC-05825: Antidepressants; ; ;
CBR-001-583-142-2,RFM-003-679-3,CBR-001-583-142-2,CC(c1ccc(c(c1)O)C)C,CBR-HVAC-06480: Antifungal Agents;Antibacterial Drugs;Antiplatelet Therapy;Oncolytic Drugs; Antioxidants;Quorum Sensing Signaling Inhibitors; Neutrophil elastase Inhibitor;
CBR-001-583-143-3,RFM-003-680-6,CBR-001-583-143-3,C=CCc1ccc(c(c1)OC)O,CBR-HVAC-05446: Antifungal Agents;Oncolytic Drugs;Vasodilators; Antioxidants;Apoptosis Inducers;Free Radical Scavengers;MAO-A Inhibitors;Quorum Sensing Signaling Inhibitors; Calcium channel; Potassium channel Kv Antagonist;
CBR-001-583-144-4,RFM-003-681-7,CBR-001-583-144-4,C=CC(CCC=C(CCC=C(C)C)C)(O)C,CBR-HVAC-10362: Antimalarials;Antileishmanials;Absorption Promoters;Antibacterial Activity Enhancers;Oncolytic Drugs; ; ;
CBR-001-583-145-5,RFM-003-682-8,CBR-001-583-145-5,FC(C(C(C(C(C(C(C(Br)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,"CBR-HVAC-02675: Asthma Therapy;Acute Respiratory Distress Syndrome (ARDS), Agents for;Magnetic Resonance Imaging Agents;Blood Substitutes;Coronary Bypass Surgery; ; ; Not applicable"
CBR-001-583-146-6,RFM-003-683-9,CBR-001-583-146-6,S=C=NCCc1ccccc1,CBR-HVAC-05442: Chemopreventive Agents;Oncolytic Drugs; Apoptosis Inducers; ;
CBR-001-583-147-7,RFM-003-684-0,CBR-001-583-147-7,CCOC(=O)C(=O)C,"CBR-HVAC-05762: Coronary Bypass Surgery;Systemic Inflammatory Response Syndrome (SIRS), Treatment of;Treatment of Shock; Free Radical Scavengers;Lipid Peroxidation Inhibitors; TNF alpha Antagonist; Tumour necrosis factor alpha antagonist; Immunosuppressant"
CBR-001-583-148-8,RFM-003-685-1,CBR-001-583-148-8,CCCCCCCCCCCCCC(=O)OC(C)C,CBR-HVAC-07247: Dermatologic Drugs; ; ;
CBR-001-583-149-9,RFM-003-686-2,CBR-001-583-149-9,CC(OC(=O)C(C)C)OC(=O)NCC1(CCCCC1)CC(=O)O,"CBR-HVAC-02289: Diabetic Neuropathy, Agents for;Restless Legs Syndrome, Treatment of;Neuropathic Pain, Treatment of;Antimigraine Drugs;Treatment of Alcohol Dependency; Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands;Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands; ; Calcium channel antagonist"
CBR-001-583-150-2,RFM-003-687-3,CBR-001-583-150-2,FC(OC(C(F)(F)F)Cl)F,CBR-HVAC-01870: Inhalation Anesthetics; ; Calcium dependent ATPase Activator; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-583-151-3,RFM-003-688-4,CBR-001-583-151-3,FCOC(C(F)(F)F)C(F)(F)F,CBR-HVAC-01880: Inhalation Anesthetics; ; ; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-583-152-4,RFM-003-689-5,CBR-001-583-152-4,CCCC(=O)OC(COC(=O)CCC)COC(=O)CCC,CBR-HVAC-00173: Leukemia Therapy;Solid Tumors Therapy; Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor; Cell cycle inhibitor; Histone deacetylase inhibitor; Apoptosis stimulant
CBR-001-583-153-5,RFM-003-690-8,CBR-001-583-153-5,CC(=O)OC(COC(=O)C)COC(=O)C,CBR-HVAC-06274: Neurologic Drugs (Miscellaneous);Antifungal Agents; ; ;
CBR-001-583-154-6,RFM-003-691-9,CBR-001-583-154-6,OCC=C(CCC=C(C)C)C,CBR-HVAC-10349: Oncolytic Drugs; Polyamine Biosynthesis Inhibitors; ;
CBR-001-583-155-7,RFM-003-692-0,CBR-001-583-155-7,CC1=CCC(CC1)C(=C)C,CBR-HVAC-04854: Oncolytic Drugs; ; ;
CBR-001-583-156-8,RFM-003-693-1,CBR-001-583-156-8,Cc1cccc(c1)O,CBR-HVAC-09776: Acetylcholinesterase Inhibitor;
CBR-001-583-157-9,RFM-003-694-2,CBR-001-583-157-9,Fc1c(F)cccc1Br,CBR-HVAC-11862: Calcitonin; Amylin Agonist; Agonist;
CBR-001-583-158-0,RFM-003-695-3,CBR-001-583-158-0,OCC[N+](C)(C)C,CBR-HVAC-00970: Choline oxidase Inhibitor; Unidentified pharmacological activity
CBR-001-583-159-1,RFM-003-696-4,CBR-001-583-159-1,OCc1ccccc1,CBR-HVAC-09723: Ectonucleoside triphosphate diphosphohydrolase 8 Inhibitor;
CBR-001-583-160-4,RFM-003-697-5,CBR-001-583-160-4,CC(COc1c(C)cccc1C)N,CBR-HVAC-01007: Sodium channel Blocker; Sodium channel antagonist
CBR-001-583-161-5,RFM-003-698-6,CBR-001-583-161-5,COCCOCCOCCOCCOCCOCCOCCOCCOCCOC(=O)c1ccc(cc1)NCCCC,CBR-HVAC-02627: Stretch receptor Inhibitor; Unidentified pharmacological activity
CBR-001-583-162-6,RFM-003-699-7,CBR-001-583-162-6,NCCCCN,CBR-HVAC-11000: Transglutaminase Inhibitor;
CBR-001-583-163-7,RFM-003-700-3,CBR-001-583-163-7,CCN(C(=O)c1cccnc1)CC,CBR-HVAC-08432: Immunostimulant
CBR-001-583-164-8,RFM-003-701-4,CBR-001-583-164-8,CCCCCCCCCC[N+](CCCCCCCCCC)(C)C,CBR-HVAC-00977: Unidentified pharmacological activity
CBR-001-583-165-9,RFM-003-702-5,CBR-001-583-165-9,FC(C(C(F)(F)F)(F)F)(N(C(C(C(F)(F)F)(F)F)(F)F)C(C(C(F)(F)F)(F)F)(F)F)F,CBR-HVAC-03018
CBR-001-583-166-0,RFM-003-703-6,CBR-001-583-166-0,OCCOC(=O)c1ccccc1O,CBR-HVAC-08761
CBR-001-583-167-1,RFM-003-704-7,CBR-001-583-167-1,Oc1ccc(cc1)S(=O)(=O)O,CBR-HVAC-08908
CBR-001-583-168-2,RFM-003-705-8,CBR-001-583-168-2,OCCOc1ccccc1,CBR-HVAC-09010
CBR-001-583-169-3,RFM-003-706-9,CBR-001-583-169-3,BrC(Br)Br,CBR-HVAC-09085
CBR-001-583-170-6,RFM-003-707-0,CBR-001-583-170-6,CCOC(c1ccccc1)CN1CCN(CC1)CC(C(=O)c1ccccc1)C,CBR-HVAC-09091
CBR-001-583-171-7,RFM-003-708-1,CBR-001-583-171-7,O=CCCCC=O,CBR-HVAC-09592
CBR-001-583-172-8,RFM-003-709-2,CBR-001-583-172-8,O=C(c1cccnc1)OCc1ccccc1,CBR-HVAC-09724
CBR-001-583-173-9,RFM-003-710-5,CBR-001-583-173-9,OCC(CO)O,CBR-HVAC-10242
CBR-001-583-174-0,RFM-003-711-6,CBR-001-583-174-0,CC1CC(OC(=O)c2ccccc2O)CC(C1)(C)C,CBR-HVAC-10245
CBR-001-583-175-1,RFM-003-712-7,CBR-001-583-175-1,CC(CC(O)(C)C)O,CBR-HVAC-10272
CBR-001-583-176-2,RFM-003-713-8,CBR-001-583-176-2,O=C1CCc2c(O1)cccc2,CBR-HVAC-10344
CBR-001-583-177-3,RFM-003-714-9,CBR-001-583-177-3,CCOC(=O)CCCCCCCCC(c1ccc(cc1)I)C,CBR-HVAC-10355
CBR-001-583-178-4,RFM-003-715-0,CBR-001-583-178-4,CC1COC(CN1)c1cccc(c1)C(F)(F)F,analog of CBR-HVAC-08921
CBR-001-583-179-5,RFM-003-716-1,CBR-001-583-179-5,CCC(c1ccccc1)C(=O)OCCN(CC)CC,CBR-HVAC-09716
CBR-001-583-180-8,RFM-003-717-2,CBR-001-583-180-8,CCOC(=O)C1=Cc2ccccc2OC1C(F)(F)F,analog of CBR-HVAC-07131
CBR-001-583-181-9,RFM-003-718-3,CBR-001-583-181-9,CCOC(=O)[C@@H]1CCC(=O)N1,analog of CBR-HVAC-07121
CBR-001-583-182-0,RFM-003-719-4,CBR-001-583-182-0,N1CCCN(CC1)c1ccccc1,analog of CBR-HVAC-07019
CBR-001-583-183-1,RFM-003-720-7,CBR-001-583-183-1,N1CCN(CC1)CC1CC1,analog of CBR-HVAC-02701
CBR-001-583-196-6,RFM-003-721-8,CBR-001-583-196-6,CCCCC(=O)N(C(C(=O)O)C(C)C)Cc1ccc(cc1)c1ccccc1c1nnn[nH]1,"CBR-HVAC-01326: Acute Myocardial Infarction, Treatment of;Heart Failure Therapy;Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 1 Antagonist; Angiotensin II 1 antagonist"
CBR-001-583-197-7,RFM-003-722-9,CBR-001-583-197-7,C[n+]1ccc(cc1)C(=O)NCc1ccccc1,CBR-HVAC-06630: Antiarthritic Drugs;Anti-Influenza Virus Drugs;Antiinfectives (Not Specified);Anti-Herpes Virus Drugs;Immunomodulators;Analgesic Drugs;Anti-Hepatitis Virus Drugs; ; ;
CBR-001-583-198-8,RFM-003-723-0,CBR-001-583-198-8,COc1cc(ccc1OCCCN1CCC(CC1)c1noc2c1ccc(c2)F)C(=O)C,"CBR-HVAC-01455: Antidepressants;Sleep Disorders, Treatment of;Antipsychotic Drugs;Bipolar Disorder, Treatment of; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; Dopamine receptor D2; 5-Hydroxytryptamine 2A receptor Antagonist; 5 Hydroxytryptamine 2A receptor antagonist; Dopamine D2 receptor antagonist"
CBR-001-583-199-9,RFM-003-724-1,CBR-001-583-199-9,FC(C1(C#CC2CC2)OC(=O)Nc2c1cc(Cl)cc2)(F)F,CBR-HVAC-01499: Anti-HIV Agents;Pancreatic Cancer Therapy;Prostate Cancer Therapy; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-583-200-5,RFM-003-725-2,CBR-001-583-200-5,COc1cc(ccc1Cc1cn(c2c1cc(cc2)NC(=O)OC1CCCC1)C)C(=O)NS(=O)(=O)c1ccccc1C,"CBR-HVAC-01820: Antimigraine Drugs;Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs;Inflammation, Treatment of;Drugs for Allergic Rhinitis;Diagnostic Agents;Antipsoriatics;Asthma Therapy; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Cysteinyl leukotriene receptor Antagonist; Leucotriene D4 antagonist; Leucotriene C4 antagonist; Leucotriene E4 antagonist"
CBR-001-583-201-6,RFM-003-726-3,CBR-001-583-201-6,OCC1OC2C(C(C1O)O)OC(=O)c1c2c(O)c(c(c1)O)OC,CBR-HVAC-09102: Antitrypanosomals;Antiarrhythmic Drugs;Antiarthritic Drugs;Antidiabetic Drugs;Immunomodulators;Hepatoprotectants;Antiulcer Drugs; IFN-gamma Production Inhibitors;IL-2 Production Inhibitors;IL-4 Production Inhibitors;IL-6 Production Inhibitors;Protein Tyrosine Phosphatase PTP-1B Inhibitors;Signal Transduction Modulators; Protein tyrosine phosphatase 1B Inhibitor;
CBR-001-583-202-7,RFM-003-727-4,CBR-001-583-202-7,CC1CCCC2(C1=CC1C(C2)OC(=O)C1=C)C,"CBR-HVAC-10178: Cognition Disorders, Treatment of;Oncolytic Drugs; Acetylcholinesterase (AChE) Inhibitors;Apoptosis Inducers;NOS2 Expression Inhibitors; 7-Ethoxyresorufin deethylase; Aminopyrine demethylase; Aniline hydroxylase; Oxidized micorosomal protein Inhibitor;"
CBR-001-583-203-8,RFM-003-728-5,CBR-001-583-203-8,O=C1CN(C(=O)N1)/N=C/c1ccc(o1)c1ccc(cc1)[N+](=O)[O-],"CBR-HVAC-01411: Muscular Dystrophy, Agents for;Cerebrovascular Diseases, Treatment of;Heat Stroke, Treatment of;Smooth Muscle Relaxants; ; Ryanodine receptor Blocker; Calcium channel antagonist"
CBR-001-583-204-9,RFM-003-729-6,CBR-001-583-204-9,COC(=O)C1C(O)CCC2C1CC1N(C2)CCc2c1[nH]c1c2cccc1,CBR-HVAC-03677: Mydriatics;Treatment of Erectile Dysfunction; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Antagonist;
CBR-001-583-205-0,RFM-003-730-9,CBR-001-583-205-0,COC(=O)C1c2cc3c(c(c2C(CC1(O)CC)OC1OC(C)C(C(C1)N(C)C)OC1CC(O)C(C(O1)C)OC1CCC(=O)C(O1)C)O)C(=O)c1c(C3=O)cccc1O,CBR-HVAC-02152: Myeloid Leukemia Therapy;Antineoplastic Antibiotics; DNA Topoisomerase II Inhibitors; DNA topoisomerase II Inhibitor; RNA synthesis inhibitor; Radical formation stimulant; DNA topoisomerase II inhibitor; DNA synthesis inhibitor; DNA topoisomerase I inhibitor
CBR-001-583-206-1,RFM-003-731-0,CBR-001-583-206-1,CN(C1C(=C(C(=O)N)C(=O)C2(C1CC1Cc3c(C(=O)C1=C2O)c(O)ccc3N(C)C)O)O)C,"CBR-HVAC-02585: Neurological Genetic Disorders, Treatment of ;Disorders Associated with Cancer Therapy, Treatment of;Multiple Sclerosis, Agents for;Ophthalmic Drugs;Acne Therapy;Cognition Disorders, Treatment of;Cerebrovascular Diseases, Treatment of;Age-Related Macular Degeneration, Treatment of;Hypertension, Treatment of;Liver and Biliary Tract Disorders, Treatment of;Antidepressants;Neurologic Drugs (Miscellaneous);Respiratory Disorders (Not Specified);Antibacterial Drugs;Bipolar Disorder, Treatment of;Huntington's Disease, Treatment of;Interstitial Lung Diseases, Treatment of;Glioblastoma Multiforme Therapy;Asthma Therapy;Neuropathy, Treatment of ;Neurologic Cancer Therapy;Lesions of the Spinal Cord and Related Structures, Treatment of;Amyotrophic Lateral Sclerosis, Agents for; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Protein Arginine Deiminase Inhibitors;Signal Transduction Modulators;30S Ribosomal Protein Inhibitors; Matrix metalloproteinase Inhibitor; Protein 30S ribosomal subunit inhibitor"
CBR-001-583-207-2,RFM-003-732-1,CBR-001-583-207-2,c1ccc2c(c1)[nH]c(n2)c1nc2c([nH]1)cccc2,analog of CBR-HVAC-08199
CBR-001-583-208-3,RFM-003-733-2,CBR-001-583-208-3,CCCCCCCCCCCC1=C(O)C(=O)C=C(C1=O)O,CBR-HVAC-10205: Oncolytic Drugs;Contraceptives;Anti-Hepatitis C Virus Drugs; Apoptosis Inducers;HCV NS3 Protease Inhibitors;Signal Transduction Modulators;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors; X-linked inhibitor of apoptosis Inhibitor;
CBR-001-583-209-4,RFM-003-734-3,CBR-001-583-209-4,CC1COC2=C1C(=O)C(=O)c1c2ccc2c1CCCC2(C)C,"CBR-HVAC-05957: Oncolytic Drugs;Immunosuppressants;Antiarthritic Drugs;Vasodilators;Thrombolytics;Cognition Disorders, Treatment of; Acetylcholinesterase (AChE) Inhibitors;Aldose Reductase Inhibitors;Angiogenesis Inhibitors;Antiinflammatory Drugs;Antioxidants;Nitric Oxide (NO) Production Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; ;"
CBR-001-583-210-7,RFM-003-735-4,CBR-001-583-210-7,COc1cccc(c1N)c1cc(=O)c2c(o1)cccc2,"CBR-HVAC-04813: Stroke, Treatment of; ERK1 Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;NADH Oxidase (NOX) Inhibitors;Signal Transduction Modulators; MAP KINASE; MEK 1 Inhibitor; MAP kinase inhibitor"
CBR-001-583-211-8,RFM-003-736-5,CBR-001-583-211-8,COc1ccc(cc1C(=O)NCCc1ccc(cc1)C(=O)O)Cl,"CBR-HVAC-01150: Type 2 Diabetes, Agents for; Potassium Channel Blockers; ; Potassium channel antagonist"
CBR-001-583-212-9,RFM-003-737-6,CBR-001-583-212-9,NCCc1ccc(c(c1)O)O,CBR-HVAC-01277: Dopamine receptor Agonist; Dopamine receptor agonist
CBR-001-583-213-0,RFM-003-738-7,CBR-001-583-213-0,COC(=O)C(Cc1ccc(c(c1)O)O)N,CBR-HVAC-02244: Dopamine receptor D1 Agonist; Dopamine receptor agonist
CBR-001-583-214-1,RFM-003-739-8,CBR-001-583-214-1,OC(=O)C1N2C(=O)C(C2SC1(C)C)NC(=O)c1c(C)onc1c1c(Cl)cccc1Cl,CBR-HVAC-02335: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-583-215-2,RFM-003-740-1,CBR-001-583-215-2,COC(=O)C1=COC(C2C1CC1N(C2)CCc2c1[nH]c1c2cccc1)C,CBR-HVAC-09267
CBR-001-583-216-3,RFM-003-741-2,CBR-001-583-216-3,O=C1NCCCCC1NC(=O)c1cccc(c1)C(F)(F)F,CBR-HVAC-10810
CBR-001-583-217-4,RFM-003-742-3,CBR-001-583-217-4,COc1ccccc1NS(=O)(=O)c1cccc(c1)NC(=O)Nc1ccc(cc1)F,analog of CBR-HVAC-05339
CBR-001-583-218-5,RFM-003-743-4,CBR-001-583-218-5,COc1ccc(cc1)CNC1=C(C(=O)C1=O)NCCCN(C)C,analog of CBR-HVAC-10400
CBR-001-583-219-6,RFM-003-744-5,CBR-001-583-219-6,O=C(Cn1c(nc2c1cccc2)c1nonc1N)Nc1cccc(c1)C(=O)C,analog of CBR-HVAC-07016
CBR-001-583-220-9,RFM-003-745-6,CBR-001-583-220-9,OC(c1ccccc1)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,analog of CBR-HVAC-03437
CBR-001-583-221-0,RFM-003-746-7,CBR-001-583-221-0,Cc1c(c2ccccc2)c(nn1c1ccccc1)c1ccccc1,analog of CBR-HVAC-07942
CBR-001-583-222-1,RFM-003-747-8,CBR-001-583-222-1,Cn1c2[nH]c(nc2c(=O)n(c1=O)C)CN1CCN(CC1)C(c1ccccc1)c1ccccc1,analog of CBR-HVAC-03613
CBR-001-583-223-2,RFM-003-748-9,CBR-001-583-223-2,COCCNC(=O)c1cccc(n1)C(=O)NCCOC,analog of CBR-HVAC-04186
CBR-001-583-224-3,RFM-003-749-0,CBR-001-583-224-3,O=C(NC1CC(C)(C)Oc2c1cccc2)CCN1C(=O)c2c(S1(=O)=O)cccc2,analog of CBR-HVAC-04065
CBR-001-583-225-4,RFM-003-750-3,CBR-001-583-225-4,OCC[N+](C1c2ccccc2c2c1cccc2)(CC)CC,analog of CBR-HVAC-09599
CBR-001-583-226-5,RFM-003-751-4,CBR-001-583-226-5,O=C1NC(=N)NC1(c1ccccc1)c1ccccc1,analog of CBR-HVAC-03130
CBR-001-583-227-6,RFM-003-752-5,CBR-001-583-227-6,Nc1nc2c(n1Cc1ccc(cc1)C(F)(F)F)cccc2,analog of CBR-HVAC-10619
CBR-001-583-228-7,RFM-003-753-6,CBR-001-583-228-7,COc1ccc(cc1)OCCN(Cc1cc(C(C)C)c(cc1O)C)C,analog of CBR-HVAC-04921
CBR-001-583-229-8,RFM-003-754-7,CBR-001-583-229-8,CCN(CCNC(=O)c1ccc(cc1OC)NC(=O)COc1cc(C)ccc1C)CC,analog of CBR-HVAC-02920
CBR-001-583-230-1,RFM-003-755-8,CBR-001-583-230-1,COc1cccc2c1N(CCC2)C(=O)c1ccc(nc1)OC(C)C,analog of CBR-HVAC-03003
CBR-001-583-232-3,RFM-003-756-9,CBR-001-583-232-3,COc1cccc(c1)CC(=O)N1CCN(CC1)C(=O)c1ccc(cc1)Cl,analog of CBR-HVAC-04402
CBR-001-583-233-4,RFM-003-757-0,CBR-001-583-233-4,O=C(C(C)C)OC1=C(C(=O)Nc2noc(c2)C)N(C)S(=O)(=O)c2c1cccc2,analog of CBR-HVAC-03598
CBR-001-583-234-5,RFM-003-758-1,CBR-001-583-234-5,O=C(C1CCN(CC1)Cc1c(nc2n1cccc2)c1ccccc1)NCc1ccccc1,analog of CBR-HVAC-08080
CBR-001-583-235-6,RFM-003-759-2,CBR-001-583-235-6,CCCNC(=O)Nc1ccc(cc1C)OC,analog of CBR-HVAC-10802
CBR-001-583-236-7,RFM-003-760-5,CBR-001-583-236-7,COc1ccc2c(c1)c(CC(=O)Oc1ccc(cc1)C#N)c(n2C(=O)c1ccc(cc1)Cl)C,analog of CBR-HVAC-10796
CBR-001-583-237-8,RFM-003-761-6,CBR-001-583-237-8,OCCCNC(=O)c1cn(CC)c2c(c1=O)cccc2,analog of CBR-HVAC-10464
CBR-001-583-238-9,RFM-003-762-7,CBR-001-583-238-9,CN1CC(=O)N(C1=O)CCCC(=O)N1CCN(CC1)c1ccccc1,analog of CBR-HVAC-07637
CBR-001-583-239-0,RFM-003-763-8,CBR-001-583-239-0,CCN(CCOC(=O)C(c1ccccc1)(C1CCCCC1)O)CC,analog of CBR-HVAC-08844
CBR-001-583-240-3,RFM-003-764-9,CBR-001-583-240-3,O=C(CN1C(=O)NC2(C1=O)CCOc1c2cccc1)NCc1cccc(c1)Cl,analog of CBR-HVAC-03232
CBR-001-583-241-4,RFM-003-765-0,CBR-001-583-241-4,Fc1ccc2c(c1)c1CCNC3(c1[nH]2)C(=O)Nc1c3cccc1,analog of CBR-HVAC-00680
CBR-001-583-242-5,RFM-003-766-1,CBR-001-583-242-5,COc1ccc(c(c1)NS(=O)(=O)c1ccc(c(c1F)F)F)NC(=O)C,analog of CBR-HVAC-10410
CBR-001-583-243-6,RFM-003-767-2,CBR-001-583-243-6,Cc1ccc(cc1)NC(=O)c1cccc(c1)c1n[nH]nn1,analog of CBR-HVAC-00843
CBR-001-583-244-7,RFM-003-768-3,CBR-001-583-244-7,CCCC(=O)NCc1ccc(cc1)C(F)(F)F,analog of CBR-HVAC-06677
CBR-001-583-245-8,RFM-003-769-4,CBR-001-583-245-8,O=C(c1ccccc1Nc1ccccc1C)N1CCCCC1,analog of CBR-HVAC-08110
CBR-001-583-246-9,RFM-003-770-7,CBR-001-583-246-9,Clc1ccc2c(c1)[nH]c(=O)n2C1CCN(CC1)CCCn1c(=O)[nH]c2c1cccc2,"CBR-HVAC-01741: Non-Ulcer Dyspepsia, Agents for;Gastrointestinal Disorders (Not Specified);Prokinetic Agents;Gastroesophageal Reflux Disease, Agents for;Nausea and Vomiting, Treatment of;Pituitary Disorder Therapy; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Dopamine Receptor Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist"
CBR-001-583-247-0,RFM-003-771-8,CBR-001-583-247-0,Cc1ccc(cc1)C(=O)CC(S(=O)(=O)c1ccccc1)c1ccccc1,analog of CBR-HVAC-09388
CBR-001-583-248-1,RFM-003-772-9,CBR-001-583-248-1,CCOc1ccc(cc1)C(=O)OCCN(CC)CC,CBR-HVAC-09928
CBR-001-583-249-2,RFM-003-773-0,CBR-001-583-249-2,CC(=O)NCC1ON=C(C1)c1ccc(cc1)c1ccccc1,analog of CBR-HVAC-11268
CBR-001-583-250-5,RFM-003-774-1,CBR-001-583-250-5,OCC(C(C(C(=O)Nc1ccc(c(c1)C)C)O)O)O,analog of CBR-HVAC-07975
CBR-001-583-251-6,RFM-003-775-2,CBR-001-583-251-6,O=C1N(CCCN2CCC(=CC2)c2c[nH]c3c2cccc3)C(=O)c2c1cccc2,analog of CBR-HVAC-05358
CBR-001-583-252-7,RFM-003-776-3,CBR-001-583-252-7,OC(=O)CCc1ccc(o1)c1ccc(cc1)Cl,analog of CBR-HVAC-10391
CBR-001-583-253-8,RFM-003-777-4,CBR-001-583-253-8,COc1ccc(cc1)OCC(CN1CCC(CC1)c1ccc(cc1)O)O,analog of CBR-HVAC-11451
CBR-001-583-254-9,RFM-003-778-5,CBR-001-583-254-9,CCOc1ccccc1n1c(C)ccc1c1ccccc1,analog of CBR-HVAC-09057
CBR-001-583-255-0,RFM-003-779-6,CBR-001-583-255-0,CCn1cc(C(=O)O)c(=O)c2c1cc(N1CCN(CC1)C(=O)CC)c(c2)F,analog of CBR-HVAC-03386
CBR-001-583-256-1,RFM-003-780-9,CBR-001-583-256-1,CO/N=C(\c1csc(n1)N)/C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)COC(=O)C,CBR-HVAC-01335: Antibacterial Drugs; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-583-257-2,RFM-003-781-0,CBR-001-583-257-2,Cc1ccc(cc1)N(c1cccc(c1)O)CC1=NCCN1,CBR-HVAC-03121: Dental Agents;Treatment of Female Sexual Dysfunction;Treatment of Erectile Dysfunction;Ophthalmic Drugs; alpha-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha adrenergic receptor Antagonist;
CBR-001-583-258-3,RFM-003-782-1,CBR-001-583-258-3,O=C1CCc2c(N1)ccc(c2)C(=O)N1CCN(CC1)Cc1ccccc1,analog of CBR-HVAC-03730
CBR-001-583-259-4,RFM-003-783-2,CBR-001-583-259-4,CO/N=C(/C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)COC(=O)N)\c1ccco1,CBR-HVAC-02330: Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-583-260-7,RFM-003-784-3,CBR-001-583-260-7,COCCOC(=O)C1=C(C)NC(=C(C1c1ccc(o1)C)C(=O)OCCOC)C,analog of CBR-HVAC-09521
CBR-001-583-261-8,RFM-003-785-4,CBR-001-583-261-8,COc1cc2c(cc1OC)OCC1C2C(=O)c2c(O1)c1C[C@H](Oc1cc2)C(=C)CO[C@@H]1O[C@@H](CO[C@@H]2OC[C@@H]([C@@H]([C@H]2O)O)O)[C@H]([C@@H]([C@H]1O)O)O,analog of CBR-HVAC-04527
CBR-001-583-263-0,RFM-003-786-5,CBR-001-583-263-0,ClCCN(c1ccc(cc1)CC(C(=O)O)NC(=O)C)CCCl,analog of CBR-HVAC-08191
CBR-001-583-264-1,RFM-003-787-6,CBR-001-583-264-1,CC(CC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N)CC(C)C)CCC(=O)N)Cc1ccc(cc1)OCc1ccccc1)N)C,analog of CBR-HVAC-11321
CBR-001-583-265-2,RFM-003-788-7,CBR-001-583-265-2,CC1CCCN(C1)CC(NC(=O)c1n[nH]c2c1cccc2)C,analog of CBR-HVAC-06071
CBR-001-583-266-3,RFM-003-789-8,CBR-001-583-266-3,COc1cc2C(=NCCc2cc1OC)CCc1ccccc1,analog of CBR-HVAC-10535
CBR-001-583-267-4,RFM-003-790-1,CBR-001-583-267-4,COc1cc(CNc2cn[nH]c(=O)c2Cl)ccc1OC,analog of CBR-HVAC-11081
CBR-001-583-268-5,RFM-003-791-2,CBR-001-583-268-5,CCc1ccccc1NC(=O)c1ccc[nH]c1=O,analog of CBR-HVAC-10143
CBR-001-583-269-6,RFM-003-792-3,CBR-001-583-269-6,Clc1ccc(cc1)c1csc(n1)NC(=O)Cn1cnc2c1n(C)c(=O)n(c2=O)C,analog of CBR-HVAC-09375
CBR-001-583-270-9,RFM-003-793-4,CBR-001-583-270-9,O=C1NC(=O)SC1Cc1ccc(cc1)C,analog of CBR-HVAC-11534
CBR-001-583-271-0,RFM-003-794-5,CBR-001-583-271-0,CC(=O)c1c(=O)[nH]c(c2c1CCCC2)C,analog of CBR-HVAC-03562
CBR-001-583-272-1,RFM-003-795-6,CBR-001-583-272-1,OC(=O)c1ccc(cc1O)NS(=O)(=O)c1ccccc1,analog of CBR-HVAC-08897
CBR-001-583-273-2,RFM-003-796-7,CBR-001-583-273-2,CCCC(=O)NCCCCNC(=O)CCC,analog of CBR-HVAC-07663
CBR-001-583-274-3,RFM-003-797-8,CBR-001-583-274-3,CCN1CCC(CC1)N(C(=O)c1ccc(cc1)n1ccnc1)C1CC1,analog of CBR-HVAC-10939
CBR-001-583-275-4,RFM-003-798-9,CBR-001-583-275-4,COc1cc(C=CC(=O)N2CCN(CC2)CC(=O)NC(C)C)cc(c1OC)OC,CBR-HVAC-14314
CBR-001-583-276-5,RFM-003-799-0,CBR-001-583-276-5,O=C(NC1C(=O)N2C1SCC(=C2C(=O)O)CSc1nnc(s1)C)Cc1ccccc1,analog of CBR-HVAC-10222
CBR-001-583-277-6,RFM-003-800-6,CBR-001-583-277-6,COc1cccc(c1)C(=O)OC1CCN(CC1)C,analog of CBR-HVAC-09933
CBR-001-583-278-7,RFM-003-801-7,CBR-001-583-278-7,O=C(Nc1c(C)cccc1C)NCCCNC(=O)C,analog of CBR-HVAC-03023
CBR-001-583-279-8,RFM-003-802-8,CBR-001-583-279-8,C1CCCCC(CC1)Nc1nnc(c2c1cccc2)c1ccccc1,analog of CBR-HVAC-04430
CBR-001-583-280-1,RFM-003-803-9,CBR-001-583-280-1,CCCCCCOc1ccc(c(c1)O)/C=N/c1ccc(cc1)CCCCCC,analog of CBR-HVAC-11884
CBR-001-583-281-2,RFM-003-804-0,CBR-001-583-281-2,CC(Cc1ccccc1)NC(=O)NS(=O)(=O)c1ccc(cc1)C,CBR-HVAC-14246
CBR-001-583-282-3,RFM-003-805-1,CBR-001-583-282-3,Cc1onc(c1)NS(=O)(=O)c1ccc(cc1)/N=C/c1ccccc1O,"CBR-HVAC-07279 Antibacterial Drugs;Inflammation, Treatment of;"
CBR-001-583-283-4,RFM-003-806-2,CBR-001-583-283-4,CN(CCCN1c2ccccc2CCc2c1cc(Cl)cc2)C,"CBR-HVAC-15138: 5-Hydroxytryptamine transporter Inhibitor; Serotonin Transporter (SERT) Inhibitors; Signal Transduction Modulators; Antidepressant; Antidepressants; Antipsychotic Drugs; Anxiolytics; Obsessive-Compulsive Disorder (OCD), Treatment of; Prevention of Premature Ejaculation; Urinary Incontinence Therapy"
CBR-001-583-284-5,RFM-003-807-3,CBR-001-583-284-5,CC(OC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC(C)C)C)C,analog of CBR-HVAC-00919
CBR-001-583-285-6,RFM-003-808-4,CBR-001-583-285-6,CC[N+](CC(COCC1COc2c(O1)cccc2)O)(CC)C,analog of CBR-HVAC-08731
CBR-001-583-286-7,RFM-003-809-5,CBR-001-583-286-7,OCc1cc(Cl)c(c(c1)Cl)OCc1ccc(cc1)Cl,analog of CBR-HVAC-00105 (pocapavir)
CBR-001-583-287-8,RFM-003-810-8,CBR-001-583-287-8,OC(=O)CC(N1C(=O)c2c(C1=O)cccc2)c1ccc(cc1)OC1CCCC1,analog of CBR-HVAC-00475 (CC-1088)
CBR-001-583-288-9,RFM-003-811-9,CBR-001-583-288-9,CCCCCOc1ccc(cc1)C(C1CCCCC1)(CCN(C)C)O,analog of CBR-HVAC-00477 (axomadol)
CBR-001-583-289-0,RFM-003-812-0,CBR-001-583-289-0,O=C1CCC(=NN1)c1ccc(cc1)N,analog of CBR-HVAC-00556 (MCI-154)
CBR-001-583-290-3,RFM-003-813-1,CBR-001-583-290-3,CN(N=Nc1nc2c(n1C)c(=O)n(c(=O)n2C)C)C,analog of CBR-HVAC-00800 (etheophazine)
CBR-001-583-291-4,RFM-003-814-2,CBR-001-583-291-4,COc1cc2c(cc1OC)CCN(C2C)Cc1ccc(cc1)C,analog of CBR-HVAC-00959 (PR-870-714A)
CBR-001-583-292-5,RFM-003-815-3,CBR-001-583-292-5,Clc1ccc(cc1)OC(C(=O)OCc1cccnc1)(C)C,analog of CBR-HVAC-01050 (eniclobrate)
CBR-001-583-294-7,RFM-003-816-4,CBR-001-583-294-7,OC1c2ccccc2C(=O)N(c2c1cccc2)C,analog of CBR-HVAC-01081 (etazepine)
CBR-001-583-295-8,RFM-003-817-5,CBR-001-583-295-8,Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ccccn1,CBR-HVAC-14189
CBR-001-583-296-9,RFM-003-818-6,CBR-001-583-296-9,Cc1ccc(cc1)c1cc(nn1c1ccc(cc1)S(=O)(=O)N)C(F)(F)F,"CBR-HVAC-01487: Actinic Keratoses, Agents for;Bladder Cancer Therapy ;Adenomatous Polyposis Therapy;Rheumatoid Arthritis, Treatment of;Non-Opioid Analgesics;Anti-Influenza A Virus Drugs;Sarcoma Therapy;Analgesic Drugs;Antiinflammatory Ophthalmic Agents;Pancreatic Cancer Therapy;Cancer Associated Disorders, Treatment of;Inflammation, Treatment of;Colorectal Cancer Therapy;Chemopreventive Agents;Ankylosing Spondylitis, Treatment of;Glioblastoma Multiforme Therapy;Breast Cancer Therapy;Respiratory Disorders (Not Specified);Ovarian Cancer Therapy;Neurologic Cancer Therapy;Osteoarthritis, Treatment of;Treatment of Gout;Age-Related Macular Degeneration, Treatment of;Antiarthritic Drugs;Non-Small Cell Lung Cancer Therapy;Head and Neck Cancer Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;Carbonic Anhydrase Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase 2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-583-297-0,RFM-003-819-7,CBR-001-583-297-0,O=C1CC(=NN1c1ccccc1)C,"CBR-HVAC-01573: Amyotrophic Lateral Sclerosis, Agents for;Hemorrhagic Stroke, Treatment of;Stroke, Treatment of;Ischemic Stroke, Treatment of;Cerebrovascular Diseases, Treatment of;Ischemia, Treatment of; Antioxidants;Free Radical Scavengers; Free radical scavengers, Hydroxy radical scavengers. Anti-ischaemic and radical scavenging activity; protective effects against reperfusion injury following ischaemia.; Free radical scavenger"
CBR-001-583-298-1,RFM-003-820-0,CBR-001-583-298-1,CC(=O)Nc1ccc(cc1)C(=O)OCCOc1ccccc1C,analog of CBR-HVAC-02097 (etersalate)
CBR-001-583-299-2,RFM-003-821-1,CBR-001-583-299-2,CC(c1cc(SC(Sc2cc(c(c(c2)C(C)(C)C)O)C(C)(C)C)Sc2cc(c(c(c2)C(C)(C)C)O)C(C)(C)C)cc(c1O)C(C)(C)C)(C)C,analog of CBR-HVAC-02360 (MDL-29311)
CBR-001-583-300-8,RFM-003-822-2,CBR-001-583-300-8,O=C(c1ccccc1)C1CCN(CC1)CCCn1c(=O)c2n(C)cnc2n(c1=O)C,analog of CBR-HVAC-02516 (flufylline)
CBR-001-583-302-0,RFM-003-823-3,CBR-001-583-302-0,O=C(c1n[nH]c2c1cccc2)N1CCCN(CC1)Cc1ccccc1,analog of CBR-HVAC-02696 (DAT-582)
CBR-001-583-304-2,RFM-003-824-4,CBR-001-583-304-2,COc1cccc(c1)NC(=O)c1ccc(cc1)CN1CCCC1,analog of CBR-HVAC-02892 (ACC-9358)
CBR-001-583-305-3,RFM-003-825-5,CBR-001-583-305-3,COC(=O)COc1ccc(cc1)S(=O)(=O)NCCc1ccccc1,analog of CBR-HVAC-03011 (Sulotroban)
CBR-001-583-306-4,RFM-003-826-6,CBR-001-583-306-4,COC(=O)c1ccccc1OC(=O)c1cccs1,analog of CBR-HVAC-03214 (Tenosal)
CBR-001-583-307-5,RFM-003-827-7,CBR-001-583-307-5,COc1ccc(c(c1)OCCCS(=O)(=O)c1ccccc1)C(=O)C,analog of CBR-HVAC-03388 (L-648051)
CBR-001-583-308-6,RFM-003-828-8,CBR-001-583-308-6,CC(COc1ccc(cc1)CNC(=O)NCCCCN1CCCC(C1)C)C,analog of CBR-HVAC-03882 (Dalcotidine)
CBR-001-583-309-7,RFM-003-829-9,CBR-001-583-309-7,CCOC(=O)C1CCN(CC1)C(=O)CCS(=O)(=O)c1ccc2c(c1)cccc2,analog of CBR-HVAC-04227 (KSG-504)
CBR-001-583-310-0,RFM-003-830-2,CBR-001-583-310-0,O=C(N1CCN(CC1)c1nccc(c1)C(F)(F)F)CC(C)(C)C,analog of CBR-HVAC-04300 (Org-13011)
CBR-001-583-311-1,RFM-003-831-3,CBR-001-583-311-1,COc1ccc(cc1)CCNC(=O)C(Cc1c[nH]c2c1cccc2)NC(=O)C,analog of CBR-HVAC-04765 (IS-159)
CBR-001-583-312-2,RFM-003-832-4,CBR-001-583-312-2,OCCNCCOc1c(cccc1C(C)C)C(C)C,analog of CBR-HVAC-04795 (Deacetyl moxisylyte hydrochloride)
CBR-001-583-313-3,RFM-003-833-5,CBR-001-583-313-3,CN1CCC(=CC1)c1c[nH]c2c1cccc2,analog of CBR-HVAC-05051 (ALX-646CL)
CBR-001-583-314-4,RFM-003-834-6,CBR-001-583-314-4,[O-][N+](=O)c1cn(c(n1)C)c1ccccc1,analog of CBR-HVAC-05528 (Nitrefazole)
CBR-001-583-315-5,RFM-003-835-7,CBR-001-583-315-5,CCCCOc1ccc(cc1)C(=O)NC(=S)Nc1cccc(c1)C(F)(F)F,analog of CBR-HVAC-06254 (GS-9132)
CBR-001-583-316-6,RFM-003-836-8,CBR-001-583-316-6,C1CN=C(N1)C1CCCc2c1cccc2,CBR-HVAC-06517: Ophthalmic Drugs;Contact Lens Materials; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators; Adrenergic receptor Inhibitor;
CBR-001-583-317-7,RFM-003-837-9,CBR-001-583-317-7,CNCC(c1ccc(cc1)O)O,"CBR-HVAC-06551: Hypertension, Treatment of;Antidepressants;Antiarthritic Drugs; alpha1-Adrenoceptor Agonists;Antiinflammatory Drugs;L-Type Calcium Channel Activators;Signal Transduction Modulators; Alpha 1 adrenoceptor Agonist;"
CBR-001-583-318-8,RFM-003-838-0,CBR-001-583-318-8,Cc1cccc(c1)NS(=O)(=O)c1ccc(c(c1)C(=O)N1CCN(CC1)CCN1CCCC1)Cl,analog of CBR-HVAC-07043 (ABT-639)
CBR-001-583-319-9,RFM-003-839-1,CBR-001-583-319-9,O=C(Cc1c[nH]c2c1cccc2)NCCc1c[nH]c2c1cccc2,analog of CBR-HVAC-07435 (AH-25086B)
CBR-001-583-320-2,RFM-003-840-4,CBR-001-583-320-2,COC(=O)C1(C)CCC2(C(C1)C1=CCC3C(C1(CC2)C)(C)CCC1C3(C)CCC(C1(C)C)O)C,analog of CBR-HVAC-07721 (deloxolone)
CBR-001-583-321-3,RFM-003-841-5,CBR-001-583-321-3,CCN(S(=O)(=O)c1ccc(cc1)NS(=O)(=O)C)CC,analog of CBR-HVAC-08533 (Wy-48986)
CBR-001-583-322-4,RFM-003-842-6,CBR-001-583-322-4,COc1ccc(cc1OCCCC)C(=O)N,analog of CBR-HVAC-08654 (DECIMEMIDE)
CBR-001-583-323-5,RFM-003-843-7,CBR-001-583-323-5,ClCCN(c1ccc(cc1)CC(C(=O)OC)N)CCCl,analog of CBR-HVAC-08714 (METAMELFALAN)
CBR-001-583-324-6,RFM-003-844-8,CBR-001-583-324-6,CCOC(=O)N1CCN(CC1)c1ncnc2c1cc(OC)c(c2)OC,analog of CBR-HVAC-08951 (PIQUIZIL)
CBR-001-583-325-7,RFM-003-845-9,CBR-001-583-325-7,N(CCc1ccccc1)CCOc1ccccc1,analog of CBR-HVAC-09064 (RACEFEMINE)
CBR-001-583-326-8,RFM-003-846-0,CBR-001-583-326-8,O=C(C12CC3CC(C2)CC(C1)C3)OCCCC[N+](C)(C)C,analog of CBR-HVAC-09139 (AMANTANIUM BROMIDE)
CBR-001-583-327-9,RFM-003-847-1,CBR-001-583-327-9,O=C1CC[C@]2([C@H](C1)CC[C@@H]1C2=CC[C@]2(C1C[C@H]([C@]2(O)C(=O)COC(=O)C)C)C)C,analog of CBR-HVAC-09399 (ANAGESTONE ACETATE)
CBR-001-583-328-0,RFM-003-848-2,CBR-001-583-328-0,CCN(CC#CCC1(C)c2ccccc2c2c1cccc2)CC,analog of CBR-HVAC-09440 (UCL-1608)
CBR-001-583-329-1,RFM-003-849-3,CBR-001-583-329-1,Clc1cccc(c1)C(=O)Oc1c(Br)cc(c2c1nccc2)Br,analog of CBR-HVAC-09732 (BROXALDINE)
CBR-001-583-330-4,RFM-003-850-6,CBR-001-583-330-4,O=C(C(c1ccccc1)c1ccccc1)O[C@@H]1CCC[C@H]1N(C)C,analog of CBR-HVAC-09930 (PINOLCAINE)
CBR-001-583-331-5,RFM-003-851-7,CBR-001-583-331-5,COc1cc(OC)ccc1C(=O)CC(=O)C,analog of CBR-HVAC-10185 (ASPIDINOL)
CBR-001-583-332-6,RFM-003-852-8,CBR-001-583-332-6,CC1CC1C(=O)Nc1ccc(cc1)C(=O)NC1CCCN(C1)Cc1cc(Cl)ccc1O,analog of CBR-HVAC-10743 (YM 43611)
CBR-001-583-333-7,RFM-003-853-9,CBR-001-583-333-7,COc1ccccc1NC(=O)CCN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F,analog of CBR-HVAC-10751 (AD 0261)
CBR-001-583-334-8,RFM-003-854-0,CBR-001-583-334-8,COc1ccccc1c1csc(n1)Cc1nc2n(c1)cccc2,analog of CBR-HVAC-10900 (CP 93318)
CBR-001-583-335-9,RFM-003-855-1,CBR-001-583-335-9,OC(=O)C(C(c1ccccc1)(c1ccccc1)OCCc1ccccc1)Oc1nc(C)cc(n1)C,analog of CBR-HVAC-11172 (LU 302872)
CBR-001-583-336-0,RFM-003-856-2,CBR-001-583-336-0,COC(=O)CCN1C(=O)NC(C1=O)(Cc1ccccc1)c1ccccc1,analog of CBR-HVAC-11194 (HMR 1794)
CBR-001-583-337-1,RFM-003-857-3,CBR-001-583-337-1,Fc1ccc(cc1)Nc1ccccc1C(=O)Nc1ccc(cc1)N1CCOCC1,analog of CBR-HVAC-11705 (AZD6703)
CBR-001-583-338-2,RFM-003-858-4,CBR-001-583-338-2,O=C(C1CC(=O)N(C1)c1ccc(cc1)F)Nc1ccc(cc1)OCc1ccccc1,analog of CBR-HVAC-11808 (R-1577)
CBR-001-583-339-3,RFM-003-859-5,CBR-001-583-339-3,Cc1cn(COCCOCc2cc(C)cc(c2)C)c(=O)[nH]c1=O,analog of CBR-HVAC-00234 (benzylacyclouridine)
CBR-001-583-340-6,RFM-003-860-8,CBR-001-583-340-6,NC(=N)N/N=C/c1ccc(cc1Cl)Cl,analog of CBR-HVAC-01978 (guanoxabenz)
CBR-001-583-341-7,RFM-003-861-9,CBR-001-583-341-7,O=C(NCC12CC3CC(C2)CC(C1)C3)CCNC(=O)c1ccccc1Cl,analog of CBR-HVAC-05670 (AZD-9056)
CBR-001-583-342-8,RFM-003-862-0,CBR-001-583-342-8,[Sr+2],analog of CBR-HVAC-08634
CBR-001-583-343-9,RFM-003-863-1,CBR-001-583-343-9,CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-01789: Antibacterial Drugs; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-583-344-0,RFM-003-864-2,CBR-001-583-344-0,Fc1ccc(c(c1)C1=C(OC(C1=O)(C)C)c1ccc(cc1)S(=O)(=O)N)F,analog of CBR-HVAC-05434
CBR-001-583-345-1,RFM-003-865-3,CBR-001-583-345-1,OCC(C(C(C(CN(C(=S)[S-])C)O)O)O)O,"CBR-HVAC-04595: Septic Shock, Treatment of ;Hypotension, Treatment of;Acute Respiratory Distress Syndrome (ARDS), Agents for;Sepsis, Treatment of; Nitric Oxide (NO) Scavengers; ;"
CBR-001-583-346-2,RFM-003-866-4,CBR-001-583-346-2,COC(=O)c1cccc(c1)CCN(Cc1ccccc1)C,CBR-HVAC-08233: ; ; ; Acetylcholine receptor agonist
CBR-001-583-347-3,RFM-003-867-5,CBR-001-583-347-3,C/C(=C\C=C\C(=C\C(=O)O)\C)/CC/C=C(/CCC=C(C)C)\C,CBR-HVAC-00069: Chemopreventive Agents;Oncolytic Drugs; Apoptosis Inducers;Retinoid RARbeta Ligands;Retinoid RXRalpha Ligands;Signal Transduction Modulators; Retinoid X receptor Modulator; Apoptosis stimulant; Retinoid X receptor agonist
CBR-001-583-348-4,RFM-003-868-6,CBR-001-583-348-4,COc1ccc2c(c1)c(CC(=O)OC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)c(n2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-02935: ; Cyclooxygenase-3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; ; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-583-349-5,RFM-003-869-7,CBR-001-583-349-5,CC[N+](Cc1ccccc1Br)(C)C,CBR-HVAC-03155: Antiarrhythmic Drugs; ; Potassium channel Blocker;
CBR-001-583-350-8,RFM-003-870-0,CBR-001-583-350-8,CC1CC=NN1C(=O)c1cccnc1,"CBR-HVAC-04032: Ischemic Stroke, Treatment of; ; Glutamate transporter Activator; Glutamate antagonist"
CBR-001-583-351-9,RFM-003-871-1,CBR-001-583-351-9,OCC1OC(O)C(C(C1O)O)NC(=O)C,"CBR-HVAC-06502: Neuromuscular Genetic Disorders, Treatment of;Treatment of Renal Diseases;Pharmacological Tools; ; ;"
CBR-001-583-352-0,RFM-003-872-2,CBR-001-583-352-0,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,CBR-HVAC-06710: Local Anesthetics; ; ;
CBR-001-583-353-1,RFM-003-873-3,CBR-001-583-353-1,COc1ccc(cc1)c1ssc(=S)c1,"CBR-HVAC-00123: Chemopreventive Agents;Sjogren's Syndrome, Agents for; Antioxidants; Free radical scavenger; Glutathione S transferase stimulant"
CBR-001-583-354-2,RFM-003-874-4,CBR-001-583-354-2,OC(CN1CCN(CC1)C(=O)C(c1ccccc1)c1ccccc1)COc1cccc2c1cccn2,CBR-HVAC-00194: Cancer Multidrug Resistance Modulators; MRP-1 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Sphingomyelin synthase; P-Glycoprotein Inhibitor; P glycoprotein inhibitor; MRP inhibitor
CBR-001-583-355-3,RFM-003-875-5,CBR-001-583-355-3,CC[C@@H](C([C@@H]1OC(=O)[C@H](C)[C@H](OC2OC(C)C(C(C2)(C)OC)O)[C@H]([C@@H]([C@@]2(OC(=C(C)C2)[C@@H]1C)C)OC1OC(C)CC(C1O)N(C)C)C)(O)C)O,CBR-HVAC-14256
CBR-001-583-356-4,RFM-003-876-6,CBR-001-583-356-4,CCCCCCCCCCCCCCCCOC[C@H](COP(=O)(OCC[N+](C)(C)C)O)O,analog of CBR-HVAC-00334 (SRI-62-834)
CBR-001-583-357-5,RFM-003-877-7,CBR-001-583-357-5,OCCC(Nc1ncc2c(n1)n(C)c(=O)c(c2)Oc1ccc(cc1F)F)CCO,"CBR-HVAC-00364: Rheumatoid Arthritis, Treatment of;Disease-Modifying Anti-Rheumatic Drugs; IL-6 Production Inhibitors;MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; p38 MAP kinase inhibitor; P38 kinase inhibitor"
CBR-001-583-358-6,RFM-003-878-8,CBR-001-583-358-6,OC[C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(cc1)O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C)Cc1ccccc1,analog of CBR-HVAC-00376 (rotigaptide)
CBR-001-583-359-7,RFM-003-879-9,CBR-001-583-359-7,CCN(CCCCCCNc1cc(OC)cc2c1nccc2C)CC,CBR-HVAC-00404: Unidentified pharmacological activity
CBR-001-583-360-0,RFM-003-880-2,CBR-001-583-360-0,COc1ccc2c(c1)c(CCN(C)C)cn2S(=O)(=O)c1ccccc1,CBR-HVAC-14219
CBR-001-583-361-1,RFM-003-881-3,CBR-001-583-361-1,COc1cc(Cc2cnc(nc2N)N)c2c(c1OC)OC(C=C2)C1CC1,CBR-HVAC-00754: Antibacterial Drugs; Dihydrofolate Reductase (DHFR) Inhibitors; Prostanoid receptor Agonist; Dihydrofolate reductase inhibitor
CBR-001-583-362-2,RFM-003-882-4,CBR-001-583-362-2,ClCCNP(=O)(NCCCl)O,CBR-HVAC-00783: Anticancer; Alkylating agent; DNA inhibitor; DNA synthesis inhibitor
CBR-001-583-363-3,RFM-003-883-5,CBR-001-583-363-3,OC[C@@H]1O[C@@H]([C@@H]([C@H]1O)F)n1cc(C)c(=O)[nH]c1=O,CBR-HVAC-00939: Antiviral Drugs; Polymerase Inhibitor; DNA synthesis inhibitor
CBR-001-583-364-4,RFM-003-884-6,CBR-001-583-364-4,COC(=O)c1nc2c(o1)ccc(c2)Cl,analog of CBR-HVAC-01085 (eclazolast)
CBR-001-583-365-5,RFM-003-885-7,CBR-001-583-365-5,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2,CBR-HVAC-01876: Antipsychotic Drugs; Dopamine D2 Antagonists;Serotonin Antagonists;Signal Transduction Modulators; Dopamine receptor Antagonist; Dopamine D2 receptor antagonist; Opioid receptor antagonist
CBR-001-583-366-6,RFM-003-886-8,CBR-001-583-366-6,Clc1ccc(cc1)c1ccc(cc1)C(=O)CC(=C)C(=O)O,analog of CBR-HVAC-01180 (itanoxone)
CBR-001-583-367-7,RFM-003-887-9,CBR-001-583-367-7,COc1cc(OCCCC(=O)O)ccc1C=O,analog of CBR-HVAC-01185 (velaresol)
CBR-001-583-368-8,RFM-003-888-0,CBR-001-583-368-8,CCCN(C(=O)C(NC(=O)c1ccccc1)Cc1ccc(cc1)OCCN(CC)CC)CCC,CBR-HVAC-01660: Antispasmodics; Cyclic AMP stimulant
CBR-001-583-369-9,RFM-003-889-1,CBR-001-583-369-9,CCN1CCCC1CNC(=O)c1cc(ccc1OC)S(=O)(=O)CC,CBR-HVAC-01678: Antipsychotic Drugs; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist
CBR-001-583-371-3,RFM-003-890-4,CBR-001-583-371-3,CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+](=O)[O-],CBR-HVAC-02101: Anti-Hepatitis C Virus Drugs;Treatment of Protozoal Diseases;Anti-Helicobacter Pylori Agents;Antiviral Drugs;Anti-Influenza Virus Drugs;Anti-Hepatitis B Virus Drugs;Antibacterial Drugs; Pyruvate ferredoxin oxidoreductase Inhibitor; Pyruvate synthase inhibitor
CBR-001-583-372-4,RFM-003-891-5,CBR-001-583-372-4,OC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(cc1)C(=N)N)C1CCCCC1,"CBR-HVAC-02664: Peripheral Vascular Disease, Treatment of;Anticoagulants; Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; Thrombin Inhibitor; Direct thrombin inhibitor; Serine protease inhibitor"
CBR-001-583-373-5,RFM-003-892-6,CBR-001-583-373-5,O=C1NC(C(=O)N1)O,analog of CBR-HVAC-03332 (NZ-419)
CBR-001-583-374-6,RFM-003-893-7,CBR-001-583-374-6,OCC1O[C@H](O[C@@H]2C(CO)NCC(C2O)O)C(C([C@@H]1O)O)O,CBR-HVAC-14254
CBR-001-583-375-7,RFM-003-894-8,CBR-001-583-375-7,O=C1CC[C@]2(C(=C1)C=C[C@@H]1[C@H]2CC[C@]2([C@@H]1[C@@H]1C[C@@H]1[C@]12CCC(=O)O1)C)C,analog of CBR-HVAC-03532 (ZK-91587)
CBR-001-583-376-8,RFM-003-895-9,CBR-001-583-376-8,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN(Cc1ccccc1)C)C,CBR-HVAC-02308
CBR-001-583-377-9,RFM-003-896-0,CBR-001-583-377-9,O=C1CCC(CC1)COS(=O)(=O)c1ccc(cc1)C,analog of CBR-HVAC-03657 (FL-386)
CBR-001-583-378-0,RFM-003-897-1,CBR-001-583-378-0,CCCCCCCC/C=C\CCCCCCCC(=O)NCc1ccc(c(c1)OC)O,CBR-HVAC-02491: TRPV1 (Vanilloid VR1 Receptor) Agonists; Vanilloid receptor 1 Agonist; Vanilloid receptor 1 agonist
CBR-001-583-379-1,RFM-003-898-2,CBR-001-583-379-1,COc1cc(cc(c1OC)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2Cc2c1cc1OCOc1c2,CBR-HVAC-14209
CBR-001-583-380-4,RFM-003-899-3,CBR-001-583-380-4,OCC#C[C@@]1(O)CC[C@H]2[C@]1(C)C[C@H](c1ccc(cc1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@H]21,analog of CBR-HVAC-04359 (Org-31710)
CBR-001-583-382-6,RFM-003-900-9,CBR-001-583-382-6,OC(=O)CCCCCOP(=O)(OCC[N+](C)(C)C)O,analog of CBR-HVAC-04530 (CPI-975)
CBR-001-583-383-7,RFM-003-901-0,CBR-001-583-383-7,OCC1=C(C)C=C2C1=C(C)C1(C(C2=O)(C)O)CC1,CBR-HVAC-04611: Liver Cancer Therapy;Melanoma Therapy;Oncolytic Drugs;Breast Cancer Therapy;Renal Cancer Therapy;Leukemia Therapy;Solid Tumors Therapy;Pancreatic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Ovarian Cancer Therapy;Endocrine Cancer Therapy;Brain Cancer Therapy;Prostate Cancer Therapy;Gastric Cancer Therapy;Colorectal Cancer Therapy; Apoptosis Inducers;Caspase 8 Activators;Caspase 9 Activators;Signal Transduction Modulators; Checkpoint kinase 2; Multidrug resistance protein Inhibitor; Modulator;
CBR-001-583-384-8,RFM-003-902-1,CBR-001-583-384-8,O=C(c1ccccc1)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2O)C,component of CBR-HVAC-08129
CBR-001-583-385-9,RFM-003-903-2,CBR-001-583-385-9,NCCN1C(=O)[C@H](OC(=O)C)[C@@H](Sc2c1cccc2)c1ccc(cc1)OC,analog of CBR-HVAC-04674 (S-2150)
CBR-001-583-386-0,RFM-003-904-3,CBR-001-583-386-0,CCCCCCCCCCCCCCCC(=O)OC[C@@H]([C@H]1OC(=O)C(=C1O)O)O,CBR-HVAC-10333: Artifactual formation of nitrosamines inhibitor;
CBR-001-583-387-1,RFM-003-905-4,CBR-001-583-387-1,CC[C@H]1Cn2nc(c3c2c(N1CC1CC1)cc(n3)C)c1ccc(cc1Cl)Cl,"CBR-HVAC-14447: CRF1 Receptor Antagonists; Signal Transduction Modulators; Anxiolytics; Irritable Bowel Syndrome, Agents for"
CBR-001-583-388-2,RFM-003-906-5,CBR-001-583-388-2,O[C@@H]1[C@@H](O)[C@H](Oc2ccc3c(c2)CC[C@@H]2[C@@H]3CC[C@]3([C@H]2CC[C@@H]3O)C)O[C@@H]([C@H]1O)C(=O)[O-],analog of CBR-HVAC-05369 (Estradiol glucoside)
CBR-001-583-389-3,RFM-003-907-6,CBR-001-583-389-3,COc1ccc(cc1)OC(=O)N(Cc1ccc(cc1)OCCc1nc(oc1C)c1ccccc1)CC(=O)O,"CBR-HVAC-05509: Type 2 Diabetes, Agents for; Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists;Signal Transduction Modulators; PPAR alpha; PPAR gamma Agonist; Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist; Insulin sensitizer; Peroxisome proliferator-activated receptor alpha/gamma agoni"
CBR-001-583-390-6,RFM-003-908-7,CBR-001-583-390-6,CO[C@]12[C@@H]3[C@@H](N3C)CN2C2=C([C@H]1COC(=O)N)C(=O)C(=C(C2=O)C)N,CBR-HVAC-04837: Head and Neck Cancer Therapy; DNA-Damaging Drugs; DNA inhibitor
CBR-001-583-391-7,RFM-003-909-8,CBR-001-583-391-7,CC(C[C@@H](C(=O)NCCC(C)C)NC(=O)[C@H]1O[C@@H]1C(=O)O)C,CBR-HVAC-14304
CBR-001-583-392-8,RFM-003-910-1,CBR-001-583-392-8,CS(=O)(=O)c1ccc(cc1)C1CCNCC1,analog of CBR-HVAC-06598 (Seridopidine)
CBR-001-583-393-9,RFM-003-911-2,CBR-001-583-393-9,OCCn1ncc2c1ccc(c2)Oc1ccc(cc1CNC(=O)Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)F,CBR-HVAC-06645: Myelodysplastic Syndrome Therapy;Antiarthritic Drugs;Oncolytic Drugs; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators;Tie2 Receptor Inhibitors; P38 MITOGEN-ACTIVATED PROTEIN KINASE; TIE2 KINASE RECEPTOR Inhibitor; Inhibitor; Inhibitor; Inhibitor;
CBR-001-583-394-0,RFM-003-912-3,CBR-001-583-394-0,O[C@H]1C[C@@H](O[C@@H]1COP(=O)([O-])[O-])n1cc(C)c(=O)[nH]c1=O,analog of CBR-HVAC-06944 (Bisphosphocin Nu-3)
CBR-001-583-395-1,RFM-003-913-4,CBR-001-583-395-1,COC(=O)[C@@H](Cc1ccc(cc1)O)NC(=O)C,analog of CBR-HVAC-07101 ((no name))
CBR-001-583-396-2,RFM-003-914-5,CBR-001-583-396-2,FC(c1nccc(c1)[C@@]1(N=C(c2c1cccc2F)N)c1cccc(c1)c1cncnc1)F,"CBR-HVAC-07153: Alzheimer's Dementia, Treatment of ; beta-Secretase 1 (BACE1) Inhibitors; Secretase beta inhibitor"
CBR-001-583-397-3,RFM-003-915-6,CBR-001-583-397-3,CCCCCCCCCCCCCC=C[C@H]([C@@H](NC(=O)CCCCCCCCCCCCC)CO)O,analog of CBR-HVAC-07259 (N-oleyldihydrosphingosine)
CBR-001-583-398-4,RFM-003-916-7,CBR-001-583-398-4,CCP([Au]S[C@@H]1O[C@H](COC(=O)C)[C@H]([C@@H]([C@H]1OC(=O)C)OC(=O)C)OC(=O)C)(CC)CC,CBR-HVAC-07487: Disease modifying antirheumatic drug; Immunosuppressant; Prostaglandin synthase inhibitor
CBR-001-583-399-5,RFM-003-917-8,CBR-001-583-399-5,N#Cc1ccc2c(c1)CN([C@@H](CN2Cc1nc[nH]c1)Cc1ccccc1)S(=O)(=O)c1cccs1,CBR-HVAC-05330: Oncolytic Drugs;Solid Tumors Therapy; Apoptosis Inducers;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators; Ras GTPase; Protein farnesyltransferase Inhibitor;
CBR-001-583-400-1,RFM-003-918-9,CBR-001-583-400-1,CC1=CC[C@@](CC1)(O)C(C)C,CBR-HVAC-14270
CBR-001-583-401-2,RFM-003-919-0,CBR-001-583-401-2,COCCCOc1ccnc(c1C)CSc1nc2c([nH]1)cccc2,analog of CBR-HVAC-07773
CBR-001-583-402-3,RFM-003-920-3,CBR-001-583-402-3,Fc1ccc2c(c1)C(=NCc1n2cnc1C(=O)N)c1ccccc1Br,CBR-HVAC-14444: Benzodiazepine receptor agonist; GABA(A) Receptor Modulators; GABA-A receptor Modulator; Signal Transduction Modulators; Anticonvulsant; Antiepileptic Drugs; Antipsychotic; Anxiolytic; Anxiolytics
CBR-001-583-403-4,RFM-003-921-4,CBR-001-583-403-4,O=C(Nc1ccc(c(c1)C(F)(F)F)Cl)Nc1ccc(cc1)Cl,CBR-HVAC-09014
CBR-001-583-404-5,RFM-003-922-5,CBR-001-583-404-5,CC(CC(=O)c1ccc(c(c1)Cl)C)CC(=O)O,analog of CBR-HVAC-09212 (BUCLOXIC ACID)
CBR-001-583-405-6,RFM-003-923-6,CBR-001-583-405-6,O=C(N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)COC(=O)C)CSc1ccncc1,CBR-HVAC-09558: Penicillin binding protein Inhibitor;
CBR-001-583-406-7,RFM-003-924-7,CBR-001-583-406-7,COc1cccc(c1)C(CNC(C)C)O,analog of CBR-HVAC-09888 (FENALCOMINE HYDROCHLORIDE)
CBR-001-583-407-8,RFM-003-925-8,CBR-001-583-407-8,CC1CC(OC(=O)c2ccccc2)CC(N1)(C)C,CBR-HVAC-09941
CBR-001-583-408-9,RFM-003-926-9,CBR-001-583-408-9,NCCCC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)O)C)C)NC(=O)C,analog of CBR-HVAC-11109 (ALADAPCIN)
CBR-001-583-409-0,RFM-003-927-0,CBR-001-583-409-0,Oc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2,CBR-HVAC-11135: Histamine H1 receptor Antagonist;
CBR-001-583-410-3,RFM-003-928-1,CBR-001-583-410-3,COc1cc(/C=C/C(=O)CC(=O)C)ccc1O,analog of CBR-HVAC-11966 (YPE-01)
CBR-001-583-638-1,RFM-003-929-2,CBR-001-583-638-1,O=C(Nc1cn2c(c1C)c(ncn2)Nc1ccc2c(c1)cnn2Cc1cccc(c1)F)OC[C@@H]1COCCN1,CBR-HVAC-06179: EGFR (HER1; erbB1) Inhibitors; EGFR kinase inhibitor; Epidermal growth factor receptor 1; Epidermal growth factor receptor 2; Epidermal growth factor receptor 4 Inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-3 antagonist; ErbB-4 tyrosine kinase inhibitor; HER2 (erbB2) Inhibitors; HER3 (erbB3) Inhibitors; HER4 (erbB4) Inhibitors; Signal Transduction Modulators; Anticancer; Neurologic Cancer Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-583-639-2,RFM-003-930-5,CBR-001-583-639-2,CCCCC1=NC2(C(=O)N1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)CCCC2,"CBR-HVAC-02582: Angiotensin AT1 Antagonists; Angiotensin II 1 antagonist; Angiotensin II receptor type 1 Antagonist; Angiotensin-type-1-receptor-antagonists; Antioxidants; Signal Transduction Modulators; Agents for Liver Fibrosis; Antiarrhythmic Drugs; Antihypertensive; Antioxidant; Arrhythmias; Diabetes; Diabetic Nephropathy, Agents for; Heart Failure Therapy; Hypertension; Hypertension, Treatment of; Ischaemic Heart Disease; Metabolic Disorders (Not Specified); Irbesartan (SR-47436, BMS-186295) is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC50 of 1.3 nM."
CBR-001-583-763-5,RFM-003-931-6,CBR-001-583-763-5,CC[C@H]([C@H](NC[C@H](CS)N)CO[C@H](C(=O)N[C@H](C(=O)OC(C)C)CCS(=O)(=O)C)Cc1ccccc1)C,CBR-HVAC-10752; Farnesyl transferase inhibitor; Ras protein kinase inhibitor; Transferase inhibitor
CBR-001-584-030-9,RFM-003-932-7,CBR-001-584-030-9,C=CC1CN2CCC1CC2C(c1ccnc2c1cccc2)O,CBR-HVAC-04349: Cancer Multidrug Resistance Modulators; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; ;
CBR-001-584-031-0,RFM-003-933-8,CBR-001-584-031-0,CC([C@@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)O)N)C,"CBR-HVAC-06752: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; ;"
CBR-001-584-032-1,RFM-003-934-9,CBR-001-584-032-1,NC(=N)N/N=C\1/C=C2C(O)CN(C2=CC1=O)C,CBR-HVAC-07424: ; ; ; Membrane permeability inhibitor; Membrane integrity inhibitor
CBR-001-584-033-2,RFM-003-935-0,CBR-001-584-033-2,OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)Br,CBR-HVAC-08849: ; ; Beta-lactamase Inhibitor;
CBR-001-584-034-3,RFM-003-936-1,CBR-001-584-034-3,Oc1ccc2c(c1Cc1c(O)ccc3c1cccc3)cccc2,"CBR-HVAC-05666: Alzheimer's Dementia, Treatment of ; Antiamyloidogenic Agents; Beta amyloid Inhibitor;"
CBR-001-584-035-4,RFM-003-937-2,CBR-001-584-035-4,CC(CCOC(=O)c1cc(=O)c2c(o1)c1ccc(c(c1[nH]c2=O)C)C)C,CBR-HVAC-02145: Antiallergy/Antiasthmatic Drugs; Mediator Release Inhibitors; ; Histamine release inhibitor
CBR-001-584-036-5,RFM-003-938-3,CBR-001-584-036-5,OCC(NCC(c1ccccc1)O)(C)C,CBR-HVAC-02123: Antiarthritic Drugs;Non-Opioid Analgesics; ; ; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-584-037-6,RFM-003-939-4,CBR-001-584-037-6,OCCN1CCN(CC1)CCCN1c2ccccc2C=Cc2c1cccc2,CBR-HVAC-03124: Antidepressants; ; Opioid receptor sigma Antagonist; Antagonist; Agonist; Antagonist;
CBR-001-584-038-7,RFM-003-940-7,CBR-001-584-038-7,O=C1CN(C)C(=O)C(N1)Cc1c([nH]c2c1cccc2)C(=O)c1ccc2c(c1)OCO2,"CBR-HVAC-07013: Antifungal Agents;Treatment of Male Sexual Dysfunction;Pulmonary Hypertension, Treatment of; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; ;"
CBR-001-584-039-8,RFM-003-941-8,CBR-001-584-039-8,CCCCCCCCCCCCCCCC(=O)OC1CCCn2c1nc(C)c(c2=O)CCN1CCC(CC1)c1noc2c1ccc(c2)F,CBR-HVAC-06156: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; ; 5 Hydroxytryptamine 2A receptor antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 7 receptor antagonist
CBR-001-584-040-1,RFM-003-942-9,CBR-001-584-040-1,Fc1ccc(c(c1)C(=O)Nc1ccc(c(c1)Cl)C(=O)N1Cc2cccn2Cc2c1cccc2)C,CBR-HVAC-00908: Diuretics;Heart Failure Therapy; Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Antagonists; VASOPRESSIN RECEPTOR V2 Antagonist; Vasopressin 2 antagonist
CBR-001-584-041-2,RFM-003-943-0,CBR-001-584-041-2,Cn1nc(c(c1)c1ccncc1)c1ccc(cc1)OCc1ccc2c(n1)cccc2,"CBR-HVAC-06488: Huntington's Disease, Treatment of;Antipsychotic Drugs; Phosphodiesterase PDE10A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 10A Inhibitor; Phosphodiesterase 10A inhibitor"
CBR-001-584-042-3,RFM-003-944-1,CBR-001-584-042-3,NC(=N)NCCN1CCCCCCC1,"CBR-HVAC-03148: Hypertension, Treatment of; Adrenergic Neuron Blockers;Signal Transduction Modulators; Adrenergic receptor Antagonist;"
CBR-001-584-043-4,RFM-003-945-2,CBR-001-584-043-4,CCC(=O)OC(C[N+](C)(C)C)CC(=O)O,"CBR-HVAC-02291: Peripheral Arterial Disease, Treatment of;Pharmacological Tools;Heart Failure Therapy;Treatment of Renal Diseases;Treatment of Intermittent Claudication;Inflammatory Bowel Disease, Agents for;Peripheral Vascular Disease, Treatment of; ; ; Carnitine O-acetyltransferase stimulant; Reducing agent; Free radical scavenger"
CBR-001-584-044-5,RFM-003-946-3,CBR-001-584-044-5,OCCOc1c(C)cc(cc1C)c1nc2cc(OC)cc(c2c(=O)[nH]1)OC,"CBR-HVAC-06794: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Atherosclerosis Therapy;Antidiabetic Drugs;Cardiovascular Diseases (Not Specified);Alzheimer's Dementia, Treatment of ; APOA1 Expression Enhancers;Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors;HDL-Cholesterol Increasing Agents; APOA1 Stimulator;"
CBR-001-584-045-6,RFM-003-947-4,CBR-001-584-045-6,Cc1ncc(nc1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,"CBR-HVAC-01610: Type 2 Diabetes, Agents for; K(ATP) Channel Blockers; Potassium channel Blocker; ATP-sensitive potassium channel antagonist; Sulfonylurea; Insulin secretagogue"
CBR-001-584-046-7,RFM-003-948-5,CBR-001-584-046-7,CC(=C)CNc1ccc(cc1)C(C(=O)O)C,CBR-HVAC-02106: ; ; Prostaglandin G/H synthase 2; Phospholipase 2 Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-584-047-8,RFM-003-949-6,CBR-001-584-047-8,CCN(CCOP(=O)(O)O)CCCOc1ccc2c(c1)ncnc2Nc1n[nH]c(c1)CC(=O)Nc1cccc(c1)F,CBR-HVAC-00885: ; ; Aurora kinase B Inhibitor; Aurora kinase inhibitor; Mitotic inhibitor; Protein kinase inhibitor
CBR-001-584-048-9,RFM-003-950-9,CBR-001-584-048-9,CN1C2CCC1CC(C2)OC1c2ccccc2CCc2c1cccc2,CBR-HVAC-09768
CBR-001-584-049-0,RFM-003-951-0,CBR-001-584-049-0,ICC(CI)O,CBR-HVAC-09257
CBR-001-584-050-3,RFM-003-952-1,CBR-001-584-050-3,COc1ccccc1OCC1CNC(=O)O1,CBR-HVAC-08890
CBR-001-584-051-4,RFM-003-953-2,CBR-001-584-051-4,OS(=O)(=O)c1ccc2c(c1)cccc2,CBR-HVAC-11644: HIV fusion inhibitor
CBR-001-584-052-5,RFM-003-954-3,CBR-001-584-052-5,[O-][N+](=O)c1nccn1CC(CO)O,CBR-HVAC-08274
CBR-001-584-053-6,RFM-003-955-4,CBR-001-584-053-6,OC[C@@]12O[C@H]2[C@H]([C@H]2[C@@H]1[C@@H](OC=C2)OC1OC(COC(=O)/C=C/c2ccccc2)C(C(C1O)O)O)O,CBR-HVAC-14276
CBR-001-584-054-7,RFM-003-956-5,CBR-001-584-054-7,Oc1ccc2c(c1)CC[C@@H]([C@H]2c1ccc(cc1)OCCN1CCCC1)c1ccccc1,"CBR-HVAC-04842: Treatment of Postmenopausal Syndrome ;Chemopreventive Agents;Disorders of Sexual Function and Reproduction, Treatment of;Treatment of Osteoporosis; Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators; Estrogen receptor Modulator; Estrogen receptor agonist; Estrogen receptor antagonist; Selective estrogen receptor modulator"
CBR-001-584-055-8,RFM-003-957-6,CBR-001-584-055-8,Clc1ccc2c(c1)CCc1c(C2=C2CCN(CC2)C(=O)C)nccc1,CBR-HVAC-03754: Antiallergy/Antiasthmatic Drugs; Histamine H1 Receptor Antagonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Histamine receptor; Platelet activating factor receptor Antagonist; Platelet activating factor antagonist; Histamine receptor antagonist
CBR-001-584-056-9,RFM-003-958-7,CBR-001-584-056-9,CC[C@]12CCCN3[C@@H]2c2n(C(=C1)C(=O)O)c1c(c2CC3)cccc1,analog of CBR-HVAC-10987
CBR-001-584-057-0,RFM-003-959-8,CBR-001-584-057-0,CC[C@@H](c1nc2cccc(c2c(=O)n1c1ccccc1)F)Nc1ncnc2c1nc[nH]2,CBR-HVAC-06320
CBR-001-584-058-1,RFM-003-960-1,CBR-001-584-058-1,Cc1ccccc1N1CCN(CC1)C1CCc2c(C1)cccc2,analog of CBR-HVAC-03262
CBR-001-584-059-2,RFM-003-961-2,CBR-001-584-059-2,SCC(C(=O)NCC(=O)O)Cc1ccccc1,CBR-HVAC-14492: Membrane metallo endopeptidase inhibitor
CBR-001-584-060-5,RFM-003-962-3,CBR-001-584-060-5,CCCCC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2O)C,analog of CBR-HVAC-05887
CBR-001-584-061-6,RFM-003-963-4,CBR-001-584-061-6,O=C(c1cc2CCC(=O)N3c2c(c1)CC3)CCC1CCN(CC1)C(=O)C,analog of CBR-HVAC-05959
CBR-001-584-062-7,RFM-003-964-5,CBR-001-584-062-7,CCCCC#Cc1nc(NC)c2c(n1)n(cn2)[C@@H]1O[C@@H]([C@@H](C1O)O)CO,analog of CBR-HVAC-03602
CBR-001-584-063-8,RFM-003-965-6,CBR-001-584-063-8,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NC1CCCCC1,CBR-HVAC-14179
CBR-001-584-064-9,RFM-003-966-7,CBR-001-584-064-9,CCn1ccc(=O)c(c1C)O,analog of CBR-HVAC-08570
CBR-001-584-065-0,RFM-003-967-8,CBR-001-584-065-0,C#CC1(O)CCC2[C@]1(C)CCC1[C@H]2CCc2c1c(C)cc(c2)O,analog of CBR-HVAC-07866
CBR-001-584-066-1,RFM-003-968-9,CBR-001-584-066-1,COc1c2c(CCC(c3c2ccc(c(=O)c3)SC)NC(=O)C)cc(c1OC)OC,CBR-HVAC-14300
CBR-001-584-067-2,RFM-003-969-0,CBR-001-584-067-2,CO/N=C/1\[C@@H](C)CC(C)(OC)[C@@H](O[C@@H]2OC(C)CC(C2O)N(C)C)[C@H](C)[C@@H](O[C@@H]2OC(C)[C@@H](C(C2)(C)OC)O)[C@H](C(=O)O[C@H](C([C@@H]([C@H]1C)O)(C)O)CC)C,analog of CBR-HVAC-07986
CBR-001-584-068-3,RFM-003-970-3,CBR-001-584-068-3,CC(=O)O[C@H]1[C@H](O[C@H]2[C@@H]1OC(O2)(C)C)[C@H]1COC(O1)(C)C,analog of CBR-HVAC-10964
CBR-001-584-070-7,RFM-003-971-4,CBR-001-584-070-7,CCN1CCCC1CNS(=O)(=O)c1cc(Cl)c(cc1OC)N,CBR-HVAC-01075; Muscarinic M1 receptor antagonist; Opioid receptor agonist; Phase 1
CBR-001-584-071-8,RFM-003-972-5,CBR-001-584-071-8,N#CC(C(=O)c1cccn1C)C(=O)Nc1ccccc1,"CBR-HVAC-03893; Antirheumatic; Analgesic; Anti-inflammatory; Discontinued - Inflammation, Pain, Rheumatoid arthritis"
CBR-001-584-072-9,RFM-003-973-6,CBR-001-584-072-9,CC(=O)Nc1cccc2c1c(=O)c1ccccc1n(c2=O)C,CBR-HVAC-09423; Adrenergic receptor inhibitor
CBR-001-584-073-0,RFM-003-974-7,CBR-001-584-073-0,COC(=O)Nc1ccc2c(c1)c1ccc(cc1o2)S(=O)(=O)N[C@H](C(=O)O)C(C)C,CBR-HVAC-09481; Matrix metallopeptidase 12 inhibitor
CBR-001-584-074-1,RFM-003-975-8,CBR-001-584-074-1,CN1CCN(CC1)c1ccccc1/C=C/1\SCCN(C1=O)c1ccc(c(c1)Cl)Cl,CBR-HVAC-11667; 5-Hydroxytryptamine 1B receptor antagonist
CBR-001-584-075-2,RFM-003-976-9,CBR-001-584-075-2,O=c1o[nH]c(n1)c1cccc(c1)NC(=O)Cn1nc(C2CCCCC2)c2c(n(c1=O)CC(=O)C1CCCC1)cccc2,CBR-HVAC-05916: CCK2 (CCKB/Gastrin) Antagonists
CBR-001-584-076-3,RFM-003-977-0,CBR-001-584-076-3,CNC(=O)c1sc2c(c1)c(cnc2)Oc1ccc(cc1)Cl,CBR-HVAC-11412; E-Selectin inhibitor; Intercellular adhesion molecule 1 inhibitor
CBR-001-584-077-4,RFM-003-978-1,CBR-001-584-077-4,O=C(c1cc(c(cc1F)C)n1cnc(c1)C1CC1)Nc1cccc(n1)c1nncn1C(C)C,CBR-HVAC-07877; Mitogen-activated protein kinase kinase kinase 5 inhibitor; Phase 2
CBR-001-584-078-5,RFM-003-979-2,CBR-001-584-078-5,CCC1N(CCc2c1ncn2CC)C(=S)NC(C)C,CBR-HVAC-07814; Gastrin inhibitor
CBR-001-584-079-6,RFM-003-980-5,CBR-001-584-079-6,OC(=O)Cc1nc(oc1c1ccco1)c1ccc(cc1)Cl,CBR-HVAC-03228; Glucuronosyltransferase ligand
CBR-001-584-080-9,RFM-003-981-6,CBR-001-584-080-9,CN1C(=O)CC(=O)N(c2c1ccc(c2)C(F)(F)F)c1ccccc1,CBR-HVAC-05611; GABA-A receptor agonist
CBR-001-584-081-0,RFM-003-982-7,CBR-001-584-081-0,C/C(=C\c1ccc(cc1)OCCN1CCOCC1)/c1ccc2c(c1)C(C)(C)CCC2(C)C,CBR-HVAC-03912: Phase I; Phase II; Oncolytic Drugs; Anticancer; Cancer;
CBR-001-584-082-1,RFM-003-983-8,CBR-001-584-082-1,CC(c1nnc(s1)COc1ccc2c(c1)oc(=O)c(c2C)C)C,CBR-HVAC-04427: Phase I; Discontinued; Phase I; Antidepressants;Antiparkinsonian Drugs; MAO-B Inhibitors; Antiparkinsonian; Antidepressant; Parkinson's disease; Monoamine oxidase B inhibitor
CBR-001-584-083-2,RFM-003-984-9,CBR-001-584-083-2,COc1cccc(c1)CS(=O)c1nc2c([nH]1)cncc2,"CBR-HVAC-04178: Phase II; Clinical; Phase II; Bone Resorption Inhibitors;Bone Diseases, Treatment of; Antiresorptive; Osteogenesis stimulator; Osteoporosis; Bone formation stimulant"
CBR-001-584-084-3,RFM-003-985-0,CBR-001-584-084-3,CCc1cc(Nc2scc(n2)c2ccc(c(c2)F)n2cnc(c2)C)c(cc1C)C,"CBR-HVAC-07049: Phase I; Alzheimer's Dementia, Treatment of; Antiamyloidogenic Agents;gamma-Secretase Modulators;"
CBR-001-584-085-4,RFM-003-986-1,CBR-001-584-085-4,O=C(c1cc2c(cc1C)C(C)(C)CCC2(C)C)Oc1ccc(cc1)C(=O)O,CBR-HVAC-09345: ; Phase I; Anticancer; Hypoglycemic agent; Cancer;
CBR-001-584-086-5,RFM-003-987-2,CBR-001-584-086-5,O=C1NC(=O)C(N1C)O,"CBR-HVAC-03332: Phase II; Phase II; Phase II; Renal Failure, Agents for;Treatment of Renal Diseases; Antioxidants; Antioxidant; Renal failure; Oxygen scavenger"
CBR-001-584-087-6,RFM-003-988-3,CBR-001-584-087-6,Nc1ccc(c2c1cccc2)c1ccc(nc1)CN1CCOCC1,CBR-HVAC-07529: ; Phase I; P38 kinase inhibitor
CBR-001-584-088-7,RFM-003-989-4,CBR-001-584-088-7,CNC(=O)OCC(=C)COC(=O)NC,CBR-HVAC-11472: ; Phase II; Immunostimulant; Oncolytic; Cancer;
CBR-001-584-089-8,RFM-003-990-7,CBR-001-584-089-8,Clc1ccc2c(c1)cc(o2)C(c1ccccc1Cl)n1cncc1,"CBR-HVAC-08999: Preclinical; PRESCRIPTION DRUG; Antifungal Agents; Antifungal; Infection, fungal;"
CBR-001-584-090-1,RFM-003-991-8,CBR-001-584-090-1,COC(c1ccc(nc1)C)CN1CCN(CC1)c1ccccc1,CBR-HVAC-07396: ; Phase I; Leucotriene synthesis inhibitor; Leucotriene D4 antagonist
CBR-001-584-091-2,RFM-003-992-9,CBR-001-584-091-2,Nc1nnc(s1)NCCCOc1cccc(c1)CN1CCCCC1,CBR-HVAC-08410: ; Phase I; Histamine H2 receptor antagonist
CBR-001-584-092-3,RFM-003-993-0,CBR-001-584-092-3,CCCCCCCCCC1(C)OCC(O1)COC(=O)N,CBR-HVAC-10101: ; PRESCRIPTION DRUG; Antiallergic; Allergy;
CBR-001-584-093-4,RFM-003-994-1,CBR-001-584-093-4,COC(=O)/C=C/C(=O)OCCN1C(=O)CCC1=O,"CBR-HVAC-07359: Phase I; Multiple Sclerosis, Agents for; Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A)  Ligands;Signal Transduction Modulators;"
CBR-001-584-094-5,RFM-003-995-2,CBR-001-584-094-5,CCNC(=S)NS(=O)(=O)c1cnccc1NC1CCCCCCC1,CBR-HVAC-11896: Preclinical; Suspended; Diuretics; Diuretic agent; Antihypertensive; Hypertension;
CBR-001-584-095-6,RFM-003-996-3,CBR-001-584-095-6,CC(NCCN(S(=O)(=O)c1ccc(cc1)NS(=O)(=O)C)C(C)C)C,CBR-HVAC-08533: Preclinical; Phase II; Antiarrhythmic Drugs; Polarisation inhibitor
CBR-001-584-096-7,RFM-003-997-4,CBR-001-584-096-7,CCC(=O)N(c1ccccc1)CC(N(CCc1ccccc1)C)C,CBR-HVAC-09990: ; PRESCRIPTION DRUG; Narcotic; Analgesic; Pain; ;2016-04-01: controlled substance
CBR-001-584-097-8,RFM-003-998-5,CBR-001-584-097-8,O=C(c1cccc(n1)C)NC1N=NN=N1,CBR-HVAC-09471: ; Phase II; ANTI-ALLERGICANTI-ASTHMATIC; Allergy;
CBR-001-584-098-9,RFM-003-999-6,CBR-001-584-098-9,[O-][N+](=O)OCc1cccc(n1)Cl,"CBR-HVAC-03325: Phase II; Phase II; Angina pectoris, Treatment of; Calcium channel antagonist"
CBR-001-584-099-0,RFM-004-000-6,CBR-001-584-099-0,O=C(NC(=O)c1ccccc1)NC1CCN(CC1)Cc1ccc2c(c1)cccc2,CBR-HVAC-08821: ; PRESCRIPTION DRUG; Antidepressant; Depression;
CBR-001-584-100-6,RFM-004-001-7,CBR-001-584-100-6,CCc1cc(O)c(cc1F)Oc1ccc(cc1F)C(=O)N,CBR-HVAC-06902: Phase I; Antibacterial Drugs; Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors;
CBR-001-584-101-7,RFM-004-002-8,CBR-001-584-101-7,CCCC(COC(=O)N)(COC(=O)NCCCC)C,CBR-HVAC-08875: ; PRESCRIPTION DRUG; Anxiolytic; Anxiety; Depression;
CBR-001-584-102-8,RFM-004-003-9,CBR-001-584-102-8,CCOC(=O)N(S(=O)(=O)C(F)(F)F)c1cccc(c1)C(=O)c1ccccc1,"CBR-HVAC-08767: ; PRESCRIPTION DRUG; Anti-inflammatory, nonsteroidal; Inflammation;"
CBR-001-584-103-9,RFM-004-004-0,CBR-001-584-103-9,NC(=N)NC(=O)c1ccc2c(c1)cccc2c1cnn(c1)C,"CBR-HVAC-06380: Phase II; Phase II; Anti-HIV Agents;Antiviral Drugs;Anti-Hepatitis C Virus Drugs;Anti-Influenza Virus Drugs; Nucleocapsid p7 Protein (NCp7) Zinc Finger Inhibitors; Antiviral; Infection, human immunodeficiency virus; Infection, hepatitis C virus; Infection, coronavirus; Infection, dengue virus;"
CBR-001-584-104-0,RFM-004-005-1,CBR-001-584-104-0,O=C(C1CCCCC1)OC(CN1C(=O)[C@@H]2[C@H](C1=O)[C@H]1C[C@@H]2C=C1)CN1CCN(CC1)c1ccncc1,CBR-HVAC-07770: ; Phase II; Unidentified pharmacological activity
CBR-001-584-139-1,RFM-004-006-2,CBR-001-584-139-1,O=C1NC(=O)C(S1)Cc1ccc2c(c1)CCC(O2)Cc1ccccc1,CBR-HVAC-03996; Peroxisome proliferator-activated receptor gamma agonist
CBR-001-584-140-4,RFM-004-007-3,CBR-001-584-140-4,O=C([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C=C(F)C(=O)N2C)NCc1nc2c([nH]1)nccc2,CBR-HVAC-06341;Androgen receptor modulator
CBR-001-584-141-5,RFM-004-008-4,CBR-001-584-141-5,O=C(Nc1cc(C)nc2c1cccc2)NCCN1CCC(CC1)(O)Cc1ccccc1,CBR-HVAC-05948;Urotensin II receptor antagonist
CBR-001-584-202-1,RFM-004-009-5,CBR-001-584-202-1,CSCC[C@@H](C(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](N(C(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](CCCNC(=N)N)N)C)Cc1ccccc1)CC(C)C,CBR-HVAC-03933: SAPK1 (JNK) Activators; Substance P Antagonist; Substance-P-inhibitors; Anticancer; Cancer; Oncolytic Drugs
CBR-001-584-285-0,RFM-004-010-8,CBR-001-584-285-0,COc1ccc(cc1/N=N/c1ncc[nH]1)Cl,CBR-HVAC-03045: Cardiovascular Diseases (Not Specified); alpha1-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha 1 adrenoreceptor agonist
CBR-001-584-286-1,RFM-004-011-9,CBR-001-584-286-1,CN(CC(CN1c2ccccc2OCOc2c1cc(Cl)cc2)C)C,CBR-HVAC-03413: Antipsychotic Drugs; Dopamine receptor Antagonist; Dopamine receptor antagonist; 5 Hydroxytryptamine receptor antagonist
CBR-001-584-287-2,RFM-004-012-0,CBR-001-584-287-2,N#Cc1ccc2c(c1)C(CC(O2)(C)C)c1cccc[n+]1[O-],analog of CBR-HVAC-09502
CBR-001-584-288-3,RFM-004-013-1,CBR-001-584-288-3,Fc1ccc(c(c1)F)COC[C@H](C(=O)N1CCC2=NN(C(=O)[C@@]2(C1)Cc1ccccn1)CC(F)(F)F)NC(=O)C(N)(C)C,CBR-HVAC-05829: Prokinetic Agents;Treatment of Growth Hormone Deficiency; GHS Receptor Agonists;Growth Hormone Secretagogues;Signal Transduction Modulators; Growth hormone secretagogue receptor Agonist;
CBR-001-584-289-4,RFM-004-014-2,CBR-001-584-289-4,COc1cc2nc(nc(c2cc1OC)NCCN1CCOCC1)c1ccc(cc1)N1CCN(CC1)C,"CBR-HVAC-06674: Systemic Lupus Erythematosus, Agents for;Rheumatoid Arthritis, Treatment of; Signal Transduction Modulators;TLR7 Receptor Antagonists;TLR8 Receptor Antagonists;TLR9 Receptor Antagonists; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; TOLL-LIKE RECEPTOR 9 Antagonist;"
CBR-001-584-290-7,RFM-004-015-3,CBR-001-584-290-7,CC(c1ccccc1c1ccc2c(c1)nc([nH]2)/C=C/c1ccc(cc1)C(F)(F)F)(O)C,CBR-HVAC-06687: Analgesic Drugs; TRPV1 (Vanilloid VR1 Receptor) Antagonists; Vanilloid receptor 1 antagonist
CBR-001-584-291-8,RFM-004-016-4,CBR-001-584-291-8,CCCNC(=O)c1nnc2c(c1N)cccc2c1c(F)cccc1OC,"CBR-HVAC-06849: Autism, Treatment of;Anxiolytics;Neurologic Drugs (Miscellaneous); GABA(A) Receptor Partial Agonists;Signal Transduction Modulators;"
CBR-001-584-292-9,RFM-004-017-5,CBR-001-584-292-9,OC(=O)CCc1csc(n1)NC(=O)c1cc2CCCCCCc2n(c1=O)CC1CCCCC1,"CBR-HVAC-06866: Atopic Dermatitis, Agents for; Cannabinoid Receptor Agonists;Signal Transduction Modulators;"
CBR-001-584-293-0,RFM-004-018-6,CBR-001-584-293-0,CC(COc1ncc(cc1Cl)n1nc(c2c1ccc(c2)C(=O)NS(=O)(=O)C)C)C,CBR-HVAC-07243: Non-Opioid Analgesics; Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers;
CBR-001-584-294-1,RFM-004-019-7,CBR-001-584-294-1,Fc1ccc(cc1)c1noc(c1COc1ccc(cn1)C(=O)N1CCS(=O)(=O)CC1)C,"CBR-HVAC-07300: Alzheimer's Dementia, Treatment of ;Neurologic Drugs (Miscellaneous); GABA(A) Receptor Subunit Alpha-5 (GABRA5) Inverse Agonists;Signal Transduction Modulators;"
CBR-001-584-295-2,RFM-004-020-0,CBR-001-584-295-2,O=C(/C=C/c1ccc(nc1)C)NCCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,CBR-HVAC-08400: 5 Lipoxygenase inhibitor; Histamine H1 receptor antagonist; Leucotriene receptor antagonist
CBR-001-584-296-3,RFM-004-021-1,CBR-001-584-296-3,CCNc1nc(OC)c(nc1Cl)C(=O)NCC1CCCN1CC,"CBR-HVAC-08543: Nausea and Vomiting, Treatment of; Unidentified pharmacological activity"
CBR-001-584-297-4,RFM-004-022-2,CBR-001-584-297-4,O=C(N1CCC(CC1)OC(c1onc(n1)c1ccc(c(c1)F)S(=O)(=O)C)C)OC(C)(C)C,CBR-HVAC-09185: G protein-coupled receptor 119; Glucagon-like peptide 1 receptor Agonist;
CBR-001-584-298-5,RFM-004-023-3,CBR-001-584-298-5,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccccc1)C,CBR-HVAC-09507: DIPEPTIDYL PEPTIDASE IV Inhibitor;
CBR-001-584-299-6,RFM-004-024-4,CBR-001-584-299-6,COc1ccc(c2c1nccc2)C(=O)Nc1cc(Cl)cnc1Cl,CBR-HVAC-10467: Phosphodiesterase 4 Inhibitor;
CBR-001-584-300-2,RFM-004-025-5,CBR-001-584-300-2,c1ccc(cc1)c1noc(c1)n1cc(c2c1cccc2)Cn1cncc1,CBR-HVAC-10681: Antiepileptic Drugs; Antiepileptic; Anticonvulsant;
CBR-001-584-301-3,RFM-004-026-6,CBR-001-584-301-3,CN(CCSc1ccc(s1)/C=c/1\[nH]c(=O)/c(=C/c2ccccc2)/[nH]c1=O)C,CBR-HVAC-10771: Oncolytic Drugs;Thrombolytics; Plasminogen Activator Inhibitor (PAI-1) Inhibitors; Plasminogen activator inhibitor 1 Inhibitor;
CBR-001-584-302-4,RFM-004-027-7,CBR-001-584-302-4,COCCN(c1nc(C)nc2c1nnn2c1ccc(cc1Br)C(C)C)CCOC,CBR-HVAC-11294: Antidepressants;Anxiolytics; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing hormone receptor 1 Antagonist;
CBR-001-584-303-5,RFM-004-028-8,CBR-001-584-303-5,NC(=O)OC(c1ccccc1Cl)Cn1nncn1,CBR-HVAC-11812: Anxiolytic;
CBR-001-584-304-6,RFM-004-029-9,CBR-001-584-304-6,Cc1csc(n1)Nc1nc2c([nH]1)cccc2,CBR-HVAC-12027: Antiulcer Drugs; Stomach acid neutralizer;;2018-01-24: ARB# 18-000007
CBR-001-584-305-7,RFM-004-030-2,CBR-001-584-305-7,OC([C@@H]1C[C@H]1c1ccncc1)(c1ccccc1)c1ccccc1,CBR-HVAC-09230
CBR-001-584-306-8,RFM-004-031-3,CBR-001-584-306-8,OC([C@@H]1C[C@H]1c1ccncc1)(c1ccccc1)c1ccccc1,CBR-HVAC-09230
CBR-001-584-419-6,RFM-004-032-4,CBR-001-584-419-6,O=C(NS(=O)(=O)c1ccc2c(c1)CCO2)Nc1ccc(c(c1)Cl)Cl,CBR-HVAC-00100:Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Melanoma Therapy;Renal Cancer Therapy; Chloride channel Blocker; Ribonucleoside diphosphate reductase inhibitor; Ribonucleoside triphosphate reductase inhibitor
CBR-001-584-420-9,RFM-004-033-5,CBR-001-584-420-9,COc1cc(ccc1OCCCN1CCC(CC1)C(c1ccc(cc1)F)(c1ccc(cc1)F)O)C(=O)C,CBR-HVAC-00214:Antiallergy/Antiasthmatic Drugs; LIPOXYGENASE 5 Inhibitor; Histamine H1 receptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist; 5 Lipoxygenase inhibitor
CBR-001-584-421-0,RFM-004-034-6,CBR-001-584-421-0,Nc1ccn(c(=O)n1)[C@H]1[C@H](O)[C@@H](C(=C1F)CO)O,CBR-HVAC-00249:Solid Tumors Therapy;Pancreatic Cancer Therapy; Antimetabolites;Cyclin-Dependent Kinase Inhibitors;DNA Methyltransferase (DNMT) Inhibitors;Signal Transduction Modulators; DNA methyltransferase Inhibitor; DNA methylase inhibitor
CBR-001-584-422-1,RFM-004-035-7,CBR-001-584-422-1,O[C@@H]1CC[C@H](CC1)Nc1nc(N)ncc1C#Cc1ccc(cc1)Cl,"CBR-HVAC-00257:Neurodegenerative Diseases, Treatment of;Neuropathy, Treatment of ;Huntington's Disease, Treatment of;Alzheimer's Dementia, Treatment of ;Neuropathic Pain, Treatment of; Nerve Growth Factor (NGF) Enhancers;Signal Transduction Modulators; Neuronal growth factor receptor Agonist; Nerve growth factor agonist"
CBR-001-584-423-2,RFM-004-036-8,CBR-001-584-423-2,NC(=N)NCCCC(C(=O)O)NC(=O)OCCCCCn1cnc2c1ncnc2N(C)C,CBR-HVAC-00293:Cytotoxic T lymphocyte stimulator; Immunostimulant
CBR-001-584-424-3,RFM-004-037-9,CBR-001-584-424-3,COc1ccc(cc1)c1nn(CC=C(C)C)c(=O)nc1c1ccc(cc1)OC,CBR-HVAC-00340:Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-584-425-4,RFM-004-038-0,CBR-001-584-425-4,COc1cc(C)c(c(c1)C)S(=O)(=O)N(CCOCC(=O)N(Cc1ccc(cc1)C1=NCCN1)C)C,CBR-HVAC-00398:Bradykinin B1 receptor Antagonist; Bradykinin B1 receptor antagonist
CBR-001-584-426-5,RFM-004-039-1,CBR-001-584-426-5,OC(=O)[C@@H](NC(=O)c1c(Cl)cc2c(c1Cl)CCN(C2)C(=O)c1ccc2c(c1)occ2)Cc1cccc(c1)S(=O)(=O)C,"CBR-HVAC-00894:Diabetic Retinopathy, Agents for;Dry Eye Syndrome, Treatment for;Antiinflammatory Ophthalmic Agents; LFA-1/ICAM-1 Interaction Inhibitors; Lymphocyte function-associated antigen 1 Antagonist; Lymphocyte function-associated molecule inhibitor"
CBR-001-584-427-6,RFM-004-040-4,CBR-001-584-427-6,CCCCNC(=O)c1cc(N)ccc1OCC#C,CBR-HVAC-01655:Non-Opioid Analgesics; Prostaglandin G/H synthase 1 Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-584-428-7,RFM-004-041-5,CBR-001-584-428-7,c1ccc(cc1)C(c1ccccc1)CCNc1ccncc1,CBR-HVAC-02078:Muscarinic receptor antagonist; Platelet aggregation inhibitor
CBR-001-584-429-8,RFM-004-042-6,CBR-001-584-429-8,COc1cc(sc1c1nc2c([nH]1)cncc2)S(=O)C,"CBR-HVAC-02683:Hypertension, Treatment of;Vasodilators; Phosphodiesterase Inhibitor; Unidentified pharmacological activity"
CBR-001-584-430-1,RFM-004-043-7,CBR-001-584-430-1,NC(=O)c1c(O)nc[nH]1,CBR-HVAC-02936: INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE Inhibitor; ANTI-CANCER; Oncolytic Drugs
CBR-001-584-431-2,RFM-004-044-8,CBR-001-584-431-2,OC(=O)Cc1sc2n(c1c1ccc(cc1)Cl)c1c(n2)cccc1,CBR-HVAC-02941:Immunosuppressants; Immunostimulator; Anti-inflammatory; Antirheumatic; Antiarthritic; Immunosuppressant
CBR-001-584-432-3,RFM-004-045-9,CBR-001-584-432-3,[O-][n+]1cccc(c1)C(=O)Oc1ccc(cc1C(C)(C)C)C1CCCCC1,"CBR-HVAC-03202:Lipoprotein Disorders, Treatment of ; Cholesterol antagonist;"
CBR-001-584-433-4,RFM-004-046-0,CBR-001-584-433-4,OC(=O)C1Oc2c(C1)cc(c(c2Cl)Cl)S(=O)(=O)N(C)C,CBR-HVAC-03450:Diuretics;Uricosurics; Antihypertensive; Diuretic; Diuretic
CBR-001-584-434-5,RFM-004-047-1,CBR-001-584-434-5,O=C(CCNC(=O)[C@@H](C(COC(=O)c1cccnc1)(C)C)OC(=O)c1cccnc1)NCCSSCCNC(=O)CCNC(=O)[C@@H](C(COC(=O)c1cccnc1)(C)C)OC(=O)c1cccnc1,"CBR-HVAC-03473:Lipoprotein Disorders, Treatment of ; Cholesterol inhibitor"
CBR-001-584-435-6,RFM-004-048-2,CBR-001-584-435-6,O/N=C(/c1ccc2c(c1)n(c(n2)N)S(=O)(=O)C(C)C)\c1ccccc1,CBR-HVAC-03666:Antiviral Drugs; RNA synthesis inhibitor; Unidentified pharmacological activity
CBR-001-584-436-7,RFM-004-049-3,CBR-001-584-436-7,CNc1scc(n1)C(c1ccc(c(c1)F)c1ccccc1)C,CBR-HVAC-03731:Antiarthritic Drugs;Immunosuppressants; Bone resorption inhibitor; Immunosuppressant; Bone formation stimulant
CBR-001-584-437-8,RFM-004-050-6,CBR-001-584-437-8,COC(=O)Nc1nc2n(c1)nc(cc2)OCc1cc(OC)c(c(c1)OC)OC,CBR-HVAC-03853:Oncolytic Drugs; Microtubule Inhibitor; Microtubule inhibitor
CBR-001-584-438-9,RFM-004-051-7,CBR-001-584-438-9,CC1SC(=O)NN=C1c1ccncc1,CBR-HVAC-03888:Vasodilators;Heart Failure Therapy; Unidentified pharmacological activity
CBR-001-584-439-0,RFM-004-052-8,CBR-001-584-439-0,CCOc1ccc(c(c1)NC(=O)CC(N)C)c1cccnc1,CBR-HVAC-03988:Antiarrhythmic Drugs;
CBR-001-584-440-3,RFM-004-053-9,CBR-001-584-440-3,NC(=O)N1CC(C1)Oc1cccc(c1)C(F)(F)F,CBR-HVAC-04109:Antiepileptic Drugs; GABA-A receptor Agonist; GABA receptor agonist
CBR-001-584-441-4,RFM-004-054-0,CBR-001-584-441-4,CN(CCOC(c1ccnn1C)c1ccccc1)C,CBR-HVAC-04148:Urinary Incontinence Therapy;Antipyretics;Non-Opioid Analgesics; Calcitonin Gene-Related Peptides (CGRP) Receptor Ligands;Drugs Acting on Tachykinin Receptors;Signal Transduction Modulators; Neurokinin 1 receptor antagonist; Calcitonin receptor-like receptor antagonist
CBR-001-584-442-5,RFM-004-055-1,CBR-001-584-442-5,CCOC(=O)c1c(Cn2ncnc2)nc2c(c1c1ccc(c(c1)OC)OC)cc(c(c2)OC)OC,"CBR-HVAC-04620:Inflammatory Bowel Disease, Agents for;Rheumatoid Arthritis, Treatment of;Bone Diseases, Treatment of; Bone resorption inhibitor; Cytokine synthesis inhibitor; Disease modifying antirheumatic drug; Immunosuppressant; T cell inhibitor"
CBR-001-584-443-6,RFM-004-056-2,CBR-001-584-443-6,NC(=O)/C=C/1\CCc2c1cc(F)cc2F,CBR-HVAC-04656: MAO-B Inhibitors; Analgesic Drugs; Antiarthritic Drugs; Antispastic Drugs
CBR-001-584-444-7,RFM-004-057-3,CBR-001-584-444-7,COc1cc(cc(c1OC)OC)N(C(=O)N)CCN(C)C,"CBR-HVAC-04752:Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Mucolytics; Membrane integrity inhibitor; Membrane permeability enhancer"
CBR-001-584-445-8,RFM-004-058-4,CBR-001-584-445-8,COc1ccccc1N1CCN(CC1)CCN(c1ccccc1[N+](=O)[O-])C(=O)C1CCCCC1,CBR-HVAC-05141:Urinary Incontinence Therapy; Signal Transduction Modulators;5-HT1A Receptor Antagonists; 5-Hydroxytryptamine 1A receptor Antagonist;
CBR-001-584-446-9,RFM-004-059-5,CBR-001-584-446-9,OCC(C(=O)Nc1ccc(cc1)NS(=O)(=O)c1cccc2c1cccc2N(C)C)(C)C,CBR-HVAC-05241:Anti-Cytomegalovirus Drugs; DNA antagonist; CMV terminase inhibitor
CBR-001-584-447-0,RFM-004-060-8,CBR-001-584-447-0,C[C@@H](c1ccc(cc1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C,"CBR-HVAC-06289:Inflammatory Bowel Disease, Agents for;Antipsoriatics;Melanoma Therapy;Type 1 Diabetes, Agents for;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Dermatologic Drugs; Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR1/CXCR2 (IL-8 Receptor) Receptor Antagonists;Chemokine CXCR2  (IL-8 beta Receptor) Antagonists;Signal Transduction Modulators; C-X-C chemokine receptor type 1; C-X-C chemokine receptor type 2 Inhibitor;"
CBR-001-584-448-1,RFM-004-061-9,CBR-001-584-448-1,COc1ccc(nc1)c1ccc(cc1)OCc1cc(oc1C)C(=O)NS(=O)(=O)c1ccccc1C,CBR-HVAC-06362:Antimigraine Drugs; Prostanoid EP4 Antagonists;Signal Transduction Modulators; Prostaglandin E receptor 2; Prostaglandin E receptor 4 Antagonist;
CBR-001-584-449-2,RFM-004-062-0,CBR-001-584-449-2,COc1ccc(cc1)S(=O)(=O)NCc1cc(CN2CCCC2)c(c(c1)CN1CCCC1)O,CBR-HVAC-06445:Antiarrhythmic Drugs; Drugs Acting on L-Type Calcium Channels; Calcium channel; Potassium channel Kv1.2; Potassium channel Kv Inhibitor;
CBR-001-584-450-5,RFM-004-063-1,CBR-001-584-450-5,CNC(=O)NCCn1/c(=N\c2cccc(c2)F)/scc1c1ccc(cc1)N1CCOCC1,CBR-HVAC-06465:Asthma Therapy; Leukotriene receptor Antagonist;
CBR-001-584-451-6,RFM-004-064-2,CBR-001-584-451-6,CCc1c(C)cc(c(=O)n1Cc1ccc(cc1)F)C(=O)NC1(CCCCC1)C(=O)O,"CBR-HVAC-06473:Atopic Dermatitis, Agents for; Cannabinoid CB2 Agonists;Signal Transduction Modulators;"
CBR-001-584-452-7,RFM-004-065-3,CBR-001-584-452-7,CC(c1cc2[nH]c(=O)n(c(=O)c2cc1c1ccnn1C)NS(=O)(=O)C)C,"CBR-HVAC-06533:Antimigraine Drugs;Antiepileptic Drugs;Tinnitus, treatment of; AMPA Receptor Antagonists;Signal Transduction Modulators;"
CBR-001-584-453-8,RFM-004-066-4,CBR-001-584-453-8,OC(=O)COc1cc(ccc1c1ncco1)N1CCN(CC1)S(=O)(=O)c1ccc(cc1)OC(C)C,"CBR-HVAC-06596:Allergy, Treatment of; Prostanoid DP (DP1) Antagonists;Signal Transduction Modulators; Prostaglandin D2 receptor DP1 antagonist"
CBR-001-584-454-9,RFM-004-067-5,CBR-001-584-454-9,COc1cc(cc(c1C(=O)NC(C(N1CCCC1)(C)C)c1ccccc1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-06704:Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Cognition Disorders, Treatment of;Antipsychotic Drugs; GlyT-1 Inhibitors; Glycine transporter 1 Inhibitor;"
CBR-001-584-455-0,RFM-004-068-6,CBR-001-584-455-0,c1ccc(cc1)c1nnc(s1)O[C@@H]1[C@@H]2C[C@@H]3C[C@H]1CN(C2)C3,"CBR-HVAC-06885:Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; Nicotinic alpha7 Agonists;Signal Transduction Modulators;"
CBR-001-584-456-1,RFM-004-069-7,CBR-001-584-456-1,O=C(Nc1[nH]cc(n1)c1ccccn1)CN(c1c(C)cc(cc1C)C)C,"CBR-HVAC-07198:Amyotrophic Lateral Sclerosis, Agents for; Unidentified pharmacological activity"
CBR-001-584-457-2,RFM-004-070-0,CBR-001-584-457-2,Clc1cccc2c1nc(cc2)Nc1ccc(cc1)OC(F)(F)F,CBR-HVAC-07310:Anti-HIV Agents;
CBR-001-584-458-3,RFM-004-071-1,CBR-001-584-458-3,Cc1cc(C)nc(n1)N1CC2C(C1)CN(C2)C(=O)c1c(F)cccc1n1nccn1,"CBR-HVAC-07349:Sleep Disorders, Treatment of; Orexin OX-2 Antagonists;Signal Transduction Modulators;"
CBR-001-584-459-4,RFM-004-072-2,CBR-001-584-459-4,CNC(=O)c1ccc(nc1)Oc1ccc2c(c1)CCN(C2)C1CCC1,CBR-HVAC-07390:Histamine H3 receptor antagonist
CBR-001-584-460-7,RFM-004-073-3,CBR-001-584-460-7,O=C1OC(c2c1cccc2)n1cc(F)c(=O)[nH]c1=O,CBR-HVAC-07400:Thymidylate synthase inhibitor; RNA synthesis inhibitor
CBR-001-584-461-8,RFM-004-074-4,CBR-001-584-461-8,C=CCOc1ccccc1OCC(CNC1CCC(CC1)N1CCNC1=O)O,CBR-HVAC-07626:Beta adrenoreceptor antagonist; Alpha adrenoreceptor antagonist
CBR-001-584-462-9,RFM-004-075-5,CBR-001-584-462-9,OC(=O)CCCN1CCC[C@@H]1COc1ccc(cc1)Oc1ccc(cc1)Cl,"CBR-HVAC-06384: Stroke, Treatment of;Acute Myocardial Infarction, Treatment of; Leukotriene A4 Hydrolase Inhibitors;Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; Leukotriene A4 hydrolase inhibitor; Leukotriene B4 receptor antagonist;"
CBR-001-584-463-0,RFM-004-076-6,CBR-001-584-463-0,Clc1nc(n(c1Cl)CCCCN1CCC(=CC1)c1cccc(c1)C(F)(F)F)C,CBR-HVAC-07774;
CBR-001-584-464-1,RFM-004-077-7,CBR-001-584-464-1,OC(=O)/C(=C/c1ccc(cc1)Cc1cccnc1)/C,CBR-HVAC-08111:Thromboxane A2 receptor antagonist
CBR-001-584-465-2,RFM-004-078-8,CBR-001-584-465-2,O=C(N1CCCC1)Cn1c2ccccc2c2c1nc(nc2N1CCCC1)N1CCCC1,CBR-HVAC-05031: IL-5 Production Inhibitors; Immunomodulator; Interleukin 5 Production Inhibitor; Mediator Release Inhibitor; Mediator Release Inhibitors; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antiinflammatory
CBR-001-584-466-3,RFM-004-079-9,CBR-001-584-466-3,Cc1ccc(c(c1)NC(c1ccccc1Cl)C(=O)N)[N+](=O)[O-],CBR-HVAC-08249:RNA directed DNA polymerase inhibitor
CBR-001-584-467-4,RFM-004-080-2,CBR-001-584-467-4,CC1CCCN(C1)Cc1cccc(c1)OCCCNC(=O)c1ccc[n+](c1)[O-],CBR-HVAC-08367:Histamine H2 receptor antagonist
CBR-001-584-468-5,RFM-004-081-3,CBR-001-584-468-5,Cc1cc(OCC2CCN(CC2)C(=N)N)cc(c1)OS(=O)(=O)c1ccccc1Cl,CBR-HVAC-08436:Thrombin inhibitor
CBR-001-584-469-6,RFM-004-082-4,CBR-001-584-469-6,C/N=C\1/SCC(N1C)(O)c1ccc(c(c1)S(=O)(=O)N)Cl,CBR-HVAC-08450:Uric acid diuretic
CBR-001-584-470-9,RFM-004-083-5,CBR-001-584-470-9,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(=O)n(c1=O)C(=O)c1ccc2c(c1)OCO2,CBR-HVAC-08451:DNA synthesis inhibitor
CBR-001-584-471-0,RFM-004-084-6,CBR-001-584-471-0,Clc1cc(ccc1C)NC(=O)c1nc[nH]c1C,CBR-HVAC-08498:Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-584-472-1,RFM-004-085-7,CBR-001-584-472-1,CCCCNC(=O)NC1CCN(CC1)c1ncnc2c1cc(OC)c(c2)OC,CBR-HVAC-08598:
CBR-001-584-473-2,RFM-004-086-8,CBR-001-584-473-2,COc1nsnc1NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08697:
CBR-001-584-474-3,RFM-004-087-9,CBR-001-584-474-3,Nc1ccc(cc1)S(=O)(=O)Nc1snc(c1)C,CBR-HVAC-08740:
CBR-001-584-475-4,RFM-004-088-0,CBR-001-584-475-4,FC(c1cc2NC=NS(=O)(=O)c2cc1S(=O)(=O)N)(F)F,CBR-HVAC-08796:Carbonic anhydrase Inhibitor;
CBR-001-584-476-5,RFM-004-089-1,CBR-001-584-476-5,NC(=N)c1ccc(o1)c1ccccc1[N+](=O)[O-],CBR-HVAC-08820: Adrenergic transmitter uptake inhibitor; Antidepressant
CBR-001-584-477-6,RFM-004-090-4,CBR-001-584-477-6,Cc1ccccc1CN1CCN(CC1)CCOC(c1ccccc1Cl)c1ccccc1,CBR-HVAC-08840:
CBR-001-584-478-7,RFM-004-091-5,CBR-001-584-478-7,O=C(C(c1ccccc1)C1CCCCC1)OCC[S+](C)C,CBR-HVAC-09054:
CBR-001-584-479-8,RFM-004-092-6,CBR-001-584-479-8,C/C(=C\CN1CCN(CC1)Cc1ccc2c(c1)OCO2)/CC/C=C(/CCC=C(C)C)\C,CBR-HVAC-09107:
CBR-001-584-480-1,RFM-004-093-7,CBR-001-584-480-1,CON(C(=O)/C=C/1\OC(OC1=O)(C)C)Cc1ccc(cc1)F,CBR-HVAC-09187:Anti-HIV Agents; HIV Integrase Inhibitors; Integrase Inhibitor;
CBR-001-584-481-2,RFM-004-094-8,CBR-001-584-481-2,N#Cc1c(N)n(nc2c1=CCSC2)c1ccc(cc1)C(C)C,CBR-HVAC-09298:Protein tyrosine phosphatase 1B Inhibitor;
CBR-001-584-482-3,RFM-004-095-9,CBR-001-584-482-3,C1CCCN(CC1)CC#CCC1(Cc2ccccc2)c2ccccc2c2c1cccc2,CBR-HVAC-09440:POTASSIUM CHANNEL Inhibitor;
CBR-001-584-483-4,RFM-004-096-0,CBR-001-584-483-4,CN(CCNC1=CC(=O)c2c(C1=O)nc(s2)C)C,CBR-HVAC-09452:Oncolytic Drugs; CDC25C Inhibitors;Signal Transduction Modulators; CDC25 Phosphatase Inhibitor;
CBR-001-584-484-5,RFM-004-097-1,CBR-001-584-484-5,COc1ccc(cc1OC)C(=O)CN(C(=O)/C=C/c1cccnc1)C,CBR-HVAC-09498:PHOSPHODIESTERASE 4; TGF BETA 1 RECEPTOR; TNF ALPHA Inhibitor; Inhibitor;
CBR-001-584-485-6,RFM-004-098-2,CBR-001-584-485-6,O=C(c1ccc(c(c1O)O)O)c1cc(O)c(c(c1)O)O,"CBR-HVAC-03722: Exifone is transformed inside the parasitized erythrocyte into a xanthone with potent antimalarial properties; Free radical scavenger; Tyrosinase Inhibitors; Cognition Disorders, Treatment of; Nootropic agent"
CBR-001-584-486-7,RFM-004-099-3,CBR-001-584-486-7,Clc1ccc2c(c1)nccc2Nc1ccccc1C(=O)OCCNC(=O)c1cccnc1,CBR-HVAC-10087:
CBR-001-584-487-8,RFM-004-100-9,CBR-001-584-487-8,CCOCCN(C(=O)C(Cl)Cl)Cc1ccc(cc1)Oc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-10102:
CBR-001-584-488-9,RFM-004-101-0,CBR-001-584-488-9,COc1ccc(cc1)CN(c1nccs1)CCN(C)C,CBR-HVAC-10121:
CBR-001-584-489-0,RFM-004-102-1,CBR-001-584-489-0,N#Cc1ccc2c(c1)C(=CC(C2=O)(C)C)n1ccccc1=O,"CBR-HVAC-10557:Hypertension, Treatment of;Bronchodilators; Potassium Channel Activators; Potassium channel Opener;"
CBR-001-584-490-3,RFM-004-103-2,CBR-001-584-490-3,OC(=O)CN1C(=O)C(=O)N(C1=O)Cc1cccc(c1)[N+](=O)[O-],"CBR-HVAC-10998:Diabetic Neuropathy, Agents for; Aldose Reductase Inhibitors; Aldose reductase Inhibitor;"
CBR-001-584-491-4,RFM-004-104-3,CBR-001-584-491-4,CCN(CCOc1cccc(c1)CNc1ncc2c(n1)n(C)c(=O)c(c2)c1ccccc1)CC,CBR-HVAC-11318:Protein tyrosine kinase Inhibitor;
CBR-001-584-492-5,RFM-004-105-4,CBR-001-584-492-5,CN(C(=O)CNc1nc(nc(c1Cl)c1ccccc1)c1ccc(cc1)C(F)(F)F)C1CC1,CBR-HVAC-11452:Protein tyrosine kinase; Mitogen-activated protein kinase Inhibitor; Modulator;
CBR-001-584-493-6,RFM-004-106-5,CBR-001-584-493-6,N#CC(c1nc2c(s1)cccc2)c1ccnc(n1)OCc1ccc(cc1)CN1CCOCC1,"CBR-HVAC-05924: JNK-mitogen-activated-protein-kinase-inhibitors; JNK1 inhibitor; JNK2 inhibitor; JNK3 inhibitor; Modulator; SAPK1 (JNK) Inhibitors; Signal Transduction Modulators; c-Jun N-terminal kinase 2; c-Jun N-terminal kinase 3; c-Jun N-terminal kinase Inhibitor; Anti-inflammatory; Cystic Fibrosis, Treatment of ; Endometriosis Therapy; Multiple Sclerosis, Agents for; Neurological Disorders; Surgery; Vasoprotectant; Women's Health"
CBR-001-584-494-7,RFM-004-107-6,CBR-001-584-494-7,CCOc1nnc(s1)c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-11698:TNF alpha; Interleukin 2; Interleukin 1 beta; Inducible nitric oxide synthase; COX-2 Antagonist; Inhibitor;
CBR-001-584-495-8,RFM-004-108-7,CBR-001-584-495-8,COc1cc(OC)cc(c1)Nc1nc2ccccc2nc1NS(=O)(=O)c1cccc(c1)NC(=O)c1ccc(c(c1)OC)C,CBR-HVAC-11856: Mistaken structure for XL-765
CBR-001-584-496-9,RFM-004-109-8,CBR-001-584-496-9,O=C1COCC2=C1C(c1ccc(c(c1)I)F)C1=C(N2)COCC1=O,CBR-HVAC-11931:Potassium channel Opener;
CBR-001-584-497-0,RFM-004-110-1,CBR-001-584-497-0,COc1ccc2c(c1)c1nc([nH]c1CCC2)c1ccncc1,CBR-HVAC-11954:Antiobesity Drugs; Neuropeptide Y5 (NPY Y5) Antagonists;Signal Transduction Modulators; Neuropeptide Y5 receptor Antagonist;
CBR-001-584-498-1,RFM-004-111-2,CBR-001-584-498-1,CCCS(=O)(=O)NC(=O)c1ccc(nn1)N(Cc1cc(Br)ccc1OCC1CC1)CC,CBR-HVAC-12040:Prostaglandin EP1 receptor Antagonist;
CBR-001-584-505-3,RFM-004-112-3,CBR-001-584-505-3,O=c1nc(C)[nH]c2c1CSCC2,CBR-HVAC-09325;Neuroprotectant; PARP inhibitor
CBR-001-584-506-4,RFM-004-113-4,CBR-001-584-506-4,Fc1ccc2c(c1)c(c([nH]2)C)c1nc2c([nH]1)c1cccnc1c1c2cccn1,"CBR-HVAC-00258; APTO-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) master transcription factor, leading to cell cycle inhibition and programmed cell death."
CBR-001-584-534-8,RFM-004-114-5,CBR-001-584-534-8,O=C(N1C[C@H](C[C@H]1C(=O)O)Sc1ccccc1)[C@@H](CSC(=O)c1ccccc1)C,"CBR-HVAC-00988: Hypertension, Treatment of;Acute Myocardial Infarction, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-584-535-9,RFM-004-115-6,CBR-001-584-535-9,O[C@@H](C[C@H](CC(=O)O)O)/C=C/c1c(nc(nc1c1ccc(cc1)F)N(S(=O)(=O)C)C)C(C)C,"CBR-HVAC-01998: Colorectal Cancer Therapy;Heart Failure Therapy;Atherosclerosis Therapy;Cardiovascular Diseases (Not Specified);Renal Failure, Agents for;Breast Cancer Therapy;Lipoprotein Disorders, Treatment of ;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Respiratory Disorders (Not Specified); HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor"
CBR-001-584-536-0,RFM-004-116-7,CBR-001-584-536-0,Oc1ccc(c(c1)S(=O)(=O)O)O,"CBR-HVAC-05497: Diabetic Retinopathy, Agents for;Hemostatics; Antioxidants;"
CBR-001-584-537-1,RFM-004-117-8,CBR-001-584-537-1,OC(=O)C(c1cccc(c1)Oc1ccccc1)C,"CBR-HVAC-03587: Osteoarthritis, Treatment of;Rheumatoid Arthritis, Treatment of;Non-Opioid Analgesics; Prostaglandin G/H synthase Inhibitor;"
CBR-001-584-538-2,RFM-004-118-9,CBR-001-584-538-2,OC[C@@H]1O[C@@H](O[C@H]([C@H](C(=O)N[C@@H]([C@H]([C@@H](C(=O)N[C@@H](C(=O)NCCc2scc(n2)c2ncc(s2)C(=O)NCCC[S+](C)C)[C@H](O)C)C)O)C)NC(=O)c2nc(nc(c2C)N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)c2nc[nH]c2)[C@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@H](CO)[C@H]([C@H]([C@@H]1O)OC(=O)N)O,analog of CBR-HVAC-08163
CBR-001-584-539-3,RFM-004-119-0,CBR-001-584-539-3,OC[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H]([C@H]([C@@H]3NC(=N)N)O)NC(=N)N)O[C@H]([C@]2(O)C=O)C)[C@H]([C@@H]([C@H]1O)O)NC,CBR-HVAC-02856: Treatment of Tuberculosis; 16S Ribosomal Protein Inhibitors;30S Ribosomal Protein Inhibitors;
CBR-001-584-540-6,RFM-004-120-3,CBR-001-584-540-6,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N1CC[N+](CC1)(C)C)C)CC[C@]1([C@H]3C[C@@H]([C@@H]1OC(=O)C)N1CC[N+](CC1)(C)C)C,CBR-HVAC-01987: Non-depolarizing Blocking Drugs;Neuromuscular Blockers; Muscarinic acetylcholine receptor Inhibitor; Neuromuscular nicotinic receptor antagonist
CBR-001-584-541-7,RFM-004-121-4,CBR-001-584-541-7,CCC(C(COC(=O)N)(COC(=O)N)C)C,CBR-HVAC-14290
CBR-001-584-542-8,RFM-004-122-5,CBR-001-584-542-8,COc1cc2c(cc1OC)CC[N+]([C@@H]2Cc1cc(OC)c(c(c1)OC)OC)(C)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc2c([C@H]1Cc1cc(OC)c(c(c1)OC)OC)cc(c(c2)OC)OC,CBR-HVAC-03693: Neuromuscular Blockers; Cholinergic receptor Antagonist;
CBR-001-584-543-9,RFM-004-123-6,CBR-001-584-543-9,CCOCCn1c(nc2c1cccc2)N1CCCN(CC1)C,"CBR-HVAC-01936: Urticaria, Treatment for;Antiallergic Ophthalmic Agents;Drugs for Allergic Rhinitis; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-584-544-0,RFM-004-124-7,CBR-001-584-544-0,OC(=O)C/C=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC=C2C(=O)O)/c1csc(n1)N,CBR-HVAC-02232: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-584-545-1,RFM-004-125-8,CBR-001-584-545-1,C=C=CCNCCCCNCC=C=C,CBR-HVAC-09180: Pharmacological Tools;Oncolytic Drugs;Prostate Cancer Therapy; Apoptosis Inducers;Polyamine Oxidase Inhibitors; Polyamine oxidase Inhibitor;
CBR-001-584-546-2,RFM-004-126-9,CBR-001-584-546-2,CN(CCn1nnnc1SCC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)Cc1csc(n1)N)C,CBR-HVAC-02164: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-584-547-3,RFM-004-127-0,CBR-001-584-547-3,CCCN1CCC[C@H]2[C@H]1Cc1cnc(nc1C2)N,CBR-HVAC-03412: Treatment of Male Sexual Dysfunction; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D3; Dopamine receptor D2 Agonist; Dopamine D2 receptor agonist
CBR-001-584-548-4,RFM-004-128-1,CBR-001-584-548-4,CN1CCN(CC1)CC(=O)n1c2ccccc2[nH]c(=O)c2c1c(C)sc2,CBR-HVAC-03033: Gastric Antisecretory Drugs;Antiulcer Drugs; Muscarinic Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Antagonist;
CBR-001-584-549-5,RFM-004-129-2,CBR-001-584-549-5,CCCCCCCCN=c1ccn(cc1)CCCCCCCCCCn1ccc(=NCCCCCCCC)cc1,"CBR-HVAC-01652: Atopic Dermatitis, Agents for;Wound-Healing Agents;Dermatologic Drugs;Dental Agents;Antibacterial Drugs; Membrane integrity inhibitor"
CBR-001-584-550-8,RFM-004-130-5,CBR-001-584-550-8,NCCNC(=O)c1ccc(cn1)Cl,"CBR-HVAC-03416: Cognition Disorders, Treatment of;Antidepressants;Antiparkinsonian Drugs; MAO-B Inhibitors; Monoamine oxidase B Inhibitor; Monoamine oxidase B inhibitor"
CBR-001-584-551-9,RFM-004-131-6,CBR-001-584-551-9,O=c1[nH]nc2n1ccc1c2cc(c(n1)c1ccc(cc1)C1(N)CCC1)c1ccccc1,CBR-HVAC-06769: Solid Tumors Therapy;Digestive/Gastrointestinal Cancer Therapy;Head and Neck Cancer Therapy;Endocrine Cancer Therapy;Liver Cancer Therapy;Oncolytic Drugs;Prostate Cancer Therapy;Ovarian Cancer Therapy;Renal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Female Reproductive System Cancer Therapy;Colorectal Cancer Therapy;Gastric Cancer Therapy;Pancreatic Cancer Therapy;Myeloid Leukemia Therapy;Breast Cancer Therapy;Lymphoma Therapy;Melanoma Therapy; Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators; Protein kinase B inhibitor
CBR-001-584-552-0,RFM-004-132-7,CBR-001-584-552-0,COc1c(ccc(c1OC)OC)CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F,"CBR-HVAC-01495: Antiglaucoma Agents;Migraine, Prophylactic Treatment of; Calcium Channel Blockers;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Calcium channel Antagonist; Calcium channel antagonist; Calcium receptor antagonist"
CBR-001-584-553-1,RFM-004-133-8,CBR-001-584-553-1,CN(CCNc1nc2cc(O)ccc2c2c1C(=O)c1c2cccc1)C,CBR-HVAC-04781: Oncolytic Drugs; DNA Topoisomerase I Inhibitors;DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; DNA topoisomerase II; DNA topoisomerase I Inhibitor;
CBR-001-584-554-2,RFM-004-134-9,CBR-001-584-554-2,COc1c(ccc(c1OC)OC)CN1CCNCC1,"CBR-HVAC-05111: Acute Myocardial Infarction, Treatment of;Angina pectoris, Treatment of; 3-Ketoacyl-CoA Thiolase (3-KAT) Inhibitors; Na+, K+ ATPase Inhibitor;"
CBR-001-584-555-3,RFM-004-135-0,CBR-001-584-555-3,O=C(c1ccc(cc1)CN1CCOCC1)N1CCN(CC1)C1CC1,"CBR-HVAC-06715: Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Histamine H3 receptor Antagonist; Histamine H3 receptor antagonist"
CBR-001-584-556-4,RFM-004-136-1,CBR-001-584-556-4,C[N+](CCC[N+]1(C)CC2CCC(C1)(C2(C)C)C)(C)C,CBR-HVAC-09246:
CBR-001-584-557-5,RFM-004-137-2,CBR-001-584-557-5,NCCNc1ccc(c2c1C(=O)c1cnccc1C2=O)NCCN,"CBR-HVAC-01934: Non-Hodgkin's Lymphoma Therapy;Multiple Sclerosis, Agents for;Breast Cancer Therapy;Myeloid Leukemia Therapy; Cytochrome P450 CYP1A2 Inhibitors;DNA Alkylating Drugs;DNA Topoisomerase II Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA inhibitor"
CBR-001-584-558-6,RFM-004-138-3,CBR-001-584-558-6,CN1CCC(=C2c3ccccc3CCc3c2nccc3)CC1,"CBR-HVAC-05114: Drugs for Allergic Rhinitis;Allergic Skin Disorders, Treatment for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Inhibitor;"
CBR-001-584-559-7,RFM-004-139-4,CBR-001-584-559-7,O=C1N(COP(=O)([O-])[O-])C(=O)NC1(c1ccccc1)c1ccccc1,"CBR-HVAC-02313: Stroke, Treatment of;Antiepileptic Drugs; Sodium Channel  Blockers; Sodium channel Blocker; Voltage-gated sodium channel antagonist"
CBR-001-584-560-0,RFM-004-140-7,CBR-001-584-560-0,COc1cc(Nc2ncc(c(n2)Nc2ccc3c(n2)N(COP(=O)(O)O)C(=O)C(O3)(C)C)F)cc(c1OC)OC,"CBR-HVAC-06322: Treatment of Renal Diseases;Myeloid Leukemia Therapy;Solid Tumors Therapy;Nephritis, Agents for;Antithrombocytopenic;Antianemics;Rheumatoid Arthritis, Treatment of;Non-Hodgkin's Lymphoma Therapy; Apoptosis Inducers;Flt3 (FLK2/STK1) Inhibitors;Signal Transduction Modulators;Syk Kinase Inhibitors; SPLEEN TYROSINE KINASE Inhibitor;"
CBR-001-584-561-1,RFM-004-141-8,CBR-001-584-561-1,C[C@H](Cc1ccc2c(c1)OC(O2)(C(=O)O)C(=O)O)NC[C@@H](c1cccc(c1)Cl)O,"CBR-HVAC-04237: Type 2 Diabetes, Agents for;Antiobesity Drugs; beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta 3 adrenoreceptor agonist"
CBR-001-584-562-2,RFM-004-142-9,CBR-001-584-562-2,O[C@@H]1[C@H](O)[C@H](O[C@H]1N1C=CCC(=C1)C(=O)N)COP(=O)(OP(=O)(OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2N)[O-])[O-],"CBR-HVAC-05427: Alzheimer's Dementia, Treatment of ;Antiparkinsonian Drugs;Pharmacological Tools;Fatigue, Treatment of;"
CBR-001-584-563-3,RFM-004-143-0,CBR-001-584-563-3,Clc1ccc2c(c1)nccc2Nc1cc(CNC(C)(C)C)c(c2c1CCCC2)O,CBR-HVAC-06627: Antimalarials;
CBR-001-584-564-4,RFM-004-144-1,CBR-001-584-564-4,CCC1=C[C@@H]2CN(C1)Cc1c3ccccc3[nH]c1[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N([C@@H]1[C@@]32CCN2[C@H]3[C@@](CC)(C=CC2)[C@H]([C@]1(O)C(=O)OC)OC(=O)C)C,CBR-HVAC-02230: Breast Cancer Therapy;Multiple Myeloma Therapy;Neurologic Cancer Therapy;Solid Tumors Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Non-Hodgkin's Lymphoma Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors; Tubulin Inhibitor; Tubulin inhibitor; Microtubule inhibitor; Vinca alkaloid; Apoptosis stimulant
CBR-001-584-565-5,RFM-004-145-2,CBR-001-584-565-5,OC(=O)[C@@H]1Cc2c(CN1C(=O)C(c1ccccc1)c1ccccc1)ncn2Cc1ccc(c(c1)C)N(C)C,"CBR-HVAC-04106: Hypertension, Treatment of;Pharmacological Tools; Angiotensin AT2 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 2 Antagonist; Angiotensin II 2 antagonist"
CBR-001-584-566-6,RFM-004-146-3,CBR-001-584-566-6,NCCC(C(=O)NC1CCNC(=O)C(NC(=O)C(CCN)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC(C)C)CC(C)C)CCN)C(O)C)NC(=O)C(C(O)C)NC(=O)C(NC(=O)CCCCC(C)C)CCN,CBR-HVAC-05484: Antibiotics
CBR-001-584-567-7,RFM-004-147-4,CBR-001-584-567-7,CNC[C@@H]1CC[C@H]([C@H](O1)O[C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@H]1OC[C@]([C@@H]([C@H]1O)NC)(C)O)N)N,CBR-HVAC-03067: Antibacterial Ophthalmic Drugs; 16S Ribosomal Protein Inhibitors;30S Ribosomal Protein Inhibitors;
CBR-001-584-568-8,RFM-004-148-5,CBR-001-584-568-8,NCCCCN([C@H]1CCCc2c1nccc2)Cc1nc2c([nH]1)cccc2,CBR-HVAC-00487: Anti-HIV Agents; Chemokine CXCR4 (SDF-1 Receptor) Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators; C-X-C chemokine receptor type 4 Antagonist; CXC chemokine receptor 4 antagonist; Chemokine receptor antagonist
CBR-001-584-569-9,RFM-004-149-6,CBR-001-584-569-9,O[C@H](CN1CCN(CC1)[C@@H]1c2ccccc2[C@@H]2[C@H](c3c1cccc3)C2(F)F)COc1cccc2c1cccn2,CBR-HVAC-04695: Myeloid Leukemia Therapy;Cancer Multidrug Resistance Modulators;Myelodysplastic Syndrome Therapy;Breast Cancer Therapy; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; P glycoprotein inhibitor
CBR-001-584-570-2,RFM-004-150-9,CBR-001-584-570-2,NCCCCC(C(=O)NC(C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(C(=O)N)CO)C)CO)CO)CC(=O)N)NC(=O)C(NC(=O)C(Cc1c[nH]c2c1cccc2)NC(=O)C(NC(=O)C(C(CC)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(C(O)C)NC(=O)C(NC(=O)C(C(O)C)NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(Cc1nc[nH]c1)N)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CC(C)C)CO)CCCCN)CCC(=O)N)CCSC)CCC(=O)O)CCC(=O)O)CCC(=O)O)C)CCCNC(=N)N)CC(C)C)Cc1ccccc1)CCC(=O)O)CC(C)C,"CBR-HVAC-12634: GLP-1 Receptor Agonists; Insulin Secretagogues; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Antiobesity Drugs; Antiparkinsonian Drugs; Cardioprotective Agents; Coronary Bypass Surgery; Type 2 Diabetes, Agents for"
CBR-001-584-571-3,RFM-004-151-0,CBR-001-584-571-3,OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)CCCNC(=N)N)CC(C)C)COC(C)(C)C)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1[nH]cnc1,"CBR-HVAC-02903: Prostate Cancer Therapy;Endometriosis Therapy;Breast Cancer Therapy;Female Infertility, Agents for; GnRH (LHRH) Agonists;Signal Transduction Modulators; Luteinizing hormone-releasing hormone Agonist;"
CBR-001-584-572-4,RFM-004-152-1,CBR-001-584-572-4,CC(=O)O[C@H]1Cc2ccccc2N(c2c1cccc2)C(=O)N,"CBR-HVAC-05227: Bipolar Disorder, Treatment of;Neuropathic Pain, Treatment of;Antiepileptic Drugs;Diabetic Neuropathy, Agents for; Sodium Channel  Blockers; SODIUM CHANNEL Blocker; Voltage-gated sodium channel antagonist"
CBR-001-584-573-5,RFM-004-153-2,CBR-001-584-573-5,Oc1cccc(c1)O,analog of CBR-HVAC-09137
CBR-001-584-574-6,RFM-004-154-3,CBR-001-584-574-6,NC(C(=O)O)CCCN,"CBR-HVAC-00829: Agents for Liver Cirrhosis;Metabolic Disorders (Not Specified);Liver and Biliary Tract Disorders, Treatment of; NF-kappaB (NFKB) Modulators;Signal Transduction Modulators; Glutamine synthetase Stimulator; Ammonia scavenger"
CBR-001-584-575-7,RFM-004-155-4,CBR-001-584-575-7,OC(=O)CCCN1CCC(CC1)O[C@H](c1ccccn1)c1ccc(cc1)Cl,"CBR-HVAC-01984: Atopic Dermatitis, Agents for;Drugs for Allergic Rhinitis;Antiallergic Ophthalmic Agents;Urticaria, Treatment for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; P-Glycoprotein Inhibitor; Histamine H1 receptor antagonist"
CBR-001-584-576-8,RFM-004-156-5,CBR-001-584-576-8,O=C1Nc2c(C1)cc(cc2)Nc1ncc(c(n1)NCc1cccnc1N(S(=O)(=O)C)C)C(F)(F)F,CBR-HVAC-11722: Solid Tumors Therapy; Focal Adhesion Kinase 1 (FADK1; PTK2) Inhibitors;Focal Adhesion Kinase 2 (FADK2; PTK2B; PYK2) Inhibitors;Signal Transduction Modulators; Focal adhesion kinase Inhibitor;
CBR-001-584-577-9,RFM-004-157-6,CBR-001-584-577-9,C[N@@+]12CCCC[C@@H]2CCC(=C(c2cccs2)c2cccs2)C1,CBR-HVAC-01990: Antispasmodics; Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist
CBR-001-584-578-0,RFM-004-158-7,CBR-001-584-578-0,O=C(C(c1ccccc1)(C1CCCC1)O)OC1CC[N+](C1)(C)C,CBR-HVAC-00146: ; MUSCARINIC RECEPTOR Antagonist; Long-acting muscarinic antagonist; Muscarinic M3 receptor antagonist
CBR-001-584-579-1,RFM-004-159-8,CBR-001-584-579-1,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N1CCCCC1)C)CC[C@]1([C@H]3C[C@@H]([C@@H]1OC(=O)C)[N+]1(C)CCCCC1)C,CBR-HVAC-01363: Non-depolarizing Blocking Drugs; Nicotinic acetylcholine receptor Inhibitor; Neuromuscular nicotinic receptor antagonist
CBR-001-584-580-4,RFM-004-160-1,CBR-001-584-580-4,CCC(C(c1ccccc1)C(=O)OCC[N+](CC)(CC)C)C,CBR-HVAC-02452: ; Acetylcholine receptor antagonist
CBR-001-584-581-5,RFM-004-161-2,CBR-001-584-581-5,COCCn1c(C)[n+](c2c1C(=O)c1ccccc1C2=O)Cc1cnccn1,CBR-HVAC-06314: Melanoma Therapy;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Prostate Cancer Therapy; Apoptosis Inducers;Signal Transduction Modulators;Survivin Inhibitors; Survivin Inhibitor;
CBR-001-584-582-6,RFM-004-162-3,CBR-001-584-582-6,OC(C12CC[N+](CC1)(CC2)CCOCc1ccccc1)(c1ccccc1)c1ccccc1,"CBR-HVAC-06581: Asthma Therapy;Dermatologic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Cytochrome P450 CYP2D6 Inhibitors;Muscarinic M3 Antagonists;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators; M3 MUSCARINIC RECEPTOR Inhibitor;"
CBR-001-584-583-7,RFM-004-163-4,CBR-001-584-583-7,N#Cc1ccccc1Cn1c(cc(=O)n(c1=O)C)N1CCC[C@H](C1)N,"CBR-HVAC-01476: Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; DIPEPTIDYL PEPTIDASE 4 Inhibitor; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue; Protease/peptidase inhibitor; Dipeptide hydrolase inhibitor"
CBR-001-584-584-8,RFM-004-164-5,CBR-001-584-584-8,[O-]C(=O)CN(CC(=O)[O-])CCN(CC(=O)[O-])CC(=O)[O-],CBR-HVAC-07080: Antagonists to Metals;Treatment of Poisoning;
CBR-001-584-585-9,RFM-004-165-6,CBR-001-584-585-9,Oc1ccc2c(c1)c(C)c(n2Cc1ccc(cc1)OCCN1CCCCCC1)c1ccc(cc1)O,"CBR-HVAC-01432: Endometriosis Therapy;Treatment of Osteoporosis;Hematologic Genetic Disorders, Treatment of ;Treatment of Postmenopausal Syndrome ; Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators; Estrogen receptor Modulator; Estrogen receptor agonist; Selective estrogen receptor modulator; Bone resorption inhibitor"
CBR-001-584-586-0,RFM-004-166-7,CBR-001-584-586-0,NC(=O)[C@@H](NCc1ccc(cc1)OCc1cccc(c1)F)C,"CBR-HVAC-00092: Antiepileptic Drugs;Antiparkinsonian Drugs;Stroke, Treatment of;Restless Legs Syndrome, Treatment of; Calcium Channel Modulators;Dopamine Reuptake Inhibitors;Glutamate Release Inhibitors;MAO-B Inhibitors;Signal Transduction Modulators;Sodium Channel  Blockers; Sodium channel; Calcium channel Antagonist; Monoamine oxidase B inhibitor; Sodium channel antagonist; Calcium channel antagonist; Glutamate release inhibitor; Dopamine reuptake inhibitor"
CBR-001-584-587-1,RFM-004-167-8,CBR-001-584-587-1,ClCC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCN(C)C)/c1ccccc1,"CBR-HVAC-01765: Chemopreventive Agents;Breast Cancer Therapy;Bone Diseases, Treatment of; Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators; Estrogen receptor Inhibitor; Estrogen receptor antagonist; Selective estrogen receptor modulator"
CBR-001-584-588-2,RFM-004-168-9,CBR-001-584-588-2,CCCc1nn(c2c1nc([nH]c2=O)c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC1)C)C,"CBR-HVAC-02568: Cardiovascular Diseases (Not Specified);Lymphoma Therapy;Treatment of Dysmenorrhea;Respiratory Disorders (Not Specified);Heart Failure Therapy;Vasodilators;Oncolytic Drugs;Diabetes Insipidus, Agents for;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Hematopoiesis Disorders Therapy;Pulmonary Hypertension, Treatment of;Stroke, Treatment of;Treatment of Erectile Dysfunction;Interstitial Lung Diseases, Treatment of;Age-Related Macular Degeneration, Treatment of;Muscular Dystrophy, Agents for;Treatment of Female Sexual Dysfunction; AMP-Activated Protein Kinase (AMPK) Activators;Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands;Insulin Sensitizers;Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor"
CBR-001-584-589-3,RFM-004-169-0,CBR-001-584-589-3,CCN(CCCc1ccccc1)CCCc1ccccc1,CBR-HVAC-03167: Antispasmodics;
CBR-001-584-590-6,RFM-004-170-3,CBR-001-584-590-6,COCC1(CCN(CC1)CCc1cccs1)N(c1ccccc1)C(=O)CC,CBR-HVAC-03368: Opioid Analgesics; Drugs Acting on Opioid and Opioid-Like Receptors;Signal Transduction Modulators; Opioid receptor mu Agonist; Opioid mu receptor agonist;2016-04-01: controlled substance
CBR-001-584-591-7,RFM-004-171-4,CBR-001-584-591-7,CCN(c1cc(NC)[n+](c(n1)C)C)c1ccccc1,"CBR-HVAC-04369: Angina pectoris, Treatment of; HCN [I(h)] Blockers; Sodium channel antagonist; Potassium channel antagonist; HCN channel antagonist"
CBR-001-584-592-8,RFM-004-172-5,CBR-001-584-592-8,Oc1cc(O)c2c(c1)[o+]c(c(c2)O)c1cc(O)c(c(c1)O)O,CBR-HVAC-00415: Cardiovascular Diseases (Not Specified);Oncolytic Drugs; Angiogenesis Inhibitors;EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Membrane permeability inhibitor; Free radical scavenger
CBR-001-584-593-9,RFM-004-173-6,CBR-001-584-593-9,CN(c1ccc2c(c1)sc1c(n2)ccc(=[N+](C)C)c1)C,"CBR-HVAC-02409: Analgesic Drugs;Diagnostic for Cancer;Hematologic Agents (Miscellaneous);Septic Shock, Treatment of ;Hematopoiesis Disorders Therapy;Bipolar Disorder, Treatment of;Antimalarials;Antiparkinsonian Drugs;Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of; MAO Inhibitors;Nitric Oxide (NO) Production Inhibitors;Tau Aggregation Inhibitors; Glutathione reductase Inhibitor; Tau aggregation inhibitor"
CBR-001-584-594-0,RFM-004-174-7,CBR-001-584-594-0,CCCCCCCCCCCCCCCC[n+]1ccccc1,CBR-HVAC-04934: Antiulcer Drugs;Antifungal Agents;Anti-Helicobacter Pylori Agents;Antibacterial Drugs;
CBR-001-584-595-1,RFM-004-175-8,CBR-001-584-595-1,Fc1cccc(c1)N(C(=O)O[C@H]1CN2CCC1CC2)Cc1cc(F)c(c(c1)F)F,CBR-HVAC-00573: Urinary Incontinence Therapy; Muscarinic M3 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M3 Antagonist; Muscarinic M3 receptor antagonist; Long-acting muscarinic antagonist
CBR-001-584-596-2,RFM-004-176-9,CBR-001-584-596-2,CCN(Cc1nccn1c1ccc(cc1C(=O)c1ccccc1Cl)[N+](=O)[O-])CC,"CBR-HVAC-02200: Cognition Disorders, Treatment of; Ion channel antagonist"
CBR-001-584-597-3,RFM-004-177-0,CBR-001-584-597-3,Oc1cc2O[C@H](c3ccc(c(c3)O)O)[C@H](Cc2c(c1)O)O,"CBR-HVAC-14445: Antioxidants; Drugs Acting on Quorum Sensing Signaling; Fatty Acid Synthase (FAS) Inhibitors; Free radical scavenger; Immunostimulant; LDL Antioxidants; Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers; Reducing agent; beta-Secretase (BACE) Inhibitors; Chemopreventive Agents; Hepatoprotectants; Lipoprotein Disorders, Treatment of ; Treatment of Autoimmune Diseases"
CBR-001-584-598-4,RFM-004-178-1,CBR-001-584-598-4,CCOC(=O)[C@@H](N[C@H]1CCCN2N(C1=O)[C@@H](CCC2)C(=O)O)CCc1ccccc1,CBR-HVAC-01918: ; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor
CBR-001-584-599-5,RFM-004-179-2,CBR-001-584-599-5,CNCc1ccc(cc1)c1[nH]c2c3c1CCNC(=O)c3cc(c2)F,CBR-HVAC-00858: Breast Cancer Therapy;Antineoplastic Enhancing Agents;Pancreatic Cancer Therapy;Ovarian Cancer Therapy; DNA Repair Inhibitors;Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors;Signal Transduction Modulators; Poly(ADP-ribose) polymerase Inhibitor; ADP ribose polymerase 1 inhibitor; ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor
CBR-001-584-600-1,RFM-004-180-5,CBR-001-584-600-1,CC(NCCc1ccccc1)C,analog of CBR-HVAC-02356
CBR-001-584-601-2,RFM-004-181-6,CBR-001-584-601-2,COc1cc(CCNCC(COc2cccc(c2)C)O)ccc1OC,"CBR-HVAC-01833: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; BETA-1 ADRENERGIC RECEPTOR Blocker; Beta 1 adrenoreceptor antagonist"
CBR-001-584-602-3,RFM-004-182-7,CBR-001-584-602-3,CCC1(Cc2c(C1)cccc2)c1c[nH]cn1,CBR-HVAC-03487: Treatment of Male Sexual Dysfunction; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Antagonist; Alpha 2 adrenoreceptor antagonist
CBR-001-584-603-4,RFM-004-183-8,CBR-001-584-603-4,Clc1ccc2c(c1NC1=NCCN1)nsn2,CBR-HVAC-01401: Antispastic Drugs; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Agonist; Alpha 2 adrenoreceptor agonist
CBR-001-584-604-5,RFM-004-184-9,CBR-001-584-604-5,O=C1N(CCc2c1c1ccccc1n2C)Cc1[nH]cnc1C,"CBR-HVAC-02815: 5 Hydroxytryptamine 3 receptor antagonist; 5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; Analgesic; Irritable Bowel Syndrome, Agents for; Non-Ulcer Dyspepsia, Agents for"
CBR-001-584-605-6,RFM-004-185-0,CBR-001-584-605-6,OC(CN1CCCC1)COc1ccccc1C,analog of CBR-HVAC-09935
CBR-001-584-606-7,RFM-004-186-1,CBR-001-584-606-7,OCC(=O)[C@@]1(O)C[C@H](O[C@@H]2C[C@@H](N)[C@@H]([C@H](O2)C)O)c2c(C1)c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2OC,CBR-HVAC-14431: DNA Topoisomerase II Inhibitors; DNA synthesis inhibitor; DNA topoisomerase II inhibitor; RNA synthesis inhibitor; Radical formation stimulant; Antineoplastic Antibiotics; Breast Cancer Therapy; Head and Neck Cancer Therapy; Lung Cancer Therapy; Lymphocytic Leukemia Therapy; Melanoma Therapy; Non-Hodgkin's Lymphoma Therapy; Sarcoma Therapy
CBR-001-584-607-8,RFM-004-187-2,CBR-001-584-607-8,CN([C@@H]1C(=C(C(=O)N)C(=O)[C@@]2([C@H]1CC1C(=C2O)C(=O)c2c([C@@]1(C)O)c(Cl)ccc2O)O)O)C,CBR-HVAC-14291
CBR-001-584-608-9,RFM-004-188-3,CBR-001-584-608-9,O=C(c1cccc2c1oc(c1ccccc1)c(c2=O)C)OCCN1CCCCC1,CBR-HVAC-02169: Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist
CBR-001-584-609-0,RFM-004-189-4,CBR-001-584-609-0,OC[C@H]1O[C@@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]([C@@H](c4ccc(O3)c(Cl)c4)O)NC(=O)[C@@H](CC(C)C)NC)c3ccc(c(c3)c3c(O)cc(cc3[C@H](NC2=O)C(=O)O)O)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@@H](C)[C@H]([C@@](C1)(C)N)O,CBR-HVAC-03517: Antibacterial Ophthalmic Drugs;Antibiotics;Antibacterial Drugs;Treatment of Neutropenia; Cell Wall Biosynthesis Inhibitors; Penicillin binding protein 2 Binder;
CBR-001-584-610-3,RFM-004-190-7,CBR-001-584-610-3,NC(=O)Nc1cc(sc1C(=O)N[C@H]1CCCNC1)c1cccc(c1)F,CBR-HVAC-11893: Antineoplastic Enhancing Agents;Solid Tumors Therapy; Checkpoint Kinase 1 (Chk1) Inhibitors;Checkpoint Kinase 2 (Chk2) Inhibitors;Signal Transduction Modulators; Checkpoint kinase 1 Inhibitor;
CBR-001-584-611-4,RFM-004-191-8,CBR-001-584-611-4,NCc1c[nH]c(=S)n1[C@H]1CCc2c(C1)cc(cc2F)F,CBR-HVAC-00408: ; DOPAMINE BETA-HYDROXYLASE Inhibitor; Alpha adrenoreceptor antagonist
CBR-001-584-612-5,RFM-004-192-9,CBR-001-584-612-5,CCCN([C@H]1CCc2c(C1)cccc2O)CCc1cccs1,"CBR-HVAC-00950: Antiparkinsonian Drugs;Neuropathic Pain, Treatment of;Restless Legs Syndrome, Treatment of; Dopamine D2 Agonists;Dopamine D3 Agonists;Signal Transduction Modulators; Dopamine receptor D1; Dopamine receptor D2; Dopamine receptor D3 Agonist; Dopamine D2 receptor agonist"
CBR-001-584-613-6,RFM-004-193-0,CBR-001-584-613-6,C=CCN1CCCC1CNC(=O)c1cc2nn[nH]c2cc1OC,"CBR-HVAC-01823: Nausea and Vomiting, Treatment of; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor Antagonist; Dopamine receptor antagonist"
CBR-001-584-614-7,RFM-004-194-1,CBR-001-584-614-7,Clc1cccc(c1)COc1ccccc1C(=C)n1cncc1,CBR-HVAC-02292: Antifungal Agents; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-584-615-8,RFM-004-195-2,CBR-001-584-615-8,CC(NCC(c1ccc(cc1)NS(=O)(=O)C)O)C,CBR-HVAC-02337: ; Beta adrenergic receptor Antagonist; Potassium channel antagonist; Polarisation inhibitor
CBR-001-584-616-9,RFM-004-196-3,CBR-001-584-616-9,CCOC(=O)C(c1ccccc1)C1CCCCN1,CBR-HVAC-06215: Neurologic Drugs (Miscellaneous); Dopamine Reuptake Inhibitors;Dopamine Transporter (DAT) Ligands;Norepinephrine Transporter (NET) Inhibitors;Signal Transduction Modulators;
CBR-001-584-617-0,RFM-004-197-4,CBR-001-584-617-0,OC(=O)C1=CCCN(C1)CCOC(c1ccc(cc1)C(F)(F)F)c1ccc(cc1)C(F)(F)F,CBR-HVAC-03968: Antiepileptic Drugs; GAT-1 Inhibitors; GABA transporter Inhibitor; GABA uptake inhibitor
CBR-001-584-618-1,RFM-004-198-5,CBR-001-584-618-1,CCNCc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,"CBR-HVAC-04287: Stroke, Treatment of;Inflammatory Bowel Disease, Agents for;Antiarthritic Drugs; Lipid Peroxidation Inhibitors; Reducing agent"
CBR-001-584-619-2,RFM-004-199-6,CBR-001-584-619-2,NC1CCN(CC1)c1cccc(n1)Cl,CBR-HVAC-04497: Antidepressants; Signal Transduction Modulators;5-HT3 Agonists; 5-HYDROXYTRYPTAMINE 3 RECEPTOR Agonist;
CBR-001-584-620-5,RFM-004-200-2,CBR-001-584-620-5,Cc1ccc(cc1)/C(=C\CN1CCCC1)/c1ccccn1,"CBR-HVAC-04643: Drugs for Allergic Rhinitis;Allergic Skin Disorders, Treatment for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine receptor Antagonist;"
CBR-001-584-621-6,RFM-004-201-3,CBR-001-584-621-6,CN([C@H](c1ccccc1)CCOc1cccc2c1cccc2)C,CBR-HVAC-01725: Antidepressants; Signal Transduction Modulators;5-HT Reuptake Inhibitors; Serotonin transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor
CBR-001-584-622-7,RFM-004-202-4,CBR-001-584-622-7,NCC(c1ccccc1)CC(=O)O,CBR-HVAC-06766: Antidepressants;Anxiolytics;Treatment of Alcohol Dependency; GABA(B) Receptor Agonists;Signal Transduction Modulators;
CBR-001-584-623-8,RFM-004-203-5,CBR-001-584-623-8,CCCN1CCO[C@@H]2[C@H]1COc1c2cc(cc1)O,CBR-HVAC-09311: Antiparkinsonian Drugs;Antihypermotility Agents;Antipsychotic Drugs; Dopamine D2 Agonists;Dopamine D3 Agonists;Signal Transduction Modulators; Dopamine receptor D3 Agonist;
CBR-001-584-624-9,RFM-004-204-6,CBR-001-584-624-9,CN([C@@H]1C(=C(C(=O)N)C(=O)[C@@]2([C@H]1[C@@H](O)[C@@H]1C(=C)c3cccc(c3C(=O)C1=C2O)O)O)O)C,CBR-HVAC-09617: ; 16S-rRNA of 30S ribosomal subunit Binder;
CBR-001-584-625-0,RFM-004-205-7,CBR-001-584-625-0,NC1=N[C@H](N=C(N1)N(C)C)C,"CBR-HVAC-00637: Type 2 Diabetes, Agents for; AMP-Activated Protein Kinase (AMPK) Activators;Signal Transduction Modulators; Gluconeogenesis inhibitor"
CBR-001-584-626-1,RFM-004-206-8,CBR-001-584-626-1,NCC(=O)N1C[C@@H](C[C@H]1C(=O)O)NC(=O)c1ccccc1,"CBR-HVAC-00716: Acute Myocardial Infarction, Treatment of;Antiarrhythmic Drugs; Gap junction modulators; Gap junction protein Modulator; Gap junction inhibitor; Gap junction stimulant"
CBR-001-584-627-2,RFM-004-207-9,CBR-001-584-627-2,O=C(c1cc2c(s1)c(Cl)ccc2)N[C@H]1CN2CCC1CC2,"CBR-HVAC-00848: Alzheimer's Dementia, Treatment of ;Smoking Cessation, Aid to;Cognition Disorders, Treatment of;Antipsychotic Drugs; Nicotinic alpha7 Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha7 Agonist; Alpha-7 nicotinic receptor agonist"
CBR-001-584-628-3,RFM-004-208-0,CBR-001-584-628-3,CN(c1ccc2c(c1)nn(c2C)C)c1ccnc(n1)Nc1ccc(c(c1)S(=O)(=O)N)C,CBR-HVAC-01453: ; Vascular endothelial growth factor receptor Inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist
CBR-001-584-629-4,RFM-004-209-1,CBR-001-584-629-4,O=C1N(C[C@@H]2c3c1cccc3CCC2)[C@@H]1CN2CCC1CC2,"CBR-HVAC-01710: Nausea and Vomiting, Treatment of; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-584-630-7,RFM-004-210-4,CBR-001-584-630-7,CNCCCCOc1ccccc1Cc1ccccc1,"CBR-HVAC-01730: Cognition Disorders, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Norepinephrine transporter Inhibitor; Adrenergic transmitter uptake inhibitor; Acetylcholine release stimulant; Reducing agent"
CBR-001-584-631-8,RFM-004-211-5,CBR-001-584-631-8,CCOC(=O)C(NC1CCc2c(N(C1=O)CC(=O)O)cccc2)CCc1ccccc1,"CBR-HVAC-02160: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin I converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-584-632-9,RFM-004-212-6,CBR-001-584-632-9,N#Cc1cc(c([nH]c1=O)C)c1ccc2n(c1)ccn2,CBR-HVAC-02240: Heart Failure Therapy; Phosphodiesterase 3 Inhibitor; Phosphodiesterase 4 inhibitor; Phosphodiesterase 3 inhibitor
CBR-001-584-633-0,RFM-004-213-7,CBR-001-584-633-0,COc1cc(CCO[C@@H]2CCCC[C@H]2N2CC[C@H](C2)O)ccc1OC,CBR-HVAC-02282: Antiarrhythmic Drugs; Cytochrome P450 CYP2D6 Inhibitors;K(ir) 3.1/3.4 (GIRK1/4; KCNJ3/5) Heterodimeric IKACh Channel Blockers;K(V) 1.5 (KCNA5) Channel Blockers;Sodium Channel  Blockers; Potassium channel antagonist; Voltage-gated sodium channel antagonist
CBR-001-584-634-1,RFM-004-214-8,CBR-001-584-634-1,O=C(COC(=O)C)NCCCOc1cccc(c1)CN1CCCCC1,CBR-HVAC-02311: Gastric Antisecretory Drugs; Histamine H2 Receptor Antagonists;Signal Transduction Modulators; Histamine H2 Receptor Antagonist; Histamine H2 receptor antagonist
CBR-001-584-635-2,RFM-004-215-9,CBR-001-584-635-2,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccc(c(c4cc3Cn1c2=O)CN(C)C)O,CBR-HVAC-02637: ; DNA topoisomerase I Inhibitor; DNA topoisomerase I inhibitor
CBR-001-584-636-3,RFM-004-216-0,CBR-001-584-636-3,O=C1N(CCc2c1c1ccccc1n2C)Cc1nc[nH]c1C,"CBR-HVAC-02815: Non-Ulcer Dyspepsia, Agents for;Irritable Bowel Syndrome, Agents for; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-584-637-4,RFM-004-217-1,CBR-001-584-637-4,CN(CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F)C,CBR-HVAC-03110: Antipsychotic Drugs; Nicotinic alpha7 Receptor Ligands;Signal Transduction Modulators;
CBR-001-584-638-5,RFM-004-218-2,CBR-001-584-638-5,OC(COc1cccc2c1CCC(=O)N2)CNC(C)(C)C,"CBR-HVAC-03153: Angina pectoris, Treatment of;Antiglaucoma Agents;Hypertension, Treatment of;Antiarrhythmic Drugs; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Inhibitor; Beta adrenoreceptor antagonist"
CBR-001-584-639-6,RFM-004-219-3,CBR-001-584-639-6,Clc1cc2N(C)C(=O)COc2c(c1)C(=O)NC1CN2CCC1CC2,"CBR-HVAC-03986: Disorders Associated with Cancer Therapy, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist;"
CBR-001-584-640-9,RFM-004-220-6,CBR-001-584-640-9,NC/C(=C/F)/CCc1ccc(cc1)F,"CBR-HVAC-03994: Antiparkinsonian Drugs;Cognition Disorders, Treatment of; MAO-B Inhibitors; Monoamine oxidase B Inhibitor; Monoamine oxidase B inhibitor"
CBR-001-584-641-0,RFM-004-221-7,CBR-001-584-641-0,ClCCN(c1ccc2c(c1)nc(n2C)CCCC(=O)O)CCCl,CBR-HVAC-04704: Lymphocytic Leukemia Therapy;Neurologic Cancer Therapy;Lymphoma Therapy;Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy;Leukemia Therapy;Small Cell Lung Cancer Therapy;Ovarian Cancer Therapy;Multiple Myeloma Therapy;Breast Cancer Therapy;Hematological Cancer Therapy; Antimetabolites;Apoptosis Inducers;DNA Alkylating Drugs;
CBR-001-584-642-1,RFM-004-222-8,CBR-001-584-642-1,CCN(CCCCC(c1ccccc1)NC(=O)c1ccc(cc1)[N+](=O)[O-])CC,CBR-HVAC-04735: Antiarrhythmic Drugs; Potassium Channel Blockers; POTASSIUM CHANNEL Blocker;
CBR-001-584-643-2,RFM-004-223-9,CBR-001-584-643-2,O=c1[nH]c(CN2CCCC2=N)c(c(=O)[nH]1)Cl,CBR-HVAC-05078: Inhibitors of the Degradation of Anticancer Drugs;Oncolytic Drugs;Antineoplastic Enhancing Agents; Angiogenesis Inhibitors;Thymidine Phosphorylase Inhibitors;
CBR-001-584-644-3,RFM-004-224-0,CBR-001-584-644-3,OC(C1CC2CC1C=C2)(c1ccccc1)CCN1CCCCC1,CBR-HVAC-05122: Antiparkinsonian Drugs; Anticholinergics;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Antagonist;
CBR-001-584-645-4,RFM-004-225-1,CBR-001-584-645-4,CCc1ccc(cc1)OCc1ccccc1C(=O)Nc1ccc2c(c1)c(N)cc(n2)C,"CBR-HVAC-05457: Opioid Analgesics; ORL1 (OP4, NOP) Antagonists;Signal Transduction Modulators; Opioid receptor like 1 Antagonist;"
CBR-001-584-646-5,RFM-004-226-2,CBR-001-584-646-5,CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(C2=O)NC(=O)/C(=C/C=C\[C@@H]([C@H](/C(=C/[C@@H]([C@H]1O)C)/C)OC(=O)N)OC)/C,CBR-HVAC-05688: Lymphoma Therapy;Hematological Cancer Therapy;Breast Cancer Therapy;Solid Tumors Therapy; Heat Shock Protein 90 (HSP90) Inhibitors; HEAT SHOCK PROTEIN 90 Inhibitor; Heat shock protein 90 antagonist
CBR-001-584-647-6,RFM-004-227-3,CBR-001-584-647-6,Clc1ccc2c(c1)[C@@H](C)CNCC2,"CBR-HVAC-05995: Antiobesity Drugs;Preventive Agents;Treatment of Cocaine Dependency;Smoking Cessation, Aid to; Signal Transduction Modulators;5-HT2C Agonists; 5-Hydroxytryptamine 2C receptor Agonist; 5 Hydroxytryptamine 2C receptor agonist"
CBR-001-584-648-7,RFM-004-228-4,CBR-001-584-648-7,O=C(Nc1cn2c(c1C)c(ncn2)Nc1ccc2c(c1)cnn2Cc1cccc(c1)F)OC[C@@H]1COCCN1,CBR-HVAC-06179: EGFR (HER1; erbB1) Inhibitors; EGFR kinase inhibitor; Epidermal growth factor receptor 1; Epidermal growth factor receptor 2; Epidermal growth factor receptor 4 Inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-3 antagonist; ErbB-4 tyrosine kinase inhibitor; HER2 (erbB2) Inhibitors; HER3 (erbB3) Inhibitors; HER4 (erbB4) Inhibitors; Signal Transduction Modulators; Anticancer; Neurologic Cancer Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-584-649-8,RFM-004-229-5,CBR-001-584-649-8,CNC(=O)[C@H](N1CCc2c([C@@H]1CCc1ccc(cc1)C(F)(F)F)cc(c(c2)OC)OC)c1ccccc1,"CBR-HVAC-06334: Sleep Disorders, Treatment of;Treatment of Eating Disorders; Cytochrome P450 CYP3A4 Inhibitors;Orexin OX-1 Antagonists;Orexin OX-2 Antagonists;Signal Transduction Modulators; Orexin receptor Antagonist; Orexin receptor antagonist"
CBR-001-584-650-1,RFM-004-230-8,CBR-001-584-650-1,c1ccc(cc1)CN(c1ccccc1)CC1=NCCN1,CBR-HVAC-09538: ; Histamine H1 receptor Inhibitor;
CBR-001-584-651-2,RFM-004-231-9,CBR-001-584-651-2,CC1NCCOC1c1ccccc1,CBR-HVAC-09636: ;2016-04-01: controlled substance
CBR-001-584-652-3,RFM-004-232-0,CBR-001-584-652-3,CCN(CCOC(=O)C(c1ccccc1)(c1ccccc1)O)CC,CBR-HVAC-09749: ; Muscarinic acetylcholine receptor Antagonist;
CBR-001-584-653-4,RFM-004-233-1,CBR-001-584-653-4,CC(Cc1ccc(cc1)Cl)(N)C,CBR-HVAC-09760: ;2016-04-01: controlled substance
CBR-001-584-654-5,RFM-004-234-2,CBR-001-584-654-5,COc1ccc(cc1)CC(N)C,CBR-HVAC-09853: ; Phenylethanolamine N-methyltransferase; 5-Hydroxytryptamine receptor Inhibitor; ;2016-04-01: controlled substance
CBR-001-584-655-6,RFM-004-235-3,CBR-001-584-655-6,CNC(Cc1ccccc1OC)C,CBR-HVAC-10083: ; Beta-1 adrenergic receptor Agonist;
CBR-001-584-656-7,RFM-004-236-4,CBR-001-584-656-7,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccc(cc4c(c3Cn1c2=O)CC)OC(=O)N1CCC(CC1)N1CCCCC1,CBR-HVAC-00280: Anticancer; DNA topoisomerase I inhibitor
CBR-001-584-657-8,RFM-004-237-5,CBR-001-584-657-8,CN/C(=N/C)/NCc1ccccc1,CBR-HVAC-02515: ; Dopamine receptor D2 Antagonist; Alpha adrenoreceptor antagonist
CBR-001-584-658-9,RFM-004-238-6,CBR-001-584-658-9,NC(=NCc1ccc2c(c1)OCCO2)N,CBR-HVAC-09131:
CBR-001-584-659-0,RFM-004-239-7,CBR-001-584-659-0,OCCn1c(N)cc[n+]1CC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N\OC)/c1csc(n1)N,CBR-HVAC-04216: Antibiotics; Cell wall synthesis inhibitor
CBR-001-584-660-3,RFM-004-240-0,CBR-001-584-660-3,C[N+]1(CCCCC1)CC1COC(O1)(C1CCCCC1)c1ccccc1,analog of CBR-HVAC-05612
CBR-001-584-661-4,RFM-004-241-1,CBR-001-584-661-4,CCC(c1ccccc1)(C(=O)OC1CC2CCC(C1)[N+]2(C)C)CO,CBR-HVAC-05324: Bronchodilators;
CBR-001-584-662-5,RFM-004-242-2,CBR-001-584-662-5,CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3C)CO,CBR-HVAC-03094: Antidiarrheal Agents;Antimigraine Drugs; 5-Hydroxytryptamine 7 receptor Antagonist;
CBR-001-584-663-6,RFM-004-243-3,CBR-001-584-663-6,CCc1cc2CC(Cc2cc1CC)NC[C@@H](c1ccc(c2c1ccc(=O)[nH]2)O)O,"CBR-HVAC-00790: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy;Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor; Muscarinic acetylcholine receptor Antagonist; Agonist; Long-acting beta 2 adrenoceptor (LABA) agonist; Beta 2 adrenoreceptor agonist"
CBR-001-584-664-7,RFM-004-244-4,CBR-001-584-664-7,CCOC(=O)Nc1ccc(nc1N)NCc1ccc(cc1)F,CBR-HVAC-01695: ; Alpha-2 adrenergic receptor Agonist; Potassium channel agonist; NMDA receptor antagonist; Opioid receptor agonist; Apoptosis inhibitor
CBR-001-584-665-8,RFM-004-245-5,CBR-001-584-665-8,NCC1CN(C/C/1=N/OC)c1nc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-14271
CBR-001-584-666-9,RFM-004-246-6,CBR-001-584-666-9,CC(C[C@H]1C(=O)N2CCC[C@H]2[C@]2(N1C(=O)[C@@](O2)(NC(=O)[C@H]1CN(C)C2C(=C1)c1cccc3c1c(C2)c([nH]3)Br)C(C)C)O)C,"CBR-HVAC-01406: Antiparkinsonian Drugs;Antiobesity Drugs;Treatment of Hyperprolactinemia;Type 2 Diabetes, Agents for;Treatment of Acromegaly; Dopamine D2 Agonists;Prolactin Secretion Inhibitors;Signal Transduction Modulators; Dopamine receptor D4; Dopamine receptor D3; Dopamine receptor D5; Dopamine receptor D1; Dopamine receptor D2 Antagonist; Dopamine D2 receptor agonist; Dopamine D1 receptor antagonist"
CBR-001-584-667-0,RFM-004-247-7,CBR-001-584-667-0,N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C,CBR-HVAC-09301: ; Vascular endothelial growth factor receptor 2; Ret proto-oncogene Inhibitor;
CBR-001-584-668-1,RFM-004-248-8,CBR-001-584-668-1,C=CC(=O)Nc1cc(Nc2nccc(n2)c2cn(c3c2cccc3)C)c(cc1N(CCN(C)C)C)OC,CBR-HVAC-00727: Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy; EGFR (Thr790Met Mutant) Inhibitors;Signal Transduction Modulators; EPIDERMAL GROWTH FACTOR RECEPTOR Inhibitor; EGFR kinase inhibitor
CBR-001-584-669-2,RFM-004-249-9,CBR-001-584-669-2,CN([C@@H]1C(=C(C(=O)N)C(=O)[C@@]2([C@H]1C[C@@H]1Cc3c(cc(c(c3C(=O)C1=C2O)O)CNCC(C)(C)C)N(C)C)O)O)C,CBR-HVAC-00878: Antibacterial Drugs; 30S Ribosomal Protein Inhibitors; Protein 30S ribosomal subunit inhibitor
CBR-001-584-670-5,RFM-004-250-2,CBR-001-584-670-5,O=C(Nc1ncc(s1)CCNc1ncnc2c1scc2)Nc1cccc(c1)Cl,CBR-HVAC-06258: Solid Tumors Therapy; Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;Signal Transduction Modulators; Aurora kinase Inhibitor;
CBR-001-584-671-6,RFM-004-251-3,CBR-001-584-671-6,Nc1nccc(n1)c1sc(nc1c1cccc(c1F)NS(=O)(=O)c1c(F)cccc1F)C(C)(C)C,CBR-HVAC-06966: Hematologic Agents (Miscellaneous);Melanoma Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Endocrine Cancer Therapy; Raf kinase B Inhibitors;Signal Transduction Modulators; BRAF KINASE; Raf B protein kinase Inhibitor; B-raf kinase inhibitor
CBR-001-584-672-7,RFM-004-252-4,CBR-001-584-672-7,CCC(=O)O[C@H](C(C)C)O[P@@](=O)(CC(=O)N1C[C@@H](C[C@H]1C(=O)[O-])C1CCCCC1)CCCCc1ccccc1,"CBR-HVAC-02171: Hypertension, Treatment of;Heart Failure Therapy; Angiotensin-I Converting Enzyme (ACE) Inhibitors;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors; Angiotensin I converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-584-673-8,RFM-004-253-5,CBR-001-584-673-8,CC(c1ccc(c2c(c1)c(C)cc2S(=O)(=O)O)C)C,"CBR-HVAC-01330: Antiinflammatory Ophthalmic Agents;Antiulcer Drugs;Topical Antiinflammatory Agents;Agents for Gastritis;Allergic Skin Disorders, Treatment for; Pepsin Inhibitor; Antacid"
CBR-001-584-674-9,RFM-004-254-6,CBR-001-584-674-9,NC(=O)N/N=C/1\C=C2CC(N(C2=CC1=O)C)S(=O)(=O)O,CBR-HVAC-06582: Hemostatics;
CBR-001-584-675-0,RFM-004-255-7,CBR-001-584-675-0,CO/N=C(/c1csc(n1)N)\C(=O)NC1C(=O)N2C1SCC(=C2C(=O)O)COC(=O)C,CBR-HVAC-01335: Antibacterial Drugs; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-584-676-1,RFM-004-256-8,CBR-001-584-676-1,COCCCOc1ccnc(c1C)CS(=O)c1nc2c([nH]1)cccc2,"CBR-HVAC-03750: Anti-Helicobacter Pylori Agents;Antiulcer Drugs;Gastroesophageal Reflux Disease, Agents for; H+/K+-ATPase Inhibitors; H+/K+ ATPase Inhibitor; H+ K+ transporting ATPase inhibitor; Gastrin inhibitor"
CBR-001-584-677-2,RFM-004-257-9,CBR-001-584-677-2,O=c1[nH]c(=O)c2c(n1)n(CC(C(C(COP(=O)(O)O)O)O)O)c1c(n2)cc(c(c1)C)C,"CBR-HVAC-05966: Therapy of Vitamin-Related Disorders;Septic Shock, Treatment of ;"
CBR-001-584-678-3,RFM-004-258-0,CBR-001-584-678-3,COc1cc(OC)cc(c1/C=C/S(=O)(=O)Cc1ccc(c(c1)NCC(=O)O)OC)OC,CBR-HVAC-06050: Ovarian Cancer Therapy;Solid Tumors Therapy;Head and Neck Cancer Therapy;Lymphoma Therapy;Lymphocytic Leukemia Therapy;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy;Pancreatic Cancer Therapy; Angiogenesis Inhibitors;Antimitotic Drugs;Apoptosis Inducers;CDK1 Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Polo-like Kinase-1 (Plk-1) Inhibitors;Signal Transduction Modulators; PHOSPHOINOSITIDE 3-KINASE Inhibitor; Modulator; Polo-like kinase 1 inhibitor; Cell cycle inhibitor; Protein kinase inhibitor; Mcl-1 antagonist
CBR-001-584-679-4,RFM-004-259-1,CBR-001-584-679-4,O=C1c2c(ccc3c2CCCC3(C)C)c2c(C1=O)c(C)c(o2)S(=O)(=O)O,CBR-HVAC-06804: Antiarrhythmic Drugs;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Apoptosis Inducers;Inward Rectifier Potassium Channel Activators;
CBR-001-584-680-7,RFM-004-260-4,CBR-001-584-680-7,OC(=O)CNC(=O)c1ccccc1NS(=O)(=O)c1ccc(cc1)OC(=O)C(C)(C)C,"CBR-HVAC-01522: Treatment of Autoimmune Diseases;Acute Respiratory Distress Syndrome (ARDS), Agents for;Respiratory Disorders (Not Specified); Leukocyte Elastase Inhibitors; Elastase 2, neutrophil Inhibitor; Elastase inhibitor; Serine protease inhibitor"
CBR-001-584-681-8,RFM-004-261-5,CBR-001-584-681-8,CCOc1ccc2c(c1C(=O)N[C@@H]1C(=O)N3[C@@H]1SC([C@@H]3C(=O)O)(C)C)cccc2,CBR-HVAC-02864: Antibiotics; Penicillin binding protein Inhibitor;
CBR-001-584-682-9,RFM-004-262-6,CBR-001-584-682-9,COc1cc(cc(c1O)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@@H](c2c1cc1OCOc1c2)O[C@@H]1O[C@@H]2CO[C@H](O[C@H]2[C@@H]([C@H]1O)O)C,CBR-HVAC-00081
CBR-001-584-683-0,RFM-004-263-7,CBR-001-584-683-0,N#CC[C@@H](n1ncc(c1)c1ncnc2c1cc[nH]2)C1CCCC1,"CBR-HVAC-02269: Pancreatic Cancer Therapy;Breast Cancer Therapy;Lung Cancer Therapy;Myeloid Leukemia Therapy;Rheumatoid Arthritis, Treatment of;Hematological Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Multiple Myeloma Therapy;Treatment of Autoimmune Diseases;Treatment of Cachexia;Antithrombocythemic;Lymphoma Therapy;Hematologic Agents (Miscellaneous);Lymphocytic Leukemia Therapy;Anti-HIV Agents;Antipsoriatics;Prostate Cancer Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Jak1 Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators;Tyk2 Inhibitors; JAK-1; JAK-2; JNK-1; JNK-2; Janus kinase 2 Inhibitor; Janus kinase 1 inhibitor; Janus kinase 2 inhibitor"
CBR-001-584-684-1,RFM-004-264-8,CBR-001-584-684-1,COc1cc2c(ccnc2cc1OC)Oc1ccc(cc1)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F,"CBR-HVAC-06110: Oncolytic Drugs;Solid Tumors Therapy;Melanoma Therapy;Sarcoma Therapy;Liver Cancer Therapy;Colorectal Cancer Therapy;Bladder Cancer Therapy ;Ovarian Cancer Therapy;Osteosarcoma Therapy;Endocrine Cancer Therapy;Glioblastoma Multiforme Therapy;Neurological Genetic Disorders, Treatment of ;Renal Cancer Therapy;Prostate Cancer Therapy;Myeloid Leukemia Therapy;Multiple Myeloma Therapy;Non-Small Cell Lung Cancer Therapy;Female Reproductive System Cancer Therapy;Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Skin Cancer Therapy;Pancreatic Cancer Therapy; Angiogenesis Inhibitors;Flt3 (FLK2/STK1) Inhibitors;HGFR (MET; c-Met) Inhibitors;KIT (C-KIT) Inhibitors;RET Inhibitors;Signal Transduction Modulators;Tie2 Receptor Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors; Tyrosine kinase receptor Inhibitor; Antagonist; MET tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; RET tyrosine kinase inhibitor; VEGFR tyrosine kinase inhibitor"
CBR-001-584-685-2,RFM-004-265-9,CBR-001-584-685-2,NC[C@@H](C(=O)N[C@@H]1C[C@H](N)C([C@@H]([C@H]1O[C@H]1OC[C@]([C@@H]([C@H]1O)NC)(C)O)O)O[C@H]1O[C@H](CN)[C@H]([C@@H]([C@H]1O)O)O)O,CBR-HVAC-14258
CBR-001-584-686-3,RFM-004-266-0,CBR-001-584-686-3,O=CN1c2cc(OC)c(cc2[C@]23[C@@H]1[C@@](O)(C(=O)OC)[C@H](OC(=O)C)C1([C@@H]3N(CC2)CC=C1)CC)[C@]1(C[C@@H]2CN(CCc3c1[nH]c1c3cccc1)C[C@](C2)(O)CC)C(=O)OC,CBR-HVAC-02211: ; Beta tubulin Inhibitor; Tubulin inhibitor; Vinca alkaloid
CBR-001-584-687-4,RFM-004-267-1,CBR-001-584-687-4,OCCC1C[C@H](C)C(O)/C=C/C=C/C[C@@H](OC(=O)CC(C([C@H]1O[C@@H]1O[C@H](C)C([C@@H](C1O)N(C)C)OC1O[C@H](C)C([C@](C1)(C)O)O)OC)OC)C,analog of CBR-HVAC-01301
CBR-001-584-688-5,RFM-004-268-2,CBR-001-584-688-5,NC1CCN(C1)c1nc2n(cc(c(=O)c2cc1F)C(=O)O)c1ccc(cc1F)F,CBR-HVAC-02314: Antibacterial Ophthalmic Drugs;Antibacterial Drugs; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-584-689-6,RFM-004-269-3,CBR-001-584-689-6,Clc1ccc2c(c1)CC(N2)C(=O)N1CCC2(CC1)N(C)C(=O)N(C2=O)C,analog of CBR-HVAC-02265
CBR-001-584-690-9,RFM-004-270-6,CBR-001-584-690-9,CC1(C)CC1(C)C,analog of CBR-HVAC-09377
CBR-001-584-691-0,RFM-004-271-7,CBR-001-584-691-0,Clc1cc(C)c(c(c1)Cl)CN1Cc2c(C1=O)cccn2,analog of CBR-HVAC-07299
CBR-001-584-692-1,RFM-004-272-8,CBR-001-584-692-1,O=C(c1c(C)n(C)c(=O)n(c1=O)C)c1ccccc1,analog of CBR-HVAC-06196
CBR-001-584-693-2,RFM-004-273-9,CBR-001-584-693-2,Brc1ccc2c(c1)c(cc(=O)[nH]2)C(F)(F)F,analog of CBR-HVAC-11695
CBR-001-584-694-3,RFM-004-274-0,CBR-001-584-694-3,CSc1nc(C)c(c(=O)[nH]1)Cc1ccccc1,analog of CBR-HVAC-11192
CBR-001-584-695-4,RFM-004-275-1,CBR-001-584-695-4,CCC(C(c1ccc(cc1)O)CC)c1ccc(cc1)O,CBR-HVAC-09796: Estrogen receptor Agonist;
CBR-001-584-696-5,RFM-004-276-2,CBR-001-584-696-5,Fc1ccccc1OCCOCCn1cnc2c(c1=O)cccc2,analog of CBR-HVAC-02722
CBR-001-584-697-6,RFM-004-277-3,CBR-001-584-697-6,OCCSSCCO,analog of CBR-HVAC-07421
CBR-001-584-698-7,RFM-004-278-4,CBR-001-584-698-7,CCc1noc(n1)CNc1cc(nc2n1nc(c2C)C)c1ccccc1,analog of CBR-HVAC-00689
CBR-001-584-699-8,RFM-004-279-5,CBR-001-584-699-8,O=C(c1cc2c(o1)cccc2)NC1CCCN(C1)CCc1ccccc1,analog of CBR-HVAC-08996
CBR-001-584-700-4,RFM-004-280-8,CBR-001-584-700-4,Clc1ccc(cc1Cl)c1cccc(n1)N1CCNCC1,analog of CBR-HVAC-08165
CBR-001-584-701-5,RFM-004-281-9,CBR-001-584-701-5,O=C(O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C)CCc1ccccc1,CBR-HVAC-14495: Androgen receptor Agonist; Androgen receptor agonist
CBR-001-584-702-6,RFM-004-282-0,CBR-001-584-702-6,S=C=Nc1ccc(cc1)[N+](=O)[O-],analog of CBR-HVAC-01208
CBR-001-584-703-7,RFM-004-283-1,CBR-001-584-703-7,c1ccc(cc1)c1ncn(c1c1ccncc1)CCCCN1CCCC1,analog of CBR-HVAC-05207
CBR-001-584-704-8,RFM-004-284-2,CBR-001-584-704-8,COC(=O)C(Oc1ccc(c(c1)Cl)Cl)C,analog of CBR-HVAC-03349
CBR-001-584-705-9,RFM-004-285-3,CBR-001-584-705-9,OC(=O)C[C@@H]1CC[C@H](CC1)c1ccc(cc1)C1=Nc2c(N)ncnc2OC1(C)C,CBR-HVAC-14242
CBR-001-584-706-0,RFM-004-286-4,CBR-001-584-706-0,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)OC(C)(C)C,analog of CBR-HVAC-01824
CBR-001-584-707-1,RFM-004-287-5,CBR-001-584-707-1,O=CN(/C(=C(\SC(=O)c1ccccc1)/CCOC(=O)c1ccccc1)/C)Cc1cnc(nc1N)C,analog of CBR-HVAC-10327
CBR-001-584-708-2,RFM-004-288-6,CBR-001-584-708-2,OC[C@@H]1O[C@@H]([C@H]([C@H]1O)F)n1ccc(=O)[nH]c1=O,CBR-HVAC-14264
CBR-001-584-709-3,RFM-004-289-7,CBR-001-584-709-3,O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@@H](C(C)C)C)C)C)/C1,CBR-HVAC-14180
CBR-001-584-710-6,RFM-004-290-0,CBR-001-584-710-6,OC(=O)Cc1ccccc1Nc1ccccc1,analog of CBR-HVAC-00559
CBR-001-584-711-7,RFM-004-291-1,CBR-001-584-711-7,Fc1ccc(cc1)C1=NN(C(C1)c1ccccc1F)c1ccc(cc1)S(=O)(=O)N,analog of CBR-HVAC-05294
CBR-001-584-712-8,RFM-004-292-2,CBR-001-584-712-8,NS(=O)(=O)OC[C@]12OC[C@@H]3C([C@@H]2OC(O1)(C)C)OC(O3)(C)C,"CBR-HVAC-01484: Treatment of Substance Dependency;Treatment of Cocaine Dependency;Antiobesity Drugs;Inflammatory Bowel Disease, Agents for;Antiepileptic Drugs;Antimigraine Drugs;Bipolar Disorder, Treatment of;Treatment of Nutritional Disorders;Treatment of Alcohol Dependency;Obsessive-Compulsive Disorder (OCD), Treatment of;Psychiatric Disorders (Not Specified);Migraine, Prophylactic Treatment of;Neuropathic Pain, Treatment of;Smoking Cessation, Aid to;Treatment of Eating Disorders;Cerebrovascular Diseases, Treatment of; AMPA Receptor Antagonists;Carbonic Anhydrase Type II Inhibitors;Kainate Receptor Antagonists;Signal Transduction Modulators;Sodium Channel  Blockers; Carbonic anhydrase Inhibitor; Carbonic anhydrase inhibitor ; GABA A receptor agonist; AMPA receptor antagonist; Kainate receptor antagonist; Voltage-gated sodium channel antagonist"
CBR-001-584-713-9,RFM-004-293-3,CBR-001-584-713-9,NC[C@@H](c1ccccc1)O,analog of CBR-HVAC-01311
CBR-001-584-714-0,RFM-004-294-4,CBR-001-584-714-0,CC(CCC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CCC/C/2=C\C=C/1\C[C@@H](O)CCC1=C)C)C,"CBR-HVAC-14334: Vitamin D receptor Agonist; Antipsychotic Drugs; Asthma Therapy; Bone Diseases, Treatment of; Colorectal Cancer Therapy; Endocrine Disorders (Not Specified); Hypertension, Treatment of; Prostate Cancer Therapy; Rodenticide; Therapy of Vitamin-Related Disorders; Type 2 Diabetes, Agents for; Vitamin supplement"
CBR-001-584-715-1,RFM-004-295-5,CBR-001-584-715-1,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1C#N)CO)Cl,analog of CBR-HVAC-10540
CBR-001-584-716-2,RFM-004-296-6,CBR-001-584-716-2,CCCC1O[C@H]2[C@](O1)(C(=O)CO)[C@@]1([C@@H](C2)[C@@H]2CCC3=CC(=O)C=C[C@@]3([C@H]2[C@H](C1)O)C)C,CBR-HVAC-00412: Beta-2 adrenergic receptor Agonist; Adenosine A1 receptor antagonist; Adenosine A2a receptor antagonist; Phosphodiesterase inhibitor; Immunosuppressant
CBR-001-584-717-3,RFM-004-297-7,CBR-001-584-717-3,Cc1ccccc1CN1CCN(CC1)Cc1c[nH]c(n1)c1ccccc1,analog of CBR-HVAC-04226
CBR-001-584-718-4,RFM-004-298-8,CBR-001-584-718-4,CC(C(=O)c1ccccc1)N(C)C,CBR-HVAC-14292
CBR-001-584-719-5,RFM-004-299-9,CBR-001-584-719-5,CCCC(c1ccc2c(c1)OC([C@H]1[C@H]2CC(=CC1)C)(C)C)(C)C,CBR-HVAC-14196
CBR-001-584-720-8,RFM-004-300-5,CBR-001-584-720-8,Cc1ccccc1Oc1cccc2c1[nH]c(cc2=O)N1CCOCC1,analog of CBR-HVAC-09496
CBR-001-584-721-9,RFM-004-301-6,CBR-001-584-721-9,OCC(=O)C12OC(OC1CC1C2(C)CC(O)C2(C1CC(C1=CC(=O)C=CC21C)F)F)(C)C,"CBR-HVAC-01482: Eczema, Treatment of;Antiinflammatory Ophthalmic Agents;Age-Related Macular Degeneration, Treatment of;Dermatologic Drugs;Diabetic Retinopathy, Agents for;Ear disorders, treatment of; Glucocorticoid receptor Binder; Corticosteroid agonist"
CBR-001-584-722-0,RFM-004-302-7,CBR-001-584-722-0,CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,analog of CBR-HVAC-08031
CBR-001-584-723-1,RFM-004-303-8,CBR-001-584-723-1,CCN(CCC(c1ccccc1)C1CCCCC1)CC,analog of CBR-HVAC-09049
CBR-001-584-724-2,RFM-004-304-9,CBR-001-584-724-2,CCCCCCCC/C=C\CCCCCCCC(=O)OCC(CO)O,analog of CBR-HVAC-10243
CBR-001-584-725-3,RFM-004-305-0,CBR-001-584-725-3,CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2c(O)c(/C=N/N4CCN(CC4)C4CCCC4)c(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)/C,CBR-HVAC-12192 RIFAPENTINE
CBR-001-584-726-4,RFM-004-306-1,CBR-001-584-726-4,CN1CCN(CC1)C1=Nc2ccccc2Nc2c1cc(s2)C,CBR-HVAC-13056: 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 2C receptor antagonist; 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 6 receptor antagonist; 5-HT2A Antagonists; Alpha 1 adrenoreceptor antagonist; Dopamine D1 receptor antagonist; Dopamine D2 Antagonists; Dopamine D2 receptor antagonist; Dopamine D3 receptor antagonist; Dopamine D4 receptor antagonist; Histamine H1 receptor antagonist; Muscarinic M1 receptor antagonist; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Muscarinic M4 receptor antagonist; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-584-727-5,RFM-004-307-2,CBR-001-584-727-5,C[C@H](CCC[C@@H](CCCC(C)C)C)CCC/C(=C/CC1=C(C)C(=O)c2c(C1=O)cccc2)/C,CBR-HVAC-14197
CBR-001-584-728-6,RFM-004-308-3,CBR-001-584-728-6,Nc1ncnc2c1ncn2CCOCP(=O)(O)O,CBR-HVAC-12206: Cell-differentiation-stimulants; DNA Polymerase Inhibitors; DNA-directed-DNA-polymerase-inhibitors; Immunomodulators; Immunostimulant; Immunosuppressants; Nucleotide reverse transcriptase inhibitor; Anti-HIV Agents; Anti-Hepatitis B Virus Drugs; Antiviral Drugs; Cancer; Rheumatic Disease; Transplant Rejection; Viral Infections
CBR-001-584-729-7,RFM-004-309-4,CBR-001-584-729-7,OC[C@H]1O[C@@H]([C@@H]([C@@H]1OP(=O)(O[C@@H](CNC(=O)CC[C@]1(C)[C@@H](CC(=O)N)[C@H]2N(/C/1=C(/C)\C1=N/C(=C\C3=N/C(=C(\C4=N[C@]2(C)[C@@](C)(CC(=O)N)[C@@H]4CCC(=O)N)/C)/[C@@]([C@@H]3CCC(=O)N)(C)CC(=O)N)/C([C@@H]1CCC(=O)N)(C)C)[Co+]C[C@H]1O[C@@H]([C@H]([C@H]1O)O)n1cnc2c1ncnc2N)C)[O-])O)n1cnc2c1cc(C)c(c2)C,analog of CBR-HVAC-05655
CBR-001-584-730-0,RFM-004-310-7,CBR-001-584-730-0,O=C(NC1C(=O)N2C1SCC(=C2C(=O)O)COC(=O)C)Cc1ccccc1,CBR-HVAC-14313
CBR-001-584-731-1,RFM-004-311-8,CBR-001-584-731-1,CN([C@@H]1C(=O)C(C(=O)NCN2CCCC2)C(=O)[C@@]2([C@H]1C[C@H]1C(C2=O)C(=O)c2c([C@@]1(C)O)cccc2O)O)C,CBR-HVAC-12737: 16S-rRNA of 30S ribosomal subunit Binder; Antibacterial; Antibacterial Drugs
CBR-001-584-732-2,RFM-004-312-9,CBR-001-584-732-2,CO[C@@]12[C@H]3N[C@H]3CN2C2=C([C@H]1COC(=O)N)C(=O)C(=C(C2=O)C)N,CBR-HVAC-12168: DNA inhibitor
CBR-001-584-733-3,RFM-004-313-0,CBR-001-584-733-3,O=C1CCC2C(=C1)CCC1C2CC[C@]2(C1CC[C@@H]2O)C,CBR-HVAC-14317
CBR-001-584-734-4,RFM-004-314-1,CBR-001-584-734-4,SC(C(=O)O)CC(C(=O)O)S,analog of CBR-HVAC-00120
CBR-001-584-735-5,RFM-004-315-2,CBR-001-584-735-5,C[C@H](C1C(=O)N2C1[C@@H](C)C(=C2C(=O)O)S[C@@H]1CN[C@@H](C1)C(=O)N(C)C)O,"CBR-HVAC-00984: Cell Wall Biosynthesis Inhibitors; Cell wall synthesis inhibitor; Cell-wall-inhibitors; It interferes with the integrity of the bacterial cell wall by binding to membrane proteins engaged in cell wall peptidoglycan synthesis.; Antibacterial; Antibacterial Drugs; Antibiotics; Bacterial Infections; Sepsis, Treatment of"
CBR-001-584-736-6,RFM-004-316-3,CBR-001-584-736-6,O=C(Nc1ccccc1)CNCC(=O)Nc1ccccc1,analog of CBR-HVAC-01197
CBR-001-584-737-7,RFM-004-317-4,CBR-001-584-737-7,CC[C@@]12CC[C@H]3[C@H]([C@@H]2CC[C@@H]1O)CCC1=C[C@H](CC[C@]31C)O,analog of CBR-HVAC-02419
CBR-001-584-738-8,RFM-004-318-5,CBR-001-584-738-8,CC(CC(C)(C)C)CC(CC(=O)O)N,analog of CBR-HVAC-06511
CBR-001-584-739-9,RFM-004-319-6,CBR-001-584-739-9,O=C1CC[C@]2(C(=C1)C(=C[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(O)C(=O)C)C)Cl)C,analog of CBR-HVAC-09392
CBR-001-584-740-2,RFM-004-320-9,CBR-001-584-740-2,CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\C/C=C\CCCCC,analog of CBR-HVAC-00395
CBR-001-584-741-3,RFM-004-321-0,CBR-001-584-741-3,CCCc1c2oc(cc(=O)c2cc2c1n(CC)c(cc2=O)C(=O)O)C(=O)O,CBR-HVAC-01419: Drugs for Allergic Rhinitis;Antiallergy/Antiasthmatic Drugs;Antiallergic Ophthalmic Agents; Mediator Release Inhibitors; Histamine release inhibitor; Histamine receptor antagonist
CBR-001-584-742-4,RFM-004-322-1,CBR-001-584-742-4,CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1[nH]oc(=O)n1)c(ccc2)C(=O)OCc1oc(=O)oc1C,"CBR-HVAC-06266: Hypertension, Treatment of;Antidiabetic Drugs; Angiotensin AT2 Antagonists;Insulin Sensitizers;Signal Transduction Modulators; Angiotensin II receptor Blocker; Angiotensin II antagonist"
CBR-001-584-743-5,RFM-004-323-2,CBR-001-584-743-5,Fc1ccc(c(c1)F)CNC(=O)c1cn2C[C@@H]3OCC[C@H](N3C(=O)c2c(c1=O)O)C,CBR-HVAC-06693: Anti-HIV Agents; HIV Integrase Inhibitors; Integrase Inhibitor; HIV integrase inhibitor
CBR-001-584-744-6,RFM-004-324-3,CBR-001-584-744-6,ONC(=O)[C@H]([C@H](C(=O)N[C@@H](c1ccccc1)C(=O)OC1CCCC1)CC(C)C)O,CBR-HVAC-00712: ; Leukotriene A4 hydrolase; Puromycin-sensitive aminopeptidase Inhibitor; Peptidase inhibitor
CBR-001-584-745-7,RFM-004-325-4,CBR-001-584-745-7,OCCN(Cc1ccc(cc1)/C=C/C(=O)NO)CCc1c[nH]c2c1cccc2,CBR-HVAC-11145: Solid Tumors Therapy; Antimitotic Drugs;Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor;
CBR-001-584-746-8,RFM-004-326-5,CBR-001-584-746-8,CCCC[C@@H](C(=O)N[C@H]1CC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)Cc1nc[nH]c1)Cc1ccccc1)CCCNC(=N)N)Cc1c[nH]c2c1cccc2)C(=O)N)NC(=O)C,CBR-HVAC-04814: Treatment of Erectile Dysfunction;Diagnostic Agents; Melanocortin Receptor Agonists;Signal Transduction Modulators;
CBR-001-584-747-9,RFM-004-327-6,CBR-001-584-747-9,CC(C[C@@H](B1OC(=O)CC(O1)(CC(=O)O)C(=O)O)NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)C,"CBR-HVAC-06976: Multiple Myeloma Therapy;Bladder Cancer Therapy ;Nephritis, Agents for;Oncolytic Drugs;Leukemia Therapy;Lymphoma Therapy;Renal Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Myelodysplastic Syndrome Therapy;Amyloidosis, Treatment of;Breast Cancer Therapy;Treatment of Autoimmune Diseases; Proteasome Inhibitors; Proteasome Inhibitor;"
CBR-001-584-748-0,RFM-004-328-7,CBR-001-584-748-0,OC(=O)C1=CC2=CC[C@@H]3[C@@H]([C@]2(CC1)C)CC[C@]1([C@H]3CC[C@@H]1C(=O)NC(C)(C)C)C,CBR-HVAC-01221: Benign Prostatic Hyperplasia Therapy; Steroid 5alpha-Reductase Inhibitors; Steroid 5-alpha-reductase Inhibitor; 5 Alpha reductase Type II inhibitor; 5 Alpha reductase Type I inhibitor
CBR-001-584-749-1,RFM-004-329-8,CBR-001-584-749-1,CCO[C@H](C(=O)O)Cc1ccc(cc1)OCCc1ccc(cc1)OS(=O)(=O)C,"CBR-HVAC-05006: Treatment of Diabetic Complications;Type 2 Diabetes, Agents for; Insulin Sensitizers;PPARalpha Agonists;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor alpha/gamma agoni; Insulin sensitizer"
CBR-001-584-750-4,RFM-004-330-1,CBR-001-584-750-4,CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@@H]4[C@]2([C@H]([C@H]1C)CC[C@H]4C)OO3,CBR-HVAC-00380: Antimalarials; Unidentified pharmacological activity
CBR-001-584-751-5,RFM-004-331-2,CBR-001-584-751-5,OC[C@H](CNC(=O)c1ccncc1Nc1ccc(cc1F)I)O,CBR-HVAC-00389: ; Mitogen-activated protein 2 kinase Inhibitor; Unidentified pharmacological activity
CBR-001-584-752-6,RFM-004-332-3,CBR-001-584-752-6,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1CCc2c(C1)cc(cn2)C(F)(F)F,"CBR-HVAC-00553: Multiple Sclerosis, Agents for;Rheumatoid Arthritis, Treatment of; Chemokine CCR2 (MCP-1 Receptor) Antagonists;Signal Transduction Modulators; C-C chemokine receptor type 2 Antagonist; CC chemokine receptor 2 antagonist; Chemokine receptor antagonist"
CBR-001-584-753-7,RFM-004-333-4,CBR-001-584-753-7,C#C[C@]1(O)C=C[C@@H]2[C@]1(CC)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,CBR-HVAC-01002: ; CYP3A4 Inhibitor; Estradiol 17 beta dehydrogenase stimulant; Estrone sulfotransferase stimulant
CBR-001-584-754-8,RFM-004-334-5,CBR-001-584-754-8,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,"CBR-HVAC-01279: Atherosclerosis Therapy;Antiparkinsonian Drugs;Treatment of Autoimmune Diseases;Diabetic Myocardiopathy, Agents for;Cognition Disorders, Treatment of;Lipoprotein Disorders, Treatment of ;Antidepressants;Antiplatelet Therapy;Antipsychotic Drugs;Peripheral Vascular Disease, Treatment of;Alzheimer's Dementia, Treatment of ;Liver and Biliary Tract Disorders, Treatment of;Huntington's Disease, Treatment of; Phospholipase A2 Inhibitor; Platelet aggregation inhibitor; Cholesterol inhibitor; Omega 3 fatty acid stimulant"
CBR-001-584-755-9,RFM-004-335-6,CBR-001-584-755-9,O=C1C=C[C@]2(C(=C1)[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2([C@H]1CC[C@]2(O)C(=O)C)C)C,CBR-HVAC-01416: ; Glucocorticoid receptor Agonist; Corticosteroid agonist
CBR-001-584-756-0,RFM-004-336-7,CBR-001-584-756-0,O/C=C/1\C[C@@]2(C)C(CC1=O)CCC1C2CC[C@]2(C1CC[C@]2(C)O)C,CBR-HVAC-01420: Antianemics; Androgen receptor Binder; Androgen receptor agonist
CBR-001-584-757-1,RFM-004-337-8,CBR-001-584-757-1,COCCOCO/N=C\1/[C@H](C)C[C@@](C)(O)[C@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@@H]([C@](C2)(C)OC)O)[C@H](C(=O)O[C@@H]([C@@]([C@@H]([C@H]1C)O)(C)O)CC)C,CBR-HVAC-01565: Antibiotics;Antibacterial Drugs;Acne Therapy; 23S-rRNA of 50S ribosomal subunit Binder; Protein 50S ribosomal subunit inhibitor
CBR-001-584-758-2,RFM-004-338-9,CBR-001-584-758-2,OC(=O)/C=C/c1cccc(n1)/C(=C/CN1CCCC1)/c1ccc(cc1)C,"CBR-HVAC-01589: Urticaria, Treatment for;Drugs for Allergic Rhinitis; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Inhibitor; Histamine H1 receptor antagonist"
CBR-001-584-759-3,RFM-004-339-0,CBR-001-584-759-3,N#C/C(=C\1/SCC(S1)c1ccccc1Cl)/n1cncc1,CBR-HVAC-01747: Dermatologic Drugs;Antifungal Agents; Sterol demethylase Inhibitor; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-584-760-6,RFM-004-340-3,CBR-001-584-760-6,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C2=O)c2c(c(c3C)O)c(O)c(c3c2nc2n3ccc(c2)C)NC(=O)C(=C/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)C,"CBR-HVAC-01794: Liver and Biliary Tract Disorders, Treatment of;Neurologic Drugs (Miscellaneous);Antiulcer Drugs;Respiratory Disorders (Not Specified);Inflammatory Bowel Disease, Agents for;Metabolic Disorders (Not Specified);Antiinfectives (Not Specified);Irritable Bowel Syndrome, Agents for;Antibiotics; Pregnane X Receptor (PXR) Agonists;Signal Transduction Modulators; DNA-dependent RNA polymerase Inhibitor; Protein 50S ribosomal subunit inhibitor; DNA directed RNA polymerase inhibitor; RNA synthesis inhibitor"
CBR-001-584-761-7,RFM-004-341-4,CBR-001-584-761-7,COC(=O)[C@@H]1CC2=CC(=O)CC[C@@]2([C@@]23C1[C@@H]1CC[C@]4([C@@]1(C)CC3O2)CCC(=O)O4)C,"CBR-HVAC-01798: Treatment of Renal Diseases;Retinopathy, Treatment of;Heart Failure Therapy;Hypertension, Treatment of;Atherosclerosis Therapy;Liver and Biliary Tract Disorders, Treatment of; Mineralocorticoid Receptor (MR) Antagonists;Signal Transduction Modulators; Mineralocorticoid receptor Antagonist; Aldosterone antagonist"
CBR-001-584-762-8,RFM-004-342-5,CBR-001-584-762-8,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2c1NC=NC[C@H]2O,"CBR-HVAC-01969: Antiarthritic Drugs;Non-Hodgkin's Lymphoma Therapy;Immunosuppressants;Leukemia Therapy;Oncolytic Drugs;Septic Shock, Treatment of ;Lymphocytic Leukemia Therapy; Adenosine Deaminase (ADA) Inhibitors;Antimetabolites; Adenosine deaminase Inhibitor; Adenosine deaminase inhibitor"
CBR-001-584-763-9,RFM-004-343-6,CBR-001-584-763-9,O=C([C@@H](c1ccccc1)N)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)OCOC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C)(C)C,CBR-HVAC-02045: Antibiotics; beta-Lactamase Inhibitors; Transpeptidase; Beta lactamase Inhibitor; Cell wall synthesis inhibitor; Lactamase inhibitor
CBR-001-584-764-0,RFM-004-344-7,CBR-001-584-764-0,CCCCCCCCCCCCCCCC(=O)O[C@@H](COP(=O)(OCCNC(=O)[C@@H](NC(=O)CC[C@H](C(=O)N)NC(=O)[C@@H](NC(=O)[C@H](O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@@H]([C@H]1O)CO)C)C)C)O)COC(=O)CCCCCCCCCCCCCCC,CBR-HVAC-02070: Immunostimulants;Osteosarcoma Therapy; Protein kinase C Activator; Macrophage stimulant
CBR-001-584-765-1,RFM-004-345-8,CBR-001-584-765-1,O=C(N[C@H]([C@H](C[C@@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)N(Cc1csc(n1)C(C)C)C)O)Cc1ccccc1)OCc1cncs1,CBR-HVAC-02138: Anti-HIV Agents;Breast Cancer Therapy;Anti-Hepatitis C Virus Drugs; HIV-1 Protease Inhibitors; Protease Inhibitor; HIV protease inhibitor; Cytochrome P450 inhibitor
CBR-001-584-766-2,RFM-004-346-9,CBR-001-584-766-2,COCC1=C(C(=O)OC(OC(=O)OC(C)C)C)N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N\OC)/c1csc(n1)N,CBR-HVAC-02328: ; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-584-767-3,RFM-004-347-0,CBR-001-584-767-3,OC[C@H]1O[C@H](O[C@H]2[C@@H](O[C@@H]([C@H]([C@@H]2O)O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)C(=O)O)OC2CCC3(C([C@@]2(C)CO)CCC2(C3CC=C3[C@@]2(C)C[C@H](C2(C3CC(C)(C)C([C@@H]2OC(=O)C)OC(=O)/C(=C/C)/C)CO)O)C)C)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-05628: Chemopreventive Agents;Allergic Skin Disorders, Treatment for;Antiallergy/Antiasthmatic Drugs;Peripheral Vascular Disease, Treatment of;Inflammation, Treatment of; IL-6 Modulators;Signal Transduction Modulators;"
CBR-001-584-768-4,RFM-004-348-1,CBR-001-584-768-4,CCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](C)[C@@]2(O)[C@H]([C@H]3[C@]1(OC(=O)C)C3(C)C)C=C(C[C@]1([C@H]2C=C(C1=O)C)O)CO,CBR-HVAC-05682: Anti-HIV Agents;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy;Lymphoma Therapy; Protein Kinase C (PKC) Activators;Signal Transduction Modulators; CD4 antagonist
CBR-001-584-769-5,RFM-004-349-2,CBR-001-584-769-5,C[C@]12Cc3c[nH]nc3CC1CCC1C2CC[C@]2(C1CC[C@]2(C)O)C,"CBR-HVAC-06195: Disorders of Sexual Function and Reproduction, Treatment of;Antianemics;Treatment of Osteoporosis;Breast Cancer Therapy;Hematologic Genetic Disorders, Treatment of ; Androgen receptor Agonist;"
CBR-001-584-770-8,RFM-004-350-5,CBR-001-584-770-8,ONC(=O)/C=C/c1ccc(cc1)CNCCc1c(C)[nH]c2c1cccc2,CBR-HVAC-06212: Sarcoma Therapy;Small Cell Lung Cancer Therapy;Head and Neck Cancer Therapy;Myelodysplastic Syndrome Therapy;Colorectal Cancer Therapy;Glioblastoma Multiforme Therapy;Hematological Cancer Therapy;Treatment of Transplant Rejection;Non-Small Cell Lung Cancer Therapy;Endocrine Cancer Therapy;Leukemia Therapy;Hematopoiesis Disorders Therapy;Gastric Cancer Therapy;Prostate Cancer Therapy;Liver Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Neurologic Cancer Therapy;Immunosuppressants;Lymphoma Therapy;Myeloid Leukemia Therapy;Breast Cancer Therapy;Renal Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Pancreatic Cancer Therapy;Bone Cancer Therapy;Anti-HIV Agents;Multiple Myeloma Therapy;Melanoma Therapy; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors; HISTONE DEACETYLASE Inhibitor; Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor
CBR-001-584-771-9,RFM-004-351-6,CBR-001-584-771-9,CCC[C@@H](c1cccnc1)Nc1nc(ncc1C)c1ccc(c(c1)OC)NC(=O)NCC,CBR-HVAC-06269: Solid Tumors Therapy;Multiple Myeloma Therapy;Oncolytic Drugs;Glioblastoma Multiforme Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors;Vascular Disrupting Agents (VDA); Tubulin Inhibitor; Tubulin inhibitor; Angiogenesis inhibitor; Microtubule inhibitor
CBR-001-584-772-0,RFM-004-352-7,CBR-001-584-772-0,Fc1cnc(nc1)[C@@H](Nc1ncc(c(n1)Nc1n[nH]c(c1)C)Cl)C,CBR-HVAC-06638: Hematopoiesis Disorders Therapy;Liver Cancer Therapy; Jak1 Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators;
CBR-001-584-773-1,RFM-004-353-8,CBR-001-584-773-1,Nc1nccn2c1c(nc2[C@@H]1C[C@](C1)(C)O)c1ccc2c(c1)nc(cc2)c1ccccc1,CBR-HVAC-06799: Breast Cancer Therapy;Sarcoma Therapy;Liver Cancer Therapy;Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Multiple Myeloma Therapy;Endocrine Cancer Therapy;Prostate Cancer Therapy; IGF-1R Inhibitors;Insulin Receptor Antagonists;Signal Transduction Modulators;
CBR-001-584-774-2,RFM-004-354-9,CBR-001-584-774-2,CC[C@H]1N(C(C)C)c2nc(ncc2N(C1=O)C)Nc1ccc(cc1OC)C(=O)N[C@@H]1CC[C@H](CC1)N1CCN(CC1)CC1CC1,CBR-HVAC-06815: Female Reproductive System Cancer Therapy;Myeloid Leukemia Therapy;Bladder Cancer Therapy ;Oncolytic Drugs;Non-Small Cell Lung Cancer Therapy;Ovarian Cancer Therapy; Antimitotic Drugs;Polo-like Kinase-1 (Plk-1) Inhibitors;Signal Transduction Modulators; POLO-LIKE KINASE 1 Inhibitor; Polo-like kinase 1 inhibitor; Protein kinase inhibitor; Apoptosis stimulant; Cell cycle inhibitor
CBR-001-584-775-3,RFM-004-355-0,CBR-001-584-775-3,O=C([C@@H]1N2C(=O)C[C@H]2S(=O)(=O)C1(C)C)OCOC(=O)C(C)(C)C,CBR-HVAC-08213: ; beta-Lactamase Inhibitors; Lactamase inhibitor
CBR-001-584-776-4,RFM-004-356-1,CBR-001-584-776-4,O=C1CC[C@]2(C(=C1)CCC1C2CC[C@]2(C1C[C@@H]1[C@]2(O[C@](O1)(C)c1ccccc1)C(=O)C)C)C,CBR-HVAC-09386:
CBR-001-584-777-5,RFM-004-357-2,CBR-001-584-777-5,ClCCN(C(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2O)C)CCCl,CBR-HVAC-10257:
CBR-001-584-778-6,RFM-004-358-3,CBR-001-584-778-6,N#Cc1c(cccc1Cl)OC[C@@H](CNC(Cc1ccc2c(c1)cccc2)(C)C)O,CBR-HVAC-11575: Bone Formation Stimulants;Treatment of Osteoporosis; Calcium-Sensing Receptor (CaSR) Antagonists;Parathyroid Hormone Secretion Stimulants;Signal Transduction Modulators; Calcium receptor Antagonist;
CBR-001-584-779-7,RFM-004-359-4,CBR-001-584-779-7,CN(C(=O)c1c(O)c2ccccc2n(c1=O)C)c1ccccc1,"CBR-HVAC-03198: Oncolytic Drugs;Antiarthritic Drugs;Multiple Sclerosis, Agents for;Immunostimulants; Angiogenesis Inhibitors; T cell stimulant; T cell inhibitor; Tumour necrosis factor alpha antagonist"
CBR-001-584-780-0,RFM-004-360-7,CBR-001-584-780-0,N#CN/C(=N/c1ccc(cc1)C1=NNC(=O)CC1C)/NC,CBR-HVAC-03291: Heart Failure Therapy;Vasodilators; Phosphodiesterase 3 inhibitor; Histamine receptor antagonist
CBR-001-584-781-1,RFM-004-361-8,CBR-001-584-781-1,CN1Cc2ccccc2[C@@H]2[C@H]1Cc1c[nH]c3c1c2ccc3,CBR-HVAC-03322: Opioid Analgesics;Antiparkinsonian Drugs; Dopamine D1 Agonists;Signal Transduction Modulators; DOPAMINE D1 RECEPTOR Agonist; Dopamine D1 receptor agonist
CBR-001-584-782-2,RFM-004-362-9,CBR-001-584-782-2,Fc1ccc(cc1)c1sc(cc1c1ccc(cc1)S(=O)(=O)C)Br,CBR-HVAC-03425: ; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor; Cyclooxygenase inhibitor
CBR-001-584-783-3,RFM-004-363-0,CBR-001-584-783-3,CC(C[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)O)Cc1ccccn1)Cc1cn(c2c1cccc2)C)NC(=O)N1CCCCCC1)C,CBR-HVAC-04379: ; Endothelin ETA Receptor Antagonists;Endothelin Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist;
CBR-001-584-784-4,RFM-004-364-1,CBR-001-584-784-4,Cn1ncc(c1)c1[nH]c2c3c1cn[nH]c(=O)c3cc(c2)NC(=O)[C@@H](C1CCCCC1)N,CBR-HVAC-06432: Solid Tumors Therapy;Antineoplastic Enhancing Agents; Checkpoint Kinase 1 (Chk1) Inhibitors;Signal Transduction Modulators; Checkpoint kinase 1 Inhibitor;
CBR-001-584-785-5,RFM-004-365-2,CBR-001-584-785-5,C/C(=N\Nc1nnc2c(n1)[nH]c1c2cccc1C)/c1ccccn1,CBR-HVAC-07261: Solid Tumors Therapy; Autophagy Inducers;
CBR-001-584-786-6,RFM-004-366-3,CBR-001-584-786-6,OC(=O)CC/C=C\C[C@@H]1CO[C@@H](O[C@@H]1c1ccccc1O)c1ccccc1Cl,CBR-HVAC-03561: Antiplatelet Therapy; Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A synthase Antagonist; Thromboxane receptor antagonist
CBR-001-584-787-7,RFM-004-367-4,CBR-001-584-787-7,OC(c1ccccc1)C1CCN(CC1)CCc1ccccc1,CBR-HVAC-03797: Antiglaucoma Agents;Antiarrhythmic Drugs;Anxiolytics; Signal Transduction Modulators;5-HT2A Antagonists; Potassium channel; 5-Hydroxytryptamine 2 receptor Antagonist; 5 Hydroxytryptamine 2 receptor antagonist
CBR-001-584-788-8,RFM-004-368-5,CBR-001-584-788-8,CN1c2ccccc2/C(=C/2\C(=O)Nc3c2cccc3)/C1=O,"CBR-HVAC-06846: Inflammatory Bowel Disease, Agents for;Systemic Lupus Erythematosus, Agents for;Oncolytic Drugs;Rheumatoid Arthritis, Treatment of;Nephritis, Agents for; Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators;"
CBR-001-584-789-9,RFM-004-369-6,CBR-001-584-789-9,CNC(=O)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NCc1cccc(c1)I,"CBR-HVAC-00845: Antiglaucoma Agents;Solid Tumors Therapy;Dry Eye Syndrome, Treatment for;Rheumatoid Arthritis, Treatment of;Antineoplastic Enhancing Agents;Oncolytic Drugs;Antipsoriatics;Colorectal Cancer Therapy;Osteoarthritis, Treatment of;Ophthalmic Drugs; Adenosine A3 Agonists;Signal Transduction Modulators; ADENOSINE A3 RECEPTOR Agonist; Adenosine A3 receptor agonist; Granulocyte colony stimulating factor agonist"
CBR-001-584-790-2,RFM-004-370-9,CBR-001-584-790-2,CCN(CC1CCCCN1CC(=O)n1c2ccccc2c(=O)[nH]c2c1nccc2)CC,CBR-HVAC-03329: Antiarrhythmic Drugs; Muscarinic M2 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M2 Antagonist; Muscarinic M1 receptor antagonist
CBR-001-584-791-3,RFM-004-371-0,CBR-001-584-791-3,OC(=O)[C@@H]1NCCN(C1)C/C=C/P(=O)(O)O,"CBR-HVAC-03776: Cognition Disorders, Treatment of;Antiepileptic Drugs;Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; NMDA receptor antagonist"
CBR-001-584-792-4,RFM-004-372-1,CBR-001-584-792-4,Clc1ccc(cc1)Cn1c2ccc(cc2c(c1CC(C(=O)O)(C)C)SC(C)(C)C)C(C)C,CBR-HVAC-03809: Antiallergy/Antiasthmatic Drugs; Leukotriene Synthesis Inhibitors;PPAR Modulators;Signal Transduction Modulators;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors; Lipoxygenase 5 Inhibitor; Five lipoxygenase activating protein antagonist
CBR-001-584-793-5,RFM-004-373-2,CBR-001-584-793-5,COc1ccccc1CC(=N)N1C[C@H]2[C@@H](C1)C(CCC2=O)(c1ccccc1)c1ccccc1,CBR-HVAC-04173: Non-Opioid Analgesics; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin receptor 1 Antagonist; Neurokinin 1 receptor antagonist; Calcium channel antagonist
CBR-001-584-794-6,RFM-004-374-3,CBR-001-584-794-6,N#CN/C(=N\C(CC)(C)C)/Nc1cccnc1,"CBR-HVAC-04331: Treatment of Erectile Dysfunction;Hypertension, Treatment of;Antiarrhythmic Drugs; K(ATP) Channel Activators; ATP-sensitive potassium channel Activator; Potassium channel agonist"
CBR-001-584-795-7,RFM-004-375-4,CBR-001-584-795-7,C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@@H](CC1CC(=O)NC(=O)C1)O,CBR-HVAC-05264: Antifungal Agents;Oncolytic Drugs; Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors;Signal Transduction Modulators;
CBR-001-584-796-8,RFM-004-376-5,CBR-001-584-796-8,CNC(=O)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(Cl)nc2NCc1cccc(c1)I,"CBR-HVAC-05220: Liver and Biliary Tract Disorders, Treatment of;Liver Cancer Therapy;Anti-Hepatitis C Virus Drugs; Adenosine A3 Agonists;Signal Transduction Modulators; Adenosine A3 receptor agonist"
CBR-001-584-797-9,RFM-004-377-6,CBR-001-584-797-9,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2c2c1c(ccc2)S(=O)(=O)N,"CBR-HVAC-03979: Stroke, Treatment of; AMPA Receptor Antagonists;Kainate Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Antagonist;"
CBR-001-584-798-0,RFM-004-378-7,CBR-001-584-798-0,NC(=N)c1ccc(cc1)OCCCOc1ccc(cc1)C(=N)N,CBR-HVAC-10296:
CBR-001-584-799-1,RFM-004-379-8,CBR-001-584-799-1,O=C(c1ccccc1)OOC(=O)c1ccccc1,CBR-HVAC-01369: Acne Therapy; Protein kinase C Inhibitor; Oxidizing agent
CBR-001-584-800-7,RFM-004-380-1,CBR-001-584-800-7,O=C1CN=C(c2c(N1)sc1c2CCCC1)c1ccccc1,CBR-HVAC-01930: Anxiolytics; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; Benzodiazepine receptor agonist
CBR-001-584-801-8,RFM-004-381-2,CBR-001-584-801-8,O=C1O[Pt]2(OC1=O)N[C@H]1[C@H](N2)CCCC1,CBR-HVAC-00917: ; DNA inhibitor; DNA synthesis inhibitor
CBR-001-584-802-9,RFM-004-382-3,CBR-001-584-802-9,OC[C@H]1O[C@H](C[C@@H]1N=[N+]=[N-])n1cc(C)c(=O)[nH]c1=O,CBR-HVAC-02235: Anti-HIV Agents; Reverse Transcriptase Inhibitors; RNA dependent DNA polymerase Inhibitor; Nucleoside reverse transcriptase inhibitor
CBR-001-584-803-0,RFM-004-383-4,CBR-001-584-803-0,Nc1ccn(c(=O)n1)[C@@H]1CS[C@@H](O1)CO,CBR-HVAC-01900: Agents for Liver Cirrhosis;Anti-Hepatitis B Virus Drugs;Anti-HIV Agents; Cytochrome P450 CYP3A4 Inhibitors;DNA Polymerase Inhibitors;Reverse Transcriptase Inhibitors; Reverse transcriptase; DNA polymerase Inhibitor; Nucleoside reverse transcriptase inhibitor
CBR-001-584-804-1,RFM-004-384-5,CBR-001-584-804-1,O=C1N(C)CC(=O)N2[C@@H]1Cc1c([C@H]2c2ccc3c(c2)OCO3)[nH]c2c1cccc2,CBR-HVAC-02379: ; Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor
CBR-001-584-805-2,RFM-004-385-6,CBR-001-584-805-2,Clc1[nH]c2c(n1)n(C)c(=O)n(c2=O)C.CN(CCOC(c1ccccc1)c1ccccc1)C,CBR-HVAC-02466: ; Histamine H1 receptor Antagonist; Unidentified pharmacological activity
CBR-001-584-806-3,RFM-004-386-7,CBR-001-584-806-3,C[C@H]([C@H]1C(=O)N2[C@@H]1[C@@H](C)C(=C2C(=O)OCOC(=O)C(C)(C)C)SC1CN(C1)C1=NCCS1)O,CBR-HVAC-02038: Antibiotics; Cell wall synthesis inhibitor
CBR-001-584-807-4,RFM-004-387-8,CBR-001-584-807-4,Clc1ccc(cc1)C1=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(c(c2)S(=O)(=O)C(F)(F)F)N[C@@H](CSc2ccccc2)CCN2CCOCC2)CC(CC1)(C)C,CBR-HVAC-00688: Prostate Cancer Therapy;Antineoplastic Enhancing Agents;Small Cell Lung Cancer Therapy;Lymphoma Therapy;Solid Tumors Therapy;Multiple Myeloma Therapy;Lymphocytic Leukemia Therapy;Liver Cancer Therapy; Apoptosis Inducers;Bcl-w Inhibitors;Bcl-xl Inhibitors;Bcl-2 Inhibitors;Signal Transduction Modulators; BCL2 Inhibitor; Bcl2 inhibitor; Apoptosis stimulant; Bcl-XL inhibitor
CBR-001-584-808-5,RFM-004-388-9,CBR-001-584-808-5,ONC(=O)CCCCCCC(=O)Nc1cccnc1,CBR-HVAC-00165: Oncolytic Drugs; Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor
CBR-001-584-809-6,RFM-004-389-0,CBR-001-584-809-6,CO/N=C(\c1csc(n1)N)/C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)OCOC(=O)C(C)(C)C)/C=C/c1scnc1C,CBR-HVAC-02047: Antibacterial Drugs;Antibiotics; Cell Wall Biosynthesis Inhibitors; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-584-810-9,RFM-004-390-3,CBR-001-584-810-9,[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3],CBR-HVAC-02470: ; Chelating agent
CBR-001-584-811-0,RFM-004-391-4,CBR-001-584-811-0,OCC1OC(Oc2cccc3c2C(=O)c2c(C3C3c4cc(cc(c4C(=O)c4c3cccc4OC3OC(CO)C(C(C3O)O)O)O)C(=O)O)cc(cc2O)C(=O)O)C(C(C1O)O)O,CBR-HVAC-09654:
CBR-001-584-812-1,RFM-004-392-5,CBR-001-584-812-1,CN1CCN(CC1)c1nc(Sc2ccc(cc2)NC(=O)C2CC2)nc(c1)Nc1n[nH]c(c1)C,CBR-HVAC-05851: Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy;Leukemia Therapy;Colorectal Cancer Therapy;Oncolytic Drugs;Hematological Cancer Therapy; Abl1 Kinase Inhibitors;Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators; Aurora kinase Inhibitor; Aurora kinase inhibitor; Flt-3 kinase inhibitor; Janus kinase 2 inhibitor; Bcr-Abl inhibitor; Mitotic inhibitor
CBR-001-584-813-2,RFM-004-393-6,CBR-001-584-813-2,Cc1ccc(cc1)c1nc2n(c1CC(=O)N(C)C)cc(cc2)C,"CBR-HVAC-01458: Sedative/Hypnotics;Cerebrovascular Diseases, Treatment of;Neurologic Drugs (Miscellaneous);Antiparkinsonian Drugs;Sleep Disorders, Treatment of; GABA(A) BZ Site 1 (Omega-1) Receptor Agonists;Signal Transduction Modulators; GABA-A receptor Inhibitor; Non-benzodiazepine hypnotic; Benzodiazepine receptor agonist"
CBR-001-584-814-3,RFM-004-394-7,CBR-001-584-814-3,CCN1CCN(CC1)Cc1ccc(cc1)c1cc2c([nH]1)ncnc2N[C@@H](c1ccccc1)C,CBR-HVAC-00516: Colorectal Cancer Therapy;Glioblastoma Multiforme Therapy;Solid Tumors Therapy; Angiogenesis Inhibitors;EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; EGFR; ERBB2; Vascular endothelial growth factor receptor Inhibitor; Inhibitor; Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor
CBR-001-584-815-4,RFM-004-395-8,CBR-001-584-815-4,CO[C@@H](C(=O)N1Cc2c(C1)[nH]nc2NC(=O)c1ccc(cc1)N1CCN(CC1)C)c1ccccc1,CBR-HVAC-00660: Multiple Myeloma Therapy;Solid Tumors Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Myeloid Leukemia Therapy;Oncolytic Drugs; Abl Kinase Inhibitors;Angiogenesis Inhibitors;Antimitotic Drugs;Apoptosis Inducers;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;FGFR1 Inhibitors;High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors;RET Inhibitors;Signal Transduction Modulators; Aurora kinase A; Aurora kinase B; Ret proto-oncogene; TRKA; FGFR1; Aurora kinase C; ABL Inhibitor; Aurora kinase inhibitor; TrkA tyrosine kinase inhibitor; Mitotic inhibitor; Protein kinase inhibitor; Bcr-Abl inhibitor
CBR-001-584-816-5,RFM-004-396-9,CBR-001-584-816-5,C[C@@H]1CCNC1c1nc2c([nH]1)cccc2C(=O)N,analog of CBR-HVAC-00751 (veliparib)
CBR-001-584-817-6,RFM-004-397-0,CBR-001-584-817-6,CC(c1ccccc1)(Cc1ccccc1)N,"CBR-HVAC-04171: Stroke, Treatment of;Autism, Treatment of;Antiepileptic Drugs;Antiarthritic Drugs;Non-Opioid Analgesics; NMDA Antagonists;Signal Transduction Modulators;"
CBR-001-584-818-7,RFM-004-398-1,CBR-001-584-818-7,CC1CCC(CC1)C(=O)CCC(=O)O,"CBR-HVAC-05110: Type 2 Diabetes, Agents for; Insulin Secretagogues;K(ATP) Channel Blockers;Signal Transduction Modulators; Glucagon-like peptide 1 receptor Antagonist; Unidentified pharmacological activity"
CBR-001-584-819-8,RFM-004-399-2,CBR-001-584-819-8,O=C(c1cc(c(cc1O)Cl)S(=O)(=O)N)Nc1c(C)cccc1C,"CBR-HVAC-01597: Diuretics;Hypertension, Treatment of;Heart Failure Therapy; Carbonic anhydrase inhibitor"
CBR-001-584-820-1,RFM-004-400-8,CBR-001-584-820-1,[O-][N+](=O)OCC(C(=O)O)(C)C,CBR-HVAC-11972:
CBR-001-584-821-2,RFM-004-401-9,CBR-001-584-821-2,O=C(N1CCCc2c1ccc(c2)OC(=O)c1ccco1)C(Cl)Cl,CBR-HVAC-01735: Antiamebics; Protein synthesis inhibitor; Microtubule inhibitor
CBR-001-584-822-3,RFM-004-402-0,CBR-001-584-822-3,N#CC[C@]1(O)CC[C@@H]2[C@]1(C)CCC1=C3CCC(=O)C=C3CC[C@@H]21,"CBR-HVAC-02018: Progesterone agonist. Inhibits ovulation, produces secretory transformation of the endometrium and has antiproliferative effects."
CBR-001-584-823-4,RFM-004-403-1,CBR-001-584-823-4,CCOC(=O)/C=C(/C=C/C=C(/C=C/c1c(C)cc(c(c1C)C)OC)\C)\C,"CBR-HVAC-02798: It is acting upon nuclear receptors. Retinoid X receptors (RXR) and retinoic acid receptors (RAR) active gene transcription by binding to DNA as homodimers or as heterodimers with vitamin D, thyroid hormone or peroxisome-proliferator-activated receptors, etc. It has the ability to influence cellular differentiation and in particular the differentiation program of epithelial cell"
CBR-001-584-824-5,RFM-004-404-2,CBR-001-584-824-5,N#Cc1nccc(c1)c1[nH]nc(n1)c1ccncc1,CBR-HVAC-00795: Treatment of Gout;Uricosurics; Xanthine Oxidase Inhibitors; XANTHINE OXIDOREDUCTASE Inhibitor; Xanthine oxidase inhibitor
CBR-001-584-825-6,RFM-004-405-3,CBR-001-584-825-6,CCCCCCC(=O)OC(COC(=O)CCCCCC)COC(=O)CCCCCC,"CBR-HVAC-02589: Huntington's Disease, Treatment of;Metabolic Disorders (Not Specified);Therapy of Inborn Errors of Metabolism; Unidentified pharmacological activity"
CBR-001-584-826-7,RFM-004-406-4,CBR-001-584-826-7,COc1ccc2c(c1)nccc2OCc1nnc2n1nc(cc2)c1ccccc1,CBR-HVAC-00248: ; c-Met Inhibitor; MET tyrosine kinase inhibitor
CBR-001-584-827-8,RFM-004-407-5,CBR-001-584-827-8,CCOc1cc2ncc(c(c2cc1NC(=O)/C=C/CN(C)C)Nc1ccc(c(c1)Cl)F)C#N,CBR-HVAC-00455: Head and Neck Cancer Therapy;Colorectal Cancer Therapy;Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; ERBB2; EGFR Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-584-828-9,RFM-004-408-6,CBR-001-584-828-9,CN(C(=S)c1ccccc1)NC(=O)CC(=O)NN(C(=S)c1ccccc1)C,CBR-HVAC-00562: Female Reproductive System Cancer Therapy;Melanoma Therapy;Sarcoma Therapy;Antineoplastic Enhancing Agents;Myeloid Leukemia Therapy; Apoptosis Inducers;DNA Topoisomerase II alpha Inhibitors;Heat Shock Protein 70 (hsp70) Inducers; Heat shock protein 70 Stimulator; Heat shock protein 70 agonist; Apoptosis stimulant
CBR-001-584-829-0,RFM-004-409-7,CBR-001-584-829-0,O[C@H]1CC[C@]2(C(=CCC3C2CC[C@]2(C3CC=C2)C)C1)C,CBR-HVAC-07444: ; Unidentified pharmacological activity
CBR-001-584-830-3,RFM-004-410-0,CBR-001-584-830-3,CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)(OCC[N+](C)(C)C)[O-])OC,CBR-HVAC-02959: Oncolytic Drugs;Antileishmanials; Angiogenesis Inhibitors;CoA-Independent Transacyclase (CoA-IT) Inhibitors; Phospholipase C inhibitor
CBR-001-584-831-4,RFM-004-411-1,CBR-001-584-831-4,Cc1ccc(c(c1)C(=O)O)NC(=O)c1ccc(cc1Cl)Cl,CBR-HVAC-08587: ; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma Agonist;
CBR-001-584-832-5,RFM-004-412-2,CBR-001-584-832-5,O=C1NC(=O)C2(N1)CCc1c(C2)cccc1,CBR-HVAC-08635:
CBR-001-584-833-6,RFM-004-413-3,CBR-001-584-833-6,O=C(c1ccc(cc1)F)NC1CCN(CC1)C(=O)C,"CBR-HVAC-00330: Alzheimer's Dementia, Treatment of ; 5-Hydroxytryptamine receptor Agonist; Somatostatin receptor agonist"
CBR-001-584-834-7,RFM-004-414-4,CBR-001-584-834-7,CC(C(=O)O)CC(=O)c1ccc(cc1)c1ccccc1,CBR-HVAC-00949: ; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-584-835-8,RFM-004-415-5,CBR-001-584-835-8,COc1ccc2c(c1)c(N)c1c(n2)CCCC1,"CBR-HVAC-03558: Cognition Disorders, Treatment of; Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Inhibitor;"
CBR-001-584-836-9,RFM-004-416-6,CBR-001-584-836-9,CCOc1ccccc1OCC1CNCCO1,CBR-HVAC-01494: ; Monoamine oxidase Inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-584-837-0,RFM-004-417-7,CBR-001-584-837-0,OC(COc1cc(Cl)ccc1Cl)CNC(C)(C)C,"CBR-HVAC-02119: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist"
CBR-001-584-838-1,RFM-004-418-8,CBR-001-584-838-1,CCCC(C(=O)NCC(=O)N)CCC,"CBR-HVAC-04677: Neurologic Drugs (Miscellaneous);Neuropathic Pain, Treatment of;Antiepileptic Drugs;Bipolar Disorder, Treatment of; Unidentified pharmacological activity"
CBR-001-584-839-2,RFM-004-419-9,CBR-001-584-839-2,O=C(c1cccc2c1cccc2)c1cn(c(c1)C(=O)O)C,CBR-HVAC-03402: Immunosuppressants; Immunosuppressant
CBR-001-584-840-5,RFM-004-420-2,CBR-001-584-840-5,O=C1NC(=O)CN(C1)C[C@@H](N1CC(=O)NC(=O)C1)C,CBR-HVAC-01469: Chemoprotective Agents;Oncolytic Drugs; DNA Topoisomerase II Inhibitors; Topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; Chelating agent
CBR-001-584-841-6,RFM-004-421-3,CBR-001-584-841-6,O=C1c2nc3ccccc3c(=O)n2c2c1cccc2,"CBR-HVAC-06229: Inflammatory Bowel Disease, Agents for;Anti-Helicobacter Pylori Agents;Oncolytic Drugs; Hepatocyte Growth Factor (HGF) Antagonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators;5-Lipoxygenase Inhibitors;"
CBR-001-584-842-7,RFM-004-422-4,CBR-001-584-842-7,Cc1cc(C)cc(c1)C(=O)NCc1ccncc1,CBR-HVAC-08200: ; Dopamine receptor antagonist; Alpha adrenoreceptor antagonist; Acetylcholine receptor antagonist
CBR-001-584-843-8,RFM-004-423-5,CBR-001-584-843-8,O=C(c1ccccn1)N1CCN(CC1)Cc1ccccc1,CBR-HVAC-02773: Antidepressants; 5 Hydroxytryptamine uptake inhibitor
CBR-001-584-844-9,RFM-004-424-6,CBR-001-584-844-9,CCN1CCCC1CNC(=O)C(c1ccccc1)(c1ccccc1)O,CBR-HVAC-10155:
CBR-001-584-845-0,RFM-004-425-7,CBR-001-584-845-0,CCN(CCCNc1ccnc2c1ccc(c2)Cl)CC,CBR-HVAC-04746: Antimalarials;
CBR-001-584-846-1,RFM-004-426-8,CBR-001-584-846-1,Oc1cc(O)c2c(c1)O[C@@H]([C@H](C2=O)O[C@@H]1O[C@@H](C)[C@@H]([C@H]([C@H]1O)O)O)c1ccc(c(c1)O)O,"CBR-HVAC-05391: Non-Opioid Analgesics;Diabetic Nephropathy, Agents for;Systemic Lupus Erythematosus, Agents for; Aldose Reductase Inhibitors;Antiinflammatory Drugs;Antioxidants;"
CBR-001-584-847-2,RFM-004-427-9,CBR-001-584-847-2,CC(C[C@@H](C(=O)O)NC(=O)C)C,"CBR-HVAC-06484: Ear disorders, treatment of;"
CBR-001-584-848-3,RFM-004-428-0,CBR-001-584-848-3,OC[C@H]([C@H]([C@@H]1O[C@@](O)(C[C@@H]([C@H]1NC(=O)C)O)C(=O)O)O)O,"CBR-HVAC-00113: Immunomodulators;Motor Function Disorders, Treatment of;Cognition Disorders, Treatment of;Neuromuscular Genetic Disorders, Treatment of;Antiinfectives (Not Specified); Unidentified pharmacological activity"
CBR-001-584-849-4,RFM-004-429-1,CBR-001-584-849-4,OC[C@H](C(=O)O)N,"CBR-HVAC-06404: Psychiatric Disorders (Not Specified);Antiparkinsonian Drugs;Posttraumatic Stress Disorder (PTSD), Treatment of;Analgesic Enhancers; NMDA Glycine-Site Agonists;Signal Transduction Modulators;"
CBR-001-584-850-7,RFM-004-430-4,CBR-001-584-850-7,O=C(C1CCC(CC1)(F)F)N[C@H](c1ccccc1)CCN1[C@@H]2CC[C@H]1CC(C2)n1c(C)nnc1C(C)C,"CBR-HVAC-02141: Colorectal Cancer Therapy;Microbicides;Immunosuppressants;Rheumatoid Arthritis, Treatment of;Anti-HIV Agents; Chemokine CCR5 Antagonists;HIV Attachment Inhibitors;Reverse Transcriptase Inhibitors;Signal Transduction Modulators; C-C chemokine receptor type 5 Antagonist; CC chemokine receptor 5 antagonist; Chemokine receptor antagonist"
CBR-001-584-851-8,RFM-004-431-5,CBR-001-584-851-8,ONC(=O)C[C@H](c1onc(n1)C(=O)N)CCCC1CCCCC1,CBR-HVAC-06045: Dermatologic Drugs; Procollagen C-Endopeptidase Inhibitors; Bone morphogenetic protein 1 Inhibitor;
CBR-001-584-852-9,RFM-004-432-6,CBR-001-584-852-9,Clc1ccc(cc1)c1nc[nH]c1C,CBR-HVAC-02482: ; Prostaglandin synthase inhibitor
CBR-001-584-853-0,RFM-004-433-7,CBR-001-584-853-0,O=C(N[C@H]([C@H](C[C@H](Cc1ccccc1)NC(=O)[C@@H](N1CCCNC1=O)C(C)C)O)Cc1ccccc1)COc1c(C)cccc1C,CBR-HVAC-04901: Anti-HIV Agents; HIV Protease Inhibitors; Protease Inhibitor;
CBR-001-584-854-1,RFM-004-434-8,CBR-001-584-854-1,O=C(c1ccc2c(c1)nccn2)N1CCCCC1,"CBR-HVAC-04638: Mental Retardation, Treatment of;Antinarcoleptic Drugs;Autism, Treatment of;Antipsychotic Drugs;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of; AMPA Receptor Positive Allosteric Modulators;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Modulator; AMPA receptor agonist; NMDA agonist"
CBR-001-584-855-2,RFM-004-435-9,CBR-001-584-855-2,OC[C@H](CONC(=O)c1ccc(c(c1Nc1ccc(cc1F)I)F)F)O,CBR-HVAC-00029: Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Melanoma Therapy;Pancreatic Cancer Therapy;Oncolytic Drugs;Colorectal Cancer Therapy; Extracellular-Regulated Kinase (ERK) Inhibitors;MEK1 Inhibitors;Signal Transduction Modulators; Mitogen-activated protein 2 kinase Inhibitor; MEK inhibitor; Protein kinase inhibitor
CBR-001-584-856-3,RFM-004-436-0,CBR-001-584-856-3,OC(=O)c1ccc(cc1)/C=C/c1cc2c(cc1Cn1cccn1)C(C)(C)CCC2(C)C,"CBR-HVAC-00037: Pulmonary Emphysema, Agents for;Bone, Muscles and Connective Tissue Genetic Disorders, Treatment of; Retinoid RARgamma Agonists;Signal Transduction Modulators; Retinoic acid receptor gamma Agonist; Retinoic acid gamma receptor agonist"
CBR-001-584-857-4,RFM-004-437-1,CBR-001-584-857-4,[S-][Mo](=S)(=S)[S-],"CBR-HVAC-00047: Amyloid-beta-protein-precursor-inhibitors; Angiogenesis Inhibitors; Angiogenesis inhibitor; Chelating-agents; Cytosolic Superoxide Dismutase (SOD1) Inhibitors; FMS-related tyrosine kinase 1 Antagonist; Fibroblast Growth Factor 2 (FGF2) Inhibitors; Fibroblast-growth-factor-inhibitors; NF-kappaB (NFKB) Activation Inhibitors; Signal Transduction Modulators; Superoxide dismutase-1 inhibitor; Transforming-growth-factor-beta-inhibitors; Vascular Endothelial Growth Factor (VEGF) Inhibitors; Agents for Liver Cirrhosis; Alzheimer's Dementia, Treatment of ; Alzheimer's Disease and Cognition Disorders; Anticancer; Breast Cancer Therapy; Connective Tissue Disorders; Digestive/Gastrointestinal Cancer Therapy; Huntington's Disease, Treatment of; Interstitial Lung Diseases, Treatment of; Liver Disorders; Metabolic Disorders; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs; Parkinson's Disease and Movement Disorders; Respiratory Tract Disorders; Wilson Disease, Agent for"
CBR-001-584-858-5,RFM-004-438-2,CBR-001-584-858-5,C=CC(=O)N1CCC[C@H](C1)n1nc(c2c1ncnc2N)c1ccc(cc1)Oc1ccccc1,"CBR-HVAC-00082: Breast Cancer Therapy;Allergy, Treatment of;Multiple Myeloma Therapy;Lymphocytic Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Myeloid Leukemia Therapy;Immunosuppressants;Rheumatoid Arthritis, Treatment of;Pancreatic Cancer Therapy;Hematological Cancer Therapy;Leukemia Therapy; Apoptosis Inducers;Bruton's Tyrosine Kinase (BTK) Inhibitors;Cytoplasmic Tyrosine-Protein Kinase BMX Inhibitors;Lck Kinase Inhibitors;Lyn Kinase Inhibitors;Signal Transduction Modulators; Bruton's tyrosine kinase Inhibitor; Bruton's tyrosine kinase inhibitor"
CBR-001-584-859-6,RFM-004-439-3,CBR-001-584-859-6,NC[C@@H]1CC[C@H](CC1)C(=O)O,CBR-HVAC-00095: Antifibrinolytics;Treatment of Menorrhagia; Tissue-Type Plasminogen Activator (t-PA) Inhibitors; Thromboxane A2 receptor Antagonist; Fibrinogen stimulant
CBR-001-584-860-9,RFM-004-440-6,CBR-001-584-860-9,O=c1[nH]/c(=C\c2nc[nH]c2C(C)(C)C)/c(=O)[nH]/c/1=C\c1ccccc1,CBR-HVAC-00111: Antineoplastic Enhancing Agents;Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Lymphoma Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors;Vascular Disrupting Agents (VDA); Tubulin Inhibitor; Tubulin inhibitor; Angiogenesis inhibitor
CBR-001-584-861-0,RFM-004-441-7,CBR-001-584-861-0,n1ccc(cc1)Nc1ccc(cc1)NCCc1c[nH]c2c1cccc2,CBR-HVAC-00138: Prostate Cancer Therapy;Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy; MDM2 (hdm2) Inhibitors; MDM2 P53-Binding protein Inhibitor; MDM2 inhibitor; Apoptosis stimulant; Oncogene inhibitor; Angiogenesis stimulant
CBR-001-584-862-1,RFM-004-442-8,CBR-001-584-862-1,Clc1ccc(c(c1)C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F)O,"CBR-HVAC-00155: Atopic Dermatitis, Agents for;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Lymphocytic Leukemia Therapy;Interstitial Lung Diseases, Treatment of;Acne Therapy; IKK-2 (IKK-beta) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; IKAPPA B KINASE BETA Inhibitor; IKK1 inhibitor; IKK2 inhibitor; Protein kinase inhibitor"
CBR-001-584-863-2,RFM-004-443-9,CBR-001-584-863-2,C/C(=C\c1ccc(cc1)C(=O)O)/c1ccc2c(c1)C(C)(C)CCC2(C)C,CBR-HVAC-00163: ; Retinoid acid receptor; Retinoid X receptor Agonist; Retinoic acid receptor agonist
CBR-001-584-864-3,RFM-004-444-0,CBR-001-584-864-3,O=C1N=C(CN1c1ccc(cc1)Cl)N1CCOCC1,CBR-HVAC-00180: Anxiolytics;Antiepileptic Drugs; GABA(A) BZ Site Receptor Partial Agonists;Signal Transduction Modulators; BENZODIAZEPINE RECEPTOR AGONIST; GABA A receptor agonist
CBR-001-584-865-4,RFM-004-445-1,CBR-001-584-865-4,Cc1csc(c1)c1nnc(c2c1cccc2)Nc1ccc(cc1)Oc1ncccc1c1ccnc(n1)N,CBR-HVAC-00244: Solid Tumors Therapy;Hematological Cancer Therapy;Ovarian Cancer Therapy; Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;Signal Transduction Modulators; Aurora kinase C; Aurora kinase A; Aurora kinase B Inhibitor; Aurora kinase inhibitor
CBR-001-584-866-5,RFM-004-446-2,CBR-001-584-866-5,NCC(=O)Nc1ccc(cc1)n1nc(cc1c1ccc2c(c1)ccc1c2cccc1)C(F)(F)F,CBR-HVAC-00264: Oncolytic Drugs;Antifungal Agents;Antibacterial Drugs;Chemopreventive Agents;Antiviral Drugs; Apoptosis Inducers;Phosphoinositide Dependent Kinase (PDK) 1 Inhibitors;Signal Transduction Modulators; 3-PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE-1 Inhibitor; 3-phosphoinositide-dependent kinase 1 inhibitor; Angiogenesis inhibitor; Apoptosis stimulant
CBR-001-584-867-6,RFM-004-447-3,CBR-001-584-867-6,CNC(=O)c1ccc(cc1F)c1cnc2n(n1)c(cn2)Cc1ccc2c(c1)cccn2,CBR-HVAC-00272: Glioblastoma Multiforme Therapy;Oncolytic Drugs;Renal Cancer Therapy;Liver Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Melanoma Therapy; HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators; MET KINASE Inhibitor; MET tyrosine kinase inhibitor
CBR-001-584-868-7,RFM-004-448-4,CBR-001-584-868-7,CCc1nc(c(s1)c1ccnc(c1)NC(=O)c1ccccc1)c1cccc(c1)C,"CBR-HVAC-00305: Rheumatoid Arthritis, Treatment of; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; p38 Mitogen-activated protein kinase Inhibitor; P38 kinase inhibitor"
CBR-001-584-869-8,RFM-004-449-5,CBR-001-584-869-8,O[C@@H]1CC[C@@H](CC1)N(c1cc(sc1C(=O)O)C#CC(C)(C)C)C(=O)[C@@H]1CC[C@H](CC1)C,CBR-HVAC-00346: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B polymerase Inhibitor; HCV nonstructural protein 5B inhibitor
CBR-001-584-870-1,RFM-004-450-8,CBR-001-584-870-1,OCCn1nc(c(c1CC)Oc1cc(C#N)cc(c1)C#N)CC,CBR-HVAC-00347: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase inhibitor
CBR-001-584-871-2,RFM-004-451-9,CBR-001-584-871-2,C[C@H](c1ccc(cc1)c1ccc(cc1)CCNS(=O)(=O)C)CNS(=O)(=O)C(C)C,"CBR-HVAC-00352: Alzheimer's Dementia, Treatment of ;Antidepressants;Antipsychotic Drugs;Stroke, Treatment of; AMPA Receptor Modulators;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Agonist; AMPA receptor agonist"
CBR-001-584-872-3,RFM-004-452-0,CBR-001-584-872-3,Clc1ccc(c(c1)F)Cc1c(C)nc2n1nc(Nc1[nH]nc(c1)C)cc2CN1CCOCC1,CBR-HVAC-00353: Hematopoiesis Disorders Therapy; Jak2 Inhibitors;Signal Transduction Modulators; Jak2 tyrosine kinase Inhibitor; Janus kinase 2 inhibitor
CBR-001-584-873-4,RFM-004-453-1,CBR-001-584-873-4,CS(=O)(=O)N1CCN(CC1)Cc1cc2c(s1)c(nc(n2)c1cccc2c1cn[nH]2)N1CCOCC1,CBR-HVAC-00355: Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Breast Cancer Therapy; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; Mechanistic target of rapamycin kinase; Phosphoinositide 3 kinase alpha Inhibitor; PI3 kinase alpha inhibitor; PI3 kinase beta inhibitor; PI3 kinase delta inhibitor; PI3 kinase gamma inhibitor
CBR-001-584-874-5,RFM-004-454-2,CBR-001-584-874-5,NC(=O)[C@H](N(S(=O)(=O)c1ccc(cc1)Cl)Cc1ccc(cc1F)c1nocn1)CCC(F)(F)F,"CBR-HVAC-00357: Alzheimer's Dementia, Treatment of ; gamma-Secretase Inhibitors; Gamma secretase Inhibitor; Secretase gamma inhibitor"
CBR-001-584-875-6,RFM-004-455-3,CBR-001-584-875-6,CN1CCN(CC1)CCOc1cc(OC2CCOCC2)c2c(c1)ncnc2Nc1c(Cl)ccc2c1OCO2,"CBR-HVAC-00362: Gastric Cancer Therapy;Breast Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Head and Neck Cancer Therapy;Pancreatic Cancer Therapy;Cancer Associated Disorders, Treatment of;Interstitial Lung Diseases, Treatment of;Hematological Cancer Therapy;Colorectal Cancer Therapy;Alzheimer's Dementia, Treatment of ;Ovarian Cancer Therapy;Endocrine Cancer Therapy;Melanoma Therapy;Osteosarcoma Therapy;Prostate Cancer Therapy; Fyn Kinase Inhibitors;Signal Transduction Modulators; ABL; c-SRC Inhibitor; Src inhibitor; Abl receptor tyrosine kinase inhibitor"
CBR-001-584-876-7,RFM-004-456-4,CBR-001-584-876-7,Ic1ccc(c(c1)Cl)Nc1c(ccc(c1F)F)C(=O)NOCC1CC1,CBR-HVAC-00372: Oncolytic Drugs; Extracellular-Regulated Kinase (ERK) Inhibitors;Mitogen-Activated Protein (MAP) Kinase Kinase (MEK) Inhibitors;Signal Transduction Modulators; Mitogen-activated protein 2 kinase 1 Inhibitor; MEK inhibitor
CBR-001-584-877-8,RFM-004-457-5,CBR-001-584-877-8,ONC(=O)C1(CCOCC1)CS(=O)(=O)c1ccc(cc1)Oc1ccc(cc1)Cl,CBR-HVAC-00413: ; Matrix metalloproteinase Inhibitor; Immunosuppressant
CBR-001-584-878-9,RFM-004-458-6,CBR-001-584-878-9,CN(CCn1c(=O)c2cc(N)cc3c2c(c1=O)ccc3)C,CBR-HVAC-00422: Prostate Cancer Therapy;Ovarian Cancer Therapy;Gastric Cancer Therapy;Colorectal Cancer Therapy;Myeloid Leukemia Therapy;Antiviral Drugs;Breast Cancer Therapy; DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor
CBR-001-584-879-0,RFM-004-459-7,CBR-001-584-879-0,CC[C@@H](c1ccccc1)NC(=O)c1c(O)c(nc2c1cccc2)c1ccccc1,"CBR-HVAC-00438: Antitussives;Irritable Bowel Syndrome, Agents for;Antipsychotic Drugs;Urinary Incontinence Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Signal Transduction Modulators;Tachykinin NK3 Antagonists; Neurokinin receptor 3 Antagonist; Neurokinin 3 receptor antagonist"
CBR-001-584-880-3,RFM-004-460-0,CBR-001-584-880-3,N#Cc1ccc(n1C)c1ccc2c(c1)C(C)(C)OC(=S)N2,CBR-HVAC-00463: Female Contraceptives;Hormone Replacement Therapy; Progesterone Receptor Agonists;Signal Transduction Modulators; Progesterone receptor Agonist; Progesterone receptor agonist
CBR-001-584-881-4,RFM-004-461-1,CBR-001-584-881-4,CCC(SSc1ncc[nH]1)C,CBR-HVAC-00525: ; Thioredoxin reductase Inhibitor; Thioredoxin inhibitor; Apoptosis stimulant
CBR-001-584-882-5,RFM-004-462-2,CBR-001-584-882-5,OC(=O)C[C@H]1CCc2c1n(Cc1ccc(cc1)Cl)c1c2cc(cc1S(=O)(=O)C)F,"CBR-HVAC-00537: Peripheral Vascular Disease, Treatment of;Asthma Therapy;Dermatologic Drugs;Drugs for Allergic Rhinitis; Prostanoid DP (DP1) Antagonists;Signal Transduction Modulators; Prostaglandin D2 receptor 1 Antagonist; Prostaglandin D2 receptor DP1 antagonist"
CBR-001-584-883-6,RFM-004-463-3,CBR-001-584-883-6,CN[C@@H](C(c1ccccc1)(C)C)C(=O)N[C@@H](C(C)(C)C)C(=O)N([C@@H](C(C)C)/C=C(/C(=O)O)\C)C,CBR-HVAC-00544: Oncolytic Drugs; Antimitotic Drugs;Tubulin Polymerization Inhibitors; Tubulin inhibitor; Microtubule inhibitor
CBR-001-584-884-7,RFM-004-464-4,CBR-001-584-884-7,OCCOc1ccc(cc1)c1c(C#N)c(SCc2csc(n2)c2ccc(cc2)Cl)nc(c1C#N)N,CBR-HVAC-00566: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Antiarrhythmic Drugs; Adenosine A1 Agonists;Signal Transduction Modulators; Adenosine A1 receptor Agonist; Adenosine A1 receptor agonist
CBR-001-584-885-8,RFM-004-465-5,CBR-001-584-885-8,OC(=O)COc1cc(C)c(c(c1)C)Cc1ccc(c(c1)C(C)C)O,"CBR-HVAC-00576: Antiobesity Drugs;Thyroid Disease Therapy;Lipoprotein Disorders, Treatment of ; Signal Transduction Modulators;Thyroid Hormone Receptor beta Agonists; Thyroid hormone receptor beta Activator; Thyroid hormone receptor beta agonist; Thyroid hormone function stimulant; Cholesterol inhibitor"
CBR-001-584-886-9,RFM-004-466-6,CBR-001-584-886-9,CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)CO)CC(C)C)CC(C)C)CCCNC(=N)N,CBR-HVAC-00595: ; Gonadotropin-releasing hormone Agonist; Luteinizing hormone releasing hormone (LHRH) agonist
CBR-001-584-887-0,RFM-004-467-7,CBR-001-584-887-0,CCC[C@@H](C(=O)Nc1ncn(c1)C(CNCC(C)(C)C)(C)C)N[C@H]1CCc2c(C1)c(F)cc(c2)F,"CBR-HVAC-00609: Alzheimer's Dementia, Treatment of ;Oncolytic Drugs;Pancreatic Cancer Therapy;Leukemia Therapy;Breast Cancer Therapy; Apoptosis Inducers;gamma-Secretase Inhibitors; Gamma-secretase Inhibitor; Secretase gamma inhibitor"
CBR-001-584-888-1,RFM-004-468-8,CBR-001-584-888-1,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)c1ccc(cc1)CNCc1cnn[nH]1,CBR-HVAC-00642: Antibacterial Drugs; Protein 30S ribosomal subunit inhibitor; Protein 50S ribosomal subunit inhibitor
CBR-001-584-889-2,RFM-004-469-9,CBR-001-584-889-2,C/C(=C\CSc1ccccc1C(=O)O)/CC/C=C(/CCC=C(C)C)\C,CBR-HVAC-00645: Solid Tumors Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Pancreatic Cancer Therapy;Hematological Cancer Therapy; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Signal Transduction Modulators;TRPA1 Agonists; RAS Inhibitor; Cell cycle inhibitor; Immunosuppressant; mTOR kinase inhibitor; Protein kinase inhibitor; Ras inhibitor
CBR-001-584-890-5,RFM-004-470-2,CBR-001-584-890-5,CCN(c1cc(cc(c1C)C(=O)NCc1c(C)cc([nH]c1=O)C)c1ccc(cc1)CN1CCOCC1)C1CCOCC1,CBR-HVAC-00669: Solid Tumors Therapy;Sarcoma Therapy;Non-Hodgkin's Lymphoma Therapy;Breast Cancer Therapy; Histone-Lysine N-Methyltransferase EZH2 Inhibitors; EZH2 Inhibitor; Histone methyltransferase inhibitor
CBR-001-584-891-6,RFM-004-471-3,CBR-001-584-891-6,ONC(=O)c1ccc(cc1)OCCNC(=O)c1oc2c(c1CN(C)C)cccc2,CBR-HVAC-00671: Lymphoma Therapy;Sarcoma Therapy;Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors;RAD51 Expression Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor
CBR-001-584-892-7,RFM-004-472-4,CBR-001-584-892-7,Cn1c(Nc2ccc(cc2)C(F)(F)F)nc2c1ccc(c2)Oc1ccnc(c1)c1ncc([nH]1)C(F)(F)F,CBR-HVAC-00673: Solid Tumors Therapy;Melanoma Therapy; Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFRbeta Inhibitors;Raf kinase B Inhibitors;Raf kinase C Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Vascular endothelial growth factor receptor; RAF Inhibitor; B-raf kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; Apoptosis stimulant; VEGFR-2 tyrosine kinase inhibitor; EGFR kinase inhibitor; Raf kinase inhibitor; C-raf kinase inhibitor
CBR-001-584-893-8,RFM-004-473-5,CBR-001-584-893-8,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1)c1ccccc1,CBR-HVAC-00677: Lymphoma Therapy;Multiple Myeloma Therapy; Histone Deacetylase 6 (HDAC6) Inhibitors; Histone deacetylase 6 Inhibitor; Histone deacetylase inhibitor
CBR-001-584-894-9,RFM-004-474-6,CBR-001-584-894-9,C[C@@H]1NCCN(C1)Cc1ccc(cc1)CC(=O)N1CCC(CC1)Nc1cccc(c1)F,"CBR-HVAC-00683: Non-Ulcer Dyspepsia, Agents for;Gastric Emptying Disorders,Treatment of; Motilin Receptor Agonists;Signal Transduction Modulators; Ghrelin receptor; Motilin receptor Agonist; Motilin receptor agonist"
CBR-001-584-895-0,RFM-004-475-7,CBR-001-584-895-0,OB([C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)c1cccc(n1)c1ccccc1)CC(C)C)O,CBR-HVAC-00685: Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy;Multiple Myeloma Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;Proteasome Inhibitors; 20S Proteasome Inhibitor; Proteasome inhibitor
CBR-001-584-896-1,RFM-004-476-8,CBR-001-584-896-1,ONC(=O)c1cnc(nc1)N1CCC(CC1)CNCc1cn(c2c1cccc2)C,CBR-HVAC-00697: Myelodysplastic Syndrome Therapy;Multiple Myeloma Therapy;Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy;Leukemia Therapy; Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors; HISTONE DEACETYLASE Inhibitor; Histone deacetylase inhibitor
CBR-001-584-897-2,RFM-004-477-9,CBR-001-584-897-2,CCCCc1nc2c(n1CCN(CC)CC)ccc(c2)/C=C/C(=O)NO,CBR-HVAC-00698: Solid Tumors Therapy;Leukemia Therapy;Prostate Cancer Therapy;Myeloid Leukemia Therapy;Hematopoiesis Disorders Therapy;Antimalarials;Sarcoma Therapy;Myelodysplastic Syndrome Therapy; Apoptosis Inducers;Histone Deacetylase 1 (HDAC1) Inhibitors;Histone Deacetylase 2 (HDAC2) Inhibitors; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4 Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor
CBR-001-584-898-3,RFM-004-478-0,CBR-001-584-898-3,COC(=O)N1CCN(CC1)Cc1cccc(c1F)NC(=O)Nc1ccc(nc1)C,CBR-HVAC-00700: ; Myosin Activator; Unidentified pharmacological activity
CBR-001-584-899-4,RFM-004-479-1,CBR-001-584-899-4,COc1cc2c(ccnc2cc1OCCCN1CCOCC1)Oc1ccc(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F,CBR-HVAC-00706: Liver Cancer Therapy;Renal Cancer Therapy;Solid Tumors Therapy;Gastric Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Head and Neck Cancer Therapy; Angiogenesis Inhibitors;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Receptor tyrosine kinase Inhibitor; MET tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; Flt-3 kinase inhibitor; TIE-2 tyrosine kinase inhibitor; Axl receptor tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor
CBR-001-584-900-0,RFM-004-480-4,CBR-001-584-900-0,Fc1ccc2n(c1)cc(n2)CCC#Cc1ccccn1,"CBR-HVAC-00709: Analgesic Drugs;Gastroesophageal Reflux Disease, Agents for;Dystonia, Treatment of;Antidepressants;Generalized Anxiety Disorder (GAD), Treatment of;Antiparkinsonian Drugs;Migraine, Prophylactic Treatment of; mgluR5 Negative Allosteric Modulators;Signal Transduction Modulators; Metabotropic glutamate receptor 5 Negative allosteric modulator; Glutamate 5 receptor antagonist"
CBR-001-584-901-1,RFM-004-481-5,CBR-001-584-901-1,Fc1ccc2c(c1)c(Cc1ccc3c(n1)cccc3)c(n2CC(=O)O)C,"CBR-HVAC-00722: Atopic Dermatitis, Agents for;Allergy, Treatment of;Drugs for Allergic Rhinitis;Asthma Therapy; Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists;Signal Transduction Modulators; G protein-coupled receptor 44 Antagonist; CRTH2 antagonist"
CBR-001-584-902-2,RFM-004-482-6,CBR-001-584-902-2,C/C(=C\CNCCNC1C2CC3CC1CC(C2)C3)/CCC=C(C)C,CBR-HVAC-00730: Antifungal Agents;Anti-Helicobacter Pylori Agents;Treatment of Tuberculosis; Cell Wall Biosynthesis Inhibitors; Cell wall synthesis inhibitor; MmpL3 inhibitor
CBR-001-584-903-3,RFM-004-483-7,CBR-001-584-903-3,OCCONC(=O)c1cc2n(C)cnc2c(c1Nc1ccc(cc1F)Br)F,"CBR-HVAC-00737: Ovarian Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Small Cell Lung Cancer Therapy;Bladder Cancer Therapy ;Melanoma Therapy;Rheumatoid Arthritis, Treatment of;Multisystem Genetic Disorders, Treatment of ;Solid Tumors Therapy;Leukemia Therapy;Colorectal Cancer Therapy; MEK1 Inhibitors;MEK2 Inhibitors;Signal Transduction Modulators; Mitogen-activated protein kinase kinase Inhibitor; MEK inhibitor; Interleukin 1b antagonist; Interleukin 6 antagonist; MAP kinase inhibitor"
CBR-001-584-904-4,RFM-004-484-8,CBR-001-584-904-4,O=C(Nc1noc(c1)C(C)(C)C)Nc1ccc(cc1)c1cn2c(n1)sc1c2ccc(c1)OCCN1CCOCC1,CBR-HVAC-00741: Myeloid Leukemia Therapy;Solid Tumors Therapy;Myelodysplastic Syndrome Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;CSF1R (c-FMS) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;RET Inhibitors;Signal Transduction Modulators; Colony stimulating factor 1 receptor; Platelet-derived growth factor receptor; FLT3; Stem cell factor receptor Inhibitor; Flt-3 kinase inhibitor
CBR-001-584-905-5,RFM-004-485-9,CBR-001-584-905-5,O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2c1cccc2)c1cn2c3c1cccc3CCC2,CBR-HVAC-00743: Renal Cancer Therapy;Gastric Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Prostate Cancer Therapy;Pancreatic Cancer Therapy;Solid Tumors Therapy;Cancer of Unspecified Body Location/System;Colorectal Cancer Therapy;Breast Cancer Therapy;Liver Cancer Therapy; Apoptosis Inducers;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators; c-MET Inhibitor; MET tyrosine kinase inhibitor; Angiogenesis inhibitor
CBR-001-584-906-6,RFM-004-486-0,CBR-001-584-906-6,OC(=O)C[C@@H](C(=O)COc1c(F)c(F)cc(c1F)F)NC(=O)[C@@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C,"CBR-HVAC-00753: Agents for Liver Cirrhosis;Liver and Biliary Tract Disorders, Treatment of;Agents for Acute Alcoholic Hepatitis;Anti-Hepatitis B Virus Drugs;Anti-Hepatitis C Virus Drugs;Treatment of Transplant Rejection;Ischemic Stroke, Treatment of;Agents for Liver Fibrosis; Apoptosis Inhibitors;Caspase Inhibitors;Signal Transduction Modulators; Caspase 8 inhibitor; Apoptosis inhibitor"
CBR-001-584-907-7,RFM-004-487-1,CBR-001-584-907-7,Clc1ccc(cc1)[C@@](c1cncn1C)(c1ccc2c(c1)c(cc(=O)n2C)c1cccc(c1)Cl)N,"CBR-HVAC-00823: Anti-Hepatitis D Virus Drugs;Prostate Cancer Therapy;Pancreatic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Multiple Myeloma Therapy;Leukemia Therapy;Neurologic Cancer Therapy;Bladder Cancer Therapy ;Non-Hodgkin's Lymphoma Therapy;Oncolytic Drugs;Brain Cancer Therapy;Myeloid Leukemia Therapy;Melanoma Therapy;Multisystem Genetic Disorders, Treatment of ;Lymphoma Therapy;Breast Cancer Therapy;Lymphocytic Leukemia Therapy;Solid Tumors Therapy;Glioblastoma Multiforme Therapy;Lung Cancer Therapy; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators; Farnesyltransferase Inhibitor; Farnesyltransferase inhibitor; Angiogenesis inhibitor; Apoptosis stimulant"
CBR-001-584-908-8,RFM-004-488-2,CBR-001-584-908-8,CNC(=O)c1ccc2c(c1)ccc(c2)[C@@]1(O)CCn2c1cnc2,"CBR-HVAC-00826: Breast Cancer Therapy;Ovarian Cancer Therapy;Prostate Cancer Therapy; Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Signal Transduction Modulators; Cytochrome P450 17A1 Inhibitor; 17,20 lyase inhibitor; Androgen receptor antagonist"
CBR-001-584-909-9,RFM-004-489-3,CBR-001-584-909-9,COc1cccc(c1C1=NCc2c(c3c1cc(Cl)cc3)nc(nc2)Nc1ccc(c(c1)OC)C(=O)O)F,CBR-HVAC-00827: Multiple Myeloma Therapy;Hematopoiesis Disorders Therapy;Leukemia Therapy;Solid Tumors Therapy;Digestive/Gastrointestinal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Small Cell Lung Cancer Therapy;Cancer of Unspecified Body Location/System;Neurologic Cancer Therapy;Breast Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Pancreatic Cancer Therapy;Female Reproductive System Cancer Therapy;Prostate Cancer Therapy;Myelodysplastic Syndrome Therapy;Colorectal Cancer Therapy;Head and Neck Cancer Therapy;Myeloid Leukemia Therapy;Sarcoma Therapy;Ovarian Cancer Therapy; Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Signal Transduction Modulators; Aurora kinase A Inhibitor; Aurora kinase inhibitor; Mitotic inhibitor; Protein kinase inhibitor
CBR-001-584-910-2,RFM-004-490-6,CBR-001-584-910-2,CCOc1cc2ncc(c(c2cc1NC(=O)/C=C/CN(C)C)Nc1ccc(c(c1)Cl)OCc1ccccn1)C#N,CBR-HVAC-00832: Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Breast Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators; ERBB2; EGFR Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-584-911-3,RFM-004-491-7,CBR-001-584-911-3,N#Cc1ccc(cc1)Oc1ccc2c(c1)COB2O,"CBR-HVAC-00844: Atopic Dermatitis, Agents for;Antipsoriatics; IFN-gamma Production Inhibitors;IL-1beta Release Inhibitors;IL-2 Production Inhibitors;IL-6 Modulators;IL-8 Modulators;Phosphodiesterase PDE4 Inhibitors;Phosphodiesterase PDE7 Inhibitors;Signal Transduction Modulators;TNF-alpha Release Inhibitors; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor; Interleukin 12 antagonist; Interleukin 23 antagonist; Tumour necrosis factor alpha antagonist"
CBR-001-584-912-4,RFM-004-492-8,CBR-001-584-912-4,NC(=O)c1cccc2c1nn(c2)c1ccc(cc1)[C@@H]1CCCNC1,CBR-HVAC-00849: Female Reproductive System Cancer Therapy;Breast Cancer Therapy;Oncolytic Drugs;Ovarian Cancer Therapy;Glioblastoma Multiforme Therapy;Melanoma Therapy;Neurologic Cancer Therapy;Solid Tumors Therapy; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors;Signal Transduction Modulators; Poly (ADP-ribose) polymerase 2; Poly (ADP-ribose) polymerase 1 Inhibitor; ADP ribose polymerase 1 inhibitor; ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor
CBR-001-584-913-5,RFM-004-493-9,CBR-001-584-913-5,OCc1cc(ccc1O)[C@H](CNCCCCCCOCCOCc1c(Cl)cccc1Cl)O,"CBR-HVAC-00852: Asthma Therapy;Bronchodilators;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; BETA 2 ADRENOCEPTOR Agonist; Long-acting beta 2 adrenoceptor (LABA) agonist; Beta 2 adrenoreceptor agonist"
CBR-001-584-914-6,RFM-004-494-0,CBR-001-584-914-6,O=C(c1cccnc1NCc1ccncc1)Nc1ccc2c(c1)NCC2(C)C,CBR-HVAC-00855: Digestive/Gastrointestinal Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Bladder Cancer Therapy ;Ovarian Cancer Therapy;Endocrine Cancer Therapy; Angiogenesis Inhibitors;KIT (C-KIT) Inhibitors;PDGFR Family Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; PDGFR; Vascular endothelial growth factor receptor; KIT Antagonist; Inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor; RET tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor
CBR-001-584-915-7,RFM-004-495-1,CBR-001-584-915-7,COc1cccc(c1)N1CCN(CC1)C1=Nc2c(F)cccc2[C@@H](N1c1cc(ccc1OC)C(F)(F)F)CC(=O)O,CBR-HVAC-00859: Anti-Cytomegalovirus Drugs; CMV terminase inhibitor
CBR-001-584-916-8,RFM-004-496-2,CBR-001-584-916-8,N#CCNC(=O)c1ccc(cc1)c1ccnc(n1)Nc1ccc(cc1)N1CCOCC1,CBR-HVAC-00864: Non-Small Cell Lung Cancer Therapy;Pancreatic Cancer Therapy;Hematopoiesis Disorders Therapy;Hematological Cancer Therapy; Jak1 Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators; JANUS KINASE 1; JANUS KINASE 2 Inhibitor; Janus kinase 1 inhibitor; Janus kinase 2 inhibitor
CBR-001-584-917-9,RFM-004-497-3,CBR-001-584-917-9,C[C@@H](OC(=O)[C@@H](N)C)COc1cn2c(c1C)c(ncn2)Oc1ccc2c(c1F)cc([nH]2)C,CBR-HVAC-00886: ; FIBROBLAST GROWTH FACTOR RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR Inhibitor; VEGFR-2 tyrosine kinase inhibitor; FGF receptor 1 tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; VEGFR-3 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor
CBR-001-584-918-0,RFM-004-498-4,CBR-001-584-918-0,N#C[C@@]1(CC[C@@H](CC1)C(=O)O)c1ccc(c(c1)OC1CCCC1)OC,"CBR-HVAC-00902: Atopic Dermatitis, Agents for;Ophthalmic Drugs;Rheumatoid Arthritis, Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy;Bronchodilators; IL-1beta Production Inhibitors;IL-12 Production Inhibitors;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; PHOSPHODIESTERASE 4 Inhibitor; Phosphodiesterase 4 inhibitor"
CBR-001-584-919-1,RFM-004-499-5,CBR-001-584-919-1,ClCCN(S(=O)(=O)C)N(S(=O)(=O)C)C(=O)NC,CBR-HVAC-00907: ; O6-alkylguanine-DNA alkyltransferase inhibitor; DNA inhibitor
CBR-001-584-920-4,RFM-004-500-1,CBR-001-584-920-4,OC(=O)CSc1nnc(n1c1ccc(c2c1cccc2)C1CC1)Br,CBR-HVAC-00911: Treatment of Gout;Uricosurics; Urate Transporter 1 (URAT1) Inhibitors; URATE TRANSPORTER 1 Inhibitor; Uric acid diuretic
CBR-001-584-921-5,RFM-004-501-2,CBR-001-584-921-5,OCC(Cn1cnc2c1c(=O)n(C)c(=O)n2C)O,CBR-HVAC-00933: ; Phosphodiesterase Inhibitor; Phosphodiesterase inhibitor; Alpha 1 adrenoreceptor antagonist
CBR-001-584-922-6,RFM-004-502-3,CBR-001-584-922-6,NCC1=CCC(C(O1)OC1C(N)CC(C(C1O)OC1OCC(C(C1O)NC)(C)O)N)N,CBR-HVAC-00954: ; 16S-rRNA of 30S ribosomal subunit Binder; Protein 30S ribosomal subunit inhibitor; DNA synthesis inhibitor
CBR-001-584-923-7,RFM-004-503-4,CBR-001-584-923-7,Oc1ccc(c(c1)Cl)C(CNC(C)(C)C)O,CBR-HVAC-00978: Cardiovascular Diseases (Not Specified);Bronchodilators; Beta-2 adrenergic receptor Agonist; Beta adrenoreceptor agonist
CBR-001-584-924-8,RFM-004-504-5,CBR-001-584-924-8,O=C1NC(=O)C(S1)Cc1ccc(cc1)OCC1(C)CCCCC1,CBR-HVAC-01021: Antidiabetic Drugs; Insulin Sensitizers;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator-activated receptor gamma Agonist; Peroxisome proliferator-activated receptor gamma agonist
CBR-001-584-925-9,RFM-004-505-6,CBR-001-584-925-9,COc1ccc(cc1)C(=O)c1c(C)n(c2c1cccc2)CCN1CCOCC1,CBR-HVAC-01140: Non-Opioid Analgesics; Cannabinoid receptor Agonist; Cyclooxygenase inhibitor; Cannabinoid CB1 receptor agonist; Cannabinoid CB2 receptor agonist
CBR-001-584-926-0,RFM-004-506-7,CBR-001-584-926-0,Clc1ccc(cc1)Cn1c(CC(C(=O)O)(C)C)c(c2c1ccc(c2)OCc1ccc2c(n1)cccc2)SC(C)(C)C,"CBR-HVAC-01225: Inflammatory Bowel Disease, Agents for; Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; Five lipoxygenase activating protein antagonist; 5 Lipoxygenase inhibitor; Leucotriene B4 antagonist"
CBR-001-584-927-1,RFM-004-507-8,CBR-001-584-927-1,CC(c1cc(/C=C/2\SC(=O)NC2=O)cc(c1O)C(C)(C)C)(C)C,CBR-HVAC-01229: Antiarthritic Drugs;Atherosclerosis Therapy; Cyclooxygenase (COX) Inhibitors;LDL Antioxidants;Signal Transduction Modulators;5-Lipoxygenase Inhibitors; COX-2 Inhibitor; Thromboxane B2 receptor antagonist; Arachidonic acid inhibitor; Leucotriene B4 antagonist
CBR-001-584-928-2,RFM-004-508-9,CBR-001-584-928-2,OC(C(Cl)(Cl)Cl)O,CBR-HVAC-01264: ; Alcohol dehydrogenase inhibitor;2016-04-01: controlled substance
CBR-001-584-929-3,RFM-004-509-0,CBR-001-584-929-3,[O-][N+](=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O,"CBR-HVAC-01289: Angina pectoris, Treatment of;Heart Failure Therapy; Guanylate cyclase stimulant; Nitric oxide stimulant"
CBR-001-584-930-6,RFM-004-510-3,CBR-001-584-930-6,CCN1CCC[C@H]1CNC(=O)c1cc(ccc1OC)S(=O)(=O)N,"CBR-HVAC-01291: Non-Ulcer Dyspepsia, Agents for;Nausea and Vomiting, Treatment of;Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-584-931-7,RFM-004-511-4,CBR-001-584-931-7,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@@H]([C@](C2)(C)OC)O)[C@H](C)[C@@H](O[C@@H]2OC(C)C[C@@H]([C@H]2O)N(C)C)[C@](C[C@H](C(=O)[C@@H]([C@H]([C@]1(C)O)O)C)C)(C)O,CBR-HVAC-01380: ; 23S-rRNA of 50S ribosomal subunit Binder; Protein 50S ribosomal subunit inhibitor
CBR-001-584-932-8,RFM-004-512-5,CBR-001-584-932-8,Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1C[C@H]([C@@H]2O)O)C,"CBR-HVAC-01414: Hormone Replacement Therapy;Cognition Disorders, Treatment of;Antidepressants;Multiple Sclerosis, Agents for;Gynecological Disorders, Treatment of ;Treatment of Hot Flushes;Female Infertility, Agents for; Estrogen receptor Agonist; Estrogen receptor agonist"
CBR-001-584-933-9,RFM-004-513-6,CBR-001-584-933-9,ClCCNC(=O)N(CCCl)N=O,CBR-HVAC-01496: ; Glutathione reductase Inhibitor; DNA inhibitor
CBR-001-584-934-0,RFM-004-514-7,CBR-001-584-934-0,NCCCC(P(=O)(O)O)(P(=O)(O)O)O,CBR-HVAC-01507: Treatment of Paget's Disease;Treatment of Hypercalcemia;Asthma Therapy;Treatment of Osteoporosis; Protein Tyrosine Phosphatase (PTP) Inhibitors;Signal Transduction Modulators; Farnesyl diphosphate synthase Inhibitor; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor
CBR-001-584-935-1,RFM-004-515-8,CBR-001-584-935-1,CCCC[C@@H](C[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC/C=C/C(=O)O)O)C,CBR-HVAC-01510: Treatment of Peripheral Obstructive Vascular Disease;Vasodilators; Prostaglandin E1 receptor agonist
CBR-001-584-936-2,RFM-004-516-9,CBR-001-584-936-2,CCNC1=Nc2ccc(cc2C(O1)(C)c1ccccc1)Cl,CBR-HVAC-01534: Anxiolytics; Drugs Acting on GABA(A) Receptors;Signal Transduction Modulators; Benzodiazepine receptor Potentiator; GABA A receptor agonist; Translocator protein agonist
CBR-001-584-937-3,RFM-004-517-0,CBR-001-584-937-3,O=C(C(c1ccc(cc1)O)N)NC1C(=O)N2C1SCC(=C2C(=O)O)C,CBR-HVAC-01572: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-584-938-4,RFM-004-518-1,CBR-001-584-938-4,CC1Nc2cc(Cl)c(cc2C(=O)N1c1ccccc1C)S(=O)(=O)N,"CBR-HVAC-01615: Hypertension, Treatment of;Diuretics; Carbonic Anhydrase Type VII Inhibitors;Pregnane X Receptor (PXR) Agonists; Carbonic anhydrase inhibitor"
CBR-001-584-939-5,RFM-004-519-2,CBR-001-584-939-5,CCCOc1ccc(cc1c1[nH]c(=O)c2c(n1)c(CCC)cn2CC)S(=O)(=O)N1CCN(CC1)CCO,"CBR-HVAC-01663: Hypertension, Treatment of;Treatment of Erectile Dysfunction; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor; Phosphodiesterase 4 inhibitor"
CBR-001-584-940-8,RFM-004-520-5,CBR-001-584-940-8,CN1CCC2=C(C1)c1ccccc1Cc1c2cccc1,CBR-HVAC-01783: Antidepressants; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Antagonist; Alpha 2 adrenoreceptor antagonist; 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 2C receptor antagonist
CBR-001-584-941-9,RFM-004-521-6,CBR-001-584-941-9,OCCCCCCCCCCC1=C(C)C(=O)C(=C(C1=O)OC)OC,"CBR-HVAC-01809: Ocular Genetic Disorders, Treatment of ;Neuromuscular Genetic Disorders, Treatment of;Multiple Sclerosis, Agents for;Alzheimer's Dementia, Treatment of ;Muscular Dystrophy, Agents for;Neurologic Drugs (Miscellaneous); Antioxidants;Calcium Channel Modulators; Reducing agent"
CBR-001-584-942-0,RFM-004-522-7,CBR-001-584-942-0,OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1cnc2c1nc(N)nc2OC,CBR-HVAC-01857: Lymphoma Therapy;Lymphocytic Leukemia Therapy; Adenosine Deaminase (ADA) Inhibitors;Antimetabolites;Purine Biosynthesis Inhibitors; DNA synthesis inhibitor; T cell inhibitor
CBR-001-584-943-1,RFM-004-523-8,CBR-001-584-943-1,N#CCCN1C(=O)C(O)N=C(c2c1ccc(c2)Cl)c1ccccc1F,CBR-HVAC-01965: Sedative/Hypnotics; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; Benzodiazepine receptor Agonist; Benzodiazepine receptor agonist
CBR-001-584-944-2,RFM-004-524-9,CBR-001-584-944-2,OCCOCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,CBR-HVAC-01977: ; Lipoxygenase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin receptor antagonist
CBR-001-584-945-3,RFM-004-525-0,CBR-001-584-945-3,ONC(=O)/C=C/c1cccc(c1)S(=O)(=O)Nc1ccccc1,CBR-HVAC-01979: Myelodysplastic Syndrome Therapy;Liver Cancer Therapy;Sarcoma Therapy;Bladder Cancer Therapy ;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Ovarian Cancer Therapy;Small Cell Lung Cancer Therapy;Multiple Myeloma Therapy;Myeloid Leukemia Therapy;Cancer of Unspecified Body Location/System;Non-Hodgkin's Lymphoma Therapy;Respiratory/Thoracic Cancer Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;Cytochrome P450 CYP2A6 Inhibitors;Cytochrome P450 CYP2C9 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Histone Deacetylase 1 (HDAC1) Inhibitors;Histone Deacetylase 2 (HDAC2) Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor
CBR-001-584-946-4,RFM-004-526-1,CBR-001-584-946-4,CCCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F)C(=O)COC(=O)C,"CBR-HVAC-02021: Antiinflammatory Ophthalmic Agents;Dry Eye Syndrome, Treatment for;Diabetic Retinopathy, Agents for;Topical Antiinflammatory Agents; Glucocorticoid receptor Agonist; Corticosteroid agonist; Arachidonic acid inhibitor; Immunosuppressant"
CBR-001-584-947-5,RFM-004-527-2,CBR-001-584-947-5,O=C1C=C[C@]2(C(=C1)C(=C)C[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C)C,CBR-HVAC-02028: Ovarian Cancer Therapy;Chemopreventive Agents;Breast Cancer Therapy; Aromatase Inhibitors; Aromatase Inhibitor; Aromatase inhibitor
CBR-001-584-948-6,RFM-004-528-3,CBR-001-584-948-6,Nc1ncc(cc1O[C@@H](c1c(Cl)ccc(c1Cl)F)C)c1cnn(c1)C1CCNCC1,CBR-HVAC-02081: Solid Tumors Therapy;Gastric Cancer Therapy;Colorectal Cancer Therapy;Glioblastoma Multiforme Therapy;Prostate Cancer Therapy;Oncolytic Drugs;Melanoma Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Neurologic Cancer Therapy;Non-Hodgkin's Lymphoma Therapy; ALK Inhibitors;ALK Tyrosine Kinase Receptor (L1196M Mutant) Inhibitors;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators; Anaplastic lymphoma kinase Inhibitor; ALK receptor tyrosine kinase inhibitor; MET tyrosine kinase inhibitor
CBR-001-584-949-7,RFM-004-529-4,CBR-001-584-949-7,OC(COc1cc(C)c(c(c1C)C)OC(=O)C)CNC(C)C,CBR-HVAC-02177: Antiglaucoma Agents; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor Antagonist; Beta adrenoreceptor antagonist
CBR-001-584-950-0,RFM-004-530-7,CBR-001-584-950-0,CN1CCOC(c2c(C1)cccc2)c1ccccc1,CBR-HVAC-02181: Non-Opioid Analgesics; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-584-951-1,RFM-004-531-8,CBR-001-584-951-1,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](c1ccc(cc1)O)C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C,CBR-HVAC-02218: Thyroid Disease Therapy;Antibiotics;Antibacterial Drugs; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-584-952-2,RFM-004-532-9,CBR-001-584-952-2,COC1=CC(=O)C[C@H]([C@@]21Oc1c(C2=O)c(OC)cc(c1Cl)OC)C,CBR-HVAC-02300: Antifungal Agents; Antimitotic Drugs;Microtubule-Stabilizing Agents;Wnt Signaling Inhibitors; Microtubule inhibitor
CBR-001-584-953-3,RFM-004-533-0,CBR-001-584-953-3,NC1=NCC2N1c1ccccc1Cc1c2cccc1,"CBR-HVAC-02302: Drugs for Allergic Rhinitis;Antiallergic Ophthalmic Agents;Antiallergy/Antiasthmatic Drugs;Allergic Skin Disorders, Treatment for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor; Histamine H2 receptor Antagonist; Histamine H1 receptor antagonist; Histamine release inhibitor"
CBR-001-584-954-4,RFM-004-534-1,CBR-001-584-954-4,O[C@@H](CCc1ccccc1)CC[C@H]1[C@H](O)C[C@@H]([C@@H]1C/C=C\CCCC(=O)OC(C)C)O,CBR-HVAC-02380: Antiglaucoma Agents; Prostanoid FP receptor Agonist; Prostaglandin F2 alpha receptor agonist
CBR-001-584-955-5,RFM-004-535-2,CBR-001-584-955-5,OC(=O)c1ccccc1O,CBR-HVAC-02387: ; Keratolytic
CBR-001-584-956-6,RFM-004-536-3,CBR-001-584-956-6,OC[C@H]1O[C@H](O)[C@@H]([C@H]([C@@H]1O)OC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CCC(=O)O)C)C)NC(=O)C,CBR-HVAC-02389: analog of SDZ-280-636 and GMDP
CBR-001-584-957-7,RFM-004-537-4,CBR-001-584-957-7,CCCC(C(=O)O)CCC,CBR-HVAC-02408: ; Sodium channel antagonist; GABA receptor agonist
CBR-001-584-958-8,RFM-004-538-5,CBR-001-584-958-8,O=C1C[C@@H]2C([C@@]1(C)CC2)(C)C,CBR-HVAC-02460: ; Unidentified pharmacological activity
CBR-001-584-959-9,RFM-004-539-6,CBR-001-584-959-9,O=C1c2ncccc2c2c(C1=O)nccc2,CBR-HVAC-02566: ; Chelating agent
CBR-001-584-960-2,RFM-004-540-9,CBR-001-584-960-2,O=c1c2ccccc2[se]n1c1ccccc1,"CBR-HVAC-02602: Restenosis Treatment of;Antiallergy/Antiasthmatic Drugs;Stroke, Treatment of;Hearing loss, treatment of;Antidiabetic Drugs;Chemoprotective Agents; Antioxidants;NADPH Oxidase (NOX) Inhibitors;Protein Kinase C (PKC) Inhibitors;Signal Transduction Modulators; Prostaglandin H synthase 2; Prostaglandin H synthase 1 Inhibitor; Leucotriene B4 antagonist; Prostaglandin receptor antagonist; Reducing agent"
CBR-001-584-961-3,RFM-004-541-0,CBR-001-584-961-3,OC(=O)[C@H](Cc1ccc(c(c1)O)O)N,CBR-HVAC-02606: ; Alpha-2 adrenergic receptor Agonist; Dopamine receptor agonist
CBR-001-584-962-4,RFM-004-542-1,CBR-001-584-962-4,CCN(CCCC(Nc1ccnc2c1ccc(c2)Cl)C)CC,CBR-HVAC-02616: ; RNA Intercalator; Unidentified pharmacological activity
CBR-001-584-963-5,RFM-004-543-2,CBR-001-584-963-5,OCC(COc1ccccc1OC)O,CBR-HVAC-02624: ; Mucolytic agent
CBR-001-584-964-6,RFM-004-544-3,CBR-001-584-964-6,FC(C(C(F)(F)F)(F)F)(C(C(C(F)(F)F)(F)F)(F)F)F,CBR-HVAC-02635: ; Not applicable
CBR-001-584-965-7,RFM-004-545-4,CBR-001-584-965-7,CC1NCCN(C1)c1cc2n(cc(c(=O)c2cc1F)C(=O)O)c1ccc(cc1F)F,CBR-HVAC-02656: Antibacterial Drugs; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-584-966-8,RFM-004-546-5,CBR-001-584-966-8,CCOC(=O)CNC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1,"CBR-HVAC-02754: Stroke, Treatment of;Cognition Disorders, Treatment of; Ionotropic glutamate receptor NMDA Antagonist; Unidentified pharmacological activity"
CBR-001-584-967-9,RFM-004-547-6,CBR-001-584-967-9,CCOCc1nc2c(n1CC(O)(C)C)c1ccccc1nc2N,"CBR-HVAC-02760: Immunostimulants;Actinic Keratoses, Agents for;Non-Hodgkin's Lymphoma Therapy;Anti-Hepatitis C Virus Drugs;Anti-Herpes Virus Drugs;Basal Cell Carcinoma Therapy; Interferon Inducers;Signal Transduction Modulators;TLR7 Receptor Agonists;TLR8 Receptor Agonists; Toll like receptor 7; Toll like receptor 8 Agonist; Agonist; Toll-like receptor 7 agonist; Toll-like receptor 8 agonist; Immunostimulant"
CBR-001-584-968-0,RFM-004-548-7,CBR-001-584-968-0,Cc1nc(C)c2c(n1)N(Cc1ccc(cc1)c1ccccc1c1nn[nH]n1)C(=O)CC2,"CBR-HVAC-02771: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor Antagonist; Angiotensin II 1 antagonist; Diuretic"
CBR-001-584-969-1,RFM-004-549-8,CBR-001-584-969-1,OC1CC2CC(C1(C)OC2(C)C)O,CBR-HVAC-02791: ; Cholesterol inhibitor
CBR-001-584-970-4,RFM-004-550-1,CBR-001-584-970-4,CCC(c1cccc(c1)C(F)(F)F)(c1ccccc1)O,CBR-HVAC-02796: Hepatoprotectants; Unidentified pharmacological activity
CBR-001-584-971-5,RFM-004-551-2,CBR-001-584-971-5,O=C1NC(=O)C(S1)Cc1ccc(cc1)OCC1(C)CCc2c(O1)c(C)c(c(c2C)O)C,"CBR-HVAC-02830: Inflammatory Bowel Disease, Agents for;Stroke, Treatment of;Type 2 Diabetes, Agents for;Breast Cancer Therapy; CCL2 Expression Inhibitors;EGR1 Expression Enhancers;Insulin Sensitizers;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor gamma Agonist; Peroxisome proliferator-activated receptor gamma agonist; Glycogen synthase stimulant; Insulin sensitizer"
CBR-001-584-972-6,RFM-004-552-3,CBR-001-584-972-6,N#Cc1ccc2c(c1)[C@@H](N1CCCC1=O)[C@@H](C(O2)(C)C)O,"CBR-HVAC-02889: Irritable Bowel Syndrome, Agents for;Urinary Incontinence Therapy;Bronchodilators;Hypertension, Treatment of;Antiallergy/Antiasthmatic Drugs;Vasodilators;Antiulcer Drugs; K(ATP) Channel Activators; Potassium channel Agonist; Potassium channel agonist"
CBR-001-584-973-7,RFM-004-553-4,CBR-001-584-973-7,OC(=O)CCCC/C=C(/c1cccnc1)\c1ccccc1,CBR-HVAC-02890: Antiplatelet Therapy; Prostanoid TP Antagonists;Signal Transduction Modulators;Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Platelet aggregation inhibitor; Thromboxane A2 receptor antagonist
CBR-001-584-974-8,RFM-004-554-5,CBR-001-584-974-8,C#C[C@]1(O)CC[C@@H]2[C@]1(CC)CC(=C)[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,CBR-HVAC-02951: Female Contraceptives;Benign Prostatic Hyperplasia Therapy;
CBR-001-584-975-9,RFM-004-555-6,CBR-001-584-975-9,O=c1n([nH]c2c1cnc1c2cccc1)c1ccccc1,CBR-HVAC-02990: Antidepressants;Antipsoriatics;Anxiolytics; GABA(A) BZ Site Receptor Antagonists;Signal Transduction Modulators; GABA-A receptor Agonist; Partial Agonist; Benzodiazepine receptor inverse agonist
CBR-001-584-976-0,RFM-004-556-7,CBR-001-584-976-0,CN1C(=O)N(C2C1N(C)C(=O)N2C)C,CBR-HVAC-03052: Anxiolytics;
CBR-001-584-977-1,RFM-004-557-8,CBR-001-584-977-1,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1CCC(NC1=O)O,CBR-HVAC-03073: Solid Tumors Therapy;Oncolytic Drugs;Myeloid Leukemia Therapy;Myelodysplastic Syndrome Therapy; Cytidine Deaminase (CDA) Inhibitors;
CBR-001-584-978-2,RFM-004-558-9,CBR-001-584-978-2,Clc1ccc2c(c1)C(=NCCN2C)c1ccccc1,CBR-HVAC-03107: Anxiolytics; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; Benzodiazepine receptor Activator; ;2016-04-01: controlled substance
CBR-001-584-979-3,RFM-004-559-0,CBR-001-584-979-3,CCC1(C(=O)NC(=O)N(C1=O)C)c1ccccc1,CBR-HVAC-03129: Sedative/Hypnotics;Antiepileptic Drugs; ;2016-04-01: controlled substance
CBR-001-584-980-6,RFM-004-560-3,CBR-001-584-980-6,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,CBR-HVAC-03177: Hormone Replacement Therapy;Oral Contraceptives;Acne Therapy; Progesterone receptor agonist
CBR-001-584-981-7,RFM-004-561-4,CBR-001-584-981-7,CCCc1c(OCCCCCOc2cc3OC(CCc3cc2C(=O)C)C(=O)O)ccc(c1O)C(=O)C,"CBR-HVAC-03209: Inflammatory Bowel Disease, Agents for;Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist; Leucotriene D4 antagonist"
CBR-001-584-982-8,RFM-004-562-5,CBR-001-584-982-8,NCCC[C@@H]1NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](Cc2c[nH]c3c2cccc3)NC(=O)CCCCCCCCC)CC(=O)N)CC(=O)O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC(=O)O)C)CC(=O)O)CO)[C@@H](CC(=O)O)C)CC(=O)c1ccccc1N,CBR-HVAC-03324: Antibiotics;Antibacterial Drugs; Drugs Acting on Potassium Channels;
CBR-001-584-983-9,RFM-004-563-6,CBR-001-584-983-9,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2c1nc(Cl)nc2N,"CBR-HVAC-03338: Antiallergy/Antiasthmatic Drugs;Lymphocytic Leukemia Therapy;Neurologic Drugs (Miscellaneous);Multiple Sclerosis, Agents for;Lymphoma Therapy;Immunomodulators;Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy; Adenosine Deaminase (ADA) Inhibitors;Antimetabolites;Apoptosis Inducers; RNA polymerase; Ribonucleotide reductase; Purine nucleoside phosphorylase; DNA polymerase Inhibitor; Inhibitor; Inhibitor; Inhibitor;"
CBR-001-584-984-0,RFM-004-564-7,CBR-001-584-984-0,NC(=N)Nc1scc(n1)c1cnc([nH]1)C,CBR-HVAC-03354: Antiarthritic Drugs;Gastric Antisecretory Drugs; Histamine H2 Receptor Antagonists;Signal Transduction Modulators;
CBR-001-584-985-1,RFM-004-565-8,CBR-001-584-985-1,O=C1OCCN1/N=C/c1ccc(o1)[N+](=O)[O-],CBR-HVAC-03392: Antibacterial Drugs;Antiulcer Drugs; Monoamine oxidase Inhibitor;
CBR-001-584-986-2,RFM-004-566-9,CBR-001-584-986-2,[NH3+][Pt-2]1([NH3+])OC(=O)C2(C(=O)O1)CCC2,"CBR-HVAC-03491: Pancreatic Cancer Therapy;Lung Cancer Therapy;Lymphoma Therapy;Ovarian Cancer Therapy;Small Cell Lung Cancer Therapy;Lymphocytic Leukemia Therapy;Breast Cancer Therapy;Female Reproductive System Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Bladder Cancer Therapy ;Non-Small Cell Lung Cancer Therapy;Renal Cancer Therapy;Ocular Genetic Disorders, Treatment of ;Brain Cancer Therapy;Prostate Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Head and Neck Cancer Therapy;Melanoma Therapy;Genitourinary Cancer Therapy;Neurologic Cancer Therapy;Cervical Cancer Therapy; DNA Alkylating Drugs;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase; PARP) Inhibitors;Signal Transduction Modulators;"
CBR-001-584-987-3,RFM-004-567-0,CBR-001-584-987-3,CC(=CCC[C@@]([C@H]1CCC(=CC1)C)(O)C)C,CBR-HVAC-03505: Antineoplastic Enhancing Agents;Antibacterial Activity Enhancers;
CBR-001-584-988-4,RFM-004-568-1,CBR-001-584-988-4,O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(CC1)c1ncccn1,CBR-HVAC-03526: Antidepressants;Anxiolytics; Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist; 5 Hydroxytryptamine 1A receptor agonist
CBR-001-584-989-5,RFM-004-569-2,CBR-001-584-989-5,NC(=N)Nc1scc(n1)CSCCN/C=N/S(=O)(=O)c1ccc(cc1)Br,CBR-HVAC-03619: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Histamine-H2-receptor-antagonists; Mucus protecting agent; Signal Transduction Modulators; Antiulcer; Gastric Antisecretory Drugs; Peptic Ulcer Disease
CBR-001-584-990-8,RFM-004-570-5,CBR-001-584-990-8,O=S(=O)(C(F)(F)F)Nc1cccc(c1)OCc1ccc2c(n1)cccc2,CBR-HVAC-03641: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Lipoxygenase Inhibitors;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist; 5 Lipoxygenase inhibitor; Cyclooxygenase inhibitor; Leucotriene D4 antagonist
CBR-001-584-991-9,RFM-004-571-6,CBR-001-584-991-9,CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N,"CBR-HVAC-03660: Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy;Pancreatic Cancer Therapy;Allergic Skin Disorders, Treatment for; Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Cell cycle inhibitor"
CBR-001-584-992-0,RFM-004-572-7,CBR-001-584-992-0,COc1ccc(nn1)NS(=O)(=O)c1ccc(cc1)N=Nc1ccc(c(c1)C(=O)O)O,"CBR-HVAC-03682: Antiulcer Drugs;Disease-Modifying Anti-Rheumatic Drugs;Inflammatory Bowel Disease, Agents for;Antiarthritic Drugs;"
CBR-001-584-993-1,RFM-004-573-8,CBR-001-584-993-1,Fc1ccc(c(c1)F)Oc1cc(ccc1NS(=O)(=O)C)C(=O)C,CBR-HVAC-03763: Antiarthritic Drugs; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor; Prostaglandin E2 receptor antagonist
CBR-001-584-994-2,RFM-004-574-9,CBR-001-584-994-2,O=C1NN=C(C(C1)C)c1ccc2c(c1)OCC(=O)N2,CBR-HVAC-03801: Heart Failure Therapy; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; Cyclic nucleotide phosphodiesterase Inhibitor; Phosphodiesterase inhibitor
CBR-001-584-995-3,RFM-004-575-0,CBR-001-584-995-3,CCOC(=O)/C=C/C(=O)O,analog of CBR-HVAC-03860: This is not the active species of the drug.
CBR-001-584-996-4,RFM-004-576-1,CBR-001-584-996-4,CCOC(=O)c1ccc(cc1)OCCC1CCN(CC1)c1ccc(nn1)C,CBR-HVAC-03896: Antiviral Drugs; Unidentified pharmacological activity
CBR-001-584-997-5,RFM-004-577-2,CBR-001-584-997-5,OC(=O)COc1ccc(s1)CCNS(=O)(=O)c1ccccc1,CBR-HVAC-03962: Antiplatelet Therapy; Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A2 receptor Antagonist; Thromboxane A2 receptor antagonist; Platelet aggregation inhibitor; Prostaglandin H2 receptor antagonist
CBR-001-584-998-6,RFM-004-578-3,CBR-001-584-998-6,CCC(/C=C/C=C/[C@H]([C@H]1CC[C@@H]2[C@]1(C)CCC/C/2=C\C=C/1\C[C@@H](O)C[C@@H](C1=C)O)C)(CC)O,CBR-HVAC-04190: Prostate Cancer Therapy;Liver Cancer Therapy; Apoptosis Inducers; Vitamin D3 receptor Agonist; Agonist; Vitamin D agonist
CBR-001-584-999-7,RFM-004-579-4,CBR-001-584-999-7,CC[C@@H]1/C=C(\C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@@H](C[C@@H]2OC)C)C(=O)C(=O)N2[C@H](C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]1CC[C@@H]([C@@H](C1)OC)Cl)/C)CCCC2,"CBR-HVAC-04208: Dermatologic Drugs;Antipruritics;Dry Eye Syndrome, Treatment for;Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs; Calcineurin (PP-2B) Inhibitors;Cytokine Production Inhibitors;FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors;Signal Transduction Modulators; Calcineurin Inhibitor;"
CBR-001-585-000-7,RFM-004-580-7,CBR-001-585-000-7,C[C@H]([C@H]1C(=O)N2[C@@H]1SC(=C2C(=O)OCc1oc(=O)oc1C)[C@H]1CCCO1)O,CBR-HVAC-04291: Antibacterial Drugs;Antibiotics; Cell wall synthesis inhibitor; Lactamase inhibitor
CBR-001-585-001-8,RFM-004-581-8,CBR-001-585-001-8,COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(cc1)O,CBR-HVAC-04308: Lymphocytic Leukemia Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Prostate Cancer Therapy;Renal Cancer Therapy;Breast Cancer Therapy;Neurologic Cancer Therapy;Solid Tumors Therapy;Hematological Cancer Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors;Vascular Disrupting Agents (VDA); Tubulin Inhibitor; Dihydropteroate synthase inhibitor; PABA antagonist; Microtubule inhibitor; Tubulin inhibitor
CBR-001-585-002-9,RFM-004-582-9,CBR-001-585-002-9,COc1cc2CN(CCc3ccc(cc3)NC(=O)c3cccc4c3[nH]c3c(OC)cccc3c4=O)CCc2cc1OC,CBR-HVAC-04316: Cancer Multidrug Resistance Modulators; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; P-Glycoprotein Inhibitor;
CBR-001-585-003-0,RFM-004-583-0,CBR-001-585-003-0,CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)C(=O)O)C(O)(C)C,"CBR-HVAC-04341: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II AT1 receptor Antagonist;"
CBR-001-585-004-1,RFM-004-584-1,CBR-001-585-004-1,CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1noc(=O)[nH]1)c(ccc2)C(=O)O,"CBR-HVAC-04383: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Angiotensin AT2 Antagonists;Insulin Sensitizers;Signal Transduction Modulators; ANGIOTENSIN II RECEPTOR Antagonist; Angiotensin II 1 antagonist"
CBR-001-585-005-2,RFM-004-585-2,CBR-001-585-005-2,CNC(=O)[C@@H](NC(=O)[C@@H]([C@@H](C(=O)NO)CSc1cccs1)CC(C)C)Cc1ccccc1,"CBR-HVAC-04397: Age-Related Macular Degeneration, Treatment of;Oncolytic Drugs;Diabetic Retinopathy, Agents for;Stroke, Treatment of;Antiarthritic Drugs;Restenosis Treatment of;Ophthalmic Drugs; Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors; Matrix metalloproteinase Inhibitor;"
CBR-001-585-006-3,RFM-004-586-3,CBR-001-585-006-3,COc1cc(/C=C/c2nc3c(n2C)c(=O)n(c(=O)n3CC)CC)ccc1OC,"CBR-HVAC-04564: Extrapyramidal Disorders, Treatment of;Antiparkinsonian Drugs;Antidepressants; Adenosine A2A Antagonists;Signal Transduction Modulators; ADENOSINE A2A RECEPTOR Antagonist; Adenosine A2a receptor antagonist; Adenosine receptor antagonist"
CBR-001-585-007-4,RFM-004-587-4,CBR-001-585-007-4,ONC(=O)[C@H]([C@H](C(=O)N[C@@H](C(C)(C)C)C(=O)NC)CC(C)C)O,CBR-HVAC-04596: Gastric Cancer Therapy;Breast Cancer Therapy;Lung Cancer Therapy;Pancreatic Cancer Therapy; Angiogenesis Inhibitors;Matrix Metalloproteinase Inhibitors; Matrix metalloproteinase Inhibitor; Matrix metalloproteinase inhibitor; Angiogenesis inhibitor
CBR-001-585-008-5,RFM-004-588-5,CBR-001-585-008-5,OC(CNC(C)(C)C)COc1ccc(cc1)NC(=O)NC1CCCCC1,"CBR-HVAC-04644: Heart Failure Therapy;Antiarrhythmic Drugs;Hypertension, Treatment of;Angina pectoris, Treatment of; beta1-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Blocker;"
CBR-001-585-009-6,RFM-004-589-6,CBR-001-585-009-6,[O-][N+](=O)c1ccc(c(c1)[N+](=O)[O-])Cl,CBR-HVAC-04645: AIDS Medicines;Immunomodulators;
CBR-001-585-010-9,RFM-004-590-9,CBR-001-585-010-9,O[C@@H]1[C@@H](O[C@@H]2O[C@H](C(=O)O)[C@H]([C@@H]([C@H]2O)O)O)[C@H](O[C@@H]([C@H]1O)C(=O)O)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]1([C@@H]2C(=O)C=C2[C@@]1(C)CC[C@@]1([C@H]2C[C@](C)(CC1)C(=O)O)C)C)C,"CBR-HVAC-04684: Antidiabetic Drugs;Antiallergy/Antiasthmatic Drugs;Immunosuppressants;Severe Acute Respiratory Syndrome (SARS), Treatment of;Thrombolytics;Anti-Hepatitis C Virus Drugs;Hepatoprotectants;Acute Respiratory Distress Syndrome (ARDS), Agents for;Chemopreventive Agents; Antioxidants;Cell Adhesion Inhibitors;Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors;"
CBR-001-585-011-0,RFM-004-591-0,CBR-001-585-011-0,O=C1O[C@@H](C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C(=O)C([C@H](C1)O)(C)C)C)O)C)/C(=C/c1csc(n1)C)/C,CBR-HVAC-04698: Non-Small Cell Lung Cancer Therapy;Liver Cancer Therapy;Ovarian Cancer Therapy;Solid Tumors Therapy;Digestive/Gastrointestinal Cancer Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;Colorectal Cancer Therapy;Female Reproductive System Cancer Therapy; Antimitotic Drugs;Apoptosis Inducers;Microtubule-Stabilizing Agents; Beta-tubulin; Hypoxia-inducible factor 1 Inhibitor; Inhibitor; Microtubule stimulant
CBR-001-585-012-1,RFM-004-592-1,CBR-001-585-012-1,CCC[C@H](c1ccc2c(c1)OCO2)NC(=O)N1C(=O)C([C@@H]1Oc1ccc(cc1)C(=O)N1CCN(CC1)C)(CC)CC,"CBR-HVAC-04740: Rheumatoid Arthritis, Treatment of;Cystic Fibrosis, Treatment of ; Elastase Inhibitors; Elastase 2, neutrophil Inhibitor;"
CBR-001-585-013-2,RFM-004-593-2,CBR-001-585-013-2,OCC(=O)N1CCN(CC1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,CBR-HVAC-04747: Antibacterial Drugs; Protein 30S ribosomal subunit inhibitor
CBR-001-585-014-3,RFM-004-594-3,CBR-001-585-014-3,Clc1ccc(cc1)C[C@@H]1C[C@H](CCN1C(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)NC(=O)c1ccnc2c1cccc2,"CBR-HVAC-04839: Antidepressants;Irritable Bowel Syndrome, Agents for;Urinary Incontinence Therapy;Anxiolytics; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin receptor 1 Antagonist;"
CBR-001-585-015-4,RFM-004-595-4,CBR-001-585-015-4,[O-][N+](=O)c1cn2c(n1)OC[C@H](C2)OCc1ccc(cc1)OC(F)(F)F,CBR-HVAC-04875: Treatment of Tuberculosis; Cell Wall Biosynthesis Inhibitors;Nitric Oxide (NO) Donors;
CBR-001-585-016-5,RFM-004-596-5,CBR-001-585-016-5,COc1cc(ccc1c1cnco1)NC(=O)Nc1cccc(c1)CNC(=O)O[C@@H]1COCC1,CBR-HVAC-04885: Anti-Hepatitis C Virus Drugs; Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors; Inosine monophosphate dehydrogenase Inhibitor; Inosine monophosphate dehydrogenase inhibitor; DNA synthesis inhibitor; RNA synthesis inhibitor
CBR-001-585-017-6,RFM-004-597-6,CBR-001-585-017-6,OC(=O)[C@@H]1[C@@H]2[C@H]1S(=O)(=O)C[C@@]2(N)C(=O)O,CBR-HVAC-04951: Antipsychotic Drugs; mgluR2 Agonists;mgluR3 Agonists;Signal Transduction Modulators; Metabotropic glutamate receptor 2; Metabotropic glutamate receptor 3 Agonist;
CBR-001-585-018-7,RFM-004-598-7,CBR-001-585-018-7,COc1nccc(n1)c1n(cnc1c1ccc(cc1)F)C1CCNCC1,CBR-HVAC-04967: Antiarthritic Drugs; MAPK p38 Inhibitors;Signal Transduction Modulators; p38 Mitogen-activated protein kinase Inhibitor;
CBR-001-585-019-8,RFM-004-599-8,CBR-001-585-019-8,CC(C[C@@H](B(O)O)NC(=O)[C@@H](NC(=O)c1cnccn1)Cc1ccccc1)C,"CBR-HVAC-05018: Myeloid Leukemia Therapy;Respiratory/Thoracic Cancer Therapy;Breast Cancer Therapy;Lymphocytic Leukemia Therapy;Treatment of Transplant Rejection;Renal Cancer Therapy;Amyloidosis, Treatment of;Endocrine Cancer Therapy;Gastric Cancer Therapy;Leukemia Therapy;Digestive/Gastrointestinal Cancer Therapy;Lymphoma Therapy;Bladder Cancer Therapy ;Liver Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Stroke, Treatment of;Multiple Myeloma Therapy;Head and Neck Cancer Therapy;Colorectal Cancer Therapy;Pancreatic Cancer Therapy;Prostate Cancer Therapy;Neurologic Cancer Therapy;Non-Hodgkin's Lymphoma Therapy; Apoptosis Inducers;Caspase 3 Activators;NF-kappaB (NFKB) Activation Inhibitors;Proteasome Inhibitors;Signal Transduction Modulators; Topoisomerase II; 26S Proteasome Inhibitor; Inhibitor; Proteasome inhibitor; Transcription factor NF-kappaB inhibitor; Apoptosis stimulant"
CBR-001-585-020-1,RFM-004-600-4,CBR-001-585-020-1,CCC(C(n1cncn1)c1ccc(cc1)Nc1nc2c(s1)cccc2)CC,"CBR-HVAC-05030: Antipsoriatics;Dermatological Genetic Disorders, Treatment of;Acne Therapy; Cytochrome P450 CYP26 Inhibitors;Retinoic Acid Metabolism Blocking Agents (RAMBA); CYP26A1 Inhibitor; Retinoic acid receptor agonist"
CBR-001-585-021-2,RFM-004-601-5,CBR-001-585-021-2,Brc1csc(c1)COc1nc(N)nc2c1nc[nH]2,CBR-HVAC-05043: Colorectal Cancer Therapy;Antineoplastic Enhancing Agents;Solid Tumors Therapy;Oncolytic Drugs;Melanoma Therapy; DNA Repair Inhibitors;O6-Alkylguanine-DNA Alkyltransferase (MGMT) Inhibitors; O6-Alkylguanine-DNA alkyltransferase Inhibitor;
CBR-001-585-022-3,RFM-004-602-6,CBR-001-585-022-3,NC(=O)Cc1cccc(c1N)C(=O)c1ccccc1,"CBR-HVAC-05084: Antiinflammatory Ophthalmic Agents;Non-Opioid Analgesics;Diabetic Retinopathy, Agents for; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor;"
CBR-001-585-023-4,RFM-004-603-7,CBR-001-585-023-4,CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@@H](c1cccc(c1)OCC(=O)NCCNC(=O)COc1cccc(c1)[C@H](OC(=O)[C@@H]1CCCCN1C(=O)[C@H](c1cc(OC)c(c(c1)OC)OC)CC)CCc1ccc(c(c1)OC)OC)CCc1ccc(c(c1)OC)OC)c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-05097: Immunosuppressants;Prostate Cancer Therapy;Solid Tumors Therapy;Antianemics;Osteosarcoma Therapy;
CBR-001-585-024-5,RFM-004-604-8,CBR-001-585-024-5,O=C1NC(=O)C(S1)Cc1ccc(cc1)OCc1nc2ccccc2c(=O)n1C,"CBR-HVAC-05157: Type 2 Diabetes, Agents for; Insulin Sensitizers;PPARgamma Partial Agonists;Signal Transduction Modulators; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Agonist; PPAR gamma partial agonist; Thiazolidinedione; Insulin sensitizer"
CBR-001-585-025-6,RFM-004-605-9,CBR-001-585-025-6,O=C1NC(=O)N(C1)/N=C/c1ccc(o1)[N+](=O)[O-],CBR-HVAC-05213: Antibacterial Drugs; Beta-lactamase Inhibitor;
CBR-001-585-026-7,RFM-004-606-0,CBR-001-585-026-7,CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@@]2(O)C#C)CCC1=CCCC[C@H]31,"CBR-HVAC-05230: Acne Therapy;Oral Contraceptives;Gynecological Disorders, Treatment of ; Progesterone receptor; Estrogen receptor alpha Agonist; Progesterone receptor agonist"
CBR-001-585-027-8,RFM-004-607-1,CBR-001-585-027-8,COc1cc2c(cc1O)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2O)C,"CBR-HVAC-05238: Treatment of Osteoporosis;Oncolytic Drugs;Multiple Myeloma Therapy;Rheumatoid Arthritis, Treatment of;Brain Cancer Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;Ovarian Cancer Therapy;Glioblastoma Multiforme Therapy;Pulmonary Hypertension, Treatment of;Age-Related Macular Degeneration, Treatment of;Solid Tumors Therapy;Renal Cancer Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors; Endothelin 1 antagonist; Prostaglandin IP2 receptor agonist; Angiogenesis inhibitor"
CBR-001-585-028-9,RFM-004-608-2,CBR-001-585-028-9,CC1=CC[C@]23[C@H]1[C@H]1OC(=O)C(=C)[C@@H]1CC[C@@]3(O2)C,CBR-HVAC-05242: Oncolytic Drugs; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators; RAS protein kinase farnesyltransferase Inhibitor;
CBR-001-585-029-0,RFM-004-609-3,CBR-001-585-029-0,C=C[C@@](/C=C/c1ccc(cc1)O)(CCC=C(C)C)C,"CBR-HVAC-05272: Type 2 Diabetes, Agents for;Skin-Whitening Agents;Acne Therapy;Hepatoprotectants; Antiinflammatory Drugs;Antioxidants;DNA Polymerase Inhibitors;Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;NF-kappaB (NFKB) Activators;Signal Transduction Modulators;"
CBR-001-585-030-3,RFM-004-610-6,CBR-001-585-030-3,C=CCC1(CC(C)C)C(=O)NC(=O)NC1=O,CBR-HVAC-05282: Sedative/Hypnotics; GABA-A receptor Inhibitor; ;2016-04-01: controlled substance
CBR-001-585-031-4,RFM-004-611-7,CBR-001-585-031-4,CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(c(c2)F)F)c2c(n1)n(nn2)[C@@H]1C[C@@H]([C@H]([C@H]1O)O)OCCO,CBR-HVAC-05285: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Cardiovascular Diseases (Not Specified);Antiplatelet Therapy; P2Y12 (P2T) Antagonists;Signal Transduction Modulators; Purinoreceptor P2Y12 antagonist
CBR-001-585-032-5,RFM-004-612-8,CBR-001-585-032-5,CN1CCC(CC1)Nc1ncc2c(n1)c(ncn2)Nc1ccc(c(c1)Cl)F,CBR-HVAC-05314: Oncolytic Drugs; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; EGFR Inhibitor; EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-585-033-6,RFM-004-613-9,CBR-001-585-033-6,OC[C@H]1O[C@H](C[C@@H]1O)n1cc(F)c(nc1=O)N,CBR-HVAC-05333: Radiopharmaceuticals;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Diagnostic for Cancer; DNA Methyltransferase (DNMT) Inhibitors;
CBR-001-585-034-7,RFM-004-614-0,CBR-001-585-034-7,CC12CCC(CC1)C(O2)(C)C,"CBR-HVAC-05371: Asthma Therapy;Inflammatory Bowel Disease, Agents for; Acetylcholinesterase (AChE) Inhibitors;"
CBR-001-585-035-8,RFM-004-615-1,CBR-001-585-035-8,O=C(Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)Nc1ccc(c2c1cccc2)OCCN1CCOCC1,"CBR-HVAC-05397: Inflammatory Bowel Disease, Agents for;Rheumatoid Arthritis, Treatment of;Antipsoriatics; Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors;MAPK p38 Inhibitors;SAPK2 (p38beta) Inhibitors;Signal Transduction Modulators; p38 Mitogen-activated protein kinase Inhibitor; P38 kinase inhibitor; Abl receptor tyrosine kinase inhibitor"
CBR-001-585-036-9,RFM-004-616-2,CBR-001-585-036-9,COc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cn1)C)c1ccncc1,"CBR-HVAC-05414: Hypertension, Treatment of;Heart Failure Therapy;Diabetic Nephropathy, Agents for; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist;"
CBR-001-585-037-0,RFM-004-617-3,CBR-001-585-037-0,COC(=O)[C@@H]([C@H](NC(=O)c1ccc(cc1)c1cc[n+](cc1)[O-])C)Cc1cccc(c1)C(=N)N,"CBR-HVAC-05437: Acute Myocardial Infarction, Treatment of;Anticoagulants;Angina pectoris, Treatment of; Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways; Coagulation factor Xa Inhibitor;"
CBR-001-585-038-1,RFM-004-618-4,CBR-001-585-038-1,CC(=CCc1c2O[C@]34[C@@]5(C/C=C(\C(=O)O)/C)OC([C@@H]4C[C@H](C5=O)C=C3C(=O)c2c(c2c1O[C@](C)(CCC=C(C)C)C=C2)O)(C)C)C,CBR-HVAC-05456: Prostate Cancer Therapy;Oncolytic Drugs;Breast Cancer Therapy; Apoptosis Inducers;Caspase Activators;DNA Topoisomerase II alpha Inhibitors;Heat Shock Protein 90 (HSP90) Inhibitors;MYC Expression Inhibitors;Signal Transduction Modulators;TERT Expression Inhibitors;
CBR-001-585-039-2,RFM-004-619-5,CBR-001-585-039-2,COC(=O)/C=C/C(=O)OC,"CBR-HVAC-05561: Psoriatic Arthritis, Treatment of ;Antipsoriatics;Immunomodulators;Rheumatoid Arthritis, Treatment of;Glioblastoma Multiforme Therapy;Neurological Genetic Disorders, Treatment of ;Multiple Sclerosis, Agents for; Kelch-like ECH-Associated Protein 1 (Keap1, INrf2) Ligands;NF-kappaB (NFKB) Activation Inhibitors;Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activators;Signal Transduction Modulators; Transcription factor Nrf2 stimulant"
CBR-001-585-040-5,RFM-004-620-8,CBR-001-585-040-5,OC(=O)C(Oc1ccc(cc1)C1CCCc2c1cccc2)(C)C,"CBR-HVAC-05609: Lipoprotein Disorders, Treatment of ; PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator-activated receptor alpha Agonist;"
CBR-001-585-041-6,RFM-004-621-9,CBR-001-585-041-6,NC(C(=O)O)Cc1c[nH]cn1,"CBR-HVAC-05617: Ischemic Stroke, Treatment of;Metabolic Disorders (Not Specified); Carbonic Anhydrase Type I Activators;"
CBR-001-585-042-7,RFM-004-622-0,CBR-001-585-042-7,O=C(c1ccc(cc1)F)NC1Cc2c(C1)cccc2,"CBR-HVAC-05758: Heart Failure Therapy;Atherosclerosis Therapy;Angina pectoris, Treatment of; NOS3 Expression Enhancers;"
CBR-001-585-043-8,RFM-004-623-1,CBR-001-585-043-8,O[C@H]([C@@H]([C@H]1OC1)O)[C@@H]1OC1,CBR-HVAC-05860: Glioblastoma Multiforme Therapy;Cervical Cancer Therapy;Ovarian Cancer Therapy;Cancer of Unspecified Body Location/System;Lung Cancer Therapy;Leukemia Therapy;Neurologic Cancer Therapy; DNA Alkylating Drugs; DNA inhibitor
CBR-001-585-044-9,RFM-004-624-2,CBR-001-585-044-9,[N-]=[N+]=N[C@]1(CO)O[C@H]([C@@H]([C@@H]1O)O)n1ccc(nc1=O)N,CBR-HVAC-05866: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B protease Inhibitor;
CBR-001-585-045-0,RFM-004-625-3,CBR-001-585-045-0,CCOCc1cc(OC)c(c(c1)OC)c1ccc(cc1)C[C@@H](C(=O)O)NC(=O)c1c(F)cccc1F,"CBR-HVAC-05872: Inflammatory Bowel Disease, Agents for;Rheumatoid Arthritis, Treatment of;Antiallergy/Antiasthmatic Drugs;Multiple Sclerosis, Agents for; Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Signal Transduction Modulators; Integrin alpha4 beta1; Integrin alpha4 beta7 Antagonist; Alpha4beta1 integrin antagonist; Alpha4beta7 integrin antagonist; Integrin antagonist; Alpha4 integrin antagonist"
CBR-001-585-046-1,RFM-004-626-4,CBR-001-585-046-1,CO[C@@H]1/C=C/C=C(\C)/Cc2cc(OC)c(c(c2)N(C(=O)C[C@@H]([C@]2([C@H]([C@@H]([C@@H]3C[C@@]1(O)NC(=O)O3)C)O2)C)OC(=O)C(C)C)C)Cl,CBR-HVAC-05930: Oncolytic Drugs;Antifungal Agents;Antibacterial Drugs; Antimitotic Drugs;
CBR-001-585-047-2,RFM-004-627-5,CBR-001-585-047-2,CC(=O)c1c(C)c2cnc(nc2n(c1=O)C1CCCC1)Nc1ccc(cn1)N1CCNCC1,CBR-HVAC-05943: Glioblastoma Multiforme Therapy;Melanoma Therapy;Leukemia Therapy;Cancer of Unspecified Body Location/System;Bladder Cancer Therapy ;Pancreatic Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Liver Cancer Therapy;Head and Neck Cancer Therapy;Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Myelodysplastic Syndrome Therapy;Sarcoma Therapy;Prostate Cancer Therapy;Breast Cancer Therapy;Colorectal Cancer Therapy;Multiple Myeloma Therapy;Oncolytic Drugs;Non-Hodgkin's Lymphoma Therapy; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;CDK4 Inhibitors;CDK4/Cyclin D3 Inhibitors;CDK6 Inhibitors;CDK6/Cyclin D3 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Signal Transduction Modulators; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6 Inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CBR-001-585-048-3,RFM-004-628-6,CBR-001-585-048-3,CC(n1c(C)ncc1c1ccnc(n1)Nc1ccc(cc1)S(=O)(=O)C)C,CBR-HVAC-05954: Solid Tumors Therapy; CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;CDK2/Cyclin E Inhibitors;Signal Transduction Modulators; Cyclin-dependent kinase 1; Cyclin-dependent kinase 2; Cyclin-dependent kinase 9 Inhibitor;;2018-01-24: ARB# 18-000008
CBR-001-585-049-4,RFM-004-629-7,CBR-001-585-049-4,N#C/C(=C\c1cccc(n1)Br)/C(=O)N[C@H](c1ccccc1)C,CBR-HVAC-05993: Oncolytic Drugs; Apoptosis Inducers;Janus Kinase (Jak) Inhibitors;Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transducer and Activator of Transcription 5 (STAT5) Inhibitors;Signal Transduction Modulators; Janus kinase 2 Inhibitor;
CBR-001-585-050-7,RFM-004-630-0,CBR-001-585-050-7,COC(=O)[C@@]12OC[C@]34[C@H]2[C@@H](OC(=O)/C=C(/C(C)C)\C)C(=O)O[C@@H]4C[C@@H]2[C@]([C@H]3[C@H]([C@@H]1O)O)(C)CC(=O)C(=C2C)O,CBR-HVAC-06010: Multiple Myeloma Therapy;Solid Tumors Therapy;Cancer Multidrug Resistance Modulators; Apoptosis Inducers;MYC Expression Inhibitors;
CBR-001-585-051-8,RFM-004-631-1,CBR-001-585-051-8,CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C,"CBR-HVAC-06035: Angiogenesis Inhibitors; Apoptosis Inducers; C-X-C chemokine receptor 2 antagonist; CXC chemokine receptor 1 antagonist; CXC chemokine receptor 2 antagonist; Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists; Chemokine CXCR2 (IL-8 beta Receptor) Antagonists; Chemokine receptor antagonist; Interleukin-8A-receptor-antagonists; Interleukin-8B-receptor-antagonists; Signal Transduction Modulators; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Antiarthritic Drugs; Antipsoriatics; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Obstructive Airways Disease; Oncolytic Drugs; Respiratory Tract Disorders; Skin Disorders"
CBR-001-585-052-9,RFM-004-632-2,CBR-001-585-052-9,OC[C@@H]1O[C@@H](O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)[C@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-06059: Neuromuscular Genetic Disorders, Treatment of;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Huntington's Disease, Treatment of; Pharmacological Chaperones; Unidentified pharmacological activity"
CBR-001-585-053-0,RFM-004-633-3,CBR-001-585-053-0,C/C(=C\CNc1ncnc2c1nc[nH]2)/CO,"CBR-HVAC-06066: Dermatologic Drugs;Alzheimer's Dementia, Treatment of ; Antioxidants;"
CBR-001-585-054-1,RFM-004-634-4,CBR-001-585-054-1,CCNC1(CCN(CC1)c1ncnc2c1nc(n2c1ccc(cc1)Cl)c1ccccc1Cl)C(=O)N,"CBR-HVAC-06074: Antiobesity Drugs;Treatment of Substance Dependency;Liver and Biliary Tract Disorders, Treatment of; Cannabinoid CB1 Antagonists;Signal Transduction Modulators; Cannabinoid receptor 1 Antagonist; Cannabinoid CB1 receptor antagonist"
CBR-001-585-055-2,RFM-004-635-5,CBR-001-585-055-2,Nc1nc(c(s1)c1ccnc(n1)Nc1ccc(cc1)N1CCOCC1)C,CBR-HVAC-06085: Solid Tumors Therapy; Angiogenesis Inhibitors;Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors;
CBR-001-585-056-3,RFM-004-636-6,CBR-001-585-056-3,FC(Oc1ccc(c2c1oc1c2cc(cc1)NS(=O)(=O)C)C(=O)Nc1c(Cl)cncc1Cl)F,"CBR-HVAC-06091: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Antiarthritic Drugs;Asthma Therapy; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor;"
CBR-001-585-057-4,RFM-004-637-7,CBR-001-585-057-4,CCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C)C(=O)CO,CBR-HVAC-06154: Acne Therapy;Hair Growth Stimulants;Dermatologic Drugs; Androgen Receptor Antagonists;Signal Transduction Modulators;
CBR-001-585-058-5,RFM-004-638-8,CBR-001-585-058-5,CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(cc1Cl)F,"CBR-HVAC-06157: Sepsis, Treatment of;Antiinfectives (Not Specified); Cytokine Production Inhibitors;Nitric Oxide (NO) Production Inhibitors;Signal Transduction Modulators;TLR4 (LPS) Receptor Antagonists; Toll-like receptor 4 Inhibitor; Toll-like receptor 4 antagonist"
CBR-001-585-059-6,RFM-004-639-9,CBR-001-585-059-6,CNCCn1c(=O)c2cc(OC)c(cc2c2c1c1cc3OCOc3cc1nc2)OC,CBR-HVAC-06171: Oncolytic Drugs;Solid Tumors Therapy; DNA Topoisomerase I Inhibitors; TOPOISOMERASE I Inhibitor;
CBR-001-585-060-9,RFM-004-640-2,CBR-001-585-060-9,CCCCCCCCCCCC(=O)OCC(CO)O,CBR-HVAC-06203: Antibacterial Drugs;Microbicides; Anthrax Lethal Factor Inhibitors;beta-Lactamase Inhibitors;Signal Transduction Modulators;
CBR-001-585-061-0,RFM-004-641-3,CBR-001-585-061-0,O=C(Nc1cc(C)ccc1F)Nc1ccc(cc1)c1cccc2c1c(N)n[nH]2,"CBR-HVAC-06207: Liver Cancer Therapy;Hematological Cancer Therapy;Colorectal Cancer Therapy;Age-Related Macular Degeneration, Treatment of;Breast Cancer Therapy;Renal Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;CSF1R (c-FMS) Inhibitors;Extracellular-Regulated Kinase (ERK) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase; PARP) Inhibitors;PDGFRbeta Inhibitors;Signal Transducer and Activator of Transcription 5 (STAT5) Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR Inhibitor; Platelet-derived growth factor receptor kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; Macrophage colony stimulating factor antagonist; VEGFR-1 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Colony stimulating factor 1 receptor antagonist; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor"
CBR-001-585-062-1,RFM-004-642-4,CBR-001-585-062-1,CCCCCCCCCCCCC/C=C/[C@H]([C@H](COP(=O)(OCC[N+](C)(C)C)[O-])N)O,CBR-HVAC-06211: Oncolytic Drugs;Dermatologic Drugs;Wound-Healing Agents; Angiogenesis Inducers;Drugs Enhancing Gene Expression;
CBR-001-585-063-2,RFM-004-643-5,CBR-001-585-063-2,ONC(=O)c1ccc(cc1)NC(=O)[C@H](c1ccccc1)C(C)C,CBR-HVAC-06245: Neurologic Cancer Therapy;Multiple Myeloma Therapy;Neurologic Drugs (Miscellaneous);Lymphoma Therapy;Lymphocytic Leukemia Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Oncolytic Drugs; Histone Deacetylase 1 (HDAC1) Inhibitors;Histone Deacetylase 2 (HDAC2) Inhibitors; Histone deacetylase Inhibitor; Histone deacetylase inhibitor; Protein kinase B inhibitor; Cell cycle inhibitor
CBR-001-585-064-3,RFM-004-644-6,CBR-001-585-064-3,OCCCc1ccc(cc1NCc1ccc2c(c1)n(Cc1nc(C)ccc1O)c(n2)NCCCN1CCOCC1)C,CBR-HVAC-06268: Anti-RSV Drugs; Viral Fusion Inhibitors; Respiratory syncytial virus protein F Inhibitor;
CBR-001-585-065-4,RFM-004-645-7,CBR-001-585-065-4,O=c1sn(c(=O)n1Cc1ccccc1)c1cccc2c1cccc2,"CBR-HVAC-06298: Neurological Genetic Disorders, Treatment of ;Neurologic Drugs (Miscellaneous);Cerebrovascular Diseases, Treatment of;Alzheimer's Dementia, Treatment of ; Glycogen Synthase Kinase 3 beta (GSK-3beta; tau Protein Kinase I) Inhibitors;Signal Transduction Modulators; Glycogen synthase kinase 3 inhibitor; Protein kinase inhibitor"
CBR-001-585-066-5,RFM-004-646-8,CBR-001-585-066-5,OC[C@@H](n1cc(C(=O)O)c(=O)c2c1cc(OC)c(c2)Cc1cccc(c1F)Cl)C(C)C,CBR-HVAC-06323: Anti-HIV Agents; HIV Integrase Inhibitors;Reverse Transcriptase Inhibitors; Integrase Inhibitor; HIV integrase inhibitor
CBR-001-585-067-6,RFM-004-647-9,CBR-001-585-067-6,COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl,"CBR-HVAC-06340: Antidiabetic Drugs;Type 2 Diabetes, Agents for; Glucagon Receptor (GCGR) Antagonists;Signal Transduction Modulators; Glucagon receptor Antagonist;"
CBR-001-585-068-7,RFM-004-648-0,CBR-001-585-068-7,O=C([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C=C(F)C(=O)N2C)NCc1nc2c([nH]1)nccc2,"CBR-HVAC-06341: Sarcopenia, Treatment of;Treatment of Osteoporosis; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators; Androgen receptor Modulator;"
CBR-001-585-069-8,RFM-004-649-1,CBR-001-585-069-8,CN1CCN(CC1)c1nc(NCc2onc(c2)C(C)C)nc(c1)Nc1n[nH]c(c1)C1CC1,CBR-HVAC-06354: Leukemia Therapy;Lymphoma Therapy;Solid Tumors Therapy; Abl Kinase Inhibitors;Angiogenesis Inhibitors;Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;FGFR Inhibitors;IGF-1R Inhibitors;Signal Transduction Modulators;Src Kinase Inhibitors;
CBR-001-585-070-1,RFM-004-650-4,CBR-001-585-070-1,OCCONC(=O)c1cc(CN2OCCCC2=O)c(c(c1Nc1ccc(cc1F)I)F)F,CBR-HVAC-06371: Solid Tumors Therapy; MEK1 Inhibitors;Signal Transduction Modulators; MEK protein kinase Inhibitor;
CBR-001-585-071-2,RFM-004-651-5,CBR-001-585-071-2,O=C(c1cc(c(n(c1=O)c1cccc(c1)C(F)(F)F)C)c1ccnn1C)NCc1ccc(cn1)S(=O)(=O)C,"CBR-HVAC-06408: Cystic Fibrosis, Treatment of ;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy; Leukocyte Elastase Inhibitors; Elastase inhibitor"
CBR-001-585-072-3,RFM-004-652-6,CBR-001-585-072-3,COc1cc2nc3[nH][nH]c(c3nc(c2cc1F)c1ccccc1Cl)C,CBR-HVAC-06412: Solid Tumors Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;CDK2 Inhibitors;FGFR1 Inhibitors;FGFR2 Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Flt-3 kinase inhibitor; Fibroblast growth factor receptor 1 antagonist; Fibroblast growth factor receptor 2 antagonist; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; Platelet-derived growth factor receptor beta kinase inhib
CBR-001-585-073-4,RFM-004-653-7,CBR-001-585-073-4,O=c1ccc2c(o1)cc1c(c2OCCCCOc2ccccc2)cco1,"CBR-HVAC-06414: Atopic Dermatitis, Agents for;Immunosuppressants;Treatment of Transplant Rejection;Multiple Sclerosis, Agents for;Treatment of Autoimmune Diseases;Antipsoriatics;Rheumatoid Arthritis, Treatment of; K(V) 1.3 (KCNA3) Channel Blockers; Voltage-gated potassium channel Kv1.3 BLOCKER;"
CBR-001-585-074-5,RFM-004-654-8,CBR-001-585-074-5,COc1cc(ccc1n1cnc(c1)C)/C=C/1\CCCN(C1=O)[C@H](c1ccc(cc1)F)C,"CBR-HVAC-06420: Alzheimer's Dementia, Treatment of ; beta-Amyloid (Abeta) Production Inhibitors;gamma-Secretase Modulators; Gamma secretase Modulator;"
CBR-001-585-075-6,RFM-004-655-9,CBR-001-585-075-6,O[C@@H]1CC[C@H](CC1)Nc1ncc2c(n1)n([C@@H]1COCC1)c(n2)Nc1c(F)cc(cc1F)F,"CBR-HVAC-06426: Treatment of Other Autoimmune Disorders;Interstitial Lung Diseases, Treatment of;Inflammation, Treatment of; SAPK1 (JNK) Inhibitors;Signal Transduction Modulators; JNK Inhibitor;"
CBR-001-585-076-7,RFM-004-656-0,CBR-001-585-076-7,OCC[C@@H]1CCCCN1c1cc(NCc2ccc[n+](c2)[O-])n2c(n1)c(CC)cn2,CBR-HVAC-06436: Breast Cancer Therapy;Melanoma Therapy;Non-Small Cell Lung Cancer Therapy;Lymphocytic Leukemia Therapy;Myeloid Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy;Multiple Myeloma Therapy; Apoptosis Inducers;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;CDK1/Cyclin B Inhibitors;CDK2/Cyclin A Inhibitors;CDK5/p25 Inhibitors;CDK9/Cyclin T1 Inhibitors;Signal Transduction Modulators; CDK1; CDK2; CDK9 Inhibitor;
CBR-001-585-077-8,RFM-004-657-1,CBR-001-585-077-8,CCCC(C(=O)Nc1ccn(c(=O)n1)[C@@H]1O[C@@H]([C@H](C1(F)F)O)CO)CCC,CBR-HVAC-06443: Oncolytic Drugs;Solid Tumors Therapy; Pyrimidine Antagonists;Ribonucleoside-Diphosphate Reductase Inhibitors;
CBR-001-585-078-9,RFM-004-658-2,CBR-001-585-078-9,Clc1ccc(cc1c1cc(C)c2c(c1)nnc(n2)Nc1ccc(cc1)OCCN1CCCC1)OC(=O)c1ccccc1,"CBR-HVAC-06522: Diabetic Retinopathy, Agents for;Age-Related Macular Degeneration, Treatment of; Angiogenesis Inhibitors;Apoptosis Inducers;EphB4 Inhibitors;PDGFR Family Inhibitors;Signal Transduction Modulators;Src Kinase Inhibitors;VEGFR Inhibitors; SRC; Proto-oncogene tyrosine-protein kinase YES; EPH receptor B4; FGFR Inhibitor;"
CBR-001-585-079-0,RFM-004-659-3,CBR-001-585-079-0,Cc1cnc(nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C)Nc1ccc(cc1)OCCN1CCCC1,CBR-HVAC-06538: Hematological Cancer Therapy;Solid Tumors Therapy;Hematologic Agents (Miscellaneous); Flt3 (FLK2/STK1) Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators; JAK-2 KINASE Inhibitor; Janus kinase 2 inhibitor; Flt-3 kinase inhibitor; RET tyrosine kinase inhibitor
CBR-001-585-080-3,RFM-004-660-6,CBR-001-585-080-3,BrCCNP(=O)(NCCBr)OCc1cnc(n1C)[N+](=O)[O-],CBR-HVAC-06539: Hematological Cancer Therapy;Liver Cancer Therapy;Pancreatic Cancer Therapy;Astrocytoma Therapy;Digestive/Gastrointestinal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Melanoma Therapy;Sarcoma Therapy;Renal Cancer Therapy;Multiple Myeloma Therapy; DNA Alkylating Drugs;
CBR-001-585-081-4,RFM-004-661-7,CBR-001-585-081-4,CN1CCN(CC1)Cc1ccc2c(c1)n(cn2)c1cc(c(s1)C(=O)N)O[C@@H](c1ccccc1C(F)(F)F)C,CBR-HVAC-06584: Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy; Antimitotic Drugs;Polo-like Kinase-1 (Plk-1) Inhibitors;Signal Transduction Modulators; Polo-like kinase 1 Inhibitor;
CBR-001-585-082-5,RFM-004-662-8,CBR-001-585-082-5,O=C1SC[C@H](N1)[C@@]1(O)C[C@H]2C[C@H](O1)CC[C@H](C)/C=C\CC/C(=C\C(=O)O2)/C,CBR-HVAC-06589: Ophthalmic Drugs;Antiglaucoma Agents; Actin Destabilizer;Antimitotic Drugs;
CBR-001-585-083-6,RFM-004-663-9,CBR-001-585-083-6,CCn1c(nc2c1c(OC[C@H]1CCCNC1)cnc2C#CC(O)(C)C)c1nonc1N,CBR-HVAC-06593: Lymphoma Therapy;Solid Tumors Therapy; PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors;PKB gamma/Akt3 Inhibitors;Signal Transduction Modulators; AKT Inhibitor; Protein kinase B inhibitor; Protein kinase inhibitor
CBR-001-585-084-7,RFM-004-664-0,CBR-001-585-084-7,O[C@H]1C[C@@H](C[C@H]1COS(=O)(=O)N)n1ccc2c1ncnc2N[C@H]1CCc2c1cccc2,CBR-HVAC-06604: Melanoma Therapy;Lymphocytic Leukemia Therapy;Myeloid Leukemia Therapy;Myelodysplastic Syndrome Therapy;Solid Tumors Therapy; NEDD8-Activating Enzyme (NAE) Inhibitors; NEDD8-ACTIVATING ENZYME Inhibitor;
CBR-001-585-085-8,RFM-004-665-1,CBR-001-585-085-8,OC(=O)[C@@H](NC1=C(Br)C(=O)C21CCCCC2)Cc1ccc(cc1)Nc1nccc2c1cncc2,"CBR-HVAC-06619: Multiple Sclerosis, Agents for; Integrin alpha4beta1 (VLA-4) Antagonists;Signal Transduction Modulators;"
CBR-001-585-086-9,RFM-004-666-2,CBR-001-585-086-9,O=C(N1CC[C@@H](C1)N[C@@H]1CC[C@](CC1)(O)c1ccc(cn1)c1ncccn1)CNC(=O)c1cccc(c1)C(F)(F)F,"CBR-HVAC-06648: Pancreatic Cancer Therapy;Analgesic Drugs;Osteoarthritis, Treatment of;Gastrointestinal Disorders (Not Specified);Agents for Liver Fibrosis;Anti-Hepatitis C Virus Drugs; Chemokine CCR2 (MCP-1 Receptor) Antagonists;Signal Transduction Modulators; C-C chemokine receptor 2 Antagonist;"
CBR-001-585-087-0,RFM-004-667-3,CBR-001-585-087-0,O=C(c1ccc(cc1)/C=C/c1n[nH]c2c1cccc2)N1CCNCC1,CBR-HVAC-06701: Oncolytic Drugs; Abl Kinase Inhibitors;Angiogenesis Inhibitors;Antimitotic Drugs;Aurora Kinase Inhibitors;FGFR1 Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Signal Transduction Modulators; Abl kinase; Aurora kinase; FLT3 Inhibitor; Inhibitor; Inhibitor; Flt-3 kinase inhibitor; Abl receptor tyrosine kinase inhibitor; Aurora kinase inhibitor; Fibroblast growth factor receptor 1 antagonist
CBR-001-585-088-1,RFM-004-668-4,CBR-001-585-088-1,NC[C@@H](NC(=O)c1oc(c(c1)c1c(Cl)cnn1C)Cl)Cc1ccc(c(c1)F)F,CBR-HVAC-06797: Solid Tumors Therapy;Melanoma Therapy;Female Reproductive System Cancer Therapy;Multiple Myeloma Therapy;Breast Cancer Therapy;Lymphoma Therapy;Cervical Cancer Therapy;Myeloid Leukemia Therapy; PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors;PKB gamma/Akt3 Inhibitors;Signal Transduction Modulators; Protein kinase B inhibitor
CBR-001-585-089-2,RFM-004-669-5,CBR-001-585-089-2,Clc1cccc(c1)C(c1ccccc1)NC(=O)N,CBR-HVAC-06801: Antiepileptic Drugs;Treatment of Alcohol Dependency;
CBR-001-585-090-5,RFM-004-670-8,CBR-001-585-090-5,O=C(N1CCC(=Cc2cccc(c2)Oc2ccc(cn2)C(F)(F)F)CC1)Nc1cccnn1,"CBR-HVAC-06821: Analgesic Drugs;Posttraumatic Stress Disorder (PTSD), Treatment of;Tourette's Syndrome, Treatment of;Treatment of Substance Dependency; Fatty Acid Amide Hydrolase (FAAH) Inhibitors; Fatty acid amide hydrolase inhibitor"
CBR-001-585-091-6,RFM-004-671-9,CBR-001-585-091-6,Cc1cc(n(n1)C)C(=O)Nc1cc(ccc1C)Oc1ccc2n(n1)cc(n2)NC(=O)C1CC1,CBR-HVAC-06827: Solid Tumors Therapy; Angiogenesis Inhibitors;PDGFR Family Inhibitors;Signal Transduction Modulators;Tyrosine Kinase Inhibitors;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors; PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR Inhibitor;
CBR-001-585-092-7,RFM-004-672-0,CBR-001-585-092-7,COc1cc(ccc1Nc1ncnc(n1)Nc1ccccc1S(=O)(=O)C(C)C)N1CCC(CC1)N1CCN(CC1)C,CBR-HVAC-06862: Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy; ALK Inhibitors;Signal Transduction Modulators; ALK TYROSINE KINASE RECEPTOR Inhibitor;
CBR-001-585-093-8,RFM-004-673-1,CBR-001-585-093-8,C[C@H](c1ncc(s1)C(=O)Nc1ncc(c(c1)C(F)(F)F)Cl)NC(=O)c1ncnc(c1Cl)N,CBR-HVAC-06863: Solid Tumors Therapy;Melanoma Therapy; Raf Kinase Inhibitors;Signal Transduction Modulators; Raf kinase inhibitor
CBR-001-585-094-9,RFM-004-674-2,CBR-001-585-094-9,CC(OC(=O)Nc1cccc(c1)Cl)C,CBR-HVAC-06874: Oncolytic Drugs;Anti-HIV Agents;
CBR-001-585-095-0,RFM-004-675-3,CBR-001-585-095-0,OC(=O)C[C@@H]1CC[C@H](CC1)c1ccc(cc1)N1CCOc2c(C1=O)c(N)ncn2,"CBR-HVAC-06887: Type 2 Diabetes, Agents for; Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitors; DIACYLGLYCEROL O ACYLTRANSFERASE 1 Inhibitor;"
CBR-001-585-096-1,RFM-004-676-4,CBR-001-585-096-1,CN(C[C@H](c1ccccc1)NC(=O)N1Cc2c(C1(C)C)[nH]nc2Nc1nc(C)nc2c1scc2)C,CBR-HVAC-06890: Solid Tumors Therapy; Serine/Threonine-Protein Kinase PAK4 Inhibitors;Signal Transduction Modulators; P21 activated kinase 4 Inhibitor;
CBR-001-585-097-2,RFM-004-677-5,CBR-001-585-097-2,OCC[C@@H](c1ccc(cc1)Cl)NC(=O)C1(N)CCN(CC1)c1ncnc2c1cc[nH]2,CBR-HVAC-06892: Female Reproductive System Cancer Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Gastric Cancer Therapy; Apoptosis Inducers;PKB alpha/Akt1 Inhibitors;PKB beta/Akt2 Inhibitors;PKB gamma/Akt3 Inhibitors;Ribosomal Protein S6 Kinase beta  (p70S6K) Inhibitors;Signal Transduction Modulators; AKT; PKB/Akt Inhibitor;
CBR-001-585-098-3,RFM-004-678-6,CBR-001-585-098-3,OC(=O)CNC(=O)c1nc(C)c2c(c1O)ccc(c2)Oc1ccccc1,"CBR-HVAC-06903: Antianemics;Sickle Cell Anemia, Agents for; Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors; Prolyl hydroxylase Inhibitor;"
CBR-001-585-099-4,RFM-004-679-7,CBR-001-585-099-4,OC(=O)C[C@@H]1CC[C@H](CC1)c1ccc(cc1)c1ccc(cn1)Nc1ccc(nc1)C(F)(F)F,"CBR-HVAC-06908: Liver and Biliary Tract Disorders, Treatment of;Lipoprotein Disorders, Treatment of ;Anti-Hepatitis C Virus Drugs;Type 2 Diabetes, Agents for;Treatment of Renal Diseases;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Metabolic and Nutritional Genetic Disorders, Treatment of ; Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitors; Diacylglycerol O-acyltransferase 1 inhibitor"
CBR-001-585-100-0,RFM-004-680-0,CBR-001-585-100-0,CC(NC(=O)COc1cccc(c1)c1nc(Nc2ccc3c(c2)cn[nH]3)c2c(n1)cccc2)C,"CBR-HVAC-06946: Nephritis, Agents for;Lesions of the Spinal Cord and Related Structures, Treatment of;Liver and Biliary Tract Disorders, Treatment of;Metabolic Disorders (Not Specified);Treatment of Other Autoimmune Disorders;Oncolytic Drugs;Antipsoriatics; Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors;Signal Transduction Modulators;"
CBR-001-585-101-1,RFM-004-681-1,CBR-001-585-101-1,OCCO[C@@H]1CC[C@H](CC1)n1c(=O)c(cc2c1nc(N)nc2C)c1ccc(nc1)OC,CBR-HVAC-06953: Oncolytic Drugs;Breast Cancer Therapy;Female Reproductive System Cancer Therapy; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; PHOSPHOINOSITIDE 3-KINASE; mTOR Inhibitor; PI3 kinase alpha inhibitor; PI3 kinase beta inhibitor; PI3 kinase gamma inhibitor; PI3 kinase delta inhibitor; mTOR kinase inhibitor
CBR-001-585-102-2,RFM-004-682-2,CBR-001-585-102-2,COc1cc(CCc2[nH]nc(c2)NC(=O)c2ccc(cc2)N2C[C@H](C)N[C@@H](C2)C)cc(c1)OC,CBR-HVAC-06960: Gastric Cancer Therapy;Bladder Cancer Therapy ;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy; Angiogenesis Inhibitors;FGFR Inhibitors;Signal Transduction Modulators;
CBR-001-585-103-3,RFM-004-683-3,CBR-001-585-103-3,CC[C@@H](C(=O)N1C[C@H](C[C@H]1Cc1c([nH]c2c1ccc(c2)F)c1[nH]c2c(c1C[C@@H]1C[C@@H](CN1C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)O)ccc(c2)F)O)NC(=O)[C@@H](NC)C,CBR-HVAC-06964: Myeloid Leukemia Therapy;Ovarian Cancer Therapy;Myelodysplastic Syndrome Therapy;Anti-Hepatitis B Virus Drugs;Lymphoma Therapy;Solid Tumors Therapy; Apoptosis Inducers;Inhibitor of Apoptosis Proteins (IAP) Inhibitors;Signal Transduction Modulators; IAP antagonist
CBR-001-585-104-4,RFM-004-684-4,CBR-001-585-104-4,CCN1CCN(CC1)c1ccc(cc1)Nc1ncnc(c1)N(C(=O)Nc1c(Cl)c(OC)cc(c1Cl)OC)C,CBR-HVAC-06967: Solid Tumors Therapy;Hematological Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Melanoma Therapy;Neurologic Cancer Therapy; Angiogenesis Inhibitors;FGFR1 Inhibitors;FGFR2 Inhibitors;FGFR3 Inhibitors;FGFR4 Inhibitors;Signal Transduction Modulators;
CBR-001-585-105-5,RFM-004-685-5,CBR-001-585-105-5,OC(=O)C1(CCC1)C(=O)O,A ligand of CBR-HVAC-06973
CBR-001-585-106-6,RFM-004-686-6,CBR-001-585-106-6,O=C(Nc1ccccc1N)CCCCCNC(=O)c1ccc(cc1)C,CBR-HVAC-06992: Neurologic Drugs (Miscellaneous); Histone Deacetylase 1 (HDAC1) Inhibitors;Histone Deacetylase 3 (HDAC3) Inhibitors; Histone deacetylase 1; Histone deacetylase 3 Inhibitor; Inhibitor;
CBR-001-585-107-7,RFM-004-687-7,CBR-001-585-107-7,Fc1ccc(cc1)n1c(C)ccc(c1=O)C(=O)Nc1ccc(c(c1)F)Oc1cc2cnn(c2cc1c1c[nH]nc1)C,"CBR-HVAC-07008: Oncolytic Drugs; Angiogenesis Inhibitors;HGFR (MET; c-Met) Inhibitors;Macrophage Stimulating 1 Receptor (MST1R, RON) Inhibitors;Signal Transduction Modulators; MET tyrosine kinase inhibitor"
CBR-001-585-108-8,RFM-004-688-8,CBR-001-585-108-8,FC(Oc1cc2cc(ccc2cc1OC(F)F)[C@](c1nn[nH]c1)(C(C)C)O)F,"CBR-HVAC-07032: Endometriosis Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;Gynecological Disorders, Treatment of ; Androgen Receptor Antagonists;Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Signal Transduction Modulators;"
CBR-001-585-109-9,RFM-004-689-9,CBR-001-585-109-9,CCNC(=O)C[C@@H]1N=C(c2ccc(cc2)Cl)c2c(n3c1nnc3C)ccc(c2)OC,"CBR-HVAC-07086: Inflammation, Treatment of;Atherosclerosis Therapy;Hematological Cancer Therapy;Oncolytic Drugs; APOA1 Expression Enhancers;Bromodomain-Containing Protein 2 (Brd2) Inhibitors;Bromodomain-Containing Protein 3 (Brd3, RING3-like protein) Inhibitors;Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors; BROMODOMAIN-CONTAINING PROTEIN 2; BROMODOMAIN-CONTAINING PROTEIN 3; BROMODOMAIN-CONTAINING PROTEIN 4 Inhibitor; Inhibitor; Inhibitor;"
CBR-001-585-110-2,RFM-004-690-2,CBR-001-585-110-2,CCCCOc1nc2N(CC(=O)Nc2c(n1)N)Cc1cccc(c1)CN1CCCC1,CBR-HVAC-07087: Anti-Hepatitis C Virus Drugs;Anti-Hepatitis B Virus Drugs;Anti-HIV Agents; Signal Transduction Modulators;TLR7 Receptor Agonists; Toll-like receptor 7 Agonist;
CBR-001-585-111-3,RFM-004-691-3,CBR-001-585-111-3,Cc1nn(c(n1)c1cn2c(n1)c1ccc(cc1OCC2)c1cnn(c1)C(C(=O)N)(C)C)C(C)C,CBR-HVAC-07111: Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Breast Cancer Therapy; Cytochrome P450 CYP3A4 Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; PI3 kinase inhibitor
CBR-001-585-112-4,RFM-004-692-4,CBR-001-585-112-4,CC(Oc1cc(C2CCNCC2)c(cc1Nc1ncc(c(n1)Nc1ccccc1S(=O)(=O)C(C)C)Cl)C)C,CBR-HVAC-07113: Pancreatic Cancer Therapy;Hematological Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Endocrine Cancer Therapy; ALK Inhibitors;Cytochrome P450 CYP2C9 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators; ANAPLASTIC LYMPHOMA KINASE Inhibitor; ALK receptor tyrosine kinase inhibitor
CBR-001-585-113-5,RFM-004-693-5,CBR-001-585-113-5,O=C(N1CCC(CC1)n1c(=O)[nH]c2c1cccn2)O[C@@H]1CC[C@H]([C@@H](c2c1nccc2)N)c1cccc(c1F)F,"CBR-HVAC-07123: Acute Attacks of Migraine, Treatment of; Calcitonin Gene-Related Peptides (CGRP) Antagonists;Signal Transduction Modulators; Calcitonin receptor-like receptor antagonist"
CBR-001-585-114-6,RFM-004-694-6,CBR-001-585-114-6,OCCN1CCN(CC1)[C@H]1CCCc2c(C1)ccc(c2OC)Nc1ncc(c(n1)Nc1ccccc1C(=O)NC)Cl,CBR-HVAC-07142: Lymphoma Therapy;Solid Tumors Therapy; ALK Inhibitors;Focal Adhesion Kinase (FAK) Inhibitors;Signal Transduction Modulators;
CBR-001-585-115-7,RFM-004-695-7,CBR-001-585-115-7,COc1cc2CC(=O)N([C@H](c2cc1OC(C)C)c1ccc(cc1)Cl)c1ccc(cc1)N(C[C@@H]1CC[C@H](CC1)N1CCN(C(=O)C1)C)C,CBR-HVAC-07149: Solid Tumors Therapy; Cellular Tumor Antigen p53 (TP53) Transactivation Inhibitors;MDM2 (hdm2) Inhibitors;Signal Transduction Modulators;
CBR-001-585-116-8,RFM-004-696-8,CBR-001-585-116-8,O=C(C1CC1)Nc1nc2n(n1)c(ccc2)c1ccc(cc1)CN1CCS(=O)(=O)CC1,"CBR-HVAC-07192: Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for; Jak1 Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators; Janus kinase 1 inhibitor"
CBR-001-585-117-9,RFM-004-697-9,CBR-001-585-117-9,CCS(=O)(=O)N1CCN(CC1)c1ccc(cc1)Nc1ncc(c(n1)NC1CC1)C(=O)N,"CBR-HVAC-07216: Rheumatoid Arthritis, Treatment of;Hematological Cancer Therapy; Janus Kinase (Jak) Inhibitors;Signal Transduction Modulators;Syk Kinase Inhibitors; Syk tyrosine kinase inhibitor; Janus kinase inhibitor"
CBR-001-585-118-0,RFM-004-698-0,CBR-001-585-118-0,CNC(=O)O[C@H]1COc2c([C@@H]1NC(=O)c1ccc(cc1)F)cc(cc2)N1CCN(CC1)C1COC1,CBR-HVAC-07231: Cardiovascular Diseases (Not Specified); Cathepsin S Inhibitors; Cathepsin S inhibitor
CBR-001-585-119-1,RFM-004-699-1,CBR-001-585-119-1,O[C@@H]1[C@@H](CN([C@@H]2C[C@@H](C2)CCc2nc3c([nH]2)ccc(c3)C(C)(C)C)C(C)C)O[C@H]([C@@H]1O)n1cnc2c1ncnc2N,"CBR-HVAC-07238: Leukemia Therapy; Histone-Lysine N-Methyltransferase, H3 Lysine-79 Specific (DOT1L) Inhibitors; DOT1L INHIBITOR;"
CBR-001-585-120-4,RFM-004-700-7,CBR-001-585-120-4,CN(c1ccc2c(c1)Sc1c(N2)ccc(c1)N(C)C)C,"CBR-HVAC-07242: Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of; MAO Inhibitors;Nitric Oxide (NO) Production Inhibitors;Tau Aggregation Inhibitors;"
CBR-001-585-121-5,RFM-004-701-8,CBR-001-585-121-5,N#CC1=C[C@@]2(C)[C@H](C(C1=O)(C)C)CC[C@@]1(C2=CC(=O)[C@H]2[C@@]1(C)CC[C@@]1([C@H]2CC(C)(C)CC1)NC(=O)C(F)(F)C)C,"CBR-HVAC-07337: Metabolic and Nutritional Genetic Disorders, Treatment of ;Ocular Antiinflammatory and Antiinfective Agents;Inflammation, Treatment of;Dermatologic Drugs;Melanoma Therapy;Solid Tumors Therapy;Neurological Genetic Disorders, Treatment of ;Non-Small Cell Lung Cancer Therapy; Nitric Oxide (NO) Production Inhibitors;Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activators;Signal Transduction Modulators; NUCLEAR FACTOR KAPPA B Inhibitor;"
CBR-001-585-122-6,RFM-004-702-9,CBR-001-585-122-6,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)C)C)C,"CBR-HVAC-04782: Progesterone receptor Agonist; Progesterone receptor agonist; Progesterone-receptor-agonists; Disorders of Sexual Function and Reproduction, Treatment of; Drug Delivery Systems; Endometriosis Therapy; Female Infertility, Agents for; Gynecological Disorders, Treatment of ; Hormone Replacement Therapy; Neurologic Drugs (Miscellaneous); Proceptive; Sleep Disorders, Treatment of; Stroke, Treatment of; Treatment of Dysmenorrhea; Treatment of Preterm Labor; Women's Health"
CBR-001-585-123-7,RFM-004-703-0,CBR-001-585-123-7,Clc1ccc(cc1)n1nc2c(c1=O)c[nH]c1c2cccc1,CBR-HVAC-07629: Antiepileptic Drugs;Anxiolytics; GABA(A) BZ Site Receptor Partial Agonists;Signal Transduction Modulators; GABA receptor agonist; Chloride channel agonist; Potassium channel agonist
CBR-001-585-124-8,RFM-004-704-1,CBR-001-585-124-8,OC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)N,CBR-HVAC-07764: ; GPIIb IIIa receptor antagonist
CBR-001-585-125-9,RFM-004-705-2,CBR-001-585-125-9,O=C(c1ccncc1)/C=C/c1ccc2c(n1)cccc2,"CBR-HVAC-08174: Oncolytic Drugs; 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) Inhibitors; Phosphofructokinase 2 inhibitor"
CBR-001-585-126-0,RFM-004-706-3,CBR-001-585-126-0,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2O)COP(=O)(O)O,monomeric unit of CBR-HVAC-08221
CBR-001-585-127-1,RFM-004-707-4,CBR-001-585-127-1,CC(=O)/C=C(/c1ccc(cc1)c1ccccc1)\C,CBR-HVAC-08536: ; Unidentified pharmacological activity
CBR-001-585-128-2,RFM-004-708-5,CBR-001-585-128-2,Cc1cc(ccc1Oc1ccn2c(c1)ncn2)Nc1ncnc2c1cc(cc2)c1ccc(o1)CNCCS(=O)(=O)C,CBR-HVAC-08568: ; HER-2 Inhibitor;
CBR-001-585-129-3,RFM-004-709-6,CBR-001-585-129-3,OCCn1ncc(c1)c1cnc2c(n1)n(nn2)Cc1ccc2c(c1)cccn2,CBR-HVAC-08569: Oncolytic Drugs; Angiogenesis Inhibitors;Apoptosis Inducers;HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators; Hepatocyte growth factor Antagonist;
CBR-001-585-130-6,RFM-004-710-9,CBR-001-585-130-6,CCOc1cc(ccc1C1=N[C@@]([C@@](N1C(=O)N1CCN(CC1)CCCS(=O)(=O)C)(C)c1ccc(cc1)Cl)(C)c1ccc(cc1)Cl)C(C)(C)C,CBR-HVAC-08577: ; MDM2 Antagonist;
CBR-001-585-131-7,RFM-004-711-0,CBR-001-585-131-7,[O-][N+](=O)c1cc(ccc1O)[As](=O)(O)O,CBR-HVAC-08658:
CBR-001-585-132-8,RFM-004-712-1,CBR-001-585-132-8,Brc1cc(C)c2c(c1O)nccc2,CBR-HVAC-08662:
CBR-001-585-133-9,RFM-004-713-2,CBR-001-585-133-9,NS(=O)(=O)c1ccc(cc1)NCc1ccccc1,CBR-HVAC-08676:
CBR-001-585-134-0,RFM-004-714-3,CBR-001-585-134-0,O=C(NS(=O)(=O)c1ccc(cc1)C)NC1CCCCCCC1,CBR-HVAC-08826:
CBR-001-585-135-1,RFM-004-715-4,CBR-001-585-135-1,CNC(=O)NC(C(Cl)(Cl)Cl)O,CBR-HVAC-08889:
CBR-001-585-136-2,RFM-004-716-5,CBR-001-585-136-2,S=C(NC(=O)Cc1ccccc1)Nc1ccc(c(c1)F)Oc1ccnc2c1sc(c2)c1ncn(c1)C,CBR-HVAC-08959: ; c-MET; Vascular endothelial growth factor receptor 1; Ron tyrosine kinase receptor; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3; TEK Tyrosine kinase receptor Antagonist; Inhibitor;
CBR-001-585-137-3,RFM-004-717-6,CBR-001-585-137-3,ClCOC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C,CBR-HVAC-08971: ; Glucocorticoid receptor Agonist;
CBR-001-585-138-4,RFM-004-718-7,CBR-001-585-138-4,CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cccc2,CBR-HVAC-08984:
CBR-001-585-139-5,RFM-004-719-8,CBR-001-585-139-5,OCCNC(=O)c1cc(CC=C)cc(c1O)OC,CBR-HVAC-09077:
CBR-001-585-140-8,RFM-004-720-1,CBR-001-585-140-8,O=C1C(c2ccc(cc2)Cl)C(=O)c2c1cccc2,CBR-HVAC-09113:
CBR-001-585-141-9,RFM-004-721-2,CBR-001-585-141-9,COc1ccc(cc1)S(=O)(=O)N1CCN(CC1)C(c1nc(OC2CCCCC2)c2c(n1)cccc2)C,CBR-HVAC-09202: ; Cystic fibrosis transmembrane conductance regulator Modulator;
CBR-001-585-142-0,RFM-004-722-3,CBR-001-585-142-0,CNCc1ccc(c(c1)NC(=O)c1ccc(cc1)Nc1nc2ccccc2c(n1)c1ccccc1)C,CBR-HVAC-09281: ; Hedgehog protein Inhibitor;
CBR-001-585-143-1,RFM-004-723-4,CBR-001-585-143-1,COc1ccc(c(c1)OC(C)C)C1=N[C@H]([C@H](N1C(=O)N1CCNC(=O)C1)c1ccc(cc1)Cl)c1ccc(cc1)Cl,CBR-HVAC-09295: Solid Tumors Therapy;Oncolytic Drugs; Apoptosis Inducers;Cellular Tumor Antigen p53 (TP53) Activators;MDM2 (hdm2) Inhibitors;Signal Transduction Modulators; MDM2 P53-Binding protein Antagonist;
CBR-001-585-144-2,RFM-004-724-5,CBR-001-585-144-2,CC(OC(=O)Nc1ccc(cc1)Cl)C,CBR-HVAC-09308: ; Reverse transcriptase Inhibitor;
CBR-001-585-145-3,RFM-004-725-6,CBR-001-585-145-3,CN1CCN(C(=O)C1c1ccc(cc1)Nc1nc(cn(c1=O)C)c1cccc(c1C)NC(=O)c1cc2c(s1)CCCC2)C,CBR-HVAC-09436: Antiarthritic Drugs; Bruton's Tyrosine Kinase (BTK) Inhibitors;Signal Transduction Modulators; Bruton's tyrosine kinase Inhibitor;
CBR-001-585-146-4,RFM-004-726-7,CBR-001-585-146-4,COc1cc2c(cc1OC)ncnc2n1nc(nc1N)c1ccccn1,CBR-HVAC-09482: ; ATM KINASE Inhibitor;
CBR-001-585-147-5,RFM-004-727-8,CBR-001-585-147-5,C/C=C(/C(=C/C)/c1ccc(cc1)O)\c1ccc(cc1)O,CBR-HVAC-09569: ; Estrogen receptor Binder;
CBR-001-585-148-6,RFM-004-728-9,CBR-001-585-148-6,NC(=O)N/N=C/c1ccc(o1)[N+](=O)[O-],CBR-HVAC-09623:
CBR-001-585-149-7,RFM-004-729-0,CBR-001-585-149-7,OC(=O)CCCC[C@@H]1SC[C@H]2[C@@H]1NC(=O)N2,CBR-HVAC-09687:
CBR-001-585-150-0,RFM-004-730-3,CBR-001-585-150-0,C=CCc1cc(cc(c1O)CN(CC)CC)c1cc(CC=C)c(c(c1)CN(CC)CC)O,CBR-HVAC-09727:
CBR-001-585-151-1,RFM-004-731-4,CBR-001-585-151-1,O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(C)O)C)C,CBR-HVAC-09816: ;2016-04-01: controlled substance
CBR-001-585-153-3,RFM-004-732-5,CBR-001-585-153-3,O=C(c1nccnc1)NCN1CCOCC1,CBR-HVAC-09848:
CBR-001-585-154-4,RFM-004-733-6,CBR-001-585-154-4,Cc1nc2ccccc2c(=O)n1c1ccccc1Cl,CBR-HVAC-09854: ; AMPA receptor Antagonist; ;2016-04-01: controlled substance
CBR-001-585-155-5,RFM-004-734-7,CBR-001-585-155-5,CCOc1ccc(cc1)NC(=O)C(O)C,CBR-HVAC-09895:
CBR-001-585-156-6,RFM-004-735-8,CBR-001-585-156-6,COc1ccc(cc1)C[C@H]1NC[C@@H]([C@H]1OC(=O)C)O,"CBR-HVAC-10024: Antineoplastic Enhancing Agents;Cognition Disorders, Treatment of;Antineoplastic Antibiotics;"
CBR-001-585-157-7,RFM-004-736-9,CBR-001-585-157-7,OCC(=O)C1CCC2C1(C=O)CC(O)C1C2CCC2=CC(=O)CCC12C,CBR-HVAC-10025: ; Angiotensin converting enzyme Inhibitor;
CBR-001-585-158-8,RFM-004-737-0,CBR-001-585-158-8,Oc1ccc(c(c1)O)C(=O)/C=C/c1ccc(c(c1)O)O,"CBR-HVAC-10027: Benign Prostatic Hyperplasia Therapy;Hypertension, Treatment of;Inflammation, Treatment of;Acne Therapy; Angiotensin-I Converting Enzyme (ACE) Inhibitors;IL-6 Production Inhibitors;IL-8 Production Inhibitors;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Steroid 5alpha-Reductase Inhibitors;TNF-alpha Production Inhibitors; EGFR Inhibitor;"
CBR-001-585-159-9,RFM-004-738-1,CBR-001-585-159-9,Oc1ccc(cc1)c1cc(=O)c2c(o1)c(c(cc2O)O)c1cc(ccc1O)c1cc(=O)c2c(o1)cc(cc2O)O,CBR-HVAC-10053: ; GABA-A receptor Modulator;
CBR-001-585-160-2,RFM-004-739-2,CBR-001-585-160-2,C1CN=C(N1)Nc1cccc2c1CCCC2,CBR-HVAC-10070: ; Alpha adrenergic receptor Agonist;
CBR-001-585-161-3,RFM-004-740-5,CBR-001-585-161-3,Oc1ccc(cc1)[As](=O)(O)O,CBR-HVAC-10107:
CBR-001-585-162-4,RFM-004-741-6,CBR-001-585-162-4,CCOc1ccc(cc1)NC(=O)CC(O)C,CBR-HVAC-10154:
CBR-001-585-163-5,RFM-004-742-7,CBR-001-585-163-5,SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N,CBR-HVAC-10268:
CBR-001-585-164-6,RFM-004-743-8,CBR-001-585-164-6,Clc1ccc2c(c1)N(CCCN1CCC(CC1)C(=O)N)c1c(S2)cccc1,CBR-HVAC-10291:
CBR-001-585-165-7,RFM-004-744-9,CBR-001-585-165-7,CC(CCCC(CCCC(C)C)C)CCCCC(CCCC(CCCC(C)C)C)C,CBR-HVAC-10313:
CBR-001-585-166-8,RFM-004-745-0,CBR-001-585-166-8,CC(=O)c1ccccc1,CBR-HVAC-10326:
CBR-001-585-167-9,RFM-004-746-1,CBR-001-585-167-9,CC1=NN(C(=O)C1)CCOc1ccc2c(c1)cccc2,CBR-HVAC-10397: ; 15-Hydroxyprostaglandin dehydrogenase; Lipoxygenase Inhibitor;
CBR-001-585-168-0,RFM-004-747-2,CBR-001-585-168-0,O=C(c1ccc2c(c1)C(C)(C)CCC2(C)C)Nc1ccc(cc1)C(=O)O,CBR-HVAC-10472: Oncolytic Drugs; Retinoid RARalpha Agonists;Signal Transduction Modulators; Retinoic acid receptor alpha Agonist;
CBR-001-585-169-1,RFM-004-748-3,CBR-001-585-169-1,CSC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2N,"CBR-HVAC-11335: Multiple Sclerosis, Agents for; Spermidine synthase Inhibitor;"
CBR-001-585-170-4,RFM-004-749-4,CBR-001-585-170-4,CN1CCN(CC1)C(=O)Cc1ccc2c(c1)cccc2,CBR-HVAC-11604: Treatment of Erectile Dysfunction;Antiarrhythmic Drugs; Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers;Signal Transduction Modulators;5-HT2C Agonists; Sodium channel Blocker;
CBR-001-585-171-5,RFM-004-750-7,CBR-001-585-171-5,COc1cc2c(ncnc2cc1OCCCN1CCOCC1)Nc1ccc(cc1)NC(=O)c1ccccc1,CBR-HVAC-11639: ; AURORA KINASE A; AURORA KINASE B Inhibitor;
CBR-001-585-172-6,RFM-004-751-8,CBR-001-585-172-6,Clc1cc(Cl)cc(c1)c1nc2c(o1)cc(cc2)C(=O)O,"CBR-HVAC-11803: Cardiovascular Diseases (Not Specified);Neurologic Drugs (Miscellaneous);Amyloidosis, Treatment of; Transthyretin Amyloid Inhibitors;"
CBR-001-585-173-7,RFM-004-752-9,CBR-001-585-173-7,Fc1ccc(cc1)c1n(Cc2ccc(cc2Cl)F)nc2c1cccc2C(F)(F)F,"CBR-HVAC-11835: Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ; ABCA1 Expression Enhancers;Oxysterol Receptor (LXR) Agonists;Signal Transduction Modulators; LIVER X RECEPTOR Agonist;"
CBR-001-585-174-8,RFM-004-753-0,CBR-001-585-174-8,N#CC1=C(N)Oc2c(C1c1cc(Br)c(c(c1)OC)OC)ccc(c2)N(C)C,CBR-HVAC-11853: Oncolytic Drugs; Antimitotic Drugs;Apoptosis Inducers;Tubulin Polymerization Inhibitors; Tubulin Inhibitor;
CBR-001-585-175-9,RFM-004-754-1,CBR-001-585-175-9,CCS(=O)(=O)c1cccc(c1)c1cc(C(=O)NC2CCN(CC2)C)c(c2c1c1cc(C)cnc1[nH]2)C,CBR-HVAC-11880: Hematological Cancer Therapy;Solid Tumors Therapy; Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;CDC-Like Kinase 1 (CLK1) Inhibitors;CDC-Like Kinase 4 (CLK4) Inhibitors;Signal Transduction Modulators; AURORA KINASE B Inhibitor;
CBR-001-585-176-0,RFM-004-755-2,CBR-001-585-176-0,CN[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1c1scc(n1)C(=O)c1ccc(cc1)F)C1CCCCC1)C,CBR-HVAC-11885: ; INHIBITOR OF APOPTOSIS PROTEIN Inhibitor;
CBR-001-585-177-1,RFM-004-756-3,CBR-001-585-177-1,CCNC(=O)NS(=O)(=O)c1sc(cc1c1ccc(cc1)Cn1c(nc(c1C=O)OC)c1ccccc1)CC(C)C,"CBR-HVAC-11922: Treatment of Renal Diseases;Hypertension, Treatment of;Atherosclerosis Therapy;Agents for Liver Cirrhosis; Angiotensin Receptor Agonists;Mas-Related G-protein Coupled Receptor  X1 (MRGX1; SNSR4) Agonists;Signal Transduction Modulators;"
CBR-001-585-178-2,RFM-004-757-4,CBR-001-585-178-2,COc1cc(ccc1OC)Cc1nc(=O)c2n([nH]1)c(nc2C)[C@H]([C@H](O)C)CCCc1ccccc1,CBR-HVAC-11924: ; PDE 2 Inhibitor;
CBR-001-585-179-3,RFM-004-758-5,CBR-001-585-179-3,COc1ccc2c(c1)cc([nH]2)C(=O)c1ccccc1,CBR-HVAC-11932: Oncolytic Drugs; Antimitotic Drugs;Microtubule Inhibitors; Tubulin Antagonist;
CBR-001-585-180-6,RFM-004-759-6,CBR-001-585-180-6,O=C(CC(O)(C)C)NCCn1ccc2c1c(ncn2)Nc1ccc(c(c1)Cl)Oc1cccc(c1)C(F)(F)F,CBR-HVAC-12054: Solid Tumors Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators;
CBR-001-585-185-1,RFM-004-760-9,CBR-001-585-185-1,N#Cc1cc(ccc1OC(C)C)c1onc(n1)c1cccc2c1CCC2NCCC(=O)O,analog of CBR-HVAC-07135: (ozanimod)
CBR-001-585-187-3,RFM-004-761-0,CBR-001-585-187-3,COc1cc2[nH]c(=O)c3c(c(=O)c2cc1OC)n[nH]n3,metabolite of CBR-HVAC-11782
CBR-001-585-188-4,RFM-004-762-1,CBR-001-585-188-4,CCCCCc1c(c2ccc3c(c2)ccc(c3)OCc2nnn[nH]2)n(c2c1cccc2)Cc1ccccc1,CBR-HVAC-00175: Thrombolytics; Plasminogen Activator Inhibitor (PAI-1) Inhibitors; PLASMINOGEN ACTIVATOR INHIBITOR-1 Inhibitor; Plasminogen activator inhibitor-1 inhibitor
CBR-001-585-189-5,RFM-004-763-2,CBR-001-585-189-5,CCOC(=O)C(c1ccccc1)(C(=O)OCC)COC(=O)Cc1ccc(c(c1)C(=O)N(C)C)NC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F,"CBR-HVAC-00354: Lipoprotein Disorders, Treatment of ;Type 2 Diabetes, Agents for; Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein Inhibitor; Microsomal trigylceride transfer protein inhibitor"
CBR-001-585-190-8,RFM-004-764-3,CBR-001-585-190-8,OC(=O)Cc1ccc(c(c1)C(=O)N(C)C)NC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F,metabolite of CBR-HVAC-00354
CBR-001-585-191-9,RFM-004-765-4,CBR-001-585-191-9,O=C1OC(CN1/N=C/c1ncc(n1C)[N+](=O)[O-])CN1CCOCC1,CBR-HVAC-01112: Antitrichomonals; DNA inhibitor
CBR-001-585-192-0,RFM-004-766-5,CBR-001-585-192-0,COc1ccc(cc1)C(c1ccccc1)OCCN1CCN(CC1)CCCC(=O)c1ccc(cc1)F,CBR-HVAC-01142: Muscarinic receptor antagonist
CBR-001-585-193-1,RFM-004-767-6,CBR-001-585-193-1,CN(CC(Oc1ccccc1)Oc1ccccc1)C,"CBR-HVAC-01760: Antidepressants;Cognition Disorders, Treatment of; 5-Hydroxytryptamine 2C receptor Inhibitor; Dopamine receptor agonist"
CBR-001-585-194-2,RFM-004-768-7,CBR-001-585-194-2,OC(=O)Cc1ccccc1Oc1ccc(cc1Cl)Cl,CBR-HVAC-02839: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-585-195-3,RFM-004-769-8,CBR-001-585-195-3,C/C(=C\c1ccc(cc1)C(=O)O)/c1ccc(s1)C(C)C,CBR-HVAC-03424: Ophthalmic Drugs;Acne Therapy;Antipsoriatics; Protein synthesis inhibitor; Protein synthesis inhibitor; Microbial collagenase inhibitor
CBR-001-585-196-4,RFM-004-770-1,CBR-001-585-196-4,Cc1cc(C)[n+](c(c1)C)[N-]C(=O)c1ccc(c(c1)S(=O)(=O)N)Cl,"CBR-HVAC-03550: Diuretics;Hypertension, Treatment of; Diuretic"
CBR-001-585-197-5,RFM-004-771-2,CBR-001-585-197-5,CCCCC1=Cc2c(C1N1CCN(CC1)C)cc1c(c2)OCO1,"CBR-HVAC-03987: Cognition Disorders, Treatment of; CALCIUM CHANNEL Modulator;"
CBR-001-585-198-6,RFM-004-772-3,CBR-001-585-198-6,OC(=O)CC(C(=O)NCCc1ccccc1)NS(=O)(=O)c1ccc2c(c1)cccc2,CBR-HVAC-04499: CCK1 (CCKA) Antagonists;Signal Transduction Modulators;
CBR-001-585-199-7,RFM-004-773-4,CBR-001-585-199-7,CCCCc1oc2c(c1C(=O)c1ccc(s1)OCCN(CC)CC)cccc2,CBR-HVAC-04569: Antiarrhythmic Drugs; Potassium channel Blocker; Polarisation inhibitor; Sodium channel antagonist
CBR-001-585-200-3,RFM-004-774-5,CBR-001-585-200-3,OC(=O)[C@H](Oc1c(C)cc(cc1C)c1c2ccccc2c(c2c1c(C)c(s2)C)Br)Cc1ccccc1,CBR-HVAC-05290: Protease inhibitor
CBR-001-585-201-4,RFM-004-775-6,CBR-001-585-201-4,OCCc1c(=O)[nH]c2c(c1c1cc(Cl)ccc1O)cc(cc2)C(F)(F)F,"CBR-HVAC-05373: Treatment of Erectile Dysfunction; Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators; Potassium large conductance calcium-activated channel, subfamily M, alpha member 1 Stimulator;"
CBR-001-585-202-5,RFM-004-776-7,CBR-001-585-202-5,CCC(NC(=N)NC#N)(C)C,"CBR-HVAC-05590: Hypertension, Treatment of; Alpha adrenoreceptor antagonist"
CBR-001-585-203-6,RFM-004-777-8,CBR-001-585-203-6,CO/N=C\1/CN([C@@H](C1)C(=O)NC[C@H](c1ccccc1)O)C(=O)c1ccc(cc1)c1ccccc1C,CBR-HVAC-05631: Treatment of Preterm Labor; Oxytocin (OT) Antagonists;Signal Transduction Modulators;
CBR-001-585-204-7,RFM-004-778-9,CBR-001-585-204-7,CO/N=C/1\CN([C@@H](C1)C(=O)NC[C@H](c1ccccc1)O)C(=O)c1ccc(cc1)c1ccccc1C,CBR-HVAC-05631: Treatment of Preterm Labor; Oxytocin (OT) Antagonists;Signal Transduction Modulators;
CBR-001-585-205-8,RFM-004-779-0,CBR-001-585-205-8,O=C1NC2(OC1C)CCCCC2Oc1cccc(c1)Cl,CBR-HVAC-05786: CNS Stimulants; 5 Hydroxytryptamine 1A receptor agonist
CBR-001-585-206-9,RFM-004-780-3,CBR-001-585-206-9,COc1ccccc1SC[C@H](CN[C@H]1CSc2c(OC1)cccc2)C,"CBR-HVAC-05875: Angina pectoris, Treatment of; Late Sodium Current (INaL) Blockers;Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers; Potassium channel Blocker; Sodium channel antagonist"
CBR-001-585-207-0,RFM-004-781-4,CBR-001-585-207-0,O=c1cc(CCCC2(C)CC2)c2c(o1)[nH]c(=O)[nH]c2=O,"CBR-HVAC-06506: Lipoprotein Disorders, Treatment of ; Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;"
CBR-001-585-208-1,RFM-004-782-5,CBR-001-585-208-1,CN(CC(=O)O)C/C=C(\c1cscc1)/c1ccc(cc1)c1ccco1,CBR-HVAC-06800: Antipsychotic Drugs; GlyT-1 Inhibitors;
CBR-001-585-209-2,RFM-004-783-6,CBR-001-585-209-2,Fc1cc(cc(c1CNC1Cc2c(C1)cccc2)F)c1cccc(c1)c1ncn[nH]1,CBR-HVAC-06877: Antiobesity Drugs;Treatment of Alcohol Dependency; mu-Opioid Antagonists;Signal Transduction Modulators; Mu-opioid receptor Agonist;
CBR-001-585-210-5,RFM-004-784-7,CBR-001-585-210-5,Fc1ccc(cn1)c1ccc2c(c1)C[C@H](C2)NS(=O)(=O)C(C)C,CBR-HVAC-07036: Antipsychotic Drugs; AMPA Receptor Positive Allosteric Modulators;Signal Transduction Modulators;
CBR-001-585-211-6,RFM-004-785-8,CBR-001-585-211-6,O=Cc1c(cccc1O)OCc1cccnc1c1ccnn1C(C)C,CBR-HVAC-07311: Hematopoiesis Disorders Therapy; Hemoglobin Subunit beta (Sickle Cell Anemia Variant) Polimerization Inhibitors;
CBR-001-585-212-7,RFM-004-786-9,CBR-001-585-212-7,CN(CCCSc1n(Cc2ccccc2)nc2c1cccc2)C,CBR-HVAC-07713: Unidentified pharmacological activity
CBR-001-585-213-8,RFM-004-787-0,CBR-001-585-213-8,Fc1cccc(c1)CNCC(=O)N[C@@H](C(C)(C)C)C(=O)N[C@H]([C@H](CN(S(=O)(=O)c1cccc(c1)N)CC(C)C)O)Cc1ccccc1,CBR-HVAC-05393: HIV protease inhibitor
CBR-001-585-214-9,RFM-004-788-1,CBR-001-585-214-9,OCCCCc1ccc2c(c1)C(=O)c1sccc1CO2,CBR-HVAC-07898: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-585-215-0,RFM-004-789-2,CBR-001-585-215-0,ClCCN(C(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12)N=O,CBR-HVAC-07998: DNA inhibitor
CBR-001-585-216-1,RFM-004-790-5,CBR-001-585-216-1,CCCCCCc1cc(cc2c1oc1ccc(cc1c2=O)C(=O)O)S(=O)(=N)C,"CBR-HVAC-08383: Allergic Skin Disorders, Treatment for; Histamine release inhibitor"
CBR-001-585-217-2,RFM-004-791-6,CBR-001-585-217-2,CCCCCCCCCCCC(=O)c1ccc(cc1)OCC[N+](Cc1ccccc1)(C)C,CBR-HVAC-09258:
CBR-001-585-218-3,RFM-004-792-7,CBR-001-585-218-3,Oc1ccc(cc1C(c1ncc(n1C)[N+](=O)[O-])O)C(C)(C)C,CBR-HVAC-09381: Antifungal;
CBR-001-585-219-4,RFM-004-793-8,CBR-001-585-219-4,N#Cc1ccccc1/C=C/C=C/C(=O)N1CCN(CC1)c1ccccn1,CBR-HVAC-09474: Antiplatelet Therapy;Heart Failure Therapy; PAR1 Antagonists;Signal Transduction Modulators; Protease-activated receptor 1; Protease activated receptor 1 Antagonist;
CBR-001-585-220-7,RFM-004-794-9,CBR-001-585-220-7,N#Cc1ccccc1/C=C/C=C/C(=O)N1CCN(CC1)c1ccccn1,CBR-HVAC-09474: Antiplatelet Therapy;Heart Failure Therapy; PAR1 Antagonists;Signal Transduction Modulators; Protease-activated receptor 1; Protease activated receptor 1 Antagonist;
CBR-001-585-221-8,RFM-004-795-0,CBR-001-585-221-8,OC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccccc1)C,metabolite of CBR-HVAC-09507
CBR-001-585-222-9,RFM-004-796-1,CBR-001-585-222-9,Cc1ccc2c(n1)c(O)c(cc2Br)Br,metabolite of CBR-HVAC-09732
CBR-001-585-223-0,RFM-004-797-2,CBR-001-585-223-0,Cc1ccc2c(n1)c(OC(=O)c1ccccc1)c(cc2Br)Br,"CBR-HVAC-09732: Involves disappearance of the cystic forms, probably by elimination of the trophozoites;"
CBR-001-585-224-1,RFM-004-798-3,CBR-001-585-224-1,COCC(=O)Nc1ccc(cc1)/N=C(/N(C)C)\C,CBR-HVAC-10180: Acetylcholine receptor Agonist;
CBR-001-585-225-2,RFM-004-799-4,CBR-001-585-225-2,O[C@@H]([C@@H](NC(=O)[C@H](NS(=O)(=O)C)CS(=O)c1ccc2c(c1)cccc2)Cc1ccccc1)Cc1ccccc1C(=O)NC(C)(C)C,CBR-HVAC-10971: Protease Inhibitor;
CBR-001-585-226-3,RFM-004-800-0,CBR-001-585-226-3,O=C1NC(=O)C(S1)Cc1ccc2c(c1)nc(o2)Cc1ccc2c(c1)cccc2,CBR-HVAC-11483: Antidiabetic Drugs; Peroxisome proliferator activated receptor gamma Agonist;
CBR-001-585-227-4,RFM-004-801-1,CBR-001-585-227-4,Fc1ccc2c(c1)c(=O)cc(o2)C(=O)NC1CCN(CC1)Cc1ccc2c(c1)OCO2,CBR-HVAC-11761: Melanin concentrating hormone receptor 1 Antagonist;
CBR-001-585-228-5,RFM-004-802-2,CBR-001-585-228-5,CC(S(=O)(=O)N[C@@H]1CC[C@H](CC1)CNc1scc(n1)c1ccccn1)C,CBR-HVAC-11859: Neuropeptide Y receptor Antagonist;
CBR-001-585-235-4,RFM-004-803-3,CBR-001-585-235-4,N(c1cnccn1)N=O,CBR-HVAC-00529:DNA synthesis inhibitor; Unidentified pharmacological activity
CBR-001-585-236-5,RFM-004-804-4,CBR-001-585-236-5,O=C1CCc2c(N1)ncc(c2)/C=C/C(=O)N(Cc1oc2c(c1C)cccc2)C,CBR-HVAC-00590:Antibacterial Drugs; Bacterial Fatty Acid Biosynthesis Inhibitors ;Enoyl-(acyl-carrier protein) Reductase Fabl Inhibitors; Enoyl-(acyl carrier protein) reductase Inhibitor; FABI inhibitor
CBR-001-585-237-6,RFM-004-805-5,CBR-001-585-237-6,NC[C@@H]1CC[C@H](CC1)C(=O)c1ccc(cc1)CCC(=O)O,CBR-HVAC-01174:Antiulcer Drugs; Unidentified pharmacological activity
CBR-001-585-238-7,RFM-004-806-6,CBR-001-585-238-7,OC(CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F)CSc1ncnc2c1nc[nH]2,CBR-HVAC-01186:Heart Failure Therapy; Sodium channel agonist
CBR-001-585-239-8,RFM-004-807-7,CBR-001-585-239-8,Fc1ccc2c(c1)[C@H](OCc1c(F)cccc1F)[C@H](S2)Cn1ccnc1,CBR-HVAC-01238:Antifungal Agents;Dermatologic Drugs; Unidentified pharmacological activity
CBR-001-585-240-1,RFM-004-808-8,CBR-001-585-240-1,ClCCNC(=O)Sc1ncnc2c1nc[nH]2,CBR-HVAC-02721:Oncolytic Drugs; Antimetabolites; Hypoxanthine phosphoribosyltransferase Inhibitor; Hypoxanthine phosphoribosyltransferase inhibitor
CBR-001-585-241-2,RFM-004-809-9,CBR-001-585-241-2,COc1ccc2c(c1)Oc1ccc(cc1N=C2C)C(=O)O,"CBR-HVAC-03652:Cognition Disorders, Treatment of;Cardiovascular Diseases (Not Specified); Na+, K+ ATPase Stimulator;"
CBR-001-585-242-3,RFM-004-810-2,CBR-001-585-242-3,Oc1ccc2c(c1)CCC1C2CC[C@@]2(C1CC[C@@H]2OC(=O)c1ccc[n+](c1)C)C,analog of CBR-HVAC-03709 (IDR-90104)
CBR-001-585-243-4,RFM-004-811-3,CBR-001-585-243-4,CC(=O)Oc1cccc2c1nc(s2)c1ccc(cc1)C,CBR-HVAC-03855:Antiarthritic Drugs;Immunosuppressants;Disease-Modifying Anti-Rheumatic Drugs; Immunomodulator; Immunosuppressant
CBR-001-585-244-5,RFM-004-812-4,CBR-001-585-244-5,CC(OP(=O)(C(P(=O)(OC(C)C)OC(C)C)Cc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)OC(C)C)C,"CBR-HVAC-03975:Leukemia Therapy;Treatment of Osteoporosis;Ovarian Cancer Therapy;Melanoma Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;Lipoprotein Disorders, Treatment of ;Lung Cancer Therapy; Apoptosis Inducers;Farnesoid X Receptor (FXR) Agonists;Signal Transduction Modulators; Hypocalcaemic agent; Apoptosis stimulant; Bisphosphonate; Bone resorption inhibitor; Farnesoid X receptor agonist"
CBR-001-585-245-6,RFM-004-813-5,CBR-001-585-245-6,O=C(N(c1cnccn1)C1CCN(CC1)CCc1ccccc1)c1ccco1,CBR-HVAC-04022:Opioid Analgesics; Opioid Receptor Agonists;Signal Transduction Modulators; Opioid receptor mu Agonist;
CBR-001-585-246-7,RFM-004-814-6,CBR-001-585-246-7,CCCCOC(=O)CS(=O)c1nc2c(s1)nccc2,CBR-HVAC-04129:Antiulcer Drugs;Gastric Antisecretory Drugs; Gastrin inhibitor
CBR-001-585-247-8,RFM-004-815-7,CBR-001-585-247-8,COC(=O)Nc1cccc(c1CNc1cccn2c1nc(c2C)C)C,CBR-HVAC-04612:Gastric Antisecretory Drugs;Antiulcer Drugs; Reversible H+/K+-ATPase Inhibitors ;
CBR-001-585-248-9,RFM-004-816-8,CBR-001-585-248-9,CCCCCCCCCCCCS[C@H](C(=O)Nc1cc(C)c(c(c1C)C)O)c1ccccc1,"CBR-HVAC-04956:Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor; Acetyl CoA transferase inhibitor"
CBR-001-585-249-0,RFM-004-817-9,CBR-001-585-249-0,NCCC(=O)NCCSSCCNC(=O)CCN,CBR-HVAC-05045:Lymphoma Therapy;Chemopreventive Agents;Multiple Myeloma Therapy;Immunostimulants;Melanoma Therapy; Anticancer; Immunostimulator;
CBR-001-585-250-3,RFM-004-818-0,CBR-001-585-250-3,NCCC(=O)NCCSSCCNC(=O)CCN,CBR-HVAC-05045:Lymphoma Therapy;Chemopreventive Agents;Multiple Myeloma Therapy;Immunostimulants;Melanoma Therapy; Anticancer; Immunostimulator;
CBR-001-585-251-4,RFM-004-819-1,CBR-001-585-251-4,CCOC(=O)c1cc(CN(CC)CC)c(c(c1)Br)N,CBR-HVAC-05838:Mucolytics;Antiulcer Drugs;
CBR-001-585-252-5,RFM-004-820-4,CBR-001-585-252-5,Cc1cc(OCP(=O)(O)O)cc(c1Cc1ccc(c(c1)C(C)C)O)C,"CBR-HVAC-06262:Lipoprotein Disorders, Treatment of ; Signal Transduction Modulators;Thyroid Hormone Receptor beta Agonists; THYROID HARMONE RECEPTOR Agonist;"
CBR-001-585-253-6,RFM-004-821-5,CBR-001-585-253-6,OCC(NC(=O)c1cccc(c1)/C=C\CCCC(=O)N(C)C)C,"CBR-HVAC-06276:Antispastic Drugs and Drugs for Muscle Spasms;Multiple Sclerosis, Agents for; Cannabinoid Receptor Agonists;Signal Transduction Modulators; Cannabinoid receptor Agonist; GPR55 agonist"
CBR-001-585-254-7,RFM-004-822-6,CBR-001-585-254-7,Clc1cccc(c1)c1onc(c1)[C@H](Oc1nnc(n1C)c1ccncc1)C,"CBR-HVAC-06564:Neuropathic Pain, Treatment of;Analgesic Drugs;Diabetic Neuropathy, Agents for;Gastroesophageal Reflux Disease, Agents for;Antidepressants; mgluR5 Antagonists;Signal Transduction Modulators;"
CBR-001-585-255-8,RFM-004-823-7,CBR-001-585-255-8,CCS(=O)(=O)c1ccc2c(c1)nc(o2)c1ccc2c(c1)cccc2,"CBR-HVAC-06609:Muscular Dystrophy, Agents for; UTRN (Utrophin gene) Expression Enhancers;"
CBR-001-585-256-9,RFM-004-824-8,CBR-001-585-256-9,OC[C@H](c1nsc(n1)Nc1ncc(cc1Oc1cccnc1C)Sc1ccccn1)O,"CBR-HVAC-06819:Type 2 Diabetes, Agents for; Glucokinase Activators;"
CBR-001-585-257-0,RFM-004-825-9,CBR-001-585-257-0,OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@@H]([C@@H]([C@H]2O)n2nnc(c2)c2cccc(c2)F)O)[C@@H]([C@H]([C@H]1O)n1nnc(c1)c1cccc(c1)F)O,"CBR-HVAC-07355:Interstitial Lung Diseases, Treatment of; Galectin 3 Inhibitors;"
CBR-001-585-258-1,RFM-004-826-0,CBR-001-585-258-1,Cc1cccc[n+]1[Pt-2]([NH3+])(Cl)Cl,CBR-HVAC-08201: Apoptosis stimulant; DNA Alkylating Drugs; DNA inhibitor; DNA synthesis inhibitor; Anticancer; Bladder Cancer Therapy ; Breast Cancer Therapy; Cervical Cancer Therapy; Colorectal Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Ovarian Cancer Therapy; Prostate Cancer Therapy; Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-001-585-259-2,RFM-004-827-1,CBR-001-585-259-2,O=C(c1cc2c(s1)c(Cl)ccc2)N[C@H]1CN2CCC1CC2,"CBR-HVAC-00848: Alzheimer's Dementia, Treatment of ;Smoking Cessation, Aid to;Cognition Disorders, Treatment of;Antipsychotic Drugs; Nicotinic alpha7 Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha7 Agonist; Alpha-7 nicotinic receptor agonist"
CBR-001-585-260-5,RFM-004-828-2,CBR-001-585-260-5,CC[As](=O)(O)O,CBR-HVAC-09069
CBR-001-585-261-6,RFM-004-829-3,CBR-001-585-261-6,CN(C(=O)CCCOC(=O)C(Oc1ccc(cc1)Cl)(C)C)C,CBR-HVAC-09268
CBR-001-585-262-7,RFM-004-830-6,CBR-001-585-262-7,CCN(CCOC(=O)c1cccc(c1O)c1ccccc1)CC,CBR-HVAC-09914
CBR-001-585-263-8,RFM-004-831-7,CBR-001-585-263-8,O=c1c2ccccc2nnn1N1CCOCC1,CBR-HVAC-10001
CBR-001-585-264-9,RFM-004-832-8,CBR-001-585-264-9,C(CP(c1ccccc1)c1ccccc1)CP(c1ccccc1)c1ccccc1,CBR-HVAC-10986:Oncolytic Drugs; Anticancer;
CBR-001-585-265-0,RFM-004-833-9,CBR-001-585-265-0,NC(=NC(=O)c1ccc2c(c1)N(C(C)C)C(=O)C(O2)(C)C)N,"CBR-HVAC-11299:Antiarrhythmic Drugs;Angina pectoris, Treatment of; Na+/H+ Exchanger (NHE) Inhibitors; Na+/H+ exchanger Inhibitor;"
CBR-001-585-266-1,RFM-004-834-0,CBR-001-585-266-1,COC(=O)[C@]12CN(C)C[C@@](C2=O)([C@@H](N([C@@H]1c1ccccn1)C)c1ccccn1)C(=O)OC,CBR-HVAC-11323:Opioid Analgesics; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist;
CBR-001-585-267-2,RFM-004-835-1,CBR-001-585-267-2,O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@]2(F)[C@@H](O)C[C@]2([C@H]1C[C@H]([C@]2(OC(=O)C1CC1)C(=O)COC(=O)C1CCCCC1)C)C)C,CBR-HVAC-11647:Glucocorticoid receptor Agonist;
CBR-001-585-268-3,RFM-004-836-2,CBR-001-585-268-3,O=C1NC(=O)/C(=C\c2ccc(c(c2)c2cc3c(cc2C)C(C)(C)CCC3(C)C)OC(F)(F)F)/S1,CBR-HVAC-11758:Retinoid Z receptor Agonist;
CBR-001-585-297-8,RFM-004-837-3,CBR-001-585-297-8,Cc1ccc(c(c1)O)Nc1nccs1,CBR-HVAC-00073:Antiinflammatory Ophthalmic Agents; Lipoxygenase 5; COX Inhibitor; Cyclooxygenase inhibitor; Lipoxygenase inhibitor
CBR-001-585-298-9,RFM-004-838-4,CBR-001-585-298-9,CNc1ncnc2c1ncn2Cc1ccccc1F,CBR-HVAC-00213:PHOSPHODIESTERASE 4 Inhibitor; Unidentified pharmacological activity
CBR-001-585-299-0,RFM-004-839-5,CBR-001-585-299-0,Fc1ccc(cc1)c1cc(OCCCCCN2CCCCC2)nc(n1)C,CBR-HVAC-00304:Calcium channel; Sodium channel Blocker; Sodium channel antagonist; Calcium channel antagonist
CBR-001-585-300-6,RFM-004-840-8,CBR-001-585-300-6,OC(=O)COc1ccc(cc1C)SCc1nn(nc1C)c1ccc(cc1)C(F)(F)F,"CBR-HVAC-00702: Peroxisome proliferator-activated receptor delta agonist from WO 2016057656 A1 20160414, frequently mislabeled as Seladelpar or MBX-8025"
CBR-001-585-301-7,RFM-004-841-9,CBR-001-585-301-7,OC(C(C)(C)C)(Cn1ncnc1)COc1ccc(cc1)Cl,CBR-HVAC-00780:Antifungal Agents; Cell wall synthesis inhibitor; Sterol demethylase inhibitor
CBR-001-585-302-8,RFM-004-842-0,CBR-001-585-302-8,Clc1ccccc1COc1nccc2c1ncn2C,CBR-HVAC-00935:Antiepileptic Drugs; Gamma-aminobutyric acid receptor Agonist; Sodium channel antagonist
CBR-001-585-303-9,RFM-004-843-1,CBR-001-585-303-9,Cc1cc(N=C(Nc2nccs2)NC2CCCCC2)c2c(n1)cccc2,CBR-HVAC-01026:COX; Lipoxygenase Inhibitor; Lipoxygenase inhibitor; Cyclooxygenase inhibitor
CBR-001-585-304-0,RFM-004-844-2,CBR-001-585-304-0,OCCNC(=O)CSc1nc(Cl)cc(n1)Nc1cccc(c1C)C,CBR-HVAC-01036:Cholesterol inhibitor
CBR-001-585-305-1,RFM-004-845-3,CBR-001-585-305-1,N1CCC(CC1)CCc1cc(nc2c1cccc2)c1ccccc1,CBR-HVAC-01211:Benzodiazepine receptor Partial agonist; Benzodiazepine receptor agonist
CBR-001-585-306-2,RFM-004-846-4,CBR-001-585-306-2,COc1cc(cc(c1OC)OC)C(=O)OCc1cccc(n1)COC(=O)c1cc(OC)c(c(c1)OC)OC,"CBR-HVAC-01817:Lipoprotein Disorders, Treatment of ; Platelet aggregation inhibitor; Cholesterol inhibitor"
CBR-001-585-307-3,RFM-004-847-5,CBR-001-585-307-3,OC(=O)Cc1nn(cc1c1ccc(cc1)Cl)c1ccc(cc1)F,CBR-HVAC-02539:COX Inhibitor; Cyclooxygenase inhibitor; Arachidonic acid inhibitor; Phospholipase C inhibitor
CBR-001-585-308-4,RFM-004-848-6,CBR-001-585-308-4,COc1ccc2c(c1CN1CCCCC1)oc1c(c2=O)cccc1,CBR-HVAC-02802:Unidentified pharmacological activity
CBR-001-585-309-5,RFM-004-849-7,CBR-001-585-309-5,CC(C[C@H]1[C@@H](OC(=O)N1CCCN1CCCCCC1)c1ccccc1)C,"CBR-HVAC-03345:Neurologic Drugs (Miscellaneous);Alzheimer's Dementia, Treatment of ; Glutamate Ionotropic Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor Antagonist; Glutamate antagonist"
CBR-001-585-310-8,RFM-004-850-0,CBR-001-585-310-8,CCC1Cn2c(=N1)c1n(C)nc(c1nc2C)C,CBR-HVAC-03687:Antipsychotic Drugs; Unidentified pharmacological activity
CBR-001-585-311-9,RFM-004-851-1,CBR-001-585-311-9,CSCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@@H]2CCC2=CC(=O)CC[C@@]12C)C(=O)CCl,CBR-HVAC-04002:Antiinflammatory Drugs;
CBR-001-585-312-0,RFM-004-852-2,CBR-001-585-312-0,COCCCNC(=O)c1ccnc(c1)C(=O)NCCCOC,CBR-HVAC-04136:Immunosuppressants; Prolyl 4-Hydroxylase (Protein Disulfide-Isomerase) Inhibitors; Proline 4-hydroxylase type I Inhibitor; Prolyl hydroxylase inhibitor
CBR-001-585-313-1,RFM-004-853-3,CBR-001-585-313-1,O=C(c1ccccc1)c1ccc(cc1)NC(=O)[C@](C(F)(F)F)(O)C,CBR-HVAC-04434:Urinary Incontinence Therapy; K(ATP) Channel Activators; Potassium channel Agonist; ATP-sensitive potassium channel agonist
CBR-001-585-314-2,RFM-004-854-4,CBR-001-585-314-2,CN1CCN(CC1)S(=O)(=O)CCCN1CCC(CC1)CNC(=O)c1cccc2c1OCCO2,CBR-HVAC-05337:Urinary Incontinence Therapy; Signal Transduction Modulators;5-HT4 Antagonists;
CBR-001-585-315-3,RFM-004-855-5,CBR-001-585-315-3,Clc1ccc(cc1)Cc1nc2c3CCCCc3ccc2c(c1O)C(=O)O,CBR-HVAC-06124:Atherosclerosis Therapy;Immunomodulators;Anticoagulants;Ophthalmic Drugs; Cell Adhesion Inhibitors;P-Selectin Inhibitors; P-Selectin Antagonist;
CBR-001-585-316-4,RFM-004-856-6,CBR-001-585-316-4,O=C(N[C@H](C(=O)N1CC[C@](C(C1)(C)C)(O)c1ccc(cc1)Cl)C(C)C)NCC(O)(C)C,"CBR-HVAC-06982:Rheumatoid Arthritis, Treatment of; Chemokine CCR1 Receptor Ligands;Signal Transduction Modulators;"
CBR-001-585-317-5,RFM-004-857-7,CBR-001-585-317-5,O=C([C@H]1CN(CCN1S(=O)(=O)c1ccc(cc1)C(F)(F)F)c1sc2c(n1)nc(nc2)C1CC1)NCc1ccc(c(c1)F)OC(F)(F)F,CBR-HVAC-07083:Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B polymerase Inhibitor;
CBR-001-585-318-6,RFM-004-858-8,CBR-001-585-318-6,Fc1ccc(nc1)C(=O)Nc1ccc(c(c1)[C@]1(C)NC(=N)N(S(=O)(=O)C1)C)F,"CBR-HVAC-07119:Alzheimer's Dementia, Treatment of ; beta-Amyloid (Abeta) Production Inhibitors;beta-Secretase 1 (BACE1) Inhibitors;"
CBR-001-585-319-7,RFM-004-859-9,CBR-001-585-319-7,COc1ccc(cc1OCCc1cccc(c1)C)C(=O)NC1(Cc2c(C1)cccc2)C(=O)O,"CBR-HVAC-07303:Scleroderma, Agents for;"
CBR-001-585-320-0,RFM-004-860-2,CBR-001-585-320-0,NC(=O)c1cccc2c1cc(n2c1nc(NCc2ccccc2)c2c(n1)CCOC2)C,"CBR-HVAC-07351:Multiple Myeloma Therapy;Solid Tumors Therapy; Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors;"
CBR-001-585-321-1,RFM-004-861-3,CBR-001-585-321-1,CCOC(=O)c1cc(nc(c1)C(=O)NC)C(=O)NC,CBR-HVAC-07687:Histamine release inhibitor; Immunosuppressant; Slow releasing substance antagonist
CBR-001-585-322-2,RFM-004-862-4,CBR-001-585-322-2,CC(N1CCN(CC1)C(=O)c1ccc(cc1)OC(=O)C1CCCc2c1cccc2)C,CBR-HVAC-07827:Chymotrypsin inhibitor
CBR-001-585-323-3,RFM-004-863-5,CBR-001-585-323-3,CC1CCN(CC1)C(=O)[C@@H](NS(=O)(=O)c1cccc2c1cccc2N(C)C)CCCNC(=N)N,CBR-HVAC-08112:Platelet aggregation inhibitor; 5 Hydroxytryptamine receptor antagonist
CBR-001-585-324-4,RFM-004-864-6,CBR-001-585-324-4,COc1ccc(cc1)c1cnn(c(=O)n1)CC(=O)C,CBR-HVAC-08374:Adrenoreceptor antagonist; 5 Hydroxytryptamine receptor antagonist
CBR-001-585-325-5,RFM-004-865-7,CBR-001-585-325-5,OCCOc1ccc(cc1c1ccc(c(c1)C(C)(C)C)N1CCCC1)c1ccc(cc1)C(=O)O,"CBR-HVAC-08468:Acne Therapy;Antipsoriatics;Dermatological Genetic Disorders, Treatment of;Eczema, Treatment of; Retinoid RARgamma Ligands;Signal Transduction Modulators; Retinoic acid gamma receptor agonist"
CBR-001-585-326-6,RFM-004-866-8,CBR-001-585-326-6,Clc1ccc(cc1Cl)Oc1cccc(c1)c1nc2c(n1CCN1CCCCC1)cccc2,CBR-HVAC-08495:Voltage-gated sodium channel antagonist
CBR-001-585-327-7,RFM-004-867-9,CBR-001-585-327-7,CN(CCCN1c2ccccc2C(c2c1cccc2)(C)C)C,CBR-HVAC-08637:
CBR-001-585-328-8,RFM-004-868-0,CBR-001-585-328-8,N#Cc1cccc(c1)c1nc(sc1n1ccnc1C)Nc1cnccn1,CBR-HVAC-09376:Adenosine A2B receptor; Adenosine A3 receptor Antagonist; Antagonist;
CBR-001-585-329-9,RFM-004-869-1,CBR-001-585-329-9,CN(CCOc1ccc2c(c1)oc1c(c2=O)ccc(c1)OCCN(C)C)C,CBR-HVAC-10067:Immunomodulators;Antiviral Drugs;
CBR-001-585-330-2,RFM-004-870-4,CBR-001-585-330-2,OC(=O)CCCCCc1c(c2cccnc2)n(c2c1cc(Cl)cc2)C,CBR-HVAC-10525:Thromboxane A synthase Inhibitor;
CBR-001-585-331-3,RFM-004-871-5,CBR-001-585-331-3,COc1nnc(o1)c1cc2CN(CCc2[nH]c1=O)Cc1ccccc1,CBR-HVAC-10734:Sedative/Hypnotics; GABA(A) BZ Site Receptor 1 (Omega-1) Ligands;Signal Transduction Modulators; Benzodiazepine receptor omega 2; Benzodiazepine receptor omega 1; Benzodiazepine receptor omega 3 Agonist;
CBR-001-585-332-4,RFM-004-872-6,CBR-001-585-332-4,CC(=O)NC1CCC(CC1)O[N+](=O)[O-],"CBR-HVAC-10867:Angina pectoris, Treatment of; Antianginal;"
CBR-001-585-333-5,RFM-004-873-7,CBR-001-585-333-5,Cc1ccc(c(c1)S(=O)(=O)O)N1CCNCC1,"CBR-HVAC-11009:Acute Myocardial Infarction, Treatment of; Na+/Ca2+ Exchanger (NCX) Inhibitors; Sodium/calcium exchanger Inhibitor;"
CBR-001-585-334-6,RFM-004-874-8,CBR-001-585-334-6,Nc1ccc(cc1)C(=CC(=O)N1CCC(CC1)Cn1c(C)nc2c1cncc2)c1ccccc1,metabolite of CBR-HVAC-04927 (dersalazine)
CBR-001-585-335-7,RFM-004-875-9,CBR-001-585-335-7,Cc1c(ccc2c1OCCO2)Nc1ncc[nH]1,CBR-HVAC-11110:Antiglaucoma Agents; alpha2A(2D)-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha-2A adrenergic receptor Agonist;
CBR-001-585-336-8,RFM-004-876-0,CBR-001-585-336-8,CCN(CCOc1ccc(cc1OC)N(C(=O)c1ccc(cc1)c1ccc(cc1)C(F)(F)F)C)CC,CBR-HVAC-11293:Antidepressants;Anxiolytics;Antiobesity Drugs; Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists;Signal Transduction Modulators; Melanin concentrating hormone receptor 1 Antagonist;
CBR-001-585-337-9,RFM-004-877-1,CBR-001-585-337-9,Clc1ccc2c(c1)nc(cc2)C=Cc1cccc(c1)COc1ccc(cc1)n1c(C)nc2c1ccnc2,CBR-HVAC-11585:Leukotriene D4 receptor; Platelet activating factor receptor Antagonist;
CBR-001-585-338-0,RFM-004-878-2,CBR-001-585-338-0,O=C(NC(=O)c1cc(F)c(cc1Cl)F)Nc1ccc(cc1OC(F)(F)F)C(=O)O,CBR-HVAC-11748:Glycogen phosphorylase Inhibitor;
CBR-001-585-339-1,RFM-004-879-3,CBR-001-585-339-1,C=CCc1c(OCCCNCc2ccccc2)ccc2c1[nH]c1c2cccc1,"CBR-HVAC-11930:Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors; Squalene synthetase Inhibitor;"
CBR-001-585-340-4,RFM-004-880-6,CBR-001-585-340-4,CCc1oc2c(c1)c1c(cc2)cnn1C[C@@H](N)C,CBR-HVAC-11964:Antiobesity Drugs;Treatment of Erectile Dysfunction; Signal Transduction Modulators;5-HT2C Agonists; 5-HT 2c receptor Agonist;
CBR-001-585-355-1,RFM-004-881-7,CBR-001-585-355-1,Clc1cc(Cl)cc(c1)N1CCN(C1=O)CCN1CCC2(CC1)OCCO2,CBR-HVAC-05823:Antipsychotic Drugs;
CBR-001-585-356-2,RFM-004-882-8,CBR-001-585-356-2,COc1ccc(cc1)c1ssc(=S)c1,"CBR-HVAC-00123:Chemopreventive Agents;Sjogren's Syndrome, Agents for; Antioxidants; Free radical scavenger; Glutathione S transferase stimulant"
CBR-001-585-357-3,RFM-004-883-9,CBR-001-585-357-3,OC(=O)CCC(=O)Oc1c(C)cc(cc1C)/C=C/c1cccs1,CBR-HVAC-10832:Lipoxygenase 5 Inhibitor;
CBR-001-585-358-4,RFM-004-884-0,CBR-001-585-358-4,OC[C@H]1O[C@H](Oc2ccc(cc2c2cccc(c2)CC(=O)O)CCCCCCc2ccc(c(c2)c2cccc(c2)CC(=O)O)O[C@H]2O[C@H](CO)[C@H]([C@@H]([C@@H]2O)O)O)[C@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-00325:Acute Respiratory Distress Syndrome (ARDS), Agents for;Antipsoriatics;Atopic Dermatitis, Agents for;Antiallergy/Antiasthmatic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; E-Selectin Inhibitors;L-Selectin Inhibitors;P-Selectin Inhibitors; Selectin Antagonist; E-selectin antagonist; P-selectin antagonist; L-selectin antagonist"
CBR-001-585-359-5,RFM-004-885-1,CBR-001-585-359-5,Brc1c(ccc2c1nccn2)NC1=NCCN1,CBR-HVAC-09549
CBR-001-585-360-8,RFM-004-886-2,CBR-001-585-360-8,CNC(=O)Nc1c(OCCN2CCCC2)c(OC)c2c(c1OC)cco2,CBR-HVAC-02930:Antiarrhythmic Drugs; Sodium channel Antagonist; Sodium channel antagonist
CBR-001-585-361-9,RFM-004-887-3,CBR-001-585-361-9,Fc1ccc(cc1)C(=O)CCCN1CCN(CC1)c1ncc2c(c1)cccc2,CBR-HVAC-01165:Opioid receptor sigma 1 Inhibitor; Sigma receptor antagonist
CBR-001-585-362-0,RFM-004-888-4,CBR-001-585-362-0,O=S1(=O)OCCOS(=O)(=O)C1,CBR-HVAC-07698:Oncolytic Drugs; DNA-Damaging Drugs; DNA inhibitor
CBR-001-585-363-1,RFM-004-889-5,CBR-001-585-363-1,CC[C@@H](CCN(c1ccccc1OCC(=O)N(c1ccccc1)C)C(=O)CNC(=O)Nc1cccc(c1)CC(=O)O)C,CBR-HVAC-10645:Gastric Antisecretory Drugs; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin B receptor Antagonist;
CBR-001-585-364-2,RFM-004-890-8,CBR-001-585-364-2,Nc1nc(N)c2c(n1)cccc2OCC1CCN(CC1)Cc1c(Cl)cccc1Cl,"CBR-HVAC-06934:Neurologic Drugs (Miscellaneous);Neuromuscular Genetic Disorders, Treatment of; SMN2 Expression Enhancers; scavenger mRNA-decapping enzyme inhibitor"
CBR-001-585-365-3,RFM-004-891-9,CBR-001-585-365-3,COc1cc2N(C)C(=O)CN=C(c2cc1c1ccccc1)c1cccc(c1)C(=O)N,CBR-HVAC-11699:PHOSPHODIESTERASE 2 Inhibitor;
CBR-001-585-366-4,RFM-004-892-0,CBR-001-585-366-4,OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1CC[C@@H]1[C@]2(C)CCC(=O)C1)F)(C)C,CBR-HVAC-08673:
CBR-001-585-367-5,RFM-004-893-1,CBR-001-585-367-5,Brc1ccc(c(c1N=C1NCCN1)C)N(C)C,CBR-HVAC-06173:Urinary Incontinence Therapy; Alpha1L-Adrenoceptor Agonists;Signal Transduction Modulators;
CBR-001-585-368-6,RFM-004-894-2,CBR-001-585-368-6,CCCC/N=C(\c1ccccc1Cl)/c1cc(Cl)ccc1O,CBR-HVAC-03301:Antiepileptic Drugs;Antidepressants; GABA receptor agonist
CBR-001-585-369-7,RFM-004-895-3,CBR-001-585-369-7,CS(=O)(=O)Nc1scc(n1)CN1CCC(CC1)c1c[nH]c2c1cccc2,CBR-HVAC-03634:Antiallergy/Antiasthmatic Drugs; Histamine H1 receptor Antagonist; Unidentified pharmacological activity
CBR-001-585-370-0,RFM-004-896-4,CBR-001-585-370-0,CCS(=O)(=O)Nc1ncc(cc1NC(=O)C1CCCCC1)C(F)(F)F,"CBR-HVAC-04261:Pancreatic Disorders, Treatment of; Cytosolic Phospholipase A2 (cPLA2) Inhibitors;Signal Transduction Modulators; Phospholipase A2 Inhibitor; Unidentified pharmacological activity"
CBR-001-585-371-1,RFM-004-897-5,CBR-001-585-371-1,CCCN(C(=O)[C@@H]1[C@H](C(=O)O)[C@H]([C@H]1C(=O)N(Cc1ccc(cc1)Oc1ccccc1)CCC)C(=O)O)Cc1ccc(cc1)Oc1ccccc1,"CBR-HVAC-11100:Antifungal Agents;Oncolytic Drugs;Lipoprotein Disorders, Treatment of ; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Squalene Synthase Inhibitors; Squalene synthase Inhibitor;"
CBR-001-585-372-2,RFM-004-898-6,CBR-001-585-372-2,OC(=O)CCNC(=O)c1ccc(cc1)[C@@H](Oc1cc(C)c(c(c1)C)c1ccc(cc1)C(C)(C)C)CCC(F)(F)F,"CBR-HVAC-06901:Type 2 Diabetes, Agents for;Type 1 Diabetes, Agents for; Glucagon Receptor (GCGR) Antagonists;Signal Transduction Modulators;"
CBR-001-585-373-3,RFM-004-899-7,CBR-001-585-373-3,O=C(c1ccc2c(c1)cccc2)Cn1cncc1,CBR-HVAC-01231:Antiepileptic Drugs; Sodium channel antagonist
CBR-001-585-374-4,RFM-004-900-3,CBR-001-585-374-4,Fc1ccc(cc1)[C@@H](Nc1nc(Nc2cnccn2)cc(c1)c1cnn(c1)C)C,CBR-HVAC-07046:Hematologic Agents (Miscellaneous); Jak2 Inhibitors;Signal Transduction Modulators;
CBR-001-585-375-5,RFM-004-901-4,CBR-001-585-375-5,CN1CCN2C(C1)c1ccccc1Oc1c2cc(C)cc1,CBR-HVAC-05807:Antimigraine Drugs; 5 Hydroxytryptamine receptor antagonist; Histamine receptor antagonist
CBR-001-585-376-6,RFM-004-902-5,CBR-001-585-376-6,COC12CCC(CC1)(CC2)c1ccc(cc1)COC(C(=O)O)(C)C,CBR-HVAC-10602:Antiarthritic Drugs; Antirheumatic;
CBR-001-585-377-7,RFM-004-903-6,CBR-001-585-377-7,C=CCNc1nc(nc(n1)NCC=C)N1CCC(CC1)NCC(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-04362:Cancer Multidrug Resistance Modulators; P-glycoprotein Modulator; General pump inhibitor; Membrane permeability inhibitor; Cell wall synthesis inhibitor
CBR-001-585-378-8,RFM-004-904-7,CBR-001-585-378-8,COc1ccc2c(c1)c(SCc1ccco1)c1c(n2)[nH]nc1C,CBR-HVAC-10974:Antiviral;
CBR-001-585-379-9,RFM-004-905-8,CBR-001-585-379-9,O=S1(=NP(=NP(=N1)(N1CC1)N1CC1)(N1CC1)N1CC1)N1CC1,CBR-HVAC-08350:DNA inhibitor
CBR-001-585-380-2,RFM-004-906-9,CBR-001-585-380-2,CC(N(C(C)C)CCO/N=C/1\CCCCC\C1=C\c1ccccc1)C,CBR-HVAC-01179:Sodium channel antagonist
CBR-001-585-381-3,RFM-004-907-0,CBR-001-585-381-3,CC(=O)Oc1ccccc1C(=O)OC1OC(=O)c2c1cccc2,CBR-HVAC-02549:Antiplatelet Therapy; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor; Thromboxane A2 receptor antagonist
CBR-001-585-382-4,RFM-004-908-1,CBR-001-585-382-4,C(NCCC(c1ccccc1)c1ccccc1)CCSc1ccccc1,CBR-HVAC-08441:Mucus protecting agent
CBR-001-585-383-5,RFM-004-909-2,CBR-001-585-383-5,CCNc1ncn(c2c1nc(n2)C(C)C)Cc1ccc(c(c1)OC1CCCC1)OC,CBR-HVAC-04666:Phosphodiesterase 4 inhibitor
CBR-001-585-384-6,RFM-004-910-5,CBR-001-585-384-6,Cc1noc(c1)CCCCCOc1c(Cl)cc(cc1Cl)C1=NCCO1,CBR-HVAC-03539:Antiviral Drugs; Antiviral; Unidentified pharmacological activity
CBR-001-585-385-7,RFM-004-911-6,CBR-001-585-385-7,CCOC(=O)C(CCCCOc1ccc(cc1)OCCCCCn1ccnc1)(C)C,CBR-HVAC-00127:Oncolytic Drugs; Anticancer; Membrane integrity inhibitor
CBR-001-585-386-8,RFM-004-912-7,CBR-001-585-386-8,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)Cc1cn(nc1C2)S(=O)(=O)C,CBR-HVAC-03540:Androgen Receptor Antagonists;Signal Transduction Modulators; Androgen receptor Antagonist; Androgen receptor antagonist; RNA directed RNA polymerase inhibitor; RNA synthesis inhibitor
CBR-001-585-387-9,RFM-004-913-8,CBR-001-585-387-9,O=C(c1ccc2c(c1)[nH]c(n2)C)N1CCC2(CC1)CC(=O)c1c(C2)cnn1C(C)C,"CBR-HVAC-07381:Type 2 Diabetes, Agents for; Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors;Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors;"
CBR-001-585-388-0,RFM-004-914-9,CBR-001-585-388-0,OC(=O)C(CCCCOc1ccc(cc1)OCCCCCn1ccnc1)(C)C,metabolite of CBR-HVAC-00127
CBR-001-585-389-1,RFM-004-915-0,CBR-001-585-389-1,CC(=O)Oc1ccccc1C(=O)O,"CBR-HVAC-01333: Angiotensin-I Converting Enzyme (ACE) Inhibitors; Cyclooxygenase inhibitor; Cyclooxygenase-3 Inhibitors; HDL-Cholesterol Increasing Agents; HMG-CoA Reductase Inhibitors; Nitric Oxide (NO) Donors; Platelet aggregation inhibitor; Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors; Prostaglandin G/H synthase Inhibitor; Prostaglandin synthase inhibitor; Signal Transduction Modulators; TP53 Expression Enhancers; Acute Myocardial Infarction, Treatment of; Adenomatous Polyposis Therapy; Analgesic; Analgesic Drugs; Angina pectoris, Treatment of; Antiplatelet Therapy; Antipyretic; Antipyretics; Chemopreventive Agents; Cytoprotectants; Hematologic Agents (Miscellaneous); Hematopoiesis Disorders Therapy; Inflammation, Treatment of; Non-Opioid Analgesics; Stroke, Treatment of"
CBR-001-585-390-4,RFM-004-916-1,CBR-001-585-390-4,CCN(c1ncnc2c1nc([nH]2)C(C)C)Cc1ccc(c(c1)OC1CCCC1)OC,CBR-HVAC-08496-B:
CBR-001-585-391-5,RFM-004-917-2,CBR-001-585-391-5,COc1cc(C)c(c(c1)OC)c1c(C)nn2c1nc(C)[nH]c2=O,metabolite of CBR-HVAC-07917
CBR-001-585-392-6,RFM-004-918-3,CBR-001-585-392-6,OC(=O)C[C@H]1Oc2c(C1)c(C)c(c(c2C)C)O,CBR-HVAC-14263: side product of CBR-HVAC-00507
CBR-001-585-393-7,RFM-004-919-4,CBR-001-585-393-7,Clc1ccc2c(c1)C(=O)CCCS2,undesired side product of CBR-HVAC-01188
CBR-001-585-394-8,RFM-004-920-7,CBR-001-585-394-8,CCNc1ncnc2c1nc(n2Cc1ccc(c(c1)OC1CCCC1)OC)C(C)C,CBR-HVAC-08496-A:
CBR-001-585-395-9,RFM-004-921-8,CBR-001-585-395-9,CCCN(C(=O)C1C(C(=O)O)C(C1C(=O)O)C(=O)N(Cc1ccc(cc1)Oc1ccccc1)CCC)Cc1ccc(cc1)Oc1ccccc1,CBR-HVAC-11100-A:
CBR-001-585-396-0,RFM-004-922-9,CBR-001-585-396-0,Nc1nc(N)c2c(n1)NCCC(=N2)c1ccccc1,undesired side product of CBR-HVAC-11946
CBR-001-585-407-6,RFM-004-923-0,CBR-001-585-407-6,CCC#CC(C1(/C=C/C)C(=O)N=C(N(C1=O)C)[O-])C,CBR-HVAC-03082: Intravenous Anesthetics
CBR-001-585-514-8,RFM-004-924-1,CBR-001-585-514-8,OC(=O)C(c1ccc2c(c1)C(=O)Cc1c(O2)ccc(c1)C)C,CBR-HVAC-02929: Non-Opioid Analgesics;Antipyretics; COX Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-585-515-9,RFM-004-925-2,CBR-001-585-515-9,Cc1cc(OP(=O)(O)O)c2c(c1OP(=O)(O)O)cccc2,CBR-HVAC-03158: Hemostatics; Prothrombogenic; Antidote;
CBR-001-585-516-0,RFM-004-926-3,CBR-001-585-516-0,NC1=NCC(O1)CN1CCN(CC1)c1ccccc1,CBR-HVAC-03220: Antidepressants; Norepinephrine release stimulant; Unidentified pharmacological activity
CBR-001-585-517-1,RFM-004-927-4,CBR-001-585-517-1,CC(Cc1ccc(cc1)C(C(=O)O)C)C,"CBR-HVAC-01286: Antiarthritic Drugs;Osteoarthritis, Treatment of;Rheumatoid Arthritis, Treatment of;Antimigraine Drugs;Non-Opioid Analgesics;Ankylosing Spondylitis, Treatment of; Cyclooxygenase-3 Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-585-518-2,RFM-004-928-5,CBR-001-585-518-2,CC(CNC1CCS(=O)(=O)c2c1cc(s2)S(=O)(=O)N)C,CBR-HVAC-03846: Antiglaucoma Agents; Carbonic Anhydrase Inhibitors; Carbonic anhydrase Inhibitor;
CBR-001-585-519-3,RFM-004-929-6,CBR-001-585-519-3,OC(=O)CNC(=O)c1nc(C)c2c(c1O)ccc(c2)Oc1ccccc1,"CBR-HVAC-06903: Antianemics;Sickle Cell Anemia, Agents for; Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors; Prolyl hydroxylase Inhibitor;"
CBR-001-585-520-6,RFM-004-930-9,CBR-001-585-520-6,Clc1ccc2c(c1)/C(=C(\c1cccs1)/O)/C(=O)N2C(=O)N,CBR-HVAC-04047: Antiarthritic Drugs; Cyclooxygenase (COX) Inhibitors;Signal Transduction Modulators;
CBR-001-585-521-7,RFM-004-931-0,CBR-001-585-521-7,Clc1ccc(cc1Cl)[C@]12CNC[C@@H]2C1,"CBR-HVAC-00799: Antiparkinsonian Drugs;Restless Legs Syndrome, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Treatment of Alcohol Dependency;Antidepressants; Dopamine Reuptake Inhibitors;Dopamine Transporter (DAT) Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; DOPAMINE TRANSPORTER; NOREPINEPHRINETRANSPORTER; SERATONIN TRANSPORTER Inhibitor; Dopamine reuptake inhibitor; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor"
CBR-001-585-522-8,RFM-004-932-1,CBR-001-585-522-8,Clc1ccc(cc1Cl)[C@@]12CNC[C@H]2C1,CBR-HVAC-15133: 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Adrenergic-uptake-inhibitors; DOPAMINE TRANSPORTER (DAT); Dopamine Transporter (DAT) Inhibitors; Dopamine reuptake inhibitor; Dopamine-uptake-inhibitors; Inhibitor; NOREPINEPHRINE TRANSPORTER; Norepinephrine Transporter (NET) Inhibitors; SEROTONIN TRANSPORTER Inhibitor; Serotonin Transporter (SERT) Inhibitors; Serotonin-norepinephrine-dopamine reuptake inhibitor; Serotonin-uptake-inhibitors; Signal Transduction Modulators; Affective Disorders; Antidepressant; Antidepressants; Antiobesity Drugs; Obesity
CBR-001-585-523-9,RFM-004-933-2,CBR-001-585-523-9,CCSc1ncccc1C(=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@H]2O[N+](=O)[O-],CBR-HVAC-12017: a likely analog of LA-419.  WO2000020420A1
CBR-001-585-524-0,RFM-004-934-3,CBR-001-585-524-0,COc1cc2OC(C)(C)[C@H]([C@H](c2c2c1c(=O)c1c(n2C)cc2c(c1)cccc2)O)O,metabolite of CBR-HVAC-00240
CBR-001-585-525-1,RFM-004-935-4,CBR-001-585-525-1,Clc1ccc2c(c1)C(=O)CCCS2(=O)=O,metabolite of CBR-HVAC-01188
CBR-001-585-526-2,RFM-004-936-5,CBR-001-585-526-2,CN(/C=C/1\N=C2N(C1=O)c1ccc(cc1C(=NC2)c1ccccc1Cl)[N+](=O)[O-])C,metabolite of CBR-HVAC-02384
CBR-001-585-527-3,RFM-004-937-6,CBR-001-585-527-3,O=C(NCc1ccc(o1)C(=O)O)CCCC(=O)O,metabolite of CBR-HVAC-04490
CBR-001-585-528-4,RFM-004-938-7,CBR-001-585-528-4,O=C(NCC(=O)O)CCSC(=O)c1ccccc1O,metabolite of CBR-HVAC-07790
CBR-001-585-529-5,RFM-004-939-8,CBR-001-585-529-5,N#Cc1ccc2c(c1)C(=CC(O2)(C)C)c1ccccn1,metabolite of CBR-HVAC-09502
CBR-001-585-530-8,RFM-004-940-1,CBR-001-585-530-8,N#Cc1ccc2c(c1)c(c1ccccn1)c(o2)C(C)C,analog of CBR-HVAC-09502
CBR-001-585-531-9,RFM-004-941-2,CBR-001-585-531-9,N#Cc1ccc2c(c1)C1(OC1C(O2)(C)C)c1cccc[n+]1[O-],metabolite of CBR-HVAC-09502
CBR-001-585-532-0,RFM-004-942-3,CBR-001-585-532-0,CC[N+](NCCC(=O)O)(C)C,metabolite of CBR-HVAC-10375
CBR-001-585-533-1,RFM-004-943-4,CBR-001-585-533-1,Oc1c(C)cc(cc1C)/C=C/c1cccs1,metabolite of CBR-HVAC-10832
CBR-001-585-534-2,RFM-004-944-5,CBR-001-585-534-2,OC(=O)CNc1ccc(cc1)S(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08745:
CBR-001-585-535-3,RFM-004-945-6,CBR-001-585-535-3,O=C(N1CCN(CC1)C(=O)CCOS(=O)(=O)C)CCOS(=O)(=O)C,CBR-HVAC-08775:
CBR-001-585-536-4,RFM-004-946-7,CBR-001-585-536-4,NCCS[As](c1ccc(cc1)Nc1nc(N)nc(n1)N)SCCN,CBR-HVAC-08853:
CBR-001-585-537-5,RFM-004-947-8,CBR-001-585-537-5,Clc1ccc(cc1)OCCO/C(=C/n1cncc1)/c1ccc(cc1Cl)Cl,CBR-HVAC-09023:
CBR-001-585-538-6,RFM-004-948-9,CBR-001-585-538-6,Cc1sc2c(c1CC1=NCCN1)cccc2,CBR-HVAC-09132:
CBR-001-585-539-7,RFM-004-949-0,CBR-001-585-539-7,CCC(N(C(CC)C)CC(c1cccn1Cc1ccccc1Cl)O)C,CBR-HVAC-09980:
CBR-001-585-540-0,RFM-004-950-3,CBR-001-585-540-0,Fc1cccc(c1)CN(c1ccc(cc1)OCc1ccc2c(c1)cccc2)Cc1ccc(cc1)C(=O)O,analog of CBR-HVAC-07797
CBR-001-585-541-1,RFM-004-951-4,CBR-001-585-541-1,COc1cccc(c1)C1(O)CCN(CC1)C[C@@H](COc1cccc2c1cc[nH]2)O,CBR-HVAC-11586: 5-Hydroxytryptamine 1 receptor Antagonist;
CBR-001-585-542-2,RFM-004-952-5,CBR-001-585-542-2,COc1cc2OC(C)(C)[C@H]([C@H](c2c2c1c(=O)c1c(n2C)cc2c(c1)cccc2)OC(=O)C)OC(=O)C,CBR-HVAC-00240: Apoptosis Inducers;CCNE1 Expression Enhancers;DNA Alkylating Drugs
CBR-001-585-543-3,RFM-004-953-6,CBR-001-585-543-3,C1NCc2c3N(C1)C[C@@H]1CCC[C@@H]1c3ccc2,CBR-HVAC-00329: 5-Hydroxytryptamine 2C receptor Agonist; 5 Hydroxytryptamine 2C receptor agonist; 5 Hydroxytryptamine 2B receptor antagonist; 5 Hydroxytryptamine receptor agonist
CBR-001-585-544-4,RFM-004-954-7,CBR-001-585-544-4,O=C(N1CCN=C1Nc1c(Cl)cccc1Cl)c1ccccc1,CBR-HVAC-07517: Alpha 2 adrenoreceptor agonist
CBR-001-585-545-5,RFM-004-955-8,CBR-001-585-545-5,O=C(N1C(=O)C(c2c1cc(F)cc2)(C)C)NCC1CCN(CC1)CC1(O)CCOCC1,"CBR-HVAC-07274: Alzheimer's Dementia, Treatment of ; Signal Transduction Modulators;5-HT4 Partial Agonists;"
CBR-001-585-546-6,RFM-004-956-9,CBR-001-585-546-6,OC1CN(C1)CCCOCCc1ccc2c(c1)ccs2,"CBR-HVAC-05907: Alzheimer's Dementia, Treatment of ;Amyotrophic Lateral Sclerosis, Agents for; Neurotrophic Agents;Signal Transduction Modulators; Amyloid fibrillogenesis inhibitor;"
CBR-001-585-547-7,RFM-004-957-0,CBR-001-585-547-7,O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2OC1=CCCC1)C)C,CBR-HVAC-09963: Androgen receptor Agonist;
CBR-001-585-548-8,RFM-004-958-1,CBR-001-585-548-8,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc(c1N)C(=O)NCc1ccc(cc1)[N+](=O)[O-])COP(=O)(O)O,"CBR-HVAC-04489: Angina pectoris, Treatment of; Adenosine receptor agonist; Platelet aggregation inhibitor"
CBR-001-585-549-9,RFM-004-959-2,CBR-001-585-549-9,OC[C@H]([C@H]([C@@H]([C@H](C(=O)O[Al](O)O)O)O)O)O,CBR-HVAC-07441: Antacid
CBR-001-585-550-2,RFM-004-960-5,CBR-001-585-550-2,Fc1ccc(cc1)CCCCOc1ccc(cc1)/C=C/c1cccc2c1oc(cc2=O)c1nnn[nH]1,CBR-HVAC-05366: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist; Leucotriene D4 antagonist; Leucotriene receptor antagonist
CBR-001-585-551-3,RFM-004-961-6,CBR-001-585-551-3,O=C([C@@H]1CSC(N1)c1cccnc1)N1CCN(CC1)CCCOc1c(oc2c(c1=O)cccc2)c1ccccc1,"CBR-HVAC-10581: Antiallergy/Antiasthmatic Drugs;Septic Shock, Treatment of ; Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Platelet activating factor receptor Antagonist;"
CBR-001-585-552-4,RFM-004-962-7,CBR-001-585-552-4,Nc1nc(=N)n(nc1c1cccc(c1Cl)Cl)C(C)C,CBR-HVAC-03266: Antiarrhythmic Drugs;
CBR-001-585-553-5,RFM-004-963-8,CBR-001-585-553-5,CCN(CCCN(C1Cc2c(C1OC)cccc2)c1ccccc1)CC,CBR-HVAC-05545: Antiarrhythmic Drugs; Alpha-1 acid glycoprotein Inhibitor;
CBR-001-585-554-6,RFM-004-964-9,CBR-001-585-554-6,CCOP(=O)(C1(NN=C(C1)C(=O)c1ccccc1)P(=O)(OCC)OCC)OCC,CBR-HVAC-10842: Antiarthritic Drugs; Osteogenesis inhibitor;
CBR-001-585-555-7,RFM-004-965-0,CBR-001-585-555-7,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)n1nncc1,CBR-HVAC-11257: Antibacterial Drugs; Protein 30S ribosomal subunit Inhibitor;
CBR-001-585-556-8,RFM-004-966-1,CBR-001-585-556-8,CCOC(=O)Nc1nc(N)c2c(n1)NCCC(=N2)c1ccccc1,CBR-HVAC-11946: Antibacterial;
CBR-001-585-557-9,RFM-004-967-2,CBR-001-585-557-9,O=C1NC(=O)C(S1)S(=O)(=O)c1ccc2c(c1)cccc2,CBR-HVAC-10477: Antidiabetic Drugs; Insulin sensitizer;
CBR-001-585-558-0,RFM-004-968-3,CBR-001-585-558-0,Clc1ccc(cc1)N1N=NCC1c1ccncc1,CBR-HVAC-03254: Antiepileptic Drugs; Ionotropic glutamate receptor NMDA Antagonist; Excitatory amino acid receptor antagonist
CBR-001-585-559-1,RFM-004-969-4,CBR-001-585-559-1,CC(Oc1ccc(cc1C(=O)C)C(=O)Nc1cc(Cl)c2c(c1Cl)CNCC2)C,"CBR-HVAC-05996: Antiepileptic Drugs;Antimigraine Drugs;Neuropathic Pain, Treatment of; Gap junction modulators; Gap junction inhibitor"
CBR-001-585-560-4,RFM-004-970-7,CBR-001-585-560-4,O=C([C@H]1CCC2[C@]1(C)CC[C@@H]1[C@@H]2CC[C@@H]2[C@]1(C)CC[C@@](C2)(C)O)CSS(=O)(=O)[O-],CBR-HVAC-11409: Antiepileptic Drugs;Anxiolytics; GABA(A) Receptor Modulators;Signal Transduction Modulators; GABA-A receptor Modulator;
CBR-001-585-561-5,RFM-004-971-8,CBR-001-585-561-5,Fc1ccc(c(c1)F)[C@](C(c1ccc(cn1)c1ccc(cc1)OCC(F)(F)F)(F)F)(Cn1cnnn1)O,CBR-HVAC-07055: Antifungal Agents; Lanosterol 14alpha-demethylase Inhibitors;
CBR-001-585-562-6,RFM-004-972-9,CBR-001-585-562-6,CC(=CCN1Cc2cccc3c2n(C[C@@H]1C)c(=S)[nH]3)C,CBR-HVAC-04010: Anti-HIV Agents; Reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-585-563-7,RFM-004-973-0,CBR-001-585-563-7,OCCc1sc[n+](c1C)CCCCCCCCCCCC[n+]1csc(c1C)CCO,CBR-HVAC-06264: Antimalarials; Choline uptake inhibitor;
CBR-001-585-564-8,RFM-004-974-1,CBR-001-585-564-8,CC(N(C(=O)CN1c2ccccc2n2c([C@@H](C1=O)Cc1c[nH]c3c1cccc3)nnc2c1ccccc1)Cc1ccccc1)C,CBR-HVAC-12050: Antiobesity Drugs; CCK1 (CCKA) Agonists;Signal Transduction Modulators;
CBR-001-585-565-9,RFM-004-975-2,CBR-001-585-565-9,COc1cc(ccc1OC)C1NC(=O)C(S1)C,CBR-HVAC-08046: Antiulcer Drugs; Gastrin inhibitor; Muscarinic M1 receptor antagonist
CBR-001-585-566-0,RFM-004-976-3,CBR-001-585-566-0,COCC(n1nnc2c1cc(C)nc2Nc1c(C)cc(cc1Cl)C)COC,CBR-HVAC-11360: Anxiolytics;Antidepressants; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing hormone receptor 1 Antagonist;
CBR-001-585-567-1,RFM-004-977-4,CBR-001-585-567-1,CCN1CCN(CC1)/C=C/1\N=C2N(C1=O)c1ccc(cc1C(=NC2)c1ccccc1Cl)[N+](=O)[O-],CBR-HVAC-02384: Benzodiazepine receptor Agonist; GABA receptor agonist
CBR-001-585-568-2,RFM-004-978-5,CBR-001-585-568-2,CCCCOc1cccc(c1)CCNCC(=O)N(C)C,"CBR-HVAC-06689: Bipolar Disorder, Treatment of;Antipsychotic Drugs; Nav1.3 (Brain Type III) Sodium Channel Blockers;Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers;Nav1.8 (SNS/PN3) Sodium Channel Blockers;"
CBR-001-585-569-3,RFM-004-979-6,CBR-001-585-569-3,CCOC(=O)CCN[N+](CC)(C)C,CBR-HVAC-10375: Calcium channel Blocker;
CBR-001-585-570-6,RFM-004-980-9,CBR-001-585-570-6,CCCCCCN(c1cc(nc2n1ncn2)N(CC)CC)CCO,CBR-HVAC-10598: Calcium channel; cAMP phosphodiesterase Inhibitor;
CBR-001-585-571-7,RFM-004-981-0,CBR-001-585-571-7,CCCCNc1nc(c(s1)C(=O)c1ccc2c(c1)[nH]c(n2)NC(=O)OC)C,CBR-HVAC-07614: Cell wall synthesis inhibitor; anthelmintics
CBR-001-585-572-8,RFM-004-982-1,CBR-001-585-572-8,O=C(NC(c1csc(n1)c1ccc(cc1)F)(C)C)O[C@@H]1CN2CCC1CC2,CBR-HVAC-07890: Ceramide glycosyltransferase inhibitor
CBR-001-585-573-9,RFM-004-983-2,CBR-001-585-573-9,OP(=O)(C(c1cccc2c1cccc2)C(=O)c1cc2ccccc2cc1C(=O)N(C1CCN(CC1)C(=O)c1ccc2c(c1)cccc2)C)O,"CBR-HVAC-05904: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy; Cathepsin G Inhibitors;Chymase Inhibitors; Cathepsin G; Chymase Inhibitor; Chymase inhibitor; Cathepsin G inhibitor; Serine protease inhibitor"
CBR-001-585-574-0,RFM-004-984-3,CBR-001-585-574-0,OCCCNCCCc1ccc(c(c1)C(=O)NCC12CC3CC(C2)CC(C1)C3)Cl,"CBR-HVAC-05670: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Inflammatory Bowel Disease, Agents for;Osteoarthritis, Treatment of;Rheumatoid Arthritis, Treatment of; P2X7 Receptor Antagonists;Signal Transduction Modulators; P2X7 receptor Antagonist;"
CBR-001-585-575-1,RFM-004-985-4,CBR-001-585-575-1,OC(=O)CCCSc1nc2c(n1Cc1csc3c1c(C)ccc3)cccc2,CBR-HVAC-11804: CHYMASE Inhibitor;
CBR-001-585-576-2,RFM-004-986-5,CBR-001-585-576-2,Clc1ccc2c(c1)sc(c2)S(=O)(=O)N1CCN(C(=O)C1)Cc1cccc(c1)C(=N)N,CBR-HVAC-11716: Coagulation factor Xa Antagonist;
CBR-001-585-577-3,RFM-004-987-6,CBR-001-585-577-3,CC(CNc1nc(=O)c2c3n1CC=C(n3nc2)c1cccc(c1)C(F)(F)F)C,"CBR-HVAC-03907: Cognition Disorders, Treatment of;"
CBR-001-585-578-4,RFM-004-988-7,CBR-001-585-578-4,Clc1ccc2c(c1)C(=C(CCS2(=O)=O)C(=O)Nc1ccc(c(c1)Cl)Cl)O,CBR-HVAC-01188: COX; Lipoxygenase Inhibitor; Cyclooxygenase inhibitor; Microbial collagenase inhibitor
CBR-001-585-579-5,RFM-004-989-8,CBR-001-585-579-5,CC(OC1=C(c2ccc(cc2)S(=O)(=O)C)C(OC1=O)(C)C)C,CBR-HVAC-11136: COX-2 Inhibitor;
CBR-001-585-580-8,RFM-004-990-1,CBR-001-585-580-8,OC(c1noc(c1)c1ccccc1)CN1CCCCC1,CBR-HVAC-02649: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-585-581-9,RFM-004-991-2,CBR-001-585-581-9,O=C(NCC(=O)O)CCSC(=O)c1ccccc1OC(=O)C,CBR-HVAC-07790: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-585-582-0,RFM-004-992-3,CBR-001-585-582-0,CNCCSC1=Cc2ccccc2Oc2c1cc(F)cc2,CBR-HVAC-07837: Cyclooxygenase inhibitor
CBR-001-585-583-1,RFM-004-993-4,CBR-001-585-583-1,CC(C(=O)c1c(C)[nH]c(c1N)c1ccccc1)C,CBR-HVAC-02550: Cyclooxygenase inhibitor; Uric acid diuretic
CBR-001-585-584-2,RFM-004-994-5,CBR-001-585-584-2,C1CNP2(=NP(=NP(=N2)(N2CC2)N2CC2)(N2CC2)N2CC2)NC1,CBR-HVAC-08158: DNA inhibitor; DNA synthesis inhibitor; Immunostimulant
CBR-001-585-585-3,RFM-004-995-6,CBR-001-585-585-3,[O-]/C(=N\c1on[n+](c1)C(Cc1ccccc1)C)/Nc1ccccc1,CBR-HVAC-09802: Dopamine transporter Inhibitor;
CBR-001-585-586-4,RFM-004-996-7,CBR-001-585-586-4,CS(=O)(=O)OCCCNCCCOS(=O)(=O)C,CBR-HVAC-01466: Estrogen receptor Modulator; DNA inhibitor; DNA synthesis inhibitor
CBR-001-585-587-5,RFM-004-997-8,CBR-001-585-587-5,O=C(C(c1cccc(c1)OCc1ccc2c(n1)cccc2)C1CCCCCC1)NS(=O)(=O)C,CBR-HVAC-07508: Five lipoxygenase activating protein antagonist
CBR-001-585-588-6,RFM-004-998-9,CBR-001-585-588-6,O=C(C(c1cccc(c1)OCc1ccc2c(n1)cccc2)C1CCCCCC1)NS(=O)(=O)C,CBR-HVAC-07508: Five lipoxygenase activating protein antagonist
CBR-001-585-589-7,RFM-004-999-0,CBR-001-585-589-7,OC(=O)CC1Cc2c(O1)c(C)c(c(c2C)OC(=O)C)C,CBR-HVAC-00507: Free radical scavenger; Reducing agent; Free radical scavenger
CBR-001-585-590-0,RFM-005-000-0,CBR-001-585-590-0,Fc1ccccc1c1nc2n(c1)c(=O)[nH]c1c2CN(CC1)Cc1cccnc1,CBR-HVAC-11643: GABA-A receptor Modulator;
CBR-001-585-591-1,RFM-005-001-1,CBR-001-585-591-1,Cn1nc(nc1NCCCOc1cccc(c1)CN1CCCCC1)CS(=O)(=O)C,CBR-HVAC-03355: Gastric Antisecretory Drugs; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist
CBR-001-585-592-2,RFM-005-002-2,CBR-001-585-592-2,OC1CCN(CC1)C(=O)[C@@H](NC(=O)c1cc2c([nH]1)cnc(c2)Cl)Cc1ccc(cc1)F,CBR-HVAC-11764: Glycogen phosphorylase Inhibitor;
CBR-001-585-593-3,RFM-005-003-3,CBR-001-585-593-3,Cc1cc2c(cc1C)C(=O)c1c(C2=O)[nH]nn1,CBR-HVAC-07562: Histamine receptor antagonist
CBR-001-585-594-4,RFM-005-004-4,CBR-001-585-594-4,N=C(NCCCc1[nH]cnc1)NCCC(c1ccccn1)c1ccc(cc1)F,CBR-HVAC-09405: HISTAMINE RECEPTOR H1 Agonist;
CBR-001-585-595-5,RFM-005-005-5,CBR-001-585-595-5,OP(=O)(C(P(=O)(O)O)Cc1ccccn1)O,CBR-HVAC-00985: Hypocalcaemic agent
CBR-001-585-596-6,RFM-005-006-6,CBR-001-585-596-6,OC(=O)C(c1ccc(c(c1)Cl)C1CCCCC1)Cl,"CBR-HVAC-01181: Inflammation, Treatment of; Prostaglandin synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor"
CBR-001-585-597-7,RFM-005-007-7,CBR-001-585-597-7,CN1Cc2cccc3c2c(S1(=O)=O)cs3,CBR-HVAC-11683: Ionotropic glutamate receptor AMPA Modulator;
CBR-001-585-598-8,RFM-005-008-8,CBR-001-585-598-8,CCCCCCCN(C(=O)Nc1ccc(cc1F)F)CCCCCSc1nc(c([nH]1)c1ccccc1)c1ccccc1,"CBR-HVAC-04029: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-585-599-9,RFM-005-009-9,CBR-001-585-599-9,CCCCn1c(=O)c(NC(=O)Nc2c(cc(cc2C(C)C)N)C(C)C)c(c2c1nccc2)c1cccc(c1)OCCCO,"CBR-HVAC-05814: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors;LDL-Receptor Up-Regulators; Acyl CoA:cholesterol acyltransferase Inhibitor; Acetyl CoA transferase inhibitor"
CBR-001-585-600-5,RFM-005-010-2,CBR-001-585-600-5,OCCNC(=O)CC(c1ccc(cc1)CC(CCCC(C)C)C)C,"CBR-HVAC-03513: Lipoprotein Disorders, Treatment of ;Uricosurics; Antihypercholesterolemic; Antiatheromatous; Cholesterol inhibitor; Collagen inhibitor"
CBR-001-585-601-6,RFM-005-011-3,CBR-001-585-601-6,CCCCC1(CCCC)CS(=O)(=O)c2c([C@H]([C@H]1O)c1ccc(cc1)OCc1ccc(cc1)C[N+]13CCN(CC1)CC3)cc(cc2)N(C)C,"CBR-HVAC-05313: Liver and Biliary Tract Disorders, Treatment of;Multisystem Genetic Disorders, Treatment of ; Ileal Bile Acid Transporter (IBAT) Inhibitors; Ileal bile acid transport inhibitor; Sodium/bile acid cotransporter inhibitor"
CBR-001-585-602-7,RFM-005-012-4,CBR-001-585-602-7,CCCCC1(CCCC)CS(=O)(=O)c2c([C@H]([C@H]1O)c1ccc(cc1)OCc1ccc(cc1)C[N+]13CCN(CC1)CC3)cc(cc2)N(C)C,"CBR-HVAC-05313: Liver and Biliary Tract Disorders, Treatment of;Multisystem Genetic Disorders, Treatment of ; Ileal Bile Acid Transporter (IBAT) Inhibitors; Ileal bile acid transport inhibitor; Sodium/bile acid cotransporter inhibitor"
CBR-001-585-603-8,RFM-005-013-5,CBR-001-585-603-8,COCCn1nc(oc1=O)c1ccc(cc1)OCCCC(F)(F)F,CBR-HVAC-11516: Monoamine oxidase B Inhibitor;
CBR-001-585-604-9,RFM-005-014-6,CBR-001-585-604-9,CCS(=O)(=O)c1ccc2c(c1)nc([nH]2)Oc1ccc(nc1)c1ccccc1,CBR-HVAC-08311: Neuropeptide Y5 receptor antagonist
CBR-001-585-605-0,RFM-005-015-7,CBR-001-585-605-0,O=C(N(C)C)CCn1nc(nc1c1ccncc1)Nc1ccc2c(c1)OC(O2)(F)F,CBR-HVAC-12008: NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA7 Modulator;
CBR-001-585-606-1,RFM-005-016-8,CBR-001-585-606-1,CC(Cc1ccc(cc1)C(C(=O)OCCN1CCN(CC1)c1cccc(c1)Cl)C)C,CBR-HVAC-03735: Non-Opioid Analgesics; Analgesic;
CBR-001-585-607-2,RFM-005-017-9,CBR-001-585-607-2,O=c1n(CC2OC2)c(=O)n(n1CC1OC1)CC1OC1,CBR-HVAC-02898: Oncolytic Drugs; Alkylating agent; DNA inhibitor
CBR-001-585-608-3,RFM-005-018-0,CBR-001-585-608-3,Clc1ccccc1CNc1ccc(nn1)n1cncc1,CBR-HVAC-11336: Oncolytic Drugs; Aromatase Inhibitors; Aromatase Inhibitor;
CBR-001-585-609-4,RFM-005-019-1,CBR-001-585-609-4,O=C(c1ccsc1)NCC1CN=C(c2c(N1C)cccc2)c1ccccc1F,CBR-HVAC-01114: Opioid Analgesics; Opioid receptor kappa Agonist; Opioid mu receptor agonist; Opioid kappa receptor agonist
CBR-001-585-610-7,RFM-005-020-4,CBR-001-585-610-7,CCC(C(=O)O)Cc1ccc(c(c1)C(=O)NCc1ccc(cc1)C(F)(F)F)OC,CBR-HVAC-07966: Peroxisome proliferator-activated receptor alpha agonist
CBR-001-585-611-8,RFM-005-021-5,CBR-001-585-611-8,OC(=O)C(Oc1ccc(cc1C)SCc1sc(nc1C)c1ccc(cc1F)C(F)(F)F)(C)C,"CBR-HVAC-05756: Lipoprotein Disorders, Treatment of ;Type 2 Diabetes, Agents for; Insulin Sensitizers;PPAR Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor Agonist;"
CBR-001-585-612-9,RFM-005-022-6,CBR-001-585-612-9,Cc1nc2[nH]c(=O)sc2cc1c1ccncc1,CBR-HVAC-11488: Phosphodiesterase 3 Inhibitor;
CBR-001-585-613-0,RFM-005-023-7,CBR-001-585-613-0,Fc1cnc(c(c1)C(=O)N[C@@H]1CC[C@@H](CC1)NC(=O)c1cc(C)ccc1O)Oc1ccc(c(c1)F)F,CBR-HVAC-11741: Phosphodiesterase 4 Inhibitor;
CBR-001-585-614-1,RFM-005-024-8,CBR-001-585-614-1,COc1cc(/C=C/C(=O)N2CCN(CC2)CC2CCn3c(S2)nc2c3cccc2)cc(c1OC)OC,CBR-HVAC-07704: Phosphodiesterase inhibitor
CBR-001-585-615-2,RFM-005-025-9,CBR-001-585-615-2,O[C@@H](CN1CC2OC(C1)CN(C2)CCNC(=O)OC(C)(C)C)COc1ccc(cc1)C#N,CBR-HVAC-11650: Potassium channel Blocker;
CBR-001-585-616-3,RFM-005-026-0,CBR-001-585-616-3,N#Cc1ccc2c(c1)C(=CC(O2)(C)C)c1cccc[n+]1[O-],CBR-HVAC-09502: POTASSIUM CHANNEL Opener;
CBR-001-585-617-4,RFM-005-027-1,CBR-001-585-617-4,CCC([C@@H](C(=O)NCc1cnc(nc1N)C)NC(=O)C[C@@H]([C@@H](NC(=O)CCNC(=O)[C@@H](NC(=O)N1CCC(CC1)N)Cc1ccccc1)CC1CCCCC1)O)C,CBR-HVAC-07782: Renin inhibitor
CBR-001-585-618-5,RFM-005-028-2,CBR-001-585-618-5,COc1cc(ccc1OCCCN1CCN(CC1)c1ccccc1F)NC(=O)C,CBR-HVAC-03597: Sedative/Hypnotics; Alpha-2 adrenergic receptor; Alpha-1 adrenergic receptor; Dopamine receptor D2 Agonist; Blocker;
CBR-001-585-619-6,RFM-005-029-3,CBR-001-585-619-6,COC(=O)Nc1nc2c([nH]1)cc(cc2)C(=O)N1CCN(CC1)c1ccccn1,CBR-HVAC-11941: Superoxide dismutase Modulator;
CBR-001-585-620-9,RFM-005-030-6,CBR-001-585-620-9,O=C1NC(=O)N(C1)S(=O)(=O)c1oc2c(c1Br)cccc2,CBR-HVAC-04003: Symptomatic Antidiabetic Agents; Aldose Reductase Inhibitors; Aldose reductase Inhibitor; Aldose reductase inhibitor
CBR-001-585-621-0,RFM-005-031-7,CBR-001-585-621-0,CCN(CCOc1ccc(cc1)[C@H]1C[C@]2(C)[C@@H](O)CC[C@H]2[C@H]2[C@H]1c1ccc(c(c1CC2)Cl)O)CC,CBR-HVAC-06072: Treatment of Osteoporosis; Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators;
CBR-001-585-622-1,RFM-005-032-8,CBR-001-585-622-1,O=C1N(CCN1S(=O)(=O)C)c1ncc(n1C)[N+](=O)[O-],CBR-HVAC-01115: Treatment of Protozoal Diseases; DNA inhibitor
CBR-001-585-623-2,RFM-005-033-9,CBR-001-585-623-2,COC(=O)[C@H](c1ccccc1)N1CCC(CC1)c1ccc(cc1)NC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F,"CBR-HVAC-00532: Type 2 Diabetes, Agents for;Antiobesity Drugs; Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein Inhibitor; Microsomal trigylceride transfer protein inhibitor"
CBR-001-585-644-7,RFM-005-034-0,CBR-001-585-644-7,COP(=O)(C(c1ccc(cc1)Cl)OP(=O)(OC)OC)OC,CBR-HVAC-02908: PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Antagonist;
CBR-001-585-645-8,RFM-005-035-1,CBR-001-585-645-8,COc1cc(OC)ccc1/C=C/1\CCCN=C1c1cccnc1,CBR-HVAC-04689: Neuronal nicotinic receptor agonist; Alpha-7 nicotinic receptor agonist
CBR-001-585-646-9,RFM-005-036-2,CBR-001-585-646-9,CO[C@H]1CNCC[C@H]1NC(=O)c1cc(Cl)c(cc1OC)N,CBR-HVAC-04835: 5 Hydroxytryptamine 4 receptor agonist; 5 Hydroxytryptamine 3 receptor antagonist
CBR-001-585-647-0,RFM-005-037-3,CBR-001-585-647-0,O=C(N1CCC(CC1)Cn1c(C)nc2c1ccnc2)/C=C(\c1ccc(cc1)/N=N/c1ccc(c(c1)C(=O)O)O)/c1ccccc1,CBR-HVAC-04927: Platelet activating factor receptor; Tumor necrosis factor Antagonist; Inhibitor;
CBR-001-585-648-1,RFM-005-038-4,CBR-001-585-648-1,CC(OC(=O)N1CCC(CC1)Oc1ncnc2c1cnn2c1ccc(cc1F)S(=O)(=O)C)C,CBR-HVAC-06370: G Protein-Coupled receptor 119 Agonist;
CBR-001-585-649-2,RFM-005-039-5,CBR-001-585-649-2,O=C(Cc1c(F)cccc1Cl)Nc1onc(c1c1ccncn1)c1ccc(cc1)F,CBR-HVAC-06453: P38 MAP KINASE Inhibitor;
CBR-001-585-650-5,RFM-005-040-8,CBR-001-585-650-5,O=C(Nc1ccccc1C(=O)O)Nc1cccc(c1)C(F)(F)F,CBR-HVAC-11228: Chloride channel antagonist; Angiogenesis inhibitor
CBR-001-585-651-6,RFM-005-041-9,CBR-001-585-651-6,C=CCONC1=Nc2ccc(cc2C(=NC1)c1ccccc1Cl)Cl,CBR-HVAC-08854:
CBR-001-585-652-7,RFM-005-042-0,CBR-001-585-652-7,O=C1CCC(C(=O)N1)(C1CCN(CC1)C/C=C/c1ccccc1)c1ccccc1,CBR-HVAC-08884:
CBR-001-585-653-8,RFM-005-043-1,CBR-001-585-653-8,COc1ccc(cc1)/C(=C(\c1ccccc1)/[N+](=O)[O-])/c1ccc(cc1)OCCN1CCCC1,CBR-HVAC-08993:
CBR-001-585-654-9,RFM-005-044-2,CBR-001-585-654-9,COC(=O)CCN1CCN(CC1)c1cccc(c1)SC(F)(F)F,CBR-HVAC-08195: 5 Hydroxytryptamine receptor agonist
CBR-001-585-655-0,RFM-005-045-3,CBR-001-585-655-0,CNCC1CC2C(O1)c1cc(F)ccc1Cc1c2cccc1,CBR-HVAC-11795: 5-Hydroxytryptamine 2C receptor; 5-Hydroxytryptamine 2A receptor Antagonist;
CBR-001-585-656-1,RFM-005-046-4,CBR-001-585-656-1,Fc1ccc(cc1)CN1CCN(C1=O)c1nc(c(s1)C(=O)NCc1cccnc1)C,CBR-HVAC-14240
CBR-001-585-657-2,RFM-005-047-5,CBR-001-585-657-2,Cc1nn(c(c1)C)CCCCCS(=O)c1nc(c([nH]1)c1ccccc1)c1ccccc1,CBR-HVAC-10709: Acyl CoA:cholesterol acyltransferase Inhibitor;
CBR-001-585-658-3,RFM-005-048-6,CBR-001-585-658-3,N#Cc1ccc(nc1)C(=O)Nc1ccc(c(c1)[C@@]1(C)N=C(N)OCC1(F)F)F,"CBR-HVAC-07145: Alzheimer's Dementia, Treatment of ; beta-Secretase (BACE) Inhibitors;"
CBR-001-585-659-4,RFM-005-049-7,CBR-001-585-659-4,O=C(c1cccs1)Oc1ccccc1C(=O)O,CBR-HVAC-03214: Analgesic Drugs;Antiarthritic Drugs; COX Inhibitor; Cyclooxygenase inhibitor; Calcium channel antagonist
CBR-001-585-660-7,RFM-005-050-0,CBR-001-585-660-7,O=C1Nc2c(Cl)ccc(c2C2(N1)CCCCC2)O[C@@H]1C[C@H](C1)C(=O)O,CBR-HVAC-11847: Analgesic;
CBR-001-585-661-8,RFM-005-051-1,CBR-001-585-661-8,CCCCc1nc(CCc2ccccc2)[nH]c(=O)c1Cc1ccc(cc1)c1ccccc1c1[nH]nnn1,CBR-HVAC-10848: Angiotensin II receptor type 1 Antagonist;
CBR-001-585-662-9,RFM-005-052-2,CBR-001-585-662-9,Clc1ccc2c(c1)nc(cc2)/C=C/c1cccc(c1)Cn1ccc2c1c(ccc2)CCc1[nH]nnn1,CBR-HVAC-10820: Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist;
CBR-001-585-663-0,RFM-005-053-3,CBR-001-585-663-0,NC(=O)c1ccn2c1CSC2c1cccnc1,CBR-HVAC-03188: Antiallergy/Antiasthmatic Drugs; Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Platelet activating factor antagonist
CBR-001-585-664-1,RFM-005-054-4,CBR-001-585-664-1,COc1ccc(cc1)Oc1c(cc(cc1S(=O)(=O)N)C(=O)O)n1cccc1,CBR-HVAC-11768: Antibacterial;
CBR-001-585-665-2,RFM-005-055-5,CBR-001-585-665-2,Cc1nnc(o1)C(c1ccccc1)(c1ccccc1)CCN1CC2CCC1CC2,CBR-HVAC-00808: Antidiarrheal Agents; Opioid receptor agonist
CBR-001-585-666-3,RFM-005-056-6,CBR-001-585-666-3,CC(=O)c1ccc(cc1)C#C[C@@]1(O)CC[C@]2([C@H](C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)C)C)C,CBR-HVAC-11410: Antiepileptic Drugs;Anxiolytics; GABA-A receptor Modulator;
CBR-001-585-667-4,RFM-005-057-7,CBR-001-585-667-4,CCOc1ccccc1OCCN[C@@H](Cc1cc2ccn(c2c(c1)C(=O)N)CCCOC(=O)C(C)(C)C)C,CBR-HVAC-05296: Antiglaucoma Agents; ALPHA 1 ADRENERGIC RECEPTOR Antagonist;
CBR-001-585-668-5,RFM-005-058-8,CBR-001-585-668-5,COC1=C(OC)C(=O)C(=C(C1=O)C)CCCCCCCCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1,"CBR-HVAC-00040: Anti-Hepatitis C Virus Drugs;Neurodegenerative Diseases, Treatment of;Liver and Biliary Tract Disorders, Treatment of;Antiparkinsonian Drugs; Antioxidants; Intercellular adhesion molecule 1 Inducer; Reducing agent"
CBR-001-585-669-6,RFM-005-059-9,CBR-001-585-669-6,O=C(CN(c1c(C)cccc1C)C(=O)C1CCS(=O)(=O)CC1)Nc1ccc(cc1)c1nocn1,CBR-HVAC-11849: Anti-Herpes Simplex Virus Drugs;Anti-Herpes Virus Drugs; Helicase Primase Inhibitors; Helicase; DNA primase Inhibitor; Inhibitor;
CBR-001-585-670-9,RFM-005-060-2,CBR-001-585-670-9,N#Cc1ccc(cc1)S(=O)(=O)Nc1cccc(c1)C(c1c(=O)oc2c(c1O)CCCCCC2)C1CC1,CBR-HVAC-04701: Anti-HIV Agents; HIV Protease Inhibitors; Reverse transcriptase Inhibitor; HIV protease inhibitor
CBR-001-585-671-0,RFM-005-061-3,CBR-001-585-671-0,O=C(NC(c1cc(Cl)c2c(c1O)nccc2)c1cccc(c1)[N](=O)O)CN(c1ccccc1)C,CBR-HVAC-11739: Anti-inflammatory;
CBR-001-585-672-1,RFM-005-062-4,CBR-001-585-672-1,Cc1cc(Nc2ccc(cc2)S(F)(F)(F)(F)F)n2c(n1)nc(n2)C(F)(F)C,CBR-HVAC-07180: Antimalarials; Dihydroorotate Dehydrogenase (pfDHODH) (Plasmodium falciparum) Inhibitors; DIHYDROOROTATE DEHYDROGENASE Inhibitor;
CBR-001-585-673-2,RFM-005-063-5,CBR-001-585-673-2,O=c1cc(OCc2ccccc2)ccn1c1ccc2c(c1)cnn2CCN1CCCC1,CBR-HVAC-11973: Antiobesity Drugs; Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists;Signal Transduction Modulators; Melanin concentrating hormone receptor 1 Antagonist;
CBR-001-585-674-3,RFM-005-064-6,CBR-001-585-674-3,CCOC(=O)C1=C(C)NC(=C(C1C)C(=O)OCCN1C(=O)c2c(S1(=O)=O)cccc2)C,CBR-HVAC-03570: Antiplatelet Therapy; Phosphodiesterase 5 Inhibitor; Platelet aggregation inhibitor
CBR-001-585-675-4,RFM-005-065-7,CBR-001-585-675-4,Fc1ccc(c(c1)C(F)(F)F)C(=O)Nc1ccc2c(c1)B(O)OC2(C)C,CBR-HVAC-06933: Antitrypanosomals; Anti-inflammatory; Unidentified pharmacological activity
CBR-001-585-676-5,RFM-005-066-8,CBR-001-585-676-5,CCCCCCC/C=C/C(=O)NCCSCCC1CCCCC1,CBR-HVAC-10682: Antiulcer Drugs; Antiulcer;
CBR-001-585-677-6,RFM-005-067-9,CBR-001-585-677-6,COc1cccc2c1c(nn2Cc1cccc(c1)CNC(=O)C(O)(C)C)NS(=O)(=O)c1ccc(s1)Cl,CBR-HVAC-07158: Asthma Therapy; Chemokine CCR4 Antagonists;Signal Transduction Modulators; CC chemokine receptor 4 antagonist
CBR-001-585-678-7,RFM-005-068-0,CBR-001-585-678-7,C[C@H](C(C)(C)C)/N=C(/Nc1ccc(cc1)C#N)\NC#N,CBR-HVAC-09459: ATP-SENSITIVE POTASSIUM CHANNEL Opener;
CBR-001-585-679-8,RFM-005-069-1,CBR-001-585-679-8,CC1CC/C(=N/Nc2ccccc2)/c2n1c(=O)c(cn2)C(=O)O,CBR-HVAC-07631: Beta adrenoreceptor antagonist
CBR-001-585-680-1,RFM-005-070-4,CBR-001-585-680-1,CCOC(=O)c1ccccc1Cc1ccc(c(c1)Nc1cc(c(c2c1C(=O)c1ccccc1C2=O)N)S(=O)(=O)O)C,CBR-HVAC-08956: BETA AMYLOID; FIBROBLAST GROWTH FACTOR Modulator; Agonist;
CBR-001-585-681-2,RFM-005-071-5,CBR-001-585-681-2,CCCC1(CCN(CC1)S(=O)(=O)c1cc2c(n1S(=O)(=O)c1ccccn1)cccc2)CNS(=O)(=O)C(F)(F)F,CBR-HVAC-14243
CBR-001-585-682-3,RFM-005-072-6,CBR-001-585-682-3,Clc1ccc(cc1)C(=O)c1ccc(cc1)OC(C(=O)NCCS(=O)(=O)O)(C)C,CBR-HVAC-07440: Cholesterol inhibitor
CBR-001-585-683-4,RFM-005-073-7,CBR-001-585-683-4,COc1ccc(cc1OC)c1c(C(=O)OC)c(C(=O)OC)c(c2c1c(OC)c(OC)c(c2)OC)O,CBR-HVAC-08396: Cholesterol inhibitor
CBR-001-585-684-5,RFM-005-074-8,CBR-001-585-684-5,CCCC(=O)Nc1ccc(c(c1)[N+](=O)[O-])Cc1ccccn1,"CBR-HVAC-03850: Cognition Disorders, Treatment of;Antidepressants; Acetylcholine receptor Agonist;"
CBR-001-585-685-6,RFM-005-075-9,CBR-001-585-685-6,OC[C@]1(C)[C@H](O)CC[C@@]2(C1CC[C@@]1([C@H]2C/C=C/2\[C@@H](COC2=O)OC(=O)/C=C/c2ccccc2)OC1)C,CBR-HVAC-09448: Cyclin dependent Kinase 4 Inhibitor;
CBR-001-585-686-7,RFM-005-076-0,CBR-001-585-686-7,Clc1ccc(cc1)C(c1ccccc1)N1CCN(CC1)CCOCCOC(=O)C(c1cccc(c1)C(=O)c1ccccc1)C,CBR-HVAC-03236: Non-Opioid Analgesics; Histamine H1 Receptor Antagonists;Signal Transduction Modulators;
CBR-001-585-687-8,RFM-005-077-1,CBR-001-585-687-8,O=C(c1ccccc1)c1cccc(c1)NS(=O)(=O)C(F)F,CBR-HVAC-01164: Cyclooxygenase inhibitor; Platelet aggregation inhibitor; Prostaglandin synthase inhibitor
CBR-001-585-688-9,RFM-005-078-2,CBR-001-585-688-9,Fc1ccc(c(c1)F)[C@@H]1CN(C[C@H]1C(=O)N1C[C@H](C)[C@@]([C@@H](C1)C)(O)c1ccccc1)C(C)(C)C,"CBR-HVAC-12049: Disorders of Sexual Function and Reproduction, Treatment of; Melanocortin MC4 Receptor Agonists;Signal Transduction Modulators;"
CBR-001-585-689-0,RFM-005-079-3,CBR-001-585-689-0,COc1c(OC)cc(nc1c1csc(n1)CCCCCC(O)C)C(=O)O,CBR-HVAC-11498: Endothelin-Converting Enzyme (ECE) Inhibitors; Endothelin converting enzyme Inhibitor;
CBR-001-585-690-3,RFM-005-080-6,CBR-001-585-690-3,COc1ccccc1OC1(C)OC(=O)c2c(O1)cccc2,CBR-HVAC-01853: Expectorants; Cyclooxygenase inhibitor; Mucolytic agent; Prostaglandin synthase inhibitor
CBR-001-585-691-4,RFM-005-081-7,CBR-001-585-691-4,COC(=O)Nc1cccc(c1CNc1cccn2c1nc(c2C)C)C,CBR-HVAC-04612: Gastric Antisecretory Drugs;Antiulcer Drugs; Reversible H+/K+-ATPase Inhibitors ;
CBR-001-585-692-5,RFM-005-082-8,CBR-001-585-692-5,N#Cc1ccccc1CN1CCSC1=O,CBR-HVAC-10595: Gastroprotective;
CBR-001-585-693-6,RFM-005-083-9,CBR-001-585-693-6,CN(Cc1ccc(o1)CSCCNc1ns(=O)nc1N)C,CBR-HVAC-07548: Histamine H2 receptor antagonist
CBR-001-585-694-7,RFM-005-084-0,CBR-001-585-694-7,O[C@H]1CO[C@]2([C@@H]1OC(=O)[C@]2(O)c1ccc(o1)C)O,"CBR-HVAC-08041: Immunomodulators;Stroke, Treatment of; Immunosuppressant"
CBR-001-585-695-8,RFM-005-085-1,CBR-001-585-695-8,COc1ccc(c(c1)C)N1CCc2c1nc(C)cc2n1ccc(n1)N1CCNC1=O,"CBR-HVAC-06153: Irritable Bowel Syndrome, Agents for;Anxiolytics;Antidepressants; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin-releasing factor receptor 1 Antagonist; Corticotropin releasing factor 1 receptor antagonist; Corticotropin releasing factor antagonist"
CBR-001-585-696-9,RFM-005-086-2,CBR-001-585-696-9,CCCCCCCCCCOc1ccc(cc1)C(=O)Nc1cc(ccc1SC)C(=O)NCCCC,"CBR-HVAC-04213: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor; Acetyl CoA transferase inhibitor"
CBR-001-585-697-0,RFM-005-087-3,CBR-001-585-697-0,CCN(Cc1cccc(c1)OCC(OCc1cscc1)(C)C)C/C=C/C#CC(C)(C)C,"CBR-HVAC-11168: Lipoprotein Disorders, Treatment of ; Squalene Monooxygenase Inhibitors; Squalene epoxidase Inhibitor;"
CBR-001-585-698-1,RFM-005-088-4,CBR-001-585-698-1,OC1(CN2CCC1CC2)c1ccc(cc1)c1ccc2c(c1)cccn2,"CBR-HVAC-11036: Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors; Squalene synthase Inhibitor;"
CBR-001-585-699-2,RFM-005-089-5,CBR-001-585-699-2,CCOc1oc(nc1CC(=O)OCC)c1ccc(cc1)Cl,"CBR-HVAC-08542: Lipoprotein Disorders, Treatment of ; Unidentified pharmacological activity"
CBR-001-585-700-8,RFM-005-090-8,CBR-001-585-700-8,CSc1nc2sc(c(c2c(n1)c1cccc(c1)OC)N)C(=O)NC(C)(C)C,CBR-HVAC-09284: LUTEINIZING HORMONE Agonist;
CBR-001-585-701-9,RFM-005-091-9,CBR-001-585-701-9,COc1cc(ccc1OC)CN1CCN(CC1)c1ccc(c(n1)OC)Br,CBR-HVAC-11688: MELANIN CONCENTRATING HORMONE RECEPTOR 1 Antagonist;
CBR-001-585-702-0,RFM-005-092-0,CBR-001-585-702-0,Fc1ccc(c(c1)F)N1CCN(CC1)CCSc1nnc2n1cccc2,CBR-HVAC-10851: Non-Opioid Analgesics; 5-Hydroxytryptamine receptor Antagonist;
CBR-001-585-703-1,RFM-005-093-1,CBR-001-585-703-1,O=C(/C=C/c1ccc(cc1)C(=O)N(C)C)NCC(=O)N(c1ccc(c(c1Cl)COc1cccn2c1nc(c2Br)C)Cl)C,CBR-HVAC-11164: Non-Opioid Analgesics;Antiarthritic Drugs; Bradykinin B2 Antagonists;Signal Transduction Modulators; Bradykinin receptor B2 Antagonist;
CBR-001-585-704-2,RFM-005-094-2,CBR-001-585-704-2,NC(=N)N/N=C/1\CCc2c1cccc2C(=N)N,CBR-HVAC-04478: Oncolytic Drugs; S-Adenosyl-L-methionine Decarboxylase Inhibitors; S-ADENOSYL-L-METHIONINE DECARBOXYLASE Inhibitor; Adenosylmethionine decarboxylase inhibitor
CBR-001-585-705-3,RFM-005-095-3,CBR-001-585-705-3,C[C@@H]1CN(CCN1c1cnc(cn1)C(O)(C)C)c1nnc(c(c1C)C)Cc1ccccc1,CBR-HVAC-07183: Oncolytic Drugs;Brain Cancer Therapy;Basal Cell Carcinoma Therapy; Hedgehog Signaling Inhibitors;Signal Transduction Modulators;Smoothened (Smo) Receptor Antagonists;
CBR-001-585-706-4,RFM-005-096-4,CBR-001-585-706-4,Nc1cc2CCN3c2c(c1)C(=N[C@H](C3=O)NC(=O)c1cccnc1)c1ccccc1,"CBR-HVAC-11020: Antiallergy/Antiasthmatic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 4 Inhibitor;"
CBR-001-585-707-5,RFM-005-097-5,CBR-001-585-707-5,OC(=O)c1ccc(cc1)CCCC1SCC(=O)N1CCC1(O)CCCCC1,CBR-HVAC-07970: Prostaglandin receptor agonist
CBR-001-585-708-6,RFM-005-098-6,CBR-001-585-708-6,NCCCn1ccc2c1cccc2c1ccnc(n1)Nc1cccc(c1)OC(C(F)F)(F)F,CBR-HVAC-11554: Protein tyrosine kinase C Inhibitor;
CBR-001-585-709-7,RFM-005-099-7,CBR-001-585-709-7,CCCCCCCCCCCCCCCCCC(c1ccc(c(c1)Cl)C(=O)O)O,"CBR-HVAC-07995: Pulmonary Emphysema, Agents for;Antiarthritic Drugs; Elastase Inhibitors; Elastase inhibitor"
CBR-001-585-710-0,RFM-005-100-3,CBR-001-585-710-0,Fc1ccc2c(n1)oc(n2)c1cnc2c(c1)ccn2C,CBR-HVAC-09438: Radiopharmaceuticals for Brain Imaging;Diagnostic for Alzheimer's Disease; Drugs Acting on Beta-Amyloid;MAO-B Inhibitors;
CBR-001-585-711-1,RFM-005-101-4,CBR-001-585-711-1,Clc1ccc(cc1)c1ccc(cc1)COC(C(=O)O)(C)C,"CBR-HVAC-01227: Rheumatoid Arthritis, Treatment of; Peroxisome proliferator activated receptor alpha Agonist; Unidentified pharmacological activity"
CBR-001-585-712-2,RFM-005-102-5,CBR-001-585-712-2,N#Cc1cc(cc2c1cc(O)cc2)c1ccc(c(c1)F)O,"CBR-HVAC-05932: Sepsis, Treatment of;Antiarthritic Drugs;Inflammatory Bowel Disease, Agents for; Estrogen Receptor (ER) beta Agonists;Signal Transduction Modulators; Estrogen receptor beta Agonist; Estrogen receptor beta agonist"
CBR-001-585-713-3,RFM-005-103-6,CBR-001-585-713-3,O=C1CCC2[C@]1(C)CCC1C2CCc2c1ccc(c2)OP(=S)(O)C,CBR-HVAC-09437: STEROID SULFATASE INHIBITOR;
CBR-001-585-714-4,RFM-005-104-7,CBR-001-585-714-4,OC(=O)c1cccc(c1)c1cccc(c1O)N/N=C/1\C(=O)N(c2c1ccc(c2)S(=O)(=O)C)c1ccc(c(c1)C)C,CBR-HVAC-11830: Thrombopoietin receptor Agonist;
CBR-001-585-715-5,RFM-005-105-8,CBR-001-585-715-5,N#Cc1cccc(c1)C(N(C(=O)c1ccccc1C(=O)c1ccccc1)CCc1nc[nH]c1)C(=O)NCC(c1ccccc1)c1ccccc1,"CBR-HVAC-05648: Treatment of Transplant Rejection;Multiple Sclerosis, Agents for; Apoptosis Inhibitors; TNF Antagonist; Tumour necrosis factor alpha antagonist; Immunosuppressant"
CBR-001-585-716-6,RFM-005-106-9,CBR-001-585-716-6,OC(=O)OCc1c(cc(cc1C(C)(C)C)SC(Sc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)(C)C)C(C)(C)C,CBR-HVAC-07433: Tumour necrosis factor alpha antagonist; Tumour necrosis factor alpha agonist
CBR-001-585-717-7,RFM-005-107-0,CBR-001-585-717-7,CCN1CCC(CC1)Nc1ccc2c(c1)/C(=C(\c1[nH]cc(n1)C)/c1cccc(c1)F)/C(=O)N2,CBR-HVAC-11561: Tyrosine kinase Antagonist; Inhibitor; Modulator;
CBR-001-585-718-8,RFM-005-108-1,CBR-001-585-718-8,COc1ccc(cc1)c1nc(C)nnc1c1ccc(cc1)OC,CBR-HVAC-01144: Unidentified pharmacological activity
CBR-001-585-719-9,RFM-005-109-2,CBR-001-585-719-9,O=C1CCC(=NN1)/C=C/c1ccncc1,CBR-HVAC-07905: Unidentified pharmacological activity
CBR-001-585-720-2,RFM-005-110-5,CBR-001-585-720-2,OC(=O)[C@@H]1[C@@H]2[C@H]1S(=O)(=O)C[C@@]2(N)C(=O)O,CBR-HVAC-04951
CBR-001-585-758-6,RFM-005-111-6,CBR-001-585-758-6,COc1cc(OC)c(cc1/C=C/C(=O)c1ccc(cc1)C(=O)O)c1cc2c([nH]1)cccc2,CBR-HVAC-08507:VCAM-1 antagonist
CBR-001-585-759-7,RFM-005-112-7,CBR-001-585-759-7,Cc1ccc(cc1)S(=O)(=O)Oc1ccc(c(c1)S(=O)(=O)O)O,"CBR-HVAC-01519:Lipoprotein Disorders, Treatment of ; HMG CoA reductase inhibitor; Lipase clearing factor stimulant"
CBR-001-585-760-0,RFM-005-113-8,CBR-001-585-760-0,OC(COC1c2ccccc2C(=O)N1c1ccccc1)CNC(C)C,CBR-HVAC-08096:Sodium channel antagonist
CBR-001-585-761-1,RFM-005-114-9,CBR-001-585-761-1,CC(CCC=C(C)C)CCOC(=O)C,CBR-HVAC-12153:Antiparasitic; Insecticide
CBR-001-585-762-2,RFM-005-115-0,CBR-001-585-762-2,COc1ccc(c(c1)CC(NCCc1cc(OC)cc(c1)OC)C)C#Cc1ccccc1,CBR-HVAC-10656:Calcium channel L-type Blocker;
CBR-001-585-763-3,RFM-005-116-1,CBR-001-585-763-3,OC[C@H](c1cnc(c(c1)Cl)C1=CCN(CC1)C(=O)Nc1ccc(cn1)C(F)(F)F)O,CBR-HVAC-07258:Non-Opioid Analgesics; TRPV1 (Vanilloid VR1 Receptor) Antagonists;
CBR-001-585-764-4,RFM-005-117-2,CBR-001-585-764-4,CNC(CCC=C(C)C)C,"CBR-HVAC-05674:Acute Attacks of Migraine, Treatment of; It acts by constricting dilated cranial and cerebral arterioles, thus reducing the stimuli that lead to migraine attack;"
CBR-001-585-765-5,RFM-005-118-3,CBR-001-585-765-5,CN(C(c1cscc1)C(=O)Nc1ccc2c(c1)cc[nH]c2=O)C,CBR-HVAC-06898:Ophthalmic Drugs;Antiglaucoma Agents; Rho Kinase Inhibitors;Signal Transduction Modulators; Rho-associated kinase inhibitor
CBR-001-585-766-6,RFM-005-119-4,CBR-001-585-766-6,N#C/N=C(/Nc1ccncc1)\NCCCCCCOc1ccc(cc1)Cl,CBR-HVAC-05002:
CBR-001-585-767-7,RFM-005-120-7,CBR-001-585-767-7,Fc1ccc2c(c1)onc2N1CCN(CC1)CC1Cc2c1cccc2,CBR-HVAC-10479:Dopamine receptor; 5-Hydroxytryptamine receptor Antagonist;
CBR-001-585-768-8,RFM-005-121-8,CBR-001-585-768-8,Oc1ccc2c(c1)CCC1C2CC[C@]2(C1CC[C@@H]2O)C,CBR-HVAC-12175:Estrogen receptor agonist
CBR-001-585-769-9,RFM-005-122-9,CBR-001-585-769-9,COCCOCCOCCOCCOC(=O)OC[n+]1ccc(cc1)N/C(=N/C#N)/NCCCCCCOc1ccc(cc1)Cl,CBR-HVAC-05878:Melanoma Therapy;Lung Cancer Therapy;Oncolytic Drugs;Lymphoma Therapy;Solid Tumors Therapy; Glycerol-3-Phosphate Dehydrogenase (NAD+) Inhibitors;Inhibitory kappaB Kinase (IKK) Inhibitors;Nicotinamide Phosphoribosyltransferase (NAmPRTase; Nampt) Inhibitors;Signal Transduction Modulators; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NUCLEAR FACTOR KAPPA B Inhibitor; IKK1 inhibitor; Nicotinamide phosphoribosyl transferase inhibitor; Apoptosis stimulant; IKK2 inhibitor; Protein kinase inhibitor
CBR-001-585-770-2,RFM-005-123-0,CBR-001-585-770-2,OC(=O)/C=C/c1nc(ccc1OCCc1ccccc1)CSc1c(Cl)cccc1Cl,CBR-HVAC-04685:Antipsoriatics; Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators; Leukotriene B4 receptor Antagonist; Leucotriene B4 antagonist
CBR-001-585-771-3,RFM-005-124-1,CBR-001-585-771-3,O=C1NC(=O)[C@]2(C1)C(=O)N(Cc1ccc(cc1F)Br)C(=O)c1n2ccc1,"CBR-HVAC-00841:Anticataract Agents;Diabetic Retinopathy, Agents for;Diabetic Neuropathy, Agents for; Aldose Reductase Inhibitors; ALDOSE REDUCATASE Inhibitor; Aldose reductase inhibitor"
CBR-001-585-772-4,RFM-005-125-2,CBR-001-585-772-4,OC[C@@H](c1ccccc1)NC(=O)C(c1ccc(cc1)Cn1c2ccccc2c2c1nc(C)cc2C)C1CCCC1,"CBR-HVAC-04838:Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal trigylceride transfer protein inhibitor"
CBR-001-585-773-5,RFM-005-126-3,CBR-001-585-773-5,Nc1ncccc1OCc1ccccc1,CBR-HVAC-12141:p38 Mitogen-activated protein kinase inhibitor
CBR-001-585-774-6,RFM-005-127-4,CBR-001-585-774-6,Fc1cc(cc(c1)N1CCOCC1)C(=O)Nc1ccc(c(c1)Nc1ccncn1)C,CBR-HVAC-11705:p38 Mitogen-activated protein kinase Inhibitor;
CBR-001-585-775-7,RFM-005-128-5,CBR-001-585-775-7,O=C(C(=O)c1c[nH]c2c1c(F)ccc2c1nocn1)N1CCN(CC1)C(=O)c1ccccc1,CBR-HVAC-11889: Glycoprotein 120 Inhibitor; HIV Attachment Inhibitors; Anti-HIV Agents; HIV uptake inhibitor
CBR-001-585-776-8,RFM-005-129-6,CBR-001-585-776-8,O=C(CCn1cnc2c1nc[nH]c2=O)NCCCN1CCCC1=O,"CBR-HVAC-04404:Cognition Disorders, Treatment of; Nootropic agent; Unidentified pharmacological activity"
CBR-001-585-777-9,RFM-005-130-9,CBR-001-585-777-9,CCC(NC(=O)c1ccc(cc1)NC(=O)C)(C)C,CBR-HVAC-12166:Reducing agent
CBR-001-585-778-0,RFM-005-131-0,CBR-001-585-778-0,Oc1c(cc(cc1C(C)(C)C)CCCOCc1cccnc1)C(C)(C)C,"CBR-HVAC-04473:Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; Antioxidants; Plasminogen activator inhibitor-1 Inhibitor; Reducing agent; Cholesterol inhibitor"
CBR-001-585-779-1,RFM-005-132-1,CBR-001-585-779-1,CN(CCCOc1ccc2c(c1)c(n[nH]2)S(=O)(=O)c1cccc2c1cccc2)C,"CBR-HVAC-11744:Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; Signal Transduction Modulators;5-HT6 Antagonists; 5-Hydroxytryptamine 6 receptor Agonist;"
CBR-001-585-780-4,RFM-005-133-2,CBR-001-585-780-4,OC(=O)CCCCc1cn(c2c1cccc2)c1ccccn1,CBR-HVAC-07628:Thromboxane A2 receptor antagonist; Thromboxane synthase inhibitor; Thromboxane B2 receptor antagonist
CBR-001-585-781-5,RFM-005-134-3,CBR-001-585-781-5,OC(=O)C(Oc1ccc(cc1)Cl)(C)C,CBR-HVAC-14319: metabolite of CBR-HVAC-09268
CBR-001-585-782-6,RFM-005-135-4,CBR-001-585-782-6,Cc1cccnc1NS(=O)(=O)c1ccc(cc1)C#Cc1ccc(c(c1)C(=O)O)O,"CBR-HVAC-11481:Inflammatory Bowel Disease, Agents for;Immunomodulators;Antiarthritic Drugs; TNF production inhibitor;"
CBR-001-585-783-7,RFM-005-136-5,CBR-001-585-783-7,Cc1ccc(cc1)c1sc2c(n1)c(O)ccc2,CBR-HVAC-03855-M1:
CBR-001-585-788-2,RFM-005-137-6,CBR-001-585-788-2,CCCCCCCCCCCCCC(=O)O[Pt]1(N[C@H]2[C@H](N1)CCCC2)OC(=O)CCCCCCCCCCCCC,CBR-HVAC-00014:Anticancer; Alkylating agent; DNA inhibitor
CBR-001-585-789-3,RFM-005-138-7,CBR-001-585-789-3,O=C(c1ccc[n+](c1)CC(=O)c1cccs1)NNS(=O)(=O)C,CBR-HVAC-00268:Glycosylation inhibitor; Glycosylation inhibitor
CBR-001-585-790-6,RFM-005-139-8,CBR-001-585-790-6,O=C([C@@H]1CC[C@]2(CC1)OC(=O)c1c2cncc1)Nc1ccn(n1)c1ccccc1F,CBR-HVAC-00401:Neuropeptide Y receptor 5 Antagonist; Neuropeptide Y5 receptor antagonist
CBR-001-585-791-7,RFM-005-140-1,CBR-001-585-791-7,ClCCNP(=O)(NCCCl)O,CBR-HVAC-00783:Anticancer; Alkylating agent; DNA inhibitor; DNA synthesis inhibitor
CBR-001-585-792-8,RFM-005-141-2,CBR-001-585-792-8,O=C1CN=C(c2c(N1)cn(c2C)C)c1ccccc1,CBR-HVAC-01025:Benzodiazepine receptor Partial Agonist; Benzodiazepine receptor agonist
CBR-001-585-793-9,RFM-005-142-3,CBR-001-585-793-9,CCN(CCNC(=O)N(C(C)C)CCS(=O)(=O)c1ccccc1)CC,CBR-HVAC-01069:Sodium channel antagonist
CBR-001-585-794-0,RFM-005-143-4,CBR-001-585-794-0,CCOC1c2ccccc2C(=O)N(c2c1cccc2)C,CBR-HVAC-01081:Dopamine receptor antagonist
CBR-001-585-795-1,RFM-005-144-5,CBR-001-585-795-1,CN1C(=Nc2c(CC1c1ccccc1)cccc2)C,CBR-HVAC-01113:5-Hydroxytryptamine receptor Inhibitor; Adrenergic transmitter uptake inhibitor; 5 Hydroxytryptamine uptake inhibitor; Dopamine reuptake inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor
CBR-001-585-796-2,RFM-005-145-6,CBR-001-585-796-2,N#C/C=C\1/c2ccccc2C(=Cc2c1ccc(c2)Cl)N1CCN(CC1)C,likely inactive stereoisomer of CBR-HVAC-01120
CBR-001-585-797-3,RFM-005-146-7,CBR-001-585-797-3,N#Cc1ccc(cc1)C(=O)N(c1ccccn1)C[C@H](N1CCN(CC1)c1cccc2c1OCCO2)C,"CBR-HVAC-02711:Alzheimer's Dementia, Treatment of ; Signal Transduction Modulators;5-HT1A Receptor Antagonists; 5-Hydroxytryptamine 1A receptor Antagonist; 5 Hydroxytryptamine 1A receptor antagonist"
CBR-001-585-798-4,RFM-005-147-8,CBR-001-585-798-4,O=C(C(c1ccsc1)C1CCCCC1)OCCN1CCCCCC1,CBR-HVAC-02806:Antisickling agent; Alpha adrenoreceptor antagonist
CBR-001-585-799-5,RFM-005-148-9,CBR-001-585-799-5,COC(=O)c1ccc(cc1)CC(NCC(c1ccccc1)O)C,CBR-HVAC-02956:Antiobesity Drugs; Beta-3 adrenergic receptor Agonist; Beta 3 adrenoreceptor agonist
CBR-001-585-800-1,RFM-005-149-0,CBR-001-585-800-1,C[C@@H]([C@@H](c1ccc2c(c1)OCO2)N1CCOCC1)O,CBR-HVAC-02960:Non-Opioid Analgesics; COX Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-585-801-2,RFM-005-150-3,CBR-001-585-801-2,O[C@@H]1CC[C@H](CC1)NCc1cc(Br)cc(c1NC(=O)c1cccs1)Br,CBR-HVAC-03328:Mucolytics;
CBR-001-585-802-3,RFM-005-151-4,CBR-001-585-802-3,OC(=O)c1ccc2c(c1)CCC(C2)Cn1cncc1,"CBR-HVAC-03436:Antiplatelet Therapy;Angina pectoris, Treatment of;Bronchodilators; Thromboxane Synthase Inhibitors; Thromboxane A2 synthetase Inhibitor; Thromboxane synthase inhibitor"
CBR-001-585-803-4,RFM-005-152-5,CBR-001-585-803-4,CCCCN1C(=O)C2C(=O)N(C(=O)C(C1=O)C2(C)C)CCCCN1CCN(CC1)c1ccccc1OC,CBR-HVAC-03555:Antipsychotic Drugs;Anxiolytics; Dopamine receptor D2; 5-Hydroxytryptamine 1A receptor Agonist; Antagonist; 5 Hydroxytryptamine 1A receptor agonist
CBR-001-585-804-5,RFM-005-153-6,CBR-001-585-804-5,CCN(CCCNC(=O)Cn1ncc(c1c1ccccc1)c1ccccc1)CC,CBR-HVAC-03745:Antiarrhythmic Drugs; Potassium channel Antagonist; Sodium channel antagonist; Beta adrenoreceptor antagonist
CBR-001-585-805-6,RFM-005-154-7,CBR-001-585-805-6,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C2=O)c2c4nc5c(O)cc(cc5oc4c(c(=O)c2c(c3C)O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)/C)N1CCN(CC1)CC(C)C,"CBR-HVAC-04050:Peripheral Vascular Disease, Treatment of;Antibacterial Drugs;Antimycobacterial Agents; RNA polymerase Inhibitor;"
CBR-001-585-806-7,RFM-005-155-8,CBR-001-585-806-7,CC(CN(c1ccccc1CS(=O)c1nc2c([nH]1)cccc2)C)C,CBR-HVAC-04205:Antiulcer Drugs; H+/K+-ATPase Inhibitors; H+/K+ ATPase Inhibitor; H+ K+ transporting ATPase inhibitor; Gastrin inhibitor; Mucus protecting agent
CBR-001-585-807-8,RFM-005-156-9,CBR-001-585-807-8,COc1ccc(cc1)N1C[C@@H](OC1=O)CN1CCC(CC1)(O)c1ccc2c(c1)OCO2,CBR-HVAC-04253:Antipsychotic Drugs; sigma Receptor Antagonists;Signal Transduction Modulators; Opioid receptor sigma Antagonist; Sigma receptor antagonist
CBR-001-585-808-9,RFM-005-157-0,CBR-001-585-808-9,Fc1ccc(cc1)C[Si](CN1CCCCC1)(C)C,CBR-HVAC-04269:Antispastic Drugs; Nav1.2 (Brain Type II) Sodium Channel Blockers;Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers; Sodium channel; Potassium channel; Calcium channel Blocker; Muscarinic receptor antagonist
CBR-001-585-809-0,RFM-005-158-1,CBR-001-585-809-0,CC[C@@H](C(=O)c1onc(c1)c1ccccc1)CN1CCCC1,CBR-HVAC-04278:Antispastic Drugs; Polysynaptic and dorsal root reflex inhibitor;
CBR-001-585-810-3,RFM-005-159-2,CBR-001-585-810-3,Fc1ccc(cc1)Oc1ccc(o1)C#C[C@H](N(C(=O)N)O)C,CBR-HVAC-04310:Antiallergy/Antiasthmatic Drugs; Leukotriene Synthesis Inhibitors;Lipoxygenase Inhibitors;Signal Transduction Modulators; Lipoxygenase 5 Inhibitor; 5 Lipoxygenase inhibitor
CBR-001-585-811-4,RFM-005-160-5,CBR-001-585-811-4,OC(=O)CCNC(=O)[C@H](Cc1ccc(cc1)c1ccccc1)NCP(=O)(Oc1ccccc1)Oc1ccccc1,"CBR-HVAC-04361:Hypertension, Treatment of;Diuretics; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Membrane metalloendopeptidase Inhibitor; Membrane metallo endopeptidase inhibitor"
CBR-001-585-812-5,RFM-005-161-6,CBR-001-585-812-5,N#CC(=C1NCCN1CCNCc1ccc(o1)CN1CCCCC1)C#N,CBR-HVAC-04428:Prokinetic Agents; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor; Acetylcholine release stimulant
CBR-001-585-813-6,RFM-005-162-7,CBR-001-585-813-6,CCCN(c1cc(C)nc2n1nc(c2c1cnc(cc1C)N(C)C)C)CCC,CBR-HVAC-04975:Antidepressants;Anxiolytics; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing factor antagonist; Corticotropin releasing factor 1 receptor antagonist
CBR-001-585-814-7,RFM-005-163-8,CBR-001-585-814-7,CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@@H]([C@H]1OC(=O)C(=C1O)O)O,"CBR-HVAC-05135:Diabetic Neuropathy, Agents for; Oxidoreductase; Aldose reductase Inhibitor; Aldose reductase inhibitor"
CBR-001-585-815-8,RFM-005-164-9,CBR-001-585-815-8,OCCNC(=O)c1cc(NCc2c(C)cccc2C)c2n(c1)c(C)c(n2)C,CBR-HVAC-05278:Gastric Antisecretory Drugs; Reversible H+/K+-ATPase Inhibitors ; Gastric H+/K+ ATPase Inhibitor;
CBR-001-585-816-9,RFM-005-165-0,CBR-001-585-816-9,COc1ccc(cc1CCc1ccc2c(c1)c(CC)ncn2)OC,"CBR-HVAC-05284:Actinic Keratoses, Agents for; Antimitotic Drugs; Microtubule inhibitor;"
CBR-001-585-817-0,RFM-005-166-1,CBR-001-585-817-0,CCOc1cccc2c1O[Mn](OC(=O)C)Oc1c(OCC)cccc1/C=N/CC/N=C/2,"CBR-HVAC-05288:Radioprotectants/Radiomitigators;Antiparkinsonian Drugs;Alzheimer's Dementia, Treatment of ;Stroke, Treatment of; Free Radical Scavengers; Catalase; Superoxide dismutase Stimulator;"
CBR-001-585-818-1,RFM-005-167-2,CBR-001-585-818-1,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2Nc1ccc(cc1F)Cl)c1nnc(o1)C(C)(C)C,"CBR-HVAC-05304:Lipoprotein Disorders, Treatment of ;Neuropathic Pain, Treatment of; Adenosine A1 Agonists;Signal Transduction Modulators; Lipid metabolism modulator; Adenosine A1 receptor agonist;"
CBR-001-585-819-2,RFM-005-168-3,CBR-001-585-819-2,Nc1c(Cl)cc(c2c1OCCO2)c1nn(c(=O)o1)C1CCN(CC1)CCc1ccccc1,"CBR-HVAC-05341:Urinary Incontinence Therapy;Alzheimer's Dementia, Treatment of ; Signal Transduction Modulators;5-HT4 Partial Agonists; 5-Hydroxytryptamine 4 receptor Partial Agonist; 5 Hydroxytryptamine 4 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-585-820-5,RFM-005-169-4,CBR-001-585-820-5,c1cnc2c(c1)O[C@@H]1[C@@]3(C2)CCN(C3)CC1,"CBR-HVAC-05417:Smoking Cessation, Aid to; Nicotinic alpha4beta2 Partial Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha4beta2 Agonist; Neuronal nicotinic receptor agonist"
CBR-001-585-821-6,RFM-005-170-7,CBR-001-585-821-6,O=C(C(Oc1ccc(cc1)Cl)(C)C)OCCSCCCCCCCCCCSCCOC(=O)C(Oc1ccc(cc1)Cl)(C)C,"CBR-HVAC-05583:Lipoprotein Disorders, Treatment of ;"
CBR-001-585-822-7,RFM-005-171-8,CBR-001-585-822-7,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCN(CC1)Cc1ccc(o1)[N+](=O)[O-],CBR-HVAC-05675:Antibacterial Drugs; 50S Ribosomal Protein Inhibitors; CYP Inhibitor;
CBR-001-585-823-8,RFM-005-172-9,CBR-001-585-823-8,O=C1NC(=N)OC1c1ccccc1,"CBR-HVAC-05677:Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;"
CBR-001-585-824-9,RFM-005-173-0,CBR-001-585-824-9,COC(=O)Nc1cc(nc2n1oc(=O)n2)N1CCC=CC1,CBR-HVAC-05776:Vasodilators;
CBR-001-585-825-0,RFM-005-174-1,CBR-001-585-825-0,O=C(C12CC3CC(C2)CC(C1)C3)Nc1ccc(cc1)c1nc2c([nH]1)ccc(c2)C(=O)Nc1ccccn1,"CBR-HVAC-05799:Drugs for Allergic Rhinitis;Anti-Herpes Virus Drugs;Antiallergy/Antiasthmatic Drugs;Oncolytic Drugs; Immunoglobulin E (IgE) Production Inhibitors; Fc fragment of IgE, low affinity II, receptor; Fc fragment of IgE, high affinity I, receptor for alpha polypeptide Antagonist; Antagonist; Unidentified pharmacological activity"
CBR-001-585-826-1,RFM-005-175-2,CBR-001-585-826-1,CC(CNC(=N)Nc1cccc(c1)NC(=O)Nc1ccc(cc1)Cl)C,CBR-HVAC-05810:Anti-Rhinovirus Drugs;
CBR-001-585-827-2,RFM-005-176-3,CBR-001-585-827-2,CNCC=C(c1ccccc1)c1ccccc1,CBR-HVAC-05833:Antidepressants;
CBR-001-585-828-3,RFM-005-177-4,CBR-001-585-828-3,COc1ccc(cc1)C(=O)Nc1ccc(cc1)S(=O)(=O)NC(C(=O)O)CC#CCN1CCOCC1,"CBR-HVAC-06034:Osteoarthritis, Treatment of;Acute Myocardial Infarction, Treatment of; MMP-13 (Collagenase 3) Inhibitors;MMP-2 (Gelatinase A) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors; Matrix metalloproteinase Inhibitor;"
CBR-001-585-829-4,RFM-005-178-5,CBR-001-585-829-4,N#Cc1cccc(c1c1cc(ccc1F)c1cnc2n1ncc(n2)C(O)(C)C)F,CBR-HVAC-06180:Anxiolytics; GABA(A) BZ Site Receptor Modulators;Signal Transduction Modulators;
CBR-001-585-830-7,RFM-005-179-6,CBR-001-585-830-7,OC[C@H]([C@H]([C@@H](c1c[nH]c(n1)/C(=N/O)/C)O)O)O,"CBR-HVAC-06486:Treatment of Autoimmune Diseases;Rheumatoid Arthritis, Treatment of; Lysophospholipid edg1 (S1P1) Receptor Ligands;Signal Transduction Modulators; Sphingosine-1-phosphate lyase Inhibitor;"
CBR-001-585-831-8,RFM-005-180-9,CBR-001-585-831-8,COc1cccc(c1)[C@H]([C@@H](NC(=O)C(F)(F)F)C)Oc1ccc2c(c1)cnn2c1ccc(cc1)F,"CBR-HVAC-06771:Asthma Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Glucocorticoid Receptor (GR) Modulators;Signal Transduction Modulators; GLUCOCORTICOID RECEPTOR Agonist;"
CBR-001-585-832-9,RFM-005-181-0,CBR-001-585-832-9,O=C(C1CC1)NCc1ccc(cc1F)C(=O)N1Cc2cnn(c2Nc2c1ccc(c2)Cl)C,CBR-HVAC-06828:Treatment of Dysmenorrhea; Signal Transduction Modulators;Vasopressin (AVP) V1 Receptor Antagonists; Vasopressin V1a receptor Antagonist;
CBR-001-585-833-0,RFM-005-182-1,CBR-001-585-833-0,COc1ccc2c(c1)[C@@H]1C[C@@]1(Cn1c2c(C2CCCCC2)c2c1cc(cc2)C(=O)NS(=O)(=O)N(C)C)C(=O)N1C2CCC1CN(C2)C,CBR-HVAC-06936:Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors;
CBR-001-585-834-1,RFM-005-183-2,CBR-001-585-834-1,C=C(c1ccc(cc1)C1CCCCC1)C1COC2(OO1)C1CC3CC2CC(C1)C3,CBR-HVAC-06994:Antimalarials; Unidentified pharmacological activity
CBR-001-585-835-2,RFM-005-184-3,CBR-001-585-835-2,CC(S(=O)(=O)N[C@H]1COC[C@H]1Oc1ccc(cc1)c1ccc(s1)C#N)C,"CBR-HVAC-07058:Antipsychotic Drugs;Hearing loss, treatment of; AMPA Receptor Positive Allosteric Modulators;Signal Transduction Modulators;"
CBR-001-585-836-3,RFM-005-185-4,CBR-001-585-836-3,OC1CN(C1)C[C@@H](N(C(=O)c1ccc(c(c1)C)F)C)C(C)C,CBR-HVAC-07167:Antiarrhythmic Drugs; K(ir) 3.1/3.4 (GIRK1/4; KCNJ3/5) Heterodimeric IKACh Channel Blockers;
CBR-001-585-837-4,RFM-005-186-5,CBR-001-585-837-4,N[C@H](Cc1ccccc1)COC(=O)N,"CBR-HVAC-05009:Sleep Apnea, Treatment of;Antidepressants;Antinarcoleptic Drugs;"
CBR-001-585-838-5,RFM-005-187-6,CBR-001-585-838-5,CCOc1ccc(cc1)n1c(nc2c(c1=O)cccn2)[C@H](N(C(=O)Cc1ccc(cc1)OC(F)(F)F)Cc1cccnc1)C,"CBR-HVAC-05847:Treatment of Transplant Rejection;Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for;Antipsoriatics;Multiple Sclerosis, Agents for; Chemokine CXCR3 Antagonists;Signal Transduction Modulators; C-X-C chemokine receptor type 3 Antagonist;"
CBR-001-585-839-6,RFM-005-188-7,CBR-001-585-839-6,CC(=O)Nc1ccc(cc1)OC(=O)Cc1ccc([nH]1)C(=O)c1ccc(cc1)C,CBR-HVAC-07486:Prostaglandin synthase inhibitor
CBR-001-585-840-9,RFM-005-189-8,CBR-001-585-840-9,CC(C[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N)CSCNC(=O)C)C(C)C)NC(=O)[C@H](CC(=O)N)N)C,CBR-HVAC-04454:Antiglaucoma Agents;
CBR-001-585-841-0,RFM-005-190-1,CBR-001-585-841-0,COc1cc(NC(CCCNC2=C(CCO2)C(=O)C)C)c2c(c1)cccn2,analog of CBR-HVAC-03978
CBR-001-585-842-1,RFM-005-191-2,CBR-001-585-842-1,COc1ccc(cc1NC(=O)Nc1ccc(cc1Cl)Cl)C(=O)c1cn(c2c1c(N)ncn2)C(C)C,CBR-HVAC-11721:Oncolytic Drugs; Angiogenesis Inhibitors;High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors;Signal Transduction Modulators;Tie2 Receptor Inhibitors;TRKB Inhibitors; Tie-2 tyrosine kinase inhibitor;
CBR-001-585-843-2,RFM-005-192-3,CBR-001-585-843-2,O=C(N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C)CSC(F)(F)F,CBR-HVAC-05591:Antibiotics; Penicillin binding protein inhibitor;
CBR-001-585-844-3,RFM-005-193-4,CBR-001-585-844-3,CCN(c1c(I)cc(c(c1I)CCC(=O)O)I)C(=O)C,CBR-HVAC-07928:Not applicable
CBR-001-585-845-4,RFM-005-194-5,CBR-001-585-845-4,Clc1ccc2c(c1)[nH]cc2C1=CCN(CC1)CC[C@@H]1CN(c2c1cccc2)C(=O)C,CBR-HVAC-05323:Antipsychotic Drugs; Dopamine D4 Antagonists;Signal Transduction Modulators;5-HT Reuptake Inhibitors; Dopamine receptor D4 Antagonist;
CBR-001-585-846-5,RFM-005-195-6,CBR-001-585-846-5,CNC(=S)C1(CCC1)C(=O)c1ccc(cc1)n1cncc1,"CBR-HVAC-08020:Hypertension, Treatment of;Vasodilators; Potassium Channel Activators; Potassium channel agonist"
CBR-001-585-847-6,RFM-005-196-7,CBR-001-585-847-6,NC/C(=C\F)/c1ccc(c(c1)OC)OC,CBR-HVAC-08024:Monoamine oxidase B inhibitor
CBR-001-585-848-7,RFM-005-197-8,CBR-001-585-848-7,CCc1nc(cc2n1nc(n2)CC)N1CCSCC1,CBR-HVAC-08250:Phosphodiesterase inhibitor
CBR-001-585-849-8,RFM-005-198-9,CBR-001-585-849-8,COc1cccc(c1)C1(CCCC=C1)CCN(C)C,CBR-HVAC-08277:Cyclooxygenase inhibitor
CBR-001-585-850-1,RFM-005-199-0,CBR-001-585-850-1,CN(CCCN1C(c2ccccc2)C(Sc2c1cccc2)C(O)C)C,CBR-HVAC-08361:Unidentified pharmacological activity
CBR-001-585-851-2,RFM-005-200-6,CBR-001-585-851-2,CCCCC1=Cc2c(C1N1CCN(CC1)C)cc1c(c2)OCO1,"CBR-HVAC-03987:Cognition Disorders, Treatment of; CALCIUM CHANNEL Modulator;"
CBR-001-585-852-3,RFM-005-201-7,CBR-001-585-852-3,COc1ccccc1OCCNCC(COc1cccc2c1nn[nH]2)O,CBR-HVAC-08467:Beta adrenoreceptor antagonist; Beta 2 adrenoreceptor agonist
CBR-001-585-853-4,RFM-005-202-8,CBR-001-585-853-4,O=C1O[C@@H](C(=C1O)O)[C@@H]1COC(O1)c1ccccc1,CBR-HVAC-08557:Oncolytic Drugs; Protein synthesis inhibitor
CBR-001-585-854-5,RFM-005-203-9,CBR-001-585-854-5,OC(=O)c1cccc2c1Nc1cc(ccc1S2)C(F)(F)F,CBR-HVAC-08760:0
CBR-001-585-855-6,RFM-005-204-0,CBR-001-585-855-6,NC1=NC(N(C(=N1)N)OCc1ccc(c(c1)Cl)Cl)(C)C,CBR-HVAC-08790:0
CBR-001-585-856-7,RFM-005-205-1,CBR-001-585-856-7,CCN(CCN=S(=O)(c1ccccc1)c1ccccc1)CC,CBR-HVAC-08952:0
CBR-001-585-857-8,RFM-005-206-2,CBR-001-585-857-8,CN1CCN(CC1)CC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C,CBR-HVAC-08972:Interleukin 1 Antagonist;
CBR-001-585-858-9,RFM-005-207-3,CBR-001-585-858-9,CCS(=O)(=O)c1ccc(cc1)/C=N/NC(=S)N,CBR-HVAC-09020:0
CBR-001-585-859-0,RFM-005-208-4,CBR-001-585-859-0,O=C(Nc1ccc(cn1)Oc1ccc(cc1)S(=O)(=O)N)N[C@@H]1[C@H]2[C@@H]1c1c(F)ccc(c1OC2)F,CBR-HVAC-09124:Non-nucleoside reverse transcriptase Inhibitor;
CBR-001-585-860-3,RFM-005-209-5,CBR-001-585-860-3,N#Cc1c(C)cc(cc1C)Oc1c(nn(c1C)CS(=O)(=O)C)C1CC1,CBR-HVAC-09296:Endometriosis Therapy; Progesterone Receptor Antagonists;Signal Transduction Modulators; Progesterone receptor Antagonist;
CBR-001-585-861-4,RFM-005-210-8,CBR-001-585-861-4,COc1cc2CCN(CCc2cc1S(=O)(=O)c1ccc(cc1)OCc1ccc(cc1)Cl)C,CBR-HVAC-09363:5-HYDROXYTRYPTAMINE 6 RECEPTOR Antagonist;
CBR-001-585-862-5,RFM-005-211-9,CBR-001-585-862-5,O=C(Nc1ccc(cc1)C(=O)O)NCCN1CCN=C1c1ccncc1,CBR-HVAC-09470:0
CBR-001-585-863-6,RFM-005-212-0,CBR-001-585-863-6,N#Cc1ccc(cc1)CC(=O)NC1CCN(CC1)[C@@H](CN(S(=O)(=O)Cc1ccccc1)c1ccccc1)C,CBR-HVAC-09505:Anti-HIV Agents; Chemokine CCR5 Agonists;Signal Transduction Modulators; C-C CHEMOKINE RECEPTOR 5 Agonist;
CBR-001-585-864-7,RFM-005-213-1,CBR-001-585-864-7,OC(=O)Cc1ccc(cc1)N1CC[C@@H](C1)N[C@@H](c1cccc2c1cccc2)C,CBR-HVAC-09518:CALCIUM SENSING RECEPTOR Agonist;
CBR-001-585-865-8,RFM-005-214-2,CBR-001-585-865-8,CCCCOCCOCCOCc1cc2OCOc2cc1CCC,CBR-HVAC-09642:CYP Inhibitor;
CBR-001-585-866-9,RFM-005-215-3,CBR-001-585-866-9,O=N[Fe-2](C#N)(C#N)(C#N)(C#N)C#N,CBR-HVAC-09657:Luciferase Inhibitor;
CBR-001-585-867-0,RFM-005-216-4,CBR-001-585-867-0,O=C(c1ccc(cc1)OCCCCc1ccccc1)Nc1cccc2c1oc(cc2=O)c1[nH]nnn1,"CBR-HVAC-03465:Asthma Therapy;Drugs for Allergic Rhinitis;Treatment of Upper Respiratory Tract Disorders;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Leukotriene CysLT1 (LTD4) Antagonists;Leukotriene CysLT2  (LTC4) Antagonists;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; Leucotriene C4 antagonist; Leucotriene D4 antagonist; Leucotriene receptor antagonist"
CBR-001-585-868-1,RFM-005-217-5,CBR-001-585-868-1,CCCCCCN1CCN(CC1)/C(=N/CC(C)C)/c1ccccc1,CBR-HVAC-10165:0
CBR-001-585-869-2,RFM-005-218-6,CBR-001-585-869-2,OC(COc1cccc2c1cccc2)CNCCNC(=O)C(NC(=O)c1nc(Cl)c(nc1N)N)(C)C,CBR-HVAC-10501:Beta adrenergic receptor Antagonist;
CBR-001-585-870-5,RFM-005-219-7,CBR-001-585-870-5,O[C@@H](CN(Cc1ccc2c(n1)cccc2)C)COc1ccc(cc1)NS(=O)(=O)C,CBR-HVAC-10503:Antiarrhythmic Drugs; Potassium current inhibitor;
CBR-001-585-871-6,RFM-005-220-0,CBR-001-585-871-6,ClCCC[P+](c1ccc(cc1)N(C)C)(c1ccc(cc1)N(C)C)c1ccc(cc1)N(C)C,CBR-HVAC-10601:Antineoplastic;
CBR-001-585-872-7,RFM-005-221-1,CBR-001-585-872-7,CN(CCCCCCCCSc1nc(ccc1C(=O)c1cccs1)C(C)C)C,"CBR-HVAC-10809:Cognition Disorders, Treatment of; Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors; Prolyl endopeptidase Inhibitor;"
CBR-001-585-873-8,RFM-005-222-2,CBR-001-585-873-8,CCCCCCCCNC(=N)NC(=N)NCc1ccc(c(c1)Cl)Cl,CBR-HVAC-10991:Antibacterial Drugs; Antibacterial; Antiseptic; Disinfectant;
CBR-001-585-874-9,RFM-005-223-3,CBR-001-585-874-9,O=C1C(=C(C1=O)NC/C=C\COc1nccc(c1)CN1CCCCC1)N,CBR-HVAC-10993: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Histamine-H2-receptor-antagonists; Signal Transduction Modulators; Antiulcer; Gastric Antisecretory Drugs; Peptic Ulcer Disease
CBR-001-585-875-0,RFM-005-224-4,CBR-001-585-875-0,O=C(CN(C(=O)c1ccncc1)Cc1ccccc1)Nc1ccc(cc1)c1csc(n1)N,CBR-HVAC-11042:Anti-Herpes Virus Drugs; Helicase Inhibitor;
CBR-001-585-876-1,RFM-005-225-5,CBR-001-585-876-1,N#Cc1c(NCCCN(C)C)[n+]([O-])c2c([n+]1[O-])cc(cc2)Cl,CBR-HVAC-11237:Hypoxia-selective agent;
CBR-001-585-877-2,RFM-005-226-6,CBR-001-585-877-2,CN1CCc2c(C1)c1[nH]c(=O)c(=O)[nH]c1cc2[N+](=O)[O-],"CBR-HVAC-11251:Stroke, Treatment of; AMPA Receptor Antagonists;Kainate Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Antagonist;"
CBR-001-585-878-3,RFM-005-227-7,CBR-001-585-878-3,N#Cc1cnn(c1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,CBR-HVAC-11265:Antibacterial Drugs; Protein 30S ribosomal subunit Inhibitor;
CBR-001-585-879-4,RFM-005-228-8,CBR-001-585-879-4,O[C@@H]1C[C@H](C[C@@H]1O)Oc1nc(nc2c1cccc2)N1CCNCC1,CBR-HVAC-11298:Oncolytic Drugs; Angiogenesis inhibitor; Tumor blood flow inhibitor;
CBR-001-585-880-7,RFM-005-229-9,CBR-001-585-880-7,OCc1ccc2c(c1)C(N1CCC(CC1)(O)c1ccccc1)c1ccccc1CO2,CBR-HVAC-11307:Non-Opioid Analgesics; Opioid receptor mu Modulator;
CBR-001-585-881-8,RFM-005-230-2,CBR-001-585-881-8,CN(CC(Oc1ccc(cc1)c1nn(c2c1cccn2)CC(=O)O)C)C,CBR-HVAC-11443:Hematopoietic Agents;Immunosuppressants; Interleukin 1 beta; Interleukin 6 Modulator;
CBR-001-585-882-9,RFM-005-231-3,CBR-001-585-882-9,O=C(c1ccccc1c1ccccc1)Nc1ccc(cc1)C(=O)N1C[C@H]2CCCN2Cc2c1cccc2,CBR-HVAC-11460:Diuretics; Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Antagonists; Vasopressin V2 receptor Antagonist;
CBR-001-585-883-0,RFM-005-232-4,CBR-001-585-883-0,CN(CCC/N=C/1\CC(Cc2c1c(=O)c1c([nH]2)ccc(c1)Cl)c1ccc(cc1Cl)Cl)C,CBR-HVAC-11496:Antimalarials; Antimalarial;
CBR-001-585-884-1,RFM-005-233-5,CBR-001-585-884-1,CSc1ccc(cc1)Cc1c(O)n[nH]c1C(F)(F)F,CBR-HVAC-11502:Sodium/glucose cotransporter Inhibitor;
CBR-001-585-885-2,RFM-005-234-6,CBR-001-585-885-2,CC(=O)N[C@H](C(=O)N[C@H](c1ccc(c(c1)C(=O)N)OCC1CCCCC1)C)Cc1ccc(cc1)OP(=O)(O)O,CBR-HVAC-11555:SRC Inhibitor;
CBR-001-585-886-3,RFM-005-235-7,CBR-001-585-886-3,COc1cc(ccc1NC(=O)Nc1ccccc1C)CC(=O)N[C@H](c1noc(c1)CCC(=O)O)CC(C)C,CBR-HVAC-11661:Antiallergy/Antiasthmatic Drugs; Integrin alpha4beta1 (VLA-4) Antagonists;Signal Transduction Modulators; Integrin alpha4 beta1 Antagonist;
CBR-001-585-887-4,RFM-005-236-8,CBR-001-585-887-4,CN(CCNC(=O)c1cc2c(cc1Oc1ccc(cc1F)F)cnn2CC(C)C)C,CBR-HVAC-11774:p38 alpha mitogen-activated protein kinase; p38 mitogen-activated protein kinase Inhibitor; Activator; Inhibitor;
CBR-001-585-888-5,RFM-005-237-9,CBR-001-585-888-5,CCCNC(=O)c1ccc(cc1)N([C@@H](c1ccccc1)CN1CC[C@@H](C1)O)C,CBR-HVAC-11800:Opioid receptor kappa agonist;
CBR-001-585-889-6,RFM-005-238-0,CBR-001-585-889-6,CSCC[C@@H](C(=O)OC(C)C)NC(=O)c1cc(NC[C@H]2NC[C@H](C2)SC(=O)c2cccnc2)ccc1CCc1ccc(cc1)F,CBR-HVAC-12024:GERANYLGERANYLTRANSFERASE Inhibitor;
CBR-001-585-890-9,RFM-005-239-1,CBR-001-585-890-9,O=C([C@@H]1CC[C@@]2(CC1)OC(=O)c1c2cncc1)Nc1ccn(n1)c1ccccc1F,"CBR-HVAC-00401-I: stereoisomer of CBR-HVAC-00401, not known to be active"
CBR-001-585-891-0,RFM-005-240-4,CBR-001-585-891-0,COc1cccc(c1)[C@@H]([C@@H](NC(=O)C(F)(F)F)C)Oc1ccc2c(c1)cnn2c1ccc(cc1)F,stereoisomer of CBR-HVAC-06771
CBR-001-585-892-1,RFM-005-241-5,CBR-001-585-892-1,Cc1cc(C)nc(n1)N1CC2C(C1)CN(C2)C(=O)c1c(F)cccc1n1ccnn1,isomer of CBR-HVAC-07349 with no known activity:
CBR-001-585-893-2,RFM-005-242-6,CBR-001-585-893-2,OCCCNC(=O)[C@@H](C(CO)(C)C)O,CBR-HVAC-02596:
CBR-001-585-894-3,RFM-005-243-7,CBR-001-585-894-3,O=C(Nc1ccc(cn1)Oc1ccc(cc1)S(=O)(=O)N)N[C@H]1[C@H]2[C@@H]1c1c(F)ccc(c1OC2)F,CBR-HVAC-09124-I:
CBR-001-585-895-4,RFM-005-244-8,CBR-001-585-895-4,O[C@@H]1C[C@@H](C[C@@H]1O)Oc1nc(nc2c1cccc2)N1CCNCC1,"CBR-HVAC-11298-I:stereoisomer of CBR-HVAC-11298, not known to be active"
CBR-001-585-896-5,RFM-005-245-9,CBR-001-585-896-5,CC(=O)N[C@H](C(=O)N[C@@H](c1ccc(c(c1)C(=O)N)OCC1CCCCC1)C)Cc1ccc(cc1)OP(=O)(O)O,CBR-HVAC-11555-I:
CBR-001-585-897-6,RFM-005-246-0,CBR-001-585-897-6,N#C/C=C/1\c2ccccc2C(=Cc2c1ccc(c2)Cl)N1CCN(CC1)C,CBR-HVAC-01120:Antipsychotic Drugs;Anxiolytics; Unidentified pharmacological activity
CBR-001-585-903-7,RFM-005-247-1,CBR-001-585-903-7,[N-]=[N+]=N[C@]1(CO)O[C@H]([C@@H]([C@@H]1O)O)n1ccc(nc1=O)N,CBR-HVAC-05866: Viral replication inhibitor; Antiviral; RNA polymerase inhibitor; NA-Directed RNA Polymerase (NS5B) Inhibitors
CBR-001-585-968-4,RFM-005-248-2,CBR-001-585-968-4,CNCCCOc1cc(F)c(c(c1)F)c1c(Cl)nc2n(c1N[C@H](C(F)(F)F)C)ncn2,CBR-HVAC-00191: Solid Tumors Therapy; Antimitotic Drugs;Microtubule-Stabilizing Agents; Tubulin Inhibitor; Beta tubulin antagonist; Microtubule stimulant
CBR-001-585-969-5,RFM-005-249-3,CBR-001-585-969-5,CN1CCC(=C2c3ccccc3Oc3c2cc(Cl)cc3)CC1,CBR-HVAC-01117: Dopamine D2 receptor antagonist
CBR-001-585-970-8,RFM-005-250-6,CBR-001-585-970-8,CSc1ccc2c(c1)c(=O)n(cn2)/C=C/C(=O)O,CBR-HVAC-02979: Antiallergy/Antiasthmatic Drugs; Mast cell degranulation inhibitor; Histamine release inhibitor; Histamine release inhibitor
CBR-001-585-971-9,RFM-005-251-7,CBR-001-585-971-9,Clc1ccc(cc1S(=O)(=O)N)S(=O)(=O)N(CC1(C)CCCO1)C,"CBR-HVAC-03152: Diuretics;Hypertension, Treatment of; Carbonic anhydrase Inhibitor;"
CBR-001-585-972-0,RFM-005-252-8,CBR-001-585-972-0,CN(C(=O)c1ccc(cc1)C(C)C)CCN1CCN(CC1)c1cccc2c1occ2,CBR-HVAC-03468: Antipsychotic Drugs; 5 Hydroxytryptamine 1 receptor antagonist
CBR-001-585-973-1,RFM-005-253-9,CBR-001-585-973-1,C=CCc1c(ccc2c1CN1C(=O)CN(C(=O)[C@H]1C2)C1CCCC1)OCc1ccccn1,"CBR-HVAC-04937: Lipoprotein Disorders, Treatment of ; Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein inhibitor;"
CBR-001-585-974-2,RFM-005-254-0,CBR-001-585-974-2,O=C(Nc1cccc(c1)C(=O)O)NCC(=O)N(c1ccccc1C(=O)c1ccccc1)CC(=O)OC(C)(C)C,CBR-HVAC-04977: Gastric Antisecretory Drugs;Antiulcer Drugs; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin B receptor Antagonist; CCK B receptor antagonist
CBR-001-585-975-3,RFM-005-255-1,CBR-001-585-975-3,O=C(N(c1nc(c(s1)S(=O)(=O)N)C)C)Cc1ccc(cc1)c1ccccn1,CBR-HVAC-05697: Anti-Herpes Simplex Virus Drugs; Helicase Primase Inhibitors; Helicase-primase Inhibitor;
CBR-001-585-976-4,RFM-005-256-2,CBR-001-585-976-4,Oc1ccc2c(c1)[C@@]1(C)CCN([C@@H](C2)[C@H]1C)Cc1ccoc1C,CBR-HVAC-05797: Opioid Analgesics; Opioid kappa receptor agonist
CBR-001-585-977-5,RFM-005-257-3,CBR-001-585-977-5,Clc1ccc(c(c1)Cl)Cn1cc(c2c1c(/C=C/C(=O)NS(=O)(=O)c1sc(c(c1)Cl)Cl)cc(c2)F)C,CBR-HVAC-06160: Antiplatelet Therapy;Treatment of Peripheral Obstructive Vascular Disease; Prostanoid EP3 Antagonists;Signal Transduction Modulators; Prostaglandin E receptor 3 Antagonist;
CBR-001-585-978-6,RFM-005-258-4,CBR-001-585-978-6,CCN(C(=O)Cc1ccc(cc1)S(=O)(=O)C)C1CCN(CC1)CC[C@@H](c1cc(F)cc(c1)F)C1CCN(CC1)S(=O)(=O)C,"CBR-HVAC-06352: Treatment of Renal Diseases;Rheumatoid Arthritis, Treatment of; Chemokine CCR5 Modulators;Signal Transduction Modulators; C-C chemokine receptor type 5 Antagonist; CC chemokine receptor 5 antagonist; Chemokine receptor antagonist"
CBR-001-585-979-7,RFM-005-259-5,CBR-001-585-979-7,CCCNC(=O)c1cn2c(c1C)c(ncn2)Nc1cc(ccc1C)C(=O)NC1CC1,"CBR-HVAC-06540: Atherosclerosis Therapy;Antipsoriatics;Rheumatoid Arthritis, Treatment of; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors;"
CBR-001-585-980-0,RFM-005-260-8,CBR-001-585-980-0,COc1ccc2c(c1)C=C1Cn3c2c(C2CCCCC2)c2c3cc(cc2)C(=O)NS(=O)(=O)N(CCOCCN(C1=O)C)C,CBR-HVAC-06990: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; NS5B POLYMERASE Inhibitor;
CBR-001-585-981-1,RFM-005-261-9,CBR-001-585-981-1,CCN(C(=O)COC(=O)/C=C/C(=O)OC)CC,"CBR-HVAC-07353: Immunomodulators;Antiparkinsonian Drugs;Antipsoriatics;Multiple Sclerosis, Agents for; Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A)  Ligands;Signal Transduction Modulators;"
CBR-001-585-982-2,RFM-005-262-0,CBR-001-585-982-2,OCCCCNC(=O)OCCn1nnnc1[C@H](NC(=O)C(N)(C)C)COCc1ccccc1,CBR-HVAC-07544: Growth hormone releasing factor agonist
CBR-001-585-983-3,RFM-005-263-1,CBR-001-585-983-3,CC(c1ccc(cc1)CC(C)C)C(=O)O[Al](OC(=O)C(c1ccc(cc1)CC(C)C)C)O,CBR-HVAC-07904: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-585-984-4,RFM-005-264-2,CBR-001-585-984-4,CCCCCC(/C=C/n1cncc1)OCc1ccccc1,CBR-HVAC-08048: Thromboxane synthase inhibitor
CBR-001-585-985-5,RFM-005-265-3,CBR-001-585-985-5,NC(=Nc1scc(n1)CSCCNC1=NS(=O)(=O)N=C(N1C)N)N,CBR-HVAC-08481: Histamine H2 receptor antagonist
CBR-001-585-986-6,RFM-005-266-4,CBR-001-585-986-6,OCC1CO[Zn]O1,CBR-HVAC-08558: Unidentified pharmacological activity
CBR-001-585-987-7,RFM-005-267-5,CBR-001-585-987-7,C1CCN(CC1)CCN(c1ccccc1)Cc1ccccn1,CBR-HVAC-08616:
CBR-001-585-988-8,RFM-005-268-6,CBR-001-585-988-8,C1CCN(CC1)CCc1onc(n1)CC(c1ccccc1)c1ccccc1,CBR-HVAC-08618:
CBR-001-585-989-9,RFM-005-269-7,CBR-001-585-989-9,NC(=N)NC(=O)c1cc2c(n1C)c(ccc2C(F)(F)F)OS(=O)(=O)O,"CBR-HVAC-09278: Acute Myocardial Infarction, Treatment of;Angina pectoris, Treatment of; Na+/H+ Exchanger (NHE) Inhibitors; Sodium/hydrogen exchanger Inhibitor;"
CBR-001-585-990-2,RFM-005-270-0,CBR-001-585-990-2,NC(=N)NC(=O)c1cc2c(n1C)c(ccc2C(F)(F)F)OS(=O)(=O)O,"CBR-HVAC-09278: Acute Myocardial Infarction, Treatment of;Angina pectoris, Treatment of; Na+/H+ Exchanger (NHE) Inhibitors; Sodium/hydrogen exchanger Inhibitor;"
CBR-001-585-991-3,RFM-005-271-1,CBR-001-585-991-3,Clc1ccc(cc1/C=N/OC(C)(C)C)NC(=S)c1ccoc1C,CBR-HVAC-11032: Reverse transcriptase Inhibitor;
CBR-001-585-992-4,RFM-005-272-2,CBR-001-585-992-4,Oc1ccc(cc1)C1=CCC[C@@H](C1)CN1CCC(=CC1)c1ccccc1,CBR-HVAC-11548: Dopamine receptor D2 Agonist;
CBR-001-585-993-5,RFM-005-273-3,CBR-001-585-993-5,Brc1ccc2c(c1)ccc1c2cc(o1)[N+](=O)[O-],CBR-HVAC-11682: Antineoplastic;
CBR-001-585-994-6,RFM-005-274-4,CBR-001-585-994-6,OCc1cc(ccc1OCC1CCOCC1)S(=O)(=O)N(c1ccc(cc1)CC)CC(C)C,CBR-HVAC-12184: Retinoid RORgamma Inverse Agonists
CBR-001-586-004-5,RFM-005-275-5,CBR-001-586-004-5,Clc1ccc(c(c1)Cl)COC(c1ccc(cc1Cl)Cl)Cn1cncc1,CBR-HVAC-14399: Antagonist; Cell wall synthesis inhibitor; Glucocorticoid receptor Inhibitor; Lanosterol 14 alpha-demethylase; Sterol demethylase inhibitor; Antifungal
CBR-001-586-005-6,RFM-005-276-6,CBR-001-586-005-6,O[C@@H](C[C@H](CC(=O)O)O)CCn1c(C(C)C)c(c(c1c1ccc(cc1)F)c1ccccc1)C(=O)Nc1ccccc1,CBR-HVAC-14325: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;HMG-CoA Reductase Inhibitors;Signal Transduction Modulators;TNFSF6 Expression Inhibitors
CBR-001-586-006-7,RFM-005-277-7,CBR-001-586-006-7,OCC1OC(O[C@H]2CC[C@]3([C@H](C2)CCC2C3C(=O)[C@H]([C@]3(C2CC2C3[C@@H]([C@]3(O2)CCC(CO3)C)C)C)O)C)C(C(C1OC1OC(CO)C(C(C1O)O)O)O)O,analog of CBR-HVAC-00814(pamaqueside)
CBR-001-586-007-8,RFM-005-278-8,CBR-001-586-007-8,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccccc4c(c3Cn1c2=O)CC,CBR-HVAC-14321
CBR-001-586-008-9,RFM-005-279-9,CBR-001-586-008-9,Clc1cc2NC(Cc3ccccc3)NS(=O)(=O)c2cc1S(=O)(=O)N,CBR-HVAC-14293
CBR-001-586-009-0,RFM-005-280-2,CBR-001-586-009-0,COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC/C=C/c1ccccc1)C,"CBR-HVAC-07642: L-type calcium channel antagonist N-type calcium channel antagonist; Hypertension, Treatment of"
CBR-001-586-010-3,RFM-005-281-3,CBR-001-586-010-3,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1ccc(nc1=O)NC(=O)C,analog of CBR-HVAC-00958(PL-AC)
CBR-001-586-011-4,RFM-005-282-4,CBR-001-586-011-4,CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O,CBR-HVAC-14162
CBR-001-586-012-5,RFM-005-283-5,CBR-001-586-012-5,CN1CCC(=C(c2ccccc2)c2ccccc2)C1,analog of CBR-HVAC-01091(pridefine)
CBR-001-586-013-6,RFM-005-284-6,CBR-001-586-013-6,CCCCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C)C(=O)CO,CBR-HVAC-14163
CBR-001-586-014-7,RFM-005-285-7,CBR-001-586-014-7,NC(=O)N/N=C/1\C=C2C(O)CN(C2=CC1=O)C,"CBR-HVAC-09751: The effect of carbazochrome sodium sulphonate (AC-17) on the accumulation of tissue-type plasminogen activator antigen (t-PA:Ag) and plasminogen activator inhibitor-1 antigen (PAI-1:Ag) and modulate the fibrinolytic balance of blood through changing the function of endothelial cells,Haemostatic"
CBR-001-586-015-8,RFM-005-286-8,CBR-001-586-015-8,CCC[C@]1(CCc2ccccc2)CC(=O)C(C(=O)O1)C(c1cccc(c1)NS(=O)(=O)c1ccc(cn1)C(F)(F)F)CC,"CBR-HVAC-01630: Tipranavir inhibits the production of mature viral components by binding to the HIV-1 protease's active site, preventing the processing of viral gag and gag-pol polyprotein precursor"
CBR-001-586-016-9,RFM-005-287-9,CBR-001-586-016-9,CCOC(=O)/C=C/1\SC(C(=O)N1C)N1CCCC1,analog of CBR-HVAC-01684(piprozolin)
CBR-001-586-017-0,RFM-005-288-0,CBR-001-586-017-0,CC(N(Cc1c(Cl)cccc1NC(=O)c1ccccc1)CC(=O)N1CCOCC1)C,analog of CBR-HVAC-01767(fominoben)
CBR-001-586-018-1,RFM-005-289-1,CBR-001-586-018-1,COc1ccc2c(c1)[nH]c1c2CCN2[C@@H]1C[C@H]1[C@@H](C2)C[C@H]([C@@H]([C@H]1C(=O)OC)OC)OC(=O)/C=C/c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-14296
CBR-001-586-019-2,RFM-005-290-4,CBR-001-586-019-2,OCCN(c1nc(c(o1)c1ccccc1)c1ccccc1)CC,analog of CBR-HVAC-01971(ditazole)
CBR-001-586-020-5,RFM-005-291-5,CBR-001-586-020-5,O=C1C=C[C@]2([C@H](N1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)Nc1cc(ccc1C(F)(F)F)C(F)(F)F)C)C,"CBR-HVAC-02023: Premenstrual Syndrome, Treatment of;Contraceptives;Hair Growth Stimulants;Neuromuscular Genetic Disorders, Treatment of;Benign Prostatic Hyperplasia Therapy;Chemopreventive Agents;Prostate Cancer Therapy; Antimitotic Drugs;Steroid 5alpha-Reductase Type 1 Inhibitors;Steroid 5alpha-Reductase Type 2 Inhibitors; Steroid 5-alpha-reductase Inhibitor; 5 Alpha reductase Type I inhibitor; 5 Alpha reductase Type II inhibitor"
CBR-001-586-021-6,RFM-005-292-6,CBR-001-586-021-6,CC(CC(=O)O)CCc1ccc(cc1)I,"analog of CBR-HVAC-02363(MP-470, Covidien)"
CBR-001-586-022-7,RFM-005-293-7,CBR-001-586-022-7,C/C(=C\C=C\C(=C\C(=O)O)\C)/C=C/C1=C(C)CCCC1(C)C,CBR-HVAC-14211
CBR-001-586-023-8,RFM-005-294-8,CBR-001-586-023-8,CN[C@@H]1[C@H](O[C@@H]2[C@@H]([C@@H]1O)O[C@@H]([C@@H](C2)N)O[C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O)N)O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)N,CBR-HVAC-14192
CBR-001-586-024-9,RFM-005-295-9,CBR-001-586-024-9,CNCc1nnc2n1c1ccc(cc1C(=NC2)c1ccccc1)Cl,analog of CBR-HVAC-02456(adinazolam mesylate)
CBR-001-586-025-0,RFM-005-296-0,CBR-001-586-025-0,NCC1(CCCCC1)CC(=O)O,"CBR-HVAC-02472: CACNA2D1-protein-modulators; Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands; Calcium Channels (Voltage-Gated) alpha2/delta-2 Subunit Ligands; Calcium channel N-type; Calcium channel antagonist; GABA-receptor-agonists; P/Q-type calcium channel Blocker; Advances in the Treatment of Nausea and Migraine; Affective Disorders; Analgesic Drugs; Anticonvulsant; Antiepileptic; Antiepileptic Drugs; Anxiety Disorders; Diabetic Neuropathy, Agents for; Epilepsy and Seizure Disorders; Fibromyalgia, Treatment of; Migraine, Prophylactic Treatment of; Neurological Disorders; Neuropathic Pain, Treatment of; Pain; Psychiatric Disorders (Not Specified); Sleep Disorders, Treatment of; Smoking Cessation, Aid to; Treatment of Alcohol Dependency; Treatment of Hot Flushes; Treatment of Substance Dependency"
CBR-001-586-026-1,RFM-005-297-1,CBR-001-586-026-1,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCc1ccc(c(c1)OC)O,CBR-HVAC-14203
CBR-001-586-027-2,RFM-005-298-2,CBR-001-586-027-2,CCN1CCC(C1)CN1c2ccccc2Sc2c1cccc2,analog of CBR-HVAC-02517(methdilazine)
CBR-001-586-028-3,RFM-005-299-3,CBR-001-586-028-3,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(OC(=O)C)C(=O)C)C)C,CBR-HVAC-14161
CBR-001-586-029-4,RFM-005-300-9,CBR-001-586-029-4,CC(CCC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CCC/C/2=C\C=C/1\C[C@@H](O)CCC1=C)C)C,"CBR-HVAC-14334: Bone Diseases, Treatment of;Endocrine Disorders (Not Specified);Asthma Therapy;Prostate Cancer Therapy;Therapy of Vitamin-Related Disorders;Type 2 Diabetes, Agents for;Colorectal Cancer Therapy;Hypertension, Treatment of;Antipsychotic Drugs"
CBR-001-586-030-7,RFM-005-301-0,CBR-001-586-030-7,CCn1c(CC)nn(c1=O)CCCN1CCN(CC1)c1cccc(c1)Cl,CBR-HVAC-02657: 5 Hydroxytryptamine 2 receptor antagonist; 5-Hydroxytryptamine 1A receptor Inhibitor; Alpha adrenoreceptor antagonist; Antidepressant; Antidepressants
CBR-001-586-031-8,RFM-005-302-1,CBR-001-586-031-8,O[C@H]1CC[C@]2([C@H](C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C)C,CBR-HVAC-14316
CBR-001-586-032-9,RFM-005-303-2,CBR-001-586-032-9,O=C1CC[C@]2(C(=C1)C(=C[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(OC(=O)C)C(=O)C)C)Cl)C,CBR-HVAC-02769
CBR-001-586-033-0,RFM-005-304-3,CBR-001-586-033-0,OC[C@H]1O[C@H]([C@@H]([C@@H]1O[C@H]1O[C@@H](CN)[C@H]([C@@H]([C@H]1N)O)O)O)O[C@@H]1[C@@H](O)[C@H](N)C[C@@H]([C@H]1O[C@H]1O[C@H](CN)[C@H]([C@@H]([C@H]1N)O)O)N,CBR-HVAC-14245
CBR-001-586-034-1,RFM-005-305-4,CBR-001-586-034-1,Clc1ccc2c(c1)cc(o2)C1CCNCC1,analog of CBR-HVAC-02885(Sercloremine hydrochloride)
CBR-001-586-035-2,RFM-005-306-5,CBR-001-586-035-2,COC(=O)[C@@]1(O)C[C@]2(CC)CCCN3[C@@H]2c2n1c1ccccc1c2CC3,CBR-HVAC-14299
CBR-001-586-036-3,RFM-005-307-6,CBR-001-586-036-3,NCC1(CN)CCC(CC1)C,analog of uninteresting ligand of CBR-HVAC-08359
CBR-001-586-037-4,RFM-005-308-7,CBR-001-586-037-4,COc1ccc(cc1)[C@@H]1Sc2ccccc2N(C(=O)[C@@H]1OC(=O)C)CCN(C)C,CBR-HVAC-07740: Calcium channel antagonist
CBR-001-586-038-5,RFM-005-309-8,CBR-001-586-038-5,O=C1NC(=O)CCC1(C)c1ccncc1,analog of CBR-HVAC-03243(Rogletimide)
CBR-001-586-039-6,RFM-005-310-1,CBR-001-586-039-6,C#C[C@@]1(CCC2C1(C)CCC1C2CC[C@@H]2C1(C)CCC(C2)OC(=O)C)OC(=O)C,analog of CBR-HVAC-03248(alpha-Anordrin)
CBR-001-586-040-9,RFM-005-311-2,CBR-001-586-040-9,OCC1OC(C(C1O)O)n1cnc2c1ncnc2NCCc1ccccc1,analog of CBR-HVAC-03255(CI-936)
CBR-001-586-041-0,RFM-005-312-3,CBR-001-586-041-0,OCC1OC(C(C1O)O)n1ncc2c1ncnc2O,CBR-HVAC-03511: Antileishmanials;
CBR-001-586-042-1,RFM-005-313-4,CBR-001-586-042-1,CCCCSc1nc(c(s1)CC(=O)O)C,analog of CBR-HVAC-03512(Tiprotimod)
CBR-001-586-043-2,RFM-005-314-5,CBR-001-586-043-2,N1CCC(CC1)OCc1cccc2c1cccc2,analog of CBR-HVAC-03568(Litoxetine)
CBR-001-586-044-3,RFM-005-315-6,CBR-001-586-044-3,COc1ccc(cc1)[C@@H]1Sc2ccccc2N(C(=O)[C@@H]1OC(=O)C)CCN(C)C,"CBR-HVAC-07740: Calcium channel Blocker; Calcium channel antagonist; L-Type Calcium Channel Blockers; Angina pectoris, Treatment of; Anorectal Disorders, Treatment of; Antiarrhythmic Drugs; Antihypertensive; Hypertension, Treatment of; Treatment of Disorders of the Coronary Arteries and Atherosclerosis"
CBR-001-586-045-4,RFM-005-316-7,CBR-001-586-045-4,CCC1(OCCc2c1[nH]c1c2cccc1)CC(=O)O,analog of CBR-HVAC-03643(Pemedolac)
CBR-001-586-046-5,RFM-005-317-8,CBR-001-586-046-5,COc1cc(N)c(cc1C(=O)NC1CCN(CC1)Cc1ccc(cc1)F)Cl,analog of CBR-HVAC-03648(BRL-34778)
CBR-001-586-047-6,RFM-005-318-9,CBR-001-586-047-6,CCC1=C(C)C2=NC1=Cc1n3[Cu]n4c(=C2)c(C=C)c(c4=CC2=NC(=C(c3c(c1C)C(=O)[O-])CC(=O)[O-])C(CCC(=O)[O-])C2C)C,analog of CBR-HVAC-03651(Midoriamin)
CBR-001-586-048-7,RFM-005-319-0,CBR-001-586-048-7,OC(=O)C1CCCN(C1)CCOC(c1ccccc1)c1ccccc1,analog of CBR-HVAC-03774(BM-212)
CBR-001-586-049-8,RFM-005-320-3,CBR-001-586-049-8,O=C1CCC2(C(=C1)CCC1C2CCC2([C@@]1(O)CCC2C(=O)C)C)C,analog of CBR-HVAC-03783(NKS-01)
CBR-001-586-050-1,RFM-005-321-4,CBR-001-586-050-1,OC1CC(OC1COP(=O)(O)O)n1cc(F)c(=O)[nH]c1=O,CBR-HVAC-14269
CBR-001-586-051-2,RFM-005-322-5,CBR-001-586-051-2,OC[C@H]1O[C@H](C(C1O)O)n1c(=O)sc2c1nc(N)nc2O,CBR-HVAC-03854: Immunomodulators;Anti-Hepatitis C Virus Drugs; Signal Transduction Modulators;TLR7 Receptor Agonists; Toll like receptor 7 Agonist; Immunostimulant
CBR-001-586-052-3,RFM-005-323-6,CBR-001-586-052-3,C[C@H](Cc1ccc(cc1)OCC(=O)O)NC[C@@H](c1cccc(c1)Cl)O,CBR-HVAC-14275
CBR-001-586-053-4,RFM-005-324-7,CBR-001-586-053-4,Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)cc(cc2)C,analog of CBR-HVAC-04035(Ocaperidone)
CBR-001-586-054-5,RFM-005-325-8,CBR-001-586-054-5,CN1[C@@H]2CC[C@H]1C[C@H](C2)NC(=O)n1c(=O)n(c2c1cccc2)C(C)C,CBR-HVAC-14490: 5-Hydroxytryptamine 4 receptor Agonist; Analgesic
CBR-001-586-055-6,RFM-005-326-9,CBR-001-586-055-6,COc1ccc(cc1O)C1CC(=O)c2c(O1)cc(cc2O)O,analog of CBR-HVAC-04119(Cyrtominetin)
CBR-001-586-056-7,RFM-005-327-0,CBR-001-586-056-7,O=C(Nc1c(cccc1C(C)C)C(C)C)NCC1(CCCC1)c1ccccc1,CBR-HVAC-14229
CBR-001-586-057-8,RFM-005-328-1,CBR-001-586-057-8,O=CC[C@H]1C[C@@H](C)C(=O)/C=C/C(=CC([C@H](OC(=O)C[C@H]([C@@H]([C@H]1OC1OC(C)[C@H](C([C@H]1O)N(C)C)O)C)O)CC)CO)C,CBR-HVAC-14323
CBR-001-586-058-9,RFM-005-329-2,CBR-001-586-058-9,CNCCc1nc2c(n1CCOC)cccc2,analog of CBR-HVAC-04350(DF-1111301)
CBR-001-586-059-0,RFM-005-330-5,CBR-001-586-059-0,CC(=O)OCCOCn1cnc2c1nc(N)nc2O,analog of CBR-HVAC-04464(Acyclovir elaidate)
CBR-001-586-060-3,RFM-005-331-6,CBR-001-586-060-3,SCC(C(=O)NCC(=O)O)Cc1ccccc1,CBR-HVAC-14492: Membrane metallo endopeptidase inhibitor
CBR-001-586-061-4,RFM-005-332-7,CBR-001-586-061-4,OC(COc1cccc2c1[nH]c(n2)O)CNC(C)(C)C,CBR-HVAC-04811: Antiobesity Drugs; beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta adrenoreceptor antagonist
CBR-001-586-062-5,RFM-005-333-8,CBR-001-586-062-5,CC1OC(=O)N2C1CCc1c2ccc(c1)O,analog of CBR-HVAC-04816(SL-251131)
CBR-001-586-063-6,RFM-005-334-9,CBR-001-586-063-6,Clc1ccc(cc1)[C@H](NCCCn1cncc1)C,analog of CBR-HVAC-04969(BTS-71321)
CBR-001-586-064-7,RFM-005-335-0,CBR-001-586-064-7,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1cc(Cl)c(c2)Cl,analog of CBR-HVAC-05000(GW-275175)
CBR-001-586-065-8,RFM-005-336-1,CBR-001-586-065-8,C(CNc1c2CCCCc2nc2c1cccc2)CCNc1c2CCCCc2nc2c1cccc2,analog of CBR-HVAC-05058(Centbucridine)
CBR-001-586-066-9,RFM-005-337-2,CBR-001-586-066-9,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(C)C)CC(C)C)Cc1c[nH]c2c1cccc2)Cc1ccccc1)Cc1c[nH]c2c1cccc2)CCC(=O)N)Cc1ccccc1)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](CCCNC(=N)N)N,CBR-HVAC-14206
CBR-001-586-067-0,RFM-005-338-3,CBR-001-586-067-0,CCCCCCCC(=O)OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1ccc(nc1=O)N,analog of CBR-HVAC-05231(Elacytarabine)
CBR-001-586-068-1,RFM-005-339-4,CBR-001-586-068-1,ONC(=O)C1(CCOCC1)NS(=O)(=O)c1ccc(cc1)Oc1ccc(cc1)Cl,analog of CBR-HVAC-05271((no name))
CBR-001-586-069-2,RFM-005-340-7,CBR-001-586-069-2,Oc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@]4(O)Cc2c1[nH]c1c2cccc1)CC1CC1,CBR-HVAC-14215
CBR-001-586-070-5,RFM-005-341-8,CBR-001-586-070-5,O=C1OC(C(=C1OCC1CC1)c1ccc(cc1)S(=O)(=O)C)(C)C,CBR-HVAC-14200
CBR-001-586-071-6,RFM-005-342-9,CBR-001-586-071-6,COCCn1nc2c(c1CC)nc(nc2O)c1cc(cnc1OCC)S(=O)(=O)N1CCN(CC1)CC,analog of CBR-HVAC-05478(UK-357903)
CBR-001-586-072-7,RFM-005-343-0,CBR-001-586-072-7,COc1cc(C)c(cc1O)S(=O)C,analog of CBR-HVAC-05576(Tolmesoxide)
CBR-001-586-073-8,RFM-005-344-1,CBR-001-586-073-8,OC1CCC2([C@H](C1)CCC1C2[C@H](O)CC2(C1CCC2C(=O)C)C)C,analog of CBR-HVAC-05633(7beta-OH-EpiA)
CBR-001-586-074-9,RFM-005-345-2,CBR-001-586-074-9,COc1cccc(c1OC(=O)C)C(=O)O,analog of CBR-HVAC-05720(Dipyrocetyl)
CBR-001-586-075-0,RFM-005-346-3,CBR-001-586-075-0,OCC(CCCC(=O)C)(C)C,analog of CBR-HVAC-05752(ESP-31015)
CBR-001-586-076-1,RFM-005-347-4,CBR-001-586-076-1,CCCCC(C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O)(O)C,analog of CBR-HVAC-05787(CL-115574)
CBR-001-586-077-2,RFM-005-348-5,CBR-001-586-077-2,CCCCCCCC(=O)OCCCC,analog of CBR-HVAC-05836(Marsilin)
CBR-001-586-078-3,RFM-005-349-6,CBR-001-586-078-3,NC(=N)Nc1scc(n1)c1cccc(c1)N,analog of CBR-HVAC-05853(CL-88277)
CBR-001-586-079-4,RFM-005-350-9,CBR-001-586-079-4,CCC(NC(C(C)C)(C)C)C,analog of CBR-HVAC-05917(Iptakalim hydrochloride)
CBR-001-586-080-7,RFM-005-351-0,CBR-001-586-080-7,CSCCC(C(=O)N)NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(Cc1ccccc1)N)Cc1ccccc1)CC(C)C,analog of CBR-HVAC-05940(Substance P(8-11))
CBR-001-586-081-8,RFM-005-352-1,CBR-001-586-081-8,OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)O)n1ccc(nc1=O)N,CBR-HVAC-14176
CBR-001-586-082-9,RFM-005-353-2,CBR-001-586-082-9,COc1ccc(c(c1)C(=O)O)OCC(C(F)F)(F)F,analog of CBR-HVAC-06029(UR-1505)
CBR-001-586-083-0,RFM-005-354-3,CBR-001-586-083-0,OC(=O)C[C@@H]1NC(=O)CNC1=O,analog of CBR-HVAC-06033(Aspartyl-alanyl-diketopiperazine)
CBR-001-586-084-1,RFM-005-355-4,CBR-001-586-084-1,OC[C@H]1O[C@@H](Oc2cc3c(O)cc(cc3[o+]c2c2ccc(c(c2)O)O)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-14172
CBR-001-586-085-2,RFM-005-356-5,CBR-001-586-085-2,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NCc1ccco1,CBR-HVAC-14213
CBR-001-586-086-3,RFM-005-357-6,CBR-001-586-086-3,CCCCC1(O)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,analog of CBR-HVAC-06232(4-Hydroxyoxyphenbutazone)
CBR-001-586-087-4,RFM-005-358-7,CBR-001-586-087-4,COc1cc(/C=C/C(=O)O)ccc1OC,analog of CBR-HVAC-06249(Sodium ferulate)
CBR-001-586-088-5,RFM-005-359-8,CBR-001-586-088-5,Oc1ccc(cc1)C1COc2c(C1c1ccc(cc1)O)ccc(c2)O,analog of CBR-HVAC-06280(Triphendiol)
CBR-001-586-089-6,RFM-005-360-1,CBR-001-586-089-6,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@]2(F)[C@@H](O)C[C@]2([C@H]1CC[C@]2(O)C(=O)C)C)C,analog of CBR-HVAC-06284(Fludrocortisone)
CBR-001-586-090-9,RFM-005-361-2,CBR-001-586-090-9,CCOP(=O)(OCC)OCC,analog of CBR-HVAC-06411(MTR-104)
CBR-001-586-091-0,RFM-005-362-3,CBR-001-586-091-0,COc1cncc(c1)/C=C/CCNC(C)(C)C,analog of CBR-HVAC-06425(TC-2696)
CBR-001-586-092-1,RFM-005-363-4,CBR-001-586-092-1,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(O)nc2N,analog of CBR-HVAC-06572(Spongosine)
CBR-001-586-093-2,RFM-005-364-5,CBR-001-586-093-2,O=C(CCC(=O)O)NCCc1c[nH]cn1,analog of CBR-HVAC-07071(Dicarbamine)
CBR-001-586-094-3,RFM-005-365-6,CBR-001-586-094-3,CCc1ccc2c(c1)C=C([C@@H](O2)C(F)(F)F)C(=O)O,analog of CBR-HVAC-07130((no name))
CBR-001-586-095-4,RFM-005-366-7,CBR-001-586-095-4,COc1cc(ccc1OC(=O)C)C1Oc2cc(ccc2OC1COC(=O)C)C1Oc2cc(OC(=O)C)cc(c2C(=O)C1OC(=O)C)OC(=O)C,analog of CBR-HVAC-07165(Silibinin dihydrogen disuccinate disodium)
CBR-001-586-096-5,RFM-005-367-8,CBR-001-586-096-5,CC(=O)Oc1ccccc1C(=O)Nc1nccs1,analog of CBR-HVAC-07195(RM-5038)
CBR-001-586-097-6,RFM-005-368-9,CBR-001-586-097-6,OCC(C(=O)NC(C(=O)NC(C(=O)N)CCC(=O)N)C(C)C)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)CC1CCCCC1)CCCNC(=N)N,analog of CBR-HVAC-07287(PZ-128)
CBR-001-586-098-7,RFM-005-369-0,CBR-001-586-098-7,OC(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)[C@@]1(C)Cn1ccnn1,CBR-HVAC-14284: Beta-lactamase Inhibitor; Chloride-channel-modulators; beta-Lactamase Inhibitors; Antibacterial; Epilepsy and Seizure Disorders; Neurological Disorders; Pain; beta-Lactam Enhancers
CBR-001-586-099-8,RFM-005-370-3,CBR-001-586-099-8,OC(=O)CCCCCNC(=N)N,analog of CBR-HVAC-07394(2-iminobiotin)
CBR-001-586-100-4,RFM-005-371-4,CBR-001-586-100-4,COc1ncnc2c1nc(n2Cc1scc(c1)Br)N,analog of CBR-HVAC-07397(4-bromothenylguanine)
CBR-001-586-101-5,RFM-005-372-5,CBR-001-586-101-5,O=C1N(C)C(=O)C(c2c1cccc2)(C)C,analog of CBR-HVAC-07467(AR-03-CL)
CBR-001-586-102-6,RFM-005-373-6,CBR-001-586-102-6,COc1cc(CCNCC(COc2cc(C)ccc2Cl)O)ccc1OC,analog of CBR-HVAC-07503(B-2476)
CBR-001-586-103-7,RFM-005-374-7,CBR-001-586-103-7,COc1ccccc1c1ncc(c(n1)O)c1n[nH]nn1,analog of CBR-HVAC-07532(BL-5255)
CBR-001-586-104-8,RFM-005-375-8,CBR-001-586-104-8,C[C@H](c1ccccc1Cl)NCCCn1cncc1,analog of CBR-HVAC-07570(BTS-71-321)
CBR-001-586-105-9,RFM-005-376-9,CBR-001-586-105-9,OC1(c2ccccc2)c2ccccc2N2C1=NCCC2,analog of CBR-HVAC-07639(ciclazindol)
CBR-001-586-106-0,RFM-005-377-0,CBR-001-586-106-0,Fc1ccc(c(c1)F)[C@@H](CNC(C)(C)C)O,analog of CBR-HVAC-07829(flerobuterol)
CBR-001-586-107-1,RFM-005-378-1,CBR-001-586-107-1,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCCC(=O)O,analog of CBR-HVAC-07856(GABA linoleamide)
CBR-001-586-108-2,RFM-005-379-2,CBR-001-586-108-2,N#Cc1[nH]c(nc1C#N)c1ccc(cc1)C,analog of CBR-HVAC-08032(mefenidil)
CBR-001-586-109-3,RFM-005-380-5,CBR-001-586-109-3,CCCCC[C@@H](/C=C/[C@H]1CCC(=O)[C@@H]1CCCCCCC(=O)NC(C(=O)O)C(C)C)O,analog of CBR-HVAC-08115(ONO-1082)
CBR-001-586-110-6,RFM-005-381-6,CBR-001-586-110-6,N#Cc1cccc(c1)NS(=O)(=O)c1ccc(cc1)c1cccc(c1)N,analog of CBR-HVAC-08173(PF-915275)
CBR-001-586-111-7,RFM-005-382-7,CBR-001-586-111-7,CC(=O)OCn1ncc2c1ncnc2O,analog of CBR-HVAC-08180(Pharmaprojects No. 1718)
CBR-001-586-112-8,RFM-005-383-8,CBR-001-586-112-8,CCOC(=O)[C@](Cc1ccc(c(c1)O)O)(N)C,analog of CBR-HVAC-08212(pivaloyloxyethyl-methyldopa)
CBR-001-586-113-9,RFM-005-384-9,CBR-001-586-113-9,O=C(c1nnn[nH]1)Nc1cccc(c1O)C(=O)C,analog of CBR-HVAC-08296(RP 42068)
CBR-001-586-114-0,RFM-005-385-0,CBR-001-586-114-0,O=C(c1ccc(cc1)OCc1ccccc1)N1CCN(CC1)c1nc(N)c2c(n1)cccc2,analog of CBR-HVAC-08302(RS-4045)
CBR-001-586-115-1,RFM-005-386-1,CBR-001-586-115-1,COc1cc(ccc1OC)C(C(C)C)(CCCN1CCc2c(C1)cc(c(c2)OC)OC)C#N,analog of CBR-HVAC-08303(RS-93007)
CBR-001-586-116-2,RFM-005-387-2,CBR-001-586-116-2,CCCC(CC(=O)O)(CC(=O)O)O,analog of CBR-HVAC-08326(SC-37111)
CBR-001-586-117-3,RFM-005-388-3,CBR-001-586-117-3,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccc(cc4c(c3Cn1c2=O)CC)O,CBR-HVAC-08349: DNA topoisomerase I inhibitor
CBR-001-586-118-4,RFM-005-389-4,CBR-001-586-118-4,O=C1CCC(C(=O)N1)N1C(=O)c2c(S1(=O)=O)cccc2,analog of CBR-HVAC-08388(supidimide)
CBR-001-586-119-5,RFM-005-390-7,CBR-001-586-119-5,CCCCCCCOC(=O)Cc1c2cc(OC)ccc2n(c1C)C(=O)c1ccc(cc1)Cl,CBR-HVAC-14201
CBR-001-586-120-8,RFM-005-391-8,CBR-001-586-120-8,COc1cccc(c1)OCC1CCCCN1,analog of CBR-HVAC-08416(TC-2696)
CBR-001-586-121-9,RFM-005-392-9,CBR-001-586-121-9,CCCOC(=O)Cc1ccc(c(c1)OC)OCC(=O)N(CC)CC,CBR-HVAC-14294
CBR-001-586-122-0,RFM-005-393-0,CBR-001-586-122-0,COCCNCC(COc1ccc2c(c1)CCC(=O)N2)O,analog of CBR-HVAC-08453(toborinone)
CBR-001-586-124-2,RFM-005-394-1,CBR-001-586-124-2,CNC1CCCc2c1c(Cl)ccc2OC,analog of CBR-HVAC-08929(LOMETRALINE)
CBR-001-586-125-3,RFM-005-395-2,CBR-001-586-125-3,CCN(CCOC(=O)C(c1cccs1)(C1CCCC1)O)CC,analog of CBR-HVAC-08933(PENTHIENATE)
CBR-001-586-126-4,RFM-005-396-3,CBR-001-586-126-4,CN(CCSC(=O)N(c1ccccc1)c1ccccc1)C,analog of CBR-HVAC-08934(PHENCARBAMIDE)
CBR-001-586-127-5,RFM-005-397-4,CBR-001-586-127-5,CNCCN1CCN(C1=O)c1cccc(c1)Cl,analog of CBR-HVAC-08936(IMIDOLINE)
CBR-001-586-128-6,RFM-005-398-5,CBR-001-586-128-6,CNC1CCc2c(C1)c1cc(F)cc(c1[nH]2)F,analog of CBR-HVAC-08981(FLUCINDOLE)
CBR-001-586-129-7,RFM-005-399-6,CBR-001-586-129-7,CN1CCC2(C(C1)Cc1c(O2)c2ccccc2cc1)O,analog of CBR-HVAC-08982(NARANOL)
CBR-001-586-130-0,RFM-005-400-2,CBR-001-586-130-0,CCCCCCC1C(=O)O[C@H](C)[C@@H](C(=O)O[C@H]([C@@H]1OC(=O)CC(C)C)C)NC(=O)c1cccc(c1O)NC=O,CBR-HVAC-14236
CBR-001-586-131-1,RFM-005-401-3,CBR-001-586-131-1,CC(N1CCCC1)CC(c1ccccc1)c1ccccc1,"analog of CBR-HVAC-09067(N,N,1-TRMETHYL-3,3-DIPHENYLPROPYLAMINE)"
CBR-001-586-132-2,RFM-005-402-4,CBR-001-586-132-2,CCOC(=O)C(c1ccccc1)N1CCCCC1,analog of CBR-HVAC-09078(BIETAMIVERINE)
CBR-001-586-133-3,RFM-005-403-5,CBR-001-586-133-3,CCCSc1ccccc1N1CCN(CC1)CCCCn1c(=O)[nH]c2c(c1=O)cc(cc2)C,analog of CBR-HVAC-09136(TIOPERIDONE)
CBR-001-586-134-4,RFM-005-404-6,CBR-001-586-134-4,O(CCOCC1OC1)CCOCC1OC1,analog of CBR-HVAC-09166(ETOGLUCID)
CBR-001-586-136-6,RFM-005-405-7,CBR-001-586-136-6,CCCCc1ccc(cc1)Nc1ncccc1C(=O)O,analog of CBR-HVAC-09417(BUTANIXIN)
CBR-001-586-137-7,RFM-005-406-8,CBR-001-586-137-7,CC(=O)C(=Cc1ccccc1)C(=O)C,analog of CBR-HVAC-09424(BALAZIPONE)
CBR-001-586-138-8,RFM-005-407-9,CBR-001-586-138-8,O[Hg]CC(CNC(=O)c1ccccc1OCC(=O)O)OC,"CBR-HVAC-09614: The stimulatory effect of mersalyl on renin secretion was rapid, reversible and concentration dependent. The stimulation was not dependent on the presence of ions such as Na+, Cl- and Ca++, and it was unaffected by inhibitors of Na+/K+/2Cl- cotransport, such as bumetanide and furosemide;"
CBR-001-586-139-9,RFM-005-408-0,CBR-001-586-139-9,CCC1(CC)C(=O)CCNC1=O,analog of CBR-HVAC-09620(METHYPRYLON)
CBR-001-586-140-2,RFM-005-409-1,CBR-001-586-140-2,COc1cc2CCN([C@@H]3c2cc1Oc1cc(ccc1O)C[C@@H]1c2c(CC[N+]1(C)C)cc(c(c2Oc1ccc(C3)cc1)O)OC)C,CBR-HVAC-14310
CBR-001-586-141-3,RFM-005-410-4,CBR-001-586-141-3,CCC(=O)c1ccc2c(c1)N(CCCN(C)C)c1c(S2)cccc1,analog of CBR-HVAC-09715(BUTAPERAZINE)
CBR-001-586-142-4,RFM-005-411-5,CBR-001-586-142-4,CCC(C(c1ccccc1)(C#N)CCN1CCCCC1)C,analog of CBR-HVAC-09803(ISOAMINILE)
CBR-001-586-143-5,RFM-005-412-6,CBR-001-586-143-5,CCN([C@@H]([C@H](c1ccccc1)O)C)CC,analog of CBR-HVAC-09813(ETAFEDRINE)
CBR-001-586-144-6,RFM-005-413-7,CBR-001-586-144-6,C=CC(NC(=S)NNC(=S)NC(C=C)C)C,analog of CBR-HVAC-09851(METALLIBURE)
CBR-001-586-145-7,RFM-005-414-8,CBR-001-586-145-7,OC[C@H]1O[C@@H](O)[C@@H]([C@H]([C@H]1OS(=O)(=O)O[O-])O[C@H]1O[C@@H](C(=O)O)[C@@H]([C@H]([C@@H]1O)O)O)NC(=O)C,analog of CBR-HVAC-09865(DERMATAN SULFATE)
CBR-001-586-146-8,RFM-005-415-9,CBR-001-586-146-8,CCCCN1CCC(C1C)(OC(=O)CC)c1ccccc1,analog of CBR-HVAC-09897(PRODILIDINE)
CBR-001-586-147-9,RFM-005-416-0,CBR-001-586-147-9,COC(=O)c1ccccc1Nc1c(Cl)ccc(c1Cl)C,analog of CBR-HVAC-09902(TEROFENAMATE)
CBR-001-586-148-0,RFM-005-417-1,CBR-001-586-148-0,S=C1NC(=O)C2(C(=O)N1)CCC=CC2,analog of CBR-HVAC-09908(THIALBARBITAL)
CBR-001-586-149-1,RFM-005-418-2,CBR-001-586-149-1,CCOc1c(N)cccc1C(=O)OCCN(CC)CC,analog of CBR-HVAC-09936(METABUTOXYCAINE)
CBR-001-586-150-4,RFM-005-419-3,CBR-001-586-150-4,CCC(=O)OC(c1ccccc1)(C1CCN(C1)C)CC,analog of CBR-HVAC-09997(PROHEPTAZINE)
CBR-001-586-151-5,RFM-005-420-6,CBR-001-586-151-5,COc1cc2c(cc1O)CC1c3c2c(OC)c(O)cc3CCN1C,CBR-HVAC-10037
CBR-001-586-152-6,RFM-005-421-7,CBR-001-586-152-6,OCC(c1ccc2c(c1)cc(cc2)OC)C,analog of CBR-HVAC-10085(NAPROXOL)
CBR-001-586-153-7,RFM-005-422-8,CBR-001-586-153-7,O=C(c1ccccc1)OC(c1ccccc1)CCN1CCCCC1,analog of CBR-HVAC-10115(PROPANOCAINE)
CBR-001-586-154-8,RFM-005-423-9,CBR-001-586-154-8,Clc1ccc(cc1)C1CNC(C1)C1CC1,analog of CBR-HVAC-10149(PICILOREX)
CBR-001-586-155-9,RFM-005-424-0,CBR-001-586-155-9,O=NC(CCCOc1cccc2c1cccc2)N,analog of CBR-HVAC-10211(NADOXOLOL)
CBR-001-586-156-0,RFM-005-425-1,CBR-001-586-156-0,OC(CN(C)C)CN(C)C,analog of CBR-HVAC-10295(PROLONIUM IODIDE)
CBR-001-586-157-1,RFM-005-426-2,CBR-001-586-157-1,CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO,analog of CBR-HVAC-10350(GLYCERYL BEHENATE)
CBR-001-586-158-2,RFM-005-427-3,CBR-001-586-158-2,CCN(C(=O)C1(CCNCC1)c1ccccc1)CC,analog of CBR-HVAC-10430(SAMERIDINE)
CBR-001-586-159-3,RFM-005-428-4,CBR-001-586-159-3,CC1CCN(CC1)c1ccc(cc1C(=O)C)N,analog of CBR-HVAC-10444(IMUPEDONE)
CBR-001-586-160-6,RFM-005-429-5,CBR-001-586-160-6,COc1c(OC)cc2c3c1Oc1cc4c(cc1OC)CCN([C@H]4Cc1ccc(Oc4cc(C[C@@H]3N(CC2)C)ccc4OC)cc1)C,"CBR-HVAC-13674: Antimitotic Drugs; Apoptosis stimulant; Calcium Channel Blockers; Calcium channel Antagonist; Immunosuppressant; Oxygen radical formation inhibitor; P glycoprotein inhibitor; T-type calcium channel antagonist; Anticancer; Antidiabetic Drugs; Antimalarial; Antimalarials; Antiviral Drugs; Cancer Multidrug Resistance Modulators; Colorectal Cancer Therapy; Hypertension, Treatment of; Oncolytic Drugs"
CBR-001-586-161-7,RFM-005-430-8,CBR-001-586-161-7,N#C/N=C(\c1cccnc1)/NCC(C)C,analog of CBR-HVAC-10559(KI 1769)
CBR-001-586-162-8,RFM-005-431-9,CBR-001-586-162-8,Nc1ncc(c(n1)N)c1ccccc1Cl,analog of CBR-HVAC-10565(BW 1003C87)
CBR-001-586-163-9,RFM-005-432-0,CBR-001-586-163-9,CC(=O)CCCCN1C(=O)C2N(C)C=NC2N(C1=O)C,analog of CBR-HVAC-10578(CT 1541)
CBR-001-586-164-0,RFM-005-433-1,CBR-001-586-164-0,COC1=C(C(OC1=O)CC(=O)O)c1ccccc1,analog of CBR-HVAC-10651(FR 62765)
CBR-001-586-165-1,RFM-005-434-2,CBR-001-586-165-1,O=C(CN1C(=O)c2c(C1=O)cccc2)NC1CCN(CC1)Cc1ccccc1,analog of CBR-HVAC-10699(F 7946T)
CBR-001-586-166-2,RFM-005-435-3,CBR-001-586-166-2,N#C/N=C(\Nc1cccnc1)/NC(C)C,analog of CBR-HVAC-10758(P 1060)
CBR-001-586-167-3,RFM-005-436-4,CBR-001-586-167-3,C#CCN1C(=O)NC2(C1=O)CCN(CC2)CC(C)C,analog of CBR-HVAC-10762(AF 185)
CBR-001-586-168-4,RFM-005-437-5,CBR-001-586-168-4,Nc1ccc2c(c1)nc(n2C(C)C)N1CCNCC1,analog of CBR-HVAC-10829(KB 6806)
CBR-001-586-169-5,RFM-005-438-6,CBR-001-586-169-5,OCC1OC(OCc2ccccc2)C(C(C1OC1OC(CO)C(C(C1O)OS(=O)(=O)O)O)O)O,analog of CBR-HVAC-10835(MCDS71)
CBR-001-586-170-8,RFM-005-439-7,CBR-001-586-170-8,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(I)nc2N,analog of CBR-HVAC-10876(OXETANOCIN)
CBR-001-586-171-9,RFM-005-440-0,CBR-001-586-171-9,CN1CCC2(CC1)CC(=O)C(O2)C,CBR-HVAC-14223
CBR-001-586-172-0,RFM-005-441-1,CBR-001-586-172-0,N#Cc1cc(c2ccncc2)c(nc1O)C,CBR-HVAC-02196: Phosphodiesterase 3 inhibitor; Phosphodiesterase Inhibitor; Phosphodiesterase PDE3 Inhibitors; Signal Transduction Modulators; Cardiotonic; Heart Failure Therapy; Phosphodiesterase inhibitor; Vasodilator
CBR-001-586-173-1,RFM-005-442-2,CBR-001-586-173-1,CC(Cc1noc(n1)C1CC2NC1CC2)C,analog of CBR-HVAC-11407(CMI 936)
CBR-001-586-174-2,RFM-005-443-3,CBR-001-586-174-2,COC(=O)c1cc(O)nc(n1)O,analog of CBR-HVAC-11538(YM 39558)
CBR-001-586-175-3,RFM-005-444-4,CBR-001-586-175-3,O=C(CCn1c2ccccc2c2c1nc1ccccc1n2)NCc1ccc(cc1)Cl,analog of CBR-HVAC-11816(ROB-803)
CBR-001-586-176-4,RFM-005-445-5,CBR-001-586-176-4,CCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCNC(=N)N)Cc1nc[nH]c1)Cc1ccc2c(c1)cccc2)CCCNC(=N)N)Cc1c[nH]c2c1cccc2)C(=O)N,analog of CBR-HVAC-06545(Setmelanotide)
CBR-001-586-177-5,RFM-005-446-6,CBR-001-586-177-5,Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@H]2O)C,CBR-HVAC-12175: Estrogen receptor agonist
CBR-001-586-178-6,RFM-005-447-7,CBR-001-586-178-6,OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1CCC1=CC(=O)C=C[C@]21C)F)(C)C,CBR-HVAC-00010: Arachidonic acid inhibitor; Immunosuppressant; Corticosteroid agonist
CBR-001-586-179-7,RFM-005-448-8,CBR-001-586-179-7,O=C1C=C[C@]2([C@H](N1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)NC(C)(C)C)C)C,CBR-HVAC-00096: 5 Alpha reductase Type II inhibitor
CBR-001-586-180-0,RFM-005-449-9,CBR-001-586-180-0,C/C(=C\c1ccc(cc1)C(=O)O)/c1ccc2c(c1)C(C)(C)CCC2(C)C,CBR-HVAC-00163: Retinoic acid receptor agonist
CBR-001-586-181-1,RFM-005-450-2,CBR-001-586-181-1,ClCCN1CCCOP1(=O)NCCBr,CBR-HVAC-00313:
CBR-001-586-182-2,RFM-005-451-3,CBR-001-586-182-2,OC1CCN(CC1)c1c(F)cc2c3c1CCC(n3cc(c2=O)C(=O)O)C,CBR-HVAC-00384: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-183-3,RFM-005-452-4,CBR-001-586-183-3,OC(COc1ccccc1C)CNCCOc1ccc(cc1)C(=O)N,CBR-HVAC-01039: Beta adrenoreceptor antagonist
CBR-001-586-184-4,RFM-005-453-5,CBR-001-586-184-4,CC(c1ccc(c2c(c1)c(C)cc2S(=O)(=O)O)C)C,"CBR-HVAC-01330: Antiinflammatory Ophthalmic Agents;Antiulcer Drugs;Topical Antiinflammatory Agents;Agents for Gastritis;Allergic Skin Disorders, Treatment for"
CBR-001-586-185-5,RFM-005-454-6,CBR-001-586-185-5,COC(=O)CCc1ccc(cc1)OCC(CNC(C)C)O,CBR-HVAC-01381: Receptor > GPCR > Adrenoceptor
CBR-001-586-186-6,RFM-005-455-7,CBR-001-586-186-6,N[C@@H]1CCCCN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-01449: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-187-7,RFM-005-456-8,CBR-001-586-187-7,CC1OC(C(C1O)O)n1cc(F)c(=O)[nH]c1=O,CBR-HVAC-01619: Thymidylate synthase inhibitor
CBR-001-586-188-8,RFM-005-457-9,CBR-001-586-188-8,CCCCC[C@@H](/C=C/C1[C@@H](O)C[C@H]2[C@@H]1C/C(=C\CCCC(=O)O)/O2)O,CBR-HVAC-01645: Prostaglandin IP2 receptor agonist; Platelet aggregation inhibitor
CBR-001-586-189-9,RFM-005-458-0,CBR-001-586-189-9,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(n2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-01842: Prostaglandin synthase inhibitor; Immunosuppressant; Cyclooxygenase 2 inhibitor
CBR-001-586-190-2,RFM-005-459-1,CBR-001-586-190-2,O[C@@H]([C@@H](NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,CBR-HVAC-01864: Enzyme > Polymerase; Enzyme > Protease/peptidase
CBR-001-586-191-3,RFM-005-460-4,CBR-001-586-191-3,CCOC(=O)[C@@H](N[C@H](C(=O)N1[C@H]2CCC[C@H]2C[C@H]1C(=O)O)C)CCc1ccccc1,CBR-HVAC-02029: inhibits angiotensin-converting enzyme (ACE)
CBR-001-586-192-4,RFM-005-461-5,CBR-001-586-192-4,CCOC(=O)C1=C[C@]2(CC)CCCN3[C@@H]2c2n1c1ccccc1c2CC3,CBR-HVAC-02032: Phosphodiesterase 1 inhibitor; Sodium channel antagonist
CBR-001-586-193-5,RFM-005-462-6,CBR-001-586-193-5,CCCCCOc1ccc(cc1)c1ccc(cc1)c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@H](CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC1=O)[C@H](O)C)C[C@@H](C2)O)[C@@H]([C@H](c1ccc(cc1)O)O)O)[C@H](O)C)C,"CBR-HVAC-02033: Semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-alphaD-glucan, an essential component of the fungal cell wall"
CBR-001-586-194-6,RFM-005-463-7,CBR-001-586-194-6,COc1c(N2C[C@@H]3[C@H](C2)CCCN3)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-02242: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-195-7,RFM-005-464-8,CBR-001-586-195-7,N[C@H](c1ccccc1)C(=O)N[C@@H]1C(=O)N2C1SCC(=C2C(=O)O)C,CBR-HVAC-02252: Binds with high affinity to penicillin binding proteins in the bacterial cell wall and inhibit peptidoglycan synthesis. It kills bacteria by interfering the cell wall synthesis.
CBR-001-586-196-8,RFM-005-465-9,CBR-001-586-196-8,CO/N=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)COC(=O)N)/c1ccco1,CBR-HVAC-02330: inds with high affinity to penicillin binding proteins in the bacterial cell wall and inhibit peptidoglycan synthesis.It kills bacteria by interfering the cell wall synthesis
CBR-001-586-197-9,RFM-005-466-0,CBR-001-586-197-9,OCC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C(C)C,"CBR-HVAC-02407: cholinergic receptor, muscarinic"
CBR-001-586-198-0,RFM-005-467-1,CBR-001-586-198-0,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN([C@@H]1N2C)C,CBR-HVAC-02441: Acetylcholinesterase inhibitor
CBR-001-586-199-1,RFM-005-468-2,CBR-001-586-199-1,COc1cc(CCNC[C@@H](c2ccc(cc2)O)O)ccc1OC,CBR-HVAC-02928: Beta adrenergic receptor agonist
CBR-001-586-200-7,RFM-005-469-3,CBR-001-586-200-7,OCC1OC(C(C1O)O)n1cnc(n1)C(=O)N,CBR-HVAC-03077: Inosine monophosphate dehydrogenase inhibitor
CBR-001-586-201-8,RFM-005-470-6,CBR-001-586-201-8,CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)C1CCCC1,CBR-HVAC-04056: Thiazide diuretic; Adenosine receptor antagonist
CBR-001-586-202-9,RFM-005-471-7,CBR-001-586-202-9,C1COc2c(O1)cccc2N1CCN(CC1)C1Cc2c(C1)cccc2,CBR-HVAC-04335: 5 Hydroxytryptamine 1A receptor antagonist; 5 Hydroxytryptamine 1A receptor agonist
CBR-001-586-203-0,RFM-005-472-8,CBR-001-586-203-0,OC[C@H]1O[C@H](C(C1O)O)n1cnc2c1nc(nc2N)n1ncc(c1)C(=O)NC,CBR-HVAC-05347: Adenosine A2a receptor agonist
CBR-001-586-205-2,RFM-005-473-9,CBR-001-586-205-2,N#Cc1ccc(c(c1Cl)C)N1C(=O)[C@H]2N(C1=O)CC[C@H]2O,CBR-HVAC-06047: Androgen receptor modulator; Androgen receptor agonist
CBR-001-586-206-3,RFM-005-474-0,CBR-001-586-206-3,[O-][N+](=O)c1cc(ccc1I)C(=O)N,CBR-HVAC-06386: Poly (ADP-ribose) polymerase 1 inhibitor
CBR-001-586-207-4,RFM-005-475-1,CBR-001-586-207-4,OC[C@H](C(C(F)(F)F)C(F)(F)F)NS(=O)(=O)c1ccc(s1)Cl,CBR-HVAC-06518: Secretase gamma inhibitor
CBR-001-586-208-5,RFM-005-476-2,CBR-001-586-208-5,O[C@H]1C[C@@H](C[C@H]1COS(=O)(=O)N)n1ccc2c1ncnc2N[C@H]1CCc2c1cccc2,CBR-HVAC-06604: NEDD8-ACTIVATING ENZYME INHIBITOR
CBR-001-586-209-6,RFM-005-477-3,CBR-001-586-209-6,OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1cnc2c1ncnc2O,CBR-HVAC-10353:
CBR-001-586-210-9,RFM-005-478-4,CBR-001-586-210-9,CCc1nc(N)nc(c1c1ccc(cc1)Cl)N,"CBR-HVAC-02443: Amyotrophic Lateral Sclerosis, Agents for;Therapy of Inborn Errors of Metabolism;Antimalarials;Treatment of Protozoal Diseases;Lymphocytic Leukemia Therapy;Treatment of Renal Diseases; Dihydrofolate Reductase (DHFR) Inhibitors;Pharmacological Chaperones;Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators; Dihydrofolate reductase Inhibitor; Hexosaminidase stimulant"
CBR-001-586-211-0,RFM-005-479-5,CBR-001-586-211-0,CCCCCN(CCC(P(=O)(O)O)(P(=O)(O)O)O)C,"CBR-HVAC-02819: Analgesic Drugs;Prostate Cancer Therapy;Breast Cancer Therapy;Treatment of Osteoporosis;Treatment of Hypercalcemia;Bone Diseases, Treatment of;Bone Resorption Inhibitors; Farnesyl diphosphate synthase Inhibitor; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor"
CBR-001-586-212-1,RFM-005-480-8,CBR-001-586-212-1,CCCN1CCC[C@H](C1)c1cccc(c1)O,CBR-HVAC-00533: Antipsychotic Drugs;Antiparkinsonian Drugs; Dopamine Receptor Agonists;Signal Transduction Modulators; Dopamine receptor D2 Partial Agonist; Dopamine receptor antagonist
CBR-001-586-213-2,RFM-005-481-9,CBR-001-586-213-2,C[C@@H]([C@@H](c1ccc(c(c1)O)O)O)N,CBR-HVAC-09609:
CBR-001-586-214-3,RFM-005-482-0,CBR-001-586-214-3,O[C@@H](c1cc(nc2c1cccc2C(F)(F)F)C(F)(F)F)[C@H]1CCCCN1,CBR-HVAC-01468: Antimalarials; Pannexin 1 (PANX1) Inhibitors; Acidifying agent non gastric; Calmodulin antagonist
CBR-001-586-215-4,RFM-005-483-1,CBR-001-586-215-4,OC(=O)[C@H]1NC[C@@H](C1)Cc1cccc(c1)F,"CBR-HVAC-06080: Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands; Calcium channel antagonist; Calcium-channel-antagonists; GABA-receptor-agonists; GABAA receptor delta subunit inhibitor; Voltage-dependent calcium channel alpha 2/delta antagonist; Analgesic; Neuropathic Pain, Treatment of; Pain"
CBR-001-586-216-5,RFM-005-484-2,CBR-001-586-216-5,OCc1cc(F)cnc1,"CBR-HVAC-05834: Cholesterol inhibitor; Lipoprotein Disorders, Treatment of"
CBR-001-586-217-6,RFM-005-485-3,CBR-001-586-217-6,C[C@H](Cc1c[nH]cn1)N,"CBR-HVAC-05402: Migraine, Prophylactic Treatment of; Histamine H3 Receptor Agonists;Signal Transduction Modulators; Histamine H3 receptor antagonist; Histamine H4 receptor antagonist"
CBR-001-586-218-7,RFM-005-486-4,CBR-001-586-218-7,O[C@@H]1[C@H](O)[C@@]2(C([C@H]1CC2)(C)C)C,CBR-HVAC-06549: Dermatologic Drugs;
CBR-001-586-219-8,RFM-005-487-5,CBR-001-586-219-8,NCC(=O)CCC(=O)OC,"CBR-HVAC-01505: Premalignant Conditions Therapy;Actinic Keratoses, Agents for;Acne Therapy;Basal Cell Carcinoma Therapy;Squamous Cell Carcinoma Therapy; Oxidizing agent"
CBR-001-586-220-1,RFM-005-488-6,CBR-001-586-220-1,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ccnc2N,CBR-HVAC-03414: Immunosuppressants;Antiarthritic Drugs;Disease-Modifying Anti-Rheumatic Drugs; Adenosylhomocysteinase inhibitor; Immunosuppressant
CBR-001-586-221-2,RFM-005-489-7,CBR-001-586-221-2,CN1C(=O)NC(C1=O)c1ccccc1,CBR-HVAC-09118:
CBR-001-586-222-3,RFM-005-490-0,CBR-001-586-222-3,CCCCCCCCCCCCCCCCCC[S+](c1ccccc1C(=O)OCC)CCC,CBR-HVAC-07399:
CBR-001-586-223-4,RFM-005-491-1,CBR-001-586-223-4,Oc1ncc(c(n1)O)F,CBR-HVAC-01470: ; Thymidylate synthase Inhibitor; RNA synthesis inhibitor; Thymidylate synthase inhibitor; DNA synthesis inhibitor
CBR-001-586-224-5,RFM-005-492-2,CBR-001-586-224-5,Fc1cnc(nc1)O,CBR-HVAC-00149: Oncolytic Drugs; Antimetabolites; Thymidylate synthase inhibitor
CBR-001-586-225-6,RFM-005-493-3,CBR-001-586-225-6,O[C@@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,CBR-HVAC-00228: Treatment of Opioid Dependency;Gastrointestinal Disorders (Not Specified); Opioid Receptor Antagonists;Signal Transduction Modulators; Opioid receptor Antagonist; Opioid receptor antagonist
CBR-001-586-226-7,RFM-005-494-4,CBR-001-586-226-7,NC[C@@H]1O[C@@H](Cc2c1ccc(c2O)O)C12CC3CC(C2)CC(C1)C3,CBR-HVAC-10548: Antiparkinsonian Drugs; Dopamine D1 Agonists;Signal Transduction Modulators; Dopamine receptor D1 Agonist;
CBR-001-586-227-8,RFM-005-495-5,CBR-001-586-227-8,C#Cc1cccc2c1c(cn2C(=O)N(C)C)C(=O)c1ccc(c(c1)F)Cn1c(C)nc2c1ccnc2,CBR-HVAC-04759: ; Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Platelet activating factor receptor Inhibitor; Platelet activating factor antagonist; Elastase inhibitor
CBR-001-586-228-9,RFM-005-496-6,CBR-001-586-228-9,Cc1ccc(nc1)c1ccc(cn1)C,CBR-HVAC-07140: Acne Therapy;Antiinfectives (Not Specified); MMP-2 (Gelatinase A) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;
CBR-001-586-229-0,RFM-005-497-7,CBR-001-586-229-0,CC(=O)O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CC=C2c2cccnc2)C)C1)C,"CBR-HVAC-02099: Prostate Cancer Therapy;Congenital Malformations, Treatment of;Breast Cancer Therapy; Androgen Biosynthesis Inhibitors;Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors;Signal Transduction Modulators; Steroid 17-alpha-hydroxylase/17,20 lyase Inhibitor; 17,20 lyase inhibitor; Steroid synthesis inhibitor"
CBR-001-586-230-3,RFM-005-498-8,CBR-001-586-230-3,CN1CCC[C@H]1c1onc(c1)C,"CBR-HVAC-04551: Alzheimer's Dementia, Treatment of ;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Nicotinic Receptor Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor Agonist; Neuronal nicotinic receptor agonist"
CBR-001-586-231-4,RFM-005-499-9,CBR-001-586-231-4,Fc1ccc(cc1)C(c1nc(Nc2n[nH]c(c2)C)c2c(n1)cccc2)O,"CBR-HVAC-07057: Rheumatoid Arthritis, Treatment of;Treatment of Autoimmune Diseases; Jak2 Inhibitors;Signal Transduction Modulators; Janus kinase 2 Inhibitor;"
CBR-001-586-232-5,RFM-005-500-5,CBR-001-586-232-5,OC[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H]([C@@H]([C@H]2O)O)O)[C@@H]([C@H]([C@@H]1O[C@H]1O[C@H](C)[C@H]([C@@H]([C@H]1O)O)N[C@H]1C=C(CO)[C@H]([C@@H]([C@H]1O)O)O)O)O,"CBR-HVAC-02950: Type 2 Diabetes, Agents for; alpha-Glucosidase Inhibitors; Alpha amylase Inhibitor;"
CBR-001-586-233-6,RFM-005-501-6,CBR-001-586-233-6,CCCC(=O)Nc1ccc(c(c1)C(=O)C)OCC(CNC(C)C)O,"CBR-HVAC-02151: Hypertension, Treatment of;Antiarrhythmic Drugs;Angina pectoris, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-1 adrenergic receptor Antagonist; Beta 1 adrenoreceptor antagonist"
CBR-001-586-234-7,RFM-005-502-7,CBR-001-586-234-7,NC(=O)C[C@H](C(=O)O)NC(=O)C,CBR-HVAC-07417: ; Antacid
CBR-001-586-235-8,RFM-005-503-8,CBR-001-586-235-8,CC(=O)Nc1ccc(cc1)OC(=O)c1ccccc1O,CBR-HVAC-10176:
CBR-001-586-236-9,RFM-005-504-9,CBR-001-586-236-9,CC(=O)O[C@@H]1CC[C@]2([C@H]([C@@]1(C)C(=O)O)CC[C@@]1([C@@H]2CC=C2[C@@]1(C)CC[C@@]1([C@H]2[C@@H](C)[C@H](C)CC1)C)C)C,CBR-HVAC-03878: Antiarthritic Drugs;
CBR-001-586-237-0,RFM-005-505-0,CBR-001-586-237-0,N[C@H](C(=O)O)[C@H]1ONC(=C1)Cl,CBR-HVAC-02543: Oncolytic Drugs; gamma-Glutamyltransferase Inhibitors; Gamma-glutamyl transpeptidase Inhibitor; Carbamoyl phosphate synthetase 2 inhibitor; Protein synthesis inhibitor
CBR-001-586-238-1,RFM-005-506-1,CBR-001-586-238-1,COc1ccc(cc1)CC(=O)NC(=C)C(=O)O,CBR-HVAC-07420: Hepatoprotectants; Radical formation inhibitor
CBR-001-586-239-2,RFM-005-507-2,CBR-001-586-239-2,CC1NC(=O)C2(NC1=O)CCCC2,"CBR-HVAC-00500: Ulcers of the Extremities, Agents for;Antiulcer Drugs; Dopamine receptor Agonist; Dopamine receptor agonist"
CBR-001-586-240-5,RFM-005-508-3,CBR-001-586-240-5,C=CCOc1ccc(cc1Cl)CC(=O)O,CBR-HVAC-01948: ; Prostaglandin G/H synthase 1 Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-586-241-6,RFM-005-509-4,CBR-001-586-241-6,CO[C@H](C(=O)O)Cc1ccc(c2c1scc2)OCCc1nc(oc1C)c1ccccc1,"CBR-HVAC-05844: Type 2 Diabetes, Agents for; PPARalpha Agonists;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma Agonist; Agonist; Peroxisome proliferator-activated receptor alpha/gamma agoni; Insulin sensitizer"
CBR-001-586-242-7,RFM-005-510-7,CBR-001-586-242-7,COc1cc2nc(nc(c2cc1OC)N)N(CCCNC(=O)C1CCCO1)C,CBR-HVAC-02154: Benign Prostatic Hyperplasia Therapy;Urologic Drugs; alpha1-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist
CBR-001-586-243-8,RFM-005-511-8,CBR-001-586-243-8,O=C1c2ccccc2C(=O)c2c1ccc(c2O)O,CBR-HVAC-10322:
CBR-001-586-244-9,RFM-005-512-9,CBR-001-586-244-9,O=Cc1cc(n(c1C)CCNC(=O)C)C,"CBR-HVAC-03804: Cognition Disorders, Treatment of; AMPA receptor antagonist"
CBR-001-586-245-0,RFM-005-513-0,CBR-001-586-245-0,C[C@@H]1C(=O)O[C@H]2[C@H]1CC[C@@]1(C2=C(C)C(=O)C=C1)C,CBR-HVAC-10130: ; 15-Lipoxygenase Inhibitor;
CBR-001-586-246-1,RFM-005-514-1,CBR-001-586-246-1,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=S)[nH]c2c(c1=O)cccc2,CBR-HVAC-07447: ; 5 Hydroxytryptamine 2 receptor antagonist; Collagen stimulant
CBR-001-586-247-2,RFM-005-515-2,CBR-001-586-247-2,OC(=O)CNC(=O)[C@@H](Cc1ccccc1)CN1CC[C@@]([C@H](C1)C)(C)c1cccc(c1)O,"CBR-HVAC-01920: Disorders Associated with Cancer Therapy, Treatment of;Gastrointestinal Disorders (Not Specified);Irritable Bowel Syndrome, Agents for;Constipation, Agents for; mu-Opioid Antagonists;Signal Transduction Modulators; Opioid receptor mu Antagonist; Opioid mu receptor antagonist"
CBR-001-586-248-3,RFM-005-516-3,CBR-001-586-248-3,CC(=O)OCC(=O)[C@@]12OC3(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1CCC1=CC(=O)C=C[C@]21C)F)CCCC3,"CBR-HVAC-02005: Dermatologic Drugs;Atopic Dermatitis, Agents for; Corticosteroid agonist; Arachidonic acid inhibitor; Immunosuppressant"
CBR-001-586-249-4,RFM-005-517-4,CBR-001-586-249-4,CCOC(=O)COc1ccc2c(c1)C[C@H](CC2)NC[C@@H](c1cccc(c1)Cl)O,"CBR-HVAC-03931: Generalized Anxiety Disorder (GAD), Treatment of;Antidepressants;Agents for Liver Cirrhosis; beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-3 adrenergic receptor Agonist; Beta 3 adrenoreceptor agonist"
CBR-001-586-250-7,RFM-005-518-5,CBR-001-586-250-7,NCCCNCCSP(=O)(O)O,"CBR-HVAC-01911: Treatment of Mucositis;Radioprotectants/Radiomitigators;Myelodysplastic Syndrome Therapy;Cancer Associated Disorders, Treatment of;Chemoprotective Agents;Liver Cancer Therapy; Oxygen scavenger; Reducing agent; Free radical scavenger"
CBR-001-586-251-8,RFM-005-519-6,CBR-001-586-251-8,CCC1(CCC(=O)NC1=O)c1ccc(cc1)N,"CBR-HVAC-01633: Cushing's Syndrome, Agents for;Breast Cancer Therapy;Prostate Cancer Therapy; Antiglucocorticoids;Aromatase Inhibitors;Signal Transduction Modulators; CYP19A1 Inhibitor; Corticosteroid antagonist; Steroid synthesis inhibitor"
CBR-001-586-252-9,RFM-005-520-9,CBR-001-586-252-9,CN(C(C(=O)Nc1c(C)n(n(c1=O)c1ccccc1)C)C)C,CBR-HVAC-09958:
CBR-001-586-253-0,RFM-005-521-0,CBR-001-586-253-0,OC[C@H]([C@H]1O[C@H]2[C@@H]([C@H]1OCCCN(C)C)OC(O2)(C)C)O,"CBR-HVAC-02975: Immunomodulators;Antiarthritic Drugs;Rheumatoid Arthritis, Treatment of; CD8 antagonist"
CBR-001-586-254-1,RFM-005-522-1,CBR-001-586-254-1,CC(CCOC(c1ccccc1)CN1CCCC1)C,CBR-HVAC-10330:
CBR-001-586-255-2,RFM-005-523-2,CBR-001-586-255-2,OC(=O)[C@@H](O)C,CBR-HVAC-02398: Dermatologic Drugs; Unidentified pharmacological activity
CBR-001-586-256-3,RFM-005-524-3,CBR-001-586-256-3,Clc1ccc2c(c1)C(=Nc1c(O2)cccc1)N1CCNCC1,CBR-HVAC-01257: Antipsychotic Drugs; Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors;5-HT2A Antagonists; 5-Hydroxytryptamine 2 receptor Antagonist; Tricyclic antidepressant; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-586-257-4,RFM-005-525-4,CBR-001-586-257-4,CCNC(=O)N1CCN(CC1)CCCC(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-03367: Non-Opioid Analgesics;Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; 5-Hydroxytryptamine 2 receptor Antagonist; Dopamine D2 receptor antagonist
CBR-001-586-258-5,RFM-005-526-5,CBR-001-586-258-5,Nc1cccc(c1)n1ccccc1=O,CBR-HVAC-10331:
CBR-001-586-259-6,RFM-005-527-6,CBR-001-586-259-6,O[C@@H]1[C@@H](COP(=O)(OP(=O)(OP(=O)(O)[O-])[O-])O)O[C@H]([C@@H]1O)n1cnc2c1ncnc2N,CBR-HVAC-02323: ; Hypercalcaemic agent
CBR-001-586-260-9,RFM-005-528-7,CBR-001-586-260-9,COc1ccccc1OC(=O)CNC(=O)Cc1ccc(n1C)C(=O)c1ccc(cc1)C,"CBR-HVAC-01851: Rheumatoid Arthritis, Treatment of;Non-Opioid Analgesics;Osteoarthritis, Treatment of; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-586-261-0,RFM-005-529-8,CBR-001-586-261-0,CCCC(=O)OCOC(=O)C(C)(C)C,CBR-HVAC-04230: Melanoma Therapy;Non-Small Cell Lung Cancer Therapy;Liver Cancer Therapy;Lymphocytic Leukemia Therapy;Immunomodulators; Angiogenesis Inhibitors;Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors; HISTONE DEACETYLASE Inhibitor; Histone deacetylase inhibitor; Apoptosis stimulant; Cell cycle inhibitor
CBR-001-586-262-1,RFM-005-530-1,CBR-001-586-262-1,N#C[C@@H]1CCCN1C(=O)CNC(CNC(=O)c1cnc2n(c1)nc(c2)C)(C)C,"CBR-HVAC-06422: Type 2 Diabetes, Agents for; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators;"
CBR-001-586-263-2,RFM-005-531-2,CBR-001-586-263-2,O=C(N1CCC[C@](C1)(Cc1ccccc1)C(=O)N(N(C)C)C)[C@H](NC(=O)C(N)(C)C)Cc1c[nH]c2c1cccc2,CBR-HVAC-00874: Growth hormone secretagogue receptor agonist
CBR-001-586-264-3,RFM-005-532-3,CBR-001-586-264-3,N#CC(c1cc(cc(c1)C(C#N)(C)C)Cn1ncnc1)(C)C,"CBR-HVAC-02111: Pulmonary Hypertension, Treatment of;Non-Small Cell Lung Cancer Therapy;Treatment of Aberrations of Pubertal Development;Breast Cancer Therapy;Female Infertility, Agents for;Treatment of Male Sexual Dysfunction; Aromatase Inhibitors; Non-steroidal Aromatase Inhibitor; Aromatase inhibitor"
CBR-001-586-265-4,RFM-005-533-4,CBR-001-586-265-4,OC[C@H]1O[C@@H]2[C@H]([C@@H]1O)Oc1n2ccc(=N)n1,CBR-HVAC-03074:
CBR-001-586-266-5,RFM-005-534-5,CBR-001-586-266-5,CC(=O)Nc1ccc(cc1)OC[C@@](C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-])(O)C,CBR-HVAC-05518: Treatment of Osteoporosis;Treatment of Hypogonadism;Treatment of Cachexia; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators;
CBR-001-586-267-6,RFM-005-535-6,CBR-001-586-267-6,CNC(=O)Oc1ccccc1C(=O)Nc1ccccc1,CBR-HVAC-09400:
CBR-001-586-268-7,RFM-005-536-7,CBR-001-586-268-7,OC[C@H](c1ccccc1)C(=O)O[C@H]1C[C@H]2C[C@@H]([C@@H](C1)N2C)O,"CBR-HVAC-05640: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Pulmonary Emphysema, Agents for;Acute Respiratory Distress Syndrome (ARDS), Agents for;Diabetic Retinopathy, Agents for; Lipid Peroxidation Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors;"
CBR-001-586-269-8,RFM-005-537-8,CBR-001-586-269-8,NCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@H](Cc2ccc(cc2)OCC)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)[C@H](O)C)[C@H](CC)C,CBR-HVAC-02565: Tocolytics; Oxytocin (OT) Antagonists;Signal Transduction Modulators; OXYTOCIN RECEPTOR; VASOPRESSIN V1A RECEPTOR Antagonist; Oxytocin receptor antagonist; Calcium channel antagonist; Prostaglandin E2 receptor antagonist
CBR-001-586-270-1,RFM-005-538-9,CBR-001-586-270-1,O=C(c1ccccc1Nc1ccnc2c1ccc(c2)C(F)(F)F)OCCN1CCN(CC1)c1cccc(c1)C(F)(F)F,CBR-HVAC-02663: ; 5-Hydroxytryptamine receptor Stimulator; Cyclooxygenase inhibitor
CBR-001-586-271-2,RFM-005-539-0,CBR-001-586-271-2,OC(=O)Cc1c(nc(nc1N(C)C)Cc1ccc(cc1)NC(=O)c1ccc(cc1)C(F)(F)F)N(C)C,CBR-HVAC-08576: ; DP2 RECEPTOR Antagonist;
CBR-001-586-272-3,RFM-005-540-3,CBR-001-586-272-3,O=C(N1CCOCC1)CCc1sc2c(c1)C(=NCc1n2c(C)nn1)c1ccccc1Cl,"CBR-HVAC-11090: Pancreatic Disorders, Treatment of;Antiallergic Ophthalmic Agents; Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Platelet activating factor receptor Antagonist;"
CBR-001-586-273-4,RFM-005-541-4,CBR-001-586-273-4,N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1NCc1ccncc1,CBR-HVAC-06312: Solid Tumors Therapy;Gastric Cancer Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Liver Cancer Therapy;Breast Cancer Therapy; Angiogenesis Inhibitors;RET Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors;
CBR-001-586-274-5,RFM-005-542-5,CBR-001-586-274-5,CCc1cccc(c1)N(C(=N)Nc1cccc2c1cccc2)C,"CBR-HVAC-10404: Stroke, Treatment of;Antiparkinsonian Drugs; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-586-275-6,RFM-005-543-6,CBR-001-586-275-6,O=C(NC12CC3CC(C2)CC(C1)C3)NC1CCN(CC1)C(=O)C,"CBR-HVAC-00506: Type 2 Diabetes, Agents for;Ischemic Stroke, Treatment of;Hypertension, Treatment of; Soluble Epoxide Hydrolase Inhibitors; SOLUBLE EPOXIDE HYDROLASE Inhibitor; Epoxide hydrolase inhibitor"
CBR-001-586-276-7,RFM-005-544-7,CBR-001-586-276-7,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,CBR-HVAC-05665: Anti-HIV Agents; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP4F2 Inhibitors;
CBR-001-586-277-8,RFM-005-545-8,CBR-001-586-277-8,OC(CSc1scc(n1)c1ccc(s1)C(=O)N)CNC(C)(C)C,"CBR-HVAC-02122: Antiarrhythmic Drugs;Hypertension, Treatment of;Tardive Dyskinesia, Treatment of;Angina pectoris, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-3 adrenergic receptor Agonist; Antagonist; Alpha adrenoreceptor antagonist; Beta adrenoreceptor antagonist"
CBR-001-586-278-9,RFM-005-546-9,CBR-001-586-278-9,OCC(C1OC(=O)C(=O)C1O)O,CBR-HVAC-09540: ; Alpha-amylase; Tyrosinase Inhibitor;
CBR-001-586-279-0,RFM-005-547-0,CBR-001-586-279-0,COc1ccc(cc1)CCN1CCC(CC1)Nc1nc2c(n1Cc1ccc(cc1)F)cccc2,CBR-HVAC-02836: Drugs for Allergic Rhinitis;Antimalarials; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Inhibitor; Histamine H1 receptor antagonist
CBR-001-586-280-3,RFM-005-548-1,CBR-001-586-280-3,COC(=O)N[C@@H](C(C)(C)C)C(=O)NN(Cc1ccc(cc1)c1ccccn1)C[C@@H]([C@H](Cc1ccccc1)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O,"CBR-HVAC-00144: Anti-HIV Agents;Type 2 Diabetes, Agents for;Type 1 Diabetes, Agents for; HIV Protease Inhibitors; Protease Inhibitor; HIV protease inhibitor"
CBR-001-586-281-4,RFM-005-549-2,CBR-001-586-281-4,CCC1(Cc2c(C1)cccc2)c1c[nH]cn1,CBR-HVAC-03487: Treatment of Male Sexual Dysfunction; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Antagonist; Alpha 2 adrenoreceptor antagonist
CBR-001-586-282-5,RFM-005-550-5,CBR-001-586-282-5,COC(=O)c1c(C)cc(c(c1O)C)OC(=O)c1c(C)cc(c(c1O)C=O)O,CBR-HVAC-10062: ; Pancreatic elastase; Trypsin Inhibitor;
CBR-001-586-283-6,RFM-005-551-6,CBR-001-586-283-6,CCCCN(C(=O)CN1C[C@@H]([C@H]([C@@H]1c1ccc(cc1)OC)C(=O)O)c1ccc2c(c1)OCO2)CCCC,"CBR-HVAC-00114: Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Brain Cancer Therapy;Prostate Cancer Therapy;Breast Cancer Therapy;Oncolytic Drugs;Diabetic Nephropathy, Agents for;Heart Failure Therapy;Renal Cancer Therapy; Angiogenesis Inhibitors;Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist; Endothelin A receptor antagonist; Angiogenesis inhibitor; Endothelin receptor antagonist"
CBR-001-586-284-7,RFM-005-552-7,CBR-001-586-284-7,NC(=O)C(c1ccccc1)(O)C,CBR-HVAC-08648:
CBR-001-586-285-8,RFM-005-553-8,CBR-001-586-285-8,OCC(c1ccccc1)C(=O)OC1CC2CCC(C1)[N+]2([O-])C,CBR-HVAC-09741: ; Muscarinic acetylcholine receptor Antagonist;
CBR-001-586-286-9,RFM-005-554-9,CBR-001-586-286-9,OC[C@@H]1CCCN1c1ncc(c(n1)NCc1ccc(c(c1)Cl)OC)C(=O)NCc1ncccn1,"CBR-HVAC-01834: Treatment of Female Sexual Dysfunction;Prevention of Premature Ejaculation;Pulmonary Hypertension, Treatment of;Treatment of Erectile Dysfunction; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 5 inhibitor"
CBR-001-586-287-0,RFM-005-555-0,CBR-001-586-287-0,CC[C@]1(C)C[C@@H](OC(=O)CSc2nnc([nH]2)N)[C@]2(C)[C@H](C)CC[C@]3([C@H]([C@@H]1O)C)[C@H]2C(=O)CC3,CBR-HVAC-00133: Antibiotics; CYTOCHROME P450 3A4 Inhibitor; Protein 70S ribosomal subunit inhibitor
CBR-001-586-288-1,RFM-005-556-1,CBR-001-586-288-1,CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@H](O[C@H]1n1ncc(=O)[nH]c1=O)COC(=O)C,CBR-HVAC-09221:
CBR-001-586-289-2,RFM-005-557-2,CBR-001-586-289-2,[N-]=[N+]=CC(=O)OC[C@@H](C(=O)O)N,CBR-HVAC-08954: ; Glutamine-fructose-6-phosphate amidotransferase Inhibitor;
CBR-001-586-290-5,RFM-005-558-3,CBR-001-586-290-5,CCN1CCc2c(CC1)nc(o2)N,"CBR-HVAC-02495: Hypertension, Treatment of; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Agonist; Alpha 2 adrenoreceptor agonist"
CBR-001-586-291-6,RFM-005-559-4,CBR-001-586-291-6,CNC1CCCN(C1)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-01789: Antibacterial Drugs; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-292-7,RFM-005-560-7,CBR-001-586-292-7,N#CC1=C[C@@]2(C)[C@H](C(C1=O)(C)C)CC[C@@]1(C2=CC(=O)[C@H]2[C@@]1(C)CC[C@@]1([C@H]2CC(C)(C)CC1)C(=O)O)C,"CBR-HVAC-00137: Inflammatory Bowel Disease, Agents for;Leukemia Therapy;Chemopreventive Agents;Stroke, Treatment of;Fibrosis, Treatment of;Solid Tumors Therapy; Angiogenesis Inhibitors;Antiinflammatory Drugs;Apoptosis Inducers;NF-kappaB (NFKB) Activators;Nitric Oxide (NO) Production Inhibitors;Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activators;PPARgamma Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor gamma; COX-2 Agonist; Inhibitor; Transcription factor Nrf2 stimulant; Reducing agent; Apoptosis stimulant"
CBR-001-586-293-8,RFM-005-561-8,CBR-001-586-293-8,OC(=O)[C@@H](c1ccc(cc1)OCc1ccc2c(n1)cccc2)C1CCCC1,"CBR-HVAC-02755: Antiallergy/Antiasthmatic Drugs;Acute Myocardial Infarction, Treatment of; Leukotriene Synthesis Inhibitors;Signal Transduction Modulators;5-Lipoxygenase-Activating Protein (FLAP) Inhibitors; 5-Lipoxygenase-activating protein Inhibitor; Five lipoxygenase activating protein antagonist"
CBR-001-586-294-9,RFM-005-562-9,CBR-001-586-294-9,O=Cc1cc(n(c1C)c1ccc(cc1)OCC(=O)O)C,CBR-HVAC-09421: ; TACE; MATRIX METALLOPEPTIDASE Inhibitor;
CBR-001-586-295-0,RFM-005-563-0,CBR-001-586-295-0,CCC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)Cl)C(=O)COC(=O)CC,"CBR-HVAC-00074: Atopic Dermatitis, Agents for;Colorectal Cancer Therapy;Antiallergy/Antiasthmatic Drugs;Immunosuppressants;Allergic Skin Disorders, Treatment for;Drugs for Allergic Rhinitis;Inflammatory Bowel Disease, Agents for;Irritable Bowel Syndrome, Agents for;Asthma Therapy;Treatment of Poisoning; Glucocorticoid receptor Agonist; Glucocorticoid agonist; Immunosuppressant"
CBR-001-586-296-1,RFM-005-564-1,CBR-001-586-296-1,CCCCC(COc1ccc(c(c1)O)c1nc(nc(n1)c1ccc(cc1)OC)c1ccc(cc1O)OCC(CCCC)CC)CC,CBR-HVAC-10335:
CBR-001-586-297-2,RFM-005-565-2,CBR-001-586-297-2,O=S1(=O)NC(Cc2ccccc2)Nc2c1cc(c(c2)C(F)(F)F)S(=O)(=O)N,CBR-HVAC-00991: ; Na+/Cl- cotransporter Inhibitor; Thiazide diuretic
CBR-001-586-298-3,RFM-005-566-3,CBR-001-586-298-3,COC(=O)C1=C(C)NC(=C([C@@H]1c1cccc(c1)[N+](=O)[O-])C(=O)O[C@@H]1CCCN(C1)Cc1ccccc1)C,"CBR-HVAC-01448: Hypertension, Treatment of;Angina pectoris, Treatment of; Calcium Channel Blockers; Calcium channel Antagonist; L-type calcium channel antagonist"
CBR-001-586-299-4,RFM-005-567-4,CBR-001-586-299-4,CCc1oc2c(c1C(=O)c1cc(Br)c(c(c1)Br)O)cccc2,CBR-HVAC-01637: Treatment of Gout;Uricosurics; Urate transporter 1 Inhibitor; Uric acid diuretic
CBR-001-586-300-0,RFM-005-568-5,CBR-001-586-300-0,CNC(=O)Oc1nc2c([nH]1)cccc2,CBR-HVAC-07520: ; Mitotic inhibitor
CBR-001-586-301-1,RFM-005-569-6,CBR-001-586-301-1,O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,CBR-HVAC-02074: Antitrypanosomals; DNA synthesis inhibitor; DNA inhibitor
CBR-001-586-302-2,RFM-005-570-9,CBR-001-586-302-2,CN(CCCOc1nn(c2c1cccc2)Cc1ccccc1)C,CBR-HVAC-02406: ; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-586-303-3,RFM-005-571-0,CBR-001-586-303-3,C[C@@H]1CC[C@]2([C@@H]([C@H]1C)C1=CC[C@H]3[C@@]([C@@]1(CC2)C)(C)CC[C@@H]1[C@]3(C)CC[C@H]([C@]1(C)C(=O)O)O)C,CBR-HVAC-03877: Antiarthritic Drugs;
CBR-001-586-304-4,RFM-005-572-1,CBR-001-586-304-4,C/C/1=C\CCC(=C)[C@@H]2[C@@H](CC1)C(C2)(C)C,CBR-HVAC-06028: Antidepressants;Antiarthritic Drugs;Antibacterial Drugs; Acetylcholinesterase (AChE) Inhibitors;Antioxidants;
CBR-001-586-305-5,RFM-005-573-2,CBR-001-586-305-5,O=C(c1ccccc1)NCCC(=O)O,CBR-HVAC-04087: ; Organic anion transporter Inhibitor;
CBR-001-586-306-6,RFM-005-574-3,CBR-001-586-306-6,OC[C@@]12CC[C@H]([C@@H]2[C@@H]2[C@](CC1)(C)[C@]1(C)CC[C@@H]3[C@]([C@H]1CC2)(C)CC[C@@H](C3(C)C)O)C(=C)C,"CBR-HVAC-06125: Lipoprotein Disorders, Treatment of ;Antiviral Drugs; ACAT 1 Inhibitors;Antioxidants;Signal Transduction Modulators;Sterol Regulatory Element Binding Protein (SREBP) Inhibitors;"
CBR-001-586-307-7,RFM-005-575-4,CBR-001-586-307-7,CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]1CC[C@H]3[C@@]([C@]1(C)CC2)(C)CC[C@@H]1[C@]3(C)CC[C@@H](C1(C)C)O)C(=O)O,CBR-HVAC-00421: ; Acyl CoA:cholesterol acyltransferase 1; Acyl CoA:cholesterol acyltransferase 2; Aminopeptidase N Inhibitor; Apoptosis stimulant
CBR-001-586-308-8,RFM-005-576-5,CBR-001-586-308-8,OC(CN1CCCCC1)CO/N=C(/c1cccnc1)\N,"CBR-HVAC-05223: Chemoprotective Agents;Antiarthritic Drugs;Radioprotectants/Radiomitigators;Acute Myocardial Infarction, Treatment of;Muscular Dystrophy, Agents for;Type 2 Diabetes, Agents for; Insulin Sensitizers;NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase; PARP) Inhibitors;Signal Transduction Modulators; Poly  ADP-ribose polymerase Inhibitor;"
CBR-001-586-309-9,RFM-005-577-6,CBR-001-586-309-9,CC#CCn1c(nc2c1c(=O)n(Cc1nc(C)c3c(n1)cccc3)c(=O)n2C)N1CCC[C@@H](C1)N,"CBR-HVAC-02261: Type 2 Diabetes, Agents for;Renal Failure, Agents for; Cytochrome P450 CYP3A4 Inhibitors;Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue"
CBR-001-586-310-2,RFM-005-578-7,CBR-001-586-310-2,CCCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2)NC(=O)NC1CCCCC1,"CBR-HVAC-10553: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor Antagonist;"
CBR-001-586-311-3,RFM-005-579-8,CBR-001-586-311-3,COC(=O)c1cc(OC)c2c(c1c1c(cc(c3c1OCO3)OC)C(=O)OC)OCO2,CBR-HVAC-03485: Anti-Hepatitis B Virus Drugs;Hepatoprotectants;
CBR-001-586-313-5,RFM-005-580-1,CBR-001-586-313-5,CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@H]([C@@H]1/C=C/[C@H](CCc1ccccc1)O)O,"CBR-HVAC-01492: Antiglaucoma Agents;Ophthalmic Drugs;Dermatological Genetic Disorders, Treatment of; Prostanoid receptor Inhibitor; Prostaglandin FP receptor agonist; Prostaglandin receptor agonist"
CBR-001-586-314-6,RFM-005-581-2,CBR-001-586-314-6,C1CN=C(N1)N/N=C/c1c2ccccc2c(c2c1cccc2)/C=N/NC1=NCCN1,CBR-HVAC-02462: Myeloid Leukemia Therapy; DNA-Intercalating Drugs; Unidentified pharmacological activity
CBR-001-586-315-7,RFM-005-582-3,CBR-001-586-315-7,O[Bi]1OC(=O)c2c(O1)cccc2,CBR-HVAC-10177:
CBR-001-586-316-8,RFM-005-583-4,CBR-001-586-316-8,COc1cnc(c2c1c(c[nH]2)C(=O)C(=O)N1CCN(CC1)C(=O)c1ccccc1)OC,CBR-HVAC-00479: Anti-HIV Agents; HIV Attachment Inhibitors; GP120env antagonist
CBR-001-586-317-9,RFM-005-584-5,CBR-001-586-317-9,COc1cccc(c1)Nc1ncnn2c1c(cc2)CN1CC[C@H]([C@@H](C1)O)N,CBR-HVAC-00478: Breast Cancer Therapy;Solid Tumors Therapy;Non-Small Cell Lung Cancer Therapy; Angiogenesis Inhibitors;EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; ERBB2; Vascular endothelial growth factor receptor 2; ERBB3; ERBB4 Antagonist; Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; Angiogenesis inhibitor; VEGFR tyrosine kinase inhibitor
CBR-001-586-318-0,RFM-005-585-6,CBR-001-586-318-0,CN1c2ccccc2CNc2c1ncnc2,"CBR-HVAC-10702: Stroke, Treatment of; Benzodiazepine receptor Agonist;"
CBR-001-586-319-1,RFM-005-586-7,CBR-001-586-319-1,Nc1ccc(cn1)C(=O)OCc1cccnc1,CBR-HVAC-07551:
CBR-001-586-320-4,RFM-005-587-8,CBR-001-586-320-4,NCc1scc(n1)c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,"CBR-HVAC-05730: Amyotrophic Lateral Sclerosis, Agents for;Antiparkinsonian Drugs;Huntington's Disease, Treatment of; Antioxidants;Cyclooxygenase (COX) Inhibitors;Lipid Peroxidation Inhibitors;Signal Transduction Modulators;Sodium Channel  Blockers; Sodium channel; COX-1; COX-2 Blocker; Inhibitor; Sodium channel antagonist; Reducing agent; Cyclooxygenase inhibitor"
CBR-001-586-321-5,RFM-005-588-9,CBR-001-586-321-5,ClC1CC2C(C1(C)CC2)(C)C,CBR-HVAC-09040:
CBR-001-586-322-6,RFM-005-589-0,CBR-001-586-322-6,CCCC[C@H](C(=O)[O-])NC(=O)[C@@H](Cc1cn(c2c1cccc2)C(=O)OC)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@H](C)CCC[C@@H]1C,"CBR-HVAC-04557: Melanoma Therapy;Hypertension, Treatment of; Endothelin ETB Receptor Antagonists;Signal Transduction Modulators; Endothelin B receptor Antagonist;"
CBR-001-586-323-7,RFM-005-590-3,CBR-001-586-323-7,Brc1c(ccc2c1nccn2)NC1=NCCN1,CBR-HVAC-09549
CBR-001-586-324-8,RFM-005-591-4,CBR-001-586-324-8,CN([C@H]1CCCC[C@@H]1NC(=O)c1ccc(cc1)Br)C,CBR-HVAC-01105: ; Opioid receptor mu Agonist; Opioid receptor agonist
CBR-001-586-325-9,RFM-005-592-5,CBR-001-586-325-9,COc1ccc(cc1)C(=O)/C(=C/C(=O)O)/Br,CBR-HVAC-03072: Oncolytic Drugs;
CBR-001-586-326-0,RFM-005-593-6,CBR-001-586-326-0,O=C1C(c2ccc(cc2)Br)C(=O)c2c1cccc2,CBR-HVAC-09111:
CBR-001-586-327-1,RFM-005-594-7,CBR-001-586-327-1,CCN(CCNC(=O)c1cc(Br)c(cc1OC)N)CC,CBR-HVAC-01670: ; Cholinesterase Blocker; Dopamine receptor antagonist
CBR-001-586-328-2,RFM-005-595-8,CBR-001-586-328-2,Clc1ccc(cc1)NC(=O)c1cc(Br)ccc1O,CBR-HVAC-09002:
CBR-001-586-329-3,RFM-005-596-9,CBR-001-586-329-3,OC(=O)[C@H](Cc1cc(Br)c(c(c1)Br)O)N,CBR-HVAC-08829:
CBR-001-586-330-6,RFM-005-597-0,CBR-001-586-330-6,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Br,CBR-HVAC-01959: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist
CBR-001-586-331-7,RFM-005-598-1,CBR-001-586-331-7,OC(c1onc(c1)Br)CNC(C)(C)C,CBR-HVAC-03245: Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-586-332-8,RFM-005-599-2,CBR-001-586-332-8,SC[C@@H](C(=O)O)NC(=O)C(S)(C)C,"CBR-HVAC-02129: Rheumatoid Arthritis, Treatment of;Disease-Modifying Anti-Rheumatic Drugs;Treatment of Gout;Immunosuppressants;Therapy of Inborn Errors of Metabolism;Osteoarthritis, Treatment of; Vascular endothelial growth factor receptor Inhibitor; Immunosuppressant; Reducing agent"
CBR-001-586-333-9,RFM-005-600-8,CBR-001-586-333-9,CCCC(=O)O[C@@H]1[C@@H]2OP(=O)(O)OC[C@H]2O[C@H]1n1cnc2c1ncnc2NC(=O)CCC,CBR-HVAC-01639: Wound-Healing Agents; Phosphodiesterase Inhibitor; Cyclic AMP stimulant; Adenosine receptor agonist
CBR-001-586-334-0,RFM-005-601-9,CBR-001-586-334-0,OC(COc1ccc(c2c1oc(=O)cc2)C)CNC(C)(C)C,"CBR-HVAC-01594: Hypertension, Treatment of;Acute Myocardial Infarction, Treatment of;Antiarrhythmic Drugs; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Membrane integrity inhibitor"
CBR-001-586-335-1,RFM-005-602-0,CBR-001-586-335-1,CCc1cccc2c1oc(c2)C(CNC(C)(C)C)O,CBR-HVAC-02487: ; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Beta 2 adrenoreceptor agonist
CBR-001-586-336-2,RFM-005-603-1,CBR-001-586-336-2,CCCCNc1cc(cc(c1Oc1ccccc1)S(=O)(=O)N)C(=O)O,CBR-HVAC-01656: Loop Diuretics;Antiepileptic Drugs; Na-K-Cl cotransporter Inhibitor; Diuretic
CBR-001-586-337-3,RFM-005-604-2,CBR-001-586-337-3,CCCCc1ccc(nc1)C(=O)N,"CBR-HVAC-05607: Hypertension, Treatment of; Unidentified pharmacological activity"
CBR-001-586-338-4,RFM-005-605-3,CBR-001-586-338-4,O[C@]1(CCN2[C@@H](C1)c1cccc3c1[C@@H](C2)c1ccccc1CC3)C(C)(C)C,CBR-HVAC-01088: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2 Antagonists; Dopamine receptor D2 Inverse Agonist; Dopamine receptor antagonist
CBR-001-586-339-5,RFM-005-606-4,CBR-001-586-339-5,CCC(c1ccccc1)C(=O)OCCOCCN(CC)CC,CBR-HVAC-01477: Asthma Therapy;Antitussives; Beta 2 adrenoreceptor agonist
CBR-001-586-340-8,RFM-005-607-5,CBR-001-586-340-8,CCCCS(=CCC(C(=O)O)N)(=O)N,CBR-HVAC-03498: Melanoma Therapy;Neurologic Cancer Therapy;Cancer Multidrug Resistance Modulators; Gamma-glutamylcysteine synthetase Inhibitor;
CBR-001-586-341-9,RFM-005-608-6,CBR-001-586-341-9,CCC(c1ccc(cc1)CC(C)C)C(=O)O,CBR-HVAC-01625: Treatment of Musculoskeletal &amp; Connective Tissue Diseases (Miscellaneous); Prostaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-586-342-0,RFM-005-609-7,CBR-001-586-342-0,COc1ccc(cc1C(C(NC(C)(C)C)C)O)OC,CBR-HVAC-10063: ; Beta-2 adrenergic receptor Antagonist;
CBR-001-586-343-1,RFM-005-610-0,CBR-001-586-343-1,OC(C(C(Cl)C)(Cl)Cl)O,CBR-HVAC-09719:
CBR-001-586-344-2,RFM-005-611-1,CBR-001-586-344-2,CCCCC1OC(=O)c2c1cccc2,CBR-HVAC-01372:
CBR-001-586-345-3,RFM-005-612-2,CBR-001-586-345-3,Clc1ccc(c(c1)Cl)C(=O)Nc1ccc(cc1C(=O)O)Oc1ncccn1,CBR-HVAC-08592: ; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma Agonist;
CBR-001-586-346-4,RFM-005-613-3,CBR-001-586-346-4,CC(=O)N(C/C=C/c1cccc(c1)Oc1ccccc1)O,CBR-HVAC-03551: Antiallergy/Antiasthmatic Drugs; Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; 5-Lipoxygenase Inhibitor; Lipoxygenase inhibitor
CBR-001-586-347-5,RFM-005-614-4,CBR-001-586-347-5,Fc1ccc(cc1)Oc1cccc(c1)/C=C/C(N(C(=O)N)O)C,CBR-HVAC-10833: Antiallergy/Antiasthmatic Drugs; Lipoxygenase Inhibitors; Lipoxygenase 5 Inhibitor;
CBR-001-586-348-6,RFM-005-615-5,CBR-001-586-348-6,O[C@H]1C[C@H](O)C(=C)/C(=C/C=C/2\CCC[C@]3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@H](C2CC2)O)C)C)/C1,CBR-HVAC-01331: Acne Therapy;Antipsoriatics;Radioprotectants/Radiomitigators; Vitamin D3 receptor Agonist; Vitamin D agonist
CBR-001-586-349-7,RFM-005-616-6,CBR-001-586-349-7,CCCCCc1cc(O)c(c(c1)O)[C@@H]1C=C(C)CC[C@H]1C(=C)C,"CBR-HVAC-02861: Brain Cancer Therapy;Antipsychotic Drugs;Rheumatoid Arthritis, Treatment of;Neurologic Drugs (Miscellaneous);Antiepileptic Drugs;Treatment of Substance Dependency;Lipoprotein Disorders, Treatment of ;Neuropathy, Treatment of ;Metabolic Disorders (Not Specified);Neuropathic Pain, Treatment of;Inflammatory Bowel Disease, Agents for;Treatment of Autoimmune Diseases;Tuberous Sclerosis, Treatment of;Neurological Genetic Disorders, Treatment of ;Glioblastoma Multiforme Therapy;Stroke, Treatment of;Neurologic Cancer Therapy;Diabetic Retinopathy, Agents for; Antioxidants;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;Cannabinoid Receptor Agonists;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;MAPK p38 Inhibitors;Signal Transduction Modulators;TRPV2 (Vanilloid VR2 Receptor) Agonists;"
CBR-001-586-350-0,RFM-005-617-7,CBR-001-586-350-0,OC(=O)CC[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2C=CC2=CC(=O)CC[C@]12C,CBR-HVAC-03162: Potassium-Sparing Diuretics; Mineralocorticoid Receptor (MR) Antagonists;Signal Transduction Modulators; Mineralocorticoid receptor Antagonist;
CBR-001-586-351-1,RFM-005-618-8,CBR-001-586-351-1,CCNC(=O)OC1CCN(CC1)c1nncc2c1cc(OC)c(c2)OC,CBR-HVAC-09276:
CBR-001-586-352-2,RFM-005-619-9,CBR-001-586-352-2,NN[C@](C(=O)O)(Cc1ccc(c(c1)O)O)C,CBR-HVAC-03076: Antiparkinsonian Drugs; Dopa decarboxylase Inhibitor;
CBR-001-586-353-3,RFM-005-620-2,CBR-001-586-353-3,OC(=O)CSC[C@@H](C(=O)O)N,"CBR-HVAC-02253: Treatment of Upper Respiratory Tract Disorders;Chronic Obstructive Bronchitis, Agents for;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Dicarbonyl/L-xylulose reductase Inhibitor; Mucolytic agent"
CBR-001-586-354-4,RFM-005-621-3,CBR-001-586-354-4,CCCCNC(=O)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-09754:
CBR-001-586-355-5,RFM-005-622-4,CBR-001-586-355-5,NC(=O)Nc1cc(ccc1O)C(CNC(C)(C)C)O,CBR-HVAC-02118: ; Beta adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-586-356-6,RFM-005-623-5,CBR-001-586-356-6,OC(=O)C(c1ccc(cc1)C(=O)CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1)(C)C,CBR-HVAC-02857: Drugs for Allergic Rhinitis;Antiallergic Ophthalmic Agents;Antiallergy/Antiasthmatic Drugs; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist
CBR-001-586-357-7,RFM-005-624-6,CBR-001-586-357-7,CC(C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(C)CO1)CC(C)C)Cc1ccccc1)NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)C,"CBR-HVAC-02139: Small Cell Lung Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy;Immunosuppressants;Lymphocytic Leukemia Therapy;Cancer of Unspecified Body Location/System;Renal Cancer Therapy;Oncolytic Drugs;Myeloid Leukemia Therapy;Multiple Myeloma Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Amyloidosis, Treatment of; Proteasome Inhibitors; PROTEASOME Inhibitor; Protease/peptidase inhibitor; Apoptosis stimulant; Proteasome inhibitor"
CBR-001-586-358-8,RFM-005-625-7,CBR-001-586-358-8,OC(=O)C(c1ccc2c(c1)[nH]c1c2cc(cc1)Cl)C,CBR-HVAC-02108: Antiarthritic Drugs; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor
CBR-001-586-359-9,RFM-005-626-8,CBR-001-586-359-9,O=c1oc2ccccc2c(=O)[nH]1,CBR-HVAC-10190: ; Poly  ADP-ribose synthetase Inhibitor;
CBR-001-586-360-2,RFM-005-627-9,CBR-001-586-360-2,NC(=O)OC[C@@H]1[C@H](NC(=O)/C(=N\OCC(=O)[O-])/c2csc(n2)N)C(=O)N1S(=O)(=O)[O-],CBR-HVAC-02163: Antibiotics; Penicillin binding protein 3 Inhibitor; Cell wall synthesis inhibitor
CBR-001-586-361-3,RFM-005-628-0,CBR-001-586-361-3,COc1ccccc1OCCNCC(COc1cccc2c1c1ccccc1[nH]2)O,CBR-HVAC-02611: ; Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor Inhibitor; Beta 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor antagonist; Alpha 1 adrenoreceptor antagonist; Reducing agent
CBR-001-586-362-4,RFM-005-629-1,CBR-001-586-362-4,Clc1ccc(cc1)c1ccc(cc1Cl)Cl,CBR-HVAC-02720:
CBR-001-586-363-5,RFM-005-630-4,CBR-001-586-363-5,C#CCOC(=O)C1CNC=NC1,"CBR-HVAC-11577: Cognition Disorders, Treatment of; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Agonist;"
CBR-001-586-364-6,RFM-005-631-5,CBR-001-586-364-6,O=CO[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C)c1ccccc1,CBR-HVAC-05806: Antibacterial Drugs;Antibiotics; Penicillin binding protein Inhibitor;
CBR-001-586-365-7,RFM-005-632-6,CBR-001-586-365-7,O=C([C@@H](c1ccc(cc1)O)N)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1c[nH]nn1,CBR-HVAC-01407: ; Cell wall synthesis inhibitor
CBR-001-586-366-8,RFM-005-633-7,CBR-001-586-366-8,Cc1nnc(s1)SCC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)Cn1cc(Cl)c(=O)c(c1)Cl,CBR-HVAC-07604: ; Cell wall synthesis inhibitor
CBR-001-586-367-9,RFM-005-634-8,CBR-001-586-367-9,CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[N+]1(C)CCCC1,CBR-HVAC-02048: Treatment of Neutropenia;Antibacterial Drugs; Cell Wall Biosynthesis Inhibitors; Cell wall synthesis inhibitor
CBR-001-586-368-0,RFM-005-635-9,CBR-001-586-368-0,N#CCSCC(=O)N[C@]1(OC)C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])CSc1nnnn1C,CBR-HVAC-02216: Antibiotics; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-586-369-1,RFM-005-636-0,CBR-001-586-369-1,CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2[C@@H]1SCC(=C2C(=O)O)COC(=O)N,CBR-HVAC-02068: Antibiotics;Antibacterial Drugs; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-586-370-4,RFM-005-637-1,CBR-001-586-370-4,CO/N=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[n+]1cccc2c1CCC2)/c1csc(n1)N,CBR-HVAC-02050: Antibacterial Drugs; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-586-371-5,RFM-005-638-2,CBR-001-586-371-5,C/C=C/C1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)[C@@H](c1ccc(cc1)O)N,CBR-HVAC-02046: Antibiotics;Antibacterial Drugs; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-586-372-6,RFM-005-639-3,CBR-001-586-372-6,O=C([C@@H](C1=CCC=CC1)N)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C,CBR-HVAC-05353: Antibiotics;Antibacterial Drugs; Penicillin binding protein; Transpeptidase Inhibitor;
CBR-001-586-373-7,RFM-005-640-6,CBR-001-586-373-7,O=C1[C@@H](NC(=O)/C(=N\OC(C(=O)O)(C)C)/c2csc(n2)N)[C@@H]2N1C(=C(CS2)C[n+]1ccccc1)C(=O)[O-],CBR-HVAC-05212: Antibiotics; Penicillin binding protein 3 Inhibitor; Cell wall synthesis inhibitor
CBR-001-586-374-8,RFM-005-641-7,CBR-001-586-374-8,Nn1cnc2c(c1=O)cc1c(c2)cccc1,CBR-HVAC-05811: Anxiolytics;Neurologic Drugs (Miscellaneous);
CBR-001-586-375-9,RFM-005-642-8,CBR-001-586-375-9,COCc1c(c2ccc(cc2)F)c(/C=C/[C@H](C[C@H](CC(=O)O)O)O)c(nc1C(C)C)C(C)C,CBR-HVAC-02841: HMGCoA reductase inhibitor
CBR-001-586-376-0,RFM-005-643-9,CBR-001-586-376-0,CSCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)CNC(=O)C([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)CCC(=O)N)CC(=O)O)Cc1ccc(cc1)OS(=O)(=O)O,"CBR-HVAC-02331: Tardive Dyskinesia, Treatment of;Oncolytic Drugs; CCK Receptor Agonists;Signal Transduction Modulators; Cholecystokinin A receptor; Cholecystokinin B receptor Activator; Activator; CCK A receptor agonist"
CBR-001-586-377-1,RFM-005-644-0,CBR-001-586-377-1,OC(=O)COCCN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1,"CBR-HVAC-01263: Antiallergy/Antiasthmatic Drugs;Allergic Skin Disorders, Treatment for;Drugs for Allergic Rhinitis;Urticaria, Treatment for;Allergy, Treatment of; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-586-378-2,RFM-005-645-1,CBR-001-586-378-2,NC[C@@H]1CC[C@H](CC1)C(=O)Oc1ccc(cc1)CCC(=O)O,CBR-HVAC-01897: Antiulcer Drugs; Protease Inhibitor; Mucus protecting agent; Gastrin inhibitor
CBR-001-586-379-3,RFM-005-646-2,CBR-001-586-379-3,[O-][N+](=O)c1cn2c(n1)OC(C2)CC,CBR-HVAC-10513: Antimycobacterial Agents;
CBR-001-586-380-6,RFM-005-647-3,CBR-001-586-380-6,NOC1CCNC(C1)C,CBR-HVAC-11902: ; Ornithine decarboxylase Inhibitor;
CBR-001-586-381-7,RFM-005-648-4,CBR-001-586-381-7,ONC(=O)[C@H](N(S(=O)(=O)c1ccc(cc1)OC)Cc1cccnc1)C(C)C,CBR-HVAC-04658: Antiarthritic Drugs;Oncolytic Drugs; Angiogenesis Inhibitors;MMP-2 (Gelatinase A) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors; Matrix metalloproteinase Inhibitor; Matrix metalloproteinase-2 inhibitor; Metalloproteinase-8 inhibitor; Matrix metalloproteinase-9 inhibitor; Stromelysin inhibitor
CBR-001-586-382-8,RFM-005-649-5,CBR-001-586-382-8,CN(CCC(c1ccccc1Cl)(c1ccccc1)O)C,CBR-HVAC-09559: ; Histamine receptor Antagonist;
CBR-001-586-383-9,RFM-005-650-8,CBR-001-586-383-9,ClCCN(c1ccc(cc1)CCCC(=O)O)CCCl,CBR-HVAC-00993: ; DNA inhibitor
CBR-001-586-384-0,RFM-005-651-9,CBR-001-586-384-0,Clc1c2C[N+](Cc2c(c(c1Cl)Cl)Cl)(C)CC[N+](C)(C)C,CBR-HVAC-09213: ; Nicotinic acetylcholine receptor Antagonist;
CBR-001-586-385-1,RFM-005-652-0,CBR-001-586-385-1,O=C(O[C@@H]1C[C@@](O)(C[C@H]([C@H]1O)O)C(=O)O)/C=C/c1ccc(c(c1)O)O,CBR-HVAC-10252: ; Glucose 6-phosphatase Inhibitor;
CBR-001-586-386-2,RFM-005-653-1,CBR-001-586-386-2,CCNC(CN1CCc2c(C1)c(=O)oc1c2cccc1)C,CBR-HVAC-03874: Bronchodilators; Anticholinergics;Signal Transduction Modulators; Acetylcholine receptor antagonist
CBR-001-586-387-3,RFM-005-654-2,CBR-001-586-387-3,OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)NC(=O)C1(N)CCCCC1,CBR-HVAC-02250: ; Penicillin binding protein Inhibitor; Cell wall synthesis inhibitor
CBR-001-586-388-4,RFM-005-655-3,CBR-001-586-388-4,Clc1ccc(cc1)C1OCc2c1cnc(c2O)C,"CBR-HVAC-00012: Diuretics;Pulmonary Hypertension, Treatment of;Hypertension, Treatment of; Histamine H1 receptor Antagonist; Prostaglandin synthase stimulant"
CBR-001-586-389-5,RFM-005-656-4,CBR-001-586-389-5,Cc1cc(C2CCCCC2)n(c(=O)c1)O,CBR-HVAC-01460: Antifungal Agents;Myeloid Leukemia Therapy; Apoptosis Inducers;Autophagy Inducers;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Signal Transduction Modulators;Wnt Signaling Inhibitors; Catalase; Peroxidase Inhibitor; Inhibitor; Membrane permeability inhibitor; Chelating agent
CBR-001-586-390-8,RFM-005-657-5,CBR-001-586-390-8,CCC(C(=O)O)(CC(=O)Nc1cccc(c1)/C=C/c1scc(n1)C1CCC1)CC,CBR-HVAC-04005: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist; Leucotriene D4 antagonist
CBR-001-586-391-9,RFM-005-658-6,CBR-001-586-391-9,CCOC(=O)CN1CCN(CC1)C(=O)/C=C/c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-01691:
CBR-001-586-392-0,RFM-005-659-7,CBR-001-586-392-0,c1ccc(cc1)/C=C/CN1CCN(CC1)C(c1ccccc1)c1ccccc1,"CBR-HVAC-03362: Treatment of Intermittent Claudication;Raynaud's Phenomenon, Treatment for ;Nausea and Vomiting, Treatment of;Migraine, Prophylactic Treatment of; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist;"
CBR-001-586-393-1,RFM-005-660-0,CBR-001-586-393-1,CCn1nc(C(=O)O)c(=O)c2c1cc1OCOc1c2,CBR-HVAC-01680: Antibacterial Drugs; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-394-2,RFM-005-661-1,CBR-001-586-394-2,OC(=O)C(Oc1ccc(cc1)C1CC1(Cl)Cl)(C)C,"CBR-HVAC-02124: Lipoprotein Disorders, Treatment of ; PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor alpha Agonist; Lipase clearing factor stimulant; Peroxisome proliferator-activated receptor alpha agonist"
CBR-001-586-395-3,RFM-005-662-2,CBR-001-586-395-3,COc1ccc2c(c1)c(nc(=O)n2CC1CC1)c1ccccc1,"CBR-HVAC-05581: Inflammation, Treatment of;Non-Opioid Analgesics;"
CBR-001-586-396-4,RFM-005-663-3,CBR-001-586-396-4,CN(C(C1CCCCC1O)c1cccc(c1)O)C,CBR-HVAC-01106: Non-Opioid Analgesics; Opioid receptor Agonist; Antagonist; Opioid mu receptor antagonist; Opioid kappa receptor agonist; Opioid delta receptor agonist
CBR-001-586-397-5,RFM-005-664-4,CBR-001-586-397-5,OC(=O)/C=C/c1c[nH]cn1,CBR-HVAC-00589: ; 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR 2A Agonist; Unidentified pharmacological activity
CBR-001-586-398-6,RFM-005-665-5,CBR-001-586-398-6,O[C@@H]1C(COP(=O)(OP(=O)(OCC[N+](C)(C)C)[O-])[O-])OC([C@@H]1O)n1ccc(nc1=O)N,"CBR-HVAC-02087: Diagnostic Agents;Neurologic Drugs (Miscellaneous);Antiparkinsonian Drugs;Ischemic Stroke, Treatment of;Treatment of Substance Dependency;Stroke, Treatment of;Cognition Disorders, Treatment of; Acetylcholinesterase (AChE) Inhibitors; Membrane permeability enhancer"
CBR-001-586-399-7,RFM-005-666-6,CBR-001-586-399-7,CCCCCCCN(C(=O)Nc1ccc(cc1F)F)Cc1ccc(cc1)CC(C)(C)C,"CBR-HVAC-03249: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor; Cholesterol inhibitor"
CBR-001-586-400-3,RFM-005-667-7,CBR-001-586-400-3,[O-]C(=O)[C@@H]1N2[C@H](O/C/1=C\CO)CC2=O,"CBR-HVAC-02636: Treatment of Erectile Dysfunction;Neurodegenerative Diseases, Treatment of;Antiparkinsonian Drugs;Antidepressants;Anxiolytics;beta-Lactam Enhancers; beta-Lactamase Inhibitors;Drugs Acting on Dopaminergic Transmission;Drugs Acting on Serotonergic Transmission;Signal Transduction Modulators; Beta-lactamase Inhibitor; Dopamine receptor agonist; 5 Hydroxytryptamine receptor agonist; Lactamase inhibitor"
CBR-001-586-401-4,RFM-005-668-8,CBR-001-586-401-4,CCC[C@H]1CN([C@@H](C1)C(=O)NC(C1O[C@H](SC)[C@@H]([C@H]([C@H]1O)O)OP(=O)(O)O)[C@@H](Cl)C)C,CBR-HVAC-01408: ; 50S-ribosomal subunit Binder; Protein 50S ribosomal subunit inhibitor
CBR-001-586-402-5,RFM-005-669-9,CBR-001-586-402-5,CCCC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F)C(=O)CCl,CBR-HVAC-02035: Topical Antiinflammatory Agents; GLUCOCORTICOID RECEPTOR Agonist; Corticosteroid agonist
CBR-001-586-403-6,RFM-005-670-2,CBR-001-586-403-6,ClC(P(=O)(O)[O-])(P(=O)(O)[O-])Cl,"CBR-HVAC-02316: Breast Cancer Therapy;Treatment of Hypercalcemia;Bone Diseases, Treatment of;Treatment of Osteoporosis;Osteoarthritis, Treatment of; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor"
CBR-001-586-404-7,RFM-005-671-3,CBR-001-586-404-7,Clc1ccc(c(c1)Cl)Cc1cc(ccc1O)C(CC(C)(C)C)(C)C,CBR-HVAC-02116: Antibacterial Drugs;Oncolytic Drugs; DNA inhibitor; RNA synthesis inhibitor; Protein synthesis inhibitor
CBR-001-586-405-8,RFM-005-672-4,CBR-001-586-405-8,NC1=NCC(O1)c1ccc(cc1)Cl,CBR-HVAC-10127:
CBR-001-586-406-9,RFM-005-673-5,CBR-001-586-406-9,COC(=O)[C@H](c1ccccc1Cl)N1CCc2c(C1)ccs2,"CBR-HVAC-00279: Antiarrhythmic Drugs;Atherosclerosis Therapy;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Thrombolytics;Peripheral Vascular Disease, Treatment of;Acute Myocardial Infarction, Treatment of;Antiplatelet Therapy;Angina pectoris, Treatment of;Stroke, Treatment of;Coagulation Disorders Therapy; P2Y12 (P2T) Antagonists;Signal Transduction Modulators; P2Y12 purinergic receptor; Thromboxane A2 synthase Antagonist; Inhibitor; Purinoreceptor P2Y12 antagonist; Platelet aggregation inhibitor; Purinoreceptor P2 antagonist"
CBR-001-586-407-0,RFM-005-674-6,CBR-001-586-407-0,Ic1cccc(c1)N(C(=N)Nc1cccc2c1cccc2)C,"CBR-HVAC-04870: Diagnostic Agents;Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators;"
CBR-001-586-408-1,RFM-005-675-7,CBR-001-586-408-1,C=C[C@@]1(C)CC(=O)[C@]2([C@@](O1)(C)[C@@H](OC(=O)C)[C@H]([C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C)OC(=O)CCN(C)C)O,CBR-HVAC-02312: ; Adenylate cyclase Stimulator; Adenylate cyclase stimulant
CBR-001-586-409-2,RFM-005-676-8,CBR-001-586-409-2,CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COP(=O)(OCC[N+](C)(C)C)[O-],"CBR-HVAC-00383: Infant Respiratory Distress Syndrome (IRDS), Treatment of; Not applicable"
CBR-001-586-410-5,RFM-005-677-9,CBR-001-586-410-5,O=C(Nc1c2CCCCc2nc2c1c(C)c(o2)C)CN1CCCC1=O,"CBR-HVAC-00564: Antidepressants;Anxiolytics;Alzheimer's Dementia, Treatment of ; Acetylcholine Release Enhancers;AMPA Receptor Agonists;Signal Transduction Modulators; AMPA RECEPTOR Enhancer; Choline uptake stimulant"
CBR-001-586-411-6,RFM-005-678-0,CBR-001-586-411-6,COc1cccc(c1)CN1C[Si](C)(C)O[Si](C1)(C)C,CBR-HVAC-07671: ; Neuromuscular nicotinic receptor antagonist
CBR-001-586-412-7,RFM-005-679-1,CBR-001-586-412-7,CCCCCCCCC(C(CCCCCCCC(=O)O)O)O,CBR-HVAC-07673:
CBR-001-586-413-8,RFM-005-680-4,CBR-001-586-413-8,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)CC(=O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-06097: Antiallergy/Antiasthmatic Drugs;Antiarthritic Drugs;Respiratory Disorders (Not Specified);Endocrine Disorders (Not Specified);
CBR-001-586-414-9,RFM-005-681-5,CBR-001-586-414-9,CC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)CC(=O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-06842: Endocrine Disorders (Not Specified);Respiratory Disorders (Not Specified);Antiallergy/Antiasthmatic Drugs;Dermatologic Drugs;Antiarthritic Drugs;
CBR-001-586-415-0,RFM-005-682-6,CBR-001-586-415-0,O=C1CC[C@H](N1C)c1cccnc1,CBR-HVAC-02430: ; Nicotinic acetylcholine receptor Activator; Unidentified pharmacological activity
CBR-001-586-416-1,RFM-005-683-7,CBR-001-586-416-1,Oc1ccc2c(c1)oc(=O)c1c2oc2c1ccc(c2)O,"CBR-HVAC-10081: Lipoprotein Disorders, Treatment of ;Treatment of Diabetic Complications;Treatment of Osteoporosis; AGE Inhibitors (Maillard's Reaction Inhibitors);Estrogen Receptor (ER) alpha Ligands;Estrogen Receptor (ER) beta Ligands;Signal Transduction Modulators; Estrogen receptor Modulator;"
CBR-001-586-417-2,RFM-005-684-8,CBR-001-586-417-2,ONC(=O)C(NS(=O)(=O)c1ccc(cc1)Oc1ccc(cc1)F)(C)C,"CBR-HVAC-11389: Acute Myocardial Infarction, Treatment of; Matrix Metalloproteinase Inhibitors; Matrix metalloproteinase Inhibitor;"
CBR-001-586-418-3,RFM-005-685-9,CBR-001-586-418-3,OC(=O)Cc1ccc(cc1)OCCNC[C@@H](c1ccc(nc1)N)O,"CBR-HVAC-04890: Type 2 Diabetes, Agents for; beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-3 adrenergic receptor Agonist;"
CBR-001-586-419-4,RFM-005-686-0,CBR-001-586-419-4,CC[C@@H]1C[C@H](N(C(=O)C)Cc2cc(cc(c2)C(F)(F)F)C(F)(F)F)c2c(N1C(=O)OC(C)C)ccc(c2)C(F)(F)F,CBR-HVAC-06686: Atherosclerosis Therapy; Cholesteryl Ester Transfer Protein (CETP) Inhibitors;HDL-Cholesterol Increasing Agents; CHOLESTERYL ESTER TRANSFER PROTEIN Inhibitor;
CBR-001-586-420-7,RFM-005-687-1,CBR-001-586-420-7,ClC(C(=O)O)Cl,"CBR-HVAC-00971: Squamous Cell Carcinoma Therapy;Solid Tumors Therapy;Therapy of Inborn Errors of Metabolism;Ischemic Stroke, Treatment of;Neurologic Drugs (Miscellaneous);Neurologic Cancer Therapy;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Apoptosis Inducers;Pyruvate Dehydrogenase Kinase (PDHK; PDK) Inhibitors;Signal Transduction Modulators; Pyruvate dehydrogenase stimulant"
CBR-001-586-421-8,RFM-005-688-2,CBR-001-586-421-8,Fc1ccc(cc1)OCCc1ccccc1O,"CBR-HVAC-10538: Hypertension, Treatment of;Diuretics;"
CBR-001-586-422-9,RFM-005-689-3,CBR-001-586-422-9,NC(=N)N(CCOP(=O)(O)O)C,"CBR-HVAC-06740: Acute Myocardial Infarction, Treatment of;Neurologic Drugs (Miscellaneous); Unidentified pharmacological activity"
CBR-001-586-423-0,RFM-005-690-6,CBR-001-586-423-0,CC(C(=O)c1ccc(cc1)N)N1CCCCCC1,"CBR-HVAC-10530: Immunostimulants;Pancreatic Disorders, Treatment of;CNS Stimulants;Antidepressants;"
CBR-001-586-424-1,RFM-005-691-7,CBR-001-586-424-1,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(Nc1ccccc1)nc2N,CBR-HVAC-10551: Vasodilators; Adenosine A2A Agonists;Adenosine A2B Agonists;Signal Transduction Modulators; Adenosine A2 receptor Agonist;
CBR-001-586-425-2,RFM-005-692-8,CBR-001-586-425-2,CN(CCC=C1c2ccccc2C=Cc2c1cccc2)C,"CBR-HVAC-01269: Fibromyalgia, Treatment of;Analgesic Drugs;Posttraumatic Stress Disorder (PTSD), Treatment of;Sleep Disorders, Treatment of;Generalized Anxiety Disorder (GAD), Treatment of;Smooth Muscle Relaxants; alpha-Adrenoceptor Ligands;Signal Transduction Modulators;5-HT2A Receptor Ligands; 5-Hydroxytryptamine 2 receptor Antagonist; Unidentified pharmacological activity"
CBR-001-586-426-3,RFM-005-693-9,CBR-001-586-426-3,CN(CCOC(=O)C(C1(O)CCCC1)c1ccccc1)C,CBR-HVAC-09566: ; Muscarinic acetylcholine receptor Blocker;
CBR-001-586-427-4,RFM-005-694-0,CBR-001-586-427-4,COc1cc(ccc1O)/C=C/1\CCC/C(=C\c2ccc(c(c2)OC)O)/C1=O,"CBR-HVAC-06739: Cancer Multidrug Resistance Modulators;Choleretic Agents;Antiarthritic Drugs;Inflammation, Treatment of;Analgesic Drugs; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;MRP-1 Inhibitors;TNF Expression Inhibitors;"
CBR-001-586-428-5,RFM-005-695-1,CBR-001-586-428-5,CC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2C=C(C2=CC(=O)[C@H]3[C@@H]([C@]12C)C3)Cl)C(=O)C,CBR-HVAC-02449: Treatment of Male Sexual Dysfunction;Prostate Cancer Therapy;Hirsutism Therapy;Acne Therapy; Androgen Receptor Antagonists;Signal Transduction Modulators; Androgen receptor Inhibitor; Testosterone receptor antagonist; Progesterone receptor agonist
CBR-001-586-429-6,RFM-005-696-2,CBR-001-586-429-6,C[C@@H]1CCC[C@@H](O)/C=C/C(=O)O[C@@]23[C@@H](/C=C/C1)[C@H](O)C(=C)[C@H]([C@H]3[C@@H](NC2=O)Cc1ccccc1)C,CBR-HVAC-03614: Atherosclerosis Therapy;Restenosis Treatment of; Phagocytosis Inhibitors;
CBR-001-586-430-9,RFM-005-697-3,CBR-001-586-430-9,CN(/N=N/c1[nH]cnc1C(=O)N)C,CBR-HVAC-05256: Sarcoma Therapy;Endocrine Cancer Therapy;Melanoma Therapy;Lymphoma Therapy;Oncolytic Drugs; DNA Alkylating Drugs;
CBR-001-586-431-0,RFM-005-698-4,CBR-001-586-431-0,COc1ccc(cc1)C(=O)Nc1cccc(c1NC(=O)c1ccc(cc1)N1CCCN(CC1)C)O,"CBR-HVAC-05975: Anticoagulants;Peripheral Vascular Disease, Treatment of;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Antiarrhythmic Drugs; Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways; FACTOR XA Antagonist; Factor Xa inhibitor; Serine protease inhibitor"
CBR-001-586-432-1,RFM-005-699-5,CBR-001-586-432-1,CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CCO2)O)C,CBR-HVAC-02030: Anti-HIV Agents; Cytochrome P450 CYP3A4 Inhibitors;HIV Protease Inhibitors; HIV protease Inhibitor; HIV protease inhibitor
CBR-001-586-433-2,RFM-005-700-1,CBR-001-586-433-2,OCCN1CCN(CC1)c1cc(nc(n1)C)Nc1ncc(s1)C(=O)Nc1c(C)cccc1Cl,CBR-HVAC-01614: Neurologic Cancer Therapy;Liver Cancer Therapy;Sarcoma Therapy;Respiratory/Thoracic Cancer Therapy;Lymphocytic Leukemia Therapy;Myeloid Leukemia Therapy;Solid Tumors Therapy;Head and Neck Cancer Therapy;Pancreatic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Oncolytic Drugs;Hematological Cancer Therapy;Myelodysplastic Syndrome Therapy;Prostate Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Glioblastoma Multiforme Therapy;Melanoma Therapy;Female Reproductive System Cancer Therapy;Small Cell Lung Cancer Therapy;Multiple Myeloma Therapy;Skin Cancer Therapy;Breast Cancer Therapy;Colorectal Cancer Therapy; Abl1 Kinase Inhibitors;Angiogenesis Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Bruton's Tyrosine Kinase (BTK) Inhibitors;Discoidin Domain-Containing Receptor 1 (DDR1) Inhibitors;Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors;EphA2 Inhibitors;Fyn Kinase Inhibitors;KIT (C-KIT) Inhibitors;Lck Kinase Inhibitors;Lyn Kinase Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;Tyrosine Kinase Inhibitors;Yes Kinase Inhibitors; CYP3A4; Tyrosine kinase Inhibitor; Bcr-Abl inhibitor; Src inhibitor; C-kit inhibitor; EphA receptor kinase inhibitor; Fyn tyrosine kinase inhibitor; Yes tyrosine kinase inhibitor; LYN tyrosine kinase inhibitor; Lymphocyte-specific tyrosine kinase inhibitor; Platelet-derived growth factor receptor beta kinase inhib
CBR-001-586-434-3,RFM-005-701-2,CBR-001-586-434-3,OC(=O)c1ccc(cc1)OCCn1cncc1,CBR-HVAC-03007: Antiplatelet Therapy; Thromboxane Synthase Inhibitors; Thromboxane A synthase Inhibitor; Thromboxane synthase inhibitor; Thromboxane B2 receptor antagonist
CBR-001-586-435-4,RFM-005-702-3,CBR-001-586-435-4,CC(=O)OCC(=O)[C@@]12NC(=C)O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@H]2[C@H]1CCC1=CC(=O)C=C[C@]21C,"CBR-HVAC-02011: Rheumatoid Arthritis, Treatment of;Antiallergy/Antiasthmatic Drugs;Allergic Skin Disorders, Treatment for;Antiarthritic Drugs;Muscular Dystrophy, Agents for; c-Jun N-terminal kinase 1 Activator; Corticosteroid agonist"
CBR-001-586-436-5,RFM-005-703-4,CBR-001-586-436-5,CCOC(=O)[C@@H](N[C@H](C(=O)N(C1Cc2c(C1)cccc2)CC(=O)O)C)CCc1ccccc1,"CBR-HVAC-01722: Hypertension, Treatment of;Angina pectoris, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-586-437-6,RFM-005-704-5,CBR-001-586-437-6,O=C(N(CCCCCCCCCCN(C(=O)Oc1cccc(c1)[N+](C)(C)C)C)C)Oc1cccc(c1)[N+](C)(C)C,CBR-HVAC-09568: ; Acetylcholinesterase Inhibitor;
CBR-001-586-438-7,RFM-005-705-6,CBR-001-586-438-7,CNCCCN1c2ccccc2CCc2c1cccc2,"CBR-HVAC-02333: Norepinephrine Transporter (NET) Inhibitors; Norepinephrine transporter Inhibitor; Serotonin and norepinephrine reuptake inhibitor; Signal Transduction Modulators; Sodium Channel Blockers; Antidepressant; Antidepressants; Autism, Treatment of; Gastroesophageal Reflux Disease, Agents for"
CBR-001-586-439-8,RFM-005-706-7,CBR-001-586-439-8,OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@H]2[C@H]1CCC1=CC(=O)C=C[C@]21C)(C)C,"CBR-HVAC-01483: Dermatologic Drugs;Atopic Dermatitis, Agents for; Antiinflammatory Drugs; Glucocorticoid receptor Agonist; Glucocorticoid agonist; Lipocortin synthesis stimulant"
CBR-001-586-440-1,RFM-005-707-8,CBR-001-586-440-1,OCC(=O)[C@H]1[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-01412: ; Phospholipase A2 inhibitor protein Inducer; Glucocorticoid agonist
CBR-001-586-441-2,RFM-005-708-9,CBR-001-586-441-2,O=C(c1cc2c([nH]1)cccc2)N[C@H]1N=C(c2ccccc2)c2c(N(C1=O)C)cccc2,CBR-HVAC-03581: Analgesic Enhancers; CCK1 (CCKA) Antagonists;Signal Transduction Modulators; Cholecystokinin A receptor; Cholecystokinin B receptor Agonist; Antagonist; CCK A receptor antagonist; Gastrin inhibitor
CBR-001-586-442-3,RFM-005-709-0,CBR-001-586-442-3,CC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)CC[C@]12C)F,CBR-HVAC-06662: ; Glucocorticoid receptor Agonist; Glucocorticoid agonist; Arachidonic acid inhibitor
CBR-001-586-443-4,RFM-005-710-3,CBR-001-586-443-4,O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@]2(F)[C@@H](O)C[C@]2([C@H]1C[C@@H]([C@]2(O)C(=O)COP(=O)(O)O)C)C)C,CBR-HVAC-01338: ; Glucocorticoid receptor Agonist; Glucocorticoid agonist; Arachidonic acid inhibitor
CBR-001-586-444-5,RFM-005-711-4,CBR-001-586-444-5,CCCCC(=O)O[C@@]1([C@@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(C2CCC2=CC(=O)C=C[C@]12C)F)C(=O)CO,CBR-HVAC-01339: ; Glucocorticoid receptor Agonist; Glucocorticoid agonist; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-586-445-6,RFM-005-712-5,CBR-001-586-445-6,CCOC(=O)/C=C/1\SC(C(=O)N1C)N1CCCCC1,CBR-HVAC-00928: ; Diuretic
CBR-001-586-446-7,RFM-005-713-6,CBR-001-586-446-7,OC(=O)C(c1cccc(c1)C(=O)c1ccccc1)C,CBR-HVAC-01272: Non-Opioid Analgesics; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-586-447-8,RFM-005-714-7,CBR-001-586-447-8,O=S(c1nc2c([nH]1)cccc2)Cc1nccc(c1C)OCC(F)(F)F,"CBR-HVAC-01379: Esophageal Diseases, Treatment of;Gastroesophageal Reflux Disease, Agents for; H+/K+-ATPase Inhibitors; Proton pump Inhibitor; H+ K+ transporting ATPase inhibitor"
CBR-001-586-448-9,RFM-005-715-8,CBR-001-586-448-9,CCC1=C(C)NN=C(c2c1cc(OC)c(c2)OC)c1ccc(c(c1)OC)OC,CBR-HVAC-02638: Treatment of Postmenopausal Syndrome ;Treatment of Disorders of Purine and Pyrimidine Metabolism;Treatment of Gout;Antiepileptic Drugs;Anxiolytics; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; Benzodiazepine receptor agonist
CBR-001-586-450-3,RFM-005-716-9,CBR-001-586-450-3,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O,CBR-HVAC-02617:
CBR-001-586-451-4,RFM-005-717-0,CBR-001-586-451-4,CCCCC/C=C\C/C=C\C/C=C\CCCCCCC(=O)O,"CBR-HVAC-00930: Atopic Dermatitis, Agents for; Prostaglandin synthase stimulant; Platelet aggregation inhibitor; Cholesterol inhibitor"
CBR-001-586-452-5,RFM-005-718-1,CBR-001-586-452-5,CCCCC1=NC2(C(=O)N1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)CCCC2,CBR-HVAC-02582: ; Angiotensin II receptor type 1 Antagonist; Angiotensin II antagonist; Interferon alpha agonist; Interferon beta agonist
CBR-001-586-453-6,RFM-005-719-2,CBR-001-586-453-6,Clc1ccc2c(c1)S(=O)(=O)NC(=N2)C,"CBR-HVAC-03447: Hypertension, Treatment of;Hyperglycemic Agents;Multisystem Genetic Disorders, Treatment of ; K(ATP) Channel Activators; Potassium channel Opener;"
CBR-001-586-454-7,RFM-005-720-5,CBR-001-586-454-7,Clc1cc(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)N,CBR-HVAC-05319: Antiglaucoma Agents;Metabolic Disorders (Not Specified); Carbonic Anhydrase Inhibitors; Carbonic anhydrase Inhibitor;
CBR-001-586-455-8,RFM-005-721-6,CBR-001-586-455-8,CCC1(CC)COC(=O)NC1=O,CBR-HVAC-08655:
CBR-001-586-456-9,RFM-005-722-7,CBR-001-586-456-9,CC/C(=C(\c1ccc(cc1)O)/CC)/c1ccc(cc1)O,CBR-HVAC-03176: Prostate Cancer Therapy; Chloride Channel Blockers;Estrogen Receptor (ER) Agonists;Signal Transduction Modulators; Estrogen receptor Agonist;
CBR-001-586-457-0,RFM-005-723-8,CBR-001-586-457-0,CC/C(=C(\c1ccc(cc1)OP(=O)(O)O)/CC)/c1ccc(cc1)OP(=O)(O)O,CBR-HVAC-09570: ; Estrogen receptor Agonist;
CBR-001-586-458-1,RFM-005-724-9,CBR-001-586-458-1,CC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F)C(=O)COC(=O)C,CBR-HVAC-02010: ; Corticosteroid agonist; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-586-459-2,RFM-005-725-0,CBR-001-586-459-2,COc1cc(cc(c1OC)OC)C(=O)OCCCN1CCCN(CC1)CCCOC(=O)c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-02206: ; Calcium channel antagonist; Platelet aggregation inhibitor
CBR-001-586-460-5,RFM-005-726-1,CBR-001-586-460-5,O=C(Nc1ccccc1)OCC(OC(=O)Nc1ccccc1)CN1CCCCC1,CBR-HVAC-09887:
CBR-001-586-461-6,RFM-005-727-2,CBR-001-586-461-6,NC(=O)Oc1ccc(cc1)Cc1ccccc1,CBR-HVAC-10227:
CBR-001-586-462-7,RFM-005-728-3,CBR-001-586-462-7,O=C1C(=C1c1ccccc1)c1ccccc1,CBR-HVAC-05748: Melanoma Therapy;Antiviral Drugs;Dermatologic Drugs;Hair Growth Stimulants;
CBR-001-586-463-8,RFM-005-729-4,CBR-001-586-463-8,CC(N(C(C)C)CCC(c1ccccc1Cl)(C(=O)N)CCN1CCCCC1)C,CBR-HVAC-01008: Antiarrhythmic Drugs; Sodium channel antagonist
CBR-001-586-464-9,RFM-005-730-7,CBR-001-586-464-9,Oc1cccc2c1c(O)c1c(c2)cccc1O,CBR-HVAC-02254: Antipsoriatics; Lipoxygenase 5 Inhibitor; Reducing agent; Mitotic inhibitor
CBR-001-586-465-0,RFM-005-731-8,CBR-001-586-465-0,OC(=O)CCc1cc(I)c(c(c1)I)Oc1ccc(cc1)O,"CBR-HVAC-00494: Lipoprotein Disorders, Treatment of ;Mental Retardation, Treatment of;Heart Failure Therapy; Thyroid hormone receptor Agonist; Thyroid hormone function stimulant"
CBR-001-586-466-1,RFM-005-732-9,CBR-001-586-466-1,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O,CBR-HVAC-02618:
CBR-001-586-467-2,RFM-005-733-0,CBR-001-586-467-2,CN(CCc1ccc(cc1)NS(=O)(=O)C)CCOc1ccc(cc1)NS(=O)(=O)C,CBR-HVAC-01768: Antiarrhythmic Drugs; K(V) 11.1 (erg1) Channel Blockers; Potassium channel hERG Blocker; Potassium channel antagonist; Polarisation inhibitor
CBR-001-586-468-3,RFM-005-734-1,CBR-001-586-468-3,[N-]=[N+]=CC(=O)CC[C@@H](C(=O)O)N,CBR-HVAC-04817: Pharmacological Tools;Oncolytic Drugs;Non-Opioid Analgesics; Glutaminase Inhibitors; Glutamate receptor Antagonist;
CBR-001-586-469-4,RFM-005-735-2,CBR-001-586-469-4,CO[C@H]1C[C@H](O[C@H]([C@@H]1O[C@@H]1C[C@H](OC)[C@H]([C@@H](O1)C)O)C)O[C@H]1[C@@H](C)/C=C/C=C/2\CO[C@H]3[C@]2(O)[C@@H](C=C([C@H]3O)C)C(=O)O[C@H]2CC(C/C=C/1\C)O[C@]1(C2)C=C[C@@H]([C@H](O1)C1CCCCC1)C,CBR-HVAC-09256: Treatment of Helminthic Diseases;
CBR-001-586-470-7,RFM-005-736-3,CBR-001-586-470-7,C[C@H]([C@H]1C(=O)N2[C@@H]1[C@@H](C)C(=C2C(=O)O)S[C@@H]1CN[C@@H](C1)CNS(=O)(=O)N)O,CBR-HVAC-04415: Antibiotics; Dehydropeptidase I Inhibitors; GABA-A receptor Inhibitor;
CBR-001-586-471-8,RFM-005-737-4,CBR-001-586-471-8,CN(CC/C=C/1\c2ccccc2SCc2c1cccc2)C,CBR-HVAC-02150: Antidepressants; Tricyclic antidepressant; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin and norepinephrine reuptake inhibitor
CBR-001-586-472-9,RFM-005-738-5,CBR-001-586-472-9,Clc1ccc(cc1Cl)C12CNCC2C1,"CBR-HVAC-00799: Antiparkinsonian Drugs;Restless Legs Syndrome, Treatment of;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Treatment of Alcohol Dependency;Antidepressants; Dopamine Reuptake Inhibitors;Dopamine Transporter (DAT) Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors; DOPAMINE TRANSPORTER; NOREPINEPHRINETRANSPORTER; SERATONIN TRANSPORTER Inhibitor; Dopamine reuptake inhibitor; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor"
CBR-001-586-473-0,RFM-005-739-6,CBR-001-586-473-0,O=C1c2ccc(cc2S(=O)(=O)c2c1cccc2)c1nnn[nH]1,CBR-HVAC-05808: Pharmacological Tools; Mediator Release Inhibitors; Unidentified pharmacological activity
CBR-001-586-474-1,RFM-005-740-9,CBR-001-586-474-1,CN(C(c1cccnc1)C1COCOC1)C,CBR-HVAC-02552: Analgesic Drugs; Opioid receptor agonist
CBR-001-586-475-2,RFM-005-741-0,CBR-001-586-475-2,N/C=C/1\Cc2c(C1=O)cccc2,CBR-HVAC-09943:
CBR-001-586-476-3,RFM-005-742-1,CBR-001-586-476-3,Fc1ccc(cc1)C(=O)CCCN1CCC(=CC1)n1c(O)nc2c1cccc2,"CBR-HVAC-02782: Bipolar Disorder, Treatment of;Nausea and Vomiting, Treatment of;Antipsychotic Drugs;Agents for Premedication; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist"
CBR-001-586-477-4,RFM-005-743-2,CBR-001-586-477-4,CCCCOc1ccc(cc1)C(=O)CCN1CCCCC1,CBR-HVAC-02338: ; Sodium channel Blocker; Sodium channel antagonist
CBR-001-586-478-5,RFM-005-744-3,CBR-001-586-478-5,CCCCCCCCC/C(=C\C1=C(C)C(=O)C(=C(C1=O)OC)OC)/C(=O)O,"CBR-HVAC-10928: Age-Related Macular Degeneration, Treatment of;Retinopathy, Treatment of;Hepatoprotectants;Oncolytic Drugs; Angiogenesis Inhibitors;Apurinic/Apyrimidinic Endonuclease 1 (Apex1) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators; TNF alpha Inhibitor;"
CBR-001-586-479-6,RFM-005-745-4,CBR-001-586-479-6,Cc1cccc(n1)CCN1CCC(CC1)C(=O)c1ccc(cc1)NS(=O)(=O)C,CBR-HVAC-03972: Antiarrhythmic Drugs; Potassium Channel Blockers; Potassium channel Blocker; Potassium channel antagonist; Polarisation inhibitor
CBR-001-586-480-9,RFM-005-746-5,CBR-001-586-480-9,O=C1/C(=C\c2ccc(cc2)/C=C\2/C3CCC(C2=O)(C3(C)C)CS(=O)(=O)O)/C2C(C1(CC2)CS(=O)(=O)O)(C)C,CBR-HVAC-04989: Ultraviolet Light Absorbers;
CBR-001-586-481-0,RFM-005-747-6,CBR-001-586-481-0,CCOP(=O)(SCC[N+](C)(C)C)OCC,"CBR-HVAC-02626: Ocular Genetic Disorders, Treatment of ;Antiglaucoma Agents; Cholinesterase Inhibitor; Acetylcholinesterase inhibitor"
CBR-001-586-482-1,RFM-005-748-7,CBR-001-586-482-1,OC(=O)[C@@H]1CCNC(=N1)C,"CBR-HVAC-06767: Inflammation, Treatment of;Alzheimer's Dementia, Treatment of ;Inflammatory Bowel Disease, Agents for;Allergy, Treatment of;Atopic Dermatitis, Agents for;Dermatologic Drugs;Drugs for Allergic Rhinitis;"
CBR-001-586-483-2,RFM-005-749-8,CBR-001-586-483-2,CC(=O)O[C@]1(C(=O)C)C(=C)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,CBR-HVAC-05206: Male Contraceptives;Hormone Replacement Therapy;Female Contraceptives; Progesterone Receptor Agonists;Signal Transduction Modulators; PROGESTERON RECEPTOR Agonist; Progesterone receptor agonist
CBR-001-586-484-3,RFM-005-750-1,CBR-001-586-484-3,Fc1ccc(cc1)CC1CCN(CC1)CC(c1ccc(cc1)Cl)O,"CBR-HVAC-03858: Multiple Sclerosis, Agents for;Ischemic Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist; NMDA receptor antagonist"
CBR-001-586-485-4,RFM-005-751-2,CBR-001-586-485-4,CCOc1c(cnn(c1=O)C)N1CCOCC1,CBR-HVAC-01700: ; Cyclooxygenase inhibitor
CBR-001-586-486-5,RFM-005-752-3,CBR-001-586-486-5,OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2ccc(cc2)O[C@@H]2COCC2)Cl)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-06713: Type 1 Diabetes, Agents for;Type 2 Diabetes, Agents for; SGLT-2 Inhibitors; SODIUM GLUCOSE COTRANSPORTER 2 Inhibitor; Sodium/glucose cotransporter 2 inhibitor"
CBR-001-586-487-6,RFM-005-753-4,CBR-001-586-487-6,CCC(OC(=O)N)(CC)C,CBR-HVAC-09830:
CBR-001-586-488-7,RFM-005-754-5,CBR-001-586-488-7,O=C(N([C@H]1CC[C@]2(C[C@@H]1N1CCCC1)CCCO2)C)Cc1cccc2c1cco2,"CBR-HVAC-04103: Ischemic Stroke, Treatment of;Opioid Analgesics;Diuretics; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist; Glutamate antagonist; Opioid kappa receptor agonist"
CBR-001-586-489-8,RFM-005-755-6,CBR-001-586-489-8,OC(=O)[C@@H](N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C)CCc1ccccc1,"CBR-HVAC-01917: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-586-490-1,RFM-005-756-7,CBR-001-586-490-1,COc1ccc(cc1)C(=O)Nc1ccccc1CCC1CCCCN1C,CBR-HVAC-02835: Antiarrhythmic Drugs; Potassium channel; Sodium channel Blocker; Sodium channel antagonist; General pump inhibitor
CBR-001-586-491-2,RFM-005-757-8,CBR-001-586-491-2,CCN(CCOc1ccc(cc1)/C(=C(\c1ccccc1)/Cl)/c1ccccc1)CC,"CBR-HVAC-02629: Type 2 Diabetes, Agents for;Treatment of Hypogonadism; Estrogen Receptor (ER) Antagonists;Signal Transduction Modulators; Aldehyde oxidase Inhibitor; Testosterone receptor agonist"
CBR-001-586-492-3,RFM-005-758-9,CBR-001-586-492-3,C=CCOC(c1ccc(cc1Cl)Cl)Cn1cncc1,CBR-HVAC-02505: ; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-586-493-4,RFM-005-759-0,CBR-001-586-493-4,O=C1CCC(C(=O)N1)N1Cc2c(C1=O)cccc2N,"CBR-HVAC-02272: Lymphoma Therapy;Leukemia Therapy;Lymphocytic Leukemia Therapy;Neuropathy, Treatment of ;Renal Cancer Therapy;Pancreatic Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Myeloid Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Glioblastoma Multiforme Therapy;Bladder Cancer Therapy ;Amyloidosis, Treatment of;Female Reproductive System Cancer Therapy;Treatment of AIDS-Associated Disorders;Hematological Cancer Therapy;Melanoma Therapy;Psychiatric Disorders (Not Specified);Prostate Cancer Therapy;Myelodysplastic Syndrome Therapy;Multiple Myeloma Therapy;Endocrine Cancer Therapy;Neurologic Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Liver Cancer Therapy;Analgesic Drugs;Hematopoiesis Disorders Therapy; Angiogenesis Inhibitors;Cereblon (CRBN) Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; TNF alpha Antagonist; Tumour necrosis factor alpha antagonist; Angiogenesis inhibitor"
CBR-001-586-494-5,RFM-005-760-3,CBR-001-586-494-5,N#Cc1ccc(cc1)OC[C@@](C(=O)Nc1ccc(c(c1)C(F)(F)F)C#N)(O)C,"CBR-HVAC-00879: Treatment of Renal Diseases;Androgen Decline in the Aging Male (Andropause), Treatment of;Treatment of Cachexia;Treatment of Postmenopausal Syndrome ;Sarcopenia, Treatment of;Breast Cancer Therapy; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators; ANDROGEN RECEPTOR Modulator; Selective androgen receptor modulator; Androgen receptor agonist"
CBR-001-586-495-6,RFM-005-761-4,CBR-001-586-495-6,OC(=O)C(=O)Cc1c[nH]c2c1cccc2,CBR-HVAC-00583: ; Melatonin receptor agonist; Glucocorticoid antagonist; Free radical scavenger
CBR-001-586-496-7,RFM-005-762-5,CBR-001-586-496-7,CCn1cc(C(=O)O)c(=O)c2c1nc(N1CCNCC1)c(c2)F,CBR-HVAC-01673: Antibacterial Drugs; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-497-8,RFM-005-763-6,CBR-001-586-497-8,CSc1ccc(cc1)C(=O)c1nc([nH]c1C)O,CBR-HVAC-01865: Heart Failure Therapy; Phosphodiesterase PDE3 Inhibitors;Signal Transduction Modulators; cAMP phosphodiesterase type IV Inhibitor; Phosphodiesterase 3 inhibitor
CBR-001-586-498-9,RFM-005-764-7,CBR-001-586-498-9,CCN(C(=O)/C(=C/c1cc(O)c(c(c1)[N+](=O)[O-])O)/C#N)CC,CBR-HVAC-01666: Antiparkinsonian Drugs; COMT Inhibitors; Catechol-O-methyltransferase Inhibitor; Catechol O methyltransferase inhibitor
CBR-001-586-499-0,RFM-005-765-8,CBR-001-586-499-0,CNCCc1ccc(c(c1)O)O,CBR-HVAC-03223: Heart Failure Therapy;
CBR-001-586-500-6,RFM-005-766-9,CBR-001-586-500-6,COc1cc(C)nc(n1)n1nc(cc1OC)C,CBR-HVAC-01814: ; Cyclooxygenase inhibitor
CBR-001-586-501-7,RFM-005-767-0,CBR-001-586-501-7,CN(CCO/N=C(/c1ccccc1F)\C=C\c1ccc(cc1)O)C,"CBR-HVAC-04030: Sleep Apnea, Treatment of;Fibromyalgia, Treatment of;Sleep Disorders, Treatment of;Antidepressants;Antipsychotic Drugs; Signal Transduction Modulators;5-HT2A Antagonists; 5-HYDROXYTRYPTAMINE 2A RECEPTOR; 5-HYDROXYTRYPTAMINE 2C RECEPTOR Antagonist; 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 2C receptor antagonist"
CBR-001-586-502-8,RFM-005-768-1,CBR-001-586-502-8,Oc1ccc2c(c1)CC=C1C2CCC2(C1CCC2=O)C,CBR-HVAC-10026:
CBR-001-586-503-9,RFM-005-769-2,CBR-001-586-503-9,O1CCN(CC1)CCCc1ccc(cc1)COc1ccccc1,CBR-HVAC-05477: Antiarrhythmic Drugs;Anesthetic Drugs; Drugs Acting on Sodium Channels (Voltage-Gated); Calcium channel alpha1E Blocker;
CBR-001-586-504-0,RFM-005-770-5,CBR-001-586-504-0,O=C(NC1CCSC1=O)CSCC(=O)O,CBR-HVAC-01952: ; Mucolytic agent; Free radical scavenger; Elastase inhibitor; Reducing agent
CBR-001-586-505-1,RFM-005-771-6,CBR-001-586-505-1,COCCOc1cc2c(ncnc2cc1OCCOC)Nc1cccc(c1)C#C,CBR-HVAC-02168: Gastric Cancer Therapy;Myelodysplastic Syndrome Therapy;Neurologic Cancer Therapy;Agents for Viral Hepatitis;Prostate Cancer Therapy;Renal Cancer Therapy;Colorectal Cancer Therapy;Premalignant Conditions Therapy;Breast Cancer Therapy;Pancreatic Cancer Therapy;Brain Cancer Therapy;Bladder Cancer Therapy ;Astrocytoma Therapy;Gastrointestinal Disorders (Not Specified);Hematological Cancer Therapy;Sarcoma Therapy;Cervical Cancer Therapy;Solid Tumors Therapy;Melanoma Therapy;Ovarian Cancer Therapy;Head and Neck Cancer Therapy;Glioblastoma Multiforme Therapy;Digestive/Gastrointestinal Cancer Therapy;Myeloid Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Liver Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; EGFR; ERBB2 Inhibitor; EGFR kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-586-506-2,RFM-005-772-7,CBR-001-586-506-2,CCC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2OC(=O)CC)C,CBR-HVAC-10256:
CBR-001-586-507-3,RFM-005-773-8,CBR-001-586-507-3,CCCCC(=O)OC1CCC2C1(C)CCC1C2CCc2c1ccc(c2)O,CBR-HVAC-12337:
CBR-001-586-508-4,RFM-005-774-9,CBR-001-586-508-4,O=C1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OS(=O)(=O)O,CBR-HVAC-09578: ; Estrogen receptor Agonist;
CBR-001-586-509-5,RFM-005-775-0,CBR-001-586-509-5,CCC(=C)C(=O)c1ccc(c(c1Cl)Cl)OCC(=O)O,"CBR-HVAC-02340: Loop Diuretics; Wnt Signaling Inhibitors; Na+, K+ ATPase Inhibitor; DNA inhibitor; Diuretic; Glutathione S transferase inhibitor"
CBR-001-586-510-8,RFM-005-776-1,CBR-001-586-510-8,CCN(C(=O)c1ccc(c(c1)OC)O)CC,CBR-HVAC-09814:
CBR-001-586-511-9,RFM-005-777-2,CBR-001-586-511-9,CCOC(=O)c1cnc2c(c1NN=C(C)C)cnn2CC,"CBR-HVAC-02433: Alzheimer's Dementia, Treatment of ;Antiparkinsonian Drugs;Antipsychotic Drugs;Ophthalmic Drugs;Oncolytic Drugs; alpha-Secretase Activators;GABA(A) Receptor Modulators;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; GABA-A receptor; Phosphodiesterase 4 Modulator; Inhibitor; Phosphodiesterase 4 inhibitor; GABA A receptor agonist"
CBR-001-586-512-0,RFM-005-778-3,CBR-001-586-512-0,CCOC(=O)c1cnc2c(c1NN=C(C)C)cnn2CC,"CBR-HVAC-02433: Alzheimer's Dementia, Treatment of ;Antiparkinsonian Drugs;Antipsychotic Drugs;Ophthalmic Drugs;Oncolytic Drugs; alpha-Secretase Activators;GABA(A) Receptor Modulators;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; GABA-A receptor; Phosphodiesterase 4 Modulator; Inhibitor; Phosphodiesterase 4 inhibitor; GABA A receptor agonist"
CBR-001-586-513-1,RFM-005-779-4,CBR-001-586-513-1,CCN1C(=O)OC(C1=O)(C)C,CBR-HVAC-09117:
CBR-001-586-514-2,RFM-005-780-7,CBR-001-586-514-2,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)O,CBR-HVAC-01415: ; Estrogen receptor Modulator; Estrogen receptor agonist
CBR-001-586-515-3,RFM-005-781-8,CBR-001-586-515-3,C#C[C@@]1(CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=C[C@H](CC[C@H]12)OC(=O)C)OC(=O)C,CBR-HVAC-09583:
CBR-001-586-516-4,RFM-005-782-9,CBR-001-586-516-4,CCOC(=O)[C@H](Cc1ccc(c(c1)O)O)N,CBR-HVAC-03607: Antiparkinsonian Drugs; Dopamine Precursors;Signal Transduction Modulators; A2a Adenosine receptor ANTAGONIST; Dopamine receptor agonist
CBR-001-586-517-5,RFM-005-783-0,CBR-001-586-517-5,CCOC(=O)C(Cc1cc(I)c(c(c1)I)Oc1cc(I)c(c(c1)I)O)(N)C,CBR-HVAC-01685: ; Cholesterol inhibitor
CBR-001-586-518-6,RFM-005-784-1,CBR-001-586-518-6,CCCC/N=C(\NC(=N)N)/NCC,CBR-HVAC-09024:
CBR-001-586-519-7,RFM-005-785-2,CBR-001-586-519-7,CCOC(=O)C1(CCCCCCOc2ccc(cc2)Cl)OC1,CBR-HVAC-00026: ; Carnitine palmitoyltransferase I Inhibitor; Carnitine palmitoyltransferase inhibitor
CBR-001-586-520-0,RFM-005-786-3,CBR-001-586-520-0,OCCCC(=O)NCCO,CBR-HVAC-05550: Sedative/Hypnotics;
CBR-001-586-521-1,RFM-005-787-4,CBR-001-586-521-1,CCCCCCOc1ccccc1C(=O)N,CBR-HVAC-00121: Antifungal Agents; Immunosuppressant; Membrane permeability inhibitor; Histamine release inhibitor
CBR-001-586-522-2,RFM-005-788-5,CBR-001-586-522-2,NCCCC[C@@H](C(=O)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc1c(C)[nH]c2c1cccc2)NC(=O)[C@H](Cc1cnc[nH]1)N)C,CBR-HVAC-04693: Treatment of Growth Hormone Deficiency; GHS Receptor Agonists;Growth Hormone Secretagogues;Signal Transduction Modulators; Growth hormone releasing hormone Agonist;
CBR-001-586-523-3,RFM-005-789-6,CBR-001-586-523-3,O=C(c1ccc(c(c1O)O)O)c1cc(O)c(c(c1)O)O,"CBR-HVAC-03722: Exifone is transformed inside the parasitized erythrocyte into a xanthone with potent antimalarial properties; Free radical scavenger; Tyrosinase Inhibitors; Cognition Disorders, Treatment of; Nootropic agent"
CBR-001-586-524-4,RFM-005-790-9,CBR-001-586-524-4,Oc1ccc(cc1)n1cc(C)ccc1=O,CBR-HVAC-06583: Agents for Liver Cirrhosis;Treatment of Renal Diseases;Agents for Liver Fibrosis; Aminotransferase Stimulator;
CBR-001-586-525-5,RFM-005-791-0,CBR-001-586-525-5,NC(=Nc1scc(n1)CSCC/C(=N/S(=O)(=O)N)/N)N,"CBR-HVAC-01896: Gastric Antisecretory Drugs;Gastroesophageal Reflux Disease, Agents for; Histamine H2 Receptor Antagonists;Signal Transduction Modulators; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist"
CBR-001-586-526-6,RFM-005-792-1,CBR-001-586-526-6,CN(CCCn1c(=O)c2ccccc2c2c1cccc2)C,CBR-HVAC-09029:
CBR-001-586-527-7,RFM-005-793-2,CBR-001-586-527-7,Fc1cnc(c(n1)C(=O)N)O,CBR-HVAC-05325: Antiviral Drugs;Anti-Influenza Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors; DNA directed RNA polymerase inhibitor
CBR-001-586-528-8,RFM-005-794-3,CBR-001-586-528-8,OC[C@H]1O[C@@H]([C@H]([C@@H]1O)F)n1cc(CC)c(=O)[nH]c1=O,CBR-HVAC-10487: Antiviral Drugs;
CBR-001-586-529-9,RFM-005-795-4,CBR-001-586-529-9,OC(=O)Cc1csc(n1)c1ccc(cc1)Cl,CBR-HVAC-10240:
CBR-001-586-530-2,RFM-005-796-5,CBR-001-586-530-2,CCC1C(=O)NC(=O)C1(C)c1ccccc1,CBR-HVAC-08980:
CBR-001-586-531-3,RFM-005-797-6,CBR-001-586-531-3,CC(Cc1ccc(cc1)O)NCC(c1cc(O)cc(c1)O)O,CBR-HVAC-02343: ; Beta-2 adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-586-532-4,RFM-005-798-7,CBR-001-586-532-4,FCCn1cc(C(=O)O)c(=O)c2c1c(F)c(N1CCN(CC1)C)c(c2)F,CBR-HVAC-01784: Antibacterial Drugs; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-533-5,RFM-005-799-8,CBR-001-586-533-5,CCCCCCCCCCCC(c1cc(C)ccc1O)N=O,CBR-HVAC-03292: ; Antiinflammatory Drugs;Lipoxygenase Inhibitors; 5 Lipoxygenase inhibitor
CBR-001-586-534-6,RFM-005-800-4,CBR-001-586-534-6,OCC(COC(=O)c1ccccc1Nc1ccnc2c1cccc2C(F)(F)F)O,CBR-HVAC-01967: ; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor
CBR-001-586-535-7,RFM-005-801-5,CBR-001-586-535-7,O[C@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1nc(F)nc2N)COP(=O)(O)O,"CBR-HVAC-01384: Neurologic Cancer Therapy;Lymphocytic Leukemia Therapy;Multisystem Genetic Disorders, Treatment of ;Melanoma Therapy;Non-Hodgkin's Lymphoma Therapy;Restenosis Treatment of; Purine Antagonists; DNA polymerase Inhibitor; DNA synthesis inhibitor; DNA repair enzyme inhibitor"
CBR-001-586-536-8,RFM-005-802-6,CBR-001-586-536-8,COc1ccc(cc1)c1[nH]c(nc1c1ccc(cc1)OC)C(F)(F)F,CBR-HVAC-02344: ; Prostaglandin synthase inhibitor
CBR-001-586-537-9,RFM-005-803-7,CBR-001-586-537-9,FC(c1ccc(cc1)C1CN=C(O1)N)(F)F,CBR-HVAC-10134:
CBR-001-586-538-0,RFM-005-804-8,CBR-001-586-538-0,Fc1ccc(cc1)C(c1ccc(cc1)F)N1CCN(CC1)C/C=C/c1ccccc1,"CBR-HVAC-02170: Migraine, Prophylactic Treatment of;Vasodilators;Neurologic Drugs (Miscellaneous); Calcium Channel Blockers; Dopamine receptor D1; Dopamine receptor D2 Inhibitor; T-type calcium channel antagonist"
CBR-001-586-539-1,RFM-005-805-9,CBR-001-586-539-1,OC(=O)c1cccnc1Nc1cccc(c1C)C(F)(F)F,CBR-HVAC-01024: ; Prostaglandin G/H synthase Inhibitor; Prostaglandin synthase inhibitor
CBR-001-586-540-4,RFM-005-806-0,CBR-001-586-540-4,OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1C[C@@H](C1=CC(=O)C=C[C@]21C)F)F)(C)C,"CBR-HVAC-01482: Eczema, Treatment of;Antiinflammatory Ophthalmic Agents;Age-Related Macular Degeneration, Treatment of;Dermatologic Drugs;Diabetic Retinopathy, Agents for;Ear disorders, treatment of; Glucocorticoid receptor Binder; Corticosteroid agonist"
CBR-001-586-541-5,RFM-005-807-1,CBR-001-586-541-5,C=COCC(F)(F)F,CBR-HVAC-09874:
CBR-001-586-542-6,RFM-005-808-2,CBR-001-586-542-6,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1,CBR-HVAC-03117: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Alpha adrenergic receptor Antagonist;
CBR-001-586-543-7,RFM-005-809-3,CBR-001-586-543-7,FCSC(=O)C1(OC(=O)c2ccco2)C(C)CC2[C@]1(C)C[C@H](O)C1([C@H]2CC(C2=CC(=O)C=C[C@]12C)F)F,CBR-HVAC-00459: Asthma Therapy;Drugs for Allergic Rhinitis; Glucocorticoid Receptor (GR) Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor; Glucocorticoid receptor Agonist; Glucocorticoid agonist
CBR-001-586-544-8,RFM-005-810-6,CBR-001-586-544-8,O=C1CC[C@]2(C(C1=O)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C)C,CBR-HVAC-02780: Breast Cancer Therapy; Aromatase Inhibitors; CYP19A1 Inhibitor; Aromatase inhibitor
CBR-001-586-545-9,RFM-005-811-7,CBR-001-586-545-9,OC(=O)CP(=O)(O)O,CBR-HVAC-00975: ; DNA directed DNA polymerase inhibitor
CBR-001-586-546-0,RFM-005-812-8,CBR-001-586-546-0,COc1ccc(cc1)c1sc(nc1c1ccc(cc1)OC)C(=O)N1CCN(CC1)C,CBR-HVAC-10949: Antiplatelet Therapy; Cyclooxygenase (COX) Inhibitors;Signal Transduction Modulators; COX-1 Inhibitor;
CBR-001-586-547-1,RFM-005-813-9,CBR-001-586-547-1,OCC(Nc1ccc(cc1C(=O)NCc1ccc(c(c1)OC)OC)[N+](=O)[O-])C,CBR-HVAC-11052: Treatment of Erectile Dysfunction; Phosphodiesterase PDE5A Inhibitors;Signal Transduction Modulators; Phosphodiesterase 5 Inhibitor;
CBR-001-586-548-2,RFM-005-814-0,CBR-001-586-548-2,CC(=O)N(CCCP(=O)(O)[O-])O,CBR-HVAC-11170: Antimalarials; 1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) Inhibitors;
CBR-001-586-549-3,RFM-005-815-1,CBR-001-586-549-3,CCC1Oc2c(C1)cc(cc2)CC(=O)O,"CBR-HVAC-01055: Non-Opioid Analgesics;Antiplatelet Therapy;Inflammation, Treatment of; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-586-550-6,RFM-005-816-2,CBR-001-586-550-6,Oc1noc2c1CCNC2,"CBR-HVAC-05322: Antidepressants;Sleep Disorders, Treatment of;Neurological Genetic Disorders, Treatment of ; GABA(A) Receptor Partial Agonists;Signal Transduction Modulators; GABA-A receptor Agonist;"
CBR-001-586-552-8,RFM-005-817-3,CBR-001-586-552-8,COc1cc(/C=C/C(=O)O[C@H]2CC[C@]34C(C2(C)C)CCC2C4(C3)CC[C@]3([C@@]2(C)CC[C@@H]3[C@@H](CCC=C(C)C)C)C)ccc1O,CBR-HVAC-08988:
CBR-001-586-553-9,RFM-005-818-4,CBR-001-586-553-9,CCN/C(=N\CC)/NCCCCC(C(=O)NC(C(=O)NC(C(=O)N1CCC[C@@H]1C(=O)N[C@@H](C(=O)N)C)CCCCN/C(=N/CC)/NCC)CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)C(NC(=O)[C@H](Cc1ccc2c(c1)cccc2)NC(=O)C)Cc1ccc(cc1)Cl)Cc1cccnc1)CO)Cc1ccc(cc1)O,"CBR-HVAC-03815: Female Infertility, Agents for; GnRH (LHRH) Antagonists;Signal Transduction Modulators;"
CBR-001-586-554-0,RFM-005-819-5,CBR-001-586-554-0,COc1cc2ncnc(c2cc1OCCCN1CCOCC1)Nc1ccc(c(c1)Cl)F,CBR-HVAC-02801: Sarcoma Therapy;Solid Tumors Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Renal Cancer Therapy;Squamous Cell Carcinoma Therapy;Gastric Cancer Therapy;Head and Neck Cancer Therapy;Bladder Cancer Therapy ;Pancreatic Cancer Therapy;Ovarian Cancer Therapy;Astrocytoma Therapy;Endocrine Cancer Therapy;Small Cell Lung Cancer Therapy;Myeloid Leukemia Therapy;Neurologic Cancer Therapy;Glioblastoma Multiforme Therapy;Liver Cancer Therapy;Breast Cancer Therapy;Cancer of Unspecified Body Location/System; EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators; EGFR Inhibitor; EGFR kinase inhibitor
CBR-001-586-555-1,RFM-005-820-8,CBR-001-586-555-1,OC[C@H]1O[C@H](C(C1O)(F)F)n1ccc(nc1=O)N,CBR-HVAC-00152: ; DNA synthesis inhibitor; DNA repair enzyme inhibitor
CBR-001-586-556-2,RFM-005-821-9,CBR-001-586-556-2,OC[C@H]1O[C@@H](O[C@H]2CC[C@]3([C@H](C2(C)C)CC[C@@]2([C@@H]3C[C@@H](O)[C@H]3[C@@]2(C)CC[C@@H]3[C@@](O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)(CCC=C(C)C)C)C)C)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-05925: Ischemic Stroke, Treatment of;Immunostimulants; Apoptosis Inhibitors;Drugs Acting on Calcium Release-Activated Channels (CRAC);"
CBR-001-586-557-3,RFM-005-822-0,CBR-001-586-557-3,OCC(COC(=O)c1ccccc1Nc1ccnc2c1ccc(c2)Cl)O,CBR-HVAC-02647:
CBR-001-586-558-4,RFM-005-823-1,CBR-001-586-558-4,OC[C@H]([C@@H]([C@@H]([C@H](C=O)N)O)O)O,CBR-HVAC-07870: ; Metalloproteinase-8 inhibitor; Stromelysin inhibitor
CBR-001-586-559-5,RFM-005-824-2,CBR-001-586-559-5,NC(=O)CC[C@@H](C(=O)O)NC(=O)[C@@H](N)C,CBR-HVAC-06235: Treatment of Mucositis;Immunomodulators;Treatment of Nutritional Disorders;
CBR-001-586-560-8,RFM-005-825-3,CBR-001-586-560-8,SC[C@@H](C(=O)NCC(=O)OC(C)C)NC(=O)CC[C@@H](C(=O)O)N,"CBR-HVAC-03689: Anticataract Agents;Antianemics;Stroke, Treatment of;Antagonists to Metals; Lipid Peroxidation Inhibitors; Free radical scavenger"
CBR-001-586-561-9,RFM-005-826-4,CBR-001-586-561-9,NCCCCC(C(=O)N1CCCC1C(=O)O)NC(=O)C(NC(=O)C(NC(=O)C)CO)CC(=O)O,CBR-HVAC-04382: Immunomodulators;Hematopoietic Agents; Immunosuppressant; Immunostimulant
CBR-001-586-562-0,RFM-005-827-5,CBR-001-586-562-0,COc1[nH]c2c(c1C(=O)OCC1CCN(CC1)CCNS(=O)(=O)C)cc(cc2)F,"CBR-HVAC-10852: Urinary Incontinence Therapy;Irritable Bowel Syndrome, Agents for; Signal Transduction Modulators;5-HT4 Antagonists; 5-Hydroxytryptamine 4 receptor Antagonist;"
CBR-001-586-563-1,RFM-005-828-6,CBR-001-586-563-1,COC(=O)N1CCN(C(C1)CN1CCCC1)C(=O)Cc1ccc(c(c1)Cl)Cl,"CBR-HVAC-10695: Opioid Analgesics;Ischemic Stroke, Treatment of; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist;"
CBR-001-586-564-2,RFM-005-829-7,CBR-001-586-564-2,OCCNC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C(C)C)NC=O)C)CC(C)C)C)CC(C)C)CC(C)C)CC(C)C,CBR-HVAC-09594:
CBR-001-586-565-3,RFM-005-830-0,CBR-001-586-565-3,CC1NCCN(C1)c1cc2c(c(c1F)C)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-02843: Antibacterial Drugs; DNA Gyrase Inhibitors; Topoisomerase IV; Topoisomerase II Inhibitor; Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-566-4,RFM-005-831-1,CBR-001-586-566-4,CCn1nc(c(c1)c1ccnc2c1cc([nH]2)c1cccc(c1)CN(C)C)c1ccc(cc1)NC(=O)N(C)C,CBR-HVAC-06634: Solid Tumors Therapy; Antimitotic Drugs;Apoptosis Inducers;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;Signal Transduction Modulators; AURORA KINASE B; AURORA KINASE C Inhibitor;
CBR-001-586-567-5,RFM-005-832-2,CBR-001-586-567-5,Fc1ccc(c(c1)F)c1ccc(c(c1)C(=O)O)O,CBR-HVAC-00940: ; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor
CBR-001-586-568-6,RFM-005-833-3,CBR-001-586-568-6,NC(=N)NCCNS(=O)(=O)c1cccc2c1ccnc2,"CBR-HVAC-03187: Angina pectoris, Treatment of; Calcium Channel Blockers;"
CBR-001-586-569-7,RFM-005-834-4,CBR-001-586-569-7,CCN(CCOc1ccc(cc1)c1sc2c(n1)cc(cc2)Cl)CC,CBR-HVAC-09028:
CBR-001-586-570-0,RFM-005-835-5,CBR-001-586-570-0,O=C(Cn1cnc2c(c1=O)cc(c(c2)Br)Cl)C[C@@H]1NCCC[C@H]1O,CBR-HVAC-00418: ; Collagen type I alpha 1 Inhibitor; Collagen inhibitor
CBR-001-586-571-1,RFM-005-836-6,CBR-001-586-571-1,OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C(=C[C@]12C)Cl)F)F,"CBR-HVAC-02006: Eczema, Treatment of;Antipsoriatics; Glucocorticoid agonist; Arachidonic acid inhibitor; Immunosuppressant"
CBR-001-586-572-2,RFM-005-837-7,CBR-001-586-572-2,Fc1ccc(cc1)C(=O)NCCN1CCC(CC1)n1c(O)nc2c1ccc(c2)Cl,CBR-HVAC-05587: Antipsychotic Drugs; Dopamine Receptor Antagonists;Phospholipase D2 (PLD2) Inhibitors;Signal Transduction Modulators; Phospholipase D2 Inhibitor;
CBR-001-586-573-3,RFM-005-838-8,CBR-001-586-573-3,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1ccc(cc1)Cl,"CBR-HVAC-03104: Tourette's Syndrome, Treatment of;Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist;"
CBR-001-586-574-4,RFM-005-839-9,CBR-001-586-574-4,ClCCOP(=O)(Oc1ccc2c(c1)oc(=O)c(c2C)Cl)OCCCl,CBR-HVAC-10048:
CBR-001-586-575-5,RFM-005-840-2,CBR-001-586-575-5,OC1(OCC[N+](C1)(C)C)c1ccc(cc1)c1ccc(cc1)C1(O)OCC[N+](C1)(C)C,CBR-HVAC-09244: ; Choline transporter Inhibitor;
CBR-001-586-576-6,RFM-005-841-3,CBR-001-586-576-6,C=CC1=C(C)C2=Cc3c(C)c(c4n3[Fe](n3c(=CC1=N2)c(C)c(c3=CC1=NC(=C4)C(=C1C)CCC(=O)O)C=C)Cl)CCC(=O)O,analog of CBR-HVAC-05627 (Hemin)
CBR-001-586-577-7,RFM-005-842-4,CBR-001-586-577-7,CC(CCCC(O)(C)C)N,CBR-HVAC-09795:
CBR-001-586-578-8,RFM-005-843-5,CBR-001-586-578-8,OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)N1C(=O)[C@H](NC1(C)C)c1ccccc1,CBR-HVAC-09597: ; Penicillin binding protein 1A; Penicillin binding protein 1B Inhibitor;
CBR-001-586-579-9,RFM-005-844-6,CBR-001-586-579-9,CC(C[C@H](N1C(=O)N(C(C1=O)(C)C)Cc1ccc(cc1)NC(=O)Nc1ccccc1C)C(=O)N[C@H](c1ccccc1)CC(=O)O)C,CBR-HVAC-05196: Antiarthritic Drugs; Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists;Signal Transduction Modulators;
CBR-001-586-580-2,RFM-005-845-7,CBR-001-586-580-2,CN(CCc1ccc(cc1)O)C,CBR-HVAC-09800: ; Monoamine oxidase B Inhibitor;
CBR-001-586-581-3,RFM-005-846-8,CBR-001-586-581-3,C/C=C/1\[C@H]2C=C(C[C@]1(N)c1c(C2)nc(cc1)O)C,CBR-HVAC-01003: ; Acetylcholinesterase; N-methyl-D-aspartate glutamate receptor Inhibitor; Inhibitor; Acetylcholinesterase inhibitor
CBR-001-586-582-4,RFM-005-847-9,CBR-001-586-582-4,CCCCCCOc1cc(C)c(c(c1C)C)O,"CBR-HVAC-04524: Stroke, Treatment of;Liver and Biliary Tract Disorders, Treatment of; Lipid Peroxidation Inhibitors;"
CBR-001-586-583-5,RFM-005-848-0,CBR-001-586-583-5,Clc1cc2NCNS(=O)(=O)c2cc1S(=O)(=O)N,CBR-HVAC-02437: ; Carbonic anhydrase Inhibitor; Thiazide diuretic
CBR-001-586-584-6,RFM-005-849-1,CBR-001-586-584-6,CCCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C)C(=O)CO,"CBR-HVAC-01344: Antipruritics;Atopic Dermatitis, Agents for;Dermatologic Drugs; Phospholipase A2 inhibitor protein Inhibitor; Immunosuppressant; Corticosteroid agonist"
CBR-001-586-585-7,RFM-005-850-4,CBR-001-586-585-7,O[C@H]1CNC(=N[C@@H]1C(=O)O)C,"CBR-HVAC-06768: Inflammation, Treatment of;Inflammatory Bowel Disease, Agents for;Alzheimer's Dementia, Treatment of ;Dermatologic Drugs;"
CBR-001-586-586-8,RFM-005-851-5,CBR-001-586-586-8,Oc1cc(C)c2c3c1C(=O)c1c(O)cc(c4c1c3c1c3c2c(C)cc(c3C(=O)c2c1c4c(O)cc2O)O)O,CBR-HVAC-00807: Anti-HIV Agents;Glioblastoma Multiforme Therapy;Non-Hodgkin's Lymphoma Therapy;Antiviral Drugs;Antipsoriatics;Diagnostic for Cancer; Protein Kinase C (PKC) Inhibitors;Signal Transduction Modulators; HSP90 Inhibitor; Unidentified pharmacological activity
CBR-001-586-587-9,RFM-005-852-6,CBR-001-586-587-9,OCC1O[C@H](CC1O)n1cc(I)c(nc1=O)N,CBR-HVAC-02532: ; DNA synthesis inhibitor
CBR-001-586-588-0,RFM-005-853-7,CBR-001-586-588-0,CC(N[C@H]([C@H](COc1ccc(c2c1CCC2)C)O)C)C,CBR-HVAC-02996: Anxiolytics; beta2-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-2 adrenergic receptor Antagonist; Beta 2 adrenoreceptor antagonist; Membrane integrity enhancer
CBR-001-586-589-1,RFM-005-854-8,CBR-001-586-589-1,COCCNC(=O)COc1ccc(cc1)OCCNC[C@@H](COc1ccccc1)O,CBR-HVAC-04245: Antidiabetic Drugs;Antiobesity Drugs; Beta-3 adrenergic receptor Agonist; Beta 3 adrenoreceptor agonist
CBR-001-586-590-4,RFM-005-855-9,CBR-001-586-590-4,C[C@@H]([C@@H]([C@@H](C(=O)O)N)C)O,"CBR-HVAC-06036: Antiobesity Drugs;Type 2 Diabetes, Agents for; Antiinflammatory Drugs;Insulin Secretagogues;Insulin Sensitizers;Signal Transduction Modulators;"
CBR-001-586-591-5,RFM-005-856-0,CBR-001-586-591-5,Fc1ccc2c(c1)[nH]cc2CCNCc1cccc(c1)OCC(C(F)(F)F)(F)F,CBR-HVAC-00850
CBR-001-586-592-6,RFM-005-857-1,CBR-001-586-592-6,Oc1ccc(cc1)C1=Cc2c(OC1)cc(cc2)O,CBR-HVAC-05142: Breast Cancer Therapy;Cervical Cancer Therapy;Squamous Cell Carcinoma Therapy;Ovarian Cancer Therapy;Pancreatic Cancer Therapy;Renal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Solid Tumors Therapy;Leukemia Therapy;Melanoma Therapy;Basal Cell Carcinoma Therapy;Lung Cancer Therapy;Prostate Cancer Therapy;Antineoplastic Enhancing Agents; Apoptosis Inducers;BIRC4 Expression Inhibitors;Signal Transduction Modulators;Sphingosine Kinase Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors; Sphingosine kinase Inhibitor;
CBR-001-586-593-7,RFM-005-858-2,CBR-001-586-593-7,ClCCNP1(=O)OCCCN1CCCl,CBR-HVAC-01752: Oncolytic Drugs; DNA Alkylating Drugs; DNA inhibitor; DNA synthesis inhibitor
CBR-001-586-594-8,RFM-005-859-3,CBR-001-586-594-8,CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(c(c1)Nc1nccc(n1)c1cccnc1)C,"CBR-HVAC-02246: Head and Neck Cancer Therapy;Ovarian Cancer Therapy;Drugs for Allergic Rhinitis;Prostate Cancer Therapy;Hematopoiesis Disorders Therapy;Melanoma Therapy;Oncolytic Drugs;Lymphocytic Leukemia Therapy;Neurologic Drugs (Miscellaneous);Skin Cancer Therapy;Acute Respiratory Distress Syndrome (ARDS), Agents for;Myeloid Leukemia Therapy;Non-Small Cell Lung Cancer Therapy;Kaposi's Sarcoma Therapy;Colorectal Cancer Therapy;Respiratory/Thoracic Cancer Therapy;Bone Cancer Therapy;Scleroderma, Agents for;Digestive/Gastrointestinal Cancer Therapy;Immunosuppressants;Neurologic Cancer Therapy;Solid Tumors Therapy;Glioblastoma Multiforme Therapy;Astrocytoma Therapy;Small Cell Lung Cancer Therapy;Pulmonary Hypertension, Treatment of;Antiallergy/Antiasthmatic Drugs;Sarcoma Therapy;Interstitial Lung Diseases, Treatment of;Type 1 Diabetes, Agents for;Female Reproductive System Cancer Therapy;Breast Cancer Therapy; Abl1 Kinase Inhibitors;Angiogenesis Inhibitors;Apoptosis Inducers;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;CSF1R (c-FMS) Inhibitors;KIT (C-KIT) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators; BCR-ABL Inhibitor; Bcr-Abl inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; Apoptosis stimulant"
CBR-001-586-595-9,RFM-005-860-6,CBR-001-586-595-9,[O-][N+](CCCN1c2ccccc2CCc2c1cccc2)(C)C,CBR-HVAC-09051:
CBR-001-586-596-0,RFM-005-861-7,CBR-001-586-596-0,CC(Cn1cnc2c1c1ccccc1nc2N)C,"CBR-HVAC-01509: Anti-Papilloma Virus Drugs;Premalignant Conditions Therapy;Melanoma Therapy;Bladder Cancer Therapy ;Immunostimulants;Basal Cell Carcinoma Therapy;Breast Cancer Therapy;Antileishmanials;Non-Hodgkin's Lymphoma Therapy;Genital Warts, Treatment for;Actinic Keratoses, Agents for;Skin Cancer Therapy;Dermatologic Drugs; Interferon Inducers;Signal Transduction Modulators;TLR7 Receptor Agonists; Toll like receptor 7 Agonist; Immunostimulant"
CBR-001-586-597-1,RFM-005-862-8,CBR-001-586-597-1,NC(=O)C1C(=O)C[C@H]2[C@](C1=O)(O)C(=O)C1[C@H](C2)Cc2c(C1=O)c(O)ccc2,CBR-HVAC-00327: Renal Cancer Therapy;Solid Tumors Therapy;Melanoma Therapy;Brain Cancer Therapy;Lymphoma Therapy;Kaposi's Sarcoma Therapy;Acne Therapy; Angiogenesis Inhibitors;MMP-2 (Gelatinase A) Inhibitors;MMP-9 (Gelatinase B) Inhibitors;Signal Transduction Modulators;Vascular Endothelial Growth Factor (VEGF) Inhibitors; Matrix metalloproteinase Inhibitor; Matrix metalloproteinase inhibitor; Angiogenesis inhibitor
CBR-001-586-598-2,RFM-005-863-9,CBR-001-586-598-2,N1CCC(CC1)CCc1c[nH]c2c1cccc2,CBR-HVAC-02670: ; 5-Hydroxytryptamine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor
CBR-001-586-599-3,RFM-005-864-0,CBR-001-586-599-3,[O-]S(=O)(=O)CCCCN1c2ccc3c(c2C(/C/1=C\C=C\C=C\C=C\C1=[N+](CCCCS(=O)(=O)[O-])c2c(C1(C)C)c1ccccc1cc2)(C)C)cccc3,CBR-HVAC-01346: Diagnostic Agents; Not applicable
CBR-001-586-600-9,RFM-005-865-1,CBR-001-586-600-9,OC(=O)C(c1ccc(cc1)N1Cc2c(C1=O)cccc2)C,"CBR-HVAC-02644: Analgesic Drugs;Antiarthritic Drugs;Inflammation, Treatment of;Neurologic Drugs (Miscellaneous); Prostaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor"
CBR-001-586-601-0,RFM-005-866-2,CBR-001-586-601-0,OC(=O)[C@@H](Cc1cn(c2c1cccc2)C)N,"CBR-HVAC-00265: Melanoma Therapy;Brain Cancer Therapy;Prostate Cancer Therapy;Immunomodulators;Pancreatic Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy; Indoleamine 2,3-dioxygenase Inhibitors; Indoleamine-pyrrole 2,3-dioxygenase Inhibitor; Indoleamine-pyrrole 2,3 dioxygenase inhibitor"
CBR-001-586-602-1,RFM-005-867-3,CBR-001-586-602-1,OCC(CN(c1c(I)c(C(=O)NCC(CO)O)c(c(c1I)C(=O)NCC(CO)O)I)C(=O)C)O,CBR-HVAC-01347: Contrast Media; Not applicable
CBR-001-586-603-2,RFM-005-868-4,CBR-001-586-603-2,COCC(CN(c1c(I)c(C(=O)NCC(CO)O)c(c(c1I)C(=O)NCC(CO)O)I)C(=O)C)O,CBR-HVAC-01859: Contrast Media; Not applicable
CBR-001-586-604-3,RFM-005-869-5,CBR-001-586-604-3,CC(Oc1ccc2c(c1)occ(c2=O)c1ccccc1)C,CBR-HVAC-01547: Treatment of Osteoporosis; IGF1R Modulator; Bone resorption inhibitor
CBR-001-586-605-4,RFM-005-870-8,CBR-001-586-605-4,CN(CCCn1c2CCCCCCc2c2c1cccc2)C,CBR-HVAC-03126: Antidepressants; Norepinephrine transporter; 5-Hydroxytryptamine transporter Inhibitor;
CBR-001-586-606-5,RFM-005-871-9,CBR-001-586-606-5,Cc1onc(c1)C(=O)NNCc1ccccc1,"CBR-HVAC-03122: Migraine, Prophylactic Treatment of;Antidepressants; Monoamine oxidase Inhibitor;"
CBR-001-586-607-6,RFM-005-872-0,CBR-001-586-607-6,Oc1ccc(cc1)/C=C/C(=O)c1ccc(cc1O)O,"CBR-HVAC-10889: Antiallergy/Antiasthmatic Drugs;Antiulcer Drugs;Oncolytic Drugs;Inflammation, Treatment of;Hepatoprotectants;Antidiabetic Drugs;Chemopreventive Agents; Aldose Reductase Inhibitors;Angiogenesis Inhibitors;Apoptosis Inducers;Guanylate Cyclase Activators;Histamine H2 Receptor Antagonists;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;NMDA Antagonists;Signal Transduction Modulators; Aldose reductase Inhibitor;"
CBR-001-586-608-7,RFM-005-873-1,CBR-001-586-608-7,O=C(c1ccncc1)NNCS(=O)(=O)O,CBR-HVAC-08807:
CBR-001-586-609-8,RFM-005-874-2,CBR-001-586-609-8,NC(=S)C1CCCc2c1nccc2C,CBR-HVAC-01040:
CBR-001-586-610-1,RFM-005-875-3,CBR-001-586-610-1,O=C(C1C(=O)c2ccccc2S(=O)(=O)N1C)Nc1noc(c1)C,"CBR-HVAC-02661: Rheumatoid Arthritis, Treatment of;Osteoarthritis, Treatment of; 15-Lipoxygenase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-586-611-2,RFM-005-876-4,CBR-001-586-611-2,CC(NC(C(c1ccc(cc1)O)O)C)COc1ccccc1,CBR-HVAC-09821: ; Beta-1 adrenergic receptor Agonist;
CBR-001-586-612-3,RFM-005-877-5,CBR-001-586-612-3,C[C@]12CCC(=C[C@@H]1C(=O)C[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C)NOCCN,"CBR-HVAC-00714: Heart Failure Therapy;Positive Inotropic Agents; Na+/K+-ATPase Inhibitors; Na+, K+ ATPase Inhibitor; Na+ K+ transporting ATPase inhibitor"
CBR-001-586-613-4,RFM-005-878-6,CBR-001-586-613-4,COc1ccc(cc1)c1sc(nc1c1ccc(cc1)OC)C(F)(F)F,CBR-HVAC-02917: Antiplatelet Therapy; Platelet aggregation inhibitor
CBR-001-586-614-5,RFM-005-879-7,CBR-001-586-614-5,COc1cc(ccc1OC)C(=O)NCc1ccc(cc1)OCCN(C)C,"CBR-HVAC-01436: Prokinetic Agents;Gastroesophageal Reflux Disease, Agents for;Non-Ulcer Dyspepsia, Agents for; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Inhibitor; Dopamine D2 receptor antagonist; Acetylcholinesterase inhibitor"
CBR-001-586-615-6,RFM-005-880-0,CBR-001-586-615-6,CO[C@H]1C[C@H](O[C@H]2[C@@H](C)/C=C/C=C/3\CO[C@H]4[C@]3(O)[C@@H](C=C([C@H]4O)C)C(=O)O[C@H]3C[C@@H](C/C=C/2\C)O[C@]2(C3)CC[C@@H]([C@H](O2)[C@H](CC)C)C)O[C@H]([C@@H]1O[C@H]1C[C@H](OC)[C@H]([C@@H](O1)C)O)C,CBR-HVAC-01528: ; GABA receptor Modulator; GABA release stimulant; GABA receptor agonist
CBR-001-586-616-7,RFM-005-881-1,CBR-001-586-616-7,COc1ccc(cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(c1)N)Br,CBR-HVAC-00473: Solid Tumors Therapy; Angiogenesis Inhibitors;EphB4 Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; EPHB4; PDGFR beta; VEGFR2 Inhibitor; VEGFR-2 tyrosine kinase inhibitor; EphB receptor kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Angiogenesis inhibitor
CBR-001-586-617-8,RFM-005-882-2,CBR-001-586-617-8,COc1c(ncnc1Nc1ccc(nc1C)S(=O)(=O)C)OC1CCN(CC1)C(=O)OC(C)C,"CBR-HVAC-06865: Type 2 Diabetes, Agents for; Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119)  Agonists;Signal Transduction Modulators; G-protein coupled receptor-119 Agonist;"
CBR-001-586-618-9,RFM-005-883-3,CBR-001-586-618-9,OC[C@H]1O[C@H]([C@@H]([C@H]([C@@H]1O)O)O)c1c(O)ccc2c1occ(c2=O)c1ccc(cc1)O,"CBR-HVAC-05701: Liver and Biliary Tract Disorders, Treatment of;Treatment of Alcohol Dependency;Angina pectoris, Treatment of;Lipoprotein Disorders, Treatment of ;Diabetic Retinopathy, Agents for;Antidiabetic Drugs; Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators;L-Type Calcium Channel Blockers; Beta adrenergic receptor Blocker;"
CBR-001-586-619-0,RFM-005-884-4,CBR-001-586-619-0,CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCO,CBR-HVAC-11545: ; Cannabinoid receptor 1 Antagonist;
CBR-001-586-620-3,RFM-005-885-5,CBR-001-586-620-3,CN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1,CBR-HVAC-02620: ; Histamine H1 receptor Inhibitor; Histamine H1 receptor antagonist
CBR-001-586-621-4,RFM-005-886-6,CBR-001-586-621-4,c1coc(c1)CNc1ncnc2c1nc[nH]2,CBR-HVAC-05143: Neurologic Drugs (Miscellaneous);Dermatologic Drugs;
CBR-001-586-622-5,RFM-005-887-7,CBR-001-586-622-5,COc1cc2c(NCCCCCO[N+](=O)[O-])ncnc2c(c1OC)OC,"CBR-HVAC-10672: Hypertension, Treatment of;Vasodilators;Angina pectoris, Treatment of;"
CBR-001-586-623-6,RFM-005-888-8,CBR-001-586-623-6,CCc1oc2c(c1C(=O)c1ccc(cc1)OCC(=O)O)cccc2,CBR-HVAC-00336: Uricosurics; Uric acid diuretic
CBR-001-586-624-7,RFM-005-889-9,CBR-001-586-624-7,O=C(CS(=O)Cc1ccco1)NC/C=C\COc1nccc(c1)CN1CCCCC1,"CBR-HVAC-01925: Agents for Gastritis;Gastroesophageal Reflux Disease, Agents for;Gastric Antisecretory Drugs; Histamine H2 Receptor Antagonists;Signal Transduction Modulators; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist"
CBR-001-586-625-8,RFM-005-890-2,CBR-001-586-625-8,Fc1cccc(c1)COc1ccc(cc1Cl)Nc1ncnc2c1cc(cc2)c1ccc(o1)CNCCS(=O)(=O)C,"CBR-HVAC-01434: Pancreatic Cancer Therapy;Neurological Genetic Disorders, Treatment of ;Colorectal Cancer Therapy;Liver Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Endocrine Cancer Therapy;Lung Cancer Therapy;Cancer of Unspecified Body Location/System;Breast Cancer Therapy;Glioblastoma Multiforme Therapy;Neurologic Cancer Therapy;Ovarian Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Renal Cancer Therapy;Prostate Cancer Therapy;Gastric Cancer Therapy;Bladder Cancer Therapy ;Head and Neck Cancer Therapy;Cervical Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators; EGFR; ERBB2 Inhibitor; ErbB-2 tyrosine kinase inhibitor; Epidermal growth factor antagonist; Tyrosine kinase inhibitor (TKI); EGFR kinase inhibitor"
CBR-001-586-626-9,RFM-005-891-3,CBR-001-586-626-9,NC(=O)CN1CCN(CC1)Cc1onc(n1)c1cn(c2c1cccc2Cl)CC1CCOCC1,"CBR-HVAC-07220: Neuropathic Pain, Treatment of; Cannabinoid CB1 Agonists;Signal Transduction Modulators;"
CBR-001-586-627-0,RFM-005-892-4,CBR-001-586-627-0,CCOC=c1[nH]c(=O)c2c([nH]1)nccn2,CBR-HVAC-04100: Antiallergy/Antiasthmatic Drugs; Mediator Release Inhibitors; Histamine receptor Antagonist; Histamine release inhibitor
CBR-001-586-628-1,RFM-005-893-5,CBR-001-586-628-1,NC(=O)NCCCC(C(=O)O)N,CBR-HVAC-02354: ; Nitric oxide stimulant
CBR-001-586-629-2,RFM-005-894-6,CBR-001-586-629-2,O=C(c1cnoc1C)Nc1ccc(cc1)C(F)(F)F,"CBR-HVAC-01621: Treatment of Transplant Rejection;Anti-HIV Agents;Rheumatoid Arthritis, Treatment of;Immunosuppressants;Psoriatic Arthritis, Treatment of ;Melanoma Therapy;Multiple Myeloma Therapy;Prostate Cancer Therapy;Disease-Modifying Anti-Rheumatic Drugs;Brain Cancer Therapy;Ovarian Cancer Therapy; Angiogenesis Inhibitors;Dihydroorotate Dehydrogenase (DHODH) Inhibitors;Jak3 Inhibitors;PDGFR Family Inhibitors;Signal Transducer and Activator of Transcription 6 (STAT6) Inhibitors;Signal Transduction Modulators; Dihydroorotate dehydrogenase Inhibitor; Disease modifying antirheumatic drug; Dihydroorotate dehydrogenase inhibitor; Immunosuppressant; Platelet-derived growth factor receptor kinase inhibitor"
CBR-001-586-630-5,RFM-005-895-7,CBR-001-586-630-5,O=C(N(C)C)Oc1cc(cc(c1)OC(=O)N(C)C)C(CNC(C)(C)C)O,CBR-HVAC-02355: ; Beta-2 adrenergic receptor Agonist; Unidentified pharmacological activity
CBR-001-586-631-6,RFM-005-896-8,CBR-001-586-631-6,O[C@H](C[N+](C)(C)C)CC(=O)[O-],CBR-HVAC-01417: ; Carnitine acetyltransferase Inhibitor; Carnitine O-acetyltransferase stimulant
CBR-001-586-632-7,RFM-005-897-9,CBR-001-586-632-7,COc1ccc2c(c1)N(C[C@@H](CN(C)C)C)c1c(S2)cccc1,CBR-HVAC-03109: Antipsychotic Drugs;Therapy of Inborn Errors of Metabolism; Dopamine receptor D2 Antagonist;
CBR-001-586-633-8,RFM-005-898-0,CBR-001-586-633-8,CN1CCC(CC1)OC(=O)C(Oc1ccc(cc1)Cl)Oc1ccc(cc1)Cl,"CBR-HVAC-08986: Lipoprotein Disorders, Treatment of ;"
CBR-001-586-634-9,RFM-005-899-1,CBR-001-586-634-9,CCC/C=C/1\OC(=O)C2=C1CCC=C2,"CBR-HVAC-06279: Analgesic Drugs;Treatment of Osteoporosis;Vasodilators;Inflammation, Treatment of;Ischemia, Treatment of;Treatment of Shock;Treatment of Dysmenorrhea;Stroke, Treatment of;Cognition Disorders, Treatment of; Calcium Channel Blockers;IL-1B Expression Inhibitors ;IL-6 Expression Inhibitors;NF-kappaB (NFKB) Modulators;Signal Transduction Modulators;TNF-alpha Production Inhibitors;"
CBR-001-586-635-0,RFM-005-900-7,CBR-001-586-635-0,Clc1ccccc1OCCNC1CC1,CBR-HVAC-07988: Antidepressants; MAO-A Inhibitors; Monoamine oxidase A inhibitor
CBR-001-586-636-1,RFM-005-901-8,CBR-001-586-636-1,Cl[C@@H]1[C@H](Cl)[C@@H](Cl)[C@@H]([C@@H]([C@H]1Cl)Cl)Cl,CBR-HVAC-09610:
CBR-001-586-637-2,RFM-005-902-9,CBR-001-586-637-2,O=C1N(c2ccccc2)c2c(C1(Cc1ccncc1)Cc1ccncc1)cccc2,"CBR-HVAC-03653: Cognition Disorders, Treatment of; Acetylcholine Release Enhancers;Signal Transduction Modulators; Potassium channel KCNQ Blocker; Neurotransmitter agonist; Acetylcholine release stimulant"
CBR-001-586-638-3,RFM-005-903-0,CBR-001-586-638-3,OC(=O)[C@H](Cc1cc(I)c(c(c1)I)Oc1ccc(c(c1)I)O)N,CBR-HVAC-02357: Heart Failure Therapy;Thyroid Disease Therapy; Thyroid receptor Agonist; Thyroid hormone function stimulant
CBR-001-586-639-4,RFM-005-904-1,CBR-001-586-639-4,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O)O,CBR-HVAC-01292: ; Prostaglandin E receptor 1 Agonist; Prostaglandin EP1 receptor agonist; Prostaglandin E1 receptor agonist; Platelet aggregation inhibitor
CBR-001-586-640-7,RFM-005-905-2,CBR-001-586-640-7,CC(=O)OC(OC(=O)C(c1ccc(c(c1)F)c1ccccc1)C)C,"CBR-HVAC-02297: Analgesic Drugs;Inflammation, Treatment of;Non-Opioid Analgesics; Cyclooxygenase (COX) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-586-641-8,RFM-005-906-3,CBR-001-586-641-8,O[C@H](c1ccccc1)C[C@@H]1CCC[C@@H](N1C)CC(=O)c1ccccc1,"CBR-HVAC-01111: Treatment of Substance Dependency;Neurologic Drugs (Miscellaneous);Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Dopamine Receptor Modulators;mu-Opioid Antagonists;Nicotinic alpha4beta2 Antagonists;Signal Transduction Modulators;Vesicular Monoamine Transporter 2 (VMAT2) Ligands; Nicotinic acetylcholine receptor Agonist; Neuronal nicotinic receptor antagonist"
CBR-001-586-642-9,RFM-005-907-4,CBR-001-586-642-9,CCOC(=O)C(=O)Nc1cc(C#N)cc(c1Cl)NC(=O)C(=O)OCC,CBR-HVAC-05790: Antiallergy/Antiasthmatic Drugs;
CBR-001-586-643-0,RFM-005-908-5,CBR-001-586-643-0,OC(=O)Cc1cn(nc1c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-01512: ; Cyclooxygenase inhibitor; Arachidonic acid inhibitor
CBR-001-586-644-1,RFM-005-909-6,CBR-001-586-644-1,Clc1ccc(c(c1)Cl)Cn1nc(c2c1cccc2)C(=O)O,CBR-HVAC-01945: Oncolytic Drugs;Benign Prostatic Hyperplasia Therapy; Hexokinase Inhibitor; Protein synthesis inhibitor
CBR-001-586-645-2,RFM-005-910-9,CBR-001-586-645-2,Clc1ccc(cc1)C1(O)CCN(CC1)CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1,CBR-HVAC-01351: ; Opioid receptor Agonist; Opioid receptor agonist
CBR-001-586-646-3,RFM-005-911-0,CBR-001-586-646-3,CCOC(=O)N1CCC(=C2c3ccc(cc3CCc3c2nccc3)Cl)CC1,"CBR-HVAC-01693: Drugs for Allergic Rhinitis;Urticaria, Treatment for;Antipruritics;Antiallergy/Antiasthmatic Drugs;Non-Opioid Analgesics;Inflammatory Bowel Disease, Agents for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Inhibitor; Histamine H1 receptor antagonist"
CBR-001-586-647-4,RFM-005-912-1,CBR-001-586-647-4,O=C(c1ccc(nc1)c1cc(cc(c1C)F)C(=O)NC1CC1)NCC(C)(C)C,"CBR-HVAC-00745: Atherosclerosis Therapy;Neuropathic Pain, Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Lipoprotein Disorders, Treatment of ;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Antipsoriatics;Antidepressants;Treatment of Renal Diseases;Rheumatoid Arthritis, Treatment of; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators; P38 kinase inhibitor"
CBR-001-586-648-5,RFM-005-913-2,CBR-001-586-648-5,ClCOC(=O)[C@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C)OC(=O)OCC,CBR-HVAC-04139: Antiinflammatory Ophthalmic Agents;Ocular Antiinflammatory and Antiinfective Agents;Antiallergic Ophthalmic Agents;Asthma Therapy;Drugs for Allergic Rhinitis;Dermatologic Drugs; Phospholipase A1 inhibitor; Corticosteroid agonist
CBR-001-586-649-6,RFM-005-914-3,CBR-001-586-649-6,C=CCn1c(=O)n(c2c1c(O)nc(n2)N)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)CO,CBR-HVAC-03965: Immunostimulants; Signal Transduction Modulators;TLR7 Receptor Ligands; Toll-like receptor 7 Agonist;
CBR-001-586-650-9,RFM-005-915-4,CBR-001-586-650-9,N=C(c1cccs1)Nc1ccccc1,CBR-HVAC-07999:
CBR-001-586-651-0,RFM-005-916-5,CBR-001-586-651-0,CNC(=O)c1cccc2c1ccc(c2)Oc1ccnc2c1cc(OC)c(c2)OCC1(N)CC1,CBR-HVAC-00704: Oncolytic Drugs;Small Cell Lung Cancer Therapy;Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Angiogenesis Inhibitors;CSF1R (c-FMS) Inhibitors;FGFR1 Inhibitors;FGFR2 Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Platelet-derived growth factor receptor beta; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3 Inhibitor; FGF receptor 1 tyrosine kinase inhibitor; FGF receptor 2 tyrosine kinase inhibitor; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; FGF receptor 3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor alpha kinase inhib; Platelet-derived growth factor receptor beta kinase inhib
CBR-001-586-652-1,RFM-005-917-6,CBR-001-586-652-1,O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1,"CBR-HVAC-01450: Antipsychotic Drugs;Bipolar Disorder, Treatment of;Antidepressants; Dopamine D2 Antagonists;Serotonin Antagonists;Serotonin Partial Agonists;Signal Transduction Modulators;5-HT1A Receptor Partial Agonists;5-HT2A Antagonists;5-HT7 Antagonists; 5-hydroxytryptamine 1A receptor; Adrenergic alpha 2C receptor; 5-hydroxytryptamine 7 receptor; 5-hydroxytryptamine 2A receptor; D2 dopamine receptor Antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 7 receptor antagonist; 5 Hydroxytryptamine 1A receptor antagonist; 5 Hydroxytryptamine 2A receptor antagonist"
CBR-001-586-653-2,RFM-005-918-7,CBR-001-586-653-2,C/C(=C\C=C\C=C(\C=C\C=C(\C=C\C1=C(C)C[C@H](CC1(C)C)O)/C)/C)/C=C/C=C(/C=C/[C@H]1C(=C[C@@H](CC1(C)C)O)C)\C,CBR-HVAC-05565: Ultraviolet Light Absorbers;Atherosclerosis Therapy;Chemopreventive Agents; Antioxidants;
CBR-001-586-654-3,RFM-005-919-8,CBR-001-586-654-3,CCc1cc(C(=O)C)c(cc1OCCCCCC(c1nnn[nH]1)(C)C)O,"CBR-HVAC-10505: Antipsoriatics;Antiallergy/Antiasthmatic Drugs;Inflammatory Bowel Disease, Agents for; Leukotriene Antagonists;Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators; Leukotriene B4 receptor Antagonist;"
CBR-001-586-655-4,RFM-005-920-1,CBR-001-586-655-4,CC(Oc1cccc(c1)n1c(CCc2c[nH]c3c2cc(Br)cc3)nc2c(c1=O)cccc2)C,"CBR-HVAC-09427: Non-Opioid Analgesics;Irritable Bowel Syndrome, Agents for; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; CCKB receptor ANTAGONIST;"
CBR-001-586-656-5,RFM-005-921-2,CBR-001-586-656-5,C/C(=C\C=C\C=C(\C=C\C=C(\C=C\C=C(\CCC=C(C)C)/C)/C)/C)/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C,"CBR-HVAC-04883: Hypertension, Treatment of;Chemopreventive Agents; Antioxidants;Free Radical Scavengers;"
CBR-001-586-657-6,RFM-005-922-3,CBR-001-586-657-6,OC(c1cc(Cl)c(c(c1)C(F)(F)F)N)CNC(C)(C)C,CBR-HVAC-02117: Bronchodilators; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-586-658-7,RFM-005-923-4,CBR-001-586-658-7,CCOC(=O)CC(C(=O)OCC)SP(=S)(OC)OC,CBR-HVAC-06870: Antiinfectives (Not Specified); Acetylcholinesterase Inhibitor;
CBR-001-586-659-8,RFM-005-924-5,CBR-001-586-659-8,OC1O[C@H](COP(=O)([O-])[O-])[C@H]([C@@H]([C@H]1O)O)O,CBR-HVAC-06303: Treatment of Postmenopausal Syndrome ;Ophthalmic Drugs;Wound-Healing Agents; Signal Transduction Modulators;TGF-beta 1 Inhibitors;
CBR-001-586-660-1,RFM-005-925-6,CBR-001-586-660-1,O=CC(C(C(C(COP(=O)(O)O)O)O)O)O,CBR-HVAC-00538: ; Transforming growth factor beta 1 antagonist; Transforming growth factor beta 2 antagonist
CBR-001-586-661-2,RFM-005-926-7,CBR-001-586-661-2,CN1CCN(CC1)c1c(F)cc2c3c1OCN(n3cc(c2=O)C(=O)O)C,CBR-HVAC-03719: Antibacterial Drugs;
CBR-001-586-662-3,RFM-005-927-8,CBR-001-586-662-3,CSc1nc(Nc2ccccc2)c2c(n1)nccc2,"CBR-HVAC-10539: Hypertension, Treatment of;Diuretics;"
CBR-001-586-663-4,RFM-005-928-9,CBR-001-586-663-4,Clc1ccc2c(c1)nc(c(c2O)c1ccccc1)O,"CBR-HVAC-10862: Antiepileptic Drugs;Stroke, Treatment of; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-586-664-5,RFM-005-929-0,CBR-001-586-664-5,[O-][N+]1=Cc2ccccc2CC1(C)C,"CBR-HVAC-11526: Stroke, Treatment of;Septic Shock, Treatment of ; Lipid Peroxidation Inhibitors;"
CBR-001-586-665-6,RFM-005-930-3,CBR-001-586-665-6,NNC(c1ccccc1)C,CBR-HVAC-09820: ; Monoamine oxidase Inhibitor;
CBR-001-586-666-7,RFM-005-931-4,CBR-001-586-666-7,OC(=O)CN(CC(=O)Nc1c(C)cc(c(c1C)Br)C)CC(=O)O,CBR-HVAC-03026: Diagnostic Agents; Not applicable
CBR-001-586-667-8,RFM-005-932-5,CBR-001-586-667-8,O=C1CC[C@]2(C(=C1)[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(O)C(=O)C)C)C,CBR-HVAC-00981: ; Progesterone receptor agonist; Interleukin 6 antagonist
CBR-001-586-668-9,RFM-005-933-6,CBR-001-586-668-9,OC(=O)CC(CC(=O)O)(O)C,CBR-HVAC-01551: ; HMGCoA reductase inhibitor
CBR-001-586-669-0,RFM-005-934-7,CBR-001-586-669-0,OC(COc1cccc2c1cc([nH]2)C)CNC(C)C,"CBR-HVAC-01542: Hypertension, Treatment of;Angina pectoris, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist"
CBR-001-586-670-3,RFM-005-935-8,CBR-001-586-670-3,CCCNC(COC(=O)c1ccccc1)(C)C,CBR-HVAC-09844: ; Sodium channel Blocker;
CBR-001-586-671-4,RFM-005-936-9,CBR-001-586-671-4,CCCCN1C(=O)C(=C/C=C/C=c/2\oc3c(n2CCCS(=O)(=O)O)cccc3)C(=O)N(C1=S)CCCC,CBR-HVAC-10735:
CBR-001-586-672-5,RFM-005-937-0,CBR-001-586-672-5,OCc1c(CO)cnc(c1O)C,CBR-HVAC-02295: Catechol-O-methyltransferase Inhibitor; Neurologic Drugs (Miscellaneous); Vitamin supplement
CBR-001-586-673-6,RFM-005-938-1,CBR-001-586-673-6,Clc1ccc(cc1)[C@H](C(=O)O)Oc1cccc(c1)C(F)(F)F,CBR-HVAC-11706: ; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; URATE TRANSPORTER 1 Modulator;
CBR-001-586-674-7,RFM-005-939-2,CBR-001-586-674-7,CC(C(c1cccc(c1)O)O)N,"CBR-HVAC-04563: Treatment of Male Sexual Dysfunction;Hypotension, Treatment of;Anorexigenics;Antiobesity Drugs; Adrenoceptor Agonists;Signal Transduction Modulators; Alpha adrenergic receptor Agonist;"
CBR-001-586-675-8,RFM-005-940-5,CBR-001-586-675-8,O=C(c1ccncc1)NNCNNC(=O)c1ccncc1,CBR-HVAC-08814:
CBR-001-586-676-9,RFM-005-941-6,CBR-001-586-676-9,O=C(OCc1ccccc1)NC[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C,"CBR-HVAC-02039: Vasodilators;Treatment of Hyperprolactinemia;Migraine, Prophylactic Treatment of; 5-Hydroxytryptamine receptor Antagonist; Dopamine D2 receptor agonist; Prolactin inhibitor; 5 Hydroxytryptamine receptor antagonist"
CBR-001-586-677-0,RFM-005-942-7,CBR-001-586-677-0,CCC1(CC(=C)C)C(=O)NC(=S)NC1=O,CBR-HVAC-08916:
CBR-001-586-678-1,RFM-005-943-8,CBR-001-586-678-1,COC1(COc2c(O1)cccc2)C1=NCCN1,"CBR-HVAC-03353: Antidepressants;Stroke, Treatment of; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators; Alpha 2 adrenoreceptor antagonist"
CBR-001-586-679-2,RFM-005-944-9,CBR-001-586-679-2,CCC(CC(N)C)C,CBR-HVAC-09260:
CBR-001-586-680-5,RFM-005-945-0,CBR-001-586-680-5,CC(C#C)(OC(=O)N)CC,CBR-HVAC-09835:
CBR-001-586-681-6,RFM-005-946-1,CBR-001-586-681-6,OC(=O)CCC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)C,"CBR-HVAC-05240: Urologic Drugs;Treatment of Musculoskeletal &amp; Connective Tissue Diseases (Miscellaneous);Dermatologic Drugs;Endocrine Disorders (Not Specified);Gastrointestinal Disorders (Not Specified);Cardiovascular Diseases (Not Specified);Antiallergy/Antiasthmatic Drugs;Immunosuppressants;Hematological Cancer Therapy;Ophthalmic Drugs;Neurologic Drugs (Miscellaneous);Hematologic Agents (Miscellaneous);Treatment of Renal Diseases;Respiratory Disorders (Not Specified);Multiple Sclerosis, Agents for;Rheumatoid Arthritis, Treatment of;"
CBR-001-586-682-7,RFM-005-947-2,CBR-001-586-682-7,COc1cccc(c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C)OC,CBR-HVAC-02850: Antibiotics; Penicillin binding protein Inhibitor;
CBR-001-586-683-8,RFM-005-948-3,CBR-001-586-683-8,O=C(c1ccc(c(c1)S(=O)(=O)N)Cl)NN(c1ccccc1)C,CBR-HVAC-08044: ; Diuretic
CBR-001-586-684-9,RFM-005-949-4,CBR-001-586-684-9,CN1CCCC(C1)CC1c2ccccc2Sc2c1cccc2,CBR-HVAC-03136: Antiparkinsonian Drugs; Muscarinic Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Antagonist;
CBR-001-586-685-0,RFM-005-950-7,CBR-001-586-685-0,CCN(CCNC(=O)c1cc(Cl)c(cc1OC)N)CC,"CBR-HVAC-01300: Nausea and Vomiting, Treatment of;Gastroesophageal Reflux Disease, Agents for;Oncolytic Drugs;Antimigraine Drugs;Prokinetic Agents;Treatment of Diabetic Complications; Dopamine Receptor Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-586-686-1,RFM-005-951-8,CBR-001-586-686-1,COP(=O)(C(C(Cl)(Cl)Cl)O)OC,"CBR-HVAC-01241: Treatment of Helminthic Diseases;Alzheimer's Dementia, Treatment of ; Butyrylcholinesterase Inhibitors; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor"
CBR-001-586-687-2,RFM-005-952-9,CBR-001-586-687-2,OC[C@H]1OC(O)[C@@H]([C@H]([C@@H]1O)O)NC(=O)c1c(I)c(NC(=O)C)c(c(c1I)N(C(=O)C)C)I,CBR-HVAC-02058: ; Not applicable
CBR-001-586-688-3,RFM-005-953-0,CBR-001-586-688-3,O=C([C@@H](c1ccccc1)NC(=O)N1CCN(C1=O)S(=O)(=O)C)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C,CBR-HVAC-02228: Antibiotics; Cell wall synthesis inhibitor
CBR-001-586-689-4,RFM-005-954-1,CBR-001-586-689-4,COc1ccc(cc1C(CNC(=O)CN)O)OC,"CBR-HVAC-02179: Treatment of Male Sexual Dysfunction;Hypotension, Treatment of;Neurologic Drugs (Miscellaneous);Anti-Influenza A Virus Drugs; alpha1-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha-1 adrenergic receptor Agonist; Alpha 1 adrenoreceptor agonist"
CBR-001-586-690-7,RFM-005-955-2,CBR-001-586-690-7,CC#C[C@]1(O)CC[C@@H]2[C@]1(C)C[C@H](c1ccc(cc1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@H]21,"CBR-HVAC-02017: Cushing's Syndrome, Agents for;Gynecological Disorders, Treatment of ;Antiobesity Drugs;Female Reproductive System Cancer Therapy;Posttraumatic Stress Disorder (PTSD), Treatment of;Anti-Hepatitis C Virus Drugs;Antipsychotic Drugs;Cognition Disorders, Treatment of;Digestive/Gastrointestinal Cancer Therapy;Ovarian Cancer Therapy;Bipolar Disorder, Treatment of;Alzheimer's Dementia, Treatment of ;Ophthalmic Drugs;Breast Cancer Therapy;Abortifacients;Anti-HIV Agents;Treatment of Alcohol Dependency; Androgen Receptor Ligands;Glucocorticoid Receptor (GR) Antagonists;Internal Ribosomal Entry Site (IRES) Inhibitors;Progesterone Receptor Antagonists;Signal Transduction Modulators; Progesterone receptor; Glucocorticoid receptor Antagonist; Progesterone receptor antagonist; Glucocorticoid antagonist"
CBR-001-586-691-8,RFM-005-956-3,CBR-001-586-691-8,CCCCCCCC/C=C\CCCCCCC(C(=O)O)O,"CBR-HVAC-06275: Hypertension, Treatment of;Oncolytic Drugs;Neurologic Cancer Therapy;Solid Tumors Therapy;Sleep Disorders, Treatment of; Fatty Acid Amide Hydrolase (FAAH) Inhibitors;Protein Kinase C (PKC) Activators;Signal Transduction Modulators; Unidentified pharmacological activity"
CBR-001-586-692-9,RFM-005-957-4,CBR-001-586-692-9,CC(c1ccc(cc1)c1nc2n(c1)cccc2)C(=O)O,CBR-HVAC-01216: ; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-586-693-0,RFM-005-958-5,CBR-001-586-693-0,O=C(N1C[C@@H]2[C@H](C1)CCCC2)C[C@@H](C(=O)O)Cc1ccccc1,"CBR-HVAC-01997: Type 2 Diabetes, Agents for; Insulin Secretagogues;Signal Transduction Modulators; ATP-sensitive potassium channel Antagonist; ATP-sensitive potassium channel antagonist; Meglitinide; Insulin secretagogue"
CBR-001-586-694-1,RFM-005-959-6,CBR-001-586-694-1,BrC[C@H]([C@H]([C@@H]([C@@H](CBr)O)O)O)O,CBR-HVAC-02243: Brain Cancer Therapy;Oncolytic Drugs; DNA-Damaging Drugs; DNA inhibitor
CBR-001-586-695-2,RFM-005-960-9,CBR-001-586-695-2,ClC(C(c1ccccc1Cl)c1ccc(cc1)Cl)Cl,"CBR-HVAC-06014: Solid Tumors Therapy;Cushing's Syndrome, Agents for;"
CBR-001-586-696-3,RFM-005-961-0,CBR-001-586-696-3,CCOC(=O)Nc1nc(N)c2c(c1)[nH]c(c([nH]2)c1ccccc1)C,CBR-HVAC-00429: Leukemia Therapy;Brain Cancer Therapy;Lung Cancer Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors; Tubulin Antagonist; Tubulin inhibitor; Mitotic inhibitor
CBR-001-586-697-4,RFM-005-962-1,CBR-001-586-697-4,COc1ccc(cc1)c1c(onc1c1ccc(cc1)OC)CC(=O)O,CBR-HVAC-01829: Non-Opioid Analgesics; Prostaglandin G/H synthase 1 Inhibitor; Cyclooxygenase inhibitor; Arachidonic acid inhibitor; Platelet aggregation inhibitor
CBR-001-586-698-5,RFM-005-963-2,CBR-001-586-698-5,CCOC(=O)CC(=O)N1CCSC1COc1ccccc1OC,CBR-HVAC-03838: Antitussives; Potassium channel Activator; Acetylcholine receptor antagonist
CBR-001-586-699-6,RFM-005-964-3,CBR-001-586-699-6,ClCC(=O)[C@@]1(OC(=O)c2ccco2)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)Cl,"CBR-HVAC-01526: Atopic Dermatitis, Agents for;Treatment of Upper Respiratory Tract Disorders;Drugs for Allergic Rhinitis;Nasal Decongestants;Dermatologic Drugs;Antipsoriatics;Asthma Therapy;Eczema, Treatment of; Antiinflammatory Drugs;Cytochrome P450 CYP3A4 Inhibitors; Progesterone receptor Agonist; Glucocorticoid agonist; Immunosuppressant"
CBR-001-586-700-2,RFM-005-965-4,CBR-001-586-700-2,O[C@H]1C[C@H]2C([C@@]1(CC2)CS(=O)(=O)N(C1CCCCC1)C1CCCCC1)(C)C,CBR-HVAC-08588: Non-Small Cell Lung Cancer Therapy; Apoptosis Inducers; CD19 Inhibitor; Modulator;
CBR-001-586-701-3,RFM-005-966-5,CBR-001-586-701-3,OC(=O)CCc1ccc(n1c1ccc(cc1C)C(=O)N)c1ccc(cc1)n1cncc1,"CBR-HVAC-07041: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Inflammatory Bowel Disease, Agents for;Asthma Therapy;Inflammation, Treatment of;Cystic Fibrosis, Treatment of ; Alcohol Dehydrogenase class-3 (GSNOR; ADH5) Inhibitors; S-Nitrosoglutathione reductase (GSNOR) Inhibitor;"
CBR-001-586-702-4,RFM-005-967-6,CBR-001-586-702-4,OC(COc1cccc2c1C[C@H](O)[C@@H](C2)O)CNC(C)(C)C,"CBR-HVAC-01418: Cystic Fibrosis, Treatment of ;Antiarrhythmic Drugs;Hypertension, Treatment of;Angina pectoris, Treatment of;Asthma Therapy;Migraine, Prophylactic Treatment of;Smoking Cessation, Aid to;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Agents for Liver Cirrhosis; beta-Adrenoceptor Antagonists;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor Antagonist; Beta adrenoreceptor antagonist"
CBR-001-586-703-5,RFM-005-968-7,CBR-001-586-703-5,O=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CC2)ccc1O)O,CBR-HVAC-00802: ; Opioid receptor Antagonist; Opioid receptor antagonist
CBR-001-586-704-6,RFM-005-969-8,CBR-001-586-704-6,CCC(c1ccc(cc1)c1ccccc1)C(=O)O,CBR-HVAC-10084:
CBR-001-586-705-7,RFM-005-970-1,CBR-001-586-705-7,CNS(=O)(=O)CCc1ccc2c(c1)c(c[nH]2)C1CCN(CC1)C,"CBR-HVAC-02180: Acute Attacks of Migraine, Treatment of;Antimigraine Drugs; Signal Transduction Modulators;5-HT1B Agonists;5-HT1D Agonists; 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; 5 Hydroxytryptamine 1D receptor agonist; 5 Hydroxytryptamine 1B receptor agonist"
CBR-001-586-706-8,RFM-005-971-2,CBR-001-586-706-8,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@H]([C@@H]([C@@H]2O)N)O)C[C@@H]2O[C@@](C[C@H](C[C@@H]3[C@@H](/C=C/C(=O)O1)O3)O)(O)C[C@@H]([C@H]2C(=O)O)O,CBR-HVAC-06857: Antifungal Agents;
CBR-001-586-707-9,RFM-005-972-3,CBR-001-586-707-9,CNC(C(c1ccc(c(c1)O)O)O)C(=O)O,CBR-HVAC-08076: ; Dopamine receptor agonist
CBR-001-586-708-0,RFM-005-973-4,CBR-001-586-708-0,O=C(C(=O)NC1CC(C)(C)NC(C1)(C)C)Nc1ccc(cc1)Br,CBR-HVAC-09495:
CBR-001-586-709-1,RFM-005-974-5,CBR-001-586-709-1,COc1cc(NC)c(cc1C(=O)NC1CCN([C@H]1C)Cc1ccccc1)Cl,CBR-HVAC-01788: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2; Dopamine receptor D3 Inhibitor; Dopamine D2 receptor antagonist; Dopamine D3 receptor antagonist
CBR-001-586-710-4,RFM-005-975-6,CBR-001-586-710-4,NCCCCCC(P(=O)(O)O)(P(=O)(O)O)O,"CBR-HVAC-01910: Treatment of Osteoporosis;Treatment of Paget's Disease;Bone Diseases, Treatment of;Neuropathic Pain, Treatment of;Osteoarthritis, Treatment of; Farnesyl diphosphate synthase Inhibitor; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor"
CBR-001-586-711-5,RFM-005-976-7,CBR-001-586-711-5,N=C(N[N+](=O)[O-])NCCC[C@@H](C(=O)O)N,CBR-HVAC-04240: Cardiovascular Diseases (Not Specified); Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators; Nitric oxide synthase Inhibitor;
CBR-001-586-712-6,RFM-005-977-8,CBR-001-586-712-6,CO[C@]12C[C@@H](COC(=O)c3cncc(c3)Br)CN([C@@H]1Cc1c3c2cccc3n(c1)C)C,"CBR-HVAC-01527: Vasodilators;Cerebrovascular Diseases, Treatment of; Alpha-1 adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist"
CBR-001-586-713-7,RFM-005-978-9,CBR-001-586-713-7,[O-][N+](=O)OCCNC(=O)c1cccnc1,"CBR-HVAC-02075: Angina pectoris, Treatment of;Heart Failure Therapy;Vasodilators;Cerebrovascular Diseases, Treatment of;Acute Myocardial Infarction, Treatment of; K(ATP) Channel Activators;Nitric Oxide (NO) Donors; Sulfonylurea receptor 2A; Sulfonylurea receptor 2B Inhibitor; Potassium channel agonist"
CBR-001-586-714-8,RFM-005-979-0,CBR-001-586-714-8,CN1CCCC1c1cccnc1,"CBR-HVAC-02439: Smoking Cessation, Aid to;Extrapyramidal Disorders, Treatment of;Inflammatory Bowel Disease, Agents for;Antiparkinsonian Drugs;Nausea and Vomiting, Treatment of; Nicotinic Receptor Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor Ligand; Neuronal nicotinic receptor agonist"
CBR-001-586-715-9,RFM-005-980-3,CBR-001-586-715-9,O=C(N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1ccc(cc1)[N+](=O)[O-])CNC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)CCS(=O)C,CBR-HVAC-08089: ; Opioid receptor agonist; Neurotransmitter antagonist
CBR-001-586-716-0,RFM-005-981-4,CBR-001-586-716-0,OCCN(CCNc1cc(=O)n(c(=O)n1C)C)CCCc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-01452: Antiarrhythmic Drugs; Potassium Channel Blockers; Potassium channel Antagonist; Potassium channel antagonist
CBR-001-586-717-1,RFM-005-982-5,CBR-001-586-717-1,Cc1ncn(c1)c1cc(NC(=O)c2ccc(c(c2)Nc2nccc(n2)c2cccnc2)C)cc(c1)C(F)(F)F,CBR-HVAC-01607: ; BCR-ABL Inhibitor; Bcr-Abl inhibitor; C-kit inhibitor; Platelet-derived growth factor receptor kinase inhibitor; Abl receptor tyrosine kinase inhibitor
CBR-001-586-718-2,RFM-005-983-6,CBR-001-586-718-2,O=C1NC(C(=O)N1c1ccc(c(c1)C(F)(F)F)[N+](=O)[O-])(C)C,CBR-HVAC-01567: Prostate Cancer Therapy; Androgen Receptor Antagonists;Signal Transduction Modulators; Androgen receptor Antagonist; Androgen receptor antagonist; RNA directed RNA polymerase inhibitor
CBR-001-586-719-3,RFM-005-984-7,CBR-001-586-719-3,CN1CC(c2ccccc2)c2c(C1)c(N)ccc2,CBR-HVAC-05266: Antidepressants; Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;
CBR-001-586-720-6,RFM-005-985-8,CBR-001-586-720-6,O=C(c1ccc(cc1)F)CCCN1CC2CCC(C1)CC2,CBR-HVAC-08098: ; Dopamine receptor antagonist
CBR-001-586-721-7,RFM-005-986-9,CBR-001-586-721-7,NC[C@@H](c1ccc(c(c1)O)O)O,"CBR-HVAC-02854: Septic Shock, Treatment of ;Radioprotectants/Radiomitigators;Antiarrhythmic Drugs;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Antidepressants;Hypotension, Treatment of; alpha-Adrenoceptor Agonists;beta-Adrenoceptor Agonists;Signal Transduction Modulators; Free radical scavenger; DNA inhibitor"
CBR-001-586-722-8,RFM-005-987-0,CBR-001-586-722-8,O=NC1CC[C@H]2C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(C#C)OC(=O)C)CC,CBR-HVAC-03063: Contraceptives;Acne Therapy; Progesterone receptor Agonist; Progesterone receptor agonist; Estrogen receptor agonist
CBR-001-586-723-9,RFM-005-988-1,CBR-001-586-723-9,NCCCC(=O)N(CCC=C1c2ccccc2CCc2c1cccc2)C,"CBR-HVAC-06754: Neuropathic Pain, Treatment of; Calcium Channel Blockers;Cytokine Production Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;"
CBR-001-586-724-0,RFM-005-989-2,CBR-001-586-724-0,Oc1cc2OC(C)(C)CC(=O)c2c(c1)O,CBR-HVAC-12018:
CBR-001-586-725-1,RFM-005-990-5,CBR-001-586-725-1,OC[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCCNC(=N)N)Cc1ccccc1)Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](CCCNC(=N)N)N)CCCNC(=N)N)O,CBR-HVAC-04165: Drugs for Allergic Rhinitis; Bradykinin B2 Antagonists;Signal Transduction Modulators; Bradykinin receptor B2 Antagonist; Bradykinin receptor antagonist
CBR-001-586-726-2,RFM-005-991-6,CBR-001-586-726-2,Cc1ccc(cc1Br)Nc1nnc(c2c1cccc2)Cc1ccncc1,CBR-HVAC-11565: Oncolytic Drugs; Angiogenesis Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Vascular endothelial growth factor receptor Inhibitor;
CBR-001-586-727-3,RFM-005-992-7,CBR-001-586-727-3,CC(NC(C(c1ccc(cc1)O)O)C)CCc1ccccc1,CBR-HVAC-01249: ; Beta adrenergic receptor Agonist; Beta adrenoreceptor agonist
CBR-001-586-728-4,RFM-005-993-8,CBR-001-586-728-4,CCCC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C)CCC,CBR-HVAC-05695: Antispasmodics; Muscarinic acetylcholine receptor Inhibitor;
CBR-001-586-729-5,RFM-005-994-9,CBR-001-586-729-5,OC[C@H]1O[C@@H](O[C@@H]2OC=C([C@H](/C/2=C\C)CC(=O)OCCc2ccc(c(c2)O)O)C(=O)OC)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-10367: Immunomodulators;Treatment of Protozoal Diseases;Lipoprotein Disorders, Treatment of ;Oncolytic Drugs;Antibacterial Drugs;Antiviral Drugs; Antioxidants;Free Radical Scavengers;LDL Antioxidants;Lipid Lowering Agents;"
CBR-001-586-730-8,RFM-005-995-0,CBR-001-586-730-8,NC(C(=O)c1ccc2c(c1)OCO2)N,CBR-HVAC-09158:
CBR-001-586-731-9,RFM-005-996-1,CBR-001-586-731-9,COc1ccc2c(c1)nc([nH]2)S(=O)Cc1ncc(c(c1C)OC)C,"CBR-HVAC-03183: Anti-Helicobacter Pylori Agents;Gastroesophageal Reflux Disease, Agents for; H+/K+-ATPase Inhibitors;"
CBR-001-586-732-0,RFM-005-997-2,CBR-001-586-732-0,Oc1cc(cc(c1O)[N+](=O)[O-])c1onc(n1)c1c(C)c(Cl)c([n+](c1Cl)[O-])C,CBR-HVAC-00893: Antiparkinsonian Drugs; COMT Inhibitors; CATECHOL O-METHYLTRANSFERASE Inhibitor; Catechol O methyltransferase inhibitor
CBR-001-586-733-1,RFM-005-998-3,CBR-001-586-733-1,C[C@@H]1N[C@H](C)CN(C1)c1c(F)c(F)c2c(c1F)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-04409: Antibacterial Drugs;
CBR-001-586-734-2,RFM-005-999-4,CBR-001-586-734-2,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,CBR-HVAC-03314: Antiobesity Drugs;Treatment of Eating Disorders; Fatty Acid Synthase (FAS) Inhibitors;Gastric Triacylglycerol Lipase Inhibitors;Pancreatic Triacylglycerol Lipase Inhibitors;Sn1-Specific Diacylglycerol Lipase alpha (DGL-alpha) Inhibitors; Pancreatic lipase Inhibitor; Lipase inhibitor; Cholesterol inhibitor
CBR-001-586-735-3,RFM-006-000-4,CBR-001-586-735-3,N#Cc1ccc(c(c1)F)[C@H]1CCc2n1cnc2,"CBR-HVAC-06532: Heart Failure Therapy;Cushing's Syndrome, Agents for;Hypertension, Treatment of; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP11B1 (Steroid 11-beta Hydroxylase) Inhibitors;Cytochrome P450 CYP2C19 Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors; 11 BETA-HYDROXYLASE; ALDOSTERONE SYNTHASE (CYP11B2) Inhibitor;"
CBR-001-586-736-4,RFM-006-001-5,CBR-001-586-736-4,CCCN1CCC[C@H](C1)c1cccc(c1)S(=O)(=O)C,"CBR-HVAC-00065: Treatment of Alcohol Dependency;Huntington's Disease, Treatment of;Antiparkinsonian Drugs;Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Partial Agonists; Dopamine receptor Antagonist; Dopamine D2 receptor antagonist"
CBR-001-586-737-5,RFM-006-002-6,CBR-001-586-737-5,N[C@@H]1CCCC[C@H]1N,uninteresting ligand of CBR-HVAC-03277
CBR-001-586-738-6,RFM-006-003-7,CBR-001-586-738-6,ONC(=O)Cc1c(C)n(c2c1cc(OC)cc2)C(=O)c1ccc(cc1)Cl,CBR-HVAC-01841: ; Prostaglandin synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-586-739-7,RFM-006-004-8,CBR-001-586-739-7,ONC(=O)/C=C/C#Cc1cccc(c1)NS(=O)(=O)c1ccccc1,CBR-HVAC-10784: Oncolytic Drugs; Histone Deacetylase (HDAC) Inhibitors; Histone deacetylase Inhibitor;
CBR-001-586-740-0,RFM-006-005-9,CBR-001-586-740-0,OCc1cc2CCC(Nc2cc1[N+](=O)[O-])CNC(C)C,CBR-HVAC-06415: Treatment of Helminthic Diseases;
CBR-001-586-741-1,RFM-006-006-0,CBR-001-586-741-1,NC(=O)CN1CC(CC1=O)O,"CBR-HVAC-02805: Cognition Disorders, Treatment of; Acetylcholine receptor agonist"
CBR-001-586-742-2,RFM-006-007-1,CBR-001-586-742-2,OC(=O)c1c(O)c(nc2c1cccc2)c1ccccc1,CBR-HVAC-08949:
CBR-001-586-743-3,RFM-006-008-2,CBR-001-586-743-3,COc1cc2c(cc1OC)[nH]c(c2CCN1CCN(CC1)c1ccccc1)C,CBR-HVAC-03106: Anxiolytics; Dopamine receptor Depletor;
CBR-001-586-744-4,RFM-006-009-3,CBR-001-586-744-4,CCCCC1C(=O)N(N(C1=O)c1ccc(cc1)O)c1ccccc1,"CBR-HVAC-05444: Treatment of Gout;Treatment of Tuberculosis;Rheumatoid Arthritis, Treatment of;Ankylosing Spondylitis, Treatment of;Osteoarthritis, Treatment of;Inflammation, Treatment of; Prostaglandin G/H synthase Inhibitor;"
CBR-001-586-745-5,RFM-006-010-6,CBR-001-586-745-5,Oc1ccc(cc1)C1(c2ccc(cc2)O)C(=O)Nc2c1cccc2,CBR-HVAC-09434:
CBR-001-586-746-6,RFM-006-011-7,CBR-001-586-746-6,OC(=O)/C=C/1\SC(C(=O)N1C)N1CCCCC1,CBR-HVAC-08139: ; Diuretic
CBR-001-586-747-7,RFM-006-012-8,CBR-001-586-747-7,CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@@]1(O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O)C(C)C,CBR-HVAC-01310: ; Alpha adrenergic receptor Antagonist; Dopamine D2 receptor agonist; Prolactin inhibitor
CBR-001-586-749-9,RFM-006-013-9,CBR-001-586-749-9,NC(=S)N/N=C/c1ncccc1N,"CBR-HVAC-04535: Antiviral Drugs;Renal Cancer Therapy;Alzheimer's Dementia, Treatment of ;Breast Cancer Therapy;Stroke, Treatment of;Leukemia Therapy;Antineoplastic Enhancing Agents;Head and Neck Cancer Therapy;Prostate Cancer Therapy;Myelodysplastic Syndrome Therapy;Non-Small Cell Lung Cancer Therapy;Cervical Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Pancreatic Cancer Therapy;Ovarian Cancer Therapy;Gastric Cancer Therapy; Antimetabolites;Apoptosis Inhibitors;Chelating Agents;Free Radical Scavengers;Ribonucleoside-Diphosphate Reductase Inhibitors; RIBONUCLEOTIDE REDUCTASE Inhibitor;"
CBR-001-586-750-2,RFM-006-014-0,CBR-001-586-750-2,COc1ccc(cc1OC)Cc1nccc2c1cc(OC)c(c2)OC,CBR-HVAC-02370: ; cAMP phosphodiesterase; cGMP phosphodiesterase Inhibitor; Phosphodiesterase 10A inhibitor
CBR-001-586-751-3,RFM-006-015-1,CBR-001-586-751-3,NC(=N)c1ccc(cc1)C=C1c2ccccc2c2c1cccc2,"CBR-HVAC-08969: Anti-inflammatory, nonsteroidal"
CBR-001-586-752-4,RFM-006-016-2,CBR-001-586-752-4,CCCCc1ccc2c(c1)nc([nH]2)NC(=O)OC,CBR-HVAC-10052: ; Tubulin Inhibitor;
CBR-001-586-753-5,RFM-006-017-3,CBR-001-586-753-5,CCC(=O)NS(=O)(=O)c1ccc(cc1)c1c(C)onc1c1ccccc1,CBR-HVAC-01521: Analgesic Drugs; Cytochrome P450 CYP2C9 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase 2 Inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-586-754-6,RFM-006-018-4,CBR-001-586-754-6,CCC([C@@H](C(=O)O)NC(=O)c1ccccc1SSc1ccccc1C(=O)N[C@@H](C(CC)C)C(=O)O)C,CBR-HVAC-04807: Antiviral Drugs;
CBR-001-586-755-7,RFM-006-019-5,CBR-001-586-755-7,OC[C@H]1O[C@H](C[C@@H]1O)n1cnc2c1NC=NC[C@H]2O,"CBR-HVAC-01969: Antiarthritic Drugs;Non-Hodgkin's Lymphoma Therapy;Immunosuppressants;Leukemia Therapy;Oncolytic Drugs;Septic Shock, Treatment of ;Lymphocytic Leukemia Therapy; Adenosine Deaminase (ADA) Inhibitors;Antimetabolites; Adenosine deaminase Inhibitor; Adenosine deaminase inhibitor"
CBR-001-586-756-8,RFM-006-020-8,CBR-001-586-756-8,FC12C(F)(C(F)(F)C(C(C2(F)F)(F)F)(F)F)C(F)(F)C(C(C1(F)F)(F)F)(F)F,CBR-HVAC-03017: Blood Substitutes;
CBR-001-586-757-9,RFM-006-021-9,CBR-001-586-757-9,ClCCN(P1(=O)OCCC(N1)OO)CCCl,CBR-HVAC-01195: Oncolytic Drugs; DNA-Damaging Drugs; DNA inhibitor; Immunosuppressant
CBR-001-586-758-0,RFM-006-022-0,CBR-001-586-758-0,N#Cc1ccc2c(c1)N(CCCN1CCC(CC1)O)c1c(S2)cccc1,CBR-HVAC-03113: Antipsychotic Drugs;
CBR-001-586-759-1,RFM-006-023-1,CBR-001-586-759-1,ClC(=CC1C(C1(C)C)C(=O)OCc1cccc(c1)Oc1ccccc1)Cl,CBR-HVAC-02459: ; Calcium ATPase; Adenylate cyclase; Phosphodiesterase Inhibitor; Inhibitor; Inhibitor; Sodium channel agonist
CBR-001-586-760-4,RFM-006-024-2,CBR-001-586-760-4,CNC(=O)c1ccc(c(n1)N)c1cc(Cl)cc(c1Cl)Cl,"CBR-HVAC-11986: Neuropathic Pain, Treatment of;Non-Opioid Analgesics;Multiple Sclerosis, Agents for; Nav1.8 (SNS/PN3) Sodium Channel Blockers; Sodium Channel Nav1.8 Inhibitor;"
CBR-001-586-761-5,RFM-006-025-3,CBR-001-586-761-5,Clc1ccc(cc1)c1c2OCCN(C(=O)c2nn1c1ccccc1Cl)CC(F)(F)C,CBR-HVAC-11733: Antiobesity Drugs; Cannabinoid CB1 Antagonists;Signal Transduction Modulators; Cannabinoid receptor 1 Antagonist;
CBR-001-586-762-6,RFM-006-026-4,CBR-001-586-762-6,Clc1cc(N)cc(c1N=C1NCCN1)Cl,CBR-HVAC-02372: ; Alpha-1 adrenergic receptor; Alpha-2 adrenergic receptor Agonist; Membrane permeability inhibitor
CBR-001-586-763-7,RFM-006-027-5,CBR-001-586-763-7,COc1ccc(cc1)C1C(=O)c2c(C1=O)cccc2,CBR-HVAC-02373: ; Sodium channel Inhibitor; Cholesterol inhibitor
CBR-001-586-764-8,RFM-006-028-6,CBR-001-586-764-8,CCOc1ccc(cc1)NC(=C)Nc1ccc(cc1)OCC,CBR-HVAC-09929: ; Calmodulin Antagonist;
CBR-001-586-765-9,RFM-006-029-7,CBR-001-586-765-9,CN(CCN(c1ccccc1)Cc1ccccc1)C,CBR-HVAC-10285:
CBR-001-586-766-0,RFM-006-030-0,CBR-001-586-766-0,NNCCc1ccccc1,CBR-HVAC-03105: Antidepressants; MAO Inhibitors; Monoamine oxidase Inhibitor;
CBR-001-586-767-1,RFM-006-031-1,CBR-001-586-767-1,CCC1(CC)C(=O)NC(=O)N(C1=O)c1ccccc1,CBR-HVAC-08630:
CBR-001-586-768-2,RFM-006-032-2,CBR-001-586-768-2,N=C(NC(=N)N)NCCc1ccccc1,CBR-HVAC-10059: ; AMP-activated protein kinase Activator;
CBR-001-586-769-3,RFM-006-033-3,CBR-001-586-769-3,NNC(Cc1ccccc1)C,CBR-HVAC-08987: ; Monoamine oxidase Irreversible inhibitor;
CBR-001-586-770-6,RFM-006-034-4,CBR-001-586-770-6,CCOc1ccc(cc1)NC(=O)CN,CBR-HVAC-10092:
CBR-001-586-771-7,RFM-006-035-5,CBR-001-586-771-7,Oc1nn(c(c1c1ccccc1)O)c1ccccc1,CBR-HVAC-10093:
CBR-001-586-772-8,RFM-006-036-6,CBR-001-586-772-8,O=C(Nc1ccccc1)Oc1ccc2c(c1)[C@]1(C)CCN([C@@H]1N2C)C,"CBR-HVAC-00162: Huntington's Disease, Treatment of;Antiparkinsonian Drugs;Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of; beta-Amyloid (Abeta) Production Inhibitors; Beta secretase Inhibitor; Acetylcholinesterase inhibitor; Beta amyloid precursor protein antagonist"
CBR-001-586-773-9,RFM-006-037-7,CBR-001-586-773-9,CNC[C@H](c1cccc(c1)O)O,"CBR-HVAC-02823: Mydriatics;Hypotension, Treatment of;Nasal Decongestants;Urinary Incontinence Therapy;Angina pectoris, Treatment of;Anorectal Disorders, Treatment of;Asthma Therapy;Antimigraine Drugs;Congenital Malformations, Treatment of;Treatment of Upper Respiratory Tract Disorders;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; alpha1A-Adrenoceptor Ligands;alpha1-Adrenoceptor Agonists;Cytochrome P450 CYP3A4 Inhibitors;Histamine H1 Receptor Antagonists;MAO Inhibitors;Signal Transduction Modulators; Alpha-1 adrenergic receptor Agonist; Alpha adrenoreceptor agonist; Beta adrenoreceptor agonist"
CBR-001-586-774-0,RFM-006-038-8,CBR-001-586-774-0,CNCC(c1ccccc1)C,CBR-HVAC-09044:
CBR-001-586-775-1,RFM-006-039-9,CBR-001-586-775-1,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2,CBR-HVAC-01876: Antipsychotic Drugs; Dopamine D2 Antagonists;Serotonin Antagonists;Signal Transduction Modulators; Dopamine receptor Antagonist; Dopamine D2 receptor antagonist; Opioid receptor antagonist
CBR-001-586-776-2,RFM-006-040-2,CBR-001-586-776-2,ClCCCCC(=O)NNC(=O)N1Cc2ccccc2Oc2c1cc(Cl)cc2,CBR-HVAC-02508: ; Prostaglandin receptor Antagonist; Unidentified pharmacological activity
CBR-001-586-777-3,RFM-006-041-3,CBR-001-586-777-3,OC(COc1cccc2c1cc[nH]2)CNC(C)C,CBR-HVAC-00038: ; 5-Hydroxytryptamine 1A receptor Antagonist; Beta adrenoreceptor antagonist
CBR-001-586-778-4,RFM-006-042-4,CBR-001-586-778-4,Oc1cc2OC(CC(=O)c2c(c1)O)c1ccccc1,"CBR-HVAC-03647: Oncolytic Drugs;Ischemic Stroke, Treatment of;Benign Prostatic Hyperplasia Therapy;Bronchodilators; Androgen Receptor Ligands;Signal Transduction Modulators;Steroid 5alpha-Reductase Inhibitors;"
CBR-001-586-779-5,RFM-006-043-5,CBR-001-586-779-5,CCc1ccc(nc1)CCOc1ccc(cc1)Cc1sc(nc1O)O,CBR-HVAC-01720: ; Peroxisome proliferator-activated receptor (PPAR) gamma Agonist; Peroxisome proliferator-activated receptor gamma agonist; Thiazolidinedione; Insulin sensitizer
CBR-001-586-780-8,RFM-006-044-6,CBR-001-586-780-8,CC1CCCCN1CCCOC(=O)c1ccccc1,CBR-HVAC-09931: ; Nicotinic acetylcholine receptor Blocker;
CBR-001-586-781-9,RFM-006-045-7,CBR-001-586-781-9,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C,CBR-HVAC-01649: ; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist
CBR-001-586-782-0,RFM-006-046-8,CBR-001-586-782-0,CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C,CBR-HVAC-01649: ; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist
CBR-001-586-783-1,RFM-006-047-9,CBR-001-586-783-1,CN1CCN(CC1)CC(=O)n1c2ccccc2c(=O)[nH]c2c1nccc2,"CBR-HVAC-02184: Antiulcer Drugs;Myopia,Treatment for;Alzheimer's Dementia, Treatment of ; Muscarinic M1 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Antagonist; Muscarinic M1 receptor antagonist"
CBR-001-586-784-2,RFM-006-048-0,CBR-001-586-784-2,CCn1cc(C(=O)O)c(=O)c2c1nc(nc2)N1CCCC1,CBR-HVAC-08672:
CBR-001-586-785-3,RFM-006-049-1,CBR-001-586-785-3,NCCCNc1ccc2c3c1c(=O)c1c(c3nn2CCNCCO)c(O)ccc1O,CBR-HVAC-03396: Oncolytic Drugs; DNA-Intercalating Drugs; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA inhibitor
CBR-001-586-786-4,RFM-006-050-4,CBR-001-586-786-4,OCc1nn2c(c1)c1ccccc1[nH]c2=O,"CBR-HVAC-08210: Antiallergy/Antiasthmatic Drugs;Allergic Skin Disorders, Treatment for; Histamine release inhibitor"
CBR-001-586-787-5,RFM-006-051-5,CBR-001-586-787-5,O=C([C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)/N=C/N1CCCCCC1)OCOC(=O)C(C)(C)C,CBR-HVAC-03078: Antibiotics; Cell wall synthesis inhibitor
CBR-001-586-788-6,RFM-006-052-6,CBR-001-586-788-6,NN(C(=N)NN)CC(=O)O,CBR-HVAC-11258: Antidiabetic Drugs;
CBR-001-586-789-7,RFM-006-053-7,CBR-001-586-789-7,CCCNCCc1ccc(cc1)NS(=O)(=O)c1ccc(cc1)OC(F)(F)F,CBR-HVAC-00218: Antipsychotic Drugs; Dopamine D3 Antagonists;Signal Transduction Modulators; Dopamine receptor D3 Antagonist; Dopamine D3 receptor antagonist
CBR-001-586-790-0,RFM-006-054-8,CBR-001-586-790-0,O=C1CCC(C(=O)N1)N1C(=O)c2c(C1=O)c(N)ccc2,CBR-HVAC-00008: Solid Tumors Therapy;Multiple Myeloma Therapy;Immunomodulators; Angiogenesis Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; Angiogenesis inhibitor; T cell stimulant; Natural killer cell stimulant
CBR-001-586-791-1,RFM-006-055-9,CBR-001-586-791-1,CCCNC1CCc2c(C1)sc(n2)N,"CBR-HVAC-00016: Treatment of Cocaine Dependency;Tourette's Syndrome, Treatment of;Obsessive-Compulsive Disorder (OCD), Treatment of;Treatment of Eating Disorders;Fibromyalgia, Treatment of;Antiparkinsonian Drugs;Antidepressants;Bipolar Disorder, Treatment of;Restless Legs Syndrome, Treatment of; Dopamine D3 Agonists;Signal Transduction Modulators; Dopamine D3 receptor agonist"
CBR-001-586-792-2,RFM-006-056-0,CBR-001-586-792-2,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1=CC2CCC1C=C2,CBR-HVAC-10035: ; Alpha-1 adrenergic receptor Antagonist;
CBR-001-586-793-3,RFM-006-057-1,CBR-001-586-793-3,CC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C,"CBR-HVAC-03120: Antiinflammatory Ophthalmic Agents;Inflammation, Treatment of; Glucocorticoid receptor Agonist;"
CBR-001-586-794-4,RFM-006-058-2,CBR-001-586-794-4,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)CC(=O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C,CBR-HVAC-02414: ; Glucocorticoid receptor Inhibitor; Glucocorticoid agonist
CBR-001-586-795-5,RFM-006-059-3,CBR-001-586-795-5,NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc1nc[nH]c1)NC(=O)CN,ligand of CBR-HVAC-04507
CBR-001-586-796-6,RFM-006-060-6,CBR-001-586-796-6,CNNCc1ccc(cc1)C(=O)NC(C)C,CBR-HVAC-05275: Astrocytoma Therapy;Non-Hodgkin's Lymphoma Therapy;Neurologic Cancer Therapy;Lymphoma Therapy; DNA Alkylating Drugs;
CBR-001-586-797-7,RFM-006-061-7,CBR-001-586-797-7,CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-02442: ; Dopamine receptor D2 Antagonist; Dopamine D2 receptor antagonist
CBR-001-586-798-8,RFM-006-062-8,CBR-001-586-798-8,OC(c1ccccc1)(C1CCCCC1)CCN1CCCC1,CBR-HVAC-04125: Antiparkinsonian Drugs; Anticholinergics;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M4 Antagonist; Antagonist; Antagonist;
CBR-001-586-799-9,RFM-006-063-9,CBR-001-586-799-9,O=C1SC[C@H](N1)C(=O)O,"CBR-HVAC-01239: Amyotrophic Lateral Sclerosis, Agents for;Hepatoprotectants;Acute Respiratory Distress Syndrome (ARDS), Agents for;Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Anti-HIV Agents; Antiinflammatory Drugs; Reducing agent; Glutathione synthase stimulant"
CBR-001-586-800-5,RFM-006-064-0,CBR-001-586-800-5,CCCC1(OCCc2c1[nH]c1c2cccc1)CC(=O)O,"CBR-HVAC-01058: Non-Opioid Analgesics;Inflammation, Treatment of; Prostaglandin G/H synthase Inhibitor; Unidentified pharmacological activity"
CBR-001-586-801-6,RFM-006-065-1,CBR-001-586-801-6,CCCOc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2OC)C,CBR-HVAC-02025: ; Estrogen receptor agonist; DNA directed RNA polymerase stimulant
CBR-001-586-802-7,RFM-006-066-2,CBR-001-586-802-7,CC(NCC(c1ccc2c(c1)cccc2)O)C,CBR-HVAC-10015: ; Beta-2 adrenergic receptor Blocker;
CBR-001-586-803-8,RFM-006-067-3,CBR-001-586-803-8,CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC,CBR-HVAC-02382: ; Sodium channel Blocker; Sodium channel antagonist; Potassium channel antagonist; Membrane integrity inhibitor
CBR-001-586-804-9,RFM-006-068-4,CBR-001-586-804-9,NC(C(=O)O)CC#C,CBR-HVAC-11276: ; Cystathionase Inhibitor;
CBR-001-586-805-0,RFM-006-069-5,CBR-001-586-805-0,CCCOC(c1ccccc1)(c1ccccc1)C(=O)OC1CCN(CC1)C,CBR-HVAC-01454: Urinary Incontinence Therapy; Muscarinic Antagonists;Signal Transduction Modulators; Calcium channel Antagonist; Muscarinic M1 receptor antagonist; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Muscarinic M4 receptor antagonist; L-type calcium channel antagonist
CBR-001-586-806-1,RFM-006-070-8,CBR-001-586-806-1,CC(c1cccc(c1O)C(C)C)C,CBR-HVAC-02469: ; Sodium channel; GABAA receptor; Gamma-Aminobutyric Acid Type A receptor Modulator; Agonist; Blocker; Agonist; Membrane integrity inhibitor; Membrane permeability inhibitor
CBR-001-586-807-2,RFM-006-071-9,CBR-001-586-807-2,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,CBR-HVAC-09648: ; Sodium channel Inhibitor;
CBR-001-586-808-3,RFM-006-072-0,CBR-001-586-808-3,CC(Cc1ccc2c(c1)OCO2)NCC(c1ccc(c(c1)O)O)O,CBR-HVAC-09649: ; Beta adrenergic receptor Agonist;
CBR-001-586-809-4,RFM-006-073-1,CBR-001-586-809-4,CNCCCC1c2ccccc2C=Cc2c1cccc2,CBR-HVAC-03125: Antidepressants; Sodium channel Blocker;
CBR-001-586-810-7,RFM-006-074-2,CBR-001-586-810-7,Oc1c(I)cc2c(c1I)Oc1c(C32OC(=O)c2c3c(Cl)c(Cl)c(c2Cl)Cl)cc(c(c1I)O)I,"CBR-HVAC-02607: Actinic Keratoses, Agents for;Liver Cancer Therapy;Breast Cancer Therapy;Atopic Dermatitis, Agents for;Antipsoriatics;Eczema, Treatment of;Melanoma Therapy;Ulcers of the Extremities, Agents for;Prostate Cancer Therapy; Immunostimulant"
CBR-001-586-811-8,RFM-006-075-3,CBR-001-586-811-8,OC(=O)CC[Ge](=O)O[Ge](=O)CCC(=O)O,CBR-HVAC-02276: ; C-C chemokine receptor type 2 Inhibitor; Interferon alpha agonist; Interferon beta agonist
CBR-001-586-812-9,RFM-006-076-4,CBR-001-586-812-9,O=c1oc(c(o1)CN1CCN(CC1)c1cc2c(cc1F)c(=O)c(c1n2C(C)S1)C(=O)O)C,CBR-HVAC-01622: Antibacterial Drugs; DNA Gyrase Inhibitors; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-814-1,RFM-006-077-5,CBR-001-586-814-1,CC[C@H](c1ccc(o1)C)NC1=C(C(=O)C1=O)Nc1cccc(c1O)C(=O)N(C)C,"CBR-HVAC-06035: Angiogenesis Inhibitors; Apoptosis Inducers; C-X-C chemokine receptor 2 antagonist; CXC chemokine receptor 1 antagonist; CXC chemokine receptor 2 antagonist; Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists; Chemokine CXCR2 (IL-8 beta Receptor) Antagonists; Chemokine receptor antagonist; Interleukin-8A-receptor-antagonists; Interleukin-8B-receptor-antagonists; Signal Transduction Modulators; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Antiarthritic Drugs; Antipsoriatics; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Obstructive Airways Disease; Oncolytic Drugs; Respiratory Tract Disorders; Skin Disorders"
CBR-001-586-815-2,RFM-006-078-6,CBR-001-586-815-2,C=Cc1cccc[n+]1[O-],CBR-HVAC-08244:
CBR-001-586-816-3,RFM-006-079-7,CBR-001-586-816-3,C1CCN(C1)CCN1c2ccccc2Sc2c1cccc2,CBR-HVAC-10301: ; Histamine H1 receptor Antagonist;
CBR-001-586-817-4,RFM-006-080-0,CBR-001-586-817-4,COc1ccc2c(c1)c1nn(c3c1c([nH]2)c(cc3)[N+](=O)[O-])CCCN(C)C,CBR-HVAC-04061: Breast Cancer Therapy;Bladder Cancer Therapy ;Solid Tumors Therapy;Glioblastoma Multiforme Therapy;Pancreatic Cancer Therapy;Melanoma Therapy;Ovarian Cancer Therapy;Neurologic Cancer Therapy;Brain Cancer Therapy; DNA Topoisomerase I Inhibitors;DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; DNA topoisomerase II; DNA topoisomerase I Inhibitor; DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor
CBR-001-586-818-5,RFM-006-081-1,CBR-001-586-818-5,NCc1c(CO)cnc(c1O)C,"CBR-HVAC-00721: Urolithiasis, Agents for;Renal Failure, Agents for;Diabetic Nephropathy, Agents for; AGE Inhibitors (Maillard's Reaction Inhibitors); Glycosylation inhibitor"
CBR-001-586-819-6,RFM-006-082-2,CBR-001-586-819-6,CCC1(CC)C(=O)NC=CC1=O,CBR-HVAC-10303:
CBR-001-586-820-9,RFM-006-083-3,CBR-001-586-820-9,CCOC(=O)[C@@H](N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C)CCc1ccccc1,CBR-HVAC-02623: ; Angiotensin I converting enzyme Inhibitor; Aminopeptidase A inhibitor; Angiotensin I converting enzyme inhibitor
CBR-001-586-821-0,RFM-006-084-4,CBR-001-586-821-0,COc1cc2c(CC)ncnc2cc1OC,CBR-HVAC-08720: ; Phosphodiesterase Inhibitor;
CBR-001-586-822-1,RFM-006-085-5,CBR-001-586-822-1,CCOC(=O)[C@@H](N[C@H](C(=O)N1Cc2ccccc2C[C@H]1C(=O)O)C)CCc1ccccc1,"CBR-HVAC-01919: Heart Failure Therapy;Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-586-823-2,RFM-006-086-6,CBR-001-586-823-2,C#CC1(O)CCC2C1(C)CCC1C2CCc2c1ccc(c2)OC1CCCC1,CBR-HVAC-01575: ; Estrogen receptor Inhibitor; Estrogen receptor agonist
CBR-001-586-824-3,RFM-006-087-7,CBR-001-586-824-3,C=C[C@H]1CN2CCC1C[C@@H]2[C@H](c1ccnc2c1cc(OC)cc2)O,CBR-HVAC-03599: Antiarrhythmic Drugs; Cytochrome P450 CYP2D6 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Potassium channel Kv1.5 Inhibitor;
CBR-001-586-825-4,RFM-006-088-8,CBR-001-586-825-4,Fc1ccc2c(c1)c(C(=O)O)c(c(n2)c1ccc(cc1)c1ccccc1F)C,CBR-HVAC-02707: ; Dihydroorotate dehydrogenase Inhibitor; E-selectin antagonist
CBR-001-586-826-5,RFM-006-089-9,CBR-001-586-826-5,Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O,"CBR-HVAC-01734: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Hematologic Agents (Miscellaneous);Alzheimer's Dementia, Treatment of ;Treatment of Osteoporosis;Anti-Hepatitis C Virus Drugs;Breast Cancer Therapy; ACVRL1 Expression Enhancers;ENG Expression Enhancers;Selective Estrogen Receptor Modulators (SERM);Signal Transduction Modulators; Estrogen receptor Modulator; Selective estrogen receptor modulator; Estrogen receptor agonist; Estrogen receptor antagonist; Cholesterol inhibitor"
CBR-001-586-827-6,RFM-006-090-2,CBR-001-586-827-6,CCC(=O)NCC[C@@H]1CCc2c1c1CCOc1cc2,"CBR-HVAC-01624: Sleep Disorders, Treatment of;Bipolar Disorder, Treatment of;Antimigraine Drugs; Melatonin MT1 Agonists;Melatonin MT2 Agonists;Signal Transduction Modulators; Melatonin receptor Agonist; Melatonin 1 receptor agonist; Melatonin 2 receptor agonist"
CBR-001-586-828-7,RFM-006-091-3,CBR-001-586-828-7,CN/C(=C/[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C,CBR-HVAC-01523: Anti-Helicobacter Pylori Agents;Gastric Antisecretory Drugs; Histamine H2 Receptor Antagonists;Signal Transduction Modulators; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Membrane permeability inhibitor
CBR-001-586-829-8,RFM-006-092-4,CBR-001-586-829-8,C#CCN[C@@H]1CCc2c1cccc2,"CBR-HVAC-04188: Amyotrophic Lateral Sclerosis, Agents for;Antiparkinsonian Drugs;Neurologic Drugs (Miscellaneous);Alzheimer's Dementia, Treatment of ;Psychiatric Disorders (Not Specified); MAO-B Inhibitors; Monoamine oxidase B Inhibitor; Monoamine oxidase B inhibitor"
CBR-001-586-830-1,RFM-006-093-5,CBR-001-586-830-1,N#Cc1ccc(cc1)c1csc(n1)[C@@H](C(c1ccc(cc1F)F)(Cn1cncn1)O)C,CBR-HVAC-04742: Treatment of Protozoal Diseases;Antifungal Agents; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-586-831-2,RFM-006-094-6,CBR-001-586-831-2,OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O,"CBR-HVAC-06553: Pancreatic Cancer Therapy;Oncolytic Drugs;Liver Cancer Therapy;Antiarthritic Drugs;Irritable Bowel Syndrome, Agents for;Solid Tumors Therapy;Inflammation, Treatment of;Digestive/Gastrointestinal Cancer Therapy; MEK1 Inhibitors;MEK2 Inhibitors;Signal Transduction Modulators; MEK inhibitor"
CBR-001-586-832-3,RFM-006-095-7,CBR-001-586-832-3,COc1ccc2c(c1)[nH]c1c2CCN2[C@@H]1C[C@H]1[C@@H](C2)C[C@H]([C@@H]([C@H]1C(=O)OC)OC)OC(=O)c1cc(OC)c(c(c1)OC)OC,"CBR-HVAC-03142: Hypertension, Treatment of; Sodium channel Blocker;"
CBR-001-586-833-4,RFM-006-096-8,CBR-001-586-833-4,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@@H]2C[C@H]3CC[C@@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3([C@H]([C@@H]1O)C)[C@H]2C(=O)CC3,CBR-HVAC-01586: Antibiotics; Protein synthesis inhibitor
CBR-001-586-834-5,RFM-006-097-9,CBR-001-586-834-5,C=CCNc1c(O)cc2c(c1C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)/[C@@H]([C@H](/C=C\C=C(\C(=O)N2)/C)OC)OC(=O)N)O,CBR-HVAC-00297: Breast Cancer Therapy;Melanoma Therapy;Digestive/Gastrointestinal Cancer Therapy;Multiple Myeloma Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Sarcoma Therapy; Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor; Heat shock protein 90 antagonist; Apoptosis stimulant
CBR-001-586-835-6,RFM-006-098-0,CBR-001-586-835-6,O=C/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,CBR-HVAC-05163: Dermatologic Drugs;
CBR-001-586-836-7,RFM-006-099-1,CBR-001-586-836-7,COc1cc(cc(c1OC)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@H](c2c1cc1OCOc1c2)O,"CBR-HVAC-00409: Antimitotic Drugs; Disease modifying antirheumatic drug; Microtubule inhibitor; Potassium Channel Subfamily K Member 18 (TRESK; KCNK18) Blockers; Tubulin Binder; Antimitotic; Genital Warts, Treatment for"
CBR-001-586-837-8,RFM-006-100-7,CBR-001-586-837-8,COC(=O)c1ccccc1c1c2ccc(=N)cc2oc2c1ccc(c2)N,CBR-HVAC-09356: ; P-GLYCOPROTEIN Substrate;
CBR-001-586-838-9,RFM-006-101-8,CBR-001-586-838-9,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NCC=C(C)C,CBR-HVAC-08883:
CBR-001-586-839-0,RFM-006-102-9,CBR-001-586-839-0,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2c1c(F)cnc2,"CBR-HVAC-06608: Age-Related Macular Degeneration, Treatment of;Ophthalmic Drugs;Diabetic Retinopathy, Agents for;Antiglaucoma Agents; Rho Kinase 1 (ROCK 1; p160-ROCK) Inhibitors;Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors;Signal Transduction Modulators; RHO KINASE Inhibitor; Rho-associated kinase inhibitor; Protein kinase inhibitor"
CBR-001-586-840-3,RFM-006-103-0,CBR-001-586-840-3,CCn1nc(c2c1C(=NCC(=O)N2)c1ccccc1)C,CBR-HVAC-01077: Anxiolytics; Drugs Acting on GABA(A) Receptors;Signal Transduction Modulators; Benzodiazepine receptor Inhibitor; GABA receptor agonist
CBR-001-586-841-4,RFM-006-104-1,CBR-001-586-841-4,Oc1ccc(cc1)CCN[C@H]([C@@H](c1ccc(cc1)O)O)C,CBR-HVAC-02188: Treatment of Preterm Labor;Smooth Muscle Relaxants; beta2-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-2 adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-586-842-5,RFM-006-105-2,CBR-001-586-842-5,CNCC/C=C/c1cccnc1,CBR-HVAC-00410: ; Nicotinic acetylcholine receptor alpha; Nicotinic acetylcholine receptor alpha3beta4 Agonist; Neuronal nicotinic receptor agonist
CBR-001-586-843-6,RFM-006-106-3,CBR-001-586-843-6,O=C1OCC(=C1c1ccccc1)c1ccc(cc1)S(=O)(=O)C,"CBR-HVAC-02838: Treatment of Dysmenorrhea;Analgesic Drugs;Osteoarthritis, Treatment of;Non-Opioid Analgesics;Rheumatoid Arthritis, Treatment of;Dental Agents;Colorectal Cancer Therapy;Alzheimer's Dementia, Treatment of ;Acute Attacks of Migraine, Treatment of;Antiarthritic Drugs; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Cyclooxygenase 2 Inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-586-844-7,RFM-006-107-4,CBR-001-586-844-7,OC(=O)c1ccc2c(c1)C=C(CC2)n1cncc1,"CBR-HVAC-02691: Nephritis, Agents for;Antiplatelet Therapy; Thromboxane Synthase Inhibitors; Thromboxane A synthase Inhibitor; Thromboxane synthase inhibitor; Thromboxane B2 receptor antagonist; Platelet aggregation inhibitor"
CBR-001-586-845-8,RFM-006-108-5,CBR-001-586-845-8,O=C([C@H]1CCC(=O)N1)N[C@@H]1C[C@H]1c1ccccc1,CBR-HVAC-08599: ; Monoamine oxidase Inhibitor;
CBR-001-586-846-9,RFM-006-109-6,CBR-001-586-846-9,O=C1CCC2N1C(=O)CC2,CBR-HVAC-08291:
CBR-001-586-847-0,RFM-006-110-9,CBR-001-586-847-0,Cc1cccc(n1)/C=N/N1CCN(CC1)C(c1ccccc1)c1ccccc1,CBR-HVAC-01034: ; GABA receptor agonist
CBR-001-586-848-1,RFM-006-111-0,CBR-001-586-848-1,O=C(O[C@@H](C(=O)O)Cc1ccc(c(c1)O)O)/C=C/c1ccc(c(c1)O)O,"CBR-HVAC-02964: Antidepressants;Cognition Disorders, Treatment of;Immunomodulators;Acute Respiratory Distress Syndrome (ARDS), Agents for;Oncolytic Drugs;Antiallergy/Antiasthmatic Drugs; Angiogenesis Inhibitors;Antioxidants;"
CBR-001-586-849-2,RFM-006-112-1,CBR-001-586-849-2,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4cccc(c4cc3Cn1c2=O)[N+](=O)[O-],CBR-HVAC-00437: Sarcoma Therapy;Myelodysplastic Syndrome Therapy;Head and Neck Cancer Therapy;Pancreatic Cancer Therapy;Prostate Cancer Therapy;Myeloid Leukemia Therapy;Ovarian Cancer Therapy;Anti-HIV Agents;Lymphoma Therapy;Small Cell Lung Cancer Therapy;Melanoma Therapy;Brain Cancer Therapy;Breast Cancer Therapy;Colorectal Cancer Therapy;Gastric Cancer Therapy; DNA Topoisomerase I Inhibitors; DNA topoisomerase I inhibitor
CBR-001-586-850-5,RFM-006-113-2,CBR-001-586-850-5,Cc1cncc(c1)CN1CCC(=C2c3ccc(cc3CCc3c2nccc3)Cl)CC1,"CBR-HVAC-02198: Drugs for Allergic Rhinitis;Urticaria, Treatment for;Dermatologic Drugs; Histamine H1 Receptor Antagonists;Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Histamine H1 receptor Inhibitor; Platelet activating factor antagonist; Histamine H1 receptor antagonist"
CBR-001-586-851-6,RFM-006-114-3,CBR-001-586-851-6,CC1Cc2c(N1NC(=O)c1ccc(c(c1)S(=O)(=O)N)Cl)cccc2,CBR-HVAC-00987: ; Delayed rectifier potassium channel subunit IsK Blocker; Beta adrenoreceptor antagonist; Diuretic
CBR-001-586-852-7,RFM-006-115-4,CBR-001-586-852-7,O=CC1=C(C)C=CCC1(C)C,CBR-HVAC-06541: Antitussives;Antiepileptic Drugs;
CBR-001-586-853-8,RFM-006-116-5,CBR-001-586-853-8,OC[C@H]1O[C@@H](Oc2ccccc2CO)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-05252: Acute Attacks of Migraine, Treatment of; Thrombin Inhibitor;"
CBR-001-586-854-9,RFM-006-117-6,CBR-001-586-854-9,COC(=O)[C@@H]1C[C@H](OC(=O)C)C(=O)[C@H]2[C@@]1(C)CC[C@@H]1[C@]2(C)C[C@H](OC1=O)c1cocc1,CBR-HVAC-06044: Treatment of Cocaine Dependency;Antidiarrheal Agents;Analgesic Drugs; kappa-Opioid Agonists;Signal Transduction Modulators;
CBR-001-586-855-0,RFM-006-118-7,CBR-001-586-855-0,CCc1noc(c1c1[nH]c2c(c1C(CN(C)C)O)cccc2)C,CBR-HVAC-08320:
CBR-001-586-856-1,RFM-006-119-8,CBR-001-586-856-1,N#C[C@@H]1C[C@H]2[C@@H](N1C(=O)[C@H]([C@]13C[C@@H]4C[C@H](C1)C[C@](C3)(C4)O)N)C2,"CBR-HVAC-01893: Type 2 Diabetes, Agents for; Cytochrome P450 CYP3A4 Inhibitors;Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue"
CBR-001-586-857-2,RFM-006-120-1,CBR-001-586-857-2,O=C(c1c[nH]c2c1cccc2)OCCN1CCCCC1,CBR-HVAC-10533: ; Signal Transduction Modulators;5-HT4 Antagonists; 5-Hydroxytryptamine 4 receptor Antagonist;
CBR-001-586-858-3,RFM-006-121-2,CBR-001-586-858-3,Nc1ncc(cn1)c1nc(nc2c1nc(n2C(C)C)C)N1CCOCC1,CBR-HVAC-07056: Cancer of Unspecified Body Location/System;Solid Tumors Therapy;Lymphoma Therapy;Oncolytic Drugs; Apoptosis Inducers;mTOR Complex 1 (mTORC1) Inhibitors;mTOR Complex 2 (mTORC2) Inhibitors;Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors;Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors;Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors;Signal Transduction Modulators; mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; PI3 kinase alpha inhibitor
CBR-001-586-859-4,RFM-006-122-3,CBR-001-586-859-4,N[C@H](C(=O)O)Cc1cc(cc(c1)c1ccccc1Cl)CP(=O)(O)O,"CBR-HVAC-11464: Stroke, Treatment of;Non-Opioid Analgesics; NMDA Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-586-860-7,RFM-006-123-4,CBR-001-586-860-7,C[C@@H](N(CC#C)C)Cc1ccccc1,CBR-HVAC-00964: ; Monoamine oxidase B Inhibitor; Monoamine oxidase B inhibitor
CBR-001-586-861-8,RFM-006-124-5,CBR-001-586-861-8,C[Se]C[C@@H](C(=O)O)N,CBR-HVAC-06039: Chemopreventive Agents;Non-Hodgkin's Lymphoma Therapy;
CBR-001-586-862-9,RFM-006-125-6,CBR-001-586-862-9,CCOC(=O)OC[C@H]1O[C@@H](Oc2ccccc2Cc2ccc(cc2)OC)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-00308: Type 2 Diabetes, Agents for;Antiobesity Drugs; SGLT-2 Inhibitors; Sodium/glucose cotransporter 2 Inhibitor; Sodium/glucose cotransporter 2 inhibitor"
CBR-001-586-863-0,RFM-006-126-7,CBR-001-586-863-0,CCCCP(=O)(CCCN)O,"CBR-HVAC-03905: Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of;Therapy of Inborn Errors of Metabolism;Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; GABA(B) Receptor Antagonists;GABA(C) Receptors Antagonists;Signal Transduction Modulators; GABA-B receptor Antagonist;"
CBR-001-586-864-1,RFM-006-127-8,CBR-001-586-864-1,C[Si](O[Si](C)(C)C)(C)C,CBR-HVAC-09655:
CBR-001-586-865-2,RFM-006-128-9,CBR-001-586-865-2,COC1=C[C@@H]2[C@@H]3Cc4c([C@@]2(CC1=O)CCN3C)c(O)c(cc4)OC,CBR-HVAC-11513: ; Opioid receptor mu Activator;
CBR-001-586-866-3,RFM-006-129-0,CBR-001-586-866-3,Fc1cc(cc(c1)F)Cn1ccnc1S,CBR-HVAC-10452: ; Dopamine beta-hydroxylase Inhibitor;
CBR-001-586-867-4,RFM-006-130-3,CBR-001-586-867-4,C=CCN1CCc2c(C(C1)c1ccccc1)cc(c(c2)O)O,CBR-HVAC-11599: ; Dopamine D1 Agonists;Signal Transduction Modulators; Dopamine receptor D1 Agonist;
CBR-001-586-868-5,RFM-006-131-4,CBR-001-586-868-5,Clc1cccc(c1)[C@H](CNCCNc1cccc(c1)c1cccc(c1)C(=O)O)O,"CBR-HVAC-00423: Urinary Incontinence Therapy;Type 2 Diabetes, Agents for;Irritable Bowel Syndrome, Agents for; beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-3 adrenergic receptor Agonist; Beta 3 adrenoreceptor agonist"
CBR-001-586-869-6,RFM-006-132-5,CBR-001-586-869-6,OC[C@@H]1O[C@@H](C(C1O)O)n1cnc2c1nc(OCCc1ccc(cc1)Cl)nc2N,CBR-HVAC-00536: Wound-Healing Agents; Adenosine A2A Agonists;Signal Transduction Modulators; Adenosine A2 receptor Agonist; Adenosine A2a receptor agonist; Adenosine receptor agonist
CBR-001-586-870-9,RFM-006-133-6,CBR-001-586-870-9,O=C(CC(C(=O)O)NC(=O)C)NC(C(=O)O)CCC(=O)O,CBR-HVAC-09367:
CBR-001-586-871-0,RFM-006-134-7,CBR-001-586-871-0,C[C@@H]1N[C@H](C)CN(C1)c1c(F)c(N)c2c(c1F)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-02812: Antibacterial Drugs; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-586-872-1,RFM-006-135-8,CBR-001-586-872-1,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1,CBR-HVAC-02855: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;
CBR-001-586-873-2,RFM-006-136-9,CBR-001-586-873-2,O=C1c2cc(ccc2OC21CC2)C(=O)C,CBR-HVAC-02671: Antiulcer Drugs; Mucus protecting agent; Gastrin inhibitor
CBR-001-586-874-3,RFM-006-137-0,CBR-001-586-874-3,OC(=O)c1ccccc1Nc1cccc(c1)OCc1ccc2c(n1)cccc2,CBR-HVAC-03861: Pharmacological Tools;Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Signal Transduction Modulators; Leucotriene D4 antagonist; Leucotriene E4 antagonist
CBR-001-586-875-4,RFM-006-138-1,CBR-001-586-875-4,OC(=O)CNC(=O)C(SC(=O)c1cccs1)C,CBR-HVAC-01561: ; Mucolytic agent
CBR-001-586-876-5,RFM-006-139-2,CBR-001-586-876-5,O[C@H](CN1CCOCC1)CNC(=O)c1c(C)[nH]c(c1C)/C=C/1\C(=O)Nc2c1cc(F)cc2,CBR-HVAC-11693: Breast Cancer Therapy; Angiogenesis Inhibitors;Flt3 (FLK2/STK1) Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; PDGFR beta; Vascular endothelial growth factor receptor; KIT Inhibitor;
CBR-001-586-877-6,RFM-006-140-5,CBR-001-586-877-6,OC(=O)CCC(=O)Oc1c(cc(cc1C(C)(C)C)SC(Sc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)(C)C)C(C)(C)C,"CBR-HVAC-05015: Atherosclerosis Therapy;Type 2 Diabetes, Agents for;Restenosis Treatment of; Antioxidants;CCL2 Expression Inhibitors;ERK1 Inhibitors;ERK2 Inhibitors;MAPK p38 Inhibitors;SAPK1 (JNK) Inhibitors;SAPK2 (p38beta) Inhibitors;Signal Transduction Modulators;VCAM1 Expression Inhibitors; Vascular cell adhesion molecule 1 Inhibitor;"
CBR-001-586-878-7,RFM-006-141-6,CBR-001-586-878-7,O=C(Nc1ccc(cc1)S(=O)(=O)Nc1nccs1)CCC(=O)O,CBR-HVAC-08682:
CBR-001-586-879-8,RFM-006-142-7,CBR-001-586-879-8,[O-]S(=O)(=O)O[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])O[C@]1(COS(=O)(=O)[O-])O[C@@H]([C@H]([C@@H]1OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al+]O.O[Al+]O.O[Al+]O.O[Al+]O.O[Al+]O.O[Al+]O.O[Al+]O.O[Al+]O,CBR-HVAC-09871: Gastric secretion modulator;
CBR-001-586-880-1,RFM-006-143-8,CBR-001-586-880-1,O=C(NS(=O)(=O)c1ccc(cc1)N)C=C(C)C,CBR-HVAC-08687:
CBR-001-586-881-2,RFM-006-144-9,CBR-001-586-881-2,O=C1N(c2ccccc2)N(C(=O)C1CCS(=O)c1ccccc1)c1ccccc1,CBR-HVAC-00996: ; Beta-lactamase Inhibitor; Uric acid diuretic; Platelet aggregation inhibitor; Prostaglandin synthase inhibitor
CBR-001-586-882-3,RFM-006-145-0,CBR-001-586-882-3,CCCCCCCCN[C@@H]([C@H](c1ccc(cc1)SC(C)C)O)C,CBR-HVAC-02831: ; Calcium channel Blocker; Alpha adrenoreceptor antagonist; Platelet aggregation inhibitor
CBR-001-586-883-4,RFM-006-146-1,CBR-001-586-883-4,CCOCC(COc1ccc(cc1)NC(=O)CC[S+](C)C)O,"CBR-HVAC-01590: Antiallergy/Antiasthmatic Drugs;Atopic Dermatitis, Agents for;Drugs for Allergic Rhinitis;Urologic Drugs; Mediator Release Inhibitors; Histamine release inhibitor; Immunoglobulin E inhibitor"
CBR-001-586-884-5,RFM-006-147-2,CBR-001-586-884-5,OC(=O)C(c1ccc(cc1)C(=O)c1cccs1)C,CBR-HVAC-02785: ; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-586-885-6,RFM-006-148-3,CBR-001-586-885-6,CC(OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@H]([C@@H]1/C=C/C(COc1ccccc1)(F)F)O)C,CBR-HVAC-05076: Ophthalmic Drugs;Antiglaucoma Agents; Prostanoid FP Agonists;Signal Transduction Modulators; Prostanoid FP receptor Agonist;
CBR-001-586-886-7,RFM-006-149-4,CBR-001-586-886-7,C=CCN1CCc2c(CC1)nc(s2)N,CBR-HVAC-01906: Nasal Decongestants;Antiparkinsonian Drugs; alpha2-Adrenoceptor Agonists;Dopamine Autoreceptor Agonists;Dopamine D2 Agonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor; Dopamine receptor D2 Inhibitor; Alpha 2 adrenoreceptor agonist; Dopamine D2 receptor agonist; 5 Hydroxytryptamine 3 receptor antagonist
CBR-001-586-887-8,RFM-006-150-7,CBR-001-586-887-8,CN1C(=O)C[C@H](NC1=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1[nH]cnc1,"CBR-HVAC-01440: Neurodegenerative Diseases, Treatment of; Thyrotropin releasing hormone receptor Agonist; Thyrotropin releasing hormone receptor agonist; Acetylcholine receptor agonist"
CBR-001-586-888-9,RFM-006-151-8,CBR-001-586-888-9,Oc1c(/N=N/c2ccc(cc2)S(=O)(=O)O)c(nn1c1ccc(cc1)S(=O)(=O)O)C(=O)O,CBR-HVAC-10319:
CBR-001-586-889-0,RFM-006-152-9,CBR-001-586-889-0,CCC(=O)NC[C@@H]1C[C@H]1c1cccc2c1CCO2,"CBR-HVAC-05699: Antidepressants;Sleep Disorders, Treatment of; Cytochrome P450 CYP1A2 Inhibitors;Cytochrome P450 CYP3A4 Inhibitors;Melatonin MT1 Agonists;Melatonin MT2 Agonists;Signal Transduction Modulators; Melatonin receptor Agonist; Melatonin 1 receptor agonist; Melatonin 2 receptor agonist"
CBR-001-586-890-3,RFM-006-153-0,CBR-001-586-890-3,COc1cc(cc(c1O)OC)[C@H]1[C@H]2C(=O)OC[C@@H]2[C@@H](c2c1cc1OCOc1c2)O[C@@H]1O[C@@H]2CO[C@H](O[C@H]2[C@@H]([C@H]1O)O)c1cccs1,CBR-HVAC-01815: Oncolytic Drugs; DNA Topoisomerase II Inhibitors; Topoisomerase II Inhibitor; DNA inhibitor; DNA repair enzyme inhibitor; DNA topoisomerase II inhibitor; Mitotic inhibitor
CBR-001-586-891-4,RFM-006-154-1,CBR-001-586-891-4,C[C@H](Cn1cnc2c1ncnc2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C,"CBR-HVAC-01935: Microbicides;Anti-Hepatitis B Virus Drugs;Neurological Genetic Disorders, Treatment of ;Anti-HIV Agents;Fibrosis, Treatment of; Cytochrome P450 CYP3A4 Inhibitors;DNA Polymerase Inhibitors;Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Nucleotide reverse transcriptase inhibitor"
CBR-001-586-892-5,RFM-006-155-2,CBR-001-586-892-5,C/C(=C\CC/C(=C/CCC(=O)C)/C)/CC/C=C(/CCC=C(C)C)\C,CBR-HVAC-02133: Antiulcer Drugs; Histamine H2 receptor Antagonist; Mucus protecting agent
CBR-001-586-893-6,RFM-006-156-3,CBR-001-586-893-6,CN(Cc1cccc2c1cccc2)C/C=C/C#CC(C)(C)C,CBR-HVAC-02464: Antifungal Agents; Squalene Monooxygenase Inhibitors (Fungal); Squalene epoxidase Inhibitor; Squalene epoxidase inhibitor; Steroid synthesis inhibitor
CBR-001-586-894-7,RFM-006-157-4,CBR-001-586-894-7,OC(c1ccc(cc1)C(C)(C)C)CCCN1CCC(CC1)C(c1ccccc1)(c1ccccc1)O,CBR-HVAC-02813: Drugs for Allergic Rhinitis; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist
CBR-001-586-895-8,RFM-006-158-5,CBR-001-586-895-8,O=C1NOCC1/N=C/c1ccc(cc1)/C=N/C1CONC1=O,CBR-HVAC-09021:
CBR-001-586-896-9,RFM-006-159-6,CBR-001-586-896-9,CSC[C@@H](C(=O)N[C@H]([C@H](C(=O)OC(C)C)O)CC1CCCCC1)NC(=O)[C@@H](NC(=O)N1CCOCC1)Cc1ccccc1,"CBR-HVAC-04275: Hypertension, Treatment of; Renin Inhibitors; Renin Inhibitor; Renin inhibitor"
CBR-001-586-897-0,RFM-006-160-9,CBR-001-586-897-0,COc1cc2c(cc1OCC1C[C@@H]3[C@H](C1)CN(C3)C)ncnc2Nc1ccc(c(c1F)Cl)Cl,CBR-HVAC-00819: Breast Cancer Therapy;Treatment of Renal Diseases;Non-Small Cell Lung Cancer Therapy; Angiogenesis Inhibitors;EGFR (HER1; erbB1) Inhibitors;EphB4 Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators;Src Kinase Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; EGFR; HER-2; VEGFR2 Inhibitor; Antagonist; ErbB-2 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Src inhibitor
CBR-001-586-898-1,RFM-006-161-0,CBR-001-586-898-1,CCCCNc1ccc(cc1)C(=O)OCCN(C)C,CBR-HVAC-01322: Local Anesthetics; Sodium channel Inhibitor; Sodium channel antagonist; Potassium channel antagonist; Membrane integrity inhibitor
CBR-001-586-899-2,RFM-006-162-1,CBR-001-586-899-2,CNc1n(C)nc2c1CCCC2,CBR-HVAC-09918:
CBR-001-586-900-8,RFM-006-163-2,CBR-001-586-900-8,CCCC1O[C@H]2[C@](O1)(C(=O)CO)[C@@]1([C@@H](C2)[C@@H]2CCC3=CC(=O)C=C[C@@]3([C@H]2[C@H](C1)O)C)C,CBR-HVAC-00412: ; Beta-2 adrenergic receptor Agonist; Adenosine A1 receptor antagonist; Adenosine A2a receptor antagonist; Phosphodiesterase inhibitor; Immunosuppressant
CBR-001-586-901-9,RFM-006-164-3,CBR-001-586-901-9,Nc1nc(Sc2n(C)cnc2[N+](=O)[O-])c2c(n1)nc[nH]2,CBR-HVAC-09075:
CBR-001-586-902-0,RFM-006-165-4,CBR-001-586-902-0,OC[C@H]([C@@H](c1ccc(cc1)S(=O)(=O)C)O)NC(=O)C(Cl)Cl,CBR-HVAC-03305: Antibiotics;
CBR-001-586-903-1,RFM-006-166-5,CBR-001-586-903-1,CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C,CBR-HVAC-08922: ; Dopamine receptor Antagonist;
CBR-001-586-904-2,RFM-006-167-6,CBR-001-586-904-2,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1c(S2)cccc1,CBR-HVAC-00997: ; Dopamine receptor Inhibitor; Dopamine receptor antagonist; Alpha adrenoreceptor antagonist; Acetylcholine receptor antagonist
CBR-001-586-905-3,RFM-006-168-7,CBR-001-586-905-3,S=P(N1CC1)(N1CC1)N1CC1,CBR-HVAC-04802: Solid Tumors Therapy;Oncolytic Drugs;Hematologic Agents (Miscellaneous); Cytochrome P450 CYP3A4 Inhibitors;Cytochrome P450 Oxidase Inhibitors;
CBR-001-586-906-4,RFM-006-169-8,CBR-001-586-906-4,N#CCCCSC(=N)N,CBR-HVAC-06756: Ovarian Cancer Therapy;Myeloid Leukemia Therapy;Renal Cancer Therapy;Brain Cancer Therapy;Oncolytic Drugs;Multiple Myeloma Therapy;Lymphoma Therapy;Solid Tumors Therapy; Apoptosis Inducers;Caspase 3 Activators;Histone Deacetylase 2 (HDAC2) Inhibitors;MAPK p38 Inhibitors;Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators; AKT protein kinase; p38 MAP kinase; mTOR kinase Inhibitor;
CBR-001-586-907-5,RFM-006-170-1,CBR-001-586-907-5,Oc1nc(oc1c1ccccc1)N(C)C,CBR-HVAC-08601:
CBR-001-586-908-6,RFM-006-171-2,CBR-001-586-908-6,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)O)C(C)C)CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)N,CBR-HVAC-02137: Immunomodulators; Peptide agonist; Interleukin 2 agonist; Cell cycle inhibitor
CBR-001-586-909-7,RFM-006-172-3,CBR-001-586-909-7,OCCN1CCN(CC1)C(=O)Cn1c(=O)sc2c1cc(Cl)cc2,CBR-HVAC-01975: ; Beta 2 adrenoreceptor agonist; Immunosuppressant
CBR-001-586-910-0,RFM-006-173-4,CBR-001-586-910-0,OC[C@H]1O[C@H](C(C1O)O)c1scc(n1)C(=O)N,CBR-HVAC-02528: ; Inosine monophosphate dehydrogenase Inhibitor; Inosine monophosphate dehydrogenase inhibitor
CBR-001-586-911-1,RFM-006-174-5,CBR-001-586-911-1,CC(C(c1ccc2c(c1)CCS2)O)NCCCCc1ccccc1,CBR-HVAC-00966: ; Alpha-1 adrenergic receptor Antagonist; Alpha 2 adrenoreceptor antagonist
CBR-001-586-912-2,RFM-006-175-6,CBR-001-586-912-2,C[N+]1(CCOCC1)CCC(c1cccs1)(c1ccccc1)O,CBR-HVAC-01517: ; Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist
CBR-001-586-913-3,RFM-006-176-7,CBR-001-586-913-3,CC(C(=O)NCC(=O)O)S,CBR-HVAC-01560: Metabolic Disorders (Not Specified); Angiotensin I converting enzyme Inhibitor; Chelating agent; Mucolytic agent; Reducing agent
CBR-001-586-914-4,RFM-006-177-8,CBR-001-586-914-4,Clc1ccc2c(c1NC1=NCCN1)nsn2,CBR-HVAC-01401: Antispastic Drugs; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Agonist; Alpha 2 adrenoreceptor agonist
CBR-001-586-915-5,RFM-006-178-9,CBR-001-586-915-5,OC(=O)[C@H]1O[C@@H](Oc2cc3oc(cc(=O)c3c(c2O)O)c2ccccc2)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-00019: ; Reverse transcriptase Inhibitor; Beta-glucuronidase inhibitor
CBR-001-586-916-6,RFM-006-179-0,CBR-001-586-916-6,CCOC(=O)NNc1nncc2c1cccc2,CBR-HVAC-08990:
CBR-001-586-917-7,RFM-006-180-3,CBR-001-586-917-7,COc1cc2C3CN(C)CCC3N=C(c2cc1OC)c1ccc(cc1)NS(=O)(=O)c1ccc(cc1)C,CBR-HVAC-04588: Bronchodilators; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators; Phosphodiesterase 3; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 3 inhibitor; Phosphodiesterase 4 inhibitor
CBR-001-586-918-8,RFM-006-181-4,CBR-001-586-918-8,OC(=O)c1ccccc1Nc1cccc(c1C)Cl,CBR-HVAC-01577: Antiarthritic Drugs;Antimigraine Drugs;Prostate Cancer Therapy;Colorectal Cancer Therapy;Pancreatic Cancer Therapy; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase inhibitor; Prostaglandin receptor antagonist; Prostaglandin synthase inhibitor; Leucotriene synthesis inhibitor
CBR-001-586-919-9,RFM-006-182-5,CBR-001-586-919-9,Cc1ccc(c(c1)Cl)NC1=NCCN1,CBR-HVAC-01592: ; Alpha 2 adrenoreceptor agonist
CBR-001-586-920-2,RFM-006-183-6,CBR-001-586-920-2,CC(C(=O)c1ccc(cc1)C)CN1CCCCC1,"CBR-HVAC-01360: Muscle Spasms, Drugs for; Voltage-gated sodium channel antagonist"
CBR-001-586-921-3,RFM-006-184-7,CBR-001-586-921-3,Cc1ccc(c(c1)C(c1ccccc1)CCN(C(C)C)C(C)C)O,CBR-HVAC-02194: Urinary Incontinence Therapy; Muscarinic M3 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Antagonist; Muscarinic M1 receptor antagonist; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Muscarinic M4 receptor antagonist
CBR-001-586-922-4,RFM-006-185-8,CBR-001-586-922-4,CCCc1c(OCCCCc2nnn[nH]2)ccc(c1O)C(=O)C,CBR-HVAC-02967: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; LEUKOTRIENE D4 RECEPTOR Antagonist; Leucotriene D4 antagonist
CBR-001-586-923-5,RFM-006-186-9,CBR-001-586-923-5,CCCCNc1c(C(=O)OCC)c(C)nc2c1cnn2CC,CBR-HVAC-08459: Anxiolytics; GABA receptor agonist
CBR-001-586-924-6,RFM-006-187-0,CBR-001-586-924-6,C[C@@H](C(=O)N1[C@@H]2CCCCC2CC1C(=O)O)N[C@H](C(=O)O)CCc1ccccc1,CBR-HVAC-01524: ; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor
CBR-001-586-925-7,RFM-006-188-1,CBR-001-586-925-7,CCCCC/C=C\C=C\CCCCCCCCC(=O)O,CBR-HVAC-05586: Chemopreventive Agents;Atherosclerosis Therapy;
CBR-001-586-926-8,RFM-006-189-2,CBR-001-586-926-8,CC(OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@H]([C@@H]1/C=C/[C@H](COc1cccc(c1)C(F)(F)F)O)O)C,CBR-HVAC-01481: Antiglaucoma Agents;Ophthalmic Drugs; Prostanoid FP Agonists;Signal Transduction Modulators; Prostanoid FP receptor Agonist; Prostaglandin F2 alpha receptor agonist; Prostaglandin FP receptor agonist
CBR-001-586-927-9,RFM-006-190-5,CBR-001-586-927-9,Clc1cccc(c1)N1CCN(CC1)CCCn1nc2n(c1=O)cccc2,CBR-HVAC-02192: Antidepressants; alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators;5-HT Reuptake Inhibitors;5-HT2 Antagonists; 5-Hydroxytryptamine 2A receptor Antagonist; 5 Hydroxytryptamine uptake inhibitor; Alpha 1 adrenoreceptor antagonist; Histamine H1 receptor antagonist
CBR-001-586-928-0,RFM-006-191-6,CBR-001-586-928-0,CN(C1Cc2ccccc2OC1C)C,CBR-HVAC-01048: Antidepressants;Antipsychotic Drugs; Unidentified pharmacological activity
CBR-001-586-929-1,RFM-006-192-7,CBR-001-586-929-1,COc1cc2c(cc1OC)CCn1c2c/c(=N\c2c(C)cc(cc2C)C)/n(c1=O)C,"CBR-HVAC-10443: Hypertension, Treatment of;Hair Growth Stimulants; Potassium Channel Subfamily K Member 18 (TRESK; KCNK18) Blockers; PHOSPHODIESTERASE 3 Inhibitor;"
CBR-001-586-930-4,RFM-006-193-8,CBR-001-586-930-4,CC(=O)O[C@@H]1C[C@@H]2[C@]([C@@]1(O)C(=O)COC(=O)C)(C)C[C@@H]([C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F)O,CBR-HVAC-02421: ; Corticosteroid agonist
CBR-001-586-931-5,RFM-006-194-9,CBR-001-586-931-5,OCC(=O)[C@@]1(O)[C@H](O)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-02598: ; Glucocorticoid receptor Inhibitor; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-586-932-6,RFM-006-195-0,CBR-001-586-932-6,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cc2c3c1ncnc3n(nc2N)C)COP(=O)(O)O,CBR-HVAC-00621: Solid Tumors Therapy;Anti-HIV Agents;Multiple Myeloma Therapy;Ovarian Cancer Therapy;Breast Cancer Therapy;Antiviral Drugs;Leukemia Therapy; Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators; AKT Inhibitor; Protein kinase B inhibitor
CBR-001-586-933-7,RFM-006-196-1,CBR-001-586-933-7,NCCNCCNCCN,"CBR-HVAC-02943: Diabetic Myocardiopathy, Agents for;Wilson Disease, Agent for;Antagonists to Metals; Chelating Agents;Telomerase Inhibitors; Copper uptake inhibitor; Chelating agent"
CBR-001-586-934-8,RFM-006-197-2,CBR-001-586-934-8,C1CN1c1nc(nc(n1)N1CC1)N1CC1,CBR-HVAC-09266:
CBR-001-586-935-9,RFM-006-198-3,CBR-001-586-935-9,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)(O)c1cccc(c1)C(F)(F)F,CBR-HVAC-10071: ; Dopamine receptor D2 Antagonist;
CBR-001-586-936-0,RFM-006-199-4,CBR-001-586-936-0,OC(=O)Cc1cc(I)c(c(c1)I)Oc1ccc(c(c1)I)O,CBR-HVAC-05972: Dermatologic Drugs;Thyroid Disease Therapy;
CBR-001-586-937-1,RFM-006-200-0,CBR-001-586-937-1,O=C1OC(C(=O)N1C)(C)C,"CBR-HVAC-03226: Antiepileptic Drugs;Pancreatic Disorders, Treatment of; Sodium channel Inhibitor;"
CBR-001-586-938-2,RFM-006-201-1,CBR-001-586-938-2,NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)CCC(=O)O,"CBR-HVAC-15130: Caspase III dependent apoptosis inhibitor; NMDA Receptor Ligands; Alzheimer's Disease and Cognition Disorders; Anti-inflammatory; Antidepressants; Antiepileptic Drugs; Apoptosis inhibitor; Cognition Disorders, Treatment of; Neurologic Drugs (Miscellaneous); Neuroprotectant; Psychiatric Disorders (Not Specified)"
CBR-001-586-939-3,RFM-006-202-2,CBR-001-586-939-3,CO[C@H]1C[C@@H](O[C@H]([C@@H]1OC(=O)C)C)O[C@H]1[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2OC(=O)C)N(C)C)[C@@H](C)C[C@]2(OC2)C(=O)[C@@H]([C@H]([C@H]([C@H](OC(=O)[C@@H]1C)C)C)OC(=O)C)C,CBR-HVAC-00999: ; Protein 50S ribosomal subunit inhibitor
CBR-001-586-940-6,RFM-006-203-3,CBR-001-586-940-6,CCN(C(=O)C(c1ccccc1)CO)Cc1ccncc1,CBR-HVAC-02446: Neurologic Drugs (Miscellaneous);Ophthalmic Drugs; Anticholinergics;Muscarinic Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor Inhibitor; Muscarinic receptor antagonist
CBR-001-586-941-7,RFM-006-204-4,CBR-001-586-941-7,COc1ccc2c(c1)c(CC(=O)OCC(c1ccccc1)C(=O)O)c(n2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-02237: ; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-586-942-8,RFM-006-205-5,CBR-001-586-942-8,CC(Cn1nnnc1c1cccc(c1)N)C,CBR-HVAC-09515:
CBR-001-586-943-9,RFM-006-206-6,CBR-001-586-943-9,CN1C[C@@H](CC2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O,CBR-HVAC-02640: ; 5-Hydroxytryptamine 1B receptor Agonist; Alpha adrenoreceptor antagonist; Dopamine receptor agonist; Prolactin inhibitor
CBR-001-586-944-0,RFM-006-207-7,CBR-001-586-944-0,NC(=O)/C=C/c1ccccc1C,CBR-HVAC-10827: Oncolytic Drugs;
CBR-001-586-945-1,RFM-006-208-8,CBR-001-586-945-1,NCCCC[C@@H](C(=O)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1cnc[nH]1)N)C,CBR-HVAC-03758: ; GHS Receptor Agonists;Growth Hormone Secretagogues;Melanin Inhibitors;Signal Transduction Modulators;
CBR-001-586-946-2,RFM-006-209-9,CBR-001-586-946-2,O[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)[C@@H](Cc1ccccc1)N,CBR-HVAC-02998: Leukemia Therapy;Immunostimulants;Lung Cancer Therapy; Leukotriene A4 Hydrolase Inhibitors;Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors; Aminopeptidase Inhibitor;
CBR-001-586-947-3,RFM-006-210-2,CBR-001-586-947-3,COC1=C(OC)C(=O)C(=C(C1=O)C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)C,"CBR-HVAC-02594: Amyotrophic Lateral Sclerosis, Agents for;Pancreatic Cancer Therapy;Myelodysplastic Syndrome Therapy;Bipolar Disorder, Treatment of;Lung Cancer Therapy;Muscular Dystrophy, Agents for;Therapy of Inborn Errors of Metabolism;Fatigue, Treatment of;Motor Function Disorders, Treatment of;Huntington's Disease, Treatment of;Heart Failure Therapy;Renal Cancer Therapy;Basal Cell Carcinoma Therapy;Leukemia Therapy;Solid Tumors Therapy;Wound-Healing Agents;Squamous Cell Carcinoma Therapy; Antioxidants; Reducing agent"
CBR-001-586-948-4,RFM-006-211-3,CBR-001-586-948-4,OCCNc1nc(CCC)nc(n1)N1CCOCC1,"CBR-HVAC-03973: Cognition Disorders, Treatment of; Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Inhibitor; Unidentified pharmacological activity"
CBR-001-586-949-5,RFM-006-212-4,CBR-001-586-949-5,NCCNC(C(=O)O)Cc1c[nH]cn1,CBR-HVAC-09341:
CBR-001-586-950-8,RFM-006-213-5,CBR-001-586-950-8,ClCCN(c1cnc(nc1O)O)CCCl,CBR-HVAC-07327: Oncolytic Drugs;Lymphocytic Leukemia Therapy;Myeloid Leukemia Therapy;Non-Hodgkin's Lymphoma Therapy; DNA Alkylating Drugs;
CBR-001-586-951-9,RFM-006-214-6,CBR-001-586-951-9,OC(=O)CC(C(=O)O)NC(=O)N,CBR-HVAC-02804:
CBR-001-586-952-0,RFM-006-215-7,CBR-001-586-952-0,C/C=C/C[C@H](C(=O)[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)C,CBR-HVAC-04270: Cancer Multidrug Resistance Modulators; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; P-Glycoprotein Inhibitor; P glycoprotein inhibitor
CBR-001-586-953-1,RFM-006-216-8,CBR-001-586-953-1,OC[C@@H]1O[C@@H](CC1OC(=O)[C@H](C(C)C)N)n1ccc(nc1=O)N,CBR-HVAC-05897: Anti-Hepatitis B Virus Drugs; DNA Polymerase Inhibitors;
CBR-001-586-954-2,RFM-006-217-9,CBR-001-586-954-2,COc1cc2c(ncnc2cc1OCC1CCN(CC1)C)Nc1ccc(cc1F)Br,"CBR-HVAC-01825: Genitourinary Cancer Therapy;Endocrine Cancer Therapy;Neurological Genetic Disorders, Treatment of ;Breast Cancer Therapy;Liver Cancer Therapy;Neurologic Cancer Therapy;Pancreatic Cancer Therapy;Cancer Associated Disorders, Treatment of;Female Reproductive System Cancer Therapy;Prostate Cancer Therapy;Glioblastoma Multiforme Therapy;Respiratory/Thoracic Cancer Therapy;Colorectal Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Bladder Cancer Therapy ;Head and Neck Cancer Therapy;Renal Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Abl Kinase Inhibitors;Angiogenesis Inhibitors;EGFR (HER1; erbB1) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;RET Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors; EGFR; Vascular endothelial growth factor receptor 2 Inhibitor; VEGFR-2 tyrosine kinase inhibitor; RET tyrosine kinase inhibitor; EGFR kinase inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor"
CBR-001-586-955-3,RFM-006-218-0,CBR-001-586-955-3,C[C@@H]1COC(=N1)Nc1ccc2c(c1)c(ncn2)Nc1ccc(c(c1)Cl)OCc1nccs1,CBR-HVAC-00711: Solid Tumors Therapy;Breast Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Gastric Cancer Therapy;Pancreatic Cancer Therapy; EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators; ERBB2 Inhibitor; EGFR kinase inhibitor; ErbB-2 tyrosine kinase inhibitor; ErbB-4 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-586-956-4,RFM-006-219-1,CBR-001-586-956-4,O=C([C@@H]1CC[C@H](CC1)NS(=O)(=O)C(C)(C)C)Nc1ccc(cn1)C(F)(F)F,CBR-HVAC-00375: Antiobesity Drugs; Neuropeptide Y5 (NPY Y5) Antagonists;Signal Transduction Modulators; Neuropeptide Y receptor 5 Antagonist; Neuropeptide Y5 receptor antagonist
CBR-001-586-957-5,RFM-006-220-4,CBR-001-586-957-5,NC(C=C)CCC(=O)O,"CBR-HVAC-01894: Treatment of Alcohol Dependency;Treatment of Cocaine Dependency;Tourette's Syndrome, Treatment of;Treatment of Substance Dependency;Antiepileptic Drugs; GABA Aminotransferase Inhibitors; GABA aminotransferase Inhibitor; GABA aminotransferase inhibitor"
CBR-001-586-958-6,RFM-006-221-5,CBR-001-586-958-6,CC[C@@]1(CO)CCCN2[C@@H]1c1[nH]c3c(c1CC2)cccc3,CBR-HVAC-03456: Cardiovascular Diseases (Not Specified); Calcium channel; 5-Hydroxytryptamine receptor Antagonist; Calcium channel antagonist; 5 Hydroxytryptamine receptor antagonist; Nitric oxide stimulant
CBR-001-586-959-7,RFM-006-222-6,CBR-001-586-959-7,NCCCCCCNS(=O)(=O)c1cccc2c1cccc2Cl,CBR-HVAC-01228: ; Calmodulin Antagonists;K(V) 11.1 (erg1) Channel Blockers;K(V) 1.5 (KCNA5) Channel Blockers; Calmodulin Antagonist; Calcium channel antagonist; Platelet aggregation inhibitor; Colony stimulating factor antagonist
CBR-001-586-960-0,RFM-006-223-7,CBR-001-586-960-0,COc1ccccc1N1CCN(CC1)CC(C(=O)NC(C)(C)C)c1ccccc1,CBR-HVAC-10830: Anxiolytics; Signal Transduction Modulators;5-HT1A Receptor Antagonists; 5-Hydroxytryptamine 1A receptor Antagonist;
CBR-001-586-961-1,RFM-006-224-8,CBR-001-586-961-1,CNC(=O)OC1CN2CC1CC2,"CBR-HVAC-11506: Cognition Disorders, Treatment of; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Agonist;"
CBR-001-586-962-2,RFM-006-225-9,CBR-001-586-962-2,CCOC(=O)C(=O)Nc1cccc(c1C(=O)N)OC,CBR-HVAC-08528: Antiallergy/Antiasthmatic Drugs;Bronchodilators; Histamine release inhibitor; 5 Hydroxytryptamine release inhibitor
CBR-001-586-963-3,RFM-006-226-0,CBR-001-586-963-3,c1cnc(nc1)NCc1ccc(cc1)CNc1ncccn1,"CBR-HVAC-06450: Disorders Associated with Cancer Therapy, Treatment of;Solid Tumors Therapy;Anti-HIV Agents; Angiogenesis Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators;"
CBR-001-586-964-4,RFM-006-227-1,CBR-001-586-964-4,Cc1cccc(c1)NC(=O)N[C@@H]1N=C(c2ccccc2)c2c(N(C1=O)CC(=O)c1ccccc1C)cccc2,CBR-HVAC-04323: ; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin B receptor Antagonist; CCK B receptor antagonist; Gastrin inhibitor
CBR-001-586-965-5,RFM-006-228-2,CBR-001-586-965-5,CCc1ccc2c(n1)n(CC)c(=O)nc2c1cccc(c1)Cl,"CBR-HVAC-04947: Antiallergy/Antiasthmatic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor"
CBR-001-586-966-6,RFM-006-229-3,CBR-001-586-966-6,O=C(N[C@@H]1CN(C2CCCCC2)c2c(N(C1=O)CC(=O)C(C)(C)C)cccc2)Nc1cccc(c1)C(=O)O,"CBR-HVAC-00652: Gastroesophageal Reflux Disease, Agents for;Antiulcer Drugs;Digestive/Gastrointestinal Cancer Therapy;Pancreatic Cancer Therapy; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin B receptor Antagonist; CCK B receptor antagonist; Gastrin inhibitor"
CBR-001-586-967-7,RFM-006-230-6,CBR-001-586-967-7,O=C(NC(C)(C)C)CN1CCC(CC1)CNC(=O)c1cc(F)cc(c1)Cl,"CBR-HVAC-06975: Inflammation, Treatment of;Analgesic Drugs;Antiepileptic Drugs;Non-Opioid Analgesics;Neuropathic Pain, Treatment of; T-Type Calcium Channel Blockers;"
CBR-001-586-968-8,RFM-006-231-7,CBR-001-586-968-8,OC[C@H]([C@H]([C@@H]1OC(=C[C@@H]([C@H]1NC(=O)C)NC(=N)N)C(=O)O)O)O,CBR-HVAC-02096: Anti-Influenza Virus Drugs; Neuraminidase (Sialidase) Inhibitors; Neuraminidase Inhibitor; Neuraminidase inhibitor
CBR-001-586-969-9,RFM-006-232-8,CBR-001-586-969-9,COc1ccc(cc1OC)CCN(CCCN1CCc2c(CC1=O)cc(c(c2)OC)OC)C,"CBR-HVAC-02976: Angina pectoris, Treatment of; HCN [I(f)] Blockers; Potassium channel Kv1.2 Blocker; HCN channel antagonist; Potassium channel antagonist; Sodium channel antagonist"
CBR-001-586-970-2,RFM-006-233-9,CBR-001-586-970-2,Brc1ccc(c(c1)F)Cn1c(=O)c2ccc(cc2n(c1=O)CC(=O)O)Cl,"CBR-HVAC-03580: Diabetic Neuropathy, Agents for; Aldose Reductase Inhibitors; ALDOSE REDUCTASE Inhibitor; Aldose reductase inhibitor"
CBR-001-586-971-3,RFM-006-234-0,CBR-001-586-971-3,CN(C/C=C(\c1cccnc1)/c1ccc(cc1)Br)C,CBR-HVAC-02828: Antidepressants; Signal Transduction Modulators;5-HT Reuptake Inhibitors; 5-Hydroxytryptamine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor
CBR-001-586-972-4,RFM-006-235-1,CBR-001-586-972-4,O=C1Nc2c(C1)cc(c(c2)Cl)CCN1CCN(CC1)c1nsc2c1cccc2,"CBR-HVAC-02193: Antidepressants;Bipolar Disorder, Treatment of;Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT2A Antagonists; Dopamine receptor Antagonist; 5 Hydroxytryptamine 1A receptor agonist; 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 1D receptor antagonist; Dopamine D2 receptor antagonist; Serotonin and norepinephrine reuptake inhibitor"
CBR-001-586-973-5,RFM-006-236-2,CBR-001-586-973-5,OC(=O)Cc1cc(c(n1C)C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-05251: Non-Opioid Analgesics; Prostaglandin G/H synthase Inhibitor;
CBR-001-586-974-6,RFM-006-237-3,CBR-001-586-974-6,Clc1cccc(c1)C1=NCCNc2c1c(C)nn2C,CBR-HVAC-01047: Antidepressants; Unidentified pharmacological activity
CBR-001-586-975-7,RFM-006-238-4,CBR-001-586-975-7,OC(=O)C=c1[nH]n(Cc2nc3c(s2)ccc(c3)C(F)(F)F)c(=O)c2c1cccc2,"CBR-HVAC-03622: Diabetic Myocardiopathy, Agents for;Diabetic Nephropathy, Agents for; Aldose Reductase Inhibitors; Aldose reductase Inhibitor; Aldose reductase inhibitor"
CBR-001-586-976-8,RFM-006-239-5,CBR-001-586-976-8,CN(CCOC1=Cc2ccccc2Sc2c1cc(Cl)cc2)C,CBR-HVAC-01764: Antipsychotic Drugs; Dopamine D2 Antagonists;Serotonin Antagonists;Signal Transduction Modulators; Alpha-1A adrenergic receptor; Dopamine receptor D2; 5-Hydroxytryptamine 7 receptor; 5-Hydroxytryptamine 2C receptor; Histamine H1 receptor; 5-Hydroxytryptamine 2A receptor; 5-hydroxytryptamine 6 receptor Antagonist; Adrenergic transmitter uptake inhibitor; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 2A receptor antagonist
CBR-001-586-977-9,RFM-006-240-8,CBR-001-586-977-9,OC(=O)CCC(C(=O)O)NC(=O)C(NC(=O)C)CC(=O)O,CBR-HVAC-04243: Antiallergy/Antiasthmatic Drugs; Mediator Release Inhibitors; Membrane permeability enhancer; Complement factor inhibitor; Leucotriene receptor antagonist; Histamine release inhibitor
CBR-001-586-978-0,RFM-006-241-9,CBR-001-586-978-0,NCc1cc(cc(c1O)I)C(C)(C)C,CBR-HVAC-12338: Potassium sparing diuretic; Free radical scavenger; Prostaglandin synthase stimulant
CBR-001-586-979-1,RFM-006-242-0,CBR-001-586-979-1,O=C(c1cc2c(cc1O)C(C)(C)CCC2(C)C)Nc1cc(F)c(c(c1)F)C(=O)O,analog of CBR-HVAC-09347 (AGN-191379)
CBR-001-586-980-4,RFM-006-243-1,CBR-001-586-980-4,NC(=O)[C@@H]1OC(=O)N(C1)c1ccc(cc1)c1ccc(nc1)c1nnc(s1)C,analog of CBR-HVAC-11264 (PNU 171832)
CBR-001-586-981-5,RFM-006-244-2,CBR-001-586-981-5,COC(=O)Nc1cccc(c1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,analog of CBR-HVAC-11266 (PNU 172614)
CBR-001-586-982-6,RFM-006-245-3,CBR-001-586-982-6,CSc1ccc(cc1)CN1CCCC(C1)Nc1ccc2c(c1)cn[nH]2,CBR-HVAC-12079: Rho-associated kinase inhibitor; Protein kinase inhibitor
CBR-001-586-983-7,RFM-006-246-4,CBR-001-586-983-7,Fc1ccc2c(c1)c(=O)cc(o2)C(=O)NC1CCN(CC1)Cc1ccc2c(c1)OCO2,CBR-HVAC-11761: Melanin concentrating hormone receptor 1 Antagonist;
CBR-001-586-984-8,RFM-006-247-5,CBR-001-586-984-8,CNCc1ccc(c(c1)NC(=O)c1ccc(cc1)Nc1nc2ccccc2c(n1)c1ccccc1)C,CBR-HVAC-09281: Hedgehog protein Inhibitor;
CBR-001-586-985-9,RFM-006-248-6,CBR-001-586-985-9,Clc1ccccc1C(c1nc(cn1c1ccc(cc1)c1cccc(c1)S(=O)(=O)C)C(O)(C)C)(C)C,CBR-HVAC-06876: Oxysterol Receptor (LXR) Partial Agonists; Oxysterol Receptor LXRalpha Partial Agonists; Oxysterol Receptor LXRbeta Partial Agonists; Signal Transduction Modulators; Atherosclerosis Therapy
CBR-001-586-986-0,RFM-006-249-7,CBR-001-586-986-0,CCOC(=O)[C@@H](NC1=C(Br)C(=O)C21CCCCC2)Cc1ccc(cc1)Nc1nccc2c1cncc2,"CBR-HVAC-05884: Antiallergy/Antiasthmatic Drugs;Multiple Sclerosis, Agents for;Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for; Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (MAdCAM) Antagonists;Signal Transduction Modulators;"
CBR-001-586-987-1,RFM-006-250-0,CBR-001-586-987-1,OCCN(S(=O)(=O)C)c1c(Cl)c(Cl)cc2c1[nH]c(=O)c(=O)[nH]2,"CBR-HVAC-05344: Stroke, Treatment of; NMDA Glycine-Site Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-586-988-2,RFM-006-251-1,CBR-001-586-988-2,O[C@@H](CNC(Cc1ccc(cc1)Oc1ccc(cn1)C(=O)N)(C)C)COc1cccc2c1c1ccccc1[nH]2,CBR-HVAC-05147: Antiobesity Drugs; beta1-Adrenoceptor Antagonists;beta2-Adrenoceptor Antagonists;beta3-Adrenoceptor Agonists;Signal Transduction Modulators; Beta-3 adrenergic receptor Agonist;
CBR-001-586-989-3,RFM-006-252-2,CBR-001-586-989-3,OC(=O)CCC/C=C\C[C@H]1C[C@H]2C[C@@H]([C@@H]1NC(=O)c1csc3c1cc(O)cc3)C2(C)C,CBR-HVAC-04990: Drugs for Allergic Rhinitis;Antiallergy/Antiasthmatic Drugs; Prostanoid DP (DP1) Antagonists;Signal Transduction Modulators; Prostaglandin D2 receptor Antagonist;
CBR-001-586-990-6,RFM-006-253-3,CBR-001-586-990-6,O=C(N1CSC[C@H]1C(=O)N1CCCC1)CC1Cc2c(C1)cccc2,"CBR-HVAC-04072: Alzheimer's Dementia, Treatment of ; Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors; Prolyl endopeptidase Inhibitor;"
CBR-001-586-991-7,RFM-006-254-4,CBR-001-586-991-7,CN1Cc2c(ncn2c2c(C1=O)c(Cl)ccc2)C(=O)OCC,"CBR-HVAC-03405: Cognition Disorders, Treatment of;Pharmacological Tools; Benzodiazepine receptor Partial Inverse Agonist;"
CBR-001-586-992-8,RFM-006-255-5,CBR-001-586-992-8,OC(=O)C(Cc1ccc(cc1)OCCN(c1nc2c(o1)cccc2)C)OCC(F)(F)F,CBR-HVAC-11623_A: Insulin sensitizer; PPAR gamma agonist
CBR-001-586-993-9,RFM-006-256-6,CBR-001-586-993-9,OC(=O)C(Cc1ccc(cc1)OCCN(c1nc2c(o1)cccc2)C)OCC(F)(F)F,CBR-HVAC-11623_B: Insulin sensitizer; PPAR gamma agonist
CBR-001-586-994-0,RFM-006-257-7,CBR-001-586-994-0,OC(=O)CN(c1ccccc1OCCOc1ccccc1N(CC(=O)O)CC(=O)O)CC(=O)O,CBR-HVAC-05228M1: metabolite of  CBR-HVAC-05228
CBR-001-586-995-1,RFM-006-258-8,CBR-001-586-995-1,OC(=O)COc1cccc(c1)CN(S(=O)(=O)c1cccnc1)Cc1ccc(cc1)n1cccn1,CBR-HVAC-08408: Prostaglandin EP2 receptor agonist
CBR-001-586-996-2,RFM-006-259-9,CBR-001-586-996-2,OC[C@@H]1C=C[C@@H](O1)n1cnc2c1ncnc2N,CBR-HVAC-08567M1: metabolite of CBR-HVAC-08567
CBR-001-586-997-3,RFM-006-260-2,CBR-001-586-997-3,Fc1ccc(cc1)Cn1c(nc2c1cccc2)N1CCC(CC1)n1ncc(c1)C,CBR-HVAC-07891: Histamine H1 receptor antagonist
CBR-001-586-998-4,RFM-006-261-3,CBR-001-586-998-4,CN1CCN(CC1)NC(=O)CN1CCN([C@@H](C1)Cc1c[nH]c2c1cccc2)C(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,CBR-HVAC-07826: Neurokinin 1 receptor antagonist
CBR-001-586-999-5,RFM-006-262-4,CBR-001-586-999-5,CC(Sc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)(Sc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)C,CBR-HVAC-08148: Reducing agent; Apoptosis inhibitor
CBR-001-587-000-5,RFM-006-263-5,CBR-001-587-000-5,CN(CCn1c2ccccc2c2c1nc1cc(C)c(cc1n2)C)C,CBR-HVAC-09333: Anticancer; Anti-inflammatory; Antiviral;
CBR-001-587-001-6,RFM-006-264-6,CBR-001-587-001-6,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4cccc(c4cc3Cn1c2=O)N,CBR-HVAC-11324: DNA topoisomerase I Inhibitor;
CBR-001-587-002-7,RFM-006-265-7,CBR-001-587-002-7,COCCCCOC(=O)/C=C/c1ccc(cc1)c1nc2c([nH]1)c(=O)n(c(=O)n2CC1CCCCC1)CC1CCCCC1,CBR-HVAC-11675: E-Selectin; Intercellular adhesion molecule Inhibitor;
CBR-001-587-003-8,RFM-006-266-8,CBR-001-587-003-8,COc1c(NC(=O)C(=O)c2ccc(c3c2cccc3)OCCN2CCOCC2)cc(cc1NS(=O)(=O)C)C(C)(C)C,CBR-HVAC-06864: Anti-Hepatitis C Virus Drugs; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators;Viral Entry Inhibitors; P38 MAP KINASE Inhibitor;
CBR-001-587-004-9,RFM-006-267-9,CBR-001-587-004-9,CN(C1=NCC(C1)c1cc2c(o1)cccc2)C,CBR-HVAC-02511: Polarisation inhibitor
CBR-001-587-005-0,RFM-006-268-0,CBR-001-587-005-0,CC[N+]1(C)CCC(CC1)OC(=O)C(c1noc2c1cccc2)N1CCCCCC1,CBR-HVAC-03059: Antispasmodics; Muscarinic receptor antagonist
CBR-001-587-006-1,RFM-006-269-1,CBR-001-587-006-1,OC1=NC(=O)C(N1)(c1ccccc1)c1cccs1,CBR-HVAC-09119:
CBR-001-587-007-2,RFM-006-270-4,CBR-001-587-007-2,CN(CC1=CC(C=C1CNc1ccnc2c1ccc(c2)Cl)[Fe]C1C=CC=C1)C,CBR-HVAC-05569: Antimalarials; Antiparasitic; Antimalarial;
CBR-001-587-008-3,RFM-006-271-5,CBR-001-587-008-3,Fc1cccc(c1)C1(CCN2C3CCC2CC(C3)n2c(C)nc3c2cccc3)CCN(CC1)C(=O)c1cc(c(cc1Cl)F)S(=O)(=O)NC(C)(C)C,CBR-HVAC-08597: C-C chemokine receptor type 5 Antagonist;
CBR-001-587-009-4,RFM-006-272-6,CBR-001-587-009-4,CCSc1nn(c2ccc(cc2)OC)c(=O)c2c1csc2N,"CBR-HVAC-05183: Type 2 Diabetes, Agents for; Protein Tyrosine Phosphatase (PTP) Inhibitors;Signal Transduction Modulators;"
CBR-001-587-010-7,RFM-006-273-7,CBR-001-587-010-7,Clc1ccc2c(c1)N(CCCCS2)CC1=NCCN1C(C)C,CBR-HVAC-05548: Antiarrhythmic Drugs;
CBR-001-587-011-8,RFM-006-274-8,CBR-001-587-011-8,Cc1csc(c1Nc1nc2c([nH]1)cccc2)Cl,CBR-HVAC-11845: Sodium hydrogen exchanger 3 Inhibitor;
CBR-001-587-012-9,RFM-006-275-9,CBR-001-587-012-9,O/N=C/Nc1ccc(c(c1)Cl)N1CCOCC1,"CBR-HVAC-00166: Stroke, Treatment of; 20-Hydroxyeicosatetraenoic acid (20-HETE) Production Inhibitors; 20-HYDROXYEICOSATETRAENOIC ACID SYNTHESIS INHIBITOR; Unidentified pharmacological activity"
CBR-001-587-013-0,RFM-006-276-0,CBR-001-587-013-0,OC(COc1ccccc1NC(=O)c1ccco1)CNC(C)(C)C,CBR-HVAC-01223: BETA ADRENERGIC RECEPTOR Blocker; Beta adrenoreceptor antagonist
CBR-001-587-014-1,RFM-006-277-1,CBR-001-587-014-1,Brc1ccc(cc1)OC(=O)N1CCN2CC1CC2,CBR-HVAC-08370: nicotinic acetylcholine receptor modulator
CBR-001-587-015-2,RFM-006-278-2,CBR-001-587-015-2,O=C([C@H](NC(=O)C(N)(C)C)CCCc1ccccc1)N1CCC(CC1)c1ccccc1CCc1nnn[nH]1,CBR-HVAC-11209: Growth Hormone Secretagogues;Signal Transduction Modulators; Growth hormone secretagogue;
CBR-001-587-016-3,RFM-006-279-3,CBR-001-587-016-3,NC(=N)NCCSSCCNC(=N)N,CBR-HVAC-05906: Antiinflammatory Ophthalmic Agents;Dental Agents;Preventive Agents; Free Radical Scavengers;Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Signal Transduction Modulators; INDUCIBLE NITRIC OXIDE SYNTHASE Inhibitor;
CBR-001-587-017-4,RFM-006-280-6,CBR-001-587-017-4,CCOC(=O)Cc1c2CCC(Cn2c2c1cccc2F)OS(=O)(=O)C,CBR-HVAC-12029_B: Antiasthmatic
CBR-001-587-018-5,RFM-006-281-7,CBR-001-587-018-5,O/N=C(/c1ccc(cc1)OCCCCCOc1ccc(cc1)c1nc(sc1C(C)C)C)\N,CBR-HVAC-05700: Treatment of Osteoporosis; Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators;
CBR-001-587-019-6,RFM-006-282-8,CBR-001-587-019-6,CC(n1c(=O)c(C(=O)NCCCN2CCCCC2)c(c2c1scc2)O)C,"CBR-HVAC-06348: Neurologic Drugs (Miscellaneous);Alzheimer's Dementia, Treatment of ;Posttraumatic Stress Disorder (PTSD), Treatment of; Signal Transduction Modulators;5-HT4 Partial Agonists;"
CBR-001-587-020-9,RFM-006-283-9,CBR-001-587-020-9,C[C@@H]1CNCCN1c1nccnc1OCCOc1cccnc1,CBR-HVAC-05474: Antiglaucoma Agents;Antiobesity Drugs;Antidiabetic Drugs; Signal Transduction Modulators;5-HT2C Agonists;
CBR-001-587-021-0,RFM-006-284-0,CBR-001-587-021-0,Clc1ccc(cc1)C(=O)/C(=C/c1ccc(cc1Cl)Cl)/n1cncc1,CBR-HVAC-03779: Dermatologic Drugs;Antifungal Agents; Unidentified pharmacological activity
CBR-001-587-022-1,RFM-006-285-1,CBR-001-587-022-1,CN1CCN(CC1)c1c(F)cc2c3c1OCc1n3c(c(c2=O)C(=O)O)sc1,CBR-HVAC-03816: Antibacterial Drugs; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-587-023-2,RFM-006-286-2,CBR-001-587-023-2,CCCCCC(CC(=O)CCc1ccc(c(c1)OC)O)O,"CBR-HVAC-05197: Antioxidants; Apoptosis Inducers; Nitric Oxide Synthase Inhibitors; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Colorectal Cancer Therapy; Non-Opioid Analgesics"
CBR-001-587-024-3,RFM-006-287-3,CBR-001-587-024-3,O=c1c2ccccc2ncn1c1nnn[nH]1,CBR-HVAC-00201: 5 Hydroxytryptamine release inhibitor; Histamine release inhibitor
CBR-001-587-025-4,RFM-006-288-4,CBR-001-587-025-4,Clc1ccc(c(c1)Cc1cccc(n1)C(=O)O)OCc1ccc(cc1F)Cl,CBR-HVAC-00170: Non-Opioid Analgesics; Prostanoid EP1 Antagonists;Signal Transduction Modulators; Prostaglandin E1 receptor Antagonist; Prostaglandin EP1 receptor antagonist; Prostaglandin E1 receptor antagonist
CBR-001-587-026-5,RFM-006-289-5,CBR-001-587-026-5,CCCCCCCOc1ccccc1NC(=O)OC(CN(CC)CC)C,CBR-HVAC-00004: Local Anesthetics; Anesthetic; Sodium channel antagonist; Potassium channel antagonist; Membrane integrity inhibitor
CBR-001-587-027-6,RFM-006-290-8,CBR-001-587-027-6,COc1cccc(c1)C(=O)Nc1ccc(c(c1)c1ccnn1C)OCCN1CCOCC1,CBR-HVAC-00031: Antiplatelet Therapy; Signal Transduction Modulators;5-HT2A Inverse Agonists; 5-Hydroxytryptamine 2A receptor Agonist; 5 Hydroxytryptamine 2A receptor agonist
CBR-001-587-028-7,RFM-006-291-9,CBR-001-587-028-7,COc1cc(CNCCC2CCOCC2)ccc1Oc1cnc(cn1)C(=O)N,"CBR-HVAC-00857: Gastrointestinal Disorders (Not Specified);Constipation, Agents for; mu-Opioid Antagonists;Signal Transduction Modulators; OPIOID RECEPTOR MU Antagonist; Opioid mu receptor antagonist"
CBR-001-587-029-8,RFM-006-292-0,CBR-001-587-029-8,O/N=C/1\CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CCCC(C)C)C)C)C,"CBR-HVAC-00882: Diabetic Neuropathy, Agents for;Antiparkinsonian Drugs;Amyotrophic Lateral Sclerosis, Agents for;Multiple Sclerosis, Agents for;Huntington's Disease, Treatment of;Neurologic Drugs (Miscellaneous);Neuropathy, Treatment of ;Liver and Biliary Tract Disorders, Treatment of; Apoptosis inhibitor; Apoptosis inhibitor"
CBR-001-587-030-1,RFM-006-293-1,CBR-001-587-030-1,CN1CCN(CC1)C1=Nc2ccccc2Sc2n1ccn2,CBR-HVAC-01233: Treatment of Substance Dependency;Antipsychotic Drugs; Drugs Acting on Dopaminergic Transmission;Signal Transduction Modulators; GABA receptor agonist; Alpha adrenoreceptor antagonist
CBR-001-587-031-2,RFM-006-294-2,CBR-001-587-031-2,CCC(c1nccs1)(c1cccc(c1)OCc1ccc2c(c1)cccc2)OC,CBR-HVAC-02679: 5-Lipoxygenase Inhibitor; 5 Lipoxygenase inhibitor
CBR-001-587-032-3,RFM-006-295-3,CBR-001-587-032-3,C/C(=N\Nc1ccc(nn1)N1CCOCC1)/CC(=O)OC(C)(C)C,"CBR-HVAC-03041: Hypertension, Treatment of; Noradrenaline release modulator;"
CBR-001-587-033-4,RFM-006-296-4,CBR-001-587-033-4,CN1CCN(CC1)C(=O)/C=c\1/c2ccccc2[nH]c(=O)c2c1cccc2,CBR-HVAC-03190: Antiulcer Drugs; Muscarinic M1 receptor antagonist
CBR-001-587-034-5,RFM-006-297-5,CBR-001-587-034-5,CN(CCOC(=O)C1Oc2ccccc2c2c1cccc2)C,CBR-HVAC-03339: Immunomodulators; Immunomodulator; Antiviral; Immunostimulant
CBR-001-587-035-6,RFM-006-298-6,CBR-001-587-035-6,CCCCn1c2nn(c(c2c(=O)n(c1=O)CCC)NC)C(=O)OC,CBR-HVAC-03725: Arachidonic acid release inhibitor; Unidentified pharmacological activity
CBR-001-587-036-7,RFM-006-299-7,CBR-001-587-036-7,O=C(c1sc2=NC(Cn2c1C)(C)C)NCCc1ccccc1,CBR-HVAC-03756: Immunosuppressants;Antiarthritic Drugs;Immunomodulators; Immunosuppressant; Immunomodulator; Antiarthritic; Unidentified pharmacological activity
CBR-001-587-037-8,RFM-006-300-3,CBR-001-587-037-8,COCCn1c(N[C@H](c2ccc(c(c2)OC)OC)CO)nc2c1c(=O)n(c(=O)n2C)C,CBR-HVAC-04142: Bronchodilators; Cyclic nucleotide phosphodiesterase; Phosphodiesterase 3 Inhibitor; Phosphodiesterase 3 inhibitor
CBR-001-587-038-9,RFM-006-301-4,CBR-001-587-038-9,OC(=O)CCC(Sc1ccc(cc1)C(=O)O)/C=C\Cc1ccc(cc1)OCCCCOc1ccccc1,CBR-HVAC-04315_A: Leucotriene D4 antagonist; Leucotriene C4 antagonist; Leucotriene E4 antagonist
CBR-001-587-039-0,RFM-006-302-5,CBR-001-587-039-0,OC(=O)CCC(Sc1ccc(cc1)C(=O)O)/C=C\Cc1ccc(cc1)OCCCCOc1ccccc1,CBR-HVAC-04315_B: Leucotriene D4 antagonist; Leucotriene C4 antagonist; Leucotriene E4 antagonist
CBR-001-587-040-3,RFM-006-303-6,CBR-001-587-040-3,CCCCNC(=O)Nc1c(OCCCn2cnc(c2CC)c2ccccc2)cccc1C,"CBR-HVAC-04426: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor; Acetyl CoA transferase inhibitor"
CBR-001-587-041-4,RFM-006-304-7,CBR-001-587-041-4,C=CCN1C[C@H](C)N(C[C@H]1C)[C@@H](c1cccc(c1)O)c1cccc(c1)C(=O)N(c1cccc(c1)F)C,CBR-HVAC-04682: Opioid Analgesics; delta-Opioid Agonists;mu-Opioid Agonists;Signal Transduction Modulators; DELTA OPIOD RECEPTOR; KAPPA OPIOID RECEPTOR; MU OPIOD RECEPTOR Agonist; Opioid delta receptor agonist; Opioid mu receptor agonist
CBR-001-587-042-5,RFM-006-305-8,CBR-001-587-042-5,CCn1/c(=C\c2cccc[n+]2CC)/s/c(=c\2/sc3c(n2C)cccc3)/c1=O,CBR-HVAC-04848: Oncolytic Drugs; Heat Shock Protein 70 (hsp70) Inhibitors; Telomerase Inhibitor; Unidentified pharmacological activity
CBR-001-587-043-6,RFM-006-306-9,CBR-001-587-043-6,CCOP(=O)(Cc1ccc(cc1)NC(=O)[C@@H]1S[C@@H](C)C(=O)c2c(C1)cc1OCOc1c2)OCC,CBR-HVAC-04857: Agents for Bone Repair;Bone Formation Stimulants; Alkaline phosphatase modulator; Bone metabolism modulator; Alkaline phosphatase stimulant
CBR-001-587-044-7,RFM-006-307-0,CBR-001-587-044-7,CCC(CC(=O)c1c(C(=O)OC)c(c2ccc(c(c2)OC)OC)c2c(c1O)cc(c(c2OC)OC)OC)CC,"CBR-HVAC-05016: Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; Ileal Bile Acid Transporter (IBAT) Inhibitors; Solute carrier family 10 (sodium/bile acid cotransporter family), member 2 Inhibitor; Sodium/bile acid cotransporter inhibitor; Ileal bile acid transport inhibitor"
CBR-001-587-045-8,RFM-006-308-1,CBR-001-587-045-8,O=c1c2ccccc2nc2n1OCC2,CBR-HVAC-05818: Non-Opioid Analgesics;
CBR-001-587-046-9,RFM-006-309-2,CBR-001-587-046-9,CCCCCOc1ccc(cc1C(F)(F)F)NC(=S)NC(=O)c1cccnc1,CBR-HVAC-06254: Anti-Hepatitis C Virus Drugs; HCV NS3 NS4A Protease Inhibitors; NS4A protease Antagonist;
CBR-001-587-047-0,RFM-006-310-5,CBR-001-587-047-0,CCc1nc2c(n1CCCCNS(=O)(=O)C)c1ccccc1nc2N,CBR-HVAC-06448: Anti-Hepatitis C Virus Drugs;Immunostimulants;Hematological Cancer Therapy;Melanoma Therapy; Signal Transduction Modulators;TLR7 Receptor Agonists;
CBR-001-587-048-1,RFM-006-311-6,CBR-001-587-048-1,CC(=O)Oc1ccccc1C(=O)O[C@@H]([C@@H](C(=O)O)N)C,CBR-HVAC-06459: Antiplatelet Therapy;
CBR-001-587-049-2,RFM-006-312-7,CBR-001-587-049-2,Fc1ccc2c(c1)Oc1c(S2(=O)=O)ccc(c1)OCC(F)(F)F,CBR-HVAC-06508: Anxiolytics;Antidepressants; MAO-A Inhibitors; Monoamine oxidase A Inhibitor;
CBR-001-587-050-5,RFM-006-313-8,CBR-001-587-050-5,COCC(Cn1c(=O)cnn(c1=O)c1ccc(c(c1)C(=O)NCC1(O)CCCCCC1)Cl)O,CBR-HVAC-06527_A: P2X7 Receptor Antagonists
CBR-001-587-051-6,RFM-006-314-9,CBR-001-587-051-6,COCC(Cn1c(=O)cnn(c1=O)c1ccc(c(c1)C(=O)NCC1(O)CCCCCC1)Cl)O,CBR-HVAC-06527_B: P2X7 Receptor Antagonists
CBR-001-587-052-7,RFM-006-315-0,CBR-001-587-052-7,Clc1ccc(cc1)C12N(CCN1C(=O)c1c2cncc1)C(=O)c1cccnc1,CBR-HVAC-06636_A: Viral Fusion Inhibitors
CBR-001-587-053-8,RFM-006-316-1,CBR-001-587-053-8,Clc1ccc(cc1)C12N(CCN1C(=O)c1c2cncc1)C(=O)c1cccnc1,CBR-HVAC-06636_B: Viral Fusion Inhibitors
CBR-001-587-054-9,RFM-006-317-2,CBR-001-587-054-9,CN1CCC(CC1)CCCNc1ncc(c(n1)C)c1nc2c([nH]1)cc(cc2C)C,"CBR-HVAC-06672: Antipsoriatics;Asthma Therapy;Rheumatoid Arthritis, Treatment of; Histamine H4 Receptor Ligands;Signal Transduction Modulators; Histamine H4 receptor antagonist"
CBR-001-587-055-0,RFM-006-318-3,CBR-001-587-055-0,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCc1cccnc1,CBR-HVAC-06700: Antiarrhythmic Drugs; K(V) 1.5 (KCNA5) Channel Blockers;
CBR-001-587-056-1,RFM-006-319-4,CBR-001-587-056-1,OC(=O)CN1CCN(CC1)C(c1cccc(c1)C(F)(F)F)c1ccccc1,CBR-HVAC-06705_A: GlyT-1 Inhibitors
CBR-001-587-057-2,RFM-006-320-7,CBR-001-587-057-2,OC(=O)CN1CCN(CC1)C(c1cccc(c1)C(F)(F)F)c1ccccc1,CBR-HVAC-06705_B: GlyT-1 Inhibitors
CBR-001-587-058-3,RFM-006-321-8,CBR-001-587-058-3,c1ccc(cc1)c1ncc2c(n1)ccc(c2)n1cncc1,"CBR-HVAC-06721: Fibromyalgia, Treatment of;Analgesic Drugs;Osteoarthritis, Treatment of;Neuropathic Pain, Treatment of; IL-1beta Production Inhibitors;IL-6 Production Inhibitors;Imidazoline I2 Receptor Ligands;Signal Transduction Modulators; Imidazoline I2 receptor agonist"
CBR-001-587-059-4,RFM-006-322-9,CBR-001-587-059-4,CC(OC(=O)COc1cccc(c1)CN(S(=O)(=O)c1cccnc1)Cc1ccc(cc1)n1cccn1)C,CBR-HVAC-06722: Antiglaucoma Agents; Prostanoid EP2 Agonists;Signal Transduction Modulators; C-MET Inhibitor;
CBR-001-587-060-7,RFM-006-323-0,CBR-001-587-060-7,CCOC[C@@]12Cc3cnn(c3C=C2CCN(C1)S(=O)(=O)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)F,CBR-HVAC-06743: Antiobesity Drugs;Antidiabetic Drugs; Glucocorticoid Receptor (GR) Antagonists;Signal Transduction Modulators; Glucocorticoid antagonist
CBR-001-587-061-8,RFM-006-324-1,CBR-001-587-061-8,C1S[Zn]OC(=O)C1[NH3+],"CBR-HVAC-06854: Age-Related Macular Degeneration, Treatment of;Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of; NMDA Modulators;Signal Transduction Modulators; Unidentified pharmacological activity"
CBR-001-587-062-9,RFM-006-325-2,CBR-001-587-062-9,O=C(C(n1cnc(c1)C(F)(F)F)CC1CCCC1)Nc1ccc(cn1)C(=O)O,CBR-HVAC-07025_A: Glucokinase Activators
CBR-001-587-063-0,RFM-006-326-3,CBR-001-587-063-0,O=C(C(n1cnc(c1)C(F)(F)F)CC1CCCC1)Nc1ccc(cn1)C(=O)O,CBR-HVAC-07025_B: Glucokinase Activators
CBR-001-587-064-1,RFM-006-327-4,CBR-001-587-064-1,CCO[C@H](C(=O)O)Cc1ccc(cc1)OCCn1c(C)ccc1c1ccc(cc1)SC,"CBR-HVAC-07281: Liver and Biliary Tract Disorders, Treatment of;Lipoprotein Disorders, Treatment of ; PPAR Agonists;Signal Transduction Modulators;"
CBR-001-587-065-2,RFM-006-328-5,CBR-001-587-065-2,CC/C(=C(\c1ccc2c(c1)cn[nH]2)/c1ccc(cc1)/C=C/C(=O)O)/c1ccc(cc1Cl)F,CBR-HVAC-07291: Breast Cancer Therapy; Selective Estrogen Receptor Destabilizers (SERD);Signal Transduction Modulators;
CBR-001-587-066-3,RFM-006-329-6,CBR-001-587-066-3,N#Cc1ccc2c(c1C(F)(F)F)ccn2[C@@H](CS(=O)(=O)C)C,CBR-HVAC-07346: Heart Failure Therapy;Treatment of Cachexia; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators;
CBR-001-587-067-4,RFM-006-330-9,CBR-001-587-067-4,CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(c2)C)nc2c1c(Cl)c[nH]2)C(=O)C=C,CBR-HVAC-07377: Non-Small Cell Lung Cancer Therapy; EGFR (Thr790Met Mutant) Inhibitors;Signal Transduction Modulators;
CBR-001-587-068-5,RFM-006-331-0,CBR-001-587-068-5,N#Cc1cc(cc(c1)F)Oc1ccc(c2c1CC([C@H]2O)(F)F)S(=O)(=O)C,CBR-HVAC-07382: Renal Cancer Therapy; Hypoxia Inducible Factor 2-alpha (HIF-2alpha) Inhibitors;Signal Transduction Modulators;
CBR-001-587-069-6,RFM-006-332-1,CBR-001-587-069-6,C=CC(=O)N[C@@H]1CN(C[C@H]1F)c1nc(Nc2cn(nc2OC)C)c2c(n1)n(C)cn2,CBR-HVAC-07383: Non-Small Cell Lung Cancer Therapy; EGFR (Thr790Met Mutant) Inhibitors;Signal Transduction Modulators;
CBR-001-587-070-9,RFM-006-333-2,CBR-001-587-070-9,CCN(CCCNC(=O)C1Cc2cc(OC)c(cc2S(=O)(=O)O1)OC)CC,CBR-HVAC-07389: Unidentified pharmacological activity
CBR-001-587-071-0,RFM-006-334-3,CBR-001-587-071-0,N#Cc1c(N)[nH]c2c1cc(cc2)Sc1ccccc1,CBR-HVAC-07457: Microtubule inhibitor
CBR-001-587-072-1,RFM-006-335-4,CBR-001-587-072-1,CC[O-][Ti]12([O-]CC)([O]=C(C)[CH-]C(=[O]2)c2ccccc2)[O]=C(C)[CH-]C(=[O]1)c1ccccc1,CBR-HVAC-07573: Alkylating-agents; Antineoplastic; ANTINEOPLASTIC; Cancer; Oncolytic Drugs
CBR-001-587-073-2,RFM-006-336-5,CBR-001-587-073-2,Cc1ccc2c(c1)c(c1ccccc1)[n+]1n2CCC1,CBR-HVAC-07828: Phosphodiesterase inhibitor
CBR-001-587-074-3,RFM-006-337-6,CBR-001-587-074-3,CC(OC(=O)C(=C1SCS1)C(=O)Nc1scc(n1)C)C,CBR-HVAC-08050: Hepatoprotectants;Anti-Hepatitis B Virus Drugs; Protein synthesis stimulant; Lipid peroxidase inhibitor
CBR-001-587-075-4,RFM-006-338-7,CBR-001-587-075-4,N#Cc1cc(c2ccc3c(n2)N(C)C(=O)CO3)c([nH]c1=O)C,CBR-HVAC-08264: Beta adrenoreceptor agonist
CBR-001-587-076-5,RFM-006-339-8,CBR-001-587-076-5,O=C(N1CC2(OC1=O)CCN(CC2)CCc1ccccc1)Cn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-08358: Phosphodiesterase inhibitor
CBR-001-587-077-6,RFM-006-340-1,CBR-001-587-077-6,NC(=N)Nc1ccc(cc1)C(=O)NCCC[C@H]1C(=O)N(CCN1C(=O)CNC(=O)c1ccc(cc1)NC(=N)N)CC(=O)O,CBR-HVAC-08401: GPIIb IIIa receptor antagonist
CBR-001-587-078-7,RFM-006-341-2,CBR-001-587-078-7,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)c1nnc(o1)SC,CBR-HVAC-08439: Alpha adrenoreceptor antagonist
CBR-001-587-079-8,RFM-006-342-3,CBR-001-587-079-8,COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OCC1C=C[C@@H](O1)n1cnc2c1ncnc2N)C,CBR-HVAC-08567_A: Thymidine kinase inhibitor
CBR-001-587-080-1,RFM-006-343-4,CBR-001-587-080-1,COC(=O)[C@@H](NP(=O)(Oc1ccccc1)OCC1C=C[C@@H](O1)n1cnc2c1ncnc2N)C,CBR-HVAC-08567_B: Thymidine kinase inhibitor
CBR-001-587-081-2,RFM-006-344-5,CBR-001-587-081-2,CCc1nc(nc(n1)CC)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08741:
CBR-001-587-082-3,RFM-006-345-6,CBR-001-587-082-3,COc1cc(cc(c1OC)OC)C(=O)OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-08847: Calcium/calmodulin-dependent phosphodiesterase Inhibitor;
CBR-001-587-083-4,RFM-006-346-7,CBR-001-587-083-4,COc1c(oc2c1n(c1ccccc1)c1c2cc(cc1)OC)C(=O)Nc1nnn[nH]1,CBR-HVAC-09170: 15-Lipoxygenase Inhibitor;
CBR-001-587-084-5,RFM-006-347-8,CBR-001-587-084-5,CCOC(C(=O)c1ccc(cc1)c1ccccc1)Nc1ccc(cc1)C(=O)O,CBR-HVAC-09173:
CBR-001-587-085-6,RFM-006-348-9,CBR-001-587-085-6,Cc1sc(c2c1c1[nH]ncc1CCC2)C,CBR-HVAC-09184: Dopamine receptor D4 Antagonist;
CBR-001-587-086-7,RFM-006-349-0,CBR-001-587-086-7,Clc1ccc2c(c1)c(cs2)C(P(=O)(O)O)C(=O)Nc1ccc2c(c1)cccc2,CBR-HVAC-09207: Asthma Therapy;Antiarthritic Drugs; Chymase Inhibitors; Chymase; Trypsin; Factor IIa; Cathepsin G; Serine protease; Tryptase Inhibitor; Antagonist;
CBR-001-587-087-8,RFM-006-350-3,CBR-001-587-087-8,CCOc1ccc(cc1)c1c(Cl)ncn1c1ccc(cc1)S(=O)(=O)N,CBR-HVAC-09330: Prostaglandin-endoperoxide synthase 2 Inhibitor;
CBR-001-587-088-9,RFM-006-351-4,CBR-001-587-088-9,CCOC(=O)c1nc(=O)c2c([nH]1)nc1c(c2)cc(c(c1)OC)OC,CBR-HVAC-10216:
CBR-001-587-089-0,RFM-006-352-5,CBR-001-587-089-0,CN(CCc1c[nH]c2c1c(ccc2)OP(=O)(O)O)C,CBR-HVAC-10300: 5-Hydroxytryptamine 2A receptor; 5-Hydroxytryptamine 1A receptor Agonist;
CBR-001-587-090-3,RFM-006-353-6,CBR-001-587-090-3,CCSC(=O)c1cccc(c1)C(=O)SCC,CBR-HVAC-10347: Antileprotic;
CBR-001-587-091-4,RFM-006-354-7,CBR-001-587-091-4,[O-][N+](=O)OCc1cccc(c1)Cl,analog of CBR-HVAC-03325
CBR-001-587-092-5,RFM-006-355-8,CBR-001-587-092-5,S1SCc2c(C1)cccc2,CBR-HVAC-10629: Antiviral Drugs;Anti-RSV Drugs; Viral replication inhibitor;
CBR-001-587-093-6,RFM-006-356-9,CBR-001-587-093-6,CCCCCCc1ccc(cc1)N=C1SCCS1,CBR-HVAC-10670: Prostaglandin synthesis inhibitor;
CBR-001-587-094-7,RFM-006-357-0,CBR-001-587-094-7,Nc1cc2c(c(c1N1CCc3c(C1)cccc3)C)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-10726: DNA Gyrase Inhibitors; DNA gyrase Inhibitor;
CBR-001-587-095-8,RFM-006-358-1,CBR-001-587-095-8,COc1ccccc1N1CCN(CC1)CCc1ccc2c(c1)sc(=O)n2C,CBR-HVAC-10733: Antipsychotic;
CBR-001-587-096-9,RFM-006-359-2,CBR-001-587-096-9,COc1ccc(cc1)/C=C/c1ccc2c(c1)cnn(c2=O)CCCN(C)C,CBR-HVAC-10850: Immunosuppressants;Antiarthritic Drugs; Immunosuppressant; Antiarthritic; Antirheumatic;
CBR-001-587-097-0,RFM-006-360-5,CBR-001-587-097-0,CCOC(=O)Nc1cccc2c1CN(C)CC2c1ccc(cc1)Cl,CBR-HVAC-10875: Gastric Antisecretory Drugs;Antidepressants;Antiulcer Drugs; Antiulcer; Antidepressive;
CBR-001-587-098-1,RFM-006-361-6,CBR-001-587-098-1,CCN(CC(COC(=O)c1ccc(o1)c1ccc(cc1)C(F)(F)F)(C)C)CC,"CBR-HVAC-10912: Stroke, Treatment of;Antiepileptic Drugs; Antiepileptic; Anticonvulsant;"
CBR-001-587-099-2,RFM-006-362-7,CBR-001-587-099-2,CC(=O)NCCNC(=N)NN,"CBR-HVAC-11034: Diabetic Nephropathy, Agents for; AGE Inhibitors (Maillard's Reaction Inhibitors); Glycosylation antagonist;"
CBR-001-587-100-8,RFM-006-363-8,CBR-001-587-100-8,CN(CCNC(=O)c1cc(cc(c1)c1cc(sc1Cl)Cl)C(=O)N=C(N)N)C,"CBR-HVAC-11165: Antiarrhythmic Drugs;Angina pectoris, Treatment of; Na+/H+ Exchanger (NHE) Inhibitors; Na+/H+ exchanger Inhibitor;"
CBR-001-587-101-9,RFM-006-364-9,CBR-001-587-101-9,CN(CCn1c2ccccc2c(c1C(=O)N1CCN(CC1)c1ccccc1Cl)C(c1ccc(cc1)O)c1ccc(cc1)O)C,CBR-HVAC-11201: Bone Resorption Inhibitors;Treatment of Osteoporosis; Serum alkaline phosphatase Inhibitor;
CBR-001-587-102-0,RFM-006-365-0,CBR-001-587-102-0,N#Cc1cnc(s1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,CBR-HVAC-11269: Antibacterial Drugs; Protein synthesis inhibitor;
CBR-001-587-103-1,RFM-006-366-1,CBR-001-587-103-1,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)c1ccno1,CBR-HVAC-11271: Protein 30S ribosomal subunit Inhibitor;
CBR-001-587-104-2,RFM-006-367-2,CBR-001-587-104-2,c1ccc(nc1)C12NC(=Nc3nc4c([nH]3)cccc4)NC2(NC(=Nc2nc3c([nH]2)cccc3)N1)c1ccccn1,CBR-HVAC-11290: Hematopoietic Agents;Chemoprotective Agents; G-CSF Mimetics;G-CSF Receptor Agonists;Signal Transduction Modulators; Granulocyte colony stimulating factor receptor Activator;
CBR-001-587-105-3,RFM-006-368-3,CBR-001-587-105-3,CC(=CCN(c1ccc(cc1)CCC(C)(C)C)C1CCN(CC1)Cc1ccc(cc1)N(C)C)C,CBR-HVAC-11348: Calcium channel N-type Blocker;
CBR-001-587-106-4,RFM-006-369-4,CBR-001-587-106-4,F/C(=C\1/CN2CCC1CC2)/COc1ccc2c(c1)[nH]c1c2cccc1,"CBR-HVAC-11540: Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors;Triglyceride Lowering Agents; Squalene synthase Inhibitor;"
CBR-001-587-107-5,RFM-006-370-7,CBR-001-587-107-5,Oc1cccc(c1)S(=O)(=O)c1ccc2c(c1)[C@@H](Oc1ccc(=O)n(n1)C)[C@](C(O2)(C)C)(C)O,CBR-HVAC-11737: Hair Growth Stimulants; Potassium Channel Activators; POTASSIUM CHANNEL Opener;
CBR-001-587-108-6,RFM-006-371-8,CBR-001-587-108-6,OCCn1ccc(=O)c(c1C(c1ccccc1)O)O,CBR-HVAC-11952: Chelating agent;
CBR-001-587-109-7,RFM-006-372-9,CBR-001-587-109-7,CCC(c1c(O)c(=O)cc(n1C)C)OC,CBR-HVAC-11984: Iron chelator;
CBR-001-587-110-0,RFM-006-373-0,CBR-001-587-110-0,NC(=O)NO,"CBR-HVAC-02615:Inhibits DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein"
CBR-001-587-118-8,RFM-006-374-1,CBR-001-587-118-8,Clc1cccc(c1)[C@@H](CNc1cc[nH]c(=O)c1c1nc2c([nH]1)cc(cc2C)N1CCOCC1)O,CBR-HVAC-12149: Insulin-like growth factor 1 receptor inhibitor
CBR-001-587-119-9,RFM-006-375-2,CBR-001-587-119-9,OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,"CBR-HVAC-12109: Anti-inflammatory; Antiinflammatory Drugs; Glucocorticoid agonist; Anti-inflammatory; Antiallergic Ophthalmic Agents; Antiallergy/Antiasthmatic Drugs; Antiarthritic Drugs; Antibacterial Ophthalmic Drugs; Antiinflammatory Ophthalmic Agents; Dermatologic Drugs; Diagnostic Agents; Ear disorders, treatment of; Edema, Treatment of; Hypertension, Treatment of; Inflammatory Bowel Disease, Agents for; Lymphocytic Leukemia Therapy; Lymphoma Therapy; Multiple Myeloma Therapy; Neuropathy, Treatment of ; Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Ophthalmic Drugs; Oral Cavity, Salivary Glands and Jaws Disorders, Treatment of ; Respiratory Disorders (Not Specified); Treatment of Transplant Rejection"
CBR-001-587-120-2,RFM-006-376-3,CBR-001-587-120-2,CCNCCS(=O)(=O)NC[C@@]1(SC(=NN1C(=O)C(C)(C)C)NC(=O)C(C)(C)C)c1ccccc1,"CBR-HVAC-00368: Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitor"
CBR-001-587-121-3,RFM-006-377-4,CBR-001-587-121-3,CCNCCS(=O)(=O)NC[C@]1(SC(=NN1C(=O)C(C)(C)C)NC(=O)C(C)(C)C)c1ccccc1,"CBR-HVAC-00368: Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitor"
CBR-001-587-122-4,RFM-006-378-5,CBR-001-587-122-4,N=C(N1CCOCC1)NC(=N)N,CBR-HVAC-08906: Antiviral
CBR-001-587-123-5,RFM-006-379-6,CBR-001-587-123-5,Fc1ccc(cc1)c1nc(=O)n(c2c1cc1OCOc1c2)C(C)C,CBR-HVAC-12160: Prostaglandin synthase inhibitor
CBR-001-587-124-6,RFM-006-380-9,CBR-001-587-124-6,O=C(N(C1CCCCC1)C1CCCCC1)Nc1scc(n1)CC(=O)O,CBR-HVAC-12131: Glucokinase activator
CBR-001-587-125-7,RFM-006-381-0,CBR-001-587-125-7,O=C1NC(=O)C(S1)Cc1ccc(cc1)OCCn1nc(C)c2c(c1=O)cccc2,CBR-HVAC-11958: Insulin receptor sensitizer; PPAR-gamma agonist
CBR-001-587-126-8,RFM-006-382-1,CBR-001-587-126-8,COC1(CCN(CC1)CCc1c[nH]c2c1cc(F)cc2)CS(=O)c1ccccc1,CBR-HVAC-10843: Tachykinin receptor 2 antagonist
CBR-001-587-127-9,RFM-006-383-2,CBR-001-587-127-9,CC(=O)N(c1cc(ccc1F)c1ccnc2n1ncc2C(=O)c1cccs1)C,"CBR-HVAC-00263: gamma-aminobutyric acid (GABA) A receptor, alpha 1"
CBR-001-587-128-0,RFM-006-384-3,CBR-001-587-128-0,NC(=O)c1cnc2c(c1N[C@@H]1[C@H]3CC4C[C@@H]1C[C@@](C3)(C4)O)cc[nH]2,CBR-HVAC-00860: Janus kinase 1 inhibitor; Janus kinase 3 inhibitor; Immunosuppressant
CBR-001-587-129-1,RFM-006-385-4,CBR-001-587-129-1,C[C@H]([C@H]1C(=O)N2[C@@H]1[C@@H](C)C(=C2C(=O)O)S[C@@H]1CN[C@@H](C1)C(=O)N(C)C)O,"CBR-HVAC-00984: Cell Wall Biosynthesis Inhibitors; Cell wall synthesis inhibitor; Cell-wall-inhibitors; It interferes with the integrity of the bacterial cell wall by binding to membrane proteins engaged in cell wall peptidoglycan synthesis.; Antibacterial; Antibacterial Drugs; Antibiotics; Bacterial Infections; Sepsis, Treatment of"
CBR-001-587-130-4,RFM-006-386-5,CBR-001-587-130-4,O=C(NC(C(=O)O)Cc1c[nH]cn1)CCNC(=O)C,"CBR-HVAC-05562: N-acetylcarnosine, a prodrug of the antioxidant L-carnosine, acts in the aqueous humor of the eye, where it scavenges the radicals of tryptophan/kynurenine and ascorbate"
CBR-001-587-131-5,RFM-006-387-6,CBR-001-587-131-5,CCC(=O)Nc1ccc(c(c1)NC(=O)c1ccc(cc1)C(=O)O)C(=O)O,metabolite of CBR-HVAC-03680
CBR-001-587-132-6,RFM-006-388-7,CBR-001-587-132-6,CN1CCN(CC1)c1nccn(c1=O)CCOc1cc(F)c(cc1F)F,CBR-HVAC-12126: 5 Hydroxytryptamine 2A receptor antagonist
CBR-001-587-136-0,RFM-006-389-8,CBR-001-587-136-0,CSCC[C@@H](C(=O)N[C@]1(CS(=O)(=O)[C@@H]2[C@H]1[C@H]2C(=O)O)C(=O)O)N,"CBR-HVAC-00035: Antipsychotic Drugs;Posttraumatic Stress Disorder (PTSD), Treatment of; mgluR2 Agonists;mgluR3 Agonists;Signal Transduction Modulators; Metabotropic glutamate receptor 2; Metabotropic glutamate receptor 3 Agonist; Glutamate 2 receptor agonist; Glutamate 3 receptor agonist"
CBR-001-587-137-1,RFM-006-390-1,CBR-001-587-137-1,C[N@+]12CC[C@H](CC1)C(C2)CN1c2ccccc2Sc2c1cccc2,CBR-HVAC-08035: Histamine receptor antagonist; Acetylcholine receptor antagonist; Platelet activating factor antagonist
CBR-001-587-138-2,RFM-006-391-2,CBR-001-587-138-2,C[N@+]12CC[C@H](CC1)C(C2)CN1c2ccccc2Sc2c1cccc2,CBR-HVAC-08035: Histamine receptor antagonist; Acetylcholine receptor antagonist; Platelet activating factor antagonist
CBR-001-587-139-3,RFM-006-392-3,CBR-001-587-139-3,COc1ccc(cc1Oc1ccc(cc1CSC(C)(C)C)NC(=O)C(C)(C)C)CC(=O)O,CBR-HVAC-00187: G protein-coupled receptor 44 Antagonist; Prostaglandin D2 receptor DP1 antagonist; CRTH2 antagonist
CBR-001-587-140-6,RFM-006-393-4,CBR-001-587-140-6,CC/C(=C(/C(=O)O)\CC)/C(=O)O,CBR-HVAC-00198: beta-Lactam Enhancers; beta-Lactamase Inhibitors; Beta-lactamase Inhibitor; Lactamase inhibitor
CBR-001-587-141-7,RFM-006-394-5,CBR-001-587-141-7,O=C1NC(=O)NC(=O)C1(c1ccccc1)c1ccccc1,CBR-HVAC-00200: Antiepileptic Drugs; GABA-A receptor Agonist; GABA A receptor agonist
CBR-001-587-142-8,RFM-006-395-6,CBR-001-587-142-8,NC(=O)/N=N/C(=O)N,CBR-HVAC-00484: Anti-HIV Agents; Nucleocapsid p7 Protein (NCp7) Zinc Finger Inhibitors; Viral uncoating inhibitor; HIV-1 zinc finger inhibitor; DNA synthesis inhibitor
CBR-001-587-143-9,RFM-006-396-7,CBR-001-587-143-9,O=C1O[C@H](CN1[C@@H](c1ccccc1)CCN1CCOCC1)Cc1ccccc1,CBR-HVAC-00492: Urinary Incontinence Therapy; Unidentified pharmacological activity
CBR-001-587-144-0,RFM-006-397-8,CBR-001-587-144-0,N(c1cnccn1)N=O,CBR-HVAC-00529: DNA synthesis inhibitor; Unidentified pharmacological activity
CBR-001-587-145-1,RFM-006-398-9,CBR-001-587-145-1,CCCCCC(c1ccc(cc1)N1[C@@H](COCc2ccc(s2)C(=O)OC(C)C)CCC1=O)O,CBR-HVAC-00547: Prostaglandin F2 alpha receptor Agonist; Unidentified pharmacological activity
CBR-001-587-146-2,RFM-006-399-0,CBR-001-587-146-2,CCCCCC(c1ccc(cc1)N1[C@@H](COCc2ccc(s2)C(=O)OC(C)C)CCC1=O)O,CBR-HVAC-00547: Prostaglandin F2 alpha receptor Agonist; Unidentified pharmacological activity
CBR-001-587-147-3,RFM-006-400-6,CBR-001-587-147-3,CCCCN(CCCC)CCCOc1c(C)cc(cc1C)C(=O)c1cc(=O)c2c(o1)cccc2,CBR-HVAC-01064: Polarisation inhibitor
CBR-001-587-148-4,RFM-006-401-7,CBR-001-587-148-4,Cn1cnc2c1c(=O)[nH]c(=O)n2C,CBR-HVAC-01254: Phosphodiesterase inhibitor
CBR-001-587-149-5,RFM-006-402-8,CBR-001-587-149-5,COC(=O)C(c1ccccc1)C1CCCCN1,"CBR-HVAC-01299: Fibromyalgia, Treatment of;Psychiatric Disorders (Not Specified);Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Cancer Associated Disorders, Treatment of;Sleep Disorders, Treatment of; Dopamine Transporter (DAT) Inhibitors;Signal Transduction Modulators; Dopamine transporter; Norepinephrine transporter Blocker; Unidentified pharmacological activity"
CBR-001-587-150-8,RFM-006-403-9,CBR-001-587-150-8,COC(=O)C(c1ccccc1)C1CCCCN1,"CBR-HVAC-01299: Fibromyalgia, Treatment of;Psychiatric Disorders (Not Specified);Attention Deficit Hyperactivity Disorder (ADHD), Treatment of;Cancer Associated Disorders, Treatment of;Sleep Disorders, Treatment of; Dopamine Transporter (DAT) Inhibitors;Signal Transduction Modulators; Dopamine transporter; Norepinephrine transporter Blocker; Unidentified pharmacological activity"
CBR-001-587-151-9,RFM-006-404-0,CBR-001-587-151-9,Nc1nccc(n1)/C=C/c1ncc(n1C)[N+](=O)[O-],CBR-HVAC-01771: Cell wall synthesis inhibitor; Sterol demethylase inhibitor
CBR-001-587-152-0,RFM-006-405-1,CBR-001-587-152-0,CNCCON=c1c2ccccc2ccc2c1cccc2,CBR-HVAC-01791: Antidepressants; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-587-153-1,RFM-006-406-2,CBR-001-587-153-1,OP(=O)(C(P(=O)(O)O)NC1CCCCCC1)O,CBR-HVAC-02286: Bone Resorption Inhibitors;Treatment of Osteoporosis;Treatment of Hypercalcemia;Treatment of Periodontitis; Farnesyl diphosphate synthase Inhibitor; Osteoclast inhibitor; Bisphosphonate; Bone resorption inhibitor
CBR-001-587-154-2,RFM-006-407-3,CBR-001-587-154-2,NC(=O)CCC/N=C(/c1cc(F)ccc1O)\c1ccc(cc1)Cl,CBR-HVAC-02665: Antiepileptic Drugs; GABA-A receptor Agonist; GABA receptor agonist; Epoxide hydrolase inhibitor
CBR-001-587-155-3,RFM-006-408-4,CBR-001-587-155-3,Fc1ccc(cc1)COc1nncc2c1n(CC1CC1C)c(c2C)C,"CBR-HVAC-02693: Anti-Helicobacter Pylori Agents;Gastric Antisecretory Drugs;Gastroesophageal Reflux Disease, Agents for; Reversible H+/K+-ATPase Inhibitors ; Gastric H+/K+ ATPase Inhibitor; Potassium-competitive acid antagonist"
CBR-001-587-156-4,RFM-006-409-5,CBR-001-587-156-4,COCCN1CCN(CC1)CC1CCN(C1=O)c1ccc(cc1)Cl,CBR-HVAC-02741: Antipsychotic Drugs; sigma Receptor Antagonists;Signal Transduction Modulators; Opioid receptor sigma 1 Antagonist; Sigma receptor antagonist
CBR-001-587-157-5,RFM-006-410-8,CBR-001-587-157-5,COCCN1CCN(CC1)CC1CCN(C1=O)c1ccc(cc1)Cl,CBR-HVAC-02741: Antipsychotic Drugs; sigma Receptor Antagonists;Signal Transduction Modulators; Opioid receptor sigma 1 Antagonist; Sigma receptor antagonist
CBR-001-587-158-6,RFM-006-411-9,CBR-001-587-158-6,O=C(N(c1cccc(c1)OCCN1CCOCC1)CC1=CC(CC1)(Cc1ccccc1)NC(=O)C(Cl)(Cl)Cl)Nc1ccccc1,"CBR-HVAC-02744: Irritable Bowel Syndrome, Agents for;Gastroesophageal Reflux Disease, Agents for; Motilin Receptor Antagonists;Signal Transduction Modulators; Motilin receptor Antagonist; Motilin antagonist"
CBR-001-587-159-7,RFM-006-412-0,CBR-001-587-159-7,O=C(N(c1cccc(c1)OCCN1CCOCC1)CC1=CC(CC1)(Cc1ccccc1)NC(=O)C(Cl)(Cl)Cl)Nc1ccccc1,"CBR-HVAC-02744: Irritable Bowel Syndrome, Agents for;Gastroesophageal Reflux Disease, Agents for; Motilin Receptor Antagonists;Signal Transduction Modulators; Motilin receptor Antagonist; Motilin antagonist"
CBR-001-587-160-0,RFM-006-413-1,CBR-001-587-160-0,C1COC(CN1)COc1ccccc1Cc1cccs1,"CBR-HVAC-02932: Cognition Disorders, Treatment of;Antiulcer Drugs; Norepinephrine uptake inhibitor; Alpha 2 adrenoreceptor agonist; 5 Hydroxytryptamine 2B receptor antagonist"
CBR-001-587-161-1,RFM-006-414-2,CBR-001-587-161-1,O=c1nc(NCCSCc2nc[nH]c2C)[nH]cc1Cc1ccc2c(c1)OCO2,CBR-HVAC-03038: Antiulcer Drugs; Histamine H2 Receptor Antagonists;Signal Transduction Modulators;
CBR-001-587-162-2,RFM-006-415-3,CBR-001-587-162-2,COC1=Cc2ccccc2/C(=C\C(=O)O)/c2c1scc2,CBR-HVAC-03251: Antiarthritic Drugs; IL-1 Inhibitors;Signal Transduction Modulators; Interleukin 1 release inhibitor; Interleukin 1 antagonist
CBR-001-587-163-3,RFM-006-416-4,CBR-001-587-163-3,CC(n1nc(c2cccc(c2Cl)Cl)c(=N)[nH]c1=N)C,CBR-HVAC-03266: Antiarrhythmic Drugs;
CBR-001-587-164-4,RFM-006-417-5,CBR-001-587-164-4,O=C1SCC(=NN1)c1ccc2c(c1)CCC(=O)N2,CBR-HVAC-03431: Heart Failure Therapy; Cyclic AMP phosphodiesterase Inhibitor; Phosphodiesterase inhibitor; Cyclic AMP inhibitor
CBR-001-587-165-5,RFM-006-418-6,CBR-001-587-165-5,CCCc1c(OCCCOc2cc(NC(=O)c3nnn[nH]3)c(cc2Cl)C)ccc(c1O)C(=O)C,CBR-HVAC-03462: Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Signal Transduction Modulators; LEUKOTRIENE C4 RECEPTOR; LEUKOTRIENE D4 RECEPTOR; PHOSPHOLIPASE A2 Antagonist; Antagonist; Inhibitor; Leucotriene receptor antagonist; Phospholipase A2 inhibitor; Phospholipase C inhibitor
CBR-001-587-166-6,RFM-006-419-7,CBR-001-587-166-6,CC(=O)Nc1ccc(cc1)OC(=O)/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,CBR-HVAC-03518: Acne Therapy; Protein synthesis inhibitor; Retinoic acid receptor agonist; Retinoic acid receptor agonist; Protein synthesis inhibitor; Microbial collagenase inhibitor
CBR-001-587-167-7,RFM-006-420-0,CBR-001-587-167-7,OC(=O)CCCCCCCOc1nc(c(n1c1ccccc1)c1ccccc1)c1ccccc1,"CBR-HVAC-03519: Lipoprotein Disorders, Treatment of ;Antiplatelet Therapy; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-587-168-8,RFM-006-421-1,CBR-001-587-168-8,C[n+]1ccn(c1)CC(c1ccc(cc1)NS(=O)(=O)C)O,CBR-HVAC-03537: Antiarrhythmic Drugs; Antiarrhythmic agent;
CBR-001-587-169-9,RFM-006-422-2,CBR-001-587-169-9,CCCc1c(OCc2cccn3c2ncc(c3=O)c2nnn[nH]2)ccc(c1O)C(=O)C,CBR-HVAC-03600: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Mediator Release Inhibitors;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist;
CBR-001-587-170-2,RFM-006-423-3,CBR-001-587-170-2,CC(C[C@@H]1CC[C@H](CC1)C(=O)COS(=O)(=O)c1ccccc1)C,"CBR-HVAC-03657: Lipoprotein Disorders, Treatment of ; Pancreatic lipase Inhibitor; Lipase clearing factor inhibitor"
CBR-001-587-171-3,RFM-006-424-4,CBR-001-587-171-3,Clc1ccc2c(c1)N(CC/C/2=N/OS(=O)(=O)[O-])C(=O)c1ccccc1C,CBR-HVAC-03724: Loop Diuretics;Diuretics; Diuretic; Antihypertensive; Diuretic
CBR-001-587-172-4,RFM-006-425-5,CBR-001-587-172-4,C(CCn1cncc1)CNC1=Nc2c3c1cccc3ccc2,CBR-HVAC-04135: Antiarrhythmic Drugs;Heart Failure Therapy; Sodium channel antagonist; Beta adrenoreceptor antagonist
CBR-001-587-173-5,RFM-006-426-6,CBR-001-587-173-5,Nc1[nH]c2c(c1Cc1cscc1)nc([nH]c2=O)N,CBR-HVAC-04231: Antipsoriatics;Antiarthritic Drugs;Immunosuppressants; Purine-Nucleoside Phosphorylase Inhibitors; Purine nucleoside phosphorylase Inhibitor; Purine nucleoside phosphorylase inhibitor; T cell inhibitor
CBR-001-587-174-6,RFM-006-427-7,CBR-001-587-174-6,Clc1cc(/C=C\CN2CCCCCC2)ccc1C1CCCCC1,CBR-HVAC-04254: Antipsychotic Drugs; sigma Receptor Antagonists;Signal Transduction Modulators; Sigma receptor antagonist
CBR-001-587-175-7,RFM-006-428-8,CBR-001-587-175-7,CO/N=C(\c1ccc(cc1)C(=O)C(C)(C)C)/OC(=O)c1ccc(cc1)C(=O)C(C)(C)C,"CBR-HVAC-04260: Lipoprotein Disorders, Treatment of ;Antidiabetic Drugs; Carnitine O-Palmitoyltransferase Inhibitors; Carnitine palmitoyltransferase II Inhibitor; Carnitine palmitoyltransferase inhibitor"
CBR-001-587-176-8,RFM-006-429-9,CBR-001-587-176-8,O=C(C(C)(C)C)c1ccc(cc1)C(=O)O,CBR-HVAC-04260M1: metabolite of CBR-HVAC-04260
CBR-001-587-177-9,RFM-006-430-2,CBR-001-587-177-9,[O-][n+]1ccccc1C1=NC(C)(C)Oc2c1cc(Br)c(c2)Cl,"CBR-HVAC-04295: Hypertension, Treatment of; Potassium Channel Activators; Potassium channel Opener; Potassium channel agonist"
CBR-001-587-178-0,RFM-006-431-3,CBR-001-587-178-0,COc1cc(ccc1S(=O)c1ccccc1)c1cnn2c1ncnc2O,CBR-HVAC-04332: Treatment of Gout; Xanthine Oxidase Inhibitors; Xanthine oxidase inhibitor
CBR-001-587-179-1,RFM-006-432-4,CBR-001-587-179-1,N/C(=N/c1ccccc1N1CCOCC1)/N(C)C,CBR-HVAC-04394: Antidiabetic Drugs; Potassium channel Blocker; Insulinotropin agonist
CBR-001-587-180-4,RFM-006-433-5,CBR-001-587-180-4,C/C(=C\CC/C(=C/CCC(P(=O)(O)O)O)/C)/CCC=C(C)C,CBR-HVAC-04463: Oncolytic Drugs; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;
CBR-001-587-181-5,RFM-006-434-6,CBR-001-587-181-5,O=C(C1CCc2c1cc(Cl)c(c2)Cl)N1CCSC[C@H]1CN1CCCC1,CBR-HVAC-04555: Opioid Analgesics; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist; Opioid kappa receptor agonist
CBR-001-587-182-6,RFM-006-435-7,CBR-001-587-182-6,OP(=O)(C(S(=O)(=O)O)CCCc1cccc(c1)Oc1ccccc1)O,"CBR-HVAC-04581: Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors; SQUALENE SYNTHASE Inhibitor;"
CBR-001-587-183-7,RFM-006-436-8,CBR-001-587-183-7,O=C1CCCN1C1=CC(C)(Oc2c1cc(cc2)[N+](=O)[O-])C1OCCO1,"CBR-HVAC-04589: Hypertension, Treatment of;Vasodilators;Cardioprotective Agents;Antiulcer Drugs; Potassium Channel Activators; Potassium channel Opener; ATP-sensitive potassium channel agonist"
CBR-001-587-184-8,RFM-006-437-9,CBR-001-587-184-8,O=C1CCCN1C1=CC(C)(Oc2c1cc(cc2)[N+](=O)[O-])C1OCCO1,"CBR-HVAC-04589: Hypertension, Treatment of;Vasodilators;Cardioprotective Agents;Antiulcer Drugs; Potassium Channel Activators; Potassium channel Opener; ATP-sensitive potassium channel agonist"
CBR-001-587-185-9,RFM-006-438-0,CBR-001-587-185-9,O=C(C1NCc2c(C1)c1ccccc1s2)NCc1ccc2c(c1)OCO2,CBR-HVAC-04613: Anxiolytics; Signal Transduction Modulators;5-HT1A Receptor Antagonists; 5-HYDROXYTRYPTAMINE 1A RECEPTOR Antagonist; 5 Hydroxytryptamine 1A receptor antagonist; 5 Hydroxytryptamine 1A receptor agonist
CBR-001-587-186-0,RFM-006-439-1,CBR-001-587-186-0,O=C(C1NCc2c(C1)c1ccccc1s2)NCc1ccc2c(c1)OCO2,CBR-HVAC-04613: Anxiolytics; Signal Transduction Modulators;5-HT1A Receptor Antagonists; 5-HYDROXYTRYPTAMINE 1A RECEPTOR Antagonist; 5 Hydroxytryptamine 1A receptor antagonist; 5 Hydroxytryptamine 1A receptor agonist
CBR-001-587-187-1,RFM-006-440-4,CBR-001-587-187-1,N[C@H]1CCN(C1)c1c(F)cn2c(c1C)c(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-04614: Antibacterial Drugs; DNA Gyrase Inhibitors; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-587-188-2,RFM-006-441-5,CBR-001-587-188-2,CCc1cccc2c1nc(s2)Sc1ccc2c(c1)CC[C@@H]1[C@]2(C)CCC(=O)N1C,CBR-HVAC-04819: Prostate Cancer Therapy; Steroid 5alpha-Reductase Type 1 Inhibitors;Steroid 5alpha-Reductase Type 2 Inhibitors; Steroid 5-alpha-reductase Inhibitor;
CBR-001-587-189-3,RFM-006-442-6,CBR-001-587-189-3,COCN1C(=O)N(COC)C(=O)C(C1=O)(c1ccccc1)c1ccccc1,"CBR-HVAC-05167: Extrapyramidal Disorders, Treatment of;Antiepileptic Drugs; Anticonvulsant;"
CBR-001-587-190-6,RFM-006-443-7,CBR-001-587-190-6,CCc1ccc(cc1)C1=CC(C)(C)Sc2c1cc(C#Cc1ccc(cc1)C(=O)O)cc2,"CBR-HVAC-05178: Antipsoriatics;Acne Therapy;Atopic Dermatitis, Agents for;Eczema, Treatment of; Retinoid RAR Antagonists;Signal Transduction Modulators; Retinoic acid receptor Antagonist; Retinoic acid receptor antagonist"
CBR-001-587-191-7,RFM-006-444-8,CBR-001-587-191-7,O=C(Cn1c(ncc(c1=O)N)c1ccccc1)N[C@H](C(=O)c1nnc(o1)C(C)(C)C)C(C)C,"CBR-HVAC-05315: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Leukocyte Elastase Inhibitors;"
CBR-001-587-192-8,RFM-006-445-9,CBR-001-587-192-8,CC(=O)/N=c\1/sc(nn1C)S(=O)(=O)N,"CBR-HVAC-05320: Type 2 Diabetes, Agents for;Oncolytic Drugs;Antiepileptic Drugs;Antiglaucoma Agents; Carbonic Anhydrase Type I Inhibitors;Carbonic Anhydrase Type II Inhibitors;Insulin Sensitizers;Signal Transduction Modulators; Carbonic anhydrase Inhibitor;"
CBR-001-587-193-9,RFM-006-446-0,CBR-001-587-193-9,N#Cc1ccc2c(c1)CN([C@@H](CN2Cc1nc[nH]c1)Cc1ccccc1)S(=O)(=O)c1cccs1,CBR-HVAC-05330: Oncolytic Drugs;Solid Tumors Therapy; Apoptosis Inducers;Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators; Ras GTPase; Protein farnesyltransferase Inhibitor;
CBR-001-587-194-0,RFM-006-447-1,CBR-001-587-194-0,CCN(CC/C(=N\OC(=O)Nc1ccc(cc1)OC)/c1ccccc1)CC,CBR-HVAC-05589: Non-Opioid Analgesics;
CBR-001-587-195-1,RFM-006-448-2,CBR-001-587-195-1,CCCn1cnc(c1)CC(C(=O)O)CCCN,"CBR-HVAC-05689: Interstitial Lung Diseases, Treatment of;Thrombolytics; Carboxypeptidase U (TAFIa) Inhibitors; Thrombin activatable fibrinolysis inhibitor Inhibitor;"
CBR-001-587-196-2,RFM-006-449-3,CBR-001-587-196-2,CCCn1cnc(c1)CC(C(=O)O)CCCN,"CBR-HVAC-05689: Interstitial Lung Diseases, Treatment of;Thrombolytics; Carboxypeptidase U (TAFIa) Inhibitors; Thrombin activatable fibrinolysis inhibitor Inhibitor;"
CBR-001-587-197-3,RFM-006-450-6,CBR-001-587-197-3,c1cnc2c(c1)CC1(O2)CN2CCC1CC2,"CBR-HVAC-05877: Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; Nicotinic alpha7 Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha7 Agonist;"
CBR-001-587-198-4,RFM-006-451-7,CBR-001-587-198-4,c1cnc2c(c1)CC1(O2)CN2CCC1CC2,"CBR-HVAC-05877: Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; Nicotinic alpha7 Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha7 Agonist;"
CBR-001-587-199-5,RFM-006-452-8,CBR-001-587-199-5,CCCCc1nc(N)c2c(n1)n(C)c(n2)n1nccn1,CBR-HVAC-05882: Antiparkinsonian Drugs; Adenosine A1 Receptor Ligands;Adenosine A2A Antagonists;Adenosine A2A Receptor Ligands;Signal Transduction Modulators; Adenosine A2A receptor Antagonist; Adenosine A2a receptor antagonist
CBR-001-587-200-1,RFM-006-453-9,CBR-001-587-200-1,COCC(=O)NC/C=C/c1ccc2c(c1)c(ncn2)Nc1ccc(c(c1)C)Oc1ccc(nc1)C,CBR-HVAC-05921: Breast Cancer Therapy; HER2 (erbB2) Inhibitors;Signal Transduction Modulators; ErbB-2 tyrosine kinase inhibitor; Tyrosine kinase inhibitor (TKI)
CBR-001-587-201-2,RFM-006-454-0,CBR-001-587-201-2,NC(=N)Nc1ncc(c2c1cc(cc2)c1cccc(c1)C(=O)O)Cl,CBR-HVAC-06089: Wound-Healing Agents;Oncolytic Drugs; Urokinase (u-PA) Inhibitors;
CBR-001-587-202-3,RFM-006-455-1,CBR-001-587-202-3,CNC(=O)c1c(C)oc2c1ccc(c2)Oc1ccnc2c1ccc(c2)OCCN1CCOCC1,CBR-HVAC-06140: Oncolytic Drugs; Angiogenesis Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Vascular endothelial growth factor receptor 2 Inhibitor;
CBR-001-587-203-4,RFM-006-456-2,CBR-001-587-203-4,CCN(CCOC(=O)[C@@H](NC(=O)c1c(C)cccc1Cl)Cc1ccc(cc1)NC(=O)c1c(Cl)cccc1Cl)CC,"CBR-HVAC-06273: Asthma Therapy;Multiple Sclerosis, Agents for; Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Signal Transduction Modulators; Alpha4beta1 integrin antagonist; Alpha4beta7 integrin antagonist; Integrin antagonist; Alpha4 integrin antagonist"
CBR-001-587-204-5,RFM-006-457-3,CBR-001-587-204-5,OC[C@@H](Oc1cc(Oc2ccc(nc2)S(=O)(=O)CC)cc(c1)C(=O)Nc1ccn(n1)C)C,"CBR-HVAC-06339: Type 2 Diabetes, Agents for; Glucokinase Activators; Glucokinase Activator;"
CBR-001-587-205-6,RFM-006-458-4,CBR-001-587-205-6,CNC(=O)C1CCN(CC1)Cc1cc(cc(c1)F)NC(=O)Nc1ccc(nc1)C,CBR-HVAC-06365: Heart Failure Therapy; Cardiac Myosin Activators;
CBR-001-587-206-7,RFM-006-459-5,CBR-001-587-206-7,Fc1ccc(cc1)C(C(c1cccnc1)c1cccnc1)c1cccc(n1)NS(=O)(=O)C,CBR-HVAC-06377: Cardiovascular Diseases (Not Specified);Antiarrhythmic Drugs; K(V) 1.5 (KCNA5) Channel Blockers; KV1.5 POTASSIUM CHANNEL Inhibitor;
CBR-001-587-207-8,RFM-006-460-8,CBR-001-587-207-8,Fc1ccc(cc1)C(C(c1cccnc1)c1cccnc1)c1cccc(n1)NS(=O)(=O)C,CBR-HVAC-06377: Cardiovascular Diseases (Not Specified);Antiarrhythmic Drugs; K(V) 1.5 (KCNA5) Channel Blockers; KV1.5 POTASSIUM CHANNEL Inhibitor;
CBR-001-587-208-9,RFM-006-461-9,CBR-001-587-208-9,OC(C12CC[N+](CC1)(CC2)CCOCc1ccccc1)(c1ccccc1)c1ccccc1,"CBR-HVAC-06581: Asthma Therapy;Dermatologic Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Cytochrome P450 CYP2D6 Inhibitors;Muscarinic M3 Antagonists;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Signal Transduction Modulators; M3 MUSCARINIC RECEPTOR Inhibitor;"
CBR-001-587-209-0,RFM-006-462-0,CBR-001-587-209-0,OCc1[nH]c(C)c(c(=O)c1c1ccc(cc1)Oc1ccc(cc1)OC(F)(F)F)Cl,CBR-HVAC-06612: Antimalarials; Cytochrome b-c1 Complex (Complex III subunit 3) (Plasmodium falciparum) Inhibitors; Electron transport inhibitor;
CBR-001-587-210-3,RFM-006-463-1,CBR-001-587-210-3,CCCCn1ccc(c(c1=O)Cl)N1CCC(CC1)c1ccccc1,CBR-HVAC-06917: Psychiatric Disorders (Not Specified);Anxiolytics; mgluR2 Positive Allosteric Modulators;Signal Transduction Modulators;
CBR-001-587-211-4,RFM-006-464-2,CBR-001-587-211-4,COc1cc(ccc1OCC(C1CC1)O)n1cnc2c(c1=O)sc(c2)c1ccc(cc1)Cl,"metabolite of CBR-HVAC-06920, enantiomer A"
CBR-001-587-212-5,RFM-006-465-3,CBR-001-587-212-5,COc1cc(ccc1OCC(C1CC1)O)n1cnc2c(c1=O)sc(c2)c1ccc(cc1)Cl,metabolite of CBR-HVAC-06920. enantiomer B
CBR-001-587-213-6,RFM-006-466-4,CBR-001-587-213-6,OC[C@H]1CN(C(=O)O1)c1ccc(c(c1)F)N1CCN(N=C1)C,CBR-HVAC-06943: Antibacterial Drugs; Protein 30S ribosomal subunit inhibitor
CBR-001-587-214-7,RFM-006-467-5,CBR-001-587-214-7,O[C@H]1CCN(C1)C(=O)Nc1cnn2c1nc(cc2)N1CCCC1c1cc(F)ccc1F,CBR-HVAC-07050: Lung Cancer Therapy;Sarcoma Therapy;Non-Opioid Analgesics;Solid Tumors Therapy; High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors;Signal Transduction Modulators;TRKB Inhibitors;TRKC Inhibitors;
CBR-001-587-215-8,RFM-006-468-6,CBR-001-587-215-8,O[C@H]1CCN(C1)C(=O)Nc1cnn2c1nc(cc2)N1CCCC1c1cc(F)ccc1F,CBR-HVAC-07050: Lung Cancer Therapy;Sarcoma Therapy;Non-Opioid Analgesics;Solid Tumors Therapy; High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors;Signal Transduction Modulators;TRKB Inhibitors;TRKC Inhibitors;
CBR-001-587-216-9,RFM-006-469-7,CBR-001-587-216-9,CCN1CCC(CC1)Oc1c(C#N)ncc2c1c1cccnc1[nH]2,CBR-HVAC-07161: Oncolytic Drugs;Lymphoma Therapy; Checkpoint Kinase 1 (Chk1) Inhibitors;Signal Transduction Modulators;
CBR-001-587-217-0,RFM-006-470-0,CBR-001-587-217-0,OC(=O)c1ccc(cc1)CN1C[C@@H]2C[C@H]1CN2Cc1ccc(cc1)Oc1ccc(cc1)c1ncco1,"CBR-HVAC-07194: Inflammation, Treatment of;Treatment of Gout;Acne Therapy;Cystic Fibrosis, Treatment of ;Respiratory Disorders (Not Specified);Multiple Sclerosis, Agents for; Leukotriene A4 Hydrolase Inhibitors; Leucotriene A4 antagonist"
CBR-001-587-218-1,RFM-006-471-1,CBR-001-587-218-1,O=C1CCc2c(N1)nccc2Oc1ccc2c(c1)C1C(O2)C1c1nc2c([nH]1)cc(cc2)C(F)(F)F,CBR-HVAC-07306: Solid Tumors Therapy; Raf kinase B Inhibitors;Signal Transduction Modulators;
CBR-001-587-219-2,RFM-006-472-2,CBR-001-587-219-2,COc1cc(ccc1Nc1nc2n(n1)ccc(c2)c1ccc(cc1)NC(=O)C(c1ccc(cc1)F)C)S(=O)(=O)C,CBR-HVAC-07309: Oncolytic Drugs; Dual specificity protein kinase TTK (MPS1; MPS1L1) Inhibitors;Signal Transduction Modulators;
CBR-001-587-220-5,RFM-006-473-3,CBR-001-587-220-5,COc1cc(ccc1Nc1nc2n(n1)ccc(c2)c1ccc(cc1)NC(=O)C(c1ccc(cc1)F)C)S(=O)(=O)C,CBR-HVAC-07309: Oncolytic Drugs; Dual specificity protein kinase TTK (MPS1; MPS1L1) Inhibitors;Signal Transduction Modulators;
CBR-001-587-221-6,RFM-006-474-4,CBR-001-587-221-6,O=C(CCCC[C@@H]1SCC2C1NC(=O)N2)NCCS(=O)c1sc2n(n1)cc(n2)c1c(F)c(F)c(c(c1F)F)N=[N+]=[N-],CBR-HVAC-07427: Heat shock protein 70 agonist; Apoptosis inhibitor
CBR-001-587-222-7,RFM-006-475-5,CBR-001-587-222-7,C#CCN(c1ccc(cc1)S(=O)(=O)n1ccc2c1cccc2)Cc1ccc2c(c1)c(=O)nc([nH]2)C,CBR-HVAC-07432: Thymidylate synthase inhibitor
CBR-001-587-223-8,RFM-006-476-6,CBR-001-587-223-8,C/C(=C\c1ccccc1)/CN/N=C(/C(=O)O)\C,CBR-HVAC-07537: Unidentified pharmacological activity
CBR-001-587-224-9,RFM-006-477-7,CBR-001-587-224-9,ClCCN(C(=O)NCCSSCCNC(=O)N(N=O)CCCl)N=O,CBR-HVAC-07746: DNA inhibitor
CBR-001-587-225-0,RFM-006-478-8,CBR-001-587-225-0,CSc1ccccc1N(C(=O)CN(C(=O)OCC(C)C)CCN(C)C)Cc1ccc(cc1)C(F)(F)F,CBR-HVAC-07832: Calcium channel antagonist
CBR-001-587-226-1,RFM-006-479-9,CBR-001-587-226-1,COc1ccnc(c1)c1cccc(c1S(=O)c1nc2c([nH]1)cccc2)C,CBR-HVAC-07850: H+ K+ transporting ATPase inhibitor
CBR-001-587-227-2,RFM-006-480-2,CBR-001-587-227-2,OCCOc1cc(O[C@@H]2O[C@H](CO[C@@H]3O[C@@H](C)[C@@H]([C@H]([C@H]3O)O)O)[C@H]([C@@H]([C@H]2O)O)O)cc2c1c(=O)cc(o2)c1ccc(c(c1)OCCO)OC,CBR-HVAC-03606: Membrane permeability inhibitor; CARDIOVASCULAR AGENT; Cardiovascular Diseases (Not Specified)
CBR-001-587-228-3,RFM-006-481-3,CBR-001-587-228-3,N=C(Nc1ccn(n1)CCCCC(=O)N)NCC(F)(F)F,CBR-HVAC-07906: Histamine H2 receptor antagonist
CBR-001-587-229-4,RFM-006-482-4,CBR-001-587-229-4,O=C1O[Mn]OC(=O)CN(CCN(C1)Cc1c(cnc(c1O)C)COP(=O)([O-])[O-])Cc1c(cnc(c1O)C)COP(=O)([O-])[O-],"CBR-HVAC-04164: Antioxidants; Enhances hepatobiliary imaging.; Iron-chelating-agents; Magnetic-resonance-imaging-enhancers; Acute Myocardial Infarction, Treatment of; Antineurotoxic Agents; Diagnostic Agents; Disorders Associated with Cancer Therapy, Treatment of; Haematological Disorders; Ischaemic Heart Disease; Liver Disorders; MRI agent"
CBR-001-587-230-7,RFM-006-483-5,CBR-001-587-230-7,ONC(=O)CN1CCC(CC1)(C#N)c1ccc(c(c1)OC1CCCC1)OC,CBR-HVAC-08119: Phosphodiesterase 4 inhibitor
CBR-001-587-231-8,RFM-006-484-6,CBR-001-587-231-8,ClC(c1nc2c(c(c1C(=O)Nc1nccs1)O)cccc2C(F)(F)F)Cl,CBR-HVAC-08304: Prostaglandin synthase inhibitor; Prostaglandin receptor antagonist
CBR-001-587-232-9,RFM-006-485-7,CBR-001-587-232-9,COc1ccc2c(c1)c(O)c(cn2)C(=O)NC1=NCCS1,CBR-HVAC-08306: Benzodiazepine receptor agonist
CBR-001-587-233-0,RFM-006-486-8,CBR-001-587-233-0,O=C(NC(C)(C)C)Nc1nc2nc(ncc2cc1c1c(Cl)cccc1Cl)Nc1ccc2c(c1)nsn2,CBR-HVAC-08319: Src inhibitor
CBR-001-587-234-1,RFM-006-487-9,CBR-001-587-234-1,OC(=O)CCc1ccc(cc1)c1sccc1C,CBR-HVAC-08392: Unidentified pharmacological activity
CBR-001-587-235-2,RFM-006-488-0,CBR-001-587-235-2,COc1c(OC)cc(cc1OC)C(=O)N1CCN(CC1)Cc1c(=O)[nH]c2c(c1c1ccccc1)cc(cc2)Cl,CBR-HVAC-08458: Unidentified pharmacological activity
CBR-001-587-236-3,RFM-006-489-1,CBR-001-587-236-3,N#C/N=C(\NCCCOc1cccc2c1ccnc2)/SC,CBR-HVAC-08524: Mucus protecting agent; Thromboxane synthase inhibitor
CBR-001-587-237-4,RFM-006-490-4,CBR-001-587-237-4,CN(CCC1(C)OCCC2=C1Cc1c2cccc1)C,CBR-HVAC-08822: Antidepressant
CBR-001-587-238-5,RFM-006-491-5,CBR-001-587-238-5,NC(=N)NC(=O)c1cc2c(n1CCCS(=O)(=O)O)cccc2Cl,"CBR-HVAC-08978: Angina pectoris, Treatment of;Acute Myocardial Infarction, Treatment of; Na+/H+ Exchanger (NHE) Inhibitors; Sodium/hydrogen exchanger Inhibitor;"
CBR-001-587-239-6,RFM-006-492-6,CBR-001-587-239-6,CCCCC(C1NC(=O)N(C1=O)SC(Cl)(Cl)Cl)CC,CBR-HVAC-09005: Antifungal
CBR-001-587-240-9,RFM-006-493-7,CBR-001-587-240-9,O=C(OC(C)(C)C)N[C@H]1CCCCCCCCC[C@H](NC(=O)[C@H]2N(C1=O)C[C@@H](C2)OC(=O)N1Cc2c(C1)cccc2)B(O)O,CBR-HVAC-09198: NS3/4A PROTEASE Inhibitor;
CBR-001-587-241-0,RFM-006-494-8,CBR-001-587-241-0,ONC(=O)[C@H]([C@H](C(=O)N[C@@H](C(C)(C)C)c1noc(n1)c1cccs1)CC(C)C)O,CBR-HVAC-09204: Matrix metalloproteinase 12 Inhibitor;
CBR-001-587-242-1,RFM-006-495-9,CBR-001-587-242-1,COC1/C=C/OC2(C)Oc3c(C2=O)c2c(O)c(/C=N/N4CCN5C(C4)CCCC5)c(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C\C(C(C(C(C(C(C1C)OC(=O)C)C)O)C)O)C)/C,CBR-HVAC-09467: PROTEIN KINASE Inhibitor;
CBR-001-587-243-2,RFM-006-496-0,CBR-001-587-243-2,CCn1ccc(nc1=O)NS(=O)(=O)c1ccc(cc1)N,CBR-HVAC-09661: Dihydropteroate synthase Inhibitor;
CBR-001-587-244-3,RFM-006-497-1,CBR-001-587-244-3,CC(=O)OC1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)CC(Cl)/C(=N\Oc1ccc(cc1)[N+](=O)[O-])/C2,"CBR-HVAC-10094: Disorders of Sexual Function and Reproduction, Treatment of;"
CBR-001-587-245-4,RFM-006-498-2,CBR-001-587-245-4,CCN(CCOC1(CCN(CC1)CCNc1ccccc1)c1ccccc1)CC,CBR-HVAC-10123:
CBR-001-587-246-5,RFM-006-499-3,CBR-001-587-246-5,CC(=C/C(=N/N=c/1\[nH]ncc2c1cccc2)/C)C,CBR-HVAC-10160: Alpha adrenergic receptor Agonist;
CBR-001-587-247-6,RFM-006-500-9,CBR-001-587-247-6,CCCc1cc(Cl)c2c(c1O)c(C)c(o2)Cc1ccc(cc1)OC,CBR-HVAC-10485: Lipoxygenase 5 Inhibitor;
CBR-001-587-248-7,RFM-006-501-0,CBR-001-587-248-7,CCCCC(C(=O)O)Oc1ccccc1CNc1cccc(c1)/C=C/c1ccc2c(n1)ccc(c2)Cl,CBR-HVAC-10754: Leukotriene D4 receptor Antagonist;
CBR-001-587-249-8,RFM-006-502-1,CBR-001-587-249-8,CCCCC(C(=O)O)Oc1ccccc1CNc1cccc(c1)/C=C/c1ccc2c(n1)ccc(c2)Cl,CBR-HVAC-10754: Leukotriene D4 receptor Antagonist;
CBR-001-587-250-1,RFM-006-503-2,CBR-001-587-250-1,O=C1Cc2c(N1C)nc(nc2)N1CCCCC1,"CBR-HVAC-10763: Cognition Disorders, Treatment of; Neurotrophic Agents;Signal Transduction Modulators; Neuroprotectant;"
CBR-001-587-251-2,RFM-006-504-3,CBR-001-587-251-2,NC1CCN(C1)c1c(F)cc2c3c1oc1ccccc1n3cc(c2=O)C(=O)O,CBR-HVAC-14208: metabolite of CBR-HVAC-10982
CBR-001-587-252-3,RFM-006-505-4,CBR-001-587-252-3,Oc1cccc(c1)SCc1ccccc1N(C)C,analog of CBR-HVAC-03953
CBR-001-587-253-4,RFM-006-506-5,CBR-001-587-253-4,CCC(n1c(C)cc2c1ccc1c2c(N)nc(n1)N)CC,CBR-HVAC-11115: Oncolytic Drugs; Antimetabolites;Dihydrofolate Reductase (DHFR) Inhibitors; Dihydrofolate reductase Inhibitor;
CBR-001-587-254-5,RFM-006-507-6,CBR-001-587-254-5,O=C(N(C)C)Oc1ccc2c(c1)[nH]c(=O)c1c2oc2c1ccc(c2)OC(=O)N(C)C,CBR-HVAC-11302: Bone Resorption Inhibitors;Treatment of Osteoporosis; Protein Kinase Inhibitors;Signal Transduction Modulators; Alkaline phosphatase Agonist;
CBR-001-587-255-6,RFM-006-508-7,CBR-001-587-255-6,NC(=NC(=O)c1ccc(c(c1)S(=O)(=O)C)N1CCN(CC1)C(=O)c1ccco1)N,"CBR-HVAC-11364: Angina pectoris, Treatment of;Antiarrhythmic Drugs; Na+/H+ Exchanger type 1 (NHE-1) Inhibitors; Sodium/hydrogen exchanger isoform 1 Inhibitor;"
CBR-001-587-256-7,RFM-006-509-8,CBR-001-587-256-7,Nc1sc2c(n1)c1sc3n(c1CC2)cc(n3)c1ccccc1,CBR-HVAC-11445: Urease Inhibitor;
CBR-001-587-257-8,RFM-006-510-1,CBR-001-587-257-8,CCCC(=O)c1cnc2c(c1Sc1ccccc1N)cccc2OC,CBR-HVAC-11450: Proton pump inhibitor;
CBR-001-587-258-9,RFM-006-511-2,CBR-001-587-258-9,c1ccc(cc1)CCCC(C1=NCCN1)Oc1ccccc1OCc1ccccc1,CBR-HVAC-11588: Ionotropic glutamate receptor NMDA Antagonist;
CBR-001-587-259-0,RFM-006-512-3,CBR-001-587-259-0,CCCCCCCCCC(=O)c1ccc(c(c1)C(=O)Nc1ccc(cc1)[N+](=O)[O-])O,CBR-HVAC-11625: Dental Agents;Dermatologic Drugs;Antibacterial Drugs; Antiinflammatory Drugs; Hemoglobin modulator;
CBR-001-587-260-3,RFM-006-513-4,CBR-001-587-260-3,OC(=O)Cc1cccc2c1Cc1c2[nH]c(=O)c2n1cc(n2)C(=O)O,"CBR-HVAC-11680: Antiepileptic Drugs;Ischemic Stroke, Treatment of; AMPA Receptor Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor AMPA Antagonist;"
CBR-001-587-261-4,RFM-006-514-5,CBR-001-587-261-4,Clc1ccc(c(c1)Cl)Nc1ncc(c(c1)C1CC1)C(=O)NCC1CCOCC1,CBR-HVAC-11724: Cannabinoid receptor 2 Agonist;
CBR-001-587-262-5,RFM-006-515-6,CBR-001-587-262-5,O=C([C@@H]1COC(CN1CC(=O)N1CCCC1)(C)C)Nc1cc(Cl)cc2c1[nH]c1c2ccnc1,analog of CBR-HVAC-11729 (MLN-0415)
CBR-001-587-263-6,RFM-006-516-7,CBR-001-587-263-6,O[C@@H]1CC[C@H](CC1)N(c1cc(sc1C(=O)O)c1ccccc1)C(=O)C1CCC(CC1)C,CBR-HVAC-11751: NS5B polymerase Inhibitor;
CBR-001-587-264-7,RFM-006-517-8,CBR-001-587-264-7,S=c1[nH]cc([nH]1)CC1CC=CC1,CBR-HVAC-11777: Alpha adrenergic receptor agonist;
CBR-001-587-265-8,RFM-006-518-9,CBR-001-587-265-8,O/N=C(\c1cc[n+](cc1)C)/C(=O)C,CBR-HVAC-11792: Histamine receptor antagonist; PDE 3 inhibitor;
CBR-001-587-266-9,RFM-006-519-0,CBR-001-587-266-9,Clc1cc(N2CCNCC2)c2c(c1)N(Cc1ccccc1)C(=O)C(C2=O)(C)c1ccc(cc1)O,"CBR-HVAC-11820: Cognition Disorders, Treatment of;Antipsychotic Drugs;Antidepressants; Signal Transduction Modulators;5-HT6 Antagonists; 5-HYDROXYTRYPTAMINE RECEPTOR 6 Antagonist;"
CBR-001-587-267-0,RFM-006-520-3,CBR-001-587-267-0,OC(=O)Cc1ccc(cc1)COc1cccc(c1)c1c(cnc2c1cccc2C(F)(F)F)Cc1ccccc1,"CBR-HVAC-11834: Atherosclerosis Therapy;Lipoprotein Disorders, Treatment of ; ABCA1 Expression Enhancers;Oxysterol Receptor LXRalpha Agonists;Oxysterol Receptor LXRbeta Agonists;Signal Transduction Modulators; Liver X receptor Agonist;"
CBR-001-587-268-1,RFM-006-521-4,CBR-001-587-268-1,COC(=O)c1ccccc1c1c2ccc(c(c2oc2c1ccc(=N)c2Br)Br)N,CBR-HVAC-04798: Immunosuppressants;Myeloid Leukemia Therapy;Treatment of Autoimmune Diseases;Non-Hodgkin's Lymphoma Therapy;
CBR-001-587-269-2,RFM-006-522-5,CBR-001-587-269-2,O=C1CC[C@@]2(C(=C1)c1ccc3c(c1C2)nnn3C(C)(C)C)CCOc1ccccc1,CBR-HVAC-11875: ESTROGEN RECEPTOR Modulator;
CBR-001-587-270-5,RFM-006-523-6,CBR-001-587-270-5,FCCC1CCN(CC1)C(=O)[C@@H](NS(=O)(=O)c1cnccc1N[C@@H](Cc1ccccc1)CO)Cc1ccc(cc1)N,CBR-HVAC-11936: Thrombin Inhibitor;
CBR-001-587-271-6,RFM-006-524-7,CBR-001-587-271-6,CNc1ccc(c(n1)F)c1cc2c(o1)ccc(c2)O,CBR-HVAC-12011: Diagnostic for Alzheimer's Disease;Radiopharmaceuticals for Brain Imaging; Drugs Acting on Beta-Amyloid; Beta amyloid fibril Inhibitor;
CBR-001-587-272-7,RFM-006-525-8,CBR-001-587-272-7,CC(Oc1ccc(cc1)c1ccccc1C(=O)Nc1ccc2c(n1)ccc(c2)C(=O)N[C@H](C(=O)N(Cc1ccc(cc1)F)C)c1ccccc1)C,CBR-HVAC-12055: Antiobesity Drugs; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors;
CBR-001-592-661-1,RFM-006-526-9,CBR-001-592-661-1,OC(=O)C1Oc2c(C1)cc1c(c2Cl)onc1c1ccccc1F,CBR-HVAC-00141: Diuretics; Antidiuretic; Diuretic; Uric acid diuretic
CBR-001-592-662-2,RFM-006-527-0,CBR-001-592-662-2,CCCCCC(c1ccc(cc1)N1[C@@H](CCCc2ccc(s2)C(=O)O)CCC1=O)O,CBR-HVAC-06482: Antiglaucoma Agents; Prostanoid EP2 Agonists;Signal Transduction Modulators; ANTIGLAUCOMA; GLAUCOMA;
CBR-001-592-663-3,RFM-006-528-1,CBR-001-592-663-3,CCCCCC(c1ccc(cc1)N1[C@@H](CCCc2ccc(s2)C(=O)O)CCC1=O)O,CBR-HVAC-06482: Antiglaucoma Agents; Prostanoid EP2 Agonists;Signal Transduction Modulators; ANTIGLAUCOMA; GLAUCOMA;
CBR-001-592-664-4,RFM-006-529-2,CBR-001-592-664-4,C/C(=C\c1ccc(s1)C(=O)O)/c1cc2c(cc1C)C(C)(C)CCC2(C)C,CBR-HVAC-09344: ; Anticancer; Hypoglycemic agent; NON-SMALL-CELL LUNG CANCER; DIABETES MELLITUS; CANCER; METABOLIC DISORDER; NEOPLASM;
CBR-001-592-665-5,RFM-006-530-5,CBR-001-592-665-5,CC1(C)CN[Se]c2c1cccc2,"CBR-HVAC-00374: Restenosis Treatment of;Inflammatory Bowel Disease, Agents for;Antipsoriatics;Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Antioxidants; Anti-inflammatory; Neuroprotectant; Cardiovascular disease; Diabetes; Glutathione peroxidase stimulant; Reducing agent; Free radical scavenger"
CBR-001-592-666-6,RFM-006-531-6,CBR-001-592-666-6,CCOC(=O)/N=C(/c1ccc(cc1)OCc1cccc(c1)COc1ccc(cc1)C(c1ccc(cc1)O)(C)C)\N,"CBR-HVAC-05050: Rheumatoid Arthritis, Treatment of;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Cystic Fibrosis, Treatment of ;Asthma Therapy; Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators; Leucotriene B4 antagonist; Leucotriene receptor antagonist"
CBR-001-592-667-7,RFM-006-532-7,CBR-001-592-667-7,NC(=O)CS[Sb](SCC(=O)N)SCC(=O)N,CBR-HVAC-10125: ; Anthelmintic; Trypanosomiasis; Kala azar; Filariasis;
CBR-001-592-668-8,RFM-006-533-8,CBR-001-592-668-8,COCCCS(=O)(=O)c1ccc(cc1)c1ccc(cc1)CCN1CCC[C@@H]1C,CBR-HVAC-06825: Antinarcoleptic Drugs; Histamine H3 Receptor Inverse Agonists;Signal Transduction Modulators; Psychostimulant; SLEEP DISORDER; NARCOLEPSY; CATAPLEXY;
CBR-001-592-669-9,RFM-006-534-9,CBR-001-592-669-9,O=C1Cc2c(N1)ccc1c2OC(CNCc2ccccc2)CO1,"CBR-HVAC-04949: Antiparkinsonian Drugs;Restless Legs Syndrome, Treatment of;Antipsychotic Drugs; Dopamine D2 Receptor Partial Agonists;Signal Transduction Modulators; Antipsychotic; Antiparkinsonian; Schizophrenia; Dopamine D2 receptor agonist; Dopamine D3 receptor agonist"
CBR-001-592-670-2,RFM-006-535-0,CBR-001-592-670-2,O=C1Cc2c(N1)ccc1c2OC(CNCc2ccccc2)CO1,"CBR-HVAC-04949: Antiparkinsonian Drugs;Restless Legs Syndrome, Treatment of;Antipsychotic Drugs; Dopamine D2 Receptor Partial Agonists;Signal Transduction Modulators; Antipsychotic; Antiparkinsonian; Schizophrenia; Dopamine D2 receptor agonist; Dopamine D3 receptor agonist"
CBR-001-592-671-3,RFM-006-536-1,CBR-001-592-671-3,COc1cncnc1N1CCN(CC1)CCCc1c[nH]c2c1cc(cc2)NS(=O)(=O)C,CBR-HVAC-07490: ; 5 Hydroxytryptamine 1D receptor agonist
CBR-001-592-672-4,RFM-006-537-2,CBR-001-592-672-4,O=C1C(=CC(=O)c2c1cccn2)NC1CCCCCCC1,"CBR-HVAC-10558: Antimycobacterial Agents; ANTI-LEPROTIC; Infection, mycobacterium leprae;"
CBR-001-592-673-5,RFM-006-538-3,CBR-001-592-673-5,CC(=O)NCC1CN(C(=O)O1)c1ccc(c(c1)F)OCC1(CCN(CC1)c1cc2n(cc(c(=O)c2cc1F)C(=O)O)C1CC1)OP(=O)(O)O,CBR-HVAC-06064: Antimigraine Drugs; Calcitonin Gene-Related Peptides (CGRP) Antagonists;Signal Transduction Modulators;
CBR-001-592-674-6,RFM-006-539-4,CBR-001-592-674-6,COCCN(c1nc(C)nc2n1nc(c2c1ccc(cc1C)OC)C)CCOC,CBR-HVAC-06256: Antidepressants;Anxiolytics; CRF1 Receptor Antagonists;Signal Transduction Modulators; ANTIDEPRESSANTANXIOLYTIC; DEPRESSION;
CBR-001-592-675-7,RFM-006-540-7,CBR-001-592-675-7,ONC(=O)[C@H](N1CC[C@@](C1=O)(N)c1ccc(cc1)OCc1cc(C)nc2c1cccc2)CC(C)C,"CBR-HVAC-00341: Antipsoriatics;Treatment of Cachexia;Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for; Disintegrin And Metalloproteinase Domain-Containing Protein 17 (ADAM17; TACE) Inhibitors;Signal Transduction Modulators; Antiinflammatory; Rheumatoid arthritis; Inflammatory bowel disease; TNF convertase inhibitor; Tumour necrosis factor alpha antagonist"
CBR-001-592-676-8,RFM-006-541-8,CBR-001-592-676-8,CCNCCCNC/C=C\CNCCCNCC,"CBR-HVAC-05093: Lymphoma Therapy;Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy;Age-Related Macular Degeneration, Treatment of;Prostate Cancer Therapy; Polyamine Biosynthesis Inhibitors; Anticancer; Age-related macular degeneration; HIV associated dementia; Lymphoma; Prostate tumor; Cancer; Solid tumor;"
CBR-001-592-677-9,RFM-006-542-9,CBR-001-592-677-9,COC(=O)C[C@H](C[C@H](/C=C/C=C(c1ccccc1)c1ccccc1)O)O,"CBR-HVAC-10654: Lipoprotein Disorders, Treatment of ; HMG-CoA Reductase Inhibitors; Antihyperlipidemic; Antihypercholesterolemic; Hyperlipidemia; Atherosclerosis;"
CBR-001-592-678-0,RFM-006-543-0,CBR-001-592-678-0,Fc1ccc2c(c1)nc(cc2)COc1ccc(cc1)CC(C(=O)O)NC(=O)c1ccc2c(n1)cccc2,"CBR-HVAC-05519: Antiallergy/Antiasthmatic Drugs;Inflammation, Treatment of; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Anti-inflammatory; Bronchial asthma;"
CBR-001-592-679-1,RFM-006-544-1,CBR-001-592-679-1,OCC(CCc1ccc(n1C)C(=O)CCCc1ccc(cc1)C)(N)C,"CBR-HVAC-06416: Immunomodulators;Multiple Sclerosis, Agents for; Lysophospholipid edg1 (S1P1) Receptor Agonists;Signal Transduction Modulators; Immunomodulator; Immunosuppressant; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection; Sphingosine 1-phosphate 1 receptor agonist; Immunosuppressant"
CBR-001-592-680-4,RFM-006-545-2,CBR-001-592-680-4,OCC(CCc1ccc(n1C)C(=O)CCCc1ccc(cc1)C)(N)C,"CBR-HVAC-06416: Immunomodulators;Multiple Sclerosis, Agents for; Lysophospholipid edg1 (S1P1) Receptor Agonists;Signal Transduction Modulators; Immunomodulator; Immunosuppressant; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Transplant rejection; Sphingosine 1-phosphate 1 receptor agonist; Immunosuppressant"
CBR-001-592-681-5,RFM-006-546-3,CBR-001-592-681-5,CCc1ccccc1c1n[nH]c(n1)c1cccc(c1)OC,"CBR-HVAC-00003: Multiple Sclerosis, Agents for;Treatment of Autoimmune Diseases;Inflammatory Bowel Disease, Agents for; Immunosuppressant; AUTOIMMUNE DISEASES; INFERTILITY; Unidentified pharmacological activity"
CBR-001-592-682-6,RFM-006-547-4,CBR-001-592-682-6,COc1ccc(cc1)C[C@H](N(S(=O)(=O)Cc1ccccc1)C)C(=O)N[C@H](c1cccc2c1cccc2)C,CBR-HVAC-09351: ; Neuroprotectant; Alzheimer's disease;
CBR-001-592-683-7,RFM-006-548-5,CBR-001-592-683-7,CNC(=O)c1ccc2c(c1)n(cc2)C1CCN(CC1)CCc1c(OC)ccc2c1OC(C)(C)CC2=O,CBR-HVAC-06321: Urinary Incontinence Therapy; Signal Transduction Modulators;5-HT1A Receptor Antagonists; Renal system agent; Overactive bladder;
CBR-001-592-684-8,RFM-006-549-6,CBR-001-592-684-8,Fc1ccc(cc1)C1=CCN(CC1)CCCCn1cncn1,CBR-HVAC-00518: ; Antipsychotic; Schizophrenia; 5 Hydroxytryptamine uptake inhibitor; Sigma 1 receptor antagonist
CBR-001-592-685-9,RFM-006-550-9,CBR-001-592-685-9,CN(CCNC(=O)NC[C@H]1CC[C@@H]2[C@H](O1)c1cc(ccc1N[C@H]2c1ccccc1)C(F)(F)F)C,"CBR-HVAC-06699: Hematological Cancer Therapy;Solid Tumors Therapy; Antimitotic Drugs;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors; Anticancer; CANCER; TUMOR, SOLID; HEMATOLOGICAL, NEOPLASM;"
CBR-001-592-686-0,RFM-006-551-0,CBR-001-592-686-0,CN(Cc1onc(n1)c1ncn2c1CN(C)C(=O)c1c2cccc1Cl)C,CBR-HVAC-11681: ; Hypnotic; Neurological disorders;
CBR-001-592-687-1,RFM-006-552-1,CBR-001-592-687-1,O=C(N[C@H](C(=O)NCC(=O)N1CCC(CC1)Oc1ncnc(c1)C(F)(F)F)Cc1ccccn1)/C=C/c1ccc(cc1)Cl,CBR-HVAC-11968: Treatment of Transplant Rejection;Treatment of Renal Diseases; Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Signal Transduction Modulators; Anti-inflammatory; TRANSPLANT REJECTION; INFLAMMATORY DISEASES;
CBR-001-592-688-2,RFM-006-553-2,CBR-001-592-688-2,Clc1ccc(c(c1)Cl)C(=O)NC[C@@]1(CC[C@@H](CC1)S(=O)(=O)CC1CC1)CC1CC1,CBR-HVAC-00153: Antipsychotic Drugs; GlyT-1 Inhibitors; Neuroprotectant; Antipsychotic; DEMENTIA; SCHIZOPHRENIA; Glycine transporter 1 inhibitor
CBR-001-592-689-3,RFM-006-554-3,CBR-001-592-689-3,CCCCCCCO[C@H]1[C@@H](CCNCc2ccccn2)O[C@H]2[C@@H]1OC(O2)(C)C,CBR-HVAC-07886: mistakenly synthesized analog of CBR-HVAC-12340 (GW-92527)
CBR-001-592-690-6,RFM-006-555-4,CBR-001-592-690-6,Fc1ccc(c(c1)C(F)(F)F)N1CCN([C@@H](C1)C)S(=O)(=O)c1cccc(c1)C(C(F)(F)F)(O)C,CBR-HVAC-06779: Antidiabetic Drugs; 11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors; Hypoglycemic agent; Diabetes; 11 Beta hydroxysteroid dehydrogenase inhibitor
CBR-001-592-691-7,RFM-006-556-5,CBR-001-592-691-7,COc1cc(Cc2cnc(nc2N)N)c2c(c1OC)OC(C=C2)C1CC1,CBR-HVAC-00754: Antibacterial Drugs; Dihydrofolate Reductase (DHFR) Inhibitors; Ophthalmological agent; Glaucoma; Ocular hypertension; Dihydrofolate reductase inhibitor
CBR-001-592-692-8,RFM-006-557-6,CBR-001-592-692-8,COc1cc(Cc2cnc(nc2N)N)c2c(c1OC)OC(C=C2)C1CC1,CBR-HVAC-00754: Antibacterial Drugs; Dihydrofolate Reductase (DHFR) Inhibitors; Ophthalmological agent; Glaucoma; Ocular hypertension; Dihydrofolate reductase inhibitor
CBR-001-592-693-9,RFM-006-558-7,CBR-001-592-693-9,O=C1CC(=O)[O-][Pt+2]2([O-]1)NCCN2,CBR-HVAC-07948: ; DNA inhibitor
CBR-001-592-694-0,RFM-006-559-8,CBR-001-592-694-0,NC(=N)NOCC1(COc2cc(C)cc(c2)OS(=O)(=O)c2ccccc2S(=O)(=O)C)CC1,CBR-HVAC-05950: Anticoagulants; Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; Antithrombotic; Arterial thrombosis;
CBR-001-592-695-1,RFM-006-560-1,CBR-001-592-695-1,CCOc1cc2c(cc1OCC)nc(nc2N1CCC(CC1)n1c(=O)c2cc(C)ccc2n(c1=O)C)N1CCOCC1,CBR-HVAC-11306: ; Anti-inflammatory; Anti-pancreatitis; Acute pancreatitis; Inflammation;
CBR-001-592-696-2,RFM-006-561-2,CBR-001-592-696-2,CCCc1cc(cc(c1OC)OC)C1=N[C@H](CO1)C(=O)NO,CBR-HVAC-11202: Antibacterial Drugs; UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors; Antibacterial; Gram-negative bacterial infection; Septic shock;
CBR-001-592-697-3,RFM-006-562-3,CBR-001-592-697-3,CCCc1cc(ccc1OC(C(=O)NS(=O)(=O)c1ccc(cc1)C(C)C)c1ccc2c(c1)OCO2)C(=O)O,CBR-HVAC-14237
CBR-001-592-698-4,RFM-006-563-4,CBR-001-592-698-4,NC[C@H](CP(=O)O)F,"CBR-HVAC-05556: Gastroesophageal Reflux Disease, Agents for; GABA(B) Receptor Agonists;Signal Transduction Modulators; Antispasm; Gastroesophageal reflux disease; GABA B receptor agonist"
CBR-001-592-699-5,RFM-006-564-5,CBR-001-592-699-5,C[C@H]1C[C@@H](N)C[C@H](C1)c1ccncc1NC(=O)c1ccc(c(n1)c1c(F)cccc1F)F,CBR-HVAC-07026: Non-Hodgkin's Lymphoma Therapy;Multiple Myeloma Therapy;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy;Hematopoiesis Disorders Therapy; Pim-1 Kinase Inhibitors;Pim-2 Kinase Inhibitors;Pim-3 Kinase Inhibitors;Signal Transduction Modulators;
CBR-001-592-700-1,RFM-006-565-6,CBR-001-592-700-1,C[C@H]1C[C@@H](N)C[C@H](C1)c1ccncc1NC(=O)c1ccc(c(n1)c1c(F)cccc1F)F,CBR-HVAC-07026: Non-Hodgkin's Lymphoma Therapy;Multiple Myeloma Therapy;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy;Hematopoiesis Disorders Therapy; Pim-1 Kinase Inhibitors;Pim-2 Kinase Inhibitors;Pim-3 Kinase Inhibitors;Signal Transduction Modulators;
CBR-001-592-701-2,RFM-006-566-7,CBR-001-592-701-2,CCOC(=O)CC(c1cccc2c1[nH]c(n2)CCc1ccccc1)O,CBR-HVAC-11061: Antiallergy/Antiasthmatic Drugs;Immunomodulators; IL-4 Production Inhibitors;IL-5 Production Inhibitors;Signal Transduction Modulators; Immunomodulator; Antiallergic; Allergy;
CBR-001-592-702-3,RFM-006-567-8,CBR-001-592-702-3,Clc1ccc(c(c1)Cl)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCC1CCOCC1,CBR-HVAC-06053: Antibacterial Drugs;
CBR-001-592-703-4,RFM-006-568-9,CBR-001-592-703-4,NCc1cccc(c1)C[C@@H](C(=O)NCc1ccc(cc1)C(=N)N)NC(=O)[C@H](NS(=O)(=O)Cc1cccc(c1)C(=O)O)CCCc1ccccc1,CBR-HVAC-06790: Antifibrinolytics; Kallikrein B (Plasma Kallikrein; KLKB1) Inhibitors; Blood system agent; BLEEDING DISORDERS;
CBR-001-592-704-5,RFM-006-569-0,CBR-001-592-704-5,CCOC(=O)Cc1c2CCC(Cn2c2c1cccc2F)OS(=O)(=O)C,CBR-HVAC-12029: ; Antiasthmatic; ASTHMA;
CBR-001-592-705-6,RFM-006-570-3,CBR-001-592-705-6,Fc1ccc(cc1)c1nc(c(o1)Sc1ccc(cn1)Cl)c1ccc(nc1)C(O)(C)C,CBR-HVAC-06995: Analgesic Drugs; Fatty Acid Amide Hydrolase (FAAH) Inhibitors; Unidentified pharmacological activity
CBR-001-592-706-7,RFM-006-571-4,CBR-001-592-706-7,CCCCCC(C(c1cc(OC(=O)CCCN2CCCCC2)c2c(c1)OC(C1=C2CN(CC#C)CC1)(C)C)C)C,"CBR-HVAC-03021: Non-Opioid Analgesics;Nausea and Vomiting, Treatment of; Antiemetic; Analgesics; Emesis; Pain;"
CBR-001-592-707-8,RFM-006-572-5,CBR-001-592-707-8,O/N=C\1/CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CCCC(C)C)C)C)C,"CBR-HVAC-00882: Diabetic Neuropathy, Agents for;Antiparkinsonian Drugs;Amyotrophic Lateral Sclerosis, Agents for;Multiple Sclerosis, Agents for;Huntington's Disease, Treatment of;Neurologic Drugs (Miscellaneous);Neuropathy, Treatment of ;Liver and Biliary Tract Disorders, Treatment of; Neuroprotectant; Apoptosis inhibitor; Analgesic; Diabetic neuropathy; Huntington's chorea; Motor neurone disease; Amyotrophic lateral sclerosis; Spinal muscular atrophy; Apoptosis inhibitor"
CBR-001-592-708-9,RFM-006-573-6,CBR-001-592-708-9,COc1c([nH]c(=O)c([n+]1[O-])CC(C)C)Cc1c[nH]c2c1cccc2,CBR-HVAC-10428: ; Lipid Peroxidation Inhibitors; Antioxidative; Anti-inflammatory; Cardioprotectant; Inflammation; Angina; Renal disease;
CBR-001-592-709-0,RFM-006-574-7,CBR-001-592-709-0,O=C1CCc2c(N1)ccc(c2)OCCCS(=O)c1nccn1c1ccccc1C,CBR-HVAC-08122: ; Unidentified pharmacological activity
CBR-001-592-710-3,RFM-006-575-8,CBR-001-592-710-3,O=C1CCc2c(N1)ccc(c2)OCCCS(=O)c1nccn1c1ccccc1C,CBR-HVAC-08122: ; Unidentified pharmacological activity
CBR-001-592-711-4,RFM-006-576-9,CBR-001-592-711-4,C=CCC(c1ccccc1c1noc2c1cccc2)N,CBR-HVAC-04995: Antidepressants; Drugs Acting on Hyperpolarization-activated Cyclic Nucleotide-Gated (HCN) Channels; Antidepressant; DEPRESSION;
CBR-001-592-712-5,RFM-006-577-0,CBR-001-592-712-5,C=CCC(c1ccccc1c1noc2c1cccc2)N,CBR-HVAC-04995: Antidepressants; Drugs Acting on Hyperpolarization-activated Cyclic Nucleotide-Gated (HCN) Channels; Antidepressant; DEPRESSION;
CBR-001-592-713-6,RFM-006-578-1,CBR-001-592-713-6,CC#C[C@]1(O)CCC2[C@]1(C)C[C@H](c1ccc3c(c1)OCO3)C1=C3CCC(=O)C=C3CCC21,CBR-HVAC-00504: Antidepressants; Glucocorticoid Receptor (GR) Antagonists;Signal Transduction Modulators; Antihypertensive; Antidepressant; Hypoglycemic; Antiglaucoma; Cushing's disease; Hypertension; Diabetes; Glaucoma; Obesity; Immunodeficiency; Glucocorticoid antagonist
CBR-001-592-714-7,RFM-006-579-2,CBR-001-592-714-7,NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc(cc1)SCCN1C(=O)CCC1=O,"CBR-HVAC-03563: Pancreatic Disorders, Treatment of; Trypsin Inhibitors; Hypertensive; Hypotension; Myocardial Depression; Trypsin inhibitor"
CBR-001-592-715-8,RFM-006-580-5,CBR-001-592-715-8,CC(=O)NN1CC(C)(C)C(=O)c2c1cc(cc2)S(=O)(=O)C(F)(F)F,"CBR-HVAC-10782: Hypertension, Treatment of; Potassium Channel Activators; Antihypertensive; Hypertension;"
CBR-001-592-716-9,RFM-006-581-6,CBR-001-592-716-9,COCc1nnc(n1c1ccc(nc1)OC)N1CC(C1)Oc1ccc(cc1Cl)F,"CBR-HVAC-06525: Urinary Incontinence Therapy;Disorders of Sexual Function and Reproduction, Treatment of; Oxytocin (OT) Antagonists;Signal Transduction Modulators; Antibacterial; Sexual dysfunction;"
CBR-001-592-717-0,RFM-006-582-7,CBR-001-592-717-0,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C[C@H](C(=O)[C@@H]([C@@H]2[C@]1(C)OC(=O)N2C1CN(C1)Cc1c(O)cnc2c1nccc2)C)C)(C)OC,"CBR-HVAC-11871: Antibacterial Drugs; Respiratory system agent; Macrolide antibiotic; Infection, bacterial;"
CBR-001-592-718-1,RFM-006-583-8,CBR-001-592-718-1,CCCCOc1ccc(cc1)S(=O)(=O)N1CC2(C[C@@H]1C(=O)NO)OCCCO2,CBR-HVAC-09060: ; Cardioprotectant; Myocardial infarction; Osteoarthritis;
CBR-001-592-719-2,RFM-006-584-9,CBR-001-592-719-2,CCCN(C1Cc2c(C1)cc(c(c2)C(=O)N)OCC)CCC,CBR-HVAC-11024: ; Antipsychotic; Psychosis; Schizophrenia;
CBR-001-592-720-5,RFM-006-585-0,CBR-001-592-720-5,CCCN(C1Cc2c(C1)cc(c(c2)C(=O)N)OCC)CCC,CBR-HVAC-11024: ; Antipsychotic; Psychosis; Schizophrenia;
CBR-001-592-721-6,RFM-006-586-1,CBR-001-592-721-6,O=C(c1cn(C)c2c(c1=O)cc(cc2)CN1CCOCC1)NCc1ccc(cc1)Cl,CBR-HVAC-12339: DNA Polymerase Inhibitors;
CBR-001-592-722-7,RFM-006-587-2,CBR-001-592-722-7,NNc1ccc(nn1)c1ccccc1OCC(CNC(C)(C)C)O,CBR-HVAC-08232: ; Beta adrenoreceptor antagonist
CBR-001-592-723-8,RFM-006-588-3,CBR-001-592-723-8,CC[C@@H]([C@@H]1C(=O)N[C@@H](C(=O)N1[C@@H](C(=O)N1CCOCC1)c1coc(n1)C)C1Cc2c(C1)cccc2)C,CBR-HVAC-00744: Treatment of Preterm Labor; Oxytocin (OT) Antagonists;Signal Transduction Modulators; Gynecological agent; Premature labor; Oxytocin receptor antagonist
CBR-001-592-724-9,RFM-006-589-4,CBR-001-592-724-9,N#CC1ON=C(C1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,close structural analog to CBR-HVAC-11154 (RWJ-306490) based on Cortellis database
CBR-001-592-725-0,RFM-006-590-7,CBR-001-592-725-0,NC(=N)NC(=O)c1ccc(c(c1)C(F)(F)F)N1CCN(CC1)C(=O)c1[nH]ccc1,"CBR-HVAC-05343: Antiarrhythmic Drugs;Cardioprotective Agents;Angina pectoris, Treatment of; Na+/H+ Exchanger type 1 (NHE-1) Inhibitors; Antianginal; Ischemic heart diseases;"
CBR-001-592-726-1,RFM-006-591-8,CBR-001-592-726-1,Cc1sc(c2c1c1c(CS2)cnn1C)C,CBR-HVAC-09186: ; Antipsychotic; Schizophrenia;
CBR-001-592-727-2,RFM-006-592-9,CBR-001-592-727-2,CCCC(=O)c1cnc2c(c1Nc1ccccc1C)cccc2OCCO,CBR-HVAC-04326: Gastric Antisecretory Drugs; Reversible H+/K+-ATPase Inhibitors ;
CBR-001-592-728-3,RFM-006-593-0,CBR-001-592-728-3,O=CNc1cn(c(c1)C(=O)Nc1cn(c(c1)C(=O)Nc1cn(c(c1)C(=O)NCCC(=N)N)C)C)C,"CBR-HVAC-08659: ; Antibiotic; Infection, bacterial;"
CBR-001-592-729-4,RFM-006-594-1,CBR-001-592-729-4,OC(c1ccc(c(c1)CS(=O)(=O)C)O)CNC(C)(C)C,"CBR-HVAC-08722: ; Bronchodilator; Depression, respiratory;"
CBR-001-592-730-7,RFM-006-595-2,CBR-001-592-730-7,Fc1ccc(c(c1)F)C(C(C(=O)N)(F)F)(Cn1cncn1)O,CBR-HVAC-10755: Antifungal Agents; Fungicide; Aspergillosis; Candida albicans infection;
CBR-001-592-731-8,RFM-006-596-3,CBR-001-592-731-8,Fc1ccc(c(c1)F)C(C(C(=O)N)(F)F)(Cn1cncn1)O,CBR-HVAC-10755: Antifungal Agents; Fungicide; Aspergillosis; Candida albicans infection;
CBR-001-592-732-9,RFM-006-597-4,CBR-001-592-732-9,NCCCNCCCCNC(=O)OCC(=O)NCCCCCCNC(=N)N,CBR-HVAC-04599: Immunosuppressants; Immunosuppressant; Autoimmune disorders; Transplant rejection; Immunosuppressant
CBR-001-592-733-0,RFM-006-598-5,CBR-001-592-733-0,c1[nH]cc(n1)Cc1ccc2c(c1)[nH]c1c2cccc1,"CBR-HVAC-04922: Oncolytic Drugs; 17,20 lyase inhibitor; Testosterone receptor antagonist"
CBR-001-592-734-1,RFM-006-599-6,CBR-001-592-734-1,CCN1C(C(c2ccc(c(c2)Cl)Cl)CCN2CCC(CC2)c2ccccc2S(=O)C)c2c(C1=O)cccc2,CBR-HVAC-02747: ; Antiasthmatictic; Antiallergic; Asthma; Allergy; Neurokinin 2 receptor antagonist
CBR-001-592-735-2,RFM-006-600-2,CBR-001-592-735-2,COc1ccccc1N1CCN(CC1)CCc1oc(=O)[nH]c1c1ccc(cc1)F,CBR-HVAC-01155: Antipsychotic Drugs; Antidepressant; Depression; Dopamine receptor antagonist; Alpha adrenoreceptor antagonist
CBR-001-592-736-3,RFM-006-601-3,CBR-001-592-736-3,CCCCCCCCCCCCCCCCCCc1cc2c([nH]1)ccc(c2)C(=O)O,CBR-HVAC-03398: Cholesterol inhibitor
CBR-001-592-737-4,RFM-006-602-4,CBR-001-592-737-4,COCC1=C(C(=O)OC(OC(=O)C(C)(C)C)C)N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N\O)/c1csc(n1)N,CBR-HVAC-04217: Cell wall synthesis inhibitor
CBR-001-592-738-5,RFM-006-603-5,CBR-001-592-738-5,Oc1ccc(cc1)C(c1ccc(cc1)OCc1cccc(c1)COc1ccc(cc1)C(=N)N)(C)C,CBR-HVAC-14225: metabolite of CBR-HVAC-05050
CBR-001-592-739-6,RFM-006-604-6,CBR-001-592-739-6,OCCn1c2nc(n(c2c(=O)n(c1=O)CC)Cc1ccc(c(c1)Br)OC)N[C@@H]1CCC[C@H]1O,CBR-HVAC-05708: Phosphodiesterase 5 inhibitor
CBR-001-592-740-9,RFM-006-605-7,CBR-001-592-740-9,CC(=O)NCC1CN(C(=O)O1)c1ccc(c(c1)F)OCC1(O)CCN(CC1)c1nc2n(cc(c(=O)c2cc1F)C(=O)O)C1CC1,metabolite of CBR-HVAC-06064
CBR-001-592-741-0,RFM-006-606-8,CBR-001-592-741-0,CN1CCN(CC1)C1CCN(CC1)C(=O)[C@H](CC(=O)N1CCC(CC1)N1CCc2c(NC1=O)cccc2)Cc1cc(Cl)c(c(c1)C(F)(F)F)N,CBR-HVAC-06077: Calcitonin Gene-Related Peptides (CGRP) Antagonists
CBR-001-592-742-1,RFM-006-607-9,CBR-001-592-742-1,CCNC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]([C@@H]2[C@H]1O[C@H](O2)/C=C/c1ccccc1)COP(=O)(O)O,CBR-HVAC-06152: P2Y12 (P2T) Antagonists
CBR-001-592-743-2,RFM-006-608-0,CBR-001-592-743-2,BrCC(=O)N1CC(C1)([N+](=O)[O-])[N+](=O)[O-],CBR-HVAC-07110: Vascular Disrupting Agents (VDA)
CBR-001-592-744-3,RFM-006-609-1,CBR-001-592-744-3,[O-][N+](=O)O[C@H]1CO[C@H]2[C@@H]1OC[C@@H]2NCCCn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-08427: Guanylate cyclase stimulant
CBR-001-592-745-4,RFM-006-610-4,CBR-001-592-745-4,CCC[C@@H](C(=O)NC1CCN(C1)c1c(F)cc2c3c1oc1ccccc1n3cc(c2=O)C(=O)O)N,CBR-HVAC-10982
CBR-001-592-746-5,RFM-006-611-5,CBR-001-592-746-5,OC(=O)/C=C/c1ccc(cc1)c1[nH]c2c(n1)n(CC1CCCCC1)c(=O)n(c2=O)CC1CCCCC1,CBR-HVAC-14318: metabolite of CBR-HVAC-11675
CBR-001-592-747-6,RFM-006-612-6,CBR-001-592-747-6,N#Cc1cc(CCC(=O)O)ccc1OC[C@@H](CNC(CC1Cc2c(C1)cccc2)(C)C)O,CBR-HVAC-12191: Calcium-Sensing Receptor (CaSR) Antagonists
CBR-001-593-048-0,RFM-006-613-7,CBR-001-593-048-0,OCC(C(=O)NNCc1ccc(c(c1O)O)O)N,CBR-HVAC-09686: Benserazide HCl is a peripherally-acting aromatic L-amino acid decarboxylase (AAAD) or DOPA decarboxylase inhibitor.
CBR-001-593-049-1,RFM-006-614-8,CBR-001-593-049-1,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(=O)N)CCC(=O)O)C)CCC(=O)O)CCC(=O)O)C(C)C)C(C)C)CCC(=O)O)CCCCN)CCCCN)CCC(=O)O)CCCCN)CC(C)C)CC(=O)O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CO)CC(=O)O)C)C)CC(=O)O)CO)CO)CCC(=O)O,"CBR-HVAC-04653: Thymalfasin is used as an adjuvant for both influenza and hepatitis B vaccines. Influences T-cell production and maturation, stimulates production of Th1 cytokines (interferon-gamma and interleukin-2). Ref: Annals of the New York Academy of Sciences. 2007; 1112, 326-338."
CBR-001-593-051-5,RFM-006-615-9,CBR-001-593-051-5,C=C[C@]1(C)C[C@@H](OC(=O)CSc2cccc(c2)CO)[C@]2(C)C(C)CCC3([C@H]([C@@H]1O)C)C2C(=O)CC3,CBR-HVAC-00243: Antibacterial Ophthalmic Drugs
CBR-001-593-052-6,RFM-006-616-0,CBR-001-593-052-6,C=C[C@]1(C)C[C@@H](O)[C@]2(C)C(C)CCC3([C@H]([C@@H]1O)C)C2C(=O)CC3,metabolite of CBR-HVAC-00243-A
CBR-001-593-053-7,RFM-006-617-1,CBR-001-593-053-7,OCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@@H](C23C([C@@]1(C)C(C)CC2)C(=O)CC3)C,metabolite of CBR-HVAC-00243-B
CBR-001-593-054-8,RFM-006-618-2,CBR-001-593-054-8,C/C(=C\CCC1=CC[C@@H](O[C@H]1O)C1=CC(=O)O[C@H]1O)/CCC1=C(C)CCCC1(C)C,CBR-HVAC-03642: Ornithine Decarboxylase Inhibitors; Phospholipase A2 (PLA2) Inhibitors; Signal Transduction Modulators
CBR-001-593-055-9,RFM-006-619-3,CBR-001-593-055-9,CCc1c(C)c2n3c1C=C1C(=C(C4=[N+]1[Sn]13[N+]3=C(C(=C(C3=C2)CC)C)C=c2n1c(=C4)c(c2C)CCC(=O)O)CCC(=O)O)C,CBR-HVAC-05133: Decyclizing-heme-oxygenase-inhibitors; HEME OXYGENASE Inhibitor; Haem oxygenase 1 inhibitor; Heme Oxygenase (HO) Inhibitors; Heme oxygenase inhibitor; Liver Disorders; Metabolic Disorders; Treatment of Hyperbilirubinemia
CBR-001-593-056-0,RFM-006-620-6,CBR-001-593-056-0,OCCOc1cc(O[C@@H]2O[C@H](CO[C@@H]3O[C@@H](C)[C@@H]([C@H]([C@H]3O)O)O)[C@H]([C@@H]([C@H]2O)O)O)cc2c1c(=O)cc(o2)c1ccc(c(c1)OCCO)OC,CBR-HVAC-03606: Membrane permeability inhibitor; CARDIOVASCULAR AGENT; Cardiovascular Diseases (Not Specified)
CBR-001-593-065-1,RFM-006-621-7,CBR-001-593-065-1,Clc1ccc2c3c1nc(n3CC/C/2=N\OS(=O)(=O)[O-])C1CCCCC1,CBR-HVAC-04154: Loop Diuretics;Diuretics;
CBR-001-593-066-2,RFM-006-622-8,CBR-001-593-066-2,OC(=O)CC1CCc2c1[nH]c1c2cc(cc1)OCc1ccc(c(c1)C(F)(F)F)C1CCCC1,"CBR-HVAC-07007: Multiple Sclerosis, Agents for;Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for;Antipsoriatics; Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists;Signal Transduction Modulators;"
CBR-001-593-067-3,RFM-006-623-9,CBR-001-593-067-3,OC(=O)CC1CCc2c1[nH]c1c2cc(cc1)OCc1ccc(c(c1)C(F)(F)F)C1CCCC1,"CBR-HVAC-07007: Multiple Sclerosis, Agents for;Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for;Antipsoriatics; Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists;Signal Transduction Modulators;"
CBR-001-593-068-4,RFM-006-624-0,CBR-001-593-068-4,CCOC(=O)C(NC(=O)c1c(F)cccc1F)Cc1ccc(cc1)c1c(C)n(C)c(=O)n(c1=O)C,"CBR-HVAC-07079: Multiple Sclerosis, Agents for;Antiallergy/Antiasthmatic Drugs;Rheumatoid Arthritis, Treatment of; Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Signal Transduction Modulators;"
CBR-001-593-069-5,RFM-006-625-1,CBR-001-593-069-5,CCCS(=O)(=O)N1CCN(CC1)Cc1ccc(cc1)NC(=O)c1ccc(cc1)c1cc(ccc1OC(F)(F)F)NC(=O)C1CC1,CBR-HVAC-06692: Anti-Hepatitis C Virus Drugs; HCV NS5A Inhibitors; NS5A protein Inhibitor;
CBR-001-593-070-8,RFM-006-626-2,CBR-001-593-070-8,COC(=O)CCc1nsnc1OCC(CNC(C)(C)C)O,analog of CBR-HVAC-07416 (ACC-9447)
CBR-001-593-071-9,RFM-006-627-3,CBR-001-593-071-9,Cc1c(ccc2c1NCCO2)N=C1NCCN1,CBR-HVAC-11113: Antiglaucoma Agents; alpha2-Adrenoceptor Agonists;Signal Transduction Modulators; Alpha-2 adrenergic receptor Agonist;
CBR-001-593-072-0,RFM-006-628-4,CBR-001-593-072-0,C=CC/N=C/1\S[Cu-]OC(=O)c2cc(N1)ccc2,CBR-HVAC-10172:
CBR-001-593-073-1,RFM-006-629-5,CBR-001-593-073-1,COc1ccccc1C(=C(c1ccccc1)c1ccccc1)C(=O)O,CBR-HVAC-09401: Antihyperlipidemic;
CBR-001-593-074-2,RFM-006-630-8,CBR-001-593-074-2,CCOC(=O)N1CCC(=O)N(c2c1cc(Cl)cc2)c1ccccc1,analog of CBR-HVAC-01080
CBR-001-593-075-3,RFM-006-631-9,CBR-001-593-075-3,OCC1CS[As](S1)c1ccc(c(c1)NC(=O)C)O,CBR-HVAC-10332: Leukemia Therapy;Treatment of Protozoal Diseases; Antiprotozoal;
CBR-001-593-076-4,RFM-006-632-0,CBR-001-593-076-4,N#Cc1cccc(c1)C1C=C(NC2=C1C(=O)CCC2)C(F)(F)F,CBR-HVAC-11006: Urinary Incontinence Therapy; K(ATP) Channel Activators; Potassium channel Activator;
CBR-001-593-077-5,RFM-006-633-1,CBR-001-593-077-5,N#Cc1cccc(c1)C1C=C(NC2=C1C(=O)CCC2)C(F)(F)F,CBR-HVAC-11006: Urinary Incontinence Therapy; K(ATP) Channel Activators; Potassium channel Activator;
CBR-001-593-078-6,RFM-006-634-2,CBR-001-593-078-6,O=CN(CC(C(=O)N[C@@H](C(C)(C)C)C(=O)N1CCN(CC1)Cc1nccs1)CC1CCCC1)O,CBR-HVAC-11022: Deformylase Inhibitor; Deformylase inhibitor; Peptide Deformylase (PDF) (Bacterial) Inhibitors; Antibacterial; Antibacterial Drugs; Antibiotic
CBR-001-593-079-7,RFM-006-635-3,CBR-001-593-079-7,Oc1ccc(cc1)C(P(=O)(O)O)(P(=O)(O)O)N,analog of CBR-HVAC-07511
CBR-001-593-080-0,RFM-006-636-4,CBR-001-593-080-0,CCOCCc1c(nc(n2c1ncn2)N)c1ccccc1,"CBR-HVAC-00310: Hypertension, Treatment of;Diuretics; Antihypertensive; Renal vasodilator; Diuretic; Diuretic; Alpha 1 adrenoreceptor antagonist"
CBR-001-593-081-1,RFM-006-637-5,CBR-001-593-081-1,[O-][N+](=O)/C=C(/NS(=O)(=O)c1cnccc1NC1CCCCCC1)\NC1CCCCC1,CBR-HVAC-11394: Anticonvulsant;
CBR-001-593-082-2,RFM-006-638-6,CBR-001-593-082-2,O[C@@H]([C@H](Cc1ccc(cc1)OCC(=O)N1CCOCC1)NC(=O)OC(C)(C)C)CNC[C@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)O,CBR-HVAC-10967: Protease Inhibitor;
CBR-001-593-083-3,RFM-006-639-7,CBR-001-593-083-3,COc1ccc(cc1NS(=O)(=O)c1cc(OC2CCNCC2)c2c(c1)cco2)C,CBR-HVAC-06468: Antiobesity Drugs; Signal Transduction Modulators;5-HT6 Antagonists; 5-Hydroxytryptamine 6 receptor Antagonist;
CBR-001-593-084-4,RFM-006-640-0,CBR-001-593-084-4,CN(CCCCNc1c2ccccc2nc2c1c(ccc2)[N+](=O)[O-])C,"CBR-HVAC-03283: Oncolytic Drugs;Actinic Keratoses, Agents for;"
CBR-001-593-085-5,RFM-006-641-1,CBR-001-593-085-5,CCCCSc1ccc(cc1)C(c1ccccc1)SCCN(C)C,CBR-HVAC-09713: Tranquilliser and anxiolytic agent;
CBR-001-593-086-6,RFM-006-642-2,CBR-001-593-086-6,O=C([C@H]1CCCN([C@H]1c1ccc(cc1)NC1CCCC1)C(=O)c1c(C)cccc1F)Nc1ccc(c(c1)C(F)(F)F)C,"CBR-HVAC-06895: Renal and Urinary System Genetic Disorders, Treatment of ;Treatment of Renal Diseases;Vasculitis, Agents for; C5a Anaphylatoxin Chemotactic Receptor 1 (C5aR; CD88) Antagonists;Signal Transduction Modulators; C5a inhibitor"
CBR-001-593-087-7,RFM-006-643-3,CBR-001-593-087-7,O=C([C@H]1CCCN([C@H]1c1ccc(cc1)NC1CCCC1)C(=O)c1c(C)cccc1F)Nc1ccc(c(c1)C(F)(F)F)C,"CBR-HVAC-06895: Renal and Urinary System Genetic Disorders, Treatment of ;Treatment of Renal Diseases;Vasculitis, Agents for; C5a Anaphylatoxin Chemotactic Receptor 1 (C5aR; CD88) Antagonists;Signal Transduction Modulators; C5a inhibitor"
CBR-001-593-088-8,RFM-006-644-4,CBR-001-593-088-8,COc1ccc2c(c1)[C@]1(CC1c1ccc3c(c1)[nH]nc3/C=C/c1ccc(cc1)CN1C[C@H](C)O[C@@H](C1)C)C(=O)N2,CBR-HVAC-07333: Oncolytic Drugs; Antimitotic Drugs;Polo-like Kinase-4 (Plk-4) Inhibitors;Signal Transduction Modulators;
CBR-001-593-089-9,RFM-006-645-5,CBR-001-593-089-9,COc1ccc2c(c1)[C@]1(CC1c1ccc3c(c1)[nH]nc3/C=C/c1ccc(cc1)CN1C[C@H](C)O[C@@H](C1)C)C(=O)N2,CBR-HVAC-07333: Oncolytic Drugs; Antimitotic Drugs;Polo-like Kinase-4 (Plk-4) Inhibitors;Signal Transduction Modulators;
CBR-001-593-090-2,RFM-006-646-6,CBR-001-593-090-2,O=C1CCc2c1cc(Oc1ccccc1)c(c2)NS(=O)(=O)C,CBR-HVAC-03427: COX-2 Inhibitor; Prostaglandin synthase inhibitor
CBR-001-593-091-3,RFM-006-647-7,CBR-001-593-091-3,COC[C@@]1(O)CC[C@]2([C@H](C1)CCC1C2CC[C@]2(C1CC[C@@H]2C(=O)COc1ccc2c(c1)ccc[n+]2[O-])C)C,CBR-HVAC-11411: Sedative/Hypnotics; GABA-A receptor Modulator;
CBR-001-593-092-4,RFM-006-648-8,CBR-001-593-092-4,CSC[C@@H](C(=O)N[C@H]([C@H](C(=O)OC(C)C)O)CC1CCCCC1)NC(=O)[C@@H](CC(=O)N1CCC(CC1)NC)Cc1ccccc1,CBR-HVAC-07674: Renin inhibitor
CBR-001-593-093-5,RFM-006-649-9,CBR-001-593-093-5,OC(=O)[C@H]1CC(=C(F)F)[C@H](C1)N,CBR-HVAC-00267: Neurologic Drugs (Miscellaneous);Treatment of Substance Dependency;Antiepileptic Drugs; GABA Aminotransferase Inhibitors; Gamma-aminobutyric acid transaminase Inhibitor; GABA aminotransferase inhibitor
CBR-001-593-094-6,RFM-006-650-2,CBR-001-593-094-6,NCCO[C@@H](c1ccccc1)CNC(=O)[C@@H]1C[C@H](C)CC[C@H]1C(C)C,analog of CBR-HVAC-06831
CBR-001-593-095-7,RFM-006-651-3,CBR-001-593-095-7,O=C(Nc1cccc(c1C)F)Nc1ccc(c(c1O)S(=O)(=O)[C@H]1CCCNC1)Cl,"CBR-HVAC-07002: Anti-Influenza Virus Drugs;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Chemokine CXCR2  (IL-8 beta Receptor) Antagonists;Signal Transduction Modulators; CXC chemokine receptor 2 antagonist; Chemokine receptor antagonist"
CBR-001-593-096-8,RFM-006-652-4,CBR-001-593-096-8,Clc1ccc(cc1)C(c1ccccn1)(C1=NCCN1)O,CBR-HVAC-09122:
CBR-001-593-097-9,RFM-006-653-5,CBR-001-593-097-9,O[C@H]1[C@H](OC2=NNC(=O)C3C2C3)c2cc(ccc2OC1(C)C)C#N,"CBR-HVAC-10609: Hypertension, Treatment of;Angina pectoris, Treatment of; Potassium Channel Activators; Potassium channel Opener;"
CBR-001-593-098-0,RFM-006-654-6,CBR-001-593-098-0,O[C@H]1[C@H](OC2=NNC(=O)C3C2C3)c2cc(ccc2OC1(C)C)C#N,"CBR-HVAC-10609: Hypertension, Treatment of;Angina pectoris, Treatment of; Potassium Channel Activators; Potassium channel Opener;"
CBR-001-593-099-1,RFM-006-655-7,CBR-001-593-099-1,OC(=O)[C@@H](Cc1nc2c(n1CP(=O)(O)O)ccc(c2)Cl)N,"CBR-HVAC-10382: Stroke, Treatment of;Antiepileptic Drugs; AMPA Receptor Antagonists;NR2A Antagonists;Signal Transduction Modulators; Ionotropic glutamate receptor NMDA Antagonist;"
CBR-001-593-100-7,RFM-006-656-8,CBR-001-593-100-7,Cc1ccc2c(c1)c(c1ccc(cc1)Cl)c(o2)CN(C(=O)Nc1c(F)cc(cc1F)F)Cc1ccccc1,"CBR-HVAC-11163: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-593-101-8,RFM-006-657-9,CBR-001-593-101-8,NC(=N)N/N=C(\c1cc(Cl)ccc1N)/c1ccccc1,CBR-HVAC-04176: Antiarrhythmic Drugs;
CBR-001-593-102-9,RFM-006-658-0,CBR-001-593-102-9,NC(=N)N/N=C(/c1cc(Cl)ccc1N)\c1ccccc1,CBR-HVAC-04176: Antiarrhythmic Drugs;
CBR-001-593-103-0,RFM-006-659-1,CBR-001-593-103-0,N#Cc1ccc2c(c1C(F)(F)F)cc(n2Cc1noc(n1)c1cccc(c1)C(F)(F)F)C,"CBR-HVAC-06694: Sarcopenia, Treatment of; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators;"
CBR-001-593-104-1,RFM-006-660-4,CBR-001-593-104-1,Fc1ccc(c(c1)C(F)(F)F)N1CCN([C@@H](C1)C)S(=O)(=O)c1cccc(c1)C(C(F)(F)F)(O)C,CBR-HVAC-06779: Antidiabetic Drugs; 11beta-Hydroxysteroid Dehydrogenase (11beta-HSD) Inhibitors; HYDROXYSTEROID (11-BETA) DEHYDROGENASE 1 Inhibitor; 11 Beta hydroxysteroid dehydrogenase inhibitor
CBR-001-593-105-2,RFM-006-661-5,CBR-001-593-105-2,CCOP1(=O)N=C(Nc2c1cc(cc2)NS(=O)(=O)C)C1C(=O)N(C(C1=O)C(C)(C)C)CCC(C)(C)C,CBR-HVAC-06785: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors;
CBR-001-593-106-3,RFM-006-662-6,CBR-001-593-106-3,CCOP1(=O)N=C(Nc2c1cc(cc2)NS(=O)(=O)C)C1C(=O)N(C(C1=O)C(C)(C)C)CCC(C)(C)C,CBR-HVAC-06785: Anti-Hepatitis C Virus Drugs; RNA-Directed RNA Polymerase (NS5B) Inhibitors;
CBR-001-593-107-4,RFM-006-663-7,CBR-001-593-107-4,OC(=O)CCCc1cc2c(n1S(=O)(=O)c1ccc3c(c1)scn3)ccc(c2)Cl,"CBR-HVAC-07302: Type 2 Diabetes, Agents for;Treatment of Musculoskeletal &amp; Connective Tissue Diseases (Miscellaneous);Interstitial Lung Diseases, Treatment of; Unidentified pharmacological activity"
CBR-001-593-108-5,RFM-006-664-8,CBR-001-593-108-5,C=CCN(C(Cc1ccc(c(c1)Cl)Cl)(CO)C)C,CBR-HVAC-07952: Unidentified pharmacological activity
CBR-001-593-109-6,RFM-006-665-9,CBR-001-593-109-6,N#CCCNC(=S)C1=CC(CF)(CF)Oc2c1cc(cc2)[N+](=O)[O-],"CBR-HVAC-10676: Hypertension, Treatment of; Potassium Channel Activators; Potassium channel Opener;"
CBR-001-593-110-9,RFM-006-666-0,CBR-001-593-110-9,N#C/N=C(\NC1=CC(C)(C)Oc2c1cc(C#N)cc2)/C,CBR-HVAC-10920: Nuclear factor kappa B Modulator;
CBR-001-593-111-0,RFM-006-667-1,CBR-001-593-111-0,OCc1ccccc1/C=C/Cc1cc2OCCc2cc1O,CBR-HVAC-03269: Lipoxygenase 5 Inhibitor; Prostaglandin synthase inhibitor; 5 Lipoxygenase inhibitor
CBR-001-593-112-1,RFM-006-668-2,CBR-001-593-112-1,NCCCCC1NC(=O)C(NC(=O)C(Cc2ccc(cc2)O)NC(=O)C(CSSCC(NC(=O)C(NC1=O)C(C)C)C(=O)NC(C(=O)N)C(O)C)NC(=O)C(Cc1ccc2c(c1)cccc2)N)CC1=NCc2c1cccc2,CBR-HVAC-07978: Somatostatin receptor agonist
CBR-001-593-113-2,RFM-006-669-3,CBR-001-593-113-2,CCCOc1ccc(cc1c1nc2c([nH]1)c1nncn1c(=O)n2CCC)S(=O)(=O)N1CCCN(CC1)CCO,analog of CBR-HVAC-11025 (LAS 34179)
CBR-001-593-114-3,RFM-006-670-6,CBR-001-593-114-3,O=c1[nH]c2ccc(cc2c(c1)C(F)(F)F)N1[C@H](C)CC[C@@H]1C(C(F)(F)F)O,"CBR-HVAC-06666: Hormone Replacement Therapy;Treatment of Hypogonadism;Bone Diseases, Treatment of;Treatment of Female Sexual Dysfunction;Treatment of Osteoporosis; Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators; Androgen receptor Modulator;"
CBR-001-593-115-4,RFM-006-671-7,CBR-001-593-115-4,N#Cc1nn(c2cc(Cl)c(c(c2)Cl)Oc2n[nH]c(=O)c(c2)C(C)C)c(=O)[nH]c1=O,"CBR-HVAC-06550: Lipoprotein Disorders, Treatment of ;Liver and Biliary Tract Disorders, Treatment of;Antidiabetic Drugs; Signal Transduction Modulators;Thyroid Hormone Receptor beta Agonists; Thyroid hormone receptor beta agonist"
CBR-001-593-116-5,RFM-006-672-8,CBR-001-593-116-5,C=CCN(C(=O)OCc1ccc(cc1)[N+](=O)[O-])C1CCN(CC1)C[C@H]1CN(C[C@]1(O)c1ccccc1)C(=O)C1CCCC1,CBR-HVAC-11848: Anti-HIV Agents; Chemokine CCR5 Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators; C-C CHEMOKINE RECEPTOR 5 Antagonist;
CBR-001-593-117-6,RFM-006-673-9,CBR-001-593-117-6,O=C([C@@H](NC(=O)C1CCCCN1C(=O)[C@@H](Cc1ccccc1)N)CCCN=C(N)N)Nc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-11857: 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE Agonist; Inhibitor;
CBR-001-593-118-7,RFM-006-674-0,CBR-001-593-118-7,O=C([C@@H](NC(=O)C1CCCCN1C(=O)[C@@H](Cc1ccccc1)N)CCCN=C(N)N)Nc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-11857: 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE Agonist; Inhibitor;
CBR-001-593-119-8,RFM-006-675-1,CBR-001-593-119-8,CCCc1nc(ccc1/C=C/C(=O)N[C@@H](c1cc(F)c(c(c1)F)NS(=O)(=O)C)C)C(F)(F)F,"CBR-HVAC-07151: Antipruritics;Atopic Dermatitis, Agents for;Acne Therapy; TRPV1 (Vanilloid VR1 Receptor) Antagonists; Vanilloid receptor 1 antagonist"
CBR-001-593-120-1,RFM-006-676-2,CBR-001-593-120-1,CNC(=O)c1ncc(c(c1)OC)O[C@H](C(=O)N1CCN(C[C@H]1C)C(=O)c1ccccc1)C,CBR-HVAC-09497: Anti-HIV Agents; Viral Entry Inhibitors; GP120 MEDIATED CELL-CELL FUSION INHIBITOR;
CBR-001-593-121-2,RFM-006-677-3,CBR-001-593-121-2,NC(=O)C1OC(=O)N(C1)c1ccc2c(c1)CC(=O)N2C(C)C,CBR-HVAC-11725: Antibacterial Drugs; Antibacterial;
CBR-001-593-122-3,RFM-006-678-4,CBR-001-593-122-3,NC(=O)C1OC(=O)N(C1)c1ccc2c(c1)CC(=O)N2C(C)C,CBR-HVAC-11725: Antibacterial Drugs; Antibacterial;
CBR-001-593-123-4,RFM-006-679-5,CBR-001-593-123-4,CCOC(=O)C(=Cc1ncc(n1C)[N+](=O)[O-])C(=O)C,CBR-HVAC-09368:
CBR-001-593-124-5,RFM-006-680-8,CBR-001-593-124-5,CCOC(=O)CCc1cc(Cl)ccc1C(=O)CCCNC(=O)C,"CBR-HVAC-10857: Cognition Disorders, Treatment of; Nootropic;"
CBR-001-593-125-6,RFM-006-681-9,CBR-001-593-125-6,OCC(c1cnc(cn1)NC(=O)C(c1ccc(c(c1)Cl)S(=O)(=O)C)CC1CCCC1)O,"CBR-HVAC-06094: Type 2 Diabetes, Agents for; Glucokinase Activators;"
CBR-001-593-126-7,RFM-006-682-0,CBR-001-593-126-7,OCC(c1cnc(cn1)NC(=O)C(c1ccc(c(c1)Cl)S(=O)(=O)C)CC1CCCC1)O,"CBR-HVAC-06094: Type 2 Diabetes, Agents for; Glucokinase Activators;"
CBR-001-593-127-8,RFM-006-683-1,CBR-001-593-127-8,NC(=N)NOCCNC(=O)Cn1c(C)cnc(c1=O)NCC(c1ccccc1)(F)F,CBR-HVAC-11960: Factor IIa Antagonist;
CBR-001-593-128-9,RFM-006-684-2,CBR-001-593-128-9,OC(=O)C(c1ncn(c1)C1CCCCC1)Cc1ccc(nc1)N,"CBR-HVAC-07177: Ischemic Stroke, Treatment of; Carboxypeptidase U (TAFIa) Inhibitors;"
CBR-001-593-129-0,RFM-006-685-3,CBR-001-593-129-0,CN(c1ccccc1)/N=N/N(c1ccccc1)C,CBR-HVAC-08885:
CBR-001-593-130-3,RFM-006-686-4,CBR-001-593-130-3,CC(=O)N[C@H]1CSSC(C)(C)[C@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](N(C1=O)C)CCCNC(=N)N)CC(=O)O)C(=O)N,CBR-HVAC-10724: Antiplatelet Therapy; Integrin alpha2b beta3 Antagonist;
CBR-001-593-131-4,RFM-006-687-5,CBR-001-593-131-4,COCCO[C@H]1[C@H](O)[C@H](Nc2c1ccn1c2nc(c1C)C)c1ccccc1,"CBR-HVAC-00480: Antiulcer Drugs;Ocular Genetic Disorders, Treatment of ; Reversible H+/K+-ATPase Inhibitors ; H+/K+ ATPase inhibitor; Gastric secretion inhibitor; Potassium-competitive acid antagonist"
CBR-001-593-132-5,RFM-006-688-6,CBR-001-593-132-5,CN(CCC1CCc2c(C1)ccc(c2)OCc1ccc(cc1)c1ccccc1)C,"CBR-HVAC-11780: Alzheimer's Dementia, Treatment of ; beta-Secretase 1 (BACE1) Inhibitors; BETA SECRETASE 1 INHIBITOR; AMYLOID PROTEIN DEPOSITION INHIBITOR;"
CBR-001-593-133-6,RFM-006-689-7,CBR-001-593-133-6,CN(CCC1CCc2c(C1)ccc(c2)OCc1ccc(cc1)c1ccccc1)C,"CBR-HVAC-11780: Alzheimer's Dementia, Treatment of ; beta-Secretase 1 (BACE1) Inhibitors; BETA SECRETASE 1 INHIBITOR; AMYLOID PROTEIN DEPOSITION INHIBITOR;"
CBR-001-593-134-7,RFM-006-690-0,CBR-001-593-134-7,NCCCC[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)c2cc(ccc2OCC[C@H](NC1=O)C(=O)NCC(=O)O)[N+](=O)[O-],"CBR-HVAC-06611: Dry Eye Syndrome, Treatment for;Antiglaucoma Agents; Mucin Production, Enhancers;Signal Transduction Modulators;TRKA Activators;"
CBR-001-593-135-8,RFM-006-691-1,CBR-001-593-135-8,N#C/C=C\1/c2cscc2C(=Nc2c1csc2)N1CCN(CC1)C,CBR-HVAC-02520: Sedative/Hypnotics; 5-Hydroxytryptamine 2C receptor Agonist; GABA receptor agonist
CBR-001-593-136-9,RFM-006-692-2,CBR-001-593-136-9,C[C@@H]1OC(=O)C(=C1O[Pt-2]1(OC2=C(C(=O)C)C(=O)O[C@H]2C)[NH2+][C@H]2[C@H]([NH2+]1)CCCC2)C(=O)C,CBR-HVAC-08475: DNA inhibitor
CBR-001-593-137-0,RFM-006-693-3,CBR-001-593-137-0,OC(=O)C(CC1(CCCC1)C(=O)NCCCc1ccc2c(c1)sc(n2)C)C,CBR-HVAC-11652: NEUTRAL ENDOPEPTIDASE Inhibitor;
CBR-001-593-138-1,RFM-006-694-4,CBR-001-593-138-1,OC(=O)C(CC1(CCCC1)C(=O)NCCCc1ccc2c(c1)sc(n2)C)C,CBR-HVAC-11652: NEUTRAL ENDOPEPTIDASE Inhibitor;
CBR-001-593-139-2,RFM-006-695-5,CBR-001-593-139-2,CC(=O)OCCCCc1cc2cccnc2n(c1=O)c1ccccc1,CBR-HVAC-08492: Antiulcer Drugs;Gastric Antisecretory Drugs; Gastrin inhibitor
CBR-001-593-140-5,RFM-006-696-6,CBR-001-593-140-5,ONC(=O)CN(C(=O)N1CCC[C@H]1C(=O)Nc1ccc2c(c1)OCO2)CCC1CCCC1,CBR-HVAC-09305: Peptide deformylase Inhibitor;
CBR-001-593-141-6,RFM-006-697-7,CBR-001-593-141-6,ONC(=O)CN(C(=O)N1CCC[C@H]1C(=O)Nc1nccs1)CCC1CCCC1,CBR-HVAC-09306: Peptide deformylase Inhibitor;
CBR-001-593-142-7,RFM-006-698-8,CBR-001-593-142-7,CC(n1c(=O)c(C(=O)NCCCN2CCCCC2)c(c2c1scc2)O)C,"CBR-HVAC-06348: Neurologic Drugs (Miscellaneous);Alzheimer's Dementia, Treatment of ;Posttraumatic Stress Disorder (PTSD), Treatment of; Signal Transduction Modulators;5-HT4 Partial Agonists;"
CBR-001-593-143-8,RFM-006-699-9,CBR-001-593-143-8,O=c1[nH]c2c([nH]1)cc(c(n2)C(F)(F)F)c1ccncc1,CBR-HVAC-11490: Phosphodiesterase 3 Inhibitor;
CBR-001-593-144-9,RFM-006-700-5,CBR-001-593-144-9,COc1ccc2c(c1)ccc(c2)[C@@H](C(=O)O)C,"CBR-HVAC-03093: Alzheimer's Dementia, Treatment of ;Analgesic Drugs;Ankylosing Spondylitis, Treatment of;Rheumatoid Arthritis, Treatment of;Antiarthritic Drugs;Non-Opioid Analgesics;Osteoarthritis, Treatment of;Treatment of Dysmenorrhea;Treatment of Gout; Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Prostaglandin G/H synthase Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin synthase inhibitor"
CBR-001-593-145-0,RFM-006-701-6,CBR-001-593-145-0,FC(c1cccc(c1)N1CCN(CC1)CCSc1nnc2n1cccc2)(F)F,CBR-HVAC-03706: Non-Opioid Analgesics;
CBR-001-593-146-1,RFM-006-702-7,CBR-001-593-146-1,COc1cc(CCN(CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3c(n2C)cccc3)C)ccc1OC,"CBR-HVAC-04446: Hypertension, Treatment of; Calcium Channel Blockers; Calcium channel antagonist"
CBR-001-593-147-2,RFM-006-703-8,CBR-001-593-147-2,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1cc(c(s1)CCC1CNc2c(C1)c(=O)[nH]c(n2)N)C,CBR-HVAC-04619: Colorectal Cancer Therapy;Oncolytic Drugs; Antimetabolites;Glycinamide Ribonucleotide Formyltransferase (GARTFase) Inhibitors;
CBR-001-593-148-3,RFM-006-704-9,CBR-001-593-148-3,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1cc(c(s1)CCC1CNc2c(C1)c(=O)[nH]c(n2)N)C,CBR-HVAC-04619: Colorectal Cancer Therapy;Oncolytic Drugs; Antimetabolites;Glycinamide Ribonucleotide Formyltransferase (GARTFase) Inhibitors;
CBR-001-593-149-4,RFM-006-705-0,CBR-001-593-149-4,OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CS)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)C)Cc1nc[nH]c1,"CBR-HVAC-05302: Neurologic Cancer Therapy;Oncolytic Drugs;Renal Cancer Therapy;Inflammatory Bowel Disease, Agents for; Angiogenesis Inhibitors;Integrin alphavbeta3 (Vitronectin) Antagonists;Integrin alpha5beta1 (VLA-5) Antagonists;Signal Transduction Modulators; Integrin alpha5 beta1; Integrin alpha5 beta3 Antagonist;"
CBR-001-593-150-7,RFM-006-706-1,CBR-001-593-150-7,COc1ccc(cc1)C(=O)Nc1ccc(cc1)S(=O)(=O)NC(C(=O)O)CC#CCN1CCOCC1,"CBR-HVAC-06034: Osteoarthritis, Treatment of;Acute Myocardial Infarction, Treatment of; MMP-13 (Collagenase 3) Inhibitors;MMP-2 (Gelatinase A) Inhibitors;MMP-3 (Stromelysin 1) Inhibitors;MMP-8 (Neutrophil Collagenase) Inhibitors;MMP-9 (Gelatinase B) Inhibitors; Matrix metalloproteinase Inhibitor;"
CBR-001-593-151-8,RFM-006-707-2,CBR-001-593-151-8,BrCCNP(=O)(NCCBr)OCc1cnc(n1C)[N+](=O)[O-],CBR-HVAC-06539: Hematological Cancer Therapy;Liver Cancer Therapy;Pancreatic Cancer Therapy;Astrocytoma Therapy;Digestive/Gastrointestinal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Melanoma Therapy;Sarcoma Therapy;Renal Cancer Therapy;Multiple Myeloma Therapy; DNA Alkylating Drugs; Anticancer; Alkylating agent; Bioreducible cytotoxin;
CBR-001-593-152-9,RFM-006-708-3,CBR-001-593-152-9,CCCCCCO[C@H](c1cccc(c1OC)c1csc(n1)NC(=O)c1cc(Cl)c(c(c1)Cl)/C=C(/C(=O)O)\C)C,CBR-HVAC-06659: Antithrombocytopenic; Signal Transduction Modulators;Thrombopoietin Receptor (TpoR) Agonists; Thrombopoietin agonist
CBR-001-593-153-0,RFM-006-709-4,CBR-001-593-153-0,Nc1ccn(c(=O)n1)C[C@@H]1COP(=O)(CO1)O,CBR-HVAC-04624: DNA directed DNA polymerase inhibitor; Antiviral Drugs
CBR-001-593-154-1,RFM-006-710-7,CBR-001-593-154-1,CSCC[C@@H](C(=O)O)NC(=O)c1ccc(cc1c1ccccc1C)CNCc1c[nH]cn1,CBR-HVAC-14185: metabolite of CBR-HVAC-11246
CBR-001-593-162-1,RFM-006-711-8,CBR-001-593-162-1,Brc1ccc(c(c1)NS(=O)(=O)c1cccc2c1nccn2)C(=O)N[C@@H](c1ccc(cc1F)F)C,CBR-HVAC-00203: Gastric Antisecretory Drugs; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin CCK2 receptor Modulator; CCK B receptor antagonist
CBR-001-593-163-2,RFM-006-712-9,CBR-001-593-163-2,CC(=O)N(c1cc(ccc1F)c1ccnc2n1ncc2C(=O)c1cccs1)C,CBR-HVAC-00263: Anxiolytics;Antiepileptic Drugs;Sedative/Hypnotics; Drugs Acting on GABA(A) Receptors;Signal Transduction Modulators; GABA-A RECEPTOR Modulator; GABA A receptor antagonist
CBR-001-593-164-3,RFM-006-713-0,CBR-001-593-164-3,CCCN(n1ccc2c1cccc2)c1ccncc1,"CBR-HVAC-00457: Urinary Incontinence Therapy;Cognition Disorders, Treatment of; Voltage-Gated K(V) Channel Blockers; Alpha-1 adrenergic receptor; Alpha-2 adrenergic receptor Agonist; Antagonist; Acetylcholine receptor agonist; Alpha 2 adrenoreceptor agonist; Sodium channel antagonist"
CBR-001-593-165-4,RFM-006-714-1,CBR-001-593-165-4,OC(=O)CNC(=O)Oc1cc(ccc1O)c1oc2cc(O)cc(c2c(=O)c1O)O,CBR-HVAC-00466: Oncolytic Drugs; Unidentified pharmacological activity
CBR-001-593-166-5,RFM-006-715-2,CBR-001-593-166-5,CC[C@@](C(F)(F)F)(c1nnc(o1)NCc1ccc2c(c1)oc(=O)cc2c1ccc(cc1)F)O,"CBR-HVAC-00548: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Asthma Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; 5-Lipoxygenase Inhibitors; Antiarteriosclerotic; 5 Lipoxygenase inhibitor"
CBR-001-593-167-6,RFM-006-716-3,CBR-001-593-167-6,COc1ccc2c(c1)CN(CCS2)C(=O)C(=O)O,CBR-HVAC-00675: Antiarrhythmic Drugs;Heart Failure Therapy; Drugs Acting on Ryanodine Receptor (RyR) Channels; Calcium channel antagonist
CBR-001-593-168-7,RFM-006-717-4,CBR-001-593-168-7,OC(COc1ccc(cc1)C(=O)O)CCc1ccc(cc1)C(C)(C)C,"CBR-HVAC-00781: Lipoprotein Disorders, Treatment of ; HMG-CoA synthase Inhibitor; Cholesterol synthesis inhibitor"
CBR-001-593-169-8,RFM-006-718-5,CBR-001-593-169-8,CCn1c(/N=N/N(C)C)nc2c1c(=O)n(c(=O)n2C)C,CBR-HVAC-00800: Anticancer; Unidentified pharmacological activity
CBR-001-593-170-1,RFM-006-719-6,CBR-001-593-170-1,NC(=O)c1cnc2c(c1NC1[C@@H]3CC4C[C@H]1C[C@](C3)(C4)O)cc[nH]2,"CBR-HVAC-00860: Antipsoriatics;Treatment of Transplant Rejection;Rheumatoid Arthritis, Treatment of;Inflammatory Bowel Disease, Agents for; Jak3 Inhibitors;Signal Transduction Modulators; JANUS KINASE Inhibitor; Janus kinase 1 inhibitor; Janus kinase 3 inhibitor; Immunosuppressant"
CBR-001-593-171-2,RFM-006-720-9,CBR-001-593-171-2,Clc1cccc(c1)N1CCN(CC1)CCc1n[nH]c(c1)C,CBR-HVAC-01030: Unidentified pharmacological activity
CBR-001-593-172-3,RFM-006-721-0,CBR-001-593-172-3,CCCCCOc1cccc(c1)NC(=O)O[C@H]1CCCC[C@@H]1N1CCCC1,CBR-HVAC-01063: Local Anesthetics;Antispasmodics;Anti-Helicobacter Pylori Agents;Antiulcer Drugs; Stimulates gastric mucus secretion; Sodium channel antagonist; Potassium channel antagonist; Membrane integrity inhibitor
CBR-001-593-173-4,RFM-006-722-1,CBR-001-593-173-4,CCOc1ccc2c(c1)sc(n2)SC(c1ccccc1)(C(=O)O)C,CBR-HVAC-01082: Lipid metabolism inhibitor; Cholesterol inhibitor
CBR-001-593-174-5,RFM-006-723-2,CBR-001-593-174-5,Fc1ccc2c(c1)onc2CCCN1CCC(CC1)n1c(=O)[nH]c2c1cccc2,CBR-HVAC-01094: Dopamine receptor antagonist
CBR-001-593-175-6,RFM-006-724-3,CBR-001-593-175-6,CSc1ccc(cc1)C(=O)c1cc(CC(=O)O)cc2c1occ2,CBR-HVAC-01160: Non-Opioid Analgesics; Cyclooxygenase inhibitor
CBR-001-593-176-7,RFM-006-725-4,CBR-001-593-176-7,CCCCC(CNC(=O)CC(OC(=O)CCC(=O)O)C)CC,CBR-HVAC-01644: Increases 5-HT levels; Unidentified pharmacological activity
CBR-001-593-177-8,RFM-006-726-5,CBR-001-593-177-8,CCC(=O)N([C@@H]1CCC[C@H]1N(C)C)c1ccc(c(c1)Cl)Cl,CBR-HVAC-02483: Antidepressants; Adrenergic transmitter uptake inhibitor; Alpha 2 adrenoreceptor antagonist
CBR-001-593-178-9,RFM-006-727-6,CBR-001-593-178-9,CCOC(=O)C1(CCC=CC1N(C)C)c1ccccc1,CBR-HVAC-02632: Opioid receptor mu Agonist; Opioid mu receptor agonist
CBR-001-593-179-0,RFM-006-728-7,CBR-001-593-179-0,CN(CCCN1c2ncccc2N=C(c2c1cccc2)c1ccccc1)C,CBR-HVAC-02887: Antidepressants; Norepinephrine transporter Inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-593-180-3,RFM-006-729-8,CBR-001-593-180-3,O=C(c1cc(CN2CCCC2)c(c(c1)CN1CCCC1)O)Nc1ccccc1,CBR-HVAC-02892: Antiarrhythmic Drugs; Sodium channel Blocker; Polarisation inhibitor
CBR-001-593-181-4,RFM-006-730-1,CBR-001-593-181-4,OC(COc1c(Cl)ccc(c1C(=C)n1cncc1)Cl)CNC(C)C,CBR-HVAC-02973: Antiarrhythmic Drugs; Sodium channel Blocker; Sodium channel antagonist; Acetylcholine receptor antagonist
CBR-001-593-182-5,RFM-006-731-2,CBR-001-593-182-5,CN(CCCn1cc(c(n1)c1ccccc1)c1ccccc1)C,CBR-HVAC-03043: Antidepressants; Monoamine oxidase inhibitor
CBR-001-593-183-6,RFM-006-732-3,CBR-001-593-183-6,Clc1ccc(cc1)c1nn2c(n1)c1ccccc1cc2,CBR-HVAC-03192: Contraceptives;
CBR-001-593-184-7,RFM-006-733-4,CBR-001-593-184-7,CCCc1c(OCCCSc2nnc(s2)SCC(=O)O)ccc(c1O)C(=O)C,CBR-HVAC-03463: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Leukotriene D4 receptor Antagonist; Leucotriene receptor antagonist; Leucotriene D4 antagonist; Leucotriene E4 antagonist
CBR-001-593-185-8,RFM-006-734-5,CBR-001-593-185-8,OC(c1ccc(cc1)NS(=O)(=O)C)CN1CCN(CC1)c1ccncc1,CBR-HVAC-03627: Antiarrhythmic Drugs; Potassium channel Blocker; Polarisation inhibitor
CBR-001-593-186-9,RFM-006-735-6,CBR-001-593-186-9,ClCC[N+]12CC[N+](C2)(CC1)CCCl,CBR-HVAC-03936: Oncolytic Drugs; DNA-Damaging Drugs; Unidentified pharmacological activity
CBR-001-593-187-0,RFM-006-736-7,CBR-001-593-187-0,OC(=O)CCCn1nc(ccc1=O)c1c(nn2c1cccc2)c1ccccc1,"CBR-HVAC-04098: Diuretics;Hypertension, Treatment of; Adenosine A1 Antagonists;Signal Transduction Modulators; Adenosine A1 receptor Antagonist; Adenosine A1 receptor antagonist"
CBR-001-593-188-1,RFM-006-737-8,CBR-001-593-188-1,CC(=O)N[C@H](C(=O)O)CSC(=O)c1ccccc1O,CBR-HVAC-04455: Acne Therapy;Antipsoriatics; Nonsteroidal antiinflammatory; Unidentified pharmacological activity
CBR-001-593-189-2,RFM-006-738-9,CBR-001-593-189-2,CCc1nn(/c(=N/C(=O)C2=C(CCC2)C(=O)O)/s1)Cc1ccc(cc1)c1ccccc1c1nnn[nH]1,"CBR-HVAC-04756: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 1 Antagonist; Angiotensin II antagonist"
CBR-001-593-190-5,RFM-006-739-0,CBR-001-593-190-5,CCCn1nc(c(c1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)C(=O)O)C(C)C,"CBR-HVAC-05053: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 1 Antagonist;"
CBR-001-593-191-6,RFM-006-740-3,CBR-001-593-191-6,CCOC(=O)c1ccc2c(c1)c1cc3c4cc(ccc4[nH]c3c(c1[nH]2)OC)C(=O)OCC,CBR-HVAC-05881: Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Oncolytic Drugs; Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators; AKT Inhibitor;
CBR-001-593-192-7,RFM-006-741-4,CBR-001-593-192-7,N#Cc1cncc(c1)N1C[C@@H]2[C@H]1CNC2,"CBR-HVAC-06101: Neuropathic Pain, Treatment of; Nicotinic alpha4beta2 Partial Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha4beta2 Agonist; Neuronal nicotinic receptor agonist"
CBR-001-593-193-8,RFM-006-742-5,CBR-001-593-193-8,CCOC(=O)N1CCN(CC1)C(=O)[C@@H](NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C)Cc1cccc(c1)/C(=N\O)/N,CBR-HVAC-06109: Head and Neck Cancer Therapy;Pancreatic Cancer Therapy;Breast Cancer Therapy; Urokinase (u-PA) Inhibitors;
CBR-001-593-194-9,RFM-006-743-6,CBR-001-593-194-9,CC#CCn1c(nc2c1c(=O)n(nc2)C)N1CCNCC1,CBR-HVAC-06188: Antidiabetic Drugs; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators; Dipeptidyl peptidase 4 Inhibitor;
CBR-001-593-195-0,RFM-006-744-7,CBR-001-593-195-0,OC(=O)[C@@H]1CCC[C@@H]1C(=O)c1ccc(cc1)c1ccc(c(c1)F)Nc1nc2c(s1)cc(cc2)F,"CBR-HVAC-06438: Antiobesity Drugs;Type 2 Diabetes, Agents for; Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitors;"
CBR-001-593-196-1,RFM-006-745-8,CBR-001-593-196-1,O=C(Cc1c(F)cccc1Cl)Nc1onc(c1c1ccncn1)c1ccc(cc1)F,"CBR-HVAC-06453: Inflammatory Bowel Disease, Agents for; MAPK p38 Inhibitors;Signal Transduction Modulators;"
CBR-001-593-197-2,RFM-006-746-9,CBR-001-593-197-2,CCN1CCN([C@@H]2[C@@H]1c1c(C)c3c(n1CC2)cccc3)C(C)C,CBR-HVAC-07484: Alpha 1 adrenoreceptor antagonist
CBR-001-593-198-3,RFM-006-747-0,CBR-001-593-198-3,OCc1cc(ccc1O)C(CNC(C)(C)C)O,CBR-HVAC-02587: Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Inhibitor; Beta-2-adrenergic-receptor-agonists; Short-acting beta 2 adrenoceptor (SABA) agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Bronchodilator; Bronchodilators; Obstructive Airways Disease; Respiratory Tract Disorders; Treatment of Autoimmune Diseases
CBR-001-593-199-4,RFM-006-748-1,CBR-001-593-199-4,C/C(=C\1/C(=O)OC(=O)C(=C1O)C(=O)C)/Nc1ccc(c(c1)N)O,CBR-HVAC-08346: Histamine release inhibitor; Slow releasing substance antagonist
CBR-001-593-200-0,RFM-006-749-2,CBR-001-593-200-0,OC(=O)Cc1ccc2c(c1)C(=O)c1ccccc1CN2C,CBR-HVAC-08484: Unidentified pharmacological activity
CBR-001-593-201-1,RFM-006-750-5,CBR-001-593-201-1,c1ccc(cc1)C(c1ccccc1)N1CCN(CC1)Cc1ccc2c(c1)OCO2,CBR-HVAC-08718:
CBR-001-593-202-2,RFM-006-751-6,CBR-001-593-202-2,ClCCN(CC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2OC(=O)C(N)C)C)CCl,CBR-HVAC-08738:
CBR-001-593-203-3,RFM-006-752-7,CBR-001-593-203-3,NC(=O)NC1N=C(NC1=O)O[Al](O)O,CBR-HVAC-09101:
CBR-001-593-204-4,RFM-006-753-8,CBR-001-593-204-4,Fc1ccc(cc1)C1=CCN(CC1)CCCc1nc2c(Cl)cccc2c(=O)[nH]1,"CBR-HVAC-09195: Antiparkinsonian Drugs;Ischemic Stroke, Treatment of; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Signal Transduction Modulators; Poly  ADP-ribose polymerase 1 Inhibitor;"
CBR-001-593-205-5,RFM-006-754-9,CBR-001-593-205-5,c1ccc(cc1)Cn1cc(c2c1cccc2)CCc1ccncc1,CBR-HVAC-09263:
CBR-001-593-206-6,RFM-006-755-0,CBR-001-593-206-6,COc1cc2nc3c(nc2cc1C(=O)[O-])c(C(=O)NCCN(C)C)c(c1c3cccc1)O,CBR-HVAC-09484: TOPOISOMERASE II INHIBITOR;
CBR-001-593-207-7,RFM-006-756-1,CBR-001-593-207-7,O=C(C(c1ccccc1)Oc1ccccc1)NCCCCN1C(C)CCCC1C,CBR-HVAC-10212:
CBR-001-593-208-8,RFM-006-757-2,CBR-001-593-208-8,Oc1ccc2c(c1)CC[N+]1=C2CCC2C1CCC2,CBR-HVAC-10214:
CBR-001-593-209-9,RFM-006-758-3,CBR-001-593-209-9,NC(=N)NNCCOc1c(Cl)cccc1Cl,CBR-HVAC-10269: Dopamine beta-oxidase Inhibitor;
CBR-001-593-210-2,RFM-006-759-4,CBR-001-593-210-2,O=C1O[Pt]2([NH2]C[C@@H]3[NH]2CCC3)OC(=O)C21CCC2,CBR-HVAC-10403: DNA polymerase Inhibitor;
CBR-001-593-211-3,RFM-006-760-7,CBR-001-593-211-3,O=C(NC(c1ccccc1N1CCCCC1)c1ccccc1)Cc1ccc(cc1)C(=O)O,CBR-HVAC-10478: ATP-sensitive potassium channel Inhibitor;
CBR-001-593-212-4,RFM-006-761-8,CBR-001-593-212-4,N#Cc1ccc(cc1)C(=O)CC1CCN(CC1)CC1CC1,CBR-HVAC-10509: Antipsychotic Drugs; sigma Receptor Antagonists;Signal Transduction Modulators; Opioid receptor sigma Antagonist;
CBR-001-593-213-5,RFM-006-762-9,CBR-001-593-213-5,N#CC(c1cccnc1C)N1CCN(CC1)C(=O)CNC(c1ccccc1)c1ccccc1,CBR-HVAC-10603: Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Platelet activating factor receptor Antagonist;
CBR-001-593-214-6,RFM-006-763-0,CBR-001-593-214-6,O=C1CCCN1c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-10712: Anti-inflammatory; Antiarthritic;
CBR-001-593-215-7,RFM-006-764-1,CBR-001-593-215-7,[O-][N+](=O)OCCCCOC(=O)c1ccccc1OC(=O)C,CBR-HVAC-10756: COX Inhibitor;
CBR-001-593-216-8,RFM-006-765-2,CBR-001-593-216-8,COc1cc(CCCCN2CCCN(CC2)CCCCc2cc(OC)c(c(c2)OC)OC)cc(c1OC)OC,"CBR-HVAC-10898: Cognition Disorders, Treatment of;Ischemic Stroke, Treatment of; Free radical scavenger; Neuroprotectant; Cardioprotectant; Antiischemic;"
CBR-001-593-217-9,RFM-006-766-3,CBR-001-593-217-9,Fc1ccc2c(c1)OCc1c(C2N2CCN(CC2)C/C=C/c2ccccc2)cccc1,"CBR-HVAC-11102: Cognition Disorders, Treatment of; Calcium channel Antagonist;"
CBR-001-593-218-0,RFM-006-767-4,CBR-001-593-218-0,O=C(Cc1ccccc1Nc1c(Cl)cccc1Cl)OCCCCO[N+](=O)[O-],CBR-HVAC-11148: Anti-inflammatory;
CBR-001-593-219-1,RFM-006-768-5,CBR-001-593-219-1,OCC(COP(=O)(N[C@H](C(=O)N[C@H](C(=O)O)Cc1c[nH]c2c1cccc2)CC(C)C)O)O,stereoisomer of CBR-HVAC-11159
CBR-001-593-220-4,RFM-006-769-6,CBR-001-593-220-4,Fc1ccc(cc1)Oc1ccc(cc1)CN(C(=O)Nc1c(cc(nc1S(=O)(=O)C)C)S(=O)(=O)C)C1CCCCCC1,"CBR-HVAC-11167: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-593-221-5,RFM-006-770-9,CBR-001-593-221-5,OC(=O)C1CCc2c1cc(O)c(c2)C(=O)c1ccccc1,CBR-HVAC-11183: COX Inhibitor;
CBR-001-593-222-6,RFM-006-771-0,CBR-001-593-222-6,CCOC(=O)[C@H]1CC2(c3c1cccc3)CCN(CC2)C(=O)[C@H](NC(=O)C(N)(C)C)CCCc1ccccc1,CBR-HVAC-11208: Growth Hormone Secretagogues;Signal Transduction Modulators; Growth hormone release stimulator;
CBR-001-593-223-7,RFM-006-772-1,CBR-001-593-223-7,CCOC(=O)[C@H]1CC2(c3c1cccc3)CCN(CC2)C(=O)[C@H](NC(=O)C(N)(C)C)CCCc1ccccc1,CBR-HVAC-11208: Growth Hormone Secretagogues;Signal Transduction Modulators; Growth hormone release stimulator;
CBR-001-593-224-8,RFM-006-773-2,CBR-001-593-224-8,CCCCS(=O)(=O)N[C@H](C(=O)O)CNC(=O)c1cc2n(n1)CCN(C2=O)CCC1CCNCC1,CBR-HVAC-11224: Antiplatelet Therapy; Inhibitors of Blood Coagulation Pathways;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Signal Transduction Modulators; Integrin alpha2b beta3 Antagonist;
CBR-001-593-225-9,RFM-006-774-3,CBR-001-593-225-9,Cc1ccc(cc1)S(=O)(=O)[N-]c1on[n+](n1)c1cccc(c1C)Cl,"CBR-HVAC-11250: Angina pectoris, Treatment of;Vasodilators; Nitric Oxide (NO) Donors; Antihypertensive;"
CBR-001-593-226-0,RFM-006-775-4,CBR-001-593-226-0,c1ccc2c(c1)c1nc(sc1C2)Cc1c[nH]cn1,CBR-HVAC-11535: Prokinetic Agents; Signal Transduction Modulators;5-HT3 Agonists; 5-Hydroxytryptamine 3 receptor Agonist;
CBR-001-593-227-1,RFM-006-776-5,CBR-001-593-227-1,C[C@H](n1cncc1)c1ccc2c(c1)[nH]c1c2cccc1,"CBR-HVAC-11542: Oncolytic Drugs; Steroid 17,20 lyase Inhibitor;"
CBR-001-593-228-2,RFM-006-777-6,CBR-001-593-228-2,COCCOCOCCN(C(=O)C[C@H](C(=O)N[C@H](C(=O)N[C@H]([C@H]([C@H]1OC(=O)N(C1)CC)O)CC1CCCCC1)Cc1cnc[nH]1)Cc1ccccc1)C,"CBR-HVAC-11750: Hypertension, Treatment of; Renin Inhibitors; Renin Inhibitor;"
CBR-001-593-229-3,RFM-006-778-7,CBR-001-593-229-3,Cc1cccc(n1)C(CNC(=O)C1CCN(CC1)C(=O)Cn1c(=O)sc2c1cc(Cl)cc2)O,CBR-HVAC-11955: Antiobesity Drugs; Neuropeptide Y5 (NPY Y5) Antagonists;Signal Transduction Modulators; Neuropeptide Y5 receptor Antagonist;
CBR-001-593-230-6,RFM-006-779-8,CBR-001-593-230-6,O=C1NC(=O)C(S1)Cc1ccc(cc1)OCCn1nc(C)c2c(c1=O)cccc2,CBR-HVAC-11958: Insulin receptor; PPAR gamma Modulator;
CBR-001-593-231-7,RFM-006-780-1,CBR-001-593-231-7,Nc1ccc(cn1)S(=O)(=O)Nc1cccc2c1[nH]cc2Cl,CBR-HVAC-12007: Oncolytic Drugs; Anticancer;
CBR-001-593-232-8,RFM-006-781-2,CBR-001-593-232-8,COc1c(ccc2c1C=CC(O2)(C)C)C(n1cnc2c1cccn2)C,CBR-HVAC-12034: Hypoxia-inducible factor 1 Inhibitor;
CBR-001-593-233-9,RFM-006-782-3,CBR-001-593-233-9,CCn1ncc(c1)[C@]1(N[C@H](Cc2c1[nH]c1c2cccc1)c1[nH]cc(n1)c1ccc(cn1)F)c1nn(c(=O)o1)C,"CBR-HVAC-12059: Type 2 Diabetes, Agents for; Glucose Lowering Agents;Insulin Secretagogues;Signal Transduction Modulators;Somatostatin srif1C (sst3) Antagonists;"
CBR-001-593-234-0,RFM-006-783-4,CBR-001-593-234-0,O=C1NC(=O)C2(N1)c1cc(Cl)cc(c1N(C2=O)Cc1cccc(c1)C(F)(F)F)C,CBR-HVAC-12082: Analgesic
CBR-001-593-235-1,RFM-006-784-5,CBR-001-593-235-1,OC(=O)CN(CCC(c1ccccc1)Oc1ccc(cc1)C(F)(F)F)C,CBR-HVAC-12084: Glycine transporter 1 inhibitor
CBR-001-593-236-2,RFM-006-785-6,CBR-001-593-236-2,C[C@H]1CC[C@H]([C@@H](C1)OCC(=O)Nc1cc(ccc1[N+](=O)[O-])Oc1ccc(cc1)C(=O)O)C(C)C,analog of CBR-HVAC-12094
CBR-001-593-237-3,RFM-006-786-7,CBR-001-593-237-3,OCC(=O)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-12099: Antiedematic
CBR-001-593-238-4,RFM-006-787-8,CBR-001-593-238-4,C[C@H]1CN(CCN1C(=O)c1cccnc1C)S(=O)(=O)c1ccc(cc1)C(F)(F)F,CBR-HVAC-12102: Calcium Cav2.2 channel blocker
CBR-001-593-239-5,RFM-006-788-9,CBR-001-593-239-5,Clc1ccc2c(c1)[nH]cc2C1CC(=NN1c1ccc(cc1)S(=O)(=O)N)C(F)(F)F,CBR-HVAC-12105: Cyclooxygenase 2 inhibitor; 5-Lipoxygenase inhibitor
CBR-001-593-240-8,RFM-006-789-0,CBR-001-593-240-8,COc1ccc(cc1)CN(S(=O)(=O)c1ccc(cc1)C)CCC(=O)O,CBR-HVAC-12121: DNA synthesis inhibitor; RNA synthesis inhibitor; DNA topoisomerase II inhibitor
CBR-001-593-241-9,RFM-006-790-3,CBR-001-593-241-9,OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCNC(=N)N)CC(C)C)Cc1c[nH]c2c1cccc2)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1nc[nH]c1,"CBR-HVAC-08473: GnRH (LHRH) Agonists; Luteinizing hormone releasing hormone (LHRH) agonist; Signal Transduction Modulators; Triptorelin is a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses; Antineoplastic; Breast Cancer Therapy; Endocrine Disorders (Not Specified); Endometriosis Therapy; Female Infertility, Agents for; Hirsutism Therapy; Prostate Cancer Therapy; Treatment of Aberrations of Pubertal Development; Treatment of Autoimmune Diseases; Treatment of Male Sexual Dysfunction"
CBR-001-593-246-4,RFM-006-791-4,CBR-001-593-246-4,O[C@@H](COc1cc(CCC(=O)O)cc(c1F)F)CNC(CC1Cc2c(C1)cccc2)(C)C,CBR-HVAC-00049: Treatment of Osteoporosis;Agents for Bone Repair;Hematologic Agents (Miscellaneous); Calcium-Sensing Receptor (CaSR) Antagonists;Signal Transduction Modulators; CALCIUM-SENSING RECEPTOR Antagonist; Modulator; Calcium receptor antagonist; Calcium-sensing receptor antagonist; Bone formation stimulant
CBR-001-593-247-5,RFM-006-792-5,CBR-001-593-247-5,CNS(=O)(=O)Nc1nccc(c1F)Cc1c(=O)oc2c(c1C)ccc(c2)Oc1ncccn1,CBR-HVAC-00246: Multiple Myeloma Therapy;Solid Tumors Therapy; MEK1 Inhibitors;Raf kinase B Inhibitors;Raf kinase C Inhibitors;Signal Transduction Modulators; MEK; Raf Inhibitor; MEK inhibitor; Raf kinase inhibitor
CBR-001-593-248-6,RFM-006-793-6,CBR-001-593-248-6,CCCc1c(ncn2c1nc(n2)C)Cn1ccnc1c1ncccc1F,CBR-HVAC-00446: Anxiolytics;Sedative/Hypnotics; GABA(A) Receptor Partial Agonists;Signal Transduction Modulators; GABA-A receptor alpha 3 Partial Agonist; GABA A receptor agonist
CBR-001-593-249-7,RFM-006-794-7,CBR-001-593-249-7,CCn1c2ccccc2c2c1C(C)(SCC2)CCN(C)C,CBR-HVAC-01073: Antidepressants; Drugs Acting on Adrenergic Transmission;Signal Transduction Modulators; Norepinephrine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor
CBR-001-593-250-0,RFM-006-795-8,CBR-001-593-250-0,N#C/C=C/1\c2ccc(cc2C(=Cc2c1cccc2)N1CCN(CC1)C)Cl,undesired regioisomer of CBR-HVAC-01120
CBR-001-593-251-1,RFM-006-796-9,CBR-001-593-251-1,N#C/C=C\1/c2ccc(cc2C(=Cc2c1cccc2)N1CCN(CC1)C)Cl,undesired regioisomer of CBR-HVAC-01120
CBR-001-593-252-2,RFM-006-797-0,CBR-001-593-252-2,COc1ccc(cc1)Oc1ncnc(c1)N(CCOc1ccc(cc1)CC1SC(=O)NC1=O)C,CBR-HVAC-01835: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA Agonist; Thiazolidinedione; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor alpha agonist; Insulin sensitizer; Peroxisome proliferator-activated receptor alpha/gamma agoni
CBR-001-593-253-3,RFM-006-798-1,CBR-001-593-253-3,N#CC1=C(O)[C@@]2([C@]3([C@@](C1)(C)[C@H]1CC[C@]4([C@H]([C@@H]1CC3)CC[C@]4(C)O)C)O2)C,CBR-HVAC-02770: Progesterone Receptor Antagonists;Signal Transduction Modulators; 3-Beta hydroxysteroid dehydrogenase Inhibitor; Steroid synthesis inhibitor; Hydroxysteroid dehydrogenase inhibitor
CBR-001-593-254-4,RFM-006-799-2,CBR-001-593-254-4,C[C@H]([C@H](c1ccc2c(c1)OCO2)N1CCOCC1)O,CBR-HVAC-02960: Non-Opioid Analgesics; COX Inhibitor; Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-593-255-5,RFM-006-800-8,CBR-001-593-255-5,CN1CCCN=C1COC(=O)C(c1ccccc1)(C1CCCCC1)O,CBR-HVAC-03169: Antispasmodics; Muscarinic receptor antagonist;
CBR-001-593-256-6,RFM-006-801-9,CBR-001-593-256-6,CC(N(C(C)C)CC[C@@]1(C(=O)N=C(N2[C@@H]1CCCC2)C)c1ccccc1)C,CBR-HVAC-03261: Antiarrhythmic Drugs; Sodium channel Antagonist; Sodium channel antagonist
CBR-001-593-257-7,RFM-006-802-0,CBR-001-593-257-7,CCn1c(cc2c1cc(O)cc2Cl)c1c(Cl)cc(cc1Cl)O,CBR-HVAC-03461: Oncolytic Drugs;
CBR-001-593-258-8,RFM-006-803-1,CBR-001-593-258-8,CCN(CCNC1c2cc(OC)ccc2OCc2c1cccn2)CC,CBR-HVAC-03695: Antiarrhythmic Drugs; Calcium channel antagonist
CBR-001-593-259-9,RFM-006-804-2,CBR-001-593-259-9,O=c1c2[nH]nnc2nc2n1nc(s2)CCC1CCCCC1,CBR-HVAC-03781: Antiulcer Drugs;Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Leukotriene C4 receptor; Leukotriene E4 receptor; Leukotriene D4 receptor; Leukotriene receptor Antagonist; Leucotriene D4 antagonist; Leucotriene C antagonist; Leucotriene E4 antagonist
CBR-001-593-260-2,RFM-006-805-3,CBR-001-593-260-2,Clc1ccc(cc1)n1nc2c(cc1=O)CCS(=O)c1c2cccc1,CBR-HVAC-03823: Anxiolytics; GABA(A) BZ Site Receptor Partial Agonists;Signal Transduction Modulators; Benzodiazepine receptor Agonist;
CBR-001-593-261-3,RFM-006-806-4,CBR-001-593-261-3,[N-]=[N+]=NC1CC(OC1COP(=O)(OCC1CCC(O1)n1cnc2c1nc[nH]c2=O)O)n1cc(C)c(=O)[nH]c1=O,CBR-HVAC-04069: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor;
CBR-001-593-262-4,RFM-006-807-5,CBR-001-593-262-4,O1CCc2c(C1)c1nc([nH]c1cn2)c1nocc1,"CBR-HVAC-04491: Vascular Dementia, Treatment of;Alzheimer's Dementia, Treatment of ; GABA(A) BZ Site Receptor Inverse Agonists;Signal Transduction Modulators; Benzodiazepine receptor Inverse Agonist; Benzodiazepine receptor inverse agonist"
CBR-001-593-263-5,RFM-006-808-6,CBR-001-593-263-5,OCC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)NCc1ccccc1,"CBR-HVAC-04584: Cognition Disorders, Treatment of; Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors; Prolyl endopeptidase Inhibitor; Endopeptidase inhibitor; Acetylcholine release stimulant"
CBR-001-593-264-6,RFM-006-809-7,CBR-001-593-264-6,COc1cccc(c1)C#CCO/N=C/1\CN2C[C@H]1CC2,"CBR-HVAC-04709: Alzheimer's Dementia, Treatment of ; Muscarinic M1 Agonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M1 Agonist; Muscarinic M1 receptor agonist; Muscarinic M4 receptor agonist; Muscarinic M3 receptor agonist"
CBR-001-593-265-7,RFM-006-810-0,CBR-001-593-265-7,Fc1ccc2c(c1)nc(s2)COc1ccc2c(c1)[C@@H](O)[C@H](CO2)Cc1cccc(c1)C(=O)O,CBR-HVAC-04723: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Cysteinyl leukotriene receptor 1 Antagonist;
CBR-001-593-266-8,RFM-006-811-1,CBR-001-593-266-8,Fc1ccc2c(c1)nc(s2)COc1ccc2c(c1)[C@H](O)[C@@H](CO2)Cc1cccc(c1)C(=O)O,CBR-HVAC-04723: Antiallergy/Antiasthmatic Drugs; Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Cysteinyl leukotriene receptor 1 Antagonist;
CBR-001-593-267-9,RFM-006-812-2,CBR-001-593-267-9,Fc1ccc(cc1)Nc1ncnc2c1c(cn2[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C)c1ccccc1,CBR-HVAC-04806: Antiepileptic Drugs; Adenosine Kinase Inhibitors; Adenosine kinase Inhibitor; Adenosine kinase inhibitor (AKI)
CBR-001-593-268-0,RFM-006-813-3,CBR-001-593-268-0,O=C(N(c1c(C)cccc1C)CCCc1cccnc1)[C@H](N)C,CBR-HVAC-05082: Antiarrhythmic Drugs; Thromboxane Synthase Inhibitors; Sodium channel Antagonist; Sodium channel antagonist; Thromboxane A2 receptor antagonist
CBR-001-593-269-1,RFM-006-814-4,CBR-001-593-269-1,c1cnc2c(c1)O[C@H]1[C@]3(C2)CCN(C3)CC1,"CBR-HVAC-05417: Smoking Cessation, Aid to; Nicotinic alpha4beta2 Partial Agonists;Signal Transduction Modulators; Nicotinic acetylcholine receptor alpha4beta2 Agonist; Neuronal nicotinic receptor agonist"
CBR-001-593-270-4,RFM-006-815-5,CBR-001-593-270-4,Clc1ccc(cc1)C1(CCCN(C(C(=O)O)C)C)CCc2c1ccc(c2)Cl,CBR-HVAC-05678: Antipsychotic Drugs; GlyT-1 Inhibitors;
CBR-001-593-271-5,RFM-006-816-6,CBR-001-593-271-5,OC[C@H]1Cc2c(C1)c(ccc2)Oc1cccc(c1)OS(=O)(=O)CCCC(F)(F)F,"CBR-HVAC-05731: Ischemic Stroke, Treatment of;Stroke, Treatment of;Cerebrovascular Diseases, Treatment of; Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists;Signal Transduction Modulators; Cannabinoid receptor 1 Agonist;"
CBR-001-593-272-6,RFM-006-817-7,CBR-001-593-272-6,OC[C@@H]1Cc2c(C1)c(ccc2)Oc1cccc(c1)OS(=O)(=O)CCCC(F)(F)F,"CBR-HVAC-05731: Ischemic Stroke, Treatment of;Stroke, Treatment of;Cerebrovascular Diseases, Treatment of; Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists;Signal Transduction Modulators; Cannabinoid receptor 1 Agonist;"
CBR-001-593-273-7,RFM-006-818-8,CBR-001-593-273-7,CC(=O)CCN1CCC2=C(c3c(C2C1)cccc3)C,CBR-HVAC-05865: Antipsychotic Drugs;Antiepileptic Drugs; Unidentified pharmacological activity
CBR-001-593-274-8,RFM-006-819-9,CBR-001-593-274-8,COC[C@H]1OC(=O)/C(=C\N(CC=C)CC=C)/C2=C(C(=O)C3=C([C@@]12C)[C@H](OC(=O)C)C[C@]1([C@H]3CCC1=O)C)O,CBR-HVAC-06100: Antineoplastic Enhancing Agents;Glioblastoma Multiforme Therapy;Non-Small Cell Lung Cancer Therapy;Colorectal Cancer Therapy;Oncolytic Drugs;Melanoma Therapy;Head and Neck Cancer Therapy;Solid Tumors Therapy;Prostate Cancer Therapy; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; Phosphoinositide 3 kinase Inhibitor;
CBR-001-593-275-9,RFM-006-820-2,CBR-001-593-275-9,CCN(CCOC(=O)[C@@H](NC(=O)c1c(C)cccc1Cl)Cc1ccc(cc1)NC(=O)c1c(Cl)cccc1Cl)CC,"CBR-HVAC-06273: Asthma Therapy;Multiple Sclerosis, Agents for; Integrin alpha4beta1 (VLA-4) Antagonists;Integrin alpha4beta7 (LPAM-1) Antagonists;Signal Transduction Modulators; Alpha4beta1 integrin antagonist; Alpha4beta7 integrin antagonist; Integrin antagonist; Alpha4 integrin antagonist"
CBR-001-593-276-0,RFM-006-821-3,CBR-001-593-276-0,Clc1ccc2c(c1)OC[C@@H](O2)CNS(=O)(=O)N,CBR-HVAC-06356: Antidepressants;Antiepileptic Drugs;
CBR-001-593-277-1,RFM-006-822-4,CBR-001-593-277-1,CCOc1ncc(c2c1[C@H](C(=C(N2)C)C(=O)N)c1ccc(cc1OC)C#N)C,"CBR-HVAC-06806: Heart Failure Therapy;Diabetic Nephropathy, Agents for;Treatment of Renal Diseases; Mineralocorticoid Receptor (MR) Antagonists;Signal Transduction Modulators; Aldosterone antagonist"
CBR-001-593-278-2,RFM-006-823-5,CBR-001-593-278-2,CCOc1ncc(c2c1[C@@H](C(=C(N2)C)C(=O)N)c1ccc(cc1OC)C#N)C,"CBR-HVAC-06806: Heart Failure Therapy;Diabetic Nephropathy, Agents for;Treatment of Renal Diseases; Mineralocorticoid Receptor (MR) Antagonists;Signal Transduction Modulators; Aldosterone antagonist"
CBR-001-593-279-3,RFM-006-824-6,CBR-001-593-279-3,OCCSc1ccccc1c1nnc2n1cc(cc2)Sc1ccccc1CNC(=O)Nc1cc(nn1c1ccc(c(c1)Cl)O)C(C)(C)C,"CBR-HVAC-06817: Asthma Therapy;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; MAPK14 (MAPK p38 alpha) Inhibitors;Signal Transduction Modulators;"
CBR-001-593-280-6,RFM-006-825-7,CBR-001-593-280-6,Cc1nc2cccc(c2c(=O)n1c1ccc(cc1)OC1CCN(CC1)C1CCC1)C(F)(F)F,"CBR-HVAC-06837: Cognition Disorders, Treatment of; Histamine H3 Receptor Inverse Agonists;Signal Transduction Modulators;"
CBR-001-593-281-7,RFM-006-826-8,CBR-001-593-281-7,CN(/N=N/c1ccc(cc1)C(=O)c1ccc(cc1)OCCC(=O)NCC(=O)O)C,CBR-HVAC-06853: Sarcoma Therapy;Solid Tumors Therapy;
CBR-001-593-282-8,RFM-006-827-9,CBR-001-593-282-8,OC(=O)COC[C@@H]1CC[C@H](CC1)COC(=O)N(c1ccc(cc1)Cl)c1ccccc1,"CBR-HVAC-06949: Pulmonary Hypertension, Treatment of; Prostanoid IP Agonists;Signal Transduction Modulators; Prostaglandin IP2 receptor agonist"
CBR-001-593-283-9,RFM-006-828-0,CBR-001-593-283-9,CC(S(=O)(=O)N[C@@H]1COC[C@@H]1Oc1ccc(cc1)c1ccc(s1)C#N)C,"CBR-HVAC-07058: Antipsychotic Drugs;Hearing loss, treatment of; AMPA Receptor Positive Allosteric Modulators;Signal Transduction Modulators;"
CBR-001-593-284-0,RFM-006-829-1,CBR-001-593-284-0,O=C(N([C@H](c1ccc(cc1)c1ccc(cc1)C(=O)O)CN1CCOCC1)C)CN1C(=O)COc2c1cc(Cl)c(c2)Cl,CBR-HVAC-07114: Asthma Therapy; Signal Transduction Modulators;Urotensin-II Antagonists; Urotensin II antagonist
CBR-001-593-285-1,RFM-006-830-4,CBR-001-593-285-1,O=C(NCC(=O)N[C@H](C(=O)O)CCCNC(=N)N)CCSC(=O)c1ccccc1,CBR-HVAC-07471: Radical formation stimulant
CBR-001-593-286-2,RFM-006-831-5,CBR-001-593-286-2,COc1cc(CCNCC(COc2ccc(nn2)NN=C(C)C)O)ccc1OC,CBR-HVAC-07758: Beta adrenoreceptor antagonist
CBR-001-593-287-3,RFM-006-832-6,CBR-001-593-287-3,OC(=O)[C@H](c1cc(Cl)c(c(c1)c1ccc(cc1)C(F)(F)F)OCC(F)(F)F)CC1CCC1,"CBR-HVAC-07805: Alzheimer's Dementia, Treatment of ; gamma-Secretase Modulators; Secretase gamma inhibitor"
CBR-001-593-288-4,RFM-006-833-7,CBR-001-593-288-4,OC(=O)[C@@H](c1cc(Cl)c(c(c1)c1ccc(cc1)C(F)(F)F)OCC(F)(F)F)CC1CCC1,"CBR-HVAC-07805: Alzheimer's Dementia, Treatment of ; gamma-Secretase Modulators; Secretase gamma inhibitor"
CBR-001-593-289-5,RFM-006-834-8,CBR-001-593-289-5,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCCCNC(=O)[C@@H](C(CO)(C)C)O,CBR-HVAC-07809: Omega 3 fatty acid stimulant
CBR-001-593-290-8,RFM-006-835-9,CBR-001-593-290-8,O=C(c1ccco1)CCn1c(CN2CCN(CC2)C/C=C/c2ccccc2)nc2c1cccc2,CBR-HVAC-07853: Histamine receptor antagonist; Acetylcholine receptor antagonist
CBR-001-593-291-9,RFM-006-836-0,CBR-001-593-291-9,OC(=O)CC[C@@H](C(=O)O)NC(=O)[C@@H]1CC[C@H](C1)Oc1ccc(c(c1Cl)Cl)C(=O)c1ccccc1,CBR-HVAC-08116: Prolyl endopeptidase inhibitor
CBR-001-593-292-0,RFM-006-837-1,CBR-001-593-292-0,OC(=O)CC[C@@H](C(=O)O)NC(=O)[C@H]1CC[C@@H](C1)Oc1ccc(c(c1Cl)Cl)C(=O)c1ccccc1,CBR-HVAC-08116: Prolyl endopeptidase inhibitor
CBR-001-593-293-1,RFM-006-838-2,CBR-001-593-293-1,COc1ccc2c(c1)cccc2C1COC(OC1)CCCNC(=O)C,CBR-HVAC-08347: Sodium channel antagonist; GABA A receptor agonist
CBR-001-593-294-2,RFM-006-839-3,CBR-001-593-294-2,NCc1ccc(cc1)S(=O)(=O)c1ccc(cc1)N,CBR-HVAC-08749:
CBR-001-593-295-3,RFM-006-840-6,CBR-001-593-295-3,CN1CCC(=C2c3ccccc3Oc3c2cccn3)CC1,CBR-HVAC-08945:
CBR-001-593-296-4,RFM-006-841-7,CBR-001-593-296-4,Cl[Hg]c1ccccc1O,CBR-HVAC-09161: Antiseptic
CBR-001-593-297-5,RFM-006-842-8,CBR-001-593-297-5,CN(CCCN([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CC[C@@H](C2)O)C)C,CBR-HVAC-09407: Delta 24-Reductase Blocker;
CBR-001-593-298-6,RFM-006-843-9,CBR-001-593-298-6,N#Cc1ccc(cc1)CC(=O)NC1CCN(CC1)[C@H](CN(S(=O)(=O)Cc1ccccc1)c1ccccc1)C,CBR-HVAC-09505: Anti-HIV Agents; Chemokine CCR5 Agonists;Signal Transduction Modulators; C-C CHEMOKINE RECEPTOR 5 Agonist;
CBR-001-593-299-7,RFM-006-844-0,CBR-001-593-299-7,O[C@H]1CCCC[C@@H]1n1cnc2c(c1=O)cc(c1c2cccc1)Cc1ccc(nc1)C,CBR-HVAC-09524: MUSCARINIC M1 RECEPTOR Positive allosteric modulator;
CBR-001-593-300-3,RFM-006-845-1,CBR-001-593-300-3,CC[n+]1c(/C=C/c2ccc(cc2)N2CCCC2)cccc1/C=C/c1ccc(cc1)N1CCCC1,CBR-HVAC-10132: Antihelminthic
CBR-001-593-301-4,RFM-006-846-2,CBR-001-593-301-4,CC(NC(=O)OCc1c(COC(=O)NC(C)C)c2n(c1c1ccc(c(c1)Cl)Cl)CCC2)C,CBR-HVAC-10585: Antineoplastic;
CBR-001-593-302-5,RFM-006-847-3,CBR-001-593-302-5,COc1ccc(cc1[C@](c1ccccc1OCC(=O)N)([C@H](N(C)C)C)O)C(C)(C)C,CBR-HVAC-10673: ATP-sensitive potassium channel Blocker;
CBR-001-593-303-6,RFM-006-848-4,CBR-001-593-303-6,CC(NC(=O)NS(=O)(=O)c1cnc(nc1N[C@H]1C[C@@H]2C[C@H]1CC2)N)C,CBR-HVAC-10855: Diuretics; Diuretic; Antihypertensive;
CBR-001-593-304-7,RFM-006-849-5,CBR-001-593-304-7,N#CN/C(=N\CCO[N+](=O)[O-])/c1cccnc1,"CBR-HVAC-10878: ATP-dependent potassium channel Opener; Guanylate cyclase stimulant; Potassium Channel Activators; Potassium channel agonist; Potassium-channel-agonists; Angina pectoris, Treatment of; Arrhythmias; Ischaemic Heart Disease; Vasodilator; Vasodilators"
CBR-001-593-305-8,RFM-006-850-8,CBR-001-593-305-8,CCc1[nH]c(=O)n(c1C(=O)c1ccc(cc1)n1ccnc1C)C(=O)c1ccccc1,analog of CBR-HVAC-11053
CBR-001-593-306-9,RFM-006-851-9,CBR-001-593-306-9,Nc1ccc(cc1)C(=O)N1CCc2c1ccc(c2)S(=O)(=O)N1C[C@@H](NC1=O)c1ccccc1,CBR-HVAC-11363: Oncolytic Drugs; Apoptosis inducer;
CBR-001-593-307-0,RFM-006-852-0,CBR-001-593-307-0,Nc1sc2c(n1)c1c(CC2)nc2n1cccc2,CBR-HVAC-11446: Antiulcer Drugs;Gastric Antisecretory Drugs; H+/K+-ATPase Inhibitors; H+/K+ ATPase Inhibitor;
CBR-001-593-308-1,RFM-006-853-1,CBR-001-593-308-1,COC(=O)Nc1ccc(cc1)S(=O)(=O)/N=c/1\cc([nH]c2c1c(Cl)cc(c2)Cl)C(=O)O,CBR-HVAC-11527: Glycine receptor Antagonist;
CBR-001-593-309-2,RFM-006-854-2,CBR-001-593-309-2,COc1cc2c(cc1OC)[nH]c(=O)c1c(c2=O)nn(n1)C(C(C)C)OC(=O)OC(C)C,CBR-HVAC-11782: Immunomodulator; Anti-inflammatory;
CBR-001-593-310-5,RFM-006-855-3,CBR-001-593-310-5,CC(=O)Nc1ccc(cc1OC[C@](CNC1CCN(CC1)Cc1ccc(cc1)Cl)(O)C)O,CBR-HVAC-11811: C-C chemokine receptor type 1 Antagonist;
CBR-001-593-311-6,RFM-006-856-4,CBR-001-593-311-6,O=C(c1ccccc1c1ccc(cc1)C(F)(F)F)Nc1c(C)ccc2c1nc(n2CCCCC1(C(=O)NCC(F)(F)F)c2ccccc2c2c1cccc2)C,"CBR-HVAC-11914: Lipoprotein Disorders, Treatment of ; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein Inhibitor;"
CBR-001-593-312-7,RFM-006-857-5,CBR-001-593-312-7,CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](S[C@H]1CN(C[C@H]1S)C(=O)NCCN1C(=O)c2c(C1=O)cccc2)CC(C)C,CBR-HVAC-12036: MMP-2; MMP-1; MMP-3; MMP-7; MMP-9; MT1-MMP Inhibitor;
CBR-001-593-313-8,RFM-006-858-6,CBR-001-593-313-8,CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](S[C@@H]1CN(C[C@@H]1S)C(=O)NCCN1C(=O)c2c(C1=O)cccc2)CC(C)C,CBR-HVAC-12036: MMP-2; MMP-1; MMP-3; MMP-7; MMP-9; MT1-MMP Inhibitor;
CBR-001-593-404-0,RFM-006-859-7,CBR-001-593-404-0,CC(=O)NC[C@H]1CN(C(=O)O1)c1ccc(c(c1)F)N1Cc2c(C1)cccn2,CBR-HVAC-00223: Antibacterial Drugs; Protein synthesis inhibitor; Unidentified pharmacological activity
CBR-001-593-405-1,RFM-006-860-0,CBR-001-593-405-1,COc1cc2c(cc1OCCCOc1cc3N=C[C@H]4N(C(=O)c3cc1OC)CC(=C)C4)N=C[C@H]1N(C2=O)CC(=C)C1,CBR-HVAC-00276: Leukemia Therapy;Oncolytic Drugs;Antibacterial Drugs;Ovarian Cancer Therapy; DNA-Intercalating Drugs; DNA intercalator; DNA inhibitor; Caspase 3 stimulant
CBR-001-593-406-2,RFM-006-861-1,CBR-001-593-406-2,OC[C@@H](C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1C2CCCCC2C[C@H]1C(=O)N[C@H](C(=O)O)CCCNC(=N)N)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](NC(=O)[C@H](CCCNC(=N)N)N)CCCNC(=N)N)O,"CBR-HVAC-01882: Treatment of Disorders of the Coronary Arteries and Atherosclerosis;Osteoarthritis, Treatment of;Hematologic Genetic Disorders, Treatment of ;Edema, Treatment of;Asthma Therapy;Liver and Biliary Tract Disorders, Treatment of;Dermatologic Drugs;Antiallergy/Antiasthmatic Drugs;Cardiovascular Diseases (Not Specified);Drugs for Allergic Rhinitis; Bradykinin B2 Antagonists;Signal Transduction Modulators; Bradykinin receptor B2 Antagonist; Bradykinin B2 receptor antagonist; Bradykinin B2 receptor agonist"
CBR-001-593-407-3,RFM-006-862-2,CBR-001-593-407-3,CCN(CCCC(Nc1c2cc(OC)ccc2nc2c1ccc(c2)Cl)C)CC,"CBR-HVAC-02593: Prion Diseases, Treatment of;Treatment of Protozoal Diseases;Antimalarials;Renal Cancer Therapy;Liver Cancer Therapy;Prostate Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Cytokine Production Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Secretory Phospholipase A2 (sPLA2) Inhibitors;Signal Transduction Modulators;TP53 Expression Enhancers; Nicotinic acetylcholine receptor; NADPH oxidase; Phospholipase 2 Inhibitor; Transcription factor NF-kappaB inhibitor; p53 stimulant; Acetylcholinesterase inhibitor; PI3 kinase inhibitor; mTOR kinase inhibitor; Protein kinase B inhibitor; Apoptosis stimulant; DNA inhibitor"
CBR-001-593-408-4,RFM-006-863-3,CBR-001-593-408-4,Oc1ccc2c(c1)c1c([nH]2)c(C)c2c(c1C)c[n+](cc2)C,CBR-HVAC-03068: Breast Cancer Therapy; AKT INHIBITOR;
CBR-001-593-409-5,RFM-006-864-4,CBR-001-593-409-5,CCCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C)C(=O)CSC(=O)CC,CBR-HVAC-03265: Antiallergy/Antiasthmatic Drugs;Antiarthritic Drugs; Glucocorticoid receptor Agonist; Arachidonic acid inhibitor; Immunosuppressant; Platelet activating factor antagonist
CBR-001-593-410-8,RFM-006-865-5,CBR-001-593-410-8,O=C(N([C@@H]1[C@H](Cc2c1cccc2)N1CCCC1)C)Cc1cccc(c1)[N+](=O)[O-],CBR-HVAC-04031: Diuretics;Opioid Analgesics;Antiarrhythmic Drugs; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist;
CBR-001-593-411-9,RFM-006-866-6,CBR-001-593-411-9,O=C1C=C(C)C(=O)c2c1cccc2,CBR-HVAC-04670: Hemostatics;Chemoprotective Agents; Cell Division Cycle CDC25 Phosphatase Inhibitors;Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors;Signal Transduction Modulators; DT-diaphorase Activator;
CBR-001-593-412-0,RFM-006-867-7,CBR-001-593-412-0,NCCCC[C@@H](C(=O)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)[C@@H](NC(=O)C(N)(C)C)Cc1c[nH]cn1,"CBR-HVAC-05087: Gastric Emptying Disorders,Treatment of;Treatment of Growth Hormone Deficiency; GHS Receptor Agonists;Growth Hormone Secretagogues;Signal Transduction Modulators; GHRELIN RECEPTOR Agonist;"
CBR-001-593-413-1,RFM-006-868-8,CBR-001-593-413-1,O=c1oc2c(CCc3ccccc3)c(OCCc3cncn3Cc3ccccc3)ccc2c(c1)c1ccccc1Cl,CBR-HVAC-05441: Restenosis Treatment of;Atherosclerosis Therapy; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators;
CBR-001-593-414-2,RFM-006-869-9,CBR-001-593-414-2,CC(=O)Nc1c(cccc1S(=O)(=O)NC(C(=O)N1CCC(=C(F)F)CC1)CCCc1ccc(cn1)N)c1ccccc1,CBR-HVAC-05540: Anticoagulants; Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; Thrombin Inhibitor;
CBR-001-593-415-3,RFM-006-870-2,CBR-001-593-415-3,CCN(C(=O)c1ccc(c(c1)[C@@]1(C)c2cc(Cl)ccc2N(C1=O)Cc1ccc(cc1OC)OC)Cl)Cc1cccnc1,CBR-HVAC-05879: Treatment of Preterm Labor; Oxytocin (OT) Antagonists;Signal Transduction Modulators; Oxytocin receptor Antagonist;
CBR-001-593-416-4,RFM-006-871-3,CBR-001-593-416-4,COCc1cc(OC)c(c(c1)OC)c1cccc2n1nc(c2N(CC1CC1)CC1CCOCC1)CC,CBR-HVAC-06084: Anxiolytics;Antidepressants; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing factor 1 receptor antagonist; Corticotropin releasing factor antagonist
CBR-001-593-417-5,RFM-006-872-4,CBR-001-593-417-5,CN(CCNC(=O)Cn1c2ccc(cc2c2c1nc1cc(C)c(cc1n2)C)Cl)C,"CBR-HVAC-06351: Rheumatoid Arthritis, Treatment of;Multiple Sclerosis, Agents for; CD45 antagonist"
CBR-001-593-418-6,RFM-006-873-5,CBR-001-593-418-6,O=c1n(CCn2[se]c3c(c2=O)cccc3)[se]c2c1cccc2,CBR-HVAC-06552: Oncolytic Drugs;
CBR-001-593-419-7,RFM-006-874-6,CBR-001-593-419-7,CC(COC(=O)[C@@H](NP(=O)(N[C@H](C(=O)OCC(C)C)Cc1ccccc1)COCCn1cnc2c1nc(N)nc2NC1CC1)Cc1ccccc1)C,CBR-HVAC-06669: Anti-Papilloma Virus Drugs; DNA synthesis inhibitor;
CBR-001-593-420-0,RFM-006-875-7,CBR-001-593-420-0,Cc1c(ccc2c1nccn2)NC1=NCCN1,CBR-HVAC-07434: Alpha 2 adrenoreceptor agonist
CBR-001-593-421-1,RFM-006-876-8,CBR-001-593-421-1,Clc1ccc(cc1)c1oc2c(c1)c(=O)n(cc2)c1ccc2c(c1)cnn2CCN1CCCC1,CBR-HVAC-07437: Antiobesity Drugs; Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists;Signal Transduction Modulators; Melanin concentrating hormone-1 receptor antagonist
CBR-001-593-422-2,RFM-006-877-9,CBR-001-593-422-2,O=C(C(c1cccs1)(c1cccs1)O)O[C@@H]1C[C@H]2[C@@H]3[C@H]([C@@H](C1)[N+]2(C)C)O3,"CBR-HVAC-01991: Long-acting muscarinic antagonist; Muscarinic M3 Receptor Antagonists; Muscarinic M3 receptor antagonist; Muscarinic Receptor Antagonists; Muscarinic acetylcholine receptor Antagonist; Signal Transduction Modulators; Anticholinergic; Asthma Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Cystic Fibrosis, Treatment of"
CBR-001-593-423-3,RFM-006-878-0,CBR-001-593-423-3,C1CCCC(=NCC1)N/C(=N\c1ccccc1)/N1CCOCC1,CBR-HVAC-07613: Unidentified pharmacological activity
CBR-001-593-424-4,RFM-006-879-1,CBR-001-593-424-4,CC[C@@H](Nc1nc(C)nc2n1nc(c2c1c(C)cc(cc1OC)OC)C)C,CBR-HVAC-07917: Corticotropin releasing factor 1 receptor antagonist; Corticotropin releasing factor 2 receptor antagonist
CBR-001-593-425-5,RFM-006-880-4,CBR-001-593-425-5,NCCC(=O)N1[Zn]OC(=O)[C@@H]1Cc1cnc[nH]1,CBR-HVAC-08220: Mucus protecting agent
CBR-001-593-426-6,RFM-006-881-5,CBR-001-593-426-6,OC(=O)c1cc(=O)c2c(o1)cc1c(c2)c2ccccc2C(O1)(C)C,CBR-HVAC-08226: 5 Hydroxytryptamine release inhibitor; Histamine release inhibitor; Bradykinin receptor antagonist
CBR-001-593-427-7,RFM-006-882-6,CBR-001-593-427-7,CC(COC(=O)C1(F)C(=O)NC(=O)NC1O/N=C/c1ccco1)C,CBR-HVAC-08398: Thymidylate synthase inhibitor; DNA synthesis inhibitor
CBR-001-593-428-8,RFM-006-883-7,CBR-001-593-428-8,O=C1NC(=O)C2=C(C1=Cc1ccccc1)CCCC2,CBR-HVAC-08758:
CBR-001-593-429-9,RFM-006-884-8,CBR-001-593-429-9,NNC(=O)CC#N,CBR-HVAC-08804: Antibacterial
CBR-001-593-430-2,RFM-006-885-9,CBR-001-593-430-2,C[C@@]12Cc3cnoc3C(C2=CC[C@@H]2[C@@H]1CC[C@]1([C@H]2CC[C@]1(C)O)C)(C)C,CBR-HVAC-09409: 3 beta-Hydroxysteroid dehydrogenase Inhibitor;
CBR-001-593-431-3,RFM-006-886-0,CBR-001-593-431-3,ClC(COP(=O)(O)O)(Cl)Cl,"CBR-HVAC-09674: The primary central nervous system effects are attributed to its active metabolite, trichlorethanol;"
CBR-001-593-432-4,RFM-006-887-1,CBR-001-593-432-4,[O-][N+](=O)OCCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-],CBR-HVAC-10210:
CBR-001-593-433-5,RFM-006-888-2,CBR-001-593-433-5,CCOC(=O)c1ccc(cc1NC(=O)c1ccc(cc1)C(=O)O)NC(=O)CC,CBR-HVAC-03680: Antiallergy/Antiasthmatic Drugs; Cyclic AMP stimulant
CBR-001-593-434-6,RFM-006-889-3,CBR-001-593-434-6,CC[C@@H]([C@@H](C(=O)n1nc(c2c1nc1ccc(cc1c2Cl)OC)C)N)C,CBR-HVAC-10975: Antiviral;
CBR-001-593-435-7,RFM-006-890-6,CBR-001-593-435-7,Cc1ccn(n1)c1ccc(c(c1)C(F)(F)F)C(=O)N1Cc2cccnc2Nc2c1cccc2,CBR-HVAC-11507: Treatment of Renal Diseases;Antidiuretics; Signal Transduction Modulators;Vasopressin (AVP) V2 Receptor Agonists; Arginine vasopressin receptor 2 Agonist;
CBR-001-593-436-8,RFM-006-891-7,CBR-001-593-436-8,OCCn1c(CN2CCN(CC2=O)S(=O)(=O)c2cc3c(s2)cc(cc3)Cl)cc2c1ccnc2,CBR-HVAC-11749: Coagulation factor Xa Antagonist;
CBR-001-593-437-9,RFM-006-892-8,CBR-001-593-437-9,C1CCC2(CC1)OOC1(O2)C2CC3CC1CC(C2)C3,CBR-HVAC-11789: Antimalarials; Antiparasitic;
CBR-001-593-438-0,RFM-006-893-9,CBR-001-593-438-0,OCC(COc1ccc(cc1)CCCCNC(=N)NC(=O)c1nc(Cl)c(nc1N)N)O,CBR-HVAC-11851: Sodium channel blocker; Sodium channel blocker;
CBR-001-593-439-1,RFM-006-894-0,CBR-001-593-439-1,NC(=N)NCCC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N)CCCNC(=N)N)C)CCCNC(=N)N)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)C)CSSC[C@@H](C(=O)O)N)C)CCCNC(=N)N,CBR-HVAC-12003: CALCIUM SENSING RECEPTOR Inhibitor;
CBR-001-593-440-4,RFM-006-895-1,CBR-001-593-440-4,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)Cc1c[nH]c2c1cccc2)CC(=O)N)Cc1c[nH]c2c1cccc2)CC(C)C)CO)C)Cc1c[nH]c2c1cccc2)CCCCN)CC(=O)O)CC(C)C)CCC(=O)O)CC(C)C)CC(C)C)CCC(=O)O)CCC(=O)N)CCC(=O)O)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)C)CO)CC(C)C)Cc1c[nH]cn1)CO)CC(C)C)CCC(=O)O)CCC(=O)O)CO)CCC(=O)N)CC(=O)N)CCC(=O)N)CCC(=O)N)CCC(=O)O,CBR-HVAC-12247: HIV Fusion Inhibitors
CBR-001-593-441-5,RFM-006-896-2,CBR-001-593-441-5,COCCn1/c(=N/C(=O)C2C(C2(C)C)(C)C)/sc(c1C)C,CBR-HVAC-12250: Cannabinoid Receptor 2 agonist
CBR-001-593-442-6,RFM-006-897-3,CBR-001-593-442-6,Cc1cc(NC2CCCCC2)nc(n1)n1nc(cc1C)C,"CBR-HVAC-12253: Small Conductance SK(Ca) 2.3 (SK3, SKCa3, hKCa3) Channel Activators"
CBR-001-593-443-7,RFM-006-898-4,CBR-001-593-443-7,Fc1cccc(c1)n1cc(C)ccc1=O,CBR-HVAC-12256: MAPK p38 Inhibitors; TGF-beta Inhibitors; Signal Transduction Modulators; TNF-alpha Production Inhibitors
CBR-001-593-444-8,RFM-006-899-5,CBR-001-593-444-8,CCCNC(=O)c1c(sc2c1CCOC2)NC(=O)C12CC3CC(C2)CC(C1)C3,CBR-HVAC-12269: Cannabinoid CB2 receptor agonist
CBR-001-593-445-9,RFM-006-900-1,CBR-001-593-445-9,CCn1c(=O)[nH]c2c1cccc2,CBR-HVAC-12272: Potassium Channel Activators
CBR-001-593-446-0,RFM-006-901-2,CBR-001-593-446-0,Clc1ccccc1Cn1ccc(cc1=O)OCCCn1c2ccccc2c2c1cccc2,CBR-HVAC-12291: Inhibin alpha inhibitor
CBR-001-593-447-1,RFM-006-902-3,CBR-001-593-447-1,CCOc1ccc2c(c1)c(ccn2)[C@H]([C@@H]1CC2CCN1C[C@@H]2CC)O,CBR-HVAC-12294:
CBR-001-593-448-2,RFM-006-903-4,CBR-001-593-448-2,N#Cc1cccc(c1)C(=O)c1cc(Cl)ccc1OCC(=O)Nc1ccc(cc1C)S(=O)(=O)N,CBR-HVAC-12298: Reverse transcriptase inhibitor
CBR-001-593-449-3,RFM-006-904-5,CBR-001-593-449-3,COc1cc2c(cc1OC)CCN(C2C)S(=O)(=O)c1cn(c(n1)C)C,CBR-HVAC-12299: Cystic fibrosis transmembrane conductance regulator corrector
CBR-001-593-450-6,RFM-006-905-6,CBR-001-593-450-6,CCCCc1c([nH]c2c1nccn2)c1ccccc1F,CBR-HVAC-12313: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CHLORIDE CHANNEL ACTIVATOR
CBR-001-593-451-7,RFM-006-906-7,CBR-001-593-451-7,Cc1cccc(n1)c1[nH]c(nc1c1ccc2c(c1)nccn2)C(C)(C)C,CBR-HVAC-12314: Activin receptor like kinase 5 inhibitor; Transforming growth factor beta 1 inhibitor
CBR-001-593-452-8,RFM-006-907-8,CBR-001-593-452-8,CCC(=O)SCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,metabolite of  CBR-HVAC-03265
CBR-001-593-453-9,RFM-006-908-9,CBR-001-593-453-9,CC1c2ccccc2Cn2c1c1C(=O)c3cccc(c3C(=O)c1c2)O,metabolite of CBR-HVAC-03708
CBR-001-593-454-0,RFM-006-909-0,CBR-001-593-454-0,CC(=CCOc1cc(ccc1Cl)NC(=O)c1ccoc1C)C,CBR-HVAC-14148: metabolite of CBR-HVAC-04820
CBR-001-593-455-1,RFM-006-910-3,CBR-001-593-455-1,OC1CC2C3C(C(C1)[N+]2(C)C)O3,metabolite of CBR-HVAC-07514
CBR-001-593-456-2,RFM-006-911-4,CBR-001-593-456-2,O=C1NC(=O)C(S1)Sc1ccc2c(c1)cccc2,metabolite of CBR-HVAC-10477
CBR-001-593-457-3,RFM-006-912-5,CBR-001-593-457-3,CNC(=S)C1(CCCC[S+]1[O-])c1cccnc1,stereoisomer of CBR-HVAC-03760
CBR-001-593-458-4,RFM-006-913-6,CBR-001-593-458-4,CNC(=S)C1(CCCC[S+]1[O-])c1cccnc1,stereoisomer of CBR-HVAC-03760
CBR-001-593-459-5,RFM-006-914-7,CBR-001-593-459-5,CNC(=S)C1(CCCC[S+]1[O-])c1cccnc1,stereoisomer of CBR-HVAC-03760
CBR-001-593-460-8,RFM-006-915-8,CBR-001-593-460-8,CNC(=S)C1(CCCC[S+]1[O-])c1cccnc1,stereoisomer of CBR-HVAC-03760
CBR-001-593-461-9,RFM-006-916-9,CBR-001-593-461-9,FC(c1c(nc2c(c1C1CCCCC1)[C@@H](O)CC(C2)(C)C)C1CCCC1)c1ccc(cc1)C(F)(F)F,stereoisomer of CBR-HVAC-11827
CBR-001-593-462-0,RFM-006-917-0,CBR-001-593-462-0,FC(c1c(nc2c(c1C1CCCCC1)[C@@H](O)CC(C2)(C)C)C1CCCC1)c1ccc(cc1)C(F)(F)F,stereoisomer of CBR-HVAC-11827
CBR-001-593-463-1,RFM-006-918-1,CBR-001-593-463-1,Clc1ccccc1C(=O)c1cccnc1c1nnn(c1c1ccncc1)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-00664: Social Phobia, Treatment for;Atopic Dermatitis, Agents for;Treatment of Alcohol Dependency; Signal Transduction Modulators;Tachykinin NK1 Antagonists; Neurokinin 1 receptor antagonist; Neurokinin 1 receptor antagonist"
CBR-001-593-464-2,RFM-006-919-2,CBR-001-593-464-2,Clc1ccc(cc1)OC[C@@H]1CN2[C@@](O1)(CCC2=O)c1ccc(c(c1)Cl)Cl,CBR-HVAC-02698: Insulin sensitizer; Unidentified pharmacological activity
CBR-001-593-465-3,RFM-006-920-5,CBR-001-593-465-3,COCCCC/C(=N/OCCN)/c1ccc(cc1)Cl,CBR-HVAC-02938: Antidepressants; 5-Hydroxytryptamine transporter Inhibitor; 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-593-466-4,RFM-006-921-6,CBR-001-593-466-4,O=C[C@@H]1CCCN1C(=O)CCC(=O)NCc1ccc(cc1)Cl,"CBR-HVAC-03661: Cognition Disorders, Treatment of; Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors; Prolyl endopeptidase Inhibitor;"
CBR-001-593-467-5,RFM-006-922-7,CBR-001-593-467-5,CCOC(=O)c1ccc(cc1NC(=O)c1ccc(cc1)C(=O)O)NC(=O)CC,CBR-HVAC-03680: Antiallergy/Antiasthmatic Drugs; Cyclic AMP stimulant
CBR-001-593-468-6,RFM-006-923-8,CBR-001-593-468-6,CC(c1cc(CC2SCNC2=O)cc(c1O)C(C)(C)C)(C)C,"CBR-HVAC-04177: Inflammatory Bowel Disease, Agents for; Antioxidant; Free radical scavenger; Reducing agent; Free radical scavenger"
CBR-001-593-469-7,RFM-006-924-9,CBR-001-593-469-7,OC(=O)CCCn1cc(c2c1cccc2)C(=O)c1cccc(c1)NC(c1ccc(cc1)CC(C)C)c1ccc(cc1)CC(C)C,CBR-HVAC-04248: Benign Prostatic Hyperplasia Therapy; Steroid 5alpha-Reductase Inhibitors; Steroid 5-alpha-reductase Inhibitor; 5 Alpha reductase
CBR-001-593-470-0,RFM-006-925-0,CBR-001-593-470-0,Nc1ccc(cc1)SC[C@@H]1CO[C@](O1)(CCc1ccc(cc1)Cl)Cn1ccnc1,"CBR-HVAC-04363: Lipoprotein Disorders, Treatment of ; Lanosterol 14alpha-demethylase Inhibitors; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor"
CBR-001-593-471-1,RFM-006-926-1,CBR-001-593-471-1,COc1ccc(cc1)CCN1CCC[C@@H]1CN1c2ccccc2OCc2c1cccc2,"CBR-HVAC-05422: Irritable Bowel Syndrome, Agents for; L-Type Calcium Channel Blockers; Calcium channel Antagonist;"
CBR-001-593-472-2,RFM-006-927-2,CBR-001-593-472-2,COc1cccc(c1c1ccc(cc1)C(F)(F)F)C(=O)Nc1ccc2c(c1)CCN(C2)C(=O)Oc1ccccc1,"CBR-HVAC-06294: Lipoprotein Disorders, Treatment of ;Type 2 Diabetes, Agents for;Antiobesity Drugs; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors;"
CBR-001-593-473-3,RFM-006-928-3,CBR-001-593-473-3,N#Cc1ccc(c(c1)C(=O)NCCN1CCC(CC1)C(=O)c1ccc(cc1)F)OC,CBR-HVAC-08231: Dopamine receptor antagonist
CBR-001-593-474-4,RFM-006-929-4,CBR-001-593-474-4,COc1c(OC)cccc1C(=O)N[C@@H]1C[C@H]2CC[C@@H](C1)N2Cc1ccccc1,CBR-HVAC-08477: Dopamine D2 receptor antagonist
CBR-001-593-475-5,RFM-006-930-7,CBR-001-593-475-5,CCCC[C@@H](C(=O)N(Cc1cccs1)Cc1cccs1)NC(=O)N[C@H](c1ccc2c(c1)OCO2)CC(=O)O,CBR-HVAC-09182: Antiarthritic Drugs;Antiallergy/Antiasthmatic Drugs; Integrin alpha4beta1 (VLA-4) Antagonists;Signal Transduction Modulators;VCAM-1 Antagonists; Integrin alpha4; Integrin beta 1; Vascular cell adhesion molecule 1 Antagonist;
CBR-001-593-476-6,RFM-006-931-8,CBR-001-593-476-6,CN(CCC(c1ccccc1)Oc1ccc2c(c1)c(=O)cc(o2)c1ccccc1)C,CBR-HVAC-09403:
CBR-001-593-477-7,RFM-006-932-9,CBR-001-593-477-7,COC1(CCN(CC1)CCc1c[nH]c2c1cc(F)cc2)CS(=O)c1ccccc1,CBR-HVAC-10843: Tachykinin receptor 2 Antagonist;
CBR-001-593-478-8,RFM-006-933-0,CBR-001-593-478-8,CCCCc1c(Cc2ccc(cc2)c2ccccc2c2nnn[nH]2)c(O)nc2n1ncn2,"CBR-HVAC-10966: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 1 Antagonist;"
CBR-001-593-479-9,RFM-006-934-1,CBR-001-593-479-9,OCC(c1cnc(c(c1)Cl)N1CCN([C@@H](C1)C)c1nc2c([nH]1)cc(cc2c1cc(F)c(c(c1)F)F)C(F)(F)F)O,CBR-HVAC-11714: Non-Opioid Analgesics; TRPV1 (Vanilloid VR1 Receptor) Antagonists; Vascular endothelial growth factor receptor 2 Antagonist;
CBR-001-593-480-2,RFM-006-935-2,CBR-001-593-480-2,CC(OC(=O)CNc1cccc(n1)CN(S(=O)(=O)c1cccnc1)Cc1ccc(cc1)n1cccn1)C,CBR-HVAC-12071: Prostaglandin EP2 receptor agonist
CBR-001-593-482-4,RFM-006-936-3,CBR-001-593-482-4,O=C(c1sc2c(c1O)cc(cc2)C(F)(F)F)N/C=C(\c1cccs1)/c1ccccc1,CBR-HVAC-07971
CBR-001-593-483-5,RFM-006-937-4,CBR-001-593-483-5,NC(=NC(=O)c1cc2CCCCC(c2nc1C)COS(=O)(=O)O)N,"CBR-HVAC-06476: Acute Myocardial Infarction, Treatment of; Na+/H+ Exchanger type 1 (NHE-1) Inhibitors;"
CBR-001-593-484-6,RFM-006-938-5,CBR-001-593-484-6,CCC(C(=O)C(=O)N1CCCCC1C(=O)OC(c1cccc(c1)OCC(=O)Nc1c(/N=N/c2ccc(cc2)c2ccc(cc2)/N=N/c2cc(c3c(c2N)cccc3)S(=O)(=O)O)cc(c2c1cccc2)S(=O)(=O)O)CCc1ccc(c(c1)OC)OC)(C)C,"CBR-HVAC-06048: Alzheimer's Dementia, Treatment of ;Antiparkinsonian Drugs; Antiamyloidogenic Agents;"
CBR-001-593-485-7,RFM-006-939-6,CBR-001-593-485-7,CN(CC(=O)O)C/C=C(\c1ccccc1)/C#Cc1ccc(cc1)c1cocc1,"CBR-HVAC-05516: Alzheimer's Dementia, Treatment of ;Cognition Disorders, Treatment of;Antipsychotic Drugs; GlyT-1 Inhibitors;"
CBR-001-593-486-8,RFM-006-940-9,CBR-001-593-486-8,COc1ccc2c(c1)ccc(c2)[C@@H](C(=O)OCCS(=O)(=O)C)C,"CBR-HVAC-00535: Antiarthritic Drugs;Osteoarthritis, Treatment of;Inflammation, Treatment of;Analgesic Drugs; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-593-487-9,RFM-006-941-0,CBR-001-593-487-9,NCCCC[C@@H](C(=O)Nc1ccc(c(c1)C(=O)N[C@H](C(=O)Nc1ccc(c(c1)C(=O)N)OC)CCCCN)OC)NC(=O)c1cc(ccc1OC)NC(=O)[C@@H](NC(=O)c1cc(ccc1OC)NC(=O)[C@H](CCCCN)N)CCCCN,CBR-HVAC-00067: Anticoagulant-Reversing Agents; Heparin Neutralizers; Heparin; Low molecular weight heparin Antagonist; Thrombin stimulant; Heparin inhibitor
CBR-001-593-488-0,RFM-006-942-1,CBR-001-593-488-0,C[C@H]1COCCN1c1nc(C)c(c(n1)n1cncc1)[N+](=O)[O-],CBR-HVAC-05387: CMV primase inhibitor; Cytomegalovirus-replication-inhibitors; DNA primase Inhibitor; Anti-Cytomegalovirus Drugs; Antiviral; Prophylactic agent; Viral Infections
CBR-001-593-489-1,RFM-006-943-2,CBR-001-593-489-1,CCCN(c1cc(C)nc2n1nc(c2c1cnc(cc1C)N(C)C)C)CCC,CBR-HVAC-04975: Antidepressants;Anxiolytics; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing factor antagonist; Corticotropin releasing factor 1 receptor antagonist
CBR-001-593-490-4,RFM-006-944-3,CBR-001-593-490-4,Fc1ccc(c(c1)F)[C@]([C@H](N1CCN(C1=O)c1ccc(cc1)n1cnnn1)C)(Cn1ncnc1)O,CBR-HVAC-11065: Antifungal Agents; Lanosterol 14 alpha-demethylase Inhibitor;
CBR-001-593-491-5,RFM-006-945-4,CBR-001-593-491-5,CSCC[C@@H](C(=O)OC)NC(=O)c1ccc(cc1c1ccccc1C)CNCc1c[nH]cn1,CBR-HVAC-11246: Antimalarials;Antitrypanosomals;Oncolytic Drugs;Agents for Viral Hepatitis; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors;Signal Transduction Modulators; Farnesyltransferase Inhibitor;
CBR-001-593-492-6,RFM-006-946-5,CBR-001-593-492-6,Nc1cccc(c1)OCCCNCC1COc2c(O1)cc1c(c2)OCO1,CBR-HVAC-11505: Antipsychotic Drugs; Dopamine D2 Receptor Partial Agonists;Signal Transduction Modulators; Dopamine receptor D2 Agonist;
CBR-001-593-493-7,RFM-006-947-6,CBR-001-593-493-7,Nc1cccc(c1)OCCCNCC1COc2c(O1)cc1c(c2)OCO1,CBR-HVAC-11505: Antipsychotic Drugs; Dopamine D2 Receptor Partial Agonists;Signal Transduction Modulators; Dopamine receptor D2 Agonist;
CBR-001-593-494-8,RFM-006-948-7,CBR-001-593-494-8,N[C@H]1CCN(C1)c1nc2cc(nn2cc1C)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(=O)(=O)C,CBR-HVAC-07367: Anti-RSV Drugs; Viral Fusion Inhibitors;
CBR-001-593-495-9,RFM-006-949-8,CBR-001-593-495-9,CCCCOC(=O)c1ccccc1OP1(=O)CO[C@@H](CO1)Cn1ccc(nc1=O)N,CBR-HVAC-11151: Antiviral Drugs; DNA polymerase Inhibitor;
CBR-001-593-496-0,RFM-006-950-1,CBR-001-593-496-0,Cc1ccc2c(c1)nc(o2)NC(c1ccccn1)CC1CCCCC1,CBR-HVAC-04474: Arachidonic acid inhibitor; Leucotriene B4 antagonist; Platelet activating factor antagonist
CBR-001-593-497-1,RFM-006-951-2,CBR-001-593-497-1,Cc1ccc2c(c1)nc(o2)NC(c1ccccn1)CC1CCCCC1,CBR-HVAC-04474: Arachidonic acid inhibitor; Leucotriene B4 antagonist; Platelet activating factor antagonist
CBR-001-593-498-2,RFM-006-952-3,CBR-001-593-498-2,CCCC(c1ccc(cc1)CC(C)C)Oc1ccc(cc1)C(=O)c1cc(n2c1cccc2)CCCC(=O)O,CBR-HVAC-04953: Benign Prostatic Hyperplasia Therapy; Steroid 5alpha-Reductase Type 1 Inhibitors;Steroid 5alpha-Reductase Type 2 Inhibitors; 5-Alpha reductase Inhibitor;
CBR-001-593-499-3,RFM-006-953-4,CBR-001-593-499-3,CCCC(c1ccc(cc1)CC(C)C)Oc1ccc(cc1)C(=O)c1cc(n2c1cccc2)CCCC(=O)O,CBR-HVAC-04953: Benign Prostatic Hyperplasia Therapy; Steroid 5alpha-Reductase Type 1 Inhibitors;Steroid 5alpha-Reductase Type 2 Inhibitors; 5-Alpha reductase Inhibitor;
CBR-001-593-500-9,RFM-006-954-5,CBR-001-593-500-9,CCOC(=O)Nc1ncc2c(c1)c1ccccc1[nH]2,analog of CBR-HVAC-08340 (SH-426)
CBR-001-593-501-0,RFM-006-955-6,CBR-001-593-501-0,COc1ccc2c(c1)c(OC(C)C)c(s2=O)C(=O)N,CBR-HVAC-11350: Calcineurin Inhibitor;
CBR-001-593-502-1,RFM-006-956-7,CBR-001-593-502-1,CCc1cccc2c1n(CC1CCCCC1)cc2c1nsc(n1)CN1CCCC1,CBR-HVAC-11887: Cannabinoid receptor 1 Agonist;
CBR-001-593-503-2,RFM-006-957-8,CBR-001-593-503-2,OC1CCC2C(C1)c1c(NC2C)cc(cc1OC(=O)C)O[C@@H](CCCc1ccccc1)C,CBR-HVAC-01013: Cannabinoid receptor Agonist; Cannabinoid receptor agonist
CBR-001-593-504-3,RFM-006-958-9,CBR-001-593-504-3,CCCCN(c1cc(C)nc2c1NC(=O)CN2c1ccc(nc1OC)OC)CC,CBR-HVAC-07686: Corticotropin releasing factor 1 receptor antagonist
CBR-001-593-505-4,RFM-006-959-0,CBR-001-593-505-4,CCCCC/C=C\C/C=C\CCCCCCCc1ccco1,CBR-HVAC-06344: Dermatologic Drugs;
CBR-001-593-506-5,RFM-006-960-3,CBR-001-593-506-5,CCCCN(CCCC)CCC(c1cc(nc(c1)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)C(F)(F)F)O,CBR-HVAC-08526: Dihydrofolate reductase inhibitor
CBR-001-593-507-6,RFM-006-961-4,CBR-001-593-507-6,OC(=O)C[C@@H]1CCC(CC1)[C@H]1CCCN1c1ncc(cc1CN(c1nnn(n1)C)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(F)(F)F,CBR-HVAC-08574: Dipeptidyl peptidase 4 Inhibitor;
CBR-001-593-508-7,RFM-006-962-5,CBR-001-593-508-7,CCn1cc(C(=O)O)c(=O)c2c1nc1ccoc1c2,CBR-HVAC-07747: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-593-509-8,RFM-006-963-6,CBR-001-593-509-8,C[C@H](N1CC[C@@H](C1=O)NS(=O)(=O)/C=C/c1ccc(s1)Cl)C(=O)N1CCOCC1,CBR-HVAC-09491: FACTOR XA Inhibitor;
CBR-001-593-510-1,RFM-006-964-7,CBR-001-593-510-1,CN1CCN(CC1)C(=O)CC1NC(=O)c2c1cc1CCCc1c2,CBR-HVAC-08065: GABA A receptor agonist; Benzodiazepine receptor agonist
CBR-001-593-511-2,RFM-006-965-8,CBR-001-593-511-2,CN1CCN(CC1)C(=O)CC1NC(=O)c2c1cc1CCCc1c2,CBR-HVAC-08065: GABA A receptor agonist; Benzodiazepine receptor agonist
CBR-001-593-512-3,RFM-006-966-9,CBR-001-593-512-3,NC[C@@H](CP(=O)O)O,CBR-HVAC-11810: GABAB receptor agonist; Transient lower sphincter relaxation inhibitor;
CBR-001-593-513-4,RFM-006-967-0,CBR-001-593-513-4,COc1cc(/N=N/c2c(O)c3c(NC(=O)c4cccc(c4Cl)Cl)cc(cc3cc2S(=O)(=O)[O-])S(=O)(=O)[O-])c(cc1/N=N/c1c(O)c2c(NC(=O)c3ccc(cc3Cl)Cl)cc(cc2cc1S(=O)(=O)[O-])S(=O)(=O)[O-])OC,CBR-HVAC-04718: GP120env antagonist; HIV Fusion Inhibitors; HIV-fusion-inhibitors; Inhibitor of gp120-CD4 interaction; Anti-HIV; Anti-HIV Agents; Viral Infections
CBR-001-593-514-5,RFM-006-968-1,CBR-001-593-514-5,Fc1ccc2c(c1)c1ccc3c(c1C(O2)c1cccc(c1)Cl)C(=CC(N3)(C)C)C,"CBR-HVAC-10379: Gynecological Disorders, Treatment of ; Progesterone Receptor Agonists;Signal Transduction Modulators; Progesterone receptor Agonist;"
CBR-001-593-515-6,RFM-006-969-2,CBR-001-593-515-6,Fc1ccc2c(c1)c1ccc3c(c1C(O2)c1cccc(c1)Cl)C(=CC(N3)(C)C)C,"CBR-HVAC-10379: Gynecological Disorders, Treatment of ; Progesterone Receptor Agonists;Signal Transduction Modulators; Progesterone receptor Agonist;"
CBR-001-593-516-7,RFM-006-970-5,CBR-001-593-516-7,CCN(CCCc1c(=O)nc([nH]c1C)CCSCc1csc(n1)NC(=N)N)CC,CBR-HVAC-10564: Histamine H2 receptor Antagonist;
CBR-001-593-517-8,RFM-006-971-6,CBR-001-593-517-8,OC(=O)CC1C2CCCC1CN(C2)Cc1ccc2c(c1)Nc1c(S2)nccn1,CBR-HVAC-11987: ICAM-1 Inhibitor;
CBR-001-593-518-9,RFM-006-972-7,CBR-001-593-518-9,OC(=O)CC1C2CCCC1CN(C2)Cc1ccc2c(c1)Nc1c(S2)nccn1,CBR-HVAC-11987: ICAM-1 Inhibitor;
CBR-001-593-519-0,RFM-006-973-8,CBR-001-593-519-0,N#CC1CN1C(N1CC1C(=O)N)(C)C,CBR-HVAC-07501: Immunostimulant
CBR-001-593-520-3,RFM-006-974-9,CBR-001-593-520-3,Fc1ccc(cc1)CNC(=O)c1nc(N(C(=O)C(=O)C)C)c2c(c1O)nccc2,CBR-HVAC-11713: Integrase Inhibitor;
CBR-001-593-521-4,RFM-006-975-0,CBR-001-593-521-4,NCCCN(C(c1oc2cc(Cl)ccc2c(=O)c1Cc1ccccc1)C(C)C)C(=O)c1ccc(cc1)C,"CBR-HVAC-06069: Lymphoma Therapy;Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy; Antimitotic Drugs;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors;"
CBR-001-593-522-5,RFM-006-976-1,CBR-001-593-522-5,COc1cc(ccc1OCC(C1CC1)OP(=O)(O)O)n1cnc2c(c1=O)sc(c2)c1ccc(cc1)Cl,CBR-HVAC-06920: MCHR1-protein-inhibitors; Melanin concentrating hormone-1 receptor antagonist; Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists; Melanin-concentrating hormone 1 receptor Antagonist; Signal Transduction Modulators; Antiobesity; Antiobesity Drugs; Obesity
CBR-001-593-523-6,RFM-006-977-2,CBR-001-593-523-6,N#Cc1ccc(cc1OC[C@@H](CNC(CC1Cc2c(C1)cccc2)(C)C)O)CCC(=O)O,CBR-HVAC-11826: CALCIUM SENSING RECEPTOR Antagonist; Calcitonin modulator; Calcium absorption promotor; Calcium channel antagonist; Osteoclast modulator; PTH antagonist
CBR-001-593-524-7,RFM-006-978-3,CBR-001-593-524-7,Nc1ncc2c(n1)n(cn2)CC1(CC1)OCP(=O)(O)O,CBR-HVAC-05755
CBR-001-593-525-8,RFM-006-979-4,CBR-001-593-525-8,COc1ccccc1/C(=C/CN(CCCC(P(=O)(O)O)P(=O)(O)O)C)/C,metabolite of CBR-HVAC-11374
CBR-001-593-526-9,RFM-006-980-7,CBR-001-593-526-9,CCCCOCC(CN1C(=O)N(CC(OC(=O)N)COCCCC)C(=O)C(C1=O)(CC)c1ccccc1)OC(=O)N,CBR-HVAC-01321: Muscle relaxant and tremor reducing agent; Anxiolytic agent; GABA receptor agonist
CBR-001-593-527-0,RFM-006-981-8,CBR-001-593-527-0,O=C(CNC(=O)[C@@H](Cc1ccccc1)CSC(=O)C)OCc1ccccc1,CBR-HVAC-02402: Neprilysin Inhibitor; Membrane metallo endopeptidase inhibitor
CBR-001-593-528-1,RFM-006-982-9,CBR-001-593-528-1,CC(/N=C(/c1ccccc1O)\c1ccccc1)Cc1c[nH]cn1,CBR-HVAC-00414: Non-Opioid Analgesics;Antiarthritic Drugs; Histamine H3 Receptor Agonists;Signal Transduction Modulators; Histamine H3 receptor Agonist; Histamine H3 receptor agonist
CBR-001-593-529-2,RFM-006-983-0,CBR-001-593-529-2,CC(/N=C(/c1ccccc1O)\c1ccccc1)Cc1c[nH]cn1,CBR-HVAC-00414: Non-Opioid Analgesics;Antiarthritic Drugs; Histamine H3 Receptor Agonists;Signal Transduction Modulators; Histamine H3 receptor Agonist; Histamine H3 receptor agonist
CBR-001-593-530-5,RFM-006-984-1,CBR-001-593-530-5,CN(c1ccc2c3c1cccc3c(=N)[nH]2)Cc1ccc(cc1)S(=O)(=O)N1CCOCC1,CBR-HVAC-04297: Oncolytic Drugs; Antimetabolites;Thymidylate Synthase Inhibitors;
CBR-001-593-531-6,RFM-006-985-2,CBR-001-593-531-6,COc1ccc(c(c1F)F)Oc1cc(NCCC(F)(F)F)c2n(n1)c(cn2)c1ccc(c(c1)C)C(=O)NC1CC1,CBR-HVAC-07370: Oncolytic Drugs; Dual specificity protein kinase TTK (MPS1; MPS1L1) Inhibitors;Signal Transduction Modulators;
CBR-001-593-532-7,RFM-006-986-3,CBR-001-593-532-7,CCOC(=O)c1c(C)cc2c(c1C)c(=O)[nH]nc2CO,CBR-HVAC-08136: Phosphodiesterase 4 inhibitor; Thromboxane A2 receptor antagonist
CBR-001-593-533-8,RFM-006-987-4,CBR-001-593-533-8,N#Cc1ccc2c(c1)[C@@H](Oc1ccc(=O)[nH]n1)[C@@H](C(C2=O)(C)C)O,CBR-HVAC-08494: Potassium Channel Activators; Potassium channel agonist
CBR-001-593-534-9,RFM-006-988-5,CBR-001-593-534-9,COc1cc(C(C)C)c2c(c1)S(=O)(=O)N(C2=O)COC(=O)c1c(Cl)ccc(c1Cl)OCCN1CCOCC1,"CBR-HVAC-11491: Pulmonary Emphysema, Agents for; Elastase Inhibitors; Neutrophil elastase 2 Inhibitor;"
CBR-001-593-535-0,RFM-006-989-6,CBR-001-593-535-0,O[C@H]([C@@H](NC(=O)c1cnc2c(n1)cccc2)Cc1cccc(c1)F)C[C@H](C(=O)N)CCC(O)(C)C,"CBR-HVAC-06058: Rheumatoid Arthritis, Treatment of; Chemokine CCR1 Antagonists;Signal Transduction Modulators; C-C chemokine receptor type 1 Antagonist;"
CBR-001-593-536-1,RFM-006-990-9,CBR-001-593-536-1,OC1C(COc2c1ccc(c2)c1cc(ccc1C(=O)O)C(F)(F)F)Cc1ccccc1,"CBR-HVAC-11385: Rheumatoid Arthritis, Treatment of;Antiallergy/Antiasthmatic Drugs; Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators; Leukotriene B4 receptor Antagonist;"
CBR-001-593-537-2,RFM-006-991-0,CBR-001-593-537-2,Nc1ncc2c(n1)n(cn2)CC1(CC1)OCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C,CBR-HVAC-05754: Anti-Hepatitis B Virus Drugs; DNA Polymerase Inhibitors; Nucleoside reverse transcriptase Inhibitor;
CBR-001-593-538-3,RFM-006-992-1,CBR-001-593-538-3,OC(=O)[C@@H]1NC(=O)[C@@](C1)(N)C[n+]1ccccc1,CBR-HVAC-06834: Solid Tumors Therapy; Unidentified pharmacological activity
CBR-001-593-539-4,RFM-006-993-2,CBR-001-593-539-4,CCCCCCCCOCCOC(=O)CN(c1ccccc1OCCOc1ccccc1N(CC(=O)OCCOCCCCCCCC)CC(=O)O)CC(=O)O,"CBR-HVAC-05228: Stroke, Treatment of;Neurologic Drugs (Miscellaneous);Pancreatic Disorders, Treatment of; Chelating Agents; MATRIX METALLOPEPTIDASE 9 ; Inhibitor; Hypocalcaemic agent; Apoptosis inhibitor; Chelating agent"
CBR-001-593-540-7,RFM-006-994-3,CBR-001-593-540-7,O=C(Cc1ccccc1C)Nc1cc(C)c(c(c1)C)S(=O)(=O)C[N+](=O)[O-],CBR-HVAC-10680: Symptomatic Antidiabetic Agents; Aldose Reductase Inhibitors; Aldose reductase Inhibitor;
CBR-001-593-541-8,RFM-006-995-4,CBR-001-593-541-8,O[C@H](CNC(Cc1ccc(c(c1)F)Cl)(C)C)CO[C@@H](c1ccccc1c1ccc(c(c1)C)C(=O)O)C,CBR-HVAC-06248: Treatment of Osteoporosis; Calcium-Sensing Receptor (CaSR) Antagonists;Signal Transduction Modulators;
CBR-001-593-542-9,RFM-006-996-5,CBR-001-593-542-9,CO/N=C/1\CN([C@@H](C1)C(=O)NC[C@H](c1ccccc1)O)C(=O)c1ccc(cc1)c1ccccc1C,CBR-HVAC-05631: Treatment of Preterm Labor; Oxytocin (OT) Antagonists;Signal Transduction Modulators;
CBR-001-593-543-0,RFM-006-997-6,CBR-001-593-543-0,CO/N=C/1\CN([C@@H](C1)C(=O)NC[C@H](c1ccccc1)O)C(=O)c1ccc(cc1)c1ccccc1C,CBR-HVAC-05631: Treatment of Preterm Labor; Oxytocin (OT) Antagonists;Signal Transduction Modulators;
CBR-001-593-544-1,RFM-006-998-7,CBR-001-593-544-1,NC/C(=C\F)/COc1ccc(cc1)C(=O)NC(C)(C)C,"CBR-HVAC-07246: Treatment of Renal Diseases;Inflammation, Treatment of;Liver and Biliary Tract Disorders, Treatment of; Semicarbazide-Sensitive Amine Oxidase (SSAO; VAP-1)  Inhibitors;"
CBR-001-593-545-2,RFM-006-999-8,CBR-001-593-545-2,CC[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C)Oc1ccccc1,CBR-HVAC-08930
CBR-001-593-546-3,RFM-007-000-8,CBR-001-593-546-3,N=C(NC(=N)NP(=O)(O)O)NCc1ccccc1,CBR-HVAC-09009:
CBR-001-596-988-7,RFM-007-001-9,CBR-001-596-988-7,Fc1ccc(c(c1)c1nnc2n1nc(OCc1ncnn1C)c(c2)C(C)(C)C)F,CBR-HVAC-14190
CBR-001-596-989-8,RFM-007-002-0,CBR-001-596-989-8,Fc1ccc(cc1)[C@@]1(Cn2cncn2)O[C@H]1c1ccccc1Cl,analog of CBR-HVAC-01096
CBR-001-596-990-1,RFM-007-003-1,CBR-001-596-990-1,COC(=O)[C@H]1NC[C@H](C1)Oc1ccc(cc1)Cl,analog of CBR-HVAC-06079
CBR-001-596-991-2,RFM-007-004-2,CBR-001-596-991-2,CO/N=C(/c1csc(n1)N)\C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)COC,CBR-HVAC-12700
CBR-001-596-992-3,RFM-007-005-3,CBR-001-596-992-3,C=C[C@H]1CNCC[C@H]1CCC(=O)c1ccnc2c1cc(OC)cc2,analog of CBR-HVAC-10233
CBR-001-596-993-4,RFM-007-006-4,CBR-001-596-993-4,COc1c(OC)cc2c(c1OC)c1ccc(c(=O)cc1C(CC2)N)OC,analog of CBR-HVAC-10425
CBR-001-596-994-5,RFM-007-007-5,CBR-001-596-994-5,O=C(CN1[C@@H](CNC2(C1=O)CCCC2)c1cc(F)cc(c1)F)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2c1cccn2,CBR-HVAC-00126: Calcitonin gene related peptide receptor antagonist
CBR-001-596-995-6,RFM-007-008-6,CBR-001-596-995-6,CNCC12CCC(c3c1cccc3)c1c2cccc1,CBR-HVAC-01093:
CBR-001-596-997-8,RFM-007-009-7,CBR-001-596-997-8,OCc1nc(ccc1O)C(CNC(C)(C)C)O,CBR-HVAC-02234: beta2-Adrenoceptor Agonists; Signal Transduction Modulators
CBR-001-596-998-9,RFM-007-010-0,CBR-001-596-998-9,O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1,CBR-HVAC-02970: 5-HT1A Receptor Agonists; ignal Transduction Modulators
CBR-001-596-999-0,RFM-007-011-1,CBR-001-596-999-0,CCCCCCCCCCCCCCCCCCNC(=O)OCC(COC(=O)N(C(=O)C)Cc1cccc[n+]1CC)OC,CBR-HVAC-03330: Endothelin Receptor Antagonists; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators
CBR-001-597-000-0,RFM-007-012-2,CBR-001-597-000-0,OC(COc1ccc(cc1C(=O)C)NC(=O)C)CNC(C)C,CBR-HVAC-05547: beta-Adrenoceptor Antagonists; Signal Transduction Modulators
CBR-001-597-001-1,RFM-007-013-3,CBR-001-597-001-1,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCCn1c(=O)[nH]c2c1ccc(c2)Cl,CBR-HVAC-05588: Antipsychotic Drugs
CBR-001-597-002-2,RFM-007-014-4,CBR-001-597-002-2,C#CCOC[C@H]1CO[C@](O1)(Cn1cncc1)c1ccc(cc1Cl)Cl,"CBR-HVAC-08965: Imidazoles, Antifungal Agents"
CBR-001-597-003-3,RFM-007-015-5,CBR-001-597-003-3,COc1cc(cc(c1OC)OC)C(=O)OCCCN(CCN(CCCOC(=O)c1cc(OC)c(c(c1)OC)OC)C)C,"CBR-HVAC-09798: Hexobendine increases the efficiency of adenosine and induces a number of biochemical changes, which in turn, contribute to normalization of reduced cell function. Furthermore, an increased blood flow in the area of the brain and the myocardium is achieved. Additionally, hexobendine produces inhibition of the platelet aggregation"
CBR-001-597-004-4,RFM-007-016-6,CBR-001-597-004-4,CCN(C(CC(=O)Nc1ccccc1)C)CC,"CBR-HVAC-09940: Stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia"
CBR-001-597-005-5,RFM-007-017-7,CBR-001-597-005-5,O=C(C(C(=O)Oc1ccc2c(c1)CCC2)c1ccccc1)N[C@@H]1C(=O)N2[C@H]1SC([C@H]2C(=O)O)(C)C,CBR-HVAC-10221: Penicillin binding protein inhibitor
CBR-001-597-006-6,RFM-007-018-8,CBR-001-597-006-6,CCN(C(=S)SC(=S)N(CC)CC)CC,CBR-HVAC-10361: Ectoparasiticide; Antiscabies
CBR-001-597-007-7,RFM-007-019-9,CBR-001-597-007-7,C#Cc1cncc(c1)[C@@H]1CCCN1C,CBR-HVAC-04771: Nicotinic Receptor Agonists;
CBR-001-597-008-8,RFM-007-020-2,CBR-001-597-008-8,COc1ccc(cc1)CC(=O)NCc1ccccc1c1ccccc1C(=O)NCCc1cccnc1,CBR-HVAC-05798: Potassium Channel Blockers
CBR-001-597-009-9,RFM-007-021-3,CBR-001-597-009-9,COCC(=O)O[C@]1(CCN(CCCc2nc3c([nH]2)cccc3)C)CCc2c([C@@H]1C(C)C)ccc(c2)F,CBR-HVAC-02826: T-type calcium channel antagonist; Angiogenesis inhibitor
CBR-001-597-018-0,RFM-007-022-4,CBR-001-597-018-0,CN[C@@H]1C[C@H]2O[C@]([C@@H]1OC)(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3[C@@H](NC1=O)O,CBR-HVAC-03596: Compound arrests tumor cells in G1/S phase of cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase CHK1 resulting in apoptosis
CBR-001-597-019-1,RFM-007-023-5,CBR-001-597-019-1,Fc1ccc(cc1)[C@H](N(C(=O)c1cnc2c(c1)cccc2)Cc1cccc(c1)C(=O)O)C,CBR-HVAC-07257: TRPM8 (TRP-p8; CMR1) Antagonists
CBR-001-597-020-4,RFM-007-024-6,CBR-001-597-020-4,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)CC[C@H]1CNc2c(C1)c(=O)nc([nH]2)N,CBR-HVAC-04090: DNA synthesis inhibitor; Folate antagonist; GAR transformylase inhibitor
CBR-001-597-021-5,RFM-007-025-7,CBR-001-597-021-5,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O)N(C(=O)c1ccccc1)C,CBR-HVAC-00839: Angiogenesis Inhibitors; Apoptosis Inducers; Flt3 (FLK2/STK1) Inhibitors; KIT (C-KIT) Inhibitors; Prenyl-binding protein (PrBP)/delta inhibitor; Protein Kinase C (PKC) Inhibitors; Signal Transduction Modulators
CBR-001-597-022-6,RFM-007-026-8,CBR-001-597-022-6,CNC(=O)[C@H](N(C(=O)[C@H](N(C(=O)/C=C/CC(N)(C)C)C)Cc1ccc2c(c1)cccc2)C)Cc1ccccc1,CBR-HVAC-04965: Growth hormone releasing factor agonist; CYP3A4 activity inhibitor
CBR-001-597-029-3,RFM-007-027-9,CBR-001-597-029-3,Cc1cnc(cn1)NC(=O)c1cc(Oc2cnc(nc2)C(=O)N(C)C)c2c(c1)oc(c2)C,CBR-HVAC-00618: Glucokinase Activator; Hexokinase stimulant
CBR-001-597-030-6,RFM-007-028-0,CBR-001-597-030-6,OC(c1cc(Cl)c(c(c1)Cl)N)CNCCCCCCOCCc1ccccn1,CBR-HVAC-04238: Bronchodilators; Beta-2 adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-597-031-7,RFM-007-029-1,CBR-001-597-031-7,OC(c1cc(Cl)c(c(c1)Cl)N)CNCCCCCCOCCc1ccccn1,CBR-HVAC-04238: Bronchodilators; Beta-2 adrenergic receptor Agonist; Beta 2 adrenoreceptor agonist
CBR-001-597-032-8,RFM-007-030-4,CBR-001-597-032-8,O=C(C(C)(C)C)OCOP(=O)(C(S(=O)(=O)O)CCCc1cccc(c1)Oc1ccccc1)OCOC(=O)C(C)(C)C,"CBR-HVAC-04582: Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors; Squalene synthase Inhibitor;"
CBR-001-597-033-9,RFM-007-031-5,CBR-001-597-033-9,NC(=O)[C@@H](NS(=O)(=O)c1cnc2n1[C@](C)(Cc1ccc(cc1)OC(F)(F)F)C(=O)N2c1cc(Cl)cc(c1)Cl)C,CBR-HVAC-06081: Antipsoriatics;Treatment of Autoimmune Diseases;Antiarthritic Drugs;Asthma Therapy; LFA-1/ICAM-1 Interaction Inhibitors;
CBR-001-597-034-0,RFM-007-032-6,CBR-001-597-034-0,OC(=O)C1Cc2c(C1)c(ccc2)S(=O)(=O)N1[C@H](C)CN(C[C@@H]1C)c1ccc(cc1)OC(F)(F)F,CBR-HVAC-06429: Anti-Hepatitis Virus Drugs;Antiobesity Drugs;Antidiabetic Drugs; PPARdelta Agonists;Signal Transduction Modulators; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA Agonist;
CBR-001-597-035-1,RFM-007-033-7,CBR-001-597-035-1,O=C(C1CCC(CC1)(F)F)N[C@H](c1ccccc1)CCN1[C@@H]2CC[C@H]1C[C@]1(C2)CN(C(=O)N1C(C)C)CC1CCOCC1,CBR-HVAC-06440: Anti-HIV Agents; Chemokine CCR5 Antagonists;Signal Transduction Modulators;
CBR-001-597-036-2,RFM-007-034-8,CBR-001-597-036-2,NCC(C(=O)Nc1ccc2c(c1)ccnc2)c1ccc(cc1)COC(=O)c1ccc(cc1C)C,CBR-HVAC-07318: Ophthalmic Drugs;Antiglaucoma Agents; Norepinephrine Transporter (NET) Inhibitors;Rho Kinase Inhibitors;Signal Transduction Modulators; Adrenergic transmitter uptake inhibitor; Rho-associated kinase 2 inhibitor
CBR-001-597-037-3,RFM-007-035-9,CBR-001-597-037-3,NCC(C(=O)Nc1ccc2c(c1)ccnc2)c1ccc(cc1)COC(=O)c1ccc(cc1C)C,CBR-HVAC-07318: Ophthalmic Drugs;Antiglaucoma Agents; Norepinephrine Transporter (NET) Inhibitors;Rho Kinase Inhibitors;Signal Transduction Modulators; Adrenergic transmitter uptake inhibitor; Rho-associated kinase 2 inhibitor
CBR-001-597-038-4,RFM-007-036-0,CBR-001-597-038-4,Cc1ccc(cc1)S(=O)(=O)CC(C(=O)O)CC#Cc1ccc(cc1)Cl,CBR-HVAC-07536: Unidentified pharmacological activity
CBR-001-597-039-5,RFM-007-037-1,CBR-001-597-039-5,Fc1ccc(cc1)COCC1Oc2c(C1)cc(cc2)C(=O)Nc1cccc2c1oc(cc2=O)c1nnn[nH]1,CBR-HVAC-10636: Leukotriene CysLT1 (LTD4) Antagonists; Leukotriene D4 receptor Antagonist; Leukotriene-D4-receptor-antagonists; Signal Transduction Modulators; ANTI-ASTHMATIC; Antiallergy/Antiasthmatic Drugs; Obstructive Airways Disease
CBR-001-597-040-8,RFM-007-038-2,CBR-001-597-040-8,COCC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N\O)/c1csc(n1)N,CBR-HVAC-10223
CBR-001-597-041-9,RFM-007-039-3,CBR-001-597-041-9,O=C1NN=C(C(C1)C)c1ccc2c(c1)ncnc2NCc1ccccc1,CBR-HVAC-10747: Heart Failure Therapy; Phosphodiesterase Inhibitor;
CBR-001-597-042-0,RFM-007-040-6,CBR-001-597-042-0,Oc1cc(F)c(cc1/C(=N/OC(C)(C)C)/c1c(O)ccc[n+]1[O-])Br,"CBR-HVAC-10753: Hypertension, Treatment of;Angina pectoris, Treatment of; Potassium Channel Activators; Potassium channel Opener;"
CBR-001-597-043-1,RFM-007-041-7,CBR-001-597-043-1,CN1CCN(CC1)C1=Nc2ccccc2Cc2n1nc(n2)C,CBR-HVAC-10777: Antipsychotic Drugs; Antipsychotic;
CBR-001-597-044-2,RFM-007-042-8,CBR-001-597-044-2,O=C(NC1N=C(c2ccccc2)c2c(N(C1=O)C)cccc2)NC(C(CSc1nnnn1C)O)CC1CCCCC1,"CBR-HVAC-10869: Hypertension, Treatment of; Renin Inhibitors; Renin Inhibitor;"
CBR-001-597-045-3,RFM-007-043-9,CBR-001-597-045-3,COc1cc(cc(c1OC)OC)C1CCC(S1)c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-11582: Platelet activating factor receptor Antagonist;
CBR-001-597-046-4,RFM-007-044-0,CBR-001-597-046-4,COc1cc(cc(c1OC)OC)C1CCC(S1)c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-11582: Platelet activating factor receptor Antagonist;
CBR-001-597-047-5,RFM-007-045-1,CBR-001-597-047-5,CCCC(c1ccc(cc1)OCc1ccc(cc1)c1csc(n1)CN(Cc1ncc(s1)C(C)(C)C)CC(=O)O)CCC,"CBR-HVAC-11755: Type 2 Diabetes, Agents for; Protein Tyrosine Phosphatase PTP-1B Inhibitors;Signal Transduction Modulators; PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) Inhibitor;"
CBR-001-597-048-6,RFM-007-046-2,CBR-001-597-048-6,Clc1cc(NCCN2CCCC2)c(c(c1)N1CCN(CC1)c1ncnc2c1c(Br)n[nH]2)C,analog of CBR-HVAC-11868
CBR-001-597-100-3,RFM-007-047-3,CBR-001-597-100-3,Clc1ccc2c(c1)n(C)c1c2c(CC(=O)N(C)C)nn(c1=O)c1ccccc1,CBR-HVAC-02699: Benzodiazepine receptor antagonist; Neuroprotectant; Nootropic
CBR-001-597-102-5,RFM-007-048-4,CBR-001-597-102-5,CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@@H]([C@@H](CCCCCCCCCCCCCC)O)O)CO[C@H]1O[C@H](CO)[C@@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-04697: KRN-7000 is an immunostimulant which had been in early clinical trials at Kirin Brewery for the treatment of hepatitis C, for the treatment of previously untreated asymptomatic multiple myeloma and for the treatment of cancer. However, no recent development has been reported for this research. The drug has been found to increase natural killer T-cell counts in the liver, interferon gamma and IL-12"
CBR-001-597-103-6,RFM-007-049-5,CBR-001-597-103-6,COc1ccc(c(c1)Cl)OCc1ccc(cc1)COc1c(Cl)cccc1Cl,CBR-HVAC-00105:Antiviral Drugs; Virus uptake inhibitor; Poliovirus capsid inhibitor
CBR-001-597-104-7,RFM-007-050-8,CBR-001-597-104-7,Cc1ccc(cc1)Cn1nc([nH]c1=O)CCCc1ccc(cc1)OC(C(=O)O)(C)C,"CBR-HVAC-00338:Antidiabetic Drugs;Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator activated receptor alpha Agonist; Peroxisome proliferator-activated receptor alpha agonist; Retinoid X receptor agonist"
CBR-001-597-105-8,RFM-007-051-9,CBR-001-597-105-8,Cc1ccc(cc1)S(=O)(=O)Oc1ccc(c(c1)S(=O)(=O)O)O,"CBR-HVAC-01519:Lipoprotein Disorders, Treatment of ; HMG CoA reductase inhibitor; Lipase clearing factor stimulant"
CBR-001-597-106-9,RFM-007-052-0,CBR-001-597-106-9,Fc1ccc(cc1)C(=O)CCCN1CCN2C(C1)Cc1c(C2)[nH]c2c1cccc2,CBR-HVAC-01874:Antipsychotic Drugs; Dopamine receptor D3 Antagonist; Dopamine D1 receptor antagonist; 5 Hydroxytryptamine 2 receptor antagonist; Dopamine D2 receptor antagonist
CBR-001-597-107-0,RFM-007-053-1,CBR-001-597-107-0,CO[C@H]([C@@H]([C@@H](COS(=O)(=O)C)O)OC)[C@@H](COS(=O)(=O)C)O,CBR-HVAC-03280:Oncolytic Drugs; Antineoplastic; DNA inhibitor
CBR-001-597-108-1,RFM-007-054-2,CBR-001-597-108-1,OC(=O)Cc1cscc1Nc1c(Cl)cccc1Cl,CBR-HVAC-03300:Non-Opioid Analgesics; COX Inhibitor; Cyclooxygenase inhibitor
CBR-001-597-109-2,RFM-007-055-3,CBR-001-597-109-2,CC([C@@H](C(=O)N1CCC[C@H]1C(=O)NC(C(=O)C(F)(F)F)C(C)C)NC(=O)c1ccc(cc1)C(=O)NS(=O)(=O)c1ccc(cc1)Cl)C,"CBR-HVAC-03536:Acute Respiratory Distress Syndrome (ARDS), Agents for;Pulmonary Emphysema, Agents for; Leukocyte Elastase Inhibitors; Elastase inhibitor"
CBR-001-597-110-5,RFM-007-056-4,CBR-001-597-110-5,CCN(CCNc1ccc(c2c1c(=O)c1c(s2)cccc1)CNS(=O)(=O)C)CC,CBR-HVAC-04376:Oncolytic Drugs; Topoisomerase II Inhibitor; DNA inhibitor
CBR-001-597-111-6,RFM-007-057-5,CBR-001-597-111-6,OC[C@@H](c1ccccc1)NC(=O)[C@H](c1ccc(cc1)Cn1c2ccccc2c2c1nc(C)cc2C)C1CCCC1,"CBR-HVAC-04838:Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal trigylceride transfer protein inhibitor"
CBR-001-597-112-7,RFM-007-058-6,CBR-001-597-112-7,OC[C@@H](c1ccccc1)NC(=O)[C@@H](c1ccc(cc1)Cn1c2ccccc2c2c1nc(C)cc2C)C1CCCC1,"CBR-HVAC-04838:Lipoprotein Disorders, Treatment of ;Atherosclerosis Therapy; ApoB Secretion Inhibitors;Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal trigylceride transfer protein inhibitor"
CBR-001-597-113-8,RFM-007-059-7,CBR-001-597-113-8,COc1ncccc1C(=O)NCCC1CCN(CC1)S(=O)(=O)NC(=O)NC[C@H]1C[C@H]2C[C@@H]1C=C2,CBR-HVAC-05614:Antidiabetic Drugs;
CBR-001-597-114-9,RFM-007-060-0,CBR-001-597-114-9,OC(=O)C(c1ccc2c(c1)oc1c2cc(cc1)Cl)C,CBR-HVAC-08282:Unidentified pharmacological activity
CBR-001-597-115-0,RFM-007-061-1,CBR-001-597-115-0,CCNC/C=C\CNCCCCNCCCCNC/C=C\CNCC,CBR-HVAC-09519:
CBR-001-597-116-1,RFM-007-062-2,CBR-001-597-116-1,CCN(CCn1c(Cc2ccc(cc2)Cl)nc2c1ccc(c2)[N+](=O)[O-])CC,CBR-HVAC-09948:
CBR-001-597-117-2,RFM-007-063-3,CBR-001-597-117-2,NC[C@@H]1Cc2ccc(cc2[C@@H](O1)c1ccccc1)F,CBR-HVAC-10111:
CBR-001-597-118-3,RFM-007-064-4,CBR-001-597-118-3,COc1ccc2c(c1)n(C(=O)O[C@@H]1C[C@@H]3CC[C@H](C1)N3C)c(=O)[nH]2,CBR-HVAC-10471:Signal Transduction Modulators;5-HT4 Antagonists; 5-Hydroxytryptamine 4 receptor Antagonist;
CBR-001-597-119-4,RFM-007-065-5,CBR-001-597-119-4,CCC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)[C@@H]1CC[S@+](CC1)[O-],CBR-HVAC-11272:Antibacterial Drugs; Monoamine oxidase A; Protein 30S ribosomal subunit Inhibitor;
CBR-001-597-120-7,RFM-007-066-6,CBR-001-597-120-7,C=CCOC(=O)N[C@H](C(=O)COc1cc2ccccc2cc1c1[nH]ccn1)CC(=O)O,CBR-HVAC-11465:Cell cycle inhibitor;
CBR-001-597-121-8,RFM-007-067-7,CBR-001-597-121-8,CCOc1ccc(cc1)C[C@H](C(=O)N[C@H](C(=O)NCc1ccc(cc1)CN)Cc1ccccc1)NC(=O)c1ccccc1,CBR-HVAC-12066:Kallikrein inhibitor
CBR-001-597-122-9,RFM-007-068-8,CBR-001-597-122-9,N#Cc1ccc(cc1)CC(C(=O)NC(C(=O)O)C1CCCCC1)NC(=O)C,CBR-HVAC-12086:Coagulation Factor Xa Inhibitors; Inhibitors of Blood Coagulation Pathways
CBR-001-597-123-0,RFM-007-069-9,CBR-001-597-123-0,CCN(C(=O)c1ccc(cc1)C(N1C[C@@H](C)N(C[C@@H]1C)Cc1cccc(c1)F)c1ccccc1)CC,CBR-HVAC-12104: Protein tyrosine phosphatase delta stimulator
CBR-001-597-124-1,RFM-007-070-2,CBR-001-597-124-1,CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-12114:Androgen Receptor Agonists; Signal Transduction Modulators
CBR-001-597-246-0,RFM-007-071-3,CBR-001-597-246-0,OC(=O)C(c1ccc(cc1)/C=C/1\CCCC1=O)C,analog of CBR-HVAC-01508
CBR-001-597-247-1,RFM-007-072-4,CBR-001-597-247-1,C=C1CC2(OC1C)CCNCC2,analog of CBR-HVAC-03894
CBR-001-597-248-2,RFM-007-073-5,CBR-001-597-248-2,O=c1cc(C)n(nc1N)c1ccc(cc1)C(F)(F)F,analog of CBR-HVAC-04120
CBR-001-597-249-3,RFM-007-074-6,CBR-001-597-249-3,Cc1cnc2c(c1)nc(n2Cc1ccc(cc1)C(=O)O)C1CCCCC1,analog of CBR-HVAC-04159
CBR-001-597-250-6,RFM-007-075-7,CBR-001-597-250-6,NCC1OB(c2c1cccc2)O,CBR-HVAC-14281
CBR-001-597-251-7,RFM-007-076-8,CBR-001-597-251-7,OC(=O)CCCc1cc(O)c(c(c1C)C)O,analog of CBR-HVAC-07672
CBR-001-597-252-8,RFM-007-077-9,CBR-001-597-252-8,OCCn1c(=O)c2ccc(cc2n(c1=O)C)C(F)(F)F,analog of CBR-HVAC-07892
CBR-001-597-253-9,RFM-007-078-0,CBR-001-597-253-9,COc1ccc2c(c1)C1CCCNC1CO2,analog of CBR-HVAC-07943
CBR-001-597-254-0,RFM-007-079-1,CBR-001-597-254-0,Fc1cccc(c1)Cn1c(cc2c1cncc2)C(=O)Nc1ccc2c(c1)nc(n2C)C,analog of CBR-HVAC-09337
CBR-001-597-255-1,RFM-007-080-4,CBR-001-597-255-1,OCC1CNc2c(N1)c(N)nc(n2)N,analog of CBR-HVAC-09354
CBR-001-597-256-2,RFM-007-081-5,CBR-001-597-256-2,COc1cc(ccc1OC)c1csc(n1)CN,analog of CBR-HVAC-10451
CBR-001-597-257-3,RFM-007-082-6,CBR-001-597-257-3,CN1CCC(CC1)NC(=O)c1cccn2c1ncc2,analog of CBR-HVAC-10504
CBR-001-597-258-4,RFM-007-083-7,CBR-001-597-258-4,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](N(C(=O)[C@H]3N(C1=O)CCC3)C)Cc1ccccc1)CCC(=O)C2)c1ccccc1,component of mixture CBR-HVAC-11436
CBR-001-597-259-5,RFM-007-084-8,CBR-001-597-259-5,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)Cc1ccc(cc1)O)C(C)C)CCCCN)C(C)C)CCCNC(=N)N)CCCNC(=N)N)CCCCN)CCCCN)C(C)C)NC(=O)CNC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)N)Cc1ccc(cc1)O)CO)CCSC)CCC(=O)O)Cc1c[nH]cn1)Cc1ccccc1)CCCNC(=N)N,CBR-HVAC-12691
CBR-001-597-260-8,RFM-007-085-9,CBR-001-597-260-8,CCN1CCC2N(C1=O)CCN(C2)C,CBR-HVAC-00452:Phosphoenolpyruvate carboxykinase inhibitor; Fumarate reductase inhibitor; Succinic dehydrogenase inhibitor
CBR-001-597-261-9,RFM-007-086-0,CBR-001-597-261-9,Clc1ccc2c(c1)[C@H]1CN(C[C@@H]1c1c(O2)cccc1)C,"CBR-HVAC-01472:Acts as antagonist of dopamine receptor D2, 5-Hydroxytryptamine 2A receptor, alpha adrenergic receptor, histamine receptor"
CBR-001-597-262-0,RFM-007-087-1,CBR-001-597-262-0,NNc1nnc2c(c1)CN(CC2)C(=O)c1ccccc1,CBR-HVAC-01912:Vasodilator;Antihypertensive
CBR-001-597-263-1,RFM-007-088-2,CBR-001-597-263-1,Cc1csc(c1NC1=NCCN1)Cl,CBR-HVAC-02794:alpha2-Adrenoceptor Antagonists; Signal Transduction Modulators
CBR-001-597-264-2,RFM-007-089-3,CBR-001-597-264-2,COc1cc(NCc2ccc3c(c2C)c(N)nc(n3)N)cc(c1OC)OC,CBR-HVAC-02916:Dihydrofolate reductase inhibitor; Thymidylate synthase inhibitor
CBR-001-597-265-3,RFM-007-090-6,CBR-001-597-265-3,CCCCCCCCCCCCCCC[C@@H]([C@H](CO)N)O,CBR-HVAC-04373:Protein kinase C inhibitor
CBR-001-597-266-4,RFM-007-091-7,CBR-001-597-266-4,O=C(c1ccncc1)Nn1c(C)c(cc1c1ccccc1)CN1CCN(CC1)c1cccc(c1)C(F)(F)F,CBR-HVAC-06060:Antibacterial
CBR-001-597-267-5,RFM-007-092-8,CBR-001-597-267-5,CCCCCCCC/C=C\CCCCCCCC(=O)OC(CO)CO,"CBR-HVAC-07052:Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Ligands; Signal Transduction Modulators"
CBR-001-597-268-6,RFM-007-093-9,CBR-001-597-268-6,Cc1nc(O)c(cc1c1ccccc1)N,CBR-HVAC-07465:
CBR-001-597-269-7,RFM-007-094-0,CBR-001-597-269-7,Oc1ccc(cc1)CCNCC1CCc2c(C1=O)cccc2,CBR-HVAC-07512:alpha-Adrenoceptor Antagonists; Signal Transduction Modulators
CBR-001-597-270-0,RFM-007-095-1,CBR-001-597-270-0,O=C1CN(CCN2CC(=O)N(C(=O)C2)CN2CCOCC2)CC(=O)N1CN1CCOCC1,CBR-HVAC-07527:DNA Topoisomerase II Inhibitors
CBR-001-597-271-1,RFM-007-096-2,CBR-001-597-271-1,OCC(=O)C1(O)CC(OC2CC(N)C(C(O2)C)O)c2c(C1)c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2OC,CBR-HVAC-15141: DNA Topoisomerase II alpha Inhibitors; DNA synthesis inhibitor; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA-Intercalating Drugs; RNA synthesis inhibitor; Antineoplastic; Antineoplastic Antibiotics; Brain Cancer Therapy; Breast Cancer Therapy; Head and Neck Cancer Therapy; Liver Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs; Treatment of AIDS-Associated Disorders
CBR-001-597-272-2,RFM-007-097-3,CBR-001-597-272-2,ClCCCN1CCN(CC1)c1ccc2c(n1)cccc2,CBR-HVAC-11103:Non-Steroidal Antiinflammatory Drugs (NSAIDs)
CBR-001-597-273-3,RFM-007-098-4,CBR-001-597-273-3,Clc1cccc(c1)[C@@H]1CCOP(=O)(O1)COc1cc(C)c(c(c1)C)Cc1ccc(c(c1)C(C)C)O,"CBR-HVAC-00230: Lipoprotein Disorders, Treatment of ; Signal Transduction Modulators;Thyroid Hormone Receptor beta Agonists; Thyroid hormone receptor Agonist; Thyroid hormone receptor beta agonist"
CBR-001-597-274-4,RFM-007-099-5,CBR-001-597-274-4,c1ccc(cc1)OCc1n[nH]c2c([nH]1)cncc2,CBR-HVAC-01212: Unidentified pharmacological activity
CBR-001-597-275-5,RFM-007-100-1,CBR-001-597-275-5,CN1CCN(CC1)C(=O)CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C,CBR-HVAC-03380: Antiulcer Drugs; Gastrin inhibitor
CBR-001-597-276-6,RFM-007-101-2,CBR-001-597-276-6,CCCCCCCCCCCCCCCCSCC(COP(=O)(OCC[N+](C)(C)C)[O-])COC,CBR-HVAC-03409: Oncolytic Drugs; Protein tyrosine kinase C Inhibitor; Phosphocholine acyltransferase inhibitor; Platelet aggregation inhibitor
CBR-001-597-277-7,RFM-007-102-3,CBR-001-597-277-7,O/N=C(/c1ccc(cc1)CCc1ccccc1)\CN1CCN(CC1)C,CBR-HVAC-03990: Antiulcer Drugs; Secretin Modulator; Gastrin inhibitor
CBR-001-597-278-8,RFM-007-103-4,CBR-001-597-278-8,O[C@H]([C@@H]([C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)N(Cc1ccccn1)C)O)[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)N(Cc1ccccn1)C,CBR-HVAC-04143: Anti-HIV Agents; Protease Inhibitor;
CBR-001-597-279-9,RFM-007-104-5,CBR-001-597-279-9,OC(=O)[C@H]1[C@H]2[C@@H]1[C@](CC2)(N)C(=O)O,"CBR-HVAC-04796: Stroke, Treatment of;Anxiolytics;Antipsychotic Drugs; mgluR2 Agonists;mgluR3 Agonists;Signal Transduction Modulators; Metabotropic glutamate receptor 2; Metabotropic glutamate receptor 3 Agonist; Glutamate 2 receptor agonist; Glutamate 3 receptor agonist"
CBR-001-597-280-2,RFM-007-105-6,CBR-001-597-280-2,CC(=N)NCCCCC(C(=O)Nc1nnn[nH]1)N,CBR-HVAC-04849: Antiarthritic Drugs;Chemopreventive Agents;Asthma Therapy; Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Signal Transduction Modulators; INDUCIBLE NITRICOXIDE SYNTHASE Inhibitor;
CBR-001-597-281-3,RFM-007-106-7,CBR-001-597-281-3,NCCc1c[nH]c(=S)n1[C@H]1COc2c(C1)cc(cc2F)F,"CBR-HVAC-06068: Heart Failure Therapy;Hypertension, Treatment of; Dopamine beta-monooxygenase Inhibitors; Dopamine beta-hydroxylase Inhibitor; Dopamine b hydroxylase inhibitor"
CBR-001-597-282-4,RFM-007-107-8,CBR-001-597-282-4,CCC(CNC(=O)Cn1cccc(c1=O)NC(=O)[C@@H](NC(=O)c1cncn1C)CC/C=C/C(=O)OC)CC,"CBR-HVAC-07347: Celiac Disease, Treatment of; Tissue Transglutaminase (TGM2) Inhibitors;"
CBR-001-597-283-5,RFM-007-108-9,CBR-001-597-283-5,CCN1CCC(CC1)c1cc(C)c2n(c1)c(=O)cc(n2)c1nn2c(c1)c(C)nc(c2)C,"CBR-HVAC-07368: Neuromuscular Genetic Disorders, Treatment of; SMN2 Splicing Modulators;"
CBR-001-597-284-6,RFM-007-109-0,CBR-001-597-284-6,CC(C(=O)NCC(=O)OCc1cccc(n1)COC(=O)CNC(=O)C(SC(=O)c1ccccc1)C)SC(=O)c1ccccc1,CBR-HVAC-07730: Free radical scavenger
CBR-001-597-285-7,RFM-007-110-3,CBR-001-597-285-7,OC(=O)C[C@H](N(C(=O)CN1C(=O)N(C(C1=O)(C)c1ccc(cc1)C(=N)N)Cc1ccc(cc1)c1ccccc1)C)C(=O)N[C@@H](c1ccccc1)C(=O)O,CBR-HVAC-08520: Alpha4beta1 integrin antagonist
CBR-001-597-286-8,RFM-007-111-4,CBR-001-597-286-8,CCCN(C1CCc2c(C1)c(ccc2)CS(=O)(=O)NC)CCC,CBR-HVAC-10646: Antimigraine Drugs; Signal Transduction Modulators;5-HT1D Agonists; 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 1D receptor Agonist;
CBR-001-597-287-9,RFM-007-112-5,CBR-001-597-287-9,CCCN(C1CCc2c(C1)c(ccc2)CS(=O)(=O)NC)CCC,CBR-HVAC-10646: Antimigraine Drugs; Signal Transduction Modulators;5-HT1D Agonists; 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 1D receptor Agonist;
CBR-001-597-288-0,RFM-007-113-6,CBR-001-597-288-0,CCCc1c(OCCCOc2ccc(c(c2CC2CC2)OC)c2cscn2)ccc2c1OC(CC2)C(=O)O,CBR-HVAC-10713: Antidiarrheal Agents;Antiallergy/Antiasthmatic Drugs;Antipsoriatics; Leukotriene Antagonists;Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators; Leukotriene B4 receptor Antagonist;
CBR-001-597-289-1,RFM-007-114-7,CBR-001-597-289-1,CC(C[C@@H]([C@@H]([C@@H](NC(=O)C(CC(=O)N(CC(=O)N(CCc1ccccn1)C)CC1CCCCC1)Cc1csc(n1)N)CC1CCCCC1)O)O)C,"CBR-HVAC-10769: Hypertension, Treatment of;Heart Failure Therapy; Renin Inhibitors; Renin Inhibitor;"
CBR-001-597-290-4,RFM-007-115-8,CBR-001-597-290-4,CC(C[C@@H]([C@@H]([C@@H](NC(=O)C(CC(=O)N(CC(=O)N(CCc1ccccn1)C)CC1CCCCC1)Cc1csc(n1)N)CC1CCCCC1)O)O)C,"CBR-HVAC-10769: Hypertension, Treatment of;Heart Failure Therapy; Renin Inhibitors; Renin Inhibitor;"
CBR-001-597-291-5,RFM-007-116-9,CBR-001-597-291-5,CC(CC(=O)O[C@@H](C[N+](C)(C)C)CC(=O)OC/C=C/1\OC(=O)c2c1cc(Cl)cc2)C,"CBR-HVAC-11478: Septic Shock, Treatment of ; Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; Platelet activating factor receptor Antagonist;"
CBR-001-597-292-6,RFM-007-117-0,CBR-001-597-292-6,O=C([C@@H](N)C)N[C@]1(CC[C@@H]2[C@H]1[C@H]2C(=O)O)C(=O)O,CBR-HVAC-11646: Anxiolytics; METABOTROPHIC GLUTAMATE RECEPTOR 2; METABOTROPHIC GLUTAMATE RECEPTOR 3 Agonist;
CBR-001-597-293-7,RFM-007-118-1,CBR-001-597-293-7,C#Cc1c(ncnc1Nc1ccc(cc1F)C#N)OC1CCN(CC1)C(=O)OC(C)C,CBR-HVAC-11766: Dipeptidyl peptidase 4 Inhibitor;
CBR-001-597-294-8,RFM-007-119-2,CBR-001-597-294-8,C=CCN1C[C@H](C)N(C[C@H]1C)C(c1cccc(c1)O)c1ccsc1,CBR-HVAC-11837: DELTA OPIOD RECEPTOR Agonist;
CBR-001-597-295-9,RFM-007-120-5,CBR-001-597-295-9,O=C(c1ccc(cc1)O[C@@H]1C[C@H](C1)N1CCCCC1)N1CCOCC1,Analog of CBR-HVAC-11948; Histamine H3 receptor Antagonist;
CBR-001-597-296-0,RFM-007-121-6,CBR-001-597-296-0,OC(=O)CNC(=O)[C@H](CSCC(=O)N1CC(C1)([N+](=O)[O-])[N+](=O)[O-])N,metabolite of CBR-HVAC-07110
CBR-001-597-299-3,RFM-007-122-7,CBR-001-597-299-3,OC(=O)/C=C/C(=O)O,CBR-HVAC-00967
CBR-001-597-300-9,RFM-007-123-8,CBR-001-597-300-9,Clc1ccc(c(c1)Cl)[C@]1(OCC(O1)COc1ccc(cc1)N1CCN(CC1)C(=O)C)Cn1cncc1,"CBR-HVAC-00024: Cushing's Syndrome, Agents for;Antifungal Agents;Metabolic Disorders (Not Specified);Type 2 Diabetes, Agents for; Cortisol Synthesis Inhibitors;Lanosterol 14alpha-demethylase Inhibitors; Lanosterol 14 alpha-demethylase Inhibitor; Cell wall synthesis inhibitor; Sterol demethylase inhibitor"
CBR-001-597-301-0,RFM-007-124-9,CBR-001-597-301-0,COC1=CC(=N/C/1=C\c1[nH]c(cc1C)C)c1cc2c([nH]1)cccc2,CBR-HVAC-00318: ; BCL2 Inhibitor; Bcl2 inhibitor; Mcl-1 antagonist
CBR-001-597-302-1,RFM-007-125-0,CBR-001-597-302-1,COc1cc(ccc1Nc1ncc(c(n1)Nc1ccccc1P(=O)(C)C)Cl)N1CCC(CC1)N(C)C,CBR-HVAC-00676: ; Anaplastic lymphoma kinase receptor tyrosine kinase Inhibitor; ALK receptor tyrosine kinase inhibitor; ROS receptor tyrosine kinase inhibitor; EGFR antagonist
CBR-001-597-303-2,RFM-007-126-1,CBR-001-597-303-2,O=C(C1(CC1)c1ccc2c(c1)OC(O2)(F)F)Nc1ccc(c(n1)c1cccc(c1)C(=O)O)C,"CBR-HVAC-00703: Cystic Fibrosis, Treatment of ; CFTR Channel (DeltaF508-CFTR Mutant) Correctors; Cystic fibrosis transmembrane conductance regulator Modulator; CF transmembrane conductance regulator agonist"
CBR-001-597-304-3,RFM-007-127-2,CBR-001-597-304-3,O=C(Nc1c[nH]nc1c1nc2c([nH]1)ccc(c2)CN1CCOCC1)NC1CC1,CBR-HVAC-00764: Leukemia Therapy;Myelodysplastic Syndrome Therapy;Myeloid Leukemia Therapy;Multiple Myeloma Therapy;Non-Hodgkin's Lymphoma Therapy;Solid Tumors Therapy; Abl1 Kinase Inhibitors;Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Jak2 Inhibitors;Jak3 Inhibitors;Signal Transduction Modulators; Abl kinase; Aurora kinase A; Aurora kinase B; JAK2 kinase; JAK3 kinase Inhibitor; Inhibitor; Inhibitor; Inhibitor; Inhibitor; Aurora kinase inhibitor; Janus kinase 2 inhibitor; Mitotic inhibitor; Protein kinase inhibitor
CBR-001-597-305-4,RFM-007-128-3,CBR-001-597-305-4,CN1CCN(CC1)c1ccc2c(c1)[nH]c(n2)c1c(=O)[nH]c2c(c1N)c(F)ccc2,"CBR-HVAC-00853: Multiple Myeloma Therapy;Gastric Cancer Therapy;Endocrine Cancer Therapy;Pancreatic Cancer Therapy;Female Reproductive System Cancer Therapy;Prostate Cancer Therapy;Solid Tumors Therapy;Bladder Cancer Therapy ;Respiratory/Thoracic Cancer Therapy;Liver Cancer Therapy;Glioblastoma Multiforme Therapy;Renal Cancer Therapy;Neurological Genetic Disorders, Treatment of ;Digestive/Gastrointestinal Cancer Therapy;Melanoma Therapy;Non-Small Cell Lung Cancer Therapy;Head and Neck Cancer Therapy;Breast Cancer Therapy;Myeloid Leukemia Therapy;Colorectal Cancer Therapy; Angiogenesis Inhibitors;EGFR (HER1; erbB1) Inhibitors;FGFR1 Inhibitors;FGFR3 Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors; C-KIT; CSF-1R; FIBROBLAST GROWTH FACTOR; FMS-RELATED TYROSINE KINASE 3; PLATELET-DERIVED GROWTH FACTOR RECEPTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR Antagonist; Inhibitor; Fibroblast growth factor receptor 1 antagonist; Fibroblast growth factor receptor 3 antagonist; VEGFR-1 tyrosine kinase inhibitor; VEGFR-2 tyrosine kinase inhibitor; VEGFR-3 tyrosine kinase inhibitor; Platelet-derived growth factor receptor kinase inhibitor; C-kit inhibitor; Flt-3 kinase inhibitor; EGFR kinase inhibitor; Angiogenesis inhibitor; Vascular endothelial growth factor (VEGF)receptor antagonist; VEGFR tyrosine kinase inhibitor; FGF receptor tyrosine kinase inhibitor"
CBR-001-597-306-5,RFM-007-129-4,CBR-001-597-306-5,CCN1CCN(CC1)Cc1ccc(nc1)Nc1ncc(c(n1)c1cc(F)c2c(c1)n(C(C)C)c(n2)C)F,CBR-HVAC-00868: Non-Hodgkin's Lymphoma Therapy;Non-Small Cell Lung Cancer Therapy;Breast Cancer Therapy; CDK4 Inhibitors;CDK6 Inhibitors;Pim-1 Kinase Inhibitors;Signal Transduction Modulators; CDK4/CDK6 Inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CBR-001-597-307-6,RFM-007-130-7,CBR-001-597-307-6,CO/N=C(/c1nsc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C[n+]1ccn2c1cccn2,CBR-HVAC-01796: Antibiotics; Penicillin binding protein 5 Inhibitor; Cell wall synthesis inhibitor
CBR-001-597-308-7,RFM-007-131-8,CBR-001-597-308-7,CCC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F)C(=O)CCl,"CBR-HVAC-02009: Allergic Skin Disorders, Treatment for;Antipsoriatics; Antiinflammatory Drugs; Glucocorticoid agonist; Immunosuppressant"
CBR-001-597-309-8,RFM-007-132-9,CBR-001-597-309-8,O=C(C(C)C)OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@H]2[C@H]1CCC1=CC(=O)C=C[C@]21C)C1CCCCC1,CBR-HVAC-02013: Asthma Therapy;Drugs for Allergic Rhinitis; Glucocorticoid receptor Binder; Glucocorticoid agonist; Immunosuppressant
CBR-001-597-310-1,RFM-007-133-0,CBR-001-597-310-1,O[C@H]1CC[C@]2(C(=CCC3C2CC[C@]2(C3CC[C@@H]2C(=O)C)C)C1)C,CBR-HVAC-02415: ; Progesterone receptor agonist
CBR-001-597-311-2,RFM-007-134-1,CBR-001-597-311-2,N#CC1=C[C@@]2(C)[C@H](C(C1=O)(C)C)CC[C@@]1(C2=CC(=O)[C@H]2[C@@]1(C)CC[C@@]1([C@H]2CC(C)(C)CC1)C(=O)OC)C,"CBR-HVAC-02761: Rheumatoid Arthritis, Treatment of;Pancreatic Cancer Therapy;Melanoma Therapy;Solid Tumors Therapy;Hypertension, Treatment of;Interstitial Lung Diseases, Treatment of;Treatment of Renal Diseases;Inflammatory Bowel Disease, Agents for;Chemopreventive Agents;Treatment of Autoimmune Diseases; Angiogenesis Inhibitors;Antiinflammatory Drugs;Apoptosis Inducers;Bcl-2 Inhibitors;Glutathione Reductase (NADPH) Activators;Heme Oxygenase Activators;IKK-1 (IKK-alpha) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Nitric Oxide (NO) Production Inhibitors;Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activators;PPARgamma Agonists;Signal Transduction Modulators; Ribonucleotide reductase; Nuclear factor, erythroid derived 2, like 2; IKK beta Inhibitor; Activator; Inhibitor; Transcription factor Nrf2 stimulant; Reducing agent; Apoptosis stimulant"
CBR-001-597-312-3,RFM-007-135-2,CBR-001-597-312-3,ClCCN(P1(=O)NCCCO1)CCCl,"CBR-HVAC-02848: Immunosuppressants;Melanoma Therapy;Multisystem Genetic Disorders, Treatment of ;Treatment of Renal Diseases;Hematopoiesis Disorders Therapy;Systemic Lupus Erythematosus, Agents for;Inflammatory Bowel Disease, Agents for;Ovarian Cancer Therapy;Non-Hodgkin's Lymphoma Therapy;Scleroderma, Agents for;Multiple Myeloma Therapy;Endocrine Cancer Therapy;Neurologic Cancer Therapy;Oncolytic Drugs;Disease-Modifying Anti-Rheumatic Drugs;Treatment of Autoimmune Diseases;Neurologic Drugs (Miscellaneous);Lymphoma Therapy; Apoptosis Inducers;BCL2 Expression Inhibitors;LGALS1 Expression Inhibitors;"
CBR-001-597-313-4,RFM-007-136-3,CBR-001-597-313-4,OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)NC(=O)c1c(C)onc1c1ccccc1,CBR-HVAC-02851: Antibiotics; Penicillin binding protein Inhibitor;
CBR-001-597-314-5,RFM-007-137-4,CBR-001-597-314-5,COc1ccc(cc1)CN(c1ccccn1)CCN(C)C,"CBR-HVAC-02860: Local Anesthetics;Antipruritics;Allergic Skin Disorders, Treatment for; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist;"
CBR-001-597-315-6,RFM-007-138-5,CBR-001-597-315-6,CSCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)CCNC(=O)OC(C)(C)C,CBR-HVAC-02867: Diagnostic Agents; CCK2 (CCKB/Gastrin) Agonists;Signal Transduction Modulators;
CBR-001-597-316-7,RFM-007-139-6,CBR-001-597-316-7,CC[N+](CCOc1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC)(CC)CC,CBR-HVAC-03086: Neuromuscular Blockers; Muscarinic M2 Antagonists;Signal Transduction Modulators; Muscarinic acetylcholine receptor M2 Antagonist;
CBR-001-597-317-8,RFM-007-140-9,CBR-001-597-317-8,CN(CC/C=C\1/c2ccccc2Sc2c1cc(Cl)cc2)C,CBR-HVAC-03112: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators; Dopamine receptor D2 Antagonist;
CBR-001-597-318-9,RFM-007-141-0,CBR-001-597-318-9,CCC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)C)C(=O)COC(=O)C,"CBR-HVAC-03193: Atopic Dermatitis, Agents for;Topical Antiinflammatory Agents;Dermatologic Drugs;Eczema, Treatment of; Antiinflammatory Drugs;"
CBR-001-597-319-0,RFM-007-142-1,CBR-001-597-319-0,C1O[Pt]OC1=O,CBR-HVAC-03250: Non-Small Cell Lung Cancer Therapy;Genitourinary Cancer Therapy;Bladder Cancer Therapy ;Digestive/Gastrointestinal Cancer Therapy;Small Cell Lung Cancer Therapy;Female Reproductive System Cancer Therapy;Cervical Cancer Therapy;Ovarian Cancer Therapy;Head and Neck Cancer Therapy;
CBR-001-597-320-3,RFM-007-143-2,CBR-001-597-320-3,CCN1CCN(CC1)c1nc2ccccc2c(c1)c1ccccc1,CBR-HVAC-03553: Gastric Antisecretory Drugs;Anti-Helicobacter Pylori Agents;Antiulcer Drugs;
CBR-001-597-321-4,RFM-007-144-3,CBR-001-597-321-4,OC[C@H]1O[C@H](C[C@@H]1F)n1cc(C)c(=O)[nH]c1=O,CBR-HVAC-03649: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase Inhibitor;
CBR-001-597-322-5,RFM-007-145-4,CBR-001-597-322-5,CCC(c1c(=O)oc2c(c1O)cccc2)c1ccccc1,"CBR-HVAC-04635: Anticoagulants;Acute Myocardial Infarction, Treatment of; Vitamin K epoxide reductase Antagonist;"
CBR-001-597-323-6,RFM-007-146-5,CBR-001-597-323-6,CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)OP(=O)([O-])[O-])C,CBR-HVAC-05311: Anti-HIV Agents; Cytochrome P450 CYP3A4 Inhibitors;HIV Protease Inhibitors; Protease Inhibitor;
CBR-001-597-324-7,RFM-007-147-6,CBR-001-597-324-7,N#Cc1c(N2C[C@H]3[C@H](C2)NCCO3)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-05431: Antibacterial Drugs;Anti-Helicobacter Pylori Agents;
CBR-001-597-325-8,RFM-007-148-7,CBR-001-597-325-8,OCC(=O)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F,CBR-HVAC-05534: Dermatologic Drugs;
CBR-001-597-326-9,RFM-007-149-8,CBR-001-597-326-9,COCCOc1ccc(cc1)N1CCN(CC1)CCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1,"CBR-HVAC-05656: Extrapyramidal Disorders, Treatment of;Antiparkinsonian Drugs; Adenosine A2A Antagonists;Signal Transduction Modulators; Adenosine A2A receptor Antagonist; Adenosine A2a receptor antagonist; Adenosine receptor antagonist"
CBR-001-597-327-0,RFM-007-150-1,CBR-001-597-327-0,CCO[C@@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)(C)C)NC(=O)c1ccc(c(c1)Cl)N,CBR-HVAC-05785: Antiepileptic Drugs;Antipsoriatics; Caspase 1 (IL-1beta Converting Enzyme) Inhibitors;Signal Transduction Modulators; Interleukin 1beta converting enzyme inhibitor; Interleukin 18 antagonist
CBR-001-597-328-1,RFM-007-151-2,CBR-001-597-328-1,CCNC(=O)CC[C@@H](C(=O)O)N,"CBR-HVAC-05848: Antineoplastic Enhancing Agents;Ischemic Stroke, Treatment of;Chemoprotective Agents;Antipsychotic Drugs; Glutamate Ionotropic Antagonists;Signal Transduction Modulators;"
CBR-001-597-329-2,RFM-007-152-3,CBR-001-597-329-2,CN(CC(=O)NC[C@@H](NC(=O)c1ccc(c(c1)Cl)OC(C)C)Cc1ccc(cc1)c1nc2n(c1)cccc2[C@@H](O)C)C,CBR-HVAC-06324: Solid Tumors Therapy; Antimitotic Drugs;Centromere Associated Protein (CENP) Inhibitors; Centromere-associated protein E Inhibitor;
CBR-001-597-330-5,RFM-007-153-4,CBR-001-597-330-5,C1/C=C/COCc2cc(ccc2OCCN2CCCC2)/N=c/2\nc(c3cc(CO1)ccc3)cc[nH]2,CBR-HVAC-06622: Myeloid Leukemia Therapy;Hematopoiesis Disorders Therapy;Lymphoma Therapy;Colorectal Cancer Therapy; CDK2 Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators; Janus kinase 2; FLT-3 Inhibitor; Inhibitor;
CBR-001-597-331-6,RFM-007-154-5,CBR-001-597-331-6,Cc1cc(nn1c1ccc2c(c1)cccc2)OCCN1CCOCC1,"CBR-HVAC-07000: Neuropathic Pain, Treatment of;Non-Opioid Analgesics; sigma1 Receptor Antagonists;Signal Transduction Modulators; Sigma 1 receptor antagonist"
CBR-001-597-332-7,RFM-007-155-6,CBR-001-597-332-7,[O-]C(=O)C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F,CBR-HVAC-07061: Oncolytic Drugs; Pim Kinase Inhibitors;Signal Transduction Modulators;
CBR-001-597-333-8,RFM-007-156-7,CBR-001-597-333-8,COc1nc(CNC(=O)c2cc(ncc2c2nccs2)c2cncc(c2)C)ccc1OC,"CBR-HVAC-07193: Sleep Disorders, Treatment of; Orexin OX-2 Antagonists;Signal Transduction Modulators; Orexin receptor antagonist"
CBR-001-597-334-9,RFM-007-157-8,CBR-001-597-334-9,OC[C@H](c1cccc(c1)Cl)NC(=O)c1[nH]cc(c1)c1cc(ncc1Cl)NC(C)C,CBR-HVAC-07579: Myeloid Leukemia Therapy;Oncolytic Drugs;Melanoma Therapy;Solid Tumors Therapy; ERK1 Inhibitors;ERK2 Inhibitors;Signal Transduction Modulators; MAP kinase inhibitor
CBR-001-597-335-0,RFM-007-158-9,CBR-001-597-335-0,O=c1n([nH]cc1n1ccnn1)c1ncnc(c1)N1CCOCC1,CBR-HVAC-08061: ; HIF prolyl hydroxylase inhibitor
CBR-001-597-336-1,RFM-007-159-0,CBR-001-597-336-1,COc1ccc2c(c1)/C(=C/c1c[nH]cn1)/C(=O)N2,CBR-HVAC-08379: ; Cyclin-dependent kinase 2 inhibitor; Apoptosis stimulant
CBR-001-597-337-2,RFM-007-160-3,CBR-001-597-337-2,CC(=O)OC[C@@H](C(=O)O)N,CBR-HVAC-08437: ; Thromboxane A2 receptor antagonist
CBR-001-597-338-3,RFM-007-161-4,CBR-001-597-338-3,O=C([C@@]1(C[C@H]1C1CCCCC1)c1ccc(cc1)S(=O)(=O)C1CC1)Nc1ncc(s1)SCCN1CCCC1,CBR-HVAC-09447: ; Glucokinase Activator;
CBR-001-597-339-4,RFM-007-162-5,CBR-001-597-339-4,N=C1SCC[C@@](N1)(C)c1cc(c2cncnc2)c(cc1F)F,"CBR-HVAC-09492: Alzheimer's Dementia, Treatment of ; beta-Secretase 1 (BACE1) Inhibitors; BETA-SITE APP-CLEAVING ENZYME 1 Inhibitor;"
CBR-001-597-340-7,RFM-007-163-6,CBR-001-597-340-7,OC(C1CCCCC1)CC1c2ccccc2c2n1cnc2,"CBR-HVAC-09522: ; INDOLEAMINE 2,3-DIOXYGENASE Inhibitor;"
CBR-001-597-341-8,RFM-007-164-7,CBR-001-597-341-8,Brc1c(ccc2c1nccn2)NC1=NCCN1,CBR-HVAC-09549: ; Alpha adrenergic receptor Inhibitor;
CBR-001-597-342-9,RFM-007-165-8,CBR-001-597-342-9,COc1cc2c(ncnc2cc1OC)Nc1ccc(cc1)O,"CBR-HVAC-11484: Inflammation, Treatment of;Drugs for Allergic Rhinitis;Colorectal Cancer Therapy;Immunosuppressants;Leukemia Therapy; Cell Adhesion Inhibitors;Jak3 Inhibitors;Signal Transduction Modulators; Janus kinase 3 Inhibitor;"
CBR-001-597-343-0,RFM-007-166-9,CBR-001-597-343-0,Fc1ccc(cc1)c1c[nH]cc(c1=O)C(=O)Nc1ccc(c(c1)F)Oc1ccnc(c1Cl)N,"CBR-HVAC-11938: Angiogenesis Inhibitors; Hepatocyte Growth Factor Receptor (HGFR, MET) Inhibitors; Hepatocyte growth factor receptor Antagonist; Signal Transduction Modulators; VEGFR-2 (FLK-1/KDR) Inhibitors; ANTICANCER; Oncolytic Drugs"
CBR-001-597-344-1,RFM-007-167-0,CBR-001-597-344-1,CC(=O)O[Pt](OC(=O)C)(NC1CCCCC1)(Cl)(Cl)N,CBR-HVAC-04304: DNA Alkylating Drugs
CBR-001-597-345-2,RFM-007-168-1,CBR-001-597-345-2,CN1CCCN/C/1=C\OC(=O)C(c1ccccc1)(C1CCCCC1)O,CBR-HVAC-03169: Antispasmodics
CBR-001-597-346-3,RFM-007-169-2,CBR-001-597-346-3,O/N=C(\c1cc2c(s1)cc(c(c2)OC)OC)/N,CBR-HVAC-03868: Phosphodiesterase 3 inhibitor; Phosphodiesterase 4 inhibitor; Calcium channel stimulator
CBR-001-597-347-4,RFM-007-170-5,CBR-001-597-347-4,N#CC(c1nc2c(s1)cccc2)c1ccnc(n1)OCc1ccc(cc1)CN1CCOCC1,"CBR-HVAC-05924: Endometriosis Therapy;Cystic Fibrosis, Treatment of ;Multiple Sclerosis, Agents for; Endometriosis Therapy;Cystic Fibrosis, Treatment of ;Multiple Sclerosis, Agents for; SAPK1 (JNK) Inhibitors;Signal Transduction Modulators; ; JNK1 inhibitor; JNK2 inhibitor; JNK3 inhibitor"
CBR-001-597-348-5,RFM-007-171-6,CBR-001-597-348-5,CC(=O)N(c1cccc(c1)c1ccnc2n1ncc2C(=O)c1cccs1)C,CBR-HVAC-05119: GABA(A) Receptor Agonists; Signal Transduction Modulators
CBR-001-597-349-6,RFM-007-172-7,CBR-001-597-349-6,n1ccc(cc1)Cc1c[nH]cn1,CBR-HVAC-06062: Histamine H3 Receptor Agonists
CBR-001-597-350-9,RFM-007-173-8,CBR-001-597-350-9,O=C(Nc1ccc(c(c1)C(F)(F)F)Cl)Nc1ccc(cc1)Cl,CBR-HVAC-09014:
CBR-001-597-351-0,RFM-007-174-9,CBR-001-597-351-0,O=C1CCc2c(N1)cc(cc2)OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl,CBR-HVAC-01428: Efficacy of aripiprazole is mediated through a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors
CBR-001-597-352-1,RFM-007-175-0,CBR-001-597-352-1,CC[C@@H](c1cccc(c1)O)[C@H](CN(C)C)C,CBR-HVAC-01467: mu-Opioid Agonists; Norepinephrine Reuptake Inhibitors
CBR-001-597-353-2,RFM-007-176-1,CBR-001-597-353-2,CCCC(COC(=O)N)(COC(=O)NC(C)C)C,CBR-HVAC-01261: Nicotinic receptor antagonist
CBR-001-597-354-3,RFM-007-177-2,CBR-001-597-354-3,OC[C@H]1O[C@H]([C@H]([C@@H]1O)F)n1cc(C)c(=O)[nH]c1=O,CBR-HVAC-00939: Hepatitis B polymerase inhibitor
CBR-001-597-355-4,RFM-007-178-3,CBR-001-597-355-4,CCc1oc2c(c1C(=O)c1cc(Br)c(c(c1)Br)O)ccc(c2)S(=O)(=O)N(C)C,CBR-HVAC-08562: Hepatocyte growth factor agonist; HGF mimetic
CBR-001-597-356-5,RFM-007-179-4,CBR-001-597-356-5,Fc1ccc2c(c1)nc(c(c2)[C@@H](Nc1ncnc2c1nc[nH]2)C)c1ccccn1,CBR-HVAC-07105: Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors
CBR-001-597-357-6,RFM-007-180-7,CBR-001-597-357-6,COc1ccc(cc1)c1ssc(=S)c1,"CBR-HVAC-00123: Antioxidants; Sjogren's Syndrome, Agents for"
CBR-001-597-358-7,RFM-007-181-8,CBR-001-597-358-7,C1CN=C(N1)C1CCCc2c1cccc2,CBR-HVAC-06517: alpha2-Adrenoceptor Agonists
CBR-001-597-359-8,RFM-007-182-9,CBR-001-597-359-8,C(CP(c1ccccc1)c1ccccc1)CP(c1ccccc1)c1ccccc1,CBR-HVAC-10986: Oncolytic Drugs
CBR-001-597-360-1,RFM-007-183-0,CBR-001-597-360-1,COc1ccc(c(c1F)F)Oc1cc(NCCC(F)(F)F)c2n(n1)c(cn2)c1ccc(c(c1)C)C(=O)NC1CC1,CBR-HVAC-07370: BAY-1217389 is a dual specificity protein kinase TTK (MPS1; MPS1L1) inhibitor in phase I clinical studies at Bayer for the treatment of patients with advanced malignancies in combination with intravenous paclitaxel
CBR-001-597-361-2,RFM-007-184-1,CBR-001-597-361-2,COc1nc(CNC(=O)c2cc(cnc2c2ccccn2)c2cncc(c2)Cl)ccc1OC,CBR-HVAC-06996: Orexin OX-2 Antagonists
CBR-001-597-362-3,RFM-007-185-2,CBR-001-597-362-3,CCCCCS(=O)(=O)NC(=O)c1ccc2c(c1)n(Cc1ccc(cc1Cl)Cl)c(n2)C,CBR-HVAC-05289: Insulin Sensitizers; PPARgamma Agonists; Signal Transduction Modulators
CBR-001-597-363-4,RFM-007-186-3,CBR-001-597-363-4,COc1cc(ccc1N1CCC(CC1)N1CCN(CC1)C)Nc1nc(NC2CCOCC2)c(nc1C(=O)N)CC,CBR-HVAC-07317: AXL Kinase Inhibitors; Flt3 (FLK2/STK1) Inhibitors
CBR-001-597-364-5,RFM-007-187-4,CBR-001-597-364-5,Nc1ncc(cc1c1ccc(nc1)C(F)(F)F)c1ccc(cc1)S(=O)(=O)C,CBR-HVAC-07206:
CBR-001-597-365-6,RFM-007-188-5,CBR-001-597-365-6,Cc1ccc(cc1)c1ccc(cn1)OC1CN2CCC1CC2,CBR-HVAC-06057: Nicotinic alpha7 Partial Agonists
CBR-001-597-366-7,RFM-007-189-6,CBR-001-597-366-7,CNC1=Nc2ccc(cc2C(=[N+](C1)[O-])c1ccccc1)Cl,CBR-HVAC-03090: GABA(A) BZ Site Receptor Agonists
CBR-001-597-367-8,RFM-007-190-9,CBR-001-597-367-8,CCCC(C(CO)CC)O,CBR-HVAC-10260:
CBR-001-597-368-9,RFM-007-191-0,CBR-001-597-368-9,ClNC(=N)/N=N/C(=N)NCl,CBR-HVAC-09133:
CBR-001-597-369-0,RFM-007-192-1,CBR-001-597-369-0,[O-][N+](=O)c1cc2cccc3c2c(c1)c(=O)n(c3=O)CCN1CCCC1,CBR-HVAC-08205: Immunostimulant
CBR-001-597-370-3,RFM-007-193-2,CBR-001-597-370-3,CNC(=O)c1c(C)oc2c1ccc(c2)Oc1ncnc2c1cc(OC)c(c2)OC,CBR-HVAC-06968: Angiogenesis Inhibitors; VEGFR-1 (Flt-1) Inhibitors; VEGFR-2 (FLK-1/KDR) Inhibitors; VEGFR-3 (FLT4) Inhibitors
CBR-001-597-371-4,RFM-007-194-3,CBR-001-597-371-4,O=C1OC[C@]2([C@H](C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(C)O)C)C,CBR-HVAC-01569: RNA directed RNA polymerase stimulant; Androgen receptor agonist; Corticosteroid agonist
CBR-001-597-372-5,RFM-007-195-4,CBR-001-597-372-5,Oc1ccc2c(c1)CC[C@@H]([C@@H]2c1ccc(cc1)OCCN1CCCC1)c1ccccc1,CBR-HVAC-04842: Selective Estrogen Receptor Modulators (SERM)
CBR-001-597-373-6,RFM-007-196-5,CBR-001-597-373-6,Oc1ccc(cc1)C[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N)Cc1ccc(cc1)O)C)Cc1ccccc1)C)N,CBR-HVAC-07593: Antidiarrheal Agents; Opioid Analgesics
CBR-001-597-374-7,RFM-007-197-6,CBR-001-597-374-7,CCCN(C(=O)C(NC(=O)c1ccccc1)CCC(=O)OCCCN1CCN(CC1)CCOC(=O)Cc1c2cc(OC)ccc2n(c1C)C(=O)c1ccc(cc1)Cl)CCC,CBR-HVAC-01933: Cyclooxygenase-3 Inhibitors; Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors
CBR-001-597-375-8,RFM-007-198-7,CBR-001-597-375-8,N#CN/C(=N\CCCCCCOc1ccc(cc1)Cl)/Nc1ccncc1,CBR-HVAC-05002: Inhibitory kappaB Kinase (IKK) Inhibitors; NF-kappaB (NFKB) Activation Inhibitors; Nicotinamide Phosphoribosyltransferase (NAmPRTase; Nampt) Inhibitors; Signal Transduction Modulators
CBR-001-597-376-9,RFM-007-199-8,CBR-001-597-376-9,Cc1ccc(c(c1)C(=O)N1CCN(CC[C@H]1C)c1oc2c(n1)cc(cc2)Cl)n1nccn1,CBR-HVAC-06696: Cytochrome P450 CYP2C19 Inhibitors; Cytochrome P450 CYP3A4 Inhibitors; Orexin OX-1 Antagonists; Orexin OX-2 Antagonists; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Signal Transduction Modulators
CBR-001-597-377-0,RFM-007-200-4,CBR-001-597-377-0,Fc1cc(cc(c1)F)N[C@@H](c1cc(cc2c1oc(cc2=O)N1CCOCC1)C(=O)N(C)C)C,CBR-HVAC-07147: Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors; Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors; Signal Transduction Modulators
CBR-001-597-378-1,RFM-007-201-5,CBR-001-597-378-1,Cc1ncc(nc1)C(=O)N[C@@H]1CCCCC/C=C\[C@H]2C(NC(=O)[C@H]3N(C1=O)CC(C3)Oc1nc3ccccc3c3c1cccc3)(C2)C(=O)NS(=O)(=O)C1CC1,CBR-HVAC-07345: HCV NS3 NS4A Protease Inhibitors
CBR-001-597-379-2,RFM-007-202-6,CBR-001-597-379-2,NCC1(CCN(CC1)c1ncnc2c1c(C)c[nH]2)C(=O)Nc1cccc(c1)OC(=O)N(C)C,CBR-HVAC-07229: LIM Domain Kinase 1 (LIMK1) Inhibitors; LIM Domain Kinase 2 (LIMK2) Inhibitors; Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors; Signal Transduction Modulators
CBR-001-597-380-5,RFM-007-203-7,CBR-001-597-380-5,COc1cc(ccc1Nc1nc2n(n1)cc(cc2)c1ccc(cc1)NC(=O)[C@@H](c1ccc(cc1)F)C)S(=O)(=O)C,CBR-HVAC-07309: BAY-1161909 is an oral dual specificity protein kinase TTK inhibitor in early clinical trials at Bayer for the treatment of advanced malignancies in combination with paclitaxel
CBR-001-597-381-6,RFM-007-204-8,CBR-001-597-381-6,CC/C(=C(\c1ccc2c(c1)cn[nH]2)/c1ccc(cc1)/C=C/C(=O)O)/c1ccc(cc1Cl)F,CBR-HVAC-07291: Selective Estrogen Receptor Destabilizers (SERD); Signal Transduction Modulators
CBR-001-597-382-7,RFM-007-205-9,CBR-001-597-382-7,N#Cc1cc(cc(c1)F)Oc1ccc(c2c1CC([C@H]2O)(F)F)S(=O)(=O)C,CBR-HVAC-07382: Hypoxia Inducible Factor 2-alpha (HIF-2alpha) Inhibitors; Signal Transduction Modulators
CBR-001-597-383-8,RFM-007-206-0,CBR-001-597-383-8,Nc1ncc(c(c1)C(F)(F)F)c1nc(nc(n1)N1CCOCC1)N1CCOCC1,CBR-HVAC-07023: PQR-309 is a phosphatidylinositol 3-Kinase (PI3K) and mammalian target of rapamycin (mTOR; FRAP1) inhibitor developed by Universität Basel
CBR-001-597-384-9,RFM-007-207-1,CBR-001-597-384-9,OC[C@H]1O[C@]2(OCc3c2cc(cc3)Cc2ccc(cc2)CC)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-00901: Sodium/glucose cotransporter 2 inhibitor
CBR-001-597-385-0,RFM-007-208-2,CBR-001-597-385-0,CCC1(O)C(=O)OCc2c1cc1c3nc4cc(F)c(c5c4c(c3Cn1c2=O)C(N)CC5)C,CBR-HVAC-04459: DNA Topoisomerase I Inhibitors
CBR-001-597-386-1,RFM-007-209-3,CBR-001-597-386-1,Cc1ccc(cc1)c1cc(nn1c1ccc(cc1)S(=O)(=O)N)C(F)(F)F,CBR-HVAC-01487: Angiogenesis Inhibitors; Apoptosis Inducers; Carbonic Anhydrase Inhibitors; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors
CBR-001-597-387-2,RFM-007-210-6,CBR-001-597-387-2,OC(=O)C1(CC1)c1ccc(c(c1)F)c1ccc(c(c1)Cl)Cl,CBR-HVAC-00633: Beta-amyloid protein 42 release inhibitor; Cyclooxygenase 1 inhibitor
CBR-001-597-388-3,RFM-007-211-7,CBR-001-597-388-3,COc1cc2c(cc1OCCCOc1cc3N=C[C@H]4N(C(=O)c3cc1OC)CC(=C)C4)N=C[C@H]1N(C2=O)CC(=C)C1,CBR-HVAC-00276: DNA intercalator
CBR-001-597-389-4,RFM-007-212-8,CBR-001-597-389-4,ClCCNP(=O)(NCCCl)O,CBR-HVAC-00783: DNA inhibitor; DNA synthesis inhibitor
CBR-001-597-390-7,RFM-007-213-9,CBR-001-597-390-7,Nc1ccn(c(=O)n1)[C@H]1[C@H](O)[C@@H](C(=C1F)CO)O,CBR-HVAC-00249: DNA SYNTHESIS INHIBITOR; RNA SYNTHESIS INHIBITOR
CBR-001-597-391-8,RFM-007-214-0,CBR-001-597-391-8,O=C1NC(=O)[C@]2(C1)C(=O)N(Cc1ccc(cc1F)Br)C(=O)c1n2ccc1,CBR-HVAC-00841: Aldose Reductase Inhibitors
CBR-001-597-392-9,RFM-007-215-1,CBR-001-597-392-9,N[C@H]1CCN(C1)c1nc2cc(nn2cc1C)[C@@H]1CCCCN1C(=O)c1cc(Cl)ccc1NS(=O)(=O)C,"CBR-HVAC-07367: GS-5806, an oral viral fusion inhibitor, is in phase II trials at Gilead for the treatment of respiratory syncytial virus (RSV) infections."
CBR-001-597-393-0,RFM-007-216-2,CBR-001-597-393-0,O=C1CCc2c(=N1)[nH]cc(c2)/C=C/C(=O)N(Cc1oc2c(c1C)cccc2)C,CBR-HVAC-00590:  Enoyl-[acyl-carrier-protein] reductase inhibitor
CBR-001-597-394-1,RFM-007-217-3,CBR-001-597-394-1,COc1cc(OC)cc(c1)N(c1ccc2c(c1)nc(cn2)c1cnn(c1)C)CCNC(C)C,CBR-HVAC-07266: FGFR1 Inhibitors; FGFR2 Inhibitors;FGFR3 Inhibitors;FGFR4 Inhibitors
CBR-001-597-395-2,RFM-007-218-4,CBR-001-597-395-2,CCCCc1nc(cn1c1ccc(cc1)Oc1ccc(cc1)Cl)c1ccc(cc1)OCCCN(CC)CC,CBR-HVAC-06189: Antiamyloidogenic Agents; RAGE Receptor Antagonists
CBR-001-597-396-3,RFM-007-219-5,CBR-001-597-396-3,OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@H]2[C@H]1C[C@@H](C1=CC(=O)CC[C@]21C)F)(C)C,CBR-HVAC-06760: Corticosteroids
CBR-001-597-397-4,RFM-007-220-8,CBR-001-597-397-4,COC(=O)C(c1ccccc1)C1CCCCN1,CBR-HVAC-01299: Blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space
CBR-001-597-398-5,RFM-007-221-9,CBR-001-597-398-5,CC(=O)Oc1ccccc1C(=O)Nc1ncc(s1)[N+](=O)[O-],CBR-HVAC-02101: The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism.
CBR-001-597-399-6,RFM-007-222-0,CBR-001-597-399-6,O=C1CC(=NN1c1ccccc1)C,"CBR-HVAC-01573: Free radical scavengers, Hydroxy radical scavengers. Anti-ischaemic and radical scavenging activity; protective effects against reperfusion injury following ischaemia."
CBR-001-597-400-2,RFM-007-223-1,CBR-001-597-400-2,COc1cc(O)cc(c1C(=O)c1c(O)cc(cc1O)C)C(=O)OC,CBR-HVAC-09178:  Eosinophilic degranulation inhibitor; Vascular endothelial growth factor inhibitor
CBR-001-597-401-3,RFM-007-224-2,CBR-001-597-401-3,CCN(CCOC(=O)C(c1ccccc1)C1CCCCC1)CC,CBR-HVAC-09016:
CBR-001-597-402-4,RFM-007-225-3,CBR-001-597-402-4,CCCCC(C/N=C(\N/C(=N/CCCCCC/N=C(\N/C(=N/CC(CCCC)CC)/N)/N)/N)/N)CC,CBR-HVAC-10022:
CBR-001-597-403-5,RFM-007-226-4,CBR-001-597-403-5,c1ccc2c(c1)C1=N/C/2=N\c2c3ccccc3c3n2[Zn]n2/c(=N\1)/c1ccccc1/c/2=N/C1=N/C(=N\3)/c2c1cccc2,CBR-HVAC-04549: Apoptosis Inducers; Caspase 3 Activators; Caspase 9 Activators; Radical formation agonist; Reactive-oxygen-species-stimulants; Signal Transduction Modulators; Anticancer; Cancer; Photosensitizer; Radical donator; Radiochemosensitizer
CBR-001-597-404-6,RFM-007-227-5,CBR-001-597-404-6,S1SCc2c(C1)cccc2,CBR-HVAC-10629: Viral replication inhibitor
CBR-001-597-405-7,RFM-007-228-6,CBR-001-597-405-7,O=C1NC(=O)C(N1C)O,CBR-HVAC-03332:
CBR-001-597-406-8,RFM-007-229-7,CBR-001-597-406-8,CCC(NC(=N)NC#N)(C)C,CBR-HVAC-05590:
CBR-001-597-407-9,RFM-007-230-0,CBR-001-597-407-9,Clc1c[nH]cc1c1cccc(c1[N+](=O)[O-])Cl,CBR-HVAC-10306:
CBR-001-597-408-0,RFM-007-231-1,CBR-001-597-408-0,[O-][N+](=O)c1ccc(cc1)n1cc(nc1C)[N+](=O)[O-],CBR-HVAC-05528: Antitrichomonals
CBR-001-597-409-1,RFM-007-232-2,CBR-001-597-409-1,Nc1ccc(cc1)S(=O)(=O)c1cnc(s1)N,CBR-HVAC-08750:
CBR-001-597-410-4,RFM-007-233-3,CBR-001-597-410-4,CNCC(c1ccc(cc1)O)O,CBR-HVAC-06551: alpha1-Adrenoceptor Agonists; Antiinflammatory Drugs; L-Type Calcium Channel Activators
CBR-001-597-411-5,RFM-007-234-4,CBR-001-597-411-5,O=C1OC(OC1(c1ccccc1)c1ccccc1)CCN1CCCCC1,CBR-HVAC-08604:
CBR-001-597-412-6,RFM-007-235-5,CBR-001-597-412-6,Nc1ccc(cc1)S(=O)(=O)Nc1noc(c1C)C,CBR-HVAC-08743:
CBR-001-597-413-7,RFM-007-236-6,CBR-001-597-413-7,C[As](SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C,CBR-HVAC-00638:  C-Jun N-terminal kinase inhibitor; Glucocorticoid receptor agonist; Topoisomerase II inhibitor; Tubulin inhibitor
CBR-001-597-419-3,RFM-007-237-7,CBR-001-597-419-3,O=C([C@@](C(F)(F)F)(O)C)Nc1cccc2c1C(=O)c1sccc1CS2(=O)=O,"CBR-HVAC-00337: Irritable Bowel Syndrome, Agents for;Urinary Incontinence Therapy; Potassium Channel Activators; Putative afferent nerve inhibitor; Potassium channel agonist"
CBR-001-597-420-6,RFM-007-238-8,CBR-001-597-420-6,COC(=O)[C@@H](c1ccccc1)N1CCC(CC1)c1ccc(cc1)NC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F,"CBR-HVAC-00532: Type 2 Diabetes, Agents for;Antiobesity Drugs; Microsomal Triglyceride Transfer Protein (MTTP) Inhibitors; Microsomal triglyceride transfer protein Inhibitor; Microsomal trigylceride transfer protein inhibitor"
CBR-001-597-421-7,RFM-007-239-9,CBR-001-597-421-7,O=CN(C[C@H](C(=O)NNc1nc(C)nc(c1F)N1CCN2[C@@H](C1)COCC2)CC1CCCC1)O,CBR-HVAC-00766: Antibacterial Drugs; Peptide Deformylase (PDF) Inhibitors; PEPTIDE DEFORMYLASE Inhibitor; Deformylase inhibitor
CBR-001-597-422-8,RFM-007-240-2,CBR-001-597-422-8,OC[C@H]1OC(C[C@@H]1O)n1cnc(nc1=O)N,"CBR-HVAC-01908: Hematologic Agents (Miscellaneous);Small Cell Lung Cancer Therapy;Renal Cancer Therapy;Lung Cancer Therapy;Digestive/Gastrointestinal Cancer Therapy;Solid Tumors Therapy;Breast Cancer Therapy;Colorectal Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Sickle Cell Anemia, Agents for;Myelodysplastic Syndrome Therapy;Melanoma Therapy;Myeloid Leukemia Therapy;Lymphocytic Leukemia Therapy;Bladder Cancer Therapy ;Ovarian Cancer Therapy;Hematopoiesis Disorders Therapy; Antimetabolites;DNA Methyltransferase (DNMT) Inhibitors; DNA methyltransferase Inhibitor; DNA methylase inhibitor"
CBR-001-597-423-9,RFM-007-241-3,CBR-001-597-423-9,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-02037: DNA gyrase; DNA topoisomerase IV Inhibitor; Protein 50S ribosomal subunit inhibitor; Protein synthesis inhibitor
CBR-001-597-424-0,RFM-007-242-4,CBR-001-597-424-0,CCOC(=O)C1(CCN(CC1)C)c1ccccc1,CBR-HVAC-03091: Opioid Analgesics; Opioid Receptor Agonists;Signal Transduction Modulators; Opioid receptor mu Modulator;
CBR-001-597-425-1,RFM-007-243-5,CBR-001-597-425-1,O=C1c2c(cccc2C(=O)c2c1cn1c2C(C)c2c(C1)cccc2)OP(=O)(OCc1ccccc1)O,CBR-HVAC-03708: Oncolytic Drugs; DNA topoisomerase II Inhibitor; Unidentified pharmacological activity
CBR-001-597-426-2,RFM-007-244-6,CBR-001-597-426-2,OC(=O)C1=Cc2c(CC1)cc(s2)Cn1cncc1,CBR-HVAC-03720: Antiallergy/Antiasthmatic Drugs; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Platelet aggregation inhibitor
CBR-001-597-427-3,RFM-007-245-7,CBR-001-597-427-3,Cc1ccc(c(c1)NC(c1c(Cl)cccc1Cl)C(=O)N)C(=O)C,CBR-HVAC-04298: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; RNA directed DNA polymerase inhibitor
CBR-001-597-428-4,RFM-007-246-8,CBR-001-597-428-4,CCOCn1c(=O)[nH]c(=O)c(c1Cc1ccccc1)C(C)C,CBR-HVAC-04498: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-597-429-5,RFM-007-247-9,CBR-001-597-429-5,CC(=CCOc1cc(ccc1Cl)NC(=S)c1ccoc1C)C,CBR-HVAC-04820: Microbicides;Anti-HIV Agents; Reverse Transcriptase Inhibitors; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-597-430-8,RFM-007-248-0,CBR-001-597-430-8,CN(C(=O)CC(C)(C)C)Cc1cc(ccc1c1ccccc1S(=O)(=O)Nc1noc(c1C)C)c1ncco1,CBR-HVAC-05136: Heart Failure Therapy; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist;
CBR-001-597-431-9,RFM-007-249-1,CBR-001-597-431-9,O=C(Cn1c(ncc(c1=O)N)c1ccccc1)NC(C(=O)c1nnc(o1)C(C)(C)C)C(C)C,"CBR-HVAC-05315: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Leukocyte Elastase Inhibitors;"
CBR-001-597-432-0,RFM-007-250-4,CBR-001-597-432-0,CC[N+](CCSC1=Nc2ccccc2N=C(C1)c1ccc(cc1)Sc1ccccc1)(CC)C,CBR-HVAC-05530: Antibacterial Drugs; Protein synthesis inhibitor
CBR-001-597-433-1,RFM-007-251-5,CBR-001-597-433-1,CCn1c2ncc(cc2c(=O)n(c2c1nccc2)C)CCOc1cc[n+](c2c1cccc2)[O-],CBR-HVAC-05662: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase Inhibitor;
CBR-001-597-434-2,RFM-007-252-6,CBR-001-597-434-2,COc1cccc(c1OC)[C@H]1O[C@H](CC(=O)N2CCC(CC2)CC(=O)O)C(=O)N(c2c1cc(Cl)cc2)CC(COC(=O)C)(C)C,"CBR-HVAC-05718: Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors; SQUALENE SYNTHASE Inhibitor; Squalene synthetase inhibitor; Farnesyltransferase inhibitor"
CBR-001-597-435-3,RFM-007-253-7,CBR-001-597-435-3,N#Cc1cc(Cl)cc(c1)C(=O)c1cc(Cl)ccc1OCC(=O)Nc1ccc(cc1C)S(=O)(=O)N,CBR-HVAC-05770: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase Inhibitor;
CBR-001-597-436-4,RFM-007-254-8,CBR-001-597-436-4,CO[C@H]1C[C@H](N(C1)C(=O)Cc1cc(Cl)c(cc1Cl)NC(=O)c1cn(c2c1cccc2)C)CO[C@@H]1CC[C@H](CC1)C(=O)O,CBR-HVAC-06205: Antiarthritic Drugs;Antiallergy/Antiasthmatic Drugs;Oncolytic Drugs; Cell Adhesion Inhibitors;Integrin alpha4beta1 (VLA-4) Antagonists;Signal Transduction Modulators;
CBR-001-597-437-5,RFM-007-255-9,CBR-001-597-437-5,CSCC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)CCC(=O)O)CS)CC(=O)O)NC=O,CBR-HVAC-06520: Colorectal Cancer Therapy;Breast Cancer Therapy;Prostate Cancer Therapy;
CBR-001-597-438-6,RFM-007-256-0,CBR-001-597-438-6,CCCNC(=O)COc1c(ccc(c1OC)OC)C(=O)Cc1c(Cl)cncc1Cl,"CBR-HVAC-07362: Eczema, Treatment of;Atopic Dermatitis, Agents for;Antipsoriatics; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Release Inhibitors;"
CBR-001-597-439-7,RFM-007-257-1,CBR-001-597-439-7,CCCCN(CCCC)CCCOc1ccc(cc1Cl)C(=O)c1c(c2ccccc2)c(c2n1cccc2)Br,CBR-HVAC-08270: Polarisation inhibitor
CBR-001-597-440-0,RFM-007-258-2,CBR-001-597-440-0,CC(CCCC(C1CCC2[C@]1(C)CCC1C2CCC2[C@]1(C)CC[C@H](C2)N1CC(C1)OS(=O)(=O)C)C)C,CBR-HVAC-08329: Corticosteroid agonist; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-597-441-1,RFM-007-259-3,CBR-001-597-441-1,CC(CCCC(C1CCC2[C@]1(C)CCC1C2CCC2[C@]1(C)CC[C@@H](C2)N1CC(C1)OS(=O)(=O)C)C)C,CBR-HVAC-08329: Corticosteroid agonist; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-597-442-2,RFM-007-260-6,CBR-001-597-442-2,Clc1ccc2c(c1)N(C(=O)N)c1ccccc1CO2,CBR-HVAC-08360: Antidepressants; Unidentified pharmacological activity
CBR-001-597-443-3,RFM-007-261-7,CBR-001-597-443-3,O=C(N[C@H](c1ccc2c(c1)OCO2)CC(=O)O)N[C@H](CSc1ccccc1)CSCc1ccccc1,CBR-HVAC-09206: Integrin alpha4 beta1 Antagonist;
CBR-001-597-444-4,RFM-007-262-8,CBR-001-597-444-4,COc1ccc(cc1Cl)CNc1nc(nc2c1c1ccccc1s2)[C@@H]1CC[C@H](CC1)C(=O)O,CBR-HVAC-09327: Phosphodiesterase 5A Inhibitor;
CBR-001-597-445-5,RFM-007-263-9,CBR-001-597-445-5,CN(CC(C1(CCCCC1c1ccccc1)OC(=O)C)C)C,CBR-HVAC-10086:
CBR-001-597-446-6,RFM-007-264-0,CBR-001-597-446-6,OC(=O)CC[C@@H](C(=O)Nc1ccccc1)NC(=O)[C@H](Cc1ccccc1)CSC1OC(=O)c2c1cccc2,"CBR-HVAC-10429: Antiepileptic Drugs;Opioid Analgesics;Anxiolytics; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Membrane metalloendopeptidase Inhibitor;"
CBR-001-597-447-7,RFM-007-265-1,CBR-001-597-447-7,O=C(C12C3C4C2C2(C1C3C4C12OCCO1)Br)NCCCOc1cccc(c1)CN1CCCCC1,analog of CBR-HVAC-11482
CBR-001-597-448-8,RFM-007-266-2,CBR-001-597-448-8,CCC(=O)Nc1ccc(c(c1)NC(=O)c1ccc(cc1)C(=O)O)C(=O)O,metabolite of CBR-HVAC-03680
CBR-001-597-449-9,RFM-007-267-3,CBR-001-597-449-9,CCC1NCCN(C1)c1cc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-12307: DNA gyrase inhibitor; Topoisomerase IV inhibitor
CBR-001-597-450-2,RFM-007-268-4,CBR-001-597-450-2,CCCCCCCCc1ccc(cc1)c1noc(n1)C[C@@H]1CCCN1C(=N)N,CBR-HVAC-12266: Sphingosine Kinase 1 (SphK1) Inhibitors
CBR-001-597-451-3,RFM-007-269-5,CBR-001-597-451-3,CCCc1cc(O)c(c(c1)O)[C@H]1C=C(C)CC[C@@H]1C(=C)C,CBR-HVAC-12262: TRPA1 Agonists; TRPM8 (TRP-p8; CMR1) Antagonist; TRPV1 (Vanilloid VR1 Receptor) Agonists; TRPV2 (Vanilloid VR2 Receptor) Agonists
CBR-001-597-452-4,RFM-007-270-8,CBR-001-597-452-4,CCC(C(=O)Nc1ncc(c(c1)CN1CCOCC1)C)(C)C,CBR-HVAC-12327: Cannabinoid CB2 receptor agonist
CBR-001-597-453-5,RFM-007-271-9,CBR-001-597-453-5,CC1NCCN(C1)c1cc2c(cc1F)c(=O)c(cn2C(C)(C)C)C(=O)O,CBR-HVAC-12201: Antibacterial Drugs
CBR-001-597-454-6,RFM-007-272-0,CBR-001-597-454-6,CCc1c(=O)[nH]c(=O)n(c1C(=O)c1cc(C)cc(c1)C)CC1CC=CC1,CBR-HVAC-12260:  Non-nucleoside reverse transcriptase inhibitor
CBR-001-597-455-7,RFM-007-273-1,CBR-001-597-455-7,COc1ccccc1N1CCN(CC1)S(=O)(=O)c1ccc(cc1)C,CBR-HVAC-12301: Cystic fibrosis transmembrane conductance regulator modulator
CBR-001-597-456-8,RFM-007-274-2,CBR-001-597-456-8,Cc1cc(Nc2cc(cc(c2)C(=O)C)C(=O)C)nc(n1)N,CBR-HVAC-12255: HIV replication inhibitor
CBR-001-597-457-9,RFM-007-275-3,CBR-001-597-457-9,CCS(=O)(=O)c1ccc(nc1)CNC(=O)c1cnc2c(c1)CN([C@H]2C(C)C)C[C@@H]1CC[C@H](CC1)C(F)(F)F,"CBR-HVAC-12182: VTP-43742 is a RORgammat inhibitor developed at Vitae Pharmaceuticals in early phase clinical trials for the treatment of autoimmune disorders, including moderate to severe psoriasis"
CBR-001-598-249-7,RFM-007-276-4,CBR-001-598-249-7,CC(=O)Oc1ccc(cc1I)Oc1c(I)cc(cc1I)C(=O)O,CBR-HVAC-09382: Antihyperlipidemic;
CBR-001-598-250-0,RFM-007-277-5,CBR-001-598-250-0,CC(=O)NC/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,shipped as CBR-HVAC-00207; unstable when Pharmaron synthesized. Discarded stock.
CBR-001-598-251-1,RFM-007-278-6,CBR-001-598-251-1,CC1=C(/C=C/C#Cc2ccc(cc2)C(=O)O)C(CCC1)(C)C,CBR-HVAC-09346: Retinoid X receptor; Retinoid acid receptor Agonist;
CBR-001-598-252-2,RFM-007-279-7,CBR-001-598-252-2,OC(=O)c1ccc(cc1)C#Cc1ccc(c(c1)OC1CCCCO1)C(C)(C)C,CBR-HVAC-09342: Retinoid X receptor; Retinoid acid receptor Agonist;
CBR-001-598-253-3,RFM-007-280-0,CBR-001-598-253-3,CCCc1cc2c(cc1N(CC)CC)ncc(c2O)C(=O)OC,CBR-HVAC-08789:
CBR-001-598-254-4,RFM-007-281-1,CBR-001-598-254-4,CCO/N=C(\c1ccc(cc1)Br)/C1CCN(CC1)C1(C)CCN(CC1)C(=O)c1c(C)cc[n+](c1C)[O-],CBR-HVAC-05527: Anti-HIV Agents; Chemokine CCR5 Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators; C-C chemokine receptor type 5 Antagonist;
CBR-001-598-255-5,RFM-007-282-2,CBR-001-598-255-5,CCN(CCCN1C(=O)C(C)(C)c2c(C1=O)c1[nH]c(nc1cc2)c1ccccc1)CC,CBR-HVAC-07473: Sodium channel antagonist
CBR-001-598-256-6,RFM-007-283-3,CBR-001-598-256-6,O=C(N1CCN(CC1)C(=O)[C@@H]1NCCN(C1)C(C)(C)C)Nc1ccc(c(c1)F)Cl,CBR-HVAC-09332: CHEMOKINE RECEPTOR 2 Antagonist;
CBR-001-598-257-7,RFM-007-284-4,CBR-001-598-257-7,CCCCCCCCCCCCCCN([C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1NC(=O)CN)O)O)C(=O)CCCCCCCCCCC,CBR-HVAC-10937: Immunostimulants; Immunostimulator;
CBR-001-598-258-8,RFM-007-285-5,CBR-001-598-258-8,CCCc1c(cc(c(c1c1ccc(cc1)F)C(O)C)C(C)C)C(C)C,"CBR-HVAC-05204: Type 2 Diabetes, Agents for; Glucagon Receptor (GCGR) Antagonists;Signal Transduction Modulators; Glucagon receptor Antagonist;"
CBR-001-598-259-9,RFM-007-286-6,CBR-001-598-259-9,OP(=O)([C@@H](S(=O)(=O)O)CCCc1cccc(c1)Oc1ccccc1)O,"CBR-HVAC-04581: Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors; SQUALENE SYNTHASE Inhibitor;"
CBR-001-598-260-2,RFM-007-287-7,CBR-001-598-260-2,OP(=O)([C@H](S(=O)(=O)O)CCCc1cccc(c1)Oc1ccccc1)O,"CBR-HVAC-04581: Lipoprotein Disorders, Treatment of ; Squalene Synthase Inhibitors; SQUALENE SYNTHASE Inhibitor;"
CBR-001-598-261-3,RFM-007-288-8,CBR-001-598-261-3,OC(=O)/C=C(\C(=C\c1ccc2c(c1)cc1c(c2)C(C)(C)CCC1(C)C)\c1cccc(c1)C(=O)O)/C,CBR-HVAC-09465: Antiinflammatory Drugs; Phospholipase A2 (PLA2) Inhibitors; Phospholipase A2 inhibitor; Signal Transduction Modulators; phospholipase A2 type II INHIBITOR; ANTIPSORIATIC; Antipsoriatics
CBR-001-598-262-4,RFM-007-289-9,CBR-001-598-262-4,CCCCCCCCC#CCC#CCC#CCCCC(=O)NCCOCCO,CBR-HVAC-03572: Antiinflammatory Drugs;
CBR-001-598-263-5,RFM-007-290-2,CBR-001-598-263-5,O=C(C(c1ccc(cc1)C(C(=O)Oc1ccc(cc1)S(=O)(=O)CC(C(=O)O)(C)C)(C)C)(C)C)Oc1ccc(cc1)S(=O)(=O)CC(C(=O)O)(C)C,"CBR-HVAC-04391: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Leukocyte Elastase Inhibitors; Leukocyte elastase Inhibitor; Elastase inhibitor"
CBR-001-598-264-6,RFM-007-291-3,CBR-001-598-264-6,COc1cc2nc(sc2cc1NC(=S)SCCC(=O)O)C(C)(C)C,CBR-HVAC-03620: Treatment of Helminthic Diseases; Unidentified pharmacological activity
CBR-001-598-265-7,RFM-007-292-4,CBR-001-598-265-7,COc1ccc2c(c1NC(=S)SCCC(=O)O)nc(s2)C(C)(C)C,CBR-HVAC-03620: Treatment of Helminthic Diseases; Unidentified pharmacological activity
CBR-001-598-266-8,RFM-007-293-5,CBR-001-598-266-8,CC(N[C@@H]1C=CC(C1)(c1ccccc1)c1ccccc1)(C)C,CBR-HVAC-04652: Urinary Incontinence Therapy; Anticholinergics;Signal Transduction Modulators; Acetylcholine receptor antagonist
CBR-001-598-267-9,RFM-007-294-6,CBR-001-598-267-9,CC(N[C@H]1C=CC(C1)(c1ccccc1)c1ccccc1)(C)C,CBR-HVAC-04652: Urinary Incontinence Therapy; Anticholinergics;Signal Transduction Modulators; Acetylcholine receptor antagonist
CBR-001-598-268-0,RFM-007-295-7,CBR-001-598-268-0,OC(=O)COc1cccc2c1CC[C@](C2)(O)COC(=O)N(c1ccccc1)c1ccccc1,CBR-HVAC-04764: Vasodilators;Antiplatelet Therapy;Agents for Viral Hepatitis; Prostanoid IP Agonists;Signal Transduction Modulators; Prostaglandin I2 receptor Agonist; Prostaglandin IP2 receptor agonist; Immunosuppressant
CBR-001-598-269-1,RFM-007-296-8,CBR-001-598-269-1,OC(=O)COc1cccc2c1CC[C@@](C2)(O)COC(=O)N(c1ccccc1)c1ccccc1,CBR-HVAC-04764: Vasodilators;Antiplatelet Therapy;Agents for Viral Hepatitis; Prostanoid IP Agonists;Signal Transduction Modulators; Prostaglandin I2 receptor Agonist; Prostaglandin IP2 receptor agonist; Immunosuppressant
CBR-001-598-270-4,RFM-007-297-9,CBR-001-598-270-4,N#Cc1cc2cc(oc2c(c1)c1cccc(c1)F)[C@@](c1cncn1C)(c1ccc(cc1)C#N)N,CBR-HVAC-11959: Protein farnesyl transferase Inhibitor;
CBR-001-598-271-5,RFM-007-298-0,CBR-001-598-271-5,N#Cc1cc2cc(oc2c(c1)c1cccc(c1)F)[C@](c1cncn1C)(c1ccc(cc1)C#N)N,CBR-HVAC-11959: Protein farnesyl transferase Inhibitor;
CBR-001-598-272-6,RFM-007-299-1,CBR-001-598-272-6,O=C([C@H](Cc1ccccc1F)NC(=O)c1cc2[nH]cnc2cc1C(=O)NCC1CCCCCC1)Nc1cc(cc(c1)C(=O)O)C(=O)O,CBR-HVAC-05724: Pancreatic Cancer Therapy;Gastric Antisecretory Drugs; CCK2 (CCKB/Gastrin) Antagonists;Signal Transduction Modulators; Cholecystokinin B receptor Antagonist;
CBR-001-598-273-7,RFM-007-300-7,CBR-001-598-273-7,COc1ccc(cc1NC(=O)Cc1ccc(cc1)S(=O)(=O)Nc1ncc(cn1)CC(C)C)Cl,CBR-HVAC-01230: Antidiabetic Drugs; Unidentified pharmacological activity
CBR-001-598-274-8,RFM-007-301-8,CBR-001-598-274-8,COCCN1CCC(CC1)N(C(=O)Cn1c(CCc2cccc(c2F)F)cc(=O)c2c1nccc2)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-05709: Atherosclerosis Therapy; Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors;Signal Transduction Modulators; Lipoprotein associated phospholipase A2 inhibitor;
CBR-001-598-275-9,RFM-007-302-9,CBR-001-598-275-9,O=c1c2c(n[nH]c2c2c(n1c1ccccc1)nccc2)Cc1ccccc1,CBR-HVAC-07875: Phosphodiesterase 4 inhibitor
CBR-001-598-276-0,RFM-007-303-0,CBR-001-598-276-0,O=C1NN=C(C(C1)C)c1ccc(c(c1)[N+](=O)[O-])N1CCN(CC1)C(=N)NCCCc1c[nH]cn1,CBR-HVAC-11608: Heart Failure Therapy; Ionotropic glutamate receptor Antagonist;
CBR-001-598-277-1,RFM-007-304-1,CBR-001-598-277-1,CCCCCCNC(=O)NC(=N)NCCCN1CCN(CC1)CCCNC(=N)NC(=O)NCCCCCC,CBR-HVAC-05544: Dental Caries Prophylactics; Unidentified pharmacological activity
CBR-001-598-278-2,RFM-007-305-2,CBR-001-598-278-2,C/C=C/1\CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2[C@@H](O)[C@@H]([C@@H]2[C@]1(C)CC[C@@H](C2)O)O,CBR-HVAC-05118: Leukocyte inhibitor; Antiallergy/Antiasthmatic Drugs; Antiinflammatory; Dermatologic Drugs; Ocular Antiinflammatory and Antiinfective Agents
CBR-001-598-279-3,RFM-007-306-3,CBR-001-598-279-3,COCC1(COC)Oc2ccc(cc2[C@H]([C@@H]1O)Nc1ccc(=O)n(n1)C)C#N,"CBR-HVAC-04730: Asthma Therapy;Angina pectoris, Treatment of; Potassium Channel Activators; Potassium channel Opener; Potassium channel agonist"
CBR-001-598-280-6,RFM-007-307-4,CBR-001-598-280-6,CN(CC(Oc1cccc(c1c1cc2c(c3c1c(=O)n(c3=O)C)c1c(n2C)cccc1)Br)C)C,CBR-HVAC-11309: Chemoprotective Agents; Antithrombocytopenic;
CBR-001-598-281-7,RFM-007-308-5,CBR-001-598-281-7,C[C@@H](c1ccc(cc1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C,"CBR-HVAC-06289: Inflammatory Bowel Disease, Agents for;Antipsoriatics;Melanoma Therapy;Type 1 Diabetes, Agents for;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Dermatologic Drugs; Chemokine CXCR1 (IL-8 alpha Receptor) Antagonists;Chemokine CXCR1/CXCR2 (IL-8 Receptor) Receptor Antagonists;Chemokine CXCR2  (IL-8 beta Receptor) Antagonists;Signal Transduction Modulators; C-X-C chemokine receptor type 1; C-X-C chemokine receptor type 2 Inhibitor;"
CBR-001-598-282-8,RFM-007-309-6,CBR-001-598-282-8,COC(COc1c(C)csc1C(=O)CCc1ccccc1)CNCC(C)C,CBR-HVAC-10804: Antiarrhythmic Drugs; Sodium channel Antagonist;
CBR-001-598-283-9,RFM-007-310-9,CBR-001-598-283-9,CCCc1c(COc2ccc(cc2)Cc2nnn[nH]2)ccc(c1O)C(=O)C,CBR-HVAC-10908: Leukotriene E4 receptor; Leukotriene D4 receptor Antagonist;
CBR-001-598-284-0,RFM-007-311-0,CBR-001-598-284-0,COc1c(OCc2ccc(cc2)c2ccccc2c2[nH]nnn2)cc(nc1C)C,"CBR-HVAC-04351: Hypertension, Treatment of; Angiotensin AT1 Antagonists;Signal Transduction Modulators; Angiotensin II receptor type 1 Antagonist; Angiotensin II 1 antagonist"
CBR-001-598-285-1,RFM-007-312-1,CBR-001-598-285-1,COc1ccnc2c1CCCCC2S(=O)c1nc2c([nH]1)cccc2,CBR-HVAC-10421: H+/K+ ATPase Inhibitor;
CBR-001-598-286-2,RFM-007-313-2,CBR-001-598-286-2,Cc1ccc(cc1)c1oc(c(n1)CCCC[C@@H]1CO[C@](OC1)(C)C(=O)O)C,"CBR-HVAC-05654: Lipoprotein Disorders, Treatment of ; PPARalpha Agonists;Signal Transduction Modulators; Peroxisome proliferator-activated receptor alpha agonist"
CBR-001-598-287-3,RFM-007-314-3,CBR-001-598-287-3,CCOC(=O)c1c[n+](C)c2n(c1=O)C(C)CCC2,CBR-HVAC-01457: Cyclooxygenase inhibitor
CBR-001-598-288-4,RFM-007-315-4,CBR-001-598-288-4,Clc1ccccc1C1=NCc2n(c3c1cccc3)cnc2C(=O)N,CBR-HVAC-08286: Benzodiazepine receptor agonist
CBR-001-598-289-5,RFM-007-316-5,CBR-001-598-289-5,O=C(Nc1cccc(c1)[C@@H](C(=O)O)C)NCC(=O)N1[C@@H](CS[C@@H]1c1ccccc1F)C(=O)OC(C)(C)C,CBR-HVAC-11807: Cholecystokinin B receptor Antagonist;
CBR-001-598-290-8,RFM-007-317-6,CBR-001-598-290-8,NC(=N)NCCC[C@@H](C(=O)c1nc2c(s1)cccc2)NC(=O)[C@@H]1C[C@H](CN1C(=O)C)O,CBR-HVAC-09450: TRYPSIN; TRYPTASE Inhibitor; Inhibitor;
CBR-001-598-291-9,RFM-007-318-7,CBR-001-598-291-9,O[C@H](COc1ccc(cc1)O)CNCCc1ccc(cc1)OCP(=O)(O)O,CBR-HVAC-08322: Beta 3 adrenoreceptor agonist
CBR-001-598-292-0,RFM-007-319-8,CBR-001-598-292-0,CCN(CCN1c2cc(cc(c2[C@](C1=O)(O)c1ccccc1Cl)C(F)(F)F)C(=O)N)CC,CBR-HVAC-11062: Treatment of Growth Hormone Secretion Disorders; Growth Hormone Secretagogues;Signal Transduction Modulators; Growth hormone secretagogue receptor Partial Agonist;
CBR-001-598-293-1,RFM-007-320-1,CBR-001-598-293-1,CCN(CCN1c2cc(cc(c2[C@@](C1=O)(O)c1ccccc1Cl)C(F)(F)F)C(=O)N)CC,CBR-HVAC-11062: Treatment of Growth Hormone Secretion Disorders; Growth Hormone Secretagogues;Signal Transduction Modulators; Growth hormone secretagogue receptor Partial Agonist;
CBR-001-598-294-2,RFM-007-321-2,CBR-001-598-294-2,ONC(=O)[C@H]([C@H](C(=O)N[C@@H](C(C)(C)C)C(=O)Nc1ccccn1)CC(C)C)OC,CBR-HVAC-10465: Matrix metalloproteinase Inhibitor;
CBR-001-598-295-3,RFM-007-322-3,CBR-001-598-295-3,CCCCCCCCCCCCCCNC(=O)N[C@@H](C[N+](C)(C)C)CC(=O)[O-],"CBR-HVAC-00448: Type 2 Diabetes, Agents for; Carnitine O-Palmitoyltransferase 1 (CPT-1) Inhibitors; Carnitine palmitoyltransferase Inhibitor; Carnitine palmitoyltransferase inhibitor"
CBR-001-598-296-4,RFM-007-323-4,CBR-001-598-296-4,COc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)/C=C/c1ccccc1)c1ncccn1,CBR-HVAC-05056: Analgesic Drugs;Prostate Cancer Therapy; Endothelin ETA Receptor Antagonists;Signal Transduction Modulators; Endothelin A receptor Antagonist;
CBR-001-598-297-5,RFM-007-324-5,CBR-001-598-297-5,COc1ccccc1Oc1cnc(nc1NS(=O)(=O)/C=C/c1ccccc1)c1ncccn1,analog of CBR-HVAC-05056
CBR-001-598-298-6,RFM-007-325-6,CBR-001-598-298-6,OC(=O)CC/C=C\C[C@@H]1CO[C@H](O[C@H]1c1cccnc1)C(Oc1ccc(cc1[N+](=O)[O-])C)(C)C,CBR-HVAC-10510: Antiplatelet Therapy; Thromboxane Synthase Inhibitors; Thromboxane A synthase; Thromboxane A2 receptor Antagonist; Inhibitor;
CBR-001-598-299-7,RFM-007-326-7,CBR-001-598-299-7,COc1c(C(CCc2ccc(cc2)O)O)c(OCCN2CCCCC2)c(c2c1cco2)OC,CBR-HVAC-01131: Calcium channel antagonist; Calmodulin antagonist
CBR-001-598-300-3,RFM-007-327-8,CBR-001-598-300-3,O=C(Cc1cccs1)N[C@H]1CC[C@H](OB1O)CC(=O)O,CBR-HVAC-07200: Antibacterial Drugs; beta-Lactamase Inhibitors;
CBR-001-598-301-4,RFM-007-328-9,CBR-001-598-301-4,Cl/N=C(/N=N/C(=N/Cl)/N)\N,CBR-HVAC-09133:
CBR-001-598-302-5,RFM-007-329-0,CBR-001-598-302-5,CCC(c1ccc(cn1)N1CCC(C1=O)Cc1ccccc1N1CCN(CC1)C)(CC)O,CBR-HVAC-09475: 5-HT1B Receptor Inverse Agonists; 5-Hydroxytryptamine 1B receptor Antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants
CBR-001-598-303-6,RFM-007-330-3,CBR-001-598-303-6,N=C1C[C@H](C)[C@@H]2[C@H](N1)[C@@H]2Cl,CBR-HVAC-10388: Inducible nitric oxide synthase Inhibitor;
CBR-001-598-304-7,RFM-007-331-4,CBR-001-598-304-7,O[Pt]([NH2+]C1CCCCC1)([NH3+])(Cl)(Cl)O,CBR-HVAC-10571: Anticancer;
CBR-001-598-305-8,RFM-007-332-5,CBR-001-598-305-8,COc1cc(cc(c1OC)OC)C(=O)N1CCO[C@](C1)(CCN1CCC2(CC1)S(=O)Cc1c2cccc1)c1ccc(c(c1)Cl)Cl,"CBR-HVAC-11002: Neurokinin 1 receptor antagonist; Neurokinin 2 receptor antagonist; Neurokinin 3 receptor antagonist; Neurokinin receptor Antagonist; Signal Transduction Modulators; Tachykinin NK1 Receptor Antagonists; Tachykinin NK2 Receptor Antagonists; Tachykinin NK3 Receptor Antagonists; Tachykinin-receptor-antagonists; Antiasthmatic; Asthma Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Obstructive Airways Disease; Respiratory Tract Disorders"
CBR-001-598-306-9,RFM-007-333-6,CBR-001-598-306-9,Nc1sc2c(n1)c(ccc2)Oc1ncnc(c1)c1ccc(nc1NCc1ccc(c(c1)F)NS(=O)(=O)C)C(F)(F)F,CBR-HVAC-11678: Vanilloid receptor 1 Antagonist;
CBR-001-598-307-0,RFM-007-334-7,CBR-001-598-307-0,N#C[C@@H]1CCCN1C(=O)[C@H](CN1[C@H]2C[C@@H](C1=O)N(C2)S(=O)(=O)c1cccc(c1)F)N,CBR-HVAC-11745: DIPEPTIDYL PEPTIDASE 4 Inhibitor;
CBR-001-598-308-1,RFM-007-335-8,CBR-001-598-308-1,CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](Cn1cnc2c1ncnc2N)C)O,CBR-HVAC-00256: Anti-HIV Agents;AIDS Medicines;Anti-Hepatitis B Virus Drugs; Reverse Transcriptase Inhibitors; NUCLEOSIDE REVERSE TRANSCRIPTASE Inhibitor; Nucleotide reverse transcriptase inhibitor
CBR-001-598-309-2,RFM-007-336-9,CBR-001-598-309-2,O=c1[nH]c(=O)[nH]c(c1)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1nc[nH]c1,CBR-HVAC-00320: Antidepressants;CNS Stimulants; 5-Hydroxytryptamine 1 receptor; 5-Hydroxytryptamine 2 receptor Agonist; Thyrotropin releasing hormone receptor agonist
CBR-001-598-310-5,RFM-007-337-0,CBR-001-598-310-5,CSc1ccc(cc1)C(=O)/C=C/c1cc(C)c(c(c1)C)OC(C(=O)O)(C)C,"CBR-HVAC-00591: Lipoprotein Disorders, Treatment of ;Antidiabetic Drugs;Agents for Liver Cirrhosis;Type 2 Diabetes, Agents for;Agents for Liver Fibrosis;Liver Cancer Therapy;Atherosclerosis Therapy;Liver and Biliary Tract Disorders, Treatment of;Solid Tumors Therapy;Leukemia Therapy;Metabolic Disorders (Not Specified); PPARalpha Agonists;PPARdelta Agonists;Signal Transduction Modulators; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA Agonist; Agonist; Peroxisome proliferator-activated receptor alpha agonist"
CBR-001-598-311-6,RFM-007-338-1,CBR-001-598-311-6,CC[C@@H]([C@@H]1C(=O)N[C@@H](C(=O)N1[C@@H](c1ccc(nc1C)C)C(=O)N1CCOCC1)C1Cc2c(C1)cccc2)C,"CBR-HVAC-00708: Disorders of Sexual Function and Reproduction, Treatment of;Prevention of Premature Ejaculation; Oxytocin (OT) Antagonists;Signal Transduction Modulators; Reproductive system modulator; Oxytocin receptor antagonist"
CBR-001-598-312-7,RFM-007-339-2,CBR-001-598-312-7,CC[C@@H]([C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](c1ccc(nc1C)C)C(=O)N1CCOCC1)C1Cc2c(C1)cccc2)C,"CBR-HVAC-00708: Disorders of Sexual Function and Reproduction, Treatment of;Prevention of Premature Ejaculation; Oxytocin (OT) Antagonists;Signal Transduction Modulators; Reproductive system modulator; Oxytocin receptor antagonist"
CBR-001-598-313-8,RFM-007-340-5,CBR-001-598-313-8,OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1sc(c(n1)c1scc(c1)Cl)N1CCN(CC1)C1CCCCC1,CBR-HVAC-00738: Antithrombocytopenic; Signal Transduction Modulators;Thrombopoietin Receptor (TpoR) Agonists; Thrombopoietin receptor Agonist; Thrombopoietin agonist
CBR-001-598-314-9,RFM-007-341-6,CBR-001-598-314-9,O=C1NCCN1C1CCN(CC1)CC[C@H]1COc2c(O1)cccc2,CBR-HVAC-01178: CNS Stimulants; Unidentified pharmacological activity
CBR-001-598-315-0,RFM-007-342-7,CBR-001-598-315-0,O[C@H]1CO[C@H]([C@@H]([C@H]1O)O)[n+]1ccc2c(c1)c(C)c1c(c2C)[nH]c2c1cc(O)cc2,CBR-HVAC-03594: Oncolytic Drugs; Unidentified pharmacological activity
CBR-001-598-316-1,RFM-007-343-8,CBR-001-598-316-1,OC[C@@H]1CC[C@@H](O1)n1cnc2c1nc[nH]c2=O,CBR-HVAC-03748: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor;
CBR-001-598-317-2,RFM-007-344-9,CBR-001-598-317-2,CCc1cc(NCc2nc3c(o2)c(Cl)ccc3Cl)c(=O)[nH]c1C,CBR-HVAC-04210: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-598-318-3,RFM-007-345-0,CBR-001-598-318-3,COc1ccc(c2c1nccc2)C(=O)Nc1c(Cl)cncc1Cl,CBR-HVAC-04876: Antiallergy/Antiasthmatic Drugs; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Release Inhibitors;
CBR-001-598-319-4,RFM-007-346-1,CBR-001-598-319-4,COc1ccc(c2c1nc(cc2)C(F)(F)F)C(=O)Nc1c(Cl)c[n+](cc1Cl)[O-],"CBR-HVAC-05360: Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Asthma Therapy; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; Phosphodiesterase 4 Inhibitor;"
CBR-001-598-320-7,RFM-007-347-2,CBR-001-598-320-7,CCCCOC(=O)COc1cc(ccc1CCNS(=O)(=O)c1cc(ccc1O)C(=NO)N)c1ccccc1S(=O)(=O)C,CBR-HVAC-05727: Anticoagulants; Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways; FACTOR XA Inhibitor;
CBR-001-598-321-8,RFM-007-348-3,CBR-001-598-321-8,CC(=O)N1CCC(CC1)C(=O)N(c1ccc(c(c1)Cl)C)CCCN1CCC(CC1)Cc1ccc(cc1)C(=O)N,CBR-HVAC-05869: Anti-HIV Agents; Chemokine CCR5 Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators; C-C CHEMOKINE RECEPTOR TYPE 5 Antagonist; CC chemokine receptor 5 antagonist; Chemokine receptor antagonist
CBR-001-598-322-9,RFM-007-349-4,CBR-001-598-322-9,CSCC[C@@H](CSSC[C@H](C(=O)NCC(=O)OC(OC(=O)OCC)C)Cc1ccccc1)N,"CBR-HVAC-06607: Non-Opioid Analgesics; Membrane Alanine Aminopeptidase (Aminopeptidase N) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Neutral endopeptidase; Aminopeptidase N Inhibitor;"
CBR-001-598-323-0,RFM-007-350-7,CBR-001-598-323-0,COc1cc2c(cc1N1CCC(CC1)N1CCCC1)ncc(c2Nc1ccc(c(c1)Cl)Sc1nccn1C)C#N,CBR-HVAC-07504: Oncolytic Drugs; Raf Kinase Inhibitors;Signal Transduction Modulators; Unidentified pharmacological activity
CBR-001-598-324-1,RFM-007-351-8,CBR-001-598-324-1,O=C1C=CC(C=C1)(O)c1cc2c(n1S(=O)(=O)c1ccccc1)cccc2,CBR-HVAC-07580: Oncolytic Drugs; Thioredoxin Reductase Inhibitors; Thioredoxin inhibitor; Angiogenesis inhibitor
CBR-001-598-325-2,RFM-007-352-9,CBR-001-598-325-2,COc1cc2c(cc1OC)N[C@H]([C@H]2CCN1CCN(CC1)c1ccccc1)C,CBR-HVAC-07653: Adrenoreceptor antagonist
CBR-001-598-326-3,RFM-007-353-0,CBR-001-598-326-3,COc1cc2c(cc1OC)N[C@@H]([C@@H]2CCN1CCN(CC1)c1ccccc1)C,CBR-HVAC-07653: Adrenoreceptor antagonist
CBR-001-598-327-4,RFM-007-354-1,CBR-001-598-327-4,OC(=O)CCNC(=O)c1ccc(cc1)C1CCCC1c1cnc(nc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-08169: Glucagon receptor antagonist
CBR-001-598-328-5,RFM-007-355-2,CBR-001-598-328-5,OC(=O)CCNC(=O)c1ccc(cc1)C1CCCC1c1cnc(nc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-08169: Glucagon receptor antagonist
CBR-001-598-329-6,RFM-007-356-3,CBR-001-598-329-6,O=N(=O)[O-][Pt+2]1([NH2][C@H]2[C@H]([NH2]1)CCCC2)[O-]N(=O)=O,analog of CBR-HVAC-08246
CBR-001-598-330-9,RFM-007-357-4,CBR-001-598-330-9,COCCOC[C@@H](C(=O)O)CC1(CCCC1)C(=O)N[C@@H]1CC[C@@H](CC1)C(=O)O,"CBR-HVAC-03963: Diuretics;Heart Failure Therapy;Hypertension, Treatment of; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Atriopeptidase inhibitor"
CBR-001-598-331-0,RFM-007-358-5,CBR-001-598-331-0,CCCNc1nc(NC)nc2c1ccc(c2)n1ccc(c1)CCC(=O)NCCN1CCCCC1,"CBR-HVAC-11049: Gastroesophageal Reflux Disease, Agents for;Irritable Bowel Syndrome, Agents for;Prokinetic Agents; Signal Transduction Modulators;5-HT4 Agonists; 5-Hydroxytryptamine 4 receptor Agonist;"
CBR-001-598-332-1,RFM-007-359-6,CBR-001-598-332-1,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C2=O)c2c(O)c(N4CCN(CC4)Cc4c(C)cc(cc4C)C)c(c(c2c(c3C)O)O)NC(=O)/C(=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)/C,CBR-HVAC-12195: Protein 50S ribosomal subunit inhibitor
CBR-001-598-333-2,RFM-007-360-9,CBR-001-598-333-2,CCNC(=O)NC(=O)C(OC(=O)c1c2CC/C(=C\c3ccc(c(c3)OC)OC)/c2nc2c1cccc2)C,CBR-HVAC-12204: Protein phosphatase 1 (PP-1) Inhibitors; Anti-HIV Agents;Antiviral Drugs
CBR-001-598-334-3,RFM-007-361-0,CBR-001-598-334-3,CCN(C(=O)c1ccc2c(c1)NC(=O)/C/2=C(\c1ccccc1)/Nc1ccc(cc1)CN1CCCCC1)C,CBR-HVAC-12270: Transforming Growth Factor (TGF)-beta Receptor Type I Inhibitors
CBR-001-598-335-4,RFM-007-362-1,CBR-001-598-335-4,CCS(=O)(=O)n1c2CCN(Cc2c2c1ccc(c2)C(=O)N1CCC(CC1)C)C1CCOCC1,CBR-HVAC-12274: Cannabinoid receptor agonist
CBR-001-598-336-5,RFM-007-363-2,CBR-001-598-336-5,COc1cc(ccc1OC)/C=C/1\C(=O)OC[C@@H]1Cc1ccc2c(c1)OCO2,CBR-HVAC-12278: Lignans; Agents for Liver Fibrosis
CBR-001-598-337-6,RFM-007-364-3,CBR-001-598-337-6,S=C1S/C(=C\c2ccc(cc2)C(=O)O)/C(=O)N1c1cccc(c1)C(F)(F)F,CBR-HVAC-12290:  Cystic fibrosis transmembrane conductance regulator inhibitor
CBR-001-598-338-7,RFM-007-365-4,CBR-001-598-338-7,CCOC(=O)C1=C(c2ccccc2)c2c(/C/1=[N+](\C)/[O-])cc(cc2)OCCCc1ccccc1,CBR-HVAC-12302:  Peroxisome proliferator-activated receptor gamma agonist
CBR-001-598-339-8,RFM-007-366-5,CBR-001-598-339-8,Clc1ccc(cc1)Nc1cc2nc3cc(C)ccc3n(c2c/c/1=N\C1CCCCCCC1)c1ccc(cc1)Cl,CBR-HVAC-12305: Preclinical - Tuberculosis
CBR-001-598-340-1,RFM-007-367-6,CBR-001-598-340-1,CCCn1c(nc2c(c1=O)cccc2)C(N1CCN(CC1)S(=O)(=O)c1ccc(cc1)Br)C,CBR-HVAC-12319:  Cystic fibrosis transmembrane conductance regulator modulator
CBR-001-598-341-2,RFM-007-368-7,CBR-001-598-341-2,O=C1NCCN1C1CCN(CC1)CC[C@@H]1COc2c(O1)cccc2,enantiomer of CBR-HVAC-01178
CBR-001-598-342-3,RFM-007-369-8,CBR-001-598-342-3,COc1cccc(c1OC)[C@H]1O[C@H](CC(=O)N2CCC(CC2)CC(=O)O)C(=O)N(c2c1cc(Cl)cc2)CC(CO)(C)C,"CBR-HVAC-14448: Squalene Synthase Inhibitors; Lipoprotein Disorders, Treatment of"
CBR-001-598-343-4,RFM-007-370-1,CBR-001-598-343-4,ON=C(c1ccc(c(c1)S(=O)(=O)NCCc1ccc(cc1OCC(=O)O)c1ccccc1S(=O)(=O)C)O)N,metabolite of CBR-HVAC-05727
CBR-001-598-344-5,RFM-007-371-2,CBR-001-598-344-5,Clc1ccc(cc1)Nc1cc2nc3cc(C)ccc3n(c2cc1=N)c1ccc(cc1)Cl,CBR-HVAC-14156: metabolite of CBR-HVAC-12305
CBR-001-598-667-1,RFM-007-372-3,CBR-001-598-667-1,Cc1cccc(c1)N(C(=S)Oc1ccc2c(c1)C1CCC2C1)C,CBR-HVAC-01754: Antifungal Agents; Squalene epoxidase Inhibitor; Cell wall synthesis inhibitor
CBR-001-598-668-2,RFM-007-373-4,CBR-001-598-668-2,COc1c(N2C[C@@H]3[C@H](C2)CCCN3)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-02242: Antibacterial Ophthalmic Drugs;Antibacterial Drugs;Treatment of Tuberculosis; DNA Gyrase Inhibitors;DNA Topoisomerase IV Inhibitors; Topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-598-669-3,RFM-007-374-5,CBR-001-598-669-3,COCC(=O)N(c1ccccc1F)[C@@H]1CCN(C[C@@H]1C)CCn1nnn(c1=O)CC,CBR-HVAC-02496: Opioid Analgesics; Opioid receptor agonist
CBR-001-598-670-6,RFM-007-375-6,CBR-001-598-670-6,O=C1NC(CN1c1ncc(c(n1)N)C(=O)Nc1cccc(c1)C(F)(F)F)(C)C,"CBR-HVAC-03302: Antiplatelet Therapy;Lipoprotein Disorders, Treatment of ; Very low density-lipoprotein inhibitor; Cholesterol inhibitor"
CBR-001-598-671-7,RFM-007-376-7,CBR-001-598-671-7,CON1CC/C(=C\c2cc(c(c(c2)C(C)(C)C)O)C(C)(C)C)/C1=O,CBR-HVAC-03534: Antiarthritic Drugs; COX Inhibitor; Prostaglandin E2 receptor antagonist; Platelet aggregation inhibitor
CBR-001-598-672-8,RFM-007-377-8,CBR-001-598-672-8,OC(=O)CCNC(=O)[C@@H](NC(C(=O)OCC1COC(O1)(C)C)Cc1ccccc1)Cc1ccccc1,"CBR-HVAC-03672: Opioid Analgesics; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Membrane metalloendopeptidase Inhibitor; Membrane metallo endopeptidase inhibitor"
CBR-001-598-673-9,RFM-007-378-9,CBR-001-598-673-9,NC(=N)Nc1ccc(cc1)C(=O)Oc1ccc(cc1)S(=O)(=O)N,CBR-HVAC-03948: Anticoagulants; TRYPSIN Inhibitor; Protease/peptidase inhibitor
CBR-001-598-674-0,RFM-007-379-0,CBR-001-598-674-0,O=c1[nH]c(=O)on1Cc1ccc(cc1)OC/C=C/COc1ccc(cc1)Cn1oc(=O)[nH]c1=O,"CBR-HVAC-05010: Type 2 Diabetes, Agents for; Insulin Sensitizers;Signal Transduction Modulators; Insulin sensitizer; Hypoglycemic; Insulin sensitizer"
CBR-001-598-675-1,RFM-007-380-3,CBR-001-598-675-1,NCC1(CCN(CC1)c1ncnc2c1c(C)c[nH]2)C(=O)Nc1cccc(c1)OC(=O)N(C)C,CBR-HVAC-07229: Ophthalmic Drugs;Antiglaucoma Agents; LIM Domain Kinase 1 (LIMK1) Inhibitors;LIM Domain Kinase 2 (LIMK2) Inhibitors;Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors;Signal Transduction Modulators; Lim kinase inhibitor; Rho-associated kinase inhibitor
CBR-001-598-676-2,RFM-007-381-4,CBR-001-598-676-2,CCNC(=O)Nc1cccc(c1)[C@H](c1ccc(c(c1)OC1CCCC1)OC)Cc1ccncc1,CBR-HVAC-08590: Phosphodiesterase 4 Inhibitor;
CBR-001-598-677-3,RFM-007-382-5,CBR-001-598-677-3,CCNC(=O)Nc1cccc(c1)[C@H](c1ccc(c(c1)OC1CCCC1)OC)Cc1ccncc1,CBR-HVAC-08590: Phosphodiesterase 4 Inhibitor;
CBR-001-598-678-4,RFM-007-383-6,CBR-001-598-678-4,CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H]([C@@H](C(=O)NO)CC=C)CC(C)C,CBR-HVAC-10759: Neurologic Drugs (Miscellaneous);Antiarthritic Drugs; Collagenase Inhibitors; Matrix metalloproteinase; TNF alpha Inhibitor;
CBR-001-598-679-5,RFM-007-384-7,CBR-001-598-679-5,O=C(Cn1c(C)ccc(c1=O)NS(=O)(=O)Cc1ccccc1)NCC1CCN(CC1)C(=N)N,CBR-HVAC-11217: Anticoagulants; Inhibitors of Blood Coagulation Pathways;Thrombin Inhibitors; Thrombin Inhibitor;
CBR-001-598-680-8,RFM-007-385-8,CBR-001-598-680-8,CCCOC(=O)N[C@H](C(SC(C)C)(C)C)C(=O)N1CCC[C@H]1C(=O)NC[C@@H]1CC[C@H](CC1)N,CBR-HVAC-11747: Coagulation factor IIa Antagonist;
CBR-001-598-681-9,RFM-007-386-9,CBR-001-598-681-9,C[C@@H]1C(=O)O[C@H]2[C@H]1CCC(=C1[C@@H]2C(=CC1=O)C)C,"CBR-HVAC-12091: Angina pectoris, Treatment of; Antiplatelet Therapy; Lipoprotein Disorders, Treatment of;"
CBR-001-598-682-0,RFM-007-387-0,CBR-001-598-682-0,CCCCCCCCC1OOC(O1)CCCCCCCC(=O)OC,"CBR-HVAC-12111: Phase III - HIV infection, Respiratory disease, Rheumatoid arthritis; Phase II - HIV infection; Phase I - HIV infection"
CBR-001-598-683-1,RFM-007-388-1,CBR-001-598-683-1,COc1cc(ccc1OC)C1=NN(C(=O)SC1)Cc1cccc(c1)NC(=O)OCCCN(C)C,CBR-HVAC-12101: Hepatocyte growth factor antagonist
CBR-001-598-684-2,RFM-007-389-2,CBR-001-598-684-2,COc1ccc(cc1)C1(CCCN(C)C)OCc2c1ccc(c2)C#N,CBR-HVAC-12103: Serotonin transporter inhibitor
CBR-001-598-685-3,RFM-007-390-5,CBR-001-598-685-3,Brc1ccc(cc1)/C(=C\1/CCOC1=O)/c1ccc(cc1)S(=O)(=O)C,CBR-HVAC-12087: Cyclooxygenase 2 inhibitor
CBR-001-598-686-4,RFM-007-391-6,CBR-001-598-686-4,CNC1Cc2ccccc2N(c2c1cccc2)C,CBR-HVAC-05529: NMDA Antagonists
CBR-001-598-730-1,RFM-007-392-7,CBR-001-598-730-1,Cn1c(CCN2CCNCC2)nc2c1c(=O)n(c(=O)n2C)C,analog of CBR-HVAC-00299
CBR-001-598-731-2,RFM-007-393-8,CBR-001-598-731-2,CNCc1[nH]c2c(n1)n(CC(C)C)c(=O)n(c2=O)C,analog of CBR-HVAC-01051
CBR-001-598-732-3,RFM-007-394-9,CBR-001-598-732-3,CN1CCCC(C1)C(c1cccc(c1)O)C,analog of CBR-HVAC-02501
CBR-001-598-733-4,RFM-007-395-0,CBR-001-598-733-4,CNC1C2C=CCC1c1c(C2)cccc1,analog of CBR-HVAC-03340
CBR-001-598-734-5,RFM-007-396-1,CBR-001-598-734-5,OC(=O)COCCN1CCN(CC1)C(c1ccc(cc1)F)c1ccccc1,analog of CBR-HVAC-04626
CBR-001-598-735-6,RFM-007-397-2,CBR-001-598-735-6,CCN1Cc2c(C1=O)cnc(n2)N1CCNCC1,analog of CBR-HVAC-11283
CBR-001-598-736-7,RFM-007-398-3,CBR-001-598-736-7,COc1ccc(cc1OC)C(=O)N1CCN(CC1)c1ccc2c(c1)CCC(=O)N2,"CBR-HVAC-01831: Immunomodulators, Phosphodiesterase inhibitors. Positive inotropic effects; inhibition of TNF-alpha and interleukin-6 production; antitumour activity against a human pancreatic cancer model."
CBR-001-598-737-8,RFM-007-399-4,CBR-001-598-737-8,Clc1cc(C)c2c(c1)nc(o2)N1CCNCCC1,CBR-HVAC-02750: 5-hydroxytryptamine 3 receptor partial agonist
CBR-001-598-971-6,RFM-007-400-0,CBR-001-598-971-6,N#Cc1ccc(cc1C(F)(F)F)N1C(=O)C2C(C1=O)C1(OC2(C)CC1NS(=O)(=O)CC)C,CBR-HVAC-06456: Prostate Cancer Therapy; Androgen Receptor Antagonists;Signal Transduction Modulators; Androgen receptor Antagonist;
CBR-001-598-972-7,RFM-007-401-1,CBR-001-598-972-7,COc1cc(CCN(CCCNC(=O)C/C=C/c2ccc(cc2)n2cncc2)C)cc(c1)OC,"CBR-HVAC-10497: Angina pectoris, Treatment of; Calcium channel; Potassium channel Blocker; Opener;"
CBR-001-598-973-8,RFM-007-402-2,CBR-001-598-973-8,CN(CCNc1nc2cc(O)ccc2c2c1C(=O)c1c2cccc1)C,CBR-HVAC-04781: Oncolytic Drugs; DNA Topoisomerase I Inhibitors;DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; DNA topoisomerase II; DNA topoisomerase I Inhibitor;
CBR-001-598-974-9,RFM-007-403-3,CBR-001-598-974-9,CCCCC(CNC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NCC(CCCC)CC)CC,CBR-HVAC-10022: Phospholipase Inhibitor;
CBR-001-598-975-0,RFM-007-404-4,CBR-001-598-975-0,O=C1O[C@@](CCN1[C@H](c1ccc(cc1)c1ccn(c(=O)c1)C)C)(CC(O)(C)C)c1ccccc1,"CBR-HVAC-07037: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; Type 2 Diabetes, Agents for"
CBR-001-598-976-1,RFM-007-405-5,CBR-001-598-976-1,C/C(=C\CCC(=O)OC/C=C(/CCC=C(C)C)\C)/CC/C=C(/CCC=C(C)C)\C,"CBR-HVAC-01001: Antiulcer Drugs;Dry Eye Syndrome, Treatment for; Mucin Production, Enhancers; Anti-ulcer; Mucus protecting agent"
CBR-001-598-977-2,RFM-007-406-6,CBR-001-598-977-2,O=C1c2ccc(cc2C(=CC1(C)C)c1cccc[n+]1[O-])C(C(F)(F)F)(F)F,CBR-HVAC-10615: Bronchodilators; Potassium Channel Activators; Potassium channel Opener;
CBR-001-598-978-3,RFM-007-407-7,CBR-001-598-978-3,COc1cc2c(ccnc2cc1OCC1(N)CC1)Oc1ccc2c(c1F)cc([nH]2)C,CBR-HVAC-12190: Angiogenesis Inhibitors; FGFR Inhibitors; PDGFRbeta Inhibitors; Signal Transduction Modulators; VEGFR-2 (FLK-1/KDR) Inhibitors; VEGFR-3 (FLT4) Inhibitors
CBR-001-598-979-4,RFM-007-408-8,CBR-001-598-979-4,CCOc1noc2c1ccc(c2)OCCC1CCN(CC1)c1ccc(nn1)C,CBR-HVAC-06056: Anti-Rhinovirus Drugs; Viral Entry Inhibitors; CAPSID VIRAL PROTEIN Inhibitor;
CBR-001-598-980-7,RFM-007-409-9,CBR-001-598-980-7,CCN(Cc1ccc2c(c1)ccc(c2)COC(=O)Nc1ccc(cc1)C(=O)NO)CC,"CBR-HVAC-00666: Hematopoiesis Disorders Therapy;Antiarthritic Drugs;Lymphocytic Leukemia Therapy;Hematological Cancer Therapy;Multiple Myeloma Therapy;Inflammatory Bowel Disease, Agents for;Immunosuppressants;Muscular Dystrophy, Agents for;Rheumatoid Arthritis, Treatment of;Lymphoma Therapy; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors;IL-1beta Production Inhibitors;Signal Transduction Modulators;TNF-alpha Release Inhibitors; Histone deacetylase Inhibitor; Tumour necrosis factor alpha antagonist; Interleukin 1b antagonist; Histone deacetylase inhibitor; Interleukin 6 receptor antagonist"
CBR-001-598-981-8,RFM-007-410-2,CBR-001-598-981-8,FC(C(c1ccccc1)(F)F)(c1ccc(cc1)C(N)(C)C)F,CBR-HVAC-08056: Antiarrhythmic Drugs; Sodium channel antagonist
CBR-001-598-982-9,RFM-007-411-3,CBR-001-598-982-9,c1ccc2c(c1)C1=N/C/2=N\c2c3ccccc3c3n2[Zn]n2/c(=N\1)/c1ccccc1/c/2=N/C1=N/C(=N\3)/c2c1cccc2,CBR-HVAC-04549: Apoptosis Inducers; Caspase 3 Activators; Caspase 9 Activators; Radical formation agonist; Reactive-oxygen-species-stimulants; Signal Transduction Modulators; Anticancer; Cancer; Photosensitizer; Radical donator; Radiochemosensitizer
CBR-001-598-983-0,RFM-007-412-4,CBR-001-598-983-0,CC(NC[C@H](c1ccccc1)NC(=O)N1Cc2c(C1(C)C)[nH]nc2Nc1nc(C)nc2c1scc2)C,analog of CBR-HVAC-08171:
CBR-001-598-984-1,RFM-007-413-5,CBR-001-598-984-1,CCCCc1nc(cn1c1ccc(cc1)Oc1ccc(cc1)Cl)c1ccc(cc1)OCCCN(CC)CC,"CBR-HVAC-06189: Diabetic Nephropathy, Agents for;Alzheimer's Dementia, Treatment of ; Antiamyloidogenic Agents;RAGE Receptor Antagonists;Signal Transduction Modulators; Advanced glycosylation end product receptor antagonist"
CBR-001-598-985-2,RFM-007-414-6,CBR-001-598-985-2,CCCc1sc2c(c1)[C@@H]1[C@@H](NC2)CCc2c1cc(O)c(c2)O,CBR-HVAC-11105: Dopamine receptor D1 Agonist;
CBR-001-598-986-3,RFM-007-415-7,CBR-001-598-986-3,COc1ccc2c(c1)C(O)(CCCN(C)C)c1c(S2)cccc1,CBR-HVAC-08613:
CBR-001-598-987-4,RFM-007-416-8,CBR-001-598-987-4,CC(CCC([C@@H](NC(=O)C(N(C(=O)[C@@H](OC(=O)N(CCN(C(=O)N1CCOCC1)C)C)Cc1ccccc1)C)Cc1cnc[nH]1)CC1CCCCC1)O)C,"CBR-HVAC-04339: Hypertension, Treatment of; Renin Inhibitors; Renin Inhibitor;"
CBR-001-598-988-5,RFM-007-417-9,CBR-001-598-988-5,Clc1ccc(c(c1)Cl)c1cccc2c1nc(C)cc2N1CCC(=CC1)C(=O)N,CBR-HVAC-08478: Corticotropin releasing factor 1 receptor antagonist; Corticotropin releasing factor antagonist
CBR-001-598-989-6,RFM-007-418-0,CBR-001-598-989-6,Nc1ncc(cc1c1ccc(nc1)C(F)(F)F)c1ccc(cc1)S(=O)(=O)C,CBR-HVAC-07206: Antimalarials;
CBR-001-598-990-9,RFM-007-419-1,CBR-001-598-990-9,OCC(NCC(=O)N1C[C@H](C[C@H]1C(=O)c1nnc(o1)C(C)(C)C)F)(C)C,CBR-HVAC-09464: DIPEPTIDYL PEPTIDASE 4 Inhibitor;
CBR-001-598-991-0,RFM-007-420-4,CBR-001-598-991-0,COc1cccc2c1c1c([nH]2)c2CCCc2c2c1c(=O)n(c2=O)CN1CCN(CC1)C,CBR-HVAC-06747: Antineoplastic Enhancing Agents;Non-Small Cell Lung Cancer Therapy; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors;Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors;Signal Transduction Modulators;
CBR-001-598-992-1,RFM-007-421-5,CBR-001-598-992-1,COc1cccc2c1c1c([nH]2)c2CCCc2c2c1c(=O)[nH]c2=O,CBR-HVAC-14307: metabolite of CBR-HVAC-11872
CBR-001-598-993-2,RFM-007-422-6,CBR-001-598-993-2,CCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc1ccc(c[n+]1[O-])F)CN(C=O)O,CBR-HVAC-05987: Antibacterial Drugs; Peptide Deformylase (PDF) Inhibitors; PEPTIDE DEFORMYLASE Inhibitor;
CBR-001-598-994-3,RFM-007-423-7,CBR-001-598-994-3,Ic1ccc(cc1)CCCCCCCCCCCCCCCCCCOP(=O)(OCC[N+](C)(C)C)[O-],CBR-HVAC-09461: Oncolytic Drugs; Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors;Signal Transduction Modulators;
CBR-001-598-995-4,RFM-007-424-8,CBR-001-598-995-4,CO[C@H]1CN(CCCCCC(=O)O[C@H]2CN3CCC2CC3)CC[C@H]1NC(=O)c1cc(Cl)c(cc1OC)N,"CBR-HVAC-06042: Prokinetic Agents;Gastrointestinal Disorders (Not Specified);Gastroesophageal Reflux Disease, Agents for;Constipation, Agents for; Signal Transduction Modulators;5-HT4 Agonists; 5 Hydroxytryptamine 4 receptor agonist"
CBR-001-598-996-5,RFM-007-425-9,CBR-001-598-996-5,CC[Hg]Sc1ccccc1C(=O)[O-],CBR-HVAC-09110: Glutathione Transferase Inhibitors; Lipoxygenase Inhibitors; Antibacterial Drugs; Antifungal Agents; Antiseptic
CBR-001-598-997-6,RFM-007-426-0,CBR-001-598-997-6,OC(=O)C1(CCCC1)c1ccc2c(c1)OC[C@@H]([C@H]2O)Cc1ccc(cc1)c1ccccc1,"CBR-HVAC-04481:Antiarthritic Drugs;Inflammatory Bowel Disease, Agents for;Antipsoriatics; Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators; Leukotriene B4 receptor Antagonist; Leucotriene B4 antagonist; Leucotriene receptor antagonist"
CBR-001-598-998-7,RFM-007-427-1,CBR-001-598-998-7,OC(=O)C1(CCCC1)c1ccc2c(c1)OC[C@H]([C@@H]2O)Cc1ccc(cc1)c1ccccc1,"CBR-HVAC-04481:Antiarthritic Drugs;Inflammatory Bowel Disease, Agents for;Antipsoriatics; Leukotriene BLT (LTB4) Antagonists;Signal Transduction Modulators; Leukotriene B4 receptor Antagonist; Leucotriene B4 antagonist; Leucotriene receptor antagonist"
CBR-001-598-999-8,RFM-007-428-2,CBR-001-598-999-8,OC(=O)CCC[C@@H](C(=O)O)NC(=O)c1ccc2c(c1)SCCN2Cc1cnc2c(n1)c(N)nc(n2)N,"CBR-HVAC-04724:Rheumatoid Arthritis, Treatment of; Antimetabolites; Dihydrofolate reductase Inhibitor; Dihydrofolate reductase inhibitor; Thymidylate synthase inhibitor"
CBR-001-599-000-8,RFM-007-429-3,CBR-001-599-000-8,N#Cc1ccc(c(c1)S(=O)(=O)C)[C@H]1N(C)C(=O)N(C(=C1C#N)C)c1cccc(c1)C(F)(F)F,CBR-HVAC-06924:Respiratory Disorders (Not Specified); Leukocyte Elastase Inhibitors;
CBR-001-599-001-9,RFM-007-430-6,CBR-001-599-001-9,COc1cc2CC(OS(=O)(=O)c2cc1OC)C(=O)NC(CC(N(C)C)(C)C)C,CBR-HVAC-08603:
CBR-001-599-002-0,RFM-007-431-7,CBR-001-599-002-0,CCNC(Cc1cccc(c1)SC(F)(F)F)C,CBR-HVAC-10150:
CBR-001-599-003-1,RFM-007-432-8,CBR-001-599-003-1,Brc1ccc2c(c1)C(C(=O)Nc1c(cccc1C(C)C)C(C)C)c1ccccc1CO2,"CBR-HVAC-10918:Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-599-004-2,RFM-007-433-9,CBR-001-599-004-2,NC(=N)N/N=C/1\C[C@H](Cc2c1c(C)ccn2)c1cc(F)ccc1C,"CBR-HVAC-11050:Antiarrhythmic Drugs;Angina pectoris, Treatment of; Na+/H+ Exchanger (NHE) Inhibitors; Sodium/hydrogen exchanger Inhibitor;"
CBR-001-599-005-3,RFM-007-434-0,CBR-001-599-005-3,Clc1ccc(c(c1)c1cc(c2n1CCCC2)C(=O)N(c1ccc2c(c1)ccn2C)c1ccc(cc1)O)C(=O)N1Cc2ccccc2C[C@H]1CN1CCOCC1,CBR-HVAC-12061:Apoptosis Inducers; Bcl-2 Inhibitors
CBR-001-599-006-4,RFM-007-435-1,CBR-001-599-006-4,OC[C@@H](COc1c(C)cc(cc1CC)c1noc(n1)c1cc(OC)nc(c1)C1CCCC1)O,CBR-HVAC-12063:
CBR-001-599-007-5,RFM-007-436-2,CBR-001-599-007-5,COc1ccccc1n1cc(nc1c1ccccc1OC)Nc1ccccc1,CBR-HVAC-12068:
CBR-001-599-008-6,RFM-007-437-3,CBR-001-599-008-6,CO[C@H](C(=O)O)Cc1ccc(cc1)NC(=O)C,CBR-HVAC-12078:PPARgamma Modulators; Signal Transduction Modulators
CBR-001-599-009-7,RFM-007-438-4,CBR-001-599-009-7,CCNC(=O)c1nc(c2ccnn2c2ccc(cc2)C#N)c(n(c1=O)c1cccc(c1)C(F)(F)F)C,CBR-HVAC-12096:Neutrophil elastase inhibitor
CBR-001-599-010-0,RFM-007-439-5,CBR-001-599-010-0,OC(=O)CCc1cc(N)c(c(c1)c1ccc2c(c1)cnn2C)OC1Cc2c(C1)cccc2,CBR-HVAC-12112:Anti-inflammatory
CBR-001-599-065-5,RFM-007-440-8,CBR-001-599-065-5,Nc1nc(C)c(c(n1)N)C1CCCCC1,analog of CBR-HVAC-03044
CBR-001-599-066-6,RFM-007-441-9,CBR-001-599-066-6,O=C1COCCN1CCc1csc(n1)NS(=O)(=O)c1cccc(c1C)Cl,CBR-HVAC-11677: 11-Hydroxysteroid dehydrogenase inhibitor; Glucocorticoid antagonist
CBR-001-599-069-9,RFM-007-442-0,CBR-001-599-069-9,COC(=O)c1ccccc1C(=O)N1CSCC1,analog of CBR-HVAC-03246
CBR-001-599-070-2,RFM-007-443-1,CBR-001-599-070-2,O=C(N[C@H](C(=O)Nc1c(Br)cc(cc1CN(C1CCCCC1)C)Br)CSSC[C@@H](C(=O)O)NC(=O)OCc1ccccc1)OCc1ccccc1,analog of CBR-HVAC-03360
CBR-001-599-071-3,RFM-007-444-2,CBR-001-599-071-3,COc1ccc2c(c1)ccc(c2Oc1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)S(=O)(=O)C,analog of CBR-HVAC-06031
CBR-001-599-072-4,RFM-007-445-3,CBR-001-599-072-4,CCNCCS(=O)(=O)NCC1(SC(=NN1C(=O)C(C)(C)C)NC(=O)C(C)(C)C)c1ccccc1,"CBR-HVAC-00368: Breast Cancer Therapy;Small Cell Lung Cancer Therapy;Leukemia Therapy;Solid Tumors Therapy;Oncolytic Drugs; Antimitotic Drugs;Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors; Kinesin Eg5 Inhibitor; Kinesin inhibitor"
CBR-001-599-073-5,RFM-007-446-4,CBR-001-599-073-5,Cc1c(c2ccccc2)[n+](c2n1cccc2)/N=N/[n+]1c2ccccn2c(c1c1ccccc1)C,"CBR-HVAC-01988: Non-depolarizing Blocking Drugs; Fazadinium bromide is a neuromuscular blocking agent and recommended as the relaxant of choice, whenever it is desirable to rapidly secure a clear air way by endotracheal intubation, and also to provide prolonged skeletal muscle relaxation, without altering intra-abdominal, intraocular, intra-cranial and intra-vascular pressures; Neuromuscular nicotinic receptor antagonist"
CBR-001-599-074-6,RFM-007-447-5,CBR-001-599-074-6,O=C(c1ccccc1C(=O)O)N1CSCC1,CBR-HVAC-03246: Mucolytics;Expectorants; Mucolytic agent; Mucolytic agent
CBR-001-599-075-7,RFM-007-448-6,CBR-001-599-075-7,O=C(N[C@H](C(=O)Nc1c(Br)cc(cc1CN(C1CCCCC1)C)Br)CSSC[C@@H](C(=O)Nc1c(Br)cc(cc1CN(C1CCCCC1)C)Br)NC(=O)OCc1ccccc1)OCc1ccccc1,CBR-HVAC-03360: Expectorants;Antitussives; Mucolytic agent
CBR-001-599-076-8,RFM-007-449-7,CBR-001-599-076-8,CCOC(=O)C(=O)Nc1cc(C)c(c(c1)C)Oc1ccc(c(c1)C(c1ccc(cc1)F)O)O,"CBR-HVAC-04536: Lipoprotein Disorders, Treatment of ; Signal Transduction Modulators;Thyroid Hormone Receptor beta Agonists; LDL receptor function stimulant"
CBR-001-599-077-9,RFM-007-450-0,CBR-001-599-077-9,COc1ccc(cc1)C1CC(C(N1)(C)C)c1ccncc1,"CBR-HVAC-05845: Analgesic Drugs;Inflammation, Treatment of; Cyclooxygenase inhibitor"
CBR-001-599-078-0,RFM-007-451-1,CBR-001-599-078-0,NCC1(CCN(CC1)c1ncnc2c1c(C)c[nH]2)C(=O)Nc1cccc(c1)OC(=O)N(C)C,CBR-HVAC-07229: Ophthalmic Drugs;Antiglaucoma Agents; LIM Domain Kinase 1 (LIMK1) Inhibitors;LIM Domain Kinase 2 (LIMK2) Inhibitors;Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors;Signal Transduction Modulators; Lim kinase inhibitor; Rho-associated kinase inhibitor
CBR-001-599-079-1,RFM-007-452-2,CBR-001-599-079-1,OC(=O)c1ccc2c(c1)C(=O)O[Pt]1(OC2=O)N[C@H]2[C@H](N1)CCCC2,CBR-HVAC-07950: DNA inhibitor
CBR-001-599-080-4,RFM-007-453-3,CBR-001-599-080-4,O=C1C(=C(N2CC2)C(=O)C=C1N1CC1)N1CC1,CBR-HVAC-09076
CBR-001-599-081-5,RFM-007-454-4,CBR-001-599-081-5,CN(CCC(c1ccccc1)Oc1ccc2c(c1)C(=O)CC(O2)c1ccccc1)C,analog of CBR-HVAC-09403 (ANSOXETINE)
CBR-001-599-082-6,RFM-007-455-5,CBR-001-599-082-6,[O-][n+]1ccccc1C1=CC(C)(C)COc2c1cc(Cl)c(c2)Cl,"CBR-HVAC-10785: Hypertension, Treatment of;Bronchodilators;Urinary Incontinence Therapy;Antiallergy/Antiasthmatic Drugs; Potassium Channel Activators; Potassium channel Agonist;"
CBR-001-599-083-7,RFM-007-456-6,CBR-001-599-083-7,O=c1[nH]c2c([nH]1)cc1c(n2)ccc(c1)OCCCCNC1CCCCC1,CBR-HVAC-11355: cAMP phosphodiesterase Inhibitor;
CBR-001-599-084-8,RFM-007-457-7,CBR-001-599-084-8,ONS(=O)(=O)c1cccc(c1)S(=O)(=O)C,CBR-HVAC-12067: CXL-1427 acts as a nitric oxid donor and is being evaluated in phase II clinical trials at Cardioxyl Pharmaceuticals for the treatment of hospitalized patients with decompensated heart failure. Phase I clinical trials are also ongoing at the company for the treatment of patients with acute decompensated heart failure
CBR-001-599-085-9,RFM-007-458-8,CBR-001-599-085-9,O[C@H]1CC[C@]2(C(=C1)CC[C@H]1[C@@H]2CC[C@@]2([C@H]1CC=C2)C)C,"CBR-HVAC-12127: PH-94B is a vomeropherin, a unique family of pharmaceuticals, in phase II clinical trials at Pherin for the treatment of acute social phobia in female patients.  Vomeropherins act directly on the human vomeronasal organ (VNO) to send electrical signals to the hypothalamic center of the brain.  Vomeropherins act rapidly and directly on the end-organ, eliminating the need for systemic exposure and produce discrete responses in the hypothalamus in picogram quantities"
CBR-001-599-086-0,RFM-007-459-9,CBR-001-599-086-0,O=C[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)NC(=O)C,CBR-HVAC-12135: Phase III - Osteoarthritis
CBR-001-599-087-1,RFM-007-460-2,CBR-001-599-087-1,O=C(C1CCn2c1ccc2C(=O)c1ccccc1)OCCCCO[N+](=O)[O-],CBR-HVAC-12136: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Nitric oxide stimulant
CBR-001-599-088-2,RFM-007-461-3,CBR-001-599-088-2,Clc1ccc(cc1)N(c1cc[n+](c2c1cccc2)Cc1ccc(cc1)c1ccc(cc1)C[n+]1ccc(c2c1cccc2)N(c1ccc(cc1)Cl)C)C,CBR-HVAC-12137: Choline kinase alpha inhibitor
CBR-001-599-089-3,RFM-007-462-4,CBR-001-599-089-3,Brc1cnc2n(c1)nc(c2)C(=O)N1CCc2c([C@H]1C)cccc2,CBR-HVAC-12138: Metabotropic glutamate receptor 5 modulator
CBR-001-599-090-6,RFM-007-463-5,CBR-001-599-090-6,Brc1cnc2n(c1)nc(c2)C(=O)N1CCc2c([C@@H]1C)cccc2,CBR-HVAC-12138: Metabotropic glutamate receptor 5 modulator
CBR-001-599-091-7,RFM-007-464-6,CBR-001-599-091-7,COc1ccc(cc1)C(=O)NCCCCN1CCN(CC1)c1csc2c1ccc(c2)C(F)(F)F,CBR-HVAC-12143: Dopamine receptor D3 antagonist
CBR-001-599-092-8,RFM-007-465-7,CBR-001-599-092-8,Fc1cc(cc(c1)N1CCOCC1)C(=O)Nc1ccc(c(c1)COc1cccnc1)Cl,CBR-HVAC-12144: p38 Mitogen-activated protein kinase inhibitor
CBR-001-599-093-9,RFM-007-466-8,CBR-001-599-093-9,CCOc1cccc(c1)[C@@]1(CCC(CC1)C)N1CCN(CC1)c1ccccc1,CBR-HVAC-12146: Neuropeptide Y receptor 1 antagonist; Neuropeptide Y receptor 5 antagonist
CBR-001-599-094-0,RFM-007-467-9,CBR-001-599-094-0,CCCCCCCCCCCCCCCC=O,CBR-HVAC-12164: Arachidonic acid inhibitor; Immunosuppressant; Platelet activating factor antagonist
CBR-001-599-095-1,RFM-007-468-0,CBR-001-599-095-1,Clc1ccc(cc1)C1C(=O)c2c(C1=O)c(ccc2)c1ccccc1,CBR-HVAC-12165: Cyclooxygenase inhibitor; Lipoxygenase inhibitor
CBR-001-599-096-2,RFM-007-469-1,CBR-001-599-096-2,CCCC(=O)c1cnc2c(c1Nc1ccccc1C)cccc2OCCS(=O)C,CBR-HVAC-12173: General pump inhibitor
CBR-001-599-097-3,RFM-007-470-4,CBR-001-599-097-3,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)C(c1ccc(cc1)F)O,CBR-HVAC-12176
CBR-001-599-098-4,RFM-007-471-5,CBR-001-599-098-4,CCOP(=O)(COc1cc(C)c(c(c1)C)Cc1ccc(c(c1)C(C)C)O)OCC,metabolite of CBR-HVAC-06262
CBR-001-599-099-5,RFM-007-472-6,CBR-001-599-099-5,CN1C[C@]2(C(=O)O)[C@H](c3ccccn3)N([C@@H]([C@](C1)(C2=O)C(=O)O)c1ccccn1)C,metabolite of CBR-HVAC-11323
CBR-001-599-100-1,RFM-007-473-7,CBR-001-599-100-1,O=C(c1ccccc1)OCCCc1ccccc1,One component of the mixture CBR-HVAC-12159
CBR-001-599-101-2,RFM-007-474-8,CBR-001-599-101-2,CCOC(=O)c1cc(OC)ccc1O,One component of the mixture CBR-HVAC-12159
CBR-001-599-545-6,RFM-007-475-9,CBR-001-599-545-6,[N-]=[N+]=N[C@H]1C[C@@H](O[C@@H]1COP(=O)O)n1cc(C)c(=O)[nH]c1=O,CBR-HVAC-14494: Reverse Transcriptase Inhibitors; Anti-HIV Agents
CBR-001-599-546-7,RFM-007-476-0,CBR-001-599-546-7,CCCCN(CC(c1cc(nc(c1)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)C(F)(F)F)O)CCCC,CBR-HVAC-14491: ANTI-SCHISTOSOMALANTI-MALARIAL
CBR-001-599-547-8,RFM-007-477-1,CBR-001-599-547-8,O=C(c1cn(c2c1cccn2)Cc1ccc(cc1)F)C(=O)Nc1c(Cl)cncc1Cl,CBR-HVAC-00140: Phosphodiesterase 4 inhibitor
CBR-001-599-548-9,RFM-007-478-2,CBR-001-599-548-9,NC(=O)c1cnc2n1CCc1c(C32CCNCC3)cccc1,CBR-HVAC-00543: Histamine H1 receptor antagonist
CBR-001-599-549-0,RFM-007-479-3,CBR-001-599-549-0,OC(=O)COc1ccc(cc1)CCNS(=O)(=O)c1ccccc1,CBR-HVAC-03011: Thromboxane A2 receptor antagonist
CBR-001-599-550-3,RFM-007-480-6,CBR-001-599-550-3,OC(=O)CCCCCCCn1c2ccccc2c(c1c1cccnc1)C,CBR-HVAC-03381: Thromboxane A2 synthase inhibitor
CBR-001-599-551-4,RFM-007-481-7,CBR-001-599-551-4,OC(CC(/C=C/C(=C(c1ccc(cc1)F)c1ccc(cc1)F)c1nnnn1C)O)CC(=O)O,CBR-HVAC-03784: HMG CoA reductase inhibitor
CBR-001-599-552-5,RFM-007-482-8,CBR-001-599-552-5,CCNC(=O)NCCCOc1cccc(c1)CN1CCCCC1,CBR-HVAC-03882: Histamine H2 receptor antagonist
CBR-001-599-553-6,RFM-007-483-9,CBR-001-599-553-6,O=C(NCc1ccc(o1)C(=O)Oc1ccc2c(c1)ccc(c2)C(=N)N)CCCC(=O)O,CBR-HVAC-04490: Trypsin Inhibitors
CBR-001-599-554-7,RFM-007-484-0,CBR-001-599-554-7,CCC(c1cc(O)c(c(=O)o1)C(c1ccccc1)CC)Cc1ccccc1,CBR-HVAC-04583: HIV-1 protease inhibitor
CBR-001-599-555-8,RFM-007-485-1,CBR-001-599-555-8,Nc1cccc(c1)CN1[C@H](Cc2ccccc2)[C@H](O)[C@H]([C@H](N(C1=O)Cc1cccc(c1)N)Cc1ccccc1)O,CBR-HVAC-04671: HIV-1 protease inhibitor
CBR-001-599-556-9,RFM-007-486-2,CBR-001-599-556-9,Clc1ccc(c(c1)C(=O)c1cc[n+](cc1)[O-])NS(=O)(=O)c1ccc(cc1)C(C)(C)C,CBR-HVAC-06005:  CCR9 receptor antagonist
CBR-001-599-557-0,RFM-007-487-3,CBR-001-599-557-0,CNc1nc2cc(OC)c(cc2c(n1)c1cccc(c1)NC(=O)c1ccc(cc1)C(=O)OC)OC,CBR-HVAC-06808: Phosphodiesterase 4 inhibitor
CBR-001-599-558-1,RFM-007-488-4,CBR-001-599-558-1,CCN(c1nc2c(o1)cc(cc2)C(=O)N(C[C@H]([C@H](Cc1ccccc1)NC(=O)OCc1cncs1)O)CC(C)C)C,CBR-HVAC-06915: Cytochrome P450 Inhibitors; Phase I initiated by Tibotec for the treatment of human immunodeficiency virus-type 1 (HIV-1) infection; alone or in combination with TMC-310911
CBR-001-599-559-2,RFM-007-489-5,CBR-001-599-559-2,COc1c(ccc2c1cccc2)C(C(=O)S[C@H](C(=O)NCC(=O)O)C)C,CBR-HVAC-08104: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-599-560-5,RFM-007-490-8,CBR-001-599-560-5,COc1c(ccc2c1cccc2)C(C(=O)S[C@H](C(=O)NCC(=O)O)C)C,CBR-HVAC-08104: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-599-561-6,RFM-007-491-9,CBR-001-599-561-6,COc1cc2c(cc1OC)ncnc2N1CCN(CC1)C(=O)OCC(C)C,CBR-HVAC-08951:
CBR-001-599-562-7,RFM-007-492-0,CBR-001-599-562-7,O=C(/C=C/c1ccc(cc1Cl)Cl)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-09322: Bacterial protein synthesis inhibitor
CBR-001-599-563-8,RFM-007-493-1,CBR-001-599-563-8,COCCOCCNCC1COc2c(O1)cccc2,CBR-HVAC-09394:
CBR-001-599-564-9,RFM-007-494-2,CBR-001-599-564-9,CCCCCCCCOc1ccccc1CC(=O)NC(c1ccccc1)Cc1ccccc1,CBR-HVAC-10561: Acyl-CoA:cholesterol acyltransferase inhibitor
CBR-001-599-565-0,RFM-007-495-3,CBR-001-599-565-0,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC/C=C/c1ccc(cc1)Cn1cncc1)C,CBR-HVAC-10683:  Calcium channel antagonist; Platelet activating factor antagonist; Thromboxane A2 synthase inhibitor
CBR-001-599-566-1,RFM-007-496-4,CBR-001-599-566-1,COc1cc(NC(=O)C2CC2)c(cc1C(=O)N[C@@H]1CCN(C1)Cc1ccccc1)Cl,CBR-HVAC-10743: Dopamine receptor D2 antagonist; Dopamine receptor D3 antagonist; Dopamine receptor D4 antagonist
CBR-001-599-567-2,RFM-007-497-5,CBR-001-599-567-2,CCN(CCc1ccc2c(c1)C(=O)c1ccccc1CO2)O,CBR-HVAC-10861:  Cyclooxygenase inhibitor; 5-Lipoxygenase inhibitor; Prostaglandin E2 receptor antagonist; Oxidoreductase inhibitor
CBR-001-599-568-3,RFM-007-498-6,CBR-001-599-568-3,Fc1ccc2c(c1)C(OCC1CC1)(c1c(N2)[n+]([O-])ccc1)C(F)(F)F,CBR-HVAC-11547:  Non-nucleoside reverse transcriptase inhibitor
CBR-001-599-569-4,RFM-007-499-7,CBR-001-599-569-4,Fc1ccc2c(c1)C(OCC1CC1)(c1c(N2)[n+]([O-])ccc1)C(F)(F)F,CBR-HVAC-11547:  Non-nucleoside reverse transcriptase inhibitor
CBR-001-599-570-7,RFM-007-500-3,CBR-001-599-570-7,Fc1ccc(cc1)c1[nH]c(nc1c1ccncc1)[C@@H]1OC[C@@](CO1)(C)C(=O)N1CCOCC1,CBR-HVAC-11620: p38 MAP kinase inhibitor
CBR-001-599-571-8,RFM-007-501-4,CBR-001-599-571-8,Fc1ccc(cc1)c1[nH]c(nc1c1ccncc1)[C@@H]1OC[C@](CO1)(C)C(=O)N1CCOCC1,CBR-HVAC-11620: p38 MAP kinase inhibitor
CBR-001-599-572-9,RFM-007-502-5,CBR-001-599-572-9,O=C(c1ccc(cc1)C(=O)N1CCC(CC1)NC(=N)NC(=O)c1nc(Cl)c(nc1N)N)N1CCC(CC1)NC(=N)NC(=O)c1nc(Cl)c(nc1N)N,"CBR-HVAC-12188: Epithelial Sodium Channels (ENaC) Blockers; Epithelial sodium channel antagonist; Cystic Fibrosis, Treatment of"
CBR-001-599-573-0,RFM-007-503-6,CBR-001-599-573-0,O=C(Nc1sc2c(c1C(=O)N)ccc(c2Cl)O)Nc1ccc2c(c1)OCO2,CBR-HVAC-12317: Protein kinase G inhibitor; Protein kinase B inhibitor; Nicotinamide adenine dinucleotide (NAD) synthetase inhibitor; Nicotinamide adenine dinucleotide kinase inhibitor
CBR-001-600-178-8,RFM-007-504-7,CBR-001-600-178-8,COc1ccc(cc1)CCC(NCC(c1ccc(c(c1)S(=O)C)O)O)C,CBR-HVAC-01148: Beta 1 adrenoreceptor antagonist; Alpha adrenoreceptor antagonist
CBR-001-600-179-9,RFM-007-505-8,CBR-001-600-179-9,O=CNCc1ccc(c2c1sc1ccc(cc1c2=O)OC)NCCN(CC)CC,CBR-HVAC-05156: DNA inhibitor
CBR-001-600-180-2,RFM-007-506-9,CBR-001-600-180-2,NCCCCCCNC(=N)NC(=N)NCCCCCCNC(=N)NC#N,CBR-HVAC-12090: Antibacterial Ophthalmic Drugs
CBR-001-600-181-3,RFM-007-507-0,CBR-001-600-181-3,O=C1O[Cr]23(NC1Cc1[nH]cnc1)(NC(C(=O)O3)Cc1[nH]cnc1)NC(C(=O)O2)Cc1[nH]cnc1,"CBR-HVAC-07289: Type 2 Diabetes, Agents for"
CBR-001-600-182-4,RFM-007-508-1,CBR-001-600-182-4,OC(=O)C[C@H](c1cccc2c1cccc2)CC(=O)Nc1c(C)cc(cc1C(=O)N1CCC2(CC1)CCCC2)C,CBR-HVAC-00607: Cholecystokinin B receptor antagonist
CBR-001-600-183-5,RFM-007-509-2,CBR-001-600-183-5,OCCN(C(=O)c1ccc(cc1)C(=C1CCN(CC1)Cc1cscn1)c1cccc2c1nccc2)C,CBR-HVAC-12107: Drugs Acting on Opioid and Opioid-Like Receptors; Opioid delta receptor agonist; Opioid receptor delta Agonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics
CBR-001-600-184-6,RFM-007-510-5,CBR-001-600-184-6,CCC(=O)c1cc(cc(c1O)CN)C(C)(C)C,CBR-HVAC-08117: Prostaglandin hydroperoxidase stimulator; Thromboxane synthetase inhibitor
CBR-001-600-185-7,RFM-007-511-6,CBR-001-600-185-7,CSc1ccc(cc1)CN1CCCC(C1)Nc1ccc2c(c1)cn[nH]2,CBR-HVAC-12079: Rho kinase Inhibitor
CBR-001-600-186-8,RFM-007-512-7,CBR-001-600-186-8,OC[C@H](c1cnc(c(c1)Cl)C1=CCN(CC1)C(=O)Nc1ccc(cn1)C(F)(F)F)O,CBR-HVAC-07258: TRPV1 (Vanilloid VR1 Receptor) Antagonists
CBR-001-600-187-9,RFM-007-513-8,CBR-001-600-187-9,CN(C[C@@]1(CC[C@](CC1)(C)O)c1ccc(c(c1)Cl)Cl)C,CBR-HVAC-12115: SEROTONIN REUPTAKE INHIBITOR; NOREPINEPHRINE REUPTAKE INHIBITOR; DOPAMINE REUPTAKE INHIBITOR
CBR-001-600-188-0,RFM-007-514-9,CBR-001-600-188-0,N#Cc1ccc2c(c1)c(NCc1ccc(c(c1)Cl)OC)nnc2N1CCC(CC1)O,CBR-HVAC-12088: Phosphodiesterase 5 inhibitor
CBR-001-600-189-1,RFM-007-515-0,CBR-001-600-189-1,N#C/N=C(/N[C@@H]1c2cc(N)ccc2O[C@]([C@H]1O)(C)C(OC)OC)\NCc1ccccc1,CBR-HVAC-00396: Neuroprotectant; Antihypertensive
CBR-001-600-190-4,RFM-007-516-1,CBR-001-600-190-4,ClCCN(CCOC(=O)CCNc1c2ccccc2nc2c1cccc2)CCCl,CBR-HVAC-05011: Antiviral Drugs
CBR-001-600-191-5,RFM-007-517-2,CBR-001-600-191-5,CCNC(=O)[C@H]1C[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nccc2N[C@@H](Cc1sccc1Cl)CC,CBR-HVAC-05071: Adenosine A1 receptor agonist; Adenosine A2a receptor agonist
CBR-001-600-192-6,RFM-007-518-3,CBR-001-600-192-6,COc1ccc2c(c1)c(ccn2)C(CC[C@@H]1CCN(C[C@@H]1C(=O)O)CCSc1cccs1)O,CBR-HVAC-05719: Bacterial nucleic acid synthesis inhibitor; DNA topoisomerase IV inhibitor
CBR-001-600-193-7,RFM-007-519-4,CBR-001-600-193-7,CO[C@H]1COCC[C@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1C[C@@H]2C[C@H]1CN2c1ncnc(c1)C(F)(F)F,CBR-HVAC-07030: CCR2 CHEMOKINE ANTAGONIST
CBR-001-600-194-8,RFM-007-520-7,CBR-001-600-194-8,CO[C@@H]1COCC[C@@H]1N[C@@H]1CC[C@](C1)(C(C)C)C(=O)N1C[C@@H]2C[C@H]1CN2c1ncnc(c1)C(F)(F)F,CBR-HVAC-07030: CCR2 CHEMOKINE ANTAGONIST
CBR-001-600-195-9,RFM-007-521-8,CBR-001-600-195-9,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C[C@H](C(=O)[C@@H]([C@@H]2[C@]1(C)OC(=O)N2NCCCc1ccnc2c1cccc2)C)C)(C)OC,CBR-HVAC-08307:  Macrolide antibiotic
CBR-001-600-196-0,RFM-007-522-9,CBR-001-600-196-0,CC1=CCN([C@H](C1)C(=O)O)C(=O)[C@@H](NS(=O)(=O)c1ccc2c(c1)CN(CC2)C)Cc1ccc(cc1)C(=N)N,CBR-HVAC-08486: Thrombin inhibitor; coagulation factor II (thrombin)
CBR-001-600-199-3,RFM-007-523-0,CBR-001-600-199-3,COc1cc(/C=C/C(=O)OCCCCO[N+](=O)[O-])ccc1OC(=O)C(c1ccc(c(c1)F)c1ccccc1)C,"CBR-HVAC-02742: Alzheimer's Dementia, Treatment of ; Antioxidants;Nitric Oxide (NO) Donors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Cyclooxygenase-1; Cyclooxygenase-2 Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Nitric oxide stimulant"
CBR-001-600-200-9,RFM-007-524-1,CBR-001-600-200-9,CCOC(=O)C1(CCN(CC1)CCN1CCOCC1)c1ccccc1,CBR-HVAC-09973: Analgesic; Narcotic
CBR-001-600-201-0,RFM-007-525-2,CBR-001-600-201-0,C(Oc1cccc(c1)OCc1ccc2c(n1)cccc2)CCc1nnn[nH]1,CBR-HVAC-04004: Antiallergy/Antiasthmatic Drugs; Leukotriene Antagonists;Leukotriene CysLT1 (LTD4) Antagonists;Signal Transduction Modulators; Leucotriene D4 antagonist; Leucotriene C antagonist; Leucotriene E4 antagonist
CBR-001-600-202-1,RFM-007-526-3,CBR-001-600-202-1,N#Cc1cc(NC(=O)COC(=O)C)c(c(c1)NC(=O)COC(=O)C)Cl,"CBR-HVAC-00078: Antiallergy/Antiasthmatic Drugs;Atopic Dermatitis, Agents for; Mediator Release Inhibitors; Cell adhesion inhibitor; Histamine release inhibitor; Thromboxane B2 (TxB2) production inhibitor; Immunosuppressant"
CBR-001-600-203-2,RFM-007-527-4,CBR-001-600-203-2,OC(=O)c1cc(NCCc2ccc(cc2)C(F)(F)F)ccc1O,"CBR-HVAC-00253: Antiarthritic Drugs;Antiparkinsonian Drugs;Ischemic Stroke, Treatment of;Amyotrophic Lateral Sclerosis, Agents for;Alzheimer's Dementia, Treatment of ; Antiamyloidogenic Agents;Antioxidants;Cytokine Production Inhibitors;Free Radical Scavengers;Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors;Signal Transduction Modulators; Microsomal prostaglandin E synthase-1 Inhibitor; Prostaglandin E2 receptor antagonist; Reducing agent"
CBR-001-600-204-3,RFM-007-528-5,CBR-001-600-204-3,CN(CCn1c2nc3cc(C)c(cc3nc2c2c1ccc(c2)O)C)C,CBR-HVAC-09334: Anticancer; Anti-inflammatory; Antiviral;
CBR-001-600-205-4,RFM-007-529-6,CBR-001-600-205-4,CCc1cccc2c1S(=O)(=O)c1c(O2)cccc1,CBR-HVAC-04158: Antidepressants; MAO-A Inhibitors; Monoamine oxidase A Inhibitor; Monoamine oxidase A inhibitor
CBR-001-600-206-5,RFM-007-530-9,CBR-001-600-206-5,CCCCN1C[C@H](OC(=O)CCC)[C@H]([C@@H]([C@H]1COC(=O)CCC)OC(=O)CCC)OC(=O)CCC,CBR-HVAC-04141: Anti-HIV Agents; alpha-Glucosidase Inhibitors; Alpha-glucosidase I Inhibitor; Alpha glucosidase inhibitor; Prostaglandin E2 receptor agonist
CBR-001-600-207-6,RFM-007-531-0,CBR-001-600-207-6,CNCC(=O)N[C@@H](C(C)(C)C)C(=O)N[C@H]([C@@H](CN(C(=O)NC(C)(C)C)CCC(C)C)O)Cc1ccccc1,CBR-HVAC-10588: Anti-HIV Agents; HIV Protease Inhibitors; Protease Inhibitor;
CBR-001-600-208-7,RFM-007-532-1,CBR-001-600-208-7,CCC(=O)NS(=O)(=O)c1ccc(c(c1)C)NC(=O)COc1ccc(cc1C(=O)c1cc(Cl)cc(c1)C#N)Cl,CBR-HVAC-05769: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Non-nucleoside reverse transcriptase inhibitor
CBR-001-600-209-8,RFM-007-533-2,CBR-001-600-209-8,CCc1cc(NCc2nc3c(o2)c(C)ccc3C)c(=O)[nH]c1C,CBR-HVAC-04211: Anti-HIV Agents; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Non-nucleoside reverse transcriptase inhibitor
CBR-001-600-210-1,RFM-007-534-3,CBR-001-600-210-1,OCC1OCC(O1)n1cnc2c1nc(N)nc2N,CBR-HVAC-00569: Anti-HIV Agents;Anti-Hepatitis B Virus Drugs; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; DNA synthesis inhibitor; Nucleoside reverse transcriptase inhibitor
CBR-001-600-211-2,RFM-007-535-4,CBR-001-600-211-2,O=C(OC(COC(=O)CCCc1ccccc1)COC(=O)CCCc1ccccc1)CCCc1ccccc1,"CBR-HVAC-06665: Antiparkinsonian Drugs;Aminoacidopathies, Treatment for;Agents for Liver Cirrhosis;Liver and Biliary Tract Disorders, Treatment of; Apoptosis Inducers;Histone Deacetylase (HDAC) Inhibitors; Nitrogen metabolism Modulator; Ammonia scavenger"
CBR-001-600-212-3,RFM-007-536-5,CBR-001-600-212-3,OC(=O)Cc1ccc(cc1)CCNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-03442: Antiplatelet Therapy;Restenosis Treatment of;Antiallergy/Antiasthmatic Drugs; Prostanoid TP Antagonists;Signal Transduction Modulators; Thromboxane A2 receptor Antagonist; Thromboxane receptor antagonist; Platelet aggregation inhibitor
CBR-001-600-213-4,RFM-007-537-6,CBR-001-600-213-4,O=C1CCCc2c1ccn2CCCCN1CCN(CC1)c1cccc(c1)C(F)(F)F,CBR-HVAC-09200: Antipsychotic Drugs; Dopamine D4 Antagonists;Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 2A receptor Agonist; Antagonist;
CBR-001-600-214-5,RFM-007-538-7,CBR-001-600-214-5,Fc1ccc(c(c1)C)Nc1ccc(c(c1)Cl)C(=O)c1ccccc1C,"CBR-HVAC-05994: Atopic Dermatitis, Agents for;Acne Therapy; MAPK p38 Inhibitors;Signal Transduction Modulators;"
CBR-001-600-215-6,RFM-007-539-8,CBR-001-600-215-6,OCCN1C(=O)CN2C(c3c1ccc(c3)Cl)(OCC2)c1ccccc1F,CBR-HVAC-01973: Benzodiazepine receptor agonist
CBR-001-600-216-7,RFM-007-540-1,CBR-001-600-216-7,OCCOCCOCCN1CCC(=C(c2ccccc2)c2ccccc2)CC1,CBR-HVAC-05601: Bronchodilators;
CBR-001-600-217-8,RFM-007-541-2,CBR-001-600-217-8,COc1cc(cc(c1OC)OC)C1CC(O)c2c(O1)c1ccccc1cc2,CBR-HVAC-09304: Chemopreventive Agents; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors;Signal Transduction Modulators; Matrix metalloproteinase 2 Inhibitor;
CBR-001-600-218-9,RFM-007-542-3,CBR-001-600-218-9,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(=O)C,CBR-HVAC-09531: Cholinergic receptor; Alpha-1 adrenergic receptor; Histamine receptor; Dopamine receptor Inhibitor;
CBR-001-600-219-0,RFM-007-543-4,CBR-001-600-219-0,OC(=O)C(c1ccc2c(c1)nc(o2)c1ccc(cc1)F)C,CBR-HVAC-02341: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-600-220-3,RFM-007-544-5,CBR-001-600-220-3,CCCCCCCCCC(=O)OCCN1CCN(CC1)CC/C=C/1\c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-01648: Dopamine D2 receptor antagonist; Dopamine D1 receptor antagonist
CBR-001-600-221-4,RFM-007-545-6,CBR-001-600-221-4,O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@H]1S[C@H]1C2,CBR-HVAC-01576: Drug causes apoptosis of mammary tumors by interfering with the hormone-dependent growth control mechanisms; RNA directed RNA polymerase stimulant; Androgen receptor agonist
CBR-001-600-222-5,RFM-007-546-7,CBR-001-600-222-5,NCCCCCCCCCCCNC(=N)NC(=O)c1nc(Cl)c(nc1N)N,CBR-HVAC-12309: EPITHELIAL SODIUM CHANNEL BLOCKER
CBR-001-600-223-6,RFM-007-547-8,CBR-001-600-223-6,COc1ccc2c(c1)c(CC(=O)OCCSCC(=O)NCCCOc1cccc(c1)CN1CCCCC1)c(n2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-10498: Gastric Antisecretory Drugs; Cyclooxygenase-3 Inhibitors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; Histamine H2 receptor Antagonist;
CBR-001-600-224-7,RFM-007-548-9,CBR-001-600-224-7,CCn1c(cc2c1nc(Nc1nn(c(c1)C)C)c1c2n(C)cn1)C(=O)N(C1CC1)C1CC1,CBR-HVAC-07075: Hematologic Agents (Miscellaneous);Hematopoiesis Disorders Therapy; Jak2 Inhibitors;Signal Transduction Modulators;
CBR-001-600-225-8,RFM-007-549-0,CBR-001-600-225-8,CNC(=O)COc1ccccc1OCC(CNC(C)(C)C)O,"CBR-HVAC-02910: Hypertension, Treatment of; beta-Adrenoceptor Antagonists;Signal Transduction Modulators; Beta-adrenergic receptor Antagonist; Beta 1 adrenoreceptor antagonist"
CBR-001-600-226-9,RFM-007-550-3,CBR-001-600-226-9,COc1ccccc1C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCC1,CBR-HVAC-01847: Insulinotropin agonist. Sulphonylurea oral hypoglycaemic agent.; Potassium channel antagonist
CBR-001-600-227-0,RFM-007-551-4,CBR-001-600-227-0,O=C([C@H](NC(=O)C1(CCCC1)NC(=O)c1cc2c(s1)cc(cc2)C)Cc1ccccc1)NCC1CCN(CC1)CC1CCOCC1,"CBR-HVAC-00723: Irritable Bowel Syndrome, Agents for;Analgesic Drugs; Signal Transduction Modulators;Tachykinin NK2 Antagonists; NEUROKININ RECEPTOR 2 Antagonist; Neurokinin 2 receptor antagonist"
CBR-001-600-228-1,RFM-007-552-5,CBR-001-600-228-1,CCN(C(CC(C)C)COC(=O)c1ccc(cc1)N)CC,CBR-HVAC-09891: Local anesthetic
CBR-001-600-229-2,RFM-007-553-6,CBR-001-600-229-2,COc1cccc(c1F)c1c(=O)n(C[C@@H](c2ccccc2)N)c(=O)n(c1C)Cc1c(F)cccc1F,CBR-HVAC-08077: Luteinizing hormone releasing hormone (LHRH) antagonist
CBR-001-600-230-5,RFM-007-554-7,CBR-001-600-230-5,N#CCC(=O)c1onc(n1)c1cccs1,CBR-HVAC-12287: Mycolic acid synthase Inhibitor
CBR-001-600-231-6,RFM-007-555-8,CBR-001-600-231-6,CCN(CCNC(=O)c1cc(Cl)c(cc1OC(C(=O)C)C)N)CC,"CBR-HVAC-03679: Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5 Hydroxytryptamine 3 receptor antagonist"
CBR-001-600-232-7,RFM-007-556-9,CBR-001-600-232-7,CN1[C@@H]2CC[C@H]1C[C@H](C2)NC(=O)c1cnc2c(c1O)cccc2,"CBR-HVAC-10527: Nausea and Vomiting, Treatment of; Signal Transduction Modulators;5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist;"
CBR-001-600-233-8,RFM-007-557-0,CBR-001-600-233-8,C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1,CBR-HVAC-09631: Nicotinic acetylcholine receptor Antagonist;
CBR-001-600-234-9,RFM-007-558-1,CBR-001-600-234-9,COc1ccc(cc1)n1nc(cc1c1ccc(cc1)S(=O)C)C(F)F,CBR-HVAC-11041: Non-Opioid Analgesics;Antiarthritic Drugs; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; COX-2 Inhibitor;
CBR-001-600-235-0,RFM-007-559-2,CBR-001-600-235-0,CC(=O)Nc1ccc(cc1)OC(=O)CCCO[N+](=O)[O-],"CBR-HVAC-02748: Non-Opioid Analgesics;Neuropathic Pain, Treatment of;Antipyretics; Nitric Oxide (NO) Donors; Nitric oxide donor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Nitric oxide stimulant"
CBR-001-600-236-1,RFM-007-560-5,CBR-001-600-236-1,OC[C@H]1O[C@@H]([C@@H]([C@@H]1OP(=O)(OC(CNC(=O)CC[C@@]1(C)C2=N[C@H]([C@@H]1CC(=O)N)[C@]1(C)N([Co+]C)/C(=C(/C)\C3=N/C(=C\C4=N/C(=C\2/C)/[C@@H](CCC(=O)N)C4(C)C)/[C@H]([C@]3(C)CC(=O)N)CCC(=O)N)/[C@H]([C@]1(C)CC(=O)N)CCC(=O)N)C)[O-])O)n1cnc2c1cc(C)c(c2)C,CBR-HVAC-12750: Nucleosides;methylated form of vitamin B12
CBR-001-600-237-2,RFM-007-561-6,CBR-001-600-237-2,ClCCn1nnc2n(c1=O)cnc2C(=O)N,CBR-HVAC-03004: Oncolytic Drugs; Alkylating agent; DNA inhibitor
CBR-001-600-238-3,RFM-007-562-7,CBR-001-600-238-3,SCC(C(=O)NCCCCCCC(=O)O)Cc1ccccc1,"CBR-HVAC-10805: Opioid Analgesics; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Membrane metalloendopeptidase Inhibitor;"
CBR-001-600-239-4,RFM-007-563-8,CBR-001-600-239-4,CCOC(=O)C1(CCN(CC1)CCc1ccc(cc1)N)c1ccccc1,CBR-HVAC-09537: Opioid receptor Agonist;
CBR-001-600-240-7,RFM-007-564-9,CBR-001-600-240-7,c1ccc(cc1)N1CCN(CC1)CCCOc1ccc2c(c1)OCO2,"CBR-HVAC-10506: Pharmacological Tools;Hypertension, Treatment of; Signal Transduction Modulators;5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist;"
CBR-001-600-241-8,RFM-007-565-0,CBR-001-600-241-8,Oc1ccc(cc1O)Cc1nccc2c1cc(O)c(c2)O,CBR-HVAC-02808: Phosphodiesterase inhibitor
CBR-001-600-242-9,RFM-007-566-1,CBR-001-600-242-9,CSc1ccc(cc1)Oc1ccc(cc1CN(C)C)S(=O)(=O)N,CBR-HVAC-05629: 5-HT Reuptake Inhibitors; 5-Hydroxytryptamine receptor modulator; Reproductive system modulator; Signal Transduction Modulators; 5-HT modulator; Prevention of Premature Ejaculation; Reproductive system modulator
CBR-001-600-243-0,RFM-007-567-2,CBR-001-600-243-0,COc1cc2c(cc1OC)CCN(C2C)CCc1ccc(cc1)N,CBR-HVAC-00959: Prostaglandin synthase inhibitor
CBR-001-600-244-1,RFM-007-568-3,CBR-001-600-244-1,CN1CCN(CC1)c1ccc(cc1)Nc1ncc2c(n1)n(C1CCCC1)c(=O)c(c2C)Br,CBR-HVAC-12318: PROTEIN KINASE B; PROTEIN KINASE G Inhibitor
CBR-001-600-245-2,RFM-007-569-4,CBR-001-600-245-2,CCC[C@H](c1ccc(cc1)C)NC(=O)N1C(=O)C([C@H]1Oc1ccc(cc1)CC(=O)O)(CC)CC,"CBR-HVAC-11220: Pulmonary Emphysema, Agents for; Elastase Inhibitors; Elastase 2, neutrophil Inhibitor;"
CBR-001-600-246-3,RFM-007-570-7,CBR-001-600-246-3,CCC[C@H](c1ccc(cc1)C)NC(=O)N1C(=O)C([C@@H]1Oc1ccc(cc1)CC(=O)O)(CC)CC,"CBR-HVAC-11220: Pulmonary Emphysema, Agents for; Elastase Inhibitors; Elastase 2, neutrophil Inhibitor;"
CBR-001-600-247-4,RFM-007-571-8,CBR-001-600-247-4,COc1cc2nc(N[C@@H]3CC[C@H](CC3)O)cnc2cc1OC,CBR-HVAC-11975: Restenosis Treatment of; Angiogenesis Inhibitors;PDGFR Family Inhibitors;Signal Transduction Modulators; Protein tyrosine kinase Inhibitor;
CBR-001-600-248-5,RFM-007-572-9,CBR-001-600-248-5,CN1C(=O)CN=C(c2c1ccc(c2)[N+](=O)[O-])c1ccccc1F,CBR-HVAC-03100: Sedative/Hypnotics;Agents for Premedication; GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators; Benzodiazepine receptor Agonist;
CBR-001-600-249-6,RFM-007-573-0,CBR-001-600-249-6,CCN(CCOc1cccc(c1)c1cn2c(n1)sc1c2cccc1)CC,CBR-HVAC-11920: Solid Tumors Therapy; Angiogenesis Inhibitors; Anticancer; Angiogenesis inhibitor;
CBR-001-600-250-9,RFM-007-574-1,CBR-001-600-250-9,OC[C@H](Nc1nc(ncc1Br)Nc1ccc(cc1)S(=O)(=O)N)C,CBR-HVAC-05939: Solid Tumors Therapy; Angiogenesis Inhibitors;Apoptosis Inducers;CDK1/Cyclin B Inhibitors;CDK2/Cyclin E Inhibitors;CDK4 Inhibitors;CDK7 Inhibitors;CDK9/Cyclin T1 Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-1 (Flt-1) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors;
CBR-001-600-251-0,RFM-007-575-2,CBR-001-600-251-0,OCCOC1c2cc3ccccc3nc2c2n1c(=O)c1c(c2)[C@@](O)(CC)C(=O)OC1,CBR-HVAC-05259: Solid Tumors Therapy; DNA Topoisomerase I Inhibitors; DNA topoisomerase I inhibitor
CBR-001-600-252-1,RFM-007-576-3,CBR-001-600-252-1,Cn1ccc(n1)S(=O)(=O)N1CCCC(C1)Nc1nccc(n1)c1c(nc2n1cco2)c1cccc(c1)OCOP(=O)([O-])[O-],CBR-HVAC-07031: Solid Tumors Therapy;Melanoma Therapy;Colorectal Cancer Therapy;Endocrine Cancer Therapy; Raf kinase B Inhibitors;Raf kinase C Inhibitors;Signal Transduction Modulators; B-Raf Inhibitor;
CBR-001-600-253-2,RFM-007-577-4,CBR-001-600-253-2,COc1cc(F)cc2c1c1c(OC)cc(cc1C12NC(=O)NC1=O)F,CBR-HVAC-11106: Symptomatic Antidiabetic Agents; Aldose Reductase Inhibitors; Aldose reductase Inhibitor;
CBR-001-600-254-3,RFM-007-578-5,CBR-001-600-254-3,OC(=O)[C@H](c1ccccc1)N1CCC(CC1)c1ccc(cc1)NC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F,CBR-HVAC-14138: metabolite of CBR-HVAC-00532
CBR-001-600-255-4,RFM-007-579-6,CBR-001-600-255-4,OC(=O)[C@@H](c1ccccc1)N1CCC(CC1)c1ccc(cc1)NC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F,CBR-HVAC-14138: metabolite of CBR-HVAC-00532
CBR-001-600-256-5,RFM-007-580-9,CBR-001-600-256-5,Brc1cc(Nc2nnc(c3c2cccc3)Cc2ccncc2)cc(c1)C(F)(F)F,CBR-HVAC-11564: Vascular endothelial growth factor receptor Inhibitor;
CBR-001-600-257-6,RFM-007-581-0,CBR-001-600-257-6,Nc1cc(N)c(c(c1)C(=O)O)N=Nc1ccc(cc1)S(=O)(=O)N,CBR-HVAC-08685:
CBR-001-600-258-7,RFM-007-582-1,CBR-001-600-258-7,FCC(Cn1cnc2c1ncnc2N)O,CBR-HVAC-13673: metabolite of CBR-HVAC-10566
CBR-001-600-259-8,RFM-007-583-2,CBR-001-600-259-8,CCOc1ccc(nc1)Cc1nc2c(n1CC1CCCCC1)ccc(c2)N(S(=O)(=O)c1cccs1)C,CBR-HVAC-12273: Cannabinoid CB1 Agonists; Cannabinoid CB2 Partial Agonists; Signal Transduction Modulators
CBR-001-600-260-1,RFM-007-584-3,CBR-001-600-260-1,Clc1cccc(c1)Nc1ncc(c2c1ccn2C)C(=O)N1CCOCC1,CBR-HVAC-12277: Cannabinoid receptor 2 agonist
CBR-001-600-261-2,RFM-007-585-4,CBR-001-600-261-2,OCCn1ncc(c1)c1cc(ccc1F)c1c[nH]nc1c1cccc(n1)C,CBR-HVAC-12258: Activin Receptor Like Kinase 5 (ALK5; TbetaR-I) Inhibitors
CBR-001-600-632-9,RFM-007-586-5,CBR-001-600-632-9,CCc1nc2n(c1C(=O)NCc1ccc(cc1)N1CCC(CC1)c1ccc(cc1)OC(F)(F)F)cc(cc2)Cl,CBR-HVAC-07320:Phase I initiated by Qurient in US for the treatment of tuberculosis
CBR-001-601-436-1,RFM-007-587-6,CBR-001-601-436-1,CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@@H]([C@H]([C@H]1O)O)COP(=O)(OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O,CBR-HVAC-00070: P2Y12 purinoceptor antagonist; Platelet ADP receptor antagonist; Platelet aggregation inhibitor
CBR-001-601-437-2,RFM-007-588-7,CBR-001-601-437-2,O=C1CCC(N1)C(=O)N1CCCCC1,CBR-HVAC-00103: Acetylcholine modulator; GABA modulator; Metabotropic glutamate receptor stimulator
CBR-001-601-438-3,RFM-007-589-8,CBR-001-601-438-3,CCn1ncc2c1ncc(c2NC1CCOCC1)c1nnc(o1)Cc1sc(nc1C)C,CBR-HVAC-00176: PHOSPHODIESTERASE 4 Inhibitor; Antidepressant; Anxiolytic; Depressive disorders; Huntington's disease
CBR-001-601-439-4,RFM-007-590-1,CBR-001-601-439-4,CNCCCOc1cc(F)c(c(c1)F)c1c(Cl)nc2n(c1N[C@H](C(F)(F)F)C)ncn2,CBR-HVAC-00191: Tubulin Inhibitor; Anticancer; Solid tumor
CBR-001-601-440-7,RFM-007-591-2,CBR-001-601-440-7,Fc1ccc(cc1)c1cc(OCCCCCN2CCCCC2)nc(n1)C,CBR-HVAC-00304: Calcium channel; Sodium channel Blocker; Neuroprotectant; Cerebrovascular ischemia; Stroke
CBR-001-601-441-8,RFM-007-592-3,CBR-001-601-441-8,NC(=O)/N=N/C(=O)N,"CBR-HVAC-00484: Viral uncoating inhibitor; HIV-1 zinc finger inhibitor; Antiviral; Immunosuppressant; Viral infections; Infection, human immunodeficiency virus; Foaming"
CBR-001-601-442-9,RFM-007-593-4,CBR-001-601-442-9,OCCC(C(=O)[O-])O/N=C/1\C(=O)Nc2c1cc(c1ccc(cc1)S(=O)(=O)N(C)C)c1c2CN(CC1)C,CBR-HVAC-00521: Glutamate receptor 5; Ionotropic glutamate receptor AMPA Antagonist; Neuroprotectant; Analgesic; Anticonvulsant; Epilepsy; Neuropathic pain; Pain; Cerebrovascular ischemia; Brain injury
CBR-001-601-443-0,RFM-007-594-5,CBR-001-601-443-0,CO[C@H]1OCCN(C1)[C@H]1C[C@@H](O[C@H]([C@H]1O)C)O[C@H]1C[C@@](O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)c(OC)ccc2)C(=O)CO,CBR-HVAC-00626: DNA topoisomerase I Inhibitor; Antineoplastic; Liver cancer; Solid tumor
CBR-001-601-444-1,RFM-007-595-6,CBR-001-601-444-1,C(NC[C@H]1COc2c(O1)cccc2)CCOc1ccc2c(c1)OCO2,CBR-HVAC-00816: 5-Hydroxytryptamine 1A receptor Agonist; ANTI-DEPRESSANT¬ANXIOLYTIC; Depression; Mood disorder; Anxiety
CBR-001-601-445-2,RFM-007-596-7,CBR-001-601-445-2,O[C@H]1CCN(C1)C[C@@H](N(C(=O)C(c1ccccc1)c1ccccc1)C)c1ccccc1,CBR-HVAC-00820: Opioid receptor Kappa agonist
CBR-001-601-446-3,RFM-007-597-8,CBR-001-601-446-3,COc1cccc(c1F)c1c(=O)n(C[C@@H](c2ccccc2)NCCCC(=O)O)c(=O)n(c1C)Cc1c(F)cccc1C(F)(F)F,CBR-HVAC-00870: GONADOTROPIN RELEASING HORMONE Antagonist; Anticancer; Benign prostatic hyperplasia; Menorrhagia; Uterine fibroid; Dysmenorrhea
CBR-001-601-447-4,RFM-007-598-9,CBR-001-601-447-4,O=C(Nc1cc(F)c2c(c1O)C(=O)C1[C@@H](C2)C[C@@H]2[C@@](C1=O)(O)C(=O)C(C(=O)[C@H]2N(C)C)C(=O)N)CN1CCCC1,CBR-HVAC-00876: Protein 30S ribosomal subunit inhibitor
CBR-001-601-448-5,RFM-007-599-0,CBR-001-601-448-5,O/N=C/1\CC[C@]2(C(=C1)CCC1C2CC[C@]2(C1CCC2[C@@H](CCCC(C)C)C)C)C,CBR-HVAC-00882: Apoptosis inhibitor
CBR-001-601-449-6,RFM-007-600-6,CBR-001-601-449-6,C/C(=C\CCC(=O)OC/C=C(/CCC=C(C)C)\C)/CC/C=C(/CCC=C(C)C)\C,"CBR-HVAC-01001: Anti-ulcer; Anti-ulcer; ULCER, GASTRIC; DRY EYE SYNDROME"
CBR-001-601-450-9,RFM-007-601-7,CBR-001-601-450-9,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCc1c(C)nc2n(c1=O)CCS2,CBR-HVAC-01046: Dopamine receptor D2 Agonist; Antipsychotic; Psychosis
CBR-001-601-451-0,RFM-007-602-8,CBR-001-601-451-0,C[C@H]([C@H]1C(=O)N2[C@@H]1CC(=C2C(=O)O)S[C@H]1CCN(C1)C(=C)N)O,CBR-HVAC-02256:
CBR-001-601-452-1,RFM-007-603-9,CBR-001-601-452-1,CCN1C(=O)CC2(C1=O)CCN(CC2)C,CBR-HVAC-02883: Muscarinic acetylcholine receptor M1 Agonist; Nootropic; Alzheimer's disease
CBR-001-601-453-2,RFM-007-604-0,CBR-001-601-453-2,CC/C(=C(\c1cccc(c1)O)/c1ccc(cc1)OCCN(C)C)/c1ccccc1,CBR-HVAC-02899: Estrogen receptor Modulator; Anticancer; Antihyperlipidemic; Breast cancer; Cardiovascular diseases; Male osteoporosis; Postmenopausal osteoporosis; Postmenopausal osteoporosis
CBR-001-601-454-3,RFM-007-605-1,CBR-001-601-454-3,CC(N1CC(=O)N(C(=O)C1)CN1CCOCC1)CN1CC(=O)N(C(=O)C1)CN1CCOCC1,CBR-HVAC-03221: Antineoplastic; Antineoplastic; Cancer
CBR-001-601-455-4,RFM-007-606-2,CBR-001-601-455-4,CCCC/N=C(\c1ccccc1Cl)/c1cc(Cl)ccc1O,CBR-HVAC-03301: GABA receptor agonist
CBR-001-601-456-5,RFM-007-607-3,CBR-001-601-456-5,O=C1NNC(=C(C1)C)c1ccc(cc1)n1cncc1,CBR-HVAC-03375: Phosphodiesterase 3 inhibitor
CBR-001-601-457-6,RFM-007-608-4,CBR-001-601-457-6,O=S(c1nc2c([nH]1)cccc2)Cc1ccccc1N(C)C,"CBR-HVAC-03440: PROTON PUMP Inhibitor; Gastroprotectant; Ulcer, gastric; Acid-related gastrointestinal disorders"
CBR-001-601-458-7,RFM-007-609-5,CBR-001-601-458-7,CNc1sc2c(n1)c(Cc1cccnc1)c(c(c2C)O)C,CBR-HVAC-04352: Thromboxane A synthase; Lipoxygenase 5 Inhibitor; Antiinflammatory; Inflammatory Bowel Diseases; Ulcerative Colitis
CBR-001-601-459-8,RFM-007-610-8,CBR-001-601-459-8,S=C(Nc1ccc(cn1)Br)NCCc1ccccn1,CBR-HVAC-04438: Reverse transcriptase Inhibitor; Anti-HIV; Viral infection
CBR-001-601-460-1,RFM-007-611-9,CBR-001-601-460-1,COc1cc(CCN(CCCOc2ccc(cc2)S(=O)(=O)c2c(C(C)C)c3c(n2C)cccc3)C)ccc1OC,CBR-HVAC-04446: Calcium Channel Blockers
CBR-001-601-461-2,RFM-007-612-0,CBR-001-601-461-2,CCCc1c(OCCCOc2cc(O)c(cc2CC)c2ccc(cc2)F)cccc1Oc1ccccc1C(=O)O,CBR-HVAC-04456: LEUKOTRIENE B4 RECEPTOR; PPAR GAMMA Antagonist; Anti-inflammatory; Anticancer; Psoriasis
CBR-001-601-462-3,RFM-007-613-1,CBR-001-601-462-3,CCCCc1nc(C)n(c(=O)c1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)Cc1sccc1C(=O)OC,CBR-HVAC-04598: Angiotensin II converting enzyme inhibitor antagonist
CBR-001-601-463-4,RFM-007-614-2,CBR-001-601-463-4,OC(=O)CCc1c(C)ccc2c1CC[C@@H](C2)NS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-04706: Thromboxane A2 receptor Antagonist; Vasodilator; Diabetic nephropathy; Thrombosis; Arterial occlusive disease; Atherosclerosis; Cardiovascular disease; Coronary artery disease
CBR-001-601-464-5,RFM-007-615-3,CBR-001-601-464-5,CCn1/c(=C/c2cccc[n+]2CC)/s/c(=c\2/sc3c(n2C)cccc3)/c1=O,CBR-HVAC-04848: Telomerase Inhibitor; Anticancer; Malaria; Cancer
CBR-001-601-465-6,RFM-007-616-4,CBR-001-601-465-6,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(cc1)C(=N)NO)C1CCCCC1,CBR-HVAC-04971: Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitors
CBR-001-601-466-7,RFM-007-617-5,CBR-001-601-466-7,Oc1nc(c(s1)Cc1ccc(cc1)OCCN(c1ccccn1)C)O,CBR-HVAC-01932:
CBR-001-601-467-8,RFM-007-618-6,CBR-001-601-467-8,C#CCN(CC1=Cc2ccccc2Oc2c1cccc2)C,CBR-HVAC-05040: Antiapoptotic; Neuroprotectant; Nootropic; Antiparkinsonian; Neuroprotectant; Nootropic; Antiparkinsonian; Neurodegenerative diseases; Parkinson's disease; Amyotrophic lateral sclerosis
CBR-001-601-468-9,RFM-007-619-7,CBR-001-601-468-9,O=c1n(CCCCN2CCN(CC2)c2ncccn2)ncc(=O)n1C,CBR-HVAC-05068: 5-Hydroxytryptamine 1A receptor Agonist; Antidepressant; Anxiolytic; Anxiety; Depressive disorders
CBR-001-601-469-0,RFM-007-620-0,CBR-001-601-469-0,CCOC(=O)[C@@H](NC(=O)c1cc(Cl)c(c(c1O)Cl)OCCN1CCN(CC1)C)Cc1ccccc1,CBR-HVAC-05249: Cytokine synthesis inhibitor; TNF production inhibitor; Multiple cytokine inhibitor
CBR-001-601-470-3,RFM-007-621-1,CBR-001-601-470-3,O=C(Cn1c(ncc(c1=O)N)c1ccccc1)NC(C(=O)c1nnc(o1)C(C)(C)C)C(C)C,CBR-HVAC-05315: Leukocyte Elastase Inhibitors
CBR-001-601-471-4,RFM-007-622-2,CBR-001-601-471-4,CC(OC(=O)COC/C=C\C[C@H]1[C@H](Cl)C[C@H]([C@@H]1CC[C@H](C1CCCCC1)O)O)C,CBR-HVAC-05510: Prostaglandin D2 receptor Agonist; Antiglaucoma; Glaucoma
CBR-001-601-472-5,RFM-007-623-3,CBR-001-601-472-5,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccc(cc1)OCc1ccccc1)Cc1ccccc1)C[C@@H](C2)OC(=O)NCCN)c1ccccc1)Cc1c[nH]c2c1cccc2,CBR-HVAC-05523: Somatostatin receptor agonist
CBR-001-601-473-6,RFM-007-624-4,CBR-001-601-473-6,Cc1c(OC=C2NCCN2)ccc(c1NS(=O)(=O)C)Cl,CBR-HVAC-05743: Alpha-1A adrenergic receptor agonist
CBR-001-601-474-7,RFM-007-625-5,CBR-001-601-474-7,c1cnc2c(c1)CC1(O2)CN2CCC1CC2,CBR-HVAC-05877: Nicotinic acetylcholine receptor alpha7 agonist
CBR-001-601-475-8,RFM-007-626-6,CBR-001-601-475-8,CNC(=O)c1ccc(nc1)Oc1ccc2c(c1)CCN(CC2)C1CCC1,CBR-HVAC-06098: Histamine H3 receptor Antagonist; Histamine H3 receptor antagonist; Mild cognitive impairment; Dementia; Hyperalgesia
CBR-001-601-476-9,RFM-007-627-7,CBR-001-601-476-9,COc1cc(c(cc1OC)NC(=O)c1cc(=O)c2c(o1)cccc2)c1nnn(n1)c1ccc(cc1)CCN1CCc2c(C1)cc(c(c2)OC)OC,CBR-HVAC-06244: Topoisomerase I; P-Glycoprotein Inhibitor; Anticancer; CANCER
CBR-001-601-477-0,RFM-007-628-8,CBR-001-601-477-0,OC[C@H](NC(=O)c1cccc(c1)/C=C/CCCC(=O)N(C)C)C,CBR-HVAC-06276: Cannabinoid receptor agonist
CBR-001-601-478-1,RFM-007-629-9,CBR-001-601-478-1,CCCc1ccc(c(c1)OC)COc1ccc2c(c1)CCC(=C2C)CN1CC(C1)C(=O)O,CBR-HVAC-06444: Lysophospholipid edg1 (S1P1) Receptor Agonists
CBR-001-601-479-2,RFM-007-630-2,CBR-001-601-479-2,CC[C@@H](c1ccccc1)NC(=O)c1c(NS(=O)(=O)C)c(nc2c1cccc2)c1ccccc1,CBR-HVAC-06566: Neurokinin-3 receptor Antagonist; Antipsychotic; Schizophrenia
CBR-001-601-480-5,RFM-007-631-3,CBR-001-601-480-5,OCCn1ncc2c1ccc(c2)Oc1ccc(cc1CNC(=O)Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)F,CBR-HVAC-06645: P38 MITOGEN-ACTIVATED PROTEIN KINASE; TIE2 KINASE RECEPTOR Inhibitor; Inhibitor; Inhibitor; Inhibitor; Anticancer; Anti-inflammatory; Cancer; Inflammation
CBR-001-601-481-6,RFM-007-632-4,CBR-001-601-481-6,CC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)CC[C@]12C)F,CBR-HVAC-06662: Fludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises extracellular fluid volume and blood pressure and lowers potassium levels
CBR-001-601-482-7,RFM-007-633-5,CBR-001-601-482-7,Fc1ccc(cc1)C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCN3C,CBR-HVAC-06956: 5-HYDROXYTRYPTAMINE 2A RECEPTOR; DOPAMINE RECEPTOR Antagonist; Modulator; Antipsychotic; Schizophrenia
CBR-001-601-483-8,RFM-007-634-6,CBR-001-601-483-8,COc1ccc2c(c1)C=C1Cn3c2c(C2CCCCC2)c2c3cc(cc2)C(=O)NS(=O)(=O)N(CCOCCN(C1=O)C)C,"CBR-HVAC-06990: NS5B POLYMERASE Inhibitor; ; Infection, hepatitis c virus"
CBR-001-601-484-9,RFM-007-635-7,CBR-001-601-484-9,FC(c1nccc(c1)[C@@]1(N=C(c2c1cccc2F)N)c1cccc(c1)c1cncnc1)F,CBR-HVAC-07153: beta-Secretase 1 (BACE1) Inhibitors
CBR-001-601-485-0,RFM-007-636-8,CBR-001-601-485-0,O=C1CC2(CCCC2)C(C(=O)N1CCCCN1CCN(CC1)c1ncccn1)O,CBR-HVAC-07159:
CBR-001-601-486-1,RFM-007-637-9,CBR-001-601-486-1,Cc1ncnc(c1)c1ccc2c(c1)CC[C@H]2N1CC2(C1)CCN(CC2)C(=O)Cc1nc2n(c1)cc(s2)C,CBR-HVAC-07176: GHS Receptor Inverse Agonists; Signal Transduction Modulators
CBR-001-601-487-2,RFM-007-638-0,CBR-001-601-487-2,CC(Oc1ccc(cc1F)c1nn(c2c1c(N)ncn2)[C@H](c1oc2ccc(cc2c(=O)c1c1cccc(c1)F)F)C)C,CBR-HVAC-07211: Apoptosis Inducers; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors
CBR-001-601-488-3,RFM-007-639-1,CBR-001-601-488-3,CCO[C@H](C(=O)O)Cc1ccc(cc1)OCCn1c(C)ccc1c1ccc(cc1)SC,CBR-HVAC-07281: Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma Agonist; Lipid metabolism modulator; Insulin sensitizer; Diabetic Dyslipidemia; Hypertriglyceridemia; Type 2 Diabetes Mellitus
CBR-001-601-489-4,RFM-007-640-4,CBR-001-601-489-4,COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(c1)[nH]nc3/C=C/c1ccc(cc1)CN1C[C@H](C)O[C@@H](C1)C)C(=O)N2,CBR-HVAC-07333: Antimitotic Drugs; Polo-like Kinase-4 (Plk-4) Inhibitors
CBR-001-601-490-7,RFM-007-641-5,CBR-001-601-490-7,NC(=O)c1cccc2c1cc(n2c1nc(NCc2ccccc2)c2c(n1)CCOC2)C,"CBR-HVAC-07351: Transitional Endoplasmic Reticulum ATPase (VCP, p97) Inhibitors"
CBR-001-601-491-8,RFM-007-642-6,CBR-001-601-491-8,CO[C@H]1CN(C[C@@H]1COc1nc(Nc2cnn(c2)C)nc2c1c(Cl)c[nH]2)C(=O)C=C,CBR-HVAC-07377: EGFR (Thr790Met Mutant) Inhibitors
CBR-001-601-492-9,RFM-007-643-7,CBR-001-601-492-9,CCN(CC(=O)NC1c2ccccc2CS(=O)(=O)c2c1cccc2)CC,"CBR-HVAC-07453: calcium channel, voltage-dependent, L type, alpha 1C subunit"
CBR-001-601-493-0,RFM-007-644-8,CBR-001-601-493-0,OCCOCn1cnc2c1nc(N)nc2N,CBR-HVAC-07585: DNA directed DNA polymerase inhibitor
CBR-001-601-494-1,RFM-007-645-9,CBR-001-601-494-1,CN(CCCn1nc(c2c1ccc(c2)C)c1ccccc1)C,CBR-HVAC-07852: 5 Hydroxytryptamine uptake inhibitor; Dopamine reuptake inhibitor
CBR-001-601-495-2,RFM-007-646-0,CBR-001-601-495-2,OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NNC(=O)N)CCCNC(=N)N)CC(C)C)COC(C)(C)C)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1nc[nH]c1,CBR-HVAC-07873: Luteinizing hormone releasing hormone (LHRH) agonist
CBR-001-601-496-3,RFM-007-647-1,CBR-001-601-496-3,N=C(Nc1ccn(n1)CCCCC(=O)N)NCC(F)(F)F,CBR-HVAC-07906: Histamine H2 receptor antagonist
CBR-001-601-497-4,RFM-007-648-2,CBR-001-601-497-4,NCCCC[C@@H](C(=O)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)[C@@H](NC(=O)C(N)(C)C)Cc1c[nH]cn1,"CBR-HVAC-05087: Gastric Emptying Disorders,Treatment of;Treatment of Growth Hormone Deficiency; GHS Receptor Agonists;Growth Hormone Secretagogues;Signal Transduction Modulators; GHRELIN RECEPTOR Agonist;"
CBR-001-601-498-5,RFM-007-649-3,CBR-001-601-498-5,CC(OC(=O)C(=C1SCS1)C(=O)Nc1scc(n1)C)C,CBR-HVAC-08050: Cytochrome P450 reductase modulator
CBR-001-601-499-6,RFM-007-650-6,CBR-001-601-499-6,CCC(=O)c1cc(cc(c1O)CN)C(C)(C)C,CBR-HVAC-08117: Thromboxane A synthase Inhibitor; Stimulator; Cardioplegic; Anti-inflammatory; Ischemic heart diseases; Asthma
CBR-001-601-500-2,RFM-007-651-7,CBR-001-601-500-2,Clc1ccc(cc1)c1cc(cc(c1O)CNC(C)(C)C)C(C)(C)C,CBR-HVAC-08527: Acidifying agent non gastric; Calmodulin antagonist
CBR-001-601-501-3,RFM-007-652-8,CBR-001-601-501-3,CN(C1C(=O)C(C(=O)N)C(=O)C2(C1CC1Cc3c(C(=O)C1C2=O)c(O)ccc3[N+](=O)[O-])O)C,CBR-HVAC-08754:
CBR-001-601-502-4,RFM-007-653-9,CBR-001-601-502-4,CN(CCON=C1c2ccccc2CCc2c1cccc2)C,CBR-HVAC-08919: ; Antidepressant; Depression
CBR-001-601-503-5,RFM-007-654-0,CBR-001-601-503-5,Clc1ccc(cc1)C(c1ccccn1)(C1=NCCN1)O,CBR-HVAC-09122: ; Antidepressant; Depression
CBR-001-601-504-6,RFM-007-655-1,CBR-001-601-504-6,O=C(N[C@@H](c1ccc(cn1)OCC(F)(F)F)C)Cc1ccc(cc1)c1nccnc1C,CBR-HVAC-09479: T-Type calcium channel INHIBITOR; HYPNOTIC; SEDATIVE; SLEEP DISORDER
CBR-001-601-505-7,RFM-007-656-2,CBR-001-601-505-7,CON(Cc1ccc(c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(=O)C(C(=O)[C@]3(C(=O)C1C2=O)O)C(=O)N)O)C,CBR-HVAC-07240: Bacterial protein synthesis inhibitor; Protein 30S ribosomal subunit inhibitor; Ribosomal-protein-inhibitors; ANTI-BACTERIAL; Acne Therapy; Antibacterial Drugs; Bacterial Infections; Dermatologic Drugs; Skin Disorders
CBR-001-601-506-8,RFM-007-657-3,CBR-001-601-506-8,OCC([C@H](C(=O)NCCC(=O)O)O)(C)C,"CBR-HVAC-09627: Pantothenic acid is a component of coenzyme A, acyl COA synthetase, and acyl carrier protein. The coenzyme form of the vitamin is therefore responsible for acyl group transfer reaction.; Nutritional supplement; Release of energy from protein, carbohydrates, and fat, carbohydrate, protein and fat metabolism and hemoglobin synthesis"
CBR-001-601-507-9,RFM-007-658-4,CBR-001-601-507-9,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2C1(C)C[C@H](O)C1C2C[C@@H](C2=CC(=O)C=CC12C)F,CBR-HVAC-09629: Glucocorticoid receptor Agonist; Corticosteroid; Inflammatory disorder; Autoimmune disorder
CBR-001-601-508-0,RFM-007-659-5,CBR-001-601-508-0,OCCN(CCn1c(Cc2ccccc2)nc2c1c(=O)n(C)c(=O)n2C)CC,CBR-HVAC-09745: Adenosine A1 receptor Antagonist; Bronchodilator; Asthma; Respiratory diseases
CBR-001-601-509-1,RFM-007-660-8,CBR-001-601-509-1,CCN(CCOCCC1=CCC2CC1C2(C)C)CC,"CBR-HVAC-09938: ; Local anesthetic; Anesthesia, local"
CBR-001-601-510-4,RFM-007-661-9,CBR-001-601-510-4,CC(=O)OCC1=C(N2[C@H](SC1)[C@@H](C2=O)NC(=O)CC#N)C(=O)O,CBR-HVAC-10338: Compound binds with penicillin binding protein inhibiting its activity thereby inhibiting cell wall synthesis; Antibiotic; Bacterial infections
CBR-001-601-511-5,RFM-007-662-0,CBR-001-601-511-5,Fc1ccc(cc1)N1CCN(CC1)CCn1c(=N)sc2c1ccc(c2)OC(F)(F)F,CBR-HVAC-10700: Sodium channel Blocker; Anticonvulsant; Neuroprotectant; Epilepsy; Cerebral infarction; Cerebrovascular ischemia
CBR-001-601-512-6,RFM-007-663-1,CBR-001-601-512-6,CN(CCCCCCCCSc1nc(ccc1C(=O)c1cccs1)C(C)C)C,CBR-HVAC-10809: Prolyl endopeptidase Inhibitor; Prolyl endopeptidase inhibitor; Alzheimer's disease
CBR-001-601-513-7,RFM-007-664-2,CBR-001-601-513-7,O=C1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OS(=O)(=O)N,CBR-HVAC-11120: STEROID SULFATASE Inhibitor; ANTI-INFLAMMATORY; Inflammatory diseases
CBR-001-601-514-8,RFM-007-665-3,CBR-001-601-514-8,NC(=C)NCCCC[C@@H](C(=O)O)N,CBR-HVAC-11332: Nitric oxide synthase inhibitor
CBR-001-601-515-9,RFM-007-666-4,CBR-001-601-515-9,CNC(=S)N/N=C/1\SCC(=O)N1CC=C,CBR-HVAC-11421: Retinoid Z receptor Agonist; Antiinflammatory; Rheumatoid arthritis
CBR-001-601-516-0,RFM-007-667-5,CBR-001-601-516-0,COC[C@H]1OC(=O)c2c3[C@@]1(C)C1=C(C(=O)c3oc2)[C@H]2[C@@](C[C@H]1OC(=O)C)(C)C(=O)CC2,CBR-HVAC-11494: Phosphatidylinositol 3-kinase inhibitor
CBR-001-601-517-1,RFM-007-668-6,CBR-001-601-517-1,OCC(COc1ccc(cc1)CCCCNC(=N)NC(=O)c1nc(Cl)c(nc1N)N)O,CBR-HVAC-11851: Sodium channel blocker; Sodium channel blocker; Anti-fibrotic; Sjogrens syndrome; Cystic fibrosis
CBR-001-601-534-2,RFM-007-669-7,CBR-001-601-534-2,CC(=O)Nc1ccc(cc1)OCCOC(=O)c1ccccc1OC(=O)C,CBR-HVAC-02097: ; Analgesic; Anti-inflammatory; Antipyretic; Pain; Inflammation
CBR-001-601-535-3,RFM-007-670-0,CBR-001-601-535-3,CCCCCCN(Cc1ccc(cc1)OCCOc1ccc(cc1)CN(CCCCCC)C)C,CBR-HVAC-10195: ; Antiamebic; Amebiasis
CBR-001-601-536-4,RFM-007-671-1,CBR-001-601-536-4,NC(=O)C(c1ccccc1)(c1ccccc1)CCN1CCN2C(C1)CCC2,CBR-HVAC-10213: ; Antiarrhythmic; Cardiac depression
CBR-001-601-537-5,RFM-007-672-2,CBR-001-601-537-5,Clc1ccc(cc1)OC(C(=O)N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C)c1ccccc1)(C)C,"CBR-HVAC-08730: ; Antibacterial; Infection, bacterial"
CBR-001-601-538-6,RFM-007-673-3,CBR-001-601-538-6,COc1nccnc1N(S(=O)(=O)c1ccc(cc1)N)C(=O)C,CBR-HVAC-08675: ; Antibiotic; Leprosy
CBR-001-601-539-7,RFM-007-674-4,CBR-001-601-539-7,CC(c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1)O,CBR-HVAC-08827: ; Antidiabetic; Diabetes
CBR-001-601-540-0,RFM-007-675-5,CBR-001-601-540-0,CN(CC(COc1ccc(cc1)c1nc2c(N)nc(nc2nc1N)N)O)C,CBR-HVAC-08300: ; ANTI-DIURETIC; Diuresis
CBR-001-601-541-1,RFM-007-676-6,CBR-001-601-541-1,OC(=O)CCC(=O)c1ccc(c(c1)Cl)C1CCCCC1,CBR-HVAC-09212: ; Anti-inflammatory; Analgesic; Antipyretic; Inflammation; Neuronal dysfunction; Diabetes; Hypertension; Artheriosclerosis
CBR-001-601-542-2,RFM-007-677-7,CBR-001-601-542-2,CC(=O)OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-09135: ; Antipsychotic; Psychosis
CBR-001-601-543-3,RFM-007-678-8,CBR-001-601-543-3,Clc1ccc2c(c1)N(CCCN1CCC(CC1)(C(=O)N)N1CCCCC1)c1ccccc1CC2,CBR-HVAC-01889: ; Antipsychotic; Psychosis; Schizophrenia
CBR-001-601-544-4,RFM-007-679-9,CBR-001-601-544-4,Oc1cc2O[C@H](c3ccc4c(c3)OC(O4)(c3ccccc3)c3ccccc3)[C@H](Cc2c(c1)O)O,CBR-HVAC-01176: ; Antispasmodic; Spasms
CBR-001-601-545-5,RFM-007-680-2,CBR-001-601-545-5,O=C(Nc1c(C)cccc1Cl)CCN1CCCC2C1CCC2,"CBR-HVAC-10118: ; Local anesthetic; Anesthesia, local"
CBR-001-601-546-6,RFM-007-681-3,CBR-001-601-546-6,O=C(Nc1c(C)cccc1Cl)CCN1CCCC2C1CCC2,"CBR-HVAC-10118: ; Local anesthetic; Anesthesia, local"
CBR-001-601-547-7,RFM-007-682-4,CBR-001-601-547-7,O=C(c1ccccc1N)OCCC1CCCCN1,"CBR-HVAC-09932: ; Local anesthetic; Anesthesia, local; Headache"
CBR-001-601-548-8,RFM-007-683-5,CBR-001-601-548-8,Clc1cnn(c1)CCCCN1CCN(CC1)c1ncccn1,CBR-HVAC-04060: 5-Hydroxytryptamine 1A receptor Agonist; Anxiolytic; Anxiety disorder; Alcohol dependency
CBR-001-601-549-9,RFM-007-684-6,CBR-001-601-549-9,Clc1cccc(c1)N1CCN(CC1)CCn1ccc2c1CCCC2=O,CBR-HVAC-09199: 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 2A receptor Antagonist; Agonist; Antipsychotic; Psychotic disorder; Schizophrenia
CBR-001-601-550-2,RFM-007-685-7,CBR-001-601-550-2,CN(CCCSCC(=O)C1(CCC1)c1ccc(c(c1)Cl)Cl)C,CBR-HVAC-05036: 5-Hydroxytryptamine transporter; Dopamine transporter; Monoamine transporter; Norepinephrine transporter Inhibitor; Antidepressant; Antiparkinsonian; Attention deficit-hyperactivity disorder; Depression; Parkinson's disease
CBR-001-601-551-3,RFM-007-686-8,CBR-001-601-551-3,CCC(=O)Nc1c(C)cc(cc1C)C(=O)N1CCC(CC1)N(CCc1ccccc1)C,"CBR-HVAC-05021: Adrenergic alpha 2C receptor Antagonist; Alpha-2 adrenergic receptor antagonist; Occlusion, peripheral arterial disease; Peripheral vascular disease; Raynaud's syndrome; Claudication, intermittent"
CBR-001-601-552-4,RFM-007-687-9,CBR-001-601-552-4,O=C1NC(=O)C2(N1)c1cc(F)ccc1c1c2cc(F)cc1,CBR-HVAC-03268: Aldose reductase Inhibitor; Anticataract; Diabetic cataract; Diabetic complications; Symptomatic diabetes; Glaucoma; Diabetic neuropathy
CBR-001-601-553-5,RFM-007-688-0,CBR-001-601-553-5,CCOC(c1cccnc1)CN1CCN(CC1)c1ccccc1OC,CBR-HVAC-07931: Alpha-1 adrenergic receptor Antagonist; Antihypertensive; Hypertension
CBR-001-601-554-6,RFM-007-689-1,CBR-001-601-554-6,CCOC(=O)c1ccc(cc1)OCCN1C[C@H](O)[C@H]([C@@H]([C@H]1CO)O)O,CBR-HVAC-03207: Alpha-glucosidase Inhibitor; Hypoglycemic; Type II diabetes mellitus
CBR-001-601-555-7,RFM-007-690-4,CBR-001-601-555-7,CCOC(=O)[C@@H](N[C@H](C(=O)N1CCC[C@H]1C(=O)OCCCO[N+](=O)[O-])C)CCc1ccccc1,CBR-HVAC-09210: Angiotensin converting enzyme Inhibitor; Antihypertensive; Hypertension
CBR-001-601-556-8,RFM-007-691-5,CBR-001-601-556-8,CCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1[nH]nnn1)C(=O)CCCC2,CBR-HVAC-00809: ANGIOTENSIN II RECEPTOR TYPE 1 Blocker; Antihypertensive; Atherosclerosis; Diabetic nephropathy; Glomerulonephritis; Hypertension
CBR-001-601-557-9,RFM-007-692-6,CBR-001-601-557-9,N#Cc1ccc(cc1)C(n1cncn1)C(Cc1ccc(cc1)F)O,CBR-HVAC-04600: Aromatase Inhibitor; Anticancer; Cancer; Urination disorders
CBR-001-601-558-0,RFM-007-693-7,CBR-001-601-558-0,Clc1ccc2c(c1)C(=NCC(=O)N2C)C1=CCCCC1,CBR-HVAC-10320: Benzodiazepine receptor Agonist; Tranquilizer; Muscle relaxant; Anticonvulsant; Anxiolytic; Hypnotic; MUSCLE SPASM; DEPRESSION; AGORAPHOBIA; PREMENSTRUAL SYNDROME; ANXIETY DISORDER
CBR-001-601-559-1,RFM-007-694-8,CBR-001-601-559-1,COc1cc(ccc1O)C(CNC(CCn1cnc2c1cccc2)C)O,CBR-HVAC-10811: Beta-2 adrenergic receptor Agonist; Antiasthmatic; Asthma
CBR-001-601-560-4,RFM-007-695-9,CBR-001-601-560-4,COc1ccc(cc1OC)CCNCCC(=O)N1CCCSc2c1cccc2,CBR-HVAC-03260: Calcium channel Antagonist; Antihypertensive; Antiarrhythmic; Arrhythmia; Hypertension; Ischemic heart diseases
CBR-001-601-561-5,RFM-007-696-0,CBR-001-601-561-5,C#CC1(CCCCC1)OC(=O)N,CBR-HVAC-10259: Carbonic anhydrase 2; Carbonic anhydrase 1 Inhibitor; Sedative; Hypnotic; INSOMNIA
CBR-001-601-562-6,RFM-007-697-1,CBR-001-601-562-6,OCC(COC(=O)[C@@]12CC[C@H]([C@@H]2[C@@H]2[C@](CC1)(C)[C@]1(C)CC[C@@H]3[C@]([C@H]1CC2)(C)CC[C@@H](C3(C)C)OC(=O)C)C(=C)C)(CO)N,CBR-HVAC-06327: Caspase 9 Modulator; Anticancer; Cancer
CBR-001-601-563-7,RFM-007-698-2,CBR-001-601-563-7,CC(c1cc(/C=C/2\SCNC2=O)cc(c1O)C(C)(C)C)(C)C,CBR-HVAC-11532: COX; Lipoxygenase 5; Phospholipase A2 Inhibitor; Anti-inflammatory; Immunosuppressant; Inflammatory disorders; Neurodegenerative diseases
CBR-001-601-564-8,RFM-007-699-3,CBR-001-601-564-8,COc1cc(Cc2cnc(nc2N)N)c2c(c1OC)oc(c2)Cc1c([nH]c2c1cc(Cl)cc2)C(=O)N(C)C,CBR-HVAC-06185: Dihydrofolate reductase Inhibitor; Antibacterial; Gram positive bacterium infection
CBR-001-601-565-9,RFM-007-700-9,CBR-001-601-565-9,N#C/C(=C(\CCC#C)/O)/C(=O)Nc1ccc(cc1)C(F)(F)F,CBR-HVAC-04509: Dihydroorotate dehydrogenase inhibitor; Immunosuppressant; Transplant rejection
CBR-001-601-566-0,RFM-007-701-0,CBR-001-601-566-0,CC(N1CCC(CC1)(c1ccccc1)c1ccccc1)C,CBR-HVAC-00960: Dipeptidyl peptidase 4 Inhibitor; Antiparkinsonian; Parkinson's disease
CBR-001-601-567-1,RFM-007-702-1,CBR-001-601-567-1,O=C(c1ccc2c(c1)OC(O2)(F)F)NC1Cc2c(C1)cccc2,CBR-HVAC-06175: ENDOTHELIAL NITRIC OXIDE SYNTHASE Enhancer; Antihypertensive; Vasodilator; Angina; Congestive heart failure
CBR-001-601-568-2,RFM-007-703-2,CBR-001-601-568-2,COc1cc2c(cc1OCc1ccccc1)n(c(c2c1ccc2c(c1)OCO2)C(=O)O)Cc1ccc2c(c1)OCO2,"CBR-HVAC-11313: Endothelin A receptor; Endothelin B receptor Antagonist; Antihypertensive; Renal failure, acute; Chronic renal failure; Congestive heart failure; Hypertension, pulmonary; Hemorrhage, subarachnoid; Cerebral ischemia; Hypertension"
CBR-001-601-569-3,RFM-007-704-3,CBR-001-601-569-3,Clc1ccc2c(c1)N(C(=O)CC(=O)N2C)c1ccccc1,CBR-HVAC-01777: GABA receptor Modulator; Anxiolytic; Anxiety; Hypnotic
CBR-001-601-570-6,RFM-007-705-4,CBR-001-601-570-6,CCO/N=C(/c1ccc2c(c1)ncn2c1cccc(c1)c1cccnc1)\C,CBR-HVAC-04888: GABA-A receptor Modulator; Partial Agonist; Anxiolytic; Anxiety disorder
CBR-001-601-571-7,RFM-007-706-5,CBR-001-601-571-7,OC(=O)C(c1cn2c(n1)ccc(n2)NCCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1)(C)C,CBR-HVAC-10438: Histamine H1 receptor Antagonist; Anti-inflammatory; Immunosuppressant; Atopic dermatitis; Allergic rhinitis
CBR-001-601-572-8,RFM-007-707-6,CBR-001-601-572-8,CN(Cc1ccc(o1)CSCCN/C(=C/[N+](=O)[O-])/NCc1ccc2c(c1)OCO2)C,CBR-HVAC-01762: Histamine H2 receptor Antagonist; Antiulcer; Ulcer
CBR-001-601-573-9,RFM-007-708-7,CBR-001-601-573-9,CC(Cn1c(C)nc2c1c1ncccc1nc2N)C,CBR-HVAC-00514: Immunomodulator; Antineoplastic; Keratolytic; Immunomodulator; Antineoplastic; Keratolytic; Dermatologic diseases; Actinic keratosis; Cancer
CBR-001-601-574-0,RFM-007-709-8,CBR-001-601-574-0,CCN1CC/C(=C\c2cc(c(c(c2)C(C)(C)C)O)C(C)(C)C)/S1(=O)=O,CBR-HVAC-04575: Interleukin 6; COX-2 Inhibitor; Immunomodulator; Anti-inflammatory; Analgesic; Rheumatoid arthritis
CBR-001-601-575-1,RFM-007-710-1,CBR-001-601-575-1,Brc1cccc(c1)CN1C(Nc2c(S1(=O)=O)c(Cl)cc(c2)Cl)C(=O)O,CBR-HVAC-10577: Ionotropic glutamate receptor NMDA Antagonist; Neurodegenerative; Neurodegenerative diseases disease; Stroke
CBR-001-601-576-2,RFM-007-711-2,CBR-001-601-576-2,O=C(N1CCCCC1CN1CCCC1)Cc1ccc(cc1)C(F)(F)F,CBR-HVAC-03717: KAPPA OPIOID RECEPTOR AGONIST; CARDIOTONIC; DIURESIS; HYPERTENSION
CBR-001-601-577-3,RFM-007-712-3,CBR-001-601-577-3,O=C(N1CCCCC1CN1CCCC1)Cc1ccc(cc1)C(F)(F)F,CBR-HVAC-03717: KAPPA OPIOID RECEPTOR AGONIST; CARDIOTONIC; DIURESIS; HYPERTENSION
CBR-001-601-578-4,RFM-007-713-4,CBR-001-601-578-4,CC(c1cc(/C=C/2\CCOC2=O)cc(c1O)C(C)(C)C)(C)C,CBR-HVAC-03206: Lipoxygenase 5 Inhibitor; Anti-inflammatory; Antirheumatic; Rheumatic diseases
CBR-001-601-579-5,RFM-007-714-5,CBR-001-601-579-5,CCO/N=C/c1ccc(cc1)OCCC1CCN(CC1)c1ccc(nn1)C,CBR-HVAC-11433: Low density lipoprotein receptor Inhibitor; Antiviral; Rhinovirus infections
CBR-001-601-580-8,RFM-007-715-6,CBR-001-601-580-8,CC(C(F)(F)F)Oc1ccc2c(c1)Oc1c(S2(=O)=O)cccc1,CBR-HVAC-11087: Monoamine oxidase A Inhibitor; Anti-anxiety; Antidepressant; Anxiety disorder; Depression
CBR-001-601-581-9,RFM-007-716-7,CBR-001-601-581-9,CCn1nnc(n1)C1=CCCN(C1)C,CBR-HVAC-11550: Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2; Muscarinic acetylcholine receptor M3 Agonist; Antagonist; Muscarinic M1 receptor agonist; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Alzheimer's disease; Urinary incontinence
CBR-001-601-582-0,RFM-007-717-8,CBR-001-601-582-0,FC(c1cccc(c1)C1=CCN(CC1)CCc1ccc(cc1)c1ccccc1)(F)F,CBR-HVAC-11692: Neuroprotectant; Nootropic; Neuroprotectant; Nootropic; Alzheimer's disease; Parkinson's disease
CBR-001-601-583-1,RFM-007-718-9,CBR-001-601-583-1,N#CC(c1ccccc1)(c1ccccc1)CCN1CCC(CC1)(N1CCCCC1)C(=O)N,"CBR-HVAC-06394: Opioid receptor Agonist; Analgesic; Narcotic; Pain, postoperative"
CBR-001-601-584-2,RFM-007-719-0,CBR-001-601-584-2,O=C(c1ccccc1)c1cccc(c1)NC(=O)c1ccn2c1CSC2c1cccnc1,CBR-HVAC-03739: Platelet activating factor receptor Antagonist; Antianginal; Antiarrhythmic; Antiasthmatic; Myocardial ischemia
CBR-001-601-585-3,RFM-007-720-3,CBR-001-601-585-3,Nc1ccc(cc1)C(=O)N1C[C@@H]2CN(C[C@H](C1)C2)Cc1ccccc1,CBR-HVAC-03789: Potassium channel; Sodium channel Antagonist; Blocker; Class III antiarrhythmic; Antifibrillator; Cardiac arrhythmia
CBR-001-601-586-4,RFM-007-721-4,CBR-001-601-586-4,COc1ccc(c(c1)OC)CS(=O)c1ncccc1C(=O)Nc1ccnc(c1)N(C)C,CBR-HVAC-10632: Proton pump Inhibitor; Gastric antisecretory; Gastrointestinal disorders
CBR-001-601-587-5,RFM-007-722-5,CBR-001-601-587-5,OCCCO[C@@H]1[C@H](O)C/C(=C/C=C/2\CCC[C@]3([C@H]2CC[C@@H]3[C@@H](CCCC(O)(C)C)C)C)/C(=C)[C@H]1O,CBR-HVAC-02284: Vitamin D receptor; Vitamin D-binding protein Binder; Anti-osteoporotic agent; Osteoporosis
CBR-001-601-588-6,RFM-007-723-6,CBR-001-601-588-6,CCCCCC(=O)N[C@H](C(=O)OC)Cc1ccc(cc1)O,"CBR-HVAC-07101: Antibacterial Drugs; Atopic Dermatitis, Agents for"
CBR-001-601-589-7,RFM-007-724-7,CBR-001-601-589-7,Cc1nn(c(c1)C)CCCCCSc1nc(c([nH]1)c1ccccc1)c1ccccc1,CBR-HVAC-04271: ACAT Inhibitors
CBR-001-601-590-0,RFM-007-725-8,CBR-001-601-590-0,OC(=O)CC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2[C@H](C[C@H]2[C@]1(C)CC[C@H](C2)OS(=O)(=O)O)OS(=O)(=O)O)C,CBR-HVAC-03373: Steroids; Phase I initiated for the prevention of recurrence of colorectal polyps
CBR-001-601-591-1,RFM-007-726-9,CBR-001-601-591-1,COC(=O)C1(CC1)OC(=O)c1cncn1[C@@H](c1ccccc1)C,CBR-HVAC-07357: Anesthetic Drugs; Sedative/Hypnotics
CBR-001-601-592-2,RFM-007-727-0,CBR-001-601-592-2,CCOC(=O)C1N=C(c2c(NC1=O)ccc(c2)Cl)c1ccccc1Cl,CBR-HVAC-07802: GABA receptor agonist; Chloride channel agonist; Potassium channel agonist
CBR-001-601-593-3,RFM-007-728-1,CBR-001-601-593-3,O=C(C1CC1)Nc1cnc(c(n1)c1cccnc1)c1ccncc1F,CBR-HVAC-06561: Adenosine A2B Antagonists
CBR-001-601-594-4,RFM-007-729-2,CBR-001-601-594-4,C=CCN1CCN(CC1)C(c1ccccc1)c1ccccc1,CBR-HVAC-05796: Calcium Channel Blockers
CBR-001-601-595-5,RFM-007-730-5,CBR-001-601-595-5,ClCCN(c1ccc(cc1)CCCC(=O)OCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OC(=O)c1ccccc1)CCCl,CBR-HVAC-02921: DNA inhibitor; DNA synthesis inhibitor
CBR-001-601-596-6,RFM-007-731-6,CBR-001-601-596-6,COc1ccccc1OC1CCN(C1)CCCC(=O)c1ccc(cc1)F,CBR-HVAC-07436: Dopamine receptor antagonist
CBR-001-601-597-7,RFM-007-732-7,CBR-001-601-597-7,OC(C1COc2c(O1)cccc2)CNCC(C1COc2c(O1)cccc2)O,CBR-HVAC-07625: Beta 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor antagonist; Alpha 1 adrenoreceptor antagonist
CBR-001-601-601-6,RFM-007-733-8,CBR-001-601-601-6,CCCCCCCNC(=O)Nc1c(F)cc(cc1CCc1ccc(cc1)CC(C)(C)C)F,CBR-HVAC-04013: Acyl CoA:cholesterol acyltransferase Inhibitor; Antiarteriosclerotic; Antihypercholesterolemic
CBR-001-601-602-7,RFM-007-734-9,CBR-001-601-602-7,OCC(NCc1ccc2c3c1cccc3c1c2cccc1)(CO)C,CBR-HVAC-03522: DNA topoisomerase II Inhibitor; Anticancer; Antineoplastic; Intercalating
CBR-001-601-603-8,RFM-007-735-0,CBR-001-601-603-8,OC(C(=O)N1CSC([C@@H]1C(=O)NCc1ccccc1C)(C)C)C(NC(=O)c1cccc(c1C)O)Cc1ccccc1,CBR-HVAC-05044: Protease Inhibitor; Antiviral
CBR-001-601-604-9,RFM-007-736-1,CBR-001-601-604-9,O=C(c1cc2c(c(c1O)Cl)C(C)(C)CCC2(C)C)Nc1cc(F)c(c(c1)F)C(=O)O,CBR-HVAC-05625: Retinoic acid receptor alpha Agonist; Anticancer; Immunostimulant
CBR-001-601-605-0,RFM-007-737-2,CBR-001-601-605-0,C=CCC1(CC=C)C(=O)NC(=O)NC1=O,CBR-HVAC-09701: GABA-A receptor Agonist; Sedative
CBR-001-601-606-1,RFM-007-738-3,CBR-001-601-606-1,C=CCN1C(=O)OC(C1=O)C,CBR-HVAC-08646: ; Anticonvulsant
CBR-001-601-607-2,RFM-007-739-4,CBR-001-601-607-2,OCC(=O)[C@@]12O[C@](O[C@@H]1C[C@@H]1C2(C)C[C@H](O)[C@]2(C1CCC1=CC(=O)C=CC21C)F)(C)c1ccccc1,"CBR-HVAC-08771: ; Anti-inflammatory, steroidal"
CBR-001-601-608-3,RFM-007-740-7,CBR-001-601-608-3,COc1ccccc1N1CCN(CC1)CCCC(c1ccc(cc1)F)O,CBR-HVAC-09402: Antipsychotic; ANTIPSYCHOTIC
CBR-001-601-609-4,RFM-007-741-8,CBR-001-601-609-4,O=C(Nc1ccc(cc1C(=O)c1ccccc1)Cl)CN(CC(=O)O)CC(=O)O,CBR-HVAC-02540: ; DIAGNOSTIC AID
CBR-001-601-610-7,RFM-007-742-9,CBR-001-601-610-7,COCCc1ccc(cc1)OCC(C(N)(C)C)O,CBR-HVAC-01157: Beta Adrenergic receptor Blocker; OCULAR HYPERTENSIVE AGENT
CBR-001-601-611-8,RFM-007-743-0,CBR-001-601-611-8,C[C@H]1[C@@H](OCc2ccc(cc2)C(=O)O)O[C@H]2[C@@]34[C@H]1CC[C@H]([C@@H]4CC[C@](O2)(OO3)C)C,CBR-HVAC-03668: ; ANTIMALARIAL
CBR-001-601-612-9,RFM-007-744-1,CBR-001-601-612-9,CC(=O)Nc1ccc(cc1)OC(=O)Cc1ccc(n1C)C(=O)c1ccc(cc1)C,CBR-HVAC-10446: Anti-inflammatory; Anti-inflammatory
CBR-001-601-613-0,RFM-007-745-2,CBR-001-601-613-0,COc1cncnc1N1CCN(CC1)CCCc1c[nH]c2c1cc(cc2)CS(=O)(=O)NC,CBR-HVAC-04708: 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; Antimigraine
CBR-001-601-614-1,RFM-007-746-3,CBR-001-601-614-1,COC(=O)c1[nH]cc(c1N1CCOCC1)c1ccc(cc1)Br,CBR-HVAC-04703: Sodium channel Blocker; Antiepileptic; Anticonvulsant
CBR-001-601-615-2,RFM-007-747-4,CBR-001-601-615-2,O=C(C1CC[C@H](CC1)CNC(=N)N)Oc1ccc(cc1)C(C)(C)C,CBR-HVAC-00509: Histamine H1 receptor; Protease; Trypsin Antagonist; Inhibitor; Inhibitor; Antiallergic; Antiasthmatic
CBR-001-601-616-3,RFM-007-748-5,CBR-001-601-616-3,CCOC(=O)CC1CCN(CC1)CCOC(c1ccccc1)c1ccccc1,CBR-HVAC-03773: Histamine H1 receptor Antagonist; Antiallergic
CBR-001-601-617-4,RFM-007-749-6,CBR-001-601-617-4,CC(NC(=O)NS(=O)(=O)c1cc(ccc1Nc1cccc(c1)C)[N+](=O)[O-])C,CBR-HVAC-11395: Thromboxane A2 receptor Antagonist; Antithrombotic
CBR-001-601-618-5,RFM-007-750-9,CBR-001-601-618-5,Cc1c(C)noc1NS(=O)(=O)c1ccccc1c1ccc(cc1)c1ncco1,CBR-HVAC-04829: Endothelin A receptor Antagonist; Antihypertensive; Vasodilator
CBR-001-601-619-6,RFM-007-751-0,CBR-001-601-619-6,OC(=O)COc1cccc(c1)CCc1nc(c(o1)c1ccccc1)c1ccccc1,CBR-HVAC-10516: Prostacyclin receptor Partial Agonist; Antithrombotic
CBR-001-601-620-9,RFM-007-752-1,CBR-001-601-620-9,Fc1cccc(c1Cn1nnc2c1ccnc2N)F,CBR-HVAC-04112: Sodium channel Inhibitor; Anticonvulsant
CBR-001-601-621-0,RFM-007-753-2,CBR-001-601-621-0,OC(=O)C(CCCOc1ccc(c(c1)c1ccccc1)OCCCC(C(=O)O)(C)C)(C)C,CBR-HVAC-07636: ; HYPOLIPIDEMIC
CBR-001-601-622-1,RFM-007-754-3,CBR-001-601-622-1,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)C(=O)c1ccc(cc1)Cl,CBR-HVAC-00914: ; Antipsychotic
CBR-001-601-623-2,RFM-007-755-4,CBR-001-601-623-2,FC(c1ccc2c(c1)[C@@H]1CNC[C@H]2C1)(F)F,CBR-HVAC-05919: ALPHA 3 BETA 4 NICOTINIC ACETYLCHOLINE RECEPTOR Agonist; CENTRAL NERVOUS SYSTEM STIMULANT
CBR-001-601-624-3,RFM-007-756-5,CBR-001-601-624-3,COc1cc2c(cc1OC)CCN(C2C(c1ccc2c(c1)ccc(c2)OC)C)C(=O)CN1CCCCC1,CBR-HVAC-10534: Calcium channel L-type Blocker; Antiarrhythmic; Antihypertensive
CBR-001-601-625-4,RFM-007-757-6,CBR-001-601-625-4,CCN(CCOCC(COc1ccccc1OC)OCCN(CC)CC)CC,CBR-HVAC-03057:
CBR-001-601-626-5,RFM-007-758-7,CBR-001-601-626-5,OCC(NCc1cc2c3ccccc3ccc2c2c1cccc2)(CO)C,CBR-HVAC-03529: DNA topoisomerase II Inhibitor; Anticancer; DNA Intercalator
CBR-001-601-627-6,RFM-007-759-8,CBR-001-601-627-6,N#CC(c1ccccc1)(c1ccccc1)C[C@@H]1C[C@@H]2CC[C@H](C1)[N+]2(C)C,CBR-HVAC-06253: Muscarinic acetylcholine receptor; Beta-2 adrenergic receptor Agonist; Bronchodilator
CBR-001-601-628-7,RFM-007-760-1,CBR-001-601-628-7,Cc1cc2c(s1)nc(nc2c1ccccc1F)N1CCNCC1,CBR-HVAC-04167: 5-Hydroxytryptamine 3 receptor Antagonist; Analgesic
CBR-001-601-629-8,RFM-007-761-2,CBR-001-601-629-8,Oc1ccc(c(c1)O)C1=NC(CS1)(C)C(=O)O,CBR-HVAC-00439: Iron chelator; Iron metabolism modulator; Iron chelator; Iron metabolism modulator
CBR-001-601-630-1,RFM-007-762-3,CBR-001-601-630-1,NCC(=O)NCC(=O)NCC(=O)NCCCOc1ccc2c(c1)c(CC)c1c(n2)c2n(C1)c(=O)c1c(c2)[C@](O)(CC)C(=O)OC1,CBR-HVAC-11029: DNA topoisomerase I Inhibitor; Anticancer
CBR-001-601-631-2,RFM-007-763-4,CBR-001-601-631-2,CCCCN(C(=O)OCC[N+](CC)(C)C)CCCC,CBR-HVAC-08841: ; Antispasmodic; Anticholinergic
CBR-001-601-632-3,RFM-007-764-5,CBR-001-601-632-3,N#CC(c1ccccc1)(c1ccccc1)CCN1CCC(CC1)(C(=O)O)c1ccccc1,CBR-HVAC-03172: Opioid receptor Agonist; Antidiarrheal
CBR-001-601-633-4,RFM-007-765-6,CBR-001-601-633-4,CCOC(=O)C(c1ccccc1)(c1ccccc1)CCN1CCOCC1,CBR-HVAC-09945: ; Analgesic; Narcotic; Antispasmodic
CBR-001-601-634-5,RFM-007-766-7,CBR-001-601-634-5,O=C(C1(CC1)c1ccccc1)Nc1ccc(cc1)CC1SC(=O)NC1=O,CBR-HVAC-11361: Aldose reductase Inhibitor; Hypoglycemic; Antidiabetic
CBR-001-601-635-6,RFM-007-767-8,CBR-001-601-635-6,CSCC[C@@H](C(=O)NCCc1ccc(c(c1)OC(=O)OCC)OC(=O)OCC)NC(=O)C,CBR-HVAC-01699: Dopamine receptor Agonist; Cardiotonic
CBR-001-601-636-7,RFM-007-768-9,CBR-001-601-636-7,FC([C@@]1(/C=C/C2CC2)NC(=O)Nc2c1cc(Cl)cc2)(F)F,CBR-HVAC-10436: Non-nucleoside reverse transcriptase Inhibitor; Antiviral
CBR-001-601-637-8,RFM-007-769-0,CBR-001-601-637-8,O=C1Nc2ccc(c(c2[C@@](N1)(C#CC1CC1)C(F)(F)F)F)F,CBR-HVAC-00215: Reverse transcriptase Inhibitor; Antiviral
CBR-001-601-638-9,RFM-007-770-3,CBR-001-601-638-9,NCc1cccc(c1)n1nc(cc1C(=O)Nc1ccc(cc1F)c1ccccc1S(=O)(=O)C)C(F)(F)F,CBR-HVAC-05368: Coagulation factor X Inhibitor; Antithrombotic
CBR-001-601-639-0,RFM-007-771-4,CBR-001-601-639-0,O=C(c1cccnc1)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OC(=O)c1cccnc1,CBR-HVAC-04650: Estrogen Receptor (ER) Agonists
CBR-001-601-640-3,RFM-007-772-5,CBR-001-601-640-3,Fc1cccc(c1)CN(c1ccc(cc1)OCc1ccc2c(n1)cccc2)Cc1ccc(cc1)C(=O)O,CBR-HVAC-04184: Lipoxygenase 5 Inhibitor; Antiinflammatory
CBR-001-601-641-4,RFM-007-773-6,CBR-001-601-641-4,CCC(c1ccc(cc1)OCCNC(Cc1ccccc1)C)O,CBR-HVAC-09888: ; Local anesthetic
CBR-001-601-642-5,RFM-007-774-7,CBR-001-601-642-5,CCCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1[nH]nnn1)nccc2,CBR-HVAC-04408: Angiotensin II receptor Antagonist; Antihypertensive
CBR-001-601-643-6,RFM-007-775-8,CBR-001-601-643-6,CC(=O)N[C@H](C(=O)O)CNC(=O)[C@@H]1CCCN(C1)C(=O)CCC1CCNCC1,CBR-HVAC-05891: GPIIb/IIIa Antagonist; Platelet aggregation inhibitor; Anti-coagulant
CBR-001-601-644-7,RFM-007-776-9,CBR-001-601-644-7,CCCCC1(CCCC)CCc2c(C1O)cccc2OCc1ccc2c(n1)cccc2,CBR-HVAC-10884: Lipoxygenase 5 Inhibitor; Antiinflammatory
CBR-001-601-645-8,RFM-007-777-0,CBR-001-601-645-8,N#Cc1cccc(c1c1cc(ccc1F)c1cnc2n1ccc(n2)C(O)(C)C)F,"CBR-HVAC-07857: GABAalpha2/alpha3 agonists, Merck"
CBR-001-601-646-9,RFM-007-778-1,CBR-001-601-646-9,Cc1onc(c1)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,CBR-HVAC-01583: Peroxisome proliferator-activated receptor gamma Agonist; Antidiabetic
CBR-001-601-647-0,RFM-007-779-2,CBR-001-601-647-0,CN(CCNC(=O)c1nc(Cl)c(nc1N)N)CCNCc1cc(cc(c1O)Br)C(C)(C)C,CBR-HVAC-10518: Calcium channel Blocker; Diuretic; Antihypertensive
CBR-001-601-648-1,RFM-007-780-5,CBR-001-601-648-1,OC(=O)COc1cccc(c1)C(N(C(=O)Cc1ccc(c(c1)Cl)Cl)C)CN1CCCC1,CBR-HVAC-11715: Opioid receptor kappa Agonist; Analgesic; Antinociceptive
CBR-001-601-649-2,RFM-007-781-6,CBR-001-601-649-2,C=CCC1(CCCC)C(=O)NC(=O)NC1=O,CBR-HVAC-09840: It acts as depressant on the central nervous system; Hypnotic; Barbiturate
CBR-001-601-650-5,RFM-007-782-7,CBR-001-601-650-5,Cc1ccc(cc1)n1c(COc2ccc(c(c2)C)Cl)n[nH]c1=O,CBR-HVAC-10901: 5-Hydroxytryptamine transporter Inhibitor; Antidepressant
CBR-001-601-651-6,RFM-007-783-8,CBR-001-601-651-6,OC(=O)C(=C)CC(=O)c1ccc(cc1)c1ccccc1Cl,CBR-HVAC-01180: ; Antilipemic; Anti-inflammatory
CBR-001-601-652-7,RFM-007-784-9,CBR-001-601-652-7,ClCCN(c1ccc(cc1)C[C@@H](C(=O)N[C@H](C(=O)OCC)Cc1ccc(cc1)F)N)CCCl,CBR-HVAC-05664: Caspase 3 Stimulator; Anticancer
CBR-001-601-653-8,RFM-007-785-0,CBR-001-601-653-8,O=C(Nc1cc(Cl)nc(c1)Cl)NNc1cc(C(C)C)c2c(n1)n(C)nc2C,CBR-HVAC-12251: SPHINGOSINE 1-PHOSPHATE RECEPTOR 2 Antagonist; Cardioprotectant; Anti-cancer
CBR-001-601-654-9,RFM-007-786-1,CBR-001-601-654-9,CCCCC1CCc2c3n1c(C)c(c3cc(c2)O)CCN1CCN(CC1)c1nccc(c1)C,CBR-HVAC-11300: Lipoxygenase 5 Inhibitor; Antiinflammatory
CBR-001-601-655-0,RFM-007-787-2,CBR-001-601-655-0,COc1ccc(c2c1OCCO2)[C@@]1(CC[C@H](CC1)C(=O)O)C#N,CBR-HVAC-05335: Phosphodiesterase 4 Inhibitor; Bronchodilator
CBR-001-601-656-1,RFM-007-788-3,CBR-001-601-656-1,O=C(Cc1ccc(cn1)c1ccc(cc1)N1CCOCC1)NCc1cccc(c1)F,CBR-HVAC-06999: C-SRC KINASE; TUBULIN Inhibitor; Inhibitor; ANTI-CANCER
CBR-001-601-657-2,RFM-007-789-4,CBR-001-601-657-2,Brc1ccc(nc1)OC1=C(c2ccc(cc2)S(=O)(=O)C)C(OC1=O)(C)C,CBR-HVAC-12002: Cyclooxygenase 2 Inhibitor; Anti-inflammatory; Analgesic; Antipyretic
CBR-001-601-658-3,RFM-007-790-7,CBR-001-601-658-3,OC(c1ccc(cc1)F)(c1ccc(cc1)F)C1CCN(CC1)CCOc1c(C)cccc1C,CBR-HVAC-10500: Calcium channel Blocker; Antihypertensive
CBR-001-601-659-4,RFM-007-791-8,CBR-001-601-659-4,CCCCCCCC/C=C\CCCCCCCC(=O)Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C,CBR-HVAC-04958: Antiobese; Antiobesity
CBR-001-601-660-7,RFM-007-792-9,CBR-001-601-660-7,COCC1CN=C(c2c(N1C)ccc(c2)Br)c1ccccc1Cl,CBR-HVAC-01860: Benzodiazepine receptor Binder; Anxiolytic
CBR-001-601-661-8,RFM-007-793-0,CBR-001-601-661-8,OC(=O)CC(Cc1nc2c(n1Cc1ccc(cc1)Cl)ncc(c2)Cl)(C)C,CBR-HVAC-11591: Thromboxane A2 receptor Antagonist; Antiplatelet
CBR-001-601-662-9,RFM-007-794-1,CBR-001-601-662-9,Clc1ccc(cc1)c1cc2C(NC(=O)c3n[nH]c(c3)C)CC(Oc2nc1c1ccc(cc1Cl)Cl)(C)C,CBR-HVAC-12254: CANNABINOID 1 RECEPTOR Inverse Agonist; ANTI-OBESITY
CBR-001-601-663-0,RFM-007-795-2,CBR-001-601-663-0,Clc1ccc(cc1)c1cc2C(NC(=O)c3n[nH]c(c3)C)CC(Oc2nc1c1ccc(cc1Cl)Cl)(C)C,CBR-HVAC-12254: CANNABINOID 1 RECEPTOR Inverse Agonist; ANTI-OBESITY
CBR-001-601-664-1,RFM-007-796-3,CBR-001-601-664-1,Cc1cc(Cl)c(c(c1)Cl)OCCOc1ccc(cc1)C1=C(C2NC(C1)CNC2)C(=O)N(C1CC1)Cc1cccc(c1C)C,CBR-HVAC-06458: Renin Inhibitor; Cardioprotectant
CBR-001-601-665-2,RFM-007-797-4,CBR-001-601-665-2,Cc1cc(Cl)c(c(c1)Cl)OCCOc1ccc(cc1)C1=C(C2NC(C1)CNC2)C(=O)N(C1CC1)Cc1cccc(c1C)C,CBR-HVAC-06458: Renin Inhibitor; Cardioprotectant
CBR-001-601-666-3,RFM-007-798-5,CBR-001-601-666-3,COc1cccc2c1ccc1c2nc2c(n1)cccc2C(=O)N[C@@H](CN(C)C)C,CBR-HVAC-00216: DNA topoisomerase I; DNA topoisomerase II Inhibitor; Anticancer
CBR-001-601-667-4,RFM-007-799-6,CBR-001-601-667-4,COc1nccc(c1)NC(=O)C(=O)c1c2cc(C)ccc2n(c1C)Cc1ccc(cc1)Cl,CBR-HVAC-07267: Fatty Acid Amide Hydrolase (FAAH) Inhibitors
CBR-001-601-668-5,RFM-007-800-2,CBR-001-601-668-5,COCCOCOc1ccc(cc1C12CC3CC(C2)CC(C1)C3)C(=O)/C=C/c1ccc(cc1)C(=O)O,CBR-HVAC-11240: Retinoic acid receptor Antagonist; Anticancer
CBR-001-601-669-6,RFM-007-801-3,CBR-001-601-669-6,O=C(C(c1cccc2c1cccc2)C)OCCN1CCN(CC1)CCOC(=O)C(c1cccc2c1cccc2)C,CBR-HVAC-08638: ; Antispasmodic
CBR-001-601-670-9,RFM-007-802-4,CBR-001-601-670-9,Cc1cn(c(n1)C)c1cc(C)c2c(c1)ccc(=O)[nH]2,CBR-HVAC-03394: Phosphodiesterase Inhibitor; Inotropic
CBR-001-601-671-0,RFM-007-803-5,CBR-001-601-671-0,BrC(=C)CC1(C(C)C)C(=O)NC(=O)N(C1=O)C,CBR-HVAC-08628: ; Anticonvulsant
CBR-001-601-672-1,RFM-007-804-6,CBR-001-601-672-1,CCCCCCCC/C=C\CCCCCCCC(=O)NCc1ccc(c(c1)OC)OCCN,CBR-HVAC-03787: ; ANALGESIC
CBR-001-601-673-2,RFM-007-805-7,CBR-001-601-673-2,N[C@H](C(=O)NC1CCC(CC1)(C)C)CCC(=O)O,CBR-HVAC-00604: Norepinephrine transporter; NMDA receptor Inhibitor; Agonist; Antidepressant; Anxiolytic; Antipsychotic
CBR-001-601-674-3,RFM-007-806-8,CBR-001-601-674-3,Cc1ccc(o1)Cn1c(NC2CCNCC2)nc2c1nccc2,CBR-HVAC-03772: Histamine H1 receptor Antagonist; Antiasthmatic
CBR-001-601-675-4,RFM-007-807-9,CBR-001-601-675-4,O=C(NC(=O)c1ccccc1N(C)C)Nc1ccc(c(c1)C)Oc1ncc(cn1)Br,CBR-HVAC-04144: Tubulin Inhibitor; Anticancer
CBR-001-601-676-5,RFM-007-808-0,CBR-001-601-676-5,COc1cccc2c1CCC(=O)N2CCCN1CCN(CC1)c1cccc(c1)Cl,CBR-HVAC-00522: 5-Hydroxytryptamine 1A receptor; Opioid receptor sigma 1 Agonist; Antidepressant
CBR-001-601-677-6,RFM-007-809-1,CBR-001-601-677-6,COc1cc2sc(cc2cc1OC)C1=NNC(=O)CC1C,CBR-HVAC-11182: Phosphodiesterase 3 Inhibitor; Bronchodilator
CBR-001-601-678-7,RFM-007-810-4,CBR-001-601-678-7,FC(c1ccc2c(c1)N(CCCN1CCN(CC1)CCC1OCCCO1)c1c(S2)cccc1)(F)F,CBR-HVAC-08983: ; Antipsychotic
CBR-001-601-679-8,RFM-007-811-5,CBR-001-601-679-8,OC(=O)Cc1ccc2c(c1)OCc1c(C2=O)cccc1,"CBR-HVAC-01184: 15-Lipoxygenase; Prostaglandin G/H synthase Inhibitor; Anti-inflammatory, nonsteroidal"
CBR-001-601-680-1,RFM-007-812-6,CBR-001-601-680-1,COc1ccccc1N1CCC(CC1)CCCN1C(=O)CCCC1=O,CBR-HVAC-11611: Alpha-1 adrenergic receptor Antagonist; Antihyperplasia
CBR-001-601-681-2,RFM-007-813-7,CBR-001-601-681-2,Cc1cccc(c1)c1ccc2c(c1)c(cn2Cc1ccc(cc1)C(C)(C)C)C(=O)C(=O)O,CBR-HVAC-06702: PLASMINOGEN ACTIVATOR INHIBITOR-1 Inhibitor; Nootropic
CBR-001-601-682-3,RFM-007-814-8,CBR-001-601-682-3,Oc1cccc(c1)OC1CN(C1)C(CCC(c1ccccc1)(c1ccccc1)C(=O)N)(C)C,CBR-HVAC-06818: Muscarinic M3 receptor Antagonist; Anti-inflammatory
CBR-001-601-683-4,RFM-007-815-9,CBR-001-601-683-4,CCOC(C(=O)O)Cc1ccc(cc1)OCCN1c2ccccc2Oc2c1cccc2,CBR-HVAC-05179: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Antihyperlipidemic; Hypoglycemic
CBR-001-601-684-5,RFM-007-816-0,CBR-001-601-684-5,CCOC(C(=O)O)Cc1ccc(cc1)OCCN1c2ccccc2Oc2c1cccc2,CBR-HVAC-05179: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Antihyperlipidemic; Hypoglycemic
CBR-001-601-685-6,RFM-007-817-1,CBR-001-601-685-6,CNC1=Nc2ccc(cc2C(=NC1)c1ccc[nH]1)Cl,CBR-HVAC-04256: TAT PROTEIN Antagonist; ANTI-VIRAL
CBR-001-601-686-7,RFM-007-818-2,CBR-001-601-686-7,Clc1ccc(cc1)OC(C(=O)OCCCOC(=O)c1cccnc1)(C)C,CBR-HVAC-03469: ; Hypolipemiant
CBR-001-601-687-8,RFM-007-819-3,CBR-001-601-687-8,OC(=O)CCNC(=O)C1CCCN(C1)C(=O)CCC1CCNCC1,CBR-HVAC-10968: Integrin alpha2b beta3 Antagonist; Antiplatelet
CBR-001-601-688-9,RFM-007-820-6,CBR-001-601-688-9,Fc1ccc2c(c1)onc2C1CCN(CC1)CCN1CCN(C1=O)c1ccccc1,CBR-HVAC-05049: Alpha-1 adrenergic receptor; Alpha-2 adrenergic receptor Antagonist; Antipsychotic
CBR-001-601-689-0,RFM-007-821-7,CBR-001-601-689-0,Clc1cccc(c1)S(=O)(=O)c1ccc(cc1)CC1CCN(CC1)C1CCN(CC1)C(=O)c1cccc(c1N)C,CBR-HVAC-05501: Muscarinic acetylcholine receptor M2 Antagonist; Neuroprotectant
CBR-001-601-690-3,RFM-007-822-8,CBR-001-601-690-3,O=C(N[C@@H](C(=O)O)Cc1c[nH]c2c1cccc2)CC[C@H](C(=O)O)N,CBR-HVAC-00015: Antibacterial; Immunostimulator; Antiviral; Antibacterial; Immunostimulant; Antiviral
CBR-001-601-691-4,RFM-007-823-9,CBR-001-601-691-4,O=C(/C=C/c1ccc2c(c1)OCO2)OCc1occ(c(=O)c1)O,CBR-HVAC-06614: Retinoic acid receptor Agonist; Retinoic acid receptor agonist
CBR-001-601-692-5,RFM-007-824-0,CBR-001-601-692-5,Brc1ccc(cc1)OC(=O)N1CCN2CCC1CC2,CBR-HVAC-05430: Nicotinic acetylcholine receptor alpha7 Agonist; Antipsychotic; Neuroprotectant; Nootropic
CBR-001-601-693-6,RFM-007-825-1,CBR-001-601-693-6,O=C1COc2c(C(=O)N1CCCCN1CCN(CC1)c1ncccn1)cccc2,CBR-HVAC-02684: 5-Hydroxytryptamine 1A receptor Agonist; Anxiolytic
CBR-001-601-694-7,RFM-007-826-2,CBR-001-601-694-7,O=C(/C=C/c1ccc(nc1)C)NCCCCN1CCN(CC1)C(c1ccccc1)c1ccccc1,CBR-HVAC-03544: Lipoxygenase 5; Histamine H1 receptor Antagonist; Inhibitor; Anti-inflammatory
CBR-001-601-695-8,RFM-007-827-3,CBR-001-601-695-8,CCOC(=O)c1cc(ccc1OCC(CNC(C)(C)C)O)NC(=O)c1cccs1,CBR-HVAC-04043: Beta adrenergic receptor Antagonist; Antihypertensive; Diuretic
CBR-001-601-696-9,RFM-007-828-4,CBR-001-601-696-9,O=C1CC[C@]2(C(=C1)CCC1C2[C@@H](O)C[C@]2(C1CC[C@]2(O)C(=O)CSC(=O)C(C)(C)C)C)C,CBR-HVAC-01514: ; Anti-allergic; Anti-inflammatory
CBR-001-601-697-0,RFM-007-829-5,CBR-001-601-697-0,O=C([C@@H](N(C(=O)[C@@H]1CCCN1c1nc2ccccc2c(=O)[nH]1)C)Cc1ccc2c(c1)cccc2)N(Cc1ccccc1)C,CBR-HVAC-05405: NK1 receptor Antagonist; Analgesic
CBR-001-601-698-1,RFM-007-830-8,CBR-001-601-698-1,CCc1nn(c2c1CCn1c2nnc1c1cccs1)C1CCCC1,CBR-HVAC-04905: Phosphodiesterase 4 Inhibitor; Antiasthmatic; Bronchodilator; PDE 4 inhibitor; TNF-alpha antagonist
CBR-001-601-699-2,RFM-007-831-9,CBR-001-601-699-2,OC[C@@H](C(=O)N[C@H](C(=O)O)CC(C)C)NC(=O)[C@H](Cc1ccc(cc1)O)N,CBR-HVAC-06117: Anticancer; Anticancer
CBR-001-601-700-8,RFM-007-832-0,CBR-001-601-700-8,O1CCN(CC1)CCn1c2ccccc2c2c1nc(nc2N1CCCC1)N1CCCC1,CBR-HVAC-04760: Lipid peroxidation inhibitor; Neuroprotectant; Antioxidant
CBR-001-601-701-9,RFM-007-833-1,CBR-001-601-701-9,O=C(Nc1ccccc1CCC1CCCCN1C)/C=C/c1ccccc1,CBR-HVAC-00770:  5-hydroxytryptamine 2A receptor antagonist
CBR-001-601-702-0,RFM-007-834-2,CBR-001-601-702-0,O=C(Nc1ccccc1CCC1CCCCN1C)/C=C/c1ccccc1,CBR-HVAC-00770:  5-hydroxytryptamine 2A receptor antagonist
CBR-001-601-703-1,RFM-007-835-3,CBR-001-601-703-1,Cc1nc(C)cc(c1)c1cc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-12202: Antimicrobial; Antibacterial; Antimicrobial; Antibacterial
CBR-001-601-704-2,RFM-007-836-4,CBR-001-601-704-2,NC(=O)OC(c1ccccc1)CN1CCC(CC1)C(=O)c1ccc(cc1)F,CBR-HVAC-05965: 5-HYDROXYTRYPTAMINE 2A RECEPTOR; 5-HYDROXYTRYPTAMINE 2C RECEPTOR; DOPAMINE D2 RECEPTOR; DOPAMINE D3 RECEPTOR Inhibitor; ANTIPSYCHOTIC; ANTISCHIZOPHRENIC
CBR-001-601-705-3,RFM-007-837-5,CBR-001-601-705-3,[N-]=[N+]=Nc1ccc(cc1)C(=O)n1c2ccc(cc2c(c1C)CC(=O)O)OC,CBR-HVAC-11448: Anti-inflammatory; Analgesic; Antiinflammatory; Analgesic
CBR-001-601-706-4,RFM-007-838-6,CBR-001-601-706-4,Oc1ccc2c(c1)c(C)c(n2CCCCCCN1CCCC1)c1ccc(cc1)O,CBR-HVAC-10737: Estrogen receptor Antagonist; Anticancer; Antiproliferative
CBR-001-601-707-5,RFM-007-839-7,CBR-001-601-707-5,COC[C@H]1C[C@](N([C@H]1c1nccs1)C(=O)c1ccc(c(c1)OC)C(C)(C)C)(C#N)Cn1cccn1,analog of CBR-HVAC-11818:
CBR-001-601-708-6,RFM-007-840-0,CBR-001-601-708-6,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1CC2CCC1C=C2,CBR-HVAC-03429: Alpha 1 adrenoreceptor antagonist
CBR-001-601-709-7,RFM-007-841-1,CBR-001-601-709-7,Cc1cc(NCCN2CCN(CC2)C(c2ccccc2)c2ccccc2)c(c(n1)C)[N+](=O)[O-],CBR-HVAC-03590: Histamine H1 Receptor Antagonists; Mediator Release Inhibitors; Platelet-Activating Factor Receptor (PAFR) Antagonists
CBR-001-601-710-0,RFM-007-842-2,CBR-001-601-710-0,Cc1ccc2c(c1)[nH]c(n2)S(=O)Cc1ccccc1N(C)C,CBR-HVAC-03644: H+/K+-ATPase Inhibitors
CBR-001-601-711-1,RFM-007-843-3,CBR-001-601-711-1,Brc1ccc(c(c1)F)Cn1c(=O)c2ccc(cc2n(c1=O)CC(=O)O)F,CBR-HVAC-04580: Uricosurics
CBR-001-601-712-2,RFM-007-844-4,CBR-001-601-712-2,COc1ccccc1N1CCN(CC1)CCCCn1c(=O)sc2c1ccc(c2)CCN1CCC(CC1)C(=O)c1ccc(cc1)F,CBR-HVAC-05286: Drugs Acting on Dopamine Receptors; Drugs Acting on 5-Hydroxytryptamine Receptors
CBR-001-601-713-3,RFM-007-845-5,CBR-001-601-713-3,CC(CC1CCCCC1)NCCC(c1ccccc1)c1ccccc1,CBR-HVAC-05599: Beta 2 adrenoreceptor agonist
CBR-001-601-714-4,RFM-007-846-6,CBR-001-601-714-4,COn1cc(C(=O)O)c(=O)c2c1cc1OCOc1c2,CBR-HVAC-05859: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-601-715-5,RFM-007-847-7,CBR-001-601-715-5,OC[C@@H](Oc1cc(Oc2ccc(cc2)S(=O)(=O)C)cc(c1)C(=O)Nc1ccn(n1)C)C,CBR-HVAC-06167: Glucokinase Activators
CBR-001-601-716-6,RFM-007-848-8,CBR-001-601-716-6,Fc1ccc(cc1)Oc1ccc(cn1)C(=O)N1CCCN(CC1)C1CCC1,CBR-HVAC-07034: Histamine H3 Receptor Antagonists
CBR-001-601-717-7,RFM-007-849-9,CBR-001-601-717-7,O=C(NCCOCCOCCNS(=O)(=O)c1cccc(c1)C1CN(C)Cc2c1cc(Cl)cc2Cl)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c1cccc(c1)C1CN(C)Cc2c1cc(Cl)cc2Cl,CBR-HVAC-07241: Sodium/hydrogen exchange inhibitor
CBR-001-601-718-8,RFM-007-850-2,CBR-001-601-718-8,O=C(NCCOCCOCCNS(=O)(=O)c1cccc(c1)C1CN(C)Cc2c1cc(Cl)cc2Cl)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c1cccc(c1)C1CN(C)Cc2c1cc(Cl)cc2Cl,CBR-HVAC-07241: Sodium/hydrogen exchange inhibitor
CBR-001-601-719-9,RFM-007-851-3,CBR-001-601-719-9,CCCCCCCCCCCCOC(=O)CCCc1nc2c(n1C)ccc(c2)N(CCCl)CCCl,CBR-HVAC-07356: DNA Alkylating Drugs
CBR-001-601-720-2,RFM-007-852-4,CBR-001-601-720-2,COc1cc(CCN(CCCN2CCc3c(C2=O)cc(c(c3)OC)OC)C)ccc1OC,CBR-HVAC-07466: Calcium channel antagonist
CBR-001-601-721-3,RFM-007-853-5,CBR-001-601-721-3,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OS(=O)(=O)C(C)C,CBR-HVAC-07798: Estrogen receptor agonist
CBR-001-601-722-4,RFM-007-854-6,CBR-001-601-722-4,CCOC(=O)C1=C(C)N(CCN2CCOCC2)C(=C(C1c1ccccc1C(F)(F)F)C(=O)OCC)C,"CBR-HVAC-07831: calcium channel, voltage-dependent, L type, alpha 1C subunit"
CBR-001-601-723-5,RFM-007-855-7,CBR-001-601-723-5,Fc1ccc(cc1)c1cc(nn1c1ccc(cc1)S(=O)(=O)N)C(F)(F)F,CBR-HVAC-08019: Cyclooxygenase 2 inhibitor
CBR-001-601-724-6,RFM-007-856-8,CBR-001-601-724-6,O=C(c1ccncc1)/C=C/c1ccc2c(n1)cc(cc2)C(F)(F)F,CBR-HVAC-08175: Phosphofructokinase inhibitor
CBR-001-601-725-7,RFM-007-857-9,CBR-001-601-725-7,COc1ccc2c(c1)c(CC(=O)SCc1cccnc1)c(n2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-08204: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-601-726-8,RFM-007-858-0,CBR-001-601-726-8,OS(=O)(=O)C(Nc1ccc(cc1)S(=O)(=O)N)CC(S(=O)(=O)O)c1ccccc1,CBR-HVAC-08679:
CBR-001-601-727-9,RFM-007-859-1,CBR-001-601-727-9,Cc1nn(c(c1)C(=O)Nc1cc(ccc1F)Nc1ccc2c(c1)[nH]nc2/C=C/c1ccccn1)C,CBR-HVAC-12048: Angiogenesis Inhibitors; PDGFR Family Inhibitors; Signal Transduction Modulators; VEGFR-2 (FLK-1/KDR) Inhibitors
CBR-001-601-728-0,RFM-007-860-4,CBR-001-601-728-0,CC#CCOc1cc(/C=C/C(=O)Nc2ccccc2C(=O)O)ccc1OC,"CBR-HVAC-12237: Diabetic Myocardiopathy, Agents for; Fibrosis, Treatment of"
CBR-001-601-729-1,RFM-007-861-5,CBR-001-601-729-1,CO[C@H]1O[C@@H]2O[C@]3(C)CC[C@@H]4[C@]2([C@H]([C@H]1C)CC[C@H]4C)OO3,CBR-HVAC-12213: Antimalarials
CBR-001-601-730-4,RFM-007-862-6,CBR-001-601-730-4,O=C([C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O)NC1CCNCC1,CBR-HVAC-06928: Beta lactamase inhibitor
CBR-001-601-731-5,RFM-007-863-7,CBR-001-601-731-5,N#Cc1ccc(cc1)Oc1ccc(cc1)NC(=O)Nc1ccc(c(c1)C(F)(F)F)Cl,CBR-HVAC-12226: Apoptosis Inducers; Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors
CBR-001-601-732-6,RFM-007-864-8,CBR-001-601-732-6,Oc1cc(O)c2c(c1)oc(c(c2=O)O)c1ccc(c(c1)O)O,CBR-HVAC-12629: ; Anti-inflammatory; Anti-oxidant; Anti-allergic; Anti-proliferative
CBR-001-601-733-7,RFM-007-865-9,CBR-001-601-733-7,CC(=O)Nc1ccc(cc1F)/C=N/NC(=S)N,CBR-HVAC-12200: ; ANTITUBERCULOSIS
CBR-001-601-734-8,RFM-007-866-0,CBR-001-601-734-8,FC(Oc1ccc(cc1)OC1CCN(CC1)c1ccc(cc1)OC[C@]1(C)Oc2n(C1)cc(n2)[N+](=O)[O-])(F)F,CBR-HVAC-06326: ; ANTI-TUBERCULOSIS
CBR-001-601-735-9,RFM-007-867-1,CBR-001-601-735-9,c1csc(n1)c1ccc2c(c1)OCO2,CBR-HVAC-12231: Antiviral; ANTIVIRAL; ANTI-FIBROTIC
CBR-001-601-736-0,RFM-007-868-2,CBR-001-601-736-0,N#Cc1c(cccc1C(F)(F)F)Oc1cccc(c1)OS(=O)(=O)CCCC(F)(F)F,CBR-HVAC-12225: Cannabinoid receptor Agonist; ANALGESIC
CBR-001-601-737-1,RFM-007-869-3,CBR-001-601-737-1,C=CCN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N(C(=O)NCC)CCCN(C)C,CBR-HVAC-02026: Dopamine receptor D2 Agonist; Antihyperprolactinemic
CBR-001-601-738-2,RFM-007-870-6,CBR-001-601-738-2,C[C@@H]1CC[C@]2([C@@H]([C@H]1C)C1=CC[C@H]3[C@@]([C@@]1(CC2)C)(C)CC[C@@H]1[C@]3(C)CC[C@@H](C1(C)C)O)C(=O)O,CBR-HVAC-12212: Estrone sulfatase; Protease Inhibitor; Anti-infective; Antineoplastic
CBR-001-601-739-3,RFM-007-871-7,CBR-001-601-739-3,N#CCC(=O)N1CCC(CC1)c1onc(n1)c1cccs1,CBR-HVAC-12230: EthR INHIBITOR; ANTITUBERCULOSIS
CBR-001-601-740-6,RFM-007-872-8,CBR-001-601-740-6,O=Cc1c(cccc1O)OCc1ccc(cc1)C(=O)O,CBR-HVAC-03295: Immunostimulator; Anticancer; Hemoglobin modulator; Immunostimulant; Anticancer; Hemoglobin modulator; Anti-sickling
CBR-001-601-741-7,RFM-007-873-9,CBR-001-601-741-7,Clc1ccc(cc1)NC(=O)C1CCCN(C1)C(=O)c1cccc(c1)c1ccco1,CBR-HVAC-12222: INHIBITS FIBROSIS BY TARGETING THE MRTF/SRF GENE TRANSCRIPTION PATHWAY; ANTI-FIBROTIC
CBR-001-601-742-8,RFM-007-874-0,CBR-001-601-742-8,OC(c1ccccc1)(C1CCCCC1)CCN1CCCCC1,CBR-HVAC-12232: Muscarinic acetylcholine receptor Inhibitor; Anticholinergic
CBR-001-601-743-9,RFM-007-875-1,CBR-001-601-743-9,Nc1nccc2c1ncn2[C@@H]1C=C([C@H]([C@H]1O)O)CO,CBR-HVAC-12197: S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE Inhibitor; Antiviral
CBR-001-601-744-0,RFM-007-876-2,CBR-001-601-744-0,CC(=O)C(=Cc1ccc(cc1)S(=O)(=O)C)C(=O)C,CBR-HVAC-04939: TNF alpha Inhibitor; Immunosuppressant; Immunomodulator; Anti-eosinophilic
CBR-001-606-583-1,RFM-007-877-3,CBR-001-606-583-1,Oc1c(cnn1c1ncnc(c1)N1CCOCC1)n1nncc1,CBR-HVAC-07233: Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors
CBR-001-606-584-2,RFM-007-878-4,CBR-001-606-584-2,Cn1ncc(c1)c1ccc(=O)n(n1)Cc1cccc(c1)c1ncc(cn1)OCCN1CCOCC1,CBR-HVAC-07015: HGFR (MET; c-Met) Inhibitors
CBR-001-606-585-3,RFM-007-879-5,CBR-001-606-585-3,COC(=O)c1nc(n2c1CN(CC2)C(=O)CC(Cc1cc(F)c(cc1F)F)N)C(F)(F)F,CBR-HVAC-07072: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors
CBR-001-606-586-4,RFM-007-880-8,CBR-001-606-586-4,COCCNCc1ccc(nc1)c1sc2c(c1)nccc2Oc1ccc(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccc(cc1)F,CBR-HVAC-06896: Angiogenesis Inhibitors; Apoptosis Inducers; Ephrin (EPH) Inhibitors; HGFR (MET; c-Met) Inhibitors; RET Inhibitors; Signal Transduction Modulators; Tie2 Receptor Inhibitors; VEGFR-1 (Flt-1) Inhibitors; VEGFR-2 (FLK-1/KDR) Inhibitors; VEGFR-3 (FLT4) Inhibitors
CBR-001-606-587-5,RFM-007-881-9,CBR-001-606-587-5,Clc1ccc(cc1)c1sc(c(n1)C)C(=O)N[C@H]1CCCN(C1)c1cccc(c1)C(=O)O,CBR-HVAC-06382: PPARalpha Agonists; Discontinued by Kyorin for the treatment of dyslipidemia; Formerly in phase I
CBR-001-606-588-6,RFM-007-882-0,CBR-001-606-588-6,CCCN1CC(=C(C1=O)c1ccc(cc1)C)c1ccc(cc1)S(=O)(=O)C,CBR-HVAC-07920: Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors
CBR-001-606-589-7,RFM-007-883-1,CBR-001-606-589-7,CN(CCc1sc2c(c1[C@H](c1ccccn1)C)cccc2)C,CBR-HVAC-06293: Histamine H1 Receptor Antagonists; Phase I initiated by Neurocrine Biosciences for the treatment of insomnia; Oral
CBR-001-606-590-0,RFM-007-884-2,CBR-001-606-590-0,CCCCCCCCCCCC(=O)OCN1C(=O)CCc2c1cc(OCCCCN1CCN(CC1)c1cccc(c1Cl)Cl)cc2,CBR-HVAC-07097: Dopamine D2 Receptor Partial Agonists; Signal Transduction Modulators; 5-HT1A Receptor Partial Agonists; 5-HT2A Antagonists
CBR-001-606-591-1,RFM-007-885-3,CBR-001-606-591-1,CC(CNC(=O)c1ccccc1SSc1ccccc1C(=O)NCC(O)C)O,CBR-HVAC-07964: Platelet aggregation inhibitor
CBR-001-606-592-2,RFM-007-886-4,CBR-001-606-592-2,Cc1cc(C)nc(c1)N1CCN(CC1)c1ccc(cc1)NC(=O)C(=O)c1n(C)c(cc1c1ccccc1)C,CBR-HVAC-06822: Phase I initiated by F2G Ltd for the treatment of fungal infection; Oral
CBR-001-606-593-3,RFM-007-887-5,CBR-001-606-593-3,O=C1NC(=O)C(=C1c1cn(c2c1ccc(c2)[N+](=O)[O-])C)c1cn(c2c1cccc2)C,CBR-HVAC-05332: Angiogenesis Inhibitors; Antimitotic Drugs; Apoptosis Inducers; The drug candidate arrests cellular mitosis by inhibiting a novel intracellular target important in cellular trafficking that has been shown to be involved in cell division.
CBR-001-606-594-4,RFM-007-888-6,CBR-001-606-594-4,O=C1C(=C(C1=O)NCCCOc1cccc(c1)CN1CCCCC1)N,CBR-HVAC-03048: Histamine H2 receptor Antagonist; Antiulcer; Gastric ulcer;
CBR-001-606-595-5,RFM-007-889-7,CBR-001-606-595-5,CCC(C(=O)OCc1cccnc1)(Oc1ccc(cc1)Cc1ccc(cc1)Cl)C,CBR-HVAC-01050: ; Antilipemic; Hypocholesterolemia;
CBR-001-606-596-6,RFM-007-890-0,CBR-001-606-596-6,CN(CCCOC(c1ccccc1)CCCCc1ccccc1)C,CBR-HVAC-00324: ; CARDIOVASCULAR AGENT; Neurological disease; Cognition disorder;
CBR-001-606-597-7,RFM-007-891-1,CBR-001-606-597-7,CC1=NN(C(=O)/C/1=N/Nc1cccc(c1O)c1cccc(c1)c1nnn[nH]1)c1ccc(c(c1)C)C,CBR-HVAC-00171: MGDF agonist; Thrombopoietin agonist; Antiplatelet; Thrombocytopenia;
CBR-001-606-598-8,RFM-007-892-2,CBR-001-606-598-8,CCCCC(C(=O)N(c1ccccc1)Nc1ccccc1)C(=O)O,"CBR-HVAC-10199: Albumin Binder; Antipyretic; Anticholinergic; Anti-inflammatory; Inflammation; Arthritis, rheumatoid;"
CBR-001-606-599-9,RFM-007-893-3,CBR-001-606-599-9,CC(OC(=O)C1=C(C)NC(=C(C1c1cccc2c1OCO2)C(=O)OCCN(Cc1ccc(cc1)F)C)C)C,"CBR-HVAC-03851: Calcium channel Antagonist; Antihypertensive; Vasodilator; Angina; Hypertension; Heart failure, congestive; Atherosclerosis;"
CBR-001-606-600-5,RFM-007-894-4,CBR-001-606-600-5,CCOC(=O)N1CCN(CC1)C(=O)[C@@H](NS(=O)(=O)c1c(cc(cc1C(C)C)C(C)C)C(C)C)Cc1cccc(c1)C(=N)N,CBR-HVAC-00454: Urokinase plasminogen activator Inhibitor; Anticancer; Solid tumor;
CBR-001-606-601-6,RFM-007-895-5,CBR-001-606-601-6,CC(C(=O)c1ccc2c(c1)cccc2)CN1CCCCC1,CBR-HVAC-07968: ; ANTI-ALLERGIC; Allergy;
CBR-001-606-602-7,RFM-007-896-6,CBR-001-606-602-7,COc1ccc(cc1OCC(=O)N1CCN(CC1)Cc1ccccc1)CNc1cn[nH]c(=O)c1Cl,CBR-HVAC-00217: Phosphodiesterase 3 Inhibitor; Antiasthmatic; Asthma;
CBR-001-606-603-8,RFM-007-897-7,CBR-001-606-603-8,CCCCN1CCCC1CNC(=O)c1cc(cc2c1OC(C2)C)S(=O)(=O)N,CBR-HVAC-03241: Dopamine receptor D2 Antagonist; Antipsychotic; Neuroleptic; Psychotic disorder;
CBR-001-606-604-9,RFM-007-898-8,CBR-001-606-604-9,Nc1nccc(n1)c1n(cnc1c1ccc(cc1)F)C1CCNCC1,CBR-HVAC-11284: p38 Mitogen-activated protein kinase Inhibitor; Anticancer; Anti-inflammatory; Inflammation; Arthritis; Cancer; Diabetic retinopathy; Macular degeneration;
CBR-001-606-605-0,RFM-007-899-9,CBR-001-606-605-0,O1CCN(CC1)CCn1c2CCCCc2c2c1nc(nc2N1CCCC1)N1CCCC1,CBR-HVAC-11252: Lipid peroxidation inhibitor; Neuroprotectant; Asthma; Stroke;
CBR-001-606-606-1,RFM-007-900-5,CBR-001-606-606-1,[O-][n+]1ccc(cc1)C(=O)N1CCC(=C2c3ccc(cc3CCc3c2nccc3)Cl)CC1,CBR-HVAC-09192: Histamine receptor; Platelet activating factor receptor Antagonist; Anti-inflammatory; Bronchodilator; Anti-asthmatic; Asthma;
CBR-001-606-607-2,RFM-007-901-6,CBR-001-606-607-2,CNC(=O)Cc1ccc2c(c1)n(cc2)C1CCN(CC1)CCc1ccccc1F,CBR-HVAC-05237: 5-Hydroxytryptamine 2 receptor; 5-Hydroxytryptamine 1A receptor Antagonist; Antispastic; Spasticity;
CBR-001-606-608-3,RFM-007-902-7,CBR-001-606-608-3,O=C(N(CCc1ccccc1)C)Cc1cc(cc2c1cccc2OCc1ccccc1)C(=O)O,CBR-HVAC-10495: Leukotriene B4 receptor Antagonist; Antiinflammatory; Asthma;
CBR-001-606-609-4,RFM-007-903-8,CBR-001-606-609-4,Cn1nccc1c1ccc(cc1)Sc1cccc(c1)C1(CCOCC1)C(=O)N,CBR-HVAC-00315: 5-Lipoxygenase Inhibitor; Analgesic; Anti-inflammatory; Asthma; Pain;
CBR-001-606-610-7,RFM-007-904-9,CBR-001-606-610-7,CN(C(CSc1nc2ccccc2cc1c1ccccc1)(C)C)C,CBR-HVAC-03743: 5-HYDROXYTRYPTAMINE 2 RECEPTOR Antagonist; OPHTHALMIC AGENT; Miosis;
CBR-001-606-611-8,RFM-007-905-0,CBR-001-606-611-8,OC(=O)COC1CCN(CC1)C(=O)[C@@H](NC(=O)c1ccc(cc1)C(=N)N)C,CBR-HVAC-10768: Integrin alpha2b beta3 Antagonist; Integrin alpha2bbeta3 antagonist; Arterial thrombosis;
CBR-001-606-612-9,RFM-007-906-1,CBR-001-606-612-9,CCCCN1CC[C@@H]([C@H](C1)COc1ccc(cc1)C(F)(F)F)c1ccc(cc1)N(C)C,CBR-HVAC-10940: Sodium channel; Calcium channel Inhibitor; Neuroprotectant; Antihypertensive; Cerebrovascular ischemia; Hypertension;
CBR-001-606-613-0,RFM-007-907-2,CBR-001-606-613-0,CC(=O)OCC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)c1c(C)onc1c1ccccc1Cl,"CBR-HVAC-08727: Penicillin binding protein Inhibitor; Antibacterial; Infection, bacterial;"
CBR-001-606-614-1,RFM-007-908-3,CBR-001-606-614-1,C=CCC1(CC(=C)Br)C(=O)NC(=O)NC1=O,CBR-HVAC-09730: GABA-A receptor Agonist; Sedative; Sedation;
CBR-001-606-615-2,RFM-007-909-4,CBR-001-606-615-2,OC(=O)[C@H]1Cc2c(N1S(=O)(=O)c1ccc(cc1)OCc1nc(oc1C)c1ccc(cc1)C(F)(F)F)cccc2,CBR-HVAC-06358: Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma Agonist; Antihyperlipidemic; Obesity; Lipid metabolism disorder; Non-insulin dependent diabetes; Metabolic syndrome; Insulin resistance; Elevated cholesterol; High blood pressure;
CBR-001-606-616-3,RFM-007-910-7,CBR-001-606-616-3,CCn1cc(C(=O)O)c(=O)c2c1cc(cc2)c1ccncc1,CBR-HVAC-01674: Topoisomerase II; Topoisomerase IV Inhibitor; Antibiotic; Acute gonococcal urethritis;
CBR-001-606-617-4,RFM-007-911-8,CBR-001-606-617-4,O=C(Nc1ccc(cc1)C)NCCCCN1CCN(CC1)c1csc2c1ccc(c2)C(F)(F)F,CBR-HVAC-05702: Dopamine receptor D3 Antagonist; Antipsychotic; Schizophrenia;
CBR-001-606-618-5,RFM-007-912-9,CBR-001-606-618-5,COc1cc2n(C)cc(c2cc1C(=O)N1CCC(CC1)Cc1ccc(cc1)F)C(=O)C(=O)N(C)C,"CBR-HVAC-09313: p38 Mitogen-activated protein kinase Inhibitor; Antiarthritic; MYELODYSPLASTIC SYNDROME; DIABETES MELLITUS; ISCHEMIA, CEREBROVASCULAR; ARTHRITIS, RHEUMATOID; MYELOMA, MULTIPLE;"
CBR-001-606-619-6,RFM-007-913-0,CBR-001-606-619-6,C=CCC1CN(C)CCC1(OC(=O)CC)c1ccccc1,CBR-HVAC-09967: Opioid receptor mu Agonist; Analgesic; Narcotic; Pain; Inflammation;
CBR-001-606-620-9,RFM-007-914-1,CBR-001-606-620-9,O[C@@H]1[C@H](Cc2c1cc(cc2)[N+](=O)[O-])N1CCN(CC1)c1cccc2c1OCCO2,CBR-HVAC-11627: 5-Hydroxytryptamine 1A receptor Antagonist; Antidepressant; Anxiolytic; Anxiety; Depression;
CBR-001-606-621-0,RFM-007-915-2,CBR-001-606-621-0,O[C@@H]1[C@H](Cc2c1cc(cc2)[N+](=O)[O-])N1CCN(CC1)c1cccc2c1OCCO2,CBR-HVAC-11627: 5-Hydroxytryptamine 1A receptor Antagonist; Antidepressant; Anxiolytic; Anxiety; Depression;
CBR-001-606-622-1,RFM-007-916-3,CBR-001-606-622-1,COc1ccc(cc1)Sc1nc(N)nc2c1ncn2CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F,CBR-HVAC-05468: DNA Polymerase Inhibitor; Antiviral; Hepatitis B;
CBR-001-606-623-2,RFM-007-917-4,CBR-001-606-623-2,Oc1c(N2CCCC2)c(=O)n(c2c1cccn2)c1ccccc1,CBR-HVAC-03582: Leukotriene D4 receptor Inhibitor; Antiallergic; Antihistaminic; Allergic rhinitis; Asthma;
CBR-001-606-624-3,RFM-007-918-5,CBR-001-606-624-3,COc1ccc(cc1)S(=O)(=O)Nc1cccc2c1Nc1ccc(cc1CN2)F,CBR-HVAC-11377: Tubulin polymerization inhibitor; Anticancer; Cancer;
CBR-001-606-625-4,RFM-007-919-6,CBR-001-606-625-4,CCCCOc1ccc(cc1)OCC(CNCCNc1cc(=O)n(c(=O)n1C)C)O,CBR-HVAC-01065: Beta adrenergic receptor blocker; Antihypertensive; Antianginal; Antiarrhythmic; Hypertension; Angina pectoris; Arrhythmia;
CBR-001-606-626-5,RFM-007-920-9,CBR-001-606-626-5,COC(=O)c1cccnc1N1CCN(CC1)CCCC(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-10828: 5-Hydroxytryptamine 2A receptor; 5-Hydroxytryptamine 1A receptor Agonist; Antagonist; Antidepressant; Anxiolytic; Anxiety disorder; Depression;
CBR-001-606-627-6,RFM-007-921-0,CBR-001-606-627-6,CC(=O)NCC1(CCN(CC1)C[C@@H]1COc2c(O1)cccc2)c1ccccc1,CBR-HVAC-09383: Vasodilator; VASODILATOR; ANTIHYPERTENSIVE; HYPERTENSION;
CBR-001-606-628-7,RFM-007-922-1,CBR-001-606-628-7,Cc1c(CC(=O)NO)c2c([nH]1)ccc(c2)OC,CBR-HVAC-07714: Antiulcer; Antiulcer; Ulcer;
CBR-001-606-629-8,RFM-007-923-2,CBR-001-606-629-8,OC(COc1ccc(cc1)CCNC(=O)NC(C)C)CNC(C)C,CBR-HVAC-03273: Beta-1 adrenergic receptor Antagonist; Antiarrhythmic; Antihypertensive; Arrhythmia; Hypertension;
CBR-001-606-630-1,RFM-007-924-3,CBR-001-606-630-1,OC(COc1ccccc1OCC1CCCO1)CNC(C)(C)C,CBR-HVAC-10197: Beta adrenergic receptor blocker; Antiarrhythmic; Antianginal; Arrhythmia; Angina pectoris;
CBR-001-606-631-2,RFM-007-925-4,CBR-001-606-631-2,CC(=O)Nc1c(cc(cc1Br)Br)CN(C12CC3CC(C2)CC(C1)C3)C,CBR-HVAC-09385: ; MUCOLYTIC; EXPECTORANT; BRONCHITIS;
CBR-001-606-632-3,RFM-007-926-5,CBR-001-606-632-3,CN(C1CC(c2c1cccc2)c1ccccc1)C,CBR-HVAC-09942: ; Analgesic; Pain;
CBR-001-606-633-4,RFM-007-927-6,CBR-001-606-633-4,BrCCN(c1c(cc(cc1[N+](=O)[O-])[N+](=O)[O-])C(=O)NCCOP(=O)(O)O)CCOS(=O)(=O)C,"CBR-HVAC-06114: PR-104 IS CONVERTED BY SYSTEMIC PHOSPHATASES TO THE ALCOHOL INTERMEDIATE PR-104A, WHICH IS REDUCED TO FORM THE ACTIVE DNA-CROSSLINKING MUSTARD SPECIES HYDROXYLAMINE PR-104H INTRACELLULARLY UNDER HYPOXIC CONDITIONS. PR-104H CROSSLINKS HYPOXIC TUMOR CELL DNA, INHIBITS DNA REPAIR AND SYNTHESIS, CELL-CYCLE ARREST, AND APOPTOSIS IN SUSCEPTIBLE HYPOXIC TUMOR CELLS WHILE SPARING NORMOXIC TISSUES; Anticancer; Solid tumors;"
CBR-001-606-634-5,RFM-007-928-7,CBR-001-606-634-5,Clc1ccc(cc1)c1oc(=O)oc1CCN1CCN(CC1)c1ccccc1,CBR-HVAC-07659: Hypocholesterolemic; Hypocholesterolemic; Lipoprotein disorder;
CBR-001-606-636-7,RFM-007-929-8,CBR-001-606-636-7,Cc1c2OC(C)(CCc2c(c(c1C)O)C)CC[P+](c1ccccc1)(c1ccccc1)c1ccccc1,"CBR-HVAC-12004: Mitochondria-targeted vitamin E antioxidant; Antioxidant agent; FETAL ALCOHOL SYNDROME; ATAXIA, FRIEDREICH'S;"
CBR-001-606-637-8,RFM-007-930-1,CBR-001-606-637-8,O=C(CNc1ccc2c(c1)cccc2)N/N=C/c1cc(Br)c(c(c1O)Br)O,CBR-HVAC-12297: CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Inhibitor; ANTIFIBROTIC; Cystic fibrosis;
CBR-001-606-638-9,RFM-007-931-2,CBR-001-606-638-9,N#Cc1cc(cc(c1)Cl)Oc1c(=O)n(ccc1C(F)(F)F)Cc1n[nH]c(=O)n1C,"CBR-HVAC-00748: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE Inhibitor; ANTI-VIRAL; Infection, Human immunodeficiency virus;"
CBR-001-606-639-0,RFM-007-932-3,CBR-001-606-639-0,OC(=O)CCC(c1ccc(cc1)OCc1ccc2c(n1)cccc2)(c1ccc(cc1)OCc1ccc2c(n1)cccc2)C,CBR-HVAC-04911: 5-Lipoxygenase activating protein Antagonist; Anti-inflammatory; Antiallergic; Antiasthmaitctic; Asthma;
CBR-001-606-640-3,RFM-007-933-4,CBR-001-606-640-3,CO[C@@]1(NC(=O)C(c2cscc2)C(=O)[O-])C(=O)N2[C@@H]1SC(C2C(=O)[O-])(C)C,"CBR-HVAC-03066: Activity against clinical isolates of Berkholderia cepacia isolated from cystic fibrosis patients; Antibacterial; Infection, bacterial; Cystic fibrosis-associated respiratory tract infection;"
CBR-001-606-641-4,RFM-007-934-5,CBR-001-606-641-4,C[C@@H](c1cccc(c1C)C)c1c[nH]c(=S)[nH]1,CBR-HVAC-00687: Adrenergic alpha-2 receptor Agonist; Analgesic; Diabetic neuropathy; Pain;
CBR-001-606-642-5,RFM-007-935-6,CBR-001-606-642-5,N[C@H]1CCN(C1)c1nc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-04085: DNA topoisomerase II Inhibitor; Antibacterial; Bacterial infections;
CBR-001-606-643-6,RFM-007-936-7,CBR-001-606-643-6,ClCC/C(=C(/c1ccccc1)\c1ccc(cc1)OCCOCCO)/c1ccccc1,CBR-HVAC-00636: Estrogen receptor Antagonist; Estrogen receptor antagonist; Muscle weakness; Osteoporosis; Urinary tract symptoms; Sexual dysfunction in elderly men; Andropause;
CBR-001-606-644-7,RFM-007-937-8,CBR-001-606-644-7,CC(=O)OCCN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-02104: ; ANTIPSYCHOTIC; SCHIZOPHRENIA;
CBR-001-606-645-8,RFM-007-938-9,CBR-001-606-645-8,CN(CC#CC=C1c2ccccc2C=Cc2c1cccc2)C,CBR-HVAC-01107: ; Antidepressant; Depression;
CBR-001-606-646-9,RFM-007-939-0,CBR-001-606-646-9,O=C([C@@H](NC(=O)[C@H](C(C)C)O)C)NC1c2ccccc2c2c(N(C1=O)C)cccc2,CBR-HVAC-07235: GAMMA-SECRETASE Inhibitor; ANTI-CANCER; Advanced cancer;
CBR-001-606-647-0,RFM-007-940-3,CBR-001-606-647-0,O=C([C@@H](NC(=O)[C@H](C(C)C)O)C)NC1c2ccccc2c2c(N(C1=O)C)cccc2,CBR-HVAC-07235: GAMMA-SECRETASE Inhibitor; ANTI-CANCER; Advanced cancer;
CBR-001-606-648-1,RFM-007-941-4,CBR-001-606-648-1,CO/N=C(\c1ccc(cc1)c1ccc(o1)c1ccc(cc1)/C(=N\OC)/N)/N,"CBR-HVAC-04898: DNA Topoisomerase II Inhibitors; DNA inhibitor; DNA synthesis inhibitor; DNA topoisomerase II Inhibitor; DNA-inhibitors; Antibacterial; Antimalarials; Antiparasitic; Antitrypanosomals; Cancer; Fungicide; Mycoses; Oncolytic Drugs; Parasitic Infections; Pneumocystis jiroveci Pneumonia, Agents for"
CBR-001-606-658-3,RFM-007-942-5,CBR-001-606-658-3,c1ccc(cc1)c1ccc(cc1)C(n1ccnc1)c1ccccc1,CBR-HVAC-02092: Antifungal Agents; HMG-CoA reductase Inhibitor; Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-606-659-4,RFM-007-943-6,CBR-001-606-659-4,OC(=O)CCCN1CCC[C@H]1COc1ccc(cc1)Oc1ccc(cc1)Cl,"CBR-HVAC-06384: Stroke, Treatment of;Acute Myocardial Infarction, Treatment of; Leukotriene A4 Hydrolase Inhibitors;Leukotriene Synthesis Inhibitors;Signal Transduction Modulators; Leukotriene A4 hydrolase inhibitor; Leukotriene B4 receptor antagonist"
CBR-001-607-219-8,RFM-007-944-7,CBR-001-607-219-8,[O-][N+](=O)c1cc(C)c(cc1NS(=O)(=O)c1cccc(c1)C(=O)O)c1cccnc1,CBR-HVAC-07338: Angiogenesis Inhibitors; FGFR2 Inhibitors
CBR-001-607-220-1,RFM-007-945-8,CBR-001-607-220-1,N#C/N=c\1/n(c2ccc(nc2)C(C#N)(C)C)c2c(n1C)cnc1c2cc(cc1)c1cnc(c(c1)C(F)(F)F)N,CBR-HVAC-07214: Activin Receptor Like Kinase 1 (ALK1) Inhibitors; DNA-Dependent Protein Kinase (DNA-PK) Inhibitors; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors; Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors
CBR-001-607-221-2,RFM-007-946-9,CBR-001-607-221-2,OC[C@H]1O[C@@H](Oc2ccsc2Cc2ccc(cc2)OC)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-12046: Glucose Lowering Agents; SGLT-2 Inhibitors
CBR-001-607-222-3,RFM-007-947-0,CBR-001-607-222-3,O=C(N1CCC(C1)(F)F)[C@H]1NC[C@H](C1)N1CCN(CC1)c1ncccn1,CBR-HVAC-06325: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors
CBR-001-607-223-4,RFM-007-948-1,CBR-001-607-223-4,OC(COc1ccc(cc1)C(C)(C)C)COc1ccc(cc1)C(=O)O,CBR-HVAC-08429: Cholesterol inhibitor; Platelet aggregation inhibitor
CBR-001-607-224-5,RFM-007-949-2,CBR-001-607-224-5,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-07765: Dopamine receptor antagonist; Adenylate cyclase inhibitor; Alpha adrenoreceptor antagonist
CBR-001-607-225-6,RFM-007-950-5,CBR-001-607-225-6,CN(CCOc1cc(cc(c1C)O)C(C)C)C,CBR-HVAC-04795: Treatment of Male Sexual Dysfunction
CBR-001-607-226-7,RFM-007-951-6,CBR-001-607-226-7,COC(=O)NCCc1ccc(cc1)OCC(CNC(C)C)O,CBR-HVAC-08147: Beta 1 adrenoreceptor antagonist
CBR-001-607-227-8,RFM-007-952-7,CBR-001-607-227-8,C/C(=C\c1ccccc1)/c1ccc2c(c1)C(C)(C)CCC2(C)C,CBR-HVAC-08423:
CBR-001-607-228-9,RFM-007-953-8,CBR-001-607-228-9,O=C1NC2=Nc3c(CN2C1C)c(C)c(cc3)Br,CBR-HVAC-08278: Phosphodiesterase 4 inhibitor; Platelet aggregation inhibitor
CBR-001-607-229-0,RFM-007-954-9,CBR-001-607-229-0,CCCCCCCCCCCCCCCCNCc1cccc(c1)CNCCCCCCCCCCCCCCCC,CBR-HVAC-05846: Interferon Inducers
CBR-001-607-230-3,RFM-007-955-0,CBR-001-607-230-3,CC(NC(C(c1ccc(cc1)OC(=O)C(C)(C)C)O)C)COc1ccccc1,CBR-HVAC-07945: Beta adrenoreceptor agonist
CBR-001-607-231-4,RFM-007-956-1,CBR-001-607-231-4,CCN(CCC1(CCC(=O)NC1=O)c1ccccc1)CC,CBR-HVAC-08935: Muscarinic acetylcholine receptor antagonist
CBR-001-607-232-5,RFM-007-957-2,CBR-001-607-232-5,COc1c(cccc1C(C)(C)C)C(c1ncc(n1C)[N+](=O)[O-])O,CBR-HVAC-07586: DNA inhibitor
CBR-001-607-233-6,RFM-007-958-3,CBR-001-607-233-6,CCN(CC(=O)Nc1ccc(cc1)OC(=O)Cc1c2cc(OC)ccc2n(c1C)C(=O)c1ccc(cc1)Cl)CC,CBR-HVAC-07683:
CBR-001-607-234-7,RFM-007-959-4,CBR-001-607-234-7,CCOC(=O)Cc1nc(oc1c1ccco1)c1ccc(cc1)Cl,CBR-HVAC-03316: Cholesterol inhibitor; Platelet aggregation inhibitor
CBR-001-607-235-8,RFM-007-960-7,CBR-001-607-235-8,CN(C1CC(c2c1cccc2)c1ccc(c(c1)Cl)Cl)C,"CBR-HVAC-02321: Dopamine reuptake inhibitor; solute carrier family 6 (neurotransmitter transporter), member 3"
CBR-001-607-236-9,RFM-007-961-8,CBR-001-607-236-9,Fc1ccc(cc1)CC[N+]12CCC(CC1)[C@H](C2)OC(=O)C(c1ccccc1)(N1CCCCC1)C,CBR-HVAC-06772: Muscarinic receptor antagonist
CBR-001-607-237-0,RFM-007-962-9,CBR-001-607-237-0,Fc1ccc(cc1)CC[N+]12CCC(CC1)[C@H](C2)OC(=O)C(c1ccccc1)(N1CCCCC1)C,CBR-HVAC-06772: Muscarinic receptor antagonist
CBR-001-607-238-1,RFM-007-963-0,CBR-001-607-238-1,Fc1ccc(c(c1)F)Sc1cc2C(=O)CCc2cc1NS(=O)(=O)C,CBR-HVAC-04590: Cyclooxygenase 2 inhibitor
CBR-001-607-239-2,RFM-007-964-1,CBR-001-607-239-2,ClCCC1NC(=O)c2c(O1)cccc2,CBR-HVAC-10191: ; Analgesic; Pain
CBR-001-607-240-5,RFM-007-965-2,CBR-001-607-240-5,N#Cc1ccc2c(c1)N(CCCN(C)C)c1ccccc1CC2,CBR-HVAC-00772: 5-Hydroxytryptamine transporter Inhibitor; ANTI-DEPRESSANT; Mood disorder
CBR-001-607-241-6,RFM-007-966-3,CBR-001-607-241-6,CCC(c1ccccc1)(COC(=O)N)O,CBR-HVAC-09846: Inhibition on the level under cortical (reticulae formation and thalamus).Anxiolytic by reduction in the exitability of the limbic system (emotional center). Myorelaxant: antagonise the reflexes polysynaptic and decreases the influence of the reticulae formation on the muscular tone; Tranquilizer; Anxiety; Tension
CBR-001-607-242-7,RFM-007-967-4,CBR-001-607-242-7,Cc1ccc(cc1)Sc1ccccc1C1CCNCC1,CBR-HVAC-00586: 5-HYDROXYTRYPTAMINE 2C RECEPTOR; 5-HYDROXYTRYPTAMINE 3 RECEPTOR; MONOAMINE TRANSPORTER Antagonist; Antagonist; Antidepressant; Major depressive disorder
CBR-001-607-243-8,RFM-007-968-5,CBR-001-607-243-8,COc1ccc(c(c1)CCc1ccc(c(c1)C(=O)OC)O)OC,CBR-HVAC-04441: Protein tyrosine kinase Inhibitor; Anticancer; Cancer; Skin diseases
CBR-001-607-244-9,RFM-007-969-6,CBR-001-607-244-9,C1CCCCN(C1)CCC(c1ccccc1)c1ccccc1,"CBR-HVAC-09063: ; Antispasmodic; Spasm, muscular"
CBR-001-607-245-0,RFM-007-970-9,CBR-001-607-245-0,[O-][N+](=O)OCc1ccc(cc1)C(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C,CBR-HVAC-05340: Glucocorticoid receptor Agonist; Steroidal antiinflammatory; Inflammatory bowel disease; Rheumatoid arthritis; Asthma
CBR-001-607-246-1,RFM-007-971-0,CBR-001-607-246-1,O=C1NC(=O)C(S1)Cc1ccc(cc1)OCCc1nc(oc1C)c1ccccc1,CBR-HVAC-11380: Insulin sensitizer; Hypoglycemic; Antidiabetic; Diabetes mellitus
CBR-001-607-247-2,RFM-007-972-1,CBR-001-607-247-2,CNC(=O)N1CC(C1)Oc1cccc(c1)C(F)(F)F,CBR-HVAC-08657: ; Anticonvulsant; Convulsion
CBR-001-607-248-3,RFM-007-973-2,CBR-001-607-248-3,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCCCCOc1n[nH]c(c1)c1ccccc1)C,CBR-HVAC-03290: Calcium channel Blocker; Neuroprotectant; Antihypertensive; Antiasthmatic; Hypertension; Asthma
CBR-001-607-249-4,RFM-007-974-3,CBR-001-607-249-4,OCC(=O)NCCCOc1cccc(c1)CN1CCCCC1,"CBR-HVAC-01192: Histamine H2 receptor Antagonist; Antiulcer; Ulcer, gastric"
CBR-001-607-250-7,RFM-007-975-4,CBR-001-607-250-7,CC(CC(C1(CCC1)c1ccc(cc1)Cl)N(C)C)C,CBR-HVAC-02645: Norepinephrine transporter; 5-Hydroxytryptamine Inhibitor; Antiobesity; Antidepressant; Obesity; Depression
CBR-001-607-251-8,RFM-007-976-5,CBR-001-607-251-8,C[C@H](C(=O)O)Oc1ccc(c(c1)F)CNC(=O)c1cccnc1Oc1ccc2c(c1)OCO2,CBR-HVAC-09453: PHOSPHODIESTERASE 4 Inhibitor; ANTIASTHMATIC; ANTI-INFLAMMATORY; CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CBR-001-607-252-9,RFM-007-977-6,CBR-001-607-252-9,COc1cc2cc(oc2c(c1)Br)C1CCNCC1,CBR-HVAC-02957: Monoamine oxidase A Inhibitor; Antidepressant; Anxiolytic; Anxiety; Depression
CBR-001-607-253-0,RFM-007-978-7,CBR-001-607-253-0,O=C(c1ccc(cc1)F)CC1CCN(CC1)CC1CC1,CBR-HVAC-00134: Opioid receptor sigma; 5-Hydroxytryptamine 2 receptor Antagonist; Antipsychotic; Psychosis; Schizophrenia
CBR-001-607-254-1,RFM-007-979-8,CBR-001-607-254-1,Cc1ccc(cc1Nc1nccc(n1)c1cccnc1)NC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-06397: Abl tyrosine kinase Inhibitor; Anticancer; LEUKEMIA, MYELOID, CHRONIC"
CBR-001-607-255-2,RFM-007-980-1,CBR-001-607-255-2,CCOC(=O)C1(CCN(CC1)CCC(c1ccccc1)O)c1ccccc1,CBR-HVAC-09692: Opioid receptor Agonist; Opioid analgesic; Analgesia; Neuroleptanalgesia; Premedication; Postoperative analgesia
CBR-001-607-256-3,RFM-007-981-2,CBR-001-607-256-3,C=CCc1ccccc1OC/C(=N/O)/CNC(C)C,CBR-HVAC-04051: Beta adrenergic receptor Blocker; Antihypertensive; Glaucoma
CBR-001-607-257-4,RFM-007-982-3,CBR-001-607-257-4,CN(C(c1ccccc1)Cc1ccccc1)C,"CBR-HVAC-10144: Opioid receptor Agonist; Analgesic; Anti-inflammatory; Anesthetic, local; Pain; Inflammation"
CBR-001-607-258-5,RFM-007-983-4,CBR-001-607-258-5,COc1ccccc1N1CCN(CC1)CCCNc1ncccc1C(=O)N(C)C,CBR-HVAC-04845: Alpha-1A adrenergic receptor Antagonist; Antihyperplasia; Benign prostate hyperplasia
CBR-001-607-259-6,RFM-007-984-5,CBR-001-607-259-6,CN1[C@@H]2CC[C@H]1C[C@H](C2)N1Cc2c(C1=O)c1ccccc1cc2,CBR-HVAC-11943: 5-hydroxytryptamine 3 receptor Antagonist; ANTI-EMETIC; Drug abuse; Fibromyalgia; Chemotherapy-induced toxicity
CBR-001-607-260-9,RFM-007-985-6,CBR-001-607-260-9,OCCN1C(=O)C(O)N=C(c2c1ccc(c2)Cl)c1ccccc1F,CBR-HVAC-01972: Benzodiazepine receptor Agonist; Sedative; Hypnotic; Sedative and hypnotic
CBR-001-607-261-0,RFM-007-986-7,CBR-001-607-261-0,CSc1ccc(c(c1)NC(=N)N(c1cccc(c1)SC)C)Cl,CBR-HVAC-04762: Ionotropic glutamate receptor NMDA Antagonist; Analgesic; Antipyretic; Neuropathic pain
CBR-001-607-262-1,RFM-007-987-8,CBR-001-607-262-1,O=C1NN=C(C(C1)C)c1ccc(cc1)NC1=C(C)C(=O)CC1,CBR-HVAC-03949: Phosphodiesterase 3 Inhibitor; Vasoprotectant; Coronary artery disease
CBR-001-607-263-2,RFM-007-988-9,CBR-001-607-263-2,CCCCOC(=O)C(=O)Nc1cccc(c1)c1nnn[nH]1,CBR-HVAC-01657: Mast cell stabiliser. Inhibits airway hyperresponsiveness in guinea-pigs.; Antiasthmatic; Asthma
CBR-001-607-264-3,RFM-007-989-0,CBR-001-607-264-3,O=c1c(cn(c2c1cccc2)C)NS(=O)(=O)C,CBR-HVAC-11813: Phosphodiesterase 3 Inhibitor; Antihypertensive; Hypertension
CBR-001-607-265-4,RFM-007-990-3,CBR-001-607-265-4,N#C/C(=C(\C1CC1)/O)/C(=O)Nc1ccc(c(c1)C)C(F)(F)F,CBR-HVAC-07974: Dihydroorotate dehydrogenase Inhibitor; Immunosuppressant; Anticancer; Antiarthritic; Rheumatoid arthritis; Cancer
CBR-001-607-266-5,RFM-007-991-4,CBR-001-607-266-5,NCCCC(=O)OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-00775: DOPAMINE D2 RECEPTOR; GABA A Agonist; Antagonist; Antipsychotic; Schizophrenia
CBR-001-607-267-6,RFM-007-992-5,CBR-001-607-267-6,CN1CCC/C/1=N\C(=N\c1ccccc1)\N1CCCC1,CBR-HVAC-01004: ; Antidiabetic; Diabetes
CBR-001-607-268-7,RFM-007-993-6,CBR-001-607-268-7,COc1ccc(cc1OCCCN1CCC(CC1)C(=O)c1ccc(cc1)F)C1CNC(=O)C1,CBR-HVAC-01147: 5-Hydroxytryptamine receptor; Alpha-1 adrenergic receptor Inhibitor; Antidepressant; Depression
CBR-001-607-269-8,RFM-007-994-7,CBR-001-607-269-8,C1CCC2N(C1)CC1c3c2cccc3CCc2c1cccc2,CBR-HVAC-01215: ; Anxiolytic; Anxiety
CBR-001-607-270-1,RFM-007-995-8,CBR-001-607-270-1,OC(COc1cccc2c1CC1(C2=O)CCCCC1)CNC(C)(C)C,CBR-HVAC-01222: Beta2-adrenergic receptor blocker; Antihypertensive; Antianginal; Antiarrhythmic; Hypertension; Angina pectoris; Arrhythmia
CBR-001-607-271-2,RFM-007-996-9,CBR-001-607-271-2,CC(=O)NC[C@@H]1OC(=O)N(C1)c1cc(F)c(c(c1)F)N1CCS(=O)(=O)CC1,CBR-HVAC-05667: Protein synthesis inhibitor; Antibacterial; Bacterial infection
CBR-001-607-272-3,RFM-007-997-0,CBR-001-607-272-3,[Ag+],CBR-HVAC-08877: ; Antiprotozoal; Protozoal diseases
CBR-001-607-273-4,RFM-007-998-1,CBR-001-607-273-4,CSCC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,"CBR-HVAC-09314: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-607-274-5,RFM-007-999-2,CBR-001-607-274-5,O=C(CCc1ccccc1)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,"CBR-HVAC-09317: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-607-275-6,RFM-008-000-2,CBR-001-607-275-6,C=CCCC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,"CBR-HVAC-09319: Bacterial protein synthesis inhibitor; Antibacterial; INFECTION, BACTERIAL"
CBR-001-607-276-7,RFM-008-001-3,CBR-001-607-276-7,CNC(=O)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,"CBR-HVAC-09320: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-607-277-8,RFM-008-002-4,CBR-001-607-277-8,COc1cc2ncnc(c2cc1OCCN1CC2(C3(C1)CC3)OCCO2)Nc1ccc(c(c1)Cl)F,CBR-HVAC-09506: EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE Inhibitor; ANTI-CANCER; Non-small cell lung cancer
CBR-001-607-278-9,RFM-008-003-5,CBR-001-607-278-9,CCC(=O)n1c(=O)n(c2c1cccc2)C1CCN(CC1)CCC(c1ccccc1)(c1ccccc1)C#N,CBR-HVAC-09726: Opioid receptor Agonist; Analgesic; Pain
CBR-001-607-279-0,RFM-008-004-6,CBR-001-607-279-0,COc1ccc(cc1)CC(NCC(c1cc(N)cc(c1)CO)O)C,CBR-HVAC-10880: Beta-2 adrenergic receptor Agonist; Bronchodilator; Antiasthmatic; Asthma
CBR-001-607-280-3,RFM-008-005-7,CBR-001-607-280-3,CCCCN(c1ncncc1C(=O)O)Cc1ccc(cc1)c1ccccc1c1nnn[nH]1,CBR-HVAC-10913: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension
CBR-001-607-281-4,RFM-008-006-8,CBR-001-607-281-4,O=C1NC(=O)C(S1)Cc1cnc2c(c1)ccc(c2)OCc1ccccc1,CBR-HVAC-11312: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Insulin sensitizer; Diabetes mellitus type-2
CBR-001-607-282-5,RFM-008-007-9,CBR-001-607-282-5,CNC(=O)c1sc2c(c1)c(cnc2)Oc1ccc(cc1)C(F)(F)F,CBR-HVAC-11415: E-Selectin; Intercellular adhesion molecule 1 Inhibitor; Antiallergic; Antiasthmatic; Antiarthritic; Asthma
CBR-001-607-283-6,RFM-008-008-0,CBR-001-607-283-6,NC(=O)C1c2ccccc2C=Cc2c1cccc2,CBR-HVAC-08652: ; Anticonvulsant; Convulsion
CBR-001-607-284-7,RFM-008-009-1,CBR-001-607-284-7,COc1ccccc1OCCOCCOCCN1CCCCC1,CBR-HVAC-09093: ; Antitussive; Cough
CBR-001-607-285-8,RFM-008-010-4,CBR-001-607-285-8,CC(Oc1ccc(cc1)C(=O)NS(=O)(=O)c1ccc(cc1)N)C,"CBR-HVAC-08967: ; Antibiotic; Infection, bacterial"
CBR-001-607-286-9,RFM-008-011-5,CBR-001-607-286-9,Cn1c(=O)n(C)c2c(c1=O)n(CCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1)cn2,CBR-HVAC-11500: Histamine H1 receptor Antagonist; Antiallergic; Allergy
CBR-001-607-287-0,RFM-008-012-6,CBR-001-607-287-0,O=C(NC(c1ccccc1)c1ccccc1)OC1CCN(CC1)Cc1cccc(c1)N,CBR-HVAC-11536: Muscarinic acetylcholine receptor M3 Antagonist; Muscarinic acetylcholine receptor M3 antagonist; Urinary incontinence
CBR-001-607-288-1,RFM-008-013-7,CBR-001-607-288-1,COc1cc2c(ncnc2cc1OCCn1nncc1)Nc1ccc(cc1F)Br,CBR-HVAC-11551: Vascular endothelial growth factor receptor Inhibitor; Antitumor; Solid tumor
CBR-001-607-289-2,RFM-008-014-8,CBR-001-607-289-2,CNC(=O)c1sc2c(c1)c(cnc2)Oc1ccc(cc1)Br,CBR-HVAC-11414: E-Selectin; Intercellular adhesion molecule 1 Inhibitor; Antiallergic; Antiasthmatic; Antiarthritic; Asthma
CBR-001-607-290-5,RFM-008-015-9,CBR-001-607-290-5,NC(=O)C(c1ccccc1)(c1ccccc1)CC[N+]1(C)CCCCCC1,CBR-HVAC-08837: ; Anticholinergic;
CBR-001-607-291-6,RFM-008-016-0,CBR-001-607-291-6,COc1cc(/C=C\2/C(=C(c3c2ccc(c3)F)CC(=O)NCc2ccccc2)C)cc(c1OC)OC,CBR-HVAC-11386: Mitogen-activated protein 2 kinase 1; cGMP phosphodiesterase; c-Jun N-terminal kinase 1; Mitogen-activated protein 2 kinase 4 Inhibitor; Anticancer; Esophageal disease
CBR-001-607-292-7,RFM-008-017-1,CBR-001-607-292-7,Fc1ccc(cc1)C(c1ccc(cc1)F)N1CCN(CC1)CCCNc1cc(C)ccc1O,CBR-HVAC-10751: Lipoxygenase 5 Inhibitor; Anti-inflammatory; Antiallergic; Inflammation
CBR-001-607-293-8,RFM-008-018-2,CBR-001-607-293-8,CCCNC(=O)c1nnc2c(c1N)cccc2c1cc(OC)ccc1OC,CBR-HVAC-06565: Anxiolytic; Anxiolytic; Anxiety
CBR-001-607-294-9,RFM-008-019-3,CBR-001-607-294-9,NC(=N)c1ccc(cc1)/C=C/c1ccc(cc1)C(=N)N,CBR-HVAC-08852: ; Antiprotozoal; Protozoal diseases
CBR-001-607-295-0,RFM-008-020-6,CBR-001-607-295-0,OCCCC(=O)NCC(c1cccc(c1)OC)(CC)CC,"CBR-HVAC-09773: ; Anesthetic; Anesthesia, local"
CBR-001-607-296-1,RFM-008-021-7,CBR-001-607-296-1,CCN1CC(CN1CC)NC(=O)c1cc(Cl)c(cc1OC)N,CBR-HVAC-00345: 5-Hydroxytryptamine 3 receptor Antagonist; 5-hydroxytryptamine 3 receptor antagonist; Nausea; Vomiting
CBR-001-607-297-2,RFM-008-022-8,CBR-001-607-297-2,N#Cc1ccc(cc1)Cc1cc(c2n1cccc2)C(=O)C(=O)Nc1snc(c1)C,CBR-HVAC-00220: Tubulin Inhibitor; Anticancer; Leukemia; Hematological malignancy; Lymphoma; Metastatic solid tumor
CBR-001-607-298-3,RFM-008-023-9,CBR-001-607-298-3,O=C(NS(=O)(=O)c1ccc2c(c1)CCC2)NC1CCCCC1,CBR-HVAC-08825: ; Antidiabetic; Diabetes
CBR-001-607-299-4,RFM-008-024-0,CBR-001-607-299-4,[O-][N+](=O)OCCCCOC(=O)C(c1ccc(c(c1)F)c1ccccc1)C,CBR-HVAC-02756: Cyclooxygenase 2; Cyclooxygenase 1 Inhibitor; Inhibitor; Antiparkinsonian; Anticancer; Alzheimer's disease; Parkinson's disease; Osteoporosis; Inflammatory joint disease; Paget's disease
CBR-001-607-300-0,RFM-008-025-1,CBR-001-607-300-0,OC(=O)CCN(C(=O)c1ccc2c(c1)cc(cc2)C(=N)N)c1ccc(cc1)OC1CCN(CC1)C(=N)C,CBR-HVAC-12005: COAGULATION FACTOR X Antagonist; Fibrinolysis stimulator; Antithrombotic; THROMBOSIS
CBR-001-607-301-1,RFM-008-026-2,CBR-001-607-301-1,OC(=O)c1c(COCCCOCc2coc(n2)c2ccccc2)cccc1C,CBR-HVAC-11746: Peroxisome proliferator-activated receptor alpha Agonist; Hypoglycemic; Antihyperlipidemic; Congestive heart failure; Hyperlipidemia; Non-insulin dependent diabetes
CBR-001-607-302-2,RFM-008-027-3,CBR-001-607-302-2,COC[C@@H](COc1ccc(cc1)OCc1cccc(c1)Cl)O,CBR-HVAC-10490: Monoamine oxidase B Inhibitor; Antiparkinsonian; Parkinson's disease
CBR-001-607-303-3,RFM-008-028-4,CBR-001-607-303-3,COc1ccc(cc1)S(=O)(=O)n1cc(c2c1ccc(c2)OC)CCC(=O)O,CBR-HVAC-00558: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor delta; Peroxisome proliferator activated receptor gamma Agonist; Antihypertensive; Inflammation; Cardiovascular disease; Non-insulin dependent diabetes
CBR-001-607-304-4,RFM-008-029-5,CBR-001-607-304-4,OC(COc1cccc2c1cc([nH]2)C)CNC(CCn1cnc2c1c(=O)n(C)c(=O)n2C)C,CBR-HVAC-01014: Beta adrenergic receptor blocker; Antihypertensive; Antianginal; Antiarrhythmic; Hypertension; Angina pectoris; Arrhythmia
CBR-001-607-305-5,RFM-008-030-8,CBR-001-607-305-5,COCC(c1c(=O)oc2c(c1O)cccc2)c1c(=O)oc2c(c1O)cccc2,CBR-HVAC-09114: ; Anticoagulant; Thrombosis
CBR-001-607-306-6,RFM-008-031-9,CBR-001-607-306-6,OC(Cn1cnc2c1c(=O)n(C)c(=O)n2C)CN1CCN(CC1)CCCSc1ccccc1,CBR-HVAC-03654: Histamine H1 receptor Antagonist; Antihistamine; Antiallergic; Allergic rhinitis; Asthma
CBR-001-607-307-7,RFM-008-032-0,CBR-001-607-307-7,CCCCOC(=O)CN1CCC(CC1)NC(=O)c1cc(Cl)c(cc1OC)N,CBR-HVAC-05149: 5-Hydroxytryptamine 4 receptor Modulator; Laxative; Irritable bowel syndrome
CBR-001-607-308-8,RFM-008-033-1,CBR-001-607-308-8,COc1cc(CCN(CCCOc2ccc(cc2)S(=O)(=O)c2c(cn3c2cccc3)C(C)C)C)ccc1OC,CBR-HVAC-03633: Calcium channel Antagonist; Antihypertensive; Class IV antiarrhythmic; Angina pectoris
CBR-001-607-309-9,RFM-008-034-2,CBR-001-607-309-9,OC(COc1cccc2c1oc(c2)C(=O)C)CNC(C)C,CBR-HVAC-02159: Beta-adrenoceptor Blocker; Antiglaucoma; GLAUCOMA
CBR-001-607-310-2,RFM-008-035-3,CBR-001-607-310-2,OC(=O)C1CCN(CC1)c1nc(NCc2ccc3c(c2)OCO3)c2c(n1)ccc(c2)Cl,CBR-HVAC-04479: Phosphodiesterase 5 Inhibitor; Vasodilator; Chronic heart failure
CBR-001-607-311-3,RFM-008-036-4,CBR-001-607-311-3,CN1[C@@H]2CC[C@H]1C[C@H](C2)NC(=O)c1cn(C2CCCCC2)c2c(c1=O)cccc2,CBR-HVAC-04180: 5-Hydroxytryptamine 3 receptor Antagonist; Anxiolytic; Anxiety; Cognition disorder; Sleep disorders
CBR-001-607-312-4,RFM-008-037-5,CBR-001-607-312-4,O=C(N[C@H](C(=O)O)CC(=O)O)Cc1cc(c2nc3c([nH]2)ccc(c3)C(=N)N)c(c(c1)c1cc(ccc1O)S(=O)(=O)N)O,CBR-HVAC-06331: Factor VIIa Antagonist; Anticancer; Anti-inflammatory; Anticoagulant; Thrombosis; Inflammatory diseases; Cancer
CBR-001-607-313-5,RFM-008-038-6,CBR-001-607-313-5,Clc1ccc(cc1)S(=O)(=O)N(C1CCCCNC1=O)Cc1ccc(cc1)Br,CBR-HVAC-09286: Gamma secretase Inhibitor; Nootropic agent; Alzheimer's disease
CBR-001-607-314-6,RFM-008-039-7,CBR-001-607-314-6,CC#CC(Oc1cc(N)c(cc1C(=O)NC1C[C@@H]2CC[C@H](C1)N2C)Cl)C,CBR-HVAC-04516: 5-Hydroxytryptamine 3 receptor; 5-Hydroxytryptamine 4 receptor Agonist; Antagonist; Anti-emetic; Gastroprokinetic; Gastrointestinal motility disorders; Irritable bowel syndrome; Anorexia associated with chronic gastritis; Diarrhea; Sense of fullness
CBR-001-607-315-7,RFM-008-040-0,CBR-001-607-315-7,CNC1Cc2c(CC1)[nH]c1c2cc(cc1)C(=O)N,CBR-HVAC-01769: 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; Antimigraine; Menstrual migraine; Migraine; Migraine aura
CBR-001-607-316-8,RFM-008-041-1,CBR-001-607-316-8,CNC1Cc2c(CC1)[nH]c1c2cc(cc1)C(=O)N,CBR-HVAC-01769: 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; Antimigraine; Menstrual migraine; Migraine; Migraine aura
CBR-001-607-317-9,RFM-008-042-2,CBR-001-607-317-9,CCC(=O)O[C@](c1ccccc1)([C@H](CN(C)C)C)Cc1ccccc1,"CBR-HVAC-01273: ; Antitussive; Pain, mild to moderate"
CBR-001-607-318-0,RFM-008-043-3,CBR-001-607-318-0,COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1Cl)C#N)C(=O)OC(C)C)C,CBR-HVAC-04726: Calcium channel L-type Antagonist; Neuroprotectant; Psychosedative; Mild cognitive impairment; Vascular dementia; Alzheimer's disease; Bipolar disorder
CBR-001-607-319-1,RFM-008-044-4,CBR-001-607-319-1,COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1Cl)C#N)C(=O)OC(C)C)C,CBR-HVAC-04726: Calcium channel L-type Antagonist; Neuroprotectant; Psychosedative; Mild cognitive impairment; Vascular dementia; Alzheimer's disease; Bipolar disorder
CBR-001-607-320-4,RFM-008-045-5,CBR-001-607-320-4,CC[C@H](Nc1nc(C)nc2n1nc(c2c1ccc(nc1C)OC)C)C,CBR-HVAC-00817: Corticotropin-releasing factor 1 receptor Antagonist; Antidepressant; Anxiolytic; Depression; Irritable bowel syndrome; Anxiety disorders
CBR-001-607-321-5,RFM-008-046-6,CBR-001-607-321-5,CN1CCN(CC1)C1CCC(CC1)n1cc(c2c1ncnc2N)c1ccc(c(c1)F)NS(=O)(=O)c1cccc(c1Cl)Cl,CBR-HVAC-11560: TIE-2 receptor Inhibitor; Anticancer; Cancer
CBR-001-607-322-6,RFM-008-047-7,CBR-001-607-322-6,CC(C(=O)c1ccc(cc1)C(F)(F)F)CN1CCCC1,CBR-HVAC-03870: Muscular relaxant; Muscle relaxant; Spastic paralysis; Temporomandibular joint disorder; Lumbago
CBR-001-607-323-7,RFM-008-048-8,CBR-001-607-323-7,CC(C(=O)c1ccc(cc1)C(F)(F)F)CN1CCCC1,CBR-HVAC-03870: Muscular relaxant; Muscle relaxant; Spastic paralysis; Temporomandibular joint disorder; Lumbago
CBR-001-607-324-8,RFM-008-049-9,CBR-001-607-324-8,CN1CCN(CC1)C(=O)[C@]1(C)CO[C@H](OC1)c1[nH]c(c(n1)c1ccnc(n1)NCC1CC1)c1ccc(cc1)F,CBR-HVAC-11563: p38 Mitogen-activated protein kinase Inhibitor; Antiarthritic; Rheumatoid arthritis
CBR-001-620-086-5,RFM-008-050-2,CBR-001-620-086-5,COc1cccc2c1nc(n2c1nc(nc(n1)N1CCOCC1)c1ccc(cc1)NS(=O)(=O)CCN(C)C)C(F)F,CBR-HVAC-07044: Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors
CBR-001-620-087-6,RFM-008-051-3,CBR-001-620-087-6,Fc1ccc2c(c1)c(C)c(s2)S(=O)(=O)Nc1ccc(cc1S(=O)(=O)C)c1scc(n1)C(=O)O,CBR-HVAC-12252: Chymase Inhibitors
CBR-001-620-088-7,RFM-008-052-4,CBR-001-620-088-7,CCOCn1cnc2c1c(=O)n(CCCCC(O)(C)C)c(=O)n2C,CBR-HVAC-03548: Methylxanthines
CBR-001-620-089-8,RFM-008-053-5,CBR-001-620-089-8,COC[C@@H]1C[C@@](N([C@@H]1c1nccs1)C(=O)c1ccc(c(c1)OC)C(C)(C)C)(C#N)Cn1cccn1,CBR-HVAC-14139: analog of CBR-HVAC-11818
CBR-001-620-090-1,RFM-008-054-6,CBR-001-620-090-1,OCC(NCc1ccc2c(c1)c1cccc3c1c2ccc3)(CO)C,CBR-HVAC-14140: analog of CBR-HVAC-03522 (regioisomer)
CBR-001-620-091-2,RFM-008-055-7,CBR-001-620-091-2,O=C(O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)O)CCc1ccccc1,component of CBR-HVAC-08129
CBR-001-620-092-3,RFM-008-056-8,CBR-001-620-092-3,OC[C@H]1O[C@@H](O[C@@H](C(O)(C)C)CC[C@H]([C@H]2CC[C@@]3([C@]2(C)C[C@@H](O)[C@@]2([C@H]3CC=C3[C@H]2CC[C@@H](C3(C)C)O[C@@H]2O[C@H](CO[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O)[C@H]([C@@H]([C@H]2O)O)O)C)C)C)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O,CBR-HVAC-07364: Drugs Acting on Toll-Like Receptors (TLR
CBR-001-620-093-4,RFM-008-057-9,CBR-001-620-093-4,OCCN1CCN(CC1)CC/C=C/1\c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-01974: Dopamine receptor D1; Dopamine receptor D2 Inhibitor; Antipsychotic; Schizophrenia; Manic-depresive psychosis; Learning disability; Dementia;
CBR-001-620-094-5,RFM-008-058-0,CBR-001-620-094-5,OC(=O)CCCOc1c(cc(cc1C(C)(C)C)SC(Sc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)(C)C)C(C)(C)C,CBR-HVAC-05620: Vascular cell adhesion molecule 1 Inhibitor; Immunosuppressant; Solid organ transplant rejection;
CBR-001-620-095-6,RFM-008-059-1,CBR-001-620-095-6,Cc1c(Nc2ncccc2C(=O)OCC(CO)O)cccc1Cl,CBR-HVAC-10139: ; Analgesic; Pain;
CBR-001-620-096-7,RFM-008-060-4,CBR-001-620-096-7,O=C1C=C[C@]2([C@H](N1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)c1ccccc1)C)C,CBR-HVAC-04145: Steroid 5-alpha-reductase Inhibitor; Steroid 5-alpha-reductase inhibitor; Acne; Alopecia; Benign prostate hyperplasia; Hirsutism; Prostate cancer; Seborrheic dermatitis;
CBR-001-620-097-8,RFM-008-061-5,CBR-001-620-097-8,O[C@@H]([C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)NC(=O)c1ccc2c(n1)cccc2)CN1CC[C@H](C[C@H]1C(=O)NC(C)(C)C)OCc1ccncc1,CBR-HVAC-11343: Protease Inhibitor; Antiviral; HIV infection;
CBR-001-620-098-9,RFM-008-062-6,CBR-001-620-098-9,COc1ccccc1N1CCN(CC1)CC1CN=c2n1c(SC)nc1c2cccc1,CBR-HVAC-04983: Alpha-1 adrenergic receptor Blocker; Antiarrhythmic; Antihypertensive; Hypertension;
CBR-001-620-099-0,RFM-008-063-7,CBR-001-620-099-0,CCCCCCCN(C(=O)Nc1c(C)cc(cc1C)Cl)Cc1ccc(cc1)CCC(C)C,CBR-HVAC-04753: Acyl CoA:cholesterol acyltransferase Inhibitor; Antihypercholesterolemic; Antiarteriosclerotic; Atherosclerosis; Hypercholesterolemia;
CBR-001-620-100-6,RFM-008-064-8,CBR-001-620-100-6,Fc1ccc(cc1F)n1ncc(c(c1=O)OCCC(O)(C)C)c1ccc(cc1)S(=O)(=O)C,"CBR-HVAC-00510: Cyclooxygenase-2 Inhibitor; Analgesic; Non-steroidal anti-inflammatory; Antiarthritic; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; PAIN, ARTHRITIS;"
CBR-001-620-101-7,RFM-008-065-9,CBR-001-620-101-7,CCCC(N1CCCC1)Cc1ccccc1,CBR-HVAC-08994: ; Antidepressant; Depression; Fatigue;
CBR-001-620-102-8,RFM-008-066-0,CBR-001-620-102-8,CC(=O)OCCN1CCN(CC1)CC/C=C/1\c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-02104: ; ANTIPSYCHOTIC; SCHIZOPHRENIA;
CBR-001-620-103-9,RFM-008-067-1,CBR-001-620-103-9,O=C(Nc1cccc(c1)OC(F)(F)F)O[C@@H]1COc2n(C1)cc(n2)[N+](=O)[O-],"CBR-HVAC-11340: Protein synthesis inhibitor; Antimycobacterial; Infection, mycobacterium tuberculosis;"
CBR-001-620-104-0,RFM-008-068-2,CBR-001-620-104-0,CCC[C@@]1(OCCc2c1[nH]c1c2c(C#N)ccc1C)CC(=O)O,"CBR-HVAC-06003: HCV NS5B polymerase Inhibitor; ANTIVIRAL; INFECTION, HCV;"
CBR-001-620-105-1,RFM-008-069-3,CBR-001-620-105-1,O=c1c2CN([C@@H](c2[nH]c2c1cccc2)c1ccc2c(c1)CCO2)c1ncc(cn1)c1ccccn1,CBR-HVAC-05647: Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor; Erectile dysfunction;
CBR-001-620-106-2,RFM-008-070-6,CBR-001-620-106-2,Cc1nn(c(c1)C(=O)Nc1ccc(cc1)c1ccccc1S(=O)(=O)N)c1cccc(c1)C(=N)N,CBR-HVAC-07756: Coagulation factor Xa Inhibitor; Anticoagulant; Thrombosis;
CBR-001-620-107-3,RFM-008-071-7,CBR-001-620-107-3,CCCCCCCCCCCCCCCCS(=O)(=O)N1CCc2c(C1)sc1c2C(=NCc2n1c(C)nn2)c1ccccc1Cl,CBR-HVAC-04078: Platelet activating factor receptor Antagonist; Neuroprotectant; Vasoprotectant; Arrhythmia; Cerebral ischemia; Myocardial ischemia; Stroke; Cerebral infarction;
CBR-001-620-108-4,RFM-008-072-8,CBR-001-620-108-4,O=C(NC1C(=O)N(c2ccccc2)c2c(N(C1=O)CC(=O)N(c1ccccc1)C(C)C)cccc2)Nc1cccc(c1)C(=O)O,CBR-HVAC-05454: CHOLECYSTOKININ B RECEPTOR Agonist; ANTI-OBESITY; Nutritional diseases;
CBR-001-620-109-5,RFM-008-073-9,CBR-001-620-109-5,O=C(NC1C(=O)N(c2ccccc2)c2c(N(C1=O)CC(=O)N(c1ccccc1)C(C)C)cccc2)Nc1cccc(c1)C(=O)O,CBR-HVAC-05454: CHOLECYSTOKININ B RECEPTOR Agonist; ANTI-OBESITY; Nutritional diseases;
CBR-001-620-110-8,RFM-008-074-0,CBR-001-620-110-8,O=C(Cn1c(C)ccc(c1=O)NS(=O)(=O)Cc1ccccc1)NCc1ccc(nc1C)N,CBR-HVAC-10641: Thrombin Inhibitor; Anticoagulant; Thrombosis;
CBR-001-620-111-9,RFM-008-075-1,CBR-001-620-111-9,Fc1ccc(cc1)c1ccc([nH]1)CN1CCN(CC1)c1cccc2c1occ2,CBR-HVAC-03822: 5-Hydroxytryptamine 1A receptor; Dopamine receptor D2 Agonist; Antagonist; Antipsychotic; Psychosis;
CBR-001-620-112-0,RFM-008-076-2,CBR-001-620-112-0,O=C(N[C@@H](C(S(=O)(=O)C)(C)C)C(=O)N[C@H]([C@@H](CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)O)Cc1ccccc1)COc1cccnc1,CBR-HVAC-11685: Reverse transcriptase Inhibitor; Anti-HIV; Viral infection;
CBR-001-620-113-1,RFM-008-077-3,CBR-001-620-113-1,CCCC(C(=O)NCC(=O)NCCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O)CCC,CBR-HVAC-10887: Thymidylate synthase Inhibitor; Anticancer; Antineoplastic; Cancer;
CBR-001-620-114-2,RFM-008-078-4,CBR-001-620-114-2,O=C(Nc1cccc(c1)CC(=O)O)NCC(=O)N(c1ccccc1)CC(=O)N(c1ccccc1)C,CBR-HVAC-10717: Cholecystokinin B receptor Antagonist; Antiulcer; Peptic ulcer;
CBR-001-620-115-3,RFM-008-079-5,CBR-001-620-115-3,CN(CCNC(=O)c1nccc2c1cc1c(c2C)n(c2c1cc(O)cc2)C)C,CBR-HVAC-04574: DNA topoisomerase II Inhibitor; Anticancer; Cancer;
CBR-001-620-116-4,RFM-008-080-8,CBR-001-620-116-4,CCCc1nc(C)n2c(c1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)nc(=O)[nH]2,CBR-HVAC-04390: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Atherosclerosis; Coronary artery restenosis; Heart failure; Hypertension;
CBR-001-620-117-5,RFM-008-081-9,CBR-001-620-117-5,CO[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(cc1)Cl)C(=O)Nc1ccc(cc1F)n1ccccc1=O,CBR-HVAC-00350: Coagulation factor X inhibitor; Antithrombotic; Thrombosis;
CBR-001-620-118-6,RFM-008-082-0,CBR-001-620-118-6,COC(=O)C1=C(CF)NC(=C(C1c1c(F)ccc(c1C(F)(F)F)Cl)C(=O)OC(C)C)C,CBR-HVAC-03533: Calcium channel Blocker; Antihypertensive; Hypertension; Ischemic heart diseases;
CBR-001-620-119-7,RFM-008-083-1,CBR-001-620-119-7,CCc1oc(nc1CCOc1ccc2c(c1)CCC2CC(=O)O)c1ccc(cc1)OC,CBR-HVAC-00262: Insulin receptor; PPAR gamma; PPAR delta Agonist; Sensitizer; Hypoglycemic; Antihypertriglyceridemic; NON-INSULIN DEPENDENT DIABETES MELLITUS;
CBR-001-620-120-0,RFM-008-084-2,CBR-001-620-120-0,Cc1cc(C)c(c(c1)C(=O)C)NC(=O)c1sccc1S(=O)(=O)Nc1onc(c1C)C,CBR-HVAC-05263: Endothelin A receptor Antagonist; Neuroprotectant; Antihypertensive; Anti-inflammatory; Congestive heart failure; Hypertension;
CBR-001-620-121-1,RFM-008-085-3,CBR-001-620-121-1,CN(CCc1c[nH]c2c1cc(cc2)C1=CCN(CC1)C)C,CBR-HVAC-05051: 5-Hydroxytryptamine 1D receptor Agonist; Vasoconstrictor; Antimigraine; Migraine;
CBR-001-620-122-2,RFM-008-086-4,CBR-001-620-122-2,COc1cc(ccc1C(=O)N1CCC(CC1)N1C(=O)OCc2c1cccc2)OC1CCN(CC1)Cc1ccc[n+](c1C)[O-],CBR-HVAC-11216: Oxytocin receptor Antagonist; Oxytocin receptor antagonist; Preterm labor;
CBR-001-620-123-3,RFM-008-087-5,CBR-001-620-123-3,COc1ccc(cc1)c1sc(cc1c1ccc(cc1)OC)CCCC(=O)N(O)C,CBR-HVAC-11160: Lipoxygenase 5 Inhibitor; Analgesic; Anti-inflammatory; Rheumatic disorder; Inflammation; Pain;
CBR-001-620-124-4,RFM-008-088-6,CBR-001-620-124-4,Cc1noc(c1)CCCCCCCOc1ccc(cc1)C1=NCCO1,"CBR-HVAC-01029: ; Antiviral; Infection, viral;"
CBR-001-620-125-5,RFM-008-089-7,CBR-001-620-125-5,C[C@@H]1CCCN1CCCOc1ccc(cc1)c1ccc(=O)[nH]n1,CBR-HVAC-00588: Histamine H3 receptor Antagonist; Nootropic agent; Psychostimulant; SLEEP DISORDER; COGNITIVE DISORDER;
CBR-001-620-126-6,RFM-008-090-0,CBR-001-620-126-6,Cc1cn2c(c1)[nH]cc(c2=O)C(=O)Nc1ccc(cc1C(F)(F)F)N1CCC(C1)(C)C,CBR-HVAC-12281: ATP-BINDING CASSETTE TRANSPORTER Activator; ANTI-INFERTILITYANTIFIBROTIC; SJOGREN'S SYNDROME; CYSTIC FIBROSIS; NEURODEGENERATIVE DISEASES; RESPIRATORY DISEASE; LIPID DISORDERS; MALE INFERTILITY;
CBR-001-620-127-7,RFM-008-091-1,CBR-001-620-127-7,CN1CCN(CC1)C1=Nc2ccc(cc2Nc2c1c1ccccc1s2)F,CBR-HVAC-11066: Dopamine receptor D2 Antagonist; Antipsychotic; Schizophrenia;
CBR-001-620-128-8,RFM-008-092-2,CBR-001-620-128-8,OC(c1ccccc1)C(=O)OC1CC2CCC(C1)[N+]2(C)CC(=O)c1ccccc1,CBR-HVAC-09042: Cholinesterase Inhibitor; Antihypertensive; Anticholinergic; Hypertension; Deaf-Mutism;
CBR-001-620-129-9,RFM-008-093-3,CBR-001-620-129-9,NC(=O)C12NC(c3c2cccc3)Cc2c1cccc2,CBR-HVAC-04123: Ionotropic glutamate receptor NMDA; Voltage-gated sodium channel Blocker; Blocker; Neuroprotectant; Anticonvulsant; Epilepsy; Seizures; Stroke;
CBR-001-620-130-2,RFM-008-094-4,CBR-001-620-130-2,COc1ccc(cc1OC)[C@@H](CN1CCN(CC1)c1cccccc1=O)O,CBR-HVAC-01199: Dopamine receptor Agonist; Antiparkinsonian; Parkinson's disease;
CBR-001-620-131-3,RFM-008-095-5,CBR-001-620-131-3,COc1ccc(cc1OC)[C@@H](CN1CCN(CC1)c1cccccc1=O)O,CBR-HVAC-01199: Dopamine receptor Agonist; Antiparkinsonian; Parkinson's disease;
CBR-001-620-132-4,RFM-008-096-6,CBR-001-620-132-4,OC(=O)[C@H](C(c1ccccc1)(c1ccccc1)C)Oc1nc(C)cc(n1)C,CBR-HVAC-05001: Endothelin A receptor Antagonist; Antihypertensive; Congestive heart failure; Hypertension;
CBR-001-620-133-5,RFM-008-097-7,CBR-001-620-133-5,COc1ccc(cc1)n1nc(cc1c1ccc(cc1)OC)C(c1ccc(c(c1)C(=O)N)Cl)(OC)OC,CBR-HVAC-11376: Lipoxygenase 5; COX Inhibitor; Non-Steroidal Antiinflammatory; Inflammatory diseases;
CBR-001-620-134-6,RFM-008-098-8,CBR-001-620-134-6,O[C@@H]1C[C@@H](N(C1)C(=O)Nc1ccc(cc1)Cl)C(=O)Nc1ccc(cc1F)N1CCOCC1=O,CBR-HVAC-11773: FACTOR XA Inhibitor; Antithrombotic; Arterial thrombosis;
CBR-001-620-135-7,RFM-008-099-9,CBR-001-620-135-7,COC1(CCOCC1)c1cc(OCc2ccc3c(c2)ccc(=O)n3C)cc(c1)F,CBR-HVAC-04111: Lipoxygenase 5 Inhibitor; Antiinflammatory; Asthma; Rheumatoid arthritis;
CBR-001-620-136-8,RFM-008-100-5,CBR-001-620-136-8,COc1ccc(c2c1OCCO2)[C@@]1(CC[C@@H](CC1)C(=O)O)C#N,"CBR-HVAC-05335: Atopic Dermatitis, Agents for;Rheumatoid Arthritis, Treatment of;Asthma Therapy; IL-1beta Production Inhibitors;IL-12 Production Inhibitors;Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors; Phosphodiesterase 4 Inhibitor;"
CBR-001-620-137-9,RFM-008-101-6,CBR-001-620-137-9,O=C1Nc2ccc(c(c2[C@](N1)(C#CC1CC1)C(F)(F)F)F)F,"CBR-HVAC-00215: Reverse transcriptase Inhibitor; Antiviral; Infections, hiv;"
CBR-001-620-138-0,RFM-008-102-7,CBR-001-620-138-0,OCCCc1ccc(cc1)CC(C(=O)N[C@@H]1[C@H](O)Cc2c1cccc2)C[C@@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)O,CBR-HVAC-10502: Protease Inhibitor; Antiviral; HIV infection;
CBR-001-620-139-1,RFM-008-103-8,CBR-001-620-139-1,OCCCc1ccc(cc1)CC(C(=O)N[C@@H]1[C@H](O)Cc2c1cccc2)C[C@@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)O,CBR-HVAC-10502: Protease Inhibitor; Antiviral; HIV infection;
CBR-001-620-140-4,RFM-008-104-9,CBR-001-620-140-4,FC([C@]1(/C=C/C2CC2)NC(=O)Nc2c1cc(Cl)cc2)(F)F,CBR-HVAC-10436: Non-nucleoside reverse transcriptase Inhibitor; Antiviral; Viral infection;
CBR-001-620-141-5,RFM-008-105-0,CBR-001-620-141-5,OC[C@H]1O[C@H](C[C@@H]1F)n1cc(Cl)c(=O)[nH]c1=O,"CBR-HVAC-02749: Reverse transcriptase Inhibitor; Antiviral; Infections, HIV;"
CBR-001-620-142-6,RFM-008-106-1,CBR-001-620-142-6,CC(CN(C(=O)c1cccc(c1Cl)Cl)[C@@H]1CNCC1)C,CBR-HVAC-00211: Norepinephrine transporter; 5-Hydroxytryptamine transporter Inhibitor; Norepinephrine transporter inhibitor; 5-hydroxytryptamine transporter inhibitor; Stress urinary incontinence;
CBR-001-620-143-7,RFM-008-107-2,CBR-001-620-143-7,CCOC(=O)COC1CCN(CC1)C(=O)[C@@H](NC(=O)c1ccc(cc1)/C(=N/O)/N)C,CBR-HVAC-11529: Integrin alpha2b beta3 Antagonist; Antithrombotic; Acute coronary syndrome; Arterial thrombosis; Myocardial infarction; Unstable angina pectoris;
CBR-001-620-144-8,RFM-008-108-3,CBR-001-620-144-8,Cc1cc2CCN3c2c(c1)C(=NC(C3=O)NC(=O)c1ccncc1)c1ccccc1,CBR-HVAC-05023: Phosphodiesterase 4 Inhibitor; Antiinflammatory; Bronchodilator; Inflammation; Asthma;
CBR-001-620-145-9,RFM-008-109-4,CBR-001-620-145-9,Cc1cc2CCN3c2c(c1)C(=NC(C3=O)NC(=O)c1ccncc1)c1ccccc1,CBR-HVAC-05023: Phosphodiesterase 4 Inhibitor; Antiinflammatory; Bronchodilator; Inflammation; Asthma;
CBR-001-620-146-0,RFM-008-110-7,CBR-001-620-146-0,COc1cccc2c1ccc1c2nc2c(n1)cccc2C(=O)N[C@H](CN(C)C)C,CBR-HVAC-00216: DNA topoisomerase I; DNA topoisomerase II Inhibitor; Anticancer; Cancer;
CBR-001-620-147-1,RFM-008-111-8,CBR-001-620-147-1,CN/C(=N\S(=O)(=O)c1ccc(cc1)C(F)(F)F)/N1C[C@@H](C(=N1)c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-12276: Cannabinoid receptor 1 Antagonist; Neuroprotectant; Psychiatric disorder;
CBR-001-620-148-2,RFM-008-112-9,CBR-001-620-148-2,CCCCCCCCCCCCCCOP(=O)(O[C@@H](C[N+](C)(C)C)CC(=O)O)[O-],CBR-HVAC-04530: Carnitine palmitoyltransferase I Inhibitor; Antidiabetic; Diabetes mellitus;
CBR-001-620-149-3,RFM-008-113-0,CBR-001-620-149-3,CN/C(=N\S(=O)(=O)N1CCCCC1)/N1C[C@@H](C(=N1)c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-05896: Cannabinoid receptor 1 Antagonist; Nootropic; Cognitive disorder;
CBR-001-620-160-8,RFM-008-114-1,CBR-001-620-160-8,S=C(C(=O)O)Cc1ccc(cc1)I,"CBR-HVAC-11352: Calpain Inhibitor; Calpain Inhibitors; Cognition Disorders, Treatment of; Neuroprotectant; Stroke, Treatment of"
CBR-001-622-475-2,RFM-008-115-2,CBR-001-622-475-2,OCCC(=O)N1CCC(CC1)c1nn(c(n1)c1cnc(c(n1)c1nnc(o1)C(C)(C)C)N)CC,CBR-HVAC-07375: Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors
CBR-001-622-476-3,RFM-008-116-3,CBR-001-622-476-3,O=C1CCN(C=C1)c1c(F)cc(c(c1F)F)N1C[C@@H](OC1=O)CNc1ccon1,CBR-HVAC-07003: MAO-A Inhibitors
CBR-001-622-477-4,RFM-008-117-4,CBR-001-622-477-4,CN(C[C@@H]1C(=O)O[C@H]2[C@H]1CC/C(=C/CC[C@@]1([C@@H]2O1)C)/C)C,CBR-HVAC-06225: NF-kappaB (NFKB) Activation Inhibitors; Signal Transduction Modulators
CBR-001-622-478-5,RFM-008-118-5,CBR-001-622-478-5,CCN(CCN(C(=O)Cn1cc(Cc2cnn(c2)C)c(=O)nc1SCc1ccc(cc1)F)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F)CC,CBR-HVAC-05452: Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors
CBR-001-622-479-6,RFM-008-119-6,CBR-001-622-479-6,COc1cccc(c1)N(C(=O)CNC(=O)Nc1cccc(c1)C(C(=O)O)C)CC(=O)N(c1ccccc1)C,CBR-HVAC-02865: CCK2 (CCKB/Gastrin) Antagonists
CBR-001-622-480-9,RFM-008-120-9,CBR-001-622-480-9,CCCC1O[C@H]2[C@](O1)(C(=O)COC(=O)c1ccc(cc1)CO[N+](=O)[O-])[C@@]1([C@@H](C2)[C@@H]2CCC3=CC(=O)C=C[C@@]3([C@H]2[C@H](C1)O)C)C,CBR-HVAC-05595: Corticosteroids
CBR-001-622-481-0,RFM-008-121-0,CBR-001-622-481-0,COC(c1ccc(c(c1)Cl)Cl)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C,"CBR-HVAC-10224: Penicillin binding protein inhibitor; Antibacterial; Infection, bacterial"
CBR-001-622-482-1,RFM-008-122-1,CBR-001-622-482-1,CCCN(Cc1onc(n1)c1ncn2c1CN(C)C(=O)c1c2ccc(c1)F)CCC,CBR-HVAC-04861: Benzodiazepine receptor Agonist; Anxiolytic; Anesthesia; Anxiety
CBR-001-622-483-2,RFM-008-123-2,CBR-001-622-483-2,NCCOCCOCC1=C(C(=O)OCC)C(C(=C(N1)C)C(=O)OC)c1cccc(c1Cl)Cl,CBR-HVAC-04163: Calcium channel Blocker; Antihypertensive; Heart failure; Hypertension; Ischemic heart diseases
CBR-001-622-484-3,RFM-008-124-3,CBR-001-622-484-3,FCCCNCc1ccc(cc1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,CBR-HVAC-11767: Bacterial protein synthesis inhibitor; Antibacterial; Nosocomial infections
CBR-001-622-485-4,RFM-008-125-4,CBR-001-622-485-4,CCCc1c(OCCCS(=O)(=O)c2ccc(cc2)C(=O)CCC(=O)O)ccc(c1O)C(=O)C,CBR-HVAC-03388: Leukotriene D4 receptor Antagonist; Antiinflammatory; Asthma
CBR-001-622-486-5,RFM-008-126-5,CBR-001-622-486-5,CCCCc1nc(C)n(c(=O)c1Cc1ccc(cc1)c1ccccc1c1[nH]nnn1)Cc1ccccc1C(=O)O,CBR-HVAC-10701: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension
CBR-001-622-487-6,RFM-008-127-6,CBR-001-622-487-6,O[C@@H]1CC[C@H](C1)C(=O)N[C@@H](C(=O)N1CC[C@](C(C1)(C)C)(O)c1ccc(cc1)Cl)C(C)C,CBR-HVAC-02734: C-C CHEMOKINE RECEPTOR 1 Antagonist; ANTI-INFLAMMATORY; Rheumatoid arthritis
CBR-001-622-488-7,RFM-008-128-7,CBR-001-622-488-7,CCc1cc(OCc2ccc(cc2)c2ccccc2c2nnn[nH]2)c2c(n1)CCCC2,CBR-HVAC-04293: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-622-489-8,RFM-008-129-8,CBR-001-622-489-8,CCCCNCC(c1cc(nc(c1)c1ccc(cc1)C(F)(F)F)c1ccc(cc1)C(F)(F)F)O,CBR-HVAC-12321: ; ANTI-SCHISTOSOMALANTI-MALARIAL; Schistosomiasis; Malaria
CBR-001-622-490-1,RFM-008-130-1,CBR-001-622-490-1,O=C1NCCCN1CCCNCC1CCc2c(O1)cccc2,CBR-HVAC-05214: 5-Hydroxytryptamine 1A receptor Agonist; 5-hydroxytryptamine 1A receptor agonist; Dyspepsia
CBR-001-622-491-2,RFM-008-131-2,CBR-001-622-491-2,O=C1NCCCN1CCCNCC1CCc2c(O1)cccc2,CBR-HVAC-05214: 5-Hydroxytryptamine 1A receptor Agonist; 5-hydroxytryptamine 1A receptor agonist; Dyspepsia
CBR-001-622-492-3,RFM-008-132-3,CBR-001-622-492-3,Fc1ccc(cc1)Oc1ccc2c(c1)O[C@H](CO2)CN(C(=O)N)O,CBR-HVAC-10776: Lipoxygenase 5 Inhibitor; Antiasthmatic; Anti-inflammatory; Inflammation; Asthma
CBR-001-622-493-4,RFM-008-133-4,CBR-001-622-493-4,CC(NC(=O)C[C@H]1CCCN(c2c1cccc2)C(=O)c1ccc(cc1Cl)N1CCCC1)C,CBR-HVAC-05055: Vasopressin V2 receptor Agonist; Antidiuretic; Diabetes insipidus
CBR-001-622-494-5,RFM-008-134-5,CBR-001-622-494-5,NCCCC[C@@H](C(=O)NCC(=O)N(c1ccc(cc1C(=O)c1ccccc1)Cl)C)N,CBR-HVAC-08649: ; Anticonvulsant; Epilepsy
CBR-001-622-495-6,RFM-008-135-6,CBR-001-622-495-6,CN(CCn1nnnc1SCC1=C(C(=O)OC(OC(=O)OC2CCCCC2)C)N2[C@H](SC1)[C@@H](C2=O)NC(=O)Cc1csc(n1)N)C,"CBR-HVAC-01723: Penicillin binding protein Inhibitor; Antibacterial; Bronchitis, acute; Pneumonia, acute; Chronic Respiratory Tract Infection; Urinary tract infection; Superficial suppurative infections; Wound Infections; Otitis media; Sinusitis; Tonsillitis; Pharyngolaryngitis; Opthalmic Infections"
CBR-001-622-496-7,RFM-008-136-7,CBR-001-622-496-7,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-02516: ; Antihypertensive; Hypertension
CBR-001-622-497-8,RFM-008-137-8,CBR-001-622-497-8,CCN(CCNC(=O)c1cc(C#N)c(cc1OC)Cl)CC,CBR-HVAC-04866: Dopamine receptor Antagonist; Antidepressant; Major depressive disorder
CBR-001-622-498-9,RFM-008-138-9,CBR-001-622-498-9,OCCN(C(=O)C(Cl)Cl)Cc1ccc(cc1)Oc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-09765: ; Antiamebic; Amebiasis
CBR-001-622-499-0,RFM-008-139-0,CBR-001-622-499-0,COc1ccc(cc1)CN[C@H]([C@@H]([C@@H](NC(=O)[C@H](C(C)(C)C)NC(=O)OCc1ccccc1)Cc1ccccc1)O)C(=O)N[C@@H]1[C@H](O)Cc2c1cccc2,CBR-HVAC-11466: Reverse transcriptase Inhibitor; Antiviral; HIV infection
CBR-001-622-500-6,RFM-008-140-3,CBR-001-622-500-6,CNCC(c1cccc(c1)NS(=O)(=O)C)O,"CBR-HVAC-09710: Alpha-1A adrenergic receptor Agonist; Sympathomimetic; Congestion, nasal"
CBR-001-622-501-7,RFM-008-141-4,CBR-001-622-501-7,Cc1ccc(nc1)CNCC1(F)CCN(CC1)C(=O)c1ccc(c(c1)Cl)F,CBR-HVAC-00758: 5-Hydroxytryptamine 1A receptor Agonist; Antidepressant; Analgesic; Chronic pain
CBR-001-622-502-8,RFM-008-142-5,CBR-001-622-502-8,O=C(N1CCC(CC1)Cn1c(C)nc2c1ccnc2)CC(c1ccccc1)c1ccccc1,CBR-HVAC-10749: Platelet activating factor receptor Antagonist; Antiinflammatory; Asthma
CBR-001-622-503-9,RFM-008-143-6,CBR-001-622-503-9,COc1ccc(c2c1cccc2)NC(=N)Nc1ccc2c3c1cccc3CC2,CBR-HVAC-10520: Calcium channel; Sodium channel Inhibitor; Neuroprotectant; Cardioprotectant; Brain damage; Myocardial infarction; Cerebrovascular ischemia; Stroke
CBR-001-622-504-0,RFM-008-144-7,CBR-001-622-504-0,CC(=O)OCCN(C(=O)[C@H]1CN(C)[C@H]2C(C1)c1cccc3c1c(C2)c[nH]3)CCOC(=O)C,CBR-HVAC-03924: 5-Hydroxytryptamine 2 receptor Antagonist; Nootropic; Cognition disorder
CBR-001-622-505-1,RFM-008-145-8,CBR-001-622-505-1,CCC(c1ccccc1)C(=O)OCCN1CCOC(C1C)c1ccccc1,CBR-HVAC-09838: Growth regulator by depression of the center of the hunger on the level of the core ventrolateral of the hypothalamus. Peripheral action: slow and progressive mobilization of the lipidic reserves; Anorectic; Anorectic agent
CBR-001-622-506-2,RFM-008-146-9,CBR-001-622-506-2,Clc1ccc(cc1)c1cc2c(s1)c(=O)n(cn2)c1ccc2c(c1)n(C)c(n2)N(C)C,CBR-HVAC-11718: Melanin concentrating hormone receptor Antagonist; Antidepressant; Anxiolytic; Obesity; Anxiety; Depression
CBR-001-622-507-3,RFM-008-147-0,CBR-001-622-507-3,CONC1=NC(=O)/C(=C/c2cc(c(c(c2)C(C)(C)C)O)C(C)(C)C)/S1,CBR-HVAC-11349: COX-2 Inhibitor; Anti-inflammatory; Analgesic; Inflammation; Pain
CBR-001-622-508-4,RFM-008-148-1,CBR-001-622-508-4,O=C1Nc2ccc(cc2C2(N(C1)C(C)CO2)c1ccccc1Cl)Cl,"CBR-HVAC-01611: Psychomotor and anxiolytic agent; Anxiolytic; Anxiety disorder, generalized"
CBR-001-622-509-5,RFM-008-149-2,CBR-001-622-509-5,O=Cc1ccc(cc1C)N(CCOS(=O)(=O)C)CCOS(=O)(=O)C,CBR-HVAC-05435: Alkylating agent; Anticancer; Cancer
CBR-001-622-510-8,RFM-008-150-5,CBR-001-622-510-8,CN(c1cc2OCOc2cc1Sc1nc2c(n1CCNCC(C)(C)C)ccnc2N)C,CBR-HVAC-06781: HEAT SHOCK PROTEIN 90 Inhibitor; Anticancer; Cancer
CBR-001-622-511-9,RFM-008-151-6,CBR-001-622-511-9,CCOP(=O)(Cc1ccc(cc1)c1nc2c(s1)cccc2)OCC,CBR-HVAC-05780: Voltage-sensitive calcium channel Antagonist; Antihypertensive; Antiarrhythmic; ANGINA PECTORIS; HEART DISEASE
CBR-001-622-512-0,RFM-008-152-7,CBR-001-622-512-0,N#CCOC(=O)[C@@]1(OC(=O)C2C(C2(C)C)(C)C)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F,CBR-HVAC-06186: GLUCOCORTICOID RECEPTOR Agonist; Antiasthmatic; Asthma
CBR-001-622-513-1,RFM-008-153-8,CBR-001-622-513-1,O=C([C@H](NC(=O)C(N)(C)C)CCCc1ccccc1)N1CCC2(CC1)CN(c1c2cccc1)S(=O)(=O)C,CBR-HVAC-11207: Growth hormone release stimulator; Growth hormone releasing hormone stimulator; Somatotropin deficiency; Gonadotropin deficiency
CBR-001-622-514-2,RFM-008-154-9,CBR-001-622-514-2,CCCCCCCCCCCCC(c1ccccc1)(CCCN(CCc1ccccc1)C)C#N,CBR-HVAC-01061: ; Vasodilator; Hypertension; Angina pectoris
CBR-001-622-515-3,RFM-008-155-0,CBR-001-622-515-3,Cc1ccc2c(n1)cccc2N1CCN(CC1)CCc1cccc(c1)N1CCNC1=O,CBR-HVAC-06135: 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 1D receptor Antagonist; Antidepressant; Anxiolytic; Anxiety disorder; Major depressive disorder
CBR-001-622-516-4,RFM-008-156-1,CBR-001-622-516-4,[O-][N+](=O)c1ccc(o1)/C=N/N(C(=O)N)CCO,CBR-HVAC-09271: ; ; Infection
CBR-001-622-517-5,RFM-008-157-2,CBR-001-622-517-5,Fc1ccc(cc1)c1sc(nc1C(=O)N1CCCC[C@H]1CNC(=O)c1cccc2c1cco2)C,CBR-HVAC-00549: Orexin receptor 1 Antagonist; Sedative; Appetite modulator; Hypnotic; Sleep disorders; Obesity; Eating disorders
CBR-001-622-518-6,RFM-008-158-3,CBR-001-622-518-6,NC(=O)C1(CCN(CC1)CCCN1c2ccccc2CCc2c1cccc2)N1CCCCC1,CBR-HVAC-01890: 5-Hydroxytryptamine 2 receptor Antagonist; Tranquilizer; Antipsychotic; Antidepressant; Neuroleptic; Anxiolytic; Neurotic syndrome; Schizophrenia; Psychosis; Depression; Anxiety
CBR-001-622-519-7,RFM-008-159-4,CBR-001-622-519-7,CN[C@H]1[C@H](O)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)O,CBR-HVAC-03916: Sodium channel Blocker; Class I antiarrhythmic; Fibrillation
CBR-001-622-520-0,RFM-008-160-7,CBR-001-622-520-0,COC(c1ccccc1)CN1CCN(CC1)CCC(c1ccccc1)O,CBR-HVAC-08947: Histamine H1 receptor Antagonist; Bronchodilator; Bronchiolitis
CBR-001-622-521-1,RFM-008-161-8,CBR-001-622-521-1,OC(CN1CCN(CC1)CCCC(c1ccc(cc1)F)c1ccc(cc1)F)CNc1ccccc1,CBR-HVAC-11273: Dopamine transporter Inhibitor; Antiparkinsonian; Parkinson's disease
CBR-001-622-522-2,RFM-008-162-9,CBR-001-622-522-2,COC(=O)CCNCCC1COc2c(C1)cccc2,CBR-HVAC-04547: Neuroprotectant; Nootropic; Nootropic; Alzheimer's disease; Cognition disorder
CBR-001-622-523-3,RFM-008-163-0,CBR-001-622-523-3,COC(=O)CCNCCC1COc2c(C1)cccc2,CBR-HVAC-04547: Neuroprotectant; Nootropic; Nootropic; Alzheimer's disease; Cognition disorder
CBR-001-622-524-4,RFM-008-164-1,CBR-001-622-524-4,CCN(CCOCC(c1ccc2c(c1)ccs2)O)CC,CBR-HVAC-00526: Acetylcholine release stimulator; Protein kinase stimulator; Antiglaucoma; Neuroprotectant; Alzheimer's disease; Amyotrophic arteriosclerosis; Neuroprotection; Motor neuron disease; Glaucoma; Amyotrophic lateral sclerosis; Motor neuropathy; Cerebrovascular diseases
CBR-001-622-525-5,RFM-008-165-2,CBR-001-622-525-5,CCN(CCOCC(c1ccc2c(c1)ccs2)O)CC,CBR-HVAC-00526: Acetylcholine release stimulator; Protein kinase stimulator; Antiglaucoma; Neuroprotectant; Alzheimer's disease; Amyotrophic arteriosclerosis; Neuroprotection; Motor neuron disease; Glaucoma; Amyotrophic lateral sclerosis; Motor neuropathy; Cerebrovascular diseases
CBR-001-622-526-6,RFM-008-166-3,CBR-001-622-526-6,CN/C(=N\S(=O)(=O)N1CCCCC1)/N1C[C@H](C(=N1)c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-05896: Cannabinoid receptor 1 Antagonist; Nootropic; Cognitive disorder
CBR-001-622-527-7,RFM-008-167-4,CBR-001-622-527-7,CN/C(=N\S(=O)(=O)c1ccc(cc1)C(F)(F)F)/N1C[C@H](C(=N1)c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-12276: Cannabinoid receptor 1 Antagonist; Neuroprotectant; Psychiatric disorder
CBR-001-622-528-8,RFM-008-168-5,CBR-001-622-528-8,O=C(N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1S(=O)(=O)CC(=C2C(=O)OC(C)(C)C)COC(=O)C)C(C)C)OCc1ccccc1,"CBR-HVAC-10627: Elastase 2, neutrophil Inhibitor; Antiinflammatory; Pulmonary emphysema; Chronic bronchitis; Cystic fibrosis; Adult respiratory distress syndrome"
CBR-001-622-529-9,RFM-008-169-6,CBR-001-622-529-9,CCC[C@]1(OCCc2c1[nH]c1c2c(C#N)ccc1C)CC(=O)O,"CBR-HVAC-06003: HCV NS5B polymerase Inhibitor; ANTIVIRAL; INFECTION, HCV"
CBR-001-622-530-2,RFM-008-170-9,CBR-001-622-530-2,ONC(=O)c1cnc(nc1)N1C[C@@H]2[C@H](C1)[C@H]2NCc1ccc2c(n1)ccc(c2)F,"CBR-HVAC-06558: Histone deacetylase inhibitor; Anticancer; Antiinflammatory; Solid tumor; Myeloma, multiple"
CBR-001-622-531-3,RFM-008-171-0,CBR-001-622-531-3,Oc1ccc(cc1)CCC1(CC(=C(C(=O)O1)Sc1cc(C)c(cc1C(C)(C)C)N)O)C(C)C,CBR-HVAC-11319: Protease Inhibitor; Anti-HIV; HIV infection
CBR-001-622-532-4,RFM-008-172-1,CBR-001-622-532-4,O=c1c2CN([C@H](c2[nH]c2c1cccc2)c1ccc2c(c1)CCO2)c1ncc(cn1)c1ccccn1,CBR-HVAC-05647: Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor; Erectile dysfunction
CBR-001-622-533-5,RFM-008-173-2,CBR-001-622-533-5,CCNCCCCNCCCCNCCCCNCC,CBR-HVAC-04840: Polyamine synthesis inhibitor; Anticancer; Antidiarrhoeal; Antihypertensive; Antineoplastic; Cancer; Diarrhea; Gastritis; Colitis; Ulcerative colitis; Melanoma
CBR-001-622-611-2,RFM-008-174-3,CBR-001-622-611-2,CCCCCCOc1cccc2c1oc(=O)c(c2)c1nnn[nH]1,CBR-HVAC-00306: 5-LIPOXYGENASE Inhibitor; ; Allergy
CBR-001-622-612-3,RFM-008-175-4,CBR-001-622-612-3,CC(Cc1ccc2c(c1)OCC(O2)C(=O)O)NCC(c1cccc(c1)Cl)O,CBR-HVAC-00343: Beta-3 adrenergic receptor Agonist; Hypoglycemic; Antihyperlipidemic; Diabetes mellitus Obesity
CBR-001-622-613-4,RFM-008-176-5,CBR-001-622-613-4,Fc1ccc(c(c1)C)C1CNCCN1C(=O)N(C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)C,CBR-HVAC-00425: Neurokinin receptor 1 Antagonist; Anxiolytic; Antidepressant; Anti-emetic; Emesis; Nausea; Anxiety disorder; Chemotherapy-induced emesis; Dyspepsia; Major depressive disorder
CBR-001-622-614-5,RFM-008-177-6,CBR-001-622-614-5,O[C@@H]1CCCC[C@H]1N(C(=O)NCCCOc1ccc2c(c1)ccc(=O)[nH]2)C1CC1,CBR-HVAC-00523: Phosphodiesterase 3 Inhibitor; Vasoprotectant; Antiarteriosclerotic; Antiplatelet; Antithrombotic; Thrombosis; Arteriosclerosis obliterans; Restenosis
CBR-001-622-615-6,RFM-008-178-7,CBR-001-622-615-6,O[C@@H]1CCCC[C@H]1N(C(=O)NCCCOc1ccc2c(c1)ccc(=O)[nH]2)C1CC1,CBR-HVAC-00523: Phosphodiesterase 3 Inhibitor; Vasoprotectant; Antiarteriosclerotic; Antiplatelet; Antithrombotic; Thrombosis; Arteriosclerosis obliterans; Restenosis
CBR-001-622-616-7,RFM-008-179-8,CBR-001-622-616-7,CCN(CCNc1ccc(c2c1c(=O)c1c(s2)cccc1)C)CC,CBR-HVAC-00611: DNA topoisomerase II Inhibitor; Anticancer; Glioblastoma multiforme; Non-small cell lung cancer
CBR-001-622-617-8,RFM-008-180-1,CBR-001-622-617-8,Fc1ccc(c(c1)F)Oc1cc2C(=O)CCc2cc1NS(=O)(=O)C,CBR-HVAC-01158: Cyclooxygenase 2 Inhibitor; Analgesic; Anti-inflammatory; Antirheumatic; RHEUMATOID ARTHRITIS; PAIN; OSTEOARTHROSIS
CBR-001-622-618-9,RFM-008-181-2,CBR-001-622-618-9,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCC(CC1)n1c(=O)[nH]c2c1ccc(c2)Cl,CBR-HVAC-01166: Calcium channel Antagonist; Antipsychotic; Antischizophrenic; Psychosis; Schizophrenia
CBR-001-622-619-0,RFM-008-182-3,CBR-001-622-619-0,CC(c1ccc(cc1)Nc1ccccc1C(=O)O)C(=O)O,CBR-HVAC-01217: Anti-inflammatory; ANTI-INFLAMMATORY; INFLAMMATORY DISEASES
CBR-001-622-620-3,RFM-008-183-4,CBR-001-622-620-3,CCCCN(C(=O)c1cccc2c1cccc2)CCN(CC)CC,CBR-HVAC-01654: Antiarrhythmic that prolongs myocardial refractory period and stabilizes cell membranes.; Antiarrhythmic; Arrhythmia
CBR-001-622-621-4,RFM-008-184-5,CBR-001-622-621-4,C/C(=C\C(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C)/CC/C=C(/CCC=C(C)C)\C,"CBR-HVAC-02131: Arachidonic acid antagonist; Anti-inflammatory; Arthritis, osteoarthritis; Arthritis, rheumatoid; Tenosynovitis"
CBR-001-622-622-5,RFM-008-185-6,CBR-001-622-622-5,C/C(=C\C(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C)/CC/C=C(/CCC=C(C)C)\C,"CBR-HVAC-02131: Arachidonic acid antagonist; Anti-inflammatory; Arthritis, osteoarthritis; Arthritis, rheumatoid; Tenosynovitis"
CBR-001-622-623-6,RFM-008-186-7,CBR-001-622-623-6,CN(CCCNc1c2ccccc2nc2c1c(ccc2)[N+](=O)[O-])C,CBR-HVAC-02205: ; Antineoplastic; Cancer
CBR-001-622-624-7,RFM-008-187-8,CBR-001-622-624-7,O=C1CCC(=NN1)c1ccc2c(c1)C(C)(C)C(=O)N2,CBR-HVAC-02477: Cyclic nucleotide phosphodiesterase Inhibitor; Cardiotonic; Heart disease
CBR-001-622-625-8,RFM-008-188-9,CBR-001-622-625-8,CN1CCC(CC1)C(=O)n1c2ccccc2[nH]c(=O)c2c1nccc2,CBR-HVAC-02503: Muscarinic acetylcholine receptor M1 Antagonist; Anticholinergic; Ataxia; Xerostomia; Tachycardia
CBR-001-622-626-9,RFM-008-189-0,CBR-001-622-626-9,OCCn1ncc(c1)c1cnc(c2c1scc2c1ccc(cc1)NC(=O)Nc1cccc(c1)F)N,"CBR-HVAC-02562: Aurora A kinase; Aurora B kinase; Aurora C kinase; Platelet-derived growth factor receptor; Src kinase; Vascular endothelial growth factor receptor Inhibitor; Anticancer; Advanced Solid Tumors; Leukemia, Acute Lymphoblastic; Leukemia, Chronic Lymphocytic, B Cell; Hematological Malignancy; Myelodysplasia; Chronic Myelogenous Leukemia"
CBR-001-622-627-0,RFM-008-190-3,CBR-001-622-627-0,CC1CC(OC(=O)C(c2ccccc2)OC(=O)c2cccnc2)CC(C1)(C)C,CBR-HVAC-03031: Prostaglandin receptor agonist
CBR-001-622-628-1,RFM-008-191-4,CBR-001-622-628-1,CN1CCCC1COC(=O)C(c1ccccc1)(c1ccccc1)O,"analog of CBR-HVAC-03166, delivered in error:"
CBR-001-622-629-2,RFM-008-192-5,CBR-001-622-629-2,COc1ccc(c(c1)CCC(N(CCc1ccc(c(c1)OC)OC)C)C)C#Cc1ccccc1,CBR-HVAC-03312: Calcium channel Blocker; Antihypertensive; Angina pectoris; Atherosclerosis
CBR-001-622-630-5,RFM-008-193-6,CBR-001-622-630-5,O=C1CCc2c(N1)ccc(c2)C(CNC(CCc1ccccc1)(C)C)O,CBR-HVAC-03484: Beta adrenergic receptor Antagonist; Antiarrhythmic; Antihypertensive; Angina pectoris; Arrhythmia; Hypertension
CBR-001-622-631-6,RFM-008-194-7,CBR-001-622-631-6,CCCCCNC(=N)Nc1scc(n1)c1c[nH]c(n1)C,CBR-HVAC-03500: Histamine H2 receptor Antagonist; Antiulcer; Peptic ulcer
CBR-001-622-632-7,RFM-008-195-8,CBR-001-622-632-7,O=C1N(CCCCN2CCN(CC2)c2ncccn2)C(=O)[C@@H]2[C@H]1[C@H]1C=C[C@@H]2[C@H]2[C@@H]1C=C2,CBR-HVAC-03640: 5-Hydroxytryptamine 1A receptor; Dopamine receptor D2 Agonist; Anxiolytic; Antidepressant; Anxiety; Depression
CBR-001-622-633-8,RFM-008-196-9,CBR-001-622-633-8,CSc1ccccc1N(C(=O)CN(C(=O)OCC(C)C)CCN(C)C)Cc1cccc(c1)C(F)(F)F,CBR-HVAC-03698: Calcium channel Antagonist; Antianginal; Hypertension
CBR-001-622-634-9,RFM-008-197-0,CBR-001-622-634-9,NCCCC[C@@H](C(=O)OC(COc1cccc2c1c(=O)cc(o2)C(=O)OCC)COc1cccc2c1c(=O)cc(o2)C(=O)OCC)N,CBR-HVAC-03707: Mediator Release Inhibitors; Antiallergy/Antiasthmatic Drugs
CBR-001-622-635-0,RFM-008-198-1,CBR-001-622-635-0,COc1ccc2c(c1)c(OC(C)C)c(n2c1ccccc1)C(=O)Nc1nnn[nH]1,CBR-HVAC-03825: Leukotriene B4 receptor; Thromboxane A2 receptor Antagonist; Anti-inflammatory; Antiasthmatic; Antiallergic; Asthma; Allergy; Inflammation; Psoriasis
CBR-001-622-636-1,RFM-008-199-2,CBR-001-622-636-1,CO/N=C/C1=CCCN(C1)C(=O)Oc1ccc(cc1)Cl,CBR-HVAC-03865: Acetylcholinesterase; Muscarinic acetylcholine receptor Agonist; Inhibitor; Nootropic; Anti-amnesic; Alzheimer's disease; Cognitive disorder; Dementia
CBR-001-622-637-2,RFM-008-200-8,CBR-001-622-637-2,CN1[C@@H]2CC[C@H]1C[C@H](C2)NC(=O)c1cc(Cl)cc2c1OC(C2)(C)C,CBR-HVAC-03998: 5-Hydroxytryptamine 3 receptor Antagonist; Anxiolytic; Anti-emetic; Anxiety; Emesis; Migraine
CBR-001-622-638-3,RFM-008-201-9,CBR-001-622-638-3,Clc1cc2[C@@H]3CCCC[C@@H]3Oc2c(c1)C(=O)N[C@@H]1CN2CCC1CC2,CBR-HVAC-04007: 5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Emesis
CBR-001-622-639-4,RFM-008-202-0,CBR-001-622-639-4,COc1cccc(c1)N1CCN(CC1)CC(=O)NC1c2c(O)c(C)cc(c2CC1(C)C)C,CBR-HVAC-04183: Lipid peroxidation inhibitor; Superoxide radical scavenger; Neuroprotectant; Antiparkinsonian; Cerebral ischemia; CNS trauma; Cognition disorder; Huntington's disease; Parkinson's disease
CBR-001-622-640-7,RFM-008-203-1,CBR-001-622-640-7,CC(c1cc(/C=C/2\SC(=NC2=O)N)cc(c1O)C(C)(C)C)(C)C,CBR-HVAC-04232: COX-2 Inhibitor; Antiarthritic; Antiinflammatory; Rheumatic diseases; Inflammatory diseases
CBR-001-622-641-8,RFM-008-204-2,CBR-001-622-641-8,CCc1cc(OCc2ccc(cc2)c2ccccc2c2nnn[nH]2)c2c(n1)cccc2,CBR-HVAC-04286: Angiotensin AT1 Antagonists; Signal Transduction Modulators
CBR-001-622-642-9,RFM-008-205-3,CBR-001-622-642-9,O[C@@H]1[C@@H](CNCc2ccccc2)O[C@H]([C@@H]1O)n1cnc(c1N)C(=O)N,CBR-HVAC-04324: Antithrombotic; Antiischemic; Anti-thrombotic; Anti-ischemic; Cardiovascular disease; Cerebrovascular diseases; Ischemic diseases
CBR-001-622-643-0,RFM-008-206-4,CBR-001-622-643-0,N#C/N=C(\NC(C)(C)C)/Nc1cccc(c1)/C(=C\CCCC(=O)O)/c1cccnc1,CBR-HVAC-04467: Thromboxane A synthase; Thromboxane A2 receptor Antagonist; Inhibitor; Antiangina; Antithrombotic; Angina; Peripheral vascular disease; Pulmonary disease; Thromboembolism
CBR-001-622-644-1,RFM-008-207-5,CBR-001-622-644-1,CCc1nc2c(n1Cc1ccc(cc1)c1ccccc1S(=O)(=O)NC(=O)c1ccccc1)nc(cc2C)C,CBR-HVAC-04475: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension
CBR-001-622-645-2,RFM-008-208-6,CBR-001-622-645-2,O=C([C@@H]1CCCN1C(=O)[C@H](NS(=O)(=O)C)Cc1ccccc1)NCC1CCN(CC1)C(=N)N,CBR-HVAC-04602: Thrombin Inhibitor; Antithrombotic; Thrombosis
CBR-001-622-646-3,RFM-008-209-7,CBR-001-622-646-3,O=C(C[C@@H](C(=O)N(C1CC1)CC(=O)O)NS(=O)(=O)c1ccc2c(c1)cccc2)NC[C@@H]1CCCN(C1)C(=N)N,CBR-HVAC-04604: Thrombin Inhibitor; Anticoagulant; Antithrombotic; Thrombosis
CBR-001-622-647-4,RFM-008-210-0,CBR-001-622-647-4,O=C(C(c1ccc(cc1)OCc1ccc2c(n1)cccc2)C1CCCCCC1)NS(=O)(=O)C,CBR-HVAC-04607: 5-Lipoxygenase activating protein Inhibitor; Antiinflammatory; Asthma
CBR-001-622-648-5,RFM-008-211-1,CBR-001-622-648-5,O=C(C(c1ccc(cc1)OCc1ccc2c(n1)cccc2)C1CCCCCC1)NS(=O)(=O)C,CBR-HVAC-04607: 5-Lipoxygenase activating protein Inhibitor; Antiinflammatory; Asthma
CBR-001-622-649-6,RFM-008-212-2,CBR-001-622-649-6,O=C(Cn1ccnc1[N+](=O)[O-])NCC(C(F)(F)F)(F)F,"CBR-HVAC-04609: Prostaglandin synthase Stimulator; Antiarthritic; Immunosuppressant; Diagnostic aid; Arthritis, rheumatoid; Sjogren's syndrome"
CBR-001-622-650-9,RFM-008-213-3,CBR-001-622-650-9,Clc1cc(Cl)c2c(c1)[nH]c(c2/C=C/1\CCN(C1=O)c1ccccc1)C(=O)O,"CBR-HVAC-04729: Glycine receptor Antagonist; Analgesic; Headache, migraine; Pain"
CBR-001-622-651-0,RFM-008-214-4,CBR-001-622-651-0,CCCCOC(=O)COc1cc(ccc1OCC(=O)OCCCC)C(=O)CNC(=O)c1sc2c(c1)CNCC2,CBR-HVAC-13699: GLYCOPROTEIN IIB/IIIA RECEPTOR ANTAGONIST; GPIIb-IIIa-antagonists; Inhibitors of Blood Coagulation Pathways; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; ANTIPLATELET; Antiplatelet Therapy; Thromboses; prodrug of CBR-HVAC-04734
CBR-001-622-652-1,RFM-008-215-5,CBR-001-622-652-1,CCc1nc2c(n1Cc1ccc(cc1)c1ccccc1C(=O)O)cc(cc2C)c1nc2n(c1)CCCC2,CBR-HVAC-04761: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-622-653-2,RFM-008-216-6,CBR-001-622-653-2,Cc1c2CC(Oc2c(c(c1N)C)C)(C)CN1CCC(CC1)c1ccccc1,"CBR-HVAC-04821: Suppression of aberrant dopamine release; Modulation of sodium ion influx; Inhibition of lipid peroxidation; Neuroprotectant; Antihypertensive; Antiischemic; Antioxidant; Ischemia, cerebral; Head injury; Hemorrhage; Stroke; CNS trauma; Edema, cerebral; Cerebrovascular disease"
CBR-001-622-654-3,RFM-008-217-7,CBR-001-622-654-3,CCCN(Cc1cnc(o1)c1ncn2c1CN(C)C(=O)c1c2ccc(c1)F)CCC,CBR-HVAC-04860: Antianxiety; Anxiolytic; Anxiety; Dementia; Major depressive disorder
CBR-001-622-655-4,RFM-008-218-8,CBR-001-622-655-4,O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)OS(=O)(=O)N,CBR-HVAC-04865: Estrogen agonist; Contraceptive; Contraception; Menopausal syndrome
CBR-001-622-656-5,RFM-008-219-9,CBR-001-622-656-5,Cc1nc2ccccn2c(=O)c1CCN1CCc2c(C1)c1ccccc1o2,CBR-HVAC-05091: Alpha-2A adrenergic receptor Antagonist; Antidepressant; Depression; Parkinson's disease
CBR-001-622-657-6,RFM-008-220-2,CBR-001-622-657-6,Fc1ccc(cc1)N1CCN(CC1)CCCN1CCC(c2c(C1=O)ccn2C)O,CBR-HVAC-05148: 5-HYDROXYTRYPTAMINE 2 RECEPTOR Antagonist; Blocker; Antiplatelet; Vasodilator; Anti-atherosclerotic; Coagulation disorder; Peripheral vascular disease
CBR-001-622-658-7,RFM-008-221-3,CBR-001-622-658-7,Fc1ccc(cc1)N1CCN(CC1)CCCN1CCC(c2c(C1=O)ccn2C)O,CBR-HVAC-05148: 5-HYDROXYTRYPTAMINE 2 RECEPTOR Antagonist; Blocker; Antiplatelet; Vasodilator; Anti-atherosclerotic; Coagulation disorder; Peripheral vascular disease
CBR-001-622-659-8,RFM-008-222-4,CBR-001-622-659-8,Cc1ccn(n1)c1ccc(c(c1)Cl)C(=O)N1Cc2cccn2Cc2c1cccc2,CBR-HVAC-05270: Vasopressin V2 receptor Agonist; Antidiuretic; Endocrine disease; Von Willebrand's disease; Urinary dysfunction; Diabetes insipidus
CBR-001-622-660-1,RFM-008-223-5,CBR-001-622-660-1,CC(=O)NCCOC(=O)C(c1ccc(cc1)Cl)Oc1cccc(c1)C(F)(F)F,CBR-HVAC-05310: Peroxisome proliferator-activated receptor gamma Modulator; Antidiabetic; Antihyperlipoproteinemic; Antirheumatic; Antilipemic; Diabetes
CBR-001-622-661-2,RFM-008-224-6,CBR-001-622-661-2,COC(=O)/C(=C/c1cc(OC)cc(c1)OC)/c1ccc(cc1)Oc1ccc(cc1)CC1SC(=O)NC1=O,CBR-HVAC-05361: PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Agonist; Antidiabetic; Non-insulin dependent diabetes
CBR-001-622-662-3,RFM-008-225-7,CBR-001-622-662-3,[O-][N+](=O)OCc1ccc(cc1)C(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,"CBR-HVAC-05466: Corticosteroid agonist; Antiinflammatory; Psoriasis, Dermatitis"
CBR-001-622-663-4,RFM-008-226-8,CBR-001-622-663-4,OC(=O)COc1cccc(c1)CN(S(=O)(=O)c1cccnc1)Cc1ccc(cc1)C(C)(C)C,CBR-HVAC-05707: Prostaglandin E receptor 2 Agonist; Antiosteoporotic; Osteoporosis
CBR-001-622-664-5,RFM-008-227-9,CBR-001-622-664-5,CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(=O)N)C(=O)C(=C(C1=O)C)Nc1ccc(cc1)O,CBR-HVAC-05778: DNA inhibitor
CBR-001-622-665-6,RFM-008-228-0,CBR-001-622-665-6,O=C(C(c1cccc(c1)C(=O)c1ccccc1)C)OCCCN1CCCCC1=O,CBR-HVAC-05908: Non-Steroidal Antiinflammatory Drugs (NSAIDs); Antiarthritic Drugs
CBR-001-622-666-7,RFM-008-229-1,CBR-001-622-666-7,CCC(Oc1cc(C)nc(c1C)Oc1c(C)cc(cc1C)C)CC,CBR-HVAC-06143: Corticotropin releasing hormone receptor 1 antagonist; Antidepressant; Major depressive disorder; Depression; Anxiety
CBR-001-622-667-8,RFM-008-230-4,CBR-001-622-667-8,COc1cc2c(cc1C(=O)N)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC=C2)C,CBR-HVAC-06178: Hypoxia-inducible factor 1 Inhibitor; Anticancer; Cancer
CBR-001-622-668-9,RFM-008-231-5,CBR-001-622-668-9,ONC(=O)c1ccc(cc1)C#CCNC(=O)c1cc2c([nH]1)ccc(c2)OCCN(C)C,CBR-HVAC-06222: HISTONE DEACETYLASE Inhibitor; Anticancer; Antiangiogenic; Solid tumors
CBR-001-622-669-0,RFM-008-232-6,CBR-001-622-669-0,CCN1CCC(CC1)c1cccc(c1F)S(=O)(=O)C,CBR-HVAC-06346: DOPAMINE RECEPTOR Modulator; Antidepressant; Antipsychotic; Bipolar disorder
CBR-001-622-670-3,RFM-008-233-7,CBR-001-622-670-3,O=C([C@@H](NP(=O)(Oc1ccccc1)OC[C@H]1O[C@H](C([C@@H]1O)(F)F)n1ccc(nc1=O)N)C)OCc1ccccc1,CBR-HVAC-06357: ; ANTI-CANCER; Pancreatic cancer
CBR-001-622-671-4,RFM-008-234-8,CBR-001-622-671-4,C/C(=C\CC(P(=O)([O-])[O-])(P(=O)([O-])[O-])C/C=C(/CCC=C(C)C)\C)/CCC=C(C)C,CBR-HVAC-06393: Apoptosis Inducers; Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitors
CBR-001-622-672-5,RFM-008-235-9,CBR-001-622-672-5,C#CCOc1ccc(cc1)Nc1nc(ncc1F)Nc1ccc(c(c1)S(=O)(=O)NC(=O)CC)C,CBR-HVAC-06487: Jak3 Inhibitors; Signal Transduction Modulators; Syk Kinase Inhibitors
CBR-001-622-673-6,RFM-008-236-0,CBR-001-622-673-6,N#Cc1ccc(c(c1)F)OCCN1CC2CN(CC(C1)O2)CCNC(=O)OC(C)(C)C,CBR-HVAC-06534: Antiarrhythmic; Antiarrhythmic; Arrhythmia
CBR-001-622-674-7,RFM-008-237-1,CBR-001-622-674-7,N#Cc1ccc(cc1)c1csc(n1)N1C(=O)OCC1(C)C,CBR-HVAC-06730: Progesterone receptor Antagonist; Antitumor; Uterine fibroid
CBR-001-622-675-8,RFM-008-238-2,CBR-001-622-675-8,OC(=O)COC/C=C/CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-06780: Histamine H1 receptor Antagonist; Anti-inflammatory; Seasonal and perennial allergic rhinitis; Urticaria
CBR-001-622-676-9,RFM-008-239-3,CBR-001-622-676-9,C#CCOc1ccc(cc1)Nc1nc(ncc1F)Nc1ccc(c(c1)S(=O)(=O)N)C,"CBR-HVAC-06786: Jak3 Inhibitors; Signal Transduction Modulators; Syk Kinase Inhibitors; Systemic Lupus Erythematosus, Agents for"
CBR-001-622-677-0,RFM-008-240-6,CBR-001-622-677-0,CC(NC1CN(C1)c1c(F)cc2c(c1C)n(cc(c2=O)C(=O)O)c1nc(N)c(cc1F)F)C,"CBR-HVAC-06829: ; ANTI-BACTERIAL; Infection, bacterial"
CBR-001-622-678-1,RFM-008-241-7,CBR-001-622-678-1,COc1cc(N)c(cc1C(=O)NCC1CCN(CC1)CCCn1ccnn1)Cl,"CBR-HVAC-07181: Signal Transduction Modulators; 5-HT4 Agonists; Irritable Bowel Syndrome, Agents for"
CBR-001-622-679-2,RFM-008-242-8,CBR-001-622-679-2,CCc1cc(ccc1n1nc(c2c1nccc2n1cnc(c1)c1cnn(c1)C)C(C)C)C(=O)N,CBR-HVAC-07272: Heat Shock Protein HSP 90-alpha (HSP90A; HSP86) Inhibitors; Heat Shock Protein HSP 90-beta (HSP90B; HSP84) Inhibitors
CBR-001-622-680-5,RFM-008-243-9,CBR-001-622-680-5,OC(=O)c1ccc(cc1)CN1CCC(CC1)CN[C@@H]1C[C@H]1c1ccccc1,CBR-HVAC-07344: Lysine-Specific Histone Demethylase 1A (KDM1A; LSD1) Inhibitors
CBR-001-622-681-6,RFM-008-244-0,CBR-001-622-681-6,CN(CCCN1C(=O)C2C(C1=O)[C@@H]1C[C@H]2C(C1)OC(=O)c1c[nH]c2c1cccc2)C,CBR-HVAC-07531: Sodium channel antagonist
CBR-001-622-682-7,RFM-008-245-1,CBR-001-622-682-7,CCCCC(=O)OCC(COC(=O)C(C)(C)C)C,CBR-HVAC-07630: GABA receptor agonist; Sodium channel antagonist
CBR-001-622-683-8,RFM-008-246-2,CBR-001-622-683-8,CCNCC1CCN(C1)c1c(F)cc2c(c1F)n(CC)cc(c2=O)C(=O)O,CBR-HVAC-07638: DNA topoisomerase II Inhibitor; Antibacterial; Bacterial infection
CBR-001-622-684-9,RFM-008-247-3,CBR-001-622-684-9,O=C(O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]1(C2=CC[C@H]2[C@@]1(C)CC[C@@]1([C@H]2C[C@](C)(CC1)C(=O)O)C)C)C)CCC(=O)O,CBR-HVAC-07721: Cytoprotective; Antiulcer; Ulcer
CBR-001-622-685-0,RFM-008-248-4,CBR-001-622-685-0,O[C@@H]1[C@@H](O)C(O[C@@H]([C@H]1O)C(=O)O)Oc1ccc2c3c1O[C@@H]1[C@@]43CCN([C@H](C2)[C@]4(O)CCC1=C)CC1CC1,CBR-HVAC-08073: Opioid receptor antagonist
CBR-001-622-686-1,RFM-008-249-5,CBR-001-622-686-1,CSC(=O)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-08438: Corticosteroid agonist; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-622-687-2,RFM-008-250-8,CBR-001-622-687-2,ClCSC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F,"CBR-HVAC-08773: Anti-inflammatory, steroidal"
CBR-001-622-688-3,RFM-008-251-9,CBR-001-622-688-3,Clc1ccc2c(c1)N(CCCN1CCC3(CC1)SCC(=O)N3)c1c(S2)cccc1,CBR-HVAC-08975: ; Antipsychotic; Psychosis
CBR-001-622-689-4,RFM-008-252-0,CBR-001-622-689-4,N=C(N1CCN(CC1)C(=N)NC(=N)Nc1ccc(cc1)Cl)NC(=N)Nc1ccc(cc1)Cl,"CBR-HVAC-09045: ; Antiseptic; Antibiotic; Infection, bacterial"
CBR-001-622-690-7,RFM-008-253-1,CBR-001-622-690-7,C/C=C(/C(=O)O[C@@H]1C[C@H]2CC[C@@H](C1)N2C)\C,"CBR-HVAC-09066: ; Antispasmodic; Spasm, muscular"
CBR-001-622-691-8,RFM-008-254-2,CBR-001-622-691-8,CCCCCCCCCC[N+](CCOC(=O)C12CC3CC(C2)CC(C1)C3)(C)C,CBR-HVAC-09139: ; Antiseptic; Skin diseases
CBR-001-622-692-9,RFM-008-255-3,CBR-001-622-692-9,COC(=O)N1C[C@H]([C@](C1)(C)C(=O)C)c1ccc(c(c1)OC1CCCC1)OC,"CBR-HVAC-09293: Phosphodiesterase 4 Inhibitor; Anti-inflammatory; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ARTHRITIS, RHEUMATOID; INFLAMMATORY DISEASE"
CBR-001-622-693-0,RFM-008-256-4,CBR-001-622-693-0,COC(=O)N1C[C@H]([C@](C1)(C)C(=O)C)c1ccc(c(c1)OC1CCCC1)OC,"CBR-HVAC-09293: Phosphodiesterase 4 Inhibitor; Anti-inflammatory; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ARTHRITIS, RHEUMATOID; INFLAMMATORY DISEASE"
CBR-001-622-694-1,RFM-008-257-5,CBR-001-622-694-1,CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)c(ccc2)C(=O)OC(OC(=O)C1C[C@@H]([C@H](C1)OC)O[N+](=O)[O-])C,CBR-HVAC-09508:
CBR-001-622-695-2,RFM-008-258-6,CBR-001-622-695-2,CN(CCc1c[nH]c2c1cc(O)cc2)C,CBR-HVAC-09735: 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 2 receptor Agonist; Antipsychotic; Psychosis
CBR-001-622-696-3,RFM-008-259-7,CBR-001-622-696-3,CC(Cc1ccccc1)NCCn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-09789: ; Sympathomimetic; Hyperkinesia; Narcolepsy
CBR-001-622-697-4,RFM-008-260-0,CBR-001-622-697-4,CCC(=O)C1(CCN(CC1)C)c1cccc(c1)O,"CBR-HVAC-09822: Opioid receptor mu Inhibitor; Narcotic; Analgesic; Antitussive; Pain, moderate to moderately severe; Diarrhea; Anti-tussive agent"
CBR-001-622-698-5,RFM-008-261-1,CBR-001-622-698-5,CC(=O)OC(c1ccccc1)(C(CN1CCCC1)C)Cc1ccccc1,CBR-HVAC-09917: ; Analgesic; Pain
CBR-001-622-699-6,RFM-008-262-2,CBR-001-622-699-6,O=C(C(c1ccccc1)c1ccccc1)OC(C1CCCCN1C)(C)C,"CBR-HVAC-09930: ; Local anesthetic; Anesthesia, local"
CBR-001-622-700-2,RFM-008-263-3,CBR-001-622-700-2,CCC(=O)N(c1ccccc1)C(CN1CCCCC1)C,CBR-HVAC-09995: Opioid receptor mu Agonist; Analgesic; Pain
CBR-001-622-701-3,RFM-008-264-4,CBR-001-622-701-3,ClCCCNC(Cc1ccccc1)C,CBR-HVAC-10148: Anorectic agent with little central stimulant activity; Anorectic; Obesity
CBR-001-622-702-4,RFM-008-265-5,CBR-001-622-702-4,OC(CC(c1ccccc1)c1ccccc1)CNC(C)C,"CBR-HVAC-10153: ; Antiarrhythmic; Arrhythmia, cardiac"
CBR-001-622-703-5,RFM-008-266-6,CBR-001-622-703-5,SCC(C(=O)NC(C(=O)O)Cc1ccc(cc1)c1nccs1)Cc1ccccc1,CBR-HVAC-10437: Endopeptidase; Angiotensin converting enzyme Inhibitor; Antihypertensive; Hypertension
CBR-001-622-704-6,RFM-008-267-7,CBR-001-622-704-6,CCCCc1nc2c(n1Cc1ccc(cc1)NC(=O)c1c(Cl)ccc(c1C(=O)O)Cl)cc(cc2)N(C(=O)NC)CCCCC,CBR-HVAC-10483: Angiotensin II receptor Antagonist; Antihypertensive; Heart failure; Hypertension
CBR-001-622-705-7,RFM-008-268-8,CBR-001-622-705-7,CCc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)nc(cc2C)C(=O)O,CBR-HVAC-10707: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-622-706-8,RFM-008-269-9,CBR-001-622-706-8,CN1Cc2c(ncn2c2c(C1=O)cccc2)c1noc(n1)C1CC1,CBR-HVAC-10729: Benzodiazepine receptor Agonist; Anxiolytic; Anticonvulsant; Epilepsy; Anxiety
CBR-001-622-707-9,RFM-008-270-2,CBR-001-622-707-9,OC(CN1CCCC1=O)CN1CCN(CC1)c1ccccc1,CBR-HVAC-10731: Histone deacetylase Inhibitor; Antiarrhythmic; Fungicide; Arrhythmia; Fungal infection
CBR-001-622-708-0,RFM-008-271-3,CBR-001-622-708-0,Cc1ccc(cc1)CC(=O)N([C@@H](C(=O)N[C@@H]1CCCC[C@@H]1NC(=O)c1c[nH]c2c1cccc2)Cc1ccc2c(c1)cccc2)C,CBR-HVAC-10792: Neurokinin receptor 1 Antagonist; Antiinflammatory; Tachykinin mediated respiratory tract inflammation
CBR-001-622-709-1,RFM-008-272-4,CBR-001-622-709-1,Cc1ccc(cc1)CC(=O)N([C@@H](C(=O)N[C@H]1CCCC[C@H]1NC(=O)c1c[nH]c2c1cccc2)Cc1ccc2c(c1)cccc2)C,CBR-HVAC-10792: Neurokinin receptor 1 Antagonist; Antiinflammatory; Tachykinin mediated respiratory tract inflammation
CBR-001-622-710-4,RFM-008-273-5,CBR-001-622-710-4,CCCN(C(=O)c1ccccc1)c1ccc2c(c1)c(=O)n(c(n2)CCC)Cc1ccc(cc1)c1ccccc1c1[nH]nnn1,CBR-HVAC-10860: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-622-711-5,RFM-008-274-6,CBR-001-622-711-5,CCCCc1nc(nn1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)CCCC,CBR-HVAC-10865: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-622-712-6,RFM-008-275-7,CBR-001-622-712-6,CCCN(c1ncccc1C(=O)O)Cc1ccc(cc1)c1ccccc1c1nnn[nH]1,CBR-HVAC-10914: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension
CBR-001-622-713-7,RFM-008-276-8,CBR-001-622-713-7,CC(C(=O)O)NC(=O)C(C(c1ccccc1)C)CSC(=O)c1ccccc1,"CBR-HVAC-10942: Angiotensin-I Converting Enzyme (ACE) Inhibitors; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors"
CBR-001-622-714-8,RFM-008-277-9,CBR-001-622-714-8,SCC(C(c1ccccc1)C)C(=O)NC(C(=O)O)C,"CBR-HVAC-04533: Angiotensin I converting enzyme inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Membrane metallo endopeptidase inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Hypertension, Treatment of"
CBR-001-622-715-9,RFM-008-278-0,CBR-001-622-715-9,SCC(C(c1ccccc1)C)C(=O)NC(C(=O)O)C,"CBR-HVAC-04533: Angiotensin I converting enzyme inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Membrane metallo endopeptidase inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Hypertension, Treatment of"
CBR-001-622-716-0,RFM-008-279-1,CBR-001-622-716-0,CCCCOC(=O)NS(=O)(=O)c1ccccc1c1ccc(cc1)Cn1c(CCCC)nc2c1nc(C)c(c2)NC(=O)CCCC,CBR-HVAC-10969: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-622-717-1,RFM-008-280-4,CBR-001-622-717-1,CN(CCN1c2ccc(cc2SC(C(C1=O)OC(=O)C)c1ccc(cc1)C)C)C,CBR-HVAC-10995: Calcium channel Antagonist; Antiplatelet; Antithrombotic; Peripheral vascular disease; Arteriosclerosis
CBR-001-622-718-2,RFM-008-281-5,CBR-001-622-718-2,Clc1nn(c(c1)c1ccc(cc1)S(=O)(=O)C)c1ccccc1,CBR-HVAC-11166: COX-2 Inhibitor; Antiinflammatory; Rheumatoid arthritis
CBR-001-622-719-3,RFM-008-282-6,CBR-001-622-719-3,O=C(NC1N=C(c2ccccc2)c2c(N(C1=O)CC(C)C)cccc2)Nc1cccc(c1)c1nnn[nH]1,CBR-HVAC-11211: Cholecystokinin B receptor Antagonist; Anxiolytic; Antipsychotic; Analgesic; Gastrointestinal disease; Anxiety; Pain; Schizophrenia
CBR-001-622-720-6,RFM-008-283-7,CBR-001-622-720-6,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)c1cncs1,CBR-HVAC-11270: Protein 30S ribosomal subunit Inhibitor; Antibacterial; Bacterial infection
CBR-001-622-721-7,RFM-008-284-8,CBR-001-622-721-7,CCCNC(C(=O)O)Cc1ccc(cc1)OCCc1nc(oc1C)c1ccccc1,CBR-HVAC-11430: Hypoglycemic; Hypoglycemic; Non-insulin dependent diabetes
CBR-001-622-722-8,RFM-008-285-9,CBR-001-622-722-8,O=C1N=c2n(C1(Cc1ccccc1)Cc1ccccc1)cccc2,CBR-HVAC-11438: Choline acetyltransferase Stimulator; Nootropic; Alzheimer's disease
CBR-001-622-723-9,RFM-008-286-0,CBR-001-622-723-9,Clc1cc(Cl)c2c(c1)[nH]c(c2/C=C(/c1ccccc1)\C(=O)O)C(=O)O,CBR-HVAC-11589: Ionotropic glutamate receptor NMDA Antagonist; NMDA receptor antagonist; Neuro disorders
CBR-001-622-724-0,RFM-008-287-1,CBR-001-622-724-0,Cc1cccnc1NS(=O)(=O)c1ccc(cc1)/N=N/c1ccc(c(c1)C(=O)O)O,CBR-HVAC-11624: Anti-inflammatory; Antiinflammatory; Inflammation
CBR-001-622-725-1,RFM-008-288-2,CBR-001-622-725-1,Fc1cccc(c1)Oc1cccc(c1)/C=C/C(N(C(=O)C)O)C,CBR-HVAC-11641: 15-Lipoxygenase Inhibitor; Antiasthmatic; Asthma
CBR-001-622-726-2,RFM-008-289-3,CBR-001-622-726-2,O=C(NC(C(=O)N[C@H]1CCCC[C@@H]1O)(Cc1c[nH]c2c1cccc2)C)OC1C2CC3CC1CC(C2)C3,CBR-HVAC-11662: Cholecystokinin B receptor Antagonist; Anxiolytic; Analgesic; Pain; Anxiety disorder
CBR-001-622-727-3,RFM-008-290-6,CBR-001-622-727-3,O=C(NC(C(=O)N[C@H]1CCCC[C@@H]1O)(Cc1c[nH]c2c1cccc2)C)OC1C2CC3CC1CC(C2)C3,CBR-HVAC-11662: Cholecystokinin B receptor Antagonist; Anxiolytic; Analgesic; Pain; Anxiety disorder
CBR-001-622-728-4,RFM-008-291-7,CBR-001-622-728-4,O=C([C@@H](c1ccc(cc1)S(=O)(=O)C1CC1)CC1CCOCC1)Nc1ncc(s1)F,CBR-HVAC-11703: Glucokinase Stimulator; Antidiabetic; Diabetes mellitus
CBR-001-622-729-5,RFM-008-292-8,CBR-001-622-729-5,O=C(NC(c1ccc(cn1)OCC(F)(F)F)C)Cc1ccc(cc1)C(C)C,CBR-HVAC-11839: T-TYPE CALCIUM CHANNEL Antagonist; Hypnotic; Schizophrenia
CBR-001-622-730-8,RFM-008-293-9,CBR-001-622-730-8,CO[C@H]1CN(CC[C@H]1NC(=O)c1cc(Cl)c(cc1OC)N)CCC(=O)Nc1cccc2c1cccn2,CBR-HVAC-11867: 5-hydroxytryptamine 4 receptor Agonist; Antispasmodic; Anticholinergic; GASTROESOPHAGEAL REFLUX DISEASE; DYSPEPSIA; IRRITABLE BOWEL SYNDROME
CBR-001-622-731-9,RFM-008-294-0,CBR-001-622-731-9,CO[C@@H]1CN(CC[C@@H]1NC(=O)c1cc(Cl)c(cc1OC)N)CCC(=O)Nc1cccc2c1cccn2,CBR-HVAC-11867: 5-hydroxytryptamine 4 receptor Agonist; Antispasmodic; Anticholinergic; GASTROESOPHAGEAL REFLUX DISEASE; DYSPEPSIA; IRRITABLE BOWEL SYNDROME
CBR-001-622-732-0,RFM-008-295-1,CBR-001-622-732-0,O=C(C=C1CCN(CC1)C(=O)c1ccc(nn1)C)N[C@@H]1CCN(C1)Cc1ccc2c(c1)ccc(c2)F,CBR-HVAC-11965: Chemokine CCR3 receptor; Histamine H1 Receptor Antagonist; Anti-inflammatory; INFLAMMATION; ALLERGY
CBR-001-622-733-1,RFM-008-296-2,CBR-001-622-733-1,CCCCc1cc(OC)c2c(c1OC(=O)C)cccc2,CBR-HVAC-11982: 5-Lipoxygenase Inhibitor; Anti-inflammatory; ASTHMA; INFLAMMATION
CBR-001-622-734-2,RFM-008-297-3,CBR-001-622-734-2,CCCCCN(C(=O)c1ccccc1)c1ccc2c(c1)c(=O)n(c(n2)CCC)Cc1ccc(cc1)c1ccccc1c1[nH]nnn1,"CBR-HVAC-14129: The true structure of L 159689 is controversial, see CBR-HVAC-10860 for another possible structure"
CBR-001-623-255-6,RFM-008-298-4,CBR-001-623-255-6,Oc1cc(ccc1c1ccc(nn1)OC1CC(C)(C)NC(C1)(C)C)c1c[nH]nc1,CBR-HVAC-07376: Survival Motor Neuron Protein (SMN1) Modulators
CBR-001-623-256-7,RFM-008-299-5,CBR-001-623-256-7,COc1cc(N)c(cc1C(=O)NCC1CCN(CC1)CCC(c1ccc(cc1)F)OC(=O)N)Cl,CBR-HVAC-08260: 5-HT4 Agonists; 5-HT4 Partial Agonists
CBR-001-623-257-8,RFM-008-300-1,CBR-001-623-257-8,COc1cc(N)c(cc1C(=O)NCC1CCN(CC1)CCC(c1ccc(cc1)F)OC(=O)N)Cl,CBR-HVAC-08260: 5-HT4 Agonists; 5-HT4 Partial Agonists
CBR-001-623-258-9,RFM-008-301-2,CBR-001-623-258-9,OC(=O)C(CC(=O)c1ccc(cc1)F)Cc1ccccc1,CBR-HVAC-07784: Insulin secretagogue
CBR-001-623-259-0,RFM-008-302-3,CBR-001-623-259-0,CCCc1c(OCc2ccc(cc2)C(c2cccc(c2)C(=O)O)O)ccc(c1O)C(=O)C,CBR-HVAC-06433: Leukotriene CysLT1 (LTD4) Antagonists; mgluR2 Agonists
CBR-001-623-260-3,RFM-008-303-4,CBR-001-623-260-3,CCCCCC(OC(=O)c1cccnc1)/C=C/n1cncc1,CBR-HVAC-08088: Thromboxane synthase inhibitor; Thromboxane A2 receptor antagonist; Thromboxane B2 receptor antagonist
CBR-001-623-261-4,RFM-008-304-5,CBR-001-623-261-4,COCCOC(=O)N1CCN([C@H](C1)C(=O)NO)S(=O)(=O)c1cc(F)c(c(c1)F)Oc1ccc(cc1)Cl,CBR-HVAC-06017: ADAM10 Inhibitors; Angiogenesis Inhibitors; MMP-2 (Gelatinase A) Inhibitors; Signal Transduction Modulators
CBR-001-623-262-5,RFM-008-305-6,CBR-001-623-262-5,CCN(CCNC(=O)c1cc(Cl)c(cc1OCCS(=O)(=O)C)N)CC,CBR-HVAC-14160: metabolite of CBR-HVAC-10523
CBR-001-623-263-6,RFM-008-306-7,CBR-001-623-263-6,CCN(CCNC(=O)c1cc(Cl)c(cc1OCCS(=O)C)N)CC,CBR-HVAC-10523: 5-Hydroxytryptamine 3 receptor antagonist; 5-Hydroxytryptamine 4 receptor agonist
CBR-001-623-264-7,RFM-008-307-8,CBR-001-623-264-7,C[C@H](C(=O)SC[C@H](C(=O)N1CCC[C@H]1C(=O)O)C)NC(=O)C1CCCCC1,CBR-HVAC-03225: Angiotensin I converting enzyme inhibitor
CBR-001-623-265-8,RFM-008-308-9,CBR-001-623-265-8,Clc1cc(ccc1Cl)c1[nH]c(nc1c1ccccc1)S(=O)(=O)C(C(F)F)(F)F,CBR-HVAC-07785: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-623-266-9,RFM-008-309-0,CBR-001-623-266-9,CN1CC[C@@]2([C@H]1N(C)c1c2cc(cc1)O)C,CBR-HVAC-14147: Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase inhibitor; Opioid receptor agonist; Opioid Analgesics; metabolite of CBR-HVAC-03810
CBR-001-623-267-0,RFM-008-310-3,CBR-001-623-267-0,CN1CCC(CC1)(C(=O)O)c1ccccc1,CBR-HVAC-13671: metabolite of CBR-HVAC-03091
CBR-001-623-268-1,RFM-008-311-4,CBR-001-623-268-1,OC(COc1ccc(c2c1C1CCC2CC1)O)CNC(C)(C)C,CBR-HVAC-05542: Beta adrenoreceptor antagonist
CBR-001-623-269-2,RFM-008-312-5,CBR-001-623-269-2,N[C@H]1CC[C@@H](c2c1cccc2)c1ccc(c(c1)Cl)Cl,CBR-HVAC-06428: Adrenergic transmitter uptake inhibitor; Dopamine reuptake inhibitor; 5 Hydroxytryptamine uptake inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor
CBR-001-623-270-5,RFM-008-313-6,CBR-001-623-270-5,COc1c(OC)cc(cc1C(=O)NCC1CCCN1C)S(=O)(=O)NC,CBR-HVAC-08386: Dopamine receptor antagonist
CBR-001-623-271-6,RFM-008-314-7,CBR-001-623-271-6,OCCN(C(=O)[C@H]1CN(C)[C@H]2C(C1)c1cccc3c1c(C2)c[nH]3)CCO,CBR-HVAC-14158: 5-HT2A Receptor Antagonists; Signal Transduction Modulators; Antiplatelet Therapy
CBR-001-623-272-7,RFM-008-315-8,CBR-001-623-272-7,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(=O)C(c1ccccc1)c1ccccc1,CBR-HVAC-09216: Anticholinergic
CBR-001-623-273-8,RFM-008-316-9,CBR-001-623-273-8,O=C([C@@H](N)C)N[C@H]1CCN(C1)c1nc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-04092: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-623-274-9,RFM-008-317-0,CBR-001-623-274-9,CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)O)CCCNC(=N)N)CC(C)C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)N)CCC(=O)O)CC(=O)N)CC(C)C)CCCNC(=N)N)C,CBR-HVAC-04651: Synthetic peptide mimicking certain regions of soluble human leukocyte antigen (sHLA) molecules;Arginyl-glutamyl-asparaginyl-leucyl-arginyl-isoleucyl-alanyl-leucyl-arginyl-tyrosine; Immunosuppressants
CBR-001-623-275-0,RFM-008-318-1,CBR-001-623-275-0,CCn1cc(C(=O)O)c(=O)c2c1cc(c(c2)F)n1cccc1,CBR-HVAC-03224: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-623-276-1,RFM-008-319-2,CBR-001-623-276-1,COC(=O)N1CCC(CC1)CN1CCC(CC1)CNC(=O)c1cccc2c1nc([nH]2)C(C)C,CBR-HVAC-00622: 5-Hydroxytryptamine 4 receptor Agonist; Nootropic; Cognitive disorder; Gastrointestinal motility disorders
CBR-001-623-277-2,RFM-008-320-5,CBR-001-623-277-2,N[C@H](Cc1cc(F)c(cc1F)F)CC(=O)N1CCNC(=O)[C@H]1COC(C)(C)C,CBR-HVAC-00752: DIPEPTIDYL PEPTIDASE 4 Inhibitor; Hypoglycemic agent; Antidiabetic; Type 2 diabetes mellitus
CBR-001-623-278-3,RFM-008-321-6,CBR-001-623-278-3,O=CN1CCc2c(C1)cccc2OCC(CNC(C)(C)C)O,CBR-HVAC-00905: BETA ADRENERGIC RECEPTOR Blocker; Antihypertensive; Hypertension
CBR-001-623-279-4,RFM-008-322-7,CBR-001-623-279-4,CN(CCCN1c2ccccc2C=Cc2c1cccc2)C,CBR-HVAC-00931: ; Antidepressant; Depression
CBR-001-623-280-7,RFM-008-323-8,CBR-001-623-280-7,Clc1ccc2c(n1)C(=NC(C(=O)N2)O)c1ccccc1Cl,CBR-HVAC-01191: ; Anxiolytic; Anxiety
CBR-001-623-281-8,RFM-008-324-9,CBR-001-623-281-8,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)Nc1nc2c(n1Cc1ccco1)nccc2,CBR-HVAC-01248: HISTAMINE H1 RECEPTOR Antagonist; ANTI-HISTAMINE; Allergic disorder
CBR-001-623-282-9,RFM-008-325-0,CBR-001-623-282-9,Clc1ccc2c(c1)C(=NCC(=O)N2CC1CC1)c1ccccc1F,CBR-HVAC-01877: Benzodiazepine receptor Agonist; Anxiolytic; Anxiety
CBR-001-623-283-0,RFM-008-326-1,CBR-001-623-283-0,Clc1ccc(cc1)OCCO/C(=C(\n1cncc1)/C)/c1ccc(cc1Cl)Cl,CBR-HVAC-02233: Lanosterol 14 alpha-demethylase Inhibitor; Ergosterol synthesis inhibitor; Antifungal; Lanosterol-14 demethylase inhibitor; Fungal infection
CBR-001-623-284-1,RFM-008-327-2,CBR-001-623-284-1,CCc1[nH]c(=O)[nH]c1C(=O)c1ccc(cc1)n1cncc1,CBR-HVAC-02738: cAMP phosphodiesterase type III Inhibitor; Inotropic; Vasodilator; Congestive heart failure
CBR-001-623-285-2,RFM-008-328-3,CBR-001-623-285-2,Cc1nn2c(c1C(=O)C1=CNCCC1)cccc2,CBR-HVAC-03219: COX Inhibitor; Antiplatelet; Thromboembolic disorder
CBR-001-623-286-3,RFM-008-329-4,CBR-001-623-286-3,COc1cc2c(cc1OC)CC(=NN=C2c1ccc(cc1)N)C,CBR-HVAC-03403: Benzodiazepine receptor; 5-Hydroxytryptamine 1A receptor Agonist; Antagonist; Anxiolytic; Anxiety disorder
CBR-001-623-287-4,RFM-008-330-7,CBR-001-623-287-4,Clc1ccc2c(n1)nc(cc2)N1C(CC(=O)N2CCC3(CC2)OCCO3)c2c(C1=O)cccc2,CBR-HVAC-03423: Benzodiazepine receptor Partial Agonist; Anxiolytic; Anxiety disorders
CBR-001-623-288-5,RFM-008-331-8,CBR-001-623-288-5,OCC(COc1ccc(cc1)CCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC)C)O,CBR-HVAC-03466: Calcium channel Antagonist; Antihypertensive; Hypertension
CBR-001-623-289-6,RFM-008-332-9,CBR-001-623-289-6,COC(=O)C1=C(C)NC(=C(C1c1cc(ccc1F)[N+](=O)[O-])C(=O)OCC(CN(Cc1ccccc1)C)(C)C)C,CBR-HVAC-03623: Calcium channel Antagonist; Antihypertensive; Vasodilator; Antianginal; Angina pectoris; Hypertension
CBR-001-623-290-9,RFM-008-333-0,CBR-001-623-290-9,Nc1ccc2c(c1)CN1C(=N2)c2c(C1=O)cccc2,CBR-HVAC-03726: DNA topoisomerase II; DNA topoisomerase I Inhibitor; Anticancer; Lymphoma; Cancer; Solid tumor
CBR-001-623-291-0,RFM-008-334-1,CBR-001-623-291-0,NC(=N)NCCCCCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)CC(=O)O,CBR-HVAC-04197: Integrin alpha2b beta3 Antagonist; Antiplatelet; Thromboembolism
CBR-001-623-292-1,RFM-008-335-2,CBR-001-623-292-1,C[C@@H]1NCCN(C1)c1c(F)cc2c(c1OC(F)F)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-04508: DNA topoisomerase II Inhibitor; Antibacterial; Bacterial infection
CBR-001-623-293-2,RFM-008-336-3,CBR-001-623-293-2,O=C(c1cc2n(n1)CCCN(C2=O)CCC1CCNCC1)NC[C@@H](C(=O)O)NS(=O)(=O)c1ccc(cc1)C,CBR-HVAC-04627: Integrin alpha2b beta3 Inhibitor; Antiischemic; Antithrombolytic; Thromboembolism; Cerebrovascular ischemia
CBR-001-623-294-3,RFM-008-337-4,CBR-001-623-294-3,NCCc1c[nH]c2c1cc(OCC(=O)N[C@H](C(=O)NCC(=O)N)Cc1ccc(cc1)O)cc2,CBR-HVAC-04765: 5-Hydroxytryptamine 1D receptor; 5-Hydroxytryptamine 1B receptor Agonist; Antimigraine; Migraine
CBR-001-623-295-4,RFM-008-338-5,CBR-001-623-295-4,COc1ccc(cc1CN[C@H]1CCCN[C@H]1c1ccccc1)n1nnnc1C(F)(F)F,CBR-HVAC-04832: Neurokinin receptor 1 Antagonist; Analgesic; Anti-inflammatory; Anti-emetic; Emesis; Inflammation; Migraine; Nausea
CBR-001-623-296-5,RFM-008-339-6,CBR-001-623-296-5,O=C(N1CCc2c1cc(c(c2)C)C(F)(F)F)Nc1ccc(nc1)OCc1ccccn1,CBR-HVAC-05014: 5-Hydroxytryptamine 1C receptor Inverse Agonist; Antidepressant; Anxiolytic; Anxiety; Depression
CBR-001-623-297-6,RFM-008-340-9,CBR-001-623-297-6,O=C(Nc1c(C)cccc1C)CN1CCN(CC1)[C@H]1CCN([C@@H](C1)Cc1ccccc1)C(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-05317: Neurokinin receptor 1 Antagonist; Analgesic; PAIN; ALLERGY; INFLAMMATION; EMESIS; ANXIETY, STRESS-INDUCED; ASTHMA"
CBR-001-623-298-7,RFM-008-341-0,CBR-001-623-298-7,O=CN([C@@H]([C@H]1COC(O1)(C)C)CS(=O)(=O)c1ccc(cc1)Oc1ccc(cc1)OC(F)(F)F)O,CBR-HVAC-05432: Matrix metalloproteinase Inhibitor; Anticancer; Solid tumors
CBR-001-623-299-8,RFM-008-342-1,CBR-001-623-299-8,CCN(C1CCCCC1)C/C=C\c1cc(Cl)c(c(c1)Cl)C1C2CC3CC1CC(C2)C3,CBR-HVAC-05476: Opioid receptor sigma Modulator; Anticancer; Anti-inflammatory; Cancer; Inflammation
CBR-001-623-300-4,RFM-008-343-2,CBR-001-623-300-4,COc1cccc(c1)c1oc(c(n1)CO[C@H]1CCC[C@H](C1)OCc1cccc(c1C(=O)O)C)C,CBR-HVAC-05892: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA Agonist; Agonist; Hypoglycemic; Type 2 diabetes mellitus
CBR-001-623-301-5,RFM-008-344-3,CBR-001-623-301-5,CN1C[C@@H]2[C@H](C1)N(CC2)c1ccc(cc1)c1ccc(cc1)n1ncccc1=O,CBR-HVAC-06653: Histamine H3 receptor Antagonist; Nootropic agent; Antipsychotic; Alzheimer's disease; Schizophrenia; Cognitive impairment
CBR-001-623-302-6,RFM-008-345-4,CBR-001-623-302-6,NCC(=O)N1CCn2c(C1(C)C)nc(c2Nc1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-07092: ; ANTI-MALARIAL; Malaria
CBR-001-623-303-7,RFM-008-346-5,CBR-001-623-303-7,CNC(=O)COc1cccc(c1)Nc1ncc(c(n1)Nc1ccc2c(c1)NC(=O)C(O2)(F)F)F,CBR-HVAC-08596: Spleen tyrosine kinase Inhibitor; Anti-inflammatory; Asthma
CBR-001-623-304-8,RFM-008-347-6,CBR-001-623-304-8,OCC(c1ccccc1)C(=O)OCC(CN(CC)CC)(C)C,CBR-HVAC-08851: ; Anticholinergic; Ulcer
CBR-001-623-305-9,RFM-008-348-7,CBR-001-623-305-9,OC(=O)C1CCN1C12CC3CC(C2)CC(C1)C3,CBR-HVAC-08927: ; Antiparkinsonian; Parkinson's disease
CBR-001-623-306-0,RFM-008-349-8,CBR-001-623-306-0,COc1ccc(cc1OC)CCN(CCOc1ccc(cc1N)NS(=O)(=O)C)C,CBR-HVAC-09439: POTASSIUM CHANNEL BLOCKER; ANTIARRHYTHMIC; CLASS III ANTIARRHYTHMIC; ARRHYTHMIA
CBR-001-623-307-1,RFM-008-350-1,CBR-001-623-307-1,COc1c(CC(=O)c2ccc(c(c2C(=O)O)OC)OC)c(CCN(C)C)cc2c1OCO2,CBR-HVAC-09961: ; Analgesic; Narcotic; Pain
CBR-001-623-308-2,RFM-008-351-2,CBR-001-623-308-2,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCC1COC2(O1)CCN(CC2)c1ccc(cc1)Cl)C,CBR-HVAC-10399: Calcium channel Blocker; Antihypertensive; Hypertension; Ischemic heart diseases
CBR-001-623-309-3,RFM-008-352-3,CBR-001-623-309-3,O=C(N[C@@H](CC(=O)O)CCc1c[nH]c2c1cccc2)CNC(=O)CCCC1CCNCC1,CBR-HVAC-10590: Integrin alpha2b beta3 Antagonist; Antithrombotic; Thromboembolism
CBR-001-623-310-6,RFM-008-353-4,CBR-001-623-310-6,Fc1ccc(cc1)C(c1ccc(cc1)F)OCCNCCc1ccccc1,CBR-HVAC-10649: Calcium channel Blocker; Cardioprotectant; Vasodilator; Angina pectoris; Myocardial ischemia
CBR-001-623-311-7,RFM-008-354-5,CBR-001-623-311-7,COc1ccc(cc1Cc1nc2ccc(cc2c(=O)n1CCN(C)C)OC(C)C)OC,CBR-HVAC-10655: Calcium channel Blocker; Antianginal; Vasodilator; Ischemic heart diseases
CBR-001-623-312-8,RFM-008-355-6,CBR-001-623-312-8,CCc1nc2ccc(cc2c(=O)n1Cc1ccc(cc1F)c1ccccc1S(=O)(=O)NC(=O)OCCC1CC1)NC(=O)N(C(C)C)C,CBR-HVAC-10981: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-623-313-9,RFM-008-356-7,CBR-001-623-313-9,N=C(c1cccs1)Nc1ccc(cc1)N1CCN(CC1)C(=O)[C@]1(C)CCc2c(O1)c(C)c(c(c2C)O)C,CBR-HVAC-11055: Neuronal nitric oxide synthase Inhibitor; Free radical scavenger; Neuroprotectant; Antioxidant; Cerebrovascular ischemia; Acute neurodegenerative disease
CBR-001-623-314-0,RFM-008-357-8,CBR-001-623-314-0,O=C(N(O)C)CCc1ccc2c(c1)Cc1ccccc1CO2,CBR-HVAC-11184: Lipoxygenase 5; COX Inhibitor; Antiinflammatory; Atopic dermatitis; Eczema; Psoriasis
CBR-001-623-315-1,RFM-008-358-9,CBR-001-623-315-1,CCCCc1nn(c(=O)n1Cc1ccc(cc1)c1ccccc1S(=O)(=O)NC(=O)OC(C)(C)C)c1cc(ccc1C(F)(F)F)NC(=O)CC,CBR-HVAC-11206: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-623-316-2,RFM-008-359-0,CBR-001-623-316-2,CCn1c(=O)cc(c2c1nc(C)cc2)c1cccc(c1)Br,CBR-HVAC-11439: Phosphodiesterase Inhibitor; Bronchodilator; Asthma
CBR-001-623-317-3,RFM-008-360-3,CBR-001-623-317-3,O=C1CCc2c(N1)nc(cc2)OCCCCN1CCN(CC1)c1cccc2c1cccc2,CBR-HVAC-11726: DOPAMINE RECEPTOR D2 Agonist; Antipsychotic; Bipolar disorder
CBR-001-623-318-4,RFM-008-361-4,CBR-001-623-318-4,CC(=O)COC(=O)/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C,CBR-HVAC-11770: Retinoid modulator; Retinoid modulator;
CBR-001-623-319-5,RFM-008-362-5,CBR-001-623-319-5,O=C(/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C)OCC(=O)C(C)(C)C,CBR-HVAC-11781: Retinoid modulator; Antiacne; Acne; Aging
CBR-001-623-320-8,RFM-008-363-6,CBR-001-623-320-8,OC(=O)CC[C@@H](C(=O)N[C@H](C(=O)O)Cc1c[nH]c2c1cccc2)N,CBR-HVAC-00432: Vascular endothelial growth factor receptor Antagonist; Anticancer; Antibacterial; Immunomodulator; Antiviral; Hepatitis C virus infection; Influenza virus infection; Melanoma; Prostate tumor; Bacterial infection; Cancer; Ovary tumor; Kaposis sarcoma; Colorectal tumor; Renal tumor
CBR-001-623-321-9,RFM-008-364-7,CBR-001-623-321-9,CCCC(C(=O)O)Oc1c(cccc1Cl)COc1ccc(cc1)OCc1ccc2c(n1)cccc2,CBR-HVAC-10584: Leukotriene D4 receptor Antagonist; Antiinflammatory; Asthma
CBR-001-623-322-0,RFM-008-365-8,CBR-001-623-322-0,CCCC(C(=O)O)Oc1c(cccc1Cl)COc1ccc(cc1)OCc1ccc2c(n1)cccc2,CBR-HVAC-10584: Leukotriene D4 receptor Antagonist; Antiinflammatory; Asthma
CBR-001-623-323-1,RFM-008-366-9,CBR-001-623-323-1,CN1CCCC1CCNC(=O)c1cn2c3cc4ccccc4cc3oc3c2c(c1=O)cc(c3N1CCC(C1)c1cnccn1)F,CBR-HVAC-00034: c-Myc Inhibitor; Anticancer; Cancer
CBR-001-623-324-2,RFM-008-367-0,CBR-001-623-324-2,Oc1ccc2c(c1)OC(C(=C2C)c1ccc(cc1)O)c1ccc(cc1)OCCN1CCCCC1,"CBR-HVAC-00835: Estrogen receptor Modulator; ANTI-CANCER¬ANTI-ESTROGENIC; Carcinoma, breast"
CBR-001-623-325-3,RFM-008-368-1,CBR-001-623-325-3,Oc1ccc2c(c1)OC(C(=C2C)c1ccc(cc1)O)c1ccc(cc1)OCCN1CCCCC1,"CBR-HVAC-00835: Estrogen receptor Modulator; ANTI-CANCER¬ANTI-ESTROGENIC; Carcinoma, breast"
CBR-001-623-326-4,RFM-008-369-2,CBR-001-623-326-4,CNCC(CC12CCC(c3c1cccc3)c1c2cccc1)O,CBR-HVAC-00952: ; Antidepressant; Depression
CBR-001-623-327-5,RFM-008-370-5,CBR-001-623-327-5,OC(COc1ccc(cc1)OCCOCCc1ccc(cc1)F)CNC(C)C,CBR-HVAC-01010: Beta-1 adrenergic receptor Blocker; Antiarrhythmic; Antihypertensive; Antianginal; Arrhythmia; Angina; Hypertension
CBR-001-623-328-6,RFM-008-371-6,CBR-001-623-328-6,OC[C@@H]([C@@H](c1ccccc1)O)NC(COc1ccccc1)C,CBR-HVAC-04133: Antiarrhythmic; Antiarrhythmic; Angina pectoris; Arrhythmia
CBR-001-623-329-7,RFM-008-372-7,CBR-001-623-329-7,OC[C@@H]([C@@H](c1ccccc1)O)NC(COc1ccccc1)C,CBR-HVAC-04133: Antiarrhythmic; Antiarrhythmic; Angina pectoris; Arrhythmia
CBR-001-623-330-0,RFM-008-373-8,CBR-001-623-330-0,COC[C@H]1CN(C(=O)O1)c1ccc(cc1)OCCC(C(F)(F)F)O,CBR-HVAC-04311: Monoamine oxidase A Inhibitor; Antidepressant; Anxiolytic; Smoking cessation; Depressive disorders; Anxiety
CBR-001-623-331-1,RFM-008-374-9,CBR-001-623-331-1,COC[C@H]1CN(C(=O)O1)c1ccc(cc1)OCCC(C(F)(F)F)O,CBR-HVAC-04311: Monoamine oxidase A Inhibitor; Antidepressant; Anxiolytic; Smoking cessation; Depressive disorders; Anxiety
CBR-001-623-332-2,RFM-008-375-0,CBR-001-623-332-2,c1ccc(cc1)C1=CCN(CC1)CC1CCC=C(C1)c1ccccc1,CBR-HVAC-04457: Dopamine receptor Agonist; Antipsychotic; Schizophrenia; Psychosis
CBR-001-623-333-3,RFM-008-376-1,CBR-001-623-333-3,c1ccc(cc1)C1=CCN(CC1)CC1CCC=C(C1)c1ccccc1,CBR-HVAC-04457: Dopamine receptor Agonist; Antipsychotic; Schizophrenia; Psychosis
CBR-001-623-334-4,RFM-008-377-2,CBR-001-623-334-4,N#Cc1ccc2c(c1)[C@@H](N(c1ccc(cc1)Cl)Cc1ncc[nH]1)[C@@H](C(O2)(C)C)O,"CBR-HVAC-04824: Cardiac mitochondrial ATP-sensitive potassium channel Opener; Vasodilator; Cardioprotective; Antianginal; Ischemia, myocardial"
CBR-001-623-335-5,RFM-008-378-3,CBR-001-623-335-5,CC(NC(=O)C[C@@H]1CCCN(c2c1cccc2)C(=O)c1ccc(cc1Cl)N1CCCC1)C,CBR-HVAC-05055: Vasopressin V2 receptor Agonist; Antidiuretic; Diabetes insipidus
CBR-001-623-336-6,RFM-008-379-4,CBR-001-623-336-6,O=C(Nc1c(C)cccc1C)CN1CCN(CC1)[C@@H]1CCN([C@H](C1)Cc1ccccc1)C(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-05317: Neurokinin receptor 1 Antagonist; Analgesic; PAIN; ALLERGY; INFLAMMATION; EMESIS; ANXIETY, STRESS-INDUCED; ASTHMA"
CBR-001-623-337-7,RFM-008-380-7,CBR-001-623-337-7,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCN(CC1)c1ccccn1,"CBR-HVAC-09316: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-623-338-8,RFM-008-381-8,CBR-001-623-338-8,OC[C@@]1(O)CC[C@]23C[C@H]1C[C@@H]2CC[C@@H]1[C@]3(C)CC[C@H]([C@@]1(C)CO)O,"CBR-HVAC-10454: DNA polymerase Inhibitor; Anticancer; Antiviral; Cancer; HSV infections; Infection, human immunodeficiency virus"
CBR-001-623-339-9,RFM-008-382-9,CBR-001-623-339-9,CCO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@@H]4[C@]2([C@H]([C@H]1C)CC[C@H]4C)OO3,"CBR-HVAC-00380: Antimalarial activity comparable to artemether and artesunate, and twice as potent as artemisinin, in animals with Plasmodium falciparum malaria.; Antimalarial; Malaria; Toxoplasmosis"
CBR-001-623-353-7,RFM-008-383-0,CBR-001-623-353-7,CSCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)CO)Cc1ccccc1)C(C)C)CCC(=O)N)CC(=O)O)NC(=O)[C@H]([C@H](CC)C)N,"CBR-HVAC-06359: Cancer Vaccines; Oligopeptides, less than 10 AA; Peptide Vaccines"
CBR-001-623-354-8,RFM-008-384-1,CBR-001-623-354-8,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)O)CCC(=O)N)CCCCN)CC(=O)N)CCCNC(=N)N)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)[C@H](Cc1ccccc1)N)Cc1ccccc1)Cc1ccc(cc1)O)CCC(=O)O)CC(C)C)CCC(=O)N)CCCNC(=N)N)CC(C)C)CCC(=O)N)CCC(=O)O,CBR-HVAC-12994: Motilin Receptor Agonists
CBR-001-623-355-9,RFM-008-385-2,CBR-001-623-355-9,O=C(N[C@H](C(=O)O)Cc1c[nH]c2c1cccc2)CC[C@H](C(=O)O)N,CBR-HVAC-14157: Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors
CBR-001-623-356-0,RFM-008-386-3,CBR-001-623-356-0,CCCCOC(=O)c1ccccc1Nc1cccc(c1)C(F)(F)F,CBR-HVAC-02281: Antiinflammatory Drugs
CBR-001-623-357-1,RFM-008-387-4,CBR-001-623-357-1,OCC(C(=O)NC(C(=O)N[C@@H](C(=O)NC(C(=O)NC(C(=O)N1CCCC1C(=O)NCC(=O)N)CCCNC(=N)N)CC(C)C)Cc1ccc2c(c1)cccc2)Cc1ccc(cc1)O)NC(=O)C(Cc1c[nH]c2c1cccc2)NC(=O)C(NC(=O)C1CCC(=O)N1)CC1N=CN=C1,CBR-HVAC-08072: Luteinizing hormone releasing hormone (LHRH) agonist
CBR-001-623-358-2,RFM-008-388-5,CBR-001-623-358-2,CCCCCCCCCCOc1cc(OCCCCCCCCCC)cc(c1)N(CC(=O)O)CC(=O)O,CBR-HVAC-10932: Phospholipase A2 inhibitor
CBR-001-623-359-3,RFM-008-389-6,CBR-001-623-359-3,COc1ccccc1N1CCN(CC1)CCCCNC(=O)c1ccc2c(c1)cccc2,CBR-HVAC-00541: Dopamine receptor D3 agonist; Dopamine receptor D3 antagonist
CBR-001-623-360-6,RFM-008-390-9,CBR-001-623-360-6,COC1C(O)[C@@H](O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]2[C@@H]3CC[C@]3([C@]2(O)CC[C@@H]3C2=CC(=O)OC2)C)C=O)OC([C@H]1O)C,CBR-HVAC-07219: Steroidal Saponins
CBR-001-623-382-2,RFM-008-391-0,CBR-001-623-382-2,CCCCCCCCNC1=[O][V]2(=O)(SCC1N)SCC(C(=[O]2)NCCCCCCCC)N,CBR-HVAC-02493:
CBR-001-623-383-3,RFM-008-392-1,CBR-001-623-383-3,CC(=O)O[Hg]c1cc(ccc1O)C(CC(C)(C)C)(C)C,CBR-HVAC-09138: Antiseptic
CBR-001-623-384-4,RFM-008-393-2,CBR-001-623-384-4,NCCCCNCCCN[C@H]1CC[C@]2([C@H](C1)C[C@H]([C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CC[C@H](C(C)C)OS(=O)(=O)O)C)C)O)C,CBR-HVAC-00646: Apoptosis stimulant; VEGFR antagonist; Growth factor antagonist; Integrin antagonist; Angiogenesis inhibitor; Na+/H+ Exchange Inhibitor; Calmodulin modulator
CBR-001-623-385-5,RFM-008-394-3,CBR-001-623-385-5,CO[C@@H]1[C@@H](CO)CC1n1cnc2c1nc(N)[nH]c2=O,analog of CBR-HVAC-13036:
CBR-001-623-386-6,RFM-008-395-4,CBR-001-623-386-6,C#CC[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C,CBR-HVAC-00143: ANTITUMOR
CBR-001-623-387-7,RFM-008-396-5,CBR-001-623-387-7,CCCCCCCCCCCCCCCC(=O)O[C@@H]1CC(=C(C(C1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C1=C(C)C[C@H](CC1(C)C)OC(=O)CCCCCCCCCCCCCCC)\C)\C)/C)/C)C,CBR-HVAC-04997: Antioxidants
CBR-001-623-393-5,RFM-008-397-6,CBR-001-623-393-5,O=C([C@@H]1CCCCN1C(=O)N1CCS(=O)(=O)CC1)Nc1noc(c1)C(C)(C)C,CBR-HVAC-12324: Cannabinoid CB2 receptor agonist
CBR-001-623-394-6,RFM-008-398-7,CBR-001-623-394-6,Fc1cccc(c1C1SCc2n1c1ccccc1n2)F,CBR-HVAC-04318: Reverse Transcriptase Inhibitors
CBR-001-623-395-7,RFM-008-399-8,CBR-001-623-395-7,CC(c1onc(c1COc1ccc(cc1)c1ccc2c(c1)cccc2C(=O)O)c1c(Cl)cccc1Cl)C,CBR-HVAC-12245: Farnesoid X Receptor agonist
CBR-001-623-396-8,RFM-008-400-4,CBR-001-623-396-8,O=C(Nc1cccc(c1)c1cocc1)COCC(=O)Nc1ccc(cc1C(=O)O)Cl,CBR-HVAC-12224: Plasminogen Activator Inhibitor (PAI-1) Inhibitors
CBR-001-623-397-9,RFM-008-401-5,CBR-001-623-397-9,O=C(NNS(=O)(=O)c1ccc(s1)CNC(=O)c1ccc(cc1)Cl)CCCNc1ncc(cc1Cl)C(F)(F)F,CBR-HVAC-12285: JNK inhibitor
CBR-001-623-398-0,RFM-008-402-6,CBR-001-623-398-0,Clc1ccc(cc1)C(=O)NCc1ccc(s1)S(=O)(=O)N1CCC(CC1)n1nnc2c1cccc2,CBR-HVAC-12286: JNK modulator; JNK2 inhibitor; JNK3 inhibitor
CBR-001-623-399-1,RFM-008-403-7,CBR-001-623-399-1,CCN(CCCC(Nc1cc(OC)cc2c1nccc2)C)CC,CBR-HVAC-12306:
CBR-001-623-400-7,RFM-008-404-8,CBR-001-623-400-7,O[C@H]1O[C@@H]2OC3(C)CC[C@@H]4[C@@]2([C@H]([C@H]1C)CC[C@H]4C)OO3,CBR-HVAC-12293: Antimalarial;Angiogenesis Inhibitors; Apoptosis Inducers; Cytochrome P450 CYP1A2 Inhibitors
CBR-001-623-401-8,RFM-008-405-9,CBR-001-623-401-8,OCCNC(=O)CCCCCCCC(=O)NCCO,"CBR-HVAC-12210: Adelmidrol, a synthetic aliamide derived from palmitoylethanolamide (PEA), had been in early clinical trials at Innovet for the treatment of atopic dermatitis in a topical emulsion formulation"
CBR-001-623-402-9,RFM-008-406-0,CBR-001-623-402-9,Clc1ccc(cc1)C1CC(=NN1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1,CBR-HVAC-12227:  Appetite suppressant; Cannabinoid receptor 1 antagonist; TNF alpha antagonist; IL-2 antagonist; Metabolic modulator
CBR-001-623-403-0,RFM-008-407-1,CBR-001-623-403-0,O=C1NCN(C1)C(=O)c1cc(n(n1)c1ccc(c(c1)Cl)F)c1cc(F)cc(c1)Cl,CBR-HVAC-07115: Reverse Transcriptase Inhibitors
CBR-001-623-404-1,RFM-008-408-2,CBR-001-623-404-1,Fc1cc(Cl)cc(c1)c1cc(nn1c1ccc(c(c1)Cl)F)C(=O)N,metabolite of CBR-HVAC-07115
CBR-001-623-654-7,RFM-008-409-3,CBR-001-623-654-7,O=n1cc(Cl)c(c(c1)Cl)C[C@@H](c1ccc(c(c1)OCC1CC1)OC(F)F)OC(=O)c1ccc(c(c1)OCC1CC1)NS(=O)(=O)C,CBR-HVAC-07199: Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators
CBR-001-623-655-8,RFM-008-410-6,CBR-001-623-655-8,CCCC(=O)N(Cc1c(nc2n1cccc2)c1ccc(cc1)Cl)C,CBR-HVAC-04026: Anxiolytics
CBR-001-623-656-9,RFM-008-411-7,CBR-001-623-656-9,O/N=C(/c1ccc(nn1)N1CCC(CC1)Oc1ccccc1)\N,CBR-HVAC-08328: Acyl CoA desaturase-1 inhibitor
CBR-001-623-657-0,RFM-008-412-8,CBR-001-623-657-0,O=C1OCC2=C1CC[C@]1([C@H]2C[C@H]2[C@@]3([C@@]41O[C@H]4[C@@H]1O[C@@]1([C@H]3OCOP(=O)([O-])[O-])C(C)C)O2)C,CBR-HVAC-07068: Angiogenesis Inhibitors;Heat Shock Protein 70 (hsp70) Inhibitors;2018-01-24: ARB# 18-000013
CBR-001-623-658-1,RFM-008-413-9,CBR-001-623-658-1,NC(C(=O)NCCCN1CCN(CC1)CCCNC(=O)C(CCCNC(=N)N)N)CCCNC(=N)N,CBR-HVAC-07312: Heparin Neutralizers
CBR-001-623-659-2,RFM-008-414-0,CBR-001-623-659-2,O=C(Cc1ccccc1)N[C@H](C(=O)N)CCC(=O)O,CBR-HVAC-03435:
CBR-001-623-660-5,RFM-008-415-1,CBR-001-623-660-5,COc1ccc(cc1Nc1cccc(n1)N(c1ccc2c(c1)[nH]nc2C)C)S(=O)(=O)CC,CBR-HVAC-14327: analog of CBR-HVAC-11559
CBR-001-623-661-6,RFM-008-416-2,CBR-001-623-661-6,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1[nH]cc(n1)c1ccc2c(c1)ccc(c2)c1ccc2c(c1)nc([nH]2)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)C(C)C,CBR-HVAC-07125:  non-structural 5A (NS5A) protein of hepatitis C virus (HCV) inhibitor
CBR-001-623-662-7,RFM-008-417-3,CBR-001-623-662-7,N[C@@H]1CC[C@H](c2c1cccc2)c1ccc(c(c1)Cl)Cl,CBR-HVAC-06428: Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors
CBR-001-623-663-8,RFM-008-418-4,CBR-001-623-663-8,CN(C[C@@H]1CCCC[C@@]1(O)c1cccc(c1)O)C,CBR-HVAC-07020: mu-Opioid Agonists;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators
CBR-001-623-664-9,RFM-008-419-5,CBR-001-623-664-9,CN(C[C@H]1CCCC[C@]1(O)c1cccc(c1)O)C,CBR-HVAC-07020: mu-Opioid Agonists;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators
CBR-001-623-665-0,RFM-008-420-8,CBR-001-623-665-0,COc1cc(O)c(c(c1C(=O)/C=C/c1ccc(cc1)O)O)CC=C(C)C,CBR-HVAC-14130: Angiogenesis Inhibitors;Antioxidants;Apoptosis Inducers;Aromatase Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors
CBR-001-623-666-1,RFM-008-421-9,CBR-001-623-666-1,O[C@@H]1CC[C@H](CC1)N(c1cc(sc1C(=O)O)c1ccccc1)C(=O)C1CCC(CC1)C,CBR-HVAC-11751: Non-nucleoside NS5 polymerase inhibitor
CBR-001-623-667-2,RFM-008-422-0,CBR-001-623-667-2,OCc1cccc(c1O)Cc1c[nH]cn1,CBR-HVAC-10764: Antianginal; Antianginal; Angina pectoris
CBR-001-623-668-3,RFM-008-423-1,CBR-001-623-668-3,Clc1cc(ccc1C(=O)N1C[C@H]2COCCN2Cc2c1cccc2)NC(=O)c1ccccc1c1ccccc1,CBR-HVAC-00461: Arginine vasopressin receptor 1A; Arginine vasopressin receptor 2 Antagonist; Antihypertensive; Diuretic; Edema; Cardiac failure; Hypertension; Hyponatremia; Renal disease
CBR-001-623-669-4,RFM-008-424-2,CBR-001-623-669-4,CC[C@@](c1ccccc1)(C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1,CBR-HVAC-08905: ; Antiparkinsonian; Parkinson's disease
CBR-001-623-670-7,RFM-008-425-3,CBR-001-623-670-7,N[C@@H]1CC[C@H](CC1)CNC(=O)[C@@H]1CCCN1C(=O)C1(O)c2ccccc2c2c1cccc2,CBR-HVAC-11215: Thrombin Inhibitor; Antithrombotic; Thrombosis
CBR-001-623-671-8,RFM-008-426-4,CBR-001-623-671-8,OC(=O)C[C@@H]1Nc2ccc(cc2CN(C1=O)C)C(=O)N1CCC(CC1)C1CCNCC1,CBR-HVAC-04758: Integrin alpha2b beta3 Antagonist; Antithrombotic; Thrombosis
CBR-001-623-672-9,RFM-008-427-5,CBR-001-623-672-9,COc1ccc(cc1N1CCN(CC1)CCCNc1nccc(n1)C(=O)N)Cl,CBR-HVAC-04470: Alpha-1 adrenergic receptor Antagonist; Alpha-1 adrenergic receptor antagonist; Benign prostate hyperplasia hypertrophy
CBR-001-623-673-0,RFM-008-428-6,CBR-001-623-673-0,COc1ccc2c(c1)n(C)c(n2)COc1ccc(cc1)CC1SC(=O)NC1=O,CBR-HVAC-05261: Peroxisome proliferator activated receptor gamma Agonist; Hypoglycemic; Type 2 diabetes mellitus; Dry eye syndrome
CBR-001-623-674-1,RFM-008-429-7,CBR-001-623-674-1,CCCCCN(C(=O)NCCCc1ccncc1)CCC12CC3CC(C2)CC(C1)C3,CBR-HVAC-00450: TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 Agonist; ANTI-INFLAMMATORYIMMUNOMODULATOR; Inflammation
CBR-001-623-675-2,RFM-008-430-0,CBR-001-623-675-2,CNC(=O)c1ncn(c1)c1nnc(c2c1cnc1c2cnn1CC)NCc1ccc(c(c1)Cl)OC,CBR-HVAC-05426: Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor; ERECTILE DYSFUNCTION
CBR-001-623-676-3,RFM-008-431-1,CBR-001-623-676-3,OB(CCCCCn1cnc2c1nc(N)nc2Cl)O,CBR-HVAC-12208: TNF alpha Inhibitor; Antibacterial; Antiviral; Immunomodulator; HIV-1 infection; Mycobacterium tuberculosis infection; Osteoarthritis; Psoriasis; Rheumatoid arthritis; Asthma; Crohn's disease
CBR-001-623-677-4,RFM-008-432-2,CBR-001-623-677-4,CN[C@H](C/C=C/c1cncc(c1)OC(C)C)C,CBR-HVAC-00314: Nicotinic acetylcholine receptor alpha4 beta2 Partial Agonist; Nootropic; Neuroprotectant; Mild cognitive impairment; Age-associated memory impairment; Dementia
CBR-001-623-678-5,RFM-008-433-3,CBR-001-623-678-5,CCOC(=O)C1=C(C)NC(=C(C1c1cccnc1SC)C(=O)OCC)C,CBR-HVAC-01079: Calcium channel Blocker; Vasodilator; Hypertension; Angina pectoris
CBR-001-623-679-6,RFM-008-434-4,CBR-001-623-679-6,COc1cc(Cc2cnc(nc2N)N)cc(c1N(C)C)OC,"CBR-HVAC-01133: Dihydrofolate reductase Inhibitor; Antibiotic; Infection, microbial"
CBR-001-623-680-9,RFM-008-435-5,CBR-001-623-680-9,CC(NC1CCC(CC1)(c1ccccc1)c1ccccc1)C,"CBR-HVAC-01539: ; Antispasmodic; Spasm, muscular"
CBR-001-623-681-0,RFM-008-436-6,CBR-001-623-681-0,CCOC(=O)Oc1ccc(cc1OC)/C=C/C=C/C(=O)NCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,CBR-HVAC-03603: Lipoxygenase 5 Inhibitor; Antiallergic; Anti-inflammatory; Asthma
CBR-001-623-682-1,RFM-008-437-7,CBR-001-623-682-1,OCC(N(C)C)(Cc1ccc(c(c1)Cl)Cl)C,CBR-HVAC-03632: 5-Hydroxytryptamine transporter Inhibitor; Antidepressant; Anxiolytic; Anxiety; Panic disorders; Obsessive compulsive disorders; Alcoholism
CBR-001-623-683-2,RFM-008-438-8,CBR-001-623-683-2,COc1cc2c(cc1OC)CC(=NN=C2c1cccc(c1)Cl)C,CBR-HVAC-03683: Benzodiazepine receptor Antagonist; Anxiolytic; Antidepressant; Anxiety; Depression
CBR-001-623-684-3,RFM-008-439-9,CBR-001-623-684-3,COc1cc2oc(=O)c(c(c2cc1OCCCN1CCN(CC1)c1ccccc1OC)C)C,CBR-HVAC-04629: Acetylcholinesterase Inhibitor; Nootropic; Alzheimer's disease
CBR-001-623-685-4,RFM-008-440-2,CBR-001-623-685-4,N#Cc1ccc2c(c1)[C@H](N(c1ccc(cc1)Cl)Cc1ncc[nH]1)[C@H](C(O2)(C)C)O,"CBR-HVAC-04824: Cardiac mitochondrial ATP-sensitive potassium channel Opener; Vasodilator; Cardioprotective; Antianginal; Ischemia, myocardial"
CBR-001-623-686-5,RFM-008-441-3,CBR-001-623-686-5,COc1cc2cc(oc(=O)c2c(c1)O)C(C(=O)O)C,CBR-HVAC-04880: Vascular endothelial growth factor receptor Inhibitor; Anti-arthritis; Anticancer; Cancer; Arthritis
CBR-001-623-687-6,RFM-008-442-4,CBR-001-623-687-6,OC(=O)C(CCCCOCCCCC(C(=O)O)(C)C)(C)C,CBR-HVAC-04881: Lipoprotein A Antagonist; Antihypercholesterolemic; Hypercholesterolemia; Atherosclerosis
CBR-001-623-688-7,RFM-008-443-5,CBR-001-623-688-7,COCCN([C@@H](C(=O)Oc1c(OC)cc(cc1OC)C)CC)CCOC,CBR-HVAC-05424: GABA-A receptor Modulator; Anesthetic; Anesthesia
CBR-001-623-689-8,RFM-008-444-6,CBR-001-623-689-8,C=CCNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@H]([C@@H](NC(=O)c1cccc(c1C)O)Cc1ccccc1)O,CBR-HVAC-05920: PROTEASE INHIBITOR; ANTIVIRAL; HIV-1 INFECTION
CBR-001-623-690-1,RFM-008-445-7,CBR-001-623-690-1,NC/C(=C\1/CCCN(C1)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1)/F,"CBR-HVAC-06835: TOPOISOMERASE IV Inhibitor; ANTIBIOTIC; Pneumonia, community-acquired"
CBR-001-623-691-2,RFM-008-446-8,CBR-001-623-691-2,COc1cc2c(cc1OC)CCC(C2=O)CN1CCC(CC1)(O)c1ccccc1,CBR-HVAC-07779: Antipsychotic; Antipsychotic; Psychosis
CBR-001-623-692-3,RFM-008-447-9,CBR-001-623-692-3,Clc1cccc(c1)N1CCN(C1=O)CCN1CC(C1)(C)C,CBR-HVAC-08555: Dopamine receptor D2 Antagonist; Antipsychotic; Psychosis
CBR-001-623-693-4,RFM-008-448-0,CBR-001-623-693-4,N#Cc1ccc(cc1)Nc1nc(Oc2c(C)cc(cc2C)C#N)c2c(n1)[nH]cc2,"CBR-HVAC-08584: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE Inhibitor; Antiviral; Infection, human immunodeficiency virus"
CBR-001-623-694-5,RFM-008-449-1,CBR-001-623-694-5,OCc1cc(N)cc(c1)C(CNC(Cc1ccc(cc1)O)C)O,CBR-HVAC-10879: Beta-2 adrenergic receptor Agonist; Antiasthmatic; Asthma
CBR-001-623-695-6,RFM-008-450-4,CBR-001-623-695-6,CCC1(OCCc2c1[nH]c1c2cc(cc1CC)OCc1ccc2c(n1)cccc2)CC(=O)O,CBR-HVAC-10935: Lipoxygenase 5 Inhibitor; Antiallergy; Antiasthamatic; Anti-inflammatory; Asthma; Inflammatory diseases
CBR-001-623-696-7,RFM-008-451-5,CBR-001-623-696-7,CCOc1cccc(c1)C(n1nc(c2c1c1ccc(cc1CC2)OCc1cncnc1)C(=O)O)CC,CBR-HVAC-11114: Endothelin B receptor; Endothelin A receptor Antagonist; Antiarteriosclerotic; Reperfusion injury; Atherosclerosis; Vascular disease
CBR-001-623-697-8,RFM-008-452-6,CBR-001-623-697-8,OCC(=O)N1CCC(CC1)Oc1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,CBR-HVAC-11154: Protein synthesis inhibitor; Antibacterial; Gram-positive infections
CBR-001-623-698-9,RFM-008-453-7,CBR-001-623-698-9,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1Cc2c(C1)ccnc2,CBR-HVAC-11156: Protein synthesis inhibitor; Antibacterial; Bacterial infection
CBR-001-623-699-0,RFM-008-454-8,CBR-001-623-699-0,COc1ccccc1N1CCN(CC1)CCC(c1csc2c1cccc2)O,CBR-HVAC-11459: 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine transporter Antagonist; Inhibitor; Antidepressant; Depression; Major depressive disorder
CBR-001-623-700-6,RFM-008-455-9,CBR-001-623-700-6,COc1ccc(cc1F)c1c(Cl)ncn1c1ccc(cc1)S(=O)(=O)NP(=O)(O)O,CBR-HVAC-11904: Cyclooxygenase 2 Inhibitor; Analgesic; Non-steroidal anti-inflammatory; Pain
CBR-001-623-701-7,RFM-008-456-0,CBR-001-623-701-7,Fc1ccc(cc1)C(=C1CCN(CC1)CCc1c(C)nc2n(c1=O)cccc2)c1ccc(cc1)F,CBR-HVAC-03234: 5-HYDROXYTRYPTAMINE 2A RECEPTOR Antagonist; SLEEP PROMOTOR; Sleep disorder
CBR-001-623-702-8,RFM-008-457-1,CBR-001-623-702-8,Clc1ccc2c(c1)c(CCCc1ccc(cc1)C(=O)O)c(n2C(c1ccccc1)c1ccccc1)CCNS(=O)(=O)Cc1ccc(c(c1)Cl)Cl,CBR-HVAC-06030: Cytosolic phospholipase A2 Inhibitor; Antiarteriosclerotic; Analgesic; Anti-inflammatory; Osteoarthritis; Rheumatoid arthritis; Pain
CBR-001-623-703-9,RFM-008-458-2,CBR-001-623-703-9,O=C1N=c2n(C31Cc1c(C3)cccc1)cccc2,CBR-HVAC-00528: Acetylcholine release stimulator; Nootropic; Cognition disorder
CBR-001-623-704-0,RFM-008-459-3,CBR-001-623-704-0,Cc1cccc(c1)N1CCN(CC1)CCc1ccc2c(n1)cccc2,CBR-HVAC-02989: 5-Hydroxytryptamine transporter Inhibitor; Antihypertensive; Hypertension
CBR-001-623-705-1,RFM-008-460-6,CBR-001-623-705-1,CC(=CCN1Cc2cc(Cl)cc3c2n(C[C@@H]1C)c(=S)[nH]3)C,CBR-HVAC-04011: Reverse transcriptase Inhibitor; Anti-HIV; HIV infection
CBR-001-623-706-2,RFM-008-461-7,CBR-001-623-706-2,COc1ccccc1CN(C(=O)C)C[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)CN1CCC(CC1)N1CCCCC1,CBR-HVAC-04725: Neurokinin receptor 1 Antagonist; Analgesic; Anti-inflammatory; Migraine; Neuropathic pain
CBR-001-623-707-3,RFM-008-462-8,CBR-001-623-707-3,OCCNC(=O)c1c(O)c2ncc(cc2n(c1=O)C)Cc1ccc(cc1)F,CBR-HVAC-06410: HIV 1 integrase Inhibitor; Antiviral; HIV infection
CBR-001-623-708-4,RFM-008-463-9,CBR-001-623-708-4,ClCCN(c1cccc(c1)CC(C(=O)O)N)CCCl,CBR-HVAC-08714: ; Antineoplastic; Cancer
CBR-001-623-709-5,RFM-008-464-0,CBR-001-623-709-5,O=C(Nc1ccccc1)OCC1(CCCC1)COC(=O)Nc1ccccc1,CBR-HVAC-08899: ; Anxiolytic; Anxiety
CBR-001-623-710-8,RFM-008-465-1,CBR-001-623-710-8,CCN(CCC1(c2ccccc2)C(=O)Oc2c1cccc2)CC,"CBR-HVAC-09910: ; Local anesthetic; Anesthesia, local"
CBR-001-623-711-9,RFM-008-466-2,CBR-001-623-711-9,O/N=C\1/C(=O)Nc2c1cc(c1c2CCCC1)S(=O)(=O)N(C)C,CBR-HVAC-11080: Ionotropic glutamate receptor AMPA Antagonist; Antiepileptic; Epilepsy
CBR-001-623-712-0,RFM-008-467-3,CBR-001-623-712-0,CCOC(=O)C1=C(CN(CC(NCC(COc2ccccc2OC)O)(C)C)C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCC)C,CBR-HVAC-11607: Beta adrenergic receptor; Calcium channel Antagonist; Blocker; Antianginal; Antihypertensive; Hypertension; Ischemic heart diseases; Angina
CBR-001-623-713-1,RFM-008-468-4,CBR-001-623-713-1,OC(=O)[C@H](c1ccc2c(c1)ccc(c2)OCc1ccc2c(n1)cccc2)C,CBR-HVAC-04024: Lipoxygenase 5 Inhibitor; Anti-inflammatory; Immunosuppressant; Arthritis; Asthma; Psoriasis
CBR-001-623-714-2,RFM-008-469-5,CBR-001-623-714-2,OC(=O)Cc1ccc2c(c1)CC(C2)CNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-04736: Thromboxane A2 receptor Antagonist; Thromboxane A2 receptor antagonist; Asthma; Thrombosis; Myocardial infarction
CBR-001-623-715-3,RFM-008-470-8,CBR-001-623-715-3,O=C(Nc1ccc(cc1Cl)C(=O)O)CSc1nnc(n1c1ccc(c2c1cccc2)C1CC1)Br,"CBR-HVAC-06529: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE Inhibitor; HIV replication inhibitor; Infections, HIV"
CBR-001-623-716-4,RFM-008-471-9,CBR-001-623-716-4,CCOC(=O)CN(Cc1ccccc1O)CCN(Cc1ccccc1O)CC(=O)O,CBR-HVAC-11427: Chelating agent; Chelating agent; Iron overload
CBR-001-623-717-5,RFM-008-472-0,CBR-001-623-717-5,Clc1ccc(cc1)OCCO/C(=C(/n1cncc1)\C)/c1ccc(cc1Cl)Cl,CBR-HVAC-02233: Lanosterol 14 alpha-demethylase Inhibitor; Ergosterol synthesis inhibitor; Antifungal; Lanosterol-14 demethylase inhibitor; Fungal infection
CBR-001-623-718-6,RFM-008-473-1,CBR-001-623-718-6,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCCNC[C@@H](COc1ccccc1)O)C,CBR-HVAC-04025: Beta adrenergic receptor Antagonist; Antihypertensive; Antiangina; Angina; Hypertension
CBR-001-623-719-7,RFM-008-474-2,CBR-001-623-719-7,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCCNC[C@@H](COc1ccccc1)O)C,CBR-HVAC-04025: Beta adrenergic receptor Antagonist; Antihypertensive; Antiangina; Angina; Hypertension
CBR-001-623-720-0,RFM-008-475-3,CBR-001-623-720-0,Fc1ccc(cc1)C(C(n1cncc1)C)(c1ccc(cc1)F)O,CBR-HVAC-10933: Cytochrome P450 reductase Inhibitor; Antipsoriatics; Anti-inflammatory; Dermatitis; Psoriasis; Inflammatory disorder
CBR-001-623-721-1,RFM-008-476-4,CBR-001-623-721-1,Fc1ccc(cc1)C(C(n1cncc1)C)(c1ccc(cc1)F)O,CBR-HVAC-10933: Cytochrome P450 reductase Inhibitor; Antipsoriatics; Anti-inflammatory; Dermatitis; Psoriasis; Inflammatory disorder
CBR-001-623-722-2,RFM-008-477-5,CBR-001-623-722-2,COCCN([C@H](C(=O)Oc1c(OC)cc(cc1OC)C)CC)CCOC,CBR-HVAC-05424: GABA-A receptor Modulator; Anesthetic; Anesthesia
CBR-001-623-723-3,RFM-008-478-6,CBR-001-623-723-3,COc1ccc(cc1CN[C@@H]1CCCN[C@@H]1c1ccccc1)n1nnnc1C(F)(F)F,CBR-HVAC-04832: Neurokinin receptor 1 Antagonist; Analgesic; Anti-inflammatory; Anti-emetic; Emesis; Inflammation; Migraine; Nausea
CBR-001-623-724-4,RFM-008-479-7,CBR-001-623-724-4,Nc1nc(=O)n(cc1F)[C@H]1O[C@H](C=C1)CO,CBR-HVAC-00289: Reverse transcriptase Inhibitor; Anti-HIV; HIV infection; Hepatitis B virus infection
CBR-001-623-725-5,RFM-008-480-0,CBR-001-623-725-5,O[C@H]1CC[C@]2([C@H](C1)CCC1C2CC[C@]2([C@H]1C[C@H](C2=O)Br)C)C,"CBR-HVAC-00579: Glucose-6-phosphate dehydrogenase Inhibitor; Antiviral; Anti-inflammatory; Infection, hepatitis c virus; Infections, HIV; Infection, hepatitis b; Infection, plasmodium; Infection, mycobacterium tuberculosis"
CBR-001-623-726-6,RFM-008-481-1,CBR-001-623-726-6,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2C=C(C2=CC(=O)C=C[C@]12C)Cl,CBR-HVAC-02019: ; Synthetic glucocorticoid; RHEUMATOID ARTHRITIS; ASTHMA
CBR-001-623-727-7,RFM-008-482-2,CBR-001-623-727-7,Cc1ccc(cc1)S(=O)(=O)NC(=O)N[C@H]1[C@@H](O)[C@@]2(C([C@H]1CC2)(C)C)C,CBR-HVAC-05300: Potentiates glucose-stimulated insulin release from functioning pancreatic islet beta-cells; Antidiabetic; Non-insulin dependent diabetes
CBR-001-623-728-8,RFM-008-483-3,CBR-001-623-728-8,OCC1O[C@@H](O[C@H]2CC[C@@H]3[C@]2(C)CC[C@H]2[C@H]3CCC3=CC(=O)CC[C@]23C)C([C@H]([C@@H]1O)O)O,"CBR-HVAC-05449: Steroid agent; Steroid agent; Hypogonadism, male"
CBR-001-623-729-9,RFM-008-484-4,CBR-001-623-729-9,C[C@H]1[C@@H](O[C@H]2[C@@]34[C@H]1CC[C@H]([C@@H]4CC[C@](O2)(OO3)C)C)N1CCS(=O)(=O)CC1,CBR-HVAC-06169: Antimalarial; Antimalarial; Malaria
CBR-001-623-730-2,RFM-008-485-5,CBR-001-623-730-2,NC(=N)NCCC[C@@H](C(=O)O)NC(=O)OCCCCCn1cnc2c1ncnc2O,CBR-HVAC-03337: Immunostimulator; Anticancer; Immunostimulant; Anticancer; Cancer; Immune deficiency
CBR-001-623-731-3,RFM-008-486-6,CBR-001-623-731-3,C#CCN(c1ccc(cc1)C(=O)N[C@H](C(=O)O)CCC(=O)O)Cc1ccc2c(c1)c(=O)[nH]c(n2)N,CBR-HVAC-03024: Thymidylate synthase Inhibitor; Anticancer; Cancer
CBR-001-623-732-4,RFM-008-487-7,CBR-001-623-732-4,OC(COc1cccc2c1cns2)CNC(C)C,CBR-HVAC-08001: beta-Adrenoceptor Antagonists;Signal Transduction Modulators
CBR-001-623-733-5,RFM-008-488-8,CBR-001-623-733-5,COCCN(CCOc1ccc2c(c1)cc([nH]2)c1cc2ccccc2[nH]c1=O)C,CBR-HVAC-05740: Angiogenesis Inhibitors;Flt3 (FLK2/STK1) Inhibitors;KIT (C-KIT) Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors;VEGFR-3 (FLT4) Inhibitors
CBR-001-623-734-6,RFM-008-489-9,CBR-001-623-734-6,Fc1cc(Cl)c(cc1S(=O)(=O)Nc1ccccc1F)C(=O)N1CCN2[C@@H](C1)CCC2,CBR-HVAC-07043: T-Type Calcium Channel Blockers
CBR-001-623-735-7,RFM-008-490-2,CBR-001-623-735-7,Oc1ccc(cc1)[C@H]1Cc2c([C@H]1NC(=O)C(c1ccccc1)c1ccccc1)cccc2,CBR-HVAC-04552: ACAT Inhibitors
CBR-001-623-736-8,RFM-008-491-3,CBR-001-623-736-8,Oc1ccc(cc1)[C@@H]1Cc2c([C@@H]1NC(=O)C(c1ccccc1)c1ccccc1)cccc2,CBR-HVAC-04552: ACAT Inhibitors
CBR-001-623-737-9,RFM-008-492-4,CBR-001-623-737-9,Fc1ccc(cc1)C(=O)CN1CCC(CC1)CN1Cc2c(C1=O)cccc2,CBR-HVAC-05935: sigma 2 Receptor Antagonists;Signal Transduction Modulators;5-HT2A Antagonists
CBR-001-623-738-0,RFM-008-493-5,CBR-001-623-738-0,COc1ccc(cc1c1ccccc1)Nc1ccc(cc1)CCNC[C@@H](c1ccc(c2c1ccc(=O)[nH]2)O)O,CBR-HVAC-07352: beta2-Adrenoceptor Agonists;Signal Transduction Modulators
CBR-001-623-739-1,RFM-008-494-6,CBR-001-623-739-1,CNCc1ccc(cc1)NC(=O)c1c[nH]c2c1C(=O)CCC2,CBR-HVAC-04623:  GABA(A) Receptor Partial Agonists;Signal Transduction Modulators
CBR-001-623-740-4,RFM-008-495-7,CBR-001-623-740-4,COc1c(/C=C/c2ccc(cc2)NS(=O)(=O)C)cc(cc1C(C)(C)C)n1ccc(=O)[nH]c1=O,CBR-HVAC-06812: RNA-Directed RNA Polymerase (NS5B) Inhibitors
CBR-001-623-741-5,RFM-008-496-8,CBR-001-623-741-5,CC(=O)OCC(=O)[C@@]1(OC(=O)c2ccco2)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-07723: Glucocorticoid agonist; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-623-742-6,RFM-008-497-9,CBR-001-623-742-6,Clc1ccc(cc1)Cc1nn(C[C@H]2CCCN2CCCCc2ccc(cc2)OCCCN2CCCCCC2)c(=O)c2c1cccc2,CBR-HVAC-06678: Histamine H1 Receptor Antagonists;Histamine H3 Receptor Antagonists;Signal Transduction Modulators
CBR-001-623-743-7,RFM-008-498-0,CBR-001-623-743-7,O=C(Nc1cc(nn1c1ccc(cc1)C)C(C)(C)C)Nc1ccc(c2c1cccc2)c1ccc(nc1)CN1CCOCC1,CBR-HVAC-06658: MAPK p38 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors
CBR-001-623-744-8,RFM-008-499-1,CBR-001-623-744-8,O=C(c1ncn2c1C1CCN1C(=O)c1c2cccc1Cl)OCC1CC1,"CBR-HVAC-08280: gamma-aminobutyric acid (GABA) A receptor, alpha 1; gamma-aminobutyric acid (GABA) A receptor, alpha 2; gamma-aminobutyric acid (GABA) A receptor, alpha 3; gamma-aminobutyric acid (GABA) A receptor, alpha 5"
CBR-001-623-745-9,RFM-008-500-7,CBR-001-623-745-9,O=C(c1ncn2c1C1CCN1C(=O)c1c2cccc1Cl)OCC1CC1,"CBR-HVAC-08280: gamma-aminobutyric acid (GABA) A receptor, alpha 1; gamma-aminobutyric acid (GABA) A receptor, alpha 2; gamma-aminobutyric acid (GABA) A receptor, alpha 3; gamma-aminobutyric acid (GABA) A receptor, alpha 5"
CBR-001-623-746-0,RFM-008-501-8,CBR-001-623-746-0,COc1c(OC)c2Oc3cc4c(cc3OC)CCN([C@H]4Cc3ccc(Oc4cc(C[C@H]5c2c(c1Br)CCN5C)ccc4OC)cc3)C,CBR-HVAC-06163: Cancer Multidrug Resistance Modulators
CBR-001-623-747-1,RFM-008-502-9,CBR-001-623-747-1,SCC(C(c1ccccc1)C)C(=O)NC(C(=O)O)C,"CBR-HVAC-04533: Angiotensin I converting enzyme inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Membrane metallo endopeptidase inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Hypertension, Treatment of"
CBR-001-623-748-2,RFM-008-503-0,CBR-001-623-748-2,SCC(C(c1ccccc1)C)C(=O)NC(C(=O)O)C,"CBR-HVAC-04533: Angiotensin I converting enzyme inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Membrane metallo endopeptidase inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Hypertension, Treatment of"
CBR-001-623-749-3,RFM-008-504-1,CBR-001-623-749-3,OCCN1CCCCC1C(=O)Nc1c(C)cccc1C,CBR-HVAC-10218: Sodium channel antagonist; General pump inhibitor
CBR-001-623-750-6,RFM-008-505-2,CBR-001-623-750-6,COc1cccc(c1)CNCC(COc1ccc2c(c1)ccc(=O)[nH]2)O,CBR-HVAC-04347: Heart Failure Therapy
CBR-001-623-751-7,RFM-008-506-3,CBR-001-623-751-7,CNC(=O)c1c(oc2c1cc(OC(C)C)c(c2)NS(=O)(=O)C)c1ccc(cc1)F,"CBR-HVAC-06027: HCV NS5B polymerase INHIBITOR; ANTIVIRAL; INFECTION, HCV"
CBR-001-623-752-8,RFM-008-507-4,CBR-001-623-752-8,CCCCOC(=O)NS(=O)(=O)c1ccc(cc1c1ccc(cc1)Cn1c(CC)nc2c1nc(C)cc2C)CCC,CBR-HVAC-11204: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension; Congestive heart failure
CBR-001-623-753-9,RFM-008-508-5,CBR-001-623-753-9,C=CCN1CCCC1CNC(=O)c1cc(c(cc1OC)N)S(=O)(=O)NC,CBR-HVAC-01792: ; Antimigraine; Migraine
CBR-001-623-754-0,RFM-008-509-6,CBR-001-623-754-0,OCc1coc2c(c1=O)ccc(c2)OCCCN1CCC(CC1)c1noc2c1ccc(c2)F,CBR-HVAC-05109: Dopamine receptor D3; 5-Hydroxytryptamine 2A receptor; Dopamine receptor D2 Antagonist; Antipsychotic; Schizophrenia; Psychosis
CBR-001-623-755-1,RFM-008-510-9,CBR-001-623-755-1,CC(C(=O)C)Oc1cc(N)c(cc1C(=O)NC1CN2CCC1CC2)Cl,CBR-HVAC-10524: 5-Hydroxytryptamine 3 receptor Antagonist; Antipsychotic; Anti-emetic; Schizophrenia; Emesis
CBR-001-623-756-2,RFM-008-511-0,CBR-001-623-756-2,Fc1ccc2c(c1)onc2C1CCN(CC1)CCN1C(=O)c2c(C1=O)cccc2,CBR-HVAC-10866: Dopamine receptor D2; 5-Hydroxytryptamine 2 receptor Antagonist; Antipsychotic; Psychotic disorder
CBR-001-623-757-3,RFM-008-512-1,CBR-001-623-757-3,OC(=O)c1ccc2c(c1)C(SCCN1CCC(CC1)Cc1ccccc1)c1ccccc1CO2,CBR-HVAC-10494: Thromboxane A2 receptor Antagonist; Antiallergic; Antiasthmatic; Respiratory tract disorders
CBR-001-623-758-4,RFM-008-513-2,CBR-001-623-758-4,OC(CNC(CNC(=O)N)(C)C)COC(=O)c1ccccc1F,CBR-HVAC-02955: Beta adrenergic receptor Antagonist; Antiarrhythmic; Arrhythmia; Ischemic heart diseases
CBR-001-623-759-5,RFM-008-514-3,CBR-001-623-759-5,OC1CCN(CC1)CCCCCCOc1ccc2c(c1)c(=O)c(c(o2)c1ccccc1)C,CBR-HVAC-10824: Opioid receptor sigma Antagonist; Antipsychotic; Neuroprotective; Neuroprotection; Psychotic disorder; Stroke
CBR-001-623-760-8,RFM-008-515-4,CBR-001-623-760-8,CN(c1ccc(cc1)NC(=O)N(C1CCCCCC1)Cc1cccc(c1)CN(C(=O)Nc1ccc(cc1)N(C)C)C1CCCCCC1)C,CBR-HVAC-04203: Acyl CoA:cholesterol acyltransferase Inhibitor; Antiarteriosclerotic; Antihypercholesterolemic; Hypercholesterolemia
CBR-001-623-761-9,RFM-008-516-5,CBR-001-623-761-9,C/C=C/CC1(CC)C(=O)NC(=O)NC1=O,CBR-HVAC-10253: ; Sedative; Hypnotic; INSOMNIA
CBR-001-623-762-0,RFM-008-517-6,CBR-001-623-762-0,NC(=O)CNc1ccc(cc1)[As](=O)(O)O,CBR-HVAC-09220: ; Antiprotozoal; Protozoal infections
CBR-001-623-763-1,RFM-008-518-7,CBR-001-623-763-1,CC(=O)NCCOC(=O)C(c1ccc(cc1)Cl)Oc1cccc(c1)C(F)(F)F,CBR-HVAC-05310: Peroxisome proliferator-activated receptor gamma Modulator; Antidiabetic; Antihyperlipoproteinemic; Antirheumatic; Antilipemic; Diabetes
CBR-001-623-764-2,RFM-008-519-8,CBR-001-623-764-2,Cc1cnc(nc1)CNCC1(F)CCN(CC1)C(=O)c1ccc(c(c1)Cl)F,CBR-HVAC-06478: 5-HT1A receptor Agonist; DIAGNOSTIC AIDIMAGING AGENT; Diagnostic aid
CBR-001-623-765-3,RFM-008-520-1,CBR-001-623-765-3,Fc1ccc(cc1)[C@@H]1C[C@H](c2c1cccc2)N1CCN(CC1)CCN1CCNC1=O,CBR-HVAC-03356: 5-Hydroxytryptamine 2 receptor Antagonist; Antihypertensive; Hypertension
CBR-001-623-766-4,RFM-008-521-2,CBR-001-623-766-4,CCCCNC(=O)c1ccc(c(c1)NS(=O)(=O)c1ccc(cc1Cl)Cl)Oc1ccc(cc1OC)CC(=O)O,"CBR-HVAC-06131: CRTH2; DP1 RECEPTOR Antagonist; Anti-inflammatory; Rhinitis, allergic; Asthma"
CBR-001-623-767-5,RFM-008-522-3,CBR-001-623-767-5,C=CCC1(CC(O)C)C(=O)NC(=O)NC1=O,CBR-HVAC-10299: ; Hypnotic; Sedative; MIGRAINE; MENOPAUSE; CEPHALGIA
CBR-001-623-768-6,RFM-008-523-4,CBR-001-623-768-6,O=C1ONC(=O)C1Cc1ccc(cc1)OCCc1nc(oc1C)c1ccccc1,CBR-HVAC-10414: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Agonist; Antidiabetic; Type II diabetes mellitus
CBR-001-623-769-7,RFM-008-524-5,CBR-001-623-769-7,CCOCCn1c(CN2CCN(CC2)CCCCn2cccn2)nc2c1cccc2,CBR-HVAC-04407: Histamine H1 receptor Blocker; Antiallergic; Anti-inflammatory; Antiasthmatic; Allergy
CBR-001-623-770-0,RFM-008-525-6,CBR-001-623-770-0,Fc1ccc(cc1)c1nn2c(c1c1ccncc1)NN(CC2)C(=O)C(=O)c1ccccc1,CBR-HVAC-11038: TNF alpha Inhibitor; Lymphocyte migration inhibitor; Lymphocyte inhibitor; Tumor necrosis factor alpha inhibitor; Interleukin 6 stimulator; Type 2 cytokine production inhibitor; Disseminated intravascular coagulation; Inflammatory bowel disease
CBR-001-623-771-1,RFM-008-526-7,CBR-001-623-771-1,C[C@H]1CCCC[C@]1(N1CCCCC1)c1cccs1,CBR-HVAC-00119: Ionotropic glutamate receptor NMDA Antagonist; Neuroprotectant; Acute neuronal injury; Traumatic brain injury
CBR-001-623-772-2,RFM-008-527-8,CBR-001-623-772-2,CCNC1(CCCCC1=O)c1cccs1,CBR-HVAC-09120: Ionotropic glutamate receptor NMDA Antagonist; Anticonvulsant; Anesthetic; Epilepsy; Anesthesia
CBR-001-623-773-3,RFM-008-528-9,CBR-001-623-773-3,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN1CCN(CC1)c1ccc(c(c1)Cl)Cl)C,CBR-HVAC-03636: CALCIUM CHANNEL Antagonist; ANTI-ANGINALANTI-HYPERTENSIVE; Angina
CBR-001-623-774-4,RFM-008-529-0,CBR-001-623-774-4,CCn1ncnc1COc1nn2c(cc1C(C)(C)C)nnc2c1ccccc1F,CBR-HVAC-00453: GABAA receptor Modulator; Nootropic agent; Antipsychotic; Schizophrenia
CBR-001-623-775-5,RFM-008-530-3,CBR-001-623-775-5,Fc1ccc(cc1)c1nc(sc1CCN1CCC(=Cc2cccc(c2)F)CC1)C(=O)N,CBR-HVAC-11227: Dopamine receptor D4 Antagonist; Antipsychotic; Psychotic disorder
CBR-001-623-776-6,RFM-008-531-4,CBR-001-623-776-6,N[C@@H]1CN(CC21CC2)c1c(F)c(N)c2c(c1C)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-04744: DNA gyrase Inhibitor; Antibacterial; Bacterial infection
CBR-001-623-777-7,RFM-008-532-5,CBR-001-623-777-7,OC(=O)C(Oc1cccc(c1C)C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-09985: ; Anti-inflammatory; Analgesic; Pain; Inflammation
CBR-001-623-778-8,RFM-008-533-6,CBR-001-623-778-8,O=C(OC1c2ccccc2C(=O)N1c1ccc2c(n1)nc(cc2)Cl)CCCNC(=O)C,CBR-HVAC-10844: Benzodiazepine receptor Agonist; Anxiolytic; Anticonvulsant; Anxiety; Epilepsy
CBR-001-623-779-9,RFM-008-534-7,CBR-001-623-779-9,[N-]=[N+]=Nc1cc(ccc1Cl)c1c(N)nc(nc1CC)N,"CBR-HVAC-03294: DIHYDROFOLATE REDUCTASE Inhibitor; ONCOLYTIC; Sarcoma, soft tissue"
CBR-001-623-780-2,RFM-008-535-8,CBR-001-623-780-2,COc1ccccc1N1CCN(CC1)CC(COc1ccc(cc1)c1cc(C#N)c(=O)[nH]c1C)O,CBR-HVAC-00317: Alpha-1 adrenergic receptor; Phosphodiesterase 3 Antagonist; Inhibitor; Cardioprotectant; Vasodilator; Inotropic; Cardiac failure
CBR-001-623-781-3,RFM-008-536-9,CBR-001-623-781-3,COc1cc(/C=C/C(=O)CCCCc2ccccc2)cc(c1O)OC,CBR-HVAC-11966: 5-Lipooxynase Inhibitor; Anti-inflammatory; INFLAMMATION
CBR-001-623-782-4,RFM-008-537-0,CBR-001-623-782-4,CCOc1ccc(cc1)Cc1nc2c(n1CCN(CC)CC)ccc(c2)[N+](=O)[O-],CBR-HVAC-10166: Opioid receptor mu Agonist; Analgesic; Narcotic; Pain
CBR-001-623-783-5,RFM-008-538-1,CBR-001-623-783-5,S=C(N1CCN(CC1)c1ccccn1)N/N=C\1/CCCc2c1nccc2,CBR-HVAC-06784: AKT2 protein kinase; AKT1 protein kinase Inhibitor; Modulator; Anticancer; Small cell lung cancer
CBR-001-623-784-6,RFM-008-539-2,CBR-001-623-784-6,CCCOc1ccc2c(c1)[C@H]([C@@H]([C@H]2c1ccc2c(c1)OCO2)C(=O)O)c1ccc(cc1OCC(=O)O)OC,CBR-HVAC-04571: Endothelin A receptor; Endothelin B receptor Antagonist; Vasoprotectant; Antimigraine; Migraine; Acute renal failure; Restenosis
CBR-001-623-785-7,RFM-008-540-5,CBR-001-623-785-7,OC[C@@H](C(=O)Nc1cc(/C=C\c2cc(OC)c(c(c2)OC)OC)ccc1OC)N,"CBR-HVAC-00061: Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrata, tumor blood vessels collapse, the acute disruption of tumor blood flow may result in tumor necrosis; Anticancer; Solid tumors"
CBR-001-623-786-8,RFM-008-541-6,CBR-001-623-786-8,COc1cc(CN(CCN(CCC(c2ccc(cc2)F)c2ccc(cc2)F)C)C)cc(c1OC)OC,CBR-HVAC-03829: Calcium channel Antagonist; Anti-atherosclerotic; Antianginal; Hyperlipidemia; Ischemic heart diseases; Aortic atherosclerosis
CBR-001-623-787-9,RFM-008-542-7,CBR-001-623-787-9,O=S(c1[nH]c2c(n1)csc2)Cc1nccc(c1)OCC(C(C(F)(F)F)(F)F)(F)F,CBR-HVAC-04001: H+/K+ ATPase Inhibitor; Antiulcer; Peptic ulcer
CBR-001-623-788-0,RFM-008-543-8,CBR-001-623-788-0,CN(CCCNc1ncc(c2c1c1c([nH]2)ccc2c1ccc(c2)O)C)C,CBR-HVAC-04018: DNA topoisomerase II; DNA topoisomerase I Inhibitor; Antineoplastic; Anticancer; Unspecified adult solid tumor; Cancer; Metastasis; Solid tumor
CBR-001-623-789-1,RFM-008-544-9,CBR-001-623-789-1,OC(=O)CC/C(=N\OCc1ccc(cc1)OCc1nc(oc1C)c1ccccc1)/c1ccccc1,CBR-HVAC-05287: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Activator; Hypoglycemic; Antidiabetic; Antihyperglycemic; Antihyperlipidemic; Non-insulin dependent diabetes; Hypercholesterolemia
CBR-001-623-790-4,RFM-008-545-0,CBR-001-623-790-4,CNC1CN(C1)c1c(F)cc2c(c1Br)n(cc(c2=O)C(=O)O)c1nc(N)c(cc1F)F,CBR-HVAC-10648: DNA gyrase; DNA topoisomerase II Inhibitor; Antibacterial; Bacterial infection
CBR-001-623-791-5,RFM-008-546-1,CBR-001-623-791-5,N#Cc1cnc(nc1c1ccc(cc1)C(N)(C)C)Nc1ccc(cc1)CCN1CCOCC1,CBR-HVAC-12001: VEGFR2 Modulator; Anticancer; CANCER
CBR-001-623-792-6,RFM-008-547-2,CBR-001-623-792-6,Brc1ccc2c(c1)cc1c([n+]2[O-])c(O)n[nH]c1=O,CBR-HVAC-11280: Ionotropic glutamate receptor NMDA Antagonist; Antidepressant; Neuroprotective; Chronic pain; Visceral pain
CBR-001-623-793-7,RFM-008-548-3,CBR-001-623-793-7,Clc1ccc(cc1)CS(=O)(=O)/C=C/c1ccc(cc1)C(=O)O,CBR-HVAC-06054: Phosphoinositide 3-kinase; ERK; AKT Inhibitor; Anticancer; Radioprotectant; RADIATION SICKNESS; CANCER
CBR-001-623-794-8,RFM-008-549-4,CBR-001-623-794-8,CCc1cn(n2c1nc(n2)CC)Cc1ccc(cc1)c1ccccc1c1nnn[nH]1,CBR-HVAC-04418: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension; Cardiac failure
CBR-001-623-795-9,RFM-008-550-7,CBR-001-623-795-9,Fc1ccc(cc1)N1CCN(CC1)c1cc2nc3n(C)cc(c(=O)c3cc2cc1F)C(=O)O,CBR-HVAC-11063: Antibacterial; Antibacterial; Bacterial infection
CBR-001-623-796-0,RFM-008-551-8,CBR-001-623-796-0,CC[C@H]1OC(=O)[C@H](C)[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)CC([C@H]2O)N(C(=O)C)C)[C@](C[C@H]([C@@H]([C@@H]([C@H]([C@]1(C)O)O)C)O)C)(C)O,CBR-HVAC-06037: Anti-inflammatory; Anti-inflammatory; Inflammation
CBR-001-623-797-1,RFM-008-552-9,CBR-001-623-797-1,OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)NC(=O)/C(=N\OC1CCCC1)/c1csc(n1)N,"CBR-HVAC-03902: Cell wall synthesis inhibitor; Antibacterial; Infection, bacterial"
CBR-001-623-798-2,RFM-008-553-0,CBR-001-623-798-2,CCOC(=O)C1=C(C)NC(=C(C1c1ccccc1/C=C/C(=O)OC(C)(C)C)C(=O)OCC)CN(C)C,CBR-HVAC-03930: Calcium channel Blocker; Anticancer; Cancer
CBR-001-623-799-3,RFM-008-554-1,CBR-001-623-799-3,OCC(C(C(C(NC(=O)Cc1c2cc(OC)ccc2n(c1C)C(=O)c1ccc(cc1)Cl)C=O)O)O)O,"CBR-HVAC-01840: ; Anti-inflammatory, nonsteroidal; Inflammation"
CBR-001-623-800-9,RFM-008-555-2,CBR-001-623-800-9,COc1cc(cc(c1O)OC)C1C2C(=O)OCC2C(c2c1cc1OCOc1c2)CCN(CCN(C)C)C,CBR-HVAC-04327: DNA topoisomerase II Inhibitor; Antitumor; Lung cancer
CBR-001-623-801-0,RFM-008-556-3,CBR-001-623-801-0,CN(CCO[C@@]1(C[C@@H]2C([C@@]1(C)CC2)(C)C)c1ccccc1)C,CBR-HVAC-03771: 5-Hydroxytryptamine 2A receptor; 5-Hydroxytryptamine 2C receptor Antagonist; Inverse agonist; Anxiolytic; Generalized anxiety disorder
CBR-001-623-802-1,RFM-008-557-4,CBR-001-623-802-1,CC(=O)OC(c1ccccc1)C1CCCCN1,CBR-HVAC-10135: ; Anorectic; Antidepressant; Anorexia; Depression
CBR-001-623-803-2,RFM-008-558-5,CBR-001-623-803-2,O=C(NC(=O)c1ccccc1OCC1CC1)N[C@@H]1C[C@@H]2CC[C@H](C1)N2C,CBR-HVAC-04155: 5-Hydroxytryptamine 3 receptor Antagonist; Anxiolytic; Antipsychotic; Anxiety; Psychosis
CBR-001-623-804-3,RFM-008-559-6,CBR-001-623-804-3,Fc1ccc(cc1)[C@H]1CC(c2c1cccc2)N1CCN(CC1)CCN1CCNC1=O,CBR-HVAC-03356: 5-Hydroxytryptamine 2 receptor Antagonist; Antihypertensive; Hypertension
CBR-001-623-805-4,RFM-008-560-9,CBR-001-623-805-4,NC(=N)NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC1CCCCC1)NCC(=O)O,CBR-HVAC-04510: Thrombin Inhibitor; Anticoagulant; Antianginal; Thromboembolic disorders; Unstable angina pectoris
CBR-001-623-806-5,RFM-008-561-0,CBR-001-623-806-5,Cc1[nH]cnc1CC1CCc2n(C1=O)c1ccccc1c2C,CBR-HVAC-04281: 5-Hydroxytryptamine 3 receptor; 5-Hydroxytryptamine 4 receptor Antagonist; Antiemetic; Emesis; Irritable bowel syndrome
CBR-001-623-807-6,RFM-008-562-1,CBR-001-623-807-6,Cc1[nH]cnc1CC1CCc2n(C1=O)c1ccccc1c2C,CBR-HVAC-04281: 5-Hydroxytryptamine 3 receptor; 5-Hydroxytryptamine 4 receptor Antagonist; Antiemetic; Emesis; Irritable bowel syndrome
CBR-001-623-808-7,RFM-008-563-2,CBR-001-623-808-7,Fc1ccc(cc1)c1cncc(c1)CNCC1CCc2c(O1)cccc2,CBR-HVAC-00755: 5-HYDROXYTRYPTAMINE 1A RECEPTOR; DOPAMINE D2 RECEPTOR Agonist; Antagonist; Antipsychotic; Rett's syndrome
CBR-001-623-809-8,RFM-008-564-3,CBR-001-623-809-8,Fc1ccc(cc1)c1cncc(c1)CNCC1CCc2c(O1)cccc2,CBR-HVAC-00755: 5-HYDROXYTRYPTAMINE 1A RECEPTOR; DOPAMINE D2 RECEPTOR Agonist; Antagonist; Antipsychotic; Rett's syndrome
CBR-001-623-810-1,RFM-008-565-4,CBR-001-623-810-1,COc1c(OC)ccc2c1c(C)[nH]c(=O)n2,CBR-HVAC-11432: Phosphodiesterase 3 Inhibitor; PDE3 inhibitor; Heart failure
CBR-001-623-828-1,RFM-008-566-5,CBR-001-623-828-1,CN(CCOC(c1ccnn1C)c1cccs1)C,CBR-HVAC-11571: Neurokinin receptor 1 antagonist
CBR-001-623-845-2,RFM-008-567-6,CBR-001-623-845-2,O=C1C(=CC(=O)C(=C1C)C)CCCCCCCCCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1,"CBR-HVAC-14339: Alzheimer's Dementia, Treatment of ;Age-Related Disorders, Treatment of;Dry Eye Syndrome, Treatment for;Neurologic Drugs (Miscellaneous);Oncolytic Drugs"
CBR-001-623-846-3,RFM-008-568-7,CBR-001-623-846-3,ClCCN(c1ccc2c(c1)nc(n2C)CCCCCCC(=O)NO)CCCl,CBR-HVAC-14340: Histone deacetylase inhibitor
CBR-001-623-862-3,RFM-008-569-8,CBR-001-623-862-3,OCC(=O)N1CCc2c(C1)ccc(n2)Nc1ncc2c(n1)n([C@@H]1CC[C@H](CC1)C)c1c2ccnc1,CBR-HVAC-14342: CDK4 Inhibitors;CDK6 Inhibitors;Flt3 (FLK2/STK1) Inhibitors;Signal Transduction Modulators
CBR-001-623-863-4,RFM-008-570-1,CBR-001-623-863-4,CC(=O)c1cc2c(o1)C(=O)c1c(C2=O)cccc1,CBR-HVAC-14371: Drugs Targeting Cancer Stem Cells;Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators
CBR-001-623-864-5,RFM-008-571-2,CBR-001-623-864-5,CO[C@@H]1CC[C@H](CC1)N1C(=O)CNc2c1nc(cn2)c1ccc(nc1)C(O)(C)C,CBR-HVAC-14360: mTOR Complex 1 (mTORC1) Inhibitors;mTOR Complex 2 (mTORC2) Inhibitors;Signal Transduction Modulators
CBR-001-623-865-6,RFM-008-572-3,CBR-001-623-865-6,CCN1C(=O)CNc2c1nc(cn2)c1ccc(nc1C)c1nc[nH]n1,CBR-HVAC-14359: DNA-Dependent Protein Kinase (DNA-PK) Inhibitors;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Signal Transduction Modulators
CBR-001-623-866-7,RFM-008-573-4,CBR-001-623-866-7,CC(CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)c1cccc(n1)C(F)(F)F)(O)C,"CBR-HVAC-14363: Isocitrate Dehydrogenase (NADP+) (IDPc, IDH1) Inhibitors;Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) Inhibitors"
CBR-001-623-867-8,RFM-008-574-5,CBR-001-623-867-8,COCCOc1cnc2c(c1)c(=O)n(cc2)[C@@H](c1nnc2n1cc(cc2F)c1cnn(c1)C)C,CBR-HVAC-14350: HGFR (MET; c-Met) Inhibitors;Signal Transduction Modulators
CBR-001-623-868-9,RFM-008-575-6,CBR-001-623-868-9,OC[C@H]1O[C@@H](OCCc2ccc(c(c2)O)O)[C@@H]([C@H]([C@@H]1OC(=O)/C=C/c1ccc(c(c1)O)O)O[C@@H]1O[C@@H](C)[C@@H]([C@H]([C@H]1O)O)O)O,CBR-HVAC-14335: Antioxidants;Apoptosis Inducers;Free Radical Scavengers;HIV Integrase Inhibitors;Protein Kinase C (PKC) Inhibitors;Signal Transduction Modulators
CBR-001-623-872-5,RFM-008-576-7,CBR-001-623-872-5,O=C1CC23CC(=O)O[Bi-5]456(O1)(O2)(OC(=O)CC(O6)(C(=O)O5)CC(=O)O4)OC3=O,CBR-HVAC-14331: Antiulcer Drugs
CBR-001-624-013-4,RFM-008-577-8,CBR-001-624-013-4,OC(=O)CCSCc1ccc(cc1)c1onc(c1NC(=O)OC(c1ccccc1Cl)C)C,CBR-HVAC-14390: Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2) Antagonists;Lysophosphatidic Acid Receptor 3 (LPAR3; EDG7) Antagonists;Signal Transduction Modulators
CBR-001-624-014-5,RFM-008-578-9,CBR-001-624-014-5,OC(=O)c1ccccc1SCCCn1c(=O)c2cccc3c2c(c1=O)ccc3,CBR-HVAC-14389: Apoptosis Inhibitors;Lysophosphatidic Acid Receptor 2 (LPAR2; EDG4) Agonists;Signal Transduction Modulators
CBR-001-624-024-7,RFM-008-579-0,CBR-001-624-024-7,CCN(CCn1c2cc(OC)ccc2c2c1[C@H]1C[C@H]3[C@@H](CN1CC2)C[C@H]([C@@H]([C@H]3C(=O)OC)OC)OC(=O)c1cc(OC)c(c(c1)OC)OC)CC,CBR-HVAC-08830: Cyclic AMP phosphodiesterase inhibitor
CBR-001-624-025-8,RFM-008-580-3,CBR-001-624-025-8,C=CCN1CC[C@@]23C([C@H]1Cc1c3cc(cc1)O)CCCC2,CBR-HVAC-09608: OPIOID RECEPTOR
CBR-001-624-026-9,RFM-008-581-4,CBR-001-624-026-9,Cc1cccc(n1)c1[nH]c(nc1c1ccc2c(c1)nccn2)Cc1cccc(c1)C(=O)N,CBR-HVAC-12259: Activin Receptor Like Kinase 4 (ALK4; ActR-IB) Inhibitors;Activin Receptor Like Kinase 5 (ALK5; TbetaR-I) Inhibitors;Signal Transduction Modulators
CBR-001-624-027-0,RFM-008-582-5,CBR-001-624-027-0,O[C@H]1[C@@H](C[C@@H]([C@H]1O)COS(=O)(=O)N)Nc1ccnc2n1nc(c2)c1cccc(c1)SC(F)(F)F,CBR-HVAC-07323: Apoptosis Inducers;Ubiquitin-Activating Enzyme E1 Inhibitors
CBR-001-624-028-1,RFM-008-583-6,CBR-001-624-028-1,CCOC(=O)Oc1c(OC)cc(cc1OC)C(=O)O[C@@H]1C[C@@H]2CN3CCc4c([C@H]3C[C@@H]2[C@@H]([C@H]1OC)C(=O)OC)[nH]c1c4ccc(c1)OC,CBR-HVAC-09018: Lowers blood pressure by stimulating dopamine receptors which decreases noradrenaline release and consequently sympathetic vasomotor tone
CBR-001-624-532-2,RFM-008-584-7,CBR-001-624-532-2,CN([C@@H]1C(=C(C(=O)N)C(=O)[C@@]2([C@H]1[C@@H](O)[C@@H]1[C@@H](C)c3cccc(c3C(=O)C1=C2O)O)O)O)C,"CBR-HVAC-02450: Doxycycline has its main mechanism of action on protein synthesis. Inside the bacterial cell, doxycycline inhibits protein synthesis by binding specifically to the 30S ribosomes; Matrix Metalloproteinase Inhibitors; Protein 30S ribosomal subunit inhibitor; Protein-Arginine Deiminase Inhibitors; Acne Therapy; Antibiotic; Antibiotics; Antiinfectives (Not Specified); Antimalarial; Antimalarials; Breast Cancer Therapy; Cardiovascular Diseases (Not Specified); Female Reproductive System Cancer Therapy"
CBR-001-624-533-3,RFM-008-585-8,CBR-001-624-533-3,NCCCCC1NC(=O)C(NC(=O)C(Cc2ccccc2)NC(=O)C(CSSCC(NC(=O)C(NC1=O)C(O)C)C(=O)NC(C(O)C)CO)NC(=O)C(Cc1ccccc1)N)Cc1c[nH]c2c1cccc2,CBR-HVAC-13580: Growth hormone releasing factor antagonist; Insulinotropin antagonist
CBR-001-624-534-4,RFM-008-586-9,CBR-001-624-534-4,CNC(CC1CCCCC1)C,CBR-HVAC-13060: Alpha-adrenergic receptor Stimulator; Sympathomimetic
CBR-001-624-535-5,RFM-008-587-0,CBR-001-624-535-5,N/C(=N\Nc1ccccc1)/c1ccccc1,CBR-HVAC-07596: Cyclooxygenase inhibitor; 5 Lipoxygenase inhibitor; 5 Hydroxytryptamine release inhibitor
CBR-001-624-536-6,RFM-008-588-1,CBR-001-624-536-6,CCCCC1CCN(CC1)CCCC(=O)c1ccccc1C,CBR-HVAC-13758: 5-HT2A Antagonists; Dopamine D2 Antagonists; Muscarinic M1 Agonists; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-624-537-7,RFM-008-589-2,CBR-001-624-537-7,CCNCC(c1cccc(c1)O)O,CBR-HVAC-13467: Alpha adrenergic receptor Agonist; Sympathomimetic
CBR-001-624-538-8,RFM-008-590-5,CBR-001-624-538-8,CN(CCn1cnc2c1c(=O)n(C)c(=O)n2C)C,CBR-HVAC-13421: Antidepressant
CBR-001-624-539-9,RFM-008-591-6,CBR-001-624-539-9,CCCOc1ccc(cc1)C(=O)CCN1CCCCC1,CBR-HVAC-13470: Local anesthetic
CBR-001-624-540-2,RFM-008-592-7,CBR-001-624-540-2,O=C1CCC(C(=O)N1)(C1CCN(CC1)Cc1ccccc1)c1ccccc1,CBR-HVAC-10343: Muscarinic receptor M4 Antagonist;
CBR-001-624-541-3,RFM-008-593-8,CBR-001-624-541-3,OC(c1ccccc1)(c1ccccc1)CCCN1CCCCC1,"CBR-HVAC-12702: Muscarinic M1 Receptor Ligands; Muscarinic M3 Receptor Ligands; Muscarinic M4 Receptor Ligands; Muscarinic acetylcholine receptor Antagonist; Signal Transduction Modulators; Antiemetic; Ear disorders, treatment of"
CBR-001-624-542-4,RFM-008-594-9,CBR-001-624-542-4,OC1CCC2(C34C1Oc1c4c(CC2N(CC3)CC2CCC2)ccc1O)O,CBR-HVAC-02366: Opioid receptor Antagonist; Opioid receptor agonist
CBR-001-624-543-5,RFM-008-595-0,CBR-001-624-543-5,CCN(CC(=O)Nc1c(C)cc(cc1C)C)CC,CBR-HVAC-13435: Sodium channel Blocker; Antiarrhythmic; Local anesthetic
CBR-001-624-544-6,RFM-008-596-1,CBR-001-624-544-6,CN(c1ccc2c(c1)ccc([n+]2C)/C=C/c1cc(n(c1C)c1ccccc1)C)C,"CBR-HVAC-13055: Androgen Receptor Antagonists; Prevent the parasite from utilizing exogenous carbohydrates.; Protein Kinase B (PKB/Akt) Inhibitors; Signal Transduction Modulators; Wnt Signaling Inhibitors; Antihelminthic; Gastrointestinal Genetic Disorders, Treatment of ; Oncolytic Drugs; Treatment of Helminthic Diseases"
CBR-001-624-545-7,RFM-008-597-2,CBR-001-624-545-7,CNC(=NC)NCc1ccc(cc1)OC,CBR-HVAC-10206: Antiarrhythmic; Antifibrillatory
CBR-001-624-546-8,RFM-008-598-3,CBR-001-624-546-8,N[C@H]1CCN(C1)S(=O)(=O)c1cccc2c1ccnc2,analog of CBR-HVAC-13766
CBR-001-624-547-9,RFM-008-599-4,CBR-001-624-547-9,C1CCC(CC1)c1ccc2c(c1)c1CCCC3c1n2CCN3,"CBR-HVAC-12943: MAO-A Inhibitors; Monoamine oxidase A Inhibitor; Antidepressant; Antidepressants; Cognition Disorders, Treatment of"
CBR-001-624-548-0,RFM-008-600-0,CBR-001-624-548-0,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C)C(=O)N[C@@H]([C@H](O)C)CO)NC(=O)[C@@H](Cc1ccccc1)N)Cc1c[nH]c2c1cccc2,"CBR-HVAC-12609: Growth Hormone Release Inhibitors; Signal Transduction Modulators; Somatostatin Agonists; Somatostatin receptor Agonist; Antidiarrheal; Antihemorrhagic; Breast Cancer Therapy; Cancer Associated Disorders, Treatment of; Diabetic Retinopathy, Agents for; Digestive/Gastrointestinal Cancer Therapy; Endocrine Cancer Therapy; Hypertension, Treatment of; Interstitial Lung Diseases, Treatment of; Irritable Bowel Syndrome, Agents for; Liver Cancer Therapy; Liver and Biliary Tract Disorders, Treatment of; Oncolytic Drugs; Prostate Cancer Therapy; Respiratory/Thoracic Cancer Therapy; Rheumatoid Arthritis, Treatment of; Treatment of Acromegaly"
CBR-001-624-549-1,RFM-008-601-1,CBR-001-624-549-1,O=CO[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])CSc1nnnn1C)c1ccccc1,CBR-HVAC-05806: Antibacterial Drugs;Antibiotics; Penicillin binding protein Inhibitor;
CBR-001-624-550-4,RFM-008-602-2,CBR-001-624-550-4,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-01386: Antipruritics;Endocrine Disorders (Not Specified);Dermatologic Drugs; Phospholipase A2 Inhibitor; Corticosteroid agonist
CBR-001-624-551-5,RFM-008-603-3,CBR-001-624-551-5,O=C1N[C@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)CC(=O)N([C@H](C(=O)O[C@@H]([C@@H]1NC(=O)c1c2nc3c(ccc(c3oc2c(c(=O)c1N)C)C)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C(=O)[C@H]2N(C(=O)[C@H](NC1=O)C(C)C)CCC2)C)C)C(C)C)C,CBR-HVAC-02401
CBR-001-624-552-6,RFM-008-604-4,CBR-001-624-552-6,O=C1NC(C(C)C)C(=O)N2CCCC2C(=O)N(C)CC(=O)N(C(C(=O)OC(C1NC(=O)c1c2nc3c(ccc(c3oc2c(c(=O)c1N)C)C)C(=O)NC1C(C)OC(=O)C(C(C)C)N(C)C(=O)CN(C(=O)C2N(C(=O)C(NC1=O)C(C)C)CCC2)C)C)C(C)C)C,CBR-HVAC-02401
CBR-001-624-553-7,RFM-008-605-5,CBR-001-624-553-7,CCC(c1ccccc1)c1noc(n1)CCN(CC)CC,CBR-HVAC-08606: Antispasmodic
CBR-001-624-554-8,RFM-008-606-6,CBR-001-624-554-8,COc1cc(NCCCCCNC(C)C)c2c(c1)cccn2,CBR-HVAC-08792: Antimalarial
CBR-001-624-555-9,RFM-008-607-7,CBR-001-624-555-9,Oc1ccc(cc1C(=O)NO)Br,CBR-HVAC-08803: Antibacterial
CBR-001-624-556-0,RFM-008-608-8,CBR-001-624-556-0,CN1C2CCC1CC(C2)OC(=O)C(=C)c1ccccc1,CBR-HVAC-08835: Anticholinergic
CBR-001-624-557-1,RFM-008-609-9,CBR-001-624-557-1,COc1cc(/C=C/C(=O)N)cc(c1OC)OC,CBR-HVAC-08886: Antipsychotic
CBR-001-624-558-2,RFM-008-610-2,CBR-001-624-558-2,CCCCCCC(NN)C,CBR-HVAC-08920: Antidepressant
CBR-001-624-559-3,RFM-008-611-3,CBR-001-624-559-3,CCOP(=S)(Oc1ccc2c(c1)oc(=O)cc2C)OCC,CBR-HVAC-09056: Antispasmodic
CBR-001-624-560-6,RFM-008-612-4,CBR-001-624-560-6,NC(=O)Nc1ccc(cc1)S(=O)(=O)c1ccc(cc1)N,CBR-HVAC-09148: Antiviral
CBR-001-624-561-7,RFM-008-613-5,CBR-001-624-561-7,NC(C(=O)c1ccc2c(c1)OCO2)N,CBR-HVAC-09158: Antihypertensive
CBR-001-624-562-8,RFM-008-614-6,CBR-001-624-562-8,CC(c1ccccc1)NNC(=O)c1ccccc1,CBR-HVAC-09226: Antidepressant
CBR-001-624-563-9,RFM-008-615-7,CBR-001-624-563-9,CC(NNC(=O)COc1ccc(cc1)Cl)C,CBR-HVAC-09233: Antidepressant
CBR-001-624-564-0,RFM-008-616-8,CBR-001-624-564-0,O=C1C(C2C(C1(C)CC2)(C)C)S(=O)(=O)O,CBR-HVAC-09275: Cardiotonic
CBR-001-624-565-1,RFM-008-617-9,CBR-001-624-565-1,C=CCc1ccc(c(c1)OC)OCC(=O)N(CC)CC,CBR-HVAC-09905: Anesthetic
CBR-001-624-566-2,RFM-008-618-0,CBR-001-624-566-2,CNCC(C1CCCCC1)C,CBR-HVAC-10129: Anorectic
CBR-001-624-567-3,RFM-008-619-1,CBR-001-624-567-3,COC1CC(OC2C(C)/C=C/C=C3COC4C3(O)C(C=C(C4O)C)C(=O)OC3CC(CC=C2C)OC2(C3)C=CC(C(O2)C(C)C)C)OC(C1OC1CC(OC)C(C(O1)C)NC(=O)C)C,CBR-HVAC-10215: Antihelmintic
CBR-001-624-568-4,RFM-008-620-4,CBR-001-624-568-4,CCCCCCCCCCCCCCCCCCO,CBR-HVAC-13211
CBR-001-624-569-5,RFM-008-621-5,CBR-001-624-569-5,CCCCCCCCC(CCCCCC)CO,CBR-HVAC-13220
CBR-001-624-570-8,RFM-008-622-6,CBR-001-624-570-8,CCCCCC/C=C/C=C\CCCCCCCC(=O)O,CBR-HVAC-12129
CBR-001-624-571-9,RFM-008-623-7,CBR-001-624-571-9,CCC[C@H]1CN([C@@H](C1)C(=O)N[C@@H]([C@H]1O[C@H](SC)[C@@H]([C@H]([C@H]1O)O)O)[C@@H](Cl)C)C,CBR-HVAC-12895: 16S Ribosomal Protein Inhibitors; 30S Ribosomal Protein Inhibitors; 50S-ribosomal subunit Binder; Acne Therapy; Antibacterial; Antibiotics
CBR-001-624-572-0,RFM-008-624-8,CBR-001-624-572-0,CN([C@@H]1C(=O)C(C(=O)N)C(=O)[C@@]2([C@H]1[C@@H](O)[C@H]1C(C2=O)C(=O)c2c([C@@]1(C)O)cccc2O)O)C,CBR-HVAC-12823: 16S-rRNA of 30S ribosomal subunit Inhibitor; Acne Therapy; Antibacterial; Antibacterial Drugs
CBR-001-624-573-1,RFM-008-625-9,CBR-001-624-573-1,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@H]([C@@H](O2)C)O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C[C@H](C(=O)[C@@H]([C@H]([C@]1(C)O)O)C)C)(C)OC,CBR-HVAC-12999: 23S-rRNA of 50S ribosomal subunit Binder; Cytochrome P450 CYP3A4 Inhibitors; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Protein 50S ribosomal subunit inhibitor; Anti-Helicobacter Pylori Agents; Antibacterial; Antibacterial Drugs; Antibiotics; Antimycobacterial Agents
CBR-001-624-574-2,RFM-008-626-0,CBR-001-624-574-2,O=CC[C@H]1C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]([C@H]1O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@H]1O)N(C)C)O[C@@H]1O[C@@H](C)[C@@H]([C@](C1)(C)O)OC(=O)CC(C)C)OC)OC(=O)C)C,CBR-HVAC-12893: 23S-rRNA of 50S ribosomal subunit Inhibitor; Protein 50S ribosomal subunit inhibitor; Antibiotic; Antibiotics
CBR-001-624-575-3,RFM-008-627-1,CBR-001-624-575-3,CN[C@H]1[C@H](O)[C@H]2O[C@@H]3O[C@H](C)CC(=O)[C@@]3(O[C@@H]2[C@H]([C@H]1O)NC)O,CBR-HVAC-13029: 30S-ribosomal subunit Binder; Antibacterial Drugs; Antimicrobial
CBR-001-624-576-4,RFM-008-628-2,CBR-001-624-576-4,CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(Cl)cc2,"CBR-HVAC-12688: 5 Hydroxytryptamine 2 receptor antagonist; 5-HT2 Antagonists; Dopamine D1 Receptor Ligands; Dopamine D2 Antagonists; Dopamine D2 receptor antagonist; Dopamine D3 Receptor Ligands; Dopamine D4 Receptor Ligands; Dopamine receptor D2; Dopamine receptor D3 Antagonist; Signal Transduction Modulators; Antianxiety; Antidepressant; Antimigraine Drugs; Antipsychotic; Antipsychotic Drugs; Mood Disorders, Treatment of"
CBR-001-624-577-5,RFM-008-629-3,CBR-001-624-577-5,CN(CCCN1c2ccccc2CCc2c1cccc2)C,"CBR-HVAC-12761: 5 Hydroxytryptamine uptake inhibitor; 5-HT Reuptake Inhibitors; 5-Hydroxytryptamine transporter Inhibitor; Adrenergic transmitter uptake inhibitor; Norepinephrine Reuptake Inhibitors; Serotonin and norepinephrine reuptake inhibitor; Signal Transduction Modulators; Sodium Channel  Blockers; Tricyclic antidepressant; Antidepressant; Antidepressants; Non-Ulcer Dyspepsia, Agents for; Renal and Urinary System Genetic Disorders, Treatment of"
CBR-001-624-578-6,RFM-008-630-6,CBR-001-624-578-6,CN(CC(CN1c2ccccc2CCc2c1cccc2)C)C,"CBR-HVAC-12762: 5 Hydroxytryptamine uptake inhibitor; 5-Hydroxytryptamine) in the central nervous system (CNS). One theory suggests that these neurotransmitters are increased through inhibition of their reuptake by the presynaptic neuronal membrane; Adrenergic transmitter uptake inhibitor; Although the exact mechanism of action in the treatment of depression is unclear, tricyclic antidepressants have been thought to increase the synaptic concentration of norepinephrine (levarterenol; NE) and/or serotonin (5-Hydroxytryptamine; Norepinephrine Transporter (NET) Inhibitors; Serotonin Transporter (SERT) Inhibitors; Signal Transduction Modulators; Tricyclic antidepressant; Antidepressant; Antidepressants"
CBR-001-624-579-7,RFM-008-631-7,CBR-001-624-579-7,CNCCCN1c2ccccc2CCc2c1cc(Cl)cc2,CBR-HVAC-00288: 5 Hydroxytryptamine uptake inhibitor; 5-Hydroxytryptamine receptor Inhibitor; Adrenergic transmitter uptake inhibitor; Reproductive system modulator
CBR-001-624-580-0,RFM-008-632-8,CBR-001-624-580-0,O=S(=O)(c1cnc2c(c1)cccc2N1CCNCC1)c1ccccc1,"CBR-HVAC-00657: 5 Hydroxytryptamine 6 receptor antagonist; 5-HT6 Antagonists; 5-Hydroxytryptamine 6 receptor Antagonist; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Antipsychotic; Antipsychotic Drugs; Neurologic Drugs (Miscellaneous); Nootropic"
CBR-001-624-581-1,RFM-008-633-9,CBR-001-624-581-1,O=C(N1CCC(CC1)C(=O)O)OC(C)(C)C,"CBR-HVAC-13724: 5-HT2B Antagonists; Signal Transduction Modulators; Atopic Dermatitis, Agents for"
CBR-001-624-582-2,RFM-008-634-0,CBR-001-624-582-2,OC1(CCOCC1)CN1CCC(CC1)COc1noc2c1c(ccc2)O[C@H]1COCC1,"CBR-HVAC-12058: 5-HT4 Partial Agonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of"
CBR-001-624-583-3,RFM-008-635-1,CBR-001-624-583-3,CNCCC=C1c2ccccc2CCc2c1cccc2,"CBR-HVAC-12686: 5-Hydroxytryptamine receptor; Acetylcholine receptor Inhibitor; Histamine receptor; K(ir) 4.1 Channel Blockers; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors; Signal Transduction Modulators; Antidepressant; Antidepressants; Gastric Emptying Disorders,Treatment of"
CBR-001-624-584-4,RFM-008-636-2,CBR-001-624-584-4,CN[C@@H]1C[C@H](c2c1cccc2)c1ccc(c(c1)Cl)Cl,CBR-HVAC-13077: 5-Hydroxytryptamine transporter Inhibitor; Anxiolytic
CBR-001-624-585-5,RFM-008-637-3,CBR-001-624-585-5,C[n+]1cc2c3OCOc3ccc2c2c1c1cc3OCOc3cc1cc2,CBR-HVAC-12733: Acetylcholinesterase (AChE) Inhibitors; Apoptosis Inducers; Caspase 3 Activators; FtsZ Inhibitors; Rho GTPase Inhibitors; Signal Transduction Modulators; Antibacterial Drugs; Treatment of Periodontitis
CBR-001-624-586-6,RFM-008-638-4,CBR-001-624-586-6,CC(=O)CCCCn1c(=O)c2n(C)cnc2n(c1=O)C,"CBR-HVAC-12825: Acetylcholinesterase (AChE) Inhibitors; Chitinase Inhibitors; Phosphodiesterase Inhibitor; Phosphodiesterase Inhibitors; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Unidentified pharmacological activity; Agents for Liver Cirrhosis; Amyotrophic Lateral Sclerosis, Agents for; Antileishmanials; Cardiovascular Diseases (Not Specified); Fibrosis, Treatment of; Hemorrhoid, Treatment of; Interstitial Lung Diseases, Treatment of; Liver and Biliary Tract Disorders, Treatment of; Muscular Dystrophy, Agents for; Nephritis, Agents for; Respiratory Disorders (Not Specified); Treatment of Peripheral Obstructive Vascular Disease; Treatment of Renal Diseases; Vasculitis, Agents for; Vasodilator"
CBR-001-624-587-7,RFM-008-639-5,CBR-001-624-587-7,COc1ccc(cc1c1cc2c(N=O)c([nH]c2c2c1CCN(C2)C)O)F,CBR-HVAC-13812: Acid-Sensing Ion Channels (ASIC) Blockers; Non-Opioid Analgesics
CBR-001-624-588-8,RFM-008-640-8,CBR-001-624-588-8,Cn1c(=O)n(C)c2c(c1=O)nc[nH]2,"CBR-HVAC-12189: Adenosine A1 Antagonists; Adenosine A1 receptor antagonist; Adenosine A2a receptor antagonist; Chitinase Inhibitors; GABA(A) Receptor Antagonists; Phosphodiesterase Inhibitor; Phosphodiesterase inhibitor; Signal Transduction Modulators; Asthma Therapy; Bronchodilator; Bronchodilators; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Endocrine Genetic Disorders, Treatment of; Respiratory Disorders (Not Specified)"
CBR-001-624-589-9,RFM-008-641-9,CBR-001-624-589-9,Cn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-13375: Adenosine receptor Inhibitor; Phosphodiesterase; CNS stimulant
CBR-001-624-590-2,RFM-008-642-0,CBR-001-624-590-2,CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COP(=O)(OCC[N+](C)(C)C)[O-],"CBR-HVAC-13214: After reconstitution and intravenous injection, it increases the ultrasound reflectivity of blood in the left ventricle, thereby enhancing the ultrasound signal; Diagnostic agent"
CBR-001-624-591-3,RFM-008-643-1,CBR-001-624-591-3,NCCC(=O)N[C@H](C(=O)O)Cc1[nH]cnc1,"CBR-HVAC-12908: AGE Inhibitors (Maillard's Reaction Inhibitors); Antioxidants; Cognition Disorders, Treatment of; Heart Failure Therapy; Immunomodulators; Neurologic Drugs (Miscellaneous); Psychiatric Disorders (Not Specified)"
CBR-001-624-592-4,RFM-008-644-2,CBR-001-624-592-4,COC(=O)CCC1=C(C)C2=NC1=Cc1[nH]c(c(c1CCC(=O)O)C)C=C1N=C(C=C3NC(=C2)[C@]2(C)[C@H](C(=O)OC)C(=CC=C32)C(=O)OC)C(=C1C=C)C,"CBR-HVAC-12652: Age-Related Macular Degeneration, Treatment of; Antipsoriatics; Oncolytic Drugs; Ophthalmic Drugs"
CBR-001-624-593-5,RFM-008-645-3,CBR-001-624-593-5,CC1CC2(NC(=O)NC2=O)c2c(O1)ccc(c2)F,CBR-HVAC-12980: Aldose Reductase Inhibitors; Aldose reductase Inhibitor; Aldose reductase inhibitor; Anticataract Agents; Antidiabetic; Symptomatic Antidiabetic Agents
CBR-001-624-594-6,RFM-008-646-4,CBR-001-624-594-6,CCC[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]2[C@@H]1[C@@H]1CC[C@@]([C@]1(CC2)C)(O)CCC(=O)[O-])C,CBR-HVAC-13651: Aldosterone antagonist
CBR-001-624-595-7,RFM-008-647-5,CBR-001-624-595-7,CC(CCCC(N)C)C,CBR-HVAC-13073: Alpha adrenergic receptor Agonist; Local anesthetic; Vasoconstrictor
CBR-001-624-596-8,RFM-008-648-6,CBR-001-624-596-8,Cc1cccc(c1C)Cc1c[nH]cn1,CBR-HVAC-12765: Alpha-2 adrenergic receptor Agonist; Analgesic; Sedative; Sedative/Hypnotics
CBR-001-624-597-9,RFM-008-649-7,CBR-001-624-597-9,Cc1cccc(c1C)Cc1c[nH]cn1,CBR-HVAC-12765: Alpha-2 adrenergic receptor Agonist; Analgesic; Sedative; Sedative/Hypnotics
CBR-001-624-598-0,RFM-008-650-0,CBR-001-624-598-0,O[C@@H]1[C@@H](O)CN2[C@@H]([C@H]1O)[C@@H](O)CC2,CBR-HVAC-12236: alpha-Glucosidase Inhibitors; AIDS Medicines; Anti-HIV Agents; Anti-Hepatitis C Virus Drugs; Antidiabetic Drugs; Antiviral Drugs; Oncolytic Drugs; Treatment of Transplant Rejection
CBR-001-624-599-1,RFM-008-651-1,CBR-001-624-599-1,Clc1cc(Cl)c2c(c1O)nccc2,"CBR-HVAC-13552: Although the mechanism of action is not understood, chloroxine may slow down mitotic activity in the epidermis, thereby reducing excessive scaling associated with dandruff or seborrheic dermatitis of the scalp; Antiseborrheic"
CBR-001-624-600-7,RFM-008-652-2,CBR-001-624-600-7,OC(CCCCCC(C(=O)O)(C)C)CCCCCC(C(=O)O)(C)C,"CBR-HVAC-12903: AMP-Activated Protein Kinase (AMPK) Activators; AMP-activated protein kinase; AMPK stimulant; ATP Citrate Lyase Inhibitors; ATP citrate lyase Activator; ATP citrate pro 3S lyase inhibitor; Inhibitor; Signal Transduction Modulators; Cholesterol synthesis inhibitor; Hypertension, Treatment of; Lipid metabolism modulator; Lipoprotein Disorders, Treatment of"
CBR-001-624-601-8,RFM-008-653-3,CBR-001-624-601-8,OC1CCC(O)C(O)CC(O)CC2(O)CC(O)C(C(O2)CC(/C=C/C=C/C=C/C=C/C=C/C=C\C=C\C(C(C(C(OC(=O)CC(C1)O)C)C)O)C)OC1OC(C)C(C(C1O)N)O)C(=O)O,"CBR-HVAC-13066: Amphotericin binds to ergosterol in the fungal cell membrane resulting in an increase of membrane permeability that allows leakage of the cellular contents; Membrane permeability enhancer; Antifungal; Antifungal Agents; Antileishmanials; Creutzfeldt-Jakob Disease, Treatment of; Membrane permeability enhancer"
CBR-001-624-602-9,RFM-008-654-4,CBR-001-624-602-9,O[C@@H]1CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@@H](O2)C[C@H](/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H]([C@H]([C@H]([C@@H](OC(=O)C[C@@H](C1)O)C)C)O)C)O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@@H]1O)N)O)C(=O)O,"CBR-HVAC-13066: Amphotericin binds to ergosterol in the fungal cell membrane resulting in an increase of membrane permeability that allows leakage of the cellular contents; Membrane permeability enhancer; Antifungal; Antifungal Agents; Antileishmanials; Creutzfeldt-Jakob Disease, Treatment of; Membrane permeability enhancer"
CBR-001-624-603-0,RFM-008-655-5,CBR-001-624-603-0,CC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C(=CC(=O)C2)C,CBR-HVAC-13156: Anabolic steroid
CBR-001-624-604-1,RFM-008-656-6,CBR-001-624-604-1,O=C(c1ccccc1O)Oc1ccccc1,CBR-HVAC-13305: Analgesic
CBR-001-624-605-2,RFM-008-657-7,CBR-001-624-605-2,OCC(n1cc(c2c1nc(N)nc2)C(=O)c1cncc(c1)NC(=O)Cc1ccc(cn1)Cl)(C)C,CBR-HVAC-12539: ANALGESIC
CBR-001-624-606-3,RFM-008-658-8,CBR-001-624-606-3,COc1cc(C(C)C)c(cc1I)Oc1cnc(nc1N)N,CBR-HVAC-13872: Analgesic Drugs
CBR-001-624-607-4,RFM-008-659-9,CBR-001-624-607-4,Oc1ccc(cc1)c1coc2c(c1=O)ccc(c2)O,"CBR-HVAC-12713: Analgesic Drugs; Bone Diseases, Treatment of; Oncolytic Drugs; Pulmonary Hypertension, Treatment of"
CBR-001-624-608-5,RFM-008-660-2,CBR-001-624-608-5,OC(=O)[C@@H]1CCCN1,"Less interesting component of CBR-HVAC-12100, acquired in error"
CBR-001-624-609-6,RFM-008-661-3,CBR-001-624-609-6,CCOc1ccc(cc1)NC(=O)C,CBR-HVAC-13319: Analgesic; Antipyretic
CBR-001-624-610-9,RFM-008-662-4,CBR-001-624-610-9,O=C1CC[C@]2(C(=C1)[C@@H](C)C[C@@H]1C2CC[C@]2(C1CC[C@]2(OC(=O)C)C(=O)C)C)C,CBR-HVAC-01341: Androgen receptor Antagonist; Estrogen receptor agonist
CBR-001-624-611-0,RFM-008-663-5,CBR-001-624-611-0,C=CC[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CCCC[C@H]12,CBR-HVAC-13428: Androgen receptor Antagonist; Progestogen
CBR-001-624-612-1,RFM-008-664-6,CBR-001-624-612-1,OCC(COc1ccc(cc1)C(c1ccc(cc1)OCC(CCl)O)(C)C)O,CBR-HVAC-13864: Androgen Receptor Antagonists; Signal Transduction Modulators; Prostate Cancer Therapy
CBR-001-624-613-2,RFM-008-665-7,CBR-001-624-613-2,N#Cc1ccc(cc1Cl)c1ccn(n1)C[C@@H](NC(=O)c1n[nH]c(c1)C(O)C)C,CBR-HVAC-12553: ANDROGEN RECEPTOR Inhibitor
CBR-001-624-614-3,RFM-008-666-8,CBR-001-624-614-3,Cc1c2OC(C)(C)CCc2c(c(c1C)O)C,CBR-HVAC-12077: Androgen Receptor Ligands; Androgen receptor antagonist; Reducing agent; Signal Transduction Modulators; ANTICANCER; Prostate Cancer Therapy
CBR-001-624-615-4,RFM-008-667-9,CBR-001-624-615-4,OCCO[C@@H]1CC[C@H](C[C@H]1OC)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C1)C)/C)O)OC)C)C)/C)C,"CBR-HVAC-13006: Angiogenesis Inhibitors; Angiogenesis inhibitor; Cell cycle inhibitor; FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors; Immunosuppressant; MAMMALIAN TARGET OF RAPAMYCIN (MTOR); Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors; Protein kinase inhibitor; Signal Transduction Modulators; mTOR kinase Antagonist; mTOR kinase inhibitor; Age-Related Macular Degeneration, Treatment of; Allergic Skin Disorders, Treatment for; Antiepileptic Drugs; Astrocytoma Therapy; Bladder Cancer Therapy ; Bone Cancer Therapy; Breast Cancer Therapy; Cancer of Unspecified Body Location/System; Cervical Cancer Therapy; Colorectal Cancer Therapy; Digestive/Gastrointestinal Cancer Therapy; Endocrine Cancer Therapy; Female Reproductive System Cancer Therapy; Gastric Cancer Therapy; Gastrointestinal Genetic Disorders, Treatment of ; Head and Neck Cancer Therapy; Hematological Cancer Therapy; Immunosuppressant; Immunosuppressants; Interstitial Lung Diseases, Treatment of; Leukemia Therapy; Liver Cancer Therapy; Liver and Biliary Tract Disorders, Treatment of; Lymphoma Therapy; Melanoma Therapy; Multiple Myeloma Therapy; Neurologic Cancer Therapy; Neurologic Drugs (Miscellaneous); Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Prostate Cancer Therapy; Renal Cancer Therapy; Respiratory/Thoracic Cancer Therapy; Rheumatoid Arthritis, Treatment of; Sarcoma Therapy; Small Cell Lung Cancer Therapy; Treatment of Transplant Rejection; Tuberous Sclerosis, Treatment of"
CBR-001-624-616-5,RFM-008-668-0,CBR-001-624-616-5,Cn1ncc(c1)c1nccc(c1)Oc1cc(F)c(cc1F)NC(=O)C1(CC1)C(=O)Nc1ccccc1,CBR-HVAC-13993: Angiogenesis Inhibitors; Apoptosis Inducers; KIT (C-KIT) Inhibitors; PDGFRalpha Inhibitors; Signal Transduction Modulators; Digestive/Gastrointestinal Cancer Therapy; Myeloid Leukemia Therapy
CBR-001-624-617-6,RFM-008-669-1,CBR-001-624-617-6,CCOC(=O)[C@@H](N[C@H](C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(=O)O)C)CCc1ccccc1,"CBR-HVAC-12826: Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Antihypertensive; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-624-618-7,RFM-008-670-4,CBR-001-624-618-7,COC(=O)[C@@H]1[C@@H](OC)[C@@H](C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c1[nH]c1c2cccc1)OC(=O)c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-13350: Angiotensin converting enzyme Inhibitor; Antihypertensive
CBR-001-624-619-8,RFM-008-671-5,CBR-001-624-619-8,CC(=O)O[C@@]1(CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2C=C(C2=CC(=O)CC[C@H]12)C)C(=O)C,CBR-HVAC-12885: Antagonist; MINERALOCORTICOID RECEPTOR Inhibitor; Progesterone receptor agonist; CONTRACEPTIVE
CBR-001-624-620-1,RFM-008-672-6,CBR-001-624-620-1,N#C[C@@]1(CC[C@@H](CC1)N1CC[C@]([C@@H](C1)C)(C(=O)O)c1ccccc1)c1ccc(cc1)F,"CBR-HVAC-02085: Antiallergic Ophthalmic Agents;Drugs for Allergic Rhinitis;Allergy, Treatment of; Histamine H1 Receptor Antagonists;Signal Transduction Modulators; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist"
CBR-001-624-621-2,RFM-008-673-7,CBR-001-624-621-2,OC(=O)CCn1c2ccccc2c(c1C)Cn1cncc1,CBR-HVAC-03006: Antiallergy/Antiasthmatic Drugs;Antiplatelet Therapy; Prostanoid TP Antagonists;Signal Transduction Modulators;Thromboxane Synthase Inhibitors; Thromboxane A synthase Inhibitor; Thromboxane synthase inhibitor
CBR-001-624-622-3,RFM-008-674-8,CBR-001-624-622-3,CN(CCN(c1scc(n1)c1c(cc(cc1C(C)C)C(C)C)C(C)C)Cc1cccnc1)C,"CBR-HVAC-04199: Antiallergy/Antiasthmatic Drugs;Irritable Bowel Syndrome, Agents for; Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators; PLATELET ACTIVATING FACTOR RECEPTOR Antagonist; Platelet activating factor antagonist"
CBR-001-624-623-4,RFM-008-675-9,CBR-001-624-623-4,CCOc1cc(CNc2cnnc(c2Cl)O)ccc1OC,CBR-HVAC-11081: Antiallergy/Antiasthmatic Drugs; Mediator Release Inhibitors; Immunosuppressant; Antiasthmatic;
CBR-001-624-624-5,RFM-008-676-0,CBR-001-624-624-5,NCCCBr,CBR-HVAC-13706: Antiallergic Ophthalmic Agents
CBR-001-624-625-6,RFM-008-677-1,CBR-001-624-625-6,COc1ccc(cc1OC)CCNCCCNC(=O)c1ccc(cc1)[N+](=O)[O-],CBR-HVAC-10433: Antiarrhythmic Drugs; Calcium Channel Blockers;Potassium Channel Blockers; Potassium channel; Calcium channel Blocker;
CBR-001-624-626-7,RFM-008-678-2,CBR-001-624-626-7,COc1ccc2c(c1)ccc(c2)[C@@H](C(=O)OCCCCO[N+](=O)[O-])C,"CBR-HVAC-04710: Antiarthritic Drugs;Muscular Dystrophy, Agents for;Osteoarthritis, Treatment of;Non-Opioid Analgesics; Nitric Oxide (NO) Donors;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Signal Transduction Modulators; CYCLOOXYGENASE Inhibitor; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Nitric oxide stimulant; Prostaglandin synthase inhibitor"
CBR-001-624-627-8,RFM-008-679-3,CBR-001-624-627-8,CC(Cn1cnc2c1c(=O)n(C)c(=O)n2C)O,CBR-HVAC-13503: Antiasthmatic
CBR-001-624-628-9,RFM-008-680-6,CBR-001-624-628-9,O[C@@H]1CC[C@]2([C@@H](C1)[C@@H](O)C[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)O)C)C)C,CBR-HVAC-12354: ANTIATHEROSCLEROTIC
CBR-001-624-629-0,RFM-008-681-7,CBR-001-624-629-0,CCN1CCN(C(=O)C1=O)C(=O)N[C@@H](C(=O)N[C@]1(OC)C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C)[C@@H](O)C,CBR-HVAC-02055: Antibacterial Drugs; Antibiotic; Cell wall synthesis inhibitor
CBR-001-624-630-3,RFM-008-682-8,CBR-001-624-630-3,Fc1ccc(c(c1)F)n1cc(C(=O)O)c(=O)c2c1nc(N1C[C@@H]3[C@H](C1)C3NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)c(c2)F,CBR-HVAC-02561: Antibacterial Drugs; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-624-631-4,RFM-008-683-9,CBR-001-624-631-4,N[C@H](C(=O)O)CCCCNCNC(=O)C1C(=O)[C@@H](N(C)C)[C@H]2[C@](C1=O)(O)C(=O)C1[C@H](C2)[C@](C)(O)c2c(C1=O)c(O)ccc2,CBR-HVAC-05641: Antibacterial Drugs;Acne Therapy;
CBR-001-624-632-5,RFM-008-684-0,CBR-001-624-632-5,CCN1CCN(CC1)c1cc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-12993: Antibacterial Drugs
CBR-001-624-633-6,RFM-008-685-1,CBR-001-624-633-6,CN1CCN(CC1)c1cc2c(cc1F)c(=O)c(cn2c1ccc(cc1)F)C(=O)O,CBR-HVAC-12803: Antibacterial; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-624-634-7,RFM-008-686-2,CBR-001-624-634-7,CC1OC1P(=O)([O-])[O-],CBR-HVAC-02570: Antibiotics; Cytokine Production Inhibitors;Signal Transduction Modulators; Enolpyruvyl transferase Inhibitor; Cell wall synthesis inhibitor; Enolpyruvyl transferase inhibitor; Protein synthesis inhibitor
CBR-001-624-635-8,RFM-008-687-3,CBR-001-624-635-8,CN([C@@H]1C(=O)C(C(=O)N)C(=O)[C@@]2([C@H]1C[C@@H]1Cc3cccc(c3C(=O)C1C2=O)O)O)C,CBR-HVAC-13330: Antibiotic
CBR-001-624-636-9,RFM-008-688-4,CBR-001-624-636-9,O[C@@H]1CC[C@]2([C@@H](C1)C[C@@H]([C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)O)C)C)O)C,"CBR-HVAC-12353: Antioxidants; Apoptosis-inhibitors; Cholesterol inhibitor; Cholesterol-inhibitors; Immunomodulators; Immunosuppressants; Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activators; Signal Transduction Modulators; ANTIBIOTIC; Adenomatous Polyposis Therapy; Agents for Gallstone Disease; Cancer; Colorectal Cancer Therapy; Digestive System Disorders; Gastrointestinal Disorders (Not Specified); Huntington's Disease, Treatment of; Hyperlipidaemia; Lipoprotein Disorders, Treatment of ; Liver Disorders; Liver and Biliary Tract Disorders, Treatment of; Ophthalmic Drugs; Transplant Rejection"
CBR-001-624-637-0,RFM-008-689-5,CBR-001-624-637-0,O=C(N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nncs1)Cn1cnnn1,CBR-HVAC-13538: Antibiotic; Antibiotic
CBR-001-624-638-1,RFM-008-690-8,CBR-001-624-638-1,O=C(Cc1ccccc1)N[C@@H]1C(=O)N2[C@@H]1SC(C2C(=O)O)(C)C,CBR-HVAC-12616: Antibiotics
CBR-001-624-639-2,RFM-008-691-9,CBR-001-624-639-2,Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1[C@@H](O)[C@H]([C@@H]2O)O)C,"CBR-HVAC-12796: Anticancer; Selective Estrogen Receptor alpha Modulators (SERAM); Signal Transduction Modulators; Anticancer; Breast Cancer Therapy; Contraceptives; Sjogren's Syndrome, Agents for; Treatment of Osteoporosis; Treatment of Postmenopausal Syndrome"
CBR-001-624-640-5,RFM-008-692-0,CBR-001-624-640-5,CC[N+](CCOC(=O)C(c1ccccc1)(c1ccccc1)O)(CC)C,CBR-HVAC-13168: Anticholinergic
CBR-001-624-641-6,RFM-008-693-1,CBR-001-624-641-6,CC(NCCC(C)C)CCCC(C)C,CBR-HVAC-13094: Anticholinergic
CBR-001-624-642-7,RFM-008-694-2,CBR-001-624-642-7,O=C1Oc2ccccc2C(=O)C1C(C1C(=O)Oc2c(C1=O)cccc2)C,CBR-HVAC-13125: Anticoagulant
CBR-001-624-643-8,RFM-008-695-3,CBR-001-624-643-8,CCCCCCCC(=O)OC(COC(=O)CCCCCCC)COC(=O)CCCCCCC,CBR-HVAC-13027: Anticoagulants
CBR-001-624-644-9,RFM-008-696-4,CBR-001-624-644-9,[O-]C(=O)CC(O)C,"CBR-HVAC-12708: Anticognitive; Neuroprotectant; Nootropic; Unidentified pharmacological activity; Anti-cognitive; Antiepileptic Drugs; Cognition Disorders, Treatment of; Neuroprotectant; Nootropic"
CBR-001-624-645-0,RFM-008-697-5,CBR-001-624-645-0,O=C1NC(=O)C(O1)(C)C,CBR-HVAC-13492: Anticonvulsant
CBR-001-624-646-1,RFM-008-698-6,CBR-001-624-646-1,CC(CC(C)(C)C)Cc1cc(C)cc(=O)n1O,CBR-HVAC-13334: Antidandruff; Antiseborreic
CBR-001-624-647-2,RFM-008-699-7,CBR-001-624-647-2,CN1CC2[C@H]3CC(=O)N[C@]2(CC1)Oc1c3cc(Cl)cc1,CBR-HVAC-02518: Antidepressants; Norepinephrine transporter; 5-Hydroxytryptamine transporter; Dopamine transporter Inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-624-648-3,RFM-008-700-3,CBR-001-624-648-3,NCC[C@@H](c1ccccc1)Oc1ccc(cc1)C(F)(F)F,CBR-HVAC-13480: Antidepressant
CBR-001-624-649-4,RFM-008-701-4,CBR-001-624-649-4,OC(=O)C(Cc1c[nH]c2c1cccc2)(N)C,CBR-HVAC-13031: Antidepressants
CBR-001-624-650-7,RFM-008-702-5,CBR-001-624-650-7,N#C[C@@H]1C[C@@H](CN1C(=O)CNC(CC(=O)N1CCCC1)(C)C)F,CBR-HVAC-13780: Antidiabetic Drugs
CBR-001-624-651-8,RFM-008-703-6,CBR-001-624-651-8,COC(=O)C1C(C)CC(=CC1=O)Nc1ccc(cc1)Cl,CBR-HVAC-10570: Antiepileptic;
CBR-001-624-652-9,RFM-008-704-7,CBR-001-624-652-9,OC(=O)C1CC2CCC1CC2,CBR-HVAC-13710: Antiepileptic Drugs
CBR-001-624-653-0,RFM-008-705-8,CBR-001-624-653-0,C=C1C[C@@H]([C@@H](C1)C(=O)O)N,CBR-HVAC-05073: Antifungal Agents; Isoleucyl-tRNA Synthetase Inhibitors; Isoleucyl-tRNA synthetase Inhibitor; Isoleucyl-tRNA synthetase inhibitor
CBR-001-624-654-1,RFM-008-706-9,CBR-001-624-654-1,Oc1ncc(c(n1)O)/N=C/c1cc(Cl)cc(c1O)Cl,CBR-HVAC-13755: Antifungal Agents
CBR-001-624-655-2,RFM-008-707-0,CBR-001-624-655-2,Oc1ccc(cc1Sc1cc(Cl)ccc1O)Cl,CBR-HVAC-13553: Antifungal; Antiseptic
CBR-001-624-656-3,RFM-008-708-1,CBR-001-624-656-3,CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@@H]([C@@H]1C/C=C\CCCC(=O)O)O,CBR-HVAC-04319: Antiglaucoma Agents;
CBR-001-624-657-4,RFM-008-709-2,CBR-001-624-657-4,Oc1ccc(cc1Cc1cc(Cl)ccc1O)Cl,CBR-HVAC-13341: Antihelminthic
CBR-001-624-658-5,RFM-008-710-5,CBR-001-624-658-5,CCCCCCCCCCCCCCCCCCN(C)C,CBR-HVAC-13217: Antihelmintic
CBR-001-624-659-6,RFM-008-711-6,CBR-001-624-659-6,COc1ccc2c(c1)nc(cc2O[C@@H]1C[C@@H]2N(C1)C(=O)[C@H](CCCCC/C=C\[C@H]1[C@](NC2=O)(C1)C(=O)O)NC(=O)OC1CCCC1)c1csc(n1)NC(C)C,CBR-HVAC-11072: Anti-Hepatitis C Virus Drugs; HCV NS3 Protease Inhibitors; NS3/4A protease Inhibitor;
CBR-001-624-660-9,RFM-008-712-7,CBR-001-624-660-9,Clc1ccc(cc1)C(c1ccccc1)OCCN1CCCCC1,CBR-HVAC-13059: Antihistamine
CBR-001-624-661-0,RFM-008-713-8,CBR-001-624-661-0,Clc1ccc(cc1)C(c1ccccc1)OC1CC2CCC(C1)N2C,CBR-HVAC-13519: Antihistamine
CBR-001-624-662-1,RFM-008-714-9,CBR-001-624-662-1,O=C(CC(C(=O)O)(C)C)O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]1([C@@H]2CC[C@H]2[C@@]1(C)CC[C@@]1([C@@H]2[C@@H](CC1)C(=C)C)C(=O)O)C)C,CBR-HVAC-04904: Anti-HIV Agents; Viral Maturation Inhibitors; Protease Inhibitor; HIV gag inhibitor; HIV capsid assembly inhibitor
CBR-001-624-663-2,RFM-008-715-0,CBR-001-624-663-2,CC(COC[C@H]1O[C@@H]2O[C@@H]3[C@@H](COCC(O)C)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](COCC(O)C)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](COCC(O)C)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O[C@H]1[C@@H]([C@H]2O)O)[C@H](O)[C@H]5O)COCC(O)C)[C@H](O)[C@H]4O)COCC(O)C)[C@H](O)[C@H]3O)COCC(O)C)O,CBR-HVAC-12768: Anti-HIV Agents; Anti-Herpes Labialis Drugs; Therapy of Inborn Errors of Metabolism
CBR-001-624-664-3,RFM-008-716-1,CBR-001-624-664-3,O=CC[C@H]1C[C@@H](C)[C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]([C@H]1O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@H]1O)N(C)C)O[C@@H]1O[C@@H](C)[C@@H]([C@](C1)(C)OC(=O)C)OC(=O)CC)OC)OC(=O)CC)C)OC(=O)C,CBR-HVAC-12983: Anti-Infective; Antibiotic; Anti-Infective; Antibiotic; Antibiotics
CBR-001-624-665-4,RFM-008-717-2,CBR-001-624-665-4,CCCCCCCCC(=O)O,CBR-HVAC-13143: Anti-infective; Antifungal
CBR-001-624-666-5,RFM-008-718-3,CBR-001-624-666-5,CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,CBR-HVAC-13081: Anti-inflammatory
CBR-001-624-667-6,RFM-008-719-4,CBR-001-624-667-6,CCCCC1C(=O)NN(C1=O)c1ccccc1,"CBR-HVAC-13422: Anti-inflammatory, nonsteroidal"
CBR-001-624-668-7,RFM-008-720-7,CBR-001-624-668-7,COc1cc(ccc1OC)Cc1cnc(nc1N)N,CBR-HVAC-12746: Anti-inflammatory; Dihydrofolate Reductase (DHFR) Inhibitors; Radical formation inhibitor; Reducing agent; Anti-inflammatory; Antiprotozoal; Treatment of Protozoal Diseases
CBR-001-624-669-8,RFM-008-721-8,CBR-001-624-669-8,O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](CCCC(O)(C)C)C)C)/C1,CBR-HVAC-12106: Anti-inflammatory; Vitamin D agonist; Anti-inflammatory; Antineoplastic Enhancing Agents; Antipsoriatics; Lung Cancer Therapy; Myelodysplastic Syndrome Therapy; Non-Small Cell Lung Cancer Therapy; Pancreatic Cancer Therapy; Prostate Cancer Therapy; Thyroid Disease Therapy; Treatment of Hyperparathyroidism; Treatment of Osteoporosis; Treatment of Renal Diseases
CBR-001-624-670-1,RFM-008-722-9,CBR-001-624-670-1,OCC(CCCCCCC(CO)(C)C)(C)C,"CBR-HVAC-12778: Antilipemic; Lipoprotein Disorders, Treatment of"
CBR-001-624-671-2,RFM-008-723-0,CBR-001-624-671-2,O=c1n(Cl)c(=O)[nH]c(=O)n1Cl,CBR-HVAC-13202: Antimicrobial; Disinfectant
CBR-001-624-672-3,RFM-008-724-1,CBR-001-624-672-3,CCCCCCCCNC(=O)/C(=C\c1c2ccccc2n(c1C)CCCN(C)C)/C#N,CBR-HVAC-13905: Actin Destabilizer;Antimitotic Drugs;Apoptosis Inducers;Tropomyosin alpha-3 Chain (TPM3) Inhibitors
CBR-001-624-673-4,RFM-008-725-2,CBR-001-624-673-4,Clc1ccc(c(c1)Cl)C(=O)O,CBR-HVAC-13718: Antioxidants; Antipyretics; Opioid Analgesics
CBR-001-624-674-5,RFM-008-726-3,CBR-001-624-674-5,Oc1ccc(cc1)[C@@H]1CC(=O)c2c(O1)cc(cc2O)O,CBR-HVAC-12941: Antioxidants; Apoptosis Inducers; Aromatase Inhibitors; Cell Adhesion Inhibitors; Drugs Acting on Quorum Sensing Signaling; Estrogen Receptor (ER) beta Agonists; Signal Transduction Modulators; TRPM3 Antagonists; Anti-Hepatitis C Virus Drugs; Atherosclerosis Therapy; Oncolytic Drugs; Skin-Whitening Agents
CBR-001-624-675-6,RFM-008-727-4,CBR-001-624-675-6,CSCC[C@@H](C(=O)O)N,"CBR-HVAC-12615: Antioxidants; Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands; Catechol-O-methyltransferase Inhibitor; Antidepressants; Essential amino acid; Inflammation, Treatment of; Ophthalmic Drugs; Treatment of Hot Flushes"
CBR-001-624-676-7,RFM-008-728-5,CBR-001-624-676-7,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O1)cc(cc2O)O[C@@H]1O[C@H](CO[C@@H]2O[C@@H](C)[C@@H]([C@H]([C@H]2O)O)O)[C@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-12677: Antioxidants; Free Radical Scavengers; Anti-Influenza Virus Drugs; Antidepressants; Cerebrovascular Diseases, Treatment of; Chemopreventive Agents; Metabolic Disorders (Not Specified); Treatment of Osteoporosis"
CBR-001-624-677-8,RFM-008-729-6,CBR-001-624-677-8,CCCCCCCCCCCC(=O)O,CBR-HVAC-12902: Anti-Parainfluenza Virus Drugs; Anti-RSV Drugs; Antibacterial Drugs
CBR-001-624-678-9,RFM-008-730-9,CBR-001-624-678-9,Fc1ccc(cc1)c1cncc(c1)CN1CCN(CC1)c1cccc2c1OCCO2,CBR-HVAC-05169: Antipsychotic Drugs; Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT1A Receptor Agonists; Dopamine receptor D2; 5-Hydroxytryptamine 1A receptor Agonist; Antagonist; Dopamine D2 receptor antagonist; 5 Hydroxytryptamine 1A receptor agonist
CBR-001-624-679-0,RFM-008-731-0,CBR-001-624-679-0,CN1C[C@@H]2[C@H](C1)[C@H]2CN(C(=O)c1ncn(c1)C)Cc1ccc(c(c1)Cl)F,CBR-HVAC-06647: Antipsychotic Drugs; GlyT-1 Inhibitors; Glycine transporter 1 Inhibitor;
CBR-001-624-680-3,RFM-008-732-1,CBR-001-624-680-3,CCCCCCCCCCCCCC[N+](C)(C)C,"CBR-HVAC-09756: Antiseptic agent which is active against a wide range of bacteria. It binds strongly to skin, mucosa and other tissues and is therefore poorly absorbed;"
CBR-001-624-681-4,RFM-008-733-2,CBR-001-624-681-4,CC1=CCC(CC1)C(O)(C)C,CBR-HVAC-13216: Antiseptic
CBR-001-624-682-5,RFM-008-734-3,CBR-001-624-682-5,NC(=N)c1ccc(cc1)N/N=N/c1ccc(cc1)C(=N)N,"CBR-HVAC-07280: Antitrypanosomals;Pulmonary Hypertension, Treatment of;Fibrosis, Treatment of; Angiotensin-I Converting Enzyme-Related Carboxypeptidase (ACE2) Activators;DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs;Signal Transduction Modulators;"
CBR-001-624-683-6,RFM-008-735-4,CBR-001-624-683-6,CCN(CCOCCOC(=O)C(c1ccccc1)(CC)CC)CC,CBR-HVAC-13287: Antitussive
CBR-001-624-684-7,RFM-008-736-5,CBR-001-624-684-7,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CO)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@@H](CO)O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O[C@H]1[C@@H]([C@H]2O)O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO,CBR-HVAC-03022: Antiulcer Drugs;
CBR-001-624-685-8,RFM-008-737-6,CBR-001-624-685-8,c1nc(cc(n1)n1cccn1)n1cccn1,CBR-HVAC-03710: Antiulcer Drugs; Antacid
CBR-001-624-686-9,RFM-008-738-7,CBR-001-624-686-9,N[C@H](C(=O)O)CSCC=C,CBR-HVAC-13711: Antiulcer Drugs
CBR-001-624-687-0,RFM-008-739-8,CBR-001-624-687-0,CCCCCCCCCCCCCCCCCCCCCCCCCCCCO,CBR-HVAC-13221: Antiviral
CBR-001-624-688-1,RFM-008-740-1,CBR-001-624-688-1,OC(COc1ccccc1n1cccc1)CNC(C)C,CBR-HVAC-03289: Anxiolytics; Beta adrenergic receptor; 5-Hydroxytryptamine 1B receptor Antagonist; Beta adrenoreceptor antagonist
CBR-001-624-689-2,RFM-008-741-2,CBR-001-624-689-2,O=C(N1CCN(CC1)Cc1ccc2c(c1)OC(O2)(F)F)Nc1cnccc1Cl,"CBR-HVAC-13887: Anxiolytics; Social Phobia, Treatment for"
CBR-001-624-690-5,RFM-008-742-3,CBR-001-624-690-5,OC(=O)CC1=C(C)/C(=C/c2ccc(cc2)S(=O)(=O)C)/c2c1cc(F)cc2,"CBR-HVAC-12964: Apoptosis Inducers; Apoptosis stimulant; Phosphodiesterase 2 inhibitor; Phosphodiesterase 5 Inhibitor; Phosphodiesterase 5 inhibitor; Phosphodiesterase PDE5A Inhibitors; Signal Transduction Modulators; Adenomatous Polyposis Therapy; Anticancer; Apoptosis stimulant; Breast Cancer Therapy; Chemopreventive Agents; Colorectal Cancer Therapy; Congenital Malformations, Treatment of; Esophageal Diseases, Treatment of; Non-Small Cell Lung Cancer Therapy; Prostate Cancer Therapy"
CBR-001-624-691-6,RFM-008-743-4,CBR-001-624-691-6,O=C1OC(=O)C2C1C1CCC2O1,CBR-HVAC-12723: Apoptosis Inducers; Apoptosis stimulant; Protein Phosphatase 2A (PP-2A) Inhibitors; Protein phosphatase 1 (PP-1) Inhibitors; Protein phosphatase 2A Inhibitor; Protein phosphatase 2A inhibitor; Signal Transduction Modulators; Anticancer; Oncolytic Drugs
CBR-001-624-692-7,RFM-008-744-5,CBR-001-624-692-7,OC[C@H]1O[C@@H](O[C@]([C@H]2CC[C@@]3([C@@H]2[C@H](O)C[C@H]2[C@@]3(C)CC[C@@H]3[C@]2(C)CC[C@@H](C3(C)C)O)C)(CCC=C(C)C)C)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-12818: Apoptosis Inducers; Apoptosis stimulator; Caspase 3 Activators; Glucocorticoid Receptor (GR) Agonists; NF-kappaB (NFKB) Activation Inhibitors; Nitric Oxide (NO) Production Inhibitors; Signal Transduction Modulators; Anticancer; Oncolytic Drugs
CBR-001-624-693-8,RFM-008-745-6,CBR-001-624-693-8,CCCC(=O)O,"CBR-HVAC-12987: Apoptosis Inducers; Histone Deacetylase (HDAC) Inhibitors; Antidepressants; Antiobesity Drugs; Inflammatory Bowel Disease, Agents for; Metabolic Disorders (Not Specified); Oncolytic Drugs; Stroke, Treatment of; Type 2 Diabetes, Agents for"
CBR-001-624-694-9,RFM-008-746-7,CBR-001-624-694-9,CN[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1CN(C(=O)C(F)(F)F)CCc1ccccc1)[C@H](OCC#CC#CCO[C@@H]([C@@H](C(=O)N1CCC[C@H]1CN(C(=O)C(F)(F)F)CCc1ccccc1)NC(=O)[C@@H](NC)C)C)C)C,CBR-HVAC-14117: Apoptosis Inducers; Inhibitor of Apoptosis Proteins (IAP) Inhibitors; Signal Transduction Modulators; Hematological Cancer Therapy; Solid Tumors Therapy
CBR-001-624-695-0,RFM-008-747-8,CBR-001-624-695-0,O=C(NCc1cc2c(o1)c(cc(c2)c1ccc(cc1)C(=O)N1CCC(CC1)(F)F)c1ccc(cc1)F)/C=C/c1ccc(nc1)N,CBR-HVAC-14070: Apoptosis Inducers; Serine/Threonine-Protein Kinase PAK4 Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-001-624-696-1,RFM-008-748-9,CBR-001-624-696-1,O[C@@H]1CC[C@]2([C@@H](C1)C[C@@H]([C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)NCCS(=O)(=O)O)C)C)O)C,"CBR-HVAC-12997: Apoptosis Inhibitors; Cholesterol inhibitor; Hepatoprotectants; Retinoprotectors; Stroke, Treatment of"
CBR-001-624-697-2,RFM-008-749-0,CBR-001-624-697-2,N[C@@H]1CCN(C1)c1cc(nc(n1)N)C(C)C,"CBR-HVAC-06940: Asthma Therapy;Atopic Dermatitis, Agents for;Rheumatoid Arthritis, Treatment of; Histamine H4 Receptor Antagonists;Signal Transduction Modulators;"
CBR-001-624-698-3,RFM-008-750-3,CBR-001-624-698-3,CCCCCC[C@H](C(=O)O)CCC,"CBR-HVAC-12900: Astrocyte modulator; Unidentified pharmacological activity; beta-Amyloid (Abeta) Production Inhibitors; Alzheimer's Dementia, Treatment of ; Amyotrophic Lateral Sclerosis, Agents for; Antiparkinsonian; Antiparkinsonian Drugs; Neuroprotectant; Stroke, Treatment of"
CBR-001-624-699-4,RFM-008-751-4,CBR-001-624-699-4,OC1CCCCCc2cc(O)cc(c2C(=O)OC(CCC1)C)O,CBR-HVAC-09964: Atherosclerosis Therapy; Estrogen receptor Agonist;
CBR-001-624-700-0,RFM-008-752-5,CBR-001-624-700-0,OC[C@@]1(O)OC[C@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-12630: Atherosclerosis Therapy; Dental Agents; Lipoprotein Disorders, Treatment of ; Pharmaceutical Aids; Type 2 Diabetes, Agents for"
CBR-001-624-701-1,RFM-008-753-6,CBR-001-624-701-1,[O-]C(=O)CC(C(C(=O)[O-])O)(C(=O)[O-])O,CBR-HVAC-12815: ATP Citrate Lyase Inhibitors; Antiobesity Drugs
CBR-001-624-702-2,RFM-008-754-7,CBR-001-624-702-2,CC[C@@H]([C@@H]1NC(=O)[C@@H](NC(=O)CCCSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCC(=O)N)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)Cc1ccc(cc1)OC)C,"CBR-HVAC-12725: Autism, Treatment of; Multisystem Genetic Disorders, Treatment of ; Uterine Stimulants"
CBR-001-624-703-3,RFM-008-755-8,CBR-001-624-703-3,COc1ccc(c(c1)F)N,CBR-HVAC-13707: Benign Prostatic Hyperplasia Therapy
CBR-001-624-704-4,RFM-008-756-9,CBR-001-624-704-4,COc1cc(CCNCC(COc2ccc(cc2Cl)Cl)O)ccc1OC,CBR-HVAC-07503: Beta 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor agonist
CBR-001-624-705-5,RFM-008-757-0,CBR-001-624-705-5,CC(NCC(c1ccc(c(c1)O)O)O)C,CBR-HVAC-13457: Beta adrenergic receptor Agonist; Bronchodilator
CBR-001-624-706-6,RFM-008-758-1,CBR-001-624-706-6,OC(c1cc(O)cc(c1)O)CNC(C)C,CBR-HVAC-13007: Beta adrenergic receptor Agonist; Bronchodilator; Bronchodilators; Positive Inotropic Agents
CBR-001-624-707-7,RFM-008-759-2,CBR-001-624-707-7,CN(CC(=O)O)C,CBR-HVAC-13169: Betaine-homocysteine methyl transferase Inhibitor; Anti-stress nutrient; Antiepileptic; Antioxidant
CBR-001-624-708-8,RFM-008-760-5,CBR-001-624-708-8,C=CC[C@@H]1/C=C(\C)/C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@@H](C[C@@H]2OC)C)C(=O)C(=O)N2[C@H](C(=O)O[C@@H]([C@@H]([C@H](CC1=O)O)C)/C(=C/[C@@H]1CC[C@H]([C@@H](C1)OC)O)/C)CCCC2,"CBR-HVAC-12813: Bone morphogenetic protein stimulant; Calcineurin (PP-2B) Inhibitors; Calcineurin Inhibitor; Cytochrome P450 CYP3A4 Inhibitors; FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors; INS Expression Inhibitors; Signal Transduction Modulators; Antiallergic Ophthalmic Agents; Antiallergy/Antiasthmatic Drugs; Antipsoriatics; Atopic Dermatitis, Agents for; Calcineurin inhibitor; Dry Eye Syndrome, Treatment for; Eczema, Treatment of; Immunosuppressant; Immunosuppressants; Inflammatory Bowel Disease, Agents for; Interstitial Lung Diseases, Treatment of; Myasthenia Gravis, Agents for; Ophthalmic Drugs; Pulmonary Hypertension, Treatment of; Rheumatoid Arthritis, Treatment of; Stroke, Treatment of; Systemic Lupus Erythematosus, Agents for; Treatment of Autoimmune Diseases; Treatment of Transplant Rejection; Urologic Drugs"
CBR-001-624-709-9,RFM-008-761-6,CBR-001-624-709-9,C/C(=C/C=C/C=C(\C=C\C=C(/C(=O)O)\C)/C)/C=C/C=C(\C(=O)O)/C,"CBR-HVAC-00596: Brain Cancer Therapy;Stroke, Treatment of;Treatment of Shock;Glioblastoma Multiforme Therapy;Treatment of Intermittent Claudication;Neurologic Cancer Therapy; TSC improves oxygenation in hypoxic tissues by exerting hydrophobic effects on water molecules in blood plasma and thereby increasing the hydrogen bonding between the water molecules. This in turn causes the overall organization of water molecules in plasma to become more structured, which facilitates the diffusion of oxygen through plasma and promotes the movement of oxygen into tissues.; Unidentified pharmacological activity"
CBR-001-624-710-2,RFM-008-762-7,CBR-001-624-710-2,ONC(=O)[C@@H]1N(CCSC1(C)C)S(=O)(=O)c1ccc(cc1)Oc1ccncc1,"CBR-HVAC-04779: Breast Cancer Therapy;Non-Small Cell Lung Cancer Therapy;Prostate Cancer Therapy;Age-Related Macular Degeneration, Treatment of;Glioblastoma Multiforme Therapy; Angiogenesis Inhibitors;MMP-2 (Gelatinase A) Inhibitors;MMP-9 (Gelatinase B) Inhibitors; Matrix metalloproteinase Inhibitor; Matrix metalloproteinase inhibitor; Angiogenesis inhibitor"
CBR-001-624-711-3,RFM-008-763-8,CBR-001-624-711-3,CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-12810: Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors; Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors; Dopamine D2 Antagonists; Nav1.4 (SkM1) Sodium Channel Blockers; Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers; Signal Transduction Modulators; Antidepressants; Antipsychotic Drugs; Anxiolytics
CBR-001-624-712-4,RFM-008-764-9,CBR-001-624-712-4,C=CC(=O)N1CCC[C@@H](C1)n1c(=O)n(c2c1ncnc2N)c1ccc(cc1)Oc1ccccc1,analog of CBR-HVAC-12547
CBR-001-624-713-5,RFM-008-765-0,CBR-001-624-713-5,CCN(C(CN1c2ccccc2Sc2c1cccc2)C)CC,CBR-HVAC-13475: Butyrylcholinesterase Inhibitor; Antidyskinetic; Antiparkinsonian
CBR-001-624-714-6,RFM-008-766-1,CBR-001-624-714-6,CCN(CCn1c(=O)c(=Cc2ccc(cc2)OC)[nH]c2c1cccc2)CC,CBR-HVAC-01006: Calcium channel antagonist
CBR-001-624-715-7,RFM-008-767-2,CBR-001-624-715-7,COCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC(C)C)C,"CBR-HVAC-12914: Calcium Channel Blockers; Calcium channel Blocker; L-type calcium channel antagonist; Calcium channel blocker; Stroke, Treatment of"
CBR-001-624-716-8,RFM-008-768-3,CBR-001-624-716-8,CCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC)C,"CBR-HVAC-12705: Calcium Channel Blockers; Calcium channel L-type Blocker; L-type calcium channel antagonist; Antihypertensive; Hypertension, Treatment of"
CBR-001-624-717-9,RFM-008-769-4,CBR-001-624-717-9,O=C1C=C[C@]2(C(=C1)CC[C@@H]1C2=CC[C@]2([C@H]1CC[C@@H]2C(=O)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1)C)C,"CBR-HVAC-02397: Cancer Multidrug Resistance Modulators;Stroke, Treatment of; Lipid Peroxidation Inhibitors; Lipid peroxidation inhibitor; Oxygen radical scavenger; Oxygen scavenger"
CBR-001-624-718-0,RFM-008-770-7,CBR-001-624-718-0,ClC(C1Nc2cc(Cl)c(cc2S(=O)(=O)N1)S(=O)(=O)N)Cl,CBR-HVAC-12891: Carbonic anhydrase Inhibitor; Antihypertensive; Diuretics
CBR-001-624-719-1,RFM-008-771-8,CBR-001-624-719-1,O=C(Nc1ccc(cc1)F)Nc1ccc(cc1)S(=O)(=O)N,CBR-HVAC-13763: Carbonic Anhydrase Type IX Inhibitors; Carbonic Anhydrase Type XII Inhibitors; Solid Tumors Therapy
CBR-001-624-720-4,RFM-008-772-9,CBR-001-624-720-4,[O-][N+](=O)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NC1CCCC1,CBR-HVAC-00690: Cardiovascular Diseases (Not Specified);Antiglaucoma Agents; Adenosine A1 Agonists;Adenosine A1 Antagonists;Signal Transduction Modulators; ADENOSINE A1 RECEPTOR Agonist; Adenosine A1 receptor agonist
CBR-001-624-721-5,RFM-008-773-0,CBR-001-624-721-5,Clc1ccc(cc1)COC(c1ccc(cc1Cl)Cl)Cn1cncc1,CBR-HVAC-12848: Cell wall synthesis inhibitor; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Antifungal; Antifungal Agents
CBR-001-624-722-6,RFM-008-774-1,CBR-001-624-722-6,C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)/[C@@H]([C@H](/C=C\C=C(\C(=O)NC(=CC1=O)C2=O)/C)OC)OC(=O)N,CBR-HVAC-12678: CHK1 Expression Inhibitors; Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor; Heat shock protein 90 antagonist; Signal Transduction Modulators; ANTI-CANCER; Breast Cancer Therapy; Endocrine Cancer Therapy; Leukemia Therapy; Lymphoma Therapy; Melanoma Therapy; Multiple Myeloma Therapy; Myelodysplastic Syndrome Therapy; Myeloid Leukemia Therapy; Prostate Cancer Therapy; Renal Cancer Therapy; Sarcoma Therapy; Solid Tumors Therapy
CBR-001-624-723-7,RFM-008-775-2,CBR-001-624-723-7,OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F,"CBR-HVAC-13521: Chloride channel Blocker; Anti-inflammatory, nonsteroidal"
CBR-001-624-724-8,RFM-008-776-3,CBR-001-624-724-8,ClC(Cl)Cl,CBR-HVAC-13201: Chloroform bind covalently and irreversibly to cellular macromolecules are believed to account for cellular damage within the liver and kidney; General anesthetic
CBR-001-624-725-9,RFM-008-777-4,CBR-001-624-725-9,CCOC(=O)N1[C@H](CC)C[C@@H](c2c1ccc(c2)C(F)(F)F)N(C(=O)OC)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-12747: Cholesterol ester transfer protein Inhibitor; Cholesterol ester transfer protein antagonist; Cholesteryl Ester Transfer Protein (CETP) Inhibitors; HDL-Cholesterol Increasing Agents; Antihypercholesterolemic; Atherosclerosis Therapy; Lipoprotein Disorders, Treatment of"
CBR-001-624-726-0,RFM-008-778-5,CBR-001-624-726-0,C/C=C/1\C(=O)C[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CCC12C,CBR-HVAC-13604: Cholesterol inhibitor
CBR-001-624-727-1,RFM-008-779-6,CBR-001-624-727-1,COc1cc(CC2NCCc3c2cc(O)c(c3)O)cc(c1OC)OC,"CBR-HVAC-01819: Chronic Obstructive Bronchitis, Agents for;Asthma Therapy; Beta adrenergic receptor agonist; Beta 2 adrenoreceptor agonist"
CBR-001-624-728-2,RFM-008-780-9,CBR-001-624-728-2,C1COC(CN1)COc1cccc2c1CC=C2,"CBR-HVAC-02259: Cognition Disorders, Treatment of; 5 Hydroxytryptamine uptake inhibitor"
CBR-001-624-729-3,RFM-008-781-0,CBR-001-624-729-3,CCCC1(CCC)CCC2(CC1)CCN(C2)CCCN(CC)CC,"CBR-HVAC-00431: Colorectal Cancer Therapy;Inflammatory Bowel Disease, Agents for;Rheumatoid Arthritis, Treatment of;Multiple Myeloma Therapy;Oncolytic Drugs;Endocrine Cancer Therapy;Bone Resorption Inhibitors; Angiogenesis Inhibitors;Apoptosis Inducers;Caspase 3 Activators;Caspase 9 Activators;IL-6 Production Inhibitors;Protein Kinase B (PKB/Akt) Inhibitors;Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators;Vascular Endothelial Growth Factor (VEGF) Inhibitors; Interleukin 6 Inhibitor; Immunosuppressant; Bone resorption inhibitor; Osteoclast inhibitor; Angiogenesis inhibitor; Apoptosis stimulant"
CBR-001-624-730-6,RFM-008-782-1,CBR-001-624-730-6,COc1ccc2c(c1)C(CCC2)C(=O)N(c1ccc(cc1)C(C)C)Cc1ccc(cc1)N(C)C,CBR-HVAC-12440: Complement component 5a Antagonist; Anti-inflammatory; Immunomodulator
CBR-001-624-731-7,RFM-008-783-2,CBR-001-624-731-7,CC(=O)Nc1c(I)c(N(C(=O)C)C)c(c(c1I)C(=O)O)I,CBR-HVAC-13165: Contrast media
CBR-001-624-732-8,RFM-008-784-3,CBR-001-624-732-8,OCC1OC(C(C1O)O)N1C=CC(=O)CC1=O,CBR-HVAC-11544: CTP synthase Inhibitor;
CBR-001-624-733-9,RFM-008-785-4,CBR-001-624-733-9,O=C1N=C(S/C/1=C\c1ccc2c(c1)cccn2)NCc1cccs1,CBR-HVAC-13805: Cyclin-Dependent Kinase Inhibitors; Signal Transduction Modulators; Solid Tumors Therapy
CBR-001-624-734-0,RFM-008-786-5,CBR-001-624-734-0,Sc1nnc(s1)c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-10543: Cyclooxygenase (COX) Inhibitors;Lipoxygenase Inhibitors;Signal Transduction Modulators; COX; Lipoxygenase 5 Inhibitor;
CBR-001-624-735-1,RFM-008-787-6,CBR-001-624-735-1,O=C(c1ccc(cc1)c1ccccc1)CCC(=O)O,"CBR-HVAC-12889: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin G/H synthase Inhibitor; Ankylosing Spondylitis, Treatment of; Anti-inflammatory; Osteoarthritis, Treatment of; Rheumatoid Arthritis, Treatment of"
CBR-001-624-736-2,RFM-008-788-7,CBR-001-624-736-2,CC(CCC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CCC/C/2=C\C=C/1\C[C@@H](O)C[C@@H](C1=C)O)C)C,"CBR-HVAC-12728: Cytosolic nuclear receptor Inhibitor; Hypercalcaemic agent; Vitamin D agonist; Antiarthritic Drugs; Bone Diseases, Treatment of; Nutritional supplement; Therapy of Vitamin-Related Disorders; Treatment of Hyperparathyroidism; Treatment of Osteoporosis"
CBR-001-624-737-3,RFM-008-789-8,CBR-001-624-737-3,[O-]C(=O)CCCCCCCNC(=O)c1ccccc1O,CBR-HVAC-04893: Delivery Agents;
CBR-001-624-738-4,RFM-008-790-1,CBR-001-624-738-4,OCC(O)C,CBR-HVAC-13700: Dermatologic Drugs
CBR-001-624-739-5,RFM-008-791-2,CBR-001-624-739-5,O=C1CCC2(C(=C1)CCC1C2CCC2(C1CC[C@]2(O)C(=O)C)C)C,CBR-HVAC-13067: Develops decidual stroma of the uterus similar to that seen in early pregnancy; Progestogen
CBR-001-624-740-8,RFM-008-792-3,CBR-001-624-740-8,O[C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]2([C@H]3CCC2=O)C)C1)C,"CBR-HVAC-12950: DHEA increases EC proliferation in vitro by mechanism(s) independently of either androgen receptor or estrogen receptor and in vivo enhances large and small vessel EC function in postmenopausal women.; Dehydroepiandrosterone inhibits nuclear factor-kappaB and the secretion of interleukin-6 and interleukin-12 via the peroxisome proliferator-activated receptor alpha; HSD11B1 Expression Inhibitors; Acute Myocardial Infarction, Treatment of; Adrenocortical Dysfunction Therapy; Disorders of Sexual Function and Reproduction, Treatment of; Immunosuppressants; Inflammatory Bowel Disease, Agents for; Muscular Dystrophy, Agents for; Steroid; Stroke, Treatment of; Systemic Lupus Erythematosus, Agents for; Treatment of Anorexia Nervosa; Treatment of Female Sexual Dysfunction"
CBR-001-624-741-9,RFM-008-793-4,CBR-001-624-741-9,Clc1cc2[nH]cc(c2cc1c1ccc(cc1)C1(O)CCC1)C(=O)O,"CBR-HVAC-13795: Diabetic Nephropathy, Agents for"
CBR-001-624-742-0,RFM-008-794-5,CBR-001-624-742-0,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)N(Cc1cnc2c(n1)c(N)nc(n2)N)C,"CBR-HVAC-12685: Dihydrofolate Reductase (DHFR) Inhibitors; Dihydrofolate reductase inhibitor; Folate Antagonists; Thymidylate synthase inhibitor; Antiarthritic Drugs; Antimalarials; Antipsoriatics; Breast Cancer Therapy; Cardiovascular Diseases (Not Specified); Head and Neck Cancer Therapy; Immunosuppressants; Leukemia Therapy; Lymphocytic Leukemia Therapy; Myasthenia Gravis, Agents for; Oncolytic Drugs; Rheumatoid Arthritis, Treatment of"
CBR-001-624-743-1,RFM-008-795-6,CBR-001-624-743-1,Nc1ccc(cc1)S(=O)(=O)Nc1nc(C)cc(n1)C,CBR-HVAC-13348: Dihydropteroate synthase Inhibitor; Antibacterial
CBR-001-624-744-2,RFM-008-796-7,CBR-001-624-744-2,OC(=O)[C@H](CCCNC(=N)N(C)C)N,CBR-HVAC-13020: Dimethylarginine Dimethylaminohydrolase (DDAH) Inhibitors; Nitric Oxide Synthase Inhibitors; Signal Transduction Modulators; Cardiovascular Diseases (Not Specified)
CBR-001-624-745-3,RFM-008-797-8,CBR-001-624-745-3,CCn1cc(C(=O)O)c(=O)c2c1cc(N1CCNCC1)c(c2)F,CBR-HVAC-12933: DNA Gyrase Inhibitors; DNA Topoisomerase IV Inhibitors; DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs; Antibacterial Ophthalmic Drugs
CBR-001-624-746-4,RFM-008-798-9,CBR-001-624-746-4,Fc1cc2c(cc1N1CCNCC1)n(cc(c2=O)C(=O)O)C1CC1,"CBR-HVAC-12158: DNA Gyrase Inhibitors; DNA Topoisomerase IV Inhibitors; Melanin Ligands; Unidentified pharmacological activity; Antibacterial Drugs; Antibacterial Ophthalmic Drugs; Antibiotics; Cystic Fibrosis, Treatment of ; Respiratory Disorders (Not Specified)"
CBR-001-624-747-5,RFM-008-799-0,CBR-001-624-747-5,OC(=O)[C@]1(C)CCC[C@@]2([C@@H]1CC[C@]13[C@H]2CC[C@@](C3)(C(=O)C1)C)C,CBR-HVAC-13502: DNA POLYMERASE; DNA TOPOISOMERASE II INHIBITOR; ANTICANCER; ANTIDIABETIC; ANTIHYPERTENSIVE
CBR-001-624-748-6,RFM-008-800-6,CBR-001-624-748-6,OC(=O)CCCCCCCC(=O)O,CBR-HVAC-12901: DNA synthesis inhibitor; Oxidoreductase unspecified inhibitor; Thioredoxin Reductase Inhibitors; Thioredoxin reductase Inhibitor; Tyrosinase Inhibitors; Acne Therapy; Antibacterial; Dermatologic Drugs
CBR-001-624-749-7,RFM-008-801-7,CBR-001-624-749-7,CN1CCN(CC1)C1Cc2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-02274: Dopamine receptor D2 Antagonist; Dopamine receptor antagonist
CBR-001-624-750-0,RFM-008-802-8,CBR-001-624-750-0,CCCN1CC[C@@H]2[C@H]1CCc1c2cc(cc1)O,CBR-HVAC-13561: Dopamine receptor D3 Agonist; Antipsychotic
CBR-001-624-751-1,RFM-008-803-9,CBR-001-624-751-1,C#Cc1cccc(c1)Nc1ncnc2c1cc1OCCOCCOCCOc1c2,CBR-HVAC-12793: EGF receptor Inhibitor; EGFR (HER1; erbB1) Inhibitors; EGFR antagonist; Signal Transduction Modulators; Anticancer; Brain Cancer Therapy; Digestive/Gastrointestinal Cancer Therapy; Head and Neck Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Pancreatic Cancer Therapy
CBR-001-624-752-2,RFM-008-804-0,CBR-001-624-752-2,CN(C/C=C/C(=O)N1CCCC[C@H](C1)n1c(NC(=O)c2ccnc(c2)C)nc2c1c(Cl)ccc2)C,CBR-HVAC-13998: EGFR (Thr790Met Mutant) Inhibitors; Signal Transduction Modulators; Non-Small Cell Lung Cancer Therapy
CBR-001-624-753-3,RFM-008-805-1,CBR-001-624-753-3,C=CC(=O)Nc1cccc(c1)Oc1nc(Nc2ccc(cc2)N2CCN(CC2)C)nc2c1scc2,CBR-HVAC-12592: EGFR Inhibitor; ANTICANCER
CBR-001-624-754-4,RFM-008-806-2,CBR-001-624-754-4,O[C@H]1CCC(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@@H](C(C)C)C)C)C)/C1,"CBR-HVAC-12770: Ergocalciferol is a synthetic calcium regulator. It's metabolites promote the active absorption of calcium and phosphorous by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization; Antirachitic; Bone Diseases, Treatment of; Therapy of Vitamin-Related Disorders; Thyroid Disease Therapy; Treatment of Hyperparathyroidism; Treatment of Osteoporosis"
CBR-001-624-755-5,RFM-008-807-3,CBR-001-624-755-5,CC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCN(C)C)/c1ccccc1,"CBR-HVAC-12792: Estrogen receptor Modulator; Estrogen receptor antagonist; Protein Kinase C (PKC) Inhibitors; Selective Estrogen Receptor Modulators (SERM); Selective estrogen receptor modulator; Signal Transduction Modulators; Antiestrogenic; Antineoplastic; Bipolar Disorder, Treatment of; Bladder Cancer Therapy ; Breast Cancer Therapy; Female Infertility, Agents for; Melanoma Therapy; Neurologic Cancer Therapy"
CBR-001-624-756-6,RFM-008-808-4,CBR-001-624-756-6,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@@H]([C@@]3(C)CC[C@@H]2[C@@]2([C@H]1C[C@H](O)CC2)C)[C@@H](CCC(=O)O)C,"CBR-HVAC-13054: Farnesoid X Receptor (FXR) Agonists; Farnesoid X receptor agonist; Farnesoid X-activated receptor Agonist; Signal Transduction Modulators; Farnesoid X receptor agonist; Hepatoprotectants; Liver and Biliary Tract Disorders, Treatment of"
CBR-001-624-757-7,RFM-008-809-5,CBR-001-624-757-7,CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)O)Cc1c[nH]c2c1cccc2)N)C,CBR-HVAC-08591: GABA A RECEPTOR Modulator;
CBR-001-624-758-8,RFM-008-810-8,CBR-001-624-758-8,COC(=O)CC[C@@H]1N=C(c2ccccn2)c2c(n3c1ncc3C)ccc(c2)Br,CBR-HVAC-00593: GABA-A receptor Agonist; GABA A receptor agonist
CBR-001-624-759-9,RFM-008-811-9,CBR-001-624-759-9,OCC(=O)C1CCC2C1(C)CC(=O)C1C2CCC2C1(C)CCC(C2)O,CBR-HVAC-13499: GABA-A receptor Agonist; Anesthetic
CBR-001-624-760-2,RFM-008-812-0,CBR-001-624-760-2,N#Cc1ccccc1c1cccc(c1)n1cnc2c1ccc(c2)C(O)(C)C,CBR-HVAC-12427: GAMMA-AMINOBUTYRIC ACID (GABA) A RECEPTOR Modulator; Analgesic; Anticonvulsant; Anxiolytic; Hypnotic
CBR-001-624-761-3,RFM-008-813-1,CBR-001-624-761-3,C[N+](CCCCC[N+](C)(C)C)(C)C,CBR-HVAC-09041: Ganglionic blocking agent; Nicotinolytic and Coronary vasodilator;
CBR-001-624-762-4,RFM-008-814-2,CBR-001-624-762-4,O=C1CCC[C@@H](C1)c1ccccc1,CBR-HVAC-13714: Gastrointestinal Disorders (Not Specified)
CBR-001-624-763-5,RFM-008-815-3,CBR-001-624-763-5,NCCCCC(C(=O)NC(=O)C(N)C)NC(=O)C(Cc1ccccc1)NC(=O)C(Cc1c[nH]c2c1cccc2)NC(=O)C(NC(=O)C(Cc1ccc2c(c1)cccc2)N)C,CBR-HVAC-13482: GH secretion stimulator; Diagnostic agent
CBR-001-624-764-6,RFM-008-816-4,CBR-001-624-764-6,CN(CCNC(=O)c1cccc2c1nc1ccccc1c2)C,CBR-HVAC-00231: Glioblastoma Multiforme Therapy;Colorectal Cancer Therapy;Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy; DNA Topoisomerase I Inhibitors;DNA Topoisomerase II Inhibitors;DNA-Intercalating Drugs; DNA topoisomerase II; DNA topoisomerase I Inhibitor; Dihydropteroate synthase inhibitor; PABA antagonist; Folate antagonist
CBR-001-624-765-7,RFM-008-817-5,CBR-001-624-765-7,CC(=O)OCC(=O)C1(O)C(C)CC2C1(C)CC(O)C1(C2CCC2=CC(=O)C=CC12C)F,CBR-HVAC-02604: Glucocorticoid receptor Agonist; Glucocorticoid agonist; Arachidonic acid inhibitor
CBR-001-624-766-8,RFM-008-818-6,CBR-001-624-766-8,CC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,"CBR-HVAC-12831: Glucocorticoid receptor Agonist; Anorectal Disorders, Treatment of; Anti-inflammatory; Corticosteroid; Dermatologic Drugs; Hemorrhoid, Treatment of; Inflammatory Bowel Disease, Agents for"
CBR-001-624-767-9,RFM-008-819-7,CBR-001-624-767-9,[O-]C(=O)CCC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,"CBR-HVAC-12830: Glucocorticoid receptor Agonist; Anti-inflammatory; Asthma Therapy; Corticosteroid; Sepsis, Treatment of; Stroke, Treatment of"
CBR-001-624-768-0,RFM-008-820-0,CBR-001-624-768-0,O=C1C=CC2(C(=C1)[C@@H](F)CC1[C@]2(F)C(O)CC2(C1C[C@H]([C@]2(O)C(=O)COC(=O)C(C)(C)C)C)C)C,CBR-HVAC-13333: Glucocorticoid receptor Agonist; Glucocorticoid
CBR-001-624-769-1,RFM-008-821-1,CBR-001-624-769-1,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)C,"CBR-HVAC-12949: Glucocorticoid receptor Inhibitor; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Corticosteroid; Ear disorders, treatment of; Immunosuppressant; Lymphocytic Leukemia Therapy"
CBR-001-624-770-4,RFM-008-822-2,CBR-001-624-770-4,OC[C@H]1CNC[C@H]([C@@H]1O)O,CBR-HVAC-13709: Glucose Lowering Agents; Glycogen Phosphorylase Inhibitors; Antidiabetic Drugs
CBR-001-624-771-5,RFM-008-823-3,CBR-001-624-771-5,OC[C@H]1OC(O)C[C@H]([C@@H]1O)O,CBR-HVAC-12659: GLUCOSE TRANSPORT INHIBITOR; GLYCOLYSIS INHIBITOR; Anticancer; Antiepileptic Drugs; Antimalarials; Antineoplastic Enhancing Agents; Prostate Cancer Therapy; Solid Tumors Therapy
CBR-001-624-772-6,RFM-008-824-4,CBR-001-624-772-6,O[C@H]1CC[C@]2([C@H](C1(C)C)CC[C@@]1([C@@H]2CC=C2[C@@]1(C)CC[C@@]1([C@H]2CC(C)(C)CC1)C(=O)O)C)C,CBR-HVAC-13112: Glycogen phosphorylase Inhibitor; Anti-inflammatory; Antihepatitis; Antitumor
CBR-001-624-773-7,RFM-008-825-5,CBR-001-624-773-7,CNCC(=O)O,"CBR-HVAC-12709: GlyT-1 Inhibitors; Antidepressants; Antipsychotic Drugs; Obsessive-Compulsive Disorder (OCD), Treatment of; Psychiatric Disorders (Not Specified)"
CBR-001-624-774-8,RFM-008-826-6,CBR-001-624-774-8,OC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCNC(=N)N)CC(C)C)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1nc[nH]c1,"CBR-HVAC-12861: Gonadotropin-Releasing Factor Hormone Receptor (GnRH, LHRH) Ligands; Signal Transduction Modulators; Diagnostic Agents; Disorders of Sexual Function and Reproduction, Treatment of; Female Infertility, Agents for; Male Infertility, Agents for; Treatment of Male Sexual Dysfunction"
CBR-001-624-775-9,RFM-008-827-7,CBR-001-624-775-9,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C)C(=O)N[C@@H]([C@H](O)C)CO)NC(=O)[C@@H](Cc1ccccc1)N)Cc1c[nH]c2c1cccc2,"CBR-HVAC-12609: Growth Hormone Release Inhibitors; Signal Transduction Modulators; Somatostatin Agonists; Somatostatin receptor Agonist; Antidiarrheal; Antihemorrhagic; Breast Cancer Therapy; Cancer Associated Disorders, Treatment of; Diabetic Retinopathy, Agents for; Digestive/Gastrointestinal Cancer Therapy; Endocrine Cancer Therapy; Hypertension, Treatment of; Interstitial Lung Diseases, Treatment of; Irritable Bowel Syndrome, Agents for; Liver Cancer Therapy; Liver and Biliary Tract Disorders, Treatment of; Oncolytic Drugs; Prostate Cancer Therapy; Respiratory/Thoracic Cancer Therapy; Rheumatoid Arthritis, Treatment of; Treatment of Acromegaly"
CBR-001-624-776-0,RFM-008-828-8,CBR-001-624-776-0,CCOC(=O)NNc1ccc(nn1)N(CC(O)C)CC,CBR-HVAC-01697: Guanylate cyclase stimulant
CBR-001-624-777-1,RFM-008-829-9,CBR-001-624-777-1,COC(=O)Nc1c(N)nc(nc1N)c1nn(c2c1cc(F)cn2)Cc1ccccc1F,CBR-HVAC-12959: Guanylate Cyclase Activators; Guanylate cyclase stimulant; Heart Failure Therapy
CBR-001-624-778-2,RFM-008-830-2,CBR-001-624-778-2,[O-][N+](=O)O[C@@H]1CO[C@H]2[C@@H]1OC[C@@H]2O[N+](=O)[O-],"CBR-HVAC-12849: Guanylate cyclase stimulant; Nitric oxide stimulant; The principal pharmacological action of isosorbide dinitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter; Acute Myocardial Infarction, Treatment of; Angina pectoris, Treatment of; Antianginal; Heart Failure Therapy; Vasodilator"
CBR-001-624-779-3,RFM-008-831-3,CBR-001-624-779-3,CC[C@H](NC(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CO,"CBR-HVAC-07307: Gynecological Disorders, Treatment of ;"
CBR-001-624-780-6,RFM-008-832-4,CBR-001-624-780-6,OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)F)n1ccc(nc1=O)N,CBR-HVAC-12816: HCV nonstructural protein 5B inhibitor; NS5B protease Inhibitor; RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs; Antiviral
CBR-001-624-781-7,RFM-008-833-5,CBR-001-624-781-7,CCC(C(=O)O[C@H]1C[C@@H](C)C=C2[C@H]1[C@@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@H](C=C2)C)(C)C,"CBR-HVAC-12878: HDL-Cholesterol Increasing Agents; HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor; Alzheimer's Dementia, Treatment of ; Antihyperlipidaemia; Antipsychotic Drugs; Asthma Therapy; Bipolar Disorder, Treatment of; Coagulation Disorders Therapy; Colorectal Cancer Therapy; Cystic Fibrosis, Treatment of ; Dermatologic Drugs; Hematopoiesis Disorders Therapy; Lipoprotein Disorders, Treatment of ; Oncolytic Drugs; Pulmonary Hypertension, Treatment of; Restenosis Treatment of; Sepsis, Treatment of; Treatment of Disorders of the Coronary Arteries and Atherosclerosis; Treatment of Erectile Dysfunction"
CBR-001-624-782-8,RFM-008-834-6,CBR-001-624-782-8,OC(COc1ccc(cc1)O)CNCCNC(=O)N1CCOCC1,CBR-HVAC-02650: Heart Failure Therapy;Antiobesity Drugs; beta1-Adrenoceptor Agonists;Signal Transduction Modulators; Beta adrenergic receptor Agonist; Beta 1 adrenoreceptor agonist
CBR-001-624-783-9,RFM-008-835-7,CBR-001-624-783-9,Nc1c2ccccc2nc2c1cccc2,CBR-HVAC-13427: Heat shock protein 90 Inhibitor; Antifungal; Antihelminthic
CBR-001-624-784-0,RFM-008-836-8,CBR-001-624-784-0,CCCCCCCCCC(=O)O,CBR-HVAC-13713: Hematopoietic Agents
CBR-001-624-785-1,RFM-008-837-9,CBR-001-624-785-1,CN(CCC(c1ccccn1)c1ccccc1)C,CBR-HVAC-09635: Histamine H1 receptor Antagonist;
CBR-001-624-786-2,RFM-008-838-0,CBR-001-624-786-2,CN(C(CN1c2ccccc2Sc2c1cccc2)C)C,"CBR-HVAC-13019: Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Signal Transduction Modulators; Anticholinergic; Antiemetic; Antihistamine; Drugs for Allergic Rhinitis; Nausea and Vomiting, Treatment of"
CBR-001-624-787-3,RFM-008-839-1,CBR-001-624-787-3,CN(C(CN1c2ccccc2Sc2c1cccc2)C)C,"CBR-HVAC-13019: Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Signal Transduction Modulators; Anticholinergic; Antiemetic; Antihistamine; Drugs for Allergic Rhinitis; Nausea and Vomiting, Treatment of"
CBR-001-624-788-4,RFM-008-840-4,CBR-001-624-788-4,CN1CCN(CC1)C(c1ccc(cc1)Cl)c1ccccc1,CBR-HVAC-12714: Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Signal Transduction Modulators; Antihistamine; Antipruritics; Asthma Therapy; Treatment of Upper Respiratory Tract Disorders
CBR-001-624-789-5,RFM-008-841-5,CBR-001-624-789-5,C1CCN(CC1)CCCOc1ccc(cc1)CN1CCCCC1,CBR-HVAC-12417: Histamine H3 receptor Antagonist; Histamine H3 receptor antagonist
CBR-001-624-790-8,RFM-008-842-6,CBR-001-624-790-8,CC(CCC[C@H]([C@H]1CC(=O)C2=C3C(CC[C@]12C)[C@@]1(C)CC[C@@H](C[C@@H]1CC3)O)C)C,CBR-HVAC-13615: HMGCoA reductase inhibitor
CBR-001-624-791-9,RFM-008-843-7,CBR-001-624-791-9,O=C1CC[C@]2(C(=C1)C(=C[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@]2(C)C(=O)C)C)C)C,CBR-HVAC-13082: Hydroxysteroid (17-beta) dehydrogenase; Sulfatase Inhibitor; Antineoplastic
CBR-001-624-792-0,RFM-008-844-8,CBR-001-624-792-0,CCOC(=O)C(NC(C(=O)N1CC2(CC1C(=O)O)SCCS2)C)CCc1ccccc1,"CBR-HVAC-02816: Hypertension, Treatment of; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Angiotensin converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor"
CBR-001-624-793-1,RFM-008-845-9,CBR-001-624-793-1,OC[C@H]1O[C@@H](O[C@@]23CC[C@@H]4[C@@](C2)(CC3=C)CC[C@H]2[C@@]4(C)CCC[C@@]2(C)C(=O)O[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O,"CBR-HVAC-05410: Hypertension, Treatment of;Type 2 Diabetes, Agents for;Chemopreventive Agents;Antiarthritic Drugs;"
CBR-001-624-794-2,RFM-008-846-0,CBR-001-624-794-2,CC[C@@H]1/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@@H]([C@H]([C@@H](/C=C/C(=O)O[C@H]2[C@H]([C@@H](CC1)O[C@@]1(CC[C@H]([C@H](O1)C[C@@H](O)C)C)[C@@H]2C)C)C)O)C,CBR-HVAC-13404: Hypoxia-inducible factor 1 Inhibitor; Antifungal
CBR-001-624-795-3,RFM-008-847-1,CBR-001-624-795-3,OCC(=O)[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-13149: Increase in the reabsorption of the ion sodium and water and reduces reabsorption of the hydrogen ions and potassium; Corticosteroid
CBR-001-624-796-4,RFM-008-848-2,CBR-001-624-796-4,Oc1ccc(cc1)C[C@H]1C(=O)N(C[C@H]2N1C(=O)CCN2C(=O)NCc1ccccc1)Cc1cccc2c1cccc2,"CBR-HVAC-12436: INHIBITOR OF THE CANONICAL WNT SIGNALING PATHWAY IN CANCER STEM CELLS. BLOCKING THE INTERACTION OF CBP AND BETA-CATENIN BY THIS AGENT PREVENTS GENE EXPRESSION OF MANY PROTEINS NECESSARY FOR GROWTH, THEREBY POTENTIALLY SUPPRESSING CANCER CELL GROWTH.; ANTI-CANCER"
CBR-001-624-797-5,RFM-008-849-3,CBR-001-624-797-5,CO[C@H](Cn1c(=O)n(c2c1c1cc(ccc1nc2)c1cncc(c1)C(O)(C)C)C)C,CBR-HVAC-12429: Inhibitor; MTOR; PHOSPHOINOSITIDE 3-KINASE (PI3K) Inhibitor; ANTI-CANCER
CBR-001-624-798-6,RFM-008-850-6,CBR-001-624-798-6,CCC(C(=O)NC(=O)N)(CC)Br,CBR-HVAC-13370: Inorganic bromide was found to increase the narcotic activity of carbromal and of bromoethylbutyramide. Central nervous system depression caused mainly by unchanged carbromal and by its metabolite bromoethylbutyramide; Hypnotic
CBR-001-624-799-7,RFM-008-851-7,CBR-001-624-799-7,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2([C@H]1CCC2=O)C)C,"CBR-HVAC-12988: INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR Agonist; Bone Formation Stimulants; Insulin-like growth factor I agonist; Neuropathic Pain, Treatment of; Steroid hormone modulator; Treatment of Osteoporosis"
CBR-001-624-800-3,RFM-008-852-8,CBR-001-624-800-3,O=C1CCC[C@H]2N1C[C@@H]1C[C@H]2CN2[C@H]1CCCC2,"CBR-HVAC-12979: Insulin Secretagogues; K(ATP) Channel Blockers; Signal Transduction Modulators; Sodium Channel  Blockers; Sedative/Hypnotics; Type 2 Diabetes, Agents for"
CBR-001-624-801-4,RFM-008-853-9,CBR-001-624-801-4,N#Cc1ccnc(c1)N1C(=O)CC[C@H]1C(=O)N([C@@H](c1ccccc1Cl)C(=O)NC1CC(C1)(F)F)c1cncc(c1)F,"CBR-HVAC-14063: Isocitrate Dehydrogenase (NADP+) (IDPc, IDH1) Inhibitors; Isocitrate Dehydrogenase (NADP+) (IDPm, IDH2) Inhibitors; Hematological Cancer Therapy; Neurologic Cancer Therapy; Solid Tumors Therapy"
CBR-001-624-802-5,RFM-008-854-0,CBR-001-624-802-5,CN([C@H]1CC[C@]2(C(=CC[C@@H]3[C@@H]2CC[C@]24[C@H]3CC[C@@H]4[C@@H](N(C2)C)C)C1)C)C,CBR-HVAC-13559: It acts by destroying amoeba; Antiamebic
CBR-001-624-803-6,RFM-008-855-1,CBR-001-624-803-6,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F,"CBR-HVAC-13406: It inhibits the production of arachidonic acid by phospholipase A2 in the membrane. This effect is mediated by proteins that inhibit the action of phospholipase, so finally it inhibits the production of prostaglandins and leukotrienes; Anti-inflammatory"
CBR-001-624-804-7,RFM-008-856-2,CBR-001-624-804-7,CN1C(=O)CC(C1=O)c1ccccc1,CBR-HVAC-12890: It is used to control seizures in the treatment of epilepsy. These medicines act on the central nervous system (CNS) to reduce the number and severity of seizures.; Anticonvulsant; Antiepileptic Drugs
CBR-001-624-805-8,RFM-008-857-3,CBR-001-624-805-8,O=C(NS(=O)(=O)c1ccc(cc1)C)NN1CCCCCC1,"CBR-HVAC-12820: K(ATP) Channel Blockers; Sulfonylurea receptor Inhibitor; Antidiabetic; Type 2 Diabetes, Agents for"
CBR-001-624-806-9,RFM-008-858-4,CBR-001-624-806-9,CCCCCCN1CCc2c1c(NC(=O)C(C)(C)C)c(cc2C)C,"CBR-HVAC-10978: Lipoprotein Disorders, Treatment of ; ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor;"
CBR-001-624-807-0,RFM-008-859-5,CBR-001-624-807-0,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)OC([C@@H]([C@H]2O)O)O)[C@@H]([C@H]([C@H]1O[C@@H]1O[C@H](CO)[C@@H]([C@@H]([C@H]1O)O)O)O)O,"CBR-HVAC-12707: Lipoprotein Disorders, Treatment of"
CBR-001-624-808-1,RFM-008-860-8,CBR-001-624-808-1,C/C(=C\CC/C(=C/CC1=C(C)C(=O)c2c(C1=O)cccc2)/C)/CC/C=C(/CCC=C(C)C)\C,CBR-HVAC-02132: Liver Cancer Therapy;Treatment of Vitamin K Deficiency;Treatment of Renal Diseases;Treatment of Osteoporosis;Bone Resorption Inhibitors; Induces apoptosis in leukaemia cells.; Vitamin K2 agonist; Osteoblast stimulant; Bone resorption inhibitor
CBR-001-624-809-2,RFM-008-861-9,CBR-001-624-809-2,OC(=O)Cc1ccc(cc1)c1ccc(cc1)c1onc(c1NC(=O)O[C@@H](c1ccccc1Cl)C)C,"CBR-HVAC-12284: LPA1 receptor Antagonist; Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2) Antagonists; Signal Transduction Modulators; ANTIFIBROTIC; Fibrosis, Treatment of"
CBR-001-624-810-5,RFM-008-862-0,CBR-001-624-810-5,COc1c(Cl)c(/C=N/NC(=N)N)ccc1OC,CBR-HVAC-12461: Melanocortin receptor 1 Agonist; Anti-inflammatory
CBR-001-624-811-6,RFM-008-863-1,CBR-001-624-811-6,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,"CBR-HVAC-12612: Membrane integrity inhibitor; Potassium channel antagonist; Sodium channel antagonist; Inflammatory Bowel Disease, Agents for; Local Anesthetics"
CBR-001-624-812-7,RFM-008-864-2,CBR-001-624-812-7,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,"CBR-HVAC-12612: Membrane integrity inhibitor; Potassium channel antagonist; Sodium channel antagonist; Inflammatory Bowel Disease, Agents for; Local Anesthetics"
CBR-001-624-813-8,RFM-008-865-3,CBR-001-624-813-8,CN1CCCCC1CCN1c2ccccc2Sc2c1cc(cc2)S(=O)C,"CBR-HVAC-13258: Mesoridazine besylate is a phenothiazine tranquilizer. In common with other antipsychotics it inhibits spontaneous motor activity in mice. It shows a moderate adrenergic blocking activity in vitro and in vivo and antagonizes 5-Hydroxytryptamine in vivo. It has a weak antiacetylcholine effect in vitro.*Based upon animal studies, Serentil(R) (mesoridazine besylate), as with other phenothiazines, acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex.; Antipsychotic; Tranquilliser"
CBR-001-624-814-9,RFM-008-866-4,CBR-001-624-814-9,Cc1cc[nH]n1,CBR-HVAC-13701: Metabolic Disorders (Not Specified)
CBR-001-624-815-0,RFM-008-867-5,CBR-001-624-815-0,[O-]C(=O)[C@@]1(C)CSC(=N1)c1ncccc1O,CBR-HVAC-10550: Metal intoxicant;
CBR-001-624-816-1,RFM-008-868-6,CBR-001-624-816-1,O=C1CCC2(C(=C1)CCC1C2CCC2(C1CCC2C(=O)COC(=O)C(C)(C)C)C)C,CBR-HVAC-13155: Mineralocorticoid receptor Agonist; Diuretic
CBR-001-624-817-2,RFM-008-869-7,CBR-001-624-817-2,Oc1ccc(cc1)c1cc(=O)c2c(o1)cc(cc2O)O,CBR-HVAC-13431: Monoamine oxidase Inhibitor; Antineoplastic
CBR-001-624-818-3,RFM-008-870-0,CBR-001-624-818-3,O=C(c1c(Cc2c(C)[nH]nc2C(F)(F)F)sc2c1c(=O)n(c(=O)n2C(C)C)C)N1OC[C@@](C1)(C)O,CBR-HVAC-12549: Monocarboxylate transporter-1 inhibitor; ANTICANCER
CBR-001-624-819-4,RFM-008-871-1,CBR-001-624-819-4,CC1=CC[C@@H](C[C@H]1O)C(O)(C)C,CBR-HVAC-05630: Mucolytics; Mucolytic agent
CBR-001-624-820-7,RFM-008-872-2,CBR-001-624-820-7,CCCCC[C@](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1C/C=C\CCCC(=O)O)(O)C,CBR-HVAC-12772: Mucus protecting agent; Prostaglandin E receptor 2 Agonist; Prostaglandin E2 receptor agonist; Antiulcer; Antiulcer Drugs; Gastric Antisecretory Drugs
CBR-001-624-821-8,RFM-008-873-3,CBR-001-624-821-8,CCC/N=C/1\S/C(=C/c2ccc(c(c2)Cl)OCC(CO)O)/C(=O)N1c1ccccc1C,"CBR-HVAC-00724: Multiple Sclerosis, Agents for;Treatment of Autoimmune Diseases;Antipsoriatics; Lysophospholipid edg1 (S1P1) Receptor Agonists;Signal Transduction Modulators; Sphingosine-1-phosphate receptor 1 agonist; Sphingosine 1-phosphate 1 receptor agonist; Immunosuppressant"
CBR-001-624-822-9,RFM-008-874-4,CBR-001-624-822-9,C[C@@H]1CC[C@@]2(OC1)O[C@@H]1[C@H]([C@@H]2C)[C@@]2([C@@H](C1)[C@@H]1CC[C@@H]3[C@]([C@H]1CC2)(C)CC[C@H](C3)O)C,CBR-HVAC-00361: Muscarinic acetylcholine receptor M1; Dopamine receptor Modulator; Nerve growth factor agonist; Muscarinic M1 receptor agonist
CBR-001-624-823-0,RFM-008-875-5,CBR-001-624-823-0,CCN(CCOC(=O)C(c1ccccc1)(c1ccccc1)C)CC,CBR-HVAC-13127: Muscarinic acetylcholine receptor Agonist; Anticholinergic
CBR-001-624-824-1,RFM-008-876-6,CBR-001-624-824-1,OC(c1ccccc1)C(=O)OC1CC2CCC(C1)[N+]2(C)C,CBR-HVAC-13510: Muscarinic acetylcholine receptor Antagonist; Anticholinergic
CBR-001-624-825-2,RFM-008-877-7,CBR-001-624-825-2,OC[C@H](c1ccccc1)C(=O)O[C@@H]1C[C@@H]2[C@@H]3[C@H]([C@H](C1)[N+]2(C)C)O3,"CBR-HVAC-12967: Muscarinic Antagonists; Muscarinic acetylcholine receptor Antagonist; Signal Transduction Modulators; Anticholinergic; Antihypermotility Agents; Antispasmodics; Antiulcer Drugs; Irritable Bowel Syndrome, Agents for"
CBR-001-624-826-3,RFM-008-878-8,CBR-001-624-826-3,OC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C,CBR-HVAC-13030: Muscarinic Antagonists; Signal Transduction Modulators; Ophthalmic Drugs; Treatment of Hot Flushes
CBR-001-624-827-4,RFM-008-879-9,CBR-001-624-827-4,OC(c1ccccc1)(c1ccccc1)CCCN1CCCCC1,"CBR-HVAC-12702: Muscarinic M1 Receptor Ligands; Muscarinic M3 Receptor Ligands; Muscarinic M4 Receptor Ligands; Muscarinic acetylcholine receptor Antagonist; Signal Transduction Modulators; Antiemetic; Ear disorders, treatment of"
CBR-001-624-828-5,RFM-008-880-2,CBR-001-624-828-5,NC[C@@H]1CC[C@H]1CN,ligand of CBR-HVAC-03869
CBR-001-624-829-6,RFM-008-881-3,CBR-001-624-829-6,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](C)O[C@H](C[C@@H]2OC(=O)C)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]2[C@@H]3C[C@@H](O)[C@]3([C@]2(O)CC[C@@H]3C2=CC(=O)OC2)C)C)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-09823: Na+, K+ ATPase Inhibitor;"
CBR-001-624-830-9,RFM-008-882-4,CBR-001-624-830-9,OC[C@H]1O[C@@H](O[C@@H]2[C@@H](C)O[C@H](C[C@@H]2OC(=O)C)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]2[C@@H]3CC[C@]3([C@]2(O)C[C@@H]([C@@H]3C2=CC(=O)OC2)O)C)C)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-13416: Na+, K+ ATPase Inhibitor; Cardiotonic"
CBR-001-624-831-0,RFM-008-883-5,CBR-001-624-831-0,NC(=NC(=O)c1cc(c(cc1C)n1cccc1)S(=O)(=O)C)N,"CBR-HVAC-04954: Na+/H+ Exchanger type 1 (NHE-1) Inhibitors; Sodium/hydrogen exchange inhibitor; Sodium/hydrogen exchanger isoform 1 Inhibitor; Acute Myocardial Infarction, Treatment of; Cardioprotectant"
CBR-001-624-832-1,RFM-008-884-6,CBR-001-624-832-1,O=C1OCC(=C1)[C@H]1CC[C@]2([C@]1(C)CC[C@H]1[C@H]2CC[C@H]2[C@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@@H]([C@H](O1)C)O[C@H]1C[C@H](O)[C@@H]([C@H](O1)C)O[C@H]1C[C@H](O)[C@@H]([C@H](O1)C)O)O,"CBR-HVAC-12656: Na+/K+ ATPase receptor Binder; Antiarrhythmic; Cystic Fibrosis, Treatment of ; Heart Failure Therapy"
CBR-001-624-833-2,RFM-008-885-7,CBR-001-624-833-2,CN(CC(=O)Nc1ccc2c(c1)c1ccccc1c(=O)[nH]2)C,"CBR-HVAC-13750: NAD+ ADP-Ribosyltransferase (poly(ADP-ribose)polymerase; PARP) Inhibitors; Signal Transduction Modulators; Antiarthritic Drugs; Heart Failure Therapy; Stroke, Treatment of"
CBR-001-624-834-3,RFM-008-886-8,CBR-001-624-834-3,O=C(c1sc(nc1C)c1cccnc1)Nc1ccccc1c1cn2c(n1)scc2CN1CCOCC1,CBR-HVAC-12572: NAD-dependent deacetylase sirtuin-1 Activator; Anti-inflammatory; Hypoglycemic
CBR-001-624-835-4,RFM-008-887-9,CBR-001-624-835-4,CCCCCN1c2ccccc2C2(C1=O)COc1c2cc2OCOc2c1,CBR-HVAC-13804: Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers; Analgesic Drugs
CBR-001-624-836-5,RFM-008-888-0,CBR-001-624-836-5,CC(CC(=O)O[C@@H](C[N+](C)(C)C)CC(=O)[O-])C,CBR-HVAC-00192: Nerve growth factor receptor agonist; Protease/peptidase inhibitor
CBR-001-624-837-6,RFM-008-889-1,CBR-001-624-837-6,CCC(O[C@@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)O)CC,CBR-HVAC-12923: Neuraminidase (Sialidase) Inhibitors; Anti-Influenza Virus Drugs
CBR-001-624-838-7,RFM-008-890-4,CBR-001-624-838-7,Fc1ccc2c(c1)[nH]cc2CCNCc1cccc(c1)OCC(C(F)F)(F)F,"CBR-HVAC-00850: Neurologic Drugs (Miscellaneous);Alzheimer's Dementia, Treatment of ;Antipsychotic Drugs; Signal Transduction Modulators;5-HT6 Antagonists; 5-HYDROXYTRPTAMINE 6 RECEPTOR Antagonist; 5 Hydroxytryptamine 6 receptor antagonist"
CBR-001-624-839-8,RFM-008-891-5,CBR-001-624-839-8,CCCCCCCCO,CBR-HVAC-12779: Neurologic Drugs (Miscellaneous)
CBR-001-624-840-1,RFM-008-892-6,CBR-001-624-840-1,CCc1ccc(cc1)C(=O)C(CN1CCCCC1)C,CBR-HVAC-13023: Neuromuscular nicotinic receptor antagonist; Analgesic Drugs; Anticonvulsant; Antispasmodic; Antispastic Drugs; Vasodilator
CBR-001-624-841-2,RFM-008-893-7,CBR-001-624-841-2,CN1CCCN=C1/C=C/c1cccs1,CBR-HVAC-13057: Nicotinic acetylcholine receptor Agonist; Antihelminthic; Treatment of Helminthic Diseases
CBR-001-624-842-3,RFM-008-894-8,CBR-001-624-842-3,Cc1noc(c1)C1CCCN1,CBR-HVAC-13315: Nicotinic acetylcholine receptor Agonist; Nootropic
CBR-001-624-843-4,RFM-008-895-9,CBR-001-624-843-4,C[N+](CCCCCCCCCC[N+](C)(C)C)(C)C,CBR-HVAC-13199: Nicotinic acetylcholine receptor Agonist; Skeletal muscle relaxant
CBR-001-624-844-5,RFM-008-896-0,CBR-001-624-844-5,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]1(C)CCCCC1)C)CC[C@]1([C@H]3C[C@@H]([C@@H]1OC(=O)C)[N+]1(C)CCCCC1)C,CBR-HVAC-13040: Nicotinic acetylcholine receptor Antagonist; Muscle relaxant; Non-depolarizing Blocking Drugs
CBR-001-624-845-6,RFM-008-897-1,CBR-001-624-845-6,CCN1C[C@@]2(CC[C@@H]([C@]34C1[C@](O)([C@H]([C@H]23)OC)[C@@]1([C@@H]2[C@H]4C[C@@H]([C@@H]2OC)[C@H](C1)OC)O)OC)COC(=O)c1ccccc1N1C(=O)C[C@@H](C1=O)C,CBR-HVAC-14090: Nicotinic alpha7 Agonists; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-624-846-7,RFM-008-898-2,CBR-001-624-846-7,CN1C(C)(C)CCCC1(C)C,CBR-HVAC-13569: Nicotinic ganglionic receptor Antagonist; Nicotinic ganglionic blocker
CBR-001-624-847-8,RFM-008-899-3,CBR-001-624-847-8,OCCNC(=O)c1c(I)c(C(=O)NCC(CO)O)c(c(c1I)N(C(=O)C)CC(CO)O)I,"CBR-HVAC-12844: Nonionic, water soluble, triiodinated x-ray contrast agent for intravascular injection. Intravascular injection of a radiopaque diagnostic agent opacifies those vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs; Not applicable; Contrast Media; Diagnostic agent"
CBR-001-624-848-9,RFM-008-900-9,CBR-001-624-848-9,[O-]C(=O)CCCCCCCCC(=O)[O-],CBR-HVAC-13601: Not applicable
CBR-001-624-849-0,RFM-008-901-0,CBR-001-624-849-0,OC(=O)CC(CCCCCCCCCCC(CC(=O)O)(C)C)(C)C,"CBR-HVAC-13614: ATP Citrate Lyase Inhibitors; ATP citrate lyase Inhibitor; Cholesterol-synthesis-inhibitors; Free Fatty Acid Receptor 1 (FFAR1; GPR40) Agonists; Omega 3 fatty acid stimulant; Signal Transduction Modulators; Anti-diabetic; Anti-obesity; Antidiabetic Drugs; Antiobesity Drugs; Hyperlipidaemia; Lipoprotein Disorders, Treatment of ; Metabolic Disorders; Obesity"
CBR-001-624-850-3,RFM-008-902-1,CBR-001-624-850-3,Cl[Ti](C1C=CC=C1)(C1C=CC=C1)Cl,CBR-HVAC-03449: Oncolytic Drugs; Collagenase IV Inhibitor; DNA inhibitor
CBR-001-624-851-4,RFM-008-903-2,CBR-001-624-851-4,COc1cc2c(cc1Oc1cc(OC)c(cc1CC1[NH+](C)CCc3c1cc(OC)c(c3)OC)OC)CC1c3c2c(OC)c(OC)cc3CC[NH+]1C,CBR-HVAC-03488: Oncolytic Drugs;
CBR-001-624-852-5,RFM-008-904-3,CBR-001-624-852-5,Clc1ccc(cc1)S(=O)(=O)NC(=O)c1ccc(cc1Cl)Cl,CBR-HVAC-11778: Oncolytic Drugs; Anticancer;
CBR-001-624-853-6,RFM-008-905-4,CBR-001-624-853-6,OCC1OC(Nc2ccc(cc2)C(=O)O)C(C(C1O)O)O,CBR-HVAC-12706: Oncolytic Drugs
CBR-001-624-854-7,RFM-008-906-5,CBR-001-624-854-7,O=C(N([C@H]1CC[C@]2(C[C@@H]1N1CCCC1)CCCO2)C)Cc1ccc(c(c1)Cl)Cl,CBR-HVAC-03297: Opioid Analgesics; kappa-Opioid Agonists;Signal Transduction Modulators; Opioid receptor kappa Agonist; Opioid kappa receptor agonist
CBR-001-624-855-8,RFM-008-907-6,CBR-001-624-855-8,C=CCN1CCC2(C(C1Cc1c2cc(cc1)O)C)C,CBR-HVAC-13625: Opioid mu receptor agonist; Sigma receptor agonist
CBR-001-624-856-9,RFM-008-908-7,CBR-001-624-856-9,OC(=O)C(c1ccc(s1)C(=O)c1ccccc1)C,"CBR-HVAC-02107: Osteoarthritis, Treatment of;Inflammation, Treatment of; Bradykinin receptor; Histamine receptor; Prostaglandin E receptor 2; 5-Hydroxytryptamine transporter; Acetylcholine receptor Antagonist; Antagonist; Antagonist; Antagonist; Antagonist; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor"
CBR-001-624-857-0,RFM-008-909-8,CBR-001-624-857-0,OCC1OC(O)C(C(C1O)O)N,"CBR-HVAC-05480: Osteoarthritis, Treatment of;Antiarthritic Drugs; Coagulation factor X; Facilitated glucose transporter 3 Inhibitor;"
CBR-001-624-858-1,RFM-008-910-1,CBR-001-624-858-1,CCOC1O[C@@H]([C@@H]([C@H]1O)OCc1ccccc1)[C@H](OCc1ccccc1)COCc1ccccc1,"CBR-HVAC-13976: Osteoarthritis, Treatment of"
CBR-001-624-859-2,RFM-008-911-2,CBR-001-624-859-2,O=C(Nc1snc(c1C(=O)N)OCc1c(F)cc(cc1F)Br)NCCCCN1CCCC1,CBR-HVAC-05293: Ovarian Cancer Therapy;Non-Small Cell Lung Cancer Therapy; Angiogenesis Inhibitors;Discoidin Domain-Containing Receptor 2 (DDR2) Inhibitors;EGFR (HER1; erbB1) Inhibitors;PDGFR Family Inhibitors;Signal Transduction Modulators;VEGFR-2 (FLK-1/KDR) Inhibitors; Vascular endothelial growth factor receptor 2 Inhibitor;
CBR-001-624-860-5,RFM-008-912-3,CBR-001-624-860-5,CCCCC/C=C/C/C=C/C/C=C/CCCCC(=O)O,CBR-HVAC-00974: Pancreatic Cancer Therapy; Prostaglandin G/H synthase 2 Inhibitor; Matrix metalloproteinase inhibitor; Plasminogen activator inhibitor
CBR-001-624-861-6,RFM-008-913-4,CBR-001-624-861-6,COC1CCN(CC1)C(=O)c1cc(ccc1F)C=c1[nH][nH]c(=O)c2c1cccc2,CBR-HVAC-12389: PARP Inhibitor; Anticancer
CBR-001-624-862-7,RFM-008-914-5,CBR-001-624-862-7,CCN1CCN(C(=O)C1=O)C(=O)N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)[O-])(C)C)c1ccccc1,CBR-HVAC-12703: Penicillin binding protein 3 Inhibitor; Antibacterial; Antibiotics
CBR-001-624-863-8,RFM-008-915-6,CBR-001-624-863-8,O=C(N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[n+]1ccc(cc1)C(=O)N)Cc1cccs1,CBR-HVAC-13535: Penicillin binding protein inhibitor; Antibacterial
CBR-001-624-864-9,RFM-008-916-7,CBR-001-624-864-9,Oc1ccc(cc1)C1COc2c(C1=O)ccc(c2)O,"CBR-HVAC-13731: Peripheral Vascular Disease, Treatment of; Restenosis Treatment of"
CBR-001-624-865-0,RFM-008-917-8,CBR-001-624-865-0,CN1CCC2(N(C1=O)C)CCN1C(C2)c2oc3c(c2CC1)cccc3,CBR-HVAC-03554: Pharmacological Tools; Alpha-2 adrenergic receptor Antagonist; Alpha 2 adrenoreceptor antagonist
CBR-001-624-866-1,RFM-008-918-9,CBR-001-624-866-1,O=C1O[Fe]2OC(=O)CC(C1)(O)C(=O)O2,"CBR-HVAC-12804: Phosphate antagonist; Phosphate lowering agent; Antianemics; Phosphate lowering agent; Renal Failure, Agents for"
CBR-001-624-867-2,RFM-008-919-0,CBR-001-624-867-2,Fc1cccc(n1)c1ccc(cc1)Cn1nc2c(c1Nc1ccccc1)c(=O)n(c1=N[C@H]3[C@@H](n21)CCC3)C,"CBR-HVAC-14014: Phosphodiesterase PDE1 Inhibitors; Signal Transduction Modulators; Cognition Disorders, Treatment of"
CBR-001-624-868-3,RFM-008-920-3,CBR-001-624-868-3,OP1(=O)O[C@@H]2[C@H](OP(=O)(O1)O)[C@H]1OP(=O)(O)OP(=O)(O[C@@H]1[C@@H]1[C@@H]2OP(=O)(O)OP(=O)(O1)O)O,CBR-HVAC-12410: Phosphoinositide 3-kinase Inhibitor; ANTICANCER; ANTITUMOR; CARDIOPROTECTANT
CBR-001-624-869-4,RFM-008-921-4,CBR-001-624-869-4,CCc1c(C(=O)C(=O)N)c2c(n1Cc1ccccc1)cccc2OCC(=O)O,"CBR-HVAC-13039: PHOSPHOLIPASE A2 GROUP IIA Inhibitor; Secretory Phospholipase A2 (sPLA2) Inhibitors; Signal Transduction Modulators; Acute Respiratory Distress Syndrome (ARDS), Agents for; Antiinflammatory; Inflammation, Treatment of; Inflammatory Bowel Disease, Agents for; Pancreatic Disorders, Treatment of; Respiratory Disorders (Not Specified); Septic Shock, Treatment of"
CBR-001-624-870-7,RFM-008-922-5,CBR-001-624-870-7,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O,CBR-HVAC-13603: Platelet aggregation inhibitor; Prostaglandin IP2 receptor agonist
CBR-001-624-871-8,RFM-008-923-6,CBR-001-624-871-8,CN(CC[C@@H](Nc1ccc(cc1[N+](=O)[O-])S(=O)(=O)NC(=O)c1ccc(cc1)N1CCN(CC1)Cc1ccccc1c1ccc(cc1)Cl)CSc1ccccc1)C,CBR-HVAC-14104: Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors; Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors; Signal Transduction Modulators; Ovarian Cancer Therapy; Solid Tumors Therapy
CBR-001-624-872-9,RFM-008-924-7,CBR-001-624-872-9,O=C1CCC2=C3[C@H](C[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(O)C(=O)C)C)c1ccc(cc1)N(C)C,CBR-HVAC-02465: Progesterone receptor Agonist; Antagonist; Progesterone receptor agonist; Progesterone receptor antagonist
CBR-001-624-873-0,RFM-008-925-8,CBR-001-624-873-0,C#C[C@@]1(CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12)OC(=O)C,"CBR-HVAC-12917: Progesterone receptor Binder; Contraceptive; Contraceptives; Endometriosis Therapy; Gynecological Disorders, Treatment of"
CBR-001-624-874-1,RFM-008-926-9,CBR-001-624-874-1,CN[C@@H]1COc2c([C@@H](C1)O)cccc2,CBR-HVAC-01110: Prokinetic Agents; Unidentified pharmacological activity
CBR-001-624-875-2,RFM-008-927-0,CBR-001-624-875-2,COCc1cccc(c1)C[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCSCCCC(=O)OC)O,CBR-HVAC-13064: Prostaglandin E receptor 4 Agonist; Prostaglandin EP4 receptor agonist
CBR-001-624-876-3,RFM-008-928-1,CBR-001-624-876-3,CC(Cc1ccc(cc1)CC(=O)O)C,CBR-HVAC-13141: Prostaglandin G/H synthase Inhibitor; Analgesic
CBR-001-624-877-4,RFM-008-929-2,CBR-001-624-877-4,OC[C@@]1(O)C[C@H]2O[C@]1(C)n1c3c4n2c2ccccc2c4c2c(c3c3c1cccc3)CNC2=O,CBR-HVAC-00779: Prostate Cancer Therapy;Myeloid Leukemia Therapy;Antipsoriatics;Neurologic Cancer Therapy;Pancreatic Cancer Therapy;Hematopoiesis Disorders Therapy; Flt3 (FLK2/STK1) Inhibitors;High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors;Signal Transduction Modulators;TRKB Inhibitors;TRKC Inhibitors; FMS-RELATED TYROSINE KINASE 3; JANUS KINASE 2; TYROSINE KINASE RECEPTOR A Inhibitor; Flt-3 kinase inhibitor; TrkA tyrosine kinase inhibitor; Janus kinase 2 inhibitor; Apoptosis stimulant
CBR-001-624-878-5,RFM-008-930-5,CBR-001-624-878-5,OC[C@@]12CC[C@H]([C@@H]([C@H]2C2=CC[C@H]3[C@@]([C@@]2(CC1)C)(C)CC[C@@H]1[C@]3(C)CC[C@@H](C1(C)C)O)C)C,CBR-HVAC-13563: Protease Inhibitor; Antidysrhythmic; Antineoplastic
CBR-001-624-879-6,RFM-008-931-6,CBR-001-624-879-6,COC(=O)C[C@@](C(=O)O[C@@H]1C(=C[C@]23[C@@H]1c1cc4OCOc4cc1CCN3CCC2)OC)(CCC(O)(C)C)O,CBR-HVAC-12922: Protein biosynthesis initiation inhibitor; Anticancer
CBR-001-624-880-9,RFM-008-932-7,CBR-001-624-880-9,F[C@@H]1CCN(C1)S(=O)(=O)Nc1ccc(c(c1F)C(=O)c1c[nH]c2c1cc(cn2)c1cnc(nc1)C1CC1)F,CBR-HVAC-14038: Raf kinase B Inhibitors; Signal Transduction Modulators; Leukemia Therapy; Solid Tumors Therapy
CBR-001-624-881-0,RFM-008-933-8,CBR-001-624-881-0,Oc1cccc2c1C(=O)c1c(C2=O)cccc1O,CBR-HVAC-13302: Reduce neurotoxicity related to beta-amyloid protein by both dominant inhibitory effects on membrane lipid peroxidation and glutathione deprivation.; Laxative; Purgative
CBR-001-624-882-1,RFM-008-934-9,CBR-001-624-882-1,Fc1ccc(c(c1)F)c1ccc(cc1)C(=O)CC(C(=O)O)C,"CBR-HVAC-03768: Rheumatoid Arthritis, Treatment of; Cyclooxygenase (COX) Inhibitors;Leukotriene BLT (LTB4) Antagonists;Lipoxygenase Inhibitors;Signal Transduction Modulators; Lipoxygenase 5; COX Inhibitor; Cyclooxygenase inhibitor; Lipoxygenase inhibitor; Prostaglandin synthase inhibitor"
CBR-001-624-883-2,RFM-008-935-0,CBR-001-624-883-2,[Au]SC(C(=O)[O-])CC(=O)[O-],"CBR-HVAC-05176: Rheumatoid Arthritis, Treatment of;Non-Small Cell Lung Cancer Therapy; Protein Kinase PKC iota Inhibitors;Protein Tyrosine Phosphatase (PTP) Inhibitors;Signal Transduction Modulators; Cathepsin G Inhibitor;"
CBR-001-624-884-3,RFM-008-936-1,CBR-001-624-884-3,Cc1c([C@H]2COC(=N2)N)cccc1F,"CBR-HVAC-07223: Sleep Disorders, Treatment of;Treatment of Cocaine Dependency;Antidepressants;Antipsychotic Drugs; Signal Transduction Modulators;Trace Amine-Associated Receptor 1 (TAAR1,TAR1) Agonists;"
CBR-001-624-885-4,RFM-008-937-2,CBR-001-624-885-4,CC[N+](CC(=O)Nc1c(C)cccc1C)(CC)CC,CBR-HVAC-13090: Sodium channel Blocker; Sodium channel blocker
CBR-001-624-886-5,RFM-008-938-3,CBR-001-624-886-5,CCC1=C[C@H]2CN(C1)CCc1c([C@@](C2)(C(=O)OC)c2cc3c(cc2OC)N([C@@H]2[C@@]43CCN3[C@H]4[C@@](CC)(C=CC3)[C@H]([C@]2(O)C(=O)OC)OC(=O)C)C)[nH]c2c1cccc2,CBR-HVAC-00496: Solid Tumors Therapy; Antimitotic Drugs;Tubulin Polymerization Inhibitors; Microtubule inhibitor; Cell cycle inhibitor; Microtubule inhibitor; Tubulin inhibitor
CBR-001-624-887-6,RFM-008-939-4,CBR-001-624-887-6,CCNC(=O)C#Cc1ccc2c(c1)NC(=O)/C/2=C(/c1ccccc1)\Nc1ccc(cc1)CN(C)C,CBR-HVAC-07136: Solid Tumors Therapy; Antimitotic Drugs;Aurora-A (ARK1) Kinase Inhibitors;Aurora-B (ARK2) Kinase Inhibitors;Aurora-C (ARK3) Kinase Inhibitors;MEK1 Inhibitors;MEK2 Inhibitors;Signal Transduction Modulators;
CBR-001-624-888-7,RFM-008-940-7,CBR-001-624-888-7,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,"CBR-HVAC-13154: Steroid 17-alpha-hydroxylase/Steroid 17,20 lyase Inhibitor; Progestational steroid"
CBR-001-624-889-8,RFM-008-941-8,CBR-001-624-889-8,CC(=O)OCC(=O)C1CCC2C1(C)CCC1C2CCC2=CC(=O)CCC12C,CBR-HVAC-13110: Steroid 5-alpha-reductase Inhibitor; Diuretic
CBR-001-624-890-1,RFM-008-942-9,CBR-001-624-890-1,CC(=O)OCC(=O)[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-13110: Steroid 5-alpha-reductase Inhibitor; Diuretic
CBR-001-624-891-2,RFM-008-943-0,CBR-001-624-891-2,COc1ccc(cc1n1c(N)nc2c1ccc(c2)C(F)(F)F)OC,"CBR-HVAC-10618: Stroke, Treatment of; Calcium Channel Blockers; Sodium channel; Calcium channel Inhibitor;"
CBR-001-624-892-3,RFM-008-944-1,CBR-001-624-892-3,CCOC(=O)c1cc(O)nc(n1)O,"CBR-HVAC-11538: Stroke, Treatment of; Neuroprotectant;"
CBR-001-624-893-4,RFM-008-945-2,CBR-001-624-893-4,OC1CCC(/C(=C/C=C/2\CCCC3(C2CCC3C(/C=C/C(C(C)C)C)C)C)/C1)C,"CBR-HVAC-09777: The activated form of dihydrotachysterol increases the intestinal absorption of calcium and promotes the mobilization of calcium from bone and decreases elevated parathyroid hormone and serum alkaline phosphatase levels, and reverses renal osteodystrophy and muscle weakness;"
CBR-001-624-894-5,RFM-008-946-3,CBR-001-624-894-5,CCCCN1C[C@H](O)[C@H]([C@H]([C@H]1CO)O)O,"CBR-HVAC-00101: Therapy of Inborn Errors of Metabolism;Fabry's Disease, Agents for; Ceramide Glucosyltransferase Inhibitors; Lactase; Glucosylceramide synthase Inhibitor; Unidentified pharmacological activity"
CBR-001-624-895-6,RFM-008-947-4,CBR-001-624-895-6,C[C@@H]1CCC[C@@H](N1NC(=O)c1ccc(c(c1)S(=O)(=O)N)Cl)C,"CBR-HVAC-13028: Thiazide diuretics act in the kidney to remove water from the blood into the urine, by causing an increase in the removal of salts such as potassium and sodium from the blood. This removal of salts causes water to be drawn out of the blood and into the kidneys, where it is then excreted in the urine.; Diuretic; Diuretics; Hypertension, Treatment of"
CBR-001-624-896-7,RFM-008-948-5,CBR-001-624-896-7,C=CCCCCCCCCCSC(=[NH2+])N,CBR-HVAC-05813: Topical Antiinflammatory Agents;
CBR-001-624-897-8,RFM-008-949-6,CBR-001-624-897-8,CCCCCCOC(=O)c1cccnc1,"CBR-HVAC-13374: Topical vasodilator stimulates follicular activity by improving blood flow, rubefacient effect; Vasodilator"
CBR-001-624-898-9,RFM-008-950-9,CBR-001-624-898-9,CCN(c1ccccc1)C[C@H]1COC(=N1)N,CBR-HVAC-12526: Trace amine-associated receptor 1 Agonist; ANTIDPRESSANT
CBR-001-624-899-0,RFM-008-951-0,CBR-001-624-899-0,O=C(Cn1cnc2c1c(=O)n(C)c(=O)n2C)Nc1ccc(cc1)C(C)C,CBR-HVAC-12421: Transient receptor potential ankyrin type-1 Antagonist; ANALGESIC
CBR-001-624-900-6,RFM-008-952-1,CBR-001-624-900-6,CCC1OC(=O)C(C)(F)C(=O)C(C)C(OC2OC(C)CC(C2O)N(C)C)C(CC(C(=O)C(C2C1(C)OC(=O)N2CCCCn1nnc(c1)c1cccc(c1)N)C)C)(C)OC,"CBR-HVAC-00863: Treatment of Leprosy;Inflammation, Treatment of;Antibiotics;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Liver and Biliary Tract Disorders, Treatment of;Antimalarials; 50S Ribosomal Protein Inhibitors; RNA modulator; Protein 50S ribosomal subunit inhibitor"
CBR-001-624-901-7,RFM-008-953-2,CBR-001-624-901-7,CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](Cc1ncn(c1)Cc1ccccc1)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)CO)CC(C)C)CCCNC(=N)N,CBR-HVAC-03296: Treatment of Aberrations of Pubertal Development;Prostate Cancer Therapy; GnRH (LHRH) Agonists;Signal Transduction Modulators;
CBR-001-624-902-8,RFM-008-954-3,CBR-001-624-902-8,COCCC1CC2CN3[C@@H]1[C@](C2)(C(=O)OC)c1[nH]c2c(c1CC3)cccc2,CBR-HVAC-04918: Treatment of Substance Dependency;Antiobesity Drugs;Antileishmanials;Antagonists to Narcotics; Nicotinic alpha3beta4 Antagonists;Signal Transduction Modulators; Dopamine receptor Modulator;
CBR-001-624-903-9,RFM-008-955-4,CBR-001-624-903-9,CC[N+](CCC(c1ccccc1)(C1CCCCC1)O)(CC)CC,CBR-HVAC-13411: Tridihexethyl is a cholinergic blocking agent that block or inhibit the actions of acetylcholine (ACh) at the muscarinic receptors in the parasympathetic nervous system (PSNS); Anticholinergic
CBR-001-624-904-0,RFM-008-956-5,CBR-001-624-904-0,C[C@@H]1CC[C@H]([C@@H](C1)O)C(C)C,CBR-HVAC-12618: TRPM8 (TRP-p8; CMR1) Agonists; Transient receptor potential channel V1 Activator; Analgesic Drugs; Antipruritic; Drugs for Allergic Rhinitis; Nasal Decongestants
CBR-001-624-905-1,RFM-008-957-6,CBR-001-624-905-1,Cc1cc(ccc1/N=N/c1c(O)c2c(N)cc(cc2cc1S(=O)(=O)[O-])S(=O)(=O)[O-])c1ccc(c(c1)C)/N=N/c1c(O)c2c(N)cc(cc2cc1S(=O)(=O)[O-])S(=O)(=O)[O-],"CBR-HVAC-09683: Trypan Blue selectively stains connective tissue structures in the human eye such as the anterior lens capsule of the human crystalline lens. Trypan Blue is intended to be applied directly on the anterior lens capsule, staining any portion of the capsule which comes in contact with the dye. Excess dye is washed out of the anterior chamber. The dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non-stained lens cortex and inner lens material.;"
CBR-001-624-906-2,RFM-008-958-7,CBR-001-624-906-2,Nc1nc(cc(n1)c1ccc(cc1)C[C@@H](C(=O)O)N)O[C@@H](C(F)(F)F)c1ccc(cc1n1ccc(n1)C)Cl,CBR-HVAC-12349: TRYPTOPHAN HYDROXYLASE Inhibitor; Anti-IBS
CBR-001-624-907-3,RFM-008-959-8,CBR-001-624-907-3,Oc1ccc(cc1)C[C@@](C(=O)O)(N)C,CBR-HVAC-12846: Tyrosine hydroxylase Inhibitor; Antihypertensive; Endocrine Cancer Therapy
CBR-001-624-908-4,RFM-008-960-1,CBR-001-624-908-4,CCCCCCCCCCCCOS(=O)(=O)[O-],CBR-HVAC-12977: Unidentified pharmacological activity; Viral Entry Inhibitors; Anti-HIV Agents; Anti-Herpes Simplex Virus Drugs; Antiviral Drugs; Microbicides; Vaginal Spermicides
CBR-001-624-909-5,RFM-008-961-2,CBR-001-624-909-5,OC(=O)[C@H]1[C@H]2[C@]3([C@H]4[C@]51CC(=C)[C@](C5)(O)CC4)C=C[C@@H]([C@@]2(C)C(=O)O3)O,CBR-HVAC-12122: Unidentified pharmacological activity; Vulnerary agent; Vulnerary
CBR-001-624-910-8,RFM-008-962-3,CBR-001-624-910-8,N#Cc1ccc(c2c1cccc2)c1cnccc1SC(C(=O)O)(C)C,CBR-HVAC-12562: URATE TRANSPORTER 1 Inhibitor; ANTI-INFLAMMATORYURICOSURIC
CBR-001-624-911-9,RFM-008-963-4,CBR-001-624-911-9,O=C(c1cnoc1C)N1CCCCC1,CBR-HVAC-03303: Urinary Incontinence Therapy;Non-Opioid Analgesics;Antispasmodics; Cyclooxygenase inhibitor
CBR-001-624-912-0,RFM-008-964-5,CBR-001-624-912-0,COc1cc(S(=O)C)c(cc1OC)C,CBR-HVAC-05576: Vasodilators; Unidentified pharmacological activity
CBR-001-624-913-1,RFM-008-965-6,CBR-001-624-913-1,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCn1c(=O)nc2n(c1=O)CCCC2,CBR-HVAC-10521: 5 Hydroxytryptamine 2 receptor antagonist; 5-Hydroxytryptamine 2A receptor Antagonist; Platelet aggregation inhibitor; Antiplatelet Therapy; Antithrombotic; Vasodilators
CBR-001-624-914-2,RFM-008-966-7,CBR-001-624-914-2,CCCCCCCCCCCCCCOC(=O)c1cccnc1,"CBR-HVAC-12738: Vitamin B3 agonist; Atopic Dermatitis, Agents for; Dermatologic Drugs"
CBR-001-624-915-3,RFM-008-967-8,CBR-001-624-915-3,Oc1cc2OC3(C)CCC4C(c2c(c1)OC4(C)C)C3,analog of CBR-HVAC-12248
CBR-001-624-916-4,RFM-008-968-9,CBR-001-624-916-4,CC(n1c(=O)nc(c2c1cc1OCOc1c2)c1ccccc1)C,analog of CBR-HVAC-12360
CBR-001-624-917-5,RFM-008-969-0,CBR-001-624-917-5,CC(=O)Nc1ccc(cc1)OCc1cccc(c1)F,analog of CBR-HVAC-12411
CBR-001-624-918-6,RFM-008-970-3,CBR-001-624-918-6,COc1c(ccc2c1cccc2)C(=O)Nc1cc(ccc1Oc1ccc(cc1C)Cl)C(F)(F)F,analog of CBR-HVAC-12414
CBR-001-624-919-7,RFM-008-971-4,CBR-001-624-919-7,Clc1ccc(c(c1)Cl)n1nc(c(c1c1ccc(s1)C#Cc1ccc(cc1)C(F)(F)F)CNS(=O)(=O)N1CCCC1)C(=O)NN1CCCCC1,"CBR-HVAC-14453: Cannabinoid CB1 Inverse Agonists; Cannabinoid CB2 Receptor Ligands; Signal Transduction Modulators; Antiobesity Drugs; Type 2 Diabetes, Agents for"
CBR-001-624-920-0,RFM-008-972-5,CBR-001-624-920-0,COC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccc(cc1)C(F)(F)F,analog of CBR-HVAC-12438
CBR-001-624-921-1,RFM-008-973-6,CBR-001-624-921-1,COc1ccc(cc1)[C@@H]1COc2c(C1=O)ccc(c2)OC,analog of CBR-HVAC-12445
CBR-001-624-922-2,RFM-008-974-7,CBR-001-624-922-2,OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@H](CCc2ccccc2)O)C=CC1=O,analog of CBR-HVAC-12450
CBR-001-624-923-3,RFM-008-975-8,CBR-001-624-923-3,COc1ccc(cc1Cl)C(=O)N1CCOc2c1cccc2,analog of CBR-HVAC-12451
CBR-001-624-924-4,RFM-008-976-9,CBR-001-624-924-4,CC(CNc1c2CCC=c2[nH]c2n1nc(c2c1ccccc1)C)C,analog of CBR-HVAC-12456
CBR-001-624-925-5,RFM-008-977-0,CBR-001-624-925-5,Cc1ccc(cc1)c1c(c2ccncc2)c(nc2c1cn[nH]2)c1ccc(cc1)F,analog of CBR-HVAC-12493
CBR-001-624-926-6,RFM-008-978-1,CBR-001-624-926-6,CCOC(=O)Cc1csc(n1)NC(=O)c1cn(c2c1cccc2)C,analog of CBR-HVAC-12515
CBR-001-624-927-7,RFM-008-979-2,CBR-001-624-927-7,CC(CN(S(=O)(=O)c1scc(n1)C)c1cc2CCCc2cc1OCc1ccc(cc1)C(=O)O)C,analog of CBR-HVAC-12583
CBR-001-624-928-8,RFM-008-980-5,CBR-001-624-928-8,O=S1(=O)CCN(CC1)Cc1cc(NCC2CCOCC2)c2c(c1)cc([nH]2)c1ccccc1,"CBR-HVAC-14451: Necroptosis Inhibitors; Acute Myocardial Infarction, Treatment of; Liver and Biliary Tract Disorders, Treatment of"
CBR-001-624-929-9,RFM-008-981-6,CBR-001-624-929-9,CCCCC[C@@H](/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCCO)O,CBR-HVAC-14446: Bronchodilators
CBR-001-624-930-2,RFM-008-982-7,CBR-001-624-930-2,CCCCCCCC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,analog of CBR-HVAC-12829
CBR-001-624-931-3,RFM-008-983-8,CBR-001-624-931-3,OC[C@@H]1CC[C@@H](O1)n1cc(I)c(=O)[nH]c1=O,analog of CBR-HVAC-12839
CBR-001-624-932-4,RFM-008-984-9,CBR-001-624-932-4,O=C1NC(=O)C2(N1)c1ccccc1c1c2cccc1,analog of CBR-HVAC-12841
CBR-001-624-933-5,RFM-008-985-0,CBR-001-624-933-5,OC(CN1CCN(CC1)c1nc2c(s1)cc(cc2)Cl)COc1ccc(cc1)F,analog of CBR-HVAC-12880
CBR-001-624-934-6,RFM-008-986-1,CBR-001-624-934-6,Oc1ccc(cc1)CC(C(=O)NC(C(=O)O)Cc1ccc(cc1)O)NC(=O)C(Cc1ccc(cc1)O)N,analog of CBR-HVAC-13032
CBR-001-624-935-7,RFM-008-987-2,CBR-001-624-935-7,NCCCCC1NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(N)CSSCC2C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC3CSSCC(NC1=O)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(Cc1ccc(cc1)O)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)N2)CSSCC(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC3=O)CCCNC(=N)N)CO)CCCCN)C(=O)N)CO)C(O)C,"CBR-HVAC-04451: Calcium channel Antagonist; N-Type Calcium Channel (Ca(v) 2.2) Blockers; Calcium channel blocker; Non-Opioid Analgesics; Stroke, Treatment of"
CBR-001-624-936-8,RFM-008-988-3,CBR-001-624-936-8,O=C(C(NC(=O)C(C)(C)C)C)Nc1ccc(cc1C)C,analog of CBR-HVAC-13144
CBR-001-624-937-9,RFM-008-989-4,CBR-001-624-937-9,OC(=O)Cc1ccc(cc1)C1CCCCC1,analog of CBR-HVAC-13159
CBR-001-624-938-0,RFM-008-990-7,CBR-001-624-938-0,CCCCCCCC/C=C\CCCCCCCC(=O)OC(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC,analog of CBR-HVAC-13235
CBR-001-624-939-1,RFM-008-991-8,CBR-001-624-939-1,COc1ccc2c3c1OC1[C@@]43CCN(C(C2)C24C=CC1(OC)C(C2)(C)C(O)(C)C)C,analog of CBR-HVAC-13325
CBR-001-624-940-4,RFM-008-992-9,CBR-001-624-940-4,O=C1CCC2(C(=C1)CCC1C2[C@H](O)CC2(C1CC[C@]2(O)C(=O)C)C)C,analog of CBR-HVAC-13332
CBR-001-624-941-5,RFM-008-993-0,CBR-001-624-941-5,CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)CO,analog of CBR-HVAC-13335
CBR-001-624-942-6,RFM-008-994-1,CBR-001-624-942-6,CCN(CCCCC1CCN(CC1)CC(=O)n1c2ccccc2c(=O)[nH]c2c1nccc2)CC,CBR-HVAC-14441: Muscarinic M2 receptor antagonist; Muscarinic acetylcholine receptor M2 Antagonist; ANTI-ARRHYTHMIC; Antiarrhythmic Drugs
CBR-001-624-943-7,RFM-008-995-2,CBR-001-624-943-7,Clc1cc(OCc2ccccc2)ccc1OCc1ccccc1,analog of CBR-HVAC-13441
CBR-001-624-944-8,RFM-008-996-3,CBR-001-624-944-8,COc1ccc2c(c1)c(C(=O)CN1CCN(CC1)c1ccccc1OC)c([nH]2)C,analog of CBR-HVAC-13488
CBR-001-624-945-9,RFM-008-997-4,CBR-001-624-945-9,CCCCC1=NC2(C(=O)N1Cc1ccc(c(c1)COCC)c1ccccc1S(=O)(=O)Nc1noc(c1C)C)CCCC2,"CBR-HVAC-05566: Angiotensin AT1 Antagonists; Angiotensin II 1 antagonist; Endothelin A receptor antagonist; Endothelin ETA Receptor Antagonists; Signal Transduction Modulators; Diabetic Neuropathy, Agents for; Hypertension, Treatment of; Treatment of Renal Diseases"
CBR-001-624-946-0,RFM-008-998-5,CBR-001-624-946-0,O=C1C(=O)C(CCC2CCC3C(C2)CCCC3)C(=O)c2c1cccc2,analog of CBR-HVAC-13610
CBR-001-624-947-1,RFM-008-999-6,CBR-001-624-947-1,COc1cc2CCNC(c2cc1OC)c1cc(OC)c(c(c1)OC)OC,analog of CBR-HVAC-13657
CBR-001-624-948-2,RFM-009-000-6,CBR-001-624-948-2,OCCOCCOCCOCCOCCOCCOCCOc1ccc(cc1)C(CC(C)(C)C)(C)C,analog of CBR-HVAC-13658
CBR-001-624-949-3,RFM-009-001-7,CBR-001-624-949-3,O=C1C2CCCC1C=C(C2)c1ccccc1,analog of CBR-HVAC-13721
CBR-001-624-950-6,RFM-009-002-8,CBR-001-624-950-6,OC(=O)c1ccc(nc1)CCN1CCCC1,analog of CBR-HVAC-13726
CBR-001-624-951-7,RFM-009-003-9,CBR-001-624-951-7,CC(c1ccccc1)Nc1cc(=O)n(c(=O)[nH]1)C,analog of CBR-HVAC-13737
CBR-001-624-952-8,RFM-009-004-0,CBR-001-624-952-8,CCN(C(=O)c1cc(OC)c(c(c1)OC)OC)CC(=O)NC,analog of CBR-HVAC-13778
CBR-001-624-953-9,RFM-009-005-1,CBR-001-624-953-9,N#CC1CCN(CC1)CCc1ccc2c(c1)CCO2,analog of CBR-HVAC-13788
CBR-001-624-954-0,RFM-009-006-2,CBR-001-624-954-0,O=C(N1CCN(CC1)CC(=O)N1CCCC1)CCC(=O)c1ccc(cc1)Cl,analog of CBR-HVAC-13802
CBR-001-624-955-1,RFM-009-007-3,CBR-001-624-955-1,CN(CC1CCCN1C(=O)/C=C/c1ccc(cc1)C(F)(F)F)C,analog of CBR-HVAC-13806
CBR-001-624-956-2,RFM-009-008-4,CBR-001-624-956-2,OC[C@H](Cc1ccc(cc1)O)NC(=O)CCc1ccc(cc1)C,analog of CBR-HVAC-13815
CBR-001-624-957-3,RFM-009-009-5,CBR-001-624-957-3,C[C@@H]1CC2[C@]([C@@]1(O)C(=O)C)(C)CCC1C2CC=C2[C@]1(C)CCC(C2)OP(=O)(O)O,analog of CBR-HVAC-13824
CBR-001-624-958-4,RFM-009-010-8,CBR-001-624-958-4,COc1cc(cc(c1OC)OC)C1OC(=NN1C(=O)C)c1ccncc1,analog of CBR-HVAC-13850
CBR-001-624-959-5,RFM-009-011-9,CBR-001-624-959-5,O=C1NC2C(N1C1CCN(CC1)C(=O)OC(C)(C)C)CCNC2,analog of CBR-HVAC-13862
CBR-001-624-960-8,RFM-009-012-0,CBR-001-624-960-8,CCOc1ccc2c(c1)[nH]c(c2)C(=O)Nc1nc2c([nH]1)cccc2,analog of CBR-HVAC-13863
CBR-001-624-961-9,RFM-009-013-1,CBR-001-624-961-9,COc1ccc(cc1)n1cc(ccc1=O)C(=O)N1CCCC(C1)C,analog of CBR-HVAC-13892
CBR-001-624-962-0,RFM-009-014-2,CBR-001-624-962-0,O=C(N1CCC(CC1)c1ccccc1C(F)(F)F)Nc1ccccc1C(=O)O,"CBR-HVAC-14452: Retinol-Binding Protein 4 (RBP4) Inhibitors; Age-Related Macular Degeneration, Treatment of"
CBR-001-624-963-1,RFM-009-015-3,CBR-001-624-963-1,COc1cc(ccc1OC)C(=O)c1sc(nc1N)Nc1ccccc1,analog of CBR-HVAC-13939
CBR-001-624-964-2,RFM-009-016-4,CBR-001-624-964-2,CN([C@@H]1C(=O)C(C(=O)N)C(=O)[C@@]2([C@H]1[C@@H](O)[C@@H]1C(=C)c3cccc(c3C(=O)C1C2=O)O)O)C,analog of CBR-HVAC-13952
CBR-001-624-965-3,RFM-009-017-5,CBR-001-624-965-3,COc1ccc(cc1)C(=O)N1CCc2c(C1c1ccc(cc1)Cl)[nH]c1c2cccc1,analog of CBR-HVAC-13964
CBR-001-624-966-4,RFM-009-018-6,CBR-001-624-966-4,Oc1ccc(cc1)c1c(nn2c1nc(cc2C(F)(F)F)C(F)(F)F)c1ccccc1,CBR-HVAC-14450: Estrogen Receptor (ER) beta Antagonists; Signal Transduction Modulators; Agents for Osteopetrosis; Pharmacological Tools
CBR-001-624-967-5,RFM-009-019-7,CBR-001-624-967-5,COc1cc(C)nc(c1CNC(=O)c1c(C)n(c2c1cccc2)[C@@H](C1CCOCC1)C)O,analog of CBR-HVAC-14026
CBR-001-624-968-6,RFM-009-020-0,CBR-001-624-968-6,CCOC(=O)c1cccnc1N1CCN(CC1)Cc1c(F)cccc1Cl,analog of CBR-HVAC-14035
CBR-001-624-969-7,RFM-009-021-1,CBR-001-624-969-7,O1CCN(CC1)c1ccc(cc1)Nc1ncnc2c1cc(cc2)c1ccccc1,analog of CBR-HVAC-14071
CBR-001-625-029-6,RFM-009-022-2,CBR-001-625-029-6,COc1cc(OC)cc(c1)C(=O)N1CCN(CC1)CCc1ccc(cc1)Cl,CBR-HVAC-04402: GABA receptor Agonist; ANALGESIC; PAIN
CBR-001-625-030-9,RFM-009-023-3,CBR-001-625-030-9,CC12CC3CC(C1)(C)CC(C2)(C3)N,CBR-HVAC-12681: Ionotropic glutamate receptor NMDA Antagonist; Antialzheimer's; Alzheimer's disease
CBR-001-625-031-0,RFM-009-024-4,CBR-001-625-031-0,OC(COc1cccc2c1c1ccccc1[nH]2)CNC(C)C,CBR-HVAC-13210: Beta-3 adrenergic receptor Agonist; Antianginal; Antiarrhythmic; Antihypertensive; Angina pectoris; Arrhythmia; Hypertension
CBR-001-625-032-1,RFM-009-025-5,CBR-001-625-032-1,c1ccc(cc1)C1(CC1C1=NCCN1)c1ccccc1,CBR-HVAC-02089: ATP-sensitive K+ channel Blocker; Antiarrhythmic; ATRIAL TACHYARRHYTHMIA
CBR-001-625-033-2,RFM-009-026-6,CBR-001-625-033-2,COc1cc(cc(c1OC)OC)C(=O)N1CCC(C1)(CCN1CCC(CC1)(C(=O)N)c1ccccc1)c1ccc(c(c1)Cl)Cl,CBR-HVAC-10773: Neurokinin receptor 1; Neurokinin receptor 2 Antagonist; Antiasthmatic; Asthma
CBR-001-625-034-3,RFM-009-027-7,CBR-001-625-034-3,CO/N=C(/c1csc(n1)N)\C(=O)NC1C2SCC=C(N2C1=O)C(=O)O,CBR-HVAC-02221: Cell wall synthesis inhibitor
CBR-001-625-035-4,RFM-009-028-8,CBR-001-625-035-4,O=CC[C@H]1C[C@@H](C)[C@H](/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]([C@H]1O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@H]1O)N(C)C)O[C@H]1C[C@@](C)(O)[C@H]([C@@H](O1)C)O)OC)OC(=O)C)C)O[C@H]1CC[C@@H]([C@H](O1)C)N(C)C,"CBR-HVAC-13133: ; Antibacterial; Infection, Bacterial"
CBR-001-625-036-5,RFM-009-029-9,CBR-001-625-036-5,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2SC,CBR-HVAC-11371: phosphoribosylpyrophosphatate amidotransferase Inhibitor; Anticancer; Advanced pancreatic cancer; Acute leukemia; Metastatic cancer
CBR-001-625-037-6,RFM-009-030-2,CBR-001-625-037-6,CC(C1O[C@H]2[C@H](O1)CN[Pt]1(NC2)OC(=O)CC(=O)O1)C,CBR-HVAC-02285: DNA antagonist. Antitumour activity.; Anticancer; Cancer; Gastric cancer
CBR-001-625-038-7,RFM-009-031-3,CBR-001-625-038-7,OCC(c1ccccc1)C(=O)OC1CC2CCC(C1)[N+]2(C)C,"CBR-HVAC-13190: Muscarinic acetylcholine receptor Antagonist; Anticholinergic; Parkinson's disease; Spasm, muscle"
CBR-001-625-039-8,RFM-009-032-4,CBR-001-625-039-8,CC(=O)[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2[C@]1(C)CC[C@@](C2)(C)O,CBR-HVAC-12673: GABA-A receptor Modulator; Anticonvulsant; Antimigraine; Antiepileptic; Epilepsy; Migraine
CBR-001-625-040-1,RFM-009-033-5,CBR-001-625-040-1,NC(=N)NCCCOc1ccccc1,CBR-HVAC-09050: ; Antidepressant; Depression
CBR-001-625-041-2,RFM-009-034-6,CBR-001-625-041-2,OC(=O)Cc1nn(Cc2ccc(cc2F)Br)c(=O)c2c1cccc2,CBR-HVAC-03016: Aldose reductase Inhibitor; Antidiabetic; Diabetic complications
CBR-001-625-042-3,RFM-009-035-7,CBR-001-625-042-3,CN(CC1OCCn2cc(c3c2cccc3)C2=C(c3cn(CC1)c1ccccc31)C(=O)NC2=O)C,CBR-HVAC-04727: Protein tyrosine kinase C beta Inhibitor; ANTI-DIABETIC¬CARDIOPROTECTANT; Diabetic macular edema; Diabetic nephropathy; Diabetic retinopathy; Cardiovascular disease
CBR-001-625-043-4,RFM-009-036-8,CBR-001-625-043-4,OC[C@H]([C@H]([C@@H]([C@H](C(=O)[O-])O)O)O)O,"CBR-HVAC-12608: Increases total body and serum calcium levels; Antihyperkalemic; Antihypocalcemic; Osteoporosis; Blood transfusion; Pain, eye; Osteomalacia; Rickets; Hypoparathyroidism; Cramps; Muscle weakness; Confusion disorder; Hypermagnesemia; Hydrofluoric acid burns"
CBR-001-625-044-5,RFM-009-037-9,CBR-001-625-044-5,NC(=N)NCC1COC2(O1)CCCCC2,CBR-HVAC-02208: Adrenergic receptor Blocker; Antihypertensive; Hypertension
CBR-001-625-045-6,RFM-009-038-0,CBR-001-625-045-6,CCCC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-13289: Glucocorticoid receptor Agonist; Anti-inflammatory; Corticosteroid; Eczema; Dermatitis; Psoriasis
CBR-001-625-046-7,RFM-009-039-1,CBR-001-625-046-7,NCC1CCn2c(C1)c(C1=C(C(=O)NC1=O)c1cn(c3c1cccc3)C)c1c2cccc1,CBR-HVAC-10886: Protein tyrosine kinase C Inhibitor; Anti-inflammatory; Immunomodulator; Inflammation; Cancer
CBR-001-625-047-8,RFM-009-040-4,CBR-001-625-047-8,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NC1CCCC1,CBR-HVAC-13324: Adenosine A1 receptor Agonist; Antiischemic; Ischemia
CBR-001-625-048-9,RFM-009-041-5,CBR-001-625-048-9,CO[C@@H]([C@@H]1Cc2cc3cc(O[C@H]4C[C@@H](O[C@H]5C[C@@H](O)[C@@H]([C@H](O5)C)OC)[C@@H]([C@H](O4)C)OC(=O)C)c(c(c3c(c2C(=O)[C@H]1O[C@H]1C[C@@H](OC2C[C@@H](O[C@@H]3O[C@H](C)[C@H]([C@@](C3)(C)O)OC(=O)C)[C@H]([C@H](O2)C)O)[C@@H]([C@H](O1)C)O)O)O)C)C(=O)[C@H]([C@H](O)C)O,"CBR-HVAC-13271: Inhibits GC-rich DNA-binding protein, suppress TNF-alpha-induced fractalkine mRNA expression, possibly through inhibition of transcriptional activities by NF-kappaB and Sp1; Antineoplastic; Cancer"
CBR-001-625-049-0,RFM-009-042-6,CBR-001-625-049-0,CC1(C)CC(C)(C)CC(C1)(C)N,CBR-HVAC-12614: Ionotropic glutamate receptor NMDA Antagonist; Antiparkinsonian; Alzheimer's disease; Alcoholism; Pain; Neuroprotection; Parkinson's disease
CBR-001-625-050-3,RFM-009-043-7,CBR-001-625-050-3,CC(N(C(C)C)CCC(c1ccccc1)c1ccccc1)C,CBR-HVAC-09081: ; Antispasmodic; Spasms
CBR-001-625-051-4,RFM-009-044-8,CBR-001-625-051-4,COC(=O)c1ccccc1C(=O)c1ccc(cc1)OCCN1CCCCC1,"CBR-HVAC-08605: Acetylcholinesterase Inhibitor; Antispasmodic; Spasm, muscular"
CBR-001-625-052-5,RFM-009-045-9,CBR-001-625-052-5,CNC(=O)c1cccc(c1)NCC(=O)NCCc1ccc(c(c1)OC)OC,CBR-HVAC-03441: Antiulcer; Antiulcer; Peptic ulcers
CBR-001-625-053-6,RFM-009-046-0,CBR-001-625-053-6,CC(C12CC3CC(C2)CC(C1)C3)N,"CBR-HVAC-12682: It exert its inhibitory effect early in the viral replicative cycle, possibly inhibiting the uncoating of the virus (May due to virus protein specified by the virion M2 gene which plays an important role in the susceptibility of influenza A virus); Antiviral; Influenza A virus infection"
CBR-001-625-054-7,RFM-009-047-1,CBR-001-625-054-7,CCCCCCCCCCCCCCCC[N+](Cc1ccccc1)(C)C,"CBR-HVAC-09755: Kills a variety of bacteria and fungi that may infect sore or broken skin in the mouth.; Antiviral; Disinfectant; Infection, herpes simplex; Inflammation, lining of the mouth; Ulcer, mouth; Toothache"
CBR-001-625-055-8,RFM-009-048-2,CBR-001-625-055-8,CC(NCC(c1ccccc1Cl)O)C,CBR-HVAC-13078: Beta-2 adrenergic receptor agonist; Bronchodilator; Bronchospasm
CBR-001-625-056-9,RFM-009-049-3,CBR-001-625-056-9,CCN(CCn1cnc2c1c(=O)n(C)c(=O)n2C)CC,CBR-HVAC-08948: ; Bronchodilator; Bronchiolitis
CBR-001-625-057-0,RFM-009-050-6,CBR-001-625-057-0,COC1CC(OC2CCC3(C(C2)(O)CC[C@@H]2[C@@H]3CCC3(C2(O)CCC3C2=CC(=O)OC2)C)C=O)OC(C1O)C,CBR-HVAC-13339: ; Cardiotonic; Heart disease
CBR-001-625-058-1,RFM-009-051-7,CBR-001-625-058-1,O=CC12CCC(CC2(O)CC[C@@H]2[C@@H]1CCC1(C2(O)CCC1C1=CC(=O)OC1)C)OC1OC(C)C(C(C1O)O)O,CBR-HVAC-13262: ; Cardiotonic; Heart disease
CBR-001-625-059-2,RFM-009-052-8,CBR-001-625-059-2,O=C1OCC(=C1)C1C(O)CC2(C1(C)CC[C@H]1[C@H]2CCC2C1(C)CCC(C2)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)OC1CC(O)C(C(O1)C)O)O,CBR-HVAC-13338: ; Cardiotonic; Heart disease
CBR-001-625-060-5,RFM-009-053-9,CBR-001-625-060-5,OCC1OC(OC2C(C)OC(CC2OC(=O)C)OC2C(O)CC(OC2C)OC2C(O)CC(OC2C)OC2CCC3(C(C2)CC[C@@H]2[C@@H]3CCC3(C2(O)CCC3C2=CC(=O)OC2)C)C)C(C(C1O)O)O,CBR-HVAC-13171: ; Cardiotonic; Heart disease
CBR-001-625-061-6,RFM-009-054-0,CBR-001-625-061-6,O[C@H]1[C@H](O[C@H]2CC[C@]3(C(=C2)CC[C@@H]2C3CC[C@]3([C@]2(O)CC[C@@H]3c2ccc(=O)oc2)C)C)O[C@H]([C@@H]([C@H]1O)O)C,CBR-HVAC-12888: ; Cardiotonic; Heart disease
CBR-001-625-062-7,RFM-009-055-1,CBR-001-625-062-7,N1CCN2C(C1)c1ccccc1CC2,CBR-HVAC-09408: ; CENTRAL NERVOUS SYSTEM DEPRESSANT; ANTIPSYCHOTIC; Cns disorders
CBR-001-625-063-8,RFM-009-056-2,CBR-001-625-063-8,N#Cc1ccc2c(c1)CCC(C2)N1CCC2(CC1)CC(=O)c1c(O2)ccc(c1)NS(=O)(=O)C,CBR-HVAC-04193: Potassium channel Blocker; Class III antiarrhythmic; Ventricular arrhythmias
CBR-001-625-064-9,RFM-009-057-3,CBR-001-625-064-9,Oc1ccc(c(c1)C)Cl,"CBR-HVAC-13408: ; Disinfectant; Preservative, cosmetics; Preservative, medicinal products"
CBR-001-625-065-0,RFM-009-058-4,CBR-001-625-065-0,OCC(=O)[C@@]1(O)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@H]1[C@H]2CCC2=CC(=O)C=C[C@]12C,CBR-HVAC-13148: Meprednisone stabilize the membrane lysosomes during the proteolytic catabolic phase and increases capillary tonicity during the exudative vascular reaction phase.; Glucocorticoid; Inflammation
CBR-001-625-066-1,RFM-009-059-5,CBR-001-625-066-1,O=C1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CC[C@@H](C2)OS(=O)(=O)[O-],CBR-HVAC-05445: GABAA RECEPTOR Agonist; Immunosuppressant;
CBR-001-625-067-2,RFM-009-060-8,CBR-001-625-067-2,N#CC1=C(C)NC(=C(C1c1cccc2c1cc(cn2)c1ccccc1)C(=O)OC(C)C)N,CBR-HVAC-04374: Calcium channel Agonist; Inotropic; Congestive heart failure
CBR-001-625-068-3,RFM-009-061-9,CBR-001-625-068-3,OC[C@H]1O[C@H](O)[C@@H]([C@H](C1O[C@H]1O[C@H](COC2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)C([C@@H]([C@H]1O)O)O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)O)O,"CBR-HVAC-13313: Icodextrin acts in the peritoneal cavity by exerting osmotic pressure across small intercellular pores resulting in transcapillary ultrafiltration throughout the dwell. Like other peritoneal dialysis solutions, Icodextrin also contains electrolytes to help normalize electrolyte balance and lactate to help normalize acid-base status; Osmotic agent; Peritoneal dialysis patients as the osmotic agent"
CBR-001-625-069-4,RFM-009-062-0,CBR-001-625-069-4,CC[C@H](C(C)C)CC[C@H]([C@H]1CCC2[C@]1(C)CCC1[C@H]2CC=C2[C@]1(C)CC[C@H](C2)O)C,"CBR-HVAC-13121: Protein kinase C alpha Activator; Protein kinase C-alpha inactivator; Hyperplasia, benign prostatic; Hyperlipidaemia"
CBR-001-625-070-7,RFM-009-063-1,CBR-001-625-070-7,N#Cc1ccnc(c1)N1C(=O)CC[C@H]1C(=O)N(C(c1ccccc1Cl)C(=O)NC1CC(C1)(F)F)c1cncc(c1)F,"CBR-HVAC-14062: Isocitrate Dehydrogenase (NADP+) (IDPc, IDH1) Inhibitors"
CBR-001-625-071-8,RFM-009-064-2,CBR-001-625-071-8,N#Cc1ccc2c(c1)c(c1ccc(cn1)CN1CCOCC1)c([nH]2)O,CBR-HVAC-12053: Glycogen Synthase Kinase 3 (GSK-3) Inhibitors;Signal Transduction Modulators
CBR-001-625-072-9,RFM-009-065-3,CBR-001-625-072-9,O[Bi]1Oc2c(O1)cc(cc2O)C(=O)O,CBR-HVAC-06588: Nitric Oxide Synthase Inhibitors;Signal Transduction Modulators
CBR-001-625-073-0,RFM-009-066-4,CBR-001-625-073-0,Fc1cnc(nc1)[C@@H](Nc1ncc(c(n1)Nc1n[nH]c(c1)C)Cl)C,CBR-HVAC-06638: Jak1 Inhibitors;Jak2 Inhibitors;Signal Transduction Modulators
CBR-001-625-074-1,RFM-009-067-5,CBR-001-625-074-1,NC(=N)NCCCCNC(=N)N,CBR-HVAC-13712: Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators
CBR-001-625-075-2,RFM-009-068-6,CBR-001-625-075-2,N1CCNCC1,"CBR-HVAC-13570: Piperazine blocks the response of the worm muscle (best studied in Ascaris ) to acetylcholine, presumably by causing hyperpolarization of nerve endings, resulting in flaccid paralys is of the worm"
CBR-001-625-076-3,RFM-009-069-7,CBR-001-625-076-3,O[C@@H]1[C@H]2CC[C@@H]3[C@]1(C[C@@H](O)[C@]1([C@H]([C@]3(C)O)[C@H]3[C@@H](C1(C)C)O3)O)C[C@@]2(C)O,"CBR-HVAC-13825: Hypertension, Treatment of"
CBR-001-625-077-4,RFM-009-070-0,CBR-001-625-077-4,CC1CCC(C(C1)OC(=O)C[N+](CCCCCCCCCC[N+](CC(=O)OC1CC(C)CCC1C(C)C)(C)C)(C)C)C(C)C,"CBR-HVAC-07343: Liver and Biliary Tract Disorders, Treatment of;Inflammation, Treatment of;Agents for Gastritis;Chronic Obstructive Pulmonary Diseases (COPD), Treatment of;Antibacterial Drugs"
CBR-001-625-078-5,RFM-009-071-1,CBR-001-625-078-5,OC[C@H]1O[C@@H](Oc2cc3c(O)cc(cc3[o+]c2c2ccc(c(c2)O)O)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1OC[C@H]([C@@H]([C@H]1O)O)O,CBR-HVAC-12854: Antioxidants;Free Radical Scavengers
CBR-001-625-079-6,RFM-009-072-2,CBR-001-625-079-6,OC[C@H]1O[C@@H](Oc2cc3c(O)cc(cc3[o+]c2c2cc(O)c(c(c2)O)O)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1OC[C@H]([C@@H]([C@H]1O)O)O,CBR-HVAC-12853: Antioxidants
CBR-001-625-080-9,RFM-009-073-3,CBR-001-625-080-9,NC(=N)NN=Cc1ccccc1Cl,"CBR-HVAC-13720: Neurological Genetic Disorders, Treatment of ;Neurodegenerative Diseases, Treatment of;Ocular Genetic Disorders, Treatment of"
CBR-001-625-081-0,RFM-009-074-4,CBR-001-625-081-0,Nc1c2CCCCc2nc2c1CCCC2,CBR-HVAC-12847: Acetylcholinesterase (AChE) Inhibitors;Butyrylcholinesterase Inhibitors
CBR-001-625-082-1,RFM-009-075-5,CBR-001-625-082-1,CCC[N+]12[C@H]3C[C@@]45[C@H](C2C[C@H](C3C4O)[C@@H]([C@H]1O)CC)N(C)c1c5cccc1,CBR-HVAC-12957: Antiarrhythmic Drugs
CBR-001-625-083-2,RFM-009-076-6,CBR-001-625-083-2,OC[C@H]1O[C@@H](O[C@H]2CC[C@]3(C(=CC[C@@H]4[C@@H]3CC[C@]3([C@H]4C[C@H]4[C@@H]3[C@H](C)[C@]3(O4)CC[C@H](CN3)C)C)C2)C)[C@@H]([C@H]([C@H]1O)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)O[C@@H]1O[C@@H](C)[C@@H]([C@H]([C@H]1O)O)O,CBR-HVAC-12978: Steroidal Saponins
CBR-001-625-084-3,RFM-009-077-7,CBR-001-625-084-3,CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,CBR-HVAC-13086: Cytokine release inhibitor; Phospholipase inhibitor
CBR-001-625-085-4,RFM-009-078-8,CBR-001-625-085-4,CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O,"CBR-HVAC-12904: Cancer Associated Disorders, Treatment of"
CBR-001-625-086-5,RFM-009-079-9,CBR-001-625-086-5,Oc1cc(O)c2c(c1)[o+]c(c(c2)O)c1ccc(c(c1)O)O,CBR-HVAC-12838: Oxysterol Receptor LXRalpha Agonists;Signal Transduction Modulators
CBR-001-625-087-6,RFM-009-080-2,CBR-001-625-087-6,CC(C1=NCCN1)Oc1c(Cl)cccc1Cl,CBR-HVAC-00973: alpha2-Adrenoceptor Agonists;Signal Transduction Modulators
CBR-001-625-088-7,RFM-009-081-3,CBR-001-625-088-7,O=C(NS(=O)(=O)c1ccc(cc1)C)NC(Cc1ccccc1)(C)C,analog of CBR-HVAC-14246
CBR-001-625-089-8,RFM-009-082-4,CBR-001-625-089-8,OCC1O[C@@H]2OC3C(CO)O[C@H]([C@H]([C@H]3O)O)OC3C(CO)O[C@H]([C@H]([C@H]3O)O)OC3C(CO)O[C@H]([C@H]([C@H]3O)O)OC3C(O[C@H](OC4C(O[C@H](OC5C(O[C@@H](OC6C(O[C@@H](OC1[C@@H]([C@@H]2O)O)[C@@H](O)[C@H]6O)CO)[C@@H](O)[C@H]5O)CO)[C@@H](O)[C@H]4O)CO)[C@H]([C@H]3O)O)CO,"CBR-HVAC-13232: GCD effectively lowers postprandial glycemia and insulinemia compared with MD, without resulting in appreciable carbohydrate malabsorption or gastrointestinal intolerance."
CBR-001-625-090-1,RFM-009-083-5,CBR-001-625-090-1,OCC(C(C(C(COC1OC(CO)C(C(C1O)O)O)O)O)O)O,CBR-HVAC-13225:
CBR-001-625-091-2,RFM-009-084-6,CBR-001-625-091-2,CCCCCCCCCCCC(=O)OCC([C@H]1OC[C@@H]([C@H]1O)O)O,CBR-HVAC-13213:
CBR-001-625-096-7,RFM-009-085-7,CBR-001-625-096-7,CCNC1CC(N)C(C(C1OC1OCC(C(C1O)NC)(C)O)O)OC1OC(=CCC1N)CN,CBR-HVAC-01303: 16S Ribosomal Protein Inhibitors;30S Ribosomal Protein Inhibitors
CBR-001-625-097-8,RFM-009-086-8,CBR-001-625-097-8,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)CC(=O)N)Cc1nc[nH]c1)C(C)C)CC(=O)O)CCC(=O)N)CC(C)C)CCCCN)CCCCN)CCCNC(=N)N)CC(C)C)Cc1c[nH]c2c1cccc2)CCC(=O)O)C(C)C)CCCNC(=N)N)CCC(=O)O)CCSC)CO)CC(=O)N)CC(C)C)Cc1nc[nH]c1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N)CO)CCC(=O)O)CCC(=O)N)CC(C)C)CCSC)Cc1nc[nH]c1)CC(=O)N)CC(C)C,CBR-HVAC-12613: Drugs Acting on Parathyroid Hormone Receptors (PTHR);Signal Transduction Modulators
CBR-001-625-098-9,RFM-009-087-9,CBR-001-625-098-9,NCCCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)N[C@H](C(=O)N)C(C)C)NC(=O)CNC(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)C)CO)Cc1ccc(cc1)O)CO)CCSC)CCC(=O)O)Cc1[nH]cnc1)Cc1ccccc1)CCCNC(=N)N,CBR-HVAC-12644:
CBR-001-625-099-0,RFM-009-088-0,CBR-001-625-099-0,O[C@H]1C[C@H](O)C(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](CC[C@H](C(C)C)O)C)C)/C1,CBR-HVAC-12727: Topical Antiinflammatory Agents;Antiallergy/Antiasthmatic Drugs
CBR-001-625-100-6,RFM-009-089-1,CBR-001-625-100-6,CCCCCCCCCCCC(=O)c1c(O)cc(c(c1O)C1CC(Oc2c1ccc(c2)O)c1ccc(cc1)O)O,CBR-HVAC-13257: Phospholipase A2 (PLA2) Inhibitors;Signal Transduction Modulators
CBR-001-625-101-7,RFM-009-090-4,CBR-001-625-101-7,F[Ga](F)F,analog of CBR-HVAC-00883
CBR-001-625-102-8,RFM-009-091-5,CBR-001-625-102-8,NCCCC[C@@H](C(=O)Nc1ccc2c(c1)oc(=O)cc2C)NC(=O)[C@@H](NC(=O)OCC1c2ccccc2c2c1cccc2)CC1CCCCC1,CBR-HVAC-14089: Histamine H1 Receptor Antagonists;Histamine H3 Receptor Antagonists;Signal Transduction Modulators
CBR-001-625-103-9,RFM-009-092-6,CBR-001-625-103-9,NCCCC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)CO)C)CO)CO)CC(=O)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1nc[nH]c1)N)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CC(C)C)CO)CCCCN)CCC(=O)N)CCSC)CCC(=O)O)CCC(=O)O)CCC(=O)O)C)CCCNC(=N)N)CC(C)C)Cc1ccccc1)CCC(=O)O)CC(C)C,CBR-HVAC-12634: GLP-1 Receptor Agonists;Insulin Secretagogues;Signal Transduction Modulators
CBR-001-625-108-4,RFM-009-093-7,CBR-001-625-108-4,[O]#C[Fe](C#[O])(C#[O])(C#[O])C#[O],CBR-HVAC-14332:Antianemics;Hematinic Agents
CBR-001-625-109-5,RFM-009-094-8,CBR-001-625-109-5,O=C1N(CCOc2c1cc(cc2)c1ccc(cc1)OC(F)(F)F)Cc1ncccn1,CBR-HVAC-14343:Late Sodium Current (INaL) Blockers;Nav1.5 (Cardiac/SkMII) Sodium Channel Blockers
CBR-001-625-119-7,RFM-009-095-9,CBR-001-625-119-7,OC(=O)Cc1ccccc1COc1ccc2c(c1)cc(o2)c1scc(n1)C(C)(C)C,CBR-HVAC-04414:Leukotriene CysLT1 (LTD4) Antagonists;PPARgamma Agonists;Signal Transduction Modulators
CBR-001-625-120-0,RFM-009-096-0,CBR-001-625-120-0,Clc1cnc(nc1)N1CCC(CC1)Oc1cc(=O)n(cc1Cl)c1ccc(cc1F)S(=O)(=O)C,"CBR-HVAC-07178:Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonists;Signal Transduction Modulators"
CBR-001-625-121-1,RFM-009-097-1,CBR-001-625-121-1,OCCNC(=O)OCc1nc2cc(C)c(c(c2c(=O)n1c1ccccc1S(=O)(=O)NC)C)C(=O)OCC,CBR-HVAC-05956:Cannabinoid CB1 Agonists;Cannabinoid CB2 Agonists;Signal Transduction Modulators
CBR-001-625-122-2,RFM-009-098-2,CBR-001-625-122-2,N#Cc1ncc(c(n1)NCC(C)(C)C)CNC(=O)c1ccc(cc1)N1CCN(CC1)C,CBR-HVAC-14137:Cathepsin K Inhibitors
CBR-001-625-123-3,RFM-009-099-3,CBR-001-625-123-3,NC1=NC(N(C(=N1)N)c1ccc(c(c1)Cl)OCc1cccc(c1)C(=O)N(C)C)(C)C,CBR-HVAC-03013:Dihydrofolate Reductase (DHFR) Inhibitors
CBR-001-625-124-4,RFM-009-100-9,CBR-001-625-124-4,Clc1cccc(n1)SCCN1CCOCC1,CBR-HVAC-07842:Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor
CBR-001-625-125-5,RFM-009-101-0,CBR-001-625-125-5,COc1ccc2c(c1OCc1ccccc1)C[C@@H](N(C2)C(=O)C(c1ccccc1)c1ccccc1)C(=O)O,CBR-HVAC-04545:Angiotensin AT2 Antagonists;Signal Transduction Modulators
CBR-001-625-126-6,RFM-009-102-1,CBR-001-625-126-6,COc1ccc2c(c1OCc1ccccc1)C[C@H](N(C2)C(=O)C(c1ccccc1)c1ccccc1)C(=O)O,CBR-HVAC-04545:Angiotensin AT2 Antagonists;Signal Transduction Modulators
CBR-001-625-127-7,RFM-009-103-2,CBR-001-625-127-7,Brc1ccc(cc1)C(c1ccccc1)Cn1cncc1,CBR-HVAC-07938:Sterol demethylase inhibitor; Cell wall synthesis inhibitor
CBR-001-625-128-8,RFM-009-104-3,CBR-001-625-128-8,Clc1ccc(cc1)OC(C(=O)OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F)(C)C,CBR-HVAC-07887:Dopamine D2 receptor antagonist; Dopamine D1 receptor antagonist
CBR-001-625-129-9,RFM-009-105-4,CBR-001-625-129-9,CC(N(CCOC(c1ccccc1)c1ccccc1)C)COc1ccccc1,"CBR-HVAC-08228:calcium channel, voltage-dependent, L type, alpha 1C subunit"
CBR-001-625-130-2,RFM-009-106-5,CBR-001-625-130-2,N#Cc1ccccc1Cn1c(=O)n(c2c1c(cc(n2)C)N1CCC[C@H](C1)N)C,CBR-HVAC-07152:Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators
CBR-001-625-131-3,RFM-009-107-6,CBR-001-625-131-3,CCCCCCCc1cc(O)c(c(c1)O)C/C=C(/CCC=C(C)C)\C,CBR-HVAC-12265:
CBR-001-625-132-4,RFM-009-108-7,CBR-001-625-132-4,ONC(=O)CCCCCCC(=O)Oc1ccc(cc1)C(=O)OC,CBR-HVAC-07040:Histone Deacetylase (HDAC) Inhibitors
CBR-001-625-133-5,RFM-009-109-8,CBR-001-625-133-5,CCC(=O)O[C@@]1([C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)F)C(=O)S[C@H]1CCOC1=O,CBR-HVAC-04970:Glucocorticoid Receptor (GR) Agonists;Signal Transduction Modulators
CBR-001-625-134-6,RFM-009-110-1,CBR-001-625-134-6,OCC1CN=C(c2c(N1C)ccc(c2)Cl)c1ccccc1Cl,CBR-HVAC-08870:Anxiolytic
CBR-001-625-135-7,RFM-009-111-2,CBR-001-625-135-7,CNC(=O)c1c(oc2c1cc(C1CC1)c(c2)N(S(=O)(=O)C)Cc1ccc(c(c1)F)B(O)O)c1ccc(cc1)F,CBR-HVAC-07248:RNA-Directed RNA Polymerase (NS5B) Inhibitors
CBR-001-625-136-8,RFM-009-112-3,CBR-001-625-136-8,C[C@H](N(CC#C)C)Cc1ccc(cc1)F,CBR-HVAC-08150:Monoamine oxidase B inhibito
CBR-001-625-137-9,RFM-009-113-4,CBR-001-625-137-9,C[C@@H](N(CC#C)C)Cc1ccc(cc1)F,CBR-HVAC-08150:Monoamine oxidase B inhibito
CBR-001-625-138-0,RFM-009-114-5,CBR-001-625-138-0,O=C(Cc1ccc(cc1F)c1cnc2n1ccc(c2)c1ccnc(c1)C)Nc1cccc(c1)C(F)(F)F,CBR-HVAC-07234:Angiogenesis Inhibitors;Ephrin (EPH) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;RET Inhibitors;Signal Transduction Modulators;VEGFR-3 (FLT4) Inhibitors
CBR-001-625-139-1,RFM-009-115-6,CBR-001-625-139-1,Cc1ccc(cc1)Cn1nc(cc1C(=O)N[C@H]1[C@@]2(C)CC[C@@H](C1(C)C)C2)c1ccc(c(c1)C)Cl,CBR-HVAC-14395:regioisomer of CBR-HVAC-12257
CBR-001-625-140-4,RFM-009-116-7,CBR-001-625-140-4,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@H](C(C)(C)C)NC(=O)OC(C)(C)C)OC(=O)N1Cc2c(C1)cccc2F)C(=O)NS(=O)(=O)C1CC1,CBR-HVAC-07228:HCV NS3 NS4A Protease Inhibitors
CBR-001-625-141-5,RFM-009-117-8,CBR-001-625-141-5,CNC(=S)C1(CCCS1)c1cccc(n1)C,CBR-HVAC-08295:Gastrin inhibitor
CBR-001-625-142-6,RFM-009-118-9,CBR-001-625-142-6,CCCCC1=NC2(C(=O)N1Cc1ccc(c(c1)COCC)c1ccccc1S(=O)(=O)Nc1noc(c1C)C)CCCC2,CBR-HVAC-05566:Angiotensin AT1 Antagonists;Endothelin ETA Receptor Antagonists;Signal Transduction Modulators
CBR-001-625-143-7,RFM-009-119-0,CBR-001-625-143-7,COc1cc2c(cc1OC)CCN1[C@@H]2C[C@@H](O)[C@@H](C1)CC(C)C,CBR-HVAC-07155:Signal Transduction Modulators;Vesicular Monoamine Transporter 2 (VMAT2) Ligands
CBR-001-625-144-8,RFM-009-120-3,CBR-001-625-144-8,C[C@@H](CCC[C@]1(C)CCc2c(O1)c(C)c(c(c2C)OC(=O)/C=C(/C=C/C=C(/C=C/C1=C(C)CCCC1(C)C)\C)\C)C)CCC[C@@H](CCCC(C)C)C,"CBR-HVAC-04302:Tissue repair-promoting agent, retinoic acid derivative that acts by stimulating the proliferation of fibroblasts and the migration of peritoneal macrophages, fibroblasts and vascular endothelial cells to the wound site; Protein synthesis inhibitor; Wound healing agent; Wound healing"
CBR-001-625-145-9,RFM-009-121-4,CBR-001-625-145-9,CN(C[C@@H]1CCCC[C@H]1c1cccc(c1)O)C,CBR-HVAC-00561:; Analgesic; Analgesia
CBR-001-625-146-0,RFM-009-122-5,CBR-001-625-146-0,CN(C[C@@H]1CCCC[C@H]1c1cccc(c1)O)C,CBR-HVAC-00561:; Analgesic; Analgesia
CBR-001-625-147-1,RFM-009-123-6,CBR-001-625-147-1,CCCCCCCCCCCCNCC(CCCCCCCCCn1c(=O)c2n(C)cnc2n(c1=O)C)O,CBR-HVAC-04664:Phospholipase D Stimulator; Anticancer; Cancer
CBR-001-625-148-2,RFM-009-124-7,CBR-001-625-148-2,OCC(=O)N1CCC(=CC1)c1ccc(cc1)C1=NO[C@H](C1)CNC(=O)C,CBR-HVAC-11264:Protein 30S ribosomal subunit Inhibitor; Antibacterial; Bacterial infection
CBR-001-625-149-3,RFM-009-125-8,CBR-001-625-149-3,COc1cc(/C=C/C=C/C(=O)NCCN2CCC(CC2)OC(c2ccccc2)c2ccccc2)ccc1O,CBR-HVAC-14394:5-LIPOXYGENASE Inhibitor; Inhibitor; ANTI-INFLAMMATORY; Inflammatory bowel diseases
CBR-001-625-150-6,RFM-009-126-9,CBR-001-625-150-6,OCCNCCn1nc2c3c1ccc(c3c(=O)c1c2cncc1)NCCN(C)C,CBR-HVAC-00458:Topoisomerase II Inhibitor; Anticancer; Gastric carcinoma; Ovarian cancer; Prostate cancer; Solid tumor
CBR-001-625-151-7,RFM-009-127-0,CBR-001-625-151-7,NC(=N)c1ccc(cc1)OCCCC1CCN(CC1)CCCOc1ccc(cc1)C(=N)N,"CBR-HVAC-06119:Fungicide; Fungicide; Infection, fungal"
CBR-001-625-152-8,RFM-009-128-1,CBR-001-625-152-8,OCCNc1cc(ccc(c1=O)CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F)C(C)C,CBR-HVAC-10963:Calcium channel T-type Antagonist; Vasodilator; Cerebrovascular ischemia; Stroke
CBR-001-625-153-9,RFM-009-129-2,CBR-001-625-153-9,CN(CCOC(=O)CO/N=C(/c1ccc(cc1)Cl)\C)C,"CBR-HVAC-01092:; Anti-inflammatory; Antirheumatic; Inflammation; Arthritis, rheumatoid"
CBR-001-625-154-0,RFM-009-130-5,CBR-001-625-154-0,O=C(N[C@@H]1COc2n(C1)cc(n2)[N+](=O)[O-])OCc1ccc(cc1)OC(F)(F)F,CBR-HVAC-00222:Protein synthesis inhibitor; Antimycobacterial; Tuberculosis
CBR-001-625-155-1,RFM-009-131-6,CBR-001-625-155-1,COc1ccc(cc1Cc1cnc2c(c1C)c(N)nc(n2)N)OC,CBR-HVAC-00476:Dihydrofolate reductase Inhibitor; Anticancer; Advanced bladder cancer
CBR-001-625-156-2,RFM-009-132-7,CBR-001-625-156-2,Cc1[nH]c2c(n1)n(CC1CCC=CC1)c(=O)n(c2=O)C,CBR-HVAC-01045:; Bronchodilator; Asthma
CBR-001-625-157-3,RFM-009-133-8,CBR-001-625-157-3,Nc1ccc(cc1)S(=O)(=O)NC(=N)Nc1oc(c(n1)C)C,"CBR-HVAC-01613:; Antibiotic; Infection, bacterial"
CBR-001-625-158-4,RFM-009-134-9,CBR-001-625-158-4,COc1ccc2c(c1)c(CC(=O)O)c(n2C(=O)/C=C/c1ccccc1)C,CBR-HVAC-01839:; Anti-inflammatory; Musculoskeletal and joint disorders
CBR-001-625-159-5,RFM-009-135-0,CBR-001-625-159-5,O=C(C(Oc1ccc(cc1)Cl)(C)C)NC(=O)NCN1CCOCC1,CBR-HVAC-02126:; Antilipemic; Antiaggregant; HYPERLIPOPROTEINEMIA
CBR-001-625-160-8,RFM-009-136-1,CBR-001-625-160-8,O=C(OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2c1cccc2)/C=C/c1ccccc1,CBR-HVAC-02264:Prostaglandin G/H synthase Inhibitor; Anti-inflammatory; Rheumatic disorders
CBR-001-625-161-9,RFM-009-137-2,CBR-001-625-161-9,OC(c1cc(nc2c1cccc2)C(C)(C)C)CCC1CCNCC1,CBR-HVAC-02911:Sodium channel Blocker; Antiarrhythmic; Arrhythmia
CBR-001-625-162-0,RFM-009-138-3,CBR-001-625-162-0,CCOC(=O)[C@@H]1O[C@H]1C(=O)N[C@H](C(=O)N1CCN(CC1)Cc1ccc(c(c1OC)OC)OC)CC(C)C,CBR-HVAC-02978:Cathepsin B Inhibitor; Anticancer; Antiischemic; Antiarrhythmic; Arrhythmia; Cancer; Ischemic heart diseases
CBR-001-625-163-1,RFM-009-139-4,CBR-001-625-163-1,Clc1ccc(cc1)CN1CCN(CC1)CCCOc1ccc2c(c1)oc(=O)c(c2C)C,CBR-HVAC-03075:Histamine H1 receptor Antagonist; Antiallergic; Allergic rhinitis; Allergic conjunctivitis; Asthma
CBR-001-625-164-2,RFM-009-140-7,CBR-001-625-164-2,CS(=O)c1ccc(cc1)c1nc2n(c1c1ccncc1)CCC2,CBR-HVAC-03852:5-LIPOXYGENASE; CYCLOOXYGENASE Inhibitor; Inhibitor; ANTI-INFLAMMATORYANALGESICANTI-ULCER; Endotoxic shock
CBR-001-625-165-3,RFM-009-141-8,CBR-001-625-165-3,CCc1cc(CCc2nc3c(o2)cccc3)c(=O)[nH]c1C,CBR-HVAC-04255:Reverse transcriptase Inhibitor; Anti-HIV; Viral infection
CBR-001-625-166-4,RFM-009-142-9,CBR-001-625-166-4,O=C1CCCN1[C@@H]1c2cc(ccc2OC([C@H]1O)(C)C)S(=O)(=O)c1ccccc1,CBR-HVAC-04266:Potassium channel Opener; Bronchodilator; Antiasthmatic; Antihypertensive; Asthma
CBR-001-625-167-5,RFM-009-143-0,CBR-001-625-167-5,CCCN(n1cc(c2c1cccc2)C)c1ccncc1F,CBR-HVAC-04365:Potassium channel; Sodium channel Blocker; Neuroprotectant; Nootropic; Alzheimer's disease; Neurodegenerative diseases disorders; Cognition disorder; Spinal cord injury
CBR-001-625-168-6,RFM-009-144-1,CBR-001-625-168-6,CSC[C@H]1C(=S)Nc2c(N1C(=O)OC(C)C)cc(cc2)OC,CBR-HVAC-04631:Reverse transcriptase Inhibitor; Antiviral; Viral infection
CBR-001-625-169-7,RFM-009-145-2,CBR-001-625-169-7,COc1ccc(cc1)C1=C(C(=O)O)[C@H](Oc2c1cc(cc2)OC(C)C)c1ccc2c(c1)OCO2,CBR-HVAC-05092:ENDOTHELIN A RECEPTOR Antagonist; Antihypertensive; Hypertension
CBR-001-625-170-0,RFM-009-146-3,CBR-001-625-170-0,COc1ccc(cc1)C1=C(C(=O)O)[C@H](Oc2c1cc(cc2)OC(C)C)c1ccc2c(c1)OCO2,CBR-HVAC-05092:ENDOTHELIN A RECEPTOR Antagonist; Antihypertensive; Hypertension
CBR-001-625-171-1,RFM-009-147-4,CBR-001-625-171-1,FC([C@@]1(C#CC2CC2)NC(=O)Nc2c1cc(Cl)cc2)(F)F,CBR-HVAC-05095:Non-nucleoside reverse transcriptase Inhibitor; Antiviral; Viral infection
CBR-001-625-172-2,RFM-009-148-5,CBR-001-625-172-2,CCCCN(Cc1ccc(c(c1)c1ccccc1C)C(=O)N[C@H](C(=O)O)CCSC)CCC1CCCCC1,CBR-HVAC-05329:Protein farnesyltransferase Inhibitor; Anticancer; Cancer
CBR-001-625-173-3,RFM-009-149-6,CBR-001-625-173-3,CCOC(=O)COc1cc(C)c(cc1C)CCN[C@H]([C@@H](c1ccc(cc1)O)O)C,CBR-HVAC-06290:Beta-3 adrenergic receptor Agonist; Beta-3 adrenergic receptor agonist; Urinary incontinence; Pollakiuria
CBR-001-625-174-4,RFM-009-150-9,CBR-001-625-174-4,O=C(Nc1ccc(cc1Cl)S(=O)(=O)N)CSc1nnc(n1c1ccc(c2c1cccc2)C1CC1)Br,"CBR-HVAC-06543:NON-NUCLEOSIDE REVERSE TRANSCRIPTASE Antagonist; Antiviral; Infections, HIV"
CBR-001-625-175-5,RFM-009-151-0,CBR-001-625-175-5,CCN1CCC(CC1)c1cc(F)cc(c1)S(=O)(=O)C,CBR-HVAC-06598:DOPAMINE; Voltage-gated potassium channel Kv7 Activator; Antiparkinsonian; Parkinson's disease
CBR-001-625-176-6,RFM-009-152-1,CBR-001-625-176-6,COc1ccc(cc1)c1nc2c(n1C(C)C)ccc1c2cccc1,CBR-HVAC-08455:COX-2 Inhibitor; Antiinflammatory; Analgesic; Inflammation
CBR-001-625-177-7,RFM-009-153-2,CBR-001-625-177-7,O[As](=O)(c1ccc(cc1)NCCNc1ccc(cc1)[As](=O)(O)O)O,"CBR-HVAC-08784:Pest-destroying action probably which had with an inactivation of the groupings thiols of the enzymes of the parasite.Action amoebicide known as of contact in the intestinal amoebiasis. Drug of the cure of maintenance of the amoebiasis, credit on the forms minuta of Entamoeba Dysenteriae and on its cysts.; Antihelmintic; Trichuris trichiura; Amoebiasis"
CBR-001-625-178-8,RFM-009-154-3,CBR-001-625-178-8,Cc1ccc(cc1)S(=O)(=O)NC(=O)N1N=CCC1C,CBR-HVAC-08799:; Antidiabetic; Diabetes mellitus
CBR-001-625-179-9,RFM-009-155-4,CBR-001-625-179-9,OCC(CN1C(=O)CN=C(c2c1ccc(c2)Cl)c1ccccc1F)O,CBR-HVAC-08874:; Anxiolytic; Anxiety
CBR-001-625-180-2,RFM-009-156-5,CBR-001-625-180-2,Brc1cc2c(s1)n1c(CN=C2c2ccccc2Cl)nnc1C1CCCCC1,CBR-HVAC-08895:; Anxiolytic; Anxiety
CBR-001-625-181-3,RFM-009-157-6,CBR-001-625-181-3,CCC(C(=O)O)(CC(=O)Nc1cccc(c1)OCc1ccc2c(n1)cc(cc2)F)CC,CBR-HVAC-09179:Leukotriene D4 receptor Antagonist; Antiasthmatic; Anti-inflammatory; Inflammatory disease; Asthma
CBR-001-625-182-4,RFM-009-158-7,CBR-001-625-182-4,Clc1ccc(cc1)c1ccc(cc1COc1ccc(c(c1)F)c1nc2c(n1C1CCCCC1)ccc(c2)C(=O)O)N1CCCC1=O,CBR-HVAC-09303:NS5B protease Inhibitor; Antiviral; HEPATITIS C
CBR-001-625-183-5,RFM-009-159-8,CBR-001-625-183-5,O=C(/C=C/c1ccc(cc1)[N+](=O)[O-])NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,"CBR-HVAC-09323:Bacterial protein synthesis inhibitor; Antibacterial; INFECTION, BACTERIAL"
CBR-001-625-184-6,RFM-009-160-1,CBR-001-625-184-6,OC(=O)c1ccc(cc1)C#Cc1ccc2c(c1)C(C)(C)CC(O2)(C)C,CBR-HVAC-09347:Retinoid acid receptor; Retinoid X receptor Agonist; Anticancer; Hypoglycemic agent; NON-SMALL-CELL LUNG CANCER; CANCER; METABOLIC DISORDER; DIABETES MELLITUS; NEOPLASM
CBR-001-625-185-7,RFM-009-161-2,CBR-001-625-185-7,CCOC(=O)c1c(ccc(c1OC)OC)C(=O)Cc1c(CCN(C)C)cc2c(c1OC)OCO2,CBR-HVAC-09946:Invertase Inhibitor; Analgesic; Narcotic; Antitussive; Alkaloid; Cough; Pain
CBR-001-625-186-8,RFM-009-162-3,CBR-001-625-186-8,CCOCCN(C(=O)C(Cl)Cl)Cc1ccc(cc1)CN(C(=O)C(Cl)Cl)CCOCC,"CBR-HVAC-10196:; Antiamebic; Amebiasis, intestinal"
CBR-001-625-187-9,RFM-009-163-4,CBR-001-625-187-9,Cn1c(=O)n(C)c2c(c1=O)n(CCOS(=O)(=O)O)cn2,CBR-HVAC-10302:; ; Respiratory disorder; Vascular disorder
CBR-001-625-188-0,RFM-009-164-5,CBR-001-625-188-0,ON=C1CCN(CC1)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-10562:DNA gyrase Inhibitor; Antibacterial; Bacterial infection
CBR-001-625-189-1,RFM-009-165-6,CBR-001-625-189-1,CN(Cc1cccc2c1cc(F)cc2F)C/C=C/C#CC(C)(C)C,CBR-HVAC-10704:Squalene epoxidase Inhibitor; Antihyperlipidemic; Antifungal; Hyperlipidemia; Coronary artery disease
CBR-001-625-190-4,RFM-009-166-7,CBR-001-625-190-4,NC1CN(C[C@H]1C)c1cc2n(cc(c(=O)c2cc1F)C(=O)O)c1ccon1,CBR-HVAC-10728:DNA gyrase Inhibitor; Antibacterial; Gram-negative bacterial infection; Gram-positive bacterial infection; Pseudomonas aeruginosa infection; Streptococcus infection; Streptococcus pneumoniae infection
CBR-001-625-191-5,RFM-009-167-8,CBR-001-625-191-5,CCCNCC(c1oc2c(c1CCc1ccccc1)cccc2)O,CBR-HVAC-10808:Sodium channel Blocker; Antiarrhythmic; Arrhythmia
CBR-001-625-192-6,RFM-009-168-9,CBR-001-625-192-6,CCCCCCCC[C@@H](C(=O)Nc1c(SC)cc(nc1SC)C)SCCCCCC,CBR-HVAC-10854:Acyl CoA:cholesterol acyltransferase Inhibitor; Antiarteriosclerotic; Antihypercholesterolemic; Alzheimer's disease; Hypercholesterolemia; Atherosclerosis; Hyperlipidemia
CBR-001-625-193-7,RFM-009-169-0,CBR-001-625-193-7,CCCCCCCC[C@@H](C(=O)Nc1c(SC)cc(nc1SC)C)SCCCCCC,CBR-HVAC-10854:Acyl CoA:cholesterol acyltransferase Inhibitor; Antiarteriosclerotic; Antihypercholesterolemic; Alzheimer's disease; Hypercholesterolemia; Atherosclerosis; Hyperlipidemia
CBR-001-625-194-8,RFM-009-170-3,CBR-001-625-194-8,COc1ccccc1c1csc(n1)Cc1nc[nH]c1C,CBR-HVAC-10900:5-Hydroxytryptamine 3 receptor Antagonist; Anti-emetic; Chemotherapy-induced emesis
CBR-001-625-195-9,RFM-009-171-4,CBR-001-625-195-9,O=C(C(c1ccccc1)(C1CCC1)O)CN1CCN(CC1)Cc1ccccc1,CBR-HVAC-10945:Muscarinic acetylcholine receptor M3 Antagonist; Antiasthmatic; Asthma
CBR-001-625-196-0,RFM-009-172-5,CBR-001-625-196-0,CCCCOC(=O)[C@H](CN(C(=O)N[C@H](C(=O)O)Cc1ccc2c(c1)cccc2)CC(C)C)O,CBR-HVAC-11083:Membrane metalloendopeptidase; Angiotensin converting enzyme Inhibitor; Antihypertensive; Diuretic; Heart failure; Hypertension
CBR-001-625-197-1,RFM-009-173-6,CBR-001-625-197-1,O=C(C1=CC(NC1(C)C)(C)C)NCCCN1C(=O)c2c(C1=O)cccc2,CBR-HVAC-11413:Sodium channel Blocker; Antiarrhythmic; Arrhythmia
CBR-001-625-198-2,RFM-009-174-7,CBR-001-625-198-2,Fc1ccc(cc1)C(=O)NCCC1CN=C(c2c(N1C)cccc2)c1ccccc1,CBR-HVAC-11595:Opioid receptor kappa Agonist; Anti-cognitive; Alzheimer's disease; Cognition disorder
CBR-001-625-199-3,RFM-009-175-8,CBR-001-625-199-3,CCN(CCOc1ccc(cc1)/C(=C(/c1ccc(cc1)Cl)\CC)/C#N)CC,CBR-HVAC-11655:Squalene synthase Inhibitor; Antihypercholesterolemic; Hypercholesterolemia
CBR-001-625-200-9,RFM-009-176-9,CBR-001-625-200-9,CCc1nc(C)cc(=O)n1CCOc1ccc(cc1)CC1SC(=O)NC1=O,CBR-HVAC-11957:Insulin receptor; PPAR gamma Modulator; Anti-inflammatory; Hypoglycemic; NON-INSULIN DEPENDENT DIABETES MELLITUS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; ASTHMA
CBR-001-625-201-0,RFM-009-177-0,CBR-001-625-201-0,Brc1ccc(cc1)c1c(Cn2ncnc2)c(nn1c1ccccc1Cl)c1nnc(s1)C(C)(C)C,CBR-HVAC-12239:Cannabinoid-1 receptor Antagonist; NUTRITIONAL SUPPLEMENT; NUTRITIONAL DISEASES
CBR-001-625-202-1,RFM-009-178-1,CBR-001-625-202-1,O=C([C@H](c1ccc2c(c1)ccc(c2)OCc1ccc2c(n1)cccc2)C)N(O)C,CBR-HVAC-12320:Leukotriene D4; Cyclooxygenase Antagonist; Inhibitor; Anti-inflammatory; INFLAMMATION
CBR-001-625-203-2,RFM-009-179-2,CBR-001-625-203-2,Nc1nc(=O)n(cc1F)[C@H]1CC[C@H](O1)CO,CBR-HVAC-12330:Reverse transcriptase Inhibitor; Anti-HIV; HIV infection
CBR-001-625-204-3,RFM-009-180-5,CBR-001-625-204-3,Cc1cc(ccc1OCCOCC[N+](Cc1ccccc1)(C)C)C(CC(C)(C)C)(C)C,CBR-HVAC-09259:; Antiseptic; Sepsis
CBR-001-625-205-4,RFM-009-181-6,CBR-001-625-205-4,NC(=O)Cn1c(=O)cc(c2c1cc(F)cc2)CCN1CCN(CC1)c1nccc2c1ccs2,CBR-HVAC-05342:5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 2A receptor Antagonist; Vasodilator; Cardiovascular diseases; Thrombosis
CBR-001-625-206-5,RFM-009-182-7,CBR-001-625-206-5,COCC12CN(CC(=O)N2CC2(O1)CCN(CC2)c1ccncc1)S(=O)(=O)c1ccc2c(c1)ccc(c2)Cl,CBR-HVAC-11963:Factor Xa Antagonist; Antithrombotic agent; THROMBOSIS
CBR-001-625-207-6,RFM-009-183-8,CBR-001-625-207-6,ClCC[N+](c1ccc(cc1)CC(=O)O)(CCCl)[O-],CBR-HVAC-04634:Antineoplastic; Alkylating agent; Anticancer; Antineoplastic; Anticancer; Cancer
CBR-001-625-208-7,RFM-009-184-9,CBR-001-625-208-7,CC(C[C@@H](C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)OC(=O)N1CCC(CC1)C(=O)N)NC(=O)COc1ccccc1C)C,"CBR-HVAC-08583:Integrin alpha4 Antagonist; Anti-inflammatory; Asthma; Rhinitis, allergic"
CBR-001-625-209-8,RFM-009-185-0,CBR-001-625-209-8,CN1C2C[C@H](C[C@@H]1C1C2O1)OC(=O)c1c[nH]c2c1cccc2,CBR-HVAC-10941:5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Emesis
CBR-001-625-210-1,RFM-009-186-1,CBR-001-625-210-1,CN1C2C[C@H](C[C@@H]1C1C2O1)OC(=O)c1c[nH]c2c1cccc2,CBR-HVAC-10941:5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Emesis
CBR-001-625-211-2,RFM-009-187-2,CBR-001-625-211-2,CCOC(=O)C1(CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)C(N)(C)C)Cc1cscn1,CBR-HVAC-11210:Growth hormone release stimulator; Growth hormone releasing hormone stimulator; Somatotropin deficiency; Growth hormone secretion disorders
CBR-001-625-212-3,RFM-009-188-3,CBR-001-625-212-3,CCOC(=O)C1(CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)C(N)(C)C)Cc1cscn1,CBR-HVAC-11210:Growth hormone release stimulator; Growth hormone releasing hormone stimulator; Somatotropin deficiency; Growth hormone secretion disorders
CBR-001-625-213-4,RFM-009-189-4,CBR-001-625-213-4,Clc1cc(ccc1C(=O)N1C[C@@H]2COCCN2Cc2c1cccc2)NC(=O)c1ccccc1c1ccccc1,CBR-HVAC-00461:Arginine vasopressin receptor 1A; Arginine vasopressin receptor 2 Antagonist; Antihypertensive; Diuretic; Edema; Cardiac failure; Hypertension; Hyponatremia; Renal disease
CBR-001-625-214-5,RFM-009-190-7,CBR-001-625-214-5,CN1CCCCC1C(OC(=O)c1c[nH]c2c1cccc2)C,CBR-HVAC-10684:5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Cancer chemotherapy
CBR-001-625-215-6,RFM-009-191-8,CBR-001-625-215-6,CN1CCCCC1C(OC(=O)c1c[nH]c2c1cccc2)C,CBR-HVAC-10684:5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Cancer chemotherapy
CBR-001-625-216-7,RFM-009-192-9,CBR-001-625-216-7,CN1CCCCC1C(OC(=O)c1c[nH]c2c1cccc2)C,CBR-HVAC-10684:5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Cancer chemotherapy
CBR-001-625-217-8,RFM-009-193-0,CBR-001-625-217-8,CN1CCCCC1C(OC(=O)c1c[nH]c2c1cccc2)C,CBR-HVAC-10684:5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Cancer chemotherapy
CBR-001-625-218-9,RFM-009-194-1,CBR-001-625-218-9,O=C1CCCN1[C@H]1c2cc(ccc2OC([C@@H]1O)(C)C)S(=O)(=O)c1ccccc1,CBR-HVAC-04266:Potassium channel Opener; Bronchodilator; Antiasthmatic; Antihypertensive; Asthma
CBR-001-625-219-0,RFM-009-195-2,CBR-001-625-219-0,FC([C@]1(C#CC2CC2)NC(=O)Nc2c1cc(Cl)cc2)(F)F,CBR-HVAC-05095:Non-nucleoside reverse transcriptase Inhibitor; Antiviral; Viral infection
CBR-001-625-220-3,RFM-009-196-3,CBR-001-625-220-3,CCCN(C(Cc1ccc(cc1)S(=O)(=O)C)C)CCCCN1CCNCCC1=O,CBR-HVAC-05725:Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2 Antagonist; Muscarinic acetylcholine receptor M2 antagonist; Muscarinic acetylcholine receptor M3 antagonist; Overactive bladder
CBR-001-625-221-4,RFM-009-197-4,CBR-001-625-221-4,CCCN(C(Cc1ccc(cc1)S(=O)(=O)C)C)CCCCN1CCNCCC1=O,CBR-HVAC-05725:Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2 Antagonist; Muscarinic acetylcholine receptor M2 antagonist; Muscarinic acetylcholine receptor M3 antagonist; Overactive bladder
CBR-001-625-222-5,RFM-009-198-5,CBR-001-625-222-5,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCCNC[C@H](COc1ccccc1)O)C,CBR-HVAC-04025:Beta adrenergic receptor Antagonist; Antihypertensive; Antiangina; Angina; Hypertension
CBR-001-625-223-6,RFM-009-199-6,CBR-001-625-223-6,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCCCNC[C@H](COc1ccccc1)O)C,CBR-HVAC-04025:Beta adrenergic receptor Antagonist; Antihypertensive; Antiangina; Angina; Hypertension
CBR-001-625-224-7,RFM-009-200-2,CBR-001-625-224-7,CC(CC(=O)O)COc1ccc(cc1)N1CCN(CC1)c1ccncc1,CBR-HVAC-04792:Integrin alpha2b beta3 Antagonist; Glycoprotein IIb/IIIa receptor antagonist; Platelet aggregation inhibitor; Unstable angina pectoris; Thrombosis
CBR-001-625-225-8,RFM-009-201-3,CBR-001-625-225-8,CC(CC(=O)O)COc1ccc(cc1)N1CCN(CC1)c1ccncc1,CBR-HVAC-04792:Integrin alpha2b beta3 Antagonist; Glycoprotein IIb/IIIa receptor antagonist; Platelet aggregation inhibitor; Unstable angina pectoris; Thrombosis
CBR-001-625-226-9,RFM-009-202-4,CBR-001-625-226-9,OCC(=O)N1CCC(=CC1)c1ccc(cc1)C1=NO[C@@H](C1)CNC(=O)C,CBR-HVAC-11264:Protein 30S ribosomal subunit Inhibitor; Antibacterial; Bacterial infection
CBR-001-625-227-0,RFM-009-203-5,CBR-001-625-227-0,Cc1ccc(cc1)Cn1nc(cc1c1ccc(c(c1)C)Cl)C(=O)N[C@H]1[C@@]2(C)CC[C@@H](C1(C)C)C2,CBR-HVAC-12257:Cannabinoid receptor 2 Antagonist; Cannabinoid receptor 2 antagonist; Analgesic; Obesity; Pain
CBR-001-625-228-1,RFM-009-204-6,CBR-001-625-228-1,CCCCN(Cc1ccc(c(c1)c1ccccc1C)C(=O)N[C@@H](C(=O)O)CCSC)CCC1CCCCC1,CBR-HVAC-05329:Protein farnesyltransferase Inhibitor; Anticancer; Cancer
CBR-001-625-229-2,RFM-009-205-7,CBR-001-625-229-2,COc1ccc2c(c1)nc(cc2O[C@H]1C[C@H](N(C1)C(=O)[C@H](C(C)(C)C)CC(=O)N1CCCCC1)C(=O)N[C@@]1(C[C@H]1C=C)C(=O)NS(=O)(=O)C1CC1)c1ccccc1,CBR-HVAC-00275:NS3 protease Inhibitor; Antiviral; Hepatitis C
CBR-001-625-230-5,RFM-009-206-8,CBR-001-625-230-5,CCCCCCCCCCO[C@H](COP(=O)(OC[C@H]1O[C@H](C[C@@H]1F)n1cc(C)c(=O)[nH]c1=O)O)CSCCCCCCCCCCCC,CBR-HVAC-00447:Nucleoside reverse transcriptase Inhibitor; Anti-HIV; HIV infection
CBR-001-625-231-6,RFM-009-207-9,CBR-001-625-231-6,COC(=O)c1c(Cl)cccc1c1ccc(c(c1)F)[C@H](NC(=O)C1(CC1)NC(=O)C(F)(F)F)C,CBR-HVAC-00471:Analgesic; Bone metabolism modulator; Analgesic; Pain; Osteoarthritis
CBR-001-625-232-7,RFM-009-208-0,CBR-001-625-232-7,O[C@@H]1[C@@H](CO[P@@]2(=O)OCC[C@H](O2)c2ccncc2)O[C@H]([C@H]1O)n1ccc(nc1=O)N,CBR-HVAC-00651:DNA polymerase Inhibitor; Antineoplastic; Anticancer; Primary liver cancer; Hepatocellular carcinoma
CBR-001-625-233-8,RFM-009-209-1,CBR-001-625-233-8,CCCCCOc1ccccc1/C(=C\SC)/n1cncc1,"CBR-HVAC-01721:; Antifungal; Infection, fungal"
CBR-001-625-234-9,RFM-009-210-4,CBR-001-625-234-9,O=C(C(c1ccc2c(c1)Cc1c(O2)nc(cc1)C)C)OCC(=O)N(C)C,CBR-HVAC-03794:COX-1 Inhibitor; Analgesic; Anti-inflammatory; Pain; Rheumatoid arthritis; Inflammation
CBR-001-625-235-0,RFM-009-211-5,CBR-001-625-235-0,NCCCC[C@@H](C(=O)NC[C@@H](C(=O)O)CC1(CCCC1)C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)O)NS(=O)(=O)C,CBR-HVAC-04023:Angiotensin I converting enzyme; Matrix metalloproteinase 1 Inhibitor; Antihypertensive; Congestive heart failure; Hypertension
CBR-001-625-236-1,RFM-009-212-6,CBR-001-625-236-1,OC[C@H]1O[C@H]([C@@H]([C@@H]1OC(=O)C)OC(=O)C)n1c(=O)sc2c1nc(N)nc2,CBR-HVAC-06345:Toll-like receptor 7 Agonist; Immunostimulant; Antiviral; Hepatitis B virus infection; HCV infection
CBR-001-625-237-2,RFM-009-213-7,CBR-001-625-237-2,CCC[C@@H]1O[C@H]2C(O1)(C(=O)CO)C1([C@@H](C2)[C@@H]2C[C@H](F)C3=CC(=O)CCC3([C@]2([C@H](C1)O)F)C)C,"CBR-HVAC-08288: Arachidonic-acid-inhibitors; Corticosteroid agonist; Steroid hormone receptor Agonist; Anti-inflammatory; Antiallergic; Antiasthmatic; Inflammatory Bowel Disease, Agents for; Inflammatory Bowel Disorders; Obstructive Airways Disease"
CBR-001-625-238-3,RFM-009-214-8,CBR-001-625-238-3,OC(=O)[C@@H](c1ccc2c(c1)ccc(c2)OCc1ccc2c(n1)cccc2)C,CBR-HVAC-04024:Lipoxygenase 5 Inhibitor; Anti-inflammatory; Immunosuppressant; Arthritis; Asthma; Psoriasis
CBR-001-625-239-4,RFM-009-215-9,CBR-001-625-239-4,COc1cc(NC(CCCN/C(=C\2/CCOC2=O)/C)C)c2c(c1)cccn2,CBR-HVAC-03978:Antimalarial; Antimalarial; Malaria
CBR-001-625-240-7,RFM-009-216-0,CBR-001-625-240-7,O=C(N(C)C)COC1C2=C([CH2]=[CH2][CH2]=[CH2]2)CCC2=C1[CH2]=[CH2][CH2]=[CH2]2,CBR-HVAC-08923:; Antidepressant; Depression
CBR-001-625-241-8,RFM-009-217-1,CBR-001-625-241-8,O=C1CN2C(=Nc3c(C2)cc(cc3)/C(=N/OCC(=O)N(C2CCCCC2)C)/c2ccccc2)N1,CBR-HVAC-04130:Phosphodiesterase 3 Inhibitor; Inotropic; Cardiotonic; Cardiac failure; Ischemic heart diseases
CBR-001-625-242-9,RFM-009-218-2,CBR-001-625-242-9,O[C@@H]1CC[C@]2([C@@H](C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)C)C)C,CBR-HVAC-13675:GABA-A receptor Antagonist; Antidepressant; Anxiety; Premenstrual syndrome
CBR-001-625-243-0,RFM-009-219-3,CBR-001-625-243-0,O=C1CN2C(=Nc3c(C2)cc(cc3)/C(=N\OCC(=O)N(C2CCCCC2)C)/c2ccccc2)N1,CBR-HVAC-04130:Phosphodiesterase 3 Inhibitor; Inotropic; Cardiotonic; Cardiac failure; Ischemic heart diseases
CBR-001-625-250-9,RFM-009-220-6,CBR-001-625-250-9,CNC1=[O][Gd-3]234567[N+](C1)(CC[N+]6(CC[N+]7(CC(=O)O4)CC(=[O]5)NC)CC(=O)O2)CC(=O)O3,CBR-HVAC-07858:
CBR-001-625-251-0,RFM-009-221-7,CBR-001-625-251-0,O/N=C(/c1nonc1NCCNS(=O)(=O)N)\Nc1ccc(c(c1)Br)F,"CBR-HVAC-06991: Indoleamine 2,3-dioxygenase Inhibitors"
CBR-001-625-252-1,RFM-009-222-8,CBR-001-625-252-1,C[C@@H]1COCCN1c1cc(nc(n1)c1ccnc2c1cc[nH]2)C1(CC1)[S@@](=O)(=N)C,CBR-HVAC-07292: ATR Kinase Inhibitors;Signal Transduction Modulators
CBR-001-625-253-2,RFM-009-223-9,CBR-001-625-253-2,OCCN[C@H]1CCc2c1cccc2c1noc(n1)c1ccc(c(c1)C#N)OC(C)C,CBR-HVAC-07135: Lysophospholipid edg1 (S1P1) Receptor Agonists;Lysophospholipid edg8 (S1P5) Receptor Agonists;Signal Transduction Modulators
CBR-001-625-254-3,RFM-009-224-0,CBR-001-625-254-3,ONC(=O)c1cnc(nc1)N(Cc1cc2c(s1)c(nc(n2)c1ccc(nc1)OC)N1CCOCC1)C,CBR-HVAC-07695: Histone deacetylase inhibitor; PI3 kinase inhibitor
CBR-001-625-255-4,RFM-009-225-1,CBR-001-625-255-4,CCCC[C@@]1(CC)N[C@H](c2ccccc2)c2c(S(=O)(=O)C1)cc(c(c2)OC)CNC(CC(=O)O)CC(=O)O,CBR-HVAC-07174: Ileal Bile Acid Transporter (IBAT) Inhibitors
CBR-001-625-256-5,RFM-009-226-2,CBR-001-625-256-5,OC(=O)C[C@@]1(C)C[C@H](c2cccc(c2)Cl)[C@H](N(C1=O)[C@@H](C(C)C)CS(=O)(=O)C(C)C)c1ccc(cc1)Cl,CBR-HVAC-07273: MDM2 (hdm2) Inhibitors
CBR-001-625-257-6,RFM-009-227-3,CBR-001-625-257-6,OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C1=O)C1CCCCC1,CBR-HVAC-06813: Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors
CBR-001-625-258-7,RFM-009-228-4,CBR-001-625-258-7,C#CCN(CCCOc1ccc(cc1Cl)Cl)C,CBR-HVAC-09774: MAO-A Inhibitors
CBR-001-625-259-8,RFM-009-229-5,CBR-001-625-259-8,Oc1cc(O)c2c(c1)O[C@@H]([C@@H](C2)OC(=O)c1cc(O)c(c(c1)O)O)c1ccc(c(c1)O)O,CBR-HVAC-12664: Antioxidants;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;beta-Secretase (BACE) Inhibitors;DNA Gyrase Inhibitors;Fatty Acid Synthase (FAS) Inhibitors;HCV NS3 Protease Inhibitors;SGLT-1 Inhibitors
CBR-001-625-260-1,RFM-009-230-8,CBR-001-625-260-1,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N)CCSC)CC(C)C)[C@H](CC)C)Cc1ccccc1)C)CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCC(=O)N1)CO,CBR-HVAC-07777: Leucotriene receptor agonist
CBR-001-625-261-2,RFM-009-231-9,CBR-001-625-261-2,COc1cc(ccc1Nc1ncc(c(n1)Nc1ccccc1P(=O)(C)C)Cl)N1CCC(CC1)N1CCN(CC1)C,CBR-HVAC-06897: ALK Inhibitors;EGFR (HER1; erbB1) Inhibitors;IGF-1R Inhibitors;ROS1 (MCF3) Inhibitors;Signal Transduction Modulators
CBR-001-625-262-3,RFM-009-232-0,CBR-001-625-262-3,OC[C@H]1O[C@@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)C[C@@H]2C(=O)N[C@H](C(=O)N[C@H]4C(=O)N[C@H]4C(=O)N[C@@H]([C@@H](c5ccc(O3)c(Cl)c5)O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3NC(=O)C)O)O)C(=O)N[C@H](c3c(c5cc4ccc5O)c(cc(c3)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@@H]3O)O)O)C(=O)O)c3cc(O)cc(c3)Oc3cc([C@H](C(=O)N2)N)ccc3O)[C@@H]([C@H]([C@@H]1O)O)NC(=O)CCCCCCCC(C)C,"CBR-HVAC-09869: Glycopeptide antibiotic active against Gram-positive bacteria. It is a glycopeptide antiobiotic extracted from Actinoplanes teichomyceticus, with a similar spectrum of activity to vancomycin."
CBR-001-625-263-4,RFM-009-233-1,CBR-001-625-263-4,CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)Cc1nc[nH]c1)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCCNC(=N)N)Cc1ccc(cc1)O)C,CBR-HVAC-05961: Angiotensin Receptor Agonists;Signal Transduction Modulators
CBR-001-625-264-5,RFM-009-234-2,CBR-001-625-264-5,NCCCC[C@@H](C(=O)NCC(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(cc2)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)CCC(=O)N)Cc1ccccc1,CBR-HVAC-01320: Signal Transduction Modulators;Vasopressin (AVP) V1 Receptor Ligands
CBR-001-625-265-6,RFM-009-235-3,CBR-001-625-265-6,CNCCOc1ccc(cc1)/C(=C(\c1ccccc1)/CC)/c1ccc(cc1)O,CBR-HVAC-00592: Drugs Acting on Estrogen Receptors (ER) ;Protein Kinase C (PKC) Inhibitors;Signal Transduction Modulators
CBR-001-625-266-7,RFM-009-236-4,CBR-001-625-266-7,OC[C@H]1O[C@@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]([C@@H](c4ccc(O3)c(Cl)c4)O)NC(=O)[C@@H](CC(C)C)N)c3ccc(c(c3)c3c(O)cc(cc3[C@H](NC2=O)C(=O)O)O)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@@H](C)[C@H]([C@@](C1)(C)N)O,CBR-HVAC-13038: Antibiotics
CBR-001-625-267-8,RFM-009-237-5,CBR-001-625-267-8,CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](C(C)(C)C)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)CO)CC(C)C)CCCNC(=N)N,CBR-HVAC-12860: GnRH (LHRH) Agonists;Signal Transduction Modulators
CBR-001-625-268-9,RFM-009-238-6,CBR-001-625-268-9,OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCNC(=N)N)CC(C)C)Cc1ccc2c(c1)cccc2)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1nc[nH]c1,CBR-HVAC-08072: Luteinizing hormone releasing hormone (LHRH) agonist
CBR-001-625-269-0,RFM-009-239-7,CBR-001-625-269-0,Oc1ccc(c(c1)c1cc(C)c2c(c1)nnc(n2)Nc1ccc(cc1)OCCN1CCCC1)Cl,CBR-HVAC-06300: SRC kinase; VEGFR2 Inhibitor; Anticancer; CANCER
CBR-001-625-270-3,RFM-009-240-0,CBR-001-625-270-3,O=C1N[C@@H](C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C(=O)C([C@H](C1)O)(C)C)C)O)C)/C(=C/c1csc(n1)C)/C,"CBR-HVAC-05407: Ixabepilone binds directly to -tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of a-II and a-II microtubules. Ixabepilone possesses low in vitro susceptibility to multiple tumor resistance mechanisms including effux transporters, such as MRP-l and P-glycoprotein (P-gp). Ixabepilone blocks cells in the mitotic phase of the cell division cycle, leading to cell death.; Antineoplastic; Anticancer; Cancer, breast"
CBR-001-625-271-4,RFM-009-241-1,CBR-001-625-271-4,N#C/C(=C(\Sc1ccccc1N)/N)/C(=C(/Sc1ccccc1N)\N)/C#N,CBR-HVAC-11089: Mitogen-activated protein 2 kinase 2; Mitogen-activated protein 2 kinase 1 Inhibitor; Anticancer; Antiarteriosclerotic; Anti-inflammatory; Cancer; Immune disorders; Inflammation; Psoriasis; Atherosclerosis; Rheumatoid arthritis; Asthma
CBR-001-625-272-5,RFM-009-242-2,CBR-001-625-272-5,N#Cc1cc2cnc(nc2n(c1=O)C1CCCC1)Nc1ccc(cc1)N1CCN(CC1)C,CBR-HVAC-13662: KINASE Inhibitor; ANTI-TUMOR; Tumor
CBR-001-625-273-6,RFM-009-243-3,CBR-001-625-273-6,O=C(Nc1ccccc1F)N[C@H]1N=C(c2ccccc2)c2c(NC1=O)cccc2,CBR-HVAC-00483: Viral replication inhibitor; Antiviral; Respiratory syncytial virus infection
CBR-001-625-274-7,RFM-009-244-4,CBR-001-625-274-7,COc1ccccc1N1CCN(CC1)CCN(C(=O)C1CCCCC1)c1ccccn1,CBR-HVAC-04366: 5-Hydroxytryptamine 1A receptor Antagonist; Antidepressant; Anxiety; Cognition disorder; Diabetes mellitus Eating disorder; Depression
CBR-001-625-275-8,RFM-009-245-5,CBR-001-625-275-8,Fc1ccc(cc1)c1nc([nH]c1c1ccc2c(n1)n(CC(C)(C)C)c(n2)N)C(C)(C)C,CBR-HVAC-00682: p38 Mitogen-activated protein kinase INHIBITOR; ANTINEOPLASTIC; ANTICANCER; CANCER
CBR-001-625-276-9,RFM-009-246-6,CBR-001-625-276-9,OC(=O)/C=C/c1ccc(cc1)c1ccc(c(c1)C12CC3CC(C2)CC(C1)C3)O,CBR-HVAC-05870: Retinoic acid receptor gamma Agonist; Anticancer; Cancer
CBR-001-625-277-0,RFM-009-247-7,CBR-001-625-277-0,CN1CCN(CC1)c1cccc2c1oc(=O)[nH]2,CBR-HVAC-00771: 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR 1A; DOPAMINE RECEPTOR D2; DOPAMINE RECEPTOR D3 Agonist; Agonist; Agonist; Neuroprotectant; Antidepressant; Anxiolytic; Antiparkinsonian; Anxiety disorder; Parkinsons disease; Major depressive disorder
CBR-001-625-278-1,RFM-009-248-8,CBR-001-625-278-1,COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(c1)C,CBR-HVAC-00051: METABOTROPIC GLUTAMATE RECEPTOR 5 Antagonist; Anxiolytic; Antiparkinsonian; Anxiety
CBR-001-625-279-2,RFM-009-249-9,CBR-001-625-279-2,Clc1ccc(cc1)C12CC3CC(C1)CC(C2)(C3)C(=O)NCc1ccncc1,CBR-HVAC-06313: Sphingosine kinase 2; Sphingosine kinase 1 Inhibitor; ANTI-CANCER¬ANTI-INFLAMMATORY; Diffuse large b-cell lymphoma; Solid tumor; Pancreatic cancer
CBR-001-625-280-5,RFM-009-250-2,CBR-001-625-280-5,COc1cc(cc(c1OC)OC)C(=O)c1c(C)oc2c1ccc(c2O)OC,"CBR-HVAC-00624: TUBULIN INHIBITOR; ANTICANCER; CARCINOMA, RENAL; MESOTHELIOMA; OVARIAN CANCER"
CBR-001-625-281-6,RFM-009-251-3,CBR-001-625-281-6,C[N+]1(C)CCC(=C(c2ccccc2)c2ccccc2)CC1,"CBR-HVAC-09571: Muscarinic acetylcholine receptor Inhibitor; Antimuscarinic; Ulcer, peptic; Gastric hyperacidity; Hypermotility, gastrointestinal; Gastritis; Hyperhidrosis"
CBR-001-625-282-7,RFM-009-252-4,CBR-001-625-282-7,C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H]([C@H](O)C)N)O,CBR-HVAC-00668: N-methyl-D-aspartate glutamate receptor (NMDAR) Partial Agonist; Anti-depressant; BIPOLAR DEPRESSION; TREATMENT RESISTANT DEPRESSION
CBR-001-625-283-8,RFM-009-253-5,CBR-001-625-283-8,CNCC[C@H](c1ccccc1)Oc1ccccc1C,CBR-HVAC-02157: 5-Hydroxytryptamine transporter; Norepinephrine transporter Inhibitor; Antidepressant; Norepinephrine reuptake inhibitor; Attention deficit hyperactivity disorder
CBR-001-625-284-9,RFM-009-254-6,CBR-001-625-284-9,CN([C@@H]1C(=O)C(=C(C2([C@H]1C[C@H]1C(=C(O)c3c([C@H]1O)c(Cl)ccc3O)C2=O)O)O)C(=O)N)C,CBR-HVAC-01337: 16S-rRNA of 30S ribosomal subunit Binder; Antibacterial; Diuretic
CBR-001-625-285-0,RFM-009-255-7,CBR-001-625-285-0,CNc1nc(N[C@H]2CCC[C@H](C2)C(=O)NCc2ccc(cc2C(F)(F)F)C#N)nc(n1)C,CBR-HVAC-00245: SOLUBLE EPOXIDE HYDROLASE Inhibitor; BRONCHODILATOR; Chronic obstructive pulmonary disease
CBR-001-625-286-1,RFM-009-256-8,CBR-001-625-286-1,Clc1cc(ccc1/C=C/c1cccc(c1)C(=O)O)OCc1c(onc1c1c(Cl)cccc1Cl)C(C)C,CBR-HVAC-12038: Farnesoid X receptor Agonist; Antilithic; GALLSTONES
CBR-001-625-287-2,RFM-009-257-9,CBR-001-625-287-2,C=C[C@]1(C)C[C@@H](OC(=O)CSC(CNC(=O)[C@@H](C(C)C)N)(C)C)C2(C)[C@H](C)CCC3([C@H]([C@@H]1O)C)[C@H]2C(=O)CC3,"CBR-HVAC-04899: Inhibit protein synthesis by binding to the 50S ribosomal subunit of bacteria, characterized on Escherichia coli ribosomes. It is a inhibitor of peptidyl transferase and interact with domain V of 23S RNA; Antibiotic; Enteric disease; Enzootic pneumonia; Swine dysentery"
CBR-001-625-288-3,RFM-009-258-0,CBR-001-625-288-3,CC[C@H](N1CCCC1=O)C(=O)N,CBR-HVAC-00936: The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown and does not appear to derive from any interaction with known mechanisms involved in inhibitory and excitatory neurotransmission. The antiepileptic activity of levetiracetam was assessed in a number of animal models of epileptic seizures. Levetiracetam did not inhibit single seizures induced by maximal stimulation with electrical current or different chemoconvulsants and showed only minimal activity in submaximal stimulation and in threshold tests; Anticonvulsant; Antiepileptic; Analgesic; Antiparkinsonian; Antipsychotic; Anxiolytic; Seizures in adults with epilepsy in combination with other medications
CBR-001-625-289-4,RFM-009-259-1,CBR-001-625-289-4,O=C(C(c1ccccc1)C(=O)[O-])N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)[O-])(C)C,CBR-HVAC-09554: Penicillin binding protein Inhibitor; Antibacterial; Systemic infections; Septicemia; Urinary and genitourinary tract infections; Acute and chronic respiratory infections; soft tissue infections
CBR-001-625-290-7,RFM-009-260-4,CBR-001-625-290-7,CC(c1ccccc1)NCCC(c1ccccc1)c1ccccc1,CBR-HVAC-08624: Calcium channel Blocker; Vasodilator; Angina pectoris
CBR-001-625-291-8,RFM-009-261-5,CBR-001-625-291-8,O=C(O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)O)CCC1CCCC1,"CBR-HVAC-01354: Estrogen drug products act by regulating the transcription of a limited number of genes.Estrogens diffuse through cell membranes, distribute themselves throughout the cell, and bind to and activate nuclear estrogen receptor; Antimenopausal; Hypogonadism, female; Menopause, vasomotor symptoms"
CBR-001-625-292-9,RFM-009-262-6,CBR-001-625-292-9,OC[C@H]1O[C@@H](Oc2c3Oc4ccc(cc4Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@H](C(=O)N[C@@H]4c(c3)cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](C)[C@@H]([C@@](C2)(C)N)O)[C@@H]2NC(=O)[C@H](NC4=O)c3ccc(c(c3)c3c(O)cc(cc3[C@H](NC2=O)C(=O)O)O)O)CC(=O)N)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@@H](C)[C@@H]([C@@](C1)(C)NCc1ccc(cc1)c1ccc(cc1)Cl)O,CBR-HVAC-12758: Bacterial cell wall synthesis inhibitor; Antibacterial;
CBR-001-625-293-0,RFM-009-263-7,CBR-001-625-293-0,CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)OCOC(=O)C(C)(C)C)C,CBR-HVAC-03665: Penicillin binding protein Inhibitor; Antibacterial; Bacterial infections
CBR-001-625-294-1,RFM-009-264-8,CBR-001-625-294-1,COc1cc(/C=C/C(=O)O)ccc1O,CBR-HVAC-06249: ; Antioxidant; Anti-inflammatory; Anticancer; CANCER
CBR-001-625-295-2,RFM-009-265-9,CBR-001-625-295-2,CC(P(=O)(O)O)(P(=O)(O)O)O,"CBR-HVAC-02065: The mechanism by which this antoresorptive effect occurs is not completely known, but it is thought that the biphosphonate becomes incorporated into bone matrix and is imbibed by osteoclasts during resorption.The osteoclast is then incapacitated, and resorption decreases; Antihypercalcemic; Paget's disease; Hypercalcaemia; Osteoporosis, postmenopausal"
CBR-001-625-296-3,RFM-009-266-0,CBR-001-625-296-3,O=C([C@@H](NC(=O)[C@H](C(C)C)O)C)N[C@@H]1C(=O)N(C)CCc2c1cccc2,CBR-HVAC-00359: Gamma secretase Inhibitor; Neuroprotectant; Alzheimer's disease
CBR-001-625-297-4,RFM-009-267-1,CBR-001-625-297-4,O=C(OC(C)(C)C)N[C@H]1CCCCC/C=C/[C@H]2[C@](NC(=O)[C@H]3N(C1=O)C[C@@H](C3)OC(=O)N1Cc3c(C1)cccc3F)(C2)C(=O)NS(=O)(=O)C1CC1,"CBR-HVAC-06251: NS3/4A PROTEASE Inhibitor; Antiviral; Infection, hepatitis c virus"
CBR-001-625-298-5,RFM-009-268-2,CBR-001-625-298-5,COc1cccc2c1[nH]c(c2)c1nc(n2c1c(N)ncn2)[C@@H]1CC[C@H](CC1)C(=O)O,"CBR-HVAC-06717: Mechanistic target of rapamycin kinase Inhibitor; Anticancer; Carcinoma, renal; Solid tumor"
CBR-001-625-299-6,RFM-009-269-3,CBR-001-625-299-6,C#CCC(c1ccc(cc1)C(=O)N[C@H](C(=O)O)CCC(=O)O)Cc1cnc2c(n1)c(N)nc(n2)N,"CBR-HVAC-01903: Dihydrofolate reductase Inhibitor; ANTINEOPLASTIC; T-CELL LYMPHOMA, REFRACTORY PERIPHERAL"
CBR-001-625-300-2,RFM-009-270-6,CBR-001-625-300-2,CO[C@@H]1C[C@H](CC[C@H]1OP(=O)(C)C)C[C@H]([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H](CC[C@H]2C)C[C@H](OC)/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C1)C)/C)O)OC)C)C)/C)C,CBR-HVAC-02630: Anticancer; Anticancer; NEOPLASM; CANCER
CBR-001-625-301-3,RFM-009-271-7,CBR-001-625-301-3,COc1cc2N(C)[C@@H]3[C@@]4(c2cc1[C@]1(C[C@H]2CN(Cc5c1[nH]c1c5cccc1)C[C@@H](C2)C(F)(F)C)C(=O)OC)CCN1[C@H]4[C@@]([C@H]([C@]3(O)C(=O)OC)OC(=O)C)(CC)C=CC1,CBR-HVAC-01954: Tubulin Inhibitor; Anticancer; Cancer
CBR-001-625-302-4,RFM-009-272-8,CBR-001-625-302-4,OC[C@H]1O[C@H]([C@@H]([C@@H]1O[C@H]1O[C@@H](CN)[C@H]([C@@H]([C@H]1N)O)O)O)O[C@@H]1[C@@H](O)[C@H](N)C[C@@H]([C@H]1O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1N)O)O)N,"CBR-HVAC-02779: 16S-rRNA of 30S ribosomal subunit Binder; Antibacterial; Amebiasis, intestinal; management of hepatic coma-as adjunctive therapy"
CBR-001-625-303-5,RFM-009-273-9,CBR-001-625-303-5,CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)O)CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)O)CCCNC(=N)N)CCCNC(=N)N)C(C)C)CC(C)C)Cc1c[nH]c2c1cccc2)C)[C@H](CC)C)Cc1ccccc1)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1[nH]cnc1)N)C)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CO)CO)Cc1ccc(cc1)O)CC(C)C)CCC(=O)O)CCC(=O)N)C)C,CBR-HVAC-12638: Glucagon-like peptide 1 Agonist; Hypoglycemic; OBESITY; TYPE 2 DIABETES MELLITUS
CBR-001-625-304-6,RFM-009-274-0,CBR-001-625-304-6,CCCCCCCC(=O)N[C@@H]([C@@H](c1ccc2c(c1)OCCO2)O)CN1CCCC1,CBR-HVAC-06061: GLUCOSYLCERAMIDE SYNTHASE Inhibitor; METABOLIC ACTIVATOR;
CBR-001-625-305-7,RFM-009-275-1,CBR-001-625-305-7,COCCOCCOCCOCCOCCOCCOCCO[C@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC=C)ccc1O)O,CBR-HVAC-06613: MU OPIOID RECEPTOR Antagonist; ; Opioid-induced constipation with chronic non-cancer pain
CBR-001-625-306-8,RFM-009-276-2,CBR-001-625-306-8,CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)CO)CC(C)C)CCCNC(=N)N,CBR-HVAC-12862: Gonadotropin-releasing hormone receptor Agonist; Anticancer; Precocious puberty; Growth disorder; Endometriosis; Prostate cancer
CBR-001-625-307-9,RFM-009-277-3,CBR-001-625-307-9,CC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1cnc[nH]1)C)C(C)C)C(=O)N,CBR-HVAC-05253: Cadherin 2 Antagonist; Anticancer; Cancer
CBR-001-625-308-0,RFM-009-278-4,CBR-001-625-308-0,O[C@H]1CCC(=C)/C(=C\C=C\2/CCC[C@]3([C@H]2CC[C@@H]3[C@@H](CCCC(O)(C)C)C)C)/C1,"CBR-HVAC-02628: Vitamin D receptor interacting protein Inhibitor; Antihypocalcemic; Antihypoparathyroid; Nutritional supplement; Renal osteodystrophy; Chronic renal failure, Disorders of vitamin D nutrition or metabolism"
CBR-001-625-311-5,RFM-009-279-5,CBR-001-625-311-5,C[n+]1cc2c3OCOc3ccc2c2c1c1cc3OCOc3cc1cc2,CBR-HVAC-12733: Acetylcholinesterase (AChE) Inhibitors; Apoptosis Inducers; Caspase 3 Activators; FtsZ Inhibitors; Rho GTPase Inhibitors; Signal Transduction Modulators; Antibacterial Drugs; Treatment of Periodontitis
CBR-001-625-330-8,RFM-009-280-8,CBR-001-625-330-8,O=c1sc2c([nH]1)c(O)ccc2CCNCCS(=O)(=O)CCCOCCc1ccccc1,CBR-HVAC-04586: beta2-Adrenoceptor Agonists;Dopamine D2 Agonists;Signal Transduction Modulators
CBR-001-625-331-9,RFM-009-281-9,CBR-001-625-331-9,[N-]=[N+]=N[C@]1(CO)O[C@H]([C@H]([C@@H]1O)F)n1ccc(nc1=O)N,CBR-HVAC-06852: Reverse Transcriptase Inhibitors;RNA-Directed RNA Polymerase (NS5B) Inhibitors;2018-01-24: ARB# 18-000012
CBR-001-625-332-0,RFM-009-282-0,CBR-001-625-332-0,CO[C@@]1(NC(=O)C(c2cscc2)C(=O)[O-])C(=O)N2[C@@H]1SC(C2C(=O)[O-])(C)C,CBR-HVAC-03066: Activity against clinical isolates of Berkholderia cepacia isolated from cystic fibrosis patients
CBR-001-625-333-1,RFM-009-283-1,CBR-001-625-333-1,O=C(c1ccc(s1)C(=O)O)N/N=C(/c1csc(c1O)c1ccc(c(c1)Cl)Cl)\C,CBR-HVAC-09335: Signal Transduction Modulators;Thrombopoietin Receptor (TpoR) Agonists
CBR-001-625-334-2,RFM-009-284-2,CBR-001-625-334-2,O=C(Nc1cccc(c1Cl)F)Nc1ccc(c(c1O)S(=O)(=O)N1CCNCC1)Cl,CBR-HVAC-06082: Chemokine CXCR2 (IL-8 beta Receptor) Antagonists;Signal Transduction Modulators
CBR-001-625-335-3,RFM-009-285-3,CBR-001-625-335-3,CC(N(C)C)CN1c2cc(ccc2Sc2c1cccc2)S(=O)(=O)N(C)C,CBR-HVAC-09812:
CBR-001-625-457-2,RFM-009-286-4,CBR-001-625-457-2,CCCC(=O)Nc1ccc(c(c1)c1ccno1)OCC(CNCCc1ccc(c(c1)OC)OC)O,CBR-HVAC-03379: beta-Adrenoceptor Antagonists;Signal Transduction Modulators
CBR-001-625-458-3,RFM-009-287-5,CBR-001-625-458-3,CC(=O)N1CCC(CC1)c1nccnc1Oc1ccc(cc1)C(=O)c1nc2c([nH]1)cccc2,CBR-HVAC-07204: Phosphodiesterase PDE10A Inhibitors;Signal Transduction Modulators
CBR-001-625-459-4,RFM-009-288-6,CBR-001-625-459-4,COc1ccccc1[C@@H]1CCN(C1)Cc1ccc(=O)n(c1)C(C)C,CBR-HVAC-05621: alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators
CBR-001-625-460-7,RFM-009-289-7,CBR-001-625-460-7,COc1ccccc1[C@@H]1CCN(C1)Cc1ccc(=O)n(c1)C(C)C,CBR-HVAC-05621: alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators
CBR-001-625-461-8,RFM-009-290-0,CBR-001-625-461-8,CC1CC(O)(CC(=O)O)c2c(O1)cc(c(c2)F)Cl,CBR-HVAC-04191: Aldose Reductase Inhibitors
CBR-001-625-462-9,RFM-009-291-1,CBR-001-625-462-9,OCCN(CC(=O)n1c2ccc(cc2[nH]c(=O)c2c1cccc2)Cl)CCO,CBR-HVAC-03286: Muscarinic Antagonists;Signal Transduction Modulators
CBR-001-625-463-0,RFM-009-292-2,CBR-001-625-463-0,Clc1ccc2c(c1)O[C@H](CO2)CNC[C@@H]1C[C@H]2CC[C@@H](C1)N2C(=O)c1ccccc1,CBR-HVAC-05191: Dopamine D2 Antagonists;Signal Transduction Modulators;5-HT1A Receptor Agonists
CBR-001-625-464-1,RFM-009-293-3,CBR-001-625-464-1,N[C@@H]1CC[C@H](CC1)N[C@@H]1C[C@H]1c1ccccc1,CBR-HVAC-08133: Lysine (K)-specific demethylase 1A inhibitor
CBR-001-625-465-2,RFM-009-294-4,CBR-001-625-465-2,N[C@@H]1CC[C@H](CC1)N[C@@H]1C[C@H]1c1ccccc1,CBR-HVAC-08133: Lysine (K)-specific demethylase 1A inhibitor
CBR-001-625-466-3,RFM-009-295-5,CBR-001-625-466-3,Nc1nc(NC2CC2)c2c(n1)n(CCOCP(=O)(O)O)cn2,CBR-HVAC-13691: Antiviral Drugs; Oncolytic Drugs
CBR-001-625-467-4,RFM-009-296-6,CBR-001-625-467-4,CC(NCC(c1ccc(c(c1)C(=O)N)O)O)CCc1ccc2c(c1)OCO2,CBR-HVAC-05822: alpha-Adrenoceptor Antagonists;beta2-Adrenoceptor Antagonists;Signal Transduction Modulators
CBR-001-625-468-5,RFM-009-297-7,CBR-001-625-468-5,CSCC(C(=O)O)CC(=O)c1ccc(cc1)C,CBR-HVAC-05557: Immunomodulators
CBR-001-625-469-6,RFM-009-298-8,CBR-001-625-469-6,OCCCCO[N+](=O)[O-],CBR-HVAC-13680: metabolite of CBR-HVAC-02756:
CBR-001-625-470-9,RFM-009-299-9,CBR-001-625-470-9,NCCON=C1c2ccccc2C2C(c3c1cccc3)C2,CBR-HVAC-08018: 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor
CBR-001-625-471-0,RFM-009-300-5,CBR-001-625-471-0,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1Cl)Cl)C(=O)OC(C)C)COC(=O)N,CBR-HVAC-03438: Calcium Channel Blockers
CBR-001-625-472-1,RFM-009-301-6,CBR-001-625-472-1,OC(=O)CN1CCN(CC1)C[C@H]1OC(=O)N(C1)c1ccc(cc1)C(=N)N,CBR-HVAC-13681: metabolite of CBR-HVAC-07861:
CBR-001-625-473-2,RFM-009-302-7,CBR-001-625-473-2,COc1ccc(cc1)NC(=O)N1CCc2c(C1)sc1c2C(=NCc2n1c(C)nn2)c1ccccc1Cl,CBR-HVAC-04079: Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators
CBR-001-625-474-3,RFM-009-303-8,CBR-001-625-474-3,CCOC(=O)CN1CCN(CC1)C[C@H]1OC(=O)N(C1)c1ccc(cc1)C(=N)NC(=O)OC,CBR-HVAC-07861: GPIIb IIIa receptor antagonist; Platelet aggregation inhibitor
CBR-001-625-475-4,RFM-009-304-9,CBR-001-625-475-4,O=C(Nc1ccccc1)N/N=C/c1c(ccc[n+]1C)OC(=O)N(C)C,CBR-HVAC-11337: Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor; Cognition disorder; Alzheimer's disease
CBR-001-625-476-5,RFM-009-305-0,CBR-001-625-476-5,COc1ccc(cc1)NC(=S)N1CCc2c(C1)sc1c2C(=NCc2n1c(C)nn2)c1ccccc1Cl,CBR-HVAC-04076: Platelet activating factor receptor Antagonist; Anti-inflammatory; Sepsis; Rheumatoid arthritis; Asthma
CBR-001-625-477-6,RFM-009-306-1,CBR-001-625-477-6,N#Cc1nn(c(c1)c1ccc(cc1)S(=O)(=O)C)c1ccc(cc1)F,CBR-HVAC-11162: COX-2 Inhibitor; Antiinflammatory; Inflammation; Rheumatoid arthritis
CBR-001-625-478-7,RFM-009-307-2,CBR-001-625-478-7,CCCCCOc1ccc(cc1OCC)C1SC(=O)NC1=O,CBR-HVAC-03196: Aldose reductase Inhibitor; Antidiabetic; Diabetic neuropathy; Diabetic retinopathy; Cataract; Diabetic complications
CBR-001-625-479-8,RFM-009-308-3,CBR-001-625-479-8,CCOC(=O)C[C@@H](c1ccccc1)NC(=O)CN1C(=O)N[C@@](C1=O)(C)c1ccc(cc1)C(=N)N,CBR-HVAC-11194: Integrin alpha2b beta3 Antagonist; Antithrombotic; Antiplatelet; Thromboembolism
CBR-001-625-480-1,RFM-009-309-4,CBR-001-625-480-1,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCC1Cc2c(C1=O)cc(cc2)F,CBR-HVAC-10845: Alpha-1 adrenergic receptor; Dopamine receptor D2; Histamine H1 receptor; 5-Hydroxytryptamine 2A receptor Antagonist; Antihypertensive; Antipsychotic; Psychotic disorder
CBR-001-625-481-2,RFM-009-310-7,CBR-001-625-481-2,CCCC(c1c(=O)oc2c(c1O)cccc2)c1ccc(cc1)CCCl,CBR-HVAC-09112: NULL; Anticoagulant; Thrombosis
CBR-001-625-482-3,RFM-009-311-8,CBR-001-625-482-3,C#CCOc1ccccc1OCC(CNC(C)(C)C)O,CBR-HVAC-00945: Beta adrenergic receptor blocker; Antihypertensive; Antianginal; Antiarrhythmic; Hypertension; Angina pectoris; Arrhythmia
CBR-001-625-483-4,RFM-009-312-9,CBR-001-625-483-4,Cc1nccn1Cc1csc2c(c1=O)c1ccccc1cc2,CBR-HVAC-10528: 5-Hydroxytryptamine 3 receptor Antagonist; Anti-emetic; Gastroprokinetic; Emesis
CBR-001-625-484-5,RFM-009-313-0,CBR-001-625-484-5,Cc1nc(N)c2c(n1)ccc(c2)n1nc(cc1C(=O)Nc1ccc(cc1F)c1ccccc1S(=O)(=O)N)C(F)(F)F,CBR-HVAC-11454: Coagulation factor Xa Inhibitor; Antithrombotic; Thrombosis
CBR-001-625-485-6,RFM-009-314-1,CBR-001-625-485-6,CSc1nc2sc(c(c2c(n1)c1cccc(c1)NC(=O)CN1CCOCC1)N)C(=O)NC(C)(C)C,CBR-HVAC-05893: Luteinizing hormone receptor Agonist; Anti-infertility agent; INFERTILITY
CBR-001-625-486-7,RFM-009-315-2,CBR-001-625-486-7,COc1cc(CNCC(COc2ccc3c(c2)ccc(=O)[nH]3)O)ccc1OC,CBR-HVAC-10797: Phosphodiesterase 3 Inhibitor; Inotropic; Cardiac failure
CBR-001-625-487-8,RFM-009-316-3,CBR-001-625-487-8,CCN(C(=O)N)/N=C/c1ccc(o1)[N+](=O)[O-],CBR-HVAC-08862: ; Antiprotozoal; Protozoal diseases
CBR-001-625-488-9,RFM-009-317-4,CBR-001-625-488-9,CN1CCN(CC1)c1ccc(cc1C)Nc1ncc(c(n1)N[C@@H]1[C@H]2C=C[C@@H]([C@@H]1C(=O)N)C2)F,CBR-HVAC-06347: Aurora kinase Inhibitor; Anticancer; Cancer
CBR-001-625-489-0,RFM-009-318-5,CBR-001-625-489-0,Cc1nn(c2c1c(=O)[nH]c(n2)c1ccncc1)C1CCCC1,CBR-HVAC-11487: Phosphodiesterase Inhibitor; Antihypertensive; Antianginal; Hypertension; Angina
CBR-001-625-490-3,RFM-009-319-6,CBR-001-625-490-3,O=C(c1cc(Cl)c(c2c1OCCO2)N)CCC1CCN(CC1)CCNS(=O)(=O)C,CBR-HVAC-08385: 5-HYDROXYTRYPTAMINE 4 RECEPTOR Antagonist; ANTI-ARRHYTHMIC; Atrial flutter
CBR-001-625-491-4,RFM-009-320-9,CBR-001-625-491-4,ONC(=O)CCCC/C=C(/C(=O)NCCCN(C)C)\COc1cccc2c1cccc2,CBR-HVAC-06632: Histone deacetylase Inhibitor; Anticancer; Cancer
CBR-001-625-492-5,RFM-009-321-0,CBR-001-625-492-5,CC(N1C(=O)OC2(C1=C)CCN(CC2)CCCC(c1ccc(cc1)F)c1ccc(cc1)F)(C)C,CBR-HVAC-10779: Calcium channel Antagonist; Neuroprotectant; Cerebral ischemia; Cognitive disorder
CBR-001-625-493-6,RFM-009-322-1,CBR-001-625-493-6,N#Cc1ccc2c(c1)[C@@H](n1ccccc1=O)[C@@H](C(O2)(C)C)O,CBR-HVAC-04114: ATP-sensitive potassium channel Opener; Antihypertensive; Ischemic heart diseases; Hypertension; Myocardial ischemia; Asthma
CBR-001-625-494-7,RFM-009-323-2,CBR-001-625-494-7,COc1ccc(cc1OC)CCN(CCCC1(c2ccc(c(c2)OC)OC)S(=O)(=O)CCCS1(=O)=O)C,CBR-HVAC-02993: Calcium channel Antagonist; Antihypertensive; Angina pectoris; Arrhythmia; Central nervous system disorder
CBR-001-625-495-8,RFM-009-324-3,CBR-001-625-495-8,O=C1NC2=Nc3c(CN2C1)cc(cc3)N1CCCCC1,CBR-HVAC-03385: cAMP phosphodiesterase Inhibitor; Vasoprotectant; Cardiac failure
CBR-001-625-496-9,RFM-009-325-4,CBR-001-625-496-9,n1nnc([nH]1)Cc1ccccc1COc1ccc(cc1)OCc1ccc2c(n1)cccc2,CBR-HVAC-03828: Leukotriene B4 receptor; Peroxisome proliferator activated receptor gamma Agonist; Antagonist; Antiinflammatory; Asthma; Diabetes mellitus
CBR-001-625-497-0,RFM-009-326-5,CBR-001-625-497-0,CCOCCn1c(nc2c1cccc2)C1CCN(CC1)CCc1ccc(cc1)C(C)(C)C,CBR-HVAC-01083: Histamine H1 receptor Antagonist; Antiinflammatory; Allergic rhinitis; Urticaria
CBR-001-625-498-1,RFM-009-327-6,CBR-001-625-498-1,CNc1ccc(cc1)CN1CCC(CC1)OC(=O)NC(c1ccccc1)c1ccccc1,CBR-HVAC-11543: Muscarinic acetylcholine receptor M3 Antagonist; Muscarinic acetylcholine receptor M3 antagonist; Urinary dysfunction
CBR-001-625-499-2,RFM-009-328-7,CBR-001-625-499-2,CCCCc1nc(c(n1Cc1ccc2c(c1)c(Br)c(o2)c1ccccc1c1nnn[nH]1)C(=O)O)Cl,CBR-HVAC-01060: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension
CBR-001-625-500-8,RFM-009-329-8,CBR-001-625-500-8,CCOC(=O)[C@@H](N[C@H](C(=O)N1N=C(S[C@H]1C(=O)O)C(C)(C)C)C)CCc1ccccc1,CBR-HVAC-03559: Angiotensin converting enzyme Inhibitor; Antihypertensive; Hypertension
CBR-001-625-501-9,RFM-009-330-1,CBR-001-625-501-9,CNCc1ccc(c2c1sc1ccccc1c2=O)NCCN(CC)CC,CBR-HVAC-11485: Anticancer; Anticancer; Cancer
CBR-001-625-502-0,RFM-009-331-2,CBR-001-625-502-0,CCCC1(Cc2c3N1CCc3ccc2)C1=NCCN1,CBR-HVAC-04338: Alpha-2 adrenergic receptor Inhibitor; Antidiabetic; Diabetes mellitus
CBR-001-625-503-1,RFM-009-332-3,CBR-001-625-503-1,C=CCN1CCN(CC1)CC(COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC)C)(C)C,CBR-HVAC-03840: Calcium channel Blocker; Antihypertensive; Antianginal; Angina pectoris; Cerebral thrombosis; Cerebral vasospasm; Hypertension; Glaucoma
CBR-001-625-504-2,RFM-009-333-4,CBR-001-625-504-2,O=c1cc(oc2c1cccc2/C=C/c1ccc(cc1)OCCCCc1ccccc1)c1[nH]nnn1,CBR-HVAC-10791: Leukotriene D4 receptor Antagonist; Antiasthmatic; Asthma
CBR-001-625-505-3,RFM-009-334-5,CBR-001-625-505-3,OC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)OCC1(O)CCN(CC1)c1cc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,"CBR-HVAC-00729: Antibacterial; ANTIBACTERIAL; ANTIBIOTIC; INFECTION, CLOSTRIDIUM DIFFICILE"
CBR-001-625-506-4,RFM-009-335-6,CBR-001-625-506-4,CN1CCC(CC1)n1[nH]c(c(c1=O)Cc1ccccc1)c1ccccc1,CBR-HVAC-09972: ; Analgesic; Anti-inflammatory; Antipyretic; Pain; Inflammation
CBR-001-625-507-5,RFM-009-336-7,CBR-001-625-507-5,COc1ccccc1N1CCN(CC1)CCC1CCc2c(C1=O)cccc2,CBR-HVAC-11238: Alpha-1 adrenergic receptor Antagonist; Antihypertensive; Hypertension
CBR-001-625-508-6,RFM-009-337-8,CBR-001-625-508-6,CCOC(=O)c1ccc2c(c1)NCc1c(O2)c(OC)ccc1,CBR-HVAC-07494: Platelet aggregation inhibitor; ANTI-LIPEMICANTI-COAGULANT; Lipoprotein disorder; Coagulation disorder
CBR-001-625-509-7,RFM-009-338-9,CBR-001-625-509-7,O=C1CCC(=NN1)c1ccc(cc1)Nc1ccncc1,CBR-HVAC-00556: Phosphodiesterase 3 Inhibitor; Inotropic; Cardiac failure
CBR-001-625-510-0,RFM-009-339-0,CBR-001-625-510-0,Fc1ccc(cc1)c1nc(=O)n(c2c1ccc(c2)C)C(C)C,"CBR-HVAC-01009: Prostaglandin G/H synthase Inhibitor; Analgesic; Anti-inflammatory; Pain, postoperative; Osteoarthritis; Primary dysmenorrhea"
CBR-001-625-511-1,RFM-009-340-3,CBR-001-625-511-1,CN(CCc1cccnc1)CCCCN(c1ccccc1OCC(C)C)C(=O)c1cccc(c1)C(F)(F)F,CBR-HVAC-04469: CALCIUM CHANNEL Antagonist; Antianginal; Angina
CBR-001-625-512-2,RFM-009-341-4,CBR-001-625-512-2,C(NC[C@H]1CCc2c(O1)cccc2)CCNC1=NCCCN1,CBR-HVAC-04694: 5-Hydroxytryptamine 1D receptor Agonist; Antimigraine; Vasoconstrictor; Acute migraine
CBR-001-625-513-3,RFM-009-342-5,CBR-001-625-513-3,OC(=O)C1(CCCCC1)CCN1CC[C@H]2[C@H](C1)[C@@H](C)c1c(C2)[nH]c2c1cc(cc2)C(F)(F)F,CBR-HVAC-06134: MCH-1 RECEPTOR Antagonist; Antiobesity; Obesity
CBR-001-625-514-4,RFM-009-343-6,CBR-001-625-514-4,CCCCCCC(COC(=O)c1cccnc1)(COC(=O)c1cccnc1)COC(=O)c1cccnc1,CBR-HVAC-10244: ; Vasodilator; PERIPHERAL CIRCULATORY DISORDER
CBR-001-625-515-5,RFM-009-344-7,CBR-001-625-515-5,C[C@@]1(CSC(=N1)c1cccc(c1O)OCCOCCOCCOC)C(=O)O,CBR-HVAC-00539: Hemoglobin modulator; IRON CHELATOR; IRON OVERLOAD
CBR-001-625-516-6,RFM-009-345-8,CBR-001-625-516-6,C[C@@]1(CSC(=N1)c1cccc(c1O)OCCOCCOCCOC)C(=O)O,CBR-HVAC-00539: Hemoglobin modulator; IRON CHELATOR; IRON OVERLOAD
CBR-001-625-517-7,RFM-009-346-9,CBR-001-625-517-7,CN(CCCN1c2ccccc2Oc2c(C1=O)cc(cc2)[N+](=O)[O-])C,CBR-HVAC-01726: ; ANTIDEPRESSANT; DEPRESSION; NOCTURNAL ENURESIS
CBR-001-625-518-8,RFM-009-347-0,CBR-001-625-518-8,Brc1ccc(c(c1)Cn1nc(cc1C)C(=O)O)OCc1ccc(cc1Cl)Cl,CBR-HVAC-11894: Prostaglandin E1 receptor Antagonist; Analgesic; PAIN
CBR-001-625-519-9,RFM-009-348-1,CBR-001-625-519-9,OC(=O)Cc1ccc(cc1)CC1(CCCC1)CNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-07982: Thromboxane A2 receptor/Prostaglandin H receptor 2 Antagonist; Anti-atherosclerotic; Antithrombotic; Thrombosis; Atherosclerosis
CBR-001-625-520-2,RFM-009-349-2,CBR-001-625-520-2,CCOCC1[C@H]2CC[C@H](N2C)CC1c1ccc(c(c1)Cl)Cl,CBR-HVAC-00614: Dopamine transporter; Monoamine transporter Inhibitor; Antiparkinsonian; Obesity
CBR-001-625-521-3,RFM-009-350-5,CBR-001-625-521-3,CN1CCN(CC1)c1ccc(cc1C)Nc1ncc(c(n1)N[C@H]1[C@@H]2C=C[C@H]([C@H]1C(=O)N)C2)F,CBR-HVAC-06347: Aurora kinase Inhibitor; Anticancer; Cancer
CBR-001-625-522-4,RFM-009-351-6,CBR-001-625-522-4,CC(c1ccc(cc1)c1sccc1C)C(=O)O,CBR-HVAC-04717: COX-2 Inhibitor; Immunomodulator; Anti-inflammatory; Analgesic; Inflammation; Pain; Postmenopausal osteoporosis
CBR-001-625-523-5,RFM-009-352-7,CBR-001-625-523-5,CC(c1ccc(cc1)c1sccc1C)C(=O)O,CBR-HVAC-04717: COX-2 Inhibitor; Immunomodulator; Anti-inflammatory; Analgesic; Inflammation; Pain; Postmenopausal osteoporosis
CBR-001-625-524-6,RFM-009-353-8,CBR-001-625-524-6,OCC(=O)[C@H]1[C@H](C)CC2[C@]1(C)C[C@H](O)C1C2C[C@@H](C2=CC(=O)C=C[C@]12C)F,CBR-HVAC-01518: Fluocortolone is a corticosteroid and has effect on cortisol suppression; Corticosteroid; Rheumatic diseases; Asthma; Immunosuppression
CBR-001-625-525-7,RFM-009-354-9,CBR-001-625-525-7,NC(=O)[C@@H]([C@H](C(=O)N[C@H]1N=C(c2ccccc2)c2c(N(C1=O)C)cccc2)CCC(F)(F)F)CCC(F)(F)F,"CBR-HVAC-07263: NOTCH Inhibitor; ANTI-CANCER; Leukemia, t-cell acute lymphoblastic; Advanced solid tumors; Lymphoma, t-cell, lymphoblastic"
CBR-001-625-526-8,RFM-009-355-0,CBR-001-625-526-8,CSCC[C@@H](C(=O)OCC)NC(=O)C(Cc1ccccc1C)CSC(=O)C,CBR-HVAC-04124: Membrane metalloendopeptidase Inhibitor; Antihypertensive; Hypertension; Cardiovascular disease
CBR-001-625-527-9,RFM-009-356-1,CBR-001-625-527-9,CSCC[C@@H](C(=O)OCC)NC(=O)C(Cc1ccccc1C)CSC(=O)C,CBR-HVAC-04124: Membrane metalloendopeptidase Inhibitor; Antihypertensive; Hypertension; Cardiovascular disease
CBR-001-625-528-0,RFM-009-357-2,CBR-001-625-528-0,CCCCCCC(n1cnc2c1nc[nH]c2=O)C(O)C,CBR-HVAC-02918: C-GMP PHOSPHODIESTERASE Inhibitor; IMMUNOSTIMULANT; Immunological disorders
CBR-001-625-529-1,RFM-009-358-3,CBR-001-625-529-1,O[C@H]1CNCC[C@H]1Oc1cccc(c1C)C,CBR-HVAC-02977: SEROTONIN REUPTAKE TRANSPORTER Inhibitor; ANTIDEPRESSANT; Depression
CBR-001-625-530-4,RFM-009-359-4,CBR-001-625-530-4,NCC1(CF)CCN(C1)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-10740: Antibacterial; Antibacterial; Bacterial infection
CBR-001-625-531-5,RFM-009-360-7,CBR-001-625-531-5,NCC1(CF)CCN(C1)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-10740: Antibacterial; Antibacterial; Bacterial infection
CBR-001-625-532-6,RFM-009-361-8,CBR-001-625-532-6,C(NC[C@@H]1CCc2c(O1)cccc2)CCNC1=NCCCN1,CBR-HVAC-04694: 5-Hydroxytryptamine 1D receptor Agonist; Antimigraine; Vasoconstrictor; Acute migraine
CBR-001-625-533-7,RFM-009-362-9,CBR-001-625-533-7,OCC(=O)N1CCc2c1ccc(c2)N1C[C@@H](OC1=O)CNC(=O)C,"CBR-HVAC-10921: Bacterial protein synthesis inhibitor; Antibacterial; INFECTION, BACTERIAL"
CBR-001-625-534-8,RFM-009-363-0,CBR-001-625-534-8,C1CN(CCC1c1[nH]cnc1)/C=N/C12CC3CC(C2)CC(C1)C3,CBR-HVAC-10730: Histamine H3 receptor Antagonist; Antidepressant; Anticonvulsant; Epilepsy; Alzheimer's disease; Depression
CBR-001-625-535-9,RFM-009-364-1,CBR-001-625-535-9,N=C1NC(=O)N2C1C2,"CBR-HVAC-03956: Anticancer; Anticancer; CARCINOMA, PROSTATE; CARCINOMA, PANCREATIC; CARCINOMA, BREAST; LYMPHOMA; LUNG CARCINOMA; MYELOMA, MULTIPLE; IMMUNE DISORDERS; MELANOMA; CANCER"
CBR-001-625-536-0,RFM-009-365-2,CBR-001-625-536-0,CCC(=O)O[C@H]1CCC2C(=C1)CCC1C2CCC2(C1CC[C@@H]2OC(=O)CC)C,CBR-HVAC-09955: ; Anabolic steroid; Growth substance
CBR-001-625-539-3,RFM-009-366-3,CBR-001-625-539-3,COCC(=O)N(c1ccccc1F)C1CCN(CC1)CCc1ccccc1,CBR-HVAC-01156: ; Analgesic; Narcotic; Anesthesia; Pain
CBR-001-625-540-6,RFM-009-367-4,CBR-001-625-540-6,Nc1ccc(cc1)S(=O)(=O)NC(=O)c1ccc(c(c1)C)C,"CBR-HVAC-08702: ; Antibiotic; Infection, bacterial"
CBR-001-625-541-7,RFM-009-368-5,CBR-001-625-541-7,COc1cc(nc(n1)C)NS(=O)(=O)c1ccc(cc1)N,"CBR-HVAC-08691: ; Antibiotic; Infection, bacterial"
CBR-001-625-542-8,RFM-009-369-6,CBR-001-625-542-8,C=CCN1C(=S)NC(C1=O)CC(C)C,CBR-HVAC-08645: ; Anticonvulsant; Epilepsy
CBR-001-625-543-9,RFM-009-370-9,CBR-001-625-543-9,CCN(CCNC(=O)COc1ccc(cc1)Cl)CC,CBR-HVAC-09254: ; Anti-inflammatory; Inflammation
CBR-001-625-544-0,RFM-009-371-0,CBR-001-625-544-0,CCN(C(=O)Cc1csc(n1)NS(=O)(=O)c1cccc(c1C)Cl)CC,CBR-HVAC-11754: 11-Beta hydroxysteroid dehydrogenase 1 Inhibitor; Hypoglycemic; Type II diabetes
CBR-001-625-545-1,RFM-009-372-1,CBR-001-625-545-1,O=c1ccc2c(o1)c(ccc2)N1CCNCC1,CBR-HVAC-01177: 5-HT1B RECEPTOR; 5HT1A RECEPTOR Agonist; Agonist; ANTI-PSYCHOTIC; Psychotic disorder
CBR-001-625-546-2,RFM-009-373-2,CBR-001-625-546-2,C[N+](C1c2ccccc2c2c1cccc2)(CCCCCC[N+](C1c2ccccc2c2c1cccc2)(C)C)C,CBR-HVAC-09599: Acetylcholinesterase Inhibitor; Skeletal muscle relaxant; As an adjunct with succinylcholine to prolong muscle relaxation; Succinylcholine-induced muscle fasciculations
CBR-001-625-547-3,RFM-009-374-3,CBR-001-625-547-3,OC(=O)[C@](Cc1ccc(c(c1)O)O)(N)C,CBR-HVAC-12865: Alpha-2 adrenergic receptor Agonist; Antihypertensive; Hypertension
CBR-001-625-548-4,RFM-009-375-4,CBR-001-625-548-4,c1csc(c1)C1Cn2c(=N1)scc2,CBR-HVAC-09404: Anthelmintic; ANTIHELMINTIC; HELMINTHIC INFECTIONS
CBR-001-625-549-5,RFM-009-376-5,CBR-001-625-549-5,OCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)O)C(O)C)Cc1ccc(cc1)O)CC(=O)N)C(O)C)C(O)C)C(O)C)NC(=O)C(N)C,CBR-HVAC-12756: C-C chemokine receptor type 5; TNF Antagonist; Inhibitor; Antiviral; TNF modulator; HIV associated dementia; Herpes simplex virus infection
CBR-001-625-550-8,RFM-009-377-6,CBR-001-625-550-8,OCCn1nnnc1SCC1=C(C(=O)O)N2[C@H](OC1)[C@](C2=O)(OC)NC(=O)CSC(F)F,CBR-HVAC-02043: Cell wall synthesis inhibitors.; Antibacterial; Bacterial infections
CBR-001-625-551-9,RFM-009-378-7,CBR-001-625-551-9,Nc1ccn(c(=O)n1)[C@@H]1CO[C@@H](O1)CO,"CBR-HVAC-04850: DNA POLYMERASE Inhibitor; Anticancer; Leukemia, acute myelogenous"
CBR-001-625-552-0,RFM-009-379-8,CBR-001-625-552-0,CC(NC(=O)c1cccnc1)CCN1CCN(CC1)c1ccc(cc1)F,CBR-HVAC-10363: H-1 receptor Antagonist; Sedative; Hypnotic; SLEEP DISTURBANCE
CBR-001-625-553-1,RFM-009-380-1,CBR-001-625-553-1,CCN(CCOc1ccc(cc1)Cc1ccccc1)CC,CBR-HVAC-00300: HISTAMINE RECEPTOR Antagonist; Anticancer; Chemosensitizer; Breast cancer; Prostate cancer; Gastric cancer; Hepatic cancer
CBR-001-625-554-2,RFM-009-381-2,CBR-001-625-554-2,CCOC(=O)C(=O)Nc1scc(n1)c1ccc(cc1)OC,CBR-HVAC-03304: Mediator release Inhibitor; Antiallergic; Asthma
CBR-001-625-555-3,RFM-009-382-3,CBR-001-625-555-3,OC(COc1cccc2c1N(CCC2)C(=O)c1cccnc1)CNC(C)C,CBR-HVAC-03003: Sodium channel Blocker; Class I antiarrhythmic; Arrhythmia
CBR-001-625-556-4,RFM-009-383-4,CBR-001-625-556-4,OC(=O)[C@H](Cc1cc(I)c(c(c1)I)Oc1cc(I)c(c(c1)I)O)N,CBR-HVAC-12867: Thyroid receptor Agonist; Thyroid hormone; Diagnostic agent; Congenital hypothyroidism; Acquired hypothyroidism; Primary thyroid failure; Post surgery; postradioiodine therapy
CBR-001-625-557-5,RFM-009-384-5,CBR-001-625-557-5,C1CN=C(O1)NC1CC2CC1CC2,analog of CBR-HVAC-13557:
CBR-001-625-558-6,RFM-009-385-6,CBR-001-625-558-6,CC(Cc1ccc(cc1)c1onc(n1)c1ccc(cc1)CN1CC(C1)C(=O)O)C,CBR-HVAC-14449: Lysophospholipid edg1 (S1P1) Receptor Agonists; Signal Transduction Modulators; Immunosuppressants; Treatment of Transplant Rejection
CBR-001-625-559-7,RFM-009-386-7,CBR-001-625-559-7,Oc1ccc(cc1)N(C(=O)c1cccc(c1)F)C,analog of CBR-HVAC-12432:
CBR-001-625-560-0,RFM-009-387-8,CBR-001-625-560-0,CC[C@@]1(NC(=O)N(C1=O)C)c1ccccc1,analog of CBR-HVAC-13268: CYP2B6 and CYP2C19 substrate; mephenytoin isomer; anticonvulsive; antiepileptic
CBR-001-625-561-1,RFM-009-388-9,CBR-001-625-561-1,CCCCCC1C(O)CCC1CC(=O)O,analog of CBR-HVAC-12760:
CBR-001-625-562-2,RFM-009-389-0,CBR-001-625-562-2,OB(c1cccc(c1C)C)O,"CBR-HVAC-13708: ASP-9226 had been in phase I clinical evaluation at Astellas Pharma for the treatment of neuropathic pain, however, development was discontinued in 2015"
CBR-001-625-563-3,RFM-009-390-3,CBR-001-625-563-3,O=Cc1ccc(nc1)C#N,CBR-HVAC-13704: Elastase Inhibitors
CBR-001-625-564-4,RFM-009-391-4,CBR-001-625-564-4,OB(c1cc(cc(c1)[N+](=O)[O-])C(=O)N1CCOCC1)O,CBR-HVAC-12567: Collagenase Inhibitors
CBR-001-625-565-5,RFM-009-392-5,CBR-001-625-565-5,NC(=O)CC(N1C(=O)c2c(C1=O)cccc2)c1ccccc1,CBR-HVAC-13749: Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors
CBR-001-625-566-6,RFM-009-393-6,CBR-001-625-566-6,O=C([C@H]1CCCN(C1)S(=O)(=O)c1cccc(c1C)Cl)NC1CCCCC1,CBR-HVAC-12501: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
CBR-001-625-567-7,RFM-009-394-7,CBR-001-625-567-7,O=C([C@@H](Cc1c[nH]c2c1cccc2)N)NC(C(=O)O)(C)C,CBR-HVAC-07271: Drugs Acting on Beta-Amyloid
CBR-001-625-568-8,RFM-009-395-8,CBR-001-625-568-8,C1CNC(=CC2=Cc3c(CC2)cccc3)N1,CBR-HVAC-03298: alpha2-Adrenoceptor Antagonists;Drugs Acting on Monoamine Transporters;Signal Transduction Modulators
CBR-001-625-569-9,RFM-009-396-9,CBR-001-625-569-9,Cc1ccc2c(c1)c(=O)cc(o2)c1cc(Br)ccc1O,CBR-HVAC-13786: GABA(A) Receptor Modulators;Signal Transduction Modulators
CBR-001-625-570-2,RFM-009-397-0,CBR-001-625-570-2,CCCCCCCCCC1OCCO1,CBR-HVAC-13584: SEPA absorption enhancers
CBR-001-625-571-3,RFM-009-398-1,CBR-001-625-571-3,OC(=O)Cc1ccc(cc1)C(=O)C1CC1,CBR-HVAC-08362: Cyclooxygenase inhibitor
CBR-001-625-572-4,RFM-009-399-2,CBR-001-625-572-4,COC(=O)c1cc(OC)c2c(c1c1c(CO)cc(c3c1OCO3)OC)OCO2,CBR-HVAC-12712: Hepatoprotectants
CBR-001-625-591-7,RFM-009-400-8,CBR-001-625-591-7,CCCCCCCC/C=C\CCCCCCCC(=O)C(F)(F)F,analog of oleic acid
CBR-001-625-592-8,RFM-009-401-9,CBR-001-625-592-8,,CBR-HVAC-13309
CBR-001-627-739-7,RFM-009-402-0,CBR-001-627-739-7,NCCCCCN(C(=O)CCC(=O)NCCCCCN(C(=O)CCC(=O)NCCCCCN(C(=O)C)O)O)O,CBR-HVAC-00022:Antimetabolites;APP Expression Inhibitors;Chelating Agents
CBR-001-627-740-0,RFM-009-403-1,CBR-001-627-740-0,OC(c1ccc(c(c1)NS(=O)(=O)C)O)CNC(Cc1ccccc1)(C)C,CBR-HVAC-01226:beta2-Adrenoceptor Agonists;beta3-Adrenoceptor Agonists;Signal Transduction Modulators
CBR-001-627-741-1,RFM-009-404-2,CBR-001-627-741-1,CCNCCCNCCCNCCCNCC,CBR-HVAC-04344:Antimetabolites;Ornithine Decarboxylase Inhibitors;S-Adenosyl-L-methionine Decarboxylase Inhibitors
CBR-001-627-742-2,RFM-009-405-3,CBR-001-627-742-2,OC1CCCc2c1c(NCc1ccccc1)c1c(n2)cccc1,CBR-HVAC-03908:Acetylcholinesterase (AChE) Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators
CBR-001-627-743-3,RFM-009-406-4,CBR-001-627-743-3,Fc1cccc(c1)C#Cc1nc(C)cc(c1N)C,CBR-HVAC-12601:mgluR5 Modulators;Signal Transduction Modulators
CBR-001-627-744-4,RFM-009-407-5,CBR-001-627-744-4,OC[C@@H]1O[C@@H](Oc2c3Oc4ccc(cc4)C(O[C@@H]4O[C@H](C)[C@@H]([C@@](C4)(C)N)O)C4NC(=O)C(NC(=O)C5c(c3)cc2Oc2ccc(cc2Cl)C(O)C(C(=O)NC(C(=O)N5)CC(=O)N)NC(=O)C(CC(C)C)NC)c2ccc(c(c2)c2c(C(NC4=O)C(=O)O)cc(cc2O)O)O)[C@H]([C@@H]([C@H]1O)O)O[C@@H]1O[C@H](C)[C@@H]([C@@](C1)(C)N)O,CBR-HVAC-12757:Antibiotics
CBR-001-627-745-5,RFM-009-408-6,CBR-001-627-745-5,CNCC/C=C/c1cncc(c1)OCC,CBR-HVAC-13493: Nicotinic acetylcholine receptor alpha4beta2 agonist
CBR-001-627-746-6,RFM-009-409-7,CBR-001-627-746-6,[NH3+][C@H]1C[C@@H](O[C@H]([C@H]1O)C)O[C@H]1C[C@@](O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)c(O)ccc2)C(=O)C,CBR-HVAC-13244:Antineoplastic
CBR-001-627-748-8,RFM-009-410-0,CBR-001-627-748-8,CN1C(=O)CC[C@H]1C(=O)NCc1cccc(c1Cl)C(F)(F)F,CBR-HVAC-06706:  P2X7 Receptor Antagonists;Signal Transduction Modulators
CBR-001-627-749-9,RFM-009-411-1,CBR-001-627-749-9,COC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)C)Cc1ccccc1)Cc1[nH]cnc1,CBR-HVAC-02909:  Thromboxane Synthase Inhibitors
CBR-001-627-750-2,RFM-009-412-2,CBR-001-627-750-2,CC[C@H](N(CCN([C@H](COC(=O)c1cc(OC)c(c(c1)OC)OC)CC)C)C)COC(=O)c1cc(OC)c(c(c1)OC)OC,CBR-HVAC-02214: ; ; Arrhythmic disorders
CBR-001-627-751-3,RFM-009-413-3,CBR-001-627-751-3,COC(=O)C(c1cccc(c1)C(n1cncc1)c1ccccc1)C,CBR-HVAC-01127: ; Analgesic; Anti-inflammatory; Antiulcer; Inflammation
CBR-001-627-752-4,RFM-009-414-4,CBR-001-627-752-4,OC(=O)c1ccccc1OS(=O)(=O)[O-],CBR-HVAC-09884: ; Analgesic; Anti-inflammatory; Pain
CBR-001-627-753-5,RFM-009-415-5,CBR-001-627-753-5,COc1ccc2c(c1)c(CC(=O)OC1OC(=O)c3c1cccc3)c(n2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-02558: ; Analgesic; Anti-inflammatory; Pain; Fever
CBR-001-627-754-6,RFM-009-416-6,CBR-001-627-754-6,NC(=O)N/N=C/1\C=Cc2c(C1=O)cccc2,CBR-HVAC-07251: ; Anticoagulant; VENOUS INSUFFICIENCY
CBR-001-627-755-7,RFM-009-417-7,CBR-001-627-755-7,CC(N(C)C)Cn1c(=O)c2cccnc2[nH]c2c1cccc2,CBR-HVAC-08995: ; Antidepressant; Depression
CBR-001-627-756-8,RFM-009-418-8,CBR-001-627-756-8,Clc1cccc(c1N(C1=NCCN1)C1CCCCO1)Cl,CBR-HVAC-01103: ; Antihypertensive; Hypertension
CBR-001-627-757-9,RFM-009-419-9,CBR-001-627-757-9,COc1ccc2c(c1)c(CC(=O)O)c(n2C(=O)c1cccnc1)C,"CBR-HVAC-08766: ; Anti-inflammatory, nonsteroidal; Inflammation"
CBR-001-627-758-0,RFM-009-420-2,CBR-001-627-758-0,Clc1ccc(cc1)C(=O)n1cc(c2c1cccc2)Cc1nnn[nH]1,"CBR-HVAC-01098: ; Anti-inflammatory, nonsteroidal; Inflammation"
CBR-001-627-759-1,RFM-009-421-3,CBR-001-627-759-1,OCc1cccc(n1)COC(=O)C(Oc1ccc(cc1)Cl)(C)C,CBR-HVAC-02127: ; Antilipemic; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV
CBR-001-627-760-4,RFM-009-422-4,CBR-001-627-760-4,CCOP(=O)(OCC)CCCCCCOc1ccc(cc1Cl)OC,"CBR-HVAC-02500: ; Antiviral; Infection, viral"
CBR-001-627-761-5,RFM-009-423-5,CBR-001-627-761-5,O=C(C(N1CCN(CC1)c1ccc(cn1)C(F)(F)F)(C)C)NC1C2CC3CC1CC(C2)(C3)C(=O)N,CBR-HVAC-06880: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
CBR-001-627-762-6,RFM-009-424-6,CBR-001-627-762-6,O=C(C(N1CCN(CC1)c1ccc(cn1)C(F)(F)F)(C)C)NC1C2CC3CC1CC(C2)(C3)C(=O)N,CBR-HVAC-06880: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
CBR-001-627-763-7,RFM-009-425-7,CBR-001-627-763-7,OC1CN(C1)C(=O)CC1(C2CC3CC1CC(C2)C3O)c1ccccc1,CBR-HVAC-06733: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
CBR-001-627-764-8,RFM-009-426-8,CBR-001-627-764-8,Fc1ccc(cc1)C(=O)CC1CCN(C1)CCOc1cccc2c1OCCO2,CBR-HVAC-04715: 5-Hydroxytryptamine 1A receptor Agonist; Antipsychotic; Schizophrenia; Psychosis
CBR-001-627-765-9,RFM-009-427-9,CBR-001-627-765-9,CCCN(C1COc2c(C1)c(ccc2)C(=O)C)CCCCN1C(=O)CC2(CC1=O)CCCC2,CBR-HVAC-10793: 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 7 receptor Antagonist; Antidepressant; Anxiolytic; Anxiety disorder; Depression
CBR-001-627-766-0,RFM-009-428-0,CBR-001-627-766-0,COc1cncnc1N1CCN(CC1)CCCc1c[nH]c2c1cc(F)cc2,CBR-HVAC-04296: 5-Hydroxytryptamine 1D receptor Agonist; Antidepressant; Depression
CBR-001-627-767-1,RFM-009-429-1,CBR-001-627-767-1,O=C1C(CCc2c1c1ccccc1n2C)Cc1nc[nH]c1C,CBR-HVAC-08915: 5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Vomiting; Nausea
CBR-001-627-768-2,RFM-009-430-4,CBR-001-627-768-2,O=C1C(CCc2c1c1ccccc1n2C)Cc1nc[nH]c1C,CBR-HVAC-08915: 5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Vomiting; Nausea
CBR-001-627-769-3,RFM-009-431-5,CBR-001-627-769-3,COc1cc(N)c(cc1C(=O)N[C@@H]1C[C@@H]2CCC[C@H](C1)N2CC(=O)O)Cl,CBR-HVAC-10605: 5-Hydroxytryptamine 4 receptor Agonist; Antigasrtic; Gastrointestinal disease; Gastric motility disorder
CBR-001-627-770-6,RFM-009-432-6,CBR-001-627-770-6,CSc1ccc(cc1C)Oc1ccc(cc1CN(C)C)S(=O)(=O)N,CBR-HVAC-11658: 5-Hydroxytryptamine transporter Inhibitor; 5-hydroxytryptamine transporter inhibitor; Central nervous system disease
CBR-001-627-771-7,RFM-009-433-7,CBR-001-627-771-7,COc1ccc(cc1)OC[C@H]1CN(C)CC[C@@H]1c1ccccc1,CBR-HVAC-02915: 5-Hydroxytryptamine transporter Inhibitor; Antidepressant; Alcoholism; Depression; Eating disorder
CBR-001-627-772-8,RFM-009-434-8,CBR-001-627-772-8,O=C(C(F)(F)F)c1cccc(c1)[Si](C)(C)C,CBR-HVAC-00571: Acetylcholine Esterase Inhibitor; ANTI-COGNITIVE; Neurological disorders; Cognition disorder; Alzheimer's disease
CBR-001-627-773-9,RFM-009-435-9,CBR-001-627-773-9,CCCC(CCC)(CCC)N,CBR-HVAC-08928: Acetylcholine receptor Blocker; Antiparkinsonian; Parkinson's disease
CBR-001-627-774-0,RFM-009-436-0,CBR-001-627-774-0,CN1CC[C@@]2([C@H]1N(C)c1c2cc(cc1)OC(=O)N1CCc2c(C1)cccc2)C,CBR-HVAC-04169: Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor; Alzheimer's disease; Dementia
CBR-001-627-775-1,RFM-009-437-1,CBR-001-627-775-1,C/C=C/1\[C@H]2C=C(C[C@]1(/N=C/c1cc(Cl)cc(c1O)OC)c1c(C2)[nH]c(=O)cc1)C,CBR-HVAC-05717: ACETYLCHOLINESTERASE Inhibitor; Neuroprotectant; Alzheimer's disease
CBR-001-627-776-2,RFM-009-438-2,CBR-001-627-776-2,Clc1cc2N=C3CCCCCN3Cc2c(c1)Cl,CBR-HVAC-04422: Acetylcholinesterase; Muscarinic acetylcholine receptor Antagonist; Inhibitor; Neuroprotectant; Alzheimer's disease; Cognitive disorder
CBR-001-627-777-3,RFM-009-439-3,CBR-001-627-777-3,CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)C12CCC(CC1)(CC2)CCC(=O)O,CBR-HVAC-05741: Adenosine A2A receptor; Adenosine A1 receptor Antagonist; Antagonist; Diuretic; Congestive heart failure
CBR-001-627-778-4,RFM-009-440-6,CBR-001-627-778-4,CN1CCCc2c1c(OCC1CNCCO1)ccc2,CBR-HVAC-04400: Adrenergic receptor Agonist; Neuroprotective; Nootropic; Alzheimer's disease
CBR-001-627-779-5,RFM-009-441-7,CBR-001-627-779-5,OC(=O)CC1Sc2ccccc2N(C1=O)Cc1sc2c(n1)c(F)c(cc2F)F,CBR-HVAC-04314: Aldose reductase Inhibitor; Antidiabetic; Diabetic complications
CBR-001-627-780-8,RFM-009-442-8,CBR-001-627-780-8,CC(NC(C(c1cc(I)c(c(c1)I)O)O)C)CCc1ccccc1,CBR-HVAC-08836: Alpha adrenergic receptor; Beta adrenergic receptor Agonist; Antagonist; Antihypertensive; Hypertension
CBR-001-627-781-9,RFM-009-443-9,CBR-001-627-781-9,NC1=NC2(CO1)CCc1c(C2)c(Cl)ccc1,CBR-HVAC-11037: Alpha-2 adrenergic receptor Agonist; Analgesic; Pain
CBR-001-627-782-0,RFM-009-444-0,CBR-001-627-782-0,NC1=NC2(CO1)CCc1c(C2)c(Cl)ccc1,CBR-HVAC-11037: Alpha-2 adrenergic receptor Agonist; Analgesic; Pain
CBR-001-627-783-1,RFM-009-445-1,CBR-001-627-783-1,O=C(Nc1ccccc1)NCCC1CCN(CC1)CC1=Cc2c(OC1)cccc2,CBR-HVAC-11531: Alpha-2 adrenergic receptor Antagonist; Antiparkinsonian; Alzheimer's disease; Parkinson's disease; Neurodegenerative diseases
CBR-001-627-784-2,RFM-009-446-2,CBR-001-627-784-2,CCCc1nn(c(c1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)CO)CC(F)(F)F,CBR-HVAC-11519: Angiotensin II receptor Antagonist; Antihypertensive; Hypertension
CBR-001-627-785-3,RFM-009-447-3,CBR-001-627-785-3,CCCCc1cc(cc(=O)n1Cc1ccc(cc1F)c1ccccc1c1nnn[nH]1)C(=O)OC,CBR-HVAC-10374: Angiotensin II receptor Antagonist; ANTI-HYPERTENSIVE; Hypertension
CBR-001-627-786-4,RFM-009-448-4,CBR-001-627-786-4,CCc1nc2c(n1Cc1ccc3c(c1)ccc(n3)c1ccccc1C(=O)O)nc(cc2C)C,CBR-HVAC-04556: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension
CBR-001-627-787-5,RFM-009-449-5,CBR-001-627-787-5,CCCCc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1[nH]nnn1)nc(c(c2)c1cccc[n+]1[O-])C,CBR-HVAC-11514: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension
CBR-001-627-788-6,RFM-009-450-8,CBR-001-627-788-6,CCc1nc2c(n1Cc1ccc(cc1)[C@H]([C@H](C(=O)O)C)c1ccccc1)nc(cc2C)C,CBR-HVAC-10628: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension; Congestive heart failure
CBR-001-627-789-7,RFM-009-451-9,CBR-001-627-789-7,CCc1nc2c(n1Cc1ccc(cc1)[C@H]([C@H](C(=O)O)C)c1ccccc1)nc(cc2C)C,CBR-HVAC-10628: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Hypertension; Congestive heart failure
CBR-001-627-790-0,RFM-009-452-0,CBR-001-627-790-0,CC(=O)NC[C@H]1CN(C(=O)O1)c1cc(F)c(c(c1)F)c1ccc(cc1)C(=O)C,CBR-HVAC-11266: Antibacterial
CBR-001-627-791-1,RFM-009-453-1,CBR-001-627-791-1,CCNCC[C@@H](CNCCCCNC[C@H](CCNCC)O)O,CBR-HVAC-05303: Antimetabolites; Phase I scheduled by Sun BioPharma in AU and US for the treatment of pancreatic ductal adenocarcinoma
CBR-001-627-792-2,RFM-009-454-2,CBR-001-627-792-2,CCS(=O)(=O)c1ccc(cc1)/C=C(/c1ccc2c(c1)C(C)(C)CCC2(C)C)\C,CBR-HVAC-03833: Antipsoriatics;Acne Therapy
CBR-001-627-793-3,RFM-009-455-3,CBR-001-627-793-3,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C)[C@H](CC)C)CC(=O)N)CC(=O)N)CCCNC(=N)N)CC(=O)N)CCCNC(=N)N)N,CBR-HVAC-03359: Antiulcer; Antiulcer; Peptic ulcer
CBR-001-627-794-4,RFM-009-456-4,CBR-001-627-794-4,Clc1ccc(cc1)[C@@H](c1ccc2c(c1)n(C)nn2)n1ncnc1,CBR-HVAC-04162: Aromatase Inhibitor; Anticancer; Breast cancer
CBR-001-627-795-5,RFM-009-457-5,CBR-001-627-795-5,Clc1ccc(cc1)[C@H](c1ccc2c(c1)n(C)nn2)n1ncnc1,CBR-HVAC-04162: Aromatase Inhibitor; Anticancer; Breast cancer
CBR-001-627-796-6,RFM-009-458-6,CBR-001-627-796-6,OC(=O)CC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)O)CCCNC(=N)N)Cc1ccc(cc1)c1ccccc1)N,"CBR-HVAC-11649: ATP-binding cassette, sub-family G, member 1 Ligand; Antihyperlipidemic; Atherosclerosis"
CBR-001-627-797-7,RFM-009-459-7,CBR-001-627-797-7,COc1ccc(cc1)C[C@H](NCC(c1cc(O)cc(c1)O)O)C,CBR-HVAC-06626: beta2-Adrenoceptor Agonists;Signal Transduction Modulators
CBR-001-627-798-8,RFM-009-460-0,CBR-001-627-798-8,COc1ccc(cc1)C[C@H](NCC(c1cc(O)cc(c1)O)O)C,CBR-HVAC-06626: beta2-Adrenoceptor Agonists;Signal Transduction Modulators
CBR-001-627-799-9,RFM-009-461-1,CBR-001-627-799-9,O=C(CN1[C@H](CNC2(C1=O)CCCC2)c1cc(F)cc(c1)F)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2c1cccn2,CBR-HVAC-00126: Calcitonin Gene-Related Peptides (CGRP) Antagonists;Signal Transduction Modulators
CBR-001-627-800-5,RFM-009-462-2,CBR-001-627-800-5,O=C(CN1[C@@H](CNC2(C1=O)CCCC2)c1cc(F)cc(c1)F)Nc1ccc2c(c1)C[C@@]1(C2)C(=O)Nc2c1cccn2,CBR-HVAC-00126: Calcitonin Gene-Related Peptides (CGRP) Antagonists;Signal Transduction Modulators
CBR-001-627-801-6,RFM-009-463-3,CBR-001-627-801-6,Nc1nc(NC[C@@H]2CC[C@H](CC2)CNCCCNC2CCCCC2)nc(c1)N1CCN(CC1)CCP(=O)(O)O,CBR-HVAC-06521: Chemokine CXCR4 (SDF-1 Receptor) Antagonists;Signal Transduction Modulators
CBR-001-627-802-7,RFM-009-464-4,CBR-001-627-802-7,NC(=N)N1CCc2c(C1)cc(cc2)OCC1(CCN(CC1)c1ccncc1)C(=O)O,CBR-HVAC-11001: Coagulation factor Xa Inhibitor; Anticoagulant; Thrombosis
CBR-001-627-803-8,RFM-009-465-5,CBR-001-627-803-8,FC(CN1C[C@@H]([C@H](C1)C(=O)Nc1ccc(cn1)Cl)C(=O)Nc1ccc(cc1F)n1ccccc1=O)F,CBR-HVAC-06285: Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways
CBR-001-627-804-9,RFM-009-466-6,CBR-001-627-804-9,FC(CN1C[C@@H]([C@H](C1)C(=O)Nc1ccc(cn1)Cl)C(=O)Nc1ccc(cc1F)n1ccccc1=O)F,CBR-HVAC-06285: Coagulation Factor Xa Inhibitors;Inhibitors of Blood Coagulation Pathways
CBR-001-627-805-0,RFM-009-467-7,CBR-001-627-805-0,CCN(c1ccc(cc1Br)C(C)C)c1nc(cc(n1)C)N1CCC(=CC1)c1cccc(c1)F,CBR-HVAC-11603: CORTICOTROPIN RELEASING HORMONE RECEPTOR 1 Antagonist; Anxiolytic; Antidepressant; Anxiety; Depression
CBR-001-627-806-1,RFM-009-468-8,CBR-001-627-806-1,OC(=O)CNC(=O)Cc1ccc(n1C)C(=O)c1ccc(cc1)C,CBR-HVAC-08454: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-627-807-2,RFM-009-469-9,CBR-001-627-807-2,OCc1c(COC(=O)C(c2ccc(cc2)CC(C)C)C)cnc(c1O)C,CBR-HVAC-08209: Cyclooxygenase inhibitor; Prostaglandin synthase inhibitor; Platelet aggregation inhibitor
CBR-001-627-808-3,RFM-009-470-2,CBR-001-627-808-3,CCCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)CC(=O)N,CBR-HVAC-07264: Dermatologic Drugs
CBR-001-627-809-4,RFM-009-471-3,CBR-001-627-809-4,O=C(NC(=O)c1ccccc1[N+](=O)[O-])Nc1ccc(c(c1)Cl)Oc1ncc(cn1)Br,CBR-HVAC-03479: DNA polymerase alpha Inhibitor; Anticancer; Antiviral; Cancer; Viral infections
CBR-001-627-810-7,RFM-009-472-4,CBR-001-627-810-7,CC(=O)N(c1ccc(cc1)Nc1cc(C)nc2c1c1[nH]cnc1cc2)C,CBR-HVAC-00179: DNA synthesis inhibitor; Anticancer; Cancer
CBR-001-627-811-8,RFM-009-473-5,CBR-001-627-811-8,OCC1OC(C(=C)C1O)n1ccc(nc1=O)N,CBR-HVAC-02719: DNA synthesis inhibitor; Anticancer; Colorectal cancer; Lung cancer; Non-small cell lung cancer
CBR-001-627-812-9,RFM-009-474-6,CBR-001-627-812-9,COc1cc2c(cc1OC)CCN(C[C@@H]2c1ccccc1)C,CBR-HVAC-08464: Dopamine receptor D1 Antagonist; Antipsychotic; Psychosis
CBR-001-627-813-0,RFM-009-475-7,CBR-001-627-813-0,OC(=O)C1=C(c2ccc3c(c2)OCO3)c2ccccc2S(=O)(=O)N1c1cc2OCOc2cc1Cl,CBR-HVAC-11316: Endothelin A receptor Antagonist; Anticancer; Cerebral ischemia; Cerebral vasospasm; Congestive heart failure; Hypertension; Renal failure; Chronic obstructive pulmonary disease
CBR-001-627-814-1,RFM-009-476-8,CBR-001-627-814-1,C[C@@H]1CC[C@H](C2=C(CC[C@H]12)C)/C=C(/C(=O)O)\C,CBR-HVAC-14132: GABA(A) Receptor Agonists;Signal Transduction Modulators;5-HT1A Receptor Partial Agonists
CBR-001-627-815-2,RFM-009-477-9,CBR-001-627-815-2,OC[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)CCCNC(=N)N)CC(=O)O)NC(=O)[C@H](CC(=O)O)N,CBR-HVAC-12220: GABA-A receptor Modulator; Anti-inflammatory; Antiglaucoma; Immunosuppressant; Antiasthamatic; Asthma; Rhinitis; Conjunctivitis; Glaucoma
CBR-001-627-816-3,RFM-009-478-0,CBR-001-627-816-3,OC(=O)COC1CCN(CC1)C(=O)[C@@H](NC(=O)c1ccc(cc1)C(=N)N)Cc1ccc(cc1)O,CBR-HVAC-01167: Glycoprotein IIb/IIIa Inhibitor; Anticoagulant; Antithrombotic; ACUTE CORONARY SYNDROME
CBR-001-627-817-4,RFM-009-479-1,CBR-001-627-817-4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1[nH]c2c(n1)cc(cc2)c1csc2c1scc2c1ccc(cc1)c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@@H](c1ccccc1)NC(=O)OC)C(C)C,CBR-HVAC-07146: HCV NS5A Inhibitors
CBR-001-627-818-5,RFM-009-480-4,CBR-001-627-818-5,CCOC(=O)COc1ccc(c(c1Cl)Cl)C(=O)c1ccc(c(c1)CN)O,CBR-HVAC-00001: High-Ceiling Diuretic; High-Ceiling Diuretic; Diuresis
CBR-001-627-819-6,RFM-009-481-5,CBR-001-627-819-6,OCCSCC(=O)NCCCOc1cccc(c1)CN1CCCCC1,CBR-HVAC-04378: Histamine H2 receptor Antagonist; Antiulcer; Peptic ulcer
CBR-001-627-820-9,RFM-009-482-6,CBR-001-627-820-9,CN(Cc1ccc(o1)CSCCNC(=O)c1ccc[n+](c1)[O-])C,CBR-HVAC-02512: Histamine H2 receptor Antagonist; Antiulcer; Ulcer
CBR-001-627-821-0,RFM-009-483-7,CBR-001-627-821-0,CCN(C(=O)CCCC1CCNCC1)CC(=O)N[C@H](C(=O)N[C@@H](C(=O)N)CC1CCCCC1)CC(=O)O,CBR-HVAC-04784: Inhibitors of Blood Coagulation Pathways;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Signal Transduction Modulators
CBR-001-627-822-1,RFM-009-484-8,CBR-001-627-822-1,CCOC(=O)CC1COc2c(C1)cc(cc2)NC(=O)c1ccc(cc1)C(=N)N1CCOCC1,CBR-HVAC-11281: Integrin alpha2b beta3 Antagonist; Antiplatelet; Antithrombotic; Thrombosis
CBR-001-627-823-2,RFM-009-485-9,CBR-001-627-823-2,CCOC(=O)CC1COc2c(C1)cc(cc2)NC(=O)c1ccc(cc1)C(=N)N1CCOCC1,CBR-HVAC-11281: Integrin alpha2b beta3 Antagonist; Antiplatelet; Antithrombotic; Thrombosis
CBR-001-627-824-3,RFM-009-486-0,CBR-001-627-824-3,CCCc1c(OCCCOc2ccc(c(c2CCC)OC)C(=O)C)ccc2c1OC(CC2)C(=O)O,"CBR-HVAC-00295: Leukotriene B4 receptor Antagonist; Leukotriene B4 receptor antagonist; Carcinoma, renal; Metastatic melanoma; AIDS"
CBR-001-627-825-4,RFM-009-487-1,CBR-001-627-825-4,CCCCc1oc2c(c1C(=O)c1ccc(cc1)CCCN(CCCC)CCCC)cc(cc2)C(=O)OC(C)C,CBR-HVAC-05539: L-TYPE CACLIUM CHANNEL; POTASSIUM CHANNEL; SODIUM CHANNEL Blocker; Blocker; Antiarrhythmic; Atrial fibrillation; Cardiac arrhythmia
CBR-001-627-826-5,RFM-009-488-2,CBR-001-627-826-5,CCCc1ccc(c2c1oc(cc2=O)C(=O)O)OCC(O)C,"CBR-HVAC-00199: Mast cell stabiliser; ANTI-ULCER; Ulcer, duodenal"
CBR-001-627-827-6,RFM-009-489-3,CBR-001-627-827-6,ONC(=O)CN(C(=O)N1CCC[C@H]1C(=O)NCCC(C)C)CCC(C)C,"CBR-HVAC-09280: Matrix metalloproteinase 7; Peptide deformylase Inhibitor; Antibacterial; INFECTION, BACTERIAL"
CBR-001-627-828-7,RFM-009-490-6,CBR-001-627-828-7,CCCc1c(OCCCOc2ccc3c(c2)OC(CC3)C(=O)O)ccc(c1OC)C(=O)C,CBR-HVAC-14402: metabolite of CBR-HVAC-00295
CBR-001-627-829-8,RFM-009-491-7,CBR-001-627-829-8,CCOC(=O)CN(CC(=O)OCC)CC(=O)Nc1ccc(cc1C(=O)c1ccccc1)Cl,CBR-HVAC-14408: metabolite of CBR-HVAC-02540
CBR-001-627-830-1,RFM-009-492-8,CBR-001-627-830-1,CCOC(=O)CCC(c1ccc(cc1)OCc1ccc2c(n1)cccc2)(c1ccc(cc1)OCc1ccc2c(n1)cccc2)C,CBR-HVAC-14407: metabolite of CBR-HVAC-04911
CBR-001-627-831-2,RFM-009-493-9,CBR-001-627-831-2,CCCCN(Cc1ccc(c(c1)c1ccccc1C)C(=O)N[C@@H](C(=O)OC)CCSC)CCC1CCCCC1,CBR-HVAC-14414: metabolite of CBR-HVAC-05329-B
CBR-001-627-832-3,RFM-009-494-0,CBR-001-627-832-3,CCOC(=O)C[C@@]1(CCC)OCCc2c1[nH]c1c2c(C#N)ccc1C,CBR-HVAC-14404: metabolite of CBR-HVAC-06003
CBR-001-627-833-4,RFM-009-495-1,CBR-001-627-833-4,CCOC(=O)C[C@]1(CCC)OCCc2c1[nH]c1c2c(C#N)ccc1C,CBR-HVAC-14405: metabolite of CBR-HVAC-06003-B
CBR-001-627-834-5,RFM-009-496-2,CBR-001-627-834-5,Fc1ccc2c(c1)ccc(n2)CN[C@@H]1[C@@H]2[C@H]1CN(C2)c1ncc(cn1)C(=O)O,CBR-HVAC-14417: metabolite of CBR-HVAC-06558
CBR-001-627-835-6,RFM-009-497-3,CBR-001-627-835-6,COC(=O)C(CCCOc1ccc(c(c1)c1ccccc1)OCCCC(C(=O)OC)(C)C)(C)C,CBR-HVAC-14403: metabolite of CBR-HVAC-07636
CBR-001-627-836-7,RFM-009-498-4,CBR-001-627-836-7,OC(=O)C(c1ccccc1)(c1ccccc1)CCN1CCOCC1,CBR-HVAC-14409: metabolite of CBR-HVAC-09945
CBR-001-627-837-8,RFM-009-499-5,CBR-001-627-837-8,CCCCc1nc(OCc2ccc(cc2F)c2ccccc2c2nnn[nH]2)cc(c1)C(=O)O,CBR-HVAC-14401: metabolite of CBR-HVAC-10374
CBR-001-627-838-9,RFM-009-500-1,CBR-001-627-838-9,COc1c(N2CCC(=O)CC2)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-14415: metabolite of CBR-HVAC-10562
CBR-001-627-839-0,RFM-009-501-2,CBR-001-627-839-0,Fc1ccc(cc1)C(c1ccc(cc1)F)CCCN1CCN(CC1)c1ncccc1C(=O)O,CBR-HVAC-14411: metabolite of CBR-HVAC-10828
CBR-001-627-840-3,RFM-009-502-3,CBR-001-627-840-3,CCOC(=O)CN(Cc1ccccc1O)CCN(Cc1ccccc1O)CC(=O)OCC,CBR-HVAC-14412: metabolite of CBR-HVAC-11427
CBR-001-627-841-4,RFM-009-503-4,CBR-001-627-841-4,COCC1OC(=O)N(C1)c1ccc(cc1)OCc1cccc(c1)C#N,CBR-HVAC-07643: Monoamine oxidase A Inhibitor; Antidepressant; Depression
CBR-001-627-842-5,RFM-009-504-5,CBR-001-627-842-5,Clc1ccc(cc1)C1=CCCNC21CCCCC2,CBR-HVAC-11434: Monoamine transporter Inhibitor; Antidepressant; Anxiolytic; Antiobesity; Obesity
CBR-001-627-843-6,RFM-009-505-6,CBR-001-627-843-6,O=C1CCCN1CC#CCn1cncc1C,CBR-HVAC-10891: Muscarinic acetylcholine receptor M1 Agonist; Nootropic; Alzheimer's disease; Amnesia
CBR-001-627-844-7,RFM-009-506-7,CBR-001-627-844-7,O=C(N1CCN(C[C@H]1Cc1c[nH]c2c1cccc2)Cc1n[nH]nc1CN1CCOCC1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,CBR-HVAC-05676: NEUROKININ 1 RECEPTOR Antagonist; Neurokinin receptor 1 antagonist; Irritable bowel syndrome; Chemotherapy-induced emesis; Gastric motility disorder
CBR-001-627-845-8,RFM-009-507-8,CBR-001-627-845-8,OC(=O)C(c1ccc(cc1)C(=O)c1ccco1)C,CBR-HVAC-04265: Non-Steroidal Antiinflammatory Drugs (NSAIDs)
CBR-001-627-846-9,RFM-009-508-9,CBR-001-627-846-9,COC(=O)C(c1ccc(cc1)c1cscc1)C,CBR-HVAC-03577: Non-steroidal Anti-inflammatory; Non-Steroidal Antiinflammatory; Rheumatic diseases
CBR-001-627-847-0,RFM-009-509-0,CBR-001-627-847-0,CCC(=O)N(C1(CCN(CC1)CCn1nnn(c1=O)CC)c1ccccc1)c1ccccc1F,CBR-HVAC-03993: Opioid receptor mu Agonist; Analgesic; General anesthetic; Pain
CBR-001-627-848-1,RFM-009-510-3,CBR-001-627-848-1,OCC(n1cnc(c1c1ccnc(n1)Oc1ccccc1)c1ccc(cc1)F)CO,CBR-HVAC-11556: p38 Mitogen-activated protein kinase Inhibitor; Antiallergic; Anti-inflammatory; Antiasthmatic; Antirheumatic; Asthma; Inflammatory bowel disease; Rheumatoid arthritis; Vascular restenosis
CBR-001-627-849-2,RFM-009-511-4,CBR-001-627-849-2,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N)C)CCC(=O)N)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1,CBR-HVAC-04778: Pepsin release inhibitor; Antidiarrhoeal; Antiulcer; Diarrhea; Ulcer
CBR-001-627-850-5,RFM-009-512-5,CBR-001-627-850-5,O=C1Nc2c(C1(C)C)cc1c(c2)[nH]c(n1)c1ccncc1,CBR-HVAC-01019: Phosphodiesterase 3 Inhibitor; Cardiotonic; Heart disease
CBR-001-627-851-6,RFM-009-513-6,CBR-001-627-851-6,N#Cc1ccc(cc1)C(CN1CCC(=CC1)C1=NNC(=O)CC1)O,CBR-HVAC-11297: Phosphodiesterase 3 Inhibitor; Inotropic; Chronotropic; Congestive heart failure; Cardiac failure
CBR-001-627-852-7,RFM-009-514-7,CBR-001-627-852-7,CCOCCn1nc(c2c1c(Nc1nccc(c1)C)nc(n2)N(CC)C)C(=O)NS(=O)(=O)C,CBR-HVAC-06503: Phosphodiesterase type 5 Inhibitor; Antihypertensive; Hypertension
CBR-001-627-853-8,RFM-009-515-8,CBR-001-627-853-8,COCCN1CCC(CC1)N(C(=O)Cn1c(SCc2cccc(c2F)F)cc(=O)c2c1cccc2)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-00627: Phospholipase A2 Inhibitor; Antiarteriosclerotic; Atherosclerosis
CBR-001-627-854-9,RFM-009-516-9,CBR-001-627-854-9,[O-][N+](=O)c1ccc2c(c1)N(CC(O2)(C)C)c1cccc[n+]1[O-],CBR-HVAC-04194: Potassium channel Opener; Antiasthmatic; Antihypertensive; Antianginal; Vasolidator; Asthma; Hypertension; Urinary incontinence; Micturition disorder
CBR-001-627-855-0,RFM-009-517-0,CBR-001-627-855-0,O[C@@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)CNC[C@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)O,CBR-HVAC-12242: Protease Inhibitor; Anti-HIV; AIDS; HIV infection
CBR-001-627-856-1,RFM-009-518-1,CBR-001-627-856-1,O[C@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)CNC[C@@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)O,CBR-HVAC-12242: Protease Inhibitor; Anti-HIV; AIDS; HIV infection
CBR-001-627-857-2,RFM-009-519-2,CBR-001-627-857-2,CC(CN(S(=O)(=O)c1ccc(cc1)N)C[C@H]([C@H](Cc1ccccc1)NC(=O)[C@H](C(C)(C)C)NC(=O)CNCc1cccc(c1)F)O)C,CBR-HVAC-12246: Protease Inhibitor; Anti-HIV; HIV infection
CBR-001-627-858-3,RFM-009-520-5,CBR-001-627-858-3,OCC(=O)N1CCC(=CC1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C,CBR-HVAC-11259: Protein 50S ribosomal subunit Inhibitor; Antibacterial; Bacterial infection
CBR-001-627-859-4,RFM-009-521-6,CBR-001-627-859-4,O=C1CCC2(C(=O)N1)CCC(=O)c1c2cccc1,CBR-HVAC-09390: Sedative/Hypnotic
CBR-001-627-860-7,RFM-009-522-7,CBR-001-627-860-7,CC(NC(=O)Cn1c(nc2c(c1=O)cc(cc2)OCCCN1CCCCC1)c1cccc(c1)Cl)C,CBR-HVAC-06773: Signal Transduction Modulators;Vasopressin (AVP) V1b Receptor Antagonists
CBR-001-627-861-8,RFM-009-523-8,CBR-001-627-861-8,COc1cc2c(cc1OC)CCN1[C@@H]2C[C@@H](OC(=O)[C@H](C(C)C)N)[C@@H](C1)CC(C)C,"CBR-HVAC-00733: Solute carrier family 18 (vesicular monoamine transporter), member 2 Inhibitor; CNS modulator; Tardive dyskinesia"
CBR-001-627-862-9,RFM-009-524-9,CBR-001-627-862-9,CCN(CCOc1ccc(cc1)/C(=C(\c1ccc(cc1)Cl)/CC)/C#N)CC,CBR-HVAC-11655: Squalene synthase Inhibitor; Antihypercholesterolemic; Hypercholesterolemia
CBR-001-627-863-0,RFM-009-525-0,CBR-001-627-863-0,CC(NC(=O)N(C(=O)[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)CCC(=O)N2C)C(C)C)C,CBR-HVAC-04202: Steroid 5-alpha-reductase Inhibitor; Antitumor; Prostatic hypertrophy; Prostatic tumor
CBR-001-627-864-1,RFM-009-526-1,CBR-001-627-864-1,O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N(C)C)Cc1ccccc1)Cc1c[nH]c2c1cccc2)C)CNC(=O)C1CCCCC1,CBR-HVAC-11969: Tachykinin receptor 2 Antagonist; Anxiolytic; ANXIETY DISORDER
CBR-001-627-865-2,RFM-009-527-2,CBR-001-627-865-2,OC(=O)CCC(CCCc1cccnc1)CCCCNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-04128: Thromboxane A2 receptor Antagonist; Antihypertension; Antiplatelet; Hypertension; Ischemic heart diseases; Thromboembolic disorder
CBR-001-627-866-3,RFM-009-528-3,CBR-001-627-866-3,NC/C(=C/1\CCCN(C1)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1)/F,"CBR-HVAC-06835: TOPOISOMERASE IV Inhibitor; ANTIBIOTIC; Pneumonia, community-acquired"
CBR-001-627-867-4,RFM-009-529-4,CBR-001-627-867-4,OCCOCn1cc(Cc2ccccc2)c(=O)[nH]c1=O,CBR-HVAC-00234: URIDINE PHOSPHORYLASE Inhibitor; ANTI-CANCER; Cancer
CBR-001-627-868-5,RFM-009-530-7,CBR-001-627-868-5,COc1ccc(cc1Nc1nccc(n1)N(c1ccc2c(c1)[nH]nc2C)C)S(=O)(=O)CC,CBR-HVAC-11559: Vascular endothelial growth factor receptor Inhibitor; Anticancer; Cancer
CBR-001-627-869-6,RFM-009-531-8,CBR-001-627-869-6,CNc1ccc(cc1)N1CCN(CC1)C(=O)[C@]1(C)CCc2c(O1)c(C)c(c(c2C)O)C,CBR-HVAC-14423:
CBR-001-627-870-9,RFM-009-532-9,CBR-001-627-870-9,COC(=O)c1ccc(c(c1)Cl)NC(=O)CSc1nnc(n1c1ccc(c2c1cccc2)C1CC1)Br,CBR-HVAC-14420:
CBR-001-627-871-0,RFM-009-533-0,CBR-001-627-871-0,O=C1CCCN1CC#CCn1cnc(c1)C,CBR-HVAC-14421:
CBR-001-627-872-1,RFM-009-534-1,CBR-001-627-872-1,CCCN(C(=O)C(NC(=O)c1ccc(cc1)Cl)Cc1ccc(cc1)OCCCN1CCN(CC1)C)CCC,CBR-HVAC-07681:
CBR-001-632-950-3,RFM-009-535-2,CBR-001-632-950-3,Clc1cc(ccc1Cl)[C@@H]1CNCc2c1ccc(c2)c1ccc2n(c1)ncn2,CBR-HVAC-06947: Dopamine Reuptake Inhibitors;Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors
CBR-001-632-951-4,RFM-009-536-3,CBR-001-632-951-4,CC[C@H]1C(=O)Nc2c(N1C(=O)OC(C)C)cc(cc2)F,CBR-HVAC-05123: Reverse Transcriptase Inhibitors
CBR-001-632-952-5,RFM-009-537-4,CBR-001-632-952-5,O=C(c1cnc(c(n1)OCC1CC1)N1CC(C1)(F)F)N[C@H](C(=O)N)CC1CC1,CBR-HVAC-12219: Cannabinoid CB2 Agonists;Signal Transduction Modulators
CBR-001-632-953-6,RFM-009-538-5,CBR-001-632-953-6,N#Cc1cc(cc(c1)Cl)Oc1cc(ccc1Cl)OCc1n[nH]c2c1ccc(n2)N,CBR-HVAC-06681: Reverse Transcriptase Inhibitors
CBR-001-632-954-7,RFM-009-539-6,CBR-001-632-954-7,NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N,CBR-HVAC-12221: Anti-HIV Agents
CBR-001-632-955-8,RFM-009-540-9,CBR-001-632-955-8,[O-][n+]1cccc(c1)C#Cc1cccc(c1)n1cc(C(=O)NC2CC2)c(=O)c2c1nccc2,CBR-HVAC-06343: Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators
CBR-001-632-973-0,RFM-009-541-0,CBR-001-632-973-0,OC(=O)COc1cccc2c1CCC=C2CCON=C(c1cccnc1)c1ccccc1,CBR-HVAC-04675: Prostacyclin Analogs;Prostanoid IP Agonists;Signal Transduction Modulators;Thromboxane Synthase Inhibitors
CBR-001-632-974-1,RFM-009-542-1,CBR-001-632-974-1,COC[C@H]1C[C@H](N(C1)C(=O)[C@@H](c1ccccc1)NC(=O)OC)c1ncc(n1)c1ccc2c(c1)COc1c2cc2ccc3c(c2c1)nc(n3)[C@@H]1CC[C@@H](N1C(=O)[C@H](C(C)C)NC(=O)OC)C,CBR-HVAC-14383: HCV NS5A Inhibitors
CBR-001-633-140-1,RFM-009-543-2,CBR-001-633-140-1,CCOC(=O)CNC(=O)CCCCSc1ncnc2c1ncn2,CBR-HVAC-07578: Hypoxanthine phosphoribosyltransferase inhibitor
CBR-001-633-141-2,RFM-009-544-3,CBR-001-633-141-2,Clc1ccc(cc1)N1N=C2[C@H](CC1=O)CS(=O)c1c2cccc1,CBR-HVAC-03721: GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators
CBR-001-633-142-3,RFM-009-545-4,CBR-001-633-142-3,Clc1ccc(cc1)N1N=C2[C@H](CC1=O)CS(=O)c1c2cccc1,CBR-HVAC-03721: GABA(A) BZ Site Receptor Agonists;Signal Transduction Modulators
CBR-001-633-143-4,RFM-009-546-5,CBR-001-633-143-4,Clc1ccc(cc1)c1ccc(cc1)S(=O)(=O)C[C@@](C(=O)[O-])(CSc1ccccc1)O,CBR-HVAC-05536: Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-2 (Gelatinase A) Inhibitors
CBR-001-633-144-5,RFM-009-547-6,CBR-001-633-144-5,Clc1ccc(cc1)c1ccc(cc1)S(=O)(=O)C[C@@](C(=O)[O-])(CSc1ccccc1)O,CBR-HVAC-05536: Angiogenesis Inhibitors;MMP-13 (Collagenase 3) Inhibitors;MMP-2 (Gelatinase A) Inhibitors
CBR-001-633-145-6,RFM-009-548-7,CBR-001-633-145-6,OC(=O)COc1cccc(c1)/C=C/Cn1cccc1C(=O)c1ccc(cc1)C,CBR-HVAC-13836: PPAR Modulators;PPARalpha Ligands;PPARgamma Ligands;Signal Transduction Modulators
CBR-001-633-146-7,RFM-009-549-8,CBR-001-633-146-7,Brc1c(N)nc(nc1N1CCCC1)n1cccn1,CBR-HVAC-13762: Adenosine A2A Antagonists;Signal Transduction Modulators
CBR-001-633-147-8,RFM-009-550-1,CBR-001-633-147-8,CN(C(=O)[C@H](c1ccccc1)NC(=O)c1cc2c(n1C)ccc(c2)NC(=O)c1ccccc1c1ccc(cc1)C(F)(F)F)Cc1ccccc1,CBR-HVAC-14088: Antiobesity Drugs
CBR-001-633-148-9,RFM-009-551-2,CBR-001-633-148-9,O=C1CCCN1CCCCN1CCN(CC1)c1nccc(c1)C(F)(F)F,CBR-HVAC-04300: Signal Transduction Modulators;5-HT1A Receptor Agonists
CBR-001-633-149-0,RFM-009-552-3,CBR-001-633-149-0,CCC[N+]1(C)C2CCC1CC(C2)OC1c2ccccc2SCc2c1cccc2,CBR-HVAC-08444: Acetylcholine receptor antagonist; Histamine receptor antagonist
CBR-001-633-150-3,RFM-009-553-4,CBR-001-633-150-3,COCCNCCc1cccc(c1)Nc1ncc2c(n1)c1ccccc1[C@@H](C2)c1ccccc1F,CBR-HVAC-13969: Therapy Angiogenesis Inhibitors;FGFR Inhibitors;Signal Transduction Modulators
CBR-001-633-151-4,RFM-009-554-5,CBR-001-633-151-4,COCCNCCc1cccc(c1)Nc1ncc2c(n1)c1ccccc1[C@H](C2)c1ccccc1F,CBR-HVAC-13969: Therapy Angiogenesis Inhibitors;FGFR Inhibitors;Signal Transduction Modulators
CBR-001-633-152-5,RFM-009-555-6,CBR-001-633-152-5,Cc1nc2cccc(c2c(=O)n1c1ccc(cc1)OCCCN1CCCC1)C(F)(F)F,CBR-HVAC-12897: Histamine H3 Receptor Inverse Agonists;Signal Transduction Modulators
CBR-001-633-153-6,RFM-009-556-7,CBR-001-633-153-6,OC(=O)Cn1c(C)c(c2c1ccc(c2)F)Cc1cccnc1S(=O)(=O)c1ccc(cc1)F,CBR-HVAC-13951: Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists;Signal Transduction Modulators
CBR-001-633-154-7,RFM-009-557-8,CBR-001-633-154-7,CCCCCCN(C(=O)COc1ccc(cc1)CC(C(=O)O)OCC)CCc1ccccc1,CBR-HVAC-05953: Insulin Sensitizers;PPARalpha Agonists;PPARgamma Partial Agonists;Signal Transduction Modulators
CBR-001-633-155-8,RFM-009-558-9,CBR-001-633-155-8,n1ccc(cc1)c1nc2c(n1)cc(cc2)c1ccc2c(c1)nc(n2)c1ccncc1,CBR-HVAC-07005: Antibiotics
CBR-001-633-156-9,RFM-009-559-0,CBR-001-633-156-9,OCC1OC(CC1O)n1cc(F)c(=O)n(c1=O)C(=O)c1cccc(c1)C,CBR-HVAC-07821: Thymidylate synthase inhibitor; RNA synthesis inhibitor
CBR-001-633-157-0,RFM-009-560-3,CBR-001-633-157-0,CCSCC(=O)C12OC(O[C@@H]1C[C@@H]1C2(C)C[C@H](O)[C@]2([C@H]1C[C@@H](C1=CC(=O)C=CC21C)F)F)(C)C,CBR-HVAC-03909: Antiinflammatory Drugs
CBR-001-633-158-1,RFM-009-561-4,CBR-001-633-158-1,Clc1ccc2c(c1)C(=NCc1c2ncnc1)c1ccccc1Cl,CBR-HVAC-08178: GABA receptor agonist; Chloride channel agonist; Potassium channel agonist
CBR-001-633-159-2,RFM-009-562-5,CBR-001-633-159-2,CNCC/C=C/1\c2ccccc2CC(c2c1cccc2)O,CBR-HVAC-08183: Adrenergic transmitter uptake inhibitor
CBR-001-633-160-5,RFM-009-563-6,CBR-001-633-160-5,COc1nccnc1NS(=O)(=O)c1cccc(c1Cl)Cl,CBR-HVAC-06024: Chemokine CCR4 Antagonists;Signal Transduction Modulators
CBR-001-633-161-6,RFM-009-564-7,CBR-001-633-161-6,COc1nc2nc(cn2c2c1CCCC2)C(=O)c1ccccc1,CBR-HVAC-03691: GABA(A) BZ Site Receptor Partial Agonists;Signal Transduction Modulators
CBR-001-633-162-7,RFM-009-565-8,CBR-001-633-162-7,CCCCOc1cc(N)c(cc1C(=O)NC1CCN(CC1)CC1OCCO1)Cl,CBR-HVAC-07752:
CBR-001-633-163-8,RFM-009-566-9,CBR-001-633-163-8,CCOc1c2C(OC(=O)c2c(c(c1OCC)OCC)N)C1N(C)CCc2c1c(OC)c1c(c2)OCO1,CBR-HVAC-03264: Antiallergy/Antiasthmatic Drugs
CBR-001-633-164-9,RFM-009-567-0,CBR-001-633-164-9,O=C(c1ccc(cc1)/C=C/c1cnc2c(c1)cccc2)Nc1cc(n(c1)C)C(=O)Nc1cc(n(c1)C)C(=O)NCCN1CCOCC1,CBR-HVAC-06726: DNA-Intercalating Drugs
CBR-001-633-165-0,RFM-009-568-1,CBR-001-633-165-0,O=C(c1cc2c(o1)cccc2)N[C@H]1C2CCN([C@@H]1Cc1cccnc1)CC2,CBR-HVAC-06871: Nicotinic alpha7 Agonists;Signal Transduction Modulators
CBR-001-633-166-1,RFM-009-569-2,CBR-001-633-166-1,O=C(c1cc2c(o1)cccc2)N[C@H]1C2CCN([C@@H]1Cc1cccnc1)CC2,CBR-HVAC-06871: Nicotinic alpha7 Agonists;Signal Transduction Modulators
CBR-001-633-167-2,RFM-009-570-5,CBR-001-633-167-2,CN1C[C@@H]2[C@](C1)([C@H]1C[C@@H]2CC1)c1ccc(c(c1)Cl)Cl,CBR-HVAC-07652:
CBR-001-633-168-3,RFM-009-571-6,CBR-001-633-168-3,O=C(N1CC(=O)N2C(C1)c1ccccc1CCC2)C1CCCCC1,CBR-HVAC-03240: Treatment of Helminthic Diseases
CBR-001-633-169-4,RFM-009-572-7,CBR-001-633-169-4,O=C(Nc1c(Cl)cccc1Cl)CN1CCN(C(C1)C(=O)N)CCCC(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-08049: Calcium channel antagonist
CBR-001-633-170-7,RFM-009-573-8,CBR-001-633-170-7,CCC(c1ccccc1)NC(=O)c1c2ccccc2nc(c1N(S(=O)(=O)C)C)c1ccccc1,CBR-HVAC-13973: Signal Transduction Modulators;Tachykinin NK3 Antagonists
CBR-001-633-171-8,RFM-009-574-9,CBR-001-633-171-8,OC(=O)CCCNC(=N)c1ccc(cc1)C(=O)/N=c\1/sc(c(n1C)C)C(=O)NCCC(=O)O,CBR-HVAC-11473: Inhibitors of Blood Coagulation Pathways;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Signal Transduction Modulators
CBR-001-633-172-9,RFM-009-575-0,CBR-001-633-172-9,Clc1ccc(cc1)Cn1cc(c2c1cccc2)C(=O)C(=O)Nc1ccc2c(c1)cccn2,CBR-HVAC-05894: Therapy;Oncolytic Drugs Angiogenesis Inhibitors;Antimitotic Drugs;DNA Topoisomerase II Inhibitors;Tubulin Polymerization Inhibitors
CBR-001-633-173-0,RFM-009-576-1,CBR-001-633-173-0,COc1ccc(cc1)c1sc(nc1c1ccc(cc1)OC)c1cccn1CC(=O)O,CBR-HVAC-13690: metabolite of CBR-HVAC-11068
CBR-001-633-174-1,RFM-009-577-2,CBR-001-633-174-1,O=C(c1cc(Oc2ccccc2)c2n(c1=O)cccc2)Nc1n[nH]nn1,CBR-HVAC-04045: Mediator Release Inhibitors
CBR-001-633-175-2,RFM-009-578-3,CBR-001-633-175-2,CNC(=O)CCN1CCN(CC1)CC/C=C\1/c2ccccc2Sc2c1cc(Cl)cc2,CBR-HVAC-08976: ; Antipsychotic; Psychosis
CBR-001-633-176-3,RFM-009-579-4,CBR-001-633-176-3,O=C(Nc1ccc(cc1)[As](O)O)CSC([C@H](C(=O)O)N)(C)C,CBR-HVAC-06625: Anticancer; Anticancer; CANCER
CBR-001-633-177-4,RFM-009-580-7,CBR-001-633-177-4,CCOC(=O)[C@]1(CC[C@@H]2C1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=CC12C)OC(=O)C(Cl)Cl,CBR-HVAC-00430: Corticosteroid agonist; Anti-inflammatory; Antiallergy; Antiasthmatic; Allergic rhinitis; Ulcerative colitis; Ocular inflammation; Crohn's disease
CBR-001-633-178-5,RFM-009-581-8,CBR-001-633-178-5,Fc1ccc(cc1)Oc1ccc(s1)NS(=O)(=O)C,CBR-HVAC-11158: Lipoxygenase 5; COX Inhibitor; Antiinflammatory; Antiarthritic; Inflammation; Arthritis
CBR-001-633-179-6,RFM-009-582-9,CBR-001-633-179-6,COc1cc(/C=C/C(=O)OCCCCO[N+](=O)[O-])ccc1OC(=O)CC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2[C@@H](O)C[C@H]2[C@]1(C)CC[C@H](C2)O)C,CBR-HVAC-05356: Caspase Inhibitor; Nitric oxide donor; Caspase Inhibitor; Hepatitis C; Liver diseases; Portal hypertension
CBR-001-633-180-9,RFM-009-583-0,CBR-001-633-180-9,CCOc1ccc(cc1)c1cc(cn1c1ccc(cc1)S(=O)(=O)N)C,CBR-HVAC-00568: COX-2 Inhibitor; Anticancer; Analgesic; Anti-inflammatory; Inflammation; Pain; Cancer; Colorectal tumor
CBR-001-633-181-0,RFM-009-584-1,CBR-001-633-181-0,Cc1nc(NCCCCCCc2ccccc2)nc(c1O)C,CBR-HVAC-02534: 15-Lipoxygenase Inhibitor; Antipsoriatic; Psoriasis; Inflammation
CBR-001-633-182-1,RFM-009-585-2,CBR-001-633-182-1,COc1cc(ccc1OC)c1c/c(=N\c2c(C)cc(cc2C)C)/n(c(=O)n1CC)C,CBR-HVAC-03242: ; CARDIOTONIC; Heart failure
CBR-001-633-183-2,RFM-009-586-3,CBR-001-633-183-2,COc1c2c(CN(C2=O)CCC2CCN(CC2)Cc2ccccc2)nc2c1cccc2,CBR-HVAC-00193: 5-HYDROXYTRYPTAMINE 3 RECEPTOR; ACETYLCHOLINESTERASE Inhibitor; Neuroprotectant; Alzheimer's disease
CBR-001-633-184-3,RFM-009-587-4,CBR-001-633-184-3,C=C[C@]1(C)C[C@@H](OC(=O)CS[C@H]2CCCN(C2)C(=O)[C@@H](C(C)C)N)C2(C)[C@H](C)CC[C@]3([C@H]([C@@H]1O)C)[C@H]2C(=O)CC3,CBR-HVAC-05704: Protein synthesis inhibitor; Antibacterial; Antibiotic; Bacterial respiratory tract infection; Bacterial infection
CBR-001-633-185-4,RFM-009-588-5,CBR-001-633-185-4,CN1CCCC(C1)C(=O)n1c2ccccc2[nH]c(=O)c2c1nccc2,CBR-HVAC-02686: Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1 Antagonist; Antiasthmatic; Antispasmodic; Asthma
CBR-001-633-186-5,RFM-009-589-6,CBR-001-633-186-5,Oc1ccc(cc1)N1CCN(CC1)c1ccc(cc1)n1c(C)nn(c1=O)CC(=O)c1ccc(cc1)Cl,CBR-HVAC-10825: Lipoxygenase 5 Inhibitor; Antiallergic; Antiasthmaitc; Asthma; Psoriasis
CBR-001-633-187-6,RFM-009-590-9,CBR-001-633-187-6,COc1c(OC)cc2c(c1c1ccc(cc1)F)c(N)cc(n2)N1CCCN(CC1)C(=O)N1CCOCC1,CBR-HVAC-05661: Alpha-1 adrenergic receptor Antagonist; Alpha-1 adrenergic receptor antagonist; Benign prostate hyperplasia
CBR-001-633-188-7,RFM-009-591-0,CBR-001-633-188-7,N[C@H]1C[C@@H]2CC[C@@H]3[C@@H](C2(C[C@@H]1O)C)CCC1([C@H]3CCC1=O)C,CBR-HVAC-01200: ; Antiarrhythmic; Arrhythmia
CBR-001-633-189-8,RFM-009-592-1,CBR-001-633-189-8,CN1Cc2c(ncn2c2c(C1=O)c(I)ccc2)C(=O)OCC,CBR-HVAC-04066: Benzodiazepine receptor inverse agonist; IMAGING AGENT;
CBR-001-633-190-1,RFM-009-593-2,CBR-001-633-190-1,O[C@@H](CN1CCC(CC1)c1ccc(c(c1)Cl)Cl)COc1cccc2c1cc(o2)c1nnc(o1)C,CBR-HVAC-05469: 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine transporter Antagonist; Inhibitor; Antidepressant; Major depressive disorder
CBR-001-633-191-2,RFM-009-594-3,CBR-001-633-191-2,CC[C@H](C(=O)O)Cc1ccc(c(c1)C(=O)NCc1ccc(cc1)Oc1ccc(cc1)F)OC,CBR-HVAC-05470: Peroxisome proliferator-activated receptor alpha agonist; Antihyperlipidemic; Hyperlipidemia
CBR-001-633-192-3,RFM-009-595-4,CBR-001-633-192-3,O=C(C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCC1CCCCO1)C)OCCN1C(=O)c2c(S1(=O)=O)cccc2,CBR-HVAC-11346: Calcium channel Agonist; Anticonvulsant; Antihypertensive; Hypertension
CBR-001-633-193-4,RFM-009-596-5,CBR-001-633-193-4,Clc1ccc2c(c1)c(CCOc1ccc(cc1)C(=O)O)c(n2C(c1ccccc1)c1ccccc1)CCNS(=O)(=O)Cc1ccc(c(c1)Cl)Cl,CBR-HVAC-00195: Cytosolic phospholipase A2 alpha Inhibitor; Anti-inflammatory; Antiarthritic; Anti-asthmatic; Inflammation; Osteoarthritis; Asthma; Rheumatoid arthritis; Pain
CBR-001-633-194-5,RFM-009-597-6,CBR-001-633-194-5,COC(=O)c1c2C3CN(C)CCN3c3c(Cn2c2c1cccc2)cccc3,CBR-HVAC-04053: 5-Hydroxytryptamine 2 receptor Antagonist; Anxiolytic; Anxiety
CBR-001-633-195-6,RFM-009-598-7,CBR-001-633-195-6,CC[C@@H]1C(=O)SC[C@@H]1Cc1cncn1C,CBR-HVAC-04105: Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2 Agonist; Antagonist; Nootropic; Cognitive disorder
CBR-001-633-196-7,RFM-009-599-8,CBR-001-633-196-7,CC[C@@H]1C(=O)SC[C@@H]1Cc1cncn1C,CBR-HVAC-04105: Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M2 Agonist; Antagonist; Nootropic; Cognitive disorder
CBR-001-633-197-8,RFM-009-600-4,CBR-001-633-197-8,COc1cc(CCc2ccc(cc2)c2cc3ccccc3c3=NCCn23)cc(c1OC)OC,CBR-HVAC-11092: Platelet activating factor Antagonist; Antiasthmatic; Asthma
CBR-001-633-198-9,RFM-009-601-5,CBR-001-633-198-9,CCCC(=O)c1cnc2c(c1Nc1ccccc1C)cccc2OC,CBR-HVAC-03715: Cholecystokinin B receptor; H+/K+ ATPase Antagonist; Inhibitor; Antiulcer; Peptic ulcer
CBR-001-633-199-0,RFM-009-602-6,CBR-001-633-199-0,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2N[C@@H]1CCC[C@H]1O)CSc1ccccc1F,CBR-HVAC-05733: Adenosine A1 receptor Agonist; Hypoglycemic; Antiarrhythmic; Antihyperlipidemic; Heart arrhythmia; Non-insulin dependent diabetes
CBR-001-633-200-6,RFM-009-603-7,CBR-001-633-200-6,Clc1ccc(cc1)c1cnc2c(c1)C[C@@]1(C34[C@H]2Oc2c4c(CC1N(CC3)CC1CC1)ccc2O)O,CBR-HVAC-09312: Opioid receptor delta Antagonist; Analgesic; Alcoholism; Pain
CBR-001-633-201-7,RFM-009-604-8,CBR-001-633-201-7,O=C(C(CNC(=O)c1ccccc1)C)OCC(=O)C12OC(O[C@@H]1C[C@@H]1C2(C)C[C@H](O)[C@]2([C@H]1CCC1=CC(=O)C=CC21C)F)(C)C,CBR-HVAC-02810: ; ANTI-INFLAMMATORY; SKIN DISORDERS
CBR-001-633-202-8,RFM-009-605-9,CBR-001-633-202-8,CCCCCCCCCCCCC(c1cccc(c1)OC)(CCCN(CCc1cccc(c1)OC)C)C#N,CBR-HVAC-02891: Calcium channel Blocker; Antihypertensive; Arrhythmia; Atherosclerosis; Hyperlipidemia; Hypertension; Ischemic heart diseases
CBR-001-633-203-9,RFM-009-606-0,CBR-001-633-203-9,COc1ccc2c(c1)c(CC(=O)Oc1ccc(cc1)NC(=O)C)c(n2C(=O)c1ccc(cc1)Cl)C,CBR-HVAC-03426: Anti-inflammatory; Antirheumatic; Analgesic; Antipyretic; Antiinflammatory; Antirheumatic; Analgesic; Antipyretic; Spondylitis; Osteoarthritis; Rheumatoid arthritis
CBR-001-633-204-0,RFM-009-607-1,CBR-001-633-204-0,OCCNCc1nn2c3c1ccc(c3c(=O)c1c2c(O)ccc1O)NCCCN,CBR-HVAC-04573: DNA topoisomerase II Inhibitor; Anticancer; Cancer
CBR-001-633-205-1,RFM-009-608-2,CBR-001-633-205-1,CCCCC1C(=O)NC(=O)N(C1=O)C1CCCCC1,CBR-HVAC-06218: ; Anti-inflammatory; Chronic articular rheumatism; Hyperbilirubinaemia
CBR-001-633-206-2,RFM-009-609-3,CBR-001-633-206-2,CC(=O)NCC1OC(=O)N(C1)c1ccc(c(c1)F)N1CCCCC1,"CBR-HVAC-09315: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-633-207-3,RFM-009-610-6,CBR-001-633-207-3,CCC(=O)c1ccc2c(c1)N(CC(N(C)C)C)c1c(S2)cccc1,CBR-HVAC-09647: Mechanism of action is unknown. Propiomazine is a phenothiazine compound with sedative action.; Sedative; Hypnotic; Tranquilizer; Sleepiness; Drowsiness; Anxiety; Drowsiness; Anxiety
CBR-001-633-208-4,RFM-009-611-7,CBR-001-633-208-4,O=C1CCC2(C(=C1)CC[C@@H]1[C@@H]2CCC2([C@H]1CC[C@@H]2O[Si](C)(C)C)C)C,CBR-HVAC-10095: ; Anabolic steroid;
CBR-001-633-209-5,RFM-009-612-8,CBR-001-633-209-5,OC(=O)CCSC(c1ccccc1CCCCCCCCc1ccccc1)SCCC(=O)O,CBR-HVAC-10806: Leukotriene receptor Antagonist; Antiasthmatic; Asthma
CBR-001-633-210-8,RFM-009-613-9,CBR-001-633-210-8,COc1ccc(cc1)[Si](COc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)(C)C,CBR-HVAC-11772: VASCULAR CELL ADHESION MOLECULE 1 Inhibitor; Antiarteriosclerotic; Atherosclerosis; Restenosis
CBR-001-633-211-9,RFM-009-614-0,CBR-001-633-211-9,CCN(CC#CC(OC(=O)C(c1ccccc1)(C1CCCCC1)O)(C)C)CC,CBR-HVAC-12795: Muscarinic M3 receptor; Muscarinic M2 receptor Antagonist; Antagonist; Calcium channel antagonist; Muscarinic acetylcholine receptor antagonist; Pollakiuria; Urinary incontinence
CBR-001-633-212-0,RFM-009-615-1,CBR-001-633-212-0,C=CCC1(CC(C)C)C(=O)NC(=S)NC1=O,CBR-HVAC-13300: ; Anesthetic; Anesthesia; Hypnotic
CBR-001-633-213-1,RFM-009-616-2,CBR-001-633-213-1,CCCCCCCCOc1c(O)c2ccc(cc2n(c1=O)C)NC(=O)/C=C/c1cc(OC)c(c(c1)OC)O,"CBR-HVAC-00270: Lipoxygenase 5 Inhibitor; Anti-inflammatory; Antiasthmatic; Antiallergic; Rhinitis, allergic; Asthma"
CBR-001-633-214-2,RFM-009-617-3,CBR-001-633-214-2,CCCCCCCCCCCCCCOc1ccc(o1)C(=O)C,"CBR-HVAC-08022: ; ANTI-VIRAL; Infection, rhinovirus"
CBR-001-633-215-3,RFM-009-618-4,CBR-001-633-215-3,CN[C@@H](C(=O)N1CCC[C@H]1C(=O)NC[C@@H]1CC[C@H](CC1)N)Cc1ccccc1,CBR-HVAC-11214: Thrombin Inhibitor; Antithrombotic; Thrombosis; Myocardial infarction
CBR-001-633-216-4,RFM-009-619-5,CBR-001-633-216-4,OC(=O)Cc1ccc2c(c1)SCc1c(C2=O)cccc1,"CBR-HVAC-05164: ; Analgesic; Anti-inflammatory; Antipyretic; Pain; Inflammation; Arthritis, rheumatoid"
CBR-001-633-217-5,RFM-009-620-8,CBR-001-633-217-5,CC(=O)N1CCN(CC1)CCN1[C@@H]2CC[C@H]1C[C@H](C2)NC(=O)c1nn(c2c1cccc2)C(C)C,"CBR-HVAC-06277: 5-HYDROXYTRYPTAMINE 4 RECEPTOR Agonist; 5-hydroxytryptamine 4 receptor agonist; Constipation, chronic"
CBR-001-633-218-6,RFM-009-621-9,CBR-001-633-218-6,OC(COc1ccc(cc1)OCCOCC1CC1)CNC(C)C,CBR-HVAC-03046: Beta adrenergic receptor Antagonist; Partial Agonist; Beta adrenergic receptor modulator; Heart failure; Hypertension; Ischemic heart diseases
CBR-001-633-219-7,RFM-009-622-0,CBR-001-633-219-7,Clc1sc2c(c1)S(=O)(=O)N(C(=C2O)C(=O)Nc1ccccn1)C,"CBR-HVAC-01772: Prostaglandin G/H synthase; Inducible nitric oxide synthase Inhibitor; Anti-inflammatory; Pain post-operative; Arthritis, rheumatoid"
CBR-001-633-220-0,RFM-009-623-1,CBR-001-633-220-0,O[C@@H](CN1CCC(CC1)N(c1nc2c(s1)cccc2)C)COc1ccc(c(c1)F)F,CBR-HVAC-04587: Ionotropic glutamate receptor NMDA Antagonist; Neuroprotectant; Cerebrovascular ischemia; Head injury; Neuropathy; Neuroprotection; Stroke
CBR-001-633-221-1,RFM-009-624-2,CBR-001-633-221-1,COC(=O)C1C2CC(c3cc4nc5c(c4cc3OC)CCN3C4C5(CC(CC4CC)C3)C(=O)OC)c3c(CC1N(C/C/2=C/C)C)c1ccccc1n3,CBR-HVAC-05659: ; Antimalarial; Malaria
CBR-001-633-222-2,RFM-009-625-3,CBR-001-633-222-2,C1=CCC2(CC1)COC(OC2)c1ccco1,"CBR-HVAC-09442: Trypsin Inhibitor; Tocolytic; Circulatory Disorder; Pancreatitis, Acute; Shock"
CBR-001-633-223-3,RFM-009-626-4,CBR-001-633-223-3,CCN(C1CCCCC1)C/C=C\c1ccc(c(c1)Cl)C1CCCCC1,CBR-HVAC-12984: Opioid receptor sigma Antagonist; Immunosuppressant; Anticancer; Immune diseases; Prostate cancer; Psoriasis; Rheumatoid arthritis; Autoimmune disorderss; Breast cancer; Cancer; Multiple myeloma
CBR-001-633-224-4,RFM-009-627-5,CBR-001-633-224-4,Fc1ccc(cc1)C(CCCN1CCc2c(C1)c1cc(F)ccc1n2c1ccc(cc1)F)O,CBR-HVAC-09222: Dopamine receptor Inhibitor; Antipsychotic; Psychosis
CBR-001-633-225-5,RFM-009-628-6,CBR-001-633-225-5,OC(=O)CCCc1ccc(cc1)C(NS(=O)(=O)c1ccc(cc1)F)CCCC(C(F)(F)F)(F)F,CBR-HVAC-11132: Thromboxane A2 receptor; Leukotriene D4 receptor Antagonist; Antiinflammatory; Asthma
CBR-001-633-226-6,RFM-009-629-7,CBR-001-633-226-6,Nc1ncccc1c1onc(c1)Cc1ccc(cc1)COc1ccccn1,CBR-HVAC-14160: ; ANTIFUNGAL; ASPERGILLOSIS; CANDIDIASIS
CBR-001-633-227-7,RFM-009-630-0,CBR-001-633-227-7,COC(=O)C[C@@H]1N(CCN(C1=O)CC(=O)O)C(=O)CNC(=O)c1ccc(cc1)C(=N)N,CBR-HVAC-04673: GLYCOPROTEIN IIB/IIIA RECEPTOR Antagonist; ANTI-THROMBOTIC; Arterial thrombosis
CBR-001-633-228-8,RFM-009-631-1,CBR-001-633-228-8,C1CN=C(N1)Nc1cccc2c1CCC2,CBR-HVAC-02091: Alpha adrenergic receptor Agonist; Antiallergic; Vasoconstrictor; Allergic rhinitis
CBR-001-633-229-9,RFM-009-632-2,CBR-001-633-229-9,OC(=O)C[C@@H]([C@H]1CNc2c(C1)cccc2)CC1CCN(CC1)C(=O)CCc1ccc2c(n1)NCCC2,CBR-HVAC-11970: INTEGRIN ALPHAV BETA5; INTEGRIN ALPHAV BETA3 Inhibitor; Integrin alpha-V/beta-3 inhibitor; Integrin alpha-V/beta-5 inhibitor; Angiogenesis inhibitor; RETINOPATHY
CBR-001-633-230-2,RFM-009-633-3,CBR-001-633-230-2,CN1CCc2ccccc2Oc2c(CC1)cccc2,CBR-HVAC-11567: Dopamine receptor D1; Dopamine receptor D2 Antagonist; Antipsychotic; Psychotic disorder; Schizophrenia
CBR-001-633-231-3,RFM-009-634-4,CBR-001-633-231-3,O=C(C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)N(c1cnc(cc1c1ccccc1C)N1CCOCC1)C,CBR-HVAC-00581: NK1 receptor Antagonist; Antidepressant; ANXIETY; DEPRESSION
CBR-001-633-232-4,RFM-009-635-5,CBR-001-633-232-4,COc1ccc(c(c1)C1Sc2ccccc2N(C1=O)C)OCCCN(CCOc1ccc2c(c1)OCO2)C,CBR-HVAC-03728: Calcium channel Antagonist; Antihypertensive; Antianginal; Antiplatelet; Angina; Hypertension
CBR-001-633-233-5,RFM-009-636-6,CBR-001-633-233-5,COc1ccc(c(c1)C1Sc2ccccc2N(C1=O)C)OCCCN(CCOc1ccc2c(c1)OCO2)C,CBR-HVAC-03728: Calcium channel Antagonist; Antihypertensive; Antianginal; Antiplatelet; Angina; Hypertension
CBR-001-633-234-6,RFM-009-637-7,CBR-001-633-234-6,COc1cccc(c1)[C@@]1(O)C[C@H](O)CC[C@@H]1CN(C)C,CBR-HVAC-00477: Analgesic; Analgesic; Pain
CBR-001-633-235-7,RFM-009-638-8,CBR-001-633-235-7,Fc1cc(F)cc(c1)C(=O)N[C@@H]1c2cc(ccc2OC([C@H]1O)(C)C)C(=O)C,CBR-HVAC-00205: ; ANTIMIGRAINE; MIGRAINE
CBR-001-633-236-8,RFM-009-639-9,CBR-001-633-236-8,Fc1cc(F)cc(c1)C(=O)N[C@@H]1c2cc(ccc2OC([C@H]1O)(C)C)C(=O)C,CBR-HVAC-00205: ; ANTIMIGRAINE; MIGRAINE
CBR-001-633-237-9,RFM-009-640-2,CBR-001-633-237-9,COC(C(=O)O)Cc1ccc(cc1)OCCCOc1ccc(cc1)Oc1ccccc1,CBR-HVAC-00468: Peroxisome proliferator activated receptor gamma Agonist; Insulin sensitizer; Hypoglycemic; Cardiovascular; Metabolic disorders; Non-insulin dependent diabetes
CBR-001-633-238-0,RFM-009-641-3,CBR-001-633-238-0,COC(C(=O)O)Cc1ccc(cc1)OCCCOc1ccc(cc1)Oc1ccccc1,CBR-HVAC-00468: Peroxisome proliferator activated receptor gamma Agonist; Insulin sensitizer; Hypoglycemic; Cardiovascular; Metabolic disorders; Non-insulin dependent diabetes
CBR-001-633-239-1,RFM-009-642-4,CBR-001-633-239-1,C[C@@H](C(=O)N(C1CCCC1)CC(=O)O)CSC(=O)C(C)(C)C,CBR-HVAC-01213: Angiotensin-converting enzyme Inhibitor; Antihypertensive; HYPERTENSION
CBR-001-633-240-4,RFM-009-643-5,CBR-001-633-240-4,O=C1c2ccccc2CN1C1c2cc(ccc2OC(C1O)(C)C)OC(F)(F)F,"CBR-HVAC-03885: Potassium channel Activator; ANTI-HYPERTENSIVE¬VASODILATOR¬CARDIOPROTECTANT¬GENITOURINARY AGENT; Disorders of bladder function; Urinary incontinence; Injury, myocardial ischemia"
CBR-001-633-241-5,RFM-009-644-6,CBR-001-633-241-5,OC[C@H]1OC(C[C@@H]1OCc1ccccc1)N1CC(C(=O)[N]C1=O)C(F)(F)F,CBR-HVAC-00196: Antineoplastic; null; Antitumor; Antineoplastic; Cancer
CBR-001-633-242-6,RFM-009-645-7,CBR-001-633-242-6,OC[C@H]1O[C@H](C[C@@H]1OCc1ccccc1)n1cc(c(=O)[nH]c1=O)C(F)(F)F,CBR-HVAC-00196: Antineoplastic; null; Antitumor; Antineoplastic; Cancer
CBR-001-633-243-7,RFM-009-646-8,CBR-001-633-243-7,N#C[C@@](c1ccccc1)(C(C)C)CCCN(CCc1ccccc1)C,CBR-HVAC-12961: 5-Hydroxytryptamine 2 receptor; Calcium channel Blocker; Neuroprotectant; Vasodilator; Cognition disorder
CBR-001-633-244-8,RFM-009-647-9,CBR-001-633-244-8,N#C[C@@](c1ccccc1)(C(C)C)CCCN(CCc1ccccc1)C,CBR-HVAC-12961: 5-Hydroxytryptamine 2 receptor; Calcium channel Blocker; Neuroprotectant; Vasodilator; Cognition disorder
CBR-001-633-245-9,RFM-009-648-0,CBR-001-633-245-9,OCC(=O)[C@H]1[C@H](C)C[C@@H]2C1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=CC12C)F)F,"CBR-HVAC-13383: ; Anti-inflammatory, steroidal; Inflammation"
CBR-001-633-246-0,RFM-009-649-1,CBR-001-633-246-0,O=C1[C@H](N=C(c2c(N1C)cccc2)c1ccccc1)NC(=O)c1cc2c3n1CCCc3ccc2,CBR-HVAC-04398: CCK1 receptor Antagonist; CCK1 receptor antagonist; GASTROINTESTINAL DISORDER
CBR-001-633-247-1,RFM-009-650-4,CBR-001-633-247-1,CNCCC(c1ccccc1)Oc1ccccc1SC,CBR-HVAC-11225: Norepinephrine transporter Inhibitor; Antiobesity; Eating disorders
CBR-001-633-248-2,RFM-009-651-5,CBR-001-633-248-2,CNCCC(c1ccccc1)Oc1ccccc1SC,CBR-HVAC-11225: Norepinephrine transporter Inhibitor; Antiobesity; Eating disorders
CBR-001-633-249-3,RFM-009-652-6,CBR-001-633-249-3,OC[C@H](c1ccccc1)C(=O)OC1CC2CCC(C1)[N+]2(C)CC(=O)c1ccc(cc1)c1ccccc1,CBR-HVAC-09243: ; Anticholinergic; Flatulence; Dyspepsia; Cirrosis of liver or kidney
CBR-001-633-250-6,RFM-009-653-7,CBR-001-633-250-6,FC(Oc1ccc(cc1OC1CC1)[C@@H](c1cnc(s1)C(C(F)(F)F)(C(F)(F)F)O)Cc1ccc[n+](c1)[O-])F,CBR-HVAC-11144: Phosphodiesterase 4 Inhibitor; Anti-inflammatory; Bronchodilator; Asthma; Chronic obstructive pulmonary disease; Rheumatoid arthritis
CBR-001-633-251-7,RFM-009-654-8,CBR-001-633-251-7,Clc1cc(cnc1Cl)N1C[C@@H]2[C@H](C1)CN2,"CBR-HVAC-00693: Nicotinic acetylcholine receptor alpha4beta2 Agonist; Analgesic; Pain, neuropathic; Attention deficit hyperactivity disorder"
CBR-001-633-252-8,RFM-009-655-9,CBR-001-633-252-8,SCCC(=O)N1C(CSC1c1ccccc1O)C(=O)O,CBR-HVAC-00786: Angiotensin I converting enzyme 1 Inhibitor; Antihypertensive; Hypertension
CBR-001-633-253-9,RFM-009-656-0,CBR-001-633-253-9,CN(C(CC(c1ccccn1)(c1ccccc1)C(=O)N)C)C,CBR-HVAC-04244: Muscarinic acetylcholine receptor Antagonist; Antispasmodic; Pollakiuria; Urinary incontinenc
CBR-001-633-254-0,RFM-009-657-1,CBR-001-633-254-0,O[C@@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]1[C@@H]2C[C@H](O)[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)O)C)C)O)C,CBR-HVAC-13053: ; HEPATOPROTECTOR; Liver disease
CBR-001-633-255-1,RFM-009-658-2,CBR-001-633-255-1,O=C1CCC2C(=C1)CCC1[C@@H]2CCC2([C@H]1CC[C@@H]2OC(=O)C12C[C@@H]3C[C@H](C2)C[C@H](C1)C3)C,CBR-HVAC-13074: ; Anabolic steroid; Growth substance
CBR-001-633-256-2,RFM-009-659-3,CBR-001-633-256-2,CC[N+](CCC(c1ccccc1)(c1ccccc1)C(=O)N)(C)C,"CBR-HVAC-13204: Deceleration of the rate of heartbeat by excitation of the bulbar center cardiomoderator or direct action (partial agonist), then tachycardia; Anticholinergic; Tachycardia"
CBR-001-633-257-3,RFM-009-660-6,CBR-001-633-257-3,COc1cccc(c1)CCN(CCCC(c1ccc(c(c1)OC)OC)(C(C)C)C#N)C,CBR-HVAC-13043: Calcium channel Antagonist; Antiarrhythmic; Antianginal; Arrhythmia; Angina
CBR-001-633-265-3,RFM-009-661-7,CBR-001-633-265-3,N#Cc1ccc(cc1OC[C@@H](CNC(CC1Cc2c(C1)cccc2)(C)C)O)CCC(=O)O,CBR-HVAC-11826: CALCIUM SENSING RECEPTOR Antagonist; Calcitonin modulator; Calcium absorption promotor; Calcium channel antagonist; Osteoclast modulator; PTH antagonist
CBR-001-633-292-6,RFM-009-662-8,CBR-001-633-292-6,OC(=O)C(C1O[C@@H]([C@@H]([C@@H]1O)O)n1ccc(=O)[nH]c1=O)NC(=O)C(C(C(c1ccc(cn1)O)O)C)N,CBR-HVAC-00118:Antifungal Agents
CBR-001-633-293-7,RFM-009-663-9,CBR-001-633-293-7,CCc1cc(CC[C@@]2(CC(=C(C(=O)O2)Cc2nn3c(n2)nc(cc3C)C)O)C2CCCC2)cc(n1)CC,CBR-HVAC-00371:RNA-Directed RNA Polymerase (NS5B) Inhibitors
CBR-001-633-294-8,RFM-009-664-0,CBR-001-633-294-8,O=C1NC(Nc2c1cc(c(c2)Cl)S(=O)(=O)N)c1ccccc1,"CBR-HVAC-01915:Thiazide diuretic
"
CBR-001-633-295-9,RFM-009-665-1,CBR-001-633-295-9,FC(Oc1ccc(cc1)[C@@H](Cc1ccccc1)NC[C@@H](c1ccc(c(c1)NS(=O)(=O)C)O)O)F,CBR-HVAC-04827:beta3-Adrenoceptor Agonists;Signal Transduction Modulators
CBR-001-633-296-0,RFM-009-666-2,CBR-001-633-296-0,COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F,CBR-HVAC-05978: Chemokine CCR5 Antagonists;HIV Attachment Inhibitors;Signal Transduction Modulators
CBR-001-633-297-1,RFM-009-667-3,CBR-001-633-297-1,C[C@@H]1CC(=O)c2c(C1)ccc1c2C(=O)c2c(C1=O)c(O)ccc2,CBR-HVAC-06052:Apoptosis Inducers;Signal Transducer and Activator of Transcription 3 (STAT3) Inhibitors;Signal Transduction Modulators
CBR-001-633-321-4,RFM-009-668-4,CBR-001-633-321-4,c1ccc(nc1)N1CCN(CC1)CCCOc1cc(n(n1)c1ccccc1)c1ccccc1,CBR-HVAC-14430: regioisomer of CBR-HVAC-08263
CBR-001-633-322-5,RFM-009-669-5,CBR-001-633-322-5,CCOC(=O)c1cccc(c1)COc1ccc(cc1Cl)N1C(=NC(=NC1(C)C)N)N,CBR-HVAC-14425: metabolite of CBR-HVAC-14416
CBR-001-633-323-6,RFM-009-670-8,CBR-001-633-323-6,O=C1CC[C@]2([C@H](N1C)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2C(=O)O)C)C,CBR-HVAC-14426: metabolite of CBR-HVAC-04202
CBR-001-633-324-7,RFM-009-671-9,CBR-001-633-324-7,CC(c1ccc(cc1)c1ccsc1)C(=O)O,CBR-HVAC-14424: metabolite of CBR-HVAC-03577
CBR-001-633-325-8,RFM-009-672-0,CBR-001-633-325-8,CCCCc1nc(OCc2ccc(cc2F)c2ccccc2c2nnnn2)cc(c1)C(=O)OC,CBR-HVAC-14422: metabolite of CBR-HVAC-10374
CBR-001-633-326-9,RFM-009-673-1,CBR-001-633-326-9,CSC[C@H]1C(=O)Nc2c(N1C(=O)OC(C)C)cc(cc2)OC,CBR-HVAC-14419:  metabolite of CBR-HVAC-04631
CBR-001-633-327-0,RFM-009-674-2,CBR-001-633-327-0,CCCCN(Cc1ccc(c(c1)c1ccccc1C)C(=O)N[C@H](C(=O)OC)CCSC)CCC1CCCCC1,CBR-HVAC-14413: metabolite of CBR-HVAC-05329
CBR-001-633-328-1,RFM-009-675-3,CBR-001-633-328-1,O=C(Nc1ccc2c(c1)n(CCN1CCCC1)nc2)Cc1ccc(cc1)OCc1ccccc1,CBR-HVAC-11763: Melanin concentrating hormone receptor 1 Antagonist; Appetite suppressant; Obesity
CBR-001-633-329-2,RFM-009-676-4,CBR-001-633-329-2,CNCCC1=Cc2ccccc2N(c2c1cccc2)C,CBR-HVAC-02385: Antidepressant; ANTIDEPRESSANT; DEPRESSION
CBR-001-633-330-5,RFM-009-677-5,CBR-001-633-330-5,COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1ncc(nc1)C)C,CBR-HVAC-06563: Glucokinase Activator; Antiobesity; Antidiabetic; Obesity; Diabetes mellitus
CBR-001-633-331-6,RFM-009-678-6,CBR-001-633-331-6,O=C(N1CCC(CC1)N1CCc2c(NC1=O)cccc2)C[C@@H](C(=O)N1CCC(CC1)N1CCOCC1)Cc1cc(C)c(c(c1)C)O,CBR-HVAC-06836: Calcitonin Gene-Related Peptides (CGRP) Antagonists;Signal Transduction Modulators
CBR-001-633-332-7,RFM-009-679-7,CBR-001-633-332-7,COc1cc2CCN(C(c2cc1O)C1(CC1)c1ccccc1Cl)C,CBR-HVAC-04862: Dopamine receptor D1; Dopamine receptor D5 Antagonist; Antipsychotic; Psychotic disorder
CBR-001-633-333-8,RFM-009-680-0,CBR-001-633-333-8,CCCC(=O)C1c2cccc(c2C(=O)c2c1cccc2O)O,CBR-HVAC-01057: Lipoxygenase 1 Inhibitor; Antipsoriatic; Psoriasis
CBR-001-633-334-9,RFM-009-681-1,CBR-001-633-334-9,CO[C@]12CCC(=O)C[C@]32CCN([C@@H]1Cc1c3c(OC)ccc1)CC1CC1,CBR-HVAC-14133: Opioid mu receptor antagonist
CBR-001-633-335-0,RFM-009-682-2,CBR-001-633-335-0,CCN(CCO/N=C(\c1ccc(c(c1Cl)Cl)OC)/c1ccco1)CC,"CBR-HVAC-07733: (diethylamino)ethyl]oxime Cardiovascular Diseases (Not Specified);Hypertension, Treatment of"
CBR-001-633-336-1,RFM-009-683-3,CBR-001-633-336-1,CCN(CCO/N=C(/c1ccc(c(c1Cl)Cl)OC)\c1ccco1)CC,"CBR-HVAC-07733: (diethylamino)ethyl]oxime Cardiovascular Diseases (Not Specified);Hypertension, Treatment of"
CBR-001-633-337-2,RFM-009-684-4,CBR-001-633-337-2,O=C(Cn1c(Cl)cnc(c1=O)NCC(c1ccccn1)(F)F)NCc1ncccc1F,CBR-HVAC-05471: Thrombin Inhibitor; ANTITHROMBOTIC; Stroke
CBR-001-633-338-3,RFM-009-685-5,CBR-001-633-338-3,O=C(Nc1c(Cl)cc(cc1Cl)N)CN1CCN(C[C@H]1C(=O)N)CCCCC(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-03795: Adenosine receptor Activator; Cardioprotectant; Myocardial infarction; Ischemia; Thrombosis
CBR-001-633-339-4,RFM-009-686-6,CBR-001-633-339-4,O=C(Nc1c(Cl)cc(cc1Cl)N)CN1CCN(C[C@@H]1C(=O)N)CCCCC(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-03795: Adenosine receptor Activator; Cardioprotectant; Myocardial infarction; Ischemia; Thrombosis
CBR-001-633-340-7,RFM-009-687-7,CBR-001-633-340-7,OC[C@H]1O[C@@H](Oc2nnc(c2Cc2ccc(cc2C)OCCCNCC(C(=O)N)(C)C)C(C)C)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-09181: SGLT1 Inhibitor; Hypoglycemic agent; Type 2 diabetes mellitus
CBR-001-633-341-8,RFM-009-688-8,CBR-001-633-341-8,CN1CC[C@@]2(C[C@H](C1)Cc1c2cc(cc1)O)C,CBR-HVAC-02027: Opioid receptor mu Antagonist; Analgesic; Pain
CBR-001-633-342-9,RFM-009-689-9,CBR-001-633-342-9,CC(=O)OCC(=O)C12N=C(O[C@@H]1C[C@@H]1C2(C)C[C@H](O)[C@]2(C1CCC1=CC(=O)C=CC21C)F)C,"CBR-HVAC-02012: ; Anti-inflammatory, steroidal; Inflammation"
CBR-001-633-343-0,RFM-009-690-2,CBR-001-633-343-0,Clc1ccc2c(c1)n(CC(=O)N1CCC(CC1)C(=O)Nc1ccc(c3c1cccc3)Cl)c(=O)s2,CBR-HVAC-11956: Neuropeptide Y5 receptor Antagonist; Appetite suppressant; DIABETES MELLITUS; OBESITY; EATING DISORDERS
CBR-001-633-344-1,RFM-009-691-3,CBR-001-633-344-1,O=CN(C[C@H](C(=O)N[C@@H](C(C)(C)C)C(=O)N1CCN(CC1)Cc1ccc2c(c1)OCO2)CC1CCCC1)O,CBR-HVAC-06624: Peptide Deformylase (PDF) Inhibitors
CBR-001-633-345-2,RFM-009-692-4,CBR-001-633-345-2,OC(=O)CCCN(C(=O)[C@@]1(C)CCN1C(=O)c1csc2c1cccc2)Cc1cccc(c1)Cl,CBR-HVAC-07245: Free Fatty Acid Receptor 2 (FFAR2; GPR43) Antagonists;Signal Transduction Modulators
CBR-001-633-346-3,RFM-009-693-5,CBR-001-633-346-3,OC(=O)CCC(C(=O)O)CP(=O)(Cc1c(F)c(F)c(c(c1F)F)F)O,CBR-HVAC-11232: NAALAdase Inhibitor; Antidiabetic; Antiglaucoma; Diabetic neuropathy; Glaucoma; Neuroprotection
CBR-001-633-347-4,RFM-009-694-6,CBR-001-633-347-4,Fc1cc(ccc1C12CN(CC2C1)CCCSc1nnc(n1C)c1ocnc1C)C(F)(F)F,CBR-HVAC-06576: DOPAMINE D3 RECEPTOR Antagonist; Dopamine receptor D3 antagonist; Compulsive behaviour; Obesity; Substance addiction; Nicotine dependence
CBR-001-633-348-5,RFM-009-695-7,CBR-001-633-348-5,Fc1cc(ccc1C12CN(CC2C1)CCCSc1nnc(n1C)c1ocnc1C)C(F)(F)F,CBR-HVAC-06576: DOPAMINE D3 RECEPTOR Antagonist; Dopamine receptor D3 antagonist; Compulsive behaviour; Obesity; Substance addiction; Nicotine dependence
CBR-001-633-349-6,RFM-009-696-8,CBR-001-633-349-6,OCC(Nc1nc(N)c2c(n1)n(cn2)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)c1nnn(n1)CC)Cc1ccccc1,"CBR-HVAC-08582: Adenosine A2 receptor Agonist; Anti-inflammatory; Rhinitis, allergic; Asthma; Chronic obstructive pulmonary disease; Upper respiratory inflammatory disease"
CBR-001-633-350-9,RFM-009-697-9,CBR-001-633-350-9,SCC(C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)n1cccn1)C(C)C,CBR-HVAC-06015: Angiotensin I converting enzyme; Membrane metalloendopeptidase Inhibitor; Antihypertensive; Hypertension
CBR-001-633-351-0,RFM-009-698-0,CBR-001-633-351-0,SCC(C(=O)N[C@H](C(=O)O)Cc1ccc(cc1)n1cccn1)C(C)C,CBR-HVAC-06015: Angiotensin I converting enzyme; Membrane metalloendopeptidase Inhibitor; Antihypertensive; Hypertension
CBR-001-633-352-1,RFM-009-699-1,CBR-001-633-352-1,CC(=O)OCC(OCn1cnc2c1cnc(n2)N)COC(=O)C,CBR-HVAC-10923: DNA synthesis inhibitor; Viral replication inhibitor; Antiviral; HSV infections; Orthopoxvirus infections; Respiratory infections; Cytomegalovirus infection; HSV infection
CBR-001-633-353-2,RFM-009-700-7,CBR-001-633-353-2,O=C1CC[C@@H]2[C@@]3(C1)CCN([C@@H]2Cc1c3c(O)ccc1)CC1CC1,CBR-HVAC-02545: ; Analgesic; Pain
CBR-001-633-354-3,RFM-009-701-8,CBR-001-633-354-3,CCCCn1c2ccccc2c2c(c1=O)ncn2C,CBR-HVAC-10481: Antiasthmatic; Bronchodilator; Antiasthmatic; Bronchodilator; Asthma
CBR-001-633-355-4,RFM-009-702-9,CBR-001-633-355-4,Clc1ccc(cc1)S(=O)(=O)NCCCCc1cc(c2c1ccc(cc2)C(C)C)S(=O)(=O)O,CBR-HVAC-04102: THROMBOXANE A2 RECEPTOR Antagonist; Antiplatelet; Antihypertensive; Glomerulonephritis; Pulmonary hypertension; Lupus nephritis
CBR-001-633-356-5,RFM-009-703-0,CBR-001-633-356-5,CCCC(N1CCn2c3c1cc(C)nc3c(n2)c1ccc(cc1Cl)Cl)CCC,CBR-HVAC-05363: Corticotropin releasing hormone receptor 1 Antagonist; Antidepressant; Anxiolytic; Irritable bowel syndrome; Anxiety disorder; Major depressive disorder
CBR-001-633-357-6,RFM-009-704-1,CBR-001-633-357-6,O[C@H]1CN([C@@H](C1)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N)Cc1cnc2c1cccc2)CCCNC(=N)N)C(=O)[C@H](Cc1ccc(cc1)F)N,CBR-HVAC-00534: Melanocyte stimulating hormone antagonist; Antidepressant; Depression
CBR-001-633-358-7,RFM-009-705-2,CBR-001-633-358-7,CCOC/C=C/c1ccc(cc1)c1nc(c(n1)c1ccc(cc1)NC(C)C)c1ccc(cc1)NC(C)C,CBR-HVAC-05120: P-GLYCOPROTEIN Inhibitor; Anticancer; Cancer
CBR-001-633-359-8,RFM-009-706-3,CBR-001-633-359-8,OC(P(=O)(O)O)P(=O)(O)O,"CBR-HVAC-01187: ; Bone resorption inhibitor; Osteoporosis, postmenopausal"
CBR-001-633-360-1,RFM-009-707-4,CBR-001-633-360-1,COC(=O)c1cc(ccc1C(=O)OC)C(C(=O)C)C(=O)C,CBR-HVAC-08182:
CBR-001-633-361-2,RFM-009-708-5,CBR-001-633-361-2,OC(=O)COCCOCCN1CCC(=C(c2ccccc2)c2ccccc2)CC1,CBR-HVAC-04000: Histamine H1 Receptor Antagonists;Signal Transduction Modulators
CBR-001-633-362-3,RFM-009-709-6,CBR-001-633-362-3,O=C(c1cn(C)c2c(c1=O)cc(s2)CN1CCOCC1)NCc1ccc(cc1)Cl,CBR-HVAC-09150: DNA polymerase Inhibitor
CBR-001-633-363-4,RFM-009-710-9,CBR-001-633-363-4,CN[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N)CC(C)C)Cc1ccccc1)Cc1ccccc1)C(C)C)CC(C)C,CBR-HVAC-02743: Beta amyloid Inhibitor; Beta-amyloid inhibitor; Alzheimer's disease
CBR-001-633-364-5,RFM-009-711-0,CBR-001-633-364-5,O=C(N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)CC(=O)O)CCNC(=O)c1ccc(cc1)C(=N)N,CBR-HVAC-10821: Integrin alpha2b beta3 Antagonist; Antiplatelet; Vasoprotectant; Angina; Thromboembolic disorder
CBR-001-633-365-6,RFM-009-712-1,CBR-001-633-365-6,OC(=O)Cc1csc(n1)/N=C/1\SC[C@H]2N1Cc1ccccc1C2,CBR-HVAC-08297:
CBR-001-633-366-7,RFM-009-713-2,CBR-001-633-366-7,COc1cc(cc(c1OC)OC)C(=O)N[C@@H]1OC[C@H](N2[C@H]1CCCC2)c1ccccc1,CBR-HVAC-10732: Dopamine receptor Antagonist; Anxiolytic; Anxiety
CBR-001-633-367-8,RFM-009-714-3,CBR-001-633-367-8,CCNCCCCNC[C@@H]1C[C@H]1CNCCCCNCC,CBR-HVAC-05461: Polyamine metabolism modulator; Anticancer; Antineoplastic; Dementia; Prostate cancer; Benign prostate hyperplasia; Lymphoma
CBR-001-633-368-9,RFM-009-715-4,CBR-001-633-368-9,O=C1Nc2cccc(c2O[C@@H]1C)N1CCN(CC1)CCCc1cnc2c1cc(F)cc2,CBR-HVAC-05636: DOPAMINE 2 RECEPTOR Antagonist; Inhibitor; Antipsychotic; Schizophrenia; Psychosis
CBR-001-633-369-0,RFM-009-716-5,CBR-001-633-369-0,COCc1nnc(n1c1c(Cl)c(Cl)cc2c1nc(=O)c(=O)n2)c1ccc[n+](c1)[O-],"CBR-HVAC-09353: Ionotropic glutamate receptor NMDA Antagonist; Ionotropic glutamate receptor NMDA antagonist; ISCHEMIA, CEREBROVASCULAR; STROKE"
CBR-001-633-370-3,RFM-009-717-6,CBR-001-633-370-3,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N(S(=O)(=O)C)C,"CBR-HVAC-09321: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-633-371-4,RFM-009-718-7,CBR-001-633-371-4,CC(=O)NC[C@H]1OC(=O)N(C1)c1ccc(c(c1)F)N(S(=O)(=O)C)C,"CBR-HVAC-09321: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-633-372-5,RFM-009-719-8,CBR-001-633-372-5,Nc1nc(n(n1)C)NCCCOc1cccc2c1CCC2N1CCCCC1,CBR-HVAC-08268: Histamine H2 receptor Antagonist; Antiulcer; Peptic ulcer
CBR-001-633-373-6,RFM-009-720-1,CBR-001-633-373-6,COC(=O)C1=C(C)NC(=C(C1c1cc(ccc1OCCCCNC[C@@H](COc1ccccc1)O)[N+](=O)[O-])C(=O)OC)C,CBR-HVAC-03807: Calcium channel; Beta-1 adrenergic receptor Antagonist; Blocker; Antihypertensive; Antiarrhythmic; Antianginal; Angina; Arrhythmia; Hypertension
CBR-001-633-374-7,RFM-009-721-2,CBR-001-633-374-7,NC(=O)C[C@@H]1N=C(c2ccc(cc2)Cl)c2c(c3c1onc3C)cccc2,"CBR-HVAC-07239: Bromodomain-Containing Protein 4 (Brd4, HUNK1) Inhibitors"
CBR-001-633-375-8,RFM-009-722-3,CBR-001-633-375-8,Cc1nc(c(o1)C(=O)Nc1ccc(c(c1)c1nn2c(n1)ncc(c2)c1ccccn1)F)C,"CBR-HVAC-14326: selective inhibitor of the kinetoplastid proteasome for treatment of leishmaniasis, Chagas disease and sleeping sickness"
CBR-001-633-376-9,RFM-009-723-4,CBR-001-633-376-9,[O-][n+]1cccc(c1)c1nc2c(cc1[C@H](C(F)(F)F)Nc1ncnc3c1nccc3)cccc2Cl,CBR-HVAC-13986: Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators
CBR-001-633-377-0,RFM-009-724-5,CBR-001-633-377-0,CCS(=O)(=O)Nc1ccc(c(c1)c1cn(C)c(=O)c2c1cc[nH]2)Oc1ccc(cc1F)F,CBR-HVAC-13955: Oncolytic Drugs
CBR-001-633-378-1,RFM-009-725-6,CBR-001-633-378-1,CCC(=O)N1CC[C@@H](C1)Nc1ncnc2c1CN(CC2)c1cnc(c(c1)C(F)(F)F)OC,CBR-HVAC-13938: Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators
CBR-001-633-379-2,RFM-009-726-7,CBR-001-633-379-2,COCC(NC(=O)c1nc(sc1C(=O)O)N1CC[C@H]([C@H](C1)OC)NC(=O)c1nc(c(c1Cl)Cl)C)C,CBR-HVAC-06567: DNA Topoisomerase II Inhibitors
CBR-001-633-380-5,RFM-009-727-8,CBR-001-633-380-5,COCC(NC(=O)c1nc(sc1C(=O)O)N1CC[C@H]([C@H](C1)OC)NC(=O)c1nc(c(c1Cl)Cl)C)C,CBR-HVAC-06567: DNA Topoisomerase II Inhibitors
CBR-001-633-381-6,RFM-009-728-9,CBR-001-633-381-6,COc1cc(nn1c1ccccc1F)C(=O)N[C@H](c1ccccc1C)CC(=O)O,CBR-HVAC-13867: Cathepsin A Inhibitors
CBR-001-633-382-7,RFM-009-729-0,CBR-001-633-382-7,O=C(Nc1c(C)cccc1Cl)Nc1ccncc1,CBR-HVAC-03334: Antiepileptic Drugs
CBR-001-633-383-8,RFM-009-730-3,CBR-001-633-383-8,O=C(c1c(F)c(Cl)cc2c1ncc2)N(Cc1ccc(cc1)C(C)(C)C)CCc1cccc(c1)C(F)(F)F,CBR-HVAC-14032: Cholesteryl Ester Transfer Protein (CETP) Inhibitors;HDL-Cholesterol Increasing Agents
CBR-001-633-384-9,RFM-009-731-4,CBR-001-633-384-9,c1ccc(cc1)C12OCC(O1)Cn1c2nc2c1cccc2,CBR-HVAC-08137:
CBR-001-633-385-0,RFM-009-732-5,CBR-001-633-385-0,C#CC(NCC(COc1ccc(cc1C#N)NC(=O)C(C)C)O)(C)C,CBR-HVAC-07965: Beta 1 adrenoreceptor antagonist
CBR-001-633-386-1,RFM-009-733-6,CBR-001-633-386-1,CCN1CCN(CC1)C(=O)C1CCN(CC1)Cc1cc2c(n1)cccc2,CBR-HVAC-13811: Anti-Hepatitis C Virus Drugs
CBR-001-633-387-2,RFM-009-734-7,CBR-001-633-387-2,SC[C@H](C(=O)N1C[C@H](C[C@H]1C(=O)O)Sc1ccccc1)C,CBR-HVAC-04095: Angiotensin-I Converting Enzyme (ACE) Inhibitors
CBR-001-633-388-3,RFM-009-735-8,CBR-001-633-388-3,N#Cc1ccc(cc1)NCCCN1CC2OC(C1)CN(C2)CC(=O)C(C)(C)C,CBR-HVAC-05706: Antiarrhythmic Drugs
CBR-001-633-389-4,RFM-009-736-9,CBR-001-633-389-4,[O-][N+](=O)c1cnc(n1CCc1ccncc1)C,CBR-HVAC-10106:
CBR-001-633-390-7,RFM-009-737-0,CBR-001-633-390-7,COc1ccc2c3c1O[C@@H]1[C@@]3(CCN(C2)C)C=C[C@@H](C1)OC(=O)c1ccccc1,CBR-HVAC-06789: Acetylcholinesterase (AChE) Inhibitors;Butyrylcholinesterase Inhibitors
CBR-001-633-391-8,RFM-009-738-1,CBR-001-633-391-8,COCCOC(=O)CN1CCC(CC1)NC(=O)c1cc(Cl)c(cc1OC)N,CBR-HVAC-07411: Signal Transduction Modulators;5-HT4 Agonists
CBR-001-633-392-9,RFM-009-739-2,CBR-001-633-392-9,O=c1n(cc(c(=O)n1C1CCCO1)F)C1CCCO1,CBR-HVAC-05835: Nucleosides
CBR-001-633-393-0,RFM-009-740-5,CBR-001-633-393-0,CCCC(=O)c1ccccc1OCCN(C(C)C)C(C)C,CBR-HVAC-13646: Sodium channel antagonist; Potassium channel antagonist; Membrane integrity inhibitor
CBR-001-633-394-1,RFM-009-741-6,CBR-001-633-394-1,O=C(NC(C(=O)O)Cc1c[nH]cn1)CCNC(=O)C,CBR-HVAC-05562: Antioxidants; Anticataract Agents
CBR-001-633-395-2,RFM-009-742-7,CBR-001-633-395-2,O[C@@H]1CCC2([C@@H](C1)C[C@@H]([C@@H]1[C@@H]2CCC2([C@H]1CC[C@@H]2[C@@H](CC(=O)O)C)C)O)C,"CBR-HVAC-13052: Liver and Biliary Tract Disorders, Treatment of"
CBR-001-633-396-3,RFM-009-743-8,CBR-001-633-396-3,CCCCc1nc(CCCC)nc(=O)c1Cc1ccc(cc1)c1ccccc1c1nnnn1,CBR-HVAC-13310: Platelet activating factor receptor Antagonist; Antihypertensive; Hypertension
CBR-001-633-397-4,RFM-009-744-9,CBR-001-633-397-4,NC(=N)NCCC[C@H](C(=O)N[C@@H](c1ccc(cc1)O)C)NC(=O)C(c1ccccc1)c1ccccc1,CBR-HVAC-05182: GLYCOPROTEIN IIB/IIIA RECEPTOR Antagonist; CARDIOPROTECTANT; Ischemic heart diseases
CBR-001-633-398-5,RFM-009-745-0,CBR-001-633-398-5,CCOC(=O)C1=C(COCCNCC(=O)N)NC(=C(C1c1ccccc1Cl)C(=O)OC)C,CBR-HVAC-13531: Beta-3 adrenergic receptor Agonist; Vasodilator; Cardiovascular disease
CBR-001-633-399-6,RFM-009-746-1,CBR-001-633-399-6,CN1[C@@H]2CC[C@H]1C[C@H](C2)NC(=O)N1CC(c2c1cccc2)(C)C,CBR-HVAC-03676: Acyl CoA:cholesterol acyltransferase Inhibitor; Anxiolytic; Antipsychotic; Anti-emetic; Emesis; Gastrointestinal disease; Anxiety disorder; Psychosis; Schizophrenia; Drug dependence
CBR-001-633-400-2,RFM-009-747-2,CBR-001-633-400-2,CC1c2ccccc2CCN1c1ssc(=O)c1Cl,CBR-HVAC-12161: Calcium channel; 5-Hydroxytryptamine 2 receptor Antagonist; Immunosuppressant; Antiarthritic; Rheumatoid arthritis
CBR-001-633-401-3,RFM-009-748-3,CBR-001-633-401-3,Cn1nc2c(c1)c(ccc2)NC1=NCCN1,CBR-HVAC-01116: BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR Agonist; Antihypertensive; Neurotransmitter; Vasoconstrictor; Vasopressor; Hypertension; Glaucoma
CBR-001-633-402-4,RFM-009-749-4,CBR-001-633-402-4,Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(cc1)Oc1ccc(cc1F)C(=O)N,CBR-HVAC-06930: Lactate dehydrogenase Inhibitor; ANTABUSENEUROPROTECTANT; Alcohol dependence
CBR-001-633-403-5,RFM-009-750-7,CBR-001-633-403-5,Cc1cc(C)cc(c1)[C@@H]1CCCN1Cc1ccc(cc1)Oc1ccc(cc1F)C(=O)N,CBR-HVAC-06930: Lactate dehydrogenase Inhibitor; ANTABUSENEUROPROTECTANT; Alcohol dependence
CBR-001-633-404-6,RFM-009-751-8,CBR-001-633-404-6,O=C(C1Cc2c(C1)c1c(s2)n2c(C)nnc2CN=C1c1ccccc1Cl)N1CCOCC1,CBR-HVAC-03749: Angiotensin II receptor Antagonist; Antihypertensive; Anti-inflammatory; Allergy; Asthma; Hypertension; Thromboembolic disorder; Transplant rejection
CBR-001-633-405-7,RFM-009-752-9,CBR-001-633-405-7,CCCN(C(=O)C1Cc2c(C1)c1c(s2)n2c(C)nnc2CN=C1c1ccccc1Cl)CCC,CBR-HVAC-13497: Corticotropin releasing hormone receptor 1 Antagonist; Anti-inflammatory; Allergic conditions; Asthma
CBR-001-633-406-8,RFM-009-753-0,CBR-001-633-406-8,CCOCn1c2cc(F)ccc2n2c1=C(C(=O)CC2)C(=O)Nc1ccccc1F,CBR-HVAC-05066: Leukotriene D4 receptor; Platelet activating factor receptor Antagonist; Anxiolytic; Anxiety
CBR-001-633-407-9,RFM-009-754-1,CBR-001-633-407-9,OC(=O)C[C@@H]1C[C@H](NC1=O)COc1ccc(cc1)c1ccc(cc1)C(=N)N,CBR-HVAC-02688: Farnesoid X-activated receptor Inhibitor; Anticoagulant; Unstable angina pectoris
CBR-001-633-408-0,RFM-009-755-2,CBR-001-633-408-0,CCCCC/C=C/C/C=C/CCCCCCCC(=O)NC(c1ccccc1)C,CBR-HVAC-01646: H+/K+ ATPase Inhibitor; Antihyperlipoproteinemic; Lipid metabolism disorders
CBR-001-633-409-1,RFM-009-756-3,CBR-001-633-409-1,COc1cc(ccc1O)C(=O)Nc1ccccc1CCC1CCCCN1C,CBR-HVAC-01136: ; Antiarrhythmic; Cardiac depressant
CBR-001-633-410-4,RFM-009-757-4,CBR-001-633-410-4,N#Cc1ccc(cc1)Nc1ncnc2c1CCC2O,CBR-HVAC-03507: CALCIUM CHANNEL Blocker; Antidepressant; Depression
CBR-001-633-411-5,RFM-009-758-5,CBR-001-633-411-5,CC(NCCCC1(C(=O)N)c2ccccc2c2c1cccc2)C,CBR-HVAC-02553: CC chemokine receptor 4 Antagonist; Antiarrhythmic; Arrhythmia
CBR-001-633-412-6,RFM-009-759-6,CBR-001-633-412-6,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(cc1)S(=O)C,CBR-HVAC-03626: Thromboxane A synthase Inhibitor; Antibacterial; Anaerobic bacterial infection; Gram-positive bacterial infection
CBR-001-633-413-7,RFM-009-760-9,CBR-001-633-413-7,CN([C@@H]1C(=C(C(=O)N)C(=O)C2([C@H]1C[C@@H]1Cc3ccc(c(c3C(=O)C1=C2O)O)N)O)O)C,"CBR-HVAC-08751: Antidiabetic; Antibiotic; Infection, bacterial"
CBR-001-633-414-8,RFM-009-761-0,CBR-001-633-414-8,Clc1ccc2c(c1)C(=NC(C(=O)N2)OC(=O)C(C)(C)C)c1ccccc1,CBR-HVAC-08907: 5-Hydroxytryptamine 3 receptor Antagonist; Anxiolytic; Anxiety
CBR-001-633-415-9,RFM-009-762-1,CBR-001-633-415-9,ONC(=N)c1cc2c(s1)cc(c(c2F)OC)OC,CBR-HVAC-10431: GABA receptor Agonist; Inotropic; Cardiotonic; Cardiac failure
CBR-001-633-416-0,RFM-009-763-2,CBR-001-633-416-0,CCc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1nnnn1)/C(=C/C(=O)O)/CCCC2,CBR-HVAC-10741: ; Antihypertensive; Hypertension
CBR-001-633-417-1,RFM-009-764-3,CBR-001-633-417-1,COCC(Nc1nc(C)nc2n1nc(c2c1ccc(cc1Cl)Cl)C)COC,CBR-HVAC-11056: ; Antidepressant; Anxiolytic; Anxiety; Major depressive disorder
CBR-001-633-418-2,RFM-009-765-4,CBR-001-633-418-2,CN(CC(=O)OCC(=O)N1CCN(CC1)c1ccc(cc1F)N1C[C@@H](OC1=O)CNC(=O)C)C,CBR-HVAC-11253: Thymidylate synthase Inhibitor; Antibacterial; Bacterial infection
CBR-001-633-419-3,RFM-009-766-5,CBR-001-633-419-3,Fc1ccc2c(c1)nc(s2)/C=C/c1cccc(c1)COc1ccc(cc1)n1c(C)nc2c1ccnc2,CBR-HVAC-11392: Phosphodiesterase 4 Inhibitor; Antiinflammatory; Asthma; Arthritis; Psoriasis
CBR-001-633-420-6,RFM-009-767-6,CBR-001-633-420-6,CCOC(=O)[C@@H](N[C@H](C(=O)N1C2CCC([C@H]1C(=O)O)CC2)C)CCc1ccccc1,CBR-HVAC-12827: Potassium channel Blocker; Antihypertensive; Hypertension
CBR-001-633-421-7,RFM-009-768-7,CBR-001-633-421-7,COc1cc(OC)ccc1CS(=O)c1ncccc1C(=O)Nc1cc(C)ncc1C,CBR-HVAC-13385: ; Antiulcer; Acid-related gastrointestinal disorders
CBR-001-633-422-8,RFM-009-769-8,CBR-001-633-422-8,COc1ccc(cc1)[C@@H]1Cc2c(N(C(=O)[C@@H]1OC(=O)C)CCN(C)C)cccc2C(F)(F)F,CBR-HVAC-13641: ; ; Myocardial ischemia
CBR-001-633-423-9,RFM-009-770-1,CBR-001-633-423-9,CCC(=O)O[C@@]1([C@@H](C)C[C@@H]2C1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=CC12C)Cl)C(=O)COC(=O)CC,CBR-HVAC-00074: Glucocorticoid agonist; Immunosuppressant
CBR-001-633-424-0,RFM-009-771-2,CBR-001-633-424-0,Clc1ccc2c(c1)C(=NC(C(=O)N2C)Cc1ccc2c(c1)cccc2)c1ccc(cc1)O,CBR-HVAC-13925: ; Anticancer; Anti-inflammatory; Rheumatoid arthritis; Systemic lupus erythematosus; Autoimmune disease; Cancer
CBR-001-633-425-1,RFM-009-772-3,CBR-001-633-425-1,CCN(CC(c1ccccc1)OC(=O)c1ccccc1)CC,"CBR-HVAC-09245: ; Anticholinergic; Ulcer, gastric"
CBR-001-633-426-2,RFM-009-773-4,CBR-001-633-426-2,CN(CCC1CN(C)C(=S)c2c(O1)nccc2)C,CBR-HVAC-03231: ; Antiallergic; Allergy
CBR-001-633-427-3,RFM-009-774-5,CBR-001-633-427-3,COCCOc1cc(cc(c1)OCCOC)Cn1c2ccccc2c(c1C(=O)O)c1ccc(cc1)C(C)(C)C,CBR-HVAC-06578: ; Antidiabetic; Diabetes
CBR-001-633-428-4,RFM-009-775-6,CBR-001-633-428-4,O=C(c1cc(Cl)c(c2c1OCC2)N)NC[C@@H]1CCCN1,CBR-HVAC-03742: ; Antiemetic; Analgesic; Anxiety; Emesis
CBR-001-633-429-5,RFM-009-776-7,CBR-001-633-429-5,CCOc1cc2sc(cc2cc1OCC)C(=O)O,CBR-HVAC-03635: Beta-3 adrenergic receptor Agonist; Bronchodilator; Antiasthmatic; Asthma
CBR-001-633-430-8,RFM-009-777-8,CBR-001-633-430-8,OC(=O)CNC(=O)c1ccc(cc1)/N=N/c1ccc(c(c1)C(=O)O)O,CBR-HVAC-02548: ; Analgesic; Inflammatory bowel disease
CBR-001-633-431-9,RFM-009-778-9,CBR-001-633-431-9,O=C1CC[C@H]2C(=C1)C[C@H]([C@@H]1[C@@H]2CCC2([C@H]1CC[C@@H]2O)C)C,"CBR-HVAC-12924: CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ A RECEPTOR Antagonist; Anabolic steroid; Antigonadotrophic; Hypogonadism, secondary"
CBR-001-633-432-0,RFM-009-779-0,CBR-001-633-432-0,CC(N(C[C@@H](c1ccccc1)O)C[C@@H](c1ccccc1)O)CCc1ccc(cc1)C(=O)N,CBR-HVAC-03446: Monoamine oxidase A Inhibitor; Antihyperglycemic; Anti-obesity; Antidiabetic; Diabetes mellitus Obesity
CBR-001-633-433-1,RFM-009-780-3,CBR-001-633-433-1,CC(N(C[C@@H](c1ccccc1)O)C[C@@H](c1ccccc1)O)CCc1ccc(cc1)C(=O)N,CBR-HVAC-03446: Monoamine oxidase A Inhibitor; Antihyperglycemic; Anti-obesity; Antidiabetic; Diabetes mellitus Obesity
CBR-001-633-434-2,RFM-009-781-4,CBR-001-633-434-2,CCCN(C1COc2c(C1)c(OC)ccc2)CCCCN1C(=O)CC2(CC1=O)CCCC2,CBR-HVAC-04267: ; Antidepressant; Anxiolytic; Antipsychotic; Aggression; Anxiety; Major depressive disorder
CBR-001-633-435-3,RFM-009-782-5,CBR-001-633-435-3,CCCN(C1COc2c(C1)c(OC)ccc2)CCCCN1C(=O)CC2(CC1=O)CCCC2,CBR-HVAC-04267: ; Antidepressant; Anxiolytic; Antipsychotic; Aggression; Anxiety; Major depressive disorder
CBR-001-633-436-4,RFM-009-783-6,CBR-001-633-436-4,CCCCOC(=O)NC(C(=O)OC)CNC(=O)CC1ON=C(C1)c1ccc(cc1)C(=N)N,CBR-HVAC-10990: Potassium channel Kv alpha Blocker; Antithrombotic agent; Coronary artery disease; Peripheral arterial occlusive disease
CBR-001-633-437-5,RFM-009-784-7,CBR-001-633-437-5,Clc1cccc(c1)C1OC(=O)N(C1)[C@@H](Cc1ccc(cc1)c1ncc(o1)NC(=O)C(F)(F)F)C,CBR-HVAC-11391: Locally effective on the gastric mucosa as an irritant and centrally to stimulate the CTZ; Antidiabetic; Diabetes mellitus
CBR-001-633-438-6,RFM-009-785-8,CBR-001-633-438-6,Clc1cccc(c1)C1OC(=O)N(C1)[C@H](Cc1ccc(cc1)c1ncc(o1)NC(=O)C(F)(F)F)C,CBR-HVAC-11391: Glucocorticoid receptor Agonist; Antidiabetic; Diabetes mellitus
CBR-001-633-439-7,RFM-009-786-9,CBR-001-633-439-7,OC(=O)[C@@H]1CCCN(C1)CCC=C1c2ccccc2CCc2c1cccc2,"CBR-HVAC-00400: Beta-2 adrenergic receptor Agonist; Analgesic; Anti-inflammatory; Pain, Neuropathic pain; Rheumatic diseases"
CBR-001-633-440-0,RFM-009-787-0,CBR-001-633-440-0,C[C@@H]1N=C(c2c(NC1=O)ccc(c2)[N+](=O)[O-])c1ccccc1Cl,CBR-HVAC-01041: Tubulin Inhibitor; Anxiolytic; Anxiety
CBR-001-633-441-1,RFM-009-788-1,CBR-001-633-441-1,C[C@H]1N=C(c2c(NC1=O)ccc(c2)[N+](=O)[O-])c1ccccc1Cl,CBR-HVAC-01041: F1F0 ATPase Inhibitor; Anxiolytic; Anxiety
CBR-001-633-442-2,RFM-009-789-2,CBR-001-633-442-2,CCCCCCN(CCCC(c1cc(OC)c(c(c1)OC)OC)(C(C)C)C#N)C,CBR-HVAC-04241: ; Antihypertensive; Class IV antiarrhythmic; Coronary vasodilation; Antithrombotic; Angina pectoris; Arrhythmia; Hypertension; Ischemic heart diseases; Thromboembolism
CBR-001-633-443-3,RFM-009-790-5,CBR-001-633-443-3,OC(=O)COc1ccc(cc1)CCNC(C(c1ccc(cc1)O)O)C,CBR-HVAC-05146: ; Analgesic; Pain associated with ureteral calculus
CBR-001-633-444-4,RFM-009-791-6,CBR-001-633-444-4,CC[C@H]1CN2CCc3c([C@@H]2C[C@@H]1C[C@H]1NCCc2c1cc(OC)c(c2)O)cc(c(c3)OC)OC,CBR-HVAC-13131: ; Antiemetic; Expectorant; Emesis
CBR-001-633-445-5,RFM-009-792-7,CBR-001-633-445-5,OCC(=O)[C@@]1(O)CCC2C1(C)C[C@H](O)[C@]1(C2CCC2=CC(=O)C=CC12C)F,"CBR-HVAC-13147: ; Anti-inflammatory, steroidal; Inflammation"
CBR-001-633-446-6,RFM-009-793-8,CBR-001-633-446-6,COc1ccc(cc1)OC(=O)N(C(c1ccc(cc1)OCCc1nc(oc1C)c1ccccc1)C)CC(=O)O,CBR-HVAC-13343: ; Hypoglycemic; Antihyperlipidemic; Diabetes
CBR-001-633-447-7,RFM-009-794-9,CBR-001-633-447-7,OCC(=O)C12OC(O[C@@H]1C[C@@H]1C2(C)C[C@H](O)[C@]2([C@H]1CCC1=CC(=O)C=CC21C)F)(CC)CC,"CBR-HVAC-13388: ; Anti-inflammatory, steroidal; Inflammation"
CBR-001-633-448-8,RFM-009-795-0,CBR-001-633-448-8,COc1cc(cc(c1OC)OC)C1CN=C(O1)c1ccc2c(c1)ccn2C,CBR-HVAC-13820: ; Antineoplastic; Neoplasm
CBR-001-633-449-9,RFM-009-796-1,CBR-001-633-449-9,OCC(c1ccccc1)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)CCCS(=O)(=O)O,"CBR-HVAC-08833: ; Antiulcer; Anticholinergic; Ulcer, gastric; Ulcer, duodenal"
CBR-001-633-450-2,RFM-009-797-2,CBR-001-633-450-2,OCC(c1ccccc1)C(=O)OC1C[C@@H]2CC[C@H](C1)[N+]2(C)CCCS(=O)(=O)O,"CBR-HVAC-08833: ; Antiulcer; Anticholinergic; Ulcer, gastric; Ulcer, duodenal"
CBR-001-633-451-3,RFM-009-798-3,CBR-001-633-451-3,COc1ccc(cc1OC1CCCC1)C1CC(=O)N(N1C)C(=O)NCc1cccnc1,CBR-HVAC-11504: ; Antiasthmatic; Bronchodilator; Asthma
CBR-001-633-452-4,RFM-009-799-4,CBR-001-633-452-4,COc1ccc(cc1OC1CCCC1)C1CC(=O)N(N1C)C(=O)NCc1cccnc1,CBR-HVAC-11504: ; Antiasthmatic; Bronchodilator; Asthma
CBR-001-633-453-5,RFM-009-800-0,CBR-001-633-453-5,COCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2C1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=CC12C)F,CBR-HVAC-12711: Phosphodiesterase 4 Inhibitor; Steroidal antiinflammatory; Inflammatory skin diseases
CBR-001-633-463-7,RFM-009-801-1,CBR-001-633-463-7,ONC(=O)C[C@H](C(=O)N[C@@H](C(C)(C)C)C(=O)NC)CC(C)C,"CBR-HVAC-10544:Collagenase Inhibitors; Matrix metalloproteinase inhibitor
"
CBR-001-633-664-4,RFM-009-802-2,CBR-001-633-664-4,COC(=O)C1=C(C)NC(=C(C1c1ccccc1)C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1)C,analog of CBR-HVAC-01799
CBR-001-633-665-5,RFM-009-803-3,CBR-001-633-665-5,Brc1cc(cc2c1nc(n2)c1ccc(cc1)c1ncccc1C(F)(F)F)C(F)(F)F,CBR-HVAC-13990: TRPV1 (Vanilloid VR1 Receptor) Antagonists
CBR-001-633-666-6,RFM-009-804-4,CBR-001-633-666-6,CCCC[C@@H]1CC[C@H](CC1)C(=O)O[C@H]1CCC2C1(C)CCC1C2CCC2=CC(=O)CCC12C,CBR-HVAC-13008: Male Contraceptives
CBR-001-633-667-7,RFM-009-805-5,CBR-001-633-667-7,O[C@@H]1CCC2([C@@H](C1)C[C@H]([C@@H]1[C@@H]2C[C@H](O)[C@]2([C@H]1CC[C@@H]2[C@@H](CCC(=O)N(CC(=O)O)C)C)C)O)C,CBR-HVAC-04523: Gastrointestinal Disorders (Not Specified)
CBR-001-633-668-8,RFM-009-806-6,CBR-001-633-668-8,OC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)O)Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)C)CCC(=O)N)Cc1ccc(cc1)O)CCC(=O)N)Cc1ncnc1)CCC(=O)O)C,"CBR-HVAC-12651: Treatment of Transplant Rejection;Renal Failure, Agents for"
CBR-001-633-669-9,RFM-009-807-7,CBR-001-633-669-9,CCCCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CCC12C,CBR-HVAC-13988: Androgen Receptor Agonists;Signal Transduction Modulators
CBR-001-633-670-2,RFM-009-808-8,CBR-001-633-670-2,COC(c1ccc(cc1)[N+](=O)[O-])CN1CCC(CC1)C(=O)c1ccc(cc1)F,CBR-HVAC-13852:  sigma1 Receptor Ligands;Signal Transduction Modulators
CBR-001-633-671-3,RFM-009-809-9,CBR-001-633-671-3,COC(c1ccc(cc1)[N+](=O)[O-])CN1CCC(CC1)C(=O)c1ccc(cc1)F,CBR-HVAC-13852:  sigma1 Receptor Ligands;Signal Transduction Modulators
CBR-001-633-672-4,RFM-009-810-2,CBR-001-633-672-4,N#Cc1ccc(cc1C(F)(F)F)N1C(=O)N(C(C1=O)(CO)c1ccc(cc1)O)C,CBR-HVAC-13877: Selective Androgen Receptor Modulators (SARM);Signal Transduction Modulators
CBR-001-633-673-5,RFM-009-811-3,CBR-001-633-673-5,O=C1C=CC2(C(=C1)[C@@H](F)C[C@@H]1[C@]2(F)[C@@H](O)CC2([C@H]1C[C@H]([C@]2(O)C(=O)SC1CCOC1=O)C)C)C,CBR-HVAC-05673: Glucocorticoid Receptor (GR) Agonists;Signal Transduction Modulators
CBR-001-633-674-6,RFM-009-812-4,CBR-001-633-674-6,CSCC[C@@H](C(=O)O)NC(=O)C(Cc1ccccc1C)CS,"CBR-HVAC-13697: Hypertension, Treatment of"
CBR-001-633-675-7,RFM-009-813-5,CBR-001-633-675-7,CSCC[C@@H](C(=O)O)NC(=O)C(Cc1ccccc1C)CS,"CBR-HVAC-13697: Hypertension, Treatment of"
CBR-001-633-676-8,RFM-009-814-6,CBR-001-633-676-8,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](OC(=O)[C@@]34CC[C@H]([C@@H]([C@H]4C4=CC[C@H]5[C@@]([C@@]4(CC3)C)(C)C[C@@H](O)[C@@H]3[C@]5(C)C[C@H]([C@@H]([C@@]3(C)CO)O)O)C)C)[C@@H]([C@H]([C@@H]2O)O)O)[C@@H]([C@H]([C@@H]1O[C@@H]1O[C@@H](C)[C@@H]([C@H]([C@H]1O)O)O)O)O,"CBR-HVAC-04116: Wound-Healing Agents;Antipsoriatics;Cognition Disorders, Treatment of"
CBR-001-633-677-9,RFM-009-815-7,CBR-001-633-677-9,CCN/C(=N\S(=O)(=O)c1ccc2c(c1)CCN2C(=O)C)/N1N=CC(C1)CC,"CBR-HVAC-13860: Alzheimer's Dementia, Treatment of"
CBR-001-633-678-0,RFM-009-816-8,CBR-001-633-678-0,CCCN(C1CCc2c(C1)c(ccc2)c1ccno1)CCC,CBR-HVAC-13754: Muscarinic Antagonists;Signal Transduction Modulators;5-HT1A Receptor Agonists
CBR-001-633-679-1,RFM-009-817-9,CBR-001-633-679-1,C[C@]12C=CC[C@H]2[C@H]2[C@H](CC1)c1ccccc1CC2,CBR-HVAC-13727: Kallikrein B (Plasma Kallikrein; KLKB1) Inhibitors
CBR-001-633-680-4,RFM-009-818-0,CBR-001-633-680-4,OC(=O)CC1CCN(CC1)CCOC(c1ccccc1)c1ccccc1,CBR-HVAC-03774: Histamine H1 Receptor Antagonists;Signal Transduction Modulators
CBR-001-633-681-5,RFM-009-819-1,CBR-001-633-681-5,CCO[C@@H](Cc1ccc(cc1)OCc1nc(oc1C)c1ccccc1)CN,CBR-HVAC-13821: Signal Transduction Modulators;Thyroid Hormone Receptor beta Agonists
CBR-001-633-682-6,RFM-009-820-4,CBR-001-633-682-6,COC(=O)C(Cc1ccc(cc1)Oc1ccc(cc1)/C=C\1/SC(=O)NC1=O)N,CBR-HVAC-13868: IL-6 Production Inhibitors;Signal Transduction Modulators;TNF-alpha Production Inhibitors
CBR-001-633-683-7,RFM-009-821-5,CBR-001-633-683-7,CN(CC(C1(O)CCCCC1)c1ccc(cc1)OC(=O)c1ccc(cc1)C)C,"CBR-HVAC-13847: Mood Disorders, Treatment of"
CBR-001-633-684-8,RFM-009-822-6,CBR-001-633-684-8,CCCCOc1nc(N)c2c(n1)n(CCCCCC1CCNCC1)c(=O)[nH]2,CBR-HVAC-13843: Signal Transduction Modulators;TLR7 Receptor Agonists
CBR-001-633-685-9,RFM-009-823-7,CBR-001-633-685-9,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2O)COS(=O)(=O)[O-],CBR-HVAC-05871: Cytokine Modulators;Signal Transduction Modulators
CBR-001-633-686-0,RFM-009-824-8,CBR-001-633-686-0,CCCC[C@H](C(=O)N[C@@H](C(=O)NCc1ccncc1)CCCNC(=N)N)NC(=O)[C@H](NC(=O)[C@@H](Cc1ccccc1)N)Cc1ccccc1,CBR-HVAC-06187: kappa-Opioid Agonists;Signal Transduction Modulators
CBR-001-633-687-1,RFM-009-825-9,CBR-001-633-687-1,CNC(=N)NCCC[C@@H](C(=O)N[C@H](C(=O)N)Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)NNC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](Cc1ccc(cc1)O)NC(=O)C)O)CC(=O)N)Cc1ccccc1)CC(C)C,"CBR-HVAC-07048: Gonadotropin-Releasing Factor Hormone Receptor (GnRH, LHRH) Ligands;KiSS-1 (Metastin; GPR54) Receptor Agonists;Signal Transduction Modulators"
CBR-001-633-688-2,RFM-009-826-0,CBR-001-633-688-2,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)O)CO)CCCCN)C(C)C)CS)C)C(C)C)C(C)C)C(C)C)CC(C)C)N,CBR-HVAC-05046: Oncolytic Drugs;Cancer Immunotherapy
CBR-001-633-689-3,RFM-009-827-1,CBR-001-633-689-3,COCCCN1CC[C@H]([C@@H](C1)O)CNC(=O)c1cc(Cl)c(c2c1OC(C2)(C)C)N,CBR-HVAC-05132: Signal Transduction Modulators;5-HT4 Agonists
CBR-001-633-690-6,RFM-009-828-2,CBR-001-633-690-6,COc1cc(cc(c1OC)OC)C(=O)N1CCC(C1)(CCN1CCC(CC1)(c1ccccc1)C(=O)N1CCN(CC1)CC(=O)O)c1ccc(c(c1)Cl)Cl,CBR-HVAC-05079: Signal Transduction Modulators;Tachykinin NK1 Antagonists;Tachykinin NK2 Antagonists
CBR-001-633-691-7,RFM-009-829-3,CBR-001-633-691-7,CC(C[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)[C@H](O)C)C(C)C)CCC(=O)O)NC(=O)[C@H](Cc1ccc(cc1)O)N)C,CBR-HVAC-06361: Melanoma Therapy
CBR-001-633-692-8,RFM-009-830-6,CBR-001-633-692-8,NCCCC[C@@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)NC(=O)[C@H](Cc1c(C)cc(cc1C)O)NC(=O)[C@@H](CCCNC(=N)N)N,CBR-HVAC-06447: Antioxidants;Apoptosis Inhibitors;Free Radical Scavengers
CBR-001-633-693-9,RFM-009-831-7,CBR-001-633-693-9,NCCCC[C@H](C(=O)N[C@@H](C(=O)O)Cc1cccc2c1cccc2)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1cccc2c1cccc2)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](CCCCN)N)CC(C)C)Cc1ccccc1)CCCNC(=N)N)CCC(=O)N)C,CBR-HVAC-05645: Antibacterial Drugs;Acne Therapy
CBR-001-633-694-0,RFM-009-832-8,CBR-001-633-694-0,OC[C@@]1(CCl)O[C@H]([C@@H]([C@@H]1O)F)n1ccc(nc1=O)N,CBR-HVAC-13748: Anti-RSV Drugs
CBR-001-633-695-1,RFM-009-833-9,CBR-001-633-695-1,OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)CC(=O)N)CCC(=O)O)CCC(=O)N)Cc1ccc(cc1)O)CCC(=O)N)CCC(=O)O)[C@H](O)C)NC(=O)[C@H]([C@H](O)C)N,"CBR-HVAC-14119: Cognition Disorders, Treatment of"
CBR-001-633-696-2,RFM-009-834-0,CBR-001-633-696-2,CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)O)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC(C)C)CC(C)C)CC(=O)N)Cc1ccccc1)C)CC(=O)N)CC(C)C)C,CBR-HVAC-06076: Wound-Healing Agents
CBR-001-633-697-3,RFM-009-835-1,CBR-001-633-697-3,CC(C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(=O)O)Cc1ccccc1)Cc1ccccc1)N)C,"CBR-HVAC-14078: Alzheimer's Dementia, Treatment of"
CBR-001-633-698-4,RFM-009-836-2,CBR-001-633-698-4,CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1cnc2c1cccc2)CCC(=O)O)N)C,CBR-HVAC-06400: Hematopoietic Agents;Immunostimulants
CBR-001-633-699-5,RFM-009-837-3,CBR-001-633-699-5,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCCNC(=N)N)Cc1ccc(cc1)O)C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)N)CC(=O)O,CBR-HVAC-05712: Immunomodulators
CBR-001-633-700-1,RFM-009-838-4,CBR-001-633-700-1,CC(C[C@@H](N(C(=O)[C@@H]1CCCN1)C)C(=O)NCC(=O)N)C,CBR-HVAC-13322:
CBR-001-633-701-2,RFM-009-839-5,CBR-001-633-701-2,C[C@H]([C@H]1C(=O)N2[C@@H]1SC(=C2C(=O)O)[C@@H]1CCCO1)O,CBR-HVAC-03515: Antibiotics
CBR-001-633-702-3,RFM-009-840-8,CBR-001-633-702-3,CC1CCCN1CCCOc1ccc(cc1)n1ncc(c1)C(=O)N1CCOCC1,"CBR-HVAC-13770: sleep Disorders, Treatment of"
CBR-001-633-703-4,RFM-009-841-9,CBR-001-633-703-4,CC1CCCN1CCCOc1ccc(cc1)n1ncc(c1)C(=O)N1CCOCC1,"CBR-HVAC-13770: sleep Disorders, Treatment of"
CBR-001-633-704-5,RFM-009-842-0,CBR-001-633-704-5,OC(=O)C[C@H]1[C@H](CN[C@@H]1C(=O)O)C(=C)C,"CBR-HVAC-10203: GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE"
CBR-001-633-705-6,RFM-009-843-1,CBR-001-633-705-6,NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)CCC(=O)N)C(C)C)CC(C)C)C(C)C,CBR-HVAC-00436: Zonulin Antagonist; Anti-inflammatory; Antidiabetic; Crohn's disease; Irritable bowel syndrome
CBR-001-633-706-7,RFM-009-844-2,CBR-001-633-706-7,O=C(c1ccc(cc1)Cc1c(=O)oc2c(c1O)cccc2)OC(C(F)(F)F)(C(F)(F)F)C,CBR-HVAC-00759: Vitamin K1 epoxide reductase inhibitor; Coagulation inhibitor; Anticoagulant; Thrombosis; Deep vein thrombosis; Stroke
CBR-001-633-707-8,RFM-009-845-3,CBR-001-633-707-8,NC(=O)C[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CCCNC(=N)N)N,"CBR-HVAC-12763: Vasopressin V1 receptor; Vasopressin V2 receptor Inhibitor; Antidiuretic; Varices, esophageal; Diabetes insipidus; Testing, hypothalamic-pituitary ACTH function"
CBR-001-633-708-9,RFM-009-846-4,CBR-001-633-708-9,CN([C@@H]1CCN(C1)c1ccc2c(c1)nc(n2)c1c(=O)nc2c(c1N)cccc2)C,CBR-HVAC-11552: Vascular endothelial growth factor receptor Inhibitor; Anticancer; Angiogenic disorders; Cancer
CBR-001-633-709-0,RFM-009-847-5,CBR-001-633-709-0,CN1CCN(CC1)c1c(F)cc2c3c1CCC(n3cc(c2=O)C(=O)O)C,CBR-HVAC-08123: Unidentified pharmacological activity
CBR-001-633-710-3,RFM-009-848-6,CBR-001-633-710-3,ClC[C@]1(COC(=O)C(C)C)O[C@H]([C@@H]([C@@H]1OC(=O)C(C)C)F)n1ccc(nc1=O)N,CBR-HVAC-07305: Unidentified pharmacological activity
CBR-001-633-711-4,RFM-009-849-7,CBR-001-633-711-4,NCCn1c(=O)n(c2c1cc(OC)cc2)C(=O)[C@@H]1C[C@H](C)CC[C@H]1C(C)C,CBR-HVAC-06831: TRPM8 (TRP-p8; CMR1) Agonists
CBR-001-633-712-5,RFM-009-850-0,CBR-001-633-712-5,OC(=O)COc1c(cc(cc1C(C)(C)C)SC(Sc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)(C)C)C(C)(C)C,CBR-HVAC-05483: TNF alpha Modulator; Antiinflammatory; Rheumatoid arthritis
CBR-001-633-713-6,RFM-009-851-1,CBR-001-633-713-6,O=C(Nc1cc(C)c(c(c1)C)Oc1ccc(c(c1)C(c1ccc(cc1)F)O)O)CC(=O)[O-],CBR-HVAC-12015: Thyroid hormone receptor Agonist; ANTICANCER; Liver cancer
CBR-001-633-714-7,RFM-009-852-2,CBR-001-633-714-7,Clc1ccc(cc1)S(=O)(=O)CCCc1ccc(c(c1)NC(=O)c1cccc(c1)OCc1scc(n1)C(C)(C)C)OCc1nnnn1,CBR-HVAC-04920: Thromboxane A2 receptor; Leukotriene D4 receptor Antagonist; Antiasthmatic; Asthma
CBR-001-633-715-8,RFM-009-853-3,CBR-001-633-715-8,OC(=O)c1ccc2c(c1)/C(=C/Cn1cnc3c1cc(C)c(c3)C)/c1ccccc1CO2,"CBR-HVAC-04037: Thromboxane A2 receptor Antagonist; Antiplatelet; Antithrombotic; Thromboembolism; Ischemia, cerebrovascular"
CBR-001-633-716-9,RFM-009-854-4,CBR-001-633-716-9,OC(=O)CN[C@@H](C(=O)N1CCC[C@H]1C(=O)NCc1ccc(s1)C(=N)N)C(c1ccccc1)c1ccccc1,CBR-HVAC-05386: THROMBIN Inhibitor; Coagulation factor IIa antagonist;Coagulation inhibitor; Venous thrombosis
CBR-001-633-717-0,RFM-009-855-5,CBR-001-633-717-0,O=C(Cn1c(C)cnc(c1=O)NCCc1ccccc1)NCc1ccc(nc1C)N,CBR-HVAC-11219: Thrombin Inhibitor; Antithrombotic; Thrombosis
CBR-001-633-718-1,RFM-009-856-6,CBR-001-633-718-1,N[C@H](C(=O)O)COCCN,CBR-HVAC-04846: Thrombin Inhibitor; Antineoplastic; Immunomodulator; Liver cancer
CBR-001-633-719-2,RFM-009-857-7,CBR-001-633-719-2,O=C(Nc1cccc(c1)C)Nc1ccc(cc1)c1csc2c1c(N)ncn2,CBR-HVAC-13840: STATHMIN 1/ONCOPROTEIN 18; SURVIVIN Inhibitor; Inhibitor; ANTI-CANCER; Cancer
CBR-001-633-720-5,RFM-009-858-8,CBR-001-633-720-5,CC(Cc1ccc(cc1)c1onc(n1)c1ccc(cc1)C(NC1CC(C1)C(=O)O)C)C,"CBR-HVAC-11908: Sphingosine 1 Phosphate receptor AGONIST; ANTISCLEROTIC; SCLEROSIS, MULTIPLE"
CBR-001-633-721-6,RFM-009-859-9,CBR-001-633-721-6,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N[C@H](C(=O)N)[C@H](O)C)NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)N)Cc1cnc2c1cccc2,"CBR-HVAC-12785: Somatostatin receptor Inhibitor; Antineoplastic; Proliferation; Acromegaly; Atherosclerosis; Carcinoma, breast; Carcinoid syndrome; Coronary artery restenosis; Diabetic retinopathy; Carcinoma, gastrointestinal; Leiomyoma; Carcinoma, lung; Neuroblastoma; Imaging, neuroendocrine tumors; Carcinoma, pancreatic; Portal hypertension; Carcinoma, prostate; Psoriasis; Rheumatic disorders"
CBR-001-633-722-7,RFM-009-860-2,CBR-001-633-722-7,O=c1nc2c(n1)c(cc(c2)c1c(C)noc1C)c1c(nnc1C1CC1)C1CC1,CBR-HVAC-13839: Solid Tumors Therapy;Non-Hodgkin's Lymphoma Therapy
CBR-001-633-723-8,RFM-009-861-3,CBR-001-633-723-8,OC[C@H]1O[C@@H](Oc2nnc(c2Cc2ccc(cc2)OC)C(F)(F)F)[C@@H]([C@H]([C@@H]1F)O)O,CBR-HVAC-06263: SODIUM DEPENDENT GLUCOSE COTRANSPORTER 1; SODIUM DEPENDENT GLUCOSE COTRANSPORTER 2 Inhibitor; Hypoglycemic; Non-insulin dependent diabetes
CBR-001-633-724-9,RFM-009-862-4,CBR-001-633-724-9,CCN1CC2CN(CC(C1)C2OC(=O)c1ccc(cc1)Cl)C,CBR-HVAC-03267: Sodium channel Blocker; Class I antiarrhythmic; Arrhythmia
CBR-001-633-725-0,RFM-009-863-5,CBR-001-633-725-0,CC(CNCCCC(c1ccccc1)(c1ccccc1)O)C,CBR-HVAC-13444: Sodium channel Blocker; Class I antiarrhythmic; Arrhythmia
CBR-001-633-726-1,RFM-009-864-6,CBR-001-633-726-1,CCOCn1c(=O)[nH]c(=O)c(c1[Se]c1cc(C)cc(c1)C)C(C)C,CBR-HVAC-10574: Reverse transcriptase Inhibitor; Antiviral; HIV infection
CBR-001-633-727-2,RFM-009-865-7,CBR-001-633-727-2,C/C(=C/C=C/C(=C/C(=O)O)/C)/C=C/1\CCCc2c1cccc2,CBR-HVAC-05698: Retinoid X receptor Agonist; Anticancer; Breast cancer
CBR-001-633-728-3,RFM-009-866-8,CBR-001-633-728-3,O=C(CC(C(NC(=O)C(NC(=O)C(Cc1cccc2c1cccc2)CC(=O)N1CCOCC1)Cc1ncsc1)CC1CCCCC1)O)NCCN1CCOCC1,CBR-HVAC-00132: RENIN INHIBITOR; ANTIHYPERTENSIVE; HYPERTENSION
CBR-001-633-729-4,RFM-009-867-9,CBR-001-633-729-4,COCCCOc1cc(ccc1OC)C[C@H](C(C)C)CC([C@H](C[C@H](C(=O)NCC(C(=O)N)(C)C)C(C)C)O)N,CBR-HVAC-00923: Renin Inhibitor; Antihypertensive; Antiarteriosclerotic; Antidiuretic; Hypertension
CBR-001-633-730-7,RFM-009-868-0,CBR-001-633-730-7,NCCCCC(C(=O)O)NC(=O)C(Cc1ccc(cc1)O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(NC(=O)C(Cc1cncn1)NC(=O)C(Cc1ccccc1)NC(=O)C1CCCN1C(=O)C(Cc1cncn1)NC(=O)C1CCCN1)CC(C)C)CC(C)C,CBR-HVAC-13600: Renin inhibitor
CBR-001-633-731-8,RFM-009-869-1,CBR-001-633-731-8,COc1ccc2c(n1)nc([nH]2)S(=O)Cc1ncc(c(c1C)OC)C,"CBR-HVAC-00584: H+ K+ transporting ATPase inhibitor; H+/K+-ATPase Inhibitors; Immune Checkpoint Inhibitors; Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Inhibitors; Proton pump Inhibitor; Gastric Antisecretory Drugs; Gastric antisecretory"
CBR-001-633-732-9,RFM-009-870-4,CBR-001-633-732-9,COc1cc2CCN(CCc2cc1OC)CCc1ccc(cc1)N,CBR-HVAC-09979: Prostaglandin synthase inhibitor
CBR-001-633-733-0,RFM-009-871-5,CBR-001-633-733-0,O=C1c2sc(nc2C(=O)c2c1cccc2)c1ccco1,CBR-HVAC-07925: Prostaglandin E2 receptor antagonist
CBR-001-633-734-1,RFM-009-872-6,CBR-001-633-734-1,O=C(C1CCCCN1CC1CC1)Nc1c(C)cccc1C,CBR-HVAC-12715: Potassium channel Kv4.3; Potassium channel hERG; Potassium channel Kv1.2; Potassium channel Kv1.5 Blocker; Local anesthetic; Pain
CBR-001-633-735-2,RFM-009-873-7,CBR-001-633-735-2,CCN(CCOc1c(I)cc(cc1I)C(=O)c1c(CC(=O)OC(CC)C)oc2c1cccc2)CC,CBR-HVAC-05277: Potassium channel Inhibitor; Antiarrhythmic agent; Heart arrhythmia; Tachycardia
CBR-001-633-736-3,RFM-009-874-8,CBR-001-633-736-3,COc1ccc(cc1)CC(=O)Nc1cc2c(cc1[N+](=O)[O-])OC([C@@H]([C@H]2NC1CC1)O)(C)C,CBR-HVAC-11057: POTASSIUM CHANNEL Blocker; ; Arrhythmia
CBR-001-633-737-4,RFM-009-875-9,CBR-001-633-737-4,Cc1nnc2n1c1sc(cc1C(=NC2)c1ccccc1Cl)C#CCn1c(=O)c2ccccc2c2c1cccc2,CBR-HVAC-03929: Platelet activating factor receptor Antagonist; Antiinflammatory; Asthma
CBR-001-633-738-5,RFM-009-876-0,CBR-001-633-738-5,COc1cc(N)ccc1c1nc2c(C)nn(c2c(=O)[nH]1)C1CCCCC1,CBR-HVAC-13813: Phosphodiesterase PDE7 Inhibitors;Signal Transduction Modulators
CBR-001-633-739-6,RFM-009-877-1,CBR-001-633-739-6,Cc1noc(n1)/C(=C/c1ccccc1c1cc(cc2c1nccc2)C(S(=O)(=O)C)(C)C)/c1ccc(cc1)S(=O)(=O)C,CBR-HVAC-08594: Phosphodiesterase 4 Inhibitor; Anti-inflammatory; Bronchodilator; Rheumatoid arthritis; Asthma; Chronic obstructive pulmonary disease
CBR-001-633-740-9,RFM-009-878-2,CBR-001-633-740-9,O=c1nc2c(n1)cc(c(n2)C)c1ccncc1,CBR-HVAC-11489: Phosphodiesterase 3 Inhibitor; Cardioprotectant; Cardiac failure
CBR-001-633-741-0,RFM-009-879-3,CBR-001-633-741-0,CCCCCCc1[nH]c2c(n1)n1[C@H]3CCC[C@H]3N=c1n(c2=O)C,CBR-HVAC-11626: Phosphodiesterase 1 inhibitor; Phosphodiesterase 5 inhibitor; Antihypertensive; Hypertension; Restenosis; Vascular disease
CBR-001-633-742-1,RFM-009-880-6,CBR-001-633-742-1,N#Cc1cc(Cl)ccc1OC[C@H](COc1cccc(c1)CC(C(=O)O)OC(C)C)F,CBR-HVAC-07772: Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor alpha/gamma agoni; Insulin sensitizer
CBR-001-633-743-2,RFM-009-881-7,CBR-001-633-743-2,N#Cc1cc(Cl)ccc1OC[C@H](COc1cccc(c1)CC(C(=O)O)OC(C)C)F,CBR-HVAC-07772: Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor alpha/gamma agoni; Insulin sensitizer
CBR-001-633-744-3,RFM-009-882-8,CBR-001-633-744-3,CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)[O-])C[n+]1ccc(cc1)c1cnco1,"CBR-HVAC-00498: PENICILLIN BINDING PROTEIN Inhibitor; ANTI-BACTERIAL; Infection, bacterial"
CBR-001-633-745-4,RFM-009-883-9,CBR-001-633-745-4,[O-]C(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)NC(=O)c1c(C)onc1c1ccccc1Cl,"CBR-HVAC-12767: Penicillin binding protein Inhibitor; Antibacterial; Infection, bacterial"
CBR-001-633-746-5,RFM-009-884-0,CBR-001-633-746-5,CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N2[C@@H]1S(=O)CC(=C2C(=O)O)COC(=O)C,"CBR-HVAC-00979: Penicillin binding protein Inhibitor; Antibacterial; Infection, bacterial"
CBR-001-633-747-6,RFM-009-885-1,CBR-001-633-747-6,O=C(N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nncn1)Cc1cccs1,"CBR-HVAC-08725: Penicillin binding protein Inhibitor; Antibacterial; Infection, bacterial"
CBR-001-633-748-7,RFM-009-886-2,CBR-001-633-748-7,OCC(=O)N1CCC(CC1)c1[nH]nc(c1c1ccncn1)c1ccc(cc1F)Cl,CBR-HVAC-13893: P38 MAPK Inhibitor; ; Diabetic retinopathy
CBR-001-633-749-8,RFM-009-887-3,CBR-001-633-749-8,O=C(N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1ccc(cc1)[N+](=O)[O-])CNC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C,CBR-HVAC-10389: Opioid receptor mu Agonist; Antiasthmatic; Asthma
CBR-001-633-750-1,RFM-009-888-4,CBR-001-633-750-1,Fc1ccc(cc1)C[C@@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)NC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C,CBR-HVAC-04941: Opioid receptor mu Agonist; Analgesic; Pain
CBR-001-633-751-2,RFM-009-889-5,CBR-001-633-751-2,OC[C@@H](Cn1c(=O)n(c2c1cccc2)C1CCN(CC1)CC1C2CCC(C31CC3)C2)O,CBR-HVAC-06914: Opioid receptor like 1 antagonist; Antipsychotic; Psychiatric disorder
CBR-001-633-752-3,RFM-009-890-8,CBR-001-633-752-3,CCNC(=O)[C@H](NC(=O)[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](Cc1ccc(cc1)O)NC)CC(C)C)CCCNC(=N)N)C)CCCNC(=N)N)CC(C)C,CBR-HVAC-12858: Opioid receptor kappa Agonist; Analgesic; Diuretics; Pain
CBR-001-633-753-4,RFM-009-891-9,CBR-001-633-753-4,NC(=N)NCCC[C@H](C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1ccc(cc1)[N+](=O)[O-])NC(=O)[C@H](Cc1ccc(cc1)O)N,CBR-HVAC-03564: Opioid receptor agonist; Vasopressin antagonist; Histamine receptor antagonist
CBR-001-633-754-5,RFM-009-892-0,CBR-001-633-754-5,CSCC[C@H](N(C(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C)C)C(=O)N,CBR-HVAC-08045: Opioid receptor agonist
CBR-001-633-755-6,RFM-009-893-1,CBR-001-633-755-6,NCCCC[C@H](C(=O)N1CCC(CC1)(N)C(=O)O)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1ccccc1)N)Cc1ccccc1)CC(C)C,CBR-HVAC-00602: OPIOID KAPPA RECEPTOR Agonist; ANALGESIC; Pain
CBR-001-633-756-7,RFM-009-894-2,CBR-001-633-756-7,COc1ccccc1[C@@H]([C@](C(=O)N1CCC(CC1)c1cccc(c1)C(F)(F)F)(C#N)C)c1cccc2c1cccc2,"CBR-HVAC-06130: Nuclear factor kappa B; Estrogen receptor Inhibitor; Modulator; Anti-inflammatory; ARTHRITIS, RHEUMATOID; INFLAMMATORY DISEASE"
CBR-001-633-757-8,RFM-009-895-3,CBR-001-633-757-8,CCOc1nc(N)nc2c1ncn2[C@@H]1O[C@H]2[C@H]([C@@]1(C)F)OP(=O)(OC2)OC(C)C,"CBR-HVAC-06922: NS5B POLYMERASE Inhibitor; ANTIVIRAL; INFECTION, HEPATITIS C VIRUS"
CBR-001-633-758-9,RFM-009-896-4,CBR-001-633-758-9,NC(=N)NCC1CCC(CC1)C(=O)Oc1ccccc1C(=O)OCc1ccccc1,CBR-HVAC-01887: Nitric oxide synthase Inhibitor; Antiulcer; Ulcer
CBR-001-633-759-0,RFM-009-897-5,CBR-001-633-759-0,C1NC[C@@H](C1)/C=C/c1cncnc1,CBR-HVAC-13851: Nicotinic alpha3beta4 Receptor Ligands;Nicotinic alpha4beta2 Modulators;Signal Transduction Modulators
CBR-001-633-760-3,RFM-009-898-6,CBR-001-633-760-3,CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)c1cccnc1,CBR-HVAC-04529: Nicotinic acetylcholine receptor Modulator; Antihyperlipidemic; Hyperlipidemia
CBR-001-633-761-4,RFM-009-899-7,CBR-001-633-761-4,COC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)C(F)(F)F)C(C)C)C(C)C,CBR-HVAC-04874: Neutrophil elastase Inhibitor; Cardioprotectant; Vasoprotectant; Adult respiratory distress syndrome; Bronchitis; Congestive heart failure; Chronic obstructive pulmonary disorder; Peripheral vascular disease
CBR-001-633-762-5,RFM-009-900-3,CBR-001-633-762-5,Cc1ccc2c(c1)c1nc(nc1CCC2)c1cccnc1,CBR-HVAC-11953: Neuropeptide Y5 receptor Antagonist; Appetite suppressant; EATING DISORDERS; OBESITY; DIABETES MELLITUS
CBR-001-633-763-6,RFM-009-901-4,CBR-001-633-763-6,CN1CCN(CC1)c1nccc(c1)Cn1cc(ccc1=O)c1onc(n1)c1ccc(cc1)OC(F)(F)F,CBR-HVAC-14019: NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitors
CBR-001-633-764-7,RFM-009-902-5,CBR-001-633-764-7,OC[C@@](c1ccccc1)(C(=O)O[C@H]1CN2CCC1CC2)CC[S@+](C)[O-],CBR-HVAC-04433: Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1 Antagonist; Bronchodilator; Chronic obstructive pulmonary disease
CBR-001-633-765-8,RFM-009-903-6,CBR-001-633-765-8,OC[C@@](c1ccccc1)(C(=O)O[C@H]1CN2CCC1CC2)CC[S@+](C)[O-],CBR-HVAC-04433: Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1 Antagonist; Bronchodilator; Chronic obstructive pulmonary disease
CBR-001-633-766-9,RFM-009-904-7,CBR-001-633-766-9,Fc1cccc(c1)N(C(=O)O[C@H]1C[N+]2(CCC1CC2)CC(=O)c1cccs1)Cc1cc(F)c(c(c1)F)F,CBR-HVAC-00575: Muscarinic acetylcholine receptor M3 Antagonist; Bronchodilator; Anticholinergic; Chronic obstructive pulmonary disease
CBR-001-633-767-0,RFM-009-905-8,CBR-001-633-767-0,CCN([C@H](Cc1ccc(cc1)OC)C)CCCC(=O)C1CCCCC1,CBR-HVAC-00929: Muscarinic acetylcholine receptor Antagonist; Anticholinergic; Parkinson's disease
CBR-001-633-768-1,RFM-009-906-9,CBR-001-633-768-1,CCN([C@H](Cc1ccc(cc1)OC)C)CCCC(=O)C1CCCCC1,CBR-HVAC-00929: Muscarinic acetylcholine receptor Antagonist; Anticholinergic; Parkinson's disease
CBR-001-633-769-2,RFM-009-907-0,CBR-001-633-769-2,OC(c1ccccc1)(C1CCCC1)CCN1CCCCC1,CBR-HVAC-13402: Muscarinic acetylcholine receptor Antagonist; Anticholinergic; Parkinsonism
CBR-001-633-770-5,RFM-009-908-1,CBR-001-633-770-5,CC1CCCC(N1CCCC(c1ccccn1)(c1ccccc1)O)C,CBR-HVAC-01599: Muscarinic acetylcholine receptor Antagonist; Antiarrhythmic; Ventricular arrhythmia
CBR-001-633-771-6,RFM-009-909-2,CBR-001-633-771-6,COc1cc(cc(c1OC)OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)OC(CCCc1cccnc1)CCCc1cccnc1,CBR-HVAC-04539: Multidrug resistance associated protein 1 Modulator; Anticancer; Ovarian cancer
CBR-001-633-772-7,RFM-009-910-5,CBR-001-633-772-7,CC([C@@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NC(C)(C)C)N(C(=O)[C@H](C(C)C)NC(=O)[C@@H](N(C)C)C(C)C)C)C,CBR-HVAC-00107: Microtubule inhibitor; Anticancer; Cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer
CBR-001-633-773-8,RFM-009-911-6,CBR-001-633-773-8,O=C(c1ccccc1c1ccc(cc1)C(F)(F)F)Nc1ccc2c(c1)CCN(C2)Cc1nccn1,CBR-HVAC-11388: Microsomal triglyceride transfer protein Inhibitor; Antidiabetic; Hypoglycemic; Antihypercholesterolemic; Atherosclerosis; Pancreatitis; Obesity; Hypercholesterolemia; Hypertriglyceridemia; Hyperlipidemia; Diabetes
CBR-001-633-774-9,RFM-009-912-7,CBR-001-633-774-9,OC(=O)C(C12C3C4C2C2C1C3C42C(=O)O)(CC1c2ccccc2Sc2c1cccc2)N,CBR-HVAC-11686: Metabotropic glutamate receptor Agonist; Neuroprotectant; Anxiolytic; Neurodegenerative diseases disease; Ischemia; Anxiety disorder
CBR-001-633-775-0,RFM-009-913-8,CBR-001-633-775-0,CC(Cc1cc2CCCn3c2c(c1)c(CCN1CCN(CC1)c1nccc(c1)C)c3C)C,CBR-HVAC-11301: Lipoxygenase 5; Histamine H1 receptor Antagonist; Inhibitor; Antiinflammatory; Asthma
CBR-001-633-776-1,RFM-009-914-9,CBR-001-633-776-1,COc1c(OC)c(OC(=O)C)c2c(c1OC(=O)C)ccc(c2)Cl,CBR-HVAC-03039: Lipoxygenase 5 Inhibitor; Antiinflammatory; Psoriasis
CBR-001-633-777-2,RFM-009-915-0,CBR-001-633-777-2,CCC(C(=O)O)(CC(=O)Nc1cccc(c1)/C=C/c1scc(n1)C(C)C)CC,CBR-HVAC-03713: Leukotriene D4 receptor Antagonist; Antiinflammatory; Asthma
CBR-001-633-778-3,RFM-009-916-1,CBR-001-633-778-3,CCCCN(C(=O)Nc1cc(cc(c1OCCC)OC)C1CCC(O1)c1cc(OC)c(c(c1)OC)OC)O,CBR-HVAC-11406: Leukotriene B4 receptor; Lipoxygenase 5; Platelet activating factor receptor Antagonist; Inhibitor; Antiinflammatory; Inflammatory diseases
CBR-001-633-779-4,RFM-009-917-2,CBR-001-633-779-4,COc1ccc(cc1)/C=C/CCCCOc1ccc2c(c1CCC(=O)O)oc1c(c2=O)cc(cc1)C(=O)O,CBR-HVAC-02740: Leukotriene B4 receptor Antagonist; Non-Steroidal Antiinflammatory; Inflammatory diseases
CBR-001-633-780-7,RFM-009-918-3,CBR-001-633-780-7,COc1ccc(cc1)/C=C/CCCCOc1cccc(c1CCC(=O)O)OCCCCC(=O)O,CBR-HVAC-04358: Leukotriene B4 receptor Antagonist; Antiinflammatory; Psoriasis; Inflammatory bowel disease; Behcet's syndrome; Gastritis; Ulcerative colitis
CBR-001-633-781-8,RFM-009-919-4,CBR-001-633-781-8,Clc1ccc2c(c1)nc1c(c2O)c(=O)nnc1=O,CBR-HVAC-10698: Ionotropic glutamate receptor NMDA Antagonist; Neuroprotectant; Neurological disorder; Stroke
CBR-001-633-782-9,RFM-009-920-7,CBR-001-633-782-9,NCC1(C2CC3CC1CC(C2)C3)c1cccc(c1)C,CBR-HVAC-11417: Ionotropic glutamate receptor NMDA Antagonist; Neuroprotectant; Analgesic; Neuropathic pain
CBR-001-633-783-0,RFM-009-921-8,CBR-001-633-783-0,C1CCC(NC1)C1COC(O1)(c1ccccc1)c1ccccc1,CBR-HVAC-09892: Ionotropic glutamate receptor NMDA Antagonist; Analgesic; CNS stimulant; Pain
CBR-001-633-784-1,RFM-009-922-9,CBR-001-633-784-1,C1CCC(NC1)C1COC(O1)(c1ccccc1)c1ccccc1,CBR-HVAC-09892: Ionotropic glutamate receptor NMDA Antagonist; Analgesic; CNS stimulant; Pain
CBR-001-633-785-2,RFM-009-923-0,CBR-001-633-785-2,CO[C@@H]1CC(C)(C)C[C@@H]2[C@@]1(C)CCC1(C2=CCC2[C@@]1(C)CCC1[C@]2(C)CC[C@@H]([C@]1(C)CO)O)C,CBR-HVAC-11783: Interleukin 6 Inducer; Hepatoprotectant; Antiviral; Alcoholic hepatitis; HCV infection
CBR-001-633-786-3,RFM-009-924-1,CBR-001-633-786-3,Fc1ccc(cc1)Cc1nn(C2CCCN(CC2)CCc2ccccc2)c(=O)c2c1cccc2,"CBR-HVAC-04395: Interleukin 1 Inhibitor; Anticancer; Rhinitis, allergic; Asthma; Cancer; Neoplasm"
CBR-001-633-787-4,RFM-009-925-2,CBR-001-633-787-4,NC(=N)NCCC[C@H]1NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N(C(=O)[C@H](NC1=O)CCCNC(=N)N)C)Cc1ccccc1)CC(C)C)C(C)C,CBR-HVAC-13234: Integrin alpha4 beta1 Antagonist; Antiinflammatory; Immunosuppressant; Antirheumatic; Rheumatoid arthritis; Multiple sclerosis; Inflammation
CBR-001-633-788-5,RFM-009-926-3,CBR-001-633-788-5,CC(C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)CC(=O)O)NC(=O)Cc1ccc(cc1)NC(=O)Nc1ccccc1C)C,CBR-HVAC-13396: Integrin alpha4 beta1 Antagonist; Anti-inflammatory; Asthma
CBR-001-633-789-6,RFM-009-927-4,CBR-001-633-789-6,COc1ccc(cc1)C[C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC1=O)CCCNC(=N)N)C(=O)N)NC(=O)C)CC(=O)N)CC(=O)O,CBR-HVAC-00135: Integrin alpha2b beta3 Antagonist; Fibrinolytic; Vasoprotectant; Antithrombotic; Reperfusion injury; Stroke; Thrombosis; Unstable angina pectoris; Vascular restenosis; Cerebrovascular ischemia; Restenosis
CBR-001-633-790-9,RFM-009-928-5,CBR-001-633-790-9,OC(=O)C[C@@H](NC(=O)CC(C)C)CCCCNC(=O)c1ccc(cc1)C(=N)N,CBR-HVAC-04505: Integrin alpha2b beta3 Antagonist; Antithrombotic; Thrombosis; Xenotransplant rejection; Thromboembolism; Ischemic Stroke
CBR-001-633-791-0,RFM-009-929-6,CBR-001-633-791-0,O=C(N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)CC(=O)O)CCCOc1ccc(cc1)C(=N)N,CBR-HVAC-04396: Integrin alpha2b beta3 Antagonist; Antithrombotic; Antiplatelet; Thrombosis; Coronary artery restenosis
CBR-001-633-792-1,RFM-009-930-9,CBR-001-633-792-1,OC(=O)COc1cc(ccc1OCC(=O)O)C(=O)CN(C(=O)c1ccc(cc1)C(=N)N)C,CBR-HVAC-11123: Integrin alpha2b beta3 Antagonist; Antianginal; Angina; Restenosis; Cardiac failure; Thromboembolism
CBR-001-633-793-2,RFM-009-931-0,CBR-001-633-793-2,CC[C@@H](C1NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](N)CSSCC(NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC(=O)N)CC(=O)N)C(=O)N1CCCC1C(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)C,"CBR-HVAC-13065: Inhibits the transglycosylation step of peptidoglycan biosynthesis; Antibiotic; Infection, bacterial"
CBR-001-633-794-3,RFM-009-932-1,CBR-001-633-794-3,Fc1ccc(cc1)c1ncc(s1)C(c1ccncc1)(O)C,CBR-HVAC-13756: In patients with metastatic progressive castrate resistant ASN-001; Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors
CBR-001-633-795-4,RFM-009-933-2,CBR-001-633-795-4,CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)C)C(C)C)NC(=O)[C@H](CCCNC(=N)N)N)C,CBR-HVAC-12680: Immunostimulant
CBR-001-633-796-5,RFM-009-934-3,CBR-001-633-796-5,OC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)CS)CS)Cc1ncnc1)NC(=O)[C@H](Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](N)C)Cc1ncnc1,"CBR-HVAC-06104: Immunoglobulin E antagonist; Immunomodulator; Anti-inflammatory; Multiple sclerosis; Allergic asthma; Crohn's disease; Skin disorders; Eczema; Dermatitis, contact"
CBR-001-633-797-6,RFM-009-935-4,CBR-001-633-797-6,C1CCN2C(C1)Cc1nc3c(n1CC2)ccc(c3)c1ccc2n(c1)ccn2,CBR-HVAC-07108: Histamine H3 Receptor Antagonists;Signal Transduction Modulators
CBR-001-633-798-7,RFM-009-936-5,CBR-001-633-798-7,C1CCN2C(C1)Cc1nc3c(n1CC2)ccc(c3)c1ccc2n(c1)ccn2,CBR-HVAC-07108: Histamine H3 Receptor Antagonists;Signal Transduction Modulators
CBR-001-633-799-8,RFM-009-937-6,CBR-001-633-799-8,CC(CNC(=O)[C@@H]1C[C@](C1)(F)c1ccc(c(c1)F)CN1CCCC1)C,CBR-HVAC-12937: HISTAMINE H3 RECEPTOR Antagonist; Nootropic; Anti-inflammatory; SCHIZOPHRENIA
CBR-001-633-800-4,RFM-009-938-7,CBR-001-633-800-4,O=C(NCCCOc1cccc(c1)CN1CCCCC1)CCCNC(=S)Nc1ccc2c(c1)OCO2,CBR-HVAC-04417: Histamine H2 receptor Antagonist; Antiulcer; Stomach ulcer
CBR-001-633-801-5,RFM-009-939-8,CBR-001-633-801-5,O=C(CS(=O)Cc1ccco1)NCCCOc1cccc(c1)CN1CCCCC1,CBR-HVAC-10664: Histamine H2 receptor Antagonist; Antisecretory; Cytoprotective; Antiulcer; Gastric ulcer; Stomach ulcer
CBR-001-633-802-6,RFM-009-940-1,CBR-001-633-802-6,OC(=O)[C@H]1CCCC[C@]1(O)c1ccccc1,CBR-HVAC-02807: Hepatoprotectant; HEPATOPROTECTOR; LIVER DISEASE; CHOLESTASIS
CBR-001-633-803-7,RFM-009-941-2,CBR-001-633-803-7,CN(CCOC(c1ccc(cc1)Br)(c1ccccc1)C)C,CBR-HVAC-13139: H1-receptor Antagonist; Antihistamine; Anticholinergic; ATTENTION DEFICIT HYPERACTIVITY DISORDER; NARCOLEPSY
CBR-001-633-804-8,RFM-009-942-3,CBR-001-633-804-8,COc1ccnc2c1CCCCC2[S@](=O)c1nc2c(n1)cccc2,CBR-HVAC-10421: H+/K+ ATPase Inhibitor; Proton pump inhibitor; Peptic ulcer
CBR-001-633-805-9,RFM-009-943-4,CBR-001-633-805-9,COc1ccc2c(c1)nc(n2)S(=O)Cc1nccc(c1Cl)N1CCOCC1,"CBR-HVAC-03478: H+/K+ ATPase Inhibitor; Antiulcer; Ulcer, peptic"
CBR-001-633-806-0,RFM-009-944-5,CBR-001-633-806-0,CCNc1ccccc1CS(=O)c1nc2c(n1)cc(c(c2)OC)OC,CBR-HVAC-08313: H+ K+ transporting ATPase inhibitor; Gastrin inhibitor
CBR-001-633-807-1,RFM-009-945-6,CBR-001-633-807-1,COc1ccnc(c1C)CSc1nc2c(n1)cc1c(c2)C(C)(C)C(=O)C1(C)C,CBR-HVAC-08281: H+ K+ transporting ATPase inhibitor
CBR-001-633-808-2,RFM-009-946-7,CBR-001-633-808-2,COC(=O)Nc1c(N)nc(nc1N)c1nn(c2c1cccn2)Cc1ccccc1F,CBR-HVAC-12958: Guanylate cyclase Stimulator; Cardiac agent; Chronic heart failure
CBR-001-633-809-3,RFM-009-947-8,CBR-001-633-809-3,O=C(N1CCC2=NN(C(=O)C2(C1)Cc1ccccc1)C)[C@@H](NC(=O)C(N)(C)C)COCc1ccccc1,CBR-HVAC-00620: Growth hormone secretagogue receptor Agonist; Cardioprotectant; Gastroesophageal reflux disease; Aging effect
CBR-001-633-810-6,RFM-009-948-9,CBR-001-633-810-6,O=C(N1CCC2=NN(C(=O)C2(C1)Cc1ccccc1)C)[C@H](NC(=O)C(N)(C)C)COCc1ccccc1,CBR-HVAC-00620: Growth hormone secretagogue receptor Agonist; Cardioprotectant; Gastroesophageal reflux disease; Aging effect
CBR-001-633-811-7,RFM-009-949-0,CBR-001-633-811-7,O=C(N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)CC(=O)O)CCCCc1ccc(cc1)C(=N)N,CBR-HVAC-04321: GPIIb IIIa receptor antagonist
CBR-001-633-812-8,RFM-009-950-3,CBR-001-633-812-8,[NH3+]Cc1ccc(cc1)C[C@@H]1NC(=O)[C@H]2N(CSC2(C)C)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC1=O)CC(=O)[O-])C(=O)O)NC(=O)C,CBR-HVAC-04371: GPIIb IIIa receptor antagonist
CBR-001-633-813-9,RFM-009-951-4,CBR-001-633-813-9,CC[C@H]1NC(=O)c2cccc(c2)CNC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N(C1=O)C)CCCNC(=N)N)CC(=O)O,CBR-HVAC-04514: GP IIb/IIIa receptor ANTAGONIST; ANTITHROMBOLYTIC; ANTIPLATELET; THROMBOSIS
CBR-001-633-814-0,RFM-009-952-5,CBR-001-633-814-0,CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)C(NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1)CO)CCCNC(=N)N,analog of CBR-HVAC-00595
CBR-001-633-815-1,RFM-009-953-6,CBR-001-633-815-1,O=C(CC(C)(C)C)OCC(=O)[C@@]1(O)CC[C@@H]2C1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=CC12C,CBR-HVAC-13373: Glucocorticoid receptor Agonist; Anti-inflammatory; Pain; Discomfort; Joint damage with overuse; Inflammation
CBR-001-633-816-2,RFM-009-954-7,CBR-001-633-816-2,CC(C[C@H](NC(=O)[C@H](Cc1cncn1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1NCc2c(C1)c1ccccc1n2)CCC(=O)N)C)CN[C@H](C(=O)N)CC(C)C)C,CBR-HVAC-00226: Gastrin-releasing peptide receptor Antagonist; Anticancer; Prostate cancer; Small cell lung cancer
CBR-001-633-817-3,RFM-009-955-8,CBR-001-633-817-3,COC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc1c(F)c(F)c(c(c1F)F)F)N)CCC(=O)N)C)C)Cc1ncnc1)CC(C)C,CBR-HVAC-04443: Gastrin releasing peptide receptor Antagonist; Anticancer; Cancer
CBR-001-633-818-4,RFM-009-956-9,CBR-001-633-818-4,CCN(CCNC1c2ccccc2OCc2c1cccn2)CC,CBR-HVAC-12856: Gastric acid secretion inhibitor; Antiulcer; Duodenal ulcer; Gastric ulcer
CBR-001-633-819-5,RFM-009-957-0,CBR-001-633-819-5,CCNC(=O)c1nn(c(n1)CN(C)C)c1ccc(cc1C(=O)c1ccccc1Cl)Cl,CBR-HVAC-13655: GABA receptor agonist; Chloride channel agonist; Potassium channel agonist
CBR-001-633-820-8,RFM-009-958-1,CBR-001-633-820-8,CCCCCCCCCCCCCCCC(=O)OC1Cc2c(O)cc(cc2OC1c1ccc(c(c1)O)O)O,CBR-HVAC-08561: Free radical scavenger; Reducing agent; Immunostimulant
CBR-001-633-821-9,RFM-009-959-2,CBR-001-633-821-9,CC[C@@H]([C@@H]1NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)[C@H](O)C)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)C,CBR-HVAC-09677: Follicle stimulating hormone receptor Agonist; Follicle stimulating hormone; Polycystic ovary syndrome; Infertility
CBR-001-633-822-0,RFM-009-960-5,CBR-001-633-822-0,O=C1[C@@H](NC(=O)c2c(C)onc2c2c(F)cccc2Cl)[C@@H]2N1[C@@H](C(=O)[O-])C(S2)(C)C,"CBR-HVAC-02873: Flucloxacillin, an analogue of oxacillin, is a semisynthetic penicillinase-resistant penicillin against primarily effective against staphylococci; Antibiotic; Infection, bacterial"
CBR-001-633-823-1,RFM-009-961-6,CBR-001-633-823-1,C#Cc1cccc(c1)c1cc(=O)n(c2c1cc(cc2)C(c1cncn1C)(c1ccc(cc1)Cl)O)C,"CBR-HVAC-05124: FARNESYLTRANSFERASE Inhibitor; Anticancer; Carcinoma, Bladder; Alzheimer'S Disease"
CBR-001-633-824-2,RFM-009-962-7,CBR-001-633-824-2,C#Cc1cccc(c1)c1cc(=O)n(c2c1cc(cc2)C(c1cncn1C)(c1ccc(cc1)Cl)O)C,"CBR-HVAC-05124: FARNESYLTRANSFERASE Inhibitor; Anticancer; Carcinoma, Bladder; Alzheimer'S Disease"
CBR-001-633-825-3,RFM-009-963-8,CBR-001-633-825-3,CCC(=C(c1ccccc1)c1ccc(cc1)/C=C/C(=O)O)c1ccccc1,CBR-HVAC-13810: Estrogen receptor Modulator; Anticancer; Breast cancer; Ovarian cancer; Uterine cancer
CBR-001-633-826-4,RFM-009-964-9,CBR-001-633-826-4,CCC(=C(c1ccccc1)c1ccc(cc1)/C=C/C(=O)O)c1ccccc1,CBR-HVAC-13810: Estrogen receptor Modulator; Anticancer; Breast cancer; Ovarian cancer; Uterine cancer
CBR-001-633-827-5,RFM-009-965-0,CBR-001-633-827-5,CCC(=C(c1ccc(cc1)OP(=O)(O)O)c1ccc(cc1)OCCN(C)C)c1ccc(cc1)C(C)C,CBR-HVAC-03732: Estrogen receptor Modulator; Anticancer; Breast cancer
CBR-001-633-828-6,RFM-009-966-1,CBR-001-633-828-6,CCC(=C(c1ccc(cc1)OP(=O)(O)O)c1ccc(cc1)OCCN(C)C)c1ccc(cc1)C(C)C,CBR-HVAC-03732: Estrogen receptor Modulator; Anticancer; Breast cancer
CBR-001-633-829-7,RFM-009-967-2,CBR-001-633-829-7,COc1ccc2c(c1)OC([C@@H]([C@H]2c1ccc(cc1)OCCN1CCCC1)c1ccccc1)(C)C,CBR-HVAC-00946: Estrogen receptor Antagonist; Anticancer; Breast cancer
CBR-001-633-830-0,RFM-009-968-3,CBR-001-633-830-0,COc1ccc2c(c1)OC([C@@H]([C@H]2c1ccc(cc1)OCCN1CCCC1)c1ccccc1)(C)C,CBR-HVAC-00946: Estrogen receptor Antagonist; Anticancer; Breast cancer
CBR-001-633-831-1,RFM-009-969-4,CBR-001-633-831-1,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2[C@H](C)CC2=C1CCC(=C)C2,CBR-HVAC-11988: Estrogen receptor alpha Agonist; Immunosuppressant; IMMUNE DISORDERS
CBR-001-633-832-2,RFM-009-970-7,CBR-001-633-832-2,COc1cc2ncnc(c2cc1OCCCN1CCOCC1)Nc1cccc(c1)C#C,CBR-HVAC-06929: EPIDERMAL GROWTH FACTOR RECEPTOR Inhibitor; ANTI-VIRAL; Viral infection
CBR-001-633-833-3,RFM-009-971-8,CBR-001-633-833-3,COc1nc(C)cnc1NS(=O)(=O)c1cccnc1c1ccc(cc1)CC(C(=O)O)(C)C,CBR-HVAC-04912: Endothelin A receptor Antagonist; Antihypertensive; Chronic obstructive pulmonary disease; Heart failure; Hypertension; Cardiovascular diseases
CBR-001-633-834-4,RFM-009-972-9,CBR-001-633-834-4,Oc1nc(=O)n(cc1C)CCCCN1CCN(CC1)c1cc(nc(n1)C(C)(C)C)C(F)(F)F,CBR-HVAC-11690: Dopamine receptor D3 Antagonist; Antipsychotic; Schizophrenia
CBR-001-633-835-5,RFM-009-973-0,CBR-001-633-835-5,COc1ccccc1N1CCC(CC1)CNC[C@H]1COc2c(O1)cc(cc2)Cl,CBR-HVAC-07572: Dopamine receptor D2; 5-Hydroxytryptamine 1A receptor Antagonist; Partial Agonist; Antipsychotic; Schizophrenia
CBR-001-633-836-6,RFM-009-974-1,CBR-001-633-836-6,Fc1ccc(cc1)C(=O)CCCN1CCC(CC1)C(=O)c1ccc(cc1)F,CBR-HVAC-13226: Dopamine receptor Antagonist; Antipsychotic; Schizophrenia; Depression; Anxiety
CBR-001-633-837-7,RFM-009-975-2,CBR-001-633-837-7,CCCN1CCC[C@@H](C1)c1cccc(c1)C#N,CBR-HVAC-10706: Dopamine receptor Antagonist; Antidepressant; Antipsychotic; Depression; Psychosis; Schizophrenia
CBR-001-633-838-8,RFM-009-976-3,CBR-001-633-838-8,CCCN1CCC[C@@H](C1)c1cccc(c1)C#N,CBR-HVAC-10706: Dopamine receptor Antagonist; Antidepressant; Antipsychotic; Depression; Psychosis; Schizophrenia
CBR-001-633-839-9,RFM-009-977-4,CBR-001-633-839-9,Cc1cccc(c1)C(=O)NCN1CCC(CC1)c1cccc[n+]1[O-],CBR-HVAC-06013: Dopamine D4 receptor Agonist; Erotogenic; Erectile dysfunction
CBR-001-633-840-2,RFM-009-978-5,CBR-001-633-840-2,Fc1ccc(cc1)n1cc(C(=O)O)c(=O)c2c1nc(N1CCNCC1)c(c2)F,CBR-HVAC-07407: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-633-841-3,RFM-009-979-6,CBR-001-633-841-3,Fc1cc2c(=O)c(cn(c2c(c1N1C[C@@H]2[C@H](C1)CCCN2)Cl)C1CC1)C(=O)O,CBR-HVAC-04356: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor
CBR-001-633-842-4,RFM-009-980-9,CBR-001-633-842-4,CCN(CC[n+]1ccc2c(c1)c(C)c1c(c2C)nc2c1cc(O)cc2)CC,CBR-HVAC-03624: DNA topoisomerase II Inhibitor; Anticancer; Breast tumor; Cancer
CBR-001-633-843-5,RFM-009-981-0,CBR-001-633-843-5,N[C@H]1CCN(C1)c1nc2n(cc(c(=O)c2c(c1F)C)C(=O)O)c1ccc(cc1F)F,CBR-HVAC-04236: DNA topoisomerase II Inhibitor; Antibacterial; Bacterial infections
CBR-001-633-844-6,RFM-009-982-1,CBR-001-633-844-6,OCCCOn1cnc2c1nc(N)[nH]c2=O,CBR-HVAC-10529: DNA synthesis inhibitor; Viral replication inhibitor; Antiviral; Viral infection
CBR-001-633-845-7,RFM-009-983-2,CBR-001-633-845-7,ClCCN(C(=O)NCCS(=O)(=O)N(C)C)N=O,CBR-HVAC-01108: DNA synthesis Inhibitor; RNA production Inhibitor; RNA translation Inhibitor; Anticonvulsant; Anti-alcoholic; Anticancer; CANCER
CBR-001-633-846-8,RFM-009-984-3,CBR-001-633-846-8,OC[C@H]1O[C@H]([C@H]([C@@H]1O)C#N)n1ccc(nc1=O)N,CBR-HVAC-13693: DNA repair inhibitor; Anticancer; Solid tumor
CBR-001-633-847-9,RFM-009-985-4,CBR-001-633-847-9,CCOC(=O)[C@@H](NP(=O)(N[C@H](C(=O)OCC)C)COCCn1cnc2c1nc(N)nc2NC1CC1)C,CBR-HVAC-06595: DNA polymerase Inhibitor; Anticancer; Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; Cancer
CBR-001-633-848-0,RFM-009-986-5,CBR-001-633-848-0,O=C1CP(=O)(O)O[Pt-2]2(O1)[NH2+]C1C([NH2+]2)CCCC1,CBR-HVAC-11341: DNA intercalator
CBR-001-633-849-1,RFM-009-987-6,CBR-001-633-849-1,CNn1cc(C(=O)O)c(=O)c2c1cc(N1CCN(CC1)C)c(c2)F,CBR-HVAC-02958: DNA gyrase Inhibitor; Antibacterial; Bacterial infection
CBR-001-633-850-4,RFM-009-988-7,CBR-001-633-850-4,CCCCCCCCCCCCCC(=O)O[Pt-2]1([NH2+][C@H]2[C@H]([NH2+]1)CCCC2)OC(=O)CCCCCCCCCCCCC,CBR-HVAC-03508: DNA Alkylating Drugs
CBR-001-633-851-5,RFM-009-989-8,CBR-001-633-851-5,[O-][N+](=O)OCCCCOC(=O)C(c1cccc(c1)C(=O)c1ccccc1)C,CBR-HVAC-10780: COX-2 Inhibitor; Anti-inflammatory; Inflammatory diseases; Ocular diseases
CBR-001-633-852-6,RFM-009-990-1,CBR-001-633-852-6,Fc1ccc(cc1)N1N=C(CC1c1ccc(cc1)S(=O)(=O)C)C(F)(F)F,CBR-HVAC-12154: COX-2 Inhibitor; Anti-inflammatory; Anticancer; Antiarthritic; Arthritis; Cancer; Inflammation
CBR-001-633-853-7,RFM-009-991-2,CBR-001-633-853-7,Cc1nc(c(o1)c1ccc(c(c1)F)S(=O)(=O)N)C1CCCCC1,CBR-HVAC-10377: COX-2 Inhibitor; Anticancer; Analgesic; Non-steroidal anti-inflammatory; Familial adenomatous polyposis; Inflammatory disease; Osteoarthritis; Rheumatoid arthritis
CBR-001-633-854-8,RFM-009-992-3,CBR-001-633-854-8,CCOC(=O)Cn1cccc1c1nc(c(s1)c1ccc(cc1)OC)c1ccc(cc1)OC,CBR-HVAC-11068: COX Inhibitor; Vasodilator; Chronic arterial occlusion; Ischemic brain injury
CBR-001-633-855-9,RFM-009-993-4,CBR-001-633-855-9,Fc1ccc(cc1)C1=C(CCC1)c1ccc(cc1)S(=O)(=O)C,CBR-HVAC-13433: COX Inhibitor; Antiinflammatory; Rheumatoid arthritis
CBR-001-633-856-0,RFM-009-994-5,CBR-001-633-856-0,CC(=O)Nc1ccc(cc1)OC1(C)OC(=O)c2c(O1)cccc2,CBR-HVAC-04251: COX Inhibitor; Antiinflammatory; Inflammation; Pain
CBR-001-633-857-1,RFM-009-995-6,CBR-001-633-857-1,CCN/C(=N\S(=O)(=O)c1ccc(s1)CNC(=O)c1ccccc1)/N1N=CC(C1)CC,"CBR-HVAC-13929: Cognition Disorders, Treatment of"
CBR-001-633-858-2,RFM-009-996-7,CBR-001-633-858-2,CN1CCC(CC1)N1CCN(CC1)C(=O)[C@@H](c1ccccc1)NC(=O)c1ccc2c(c1)ncc2,CBR-HVAC-06333: Coagulation factor X Inhibitor; Anticoagulant; Antithrombotic; Venous thrombosis; Arterial thrombosis
CBR-001-633-859-3,RFM-009-997-8,CBR-001-633-859-3,O=C(C(P(=O)(O)C)c1csc2c1cc(Cl)cc2)N/C=C/c1ccc(c(c1)F)F,CBR-HVAC-08566: Chymase Inhibitor; Anti-inflammatory; Asthma
CBR-001-633-860-6,RFM-009-998-9,CBR-001-633-860-6,Cc1cccc(c1)NC(=O)NC1N=C(C2CCCCC2)c2c(N(C1=O)C)cccc2,CBR-HVAC-11991: Cholecystokinin B receptor Antagonist; Anxiolytic; PANIC DISORDER
CBR-001-633-861-7,RFM-009-999-0,CBR-001-633-861-7,Cc1cccc(c1)NC(=O)NC1N=C(C2CCCCC2)c2c(N(C1=O)C)cccc2,CBR-HVAC-11991: Cholecystokinin B receptor Antagonist; Anxiolytic; PANIC DISORDER
CBR-001-633-862-8,RFM-010-000-5,CBR-001-633-862-8,Fc1ccc(cc1)NC(=O)NC1C(=O)N(C2CCCCC2)c2c(N(C1=O)CC(=O)N1CCCC1)cccc2,CBR-HVAC-11233: Cholecystokinin B receptor Antagonist; Antiulcer; Gastric ulcer
CBR-001-633-863-9,RFM-010-001-6,CBR-001-633-863-9,Fc1ccc(cc1)NC(=O)NC1C(=O)N(C2CCCCC2)c2c(N(C1=O)CC(=O)N1CCCC1)cccc2,CBR-HVAC-11233: Cholecystokinin B receptor Antagonist; Antiulcer; Gastric ulcer
CBR-001-633-864-0,RFM-010-002-7,CBR-001-633-864-0,CCSC1=C(C(=O)O)N2[C@H](S1)[C@H](C2=O)[C@H](O)C,CBR-HVAC-08331: Cell wall synthesis inhibitor
CBR-001-633-865-1,RFM-010-003-8,CBR-001-633-865-1,O=C([C@@H](c1ccc2c(c1)cccc2)N)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C,CBR-HVAC-13620: Cell wall synthesis inhibitor
CBR-001-633-866-2,RFM-010-004-9,CBR-001-633-866-2,CC(C[C@@H](C(=O)NCC#N)N[C@H](C(F)(F)F)c1ccc(cc1)c1ccc(cc1)S(=O)(=O)C)C,CBR-HVAC-11708: Cathepsin K Inhibitor; Cathepsin K inhibitor; Protease inhibitor; Bone resorption
CBR-001-633-867-3,RFM-010-005-0,CBR-001-633-867-3,CN(C(=O)c1cncc(n1)c1cn(c(n1)C(C)(C)C)CC1(F)CCOCC1)C,CBR-HVAC-13856: Cannabinoid CB2 Agonists;Signal Transduction Modulators
CBR-001-633-868-4,RFM-010-006-1,CBR-001-633-868-4,CN(CCCOC1(CCCCCC1)Cc1ccccc1)C,"CBR-HVAC-01474: Calcium channel Blocker; Vasodilator; Cerebrovascular disease; Ulcer, duodenal; Broncho obstructive syndrome"
CBR-001-633-869-5,RFM-010-007-2,CBR-001-633-869-5,CCCOCCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCOCCC)C,CBR-HVAC-00951: Calcium channel Blocker; Vasodilator; Angina pectoris
CBR-001-633-870-8,RFM-010-008-3,CBR-001-633-870-8,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCc1ccc(cc1)N1CCN(CC1)C(c1ccccc1)c1ccccc1)C,CBR-HVAC-03751: Calcium channel Blocker; Antihypertensive; Atherosclerosis; Hypertension; Stroke
CBR-001-633-871-9,RFM-010-009-4,CBR-001-633-871-9,CN(CCOc1ccc2c(c1)OCO2)CCCN1C(=O)CSC1c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-11384: Calcium channel Blocker; Antianginal; Antiarrhythmic; Cardioprotective; Arrhythmia; Ischemic heart diseases; Cardiovascular diseases
CBR-001-633-872-0,RFM-010-010-7,CBR-001-633-872-0,CN(CCOc1ccc2c(c1)OCO2)CCCN1C(=O)CSC1c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-11384: Calcium channel Blocker; Antianginal; Antiarrhythmic; Cardioprotective; Arrhythmia; Ischemic heart diseases; Cardiovascular diseases
CBR-001-633-873-1,RFM-010-011-8,CBR-001-633-873-1,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1Cl)Cl)C(=O)OCCCN1C(=O)c2c(S1(=O)=O)cccc2)C,CBR-HVAC-11345: Calcium channel Antagonist; Neuroprotective; Antihypertensive; Brain dysfunction; Cerebral ischemia; Hypertension
CBR-001-633-874-2,RFM-010-012-9,CBR-001-633-874-2,CCOC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN1CCCCC1)C,CBR-HVAC-03579: Calcium channel Antagonist; Antihypertensive; Cerebral infarction; Hypertension; Neurodegenerative diseases
CBR-001-633-875-3,RFM-010-013-0,CBR-001-633-875-3,CN[C@H](C(=O)NCCCC(c1ccc(cc1)F)c1ccc(cc1)F)CC(C)C,CBR-HVAC-11322: Calcium channel Antagonist; Analgesic; Antiparkinsonian; Pain; Stroke; Alzheimer's disease; Motor neuron diseases; Parkinson's disease
CBR-001-633-876-4,RFM-010-014-1,CBR-001-633-876-4,Cc1cc(C)c2c(n1)c(ccc2)OCc1c(Cl)ccc(c1Cl)S(=O)(=O)N1CCC[C@H]1C(=O)NCCCNC(=O)c1ccc(cc1)C(=N)N,"CBR-HVAC-00441: BRADYKININ RECEPTOR B2 Antagonist; Antiasthmatic; Antiallergic; Neuroprotectant; Anti-inflammatory; Trauma, head; Rhinitis, allergic; Asthma; Stroke"
CBR-001-633-877-5,RFM-010-015-2,CBR-001-633-877-5,CC(C(c1ccccc1)O)N(CC=C1c2ccccc2CCc2c1cccc2)C,CBR-HVAC-08462: Beta-3 adrenergic receptor Agonist; Antidiabetic; Antiobese; Diabetes mellitus Obesity; Peptic ulcer
CBR-001-633-878-6,RFM-010-016-3,CBR-001-633-878-6,OC(CO/N=C(\C1CC1)/C)CNC(C)(C)C,CBR-HVAC-02995: Beta adrenoreceptor antagonist
CBR-001-633-879-7,RFM-010-017-4,CBR-001-633-879-7,O=C(NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1)CCOc1ccc(cc1Cl)Cl,"CBR-HVAC-09318: Bacterial protein synthesis inhibitor; Antibiotic; Antibacterial; INFECTION, BACTERIAL"
CBR-001-633-880-0,RFM-010-018-5,CBR-001-633-880-0,CC[n+]1ccc(cc1)SCC1=C(C(=O)[O-])N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N\O[C@H](C(=O)O)C)/c1csc(n1)N,CBR-HVAC-03608: Bacterial cell wall synthesis inhibitor; Antibacterial; Bacterial infection
CBR-001-633-881-1,RFM-010-019-6,CBR-001-633-881-1,Nc1cc(nc([n+]1[O-])N)N1CCCCC1,CBR-HVAC-01898: ATP-sensitive potassium channel Activator; Antihypertensive; Vasodilator; Androgenetic alopecia
CBR-001-633-882-2,RFM-010-020-9,CBR-001-633-882-2,CCSSCC12CCC(=O)C=C1CC[C@@H]1[C@@H]2CCC2([C@H]1CCC2=O)C,CBR-HVAC-08128: Aromatase inhibitor
CBR-001-633-883-3,RFM-010-021-0,CBR-001-633-883-3,C[C@H]1NC[C@@H](N(C1)CC(=O)N1CC(c2c1cc(cn2)Cc1ccc(cc1)F)(C)C)CN1CCOC[C@H]1C,CBR-HVAC-14016: Apoptosis Inducers;Inhibitor of Apoptosis Protein 1 (IAP1) Inhibitors;Signal Transduction Modulators;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors
CBR-001-633-884-4,RFM-010-022-1,CBR-001-633-884-4,CCCCN(c1ccc2c(c1)[s+]c1c(n2)ccc(c1)N(CCCC)CCCC)CCCC,"CBR-HVAC-00433: Antiulcer; ANTI-ULCER; Acne vulgaris; Ulcer, diabetic foot; Wound-healing"
CBR-001-633-885-5,RFM-010-023-2,CBR-001-633-885-5,C[N+]1(CCCCCCCCCCCCCCCC[N+]2(C)CCCC2)CCCC1,"CBR-HVAC-13501: Antiparasitic; Antiparasitic; INFECTION, PLASMODIUM"
CBR-001-633-886-6,RFM-010-024-3,CBR-001-633-886-6,Clc1ccc(c(c1)C(=O)N1CC[C@@H](C1)Oc1nc(Nc2nnc(c2)C)cc(n1)N1CC(C1)(F)C1CC1)F,CBR-HVAC-14030: Antimitotic Drugs;Aurora Kinase Inhibitors;Signal Transduction Modulators
CBR-001-633-887-7,RFM-010-025-4,CBR-001-633-887-7,CCCCCCCO[C@H]1[C@H](O[C@H]2[C@@H]1OC(O2)(C)C)C(CNCc1ccccn1)O,CBR-HVAC-12340: Anti-inflammatory; Antirheumatic; Immunosuppressant; Anti-inflammatory; Antirheumatic; Immunosuppressant; Rheumatoid arthritis
CBR-001-633-888-8,RFM-010-026-5,CBR-001-633-888-8,NC(=N)NCCC[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCNC(=N)N)CCCNC(=N)N)CCCNC(=N)N,CBR-HVAC-13229: Antifungal; Antifungal; Onychomycosis; Tinea unguium
CBR-001-633-889-9,RFM-010-027-6,CBR-001-633-889-9,NS(=O)(=O)OCCCCCCCOS(=O)(=O)N,CBR-HVAC-03320: Anticancer; Anticancer; Cancer
CBR-001-633-890-2,RFM-010-028-7,CBR-001-633-890-2,O=C(c1cncc(n1)N1CCCC1)Nc1nnnn1,CBR-HVAC-03605: Antiallergic; Immunosuppressant; Antiallergic; Immunosuppressant; Asthma; Allergy
CBR-001-633-891-3,RFM-010-029-8,CBR-001-633-891-3,O=C(C(CNC(=O)C(F)(F)F)(O)C)Nc1ccc(c(c1)C(F)(F)F)[N+](=O)[O-],CBR-HVAC-05936: Androgen receptor Antagonist; Androgen antagonist; Alopecia
CBR-001-633-892-4,RFM-010-030-1,CBR-001-633-892-4,CN1C=C(C(=O)N)C(=O)N2C1CCCC2C,CBR-HVAC-07632: Analgesic; Anti-inflammatory; Cytoprotective; Gastroprotective; Analgesic; Anti-inflammatory; Cytoprotective; Gastroprotective; Peptic ulcer
CBR-001-633-893-5,RFM-010-031-2,CBR-001-633-893-5,CC(NC(=O)CNC(=O)[C@H](N(C(=O)CNC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C)C)Cc1ccccc1)C,CBR-HVAC-13275: Analgesic; Analgesic; Pain
CBR-001-633-894-6,RFM-010-032-3,CBR-001-633-894-6,O=C(c1ccc2c(c1)non2)N1CCCCC1,CBR-HVAC-05103: AMPA RECEPTOR Modulator; Neuroprotectant; Antidepressant; Antipsychotic; Schizophrenia
CBR-001-633-895-7,RFM-010-033-4,CBR-001-633-895-7,COCC1=C(C(=O)OC)[C@@H](N(C(=O)N1)C(=O)NCCCN1CCC(CC1)c1ccccn1)c1ccc(c(c1)F)F,CBR-HVAC-05348: Alpha-1A adrenergic receptor Antagonist; Alpha-1A adrenergic receptor antagonist; Benign prostate hyperplasia
CBR-001-633-896-8,RFM-010-034-5,CBR-001-633-896-8,COCC1=C(C(=O)OC)C(N(C(=O)N1)C(=O)NCCCN1CCC(CC1)c1ccccn1)c1ccc(c(c1)F)F,CBR-HVAC-05348: Alpha-1A adrenergic receptor Antagonist; Alpha-1A adrenergic receptor antagonist; Benign prostate hyperplasia
CBR-001-633-897-9,RFM-010-035-6,CBR-001-633-897-9,Fc1ccc(cc1)N1CCN(CC1)CCCC(=O)NC1c2ccccc2SCc2c1cccc2,CBR-HVAC-03630: Alpha-1 adrenergic receptor; Calcium channel Antagonist; Antihypertensive; Antihyperlipidemic; Antiarrhythmic; Angina pectoris; Arrhythmia; Atherosclerosis; Hypertension; Dyslipidemia
CBR-001-633-898-0,RFM-010-036-7,CBR-001-633-898-0,O/N=C/1\CCN(C(=O)c2c1ccn2CCCCN1CCC(CC1)C(=O)c1ccc(cc1)F)C,CBR-HVAC-04262: Alpha-1 adrenergic receptor; 5-Hydroxytryptamine 2 receptor Antagonist; Antihypertensive; Antiplatelet; Hypertension; Ischemic heart diseases; Thrombosis
CBR-001-633-899-1,RFM-010-037-8,CBR-001-633-899-1,COc1ccc(cc1)[C@@H]1Sc2cc(Cl)ccc2N(C(=O)[C@@H]1OC(=O)C)CCCN1CCN(CC1)c1ccccc1OC,CBR-HVAC-04674: Alpha-1 adrenergic receptor Antagonist; Antihypertensive; Class IV antiarrhythmic; Arrhythmia; Hypertension; Myocardial infarction
CBR-001-633-900-7,RFM-010-038-9,CBR-001-633-900-7,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)C(C)C)NC(=O)[C@@H](NC(=O)C)CSSC[C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)C(C)C)CCCCN)NC(=O)C,CBR-HVAC-05766: Alpha melanocyte stimulating hormone receptor; Nuclear factor kappa B Agonist; Inhibitor; Fungicide; Anti-inflammatory; Vulvovaginal candidiasis; Topical fungal infections; Atopic dermatitis; Inflammation
CBR-001-633-901-8,RFM-010-039-0,CBR-001-633-901-8,Cc1ccc(cc1)N(c1ccc(cc1)O)CC1=NCCN1,CBR-HVAC-08194: Alpha adrenoreceptor antagonist
CBR-001-633-902-9,RFM-010-040-3,CBR-001-633-902-9,Clc1ccc(cc1Cl)OCC1=NCCN1,CBR-HVAC-07816: Alpha adrenoreceptor agonist
CBR-001-633-903-0,RFM-010-041-4,CBR-001-633-903-0,NC(=NCCC[C@@H](C(=O)NC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)Cc1ccccc1)Cc1ncnc1)C(C)C)Cc1ccc(cc1)O)C(C)C)NC(=O)[C@H](CC(=O)N)N)N,CBR-HVAC-09235: Adrenoreceptor modulator; Calcium Channel Agonist; Vasoconstrictor; Vasopressor; Antihypotensive; Shock; Circulatory collapse
CBR-001-633-904-1,RFM-010-042-5,CBR-001-633-904-1,CSCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1CCC[C@H]1C(=O)O)Cc1ccccc1)Cc1ncnc1)CCC(=O)O)N,CBR-HVAC-03184: Adrenocorticotropic hormone receptor Agonist; Neuroprotectant; Vasoprotectant; Alzheimer's disease; Neurodegenerative diseases; Cerebrovascular ischemia; Stroke
CBR-001-633-905-2,RFM-010-043-6,CBR-001-633-905-2,CC(CCc1ccc(cc1)C(=O)N)NCC(c1ccc(c(c1)O)O)O,CBR-HVAC-10678: Adrenergic receptor Agonist; Inotropic; Myocardial infarction; Cardiac failure
CBR-001-633-906-3,RFM-010-044-7,CBR-001-633-906-3,O=C1NCCc2c3c1cccc3nc2c1ccccc1,CBR-HVAC-08152: ADP ribose polymerase inhibitor; Apoptosis stimulant
CBR-001-633-907-4,RFM-010-045-8,CBR-001-633-907-4,NCCCC[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCS(=O)(=O)C)N)CCC(=O)O)Cc1ncnc1)Cc1ccccc1,CBR-HVAC-12782: Adenylate cyclase stimulant; Cyclic AMP stimulant
CBR-001-633-908-5,RFM-010-046-9,CBR-001-633-908-5,CCCn1c2nc([nH]c2c(=O)n(c1=O)C1CC1)c1ccc(nc1)N(C(=O)c1cccnc1)CC,CBR-HVAC-11944: Adenosine A2B receptor Antagonist; HYPOGLYCEMIC; NON-INSULIN DEPENDENT DIABETES MELLITUS; CORONARY ARTERY DISEASE
CBR-001-633-909-6,RFM-010-047-0,CBR-001-633-909-6,CCNC(=O)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(C#CC(c1ccccc1)O)nc2N,CBR-HVAC-11463: Adenosine A1 receptor; Adenosine A2 receptor Agonist; Antihypertensive; Hypertension; Cardiovascular diseases
CBR-001-633-910-9,RFM-010-048-1,CBR-001-633-910-9,C#CCN[C@@H]1CCc2c1cc(cc2)OC(=O)N(CC)C,CBR-HVAC-00600: ACETYLCHOLINESTERASE; MONOAMINE OXIDASE A; MONOAMINE OXIDASE B Inhibitor; Neuroprotectant; Alzheimer's disease
CBR-001-633-911-0,RFM-010-049-2,CBR-001-633-911-0,C#CCN[C@H]1CCc2c1cc(cc2)OC(=O)N(CC)C,CBR-HVAC-00600: ACETYLCHOLINESTERASE; MONOAMINE OXIDASE A; MONOAMINE OXIDASE B Inhibitor; Neuroprotectant; Alzheimer's disease
CBR-001-633-912-1,RFM-010-050-5,CBR-001-633-912-1,CCc1ccccc1NC(=O)Oc1ccc2c(c1)C1(C)CCN(OC1N2C)C,CBR-HVAC-11008: Acetylcholinesterase Inhibitor; Neuroprotectant; Alzheimer's disease
CBR-001-633-913-2,RFM-010-051-6,CBR-001-633-913-2,CC([N+](C)(C)C)CN1c2ccccc2Sc2c1cccc2,CBR-HVAC-00989: Acetylcholine receptor antagonist; Histamine receptor antagonist; 5 Hydroxytryptamine receptor antagonist
CBR-001-633-914-3,RFM-010-052-7,CBR-001-633-914-3,Fc1ccc(cc1)OC[C@@H]1CC[C@H](O1)C#CCCN(C(=O)N)O,CBR-HVAC-04773: 5-Lipoxygenase Inhibitor; Antiinflammatory; Chronic obstructive pulmonary disease; Asthma
CBR-001-633-915-4,RFM-010-053-8,CBR-001-633-915-4,CN1CCC(=C2c3ccsc3SCc3c2cccc3)CC1,CBR-HVAC-00465: 5-HYDROXYTRYPTAMINE RECEPTOR; HISTAMINE H1 RECEPTOR Antagonist; Antagonist; ANTI-MIGRAINEANESTHETICANALGESICANTI-DEPRESSANT; Migraine
CBR-001-633-916-5,RFM-010-054-9,CBR-001-633-916-5,O=C(C12CC3CC(C2)CC(C1)C3)NC1CCN(CC1)CCNC(=O)c1nn(c2c1cccc2)C(C)C,CBR-HVAC-11179: 5-Hydroxytryptamine 4 receptor Antagonist; 5-hydroxytryptamine 4 receptor antagonist; Inflammatory bowel disease; Irritable bowel syndrome
CBR-001-633-917-6,RFM-010-055-0,CBR-001-633-917-6,Cn1cc(c2c1cccc2)C1=NCC2(O1)CN1CCC2CC1,CBR-HVAC-10877: 5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Nausea; Vomiting
CBR-001-633-918-7,RFM-010-056-1,CBR-001-633-918-7,CC(C(=O)c1ccc(cc1)OCCCN1CCC(CC1)C(c1ccc(cc1)F)(c1ccc(cc1)F)O)C,CBR-HVAC-10803: 5-Hydroxytryptamine 2 receptor; Calcium channel Antagonist; Antihypertensive; Hypertension
CBR-001-633-919-8,RFM-010-057-2,CBR-001-633-919-8,CCN1CCC2(CC1)COc1c2cc2c(c1)CCN2C(=O)c1ccc(cc1)c1ccc(cc1C)c1nnc(o1)C,CBR-HVAC-11047: 5-Hydroxytryptamine 1B receptor Agonist; Antidepressant; Anxiolytic; Anxiety; Depression
CBR-001-633-920-1,RFM-010-058-3,CBR-001-633-920-1,COc1ccc(cc1)C(NC(=O)[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C=CC(=O)N2)(C)C,"CBR-HVAC-05153: 5-alpha reductase Inhibitor; Antitumor; HYPERPLASIA, BENIGN PROSTATIC"
CBR-001-633-921-2,RFM-010-059-4,CBR-001-633-921-2,CCOC(=O)CCC(=O)O[C@H]1[C@@H](O[C@@H](C[C@@H]1N(C)C)C)O[C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@@H]([C@](C2)(C)OC)O)[C@@H](C)C(=O)O[C@H](CC)[C@@]([C@@H]([C@H](C(=O)[C@@](C[C@@]1(C)O)(C)F)C)O)(C)O,CBR-HVAC-04647: 23S-rRNA of 50S ribosomal subunit Inhibitor; Antibacterial; Lower respiratory tract bacterial infections
CBR-001-633-922-3,RFM-010-060-7,CBR-001-633-922-3,Fc1ccc2c(c1)nc1c2ccc(c1)Cc1cccnc1,"CBR-HVAC-11996: 17,20 Lyase Inhibitor; Anticancer; CARCINOMA, PROSTATE"
CBR-001-633-923-4,RFM-010-061-8,CBR-001-633-923-4,Fc1cc(F)c(c(c1)F)OC(c1nnc(n1C)c1ccc(cc1Cl)F)(C)C,CBR-HVAC-13871: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
CBR-001-633-924-5,RFM-010-062-9,CBR-001-633-924-5,O=C1CN=C(c2c(N1C)ccc(c2)[N+](=O)[O-])C1=CCCCC1,CBR-HVAC-10280: ; Hypnotic; Sedative; Anticonvulsant; Muscle relaxant; Anxiolytic; INSOMNIA
CBR-001-633-925-6,RFM-010-063-0,CBR-001-633-925-6,COC(=O)c1cc2nc(nc2cc1C)S(=O)Cc1ncccc1C,CBR-HVAC-01129: ; Antiulcer; Ulcer
CBR-001-633-926-7,RFM-010-064-1,CBR-001-633-926-7,CN(C(C(c1ccccc1)O)C)C/C=C/c1ccccc1,CBR-HVAC-09080: ; Antispasmodic; Spasms
CBR-001-633-927-8,RFM-010-065-2,CBR-001-633-927-8,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C(O)C)CCCN=C(N)N)C(O)C)C(C)C)C(CC)C)CC(=O)N)C)Cc1ccccc1)CC(C)C)Cc1ncnc1)C(C)C)C(C)C)NC(=O)[C@H](N)C,"CBR-HVAC-12133: ; ANTISCLEROTIC; SCLEROSIS, MULTIPLE"
CBR-001-633-928-9,RFM-010-066-3,CBR-001-633-928-9,OCCN1CCN(CC1)CCCC1c2cc(ccc2Sc2c1ccc(c2)F)C(F)(F)F,CBR-HVAC-01194: ; Antipsychotic; Psychosis
CBR-001-633-929-0,RFM-010-067-4,CBR-001-633-929-0,ClCCN(CCN1C(=O)NC2(C1=O)CCCCC2)CCCl,CBR-HVAC-02509: ; Antineoplastic; Cancer
CBR-001-633-930-3,RFM-010-068-5,CBR-001-633-930-3,CCCC(=O)O[C@@]1(CC[C@@H]2C1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CCC12C)C(=O)CC,"CBR-HVAC-08674: ; Anti-inflammatory, steroidal; Inflammation"
CBR-001-633-931-4,RFM-010-069-6,CBR-001-633-931-4,CC1CC2N(O1)C(=O)c1c(O2)ccc(c1)Cl,"CBR-HVAC-13514: ; Anti-inflammatory, nonsteroidal; Inflammation"
CBR-001-633-932-5,RFM-010-070-9,CBR-001-633-932-5,CCCC(=O)c1c(O)cc(c(c1O)C)OC,"CBR-HVAC-10185: ; Antihelmintic; Anti-tumor; Infection, helminth; Tumor"
CBR-001-633-933-6,RFM-010-071-0,CBR-001-633-933-6,COc1ccc(cc1C(=O)NC[C@H]1CCCN1CC1CC1)S(=O)(=O)N,CBR-HVAC-01146: ; Antiemetic; Vomiting; Nausea
CBR-001-633-934-7,RFM-010-072-1,CBR-001-633-934-7,COc1ccc(cc1C(=O)NC[C@@H]1CCCN1CC1CC1)S(=O)(=O)N,CBR-HVAC-01146: ; Antiemetic; Vomiting; Nausea
CBR-001-633-935-8,RFM-010-073-2,CBR-001-633-935-8,Cc1ccccc1C(=O)n1c(=O)c(F)cn(c1=O)C(=O)C,CBR-HVAC-03309: ; Anticancer; Cancer
CBR-001-633-936-9,RFM-010-074-3,CBR-001-633-936-9,Nc1ccc(cc1)S(=O)(=O)Nc1nc(C)c(c(n1)C)Br,"CBR-HVAC-08683: ; Antibiotic; Infection, bacterial"
CBR-001-633-937-0,RFM-010-075-4,CBR-001-633-937-0,CO/N=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1cnns1)/c1csc(n1)N,"CBR-HVAC-03307: ; ANTIBIOTIC; Infection, bacterial"
CBR-001-633-938-1,RFM-010-076-5,CBR-001-633-938-1,CO/N=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1cnns1)/c1csc(n1)N,"CBR-HVAC-03307: ; ANTIBIOTIC; Infection, bacterial"
CBR-001-633-939-2,RFM-010-077-6,CBR-001-633-939-2,CC(=O)OCOC(=O)C1N2C(=O)C(C2SC1(C)C)NC(=O)Cc1ccccc1,CBR-HVAC-13399: ; Antibiotic; ALLERGIC REACTION
CBR-001-633-940-5,RFM-010-078-7,CBR-001-633-940-5,O=C(c1ccccc1)N1CC2C(C1)COC2,CBR-HVAC-10089: ; Analgesic; Pain
CBR-001-633-941-6,RFM-010-079-8,CBR-001-633-941-6,CCc1c([nH]n(c1=O)C1CCN(CC1)C)c1ccccc1,CBR-HVAC-09894: ; Analgesic; Antispasmodic; Pain; Spasm
CBR-001-633-942-7,RFM-010-080-1,CBR-001-633-942-7,COc1nsc(n1)NC(=O)N1C[C@@H]2[C@H](C1)C[C@H](C2)N(c1ncnc2c1ccn2)C,"CBR-HVAC-13890:  Rheumatoid Arthritis, Treatment of"
CBR-001-633-943-8,RFM-010-081-2,CBR-001-633-943-8,COCCc1ccc(cn1)c1c(C)nc2n1nccc2N1CCOCC1,CBR-HVAC-13809:
CBR-001-633-944-9,RFM-010-082-3,CBR-001-633-944-9,C[C@H](Cc1ccc(cc1)OCC(=O)O)NC[C@@H](c1csc(n1)C(F)(F)F)O,CBR-HVAC-04917: Beta-3 adrenergic receptor Agonist; Antiobesity; Obesity
CBR-001-633-945-0,RFM-010-083-4,CBR-001-633-945-0,C[C@H](Cc1ccc(cc1)OCC(=O)O)NC[C@@H](c1csc(n1)C(F)(F)F)O,CBR-HVAC-04917: Beta-3 adrenergic receptor Agonist; Antiobesity; Obesity
CBR-001-633-946-1,RFM-010-084-5,CBR-001-633-946-1,OC(=O)[C@H](CC(=O)N1CCC(CC1)N1CCc2c(NC1=O)cccc2)Cc1cc(C)c(c(c1)C)O,CBR-HVAC-14433: metabolite of CBR-HVAC-06836
CBR-001-633-947-2,RFM-010-085-6,CBR-001-633-947-2,O=C1Nc2ccccc2C(N1C1CCN(CC1)Cc1cccc(c1)OC(F)(F)F)c1ccccc1,CBR-HVAC-07430: Muscarinic Antagonists;Muscarinic M3 Antagonists;Signal Transduction Modulators;Sodium Channel Blockers
CBR-001-633-948-3,RFM-010-086-7,CBR-001-633-948-3,O=C1Nc2ccccc2C(N1C1CCN(CC1)Cc1cccc(c1)OC(F)(F)F)c1ccccc1,CBR-HVAC-07430: Muscarinic Antagonists;Muscarinic M3 Antagonists;Signal Transduction Modulators;Sodium Channel Blockers
CBR-001-633-949-4,RFM-010-087-8,CBR-001-633-949-4,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)CS)CCCNC(=N)N)CCCCN)[C@H](CC)C)CCC(=O)O)CC(C)C)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)N)CC(=O)O)CCC(=O)N)CCC(=O)N)CC(C)C)CO)CCCNC(=N)N,CBR-HVAC-14366: Apoptosis Inducers
CBR-001-633-950-7,RFM-010-088-9,CBR-001-633-950-7,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CCCCN)C)C)[C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)C)C)CCC(=O)N)Cc1ccccc1)CO,"CBR-HVAC-06714: Mucin Production, Inhibitors"
CBR-001-633-951-8,RFM-010-089-0,CBR-001-633-951-8,O=C(N[C@H](C[C@@H]([C@@H](NC(=O)[C@H](C(C)C)NC(=O)OCc1ccccn1)Cc1ccccc1)OC(=O)C)Cc1ccccc1)OCc1cccnc1,CBR-HVAC-14434: metabolite of CBR-HVAC-04482
CBR-001-633-952-9,RFM-010-090-3,CBR-001-633-952-9,NCCCC[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N)CCCCN)Cc1ccccc1)Cc1cnc2c1cccc2)NC(=O)[C@@H](Cc1cnc2c1cccc2)NC(=O)[C@H](Cc1cncn1)N,CBR-HVAC-13034: GHS Receptor Antagonists;Signal Transduction Modulators
CBR-001-633-953-0,RFM-010-091-4,CBR-001-633-953-0,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@@H](NC1=O)CC)C(=O)N[C@H](C(=O)N)[C@H](O)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)CN1CCN(CC1)CCO)Cc1cnc2c1cccc2,"CBR-HVAC-04793: Diabetic Retinopathy, Agents for"
CBR-001-633-954-1,RFM-010-092-5,CBR-001-633-954-1,OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)O)Cc1ccc(cc1)O)CCCNC(=N)N)CC(C)C)CC(=O)N)CCCNC(=N)N)CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)N)CCC(=O)O,CBR-HVAC-12704: Cytotoxic T cell inhibitor; Immunosuppressant; Transplant rejection
CBR-001-633-955-2,RFM-010-093-6,CBR-001-633-955-2,CC(CN(C(=O)NC(C)(C)C)C[C@H]([C@@H](NC(=O)[C@@H](NC(=O)c1ccc2c(n1)cccc2)CC(=O)N)Cc1ccccc1)O)C,CBR-HVAC-00142: Reverse transcriptase Inhibitor; Antiviral; AIDS
CBR-001-633-956-3,RFM-010-094-7,CBR-001-633-956-3,NCCCC[C@@H]1NC(=O)[C@H](NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@@H](NC1=O)CC)C(=O)N[C@H](C(=O)N)[C@H](O)C)NC(=O)[C@H](NS(=O)(=O)CCN1CCN(CC1)CCO)Cc1ccccc1)Cc1cnc2c1cccc2,CBR-HVAC-04794: Somatostatin receptor 2 Agonist; Anticancer; Vasoprotectant; GASTROINTENTINAL DISORDER; CANCER
CBR-001-633-957-4,RFM-010-095-8,CBR-001-633-957-4,CCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N)Cc1ccc(cc1)O)CCCC)CCCC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)N)CCCC)CCCC)CCCC)CCCNC(=N)N,CBR-HVAC-07720: TNF alpha Inhibitor; Anti-inflammatory; Immunosuppressant; Diarrhea; Gastrointestinal disease; Inflammatory bowel disease; Ulcerative colitis; Gastrointestinal function disorder; Periodontal disease; Transplant rejection; Graft versus host disease; Pulmonary fibrosis; Toxicity; Crohn's disease
CBR-001-633-958-5,RFM-010-096-9,CBR-001-633-958-5,CCOC(=O)c1cn(C2CC2)c2c(c1=O)cc(c(c2OC)N1CCC(=O)CC1)F,CBR-HVAC-14429: metabolite of CBR-HVAC-14415
CBR-001-633-959-6,RFM-010-097-0,CBR-001-633-959-6,OC(=O)CN(Cc1ccccc1O)CCN(Cc1ccccc1O)CC(=O)O,CBR-HVAC-14418: Iron metabolism modulator; Iron chelator; Iron overload; Colitis
CBR-001-633-960-9,RFM-010-098-1,CBR-001-633-960-9,O=C(Nc1ccc(cc1)C1=NNC(=O)CC1)CCN1CCC(CC1)c1ccccc1,"CBR-HVAC-07448: Hypertension, Treatment of;Antiplatelet Therapy"
CBR-001-633-961-0,RFM-010-099-2,CBR-001-633-961-0,OC(CC(=O)NCCC(=O)O)CNC(=O)CCCCCCNC(=N)N,CBR-HVAC-10625: Immunostimulator; Immunostimulant; Bacterial infection; Fungal infection
CBR-001-633-962-1,RFM-010-100-8,CBR-001-633-962-1,OC[C@H]1COc2c(N1c1ccc(cn1)C)cccc2C(=O)Nc1ccc(nc1)OCC(F)(F)F,CBR-HVAC-06826: TRPV1 (Vanilloid VR1 Receptor) Antagonists
CBR-001-633-963-2,RFM-010-101-9,CBR-001-633-963-2,COc1ccc(c(c1)c1ccc(nc1N)NC(=O)c1ccnn1C)Cl,CBR-HVAC-12057: Nav1.8 (SNS/PN3) Sodium Channel Blockers
CBR-001-633-964-3,RFM-010-102-0,CBR-001-633-964-3,Clc1ncc(c(n1)NCc1ccc(cc1)CNc1ccnc(n1)NCCN1CCOCC1)F,CBR-HVAC-12229: Angiogenesis Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists;Signal Transduction Modulators
CBR-001-633-965-4,RFM-010-103-1,CBR-001-633-965-4,OC[C@@H](C(=O)N(CC1CCCCC1)CCN1[C@@H]2CC[C@H]1C[C@H](C2)c1cccc(c1)C(=O)N)O,CBR-HVAC-06657: mu-Opioid Antagonists;Signal Transduction Modulators
CBR-001-633-966-5,RFM-010-104-2,CBR-001-633-966-5,OC(=O)/C=C/c1ccc(cc1)NC(=O)C1(CCC1)NC(=O)c1ccc2c(c1)n(C)c(c2C1CCCC1)c1ccccn1,CBR-HVAC-06591: RNA-Directed RNA Polymerase (NS5B) Inhibitors
CBR-001-633-967-6,RFM-010-105-3,CBR-001-633-967-6,CCCOc1nc(N)c2c(n1)n(cn2)C1CCCCC1,CBR-HVAC-07509: Bronchodilators
CBR-001-633-968-7,RFM-010-106-4,CBR-001-633-968-7,CCOCCn1nc(c2c1c(Nc1nccc(c1)C)nc(n2)N(CC)C)C(=O)O,CBR-HVAC-14437: metabolite of CBR-HVAC-06503
CBR-001-633-969-8,RFM-010-107-5,CBR-001-633-969-8,CNCc1ccc(o1)CSCCN/C(=N/S(=O)(=O)C)/NCC(c1ccc(cc1)O)O,CBR-HVAC-03960: Histamine H2 receptor Antagonist; Antiulcer; Duodenal ulcer; Gastric ulcer
CBR-001-633-970-1,RFM-010-108-6,CBR-001-633-970-1,FC(Oc1c(ccc2c1n(cc(c2=O)C(=O)O)C1CC1)c1ccc2c(c1)CN[C@@H]2C)F,CBR-HVAC-04973: Topoisomerase IV Inhibitor; Antibiotic; GRAM NEGATIVE BACTERIAL DISEASES; GRAM POSITIVE BACTERIAL DISEASES
CBR-001-633-971-2,RFM-010-109-7,CBR-001-633-971-2,ClCCN(C[C@H]1OC(O)[C@@H]([C@H]([C@H]1O)O)O)CCCl,CBR-HVAC-03472: Antineoplastic; Antineoplastic; Carcinoma
CBR-001-633-972-3,RFM-010-110-0,CBR-001-633-972-3,Fc1ccc(c2c1CCC2)OC[C@@H]1CNCCO1,CBR-HVAC-04625: 5-Hydroxytryptamine 2A receptor; 5-Hydroxytryptamine transporter Antagonist; Inhibitor; Antidepressant; Major depressive disorder
CBR-001-633-973-4,RFM-010-111-1,CBR-001-633-973-4,COc1cc(ccc1OCCCCCOc1ccc(cc1)C(=N)N)C(=O)N(C(C)C)C(C)C,CBR-HVAC-04386: Leukotriene B4 receptor Antagonist; Anti-inflammatory; Antipsoriatic; Antirheumatic; Antiasthmatic; Antiallergy; Chronic obstructive pulmonary disease; Psoriasis; Rheumatoid arthritis; Asthma; Inflammatory bowel disease; Allergic rhinitis
CBR-001-633-974-5,RFM-010-112-2,CBR-001-633-974-5,O=C(c1cn(c2c1cc(O)cc2)Cc1ccc(cc1)F)C(=O)Nc1c(Cl)cncc1Cl,"CBR-HVAC-05067: Phosphodiesterase 4 Inhibitor; Anti-inflammatory; DERMATITIS, ATOPIC"
CBR-001-633-975-6,RFM-010-113-3,CBR-001-633-975-6,Fc1ccc2c(c1)c1CN(CCc3ccncc3)CCc1n2,CBR-HVAC-04207: Dopamine receptor D2 Antagonist; Antipsychotic; Psychosis; Schizophrenia
CBR-001-633-976-7,RFM-010-114-4,CBR-001-633-976-7,OC(=O)COc1ccc(cc1C)/C(=N/OCc1sc(nc1C)c1ccc(cc1)C(F)(F)F)/C,CBR-HVAC-12487: Peroxisome proliferator-activated receptor alpha Modulator; Hypolipemic; Antiatherosclerosis; Dyslipidemia; Hypertriglyceridemia
CBR-001-633-977-8,RFM-010-115-5,CBR-001-633-977-8,CCN(CCNC(=O)c1c(C)nc(c1C)/C=C\1/C(=O)Nc2c1cc(cc2)c1csc(n1)c1ccccc1)CC,CBR-HVAC-12430: Cancer stem cells (CSC) kinase inhibitor that blocks CSC self-renewal and induces cell death in CSCs as well as non-stem cancer cells.; Anticancer; Advanced solid tumors
CBR-001-633-978-9,RFM-010-116-6,CBR-001-633-978-9,CCOCCOC(=O)c1nc2c(o1)ccc(c2)Cl,CBR-HVAC-01085: Histamine H1 receptor Antagonist; Antiallergic; Antiasthmatic; Allergy; Asthma; Skin disorder
CBR-001-633-979-0,RFM-010-117-7,CBR-001-633-979-0,ClC1=COc2c(C(=O)N1CCCCN1CCC(=CC1)c1ccccn1)cccc2,CBR-HVAC-00460: 5-Hydroxytryptamine 1A receptor Agonist; Neuroprotectant; Stroke; Cerebral ischemia
CBR-001-633-980-3,RFM-010-118-8,CBR-001-633-980-3,FC(c1nnc(cc1c1ccccc1)N1CCNCC1)(F)F,CBR-HVAC-12460: 5-Hydroxytryptamine 6 receptor; Dopamine receptor D2; Dopamine receptor D3 Antagonist; Antipsychotic; SCHIZOPHRENIA
CBR-001-633-981-4,RFM-010-119-9,CBR-001-633-981-4,C[C@H]1COC2(O1)CCN(CC2)c1nc(=O)c2c(s1)c(cc(c2)C(F)(F)F)[N+](=O)[O-],CBR-HVAC-12216: Decaprenylphosphoryl-beta-d-ribose oxidase inhibitor; ANTIBACTERIALANTITUBERCULAR AGENT; TUBERCULOSIS
CBR-001-633-982-5,RFM-010-120-2,CBR-001-633-982-5,COc1cc(ccc1Nc1c2cccc(c2nc2c1cccc2C(=O)NC)C)NS(=O)(=O)C,CBR-HVAC-02944: TOPOISOMERASE II Inhibitor; Anticancer; Solid tumor
CBR-001-633-983-6,RFM-010-121-3,CBR-001-633-983-6,COc1ccc(cc1OC1CCCC1)/C(=N/OC(=O)N)/C,CBR-HVAC-04272: Phosphodiesterase 4 Inhibitor; Bronchodilator; Anti-inflammatory; Asthma; Inflammation
CBR-001-633-984-7,RFM-010-122-4,CBR-001-633-984-7,CC(Nc1ncnc(c1)c1csc(n1)N(C(=O)c1ccc(cc1)F)C)C,CBR-HVAC-12545: Metabotropic glutamate receptor Agonist; Antipsychotic; SCHIZOPHRENIA
CBR-001-633-985-8,RFM-010-123-5,CBR-001-633-985-8,O=C(c1ccc(cc1)c1ccc(cc1)C(F)(F)F)N[C@H](C(=O)O)Cc1ccc(cc1)c1ccccc1,CBR-HVAC-12438: Factor IX; Factor VIII Antagonist; Coagulation inhibitor; Venous thromboembolism; Embolism; Thrombosis; Hip Fracture
CBR-001-633-986-9,RFM-010-124-6,CBR-001-633-986-9,OC(=O)CNC(=O)c1nc(Cl)c2c(c1O)cccc2,CBR-HVAC-12233: HIF-prolyl hydroxylase Inhibitor; Hydroxylase inhibitor; Erythropoietin release stimulator; Cytokine modulator; Anemia
CBR-001-633-987-0,RFM-010-125-7,CBR-001-633-987-0,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1ccc2c1ncnc2N,CBR-HVAC-12205: ; Antibacterial; Tuberculosis
CBR-001-633-988-1,RFM-010-126-8,CBR-001-633-988-1,O=C(Nc1cccc(c1Cl)Cl)Nc1ccc(c(c1O)S(=O)(=O)N)Cl,CBR-HVAC-05381: C-X-C chemokine receptor type 2 Antagonist; Anti-inflammatory; Bronchodilator; Atherosclerosis; Chronic obstructive pulmonary diseases; Inflammatory bowel diseases
CBR-001-633-989-2,RFM-010-127-9,CBR-001-633-989-2,CCCc1ccc(c(=O)n1CC(=O)NCc1ccc(nc1C)N)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-11961: Thrombin Inhibitor; Thrombin inhibitor; THROMBOEMBOLISM
CBR-001-633-990-5,RFM-010-128-0,CBR-001-633-990-5,ONC(=O)CN(C(=O)[C@@H]1CCCC[C@@H]1C(=O)O)C,"CBR-HVAC-02513: Angiotensin I converting enzyme Inhibitor; Antihypertensive; Cardioprotectant; Hypertension; Infarction, myocardial"
CBR-001-633-991-6,RFM-010-129-1,CBR-001-633-991-6,OC(=O)C[C@H]1CCCCN1C(=O)/C=C/c1c(nn2c1cccc2)c1ccccc1,CBR-HVAC-04375: Adenosine A1 receptor Antagonist; Diuretic; Hypotension; Renal failure
CBR-001-633-992-7,RFM-010-130-4,CBR-001-633-992-7,Nc1cccc(c1)CN1C(Cc2ccccc2)C(O)C(C(N(C1=O)Cc1ccc2c(c1)cnn2)Cc1ccccc1)O,CBR-HVAC-11467: Reverse transcriptase Inhibitor; Antiviral; HIV infection
CBR-001-633-993-8,RFM-010-131-5,CBR-001-633-993-8,Cc1ccc(cc1)S(=O)(=O)NC(=O)N1CCC(CC1)N1CCC(CC1)Oc1ccc(c(c1)Cl)Cl,"CBR-HVAC-12475: Chemokine receptor antagonist; Antiinflammatory; Asthma, Rhinitis"
CBR-001-633-994-9,RFM-010-132-6,CBR-001-633-994-9,Fc1ccc(c(c1)F)[C@]1(CO[C@@H](O1)COc1ccc(cc1)N1CCN(CC1)c1ccc(cc1)N1CCN(C1=O)C(C)C)Cn1cncn1,CBR-HVAC-05130: CYP51 Inhibitor; Antifungal; Fungal infection
CBR-001-633-996-1,RFM-010-133-7,CBR-001-633-996-1,O[Sb+](=O)O,"CBR-HVAC-14438:Antileishmanials
"
CBR-001-633-997-2,RFM-010-134-8,CBR-001-633-997-2,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)[n+]1cccc(c1)C(=O)N,CBR-HVAC-07148:NAD-Dependent Protein Deacetylase Sirtuin-5 (SIRT5) Activators
CBR-001-634-003-7,RFM-010-135-9,CBR-001-634-003-7,COc1ccc(cc1)OCCCN(c1nc2c(o1)cccc2)Cc1cccc(c1)OC(C(=O)O)CC,CBR-HVAC-14337:PPAR Modulators;PPARalpha Agonists;Signal Transduction Modulators
CBR-001-634-059-3,RFM-010-136-0,CBR-001-634-059-3,Clc1ccc(cc1)OS(=O)(=O)c1ccc(cc1)Cl,"CBR-HVAC-14493: Insecticide; Nippon Noyaku Gakkaishi (1983), 8(3), 367-70"
CBR-001-634-060-6,RFM-010-137-1,CBR-001-634-060-6,C#Cc1cccc(c1)Nc1ncnc2c1cc(cc2)NC(=O)N(Cc1cccc(c1)F)C,CBR-HVAC-13907: EGFR (HER1; erbB1) Inhibitors;Signal Transduction Modulators
CBR-001-634-061-7,RFM-010-138-2,CBR-001-634-061-7,CCC(c1ccc(cc1)Cl)(N(C)C)C/C=C/c1ccccc1,CBR-HVAC-04067: Urinary Incontinence Therapy
CBR-001-634-062-8,RFM-010-139-3,CBR-001-634-062-8,CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(F)(F)F,CBR-HVAC-13881: possibly Acetyl-CoA Carboxylase (ACC) Inhibitors
CBR-001-634-063-9,RFM-010-140-6,CBR-001-634-063-9,C1CCN(CC1)Cc1ccc(cc1)c1cc2ccccc2c2=NCCn12,CBR-HVAC-10826: Platelet-Activating Factor Receptor (PAFR) Antagonists;Signal Transduction Modulators
CBR-001-634-064-0,RFM-010-141-7,CBR-001-634-064-0,OC(=O)C(c1ccc(cc1)Oc1nccs1)C,CBR-HVAC-01218: ; Non-steroidal anti-inflammatory; Analgesic; Inflammation; Pain
CBR-001-634-065-1,RFM-010-142-8,CBR-001-634-065-1,CC(CCC(=O)c1cocc1)O,CBR-HVAC-03681: Anticancer; Anticancer; Liver cancer; Non-small cell lung cancer
CBR-001-634-066-2,RFM-010-143-9,CBR-001-634-066-2,COc1ccc(cc1)CC(NCC(c1ccc(c(c1)CO)O)O)C,CBR-HVAC-05603: Beta adrenergic receptor Agonist; ; Chronic asthma
CBR-001-634-067-3,RFM-010-144-0,CBR-001-634-067-3,OC[C@]1(C=C(CN1C(=O)N([C@H]1CCN(C[C@H]1F)C)C)c1cc(F)ccc1F)c1ccccc1,CBR-HVAC-06338: Kinesin spindle protein Inhibitor; Anticancer; Cancer
CBR-001-634-068-4,RFM-010-145-1,CBR-001-634-068-4,C#Cc1ccc(cc1)c1ccccc1F,"CBR-HVAC-08759: ; Anti-inflammatory, nonsteroidal; Inflammation"
CBR-001-634-069-5,RFM-010-146-2,CBR-001-634-069-5,CCCCCCCCCCCCCCCC[N+](C1CCCCC1O)(C)C,CBR-HVAC-09013: ; Antiseptic; Disinfectant; Sepsis; Conjunctivitis
CBR-001-634-070-8,RFM-010-147-3,CBR-001-634-070-8,C[N+](CCOC(c1ccccc1)Cc1ccccc1)(C)C,CBR-HVAC-09728: Inhibition of the passage of the stimulus tussigene on the level of the neurons of the medulla oblongata (described like cough centers) in the dorso-side part of the bulb; Antitussive; Cough
CBR-001-634-071-9,RFM-010-148-4,CBR-001-634-071-9,OC(=O)C(c1ccc(cc1)C1=CCCCC1)C,CBR-HVAC-09904: ; Analgesic; Antipyretic; Antirheumatic; Anti-inflammatory; Pain; Inflammation
CBR-001-634-072-0,RFM-010-149-5,CBR-001-634-072-0,O=C(N(O)C)CCc1ccc2c(c1)C(=O)c1ccccc1CO2,CBR-HVAC-11429: Lipoxygenase 5; COX Inhibitor; Antiinflammatory; Psoriasis; Pruritis
CBR-001-634-073-1,RFM-010-150-8,CBR-001-634-073-1,Clc1ccc(cc1)c1ccnc(n1)Nc1ccc(cc1)C(=O)N1CCN(CC1)C(=O)C,"CBR-HVAC-11934: Nuclear factor kappa B; I-kappa B kinase beta Inhibitor; Modulator; ANTICANCER; ANTI-INFLAMMATORY; MULTIPLE SCLEROSIS; LEUKEMIA, ACUTE MYELOGENOUS; INFLAMMATIORY DISEASES; CANCER"
CBR-001-634-074-2,RFM-010-151-9,CBR-001-634-074-2,OC(=O)Cc1c(Cl)nc(nc1N(C)C)Cc1ccc(cc1)NC(=O)c1ccc2c(c1)cccc2,CBR-HVAC-12395: G-protein coupled receptor 44 Antagonist; Anti-inflammatory; Asthma
CBR-001-634-075-3,RFM-010-152-0,CBR-001-634-075-3,N#Cc1cnc(n1)C(=O)Nc1ccc(nc1C1=CCC(CC1)(C)C)C1CC(C)(C)OC(C1)(C)C,"CBR-HVAC-12449: COLONY STIMULATING FACTOR 1 RECEPTOR; FMS-like tyrosine kinase INHIBITOR; ANTIARTHRITIC; ANTINEOPLASTIC; ANTI-INFLAMMATORY; LYMPHOMA, HODGKIN'S; RHEUMATOID ARTHRITIS"
CBR-001-634-076-4,RFM-010-153-1,CBR-001-634-076-4,Nc1ncc(cn1)c1nc(N2CCOCC2)c2c(n1)n1CCOC(c1n2)(C)C,CBR-HVAC-12498: PHOSPHOINOSITIDE 3-KINASE; MTOR KINASE Inhibitor; Inhibitor; ANTICANCER; Glioblastoma; Glioma
CBR-001-634-077-5,RFM-010-154-2,CBR-001-634-077-5,Oc1c(ccc2c1cccc2)Cc1ccccc1,CBR-HVAC-12986: Lipoxygenase 5; 12-HETE receptor Antagonist; Inhibitor; Anti-inflammatory; Antipsoriatic; Atopic dermatitis; Psoriasis; Inflammation; Pruritis
CBR-001-634-078-6,RFM-010-155-3,CBR-001-634-078-6,CCCCCCCCN=c1ccn(cc1)CCCCCCCC,"CBR-HVAC-13236: ; Antibiotic; Bronchiolitis, obliterative; Sclerosis, peritoneal"
CBR-001-634-079-7,RFM-010-156-4,CBR-001-634-079-7,Cc1onc(n1)Cn1cnc2c1c(=O)[nH]c(=O)n2C,CBR-HVAC-13255: Phosphodiesterase Inhibitor; Bronchodilator; Respiratory diseases
CBR-001-634-080-0,RFM-010-157-5,CBR-001-634-080-0,O=C1NCCc2c1cc([nH]2)c1ccncc1,CBR-HVAC-13722: Cell division cycle 7 Inhibitor; Anticancer; Cancer
CBR-001-634-081-1,RFM-010-158-6,CBR-001-634-081-1,CCCCCCC1(CC)C(=O)NC(=O)NC1=O,"CBR-HVAC-13145: Barbiturate-induced anesthesia is a complex mechanism that probably involves several ligand-gated ion channel superfamilies. One of these superfamilies includes the archetypical nicotinic acetylcholine receptor (nAChR), in which barbiturates act as noncompetitive antagonist; Barbiturate; Sleep; Insomnia; Anxiety; Nervousness; Tension"
CBR-001-634-082-2,RFM-010-159-7,CBR-001-634-082-2,O[C@H]1C[C@@H](N(C1)C(=O)[C@H]1CCCN1C(=O)[C@@H](Cc1ccc(cc1)O)NC(=O)C)C(=O)NCC(=O)N[C@@H](C(=O)NCC(=O)N)C,"CBR-HVAC-00376: Gap junction protein Modulator; Antiarrhythmic; Fibrillation, atrial; Arrhythmia, ventricular"
CBR-001-634-083-3,RFM-010-160-0,CBR-001-634-083-3,COC(c1ccccc1)CN1CCN(CC1)CC(C(c1ccccc1)OC)O,CBR-HVAC-01805: ; Antitussive; Cough
CBR-001-634-084-4,RFM-010-161-1,CBR-001-634-084-4,CCOc1cnccc1c1[nH]c(=O)c2c(n1)n(nc2CC)C1CCCC1,"CBR-HVAC-11492: Phosphodiesterase 5 Inhibitor; Antianginal; Antihypertensive; Antiasthmatic; Angina; Hypertension, pulmonary; Impotence; Acute respiratory distress syndrome; Cardiovascular diseases; Asthma"
CBR-001-634-085-5,RFM-010-162-2,CBR-001-634-085-5,CCC(/N=C(/NC#N)\N[C@H]1[C@H](O)C(C)(C)Oc2c1cc(cc2)C#N)(C)C,CBR-HVAC-10822: Potassium channel Opener; Cardioprotective; Vasodilator; Anti-ischaemic; Angina; Ischemic heart diseases
CBR-001-634-086-6,RFM-010-163-3,CBR-001-634-086-6,CCC(/N=C(/NC#N)\N[C@@H]1[C@@H](O)C(C)(C)Oc2c1cc(cc2)C#N)(C)C,CBR-HVAC-10822: Potassium channel Opener; Cardioprotective; Vasodilator; Anti-ischaemic; Angina; Ischemic heart diseases
CBR-001-634-087-7,RFM-010-164-4,CBR-001-634-087-7,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)CCCNC(=N)N)NC(=O)[C@H]([C@H](O)C)N,CBR-HVAC-12974: Immunostimulator; Anti-inflammatory; Immunostimulant; Anti-inflammatory; Immunological disorders
CBR-001-634-088-8,RFM-010-165-5,CBR-001-634-088-8,CN(CCOCC(=O)N[C@]12C[C@H]3C[C@@H](C2)C[C@@H](C1)C3)C,"CBR-HVAC-00913: ; Antiviral; Infection, viral"
CBR-001-634-089-9,RFM-010-166-6,CBR-001-634-089-9,CCC(=O)O[C@@]1([C@H](C)C[C@@H]2C1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=CC12C)F)F)C(=O)SC,CBR-HVAC-03976: Corticosteroid agonist; Arachidonic acid inhibitor; Immunosuppressant
CBR-001-634-090-2,RFM-010-167-7,CBR-001-634-090-2,n1[nH]nc(n1)c1cc2ccccc2n2c1nnn2,CBR-HVAC-10813: Histamine release inhibitor; Antiallergic; Antiasthmaitc; Asthma; Allergy
CBR-001-634-091-3,RFM-010-168-8,CBR-001-634-091-3,CCC(C1(CC=C)C(=O)NC(=O)NC1=O)C,"CBR-HVAC-13113: Inhibit the phosphatase of the nervous cells and thus the synthesis of the nucleoproteines, cerebral phospholipides, phosphate coenzyme A and acetylphosphate which precede the synthesis by acetylcholine.; Sedative; Hypnotic; Insomnia"
CBR-001-634-092-4,RFM-010-169-9,CBR-001-634-092-4,O=[S@@]1CC[C@@H](C1)SC1=C(C(=O)O)N2[C@H](S1)[C@H](C2=O)[C@H](O)C,"CBR-HVAC-12044: Bacterial cell wall synthesis inhibitor; Antibacterial; Infection, bacterial"
CBR-001-634-093-5,RFM-010-170-2,CBR-001-634-093-5,COc1ccc2c(c1)CC(O2)CN1CCC2(CC1)C(=O)NCN2c1ccccc1,CBR-HVAC-08378: Dopamine receptor antagonist; Alpha adrenoreceptor antagonist
CBR-001-634-094-6,RFM-010-171-3,CBR-001-634-094-6,COc1ccc2c(c1)CC(O2)CN1CCC2(CC1)C(=O)NCN2c1ccccc1,CBR-HVAC-08378: Dopamine receptor antagonist; Alpha adrenoreceptor antagonist
CBR-001-634-095-7,RFM-010-172-4,CBR-001-634-095-7,OC(=O)CCN(c1scc(n1)c1ccc(cc1)C(=N)N)C1CCN(CC1)CC(=O)O,CBR-HVAC-10637: Integrin alpha2b beta3 Antagonist; Antiplatelet; Thrombosis
CBR-001-634-096-8,RFM-010-173-5,CBR-001-634-096-8,SCC(C(=O)NCCC(=O)O)Cc1ccccc1,CBR-HVAC-10657: Membrane metalloendopeptidase Inhibitor; Diuretic; Antihypertensive; Diuresis; Heart failure; Hypertension
CBR-001-634-097-9,RFM-010-174-6,CBR-001-634-097-9,O=C([C@H](NC(=O)c1cc(Cl)cc(c1)Cl)CCC(=O)O)N1CCC2(CC1)CCCC2,CBR-HVAC-02692: Cholecystokinin B receptor Antagonist; Anxiolytic; Anxiety disorder
CBR-001-634-098-0,RFM-010-175-7,CBR-001-634-098-0,O=C([C@H](NC(=O)c1cc(Cl)cc(c1)Cl)CCC(=O)O)N1CCC2(CC1)CCCC2,CBR-HVAC-02692: Cholecystokinin B receptor Antagonist; Anxiolytic; Anxiety disorder
CBR-001-634-099-1,RFM-010-176-8,CBR-001-634-099-1,O=C(c1cc2cccc(c2cc1O)OCc1cccnc1)NCCN1CCC(CC1)OC(c1ccccc1)c1ccccc1,CBR-HVAC-10994: Histamine receptor; Lipoxygenase 5; Thromboxane A synthase Antagonist; Inhibitor; Antiinflammatory; Allergic rhinitis; Allergy; Asthma
CBR-001-634-100-7,RFM-010-177-9,CBR-001-634-100-7,COc1ccc(cc1)C1Sc2ccccc2N(C(=O)C1OC(=O)C)CCN(C(C)C)C,CBR-HVAC-13195: Calcium channel Antagonist; Vasodilator; Antiarrhythmic; Antianginal; Arrhythmia; Ischemic heart diseases; Angina
CBR-001-634-101-8,RFM-010-178-0,CBR-001-634-101-8,Fc1ccc(c(c1)F)N1CCN(CC1)CCn1ncc2c1nc(N)n1c2nc(n1)c1ccco1,CBR-HVAC-11779: Adenosine A2A receptor Antagonist; Antiparkinsonian; Parkinson's disease
CBR-001-634-102-9,RFM-010-179-1,CBR-001-634-102-9,C=C[C@]1(C)C[C@@H](OC(=O)CSC23CCN(CC2)CC3)C2(C)[C@H](C)CC[C@@]3([C@H]([C@@H]1O)C)C2C(=O)CC3,CBR-HVAC-11292: Protein synthesis inhibitor; Antibacterial; Staphylococcus aureus skin and structural infections
CBR-001-634-103-0,RFM-010-180-4,CBR-001-634-103-0,NC(=N)NOCCNC(=O)Cn1c(C)ccc(c1=O)NS(=O)(=O)c1cccc(c1)C,CBR-HVAC-05201: FACTOR XA; THROMBIN Inhibitor; Anticoagulant; Antithrombotic; Venous thrombosis; Arterial thrombosis
CBR-001-634-104-1,RFM-010-181-5,CBR-001-634-104-1,CCCCC/C(=C\C=C\C(=O)N[C@@H](CCCc1cccnc1)C)/c1ccc(cc1)OC,CBR-HVAC-03841: Platelet activating factor receptor Antagonist; Antiinflammatory; Asthma
CBR-001-634-105-2,RFM-010-182-6,CBR-001-634-105-2,NC(=N)NC(=O)c1cc(c(cc1C)S(=O)(=O)C)S(=O)(=O)C,"CBR-HVAC-11670: Na+/H+ Exchanger type 1 (NHE-1) Inhibitors; Na+/H+ exchanger 1 Modulator; Na+/H+ exchanger 2; Na+/H+ exchanger 3; Sodium-hydrogen-antiporter-inhibitors; Antiarrhythmic Drugs; Cardioprotectant; Heart Failure; Heart Failure Therapy; Muscular Dystrophy, Agents for; Musculoskeletal Disorders"
CBR-001-634-106-3,RFM-010-183-7,CBR-001-634-106-3,O=C(C[C@@H]1CC[C@@]2(CC1)OOC1(O2)C2CC3CC1CC(C2)C3)NCC(N)(C)C,CBR-HVAC-06006: Antiparasitic; Antiparasitic; Malaria
CBR-001-634-107-4,RFM-010-184-8,CBR-001-634-107-4,CCCCCCCCCCCC(=O)O[C@H]1CN([C@@H](C1)CCOc1ccccc1CCc1cccc(c1)OC)C,CBR-HVAC-11051: 5-Hydroxytryptamine 2A receptor Antagonist; Vasoprotectant; Antipsychotic; Pancreatitis; Psychosis; Circulatory diseases
CBR-001-634-108-5,RFM-010-185-9,CBR-001-634-108-5,O=C1CCC(=NN1)c1ccc2c(c1)CN(C(=O)N2)C,CBR-HVAC-03704: Phosphodiesterase Inhibitor; Cardiotonic; Vasodilator; Cardiac failure
CBR-001-634-109-6,RFM-010-186-0,CBR-001-634-109-6,CC(C[C@@H](C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@@H]1CCCC(=O)N1)C,CBR-HVAC-13548: Thyrotropin releasing hormone receptor Agonist; Neuroprotectant; Neurodegenerative diseases
CBR-001-634-110-9,RFM-010-187-1,CBR-001-634-110-9,NCCCC[C@@H]1NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H]2CSSC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H]3N(C(=O)[C@H]4N(C1=O)CCC4)CCC3)Cc1ccc(cc1)O)CCCNC(=N)N)CCCNC(=O)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N2)Cc2ccc3c(c2)cccc3)CCCNC(=N)N)CCCNC(=N)N)CCC1,"CBR-HVAC-13454: C-X-C chemokine receptor type 4 Antagonist; Immunomodulator; INFECTION, HUMAN IMMUNODEFICIENCY VIRUS; CANCER"
CBR-001-634-111-0,RFM-010-188-2,CBR-001-634-111-0,CCN1CCC(=C2c3ccccc3CCc3c2cccc3)C1C,CBR-HVAC-01676: Dopamine uptake inhibitor; Antiparkinsonian; Parkinson's disease
CBR-001-634-112-1,RFM-010-189-3,CBR-001-634-112-1,O=C1NCCCC(NC(=O)C(Cc2ccc(cc2)O)N)C(=O)NC(C(=O)NC(C1)C(=O)N)Cc1ccccc1,CBR-HVAC-08181: Opioid mu receptor agonist
CBR-001-634-113-2,RFM-010-190-6,CBR-001-634-113-2,O=C(N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C)CCC[C@H](C(=O)O)N,CBR-HVAC-10323: ; Antibiotic; BACILLARY DYSENTERY
CBR-001-634-114-3,RFM-010-191-7,CBR-001-634-114-3,COc1ccc2c(c1)C(=CC(CO2)(C)C)/C=C/C(=C/C(=O)O)/C,CBR-HVAC-05388: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Antihyperlipidemic; Hypoglycemic; Insulin sensitizer; Non-insulin dependent diabetes
CBR-001-634-115-4,RFM-010-192-8,CBR-001-634-115-4,O=C1CCC2C(=C1O)CC[C@@H]1[C@@H]2CCC2([C@H]1CC[C@@H]2O)C,CBR-HVAC-13120: ; Anabolic steroid; Growth substance
CBR-001-634-116-5,RFM-010-193-9,CBR-001-634-116-5,CC[C@]1(O)CC[C@@H]2C1(CC)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,CBR-HVAC-13206: ; Anabolic steroid; Growth substance
CBR-001-634-117-6,RFM-010-194-0,CBR-001-634-117-6,O[C@@H](C[C@H](CC(=O)OCCCCO[N+](=O)[O-])O)CCn1c(C(C)C)c(c(c1c1ccc(cc1)F)c1ccccc1)C(=O)Nc1ccccc1,CBR-HVAC-06470: HMG-CoA reductase Inhibitor; Fibrinolysis stimulator; Thrombosis; Cardiovascular inflammation
CBR-001-634-118-7,RFM-010-195-1,CBR-001-634-118-7,OC[C@H]1N(C)C[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-13198: Alpha-glucosidase Inhibitor; Antithrombotic; Thromboembolism
CBR-001-634-119-8,RFM-010-196-2,CBR-001-634-119-8,CCCc1c2nc(cc(c2cc2c1oc(cc2=O)C(=O)O)NC)C(=O)O,CBR-HVAC-02489: ; Antiallergic; Antiasthmatic; Allergy; Asthma
CBR-001-634-120-1,RFM-010-197-3,CBR-001-634-120-1,O=C1CC[C@]2(C(=C1)[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2([C@H]1CC[C@@H]2C(=O)C)C)C,"CBR-HVAC-13068: Corticosteroids inhibit the inflammatory response to inciting agents of mechanical, chemical, or immunological nature of edema, fibrin deposition, capillary dilation and leukocyte migration, capillary proliferation, deposition of collagen and scar formation.; Glucocorticoid; Anti-inflammatory; Conjunctivitis, allergic; Conjunctivitis, vernal; Episcleritis, Epinephrine sensitivity"
CBR-001-634-121-2,RFM-010-198-4,CBR-001-634-121-2,Oc1cc2CC[n+]3c2c(c1)c1cc2OCOc2cc1c3,CBR-HVAC-04894: Acetylcholinesterase Inhibitor; Anticancer; Cancer
CBR-001-634-122-3,RFM-010-199-5,CBR-001-634-122-3,OC(=O)C(Oc1ccccc1)(Cc1ccc(cc1)OCCc1nc(oc1C)c1cccs1)C,CBR-HVAC-05421: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Antihyperlipidemic; Hypoglycemic; Insulin sensitizer; Hyperlipidemia; Metabolic disorders; Diabetes mellitus
CBR-001-634-123-4,RFM-010-200-1,CBR-001-634-123-4,OC(=O)C(Oc1ccccc1)(Cc1ccc(cc1)OCCc1nc(oc1C)c1cccs1)C,CBR-HVAC-05421: Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor gamma Agonist; Antihyperlipidemic; Hypoglycemic; Insulin sensitizer; Hyperlipidemia; Metabolic disorders; Diabetes mellitus
CBR-001-634-124-5,RFM-010-201-2,CBR-001-634-124-5,CN1CCN(CC1)/C=C/1\N=C2N(C1=O)c1ccc(cc1C(=NC2)c1ccccc1Cl)[N+](=O)[O-],CBR-HVAC-12962: Benzodiazepine receptor Agonist; Sedative; Hypnotic; Antidote treatment
CBR-001-634-125-6,RFM-010-202-3,CBR-001-634-125-6,CCN1CCN=C1CNC(=O)c1cc(Cl)c(cc1OC)N,CBR-HVAC-03542: 5-Hydroxytryptamine 4 receptor; 5-Hydroxytryptamine 3 receptor Antagonist; Antiemetic; Gastroprokinetic; Emesis; Gastroesophageal reflux; Nausea; Vomiting
CBR-001-634-126-7,RFM-010-203-4,CBR-001-634-126-7,CN[C@@]1(CC[C@]2(CC1)OCCc1c2nc2c1cc(cc2)F)c1ccccc1,CBR-HVAC-12729: Opioid ORL1 receptor agonist; Opioid mu receptor agonist
CBR-001-634-127-8,RFM-010-204-5,CBR-001-634-127-8,CCCCCO[C@]1(CO)OC[C@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-00944: Immunosuppressant
CBR-001-634-128-9,RFM-010-205-6,CBR-001-634-128-9,COc1cc2ncnc3c2cc1OCCCCCN(Cc1c(N3)cc(Br)cc1)C,CBR-HVAC-06228: EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; RET KINASE; SRC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3 Antagonist; Inhibitor; Anticancer; Cancer
CBR-001-634-129-0,RFM-010-206-7,CBR-001-634-129-0,COc1nccc(c1)N(C(=O)C(=O)c1c2cc(Cl)ccc2n(c1C)Cc1ccc(cc1)Cl)C,CBR-HVAC-13445: Fatty acid amide hydrolase Inhibitor; ANTI-INFLAMMATORY¬ANALGESIC; Pain; Inflammation
CBR-001-634-130-3,RFM-010-207-8,CBR-001-634-130-3,OC(=O)C[C@@H](C(=O)O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](Cc1cncn1)NC(=O)[C@H](C(C)C)N,CBR-HVAC-13364: Insulin receptor; Antidiabetic; HYPOGLYCEMIA; INSULIN SENSITIVITY
CBR-001-634-131-4,RFM-010-208-9,CBR-001-634-131-4,CC(NC(=O)c1[n+]([O-])onc1C(=O)NC(C)C)C,CBR-HVAC-07934: Erectile dysfunction
CBR-001-634-132-5,RFM-010-209-0,CBR-001-634-132-5,O=C(OCC(=O)[C@@]1(O)CC[C@@H]2C1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CCC12C)CCC1CCCC1,CBR-HVAC-13290: Glucocorticoid receptor Agonist; Anti-inflammatory; Corticosteroid; Severe allergies; Skin problems; Asthma; Arthritis
CBR-001-634-133-6,RFM-010-210-3,CBR-001-634-133-6,CC(CCCC(c1ccc(cc1)CCCC(=O)O)NS(=O)(=O)c1ccc(cc1)Cl)C,CBR-HVAC-10617: Leukotriene D4 receptor; Thromboxane A2 receptor Antagonist; Antiinflammatory; Asthma
CBR-001-634-134-7,RFM-010-211-4,CBR-001-634-134-7,CCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)NCC(=O)N)Cc1cnc2c1cccc2)CCCNC(=N)N)Cc1ccccc1)Cc1ncnc1)CCC(=O)N)NC(=O)C,CBR-HVAC-12886: Nitric oxide synthase; Melanocortin receptor 3; Melanocortin receptor 4 Inhibitor; Agonist; Agonist; Analgesic; Anti-emetic; Anti-inflammatory; Asthma; Inflammation; Obesity; Postoperative pain; Type II diabetes mellitus
CBR-001-634-135-8,RFM-010-212-5,CBR-001-634-135-8,O[C@H]1CCC2(C(=C[C@@H]([C@@H]3[C@@H]2CCC2([C@H]3CC[C@@H]2O)C)O)C1)C,CBR-HVAC-05412: Steroid hormone modulator; Anticancer; Immunomodulator; Steroidal anti-inflammatory; Cardiovascular and immune system related disorders
CBR-001-634-136-9,RFM-010-213-6,CBR-001-634-136-9,ONC(=N)N/N=C/c1c(Cl)cccc1Cl,CBR-HVAC-01978: ALPHA-2A ADRENERGIC RECEPTOR Agonist; Antihypertensive; ACUTE PULMONARY EDEMA
CBR-001-634-137-0,RFM-010-214-7,CBR-001-634-137-0,NC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1nc(c2c1ncnc2N)Br,CBR-HVAC-10486: Adenosine kinase Inhibitor; Antisecretory; Anti-inflammatory; Inflammation; Pain; Septic shock
CBR-001-634-138-1,RFM-010-215-8,CBR-001-634-138-1,CCCCCC(=O)O[C@@]1(CC[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12)C(=O)C,CBR-HVAC-13071: Cytostatic activity on endometrial carcinoma; Progestational steroid; Benign prostate hypertrophy
CBR-001-634-139-2,RFM-010-216-9,CBR-001-634-139-2,CCOc1ccc2c(c1)NCC2(C)C,CBR-HVAC-03827: COX Inhibitor; Analgesic; Antipyretic; Pain
CBR-001-634-140-5,RFM-010-217-0,CBR-001-634-140-5,CCc1nc(N)nc(c1c1ccc(c(c1)Cl)Cl)N,CBR-HVAC-09167: Dihydrofolate reductase Inhibitor; Antineoplastic; Cancer
CBR-001-634-141-6,RFM-010-218-1,CBR-001-634-141-6,CCOC(=O)Nc1ccc(cc1)SCC1COC(O1)(Cn1cncc1)c1ccc(cc1)OC,CBR-HVAC-03844: Microtubule modulator; Anticancer; Cancer
CBR-001-634-142-7,RFM-010-219-2,CBR-001-634-142-7,CCN(C(C(=O)NNC(=O)C)Cc1ccccc1)C(=O)CNC(=O)C(NC(=O)C(Cc1ccc(cc1)O)N)CCS(=O)C,CBR-HVAC-10380: Opioid receptor mu; Opioid receptor delta Agonist; Analgesic; Anti-inflammatory; Pain; Inflammation
CBR-001-634-143-8,RFM-010-220-5,CBR-001-634-143-8,N1CC2C(C1)(C2)c1ccc2c(c1)cccc2,CBR-HVAC-00684: Norepinephrine transporter; Serotonin transporter Inhibitor; Analeptic; ATTENTION DEFICIT HYPERACTIVITY DISORDER
CBR-001-634-144-9,RFM-010-221-6,CBR-001-634-144-9,Cc1c(C)c2nc(sc2c(c1O)C)NCc1ccc(cc1)S(=O)(=O)N,CBR-HVAC-03898: Lipoxygenase 5 Inhibitor; Antiasthmatic; Anti-inflammatory; Asthma; Allergy
CBR-001-634-145-0,RFM-010-222-7,CBR-001-634-145-0,CO/N=C/1\CN(CC1(C)CN)c1nc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-07768: Antibacterial; Antibacterial; Bacterial infection
CBR-001-634-146-1,RFM-010-223-8,CBR-001-634-146-1,CC#CC1(CCCCC1)OCC(N1CCCC1)COCC(C)C,CBR-HVAC-03792: Calcium channel Antagonist; Antianginal; Antiarrhythmic; Angina pectoris; Atherosclerosis
CBR-001-634-147-2,RFM-010-224-9,CBR-001-634-147-2,OCCOCCN1CCN(CC1)CC(CN1c2ccccc2Sc2c1cccc2)C,"CBR-HVAC-09783: ; Neuroleptic; Nausea, postoperative; Vomiting, postoperative"
CBR-001-634-148-3,RFM-010-225-0,CBR-001-634-148-3,COc1cc(CCNC(=O)CNc2cccc(c2)C(=O)N)ccc1OC,CBR-HVAC-13645:
CBR-001-634-149-4,RFM-010-226-1,CBR-001-634-149-4,CCC(=O)O[C@@]1(CC[C@@H]2C1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=CC12C)C(=O)C,CBR-HVAC-12780: Arachidonic acid antagonist; Immunosuppressants; Lipocortin synthesis agonists; Corticosteroid; Skin disorders including eczema; Dermatitis; Psoriasis; Insect stings; Alopecia areata; Insect bites
CBR-001-634-150-7,RFM-010-227-2,CBR-001-634-150-7,CCOC(=O)C1=C(C)NC(=C(C1c1cccc2c1non2)C(=O)OCC)C,CBR-HVAC-12850: Calcium channel Antagonist; Class IV antiarrhythmic; Hypertension; Ischemic heart diseases; Cerebrovascular ischemia
CBR-001-634-151-8,RFM-010-228-3,CBR-001-634-151-8,CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)c1cnn(c1)Cc1ccccc1,CBR-HVAC-12006: ADENOSINE A2B RECEPTOR Modulator; Respiratory system agent; Anti-inflammatory; Cardiac agent; Vascular disorder
CBR-001-634-152-9,RFM-010-229-4,CBR-001-634-152-9,ClCSC(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2C1(C)C[C@H](O)[C@]1(C2C[C@@H](C2=CC(=O)C=CC12C)F)F,"CBR-HVAC-08774: ; Anti-inflammatory, steroidal; Inflammation"
CBR-001-634-153-0,RFM-010-230-7,CBR-001-634-153-0,O=C1C(CCc2c1c1cccc3c1n2CCC3)Cn1ccnc1C,CBR-HVAC-02716: 5-Hydroxytryptamine 3 receptor Antagonist; GASTROPROKINETIC; Irritable bowel syndrome
CBR-001-634-154-1,RFM-010-231-8,CBR-001-634-154-1,O=C1C(CCc2c1c1cccc3c1n2CCC3)Cn1ccnc1C,CBR-HVAC-02716: 5-Hydroxytryptamine 3 receptor Antagonist; GASTROPROKINETIC; Irritable bowel syndrome
CBR-001-634-155-2,RFM-010-232-9,CBR-001-634-155-2,ClNS(=O)(=O)c1ccc(cc1)C,"CBR-HVAC-13340: ; Antibiotic; Infection, bacterial"
CBR-001-634-156-3,RFM-010-233-0,CBR-001-634-156-3,COc1c(OC)ccc2c1CCC(C2)NC(C(c1ccc(cc1)O)O)C,CBR-HVAC-04126:
CBR-001-634-157-4,RFM-010-234-1,CBR-001-634-157-4,N#CC(NC(=O)[C@H]1CC[C@@H]2C1(C)CC[C@H]1[C@H]2CC[C@@H]2C1(C)C=CC(=O)N2)(C)C,CBR-HVAC-11422: Steroid 5-alpha-reductase Inhibitor; 5-alpha reductase inhibitor; Benign prostate hyperplasia
CBR-001-634-158-5,RFM-010-235-2,CBR-001-634-158-5,Cc1cc(C)cc(c1)C(=O)N1CCC(CC1Cc1ccccc1)NCc1ccnc2c1cccc2,CBR-HVAC-04548: Neurokinin receptor 1 Antagonist; Anxiolytic; Anxiety; Depression
CBR-001-634-159-6,RFM-010-236-3,CBR-001-634-159-6,Cc1cc(C)cc(c1)C(=O)N1CCC(CC1Cc1ccccc1)NCc1ccnc2c1cccc2,CBR-HVAC-04548: Neurokinin receptor 1 Antagonist; Anxiolytic; Anxiety; Depression
CBR-001-634-160-9,RFM-010-237-4,CBR-001-634-160-9,CO/N=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)COC(=O)C)/c1ccco1,"CBR-HVAC-13498: Penicillin binding protein Inhibitor; Antibacterial; Infection, bacterial"
CBR-001-634-161-0,RFM-010-238-5,CBR-001-634-161-0,CN(CCCOC(=O)[C@@](c1cscc1)(C1CCCCC1)O)C,CBR-HVAC-11418: Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2 Inhibitor; Anticholinergic; Poisoning
CBR-001-634-162-1,RFM-010-239-6,CBR-001-634-162-1,CN(CCCOC(=O)[C@@](c1cscc1)(C1CCCCC1)O)C,CBR-HVAC-11418: Muscarinic acetylcholine receptor M3; Muscarinic acetylcholine receptor M1; Muscarinic acetylcholine receptor M2 Inhibitor; Anticholinergic; Poisoning
CBR-001-634-163-2,RFM-010-240-9,CBR-001-634-163-2,C#CCCN1CCC2(C(C1Cc1c2cc(cc1)O)(C)C)O,CBR-HVAC-07577: Opioid receptor agonist
CBR-001-634-164-3,RFM-010-241-0,CBR-001-634-164-3,CC(OCOCCCOn1cnc2c1nc(N)nc2)C,CBR-HVAC-10677: DNA synthesis inhibitor; Viral replication inhibitor; Antiviral; Viral infection
CBR-001-634-165-4,RFM-010-242-1,CBR-001-634-165-4,CN(C[C@H]1C[C@@H]1c1cnc2c1cc(cc2)C#N)C,CBR-HVAC-11939: 5-Hydroxytryptamine transporter Inhibitor; 5-HYDROXYTRYPTAMINE TRANSPORTER INHIBITOR; MALE SEXUAL DYSFUNCTION
CBR-001-634-166-5,RFM-010-243-2,CBR-001-634-166-5,Clc1ccc(cc1)CCCCCCCCCCC(C(=O)O)(Cl)Cl,CBR-HVAC-00557: Peroxisome proliferator activated receptor alpha Agonist; Antidiabetic; Hypoglycemic; Type II diabetes mellitus Lipoprotein disorders
CBR-001-634-167-6,RFM-010-244-3,CBR-001-634-167-6,CN1C2CCC1C(C(C2)OC(=O)c1ccccc1)C(=O)O,CBR-HVAC-13132: Dopamine transporter Inhibitor; Analgesic; Drug abuse
CBR-001-634-168-7,RFM-010-245-4,CBR-001-634-168-7,OC(=O)CCC(=O)OC(c1oc2c(c1C)cc(cc2)C1=CC(=O)OC1)C,CBR-HVAC-08627: ; Cardiotonic; Heart disease
CBR-001-634-169-8,RFM-010-246-5,CBR-001-634-169-8,CCN(CC(O)(C)C)CCNc1ccc(c2c1c(=O)c1c(s2)cccc1)C,"CBR-HVAC-10186: ; Antihelmintic; Infection, helminth"
CBR-001-634-170-1,RFM-010-247-6,CBR-001-634-170-1,CCCCCN(c1cc(nc2n1ncn2)N1CCCCC1)CCO,CBR-HVAC-13365: Thromboxane A2 receptor Inhibitor; Antihypertensive; Atherosclerosis; Ischemic heart diseases; Thrombosis
CBR-001-634-171-2,RFM-010-248-7,CBR-001-634-171-2,C=CCC1(C(C)C)C(=O)NC(=O)NC1=O,CBR-HVAC-13311: GABA-A receptor Agonist; Sedative; Hypnosis; Sedation
CBR-001-634-172-3,RFM-010-249-8,CBR-001-634-172-3,ClCCC1NC(=O)c2c(O1)ccc(c2)N,CBR-HVAC-09957: ; Analgesic; Pain; Fever
CBR-001-634-173-4,RFM-010-250-1,CBR-001-634-173-4,Clc1cccc(c1)N1CCN([C@H](C1)C)CCCn1nc2n(c1=O)cccc2,CBR-HVAC-13293: 5-HYDROXYTRYPTAMINE 2C RECEPTOR Antagonist; Anti-depressant; Depression; Anxiety
CBR-001-634-174-5,RFM-010-251-2,CBR-001-634-174-5,OC(=O)C1Oc2c(C1)c1onc(c1cc2Cl)c1ccccc1,CBR-HVAC-03569: Urate transporter Inhibitor; Uricosuric; Gout
CBR-001-634-175-6,RFM-010-252-3,CBR-001-634-175-6,CC[C@@H]([C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)O)N)CC(=O)N)C,CBR-HVAC-06631: CD4 antagonist; Immunosuppressant; CNS modulator; Graft versus host disease
CBR-001-634-176-7,RFM-010-253-4,CBR-001-634-176-7,FCc1nc(N)nc(c1c1cccc(c1Cl)Cl)N,CBR-HVAC-04926: Sodium channel Antagonist; Analgesic; Pain
CBR-001-634-177-8,RFM-010-254-5,CBR-001-634-177-8,OC(c1ccc(cc1)NS(=O)(=O)C)CNCC1CCc2c(C1=O)cccc2,CBR-HVAC-10459: Alpha-1 adrenergic receptor; Beta-1 adrenergic receptor; 5-Hydroxytryptamine receptor Antagonist; Antihypertensive; Hypertension
CBR-001-634-178-9,RFM-010-255-6,CBR-001-634-178-9,NCC[C@@H](C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)[C@H](O)C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)CCCCC(CC)C)CCN,CBR-HVAC-12946: Penetrates into and disrupts the bacterial cell membrane; Antibacterial; Antibiotics
CBR-001-634-179-0,RFM-010-256-7,CBR-001-634-179-0,CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCCCCCC/C=C\C/C=C\CCCCC,CBR-HVAC-14111: A type of evening primrose (Oenothera spp.) oil SCI 15 with a constant composition that delivers 40 mg of gamma-linolenic acid (gamolenic acid) per capsule. gamma-Linolenic acid is present in evening primrose oil as a triglyceride containing two linoleic acid and one gamma-linolenic acid moieties
CBR-001-634-180-3,RFM-010-257-8,CBR-001-634-180-3,OC(=O)CC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)O)CC(=O)O)NC(=O)[C@@H](N)C,CBR-HVAC-14125: Apoptosis Inhibitors
CBR-001-634-181-4,RFM-010-258-9,CBR-001-634-181-4,CNC(=N)NCCC[C@@H](C(=O)N[C@H](C(=O)N)Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)NNC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H](Cc1cnc2c1cccc2)NC(=O)[C@@H](Cc1ccc(cc1)O)NC(=O)C)CC(=O)N)Cc1ccccc1)CC(C)C,"CBR-HVAC-12996: Gonadotropin-Releasing Factor Hormone Receptor (GnRH, LHRH) Ligands;KiSS-1 (Metastin; GPR54) Receptor Agonists;Signal Transduction Modulators"
CBR-001-634-182-5,RFM-010-259-0,CBR-001-634-182-5,SC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CO)CC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(=O)N)N)CC(C)C)CCC(=O)O)Cc1ncnc1,"CBR-HVAC-06644: Antipsychotic Drugs;Neurologic Drugs (Miscellaneous);Alzheimer's Dementia, Treatment of"
CBR-001-634-183-6,RFM-010-260-3,CBR-001-634-183-6,NCC1(CC(=O)O)CC2C1CCC2,CBR-HVAC-12696: Drugs Acting on Calcium Channels (Voltage-Gated)
CBR-001-634-184-7,RFM-010-261-4,CBR-001-634-184-7,OCCc1sc[n+](c1C)CC1=C(C(=O)O)N2C(SC1)C(C2=O)NC(=O)/C(=N/OC)/c1csc(n1)N,CBR-HVAC-07688: Antibiotics
CBR-001-634-185-8,RFM-010-262-5,CBR-001-634-185-8,CN1CCCC1CCNS(=O)(=O)c1ccc2c(c1)CN(CC2)CC1CCCCC1,CBR-HVAC-13900: Histamine H3 Receptor Antagonists;Signal Transduction Modulators
CBR-001-634-186-9,RFM-010-263-6,CBR-001-634-186-9,CN1CCCC1CCNS(=O)(=O)c1ccc2c(c1)CN(CC2)CC1CCCCC1,CBR-HVAC-13900: Histamine H3 Receptor Antagonists;Signal Transduction Modulators
CBR-001-634-187-0,RFM-010-264-7,CBR-001-634-187-0,Fc1ccc(cc1)C(c1cnc(nc1)N1CCN(CC1)c1ncnn2c1cc(c2)c1cnn(c1)C)(O)C,analog of CBR-HVAC-14004
CBR-001-634-188-1,RFM-010-265-8,CBR-001-634-188-1,Fc1ccc(cc1)C(c1cnc(nc1)N1CCN(CC1)c1ncnn2c1cc(c2)c1cnn(c1)C)(O)C,analog of CBR-HVAC-14004
CBR-001-634-189-2,RFM-010-266-9,CBR-001-634-189-2,OCC1C/C(=N/OC)/CN1C(=O)c1ccc(cc1)c1ccccc1C,CBR-HVAC-13790: Oxytocin (OT) Antagonists;Signal Transduction Modulators
CBR-001-634-190-5,RFM-010-267-0,CBR-001-634-190-5,OCC1C/C(=N/OC)/CN1C(=O)c1ccc(cc1)c1ccccc1C,CBR-HVAC-13790: Oxytocin (OT) Antagonists;Signal Transduction Modulators
CBR-001-634-191-6,RFM-010-268-1,CBR-001-634-191-6,O=C1CCC2(C(=C1O)CC[C@@H]1[C@@H]2CCC2([C@H]1CC[C@@H]2O)C)C,CBR-HVAC-12812: Breast Cancer Therapy
CBR-001-634-192-7,RFM-010-269-2,CBR-001-634-192-7,CS(=O)CCNCc1ccc(o1)c1ccc2c(c1)c(ncn2)Nc1ccc(c(c1)Cl)OCc1cccc(c1)F,CBR-HVAC-12857: EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;Signal Transduction Modulators
CBR-001-634-193-8,RFM-010-270-5,CBR-001-634-193-8,COC(=O)C1(CCN(CC1)CCC(=O)O)N(c1ccccc1)C(=O)CC,CBR-HVAC-12938: Opioid Receptor Agonists;Signal Transduction Modulators
CBR-001-634-194-9,RFM-010-271-6,CBR-001-634-194-9,CCCCOC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@@H]([C@H]1O)CO)C)C)CCC(=O)N,CBR-HVAC-02954: Immunomodulators
CBR-001-634-195-0,RFM-010-272-7,CBR-001-634-195-0,CNCCC(c1cccs1)Oc1cccc2c1OCO2,CBR-HVAC-12065: Norepinephrine Reuptake Inhibitors;Signal Transduction Modulators;5-HT Reuptake Inhibitors
CBR-001-634-196-1,RFM-010-273-8,CBR-001-634-196-1,OC(=O)C[C@@H](C(=O)N)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](Cc1cncn1)NC(=O)[C@H](C(C)C)N,CBR-HVAC-06106: Glucose Lowering Agents
CBR-001-634-197-2,RFM-010-274-9,CBR-001-634-197-2,CNCCOC(=O)c1cc(OC)c2c(c1c1c(cc(c3c1OCO3)OC)C(=O)O)OCO2,CBR-HVAC-05722: Anti-Hepatitis Virus Drugs
CBR-001-634-198-3,RFM-010-275-0,CBR-001-634-198-3,COC(=O)CCc1c2/C=C/3\N=C(C(=C3CCC(=O)O)C)/C=C/3\N/C(=C\C4=N/C(=C\c(c1C)[nH]2)/C(=C4C)C=C)/C1=CC=C([C@H](C31C)C(=O)OC)C(=O)OC,"CBR-HVAC-04687: Age-Related Macular Degeneration, Treatment of; Antipsoriatics; Oncolytic Drugs; Ophthalmic Drugs"
CBR-001-634-199-4,RFM-010-276-1,CBR-001-634-199-4,N#C[C@@H]1CCCN1C(=O)CN[C@@H]1CC[C@H](CC1)C(=O)N1CCOCC1,CBR-HVAC-13801: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors;Signal Transduction Modulators
CBR-001-634-200-0,RFM-010-277-2,CBR-001-634-200-0,C=CC(=O)N1CC[C@@H](C1)n1nc(c2c1ncnc2N)C#Cc1cc(OC)cc(c1)OC,CBR-HVAC-13898: Angiogenesis Inhibitors;FGFR1 Inhibitors;FGFR2 Inhibitors;FGFR3 Inhibitors;FGFR4 Inhibitors;Signal Transduction Modulators
CBR-001-634-201-1,RFM-010-278-3,CBR-001-634-201-1,Cc1ccc(cc1)CCSC(C(=O)O)Cc1ccc(cc1)CCOc1ccc(cc1)OS(=O)(=O)C,"CBR-HVAC-14023: Lipoprotein Disorders, Treatment of"
CBR-001-634-202-2,RFM-010-279-4,CBR-001-634-202-2,O=C(C[N+]12CC[C@H](CC1)[C@H](C2)OC(=O)C(c1ccccc1)(c1ccccc1)O)Nc1nocc1,CBR-HVAC-13957: Muscarinic Antagonists;Signal Transduction Modulators
CBR-001-634-203-3,RFM-010-280-7,CBR-001-634-203-3,O=C(Nc1c(C)cc(nc1C)N1CCOCC1)OCc1ccccc1,"CBR-HVAC-13792:  Bipolar Disorder, Treatment of;Antipsychotic Drugs"
CBR-001-634-204-4,RFM-010-281-8,CBR-001-634-204-4,CCOC(=O)c1cc2cc3ccoc3cc2oc1=O,CBR-HVAC-05789: Antipsoriatics
CBR-001-634-205-5,RFM-010-282-9,CBR-001-634-205-5,O=C(c1ccc(cc1)N1CCC(C1)N(S(=O)(=O)Cc1ccccc1)C)N1C[C@@H]2CC[C@H](C1)CC2,CBR-HVAC-13982: 1-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
CBR-001-634-206-6,RFM-010-283-0,CBR-001-634-206-6,Fc1ccc(cc1)c1cc(ccc1C(N)C)C(=O)Nc1ccncc1,CBR-HVAC-13789: Rho Kinase 1 (ROCK 1; p160-ROCK) Inhibitors;Rho Kinase 2 (ROCK 2; ROCKalpha) Inhibitors;Signal Transduction Modulators
CBR-001-634-207-7,RFM-010-284-1,CBR-001-634-207-7,CCCCNC(=O)C(Cc1cnc2c1cccc2)NC(=O)c1cnc(s1)N1CCNCC1,CBR-HVAC-13947:  Drugs Acting on alpha-Synuclein (ASYN; NACP)
CBR-001-634-208-8,RFM-010-285-2,CBR-001-634-208-8,CN1CCN(CC1)Cc1cccc2c1ccn2S(=O)(=O)c1ccccc1Br,CBR-HVAC-13930: Signal Transduction Modulators;5-HT6 Antagonists
CBR-001-634-209-9,RFM-010-286-3,CBR-001-634-209-9,OC(=O)COc1ccc(cc1c1ccc(c(c1)Cl)C(=O)N1CCCC1(C)C)F,CBR-HVAC-13878: Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists;Signal Transduction Modulators
CBR-001-634-210-2,RFM-010-287-4,CBR-001-634-210-2,COc1cc(ccc1Cl)N1CCN(CC1)C(=O)Cn1nc(c2c1nccc2)c1nccn1,CBR-HVAC-13941: Chemokine CCR1 Antagonists;Signal Transduction Modulators
CBR-001-634-211-3,RFM-010-288-5,CBR-001-634-211-3,OC1CCN(CC1F)S(=O)(=O)c1cc(ccc1F)C(=O)Nc1cc(F)c(c(c1)F)F,CBR-HVAC-13937: Anti-Hepatitis B Virus Drugs
CBR-001-634-212-4,RFM-010-289-6,CBR-001-634-212-4,O=C(c1n(C)ncc1C(=O)NCC(O)(C)C)Nc1ccn2c(n1)nc(c2)c1ccccc1,CBR-HVAC-13913: Phosphodiesterase PDE10A Inhibitors;Signal Transduction Modulators
CBR-001-634-213-5,RFM-010-290-9,CBR-001-634-213-5,COc1nn(c2cccc(c2)NC(=O)C)c(=O)n(c1=O)Cc1ccc(c(c1)F)Cl,CBR-HVAC-13899: A since-corrected proposed structure for ADX-71441
CBR-001-634-214-6,RFM-010-291-0,CBR-001-634-214-6,Fc1cccc(c1)c1c(nc2n(c1=O)c(C)cs2)[C@@H](Nc1ncnc2c1ncn2)C,CBR-HVAC-13903: Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors;Signal Transduction Modulators
CBR-001-634-215-7,RFM-010-292-1,CBR-001-634-215-7,O=C1NC(=O)C(N1c1cc(C)c(c(c1)C)CCS(=O)(=O)N1CCC2(CC1)N=C(NC2=O)c1ccc(cc1)OC(F)(F)F)(C)C,CBR-HVAC-14077: Parathyroid Hormone Receptor 1 (PTHR1) Agonists;Signal Transduction Modulators
CBR-001-634-216-8,RFM-010-293-2,CBR-001-634-216-8,NC(=O)C1CCN(CC1)c1ncccc1NC(=O)c1coc(n1)N1CCOCC1,"CBR-HVAC-13873: Osteoarthritis, Treatment of;Analgesic Drugs"
CBR-001-634-217-9,RFM-010-294-3,CBR-001-634-217-9,Fc1cnc2n(c1)nc(c2C(=O)Nc1cncc(c1c1cncn1C)F)N,CBR-HVAC-13827: ATR Kinase Inhibitors;Signal Transduction Modulators
CBR-001-634-218-0,RFM-010-295-4,CBR-001-634-218-0,CCOC(=O)COc1cccc(c1)[C@@H]1CCC[C@H](C1)NCC(c1cccc(c1)Cl)O,CBR-HVAC-12118: beta3-Adrenoceptor Agonists;Signal Transduction Modulators
CBR-001-634-219-1,RFM-010-296-5,CBR-001-634-219-1,CCOc1ccc(cc1)CC1NC(=O)CCSSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)C(CC)C)CCC(=O)N)CC(=O)N)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)N)CC(C)C,CBR-HVAC-12177: Vasopressin antagonist
CBR-001-634-220-4,RFM-010-297-6,CBR-001-634-220-4,O=C(N[C@H](C(=O)O)CC(=O)NCC(=O)O)CC[C@@H](C(=O)O)NC(=O)[C@@H](N)C,CBR-HVAC-05680: Apoptosis Inhibitors
CBR-001-634-221-5,RFM-010-298-7,CBR-001-634-221-5,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2NCc1ccccc1)COP(=O)(O)O,CBR-HVAC-05842: Oncolytic Drugs
CBR-001-634-222-6,RFM-010-299-8,CBR-001-634-222-6,CC[C@]1(c2cccc(c2)NS(=O)(=O)C)[C@H]2[C@@H]1CN(C2)CC1(O)Cc2c(C1)cccc2,CBR-HVAC-11743: Urologic Drugs;Treatment of Alcohol Dependency;Antiobesity Drugs
CBR-001-634-223-7,RFM-010-300-4,CBR-001-634-223-7,CO[C@@H]([C@H](Cc1ccccc1)NC(=O)OC(C)(C)C)CN(S(=O)(=O)c1ccc2c(c1)cco2)CC(C)C,CBR-HVAC-14031: Cytochrome P450 CYP3A4 Inhibitors
CBR-001-634-224-8,RFM-010-301-5,CBR-001-634-224-8,COc1ccc(cc1OC1CCCC1)Cn1c(C)nc2c1nc(Cl)nc2C,CBR-HVAC-13853: Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators
CBR-001-634-225-9,RFM-010-302-6,CBR-001-634-225-9,COc1ccc(cc1OC1CC2CC1CC2)NC1=C(C)C(=O)CC1,CBR-HVAC-13781: Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators
CBR-001-634-226-0,RFM-010-303-7,CBR-001-634-226-0,Clc1cc2NCNS(=O)(=O)c2cc1S(=O)(=O)N.CCOc1nc2c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)c(ccc2)C(=O)OCOC(=O)OC1CCCCC1,"CBR-HVAC-13297: Angiotensin II receptor type 1 Antagonist; Antihypertensive; Vasoprotectant; Hypertension
"
CBR-001-634-528-1,RFM-010-304-8,CBR-001-634-528-1,COC(=O)NC(C(=O)N1CCCC1c1ncc(n1)c1cc(F)c2c(c1)OC(n1c2cc2c1ccc(c2)c1cnc(n1)C1CCCN1C(=O)C(C(C)C)NC(=O)OC)c1cnc(s1)C1CC1)C(C)C,CBR-HVAC-14115: Anti-Hepatitis C Virus Drugs
CBR-001-634-529-2,RFM-010-305-9,CBR-001-634-529-2,O=C(NS(=O)(=O)c1ccc(cc1)CCNC(=O)c1cccc2c1OCC2)NC1CCCCC1,"CBR-HVAC-07689: ATP-binding cassette, subfamily C (CFTR/MRP), member 8; potassium inwardly-rectifying channel, subfamily J, member 11"
CBR-001-634-530-5,RFM-010-306-0,CBR-001-634-530-5,N[C@H](c1ccccc1)C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)OCOC(=O)C(C)(C)C)C,CBR-HVAC-07602: Cell wall synthesis inhibitor
CBR-001-634-531-6,RFM-010-307-1,CBR-001-634-531-6,CCC[C@]1(O)CC[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CCC12C,CBR-HVAC-13612: Androgen receptor antagonist; Progesterone receptor agonist
CBR-001-634-532-7,RFM-010-308-2,CBR-001-634-532-7,O=C1CC(=O)O[Pt]2(O1)[NH2+]C[C@@H]1[C@@H](C[NH2+]2)OC2(O1)CCCC2,CBR-HVAC-10766: Antitumor; Antitumor
CBR-001-634-533-8,RFM-010-309-3,CBR-001-634-533-8,COc1cc(Cc2cnc(nc2N)N)cc(c1SC)OC,CBR-HVAC-01134: Dihydrofolate reductase Inhibitor; Dihydrofolate reductase inhibitor; Antibacterial; Antibiotic
CBR-001-634-534-9,RFM-010-310-6,CBR-001-634-534-9,CC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CC[C@@H](C2)O,CBR-HVAC-09950: Anabolic steroid
CBR-001-634-535-0,RFM-010-311-7,CBR-001-634-535-0,CCCC1(CCN(C1)C)c1cccc(c1)O,CBR-HVAC-09898: Opioid receptor mu Agonist; Analgesic; Anti-inflammatory
CBR-001-634-536-1,RFM-010-312-8,CBR-001-634-536-1,O=C(c1ccc(c(c1)S(=O)(=O)N)Cl)NN1C[C@@H]2[C@H](C1)[C@@H]1C[C@H]2CC1,CBR-HVAC-02041: Carbonic anhydrase inhibitor; Antihypertensive; Diuretic
CBR-001-634-537-2,RFM-010-313-9,CBR-001-634-537-2,Cc1sc(c(n1)c1ccc(cc1)OCCCCCOc1ccc(cc1)C(=N)N)C(C)C,CBR-HVAC-13525: Leukotriene B4 receptor Antagonist; Anti-osteoporotic
CBR-001-634-538-3,RFM-010-314-0,CBR-001-634-538-3,CC(CN(CC(C)C)CCCC(c1ccccc1)(c1ccccc1)O)C,CBR-HVAC-13446: Sodium channel Blocker; Class I antiarrhythmic
CBR-001-634-539-4,RFM-010-315-1,CBR-001-634-539-4,CCC(OCC(N1CCCC1)CN(c1ccc2c(c1)OCO2)Cc1ccccc1)C,analog of CBR-HVAC-03766:
CBR-001-634-540-7,RFM-010-316-2,CBR-001-634-540-7,CCOC(=O)[C@H]1[C@H](C[C@H]2N([C@@H]1CC2)C)OC(=O)c1ccccc1,CBR-HVAC-13151: HERG POTASSIUM CHANNEL; SODIUM CHANNEL NAV1.5 Antagonist; Sodium channel antagonist
CBR-001-634-541-8,RFM-010-317-3,CBR-001-634-541-8,CCOC(=O)[C@H]1[C@H](C[C@H]2N([C@@H]1CC2)C)OC(=O)c1ccccc1,CBR-HVAC-13151: HERG POTASSIUM CHANNEL; SODIUM CHANNEL NAV1.5 Antagonist; Sodium channel antagonist
CBR-001-634-542-9,RFM-010-318-4,CBR-001-634-542-9,CN1CCN(CC1)C[C@@H]1C(=O)Nc2c(S[C@@H]1c1ccccc1)cccc2,CBR-HVAC-07569: Gastrin inhibitor
CBR-001-634-543-0,RFM-010-319-5,CBR-001-634-543-0,CN1CCN(CC1)C[C@@H]1C(=O)Nc2c(S[C@@H]1c1ccccc1)cccc2,CBR-HVAC-07569: Gastrin inhibitor
CBR-001-634-544-1,RFM-010-320-8,CBR-001-634-544-1,CCC(=O)OC[C@H](c1ccccc1)C(=O)O[C@@H]1C[C@@H]2[C@@H]3[C@H]([C@H](C1)N2C)O3,CBR-HVAC-13481: Anxiolytic
CBR-001-634-545-2,RFM-010-321-9,CBR-001-634-545-2,CCC(=O)O[C@H]1CCC2(C(=C1)CC[C@@H]1[C@@H]2CCC2([C@H]1CC[C@@H]2OC(=O)CC)C)C,CBR-HVAC-13161: Anabolic steroid
CBR-001-634-546-3,RFM-010-322-0,CBR-001-634-546-3,CCCc1c(OCCCSc2ccc(c(c2CCC)O)C(=O)C)ccc(c1OCCCC(=O)O)C(=O)C,"CBR-HVAC-00064: 5-Lipoxygenase Inhibitors; Leucotriene C4 antagonist; Leucotriene D4 antagonist; Leucotriene receptor antagonist; Leukotriene CysLT1 (LTD4) Antagonists; Leukotriene CysLT2  (LTC4) Antagonists; Leukotriene D4 receptor; Phosphodiesterase 3 inhibitor; Phosphodiesterase 4 inhibitor; Phosphodiesterase PDE3 Inhibitors; Phosphodiesterase PDE4 Inhibitors; Prostanoid TP Antagonists; Signal Transduction Modulators; Thromboxane A2 receptor Antagonist; Antiallergy/Antiasthmatic Drugs; Antiinflammatory; Interstitial Lung Diseases, Treatment of; Liver and Biliary Tract Disorders, Treatment of; Urologic Drugs"
CBR-001-634-547-4,RFM-010-323-1,CBR-001-634-547-4,Clc1ccc(cc1)S(=O)(=O)NCCCCN(S(=O)(=O)c1ccccc1C(=O)O)Cc1cccc(c1)OCc1scc(n1)C(C)C,CBR-HVAC-00434: Leucotriene D4 antagonist; Leucotriene receptor antagonist; Leukotriene CysLT1 (LTD4) Antagonists; Leukotriene CysLT1 receptor; Prostanoid TP Antagonists; Signal Transduction Modulators; TP receptor antagonist; Thromboxane A2 receptor Antagonist; Thromboxane A2 receptor antagonist; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Asthma Therapy; Drugs for Allergic Rhinitis
CBR-001-634-548-5,RFM-010-324-2,CBR-001-634-548-5,COc1ccc(cc1OC1CCCC1)C(N1C(=O)c2c(C1=O)cccc2)CC(=O)N,CBR-HVAC-00475: Angiogenesis inhibitor; Phosphodiesterase 4; Phosphodiesterase 4 inhibitor; TNF alpha Inhibitor; Tumour necrosis factor alpha antagonist; Anti-inflammatory; Immunosuppressant
CBR-001-634-549-6,RFM-010-325-3,CBR-001-634-549-6,OCC(Nc1nc(c2ccc(cc2C)F)c2c(n1)n(c(=O)cc2)c1c(F)cccc1F)CO,"CBR-HVAC-00563: MAPK p38 Inhibitors; P38 kinase inhibitor; Signal Transduction Modulators; p38 mitogen-activated protein kinase Inhibitor; Acute Respiratory Distress Syndrome (ARDS), Agents for; Analgesic; Anti-inflammatory; Atherosclerosis Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Neuropathic Pain, Treatment of; Rheumatoid Arthritis, Treatment of; Treatment of Disorders of the Coronary Arteries and Atherosclerosis"
CBR-001-634-550-9,RFM-010-326-4,CBR-001-634-550-9,OC(COc1cccc2c1SCCC2)CNC(C)(C)C,"CBR-HVAC-02120: 5 Hydroxytryptamine 1A receptor antagonist; Beta adrenergic receptor Antagonist; Beta adrenoreceptor antagonist; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Antihypertensive; Hypertension, Treatment of; Vasodilator"
CBR-001-634-551-0,RFM-010-327-5,CBR-001-634-551-0,NCC(=O)NCC(=O)N(c1ccc(cc1C(=O)c1ccccc1Cl)Cl)C,CBR-HVAC-02510: Benzodiazepine receptor agonist; MAO Inhibitors; Antidepressants; Anxiolytic
CBR-001-634-552-1,RFM-010-328-6,CBR-001-634-552-1,O=C1CC(C(=O)N1c1ccc(cc1Cl)S(=O)(=O)N)c1ccccc1,CBR-HVAC-02533: Anticonvulsant; Antiepileptic Drugs
CBR-001-634-553-2,RFM-010-329-7,CBR-001-634-553-2,O=C(Cn1cncc1)OCc1ccc(cc1)c1ccccc1Cl,"CBR-HVAC-03543: Lipoprotein Disorders, Treatment of"
CBR-001-634-554-3,RFM-010-330-0,CBR-001-634-554-3,CC/C(=C(\c1ccc(cc1)I)/c1ccc(cc1)OCCN1CCCC1)/c1ccccc1,CBR-HVAC-03759: Estrogen receptor Modulator; Estrogen receptor antagonist; Selective Estrogen Receptor Modulators (SERM); Selective estrogen receptor modulator; Signal Transduction Modulators; Anticancer; Breast Cancer Therapy; Treatment of Postmenopausal Syndrome
CBR-001-634-555-4,RFM-010-331-1,CBR-001-634-555-4,O=C(c1cc(Cl)c(cc1OCC1CC1)N)NC1CN2CCC1CC2,"CBR-HVAC-03849: 5 Hydroxytryptamine 3 receptor antagonist; 5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; Antiemetic; Anxiolytic; Nausea and Vomiting, Treatment of; Stimulant"
CBR-001-634-556-5,RFM-010-332-2,CBR-001-634-556-5,CCN1C(=S)N(C(=O)C1(C)C)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)O,CBR-HVAC-04107: 5 Lipoxygenase inhibitor; Lipoxygenase Inhibitors; Antipsoriatics
CBR-001-634-557-6,RFM-010-333-3,CBR-001-634-557-6,CCCCc1nc2ccc(cc2c(=O)n1Cc1ccc(cc1)c1ccccc1c1nnnn1)C(OC)(C)C,"CBR-HVAC-04567: Angiotensin AT1 Antagonists; Angiotensin II receptor type 1 Blocker; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-634-558-7,RFM-010-334-4,CBR-001-634-558-7,Fc1ccc(cc1)C(=O)N[C@H]1c2cc(ccc2OC([C@@H]1O)(C)C)C(=O)C,CBR-HVAC-04799: ATP-sensitive potassium channel agonist; Gap junction modulators; Analgesic; Anticonvulsant; Antiepileptic; Antiepileptic Drugs; Antimigraine Drugs
CBR-001-634-559-8,RFM-010-335-5,CBR-001-634-559-8,COc1cc2CN(CCc3ccc(cc3)NC(=O)c3cccc(c3)/C=c/3\nc(=O)/c(=C/c4ccccc4)/n(c3=O)C)CCc2cc1OC,CBR-HVAC-04804: P-Glycoprotein Inhibitor; Anticancer; Cancer Multidrug Resistance Modulators
CBR-001-634-560-1,RFM-010-336-6,CBR-001-634-560-1,C[C@H](Cc1cnc2c1cccc2OCC(=O)O)NC[C@@H](c1cccc(c1)Cl)O,"CBR-HVAC-04943: Beta 3 adrenoreceptor agonist; Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Antihyperlipidemic; Antiobesity Drugs; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-634-561-2,RFM-010-337-7,CBR-001-634-561-2,[O-][N+](=O)c1cc(CNCP(=O)(O)O)c2c(c1)nc(=O)c(=O)n2,CBR-HVAC-05326: AMPA Receptor Antagonists; AMPA receptor antagonist; Ionotropic glutamate receptor AMPA Antagonist; Signal Transduction Modulators; Analgesic; Anticonvulsant; Antiepileptic Drugs; Psychomodulator
CBR-001-634-562-3,RFM-010-338-8,CBR-001-634-562-3,OC[C@H]1O[C@@H](Oc2ccc3c(c2)CC[C@@H]2[C@@H]3CCC3([C@H]2CC[C@@H]3O)C)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-05369: Hormone Replacement Therapy
CBR-001-634-563-4,RFM-010-339-9,CBR-001-634-563-4,COCN1C(=O)CN=C(c2c1ccc(c2)[N+](=O)[O-])c1ccccc1,CBR-HVAC-05578: GABA(A) BZ Site Receptor Agonists; Signal Transduction Modulators; Antiepileptic Drugs; Anxiolytic
CBR-001-634-564-5,RFM-010-340-2,CBR-001-634-564-5,O=C(C(CNC(=O)c1ccccc1)C)OCC(=O)C12OC(O[C@@H]1C[C@@H]1C2(C)C[C@H](O)[C@]2([C@H]1CCC1=CC(=O)C=CC21C)F)c1ccc(cc1)N(C)C,"CBR-HVAC-05824: Arachidonic acid inhibitor; Corticosteroid agonist; Immunosuppressant; Inflammation, Treatment of"
CBR-001-634-565-6,RFM-010-341-3,CBR-001-634-565-6,O=C1OCC2=C1CCC1([C@@]2(O)C[C@H]2[C@@]3([C@@]41O[C@H]4[C@@H]1OC1([C@H]3O)C(C)C)O2)C,"CBR-HVAC-06317: NOS2 Expression Inhibitors; Antiarthritic Drugs; Immunosuppressants; Rheumatoid Arthritis, Treatment of"
CBR-001-634-566-7,RFM-010-342-4,CBR-001-634-566-7,C#CCOc1ccc(cc1OC)/C=C/C(=O)Nc1ccccc1C(=O)O,"CBR-HVAC-06650: Diabetic Myocardiopathy, Agents for; Diabetic Nephropathy, Agents for; Fibrosis, Treatment of; Treatment of Renal Diseases; Uricosurics"
CBR-001-634-567-8,RFM-010-343-5,CBR-001-634-567-8,OCC(=O)OC[C@@H]1C=C[C@@H](C1)n1cnc2c1nc(N)nc2NC1CC1,CBR-HVAC-06757: Antipsoriatics
CBR-001-634-568-9,RFM-010-344-6,CBR-001-634-568-9,CC(NCCn1c2ccc(cc2c2c1ccc(c2)C(=O)C)C(=O)C)C,CBR-HVAC-07017: Cellular Tumor Antigen p53 (TP53) Activators; NF-kappaB (NFKB) Activation Inhibitors; Signal Transduction Modulators; Lymphoma Therapy; Solid Tumors Therapy
CBR-001-634-569-0,RFM-010-345-7,CBR-001-634-569-0,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)NCCNC(=O)c1ccccc1O,"CBR-HVAC-07184: NF-kappaB (NFKB) Activation Inhibitors; Omega 3 fatty acid stimulant; Signal Transduction Modulators; Transcription factor NF-kappaB inhibitor; Inflammatory Bowel Disease, Agents for; Muscular Dystrophy, Agents for; Type 2 Diabetes, Agents for"
CBR-001-634-570-3,RFM-010-346-8,CBR-001-634-570-3,CNC(=O)c1c(oc2c1cc(C1CC1)c(c2)N(S(=O)(=O)C)c1cc(Cl)c2c(c1)COB2O)c1ccc(cc1)F,CBR-HVAC-07285: RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-634-571-4,RFM-010-347-9,CBR-001-634-571-4,CCOC(=O)c1ccc(cc1)[C@@H]1CC[C@H](CC1)NC[C@@H](COc1ccc(c(c1)NS(=O)(=O)C)O)O,"CBR-HVAC-09338: Adrenergic, beta-3-, receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Beta 3 adrenoceptor agonist; Treatment of Preterm Labor"
CBR-001-634-572-5,RFM-010-348-0,CBR-001-634-572-5,CCOC(=O)/C=C/1\CC(C)(CC)CC(=O)N1Cc1ccc(cc1)c1ccccc1c1nnnn1,"CBR-HVAC-10555: Angiotensin AT1 Antagonists; Angiotensin II antagonist; Angiotensin II receptor type 1 Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-634-573-6,RFM-010-349-1,CBR-001-634-573-6,CN1C2CCC1CN(C2)c1cc2n(cc(c(=O)c2cc1F)C(=O)O)C1CC1,CBR-HVAC-10902: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-634-574-7,RFM-010-350-4,CBR-001-634-574-7,COc1ccc(cc1)Cc1cccc(c1)c1c(=O)nc2c(c1O)ccc(c2)Cl,"CBR-HVAC-10980: Ionotropic glutamate receptor NMDA Antagonist; NMDA Glycine B Receptor Antagonists; Signal Transduction Modulators; Anticonvulsant; Antiepileptic Drugs; Antipsychotic; Nausea and Vomiting, Treatment of; Neuroprotectant; Stroke, Treatment of"
CBR-001-634-575-8,RFM-010-351-5,CBR-001-634-575-8,OC(=O)CCc1ccc(cc1)CCN1CCCN(CCC1)c1nc2c(n1Cc1ccc(cc1)F)cccc2,CBR-HVAC-11130: Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist; Signal Transduction Modulators; Antiasthmatic
CBR-001-634-576-9,RFM-010-352-6,CBR-001-634-576-9,CC(Cn1cnc2c1c1ncccc1nc2N)C,CBR-HVAC-12619: Anticancer; Antiviral; Immunomodulator; Immunostimulant; Anticancer; Antiviral; Immunomodulator; Immunostimulants
CBR-001-634-577-0,RFM-010-353-7,CBR-001-634-577-0,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnnn1)C(=O)OCOC(=O)OC(C)C)Cl,"CBR-HVAC-12789: Angiotensin AT1 Antagonists; Signal Transduction Modulators; Hypertension, Treatment of"
CBR-001-634-578-1,RFM-010-354-8,CBR-001-634-578-1,OC1CCN(CC1)c1ccc(nn1)c1ccccc1Cl,CBR-HVAC-12791: Anticonvulsant; Sodium channel antagonist; Anticonvulsant; Antiepileptic; Antiepileptic Drugs; Sedative/Hypnotics
CBR-001-634-579-2,RFM-010-355-9,CBR-001-634-579-2,CCC(n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OC[C@@H]1CO[C@@](C1)(Cn1cncn1)c1ccc(cc1F)F)CC,CBR-HVAC-13261: Antifungal; ANTIFUNGAL; Antifungal Agents
CBR-001-634-580-5,RFM-010-356-0,CBR-001-634-580-5,CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnnn1)C(=O)O)CC,"CBR-HVAC-13308: Angiotensin II receptor Antagonist; Angiotensin Receptor Antagonists; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-634-581-6,RFM-010-357-1,CBR-001-634-581-6,OCCNCCCn1c2c3cc4OCOc4cc3C(=O)c2c2c(c1=O)cc(c(c2)OC)OC,CBR-HVAC-13345: DNA Topoisomerase I Inhibitors; DNA topoisomerase I Inhibitor; DNA-Intercalating Drugs; Anticancer; Oncolytic Drugs
CBR-001-634-582-7,RFM-010-358-2,CBR-001-634-582-7,Fc1ccc(cc1)c1noc(n1)C(c1ccncc1)(O)C,CBR-HVAC-13743
CBR-001-634-583-8,RFM-010-359-3,CBR-001-634-583-8,NCCc1ccccc1Sc1cnc2c1ccc(c2)F,"CBR-HVAC-13744: Antidepressants; Anxiolytics; Bipolar Disorder, Treatment of"
CBR-001-634-584-9,RFM-010-360-6,CBR-001-634-584-9,O=C(OCc1ccccc1)NCCC(=O)NCCS(=O)(=O)[O-],CBR-HVAC-13784: Immunostimulants
CBR-001-634-585-0,RFM-010-361-7,CBR-001-634-585-0,C[C@@H]1CN(CCN1C(=O)[C@H]1C[C@@H]1c1ccc(cc1)C(=O)N)C1CCC1,"CBR-HVAC-13793: Histamine H3 Receptor Antagonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Cognition Disorders, Treatment of; Diabetic Neuropathy, Agents for; Extrapyramidal Disorders, Treatment of"
CBR-001-634-586-1,RFM-010-362-8,CBR-001-634-586-1,FC(c1nnc2n1nc(cc2)c1ccncc1)(c1ccc2c(c1)cccn2)F,CBR-HVAC-13835: Unidentified Activity
CBR-001-634-587-2,RFM-010-363-9,CBR-001-634-587-2,CCN1CCC(CC1)CC(c1ccc(cc1)F)NC(=O)c1ccc(cc1)[N+](=O)[O-],CBR-HVAC-13870: Potassium Channel Blockers; Antiarrhythmic Drugs
CBR-001-634-588-3,RFM-010-364-0,CBR-001-634-588-3,CO[C@H](C(=O)O)Cc1ccc(cc1)NCCCc1ccc(cc1)OS(=O)(=O)C,"CBR-HVAC-13883: HDL-Cholesterol Increasing Agents; PPARalpha Agonists; PPARgamma Agonists; Signal Transduction Modulators; Atherosclerosis Therapy; Lipoprotein Disorders, Treatment of"
CBR-001-634-589-4,RFM-010-365-1,CBR-001-634-589-4,CC(Cc1ccc(cc1)C(C(=O)Oc1cccc(c1)C1(O)CCCCC1CN(C)C)C)C,CBR-HVAC-13918: 5-HT Reuptake Inhibitors; Norepinephrine Reuptake Inhibitors; Signal Transduction Modulators; mu-Opioid Agonists; Analgesic Drugs
CBR-001-634-590-7,RFM-010-366-2,CBR-001-634-590-7,COc1cc(ccc1n1cnc(c1)C)Nc1ncc2c(n1)N1CCCCCC1C(=O)N2CC,"CBR-HVAC-13928: Phosphodiesterase PDE9A Inhibitors; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Antipsychotic Drugs"
CBR-001-634-591-8,RFM-010-367-3,CBR-001-634-591-8,O=C1Nc2cc(C)cnc2N(C1)C(=O)NC(C(O)(C)C)c1ccc(c(c1)F)OC(F)(F)F,CBR-HVAC-13950: Phosphodiesterase PDE2A Inhibitors; Signal Transduction Modulators; Antipsychotic Drugs; Neurologic Drugs (Miscellaneous)
CBR-001-634-592-9,RFM-010-368-4,CBR-001-634-592-9,Oc1ccc(cc1)CC1C(=O)N(Cc2ccc3c(c2)cccc3)CC2N1C(=O)CCN2C(=O)NCc1ccccc1,CBR-HVAC-14043: Multiple Myeloma Therapy; Myeloid Leukemia Therapy
CBR-001-634-593-0,RFM-010-369-5,CBR-001-634-593-0,Clc1cccc(c1c1noc(c1COC1CCN(CC1)c1noc(n1)c1cccc(c1)C(=O)O)C1CC1)Cl,CBR-HVAC-14047: Farnesoid X Receptor (FXR) Agonists; Signal Transduction Modulators; Agents for Liver Cirrhosis; Agents for Liver Fibrosis
CBR-001-634-594-1,RFM-010-370-8,CBR-001-634-594-1,OC(=O)CCCOc1ccccc1NC(=O)c1ccc(c(c1C)C)OC(c1ccc(cc1)CC(C)C)C,CBR-HVAC-04219: 5 Alpha reductase inhibitor; Steroid 5-alpha-reductase Inhibitor; Steroid 5alpha-Reductase Inhibitors; 5-alpha reductase inhibitor; Benign Prostatic Hyperplasia Therapy
CBR-001-634-595-2,RFM-010-371-9,CBR-001-634-595-2,CCCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnnn1)C(=O)OC(OC(=O)OCC)C)Cl,"CBR-HVAC-04578: Angiotensin AT1 Antagonists; Angiotensin II 1 antagonist; Angiotensin converting enzyme Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-634-596-3,RFM-010-372-0,CBR-001-634-596-3,CN1OC2C(C1Cc1ccccc1)C(=O)CCC2,"CBR-HVAC-00567: Anxiolytic; Anxiolytic; Anxiolytics; Cognition Disorders, Treatment of; Generalized Anxiety Disorder (GAD), Treatment of"
CBR-001-634-597-4,RFM-010-373-1,CBR-001-634-597-4,OCCN1CCN(CC1)C1CC(c2c1cc(cc2)C(F)(F)F)c1ccc(cc1)F,CBR-HVAC-02923: 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Dopamine reuptake inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor; Antipsychotic Drugs
CBR-001-634-598-5,RFM-010-374-2,CBR-001-634-598-5,NCC(c1cc(ccc1F)NS(=O)(=O)C)O,CBR-HVAC-04201: Alpha 1 adrenoreceptor agonist; Alpha-1A adrenergic receptor Agonist; Signal Transduction Modulators; alpha1A-Adrenoceptor Agonists; Alpha-1A adrenergic receptor agonist; Urinary Incontinence Therapy
CBR-001-634-599-6,RFM-010-375-3,CBR-001-634-599-6,NCC(c1cc(ccc1F)NS(=O)(=O)C)O,CBR-HVAC-04201: Alpha 1 adrenoreceptor agonist; Alpha-1A adrenergic receptor Agonist; Signal Transduction Modulators; alpha1A-Adrenoceptor Agonists; Alpha-1A adrenergic receptor agonist; Urinary Incontinence Therapy
CBR-001-634-600-2,RFM-010-376-4,CBR-001-634-600-2,COc1c(N2CCC(C(C2)(C)C)N)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-05952: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; DNA topoisomerase Inhibitor; Antibacterial; Antibacterial Drugs; Antimicrobial
CBR-001-634-601-3,RFM-010-377-5,CBR-001-634-601-3,Cc1ccc(cc1)C1Oc2ccccc2C(=O)C1(C)O,CBR-HVAC-06833: Hair Growth Stimulants
CBR-001-634-602-4,RFM-010-378-6,CBR-001-634-602-4,OC(=O)CC[C@H](C(=O)NCC(=O)O)NC(=O)C(CC1CCCCC1)N,"CBR-HVAC-07138: Neutrophil adhesion inhibitor; Neutrophil infiltration inhibitor; Antiasthmatic; Asthma Therapy; Inflammation, Treatment of; Non-steroidal anti-inflammatory"
CBR-001-634-603-5,RFM-010-379-7,CBR-001-634-603-5,CC(CC(=O)Nc1cc(cc(c1)c1ccc(cc1C(=O)O)C(=O)N)C1Nc2ccc(cc2C(C1)(C)c1ccccc1)C(=N)N)C,CBR-HVAC-07546: Coagulation Factor XIa Inhibitors; Factor XIa inhibitor; Inhibitors of Blood Coagulation Pathways; Anticoagulants
CBR-001-634-604-6,RFM-010-380-0,CBR-001-634-604-6,CC(CC(=O)Nc1cc(cc(c1)c1ccc(cc1C(=O)O)C(=O)N)C1Nc2ccc(cc2C(C1)(C)c1ccccc1)C(=N)N)C,CBR-HVAC-07546: Coagulation Factor XIa Inhibitors; Factor XIa inhibitor; Inhibitors of Blood Coagulation Pathways; Anticoagulants
CBR-001-634-605-7,RFM-010-381-1,CBR-001-634-605-7,COc1cccc(c1)C1(O)CCCC[C@@H]1C[N+](C)(C)[O-],CBR-HVAC-11157: Opioid receptor Agonist; Analgesic; Opioid Analgesics
CBR-001-634-606-8,RFM-010-382-2,CBR-001-634-606-8,COc1cccc(c1)C1(O)CCCC[C@@H]1C[N+](C)(C)[O-],CBR-HVAC-11157: Opioid receptor Agonist; Analgesic; Opioid Analgesics
CBR-001-634-607-9,RFM-010-383-3,CBR-001-634-607-9,CCCOC1CCC(CC1)N(C(=O)Nc1ncc(s1)SCC(=O)O)C1CCCCC1,"CBR-HVAC-13948: Glucokinase Activators; Type 2 Diabetes, Agents for"
CBR-001-634-608-0,RFM-010-384-4,CBR-001-634-608-0,CCCOC1CCC(CC1)N(C(=O)Nc1ncc(s1)SCC(=O)O)C1CCCCC1,"CBR-HVAC-13948: Glucokinase Activators; Type 2 Diabetes, Agents for"
CBR-001-634-609-1,RFM-010-385-5,CBR-001-634-609-1,COC(=O)NC(C(=O)N1CCCC1c1ncc(n1)c1ccc(cc1)c1ccc(cc1OC(F)(F)F)NC(=O)c1ccc(nc1)N1CC(C)N(CC1C)C(=O)NC)C(C)C,CBR-HVAC-14105: HCV NS5A Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-634-610-4,RFM-010-386-6,CBR-001-634-610-4,CN1CCN(CC(C1)NC(=O)c1nnc2c1cccc2)Cc1cccc(c1)C,"CBR-HVAC-02696: 5 Hydroxytryptamine 3 receptor antagonist; 5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; Antiemetic; Nausea and Vomiting, Treatment of"
CBR-001-634-611-5,RFM-010-387-7,CBR-001-634-611-5,CN1CCN(CC(C1)NC(=O)c1nnc2c1cccc2)Cc1cccc(c1)C,"CBR-HVAC-02696: 5 Hydroxytryptamine 3 receptor antagonist; 5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; Antiemetic; Nausea and Vomiting, Treatment of"
CBR-001-634-612-6,RFM-010-388-8,CBR-001-634-612-6,O=C([C@H]1CCCC[C@H]1C(=O)O)O[C@H]1CCC2(C(C1(C)C)CCC1([C@@H]2C(=O)C=C2[C@@]1(C)CCC1([C@@H]2C[C@](C)(CC1)C(=O)O)C)C)C,CBR-HVAC-12724: Cyclooxygenase inhibitor; HSV replication inhibitor; ANTI-VIRAL; Antiviral Drugs
CBR-001-634-613-7,RFM-010-389-9,CBR-001-634-613-7,CCN1CCN(CC1)c1nc2CCCCCCc2c(c1)c1ccc(cc1)F,CBR-HVAC-01679: 5 Hydroxytryptamine 2 receptor antagonist; 5-Hydroxytryptamine 2A receptor; Dopamine D2 receptor antagonist; Dopamine receptor D2 Antagonist; Antipsychotic; Antipsychotic Drugs
CBR-001-634-614-8,RFM-010-390-2,CBR-001-634-614-8,COc1ccc(c(c1)C(=O)Nc1ccc(cn1)Cl)NC(=O)c1ccc(cc1)C(=N)N(C)C,CBR-HVAC-00873: Coagulation Factor Xa Inhibitors; FACTOR XA Inhibitor; Factor Xa inhibitor; Inhibitors of Blood Coagulation Pathways; Serine protease inhibitor; Anticoagulants; Coagulation factor Xa inhibitor; Coagulation inhibitor
CBR-001-634-615-9,RFM-010-391-3,CBR-001-634-615-9,CCCCCCCCCCCCCCCC[N+](CC)(C)C,CBR-HVAC-13513: Antiseptic; Disinfectant; Surfactant; Antiseptic; Disinfectant; Surfactant
CBR-001-634-616-0,RFM-010-392-4,CBR-001-634-616-0,BrCCC(=O)N1CC[N+]2(CC1)CC[N+]1(CC2)CCN(CC1)C(=O)CCBr,CBR-HVAC-12942: Leukemia Therapy; Oncolytic Drugs
CBR-001-634-617-1,RFM-010-393-5,CBR-001-634-617-1,OC(=O)CCCc1cc(F)ccc1[C@H](N(S(=O)(=O)c1ccc(cc1)Cl)c1cc(F)ccc1F)C,"CBR-HVAC-00202: Antiamyloidogenic Agents; Gamma secretase Inhibitor; Secretase gamma inhibitor; gamma-Secretase Inhibitors; Alzheimer's Dementia, Treatment of ; Amyloid protein deposition inhibitor; Beta amyloid antagonist; Gamma-secretase inhibitor"
CBR-001-634-618-2,RFM-010-394-6,CBR-001-634-618-2,CCOc1cc(ccc1OCC)C=C1NCCc2c1cc(OCC)c(c2)OCC,CBR-HVAC-05250: Antispastic Drugs; Phosphodiesterase PDE4 Inhibitors;Signal Transduction Modulators
CBR-001-634-619-3,RFM-010-395-7,CBR-001-634-619-3,O=C(N1CCc2c1cccc2)C1CCc2c(C1)nc(n2)C,analog of CBR-HVAC-04280
CBR-001-634-620-6,RFM-010-396-8,CBR-001-634-620-6,Cc1cccc(c1)NC(=O)N[C@@H]1N=C(c2ccccc2)c2c(N(C1=O)C)cccc2,CBR-HVAC-03793: CCK B receptor antagonist; CCK2 (CCKB/Gastrin) Antagonists; Cholecystokinin B receptor Antagonist; Gastrin inhibitor; Signal Transduction Modulators; Analgesic; Anxiolytic; Anxiolytics
CBR-001-634-621-7,RFM-010-397-9,CBR-001-634-621-7,O=C(O[C@H]1CC[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CCC12C)CCC1CCCC1,"CBR-HVAC-13011: Androgen receptor Agonist; Bone Diseases, Treatment of; Breast Cancer Therapy; Disorders of Sexual Function and Reproduction, Treatment of; Hormone Replacement Therapy; Prostate Cancer Therapy; Synthetic hormone; Treatment of Hypogonadism; Treatment of Male Sexual Dysfunction"
CBR-001-634-622-8,RFM-010-398-0,CBR-001-634-622-8,NC(=O)c1cccc2c1nc([nH]2)[C@@]1(C)CCCN1,CBR-HVAC-00751: ADP ribose polymerase 1 inhibitor; ADP ribose polymerase 2 inhibitor; DNA repair enzyme inhibitor; Poly  ADP-ribose polymerase 1 Inhibitor; Poly  ADP-ribose polymerase 2; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors; Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors; Signal Transduction Modulators; Anticancer; Antineoplastic Enhancing Agents; Breast Cancer Therapy; Cervical Cancer Therapy; Colorectal Cancer Therapy; Female Reproductive System Cancer Therapy; Glioblastoma Multiforme Therapy; Head and Neck Cancer Therapy; Liver Cancer Therapy; Lymphocytic Leukemia Therapy; Lymphoma Therapy; Melanoma Therapy; Multiple Myeloma Therapy; Neurologic Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Prostate Cancer Therapy; Small Cell Lung Cancer Therapy
CBR-001-634-623-9,RFM-010-399-1,CBR-001-634-623-9,CCC(=O)O[C@H]1CC[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CCC12C,CBR-HVAC-13013: Androgen receptor Agonist; Breast Cancer Therapy; Synthetic hormone; Treatment of Hypogonadism
CBR-001-634-624-0,RFM-010-400-7,CBR-001-634-624-0,CCCCC[C@@H](CC[C@H]1[C@H](O)C[C@H]2[C@@H]1Cc1cccc(c1C2)OCC(=O)O)O,CBR-HVAC-00117: Prostaglandin IP2 receptor agonist
CBR-001-634-625-1,RFM-010-401-8,CBR-001-634-625-1,FC(c1ccc2c(c1)N(CCCN1CCN(CC1)C13CC4CC(C3)CC(C1)C4)c1c(S2)cccc1)(F)F,analog of CBR-HVAC-13547
CBR-001-634-626-2,RFM-010-402-9,CBR-001-634-626-2,CCN[C@@H]1C[C@H](N)C([C@@H]([C@H]1O[C@H]1OC[C@]([C@@H]([C@H]1O)NC)(C)O)O)O[C@H]1O[C@H](CN)CCC1N,CBR-HVAC-13415: Protein 30S ribosomal subunit inhibitor; Antibacterial
CBR-001-634-627-3,RFM-010-403-0,CBR-001-634-627-3,CCOc1cc(N)c(cc1C(=O)NC1CCN(CC1)CC1CCC=CC1)[N+](=O)[O-],CBR-HVAC-01702: 5 Hydroxytryptamine 2 receptor antagonist; 5 Hydroxytryptamine 4 receptor agonist; 5-HT2 Antagonists; 5-HT4 Agonists; 5-Hydroxytryptamine 1 receptor Agonist; 5-Hydroxytryptamine 2 receptor; 5-Hydroxytryptamine 4 receptor; Antagonist; Dopamine D2 receptor antagonist; Dopamine Receptor Antagonists; Signal Transduction Modulators; Antiulcer; Antiulcer Drugs; Prokinetic Agents
CBR-001-634-628-4,RFM-010-404-1,CBR-001-634-628-4,NCCCC[C@@H](C(=O)NC(=O)[C@H](N)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)N)C,CBR-HVAC-13482: GH secretion stimulator; Diagnostic agent
CBR-001-634-629-5,RFM-010-405-2,CBR-001-634-629-5,ClN(S(=O)(=O)c1ccc(cc1)C)Cl,CBR-HVAC-08678: Antibiotic
CBR-001-634-630-8,RFM-010-406-3,CBR-001-634-630-8,CCN(CCOC(=O)C1(CCCC1)c1ccccc1)CC,CBR-HVAC-13464: Muscarinic acetylcholine receptor M1 Antagonist; Anticholinergic; Antitussive
CBR-001-634-631-9,RFM-010-407-4,CBR-001-634-631-9,CCC1(NC(=O)N(C1=O)C)c1ccccc1,CBR-HVAC-03131: CYP Inhibitor; Anticonvulsant; Antiepileptic Drugs
CBR-001-634-632-0,RFM-010-408-5,CBR-001-634-632-0,CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C(=CC(=O)C2)C,CBR-HVAC-13185: Anabolic steroid
CBR-001-634-633-1,RFM-010-409-6,CBR-001-634-633-1,[O-]C(=O)P(=O)([O-])[O-],CBR-HVAC-02064: DNA Polymerase Inhibitors; DNA directed DNA polymerase inhibitor; DNA polymerase Inhibitor; DNA synthesis inhibitor; RNA directed DNA polymerase inhibitor; Reverse Transcriptase Inhibitors; Reverse transcriptase; Anti-Cytomegalovirus Drugs; Anti-HIV Agents; Anti-Herpes Virus Drugs; Antiviral
CBR-001-634-634-2,RFM-010-410-9,CBR-001-634-634-2,SCC(CS(=O)(=O)[O-])S,CBR-HVAC-05791: Antioxidants; Chelating Agents; Chelating agent; ANTIDOTE; Antiviral Drugs; Radioprotectants/Radiomitigators; Treatment of Poisoning
CBR-001-634-635-3,RFM-010-411-0,CBR-001-634-635-3,CCC(=O)[C@@]1(C)[C@H](C)C[C@@H]2C1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)C=CC12C,"CBR-HVAC-01357: Corticosteroid receptor Agonist; Glucocorticoid agonist; Immunosuppressant; Mineralocorticoid agonist; Anti-inflammatory; Antiinflammatory Ophthalmic Agents; Dry Eye Syndrome, Treatment for"
CBR-001-634-636-4,RFM-010-412-1,CBR-001-634-636-4,COc1ccc(cc1)Nc1nc(c(s1)C(=O)c1ccc(cc1)OC)N,analog of CBR-HVAC-13940
CBR-001-634-637-5,RFM-010-413-2,CBR-001-634-637-5,CCn1cncc1,"CBR-HVAC-13703: Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Antiallergy/Antiasthmatic Drugs"
CBR-001-634-638-6,RFM-010-414-3,CBR-001-634-638-6,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](Cc1ccc(cc1)F)CC(=O)[C@H](C(C)C)NC(=O)c1noc(c1)C,CBR-HVAC-05075: 3C-Protease Inhibitor; HRV 3C Protease Inhibitors; Protease/peptidase inhibitor; Anti-Rhinovirus Drugs; Antiviral
CBR-001-634-639-7,RFM-010-415-4,CBR-001-634-639-7,OCC1C(O)COC1n1cc(C)c(=O)[nH]c1=O,analog of CBR-HVAC-13537
CBR-001-634-640-0,RFM-010-416-5,CBR-001-634-640-0,Oc1cc(O)c2c(c1)oc(c(c2=O)O[C@@H]1O[C@H](CO[C@@H]2O[C@@H](C)[C@@H]([C@H]([C@H]2O)O)O)[C@H]([C@@H]([C@H]1O)O)O)c1ccc(c(c1)O)O,"CBR-HVAC-14500: Aldose Reductase Inhibitors; Antioxidants; Prolyl 4-Hydroxylase (Protein Disulfide-Isomerase) Inhibitors; Antidiabetic Drugs; Coagulation Disorders Therapy; Lipoprotein Disorders, Treatment of ; Oncolytic Drugs"
CBR-001-634-641-1,RFM-010-417-6,CBR-001-634-641-1,CC(=O)Nc1ccc(cc1)[C@@H](C(=O)Nc1ncc(s1)C(C)C)C,CBR-HVAC-06437: CDK2/CYCLIN A INHIBITOR; CDK2/Cyclin A Inhibitors; Signal Transduction Modulators; Anticancer; Oncolytic Drugs
CBR-001-634-642-2,RFM-010-418-7,CBR-001-634-642-2,CC/C(=C(\c1ccc(cc1)O)/c1ccc(cc1)/C=C/C(=O)O)/c1ccccc1,CBR-HVAC-13828: Treatment of Hot Flushes
CBR-001-634-643-3,RFM-010-419-8,CBR-001-634-643-3,N#CC1CC2(C)[C@H]3CCC4([C@H]([C@@H]3CC[C@]32[C@@H](C1=O)O3)CC[C@@H]4O)C,"CBR-HVAC-03064: 3-Beta hydroxysteroid dehydrogenase Inhibitor; 3-hydroxysteroid-dehydrogenase-inhibitors; 3beta-Hydroxy-delta5-steroid dehydrogenase inhibitor; Antiglucocorticoids; Estrogen Receptor (ER) beta Modulators; Estrogen receptor beta antagonist; Estrogen-receptor-antagonists; Signal Transduction Modulators; Signal-transduction-pathway-inhibitors; Aldosteronism, Treatment of; Alzheimer's Disease and Cognition Disorders; Antiadrenergic; Breast Cancer Therapy; Cancer; Cushing's Syndrome, Agents for; Endocrine Disorders; Prostate Cancer Therapy"
CBR-001-634-644-4,RFM-010-420-1,CBR-001-634-644-4,OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N)C(C)C)CC(C)C)CCC(=O)N)CC(C)C)CC(C)C)CCCNC(=N)N)CCC(=O)N)CC(C)C)CCCNC(=N)N)C)CO)CC(=O)O)CCCNC(=N)N)CC(C)C)CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)C(NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ncnc1)N)CO)CC(=O)O)Cc1ccccc1)CO)CCC(=O)O)CC(C)C,"CBR-HVAC-12972: Autism, Treatment of; Diagnostic Agents"
CBR-001-634-645-5,RFM-010-421-2,CBR-001-634-645-5,O=C(N1CCN(CC1)c1nsc2c1cccc2)CCCC(=O)N1CCCCCC1,analog of CBR-HVAC-12881
CBR-001-634-646-6,RFM-010-422-3,CBR-001-634-646-6,CCCC(=O)Nc1nnc(s1)S(=O)(=O)N,CBR-HVAC-08942: Carbonic anhydrase Inhibitor; Diuretic
CBR-001-634-647-7,RFM-010-423-4,CBR-001-634-647-7,O=C(c1ccc(cc1)Cl)NC1CN2CCC1CC2,CBR-HVAC-12387: Nicotinic acetylcholine receptor alpha7 Agonist; Antipsychotic
CBR-001-634-648-8,RFM-010-424-5,CBR-001-634-648-8,OC[C@H]1O[C@@H](O)[C@@H]([C@H]([C@@H]1O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)O)O,CBR-HVAC-13240: Desiccant; Sweetening agent; Desiccant; Sweetening agent
CBR-001-634-649-9,RFM-010-425-6,CBR-001-634-649-9,COc1ccc(cc1)OCC(CNC(C)C)O,analog of CBR-HVAC-13647
CBR-001-634-650-2,RFM-010-426-7,CBR-001-634-650-2,CO/N=C(\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)Cn1nnc(n1)C)/c1csc(n1)N,CBR-HVAC-03186: Cell wall synthesis inhibitor
CBR-001-634-651-3,RFM-010-427-8,CBR-001-634-651-3,CCC(/C=C/C[C@@H](C1=CC[C@@H]2[C@]1(C)CCC/C/2=C\C=C/1\C[C@@H](O)C[C@@H](C1=C)F)C)(CC)O,"CBR-HVAC-05004: Signal Transduction Modulators; Vitamin D Receptor (VDR) Agonists; Vitamin D agonist; Vitamin D3 receptor Agonist; Benign Prostatic Hyperplasia Therapy; Hypoglycemic; Male Infertility, Agents for; Prostate Cancer Therapy; Treatment of Osteoporosis; Urinary Incontinence Therapy; Urologic Drugs"
CBR-001-634-652-4,RFM-010-428-9,CBR-001-634-652-4,[Li+],"CBR-HVAC-13058: Antidepressants; Bipolar Disorder, Treatment of"
CBR-001-634-653-5,RFM-010-429-0,CBR-001-634-653-5,CCCn1c(=O)c(C(=O)NNC(=O)C(C)C)c(c2c1cccc2)O,analog of CBR-HVAC-13915
CBR-001-634-654-6,RFM-010-430-3,CBR-001-634-654-6,Fc1ccc2c(c1)c(=O)n(c(n2)[C@@H](Nc1ncnc2c1ncn2)C)c1ccccc1,CBR-HVAC-07414: PI3 kinase beta inhibitor; PI3 kinase delta inhibitor; Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors; Signal Transduction Modulators; Hematological Cancer Therapy; Solid Tumors Therapy
CBR-001-634-655-7,RFM-010-431-4,CBR-001-634-655-7,CCCNCC(COc1ccccc1C(=O)CCc1ccccc1)OC,CBR-HVAC-13536: Antiarrhythmic; Antiarrhythmic; Antiarrhythmic Drugs
CBR-001-634-656-8,RFM-010-432-5,CBR-001-634-656-8,CCOc1nn(cc1CCC(=O)O)Cc1ccc(cc1)OCc1csc(n1)c1ccccc1,"CBR-HVAC-05990: Insulin Sensitizers; Insulin sensitizer; PPARgamma Agonists; Peroxisome proliferator activated receptor gamma Modulator; Signal Transduction Modulators; Thiazolidinedione; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-634-657-9,RFM-010-433-6,CBR-001-634-657-9,O=C1NC(=O)NC(=O)C1c1ccc(cc1)C,analog of CBR-HVAC-13554
CBR-001-634-658-0,RFM-010-434-7,CBR-001-634-658-0,Fc1cc(ccc1Oc1ccnc2c1ccc(c2)OCC(O)(C)C)NC(=O)c1c(C)n(n(c1=O)c1ccccc1)C,CBR-HVAC-07269: AXL Kinase Inhibitors; Angiogenesis Inhibitors; HGFR (MET; c-Met) Inhibitors; Signal Transduction Modulators; VEGFR-2 (FLK-1/KDR) Inhibitors; Neurologic Cancer Therapy
CBR-001-634-659-1,RFM-010-435-8,CBR-001-634-659-1,CN(CCOC(c1ccccc1C)c1ccccc1)C,CBR-HVAC-03135: Ionotropic glutamate receptor NMDA Antagonist; Muscarinic Antagonists; Signal Transduction Modulators; Antiparkinsonian; Antiparkinsonian Drugs
CBR-001-634-660-4,RFM-010-436-9,CBR-001-634-660-4,ClCC1Nc2cc(Cl)c(cc2S(=O)(=O)N1C)S(=O)(=O)N,"CBR-HVAC-03147: The actions of methyclothiazide are similar to other thiazide diuretics.It decreases sodium and chloride reabsorption to a minor degree at the proximal tubule with their major effect upon a Na+Cl- cotransport system; Antihypertensive; Diuretic; Diuretics; Hypertension, Treatment of"
CBR-001-634-661-5,RFM-010-437-0,CBR-001-634-661-5,CC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2C1(C)C[C@H](O)[C@H]1[C@H]2C[C@@H](C2=CC(=O)C=CC12C)C,"CBR-HVAC-13123: Primarily for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the bodys immune response to diverse stimuli; Anti-inflammatory"
CBR-001-634-662-6,RFM-010-438-1,CBR-001-634-662-6,CCCCN(CCC(c1cc2c(Cl)cc(cc2c2c1ccc(c2)C(F)(F)F)Cl)O)CCCC,CBR-HVAC-02172: Acidifying agent non gastric; Calmodulin antagonist; Potassium channel hERG Antagonist; Antimalarial; Antimalarials
CBR-001-634-663-7,RFM-010-439-2,CBR-001-634-663-7,O=C1NC(=O)C(N1)(C)c1cccc2c1cccc2,analog of CBR-HVAC-13540
CBR-001-634-664-8,RFM-010-440-5,CBR-001-634-664-8,CCNC(=O)[C@@H]1CCCN1C(=O)C(NC(=O)[C@@H](NC(=O)[C@@H](Cc1ncn(c1)Cc1ccccc1)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)C(NC(=O)[C@H](Cc1cnc2c1cccc2)NC(=O)[C@H](Cc1cncn1)NC(=O)[C@@H]1CCC(=O)N1)CO)CC(C)C)CCCNC(=N)N,CBR-HVAC-03296: GnRH (LHRH) Agonists; Gonadotropin-releasing hormone Agonist; Signal Transduction Modulators; Anticancer; Prostate Cancer Therapy; Treatment of Aberrations of Pubertal Development
CBR-001-634-665-9,RFM-010-441-6,CBR-001-634-665-9,O[C@H]1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)CC2CCC2)ccc1O)O,CBR-HVAC-02366: Opioid receptor Antagonist; Opioid receptor agonist; Signal Transduction Modulators; kappa-Opioid Agonists; mu-Opioid Antagonists; Analgesic; Dermatologic Drugs; Opioid Analgesics
CBR-001-634-666-0,RFM-010-442-7,CBR-001-634-666-0,CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,"CBR-HVAC-13012: Androgen Receptor Agonists; Androgen receptor Agonist; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Breast Cancer Therapy; Pituitary Disorder Therapy; Synthetic hormone; Treatment of Hypogonadism"
CBR-001-634-667-1,RFM-010-443-8,CBR-001-634-667-1,CCN(CC(=O)Nc1c(C)cccc1C(=O)OC)CC,CBR-HVAC-10120: Sodium channel Blocker; Local anesthetic
CBR-001-634-668-2,RFM-010-444-9,CBR-001-634-668-2,OC1CCC2(C(=CCC3C2CCC2(C3CCC2O)C)C1)C,CBR-HVAC-12981: Antiinflammatory Drugs; Estrogen receptor beta Agonist; Anabolic steroid; Chemoprotective Agents; Immunostimulants; Oncolytic Drugs; Radioprotectants/Radiomitigators
CBR-001-634-669-3,RFM-010-445-0,CBR-001-634-669-3,CCC(C1CCCCC1)OC(=O)N,CBR-HVAC-08871: Anxiolytic
CBR-001-634-670-6,RFM-010-446-1,CBR-001-634-670-6,CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccc(nc1)C,"CBR-HVAC-00787: 5-HT6 Antagonists; Energy metabolism modulator; Histamine receptor antagonist; NMDA Antagonists; Signal Transduction Modulators; Allergic Skin Disorders, Treatment for; Alzheimer's Dementia, Treatment of ; Antihistamine; Drugs for Allergic Rhinitis; Huntington's Disease, Treatment of; Nootropic"
CBR-001-634-671-7,RFM-010-447-2,CBR-001-634-671-7,CN(CCOC(c1ccccc1)(c1ccccc1)C)C,CBR-HVAC-13150: Histamine-1 receptor Antagonist; Anticholinergic; Antihistamine
CBR-001-634-672-8,RFM-010-448-3,CBR-001-634-672-8,OC(c1ccc(c(c1)O)O)CNC(C)(C)C,CBR-HVAC-13458: Beta-2 adrenergic receptor Agonist; Bronchodilator
CBR-001-634-673-9,RFM-010-449-4,CBR-001-634-673-9,CN1CCCCC1COC(=O)C1(O)c2ccccc2CCc2c1cccc2,analog of CBR-HVAC-13565
CBR-001-634-674-0,RFM-010-450-7,CBR-001-634-674-0,Clc1ccc(cc1)c1coc2c(c1=O)ccc(c2)O,analog of CBR-HVAC-13745
CBR-001-634-675-1,RFM-010-451-8,CBR-001-634-675-1,C/C(=C\CC/C(=C/CC/C(=C/CC1=C(C)C(=O)c2c(C1=O)cccc2)/C)/C)/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C,CBR-HVAC-12887: Cardiovascular Diseases (Not Specified); Treatment of Osteoporosis
CBR-001-634-676-2,RFM-010-452-9,CBR-001-634-676-2,CCOC(=O)C(=O)Nc1ccc2c(c1)c(C)cc(=O)o2,analog of CBR-HVAC-13599
CBR-001-634-677-3,RFM-010-453-0,CBR-001-634-677-3,O=NN1CCCCC1c1cccnc1,CBR-HVAC-09419: Antifungal; ANTIFUNGAL
CBR-001-634-678-4,RFM-010-454-1,CBR-001-634-678-4,OC(=O)CCC(=O)OCC(=O)[C@]1(CC[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CCC12C)OC(=O)C,analog of CBR-HVAC-12830
CBR-001-634-679-5,RFM-010-455-2,CBR-001-634-679-5,OC(=O)c1cc(ccc1O)n1c2CCc3c(c2cc1c1ccccc1)cccc3,CBR-HVAC-01182: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin G/H synthase Inhibitor; Analgesic
CBR-001-634-680-8,RFM-010-456-3,CBR-001-634-680-8,OC(=O)CCCCc1ccc(cc1)I,analog of CBR-HVAC-12907
CBR-001-634-681-9,RFM-010-457-4,CBR-001-634-681-9,NCCCCNCCCNC(=O)c1csc(n1)c1csc(n1)CCNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]([C@@H]([C@H](NC(=O)C([C@H](c1ncnc1)O[C@H]1O[C@H](CO)[C@@H]([C@H]([C@H]1O[C@H]1O[C@H](CO)[C@H]([C@H]([C@@H]1O)OC(=O)N)O)O)O)NC(=O)c1nc(nc(c1C)N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C)O)C,CBR-HVAC-12936: Angiogenesis Inhibitors; Apoptosis Inducers; EGFR Expression Inhibitors; Cardiovascular Diseases (Not Specified); Cervical Cancer Therapy; Digestive/Gastrointestinal Cancer Therapy; Head and Neck Cancer Therapy; Oncolytic Drugs
CBR-001-634-682-0,RFM-010-458-5,CBR-001-634-682-0,Fc1ccc(cc1)CNC(=O)c1nc(n(c(=O)c1O)C)N1CCCCS1(=O)=O,CBR-HVAC-09188: Integrase Inhibitor; Antiviral
CBR-001-634-683-1,RFM-010-459-6,CBR-001-634-683-1,CC(=CCc1c(O)cc(c2c1OC(CC2=O)c1ccc(cc1)O)O)C,CBR-HVAC-04864: Angiogenesis inhibitor; Oncolytic Drugs; PHYTOESTROGEN; Treatment of Osteoporosis; Treatment of Postmenopausal Syndrome
CBR-001-634-684-2,RFM-010-460-9,CBR-001-634-684-2,NCCCC[C@@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CC(=O)N)Cc1ccccc1)Cc1ccccc1)Cc1cnc2c1cccc2)CCCCN)[C@H](O)C)[C@H](O)C)C(=O)O)NC(=O)CNC(=O)[C@@H](N)C,CBR-HVAC-03270: Growth Hormone Release Inhibitors; Signal Transduction Modulators; Somatostatin SRIF1A (sst2) Receptor Ligands; Somatostatin SRIF1B (sst5) Receptor Ligands; Somatostatin SRIF2A (sst1) Receptor Ligands; Somatostatin srif1C (sst3) Agonists; Somatostatin srif2B (sst4) Receptor Ligands; Antimigraine Drugs; Gastric Antisecretory Drugs; Treatment of Growth Hormone Secretion Disorders
CBR-001-634-685-3,RFM-010-461-0,CBR-001-634-685-3,COC(=O)C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])C(=O)OC(C)C)C,analog of CBR-HVAC-01801
CBR-001-634-686-4,RFM-010-462-1,CBR-001-634-686-4,CCCCn1c(=O)[nH]c(=O)c2c1ncn2CCC(C)C,analog of CBR-HVAC-03952
CBR-001-634-687-5,RFM-010-463-2,CBR-001-634-687-5,OC[C@H]1OC2([C@H]([C@@H]1O)O[C@@]1(CO2)O[C@@H]([C@H]([C@@H]1O)O)CO)CO,"CBR-HVAC-06381: Bone Diseases, Treatment of; Metabolic Disorders (Not Specified)"
CBR-001-634-688-6,RFM-010-464-3,CBR-001-634-688-6,Cl[Mn-5]1234(Cl)[NH+]5CC[NH+]1[C@H]1[C@H]([NH+]2Cc2[n+]4c(C[NH+]3[C@H]3[C@H]5CCCC3)ccc2)CCCC1,"CBR-HVAC-05268: Superoxide Dismutase (SOD) Mimetics; Superoxide dismutase Stimulator; Analgesic; Antiarthritic; Antiarthritic Drugs; Antiparkinsonian; Antipsoriatics; Atopic Dermatitis, Agents for; Chemoprotective Agents; Inflammatory Bowel Disease, Agents for; Non-Opioid Analgesics; Treatment of Mucositis"
CBR-001-634-689-7,RFM-010-465-4,CBR-001-634-689-7,[O-]C(=O)c1ccccc1c1c2cc(I)c(c(c2oc2c1cc(I)c(=O)c2I)I)[O-],CBR-HVAC-10255: Aetiological agent; Antimicrobial
CBR-001-634-690-0,RFM-010-466-5,CBR-001-634-690-0,CCCN1CCN(CC1)c1ccc(cc1)C(=O)NC1(CCCCC1)C(=O)NCC#N,CBR-HVAC-05594: Cathepsin K Inhibitor; Cathepsin K Inhibitors; Bone Resorption Inhibitors; Bone resorption inhibitor; Cathepsin K inhibitor; Treatment of Osteoporosis
CBR-001-634-691-1,RFM-010-467-6,CBR-001-634-691-1,OC(C[N+](C(C)C)(C)C)COc1cccc2c1cccc2,CBR-HVAC-13080: Antiarrhythmic; Antiarrhythmic Drugs
CBR-001-634-692-2,RFM-010-468-7,CBR-001-634-692-2,CN[C@@H](C[C@H]1CCCOC1)CNC(=O)N1CCC[C@H](C1)[C@H](c1cccc(c1)Cl)OCCNC(=O)OC,"CBR-HVAC-06628: Renin Inhibitor; Renin Inhibitors; Antihypertensive; Hypertension, Treatment of; Treatment of Renal Diseases"
CBR-001-634-693-3,RFM-010-469-8,CBR-001-634-693-3,CCC(=O)OC1C(OC(CC1N(C)C)C)OC1C(C)C(OC2OC(C)C(C(C2)(C)OC)O)C(C)C(=O)OC(CC)C(C(C(C(=O)C(CC1(C)O)C)C)O)(C)O,CBR-HVAC-12611: Protein 50S ribosomal subunit inhibitor; Mucolytics
CBR-001-634-694-4,RFM-010-470-1,CBR-001-634-694-4,COc1cc(/C=C/C(=O)Nc2cccc3c2cccc3)ccc1OC,analog of CBR-HVAC-13773
CBR-001-634-695-5,RFM-010-471-2,CBR-001-634-695-5,CC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C(=CC(=O)C2)C,CBR-HVAC-13156: Anabolic steroid
CBR-001-634-696-6,RFM-010-472-3,CBR-001-634-696-6,CO/N=C(/c1ccco1)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)OC(OC(=O)C)C)COC(=O)N,CBR-HVAC-02963: Cell wall synthesis inhibitor; Antibacterial Drugs; Antibiotics
CBR-001-634-697-7,RFM-010-473-4,CBR-001-634-697-7,CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2C1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=CC12C)F,CBR-HVAC-12343: Steroid hormone receptor Agonist; Ophthalmic Drugs; Ophthalmological agent; Steroidal anti-inflammatory
CBR-001-634-698-8,RFM-010-474-5,CBR-001-634-698-8,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)O[C@@H]1[C@@H](O[C@@H]2O[C@@H](CN)[C@@H]([C@H]([C@@H]2N)O)O)[C@H](N)C[C@@H]([C@H]1O)N,CBR-HVAC-13231: Antibiotic
CBR-001-634-699-9,RFM-010-475-6,CBR-001-634-699-9,OC(=O)CCCCCc1cccc2n1cnc2,CBR-HVAC-02994: Platelet aggregation inhibitor; Thromboxane A synthase Inhibitor; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Anti-inflammatory; Antiasthmatic; Antiplatelet Therapy
CBR-001-634-700-5,RFM-010-476-7,CBR-001-634-700-5,Clc1ccc2c(c1)c(Sc1ccccc1)c(n2)C(=O)N,CBR-HVAC-10836: Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Anti-HIV Agents; Antiviral
CBR-001-634-701-6,RFM-010-477-8,CBR-001-634-701-6,CCc1c(=O)[nH]c(=O)[nH]c1C(=O)c1cc(C)cc(c1)C,analog of CBR-HVAC-12361
CBR-001-634-702-7,RFM-010-478-9,CBR-001-634-702-7,OC(=O)CCC(=O)c1ccc2c(c1)c1ccccc1o2,"CBR-HVAC-08798: Anti-inflammatory, nonsteroidal"
CBR-001-634-703-8,RFM-010-479-0,CBR-001-634-703-8,O=C1NCNC1(c1ccccc1)c1ccccc1,CBR-HVAC-08656: Anticonvulsant
CBR-001-634-704-9,RFM-010-480-3,CBR-001-634-704-9,CCCN1CCC(CC1)c1nc2c(n1)cccc2C(=O)N,CBR-HVAC-11852: ADP ribose polymerase inhibitor; POLY (ADP-RIBOSE) POLYMERASE Inhibitor; Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors; Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors; Signal Transduction Modulators; Anticancer; Antineoplastic Enhancing Agents
CBR-001-634-705-0,RFM-010-481-4,CBR-001-634-705-0,COC(=O)c1nc2c(o1)c1ncccc1c(c2)Cl,CBR-HVAC-03062: Mast cell degranulation inhibitor; Mediator Release Inhibitors; Antiallergy/Antiasthmatic Drugs; Antiinflammatory
CBR-001-634-706-1,RFM-010-482-5,CBR-001-634-706-1,CCCN1C[C@@H](C)[C@](C[C@@H]1C)(OC(=O)C)c1ccccc1,analog of CBR-HVAC-13114
CBR-001-634-707-2,RFM-010-483-6,CBR-001-634-707-2,C1CCC(C1)Nc1ncnc2c1nc[nH]2,analog of CBR-HVAC-13507
CBR-001-634-708-3,RFM-010-484-7,CBR-001-634-708-3,Nc1ccn(c(=O)n1)[C@@H]1C=C([C@H]([C@H]1O)O)CO,CBR-HVAC-03415: Antimetabolites; CTP synthase Inhibitor; Anti-HIV Agents; Anticancer; Antiviral; Antiviral Drugs; Oncolytic Drugs
CBR-001-634-709-4,RFM-010-485-8,CBR-001-634-709-4,[K+],CBR-HVAC-13573: Antacid; Diuretic
CBR-001-634-710-7,RFM-010-486-9,CBR-001-634-710-7,CC(=O)CCCCn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-13184: Vasodilator
CBR-001-634-711-8,RFM-010-487-0,CBR-001-634-711-8,O[C@@H]1CCC2([C@H](C1)CC[C@@H]1[C@@H]2C(=O)CC2([C@H]1CC[C@@H]2C(=O)COC(=O)C)C)C,CBR-HVAC-05927: GABA(A) Receptor Agonists; Signal Transduction Modulators; Analgesic Drugs
CBR-001-634-712-9,RFM-010-488-1,CBR-001-634-712-9,CSCC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)CCSC)Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)Cc1ccc(cc1)OS(=O)(=O)O,"CBR-HVAC-02868: CCK receptor antagonist; When secreted from the gastric mucosa, it stimulates the release of both bile from the gallbladder, and the release of digestive enzymes from the pancreas.; Antiobesity Drugs; Diagnostic Agents; Diagnostic agent"
CBR-001-634-713-0,RFM-010-489-2,CBR-001-634-713-0,O[C@@H]1CCC2([C@@H](C1)[C@@H](O)C[C@@H]1[C@@H]2CCC2([C@H]1CC[C@@H]2[C@@H](CCC(=O)NCCS(=O)(=O)O)C)C)C,CBR-HVAC-12998: Agents for Gallstone Disease
CBR-001-634-714-1,RFM-010-490-5,CBR-001-634-714-1,CN(CC(CN1c2ccccc2Sc2c1cccc2)C)C,"CBR-HVAC-12952: Histamine H1 Receptor Ligands; Histamine receptor Antagonist; Signal Transduction Modulators; Antihistamine; Antipruritics; Drugs for Allergic Rhinitis; Hypnotic; Sedative; Sedative/Hypnotics; Urticaria, Treatment for"
CBR-001-634-715-2,RFM-010-491-6,CBR-001-634-715-2,CCC(NCC(COc1ccccc1C(CC)C)O)C,analog of CBR-HVAC-08943
CBR-001-634-716-3,RFM-010-492-7,CBR-001-634-716-3,S=C(C(=O)O)Cc1ccc(cc1)I,"CBR-HVAC-11352: Calpain Inhibitor; Calpain Inhibitors; Cognition Disorders, Treatment of; Neuroprotectant; Stroke, Treatment of"
CBR-001-634-717-4,RFM-010-493-8,CBR-001-634-717-4,Fc1ccccc1CNCCC1(CCOC(C1)(C)C)c1ccccc1,analog of CBR-HVAC-13841
CBR-001-634-718-5,RFM-010-494-9,CBR-001-634-718-5,O=C([C@H](C1CCCCC1)NC(=O)c1nccnc1)N[C@@H](C(C)(C)C)C(=O)O,"CBR-HVAC-13842: Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Antipsoriatics; Atopic Dermatitis, Agents for; Dermatologic Drugs"
CBR-001-634-719-6,RFM-010-495-0,CBR-001-634-719-6,O=C1COc2c(N1)ccc(c2)CN1CCN(CC1)c1ccc(cc1)Cl,CBR-HVAC-05063: Dopamine D4 Antagonists; Dopamine D4 receptor antagonist; Dopamine receptor D4 Antagonist; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs
CBR-001-634-720-9,RFM-010-496-1,CBR-001-634-720-9,COc1ccc2c(c1)c(CCN(C(C)C)C(C)C)cn2,CBR-HVAC-05840: Psychiatric Disorders (Not Specified)
CBR-001-634-721-0,RFM-010-497-2,CBR-001-634-721-0,CCCCCCCCC[C@@H](CC(=O)CCc1ccc(c(c1)OC)O)O,CBR-HVAC-13212: Anti-inflammatory; Antibacterial ; Anticancer; Anti-inflammatory; Antibacterial; Anticancer
CBR-001-634-722-1,RFM-010-498-3,CBR-001-634-722-1,O=C(C(C)(C)C)Nc1ccc(cc1)S(=O)(=O)Nc1ccccc1,analog of CBR-HVAC-13024
CBR-001-634-723-2,RFM-010-499-4,CBR-001-634-723-2,C=CCCCCCCCCC(=O)O,CBR-HVAC-05041: Anti-Herpes Labialis Drugs; Antifungal Agents
CBR-001-634-724-3,RFM-010-500-0,CBR-001-634-724-3,COc1ccccc1n1c(CN2CCN(C(C2)C)c2ccc(cc2)C)nc2c(c1=O)cccc2,analog of CBR-HVAC-12485
CBR-001-634-725-4,RFM-010-501-1,CBR-001-634-725-4,COC(=O)c1ccccc1S(=O)(=O)NO,CBR-HVAC-13725: Nitroxyl (HNO) Donors; Heart Failure Therapy
CBR-001-634-726-5,RFM-010-502-2,CBR-001-634-726-5,CCc1c(O)c(=O)ccn1CC,CBR-HVAC-08570: Chelating agent; Iron chelator; Antiparasitic; Antiparkinsonian
CBR-001-634-727-6,RFM-010-503-3,CBR-001-634-727-6,OC(=O)Cc1c(C)n(c2c1cccn2)Cc1ccc(cc1C(F)(F)F)S(=O)(=O)C,"CBR-HVAC-06350: CRTH2 antagonist; Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists; Signal Transduction Modulators; Asthma Therapy; Atopic Dermatitis, Agents for; Drugs for Allergic Rhinitis"
CBR-001-634-728-7,RFM-010-504-4,CBR-001-634-728-7,Cc1cn(C2COC(O2)CO)c(=O)[nH]c1=O,CBR-HVAC-03958: NUCLEOSIDE REVERSE TRANSCRIPTASE Inhibitor; Reverse Transcriptase Inhibitors; Anti-HIV; Anti-HIV Agents
CBR-001-634-729-8,RFM-010-505-5,CBR-001-634-729-8,O[C@@H]1C(COP(=O)(OP(=O)(OP(=O)(OP(=O)(OCC2OC([C@@H]([C@@H]2O)O)n2ccc(=O)[nH]c2=O)[O-])[O-])[O-])[O-])OC([C@@H]1O)n1ccc(=O)[nH]c1=O,"CBR-HVAC-02267: Mucin Production, Enhancers; P2Y PURINOCEPTOR 2; P2Y2 Agonists; P2Y2 RECEPTOR Agonist; Purinoreceptor P2Y2 agonist; Signal Transduction Modulators; Chronic Obstructive Bronchitis, Agents for; Corneal Wound Healing Agents; Cystic Fibrosis, Treatment of ; Dry Eye Syndrome, Treatment for; OPHTHALMIC AGENT; Ophthalmic Drugs"
CBR-001-634-730-1,RFM-010-506-6,CBR-001-634-730-1,O[C@H]1C[C@H](O)C/C(=C\C=C\2/CCCC3([C@H]2CC[C@@H]3[C@@H](/C=C/[C@@H](C(O)(C)C)C)C)C)/C1,CBR-HVAC-01421: Parathyroid Hormone Secretion Inhibitors; Signal Transduction Modulators; Vitamin D Receptor (VDR) Agonists; Vitamin D agonist; Vitamin D receptor Activator; Antihypocalcemic; Antihypoparathyroid; Cardiovascular Diseases (Not Specified); Nutritional supplement; Prostate Cancer Therapy; Solid Tumors Therapy; Treatment of Hyperparathyroidism; Treatment of Renal Diseases
CBR-001-634-731-2,RFM-010-507-7,CBR-001-634-731-2,O=C1CN2C(N1)CCC2=O,"CBR-HVAC-03918: Acetylcholine receptor Agonist; Drugs Acting on NMDA Receptors; Signal Transduction Modulators; Anti-cognitive; Cognition Disorders, Treatment of; Neuropathic Pain, Treatment of; Osteoarthritis, Treatment of"
CBR-001-634-732-3,RFM-010-508-8,CBR-001-634-732-3,Clc1ccc(c(c1)c1c[nH]nc1N)Oc1cc(F)c(cc1Cl)S(=O)(=O)Nc1cscn1,"CBR-HVAC-12602: Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers; Voltage-gated sodium channel Nav1.7 Blocker; Analgesic; Analgesic Drugs; Diabetic Neuropathy, Agents for; Neuropathic Pain, Treatment of"
CBR-001-634-733-4,RFM-010-509-9,CBR-001-634-733-4,O=C(C1CCCCC1C(=O)O)Nc1sc(c(n1)c1ccc(cc1)F)C,analog of CBR-HVAC-13834
CBR-001-634-734-5,RFM-010-510-2,CBR-001-634-734-5,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1CNC(=NC1=O)N,CBR-HVAC-02985: Antimetabolites; DNA (cytosine-5)-methyltransferase Inhibitor; DNA synthesis inhibitor; Anticancer; Oncolytic Drugs
CBR-001-634-735-6,RFM-010-511-3,CBR-001-634-735-6,CCCC12CCC(CC1)(CC2)C(=O)O,analog of CBR-HVAC-13654
CBR-001-634-736-7,RFM-010-512-4,CBR-001-634-736-7,COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+]([C@H]3Cc1ccc(Oc3c4[C@@H](C2)[N+](C)(C)CCc4cc(c3OC)OC)cc1)(C)C,CBR-HVAC-09621: Nicotinic acetylcholine receptor Inhibitor; Neuromuscular blocking agent
CBR-001-634-737-8,RFM-010-513-5,CBR-001-634-737-8,CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccncc1,analog of CBR-HVAC-12358
CBR-001-634-738-9,RFM-010-514-6,CBR-001-634-738-9,CCCOC(=O)c1ccc(cc1)N,CBR-HVAC-13142: Local anesthetic
CBR-001-634-739-0,RFM-010-515-7,CBR-001-634-739-0,C=CCN1CCCC1CNC(=O)c1cc(cc(c1OC)OC)S(=O)(=O)N,CBR-HVAC-02800: Dopamine receptor antagonist; NEUROLEPTIC; Treatment of Postmenopausal Syndrome
CBR-001-634-740-3,RFM-010-516-8,CBR-001-634-740-3,C=CCN(c1c(Cl)cccc1Cl)C1=NCCN1,"CBR-HVAC-02984: HCN [I(f)] Blockers; HCN channel antagonist; Potassium channel Antagonist; Potassium channel antagonist; Sodium channel antagonist; Angina pectoris, Treatment of; Antiarrhythmic"
CBR-001-634-741-4,RFM-010-517-9,CBR-001-634-741-4,Clc1ccc(cc1)Cn1c(C)nc2c1cccc2,CBR-HVAC-09006: Antifungal
CBR-001-634-742-5,RFM-010-518-0,CBR-001-634-742-5,CCCCCCCCCC(=O)O[C@H]1CC[C@@H]2C1(C)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,"CBR-HVAC-13009: Nandrolone decanoate has anabolic, androgenic, progestogenic and erythropoietic activity; Androgen; Antianaemic; Antineoplastic; Treatment of Osteoporosis"
CBR-001-634-743-6,RFM-010-519-1,CBR-001-634-743-6,N[C@H](C(=O)O)CCCCNCNC(=O)C1C(=O)[C@@H](N(C)C)[C@H]2[C@](C1=O)(O)C(=O)C1[C@H](C2)[C@](C)(O)c2c(C1=O)c(O)ccc2,CBR-HVAC-05641: Antibacterial Drugs;Acne Therapy;
CBR-001-634-745-8,RFM-010-520-4,CBR-001-634-745-8,CC(C(C(=O)O)NS(=O)(=O)c1ccc(cc1)C)C,analog of CBR-HVAC-12463
CBR-001-634-746-9,RFM-010-521-5,CBR-001-634-746-9,CN(C(=O)OCc1ccccc1)C,CBR-HVAC-08589: Ionotropic glutamate receptor AMPA Antagonist; Analgesic; Anticonvulsant
CBR-001-634-747-0,RFM-010-522-6,CBR-001-634-747-0,Clc1ccc(cc1)COC(c1ccc(cc1Cl)Cl)Cn1cncc1,CBR-HVAC-12848: Cell wall synthesis inhibitor; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Antifungal; Antifungal Agents
CBR-001-634-748-1,RFM-010-523-7,CBR-001-634-748-1,CCC(c1cccc(c1O)C(CC)C)C,CBR-HVAC-12390: GABA(A) Receptor Agonists; General anesthetic; Hypnotic; Sedative; Signal Transduction Modulators; General anesthetic; Hypnotic; Intravenous Anesthetics; Sedative
CBR-001-634-749-2,RFM-010-524-8,CBR-001-634-749-2,OC(CNC(C)(C)C)COc1ccccc1C(=O)CCc1ccccc1,analog of CBR-HVAC-12953
CBR-001-634-750-5,RFM-010-525-9,CBR-001-634-750-5,C[C@H]1Cc2c3cc(F)c(cc3nc2[C@@]2(N1)C(=O)Nc1c2cc(Cl)cc1)Cl,CBR-HVAC-00680: ATPase 4 inhibitor; ATPase inhibitor; P-type ATPase4 (PfATP4) (Plasmodium falciparum) Inhibitors; Protein synthesis inhibitor; Antimalarial; Antimalarials
CBR-001-634-751-6,RFM-010-526-0,CBR-001-634-751-6,CCC1Nc2cc(Cl)c(cc2S(=O)(=O)N1)S(=O)(=O)N,analog of CBR-HVAC-13512
CBR-001-634-752-7,RFM-010-527-1,CBR-001-634-752-7,O=C(c1ccc(cc1)C(=O)O)Nc1ccc2c(c1)C(C)(C)CCC2(C)C,"CBR-HVAC-02278: Microbial collagenase inhibitor; Protein synthesis inhibitor; Retinoic acid receptor agonist; Retinoic acid receptor alpha Agonist; Retinoic acid receptor beta; Retinoid RARalpha Agonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Liver Cancer Therapy; Myeloid Leukemia Therapy; Nephritis, Agents for; Neurologic Drugs (Miscellaneous); Non-Small Cell Lung Cancer Therapy; Oncolytic agent; Ophthalmic Drugs; Solid Tumors Therapy"
CBR-001-634-753-8,RFM-010-528-2,CBR-001-634-753-8,OCCNC(=O)c1nn(c2c1CCC2)c1ccccc1F,analog of CBR-HVAC-13799
CBR-001-634-754-9,RFM-010-529-3,CBR-001-634-754-9,CC(=O)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)CC[C@]12C)F,CBR-HVAC-06662: Mineralocorticoid receptor Agonist; Adrenocortical Dysfunction Therapy; Anti-inflammatory
CBR-001-634-755-0,RFM-010-530-6,CBR-001-634-755-0,OC(=O)/C=C(/C=C/[C@@H]1C[C@]1(C)c1ccc2c(c1)C(C)(C)CCC2(C)C)\C,"CBR-HVAC-05515: ABCA1 Expression Enhancers; Retinoid RXRalpha Agonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Antiparkinsonian Drugs; Breast Cancer Therapy; Multiple Sclerosis, Agents for; Non-Small Cell Lung Cancer Therapy; Prostate Cancer Therapy; Treatment of Autoimmune Diseases; Type 2 Diabetes, Agents for"
CBR-001-634-756-1,RFM-010-531-7,CBR-001-634-756-1,Clc1ccc2c(c1)c1nc([nH]c(=O)c1o2)[C@@H]1CCCN1,CBR-HVAC-06823: Apoptosis Inducers; Cell Division Cycle 7-Related Protein Kinase (CDC7) Inhibitors; Signal Transduction Modulators; Hematological Cancer Therapy; Solid Tumors Therapy
CBR-001-634-757-2,RFM-010-532-8,CBR-001-634-757-2,COc1ccc2c3c1OC1C43CCN(C(C2)C4(O)C=CC1=O)C,analog of CBR-HVAC-01203:
CBR-001-634-758-3,RFM-010-533-9,CBR-001-634-758-3,O=C(C1=C(O)c2sccc2S(=O)(=O)N1C)Nc1ccccn1,"CBR-HVAC-01773: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin G/H synthase 1 Inhibitor; Prostaglandin synthase inhibitor; Anti-inflammatory; Antiarthritic Drugs; Osteoarthritis, Treatment of; Rheumatoid Arthritis, Treatment of"
CBR-001-634-759-4,RFM-010-534-0,CBR-001-634-759-4,[O-]P(=O)(O[C@@H]1[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)([O-])[O-])[C@H]([C@@H]([C@H]1OP(=O)([O-])[O-])OP(=O)([O-])[O-])OP(=O)([O-])[O-])[O-],CBR-HVAC-04770: Angiogenesis Inhibitors; Apoptosis Inducers; Transforming growth factor beta 2 Modulator; Antiproliferative; Chemopreventive Agents; Oncolytic Drugs
CBR-001-634-760-7,RFM-010-535-1,CBR-001-634-760-7,O=C1CC[C@@]2([C@@]34[C@H]1Oc1c4c(C[C@H]2[N+](CC3)(C)CC2CC2)ccc1O)O,"CBR-HVAC-12909: Opioid mu receptor antagonist; Opioid receptor Antagonist; Signal Transduction Modulators; mu-Opioid Antagonists; Antagonists to Narcotics; Constipation, Agents for; Disorders Associated with Cancer Therapy, Treatment of; Gastroprokinetic; Laxative; Nausea and Vomiting, Treatment of"
CBR-001-634-761-8,RFM-010-536-2,CBR-001-634-761-8,CN1CCN(CC1)c1ccc2c(c1)nc(n2)c1ccc2c(c1)nc(n2)c1ccc(cc1)O,CBR-HVAC-08199: DNA inhibitor
CBR-001-634-762-9,RFM-010-537-3,CBR-001-634-762-9,CC(=O)C(=Cc1cc(O)c(c(c1)[N+](=O)[O-])O)C(=O)C,"CBR-HVAC-03824: COMT Inhibitors; Catechol O methyltransferase inhibitor; Catechol-O-methyltransferase Inhibitor; Mucus protecting agent; Reducing agent; Antioxidant; Antiparkinsonian Drugs; Antiulcer; Antiulcer Drugs; Neuropathic Pain, Treatment of"
CBR-001-634-763-0,RFM-010-538-4,CBR-001-634-763-0,CC(=CCc1c(O)cc(c2c1oc(c1ccc(cc1)C(F)(F)F)c(c2=O)O)O)C,CBR-HVAC-13879: MDM2 (hdm2) Inhibitors; Myeloid Leukemia Therapy
CBR-001-634-764-1,RFM-010-539-5,CBR-001-634-764-1,Clc1ccc(c(c1)Cl)C(=O)NS(=O)(=O)c1ccccc1,CBR-HVAC-13423: Anticancer; Anticancer; Colorectal Cancer Therapy
CBR-001-634-765-2,RFM-010-540-8,CBR-001-634-765-2,CN(CCN(C[C@@H]([C@]12CCC3([C@@H](C2=C(C(=O)C1)C(C)C)CC[C@H]1[C@@]3(C)CC[C@@H]2[C@]1(C)CC[C@@H](C2(C)C)OC(=O)CC(C(=O)O)(C)C)C)O)Cc1ccc(cc1)Cl)C,CBR-HVAC-07308: Reverse Transcriptase Inhibitors; Viral Maturation Inhibitors; Anti-HIV Agents
CBR-001-634-766-3,RFM-010-541-9,CBR-001-634-766-3,O=C1/C(=N\c2cccc(c2)C(F)(F)F)/c2c(N1c1ccccc1)cccc2,"CBR-HVAC-00319: GALANIN RECEPTOR 3 Antagonist; Galanin GAL3 Antagonists; Galectin-3 antagonist; Signal Transduction Modulators; 5-hydroxytryptamine transporter stimulator; Antidepressants; Anxiolytics; Cognition Disorders, Treatment of; Galanin receptor 3 antagonist"
CBR-001-634-767-4,RFM-010-542-0,CBR-001-634-767-4,O=Cc1ccc(nc1)C#N,CBR-HVAC-13704: Elastase Inhibitors
CBR-001-634-768-5,RFM-010-543-1,CBR-001-634-768-5,CCN(CCCN1c2ccccc2Sc2c1cc(Cl)cc2)CC,CBR-HVAC-13438: Antipsychotic
CBR-001-634-769-6,RFM-010-544-2,CBR-001-634-769-6,CNCCC(c1ccccc1)Oc1ccccc1OC,CBR-HVAC-10010: 5-Hydroxytryptamine transporter Inhibitor; Antidepressant
CBR-001-634-770-9,RFM-010-545-3,CBR-001-634-770-9,CNC(CC1CCCC1)C,CBR-HVAC-09767: Releases noradrenalin of the adrenergic nervous terminations; Sympathomimetic
CBR-001-634-771-0,RFM-010-546-4,CBR-001-634-771-0,CCCC(=O)Nc1cc(ccc1N1CCOCC1)c1nn(C)c(=O)c2c1cccc2,analog of CBR-HVAC-13861
CBR-001-634-772-1,RFM-010-547-5,CBR-001-634-772-1,N#CC1=C(N)Oc2c(C1c1cccc(c1)F)ccc(c2)O,analog of CBR-HVAC-13751
CBR-001-634-773-2,RFM-010-548-6,CBR-001-634-773-2,OCCN(c1nc2c(n1C)c(=O)n(c(=O)n2C)C)C,CBR-HVAC-09418: DECONGESTANT
CBR-001-634-774-3,RFM-010-549-7,CBR-001-634-774-3,O=C1CN=C(c2c(N1)ccc(c2)Cl)c1ccccc1F,CBR-HVAC-00924: Benzodiazepine receptor agonist
CBR-001-634-775-4,RFM-010-550-0,CBR-001-634-775-4,CN(C[C@H]1OCCn2cc(c3c2cccc3)C2=C(c3cn(CC1)c1ccccc31)C(=O)NC2=O)C,"CBR-HVAC-04727: Protein Kinase PKC beta Inhibitors; Protein kinase C beta inhibitor; Protein kinase inhibitor; Protein tyrosine kinase C beta Inhibitor; Signal Transduction Modulators; ANTI-DIABETICÃ‚Â¬CARDIOPROTECTANT; Diabetic Retinopathy, Agents for"
CBR-001-634-776-5,RFM-010-551-1,CBR-001-634-776-5,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)O)CCCNC(=N)N)CCCCN)C(C)C)CC(C)C)Cc1cnc2c1cccc2)C)[C@H](CC)C)Cc1ccccc1)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ncnc1)N)C)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CO)CO)Cc1ccc(cc1)O)CC(C)C)CCC(=O)O)CCC(=O)N)C)C,analog of CBR-HVAC-12637
CBR-001-634-777-6,RFM-010-552-2,CBR-001-634-777-6,O=CC[C@H]1C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@H](OC(=O)C[C@H]([C@@H]([C@H]1O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@H]1O)N(C)C)O[C@@H]1O[C@@H](C)[C@@H]([C@](C1)(C)O)OC(=O)CC)OC)OC(=O)CC)C,CBR-HVAC-01301: Anti-infective; Antibacterial; Antibiotic; Protein 50S ribosomal subunit inhibitor; Anti-infective; Antibacterial; Antibiotic
CBR-001-634-778-7,RFM-010-553-3,CBR-001-634-778-7,O[C@@H]1CO[C@H](C[C@@H]1O)O[C@H]1C[C@@](N)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2)C(=O)C,CBR-HVAC-01441: DNA Topoisomerase II Inhibitors; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; Antibiotic; Antineoplastic; Antineoplastic Antibiotics; Bladder Cancer Therapy ; Breast Cancer Therapy; Multiple Myeloma Therapy; Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Respiratory/Thoracic Cancer Therapy; Sarcoma Therapy; Small Cell Lung Cancer Therapy
CBR-001-634-779-8,RFM-010-554-4,CBR-001-634-779-8,OCC(=O)C12OC(O[C@@H]1C[C@@H]1C2(C)C[C@H](O)[C@H]2[C@H]1C[C@@H](C1=CC(=O)C=CC21C)F)(C)C,CBR-HVAC-02004: Arachidonic acid inhibitor; Corticosteroid agonist; Glucocorticoid receptor Agonist; Immunosuppressant; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Drugs for Allergic Rhinitis
CBR-001-634-780-1,RFM-010-555-5,CBR-001-634-780-1,Clc1ccc(cc1)CSC(c1ccc(cc1Cl)Cl)Cn1cncc1,CBR-HVAC-02203: Cell wall synthesis inhibitor; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Antifungal; Antifungal Agents
CBR-001-634-781-2,RFM-010-556-6,CBR-001-634-781-2,NCCCC[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)O)Cc1ncnc1)CCCNC(=N)N)CCCNC(=N)N)CC(C)C)C(C)C)NC(=O)C1CSSCC(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(NC(=O)C2CCCN2C(=O)C(CO)N)CCCCN)CCSC)CCC(=O)N)CO)C(=O)NC(Cc2ccccc2)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCSC)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)N1)CC(C)C)CO)CO)CO)CO)C(CC)C)CCCNC(=N)N,CBR-HVAC-04517: Coronary Bypass Surgery; Heart Failure Therapy
CBR-001-634-782-3,RFM-010-557-7,CBR-001-634-782-3,CO[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1NS(=O)(=O)O)O)O[C@@H]1O[C@@H](C(=O)O)[C@H]([C@@H]([C@H]1OS(=O)(=O)O)O)O[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1NS(=O)(=O)O)OS(=O)(=O)O)O[C@@H]1O[C@H](C(=O)O)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@H](COS(=O)(=O)O)[C@H]([C@@H]([C@H]1NS(=O)(=O)O)O)O,"CBR-HVAC-04561: Coagulation Factor Xa Inhibitors; Coagulation factor X Inhibitor; Indirect Factor Xa inhibitor; Inhibitors of Blood Coagulation Pathways; Serine protease inhibitor; Acute Myocardial Infarction, Treatment of; Angina pectoris, Treatment of; Anticoagulant; Anticoagulants; Treatment of Disorders of the Coronary Arteries and Atherosclerosis"
CBR-001-634-783-4,RFM-010-558-8,CBR-001-634-783-4,C=CC1=C(C)C2=NC1=Cc1c(C)c(c3n1[Fe](n1c(=C2)c(C=C)c(c1=CC1=NC(=C3)C(=C1C)CCC(=O)O)C)Cl)CCC(=O)O,"CBR-HVAC-05627: Enzyme Inducers; Anti-Hepatitis B Virus Drugs; Gastric Emptying Disorders,Treatment of; Multiple Sclerosis, Agents for"
CBR-001-634-784-5,RFM-010-559-9,CBR-001-634-784-5,O=C(C[C@H](C(=O)O)C)C[C@H]([C@H]1C[C@@H](C2([C@]1(C)CC(=O)C1=C2[C@@H](O)C[C@@H]2[C@]1(C)CCC(=O)C2(C)C)C)O)C,CBR-HVAC-07221: Apoptosis Inducers; Oncolytic Drugs
CBR-001-634-785-6,RFM-010-560-2,CBR-001-634-785-6,OCCN(CCO)CCO,CBR-HVAC-09978: Analgesic
CBR-001-634-786-7,RFM-010-561-3,CBR-001-634-786-7,Oc1cccc(c1)/C=C/C1=NCCCN1C,CBR-HVAC-10162: Nicotinic acetylcholine receptor Agonist; Anthelmintic
CBR-001-634-787-8,RFM-010-562-4,CBR-001-634-787-8,OC[C@@]1(O)[C@H]2OC3(O[C@@H]1[C@H]1[C@@](C2O)([C@@H]3O)NC(=N[C@@H]1O)N)O,CBR-HVAC-10235: Sodium channel Blocker; ANESTHETIC; ANTICANCER; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM DEPRESSANT; NEUROTOXIN
CBR-001-634-788-9,RFM-010-563-5,CBR-001-634-788-9,Oc1ccc(cc1)C[C@@H](C(=O)N[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(C)C)Cc1ccccc1)C)N,CBR-HVAC-11512: Adrenergic transmitter uptake inhibitor; Opioid receptor Agonist; Opioid receptor agonist; Analgesic; Antidiarrheal; Antidiarrheal Agents; Opioid Analgesics
CBR-001-634-789-0,RFM-010-564-6,CBR-001-634-789-0,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N)CCCNC(=N)N)CCCCN)C(C)C)CC(C)C)Cc1cnc2c1cccc2)C)[C@H](CC)C)Cc1ccccc1)CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ncnc1)N)C)CCC(=O)O)Cc1ccccc1)CO)CC(=O)O)CO)CO)Cc1ccc(cc1)O)CC(C)C)CCC(=O)O)CCC(=O)N)C)C,"CBR-HVAC-12637: Insulin Secretagogues; Signal Transduction Modulators; Antiobesity Drugs; Heart Failure Therapy; Type 2 Diabetes, Agents for"
CBR-001-634-790-3,RFM-010-565-7,CBR-001-634-790-3,Fc1ccc(c(c1)F)Oc1cc2cnc(nc2n(c1=O)C)NC1CCOCC1,"CBR-HVAC-12930: MAPK p38 Inhibitors; Signal Transduction Modulators; p38 mitogen-activated protein kinase alpha inhibitor; KINASE INHIBITOR; Rheumatoid Arthritis, Treatment of"
CBR-001-634-791-4,RFM-010-566-8,CBR-001-634-791-4,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@H](CC)C)C(=O)O)[C@H](CC)C)CCC(=O)O)CCSC)CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)N)CCC(=O)O)CCC(=O)O)CO)CC(C)C)CC(=O)O)CC(C)C)Cc1ccccc1)Cc1ncnc1)CC(C)C)CC(C)C)CCCNC(=N)N)CCC(=O)O)CC(C)C)CCC(=O)O)CCSC)C)CCCNC(=N)N)C)CCC(=O)O)CCC(=O)N)CC(C)C)C)CCC(=O)N)CCC(=O)O)C)Cc1ncnc1)CO)CC(=O)N)CCCNC(=N)N,CBR-HVAC-12990:
CBR-001-634-792-5,RFM-010-567-9,CBR-001-634-792-5,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CC(C)C)[C@H](CC)C)CO)CC(=O)N)CC(C)C)Cc1ccc(cc1)O)CCCCN)CCCCN)C(C)C)C)CCSC)CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ncnc1)N)CO)CC(=O)O)C)Cc1ccccc1)CC(=O)O)CC(=O)N)Cc1ccc(cc1)O)CCCNC(=N)N)CC(C)C)CCCNC(=N)N,"CBR-HVAC-12992: Acute Respiratory Distress Syndrome (ARDS), Agents for; Antiarthritic Drugs; Inflammation, Treatment of; Interstitial Lung Diseases, Treatment of; Pulmonary Hypertension, Treatment of; Sepsis, Treatment of; Small Cell Lung Cancer Therapy; Treatment of Autoimmune Diseases; Treatment of Erectile Dysfunction"
CBR-001-634-793-6,RFM-010-568-0,CBR-001-634-793-6,OCCN(C)C,CBR-HVAC-13084: Choline oxidase Inhibitor; Anti-dyskinesia; Antidepressive
CBR-001-634-794-7,RFM-010-569-1,CBR-001-634-794-7,O[C@@H]1CC[C@@H](O)[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@@H](O2)C[C@H](/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@@H]([C@H]([C@H]([C@@H](OC(=O)C[C@@H](C[C@@H](C1)O)O)C)C)O)C)O[C@@H]1O[C@H](C)[C@H]([C@@H]([C@@H]1O)N)O)C(=O)O,CBR-HVAC-13301: Binds to sterols in the cell membrane of fungus with a resultant change in membrane permeability allowing leakage of intracellular components; Antifungal; Antifungal Agents
CBR-001-634-797-0,RFM-010-570-4,CBR-001-634-797-0,Cn1c(=O)n(C)c2c(c1=O)[nH]cn2,"CBR-HVAC-01256: Adenosine A1 receptor antagonist; Opioid receptor Agonist; Phosphodiesterase inhibitor; Bronchodilator
"
CBR-001-634-806-4,RFM-010-571-5,CBR-001-634-806-4,CCN[C@@H](Cc1cccc(c1)C(F)(F)F)C,"CBR-HVAC-14502:	5-Hydroxytryptamine transporter; Anorectic"
CBR-001-634-807-5,RFM-010-572-6,CBR-001-634-807-5,OC(=O)C(c1ccc2c(c1)nc(o2)c1ccc(cc1)Cl)C,CBR-HVAC-02842: Non-Opioid Analgesics; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-634-808-6,RFM-010-573-7,CBR-001-634-808-6,CCC(C(n1sc2c(c1=O)cccc2)C(=O)O)C,"CBR-HVAC-04809: HIV replication inhibitor
"
CBR-001-634-809-7,RFM-010-574-8,CBR-001-634-809-7,CSc1nn2c(c1S(=O)(=O)c1ccccc1)nc(cc2C)C,"CBR-HVAC-07491: 5 Hydroxytryptamine 6 receptor antagonist
"
CBR-001-634-810-0,RFM-010-575-9,CBR-001-634-810-0,Fc1ccc(cc1)c1noc(n1)C12CCC(CC1)(CC2)c1nnc(n1C)c1ccccc1C(F)(F)F,"CBR-HVAC-07388: 11Ã.-HSD1 inhibitors, Merck
"
CBR-001-634-887-1,RFM-010-576-0,CBR-001-634-887-1,S[C@@H](C(=O)N[C@H]1CCS[C@@H]2N(C1=O)[C@@H](CCC2)C(=O)O)Cc1ccccc1,"CBR-HVAC-00904: Angiotensin-I Converting Enzyme (ACE) Inhibitors;Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors
"
CBR-001-634-888-2,RFM-010-577-1,CBR-001-634-888-2,O=C1CCC2=C3[C@H](C[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@@]4(O)C(C(F)(F)F)(F)F)C)c1ccc(cc1)C(=O)C,CBR-HVAC-00578: Progesterone Receptor Antagonists;Signal Transduction Modulators
CBR-001-634-889-3,RFM-010-578-2,CBR-001-634-889-3,CN1CCN(CC1)c1ccc(c2c1C[C@@H](CC2)NC(=O)c1ccc(cc1)N1CCOCC1)C,"CBR-HVAC-05396: Signal Transduction Modulators;5-HT1B Antagonists
"
CBR-001-634-890-6,RFM-010-579-3,CBR-001-634-890-6,CCCCCCCCCCCCCCCCOC[C@H](COP(=O)(OCC[N+](C)(C)C)[O-])OCCCCC(=O)O,CBR-HVAC-06164
CBR-001-634-891-7,RFM-010-580-6,CBR-001-634-891-7,CCCN1CC(CC2C1Cc1cccc(c1C2)O)NS(=O)(=O)N(CC)CC,"CBR-HVAC-02187: Dopamine D2 Agonists;Prolactin Secretion Inhibitors;Signal Transduction Modulators
"
CBR-001-635-037-1,RFM-010-581-7,CBR-001-635-037-1,NCCCC[C@@H](C(=O)O[Mg](OC(=O)[C@H](CCCCN)N)(OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)N,CBR-HVAC-13772:
CBR-001-635-038-2,RFM-010-582-8,CBR-001-635-038-2,Fc1cccc(c1)c1nc2c(n1C)nc(nc2N)C#CC1(O)CCCC1,"CBR-HVAC-13803: Irritable Bowel Syndrome, Agents for"
CBR-001-635-039-3,RFM-010-583-9,CBR-001-635-039-3,Cc1ccc(cc1)n1c(nc2c1cncc2)c1cnc(nc1)N1CCOCC1,CBR-HVAC-13832: Anti-VAP-1
CBR-001-635-040-6,RFM-010-584-0,CBR-001-635-040-6,CCOc1ccc(c(c1)NC(=O)CC(N)C)c1ccncc1,CBR-HVAC-07956: Sodium channel antagonist
CBR-001-635-041-7,RFM-010-585-1,CBR-001-635-041-7,N#CCC1(CN(C1)C1CCN(CC1)C(=O)c1ccnc(n1)C(F)(F)F)n1ncc(c1)c1ncnc2c1ccn2,CBR-HVAC-14033: Jak1 Inhibitors;Signal Transduction Modulators
CBR-001-635-042-8,RFM-010-586-2,CBR-001-635-042-8,Fc1cnc(nc1)N1CCN(CC1)CCCCn1c(C)nc(c1Cl)Cl,CBR-HVAC-13854: Signal Transduction Modulators;5-HT1A Receptor Agonists
CBR-001-635-043-9,RFM-010-587-3,CBR-001-635-043-9,Fc1ccc(cc1)c1cn(COP(=O)(O)O)cc(c1=O)C(=O)Nc1ccc(c(c1)F)Oc1ccnc(c1Cl)N,CBR-HVAC-14060: Solid Tumors Therapy
CBR-001-635-044-0,RFM-010-588-4,CBR-001-635-044-0,CCNCC(c1cccc(c1)OC(=O)C(C)(C)C)O,CBR-HVAC-02925: Alpha adrenoreceptor agonist
CBR-001-635-045-1,RFM-010-589-5,CBR-001-635-045-1,OC1CCN(C1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-05802: Dopamine receptor antagonist; Adenylate cyclase inhibitor; Alpha adrenoreceptor antagonist
CBR-001-635-046-2,RFM-010-590-8,CBR-001-635-046-2,C=CCN(c1c(Cl)ccc2c1nsn2)C1=NCCN1,CBR-HVAC-07425: Alpha 2 adrenoreceptor agonist
CBR-001-635-047-3,RFM-010-591-9,CBR-001-635-047-3,CCOC1(COc2c(O1)cccc2)C1=NCCN1,CBR-HVAC-04368: alpha2-Adrenoceptor Antagonists;Signal Transduction Modulators
CBR-001-635-048-4,RFM-010-592-0,CBR-001-635-048-4,C=CCc1c(ccc2c1cc1Cn3c(c1n2)cc1c(c3=O)COC(=O)[C@]1(O)CC)OC(=O)N1CCC(CC1)N1CCCCC1,CBR-HVAC-07124: Cytochrome P450 CYP3A4 Inhibitors
CBR-001-635-049-5,RFM-010-593-1,CBR-001-635-049-5,COc1ccc(cc1OC1CCCC1)CC1CNC(=O)N1,CBR-HVAC-13650: 5 Hydroxytryptamine receptor agonist
CBR-001-635-050-8,RFM-010-594-2,CBR-001-635-050-8,CC[C@@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)O)N)C,CBR-HVAC-13046: Angiotensin-I Converting Enzyme (ACE) Inhibitors
CBR-001-635-051-9,RFM-010-595-3,CBR-001-635-051-9,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)CC(O)C,CBR-HVAC-00331: Alpha-1 adrenergic receptor Antagonist; Antihypertensive; Benign prostate hyperplasia
CBR-001-635-052-0,RFM-010-596-4,CBR-001-635-052-0,ClCCN(C(=O)N(CC(=O)N)C)N=O,"CBR-HVAC-00388: Cell cycle inhibitor; Anticancer; Carcinoma, colorectal"
CBR-001-635-053-1,RFM-010-597-5,CBR-001-635-053-1,OCCC1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C,CBR-HVAC-03118: Dopamine receptor D2 Antagonist; Antipsychotic; Neuroleptic; Schizophrenia; Psychotic disorders
CBR-001-635-054-2,RFM-010-598-6,CBR-001-635-054-2,CCOC(=O)CCc1ccccc1OC[C@H](CNC(C)C)O,CBR-HVAC-05209: Beta adrenergic receptor Antagonist; Vasodilator; Antiarrhythmic; Anxiolytic; Acute angina pectoris; Migraine; Cardiovascular manifestations; Acute anxiety
CBR-001-635-055-3,RFM-010-599-7,CBR-001-635-055-3,Fc1ccc(cc1)C(=O)C1CCN(CC1)CCCCn1c(=O)[nH]c2c(c1=O)cccc2,CBR-HVAC-08834: 5-Hydroxytryptamine 2 receptor; Alpha-1 adrenergic receptor; Histamine H1 receptor Antagonist; Antagonist; Antagonist; ;
CBR-001-635-056-4,RFM-010-600-3,CBR-001-635-056-4,CCN1C(=O)c2c(C1Nc1cccc(c1)OCCN1CCCCC1)cccc2,CBR-HVAC-09241: ; Anticholinergic; Flatulence; Dyspepsia; Cirrosis of liver or kidney
CBR-001-635-057-5,RFM-010-601-4,CBR-001-635-057-5,CCCCOc1ccc(cc1N)C(=O)OCCOCCN(CC)CC,"CBR-HVAC-09913: ; Local anesthetic; Anesthesia, local"
CBR-001-635-058-6,RFM-010-602-5,CBR-001-635-058-6,CCCCOc1ccc(cc1)C(=O)OCCN(CC)CC,"CBR-HVAC-10113: ; Local anesthetic; Anesthesia, local"
CBR-001-635-059-7,RFM-010-603-6,CBR-001-635-059-7,CN(CC(OC(=O)COc1ccc(cc1)Cl)CN(C)C)C,CBR-HVAC-10532: Free radical scavenger; Nootropic; CNS stimulant; Nootropic; CNS stimulant; Cognition disorder
CBR-001-635-060-0,RFM-010-604-7,CBR-001-635-060-0,O=c1n(c2ccccc2)c2ncccc2c2c1nc[nH]2,CBR-HVAC-10542: Phosphodiesterase 4 Inhibitor; Bronchodilator; Antiasthmatic; Asthma
CBR-001-635-061-1,RFM-010-605-8,CBR-001-635-061-1,CN(CC1CCCc2c1ccc(c2)O)CCc1ccccc1,CBR-HVAC-10703: Alpha-2 adrenergic receptor Antagonist; Antiglaucoma; Glaucoma
CBR-001-635-062-2,RFM-010-606-9,CBR-001-635-062-2,CN1CCC=C2C1CCc1c2nc(s1)N,CBR-HVAC-10834: Dopamine receptor D2 Agonist; Dopamine receptor D2 agonist; Cocaine abuse
CBR-001-635-063-3,RFM-010-607-0,CBR-001-635-063-3,CN1CCN(CC1)c1cc(Cl)cc(c1)C(=O)Nc1cnnc1C(=O)NC1CCCCC1,CBR-HVAC-11805: CDK1; CDK4; Vascular endothelial growth factor receptor; FMS-related tyrosine kinase 3; CDK2; PDGFR beta Inhibitor; Anticancer; Cancer
CBR-001-635-064-4,RFM-010-608-1,CBR-001-635-064-4,ON1CCOCC1C1=CCCCC1=O,CBR-HVAC-12022: Anxiolytic; Anxiolytic; Major depressive disorder; Anxiety disorder
CBR-001-635-065-5,RFM-010-609-2,CBR-001-635-065-5,Oc1ccc2c(c1)cc(n2Cc1ccc(c(c1)C(F)(F)F)Cl)C(=O)O,CBR-HVAC-12380: CHEMOKINE RECEPTOR Antagonist; Anti-inflammatory; Rheumatoid arthritis; Chronic obstructive pulmonary disease
CBR-001-635-066-6,RFM-010-610-5,CBR-001-635-066-6,C#CCOc1ccc2c(c1)c(nc(=O)n2Cc1ccc(c(c1)OCC)OC)c1ccc(cc1)C(C)C,CBR-HVAC-12425: ; Bone growth regulator; Osteoporosis
CBR-001-635-067-7,RFM-010-611-6,CBR-001-635-067-7,O=C(N1CCOc2c1cccc2)c1ccc(c(c1)Cl)O,CBR-HVAC-12451: Urate transporter 1 Inhibitor; Urate transporter 1 inhibitor; Hyperuricemia
CBR-001-635-068-8,RFM-010-612-7,CBR-001-635-068-8,CCOc1ccccc1n1c(CN2CCNCC2)nc2c(c1=O)cccc2,CBR-HVAC-12485: RAS GTPase; Voltage dependent anion channel Inhibitor; Modulator; Anticancer; Cancer
CBR-001-635-069-9,RFM-010-613-8,CBR-001-635-069-9,Fc1ccc(cc1)c1nc2nn(cc2c(c1c1ccncc1)c1ccc(cc1)F)C,CBR-HVAC-12493: P38 MAP kinase Inhibitor; ANTI-INFLAMMATORY; ANTIPSORIATIC; ANALGESIC; NEUROPATHIC PAIN
CBR-001-635-070-2,RFM-010-614-9,CBR-001-635-070-2,COc1ccc2c(c1)c(CN1CCN(CC1)C)cn2S(=O)(=O)c1ccccc1Br,CBR-HVAC-12512: 5-hydroxytryptamine 6 receptor Antagonist; Appetite suppressant; Nootropic; Amnesia
CBR-001-635-071-3,RFM-010-615-0,CBR-001-635-071-3,OC(=O)[C@@H](Oc1ccc(cc1c1ccc(c(c1)Cl)C(=O)N1CCCC1(C)C)F)C,CBR-HVAC-12530: Anti-inflammatory; Anti-inflammatory; Asthma
CBR-001-635-072-4,RFM-010-616-1,CBR-001-635-072-4,NCc1cccc(c1)C1CCN(CC1)C(=O)c1ccc(o1)C#Cc1ccccc1F,CBR-HVAC-12565: Beta-tryptase; Tryptase Inhibitor; Anti-inflammatory; Asthma
CBR-001-635-073-5,RFM-010-617-2,CBR-001-635-073-5,CC(Sc1cc(ccc1C(=O)NS(=O)(=O)C)c1ccc(cc1)CCNC[C@@H](c1ccccc1)O)C,CBR-HVAC-12587: Beta-3 adrenergic receptor Agonist; Renal system agent; Interstitial cystitis; Bladder pain syndrome
CBR-001-635-074-6,RFM-010-618-3,CBR-001-635-074-6,Cc1cc(C)c(c(c1)C)CC1=NCCN1,CBR-HVAC-13286: 5-Hydroxytryptamine 1D receptor alpha Agonist; 5-hydroxytryptamine 1D receptor alpha agonist; Migraine
CBR-001-635-075-7,RFM-010-619-4,CBR-001-635-075-7,CCCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,"CBR-HVAC-13495: ; Local anesthetic; Anesthesia, local"
CBR-001-635-076-8,RFM-010-620-7,CBR-001-635-076-8,O=C(CCC(C(=O)O)N)NCCS(=O)(=O)O,CBR-HVAC-02530: ; Anticonvulsant; Convulsion
CBR-001-635-077-9,RFM-010-621-8,CBR-001-635-077-9,CC(C[C@@H](C(=O)O)NC(=O)OCC1c2cc(C)ccc2c2c1cc(C)cc2)C,"CBR-HVAC-12811: Integrin beta2 Inhibitor; Anti-inflammatory; Immunosuppressant; Asthma; Atherosclerosis; Myocardial ischemia; Rheumatic diseases; Thrombosis; Transplant rejection; Colitis, ulcerative; Irritable bowel syndrome; Septic shock"
CBR-001-635-078-0,RFM-010-622-9,CBR-001-635-078-0,O=C(N[C@H](C[C@@H]([C@@H](NC(=O)[C@H](C(C)C)NC(=O)OCc1ccccn1)Cc1ccccc1)O)Cc1ccccc1)OCc1cccnc1,CBR-HVAC-04482: HIV Protease Inhibitors; HIV protease inhibitor; Protease Inhibitor; Anti-HIV Agents; Antiviral
CBR-001-635-079-1,RFM-010-623-0,CBR-001-635-079-1,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)C)[C@H](O)C)Cc1cncn1)CC(C)C)CCCCN)(C)C)CC(C)C)CC(C)C)CCCCN)CCC(=O)O)CC(C)C)CC(C)C)CCC(=O)O)CCCNC(=N)N)CCCNC(=N)N)CCCNC(=N)N)CC(C)C)CC(=O)O)CCC(=O)N)[C@H](CC)C)CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)C)CO)CCC(=O)O)Cc1cncn1)CCC(=O)N)CC(C)C)CC(C)C)Cc1cncn1)CC(=O)O)CCCCN,CBR-HVAC-12911: Bone Formation Stimulants;Treatment of Osteoporosis
CBR-001-635-080-4,RFM-010-624-1,CBR-001-635-080-4,O=c1n(CCCCC(O)(C)C)c(=O)c2c(n1C)nc[nH]2,"CBR-HVAC-07438: Membrane permeability inhibitor; Acute Respiratory Distress Syndrome (ARDS), Agents for; Membrane permeability inhibitor"
CBR-001-635-081-5,RFM-010-625-2,CBR-001-635-081-5,OC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1Cl)C1CC1)C(=O)NC(C)(C)C,CBR-HVAC-06926: CRTH2 antagonist; G protein-coupled receptor 44; Prostaglandin D2 receptor 2 (CRTH2; GPR44; PTGDR2) Antagonists; Prostaglandin D2 receptor Antagonist; Prostaglandin D2 receptor DP1 antagonist; Prostanoid DP (DP1) Antagonists; Signal Transduction Modulators; Anti-inflammatory; Asthma Therapy
CBR-001-635-082-6,RFM-010-626-3,CBR-001-635-082-6,N#CC(c1ccccc1)NC(Cc1ccccc1)C,CBR-HVAC-10249: Antiobesity
CBR-001-635-083-7,RFM-010-627-4,CBR-001-635-083-7,C[C@@H](C(F)(F)F)Oc1ccc(cc1C(F)(F)F)c1onc(n1)c1ccc2c(c1)ncn2,"CBR-HVAC-12505: Immunomodulator; Immunomodulator; Multiple Sclerosis, Agents for"
CBR-001-635-084-8,RFM-010-628-5,CBR-001-635-084-8,Clc1ccc(s1)c1onc(c1)Cn1c(nc2c1ccc(c2)C(=O)[O-])C(=O)NC1CCN(CC1)C1CC1,CBR-HVAC-12599: Coagulation Factor Xa Inhibitors; Factor Xa Inhibitor; Inhibitors of Blood Coagulation Pathways; ANTICOAGULANT; Anticoagulants
CBR-001-635-085-9,RFM-010-629-6,CBR-001-635-085-9,CCS(=O)(=O)Nc1ccc2c(c1)nc(n2CC1CCC(CC1)(F)F)C(C)(C)C,"CBR-HVAC-12504: Cannabinoid CB1 receptor Agonist; Cannabinoid Receptor Agonists; Signal Transduction Modulators; Analgesic; Analgesic Drugs; Neuropathic Pain, Treatment of"
CBR-001-635-086-0,RFM-010-630-9,CBR-001-635-086-0,O=C1NC(=O)NC1(C)CS(=O)(=O)N1CCC(CC1)c1ccc(cc1)F,"CBR-HVAC-12573: Protease Inhibitors; Proteinase Inhibitor; Antiinflammatory; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-635-087-1,RFM-010-631-0,CBR-001-635-087-1,O=C1NC(=O)NC1(C)CS(=O)(=O)N1CCC(CC1)c1ccc(cc1)F,"CBR-HVAC-12573: Protease Inhibitors; Proteinase Inhibitor; Antiinflammatory; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-635-088-2,RFM-010-632-1,CBR-001-635-088-2,Cn1nc(c(c1)CN1CCC(CC1)c1ccc(cc1)C(=O)Nc1ccccc1N)C,CBR-HVAC-12494: Antitumor; Histone Deacetylase (HDAC) Inhibitors; Antitumour; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-635-089-3,RFM-010-633-2,CBR-001-635-089-3,Nc1nc(=O)c2c(n1)c(cn2)Cc1cscc1,CBR-HVAC-00391: Purine nucleoside phosphorylase inhibitor; Purine-Nucleoside Phosphorylase Inhibitors; T cell inhibitor; Immunosuppressants
CBR-001-635-090-6,RFM-010-634-3,CBR-001-635-090-6,Fc1ccc(cc1)CC1CCN(CC1)CCS(=O)c1ccc2c(c1)oc(=O)n2,CBR-HVAC-11045: Ionotropic glutamate receptor NMDA Antagonist; NR2B Antagonists; Signal Transduction Modulators; Analgesic; Anticonvulsant; Antiparkinsonian; Antiparkinsonian Drugs
CBR-001-635-091-7,RFM-010-635-4,CBR-001-635-091-7,OCc1ncnc(c1)Oc1ccc2c(c1)cccc2C(=O)Nc1cccc(c1)C(F)(F)F,CBR-HVAC-12519: Antipsoriatic; Antipsoriatic; Antipsoriatics; Dermatologic Drugs
CBR-001-635-092-8,RFM-010-636-5,CBR-001-635-092-8,OC(COc1ccccc1C1CC2CC1CC2)CNC(C)C,CBR-HVAC-01011: Beta adrenergic receptor Agonist; Beta adrenoreceptor antagonist
CBR-001-635-093-9,RFM-010-637-6,CBR-001-635-093-9,O=C(OC(C)(C)C)N[C@H]([C@H](CC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCOCC1)Cc1ccccc1)C(C)C)Cc1ccccc1)O)Cc1ccccc1,CBR-HVAC-04484: HIV Protease Inhibitors; HIV protease inhibitor; Reverse transcriptase Inhibitor; Anti-HIV Agents; Antiviral
CBR-001-635-094-0,RFM-010-638-7,CBR-001-635-094-0,O=C(OC(C)(C)C)N[C@H]([C@H](CC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCOCC1)Cc1ccccc1)C(C)C)Cc1ccccc1)O)Cc1ccccc1,CBR-HVAC-04484: HIV Protease Inhibitors; HIV protease inhibitor; Reverse transcriptase Inhibitor; Anti-HIV Agents; Antiviral
CBR-001-635-095-1,RFM-010-639-8,CBR-001-635-095-1,CCc1ccc(cc1)CSc1ccc(cc1)NS(=O)(=O)c1ccc(c(c1)C(=O)O)C,CBR-HVAC-12535: Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Peroxisome proliferator activated receptor alpha Agonist; Antidiabetic; Atherosclerosis Therapy
CBR-001-635-096-2,RFM-010-640-1,CBR-001-635-096-2,CCN(c1ccc(cc1SC)C(C)C)c1nc(cc(n1)C)N1CCC(=CC1)c1cccc(c1)F,CBR-HVAC-11584: CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 Antagonist; CRF1 Receptor Antagonists; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics
CBR-001-635-097-3,RFM-010-641-2,CBR-001-635-097-3,C[C@@H](CN1CCC2(C(C1Cc1c2cccc1O)(C)C)C)OCc1ccccc1,"CBR-HVAC-05181: Sodium Channel  Blockers; Sodium channel Blocker; Analgesic; Neuroprotectant; Stroke, Treatment of"
CBR-001-635-098-4,RFM-010-642-3,CBR-001-635-098-4,C[C@@H](CN1CCC2(C(C1Cc1c2cccc1O)(C)C)C)OCc1ccccc1,"CBR-HVAC-05181: Sodium Channel  Blockers; Sodium channel Blocker; Analgesic; Neuroprotectant; Stroke, Treatment of"
CBR-001-635-099-5,RFM-010-643-4,CBR-001-635-099-5,CCCCCCCCCCOc1c(OC)cc(cc1OC)C(=O)N,CBR-HVAC-08654: Anticonvulsant
CBR-001-635-100-1,RFM-010-644-5,CBR-001-635-100-1,COC(=O)Nc1nc2c(n1)ccc(c2)Sc1ccc(cc1)NC(=O)[C@@H](N)C,CBR-HVAC-02758: Angiogenesis inhibitor; Tubulin Inhibitor; Tubulin inhibitor; Vascular Disrupting Agents (VDA); Anticancer; Solid Tumors Therapy; Vascular disrupting agent
CBR-001-635-101-2,RFM-010-645-6,CBR-001-635-101-2,OC[C@H]1NC[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-12217: Alpha glucosidase stimulant; Alpha-glucosidase Modulator; Pharmacological Chaperones; alpha-Glucosidase Inhibitors; AIDS Medicines; Alpha-glucosidase modulator; Therapy of Inborn Errors of Metabolism
CBR-001-635-102-3,RFM-010-646-7,CBR-001-635-102-3,OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@H]2[C@H]1CCC1=CC(=O)C=C[C@]21C)C1CCCCC1,CBR-HVAC-13015: Asthma Therapy; Drugs for Allergic Rhinitis
CBR-001-635-103-4,RFM-010-647-8,CBR-001-635-103-4,Clc1cc2OCCOc2c(c1)N1CCN(CC1)CCCCN1C(=O)c2c(S1(=O)=O)cccc2,CBR-HVAC-04945: 5 Hydroxytryptamine 1A receptor antagonist; 5-HT1A Receptor Antagonists; 5-Hydroxytryptamine 1A receptor Antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Antipsychotic; Anxiolytic
CBR-001-635-104-5,RFM-010-648-9,CBR-001-635-104-5,COCCCc1ccc2c(c1)cc(o2)c1ccc(c(c1)OC)OC,"CBR-HVAC-12469: Beta amyloid Inhibitor; ANTIALZHEIMER'S; Alzheimer's Dementia, Treatment of"
CBR-001-635-105-6,RFM-010-649-0,CBR-001-635-105-6,O=C(N1CCc2c(C1)sc1c2C(=NC(c2n1c(C)nn2)C)c1ccccc1Cl)C1CC1,CBR-HVAC-04034: Platelet activating factor antagonist; Platelet activating factor receptor Antagonist; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antiasthmatic
CBR-001-635-106-7,RFM-010-650-3,CBR-001-635-106-7,O=C(N1CCc2c(C1)sc1c2C(=NC(c2n1c(C)nn2)C)c1ccccc1Cl)C1CC1,CBR-HVAC-04034: Platelet activating factor antagonist; Platelet activating factor receptor Antagonist; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antiasthmatic
CBR-001-635-107-8,RFM-010-651-4,CBR-001-635-107-8,CC([C@H](N(C(=O)[C@H](C(C)(C)C)NC(=O)[C@H]1CCCCN1C(C)C)C)/C=C(/C(=O)O)\C)C,CBR-HVAC-00209: Antimitotic Drugs; Microtubule inhibitor; Microtubule polymerization inhibitor; Tubulin Polymerization Inhibitors; Tubulin inhibitor; Anticancer; Oncolytic Drugs
CBR-001-635-108-9,RFM-010-652-5,CBR-001-635-108-9,NC1C[C@@]2([C@H]1CN(C2)c1nc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O)C,CBR-HVAC-04713: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-635-109-0,RFM-010-653-6,CBR-001-635-109-0,NC1C[C@@]2([C@H]1CN(C2)c1nc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O)C,CBR-HVAC-04713: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-635-110-3,RFM-010-654-7,CBR-001-635-110-3,OC[C@@]1(C#C)O[C@H](C[C@@H]1O)n1cnc2c1nc(F)nc2N,"CBR-HVAC-12280: Anti-HIV Agents
"
CBR-001-635-111-4,RFM-010-655-8,CBR-001-635-111-4,CCCCCCN(C(=C1C(=O)OC(OC1=O)(C)C)Nc1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C)Cc1ccc(cc1)CC(C)(C)C,"CBR-HVAC-04435: ACAT Inhibitors; Acetyl CoA transferase inhibitor; Acyl CoA:cholesterol acyltransferase Inhibitor; Antihypercholesterolemic; Lipoprotein Disorders, Treatment of"
CBR-001-635-112-5,RFM-010-656-9,CBR-001-635-112-5,CCCCc1ccc(c(=O)n1Cc1ccc(cc1)c1ccccc1c1nnnn1)CN(S(=O)(=O)C)CC1CC1,"CBR-HVAC-11373: Angiotensin AT1 Antagonists; Angiotensin II receptor type 1 Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-635-113-6,RFM-010-657-0,CBR-001-635-113-6,CCOC(=O)C1(CCCN(CC1)C)c1ccccc1,CBR-HVAC-09944: Analgesic
CBR-001-635-114-7,RFM-010-658-1,CBR-001-635-114-7,CCCC[C@H](C(=O)N[C@@H](C(=O)N)CCCNC(=N)N)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)N,CBR-HVAC-13556: Opioid receptor kappa Agonist; Signal Transduction Modulators; kappa-Opioid Agonists; Analgesic; Antinociceptive; Opioid Analgesics
CBR-001-635-115-8,RFM-010-659-2,CBR-001-635-115-8,CCC(c1ccccc1)(N(C)C)COCc1cc(OC)c(c(c1)OC)OC,"CBR-HVAC-04038: Opioid kappa receptor agonist; Opioid receptor kappa Agonist; Signal Transduction Modulators; kappa-Opioid Agonists; Antinociceptive; Irritable Bowel Syndrome, Agents for; Non-Ulcer Dyspepsia, Agents for; Prokinetic Agents"
CBR-001-635-116-9,RFM-010-660-5,CBR-001-635-116-9,CCC(c1ccccc1)(N(C)C)COCc1cc(OC)c(c(c1)OC)OC,"CBR-HVAC-04038: Opioid kappa receptor agonist; Opioid receptor kappa Agonist; Signal Transduction Modulators; kappa-Opioid Agonists; Antinociceptive; Irritable Bowel Syndrome, Agents for; Non-Ulcer Dyspepsia, Agents for; Prokinetic Agents"
CBR-001-635-117-0,RFM-010-661-6,CBR-001-635-117-0,FCC(Cn1cnc2c1ncnc2N)OCP(=O)(O)O,CBR-HVAC-10566: Reverse transcriptase Inhibitor; Antiviral
CBR-001-635-118-1,RFM-010-662-7,CBR-001-635-118-1,OCC[C@H]1CCCCN1C(=O)/C=C/c1c(nn2c1cccc2)c1ccccc1,"CBR-HVAC-03842: Adenosine A1 Antagonists; Adenosine A1 Receptor Antagonist; Signal Transduction Modulators; ANTIPLATELET-CARDIOVASCULAR AGENT-DIURETIC-HEMATOLOGICAL AGENT-ANTIHYPERTENSIVE; Antiplatelet Therapy; Diuretics; Heart Failure Therapy; Hypertension, Treatment of; Renal Failure, Agents for; Uricosurics"
CBR-001-635-119-2,RFM-010-663-8,CBR-001-635-119-2,OCC[C@H]1CCCCN1C(=O)/C=C/c1c(nn2c1cccc2)c1ccccc1,"CBR-HVAC-03842: Adenosine A1 Antagonists; Adenosine A1 Receptor Antagonist; Signal Transduction Modulators; ANTIPLATELET-CARDIOVASCULAR AGENT-DIURETIC-HEMATOLOGICAL AGENT-ANTIHYPERTENSIVE; Antiplatelet Therapy; Diuretics; Heart Failure Therapy; Hypertension, Treatment of; Renal Failure, Agents for; Uricosurics"
CBR-001-635-120-5,RFM-010-664-9,CBR-001-635-120-5,COc1ccc(cc1S(=O)(=O)N)CCN1CCC(CC1)c1nc(c(o1)c1ccc(cc1)F)COCC(F)(F)F,CBR-HVAC-04869: Alpha 1 adrenoreceptor antagonist; Signal Transduction Modulators; alpha1-Adrenoceptor Antagonists; Benign Prostatic Hyperplasia Therapy
CBR-001-635-121-6,RFM-010-665-0,CBR-001-635-121-6,CCCCCn1c(=O)[nH]c(=O)c2c1nc([nH]2)Cl,"CBR-HVAC-12371: High affinity nicotinic acid receptor (HM74A) agonist; Hydroxycarboxylic Acid Receptor 3 (HCAR3; NIACR2; GPR109B) Agonists; Nicotinic ACh receptor agonist; Signal Transduction Modulators; Antihyperlipidemic; Lipoprotein Disorders, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-635-122-7,RFM-010-666-1,CBR-001-635-122-7,O=C(c1ccc(cc1)S(=O)(=O)C)N1CCN(CC1)c1ccc(cc1)OC1CCN(CC1)C1CCC1,CBR-HVAC-12468: Antiallergic; Antiallergic
CBR-001-635-123-8,RFM-010-667-2,CBR-001-635-123-8,O=C(c1cc2nc(nc2cc1N1CCNCC1)Nc1ccccc1C(F)(F)F)Nc1ccc2c(c1)nnc2,CBR-HVAC-12510: AURORA KINASE Inhibitor; Antimitotic Drugs; Aurora Kinase Inhibitors; Signal Transduction Modulators; Anticancer; Oncolytic Drugs
CBR-001-635-124-9,RFM-010-668-3,CBR-001-635-124-9,Cc1nc2c(n1)cc(cc2)C(n1cncc1)c1ccccc1,CBR-HVAC-03752: Diuretic; Uricosuric; Diuretic; Uricosuric; Uricosurics
CBR-001-635-125-0,RFM-010-669-4,CBR-001-635-125-0,N#Cc1cc(C)cc(c1)C(=O)c1n(CC)c(=O)[nH]c(=O)c1C(C)C,CBR-HVAC-12361: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE Inhibitor; Reverse Transcriptase Inhibitors; ANTI-VIRAL; Anti-HIV Agents
CBR-001-635-126-1,RFM-010-670-7,CBR-001-635-126-1,Fc1ccc(cc1)CNC(=O)c1nc(c2c(c1O)nccc2)N1CCCCS1(=O)=O,CBR-HVAC-05710: HIV Integrase Inhibitors; Integrase Inhibitor; Anti-HIV; Anti-HIV Agents
CBR-001-635-127-2,RFM-010-671-8,CBR-001-635-127-2,CCn1nc(cc(c1=O)Nc1cccc2c1cccn2)c1ccccc1,CBR-HVAC-12543: Phosphodiesterase 4 inhibitor; Antipsoriatic; Antipsoriatics
CBR-001-635-128-3,RFM-010-672-9,CBR-001-635-128-3,COc1ccc(cc1OC1CCCC1)N(c1cccc(c1)C(=O)O)Cc1cccnc1,CBR-HVAC-12551: Phosphodiesterase 4 Inhibitor; Neuroprotectant; Nootropic
CBR-001-635-129-4,RFM-010-673-0,CBR-001-635-129-4,Nc1oc2c(n1)cc(cc2)c1ccc2n(c1)c(cn2)C(=O)N1CCOCC1,CBR-HVAC-12552: Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors; Phosphoinositide 3-kinase P110 alpha Inhibitor; Signal Transduction Modulators; Anticancer; Non-Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-001-635-130-7,RFM-010-674-1,CBR-001-635-130-7,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N)C(C)C)NC(=O)CNC(=O)[C@H](Cc1cnc2c1cccc2)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cncn1)NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CO)CO)CCCNC(=N)N,"CBR-HVAC-14120: Melanocortin MC4 Receptor Modulators; Signal Transduction Modulators; Antiobesity Drugs; Type 2 Diabetes, Agents for"
CBR-001-635-131-8,RFM-010-675-2,CBR-001-635-131-8,Oc1ccc(cc1)CC1NCCc2c1cc(O)c(c2)O,"CBR-HVAC-12228: Signal Transduction Modulators; beta-Adrenoceptor Agonists; Anti-HIV Agents; Bronchodilators; Cardiovascular Diseases (Not Specified); Stroke, Treatment of; Treatment of Erectile Dysfunction"
CBR-001-635-132-9,RFM-010-676-3,CBR-001-635-132-9,NCCCC[C@H](C(=O)N[C@H](C(=O)OCCCCCCCCCC)Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCS(=O)(=O)C)N)CCC(=O)O)Cc1ncnc1)Cc1ccccc1,"CBR-HVAC-10705: Nootropic agent; Cognition Disorders, Treatment of; Nootropic"
CBR-001-635-133-0,RFM-010-677-4,CBR-001-635-133-0,CCCCCCCCN1CCc2c1c(NC(=O)C(C)(C)C)c(c(c2C)CC(=O)O)C,"CBR-HVAC-11971: ACAT Inhibitor; ACAT Inhibitors; Acetyl CoA transferase inhibitor; Lipid Peroxidation Inhibitors; Antihyperlipidemic; Atherosclerosis Therapy; Lipoprotein Disorders, Treatment of"
CBR-001-635-134-1,RFM-010-678-5,CBR-001-635-134-1,COC(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)NCCCCC(N(S(=O)(=O)c1ccc(cc1)N)CC(C)C)CO,CBR-HVAC-05974: HIV Protease Inhibitors; HIV protease inhibitor; PROTEASE Inhibitor; ANTI-VIRAL; Anti-HIV Agents
CBR-001-635-135-2,RFM-010-679-6,CBR-001-635-135-2,COC(=O)N[C@@H](C(c1ccccc1)c1ccccc1)C(=O)NCCCCC(N(S(=O)(=O)c1ccc(cc1)N)CC(C)C)CO,CBR-HVAC-05974: HIV Protease Inhibitors; HIV protease inhibitor; PROTEASE Inhibitor; ANTI-VIRAL; Anti-HIV Agents
CBR-001-635-136-3,RFM-010-680-9,CBR-001-635-136-3,Nc1nc(nc(c1)Cl)S[C@H](c1ncc2c(c1)cco2)C,CBR-HVAC-04892: Non-nucleoside reverse transcriptase inhibitor; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Anti-HIV Agents; Reverse transcriptase inhibitor
CBR-001-635-137-4,RFM-010-681-0,CBR-001-635-137-4,Nc1nc(nc(c1)Cl)S[C@@H](c1ncc2c(c1)cco2)C,CBR-HVAC-04892: Non-nucleoside reverse transcriptase inhibitor; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Anti-HIV Agents; Reverse transcriptase inhibitor
CBR-001-635-138-5,RFM-010-682-1,CBR-001-635-138-5,CCCOc1ccc(cc1)C1CNC(=O)N1c1ccc2c(c1)ncn2,"CBR-HVAC-12520: GLUTAMINYL CYCLASE Inhibitor; Glutaminyl Cyclase Inhibitors; Alzheimer's Dementia, Treatment of"
CBR-001-635-139-6,RFM-010-683-2,CBR-001-635-139-6,CCCOc1ccc(cc1)C1CNC(=O)N1c1ccc2c(c1)ncn2,"CBR-HVAC-12520: GLUTAMINYL CYCLASE Inhibitor; Glutaminyl Cyclase Inhibitors; Alzheimer's Dementia, Treatment of"
CBR-001-635-140-9,RFM-010-684-3,CBR-001-635-140-9,Fc1ccc(c(c1)F)[C@@]1(CO[C@H](O1)COc1ccc(cc1)N1CCN(CC1)c1ccc(cc1)N1CCN(C1=O)C(C)C)Cn1cncn1,CBR-HVAC-05130: CYP51 Inhibitor; Lanosterol 14alpha-demethylase Inhibitors; Antifungal; Antifungal Agents; Dermatologic Drugs
CBR-001-635-141-0,RFM-010-685-4,CBR-001-635-141-0,Fc1ccc(c(c1)F)[C@]1(CO[C@H](O1)COc1ccc(cc1)N1CCN(CC1)c1ccc(cc1)N1CCN(C1=O)C(C)C)Cn1cncn1,CBR-HVAC-05130: CYP51 Inhibitor; Lanosterol 14alpha-demethylase Inhibitors; Antifungal; Antifungal Agents; Dermatologic Drugs
CBR-001-635-142-1,RFM-010-686-5,CBR-001-635-142-1,Fc1ccc(c(c1)F)[C@@]1(CO[C@@H](O1)COc1ccc(cc1)N1CCN(CC1)c1ccc(cc1)N1CCN(C1=O)C(C)C)Cn1cncn1,CBR-HVAC-05130: CYP51 Inhibitor; Lanosterol 14alpha-demethylase Inhibitors; Antifungal; Antifungal Agents; Dermatologic Drugs
CBR-001-635-143-2,RFM-010-687-6,CBR-001-635-143-2,O[C@@H]1[C@@H](SC[C@H]([C@H]1O)O)Sc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-11328: Thrombin Inhibitor; Anticoagulants; Thrombin inhibitor
CBR-001-635-144-3,RFM-010-688-7,CBR-001-635-144-3,O=C1CN(CCN1Cc1cc2c(n1)ccnc2)S(=O)(=O)/C=C/c1ccc(s1)Cl,CBR-HVAC-11727: Coagulation Factor Xa Inhibitors; Coagulation factor X Antagonist; Inhibitors of Blood Coagulation Pathways; Anticoagulant; Anticoagulants
CBR-001-635-145-4,RFM-010-689-8,CBR-001-635-145-4,O=C([C@@H]1C[C@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CSCC1,"CBR-HVAC-04852: Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors; Prolyl endopeptidase Inhibitor; Prolyl endopeptidase inhibitor; Cognition Disorders, Treatment of; Neuropathic Pain, Treatment of; Nootropic"
CBR-001-635-146-5,RFM-010-690-1,CBR-001-635-146-5,O=C([C@H]1C[C@@H]1c1ccccc1)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)N1CSCC1,"CBR-HVAC-04852: Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors; Prolyl endopeptidase Inhibitor; Prolyl endopeptidase inhibitor; Cognition Disorders, Treatment of; Neuropathic Pain, Treatment of; Nootropic"
CBR-001-635-147-6,RFM-010-691-2,CBR-001-635-147-6,OC(=O)CCC/C=C(/c1cccnc1)\c1ccc(cc1)CCNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-00406: Inhibitor; Prostanoid TP Antagonists; Signal Transduction Modulators; THROMBOXANE A SYNTHASE; THROMBOXANE A2 RECEPTOR Antagonist; Thromboxane A2 receptor antagonist; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Antiplatelet Therapy; Antithrombotic
CBR-001-635-148-7,RFM-010-692-3,CBR-001-635-148-7,OC(=O)CCC/C=C(\c1cccnc1)/c1ccc(cc1)CCNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-14484: Inhibitor; Prostanoid TP Antagonists; Signal Transduction Modulators; THROMBOXANE A SYNTHASE; THROMBOXANE A2 RECEPTOR Antagonist; Thromboxane A2 receptor antagonist; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Antiplatelet Therapy; Antithrombotic
CBR-001-635-149-8,RFM-010-693-4,CBR-001-635-149-8,NC(=N)NCCCCC(=O)NCC(=O)NC(c1cccnc1)CC(=O)O,CBR-HVAC-11074: Inhibitors of Blood Coagulation Pathways;Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists;Integrin alphavbeta3 (Vitronectin) Antagonists;Signal Transduction Modulators
CBR-001-635-150-1,RFM-010-694-5,CBR-001-635-150-1,OC(=O)CCNC(=O)[C@@H](N[C@H](C(=O)O)Cc1ccccc1)Cc1ccccc1,"CBR-HVAC-04149: Membrane metallo endopeptidase inhibitor; Membrane metalloendopeptidase Inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Antihypertensive; Opioid Analgesics"
CBR-001-635-151-2,RFM-010-695-6,CBR-001-635-151-2,CCOC(=O)C[C@@H](C(=O)COC(=O)c1c(Cl)cccc1Cl)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)OCc1ccccc1)C,CBR-HVAC-10745: Caspase 1 (IL-1beta Converting Enzyme) Inhibitors; Interleukin 1beta converting enzyme inhibitor; Interleukin-1 beta-converting enzyme Inhibitor; Signal Transduction Modulators; Analgesic; Anti-inflammatory; Antipyretic
CBR-001-635-152-3,RFM-010-696-7,CBR-001-635-152-3,OC(=O)C[C@@H](c1ccccc1CCCCCCCCc1ccccc1)SCCC(=O)O,CBR-HVAC-03836: Leukotriene Antagonists; Leukotriene D4 receptor Antagonist; Signal Transduction Modulators; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Immunosuppressant
CBR-001-635-153-4,RFM-010-697-8,CBR-001-635-153-4,OC(=O)C[C@H](c1ccccc1CCCCCCCCc1ccccc1)SCCC(=O)O,CBR-HVAC-03836: Leukotriene Antagonists; Leukotriene D4 receptor Antagonist; Signal Transduction Modulators; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Immunosuppressant
CBR-001-635-154-5,RFM-010-698-9,CBR-001-635-154-5,CC(C[C@@H]1NC(=O)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC1=O)Cc1cnc2c1cccc2)CC(=O)O)CC(=O)N1CCN(CC1)c1ccccc1)c1cccs1)C,"CBR-HVAC-04558: Endothelin A receptor; Endothelin B receptor Antagonist; Endothelin ETA Receptor Antagonists; Endothelin ETB Receptor Antagonists; Signal Transduction Modulators; Antihypertensive; Neuroprotectant; Renal Failure, Agents for"
CBR-001-635-155-6,RFM-010-699-0,CBR-001-635-155-6,Clc1cn(Cc2cc(Cl)ccc2S(=O)(=O)C)c(=N)c(c1)C(=O)N,CBR-HVAC-12586: Alpha-1D adrenergic receptor Antagonist; Signal Transduction Modulators; alpha1D-Adrenoceptor Antagonists; GENITOURINARY AGENT; Urinary Incontinence Therapy
CBR-001-635-156-7,RFM-010-700-6,CBR-001-635-156-7,CC(=CCN1Cc2c(Cl)ccc3c2n(C[C@@H]1C)c(=S)[nH]3)C,CBR-HVAC-04328: Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Anti-HIV Agents; Antiviral
CBR-001-635-157-8,RFM-010-701-7,CBR-001-635-157-8,O[C@H]1CCCC[C@@H]1N1CCC(CC1)(N(C)C)C(=O)Nc1c(C)cccc1C,CBR-HVAC-03227: Sodium channel Blocker; Sodium channel antagonist; Antiarrhythmic; Antiarrhythmic Drugs
CBR-001-635-158-9,RFM-010-702-8,CBR-001-635-158-9,O[C@H]1CCCC[C@@H]1N1CCC(CC1)(N(C)C)C(=O)Nc1c(C)cccc1C,CBR-HVAC-03227: Sodium channel Blocker; Sodium channel antagonist; Antiarrhythmic; Antiarrhythmic Drugs
CBR-001-635-159-0,RFM-010-703-9,CBR-001-635-159-0,CC1CCCC(C1CCC([N+](CCCCCC[N+](C(CCC1C(C)CCCC1(C)C)C)(C)C)(C)C)C)(C)C,CBR-HVAC-13485: Antifungal; Antimicrobial; Antiseptic
CBR-001-635-160-3,RFM-010-704-0,CBR-001-635-160-3,CN(c1ncccn1)c1ccc(cc1)/C=C/C[C@@H](C(=O)O)NC(=O)c1c(Cl)cccc1Cl,"CBR-HVAC-12546: Drugs Acting on Integrin alpha4beta7 ; INTEGRIN ALPHA4 BETA1; INTEGRIN ALPHA4 BETA7 Antagonist; Integrin alpha4beta1 (VLA-4) Antagonists; Signal Transduction Modulators; ANTI-INFLAMMATORY; Inflammatory Bowel Disease, Agents for"
CBR-001-635-161-4,RFM-010-705-1,CBR-001-635-161-4,OCCC[C@@]1(C)/C(=N/O)/CC[C@@H]2[C@@H]1CC[C@]1([C@H]2CC[C@@H]1[C@@H](CCCC(C)C)C)C,"CBR-HVAC-06395: Mitochondrial Permeability Transition (MPT) Inhibitors; TSPO Binder; Amyotrophic Lateral Sclerosis, Agents for; CARDIOPROTECTANT; Cardiovascular Diseases (Not Specified); Huntington's Disease, Treatment of; NEUROPROTECTANT; Neurologic Drugs (Miscellaneous); Neuropathic Pain, Treatment of"
CBR-001-635-162-5,RFM-010-706-2,CBR-001-635-162-5,CC(=CCOc1cc(ccc1Cl)NC(=S)c1ccsc1C)C,CBR-HVAC-11035: Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Anti-HIV Agents; Reverse transcriptase inhibitor
CBR-001-635-163-6,RFM-010-707-3,CBR-001-635-163-6,NCCCC[C@@H](C(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)C)Cc1ncnc1)Cc1ncnc1)C)CCCNC(=N)N,CBR-HVAC-06814: Androgen Receptor Antagonists; Signal Transduction Modulators; Breast Cancer Therapy; Endometriosis Therapy; Ovarian Cancer Therapy; Prostate Cancer Therapy
CBR-001-635-164-7,RFM-010-708-4,CBR-001-635-164-7,O=C(c1cccc2c1nc1c(C)cccc1n2)NCCNCCNCCNC(=O)c1cccc2c1nc1c(C)cccc1n2,CBR-HVAC-05159: DNA inhibitor; DNA topoisomerase; DNA-Intercalating Drugs; Estrogen receptor Inhibitor; RNA synthesis inhibitor; Anticancer; Solid Tumors Therapy
CBR-001-635-165-8,RFM-010-709-5,CBR-001-635-165-8,Clc1ccc(s1)c1onc(c1)Cn1c(nc2c1cc(cc2)C(=O)[O-])C(=O)NC1CCN(CC1)C1CC1,CBR-HVAC-14485: regioisomer of CBR-HVAC-12599
CBR-001-635-166-9,RFM-010-710-8,CBR-001-635-166-9,CN1CCN(CC1)CCCn1c(C)ncc1[N+](=O)[O-],CBR-HVAC-07682: DNA inhibitor
CBR-001-635-167-0,RFM-010-711-9,CBR-001-635-167-0,OCC1OC(=O)N(C1)c1ccc(cc1)OCc1cccc(c1)C#N,CBR-HVAC-14435: metabolite of CBR-HVAC-07643
CBR-001-635-168-1,RFM-010-712-0,CBR-001-635-168-1,FCC(Cn1cnc2c1ncnc2N)OCP(=O)(OC(C)C)OC(C)C,CBR-HVAC-14462: analog of CBR-HVAC-10566
CBR-001-635-169-2,RFM-010-713-1,CBR-001-635-169-2,FCC(Cn1cnc2c1ncnc2N)OCP(=O)(OC(C)C)O,CBR-HVAC-14463: analog of CBR-HVAC-10566
CBR-001-635-170-5,RFM-010-714-2,CBR-001-635-170-5,COC(=O)Cn1c(nc2c(c1=O)cc(cc2)OCCCN1CCCCC1)c1cccc(c1)Cl,CBR-HVAC-14466: metabolite of CBR-HVAC-14428
CBR-001-635-171-6,RFM-010-715-3,CBR-001-635-171-6,OC(=O)Cn1c(nc2c(c1=O)cc(cc2)OCCCN1CCCCC1)c1cccc(c1)Cl,CBR-HVAC-14428: metabolite of CBR-HVAC-06773
CBR-001-635-172-7,RFM-010-716-4,CBR-001-635-172-7,CCOC(=O)C[C@H](c1ccccc1CCCCCCCCc1ccccc1)SCCC(=O)OCC,CBR-HVAC-14465: prodrug of CBR-HVAC-03836
CBR-001-635-173-8,RFM-010-717-5,CBR-001-635-173-8,CCOC(=O)C[C@@H](c1ccccc1CCCCCCCCc1ccccc1)SCCC(=O)OCC,CBR-HVAC-14465: prodrug of CBR-HVAC-03836
CBR-001-635-174-9,RFM-010-718-6,CBR-001-635-174-9,OC[C@@H](NC(=O)[C@@H](N(C(=O)CNC(=O)[C@H](NC(=O)[C@H](Cc1ccc(cc1)O)N)C)C)Cc1ccccc1)CCS(=O)C,CBR-HVAC-07825: Opioid growth factor receptor agonist; Opioid receptor agonist
CBR-001-635-175-0,RFM-010-719-7,CBR-001-635-175-0,CC(=O)OCC(OCn1cnc2c1nc(N)nc2)COC(=O)C,CBR-HVAC-14459: metabolite of CBR-HVAC-10923
CBR-001-635-176-1,RFM-010-720-0,CBR-001-635-176-1,CCCc1ccc(c(=O)n1CC(=O)NCc1ccc(nc1)C)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-14461: analog of CBR-HVAC-11961
CBR-001-635-177-2,RFM-010-721-1,CBR-001-635-177-2,OC(=O)C[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)O)CC(C)C)c1cccs1)CC(=O)O)CC(=O)N1CCN(CC1)c1ccccc1)NC(=O)[C@@H](Cc1cnc2c1cccc2)N,CBR-HVAC-14468: metabolite of CBR-HVAC-04558
CBR-001-635-178-3,RFM-010-722-2,CBR-001-635-178-3,Cn1nc(nc1N)NCCCOc1cccc2c1CCC2N1CCCCC1,CBR-HVAC-14464: analog of CBR-HVAC-08268
CBR-001-635-179-4,RFM-010-723-3,CBR-001-635-179-4,NCCCC[C@H](C(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCS(=O)(=O)C)N)CCC(=O)O)Cc1ncnc1)Cc1ccccc1,CBR-HVAC-14469: metabolite of CBR-HVAC-10705
CBR-001-635-180-7,RFM-010-724-4,CBR-001-635-180-7,Fc1ccc(cc1)CC1CCN(CC1)CCS(=O)(=O)c1ccc2c(c1)oc(=O)n2,CBR-HVAC-14436: metabolite of CBR-HVAC-11045
CBR-001-635-181-8,RFM-010-725-5,CBR-001-635-181-8,COc1cc2cccnc2c(c1)N1CCN(CC1)C1CCN(CC1)c1ccc(c2c1nc(cc2OC)C(F)(F)F)F,"CBR-HVAC-14054: Serotonin Antagonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of"
CBR-001-635-256-0,RFM-010-726-6,CBR-001-635-256-0,O=C(Nc1nnc(o1)c1ccco1)NCc1ccccn1,CBR-HVAC-14562: Nrf2 activator
CBR-001-635-276-4,RFM-010-727-7,CBR-001-635-276-4,C=CC1CNCCC1CCCc1ccnc2c1cc(OC)cc2,CBR-HVAC-00943:5 Hydroxytryptamine release stimulant
CBR-001-635-277-5,RFM-010-728-8,CBR-001-635-277-5,O=C1c2cn3c(c2C(=O)c2c1cccc2)Cc1c(C3)cccc1,CBR-HVAC-02536: Antineoplastic; Oncolytic Drugs
CBR-001-635-278-6,RFM-010-729-9,CBR-001-635-278-6,C1CCCN(CC1)C1C2CC3CC1CC(C2)C3,"CBR-HVAC-05505: Monoamine oxidase B inhibitor; NMDA receptor antagonist
"
CBR-001-635-279-7,RFM-010-730-2,CBR-001-635-279-7,C[C@H](NC(Cc1ccccc1)C)COc1ccccc1,CBR-HVAC-09064: Antispasmodic
CBR-001-635-280-0,RFM-010-731-3,CBR-001-635-280-0,OCCN1CCCCC1C(c1ccccc1)c1ccccc1,CBR-HVAC-10109: Anorectic
CBR-001-635-298-0,RFM-010-732-4,CBR-001-635-298-0,Cc1cccc(c1)/C=N/Nc1nc2cc(nn2c(c1)N1CCOCC1)c1ccncc1,"CBR-HVAC-14454: 1-Phosphatidylinositol 3-Phosphate 5-Kinase (PIKfyve) Inhibitors; IL-12 Production Inhibitors; Phosphatidylinositol 3-phosphate 5-kinase inhibitor; Signal Transduction Modulators; Antipsoriatics; Inflammatory Bowel Disease, Agents for; Multiple Sclerosis, Agents for; Rheumatoid Arthritis, Treatment of; Sepsis, Treatment of; Type 1 Diabetes, Agents for;2017-11-14: ARB# 16-000757;2017-11-14: ARB# 16-000757"
CBR-001-635-302-9,RFM-010-733-5,CBR-001-635-302-9,OC(=O)CNC(=O)c1nc(Cl)c2c(c1O)cccc2,CBR-HVAC-12233: HIF-prolyl hydroxylase Inhibitor; Hydroxylase inhibitor; Erythropoietin release stimulator; Cytokine modulator; Anemia
CBR-001-635-303-0,RFM-010-734-6,CBR-001-635-303-0,Clc1ncc(c(n1)NCc1ccc(cc1)CNc1ccnc(n1)NCCN1CCOCC1)F,CBR-HVAC-12229: Angiogenesis Inhibitors;Chemokine CXCR4 (SDF-1 Receptor) Antagonists;Signal Transduction Modulators
CBR-001-635-304-1,RFM-010-735-7,CBR-001-635-304-1,Oc1ccc(cc1)CC1NCCc2c1cc(O)c(c2)O,"CBR-HVAC-12228: Signal Transduction Modulators; beta-Adrenoceptor Agonists; Anti-HIV Agents; Bronchodilators; Cardiovascular Diseases (Not Specified); Stroke, Treatment of; Treatment of Erectile Dysfunction"
CBR-001-635-305-2,RFM-010-736-8,CBR-001-635-305-2,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCc1ccncc1,CBR-HVAC-12223: CANNABINOID RECEPTOR 2 Agonist; Cannabinoid CB2 Agonists; Signal Transduction Modulators; ANALGESIC; Non-Opioid Analgesics
CBR-001-635-306-3,RFM-010-737-9,CBR-001-635-306-3,OC[C@H]1NC[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-12217: Alpha glucosidase stimulant; Alpha-glucosidase Modulator; Pharmacological Chaperones; alpha-Glucosidase Inhibitors; AIDS Medicines; Alpha-glucosidase modulator; Therapy of Inborn Errors of Metabolism
CBR-001-635-307-4,RFM-010-738-0,CBR-001-635-307-4,C[C@H]1COC2(O1)CCN(CC2)c1nc(=O)c2c(s1)c(cc(c2)C(F)(F)F)[N+](=O)[O-],CBR-HVAC-12216: Decaprenylphosphoryl-beta-d-ribose oxidase inhibitor; FAD-Dependent Decaprenylphosphoryl-Beta-D-Ribofuranose 2-Oxidase (DprE1) (M.tuberculosis) Inhibitors; ANTIBACTERIALANTITUBERCULAR AGENT; Treatment of Tuberculosis
CBR-001-635-308-5,RFM-010-739-1,CBR-001-635-308-5,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1ccc2c1ncnc2N,CBR-HVAC-12205: ; Antibacterial; Tuberculosis
CBR-001-635-309-6,RFM-010-740-4,CBR-001-635-309-6,Oc1cc2O[C@@H](c3ccc(c(c3)O)O)[C@@H](C(=O)c2c(c1)O)O,"CBR-HVAC-05491: Antioxidants; ApoB Secretion Inhibitors; Cholesterol Biosynthesis Inhibitors; HMG-CoA Reductase Inhibitors; NF-kappaB (NFKB) Modulators; Reverse Transcriptase Inhibitors; Signal Transduction Modulators; beta-Amyloid (Abeta) Aggregation Inhibitors; Alzheimer's Dementia, Treatment of ; Analgesic; Anti-HIV Agents; Anti-Hepatitis A Virus Drugs; Anti-inflammatory; Antirheumatic; Atherosclerosis Therapy; Ischemic Stroke, Treatment of; Lipoprotein Disorders, Treatment of"
CBR-001-635-310-9,RFM-010-741-5,CBR-001-635-310-9,O=C(c1cn(c2c1cc(O)cc2)Cc1ccc(cc1)F)C(=O)Nc1c(Cl)cncc1Cl,"CBR-HVAC-05067: Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor; Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Atopic Dermatitis, Agents for; Bronchodilator; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Drugs for Allergic Rhinitis"
CBR-001-635-311-0,RFM-010-742-6,CBR-001-635-311-0,FC(Oc1c(ccc2c1n(cc(c2=O)C(=O)O)C1CC1)c1ccc2c(c1)CN[C@@H]2C)F,CBR-HVAC-04973: Topoisomerase IV Inhibitor; Antibiotic; GRAM NEGATIVE BACTERIAL DISEASES; GRAM POSITIVE BACTERIAL DISEASES
CBR-001-635-312-1,RFM-010-743-7,CBR-001-635-312-1,CNCCC(c1cccc(c1)F)c1cccc(c1)F,"CBR-HVAC-00167: 5-HT Reuptake Inhibitors; Ionotropic glutamate receptor NMDA Antagonist; NMDA Antagonists; NMDA receptor antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Ischemic Stroke, Treatment of"
CBR-001-635-313-2,RFM-010-744-8,CBR-001-635-313-2,CO[C@@H]1[C@@H](CC[C@@]2([C@H]1[C@]1(C)OC1CC=C(C)C)CO2)OC(=O)/C=C/c1ccc(cc1)OCCN(C)C,"CBR-HVAC-00278: Angiogenesis Inhibitors; Angiogenesis inhibitor; Methionine Aminopeptidase-2 (MetAP2) Inhibitors; Methionine aminopeptidase 2 Inhibitor; Methionine aminopeptidase-2 inhibitor; Anticancer; Antiobesity Drugs; Brain Cancer Therapy; Colorectal Cancer Therapy; Multisystem Genetic Disorders, Treatment of"
CBR-001-635-314-3,RFM-010-745-9,CBR-001-635-314-3,Cc1occc(=O)c1O[Ga+3](Oc1c(=O)ccoc1C)Oc1c(=O)ccoc1C,"CBR-HVAC-00445: Anticancer; Antimitotic Drugs; Antineoplastic; Antiviral; Bone resorption inhibitor; Ribonucleoside triphosphate reductase inhibitor; Ribonucleoside-Diphosphate Reductase Inhibitors; Anti-HIV Agents; Antibacterial Drugs; Anticancer; Antineoplastic; Antiviral; Bladder Cancer Therapy ; Bone Diseases, Treatment of; Lymphoma Therapy; Multiple Myeloma Therapy; Prostate Cancer Therapy; Rheumatoid Arthritis, Treatment of; Treatment of Paget's Disease"
CBR-001-635-315-4,RFM-010-746-0,CBR-001-635-315-4,Br/C=C/c1cn([C@H]2C[C@@H]([C@H](O2)COP(=O)(N[C@H](C(=O)OC)C)Oc2ccccc2)O)c(=O)[nH]c1=O,CBR-HVAC-00470: Antimetabolites; Apoptosis Inducers; DNA inhibitor; Thymidylate Synthase Inhibitors; Thymidylate synthase inhibitor; p21 stimulant; Anticancer; Breast Cancer Therapy; Colorectal Cancer Therapy; Head and Neck Cancer Therapy; Lung Cancer Therapy; Pancreatic Cancer Therapy; Solid Tumors Therapy
CBR-001-635-316-5,RFM-010-747-1,CBR-001-635-316-5,N#Cc1cccc(c1)S(=O)(=O)Nc1ccc(c2c1ncc2C#N)C,CBR-HVAC-00649: Alpha2 integrin antagonist; Angiogenesis Inhibitors; Angiogenesis inhibitor; Integrin Receptor Antagonists; Integrin alpha2 Inhibitor; Signal Transduction Modulators; Anticancer; Colorectal Cancer Therapy; Solid Tumors Therapy
CBR-001-635-317-6,RFM-010-748-2,CBR-001-635-317-6,O=Cc1c(OCCCCC(=O)O)cccc1O,CBR-HVAC-01185: Anticancer; Haemoglobin oxygen release inhibitor; Antianemics; Anticancer
CBR-001-635-318-7,RFM-010-749-3,CBR-001-635-318-7,COc1cc(ccc1c1nc2c(n1)ccnc2)S(=O)C,CBR-HVAC-02966: Calcium sensitizer; Phosphodiesterase 3 Inhibitor; Phosphodiesterase inhibitor; Bronchodilator; Heart Failure Therapy; Inotropic
CBR-001-635-319-8,RFM-010-750-6,CBR-001-635-319-8,CC(NCCCCOc1c(C)nc(c2c1COC2)Cc1ccccc1)C,CBR-HVAC-03189: Antiarrhythmic; Sodium channel antagonist; Antiarrhythmic Drugs; Class Ib antiarrhythmic; Local Anesthetics
CBR-001-635-320-1,RFM-010-751-7,CBR-001-635-320-1,CC1=C(Cc2cccnc2)C(=O)C(=C(C1=O)C)C,"CBR-HVAC-03674: 5 Lipoxygenase inhibitor; 5-Lipoxygenase Inhibitors; Free Radical Scavengers; Lipoxygenase 5 Inhibitor; Oxygen scavenger; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Anti-inflammatory; Antiallergic; Antineoplastic; Nephritis, Agents for; Oncolytic Drugs"
CBR-001-635-321-2,RFM-010-752-8,CBR-001-635-321-2,CN1C=CCC(=C1)C(=O)O[C@@H]1CC[C@@H]2[C@@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(c2)O,"CBR-HVAC-03709: Alzheimer's Dementia, Treatment of ; Contraceptives; Treatment of Male Sexual Dysfunction; Treatment of Postmenopausal Syndrome"
CBR-001-635-322-3,RFM-010-753-9,CBR-001-635-322-3,C1CCN(CC1)CCOc1ccc2c(c1)nc1c(c2)ccc(c1)OCCN1CCCCC1,CBR-HVAC-04049: Immunostimulant; Interferon inducer; Interferon receptor agonist; Anticancer; Antiviral; Immunosuppressant; Immunosuppressants
CBR-001-635-323-4,RFM-010-754-0,CBR-001-635-323-4,ClCCN(c1ccc(cc1)C(=O)O)CCOS(=O)(=O)C,CBR-HVAC-04264: Oncolytic Drugs
CBR-001-635-324-5,RFM-010-755-1,CBR-001-635-324-5,CC([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@H](N(C)C)C(C)C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCc1ccccc1)C,CBR-HVAC-04696: Antimitotic Drugs; Microtubule inhibitor; Tubulin Polymerization Inhibitors; Tubulin inhibitor; Breast Cancer Therapy; Oncolytic Drugs
CBR-001-635-325-6,RFM-010-756-2,CBR-001-635-325-6,OC(=O)[C@@H](Nc1ccccc1C(=O)c1ccccc1)Cc1ccc(cc1)OCCc1nc(oc1C)c1ccccc1,"CBR-HVAC-04982: Insulin Sensitizers; Insulin sensitizer; Modulator; PPARgamma Agonists; Peroxisome proliferator activated receptor gamma Agonist; Peroxisome proliferator-activated receptor gamma agonist; Signal Transduction Modulators; Agents for Liver Fibrosis; Antidiabetic; Type 2 Diabetes, Agents for"
CBR-001-635-326-7,RFM-010-757-3,CBR-001-635-326-7,CCCCCNC(=S)Nc1ccc(cc1)NC(=N)C,"CBR-HVAC-05771: Autophagy Inducers; Inducible nitric oxide synthase; Inducible nitric oxide synthase inhibitor; Matrix metalloprotease Inhibitor; Matrix metalloproteinase inhibitor; NOS2 Expression Inhibitors; Anti-inflammatory; Disorders Associated with Cancer Therapy, Treatment of; Inflammatory Bowel Disease, Agents for; Oncolytic Drugs; Treatment of Mucositis"
CBR-001-635-327-8,RFM-010-758-4,CBR-001-635-327-8,OC(CN1CCC(CC1)COc1ccccc1)COc1cccc2c1ccn2,CBR-HVAC-05788 : beta-Adrenoceptor Antagonists;Signal Transduction Modulators
CBR-001-635-328-9,RFM-010-759-5,CBR-001-635-328-9,COc1cc2CCN(CCc2cc1NS(=O)(=O)c1ccc(cc1)c1ccc(s1)Cl)C,CBR-HVAC-06467: 5-HT2A Antagonists; 5-HT2C Antagonists; 5-HT6 Antagonists; Dopamine D2 Antagonists; Dopamine D3 Antagonists; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-635-329-0,RFM-010-760-8,CBR-001-635-329-0,N#Cc1cc(cc(c1)Cl)Oc1c(Cl)ccc2c1cnn2Cc1nnc2c1cccn2,CBR-HVAC-06965: Anti-HIV Agents
CBR-001-635-330-3,RFM-010-761-9,CBR-001-635-330-3,Fc1cc(F)c(c(c1)F)OCc1ccccc1C1CCNCC1,"CBR-HVAC-07029: 5-HT Reuptake Inhibitors; Norepinephrine Reuptake Inhibitors; Serotonin and norepinephrine reuptake inhibitor; Signal Transduction Modulators; Analgesic Drugs; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Fibromyalgia, Treatment of"
CBR-001-635-331-4,RFM-010-762-0,CBR-001-635-331-4,CN(CCSC(=O)N1c2ccccc2C(c2c1cccc2)(C)C)C,CBR-HVAC-07554: Dopamine receptor agonist
CBR-001-635-332-5,RFM-010-763-1,CBR-001-635-332-5,COc1ccc2c(c1)c(=O)n(c(c2)c1ccc(cc1)OCC(CNC(C)(C)C)O)C,CBR-HVAC-07759: Beta 1 adrenoreceptor antagonist
CBR-001-635-333-6,RFM-010-764-2,CBR-001-635-333-6,COc1cc(ccc1OCCCCOc1ccc2c(c1)onc2N)C(=O)N(C(C)C)C(C)C,CBR-HVAC-07767: Bone formation stimulant; Bone resorption inhibitor; Leucotriene B4 antagonist; Leukotriene B4 receptor Antagonist; Bone resorption inhibitor; Osteoclast modulator
CBR-001-635-334-7,RFM-010-765-3,CBR-001-635-334-7,N#CCC1(CN(C1)C1CCN(CC1)C(=O)c1ccnc(c1F)C(F)(F)F)n1ncc(c1)c1ncnc2c1cc[nH]2,"CBR-HVAC-07921: Jak1 Inhibitors; Janus kinase 1 inhibitor; Signal Transduction Modulators; Antipruritics; Antipsoriatics; Hematopoiesis Disorders Therapy; Immunosuppressants; Lymphoma Therapy; Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Pancreatic Cancer Therapy; Rheumatoid Arthritis, Treatment of; Solid Tumors Therapy"
CBR-001-635-335-8,RFM-010-766-4,CBR-001-635-335-8,O=C1NC2=Nc3c(CN2C1)cc(cc3)OCCCC(=O)N(C1CCCCC1)C,CBR-HVAC-07991: Phosphodiesterase 4 inhibitor
CBR-001-635-336-9,RFM-010-767-5,CBR-001-635-336-9,CCOC(=O)C1=C(Cn2cncc2)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC)C,"CBR-HVAC-08529: Calcium Channel Blockers; Calcium channel antagonist; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Antiplatelet Therapy; Hypertension, Treatment of"
CBR-001-635-337-0,RFM-010-768-6,CBR-001-635-337-0,O=C1N=C(OC1c1ccccc1)NC1CC1,CBR-HVAC-09089: Antitussive
CBR-001-635-338-1,RFM-010-769-7,CBR-001-635-338-1,CC(Cn1nc(c(c1CC(=O)O)c1ccccc1)c1ccccc1)C,CBR-HVAC-09130: Prostaglandin synthetase inhibitor; Analgesic; Anti-inflammatory; Antipyretic
CBR-001-635-339-2,RFM-010-770-0,CBR-001-635-339-2,C#CC(c1ccccc1)(c1ccccc1)OC(=O)NC1CCCCC1,CBR-HVAC-09156: Antineoplastic
CBR-001-635-340-5,RFM-010-771-1,CBR-001-635-340-5,O=C(COc1nn(c2c1cccc2)Cc1ccccc1)OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-09413: SKIN PROTECTANT
CBR-001-635-341-6,RFM-010-772-2,CBR-001-635-341-6,CCC(C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)Sc1ccccc1,CBR-HVAC-10642: Acetylcholine release stimulator; Analgesic
CBR-001-635-342-7,RFM-010-773-3,CBR-001-635-342-7,CCC(C(=O)O[C@@H]1C[C@H]2CC[C@@H](C1)N2C)Sc1ccccc1,CBR-HVAC-10642: Acetylcholine release stimulator; Analgesic
CBR-001-635-343-8,RFM-010-774-4,CBR-001-635-343-8,CC(Cn1c(=O)cc(c2c1cccc2)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C)C,"CBR-HVAC-10674: 5 Hydroxytryptamine 3 receptor antagonist; 5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; 5-hydroxytryptamine 3 receptor antagonist; Irritable Bowel Syndrome, Agents for; Nausea and Vomiting, Treatment of"
CBR-001-635-344-9,RFM-010-775-5,CBR-001-635-344-9,CC(Cn1c(=O)cc(c2c1cccc2)C(=O)O[C@@H]1C[C@H]2CC[C@@H](C1)N2C)C,"CBR-HVAC-10674: 5 Hydroxytryptamine 3 receptor antagonist; 5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; 5-hydroxytryptamine 3 receptor antagonist; Irritable Bowel Syndrome, Agents for; Nausea and Vomiting, Treatment of"
CBR-001-635-345-0,RFM-010-776-6,CBR-001-635-345-0,COc1cc(ccc(c1=O)CN1CCCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F)C(C)C,"CBR-HVAC-10961: Calcium Channel Blockers; Calcium channel Blocker; Lipid Peroxidation Inhibitors; Antioxidant; Neuroprotectant; Stroke, Treatment of"
CBR-001-635-346-1,RFM-010-777-7,CBR-001-635-346-1,CN(CCC(c1cccs1)Sc1cccc2c1cccc2)C,CBR-HVAC-11077: 5-Hydroxytryptamine transporter Inhibitor; Antidepressant; Antidepressants
CBR-001-635-347-2,RFM-010-778-8,CBR-001-635-347-2,COC(=O)C12C(C=CC(N2N=C(C1O)C(=O)Cc1ccccn1)c1ccccc1)c1ccccc1,"CBR-HVAC-11331: Antioxidant; Antioxidants; Angina pectoris, Treatment of; Antianginal; Cardioprotectant; Cardioprotectants; Heart Failure Therapy"
CBR-001-635-348-3,RFM-010-779-9,CBR-001-635-348-3,CN(Cc1ccc(o1)CSCCNc1nnccc1[N+](=O)[O-])C,"CBR-HVAC-11580: Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Antagonist; Inhibitor; Muscarinic M2 Antagonists; Muscarinic acetylcholine receptor M2; Signal Transduction Modulators; Anti-cognitive; Cognition Disorders, Treatment of"
CBR-001-635-349-4,RFM-010-780-2,CBR-001-635-349-4,CCOC(=O)[C@@H](NC(=O)C1(CCCC1)NC(=O)[C@H](C(C)C)SC(=O)C)Cc1ccc(cc1)OC,"CBR-HVAC-11689: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Membrane metallo endopeptidase inhibitor; Membrane metalloendopeptidase Inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Antihypertensive; Heart Failure Therapy; Hypertension, Treatment of; Renal Failure, Agents for"
CBR-001-635-350-7,RFM-010-781-3,CBR-001-635-350-7,Fc1ccc2c(c1)c(cc(n2)c1ccc(cc1)CN1CCOCC1)C(=O)NCCN1CCCC1,CBR-HVAC-14333: Elongation Factor 2 (EF-2) Inhibitors; Signal Transduction Modulators; Antimalarials
CBR-001-635-351-8,RFM-010-782-4,CBR-001-635-351-8,CN(Cc1ccc2c(n1)c(O)c(cc2Cl)Cl)C,"CBR-HVAC-14338: Antiamyloidogenic Agents; Chelating Agents; Alzheimer's Dementia, Treatment of ; Huntington's Disease, Treatment of"
CBR-001-635-352-9,RFM-010-783-5,CBR-001-635-352-9,O=C1CCC(C(=O)N1)n1c(C)nc2c(c1=O)c(N)ccc2,CBR-HVAC-14341: Cereblon (CRBN) Inhibitors; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Lymphocytic Leukemia Therapy; Multiple Myeloma Therapy; Non-Hodgkin's Lymphoma Therapy; Solid Tumors Therapy
CBR-001-635-353-0,RFM-010-784-6,CBR-001-635-353-0,O=C(c1ccc(cn1)C(=O)O)N[C@H](c1ncccc1F)c1ccc(c(c1)F)OC(F)(F)F,CBR-HVAC-14349: TRPM8 (TRP-p8; CMR1) Antagonists; Antimigraine Drugs
CBR-001-635-354-1,RFM-010-785-7,CBR-001-635-354-1,NS(=O)(=O)c1cncc(c1)c1nc(NCc2ccccn2)c2c(n1)cccc2c1ccccc1,CBR-HVAC-14355: K(V) 1.5 (KCNA5) Channel Blockers; Antiarrhythmic Drugs
CBR-001-635-355-2,RFM-010-786-8,CBR-001-635-355-2,c1nc(NC2=NCC3(O2)CN2CC[C@H]3CC2)cc(n1)n1cncc1,CBR-HVAC-14357: Nicotinic alpha7 Partial Agonists; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-635-356-3,RFM-010-787-9,CBR-001-635-356-3,c1nc(NC2=NCC3(O2)CN2CCC3CC2)cc(n1)n1cncc1,CBR-HVAC-14357: Nicotinic alpha7 Partial Agonists; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-635-357-4,RFM-010-788-0,CBR-001-635-357-4,Clc1nccc(c1)N1CCN(C1=O)c1cnccc1C,CBR-HVAC-14361: Cytochrome P450 11B2 (Aldosterone Synthase) Inhibitors; Cytochrome P450 CYP17 A1 (17alpha-Hydroxylase/C17-20 Lyase) Inhibitors; Prostate Cancer Therapy
CBR-001-635-358-5,RFM-010-789-1,CBR-001-635-358-5,Fc1cnc(nc1)N1CCN(CC1)c1ccc(cc1)NC(=O)C(=O)c1n(C)c(cc1c1ccccc1)C,CBR-HVAC-14365: Dihydroorotate Dehydrogenase (DHODH) Inhibitors; Antifungal Agents
CBR-001-635-359-6,RFM-010-790-4,CBR-001-635-359-6,OC(=O)CCCn1c2c(C#Cc3ccc(cc3)OCCCCc3cccc(c3C)F)ccc(c2c(c1C)CCCC(=O)O)F,CBR-HVAC-14368: Leukotriene CysLT1 (LTD4) Antagonists; Leukotriene CysLT2  (LTC4) Antagonists; Signal Transduction Modulators; Asthma Therapy
CBR-001-635-360-9,RFM-010-791-5,CBR-001-635-360-9,COC(=O)NC(C(=O)N1[C@@H]2CCCC[C@@H]2C[C@@H]1c1nc2c(n1)cc(cc2)c1cc2CCc3ccc(CCc1cc2)cc3c1ccc2c(c1)nc(n2)[C@H]1C[C@@H]2[C@H](N1C(=O)C(C(C)C)NC(=O)OC)CCCC2)C(C)C,CBR-HVAC-14372: HCV NS5A Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-635-361-0,RFM-010-792-6,CBR-001-635-361-0,CCNCc1nc2c(O)c(Cl)cc(c2c(=O)n1C)Cl,CBR-HVAC-14373: Antiparkinsonian Drugs
CBR-001-635-362-1,RFM-010-793-7,CBR-001-635-362-1,O=C1O[C@H]([C@H](N1)C(=O)N[C@H](C(=O)N1CCC[C@H]1C)Cc1cscn1)C,"CBR-HVAC-14376: Antiparkinsonian Drugs; Cognition Disorders, Treatment of; Neurologic Drugs (Miscellaneous)"
CBR-001-635-363-2,RFM-010-794-8,CBR-001-635-363-2,COc1nc(NCCc2ccc(cc2Cl)Cl)cc(n1)c1cccc(c1)C(C(=O)O)(C)C,CBR-HVAC-14378: Prostanoid DP (DP1) Antagonists; Signal Transduction Modulators; Asthma Therapy; Drugs for Allergic Rhinitis
CBR-001-635-364-3,RFM-010-795-9,CBR-001-635-364-3,N[C@H]1CCCC[C@H]1Nc1nc(c2cnn(c2)C)c2c(c1F)CNC2=O,CBR-HVAC-14379: Signal Transduction Modulators; Syk Kinase Inhibitors; Lymphoma Therapy; Myeloid Leukemia Therapy; Solid Tumors Therapy
CBR-001-635-365-4,RFM-010-796-0,CBR-001-635-365-4,CC(OC(=O)[C@@H](N[P@@](=S)(Oc1ccccc1)OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)O)n1ccc(=O)[nH]c1=O)C)C,CBR-HVAC-14386: RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-635-366-5,RFM-010-797-1,CBR-001-635-366-5,CC(OC(=O)[C@@H](N[P@@](=S)(Oc1ccccc1)OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)O)n1ccc(=O)[nH]c1=O)C)C,CBR-HVAC-14386: RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-635-367-6,RFM-010-798-2,CBR-001-635-367-6,CCNCc1nc2c(o1)c(Cl)cc(c2C(=O)NC)Cl,CBR-HVAC-14501 : byproduct of PBT-434
CBR-001-635-368-7,RFM-010-799-3,CBR-001-635-368-7,CNCC(c1cccc(c1)C(F)(F)F)OCC,analog of CBR-HVAC-12809
CBR-001-635-369-8,RFM-010-800-9,CBR-001-635-369-8,CNCCCCNCC1CC1C,analog of CBR-HVAC-13230
CBR-001-635-370-1,RFM-010-801-0,CBR-001-635-370-1,O=C(c1ccc(cc1)OCc1ccccc1)CCC(=O)O,analog of CBR-HVAC-13767
CBR-001-635-371-2,RFM-010-802-1,CBR-001-635-371-2,CC(CCC[C@H]([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CC[C@@H](C2)OS(=O)(=O)O)C)C,analog of CBR-HVAC-13985
CBR-001-635-372-3,RFM-010-803-2,CBR-001-635-372-3,NC(=O)CNC1Cc2c(C1)cccc2,"CBR-HVAC-00370: Inhibitor; Ionotropic glutamate receptor NMDA Antagonist; MAO-A Inhibitors; Monoamine oxidase A inhibitor; Monoamine oxidase B inhibitor; NMDA Antagonists; NMDA receptor antagonist; Signal Transduction Modulators; Analgesic; Anticonvulsant; Antiepileptic Drugs; Antiparkinsonian; Diabetic Neuropathy, Agents for; Neuropathic Pain, Treatment of; Neuroprotectant; Nootropic; Respiratory Disorders (Not Specified)"
CBR-001-635-373-4,RFM-010-804-3,CBR-001-635-373-4,CN(CCC(P(=O)(O)O)(P(=O)(O)O)O)C,CBR-HVAC-00462: Bisphosphonate; Bone metabolism modulator; Bone resorption inhibitor; Osteoclast inhibitor; Bone Resorption Inhibitors; Bone metabolism modulator; Treatment of Paget's Disease
CBR-001-635-374-5,RFM-010-805-4,CBR-001-635-374-5,CCOc1cc(ccc1OCC)c1scc(n1)c1cccc(n1)C(=O)O,"CBR-HVAC-00871: Antioxidants; PHOSPHODIESTERASE 4 Inhibitor; Phosphodiesterase 4 inhibitor; Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Anti-inflammatory; Asthma Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Inflammatory Bowel Disease, Agents for; Vasoprotectant"
CBR-001-635-375-6,RFM-010-806-5,CBR-001-635-375-6,O=NN(C[C@@H](C(=O)O)N)O,CBR-HVAC-00915: Adenylosuccinate synthetase inhibitor; DNA synthesis inhibitor; ANTIBIOTIC; ANTICANCER; ANTIMETABOLITE; ANTINEOPLASTIC; Brain Cancer Therapy; Non-Small Cell Lung Cancer Therapy
CBR-001-635-376-7,RFM-010-807-6,CBR-001-635-376-7,CC(c1ccc(cc1)C1CCCCC1)C(=O)O,CBR-HVAC-00976: Cyclooxygenase inhibitor; Platelet aggregation inhibitor; Prostaglandin synthase inhibitor; Anti-inflammatory
CBR-001-635-377-8,RFM-010-808-7,CBR-001-635-377-8,CC(NS(=O)(=O)CCN1C(=O)c2c(C1=O)cccc2)C,CBR-HVAC-01012: GABA receptor agonist; Anticonvulsant; Antiepileptic
CBR-001-635-378-9,RFM-010-809-8,CBR-001-635-378-9,CN(c1ccc(nn1)NN)CC(O)C,CBR-HVAC-01017: Calcium channel antagonist; Nitric oxide stimulant; Antihypertensive; Vasodilators
CBR-001-635-379-0,RFM-010-810-1,CBR-001-635-379-0,N#CC(c1ccc(cc1Cl)n1ncc(=O)[nH]c1=O)c1ccc(cc1)Cl,CBR-HVAC-01099: Membrane integrity inhibitor; Membrane permeability enhancer; Anticoccidial
CBR-001-635-380-3,RFM-010-811-2,CBR-001-635-380-3,NC(=O)N/N=C\1/C=C2C(O)CN(C2=CC1=O)C(C)C,CBR-HVAC-01536: 5 Hydroxytryptamine receptor antagonist; 5-Hydroxytryptamine receptor Antagonist; Prostaglandin synthase inhibitor; Antimigraine
CBR-001-635-381-4,RFM-010-812-3,CBR-001-635-381-4,CCCCOCC(COc1ccccc1)O,CBR-HVAC-01659: Antiemetic; Cholesterol inhibitor; Antiemetic; Cholagogues
CBR-001-635-382-5,RFM-010-813-4,CBR-001-635-382-5,Clc1ccc(cc1)SC(P(=O)(O)O)P(=O)(O)O,"CBR-HVAC-01982: Bisphosphonate; Bone resorption inhibitor; Hypocalcaemic agent; Osteoclast inhibitor; Protein tyrosine phosphatase Inhibitor; Bone growth regulator; Ear disorders, treatment of; Treatment of Paget's Disease"
CBR-001-635-383-6,RFM-010-814-5,CBR-001-635-383-6,O[C@H](COc1cccc2c1CCCC2=O)CNC(C)(C)C,"CBR-HVAC-02224: Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Antiarrhythmic Drugs; Antiglaucoma; Hypertension, Treatment of"
CBR-001-635-384-7,RFM-010-815-6,CBR-001-635-384-7,NCC[C@@H](C(=O)N[C@@H]1C[C@H](N)[C@H]([C@@H]([C@H]1O[C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)N)O)O)O[C@H]1O[C@H](CN)CC[C@H]1N)O,"CBR-HVAC-02396: 16S Ribosomal Protein Inhibitors; 30S Ribosomal Protein Inhibitors; Interferes with polypeptide synthesis, causes codon misreading, and inhibits translocation of N-acetylphenylalanyl-RNA from the acceptor site to the donor site on ribosomes; Protein 30S ribosomal subunit inhibitor; Antibacterial; Antibiotics"
CBR-001-635-385-8,RFM-010-816-7,CBR-001-635-385-8,CCn1c(CC)nn(c1=O)CCCN1CCN(CC1)c1cccc(c1)Cl,CBR-HVAC-02657: 5 Hydroxytryptamine 2 receptor antagonist; 5-Hydroxytryptamine 1A receptor Inhibitor; Alpha adrenoreceptor antagonist; Antidepressant; Antidepressants
CBR-001-635-386-9,RFM-010-817-8,CBR-001-635-386-9,CN(Cc1cc(F)ccc1Sc1cccc(c1)O)C,CBR-HVAC-02746: 5 Hydroxytryptamine uptake inhibitor; 5-Hydroxytryptamine transporter Inhibitor; Antidepressant; Antidepressants
CBR-001-635-387-0,RFM-010-818-9,CBR-001-635-387-0,Cc1ccc(cc1)C(=O)Oc1cc(ccc1OC(=O)c1ccc(cc1)C)C(CNC(C)(C)C)O,CBR-HVAC-02818: Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Bronchodilator; Bronchodilators
CBR-001-635-388-1,RFM-010-819-0,CBR-001-635-388-1,Nc1[nH]c(=O)c2c(c1)[nH]cn2,"CBR-HVAC-02893: Antimetabolites; DNA SYNTHESIS INHIBITOR; Indoleamine 2,3-dioxygenase Inhibitors; PROTEIN SYNTHESIS INHIBITOR; Tryptophan 2,3-Dioxygenase Inhibitors; Anticancer; Antiviral Drugs; Oncolytic Drugs"
CBR-001-635-389-2,RFM-010-820-3,CBR-001-635-389-2,NC(=O)C[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)CCCNC(=N)N)N,"CBR-HVAC-03384: Neuroprotectant; Vasopressin agonist; Cognition Disorders, Treatment of; Neuroprotectant"
CBR-001-635-390-5,RFM-010-821-4,CBR-001-635-390-5,CC(Cc1ccc(cc1)CCc1sc2c(c1)C(=NC(c1n2c(C)nn1)C)c1ccccc1Cl)C,CBR-HVAC-03777: Interleukin 5 antagonist; Platelet activating factor antagonist; Platelet activating factor receptor Antagonist; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Anti-inflammatory; Antiallergic; Antiallergy/Antiasthmatic Drugs; Antiasthmaitc; Platelet activating factor antagonist
CBR-001-635-391-6,RFM-010-822-5,CBR-001-635-391-6,N#Cc1ccc(cc1)c1cc(C#N)c(nc1C)O,CBR-HVAC-03862: Phosphodiesterase Inhibitors; Signal Transduction Modulators; Heart Failure Therapy
CBR-001-635-392-7,RFM-010-823-6,CBR-001-635-392-7,CC1N(CC=C)C=CC(=O)C1=O,CBR-HVAC-03961: Antagonists to Metals
CBR-001-635-393-8,RFM-010-824-7,CBR-001-635-393-8,O=c1cc(C)n(nc1N)c1cccc(c1)C(F)(F)F,CBR-HVAC-04120: Benzodiazepine receptor Agonist; Benzodiazepine receptor agonist; Anxiolytic; Anxiolytics
CBR-001-635-394-9,RFM-010-825-8,CBR-001-635-394-9,O=C(N1CCc2c1cccc2)C1CCc2c(C1)ncn2,"CBR-HVAC-04280: 5 Hydroxytryptamine 3 receptor antagonist; 5-HT3 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; Antiemetic; Irritable Bowel Syndrome, Agents for; Nausea and Vomiting, Treatment of"
CBR-001-635-395-0,RFM-010-826-9,CBR-001-635-395-0,OC(=O)COCCN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F,CBR-HVAC-04626: Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist; Signal Transduction Modulators; Antiinflammatory; Drugs for Allergic Rhinitis
CBR-001-635-396-1,RFM-010-827-0,CBR-001-635-396-1,NC(=O)OC[C@@H](c1ccccc1Cl)O,"CBR-HVAC-05226: Sodium Channel  Blockers; Voltage-gated sodium channel Inhibitor; Acute Attacks of Migraine, Treatment of; Anticonvulsant; Antiepileptic Drugs; Neuropathic Pain, Treatment of; Treatment of Alcohol Dependency"
CBR-001-635-397-2,RFM-010-828-1,CBR-001-635-397-2,COc1ccc(cc1F)c1c(Cl)ncn1c1ccc(cc1)S(=O)(=O)N,"CBR-HVAC-05404: CYCLOOXYGENASE 2 Inhibitor; Cyclooxygenase 2 inhibitor; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors; Signal Transduction Modulators; Analgesic; Antidepressants; Antipsychotic Drugs; Non-Opioid Analgesics; Non-steroidal anti-inflammatory; Osteoarthritis, Treatment of; Rheumatoid Arthritis, Treatment of"
CBR-001-635-398-3,RFM-010-829-2,CBR-001-635-398-3,OC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N)C(C)C)CC(C)C)CCC(=O)N)CC(C)C)CC(C)C)CCCNC(=N)N)CCC(=O)N)CC(C)C)CCCNC(=N)N)C)CCC(=O)O)CCCNC(=N)N)CC(C)C)CCCNC(=N)N)NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@H](NC(=O)[C@H]([C@H](O)C)NC(=O)CNC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ncnc1)N)CO)CC(=O)O)Cc1ccccc1)CO)CCC(=O)O)CC(C)C,"CBR-HVAC-05493: Increases the volume and bicarbonate content of secreted pancreatic juices; Analgesic Drugs; Antipsychotic Drugs; Autism, Treatment of; Diagnostic Agents; Obsessive-Compulsive Disorder (OCD), Treatment of; Pancreatic Disorders, Treatment of; Peptide hormone"
CBR-001-635-399-4,RFM-010-830-5,CBR-001-635-399-4,CC(=O)Oc1c(cccc1C(=O)O)OC(=O)C,"CBR-HVAC-05720: Chelating Agents; Free Radical Scavengers; Free radical scavenger; Anti-inflammatory; Antipyretics; Non-Opioid Analgesics; Respiratory Disorders (Not Specified); Stroke, Treatment of"
CBR-001-635-400-0,RFM-010-831-6,CBR-001-635-400-0,OC[C@H]1O[C@H]([C@]([C@@H]1O)(C)O)n1ccc2c1ncnc2N,CBR-HVAC-05747: RNA polymerase Inhibitor; RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs; Antiviral; Antiviral Drugs
CBR-001-635-401-1,RFM-010-832-7,CBR-001-635-401-1,OC(=O)Cc1ccc2c(c1)c1ccccc1o2,"CBR-HVAC-05854: Inflammation, Treatment of"
CBR-001-635-402-2,RFM-010-833-8,CBR-001-635-402-2,C[C@@H]1NC(=O)[C@@H](NC1=O)CC(=O)O,"CBR-HVAC-06033: Immunomodulator; NF-kappaB (NFKB) Activation Inhibitors; Signal Transduction Modulators; Analgesic Drugs; Inflammation, Treatment of; Multiple Sclerosis, Agents for; NON-STEROIDAL ANTI-INFLAMMATORY; Osteoarthritis, Treatment of; Treatment of Autoimmune Diseases"
CBR-001-635-403-3,RFM-010-834-9,CBR-001-635-403-3,OC(=O)C1NCC(C1)Oc1cccc(c1)Cl,"CBR-HVAC-06079: Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands; Neuropathic Pain, Treatment of"
CBR-001-635-404-4,RFM-010-835-0,CBR-001-635-404-4,O=C(c1ccc(c(c1)NC(=O)c1cnn(c1C)c1ncccc1C(F)(F)F)C)NC1CC1,CBR-HVAC-06775: MAPK14 (MAPK p38 alpha) Inhibitors; P38 ALPHA MITOGEN ACTIVATED PROTEIN KINASE Inhibitor; P38 kinase inhibitor; Signal Transduction Modulators; TNF-alpha Production Inhibitors; ANTI-INFLAMMATORY; Antiarthritic Drugs
CBR-001-635-405-5,RFM-010-836-1,CBR-001-635-405-5,CCc1ccc(cc1)C1CCNCC1,CBR-HVAC-07787: Adrenergic transmitter uptake inhibitor
CBR-001-635-406-6,RFM-010-837-2,CBR-001-635-406-6,OC(c1ccccc1F)CNC(C)(C)C,CBR-HVAC-07829: Beta adrenoreceptor agonist; Beta-2 adrenergic receptor Agonist; Antidepressant; Antidepressants
CBR-001-635-407-7,RFM-010-838-3,CBR-001-635-407-7,N1CCN(CC1)c1cc2ccccc2c(n1)c1ccccc1,CBR-HVAC-08165: Adrenergic transmitter uptake inhibitor
CBR-001-635-408-8,RFM-010-839-4,CBR-001-635-408-8,OC(=O)c1cccnc1Nc1c(C)cccc1C,"CBR-HVAC-08763: Anti-inflammatory, nonsteroidal"
CBR-001-635-409-9,RFM-010-840-7,CBR-001-635-409-9,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1C[C@H]([C@]2(O)C(=O)C)O)C)C,"CBR-HVAC-08769: Anti-inflammatory, steroidal"
CBR-001-635-410-2,RFM-010-841-8,CBR-001-635-410-2,Clc1ccc2c(c1)nccc2Nc1ccc(c(c1)CN1CCCC1)O,CBR-HVAC-08788: Antimalarial
CBR-001-635-411-3,RFM-010-842-9,CBR-001-635-411-3,CC(=CC[C@@H](C1=CC(=O)c2c(C1=O)c(O)ccc2O)O)C,CBR-HVAC-08855: Angiogenesis Inhibitors; Apoptosis Inducers; Drugs Acting on Chemokine Receptors; Signal Transduction Modulators; TNF Expression Inhibitors; Anti-HIV Agents; Antiarthritic Drugs; Antidiabetic Drugs; Astringent; Immunostimulants; Oncolytic Drugs
CBR-001-635-412-4,RFM-010-843-0,CBR-001-635-412-4,Clc1ccc2c(c1)C(=NCC(=S)N2C)c1ccccc1,CBR-HVAC-08860: Anxiolytic
CBR-001-635-413-5,RFM-010-844-1,CBR-001-635-413-5,CCC(N1CCCC1=O)C,"CBR-HVAC-09073: Povidone iodine ointment is used for the treatment or prevention of infection in minor cuts and abrasions, minor surgical procedures and small areas of burns. It is also used for the treatment of fungal and bacterial skin infections and pyodermas and in the treatment of infections in decubitus and stasis ulcers (bedsores and leg ulcers). In the presence of blood, serum, purulent exudate and necrotic (dead) tissue, its action persists while the colour remains; Antiinfective; Antiseptic"
CBR-001-635-414-6,RFM-010-845-2,CBR-001-635-414-6,Clc1ccc(cc1)c1csc(n1)NC(=O)Cn1cnc2c1c(=O)n(C)c(=O)n2C,"CBR-HVAC-09375: TRPA1 Antagonist; TRPA1 Antagonists; ANALGESIC; Neuropathic Pain, Treatment of; Respiratory Disorders (Not Specified)"
CBR-001-635-415-7,RFM-010-846-3,CBR-001-635-415-7,CN(CCOC(c1ccc(cc1)Br)c1ccccc1)C,CBR-HVAC-09550: Histamine H1 receptor Antagonist; Antihistamine
CBR-001-635-416-8,RFM-010-847-4,CBR-001-635-416-8,CCC(c1ccccc1)C(=O)OCCN1CCN(CC1)CCOC(=O)C(c1ccccc1)CC,CBR-HVAC-09886: Local anesthetic
CBR-001-635-417-9,RFM-010-848-5,CBR-001-635-417-9,OCc1ccccc1O[C@@H]1O[C@H](COC(=O)c2ccccc2)[C@H]([C@@H]([C@H]1O)O)O,CBR-HVAC-09896: Analgesic; Antipyretic
CBR-001-635-418-0,RFM-010-849-6,CBR-001-635-418-0,COc1c(CC(=O)c2ccc(c(c2C(=O)O)OC)OC)c(CCN(C)C)cc2c1OCO2,CBR-HVAC-09961: Analgesic; Narcotic
CBR-001-635-419-1,RFM-010-850-9,CBR-001-635-419-1,CNCC(c1cc(OC)c(c(c1)OC)O)O,CBR-HVAC-10170: Alpha adrenergic receptor Agonist; Sympathomimetic
CBR-001-635-420-4,RFM-010-851-0,CBR-001-635-420-4,COc1cc2c(cc1OC)C[C@H]1c3c2c2OCOc2cc3CCN1C,CBR-HVAC-10816: Alpha-1 adrenergic receptor Antagonist; Analgesic Drugs; Antiplatelet Therapy; Antiproliferative; Oncolytic Drugs; Vasorelaxant
CBR-001-635-421-5,RFM-010-852-1,CBR-001-635-421-5,O=C(c1ccccc1Nc1ccnc2c1ccc(c2)C(F)(F)F)OCCN1CCCC1,CBR-HVAC-10936: COX Inhibitor; Antiinflammatory
CBR-001-635-422-6,RFM-010-853-2,CBR-001-635-422-6,CC(C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)O)Cc1ccccc1)Cc1ccccc1)NC(=O)C)C,CBR-HVAC-11841: Beta-amyloid synthesis inhibitor; Anti-Alzheimer's
CBR-001-635-423-7,RFM-010-854-3,CBR-001-635-423-7,OC(=O)[C@@]1(C)[C@H](O)CC[C@]2([C@H]1CC[C@@]1([C@@H]2CC=C2[C@@]1(C)CC[C@@]1([C@H]2CC(CC1)(C)C)C)C)C,"CBR-HVAC-12093: Antiarthritic Drugs; Multiple Sclerosis, Agents for"
CBR-001-635-424-8,RFM-010-855-4,CBR-001-635-424-8,OC(=O)COc1c(F)cc(cc1F)SCCNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-12575: ANTI-PSORIATIC; Antipsoriatics
CBR-001-635-425-9,RFM-010-856-5,CBR-001-635-425-9,OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCNC(=N)N)CC(C)C)Cc1ccc2c(c1)cccc2)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1[nH]cnc1,CBR-HVAC-08072: Luteinizing hormone releasing hormone (LHRH) agonist
CBR-001-635-426-0,RFM-010-857-6,CBR-001-635-426-0,CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)C12CC3CC2CC(C1)C3,"CBR-HVAC-12910: Adenosine A1 Antagonists; Adenosine A1 receptor Antagonist; Signal Transduction Modulators; Antihypertensive; Diuretic; Diuretics; Heart Failure Therapy; Renal Failure, Agents for; Treatment of Renal Diseases"
CBR-001-635-427-1,RFM-010-858-7,CBR-001-635-427-1,CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn(c(=O)n1)[C@@H]1O[C@@H]([C@H]([C@@H]1O)O)CO,CBR-HVAC-12944: DNA repair enzyme inhibitor; DNA synthesis inhibitor; Anticancer; Oncolytic Drugs
CBR-001-635-428-2,RFM-010-859-8,CBR-001-635-428-2,CC(N1CCC(CC1)(c1ccccc1)c1ccccc1)(C)C,CBR-HVAC-12951: Ionotropic glutamate receptor NMDA Antagonist; NMDA Antagonists; NMDA receptor antagonist; Signal Transduction Modulators; Antiparkinsonian; Antiparkinsonian Drugs
CBR-001-635-429-3,RFM-010-860-1,CBR-001-635-429-3,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)CCC(=O)O)CC(C(=O)O)C(=O)O)CC(C(=O)O)C(=O)O)CC(C)C)CCC(=O)N)CC(C(=O)O)C(=O)O)CC(=O)N)CCC(=O)N)CC(C(=O)O)C(=O)O)CC(C)C)CCCNC(=N)N)CC(C(=O)O)C(=O)O,"CBR-HVAC-12956: Ionotropic glutamate receptor NMDA Antagonist; NR2B Antagonists; Signal Transduction Modulators; Antiepileptic Drugs; NMDA receptor antagonist; Neuropathic Pain, Treatment of"
CBR-001-635-430-6,RFM-010-861-2,CBR-001-635-430-6,O[C@@H]1CC(=C(C(C1)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C1=C(C)C[C@H](CC1(C)C)O)\C)\C)/C)/C)C,CBR-HVAC-13173: Antioxidant; Antioxidant
CBR-001-635-431-7,RFM-010-862-3,CBR-001-635-431-7,O=C(C1CSC(N1)c1cccnc1)N1CCN(CC1)CCCc1ccccc1,CBR-HVAC-13188: Platelet activating factor receptor Antagonist; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antiinflammatory
CBR-001-635-432-8,RFM-010-863-4,CBR-001-635-432-8,c1ccc(cc1)CC1=NCCN1,CBR-HVAC-13299: Alpha adrenergic receptor Inhibitor; Vasodilator
CBR-001-635-433-9,RFM-010-864-5,CBR-001-635-433-9,CC(c1ccc(cc1N)[N+](=O)[O-])C,CBR-HVAC-13717: Heat Shock Protein 90 (HSP90) Inhibitors; Solid Tumors Therapy
CBR-001-635-434-0,RFM-010-865-6,CBR-001-635-434-0,CN(CCOCCOC(=O)N1c2ccccc2Sc2c1cccc2)C,CBR-HVAC-09809: Dextromethorphan binding site Inhibitor; Antitussive
CBR-001-635-450-0,RFM-010-866-7,CBR-001-635-450-0,Clc1ccc(cc1)c1cc2c(=O)nc(=S)nc2nc1C(C)(C)C,CBR-HVAC-12556: Antipruritic; Antipruritic; Antipruritics
CBR-001-635-451-1,RFM-010-867-8,CBR-001-635-451-1,F[C@@H]1C[C@@](C1)(c1ccc(cc1)Cl)c1nnc(n1C1CC1)C1CC1,"CBR-HVAC-12566: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; 11-beta-hydroxysteroid dehydrogenase type 1 Inhibitor; Antiobesity; Hypertension, Treatment of; Metabolic Disorders (Not Specified); Type 2 Diabetes, Agents for"
CBR-001-635-452-2,RFM-010-868-9,CBR-001-635-452-2,OC(=O)C1(CCOCC1)CN1CCC(CC1)COc1noc2c1c(ccc2)OCC(F)(F)F,"CBR-HVAC-12407: 5-HT4 Partial Agonists; 5-Hydroxytryptamine 4 receptor Partial agonist; Signal Transduction Modulators; Antiulcer; Gastric Emptying Disorders,Treatment of; Gastrointestinal Disorders (Not Specified); Gastroprokinetic"
CBR-001-635-453-3,RFM-010-869-0,CBR-001-635-453-3,O=C(c1ccc(c(c1)Cl)Cl)Nc1ccc(cc1)C[N+](C1CCOCC1)(C)C,CBR-HVAC-12477: C-C Chemokine receptor type 2 Antagonist; Chemokine CCR2 (MCP-1 Receptor) Antagonists; Signal Transduction Modulators; Anti-inflammatory; Drugs for Allergic Rhinitis
CBR-001-635-454-4,RFM-010-870-3,CBR-001-635-454-4,CCCCCCCC/C(=C\CCCCCCCC(=O)O)/[N+](=O)[O-],CBR-HVAC-13782: Treatment of Renal Diseases
CBR-001-635-455-5,RFM-010-871-4,CBR-001-635-455-5,N=C(Nc1c(Cl)cccc1Cl)NC(=O)N,CBR-HVAC-07525: Beta 2 adrenoreceptor agonist
CBR-001-635-456-6,RFM-010-872-5,CBR-001-635-456-6,Fc1ccc(cc1)Cc1cc(ccc1O)Oc1c(C)cc(cc1C)n1ncc(=O)[nH]c1=O,CBR-HVAC-12467: Thyroid hormone receptor Agonist; Dermatological agent; Hair Growth Stimulants
CBR-001-635-457-7,RFM-010-873-6,CBR-001-635-457-7,CN1CCN(CC1)c1nc(C)nc2c1nc(n2C1CCOCC1)c1ccccc1Cl,CBR-HVAC-12462: Cannabinoid CB2 Agonists; Cannabinoid receptor 2 Agonist; Signal Transduction Modulators; Analgesic Drugs; Anti-inflammatory
CBR-001-635-458-8,RFM-010-874-7,CBR-001-635-458-8,O=C(Nc1ccc(cc1)OCc1cccc(c1)F)CC(=O)N,"CBR-HVAC-12411: MAO-B Inhibitors; Monoamine oxidase B Inhibitor; Alzheimer's Dementia, Treatment of ; Neuroprotectant"
CBR-001-635-459-9,RFM-010-875-8,CBR-001-635-459-9,CCCCCCCCCCCCCCCCCCOP(=O)(OCC[N+]1(C)CCCCC1)[O-],CBR-HVAC-04336: Lipoxygenase inhibitor; Phospholipase A2 inhibitor; Platelet aggregation inhibitor; Oncolytic Drugs
CBR-001-635-460-2,RFM-010-876-9,CBR-001-635-460-2,CCCCCOc1ccnc(c1C)CSc1nc2c(n1)cccc2,CBR-HVAC-13794: Antiulcer Drugs
CBR-001-635-461-3,RFM-010-877-0,CBR-001-635-461-3,O=C(n1c(=O)n(c2c1cccc2)C(C)C)NCC1CCN(CC1)CC1(O)CCOCC1,"CBR-HVAC-12384: 5-HT4 Partial Agonists; 5-Hydroxytryptamine 4 receptor Partial Agonist; Agonist; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Neuroprotectant"
CBR-001-635-462-4,RFM-010-878-1,CBR-001-635-462-4,CSc1ccc(cc1)c1ccc(cc1)S(=O)(=O)N[C@@H](C(=O)O)C(C)C,"CBR-HVAC-12463: Matrix Metalloproteinase Inhibitors; Matrix metalloproteinase inhibitor; Anti-arthritic; Disease-Modifying Anti-Rheumatic Drugs; Osteoarthritis, Treatment of"
CBR-001-635-463-5,RFM-010-879-2,CBR-001-635-463-5,ClCCN(C(=O)NCCS(=O)C)N=O,CBR-HVAC-12752: Alkylating agent; DNA-Damaging Drugs; Anticancer; Oncolytic Drugs
CBR-001-635-464-6,RFM-010-880-5,CBR-001-635-464-6,O=C(c1cc(O)c(c(c1)[N+](=O)[O-])O)Cc1ccccc1,CBR-HVAC-00233: COMT Inhibitors; Catechol O methyltransferase inhibitor; Catechol-O-methyltransferase Inhibitor; Antiparkinsonian; Antiparkinsonian Drugs
CBR-001-635-465-7,RFM-010-881-6,CBR-001-635-465-7,CC(Cc1ccc(cc1)[C@H](C(=O)NS(=O)(=O)C)C)C,"CBR-HVAC-00880: Antagonist; C-X-C chemokine receptor type 1; C-X-C chemokine receptor type 2 Antagonist; CXC chemokine receptor 1 antagonist; CXC chemokine receptor 2 antagonist; Chemokine CXCR1/CXCR2 (IL-8 Receptor) Receptor Antagonists; Chemokine receptor antagonist; Immunosuppressant; Interleukin 8 antagonist; Signal Transduction Modulators; Acute Myocardial Infarction, Treatment of; Acute Respiratory Distress Syndrome (ARDS), Agents for; Antiarthritic Drugs; Breast Cancer Therapy; Immunomodulator; Treatment of Transplant Rejection; Vasoprotectant"
CBR-001-635-466-8,RFM-010-882-7,CBR-001-635-466-8,N#C/C=C(/c1ccc(cc1)OCC(CNCCc1ccc(c(c1)OC)OC)O)\C,CBR-HVAC-01149: Beta 1 adrenoreceptor antagonist; Beta adrenergic receptor blocker; Antianginal; Antiarrhythmic; Antihypertensive
CBR-001-635-467-9,RFM-010-883-8,CBR-001-635-467-9,OCCN(CC(=O)N(c1ccc(cc1C(=O)c1ccccc1Cl)Cl)C)CCO,CBR-HVAC-01236: Benzodiazepine receptor agonist; Anticonvulsant; Antiepileptic Drugs
CBR-001-635-468-0,RFM-010-884-9,CBR-001-635-468-0,O=C(c1ccc(s1)[N+](=O)[O-])N/N=C/C=C/c1ccc(o1)[N+](=O)[O-],CBR-HVAC-02072: DNA inhibitor; It strongly inhibits the adherence capacity of bacteria. It has been shown to inhibit the transfer of plasmids belonging to different compatibility groups; Antibacterial; Antibacterial Drugs
CBR-001-635-469-1,RFM-010-885-0,CBR-001-635-469-1,ONC(=O)C(c1ccc(cc1)CC(C)C)C,"CBR-HVAC-02143: Cyclooxygenase inhibitor; Platelet aggregation inhibitor; Prostaglandin synthase inhibitor; Anti-inflammatory, nonsteroidal"
CBR-001-635-470-4,RFM-010-886-1,CBR-001-635-470-4,C1CCN(CC1)CC1COc2c(O1)cccc2,CBR-HVAC-02451: Alpha 1 adrenoreceptor antagonist; Alpha-2 adrenergic receptor Antagonist; Antihypertensive
CBR-001-635-471-5,RFM-010-887-2,CBR-001-635-471-5,CCCCOC(=O)CC(c1ccccc1)N1CCCCC1,CBR-HVAC-09079: Antispasmodic
CBR-001-635-472-6,RFM-010-888-3,CBR-001-635-472-6,CCN(c1ccc(c(c1)C)NC(=O)c1ccccc1N)CC,CBR-HVAC-09116: Anticonvulsant
CBR-001-635-473-7,RFM-010-889-4,CBR-001-635-473-7,CCCCC1(CN2CCN(CC2)C)C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,CBR-HVAC-09893: Inhibits the increase in the capillary permeability. Decreases the migration of polynuclear of the monohistiomacrophages.Inhibits the exit of the lysosominal enzymes. Opposes the action transmitter substances. Inhibits in a nonspecific way the synthesis of prostaglandins. Stimulates the secretion of ACTH. Enzymatic inductor of the hepatic microsominal enzymes which ensure the biotransformation of the drugs. Actions on the renal tubules being able to increase plasmatic volume up to 50%; Analgesic; Anti-inflammatory; Antipyretic
CBR-001-635-474-8,RFM-010-890-7,CBR-001-635-474-8,CCCCCNCCOC(=O)c1ccc(cc1)N,CBR-HVAC-09939: Local anesthetic
CBR-001-635-475-9,RFM-010-891-8,CBR-001-635-475-9,[O-][N+](=O)O[C@H]([C@H](O[N+](=O)[O-])CO[N+](=O)[O-])CO[N+](=O)[O-],CBR-HVAC-10207: Guanylate cyclase Activator; Antianginal; Vasodilator
CBR-001-635-476-0,RFM-010-892-9,CBR-001-635-476-0,NS(=O)(=O)OC[C@]12OC[C@@H]3[C@H]([C@@H]2OC(O1)(C)C)OS(=O)(=O)O3,CBR-HVAC-10859: Carbonic Anhydrase Type II Inhibitors; Carbonic anhydrase Inhibitor; Anticonvulsant; Antiepileptic; Antiepileptic Drugs; Antiglaucoma Agents; Gastric Antisecretory Drugs
CBR-001-635-477-1,RFM-010-893-0,CBR-001-635-477-1,O=C1NCCCN1CN1CCOCC1,CBR-HVAC-10938: Antiviral; Antiviral; Antiviral Drugs
CBR-001-635-478-2,RFM-010-894-1,CBR-001-635-478-2,O=C(NCc1ccc(cc1C)C(=O)N1CCCCc2c1cccc2)NCC(=O)N(C)C,CBR-HVAC-11791: Vasopressin V2 receptor agonist; Antidiuretic
CBR-001-635-479-3,RFM-010-895-2,CBR-001-635-479-3,O=Cc1c(O)ccc2c1c(O)ccc2,CBR-HVAC-11903: Analgesic; Analgesic
CBR-001-635-480-6,RFM-010-896-3,CBR-001-635-480-6,Cl[Te-]1(Cl)(Cl)OCCO1,"CBR-HVAC-00686: Inflammatory Bowel Disease, Agents for;Immunomodulators;Age-Related Macular Degeneration, Treatment of;Antipsoriatics;Anti-Papilloma Virus Drugs;Chemopreventive Agents;Atopic Dermatitis, Agents for;Hair Growth Stimulants;Anti-Hepatitis C Virus Drugs;Coagulation Disorders Therapy; HCV NS3 Protease Inhibitors; AlphaVbeta3 integrin; Alpha4beta1 integrin; Reverse transcriptase Inhibitor; Antagonist; Antagonist; Alphavbeta3 integrin antagonist; Alpha4beta1 integrin antagonist; Interleukin 17 antagonist; Interleukin 1beta converting enzyme inhibitor; Interleukin 18 antagonist; Interleukin 17 receptor antagonist"
CBR-001-635-481-7,RFM-010-897-4,CBR-001-635-481-7,CN1CCc2c(C1)c1cc(C)ccc1n2CCc1ccccc1,"CBR-HVAC-12358: 5-Hydroxytryptamine receptor 6 Antagonist; Alzheimer's Dementia, Treatment of ; Antidepressant; Anxiolytic; Anxiolytics; Nootropic agent"
CBR-001-635-482-8,RFM-010-898-5,CBR-001-635-482-8,CC[N+](CCN(CC[N+](CC)(C)C)C)(C)C,CBR-HVAC-13223: Antihypertensive; Ganglioplegic
CBR-001-635-483-9,RFM-010-899-6,CBR-001-635-483-9,O=C1CCC(C(=O)N1)N1Cc2c(C1=O)cccc2,CBR-HVAC-13263: AKT Inhibitor; Janus kinase; Phosphoinositide 3 kinase; Signal transducer and activator of transcription; Anticancer
CBR-001-635-484-0,RFM-010-900-2,CBR-001-635-484-0,CCN(Cc1ccc(cc1O)Nc1ccnc2c1ccc(c2)Cl)CC,CBR-HVAC-13264: Antiparasitic; Antimalarials; Antiparasitic
CBR-001-635-485-1,RFM-010-901-3,CBR-001-635-485-1,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(=O)CC,CBR-HVAC-13524: Dopamine receptor Antagonist; Antipsychotic; Tranquilizer
CBR-001-635-486-2,RFM-010-902-4,CBR-001-635-486-2,N#Cc1ccccc1OCC(CNC(Cc1c[nH]c2c1cccc2)(C)C)O,CBR-HVAC-00060: Antagonist; Beta adrenoreceptor antagonist; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor Antagonist; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Antiarrhythmic Drugs; Antihypertensive; Heart Failure Therapy
CBR-001-635-487-3,RFM-010-903-5,CBR-001-635-487-3,N[C@@H]1CC[C@H](CC1)Nc1nc(NCc2cccc(c2)I)c2c(n1)n(cn2)C1CCCC1,CBR-HVAC-13583: Immunosuppressant
CBR-001-635-488-4,RFM-010-904-6,CBR-001-635-488-4,CNCCOC(c1ccccc1C)c1ccccc1,CBR-HVAC-13163: Anticholinergic; Antidepressant
CBR-001-635-500-3,RFM-010-905-7,CBR-001-635-500-3,OC(COc1cccc2c1C(=O)OC2)CNC(C)(C)C,"CBR-HVAC-00934: Beta Adrenergic receptor Antagonist; Beta adrenoreceptor antagonist; ANITHYPERTENSIVE
"
CBR-001-635-501-4,RFM-010-906-8,CBR-001-635-501-4,CSC1SC[C@@H]2N(C)C(=O)[C@H](C)NC(=O)[C@@H](COC(=O)[C@@H](N(C(=O)[C@@H]1N(C)C(=O)[C@H](C)NC(=O)[C@@H](COC(=O)[C@@H](N(C2=O)C)C(C)C)NC(=O)c1cnc2c(n1)cccc2)C)C(C)C)NC(=O)c1cnc2c(n1)cccc2,CBR-HVAC-03378: DNA inhibitor; DNA-Intercalating Drugs; Hypoxia-inducible factor 1 Inhibitor; Anticancer; Antineoplastic Antibiotics; Myeloid Leukemia Therapy
CBR-001-635-502-5,RFM-010-907-9,CBR-001-635-502-5,O=C(NC(=O)c1c(F)cccc1N(C)C)Nc1ccc(cc1)Cl,"CBR-HVAC-03694: Anticancer; DNA synthesis inhibitor; Anticancer; Oncolytic Drugs
"
CBR-001-635-503-6,RFM-010-908-0,CBR-001-635-503-6,F[C@@H]1C[C@@H]2[C@](C1=O)(C)CC[C@H]1[C@H]2CC=C2[C@]1(C)CCCC2,"CBR-HVAC-03729: Anti-inflammatory; Antipsoriatic; Antirheumatic; Antisoriatic; Immunomodulator; NF-kappaB (NFKB) Activation Inhibitors; Protein synthesis stimulant; Signal Transduction Modulators; Actinic Keratoses, Agents for; Anti-inflammatory; Antiarthritic Drugs; Antipsoriatic; Antipsoriatics; Antirheumatic; Antisoriatic; Immunomodulator; Metabolic Disorders (Not Specified); Multiple Sclerosis, Agents for; Oncolytic Drugs; Systemic Lupus Erythematosus, Agents for
"
CBR-001-635-504-7,RFM-010-909-1,CBR-001-635-504-7,OC[C@@H]([C@H]1OC(=O)C(=C1O)OP(=O)(Oc1c(C)c(C)c2c(c1C)CCC(O2)(C)CCCC(CCCC(CCCC(C)C)C)C)[O-])O,"CBR-HVAC-04174: AGE Inhibitors (Maillard's Reaction Inhibitors); Hydroxy radical scavenger; Lipid Peroxidation Inhibitors; Phospholipase A2 Inhibitor; Phospholipase A2 inhibitor; Antioxidant; Neuroprotective; Stroke, Treatment of
"
CBR-001-635-505-8,RFM-010-910-4,CBR-001-635-505-8,CCCn1c(=O)c(CCCOC(=O)NC)nc2c1cccc2,"CBR-HVAC-04246: Mediator Release Inhibitors; Mediator release Inhibitor; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Antiasthmatic
"
CBR-001-635-506-9,RFM-010-911-5,CBR-001-635-506-9,Fc1ccc(cc1)CSSSCc1ccc(cc1)F,"CBR-HVAC-06464: Antimitotic Drugs; Microtubule Inhibitors; Oncolytic Drugs; Solid Tumors Therapy
"
CBR-001-635-507-0,RFM-010-912-6,CBR-001-635-507-0,Clc1ccc(cc1)c1ccc(cc1)C(=O)NCC(n1cncc1)c1ccccc1,"CBR-HVAC-08186: Vitamin D3 hydroxylase inhibitor
"
CBR-001-635-508-1,RFM-010-913-7,CBR-001-635-508-1,O=C1CCCCC1(CCN1CCCCCC1)C(=O)OCc1ccccc1,"CBR-HVAC-09072: Antitussive
"
CBR-001-635-509-2,RFM-010-914-8,CBR-001-635-509-2,O=C(c1ncc2c(c1)cco2)NC1CN2CCC1CC2,"CBR-HVAC-09428: Alpha-7 nicotinic receptor agonist; Nicotinic acetylcholine receptor alpha7 agonist; Nicotinic alpha7 Agonists; Signal Transduction Modulators; ANTISCHIZOPHRENIC; Alzheimer's Dementia, Treatment of ; Antipsychotic Drugs; Cognition Disorders, Treatment of
"
CBR-001-635-510-5,RFM-010-915-9,CBR-001-635-510-5,CC(Cc1ccccc1)N=CC(Cl)(Cl)Cl,"CBR-HVAC-10122: Anorectic
"
CBR-001-635-511-6,RFM-010-916-0,CBR-001-635-511-6,CCN(CCn1c(=O)oc2c(c1=O)cccc2)CC,"CBR-HVAC-10145: Analgesic
"
CBR-001-635-512-7,RFM-010-917-1,CBR-001-635-512-7,OC(=O)CCCCCCN1CCCc2c1nc(c1ccc(cc1)C)c(n2)c1ccc(cc1)C,"CBR-HVAC-14375: Prostanoid IP Agonists; Signal Transduction Modulators; Pulmonary Hypertension, Treatment of
"
CBR-001-635-513-8,RFM-010-918-2,CBR-001-635-513-8,CC(=CCC[C@@]([C@H]1CC[C@@]2([C@@H]1[C@H](O)C[C@H]1[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](C2(C)C)O)C)(O)C)C,"CBR-HVAC-14392: 5-HT Reuptake Inhibitors; CASPASE Stimulator; Norepinephrine Reuptake Inhibitors; Selective Estrogen Receptor Modulators (SERM); Signal Transduction Modulators; ANTI-CANCER; Antidepressants; Chemopreventive Agents; Oncolytic Drugs
"
CBR-001-635-515-0,RFM-010-919-3,CBR-001-635-515-0,OC[C@H]1OC(O)[C@@H]([C@@H]([C@@H]1O)O[C@@H]1O[C@@H](CO[C@@H]2O[C@@H](CO)[C@@H]([C@H]([C@@H]2O)O)O)[C@@H]([C@H]([C@@H]1O)O[C@@H]1O[C@@H](CO)[C@@H]([C@H]([C@@H]1O)O)O)O)O,"CBR-HVAC-09155: Antiviral
"
CBR-001-635-849-9,RFM-010-920-6,CBR-001-635-849-9,NC(=N)c1ccc(c(c1)CN1CCC(C1=O)NS(=O)(=O)c1ccc(s1)c1cccnc1)O,CBR-HVAC-00219: Coagulation Factor Xa Inhibitors; Coagulation factor Xa Inhibitor; Factor Xa inhibitor; Inhibitors of Blood Coagulation Pathways; Anticoagulants; Antithrombotic
CBR-001-635-850-2,RFM-010-921-7,CBR-001-635-850-2,NCCN1CCC(CC1)Nc1nc2c(n1Cc1nc(C)ccc1O)cccc2C,CBR-HVAC-00232: RNA synthesis inhibitor; Respiratory syncytial virus protein F Inhibitor; Viral Fusion Inhibitors; Anti-RSV Drugs; Antiviral
CBR-001-635-851-3,RFM-010-922-8,CBR-001-635-851-3,COc1nc(C)ccc1CN1CC1C#N,CBR-HVAC-00773: Antidiabetic; Antirheumatic; Immunomodulator; T cell stimulant; Antidiabetic; Antirheumatic; Immunomodulator; Immunomodulators
CBR-001-635-852-4,RFM-010-923-9,CBR-001-635-852-4,Cc1ccc(n1Nc1ccc(nn1)N1CCOCC1)C,CBR-HVAC-01032: Calcium channel antagonist; Nitric oxide stimulant; Antihypertensive
CBR-001-635-853-5,RFM-010-924-0,CBR-001-635-853-5,OC(COc1ccccc1C)CNCCn1cc(C)c(=O)[nH]c1=O,CBR-HVAC-01038: Beta 1 adrenoreceptor antagonist; Beta-1 adrenergic receptor Antagonist; Antianginal; Antiarrhythmic; Antihypertensive
CBR-001-635-854-6,RFM-010-925-1,CBR-001-635-854-6,OC(CNC(CCn1c(=O)[nH]c2c1cccc2)(C)C)COc1cccc2c1cccc2,CBR-HVAC-01235: Beta adrenoreceptor antagonist; Beta-adrenoceptor Blocker; ANTIHYPERTENSIVE
CBR-001-635-855-7,RFM-010-926-2,CBR-001-635-855-7,O=C(OCC(=O)C1(O)CCC2C1(C)CC(O)C1C2CC(C2=CC(=O)C=CC12C)C)CCCCCCC(=O)N(CCS(=O)(=O)O)C,"CBR-HVAC-02257: Glucocorticoid agonist; Anti-inflammatory, steroidal; Antiallergy/Antiasthmatic Drugs; Immunosuppressants; Nephritis, Agents for; Systemic Lupus Erythematosus, Agents for"
CBR-001-635-856-8,RFM-010-927-3,CBR-001-635-856-8,O=C(c1c(cc2n1cccc2)C(C)C)c1ccc(cc1)OCCCNC(C)(C)C,"CBR-HVAC-02551: Calcium Channel Blockers; Calcium channel Blocker; Calcium channel antagonist; Antiarrhythmic; Hypertension, Treatment of"
CBR-001-635-857-9,RFM-010-928-4,CBR-001-635-857-9,[N-](c1nncs1)C#N,CBR-HVAC-03617: Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors; Antiviral Drugs
CBR-001-635-858-0,RFM-010-929-5,CBR-001-635-858-0,OC(COc1ccc(cc1)CC(=O)OCCC12CC3CC(C2)CC(C1)C3)CNC(C)C,CBR-HVAC-04068: Beta adrenergic receptor Antagonist; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Antiglaucoma; Antiglaucoma Agents
CBR-001-635-859-1,RFM-010-930-8,CBR-001-635-859-1,CCC[C@@H]1O[C@H]2[C@](O1)(SC)[C@@]1([C@@H](C2)[C@@H]2C[C@H](F)C3=CC(=O)CC[C@@]3([C@]2([C@H](C1)O)F)C)C,CBR-HVAC-04601: Glucocorticoid Receptor (GR) Agonists; Glucocorticoid agonist; Glucocorticoid receptor Agonist; Signal Transduction Modulators; Antiallergic; Antiallergy/Antiasthmatic Drugs; Antiasthmatic
CBR-001-635-860-4,RFM-010-931-9,CBR-001-635-860-4,C/C(=C\C=C\C(=C\C(=O)O)\C)/c1cc(cc(c1)C(C)(C)C)C(C)(C)C,CBR-HVAC-04712: Apoptosis stimulant; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; Retinoic acid receptor Agonist; Retinoic acid receptor agonist; Retinoid RAR Agonists; Signal Transduction Modulators; Acne Therapy; Anticancer; Antipsoriatic; Antipsoriatics; Cervical Cancer Therapy; Head and Neck Cancer Therapy; Oncolytic Drugs
CBR-001-635-861-5,RFM-010-932-0,CBR-001-635-861-5,NC(=N)NC(=O)c1cc(c(cc1C)S(=O)(=O)C)S(=O)(=O)C,"CBR-HVAC-11670: Na+/H+ Exchanger type 1 (NHE-1) Inhibitors; Na+/H+ exchanger 1 Modulator; Na+/H+ exchanger 2; Na+/H+ exchanger 3; Sodium-hydrogen-antiporter-inhibitors; Antiarrhythmic Drugs; Cardioprotectant; Heart Failure; Heart Failure Therapy; Muscular Dystrophy, Agents for; Musculoskeletal Disorders"
CBR-001-635-862-6,RFM-010-933-1,CBR-001-635-862-6,CCC[C@@H]1O[C@H]2[C@](O1)(C(=O)S[C@@H]1CCOC1=O)[C@@]1([C@@H](C2)[C@@H]2C[C@H](F)C3=CC(=O)CC[C@@]3([C@]2([C@H](C1)O)F)C)C,CBR-HVAC-04966: Steroid hormone receptor Agonist; Antiallergy/Antiasthmatic Drugs; Antiinflammatory
CBR-001-635-863-7,RFM-010-934-2,CBR-001-635-863-7,CCC[C@@H]1O[C@H]2[C@](O1)(C(=O)S[C@H]1CCOC1=O)[C@@]1([C@@H](C2)[C@@H]2C[C@H](F)C3=CC(=O)CC[C@@]3([C@]2([C@H](C1)O)F)C)C,CBR-HVAC-04966: Steroid hormone receptor Agonist; Antiallergy/Antiasthmatic Drugs; Antiinflammatory
CBR-001-635-864-8,RFM-010-935-3,CBR-001-635-864-8,N/C(=N\c1onc(c1)[C@H](c1ccc(c(c1)F)c1ccccc1)C)/N1CCOCC1,"CBR-HVAC-05100: CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II Inhibitor; Calmodulin-Dependent Protein Kinase II (CaMK-II) Inhibitors; Disease modifying antirheumatic drug; Signal Transduction Modulators; Anti-inflammatory; Antiarthritic; Disease-Modifying Anti-Rheumatic Drugs; Rheumatoid Arthritis, Treatment of"
CBR-001-635-865-9,RFM-010-936-4,CBR-001-635-865-9,COc1ccc(cn1)[C@@H](N1CCN(C1=O)CCCc1ccc2c(n1)NCCC2)CC(=O)O,CBR-HVAC-05221: Cell Adhesion Inhibitors; INTEGRIN ALPHAV BETA3 Inhibitor; Integrin alphavbeta3 (Vitronectin) Antagonists; Signal Transduction Modulators; Anticancer; Bone Cancer Therapy; Treatment of Osteoporosis
CBR-001-635-866-0,RFM-010-937-5,CBR-001-635-866-0,CN[C@H](c1ccc(cc1)OC(=O)N(C)C)CCOc1ccc(cc1)[N+](=O)[O-],"CBR-HVAC-05684: 5-Hydroxytryptamine transporter; Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Inhibitor; Serotonin Transporter (SERT) Inhibitors; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Neuroprotectant"
CBR-001-635-867-1,RFM-010-938-6,CBR-001-635-867-1,Clc1ccccc1C(c1ccccc1Cl)N1C2CCC1CC(C2)(O)c1ncccn1,"CBR-HVAC-05913: Antitussive; ORL1 (OP4, NOP) Agonists; Signal Transduction Modulators; Antitussive; Respiratory Disorders (Not Specified)"
CBR-001-635-868-2,RFM-010-939-7,CBR-001-635-868-2,CCCCCc1cc(O)c2c(c1)OC(c1c2cc(C)cc1)(C)C,"CBR-HVAC-05981: Cannabinoid CB1 Receptor Ligands; Cannabinoid CB2 Receptor Ligands; Signal Transduction Modulators; Amyotrophic Lateral Sclerosis, Agents for"
CBR-001-635-869-3,RFM-010-940-0,CBR-001-635-869-3,COc1cc(OC)c(c(c1)OC)/C=C/S(=O)(=O)Cc1ccc(c(c1)OP(=O)(O)O)OC,CBR-HVAC-06708: Apoptosis Inducers; Apoptosis stimulant; Cyclin D inhibitor; Cyclin D1 Modulator; Anticancer; Lymphocytic Leukemia Therapy; Lymphoma Therapy; Solid Tumors Therapy
CBR-001-635-870-6,RFM-010-941-1,CBR-001-635-870-6,CC(CN(S(=O)(=O)c1ccc2c(c1)sc(n2)NC1CCN(CC1)C1CCCC1)C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CCO2)O)C,CBR-HVAC-06909: HIV Protease Inhibitors; Protease Inhibitor; Anti-HIV Agents; Antiviral
CBR-001-635-871-7,RFM-010-942-2,CBR-001-635-871-7,Clc1ccccc1Oc1cccn2c1nnc2[C@]12CC[C@@](C2)(CC1)O,"CBR-HVAC-06978: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; Lipoprotein Disorders, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-635-872-8,RFM-010-943-3,CBR-001-635-872-8,CCCCC1(CCCC)CN(c2ccccc2)c2c(S(=O)(=O)N1)cc(c(c2)SC)OCC(=O)N[C@@H](C(=O)N[C@H](C(=O)O)CC)c1ccc(cc1)O,"CBR-HVAC-07244: Ileal Bile Acid Transporter (IBAT) Inhibitors; Ileal bile acid transport inhibitor; Agents for Liver Cirrhosis; Liver and Biliary Tract Disorders, Treatment of; Multisystem Genetic Disorders, Treatment of"
CBR-001-635-873-9,RFM-010-944-4,CBR-001-635-873-9,C[C@H]1O[C@@H](C)[C@@H]2N(C1)c1c(CC32C(=O)NC(=O)NC3=O)cc2c(c1F)onc2N1[C@H](C)COC1=O,CBR-HVAC-07326: DNA Gyrase Inhibitors; Antibacterial Drugs
CBR-001-635-874-0,RFM-010-945-5,CBR-001-635-874-0,CNS(=O)(=O)c1cc2sc(nc2cc1F)c1c(C)nnc1N,CBR-HVAC-07760: Interleukin 1 antagonist; Phosphodiesterase 4 inhibitor; Protein kinase inhibitor; Tumour necrosis factor alpha antagonist
CBR-001-635-875-1,RFM-010-946-6,CBR-001-635-875-1,O=C1O[Pt]2(NCC3(CN2)CCOCC3)OC(=O)C21CCC2,CBR-HVAC-07788: DNA inhibitor; Antineoplastic; Oncolytic Drugs
CBR-001-635-876-2,RFM-010-947-7,CBR-001-635-876-2,O=S1(=O)O[Pt]2(O1)NCC1(CN2)CCCCC1,CBR-HVAC-08359: DNA inhibitor
CBR-001-635-877-3,RFM-010-948-8,CBR-001-635-877-3,COc1ccc(cc1)/C=C/NC=O,CBR-HVAC-08664: Antibiotic
CBR-001-635-878-4,RFM-010-949-9,CBR-001-635-878-4,OCCCNP(=O)(N(CCCl)CCCl)OCCCl,CBR-HVAC-08782: Antineoplastic
CBR-001-635-879-5,RFM-010-950-2,CBR-001-635-879-5,CCOS(=O)(=O)c1cc(cc2c1ccc(c2)C(C)(C)C)C(C)(C)C,CBR-HVAC-09092: Antitussive
CBR-001-635-880-8,RFM-010-951-3,CBR-001-635-880-8,CCCCCC1C(=O)n2n(C1=O)c1ccccc1c(c2)c1ccccc1,"CBR-HVAC-09108: Anti-inflammatory, non-steroidal"
CBR-001-635-881-9,RFM-010-952-4,CBR-001-635-881-9,CN1CC(=CCC1)c1nc(sc1Cl)N,"CBR-HVAC-10531: 5-Hydroxytryptamine 1A receptor Agonist; Alpha-2 adrenergic receptor; Antagonist; Muscarinic M1 Agonists; Muscarinic acetylcholine receptor M1; Signal Transduction Modulators; Antidepressant; Antidepressants; Cognition Disorders, Treatment of"
CBR-001-635-882-0,RFM-010-953-5,CBR-001-635-882-0,BrC[C@@](C(=C)Cl)(CC[C@H](C(Cl)(C)C)Br)Cl,CBR-HVAC-11188: DNA methyltransferase 1 Inhibitor; Anticancer; Oncolytic Drugs
CBR-001-635-883-1,RFM-010-954-6,CBR-001-635-883-1,Clc1ccc(c(c1)S(=O)(=O)c1ccccc1F)S(=O)(=O)c1ccc(cc1)[C@@H](NS(=O)(=O)C)C,CBR-HVAC-11898: Cannabinoid CB2 receptor Inverse Agonist; Immunomodulator
CBR-001-635-884-2,RFM-010-955-7,CBR-001-635-884-2,CC(CN([C@@H]1C[C@H](N(C1)C(=O)c1ccccc1C(=O)c1ccc(cc1F)F)CNC(=O)/C=C/c1ccc(cc1)/C=C/1\SC(=O)NC1=O)Cc1ccccc1c1ccccc1)C,CBR-HVAC-11979: Phospholipase A2 Inhibitor; Anti-inflammatory
CBR-001-635-885-3,RFM-010-956-8,CBR-001-635-885-3,O[C@@H](C[C@H](CC(=O)O)O)CCn1c(nc(c1C1CC1)C(=O)NCc1cccc(c1)F)c1ccc(cc1)F,CBR-HVAC-12051: HMG-CoA Reductase Inhibitors; Atherosclerosis Therapy
CBR-001-635-886-4,RFM-010-957-9,CBR-001-635-886-4,C1CCC(NC1)CC(C1CCCCC1)C1CCCCC1,"CBR-HVAC-12308: Calcium channel blocker; Angina pectoris, Treatment of; Antianginal; Antimalarial; Cardiovascular Diseases (Not Specified); Heart Failure Therapy; Vasodilator"
CBR-001-635-887-5,RFM-010-958-0,CBR-001-635-887-5,Clc1ccc(cc1)[C@@H]([C@@H](NC(=O)C(Oc1ccc(cn1)C(F)(F)F)(C)C)C)Cc1ccc(cc1)Cl,CBR-HVAC-12326: Cannabinoid CB1 receptor antagonist
CBR-001-635-888-6,RFM-010-959-1,CBR-001-635-888-6,Oc1ccc(cc1)C(C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnc(s1)C)N,CBR-HVAC-13447: Penicillin binding protein Inhibitor; Antibacterial
CBR-001-635-889-7,RFM-010-960-4,CBR-001-635-889-7,Cc1c2O[C@@](C)(CCc2c(c(c1C)O)C)C(=O)N[C@@H]1CCCNC1,"CBR-HVAC-14345: Metabolic and Nutritional Genetic Disorders, Treatment of ; Neurological Genetic Disorders, Treatment of ; Therapy of Inborn Errors of Metabolism"
CBR-001-635-890-0,RFM-010-961-5,CBR-001-635-890-0,O[C@@H]1CCN(C1)c1ncc(cc1c1nncc1)C(=O)Nc1ccc(cc1)OC(Cl)(F)F,CBR-HVAC-14346: Bcr-Abl (Bcr-Abl1) Kinase Inhibitors; Signal Transduction Modulators; Lymphocytic Leukemia Therapy; Myeloid Leukemia Therapy
CBR-001-635-891-1,RFM-010-962-6,CBR-001-635-891-1,Cc1cc(cc2c1C(=O)N(C2)Cc1ccc(cc1)OC(F)(F)F)c1onc(n1)CN1CCNCC1,"CBR-HVAC-14351: Drugs Acting on Glutamatergic Transmission; Signal Transduction Modulators; mgluR2 Positive Allosteric Modulators; Antipsychotic Drugs; Smoking Cessation, Aid to"
CBR-001-635-892-2,RFM-010-963-7,CBR-001-635-892-2,Clc1ccc(cc1)C1(CC1)c1nnc2n1cccc2C(O)(C)C,"CBR-HVAC-14354: 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; Lipoprotein Disorders, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-635-893-3,RFM-010-964-8,CBR-001-635-893-3,OC(=O)COc1cc2onc(c2cc1C)CCc1sc(nc1C(C)C)c1ccc(cc1)C(F)(F)F,"CBR-HVAC-14367: PPARdelta Agonists; Signal Transduction Modulators; Lipoprotein Disorders, Treatment of ; Other Ocular Medications"
CBR-001-635-894-4,RFM-010-965-9,CBR-001-635-894-4,N#Cc1cc(cc(c1)Cl)Oc1c(Br)ccc(c1F)Cc1n[nH]c(=O)n1C,CBR-HVAC-14384: Reverse Transcriptase Inhibitors; Anti-HIV Agents; Microbicides
CBR-001-635-895-5,RFM-010-966-0,CBR-001-635-895-5,COc1cc(cc(c1C)OC)[C@H]([C@H](Cn1ccc(c1)CCC(=O)O)CC1Cc2c(C1)cccc2)O,CBR-HVAC-14387: Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2) Antagonists; Signal Transduction Modulators; Benign Prostatic Hyperplasia Therapy
CBR-001-635-896-6,RFM-010-967-1,CBR-001-635-896-6,CCCCCCCC/C=C\CCCCCCCCOP(=S)(O)O,CBR-HVAC-14388: Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2) Agonists; Lysophosphatidic Acid Receptor 2 (LPAR2; EDG4) Agonists; Lysophosphatidic Acid Receptor 3 (LPAR3; EDG7) Agonists; Signal Transduction Modulators; Radioprotectants/Radiomitigators
CBR-001-635-897-7,RFM-010-968-2,CBR-001-635-897-7,N/C(=N\c1onc(c1)[C@@H](c1ccc(c(c1)F)c1ccccc1)C)/N1CCOCC1,enantiomer of CBR-HVAC-05100
CBR-001-635-898-8,RFM-010-969-3,CBR-001-635-898-8,C[C@H]1O[C@H](C)[C@@H]2N(C1)c1c(CC32C(=O)NC(=O)NC3=O)cc2c(c1F)onc2N1[C@H](C)COC1=O,epimer of CBR-HVAC-07326
CBR-001-635-899-9,RFM-010-970-6,CBR-001-635-899-9,c1ccc2c(c1)C=[NH+]N2.Cl[Ru-3]([n+]1cc2c([nH]1)cccc2)([n+]1cc2c([nH]1)cccc2)(Cl)(Cl)Cl,CBR-HVAC-00237: Apoptosis stimulant; Apoptosis stimulator; DNA inhibitor; Anticancer; Solid Tumors Therapy
CBR-001-669-669-8,RFM-010-971-7,CBR-001-669-669-8,NCCCC[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H]2N(C(=O)[C@@H](NC1=O)[C@H](O)C)CCC2)CCC(=O)O)CCCCCCCC)CCC(=O)O)[C@H](O)C)[C@H](CC)C,CBR-HVAC-14398: Neutrophil elastase inhibitor
CBR-001-669-670-1,RFM-010-972-8,CBR-001-669-670-1,NCCCC[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H]2N(C(=O)[C@@H](NC1=O)[C@H](O)C)CCC2)CCC(=O)O)CCCCCCCC)CCC(=O)O)[C@H](O)C)[C@H](CC)C,CBR-HVAC-14398: Neutrophil elastase inhibitor
CBR-001-669-681-4,RFM-010-973-9,CBR-001-669-681-4,[N-]=[N+]=CC(=O)CC[C@@H](C(=O)O)NC(=O)C,CBR-HVAC-09147: Antineoplastic
CBR-001-669-793-1,RFM-010-974-0,CBR-001-669-793-1,CCC(COc1ccc2n(n1)cc(n2)C(=O)Nc1nc2c(n1)ccc(c2)c1cc(F)cc(c1)Cl)O,"CBR-HVAC-13997: beta-Secretase 1 (BACE1) Inhibitors; Alzheimer's Dementia, Treatment of"
CBR-001-669-794-2,RFM-010-975-1,CBR-001-669-794-2,Clc1ccc2n(c1)cc(n2)C(=O)Nc1nc2c(n1)ccc(c2)OCc1ccccc1,"CBR-HVAC-13896: beta-Secretase 1 (BACE1) Inhibitors; Alzheimer's Dementia, Treatment of"
CBR-001-669-795-3,RFM-010-976-2,CBR-001-669-795-3,COc1ccc(cc1C1(F)c2ccc(cc2N(C1=O)COP(=O)(O)O)C(F)(F)F)Cl,"CBR-HVAC-07545: Large Conductance K(Ca) 1.1 (BK, maxi K+) Channel Activators; Potassium channel agonist; Stroke, Treatment of"
CBR-001-669-796-4,RFM-010-977-3,CBR-001-669-796-4,O=C(C(c1ccc(cc1)/C=C/C(C)(C)C)Cc1ccc(cc1)C(=O)NCCS(=O)(=O)O)Nc1ccc(cc1)C1=Cc2c(C1)cccc2,"CBR-HVAC-14082: Glucagon Receptor (GCGR) Antagonists; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-669-797-5,RFM-010-978-4,CBR-001-669-797-5,OC[C@H](c1ccccc1)C(=O)O[C@@H]1C[C@@H]2[C@@H]3[C@H]([C@H](C1)[N+]2(C)CC1CC1)O3,"CBR-HVAC-12970: MUSCARINIC ACETYLCHOLINE RECEPTOR Antagonist; Antispasmodics; GASTROINTESTINAL AGENT; Irritable Bowel Syndrome, Agents for"
CBR-001-669-798-6,RFM-010-979-5,CBR-001-669-798-6,FCC[N+]1(C)C2CCC1CC(C2)OC(=O)C(c1ccccc1)(c1ccccc1)O,"CBR-HVAC-01992: Histamine receptor antagonist; Muscarinic Antagonists; Muscarinic receptor antagonist; Signal Transduction Modulators; Anticholinergic; Bronchodilators; Chronic Obstructive Bronchitis, Agents for; Drugs for Allergic Rhinitis"
CBR-001-669-799-7,RFM-010-980-8,CBR-001-669-799-7,C=CC[N+]1(CCCC1)[C@H]1C[C@@H]2[C@]([C@H]1OC(=O)C)(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@@H]([C@H](C2)OC(=O)C)N1CCC2(CC1)OCCO2,CBR-HVAC-11455: Neuromuscular blocker; Neuromuscular Blockers; Neuromuscular blocker; Non-depolarizing Blocking Drugs
CBR-001-669-800-3,RFM-010-981-9,CBR-001-669-800-3,OC[C@H](c1ccccc1)C(=O)O[C@@H]1C[C@@H]2[C@@H]3[C@H]([C@H](C1)[N+]2(C)CC)O3,"CBR-HVAC-12968: Anticholinergics; Muscarinic M1 receptor antagonist; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Muscarinic M4 receptor antagonist; Muscarinic acetylcholine receptor Blocker; Signal Transduction Modulators; Asthma Therapy; Bronchodilator; Chronic Obstructive Bronchitis, Agents for; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-669-801-4,RFM-010-982-0,CBR-001-669-801-4,C=CC[N+]1(CCCCC1)[C@H]1C[C@@H]2[C@]([C@H]1OC(=O)CC)(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@@H]([C@H](C2)OC(=O)C)N1CCCCC1,CBR-HVAC-04525: Neuromuscular nicotinic receptor antagonist; Neuromuscular Blockers
CBR-001-669-802-5,RFM-010-983-1,CBR-001-669-802-5,CCCC[N+]1(C)[C@@H]2C[C@H](C[C@H]1[C@H]1[C@@H]2O1)OC(=O)[C@@H](c1ccccc1)CO,CBR-HVAC-12969: Acetylcholine receptor Antagonist; Anticholinergic; Antiemetic; Antispasmodic; Antispasmodics; Antivertigo
CBR-001-669-803-6,RFM-010-984-2,CBR-001-669-803-6,COC1CC(=C(c2cccs2)c2cccs2)C[N+](C1)(C)C,CBR-HVAC-01995: Alpha adrenergic receptor Inhibitor; Muscarinic receptor antagonist; Anticholinergic
CBR-001-669-804-7,RFM-010-985-3,CBR-001-669-804-7,O=C(C[N+]12CCC(CC1)C(C2)OC(=O)C1(CCCCCC1)c1ccccc1)Nc1ccccn1,"CBR-HVAC-06987: Long-acting muscarinic antagonist; MUSCARINIC M3 RECEPTOR Antagonist; Muscarinic M3 Antagonists; Signal Transduction Modulators; BRONCHODILATOR; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-669-805-8,RFM-010-986-4,CBR-001-669-805-8,C1CCCCCNc2cc[n+](c3c2cccc3)CCCCCCCCCC[n+]2ccc(NCCCC1)c1ccccc21,CBR-HVAC-14560: analog of CBR-HVAC-08843
CBR-001-669-806-9,RFM-010-987-5,CBR-001-669-806-9,CCCCCCCCCCCCCCCCCCNC(=O)OC1CCN(CC1)C(=O)OCC(COC(=O)N(C(=O)c1ccccc1OC)Cc1cccc[n+]1CC)OC,"CBR-HVAC-03938: Platelet activating factor antagonist; Platelet activating factor receptor Antagonist; Platelet aggregation inhibitor; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Platelet activating factor receptor antagonist; Septic Shock, Treatment of"
CBR-001-669-807-0,RFM-010-988-6,CBR-001-669-807-0,Clc1ccc(c(c1)Cl)C(Cn1cc[n+](c1)CC(=O)c1ccc(cc1)F)OCc1ccc(cc1Cl)Cl,CBR-HVAC-09104: Antiseptic
CBR-001-669-808-1,RFM-010-989-7,CBR-001-669-808-1,Fc1ccc(c(c1)F)C([C@@H](S(=O)(=O)C)C)(Cn1cncn1)O,CBR-HVAC-03817: Antibacterial; Antifungal; Antiviral; Cell wall synthesis inhibitor; Sterol demethylase inhibitor; Antibacterial; Antifungal; Antifungal Agents; Antiviral
CBR-001-669-809-2,RFM-010-990-0,CBR-001-669-809-2,Fc1ccc(c(c1)F)C([C@@H](S(=O)(=O)C)C)(Cn1cncn1)O,CBR-HVAC-03817: Antibacterial; Antifungal; Antiviral; Cell wall synthesis inhibitor; Sterol demethylase inhibitor; Antibacterial; Antifungal; Antifungal Agents; Antiviral
CBR-001-669-810-5,RFM-010-991-1,CBR-001-669-810-5,CN1CCN(CC1)C(=O)c1ccc(cc1)NC(=O)c1nnc(c(c1)O[C@@H](c1c(Cl)ccc(c1Cl)F)C)N,CBR-HVAC-14041: ALK Inhibitors; ALK Tyrosine Kinase Receptor (L1196M Mutant) Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-001-669-811-6,RFM-010-992-2,CBR-001-669-811-6,Fc1ccc(cc1)C1CCN(CC1)CCCNC(=O)N1C(=O)O[C@H]([C@@H]1c1ccc(c(c1)F)F)C,CBR-HVAC-11067: Alpha-1A adrenergic receptor Antagonist; Signal Transduction Modulators; alpha1A-Adrenoceptor Antagonists; Alpha-1A adrenergic receptor antagonist; Benign Prostatic Hyperplasia Therapy
CBR-001-669-812-7,RFM-010-993-3,CBR-001-669-812-7,Clc1ccc(cc1)C1(O)CCN(CC1(C)C)CCC=C1c2cc(ccc2OCc2c1cccn2)C(O)(C)C,CBR-HVAC-14127:
CBR-001-669-813-8,RFM-010-994-4,CBR-001-669-813-8,NCCCN(C(c1nc2snc(c2c(=O)n1Cc1ccccc1)C)C(C)C)C(=O)c1ccc(cc1)C,"CBR-HVAC-06116: Antimitotic Drugs; KINESIN SPINDLE PROTEIN EG5 Inhibitor; Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors; Anticancer; Bladder Cancer Therapy ; Hematological Cancer Therapy; Lymphocytic Leukemia Therapy; Multiple Myeloma Therapy; Myeloid Leukemia Therapy; Non-Hodgkin's Lymphoma Therapy; Solid Tumors Therapy"
CBR-001-669-814-9,RFM-010-995-5,CBR-001-669-814-9,OC(COc1cccc2c1c(Cl)c(n2)C)CNCCOc1ccccc1,CBR-HVAC-07922: Beta adrenoreceptor antagonist
CBR-001-669-815-0,RFM-010-996-6,CBR-001-669-815-0,Cc1ncnc1CSCCN/C(=N/C#N)/NCC#C,CBR-HVAC-10401: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Signal Transduction Modulators; Antiulcer; Antiulcer Drugs
CBR-001-669-816-1,RFM-010-997-7,CBR-001-669-816-1,CC1N(CCOC1c1ccccc1)Cc1c(=O)n(n(c1C)C)c1ccccc1,CBR-HVAC-09806: Analgesic
CBR-001-669-817-2,RFM-010-998-8,CBR-001-669-817-2,CCC(C(C1C[C@H](C[C@H]1NC(=N)N)C(=O)O)NC(=O)C)CC,CBR-HVAC-13186: Neuraminidase (Sialidase) Inhibitors; Neuraminidase Inhibitor; Anti-Influenza Virus Drugs; Antiviral
CBR-001-669-818-3,RFM-010-999-9,CBR-001-669-818-3,CCCc1cc2c(s1)CN[C@H]1[C@H]2c2cc(OC(=O)C)c(cc2CC1)OC(=O)C,"CBR-HVAC-04700: Dopamine D1 Agonists; Dopamine D1 receptor agonist; Dopamine receptor D1 Agonist; Signal Transduction Modulators; Antiparkinsonian; Cognition Disorders, Treatment of; Treatment of Cocaine Dependency"
CBR-001-669-819-4,RFM-011-000-9,CBR-001-669-819-4,CCCCCCCCCCCOC(=O)C[C@H](C[N+](C)(C)C)OC(=O)CC(C)C,CBR-HVAC-08373: Antibacterial; Fungicide; Antibacterial; Antibacterial Drugs; Fungicide
CBR-001-669-820-7,RFM-011-001-0,CBR-001-669-820-7,CCOc1cnc(nc1)NCc1cc2c(C)nn(c2nc1N1CCOCC1)C,"CBR-HVAC-13849: Cholesteryl Ester Transfer Protein (CETP) Inhibitors; HDL-Cholesterol Increasing Agents; PCSK9 Expression Inhibitors; Atherosclerosis Therapy; Lipoprotein Disorders, Treatment of"
CBR-001-669-821-8,RFM-011-002-1,CBR-001-669-821-8,Clc1ccc(cn1)C1CC2NC1CCC2,CBR-HVAC-11195: Nicotinic acetylcholine receptor Agonist; Nicotinic acetylcholine receptor agonist; Non-Opioid Analgesics
CBR-001-669-822-9,RFM-011-003-2,CBR-001-669-822-9,COC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)[C@@H](C1=CCC=CC1)N,CBR-HVAC-05819: PENICILLIN BINDING PROTEIN Inhibitor; Antibacterial; Antibiotics
CBR-001-669-823-0,RFM-011-004-3,CBR-001-669-823-0,COc1cc2c(cc1OC)ncnc2N1CCN(CC1)C(=O)OCC(O)(C)C,CBR-HVAC-13474: Phosphodiesterase Inhibitor Inhibitor; Bronchodilator
CBR-001-669-824-1,RFM-011-005-4,CBR-001-669-824-1,N#Cc1cc(nnc1NCCN1CCOCC1)c1ccccc1,CBR-HVAC-03203: Monoamine oxidase A Inhibitor; Monoamine oxidase inhibitor; Antidepressant; Antidepressants
CBR-001-669-825-2,RFM-011-006-5,CBR-001-669-825-2,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)CCc1cnc2c(n1)c(N)nc(n2)N,CBR-HVAC-12869: Folate Antagonists; Oncolytic Drugs
CBR-001-669-826-3,RFM-011-007-6,CBR-001-669-826-3,NCC(=O)Oc1ccc2c3c1cccc3OC1(O2)C=CC(=O)c2c1cccc2O,CBR-HVAC-11927: Thioredoxin Reductase Inhibitors; Thioredoxin reductase Inhibitor; Anticancer; Oncolytic Drugs
CBR-001-669-827-4,RFM-011-008-7,CBR-001-669-827-4,O=C1N(CC[C@@H]1NS(=O)(=O)c1sc2c(c1)nccc2)Cc1nc2c(c1)ccnc2,CBR-HVAC-11129: Coagulation Factor Xa Inhibitors; Coagulation factor Xa Inhibitor; Inhibitors of Blood Coagulation Pathways; Anticoagulants; Antithrombotic
CBR-001-669-828-5,RFM-011-009-8,CBR-001-669-828-5,FC[C@H](CCN([C@H](C(C)(C)C)c1nc(cn1Cc1ccccc1)c1cc(F)ccc1F)C(=O)CO)N,"CBR-HVAC-06925: Antimitotic Drugs; Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors; Oncolytic Drugs"
CBR-001-669-829-6,RFM-011-010-1,CBR-001-669-829-6,CCCC(=O)O[C@H]1[C@H](C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@H](N1CCCCC1)[C@H](C2)OC(=O)C)[N+]1(C)CCCCC1,CBR-HVAC-04681: Neuromuscular Blockers; Non-depolarizing Blocking Drugs
CBR-001-669-830-9,RFM-011-011-2,CBR-001-669-830-9,O=C(N[C@H](C(=O)NC(C(=O)[O-])C)CCC(=O)[O-])CCCCC1SSCC1,CBR-HVAC-07070: Cardioprotective Agents
CBR-001-669-831-0,RFM-011-012-3,CBR-001-669-831-0,OCCN(C(=S)SC1=C(C(=O)[O-])N2[C@H]([C@H]1C)[C@H](C2=O)[C@H](O)C)C,CBR-HVAC-11357: Beta-lactamase Inhibitor; Cell wall synthesis inhibitor; Antibacterial
CBR-001-669-832-1,RFM-011-013-4,CBR-001-669-832-1,OCCCN(C(=O)c1ccc(c(c1)O)O)C(=O)N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)[O-])(C)C)c1ccccc1,CBR-HVAC-07460: Cell wall synthesis inhibitor
CBR-001-669-833-2,RFM-011-014-5,CBR-001-669-833-2,O[C@@H]1[C@@H](COP(=O)([O-])[O-])O[C@]([C@H]1O)(O)COP(=O)(O)[O-],"CBR-HVAC-04540: Cardioprotectant; Immunosuppressant; Vasoprotectant; Cardioprotective; Cardioprotective Agents; Coronary Bypass Surgery; Immunosuppressant; Sickle Cell Anemia, Agents for; Vasoprotectant"
CBR-001-669-834-3,RFM-011-015-6,CBR-001-669-834-3,Clc1sc2c(c1c1ccc3c(c1[O-])CCCC3)c([O-])c(c(=O)n2)c1ccccc1,"CBR-HVAC-13904: AMP-Activated Protein Kinase (AMPK) Activators; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-669-835-4,RFM-011-016-7,CBR-001-669-835-4,CSc1ccc(cc1)SC(P(=O)(O)[O-])P(=O)(O)[O-],"CBR-HVAC-04994: Bisphosphonate; Interleukin 1 beta Inhibitor; Antiinflammatory; Immunosuppressant; Rheumatoid Arthritis, Treatment of"
CBR-001-669-836-5,RFM-011-017-8,CBR-001-669-836-5,O[C@@H]1[C@H]2CO[P@@](=O)([S-])O[C@@H]3[C@@H](CO[P@](=O)(O[C@H]1[C@@H](O2)n1cnc2c1ncnc2N)[S-])O[C@H]([C@@H]3O)n1cnc2c1ncnc2N,CBR-HVAC-14091: Oncolytic Drugs
CBR-001-669-837-6,RFM-011-018-9,CBR-001-669-837-6,ClCCN(P1(=O)OCCC(N1)SCCS(=O)(=O)[O-])CCCl,CBR-HVAC-00495: Alkylating agent; DNA inhibitor; DNA synthesis inhibitor; DNA-Damaging Drugs; Antineoplastic; Oncolytic Drugs
CBR-001-669-838-7,RFM-011-019-0,CBR-001-669-838-7,C/C(=C\C(=O)c1ccccc1)/N[C@H](C(=O)[O-])Cc1ccc(cc1)OCCc1nc(oc1C)c1ccccc1,"CBR-HVAC-05225: PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA Agonist; PPARalpha Agonists; PPARgamma Agonists; Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor gamma agonist; Signal Transduction Modulators; Antihyperlipidemic; Lipoprotein Disorders, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-669-839-8,RFM-011-020-3,CBR-001-669-839-8,O=C([C@@H](c1ccccc1)NC(=O)c1cnc2c(c1O)nccc2)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)[O-])(C)C,CBR-HVAC-03070: Antibacterial; ANTIBACTERIAL; ANTIBIOTIC; Antibiotics
CBR-001-669-840-1,RFM-011-021-4,CBR-001-669-840-1,COc1ccc(cc1)C(=O)/C(=C(/c1ccc2c(c1)OCO2)\C(=O)[O-])/Cc1cccc(c1)N(C)C,"CBR-HVAC-11314: Endothelin A receptor Antagonist; Endothelin ETA Receptor Antagonists; Endothelin Receptor Antagonists; Signal Transduction Modulators; Antihypertensive; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-669-841-2,RFM-011-022-5,CBR-001-669-841-2,COc1ccc(cc1)C(=O)/C(=C(/c1ccc2c(c1)OCO2)\C(=O)[O-])/Cc1ccccc1,"CBR-HVAC-11354: Endothelin A receptor Antagonist; Endothelin Receptor Antagonists; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-669-842-3,RFM-011-023-6,CBR-001-669-842-3,COc1ccc(cn1)c1ccc(cc1)Cn1c(CC(C(=O)[O-])(C)C)c(c2c1ccc(c2)OCc1ccccn1)SC(C)(C)C,CBR-HVAC-12805: 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors; Asthma Therapy; Cardiovascular Diseases (Not Specified); Respiratory Disorders (Not Specified)
CBR-001-669-843-4,RFM-011-024-7,CBR-001-669-843-4,[O-]C(=O)COc1cccc(c1)C1CCCC(C1)NCC(c1cccc(c1)Cl)O,"CBR-HVAC-08479: Beta 3 adrenoreceptor agonist; Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Beta-3 adrenergic receptor agonist; Irritable Bowel Syndrome, Agents for; Urinary Incontinence Therapy"
CBR-001-669-844-5,RFM-011-025-8,CBR-001-669-844-5,CCN(CCCNc1nccc2c1c(C)c1c(c2C)nc2c1cc(O)cc2)CC,CBR-HVAC-08364: Oncolytic Drugs
CBR-001-669-845-6,RFM-011-026-9,CBR-001-669-845-6,CCCN(C1CCc2c(C1)ccc(c2O)O)CCCCCCNCCc1ccccc1,"CBR-HVAC-10639: Dopamine D1 Agonists; Dopamine D2 Agonists; Dopamine Receptor Agonists; Dopamine receptor D1; Dopamine receptor D2 Agonist; Signal Transduction Modulators; Antihypertensive; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-669-846-7,RFM-011-027-0,CBR-001-669-846-7,Clc1ccc(c(c1)C(=O)c1ccccc1Cl)N(C(=O)CNC1CC1)C,CBR-HVAC-03061: Sedative/Hypnotics
CBR-001-669-847-8,RFM-011-028-1,CBR-001-669-847-8,N#C[C@@H]1C[C@@H](CN1C(=O)C(C(c1ccc(cc1)F)c1ccc(cc1)F)N)F,"CBR-HVAC-06202: Dipeptide hydrolase inhibitor; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue; Protease/peptidase inhibitor; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-669-848-9,RFM-011-029-2,CBR-001-669-848-9,N#C[C@@H]1C[C@@H](CN1C(=O)C(C(c1ccc(cc1)F)c1ccc(cc1)F)N)F,"CBR-HVAC-06202: Dipeptide hydrolase inhibitor; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Insulin secretagogue; Protease/peptidase inhibitor; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-669-849-0,RFM-011-030-5,CBR-001-669-849-0,CCC1(C2=CCCCC2)C(=O)NC(=O)NC1=O,CBR-HVAC-13283: GABA-A receptor Agonist; Hypnotic
CBR-001-669-850-3,RFM-011-031-6,CBR-001-669-850-3,OC[C@H]1O[C@H](O)[C@@H]([C@H]([C@@H]1O)OC(C(=O)NC(C(=O)NC(C(=O)O)CCC(=O)N)C)C)NC(=O)C,CBR-HVAC-13668: metabolite of CBR-HVAC-09460
CBR-001-669-851-4,RFM-011-032-7,CBR-001-669-851-4,N[C@@H]1CN(C[C@H]1C)c1nc2c(cc1F)c(=O)c(cn2C(C)(C)C)C(=O)O,CBR-HVAC-12931: Antibacterial Drugs
CBR-001-669-852-5,RFM-011-033-8,CBR-001-669-852-5,CNCC(=O)OCc1cccnc1N(C(=O)OC([n+]1cnn(c1)C[C@](c1cc(F)ccc1F)([C@H](c1scc(n1)c1ccc(cc1)C#N)C)O)C)C,CBR-HVAC-05632: Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors; Cell wall synthesis inhibitor; INHIBITS ERGOSTEROL SYNTHESIS BY INHIBITING CYP450-DEPENDENT 14-ALPHA STEROL DEMETHYLASE; Lanosterol 14alpha-demethylase Inhibitors; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Antifungal Agents; Fungicide
CBR-001-669-853-6,RFM-011-034-9,CBR-001-669-853-6,O=C(N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C)Cc1ccc(cc1)C1=NCCCN1,CBR-HVAC-08728: Penicillin binding protein Inhibitor; Antibacterial
CBR-001-669-854-7,RFM-011-035-0,CBR-001-669-854-7,COc1cc(N)c(cc1C(=O)NCCC1(CCCCC1)N(C)C)Cl,CBR-HVAC-13380: 5-HT4 Agonists; 5-Hydroxytryptamine 4 receptor Agonist; Signal Transduction Modulators; Gastroprokinetic; Prokinetic Agents
CBR-001-669-855-8,RFM-011-036-1,CBR-001-669-855-8,CNCC/C=C/1\c2ccccc2C2C(c3c1cccc3)C2,CBR-HVAC-13560: Antidepressant
CBR-001-669-856-9,RFM-011-037-2,CBR-001-669-856-9,COc1c(ccc2c1n(cc(c2=O)C(=O)O)C1CC1)N1CC[C@H](C1)C(N)(C)C,CBR-HVAC-13140: DNA gyrase; DNA topoisomerase IV Inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-669-857-0,RFM-011-038-3,CBR-001-669-857-0,C[C@@H]1CN[C@@H](C2CC2)C(=O)N(C)[C@H](C)C(=O)N[C@@H](C(=O)NCCCc2c(O1)cccc2)Cc1ccc(cc1)F,"CBR-HVAC-06078: GHRELIN RECEPTOR Agonist; GHS Receptor Agonists; Growth hormone secretagogue receptor agonist; Signal Transduction Modulators; Constipation, Agents for; Gastric Emptying Disorders,Treatment of; Gastrointestinal Disorders (Not Specified); Gastroprokinetic"
CBR-001-669-858-1,RFM-011-039-4,CBR-001-669-858-1,O=C([C@@H](N)C)OC1CCN(CC1)c1c(F)cc2c3c1CCC(n3cc(c2=O)C(=O)O)C,"CBR-HVAC-06656: Antibacterial Drugs; Liver and Biliary Tract Disorders, Treatment of"
CBR-001-669-859-2,RFM-011-040-7,CBR-001-669-859-2,CC(=N)NCCSCC[C@@H](C(=O)O)N,"CBR-HVAC-05085: Inducible Nitric Oxide Synthase (NOS-2) Inhibitors; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antimigraine Drugs; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Drugs for Allergic Rhinitis; Rheumatoid Arthritis, Treatment of; Treatment of Shock"
CBR-001-669-860-5,RFM-011-041-8,CBR-001-669-860-5,CC(=O)NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCN(CC1)C(=O)COP(=O)(O)O,CBR-HVAC-11254: Protein 50S ribosomal subunit Inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-669-861-6,RFM-011-042-9,CBR-001-669-861-6,Fc1cc2c(nc1N1C[C@H]3C[C@@H]1CN3)n(cc(c2=O)C(=O)O)C(C)(C)C,CBR-HVAC-12932: Antibacterial; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial
CBR-001-669-862-7,RFM-011-043-0,CBR-001-669-862-7,OC[C@H]1C[C@@H]1C#CC#Cc1ccc(cc1)C(=O)N[C@@H](C(N)(C)C)C(=O)NO,CBR-HVAC-07275: UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors; Antibacterial Drugs
CBR-001-669-863-8,RFM-011-044-1,CBR-001-669-863-8,OC[C@@H]1C[C@H]1C#CC#Cc1ccc(cc1)C(=O)N[C@@H](C(N)(C)C)C(=O)NO,CBR-HVAC-07275: UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors; Antibacterial Drugs
CBR-001-669-864-9,RFM-011-045-2,CBR-001-669-864-9,CC([C@@H](C(=O)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cc(F)c(=O)[nH]c1=O)N)C,CBR-HVAC-03703: Antimetabolites; RNA synthesis inhibitor; Thymidylate synthase Inhibitor; Thymidylate synthase inhibitor; Anticancer; Antineoplastic; Oncolytic Drugs
CBR-001-669-865-0,RFM-011-046-3,CBR-001-669-865-0,OC[C@H](Cn1ccc(n1)NC(=O)[C@@H](N1CC(=CC1=O)Oc1ccccc1Cl)CC(C)C)O,"CBR-HVAC-13959: Glucokinase Activators; Type 2 Diabetes, Agents for"
CBR-001-669-866-1,RFM-011-047-4,CBR-001-669-866-1,CC(NC(=O)c1ccc(cc1)F)CN1CCN(CC1)c1cccc2c1CCCN2,CBR-HVAC-13865: Dopamine D2 Antagonists; Drugs Acting on 5-Hydroxytryptamine Receptors; Signal Transduction Modulators
CBR-001-669-867-2,RFM-011-048-5,CBR-001-669-867-2,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4cc5OCCOc5cc4c(c3Cn1c2=O)CN1CCN(CC1)C,CBR-HVAC-04444: DNA TOPOISOMERASE I Inhibitor; DNA Topoisomerase I Inhibitors; DNA topoisomerase I inhibitor; Anticancer; Breast Cancer Therapy; Ovarian Cancer Therapy; Small Cell Lung Cancer Therapy
CBR-001-669-868-3,RFM-011-049-6,CBR-001-669-868-3,CC[C@]1(C)NC(=O)[C@H](Cc2cccs2)NC(=O)[C@H](NC(=O)CCCSCC(NC(=O)[C@@H](NC1=O)CC(=O)N)C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](C(=O)NCC(=O)N)CCCNC(=N)N)O)Cc1ccccc1,CBR-HVAC-04667: Chemotactic factor Antagonist; Antidiuretic; Urinary Incontinence Therapy
CBR-001-669-869-4,RFM-011-050-9,CBR-001-669-869-4,CC[C@@H]([C@H](N(C(=O)[C@H](C(C)C)NC(=O)[C@@H](N(C)C)C(C)C)C)[C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@H](C(=O)NCCc1ccccc1)C)OC)OC)C,CBR-HVAC-04748: Antimitotic Drugs; Microtubule inhibitor; Tubulin Polymerization Inhibitors; Tubulin inhibitor; Vascular Disrupting Agents (VDA); Solid Tumors Therapy
CBR-001-669-870-7,RFM-011-051-0,CBR-001-669-870-7,O=C([C@H](NC(=O)C(N)(C)C)Cc1c(C)nc2c1cccc2)N[C@@H](C(=O)N)Cc1c(C)nc2c1cccc2,CBR-HVAC-11048: Growth Hormone Secretagogues; Growth hormone receptor Agonist; Signal Transduction Modulators; Growth hormone agonist; Treatment of Growth Hormone Deficiency
CBR-001-669-871-8,RFM-011-052-1,CBR-001-669-871-8,O=C([C@H](CCS(=O)(=O)C)N)N[C@H]1C[C@@H]2C([C@]1(CC2)CS(=O)(=O)N1CCN(CC1)c1ccccc1C)(C)C,CBR-HVAC-04450: OXYTOCIN RECEPTOR Antagonist; Oxytocin (OT) Antagonists; Oxytocin receptor antagonist; Signal Transduction Modulators; TOCOLYTIC; Tocolytics
CBR-001-669-872-9,RFM-011-053-2,CBR-001-669-872-9,Oc1ccc2c(c1)c(C)c(n2Cc1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O,CBR-HVAC-08206: Estrogen receptor alpha Inhibitor; Estrogen receptor antagonist; Selective Estrogen Receptor Modulators (SERM); Selective estrogen receptor modulator; Signal Transduction Modulators; Anticancer; Breast Cancer Therapy
CBR-001-669-873-0,RFM-011-054-3,CBR-001-669-873-0,OC(=O)C(Oc1nn(cc1C)Cc1ccccc1)(C)C,CBR-HVAC-08534: Cholesterol inhibitor
CBR-001-669-874-1,RFM-011-055-4,CBR-001-669-874-1,OC(C1CCCCC1)CCN1CCC(CC1)N(C(=O)c1ccco1)c1ccc(cn1)C,"CBR-HVAC-13908: Signal Transduction Modulators; mu-Opioid Antagonists; Antipruritics; Constipation, Agents for"
CBR-001-669-875-2,RFM-011-056-5,CBR-001-669-875-2,O=C1COc2c(N1)c(O)ccc2CCNCCN(C(=O)CCOCCc1ccc(cc1)CCN1CCC2(CC1)OCCN(C2)C(=O)c1csc(n1)C)C1CCCCCC1,"CBR-HVAC-14106: Muscarinic Antagonists; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-669-876-3,RFM-011-057-6,CBR-001-669-876-3,O=C(N[C@H](C(=O)O)CNc1nc(C)nc(c1C)N1CCC(CC1)c1ccc2c(n1)NCCC2)OCc1ccccc1,CBR-HVAC-12075: Angiogenesis Inhibitors; Angiogenesis inhibitor; Integrin Receptor Antagonists; Integrin alpha1 beta3 Antagonist; Integrin antagonist; Signal Transduction Modulators; Anticancer; Breast Cancer Therapy; Prostate Cancer Therapy; Solid Tumors Therapy
CBR-001-669-877-4,RFM-011-058-7,CBR-001-669-877-4,N#Cc1nccc2c1ccc(c2)N1CC(C)CNS1(=O)=O,CBR-HVAC-13759: Selective Androgen Receptor Modulators (SARM); Signal Transduction Modulators; Treatment of Cachexia
CBR-001-669-878-5,RFM-011-059-8,CBR-001-669-878-5,N#Cc1nccc2c1ccc(c2)N1CC(C)CNS1(=O)=O,CBR-HVAC-13759: Selective Androgen Receptor Modulators (SARM); Signal Transduction Modulators; Treatment of Cachexia
CBR-001-669-879-6,RFM-011-060-1,CBR-001-669-879-6,CC1NC(C)COC1(O)c1cc(F)cc(c1)F,"CBR-HVAC-04766: Adrenergic transmitter uptake inhibitor; Dopamine Reuptake Inhibitors; Dopamine reuptake inhibitor; Dopamine transporter; Norepinephrine Reuptake Inhibitors; Norepinephrine transporter Inhibitor; Norepinephrine/dopamine dual reuptake inhibitor; Signal Transduction Modulators; Antidpressant; Antiobesity Drugs; Antipsychotic; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of"
CBR-001-669-880-9,RFM-011-061-2,CBR-001-669-880-9,CC1NCCC1c1cncn1,CBR-HVAC-11569: Histamine H3 receptor Agonist; Antiallergic; Antiasthmatic
CBR-001-669-881-0,RFM-011-062-3,CBR-001-669-881-0,CCC[C@H](C[C@@H](CC(=O)O)CN)C,"CBR-HVAC-12351: Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands; Calcium channel Modulator; GABA receptor; Calcium channel modulator; GABA receptor modulator; Metabolic Disorders (Not Specified); Sleep Disorders, Treatment of; Treatment of Hot Flushes; Urologic Drugs"
CBR-001-669-882-1,RFM-011-063-4,CBR-001-669-882-1,CCC[C@H](C[C@@H](CC(=O)O)N)C,"CBR-HVAC-06511: Anxiolytic; Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands; Calcium channel agonist; Anxiolytic; Generalized Anxiety Disorder (GAD), Treatment of; Treatment of Renal Diseases"
CBR-001-669-883-2,RFM-011-064-5,CBR-001-669-883-2,C=CC(=O)N1CC[C@H](C1)Oc1nc(Nc2ccc(cc2)N2CCC(CC2)N2CCN(CC2)C)c(nc1CC)C(=O)N,CBR-HVAC-14051: EGFR (HER1; erbB1) Inhibitors; EGFR (Thr790Met Mutant) Inhibitors; Signal Transduction Modulators; Non-Small Cell Lung Cancer Therapy
CBR-001-669-884-3,RFM-011-065-6,CBR-001-669-884-3,CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1nnnn1)C=O)Cl,CBR-HVAC-13270: Angiotensin II receptor type 1 Antagonist; Antihypertensive
CBR-001-669-885-4,RFM-011-066-7,CBR-001-669-885-4,CCCCC1(CNCC1)c1ccc2c(c1)ccn2,CBR-HVAC-13730: 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Dopamine reuptake inhibitor; Dopamine transporter; Norepinephrine transporter; Serotonin transporter Inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor; ANTIDEPRESSANT; Antipsychotic Drugs
CBR-001-669-886-5,RFM-011-067-8,CBR-001-669-886-5,CCCCCCCCOc1ccc(cc1)NC(=O)C(CO)(N)C,"CBR-HVAC-13776: Lysophospholipid edg1 (S1P1) Receptor Agonists; Signal Transduction Modulators; Multiple Sclerosis, Agents for"
CBR-001-669-887-6,RFM-011-068-9,CBR-001-669-887-6,CCCCCCCCOc1ccc(cc1)NC(=O)C(CO)(N)C,"CBR-HVAC-13776: Lysophospholipid edg1 (S1P1) Receptor Agonists; Signal Transduction Modulators; Multiple Sclerosis, Agents for"
CBR-001-669-888-7,RFM-011-069-0,CBR-001-669-888-7,CCCCNC(=O)[C@@H](C[C@@H]([C@H](C[C@@H](C(C)C)Cc1ccc(c(c1)OCCCOC)OC)N)O)C,"CBR-HVAC-11423: Renin Inhibitor; Renin Inhibitors; Antihypertensive; Hypertension, Treatment of"
CBR-001-669-889-8,RFM-011-070-3,CBR-001-669-889-8,CCCN(C1CCc2c(C1)c(O)ccc2F)CCC,CBR-HVAC-11086: 5-Hydroxytryptamine 1A receptor Antagonist; Anxiolytic
CBR-001-669-890-1,RFM-011-071-4,CBR-001-669-890-1,CCN(C(=O)CCCC1CCNCC1)CC(=O)NC(C(=O)NC(C(=O)O)CC1CCCCC1)CC(=O)O,CBR-HVAC-04728: Inhibitors of Blood Coagulation Pathways; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Antiplatelet Therapy
CBR-001-669-891-2,RFM-011-072-5,CBR-001-669-891-2,CCN(CCOC(=O)C(C1(O)CCCC1)c1ccccc1)CC,CBR-HVAC-13461: Anticholinergic
CBR-001-669-892-3,RFM-011-073-6,CBR-001-669-892-3,COCCN1C[C@H](NCC)c2c(S1(=O)=O)sc(c2)S(=O)(=O)N,CBR-HVAC-11108: Carbonic Anhydrase Inhibitors; Carbonic anhydrase Inhibitor; Antiglaucoma; Antiglaucoma Agents
CBR-001-669-893-4,RFM-011-074-7,CBR-001-669-893-4,CCOC(=O)C(N[C@H](C(=O)N1CCC[C@H]1C(=O)O)C)CCCC1Cc2c(O1)cccc2,"CBR-HVAC-03753: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; ANTIHYPERTENSIVE; Hypertension, Treatment of"
CBR-001-669-894-5,RFM-011-075-8,CBR-001-669-894-5,CCOC(=O)COc1ccc2c(c1)oc(=O)c(c2C)CCN(CC)CC,CBR-HVAC-09753: Phosphodiesterase Inhibitor; Vasodilator
CBR-001-669-895-6,RFM-011-076-9,CBR-001-669-895-6,CCOc1cc(CN2CCOCC2)cc2c1c1NCCCc1c(=O)n2,"CBR-HVAC-13798: Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors; Signal Transduction Modulators; Stroke, Treatment of"
CBR-001-669-896-7,RFM-011-077-0,CBR-001-669-896-7,CCOc1ccc2c(c1)Sc1c(C2=C2CCN(CC2)C)c(OC)ccc1,"CBR-HVAC-05905: 5-HT2B Antagonists; Signal Transduction Modulators; Migraine, Prophylactic Treatment of"
CBR-001-669-897-8,RFM-011-078-1,CBR-001-669-897-8,CC[C@@H]([C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCC(=O)N)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CCCNC(C)C)C,"CBR-HVAC-02588: Signal Transduction Modulators; Vasopressin (AVP) V1a Receptor Agonists; Vasopressin 1A agonist; Septic Shock, Treatment of ; VASOCONSTRICTORÂ¬CARDIOPROTECTANT"
CBR-001-669-898-9,RFM-011-079-2,CBR-001-669-898-9,c1ccc(cc1)C(c1ccccn1)CC1=NCCN1,CBR-HVAC-02942: Alpha 2 adrenoreceptor antagonist; Alpha-2 adrenergic receptor Antagonist; Signal Transduction Modulators; beta2-Adrenoceptor Antagonists; Anti-inflammatory; Antiallergic; Antiallergy/Antiasthmatic Drugs; Antiasthmatic; Antidiabetic Drugs
CBR-001-669-899-0,RFM-011-080-5,CBR-001-669-899-0,NC(C(=O)NC(C(=O)NC(C(=O)O)C)C)CCCC(C(=O)N)N,CBR-HVAC-11109: Antibacterial; Antibacterial
CBR-001-669-900-6,RFM-011-081-6,CBR-001-669-900-6,NCCCC[C@@H](C(=O)N)NC(=O)[C@H](Cc1c(C)nc2c1cccc2)NC(=O)[C@@H](Cc1c(C)nc2c1cccc2)NC(=O)[C@@H](Cc1c(C)nc2c1cccc2)NC(=O)CCCN,CBR-HVAC-05060: Growth Hormone Secretagogues; Growth hormone Agonist; Signal Transduction Modulators; Growth hormone agonist; Treatment of Growth Hormone Deficiency
CBR-001-669-901-7,RFM-011-082-7,CBR-001-669-901-7,Fc1cn2c(c(c1N1C[C@@H]3[C@H](C1)CCCN3)C)c(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-11098: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; Antibacterial; Antibacterial Drugs; Treatment of Tuberculosis
CBR-001-669-902-8,RFM-011-083-8,CBR-001-669-902-8,NCC[C@@H](C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCN)Cc1ccccc1)CC(C)C)CCN)[C@H](O)C)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)Nc1ccccc1Cl)CCN,CBR-HVAC-06807: Bacterial protein synthesis inhibitor; Cell wall synthesis inhibitor; DNA synthesis inhibitor; Membrane integrity inhibitor; Protein synthesis inhibitor; RNA synthesis inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-669-903-9,RFM-011-084-9,CBR-001-669-903-9,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CC(C)C)[C@H](CC)C)CO)CC(=O)N)CC(C)C)Cc1ccc(cc1)O)CCCCN)CCCCN)C(C)C)C)CCCC)CCC(=O)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(O)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(O)C)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ncnc1)NCCCCCCCCCCCCCCCCCC)CO)CC(=O)O)C)Cc1ccccc1)CC(=O)O)CC(=O)N)Cc1ccc(cc1)O)CCCNC(=N)N)CC(C)C)CCCNC(=N)N,CBR-HVAC-13530: Vasoactive intestinal peptide receptor Antagonist; Vasoactive intestinal peptide receptor antagonist
CBR-001-669-904-0,RFM-011-085-0,CBR-001-669-904-0,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(C)C)CCCNC(=N)N)C)CCCNC(=N)N)C)CCCNC(=N)N)CCC(=O)O)CCC(=O)N)CC(=O)N)CO)CCC(=O)O)CCC(=O)N)CCC(=O)N)CCCNC(=N)N)CO)CCSC)[C@H](CC)C)CC(=O)O)CCC(=O)N)CC(C)C)CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)C/C=C/CC)C)CC(=O)O)C)Cc1ccccc1)CC(=O)N)CO)Cc1ccc(cc1)O)CCCNC(=N)N)CCCCN)CC(C)C)CCC(=O)N)CC(C)C)CO)C)CCCNC(=N)N,"CBR-HVAC-04919: Growth hormone releasing hormone receptor Agonist; Antiobesity; Antiobesity Drugs; Cognition Disorders, Treatment of; Cystic Fibrosis, Treatment of ; Immunomodulators; Sleep Disorders, Treatment of; Treatment of AIDS-Associated Disorders; Treatment of Cachexia; Treatment of Growth Hormone Deficiency"
CBR-001-669-905-1,RFM-011-086-1,CBR-001-669-905-1,COc1ccc(cc1)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)N)O)CO)CN[C@H](C(=O)O)CCCNC(=N)N,CBR-HVAC-04642: Bradykinin B2 Agonists; Bradykinin receptor B2 Agonist; Bradykinin receptor agonist; Membrane permeability enhancer; Signal Transduction Modulators; Anti-inflammatory; Anticancer; Brain Cancer Therapy; Vasodilator
CBR-001-669-906-2,RFM-011-087-2,CBR-001-669-906-2,CN1C[C@@H]2C[C@@H](C[C@H](C1)N2C)NC(=O)c1nnc2c1cccc2,"CBR-HVAC-01724: 5 Hydroxytryptamine 3 receptor antagonist; 5 Hydroxytryptamine 4 receptor antagonist; 5-HT3 Antagonists; 5-HT4 Antagonists; 5-Hydroxytryptamine 3 receptor Antagonist; Signal Transduction Modulators; Antiemetic; Disorders Associated with Cancer Therapy, Treatment of"
CBR-001-669-907-3,RFM-011-088-3,CBR-001-669-907-3,NCc1cccc(c1)c1ccc(cc1)C(=O)N[C@@H]([C@H](C(=O)OC)Cc1cccc(c1)C(=N)N)C,CBR-HVAC-11728: Coagulation factor X Antagonist; Anticoagulant
CBR-001-669-908-4,RFM-011-089-4,CBR-001-669-908-4,COc1ccc(cc1)C(=O)CC[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N)C)CCCNC(=N)N)CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@H](NC(=O)[C@@H](Cc1ccc2c(c1)cccc2)NC(=O)C)Cc1ccc(cc1)Cl)Cc1cccnc1)CO)CCCNC(=N)N,CBR-HVAC-03943: GnRH (LHRH) Antagonists; Signal Transduction Modulators
CBR-001-669-909-5,RFM-011-090-7,CBR-001-669-909-5,COc1cc2c(CCN3CCN(CC3)c3cccc(c3C)Cl)nn(c2cc1OC)Cc1cncn1,"CBR-HVAC-04678: Calmodulin Antagonist; Calmodulin Antagonists; Calmodulin antagonist; Ischemic Stroke, Treatment of; Neuroprotectant"
CBR-001-669-910-8,RFM-011-091-8,CBR-001-669-910-8,Oc1cc(CCNCCCCCCNCCc2ccccc2)ccc1O,CBR-HVAC-01964: Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Activator; Dopamine D1 Agonists; Dopamine receptor D1; Dopamine receptor agonist; Signal Transduction Modulators; Cardiovascular Diseases (Not Specified); Heart Failure Therapy; Inodilator
CBR-001-669-911-9,RFM-011-092-9,CBR-001-669-911-9,NCC(=O)NCc1nc(nn1c1ccc(cc1C(=O)c1ccccc1Cl)Cl)C(=O)N(C)C,CBR-HVAC-01755: Chloride channel agonist; GABA receptor agonist; Potassium channel agonist; Sedative/Hypnotic; Hypnotic; Sedative; Sedative/Hypnotics
CBR-001-669-912-0,RFM-011-093-0,CBR-001-669-912-0,CN(Cc1ccc(o1)CSCCNC1=NS(=O)(=O)c2c1csc2)C,CBR-HVAC-03027: Histamine H2 Receptor Antagonists; Histamine H2 receptor antagonist; Signal Transduction Modulators; Gastric Antisecretory Drugs
CBR-001-669-913-1,RFM-011-094-1,CBR-001-669-913-1,CN(CCN(n1cc(c2c1cccc2)c1ccccc1)C)C,CBR-HVAC-02906: 5 Hydroxytryptamine receptor agonist; Norepinephrine transporter Inhibitor; Antidepressant; Antidepressants
CBR-001-669-914-2,RFM-011-095-2,CBR-001-669-914-2,CN(CCn1c(=O)n2c3c(c1=O)cccc3c1c2ccc2c1CCCC2=O)C,CBR-HVAC-11039: DNA Topoisomerase II Inhibitors; DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA-Intercalating Drugs; Anticancer; Oncolytic Drugs
CBR-001-669-915-3,RFM-011-096-3,CBR-001-669-915-3,CN1CCC2C(C1)c1ccc(c(c1CC2c1ccccc1)O)O,analog of CBR-HVAC-11594:
CBR-001-669-916-4,RFM-011-097-4,CBR-001-669-916-4,CNC(=O)Cn1c(=O)n(c2c1cccc2)C1CCN(CC1)C1Cc2c3c1cccc3ccc2,"CBR-HVAC-06127: ORL1 (OP4, NOP) Agonists; Signal Transduction Modulators; Treatment of Alcohol Dependency"
CBR-001-669-917-5,RFM-011-098-5,CBR-001-669-917-5,CNC[C@H]1OCCn2cc(c3c2cccc3)C2=C(c3cn(CC1)c1ccccc31)C(=O)NC2=O,"CBR-HVAC-12963: Protein Kinase PKC beta Inhibitors; Signal Transduction Modulators; Diabetic Retinopathy, Agents for"
CBR-001-669-918-6,RFM-011-099-6,CBR-001-669-918-6,CO/N=C(\c1ccc(cc1)CNC(=O)[C@@H]1CCN1C(=O)C(c1cc(Cl)cc(c1)OC(F)F)O)/N,CBR-HVAC-06008: Coagulation inhibitor; Inhibitors of Blood Coagulation Pathways; K(V) 1.5 (KCNA5) Channel Blockers; Thrombin Inhibitors; Thrombin inhibitor; Antiarrhythmic Drugs; Anticoagulant; Coagulation Disorders Therapy
CBR-001-669-919-7,RFM-011-100-2,CBR-001-669-919-7,COC(=O)c1nc2c(c1)c(ccc2O)C(CNC(C)(C)C)O,CBR-HVAC-08559: Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Antiasthmatic; Bronchodilators
CBR-001-669-920-0,RFM-011-101-3,CBR-001-669-920-0,COc1cc2CCN(c2cc1N1C[C@H](C)N[C@@H](C1)C)C(=O)c1ccc(cc1)c1ccc(cc1C)c1noc(n1)C,CBR-HVAC-05958: 5-HT1B Antagonists; 5-Hydroxytryptamine 1B receptor Antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics
CBR-001-669-921-1,RFM-011-102-4,CBR-001-669-921-1,COc1cc(ccc1N1CC[C@H](C1)OC(=O)[C@H](C(C)C)N)n1cnc2c(c1=O)sc(c2)c1ccc(cc1)Cl,CBR-HVAC-15134: MCHR1 RECEPTOR Inhibitor; Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists; Signal Transduction Modulators; ANTI-OBESITY; Antiobesity Drugs
CBR-001-669-922-2,RFM-011-103-5,CBR-001-669-922-2,COc1cc(CCNCC(COc2ccc(c3c2CCC(=O)N3)OCC(=O)C)O)ccc1OC,"CBR-HVAC-10164: Beta adrenergic receptor blocker; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Antiarrhythmic; Hypertension, Treatment of"
CBR-001-669-923-3,RFM-011-104-6,CBR-001-669-923-3,COc1c(N2CC(C(C2)C)N)c(F)cc2c1n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-13455: Antibacterial; Antibacterial; Antibacterial Drugs
CBR-001-669-924-4,RFM-011-105-7,CBR-001-669-924-4,COc1c(ccc2c1n(cc(c2=O)C(=O)O)C1CC1)N1CCC[C@@H](C1)N,CBR-HVAC-13249: DNA Gyrase Inhibitors; DNA Topoisomerase IV Inhibitors; DNA gyrase Inhibitor; DNA topoisomerase IV; Antibacterial; Antibacterial Drugs
CBR-001-669-925-5,RFM-011-106-8,CBR-001-669-925-5,COc1cc(F)ccc1c1ncnc(n1)Nc1cccc(c1)CS(=O)(=N)C,CBR-HVAC-07329: Apoptosis Inducers; CDK9/Cyclin T1 Inhibitors; Signal Transduction Modulators; c-Myc Inhibitors; Leukemia Therapy; Oncolytic Drugs
CBR-001-669-926-6,RFM-011-107-9,CBR-001-669-926-6,COc1ccc(cc1CN[C@@H]1C2CCN([C@H]1C(c1ccccc1)c1ccccc1)CC2)C(C)C,"CBR-HVAC-04959: Neurokinin 1 receptor antagonist; Neurokinin receptor 1 Antagonist; Signal Transduction Modulators; Tachykinin NK1 Antagonists; Antiemetic; Nausea and Vomiting, Treatment of"
CBR-001-669-927-7,RFM-011-108-0,CBR-001-669-927-7,COc1ccc(cc1CNC1C2CCN(C1C(c1ccccc1)c1ccccc1)CC2)C(C)C,"CBR-HVAC-04959: Neurokinin 1 receptor antagonist; Neurokinin receptor 1 Antagonist; Signal Transduction Modulators; Tachykinin NK1 Antagonists; Antiemetic; Nausea and Vomiting, Treatment of"
CBR-001-669-928-8,RFM-011-109-1,CBR-001-669-928-8,O=C1NCC2(N1CCNS(=O)(=O)C)CCN1C(C2)c2oc3c(c2CC1)cccc3,CBR-HVAC-03639: Alpha 2 adrenoreceptor antagonist; Pharmacological Tools
CBR-001-669-929-9,RFM-011-110-4,CBR-001-669-929-9,O=CNCCCC[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H]1CCSC1=O)Cc1ccccc1)NC(=O)[C@H](Cc1ccc(cc1)O)N,CBR-HVAC-08107: Opioid receptor agonist
CBR-001-669-930-2,RFM-011-111-5,CBR-001-669-930-2,OC(=O)[C@H](Cc1cnoc1=O)N,CBR-HVAC-10687: AMPA Receptor Antagonists; Glutamate Ionotropic Antagonists; Ionotropic glutamate receptor Agonist; Ionotropic glutamate receptor NMDA; NMDA Antagonists; Signal Transduction Modulators; Antifungal; Antifungal Agents; Neuroprotectant; Pharmacological Tools
CBR-001-669-931-3,RFM-011-112-6,CBR-001-669-931-3,O=C(N[C@H](C(=O)O)Cc1ccc(c(c1)O)O)CC[C@@H](C(=O)O)N,CBR-HVAC-03925: Diuretics
CBR-001-669-932-4,RFM-011-113-7,CBR-001-669-932-4,NC(=N)NN1Cc2c(C1)c(Cl)ccc2Cl,CBR-HVAC-01169: ALPHA 2 ADRENERGIC RECEPTOR; Agonist; Alpha 2 adrenoreceptor agonist; IMIDAZOLINE RECEPTOR Agonist; ANTIHYPERTENSIVE
CBR-001-669-933-5,RFM-011-114-8,CBR-001-669-933-5,O=C([C@@H](Cc1cnc2c1cccc2)NC(=O)[C@@H](Cc1csc2c1cccc2)NC(=O)C1CCNCC1)N[C@H](C(=O)NC1(CCNCC1)C(=O)N)Cc1ccccc1,"CBR-HVAC-06668: GHS Receptor Agonists; Signal Transduction Modulators; Constipation, Agents for; Gastric Emptying Disorders,Treatment of; Treatment of Anorexia Nervosa; Treatment of Cachexia"
CBR-001-669-934-6,RFM-011-115-9,CBR-001-669-934-6,Fc1cccc(c1)c1sc2c(c1)c(nnc2C(=O)N)N[C@H]1CCCNC1,CBR-HVAC-13831: A since-corrected guess as to structure of Puquitinib
CBR-001-669-935-7,RFM-011-116-0,CBR-001-669-935-7,NCCCCC(C(=O)OC1Cc2c(O)cc(cc2OC1c1ccc(c(c1)O)O)O)N,CBR-HVAC-12178:
CBR-001-669-936-8,RFM-011-117-1,CBR-001-669-936-8,NCCCCC(B(O)O)NC(=O)C1(CCCC1)C(=O)NCCc1ccccc1,CBR-HVAC-11475: Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitor; Thrombin Inhibitors; Anticoagulants; Antithrombotic
CBR-001-669-937-9,RFM-011-118-2,CBR-001-669-937-9,O=C(OC12CCN(CC1)CC2)Nc1ccccc1c1ccccc1,CBR-HVAC-11539: Muscarinic M3 Antagonists; Muscarinic acetylcholine receptor M1 Antagonist; Muscarinic acetylcholine receptor M3; Signal Transduction Modulators; Antimuscarinic; Urinary Incontinence Therapy
CBR-001-669-938-0,RFM-011-119-3,CBR-001-669-938-0,Oc1cn(cc(c1=O)C(=O)O)CC1(CCCC1)n1ccc2c1nccc2,CBR-HVAC-13808: Anti-Influenza A Virus Drugs; Anti-Influenza B Virus Drugs
CBR-001-669-939-1,RFM-011-120-6,CBR-001-669-939-1,OC(=O)Cc1ccc2c(c1)/C(=C/CN1CCC(CC1)Cc1ccccc1)/c1ccccc1CO2,CBR-HVAC-10608: Histamine H1 Receptor Antagonists; Histamine H1 receptor; Prostanoid TP Antagonists; Signal Transduction Modulators; Thromboxane A2 receptor Antagonist; Antiallergy/Antiasthmatic Drugs; Antiasthmatic
CBR-001-669-940-4,RFM-011-121-7,CBR-001-669-940-4,OC(=O)CN1C(=O)[C@H](CSc2c1cccc2)NC(C(=O)O)CCCCC1CCNCC1,"CBR-HVAC-10659: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Antihypertensive; Hypertension, Treatment of"
CBR-001-669-941-5,RFM-011-122-8,CBR-001-669-941-5,OC(=O)CN1C(=O)[C@H](CSc2c1cccc2)NC(C(=O)O)CCCCC1CCNCC1,"CBR-HVAC-10659: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Antihypertensive; Hypertension, Treatment of"
CBR-001-669-942-6,RFM-011-123-9,CBR-001-669-942-6,OC(=O)COc1cc(ccc1OCC(=O)O)C(=O)CNC(=O)c1cc2c(s1)CCNC2,CBR-HVAC-04734: GPIIb IIIa receptor antagonist; Glycoprotein IIb/IIIa Antagonist; Inhibitors of Blood Coagulation Pathways; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Antiplatelet Therapy; PLATELET AGGREGATION INHIBITOR
CBR-001-669-943-7,RFM-011-124-0,CBR-001-669-943-7,OC(c1ccc(c(c1)O)O)C1CCCCN1,CBR-HVAC-03141: Beta-2 adrenergic receptor Agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Bronchodilator; Bronchodilators
CBR-001-669-944-8,RFM-011-125-1,CBR-001-669-944-8,OCC1CNCC(C1O)O,"CBR-HVAC-00407: Beta-glucosidase; Glucosylceramidase (beta-Glucocerebrosidase; beta-Glucosidase) Inhibitors; Glycogen phosphorylase Inhibitor; Pharmacological Chaperones; Antidiabetic Drugs; Beta-glucosidase inhibitor; Gaucher's Disease, Agents for; Glycogen phosphorylase, liver inhibitor"
CBR-001-669-945-9,RFM-011-126-2,CBR-001-669-945-9,NCCCN(c1nc2c(n1)c(Br)c(c(c2Br)Br)Br)CCCN,CBR-HVAC-14052: Flt3 (FLK2/STK1) Inhibitors; Pim-1 Kinase Inhibitors; Pim-2 Kinase Inhibitors; Pim-3 Kinase Inhibitors; Signal Transduction Modulators; Hematological Cancer Therapy
CBR-001-669-946-0,RFM-011-127-3,CBR-001-669-946-0,CCOC(=O)C(c1ccccc1)C(=O)OC1CC2CCC(C1)[N+]2(C)C,CBR-HVAC-02349: Anticholinergic; Antispasmodics
CBR-001-669-947-1,RFM-011-128-4,CBR-001-669-947-1,NC(=N)c1cc2c(s1)cc(cc2)OC(=O)c1cccs1,CBR-HVAC-07510: Complement factor D inhibitor; Kallikrein inhibitor; Plasmin inhibitor
CBR-001-669-948-2,RFM-011-129-5,CBR-001-669-948-2,O=C(Nc1cccnc1/C=N/NC(=S)N)OCc1cc(F)ccc1OP(=O)(O)O,CBR-HVAC-12120: Ribonucleotide reductase Inhibitor; Antitumor
CBR-001-669-949-3,RFM-011-130-8,CBR-001-669-949-3,CCC(N1Cc2cc3O[C@H](c4ccc(cc4)OCc4ccc(c(c4)Cl)Cl)C(=O)N(c3cc2C[C@H]1C(=O)NC(C(=O)O)Cc1ccc(cc1)C#N)C)c1ccccc1,CBR-HVAC-14103: analog of TTP-054 and TTP-273
CBR-001-669-950-6,RFM-011-131-9,CBR-001-669-950-6,COc1ccc(cc1)C1Sc2cc(Cl)ccc2N(C(=O)C1OC(=O)C)CCN(C)C,"CBR-HVAC-12912: Calcium Channel Blockers; Calcium channel Antagonist; Calcium channel antagonist; Angina pectoris, Treatment of; Antihypertensive; Hypertension, Treatment of; Immunosuppressant"
CBR-001-669-951-7,RFM-011-132-0,CBR-001-669-951-7,COC1CCC(CC1)OC(=O)[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C(C)C,CBR-HVAC-03723: 5-HT2A Antagonists; 5-Hydroxytryptamine 2 receptor Antagonist; Signal Transduction Modulators; Antimigraine; Antimigraine Drugs
CBR-001-669-952-8,RFM-011-133-1,CBR-001-669-952-8,O=C1Nc2c(C1)cc1c(c2)onc1CCC1CCN(CC1)Cc1ccccc1,"CBR-HVAC-04630: Acetylcholinesterase (AChE) Inhibitors; Acetylcholinesterase Inhibitor; Acetylcholinesterase inhibitor; Acetylcholinesterase inhibitor; Cognition Disorders, Treatment of"
CBR-001-669-953-9,RFM-011-134-2,CBR-001-669-953-9,COc1cc2c(ncnc2cc1OCCCN1CCN(CC1)C)Nc1ccc2c(c1)sc(n2)NC(=O)Nc1cc(C)ccc1OC,CBR-HVAC-06788: Angiogenesis Inhibitors; Flt3 (FLK2/STK1) Inhibitors; Signal Transduction Modulators; VEGFR Inhibitors; Myeloid Leukemia Therapy
CBR-001-669-954-0,RFM-011-135-3,CBR-001-669-954-0,OC(COc1ccc2c(c1)oc(cc2=O)C(=O)O)COc1ccc2c(c1)oc(cc2=O)C(=O)O,CBR-HVAC-12748: Antiallergic; Mediator Release Inhibitors; Antiallergic; Antiallergy/Antiasthmatic Drugs
CBR-001-669-955-1,RFM-011-136-4,CBR-001-669-955-1,COC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)C(c1cccc(c1)NS(=O)(=O)CC)N,CBR-HVAC-07617: Cell wall synthesis inhibitor
CBR-001-669-956-2,RFM-011-137-5,CBR-001-669-956-2,NC1CN([C@@H]1C)c1nc2c(cc1F)c(=O)c(cn2C1CC1)C(=O)O,CBR-HVAC-13361: DNA topoisomerase II Inhibitor; Antibacterial
CBR-001-669-957-3,RFM-011-138-6,CBR-001-669-957-3,O=C(N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)CC(=O)O)CCCCc1cccc(c1)C(=N)N,analog of CBR-HVAC-04321
CBR-001-669-958-4,RFM-011-139-7,CBR-001-669-958-4,C1CCN(CC1)CCC(c1ccccc1)c1ccccc1,CBR-HVAC-13331: Anticholinergic agent; Antiallergic; Antispasmodic
CBR-001-669-959-5,RFM-011-140-0,CBR-001-669-959-5,OCc1ccc(cc1O)C(CNC(C)(C)C)O,CBR-HVAC-02587: Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Inhibitor; Beta-2-adrenergic-receptor-agonists; Short-acting beta 2 adrenoceptor (SABA) agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Bronchodilator; Bronchodilators; Obstructive Airways Disease; Respiratory Tract Disorders; Treatment of Autoimmune Diseases
CBR-001-669-960-8,RFM-011-141-1,CBR-001-669-960-8,O=C1[C@@H](NC(=O)/C(=N/OC(C(=O)O)(C)C)/c2csc(n2)N)[C@@H]2N1C(=C(CS2)C[N+]1(C)Cc2c(C1)cc(c(c2)O)O)C(=O)[O-],CBR-HVAC-10660: Antibacterial; Cell wall synthesis inhibitor; Antibacterial
CBR-001-669-961-9,RFM-011-142-2,CBR-001-669-961-9,CC(COc1cccc2c1cc(n2)C(=O)NC1CCN(CC1)CCN1CCCCCC1)C,CBR-HVAC-13924: Chemokine CCR2 (MCP-1 Receptor) Antagonists; Chemokine CCR5 Antagonists; Signal Transduction Modulators; Anti-HIV Agents
CBR-001-669-962-0,RFM-011-143-3,CBR-001-669-962-0,ClCC(=O)N(c1ccc(cc1)C(=O)N1CCN(CC1)CCc1ccc(cc1)Cl)CCOC(C)C,"CBR-HVAC-10576: IL-1 Inhibitors; Interleukin 1 synthesis inhibitor; Interleukin synthesis inhibitor; Signal Transduction Modulators; TNF synthesis inhibitor; TNF-alpha Production Inhibitors; Anti-inflammatory; Antiarthritic Drugs; Immunosuppressant; Inflammatory Bowel Disease, Agents for"
CBR-001-669-963-1,RFM-011-144-4,CBR-001-669-963-1,NCCCC[C@@H](C(=O)O)NC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC,CBR-HVAC-07791:
CBR-001-669-964-2,RFM-011-145-5,CBR-001-669-964-2,Nc1ccc(cc1F)c1cc(=O)c2c(o1)c(F)c(c(c2N)F)C,CBR-HVAC-00235: Agonist; Apoptosis-stimulating protein of p53; Aryl Hydrocarbon Receptor (AhR) Ligands; Aryl Hydrocarbon Receptor Stimulator; DNA inhibitor; DNA-Damaging Drugs; HIF1A Expression Inhibitors; Signal Transduction Modulators; Anticancer; Breast Cancer Therapy; Oncolytic Drugs
CBR-001-669-965-3,RFM-011-146-6,CBR-001-669-965-3,NC1CN(C1C)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-12741: DNA gyrase Inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-669-966-4,RFM-011-147-7,CBR-001-669-966-4,O=CN1CC2(OC1C)CCN(CC2)C,"CBR-HVAC-10508: Muscarinic M1 Agonists; Muscarinic acetylcholine receptor Agonist; Muscarinic receptor agonist; Signal Transduction Modulators; Cognition Disorders, Treatment of; Nootropic"
CBR-001-669-967-5,RFM-011-148-8,CBR-001-669-967-5,CCC(NC(=O)C1(N)CCOCC1)/C=C/C(=O)N1CCc2c1cccc2,CBR-HVAC-13816: Cathepsin C (Dipeptidyl Peptidase I) Inhibitors; Respiratory Disorders (Not Specified)
CBR-001-669-968-6,RFM-011-149-9,CBR-001-669-968-6,CCC(c1cccc(c1)OC)(C(CN(C)C)C)O,CBR-HVAC-12152: Opioid mu receptor agonist; Opioid receptor mu Agonist; Analgesic
CBR-001-669-969-7,RFM-011-150-2,CBR-001-669-969-7,CCN(CCCNc1nccc2c1c(C)c1c(c2C)nc2c1cc(OC)cc2)CC,CBR-HVAC-03637: DNA Topoisomerase II Inhibitors; DNA polymerase Inhibitor; DNA-Intercalating Drugs; Reverse transcriptase; Anticancer; Antineoplastic; Oncolytic Drugs
CBR-001-669-970-0,RFM-011-151-3,CBR-001-669-970-0,CCOc1cc2c(cc1OCC)NC(=O)CN=C2c1ccc(cc1)CCCN1CCC(=O)CC1,"CBR-HVAC-13962: Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Antidepressants; Cognition Disorders, Treatment of; Inflammation, Treatment of"
CBR-001-669-971-1,RFM-011-152-4,CBR-001-669-971-1,CN(CC/C=C/1\c2ccccc2CN(c2c1cccc2)C)C,CBR-HVAC-09238: Anticholinergic
CBR-001-669-972-2,RFM-011-153-5,CBR-001-669-972-2,NNC(=N)c1ccc(cc1)CC(C(=O)N(C1CCCC1)C)NS(=O)(=O)c1ccc2c(c1)cccc2,CBR-HVAC-11147: Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitor; Thrombin Inhibitors; Thrombin inhibitor; Anticoagulant; Anticoagulants
CBR-001-669-973-3,RFM-011-154-6,CBR-001-669-973-3,CN(C(=O)[C@H](N1C(=O)[C@H]([C@H]1/C=C/c1ccccc1)N1C(=O)OC[C@@H]1c1ccccc1)CCC(=O)N1CCC(CC1)N1CCCCC1)Cc1cccc(c1)C(F)(F)F,analog of CBR-HVAC-06302
CBR-001-669-974-4,RFM-011-155-7,CBR-001-669-974-4,OC[C@@H]1N(C)CC[C@H]1c1c(O)cc(c2c1oc(cc2=O)c1ccc(cc1Cl)C(F)(F)F)O,CBR-HVAC-07168: CDK1/Cyclin B Inhibitors; CDK2/Cyclin E Inhibitors; CDK4/Cyclin D Inhibitors; CDK4/Cyclin D1 Inhibitors; CDK9/Cyclin T1 Inhibitors; Signal Transduction Modulators; Breast Cancer Therapy; Lymphocytic Leukemia Therapy; Melanoma Therapy; Non-Hodgkin's Lymphoma Therapy; Solid Tumors Therapy
CBR-001-669-975-5,RFM-011-156-8,CBR-001-669-975-5,CN1CCN2C(C1)c1cccn1Cc1c2cccc1,CBR-HVAC-01122: Alpha 2 adrenoreceptor antagonist; Alpha-2 adrenergic receptor Antagonist; Signal Transduction Modulators; alpha2-Adrenoceptor Antagonists; Antidepressant; Antidepressants
CBR-001-669-976-6,RFM-011-157-9,CBR-001-669-976-6,CNS(=O)(=O)Cc1ccc2c(c1)c(cn2)C[C@H]1CCCN1C,CBR-HVAC-04360: 5 Hydroxytryptamine 1B receptor agonist; 5 Hydroxytryptamine 1D receptor agonist; 5-HT1D Agonists; 5-Hydroxytryptamine 1B receptor Agonist; 5-Hydroxytryptamine 1D receptor; Signal Transduction Modulators; Antimigraine; Antimigraine Drugs; Vasoconstrictor
CBR-001-669-977-7,RFM-011-158-0,CBR-001-669-977-7,CO/N=C(\c1csc(n1)NC(=O)C(N)C)/C(=O)NC1C(=O)N2C1SCC=C2C(=O)O,CBR-HVAC-13682: metabolite of CBR-HVAC-07608
CBR-001-669-978-8,RFM-011-159-1,CBR-001-669-978-8,COc1cc(ccc1n1c[n+](c(c1)C)COP(=O)(O)[O-])/C=C/1\CCCN(C1=O)[C@H](c1ccc(cc1)F)C,"CBR-HVAC-14029: gamma-Secretase Modulators; Alzheimer's Dementia, Treatment of"
CBR-001-669-979-9,RFM-011-160-4,CBR-001-669-979-9,COc1cc(ccc1N1CC[C@H](C1)O)n1cnc2c(c1=O)sc(c2)c1ccc(cc1)Cl,CBR-HVAC-06255: Melanin-Concentrating Hormone MCH-R1 (SLC-1) Receptor Antagonists; Signal Transduction Modulators; Antiobesity Drugs
CBR-001-669-980-2,RFM-011-161-5,CBR-001-669-980-2,COc1cc(NCc2ccc3c(c2C)c(N)nc(n3)N)cc(c1OC)OC,"CBR-HVAC-02916: Antimetabolites; Dihydrofolate Reductase (DHFR) Inhibitors; Dihydrofolate reductase inhibitor; Thymidylate synthase inhibitor; Antimalarials; Oncolytic Drugs; Pneumocystis jiroveci Pneumonia, Agents for; Treatment of Opportunistic Infections"
CBR-001-669-981-3,RFM-011-162-6,CBR-001-669-981-3,COc1cc(ccc1OC)C1CCN(CC1)CC[C@H]1CCOc2c1cccc2,CBR-HVAC-04113: Inwardly rectifying potassium channel Blocker; Polarisation inhibitor; Potassium Channel Blockers; Potassium channel antagonist; Antiarrhythmic Drugs; Class III antiarrhythmic
CBR-001-669-982-4,RFM-011-163-7,CBR-001-669-982-4,COc1ccc(cn1)NC(=O)c1nnc2c1cc(cc2)c1cncc(c1)CN1CCC(C1)(F)F,"CBR-HVAC-14159: Osteoarthritis, Treatment of"
CBR-001-669-983-5,RFM-011-164-8,CBR-001-669-983-5,Fc1cc2CC(COc2c(c1)F)n1c(CCNCc2ccccc2)c[nH]c1=S,"CBR-HVAC-06841: Dopamine beta-monooxygenase Inhibitors; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-669-984-6,RFM-011-165-9,CBR-001-669-984-6,OC(=O)CC[C@@H](C(=O)N1CCC[C@H]1B(O)O)N,"CBR-HVAC-02725: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Dipeptidyl-peptidase 4; Fibroblast Activation Protein-alpha (FAPalpha) Inhibitors; Glucagon-like peptide 1 receptor Inhibitor; Modulator; Signal Transduction Modulators; Anticancer; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-669-985-7,RFM-011-166-0,CBR-001-669-985-7,NC1CN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)c1cc(N)c(cc1F)F,CBR-HVAC-13269: Antibacterial; Antibacterial; Antibacterial Drugs
CBR-001-669-986-8,RFM-011-167-1,CBR-001-669-986-8,OCCOCCOCCN1CCC(=C2c3ccccc3CC(=O)c3c2ccs3)CC1,CBR-HVAC-12172: 5 Hydroxytryptamine receptor antagonist; Histamine release inhibitor; Slow releasing substance antagonist
CBR-001-669-987-9,RFM-011-168-2,CBR-001-669-987-9,CCOC(=O)[C@@H](c1ncn(c1)C1CCCCC1)Cc1ccc(nc1)N,"CBR-HVAC-13797: Carboxypeptidase U (TAFIa) Inhibitors; Ischemic Stroke, Treatment of"
CBR-001-669-988-0,RFM-011-169-3,CBR-001-669-988-0,NCCC[C@H](N(C(=O)[C@@H]1CCSCCC(=O)N[C@H](Cc2cnc3c2cccc3)C(=O)NC(C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC(=O)N)[C@@H](CC)C)[C@H](CC)C)C)CO,CBR-HVAC-00717: OXYTOCIN RECEPTOR Antagonist; Oxytocin (OT) Antagonists; Oxytocin receptor antagonist; Signal Transduction Modulators; TOCOLYTIC; Treatment of Preterm Labor
CBR-001-669-989-1,RFM-011-170-6,CBR-001-669-989-1,Fc1cccc(c1)N1C(=O)C=C[C@@]21CCN([C@H](C2)C)Cc1ccc(c(c1)n1nccc1C)O,analog of CBR-HVAC-07010: :
CBR-001-669-990-4,RFM-011-171-7,CBR-001-669-990-4,C[C@H]1C[C@@]2(C)[C@H](C[C@@H]1O)CCC1C2CC[C@]2(C1CC[C@@H]2C(=O)C)C,analog of CBR-HVAC-13208:
CBR-001-669-991-5,RFM-011-172-8,CBR-001-669-991-5,CO/N=C(/C(=O)NC1C(=O)N2C1SCC=C2C(=O)OCOC(=O)C(C)(C)C)\c1csc(n1)NC(=O)C(N)C,CBR-HVAC-07608: Cell wall synthesis inhibitor; Antibiotics
CBR-001-669-992-6,RFM-011-173-9,CBR-001-669-992-6,O=C1C(=C(C1=O)NC/C=C\COc1nccc(c1)CN1CCCCC1)N,CBR-HVAC-10993: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Histamine-H2-receptor-antagonists; Signal Transduction Modulators; Antiulcer; Gastric Antisecretory Drugs; Peptic Ulcer Disease
CBR-001-669-993-7,RFM-011-174-0,CBR-001-669-993-7,CCCCCCCCCCCCCCCCCCOP(=O)(OC[C@H]1O[C@H]([C@H]([C@@H]1O)O)n1ccc(nc1=O)N)O,CBR-HVAC-02067: DNA repair enzyme inhibitor; DNA synthesis inhibitor; Antineoplastic; Oncolytic Drugs
CBR-001-669-994-8,RFM-011-175-1,CBR-001-669-994-8,NNC(=O)CN1C(=O)CN=C(c2c1ccc(c2)Br)c1ccccc1,CBR-HVAC-04751: GABA(A) BZ Site Receptor Agonists; Signal Transduction Modulators; Anxiolytics
CBR-001-669-995-9,RFM-011-176-2,CBR-001-669-995-9,COc1cc(c(cc1C=C)C(=O)Nc1ccc(cc1)C(=N)N)c1ccc(nc1C(=O)O)C(=O)NCC1CC1,"CBR-HVAC-06512: Kallikrein B (Plasma Kallikrein; KLKB1) Inhibitors; Hematologic Genetic Disorders, Treatment of"
CBR-001-669-996-0,RFM-011-177-3,CBR-001-669-996-0,BrCCNP(=O)(NCCBr)OCc1cnc(n1C)[N+](=O)[O-],CBR-HVAC-06539: Alkylating agent; Anticancer; Bioreducible cytotoxin; DNA Alkylating Drugs; Alkylating agent; Anticancer; Astrocytoma Therapy; Cytotoxic; Digestive/Gastrointestinal Cancer Therapy; Hematological Cancer Therapy; Liver Cancer Therapy; Melanoma Therapy; Multiple Myeloma Therapy; Non-Small Cell Lung Cancer Therapy; Pancreatic Cancer Therapy; Renal Cancer Therapy; Sarcoma Therapy
CBR-001-669-997-1,RFM-011-178-4,CBR-001-669-997-1,CCOc1cc(ccc1C1=N[C@@]([C@@](N1C(=O)N1CCN(CC1)CCS(=O)(=O)C)(C)c1ccc(cc1)Cl)(C)c1ccc(cc1)Cl)C(C)(C)C,CBR-HVAC-08577: Apoptosis Inducers; MDM2 (hdm2) Inhibitors; MDM2 Antagonist; MDM2 inhibitor; Anticancer; Myeloid Leukemia Therapy; Sarcoma Therapy; Solid Tumors Therapy
CBR-001-669-998-2,RFM-011-179-5,CBR-001-669-998-2,OC[C@@]1(O)CC[C@]23C[C@H]1C[C@@H]2CC[C@@H]1[C@]3(C)CC[C@H]([C@@]1(C)CO)O,CBR-HVAC-10454: DNA polymerase Inhibitor; Anticancer; Antineoplastic Antibiotics; Antiviral; Antiviral Drugs
CBR-001-669-999-3,RFM-011-180-8,CBR-001-669-999-3,COc1cc(CC(=O)NN(c2c(C)cccc2N2CCCCC2)c2ccc(cc2)Cc2ccccc2)c(cc1C(=O)O)Br,CBR-HVAC-12585: E1 protein Inhibitor; Anti-infective
CBR-001-670-000-8,RFM-011-181-9,CBR-001-670-000-8,OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)Cl,CBR-HVAC-13652: Glucocorticoid agonist; Immunosuppressant
CBR-001-670-001-9,RFM-011-182-0,CBR-001-670-001-9,COc1cccc(c1)CCc1ccccc1OCC[C@H]1C[C@H](CN1C)O,enantiomer of CBR-HVAC-13686
CBR-001-670-002-0,RFM-011-183-1,CBR-001-670-002-0,ClCC1CN(c2c1c1c(C)cnc1c(c2)O)C(=O)c1cc2c(n1)ccc(c2)N,CBR-HVAC-13687: metabolite of CBR-HVAC-03982
CBR-001-670-003-1,RFM-011-184-2,CBR-001-670-003-1,Fc1ccc(cc1)c1ccc2c(c1)n(cc2C(=O)c1ccn2c1CS[C@@H]2c1cccnc1)C(=O)N(C)C,CBR-HVAC-13692:
CBR-001-670-004-2,RFM-011-185-3,CBR-001-670-004-2,Fc1ccc(cc1)c1ccc2c(c1)n(cc2C(=O)c1ccn2c1CS[C@@H]2c1cccnc1)C(=O)N(C)C,CBR-HVAC-13692:
CBR-001-670-005-3,RFM-011-186-4,CBR-001-670-005-3,Cn1ncc(c1)c1cnc2c(c1)c(cn2)Cc1cc(F)c(cc1Cl)OCc1nc2c(n1)cccc2,CBR-HVAC-13992: Raf Kinase Inhibitors; Signal Transduction Modulators; Non-Opioid Analgesics; Treatment of Renal Diseases
CBR-001-670-006-4,RFM-011-187-5,CBR-001-670-006-4,COc1cccc(c1)CCc1ccccc1OCC[C@@H]1C[C@H](CN1C)O,CBR-HVAC-13686: 5-HT2A Receptor Antagonists; 5-HYDROXYTRYPTAMINE 2A RECEPTOR Antagonist; Signal Transduction Modulators; Antiplatelet Therapy; Treatment of Peripheral Obstructive Vascular Disease
CBR-001-670-007-5,RFM-011-188-6,CBR-001-670-007-5,CCCCC/C=C\C/C=C\CCCCCCCc1ccco1,CBR-HVAC-06344: Dermatologic Drugs
CBR-001-670-008-6,RFM-011-189-7,CBR-001-670-008-6,OC[C@@H]1O[C@@H](C[C@@H]1O)n1cnc2c1ncnc2N,CBR-HVAC-12180:
CBR-001-670-009-7,RFM-011-190-0,CBR-001-670-009-7,N#CCC(=O)N/N=C/c1c[n+]([O-])c2c([n+]1[O-])cccc2,CBR-HVAC-10217: Antibiotic
CBR-001-670-010-0,RFM-011-191-1,CBR-001-670-010-0,CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](Cn1ccc(nc1=O)N)CO)O,CBR-HVAC-00831: Antiviral; DNA Polymerase Inhibitors; DNA directed DNA polymerase inhibitor; Anti-Cytomegalovirus Drugs; Anti-Herpes Simplex Virus Drugs; Anti-Herpes Virus Drugs; Antiviral; Antiviral Drugs
CBR-001-670-011-1,RFM-011-192-2,CBR-001-670-011-1,CCOCn1cc(F)c(=O)n(c1=O)C(=O)c1cccc(c1)C(=O)Oc1nc(ccc1C#N)OC(=O)c1ccccc1,CBR-HVAC-01086: Antimetabolites; Thymidylate synthase inhibitor; Anticancer; Breast Cancer Therapy; Colorectal Cancer Therapy; Oncolytic Drugs; Pancreatic Cancer Therapy
CBR-001-670-012-2,RFM-011-193-3,CBR-001-670-012-2,O=C(N[C@@H]1N=C(c2ccccc2)c2c(N(C1=O)C)cccc2)Nc1cccc(c1)c1noc(=O)n1,CBR-HVAC-11212: Cholecystokinin B receptor Antagonist; Anxiolytic
CBR-001-670-013-3,RFM-011-194-4,CBR-001-670-013-3,OC(C(C(OS(=O)(=O)C)COS(=O)(=O)C)O)C(OS(=O)(=O)C)COS(=O)(=O)C,CBR-HVAC-08713: Antineoplastic
CBR-001-670-014-4,RFM-011-195-5,CBR-001-670-014-4,CN(CCN(C1COc2ccccc2c2n(C1)c1cc(ccc1c2C1CCCCC1)C(=O)O)C)C,CBR-HVAC-06695: HCV nonstructural protein 5B inhibitor; NS5B protease Inhibitor; Anti-Hepatitis C Virus Drugs; Antiviral
CBR-001-670-015-5,RFM-011-196-6,CBR-001-670-015-5,CCC(c1ccccc1)CC1COC(=N1)N,CBR-HVAC-13723: Antipsychotic Drugs
CBR-001-670-016-6,RFM-011-197-7,CBR-001-670-016-6,Nc1nc(C)c2c(n1)n(C1CCCC1)c(=O)c(c2)c1cnnc1,CBR-HVAC-13765: Glucocorticoid Receptor (GR) Agonists; Signal Transduction Modulators; Drugs for Allergic Rhinitis
CBR-001-670-017-7,RFM-011-198-8,CBR-001-670-017-7,COc1cccc(c1c1ccc2c(c1)CCNCC2)OCc1nccc(c1)C,"CBR-HVAC-13837: Signal Transduction Modulators; Syk Kinase Inhibitors; Urticaria, Treatment for"
CBR-001-670-018-8,RFM-011-199-9,CBR-001-670-018-8,CNCc1ccc(c(c1)[C@@]1(c2cc(Cl)ccc2N(C1=O)S(=O)(=O)c1ccc(cc1)OC)N1CCC[C@H]1c1ncco1)OC,CBR-HVAC-14093: Signal Transduction Modulators; Vasopressin (AVP) V1b Receptor Antagonists; Antidepressants; Anxiolytics; Treatment of Alcohol Dependency
CBR-001-670-019-9,RFM-011-200-5,CBR-001-670-019-9,CNCc1ccc(c(c1)[C@]1(c2cc(Cl)ccc2N(C1=O)S(=O)(=O)c1ccc(cc1)OC)N1CCC[C@H]1c1ncco1)OC,CBR-HVAC-14093: Signal Transduction Modulators; Vasopressin (AVP) V1b Receptor Antagonists; Antidepressants; Anxiolytics; Treatment of Alcohol Dependency
CBR-001-670-020-2,RFM-011-201-6,CBR-001-670-020-2,CN1CC2C(C1)(CCCC2)c1ccc(c(c1)Cl)Cl,"CBR-HVAC-13742: 5-HT Reuptake Inhibitors; Dopamine Reuptake Inhibitors; Norepinephrine Reuptake Inhibitors; Signal Transduction Modulators; Antidepressants; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Neuropathic Pain, Treatment of"
CBR-001-670-021-3,RFM-011-202-7,CBR-001-670-021-3,CN1CC2C(C1)(CCCC2)c1ccc(c(c1)Cl)Cl,"CBR-HVAC-13742: 5-HT Reuptake Inhibitors; Dopamine Reuptake Inhibitors; Norepinephrine Reuptake Inhibitors; Signal Transduction Modulators; Antidepressants; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Neuropathic Pain, Treatment of"
CBR-001-670-022-4,RFM-011-203-8,CBR-001-670-022-4,CN[C@@H](C1(CCC1)c1ccc(cc1)Cl)CC(C)C,"CBR-HVAC-12617: 5-HT Reuptake Inhibitors; Dopamine Reuptake Inhibitors; Norepinephrine Reuptake Inhibitors; Signal Transduction Modulators; Antidepressants; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of"
CBR-001-670-023-5,RFM-011-204-9,CBR-001-670-023-5,N#Cc1ccc(cc1)C(N1CCN(C(C1)c1ccc(cc1)Cl)c1ccc(cc1Cl)C#N)C,CBR-HVAC-12334: Cannabinoid CB1 Antagonists; Cannabinoid CB1 receptor antagonist; Signal Transduction Modulators; Antiobesity Drugs
CBR-001-670-024-6,RFM-011-205-0,CBR-001-670-024-6,COC1(CCOC(C1)C)/C=C/COCc1ccc2c(c1)ccc(=O)n2C,CBR-HVAC-11372: 5 Lipoxygenase inhibitor; Lipoxygenase 5 Inhibitor; Lipoxygenase Inhibitors; Antiallergic; Antiallergy/Antiasthmatic Drugs; Non-steroidal antiinflammatory
CBR-001-670-025-7,RFM-011-206-1,CBR-001-670-025-7,CCCn1cnc2c1c(=O)n(CCCCC(O)(C)C)c(=O)n2C,"CBR-HVAC-13203: TNF Antagonist; Immunosuppressant; Septic Shock, Treatment of"
CBR-001-670-026-8,RFM-011-207-2,CBR-001-670-026-8,OC(=O)CO/N=C/C(Cc1c(SC(C)(C)C)c2c(n1Cc1ccc(cc1)Cl)ccc(c2)OCc1ccc2c(n1)cccc2)(C)C,CBR-HVAC-11104: 5-Lipoxygenase activating protein Inhibitor; 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors; Leucotriene receptor antagonist; Lipoxygenase Inhibitors; Antiallergy/Antiasthmatic Drugs; Antiasthmatic
CBR-001-670-027-9,RFM-011-208-3,CBR-001-670-027-9,Oc1ccnc(n1)SCCCN1CCN(CC1)c1cc(nc(n1)C(C)(C)C)C(F)(F)F,CBR-HVAC-05152: Dopamine D3 Antagonists; Dopamine receptor D3 Antagonist; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs
CBR-001-670-028-0,RFM-011-209-4,CBR-001-670-028-0,OCC(=O)COC(=O)c1cncn1[C@@H](c1ccccc1)C,CBR-HVAC-07410: GABA receptor agonist
CBR-001-670-029-1,RFM-011-210-7,CBR-001-670-029-1,O=C(C(=O)C(NC(=O)C1CCC(=O)N1Cc1ccccc1)Cc1ccccc1)NCc1ccccn1,"CBR-HVAC-13987: Alzheimer's Dementia, Treatment of"
CBR-001-670-030-4,RFM-011-211-8,CBR-001-670-030-4,CC(=O)Oc1cc(OC(=O)C)c2c(c1)O[C@@H]([C@@H](C2)OC(=O)c1cc(OC(=O)C)c(c(c1)OC(=O)C)OC(=O)C)c1cc(OC(=O)C)c(c(c1)OC(=O)C)OC(=O)C,"CBR-HVAC-06149: AP-1 Inhibitors; Angiogenesis Inhibitors; Antioxidants; Apoptosis Inducers; Aromatase Inhibitors; Bacterial Efflux Pump Inhibitors; Fatty Acid Synthase (FAS) Inhibitors; HCV NS3 Protease Inhibitors; Indoleamine 2,3-dioxygenase Inhibitors; NF-kappaB (NFKB) Activation Inhibitors; PDGFR Family Inhibitors; Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors; Proteasome Inhibitors; SGLT-1 Inhibitors; Signal Transduction Modulators; Telomerase Inhibitors; Tumor NADH Oxidase (tNOX) Inhibitors; VEGFR-2 (FLK-1/KDR) Inhibitors; Wnt Signaling Inhibitors; beta-Amyloid (Abeta) Aggregation Inhibitors; beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors; beta-Secretase (BACE) Inhibitors; Endometriosis Therapy; Gynecological Disorders, Treatment of ; Lymphocytic Leukemia Therapy; Solid Tumors Therapy"
CBR-001-670-031-5,RFM-011-212-9,CBR-001-670-031-5,COc1ccc(cc1)Cc1cccc(c1)c1c(=O)[nH]c2c(c1OC(=O)C)ccc(c2)Cl,CBR-HVAC-15135: NMDA Glycine-Site Receptor Antagonists; Signal Transduction Modulators; Radiopharmaceuticals for Brain Imaging
CBR-001-670-032-6,RFM-011-213-0,CBR-001-670-032-6,O=C(N1CC2C3(C1=CC(=O)c1c3c(C)cn1)C2)c1nc2c(c1)cc(cc2)NC(=O)c1cc2c(o1)cccc2,CBR-HVAC-03504: DNA synthesis inhibitor; DNA topoisomerase II Inhibitor; DNA-Damaging Drugs; P glycoprotein inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-033-7,RFM-011-214-1,CBR-001-670-033-7,N#Cc1cc(NC2=NCCN2)c(c2c1ncn2)C,"CBR-HVAC-13728: Drugs Acting on Adrenergic Transmission; Signal Transduction Modulators; Hypertension, Treatment of; Treatment of Hot Flushes"
CBR-001-670-034-8,RFM-011-215-2,CBR-001-670-034-8,OCC(c1ccccc1)NC(=O)C(c1cccc(c1)Cn1c2ccccc2c2c1nc(C)cc2C)C1CCCC1,CBR-HVAC-13430: Microsomal triglyceride transfer protein Inhibitor; Antihypercholesterolemic
CBR-001-670-035-9,RFM-011-216-3,CBR-001-670-035-9,CCNCc1cncc(c1C)c1ccc2c(c1)c(nn2)c1nc2c(n1)cc(cc2F)F,CBR-HVAC-11711: Angiogenesis Inhibitors; CDK1; CDK1 Inhibitors; CDK2; CDK2 Inhibitors; CDK4 Inhibitor; CDK4 Inhibitors; Signal Transduction Modulators; Anticancer; Oncolytic Drugs;2018-01-24: ARB# 18-000014
CBR-001-670-036-0,RFM-011-217-4,CBR-001-670-036-0,CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@@H](n1cccc(c1=O)NC(=O)c1noc(c1)C)CC#C,CBR-HVAC-05955: HRV 3C Protease Inhibitors; Anti-Rhinovirus Drugs
CBR-001-670-037-1,RFM-011-218-5,CBR-001-670-037-1,OC(=O)c1ccc(cc1)C#Cc1ccc2c(c1)C(=CCC2(C)C)c1ccccc1,CBR-HVAC-09343: Retinoid X receptor Agonist; Retinoid acid receptor; Anticancer; Hypoglycemic agent
CBR-001-670-038-2,RFM-011-219-6,CBR-001-670-038-2,O=C1NC(=O)C(C1c1nc(cc2c1cccc2)N1CCNC2(C1)CC2)c1cnc2c1cccc2C,CBR-HVAC-13963: Protein Kinase Inhibitors; Signal Transduction Modulators; Antipsoriatics; Treatment of Transplant Rejection
CBR-001-670-039-3,RFM-011-220-9,CBR-001-670-039-3,COc1cc(F)cc2c1c1ccc(cc1C12NC(=O)NC1=O)F,CBR-HVAC-13274: Aldose reductase Inhibitor; Antidiabetic
CBR-001-670-040-6,RFM-011-221-0,CBR-001-670-040-6,CCC(=O)O[C@@]1([C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@H]1[C@H]2[C@H](Cl)CC2=CC(=O)C=C[C@]12C)C(=O)COC(=O)CC,CBR-HVAC-02007: Antiinflammatory Drugs; Glucocorticoid agonist; Immunosuppressant; Lipocortin Agonist; Anti-inflammatory; Antipruritic; Dermatologic Drugs
CBR-001-670-041-7,RFM-011-222-1,CBR-001-670-041-7,Clc1ccc(cc1)/C(=C/c1ccc(cc1Cl)Cl)/Cn1cncc1,CBR-HVAC-01097: Cell wall synthesis inhibitor; Sterol demethylase inhibitor; Antifungal
CBR-001-670-042-8,RFM-011-223-2,CBR-001-670-042-8,Clc1ccc(cc1)/C(=C\c1ccc(cc1Cl)Cl)/Cn1cncc1,CBR-HVAC-01097: Cell wall synthesis inhibitor; Sterol demethylase inhibitor; Antifungal
CBR-001-670-043-9,RFM-011-224-3,CBR-001-670-043-9,CCOC(=O)c1nc2c(c1CCN1CCN(CC1)c1ccccc1)cc(c(c2)OC)OC,CBR-HVAC-09391: Antipsychotic; ANTIPSYCHOTIC; TRANQUILIZER
CBR-001-670-044-0,RFM-011-225-4,CBR-001-670-044-0,Clc1ccc(cc1)[C@]1(Cn2cncn2)O[C@H]1c1ccc(cc1Cl)Cl,CBR-HVAC-01096: Cell wall synthesis inhibitor; Sterol demethylase inhibitor; Antifungal
CBR-001-670-045-1,RFM-011-226-5,CBR-001-670-045-1,CC([C@@]1(C)SC(=NC1=O)NC1C[C@@H]2C[C@H]1CC2)C,"CBR-HVAC-06367: 11 Beta hydroxysteroid dehydrogenase inhibitor; 11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors; 11-beta-hydroxysteroid dehydrogenase 1 Inhibitor; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-670-046-2,RFM-011-227-6,CBR-001-670-046-2,Nc1ccc(cc1)C(=O)Oc1c(C)c(O)c2c(c1O)cccc2,"CBR-HVAC-06759: Cardiovascular Diseases (Not Specified); Edema, Treatment of; Hemostatics; Peripheral Vascular Disease, Treatment of; Pulmonary Hypertension, Treatment of; Wound-Healing Agents"
CBR-001-670-047-3,RFM-011-228-7,CBR-001-670-047-3,CN(CC1CCOC1(c1ccccc1)c1ccccc1)C,"CBR-HVAC-06556: Drugs Acting on NMDA Receptors; Drugs Acting on Sodium Channels (Voltage-Gated); Ionotropic glutamate receptor NMDA; Lipid Peroxidation Inhibitors; Muscarinic M1 Agonists; Muscarinic M2 receptor antagonist; Muscarinic M3 receptor antagonist; Opioid receptor sigma 1; Sigma 1 receptor agonist; Signal Transduction Modulators; Sodium channel Modulator; sigma1 Receptor Agonists; Alzheimer's Dementia, Treatment of ; Amyotrophic Lateral Sclerosis, Agents for; Anti-amnesic; Anti-depressant; Anti-ischemic; Anticonvulsant; Antidiabetic Drugs; Antiepileptic Drugs; Antiparkinsonian Drugs"
CBR-001-670-048-4,RFM-011-229-8,CBR-001-670-048-4,CCCn1c2nc([nH]c2c(=O)n(c1=O)CCC)C1CCC(=O)C1,"CBR-HVAC-01066: Adenosine A1 Antagonists; Adenosine A1 Receptor Antagonist; Adenosine A1 receptor antagonist; Signal Transduction Modulators; Cognition Disorders, Treatment of; Diuretics; NEUROPROTECTIVE; NOOTROPIC"
CBR-001-670-049-5,RFM-011-230-1,CBR-001-670-049-5,OC/C=C/c1n(C)c2c(c1CO)C(=O)C(=CC2=O)N1CC1,CBR-HVAC-00838: DNA Alkylating Drugs; DNA inhibitor; DNA synthesis inhibitor; Anticancer; Bladder Cancer Therapy ; Oncolytic Drugs
CBR-001-670-050-8,RFM-011-231-2,CBR-001-670-050-8,O=C1Nc2ccccc2C(c2c1cccc2)C(=O)NC1CN2CCC1CC2,CBR-HVAC-10492: Muscarinic acetylcholine receptor M1 Antagonist; Muscarinic acetylcholine receptor M3; Bronchodilator
CBR-001-670-051-9,RFM-011-232-3,CBR-001-670-051-9,COC(=O)C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])C(=O)OCC(=O)C)C,"CBR-HVAC-01800: Calcium Channel Blockers; Calcium channel Antagonist; L-type calcium channel antagonist; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-052-0,RFM-011-233-4,CBR-001-670-052-0,O=c1nc2c(s1)c(CCNCCNS(=O)(=O)CCOCCc1ccccc1)ccc2O,"CBR-HVAC-04930: Beta-2 adrenergic receptor; Dopamine D2 Agonists; Dopamine receptor D2 Agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Antiasthmatic; Bronchodilators; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-670-053-1,RFM-011-234-5,CBR-001-670-053-1,OC(CN1CCCCC1)CON=C(c1ccc[n+](c1)[O-])Cl,"CBR-HVAC-00757: Heat Shock Transcription Factor 1 Activator; Heat shock protein agonist; Amyotrophic Lateral Sclerosis, Agents for; Hypoglycemic; Neuroprotectant; Pancreatic Disorders, Treatment of; Stroke, Treatment of; Therapy of Inborn Errors of Metabolism; Treatment of Diabetic Complications; Type 2 Diabetes, Agents for"
CBR-001-670-054-2,RFM-011-235-6,CBR-001-670-054-2,OC(CN1CCCCC1)CON=C(c1ccc[n+](c1)[O-])Cl,"CBR-HVAC-00757: Heat Shock Transcription Factor 1 Activator; Heat shock protein agonist; Amyotrophic Lateral Sclerosis, Agents for; Hypoglycemic; Neuroprotectant; Pancreatic Disorders, Treatment of; Stroke, Treatment of; Therapy of Inborn Errors of Metabolism; Treatment of Diabetic Complications; Type 2 Diabetes, Agents for"
CBR-001-670-055-3,RFM-011-236-7,CBR-001-670-055-3,Nc1ncccc1c1nc2c(n1c1ccc(cc1)C1(N)CCC1)nc(cc2)c1ccccc1,"CBR-HVAC-13911: PKB alpha/Akt1 Inhibitors; PKB beta/Akt2 Inhibitors; PKB gamma/Akt3 Inhibitors; Signal Transduction Modulators; Congenital Malformations, Treatment of; Lymphoma Therapy; Solid Tumors Therapy"
CBR-001-670-056-4,RFM-011-237-8,CBR-001-670-056-4,CCCCN(CCCC)CCCC(c1ccc(cc1)NS(=O)(=O)C)O,CBR-HVAC-12835: Polarisation inhibitor; Potassium channel agonist; Sodium channel antagonist; Antiarrhythmic Drugs
CBR-001-670-057-5,RFM-011-238-9,CBR-001-670-057-5,CCCCN(CCCC)CCCC(c1ccc(cc1)NS(=O)(=O)C)O,CBR-HVAC-12835: Polarisation inhibitor; Potassium channel agonist; Sodium channel antagonist; Antiarrhythmic Drugs
CBR-001-670-058-6,RFM-011-239-0,CBR-001-670-058-6,CCOCCOC(=O)C(=O)Nc1scc(n1)c1onc(c1)C,CBR-HVAC-01084: 5 Hydroxytryptamine receptor antagonist; Antiallergic;Antiasthmatic; Histamine receptor antagonist; Leukotriene Antagonists; Mediator Release Inhibitors; Signal Transduction Modulators; ANTIALLERGIC; ANTIASTHMATIC; Antiallergy/Antiasthmatic Drugs
CBR-001-670-059-7,RFM-011-240-3,CBR-001-670-059-7,N=C([C@H](O)C)NS(=O)(=O)c1cc(ccc1F)C(=O)C(=c1nc2c(n1)cccc2)C(=O)c1cc(F)ccc1F,CBR-HVAC-14039: GnRH (LHRH) Antagonists; Signal Transduction Modulators; Endometriosis Therapy; Prostate Cancer Therapy
CBR-001-670-060-0,RFM-011-241-4,CBR-001-670-060-0,COC(=O)N1CCC(CC1)CC#Cc1nc(N)c2c(n1)n(cn2)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)C(=O)NC1CC1,"CBR-HVAC-12693: ADENOSINE A2A RECEPTOR Agonist; Adenosine A2A Agonists; Adenosine A2a receptor agonist; Signal Transduction Modulators; Anti-inflammatory; Antiglaucoma Agents; Hematological Cancer Therapy; Inflammatory Bowel Disease, Agents for; Lesions of the Spinal Cord and Related Structures, Treatment of; Neuropathic Pain, Treatment of; Ophthalmic Drugs; Ophthalmological agent; Septic Shock, Treatment of"
CBR-001-670-061-1,RFM-011-242-5,CBR-001-670-061-1,O=C1NC(C(=O)N1c1ccc(nc1)Oc1cccc2c1C(C)CCO2)(C)C,"CBR-HVAC-13823: K(V)3.1 (KCNC1) Channel Modulators; Potassium Channel Modulators; Hearing loss, treatment of; Tinnitus, treatment of"
CBR-001-670-062-2,RFM-011-243-6,CBR-001-670-062-2,O=C1NC(C(=O)N1c1ccc(nc1)Oc1cccc2c1C(C)CCO2)(C)C,"CBR-HVAC-13823: K(V)3.1 (KCNC1) Channel Modulators; Potassium Channel Modulators; Hearing loss, treatment of; Tinnitus, treatment of"
CBR-001-670-063-3,RFM-011-244-7,CBR-001-670-063-3,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(n1)C#CC#Cc1ccc(cc1)c1cnc(n1)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)C(C)C,CBR-HVAC-07236: HCV NS5A Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-670-064-4,RFM-011-245-8,CBR-001-670-064-4,Fc1ccc(cc1)c1occ(n1)COC1CCCC(C1)OCc1cccc(c1C(=O)O)C,"CBR-HVAC-13921: Insulin Sensitizers; PPARalpha Agonists; PPARgamma Agonists; Signal Transduction Modulators; Lipoprotein Disorders, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-670-065-5,RFM-011-246-9,CBR-001-670-065-5,COc1ccc(cc1)c1nnc(o1)C(=O)N1CC(C1)Oc1ccc(cc1)CN1CC2(C1)COC2,CBR-HVAC-13956: Drugs Acting on Melanin-Concentrating Hormone (MCH) Receptors; Signal Transduction Modulators; Antiobesity Drugs
CBR-001-670-066-6,RFM-011-247-0,CBR-001-670-066-6,C[C@@H]1OCC[C@](C1)(O)c1csc(c1)Sc1ccc2c(c1)CC(=O)N2C,"CBR-HVAC-04672: 15-Lipoxygenase Inhibitor; 5 Lipoxygenase inhibitor; 5-Lipoxygenase Inhibitors; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-670-067-7,RFM-011-248-1,CBR-001-670-067-7,OC[C@@H]([C@H](Oc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O,"CBR-HVAC-06407: Chemokine CXCR2  (IL-8 beta Receptor) Receptor Ligands; Signal Transduction Modulators; Asthma Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Head and Neck Cancer Therapy; Respiratory Disorders (Not Specified)"
CBR-001-670-068-8,RFM-011-249-2,CBR-001-670-068-8,CCCCOc1nc(N)c2c(n1)n(CCCN(Cc1cccc(c1)CC(=O)OC)CCCN1CCOCC1)c(=O)[nH]2,CBR-HVAC-11850: Signal Transduction Modulators; TLR7 Receptor Agonists; Toll-like receptor 7 Agonist; Anti-inflammatory; Asthma Therapy; Drugs for Allergic Rhinitis
CBR-001-670-069-9,RFM-011-250-5,CBR-001-670-069-9,O=C1C[C@H](N1)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1ncnc1,CBR-HVAC-03215: Opioid receptor kappa Agonist; Thyroid hormone function stimulant; Anti-ischemic; Anticonvulsant; CNS Stimulants; Nootropic
CBR-001-670-070-2,RFM-011-251-6,CBR-001-670-070-2,CCOC(=O)OC(OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)/N=C/N1CCCCCC1)C,CBR-HVAC-13061: Cell wall synthesis inhibitor; Antibacterial
CBR-001-670-071-3,RFM-011-252-7,CBR-001-670-071-3,CN1C[C@H](Cn2cncn2)C[C@H]2[C@H]1Cc1cnc3c1c2ccc3,CBR-HVAC-04686: Alpha 2 adrenoreceptor agonist; Dopamine D1 Agonists; Dopamine D1 receptor agonist; Dopamine D2 Agonists; Dopamine D2 receptor agonist; Dopamine receptor Agonist; Signal Transduction Modulators; Antiparkinsonian; Antiparkinsonian Drugs
CBR-001-670-072-4,RFM-011-253-8,CBR-001-670-072-4,ONC(=O)C([C@@H](C(=O)N[C@@H](C(=O)NC)CCC(=O)OC)CC(C)C)CSc1ccc(cc1)O,"CBR-HVAC-10694: Collagenase Inhibitors; Matrix metalloproteinase Inhibitor; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Anti-inflammatory; Antiarthritic Drugs; Anticancer; Septic Shock, Treatment of"
CBR-001-670-073-5,RFM-011-254-9,CBR-001-670-073-5,ONC(=O)C([C@@H](C(=O)N[C@@H](C(=O)NC)CCC(=O)OC)CC(C)C)CSc1ccc(cc1)O,"CBR-HVAC-10694: Collagenase Inhibitors; Matrix metalloproteinase Inhibitor; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Anti-inflammatory; Antiarthritic Drugs; Anticancer; Septic Shock, Treatment of"
CBR-001-670-074-6,RFM-011-255-0,CBR-001-670-074-6,ONC(=O)[C@H]([C@H](C(=O)N[C@@H](c1ccccc1)C(=O)OC1CCCC1)CC(C)C)CC=C,CBR-HVAC-11775: Aminopeptidase inhibitor; Anti-inflamatory
CBR-001-670-075-7,RFM-011-256-1,CBR-001-670-075-7,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1c(Br)nc2c1cc(Cl)c(c2)Cl,CBR-HVAC-13453: HCMV replication inhibitor; Antiviral; Antiviral Drugs
CBR-001-670-076-8,RFM-011-257-2,CBR-001-670-076-8,CCN(CCn1c(=O)c2c(c1=O)c1c(c3c2c2cccc(c2[nH]3)Cl)n(c2c1cccc2Cl)[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)OC)CC,CBR-HVAC-04711: DNA TOPOISOMERASE I; DNA TOPOISOMERASE II Inhibitor; DNA Topoisomerase II Inhibitors; DNA topoisomerase I inhibitor; DNA topoisomerase II inhibitor; Anticancer; Antineoplastic Antibiotics; Brain Cancer Therapy; Breast Cancer Therapy; Colorectal Cancer Therapy; Liver Cancer Therapy; Lymphocytic Leukemia Therapy; Myeloid Leukemia Therapy; Non-Small Cell Lung Cancer Therapy; Renal Cancer Therapy; Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-001-670-077-9,RFM-011-258-3,CBR-001-670-077-9,O[C@H]1[C@@H](SC[C@H]([C@@H]1O)O)Sc1ccc(cc1)C#N,CBR-HVAC-04299: Antithrombotic; Anticoagulants; Antithrombotic
CBR-001-670-078-0,RFM-011-259-4,CBR-001-670-078-0,Fc1cc2nc3c4c2c(c1)c(=O)nnc4CN1C3(C)CCC1,CBR-HVAC-13753: Poly(ADP-ribose)polymerase-1 (PARP-1; ARTD1) Inhibitors; Poly(ADP-ribose)polymerase-2 (PARP-2; ARTD2) Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-001-670-079-1,RFM-011-260-7,CBR-001-670-079-1,CCCCOP(=O)(CC(CP(=O)(OCCCC)OCCCC)CCOc1ccccc1)OCCCC,"CBR-HVAC-03417: Calcium Channel Blockers; Calcium channel antagonist; L-type calcium channel Inhibitor; Angina pectoris, Treatment of; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-080-4,RFM-011-261-8,CBR-001-670-080-4,CCN(C(=O)C1CN2CCc3c(C2CC1OC(=O)C)cc(c(c3)OC)OC)CC,CBR-HVAC-09545: Dopamine receptor Antagonist; Antiemetic; Antipsychotic
CBR-001-670-081-5,RFM-011-262-9,CBR-001-670-081-5,CCc1occc(=O)c1O[V](=O)Oc1c(=O)ccoc1CC,"CBR-HVAC-06409: Insulin Sensitizers; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-670-082-6,RFM-011-263-0,CBR-001-670-082-6,CCOC(=O)C[C@H](CC(/C=C/C1=C(c2ccc(cc2)F)c2ccccc2OC21CCCC2)O)O,"CBR-HVAC-04058: HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor; Prostanoid TP Antagonists; Signal Transduction Modulators; Thromboxane A2 receptor antagonist; Antifungal; Antifungal Agents; Antihypercholesterolemic; Lipoprotein Disorders, Treatment of"
CBR-001-670-083-7,RFM-011-264-1,CBR-001-670-083-7,CCOC(=O)C[C@H](CC(/C=C/C1=C(c2ccc(cc2)F)c2ccccc2OC21CCCC2)O)O,"CBR-HVAC-04058: HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor; Prostanoid TP Antagonists; Signal Transduction Modulators; Thromboxane A2 receptor antagonist; Antifungal; Antifungal Agents; Antihypercholesterolemic; Lipoprotein Disorders, Treatment of"
CBR-001-670-084-8,RFM-011-265-2,CBR-001-670-084-8,OCC(=O)[C@@]1(OC(=O)c2ccccc2)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-09548: Glucocorticoid receptor Agonist; Anti-inflammatory
CBR-001-670-085-9,RFM-011-266-3,CBR-001-670-085-9,CCCC(=O)O[C@@]1([C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F)C(=O)COC(=O)CC,CBR-HVAC-12710: Antiinflammatory Drugs; Arachidonic acid antagonist; Arachidonic acid inhibitor; Leucotriene receptor antagonist; Leukotriene antagonist; Antipsoriatic; Dermatologic Drugs
CBR-001-670-086-0,RFM-011-267-4,CBR-001-670-086-0,OC[C@H]1O[C@@H](c2ccc(c(c2)Cc2ccc(cc2)OCCOC2CC2)Cl)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-12620: SGLT-2 Inhibitors; Type 2 Diabetes, Agents for"
CBR-001-670-087-1,RFM-011-268-5,CBR-001-670-087-1,O=C(N1CCC(CC1)N1CCc2c(NC1=O)cccc2)OC(C(=O)N1CCC(CC1)N1CCOCC1)Cc1cc(C)c(c(c1)C)O,CBR-HVAC-12108: Calcitonin gene-related peptide Antagonist; Calcitonin receptor-like receptor antagonist; Analgesic
CBR-001-670-088-2,RFM-011-269-6,CBR-001-670-088-2,O=C(N1CCC(CC1)N1CCc2c(NC1=O)cccc2)OC(C(=O)N1CCC(CC1)N1CCOCC1)Cc1cc(C)c(c(c1)C)O,CBR-HVAC-12108: Calcitonin gene-related peptide Antagonist; Calcitonin receptor-like receptor antagonist; Analgesic
CBR-001-670-089-3,RFM-011-270-9,CBR-001-670-089-3,CC(N(C(=O)C)CCC(c1ccccc1Cl)(C(=O)N)CCN1CCCCC1)C,CBR-HVAC-03470: Sodium Channel  Blockers; Sodium channel Blocker; Sodium channel antagonist; Antiarrhythmic Drugs; Class I antiarrhythmic
CBR-001-670-090-6,RFM-011-271-0,CBR-001-670-090-6,CCC(C(c1ccc(c(c1)F)O)C)c1ccc(c(c1)F)O,"CBR-HVAC-00805: Androgen Receptor Antagonists; Androgen receptor antagonist; Signal Transduction Modulators; Steroid 17-alpha-hydroxylase/Steroid 17,20 lyase Inhibitor; ANTI-HYPERPLASTIC; Oncolytic Drugs"
CBR-001-670-091-7,RFM-011-272-1,CBR-001-670-091-7,CCC(C(c1ccc(c(c1)F)O)C)c1ccc(c(c1)F)O,"CBR-HVAC-00805: Androgen Receptor Antagonists; Androgen receptor antagonist; Signal Transduction Modulators; Steroid 17-alpha-hydroxylase/Steroid 17,20 lyase Inhibitor; ANTI-HYPERPLASTIC; Oncolytic Drugs"
CBR-001-670-092-8,RFM-011-273-2,CBR-001-670-092-8,OC(CN1CCCCC1)CO/N=C(/c1cccnc1)\Cl,CBR-HVAC-04606: Heat shock protein Inducer; Heat shock protein agonist; Neuroprotectant; Treatment of Diabetic Complications
CBR-001-670-093-9,RFM-011-274-3,CBR-001-670-093-9,O=C(Oc1ccc2c(c1)[C@]1(C)CCN[C@@H]1N2)Nc1ccc(cc1)C(C)C,"CBR-HVAC-12939: Butyrylcholinesterase Inhibitor; Butyrylcholinesterase Inhibitors; Alzheimer's Dementia, Treatment of ; Neuroprotectant; Nootropic"
CBR-001-670-094-0,RFM-011-275-4,CBR-001-670-094-0,CCCCOP(=O)(OC[C@H]1O[C@H](C[C@@H]1OP(=O)(OCCCC)O)n1cc(C)c(=O)[nH]c1=O)O,CBR-HVAC-06944: Antibacterial Drugs; Antiulcer Drugs
CBR-001-670-095-1,RFM-011-276-5,CBR-001-670-095-1,O=C1NC(=O)C(S1)Cc1ccc(c2c1scc2)OCCc1nc(oc1C)c1cccs1,"CBR-HVAC-11381: Insulin Sensitizers; PPARgamma Agonists; Peroxisome proliferator activated receptor gamma Agonist; Signal Transduction Modulators; Antidiabetic; Antiobesity Drugs; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-670-096-2,RFM-011-277-6,CBR-001-670-096-2,O=C([C@@H](NC(=O)[C@H](c1cc(F)cc(c1)F)O)C)N[C@@H]1C(=O)N(C)N=Cc2c1cccc2,"CBR-HVAC-08585: Antiamyloidogenic Agents; GAMMA SECRETASE Inhibitor; gamma-Secretase Inhibitors; Alzheimer's Dementia, Treatment of ; Amyloid protein deposition inhibitor; Beta amyloid antagonist; Gamma-secretase inhibitor"
CBR-001-670-097-3,RFM-011-278-7,CBR-001-670-097-3,CCn1nc2n(c1=O)n(Cc1ccc(nc1C)C(F)(F)F)c(=O)c(c2c1ccc(cc1)Cl)c1cnc(nc1)C,CBR-HVAC-12271: Cannabinoid CB1 Antagonists; Cannabinoid CB1 receptor Antagonist; Signal Transduction Modulators; Antiobesity Drugs; Appetite suppressant
CBR-001-670-098-4,RFM-011-279-8,CBR-001-670-098-4,CN([C@@H](C(=O)N1CCC[C@H]1c1ncc(n1)c1ccc(cc1)c1ccc(cn1)c1cnc(n1)[C@@H]1CCCN1C(=O)[C@@H](c1ccccc1)N(C)C)c1ccccc1)C,CBR-HVAC-14100: Anti-Hepatitis C Virus Drugs
CBR-001-670-099-5,RFM-011-280-1,CBR-001-670-099-5,CN1Cc2cc(ccc2C(C1)c1ccc2c(c1)cccc2)c1ccc(nn1)N,CBR-HVAC-06919: 5-HT Reuptake Inhibitors; Adrenergic transmitter uptake inhibitor; DOPAMINE TRANSPORTER; Dopamine Reuptake Inhibitors; Dopamine reuptake inhibitor; Inhibitor; NOREPINEPHRIN TRANSPORTER; Norepinephrine Reuptake Inhibitors; SEROTONIN TRANSPORTER Inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor; Signal Transduction Modulators; Antidepressant; Antidepressants
CBR-001-670-100-1,RFM-011-281-2,CBR-001-670-100-1,CN1Cc2cc(ccc2C(C1)c1ccc2c(c1)cccc2)c1ccc(nn1)N,CBR-HVAC-06919: 5-HT Reuptake Inhibitors; Adrenergic transmitter uptake inhibitor; DOPAMINE TRANSPORTER; Dopamine Reuptake Inhibitors; Dopamine reuptake inhibitor; Inhibitor; NOREPINEPHRIN TRANSPORTER; Norepinephrine Reuptake Inhibitors; SEROTONIN TRANSPORTER Inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor; Signal Transduction Modulators; Antidepressant; Antidepressants
CBR-001-670-101-2,RFM-011-282-3,CBR-001-670-101-2,COC(=O)Nc1nc2c(n1)cc(cc2)C1(O)c2ccccc2C(=O)N1Cc1ccccc1,CBR-HVAC-13909: Raf kinase B Inhibitors; Raf kinase C Inhibitors; Signal Transduction Modulators; Colorectal Cancer Therapy; Melanoma Therapy
CBR-001-670-102-3,RFM-011-283-4,CBR-001-670-102-3,C/C=C/C1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N\O)/c1csc(n1)N,CBR-HVAC-13387: Antibacterial; Antimicrobial; Antibacterial; Antimicrobial
CBR-001-670-103-4,RFM-011-284-5,CBR-001-670-103-4,CCCCCCCCN(CC(P(=O)(O)O)P(=O)(O)O)C,CBR-HVAC-12288: FARNESYL DIPHOSPHATE SYNTHASE INHIBITOR; ANTIMALARIAL
CBR-001-670-104-5,RFM-011-285-6,CBR-001-670-104-5,COc1cc(N)c(cc1C(=O)NC1C[C@@H]2CCC[C@H](C1)N2Cc1ccc(cc1)F)Cl,CBR-HVAC-03648: Dopamine D2 Antagonists; Dopamine D2 receptor antagonist; Signal Transduction Modulators; Pharmacological Tools
CBR-001-670-105-6,RFM-011-286-7,CBR-001-670-105-6,COc1cc(N)c(cc1C(=O)NC1C[C@@H]2CCC[C@H](C1)N2Cc1ccc(cc1)F)Cl,CBR-HVAC-03648: Dopamine D2 Antagonists; Dopamine D2 receptor antagonist; Signal Transduction Modulators; Pharmacological Tools
CBR-001-670-106-7,RFM-011-287-8,CBR-001-670-106-7,CCCCC(=O)c1cnc2c(c1Nc1ccccc1C)cccc2OCCO,CBR-HVAC-13635: Potassium-competitive acid antagonist
CBR-001-670-107-8,RFM-011-288-9,CBR-001-670-107-8,CC(=O)NC(c1cc(Cl)ccc1C1CCN(CC1)C(=O)[C@@H]1CN(C[C@H]1c1ccc(cc1F)F)C(C)(C)C)C,CBR-HVAC-12128: Appetite suppressant; Melanocortin MC-4 receptor agonist; Antiobesity Drugs; Appetite Suppressant
CBR-001-670-108-9,RFM-011-289-0,CBR-001-670-108-9,CCCCCCC(c1cc(O)c2c(c1)OC([C@H]1[C@H]2C[C@H](O)CC1)(C)C)(C)C,CBR-HVAC-10371: Cannabinoid receptor B1; Cannabinoid receptor B2 Agonist; Cannabinomimetic
CBR-001-670-109-0,RFM-011-290-3,CBR-001-670-109-0,OC1CC(O)CC(=O)CCCC(=O)CC(=O)OC(C(CC(C(CC(=O)c2ccc(cc2)N)O)C)C)C(C)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(CC(C(C(CC(=O)CC(C1)O)O)C(=O)O)O)OC1OC(C)C(C(C1O)N)O,"CBR-HVAC-13279: Candicidin is a polyene which presumably dissolve into the cell membranes of fungi, bind to ergosterol in the membrane and increase the permeability to ions and metabolites. Leakage of ions through unregulated channels causes cell death; Antifungal"
CBR-001-670-110-3,RFM-011-291-4,CBR-001-670-110-3,Clc1ccc2c(c1)C(c1ccccc1)N(CC(=O)N2C)C(=O)N,CBR-HVAC-01237: Anxiolytic
CBR-001-670-111-4,RFM-011-292-5,CBR-001-670-111-4,Cc1nn(c(c1)NS(=O)(=O)c1ccc(c(c1)F)C(C)(C)C)c1ccc(c2c1cccn2)N,"CBR-HVAC-13945: Chemokine CCR9 Receptor Antagonists; Signal Transduction Modulators; Inflammatory Bowel Disease, Agents for"
CBR-001-670-112-5,RFM-011-293-6,CBR-001-670-112-5,CCc1noc(n1)C1CNC=NC1,"CBR-HVAC-05775: Muscarinic M1 Agonists; Muscarinic M1 receptor agonist; Signal Transduction Modulators; alpha-Secretase Activators; Alzheimer's Dementia, Treatment of ; Antipsychotic Drugs; Neurologic Drugs (Miscellaneous)"
CBR-001-670-113-6,RFM-011-294-7,CBR-001-670-113-6,COC(=O)Nc1nc2c(n1)cc(cc2)C(=O)c1ccc2c(c1)nc(n2)NC(=O)OC,CBR-HVAC-12884: Catalase; Catalase inhibitor; Glutathione peroxidase Inhibitor; Glutathione peroxidase inhibitor; Anthelmintic; Antifilarial; Treatment of Helminthic Diseases
CBR-001-670-114-7,RFM-011-295-8,CBR-001-670-114-7,C1CCN(CC1)CCOc1ccc(cc1)C1Oc2ccccc2C=C1c1ccccc1,CBR-HVAC-13527: Estrogen receptor Modulator; Selective Estrogen Receptor Modulators (SERM); Signal Transduction Modulators; Contraceptives; Estrogen receptor modulator; Oncolytic Drugs; Treatment of Osteoporosis
CBR-001-670-115-8,RFM-011-296-9,CBR-001-670-115-8,O=C([C@@H](c1cccc(c1)NS(=O)(=O)C)N)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C,CBR-HVAC-01205: Cell wall synthesis inhibitor; Penicillin binding protein inhibitor; Antibacterial; Antibiotics
CBR-001-670-116-9,RFM-011-297-0,CBR-001-670-116-9,CCCCOCCOc1ccc(cc1)c1ccc2c(c1)C=C(CCCN2CC(C)C)C(=O)Nc1ccc(cc1)[S@+](Cc1cncn1CCC)[O-],"CBR-HVAC-05883: C-C chemokine receptor type 5 Antagonist; CC chemokine receptor 2 antagonist; CC chemokine receptor 5 antagonist; Chemokine CCR2B Receptor Ligands; Chemokine CCR5 Antagonists; HIV Attachment Inhibitors; Signal Transduction Modulators; Agents for Liver Fibrosis; Anti-HIV; Anti-HIV Agents; Antiobesity Drugs; Rheumatoid Arthritis, Treatment of"
CBR-001-670-117-0,RFM-011-298-1,CBR-001-670-117-0,Clc1ccc(c(c1)Cl)c1oc(c(n1)CCC(=O)c1ccc(cc1)OC(C(=O)O)(C)C)C(C)C,"CBR-HVAC-13994: PPARdelta Agonists; Signal Transduction Modulators; Atherosclerosis Therapy; Cardiovascular Diseases (Not Specified); Lipoprotein Disorders, Treatment of"
CBR-001-670-118-1,RFM-011-299-2,CBR-001-670-118-1,CCO[C@H]1O[C@@H]([C@@H]([C@H]1O)OC)[C@@H](CNC(=O)N(N=O)C)OC,CBR-HVAC-03237: Alkylating agent; DNA inhibitor; DNA-Damaging Drugs; Anticancer; Oncolytic Drugs
CBR-001-670-119-2,RFM-011-300-8,CBR-001-670-119-2,CCC(=O)O[C@@]1([C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2C[C@@H](C2=CC(=O)C=C[C@]12C)F)Cl)C(=O)OC,CBR-HVAC-04412: Arachidonic acid inhibitor; Corticosteroid agonist; Immunosuppressant; Antiallergy/Antiasthmatic Drugs
CBR-001-670-120-5,RFM-011-301-9,CBR-001-670-120-5,CCCN1CCCC2C1COc1c2cccc1O,CBR-HVAC-03957: 5 Hydroxytryptamine 1A receptor antagonist; Alpha 2 adrenoreceptor agonist; Dopamine Autoreceptor Agonists; Dopamine receptor Agonist; Dopamine receptor agonist; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs
CBR-001-670-121-6,RFM-011-302-0,CBR-001-670-121-6,CCCC1N(CC)C2c3c1cccc3c1c(C2)ccc(c1O)O,CBR-HVAC-00332: DOPAMINE D1 RECEPTOR; DOPAMINE D2 RECEPTOR Agonist; Dopamine Receptor Agonists; Dopamine receptor agonist; Prolactin inhibitor; Signal Transduction Modulators; ANTIPARKINSONIANANTI-AKINETIC; Antiparkinsonian Drugs; Treatment of Alcohol Dependency
CBR-001-670-122-7,RFM-011-303-1,CBR-001-670-122-7,COc1cc2CCOC(c2cc1CN[C@H]1CCCN[C@H]1c1ccccc1)(C)C(F)(F)F,CBR-HVAC-05198: Neurokinin-1 receptor Antagonist; Signal Transduction Modulators; Tachykinin NK1 Antagonists; Antidepressant; Antidepressants
CBR-001-670-123-8,RFM-011-304-2,CBR-001-670-123-8,CCC(n1c(=O)[nH]c2c1c(c(cn2)Cl)c1n[nH]nn1)CC,"CBR-HVAC-13761: Troponin Activators; Motor Function Disorders, Treatment of; Neuromuscular Genetic Disorders, Treatment of"
CBR-001-670-124-9,RFM-011-305-3,CBR-001-670-124-9,N#Cc1cnn2c1N(CC=C2c1cccc(c1)C(F)(F)F)C(=O)CN1CCN(CC1)Cc1ccccc1,"CBR-HVAC-04233: 5-Hydroxytryptamine uptake inhibitor; Antidepressant; Antidepressants; Cognition Disorders, Treatment of"
CBR-001-670-125-0,RFM-011-306-4,CBR-001-670-125-0,CC(=O)NCCC1=[O][Al+3]([O-])([O-])[O-]C(=O)C(N1)Cc1cncn1,CBR-HVAC-07649: Reducing agent
CBR-001-670-126-1,RFM-011-307-5,CBR-001-670-126-1,OC(C1N(C)C(=O)[C@@H](C1c1ccccc1)O)c1ccccc1,"CBR-HVAC-11449: Apoptosis Inhibitors; Drugs Acting on Glutamate Receptors (Metabotropic; mgluR); Nootropic; Signal Transduction Modulators; Cognition Disorders, Treatment of; Nootropic"
CBR-001-670-127-2,RFM-011-308-6,CBR-001-670-127-2,O=C1CC[C@]2(C(=C1)CCC1C2CC[C@]2(C1CC[C@@H]2OC(C(Cl)(Cl)Cl)O)C)C,CBR-HVAC-10147: Anabolic steroid
CBR-001-670-128-3,RFM-011-309-7,CBR-001-670-128-3,OC1CS(=O)(=O)CC1NC(=O)c1c(C)nc(c1C)/C=C/1\C(=O)Nc2c1cc(F)cc2,"CBR-HVAC-13912: Angiogenesis Inhibitors; PDGFR Family Inhibitors; Signal Transduction Modulators; Tyrosine Kinase Inhibitors; VEGFR-2 (FLK-1/KDR) Inhibitors; Age-Related Macular Degeneration, Treatment of; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Solid Tumors Therapy"
CBR-001-670-129-4,RFM-011-310-0,CBR-001-670-129-4,O=S1CC(=C(N2[C@@H]1[C@@H](NC(=O)/C(=N/OC(C(=O)[O-])(C)C)/c1csc(n1)N)C2=O)C(=O)O)CSc1cc[n+](cc1)C,CBR-HVAC-07664: Cell wall synthesis inhibitor
CBR-001-670-130-7,RFM-011-311-1,CBR-001-670-130-7,OCCC1=CC[C@H](C[C@@H]1O)C(O)(C)C,CBR-HVAC-07668: Mucolytic agent; Mucolytics
CBR-001-670-131-8,RFM-011-312-2,CBR-001-670-131-8,OC[C@H]([C@H](C1O[C@](OC)(C[C@@H]([C@H]1NC(=O)C)O)C(=O)N[C@@H]1CC[C@]2([C@H](C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CCCC(C)C)C)C)C)O)O,"CBR-HVAC-07670: Nerve Growth Factor (NGF) Enhancers; Nerve growth factor Agonist; Nerve growth factor agonist; Signal Transduction Modulators; Diabetic Neuropathy, Agents for; Neuroprotectant"
CBR-001-670-132-9,RFM-011-313-3,CBR-001-670-132-9,CN(Cc1cc(=O)c(cn1O)O)CC1=C(C(=O)O)N2[C@H](SC1)[C@@H](C2=O)NC(=O)/C(=N/OC(C(=O)O)(C)C)/c1csc(n1)N,CBR-HVAC-10491: Antibacterial; Antibacterial
CBR-001-670-133-0,RFM-011-314-4,CBR-001-670-133-0,OC(=O)CO/N=C(/c1nncc1)\C(=O)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)CSc1nnnn1C,CBR-HVAC-07679: Cell wall synthesis inhibitor
CBR-001-670-134-1,RFM-011-315-5,CBR-001-670-134-1,Clc1cnc(c(c1)C(=O)NC1(CC1)c1ccc(cc1)C(=O)O)N1CC(C1)Oc1cccc(c1)F,"CBR-HVAC-13983: Prostanoid EP4 Antagonists; Signal Transduction Modulators; Osteoarthritis, Treatment of; Rheumatoid Arthritis, Treatment of"
CBR-001-670-135-2,RFM-011-316-6,CBR-001-670-135-2,OC(=O)CCSC1c2cc(OCc3ccc4c(n3)cc(c(c4)F)Cl)ccc2OCc2c1cccc2,CBR-HVAC-14017: Leukotriene Antagonists; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs
CBR-001-670-136-3,RFM-011-317-7,CBR-001-670-136-3,OC(=O)CCSC1c2cc(OCc3ccc4c(n3)cc(c(c4)F)Cl)ccc2OCc2c1cccc2,CBR-HVAC-14017: Leukotriene Antagonists; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs
CBR-001-670-137-4,RFM-011-318-8,CBR-001-670-137-4,COc1cc2c(cc1OC)CC[N@+]([C@H]2Cc1ccc(c(c1)OC)OC)(C)CCCOC(=O)/C=C\C(=O)OCCC[N@@+]1(C)CCc2c([C@@H]1Cc1ccc(c(c1)OC)OC)cc(c(c2)OC)OC,CBR-HVAC-14113: Neuromuscular Blockers
CBR-001-670-138-5,RFM-011-319-9,CBR-001-670-138-5,COc1ccccc1CCC(NCC(c1ccc(cc1)O)O)(C)C,CBR-HVAC-07705: Alpha adrenoreceptor antagonist; Beta 2 adrenoreceptor agonist
CBR-001-670-139-6,RFM-011-320-2,CBR-001-670-139-6,FC[C@H]1CN(C[C@H]1N)c1c(F)cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-05074: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-140-9,RFM-011-321-3,CBR-001-670-140-9,CCCc1cc(O)c2c(c1)OC([C@H]1[C@H]2C=C(C)CC1)(C)C,"CBR-HVAC-13014: Cannabinoid CB1 Antagonists; Cannabinoid CB2 Antagonists; Cannabinoid receptor 1; Cannabinoid receptor 2 Antagonist; Signal Transduction Modulators; Antidiabetic; Antiobesity; Antiobesity Drugs; Metabolic Disorders (Not Specified); Neurologic Drugs (Miscellaneous); Type 2 Diabetes, Agents for"
CBR-001-670-141-0,RFM-011-322-4,CBR-001-670-141-0,CCCCC/C=C/C/C=C/CCCCCCCC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)C=C[C@]12C)F,CBR-HVAC-01271: Anti-inflammatory; Antiinflammatory Drugs; Arachidonic acid inhibitor; Glucocorticoid agonist; Immunosuppressant; Acne Therapy; Anti-inflammatory; Antiarthritic Drugs
CBR-001-670-142-1,RFM-011-323-5,CBR-001-670-142-1,COC(=O)C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])P1(=O)OCCCO1)C,"CBR-HVAC-03348: Calcium Channel Blockers; Calcium channel Blocker; Calcium channel antagonist; Angina pectoris, Treatment of; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-143-2,RFM-011-324-6,CBR-001-670-143-2,CCOC(=O)NC1=C(N2CC2)C(=O)C(=C(C1=O)N1CC1)NC(=O)OCC,CBR-HVAC-02926: DNA inhibitor; DNA synthesis inhibitor; DNA-Damaging Drugs; Thioredoxin reductase Inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-144-3,RFM-011-325-7,CBR-001-670-144-3,CC(OC(=O)[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]2[C@@H]1[C@@H]1CC[C@]3([C@]1(CC2)C)CCC(=O)O3)C)C,CBR-HVAC-13631: Aldosterone antagonist; Diuretic
CBR-001-670-145-4,RFM-011-326-8,CBR-001-670-145-4,COc1c(N2C[C@H](C3(C2)CC3)N)c(F)cc2c1n(cc(c2=O)C(=O)O)[C@@H]1C[C@@H]1F,CBR-HVAC-05634: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-146-5,RFM-011-327-9,CBR-001-670-146-5,OC(CN(CCC1c2ccccc2OCc2c1cccc2)C)COc1ccccc1,CBR-HVAC-02514: Beta adrenergic receptor Agonist; Beta adrenoreceptor agonist
CBR-001-670-147-6,RFM-011-328-0,CBR-001-670-147-6,Fc1ccc(cc1)C1=C(COC1=O)c1ccc(cc1F)S(=O)(=O)C,CBR-HVAC-11998: Cyclooxygenase 2 Inhibitor; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors; Signal Transduction Modulators; Anti-inflammatory; Antiarthritic Drugs
CBR-001-670-148-7,RFM-011-329-1,CBR-001-670-148-7,Fc1ccc(c(c1)Cn1c(cc2c1c(=O)n(C)c(=O)n2C)N1CCCC(C1)(C)N)C,"CBR-HVAC-13889: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-670-149-8,RFM-011-330-4,CBR-001-670-149-8,CN1CCN(CC1)C1=NS(=O)(=O)c2c(N1)ccc(c2)Cl,CBR-HVAC-07763: Alpha adrenoreceptor antagonist
CBR-001-670-150-1,RFM-011-331-5,CBR-001-670-150-1,NC1CN(CC21CCC2)c1c(F)cc2c3c1OC[C@@H](n3cc(c2=O)C(=O)O)C,CBR-HVAC-04461: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-151-2,RFM-011-332-6,CBR-001-670-151-2,OC(=O)c1cn(C2CC2)c2c(c1=O)cc(c(c2)n1cccc1)F,CBR-HVAC-13307: Antibacterial; Antibacterial
CBR-001-670-152-3,RFM-011-333-7,CBR-001-670-152-3,Fc1ccc(c(c1)F)n1cc(C(=O)O)c(=O)c2c1cc(c(c2)F)N1CC(C1C)N,CBR-HVAC-04355: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-153-4,RFM-011-334-8,CBR-001-670-153-4,Fc1ccc(c(c1)F)n1cc(C(=O)O)c(=O)c2c1cc(c(c2)F)N1CC(C1C)N,CBR-HVAC-04355: DNA gyrase Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-154-5,RFM-011-335-9,CBR-001-670-154-5,COC1=C(C)C(=O)C(=C(C1=O)C)/C=C(/C(=O)O)\CCCCCc1cccnc1,CBR-HVAC-04340: Leukotriene Synthesis Inhibitors; Lipoxygenase 5 Inhibitor; Lipoxygenase Inhibitors; Signal Transduction Modulators; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Antiallergic; Antiallergy/Antiasthmatic Drugs; Antiasthmaitc; Antiinflammatory
CBR-001-670-155-6,RFM-011-336-0,CBR-001-670-155-6,O=C(N[C@H](C(=O)O)C(C)C)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCC(=O)N,"CBR-HVAC-06306: Radioprotectants/Radiomitigators; Renal Failure, Agents for; Sepsis, Treatment of; Treatment of Renal Diseases"
CBR-001-670-156-7,RFM-011-337-1,CBR-001-670-156-7,OCC(Nn1c(=O)c2c(c1=O)c1c(c3c2c2ccc(cc2n3[C@@H]2O[C@H](CO)[C@H]([C@@H]([C@H]2O)O)O)O)[nH]c2c1ccc(c2)O)CO,CBR-HVAC-04780: DNA Topoisomerase I Inhibitors; DNA topoisomerase I Inhibitor; DNA topoisomerase I inhibitor; DNA-Intercalating Drugs; Anticancer; Breast Cancer Therapy; Gastric Cancer Therapy; Solid Tumors Therapy
CBR-001-670-157-8,RFM-011-338-2,CBR-001-670-157-8,OC(=O)CC(c1cccnc1)NC(=O)[C@@H]1CCCN(C1)C(=O)CCC1CCNCC1,CBR-HVAC-02728: GPIIb IIIa receptor antagonist; Inhibitors of Blood Coagulation Pathways; Integrin alpha2b beta3 Antagonist; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Antiplatelet Therapy; Antithrombotic
CBR-001-670-158-9,RFM-011-339-3,CBR-001-670-158-9,OC(=O)CC(c1cccnc1)NC(=O)[C@@H]1CCCN(C1)C(=O)CCC1CCNCC1,CBR-HVAC-02728: GPIIb IIIa receptor antagonist; Inhibitors of Blood Coagulation Pathways; Integrin alpha2b beta3 Antagonist; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Antiplatelet Therapy; Antithrombotic
CBR-001-670-159-0,RFM-011-340-6,CBR-001-670-159-0,OCCNC(=O)N(CCCl)N=O,CBR-HVAC-00002: Anticancer; DNA inhibitor; DNA synthesis inhibitor; DNA-Damaging Drugs; Anticancer; Oncolytic Drugs
CBR-001-670-160-3,RFM-011-341-7,CBR-001-670-160-3,N#Cc1ccccc1OCC(CNCCNC(=O)Cc1ccc(cc1)O)O,"CBR-HVAC-02961: Beta 1 adrenoreceptor antagonist; Beta-1 adrenergic receptor Blocker; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-161-4,RFM-011-342-8,CBR-001-670-161-4,Clc1cc2NC(CSCC(F)(F)F)NS(=O)(=O)c2cc1S(=O)(=O)N,CBR-HVAC-13327: Reduce tissue fluid (edema) by creating osmotic draw from tissue to blood stream; Diuretic
CBR-001-670-162-5,RFM-011-343-9,CBR-001-670-162-5,CCN(CC(CNC(=O)c1c(OC)c2c(n1c1ccccc1)cccc2)O)CC,CBR-HVAC-01068: Antiarrhythmic
CBR-001-670-163-6,RFM-011-344-0,CBR-001-670-163-6,OCC(CCCCOCCCCC(CO)(C)C)(C)C,"CBR-HVAC-09454: HDL-Cholesterol Increasing Agents; Reverse lipid transport pathway transport activator; ANTIATHEROSCLEROTIC; ANTIHYPERLIPIDEMIC; Lipoprotein Disorders, Treatment of"
CBR-001-670-164-7,RFM-011-345-1,CBR-001-670-164-7,CCOC(=O)C1N=C(c2c(N(C1=O)C(=O)NC)ccc(c2)Cl)c1ccccc1F,CBR-HVAC-07801: GABA receptor agonist
CBR-001-670-165-8,RFM-011-346-2,CBR-001-670-165-8,Cc1ncc(cn1)C(Nc1ncnc2c1CN(CC2)c1ccc(cn1)C)C,"CBR-HVAC-13817: P2X7 Receptor Antagonists; Signal Transduction Modulators; Inflammation, Treatment of; Rheumatoid Arthritis, Treatment of"
CBR-001-670-166-9,RFM-011-347-3,CBR-001-670-166-9,Oc1ccc2c(c1)C(CC2)Cc1cncn1,CBR-HVAC-00043: Alpha 2 adrenoreceptor agonist; Alpha-2 adrenergic receptor Agonist; Signal Transduction Modulators; alpha2-Adrenoceptor Agonists; Analgesic; Non-Opioid Analgesics
CBR-001-670-167-0,RFM-011-348-4,CBR-001-670-167-0,O=C(Nc1c(cccc1C(C)C)C(C)C)NCC1(O[C@@H]([C@H](O1)C)C)c1ccc(cc1)OP(=O)(O)O,"CBR-HVAC-11616: ACAT Inhibitors; Acyl CoA:cholesterol acyltransferase Inhibitor; Antihypercholesterolemic; Lipoprotein Disorders, Treatment of"
CBR-001-670-168-1,RFM-011-349-5,CBR-001-670-168-1,CCOc1ccc2c(c1)c(=O)n(nc2c1cccc(c1)F)CC(=O)N(c1ccc2c(c1)oc(n2)C)C,"CBR-HVAC-13991: CFTR Channel (DeltaF508-CFTR Mutant) Correctors; Cystic Fibrosis, Treatment of"
CBR-001-670-169-2,RFM-011-350-8,CBR-001-670-169-2,CC[C@@H]([C@@H]1NC(=O)[C@@H](NC(=O)CCCSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCC(=O)N)CC(=O)N)C(=O)N(Cc1ccc(cc1)F)CC(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)Cc1ccc(cc1)O)C,CBR-HVAC-07365: OXYTOCIN RECEPTOR Agonist; Oxytocin (OT) Agonists; Signal Transduction Modulators; Endocrine Disorders (Not Specified); OXYTOCIC
CBR-001-670-170-5,RFM-011-351-9,CBR-001-670-170-5,COc1cccc2c1[C@@H]1CN(C[C@@H]1CO2)CCCCn1c(=O)[nH]c2c(c1=O)sc1c2nc(cn1)c1ccccc1,CBR-HVAC-05065: ALPHA-1A ADRENERGIC RECEPTOR; ALPHA-1D ADRENERGIC RECEPTOR Antagonist; Alpha 1a adrenoreceptor antagonist; Alpha 1d adrenoreceptor antagonist; Signal Transduction Modulators; alpha1A-Adrenoceptor Antagonists; alpha1D-Adrenoceptor Antagonists; Alpha-1A adrenergic receptor antagonist; Alpha-1D adrenergic receptor antagonist; Benign Prostatic Hyperplasia Therapy
CBR-001-670-171-6,RFM-011-352-0,CBR-001-670-171-6,O=C(c1cc2c(n1)cccc2)N[C@H]1N=C(c2ccccc2F)c2c3N(C1=O)CCc3ccc2,"CBR-HVAC-03983: CCK A receptor antagonist; CCK1 (CCKA) Antagonists; Cholecystokinin A receptor Antagonist; Signal Transduction Modulators; Cholecystokinin A receptor antagonist; Pancreatic Disorders, Treatment of"
CBR-001-670-172-7,RFM-011-353-1,CBR-001-670-172-7,O=C(c1cc2c(n1)cccc2)N[C@@H]1N=C(c2ccccc2F)c2c3N(C1=O)CCc3ccc2,"CBR-HVAC-03983: CCK A receptor antagonist; CCK1 (CCKA) Antagonists; Cholecystokinin A receptor Antagonist; Signal Transduction Modulators; Cholecystokinin A receptor antagonist; Pancreatic Disorders, Treatment of"
CBR-001-670-173-8,RFM-011-354-2,CBR-001-670-173-8,OC[C@H]1COc2c(O1)cccc2N1CCN(CC1)CCNC(=O)c1ccc(cc1)F,"CBR-HVAC-03480: 5 Hydroxytryptamine 1A receptor agonist; 5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Generalized Anxiety Disorder (GAD), Treatment of"
CBR-001-670-174-9,RFM-011-355-3,CBR-001-670-174-9,OC[C@H]1COc2c(O1)cccc2N1CCN(CC1)CCNC(=O)c1ccc(cc1)F,"CBR-HVAC-03480: 5 Hydroxytryptamine 1A receptor agonist; 5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Generalized Anxiety Disorder (GAD), Treatment of"
CBR-001-670-175-0,RFM-011-356-4,CBR-001-670-175-0,Fc1ccc2c(c1)[nH]c(=O)n2CCCN1CCC(CC1)n1c(=O)[nH]c2c1ccc(c2)Cl,CBR-HVAC-08914: Antiemetic
CBR-001-670-176-1,RFM-011-357-5,CBR-001-670-176-1,NC(=O)OCC(c1ccccc1)(COC(=O)N)F,"CBR-HVAC-09292: Voltage-gated sodium channel blocker; Anticonvulsant; Antiepileptic Drugs; Cerebrovascular Diseases, Treatment of"
CBR-001-670-177-2,RFM-011-358-6,CBR-001-670-177-2,CCCCc1nc(nn1Cc1ccc(nc1)c1ccccc1c1nnnn1)CCCC,"CBR-HVAC-04353: Angiotensin AT1 Antagonists; Angiotensin II 1 antagonist; Angiotensin II receptor type 1 Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-178-3,RFM-011-359-7,CBR-001-670-178-3,CCC1=NC(NC(=O)Nc2cccc(c2)C)C(=O)N(c2c1cccc2C)CC(=O)C1CCCCC1,"CBR-HVAC-11169: CCK1 (CCKA) Antagonists; CCK2 (CCKB/Gastrin) Antagonists; Cholecystokinin A receptor Antagonist; Cholecystokinin B receptor; Signal Transduction Modulators; Cholecystokinin A receptor antagonist; Cholecystokinin B receptor antagonist; Gastric Antisecretory Drugs; Gastrin receptor antagonist; Pancreatic Disorders, Treatment of"
CBR-001-670-179-4,RFM-011-360-0,CBR-001-670-179-4,O=C(NCC(=O)N(c1ccc(c(c1Cl)COc1cccc2c1nc(C)cc2)Cl)C)/C=C/c1ccc(nc1)/C=C/c1ccncc1,CBR-HVAC-09194: Bradykinin B2 Antagonists; Bradykinin receptor B2 Antagonist; Signal Transduction Modulators; Analgesic; Anti-inflammatory; Bronchodilators
CBR-001-670-180-7,RFM-011-361-1,CBR-001-670-180-7,OC(=O)C(c1cccc2c1occ2c1ccccc1)C,CBR-HVAC-13735: RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-670-181-8,RFM-011-362-2,CBR-001-670-181-8,O[C@H]1CC(=O)O[C@@H](C1)/C=C/c1c(nc(cc1c1ccc(cc1)F)c1ccccc1)C(C)C,"CBR-HVAC-03856: HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor; Antihypercholesterolemic; Hypolipidemic; Lipoprotein Disorders, Treatment of"
CBR-001-670-182-9,RFM-011-363-3,CBR-001-670-182-9,O=c1nc(OCC2COCCO2)cc2n1CCc1c2ccc(c1)C#CC1CCCC1,"CBR-HVAC-13880: G-Protein Coupled Receptor 84 (GPR84) Antagonists; Signal Transduction Modulators; Inflammatory Bowel Disease, Agents for"
CBR-001-670-183-0,RFM-011-364-4,CBR-001-670-183-0,O=C(OCc1ccccc1)CNC(=O)[C@H](Cc1ccc2c(c1)OCO2)CSC(=O)C,"CBR-HVAC-13336: Angiotensin converting enzyme; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Membrane metalloendopeptidase Inhibitor; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-184-1,RFM-011-365-5,CBR-001-670-184-1,O=S(=O)(C1CC1)Nc1nnc2n1cc(C1CC1)c(c2)OC[C@]12C[C@H]3C[C@@H](C2)C[C@@H](C1)C3,CBR-HVAC-13926: Nav1.7 (PN1/hNE-Na) Sodium Channel Blockers; Analgesic Drugs
CBR-001-670-185-2,RFM-011-366-6,CBR-001-670-185-2,O=C(N[C@H](C(=O)N[C@H](C(=O)O)Cc1ccccc1)CC(=O)O)CCCCCCCSC(=N)N,CBR-HVAC-10943: Inhibitors of Blood Coagulation Pathways; Integrin alpha2b beta3 Antagonist; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Antiplatelet; Antiplatelet Therapy
CBR-001-670-186-3,RFM-011-367-7,CBR-001-670-186-3,COc1cccc(c1OCC1CC1)/C=C/c1nc2sccn2c(=O)c1c1ccc(cc1)OC(F)(F)F,CBR-HVAC-14022: TRPV3 Antagonists; Analgesic Drugs
CBR-001-670-187-4,RFM-011-368-8,CBR-001-670-187-4,O=C(C(C)C)NCc1ccc(c(c1)c1nc2cc(ncc2c(=O)n1)c1ccc(cc1)C(F)(F)F)Cl,"CBR-HVAC-14008: Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors; Analgesic Drugs; Inflammation, Treatment of; Osteoarthritis, Treatment of; Rheumatoid Arthritis, Treatment of"
CBR-001-670-188-5,RFM-011-369-9,CBR-001-670-188-5,CC(CCC#CC1CC1c1ncnc1)(C)C,"CBR-HVAC-05027: Histamine H3 Receptor Antagonists; Histamine H3 receptor Antagonist; Histamine H3 receptor antagonist; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Histamine H3 receptor antagonist; Sleep Disorders, Treatment of"
CBR-001-670-189-6,RFM-011-370-2,CBR-001-670-189-6,OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1cccc(c1)S(=O)(=O)N)O,"CBR-HVAC-06911: Beta2-adrenoceptor Agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Asthma Therapy; Beta2-adrenoceptor agonist; Bronchodilators; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-670-190-9,RFM-011-371-3,CBR-001-670-190-9,OCc1cc(ccc1O)C(CNCCCCCCOCCCCc1cccc(c1)S(=O)(=O)N)O,"CBR-HVAC-06911: Beta2-adrenoceptor Agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Asthma Therapy; Beta2-adrenoceptor agonist; Bronchodilators; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-670-191-0,RFM-011-372-4,CBR-001-670-191-0,OC(=O)C(c1ccc(c(c1)Cl)CC1CCCCC1=O)C,CBR-HVAC-11187: COX Inhibitor; Cyclooxygenase (COX) Inhibitors; Signal Transduction Modulators; Antiinflammatory
CBR-001-670-192-1,RFM-011-373-5,CBR-001-670-192-1,COc1ncc(c(n1)OC)c1nc2c(n1C(C)C)[C@@H](N(C2=O)c1cc(Cl)cn(c1=O)C)c1ccc(cc1)Cl,CBR-HVAC-14048: MDM2 (hdm2) Inhibitors; Hematological Cancer Therapy; Sarcoma Therapy; Solid Tumors Therapy
CBR-001-670-193-2,RFM-011-374-6,CBR-001-670-193-2,COc1ncc(c(n1)OC)c1nc2c(n1C(C)C)[C@H](N(C2=O)c1cc(Cl)cn(c1=O)C)c1ccc(cc1)Cl,CBR-HVAC-14048: MDM2 (hdm2) Inhibitors; Hematological Cancer Therapy; Sarcoma Therapy; Solid Tumors Therapy
CBR-001-670-194-3,RFM-011-375-7,CBR-001-670-194-3,OC(=O)CCN1CCC(=C2c3ncccc3COc3c2ccc(c3)F)CC1,CBR-HVAC-04495: Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist; Signal Transduction Modulators; Antiinflammatory; Drugs for Allergic Rhinitis
CBR-001-670-195-4,RFM-011-376-8,CBR-001-670-195-4,N#CC1CCN(CC1)C(=O)c1ccc(s1)c1noc(c1C)C(F)(F)F,"CBR-HVAC-13826: MAO-B Inhibitors; Antiparkinsonian Drugs; Cognition Disorders, Treatment of"
CBR-001-670-196-5,RFM-011-377-9,CBR-001-670-196-5,CN1CCN(CC1)C(=O)c1cccc(c1)c1nc(N)nc(n1)c1ccccc1O,CBR-HVAC-13857; best guess structure wrong
CBR-001-670-197-6,RFM-011-378-0,CBR-001-670-197-6,OC(=O)c1cn2C(C)CCc3c2c(c1=O)cc(c3C)F,CBR-HVAC-12808: DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial Drugs
CBR-001-670-198-7,RFM-011-379-1,CBR-001-670-198-7,Cc1nc(NC/C=C\COc2cccc(c2)CN2CCCCC2)nc(=O)c1C,CBR-HVAC-03932: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Signal Transduction Modulators; Gastric Antisecretory Drugs; Histamine H2 receptor antagonist
CBR-001-670-199-8,RFM-011-380-4,CBR-001-670-199-8,N#CC[C@H]1CC[C@@H](CO1)n1c(nc2c1c1sccc1nc2)[C@H](O)C,CBR-HVAC-13796: Jak1 Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-001-670-200-4,RFM-011-381-5,CBR-001-670-200-4,N#CC[C@@H]1CC[C@@H](CO1)n1c(nc2c1c1sccc1nc2)[C@H](O)C,CBR-HVAC-13796: Jak1 Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-001-670-201-5,RFM-011-382-6,CBR-001-670-201-5,OC(=O)COc1cc2CC(C(=O)c2c(c1Cl)Cl)(C)c1ccccc1,CBR-HVAC-01020: Chloride ion channel Blocker; Uric acid diuretic; Antihypertensive; Diuretic
CBR-001-670-202-6,RFM-011-383-7,CBR-001-670-202-6,O[C@@H]1CN(C[C@@H]1O)C(=O)C(C(NC(=O)c1cc2c(n1)ccc(c2)Cl)Cc1ccccc1)O,"CBR-HVAC-05370: Glycogen Phosphorylase Inhibitors; Phosphorylase inhibitor; Type 2 Diabetes, Agents for"
CBR-001-670-203-7,RFM-011-384-8,CBR-001-670-203-7,CCCCCC/C=C\CCCCCCCCCC1=CC(=O)C=C(C1=O)OC,CBR-HVAC-12657: Anticancer; Apoptosis Inducers; Immunostimulator; Anticancer; Immunostimulant; Oncolytic Drugs
CBR-001-670-204-8,RFM-011-385-9,CBR-001-670-204-8,COc1ccc(cc1)[C@H]1[C@H](C(=O)O)[C@H](c2c1nccc2)c1ccc2c(c1)OCO2,CBR-HVAC-12014: Endothelin receptor Antagonist; Antihypertensive
CBR-001-670-205-9,RFM-011-386-0,CBR-001-670-205-9,OC(=O)c1ccc2c(c1)n1CCOc3c(c1c2C1CCCCC1)ccc(c3)OCc1ccccc1,CBR-HVAC-13967: Anti-Hepatitis C Virus Drugs
CBR-001-670-206-0,RFM-011-387-1,CBR-001-670-206-0,CC#C[C@H](c1ccc(cc1)OCC1=CCCC2(C1)CCCCC2)CC(=O)O,"CBR-HVAC-13822: Drugs Acting on G-Protein Coupled Receptors (GPCR); Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-670-207-1,RFM-011-388-2,CBR-001-670-207-1,N#Cc1ccc(cc1Cl)N1N=C2[C@@H]([C@@H]1C1CCCC1)CCc1c2ccc(n1)C(=O)N1CCC(CC1)O,"CBR-HVAC-14011: Drugs Acting on Nuclear Hormone Receptors; Signal Transduction Modulators; Hypertension, Treatment of; Treatment of Renal Diseases"
CBR-001-670-208-2,RFM-011-389-3,CBR-001-670-208-2,OC(=O)CN1C(=O)[C@H](CCc2c1cccc2)NC(=O)C1(CCCC1)CC(C(=O)O)CCc1ccccc1,"CBR-HVAC-04879: Endothelin converting-enzyme inhibitor; Endothelin-Converting Enzyme (ECE) Inhibitors; Endothelin-converting enzyme; Membrane metallo endopeptidase inhibitor; NEPRILYSIN INHIBITOR; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; ANTIHYPERTENSIVE; CARDIOPROTECTANT; DIURETIC; Diuretics; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-670-209-3,RFM-011-390-6,CBR-001-670-209-3,OC(=O)CN1C(=O)[C@H](CCc2c1cccc2)NC(=O)C1(CCCC1)CC(C(=O)O)CCc1ccccc1,"CBR-HVAC-04879: Endothelin converting-enzyme inhibitor; Endothelin-Converting Enzyme (ECE) Inhibitors; Endothelin-converting enzyme; Membrane metallo endopeptidase inhibitor; NEPRILYSIN INHIBITOR; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; ANTIHYPERTENSIVE; CARDIOPROTECTANT; DIURETIC; Diuretics; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-670-210-6,RFM-011-391-7,CBR-001-670-210-6,OC(=O)CCCC/C=c\1/c2ccccc2n(c(=O)c2c1cncc2)C,CBR-HVAC-10750: Thromboxane A synthase Inhibitor; Thromboxane Synthase Inhibitors; Antiinflammatory; Antiplatelet Therapy
CBR-001-670-211-7,RFM-011-392-8,CBR-001-670-211-7,OC(=O)CCCC/C=c/1\c2ccccc2n(c(=O)c2c1cncc2)C,CBR-HVAC-10750: Thromboxane A synthase Inhibitor; Thromboxane Synthase Inhibitors; Antiinflammatory; Antiplatelet Therapy
CBR-001-670-212-8,RFM-011-393-9,CBR-001-670-212-8,COc1ccc(c(c1C)C)/C=C/c1nc2c(n1C)c(=O)n(c(=O)n2C)C,CBR-HVAC-11304: Adenosine A2 receptor Antagonist; Drugs Acting on Adenosine Receptors; Signal Transduction Modulators; Adenosine A2 receptor antagonist; Diagnostic Agents
CBR-001-670-213-9,RFM-011-394-0,CBR-001-670-213-9,OC[C@H]1O[C@@H](Oc2nnc(c2Cc2ccc(cc2C)OCCCNCCC(=O)N)C(C)C)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-13196: SGLT-1 Inhibitors; Sodium/glucose cotransporter 1 Inhibitor; Antidiabetic Drugs; Hypoglycemic
CBR-001-670-214-0,RFM-011-395-1,CBR-001-670-214-0,C#CCNC(=O)[C@H]1N(CSC1(C)C)C(=O)[C@H]([C@@H](NC(=O)c1cccc(c1C)O)Cc1ccccc1)O,CBR-HVAC-11776: Protease Inhibitor; Antiviral
CBR-001-670-215-1,RFM-011-396-2,CBR-001-670-215-1,N#C/N=C(/c1cncc(c1)N)\NCCc1ccccc1Cl,"CBR-HVAC-10591: ATP-sensitive potassium channel Opener; Potassium Channel Activators; Potassium channel agonist; Angina pectoris, Treatment of; Antihypertensive; Hypertension, Treatment of; Vasodilator; Vasodilators"
CBR-001-670-216-2,RFM-011-397-3,CBR-001-670-216-2,CCCCCN(C(=O)C(CS(=O)(=O)c1ccc2c(c1)cccc2)CCC(=O)O)CCCOC,"CBR-HVAC-04227: CCK receptor antagonist; CCK-A receptor Antagonist; CCK1 (CCKA) Antagonists; Signal Transduction Modulators; Anti-inflammatory; Pancreatic Disorders, Treatment of"
CBR-001-670-217-3,RFM-011-398-4,CBR-001-670-217-3,CCCCCN(C(=O)C(CS(=O)(=O)c1ccc2c(c1)cccc2)CCC(=O)O)CCCOC,"CBR-HVAC-04227: CCK receptor antagonist; CCK-A receptor Antagonist; CCK1 (CCKA) Antagonists; Signal Transduction Modulators; Anti-inflammatory; Pancreatic Disorders, Treatment of"
CBR-001-670-218-4,RFM-011-399-5,CBR-001-670-218-4,O/N=C(\c1csc(n1)N)/C(=O)NC1C(=O)N2[C@H]1SCC(=C2C(=O)[O-])/C=C/c1onc(c1)OC,CBR-HVAC-11196: Cell wall synthesis inhibitor; Antibiotic
CBR-001-670-219-5,RFM-011-400-1,CBR-001-670-219-5,CCCCCCOC(=O)C1(O)CC2OC1(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O,CBR-HVAC-11562: P-Glycoprotein (MDR-1; ABCB1) Inhibitors; Platelet activating factor antagonist; Protein tyrosine kinase A Inhibitor; Anticancer; Cancer Multidrug Resistance Modulators
CBR-001-670-220-8,RFM-011-401-2,CBR-001-670-220-8,N#Cc1cn(c2c1cc(F)c(c2)F)c1ccc(c(c1)O)C(=O)O,CBR-HVAC-13771: Urate Transporter 1 (URAT1) Inhibitors; Xanthine Oxidase Inhibitors; Treatment of Disorders of Purine and Pyrimidine Metabolism; Treatment of Gout
CBR-001-670-221-9,RFM-011-402-3,CBR-001-670-221-9,CCc1nc2c(n1Cc1ccc3c(c1)CCc1c(N3Cc3nnnn3)cccc1)nc(cc2C)C,"CBR-HVAC-11200: Angiotensin AT1 Antagonists; Angiotensin II antagonist; Angiotensin II receptor type 1 Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-222-0,RFM-011-403-4,CBR-001-670-222-0,O=C(OC(C)(C)C)N[C@H]([C@H](C[C@H](C(=O)N[C@@H]1[C@H](O)Cc2c1cccc2)Cc1ccc(cc1)OCCN1CCOCC1)O)Cc1ccccc1,CBR-HVAC-11222: HIV Protease Inhibitors; Protease Inhibitor; Anti-HIV; Anti-HIV Agents
CBR-001-670-223-1,RFM-011-404-5,CBR-001-670-223-1,[O-]C(=O)CC1(CS[C@@H](c2cccc(c2)/C=C/c2ccc3c(n2)c(Cl)c(s3)Cl)CCc2ccccc2C(O)(C)C)CC1,CBR-HVAC-11142: Leukotriene CysLT1 (LTD4) Antagonists; Leukotriene D4 receptor Antagonist; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antiinflammatory
CBR-001-670-224-2,RFM-011-405-6,CBR-001-670-224-2,O[C@H](c1cccnc1)CNCCc1ccc(cc1)NS(=O)(=O)c1ccc(cc1)c1scc(n1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-05394: Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Antihyperlipidemic; Antiobesity Drugs
CBR-001-670-225-3,RFM-011-406-7,CBR-001-670-225-3,O[C@@H](c1cccnc1)CNCCc1ccc(cc1)NS(=O)(=O)c1ccc(cc1)c1scc(n1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-05394: Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Antihyperlipidemic; Antiobesity Drugs
CBR-001-670-226-4,RFM-011-407-8,CBR-001-670-226-4,[O-][n+]1ccc(c(c1)C)CC(c1ccc(c(c1)OC(F)F)OC(F)F)c1ccc(cc1)C(C(F)(F)F)(C(F)(F)F)O,"CBR-HVAC-00520: Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 inhibitor; Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Bronchodilator; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-670-227-5,RFM-011-408-9,CBR-001-670-227-5,[O-][n+]1ccc(cc1)CC(c1ccc(c(c1)OC(F)F)OC(F)F)c1ccc(cc1)C(C(F)(F)F)(C(F)(F)F)O,"CBR-HVAC-11769: Phosphodiesterase 4A Inhibitor; Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Bronchodilator; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-001-670-228-6,RFM-011-409-0,CBR-001-670-228-6,C[C@@H]1O[C@H](C[C@@H]([C@@H]1OS(=O)(=O)C)N1CC1)O[C@H]1C[C@@](O)(Cc2c1c(O)c1c(c2O)C(=O)c2c(C1=O)cccc2)C(=O)C,CBR-HVAC-04763: Anticancer; DNA inhibitor; Anticancer; Antineoplastic Antibiotics; Oncolytic Drugs
CBR-001-670-229-7,RFM-011-410-3,CBR-001-670-229-7,OC[C@H]([C@H]([C@@H]1OC(=C[C@@H]([C@H]1NC(=O)C)NC(=N)N)C(=O)O)OC)O,CBR-HVAC-13049: Neuraminidase (Sialidase) Inhibitors; Anti-Influenza Virus Drugs
CBR-001-670-230-0,RFM-011-411-4,CBR-001-670-230-0,COc1cc(cc(c1OCCSc1ccc(cc1)Cl)CNC(=O)N(O)C)[C@@H]1CC[C@H](O1)c1cc(OC)c(c(c1)OC)OC,"CBR-HVAC-04550: 5 Lipoxygenase inhibitor; Inhibitor; Lipoxygenase 5 Antagonist; Lipoxygenase Inhibitors; Platelet activating factor antagonist; Platelet activating factor receptor; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Antiinflammatory; Antipsoriatics; Atopic Dermatitis, Agents for"
CBR-001-670-231-1,RFM-011-412-5,CBR-001-670-231-1,COC(=O)CC1C[C@H](NC1=O)COc1ccc(cc1)c1ccc(cc1)C(=N)NC(=O)OC,CBR-HVAC-04483: Inhibitors of Blood Coagulation Pathways; Integrin alpha2b beta3 Antagonist; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Antiplatelet; Antiplatelet Therapy
CBR-001-670-232-2,RFM-011-413-6,CBR-001-670-232-2,NCCCCC(C(=O)O)N[C@H]1CCc2c(N(C1=O)CC(=O)O)cccc2,"CBR-HVAC-03418: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Vasopressin antagonist; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-233-3,RFM-011-414-7,CBR-001-670-233-3,NCCCCC(C(=O)O)N[C@H]1CCc2c(N(C1=O)CC(=O)O)cccc2,"CBR-HVAC-03418: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Vasopressin antagonist; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-234-4,RFM-011-415-8,CBR-001-670-234-4,CCN(CCOC(=O)Cc1cccc2c1oc(cc2=O)c1ccccc1)CC,CBR-HVAC-07992:
CBR-001-670-235-5,RFM-011-416-9,CBR-001-670-235-5,CC(C(O)C)OC(=O)[C@H]1CN(C)[C@H]2[C@H](C1)c1cccc3c1c(C2)cn3C(C)C,CBR-HVAC-10895: 5-Hydroxytryptamine 2 receptor Antagonist; 5-hydroxytryptamine 2 receptor antagonist
CBR-001-670-236-6,RFM-011-417-0,CBR-001-670-236-6,O[C@H](c1ccccc1)CNC(CCc1ccc(cc1)C(=O)N)(C)C,CBR-HVAC-12627: Acetylcholine receptor antagonist; Alpha adrenoreceptor antagonist; Beta adrenergic receptor Antagonist; Beta adrenoreceptor antagonist; Anticancer; Cancer Multidrug Resistance Modulators
CBR-001-670-237-7,RFM-011-418-1,CBR-001-670-237-7,CCCN1CC(CSC)C[C@H]2[C@H]1Cc1cnnc1C2,"CBR-HVAC-02999: DOPAMINE D2 RECEPTOR Agonist; ANTI-HYPERTENSIVE; Hypertension, Treatment of"
CBR-001-670-238-8,RFM-011-419-2,CBR-001-670-238-8,Cc1cccc(n1)c1nn2c(c1c1ccnc3c1cc(cc3)C(=O)N)CCC2,CBR-HVAC-00866: Activin Receptor Like Kinase 5 (ALK5; TbetaR-I) Inhibitors; Protein kinase inhibitor; Signal Transduction Modulators; TRANSFORMING GROWTH FACTOR BETA RECEPTOR I Inhibitor; Transforming growth factor beta 1 antagonist; Anti-tumor; Breast Cancer Therapy; Glioblastoma Multiforme Therapy; Liver Cancer Therapy; Myelodysplastic Syndrome Therapy; Neurologic Cancer Therapy; Pancreatic Cancer Therapy; Prostate Cancer Therapy; Solid Tumors Therapy
CBR-001-670-239-9,RFM-011-420-5,CBR-001-670-239-9,CCCCCCC(n1ccc2c1ccc(c2)c1ccccc1c1nnnn1)C(=O)O,"CBR-HVAC-11917: Angiotensin AT1 Antagonists; Angiotensin II receptor Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-240-2,RFM-011-421-6,CBR-001-670-240-2,CC#C[C@H](c1ccc(cc1)OCc1ccc(cc1)CN1CCC2(CC1)C=Cc1c2cccc1)CC(=O)O,"CBR-HVAC-07122: Free Fatty Acid Receptor 1 (FFAR1;  GPR40) Agonists; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-670-241-3,RFM-011-422-7,CBR-001-670-241-3,CC(C(=O)NCc1cnc(c(c1)C(=O)Nc1nc(c(n1)C)c1ccc(cc1)C(F)(F)F)C(F)F)C,"CBR-HVAC-13999: Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitors; Analgesic Drugs; Osteoarthritis, Treatment of"
CBR-001-670-242-4,RFM-011-423-8,CBR-001-670-242-4,CCCCOC(=O)[C@@H](NP(=O)(Oc1cccc2c1cccc2)OC([C@H]1O[C@H]([C@]([C@@H]1O)(C)O)n1ccc(=O)[nH]c1=O)C)C,CBR-HVAC-14069: RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-670-243-5,RFM-011-424-9,CBR-001-670-243-5,OC1CCC(C1)n1cnc2c1ncnc2N,"CBR-HVAC-10626: Signal Transduction Modulators; TNF alpha Inhibitor; TNF-alpha Production Inhibitors; Tumour necrosis factor receptor antagonist; Antiinflammatory; Disease-Modifying Anti-Rheumatic Drugs; Septic Shock, Treatment of"
CBR-001-670-244-6,RFM-011-425-0,CBR-001-670-244-6,COc1cccc2c1OC(CNCCN1C(=O)CC3(CC1=O)CCCC3)CO2,CBR-HVAC-10950: 5-Hydroxytryptamine 1A receptor Agonist; Antihypertensive
CBR-001-670-245-7,RFM-011-426-1,CBR-001-670-245-7,COc1cccc2c1OC(CNCCN1C(=O)CC3(CC1=O)CCCC3)CO2,CBR-HVAC-10950: 5-Hydroxytryptamine 1A receptor Agonist; Antihypertensive
CBR-001-670-246-8,RFM-011-427-2,CBR-001-670-246-8,Oc1ccc(cc1)C1COc2c(C1c1ccc(cc1)O)ccc(c2C)O,CBR-HVAC-13366: MTOR KINASE Inhibitor; ANTI-TUMOR; Breast Cancer Therapy; Cervical Cancer Therapy; Colorectal Cancer Therapy; Ovarian Cancer Therapy; Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-001-670-247-9,RFM-011-428-3,CBR-001-670-247-9,Nc1nc(Nc2ccc(cc2)[As]2SC(C(S2)C(=O)O)C(=O)O)nc(n1)N,CBR-HVAC-08856: Antiprotozoal
CBR-001-670-248-0,RFM-011-429-4,CBR-001-670-248-0,CSCC[C@H]1NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H]2CNC(=O)C[C@H](NC1=O)C(=O)N[C@H](Cc1cnc3c1cccc3)C(=O)N[C@@H](C(=O)N2)Cc1ccccc1,CBR-HVAC-10599: Neurokinin receptor 2 Antagonist; Signal Transduction Modulators; Tachykinin NK2 Antagonists; Antiasthmatic; Pharmacological Tools
CBR-001-670-249-1,RFM-011-430-7,CBR-001-670-249-1,CCCCCCCCCCCCCCC1(CO1)C(=O)OC,CBR-HVAC-01062: Carnitine palmitoyltransferase I Inhibitor; Gluconeogenesis inhibitor; Antidiabetic; Antidiabetic Drugs
CBR-001-670-250-4,RFM-011-431-8,CBR-001-670-250-4,CC(N/C=N/c1ccc(cc1)c1ncnc1)C,CBR-HVAC-03008: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Signal Transduction Modulators; Antiulcer; Gastric Antisecretory Drugs
CBR-001-670-251-5,RFM-011-432-9,CBR-001-670-251-5,O=C1C=C[C@]2(C(=C1N)C=C[C@@H]1[C@@H]2CC[C@]2([C@H]1CCC2=O)C)C,CBR-HVAC-03524: Aromatase Inhibitor; Aromatase Inhibitors; Aromatase inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-252-6,RFM-011-433-0,CBR-001-670-252-6,CCC1=CC2C(C1)CC2(CN)CC(=O)O,"CBR-HVAC-07316: Calcium Channels (Voltage-Gated) alpha2/delta Subunit Ligands; Calcium channel antagonist; Analgesic Drugs; Fibromyalgia, Treatment of; Neuropathic Pain, Treatment of"
CBR-001-670-253-7,RFM-011-434-1,CBR-001-670-253-7,N#Cc1ccc2c(c1)CCC(C2)N1CCC2(CC1)CC(O)c1c(O2)ccc(c1)NS(=O)(=O)C,"CBR-HVAC-04294: Intermediate Conductance K(Ca) 3.1 (IKCa1; Gardos channel, SK41, IK1) Channel Blockers; Polarisation inhibitor; Potassium channel hERG1 Blocker; Antiarrhythmic Drugs; Class III antiarrhythmic"
CBR-001-670-254-8,RFM-011-435-2,CBR-001-670-254-8,FC1CN(CCC1CNc1ncccn1)C(=O)OCc1ccc(cc1)C,"CBR-HVAC-00662: NMDA receptor 2B antagonist; NMDA receptor, subunit 2B antagonist; NR2B Antagonists; Signal Transduction Modulators; Antidepressants; Antiparkinsonian; Antiparkinsonian Drugs; CNS modulator"
CBR-001-670-255-9,RFM-011-436-3,CBR-001-670-255-9,OC(c1ccc(cc1)c1ccc(cc1)C(C(F)(F)F)NC(C(=O)NC1(CC1)C#N)CC(F)(C)C)C(F)F,CBR-HVAC-14028: Urinary Incontinence Therapy
CBR-001-670-256-0,RFM-011-437-4,CBR-001-670-256-0,CCOC(=O)C1=C(NC(=C(C1c1ccccc1Cl)C(=O)Nc1ccccn1)C)c1ccc(cc1)n1c(C)nc2c1ccnc2,CBR-HVAC-04212: Platelet activating factor antagonist; Platelet activating factor receptor Antagonist; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Antiinflammatory
CBR-001-670-257-1,RFM-011-438-5,CBR-001-670-257-1,CCOC(=O)C1=C(NC(=C(C1c1ccccc1Cl)C(=O)Nc1ccccn1)C)c1ccc(cc1)n1c(C)nc2c1ccnc2,CBR-HVAC-04212: Platelet activating factor antagonist; Platelet activating factor receptor Antagonist; Platelet-Activating Factor Receptor (PAFR) Antagonists; Signal Transduction Modulators; Antiinflammatory
CBR-001-670-258-2,RFM-011-439-6,CBR-001-670-258-2,O=C([C@@H]1CSC(C(=O)N1)C)N[C@H](C(=O)N1CCC[C@H]1C(=O)N)Cc1cncn1,CBR-HVAC-03032: Dopamine receptor agonist; Thyrotropin releasing hormone receptor Agonist; Thyrotropin releasing hormone receptor agonist; Antiamnestic; Antihypertensive; CNS Stimulants
CBR-001-670-259-3,RFM-011-440-9,CBR-001-670-259-3,OC(=O)CC1COc2c(C1)cc(cc2)NC(=O)c1ccc(cc1)C(=N)N1CCOCC1,CBR-HVAC-13378: Inhibitors of Blood Coagulation Pathways; Integrin alpha2b beta3 Antagonist; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Antiplatelet; Antiplatelet Therapy
CBR-001-670-260-6,RFM-011-441-0,CBR-001-670-260-6,NC(=O)c1cccc2c1ncnc2NC(c1ccc(c(c1)C(F)(F)F)Cl)CN1CCC1,CBR-HVAC-13936: Protein Kinase B (PKB/Akt) Inhibitors; Ribosomal Protein S6 Kinase beta  (p70S6K) Inhibitors; Signal Transduction Modulators; Solid Tumors Therapy
CBR-001-670-261-7,RFM-011-442-1,CBR-001-670-261-7,O=C(CSc1scc(n1)CC(=O)O)NC[C@@H]1OCCN(C1)Cc1ccc(c(c1)Cl)Cl,"CBR-HVAC-13995: Chemokine CCR3 Antagonists; Signal Transduction Modulators; Age-Related Macular Degeneration, Treatment of"
CBR-001-670-262-8,RFM-011-443-2,CBR-001-670-262-8,CNC(=O)Nc1c(OCCN2CCCCC2)c(OC)c2c(c1OC)cco2,CBR-HVAC-13643: Sodium channel antagonist
CBR-001-670-263-9,RFM-011-444-3,CBR-001-670-263-9,Cc1ccc2c(c1)c1oc(cc(=O)c1c(=O)n2)C(=O)O,CBR-HVAC-08070: 5 Hydroxytryptamine release inhibitor; Histamine release inhibitor
CBR-001-670-264-0,RFM-011-445-4,CBR-001-670-264-0,Cn1cnc2c1ncnc2NC1C[C@H]2C[C@@H]1CC2,CBR-HVAC-04242: Adenosine A1 Antagonists; Adenosine A1 receptor Antagonist; Adenosine A1 receptor antagonist; Phosphodiesterase inhibitor; Signal Transduction Modulators; Antiarrhythmic; Antihypertensive; Heart Failure Therapy; Vasodilator
CBR-001-670-265-1,RFM-011-446-5,CBR-001-670-265-1,Cn1cnc2c1ncnc2NC1C[C@H]2C[C@@H]1CC2,CBR-HVAC-04242: Adenosine A1 Antagonists; Adenosine A1 receptor Antagonist; Adenosine A1 receptor antagonist; Phosphodiesterase inhibitor; Signal Transduction Modulators; Antiarrhythmic; Antihypertensive; Heart Failure Therapy; Vasodilator
CBR-001-670-266-2,RFM-011-447-6,CBR-001-670-266-2,COc1ccc(cc1OC)C(=O)N1CCN(CC1)CCn1c(nc2c1cccc2)C(=O)N(c1cc(C)cc(n1)C)C,CBR-HVAC-10600: Calcium channel; Inhibitor; Phosphodiesterase; Potassium channel Blocker; Heart Failure Therapy; Inotropic; Vasorelaxant
CBR-001-670-267-3,RFM-011-448-7,CBR-001-670-267-3,CC[C@@H]([C@@H]1NC(=O)[C@@H](NC(=O)CCSCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCC(=O)N)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)Cc1ccc(cc1)CC)C,"CBR-HVAC-03009: Potassium sparing diuretic; Prostaglandin synthase stimulant; Hypertension, Treatment of"
CBR-001-670-268-4,RFM-011-449-8,CBR-001-670-268-4,N#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=Cc3c(C[C@]12C)cnn3c1ccc(cc1)F,CBR-HVAC-08571: Glucocorticoid receptor Antagonist; Antidepressant
CBR-001-670-269-5,RFM-011-450-1,CBR-001-670-269-5,CNc1cccc(c1)NC(=O)NC1N=C(c2ccccn2)c2c(N(C1=O)CC(=O)C(C)(C)C)cccc2,CBR-HVAC-04714: CCK B receptor antagonist; CCK2 (CCKB/Gastrin) Antagonists; Cholecystokinin B receptor Antagonist; Gastrin inhibitor; Signal Transduction Modulators; Antiulcer; Gastric Antisecretory Drugs; Premalignant Conditions Therapy
CBR-001-670-270-8,RFM-011-451-2,CBR-001-670-270-8,CNc1cccc(c1)NC(=O)NC1N=C(c2ccccn2)c2c(N(C1=O)CC(=O)C(C)(C)C)cccc2,CBR-HVAC-04714: CCK B receptor antagonist; CCK2 (CCKB/Gastrin) Antagonists; Cholecystokinin B receptor Antagonist; Gastrin inhibitor; Signal Transduction Modulators; Antiulcer; Gastric Antisecretory Drugs; Premalignant Conditions Therapy
CBR-001-670-271-9,RFM-011-452-3,CBR-001-670-271-9,COC(=O)C1=C(C)NC(=C(C1C1=COCCO1)C(=O)OC)C,CBR-HVAC-08091: Membrane permeability inhibitor
CBR-001-670-272-0,RFM-011-453-4,CBR-001-670-272-0,CCC(C(COC(=O)N)(COC(=O)NC(C)C)C)C,CBR-HVAC-13097: Anxiolytic
CBR-001-670-273-1,RFM-011-454-5,CBR-001-670-273-1,O=NSC(CC(=O)Oc1cc(C(C)C)c(cc1C)OCCN(C)C)(C)C,CBR-HVAC-11149: Alpha 1 adrenoreceptor antagonist; Alpha adrenergic receptor Antagonist; Nitric Oxide (NO) Donors; Nitric oxide stimulant; Signal Transduction Modulators; alpha-Adrenoceptor Antagonists; Alpha adrenergic receptor antagonist; Treatment of Erectile Dysfunction
CBR-001-670-274-2,RFM-011-455-6,CBR-001-670-274-2,CN1CCc2c(C(C1)c1cccc3c1occ3)cc(c(c2)Cl)O,CBR-HVAC-03521: Dopamine D1 Antagonists; Dopamine D1 receptor antagonist; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-670-275-3,RFM-011-456-7,CBR-001-670-275-3,Oc1ccc2c(c1)OC[C@@H]([C@@H]2c1ccc(cc1)OCCN1CCCC1)c1ccccc1,"CBR-HVAC-13520: Estrogen receptor Modulator; Selective Estrogen Receptor Modulators (SERM); Signal Transduction Modulators; Antidepressant; Cognition Disorders, Treatment of; Treatment of Osteoporosis; Treatment of Postmenopausal Syndrome"
CBR-001-670-276-4,RFM-011-457-8,CBR-001-670-276-4,Oc1ccc2c(c1)OC[C@H]([C@H]2c1ccc(cc1)OCCN1CCCC1)c1ccccc1,"CBR-HVAC-13520: Estrogen receptor Modulator; Selective Estrogen Receptor Modulators (SERM); Signal Transduction Modulators; Antidepressant; Cognition Disorders, Treatment of; Treatment of Osteoporosis; Treatment of Postmenopausal Syndrome"
CBR-001-670-277-5,RFM-011-458-9,CBR-001-670-277-5,CCCCCCCCCCCCCCC[C@H]([C@@H](NC(=O)CCCCCCC/C=C\CCCCCCCC)CO)O,CBR-HVAC-07259: Antipsoriatics
CBR-001-670-278-6,RFM-011-459-0,CBR-001-670-278-6,CN(C/C=C/C(=O)Nc1cc2c(ncnc2cc1C#C[C@@H]1[C@@H]2[C@H]1COC2)Nc1ccc(c(c1)Cl)F)C,CBR-HVAC-07190: EGFR (HER1; erbB1) Inhibitors; HER2 (erbB2) Inhibitors; HER4 (erbB4) Inhibitors; Signal Transduction Modulators; Solid Tumors Therapy
CBR-001-670-279-7,RFM-011-460-3,CBR-001-670-279-7,CCSC1Oc2cc(O)ccc2C=C1c1ccc(cc1)O,"CBR-HVAC-13757: Antioxidants; Atherosclerosis Therapy; Hypertension, Treatment of"
CBR-001-670-280-0,RFM-011-461-4,CBR-001-670-280-0,COCCOc1ccc(cc1)OCc1cc(Cl)ccc1/C(=C\OC)/C(=O)OC,CBR-HVAC-13882: Treatment of Osteoporosis
CBR-001-670-281-1,RFM-011-462-5,CBR-001-670-281-1,N#Cc1cc(O)c(c(c1/C=C/CC1CCCC1)C#N)O,CBR-HVAC-13736: COMT Inhibitors; Antiparkinsonian Drugs
CBR-001-670-282-2,RFM-011-463-6,CBR-001-670-282-2,N#Cc1cc(O)c(c(c1/C=C/C(C)(C)C)C#N)O,CBR-HVAC-13729: COMT Inhibitors; Antiparkinsonian Drugs
CBR-001-670-283-3,RFM-011-464-7,CBR-001-670-283-3,Brc1ccc(cc1)Cn1c(=O)c2ccc(c(c2n(c1=O)CC(O)(C)C)F)Cl,"CBR-HVAC-13949: GABA(B) Positive Allosteric Modulators; Signal Transduction Modulators; Extrapyramidal Disorders, Treatment of"
CBR-001-670-284-4,RFM-011-465-8,CBR-001-670-284-4,Clc1cccc2c1ncc2C1CC(=NN1c1ccc(cc1)S(=O)(=O)N)C(F)(F)F,CBR-HVAC-11918: 5-Lipoxygenase; Cyclooxygenase 2 Inhibitor; Anticancer
CBR-001-670-285-5,RFM-011-466-9,CBR-001-670-285-5,Clc1cccc2c1ncc2C1CC(=NN1c1ccc(cc1)S(=O)(=O)N)C(F)(F)F,CBR-HVAC-11918: 5-Lipoxygenase; Cyclooxygenase 2 Inhibitor; Anticancer
CBR-001-670-286-6,RFM-011-467-0,CBR-001-670-286-6,C[n+]1ccc(cc1)SCC1=C(C(=O)O)N2[C@H](CS1)C(C2=O)NC(=O)/C(=N\OC1CCCC1)/c1csc(n1)N,analog of CBR-HVAC-13259
CBR-001-670-287-7,RFM-011-468-1,CBR-001-670-287-7,COCC1(C)CCCN2C1c1oc3c(c1CC2)cccc3,CBR-HVAC-00292: ALPHA2C-ADRENERGIC RECEPTOR Antagonist; Alpha 2c adrenoceptor antagonist; Signal Transduction Modulators; alpha2C-Adrenoceptor Antagonists; Antidepressants; Antipsychotic Drugs; CNS modulator; Psychomodulator
CBR-001-670-288-8,RFM-011-469-2,CBR-001-670-288-8,OC[C@H]1S[C@H]([C@H]([C@@H]1O)O)n1ccc(nc1=O)N,"CBR-HVAC-05158: Angiogenesis Inhibitors; Antimetabolites; Cytidine deaminase Inhibitor; DNA directed DNA polymerase inhibitor; DNA synthesis inhibitor; Anticancer; Hematological Cancer Therapy; Rheumatoid Arthritis, Treatment of; Solid Tumors Therapy"
CBR-001-670-289-9,RFM-011-470-5,CBR-001-670-289-9,O=C(O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCC2=C(C(=O)CC[C@H]12)O)CCC1CCCC1,CBR-HVAC-09987: Anabolic steroid
CBR-001-670-290-2,RFM-011-471-6,CBR-001-670-290-2,O=C1c2ccccc2C(=O)C1(CN1CCOCC1)c1ccccc1,CBR-HVAC-08644: Vitamin K antagonist; Anticoagulant
CBR-001-670-291-3,RFM-011-472-7,CBR-001-670-291-3,CCOC(=O)CC1(COC1)c1ccc(cc1)OCc1cccc(c1)c1ccc(cc1Cl)OCC1CCS(=O)(=O)CC1,"CBR-HVAC-14066: Free Fatty Acid Receptor 1 (FFAR1;  GPR40) Agonists; Signal Transduction Modulators; Type 2 Diabetes, Agents for"
CBR-001-670-292-4,RFM-011-473-8,CBR-001-670-292-4,C[C@@H]1C[C@@H](C)OP(=O)(O1)c1c(C)nc(c(c1c1cccc(c1)[N+](=O)[O-])C(=O)OCCN1CCN(CC1)C(c1ccccc1)c1ccccc1)C,CBR-HVAC-11342: Multidrug resistance associated protein; P glycoprotein inhibitor; P-Glycoprotein Modulator; Anticancer; Cancer Multidrug Resistance Modulators
CBR-001-670-293-5,RFM-011-474-9,CBR-001-670-293-5,OCCNCCOc1ccc(cc1)/C(=C(/C(F)(F)F)\c1ccccc1)/c1ccccc1,CBR-HVAC-02969: Estrogen Receptor (ER) Antagonists; Estrogen receptor Inhibitor; Estrogen receptor antagonist; Signal Transduction Modulators; Anticancer; Oncolytic Drugs
CBR-001-670-294-6,RFM-011-475-0,CBR-001-670-294-6,O=C(C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])C(=O)OC(CN1CCOCC1)CN1CCOCC1)C)OCCN1C(=O)c2c(S1(=O)=O)cccc2,CBR-HVAC-11347: Calcium channel Antagonist; Vasodilator
CBR-001-670-295-7,RFM-011-476-1,CBR-001-670-295-7,OC1(CCC(CC1)CCN1CCN(CC1)c1ccccn1)c1cccs1,CBR-HVAC-10547: Dopamine D2 Agonists; Dopamine D2 receptor agonist; Dopamine receptor D2 Agonist; Signal Transduction Modulators; Neuroprotectant
CBR-001-670-296-8,RFM-011-477-2,CBR-001-670-296-8,OC1(CCC(CC1)CCN1CCN(CC1)c1ccccn1)c1cccs1,CBR-HVAC-10547: Dopamine D2 Agonists; Dopamine D2 receptor agonist; Dopamine receptor D2 Agonist; Signal Transduction Modulators; Neuroprotectant
CBR-001-670-297-9,RFM-011-478-3,CBR-001-670-297-9,CCOC(=O)C(CC(C(=O)N1[C@@H](Cc2c1cccc2)C(=O)O)C)C,"CBR-HVAC-01078: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; ANTIHYPERTENSIVE; Hypertension, Treatment of"
CBR-001-670-298-0,RFM-011-479-4,CBR-001-670-298-0,CCCN1C[C@H](OC[C@@H]1C)c1ccc(nc1)N,CBR-HVAC-06093: Dopamine D3 Agonists; Signal Transduction Modulators; Analgesic Drugs; Treatment of Male Sexual Dysfunction
CBR-001-670-299-1,RFM-011-480-7,CBR-001-670-299-1,Nc1ccc2c(n1)cc(cc2)C(=O)N1CCC2(CC1)CC(=O)c1c(C2)cnn1C(C)C,"CBR-HVAC-13895: Acetyl-CoA Carboxylase (ACC) Inhibitors; Type 2 Diabetes, Agents for"
CBR-001-670-300-7,RFM-011-481-8,CBR-001-670-300-7,Cn1ncc(c1c1ccc(cn1)C(F)(F)F)c1nc(n2c1c(ncn2)N1CCC1)C,CBR-HVAC-07250: Phosphodiesterase PDE2A Inhibitors; Signal Transduction Modulators; Antipsychotic Drugs
CBR-001-670-301-8,RFM-011-482-9,CBR-001-670-301-8,CC(=O)NC(c1cccc(c1)F)CCN1[C@@H]2CC[C@H]1C[C@H](C2)n1c(C)nc2c1CN(CC2)C(=O)C(C)C,CBR-HVAC-13549: Anti-HIV; Antiviral
CBR-001-670-302-9,RFM-011-483-0,CBR-001-670-302-9,O=C1[C@@H](NC(=O)/C(=N\OCc2cncn2)/c2csc(n2)N)[C@@H]2N1C(=C(CS2)C[n+]1ccccc1)C(=O)O,CBR-HVAC-07750: Cell wall synthesis inhibitor
CBR-001-670-303-0,RFM-011-484-1,CBR-001-670-303-0,N#Cc1ccc(cc1Oc1ccccc1)Cn1cncc1CN1CCN(C(=O)C1)c1cccc(c1)Cl,CBR-HVAC-08190: Farnesyltransferase inhibitor; Geranylgeranyltransferase inhibitor
CBR-001-670-304-1,RFM-011-485-2,CBR-001-670-304-1,COc1cc(CNS(=O)(=O)c2ccc(cc2)NC(=S)NCc2ccc(cc2)C(F)(F)F)c(cc1O)I,CBR-HVAC-12116: Vanilloid receptor 1 Antagonist; Vanilloid receptor 1 antagonist; Analgesic; Anti-inflammatory
CBR-001-670-305-2,RFM-011-486-3,CBR-001-670-305-2,OB([C@@H]1CCCN1C(=O)CN[C@H]1CNCC1)O,"CBR-HVAC-00349: Dipeptide hydrolase inhibitor; Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors; Dipeptidyl peptidase 4 (DPP IV) inhibitor; Dipeptidyl peptidase 4 Inhibitor; Insulin secretagogue; Protease/peptidase inhibitor; Signal Transduction Modulators; Hyperglycemic; Type 2 Diabetes, Agents for"
CBR-001-670-306-3,RFM-011-487-4,CBR-001-670-306-3,O=C(N1c2ccccc2Sc2c1nccc2)OCCOCCN1CCCCC1,CBR-HVAC-08617: Opioid receptor Inhibitor; Antitussive
CBR-001-670-307-4,RFM-011-488-5,CBR-001-670-307-4,O=C(Nc1ccncc1)Nc1ccc(cc1)c1nc(nc(n1)N1C2COCC1CC2)N1CCOCC1,CBR-HVAC-06910: Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-001-670-308-5,RFM-011-489-6,CBR-001-670-308-5,O=CN1CCN(CC1)c1ncc2c(n1)ncc(c2=O)C(=O)NC(c1ccc(cc1)O)C(=O)N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)O)(C)C,CBR-HVAC-08214: Cell wall synthesis inhibitor
CBR-001-670-309-6,RFM-011-490-9,CBR-001-670-309-6,NC(=N)NCCCCC(=O)Nc1cc(cc(c1O[C@H]1CNCC1)NC(=O)c1ncnc(c1)C(=O)Nc1cc(cc(c1O[C@H]1CNCC1)NC(=O)CCCCNC(=N)N)C(F)(F)F)C(F)(F)F,"CBR-HVAC-06753: Cell Membrane Disrupting Agents; Defensin Modulator; Anorectal Disorders, Treatment of; Antibacterial; Antibacterial Drugs; Antibacterial Ophthalmic Drugs; Treatment of Mucositis; Wound-Healing Agents"
CBR-001-670-310-9,RFM-011-491-0,CBR-001-670-310-9,C[C@@H]1N[C@H](C)CN(C1)C(=O)c1cc2c(ncn2c2c1cc(Cl)cc2)C(=O)OC(C)(C)C,"CBR-HVAC-04749: GABA(A) BZ Site Receptor Agonists; GABA(A) Receptor Modulators; GABA-A receptor alpha 1; GABA-A receptor alpha 3 Partial Agonist; GABA-A receptor alpha 5; Signal Transduction Modulators; Anxiolytic; Stroke, Treatment of"
CBR-001-670-311-0,RFM-011-492-1,CBR-001-670-311-0,CC[C@@]1(OC(=O)CNC(=O)CCCCCNC(=O)CNC(=O)C(=C)C)C(=O)OCc2c1cc1c3nc4ccccc4cc3Cn1c2=O,CBR-HVAC-11666: TOPOISOMERASE I Inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-312-1,RFM-011-493-2,CBR-001-670-312-1,CC(C[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C)Cc1ccccc1)Cc1ccccc1)C(C)C)NC(=O)CC[C@H]([C@H]1CC[C@@H]2[C@]1(C)[C@@H](O)C[C@H]1[C@H]2[C@H](O)C[C@H]2[C@]1(C)CC[C@H](C2)O)C)C,CBR-HVAC-09287: Beta amyloid peptide 1-40 Inhibitor; Neuroprotectant
CBR-001-670-313-2,RFM-011-494-3,CBR-001-670-313-2,OC(=O)CC[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2[C@H]2C[C@H]2C2=CC(=O)CC[C@]12C,CBR-HVAC-01207: Aldosterone antagonist; Aldosterone receptor Antagonist; Drugs Acting on Adrenal Cortex Hormones; Potassium sparing diuretic; Signal Transduction Modulators; Adrenocortical Dysfunction Therapy; Antihypertensive
CBR-001-670-314-3,RFM-011-495-4,CBR-001-670-314-3,OC(=O)CC[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2[C@H]2C[C@H]2C2=CC(=O)CC[C@]12C,CBR-HVAC-01207: Aldosterone antagonist; Aldosterone receptor Antagonist; Drugs Acting on Adrenal Cortex Hormones; Potassium sparing diuretic; Signal Transduction Modulators; Adrenocortical Dysfunction Therapy; Antihypertensive
CBR-001-670-315-4,RFM-011-496-5,CBR-001-670-315-4,O=Cc1cn(c2ccc(cc2F)F)c2c(c1=O)cc(c(n2)N1CCC(C1)N)F,CBR-HVAC-13432: DNA topoisomerase II Inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-316-5,RFM-011-497-6,CBR-001-670-316-5,CC(=O)Nc1cccc(c1)N1CCN(CC1)CCCCNS(=O)(=O)CC1CCCCC1,"CBR-HVAC-00542: 5 Hydroxytryptamine 1A receptor agonist; 5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Antiepileptic Drugs; Antiparkinsonian Drugs; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Generalized Anxiety Disorder (GAD), Treatment of"
CBR-001-670-317-6,RFM-011-498-7,CBR-001-670-317-6,N#Cc1cc(ccc1F)CN1CCC(CC1)Nc1ncnc2c1cc(s2)Cl,"CBR-HVAC-06213: 5 Hydroxytryptamine 2B receptor antagonist; 5-HT2B Antagonists; 5-Hydroxytryptamine 2B receptor Antagonist; Signal Transduction Modulators; Antihypertensive; Pulmonary Hypertension, Treatment of; Vasodilator"
CBR-001-670-318-7,RFM-011-499-8,CBR-001-670-318-7,OC(=O)[C@H](NC(=O)c1ccc(cc1)NCc1cnc2c(n1)c(N)nc(n2)N)CCCNC(=O)c1ccccc1C(=O)O,CBR-HVAC-03755: Antimetabolites; DIHYDROFOLATE REDUCTASE Inhibitor; Dihydrofolate Reductase (DHFR) Inhibitors; Dihydrofolate reductase inhibitor; Folylpolyglutamate Synthase Inhibitors; Anticancer; Breast Cancer Therapy; Cervical Cancer Therapy; Female Reproductive System Cancer Therapy; Gastric Cancer Therapy; Leukemia Therapy; Lymphocytic Leukemia Therapy; Non-Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-001-670-319-8,RFM-011-500-4,CBR-001-670-319-8,OC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)NC(=O)c1nc2ccccc2nc1C(=O)O,CBR-HVAC-10308: Beta-lactamase Inhibitor; Antibacterial; Antibiotic
CBR-001-670-320-1,RFM-011-501-5,CBR-001-670-320-1,CN(S(=O)(=O)c1ccc2c(c1)N(C1CN3CCC1CC3)c1c(S2)cccc1)C,CBR-HVAC-05779: Histamine H1 receptor antagonist; Gastric Antisecretory Drugs
CBR-001-670-321-2,RFM-011-502-6,CBR-001-670-321-2,O=C(c1cc2c(o1)ccc(c2)OC1CCN(CC1)c1ccc(cc1)C(F)(F)F)NC1CCN(CC1)Cc1ccncc1,"CBR-HVAC-14059: AMP-Activated Protein Kinase (AMPK) Activators; Signal Transduction Modulators; Peripheral Arterial Disease, Treatment of"
CBR-001-670-322-3,RFM-011-503-7,CBR-001-670-322-3,CC1=CCC(CC1)C(=O)N(c1cc(sc1C(=O)O)C#CC(C)(C)C)C1CCC(CC1)(O)COC1COCC1,CBR-HVAC-07157: RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-670-323-4,RFM-011-504-8,CBR-001-670-323-4,OC(=O)[C@H](Cc1ccc(cc1)NC(=O)c1c(Cl)cccc1Cl)NC(=O)C1(C)ON=C(C1)C(C)(C)C,CBR-HVAC-14027: Integrin alpha4beta1 (VLA-4) Antagonists; Signal Transduction Modulators; Asthma Therapy
CBR-001-670-324-5,RFM-011-505-9,CBR-001-670-324-5,COC(=O)CCNC(=O)[C@@H](C(COP(=O)(N[C@H](C(=O)OC)C)Oc1ccccc1)(C)C)O,"CBR-HVAC-13974: Neurodegenerative Diseases, Treatment of"
CBR-001-670-325-6,RFM-011-506-0,CBR-001-670-325-6,CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC(=O)C(CCN1C(=O)N(C(C1=O)(C)C)C)S)CC(C)C,CBR-HVAC-04936: Angiogenesis Inhibitors; MMP-1 (Interstitial Collagenase) Inhibitors; MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors; MMP-2 (Gelatinase A) Inhibitors; MMP-9 (Gelatinase B) Inhibitors; Matrix metalloproteinase 1 Inhibitor; Anticancer; Kaposi's Sarcoma Therapy; Non-Small Cell Lung Cancer Therapy; Prostate Cancer Therapy
CBR-001-670-326-7,RFM-011-507-1,CBR-001-670-326-7,CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@@H](NC(=O)C(CCN1C(=O)N(C(C1=O)(C)C)C)S)CC(C)C,CBR-HVAC-04936: Angiogenesis Inhibitors; MMP-1 (Interstitial Collagenase) Inhibitors; MMP-14 (Membrane-Type Matrix Metalloproteinase 1) Inhibitors; MMP-2 (Gelatinase A) Inhibitors; MMP-9 (Gelatinase B) Inhibitors; Matrix metalloproteinase 1 Inhibitor; Anticancer; Kaposi's Sarcoma Therapy; Non-Small Cell Lung Cancer Therapy; Prostate Cancer Therapy
CBR-001-670-327-8,RFM-011-508-2,CBR-001-670-327-8,CN1Cc2cc(Cl)ccc2n2c(C1)nnc2C1CCC(CC1)Oc1ccccn1,"CBR-HVAC-13885: Signal Transduction Modulators; Vasopressin (AVP) V1 Receptor Antagonists; Autism, Treatment of"
CBR-001-670-328-9,RFM-011-509-3,CBR-001-670-328-9,Fc1ccc(cc1)C(=CCCN1CCC2(CC1)OC(=O)N(C2=C)C)c1ccc(cc1)F,CBR-HVAC-10725: 5-Hydroxytryptamine 1 receptor Inhibitor; Alpha-1 adrenergic receptor; Dopamine D1 Antagonists; Dopamine D2 Antagonists; Dopamine receptor D1; Dopamine receptor D2; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs
CBR-001-670-329-0,RFM-011-510-6,CBR-001-670-329-0,OCC1=C(N2CC2)C(=O)C(=C(C1=O)N1CC1)C,CBR-HVAC-05429: Alkylating agent; DNA-Damaging Drugs; Anticancer; Non-Hodgkin's Lymphoma Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-670-330-3,RFM-011-511-7,CBR-001-670-330-3,O[C@H]1CCN(C1)C(=O)c1cc(c2ccccc2)c(=O)n2c1c1cc(Cl)ccc1CC2,CBR-HVAC-12868: GABA(A) BZ Site Receptor Partial Agonists; Signal Transduction Modulators; Sedative/Hypnotics
CBR-001-670-331-4,RFM-011-512-8,CBR-001-670-331-4,Cc1cccc2c1C=Cc1c(C2=CCC[N+](C)(C)[O-])cccc1,CBR-HVAC-05858: 5 Hydroxytryptamine uptake inhibitor; Adrenergic transmitter uptake inhibitor; Antidepressants
CBR-001-670-332-5,RFM-011-513-9,CBR-001-670-332-5,CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(=O)O)NC(=O)CC[C@H](C(=O)N)NC(=O)[C@@H](NC(=O)[C@H](O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@@H]([C@H]1O)CO)C)C,CBR-HVAC-03279: Immunostimulants
CBR-001-670-333-6,RFM-011-514-0,CBR-001-670-333-6,COc1ccc(cc1)C1(NC(=O)N(C1=O)CCCN1CCC(CC1)c1ccccc1)c1ccccc1,CBR-HVAC-02504: Sodium channel antagonist; Antiarrhythmic
CBR-001-670-334-7,RFM-011-515-1,CBR-001-670-334-7,COc1ccc(cc1OC1CC[C@H](C1)O)C(=O)Nc1c(Cl)c[n+](cc1Cl)[O-],CBR-HVAC-11619: Phosphodiesterase 4 Inhibitor; Antiinflammatory
CBR-001-670-335-8,RFM-011-516-2,CBR-001-670-335-8,O[C@H]1CC(=O)O[C@@H](C1)/C=C/c1c(c2ccc(cc2)F)c2ccccc2c(=O)n1C(C)C,"CBR-HVAC-08299: HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; HMGCoA reductase inhibitor; HMG-CoA reductase inhibitor; Lipoprotein Disorders, Treatment of"
CBR-001-670-336-9,RFM-011-517-3,CBR-001-670-336-9,COC(=O)[C@@H]([C@H](NC(=O)c1ccc(cc1)c1ccc(c(c1)OC)OC)C)Cc1cccc(c1)C(=N)N,CBR-HVAC-11128: Coagulation Factor Xa Inhibitors; Coagulation factor Xa Inhibitor; Inhibitors of Blood Coagulation Pathways; Anticoagulants; Antithrombotic
CBR-001-670-337-0,RFM-011-518-4,CBR-001-670-337-0,Fc1ccc(cc1)C(=O)CC1CCN(C1)CCn1c(=O)[nH]c2c(c1=O)cccc2,"CBR-HVAC-13472: 5-HT2A Antagonists; 5-Hydroxytryptamine 2A receptor; Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-338-1,RFM-011-519-5,CBR-001-670-338-1,Cc1ccc2c(c1)CC1(CC2)CNC=N1,CBR-HVAC-11606: Alpha adrenergic receptor Agonist; Signal Transduction Modulators; alpha2-Adrenoceptor Agonists; Alpha adrenergic receptor agonist; Cardiovascular Diseases (Not Specified)
CBR-001-670-339-2,RFM-011-520-8,CBR-001-670-339-2,COc1ccc2c(c1)cccc2C1COC(OC1)CCCNC(=O)OCC(=O)N,CBR-HVAC-13875: Fatty Acid Amide Hydrolase (FAAH) Inhibitors; Analgesic Drugs; Antidepressants; Anxiolytics
CBR-001-670-340-5,RFM-011-521-9,CBR-001-670-340-5,C[C@@H](C(=O)O)C[C@@H](Cc1ccc(cc1)c1ccccc1)NC(=O)CCC(=O)O,"CBR-HVAC-04494: Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Diuretics; Hypertension, Treatment of"
CBR-001-670-341-6,RFM-011-522-0,CBR-001-670-341-6,CCC(n1ncn(c1=O)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OCC1COC(O1)(Cn1cncn1)c1ccc(cc1F)F)C,CBR-HVAC-02678: Cell wall synthesis inhibitor; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Antifungal; Antifungal Agents
CBR-001-670-342-7,RFM-011-523-1,CBR-001-670-342-7,CCc1nc(c(n1Cc1ccc2c(c1)c(Br)c(o2)c1ccccc1NS(=O)(=O)C(F)(F)F)C(=O)N)C1CC1,"CBR-HVAC-01056: Angiotensin AT1 Antagonists; Angiotensin II antagonist; Angiotensin II receptor type 1 Antagonist; Signal Transduction Modulators; Antihypertensive; Cognition Disorders, Treatment of; Hypertension, Treatment of"
CBR-001-670-343-8,RFM-011-524-2,CBR-001-670-343-8,CNc1nccc(n1)c1nc2c(c1)cc(cc2)C(=O)NC(C(=O)O)CN(c1ccccn1)c1ccccc1,"CBR-HVAC-14013: IKK-2 (IKK-beta) Inhibitors; Signal Transduction Modulators; Osteoarthritis, Treatment of"
CBR-001-670-344-9,RFM-011-525-3,CBR-001-670-344-9,O=C(Nc1nc2c(s1)cc(cc2)Sc1nnc2n1nc(cc2)c1ccc(cc1)F)NCCN1CCOCC1,CBR-HVAC-07160: HGFR (MET; c-Met) Inhibitors; Signal Transduction Modulators; Non-Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-001-670-345-0,RFM-011-526-4,CBR-001-670-345-0,CC(=O)NC1(CCN(CC1)CCC(c1ccc(c(c1)Cl)Cl)CN(C(=O)c1ccccc1)C)c1ccccc1,"CBR-HVAC-04285: Neurokinin 2 receptor antagonist; Neurokinin receptor 2 Antagonist; Signal Transduction Modulators; Tachykinin NK2 Antagonists; Analgesic; Anti-inflammatory; Antiallergy/Antiasthmatic Drugs; Antidepressant; Antidepressants; Antipsychotic Drugs; Anxiolytic; Generalized Anxiety Disorder (GAD), Treatment of; Irritable Bowel Syndrome, Agents for; Urinary Incontinence Therapy"
CBR-001-670-346-1,RFM-011-527-5,CBR-001-670-346-1,COCOC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)N1C(=O)C(NC1(C)C)c1ccc(cc1)O,CBR-HVAC-05573: Cell wall synthesis inhibitor; Antibiotics
CBR-001-670-347-2,RFM-011-528-6,CBR-001-670-347-2,COCOC(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)N1C(=O)C(NC1(C)C)c1ccccc1,CBR-HVAC-13640: Cell wall synthesis inhibitor
CBR-001-670-348-3,RFM-011-529-7,CBR-001-670-348-3,OC(=O)C[C@@H]1Nc2ccc(cc2CN(C1=O)C)C(=O)N(Cc1nc2c(n1)cccc2)C,CBR-HVAC-11082: Integrin alpha5 beta3 Antagonist; Anticancer; Vasoprotectant
CBR-001-670-349-4,RFM-011-530-0,CBR-001-670-349-4,C=C[C@]1(C)C[C@@H](OC(=O)NC(=O)C23CCN(CC2)CC3)[C@]2(C)C(C)CC[C@]3([C@H]([C@@H]1O)C)C2C(=O)CC3,CBR-HVAC-11289: Protein synthesis inhibitor; Antibacterial Drugs; Dermatologic Drugs; Protein synthesis inhibitor
CBR-001-670-350-7,RFM-011-531-1,CBR-001-670-350-7,OC(=O)CC1Cc2ccc(cc2CN(C1=O)CC(F)(F)F)OCCCNc1ccccn1,"CBR-HVAC-05061: Integrin alpha5 beta3 Antagonist; Integrin alpha5 beta5; Integrin alphavbeta3 (Vitronectin) Antagonists; Signal Transduction Modulators; Age-Related Macular Degeneration, Treatment of; Integrin alpha5beta3 antagonist; Integrin alpha5beta5 antagonist; Treatment of Osteoporosis"
CBR-001-670-351-8,RFM-011-532-2,CBR-001-670-351-8,CCCc1c(OCCCOc2ccc(c(c2CC2CC2)OC)C(=O)NC)ccc2c1OC(CCC(=O)O)CC2,CBR-HVAC-10541: Leukotriene Antagonists; Leukotriene B4 receptor Antagonist; Leukotriene BLT (LTB4) Antagonists; Signal Transduction Modulators; Antiinflammatory
CBR-001-670-352-9,RFM-011-533-3,CBR-001-670-352-9,CC(CCN(C(=O)NC(C)(C)C)C[C@H]([C@H](Cc1ccccc1)NC(=O)C(C(C(=O)N)(C)C)C)O)C,CBR-HVAC-10708: HIV Protease Inhibitors; HIV protease inhibitor; Protease Inhibitor; Protease Inhibitors; Anti-HIV Agents; Antiviral
CBR-001-670-353-0,RFM-011-534-4,CBR-001-670-353-0,CC(CCN(C(=O)NC(C)(C)C)C[C@H]([C@H](Cc1ccccc1)NC(=O)C(C(C(=O)N)(C)C)C)O)C,CBR-HVAC-10708: HIV Protease Inhibitors; HIV protease inhibitor; Protease Inhibitor; Protease Inhibitors; Anti-HIV Agents; Antiviral
CBR-001-670-354-1,RFM-011-535-5,CBR-001-670-354-1,Fc1ccc(cc1)C1=C(CC2(C1)CC2)c1ccc(cc1)S(=O)(=O)C,CBR-HVAC-11296: COX Inhibitor; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors; Signal Transduction Modulators; Non-Steroidal Antiinflammatory
CBR-001-670-355-2,RFM-011-536-6,CBR-001-670-355-2,Clc1cccc(c1)n1c2CCCCc2c(=O)c2c1nccc2,CBR-HVAC-09361: 5-Lipoxygenase Inhibitor; Leucotriene receptor antagonist; Lipoxygenase Inhibitors; Mediator Release Inhibitors; ANTI-INFLAMMATORY; ANTIPSORIATIC; Antiallergy/Antiasthmatic Drugs; Antipsoriatics
CBR-001-670-356-3,RFM-011-537-7,CBR-001-670-356-3,CN1CCC2(CC1)COC(O2)C,"CBR-HVAC-03476: Muscarinic M1 Agonists; Muscarinic M1 receptor agonist; Muscarinic acetylcholine receptor M1 Agonist; Signal Transduction Modulators; Cognition Disorders, Treatment of; Muscarinic acetylcholine receptor M1 agonist"
CBR-001-670-357-4,RFM-011-538-8,CBR-001-670-357-4,OC1CCC(=C)/C(=C/C=C/2\CCC[C@]3([C@H]2CC[C@@H]3C(CCC(C(O)(C)C)O)C)C)/C1,"CBR-HVAC-00980: Vitamin D agonist; Bone Diseases, Treatment of; Calcium regulator"
CBR-001-670-358-5,RFM-011-539-9,CBR-001-670-358-5,CCC(N1CC(CC1=O)C=C(F)F)C(=O)N,CBR-HVAC-02714: Calcium channel antagonist; Synaptic Vesicle Glycoprotein 2A (SV2A) Ligands; Synaptic vesicle glycoprotein 2A Modulator; Anticonvulsant; Antiepileptic Drugs; Antiparkinsonian
CBR-001-670-359-6,RFM-011-540-2,CBR-001-670-359-6,Clc1ccc(nc1)N1C(OC(=O)N2CCNCC2)c2c(C1=O)nccn2,"CBR-HVAC-12798: Benzodiazepine receptor agonist; GABA A receptor Antagonist; GABA(A) Receptor Agonists; Non-benzodiazepine hypnotic; Signal Transduction Modulators; Antispastic Drugs; Anxiolytic; Anxiolytics; Muscle Spasms, Drugs for"
CBR-001-670-360-9,RFM-011-541-3,CBR-001-670-360-9,Clc1ccc(nc1)N1C(OC(=O)N2CCNCC2)c2c(C1=O)nccn2,"CBR-HVAC-12798: Benzodiazepine receptor agonist; GABA A receptor Antagonist; GABA(A) Receptor Agonists; Non-benzodiazepine hypnotic; Signal Transduction Modulators; Antispastic Drugs; Anxiolytic; Anxiolytics; Muscle Spasms, Drugs for"
CBR-001-670-361-0,RFM-011-542-4,CBR-001-670-361-0,Oc1ccc(cc1)C1Oc2ccc(cc2C2C1CCC2)O,CBR-HVAC-06490: ESTROGEN RECEPTOR BETA Agonist; Estrogen Receptor (ER) beta Agonists; Estrogen receptor beta agonist; Signal Transduction Modulators; Anti-prostate hyperplasia agent; Antipsychotic Drugs; Benign Prostatic Hyperplasia Therapy
CBR-001-670-362-1,RFM-011-543-5,CBR-001-670-362-1,O=C(c1cc(Cl)c(c2c1OCCO2)N)NCC1CN2CCN1CC2,"CBR-HVAC-13807: 5-HT4 Agonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of"
CBR-001-670-363-2,RFM-011-544-6,CBR-001-670-363-2,COC(=O)C1=C(C)NC(=C(C1c1cccc(c1)[N+](=O)[O-])c1onc(n1)CN(Cc1ccccc1)C)C,"CBR-HVAC-03671: Calcium Channel Blockers; Calcium channel Antagonist; Calcium channel antagonist; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-364-3,RFM-011-545-7,CBR-001-670-364-3,CCCCC/C=C\C/C=C\CCCCCCC(C(=O)O)O,CBR-HVAC-07059: Autophagy Inducers; DHFR Expression Inhibitors; Protein Kinase B (PKB/Akt) Inhibitors; Signal Transduction Modulators; mTOR Complex 1 (mTORC1) Inhibitors; mTOR Complex 2 (mTORC2) Inhibitors; Lung Cancer Therapy; Neurologic Cancer Therapy; Pancreatic Cancer Therapy
CBR-001-670-365-4,RFM-011-546-8,CBR-001-670-365-4,Br/C=C/c1cn(c(=O)[nH]c1=O)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)CO,CBR-HVAC-02820: DNA Polymerase Inhibitors; DNA directed DNA polymerase inhibitor; Dihydropyrimidine dehydrogenase Inhibitor; Anti-Herpes Virus Drugs; Anti-Varicella Zoster Virus Drugs; Anti-infective; Antiviral
CBR-001-670-366-5,RFM-011-547-9,CBR-001-670-366-5,O=C1NC2=Nc3c(CN2C1(C)C)c(Cl)c(cc3)Cl,CBR-HVAC-12081: Platelet aggregation inhibitor; Antithrombocythemic; Platelet lowering agent
CBR-001-670-367-6,RFM-011-548-0,CBR-001-670-367-6,CCOC(=O)NCc1coc2c1cc(cc2)S(=O)(=O)N(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CCO2)O)CC(C)C,CBR-HVAC-06318: HIV Protease Inhibitors; HIV protease inhibitor; Anti-HIV Agents
CBR-001-670-368-7,RFM-011-549-1,CBR-001-670-368-7,COc1ccc(cc1)C1Cc2c(N(C(=O)C1OC(=O)C)CC1CCCN1)cccc2C(F)(F)F,"CBR-HVAC-10556: Calcium Channel Blockers; Calcium channel Antagonist; Calcium channel antagonist; Antihypertensive; Class IV antiarrhythmic; Hypertension, Treatment of"
CBR-001-670-369-8,RFM-011-550-4,CBR-001-670-369-8,CN(CC1CCC(CC1)CNC(=N)c1ccc(cc1)CC(C(=O)N1CCCC1)NC(=O)C(NS(=O)(=O)c1ccc2c(c1)cccc2)Cc1ccccc1)C,CBR-HVAC-11573: Neuropeptide Y receptor 1 Antagonist; Neuropeptide Y1 (NPY Y1) Antagonists; Neurotensin Antagonists; Signal Transduction Modulators; Antidepressant; Antihypertensive; Appetite suppressant; Pharmacological Tools
CBR-001-670-370-1,RFM-011-551-5,CBR-001-670-370-1,CCOC(=O)CCN(c1scc(n1)c1ccc(cc1)/C(=N\C(=O)OCC)/N)C1CCN(CC1)CC(=O)OCC,CBR-HVAC-04877: GPIIb IIIa receptor antagonist; Inhibitors of Blood Coagulation Pathways; Integrin alpha2b beta3 Antagonist; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Anti-aggregant; Antiplatelet Therapy; Antithrombotic
CBR-001-670-371-2,RFM-011-552-6,CBR-001-670-371-2,COc1cc(Cl)c(cc1c1nc(sc1CCC1CCCCC1)NC(=O)c1cc2c(n1CC(=O)O)c(C)cc(c2)C)OC,"CBR-HVAC-10440: CCK A receptor agonist; CCK1 (CCKA) Agonists; Cholecystokinin A receptor Agonist; Signal Transduction Modulators; Antiobesity Drugs; Appetite suppressant; Tardive Dyskinesia, Treatment of"
CBR-001-670-372-3,RFM-011-553-7,CBR-001-670-372-3,CCCCCCCCCCCCCCCCCCOCC1(CCCO1)COP(=O)(OCC[N+](C)(C)C)[O-],CBR-HVAC-00334: Anticancer; Immunostimulant; Membrane permeability enhancer; ONCOLYTIC; Oncolytic Drugs
CBR-001-670-373-4,RFM-011-554-8,CBR-001-670-373-4,C[C@H](c1ccccc1)NC(=O)[C@H](N1C(=O)[C@H]([C@H]1/C=C/c1ccccc1)N1C(=O)OC[C@@H]1c1ccccc1)CC(=O)N1CCC(CC1)N1CCCCC1,"CBR-HVAC-12985: Signal Transduction Modulators; Vasopressin (AVP) V1a Receptor Antagonists; Vasopressin V1a receptor Antagonist; Antidepressants; Antipsychotic; Anxiolytics; Cardioprotectant; Heart Failure Therapy; Hypertension, Treatment of; Mood Disorders, Treatment of; Psychiatric Disorders (Not Specified)"
CBR-001-670-374-5,RFM-011-555-9,CBR-001-670-374-5,NCCO/N=C/c1c2Cn3c(c2nc2c1cccc2)cc1c(c3=O)COC(=O)[C@]1(O)CC,CBR-HVAC-00157: DNA Topoisomerase I Inhibitors; DNA topoisomerase I inhibitor; Topoisomerase I inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-375-6,RFM-011-556-0,CBR-001-670-375-6,CC(=O)CCc1nc(N)c2c(n1)n(C)c(n2)n1nccn1,CBR-HVAC-13473: ADENOSINE A2A RECEPTOR Antagonist; ANTI-PARKINSON'S
CBR-001-670-376-7,RFM-011-557-1,CBR-001-670-376-7,O=C1COc2c(CN1C1CCC1)ccc(c2)OC1CCN(CC1)C1CCC1,"CBR-HVAC-13829: Histamine H3 Receptor Antagonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of"
CBR-001-670-377-8,RFM-011-558-2,CBR-001-670-377-8,CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H]1C[C@@H](O[C@@H]1COP(=O)(OCC[N+](C)(C)C)[O-])n1cc(F)c(=O)[nH]c1=O,CBR-HVAC-03805: Antimetabolites; Antineoplastic; Thymidylate synthase inhibitor; Antineoplastic; Oncolytic Drugs
CBR-001-670-378-9,RFM-011-559-3,CBR-001-670-378-9,CC(=CCc1ccc(cc1)C(C(=O)O)C)C,CBR-HVAC-08395: Cyclooxygenase inhibitor; Platelet aggregation inhibitor; Prostaglandin synthase inhibitor
CBR-001-670-379-0,RFM-011-560-6,CBR-001-670-379-0,COc1cc(CCNCC(c2ccccc2O)O)ccc1OC,CBR-HVAC-08394:
CBR-001-670-380-3,RFM-011-561-7,CBR-001-670-380-3,Clc1ccc2c(c1)ccc(c2)S(=O)(=O)C[C@H](C(=O)N1CCC(CC1)N1CCCNC1=O)O,CBR-HVAC-06319: Coagulation Factor Xa Inhibitors; Coagulation factor Xa Inhibitor; Direct Factor Xa inhibitor; Inhibitors of Blood Coagulation Pathways; Anticoagulant; Anticoagulants
CBR-001-670-381-4,RFM-011-562-8,CBR-001-670-381-4,CNC(=O)c1cc2c(ccnc2cc1OC)Oc1ccc(cc1F)NC(=S)NC(=O)Cc1ccccc1,CBR-HVAC-06963: Angiogenesis Inhibitors; HGFR (MET; c-Met) Inhibitors; Signal Transduction Modulators; VEGFR-2 (FLK-1/KDR) Inhibitors; Solid Tumors Therapy
CBR-001-670-382-5,RFM-011-563-9,CBR-001-670-382-5,Cc1nnc(c1)Nc1nc(ccc1F)CC1(CCN(CC1)C(=O)c1cccc(c1Cl)Cl)C(=O)O,CBR-HVAC-14012: Antimitotic Drugs; Aurora-A (ARK1) Kinase Inhibitors; Signal Transduction Modulators; Solid Tumors Therapy
CBR-001-670-383-6,RFM-011-564-0,CBR-001-670-383-6,Clc1cc2NC(NS(=O)(=O)c2cc1S(=O)(=O)N)C(Cl)(Cl)Cl,CBR-HVAC-13418: Antihypertensive; Diuretic
CBR-001-670-384-7,RFM-011-565-1,CBR-001-670-384-7,O=C(c1cccc2c1oc(c1ccccc1)c(c2=O)C)OC(CN1CCCCC1)(C)C,CBR-HVAC-00311: Calcium channel antagonist; Muscarinic acetylcholine receptor Antagonist; Antispasmodic; Urinary Incontinence Therapy
CBR-001-670-385-8,RFM-011-566-2,CBR-001-670-385-8,ClCCNP(=O)(O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)NCCCl,CBR-HVAC-04367: Alkylating agent; Apoptosis Inducer; Apoptosis Inducers; DNA Alkylating Drugs; DNA inhibitor; null; Anticancer; Brain Cancer Therapy; Breast Cancer Therapy; Colorectal Cancer Therapy; Lung Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Sarcoma Therapy; Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-001-670-386-9,RFM-011-567-3,CBR-001-670-386-9,OC(c1ccc(c(c1)O)O)CNCCn1cnc2c1c(=O)n(C)c(=O)n2C,CBR-HVAC-08989: Antihypertensive; Cardiac stimulant; Vasoconstrictor
CBR-001-670-387-0,RFM-011-568-4,CBR-001-670-387-0,COc1ccncc1CN1CCC(CC1)N(C(C)C)CCCCCCCN1CC[C@H](C1)C(c1ccccc1)(c1ccccc1)C(=O)N,CBR-HVAC-12047: Muscarinic M2 Antagonists; Muscarinic M2 receptor antagonist; Muscarinic acetylcholine receptor 2 Antagonist; Signal Transduction Modulators; Urinary Incontinence Therapy; Urinary agent
CBR-001-670-388-1,RFM-011-569-5,CBR-001-670-388-1,OC(=O)CO/N=C(/c1csc(n1)N)\C(=O)N[C@@H]1C(=O)N(C1(C)C)OS(=O)(=O)O,CBR-HVAC-03326: Cell wall synthesis inhibitor; Antibacterial
CBR-001-670-389-2,RFM-011-570-8,CBR-001-670-389-2,CC(Cc1sc2c(c1C)c(=O)nc(n2)C(=O)O)C,CBR-HVAC-08446: Histamine release inhibitor
CBR-001-670-390-5,RFM-011-571-9,CBR-001-670-390-5,O=C1C=C[C@]2(C(=C1)CC[C@@H]1C2=CC[C@]2([C@H]1C[C@H]([C@@H]2C(=O)CN1CCN(CC1)c1cc(nc(n1)N1CCCC1)N1CCCC1)C)C)C,"CBR-HVAC-13033: Lipid Peroxidation Inhibitors; Lipid peroxidation inhibitor; Nitric Oxide Synthase Inhibitors; Oxygen radical scavenger; Oxygen scavenger; Signal Transduction Modulators; Lipid peroxidation inhibitor; Stroke, Treatment of"
CBR-001-670-391-6,RFM-011-572-0,CBR-001-670-391-6,OCC(Cn1cnc2c1[nH]c(N)nc2=O)CO,CBR-HVAC-05744: Antiviral Drugs
CBR-001-670-392-7,RFM-011-573-1,CBR-001-670-392-7,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)CCCc1cnc2c1c(N)nc(n2)N,CBR-HVAC-03920: Antimetabolites; Dihydrofolate Reductase (DHFR) Inhibitors; Dihydrofolate reductase Inhibitor; Dihydrofolate reductase inhibitor; Thymidylate synthase inhibitor; Anticancer; Antifolate; Oncolytic Drugs
CBR-001-670-393-8,RFM-011-574-2,CBR-001-670-393-8,CCn1cc2c3c1cccc3C1C(C2)N(C)CC(C1)NC(=O)n1nc(cc1C)C,CBR-HVAC-08879: Anticholinergic; Antidepressant
CBR-001-670-394-9,RFM-011-575-3,CBR-001-670-394-9,COCCCC(B1OC(C(O1)(C)C)(C)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](Cc1ccccc1)NC(=O)OCc1ccccc1,CBR-HVAC-05663: Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitors; Anticoagulants
CBR-001-670-395-0,RFM-011-576-4,CBR-001-670-395-0,O=C(CC(C)(C)C)OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1CCC1=CC(=O)C=C[C@]21C)F)(C)C,CBR-HVAC-12683: Principle effects in humans relate to its glucocorticoid action and suppression of inflammatory responses; Anti-inflammatory; Antiarthritic Drugs; Immunosuppressant; Metabolic Disorders (Not Specified)
CBR-001-670-396-1,RFM-011-577-5,CBR-001-670-396-1,O=C(C(C)(C)C)CCC1C(=O)N(N(C1=O)c1ccccc1)c1ccccc1,"CBR-HVAC-13414: Anti-inflammatory, nonsteroidal"
CBR-001-670-397-2,RFM-011-578-6,CBR-001-670-397-2,CC(=O)Oc1ccc(cc1)CC(c1ccccc1)C(=O)O[C@@H]1C[C@@H]2CC[C@H](C1)N2C,CBR-HVAC-09949: Alpha-1 adrenergic receptor Antagonist; Vasodilator
CBR-001-670-398-3,RFM-011-579-7,CBR-001-670-398-3,OCC(NCC(=O)N1C[C@H](C[C@H]1C#N)F)(C)C,"CBR-HVAC-06200: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors; Dipeptidyl peptidase 4 inhibitor; Signal Transduction Modulators; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-670-399-4,RFM-011-580-0,CBR-001-670-399-4,N#Cc1ccc(cc1)C1(F)CN(C1)C(=O)c1cc(c(cc1C)C)c1nc(nc1C)C1CC1,CBR-HVAC-13910: Fatty Acid Synthase (FAS) Inhibitors; Anti-Hepatitis C Virus Drugs; Solid Tumors Therapy
CBR-001-670-400-0,RFM-011-581-1,CBR-001-670-400-0,Nc1ccc(cc1)C(=O)N(c1cccnc1)CCN1CCC(CC1)C(=O)c1ccccc1,CBR-HVAC-11593: 5 Hydroxytryptamine 2 receptor antagonist; 5-HT2A Antagonists; 5-Hydroxytryptamine 2A receptor Antagonist; Signal Transduction Modulators; Antiplatelet; Antiplatelet Therapy
CBR-001-670-401-1,RFM-011-582-2,CBR-001-670-401-1,CCCN[C@@H]1Cc2cccc3c2n(C1)c(=O)[nH]3,CBR-HVAC-13516: 5-HT1A Receptor Agonists; Dopamine D2 Agonists; Dopamine receptor D2 Agonist; Signal Transduction Modulators; Antiparkinsonian; Antiparkinsonian Drugs
CBR-001-670-402-2,RFM-011-583-3,CBR-001-670-402-2,Clc1ccc(cc1)C(c1ccccc1)N1CCN(CC1)CCOc1ccc(cc1C(=O)N)C#CCCN(C(=O)N)O,CBR-HVAC-05715: 5 Lipoxygenase inhibitor; 5-Lipoxygenase Inhibitors; Histamine H1 Receptor Antagonists; Histamine H1 receptor; Histamine H1 receptor antagonist; Inhibitor; Leucotriene receptor antagonist; Lipoxygenase 5 Antagonist; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antiinflammatory; Drugs for Allergic Rhinitis
CBR-001-670-403-3,RFM-011-584-4,CBR-001-670-403-3,O=C1CCC(CN1CC1CC1)(CCN1CC(C1)N1CCN(CC1)S(=O)(=O)N)c1ccc(c(c1)Cl)Cl,CBR-HVAC-05411: Neurokinin receptor 2 Antagonist; Signal Transduction Modulators; Tachykinin NK2 Antagonists; Neurokinin receptor 2 antagonist; Urinary Incontinence Therapy
CBR-001-670-404-4,RFM-011-585-5,CBR-001-670-404-4,COCCC(C(=O)O)CC1(CCCC1)C(=O)NCCCc1ccc(cc1)Cl,"CBR-HVAC-05923: Membrane metalloendopeptidase Inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Neutral endopeptidase inhibitor; Treatment of Female Sexual Dysfunction; VIP modulator"
CBR-001-670-405-5,RFM-011-586-6,CBR-001-670-405-5,O=C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NCCc1cn(c2c1cc(C)cc2)Cc1cc(C)ccc1C)NC1CC1,CBR-HVAC-11518: Adenosine A1 Agonists; Adenosine A1 receptor Modulator; Signal Transduction Modulators; Antiinflammatory; Non-Opioid Analgesics
CBR-001-670-406-6,RFM-011-587-7,CBR-001-670-406-6,Fc1ccc(c(c1)F)C1(OCCN(C1C)C(=O)c1ccccc1C(F)(F)F)Cn1cncn1,CBR-HVAC-10461: Cell wall synthesis inhibitor; Fungicide
CBR-001-670-407-7,RFM-011-588-8,CBR-001-670-407-7,COCCCCCCCCCN1C[C@H](O)[C@H]([C@@H]([C@H]1CO)O)O,CBR-HVAC-07103: alpha-Glucosidase Inhibitors; Antiviral Drugs
CBR-001-670-408-8,RFM-011-589-9,CBR-001-670-408-8,COc1cc(cc(c1OC)OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)OC(CCCc1cccnc1)CCCc1ccccc1,"CBR-HVAC-13115: FK506 binding protein 1A Inhibitor; FK506-Binding Protein 12 (Peptidyl-Prolyl Cis-Trans Isomerase FKBP12) Inhibitors; Antiparkinsonian; Immunosuppressant; Stroke, Treatment of"
CBR-001-670-409-9,RFM-011-590-2,CBR-001-670-409-9,COC(=O)COc1cccc2c1c(C(=O)C(=O)N)c(n2Cc1ccccc1)CC,"CBR-HVAC-05488: Secretory Phospholipase A2 (sPLA2) Inhibitors; Signal Transduction Modulators; Acute Respiratory Distress Syndrome (ARDS), Agents for; Antiarthritic Drugs; Atherosclerosis Therapy; Cardiovascular Diseases (Not Specified); Inflammation, Treatment of; Inflammatory Bowel Disease, Agents for; Lipoprotein Disorders, Treatment of ; Septic Shock, Treatment of"
CBR-001-670-410-2,RFM-011-591-3,CBR-001-670-410-2,CCCC(C[C@@H](C(=O)NC1(C#N)CC1)N[C@H](C(F)(F)F)c1ccc(cc1)F)(F)F,"CBR-HVAC-13902: Cathepsin S Inhibitors; Gastrointestinal Disorders (Not Specified); Neuropathic Pain, Treatment of"
CBR-001-670-411-3,RFM-011-592-4,CBR-001-670-411-3,CCC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@H](C(C)(C)C)NC(=O)NC(C)(C)C)Oc1cc(nc2c1ccc(c2)OC)n1cccn1,CBR-HVAC-14096: Cathepsin B Inhibitors; HCV NS3 NS4A Protease Inhibitors; Agents for Liver Fibrosis; Anti-Hepatitis C Virus Drugs
CBR-001-670-412-4,RFM-011-593-5,CBR-001-670-412-4,CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CNC1C2CC3C1C3C2,CBR-HVAC-10823: Histamine H2 Receptor Antagonists; Histamine H2 receptor Antagonist; Signal Transduction Modulators; Gastric Antisecretory Drugs; Gastric antisecretory
CBR-001-670-413-5,RFM-011-594-6,CBR-001-670-413-5,Fc1ccc(cc1)Cc1ccc(s1)C#CC(N(C(=O)N)O)C,CBR-HVAC-04572: 5 Lipoxygenase inhibitor; 5-LIPOXYGENASE Inhibitor; 5-Lipoxygenase Inhibitors; Leucotriene synthesis inhibitor; Leukotriene Synthesis Inhibitors; Signal Transduction Modulators; Antiallergy; Antiallergy/Antiasthmatic Drugs; Antiasthmatic; Antiinflammatory; Treatment of Disorders of the Coronary Arteries and Atherosclerosis
CBR-001-670-414-6,RFM-011-595-7,CBR-001-670-414-6,CCN1CCc2c3C1CC=C(n3c1c2cccc1)C(=O)OC,"CBR-HVAC-02905: Neuroprotectant; Nootropic; Ischemic Stroke, Treatment of; Neuroprotectant; Nootropic"
CBR-001-670-415-7,RFM-011-596-8,CBR-001-670-415-7,NC(=O)C[C@@H]1NC(=O)[C@H](CCCN(C(=O)C)O)NC(=O)[C@H](CCCN(C(=O)C)O)NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC(C)C)Cc1ccccc1)CCCN(C(=O)C)O,CBR-HVAC-06955: Drugs Targeting Siderophore Iron Transporter 1 (Sit1) Protein; Antifungal Agents
CBR-001-670-416-8,RFM-011-597-9,CBR-001-670-416-8,O=C1Nc2cc(ccc2N2C1CCCC2)C(=O)NCCCN1CCN(CC1)c1cc(Cl)ccc1C,CBR-HVAC-14000: High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors; Signal Transduction Modulators; Analgesic Drugs
CBR-001-670-417-9,RFM-011-598-0,CBR-001-670-417-9,Fc1ccc(c(c1)F)C(C(c1ccc(cn1)c1ccc(cc1)OC(F)(F)F)(F)F)(Cn1cnnn1)O,CBR-HVAC-14021: Lanosterol 14alpha-demethylase Inhibitors; Antifungal Agents
CBR-001-670-418-0,RFM-011-599-1,CBR-001-670-418-0,COCCc1ccc(c(c1)CN(C(=O)[C@H]1CNCC[C@@H]1c1ccc(nc1)OCCOc1c(Cl)cc(cc1Cl)C)C1CC1)Cl,"CBR-HVAC-00190: Renin Inhibitor; Renin Inhibitors; Renin inhibitor; Cardiovascular agent; Hypertension, Treatment of"
CBR-001-670-419-1,RFM-011-600-7,CBR-001-670-419-1,N#CC[C@H](OC(=O)NC(c1cccc(c1)NC(=O)Nc1ccc(c(c1)OC)C#N)C)CC,CBR-HVAC-00527: Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors; Inosine monophosphate dehydrogenase inhibitor; Inosine-5'-monophosphate dehydrogenase Inhibitor; Antipsoriatic; Antipsoriatics; Immunosuppressants
CBR-001-670-420-4,RFM-011-601-8,CBR-001-670-420-4,CC(C[C@@H](C(=O)O)NC(=O)c1ccc(cc1)N1CCC(CC1)NC[C@@H](c1ccc(c(c1)NS(=O)(=O)C)O)O)C,"CBR-HVAC-11508: Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Anti-diabetic; Antiobesity; Antiobesity Drugs; Type 2 Diabetes, Agents for"
CBR-001-670-421-5,RFM-011-602-9,CBR-001-670-421-5,OC(=O)CS(=O)(=O)N(c1ccc(cc1)OC1CCN(CC1)C(=N)C)Cc1ccc2c(c1)cc(cc2)C(=N)N,CBR-HVAC-04968: Coagulation Factor Xa Inhibitors; Coagulation factor Xa Inhibitor; Direct Factor Xa inhibitor; Inhibitors of Blood Coagulation Pathways; Serine protease inhibitor; Anticoagulants; Antithrombotic
CBR-001-670-422-6,RFM-011-603-0,CBR-001-670-422-6,COc1cc2CN(CCc2cc1OC)C(=O)[C@@H]1CCCN(C1)CCNC(=O)c1ccc(cc1)F,"CBR-HVAC-11651: HCN [I(f)] Blockers; Sino-atrial node inhibitor; Angina pectoris, Treatment of; Antiarrhythmic; Antiarrhythmic Drugs"
CBR-001-670-423-7,RFM-011-604-1,CBR-001-670-423-7,COc1ccccc1N1CCN(CC1)CCC(c1ccc(cc1)C)Oc1ccc(cc1)C(=O)c1cn(c2c1cccc2)CCCC(=O)O,CBR-HVAC-10790: 5 Alpha reductase inhibitor; Alpha 1 adrenoreceptor antagonist; Alpha-1 adrenergic receptor; Inhibitor; Signal Transduction Modulators; Steroid 5-alpha-reductase Antagonist; Steroid 5alpha-Reductase Inhibitors; alpha1-Adrenoceptor Antagonists; 5-Alpha reductase inhibitor; Alpha-1 adrenergic receptor antagonist; Benign Prostatic Hyperplasia Therapy; Urinary Incontinence Therapy
CBR-001-670-424-8,RFM-011-605-2,CBR-001-670-424-8,COc1cc(ccc1Cc1cn(c2c1cc(cc2)C(=O)NCC(CC(F)(F)F)C)C)C(=O)NS(=O)(=O)c1ccccc1C,CBR-HVAC-00053: Antagonist; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE E4 RECEPTOR Antagonist; Leucotriene D4 antagonist; Leucotriene receptor antagonist; Leukotriene CysLT1 (LTD4) Antagonists; Signal Transduction Modulators; Antiallergic; Antiallergy/Antiasthmatic Drugs; Asthma Therapy; Drugs for Allergic Rhinitis
CBR-001-670-425-9,RFM-011-606-3,CBR-001-670-425-9,ClCCNP1(=O)OCCC(N1CCCl)OO,CBR-HVAC-00286: Alkylating agent; Anticancer; DNA inhibitor; Alkylating; Anticancer
CBR-001-670-426-0,RFM-011-607-4,CBR-001-670-426-0,COCc1c(ncc2c1c1c(cccc1n2)OCc1ccccc1)C(=O)OCC,CBR-HVAC-03001: Benzodiazepine receptor Partial Agonist; Benzodiazepine receptor agonist; Anticonvulsant; Antiepileptic Drugs; Anxiolytic; Anxiolytics
CBR-001-670-427-1,RFM-011-608-5,CBR-001-670-427-1,O=C(N(C)C)Nc1nccc(c1)CNc1ccccc1C(=O)Nc1ccc2c(c1)nn(c2)C,CBR-HVAC-12041: Angiogenesis Inhibitors; CSF1R (c-FMS) Inhibitors; KIT (C-KIT) Inhibitors; Raf kinase C Inhibitors; Signal Transduction Modulators; VEGFR Inhibitor; VEGFR-2 (FLK-1/KDR) Inhibitors; Anticancer; Antineoplastic Enhancing Agents; Oncolytic Drugs
CBR-001-670-428-2,RFM-011-609-6,CBR-001-670-428-2,OC(=O)Cn1c2cc(n3cncc3)c(cc2[nH]c(=O)c1=O)[N+](=O)[O-],"CBR-HVAC-04872: AMPA RECEPTOR Antagonist; AMPA Receptor Antagonists; AMPA receptor antagonist; Kainate Receptor Antagonists; Signal Transduction Modulators; Analgesic; Antipyretic; Ischemic Stroke, Treatment of; Neuroprotectant"
CBR-001-670-429-3,RFM-011-610-9,CBR-001-670-429-3,OCc1coc(c1)c1ccc(c(c1)OC(C)C)OC(F)F,"CBR-HVAC-13752: Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Atopic Dermatitis, Agents for"
CBR-001-670-430-6,RFM-011-611-0,CBR-001-670-430-6,O=C([C@H]1CCC(=O)N1C1CCN(CC1)Cc1ccc(c(c1)C)Cl)Nc1cccc(c1)c1nnnn1C,"CBR-HVAC-14015: Age-Related Macular Degeneration, Treatment of; Asthma Therapy; Drugs for Allergic Rhinitis"
CBR-001-670-431-7,RFM-011-612-1,CBR-001-670-431-7,O=C([C@H]1CCC(=O)N1C1CCN(CC1)Cc1ccc(c(c1)C)Cl)Nc1cccc(c1)c1nnnn1C,"CBR-HVAC-14015: Age-Related Macular Degeneration, Treatment of; Asthma Therapy; Drugs for Allergic Rhinitis"
CBR-001-670-432-8,RFM-011-613-2,CBR-001-670-432-8,O=C(c1cccc(c1)CCNC(=O)[C@@]12CC[C@H]([C@@H]2[C@@H]2[C@](CC1)(C)[C@]1(C)CC[C@@H]3[C@]([C@H]1CC2)(C)CC[C@@H](C3(C)C)O)C(=C)C)NCc1ccc(cn1)C(=O)NCCc1ncnc1,CBR-HVAC-14107: Viral Maturation Inhibitors; Anti-HIV Agents
CBR-001-670-433-9,RFM-011-614-3,CBR-001-670-433-9,O=C(Oc1ccccc1C(=O)N[C@@H](C(=O)N)C)CCCC[n+]1ccccc1,analog of CBR-HVAC-12322
CBR-001-670-434-0,RFM-011-615-4,CBR-001-670-434-0,CCCCCCCC(c1cc(OC(=O)CCCN(CC)CC)c2c(c1)OC(C1=C2CC(C)CC1)(C)C)C,CBR-HVAC-08918: Antiemetic
CBR-001-670-435-1,RFM-011-616-5,CBR-001-670-435-1,COc1ccc(cc1)S(=O)(=O)N(CC(C)C)CC([C@H](Cc1ccc(cc1)CNCCP(=O)(O)O)NC(=O)O[C@H]1CO[C@@H]2[C@H]1CCO2)O,CBR-HVAC-13672: metabolite of CBR-HVAC-05886
CBR-001-670-436-2,RFM-011-617-6,CBR-001-670-436-2,CCCc1c(OCCCOc2ccc(c(c2CCC)O)C(=O)C)ccc2c1oc(CCC(=O)O)cc2=O,CBR-HVAC-05820: Leukotriene Antagonists; Signal Transduction Modulators; Asthma Therapy
CBR-001-670-437-3,RFM-011-618-7,CBR-001-670-437-3,CCCCOC(=O)N1CCN(CC1)C(=O)C(CP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)NC(=O)c1cc(nc(n1)c1ccccc1)N1CCC(C1)OC,CBR-HVAC-14073: P2Y12 (P2T) Antagonists; Signal Transduction Modulators; Antiplatelet Therapy
CBR-001-670-438-4,RFM-011-619-8,CBR-001-670-438-4,COc1ccc2c(c1)c(nc(=O)n2CC(F)(F)F)c1ccccc1,CBR-HVAC-12157: Cyclooxygenase inhibitor
CBR-001-670-439-5,RFM-011-620-1,CBR-001-670-439-5,CCCOc1cc(N)c(cc1C(=O)NC1CCN(CC1)CCCC1CCCO1)Cl,CBR-HVAC-12169:
CBR-001-670-441-9,RFM-011-621-2,CBR-001-670-441-9,O=C(Cc1c(Cl)ccc([n+]1[O-])NCC(c1cccc[n+]1[O-])(F)F)N[C@@H](c1cccc(c1)Cl)C,CBR-HVAC-14002: Cannabinoid CB1 Antagonists; Signal Transduction Modulators; Antidiabetic Drugs; Antiobesity Drugs
CBR-001-670-442-0,RFM-011-622-3,CBR-001-670-442-0,CCNCc1coc2c1cc(cc2)S(=O)(=O)N(C[C@H]([C@H](Cc1ccccc1)NC(=O)OC1CO[C@@H]2[C@H]1CCO2)O)CC(C)C,CBR-HVAC-14076: Cytochrome P450 CYP3A4 Inhibitors; Anti-HIV Agents
CBR-001-670-443-1,RFM-011-623-4,CBR-001-670-443-1,N#CCC(=O)N1CC(C21CCCN(C2)c1ncnc2c1ccn2)C,"CBR-HVAC-13779: Janus Kinase (Jak) Inhibitors; Signal Transduction Modulators; Allergy, Treatment of; Atopic Dermatitis, Agents for; Dermatologic Drugs; Treatment of Autoimmune Diseases"
CBR-001-670-444-2,RFM-011-624-5,CBR-001-670-444-2,CCCc1c(oc2c(c1=O)cc(cc2)C(=O)O)[C@@H]1C[C@H]1c1ccccc1C,CBR-HVAC-12170: Histamine release inhibitor; Slow releasing substance antagonist
CBR-001-670-445-3,RFM-011-625-6,CBR-001-670-445-3,CNc1nc2cc(OC)c(cc2c(n1)c1cccc(c1)NC(=O)c1ccc(cc1)C(=O)O)OC,CBR-HVAC-13664: metabolite of CBR-HVAC-06808
CBR-001-670-446-4,RFM-011-626-7,CBR-001-670-446-4,SC[C@H](C(=O)NCC(=O)O)Cc1ccc2c(c1)OCO2,metabolite of CBR-HVAC-13336:
CBR-001-670-447-5,RFM-011-627-8,CBR-001-670-447-5,Cc1cnc(c(c1OCC1COC(OC1)(C)C)C)CS(=O)c1nc2c(n1)cccc2,"CBR-HVAC-06498: H+/K+-ATPase Inhibitors; Gastroesophageal Reflux Disease, Agents for"
CBR-001-670-448-6,RFM-011-628-9,CBR-001-670-448-6,CC[C@@H](C(C)C)CCC([C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)CC[C@@H](C2)OP(=O)(OC1=C(O)[C@H](OC1=O)[C@H](CO)O)O)C,"CBR-HVAC-12721: Lipid Lowering Agents; Lipoprotein Disorders, Treatment of"
CBR-001-670-449-7,RFM-011-629-0,CBR-001-670-449-7,Cc1ccc2c(n1)cccc2N1CCN(CC1)CCc1cccc2c1OCc1n2cnc1C(=O)N,CBR-HVAC-06580: 5-HT1A Receptor Antagonists; 5-HT1B Antagonists; 5-HT1D Antagonists; 5-Hydroxytryptamine 1A receptor; 5-Hydroxytryptamine 1B receptor; 5-Hydroxytryptamine 1D receptor Antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics
CBR-001-670-450-0,RFM-011-630-3,CBR-001-670-450-0,COC(=O)c1cnc2n1CCc1c(C2=C2CCN(CC2)CCc2ccc(cc2)OCc2ccc3c(n2)cccc3)cccc1,CBR-HVAC-00369: P glycoprotein inhibitor; P-Glycoprotein (MDR-1; ABCB1) Inhibitors; P-Glycoprotein Inhibitor; Anticancer; Cancer Multidrug Resistance Modulators
CBR-001-670-451-1,RFM-011-631-4,CBR-001-670-451-1,CCOC(=O)CCc1nsnc1OCC(CNC(C)(C)C)O,CBR-HVAC-07416: Beta adrenoreceptor antagonist
CBR-001-670-452-2,RFM-011-632-5,CBR-001-670-452-2,COc1cc(OC)ccc1CS(=O)c1ncccc1C(=O)Nc1cc(C)nc(c1)C,CBR-HVAC-10631: H+/K+-ATPase Inhibitors; Proton pump Inhibitor; Gastric Antisecretory Drugs; Gastric antisecretory
CBR-001-670-453-3,RFM-011-633-6,CBR-001-670-453-3,Nc1ncc(nc1Nc1ccc2c(c1)ccn2)c1ccncc1,CBR-HVAC-12497: CDC-Like Kinase (CLK) Inhibitors; FMS-like tyrosine kinase 3 Inhibitor; Flt3 (FLK2/STK1) Inhibitors; KIT (C-KIT) Inhibitors; Signal Transduction Modulators; Anticancer; Antineoplastic; Myeloid Leukemia Therapy
CBR-001-670-454-4,RFM-011-634-7,CBR-001-670-454-4,[O-][N+](CCC=C1c2ccccc2CCc2c1cccc2)(C)C,CBR-HVAC-05531: Antidepressant; Antidepressants
CBR-001-670-455-5,RFM-011-635-8,CBR-001-670-455-5,CCc1cccc(c1CNc1cc(cn2c1nc(c2C)C)C(=O)N)C,"CBR-HVAC-12031: GABA(B) Receptor Antagonists; H+/K+-ATPase Inhibitors; Proton pump inhibitor; Signal Transduction Modulators; Antacid; Antiulcerant; Gastroesophageal Reflux Disease, Agents for"
CBR-001-670-456-6,RFM-011-636-9,CBR-001-670-456-6,N[C@@H]1CCCN(C1)c1c(Br)cnc2c1c(cn2)NC(=O)C1CC1,CBR-HVAC-12574: CHECKPOINT KINASE 1 Inhibitor; Checkpoint Kinase 1 (Chk1) Inhibitors; Signal Transduction Modulators; ANTICANCER; Lymphoma Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-670-457-7,RFM-011-637-0,CBR-001-670-457-7,N#Cc1cc(F)c(nc1N[C@H](c1ccc(cn1)F)C)Nc1nnc(c1)OC(C)C,CBR-HVAC-12597: Antitumor; Signal Transduction Modulators; TRK Inhibitors; Antitumour; Solid Tumors Therapy
CBR-001-670-458-8,RFM-011-638-1,CBR-001-670-458-8,N#Cc1cc(F)c(nc1N[C@@H](c1ccc(cn1)F)C)Nc1nnc(c1)OC(C)C,CBR-HVAC-12597: Antitumor; Signal Transduction Modulators; TRK Inhibitors; Antitumour; Solid Tumors Therapy
CBR-001-670-459-9,RFM-011-639-2,CBR-001-670-459-9,N#Cc1cccc(c1)C(=O)c1cnn(c1N)c1cc(ccc1C)C(=O)NC1CC1,"CBR-HVAC-12459: Anti-inflammatory; Antiinflammatory Drugs; Anti-inflammatory; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Rheumatoid Arthritis, Treatment of; Treatment of Renal Diseases"
CBR-001-670-460-2,RFM-011-640-5,CBR-001-670-460-2,FC(Oc1ccc(cc1)C(c1ccc(cc1)OC(F)F)NCC(c1ccc(c(c1)NS(=O)(=O)C)O)O)F,CBR-HVAC-04826: Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Antidiabetic; Antidiabetic Drugs; Antiobesity Drugs
CBR-001-670-461-3,RFM-011-641-6,CBR-001-670-461-3,FC(Oc1ccc(cc1)C(c1ccc(cc1)OC(F)F)NCC(c1ccc(c(c1)NS(=O)(=O)C)O)O)F,CBR-HVAC-04826: Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Antidiabetic; Antidiabetic Drugs; Antiobesity Drugs
CBR-001-670-462-4,RFM-011-642-7,CBR-001-670-462-4,O=C(N[C@H](C(=O)Nc1ccc(cc1)C1S/C(=N\c2cccc(c2)F)/N(C1=O)Cc1ccco1)C)Cc1ccccc1,CBR-HVAC-12600: Antiviral; ANTIVIRAL
CBR-001-670-463-5,RFM-011-643-8,CBR-001-670-463-5,CC[C@@H]([C@H](C(=O)N([C@H]1CCCCNC1=O)C)NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](Cc1ccccc1)N)CC(C)C)Cc1ncnc1)CCC(=O)O)C,CBR-HVAC-12289: Anti-Tubercular
CBR-001-670-464-6,RFM-011-644-9,CBR-001-670-464-6,OC(=O)C1CCc2c1ccc(c2)OCCn1cncc1,CBR-HVAC-03502: Thromboxane A synthase Inhibitor; Thromboxane A2 receptor antagonist; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Antiplatelet Therapy; Antithrombotic
CBR-001-670-465-7,RFM-011-645-0,CBR-001-670-465-7,NCCCC[C@@H](C(=O)N1CCC[C@H]1C(=O)O)OP(=O)(CCCCc1ccccc1)O,"CBR-HVAC-03616: Angiotensin I converting enzyme inhibitor; Angiotensin converting enzyme Inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Antidepressants; Antihypertensive; Anxiolytic; Cognition Disorders, Treatment of; Hypertension, Treatment of; Restenosis Treatment of"
CBR-001-670-466-8,RFM-011-646-1,CBR-001-670-466-8,OC(=O)[C@@H](Nc1ccccc1C(=O)c1ccc(cc1)F)Cc1ccc(cc1)OCCn1c2ccccc2c2c1cccc2,"CBR-HVAC-00728: Insulin sensitizer; PPARalpha Agonists; PPARgamma Agonists; Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor delta; Peroxisome proliferator activated receptor gamma Agonist; Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor pan agonist; Signal Transduction Modulators; Antihyperlipidemic; Insulin sensitizer; Type 2 Diabetes, Agents for"
CBR-001-670-467-9,RFM-011-647-2,CBR-001-670-467-9,OC(=O)[C@@H](Nc1ccccc1C(=O)c1ccc(cc1)F)Cc1ccc(cc1)OCCn1c2ccccc2c2c1cccc2,"CBR-HVAC-00728: Insulin sensitizer; PPARalpha Agonists; PPARgamma Agonists; Peroxisome proliferator activated receptor alpha; Peroxisome proliferator activated receptor delta; Peroxisome proliferator activated receptor gamma Agonist; Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist; Peroxisome proliferator-activated receptor gamma agonist; Peroxisome proliferator-activated receptor pan agonist; Signal Transduction Modulators; Antihyperlipidemic; Insulin sensitizer; Type 2 Diabetes, Agents for"
CBR-001-670-468-0,RFM-011-648-3,CBR-001-670-468-0,O=C(c1ccccc1O)O[Mg-](OC(=O)c1ccccc1O)OC(=O)c1ccccc1O,CBR-HVAC-09446: Cyclooxygenase 1 Inhibitor; Cyclooxygenase 2; Inhibitor; Analgesic
CBR-001-670-469-1,RFM-011-649-4,CBR-001-670-469-1,F[C@@H]1C[C@@](C1)(CNc1ncc(cn1)n1ccc(c1)C(=O)N)c1ncccc1F,CBR-HVAC-12578: FAST SKELETAL MUSCLE TROPONIN Activator; MUSCLE SYSTEM AGENT
CBR-001-670-470-4,RFM-011-650-7,CBR-001-670-470-4,OC(=O)Cc1c(C)n(c2c1cccc2)C(=O)c1ccccc1,CBR-HVAC-01023: Cyclooxygenase inhibitor; Phosphodiesterase 4 inhibitor; Analgesic; Anti-inflammatory; Antipyretic
CBR-001-670-471-5,RFM-011-651-8,CBR-001-670-471-5,NCCCC[C@@H](C(=O)N[C@@H](C(=O)O)CCC(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O)NC(=O)c1cccnc1,"CBR-HVAC-10526: Angiotensin I converting enzyme Inhibitor; Angiotensin I converting enzyme inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Potassium channel agonist; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-472-6,RFM-011-652-9,CBR-001-670-472-6,Cc1ccc(cc1)c1ccc2c(c1)C=C(CCC2)C(=O)Nc1ccc(cc1)C[N+](C1CCOCC1)(C)C,CBR-HVAC-05186: C-C chemokine receptor type 5 Antagonist; CC chemokine receptor 2B antagonist; CC chemokine receptor 5 antagonist; Chemokine CCR2B Receptor Antagonists; Chemokine CCR5 Antagonists; Chemokine CXCR3 Antagonists; HIV Attachment Inhibitors; Signal Transduction Modulators; Anti-HIV; Anti-HIV Agents; Treatment of Transplant Rejection
CBR-001-670-473-7,RFM-011-653-0,CBR-001-670-473-7,Fc1ccc2c(c1)onc2C1CCN(CC1)CCNc1cnn(c(=O)c1Cl)C,CBR-HVAC-00182: 5 Hydroxytryptamine 2A receptor antagonist; 5 Hydroxytryptamine 7 receptor antagonist; 5-HT2A Receptor Ligands; 5-HT7 Receptor Ligands; Alpha 1a adrenoreceptor antagonist; Antipsychotic; Anxiolytic; Dopamine D2 Receptor Ligands; Dopamine D2 receptor antagonist; Nootropic agent; Signal Transduction Modulators; alpha-Adrenoceptor Ligands; Antipsychotic; Antipsychotic Drugs; Anxiolytic; Nootropic agent
CBR-001-670-474-8,RFM-011-654-1,CBR-001-670-474-8,COc1cc2c(cnc(c2cc1OC)Cc1ccc(c(c1)OC)OC)CN1CCN(CC1)c1ccccc1OC,CBR-HVAC-03216: Alpha 1 adrenoreceptor antagonist; Calmodulin Inhibitor; Calmodulin antagonist; Platelet aggregation inhibitor; Cardiovascular Diseases (Not Specified); Neuroprotectant
CBR-001-670-475-9,RFM-011-655-2,CBR-001-670-475-9,COc1cc(CCN(CCCN2Cc3c(C2=O)cc(c(c3)OC)OC)C)ccc1OC,"CBR-HVAC-02931: Calcium channel Antagonist; HCN channel antagonist; Potassium channel antagonist; Sodium channel antagonist; Angina pectoris, Treatment of; Bradycardic"
CBR-001-670-476-0,RFM-011-656-3,CBR-001-670-476-0,CC(=O)SC[C@H](C(=O)N[C@H](C(=O)OCc1ccccc1)C)Cc1ccc2c(c1)OCO2,"CBR-HVAC-00815: ANGIOTENSIN I CONVERTING ENZYME; Angiotensin I converting enzyme inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Endopeptidase inhibitor; Membrane metallo endopeptidase inhibitor; NEPRILYSIN Inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Antihypertensive; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-670-477-1,RFM-011-657-4,CBR-001-670-477-1,CC(=O)SC[C@@H](C(=O)N[C@H](C(=O)OCc1ccccc1)C)Cc1ccc2c(c1)OCO2,"CBR-HVAC-00815: ANGIOTENSIN I CONVERTING ENZYME; Angiotensin I converting enzyme inhibitor; Angiotensin-I Converting Enzyme (ACE) Inhibitors; Endopeptidase inhibitor; Membrane metallo endopeptidase inhibitor; NEPRILYSIN Inhibitor; Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitors; Antihypertensive; Heart Failure Therapy; Hypertension, Treatment of"
CBR-001-670-478-2,RFM-011-658-5,CBR-001-670-478-2,CCCCCCCC/N=C/N1CCC(CC1)C(c1ccccc1)c1ccccc1,CBR-HVAC-07817: Gastrin inhibitor; Membrane permeability inhibitor
CBR-001-670-479-3,RFM-011-659-6,CBR-001-670-479-3,Fc1ccc(cc1)c1oc(=O)oc1CCN1CCN(CC1)c1ccccc1,CBR-HVAC-07834: Cholesterol inhibitor; Lipase clearing factor stimulant
CBR-001-670-480-6,RFM-011-660-9,CBR-001-670-480-6,NCCc1ccc(c(c1CCc1ccc(c(c1)O)C)O)O,"CBR-HVAC-10596: Dopamine D1 Agonists; Dopamine receptor D1 Agonist; Signal Transduction Modulators; Antihypertensive; Heart Failure Therapy; Hypertension, Treatment of; Renal Failure, Agents for; Septic Shock, Treatment of"
CBR-001-670-481-7,RFM-011-661-0,CBR-001-670-481-7,OC(=O)CCCn1ccc2c1cccc2c1noc(n1)c1cnc(c(c1)Cl)OC(C)C,"CBR-HVAC-12550: Lysophospholipid edg1 (S1P1) Receptor Agonists; Signal Transduction Modulators; Sphingosine-1-phosphate receptor 1 Agonist; Antisclerotic; Immunosuppressant; Multiple Sclerosis, Agents for"
CBR-001-670-482-8,RFM-011-662-1,CBR-001-670-482-8,CONC(=O)c1ccccc1Nc1cc(ncc1Cl)Nc1cc(nn1C(C)C)C,CBR-HVAC-12570: Focal Adhesion Kinase (FAK) Inhibitors; Focal adhesion kinase Inhibitor; Signal Transduction Modulators; Anticancer; Neurologic Cancer Therapy; Pancreatic Cancer Therapy; Solid Tumors Therapy
CBR-001-670-483-9,RFM-011-663-2,CBR-001-670-483-9,Clc1cccc(c1)C(CNCCNc1cccc(c1)c1cc(ccc1C)C(=O)O)O,CBR-HVAC-13659: Beta 3 adrenoreceptor agonist
CBR-001-670-484-0,RFM-011-664-3,CBR-001-670-484-0,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCc1ccncc1,CBR-HVAC-12223: CANNABINOID RECEPTOR 2 Agonist; Cannabinoid CB2 Agonists; Signal Transduction Modulators; ANALGESIC; Non-Opioid Analgesics
CBR-001-670-485-1,RFM-011-665-4,CBR-001-670-485-1,O[Pt]1(N[C@H]2[C@H](N1)CCCC2)OS(=O)(=O)O,CBR-HVAC-07947: DNA inhibitor
CBR-001-670-486-2,RFM-011-666-5,CBR-001-670-486-2,O=c1c2CN([C@@H](c2nc2c1cccc2)c1ccc2c(c1)CCO2)c1ccccn1,CBR-HVAC-06146: Phosphodiesterase 5 Inhibitor; Phosphodiesterase PDE5A Inhibitors; Signal Transduction Modulators; Phosphodiesterase 5 inhibitor; Treatment of Erectile Dysfunction
CBR-001-670-487-3,RFM-011-667-6,CBR-001-670-487-3,CN(c1snc(n1)n1cncc1)CCCNCc1ccc2c(c1)OCO2,"CBR-HVAC-12596: Inducible Nitric Oxide Synthase (NOS-2) Inhibitors; Inducible nitric oxide synthase Inhibitor; Signal Transduction Modulators; Analgesic; Neuropathic Pain, Treatment of"
CBR-001-670-488-4,RFM-011-668-7,CBR-001-670-488-4,Fc1ccc2c(c1)c(C(=O)O)c1c(n2)c2ccc(cc2CCC1)c1ccccc1F,CBR-HVAC-11303: Dihydroorotate Dehydrogenase (DHODH) Inhibitors; Dihydroorotate dehydrogenase Inhibitor; Antiarthritic; Anticancer; Immunosuppressant; Immunosuppressants
CBR-001-670-489-5,RFM-011-669-8,CBR-001-670-489-5,O=C(c1cccnc1)Oc1ccc(cc1C(C)(C)C)C1CCCCC1,"CBR-HVAC-03382: Cholesterol inhibitor; Lipoprotein Disorders, Treatment of"
CBR-001-670-490-8,RFM-011-670-1,CBR-001-670-490-8,CNC(=O)NCc1ccccc1c1ccc(cc1)CN1C(=O)C(CCc2c1cccc2)NC(=O)C(N)(C)C,CBR-HVAC-11141: Growth Hormone Secretagogues; Growth hormone releasing hormone Agonist; Signal Transduction Modulators; Growth hormone releasing factor agonist
CBR-001-670-491-9,RFM-011-671-2,CBR-001-670-491-9,CNC(=O)NCc1ccccc1c1ccc(cc1)CN1C(=O)C(CCc2c1cccc2)NC(=O)C(N)(C)C,CBR-HVAC-11141: Growth Hormone Secretagogues; Growth hormone releasing hormone Agonist; Signal Transduction Modulators; Growth hormone releasing factor agonist
CBR-001-670-492-0,RFM-011-672-3,CBR-001-670-492-0,OCc1nn(c(n1)NCCCOc1cccc(c1)CN1CCCCC1)C,CBR-HVAC-00367: Histamine H2 receptor Antagonist; Histamine H2 receptor antagonist; Antiasthmatic
CBR-001-670-493-1,RFM-011-673-4,CBR-001-670-493-1,OC(=O)[C@@H]1CSSCC(C(=O)N1)(C)C,CBR-HVAC-00333: TNF-like factor Inhibitor; Agents for Liver Fibrosis; Antiviral; Hepatic protector; Hepatoprotectants; Immunomodulators
CBR-001-670-494-2,RFM-011-674-5,CBR-001-670-494-2,OC[C@@H]1C[C@@H]([C@@H](O1)n1cnc2c1ncnc2N)F,CBR-HVAC-02751: Nucleoside reverse transcriptase inhibitor; Reverse Transcriptase Inhibitors; Reverse transcriptase Inhibitor; Anti-HIV Agents; Antiviral
CBR-001-670-495-3,RFM-011-675-6,CBR-001-670-495-3,Fc1ccc(cc1CNC(=O)[C@@](C(F)(F)F)(c1ccccc1)O)C(F)(F)F,"CBR-HVAC-12555: Androgen receptor Modulator; Selective Androgen Receptor Modulators (SARM); Signal Transduction Modulators; Muscle system agent; Sarcopenia, Treatment of"
CBR-001-670-496-4,RFM-011-676-7,CBR-001-670-496-4,O=C1CCc2c(C1(C)CCN1CCCCC1)cccc2,CBR-HVAC-04015: Antitussives
CBR-001-670-497-5,RFM-011-677-8,CBR-001-670-497-5,CCCCCCCCOC(=O)C1=C(C)NC(=C(C1c1ccccc1[N+](=O)[O-])C(=O)NC1CC1)C,"CBR-HVAC-03585: Calcium Channel Blockers; Calcium channel Antagonist; Calcium channel antagonist; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-498-6,RFM-011-678-9,CBR-001-670-498-6,O=c1ccc2c(n1)cc(cc2)OCCCN1CCN(CC1)c1cccc(c1C)C,CBR-HVAC-03443: Dopamine receptor D2 Agonist; Dopamine receptor antagonist; Antipsychotic; Antipsychotic Drugs
CBR-001-670-499-7,RFM-011-679-0,CBR-001-670-499-7,CCOC(=O)CCNC(=O)N[C@H]1CCN(C1=O)c1ccc(cc1)C(=N)N,CBR-HVAC-04950: Inhibitors of Blood Coagulation Pathways; Integrin alpha2b beta3 Antagonist; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Signal Transduction Modulators; Anticoagulant; Antiplatelet Therapy
CBR-001-670-500-3,RFM-011-680-3,CBR-001-670-500-3,COc1cc(C)c(c(c1C)C)S(=O)(=O)N[C@H](C(=O)NC(C(=O)N1CCCCC1)Cc1ccc2c(c1)ccnc2N)CC(=O)OC(C)(C)C,CBR-HVAC-11842: Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitor; Thrombin Inhibitors; Anticoagulants; Antithrombotic
CBR-001-670-501-4,RFM-011-681-4,CBR-001-670-501-4,CC([C@@H](C(=O)O)NC(=O)c1onc(c1)c1ccc(cc1)Nc1nc2c(s1)cc(cc2)F)C,"CBR-HVAC-12503: DIACYLGLYCEROL O-ACYLTRANSFERASE 1 inhibitor; Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitors; ANTIDIABETIC; Antidiabetic Drugs; Lipoprotein Disorders, Treatment of ; Metabolic Disorders (Not Specified)"
CBR-001-670-502-5,RFM-011-682-5,CBR-001-670-502-5,C/C(=C\C=C\c1ccc(cc1)C(=O)O)/C=C/C1=C(C)CCCC1(C)C,CBR-HVAC-03847: Keratolytics
CBR-001-670-503-6,RFM-011-683-6,CBR-001-670-503-6,C[C@H](c1cc(F)c(c(c1)F)NS(=O)(=O)C)NC(=O)[C@H]1C[C@]1(C)c1ccc(cc1)C(F)(F)F,CBR-HVAC-13594: Vanilloid receptor 1 antagonist
CBR-001-670-504-7,RFM-011-684-7,CBR-001-670-504-7,O[C@@H]1[C@H](O[C@@H]([C@H]([C@@H]1O)O)CCP(=O)(O)O)Oc1ccc(cc1C)C,CBR-HVAC-12458: Cation-independent mannose 6-phosphate receptor Inhibitor; Immunomodulator
CBR-001-670-505-8,RFM-011-685-8,CBR-001-670-505-8,CN1CCN(CC1)c1ncc(c(n1)c1ccccc1C)N(C(=O)C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)C,"CBR-HVAC-14061: Enzyme Inhibitors; Alzheimer's Dementia, Treatment of"
CBR-001-670-506-9,RFM-011-686-9,CBR-001-670-506-9,O=C(Nc1ccccc1c1ccccc1)OC1CCN(CC1)CCN(C(=O)c1ccc(cc1)CN1CCC(CC1)C(=O)N)C,"CBR-HVAC-00619: Long-acting muscarinic antagonist; Muscarinic Antagonists; Muscarinic M3 receptor antagonist; Muscarinic acetylcholine receptor Antagonist; Signal Transduction Modulators; Anti-inflammatory; Bronchodilator; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Respiratory Disorders (Not Specified)"
CBR-001-670-507-0,RFM-011-687-0,CBR-001-670-507-0,O=c1cc(n(n1CCCN1CCN(CC1)c1ccccn1)c1ccccc1)c1ccccc1,CBR-HVAC-08263: Histamine receptor antagonist
CBR-001-670-508-1,RFM-011-688-1,CBR-001-670-508-1,O=C(C(c1ccc2c(c1)OCO2)N)N[C@@H]1C(=O)N2[C@@H]1SCC(=C2C(=O)O)C,CBR-HVAC-08023: Cell wall synthesis inhibitor; Antibiotics
CBR-001-670-509-2,RFM-011-689-2,CBR-001-670-509-2,CC(c1nnnn1)(CCCCOc1cc(cc(n1)c1ccccc1)c1ccccc1)C,CBR-HVAC-10711: Leucotriene B4 antagonist; Leukotriene Antagonists; Leukotriene B4 receptor Antagonist; Leukotriene BLT (LTB4) Antagonists; Signal Transduction Modulators; Antiallergy/Antiasthmatic Drugs; Antiinflammatory
CBR-001-670-510-5,RFM-011-690-5,CBR-001-670-510-5,Fc1cc(F)c2c(c1)OCC[C@@H]2Oc1cc(cc2c1nc(n2)C)C(=O)N(C)C,"CBR-HVAC-12582: PROTON PUMP Inhibitor; Reversible H+/K+-ATPase Inhibitors ; ANTACID; Esophageal Diseases, Treatment of; Gastroesophageal Reflux Disease, Agents for"
CBR-001-670-511-6,RFM-011-691-6,CBR-001-670-511-6,Fc1cc(F)c2c(c1)OCC[C@H]2Oc1cc(cc2c1nc(n2)C)C(=O)N(C)C,"CBR-HVAC-12582: PROTON PUMP Inhibitor; Reversible H+/K+-ATPase Inhibitors ; ANTACID; Esophageal Diseases, Treatment of; Gastroesophageal Reflux Disease, Agents for"
CBR-001-670-512-7,RFM-011-692-7,CBR-001-670-512-7,N#Cc1ccc2c(c1)[C@H]1CN(C[C@@H]1CO2)CCCCNC(=O)c1ccc(cc1)c1ccccc1,CBR-HVAC-11476: Dopamine D3 Antagonists; Dopamine receptor D3 Antagonist; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs
CBR-001-670-513-8,RFM-011-693-8,CBR-001-670-513-8,CC(=O)N[C@H](C(=O)O)CSC(=O)c1ccccc1OC(=O)C,CBR-HVAC-03692: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Mucolytics
CBR-001-670-514-9,RFM-011-694-9,CBR-001-670-514-9,CC(C[C@@H](C(=O)N1CCC[C@H]1C(=O)N)NC(=O)[C@@H](NC(=O)[C@H](C1CCCCC1)NC(=O)[C@H](Cc1ccc(cc1)C(=N)N)NC(=O)C)Cc1ccc[n+](c1)C)C,CBR-HVAC-11471: Coagulation Factor Xa Inhibitors; Coagulation factor Xa; Inhibitors of Blood Coagulation Pathways; Thrombin Inhibitor; Anticoagulant; Anticoagulants
CBR-001-670-515-0,RFM-011-695-0,CBR-001-670-515-0,CC(=O)N[C@@H]1CN(C(=O)C1)c1ccc(cc1)OCc1cccc(c1)F,"CBR-HVAC-11808: MAO-B Inhibitors; Monoamine oxidase B Inhibitor; Alzheimer's Dementia, Treatment of ; Cognition Disorders, Treatment of; Neuroprotectant; Smoking Cessation, Aid to"
CBR-001-670-516-1,RFM-011-696-1,CBR-001-670-516-1,CC(=O)OCC(CCn1cnc2c1nc(N)nc2)COC(=O)OC(C)C,CBR-HVAC-11515: DNA polymerase Inhibitor; Anti-Hepatitis B Virus Drugs; Anti-Herpes Simplex Virus Drugs; Antiviral
CBR-001-670-517-2,RFM-011-697-2,CBR-001-670-517-2,C1CC/C(=C\c2ccccc2)/C(C1)N1CCC1,CBR-HVAC-02557: Opioid receptor agonist; Opioid receptor antagonist; Analgesic
CBR-001-670-518-3,RFM-011-698-3,CBR-001-670-518-3,CCCCCCSc1nsnc1C1=CCCN(C1)C,"CBR-HVAC-04537: Muscarinic M1 Agonists; Muscarinic acetylcholine receptor M1 Agonist; Signal Transduction Modulators; Cognition Disorders, Treatment of; Nootropic"
CBR-001-670-519-4,RFM-011-699-4,CBR-001-670-519-4,O=C(/C=C/1\CCCOc2c1ccc(c2)C(F)(F)F)Nc1ccc2c(c1)NC(=O)C(O2)(C)C,CBR-HVAC-12581: ANALGESIC; Analgesic Drugs
CBR-001-670-520-7,RFM-011-700-0,CBR-001-670-520-7,Cc1ccc(cc1C(c1c(C)cc(cc1C)C(=O)O)O)n1cncc1,CBR-HVAC-03432: Thromboxane A synthase Inhibitor; Thromboxane Synthase Inhibitors; Thromboxane synthase inhibitor; Antiallergy/Antiasthmatic Drugs; Anticoagulants; Antiplatelet; Antiplatelet Therapy
CBR-001-670-521-8,RFM-011-701-1,CBR-001-670-521-8,COc1cc(ccc1OC)N1CCN(CC1)C(=O)CC(c1ccccc1)OC(=O)N,"CBR-HVAC-12523: Analgesic; Analgesic; Diabetic Neuropathy, Agents for"
CBR-001-670-522-9,RFM-011-702-2,CBR-001-670-522-9,COc1cc(ccc1OC)N1CCN(CC1)C(=O)CC(c1ccccc1)OC(=O)N,"CBR-HVAC-12523: Analgesic; Analgesic; Diabetic Neuropathy, Agents for"
CBR-001-670-523-0,RFM-011-703-3,CBR-001-670-523-0,COc1ncccc1c1cnc(c(n1)Nc1ccc2c(c1)ccn2)N,CBR-HVAC-14507: analog of CBR-HVAC-12497
CBR-001-670-524-1,RFM-011-704-4,CBR-001-670-524-1,O[C@@H](CN1CCCc2c(C1=O)c(C)c(n2)/C=C/1\C(=O)Nc2c1cc(F)cc2)CN1CCOCC1,CBR-HVAC-07120: Angiogenesis Inhibitors; Signal Transduction Modulators; VEGFR-2 (FLK-1/KDR) Inhibitors; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-670-525-2,RFM-011-705-5,CBR-001-670-525-2,O=C(c1cc2CCCCCCc2n(c1=O)CC1CCCCC1)NC(C(=O)N1CCC(CC1)NS(=O)(=O)C)(C)C,CBR-HVAC-12325: Cannabinoid CB1 Receptor Ligands; Cannabinoid CB1 receptor agonist; Cannabinoid CB2 Receptor Ligands; Cannabinoid CB2 receptor agonist; Signal Transduction Modulators; Antipruritics
CBR-001-670-526-3,RFM-011-706-6,CBR-001-670-526-3,CSc1ccc(cc1)c1nn(Cc2ccccc2)c(=O)cc1c1ccc(cc1)Cl,"CBR-HVAC-12540: Cytokine Production Inhibitors; Interleukin 1 beta Antagonist; Signal Transduction Modulators; Interleukin 1 beta antagonist; Rheumatoid Arthritis, Treatment of"
CBR-001-670-527-4,RFM-011-707-7,CBR-001-670-527-4,NCCCNCCCCNCCCNCC(=O)N[C@H]1[C@H]2COC(=O)[C@@H]2[C@@H](c2c1cc1OCOc1c2)c1cc(OC)c(c(c1)OC)O,CBR-HVAC-06310: DNA Topoisomerase II Inhibitors; DNA-Damaging Drugs; Topoisomerase II Inhibitor; Anticancer; Myeloid Leukemia Therapy; Solid Tumors Therapy
CBR-001-670-528-5,RFM-011-708-8,CBR-001-670-528-5,Clc1cccc(c1c1noc(c1COC1CCN(CC1)c1ccc2c(c1)n(C)cc2C(=O)O)C1CC1)Cl,CBR-HVAC-13595: Farnesoid X receptor agonist
CBR-001-670-529-6,RFM-011-709-9,CBR-001-670-529-6,CCOP(=O)(C(c1cc(C)c(c(c1)OC)O)CNc1ccc(nc1C)C)OCC,"CBR-HVAC-12589: Farnesoid X-activated receptor Modulator; Antihypercholesterolemic; HDL cholesterol enhancer; LDL cholesterol inhibitor; Lipoprotein Disorders, Treatment of"
CBR-001-670-530-9,RFM-011-710-2,CBR-001-670-530-9,COC(=O)[C@@H](NC(=O)c1c(Cl)cccc1Cl)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-14481: metabolite of CBR-HVAC-12546
CBR-001-670-531-0,RFM-011-711-3,CBR-001-670-531-0,NCCCC[C@@H]1NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@@H](NC1=O)CC(C)C)C(=O)N[C@@H](Cc1ncnc1)C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N2)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@@H]1CCC(=O)N1)C(=O)O)O)Cc1ccc(cc1)O,"CBR-HVAC-06176: Norepinephrine Transporter (NET) Inhibitors; Signal Transduction Modulators; Analgesic Drugs; Neuropathic Pain, Treatment of"
CBR-001-670-532-1,RFM-011-712-4,CBR-001-670-532-1,Oc1ccc(cc1)CCSC(C(=O)O)Cc1ccc(cc1)CCOc1ccc(cc1)OS(=O)(=O)C,CBR-HVAC-12441: Peroxisome proliferator-activator receptor Agonist; Anti-dyslipidemic
CBR-001-670-533-2,RFM-011-713-5,CBR-001-670-533-2,ONC(=N)c1ccc(cc1Cl)OCc1sc(nc1C)c1ccc(cc1)C(F)(F)F,"CBR-HVAC-14377: PPARdelta Agonists; Peroxisome proliferator-activated receptor beta/delta agon; Peroxisome proliferator-activated receptor delta agonist; Signal Transduction Modulators; Lipoprotein Disorders, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-670-534-3,RFM-011-714-6,CBR-001-670-534-3,FC(c1ccc(cc1)Nc1nc(nc2c1CCN(CC2)c1ncccc1C(F)(F)F)N1CCCCC1)(F)F,CBR-HVAC-13598: Vanilloid receptor 1 antagonist
CBR-001-670-535-4,RFM-011-715-7,CBR-001-670-535-4,CNC(=O)[C@@H](NC(=O)c1c(Cl)cccc1Cl)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-14521: Metabolite
CBR-001-670-536-5,RFM-011-716-8,CBR-001-670-536-5,Nc1ncc(nc1Nc1ccc2c(c1)ccn2)c1ccccc1,CBR-HVAC-14506: Metabolite
CBR-001-670-537-6,RFM-011-717-9,CBR-001-670-537-6,Cc1ccc(c(c1)C)O[C@H]1O[C@H](CCP(=O)(OC(C)C)OC(C)C)[C@H]([C@@H]([C@@H]1O)O)O,CBR-HVAC-14565: Metabolite
CBR-001-670-538-7,RFM-011-718-0,CBR-001-670-538-7,Clc1ccc(cc1)c1nc2n(c1CN(C(=O)C)C)cccc2,CBR-HVAC-14567: Metabolite
CBR-001-670-539-8,RFM-011-719-1,CBR-001-670-539-8,CC(=CCOc1cc(ccc1Cl)NC(=S)c1cccnc1)C,CBR-HVAC-14514: Metabolite
CBR-001-670-540-1,RFM-011-720-4,CBR-001-670-540-1,Nc1ncc(nc1Nc1ccc2c(c1)ccn2)c1cccnc1,CBR-HVAC-14505: Metabolite
CBR-001-670-541-2,RFM-011-721-5,CBR-001-670-541-2,CCC(=O)N(Cc1c(nc2n1cccc2)c1ccc(cc1)Cl)C,CBR-HVAC-14568: Metabolite
CBR-001-670-542-3,RFM-011-722-6,CBR-001-670-542-3,COC(=O)[C@@H]1Oc2c(C1)cc(cc2)C(=O)CNS(=O)(=O)c1ccc(cc1)Cl,CBR-HVAC-14480: Metabolite
CBR-001-670-543-4,RFM-011-723-7,CBR-001-670-543-4,O=C(C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)N(c1cnc(nc1c1ccccc1C)N1CCCCC1)C,CBR-HVAC-14558: Metabolite
CBR-001-670-544-5,RFM-011-724-8,CBR-001-670-544-5,CNCc1c(nc2n1cccc2)c1ccc(cc1)Cl,CBR-HVAC-14566: Metabolite
CBR-001-670-545-6,RFM-011-725-9,CBR-001-670-545-6,CC(=CCOc1cc(ccc1Cl)NC(=S)c1cscn1)C,CBR-HVAC-14512: Metabolite
CBR-001-670-546-7,RFM-011-726-0,CBR-001-670-546-7,CC(=CCOc1cc(ccc1Cl)NC(=S)c1ccccc1)C,CBR-HVAC-14516: Metabolite
CBR-001-670-547-8,RFM-011-727-1,CBR-001-670-547-8,O=C(C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)N(c1cnc(nc1c1ccccc1C)N1CCOCC1)C,CBR-HVAC-14559: Metabolite
CBR-001-670-548-9,RFM-011-728-2,CBR-001-670-548-9,N[C@H](C(=O)NCCC(=O)O)Cc1ccc(cc1)c1ccccc1,CBR-HVAC-14486: active metabolite of prodrug CBR-HVAC-10925
CBR-001-670-549-0,RFM-011-729-3,CBR-001-670-549-0,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)O,CBR-HVAC-14532: Metabolite
CBR-001-670-550-3,RFM-011-730-6,CBR-001-670-550-3,Cc1nc2c(n1)cc(cc2)C(c1ccccc1)O,CBR-HVAC-14504: Metabolite
CBR-001-670-551-4,RFM-011-731-7,CBR-001-670-551-4,CCCc1ccc(c(=O)n1CC(=O)Nc1ccc(nc1C)N)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-14460: Metabolite
CBR-001-670-552-5,RFM-011-732-8,CBR-001-670-552-5,CC(=CCOc1cc(ccc1Cl)NC(=O)c1ccsc1C)C,CBR-HVAC-14510: Metabolite
CBR-001-670-553-6,RFM-011-733-9,CBR-001-670-553-6,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCc1cocc1,CBR-HVAC-14536: Metabolite
CBR-001-670-554-7,RFM-011-734-0,CBR-001-670-554-7,CCCc1ccc(c(=O)n1CC(=O)NCCc1cccnc1)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-14475: Metabolite
CBR-001-670-555-8,RFM-011-735-1,CBR-001-670-555-8,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCc1ccccn1,CBR-HVAC-14535: Metabolite
CBR-001-670-556-9,RFM-011-736-2,CBR-001-670-556-9,CCCc1ccc(c(=O)n1CC(=O)NCc1cccc(c1)C)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-14474: Metabolite
CBR-001-670-557-0,RFM-011-737-3,CBR-001-670-557-0,COC(=O)[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)CCC(=O)N2C,CBR-HVAC-14483: Metabolite
CBR-001-670-558-1,RFM-011-738-4,CBR-001-670-558-1,CCCCCn1c(=O)n(CCCCC)c2c(c1=O)[nH]c(n2)Cl,CBR-HVAC-14472: Metabolite
CBR-001-670-559-2,RFM-011-739-5,CBR-001-670-559-2,CCCc1ccc(c(=O)n1CC(=O)NCc1ccccc1C)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-14476: Metabolite
CBR-001-670-560-5,RFM-011-740-8,CBR-001-670-560-5,CC(=CCOc1cc(ccc1Cl)NC(=S)c1cscc1)C,CBR-HVAC-14511: Metabolite
CBR-001-670-561-6,RFM-011-741-9,CBR-001-670-561-6,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCc1ccccc1,CBR-HVAC-14533: Metabolite
CBR-001-670-562-7,RFM-011-742-0,CBR-001-670-562-7,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCc1cccnc1,CBR-HVAC-14534: Metabolite
CBR-001-670-563-8,RFM-011-743-1,CBR-001-670-563-8,CC(=CCOc1cc(ccc1Cl)NC(=S)c1cocc1)C,CBR-HVAC-14515: Metabolite
CBR-001-670-564-9,RFM-011-744-2,CBR-001-670-564-9,NC[C@@H]1OC(=O)N(C1)c1ccc(c(c1)F)N(S(=O)(=O)C)C,CBR-HVAC-14456: Metabolite
CBR-001-670-565-0,RFM-011-745-3,CBR-001-670-565-0,NC[C@H]1OC(=O)N(C1)c1ccc(c(c1)F)N(S(=O)(=O)C)C,CBR-HVAC-14457: Metabolite
CBR-001-670-566-1,RFM-011-746-4,CBR-001-670-566-1,Cc1ccc(cc1C(=O)c1c(C)cc(cc1C)C(=O)O)n1cncc1,CBR-HVAC-14563: Metabolite
CBR-001-670-567-2,RFM-011-747-5,CBR-001-670-567-2,COC(=O)c1cn(C2CC2)c2c(c1=O)ccc(c2OC(F)F)c1ccc2c(c1)CN[C@@H]2C,CBR-HVAC-14479: Metabolite
CBR-001-670-568-3,RFM-011-748-6,CBR-001-670-568-3,CCOC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1Cl)C1CC1)C(=O)NC(C)(C)C,CBR-HVAC-14482: Metabolite
CBR-001-670-569-4,RFM-011-749-7,CBR-001-670-569-4,OC(=O)c1cnc2n1CCc1c(C2=C2CCN(CC2)CCc2ccc(cc2)OCc2ccc3c(n2)cccc3)cccc1,CBR-HVAC-14142: metabolite of CBR-HVAC-00369-A
CBR-001-670-570-7,RFM-011-750-0,CBR-001-670-570-7,Cc1nc2ccccc2c(=O)n1c1ccccc1C,CBR-HVAC-09852: AMPA receptor Antagonist; Hypnotic; Sedative
CBR-001-670-679-9,RFM-011-751-1,CBR-001-670-679-9,S1CCS[Bi-]21SCCS2,CBR-HVAC-02569:
CBR-001-670-680-2,RFM-011-752-2,CBR-001-670-680-2,Cl[Pt-2]1(Cl)(Cl)(Cl)[NH2+]C2C([NH2+]1)CCCC2,CBR-HVAC-10445: DNA inhibitor; DNA synthesis inhibitor; Antineoplastic; Oncolytic Drugs
CBR-001-670-681-3,RFM-011-753-3,CBR-001-670-681-3,O=C(CCCCCC(C)(C)C)O[Pt-2]1([NH2+][C@@H]2[C@@H]([NH2+]1)CCCC2)OC(=O)CCCCCC(C)(C)C,analog of CBR-HVAC-12896
CBR-001-670-682-4,RFM-011-754-4,CBR-001-670-682-4,OP1(=O)O[Pt]2([NH2+][C@H]3[C@H]([NH2+]2)CCCC3)OP(=O)(O1)O,CBR-HVAC-13830: Solid Tumors Therapy
CBR-001-670-683-5,RFM-011-755-5,CBR-001-670-683-5,Cl[Pt-2]([NH2+]C12CC3CC(C2)CC(C1)C3)(OC(=O)C)(OC(=O)C)([NH3+])Cl,CBR-HVAC-13572: APOPTOSIS STIMULATOR; Apoptosis Inducers; DNA inhibitor; DNA-Intercalating Drugs; HSP 90 INHIBITOR; Anticancer; Solid Tumors Therapy
CBR-001-670-684-6,RFM-011-756-6,CBR-001-670-684-6,Clc1cccc(c1)Nc1nccc2c1ccc(c2NC(=O)c1csc2c1ncnc2N)C,CBR-HVAC-14488: possible structure of HM-95573 from US9156852B2 Hanmi BRAFCRAF Oct2015 example 38
CBR-001-670-685-7,RFM-011-757-7,CBR-001-670-685-7,OCC1(CO)C[NH2+][Pt-2]2([NH2+]C1)OC(=O)C1(C(=O)O2)CCC1,CBR-HVAC-10419: DNA antagonist; DNA inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-686-8,RFM-011-758-8,CBR-001-670-686-8,OC[C@@](c1ncc(n1)c1ccc(c(c1)C(F)(F)F)OCCc1ccc(cc1)c1ccccc1)(N)C,"CBR-HVAC-13980: Lysophospholipid edg1 (S1P1) Receptor Agonists; Signal Transduction Modulators; Multiple Sclerosis, Agents for"
CBR-001-670-687-9,RFM-011-759-9,CBR-001-670-687-9,O=c1cc(C)c2c(o1)ccc(c2)NC(=O)C(=O)O,CBR-HVAC-13599:
CBR-001-670-688-0,RFM-011-760-2,CBR-001-670-688-0,O=C(c1cc(nn1C)c1cnc2c(c1)cccc2)NCCN1CCOCC1,regioisomer of CBR-HVAC-12507
CBR-001-670-689-1,RFM-011-761-3,CBR-001-670-689-1,O=C(c1ccc(c(c1)NC(=O)c1cccc2c1ccnc2N)C)Nc1cccc(c1)C(F)(F)F,CBR-HVAC-14487: possible structure of HM-95573 from US9388165B2 Hanmi BRAFCRAF July 2016 example 3
CBR-001-670-690-4,RFM-011-762-4,CBR-001-670-690-4,COc1cccc2c1nc(Nc1ccc(cc1C)F)nc2N1CCc2c(C1C)cccc2,CBR-HVAC-13589: Potassium-competitive acid antagonist
CBR-001-670-691-5,RFM-011-763-5,CBR-001-670-691-5,Cc1ccc(cc1)C(=O)c1cccn1C/C=C/c1ccc(cc1)COC(C(=O)O)(C)C,"CBR-HVAC-13894: PPAR Modulators; PPARalpha Ligands; PPARgamma Ligands; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-670-692-6,RFM-011-764-6,CBR-001-670-692-6,CCNC(=O)c1ccc(cc1)Oc1cc(Oc2ccc(cc2)F)cc(c1)NC(=O)N1CCC(CC1)(O)CC(CC)CC,"CBR-HVAC-14058: Lysophospholipid edg1 (S1P1) Receptor Antagonists; Signal Transduction Modulators; Hypertension, Treatment of"
CBR-001-670-693-7,RFM-011-765-7,CBR-001-670-693-7,COc1cc2c(cc1OC)C[C@H]1c3c2c(OC)c(OC)cc3CCN1C,CBR-HVAC-07869: Acetylcholine receptor antagonist
CBR-001-670-694-8,RFM-011-766-8,CBR-001-670-694-8,CC(NC(C(c1nc2c(n1)cccc2)(c1ccccc1)O)C)C,CBR-HVAC-07675: Beta adrenoreceptor antagonist
CBR-001-670-695-9,RFM-011-767-9,CBR-001-670-695-9,OC(COc1cccc2c1cnn2)CNCCNc1c(C)cccc1C,CBR-HVAC-13588:
CBR-001-670-696-0,RFM-011-768-0,CBR-001-670-696-0,CC(OCCn1c(=S)[nH]c(=O)c2c1cc[nH]2)C,CBR-HVAC-07498: Myeloperoxidase inhibitor
CBR-001-670-697-1,RFM-011-769-1,CBR-001-670-697-1,C[C@@H]1CC[C@@](CC1)(N1CCN(CC1)c1ccccc1)c1ccccc1,CBR-HVAC-08086: Neuropeptide Y receptor antagonist
CBR-001-670-698-2,RFM-011-770-4,CBR-001-670-698-2,Cc1cnc(c(c1OCC1COC(OC1)(C)C)C)CSc1nc2c([nH]1)cccc2,Analog of CBR-HVAC-06498
CBR-001-670-699-3,RFM-011-771-5,CBR-001-670-699-3,Clc1ccc2c(c1)C(=NC(C(=O)N2C)O)c1ccccc1F,CBR-HVAC-13660: Benzodiazepine receptor agonist
CBR-001-670-700-9,RFM-011-772-6,CBR-001-670-700-9,C/C(=C\C=C\C(=C\C(=O)O)\C)/CCC1=C(C)CCCC1(C)C,CBR-HVAC-13653: Retinoic acid receptor antagonist
CBR-001-670-701-0,RFM-011-773-7,CBR-001-670-701-0,COc1cc(N)c(cc1C(=O)NCC1CCCN1CC1CC1)S(=O)(=O)CC,CBR-HVAC-13629: Dopamine D2 receptor antagonist; Dopamine D4 receptor antagonist
CBR-001-670-702-1,RFM-011-774-8,CBR-001-670-702-1,Fc1ccc(cc1)Oc1cc(cnc1Nc1ccc(cn1)c1nnnn1)Sc1ccccn1,CBR-HVAC-13953: PPARgamma Modulators; Signal Transduction Modulators; Antidiabetic Drugs
CBR-001-670-703-2,RFM-011-775-9,CBR-001-670-703-2,ON(C(=O)N)Cc1cccc(c1)COC(c1ccc2c(c1)cccc2)c1cccnc1,CBR-HVAC-13888: Lipoxygenase Inhibitors; Thromboxane Synthase Inhibitors; Asthma Therapy
CBR-001-670-704-3,RFM-011-776-0,CBR-001-670-704-3,O=C(N(C)C)Cn1c(c2csc(n2)N(c2ccccc2)CC2CCOCC2)c(c2c1cc(cc2)C(=O)O)C1CCCCC1,CBR-HVAC-14067: RNA-Directed RNA Polymerase (NS5B) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-001-670-705-4,RFM-011-777-1,CBR-001-670-705-4,CCOC(=O)[C@H](CSC(=O)NC)N,CBR-HVAC-08101: DNA inhibitor; Oncolytic Drugs
CBR-001-670-706-5,RFM-011-778-2,CBR-001-670-706-5,NC(=O)Cc1cnc2c(c1)ccc(c2)OCc1cccc(c1)F,"CBR-HVAC-13764: MAO-B Inhibitors; Antiparkinsonian Drugs; Cognition Disorders, Treatment of; Ischemic Stroke, Treatment of"
CBR-001-670-707-6,RFM-011-779-3,CBR-001-670-707-6,CN(CCn1ccc2c1cc(cc2)NC(=N)c1cccs1)C,"CBR-HVAC-13768: Nitric Oxide Synthase Inhibitors; Serotonin Agonists; Signal Transduction Modulators; Acute Attacks of Migraine, Treatment of"
CBR-001-670-708-7,RFM-011-780-6,CBR-001-670-708-7,O=C(Nc1ccccc1N1CCCC1)Nc1cccc(c1)C1CCCN(C1)c1ncnc2c1ccn2,CBR-HVAC-13981: Bruton's Tyrosine Kinase (BTK) Inhibitors; Signal Transduction Modulators; Hematological Cancer Therapy
CBR-001-670-709-8,RFM-011-781-7,CBR-001-670-709-8,CN1CCC(=C2c3ccccc3CCc3c2cc(cc3)C(=O)O)CC1,CBR-HVAC-08059:
CBR-001-670-710-1,RFM-011-782-8,CBR-001-670-710-1,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NCCNC(=O)c1cccnc1,"CBR-HVAC-13935: Signal Transduction Modulators; Sterol Regulatory Element Binding Protein (SREBP) Inhibitors; Lipoprotein Disorders, Treatment of ; Liver and Biliary Tract Disorders, Treatment of"
CBR-001-670-711-2,RFM-011-783-9,CBR-001-670-711-2,C[n+]1ccc(=O)n2c1CCCC2C,"CBR-HVAC-13716: Angina pectoris, Treatment of; Vasodilators"
CBR-001-670-712-3,RFM-011-784-0,CBR-001-670-712-3,CCOc1cc(ccc1OC)C(N1C(=O)c2c(C1=O)cccc2)CC(=O)NOC(=O)CC,CBR-HVAC-13922: Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Antiarthritic Drugs
CBR-001-670-713-4,RFM-011-785-1,CBR-001-670-713-4,C/C(=C\CCC1(C)CCc2c(O1)ccc(c2)O)/CC/C=C(/CCC=C(C)C)\C,"CBR-HVAC-12759: HMG-CoA Reductase Inhibitors; Antiplatelet Therapy; Diabetic Neuropathy, Agents for; Lipoprotein Disorders, Treatment of"
CBR-001-670-714-5,RFM-011-786-2,CBR-001-670-714-5,N#C/C(=C\C(N(C)C)(C)C)/C(=O)N1CCC[C@H]1Cn1nc(c2c1ncnc2N)c1ccc(cc1F)Oc1ccccc1,"CBR-HVAC-14053: Bruton's Tyrosine Kinase (BTK) Inhibitors; Signal Transduction Modulators; Rheumatoid Arthritis, Treatment of"
CBR-001-670-715-6,RFM-011-787-3,CBR-001-670-715-6,O=C(C(C)(C)C)Oc1sc2c(c1)C[N+](CC2)([O-])Cc1ccccc1Cl,"CBR-HVAC-10885: Elastase 2, neutrophil Inhibitor; Elastase Inhibitors; Elastase inhibitor; Antiarthritic Drugs; Antiinflammatory; Pulmonary Emphysema, Agents for"
CBR-001-670-716-7,RFM-011-788-4,CBR-001-670-716-7,ClNCCS(=O)(=O)[O-],CBR-HVAC-05525: Nitric Oxide (NO) Production Inhibitors; Antibacterial Drugs; Antibacterial Ophthalmic Drugs; Anticoagulants; Antiviral Drugs; Immunomodulators
CBR-001-670-717-8,RFM-011-789-5,CBR-001-670-717-8,CCOCCN1CCC(CC1)(OC(=O)CC)c1ccccc1,CBR-HVAC-04772: Non-Opioid Analgesics
CBR-001-670-718-9,RFM-011-790-8,CBR-001-670-718-9,CC(=N)NCCS(=O)(=O)C[C@@H](C(=O)O)N,CBR-HVAC-05351: Inducible Nitric Oxide Synthase (NOS-2) Inhibitors; Signal Transduction Modulators; Analgesic Drugs; Treatment of Shock
CBR-001-670-719-0,RFM-011-791-9,CBR-001-670-719-0,O=Cn1cc(c2c1cccc2)C[C@H](C(=O)N[C@H](C(=O)N(Cc1ccccc1)C)Cc1ccccc1)NC(=O)[C@H]([C@H](O)C)NC(=O)C,CBR-HVAC-10893: Neurokinin 1 receptor antagonist; Neurokinin receptor 1 Antagonist; Signal Transduction Modulators; Tachykinin NK1 Antagonists; Analgesic; Bronchodilators
CBR-001-670-720-3,RFM-011-792-0,CBR-001-670-720-3,CC(Oc1ccc2c(c1)c(=O)c1c(o2)ccc(c1)C(=O)O)C,CBR-HVAC-08535: Histamine release inhibitor; Antiallergy/Antiasthmatic Drugs
CBR-001-670-721-4,RFM-011-793-1,CBR-001-670-721-4,OCC(NCC(c1cc(O)cc(c1)O)O)(C)C,CBR-HVAC-05801: Beta 2 adrenoreceptor agonist; Signal Transduction Modulators; beta-Adrenoceptor Agonists; Bronchodilators
CBR-001-670-722-5,RFM-011-794-2,CBR-001-670-722-5,C/C(=C\CC[C@](CCC1=C(C)C(=O)C(=C(C1=O)C)C)(O)C)/CC/C=C(/CCC=C(C)C)\C,"CBR-HVAC-07009: Antiparkinsonian Drugs; Autism, Treatment of; Hearing loss, treatment of; Huntington's Disease, Treatment of; Multisystem Genetic Disorders, Treatment of ; Neurological Genetic Disorders, Treatment of ; Therapy of Inborn Errors of Metabolism; Therapy of Vitamin-Related Disorders; Tourette's Syndrome, Treatment of"
CBR-001-670-723-6,RFM-011-795-3,CBR-001-670-723-6,Clc1ccc(cc1)OC(C(=O)OC(COC(=O)c1cccnc1)COC(=O)c1cccnc1)(C)C,"CBR-HVAC-12960: Lipase clearing factor stimulant; Lipoprotein Disorders, Treatment of"
CBR-001-670-724-7,RFM-011-796-4,CBR-001-670-724-7,CCCOc1sc(c(c1Br)C)C(=O)N1CCC(CC1)c1cc(CC)ccc1F,CBR-HVAC-13968: Tryptase Inhibitors; Asthma Therapy
CBR-001-670-725-8,RFM-011-797-5,CBR-001-670-725-8,O=C1CCN(c2c(N1)ccc(c2)Cl)c1ccccc1,analog of CBR-HVAC-12742:
CBR-001-670-726-9,RFM-011-798-6,CBR-001-670-726-9,CCCN1CCCC1CNC(=O)c1cc(ccc1OC)S(=O)(=O)N,CBR-HVAC-12739: Dopamine D2 receptor antagonist; Antidepressants
CBR-001-670-727-0,RFM-011-799-7,CBR-001-670-727-0,OCCOc1nc(nc(c1Oc1ccccc1OC)NS(=O)(=O)c1ccc(cn1)C)c1ccnc(c1)c1[nH]nnn1,"CBR-HVAC-07655: ENDOTHELIN RECEPTOR TYPE A Antagonist; Endothelin A receptor antagonist; Endothelin ETA Receptor Antagonists; Signal Transduction Modulators; Hemorrhagic Stroke, Treatment of; Renal Failure, Agents for; Vasoprotectant"
CBR-001-670-728-1,RFM-011-800-3,CBR-001-670-728-1,CCCCCCCCC1OC(=O)c2c1cccc2,"CBR-HVAC-12719: Hypertension, Treatment of; Vasodilators"
CBR-001-670-729-2,RFM-011-801-4,CBR-001-670-729-2,Cc1ccc(cc1)C(=O)c1nc2c(n1/C=C/c1cccc(c1)OC(C(=O)O)(C)C)cccc2,"CBR-HVAC-13923: PPAR Modulators; PPARalpha Ligands; PPARgamma Ligands; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Type 2 Diabetes, Agents for"
CBR-001-670-730-5,RFM-011-802-5,CBR-001-670-730-5,O=C1O[C@H](CN1c1ccc(c(c1)F)c1ccc(nc1)c1nnn(n1)C)COP(=O)(O)[O-],CBR-HVAC-13439: Bacterial protein synthesis inhibitor; Antibacterial
CBR-001-670-731-6,RFM-011-803-6,CBR-001-670-731-6,NC1C2C=CCC1c1c(C2)cc(cc1)Cl,CBR-HVAC-08130: 5 Hydroxytryptamine uptake inhibitor; Serotonin Antagonists; Signal Transduction Modulators; Antidepressants
CBR-001-670-732-7,RFM-011-804-7,CBR-001-670-732-7,CN(Cc1ccc(o1)CSCCNc1ncc(c(=O)n1)Cc1ccc(nc1)C)C,CBR-HVAC-08003: Histamine H2 Receptor Antagonists; Histamine H2 receptor antagonist; Signal Transduction Modulators
CBR-001-670-733-8,RFM-011-805-8,CBR-001-670-733-8,ClCCN(c1ccc(cc1)C(=O)N[C@H](C(=O)O)CCC(=O)O)CCOS(=O)(=O)C,CBR-HVAC-00150: Alkylating agent; DNA-Damaging Drugs; Antitumor; Oncolytic Drugs
CBR-001-670-734-9,RFM-011-806-9,CBR-001-670-734-9,COC[C@@]12CNCC[C@]2(C1)c1ccc(c(c1)Cl)Cl,CBR-HVAC-00186: 5 Hydroxytryptamine uptake inhibitor; 5-HT Reuptake Inhibitors; Adrenergic transmitter uptake inhibitor; DOPAMINE TRANSPORTER; Dopamine Reuptake Inhibitors; Dopamine reuptake inhibitor; NOREPINEPHRINE TRANSPORTER; Norepinephrine Reuptake Inhibitors; SEROTONIN TRANSPORTER Inhibitor; Serotonin-norepinephrine-dopamine reuptake inhibitor; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytics
CBR-001-670-735-0,RFM-011-807-0,CBR-001-670-735-0,COc1nc(c(c(c1Cl)OC)Cl)C(Cl)(Cl)Cl,CBR-HVAC-00189: DNA inhibitor; DNA-Damaging Drugs; Telomerase Inhibitor; Antitumor; Oncolytic Drugs
CBR-001-670-736-1,RFM-011-808-1,CBR-001-670-736-1,O=C(c1cc(cc(c1)[Si](C)(C)C)[Si](C)(C)C)Nc1ccc(cc1)C(=O)O,CBR-HVAC-00379: Angiogenesis Inhibitors; Angiogenesis inhibitor; Apoptosis stimulant; RETINOIC ACID RECEPTOR ALPHA Agonist; Retinoic acid alpha receptor agonist; Retinoid RARalpha Agonists; Signal Transduction Modulators; ANTICANCER; ANTINEOPLASTIC; Liver Cancer Therapy
CBR-001-670-737-2,RFM-011-809-2,CBR-001-670-737-2,CN[C@@H]1CC[C@H](c2c1cccc2)c1ccccc1,CBR-HVAC-01123: 5 Hydroxytryptamine uptake inhibitor; Antidepressant
CBR-001-670-738-3,RFM-011-810-5,CBR-001-670-738-3,Oc1ccc(cc1)CCCCNC[C@@H](c1ccc(c(c1)O)O)O,CBR-HVAC-02156: Beta adrenoreceptor agonist; Beta-1 adrenergic receptor Inhibitor; Signal Transduction Modulators; beta1-Adrenoceptor Agonists; Diagnostic agent; Stress Agents
CBR-001-670-739-4,RFM-011-811-6,CBR-001-670-739-4,COc1ccccc1OCCNCC(c1ccc(c(c1)S(=O)(=O)N)C)O,"CBR-HVAC-02296: Adrenergic receptor Antagonist; Alpha 1 adrenoreceptor antagonist; Beta adrenoreceptor antagonist; Signal Transduction Modulators; alpha1-Adrenoceptor Antagonists; beta-Adrenoceptor Antagonists; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-740-7,RFM-011-812-7,CBR-001-670-740-7,O=C(c1cccnc1)O[C@@H]1[C@@H](COC(=O)c2cccnc2)O[C@H]([C@@H]([C@H]1OC(=O)c1cccnc1)NC(=O)c1cccnc1)OC(=O)c1cccnc1,"CBR-HVAC-02535: Cholesterol inhibitor; Antioxidant; Lipoprotein Disorders, Treatment of"
CBR-001-670-741-8,RFM-011-813-8,CBR-001-670-741-8,CCOC(=O)C(Oc1ccc(cc1)Cc1ccc(cc1)Cl)(CC)C,"CBR-HVAC-02658: Cholesterol inhibitor; Platelet aggregation inhibitor; Hypolipidemic; Lipoprotein Disorders, Treatment of"
CBR-001-670-742-9,RFM-011-814-9,CBR-001-670-742-9,O=C(N[C@H]1C(=O)N(c2ccccc2)c2c(N(C1=O)CC13CC4CC(C3)CC(C1)C4)cccc2)Nc1ccccc1,CBR-HVAC-02752: CCK B receptor antagonist; CCK2 (CCKB/Gastrin) Antagonists; Signal Transduction Modulators; Anxiolytics
CBR-001-670-743-0,RFM-011-815-0,CBR-001-670-743-0,OCC1COC(O1)CI,CBR-HVAC-02809: Mucolytic; Mucolytic agent; EXPECTORANT; MUCOLYTIC; Mucolytics
CBR-001-670-744-1,RFM-011-816-1,CBR-001-670-744-1,CCOC(=O)c1ccc(cc1)/C=C(/c1ccc2c(c1)C(C)(C)CCC2(C)C)\C,CBR-HVAC-02919: Retinoic acid receptor agonist; ANTINEOPLASTIC; ANTIPSORIATIC; DERMATOLOGICAL AGENT; Oncolytic Drugs
CBR-001-670-745-2,RFM-011-817-2,CBR-001-670-745-2,CC(CCC(C#C)N)N,CBR-HVAC-03199: Ornithine decarboxylase Inhibitor; Ornithine decarboxylase inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-746-3,RFM-011-818-3,CBR-001-670-746-3,OCN(c1nc(nc(n1)N(CO)C)N(CO)C)C,CBR-HVAC-03350: DNA antagonist; DNA inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-747-4,RFM-011-819-4,CBR-001-670-747-4,COc1ccc(cc1)[C@@H]1Sc2c(N(C(=O)[C@@H]1OC(=O)C)CCN(C)C)ccc1c2cccc1,"CBR-HVAC-03576: Calcium Channel Blockers; Calcium channel Blocker; Calcium channel antagonist; Angina pectoris, Treatment of; Antihypertensive; Antiplatelet Therapy; Hypertension, Treatment of"
CBR-001-670-748-5,RFM-011-820-7,CBR-001-670-748-5,O[C@H]1CC(=O)O[C@@H](C1)/C=C/C(=C(c1ccc(cc1)F)c1ccc(cc1)F)c1nnnn1C,"CBR-HVAC-03782: Cholesterol synthesis inhibitor; HMG-CoA Reductase Inhibitors; HMG-CoA reductase Inhibitor; Antihypercholesterolemic; Lipoprotein Disorders, Treatment of"
CBR-001-670-749-6,RFM-011-821-8,CBR-001-670-749-6,CC(n1c(=O)c2c(ncn2c2c1cccc2)c1noc(n1)C1CC1)C,CBR-HVAC-03897: Benzodiazepine receptor Antagonist; Benzodiazepine receptor agonist; GABA(A) BZ Site Receptor Antagonists; Signal Transduction Modulators; Anxiolytic; Anxiolytics
CBR-001-670-750-9,RFM-011-822-9,CBR-001-670-750-9,CCCN1CC[C@@H]2[C@H]1CCc1c2c(ccc1)C(=O)N,CBR-HVAC-04380: 5 Hydroxytryptamine 1A receptor agonist; 5-HT1A Receptor Agonists; 5-Hydroxytryptamine 1A receptor Agonist; Dopamine receptor antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics
CBR-001-670-751-0,RFM-011-823-0,CBR-001-670-751-0,NC1CN(C1)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1CC1,CBR-HVAC-04511: DNA gyrase Inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-752-1,RFM-011-824-1,CBR-001-670-752-1,O=C1OC[C@@H](N1)Cc1ccc2c(c1)c(cn2)[C@@H]1C[C@H](C1)N(C)C,CBR-HVAC-04755: 5-HT1B Agonists; 5-HT1D Agonists; 5-Hydroxytryptamine 1B receptor Agonist; 5-Hydroxytryptamine 1D receptor; Signal Transduction Modulators; Antimigraine; Antimigraine Drugs
CBR-001-670-753-2,RFM-011-825-2,CBR-001-670-753-2,CCCCCCCCCCCCCCC[C@H]([C@@H](N)C)O,CBR-HVAC-05279: Angiogenesis Inhibitors; Apoptosis Inducers; Caspase 12 Activators; Caspase 3 Activators; Rho kinase Inhibitor; Signal Transduction Modulators; Sphingosine Kinase 1 (SphK1) Inhibitors; Anticancer; Gastric Cancer Therapy; Liver Cancer Therapy; Prostate Cancer Therapy; Renal Cancer Therapy
CBR-001-670-754-3,RFM-011-826-3,CBR-001-670-754-3,COc1cc2c(cc1OCCCN1CCOCC1)ncnc2N1CCN(CC1)C(=O)Nc1ccc(cc1)OC(C)C,CBR-HVAC-05693: FLT3 kinase; Flt3 (FLK2/STK1) Inhibitors; Inhibitor; PDGFR Antagonist; Signal Transduction Modulators; Antiarteriosclerotic; Anticancer; Myeloid Leukemia Therapy; Vasoprotectant
CBR-001-670-755-4,RFM-011-827-4,CBR-001-670-755-4,O=C(N1CCC(CC1)CCn1c(Sc2cc3OCOc3cc2Br)nc2c1ncnc2N)[C@@H](O)C,CBR-HVAC-06824: Heat Shock Protein 90 (HSP90) Inhibitors; Heat shock protein 90 Inhibitor; Anticancer; Oncolytic Drugs
CBR-001-670-756-5,RFM-011-828-5,CBR-001-670-756-5,COCc1nnc(n1c1c(Cl)c(Cl)cc2c1nc(=O)c(=O)n2)c1cccnc1,CBR-HVAC-08487: Glycine NMDA associated antagonist
CBR-001-670-757-6,RFM-011-829-6,CBR-001-670-757-6,O=C(NP(=O)(N1CC1)N1CC1)OCc1ccccc1,CBR-HVAC-08780: Antineoplastic
CBR-001-670-758-7,RFM-011-830-9,CBR-001-670-758-7,CC(N(C)C)CN1c2cc(ccc2Sc2c1cccc2)C(=O)C,CBR-HVAC-08892: Anxiolytic
CBR-001-670-759-8,RFM-011-831-0,CBR-001-670-759-8,OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1ncc(c2)Cl,CBR-HVAC-08977: Antipsychotic
CBR-001-670-760-1,RFM-011-832-1,CBR-001-670-760-1,Cc1ccc(c(c1)OCC1=NCCN1)C1CC1,CBR-HVAC-09142: Antihistamine; Antihypertensive; Nasal vasoconstrictor
CBR-001-670-761-2,RFM-011-833-2,CBR-001-670-761-2,C1CN(CCC1C1CCN(CC1)CC1OC1)CC1OC1,CBR-HVAC-09157: Antineoplastic
CBR-001-670-762-3,RFM-011-834-3,CBR-001-670-762-3,O=C1NC(=O)C2C1(C2)c1ccc(cc1)Cl,CBR-HVAC-09229: Antidepressant
CBR-001-670-763-4,RFM-011-835-4,CBR-001-670-763-4,CCCCCCCCCC(=O)OCCN1CCN(CC1)CC/C=C/1\c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-09586: Dopamine receptor Antagonist; Antipsychotic
CBR-001-670-764-5,RFM-011-836-5,CBR-001-670-764-5,CCCN(C(C(=O)N(C)C)CC)C(=O)C=CC,CBR-HVAC-09836: Stimulating respiratory bulbar centers; Respiratory stimulant
CBR-001-670-765-6,RFM-011-837-6,CBR-001-670-765-6,Nc1ccc(cc1)OCCCCCN1C(=O)c2c(C1=O)cccc2,CBR-HVAC-10181: Antihelmintic
CBR-001-670-766-7,RFM-011-838-7,CBR-001-670-766-7,OCC(OCn1ccnc1[N+](=O)[O-])CO,CBR-HVAC-10554: Hypoxia-selective agent; Radiochemosensitizer; Anticancer; Oncolytic Drugs
CBR-001-670-767-8,RFM-011-839-8,CBR-001-670-767-8,CN(CCNC(=O)c1nc(Cl)c(nc1N)N)CCNCc1c(O)c(Br)cc2c1CCC2(C)C,"CBR-HVAC-10679: Calcium Channel Blockers; Calcium channel Blocker; Antihypertensive; Diuretic; Diuretics; Hypertension, Treatment of"
CBR-001-670-768-9,RFM-011-840-1,CBR-001-670-768-9,N[C@H]1CN(C[C@H]1C)c1c(F)cc2c(c1Cl)n(cc(c2=O)C(=O)O)C1COC1,CBR-HVAC-10720: DNA topoisomerase II Inhibitor; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-769-0,RFM-011-841-2,CBR-001-670-769-0,CC1NN=C(c2c(C1)cc1OCOc1c2)c1ccc(cc1)N,CBR-HVAC-10897: Dopamine Receptor Agonists; Dopamine reuptake inhibitor; Dopamine uptake inhibitor; Signal Transduction Modulators; Antidepressant; Antidepressants; Antiparkinsonian Drugs; Antiparkinsoniant
CBR-001-670-770-3,RFM-011-842-3,CBR-001-670-770-3,Nc1nc(N)c2c(n1)n(CCOCP(=O)(O)O)cn2,CBR-HVAC-10907: DNA polymerase Inhibitor; Antiviral; Immunosuppressive
CBR-001-670-771-4,RFM-011-843-4,CBR-001-670-771-4,CCCCc1cc(NC(=O)c2cc(OC)c(c(c2)OC)OC)n2c(n1)ccn2,CBR-HVAC-11014: Adenosine receptor Agonist; Neurokinin 1 receptor antagonist; Signal Transduction Modulators; Tachykinin NK1 Antagonists; Analgesic; Non-Opioid Analgesics
CBR-001-670-772-5,RFM-011-844-5,CBR-001-670-772-5,COc1c(OC)c(O)c2c(c1OC)n(C)c1c(c2=O)ccc(c1OC)O,CBR-HVAC-11231: Apoptosis Inducers; Apoptosis stimulator; Caspase 9 Activators; Mitochondrial electron transport inhibitor; Nucleoside transport inhibitor; Signal Transduction Modulators; Anticancer; Oncolytic Drugs
CBR-001-670-773-6,RFM-011-845-6,CBR-001-670-773-6,C[C@@H]1CCC[C@@H](N1[n+]1noc(c1)[NH-])C,"CBR-HVAC-11369: Nitric Oxide (NO) Donors; Nitric oxide donor; Angina pectoris, Treatment of; Antihypertensive; Vasoprotectant"
CBR-001-670-774-7,RFM-011-846-7,CBR-001-670-774-7,COc1cc(ccc(c1=O)CN1CCN(CC1)C(c1ccc(cc1)F)c1ccc(cc1)F)C(C)C,"CBR-HVAC-11592: Calcium Channel Blockers; Calcium channel Antagonist; Calcium channel antagonist; Endothelin 1 antagonist; Endothelin receptor; Lipid peroxidase inhibitor; Angina pectoris, Treatment of; Antianginal"
CBR-001-670-775-8,RFM-011-847-8,CBR-001-670-775-8,COc1ncc2c(c1)CCC1C2NCC1,CBR-HVAC-11598: Nicotinic acetylcholine receptor alpha2beta4; Nicotinic acetylcholine receptor alpha4beta4 Agonist; Nicotinic alpha4beta4 Agonists; Nicotinic receptor agonist; Signal Transduction Modulators; Antiparkinsonian; Antiparkinsonian Drugs; Nootropic
CBR-001-670-776-9,RFM-011-848-9,CBR-001-670-776-9,C1COc2c(O1)c(ccc2)N1CCN(CC1)CCC1Cc2c1cccc2,CBR-HVAC-11605: 5 Hydroxytryptamine 1A receptor antagonist; 5-HT1A Receptor Antagonists; 5-Hydroxytryptamine 1A receptor Agonist; Antagonist; Signal Transduction Modulators; Anxiolytic; Anxiolytics
CBR-001-670-777-0,RFM-011-849-0,CBR-001-670-777-0,C=CCn1c2nc([nH]c2c(=O)n(c1=O)CC=C)C1CCCCC1,"CBR-HVAC-11613: Adenosine A1 receptor agonist; Chloride channel activator; Adenosine A1 receptor agonist; Chloride channel activator; Cystic Fibrosis, Treatment of"
CBR-001-670-778-1,RFM-011-850-3,CBR-001-670-778-1,C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc1cc(Cl)c(cc1F)Cl,CBR-HVAC-11784: EGFR Inhibitor; Mucolytic
CBR-001-670-779-2,RFM-011-851-4,CBR-001-670-779-2,O=C(Nc1ccncc1)NN1CCC=CC1,CBR-HVAC-11967: 5 Hydroxytryptamine receptor agonist; Dopamine receptor D2 Agonist; Antinociceptive; Non-Opioid Analgesics
CBR-001-670-780-5,RFM-011-852-5,CBR-001-670-780-5,C#C[C@H]1CCC2[C@]1(C)CCC1C2CCC2=CC(=O)CC[C@]12C,CBR-HVAC-12348: Antidepressant; Antidepressant
CBR-001-670-781-6,RFM-011-853-6,CBR-001-670-781-6,OC[C@@H]1C[C@H]([C@@H](O1)n1c(=O)sc2c1nc(N)nc2)OC(=O)C,CBR-HVAC-12350: Signal Transduction Modulators; TLR7 Receptor Agonists; Toll-like receptor 7 Agonist; Anti-Hepatitis B Virus Drugs; Anti-Hepatitis C Virus Drugs; Anticancer; Immunostimulant; Oncolytic Drugs
CBR-001-670-782-7,RFM-011-854-7,CBR-001-670-782-7,COc1ccc2c(c1)c(nc(=O)n2C(C)C)c1ccc(cc1)C(C)C,CBR-HVAC-12360: analog of CBR-HVAC-14616
CBR-001-670-783-8,RFM-011-855-8,CBR-001-670-783-8,Oc1cc(ccc1O)NC(=O)c1cccc(c1O)O,"CBR-HVAC-12363: Antiamyloidogenic Agents; Beta-amyloid protein Inhibitor; Tau Aggregation Inhibitors; beta-Amyloid (Abeta) Aggregation Inhibitors; Alzheimer's Dementia, Treatment of ; Beta-Amyloid aggregation inhibitor; Nootropic"
CBR-001-670-784-9,RFM-011-856-9,CBR-001-670-784-9,Oc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1C[C@@H]1[C@H]2O1)C,CBR-HVAC-12366: Appetite suppressant; Appetite suppressant
CBR-001-670-785-0,RFM-011-857-0,CBR-001-670-785-0,OC[C@H]1O[C@@H](Oc2nn(c(c2Cc2ccc(cc2F)OC)C)C(C)C)[C@@H]([C@H]([C@@H]1O)O)O,"CBR-HVAC-12368: SGLT-2 Inhibitors; Sodium/glucose cotransporter 2 Inhibitor; Sodium/glucose cotransporter 2 inhibitor; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-670-786-1,RFM-011-858-1,CBR-001-670-786-1,COCCN1CCC(CC1)N(C(=O)Cn1c(CCc2cccc(c2F)F)nc(=O)c2c1nccc2)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-12369: Lipoprotein Associated Phospholipase A2 (Lp-PLA2) Inhibitors; Lipoprotein-associated phospholipase A2 inhibitor; Signal Transduction Modulators; Antiarteriosclerotic; Atherosclerosis Therapy
CBR-001-670-787-2,RFM-011-859-2,CBR-001-670-787-2,O=C1CCC(C(=O)N1)N1C(=O)c2c(C1=O)c(ccc2)CNC(=O)C1CC1,CBR-HVAC-12370: Tumor necrosis factor Inhibitor; Anti-inflammatory; Anticancer; Immunomodulator; Immunomodulators; Myelodysplastic Syndrome Therapy
CBR-001-670-788-3,RFM-011-860-5,CBR-001-670-788-3,Oc1ccc(cc1)[C@@H]1COc2c([C@H]1O)ccc(c2)O,"CBR-HVAC-12374: Hormone modulator; Smooth muscle cell proliferation inhibitor; Vasoconstrictor; Antihypertensive; Atherosclerosis Therapy; Peripheral Vascular Disease, Treatment of"
CBR-001-670-789-4,RFM-011-861-6,CBR-001-670-789-4,OC(=O)C1(CCC1)CN1CCC(CC1)CNC(=O)n1c(=O)n(c2c1cccc2)C(C)C,"CBR-HVAC-12375: 5-HT4 Partial Agonists; 5-hydroxytryptamine 4 receptor Agonist; Signal Transduction Modulators; Gastroesophageal Reflux Disease, Agents for; Gastroprotectant"
CBR-001-670-790-7,RFM-011-862-7,CBR-001-670-790-7,COc1cc(ccc1Cl)N1CCN(CC1)C(=O)Cn1nc(c(c1C)Cl)C(F)(F)F,CBR-HVAC-12378: C-C chemokine receptor type 1 Antagonist; Anti-inflammatory; Immunomodulator
CBR-001-670-791-8,RFM-011-863-8,CBR-001-670-791-8,FC(c1cccc(c1)C1=CCN(CC1)CCc1ccc2c(c1)cncc2)(F)F,"CBR-HVAC-12379: C-C chemokine receptor 2 Antagonist; Chemokine CCR2 (MCP-1 Receptor) Antagonists; Signal Transduction Modulators; TNF-alpha Release Inhibitors; Anti-inflammatory; Inflammation, Treatment of; Rheumatoid Arthritis, Treatment of"
CBR-001-670-792-9,RFM-011-864-9,CBR-001-670-792-9,COCC1=C(C(=O)OC)[C@@H](N(C(=O)N1)C(=O)NCCCN1CCC(CC1)c1cccc(c1)NC(=O)C)c1ccc(c(c1)F)F,CBR-HVAC-12383: Antagonist; INTEGRIN RECEPTOR Antagonist; Antiinflammatory
CBR-001-670-793-0,RFM-011-865-0,CBR-001-670-793-0,O[C@@H](c1ccc(cc1)[C@@H](N)C)CNC(C)(C)C,CBR-HVAC-12386: Antimitotic Drugs; Polo-like Kinase-1 (Plk-1) Inhibitors; Polo-like kinase 1 Inhibitor; Signal Transduction Modulators; Anticancer; Apoptosis stimulator; Solid Tumors Therapy
CBR-001-670-794-1,RFM-011-866-1,CBR-001-670-794-1,COc1ccc2c(c1)c1C[C@@]3(C)C(=O)N(C(=O)N3[C@@H](c1n2)c1cccc(c1)O)CCN(C)C,"CBR-HVAC-12396: Antimitotic Drugs; Kinesin-Like Spindle Protein  KIF11 (KSP, Eg5) Inhibitors; Kinesin-like protein KIF11 Inhibitor; Anticancer; Lymphoma Therapy; Solid Tumors Therapy"
CBR-001-670-795-2,RFM-011-867-2,CBR-001-670-795-2,N#Cc1ccc(cc1)C(n1cncn1)(c1ccc(cc1)C#N)F,CBR-HVAC-12397: Aromatase Inhibitors; Reproductive system modulator; Endometriosis Therapy; REPRODUCTIVE SYSTEM MODULATOR; Treatment of Hypogonadism
CBR-001-670-796-3,RFM-011-868-3,CBR-001-670-796-3,Cn1nnc(n1)N(Cc1cc2cccc(c2nc1N(CC1CC1)CC1CC1)C)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-12398: CHOLESTEROL ESTER TRANSFER PROTEIN Inhibitor; Cholesteryl Ester Transfer Protein (CETP) Inhibitors; HDL-Cholesterol Increasing Agents; Atherosclerosis Therapy; Cardiovascular Diseases (Not Specified); Cardiovascular agent; Lipoprotein Disorders, Treatment of"
CBR-001-670-797-4,RFM-011-869-4,CBR-001-670-797-4,OC(=O)CSc1cnc(s1)NC(=O)[C@@H](c1ccc(cc1)S(=O)(=O)C)CC1CCCC1,"CBR-HVAC-12401: Glukokinase Activator; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-670-798-5,RFM-011-870-7,CBR-001-670-798-5,OC(=O)C(CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cccc2)(C)C,"CBR-HVAC-12404: 5-HT2A Antagonists; 5-Hydroxytryptamine 2A receptor; Histamine H1 Receptor Inverse Agonists; Histamine H1 receptor Agonist; Signal Transduction Modulators; Hypnotic; Sleep Disorders, Treatment of"
CBR-001-670-799-6,RFM-011-871-8,CBR-001-670-799-6,Fc1cccc(c1)C1=C(c2ccc(cc2)S(=O)(=O)C)C(OC1=O)(C)C,CBR-HVAC-12409: Cyclooxygenase 2 Inhibitor; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors; Signal Transduction Modulators; Anti-inflammatory
CBR-001-670-800-2,RFM-011-872-9,CBR-001-670-800-2,Clc1ccc(c(c1)C(=O)Nc1cc(ccc1Oc1ccc(c2c1cccc2)Cl)C(F)(F)F)O,CBR-HVAC-12414: Apoptosis Inducer; Apoptosis Inducers; Anticancer; Hematological Cancer Therapy; Solid Tumors Therapy
CBR-001-670-801-3,RFM-011-873-0,CBR-001-670-801-3,OC(=O)CCc1ccc(cc1)S(=O)(=O)CCc1c(CCNS(=O)(=O)Cc2ccccc2C(F)(F)F)n(c2c1cc(Cl)cc2)C(c1ccccc1)c1ccccc1,CBR-HVAC-12422: Bronchodilator; Asthma Therapy; BRONCHODILATOR
CBR-001-670-802-4,RFM-011-874-1,CBR-001-670-802-4,Fc1cccc(c1)[C@@H](Oc1cccc(c1C)C1CCNCC1)C,"CBR-HVAC-12426: 5-HT6 Antagonists; 5-Hydroxytryptamine 6 receptor Antagonist; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; NOOTROPIC AGENT"
CBR-001-670-803-5,RFM-011-875-2,CBR-001-670-803-5,OCCOc1ccc(c(c1)C)c1cccc(c1)COc1ccc(cc1)Cn1oc(=O)nc1=O,"CBR-HVAC-12431: Antidiabetic; Type 2 Diabetes, Agents for"
CBR-001-670-804-6,RFM-011-876-3,CBR-001-670-804-6,Oc1ccc(cc1)N(C(=O)c1ccc(c(c1)F)O)c1ccc(cc1)F,CBR-HVAC-12432: ESTROGEN RECEPTOR ALPHA Antagonist; Estrogen Receptor (ER) alpha Agonists; Signal Transduction Modulators; Anticancer; Prostate Cancer Therapy
CBR-001-670-805-7,RFM-011-877-4,CBR-001-670-805-7,n1ccc(cc1)c1cc(nnc1N1CCN(CC1)c1ncccn1)c1ccccc1,"CBR-HVAC-12435: IL-1beta Production Inhibitors; Inhibitor; Interleukin 1; Signal Transduction Modulators; TNF-alpha Antagonist; TNF-alpha Production Inhibitors; Alzheimer's Dementia, Treatment of ; Anti-inflammatory; Multiple Sclerosis, Agents for; Neurologic Drugs (Miscellaneous); Rheumatoid Arthritis, Treatment of"
CBR-001-670-806-8,RFM-011-878-5,CBR-001-670-806-8,OC(=O)CCc1ccc(c2c1cccc2)C(=O)N1CCC(CC1)c1ccc(cc1)OCCCN1CCCC(C1)(C)C,CBR-HVAC-12437: treatment of urticaria
CBR-001-670-807-9,RFM-011-879-6,CBR-001-670-807-9,ONC(=O)c1ccc(cc1)C1=Nc2ccccc2Oc2c1cccc2,"CBR-HVAC-12439: HISTONE DEACETYLASE Inhibitor; Histone Deacetylase (HDAC) Inhibitors; Alzheimer's Dementia, Treatment of ; Cognition Disorders, Treatment of; Nootropic"
CBR-001-670-808-0,RFM-011-880-9,CBR-001-670-808-0,OC(=O)CSC(c1ccc(cc1)OCc1ccc2c(n1)cccc2)CCCc1ccccc1,CBR-HVAC-12442: Antiproliferative; EGFR (HER1; erbB1) Inhibitors; Signal Transduction Modulators; Anticancer; Solid Tumors Therapy
CBR-001-670-809-1,RFM-011-881-0,CBR-001-670-809-1,Clc1cc2nc(ccc2c(c1)C(=O)C1CC1)N1CCN(CC1)C1CC1,CBR-HVAC-12443: Histamine H3 Receptor Antagonists; Histamine H3 receptor Antagonist; Signal Transduction Modulators; Antidiabetic Drugs; Antiobesity Drugs; Appetite suppressant
CBR-001-670-810-4,RFM-011-882-1,CBR-001-670-810-4,CC(OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@H](CCc2ccccc2)O)C=CC1=O)C,CBR-HVAC-12450: Prostanoid receptor agonist; Antiinflammatory
CBR-001-670-811-5,RFM-011-883-2,CBR-001-670-811-5,OCc1cc(C)c2c(n1)cc1c(c2)OC([C@H]([C@@H]1NCCc1ccccc1)O)(C)C,CBR-HVAC-12452: ANTIARRHYTHMIC
CBR-001-670-812-6,RFM-011-884-3,CBR-001-670-812-6,CCC(Nc1c2CCCc2nc2n1nc(c2c1ccc(cc1Cl)OC)C)CC,CBR-HVAC-12456: CRF1 Receptor Antagonists; Corticotropin releasing hormone receptor 1 Antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics
CBR-001-670-813-7,RFM-011-885-4,CBR-001-670-813-7,N#Cc1cn(c2c1cc(cc2)c1nc(c(s1)C(=O)O)C)C(C)C,CBR-HVAC-12465: Xanthine Oxidase Inhibitors; Xanthine oxidase Inhibitor; ANTIGOUT; ANTIHYPERURICEMIC; Treatment of Gout; Uricosurics
CBR-001-670-814-8,RFM-011-886-5,CBR-001-670-814-8,Cn1ncc(c1)c1nccc(c1)Oc1cc(F)c(cc1F)N(C(=O)C1(CC1)C(=O)N)c1ccccc1,CBR-HVAC-12473: KIT kinase Inhibitor; PAN C-KIT; ANTILEUKEMIC; ANTITUMOR
CBR-001-670-815-9,RFM-011-887-6,CBR-001-670-815-9,CCCCCCCOc1ccc(cc1C(F)(F)F)CCC(CO)(CO)N,"CBR-HVAC-12486: Signal Transduction Modulators; Sphingosine Kinase 1 (SphK1) Inhibitors; Sphingosine-1-phosphate receptor Antagonist; ANTISCLEROTIC; Antipsoriatics; Inflammatory Bowel Disease, Agents for; Multiple Sclerosis, Agents for; Systemic Lupus Erythematosus, Agents for"
CBR-001-670-816-0,RFM-011-888-7,CBR-001-670-816-0,CC(OC(=O)N1CCC(CC1)(C)N1CCC(CC1)N1C(=O)N[C@@H]2[C@@H]1CCCC2)C,CBR-HVAC-12499: Muscarinic acetylcholine receptor M1 Agonist; Analgesic
CBR-001-670-817-1,RFM-011-889-8,CBR-001-670-817-1,CC(NC(=O)[C@@H]1CC[C@@H](CC1)n1c(NC(=O)c2ccc(cc2)F)nc2c1cc(cc2)CN1CCC(CC1)C(O)(C)C)C,CBR-HVAC-12506: ALK Inhibitors; ANAPLASTIC LYMPHOMA KINASE ALK Inhibitor; High Affinity Nerve Growth Factor Receptor (TrKA) Inhibitors; Signal Transduction Modulators; TRKB Inhibitors; TRKC Inhibitors; ANTI-CANCER; Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-670-818-2,RFM-011-890-1,CBR-001-670-818-2,O=C(c1nn(c(c1)c1cnc2c(c1)cccc2)C)NCCN1CCOCC1,"CBR-HVAC-12507: 5-HT2B Antagonists; 5-Hydroxytryptamine 2B receptor Antagonist; Signal Transduction Modulators; GASTROINTESTINAL AGENT; Irritable Bowel Syndrome, Agents for"
CBR-001-670-819-3,RFM-011-891-2,CBR-001-670-819-3,N#Cc1ccc2c(c1)n(CCN1CC[C@@H]([C@@H](C1)F)NCc1ncc3c(c1)OCCO3)c(=O)cc2,CBR-HVAC-12511: Antibacterial; Antibacterial; Antibacterial Drugs
CBR-001-670-820-6,RFM-011-892-3,CBR-001-670-820-6,Oc1ccc2c(c1)oc(=O)c(c2Cc1ccc(cc1)OCCN1CCCCC1)c1ccccc1,CBR-HVAC-12514: Estrogen receptor Modulator; Selective Estrogen Receptor Modulators (SERM); Signal Transduction Modulators; Antitumor; Brain Cancer Therapy
CBR-001-670-821-7,RFM-011-893-4,CBR-001-670-821-7,OC(=O)Cc1csc(n1)NC(=O)c1cn(c2c1cccc2)Cc1ccccc1,CBR-HVAC-12515: Glucokinase Stimulator; Hypoglycemic
CBR-001-670-822-8,RFM-011-894-5,CBR-001-670-822-8,COC(=O)Nc1nc2c(n1)cc(cc2)C1(O)c2ccccc2C(=O)N1c1cc(Cl)ccc1C,CBR-HVAC-12517: RAF Inhibitor; Anticancer
CBR-001-670-823-9,RFM-011-895-6,CBR-001-670-823-9,CCOc1cc2c(cc1OCC)cc(c(c2c1ccnc(c1)n1nc(c2cccnc2)c2c(c1=O)cccc2)CO)CO,"CBR-HVAC-12544: Phosphodiesterase PDE4 Inhibitors; Phosphodiesterase-4 Inhibitor; Signal Transduction Modulators; Antiallergic; Atopic Dermatitis, Agents for"
CBR-001-670-824-0,RFM-011-896-7,CBR-001-670-824-0,CC(CN(S(=O)(=O)c1nccs1)c1cc2CCCc2cc1OCc1ccc(cc1C)C(=O)O)C,"CBR-HVAC-12583: Prostanoid EP receptor 1 Antagonist; Prostanoid EP1 Antagonists; Signal Transduction Modulators; Gastroesophageal Reflux Disease, Agents for; Prostanoid EP1 receptor antagonist; Urinary Incontinence Therapy"
CBR-001-670-825-1,RFM-011-897-8,CBR-001-670-825-1,COc1cc(CC(=O)NN(c2c(C)cccc2N2CCCCC2)c2ccc(cc2)Cc2ccccc2)c(cc1C(=O)O)Br,CBR-HVAC-12585: E1 protein Inhibitor; Anti-infective
CBR-001-670-826-2,RFM-011-898-9,CBR-001-670-826-2,O=S1(=O)CCN(CC1)Cc1cc(NC2CCOCC2)c2c(c1)cc(n2)c1ccccc1,"CBR-HVAC-12590: Acute Myocardial Infarction, Treatment of; CARDIOPROTECTANT"
CBR-001-670-827-3,RFM-011-899-0,CBR-001-670-827-3,OCc1cccnc1n1nc(c(c1)CN1CCC2(CC1)OCC(c1c2sc(c1)Cl)(F)F)C,"CBR-HVAC-12594: ORL1 (OP4, NOP) Antagonists; Signal Transduction Modulators; ANTIDEPRESSANT; Antidepressants; Treatment of Alcohol Dependency"
CBR-001-670-828-4,RFM-011-900-6,CBR-001-670-828-4,OC[C@H](Nc1nc(SCc2cccc(c2F)Cl)nc2c1sc(=O)n2)C,CBR-HVAC-12604: Chemokine receptor Antagonist; Anti-inflammatory; Antiarthritic
CBR-001-670-829-5,RFM-011-901-7,CBR-001-670-829-5,Clc1ccc(cc1)C1(C)OCc2c1cnc(c2O)C,CBR-HVAC-12736: Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist; Signal Transduction Modulators; Bronchodilator
CBR-001-670-830-8,RFM-011-902-8,CBR-001-670-830-8,OC(=O)C(c1ccc(c2c1cccc2)C1CCCCC1)C,"CBR-HVAC-12824: Cyclooxygenase (COX) Inhibitors; Inhibits thromboxane B2 formation and Prostaglandin synthesis; Signal Transduction Modulators; Analgesic Drugs; Anti-inflammatory, nonsteroidal; Antiarthritic Drugs"
CBR-001-670-831-9,RFM-011-903-9,CBR-001-670-831-9,COc1ccc2c(c1)N(CCCN(C)C)c1c(S2)cccc1,CBR-HVAC-13122: Antipsychotic; Tranquillizer
CBR-001-670-832-0,RFM-011-904-0,CBR-001-670-832-0,CCCCCCC(=O)OCCN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,CBR-HVAC-13205: Dopamine receptor D2 Antagonist; Antipsychotic
CBR-001-670-833-1,RFM-011-905-1,CBR-001-670-833-1,Oc1ccc2c(c1)[C@]13CCCC[C@H]3[C@@H](C2)N(CC1)CC1CCC1,CBR-HVAC-13276: Opioid receptor kappa Agonist; Signal Transduction Modulators; kappa-Opioid Agonists; mu-Opioid Agonists; Analgesic; Opioid Analgesics; Treatment of Cocaine Dependency
CBR-001-670-834-2,RFM-011-906-2,CBR-001-670-834-2,COCc1c(ncc2c1c1c(cccc1n2)OC(C)C)C(=O)OCC,CBR-HVAC-13337: Benzodiazepine receptor Partial Agonist; Anticonvulsant; Anxiolytic
CBR-001-670-835-3,RFM-011-907-3,CBR-001-670-835-3,Cn1c(=O)[nH]c2c(c1=O)n(cn2)CC(C)(C)C,CBR-HVAC-13360: Phosphodiesterase Inhibitor; Antiasthmatic; Antibronchospastic; Bronchodilators
CBR-001-670-836-4,RFM-011-908-4,CBR-001-670-836-4,CCCCCCCC[N+](CCOC(=O)C(C1CCCC1)C1CCCC1)(CC)CC,CBR-HVAC-13424: Antibiotic
CBR-001-670-837-5,RFM-011-909-5,CBR-001-670-837-5,C=CCCCCCCCCC(=O)OCCC1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)S(=O)(=O)N(C)C,CBR-HVAC-13477: Dopamine receptor D2 Antagonist; Antipsychotic; Neuroleptic
CBR-001-670-838-6,RFM-011-910-8,CBR-001-670-838-6,Fc1ccc(cc1)CC1Nc2cc(Cl)c(cc2S(=O)(=O)N1)S(=O)(=O)N,CBR-HVAC-13487: Antihypertensive; Diuretic
CBR-001-670-839-7,RFM-011-911-9,CBR-001-670-839-7,CCCC1CC(NCC)c2c(S1(=O)=O)sc(c2)S(=O)(=O)N,CBR-HVAC-13494: Carbonic Anhydrase Inhibitors; Carbonic anhydrase Inhibitor; Antiglaucoma; Antiglaucoma Agents
CBR-001-670-840-0,RFM-011-912-0,CBR-001-670-840-0,N[C@H]1C[C@@H](N(C1)c1cc2n(cc(c(=O)c2cc1F)C(=O)O)c1ccc(cc1F)F)C,CBR-HVAC-13496: DNA gyrase Inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-670-841-1,RFM-011-913-1,CBR-001-670-841-1,OC[C@@](C(=O)Nc1ccc(cc1)OCCc1ccc(cc1)c1ccccc1)(N)C,"CBR-HVAC-13858: Lysophospholipid edg1 (S1P1) Receptor Agonists; Signal Transduction Modulators; Multiple Sclerosis, Agents for"
CBR-001-670-842-2,RFM-011-914-2,CBR-001-670-842-2,F/C(=C\c1cccc(c1)C(=N)N)/CN(S(=O)(=O)CC(=O)O)c1ccc(c(c1)C(=O)N)OC1CCN(CC1)C(=N)C,CBR-HVAC-14056: Coagulation Factor Xa Inhibitors; Inhibitors of Blood Coagulation Pathways; Thrombolytics
CBR-001-670-843-3,RFM-011-915-3,CBR-001-670-843-3,CN/C(=N\C)/Cc1ccc2c(c1)cccc2,CBR-HVAC-01232: 5 Hydroxytryptamine receptor antagonist; Antidepressant; Antidepressants
CBR-001-670-844-4,RFM-011-916-4,CBR-001-670-844-4,CCCCCc1cccc(c1)CC(=O)[O-],"CBR-HVAC-07065: CTGF Expression Inhibitors; Nitric Oxide (NO) Production Inhibitors; Fibrosis, Treatment of; Interstitial Lung Diseases, Treatment of; Metabolic Disorders (Not Specified); Treatment of Neutropenia; Treatment of Renal Diseases; Type 2 Diabetes, Agents for"
CBR-001-670-845-5,RFM-011-917-5,CBR-001-670-845-5,CCC1(Cc2c(C1)ccc(c2)F)c1cncn1,CBR-HVAC-00763: ALPHA-2 ADRENERGIC RECEPTOR Antagonist; Alpha 2 adrenoreceptor antagonist; Signal Transduction Modulators; alpha2-Adrenoceptor Antagonists; Antiparkinsonian; Antiparkinsonian Drugs
CBR-001-670-846-6,RFM-011-918-6,CBR-001-670-846-6,O=C(N[C@@H]1C(=O)N(c2ccccc2)c2c(N(C1=O)CC13CC4CC(C3)CC(C1)C4)cccc2)Nc1ccccc1,CBR-HVAC-02752: CCK B receptor antagonist; CCK2 (CCKB/Gastrin) Antagonists; Signal Transduction Modulators; Anxiolytics
CBR-001-670-847-7,RFM-011-919-7,CBR-001-670-847-7,CCCCCCCCCCCCCCCCCCOC1=C(O)[C@H](OC1=O)[C@H](CO)O,"CBR-HVAC-03530: Free radical scavenger; Oxygen scavenger; Angina pectoris, Treatment of; Anti-inflammatory; Anticancer; Anticataract Agents; Cardioprotectant; Cognition Disorders, Treatment of"
CBR-001-670-848-8,RFM-011-920-0,CBR-001-670-848-8,O[C@H](COc1ccc(cc1)CCOC(=O)C)CNC(C)(C)C,CBR-HVAC-03588: Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Antiglaucoma; Antiglaucoma Agents
CBR-001-670-849-9,RFM-011-921-1,CBR-001-670-849-9,COc1cc(N)c(cc1C(=O)NC1CCN2C(C1)CCCC2C)Cl,CBR-HVAC-07561: Dopamine receptor antagonist
CBR-001-670-850-2,RFM-011-922-2,CBR-001-670-850-2,COCCCN1CC[C@H]([C@H](C1)O)CNC(=O)c1cc(Cl)c(c2c1OCC2)N,"CBR-HVAC-12352: 5-Hydroxytryptamine 4 receptor Agonist; Gastroesophageal Reflux Disease, Agents for; Gastroprokinetic"
CBR-001-670-851-3,RFM-011-923-3,CBR-001-670-851-3,COCCCN1CC[C@@H]([C@H](C1)O)CNC(=O)c1cc(Cl)c(c2c1OCC2)N,"CBR-HVAC-12352: 5-Hydroxytryptamine 4 receptor Agonist; Gastroesophageal Reflux Disease, Agents for; Gastroprokinetic"
CBR-001-670-852-4,RFM-011-924-4,CBR-001-670-852-4,OCc1cc(C)c2c(n1)cc1c(c2)OC([C@@H]([C@H]1NCCc1ccccc1)O)(C)C,CBR-HVAC-12452: ANTIARRHYTHMIC
CBR-001-670-853-5,RFM-011-925-5,CBR-001-670-853-5,CCN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1,CBR-HVAC-13130: Muscarinic receptor Blocker; Anticholinergic; Antihistamine
CBR-001-670-854-6,RFM-011-926-6,CBR-001-670-854-6,OC[C@](c1ncc(n1)c1ccc(c(c1)C(F)(F)F)OCc1ccc(cc1)c1ccccc1)(N)C,"CBR-HVAC-13965: Lysophospholipid edg1 (S1P1) Receptor Agonists; Signal Transduction Modulators; Multiple Sclerosis, Agents for"
CBR-001-670-855-7,RFM-011-927-7,CBR-001-670-855-7,Oc1ccc(cc1)CCCCNC[C@H](c1ccc(c(c1)O)O)O,enantiomer of CBR-HVAC-02156:
CBR-001-670-856-8,RFM-011-928-8,CBR-001-670-856-8,NC(=O)c1cccc(c1O)Cc1cncn1,"CBR-HVAC-03970: Alpha 2 adrenoreceptor agonist; Alpha-2 adrenergic receptor Agonist; Signal Transduction Modulators; alpha2-Adrenoceptor Agonists; Angina pectoris, Treatment of; Antiischaemic"
CBR-001-670-857-9,RFM-011-929-9,CBR-001-670-857-9,COc1ccc(cc1C(=O)NCc1cccnc1)C(=O)N,CBR-HVAC-12940: Inhibitor; Platelet aggregation inhibitor; Thromboxane A synthase; Thromboxane A2 receptor Antagonist; Thromboxane synthase inhibitor; Anti-ischemic; Antiplatelet Therapy; Antithrombotic
CBR-001-670-858-0,RFM-011-930-2,CBR-001-670-858-0,C[C@H](CCNCCCCNC(=O)OCC(=O)NCCCCCCNC(=N)N)N,CBR-HVAC-13026: Immunosuppressant; Immunosuppressant; Immunosuppressants
CBR-001-670-859-1,RFM-011-931-3,CBR-001-670-859-1,CNC(Cc1ccccc1)(C)C,CBR-HVAC-13069: Alpha adrenergic receptor Agonist; Antihypotensive; Sympathomimetic
CBR-001-670-860-4,RFM-011-932-4,CBR-001-670-860-4,CCCn1c2[nH]c(nc2c(=O)n(c1=O)CCC)c1cnn(c1)Cc1cccc(c1)C(F)(F)F,CBR-HVAC-13091: ADENOSINE A2B RECEPTOR Modulator; Anti-inflammatory; Cardiac agent; Respiratory system agent
CBR-001-670-861-5,RFM-011-933-5,CBR-001-670-861-5,COc1ccc(cc1OC)CCNCCC[C@](c1ccc(c(c1)OC)OC)(C(C)C)C#N,CBR-HVAC-13103: 5-Hydroxytryptamine 3 receptor agonist; ANTIDIARRHEAL
CBR-001-670-862-6,RFM-011-934-6,CBR-001-670-862-6,O=C1CN=C(c2c(N1)ccc(c2)Cl)C1=CCCCC1,CBR-HVAC-13138: Anxiolytic
CBR-001-670-863-7,RFM-011-935-7,CBR-001-670-863-7,COc1ccccc1OC[C@H](NC[C@H](COc1cnc(=O)c2c1cccc2)O)C,"CBR-HVAC-03197: Alpha adrenergic receptor; Alpha adrenoreceptor antagonist; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Signal Transduction Modulators; alpha-Adrenoceptor Antagonists; beta-Adrenoceptor Antagonists; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-864-8,RFM-011-936-8,CBR-001-670-864-8,COc1ccccc1OC[C@@H](NC[C@H](COc1cnc(=O)c2c1cccc2)O)C,"CBR-HVAC-03197: Alpha adrenergic receptor; Alpha adrenoreceptor antagonist; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Signal Transduction Modulators; alpha-Adrenoceptor Antagonists; beta-Adrenoceptor Antagonists; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-865-9,RFM-011-937-9,CBR-001-670-865-9,COc1ccccc1OC[C@H](NC[C@@H](COc1cnc(=O)c2c1cccc2)O)C,"CBR-HVAC-03197: Alpha adrenergic receptor; Alpha adrenoreceptor antagonist; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Signal Transduction Modulators; alpha-Adrenoceptor Antagonists; beta-Adrenoceptor Antagonists; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-866-0,RFM-011-938-0,CBR-001-670-866-0,COc1ccccc1OC[C@@H](NC[C@@H](COc1cnc(=O)c2c1cccc2)O)C,"CBR-HVAC-03197: Alpha adrenergic receptor; Alpha adrenoreceptor antagonist; Beta adrenergic receptor Blocker; Beta adrenoreceptor antagonist; Signal Transduction Modulators; alpha-Adrenoceptor Antagonists; beta-Adrenoceptor Antagonists; Antihypertensive; Hypertension, Treatment of"
CBR-001-670-867-1,RFM-011-939-1,CBR-001-670-867-1,CCCCCCCCCCCCCCCC(=O)OCC(NC(=O)CNC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)N(Cc1cnc2c(n1)c(N)nc(n2)N)C)(COC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC,CBR-HVAC-05376: Antipsoriatics
CBR-001-670-868-2,RFM-011-940-4,CBR-001-670-868-2,N#Cc1ccc(c(c1C(F)(F)F)F)N1C(=S)N(C(C1=O)(C)C)c1ccc(nc1)CCCc1ncco1,CBR-HVAC-07256: Androgen Receptor Antagonists; Signal Transduction Modulators; Oncolytic Drugs
CBR-001-670-869-3,RFM-011-941-5,CBR-001-670-869-3,NCCC[C@@H]1NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(cc2)O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@H](NC(=O)[C@@H](NC1=O)CC(C)C)Cc1ccccc1)CCC2)Cc1ccccc1)C(C)C,CBR-HVAC-08671: Antibiotic
CBR-001-670-870-6,RFM-011-942-6,CBR-001-670-870-6,CNC(=S)NCO,analog of CBR-HVAC-09273
CBR-001-670-871-7,RFM-011-943-7,CBR-001-670-871-7,CCCCCCC1(CCC1)c1cc(O)c2c(c1)OC([C@H]1[C@H]2C[C@H](O)CC1)(C)C,CBR-HVAC-12264: Cannabinoid CB1 Agonists; Signal Transduction Modulators; Non-Opioid Analgesics
CBR-001-670-875-1,RFM-011-944-8,CBR-001-670-875-1,OC(=O)[C@H](Cc1c[nH]c2c1cc(O)cc2)N.CC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc[nH]c2=O,"CBR-HVAC-03344: Antidepressants; Cognition Disorders, Treatment of; Treatment of Alcohol Dependency"
CBR-001-670-876-2,RFM-011-945-9,CBR-001-670-876-2,O=C1CC[C@H](N1)C(=O)O.OCc1c(CO)cnc(c1O)C,"CBR-HVAC-10281: 5 Hydroxytryptamine receptor antagonist; 5-HT2B Receptor Antagonists; Signal Transduction Modulators; Anti-craving; Attention Deficit Hyperactivity Disorder (ADHD), Treatment of; Hepatoprotectants; Liver and Biliary Tract Disorders, Treatment of; Mental Retardation, Treatment of"
CBR-001-671-213-3,RFM-011-946-0,CBR-001-671-213-3,COc1ccc(cc1)c1n(Cc2ccc(cc2)C(=O)N)c(nc1c1ccc(cc1)OC)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,"CBR-HVAC-14582:preclinical HSP-70; Cell Chemical Biology (2016), http://dx.doi.org/10.1016/j.chembiol.2015.12.006"
CBR-001-671-214-4,RFM-011-947-1,CBR-001-671-214-4,N#Cc1ccc(cc1)COC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1c(NCc2ccc(c(c2)Cl)Cl)nc2c1ncnc2N,CBR-HVAC-14578: Heat Shock Protein 70 (hsp70) Inhibitors
CBR-001-671-275-7,RFM-011-948-2,CBR-001-671-275-7,CCCn1c(NC(=O)C2CCCN(C2)c2cnccn2)nc2c1cccc2,"CBR-HVAC-14579: preclinical HSP-70: Chem Biol. 2014 December 18; 21(12): 1648.1659. doi:10.1016/j.chembiol.2014.10.016)
"
CBR-001-671-276-8,RFM-011-949-3,CBR-001-671-276-8,NS(=O)(=O)C#Cc1ccccc1,"CBR-HVAC-14575: Apoptosis Inducers;Autophagy Inhibitors;Heat Shock Protein 70 (hsp70) Inhibitors
"
CBR-001-671-415-1,RFM-011-950-6,CBR-001-671-415-1,O=C(c1cccnc1O)Nc1c(C)cccc1C,"CBR-HVAC-10143: Analgesic; Anti-inflammatory
"
CBR-001-671-498-0,RFM-011-951-7,CBR-001-671-498-0,C=C/C=C/C[C@H]([C@H]([C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)O)C,"CBR-HVAC-02767: 16S Ribosomal Protein Inhibitors; 16S-rRNA of 30S ribosomal subunit Binder; 30S Ribosomal Protein Inhibitors; Protein 30S ribosomal subunit inhibitor; Antibacterial; Antibiotics; Cystic Fibrosis, Treatment of ; Sepsis, Treatment of
"
CBR-001-671-499-1,RFM-011-952-8,CBR-001-671-499-1,CSCC[C@@H](C(=O)OCC)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(cc1)F)N)Cc1cccc(c1)N(CCCl)CCCl,"CBR-HVAC-02997: GABA-A receptor Modulator; Kainate Receptor Antagonists; NMDA Antagonists; Signal Transduction Modulators; Anesthetic; Anesthetic Drugs; Stroke, Treatment of
"
CBR-001-671-500-7,RFM-011-953-9,CBR-001-671-500-7,CC(=CC=C1COC(=O)C=C1C)C=CC1=C(C)CCCC1(C)C,"CBR-HVAC-03780: Iron metabolism modulator; Iron chelator
"
CBR-001-671-501-8,RFM-011-954-0,CBR-001-671-501-8,O=c1sc2c([nH]1)c(O)ccc2CCNCCCS(=O)(=O)CCOCCc1cccc2c1cccc2,"CBR-HVAC-04964: beta2-Adrenoceptor Agonists;Dopamine D2 Agonists;Signal Transduction Modulators
"
CBR-001-671-502-9,RFM-011-955-1,CBR-001-671-502-9,OC[C@H]([C@H]([C@@H]([C@H](CNC(=O)CCCCCCCCCCC(=O)NCc1ccc(cc1)N1C(=O)[C@@H]([C@H]1c1ccc(cc1)OC)CC[C@@H](c1ccc(cc1)F)O)O)O)O)O,CBR-HVAC-06128: Cholesterol Absorption Inhibitors
CBR-001-671-503-0,RFM-011-956-2,CBR-001-671-503-0,O=C(c1cc(NCCN2CCCC2)c(c(c1)N1CCN(CC1)c1ncnc2c1c(Br)n[nH]2)C)CCC(F)(F)F,"CBR-HVAC-06353: Apoptosis Inducers;Protein Kinase B (PKB/Akt) Inhibitors;Ribosomal Protein S6 Kinase beta (p70S6K) Inhibitors;Signal Transduction Modulators
"
CBR-001-671-504-1,RFM-011-957-3,CBR-001-671-504-1,OCc1c(F)cc(cc1S(=O)(=O)C)c1ccc(c(c1)F)n1cc(nc1C(c1c(Cl)cccc1Cl)(C)C)C(O)(C)C,"CBR-HVAC-07074: Oxysterol Receptor (LXR) Partial Agonists;Signal Transduction Modulators
"
CBR-001-671-505-2,RFM-011-958-4,CBR-001-671-505-2,CCCCCCCCCCCCCCC[C@H]([C@@H](NC(=O)C)CO)O,CBR-HVAC-08808: Antipsoriatic
CBR-001-671-506-3,RFM-011-959-5,CBR-001-671-506-3,N#CC1(CC1)NC(=O)[C@H](CC(F)(F)C)NC(=O)N1CCC2(CC1)CC2,"CBR-HVAC-09441: DNA topoisomerase I inhibitor
"
CBR-001-671-507-4,RFM-011-960-8,CBR-001-671-507-4,CCNc1c(C)cc(c2c1nccc2)Cc1cnc(nc1N)N,"CBR-HVAC-10219: Renin Inhibitor; Renin Inhibitors; Renin inhibitor; Antihypertensive; Hypertension, Treatment of
"
CBR-001-671-508-5,RFM-011-961-9,CBR-001-671-508-5,NCC[C@]12CCC3(CC1=CCC1C2CC[C@]2(C1CCC12OCCO1)C)OCCO3,"CBR-HVAC-10376: Phosphoribosylglycinamide formyltransferase inhibitor
"
CBR-001-671-509-6,RFM-011-962-0,CBR-001-671-509-6,OCC1OC(C(C1O)O)n1ncsc1=NC#N,"CBR-HVAC-10689: Antibacterial; Antibiotics; Antineoplastic Antibiotics
"
CBR-001-671-510-9,RFM-011-963-1,CBR-001-671-510-9,OC(CNC(Cc1cnc2c1cc(C)cc2)(C)C)COc1cccc2c1cc(n2)C,"CBR-HVAC-10840: ANGIOTENSIN II RECEPTOR TYPE 1; Angiotensin AT1 Antagonists; Angiotensin II 1 antagonist; ENDOTHELIN A RECEPTOR Antagonist; Endothelin A receptor antagonist; Endothelin ETA Receptor Antagonists; Signal Transduction Modulators; Antihypertensive; Cardioprotectant; Diabetic Neuropathy, Agents for; Hypertension, Treatment of; Treatment of Renal Diseases"
CBR-001-671-511-0,RFM-011-964-2,CBR-001-671-511-0,O=C(OCC[N+](C)(C)C)CCCC[C@H]1SSCC1,CBR-HVAC-14344: Antioxidants; Reducing agent; Eye Disorders; OPHTHALMIC AGENT; Ophthalmic Drugs
CBR-001-671-512-1,RFM-011-965-3,CBR-001-671-512-1,O=C(Nc1ncc2c(c1)c(ncn2)Nc1ccc(c(c1)Br)Cl)C=CC[N+](Cc1n(C)cnc1[N+](=O)[O-])(C)C,"CBR-HVAC-14380: EGFR (HER1; erbB1) Inhibitors;HER2 (erbB2) Inhibitors;HER4 (erbB4) Inhibitors;Signal Transduction Modulators
"
CBR-001-671-513-2,RFM-011-966-4,CBR-001-671-513-2,O=C(OCC[N+](C)(C)C)CCCC[C@@H]1SSCC1,"isomer of CBR-HVAC-14344
"
CBR-001-671-514-3,RFM-011-967-5,CBR-001-671-514-3,CC(=CC=C1COC(=O)C=C1C)C=CC1=C(C)CCCC1(C)C,"CBR-HVAC-03780: Iron metabolism modulator; Iron chelator
"
CBR-001-671-515-4,RFM-011-968-6,CBR-001-671-515-4,CCCCCCCCCCCCCCC[C@H]([C@H](NC(=O)C)CO)O,"enantiomer of CBR-HVAC-08808
"
CBR-001-671-516-5,RFM-011-969-7,CBR-001-671-516-5,ONC(=O)C[C@H](C(=O)N[C@@H](C(C)(C)C)C(=O)N)CCCc1ccc(cc1)Cl,"CBR-HVAC-10761: Immunostimulant
"
CBR-001-671-517-6,RFM-011-970-0,CBR-001-671-517-6,CCOC(=O)C(CCCOc1ccc2c(c1)C=C(CC2)c1nccn1C)(C)C,"CBR-HVAC-11614: Phosphatidylinositol 3-Kinase delta (PI3Kdelta) Inhibitors; Signal Transduction Modulators; Immunological Genetic Disorders, Treatment of 
"
CBR-001-671-518-7,RFM-011-971-1,CBR-001-671-518-7,CCc1cc(ccc1Cl)Oc1cccc(c1)N(C[C@H](C(F)(F)F)O)Cc1cccc(c1)OC(C(F)F)(F)F,"CBR-HVAC-11732: Cholesteryl Ester Transfer Protein (CETP) Inhibitors;HDL-Cholesterol Increasing Agents
"
CBR-001-671-519-8,RFM-011-972-2,CBR-001-671-519-8,FCC1COc2c3n1cc(C(=O)O)c(=O)c3cc(c2N1CCN(CC1)c1ccccn1)F,"CBR-HVAC-12311:  HIV replication inhibitor; Topoisomerase II inhibitor; DNA gyrase inhibitor
"
CBR-001-671-521-2,RFM-011-973-3,CBR-001-671-521-2,Fc1ccc(cc1)C(=O)N1CCn2c([C@H]1C)nnc2c1snc(n1)C,"CBR-HVAC-14364: Signal Transduction Modulators;Tachykinin NK3 Antagonists
"
CBR-001-671-522-3,RFM-011-974-4,CBR-001-671-522-3,O=C(C(C)(C)C)c1cc(NCCN2CCCC2)c(c(c1)N1CCN(CC1)c1ncnc2c1c(Br)n[nH]2)C,"CBR-HVAC-14574: side-product of XL-418
"
CBR-001-671-838-0,RFM-011-975-5,CBR-001-671-838-0,COc1cc(ccc1OC)c1ccc2c(c1)c(ncn2)Nc1ccc(cc1)n1cncn1,"CBR-HVAC-12531: RNA polymerase inhibitor; HCV NS5a inhibitor
"
CBR-001-671-839-1,RFM-011-976-6,CBR-001-671-839-1,CCCNc1nc(NCCC)nc(n1)N(OC)C,"CBR-HVAC-12483: Respiratory Stimulants; Respiratory stimulant; Sleep Apnea, Treatment of
"
CBR-001-671-840-4,RFM-011-977-7,CBR-001-671-840-4,Clc1ccc(c(c1)Cl)S(=O)(=O)Nc1cnc(c(c1)Cl)Oc1ncc2c(c1)cccc2,"CBR-HVAC-12457: Free fatty acid receptor 1; Insulin receptor Modulator; Sensitizer; Hypoglycemic agent; Type 2 Diabetes, Agents for
"
CBR-001-671-841-5,RFM-011-978-8,CBR-001-671-841-5,CCOc1ccc2c(n1)c(=O)c(c[nH]2)C(=O)NCc1ccccc1,"CBR-HVAC-12455: GABA(A) Receptor Inverse Agonists; GABA-A receptor Modulator; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Neuroprotectant
"
CBR-001-671-842-6,RFM-011-979-9,CBR-001-671-842-6,OCCNC(=O)C1CCCN(C1)c1nc(NCc2ccccn2)c2c(n1)scc2c1ccccc1,"CBR-HVAC-12559: IKUR CHANNEL; KV1.5 POTASSIUM CHANNEL Modulator; Antiarrhythmic
"
CBR-001-671-843-7,RFM-011-980-2,CBR-001-671-843-7,COc1ccc(cc1c1cc(=O)[nH]c(=S)n1CC(=O)N)Cl,"CBR-HVAC-12564: ANTICORONARY; ANTITHROMBOTIC; Treatment of Disorders of the Coronary Arteries and Atherosclerosis
"
CBR-001-671-844-8,RFM-011-981-3,CBR-001-671-844-8,CCCCS(=O)(=O)Nc1ccccc1C(=O)N[C@@H](c1ccc(nc1)OC)CC,"CBR-HVAC-12558: K(V) 1.5 (KCNA5) Channel Blockers; Potassium channel Blocker; Antiarrhythmic Drugs; Class III antiarrhythmic
"
CBR-001-672-088-0,RFM-011-982-4,CBR-001-672-088-0,COCCOc1ccc(cc1)OCC(CNCCOc1ccc(c(c1)O)C(=O)N)O,analog of CBR-HVAC-08470
CBR-001-672-089-1,RFM-011-983-5,CBR-001-672-089-1,NC(=O)C1CCCc2c1ncc(c2)C,analog of CBR-HVAC-08881
CBR-001-672-090-4,RFM-011-984-6,CBR-001-672-090-4,Oc1ccc(cc1)C1COc2c(C1c1ccc(cc1)O)ccc(c2)O,analog of CBR-HVAC-13555
CBR-001-672-091-5,RFM-011-985-7,CBR-001-672-091-5,N#C[C@@]1(CC[C@@](NC1)(CO[C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)c1ccccc1)n1cn[nH]c1=O,"CBR-HVAC-00515: NK-1 RECEPTOR Antagonist; Neurokinin 1 receptor antagonist; Signal Transduction Modulators; Tachykinin NK1 Antagonists; Antitussive; Nausea and Vomiting, Treatment of"
CBR-001-672-092-6,RFM-011-986-8,CBR-001-672-092-6,COc1c(ccc2c1n(cc(c2=O)C(=O)O)C1CC1)N1C[C@@H](C)C[C@@H](C1)N,CBR-HVAC-00762: DNA Topoisomerase Inhibitors; DNA gyrase; DNA topoisomerase II inhibitor; DNA topoisomerase IV inhibitor; Topoisomerase Inhibitor; Antibacterial; Antibacterial Drugs
CBR-001-672-093-7,RFM-011-987-9,CBR-001-672-093-7,OC(COc1cccc2c1C=CC2)CNC(C)C,"CBR-HVAC-01544: Beta 1 adrenoreceptor antagonist; Beta 2 adrenoreceptor agonist; Beta adrenergic receptor Blocker; Signal Transduction Modulators; beta-Adrenoceptor Antagonists; Angina pectoris, Treatment of; Antianginal; Antiarrhythmic Drugs; Hypertension, Treatment of"
CBR-001-672-094-8,RFM-011-988-0,CBR-001-672-094-8,O/N=C/1\CCCC(C1)c1ccc(cc1)C(C(=O)O)C,CBR-HVAC-03499: COX Inhibitor; Cyclooxygenase inhibitor; Platelet aggregation inhibitor; Prostaglandin synthase inhibitor; Non-Steroidal Antiinflammatory
CBR-001-672-095-9,RFM-011-989-1,CBR-001-672-095-9,OP(=O)(C(P(=O)(O)O)(CCN1CCCC1)O)O,"CBR-HVAC-03934: Bisphosphonate; Bone resorption inhibitor; Osteoclast inhibitor; Squalene synthase Inhibitor; Bone Diseases, Treatment of; Bone Resorption Inhibitors; Bone resorption inhibitor; Squalene synthase inhibitor"
CBR-001-672-096-0,RFM-011-990-4,CBR-001-672-096-0,O=C1CP(=O)(O)O[Pt-2]2(O1)[NH2+]C1C([NH2+]2)CCCC1,CBR-HVAC-11341: DNA intercalator
CBR-001-672-097-1,RFM-011-991-5,CBR-001-672-097-1,CCCCCCCCCCCCCCC[C@H]([C@@H](N)C)O,CBR-HVAC-05279: Angiogenesis Inhibitors; Apoptosis Inducers; Caspase 12 Activators; Caspase 3 Activators; Rho kinase Inhibitor; Signal Transduction Modulators; Sphingosine Kinase 1 (SphK1) Inhibitors; Anticancer; Gastric Cancer Therapy; Liver Cancer Therapy; Prostate Cancer Therapy; Renal Cancer Therapy
CBR-001-672-098-2,RFM-011-992-6,CBR-001-672-098-2,CCOC(=O)[C@@H](NP(=O)(c1ccc(o1)c1nc(sc1CC(C)C)N)N[C@H](C(=O)OCC)C)C,"CBR-HVAC-07693: Fructose bisphosphatase inhibitor; Fructose-1,6-Bisphosphatase Inhibitors; Fructose-1,6-bisphosphatase Inhibitor; Gluconeogenesis inhibitor; Hypoglycemic; Type 2 Diabetes, Agents for"
CBR-001-672-099-3,RFM-011-993-7,CBR-001-672-099-3,NC(=N)NCC1CCCCCCN1,"CBR-HVAC-07883: Alpha adrenoreceptor antagonist; Hypertension, Treatment of"
CBR-001-672-100-9,RFM-011-994-8,CBR-001-672-100-9,Nc1ccc(c(c1)C(=O)O)OS(=O)(=O)O,CBR-HVAC-07893: Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor
CBR-001-672-101-0,RFM-011-995-9,CBR-001-672-101-0,CNc1cccc(c1C#N)NC(=O)C(=O)O,CBR-HVAC-08530: ANTI-ALLERGIC; Antiallergy/Antiasthmatic Drugs
CBR-001-672-102-1,RFM-011-996-0,CBR-001-672-102-1,NC(=S)C1CCCc2c1ncc(c2)C,CBR-HVAC-08881: Histamine H2 receptor Inhibitor; Anticholinergic; Antiulcer Drugs
CBR-001-672-103-2,RFM-011-997-1,CBR-001-672-103-2,CSc1ccc(nn1)c1ccc(cc1)N1C[C@@H](OC1=O)CNC(=S)C,CBR-HVAC-09300: Bacterial protein synthesis inhibitor; Antibacterial
CBR-001-672-104-3,RFM-011-998-2,CBR-001-672-104-3,CN(CCOC(c1ccccc1C(C)(C)C)c1ccccc1)C,CBR-HVAC-09416: ANTI-EMETICÂ¬ANTI-HISTAMINEÂ¬ANTI-PARKINSON'S
CBR-001-672-105-4,RFM-011-999-3,CBR-001-672-105-4,CCCCc1nc2ccc(cc2c(=O)n1Cc1ccc(cc1)c1ccccc1c1nnnn1)[C@H]1ON2[C@@H](C1)CCC2,"CBR-HVAC-10946: Angiotensin AT1 Antagonists; Angiotensin II receptor Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of"
CBR-001-672-106-5,RFM-012-000-3,CBR-001-672-106-5,CN[C@@H]([C@@H](c1ccc(c(c1)O)O)O)C(=O)OC,CBR-HVAC-11378: Beta 3 adrenoreceptor agonist; Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Antidiabetic Drugs; Antiobesity Drugs; Hypoglycemic
CBR-001-672-107-6,RFM-012-001-4,CBR-001-672-107-6,CN[C@H]([C@H](c1ccc(c(c1)O)O)O)C(=O)OC,CBR-HVAC-11378: Beta 3 adrenoreceptor agonist; Beta-3 adrenergic receptor Agonist; Signal Transduction Modulators; beta3-Adrenoceptor Agonists; Antidiabetic Drugs; Antiobesity Drugs; Hypoglycemic
CBR-001-672-108-7,RFM-012-002-5,CBR-001-672-108-7,CCC[C@@H](Oc1nc(N)c2c(n1)n(CCCCCN1CCCCC1)c(=O)[nH]2)C,CBR-HVAC-12420: Toll-like receptor 7 agonist; ANTIRHINITISANTIASTHMATIC
CBR-001-672-109-8,RFM-012-003-6,CBR-001-672-109-8,Oc1ccc(cc1)C1COc2c(C1=O)ccc(c2Br)O,CBR-HVAC-12445: Inhibitor; THROMBOXANE SYNTHASE Agonist; Anti-inflammatory
CBR-001-672-110-1,RFM-012-004-7,CBR-001-672-110-1,N#Cc1ccc(cc1)OCCC1SC(=O)NC1=O,"CBR-HVAC-12447: Insulin Sensitizers; Signal Transduction Modulators; Antidiabetic; Type 2 Diabetes, Agents for"
CBR-001-672-111-2,RFM-012-005-8,CBR-001-672-111-2,O=C(C(C)(C)C)Oc1ccc2c(c1)O[C@H](C(=C2C)c1ccc(cc1)OC(=O)C(C)(C)C)c1ccc(cc1)OCCN1CCCCC1,CBR-HVAC-12668: Estrogen receptor Antagonist; Estrogen receptor antagonist; Selective Estrogen Receptor Modulators (SERM); Selective estrogen receptor modulator; Signal Transduction Modulators; Anticancer; Breast Cancer Therapy
CBR-001-672-112-3,RFM-012-006-9,CBR-001-672-112-3,O=C(C(C)(C)C)Oc1ccc2c(c1)O[C@@H](C(=C2C)c1ccc(cc1)OC(=O)C(C)(C)C)c1ccc(cc1)OCCN1CCCCC1,CBR-HVAC-12668: Estrogen receptor Antagonist; Estrogen receptor antagonist; Selective Estrogen Receptor Modulators (SERM); Selective estrogen receptor modulator; Signal Transduction Modulators; Anticancer; Breast Cancer Therapy
CBR-001-672-113-4,RFM-012-007-0,CBR-001-672-113-4,CCCC(C(=O)OC1CC2CCC(C1)[N+]2(C)C(C)C)CCC,CBR-HVAC-12921: Muscarinic acetylcholine receptor Antagonist; Muscarinic receptor antagonist; Antispasmodics; Spasmolytic
CBR-001-672-114-5,RFM-012-008-1,CBR-001-672-114-5,Oc1ccc(cc1)C1C(COc2c1ccc(c2)O)c1cccc(c1)O,CBR-HVAC-13555: Apoptosis Inducers; NADH oxidase Inhibitor; Tumor NADH Oxidase (tNOX) Inhibitors; Anticancer; Antineoplastic Enhancing Agents; Melanoma Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-001-672-115-6,RFM-012-009-2,CBR-001-672-115-6,CC(CC12CC3CC(C2)CC(C1)C3)(N)C,CBR-HVAC-13613:
CBR-001-672-116-7,RFM-012-010-5,CBR-001-672-116-7,CCOC(=O)C1C2C1C1(CC2=O)SCCS1,"CBR-HVAC-13732: Antipsychotic Drugs; Sleep Disorders, Treatment of"
CBR-001-672-117-8,RFM-012-011-6,CBR-001-672-117-8,COc1ccnc1/C=C/1\C(=O)Nc2c1c(C#CC1(O)CCNCC1)c(cc2)F,CBR-HVAC-13846: Cyclin-Dependent Kinase Inhibitors; Signal Transduction Modulators; Solid Tumors Therapy
CBR-001-702-565-9,RFM-012-012-7,CBR-001-702-565-9,CCCCCCCCCCCCCCCC(=O)Nc1ccn(c(=O)n1)[C@@H]1O[C@@H]([C@H]([C@@H]1C#N)O)CO,CBR-HVAC-04431: Antimetabolites;DNA Polymerase alpha Inhibitors
CBR-001-702-566-0,RFM-012-013-8,CBR-001-702-566-0,C=CC(=O)Nc1cccc(c1)Oc1nc(Nc2ccc(cc2)N2CCN(CC2)C)nc2c1scc2,CBR-HVAC-12592: EGFR Inhibitor; ANTICANCER
CBR-001-702-568-2,RFM-012-014-9,CBR-001-702-568-2,Oc1ccc(cc1)C1(C)CCCN(C1C)CC(=O)c1ccccc1,analog of CBR-HVAC-09261:
CBR-001-702-569-3,RFM-012-015-0,CBR-001-702-569-3,CCCc1nc(c(n1c1ccc(cc1)c1ccccc1c1nnn[nH]1)C(=O)OCc1oc(=O)oc1C)C(O)(C)C,analog of CBR-HVAC-09262:
CBR-001-702-570-6,RFM-012-016-1,CBR-001-702-570-6,COc1ccc2c(c1)nc(n2S(=O)(=O)c1ccc(cc1)OCC(=O)O)S(=O)Cc1ncc(c(c1C)OC)C,"CBR-HVAC-06220: H+/K+-ATPase Inhibitors
"
CBR-001-702-571-7,RFM-012-017-2,CBR-001-702-571-7,OC[C@H]1Oc2ccc(cc2O[C@@H]1c1ccc(c(c1)OC)O)[C@H]1Oc2cc(O)cc(c2C(=O)[C@@H]1O)O.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(OCC[N+](C)(C)C)O,"CBR-HVAC-13222: Angiogenesis inhibitor; Antioxidants; Estrogen receptor antagonist; Free Radical Scavengers; Reducing agent; Agents for Viral Hepatitis; Anticancer; Cancer; Hepatoprotectants; Liver Disorders; Liver and Biliary Tract Disorders, Treatment of; Ovarian Cancer Therapy; Prostate Cancer Therapy; Viral Infections"
CBR-001-702-572-8,RFM-012-018-3,CBR-001-702-572-8,Nc1nc(=O)c2c([nH]1)n(CCC(CO)O)cn2,CBR-HVAC-13634: DNA directed DNA polymerase inhibitor
CBR-001-702-573-9,RFM-012-019-4,CBR-001-702-573-9,Nc1nc(=O)c2c([nH]1)n(CCC(CO)O)cn2,CBR-HVAC-13634: DNA directed DNA polymerase inhibitor
CBR-001-702-574-0,RFM-012-020-7,CBR-001-702-574-0,Nc1nc(=O)c2c([nH]1)n(CCC(CO)O)cn2,CBR-HVAC-13634: DNA directed DNA polymerase inhibitor
CBR-001-702-575-1,RFM-012-021-8,CBR-001-702-575-1,Nc1nc(=O)c2c([nH]1)n(CCC(CO)O)cn2,CBR-HVAC-13634: DNA directed DNA polymerase inhibitor
CBR-001-702-576-2,RFM-012-022-9,CBR-001-702-576-2,O=C([C@@H](c1ccccc1)[NH3+])N[C@@H]1C(=O)N2[C@@H]1SC([C@@H]2C(=O)OCOC(=O)C(C)(C)C)(C)C.[O-]C(=O)[C@@H]1N2C(=O)[C@H]([C@H]2SC1(C)C)Br,CBR-HVAC-00968
CBR-001-702-577-3,RFM-012-023-0,CBR-001-702-577-3,NCC(=O)Nc1cccc(c1)Sc1cnc(nc1OCc1ccccc1)N1CCN(CC1)C,"CBR-HVAC-14581:heat shock protein (HSP) inhibitor; preclinical HSP-70: Cell Chemical Biology (2016), http://dx.doi.org/10.1016/j.chembiol.2015.12.006"
CBR-001-702-617-4,RFM-012-024-1,CBR-001-702-617-4,COc1cc(O)c2c(c1)cc(oc2=O)CO,CBR-HVAC-10594: Antiarthritic; Antibiotic; Antidiabetic; Antineoplastic; Immunomodulator; Anti-arthritic; Anti-diabetic; Antiarthritic Drugs; Antibacterial; Antineoplastic; Antineoplastic Antibiotics; Immunomodulator
CBR-001-702-618-5,RFM-012-025-2,CBR-001-702-618-5,NC(=N)NCCC[C@@H](C(=O)NCCc1ccccc1)NC(=O)[C@H](Cc1c2cc(cc(c2nc1C(C)(C)C)C(C)(C)C)C(C)(C)C)NC(=O)[C@H](CCCNC(=N)N)N,CBR-HVAC-06832: Antibacterial; Antibacterial Drugs; Antimicrobial
CBR-001-702-619-6,RFM-012-026-3,CBR-001-702-619-6,OCCn1cc(c(c1c1ccccc1C(F)(F)F)C)C(=O)Nc1ccc(cc1)S(=O)(=O)C,"CBR-HVAC-12508: Antihypertensive; Mineralocorticoid Receptor (MR) Antagonists; Signal Transduction Modulators; ANTIHYPERTENSIVE; Aldosteronism, Treatment of; Diabetic Nephropathy, Agents for; Hypertension, Treatment of"
CBR-001-702-620-9,RFM-012-027-4,CBR-001-702-620-9,Cc1cnc(c(c1)NS(=O)(=O)c1ccc(c(c1)C(F)(F)F)Cl)C(=O)c1ncnc2c1ccn2,"CBR-HVAC-12538: C-C chemokine receptor type 2 Antagonist; Chemokine CCR2 (MCP-1 Receptor) Antagonists; Signal Transduction Modulators; Anti-inflammatory; Diabetic Nephropathy, Agents for; Restenosis Treatment of; Treatment of Renal Diseases; Type 2 Diabetes, Agents for"
CBR-001-702-621-0,RFM-012-028-5,CBR-001-702-621-0,CCCN(c1nc(C)nc(c1C)Nc1c(Cl)cc(c2c1nccn2)C)CC1CC1,CBR-HVAC-12470: CRF1 Receptor Antagonists; Corticotropin releasing hormone receptor 1 Antagonist; Signal Transduction Modulators; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics
CBR-001-702-622-1,RFM-012-029-6,CBR-001-702-622-1,C[C@@H](n1c(=O)c2cccc3c2c(c1=O)cc(c3)[N+](=O)[O-])CNCCNC[C@H](n1c(=O)c2cccc3c2c(c1=O)cc(c3)[N+](=O)[O-])C,CBR-HVAC-04342: DNA inhibitor; DNA synthesis inhibitor; DNA-Intercalating Drugs; Nuclease unspecified inhibitor; RNA synthesis inhibitor; Antitumor; Oncolytic Drugs
CBR-001-702-623-2,RFM-012-030-9,CBR-001-702-623-2,COCCC(=O)NC1CCC(CC1)CCN1CCN(CC1)c1cccc(c1)C#N,"CBR-HVAC-12484: DOPAMINE 3 RECEPTOR Partial Agonist; ANTABUSE; Smoking Cessation, Aid to"
CBR-001-702-624-3,RFM-012-031-0,CBR-001-702-624-3,N#Cc1ccc2c(c1)[C@@H]1CN(C[C@H]1CO2)CCCCNC(=O)c1ccc(cc1)c1ccccc1,CBR-HVAC-11476: Dopamine D3 Antagonists; Dopamine receptor D3 Antagonist; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs
CBR-001-702-625-4,RFM-012-032-1,CBR-001-702-625-4,COc1c(OC)cc(cc1C(=O)NC[C@@H]1CCCN1C)S(=O)(=O)NC,CBR-HVAC-08386: Dopamine receptor antagonist
CBR-001-702-626-5,RFM-012-033-2,CBR-001-702-626-5,COc1c(OC)cc(cc1C(=O)NC[C@H]1CCCN1C)S(=O)(=O)NC,CBR-HVAC-08386: Dopamine receptor antagonist
CBR-001-702-627-6,RFM-012-034-3,CBR-001-702-627-6,CCOC(=O)C[C@H](NC(=O)CCC(=O)Nc1ccc(cc1)C(=N)N)C#C,CBR-HVAC-04487: GPIIb IIIa receptor antagonist; Glycoprotein IIb/IIIa Inhibitor; Inhibitors of Blood Coagulation Pathways; Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonists; Integrin antagonist; Platelet aggregation inhibitor; Signal Transduction Modulators; Antiplatelet Therapy; Antithrombotic
CBR-001-702-628-7,RFM-012-035-4,CBR-001-702-628-7,CCCCCCCC/C=C\CCCCCCCC(=O)O,"CBR-HVAC-03947: Immunostimulant; Motor Disorders of the Esophagus, Agents for; Peripheral Vascular Disease, Treatment of"
CBR-001-702-629-8,RFM-012-036-5,CBR-001-702-629-8,CCCCCCCCCC(=O)OC[C@H]1O[C@H](O[C@H]2O[C@H](COC(=O)CCCCCCCCC)[C@H]([C@@H]([C@H]2O)O)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-08368: Membrane integrity inhibitor
CBR-001-702-630-1,RFM-012-037-6,CBR-001-702-630-1,CC(Oc1nnc(c1)n1cnc2c1nc(cc2)N[C@H](c1ncc(cn1)F)C)C,CBR-HVAC-12577: Neurotrophic tyrosine kinase receptor Inhibitor; Signal Transduction Modulators; TRK Inhibitors; Anticancer; Neurologic Cancer Therapy
CBR-001-702-631-2,RFM-012-038-7,CBR-001-702-631-2,CCCNC(=O)c1ccc2c(c1)N(C(CN1CCCC1)C)c1c(S2)cccc1,"CBR-HVAC-04033: Opioid kappa receptor agonist; Opioid receptor kappa Agonist; Signal Transduction Modulators; kappa-Opioid Receptor Agonists; Analgesic; Opioid Analgesics; Stroke, Treatment of"
CBR-001-702-632-3,RFM-012-039-8,CBR-001-702-632-3,CCCNC(=O)c1ccc2c(c1)N(C(CN1CCCC1)C)c1c(S2)cccc1,"CBR-HVAC-04033: Opioid kappa receptor agonist; Opioid receptor kappa Agonist; Signal Transduction Modulators; kappa-Opioid Receptor Agonists; Analgesic; Opioid Analgesics; Stroke, Treatment of"
CBR-001-702-633-4,RFM-012-040-1,CBR-001-702-633-4,O=c1c2CN([C@H](c2nc2c1cccc2)c1ccc2c(c1)CCO2)c1ccccn1,CBR-HVAC-06146: Phosphodiesterase 5 Inhibitor; Phosphodiesterase PDE5A Inhibitors; Signal Transduction Modulators; Phosphodiesterase 5 inhibitor; Treatment of Erectile Dysfunction
CBR-001-702-634-5,RFM-012-041-2,CBR-001-702-634-5,C[C@H](c1cc(F)c(c(c1)F)NS(=O)(=O)C)NC(=O)[C@@H]1C[C@@]1(C)c1ccc(cc1)C(F)(F)F,CBR-HVAC-13594: Vanilloid receptor 1 antagonist
CBR-001-702-635-6,RFM-012-042-3,CBR-001-702-635-6,CNc1ncnc(c1)c1csc(n1)N(C(=O)c1ccc(cc1)F)C,CBR-HVAC-14901
CBR-001-702-636-7,RFM-012-043-4,CBR-001-702-636-7,CSc1ccc(cc1)c1nc2n(c1c1ccncc1)CCC2,CBR-HVAC-14910: IL-1 Inhibitors; Lipoxygenase Inhibitors; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Antiallergy/Antiasthmatic Drugs; Antiarthritic Drugs; Treatment of Osteoporosis
CBR-001-702-637-8,RFM-012-044-5,CBR-001-702-637-8,O=C(N[C@H](C(=O)Nc1ccc(cc1)C1S/C(=N\c2cccc(c2)F)/N(C1=O)Cc1ccco1)C)Cc1ccc(cc1)Cl,CBR-HVAC-14549
CBR-001-702-638-9,RFM-012-045-6,CBR-001-702-638-9,CCN(Cc1ccc2c(c1)OCO2)CCCN(c1snc(n1)n1ccnc1)C,CBR-HVAC-15075
CBR-001-702-639-0,RFM-012-046-7,CBR-001-702-639-0,O=C(N[C@H](C(=O)Nc1ccc(cc1)C1S/C(=N\c2cccc(c2)F)/N(C1=O)Cc1cccs1)C)Cc1ccccc1,CBR-HVAC-14550
CBR-001-702-640-3,RFM-012-047-8,CBR-001-702-640-3,Fc1cccc(c1)/N=C/1\SC(C(=O)N1Cc1ccco1)c1ccc(cc1)NC(=O)[C@@H](NC(=O)c1ccccc1)C,CBR-HVAC-14545
CBR-001-702-641-4,RFM-012-048-9,CBR-001-702-641-4,O=C(Nc1ccc(cc1)C1S/C(=N\c2cccc(c2)F)/N(C1=O)Cc1ccco1)CNC(=O)Cc1ccccc1,CBR-HVAC-14548
CBR-001-702-642-5,RFM-012-049-0,CBR-001-702-642-5,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccc(cc1)Cl)C,CBR-HVAC-14959
CBR-001-702-643-6,RFM-012-050-3,CBR-001-702-643-6,Fc1cccc(c1)/N=C/1\SC(C(=O)N1Cc1ccccc1)c1ccc(cc1)NC(=O)[C@@H](NC(=O)Cc1ccccc1)C,CBR-HVAC-14551
CBR-001-702-644-7,RFM-012-051-4,CBR-001-702-644-7,CCOC(=O)CCc1nsnc1OCC(CNC(C)C)O,CBR-HVAC-14896
CBR-001-702-645-8,RFM-012-052-5,CBR-001-702-645-8,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccc(cc1)F)C,CBR-HVAC-14997
CBR-001-702-646-9,RFM-012-053-6,CBR-001-702-646-9,CCOC(=O)CCc1nsnc1OCC(CNCC(C)C)O,CBR-HVAC-14948
CBR-001-702-647-0,RFM-012-054-7,CBR-001-702-647-0,Cc1ccc2c(n1)c(OC(=O)c1ccco1)c(cc2Br)Br,CBR-HVAC-15081
CBR-001-702-648-1,RFM-012-055-8,CBR-001-702-648-1,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccc2c(c1)cccc2)C,CBR-HVAC-15019
CBR-001-702-649-2,RFM-012-056-9,CBR-001-702-649-2,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1cccc2c1cccc2)C,CBR-HVAC-15042
CBR-001-702-650-5,RFM-012-057-0,CBR-001-702-650-5,COC(=O)[C@@H](NC(=O)Cc1ccccc1)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-15059
CBR-001-702-651-6,RFM-012-058-1,CBR-001-702-651-6,CNC(=O)[C@@H](NC(=O)c1c(F)cccc1F)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-14930
CBR-001-702-652-7,RFM-012-059-2,CBR-001-702-652-7,Clc1ccc(cc1)C(=O)Oc1c(Br)cc(c2c1nc(C)cc2)Br,CBR-HVAC-15001
CBR-001-702-653-8,RFM-012-060-5,CBR-001-702-653-8,COC(=O)[C@@H](NC(=O)c1ccccc1Cl)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-15097
CBR-001-702-654-9,RFM-012-061-6,CBR-001-702-654-9,N#Cc1ccc(cc1)C(=O)Oc1c(Br)cc(c2c1nc(C)cc2)Br,CBR-HVAC-15026
CBR-001-702-655-0,RFM-012-062-7,CBR-001-702-655-0,Fc1ccc(cc1)C(=O)Oc1c(Br)cc(c2c1nc(C)cc2)Br,CBR-HVAC-14961
CBR-001-702-656-1,RFM-012-063-8,CBR-001-702-656-1,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccc(cc1)C)C,CBR-HVAC-14898
CBR-001-702-657-2,RFM-012-064-9,CBR-001-702-657-2,O=C(N[C@H](C(=O)O)C/C=C/c1ccc(cc1)N(c1ncccn1)C)Cc1ccccc1,CBR-HVAC-15036
CBR-001-702-658-3,RFM-012-065-0,CBR-001-702-658-3,CNC(=O)[C@@H](NC(=O)c1ccccc1)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-14921
CBR-001-702-659-4,RFM-012-066-1,CBR-001-702-659-4,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccc(cc1)OC)C,CBR-HVAC-15065
CBR-001-702-660-7,RFM-012-067-2,CBR-001-702-660-7,COC(=O)[C@@H](NC(=O)c1ccccc1)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-15094
CBR-001-702-661-8,RFM-012-068-3,CBR-001-702-661-8,CN(c1ncccn1)c1ccc(cc1)/C=C/C[C@@H](C(=O)O)NC(=O)c1ccccc1Cl,CBR-HVAC-14519
CBR-001-702-662-9,RFM-012-069-4,CBR-001-702-662-9,Fc1cccc(c1)C(=O)Oc1c(Br)cc(c2c1nc(C)cc2)Br,CBR-HVAC-15085
CBR-001-702-663-0,RFM-012-070-7,CBR-001-702-663-0,CN(c1ncccn1)c1ccc(cc1)/C=C/C[C@@H](C(=O)O)NC(=O)c1c(F)cccc1F,CBR-HVAC-14520
CBR-001-702-664-1,RFM-012-071-8,CBR-001-702-664-1,COC(=O)[C@@H](NC(=O)C1CCCCC1)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-14981
CBR-001-702-665-2,RFM-012-072-9,CBR-001-702-665-2,CNC(=O)[C@@H](NC(=O)c1ccccc1Cl)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-14899
CBR-001-702-666-3,RFM-012-073-0,CBR-001-702-666-3,CC(=CCOc1cc(ccc1Cl)NC(=O)c1ncsc1C)C,CBR-HVAC-15095
CBR-001-702-667-4,RFM-012-074-1,CBR-001-702-667-4,Cc1ccc(cc1)C(=O)Oc1c(Br)cc(c2c1nc(C)cc2)Br,CBR-HVAC-14903
CBR-001-702-668-5,RFM-012-075-2,CBR-001-702-668-5,CCc1ccc(cc1)CSc1ccc(cc1)NS(=O)(=O)c1ccc(c(c1)C(=O)OC)C,CBR-HVAC-14915
CBR-001-702-669-6,RFM-012-076-3,CBR-001-702-669-6,COCCN1CCC(CC1)N(C(=O)c1ccnc(c1)F)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-15061
CBR-001-702-670-9,RFM-012-077-4,CBR-001-702-670-9,Cc1ccc2c(n1)c(OC(=O)c1ccc3c(c1)cccc3)c(cc2Br)Br,CBR-HVAC-15041
CBR-001-702-671-0,RFM-012-078-5,CBR-001-702-671-0,Cc1ccc2c(n1)c(OC(=O)c1cccc3c1cccc3)c(cc2Br)Br,CBR-HVAC-15062
CBR-001-702-672-1,RFM-012-079-6,CBR-001-702-672-1,CCOC(=O)C1CCN(CC1)c1nc(ccc1[N+](=O)[O-])N(S(=O)(=O)c1ccc(cc1)C#N)C,CBR-HVAC-15076
CBR-001-702-673-2,RFM-012-080-9,CBR-001-702-673-2,CC(=CCOc1cc(ccc1Cl)NC(=O)c1cscn1)C,CBR-HVAC-15096
CBR-001-702-674-3,RFM-012-081-0,CBR-001-702-674-3,CN(c1ncccn1)c1ccc(cc1)/C=C/C[C@@H](C(=O)O)NC(=O)c1ccccc1,CBR-HVAC-14522
CBR-001-702-675-4,RFM-012-082-1,CBR-001-702-675-4,CCOC(=O)C(NC(=O)c1cccc(c1)N(c1ccc(c(c1)OC1CCCC1)OC)Cc1cccnc1)C,CBR-HVAC-15037
CBR-001-702-676-5,RFM-012-083-2,CBR-001-702-676-5,COC(=O)[C@@H](NC(=O)c1c(F)cccc1F)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-15092
CBR-001-702-677-6,RFM-012-084-3,CBR-001-702-677-6,CNC(=O)[C@@H](NC(=O)C1CCCCC1)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-15012
CBR-001-702-678-7,RFM-012-085-4,CBR-001-702-678-7,CNC(=O)[C@@H](NC(=O)Cc1ccccc1)C/C=C/c1ccc(cc1)N(c1ncccn1)C,CBR-HVAC-15071
CBR-001-702-679-8,RFM-012-086-5,CBR-001-702-679-8,CN(c1ncccn1)c1ccc(cc1)/C=C/C[C@@H](C(=O)O)NC(=O)C1CCCCC1,CBR-HVAC-15080
CBR-001-702-680-1,RFM-012-087-6,CBR-001-702-680-1,COCCN1CCC(CC1)N(C(=O)c1cc(=O)nc(=O)n1)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-15040
CBR-001-702-681-2,RFM-012-088-7,CBR-001-702-681-2,CCOP(=O)(OCC)CCCCCCOc1ccc(cc1OC)Cl,CBR-HVAC-14973
CBR-001-702-682-3,RFM-012-089-8,CBR-001-702-682-3,COCCN1CCC(CC1)N(C(=O)c1cccs1)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-14942
CBR-001-702-683-4,RFM-012-090-1,CBR-001-702-683-4,CCOP(=O)(OCC)CCCCCCOc1ccc(cc1OC)F,CBR-HVAC-15073
CBR-001-702-684-5,RFM-012-091-2,CBR-001-702-684-5,CCOP(=O)(OCC)CCCCCCOc1ccc(c(c1)OC)F,CBR-HVAC-15082
CBR-001-702-685-6,RFM-012-092-3,CBR-001-702-685-6,COc1ccc(cc1OC1CCCC1)N(c1cccc(c1)C(=O)NC1CCCC1)Cc1cccnc1,CBR-HVAC-15011
CBR-001-702-686-7,RFM-012-093-4,CBR-001-702-686-7,OC(=O)[C@@H](NC(=O)c1onc(c1)c1ccc(cc1)Nc1nc2c(s1)cc(cc2)F)Cc1ccccc1,CBR-HVAC-15048
CBR-001-702-687-8,RFM-012-094-5,CBR-001-702-687-8,CCOC(=O)COc1ccc(cc1C)/C(=N/OCc1sc(nc1C)c1ccc(cc1)C(F)(F)F)/C,CBR-HVAC-14953
CBR-001-702-688-9,RFM-012-095-6,CBR-001-702-688-9,CC(=CCOc1cc(ccc1Cl)NC(=O)c1cccnc1)C,CBR-HVAC-15101
CBR-001-702-689-0,RFM-012-096-7,CBR-001-702-689-0,CCOP(=O)(OCC)CCCCCCOc1ccc(cc1F)OC,CBR-HVAC-15038
CBR-001-702-690-3,RFM-012-097-8,CBR-001-702-690-3,COC(=O)COc1ccc(cc1C)/C(=N/OCc1sc(nc1C)c1ccc(cc1)C(F)(F)F)/C,CBR-HVAC-14900
CBR-001-702-691-4,RFM-012-098-9,CBR-001-702-691-4,CC(=CCOc1cc(ccc1Cl)NC(=S)c1ccncc1)C,CBR-HVAC-14979
CBR-001-702-692-5,RFM-012-099-0,CBR-001-702-692-5,CCOP(=O)(OCC)CCCCCCOc1ccc(c(c1)F)OC,CBR-HVAC-15060
CBR-001-702-693-6,RFM-012-100-6,CBR-001-702-693-6,O=C(C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)N(c1cnc(nc1c1ccccc1C)NC1CCCCC1)C,CBR-HVAC-15045
CBR-001-702-694-7,RFM-012-101-7,CBR-001-702-694-7,CCOC(=O)C1(CCN(CC1)CCc1ccc(cc1)NC(=O)c1cc2c(n1)cccc2)c1ccccc1,CBR-HVAC-15017
CBR-001-702-695-8,RFM-012-102-8,CBR-001-702-695-8,Fc1ccc2c(c1)sc(n2)Nc1ccc(cc1)c1noc(c1)C(=O)O,CBR-HVAC-14938
CBR-001-702-696-9,RFM-012-103-9,CBR-001-702-696-9,O=C(Nc1ccc2c(c1)NC(=O)C(O2)(C)C)/C=C/c1ccc(cc1)[N+](=O)[O-],CBR-HVAC-15016
CBR-001-702-697-0,RFM-012-104-0,CBR-001-702-697-0,CCCNc1nc(C)nc(c1C)Nc1c(Cl)cc(c2c1nccn2)C,CBR-HVAC-15025
CBR-001-702-698-1,RFM-012-105-1,CBR-001-702-698-1,Oc1ccc(cc1)CCSC(C(=O)N)Cc1ccc(cc1)CCOc1ccc(cc1)OS(=O)(=O)C,CBR-HVAC-15031
CBR-001-702-699-2,RFM-012-106-2,CBR-001-702-699-2,Nc1ncc(nc1Nc1ccc2c(c1)ccn2)c1ccccc1C,CBR-HVAC-15047
CBR-001-702-700-8,RFM-012-107-3,CBR-001-702-700-8,CC(=CCOc1cc(ccc1Cl)NC(=O)c1ccncc1)C,CBR-HVAC-14987
CBR-001-702-701-9,RFM-012-108-4,CBR-001-702-701-9,COc1c(OC)cc(cc1C(=O)NCc1cccs1)S(=O)(=O)NC,CBR-HVAC-14983
CBR-001-702-702-0,RFM-012-109-5,CBR-001-702-702-0,CC(=CCOc1cc(ccc1Cl)NC(=O)c1ccccc1C)C,CBR-HVAC-14943
CBR-001-702-703-1,RFM-012-110-8,CBR-001-702-703-1,Oc1ccc(cc1)CCS(=O)C(C(=O)O)Cc1ccc(cc1)CCOc1ccc(cc1)OS(=O)(=O)C,CBR-HVAC-14912
CBR-001-702-704-2,RFM-012-111-9,CBR-001-702-704-2,Oc1ccc(cc1)CCS(=O)(=O)C(C(=O)O)Cc1ccc(cc1)CCOc1ccc(cc1)OS(=O)(=O)C,CBR-HVAC-14958
CBR-001-702-705-3,RFM-012-112-0,CBR-001-702-705-3,COC(=O)C(Cc1ccc(cc1)CCOc1ccc(cc1)OS(=O)(=O)C)SCCc1ccc(cc1)O,CBR-HVAC-14995
CBR-001-702-706-4,RFM-012-113-1,CBR-001-702-706-4,Cc1nc(sc1COc1ccc(c(c1)Cl)C(=O)N)c1ccc(cc1)C(F)(F)F,CBR-HVAC-14924
CBR-001-702-707-5,RFM-012-114-2,CBR-001-702-707-5,Cc1nc(Nc2c(Cl)cc(c3c2nccn3)C)c(c(n1)NCC1CC1)C,CBR-HVAC-14993
CBR-001-702-708-6,RFM-012-115-3,CBR-001-702-708-6,CC(=CCOc1cc(ccc1Cl)NC(=O)c1ccccc1)C,CBR-HVAC-15098
CBR-001-702-709-7,RFM-012-116-4,CBR-001-702-709-7,[O-][N+](=O)c1cnc(n1CCCN1CCOCC1)C,CBR-HVAC-14980
CBR-001-702-710-0,RFM-012-117-5,CBR-001-702-710-0,Cc1nc(sc1COc1ccc(c(c1)Cl)C(=O)O)c1ccc(cc1)C(F)(F)F,CBR-HVAC-14976
CBR-001-702-711-1,RFM-012-118-6,CBR-001-702-711-1,C[C@H](c1cc(F)c(c(c1)F)NS(=O)(=O)C)NC(=O)/C=C/c1ccc(cc1)C(F)(F)F,CBR-HVAC-14941
CBR-001-702-712-2,RFM-012-119-7,CBR-001-702-712-2,[O-][N+](=O)c1cnc(n1CCCN1CCNCC1)C,CBR-HVAC-14894
CBR-001-702-713-3,RFM-012-120-0,CBR-001-702-713-3,COCCN1CCC(CC1)N(C(=O)c1ccco1)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-14986
CBR-001-702-714-4,RFM-012-121-1,CBR-001-702-714-4,N[C@@H]1CCCN(C1)c1ccnc2c1c(cn2)NC(=O)C1CC1,CBR-HVAC-14503
CBR-001-702-715-5,RFM-012-122-2,CBR-001-702-715-5,CC(=CCOc1cc(ccc1Cl)NC(=S)c1ccccn1)C,CBR-HVAC-14933
CBR-001-702-716-6,RFM-012-123-3,CBR-001-702-716-6,CCOC(=O)C1(CCN(CC1)CCc1ccc(cc1)NC(=O)C(N)C)c1ccccc1,CBR-HVAC-15035
CBR-001-702-717-7,RFM-012-124-4,CBR-001-702-717-7,O=C1CCC2(C(=O)N1)CCC(=O)c1c2ccc(c1)F,CBR-HVAC-15068
CBR-001-702-718-8,RFM-012-125-5,CBR-001-702-718-8,OCCC[C@]1(C)[C@H]2CC[C@]3([C@H]([C@@H]2CCC21OCCO2)CC[C@@H]3[C@@H](CCCC(C)C)C)C,CBR-HVAC-14964
CBR-001-702-719-9,RFM-012-126-6,CBR-001-702-719-9,COCCN1CCC(CC1)N(C(=O)c1nnc(c1)C)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-15074
CBR-001-702-720-2,RFM-012-127-7,CBR-001-702-720-2,CC(=CCOc1cc(ccc1Cl)NC(=S)c1ccccc1C)C,CBR-HVAC-14913
CBR-001-702-721-3,RFM-012-128-8,CBR-001-702-721-3,COc1ccc(cc1)/C=C/C(=O)Nc1ccc2c(c1)NC(=O)C(O2)(C)C,CBR-HVAC-14985
CBR-001-702-722-4,RFM-012-129-9,CBR-001-702-722-4,O=C(c1ccc(cc1)c1ccc(cc1)C(F)(F)F)N[C@@H](c1ccccc1)C(=O)O,CBR-HVAC-15039
CBR-001-702-723-5,RFM-012-130-2,CBR-001-702-723-5,CCOC(=O)C1(CCN(CC1)CCc1ccc(cc1)NC(=O)C(CC(C)C)N)c1ccccc1,CBR-HVAC-15057
CBR-001-702-724-6,RFM-012-131-3,CBR-001-702-724-6,COc1cc2c(cc1OC)CCN(C2C)S(=O)(=O)c1ccccc1,CBR-HVAC-14940
CBR-001-702-725-7,RFM-012-132-4,CBR-001-702-725-7,CC(=CCOc1cc(ccc1Cl)NC(=O)c1cocc1)C,CBR-HVAC-15100
CBR-001-702-726-8,RFM-012-133-5,CBR-001-702-726-8,COc1ccc(cc1)/C=C/C(=O)NC[C@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-14969
CBR-001-702-727-9,RFM-012-134-6,CBR-001-702-727-9,CC(=CCOc1cc(ccc1Cl)NC(=O)c1cscc1)C,CBR-HVAC-15099
CBR-001-702-728-0,RFM-012-135-7,CBR-001-702-728-0,COC(=O)CC[C@]1(C)[C@H]2CC[C@]3([C@H]([C@@H]2CCC21OCCO2)CC[C@@H]3[C@@H](CCCC(C)C)C)C,CBR-HVAC-15013
CBR-001-702-729-1,RFM-012-136-8,CBR-001-702-729-1,COCCN1CCC(CC1)N(C(=O)C1CCC(=O)N1)Cc1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-15015
CBR-001-702-730-4,RFM-012-137-9,CBR-001-702-730-4,COc1cc2c(cc1OC)CCN(C2C)S(=O)(=O)c1ccc(cc1)C,CBR-HVAC-14984
CBR-001-702-731-5,RFM-012-138-0,CBR-001-702-731-5,O=C(c1ccccn1)Oc1ccc(cc1C(C)(C)C)C1CCCCC1,CBR-HVAC-14982
CBR-001-702-732-6,RFM-012-139-1,CBR-001-702-732-6,COCC1OC(=O)N(C1)c1ccc(cc1)OCc1cccc(c1)C(=O)N,CBR-HVAC-14970
CBR-001-702-733-7,RFM-012-140-4,CBR-001-702-733-7,COC(=O)c1cnc(nc1C(F)(F)F)Nc1cccc(c1)Cl,CBR-HVAC-15093
CBR-001-702-734-8,RFM-012-141-5,CBR-001-702-734-8,COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1noc(c1)C)C,CBR-HVAC-15072
CBR-001-702-735-9,RFM-012-142-6,CBR-001-702-735-9,CCOC(=O)c1nc2n(c1)c(C)c(c(n2)OC)CC,CBR-HVAC-14939
CBR-001-702-736-0,RFM-012-143-7,CBR-001-702-736-0,CCOC(=O)C1(CCN(CC1)CCc1ccc(cc1)NC(=O)C)c1ccccc1,CBR-HVAC-14927
CBR-001-702-737-1,RFM-012-144-8,CBR-001-702-737-1,O=C(/C=C/c1ccc(cc1)O)NC[C@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-15051
CBR-001-702-738-2,RFM-012-145-9,CBR-001-702-738-2,O=C1CCC2(C(=O)N1)CCC(=O)c1c2ccc(c1)C,CBR-HVAC-15027
CBR-001-702-739-3,RFM-012-146-0,CBR-001-702-739-3,COc1cc2c(cc1OC)CCN(C2C)S(=O)(=O)C,CBR-HVAC-15014
CBR-001-702-740-6,RFM-012-147-1,CBR-001-702-740-6,OCCN1CCN(CC1)c1nnc(c(c1)c1ccccc1)C(F)(F)F,CBR-HVAC-14909
CBR-001-702-741-7,RFM-012-148-2,CBR-001-702-741-7,CC(=O)N1CCN(CC1)c1nnc(c(c1)c1ccccc1)C(F)(F)F,CBR-HVAC-15021
CBR-001-702-742-8,RFM-012-149-3,CBR-001-702-742-8,O=C(/C=C/c1ccc(cc1)N)NC[C@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-14906
CBR-001-702-743-9,RFM-012-150-6,CBR-001-702-743-9,O=C(/C=C/c1ccc(cc1)C)NC[C@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-14998
CBR-001-702-744-0,RFM-012-151-7,CBR-001-702-744-0,O=C(/C=C/c1ccc(cc1)F)NC[C@H]1OC(=O)N(C1)c1ccc(c(c1)F)N1CCOCC1,CBR-HVAC-15024
CBR-001-702-745-1,RFM-012-152-8,CBR-001-702-745-1,NCCN1CCN(CC1)c1nnc(c(c1)c1ccccc1)C(F)(F)F,CBR-HVAC-14947
CBR-001-702-746-2,RFM-012-153-9,CBR-001-702-746-2,COc1ccc(c(c1)c1ccc(nc1N)NC(=O)c1cnn(c1)C)Cl,CBR-HVAC-14937
CBR-001-702-747-3,RFM-012-154-0,CBR-001-702-747-3,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCC1CCN(CC1)C(=O)OC(C)(C)C,CBR-HVAC-14936
CBR-001-702-748-4,RFM-012-155-1,CBR-001-702-748-4,CCCN(C(=O)C(NC(=O)c1cccc(c1)Cl)Cc1ccc(cc1)OCCCN1CCN(CC1)C)CCC,CBR-HVAC-15046
CBR-001-702-749-5,RFM-012-156-2,CBR-001-702-749-5,O=C(c1ccc(cc1)c1ccc(cc1)C(F)(F)F)N[C@H](C(=O)N)Cc1ccc(cc1)c1ccccc1,CBR-HVAC-14977
CBR-001-702-750-8,RFM-012-157-3,CBR-001-702-750-8,COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)O)C,CBR-HVAC-14935
CBR-001-702-751-9,RFM-012-158-4,CBR-001-702-751-9,CC(N1CCN(CC1)c1nnc(c(c1)c1ccccc1)C(F)(F)F)C,CBR-HVAC-14989
CBR-001-702-752-0,RFM-012-159-5,CBR-001-702-752-0,CCCN(C(=O)C(NC(=O)c1ccc(cc1)C#N)Cc1ccc(cc1)OCCCN1CCN(CC1)C)CCC,CBR-HVAC-15007
CBR-001-702-753-1,RFM-012-160-8,CBR-001-702-753-1,COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1ccn(n1)C)C,CBR-HVAC-15058
CBR-001-702-754-2,RFM-012-161-9,CBR-001-702-754-2,CCCN(C(=O)C(NC(=O)c1cccc(c1)F)Cc1ccc(cc1)OCCCN1CCN(CC1)C)CCC,CBR-HVAC-15030
CBR-001-702-755-3,RFM-012-162-0,CBR-001-702-755-3,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCc1cscc1,CBR-HVAC-14537
CBR-001-702-756-4,RFM-012-163-1,CBR-001-702-756-4,OCCCN1C(=O)CN2C(c3c1ccc(c3)Cl)(OCC2)c1ccccc1F,CBR-HVAC-15052
CBR-001-702-757-5,RFM-012-164-2,CBR-001-702-757-5,OC(=O)[C@@H](NC(=O)c1ccc(cc1)c1ccc(cc1)C(F)(F)F)Cc1ccc(cc1)O,CBR-HVAC-15049
CBR-001-702-758-6,RFM-012-165-3,CBR-001-702-758-6,O=C(c1ccncc1)Oc1ccc(cc1C(C)(C)C)C1CCCCC1,CBR-HVAC-14934
CBR-001-702-759-7,RFM-012-166-4,CBR-001-702-759-7,COc1c(OC)cc(cc1C(=O)NC[C@@H]1CCCCN1C(=O)OC(C)(C)C)S(=O)(=O)NC,CBR-HVAC-15078
CBR-001-702-760-0,RFM-012-167-5,CBR-001-702-760-0,CCCN(C(=O)C(NC(=O)c1ccc(cc1)Br)Cc1ccc(cc1)OCCCN1CCN(CC1)C)CCC,CBR-HVAC-14966
CBR-001-702-761-1,RFM-012-168-6,CBR-001-702-761-1,CCCN(C(=O)C(NC(=O)c1ccc(cc1)F)Cc1ccc(cc1)OCCCN1CCN(CC1)C)CCC,CBR-HVAC-14925
CBR-001-702-762-2,RFM-012-169-7,CBR-001-702-762-2,O=C1CCC2(C(=O)N1)CCC(=O)c1c2ccc(c1)Cl,CBR-HVAC-15054
CBR-001-702-763-3,RFM-012-170-0,CBR-001-702-763-3,COC[C@@H](Oc1cc(Oc2cnc(cn2)C(=O)N2CCC2)cc(c1)C(=O)Nc1ccc(cc1)OC)C,CBR-HVAC-15079
CBR-001-702-764-4,RFM-012-171-1,CBR-001-702-764-4,COC(=O)[C@H](Cc1ccc(cc1)c1ccccc1)NC(=O)c1ccc(cc1)c1ccc(cc1)C(F)(F)F,CBR-HVAC-14916
CBR-001-702-765-5,RFM-012-172-2,CBR-001-702-765-5,NC(=O)c1cccc(c1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCNCC1CCCCC1,CBR-HVAC-14932
CBR-001-702-766-6,RFM-012-173-3,CBR-001-702-766-6,N#CC(c1ccccc1)(c1ccccc1)CCN1CCC(C1)(C(=O)O)c1ccccc1,CBR-HVAC-14978
CBR-001-702-767-7,RFM-012-174-4,CBR-001-702-767-7,C=CCN1C(=O)CN2C(c3c1ccc(c3)Cl)(OCC2)c1ccccc1F,CBR-HVAC-15000
CBR-001-702-768-8,RFM-012-175-5,CBR-001-702-768-8,O=C(Cc1ccc(cc1)Cl)Nc1ccc2c(c1)n(CCN1CCCC1)nc2,CBR-HVAC-15070
CBR-001-702-769-9,RFM-012-176-6,CBR-001-702-769-9,COc1cc2nc(nc(c2cc1OC)N)N1CCNCC1,CBR-HVAC-14931
CBR-001-702-770-2,RFM-012-177-7,CBR-001-702-770-2,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)NCC1CCNCC1,CBR-HVAC-14975
CBR-001-702-771-3,RFM-012-178-8,CBR-001-702-771-3,CCN(c1nccc(n1)NCc1ccc(cc1)CNc1nc(Cl)ncc1F)CC,CBR-HVAC-15010
CBR-001-702-772-4,RFM-012-179-9,CBR-001-702-772-4,CCCc1ccc(c(=O)n1CC(=O)NCc1ccccc1OC)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-15077
CBR-001-702-773-5,RFM-012-180-2,CBR-001-702-773-5,CCOCCn1nc(c2c1c(Nc1nccc(c1)C)nc(n2)N(CC)C)C(=O)OC,CBR-HVAC-14914
CBR-001-702-774-6,RFM-012-181-3,CBR-001-702-774-6,Cc1nc2c(n1)cc(cc2)C(=O)c1ccccc1,CBR-HVAC-14974
CBR-001-702-775-7,RFM-012-182-4,CBR-001-702-775-7,O=C(Cc1ccc(cc1)F)Nc1ccc2c(c1)n(CCN1CCCC1)nc2,CBR-HVAC-15034
CBR-001-702-776-8,RFM-012-183-5,CBR-001-702-776-8,O=C(Cc1ccc(cc1)C(F)(F)F)Nc1ccc2c(c1)n(CCN1CCCC1)nc2,CBR-HVAC-15055
CBR-001-702-777-9,RFM-012-184-6,CBR-001-702-777-9,CCCc1ccc(c(=O)n1CC(=O)NCc1cccc(c1)OC)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-15084
CBR-001-702-778-0,RFM-012-185-7,CBR-001-702-778-0,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)N1CCCCC1,CBR-HVAC-15032
CBR-001-702-779-1,RFM-012-186-8,CBR-001-702-779-1,Clc1ccc(cc1)c1nc2n(c1CN(C(=O)c1c(Cl)cccc1Cl)C)cccc2,CBR-HVAC-14922
CBR-001-702-780-4,RFM-012-187-9,CBR-001-702-780-4,NCCN1C(=O)CN2C(c3c1ccc(c3)Cl)(OCC2)c1ccccc1F,CBR-HVAC-15064
CBR-001-702-781-5,RFM-012-188-0,CBR-001-702-781-5,COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1ccc(nc1)C)C,CBR-HVAC-15009
CBR-001-702-782-6,RFM-012-189-1,CBR-001-702-782-6,CCOC(=O)CCNC(=O)N[C@H]1CCN(C1=O)c1ccc(cc1)C(=N)NOC(=O)OCC,CBR-HVAC-15008
CBR-001-702-783-7,RFM-012-190-4,CBR-001-702-783-7,CCN1C(=O)CN2C(c3c1ccc(c3)Cl)(OCC2)c1ccccc1F,CBR-HVAC-14951
CBR-001-702-784-8,RFM-012-191-5,CBR-001-702-784-8,O=C(c1ccc(cc1)c1ccc(cc1)C(F)(F)F)N[C@H](C(=O)O)Cc1ccccc1,CBR-HVAC-14990
CBR-001-702-785-9,RFM-012-192-6,CBR-001-702-785-9,Clc1ccc2c(c1)C1(OCCN1CC(=O)N2C)c1ccccc1F,CBR-HVAC-14905
CBR-001-702-786-0,RFM-012-193-7,CBR-001-702-786-0,CCOC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccccc1OC)C(=O)NC(C)(C)C,CBR-HVAC-15087
CBR-001-702-787-1,RFM-012-194-8,CBR-001-702-787-1,COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1ccc(cn1)C)C,CBR-HVAC-14972
CBR-001-702-788-2,RFM-012-195-9,CBR-001-702-788-2,CC(=CCOc1cc(ccc1Cl)NC(=O)c1ccccn1)C,CBR-HVAC-14944
CBR-001-702-789-3,RFM-012-196-0,CBR-001-702-789-3,O=C(Cc1ccccc1)Nc1ccc2c(c1)n(CCN1CCCC1)nc2,CBR-HVAC-14971
CBR-001-702-790-6,RFM-012-197-1,CBR-001-702-790-6,Clc1cccc(c1)Nc1ncc(c(n1)C(F)(F)F)C(=O)N1CCC1,CBR-HVAC-15006
CBR-001-702-791-7,RFM-012-198-2,CBR-001-702-791-7,CCOC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1)OC)C(=O)NC(C)(C)C,CBR-HVAC-15089
CBR-001-702-792-8,RFM-012-199-3,CBR-001-702-792-8,COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1cnc(nc1)C)C,CBR-HVAC-15029
CBR-001-702-793-9,RFM-012-200-9,CBR-001-702-793-9,CN(CCNc1nccc(n1)NCc1ccc(cc1)CNc1nc(Cl)ncc1F)C,CBR-HVAC-14929
CBR-001-702-794-0,RFM-012-201-0,CBR-001-702-794-0,CC(=O)SCC(C(=O)N[C@H](C(=O)O)C)Cc1ccc2c(c1)OCO2,CBR-HVAC-14144
CBR-001-702-795-1,RFM-012-202-1,CBR-001-702-795-1,CC(=O)SCC(C(=O)N[C@H](C(=O)O)C)Cc1ccc2c(c1)OCO2,CBR-HVAC-14144
CBR-001-702-796-2,RFM-012-203-2,CBR-001-702-796-2,CCOC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1)C#N)C(=O)NC(C)(C)C,CBR-HVAC-15086
CBR-001-702-797-3,RFM-012-204-3,CBR-001-702-797-3,OCC12CN(CC(=O)N2CC2(O1)CCNCC2)S(=O)(=O)c1ccc2c(c1)ccc(c2)Cl,CBR-HVAC-14928
CBR-001-702-798-4,RFM-012-205-4,CBR-001-702-798-4,O=C(Cc1ccc(cc1)O)Nc1ccc2c(c1)n(CCN1CCCC1)nc2,CBR-HVAC-14926
CBR-001-702-799-5,RFM-012-206-5,CBR-001-702-799-5,CCOC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1)Cl)C(=O)NC(C)(C)C,CBR-HVAC-15091
CBR-001-702-800-1,RFM-012-207-6,CBR-001-702-800-1,CCCc1ccc(c(=O)n1CC(=O)NCc1ccccc1)NS(=O)(=O)Cc1ccccc1,CBR-HVAC-15063
CBR-001-702-801-2,RFM-012-208-7,CBR-001-702-801-2,COc1c(OC)cc(cc1C(=O)NC[C@@H]1CCCCN1C)S(=O)(=O)NC,CBR-HVAC-15044
CBR-001-702-802-3,RFM-012-209-8,CBR-001-702-802-3,COc1nc(N)c2c(n1)n(cn2)C1CCCC1,CBR-HVAC-15005
CBR-001-702-803-4,RFM-012-210-1,CBR-001-702-803-4,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1CCCCC1,CBR-HVAC-14968
CBR-001-702-804-5,RFM-012-211-2,CBR-001-702-804-5,CCN(CCNc1nccc(n1)NCc1ccc(cc1)CNc1nc(Cl)ncc1F)CC,CBR-HVAC-14967
CBR-001-702-805-6,RFM-012-212-3,CBR-001-702-805-6,COc1ccccc1S(=O)(=O)Nc1cc(ccc1Oc1cc(F)c(cc1Cl)CC(=O)O)C(=O)NC(C)(C)C,CBR-HVAC-14531
CBR-001-702-806-7,RFM-012-213-4,CBR-001-702-806-7,COc1cc2nc(nc(c2cc1OC)N)N1CCN(CC1)C(=O)C1CCCC1,CBR-HVAC-15004
CBR-001-702-807-8,RFM-012-214-5,CBR-001-702-807-8,Clc1ccc(cc1)c1nc2n(c1CN(C(=O)Cc1ccccc1)C)cccc2,CBR-HVAC-14962
CBR-001-702-808-9,RFM-012-215-6,CBR-001-702-808-9,CCOC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1c(Cl)cccc1Cl)C(=O)NC(C)(C)C,CBR-HVAC-15088
CBR-001-702-809-0,RFM-012-216-7,CBR-001-702-809-0,CCOCCn1nc(c2c1c(Nc1nccc(c1)C)nc(n2)N(CC)C)C(=O)N,CBR-HVAC-14965
CBR-001-702-810-3,RFM-012-217-8,CBR-001-702-810-3,O=C(C1CCN(CC1)C(=O)Cn1c(=O)sc2c1cc(Cl)cc2)Nc1ccc(cc1)C(F)(F)F,CBR-HVAC-15067
CBR-001-702-811-4,RFM-012-218-9,CBR-001-702-811-4,COc1ccc(cc1)S(=O)(=O)Nc1cc(ccc1Oc1cc(F)c(cc1Cl)CC(=O)O)C(=O)NC(C)(C)C,CBR-HVAC-14527
CBR-001-702-812-5,RFM-012-219-0,CBR-001-702-812-5,COC(=O)c1ccc(c(c1)c1cccc(c1)NCCNCC(c1cccc(c1)Cl)O)C,CBR-HVAC-14911
CBR-001-702-813-6,RFM-012-220-3,CBR-001-702-813-6,N#Cc1ccc(cc1)S(=O)(=O)Nc1cc(ccc1Oc1cc(F)c(cc1Cl)CC(=O)O)C(=O)NC(C)(C)C,CBR-HVAC-14529
CBR-001-702-814-7,RFM-012-221-4,CBR-001-702-814-7,CCOC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1)C)C(=O)NC(C)(C)C,CBR-HVAC-15090
CBR-001-702-815-8,RFM-012-222-5,CBR-001-702-815-8,O=C(c1cc2CCCCCCc2n(c1=O)CC1CCCCC1)NC(C(=O)N1CC(C1)NS(=O)(=O)C)(C)C,CBR-HVAC-15003
CBR-001-702-816-9,RFM-012-223-6,CBR-001-702-816-9,OC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1)Cl)C(=O)NC(C)(C)C,CBR-HVAC-14528
CBR-001-702-817-0,RFM-012-224-7,CBR-001-702-817-0,c1ccc(cc1)COc1ccc(cc1)CCNc1ccc2c(c1)n(CCN1CCCC1)nc2,CBR-HVAC-15002
CBR-001-702-818-1,RFM-012-225-8,CBR-001-702-818-1,NNC(=O)C(NC(=O)c1cc2CCCCCCc2n(c1=O)CC1CCCCC1)(C)C,CBR-HVAC-15056
CBR-001-702-819-2,RFM-012-226-9,CBR-001-702-819-2,CCNC(=O)c1cnc2n1CCc1c(C32CCNCC3)cccc1,CBR-HVAC-15028
CBR-001-702-820-5,RFM-012-227-0,CBR-001-702-820-5,CCCNC(=O)c1cnc2n1CCc1c(C32CCNCC3)cccc1,CBR-HVAC-15053
CBR-001-702-821-6,RFM-012-228-1,CBR-001-702-821-6,CC(NC(=O)c1cnc2n1CCc1c(C32CCNCC3)cccc1)C,CBR-HVAC-15066
CBR-001-702-822-7,RFM-012-229-2,CBR-001-702-822-7,COc1nc(N)c2c(n1)n(cn2)C1CCCCC1,CBR-HVAC-14920
CBR-001-702-823-8,RFM-012-230-5,CBR-001-702-823-8,CC(=O)C1c2cccc(c2C(=O)c2c1cccc2O)O,CBR-HVAC-14919
CBR-001-702-824-9,RFM-012-231-6,CBR-001-702-824-9,COc1ccc(cc1)NC(=O)C1CCN(CC1)C(=O)Cn1c(=O)sc2c1cc(Cl)cc2,CBR-HVAC-15050
CBR-001-702-825-0,RFM-012-232-7,CBR-001-702-825-0,CSc1ccc(cc1)Oc1ccc(cc1CN(C)C)S(=O)(=O)NC,CBR-HVAC-14918
CBR-001-702-826-1,RFM-012-233-8,CBR-001-702-826-1,CSc1ccc(cc1)Oc1ccc(cc1CN(C)C)S(=O)(=O)N(C)C,CBR-HVAC-14960
CBR-001-702-827-2,RFM-012-234-9,CBR-001-702-827-2,CC(=O)NCC1ON=C(C1)c1ccc(cc1)C1=CCNCC1,CBR-HVAC-14917
CBR-001-702-828-3,RFM-012-235-0,CBR-001-702-828-3,OC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1c(Cl)cccc1Cl)C(=O)NC(C)(C)C,CBR-HVAC-14530
CBR-001-702-829-4,RFM-012-236-1,CBR-001-702-829-4,OC(=O)C1CCN(CC1)C(=O)Cn1c(=O)sc2c1cc(Cl)cc2,CBR-HVAC-14923
CBR-001-702-830-7,RFM-012-237-2,CBR-001-702-830-7,CNC(=O)c1cnc2n1CCc1c(C32CCNCC3)cccc1,CBR-HVAC-14999
CBR-001-702-831-8,RFM-012-238-3,CBR-001-702-831-8,COC(=O)CNC(=O)C(NC(=O)c1cc2CCCCCCc2n(c1=O)CC1CCCCC1)(C)C,CBR-HVAC-15033
CBR-001-702-832-9,RFM-012-239-4,CBR-001-702-832-9,OC(=O)Cc1cc(Cl)c(cc1F)Oc1ccc(cc1NS(=O)(=O)c1ccc(cc1)C)C(=O)NC(C)(C)C,CBR-HVAC-14526
CBR-001-702-833-0,RFM-012-240-7,CBR-001-702-833-0,Clc1ccc2c(c1)n(CC(=O)N1CCC(CC1)C(=O)Nc1ccc(c3c1cccc3)Br)c(=O)s2,CBR-HVAC-15083
CBR-001-702-834-1,RFM-012-241-8,CBR-001-702-834-1,NC(=O)C1CCN(CC1)C(=O)Cn1c(=O)sc2c1cc(Cl)cc2,CBR-HVAC-14963
CBR-001-702-835-2,RFM-012-242-9,CBR-001-702-835-2,CCOc1nc(N)c2c(n1)n(cn2)C1CCCC1,CBR-HVAC-15023
CBR-001-702-836-3,RFM-012-243-0,CBR-001-702-836-3,CN(CC(COc1ccccc1C1CC2CC1CC2)O)C,CBR-HVAC-14954
CBR-001-702-837-4,RFM-012-244-1,CBR-001-702-837-4,CCCCCCCCCCCC(=O)N(Cc1c(nc2n1cccc2)c1ccc(cc1)Cl)C,CBR-HVAC-15022
CBR-001-702-838-5,RFM-012-245-2,CBR-001-702-838-5,CCOCCn1nc(c2c1c(Nc1nccc(c1)C)nc(n2)N(CC)C)C(=O)NS(=O)(=O)c1ccc(cc1)C,CBR-HVAC-14996
CBR-001-702-839-6,RFM-012-246-3,CBR-001-702-839-6,O=C(C(C)C)OC[C@H]1O[C@H](O[C@H]2O[C@H](COC(=O)C(C)C)[C@H]([C@@H]([C@H]2O)O)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-14554
CBR-001-702-840-9,RFM-012-247-4,CBR-001-702-840-9,O=C(c1cc2CCCCCCc2n(c1=O)CC1CCCCC1)NC(C(=O)N1CCC(C1)NS(=O)(=O)C)(C)C,CBR-HVAC-14957
CBR-001-702-841-0,RFM-012-248-5,CBR-001-702-841-0,CCOC(=O)CCNC(=O)N[C@H]1CCN(C1=O)c1ccc(cc1)C(=N)NO,CBR-HVAC-14956
CBR-001-702-842-1,RFM-012-249-6,CBR-001-702-842-1,CCC(=O)C1c2cccc(c2C(=O)c2c1cccc2O)O,CBR-HVAC-14955
CBR-001-702-843-2,RFM-012-250-9,CBR-001-702-843-2,CCCNCC(COc1ccccc1C1CC2CC1CC2)O,CBR-HVAC-14904
CBR-001-702-844-3,RFM-012-251-0,CBR-001-702-844-3,COC(=O)c1ccccc1c1ccc2c(n1)ccc(c2)Cn1c(CC)nc2c1nc(C)cc2C,CBR-HVAC-14908
CBR-001-702-845-4,RFM-012-252-1,CBR-001-702-845-4,CCCOc1nc(N)c2c(n1)n(cn2)C1CCCC1,CBR-HVAC-15043
CBR-001-702-846-5,RFM-012-253-2,CBR-001-702-846-5,COC(=O)C(c1ccc2c(c1)nc(o2)c1ccc(cc1)F)C,CBR-HVAC-14907
CBR-001-702-847-6,RFM-012-254-3,CBR-001-702-847-6,CCCC(=O)OC[C@H]1O[C@H](O[C@H]2O[C@H](COC(=O)CCC)[C@H]([C@@H]([C@H]2O)O)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-14553
CBR-001-702-848-7,RFM-012-255-4,CBR-001-702-848-7,CCOCCn1nc(c2c1c(Nc1nccc(c1)C)nc(n2)N(CC)C)C(=O)NS(=O)(=O)CC,CBR-HVAC-15020
CBR-001-702-849-8,RFM-012-256-5,CBR-001-702-849-8,CCOc1ccc(cn1)NC(=O)c1cccc2c1OC[C@@H](N2c1ccc(cn1)C)CO,CBR-HVAC-14994
CBR-001-702-850-1,RFM-012-257-6,CBR-001-702-850-1,CCCCC(=O)C1c2cccc(c2C(=O)c2c1cccc2O)O,CBR-HVAC-14992
CBR-001-702-851-2,RFM-012-258-7,CBR-001-702-851-2,CCOC(=O)COc1cccc(c1)CCc1nc(c(o1)c1ccccc1)c1ccccc1,CBR-HVAC-14952
CBR-001-702-852-3,RFM-012-259-8,CBR-001-702-852-3,CC(=O)NCC1ON=C(C1)c1ccc(cc1)C1=CCN(CC1)C(=O)C,CBR-HVAC-14950
CBR-001-702-853-4,RFM-012-260-1,CBR-001-702-853-4,CCOc1nc(N)c2c(n1)n(cn2)C1CCCCC1,CBR-HVAC-14949
CBR-001-702-854-5,RFM-012-261-2,CBR-001-702-854-5,COC(=O)C[C@H]1CCCCN1C(=O)/C=C/c1c(nn2c1cccc2)c1ccccc1,CBR-HVAC-14902
CBR-001-702-855-6,RFM-012-262-3,CBR-001-702-855-6,O[C@H]1[C@@H](O[C@H]2O[C@H](COC(=O)C3CCCCC3)[C@H]([C@@H]([C@H]2O)O)O)O[C@@H]([C@H]([C@@H]1O)O)COC(=O)C1CCCCC1,CBR-HVAC-14556
CBR-001-702-856-7,RFM-012-263-4,CBR-001-702-856-7,Clc1ccc2c(c1)n(CC(=O)N1CCC(CC1)C(=O)Nc1cccc3c1cccc3)c(=O)s2,CBR-HVAC-14991
CBR-001-702-857-8,RFM-012-264-5,CBR-001-702-857-8,CCNCC(COc1ccccc1C1CC2CC1CC2)O,CBR-HVAC-14988
CBR-001-702-858-9,RFM-012-265-6,CBR-001-702-858-9,CCN(CC(COc1ccccc1C1CC2CC1CC2)O)CC,CBR-HVAC-15018
CBR-001-702-859-0,RFM-012-266-7,CBR-001-702-859-0,COC(=O)COc1cccc(c1)CCc1nc(c(o1)c1ccccc1)c1ccccc1,CBR-HVAC-14897
CBR-001-702-860-3,RFM-012-267-8,CBR-001-702-860-3,CN(CCNC(=O)C(NC(=O)c1cc2CCCCCCc2n(c1=O)CC1CCCCC1)(C)C)C,CBR-HVAC-15069
CBR-001-702-861-4,RFM-012-268-9,CBR-001-702-861-4,CS(=O)(=O)c1ccc(cc1)c1nc2n(c1c1ccncc1)CCC2,CBR-HVAC-14946
CBR-001-702-862-5,RFM-012-269-0,CBR-001-702-862-5,CCCCCCC(=O)OC[C@H]1O[C@H](O[C@H]2O[C@H](COC(=O)CCCCCC)[C@H]([C@@H]([C@H]2O)O)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-14552
CBR-001-702-863-6,RFM-012-270-3,CBR-001-702-863-6,CN1CCOC(C1)COc1cccc2c1N(C)CCC2,CBR-HVAC-14895
CBR-001-702-864-7,RFM-012-271-4,CBR-001-702-864-7,CCNc1ncnc(c1)c1csc(n1)N(C(=O)c1ccc(cc1)F)C,CBR-HVAC-14945
CBR-001-703-096-5,RFM-012-272-5,CBR-001-703-096-5,CO/N=C(\c1csc(n1)N)/C(=O)NC1C(=O)N2[C@@H]1SCC(=C2C(=O)OCOC(=O)C(C)(C)C)Cn1nnc(n1)C,"CBR-HVAC-02053: Cell wall synthesis inhibitor; Inhibitor; PENICILLIN BINDING PROTEIN 1A; PENICILLIN BINDING PROTEIN 1BS; PENICILLIN BINDING PROTEIN 3 Inhibitor; ANTI-BACTERIAL; Antibiotics; Dental Agents
"
CBR-001-703-097-6,RFM-012-273-6,CBR-001-703-097-6,OC[C@H]([C@H]([C@@H]([C@H](CO)O)O)O[C@@H]1O[C@H](CO)[C@@H]([C@@H]([C@H]1O)O)O)O,"CBR-HVAC-12855: Osmosis stimulant (non-diuretic); Propulsive, Improved blood ammonia concentrations.; Constipation, Agents for; Liver and Biliary Tract Disorders, Treatment of; Propulsive

"
CBR-001-703-098-7,RFM-012-274-7,CBR-001-703-098-7,CCCCN(CCCC)CCNc1onc(n1)c1ccccc1,"CBR-HVAC-09712: It has a stimulating effect on the blood flow, without affecting the cardiovascular system. Oxygen supply in the diseased vascular areas is improved.; Vasodilator
"
CBR-001-703-099-8,RFM-012-275-8,CBR-001-703-099-8,c1ccc(cc1)Oc1nncc2c1cccc2,"CBR-HVAC-10692: Inhibition of TxB2 release; Thromboxane B2 receptor antagonist; Analgesic; Anti-inflammatory; Anticonvulsant; Antipyretic; Non-Opioid Analgesics
"
CBR-001-703-100-4,RFM-012-276-9,CBR-001-703-100-4,OCCOCn1cnc2c1nc(N)nc2,"CBR-HVAC-01173: DNA directed DNA polymerase inhibitor; Antiviral; Antiviral Drugs
"
CBR-001-703-101-5,RFM-012-277-0,CBR-001-703-101-5,CC(NC(Cc1ccc(cn1)O)C)C,"CBR-HVAC-04096: Creatine kinase inhibitor; Angina pectoris, Treatment of; Cognition Disorders, Treatment of
"
CBR-001-703-102-6,RFM-012-278-1,CBR-001-703-102-6,N#Cc1ccc(n1C)c1cc(F)c2c(c1)C(C)(C)C(=O)N2,"CBR-HVAC-06390: Progesterone Receptor Antagonists; Progesterone receptor Modulator; Progesterone receptor antagonist; Signal Transduction Modulators; Anticancer; Female Contraceptives
"
CBR-001-703-103-7,RFM-012-279-2,CBR-001-703-103-7,FC(CNC(=O)c1ccc(cc1)n1[nH]c2c(c1=O)nnc1c2cccc1F)F,"CBR-HVAC-12478: CD28; CD80 (B7-1) Inhibitors; CD80 Antagonist; Antiinflammatory; Gastrointestinal Disorders (Not Specified); Rheumatoid Arthritis, Treatment of; Treatment of Autoimmune Diseases
"
CBR-001-703-104-8,RFM-012-280-5,CBR-001-703-104-8,CCCN(c1cc(C)nc2n1nc(c2c1cnc(cc1C)N(C)C)C)CCC,CBR-HVAC-04975: Antidepressants;Anxiolytics; CRF1 Receptor Antagonists;Signal Transduction Modulators; Corticotropin releasing factor antagonist; Corticotropin releasing factor 1 receptor antagonist
CBR-001-703-201-8,RFM-012-281-6,CBR-001-703-201-8,CCn1c(=Cc2ccccn2)sc(=c2sc3c(n2C)cccc3)c1=O,CBR-HVAC-14577 : Heat Shock Protein 70 (Hsp70) Inhibitors
CBR-001-703-246-1,RFM-012-282-7,CBR-001-703-246-1,SCCNC(=O)c1cccc(c1)C(=O)NCCS,CBR-HVAC-14856: ANTI-OXIDANTCHELATING AGENT; MERCURY TOXICITY
CBR-001-703-247-2,RFM-012-283-8,CBR-001-703-247-2,CCc1nc(C)cn2c1cc(n2)c1cc(=O)n2c(n1)c(C)cc(c2)C1CCN(CC1)C,CBR-HVAC-14715: SMN2 Splicing Modulators
CBR-001-703-331-7,RFM-012-284-9,CBR-001-703-331-7,OC(=O)c1cc(F)c2c(c1)sc(n2)N1[C@@H]2CC[C@H]1C[C@H](C2)OCc1c(onc1c1ccccc1OC(F)(F)F)C1CC1,CBR-HVAC-14585: Farnesoid X Receptor (FXR) Agonists;Signal Transduction Modulators
CBR-001-703-333-9,RFM-012-285-0,CBR-001-703-333-9,CCCCCCCCCCCCCCOc1ccc(o1)C(=O)OCC(=O)N(CC(=O)OCC)C,CBR-HVAC-14759: Acetyl-CoA Carboxylase (ACC) Inhibitors
CBR-001-703-338-4,RFM-012-286-1,CBR-001-703-338-4,NCCCC[C@@H]1NC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H]3N(C(=O)[C@@H](NC1=O)Cc1ccc(cc1)O)CCC3)CCC2)CCCCCCCC)CCC(=O)O)[C@H](O)C)[C@H](CC)C,"CBR-HVAC-15104: Elastase inhibitor; Neutrophil Elastase (Leukocyte Elastase) Inhibitors; Neutrophil elastase Inhibitor; ANTI-INFLAMMATORY; Asthma Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Cystic Fibrosis, Treatment of ; Metabolic and Nutritional Genetic Disorders, Treatment of ; Multisystem Genetic Disorders, Treatment of ; Respiratory Disorders (Not Specified)"
CBR-001-703-462-7,RFM-012-287-2,CBR-001-703-462-7,OC(=O)CC[C@H](N1Cc2c(C1=O)ccc(c2)NCc1ccc2c(c1)c1c(=O)nc(nc1cc2)C)C(=O)O,CBR-HVAC-04442: Antimetabolites; THYMIDYLATE SYNTHASE Inhibitor; Thymidylate Synthase Inhibitors; Thymidylate synthase inhibitor; Antineoplastic; Antitumor; Solid Tumors Therapy
CBR-001-703-803-8,RFM-012-288-3,CBR-001-703-803-8,COc1ccccc1[C@H](Cn1c(=O)n(c(=O)c2c1sc(c2C)c1ncco1)C(C(=O)O)(C)C)OC1CCOCC1,"CBR-HVAC-14498:ACETYL-COENZYME A CARBOXYLASE 1; ACETYL-COENZYME A CARBOXYLASE 2 Inhibitor; Acetyl Coenzyme A carboxylase inhibitor; Acetyl-CoA Carboxylase 1 (ACC1) Inhibitors; Acetyl-CoA Carboxylase 2 (ACC2) Inhibitors; Lipid Lowering Agents; ANTI-OBESITY; Antidiabetic Drugs; Antiobesity Drugs; Liver and Biliary Tract Disorders, Treatment of"
CBR-001-704-005-0,RFM-012-289-4,CBR-001-704-005-0,NC(=N)NCCC[C@H]1NC(=O)[C@H](CCCCNC(C)C)NC(=O)[C@@H](Cc2ccc(cc2)O)NC(=O)[C@@H](NC(=O)CC[C@@H](NC(=O)CNC(=O)[C@@H](NC1=O)Cc1ccc2c(c1)cccc2)C(=O)N[C@H](C(=O)N)CCCCNC(C)C)Cc1ccccc1,"CBR-HVAC-14400: CXC chemokine receptor 4 antagonist; Chemokine C-X-C motif receptor 4 Inhibitor; Chemokine CXCR4 (SDF-1 Receptor) Antagonists; Chemokine receptor antagonist; Signal Transduction Modulators; Anticancer; Myeloid Leukemia Therapy; Renal Cancer Therapy; Small Cell Lung Cancer Therapy
"
CBR-001-704-006-1,RFM-012-290-7,CBR-001-704-006-1,CCCCCCCCCCCCOc1ccc(cc1NC(=N)N)NC(=N)N,"CBR-HVAC-08893: Antiprotozoal
"
CBR-001-704-007-2,RFM-012-291-8,CBR-001-704-007-2,CCCCCCCCC#CCC#CCC#CCCCC(=O)N1CCN(CC1)CCO,"CBR-HVAC-03573: Antiinflammatory Drugs; Lipoxygenase Inhibitor; Lipoxygenase inhibitor; Antiinflammatory
"
CBR-001-704-008-3,RFM-012-292-9,CBR-001-704-008-3,O=C(Nc1c(cccc1C(C)C)C(C)C)NCC1(O[C@H]([C@H](O1)C)C)c1ccc(cc1)N1CC=CC1,"CBR-HVAC-11615: Acyl CoA:cholesterol acyltransferase Inhibitor; Antiatherosclerotic; Antihyperlipidemic
"
CBR-001-704-009-4,RFM-012-293-0,CBR-001-704-009-4,C#C[C@H]1CC[C@H](N1C(=O)CNC1(C)CCN(CC1)c1nccc(c1)C(=O)O)C#N,"CBR-HVAC-06413: Dipeptidyl Peptidase IV (CD26; DPP-IV; DP-IV) Inhibitors; Dipeptidyl peptidase 4 Inhibitor; Signal Transduction Modulators; Antidiabetic; Hypoglycemic; Type 2 Diabetes, Agents for
"
CBR-001-704-010-7,RFM-012-294-1,CBR-001-704-010-7,NCCc1ccc(c2c1sc(=O)[nH]2)OCCCS(=O)(=O)CCOCCc1cccc2c1cccc2,"CBR-HVAC-14584: Byproduct of AR-C69457AA
"
CBR-001-704-011-8,RFM-012-295-2,CBR-001-704-011-8,OCC([C@H](C(=O)NCCC(=O)NCCSc1c2SCC(=O)Nc2c2c(c1O)cccc2)O)(C)C,"CBR-HVAC-11245: Aromatase Inhibitor; Anticancer
"
CBR-001-704-012-9,RFM-012-296-3,CBR-001-704-012-9,CCCCc1cc(c(n1Cc1ccc(cc1)c1ccccc1c1nnn[nH]1)C=O)CC(C)C,"CBR-HVAC-11916: Angiotensin AT1 Antagonists; Angiotensin II AT-1 receptor Antagonist; Signal Transduction Modulators; Antihypertensive; Hypertension, Treatment of
"
CBR-001-704-013-0,RFM-012-297-4,CBR-001-704-013-0,Fc1ccc(cc1)Cc1ccc(o1)C(=O)C=C(c1[nH]cnn1)O,"CBR-HVAC-05389: HIV Integrase Inhibitors; HIV integrase inhibitor; Integrase Inhibitor; Anti-HIV; Anti-HIV Agents
"
CBR-001-704-014-1,RFM-012-298-5,CBR-001-704-014-1,C[C@@H]1CN(C[C@@H](N1)C)C[C@@H](C1(O)CCCCC1)c1cccc(c1)OC(F)(F)F,"CBR-HVAC-00204: Adrenergic transmitter uptake inhibitor; Norepinephrine Reuptake Inhibitors; Norepinephrine Transporter (NET) Inhibitors; Norepinephrine transporter Inhibitor; Signal Transduction Modulators; Neurologic Drugs (Miscellaneous); Norepinephrine transporter inhibitor; Treatment of Hot Flushes
"
CBR-001-704-015-2,RFM-012-299-6,CBR-001-704-015-2,C[C@@H]1CN(C[C@@H](N1)C)C[C@H](C1(O)CCCCC1)c1cccc(c1)OC(F)(F)F,"analog of CBR-HVAC-00204
"
CBR-001-704-016-3,RFM-012-300-2,CBR-001-704-016-3,CNc1nc(Nc2ccc(c(c2)OC)n2cnc(n2)C)nc2c1CC[C@H]2c1ccc(cc1)F,"CBR-HVAC-14356: gamma-Secretase Modulators; Alzheimer's Dementia, Treatment of
"
CBR-001-704-017-4,RFM-012-301-3,CBR-001-704-017-4,CNc1nc(Nc2ccc(c(c2)OC)n2cnc(n2)C)nc2c1CC[C@@H]2c1ccc(cc1)F,"analog of CBR-HVAC-14356
"
CBR-001-704-018-5,RFM-012-302-4,CBR-001-704-018-5,COc1ccc2c(c1)N(c1ccccc1F)C(=O)[C@@]2(CCC(=O)O)NC(=O)c1ncc2c(c1)cccc2,"CBR-HVAC-04810: CCK A receptor antagonist; CCK1 (CCKA) Antagonists; Cholecystokinin A receptor Antagonist; Signal Transduction Modulators; Antipancreatitis; Pancreatic Disorders, Treatment of
"
CBR-001-704-019-6,RFM-012-303-5,CBR-001-704-019-6,COc1ccc2c(c1)N(c1ccccc1F)C(=O)[C@]2(CCC(=O)O)NC(=O)c1ncc2c(c1)cccc2,analog of CBR-HVAC-04810
CBR-001-704-020-9,RFM-012-304-6,CBR-001-704-020-9,CNC(=O)[C@@H](NC(=O)[C@@H]([C@@H](C(=O)NO)CSc1ccccc1)CC(C)C)Cc1ccccc1,"CBR-HVAC-11370: Collagenase Inhibitors; Matrix metalloproteinase Inhibitor; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Antiinflammatory; Septic Shock, Treatment of
"
CBR-001-704-024-3,RFM-012-305-7,CBR-001-704-024-3,OC(=O)CC[Ge](=O)O[Ge](=O)CCC(=O)O,CBR-HVAC-02276
CBR-001-704-025-4,RFM-012-306-8,CBR-001-704-025-4,CN1CCN(CC1)c1ccc(cc1NC(=O)c1c[nH]c(=O)cc1C(F)(F)F)c1cccc(c1)CN1CCOCC1,"CBR-HVAC-15114: Epigenetic Modifier Modulators; WD repeat-containing protein 5 (WDR5; BIG3)/MLL1 Interaction Inhibitors; Leukemia Therapy; Myeloid Leukemia Therapy
"
CBR-001-704-026-5,RFM-012-307-9,CBR-001-704-026-5,[O-][N+](=O)c1ccc(c(c1)OC1CCCCC1)NS(=O)(=O)C,"CBR-HVAC-15109: COX-2 Inhibitor; Cyclooxygenase 1 inhibitor; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors; Signal Transduction Modulators; Chemopreventive Agents; Stroke, Treatment of
"
CBR-001-704-027-6,RFM-012-308-0,CBR-001-704-027-6,OC[C@H]1O[C@@H]([C@@H]([C@@H]1OP(=O)(O[C@@H](CNC(=O)CC[C@@]1(C)C2=N[C@H]([C@@H]1CC(=O)N)[C@]1(C)N([Co+]C#N)/C(=C(/C)\C3=N/C(=C\C4=N/C(=C\2/C)/[C@@H](CCC(=O)N)C4(C)C)/[C@H]([C@]3(C)CC(=O)N)CCC(=O)N)/[C@H]([C@]1(C)CC(=O)N)CCC(=O)N)C)[O-])O)n1cnc2c1cc(C)c(c2)C,CBR-HVAC-05499: Methionine synthase stimulant; Methylmalonyl CoA mutase stimulant; Vitamin B12 agonist; Vitamin B12 plays a vital role in the activities of several enzymes. It is essential for making the genetic material of cells and thus for growth and development. Vitamin B12 is particularly important in the formation of red blood cells. It is required for the utilisation of dietary folic acid and carbohydrates. It is also necessary for maintaining a healthy nervous system; Antiallergy/Antiasthmatic Drugs; Antianemics; Therapy of Vitamin-Related Disorders; Vitamin supplement
CBR-001-704-028-7,RFM-012-309-1,CBR-001-704-028-7,C#C[C@]1(O)CC[C@@H]2[C@]1(CC)CC[C@H]1[C@H]2CCC2=CC(=O)CC[C@H]12,"CBR-HVAC-12125: Aromatase Inhibitors; Progesterone receptor Modulator; Progesterone receptor agonist; Acne Therapy; Contraceptive; Female Contraceptives; Gynecological Disorders, Treatment of ; Oral Contraceptives; Ovarian Cancer Therapy; Postcoital Contraceptives; Progestogen; Treatment of Dysmenorrhea; Treatment of Menorrhagia
"
CBR-001-704-029-8,RFM-012-310-4,CBR-001-704-029-8,COc1cc2c(ncnc2cc1OCC1CCN(CC1)C)Nc1cc(OC)ccc1Cl,"CBR-HVAC-15112: Angiogenesis Inhibitors; SRC Inhibitor; Signal Transduction Modulators; Src Kinase Inhibitors; Src inhibitor; Anticancer; Oncolytic Drugs
"
CBR-001-704-030-1,RFM-012-311-5,CBR-001-704-030-1,COc1cc(ccc1OC)C[C@H]1c2cc(OC)c(cc2CCN1[C@H](c1ccccc1)C(=O)NC(C)C)OC,"CBR-HVAC-15111: Orexin OX-1 Receptor Antagonists; Orexin receptor antagonist; Signal Transduction Modulators; Anxiolytics; Mood Disorders, Treatment of; Treatment of Eating Disorders
"
CBR-001-704-031-2,RFM-012-312-6,CBR-001-704-031-2,O[C@@H]1[C@H](O)[C@H](O[C@H]1n1ccc(=O)[nH]c1=O)COP(=O)(O)O.O[C@@H]1[C@H](O)[C@H](O[C@H]1n1cnc2c1ncnc2N)COP(=O)(O)O,"CBR-HVAC-15115: double strand of poly-A and poly-U, represented as mixture of monomers"
CBR-001-704-032-3,RFM-012-313-7,CBR-001-704-032-3,CCc1ccc(cc1)C(CCc1ccc(cc1)[N+](C)(C)C)C,"CBR-HVAC-09688: Bile Acid Sequestrants; Inhibition of sodium chloride reabsorption in distal tubule of the kidney, resulting in increased urinary excretion of Sodium and water; Antidiarrheal Agents; Atherosclerosis Therapy; 
"
CBR-001-704-033-4,RFM-012-314-8,CBR-001-704-033-4,Cc1ccc(cc1)S(=O)(=O)N,"CBR-HVAC-15107: Cancer 

"
CBR-001-704-055-0,RFM-012-315-9,CBR-001-704-055-0,CC([C@H]1[C@@H]2N(CC[C@H]2N(C1=O)S(=O)(=O)C)C(=O)/C=C/CN1CCCCC1)C,"CBR-HVAC-15106: Elastase inhibitor; Leucocyte-elastase-inhibitors; Neutrophil Elastase (Leukocyte Elastase) Inhibitors; Neutrophil elastase 2 Inhibitor; Serine protease inhibitor; Antiinflammatory; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Respiratory Tract Disorders"
CBR-001-704-518-0,RFM-012-316-0,CBR-001-704-518-0,COC(=O)C1(CCN(CC1)CCC(=O)OC)N(c1ccccc1)C(=O)CC,CBR-HVAC-00956: Opioid receptor agonist; Opioid receptor mu Agonist; Signal Transduction Modulators; mu-Opioid Receptor Agonists; Analgesic; Narcotic; Opioid Analgesics
CBR-001-704-519-1,RFM-012-317-1,CBR-001-704-519-1,CCCC(C1(CC=C)C(=O)NC(=NC1=O)O)C,CBR-HVAC-03089: GABA-A receptor Blocker; Agents for Premedication; Hypnotic; Sedative; Sedative/Hypnotic
CBR-001-704-520-4,RFM-012-318-2,CBR-001-704-520-4,CCC(C#C)(/C=C/Cl)O,"CBR-HVAC-03098: Central and parasympathetic nervous systems to slow body function, reduce sensitivity to pain, and induce sleep. Low-dose or infrequent use produces analgesia, euphoria, and stupor, blocking desire for food, sex, and other activities; Hypnotic; Sedative/Hypnotics"
CBR-001-704-521-5,RFM-012-319-3,CBR-001-704-521-5,OC[C@@H]1CNC[C@@H]([C@H]1c1ccc(cc1)OCCCOCc1ccccc1OC)OCc1cc(OC)c2c(c1)cccc2,"CBR-HVAC-08580: Renin Inhibitor; Renin Inhibitors; Antiglaucoma Agents; Antihypertensive; Renal Failure, Agents for; Restenosis Treatment of"
CBR-001-704-522-6,RFM-012-320-6,CBR-001-704-522-6,CCC#CC(C1(CC=C)C(=O)N=C(N(C1=O)C)O)C,CBR-HVAC-09619: GABA-A receptor Agonist; Anesthetic
CBR-001-704-523-7,RFM-012-321-7,CBR-001-704-523-7,CCOC(=O)C1(CCN(CC1)C)c1cccc(c1)O,CBR-HVAC-09947: Analgesic; Narcotic
CBR-001-704-524-8,RFM-012-322-8,CBR-001-704-524-8,CCOC(c1ccccc1)(c1ccccc1)C(=O)OCCN(C)C,CBR-HVAC-09991: Analgesic; Narcotic
CBR-001-704-525-9,RFM-012-323-9,CBR-001-704-525-9,CCN(CCN1C(=O)CN=C(c2c1ccc(c2)Cl)c1ccccc1F)CC,CBR-HVAC-12743: Benzodiazepine receptor Agonist; GABA(A) BZ Site Receptor Agonists; Signal Transduction Modulators; Hypnotic; Sedative/Hypnotics
CBR-001-704-526-0,RFM-012-324-0,CBR-001-704-526-0,Clc1ccc2c(c1)C(=NC(C(=O)N2C)O)c1ccccc1Cl,"CBR-HVAC-12874: Benzodiazepine receptor Antagonist; Benzodiazepine receptor agonist; GABA(A) BZ Site Receptor Agonists; Signal Transduction Modulators; Hypnotic; Sleep Disorders, Treatment of"
CBR-001-704-527-1,RFM-012-325-1,CBR-001-704-527-1,O[C@@H]([C@@H](N(C)C)C)c1ccccc1,"CBR-HVAC-13092: Bronchodilator
"
CBR-001-704-528-2,RFM-012-326-2,CBR-001-704-528-2,CCN(C(C=C(c1cccs1)c1cccs1)C)CC,CBR-HVAC-13451: Analgesic; Narcotic
CBR-001-704-534-0,RFM-012-327-3,CBR-001-704-534-0,N#Cc1ccc(nc1)N(C(=O)c1ccn2c(c1)c(cn2)c1ccc(cc1)C(=O)N)C,CBR-HVAC-15105: Preclinical for cryptosporidium
CBR-001-704-561-3,RFM-012-328-4,CBR-001-704-561-3,CCC(C(C(=O)NCCN1CCOCC1)N)C,"CBR-HVAC-15108:Amyloid-beta-protein-inhibitors; Low-affinity Nerve Growth Factor Receptor LNGFRp75 Ligands; Neurotrophic Agents; Neurotrophin receptor agonist; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Alzheimer's Disease and Cognition Disorders; Cancer Associated Disorders, Treatment of; Lesions of the Spinal Cord and Related Structures, Treatment of; Treatment of AIDS-Associated Disorders
"
CBR-001-704-562-4,RFM-012-329-5,CBR-001-704-562-4,FC([C@@](c1ccc(cc1)n1cccn1)(Cc1ncc([nH]1)CC1(CC1)C(F)(F)F)O)(F)F,"CBR-HVAC-15110: Bombesin bb3 Agonists; Bombesin receptor 3 Agonist; Bombesin-receptor-agonists; Signal Transduction Modulators; Antiobes; Antiobesity Drugs; Obesity
"
CBR-001-704-563-5,RFM-012-330-8,CBR-001-704-563-5,O=C(Nc1ccccc1Br)Nc1ccc(cc1O)[N+](=O)[O-],"CBR-HVAC-15118:CXCR-receptor-antagonists; CXCR2 CHEMOKINE RECEPTOR Antagonist; Chemokine CXCR2 (IL-8 beta Receptor) Antagonists; Interleukin-8B-receptor-antagonists; Signal Transduction Modulators; Acute Respiratory Distress Syndrome (ARDS), Agents for; Antiallergy/Antiasthmatic Drugs; Antiarthritic Drugs; Antipsoriatics; Irritable Bowel Syndrome, Agents for; RESPIRATORY STIMULANT; Respiratory Tract Disorders; Septic Shock, Treatment of"
CBR-001-704-564-6,RFM-012-331-9,CBR-001-704-564-6,NC(c1ccccc1)C(=O)Cl,"CBR-HVAC-15117: an unlikely structure for CBT-001 (Thrombin inhibitor)
"
CBR-001-704-565-7,RFM-012-332-0,CBR-001-704-565-7,Nc1nc2ccccc2c2c1ncn2CC(O)(C)C,"CBR-HVAC-15113: Immunostimulants; Immunostimulants; Viral Infections
"
CBR-001-704-566-8,RFM-012-333-1,CBR-001-704-566-8,COC1=CC(=O)c2c(C1=O)c(C)c1c(c2O)C(=O)[C@]2([C@](C1)(O)[C@H](O[C@H]1CC[C@@H]([C@H](O1)C)O[C@@H]1O[C@@H](C)[C@H]([C@](C1)(C)O)OC(=O)c1c(C)ccc(c1O)C)C(=O)/C(=C(\O)/C)/C2=O)O,"CBR-HVAC-09864: Antibacterial; Antibiotics; Antineoplastic Antibiotics; Bacterial Infections
"
CBR-001-704-567-9,RFM-012-334-2,CBR-001-704-567-9,FC(C(C1(F)C(F)(F)C(F)(F)C(C(C1(F)F)(F)F)(F)F)(C(F)(F)F)C(F)(F)F)(F)F,"CBR-HVAC-00601:Neuroprotectant; Oxygen-carriers; Vulnerary agent; Blood Substitutes; Blood system agent; Drug Withdrawal; Haematological Disorders; Neurological Disorders; Neuroprotectant; Skin Disorders; Vascular Disorders; Vulnerary agent; Wound-Healing Agents
"
CBR-001-705-015-6,RFM-012-335-3,CBR-001-705-015-6,NCCCNCCCCNCCCN[C@H]1CC[C@]2([C@H](C1)C[C@H]([C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CC[C@H](C(C)C)OS(=O)(=O)O)C)C)O)C,"CBR-HVAC-12215: Adrenergic-uptake-inhibitors; Apoptosis-stimulants; Dopamine transporter; Dopamine-uptake-inhibitors; Neuropeptide-Y-modulators; Norepinephrine transporter; Protein Tyrosine Phosphatase PTP-1B Inhibitors; Protein tyrosine phosphatase 1B Inhibitor; Protein-tyrosine-phosphatase-inhibitors; Signal Transduction Modulators; Anti-HIV Agents; Antimicrobial; Antiobesity Drugs; Appetite suppressant; Breast Cancer Therapy; Cancer; Diabetes; Obesity; Type 2 Diabetes, Agents for; Viral Infections; Women's Health"
CBR-001-839-608-2,RFM-012-336-4,CBR-001-839-608-2,CCc1nc2n(c1N(c1sc(c(n1)c1ccc(cc1)F)C#N)C)cc(cc2C)N1CCN(CC1)CC(=O)N1CC(C1)O,"CBR-HVAC-14731: AUTOTAXIN Inhibitor; Ectonucleotide Pyrophosphatase/Phosphodiesterase 2 (ENPP2; Autotaxin) Inhibitors; ANTI-INFLAMMATORY; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Interstitial Lung Diseases, Treatment of"
CBR-001-839-998-9,RFM-012-337-5,CBR-001-839-998-9,OCC(=O)[C@@]1(O)CC[C@@H]2[C@]1(C)C[C@H](O)[C@]1([C@H]2CCC2=CC(=O)CC[C@]12C)F,"CBR-HVAC-06284: Aldosterone receptor Binder; Adrenocortical Dysfunction Therapy; Anti-inflammatory
"
CBR-001-839-999-0,RFM-012-338-6,CBR-001-839-999-0,O[C@@H]1[C@@H](O)[C@@H](O[C@@H]([C@H]1O)C(=O)O)O[C@H]1C=C[C@@H]2[C@@]34[C@H]1Oc1c4c(C[C@H]2N(CC3)C)ccc1O,CBR-HVAC-03881: Signal Transduction Modulators; mu-Opioid Receptor Agonists; Opioid Analgesics
CBR-001-840-000-5,RFM-012-339-7,CBR-001-840-000-5,OC[C@@H]1O[C@@H](C[C@H]1O)n1cc(C)c(=O)[nH]c1=O,"CBR-HVAC-01605: DNA Polymerase Inhibitors; DNA directed DNA polymerase inhibitor; HBV DNA polymerase inhibitor. It is phosphorylated by cellular kinases to the active triphosphate form, which inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate, thymidine 5'-triphosphate. Incorporation of telbivudine5'-triphosphate into viral DNA causes DNA chain termination, resulting in inhibition of HBV replication; Anti-Hepatitis B Virus Drugs; Antiviral"
CBR-001-840-001-6,RFM-012-340-0,CBR-001-840-001-6,NCCC[C@@H]1NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC1=O)CCN)CCN)Cc1cnc2c1cccc2)CCN)CCN)C)CO)[C@H](O)C)Cc1cnc2c1cccc2)[C@H](CC)C,"CBR-HVAC-14719: Imp-protein-inhibitors; Antibacterial Drugs; Bacterial Infections
"
CBR-001-840-109-7,RFM-012-341-1,CBR-001-840-109-7,CC#CC(=O)N1CC[C@H](C1)n1c(=O)n(c2c1ncnc2N)c1ccc(cc1)Oc1ccccc1,"CBR-HVAC-12547: Agammaglobulinaemia-tyrosine-kinase-inhibitors; BTK TYROSINE KINASE Inhibitor; Bruton's Tyrosine Kinase (BTK) Inhibitors; Bruton's tyrosine kinase inhibitor; Signal Transduction Modulators; ANTI-CANCER; Allergy, Treatment of; Anticoagulants; Cancer; Immunological Disorders; Inflammation, Treatment of; Lymphocytic Leukemia Therapy; Non-Hodgkin's Lymphoma Therapy; Rheumatic Disease; Rheumatoid Arthritis, Treatment of"
CBR-001-840-171-3,RFM-012-342-2,CBR-001-840-171-3,CCN(CCOc1ccc2c(c1)sc(n2)N(C)C)CC,CBR-HVAC-14831: ANTI-FUNGALNEUROPROTECTANT
CBR-001-840-506-6,RFM-012-343-3,CBR-001-840-506-6,O=C(Nc1ccc(c(c1)Cl)C)NCc1ccc2c(c1)CN(C2=O)C1CCC(=O)NC1=O,CBR-HVAC-14583: Arnab (CC-885 (targeting TNFa and ubiquitin. In SciFinder. Preclinical))
CBR-001-840-508-8,RFM-012-344-4,CBR-001-840-508-8,NCCCC[C@@H]1NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@@H](NC1=O)CCCCN)CCC2)Cc1ccc(cc1)O)CCCNC(=N)N)CCCNC(=O)N)C(=O)N[C@H](C(=O)N)CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc(cc1)F)CCCNC(=N)N)CCCNC(=N)N)Cc1ccc2c(c1)cccc2,CBR-HVAC-05970: Apoptosis Inducers; Apoptosis-stimulants; C-C chemokine receptor type 4 Antagonist; CXC chemokine receptor 4 antagonist; CXCR4-receptor-antagonists; Cell-movement-activators; Chemokine CXCR4 (SDF-1 Receptor) Antagonists; Signal Transduction Modulators; Antianemics; Anticancer; Brain Cancer Therapy; Cancer; Haematological Disorders; Hematological Cancer Therapy; Immunological Disorders; Lymphocytic Leukemia Therapy; Melanoma Therapy; Multiple Myeloma Therapy; Myelodysplastic Syndrome Therapy; Myeloid Leukemia Therapy; Non-Small Cell Lung Cancer Therapy; Pancreatic Cancer Therapy
CBR-001-840-513-5,RFM-012-345-5,CBR-001-840-513-5,CNc1ccc2c(c1C(=O)O)nc(o2)C[C@H]1O[C@@]2(CC[C@H]1C)O[C@@H]([C@@H](C[C@H]2C)C)[C@@H](C(=O)c1ccc[nH]1)C,CBR-HVAC-14131: ANTIBIOTIC; Antibiotics; Pharmacological Tools Class: Intracellular Calcium. Action: . Selectivity: Ca2+. Description: Ca2+ ionophore used to potentiate responses to NMDA. but not quisqualate glutamate receptors
CBR-001-841-081-6,RFM-012-346-6,CBR-001-841-081-6,OCCCOc1cccc2c1B(O)O[C@@H]2CN,CBR-HVAC-07042: Leucyl tRNA synthetase Inhibitor; Leucyl-tRNA Synthetase (Bacterial) Inhibitors; Leucyl-tRNA synthetase inhibitor; Antbacterial; Antibacterial Drugs
CBR-001-841-090-7,RFM-012-347-7,CBR-001-841-090-7,C=CCN1CC[C@@]23C4(C1Cc1c3c(O[C@H]2C(=O)CC4)c(cc1)O)O,CBR-HVAC-02633: Opioid receptor Antagonist; Opioid receptor antagonist
CBR-001-841-238-9,RFM-012-348-8,CBR-001-841-238-9,COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc2c([nH]1)cc(c(c2)[C@H]1CC[C@@H](N1c1cc(F)c(c(c1)F)N1CCC(CC1)c1ccc(cc1)F)c1cc2nc([nH]c2cc1F)[C@@H]1CCCN1C(=O)[C@H]([C@H](OC)C)NC(=O)OC)F)[C@H](OC)C,CBR-HVAC-14374: Hepatitis-C-virus-NS-5-protein-inhibitors; NS5A Inhibitor; Non-Structural Protein 5A (NS5A) (HCV) Inhibitors; ANTI-VIRAL; Anti-Hepatitis C Virus Drugs; Viral Infections 
CBR-001-841-352-0,RFM-012-349-9,CBR-001-841-352-0,CONC(=O)Nc1ccc(cc1)c1sc2c(c1CN(Cc1ccccc1)C)c(=O)n(c(=O)n2Cc1c(F)cccc1F)c1ccccc1,"CBR-HVAC-11112: GnRH (LHRH) Antagonists; Gonadotropin-releasing hormone receptor Antagonist; Gonadotropin-releasing-hormone-inhibitors; Luteinizing hormone releasing hormone (LHRH) antagonist; Signal Transduction Modulators; Endometriosis Therapy; Gonadotropin-releasing hormone receptor antagonist; Gynecological Disorders, Treatment of ; Women's Health"
CBR-001-841-356-4,RFM-012-350-2,CBR-001-841-356-4,CO[C@H]1C[C@H](O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]2[C@@H]3CC[C@]3([C@]2(O)C[C@@H]([C@@H]3C2=CC(=O)OC2)OC(=O)C)C)C)O[C@H]([C@@H]1O)C,"CBR-HVAC-06020: NF-kappaB (NFKB) Activation Inhibitors; Na+, K+ ATPase Inhibitor; Signal Transduction Modulators; Cardiotonic; Chemopreventive Agents; Heart Failure Therapy; Oncolytic Drugs"
CBR-001-841-467-0,RFM-012-351-3,CBR-001-841-467-0,COc1cc(NC(=O)CCN2CCC(CC2)OC(=O)Nc2ccccc2c2ccccc2)c(cc1CNC[C@@H](c1ccc(c2c1ccc(=O)[nH]2)O)O)Cl,"CBR-HVAC-06649: Agonist; Beta 2 adrenoreceptor agonist; Beta-2 adrenergic receptor Antagonist; Long-acting beta 2 adrenoceptor (LABA) agonist; Long-acting muscarinic antagonist; Muscarinic M3 receptor antagonist; Muscarinic Receptor Antagonists; Muscarinic antagonist-beta 2 agonist (MABA); Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Asthma Therapy; Bronchodilator; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of
"
CBR-001-841-468-1,RFM-012-352-4,CBR-001-841-468-1,COc1ccc(cc1)CC(NC[C@@H](c1cc(O)cc2c1OCC(=O)N2)O)(C)C,"CBR-HVAC-06615: BETA ADRENERGIC RECEPTOR Agonist; Beta 2 adrenoreceptor agonist; Beta-2-adrenergic-receptor-agonists; Cytochrome P450 CYP2C9 Inhibitors; Cytochrome P450 CYP3A4 Inhibitors; Long-acting beta 2 adrenoceptor (LABA) agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Anti-inflammatory; Asthma Therapy; Bronchodilator; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Obstructive Airways Disease; Respiratory Tract Disorders
"
CBR-001-841-469-2,RFM-012-353-5,CBR-001-841-469-2,O=C([C@H]1NC[C@H](C1)SC1=C(C(=O)[O-])N2[C@H]([C@H]1C)[C@H](C2=O)[C@H](O)C)Nc1cccc(c1)C(=O)[O-],"CBR-HVAC-02060: Cell wall synthesis inhibitor; Cell-wall-inhibitors; Penicillin binding protein Binder; Antibacterial; Antibacterial Drugs; Antibiotics; Bacterial Infections; Gynecological Disorders, Treatment of
"
CBR-001-841-470-5,RFM-012-354-6,CBR-001-841-470-5,Fc1ccc2c(c1)onc2C1CCN(CC1)CCc1c(C)nc2n(c1=O)cccc2C,"CBR-HVAC-04035: 5 Hydroxytryptamine 2 receptor antagonist; 5-HT2A Receptor Antagonists; 5-HYDROXYTRYPTAMINE 2A RECEPTOR; DOPAMINE D2 RECEPTOR Antagonist; Dopamine D2 Antagonists; Dopamine D2 receptor antagonist; Dopamine-D2-receptor-antagonists; Serotonin-2-receptor-antagonists; Signal Transduction Modulators; Antipsychotic; Antipsychotic Drugs; Psychotic Disorders
"
CBR-001-841-471-6,RFM-012-355-7,CBR-001-841-471-6,OC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](NC(=O)CCC(=O)OC[N+]1(CCOCC1)c1cc(=O)c2c(o1)c(ccc2)c1ccccc1)CCCNC(=N)N,"CBR-HVAC-06139: Angiogenesis Inhibitors; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors; Phosphatidylinositol 3-Kinase (PI3K) Inhibitors; Phosphoinositide 3 kinase Inhibitor; Signal Transduction Modulators; Anticancer; Head and Neck Cancer Therapy; Liver Cancer Therapy; Neurologic Cancer Therapy; Oncolytic Drugs
"
CBR-001-841-472-7,RFM-012-356-8,CBR-001-841-472-7,OC(c1ccc(c(c1)O)O)CNCCCCCCNCC(c1ccc(c(c1)O)O)O,"CBR-HVAC-07342: Beta-2 adrenergic receptor Agonist; Signal Transduction Modulators; beta2-Adrenoceptor Agonists; Antiasthmatic; Bronchodilator; Bronchodilators; Sympathomimetic; Tocolytic; Tocolytics
"
CBR-001-841-572-0,RFM-012-357-9,CBR-001-841-572-0,OC[C@H]([C@H]1O[Sb](=O)(O[C@H]([C@H]1O)C(=O)O)O[Sb]1(=O)O[C@H]([C@@H](CO)O)[C@@H]([C@@H](O1)C(=O)O)O)O,"CBR-HVAC-05652: Protein Tyrosine Phosphatase (PTP) Inhibitors; Signal Transduction Modulators; The exact mechanism of action is unknown but antimonial compounds readily react with sulfhydryl groups. Sodium stibogluconate is primarily used for the treatment of leishmaniasis.; Tyrosine phosphatase 1B inhibitor; Tyrosine phosphatase, non-receptor type 11 inhibitor; Tyrosine phosphatase, non-receptor type 6 inhibitor; Antileishmania; Antileishmanials; Myelodysplastic Syndrome Therapy; Oncolytic Drugs; Solid Tumors Therapy
"
CBR-050-068-249-5,RFM-012-358-0,CBR-050-068-249-5,NCc1cc(no1)O,"CBR-HVAC-14599: GABA(A) Receptor Agonists; Signal Transduction Modulators; Antiepileptic Drugs; Antiparkinsonian Drugs; Huntington's Disease, Treatment of; Pharmacological Tools"
CBR-050-068-250-8,RFM-012-359-1,CBR-050-068-250-8,C=C1CCC[C@]2([C@H]1CC1=C(C)C(=O)OC1=C2)C,"CBR-HVAC-14664: 5-Lipoxygenase Inhibitors; Angiogenesis Inhibitors; Apoptosis Inducers; Nitric Oxide Synthase Inhibitors; Signal Transduction Modulators; TNF-alpha Antagonists; Antiplatelet Therapy; Cancer Associated Disorders, Treatment of; Diuretics; Gastrointestinal Disorders (Not Specified); Immunomodulators; Inflammation, Treatment of; Liver and Biliary Tract Disorders, Treatment of; Oncolytic Drugs; Respiratory Disorders (Not Specified); Sepsis, Treatment of"
CBR-050-068-251-9,RFM-012-360-4,CBR-050-068-251-9,Oc1cc2O[C@H](c3cc(O)c(c(c3)O)O)[C@H](C(=O)c2c(c1)O)O,"CBR-HVAC-14657: Antioxidants; Apoptosis Inducers; GABA(A) BZ Site Receptor Modulators; NF-kappaB (NFKB) Activation Inhibitors; Signal Transduction Modulators; Viral Entry Inhibitors; Alzheimer's Dementia, Treatment of ; Anti-HIV Agents; Hepatoprotectants; Liver and Biliary Tract Disorders, Treatment of; Oncolytic Drugs; Treatment of Alcohol Dependency"
CBR-050-068-252-0,RFM-012-361-5,CBR-050-068-252-0,ClC(C(=O)NCCCCCCCCNC(=O)C(Cl)Cl)Cl,CBR-HVAC-14765: Retinal Dehydrogenase 2 (ALDH1A2; RALDH2) Inhibitors; Retinal dehydrogenase 1 (ALDH1A1; RALDH1) Inhibitors; Male Contraceptives; Pharmacological Tools
CBR-050-068-253-1,RFM-012-362-6,CBR-050-068-253-1,C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2c(n1)ccc(c2)c1c(Cl)c(OC)cc(c1Cl)OC,CBR-HVAC-13574: Angiogenesis Inhibitors; FGFR4 Inhibitors; Fibroblast growth factor receptor antagonist; Signal Transduction Modulators; Digestive/Gastrointestinal Cancer Therapy; Liver Cancer Therapy
CBR-050-068-254-2,RFM-012-363-7,CBR-050-068-254-2,COc1cc2ncnc(c2cc1OC(=O)N1CCN(C[C@H]1C)C)Nc1cccc(c1F)Cl,CBR-HVAC-14496: EGFR (HER1; erbB1) Inhibitors; EGFR kinase inhibitor; Epidermal-growth-factor-receptor-antagonists; Signal Transduction Modulators; Cancer; Non-Small Cell Lung Cancer Therapy
CBR-050-068-255-3,RFM-012-364-8,CBR-050-068-255-3,O=C(Oc1cccc(c1)c1cccc(c1)C(=O)N)NC1CCCCC1,CBR-HVAC-14859: Fatty Acid Amide Hydrolase (FAAH) Inhibitors; Fatty acid amide hydrolase Inhibitor; Fatty acid amide hydrolase inhibitor; Fatty-acid-amide-hydrolase-inhibitors; TRPA1 Agonists; Affective Disorders; Analgesic; Analgesic Drugs; Antidepressant; Antidepressants; Anxiety Disorders; Anxiolytic; Anxiolytics; Pain
CBR-050-068-256-4,RFM-012-365-9,CBR-050-068-256-4,CN(CCCOc1ccc(cn1)c1ccc2c(c1)c1c(cn2)n(c(=O)n1C1CCOCC1)C)C,CBR-HVAC-14755: ATM Kinase Inhibitors; DNA Repair Inhibitors; Signal Transduction Modulators; Solid Tumors Therapy
CBR-050-068-257-5,RFM-012-366-0,CBR-050-068-257-5,NC(=O)c1ccc2n(n1)c(c1ccccc1)c(n2)c1ccc(cc1)C1(N)CCC1,CBR-HVAC-14681: PKB alpha/Akt1 Inhibitors; PKB beta/Akt2 Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-050-068-258-6,RFM-012-367-1,CBR-050-068-258-6,NC(=O)/C(=C/n1cnc(n1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)/c1cncnc1,"CBR-HVAC-14736: Exportin-1 (CRM1, XPO1) Antagonists; Signal Transduction Modulators; Multiple Myeloma Therapy"
CBR-050-068-259-7,RFM-012-368-2,CBR-050-068-259-7,Cn1ncc(c1)C#Cc1cccc2c1c(=O)n(c(c2)[C@@H](NC(=O)c1c(N)nn2c1nccc2)C)c1ccccc1,CBR-HVAC-14742: Phosphatidylinositol 3-Kinase gamma (PI3Kgamma) Inhibitors; Signal Transduction Modulators; Head and Neck Cancer Therapy; Melanoma Therapy; Non-Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-050-068-260-0,RFM-012-369-3,CBR-050-068-260-0,CN(CCNS(=O)(=O)Cc1cccc(c1)Nc1nccc(n1)Oc1ccc2c(c1)cc([nH]2)C)C,CBR-HVAC-14651: Angiogenesis Inhibitors; FGFR1 Inhibitors; Signal Transduction Modulators; VEGFR-2 (FLK-1/KDR) Inhibitors; Cancer of Unspecified Body Location/System; Digestive/Gastrointestinal Cancer Therapy; Endocrine Cancer Therapy; Solid Tumors Therapy
CBR-050-068-261-1,RFM-012-370-6,CBR-050-068-261-1,CC[C@H]1[C@@H](O)[C@H]2[C@@H]3CC[C@@H]([C@@]3(C)CC[C@@H]2[C@@]2([C@H]1C[C@H](O)CC2)C)[C@@H](CCOS(=O)(=O)[O-])C,"CBR-HVAC-14623: Farnesoid X Receptor (FXR) Agonists; G-Protein Coupled Bile Acid Receptor 1 (GPBAR1; TGR5; GPCR19; GPR131) Agonists; Signal Transduction Modulators; Agents for Liver Fibrosis; Diabetic Nephropathy, Agents for; Liver and Biliary Tract Disorders, Treatment of; Type 2 Diabetes, Agents for"
CBR-050-068-262-2,RFM-012-371-7,CBR-050-068-262-2,C=CC(=O)N1CC/C(=C\c2ccc(c(c2)[N+](=O)[O-])F)/C(=O)/C(=C/c2ccc(c(c2)[N+](=O)[O-])F)/C1,CBR-HVAC-14694: Inhibitor; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L5; USP14 Inhibitor; Ubiquitin C-terminal Hydrolase 14 (USP14) Inhibitors; Ubiquitin C-terminal Hydrolase L5 (UCH-L5) Inhibitors; ANTI-CANCER; Multiple Myeloma Therapy
CBR-050-068-263-3,RFM-012-372-8,CBR-050-068-263-3,CC[C@@H](C(=O)C(=O)NC1CC1)NC(=O)[C@H](CS(=O)(=O)CC1CC1)N[C@H](C(F)(F)F)c1ccc(cc1)F,CBR-HVAC-14672: Angiogenesis Inhibitors; Cathepsin B Inhibitors; Cathepsin L Inhibitors; Cathepsin S Inhibitors; Agents for Liver Cirrhosis; Oncolytic Drugs
CBR-050-068-264-4,RFM-012-373-9,CBR-050-068-264-4,CC#CC(=O)N1CCC[C@H]1c1nc(c2n1ccnc2N)c1ccc(cc1)C(=O)Nc1ccccn1,"CBR-HVAC-14744: Agammaglobulinaemia-tyrosine-kinase-inhibitors; BTK Inhibitor; Bruton's Tyrosine Kinase (BTK) Inhibitors; Bruton's tyrosine kinase inhibitor; Signal Transduction Modulators; ANTI-CANCERANTI-RHEUMATIC; Bladder Cancer Therapy ; Cancer; Glioblastoma Multiforme Therapy; Head and Neck Cancer Therapy; Lymphocytic Leukemia Therapy; Lymphoma Therapy; Multiple Myeloma Therapy; Non-Hodgkin's Lymphoma Therapy; Non-Small Cell Lung Cancer Therapy; Ovarian Cancer Therapy; Pancreatic Cancer Therapy; Rheumatic Disease; Rheumatoid Arthritis, Treatment of"
CBR-050-068-265-5,RFM-012-374-0,CBR-050-068-265-5,OC[C@H]1N[C@H]([C@@H]([C@@H]1O)O)c1c[nH]c2c1ncnc2N,CBR-HVAC-07290: RNA Polymerase Inhibitors; RNA directed RNA polymerase inhibitor; RNA-DEPENDENT RNA-POLYMERASE Inhibitor; RNA-replicase-inhibitors; ANTI-VIRAL; Antiviral Drugs; Viral Infections
CBR-050-068-266-6,RFM-012-375-1,CBR-050-068-266-6,N#Cc1cnc(cn1)Nc1ncc(c(c1)NC[C@H]1CNCCO1)C(F)(F)F,CBR-HVAC-14709: Checkpoint Kinase 1 (Chk1) Inhibitors; Signal Transduction Modulators; Antineoplastic Enhancing Agents; Non-Small Cell Lung Cancer Therapy; Pancreatic Cancer Therapy; Solid Tumors Therapy
CBR-050-068-267-7,RFM-012-376-2,CBR-050-068-267-7,O=C(Cn1cnc2c1c(=O)n(C)c(=O)n2C)Nc1ccc(nn1)c1ccccc1,CBR-HVAC-14735: PORCUPINE Inhibitor; Protein-Serine O-Palmitoleoyltransferase Porcupine (PORCN) Inhibitors; Wnt Signaling Inhibitors; ANTI-CANCER; Solid Tumors Therapy
CBR-050-068-268-8,RFM-012-377-3,CBR-050-068-268-8,CC[C@@H]1CN(C[C@@H]1c1cnc2n1c1cc[nH]c1nc2)C(=O)NCC(F)(F)F,"CBR-HVAC-14347: Jak1 Inhibitors; Janus-kinase-1-inhibitors; Janus-kinase-2-inhibitors; Janus-kinase-3-inhibitors; Signal Transduction Modulators; Antiarthritic Drugs; Antipsoriatics; Atopic Dermatitis, Agents for; Immunological Disorders; Inflammatory Bowel Disease, Agents for; Inflammatory Bowel Disorders; Rheumatic Disease; Rheumatoid Arthritis, Treatment of; Skin Disorders"
CBR-050-068-269-9,RFM-012-378-4,CBR-050-068-269-9,[O-][n+]1cccc(c1)c1ncn(c1)C(=O)N(C1CCCCC1)C,CBR-HVAC-14643: Fatty Acid Amide Hydrolase (FAAH) Inhibitors; Analgesic Drugs; Neurologic Drugs (Miscellaneous)
CBR-050-068-270-2,RFM-012-379-5,CBR-050-068-270-2,Cc1ccc(c(c1)C(=O)O)NS(=O)(=O)c1ccccc1,CBR-HVAC-14843: Methionine aminopeptidase 2 Inhibitor; Anticancer
CBR-050-068-271-3,RFM-012-380-8,CBR-050-068-271-3,Brc1ccc(cc1)NC(=O)c1cc(Br)cc(c1O)Br,CBR-HVAC-14812: ANTI-BACTERIALANTI-FUNGAL
CBR-050-068-272-4,RFM-012-381-9,CBR-050-068-272-4,C[C@@H]1OC(O)[C@H]([C@@H]([C@@H]1O)O)F,CBR-HVAC-14660: Cancer Immunotherapy; Non-Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-050-068-273-5,RFM-012-382-0,CBR-050-068-273-5,S=C(N1CCN(CC1)c1ncnc2c1oc1c2cccc1)NCc1ccc2c(c1)OCO2,"CBR-HVAC-06073: Angiogenesis Inhibitors; Apoptosis Inducers; C-kit inhibitor; DNA repair enzyme inhibitor; DNA-repair-inhibitors; Flt-3 kinase inhibitor; Flt3 (FLK2/STK1) Inhibitors; Hepatocyte Growth Factor Receptor (HGFR, MET) Inhibitors; KIT; KIT (C-KIT) Inhibitors; MET tyrosine kinase inhibitor; PDGFR; PDGFRalpha Inhibitors; Platelet-derived growth factor receptor kinase inhibitor; Platelet-derived-growth-factor-alpha-receptor-antagonists; Platelet-derived-growth-factor-receptor-antagonists; Proto-oncogene-protein-c-kit-inhibitors; Proto-oncogene-protein-c-met-inhibitors; RAD51 Expression Inhibitors; RAD51 expression inhibitor; RET Inhibitors; RET tyrosine kinase inhibitor; Rad51-recombinase-inhibitors; Ret proto-oncogene Inhibitor; Signal Transduction Modulators; Tyrosine-Protein Kinase Receptor UFO (AXL) Inhibitors; fms-like-tyrosine-kinase-3-inhibitors; Anticancer; Cancer; Glioblastoma Multiforme Therapy; Lymphoma Therapy; Oncolytic Drugs; Small Cell Lung Cancer Therapy; Solid Tumors Therapy"
CBR-050-068-274-6,RFM-012-383-1,CBR-050-068-274-6,COc1cc(OC)cc(c1)Nc1nc2ccccc2nc1NS(=O)(=O)c1ccc(cc1)NC(=O)c1ccc(c(c1)OC)C,CBR-HVAC-15136: 1-Phosphatidylinositol-3-kinase-inhibitors; mTOR-protein-inhibitors; Cancer; Women's Health
CBR-050-068-275-7,RFM-012-384-2,CBR-050-068-275-7,Cc1c[nH]nc1,CBR-HVAC-00386: Alcohol Dehydrogenase Inhibitors; Alcohol dehydrogenase Inhibitor; Alcohol-dehydrogenase-inhibitors; Alcohol dehydrogenase inhibitor; Drug Withdrawal; Specific Antidotes; Therapy of Inborn Errors of Metabolism
CBR-050-068-276-8,RFM-012-385-3,CBR-050-068-276-8,COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(c(c2)OC)O)ccc1O,CBR-HVAC-03419: Angiogenesis-inhibitors; Cyclo-oxygenase-2-inhibitors; Cystic-fibrosis-transmembrane-conductance-regulator-modulators; Immunosuppressants; Mast-cell-stabilisers; Thromboxane-synthase-inhibitors; Cancer; Inflammation
CBR-050-068-277-9,RFM-012-386-4,CBR-050-068-277-9,COc1ccc(cc1)COc1cc2oc(=O)c3c(c2cc1OC)ccc(c3)C(O)C,"CBR-HVAC-06654: AKT protein kinase; Angiogenesis Inhibitors; Angiopoietin inhibitor; Apoptosis stimulant; Fibroblast Growth Factor 2 (FGF2) Inhibitors; Hypoxia inducible factor; Hypoxia-inducible factor 1 antagonist; Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors; PI3K; Protein Kinase B (PKB/Akt) Inhibitors; Signal Transduction Modulators; TORC1; TORC2 Inhibitor; VEGFR Inhibitors; Vascular endothelial growth factor (VEGF)receptor antagonist; mTOR Complex 1 (mTORC1) Inhibitors; mTOR Complex 2 (mTORC2) Inhibitors; mTORC1 kinase inhibitor; mTORC2 kinase inhibitor; Age-Related Macular Degeneration, Treatment of; Anti-angiogenic; Anti-inflammatory; Anticancer; Anticonvulsant; Antiepileptic Drugs; Diabetic Retinopathy, Agents for; Fibrosuppressant; Glioblastoma Multiforme Therapy; Ocular anti-neovascularisation; Oncolytic Drugs"
CBR-050-068-278-0,RFM-012-387-5,CBR-050-068-278-0,OC[C@H]1O[C@@H](OC[C@H]2O[C@@H](O[C@H](c3ccccc3)C#N)[C@@H]([C@H]([C@@H]2O)O)O)[C@@H]([C@H]([C@@H]1O)O)O,CBR-HVAC-06463: Apoptosis Inducers; Caspase 3 Activators; Signal Transduction Modulators; Trehalase Inhibitor; Anticancer; Oncolytic Drugs
CBR-050-068-279-1,RFM-012-388-6,CBR-050-068-279-1,CC(=O)OCC(=O)[C@@]12OC(O[C@@H]1C[C@@H]1[C@]2(C)C[C@H](O)[C@]2([C@H]1C[C@@H](C1=CC(=O)C=C[C@]21C)F)F)(C)C,"CBR-HVAC-01532: Corticosteroid agonist; The antiinflammatory activity of fluocinonide is its main therapeutic property. This is thought to be mediated by the reduction in formation, release and action of various vasoactive chemicals released during inflammation - kinins, histamine, lysosomal enzymes, prostaglandins, leukotrienes and the complement system; Allergic Skin Disorders, Treatment for; Anti-inflammatory; Antipsoriatics"
CBR-050-068-280-4,RFM-012-389-7,CBR-050-068-280-4,O=C(c1ccc(cc1)N)NCC(=O)O,CBR-HVAC-09706: Aldose reductase Inhibitor; Diagnostic agent
CBR-050-068-281-5,RFM-012-390-0,CBR-050-068-281-5,COc1c2ccc(=O)oc2cc2c1cco2,CBR-HVAC-05563: CYP3A4 Inhibitor; Anti-HIV Agents; Antipsoriatic; Antipsoriatics; Chemopreventive Agents; Dermatologic Drugs; Oncolytic Drugs
CBR-050-068-282-6,RFM-012-391-1,CBR-050-068-282-6,OC[C@@H]1O[C@@H](O[C@H]2[C@H](O[C@@H]3[C@@H](O)[C@H](O)[C@H]([C@@H]([C@H]3NC(=N)N)O)NC(=N)N)O[C@H]([C@]2(O)CO)C)[C@H]([C@@H]([C@H]1O)O)NC,CBR-HVAC-09834: 16S-rRNA of 30S ribosomal subunit Binder; Antibacterial
CBR-050-068-283-7,RFM-012-392-2,CBR-050-068-283-7,NNC(=N)N,"CBR-HVAC-04276: AGE Inhibitors (Maillard's Reaction Inhibitors); Advanced-glycosylation-end-product-inhibitors; Glycosylation inhibitor; Inducible Nitric Oxide Synthase (NOS-2) Inhibitors; Inducible nitric oxide synthase inhibitor; Nitric oxide synthase Inhibitor; Nitric-oxide-synthase-inhibitors; Signal Transduction Modulators; Anti-inflammatory; Antiarteriosclerotic; Diabetes; Diabetic Nephropathy, Agents for; Diabetic Retinopathy, Agents for; Ischaemic Heart Disease; Neurological Disorders; Skin Disorders; Transplant Rejection; Vasoprotectant"
CBR-050-068-284-8,RFM-012-393-3,CBR-050-068-284-8,CC(=O)NO,CBR-HVAC-09679: Urease Inhibitor; Urease inhibitor
CBR-050-068-285-9,RFM-012-394-4,CBR-050-068-285-9,FC(CN(S(=O)(=O)c1ccccc1)c1ccc(cc1)C(C(F)(F)F)(C(F)(F)F)O)(F)F,"CBR-HVAC-14586: ABCA1 Expression Enhancers; Liver X receptor Agonist; Liver X receptor agonist; Oxysterol Receptor LXRalpha Agonists; Oxysterol Receptor LXRbeta Agonists; Pregnane X Receptor (PXR) Agonists; Retinoid RORalpha Inverse Agonists; Retinoid RORgamma Inverse Agonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Antihypercholesterolemic; Asthma Therapy; Atherosclerosis Therapy; Lipoprotein Disorders, Treatment of ; Pharmacological Tools; Stroke, Treatment of"
CBR-050-068-286-0,RFM-012-395-5,CBR-050-068-286-0,CNCc1ccc(cc1)c1noc(c1)c1nc(cnc1N)c1ccc(cc1)S(=O)(=O)C(C)C,CBR-HVAC-07293: ATR KINASE Inhibitor; ATR Kinase Inhibitors; Signal Transduction Modulators; ANTI-TUMOR; Antineoplastic Enhancing Agents; Bladder Cancer Therapy ; Breast Cancer Therapy; Female Reproductive System Cancer Therapy; Head and Neck Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs; Ovarian Cancer Therapy; Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-050-068-287-1,RFM-012-396-6,CBR-050-068-287-1,COc1cc(C=Cc2ccc(c(c2)O)OC)cc(c1OC)OC,CBR-HVAC-04768: Angiogenesis Inhibitors; Antimitotic Drugs; Apoptosis Inducers; Tubulin Polymerization Inhibitors; Tubulin polymerization inhibitor; Vascular Disrupting Agents (VDA); Anticancer; Antineoplastic Enhancing Agents; Oncolytic Drugs; Solid Tumors Therapy
CBR-050-068-288-2,RFM-012-397-7,CBR-050-068-288-2,C=CC(=O)N[C@H]1CCOC[C@H]1Nc1ncc2c(n1)ccc(c2)c1c(Cl)c(OC)cc(c1Cl)OC,CBR-HVAC-13574: Angiogenesis Inhibitors; FGFR4 Inhibitors; Fibroblast growth factor receptor antagonist; Signal Transduction Modulators; Digestive/Gastrointestinal Cancer Therapy; Liver Cancer Therapy
CBR-050-068-289-3,RFM-012-398-8,CBR-050-068-289-3,Nc1ccc(cc1)S(=O)(=O)Nc1cnc2c(n1)cccc2Cl,CBR-HVAC-00582: DNA topoisomerase II inhibitor; Immunosuppressant; Anticancer; Antineoplastic; Immunosuppressant; Oncolytic Drugs
CBR-050-068-290-6,RFM-012-399-9,CBR-050-068-290-6,Fc1ccc(cc1)c1[nH]c(nc1c1ccc(cc1)F)S(=O)(=O)C(C(F)F)(F)F,CBR-HVAC-01163: Immunostimulant; Prostaglandin G/H synthase Inhibitor; Prostaglandin synthase inhibitor; Antiarthritic; Antiinflammatory
CBR-050-068-291-7,RFM-012-400-5,CBR-050-068-291-7,S=C=Nc1ccc(cc1)Nc1ccc(cc1)[N+](=O)[O-],CBR-HVAC-01208: Cell wall synthesis inhibitor; Sterol demethylase inhibitor; cAMP phosphodiesterase Inhibitor; Antihelmintic; Antinematodal; Filaricide; Schistosomicide
CBR-050-068-292-8,RFM-012-401-6,CBR-050-068-292-8,CN(Cc1nnc2n1c1ccc(cc1C(=NC2)c1ccccc1)Cl)C,CBR-HVAC-02456: Benzodiazepine receptor Agonist; Benzodiazepine receptor agonist; GABA(A) BZ Site Receptor Agonists; Signal Transduction Modulators; ANTIDEPRESSANT; ANXIOLYTIC; Antidepressants; Anxiolytics; PSYCHOTROPIC DRUGS; SEDATIVE-HYPNOTIC
CBR-050-068-293-9,RFM-012-402-7,CBR-050-068-293-9,CN1C2CCC1CC(C2)NC(=O)c1c[nH]c2c1cccn2,CBR-HVAC-02739: Neuropeptide Antagonist; Antitussive; Antitussives
CBR-050-068-294-0,RFM-012-403-8,CBR-050-068-294-0,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2NCC(c1ccccc1)c1ccccc1,"CBR-HVAC-03255: Adenosine A3 Receptor Ligands; Alpha 1 adrenoreceptor antagonist; Alpha 2 adrenoreceptor antagonist; Signal Transduction Modulators; Angina pectoris, Treatment of; Antipsychotic Drugs; Hypertension, Treatment of; Non-Opioid Analgesics"
CBR-050-068-295-1,RFM-012-404-9,CBR-050-068-295-1,OC[C@H]1O[C@@H](O[C@@H]2CC[C@]3([C@H](C2)CC[C@@H]2C3CC[C@]3(C2C[C@H]2[C@@H]3[C@H](C)[C@]3(O2)CCC(CO3)C)C)C)[C@@H]([C@H]([C@H]1O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O)O)O,"CBR-HVAC-03408: Bile acid sequestrant; Cholesterol Absorption Inhibitors; Cholesterol absorption inhibitor; Cholesterol inhibitor; Antiarteriosclerotic; Antihypercholesterolemic; Antihyperlipidemic; Lipoprotein Disorders, Treatment of "
CBR-050-068-296-2,RFM-012-405-0,CBR-050-068-296-2,CN(CCSc1nc2ccccc2cc1c1ccccc1)C,CBR-HVAC-03565: 5 Hydroxytryptamine 2 receptor antagonist; 5-HT2A Antagonists; 5-Hydroxytryptamine 2A receptor Antagonist; Signal Transduction Modulators; Antihypertensive; Antimigraine; Pharmacological Tools
CBR-050-068-297-3,RFM-012-406-1,CBR-050-068-297-3,CNC(=O)CN1CCN2CCN(CC(=O)NC)CC(=O)O[Gd](OC(=O)C1)OC(=O)C2,CBR-HVAC-04118: 
CBR-050-068-298-4,RFM-012-407-2,CBR-050-068-298-4,COCCNC(=O)c1ccnc(c1)C(=O)NCCOC,CBR-HVAC-04186: Collagen inhibitor; Proline 4-hydroxylase type I Inhibitor; Prolyl 4-Hydroxylase (Protein Disulfide-Isomerase) Inhibitors; Prolyl hydroxylase inhibitor; Agents for Liver Fibrosis; Antiarthritic Drugs; Antifibrotic; Hepatoprotectants
CBR-050-068-299-5,RFM-012-408-3,CBR-050-068-299-5,Clc1ccc(cc1)C(NCCCn1cncc1)(C)C,CBR-HVAC-04969: Prostaglandin E receptor 2 Modulator; Antiallergy/Antiasthmatic Drugs; Antiasthmaitc; Antiinflammatory
CBR-050-068-300-1,RFM-012-409-4,CBR-050-068-300-1,OC(=O)[C@H](NS(=O)(=O)c1ccc(s1)C#Cc1ccc(cc1)C)Cc1c[nH]c2c1cccc2,CBR-HVAC-05017: Angiogenesis Inhibitors; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9 Inhibitor; MMP-12 (Macrophage Elastase) Inhibitors; MMP-2 (Gelatinase A) Inhibitors; MMP-9 (Gelatinase B) Inhibitors; Anticancer; Solid Tumors Therapy
CBR-050-068-301-2,RFM-012-410-7,CBR-050-068-301-2,CCCCCc1ccc(cc1)c1cc2c(o1)nc(=O)n(c2)[C@H]1C[C@@H]([C@H](O1)CO)O,CBR-HVAC-05465: Varicella zoster virus replication inhibitor; Anti-Varicella Zoster Virus Drugs; Antiviral
CBR-050-068-302-3,RFM-012-411-8,CBR-050-068-302-3,COc1ccccc1C1CCN(C1)Cc1ccc2c(c1)OCCO2,CBR-HVAC-05622: Signal Transduction Modulators; alpha2-Adrenoceptor Antagonists; Antidepressants; Antipsychotic Drugs
CBR-050-068-303-4,RFM-012-412-9,CBR-050-068-303-4,CCCN1CCOC(C1)c1cccc(c1)O,CBR-HVAC-06092: Dopamine D3 Agonists; Dopamine receptor D3 Agonist; Signal Transduction Modulators; Dopamine receptor D3 agonist; Treatment of Male Sexual Dysfunction
CBR-050-068-304-5,RFM-012-413-0,CBR-050-068-304-5,OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(OC)nc2N,"CBR-HVAC-06572: Adenosine A2A Agonists; Adenosine A2a receptor Antagonist; Signal Transduction Modulators; Anti-inflammatory; Anti-rheumatic; Diabetic Neuropathy, Agents for"
CBR-050-068-305-6,RFM-012-414-1,CBR-050-068-305-6,CC(=O)OCC(=O)[C@@]1(O)[C@H](C)CC2[C@]1(C)CC=C1[C@H]2CCC2=CC(=O)C=C[C@]12C,"CBR-HVAC-06761: Muscular Dystrophy, Agents for"
CBR-050-068-306-7,RFM-012-415-2,CBR-050-068-306-7,O=C(NCCc1c[nH]cn1)CCCC(=O)O,"CBR-HVAC-07071: Anti-Influenza Virus Drugs; Antithrombocytopenic; Disorders Associated with Cancer Therapy, Treatment of; Oncolytic Drugs; Treatment of Neutropenia"
CBR-050-068-307-8,RFM-012-416-3,CBR-050-068-307-8,CCc1cc(cc2c1O[C@H](C(=C2)C(=O)O)C(F)(F)F)OC(F)(F)F,"CBR-HVAC-07130: Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors; Signal Transduction Modulators; Inflammation, Treatment of; Non-Opioid Analgesics"
CBR-050-068-308-9,RFM-012-417-4,CBR-050-068-308-9,O=C(c1ccc(c(c1)O)O)Nc1nc(c(s1)c1ccccc1)c1ccc(c(c1)O)O,CBR-HVAC-07218: Apoptosis Inducers; RRM2 Expression Inhibitors; Solid Tumors Therapy
CBR-050-068-309-0,RFM-012-418-5,CBR-050-068-309-0,OC(=O)C(Cc1ccccc1)NCc1ccc(cc1)Cl,CBR-HVAC-07563: Cholesterol inhibitor; Collagen inhibitor; Lipase clearing factor stimulant
CBR-050-068-310-3,RFM-012-419-6,CBR-050-068-310-3,Cc1cccc(c1)N1CCN(CC1)CCCCN1C(=O)CNC1=O,CBR-HVAC-07637: Alpha adrenoreceptor antagonist
CBR-050-068-311-4,RFM-012-420-9,CBR-050-068-311-4,OC(COc1ccccc1)CNCCNC(=O)C(C)C,CBR-HVAC-07910: 
CBR-050-068-312-5,RFM-012-421-0,CBR-050-068-312-5,N#Cc1[nH]c(nc1C)c1ccccc1,CBR-HVAC-08032: 
CBR-050-068-313-6,RFM-012-422-1,CBR-050-068-313-6,O=C(c1ccccc1Nc1ccncc1)N1CCCCC1,CBR-HVAC-08110: Adrenoreceptor antagonist; Alpha 2 adrenoreceptor agonist
CBR-050-068-314-7,RFM-012-423-2,CBR-050-068-314-7,CCCCCC(NCc1c(C)cc(cc1C)C)C,CBR-HVAC-08471: Histamine receptor antagonist
CBR-050-068-315-8,RFM-012-424-3,CBR-050-068-315-8,CC(C(O)(C)C)(c1ccc(cc1)Cl)O,CBR-HVAC-08629: Anticonvulsant
CBR-050-068-316-9,RFM-012-425-4,CBR-050-068-316-9,S=C(Nc1cc(Cl)cc(c1)Cl)Nc1ccc(cc1)F,CBR-HVAC-09030: Antifungal
CBR-050-068-317-0,RFM-012-426-5,CBR-050-068-317-0,Fc1cccc(c1)Cn1c(cc2c1ccnc2)C(=O)Nc1ccc2c(c1)nc(n2C)C,"CBR-HVAC-09337: TRPV1 (Vanilloid VR1 Receptor) Antagonists; Vanilloid receptor 1 Antagonist; Analgesic; Neuropathic Pain, Treatment of"
CBR-050-068-318-1,RFM-012-427-6,CBR-050-068-318-1,CCc1cccc(c1n1c(=O)[nH]c2c(c1=O)cccc2)CC,CBR-HVAC-09499: AMINOPEPTIDASE N; Inhibitor; PUROMYCIN-SENSITIVE AMINOPEPTIDASE Inhibitor; ANTI-ALZHEIMER'S
CBR-050-068-319-2,RFM-012-428-7,CBR-050-068-319-2,O=C1CC[C@]2(C(=C1)CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2([C@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-])C)C,CBR-HVAC-09603: Phospholipase A2 Inhibitor; Anti-inflammatory; Glucocorticoid
CBR-050-068-320-5,RFM-012-429-8,CBR-050-068-320-5,OC[C@@H](c1ccc2c(c1)ccc(c2)OC)C,CBR-HVAC-10085: Analgesic; Anti-inflammatory
CBR-050-068-321-6,RFM-012-430-1,CBR-050-068-321-6,CCCCCCN1CCC(CC1)(c1ccccc1)C(=O)N(CC)C,CBR-HVAC-10430: Opioid mu receptor agonist; Opioid receptor mu Agonist; Anaesthetic; Analgesic; Local Anesthetics
CBR-050-068-322-7,RFM-012-431-2,CBR-050-068-322-7,Clc1ccc(cc1)Cn1c(N)nc2c1ccc(c2)C(F)(F)F,CBR-HVAC-10619: Calcium Channel Blockers; Calcium channel Blocker; Anti-ischemic; Antimigraine Drugs; Antipsychotic Drugs; Neuroprotectant; Vasodilator
CBR-050-068-323-8,RFM-012-432-3,CBR-050-068-323-8,O=C(CN1C(=O)c2c(C1=O)cccc2)NC1CCN(CC1)CCc1ccccc1,CBR-HVAC-10699: 5 Hydroxytryptamine receptor antagonist; Histamine H1 Receptor Antagonists; Histamine H1 receptor Antagonist; Histamine H1 receptor antagonist; Signal Transduction Modulators; Antiallergic
CBR-050-068-324-9,RFM-012-433-4,CBR-050-068-324-9,CCCCN1CCC(CC1)n1c(O)nc2c1cccc2,"CBR-HVAC-11229: Nerve growth factor receptor Agonist; Neurotrophic Agents; Signal Transduction Modulators; Neuroprotectant; Stroke, Treatment of"
CBR-050-068-325-0,RFM-012-434-5,CBR-050-068-325-0,CC(CC1Nc2cc(Cl)c(cc2S(=O)(=O)N1)S(=O)(=O)N)C,CBR-HVAC-13512: Antihypertensive; Diuretic
CBR-050-068-326-1,RFM-012-435-6,CBR-050-068-326-1,COc1cc(C)nc(c1CNC(=O)c1c(C)n(c2c1cccc2)[C@@H](C1CCN(CC1)CC(F)(F)F)C)O,CBR-HVAC-14026: Histone-Lysine N-Methyltransferase EZH2 Inhibitors; Non-Hodgkin's Lymphoma Therapy
CBR-050-068-327-2,RFM-012-436-7,CBR-050-068-327-2,OC(=O)CNC(=O)c1ncc(cc1O)c1cccc(c1)Cl,CBR-HVAC-14381: Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors; Antianemics
CBR-050-068-328-3,RFM-012-437-8,CBR-050-068-328-3,O=C1CCCCCCCCCCCCCCO1,CBR-HVAC-14591: Absorption Promoters
CBR-050-068-329-4,RFM-012-438-9,CBR-050-068-329-4,CC(C[C@H]1C(=O)O[C@H](Cc2ccc(cc2)N2CCOCC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O[C@@H](C(=O)N1C)C)CC(C)C)C)Cc1ccc(cc1)N1CCOCC1)CC(C)C)C,CBR-HVAC-14592: Treatment of Helminthic Diseases
CBR-050-068-330-7,RFM-012-439-0,CBR-050-068-330-7,NCCCC[C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)O)Cc1ccccc1)CCSC)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CCC(=O)N)N)CCCNC(=N)N)CCCNC(=N)N)CC(C)C)CO,"CBR-HVAC-14594: Apelin Receptor (Angiotensin-Receptor Like 1; APJ) Agonists; Signal Transduction Modulators; Antiobesity Drugs; Type 2 Diabetes, Agents for"
CBR-050-068-331-8,RFM-012-440-3,CBR-050-068-331-8,O=S(=O)(c1cccc2c1cccc2)c1n[nH]c2c1cc(cc2)N1CCNCC1,"CBR-HVAC-14601: 5-HT6 Receptor Antagonists; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of"
CBR-050-068-332-9,RFM-012-441-4,CBR-050-068-332-9,O=C1NC(Nc2c1cccc2)c1ccc(cc1)c1ccccc1,"CBR-HVAC-14608: Angiogenesis Inhibitors; Antimitotic Drugs; Caspase 3; Stimulator; Tubulin Antagonist; Tubulin Polymerization Inhibitors; Age-Related Macular Degeneration, Treatment of; Anticancer; Diabetic Retinopathy, Agents for"
CBR-050-068-333-0,RFM-012-442-5,CBR-050-068-333-0,CC[C@@H](C(C)C)CC[C@H]([C@H]1CCC2[C@]1(C)CCC1[C@H]2C[C@H]([C@@]2([C@]1(C)CC[C@@H](C2)O)O)O)C,CBR-HVAC-14615: Oncolytic Drugs
CBR-050-068-334-1,RFM-012-443-6,CBR-050-068-334-1,OC[C@H]1O[C@H]([C@H]([C@H]1O)O)n1cc(c2c1ncnc2N)C#N,CBR-HVAC-14619: Apoptosis Inducers; Antifungal Agents; Antineoplastic Antibiotics; Antiviral Drugs
CBR-050-068-335-2,RFM-012-444-7,CBR-050-068-335-2,C1CC[C@@H]2N(C1)C[C@@H]1C[C@H]2CN2[C@@H]1CCCC2,CBR-HVAC-14620: Antiarrhythmic Drugs
CBR-050-068-336-3,RFM-012-445-8,CBR-050-068-336-3,Oc1ccc2c(c1)oc(=O)c1c2ccc(c1)O,"CBR-HVAC-14646: Antioxidants; Free Radical Scavengers; Anxiolytics; Cardiovascular Diseases (Not Specified); Inflammation, Treatment of; Inflammatory Bowel Disease, Agents for; Lipoprotein Disorders, Treatment of ; Liver and Biliary Tract Disorders, Treatment of; Neurodegenerative Diseases, Treatment of; Oncolytic Drugs; Treatment of Musculoskeletal & Connective Tissue Diseases (Miscellaneous)"
CBR-050-068-337-4,RFM-012-446-9,CBR-050-068-337-4,S=C(N(C1CCCCC1)C)NN=C(c1ccccn1)c1ccccn1,CBR-HVAC-14656: Apoptosis Inducers; Cell-death-stimulants; Chelating Agents; Gene-expression-stimulants; Iron-chelating-agents; Reactive-oxygen-species-stimulants; Cancer; Lung Cancer Therapy; Pancreatic Cancer Therapy; Solid Tumors Therapy
CBR-050-068-338-5,RFM-012-447-0,CBR-050-068-338-5,O=C(c1c(nn(c1Oc1cccc(c1)C(F)(F)F)C)C(F)F)N[C@H](c1ccc(cc1)C(=O)O)C,CBR-HVAC-14665: Prostanoid EP4 Receptor Antagonists; Signal Transduction Modulators; Solid Tumors Therapy
CBR-050-068-339-6,RFM-012-448-1,CBR-050-068-339-6,C[C@@H]1N[C@H](C)CN(C1)C(=O)c1ccc(cc1)NC(=O)c1nnc(c(c1)O[C@@H](c1c(Cl)ccc(c1Cl)F)C)N,CBR-HVAC-14667: ALK Tyrosine Kinase Receptor (L1196M Mutant) Inhibitors; ALK Tyrosine Kinase Receptor Inhibitors; Signal Transduction Modulators; Non-Small Cell Lung Cancer Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-050-068-340-9,RFM-012-449-2,CBR-050-068-340-9,N#CCCS(=O)(=O)C,CBR-HVAC-14675: INTERLEUKIN -1 BETA PRODUCTION INHIBITOR;INTERLEUKIN -18 PRODUCTION INHIBITOR;INDUCES THE PRODUCTION OF IL-1 RECEPTOR ANTAGONIST; Interleukin-1-modulators; ANTI-OSTEOARTHRITICANALGESIC; Analgesic Drugs; Pain; Rheumatic Disease; Topical Antiinflammatory Agents
CBR-050-068-341-0,RFM-012-450-5,CBR-050-068-341-0,CCCS(=O)(=O)N[C@@H]1C[C@@H](C1)N(c1ncnc2c1cc[nH]2)C,"CBR-HVAC-14693: Jak1 Inhibitors; Signal Transduction Modulators; Antipsoriatics; Atopic Dermatitis, Agents for; Systemic Lupus Erythematosus, Agents for"
CBR-050-068-342-1,RFM-012-451-6,CBR-050-068-342-1,C=CC(=O)N1C[C@@H](CC[C@@H]1C)Nc1ncnc2c1cc[nH]2,"CBR-HVAC-14747: Jak3 Inhibitors; Signal Transduction Modulators; Hair Growth Stimulants; Inflammatory Bowel Disease, Agents for; Rheumatoid Arthritis, Treatment of"
CBR-050-068-343-2,RFM-012-452-7,CBR-050-068-343-2,OC(=O)CCc1cc(I)c(c(c1)I)Oc1ccc(c(c1)I)O,"CBR-HVAC-14754: CFTR Inhibitory Factor, Cif (Pseudomonas aeruginosa) Inhibitors; Atherosclerosis Therapy; Lipoprotein Disorders, Treatment of ; Thyroid Disease Therapy"
CBR-050-068-344-3,RFM-012-453-8,CBR-050-068-344-3,Nc1ncnc(c1)Nc1cc(C)c2n(c1=O)C1(CCCCC1)NC2=O,CBR-HVAC-14761: Inhibitor; MAPK-Interacting Kinase 1 (MNK1) Inhibitors; MAPK-Interacting Kinase 2 (MNK2) Inhibitors; MNK1; MNK2 Inhibitor; Signal Transduction Modulators; ANTI-CANCER; Hematological Cancer Therapy; Solid Tumors Therapy
CBR-050-068-345-4,RFM-012-454-9,CBR-050-068-345-4,OC(=O)C(Cl)(Cl)Cl,CBR-HVAC-14787: ANTICANCER
CBR-050-068-346-5,RFM-012-455-0,CBR-050-068-346-5,O[C@H]1CC[C@]2(C(=CC(=O)[C@@H]3[C@@H]2CC[C@]2([C@H]3CCC2=O)C)C1)C,CBR-HVAC-14792: DIETARY SUPPLEMENT. ACTS AS AGE-RELATED IMMUNE ENHANCEMENT; Immunomodulators; Anxiety Disorders; FOOD ADDITIVEIMMUNOSTIMULANT
CBR-050-068-347-6,RFM-012-456-1,CBR-050-068-347-6,OC1O[C@H](COS(=O)(=O)[O-])C([C@@H](C1NS(=O)(=O)[O-])O)O[C@@H]1OC(C(=O)[O-])C([C@@H](C1OS(=O)(=O)[O-])O)O,CBR-HVAC-14793: ANTI-THROMBOTICANTI-COAGULANT
CBR-050-068-348-7,RFM-012-457-2,CBR-050-068-348-7,OCC(c1ccccc1)(C(=O)OC1C[C@@H]2N([C@H](C1)[C@H]1[C@H]2O1)C)O,CBR-HVAC-14797: Intracellular calcium accumulation reducer; Cognitive enhancer
CBR-050-068-349-8,RFM-012-458-3,CBR-050-068-349-8,COCCOCCOc1ccc(c(c1)O)C1=N[C@@](CS1)(C)C(=O)O,CBR-HVAC-14802: Iron chelator; IRON CHELATOR
CBR-050-068-350-1,RFM-012-459-4,CBR-050-068-350-1,COc1ccc2c(c1OP(=O)(OCc1ccccc1)OCc1ccccc1)c(O)cc(n2)c1cccc(c1)F,CBR-HVAC-14810: ANTI-CANCER
CBR-050-068-351-2,RFM-012-460-7,CBR-050-068-351-2,CCCN([C@@H]1CCc2c([C@@H]1C)cccc2OC)CCC,CBR-HVAC-14815: Dopamine receptor D3 Antagonist; Antipsychotic
CBR-050-068-352-3,RFM-012-461-8,CBR-050-068-352-3,COc1ccc(cc1)C1CN(CC1C(=O)O)C(=O)OC(C)(C)C,CBR-HVAC-14834: ANALGESIC
CBR-050-068-353-4,RFM-012-462-9,CBR-050-068-353-4,C1=CCC(NC1)c1cccnc1,CBR-HVAC-14846: ANTI-INFLAMMATORYNEUROPROTECTANT
CBR-050-068-354-5,RFM-012-463-0,CBR-050-068-354-5,OC(=O)C[C@@H](c1cccc(c1)n1nc(cc1C)C)CN1CC[C@H](C1)CCc1ccc2c(n1)NCCC2,CBR-HVAC-14864: ALPHAVBETA6 INTEGRIN Antagonist; PULMONARY SURFACTANT
CBR-050-068-355-6,RFM-012-464-1,CBR-050-068-355-6,NC(=O)N/N=C/c1ccc(cc1)Oc1ccc(cc1)F,CBR-HVAC-14865: Potassium channel Kv Blocker; Sodium Channel Protein Type 2 Subunit alpha (Nav1.2) Channel Blockers; Sodium-channel-antagonists; Analgesic; Antiepileptic; Antiepileptic Drugs; Epilepsy and Seizure Disorders; Non-Opioid Analgesics; Pain
CBR-050-068-356-7,RFM-012-465-2,CBR-050-068-356-7,CCOc1cc(/C=C(\C(=O)N)/C#N)cc(c1O)CSc1ccccc1,CBR-HVAC-14867: PROTEIN TYROSINE KINASE; Protein-tyrosine-kinase-inhibitors; SRC Inhibitor; Tyrosine kinase inhibitor (TKI); ANTI-INFLAMMATORY¬ANTI-ATHEROSCLEROTIC; Hyperlipidaemia; Ischaemic Heart Disease
CBR-050-068-357-8,RFM-012-466-3,CBR-050-068-357-8,CCOC(=O)C1=C(CN2CCOCC2)NC(=NC1c1ccc(cc1Br)F)c1nccs1,CBR-HVAC-14879: CAPSID PROTEIN Inhibitor; ANTI-VIRAL; Anti-Hepatitis B Virus Drugs
CBR-050-068-358-9,RFM-012-467-4,CBR-050-068-358-9,OC(=O)[C@H]1CCCN1C(=O)CCCCC(=O)N1CCC[C@@H]1C(=O)O,"CBR-HVAC-00251: Amyloid protein deposition inhibitor; Anti-Human Serum Amyloid P (Anti-SAP); Antiamyloidogenic Agents; Serum amyloid P binding inhibitor; Serum amyloid P protein antagonist; Serum-amyloid-P-component-inhibitors; Alzheimer's Dementia, Treatment of ; Amyloidosis, Treatment of; Metabolic Disorders; Nootropic"
CBR-050-068-359-0,RFM-012-468-5,CBR-050-068-359-0,O/N=C(\c1ccccc1)/c1cc(c(c(c1)C(C)(C)C)O)C(C)(C)C,CBR-HVAC-03452: Cyclooxygenase (COX) Inhibitors; Cyclooxygenase inhibitor; Lipoxygenase Inhibitors; Lipoxygenase inhibitor; Reducing agent; Signal Transduction Modulators; Antiarthritic Drugs
CBR-050-068-360-3,RFM-012-469-6,CBR-050-068-360-3,CCOc1ccc2c(c1)nc([nH]2)SCCN1CCOCC1,"CBR-HVAC-05059: Anxiolytics; Cerebrovascular Diseases, Treatment of; Cognition Disorders, Treatment of"
CBR-050-068-361-4,RFM-012-470-9,CBR-050-068-361-4,COc1ccc2c(c1)[nH]c1c2C[C@@H]2N([C@H]1C=C(C)C)C(=O)[C@H]1N(C2=O)CCC1,CBR-HVAC-11247: ABC transporter G2 Inhibitor; Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors; Anticancer; Cancer Multidrug Resistance Modulators
CBR-050-068-362-5,RFM-012-471-0,CBR-050-068-362-5,CC(=O)Oc1ccc2c(c1)oc(=O)c(c2)Oc1ccc(cc1)Cl,CBR-HVAC-11653: Non-nucleoside reverse transcriptase Inhibitor; Anti-HIV
CBR-050-068-363-6,RFM-012-472-1,CBR-050-068-363-6,O1CCN(CC1)c1ccc(cc1)Nc1ncnc2c1cc(cc2)c1ccc2c(c1)c(ncn2)Nc1ccc(cc1)N1CCOCC1,CBR-HVAC-14071: Non-Structural Protein 5A (NS5A) (HCV) Inhibitors; Anti-Hepatitis C Virus Drugs
CBR-050-068-364-7,RFM-012-473-2,CBR-050-068-364-7,O=C1NC(=O)C(S1)Cc1ccc(cc1)OCCc1ccc(cn1)C(O)C,"CBR-HVAC-14587: Antidiabetic Drugs; Lipoprotein Disorders, Treatment of ; Neurological Genetic Disorders, Treatment of"
CBR-050-068-365-8,RFM-012-474-3,CBR-050-068-365-8,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(C)C)CCCCN)CCCCN)CC(C)C)[C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)N)CCCCN)CC(C)C)Cc1ccccc1)CCCCN,CBR-HVAC-14588: Breast Cancer Therapy
CBR-050-068-366-9,RFM-012-475-4,CBR-050-068-366-9,Cc1cn([C@H]2C[C@@H]([C@]3([C@@H]2C3)CO)O)c(=O)[nH]c1=O,CBR-HVAC-14596: Anti-Herpes Simplex Virus Drugs; Anti-Varicella Zoster Virus Drugs; Antiviral Drugs; Oncolytic Drugs
CBR-050-068-367-0,RFM-012-476-5,CBR-050-068-367-0,CCCCOC(=O)NS(=O)(=O)c1sc(cc1c1ccc(cc1)Cn1cncc1)CC(C)C,"CBR-HVAC-14597: Angiotensin AT2 Agonists; Angiotensin II agonist; Signal Transduction Modulators; Acute Myocardial Infarction, Treatment of; Antidiabetic Drugs; Cancer Associated Disorders, Treatment of; Cognition Disorders, Treatment of; Hypertension, Treatment of; Interstitial Lung Diseases, Treatment of; Ischemic Stroke, Treatment of; Lesions of the Spinal Cord and Related Structures, Treatment of; Rheumatoid Arthritis, Treatment of; Treatment of Cachexia"
CBR-050-068-368-1,RFM-012-477-6,CBR-050-068-368-1,OC(=O)CN1CCN(CC(=O)O)CC(=O)O[Ca]OC(=O)CN(CC1)CC(=O)O,CBR-HVAC-14602: Chelating Agents; Specific Antidotes
CBR-050-068-369-2,RFM-012-478-7,CBR-050-068-369-2,C#CCOc1ccc2c(c1)c(nc(=O)n2Cc1ccc(cc1)Br)c1ccc(cc1)C(C)C,CBR-HVAC-14616: Calcium-sensing receptor antagonist; Calcium-sensing-receptor-antagonists; Musculoskeletal Disorders; Treatment of Osteoporosis; Unidentified
CBR-050-068-370-5,RFM-012-479-8,CBR-050-068-370-5,CNC(=O)c1nccc(c1)Oc1ccc2c(c1)sc(n2)N[C@@H]1CCCC[C@H]1O,CBR-HVAC-14618: Angiogenesis Inhibitors; COLONY STIMULATING FACTOR 1 RECEPTOR Inhibitor; CSF1R (c-FMS) Inhibitors; Signal Transduction Modulators; ANTICANCER; Solid Tumors Therapy
CBR-050-068-371-6,RFM-012-480-1,CBR-050-068-371-6,OC[C@@H]([C@H](Nc1nc(SCc2cccc(c2F)F)nc(c1)NS(=O)(=O)N1CCC1)C)O,"CBR-HVAC-14636: Chemokine CXCR2 (IL-8 beta Receptor) Antagonists; Signal Transduction Modulators; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of"
CBR-050-068-372-7,RFM-012-481-2,CBR-050-068-372-7,CN1CCN(CC1)Cc1ccc(cc1)Nc1ncc(c(n1)Nc1ccccc1S(=O)(=O)N(C)C)Cl,CBR-HVAC-14669: AXL KINASE Inhibior; Antimitotic Drugs; Apoptosis Inducers; Aurora-A (ARK1) Kinase Inhibitors; Aurora-B (ARK2) Kinase Inhibitors; Signal Transduction Modulators; Tyrosine-Protein Kinase Receptor UFO (AXL) Inhibitors; ANTI-CANCER; Head and Neck Cancer Therapy; Leukemia Therapy; Lung Cancer Therapy; Neurologic Cancer Therapy; Pancreatic Cancer Therapy; Solid Tumors Therapy
CBR-050-068-373-8,RFM-012-482-3,CBR-050-068-373-8,ONC(=O)CCCCCCNC(=O)c1cnc(nc1)N(c1ccccc1Cl)c1ccccc1,CBR-HVAC-14741: Epigenetic Modifier Modulators; HDAC6 Inhibitor; HDAC6-protein-inhibitors; Histone Deacetylase 6 (HDAC6) Inhibitors; ANTI-NEOPLASTIC; Cancer; Multiple Myeloma Therapy; Non-Small Cell Lung Cancer Therapy; Solid Tumors Therapy
CBR-050-068-374-9,RFM-012-483-4,CBR-050-068-374-9,Fc1cc2c(C3CC(=O)NC3=O)c[nH]c2cc1,"CBR-HVAC-14773: Immune Checkpoint Inhibitors; Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Inhibitors; Brain Cancer Therapy"
CBR-050-068-375-0,RFM-012-484-5,CBR-050-068-375-0,OC1CCC2(C(=CC[C@@H]3[C@@H]2CC2=C(C)[C@]4(CC[C@@H]32)O[C@H]2[C@H]([C@H]4C)NCC(C2)C)C1)C,CBR-HVAC-14839: Hedgehog protein inhibitor; Anticancer
CBR-050-068-376-1,RFM-012-485-6,CBR-050-068-376-1,O=C(c1ccc2c(c1)sc(=O)[nH]2)c1ccccc1,CBR-HVAC-14858: ANALGESIC
CBR-050-068-377-2,RFM-012-486-7,CBR-050-068-377-2,O=C(C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)(C)C)N(c1cnc(cc1c1ccccc1C)C1CC[N+](CC1)(C)COP(=O)(O)O)C,CBR-HVAC-14889
CBR-050-068-378-3,RFM-012-487-8,CBR-050-068-378-3,CCCCOC1=C(C(=O)C1=O)OCCCC,CBR-HVAC-14890
CBR-050-068-419-5,RFM-012-488-9,CBR-050-068-419-5,O=C(OCC(Oc1ccc(cc1)C(=C)C1COC2(OO1)C1CC3CC2CC(C1)C3)(C)C)CCC(=O)O,CBR-HVAC-06165: Protozoacide; Antimalarials; Protozoacide
CBR-050-068-420-8,RFM-012-489-0,CBR-050-068-420-8,N#Cc1ccc(c(c1)O)Oc1ccc2c(c1)COB2O,analog of CBR-HVAC-12209
CBR-050-068-421-9,RFM-012-490-3,CBR-050-068-421-9,FC(c1cccc(c1)c1ccc(cc1)c1cn2c(n1)sc(n2)S(=O)(=O)N)(F)F,"CBR-HVAC-11840: Heat Shock Protein 70 (Hsp70) Inducers; Heat shock protein 70; Heat shock protein 90 Inhibitor; Modulator; Signal Transduction Modulators; Stress-Activated Protein (SAP/Jun) Kinase Inhibitors; Diabetic Neuropathy, Agents for; Disorders Associated with Cancer Therapy, Treatment of; Neuroprotectant"
CBR-050-068-422-0,RFM-012-491-4,CBR-050-068-422-0,CCCCCCCCc1ccc2c(c1)C(=O)c1n2c(=O)c2c(n1)ccnc2,CBR-HVAC-12267: Antibacterial; Antimycobacterial; Antibacterial; Antimycobacterial; Antimycobacterial Agents; Bacterial Infections
CBR-050-068-423-1,RFM-012-492-5,CBR-050-068-423-1,OC(=O)[C@@H]1C[C@H]1c1ccc(cc1F)c1cccc(c1)n1cc(C(=O)NC2CC2)c(=O)c2c1nccc2,"CBR-HVAC-00491: Phosphodiesterase 4 inhibitor; Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; Alzheimer's Dementia, Treatment of ; Neuroprotectant"
CBR-050-068-424-2,RFM-012-493-6,CBR-050-068-424-2,Clc1ccc(cc1)c1cc(cc(c1O)CNC(C)(C)C)Nc1ccnc2c1ccc(c2)Cl,CBR-HVAC-01224: Acidifying agent non gastric; Calmodulin antagonist; Antimalarial; Antiviral Drugs
CBR-050-068-425-3,RFM-012-494-7,CBR-050-068-425-3,O[C@@H]1CO[C@H]2[C@@H]1OC[C@H]2Oc1[nH]c2c(n1)nc(c(c2)Cl)c1ccc(cc1)c1ccccc1,CBR-HVAC-15124:pan-AMPK activator
CBR-050-068-426-4,RFM-012-495-8,CBR-050-068-426-4,O=C(Nc1n(C)nc(c1c1ccc(cc1F)Cl)C)Cn1c(nc2c1cccc2)C(C)C,CBR-HVAC-15128: ATPase 4 inhibitor; P-type ATPase4 (ATP4) (Plasmodium falciparum) Inhibitors; Antimalarials
CBR-050-068-427-5,RFM-012-496-9,CBR-050-068-427-5,N#Cc1cc(ccc1F)NC(=O)[C@H]1c2ccccc2C(=O)N([C@@H]1c1cccnc1)CC(F)(F)F,CBR-HVAC-14720: P-type ATPase4 (ATP4) (Plasmodium falciparum) Inhibitors; Antimalarials
CBR-050-068-428-6,RFM-012-497-0,CBR-050-068-428-6,FC(Oc1ccc(c2c1oc1c2cncc1)C(=O)Nc1c(Cl)c[n+](cc1Cl)[O-])F,"CBR-HVAC-06491: Cytokine Production Inhibitors; Phosphodiesterase 4 Inhibitor; Phosphodiesterase PDE4 Inhibitors; Signal Transduction Modulators; TNF-alpha Production Inhibitors; Type-4-cyclic-nucleotide-phosphodiesterase-inhibitors; Antiinflammatory; Asthma Therapy; Inflammation; Inflammation, Treatment of; Multiple Sclerosis, Agents for; Neurological Disorders; Obstructive Airways Disease; Respiratory Tract Disorders; Rheumatic Disease; Rheumatoid Arthritis, Treatment of"
CBR-050-068-429-7,RFM-012-498-1,CBR-050-068-429-7,OC(=O)c1ccc(c(c1)O)Oc1ccc2c(c1)COB2O,CBR-HVAC-12209: Antimalarial; ANTIMALARIAL; Antimalarials
CBR-050-068-430-0,RFM-012-499-2,CBR-050-068-430-0,OC(=O)c1ccc(c(c1)O)Oc1ccc2c(c1)COB2O,CBR-HVAC-12209: Antimalarial; ANTIMALARIAL; Antimalarials
CBR-050-068-431-1,RFM-012-500-8,CBR-050-068-431-1,CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O,CBR-HVAC-03945: Alpha glucosidase inhibitor; Alpha-glucosidase Inhibitor; Alpha-glucosidase-inhibitors; alpha-Glucosidase Inhibitors; Anti-Hepatitis C Virus Drugs; Antiviral; Antiviral Drugs; Viral Infections
CBR-050-068-432-2,RFM-012-501-9,CBR-050-068-432-2,O=C1NCc2c(N[C@H]1C)ncc(c2)/C=C/C(=O)N(Cc1oc2c(c1C)cccc2)C,CBR-HVAC-15123: Enoyl-ACP-reductase-inhibitors; FABI Inhibitor; FABI inhibitor; ANTI-INFECTIVE; Bacterial Infections
CBR-050-068-433-3,RFM-012-502-0,CBR-050-068-433-3,CC(CC(=O)Nc1cncc(c1)c1ccc2c(c1)c(n[nH]2)c1nc2c([nH]1)cncc2c1cccc(c1)F)C,CBR-HVAC-15120: Wnt-signalling-pathway-inhibitors; Respiratory Tract Disorders
CBR-050-068-434-4,RFM-012-503-1,CBR-050-068-434-4,Cc1cc(Nc2ccc(nc2)C(F)(F)F)n2c(n1)nc(n2)C(F)(F)C,CBR-HVAC-15126: DIHYDROOROTATE DEHYDROGENASE Inhibitor; Dihydroorotate-dehydrogenase-inhibitors; ANTI-MALARIAL; Parasitic Infections
CBR-050-068-435-5,RFM-012-504-2,CBR-050-068-435-5,OC(=O)CNC(=O)c1ccc(cc1)C(=O)NC(C(=O)N1CCC[C@H]1C(=O)NC(C(=O)C(F)(F)F)C(C)C)C(C)C,"CBR-HVAC-04871: Elastase inhibitor; Neutrophil Elastase (Leukocyte Elastase) Inhibitors; Neutrophil elastase Inhibitor; Acute Respiratory Distress Syndrome (ARDS), Agents for; Antiinflammatory; Pulmonary Emphysema, Agents for"
CBR-050-068-436-6,RFM-012-505-3,CBR-050-068-436-6,OC(=O)CNC(=O)c1ccc(cc1)C(=O)NC(C(=O)N1CCC[C@H]1C(=O)NC(C(=O)C(F)(F)F)C(C)C)C(C)C,"CBR-HVAC-04871: Elastase inhibitor; Neutrophil Elastase (Leukocyte Elastase) Inhibitors; Neutrophil elastase Inhibitor; Acute Respiratory Distress Syndrome (ARDS), Agents for; Antiinflammatory; Pulmonary Emphysema, Agents for"
CBR-050-068-437-7,RFM-012-506-4,CBR-050-068-437-7,CCOc1cc(ccc1OC)[C@H](N1Cc2c(C1=O)c(ccc2)NC(=O)C1CC1)CS(=O)(=O)C,CBR-HVAC-12362: Phosphodiesterase 4; Phosphodiesterase 4 inhibitor; Signal Transduction Modulators; TNF alpha Inhibitor; TNF-alpha Antagonists; Anti-inflammatory; Immunomodulators
CBR-050-068-438-8,RFM-012-507-5,CBR-050-068-438-8,O=C(C(SC(=O)c1cccs1)C)NC1CCSC1=O,"CBR-HVAC-00804: Chymotrypsin inhibitor; Chymotrypsin-inhibitors; Elastase inhibitor; Leucocyte-elastase-inhibitors; Mucolytic agent; Neutrophil Elastase (Leukocyte Elastase) Inhibitors; Neutrophil elastase Inhibitor; Serine protease inhibitor; Mucolytics; Neutrophil elastase inhibitor; Obstructive Airways Disease; Pulmonary Emphysema, Agents for; Respiratory Tract Disorders"
CBR-050-068-439-9,RFM-012-508-6,CBR-050-068-439-9,OC(C(S(=O)(=O)C)(C)C)(c1ccc(cc1)C(F)(F)F)Cn1ncnc1,CBR-HVAC-00530: 14-alpha-demethylase-inhibitors; Cell wall synthesis inhibitor; Ergosterol synthesis inhibitor; Sterol demethylase inhibitor; Antifungal; Antifungal Agents; Mycoses
CBR-050-068-440-2,RFM-012-509-7,CBR-050-068-440-2,OC(C(S(=O)(=O)C)(C)C)(c1ccc(cc1)C(F)(F)F)Cn1ncnc1,CBR-HVAC-00530: 14-alpha-demethylase-inhibitors; Cell wall synthesis inhibitor; Ergosterol synthesis inhibitor; Sterol demethylase inhibitor; Antifungal; Antifungal Agents; Mycoses
CBR-050-068-441-3,RFM-012-510-0,CBR-050-068-441-3,O=C(N1CCN(CC1)C(=O)NCc1ccc(cc1)NC(=N)N)O[C@@H]1CO[C@H]2[C@@H]1OC[C@H]2OC(=O)N1CCN(CC1)C(=O)NCc1ccc(cc1)NC(=N)N,"CBR-HVAC-05039: Peptide-hydrolase-inhibitors; Tryptase Inhibitor; Tryptase Inhibitors; Tryptase-inhibitors; Anti-inflammatory; Antipsoriatic; Antipsoriatics; Asthma Therapy; Inflammatory Bowel Disease, Agents for; Inflammatory Bowel Disorders; Skin Disorders"
CBR-050-068-442-4,RFM-012-511-1,CBR-050-068-442-4,CCCCCCCOC(=O)NC1=NC(=O)N(CN1)C1C[C@@H]([C@H](O1)CO)O,CBR-HVAC-12268: DNA inhibitor; HIV-replication-inhibitors; Nucleoside reverse transcriptase inhibitor; Reverse transcriptase Inhibitor; Anti-HIV; Anti-HIV Agents; Viral Infections
CBR-050-068-443-5,RFM-012-512-2,CBR-050-068-443-5,Fc1ccc(c(c1)F)C(C(N1CCN(CC1)c1ccc(cc1)n1cnn(c1=O)Cc1ccc(cc1)OC(F)(F)F)C)(Cn1ncnc1)O,CBR-HVAC-11044: Cell wall synthesis inhibitor; Lanosterol 14 alpha-demethylase Inhibitor; Sterol demethylase inhibitor; Antifungal Agents; Fungicide
CBR-050-068-444-6,RFM-012-513-3,CBR-050-068-444-6,Oc1ccc(cc1)C[C@H]1C(=O)N(Cc2cccc3c2nccc3)[C@H]([C@H]2N1C(=O)CN(N2C(=O)NCc1ccccc1)C)C,"CBR-HVAC-14358: Antipsoriatics; Scleroderma, Agents for"
CBR-050-068-445-7,RFM-012-514-4,CBR-050-068-445-7,COCCOc1cc2c(cc1Oc1ccnc(c1)NC(=O)c1ccc(cc1)C1CCN(CC1)CCO)ccn2C(=O)NC,CBR-HVAC-14362: Angiogenesis Inhibitors; FGFR1 Inhibitors; FGFR2 Inhibitors; FGFR3 Inhibitors; Signal Transduction Modulators; Solid Tumors Therapy
CBR-050-068-446-8,RFM-012-515-5,CBR-050-068-446-8,Nc1ccn(c(=O)n1)[C@@H]1O[C@@H](C[C@@H]1F)CO,CBR-HVAC-12235: Antiviral; RNA-directed-DNA-polymerase-inhibitors; Reverse Transcriptase Inhibitors; Anti-HIV Agents; Antiviral; Viral Infections
CBR-050-068-447-9,RFM-012-516-6,CBR-050-068-447-9,COc1cccc(n1)NCC(Cn1c2ccc(cc2c2c1ccc(c2)Br)Br)F,CBR-HVAC-14455: Nicotinamide Phosphoribosyltransferase (NAmPRTase; Nampt) Activators; Antiparkinsonian Drugs
CBR-050-068-448-0,RFM-012-517-7,CBR-050-068-448-0,COc1cccc(n1)NCC(Cn1c2ccc(cc2c2c1ccc(c2)Br)Br)F,CBR-HVAC-14455: Nicotinamide Phosphoribosyltransferase (NAmPRTase; Nampt) Activators; Antiparkinsonian Drugs
CBR-050-068-449-1,RFM-012-518-8,CBR-050-068-449-1,FCC(Cn1cnc2c1nc(N)nc2N)OCP(=O)(O)O,CBR-HVAC-12295: RNA-directed-DNA-polymerase-inhibitors; Reverse transcriptase Inhibitor; Antiviral; Viral Infections
CBR-050-068-450-4,RFM-012-519-9,CBR-050-068-450-4,Fc1ccc(cc1)CN1Cc2c(C1=O)c(O)c1c(c2N(S(=O)(=O)C)C)cccn1,CBR-HVAC-06509: HIV Integrase Inhibitors; HIV integrase inhibitor; HIV-1 INTEGRASE Inhibitor; HIV-integrase-inhibitors; Anti-HIV; Anti-HIV Agents; Viral Infections
CBR-050-068-481-1,RFM-012-520-2,CBR-050-068-481-1,CCCCCCOC(=O)CCC(=O)CN,CBR-HVAC-05485: Oxidizing agent; Photosensitisers; Bladder Cancer Therapy ; Cancer; Diagnostic for Cancer; Premalignant Conditions Therapy
CBR-050-068-482-2,RFM-012-521-3,CBR-050-068-482-2,CN(CCn1c(=O)c2cc(NC(=O)N)cc3c2c(c1=O)ccc3)C,CBR-HVAC-06594: Angiogenesis Inhibitors; Angiogenesis-inhibitors; Chemokine Receptor Antagonists; Chemokine-inhibitors; Signal Transduction Modulators; Topoisomerase II Inhibitor; Anticancer; Antineoplastic Enhancing Agents; Cancer; Lymphoma Therapy; Oncolytic Drugs; Solid Tumors Therapy
CBR-050-068-483-3,RFM-012-522-4,CBR-050-068-483-3,COc1c(OC[C@H](CN2CCOCC2)O)ccc2c1nc(NC(=O)c1cccnc1C)n1c2=NCC1,CBR-HVAC-14748: Phosphatidylinositol 3-Kinase alpha (PI3Kalpha) Inhibitors; Phosphatidylinositol 3-Kinase beta (PI3Kbeta) Inhibitors; Signal Transduction Modulators; Oncolytic Drugs
CBR-050-068-484-4,RFM-012-523-5,CBR-050-068-484-4,CC#CCC([C@@H](/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)C,"CBR-HVAC-02034: Platelet aggregation inhibitor; Prostacyclin Analogs; Prostacyclin-agonists; Prostaglandin I receptor 2 Inhibitor; Prostaglandin IP2 receptor agonist; Antiplatelet; Chemopreventive Agents; Coagulation Disorders Therapy; Drug Delivery Systems; Peripheral Arterial Disease, Treatment of; Peripheral Vascular Disease, Treatment of; Peripheral vasodilator; Platelet aggregation inhibitor; Pulmonary Hypertension, Treatment of; Raynaud's Phenomenon, Treatment for ; Respiratory Tract Disorders; Thromboses; Treatment of Peripheral Obstructive Vascular Disease; Vascular Disorders; Vasodilator"
CBR-050-068-485-5,RFM-012-524-6,CBR-050-068-485-5,O=C([C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O)NNC(=O)[C@@H]1CCCNC1,CBR-HVAC-14691: Penicillin-Binding Protein 2 (pbpA) (Acinetobacter baumannii) Inhibitors; Penicillin-binding-protein-inhibitors; ANTI-BACTERIAL; Antibacterial Drugs; Bacterial Infections
CBR-050-068-486-6,RFM-012-525-7,CBR-050-068-486-6,OC(=O)[C@H](Cc1cc(Cl)c(c(c1)Cl)OCc1cc(N)cc2c1oc(n2)c1ccccc1)N,CBR-HVAC-07011: Large Neutral Amino Acids Transporter Small Subunit 1 (SLC7A5; LAT1) Inhibitors; [14C]-LEUCINE UPTAKE INHIBITOR; Oncolytic Drugs; Solid Tumors Therapy
CBR-050-068-487-7,RFM-012-526-8,CBR-050-068-487-7,OC(=O)[C@H]1C2CCC([C@@H]1Nc1nc(ncc1F)c1c[nH]c3c1cc(F)cn3)CC2,CBR-HVAC-07154: Anti-Influenza A Virus Drugs
CBR-050-068-488-8,RFM-012-527-9,CBR-050-068-488-8,COc1cc(OCc2nc(sc2C)N2CCOCC2)c2c(c1)oc(c2)c1cn2c(n1)sc(n2)OC,CBR-HVAC-14727: PAR4 Antagonists; Platelet Adhesion Inhibitors; Signal Transduction Modulators; Thrombolytics
CBR-050-068-489-9,RFM-012-528-0,CBR-050-068-489-9,[O-]C(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)[C@@]1(C)Cn1cc[n+](n1)C,CBR-HVAC-07354: beta-Lactamase Inhibitors; Antibacterial Drugs
CBR-050-068-490-2,RFM-012-529-1,CBR-050-068-490-2,COc1ccc(cc1)C(c1ccc(cc1)OC)NC(=O)c1cnc(nc1O)c1cccnn1,CBR-HVAC-14784: Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitors; Antianemics
CBR-050-068-491-3,RFM-012-530-4,CBR-050-068-491-3,O=C(/C=C/c1cccnc1)NCCCCC1CCN(CC1)C(=O)c1ccccc1,CBR-HVAC-05019: Angiogenesis Inhibitors; Angiogenesis-inhibitors; Apoptosis Inducers; Niacinamide phosphoribosyltransferase inhibitor; Nicotinamide Phosphoribosyltransferase (NAmPRTase; Nampt) Inhibitors; Nicotinamide phosphoribosyltransferase Inhibitor; Nicotinamide-phosphoribosyltransferase-inhibitors; Anticancer; Antineoplastic Enhancing Agents; Cancer; Immunosuppressants; Leukemia Therapy; Melanoma Therapy; Non-Hodgkin's Lymphoma Therapy; Oncolytic Drugs; Treatment of Autoimmune Diseases
CBR-050-068-492-4,RFM-012-531-5,CBR-050-068-492-4,CC(=O)Nc1c(I)c(NC(=O)C)c(c(c1I)C(=O)O)I,CBR-HVAC-09682: Beta-glucuronidase Inhibitor; Diagnostic Agents; Diagnostic agent
CBR-050-068-493-5,RFM-012-532-6,CBR-050-068-493-5,O=C(Nc1c(I)cc(c(c1I)C(=O)O)I)CCCCC(=O)Nc1c(I)cc(c(c1I)C(=O)O)I,CBR-HVAC-10354: Radiopaque contrast agent; Radiopaque contrast agent
CBR-050-068-494-6,RFM-012-533-7,CBR-050-068-494-6,CSCC[C@@H](C(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](Cc1ccc(cc1)O)N,"CBR-HVAC-03308: Signal Transduction Modulators; delta-Opioid Receptor Agonists; mu-Opioid Receptor Agonists; Anti-HIV Agents; Antitumor; Cancer Immunotherapy; Head and Neck Cancer Therapy; Immunostimulants; Liver Cancer Therapy; Multiple Sclerosis, Agents for; Pancreatic Cancer Therapy; Solid Tumors Therapy"
CBR-050-068-495-7,RFM-012-534-8,CBR-050-068-495-7,CCCCCCCC(=O)OCC(CO)O,CBR-HVAC-14391: Immunomodulators; Nonsteroidal antiinflammatory; ANTI-INFLAMMATORY; Dermatologic Drugs; Skin Disorders
CBR-050-068-496-8,RFM-012-535-9,CBR-050-068-496-8,OC1CC(C)(C)N(C(C1)(C)C)[O],"CBR-HVAC-04317: Angiogenesis Inhibitors; Antioxidants; Free Radical Scavengers; Free-radical-scavengers; Age-Related Macular Degeneration, Treatment of; Bacterial Infections; Cancer; Congenital Malformations, Treatment of; Diabetic Retinopathy, Agents for; Drug Withdrawal; Hypertension, Treatment of; Neurodegenerative Diseases, Treatment of; Neurological Disorders; Radioprotectants/Radiomitigators; Rheumatic Disease"
CBR-050-068-497-9,RFM-012-536-0,CBR-050-068-497-9,CC(=O)C(=O)[O-],"CBR-HVAC-02416: Antioxidants; Antiobesity; Antiobesity Drugs; Asthma Therapy; Chronic Obstructive Pulmonary Diseases (COPD), Treatment of; Cystic Fibrosis, Treatment of ; Heart Failure Therapy"
CBR-050-068-498-0,RFM-012-537-1,CBR-050-068-498-0,NCCCS(=O)(=O)O,"CBR-HVAC-05199: Amyloid precursor protein antagonist; Amyloid protein deposition inhibitor; Antiamyloidogenic Agents; Beta amyloid precursor protein antagonist; beta-Amyloid (Abeta) Aggregation Inhibitors; Alzheimer's Dementia, Treatment of ; Hemorrhagic Stroke, Treatment of; Neuroprotectant; Nootropic; Vasoprotectant"
CBR-050-068-499-1,RFM-012-538-2,CBR-050-068-499-1,COc1cc(/C=C/c2ccc(cc2)O)cc(c1)OC,"CBR-HVAC-05765: Antioxidants; Apoptosis Inducers; Autophagy Inducers; Extracellular-regulated Kinase (ERK) Activators; Fatty Acid Amide Hydrolase (FAAH) Inhibitors; Inhibitor; PPAR ALPHA; PPARalpha Agonists; Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors; Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors; Signal Transduction Modulators; TELOMERASE Agonist; ANTI-OXIDANTHYPOLIPIDEMICANTI-CANCERANTI-INFLAMMATORYANTI-DIABETICANTI-VIRALNEUROPROTECTANT; Antiarthritic Drugs; Antidiabetic Drugs; Anxiolytics; Lipoprotein Disorders, Treatment of ; Oncolytic Drugs"
CBR-050-068-500-7,RFM-012-539-3,CBR-050-068-500-7,ClCCN(CCCl)CCCl,CBR-HVAC-13209: Antineoplastic
CBR-050-069-030-2,RFM-012-540-6,CBR-050-069-030-2,CON,CBR-HVAC-00242: Anticancer; DNA Repair Inhibitors; DNA repair enzyme inhibitor; DNA-repair-inhibitors; Anticancer; Antineoplastic Enhancing Agents; Cancer; Glioblastoma Multiforme Therapy
CBR-050-069-031-3,RFM-012-541-7,CBR-050-069-031-3,Fc1ccc(c(c1)C)[C@H]1C[C@H](CCN1C(=O)N([C@@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)C)N1CCN(CC1)C(=O)C,"CBR-HVAC-05713: NEUROKININ-1 RECEPTOR Antagonist; Neurokinin 1 receptor antagonist; Neurokinin-1-antagonists; Signal Transduction Modulators; Tachykinin NK1 Receptor Antagonists; Advances in the Treatment of Nausea and Migraine; Anti-emetic; Antidepressant; Antidepressants; Anxiolytic; Anxiolytics; Fibromyalgia, Treatment of; Nausea and Vomiting, Treatment of; Sleep Disorders, Treatment of; Urinary Incontinence Therapy"
CBR-050-069-032-4,RFM-012-542-8,CBR-050-069-032-4,CC(=CCC[C@]1(C)[C@@H](CC=C(C)C)C[C@]2(C(=O)[C@]1(C(=O)C(C)C)C(=C(C2=O)CC=C(C)C)O)CC=C(C)C)C,"CBR-HVAC-05224: 5-Lipoxygenase Inhibitors; Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors; Signal Transduction Modulators; TRPC6 Agonists; alpha-Secretase Activators; ANTIDEPRESSANT; Antidepressants; Atopic Dermatitis, Agents for; Oncolytic Drugs"
CBR-050-069-033-5,RFM-012-543-9,CBR-050-069-033-5,OC(Cn1ccnc1[N+](=O)[O-])CN1CCCCC1,CBR-HVAC-02948: Anticancer; Hypoxia-selective agent; Anticancer; Cancer; Diagnostic for Cancer; Hypoxia-selective; Oncolytic Drugs
CBR-050-069-034-6,RFM-012-544-0,CBR-050-069-034-6,O=C1CC[C@@H](C(=O)N1)N1Cc2c(C1=O)cccc2OCc1ccc(cc1)CN1CCOCC1,"CBR-HVAC-12480: Cereblon (CRBN) Inhibitors; IL-2 Production Enhancers; Signal Transduction Modulators; TNF-alpha Production Inhibitors; ANTI-INFLAMMATORY; Inflammation, Treatment of; Multiple Myeloma Therapy; Scleroderma, Agents for; Systemic Lupus Erythematosus, Agents for"
CBR-050-069-035-7,RFM-012-545-1,CBR-050-069-035-7,C[C@@H](c1ccccc1)Nc1cc(=O)n(c(=O)[nH]1)C(C)C,CBR-HVAC-13737: Drugs Targeting Myosin; Cardiovascular Diseases (Not Specified)
CBR-050-069-036-8,RFM-012-546-2,CBR-050-069-036-8,C#C[C@]1(O)CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)CC[C@H](C2)O,CBR-HVAC-00715: Androgen receptor antagonist; Androgen-receptor-antagonists; Apoptosis Inducers; Apoptosis stimulant; Apoptosis-stimulants; Raf-kinase-inhibitors; SRC Inhibitor; src-Family-kinase-inhibitors; Anticancer; Breast Cancer Therapy; Cancer; Oncolytic Drugs; Prostate Cancer Therapy
CBR-050-069-037-9,RFM-012-547-3,CBR-050-069-037-9,Nc1n[n+]([O-])c2c([n+]1[O-])cccc2,CBR-HVAC-03486: DNA inhibitor; DNA topoisomerase II Inhibitor; DNA-Damaging Drugs; Reducing agent; Type-II-DNA-topoisomerase-inhibitors; Anticancer; Antineoplastic Enhancing Agents; Cancer; Cervical Cancer Therapy; Chemosensitizer; Head and Neck Cancer Therapy; Liver Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Small Cell Lung Cancer Therapy; Women's Health
CBR-050-069-038-0,RFM-012-548-4,CBR-050-069-038-0,Cn1c(nnc1C12CCC(CC1)(CC2)c1noc(n1)C1CC(C1)(F)F)c1ccccc1C(F)(F)F,CBR-HVAC-12392: Smoothened homolog Inhibitor; Antineoplastic; Oncolytic Drugs
CBR-050-069-039-1,RFM-012-549-5,CBR-050-069-039-1,OC[C@@H](C(C)C)Nc1nc(Nc2cccc(c2)Cl)c2c(n1)n(cn2)C(C)C,"CBR-HVAC-14840: CDK Inhibitor; CDK1/Cyclin B Inhibitors; CDK2/Cyclin A Inhibitors; CDK2/Cyclin E Inhibitors; CDK4/Cyclin D1 Inhibitors; CDK5 Inhibitors; Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase (DYRK) Inhibitors; Signal Transduction Modulators; Cyclin dependent kinase inhibitor; Neurodegenerative Diseases, Treatment of; Oncolytic Drugs"
CBR-050-069-040-4,RFM-012-550-8,CBR-050-069-040-4,O=C(O[C@@H](c1ccccc1)C)Nc1c(C)noc1c1ccc(cc1)c1ccc(cc1)C1(CC1)C(=O)O,"CBR-HVAC-07078: Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2) Antagonists; Signal Transduction Modulators; Antipsoriatics; Fibrosis, Treatment of; Interstitial Lung Diseases, Treatment of; Respiratory Disorders (Not Specified)"
CBR-050-069-041-5,RFM-012-551-9,CBR-050-069-041-5,C/C(=C\C=C\C=C(\C=C\C=C(\C=C\C1=C(C)C(=O)[C@H](CC1(C)C)O)/C)/C)/C=C/C=C(/C=C/C1=C(C)C(=O)[C@H](CC1(C)C)O)\C,"CBR-HVAC-05649: Antioxidants; HDL-Cholesterol Increasing Agents; Inflammation, Treatment of; Lipoprotein Disorders, Treatment of ; Non-Opioid Analgesics; Therapy of Vitamin-Related Disorders"
CBR-050-069-042-6,RFM-012-552-0,CBR-050-069-042-6,ClCCN(C(=O)NC1CCC(CC1)C)N=O,CBR-HVAC-12872: Alkylating agent; Alkylating-agents; Anticancer; DNA Alkylating Drugs; DNA inhibitor; Anticancer; Cancer; Oncolytic Drugs
CBR-050-069-043-7,RFM-012-553-1,CBR-050-069-043-7,COc1ccc2c(c1)[C@@]13CCCC[C@@H]3[C@H](C2)N(CC1)C,"CBR-HVAC-01258: Alpha adrenoreceptor agonist; Beta adrenoreceptor agonist; Cyclooxygenase 1 inhibitor; Cyclooxygenase 2 inhibitor; Mucolytic agent; NMDA Receptor Antagonists; Neurotransmitter antagonist; Opioid antitussive substance that exerts a depressant action on the medullary cough centre, thereby elevating the cough threshold; Signal Transduction Modulators; sigma1 Receptor Agonists; Amyotrophic Lateral Sclerosis, Agents for; Antidepressants; Antiepileptic Drugs; Antitussive; Antitussives; Diabetic Neuropathy, Agents for; Diabetic Retinopathy, Agents for; Fibromyalgia, Treatment of; Multiple Sclerosis, Agents for; Neurodegenerative Diseases, Treatment of; Neurologic Drugs (Miscellaneous); Neurological Genetic Disorders, Treatment of ; Neuropathic Pain, Treatment of"
CBR-050-069-044-8,RFM-012-554-2,CBR-050-069-044-8,COc1ccc2c(c1)cc([nH]2)C(=O)N1CCC(CC1)CC(O)(C)C,CBR-HVAC-06878: Aldo-Keto Reductase Family 1 Member C3 (AKR1C3; 17beta-HSD5) Inhibitors; Prostate Cancer Therapy
CBR-050-069-045-9,RFM-012-555-3,CBR-050-069-045-9,CC[C@@]1(O)C(=O)OCc2c1cc1c3nc4ccccc4c(c3Cn1c2=O)CCNC(C)C,CBR-HVAC-01442: DNA Topoisomerase I Inhibitors; DNA topoisomerase I Inhibitor; DNA topoisomerase I inhibitor; DNA-Intercalating Drugs; DNA-topoisomerase-I-inhibitors; Anticancer; Cancer; Cervical Cancer Therapy; Colorectal Cancer Therapy; Drug Delivery Systems; Gastric Cancer Therapy; Non-Small Cell Lung Cancer Therapy; Ovarian Cancer Therapy; Small Cell Lung Cancer Therapy; Solid Tumors Therapy; Topoisomerase I inhibitor
CBR-050-069-046-0,RFM-012-556-4,CBR-050-069-046-0,OC[C@H]1O[C@@H](O[C@H]2CC[C@]3(C(C2(C)C)CC[C@@]2([C@@H]3C[C@@H](O)[C@H]3[C@@]2(C)CC[C@@H]3[C@@](O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H]([C@@H]([C@H]3O)O)O)[C@H]([C@@H]([C@H]2O)O)O)(CCC=C(C)C)C)C)C)[C@@H]([C@H]([C@@H]1O)O)O[C@@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O,CBR-HVAC-13228: Antioxidants; Apoptosis stimulator; Calcium Channel Blockers; Protein synthesis stimulant; Anticancer; Antidiabetic; Antidiabetic Drugs
CBR-050-069-047-1,RFM-012-557-5,CBR-050-069-047-1,OC1C(O)C(O)C(C(C1O)O)O,CBR-HVAC-06166: Antidepressants; Antidiabetic Drugs; Anxiolytics; Chemopreventive Agents
CBR-050-069-048-2,RFM-012-558-6,CBR-050-069-048-2,CN1CCC(C1)CN1c2ccccc2Sc2c1cccc2,CBR-HVAC-02517: Histamine H1 receptor Inhibitor; Protein synthesis inhibitor; Antihistamine
CBR-050-069-049-3,RFM-012-559-7,CBR-050-069-049-3,OC[C@H]1O[C@H](C[C@@H]1N=[N+]=[N-])n1ccc(=O)[nH]c1=O,CBR-HVAC-03876: Reverse transcriptase Inhibitor; Anti-HIV Agents; Antiviral
CBR-050-069-050-6,RFM-012-560-0,CBR-050-069-050-6,CN([C@@H]1C(=O)C(C(=O)NCN2CCCC2)C(=O)[C@@]2([C@H]1C[C@H]1C(C2=O)C(=O)c2c([C@@]1(C)O)cccc2O)O)C,CBR-HVAC-12737: 16S-rRNA of 30S ribosomal subunit Binder; Antibacterial; Antibacterial Drugs
CBR-050-069-051-7,RFM-012-561-1,CBR-050-069-051-7,O=C(/C=C\n1cnc(n1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)NNC(=O)C(C)(C)C,"CBR-HVAC-15137: Exportin-1 (CRM1, XPO1) Antagonists; Exportin-1-protein-inhibitors; Nuclear-export-inhibitors; Signal Transduction Modulators; Transcription factor NF-kappaB inhibitor; ANTI-INFLAMMATORYIMMUNOTHERAPEUTIC AGENTANTI-VIRAL; Amyotrophic Lateral Sclerosis, Agents for; Cancer; Epilepsy and Seizure Disorders; Immunological Disorders; Inflammation; Inflammation, Treatment of; Multiple Sclerosis, Agents for; Musculoskeletal Disorders; Neurological Disorders; Skin Disorders; Systemic Lupus Erythematosus, Agents for; Treatment of Autoimmune Diseases; Viral Infection"
CBR-050-069-986-5,RFM-012-562-2,CBR-050-069-986-5,N#CC(c1c(Cl)cc(cc1Cl)n1ncc(=O)[nH]c1=O)c1ccc(cc1)F,CBR-HVAC-03939: Antifungal; Antiparasitic; Anticoccidials; Antifungal; Antiparasitic; Parasitic Infections
CBR-050-069-987-6,RFM-012-563-3,CBR-050-069-987-6,CC[N+]1(CC)CCC(=C(c2ccccc2)c2ccccc2)C1C,CBR-HVAC-13505: Anticholinergic
CBR-050-069-988-7,RFM-012-564-4,CBR-050-069-988-7,O=C1CCC(=NN1)c1ccc(cc1)n1cncc1,CBR-HVAC-12735: Phosphodiesterase 3 Inhibitor; Phosphodiesterase 3 inhibitor; Heart Failure; Heart Failure Therapy; Ischaemic Heart Disease; PDE3 inhibitor
CBR-050-069-989-8,RFM-012-565-5,CBR-050-069-989-8,OC(=O)[C@H](Cc1ccc(cc1)B(O)O)N,CBR-HVAC-06574: Oncolytic Drugs
CBR-050-069-990-1,RFM-012-566-6,CBR-050-069-990-1,C1COC1=O,CBR-HVAC-09646: HMG-CoA synthase Inhibitor; Disinfectant
CBR-050-069-991-2,RFM-012-567-7,CBR-050-069-991-2,[O-]N=O,"CBR-HVAC-02599: Methemoglobin reductase Ligand; Nitric Oxide (NO) Donors; Nitric oxide stimulant; Acute Myocardial Infarction, Treatment of; Antibacterial Drugs; Antidote; Cardioprotective Agents; Cerebrovascular Diseases, Treatment of; Heart Failure Therapy; Hematopoiesis Disorders Therapy; Hemorrhagic Stroke, Treatment of; Ischemia, Treatment of; Neuropathic Pain, Treatment of; Peripheral Arterial Disease, Treatment of; Pulmonary Hypertension, Treatment of; Septic Shock, Treatment of ; Treatment of Poisoning; Ulcers of the Extremities, Agents for"